PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Sorli, SC; Le Gonidec, S; Knibiehler, B; Audigier, Y				Sorli, S. C.; Le Gonidec, S.; Knibiehler, B.; Audigier, Y.			Apelin is a potent activator of tumour neoangiogenesis	ONCOGENE			English	Article						breast cancer; neoangiogenesis; G protein-coupled receptors	ENDOTHELIAL GROWTH-FACTOR; PROTEIN-COUPLED RECEPTOR; VASCULAR DEVELOPMENT; ANGIOGENIC FACTOR; HUMAN APJ; X-MSR; EXPRESSION; VEGF; LIGAND; CELLS	Our laboratory has previously shown that apelin is mitogenic for endothelial cells. We have postulated that apelin represents an angiogenic factor secreted by tumour cells in order to promote the formation of new vessels necessary for tumour growth. We first demonstrate that apelin and its receptor are not expressed by the mouse TS/A mammary carcinoma cells. We therefore established clones of this tumoral cell type stably overexpressing the apelin cDNA (TS/A-apelin clones). Comparison of the in vitro proliferation rates between TS/A-mock and TS/A-apelin cells did not reveal any difference and confirmed the lack of receptor expression by tumour cells. On the other hand, apelin overexpression clearly increased the in vivo tumour growth and this increase was associated with an earlier onset of tumour development. In tumours derived from TS/A-apelin clones, the expression of the endothelial marker CD31 was increased and revealed the formation of large intratumoral vessels lined with CD31 positive cells. These data suggest that apelin behaves as a potent activator of tumour neoangiogenesis by a paracrine effect on host vessels. The pathological relevance of this finding is demonstrated by hypoxia-induced upregulation of apelin gene and its overexpression in one-third of human tumours.	[Sorli, S. C.; Le Gonidec, S.; Knibiehler, B.; Audigier, Y.] INSERM, U589, 12MR, Canc Dept, F-31432 Toulouse 4, France	Institut National de la Sante et de la Recherche Medicale (Inserm)	Audigier, Y (corresponding author), INSERM, U589, 12MR, Canc Dept, BP 84225,1 Ave Jean Poulhes, F-31432 Toulouse 4, France.	yves.audigier@toulouse.inserm.fr		Le Gonidec, Sophie/0000-0002-8141-690X				AUDIGIER Y, 2006, AFCS NATURE MOL PAGE; BREIER G, 1992, DEVELOPMENT, V114, P521; Brugarolas J, 2004, CANCER CELL, V6, P7, DOI 10.1016/j.ccr.2004.06.020; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; Coultas L, 2005, NATURE, V438, P937, DOI 10.1038/nature04479; Cox CM, 2006, DEV BIOL, V296, P177, DOI 10.1016/j.ydbio.2006.04.452; Devic E, 1996, MECH DEVELOP, V59, P129, DOI 10.1016/0925-4773(96)00585-0; Devic E, 1999, MECH DEVELOP, V84, P199, DOI 10.1016/S0925-4773(99)00081-7; Dvorak HF, 2002, J CLIN ONCOL, V20, P4368, DOI 10.1200/JCO.2002.10.088; Ferrara N, 2004, ENDOCR REV, V25, P581, DOI 10.1210/er.2003-0027; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; Ferrara N, 2005, NATURE, V438, P967, DOI 10.1038/nature04483; FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182; Graeven U, 2001, CANCER RES, V61, P7282; Habata Y, 1999, BBA-MOL CELL RES, V1452, P25, DOI 10.1016/S0167-4889(99)00114-7; Holash J, 2002, P NATL ACAD SCI USA, V99, P11393, DOI 10.1073/pnas.172398299; Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691; Kasai A, 2004, BIOCHEM BIOPH RES CO, V325, P395, DOI 10.1016/j.bbrc.2004.10.042; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lonser RR, 2003, LANCET, V361, P2059, DOI 10.1016/S0140-6736(03)13643-4; Masri B, 2005, CELL SIGNAL, V17, P415, DOI 10.1016/j.cellsig.2004.09.018; Masri B, 2004, FASEB J, V18, P1909, DOI 10.1096/fj.04-1930fje; Masri B, 2002, BIOCHEM BIOPH RES CO, V290, P539, DOI 10.1006/bbrc.2001.6230; Masri B, 2006, J BIOL CHEM, V281, P18317, DOI 10.1074/jbc.M600606200; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; PLATE KH, 1993, CANCER RES, V53, P5822; Prewett M, 1999, CANCER RES, V59, P5209; Pugh CW, 2003, NAT MED, V9, P677, DOI 10.1038/nm0603-677; RAK J, 1995, CANCER RES, V55, P4575; Saint-Geniez M, 2002, MECH DEVELOP, V110, P183, DOI 10.1016/S0925-4773(01)00558-5; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; SHWEIKI D, 1992, NATURE, V359, P845; Sorli SC, 2006, DRUG DISCOV TODAY, V11, P1100, DOI 10.1016/j.drudis.2006.10.011; Tatemoto K, 1998, BIOCHEM BIOPH RES CO, V251, P471, DOI 10.1006/bbrc.1998.9489; Wood JM, 2000, CANCER RES, V60, P2178	37	129	139	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 6	2007	26	55					7692	7699		10.1038/sj.onc.1210573	http://dx.doi.org/10.1038/sj.onc.1210573			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	239SK	17563744				2022-12-28	WOS:000251537800011
J	Sugino, Y; Misawa, A; Inoue, J; Kitagawa, M; Hosoi, H; Sugimoto, T; Imoto, I; Inazawa, J				Sugino, Y.; Misawa, A.; Inoue, J.; Kitagawa, M.; Hosoi, H.; Sugimoto, T.; Imoto, I.; Inazawa, J.			Epigenetic silencing of prostaglandin E receptor 2 (PTGER2) is associated with progression of neuroblastomas	ONCOGENE			English	Article						neuroblastoma; PTGER2; tumor suppressor; DNA methylation; histone modification; cAMP	CPG ISLAND AMPLIFICATION; COLORECTAL-CANCER; DNA METHYLATION; CHROMATIN-STRUCTURE; GENE-EXPRESSION; CELL-LINES; APOPTOSIS; GROWTH; ACTIVATION; EP2	We previously identified a cluster of prostanoid receptor genes, prostaglandin D2 receptor (PTGDR) and prostaglandin E receptor 2 (PTGER2), as possible targets for DNA methylation in advanced types of neuroblastoma ( NB) using bacterial artificial chromosome array-based methylated CpG island amplification method. Among them, in this study, we found that PTGER2 was frequently silenced in NB cell lines, especially in those with MYCN amplification, through epigenetic mechanisms. In NB cell lines, DNA methylation pattern within a part of CpG island was inversely correlated with PTGER2 expression, and histone H3 and H4 deacetylation and histone H3 lysine 9 methylation within the putative promoter region were more directly correlated with silencing of this gene. Methylation of PTGER2 was observed more frequently in advanced-type of primary NBs compared with early-stage tumors. Growth of NB cells lacking endogenous PTGER2 expression was inhibited by restoration of the gene product by transient and stable transfection. A PTGER2-selective agonist, butaprost, increased intracellular cyclic adenosine monophosphate ( cAMP) level, inhibited cell growth and induced apoptosis of NB cells stably expressing exogenous PTGER2. 8-Bromo-cAMP also inhibited growth of NB cells lacking PTGER2 expression, but not cells expressing this gene. Taken together, it is suggested that NB cells may lose responsiveness to PTGER2-mediated growth inhibition/apoptosis through epigenetic silencing of PTGER2 and/or disruption of downstream cAMP-dependent pathway during the neuroblastomagenesis.	Tokyo Med & Dent Univ, Sch Biomed Sci, Med Res Inst, Dept Mol Cytogenet, Tokyo, Japan; Japan Sci & Technol Corp, Core Res Evolutionary Sci & Technol, Satiama, Japan; Kyoto Prefectural Univ Med, Dept Pediat, Kyoto, Japan; Tokyo Med & Dent Univ, Grad Sch, Dept Pathol & Immunol, Tokyo, Japan; Tokyo Med & Dent Univ, Grad Sch, Hard Tissue Genom Res Ctr, Dept Genom Med, Tokyo, Japan; Tokyo Med & Dent Univ, Cent Ctr Excellence Program Mol D & R T & B 21st, Tokyo, Japan	Tokyo Medical & Dental University (TMDU); Japan Science & Technology Agency (JST); Kyoto Prefectural University of Medicine; Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU)	Inazawa, J (corresponding author), Tokyo Med & Dent Univ, Inst Med Res, Dept Mol Cytogenet, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138510, Japan.	johinaz.cgen@mri.tmd.ac.jp	Imoto, Issei/AAD-5799-2020; imoto, Issei/D-8065-2012					Abe M, 2005, CANCER RES, V65, P828; Azuara V, 2006, NAT CELL BIOL, V8, P532, DOI 10.1038/ncb1403; BRODEUR GM, 1993, J CLIN ONCOL, V11, P1466, DOI 10.1200/JCO.1993.11.8.1466; Brodeur GM, 2003, NAT REV CANCER, V3, P203, DOI 10.1038/nrc1014; Castellone MD, 2005, SCIENCE, V310, P1504, DOI 10.1126/science.1116221; Chen TC, 1998, LAB INVEST, V78, P165; Fedyk ER, 1996, MOL IMMUNOL, V33, P33, DOI 10.1016/0161-5890(95)00130-1; Frigola J, 2006, NAT GENET, V38, P540, DOI 10.1038/ng1781; FULTON AM, 1989, J CELL PHYSIOL, V139, P93, DOI 10.1002/jcp.1041390114; Hata AN, 2004, PHARMACOL THERAPEUT, V103, P147, DOI 10.1016/j.pharmthera.2004.06.003; Hoshino T, 2003, J BIOL CHEM, V278, P12752, DOI 10.1074/jbc.M212097200; Inazawa J, 2004, CANCER SCI, V95, P559, DOI 10.1111/j.1349-7006.2004.tb02486.x; Johnsen JI, 2004, CANCER RES, V64, P7210, DOI 10.1158/0008-5472.CAN-04-1795; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Kondo Y, 2003, MOL CELL BIOL, V23, P206, DOI 10.1128/MCB.23.1.206-215.2003; Lorincz MC, 2004, NAT STRUCT MOL BIOL, V11, P1068, DOI 10.1038/nsmb840; Mejia MD, 2002, ARCH MED RES, V33, P466, DOI 10.1016/S0188-4409(02)00384-3; Misawa A, 2005, CANCER RES, V65, P10233, DOI 10.1158/0008-5472.CAN-05-1073; Nakagawachi T, 2003, ONCOGENE, V22, P8835, DOI 10.1038/sj.onc.1207183; Narumiya S, 1999, PHYSIOL REV, V79, P1193, DOI 10.1152/physrev.1999.79.4.1193; Okuyama T, 2002, J LAB CLIN MED, V140, P92, DOI 10.1067/mlc.2002.125784; Regan JW, 2003, LIFE SCI, V74, P143, DOI 10.1016/j.lfs.2003.09.031; Saito-Ohara F, 2003, CANCER RES, V63, P1876; SANTORO MG, 1977, CANCER RES, V37, P3774; Schubeler D, 2000, MOL CELL BIOL, V20, P9103, DOI 10.1128/MCB.20.24.9103-9112.2000; Sonoda I, 2004, CANCER RES, V64, P3741, DOI 10.1158/0008-5472.CAN-04-0172; Stirzaker C, 2004, CANCER RES, V64, P3871, DOI 10.1158/0008-5472.CAN-03-3690; Strunnikova M, 2005, MOL CELL BIOL, V25, P3923, DOI 10.1128/MCB.25.10.3923-3933.2005; Suda M, 1996, ENDOCRINOLOGY, V137, P1698, DOI 10.1210/en.137.5.1698; Takadera T, 2004, NEUROCHEM INT, V45, P713, DOI 10.1016/j.neuint.2004.02.005; Teitz T, 2000, NAT MED, V6, P529, DOI 10.1038/75007; Thompson PM, 2001, MED PEDIATR ONCOL, V36, P28, DOI 10.1002/1096-911X(20010101)36:1<28::AID-MPO1008>3.0.CO;2-0; Toyota M, 1999, CANCER RES, V59, P2307; Wang D, 2006, GUT, V55, P115, DOI 10.1136/gut.2004.047100; Wang DZ, 2006, J EXP MED, V203, P941, DOI 10.1084/jem.20052124; Wang DZ, 2005, CANCER RES, V65, P1822, DOI 10.1158/0008-5472.CAN-04-3671; Wang WH, 2005, INORG CHEM COMMUN, V8, P109, DOI 10.1016/j.inoche.2004.11.025; Westermann F, 2002, CANCER LETT, V184, P127, DOI 10.1016/S0304-3835(02)00199-4; Wolffe AP, 1999, SCIENCE, V286, P481, DOI 10.1126/science.286.5439.481; Xiong ZG, 1997, NUCLEIC ACIDS RES, V25, P2532, DOI 10.1093/nar/25.12.2532; Yamada N, 2006, INT J CANCER, V119, P1850, DOI 10.1002/ijc.22047; Yan P, 2003, GENE CHROMOSOME CANC, V36, P129, DOI 10.1002/gcc.10150; Yang QW, 2004, CLIN CANCER RES, V10, P8493, DOI 10.1158/1078-0432.CCR-04-1331; Yang QW, 2003, CANCER RES, V63, P6299	44	39	41	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 22	2007	26	53					7401	7413		10.1038/sj.onc.1210550	http://dx.doi.org/10.1038/sj.onc.1210550			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	236DA	17533365				2022-12-28	WOS:000251282000002
J	Lehen'kyi, V; Flourakis, M; Skryma, R; Prevarskaya, N				Lehen'kyi, V.; Flourakis, M.; Skryma, R.; Prevarskaya, N.			TRPV6 channel controls prostate cancer cell proliferation via Ca2+/NFAT-dependent pathways	ONCOGENE			English	Article						prostate cancer; TRPV6; Ca2+ uptake; NFAT; proliferation; LNCaP cells	OPERATED CA2+ CURRENT; EPITHELIAL-CELLS; ANDROGEN RECEPTOR; APOPTOTIC RESISTANCE; STORE DEPLETION; EXPRESSION; HOMEOSTASIS; GROWTH; INVOLVEMENT; PROGRESSION	The transient receptor potential channel, subfamily V, member 6 (TRPV6), is strongly expressed in advanced prostate cancer and significantly correlates with the Gleason > 7 grading, being undetectable in healthy and benign prostate tissues. However, the role of TRPV6 as a highly Ca2+-selective channel in prostate carcinogenesis remains poorly understood. Here, we report that TRPV6 is directly involved in the control of prostate cancer cell (LNCaP cell line) proliferation by decreasing: (i) proliferation rate; (ii) cell accumulation in the S-phase of cell cycle and (iii) proliferating cell nuclear antigen (PCNA) expression. We demonstrate that the Ca2+ uptake into LNCaP cells is mediated by TRPV6, with the subsequent downstream activation of the nuclear factor of activated T-cell transcription factor (NFAT). TRPV6-mediated Ca2+ entry is also involved in apoptosis resistance of LNCaP cells. Our results suggest that TRPV6 expression in LNCaP cells is regulated by androgen receptor, however, in a ligand-independent manner. We conclude that the upregulation of TRPV6 Ca2+ channel in prostate cancer cells may represent a mechanism for maintaining a higher proliferation rate, increasing cell survival and apoptosis resistance as well.	Univ Sci & Tech Lille, INSERM, Lab Cell Physiol, Villeneuve Dascq, France; INSERM, Equipe Ligue Natl Contre Canc, Villeneuve Dascq, France; Univ Sci & Tech Lille, Villeneuve Dascq, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lille - ISITE; Universite de Lille; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lille - ISITE; Universite de Lille	Prevarskaya, N (corresponding author), Univ Sci & Tech Lille, INSERM, Lab Cell Physiol, Bat SN3, Villeneuve Dascq, France.	natacha.prevarskaya@univ-lille1.fr		Flourakis, Matthieu/0000-0002-5366-9125; LEHEN'KYI, V'yacheslav/0000-0003-0806-8766; Prevarskaya, natacha/0000-0003-0316-197X				Bidaux G, 2005, ENDOCR-RELAT CANCER, V12, P367, DOI 10.1677/erc.1.00969; Bodding M, 2004, J BIOL CHEM, V279, P36546, DOI 10.1074/jbc.M404679200; Bodding M, 2003, J BIOL CHEM, V278, P50872, DOI 10.1074/jbc.M308800200; Burnstein KL, 2005, J CELL BIOCHEM, V95, P657, DOI 10.1002/jcb.20460; Cooperberg MR, 2005, J CLIN ONCOL, V23, P8146, DOI 10.1200/JCO.2005.02.9751; Fixemer T, 2003, ONCOGENE, V22, P7858, DOI 10.1038/sj.onc.1206895; Korkmaz KS, 2002, J BIOL CHEM, V277, P36689, DOI 10.1074/jbc.M202414200; Legrand G, 2001, J BIOL CHEM, V276, P47608, DOI 10.1074/jbc.M107011200; Lipskaia L, 2004, BIOL CELL, V96, P55, DOI 10.1016/j.biolcel.2003.11.001; Montell C, 2002, CELL, V108, P595, DOI 10.1016/S0092-8674(02)00670-0; Peng JB, 2001, BIOCHEM BIOPH RES CO, V282, P729, DOI 10.1006/bbrc.2001.4638; Prevarskaya N, 2004, BIOCHEM BIOPH RES CO, V322, P1326, DOI 10.1016/j.bbrc.2004.08.037; Schindl R, 2002, J BIOL CHEM, V277, P26950, DOI 10.1074/jbc.M203700200; Schwarz EC, 2006, CELL CALCIUM, V39, P163, DOI 10.1016/j.ceca.2005.10.006; Skryma R, 2000, J PHYSIOL-LONDON, V527, P71, DOI 10.1111/j.1469-7793.2000.00071.x; Thebault S, 2006, CANCER RES, V66, P2038, DOI 10.1158/0008-5472.CAN-05-0376; Vanden Abeele F, 2004, J BIOL CHEM, V279, P30326, DOI 10.1074/jbc.M400106200; Vanden Abeele F, 2002, CANCER CELL, V1, P169; Vanden Abeele F, 2003, J BIOL CHEM, V278, P15381, DOI 10.1074/jbc.M212106200; Vanoverberghe K, 2004, CELL DEATH DIFFER, V11, P321, DOI 10.1038/sj.cdd.4401375; Wang LG, 1999, BIOCHEM BIOPH RES CO, V259, P21, DOI 10.1006/bbrc.1999.0655; Wang TT, 2005, MOL ENDOCRINOL, V19, P2685, DOI 10.1210/me.2005-0106; Wissenbach U, 2004, BIOCHEM BIOPH RES CO, V322, P1359, DOI 10.1016/j.bbrc.2004.08.042; Xiao F, 2005, MOL ENDOCRINOL, V19, P2964, DOI 10.1210/me.2004-0408	24	177	184	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 15	2007	26	52					7380	7385		10.1038/sj.onc.1210545	http://dx.doi.org/10.1038/sj.onc.1210545			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	231NP	17533368	Green Submitted			2022-12-28	WOS:000250955700010
J	Zantl, N; Weirich, G; Zall, H; Seiffert, BM; Fischer, SF; Kirschnek, S; Hartmann, C; Fritsch, RM; Gillissen, B; Daniel, PT; Hacker, G				Zantl, N.; Weirich, G.; Zall, H.; Seiffert, B. M.; Fischer, S. F.; Kirschnek, S.; Hartmann, C.; Fritsch, R. M.; Gillissen, B.; Daniel, P. T.; Haecker, G.			Frequent loss of expression of the pro-apoptotic protein Bim in renal cell carcinoma: evidence for contribution to apoptosis resistance	ONCOGENE			English	Article						renal cell carcinoma; apoptosis; Bim; Bcl-2; expression	BCL-2 FAMILY-MEMBER; BH3-ONLY PROTEINS; MITOCHONDRIAL-MEMBRANE; MALIGNANT-DISEASE; BH3 DOMAINS; DEATH; BAX; PATHWAY; PUMA; GENE	Renal cell carcinoma (RCC) is resistant to chemotherapy, and this resistance is mirrored by a high apoptosis resistance of many RCC lines in vitro. Here, we report the loss of the pro-apoptotic BH3-only protein Bim in a large part of clinical RCC cases and provide evidence for a functional relevance of this loss. Immunohistochemistry of clear cell renal cell carcinoma cases and corresponding normal kidney showed strong Bim reactivity in renal tubules of all cases but loss of Bim in 35 of 45 RCC samples. Out of nine RCC cell lines investigated, six showed strongly diminished or undetectable levels of Bim protein by western blotting. Four RCC lines of varying apoptosis sensitivity were analysed further. Bcl-2, Bcl-x(L), Mcl-1, Bax and Bak expression did not correlate with apoptosis sensitivity. All cell lines underwent apoptosis upon forced expression of Bax and Bim, suggesting an upstream difference. In all four lines, adriamycin induced p53 but not its targets Puma or Noxa. However, apoptosis sensitivity correlated with levels of Bim protein. Bim siRNA reduced apoptosis sensitivity in a susceptible cell line. Furthermore, inhibition of histone deacetylation restored Bim expression in cell lines. These data suggest that Bim has a function as a tumor suppressor in RCC.	Tech Univ Munich, Inst Med Microbiol, D-81675 Munich, Germany; Tech Univ Munich, Dept Urol, D-81675 Munich, Germany; Tech Univ Munich, Inst Pathol, D-81675 Munich, Germany; Tech Univ Munich, Dept Internal Med 2, D-81675 Munich, Germany; Univ Med Ctr Charite, Dept Hematol Oncol & Tumor Immunol, Berlin, Germany	Technical University of Munich; Technical University of Munich; Technical University of Munich; Technical University of Munich; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Hacker, G (corresponding author), Tech Univ Munich, Inst Med Microbiol, Trogerstr 9, D-81675 Munich, Germany.	hacker@lrz.tum.de		Fritsch, Ralph/0000-0001-9639-3213; Gillissen, Bernhard/0000-0002-1815-2091				Adams JM, 2001, TRENDS BIOCHEM SCI, V26, P61, DOI 10.1016/S0968-0004(00)01740-0; Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9; Bouillet P, 1999, SCIENCE, V286, P1735, DOI 10.1126/science.286.5445.1735; Chen L, 2005, MOL CELL, V17, P393, DOI 10.1016/j.molcel.2004.12.030; Coultas L, 2005, EMBO J, V24, P3963, DOI 10.1038/sj.emboj.7600857; Coultas L, 2004, MOL CELL BIOL, V24, P1570, DOI 10.1128/MCB.24.4.1570-1581.2004; Daniel PT, 1999, BLOOD, V94, P1100, DOI 10.1182/blood.V94.3.1100.415a16_1100_1107; Debatin KM, 2002, ONCOGENE, V21, P8786, DOI 10.1038/sj.onc.1206039; Dijkers PF, 2000, CURR BIOL, V10, P1201, DOI 10.1016/S0960-9822(00)00728-4; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; Egle A, 2004, P NATL ACAD SCI USA, V101, P6164, DOI 10.1073/pnas.0401471101; Fischer SE, 2004, J EXP MED, V200, P905, DOI 10.1084/jem.20040402; Fischer SF, 2001, INFECT IMMUN, V69, P7121, DOI 10.1128/IAI.69.11.7121-7129.2001; Gerhard MC, 2003, BRIT J CANCER, V89, P2147, DOI 10.1038/sj.bjc.6601436; Gillissen B, 2003, EMBO J, V22, P3580, DOI 10.1093/emboj/cdg343; Green DR, 2002, CANCER CELL, V1, P19, DOI 10.1016/S1535-6108(02)00024-7; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Gurova KV, 2004, CANCER RES, V64, P1951, DOI 10.1158/0008-5472.CAN-03-1541; Gurova KV, 2005, P NATL ACAD SCI USA, V102, P17448, DOI 10.1073/pnas.0508888102; Han JW, 2001, P NATL ACAD SCI USA, V98, P11318, DOI 10.1073/pnas.201208798; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Huang A, 1999, J UROLOGY, V162, P610, DOI 10.1016/S0022-5347(05)68635-1; Janzen NK, 2003, UROL CLIN N AM, V30, P843, DOI 10.1016/S0094-0143(03)00056-9; Jeffers JR, 2003, CANCER CELL, V4, P321, DOI 10.1016/S1535-6108(03)00244-7; Kallio JP, 2004, J UROLOGY, V172, P2158, DOI 10.1097/01.ju.0000144334.97639.bf; Kane RC, 2006, CLIN CANCER RES, V12, P7271, DOI 10.1158/1078-0432.CCR-06-1249; Kim H, 2006, NAT CELL BIOL, V8, P1348, DOI 10.1038/ncb1499; Kolenko V, 1999, CANCER RES, V59, P2838; Kuwana T, 2005, MOL CELL, V17, P525, DOI 10.1016/j.molcel.2005.02.003; Kuwana T, 2002, CELL, V111, P331, DOI 10.1016/S0092-8674(02)01036-X; Labi V, 2006, CELL DEATH DIFFER, V13, P1325, DOI 10.1038/sj.cdd.4401940; Letai A, 2002, CANCER CELL, V2, P183, DOI 10.1016/S1535-6108(02)00127-7; Mickisch GHJ, 2002, BJU INT, V89, P488, DOI 10.1046/j.1464-410X.2002.02654.x; Motzer RJ, 2007, NEW ENGL J MED, V356, P115, DOI 10.1056/NEJMoa065044; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; O'Connor L, 1998, EMBO J, V17, P384, DOI 10.1093/emboj/17.2.384; O'Reilly LA, 2000, AM J PATHOL, V157, P449, DOI 10.1016/S0002-9440(10)64557-9; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Phillips JL, 2001, GENE CHROMOSOME CANC, V31, P1, DOI 10.1002/gcc.1111; Putcha GV, 2001, NEURON, V29, P615, DOI 10.1016/S0896-6273(01)00238-0; Puthalakath H, 2002, CELL DEATH DIFFER, V9, P505, DOI 10.1038/sj.cdd.4400998; Puthalakath H, 1999, MOL CELL, V3, P287, DOI 10.1016/S1097-2765(00)80456-6; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Sturm I, 2006, CELL DEATH DIFFER, V13, P619, DOI 10.1038/sj.cdd.4401782; Tan TT, 2005, CANCER CELL, V7, P227, DOI 10.1016/j.ccr.2005.02.008; VAUX DL, 1994, CELL, V76, P777, DOI 10.1016/0092-8674(94)90350-6; Villunger A, 2003, SCIENCE, V302, P1036, DOI 10.1126/science.1090072; Wang XD, 2001, GENE DEV, V15, P2922; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Whitfield J, 2001, NEURON, V29, P629, DOI 10.1016/S0896-6273(01)00239-2; Willis SN, 2005, GENE DEV, V19, P1294, DOI 10.1101/gad.1304105; Zhu YN, 2004, P NATL ACAD SCI USA, V101, P7681, DOI 10.1073/pnas.0402293101	53	73	73	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2007	26	49					7038	7048		10.1038/sj.onc.1210510	http://dx.doi.org/10.1038/sj.onc.1210510			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	223YN	17486061				2022-12-28	WOS:000250412200009
J	Wang, Y; Kreisberg, JI; Bedolla, RG; Mikhailova, M; White, RWD; Ghosh, PM				Wang, Y.; Kreisberg, J. I.; Bedolla, R. G.; Mikhailova, M.; White, R. W. deVere; Ghosh, P. M.			A 90 kDa fragment of filamin A promotes Casodex-induced growth inhibition in Casodex-resistant androgen receptor positive C4-2 prostate cancer cells	ONCOGENE			English	Article						proliferation; prostate cancer; androgen receptor; Akt; bicalutamide	ACTIN-BINDING PROTEIN; C-TERMINAL REGION; PHOSPHORYLATION SITE; MEMBRANE ANTIGEN; CROSS-LINKING; AKT; PROLIFERATION; BICALUTAMIDE; PROGRESSION; EXPRESSION	Prostate tumors are initially dependent on androgens for growth, but the majority of patients treated with antiandrogen therapy progress to androgen- independence characterized by resistance to such treatment. This study investigates a novel role for. lamin A ( FlnA), a 280 kDa cytoskeletal protein ( consisting of an actin- binding domain ( ABD) followed by 24 sequential repeats), in androgen- independent ( AI) growth. Full- length FlnA is cleaved to 170 kDa ( ABD+FlnA1 - 15) and 110 kDa fragments ( FlnA16 - 24); the latter is further cleaved to a 90 kDa fragment ( repeats 16 - 23) capable of nuclear translocation and androgen receptor ( AR) binding. Here, we demonstrate that in androgen- dependent LNCaP prostate cancer cells, the cleaved 90 kDa fragment is localized to the nucleus, whereas in its AI subline C4 - 2, FlnA failed to cleave and remained cytoplasmic. Transfection of FlnA16 - 24 cDNA in C4 - 2 cells restored expression and nuclear localization of 90 kDa FlnA. Unlike LNCaP, C4 - 2 cells proliferate in androgen-reduced medium and in the presence of the AR- antagonist Casodex. They also exhibit increased Akt phosphorylation compared to LNCaP, which may contribute to their AI phenotype. Nuclear expression of 90 kDa FlnA in C4 - 2 cells decreased Akt phosphorylation, prevented proliferation in androgen- reduced medium and restored Casodex sensitivity. This effect was inhibited by constitutive activation of Akt indicating that FlnA restored Casodex sensitivity in C4 - 2 cells by decreasing Akt phosphorylation. In addition, FlnA-specific siRNA which depleted FlnA levels, but not control siRNA, induced resistance to Casodex in LNCaP cells. Our results demonstrate that expression of nuclear FlnA is necessary for androgen dependence in these cells.	VA No California Hlth Care Syst, Res Serv, Mather, CA 95655 USA; Univ Calif Davis, Sch Med, Dept Urol, Sacramento, CA 95817 USA; Univ Texas, Hlth Sci Ctr, San Antonio, TX 78285 USA	University of California System; University of California Davis; University of Texas System; University of Texas Health San Antonio	Ghosh, PM (corresponding author), VA No California Hlth Care Syst, Res Serv, 10535 Hosp Way, Mather, CA 95655 USA.	paramita.ghosh@ucdmc.ucdavis.edu	WANG, YU/E-4655-2013		NCI NIH HHS [CA109057, R21 CA109057] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R21CA109057] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anilkumar G, 2003, CANCER RES, V63, P2645; BARRY CP, 1993, J BIOL CHEM, V268, P25577; Browne KA, 2000, J BIOL CHEM, V275, P39262, DOI 10.1074/jbc.C000622200; Culig Z, 1999, BRIT J CANCER, V81, P242, DOI 10.1038/sj.bjc.6690684; Culig ZR, 2003, J UROLOGY, V170, P1363, DOI 10.1097/01.ju.0000075099.20662.7f; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; Feldman BJ, 2001, NAT REV CANCER, V1, P34, DOI 10.1038/35094009; Ghosh A, 2005, CANCER RES, V65, P727; Ghosh PM, 2005, ENDOCR-RELAT CANCER, V12, P119, DOI 10.1677/erc.1.00835; Ghosh PM, 2003, CURR DRUG METAB, V4, P487, DOI 10.2174/1389200033489226; Ghosh PM, 2002, CANCER RES, V62, P2630; Ghosh PM, 2001, AM J PHYSIOL-RENAL, V280, pF972, DOI 10.1152/ajprenal.2001.280.6.F972; GORLIN JB, 1990, J CELL BIOL, V111, P1089, DOI 10.1083/jcb.111.3.1089; Graff JR, 2000, J BIOL CHEM, V275, P24500, DOI 10.1074/jbc.M003145200; Hara T, 2003, CANCER RES, V63, P149; Heisler LE, 1997, MOL CELL ENDOCRINOL, V126, P59, DOI 10.1016/S0303-7207(96)03970-6; HSIEH JT, 1993, CANCER RES, V53, P2852; Isaacs JT, 2000, JNCI-J NATL CANCER I, V92, P1367, DOI 10.1093/jnci/92.17.1367; Jay D, 2000, ARCH BIOCHEM BIOPHYS, V377, P80, DOI 10.1006/abbi.2000.1762; Jay D, 2004, MOL CELL BIOCHEM, V260, P49, DOI 10.1023/B:MCBI.0000026052.76418.55; JENSTER G, 1992, J STEROID BIOCHEM, V41, P671, DOI 10.1016/0960-0760(92)90402-5; Kreisberg JI, 2004, CANCER RES, V64, P5232, DOI 10.1158/0008-5472.CAN-04-0272; Loy CJ, 2003, P NATL ACAD SCI USA, V100, P4562, DOI 10.1073/pnas.0736237100; Malik SN, 2002, CLIN CANCER RES, V8, P1168; Manin M, 2002, BIOCHEM J, V366, P729, DOI 10.1042/BJ20020585; Masiello D, 2002, J BIOL CHEM, V277, P26321, DOI 10.1074/jbc.M203310200; Murray JT, 2004, BIOCHEM J, V384, P489, DOI 10.1042/BJ20041058; Ozanne DM, 2000, MOL ENDOCRINOL, V14, P1618, DOI 10.1210/me.14.10.1618; Robertson SP, 2003, NAT GENET, V33, P487, DOI 10.1038/ng1119; Shi XB, 2004, PROSTATE, V60, P257, DOI 10.1002/pros.20039; Tepper CG, 2002, CANCER RES, V62, P6606; Thomas P, 1996, NEUROLOGY, V46, P1165, DOI 10.1212/WNL.46.4.1165; Tigges U, 2003, J BIOL CHEM, V278, P23561, DOI 10.1074/jbc.M302302200; van der Flier A, 2001, BBA-MOL CELL RES, V1538, P99, DOI 10.1016/S0167-4889(01)00072-6; Wen Y, 2000, CANCER RES, V60, P6841; Woo MS, 2004, MOL CELL BIOL, V24, P3025, DOI 10.1128/MCB.24.7.3025-3035.2004; WU HC, 1994, INT J CANCER, V57, P406, DOI 10.1002/ijc.2910570319	37	65	68	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP	2007	26	41					6061	6070		10.1038/sj.onc.1210435	http://dx.doi.org/10.1038/sj.onc.1210435			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	207US	17420725				2022-12-28	WOS:000249277200009
J	Fujiki, T; Miura, T; Maura, M; Shiraishi, H; Nishimura, S; Imada, Y; Uehara, N; Tashiro, K; Shirahata, S; Katakura, Y				Fujiki, T.; Miura, T.; Maura, M.; Shiraishi, H.; Nishimura, S.; Imada, Y.; Uehara, N.; Tashiro, K.; Shirahata, S.; Katakura, Y.			TAK1 represses transcription of the human telomerase reverse transcriptase gene	ONCOGENE			English	Article						telomerase; hTERT; TAK1; Sp1; HDAC	HISTONE DEACETYLASE INHIBITOR; BETA SIGNAL-TRANSDUCTION; CATALYTIC SUBUNIT HTERT; CANCER-CELLS; PROMOTER; IDENTIFICATION; ACTIVATION; DIFFERENTIATION; BINDING; PATHWAY	In human cells, telomerase activity is tightly regulated by the expression of its catalytic subunit, namely, the human telomerase reverse transcriptase ( hTERT). However, the molecular mechanisms involved in the regulation of hTERT expression have not been completely clarified. We have previously reported that transforming growth factor beta (TGF-beta) represses the expression of the hTERT gene. In the present study, we demonstrated that TGF-beta-activated kinase 1 (TAK1), originally identified as a mitogen-activated kinase kinase kinase, represses the hTERT core promoter activity in an E-box-independent manner, and it also represses the transcription of the hTERT gene in human lung adenocarcinoma cell line, A549 cells. This TAK1-induced repression was found to be caused by the recruitment of histone deacetylase to Sp1 at the hTERT promoter and a consequent reduction in the amount of acetylated histone H4 at the hTERT promoter. Finally, we demonstrated that TAK1 induces cellular senescence programs in normal human diploid cells. Thus, we assume that TAK1 triggers the repression mechanisms of the hTERT gene as a result of evoking cellular senescence programs. Considered together, TAK1 is thought to play a causative role in the determination of a finite replicative lifespan of normal and cancer cells.	Kyushu Univ, Fac Agr, Dept Genet Resources Technol, Fukuoka 8128581, Japan	Kyushu University	Katakura, Y (corresponding author), Kyushu Univ, Fac Agr, Dept Genet Resources Technol, Fukuoka 8128581, Japan.	katakura@grt.kyushu-u.ac.jp	Uehara, Norihisa/ABB-8106-2020; Uehara, Norihisa/F-5933-2012					Aisner DL, 2002, CURR OPIN GENET DEV, V12, P80, DOI 10.1016/S0959-437X(01)00268-4; Cong YS, 1999, HUM MOL GENET, V8, P137, DOI 10.1093/hmg/8.1.137; Cong YS, 2000, J BIOL CHEM, V275, P35665, DOI 10.1074/jbc.C000637200; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Ducrest AL, 2002, ONCOGENE, V21, P541, DOI 10.1038/sj.onc.1205081; EMAMI KH, 1995, MOL CELL BIOL, V15, P5906; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Horikawa I, 2002, MOL BIOL CELL, V13, P2585, DOI 10.1091/mbc.E01-11-0107; Horikawa I, 1999, CANCER RES, V59, P826; Hou M, 2002, EXP CELL RES, V274, P25, DOI 10.1006/excr.2001.5462; Ishitani T, 1999, NATURE, V399, P798, DOI 10.1038/21674; Katakura Y, 1999, BIOCHEM BIOPH RES CO, V255, P110, DOI 10.1006/bbrc.1999.0129; Katakura Y, 2005, BIOCHEM BIOPH RES CO, V334, P450, DOI 10.1016/j.bbrc.2005.06.109; Kyo S, 2002, ONCOGENE, V21, P688, DOI 10.1038/sj.onc.1205163; Shibuya H, 1996, SCIENCE, V272, P1179, DOI 10.1126/science.272.5265.1179; Takakura M, 1999, CANCER RES, V59, P551; Takakura M, 2001, NUCLEIC ACIDS RES, V29, P3006, DOI 10.1093/nar/29.14.3006; Tzukerman M, 2000, MOL BIOL CELL, V11, P4381, DOI 10.1091/mbc.11.12.4381; Won J, 2002, J BIOL CHEM, V277, P38230, DOI 10.1074/jbc.M206064200; Xu DW, 2001, P NATL ACAD SCI USA, V98, P3826, DOI 10.1073/pnas.071043198; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008	21	35	39	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 9	2007	26	36					5258	5266		10.1038/sj.onc.1210331	http://dx.doi.org/10.1038/sj.onc.1210331			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	199CQ	17325661				2022-12-28	WOS:000248674200009
J	Creighton, CJ				Creighton, C. J.			A gene transcription signature of the Akt/mTOR pathway in clinical breast tumors	ONCOGENE			English	Article						akt pathway; mTOR; human breast cancer; gene expression pro. ling; meta-analysis	CELLS IN-VITRO; EXPRESSION SIGNATURE; TARGETED THERAPIES; CANCER; AKT; TAMOXIFEN; ACTIVATION; PATTERNS; ESTROGEN; SURVIVAL	The Akt pathway is commonly deregulated in many cancers. Clinical trials are currently underway to test the effectiveness of breast cancer treatment by inhibition of various Akt pathway intermediates. A set of genes induced by Akt in a transgenic mouse model, a subset of which were sensitive to mammalian target of rapamycin (mTOR) inhibitor RAD001, was examined in five public gene expression pro. le data sets of clinical breast tumor specimens (representing > 1000 different samples in all). In each of the clinical data sets, the Akt mouse model genes as a group were significantly overexpressed in human tumors having high levels of AKT1 mRNA. The subset of genes both upregulated by Akt and dependent on mTOR activity were associated with estrogen receptor-negative status, higher grade, increasing tumor size and poor prognosis in multiple patient cohorts; these associations were either not present or not as strong for the Akt-induced, mTOR-independent genes or for AKT1 expression alone. The genes shown here to be relevant to Akt-mTOR both experimentally and pathologically have the potential for use in a molecular diagnostic to determine which patients should receive mTOR antagonist treatment.	Baylor Coll Med, Dan L Duncan Canc Ctr, Dept Med, Div Biostat, Houston, TX 77030 USA	Baylor College of Medicine	Creighton, CJ (corresponding author), Baylor Coll Med, Dan L Duncan Canc Ctr, Dept Med, Div Biostat, 1 Baylor Plaza MS 305, Houston, TX 77030 USA.	creighto@bcm.tmc.edu						Bild AH, 2006, NATURE, V439, P353, DOI 10.1038/nature04296; Bose S, 2006, MODERN PATHOL, V19, P238, DOI 10.1038/modpathol.3800525; Creighton CJ, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-4-r28; Creighton CJ, 2006, CANCER RES, V66, P3903, DOI 10.1158/0008-5472.CAN-05-4363; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Johnston SRD, 2006, CLIN CANCER RES, V12, p1061S, DOI 10.1158/1078-0432.CCR-05-2125; Kirkegaard T, 2005, J PATHOL, V207, P139, DOI 10.1002/path.1829; Lamb J, 2003, CELL, V114, P323, DOI 10.1016/S0092-8674(03)00570-1; Lehmann U, 2001, METHODS, V25, P409, DOI 10.1006/meth.2001.1263; Ma XJ, 2006, J CLIN ONCOL, V24, P4611, DOI 10.1200/JCO.2006.06.6944; Ma XJ, 2004, CANCER CELL, V5, P607, DOI 10.1016/j.ccr.2004.05.015; Majumder PK, 2004, NAT MED, V10, P594, DOI 10.1038/nm1052; Miller LD, 2005, P NATL ACAD SCI USA, V102, P13550, DOI 10.1073/pnas.0506230102; Morgensztern D, 2005, ANTI-CANCER DRUG, V16, P797, DOI 10.1097/01.cad.0000173476.67239.3b; Paik S, 2004, NEW ENGL J MED, V351, P2817, DOI 10.1056/NEJMoa041588; Saldanha AJ, 2004, BIOINFORMATICS, V20, P3246, DOI 10.1093/bioinformatics/bth349; Shaw RJ, 2006, NATURE, V441, P424, DOI 10.1038/nature04869; Sorlie T, 2003, P NATL ACAD SCI USA, V100, P8418, DOI 10.1073/pnas.0932692100; Sweet-Cordero A, 2005, NAT GENET, V37, P48, DOI 10.1038/ng1490; Tian L, 2005, P NATL ACAD SCI USA, V102, P13544, DOI 10.1073/pnas.0506577102; Tokunaga E, 2006, INT J CANCER, V118, P284, DOI 10.1002/ijc.21358; van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967; Wang YX, 2005, LANCET, V365, P671, DOI 10.1016/S0140-6736(05)17947-1	23	51	53	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 12	2007	26	32					4648	4655		10.1038/sj.onc.1210245	http://dx.doi.org/10.1038/sj.onc.1210245			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	190DJ	17213801				2022-12-28	WOS:000248037900005
J	Ollikainen, M; Hannelius, U; Lindgren, CM; Abdel-Rahman, WM; Kere, J; Peltomaki, P				Ollikainen, M.; Hannelius, U.; Lindgren, C. M.; Abdel-Rahman, W. M.; Kere, J.; Peltomaki, P.			Mechanisms of inactivation of MLH1 in hereditary nonpolyposis colorectal carcinoma: a novel approach	ONCOGENE			English	Article						hereditary nonpolyposis colorectal cancer; loss of heterozygosity; promoter methylation; colorectal cancer; endometrial cancer	REPAIR GENE-MUTATIONS; MICROSATELLITE INSTABILITY; HMLH1 PROMOTER; COLON-CANCER; ENDOMETRIAL CARCINOMA; SOMATIC MUTATIONS; PHENOTYPE; PROTEIN; HYPERMETHYLATION; METHYLATION	Mutations in the DNA mismatch repair gene MLH1 are a major cause of hereditary nonpolyposis colorectal cancer (HNPCC). No mutant phenotype is observed before the wild-type (wt) allele is somatically inactivated in target tissue. We addressed the mechanisms of MLH1 inactivation in 25 colorectal (CRC) and 32 endometrial cancers (ECs) from MLH1 mutation carriers (Mut1, in-frame genomic deletion; Mut2, out-of-frame splice site mutation; Mut3, missense mutation). By a quantitative method, matrix-assisted laser desorption/ionization-time-of-flight (MALDI-TOF), utilizing four intragenic single nucleotide polymorphisms and mutations, loss of heterozygosity (LOH) was present in 31/57 (54.4%) of tumors. The wt allele displayed LOH more often than the mutant allele (23/57 vs 8/57, P = 0.006). For Mut1, LOH was more frequent in CRC than EC (10/11 vs 1/13, P < 0.0001), whereas Mut2 and Mut3 displayed opposite LOH pattern. Moreover, although wt LOH predominated in CRC irrespective of the predisposing mutation, LOH often affected the mutant allele in EC from Mut2 and Mut3 carriers (6/19, 31.6%). MLH1 promoter methylation, which reflected a more widespread hypermethylation tendency, occurred in 4/55 (7.3%) of tumors and was inversely associated with LOH. In conclusion, the patterns of somatic events (LOH and promoter methylation) differ depending on the tissue and germline mutation, which may in part explain the differential tumor susceptibility of different organs in HNPCC. MALDI-TOF provides a novel approach for the detection and quantification of LOH.	Univ Helsinki, Dept Med Genet, Helsinki, Finland; Karolinska Univ Hosp, Karolinska Inst, Clin Res Ctr, Huddinge, Sweden	University of Helsinki; Karolinska Institutet; Karolinska University Hospital	Ollikainen, M (corresponding author), Univ Helsinki, Dept Med Genet, Biomedicum, PO Box 63 Haartmaninkatu 8, FIN-00014 Helsinki, Finland.	Miina.Ollikainen@Helsinki.fi	Ollikainen, Miina E/K-7464-2012; Kere, Juha/AAX-9117-2021; Kere, Juha/A-9179-2008	Ollikainen, Miina E/0000-0003-3661-7400; Kere, Juha/0000-0003-1974-0271; Kere, Juha/0000-0003-1974-0271; Abdel-Rahman, Wael/0000-0002-2149-1043; Lindgren, Cecilia/0000-0002-4903-9374; Peltomaki, Paivi/0000-0001-8819-2980	Wellcome Trust [090532] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Albuquerque C, 2002, HUM MOL GENET, V11, P1549, DOI 10.1093/hmg/11.13.1549; Benedet JL, 2000, INT J GYNECOL OBSTET, V70, P209; Cejka P, 2003, EMBO J, V22, P2245, DOI 10.1093/emboj/cdg216; Chadwick RB, 2001, J MED GENET, V38, P461, DOI 10.1136/jmg.38.7.461; Cunningham JM, 1998, CANCER RES, V58, P3455; de Abajo AS, 2006, ONCOGENE, V25, P2124, DOI 10.1038/sj.onc.1209233; De Rosa M, 2000, ONCOGENE, V19, P1719, DOI 10.1038/sj.onc.1203447; de Wind N, 1998, CANCER RES, V58, P248; Deng GR, 1999, CANCER RES, V59, P2029; Dixon LA, 2006, FORENSIC SCI INT, V164, P33, DOI 10.1016/j.forsciint.2005.11.011; Dukes CE, 1932, J PATHOL BACTERIOL, V35, P323, DOI 10.1002/path.1700350303; Esteller M, 2001, HUM MOL GENET, V10, P3001, DOI 10.1093/hmg/10.26.3001; Esteller M, 1998, ONCOGENE, V17, P2413, DOI 10.1038/sj.onc.1202178; Groves C, 2002, AM J PATHOL, V160, P2055, DOI 10.1016/S0002-9440(10)61155-8; HEMMINKI A, 1994, NAT GENET, V8, P405, DOI 10.1038/ng1294-405; Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870; ISOLA J, 1994, AM J PATHOL, V145, P1301; Jager AC, 1997, AM J HUM GENET, V61, P129, DOI 10.1086/513896; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; Kuismanen SA, 2000, AM J PATHOL, V156, P1773, DOI 10.1016/S0002-9440(10)65048-1; Liu B, 1996, NAT MED, V2, P169, DOI 10.1038/nm0296-169; Moisio AL, 1996, AM J HUM GENET, V59, P1243; Nagase T, 2000, DNA RES, V7, P347, DOI 10.1093/dnares/7.6.347; Nicolaides NC, 1998, MOL CELL BIOL, V18, P1635, DOI 10.1128/MCB.18.3.1635; NYSTROMLAHTI M, 1995, NAT MED, V1, P1203, DOI 10.1038/nm1195-1203; NystromLahti M, 1996, HUM MOL GENET, V5, P763, DOI 10.1093/hmg/5.6.763; Ohmae S, 2006, J BIOL CHEM, V281, P20427, DOI 10.1074/jbc.M513212200; Ollikainen M, 2005, J CLIN ONCOL, V23, P4609, DOI 10.1200/JCO.2005.06.055; Peltomaki P, 2004, DIS MARKERS, V20, P269, DOI 10.1155/2004/305058; Peltomaki P, 2001, Fam Cancer, V1, P9, DOI 10.1023/A:1011564720772; Petkovski E, 2005, J FORENSIC SCI, V50, P535; Potocnik U, 2001, CANCER GENET CYTOGEN, V126, P85, DOI 10.1016/S0165-4608(00)00399-X; Protopopov A, 2003, CANCER RES, V63, P404; Raevaara TE, 2005, GASTROENTEROLOGY, V129, P537, DOI 10.1053/j.gastro.2005.06.005; Renkonen E, 2003, J CLIN ONCOL, V21, P3629, DOI 10.1200/JCO.2003.03.181; Satoh J, 2006, J NEUROSCI METH, V152, P278, DOI 10.1016/j.jneumeth.2005.09.015; SCHWWIZER P, 2001, CANCER RES, V61, P2183; Simpkins SB, 1999, HUM MOL GENET, V8, P661, DOI 10.1093/hmg/8.4.661; Suzuki H, 1996, BIOCHEM BIOPH RES CO, V229, P902, DOI 10.1006/bbrc.1996.1900; Takagi Y, 2003, DNA REPAIR, V2, P1135, DOI 10.1016/S1568-7864(03)00134-4; Tannergard P, 1997, HUM GENET, V101, P51, DOI 10.1007/s004390050585; Toyota M, 1999, P NATL ACAD SCI USA, V96, P8681, DOI 10.1073/pnas.96.15.8681; Utsuno Hajime, 2004, Bull Tokyo Dent Coll, V45, P33, DOI 10.2209/tdcpublication.45.33; van Puijenbroek M, 2005, J MOL DIAGN, V7, P623, DOI 10.1016/S1525-1578(10)60596-X; Veigl ML, 1998, P NATL ACAD SCI USA, V95, P8698, DOI 10.1073/pnas.95.15.8698; Wheeler JMD, 2000, J MED GENET, V37, P588, DOI 10.1136/jmg.37.8.588; Wijnen J, 1999, NAT GENET, V23, P142, DOI 10.1038/13773; Yuen ST, 2002, ONCOGENE, V21, P7585, DOI 10.1038/sj.onc.1205968; ZHANG J, 2006, CANCER RES, V66, P559	49	49	51	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL	2007	26	31					4541	4549		10.1038/sj.onc.1210236	http://dx.doi.org/10.1038/sj.onc.1210236			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	187GR	17260015				2022-12-28	WOS:000247836100008
J	Dawson, DW; Hong, JS; Shen, RR; French, SW; Troke, JJ; Wu, YZ; Chen, SS; Gui, D; Regelson, M; Marahrens, Y; Morse, HC; Said, J; Plass, C; Teitell, MA				Dawson, D. W.; Hong, J. S.; Shen, R. R.; French, S. W.; Troke, J. J.; Wu, Y-Z; Chen, S-S; Gui, D.; Regelson, M.; Marahrens, Y.; Morse, H. C., III; Said, J.; Plass, C.; Teitell, M. A.			Global DNA methylation profiling reveals silencing of a secreted form of Epha7 in mouse and human germinal center B-cell lymphomas	ONCOGENE			English	Article						DNA methylation; B-cell lymphoma; TCL1	RECEPTORS; EXPRESSION; EPHRINS; GENE; LEUKEMIA; ADHESION; CANCER; HYPERMETHYLATION; EPIGENETICS	Most human lymphomas originate from transformed germinal center (GC) B lymphocytes. While activating mutations and translocations of MYC, BCL2 and BCL6 promote specific GC lymphoma subtypes, other genetic and epigenetic modi. cations that contribute to malignant progression in the GC remain poorly defined. Recently, aberrant expression of the TCL1 proto-oncogene was identified in major GC lymphoma subtypes. TCL1 transgenic mice offer unique models of both aggressive GC and marginal zone B-cell lymphomas, further supporting a role for TCL1 in B-cell transformation. Here, restriction landmark genomic scanning was employed to discover tumor-associated epigenetic alterations in malignant GC and marginal zone B-cells in TCL1 transgenic mice. Multiple genes were identified that underwent DNA hypermethylation and decreased expression in TCL1 transgenic tumors. Further, we identified a secreted isoform of EPHA7, a member of the Eph family of receptor tyrosine kinases that are able to influence tumor invasiveness, metastasis and neovascularization. EPHA7 was hypermethylated and repressed in both mouse and human GC B-cell non-Hodgkin lymphomas, with the potential to influence tumor progression and spread. These data provide the first set of hypermethylated genes with the potential to complement TCL1-mediated GC B-cell transformation and spread.	Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA; Ohio State Univ, Div Human Canc Genet, Columbus, OH 43210 USA; Univ Calif Los Angeles, David Geffen Sch Med, Dept Human Genet, Los Angeles, CA USA; NIAID, Natl Inst Hlth, Immunopathol Lab, Rockville, MD USA; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, Inst Stem Cell Biol & Med, Los Angeles, CA USA; Univ Calif Los Angeles, Calif Nanosyst Inst, Los Angeles, CA USA; Univ Calif Los Angeles, Inst Cell Mimet Studies, Los Angeles, CA USA; Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90024 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University System of Ohio; Ohio State University; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles	Teitell, MA (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol & Lab Med, 10833 LeConte Ave,Mail Code 173216, Los Angeles, CA 90095 USA.	mteitell@ucla.edu	Dawson, David/I-5917-2014; Plass, Christoph/H-7192-2014	Morse, Herbert/0000-0002-9331-3705	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD041451] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA090571, T32CA009056, R01CA107300, T32CA009120] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [PN2EY018228] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000858] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM073981] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline; NCI NIH HHS [T32CA09056, R01 CA090571, R01 CA107300, T32CA009120, T32 CA009056, T32 CA009120] Funding Source: Medline; NEI NIH HHS [PN2 EY018228, PN2 EY018228-02] Funding Source: Medline; NICHD NIH HHS [HD041451, R01 HD041451] Funding Source: Medline; NIGMS NIH HHS [R01GM073981, R01 GM073981] Funding Source: Medline; PHS HHS [T32A107126] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Aasheim HC, 2000, BLOOD, V95, P221, DOI 10.1182/blood.V95.1.221.001k01_221_230; Aasheim HC, 1997, BLOOD, V90, P3613, DOI 10.1182/blood.V90.9.3613; Bichi R, 2002, P NATL ACAD SCI USA, V99, P6955, DOI 10.1073/pnas.102181599; Brantley DM, 2002, ONCOGENE, V21, P7011, DOI 10.1038/sj.onc.1205679; Cheng N, 2003, NEOPLASIA, V5, P445, DOI 10.1016/S1476-5586(03)80047-7; CIOSSEK T, 1995, ONCOGENE, V10, P97; Costello JF, 2000, NAT GENET, V24, P132, DOI 10.1038/72785; Costello JF, 2002, METHODS, V27, P144, DOI 10.1016/S1046-2023(02)00067-1; de Saint-Vis B, 2003, BLOOD, V102, P4431, DOI 10.1182/blood-2003-02-0500; Dobrzanski P, 2004, CANCER RES, V64, P910, DOI 10.1158/0008-5472.CAN-3430-2; Esteller M, 2003, CLIN IMMUNOL, V109, P80, DOI 10.1016/S1521-6616(03)00208-0; Esteller M, 2003, ADV EXP MED BIOL, V532, P39; Esteller M, 2002, J NATL CANCER I, V94, P26; Gale NW, 1996, NEURON, V17, P9, DOI 10.1016/S0896-6273(00)80276-7; Galm O, 2006, BLOOD REV, V20, P1, DOI 10.1016/j.blre.2005.01.006; Hafner C, 2004, CLIN CHEM, V50, P490, DOI 10.1373/clinchem.2003.026849; Herman JG, 1997, CANCER RES, V57, P837; Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075; Holmberg J, 2000, NATURE, V408, P203, DOI 10.1038/35041577; Holmberg J, 2002, TRENDS NEUROSCI, V25, P239, DOI 10.1016/S0166-2236(02)02149-5; Hoyer KK, 2002, P NATL ACAD SCI USA, V99, P14392, DOI 10.1073/pnas.212410199; Kent WJ, 2002, GENOME RES, V12, P656, DOI [10.1101/gr.229202, 10.1101/gr.229202. Article published online before March 2002]; Klein U, 2005, CURR TOP MICROBIOL, V294, P31, DOI 10.1007/3-540-29933-5_3; Kondo Y, 2004, CANCER METAST REV, V23, P29, DOI 10.1023/A:1025806911782; Narducci MG, 2000, CANCER RES, V60, P2095; Palmer A, 2003, GENE DEV, V17, P1429, DOI 10.1101/gad.1093703; Pasquale EB, 2005, NAT REV MOL CELL BIO, V6, P462, DOI 10.1038/nrm1662; Rush LJ, 2004, CANCER RES, V64, P2424, DOI 10.1158/0008-5472.CAN-03-2870; Rush LJ, 2002, CANCER LETT, V185, P1, DOI 10.1016/S0304-3835(02)00288-4; Rush LJ, 2001, BLOOD, V97, P3226, DOI 10.1182/blood.V97.10.3226; Said JW, 2001, LAB INVEST, V81, P555, DOI 10.1038/labinvest.3780264; Sharfe N, 2002, EUR J IMMUNOL, V32, P3745, DOI 10.1002/1521-4141(200212)32:12<3745::AID-IMMU3745>3.0.CO;2-M; Shen RR, 2006, BLOOD, V108, P1991, DOI 10.1182/blood-2006-02-001354; Surawska H, 2004, CYTOKINE GROWTH F R, V15, P419, DOI 10.1016/j.cytogfr.2004.09.002; Teitell M, 1999, P NATL ACAD SCI USA, V96, P9809, DOI 10.1073/pnas.96.17.9809; Teitell MA, 2005, NAT REV CANCER, V5, P640, DOI 10.1038/nrc1672; Wang JD, 2005, ONCOGENE, V24, P5637, DOI 10.1038/sj.onc.1208720; Wimmer-Kleikamp SH, 2005, IUBMB LIFE, V57, P421, DOI 10.1080/15216540500138337; Wu Jiangping, 2005, Curr Opin Hematol, V12, P292, DOI 10.1097/01.moh.0000166497.26397.9f; Yan XJ, 2006, P NATL ACAD SCI USA, V103, P11713, DOI 10.1073/pnas.0604564103; Yu L, 2005, NAT GENET, V37, P265, DOI 10.1038/ng1521	41	33	43	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 21	2007	26	29					4243	4252		10.1038/sj.onc.1210211	http://dx.doi.org/10.1038/sj.onc.1210211			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	184CY	17260020	Green Accepted			2022-12-28	WOS:000247619900007
J	de Cerio, ALD; Zabalegui, N; Rodriguez-Calvillo, M; Inoges, S; Bendandi, M				de Cerio, A. Lopez-Diaz; Zabalegui, N.; Rodriguez-Calvillo, M.; Inoges, S.; Bendandi, M.			Anti-idiotype antibodies in cancer treatment	ONCOGENE			English	Review						idiotype; lymphoma; solid tumors; immunotherapy	B-CELL LYMPHOMA; HUMORAL IMMUNE-RESPONSE; NON-HODGKINS-LYMPHOMA; COLONY-STIMULATING FACTOR; IDIOTYPE VACCINATION; DNA VACCINES; T-CELL; CLINICAL BENEFIT; DENDRITIC CELLS; HIGH-RISK	As a cancer immunotherapy tool, idiotypes (Ids) have been used in different ways over the last three decades, depending on the actual human tumor cell target. It all started with passive, monoclonal, anti-Id antibody treatment of B-cell lymphoma, a setting in which results were tantalizing, but logistics unsustainable. It then moved toward the development of anti-Id vaccines for the treatment of the same tumors, a setting in which we have recently provided the first formal proof of principle of clinical benefit associated with the use of a human cancer vaccine. Meanwhile, it also expanded in the direction of exploiting the antigenic mimicry of some Ids with Id-unrelated, tumor-associated antigens for the immunotherapy of a number of solid tumors, a setting in which clinical results are still far from being consolidated. All in all, over the years Id-based immunotherapy has paved the way for a number of seminal therapeutic improvements for cancer patients, including the development of most if not all Id-unrelated monoclonal antibodies that have recently revolutionized the field.	Univ Navarra, Unic Clin, Ctr Appl Med Res, Oncol Div,Lab Immunotherapy, Pamplona 31008, Spain; Univ Navarra, Unic Clin, Cell Therapy Area, Oncol Div,Lab Immunotherapy, Pamplona 31008, Spain	University of Navarra; University of Navarra	Bendandi, M (corresponding author), Univ Navarra, Unic Clin, Ctr Appl Med Res, Oncol Div,Lab Immunotherapy, Avda Pio XII,55 & 36, Pamplona 31008, Spain.	mbendandi@unav.es	Inogés, Susana/AAW-6785-2021					Alfonso M, 2002, J IMMUNOL, V168, P2523, DOI 10.4049/jimmunol.168.5.2523; ALLEBES W, 1991, LEUKEMIA RES, V15, P215, DOI 10.1016/0145-2126(91)90123-B; ALLEBES WA, 1990, SCAND J IMMUNOL, V32, P441, DOI 10.1111/j.1365-3083.1990.tb03184.x; Baral R, 2001, INT J CANCER, V92, P88, DOI 10.1002/1097-0215(200102)9999:9999<::AID-IJC1148>3.0.CO;2-9; Barrios Y, 2002, HAEMATOLOGICA, V87, P400; Bendandi M, 2006, LEUKEMIA LYMPHOMA, V47, P29, DOI 10.1080/10428190500272473; Bendandi M, 2001, Expert Rev Anticancer Ther, V1, P65, DOI 10.1586/14737140.1.1.65; Bendandi M, 1999, NAT MED, V5, P1171, DOI 10.1038/13928; Bendandi M, 2006, REV RECENT CLIN TRIA, V1, P67, DOI 10.2174/157488706775246120; Bendandi Maurizio, 2004, Expert Rev Vaccines, V3, P163, DOI 10.1586/14760584.3.2.163; Benvenuti F, 2000, GENE THER, V7, P605, DOI 10.1038/sj.gt.3301133; Bertinetti C, 2006, CANCER RES, V66, P4496, DOI 10.1158/0008-5472.CAN-05-4233; Bertinetti C, 2006, EUR J HAEMATOL, V77, P395, DOI 10.1111/j.1600-0609.2006.00740.x; Bhattacharya-Chatterjee M, 2002, EXPERT OPIN BIOL TH, V2, P869, DOI 10.1517/14712598.2.8.869; Birebent B, 2001, CRIT REV ONCOL HEMAT, V39, P107, DOI 10.1016/S1040-8428(01)00125-1; BIREBENT B, 2001, J CANCER RES CLIN, V2, P27; Caspar CB, 1997, BLOOD, V90, P3699, DOI 10.1182/blood.V90.9.3699; Chang CC, 2005, J BIOL CHEM, V280, P10164, DOI 10.1074/jbc.M409161200; Coscia M, 2004, LEUKEMIA, V18, P139, DOI 10.1038/sj.leu.2403181; Cull G, 1999, BRIT J HAEMATOL, V107, P648; Davis TA, 1998, BLOOD, V92, P1184, DOI 10.1182/blood.V92.4.1184.416k05_1184_1190; Diaz A, 2003, CLIN IMMUNOL, V107, P80, DOI 10.1016/S1521-6616(03)00036-6; Foon KA, 1997, CLIN CANCER RES, V3, P1267; Foon KA, 1999, J CLIN ONCOL, V17, P2889, DOI 10.1200/JCO.1999.17.9.2889; Guthmann MD, 2006, J IMMUNOTHER, V29, P215, DOI 10.1097/01.cji.0000188502.11348.34; Hawkins RE, 1997, HUM GENE THER, V8, P1287, DOI 10.1089/hum.1997.8.10-1287; Herlyn D, 1989, Viral Immunol, V2, P271, DOI 10.1089/vim.1989.2.271; Hsu FJ, 1997, BLOOD, V89, P3129, DOI 10.1182/blood.V89.9.3129; Hsu FJ, 1996, NAT MED, V2, P52, DOI 10.1038/nm0196-52; Hurvitz SA, 2005, EXPERT OPIN BIOL TH, V5, P841, DOI 10.1517/14712598.5.6.841; Inoges S, 2003, HAEMATOLOGICA, V88, P1438; Inoges S, 2006, J NATL CANCER I, V98, P1292, DOI 10.1093/jnci/djj358; King CA, 1998, NAT MED, V4, P1281, DOI 10.1038/3266; Kwak LW, 1996, P NATL ACAD SCI USA, V93, P10972, DOI 10.1073/pnas.93.20.10972; KWAK LW, 1992, NEW ENGL J MED, V327, P1209, DOI 10.1056/NEJM199210223271705; Longo DL, 2006, JNCI-J NATL CANCER I, V98, P1263, DOI 10.1093/jnci/djj371; Lutzky J, 2002, SEMIN ONCOL, V29, P462, DOI 10.1053/sonc.2002.35241; MALONEY DG, 1992, BLOOD, V80, P1502; Massaia M, 1999, BLOOD, V94, P673, DOI 10.1182/blood.V94.2.673.414k30_673_683; MEEKER T, 1985, NEW ENGL J MED, V312, P1658, DOI 10.1056/NEJM198506273122602; MILLER RA, 1982, NEW ENGL J MED, V306, P517, DOI 10.1056/NEJM198203043060906; MITTELMAN A, 1994, CANCER RES, V54, P415; Mittelman A, 1995, CLIN CANCER RES, V1, P705; MOHANTY K, 2006, BREAST CANC RES TREA; Mosolits S, 2004, CLIN CANCER RES, V10, P5391, DOI 10.1158/1078-0432.CCR-04-0425; Murray JL, 2004, CANCER RES, V64, P5481, DOI 10.1158/0008-5472.CAN-04-0517; Neelapu S, 2005, BONE MARROW TRANSPL, V36, P315, DOI 10.1038/sj.bmt.1705057; Neelapu Sattva S, 2005, Clin Lymphoma, V6, P61, DOI 10.3816/CLM.2005.n.031; Neelapu SS, 2005, NAT MED, V11, P986, DOI 10.1038/nm1290; Osterborg A, 1998, BLOOD, V91, P2459, DOI 10.1182/blood.V91.7.2459.2459_2459_2466; Pfisterer J, 2006, ANN ONCOL, V17, P1568, DOI 10.1093/annonc/mdl357; PIGNATARI GC, 2006, J BIOTECHNOL; RAFFELD M, 1985, NEW ENGL J MED, V312, P1653, DOI 10.1056/NEJM198506273122601; Rasmussen T, 2003, BLOOD, V101, P4607, DOI 10.1182/blood-2002-06-1925; Redfern CH, 2006, J CLIN ONCOL, V24, P3107, DOI 10.1200/JCO.2005.04.4289; Reece DE, 2000, BONE MARROW TRANSPL, V26, P729, DOI 10.1038/sj.bmt.1702607; REECE DE, 2001, CLIN BREAST CANCER, V1, P52; Reichardt VL, 1999, BLOOD, V93, P2411, DOI 10.1182/blood.V93.7.2411.407a24_2411_2419; Reichardt VL, 2003, HAEMATOLOGICA, V88, P1139; Reinartz S, 2004, CLIN CANCER RES, V10, P1580, DOI 10.1158/1078-0432.CCR-03-0056; Reinartz S, 2003, CANCER RES, V63, P3234; Sabbatini P, 2006, CLIN CANCER RES, V12, P5503, DOI 10.1158/1078-0432.CCR-05-2670; SAHA A, 2006, CANC IMMUNOL IMMUNOT; Saleh MN, 1998, J IMMUNOTHER, V21, P379, DOI 10.1097/00002371-199809000-00006; Savelyeva N, 2001, NAT BIOTECHNOL, V19, P760, DOI 10.1038/90816; SOMASUNDARAM R, 1995, J IMMUNOL, V155, P3253; STEVENSON FK, 1995, IMMUNOL REV, V145, P211, DOI 10.1111/j.1600-065X.1995.tb00083.x; STEVENSON FK, 1995, ANN NY ACAD SCI, V27, P212; SUGIYAMA T, 1991, J IMMUNOL, V146, P3097; Timmerman JM, 2002, BLOOD, V99, P1517, DOI 10.1182/blood.V99.5.1517; Timmerman John M, 2002, Curr Treat Options Oncol, V3, P307, DOI 10.1007/s11864-002-0030-3; Titzer S, 2000, BRIT J HAEMATOL, V108, P805, DOI 10.1046/j.1365-2141.2000.01958.x; ULLENHAG GJ, 2006, CLIN CANC RES; Weng WK, 2004, J CLIN ONCOL, V22, P4717, DOI 10.1200/JCO.2004.06.003; WENG WK, 2006, BLOOD; Zhu DL, 2001, TRENDS MOL MED, V7, P566, DOI 10.1016/S1471-4914(01)02126-8	76	44	51	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2007	26	25					3594	3602		10.1038/sj.onc.1210371	http://dx.doi.org/10.1038/sj.onc.1210371			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	172PK	17530013				2022-12-28	WOS:000246816100002
J	Pfeiffer, P; Qvortrup, C; Eriksen, JG				Pfeiffer, P.; Qvortrup, C.; Eriksen, J. G.			Current role of antibody therapy in patients with metastatic colorectal cancer	ONCOGENE			English	Review						metastatic colorectal cancer; antibodies; bevacizumab; cetuximab; panitumumab	GROWTH-FACTOR RECEPTOR; MULTICENTER PHASE-II; BEVACIZUMAB PLUS FLUOROURACIL; 1ST-LINE TREATMENT; RANDOMIZED-TRIAL; MONOCLONAL-ANTIBODY; BOLUS FLUOROURACIL; MOLECULAR DETERMINANTS; 3RD-LINE CHEMOTHERAPY; CONTINUOUS-INFUSION	In less than 10 years, the number and importance of nonsurgical treatment modalities in patients with colorectal cancer (CRC) have increased dramatically, both in the adjuvant and the advanced settings. However, despite the improvement of cytotoxic therapy in CRC, many patients still develop progressive disease and unfortunately in patients with disease resistant to 5-fluorouracil/folinic acid, irinotecan and oxaliplatin, no effective cytotoxic therapy is known. The rapidly expanding knowledge in tumor biology has encouraged optimism for the possibility to find and target tumor-specific mechanisms and thereby increase both efficacy and tolerance. A great number of 'targeted drugs' are being tested in clinical trials and some of these new drugs, like bevacizumab, cetuximab and panitumumab, are available for routine use in health care. These new targeted drugs will expand the therapeutic arsenal in CRC to a great extent, but they will also add to the complexity of treatment of CRC. In this review, we summarize the current status of antibody therapy in patients with CRC.	Odense Univ Hosp, Dept Oncol, DK-5000 Odense C, Denmark	University of Southern Denmark; Odense University Hospital	Pfeiffer, P (corresponding author), Odense Univ Hosp, Dept Oncol, Sdr Blvd 29, DK-5000 Odense C, Denmark.	per.pfeiffer@ouh.regionsyddanmark.dk	Qvortrup, Camilla/AAD-3366-2019	Qvortrup, Camilla/0000-0001-9338-9841; Pfeiffer, Per/0000-0002-2925-0586				Abubakr Y, 2006, J CLIN ONCOL, V24, p160S; Adam R, 2004, ANN SURG, V240, P644, DOI 10.1097/01.sla.0000141198.92114.16; Adams GP, 2001, CANCER RES, V61, P4750; Agero ALC, 2006, J AM ACAD DERMATOL, V55, P657, DOI 10.1016/j.jaad.2005.10.010; ANDRE T, 2007, P ASCO GI; Arnold D, 2006, ANN ONCOL, V17, pX122, DOI 10.1093/annonc/mdl249; Azuma M, 2006, CLIN COLORECTAL CANC, V6, P214, DOI 10.3816/CCC.2006.n.038; Barber TD, 2004, NEW ENGL J MED, V351, P2883, DOI 10.1056/NEJM200412303512724; Baselga J, 2000, J CLIN ONCOL, V18, P904, DOI 10.1200/JCO.2000.18.4.904; BERRY SR, 2006, P ASCO GI; Borner M, 2006, J CLIN ONCOL, V24, p158S; Bouche O, 2005, ANN ONCOL, V16, P1711, DOI 10.1093/annonc/mdi300; Busam KJ, 2001, BRIT J DERMATOL, V144, P1169, DOI 10.1046/j.1365-2133.2001.04226.x; Carmichael J, 2002, J CLIN ONCOL, V20, P3617, DOI 10.1200/JCO.2002.10.129; Carson EJ, 2005, J CLIN ONCOL, V23, p284S; Cassidy J, 2006, ANN ONCOL, V17; Chen HX, 2006, J CLIN ONCOL, V24, P3354, DOI 10.1200/JCO.2005.05.1573; Chong G, 2006, ANN ONCOL, V17, P437, DOI 10.1093/annonc/mdj090; Chung KY, 2005, J CLIN ONCOL, V23, P1803, DOI 10.1200/JCO.2005.08.037; Ciardiello F, 2003, EUR J CANCER, V39, P1348, DOI 10.1016/S0959-8049(03)00235-1; Cunningham D, 2004, NEW ENGL J MED, V351, P337, DOI 10.1056/NEJMoa033025; Cunningham D, 1998, LANCET, V352, P1413, DOI 10.1016/S0140-6736(98)02309-5; Cunningham MP, 2006, CANCER RES, V66, P7708, DOI 10.1158/0008-5472.CAN-06-1000; de Gramont A, 2000, J CLIN ONCOL, V18, P2938, DOI 10.1200/JCO.2000.18.16.2938; deGramont A, 1997, J CLIN ONCOL, V15, P808, DOI 10.1200/JCO.1997.15.2.808; Dittrich C, 2006, ANN ONCOL, V17, P24; Douillard JY, 2002, J CLIN ONCOL, V20, P3605, DOI 10.1200/JCO.2002.04.123; Douillard JY, 2000, LANCET, V355, P1041, DOI 10.1016/S0140-6736(00)02034-1; Ellis LM, 2005, J CLIN ONCOL, V23, P4853, DOI 10.1200/JCO.2005.23.754; Fakih MG, 2006, CLIN COLORECTAL CANC, V6, P152, DOI 10.3816/CCC.2006.n.033; Falcone A, 2006, J CLIN ONCOL, V24, p149S; Ferrara N, 2004, ENDOCR REV, V25, P581, DOI 10.1210/er.2003-0027; Folprecht G, 2005, ANN ONCOL, V16, P1311, DOI 10.1093/annonc/mdi246; Folprecht G, 2006, ANN ONCOL, V17, P450, DOI 10.1093/annonc/mdj084; Fuchs C, 2006, J CLIN ONCOL, V24, p147S; Fyfe GA, 2004, J CLIN ONCOL, V22, p274S; Giacchetti S, 2000, J CLIN ONCOL, V18, P136, DOI 10.1200/JCO.2000.18.1.136; Giantonio BJ, 2006, ANN ONCOL, V17, P1399, DOI 10.1093/annonc/mdl161; Giantonio BJ, 2005, J CLIN ONCOL, V23, p1S; GIANTONIO BJ, 2006, J CLIN ONCOL, V24; Gibson TB, 2006, CLIN COLORECTAL CANC, V6, P29, DOI 10.3816/CCC.2006.n.01; GLIMELIUS B, 2005, EUR J CANC S, V3; Goldberg RM, 2004, J CLIN ONCOL, V22, P23, DOI 10.1200/JCO.2004.09.046; Grabau DA, 1998, APPL IMMUNOHISTOCHEM, V6, P209, DOI 10.1097/00022744-199812000-00006; Grothey A, 2004, J CLIN ONCOL, V22, P1209, DOI 10.1200/JCO.2004.11.037; Grothey A, 2005, J CLIN ONCOL, V23, P9441, DOI 10.1200/JCO.2005.04.4792; Grothey A, 2002, P AM SOC CLIN ONCOL, V21; GROTHEY A, 2003, EUR J CANC, V90; Gruenberger T, 2006, J CLIN ONCOL, V24, P2592, DOI 10.1200/JCO.2005.05.2910; HAMBLETON J, 2005, J CLIN ONCOL, V23; HAMBLETON J, 2004, J CLIN ONCOL, V22; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HARARI PM, 2003, P AM SOC CLIN ONCOL, V22; Hebbar M, 2006, ANTI-CANCER DRUG, V17, P855, DOI 10.1097/01.cad.0000217425.44584.9f; Hecht J, 2006, J CLIN ONCOL, V24, p157S; HECHT J, 2006, P ASCO GI; HEDRICK E, 2004, J CLIN ONCOL, V22; HEINEMANN V, 2006, J CLIN ONCOL, V24; Hicklin DJ, 2005, J CLIN ONCOL, V23, P1011, DOI 10.1200/JCO.2005.06.081; Hillner BE, 2005, CANCER-AM CANCER SOC, V104, P1871, DOI 10.1002/cncr.21411; Ho C, 2006, J CLIN ONCOL, V24, P3214, DOI 10.1200/JCO.2006.06.5128; HOLDEN SN, 2005, J CLIN ONCOL, V23; Howdieshell TR, 2001, J SURG RES, V96, P173, DOI 10.1006/jsre.2001.6089; Huang SM, 2004, CANCER RES, V64, P5355, DOI 10.1158/0008-5472.CAN-04-0562; HUMBLET Y, 2005, J CLIN ONCOL, V23; Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691; Ince WL, 2005, JNCI-J NATL CANCER I, V97, P981, DOI 10.1093/jnci/dji174; JENNIS A, 2005, J CLIN ONCOL, V23; Jubb AM, 2006, J CLIN ONCOL, V24, P217, DOI 10.1200/JCO.2005.01.5388; Kabbinavar F, 2003, J CLIN ONCOL, V21, P60, DOI 10.1200/JCO.2003.10.066; Kabbinavar FF, 2005, J CLIN ONCOL, V23, P3697, DOI 10.1200/JCO.2005.05.112; Kemeny N, 2004, J CLIN ONCOL, V22, P4753, DOI 10.1200/JCO.2004.03.119; Kohne CH, 2003, J CLIN ONCOL, V21, P3721, DOI 10.1200/JCO.2003.11.122; KOZLOFF M, 2006, J CLIN ONCOL, V24; KRETZSCHMAR A, 2006, ASCO GI; KUBICKA S, 2006, ASCO GI; LABIANCA R, 2006, J CLIN ONCOL, V24; Lenz HJ, 2006, J CLIN ONCOL, V24, P4914, DOI 10.1200/JCO.2006.06.7595; Leung RC, 2007, J CLIN ONCOL, V25; Lim DH, 2005, CANCER CHEMOTH PHARM, V56, P10, DOI 10.1007/s00280-004-0963-2; Luo FR, 2005, CLIN CANCER RES, V11, P5558, DOI 10.1158/1078-0432.CCR-05-0368; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Lyseng-Williamson KA, 2006, AM J CANC, V5, P43; Maindrault-Goebel F, 2007, J CLIN ONCOL, V25; Malik I, 2005, J CLIN ONCOL, V23, p251S; Matar P, 2004, CLIN CANCER RES, V10, P6487, DOI 10.1158/1078-0432.CCR-04-0870; Meropol NJ, 2005, J CLIN ONCOL, V23, P1791, DOI 10.1200/JCO.2005.10.951; Meyerhardt JA, 2005, NEW ENGL J MED, V352, P476, DOI 10.1056/NEJMra040958; MINERS AH, 2005, BMJ-BRIT MED J, V330, P365; MORELLI MP, 2006, J CLIN ONCOL, V24; Moroni M, 2005, LANCET ONCOL, V6, P279, DOI 10.1016/S1470-2045(05)70102-9; NOVOTNY WF, 2004, J CLIN ONCOL, V22; Nygren P, 2005, ACTA ONCOL, V44, P203, DOI 10.1080/02841860510029798; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Paramore LC, 2006, CLIN COLORECTAL CANC, V6, P52, DOI 10.3816/CCC.2006.n.021; PEETERS M, 2006, PHASE 3 MULTICENTER; Perez-Soler R, 2006, J CLIN ONCOL, V24, p129S; Personeni N, 2005, SEMIN ONCOL, V32, pS59, DOI 10.1053/j.seminoncol.2005.04.029; Pfeiffer P, 2006, ANN ONCOL, V17, P252, DOI 10.1093/annonc/mdj060; PFEIFFER P, 2007, P ASCO GI; PFEIFFER P, 2007, IN PRESS ACTA ONCOL; PITOT HC, 2005, J CLIN ONCOL, V23; Punt CJA, 2002, LANCET, V360, P671, DOI 10.1016/S0140-6736(02)09836-7; Ragnhammar P, 2001, ACTA ONCOL, V40, P282, DOI 10.1080/02841860151116367; Repertinger SK, 2004, J INVEST DERMATOL, V123, P982, DOI 10.1111/j.0022-202X.2004.23478.x; Robert C, 2005, LANCET ONCOL, V6, P491, DOI 10.1016/S1470-2045(05)70243-6; Rosati G, 2003, ANTICANCER RES, V23, P2981; Rothenberg ML, 2003, J CLIN ONCOL, V21, P2059, DOI 10.1200/JCO.2003.11.126; Rougier P, 1998, LANCET, V352, P1407, DOI 10.1016/S0140-6736(98)03085-2; ROUGIER P, 2004, J CLIN ONCOL, V23; Saif MW, 2006, CLIN COLORECTAL CANC, V6, P118, DOI 10.3816/CCC.2006.n.028; SALOMON DS, 1995, CRIT REV ONCOL HEMAT, V19, P183, DOI 10.1016/1040-8428(94)00144-I; Saltz L., 2001, P AM SOC CLIN ONCOL, V20, p3a; Saltz LB, 2004, J CLIN ONCOL, V22, P1201, DOI 10.1200/JCO.2004.10.182; Saltz LB, 2000, NEW ENGL J MED, V343, P905, DOI 10.1056/NEJM200009283431302; SALTZ LB, 2005, J CLIN ONCOL, V23; SALTZ LB, 2006, J CLIN ONCOL, V24; Saunders M, 2006, BRIT J CANCER, V95, P131, DOI 10.1038/sj.bjc.6603233; Scappaticci FA, 2005, J SURG ONCOL, V91, P173, DOI 10.1002/jso.20301; Scartozzi M, 2004, J CLIN ONCOL, V22, P4772, DOI 10.1200/JCO.2004.00.117; Schrag D, 2005, J NATL CANCER I, V97, P1221, DOI 10.1093/jnci/dji242; Schrag D, 2004, NEW ENGL J MED, V351, P317, DOI 10.1056/NEJMp048143; Shia J, 2005, MODERN PATHOL, V18, P1350, DOI 10.1038/modpathol.3800417; Skillings JR, 2005, J CLIN ONCOL, V23, p196S; Sorbye H, 2004, J CLIN ONCOL, V22, P31, DOI 10.1200/JCO.2004.05.188; Souglakos J, 2006, BRIT J CANCER, V94, P798, DOI 10.1038/sj.bjc.6603011; Starling Naureen, 2005, Curr Oncol Rep, V7, P173, DOI 10.1007/s11912-005-0070-5; Stern M, 2005, CRIT REV ONCOL HEMAT, V54, P11, DOI 10.1016/j.critrevonc.2004.10.011; Sugrue M, 2006, J CLIN ONCOL, V24, p154S; TABERNERO J, 2006, J CLIN ONCOL, V24; Tabernero JM, 2004, J CLIN ONCOL, V22, p248S; Tonra JR, 2006, CLIN CANCER RES, V12, P2197, DOI 10.1158/1078-0432.CCR-05-1682; Tournigand C, 2004, J CLIN ONCOL, V22, P229, DOI 10.1200/JCO.2004.05.113; Tsuchihashi Z, 2005, NEW ENGL J MED, V353, P208, DOI 10.1056/NEJM200507143530218; Vallbohmer D, 2005, J CLIN ONCOL, V23, P3536, DOI 10.1200/jco.2005.23.16_suppl.3536; Van Cutsem E, 2004, BRIT J CANCER, V90, P1190, DOI 10.1038/sj.bjc.6601676; Van Cutsem E, 2006, EUR J CANCER, V42, P2212, DOI 10.1016/j.ejca.2006.04.012; van Doorn R, 2002, BRIT J DERMATOL, V147, P598, DOI 10.1046/j.1365-2133.2002.04864.x; VANCUTSEM E, 2007, P ASCO GI; VANCUTSEM E, 2007, P ASCO GI 2007; Venook A, 2006, J CLIN ONCOL, V24, p148S; Veronese ML, 2004, EUR J CANCER, V40, P1292, DOI 10.1016/j.ejca.2004.02.014; Vincenzi B, 2006, BRIT J CANCER, V94, P792, DOI 10.1038/sj.bjc.6603018; Vincenzi B, 2006, Ann Oncol, V17, P527, DOI 10.1093/annonc/mdj014; Vincenzi B, 2006, ANN ONCOL, V17, P835, DOI 10.1093/annonc/mdl031; Wilke H, 2006, J CLIN ONCOL, V24, p158S; Willett CG, 2004, NAT MED, V10, P145, DOI 10.1038/nm988; Yamamoto Deanna Sanchez, 2004, Clin J Oncol Nurs, V8, P654	148	41	44	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2007	26	25					3661	3678		10.1038/sj.onc.1210377	http://dx.doi.org/10.1038/sj.onc.1210377			18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	172PK	17530020				2022-12-28	WOS:000246816100009
J	Wada, T; Hata, K; Yamaguchi, K; Shiozaki, K; Koseki, K; Moriya, S; Miyagi, T				Wada, T.; Hata, K.; Yamaguchi, K.; Shiozaki, K.; Koseki, K.; Moriya, S.; Miyagi, T.			A crucial role of plasma membrane-associated sialidase in the survival of human cancer cells	ONCOGENE			English	Article						sialidase; apoptosis; cancer; gangliosides; Ras; EGFR	GROWTH-FACTOR RECEPTOR; GANGLIOSIDE SIALIDASE; MOLECULAR-CLONING; GM3; GLYCOSYLATION; EXPRESSION; PHOSPHORYLATION; APOPTOSIS; NEU3; OVEREXPRESSION	Human plasma membrane-associated sialidase (NEU3), a key enzyme for ganglioside degradation, is markedly upregulated in human cancers, leading to apoptosis suppression. To de. ne molecular mechanisms and the possible target for NEU3, its encoding gene was silenced by small interference RNA (siRNA) or overexpressed in human cells. NEU3 siRNA-induced apoptosis with no special stimuli in HeLa cells, accompanied with decreased Bcl-xL and increased mda7 and GM3 synthase mRNA levels, whereas overexpression resulted in the opposite. Carcinoma HT-29 and MCF-7 cells appeared to be similarly affected, but normal cell lines demonstrated no significant changes. NEU3 siRNA was found to inhibit and NEU3 overexpression to stimulate Ras activation with consequent influence on extracellular signal-regulated kinases and Akt. Ras activation by NEU3 was abrogated by PP2 (src inhibitor) or AG1478 (epidermal growth factor receptor (EGFR) inhibitor), and NEU3 actually enhanced EGF-stimulated tyrosine-phosphorylation of EGFR, suggesting that the upstream targets might be tyrosine kinases including src and EGFR, and the subsequent stimulation of Ras cascade leads to the inhibition of cell apoptosis. Glycolipid changes observed seemed to be one of the causes of the cell effects. NEU3 may thus be an essential gene for cancer cell survival and siRNAs targeting this protein could have utility for gene-based therapy of human cancers.	Miyagi Canc Ctr, Inst Res, Div Biochem, Natori, Miyagi 9811293, Japan	Miyagi Cancer Center	Miyagi, T (corresponding author), Miyagi Canc Ctr, Inst Res, Div Biochem, 47-1 Nodayama, Natori, Miyagi 9811293, Japan.	miyagi-ta173@pref.miyagi.jp		Shiozaki, Kazuhiro/0000-0002-0523-838X				Adjei AA, 2001, JNCI-J NATL CANCER I, V93, P1062, DOI 10.1093/jnci/93.14.1062; Allan LA, 2003, NAT CELL BIOL, V5, P647, DOI 10.1038/ncb1005; Biscardi JS, 1999, J BIOL CHEM, V274, P8335, DOI 10.1074/jbc.274.12.8335; BREMER EG, 1986, J BIOL CHEM, V261, P2434; Cox AD, 2003, ONCOGENE, V22, P8999, DOI 10.1038/sj.onc.1207111; Da Silva JS, 2005, NAT NEUROSCI, V8, P606, DOI 10.1038/nn1442; Dennis JW, 1999, BBA-GEN SUBJECTS, V1473, P21, DOI 10.1016/S0304-4165(99)00167-1; Dent P, 2005, J CELL BIOCHEM, V95, P712, DOI 10.1002/jcb.20502; Hakomori S, 1996, CANCER RES, V56, P5309; Hakomori S, 2002, P NATL ACAD SCI USA, V99, P10231, DOI 10.1073/pnas.172380699; Hasegawa T, 2000, J BIOL CHEM, V275, P8007, DOI 10.1074/jbc.275.11.8007; Holmstrom TH, 1999, MOL CELL BIOL, V19, P5991; Kakugawa Y, 2002, P NATL ACAD SCI USA, V99, P10718, DOI 10.1073/pnas.152597199; Kato K, 2006, BIOCHEM J, V394, P647, DOI 10.1042/BJ20050737; Kim YJ, 1997, GLYCOCONJUGATE J, V14, P569, DOI 10.1023/A:1018580324971; LI K, 1992, J CHROMATOGR-BIOMED, V579, P209, DOI 10.1016/0378-4347(92)80384-3; MACALA LJ, 1983, J LIPID RES, V24, P1243; MANGENEY M, 1991, EUR J IMMUNOL, V21, P1131, DOI 10.1002/eji.1830210507; Miura Y, 2004, P NATL ACAD SCI USA, V101, P16204, DOI 10.1073/pnas.0407297101; Miyagi T, 2004, TRENDS GLYCOSCI GLYC, V16, P371, DOI 10.4052/tigg.16.371; Miyagi T, 2003, GLYCOCONJUGATE J, V20, P189, DOI 10.1023/B:GLYC.0000024250.48506.bf; Miyagi T, 1999, J BIOL CHEM, V274, P5004, DOI 10.1074/jbc.274.8.5004; Monti E, 2000, BIOCHEM J, V349, P343, DOI 10.1042/0264-6021:3490343; Monti E, 2002, NEUROCHEM RES, V27, P649, DOI 10.1023/A:1020276000901; Sasaki A, 2003, J BIOL CHEM, V278, P27896, DOI 10.1074/jbc.M212200200; Sohn H, 2006, FASEB J, V20, P1248, DOI 10.1096/fj.05-4911fje; Testa JR, 2001, P NATL ACAD SCI USA, V98, P10983, DOI 10.1073/pnas.211430998; Tran SEF, 2001, J BIOL CHEM, V276, P16484, DOI 10.1074/jbc.M010384200; Ueno S, 2006, J BIOL CHEM, V281, P7756, DOI 10.1074/jbc.M509668200; Valaperta R, 2006, FASEB J, V20, P1227, DOI 10.1096/fj.05-5077fje; Wada T, 1999, BIOCHEM BIOPH RES CO, V261, P21, DOI 10.1006/bbrc.1999.0973; Wang XQ, 2003, J BIOL CHEM, V278, P48770, DOI 10.1074/jbc.M308818200; Wang Y, 2002, J BIOL CHEM, V277, P26252, DOI 10.1074/jbc.M110515200; Watanabe R, 2002, CANCER RES, V62, P3850; Yamaguchi K, 2005, BIOCHEM J, V390, P85, DOI 10.1042/BJ20050017	35	81	103	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 12	2007	26	17					2483	2490		10.1038/sj.onc.1210341	http://dx.doi.org/10.1038/sj.onc.1210341			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	158YG	17334392				2022-12-28	WOS:000245831000008
J	Rigas, AC; Robson, CN; Curtin, NJ				Rigas, A. C.; Robson, C. N.; Curtin, N. J.			Therapeutic potential of CDK inhibitor NU2058 in androgen-independent prostate cancer	ONCOGENE			English	Article						androgen-independent prostate cancer; bicalutamide; cyclin-dependent kinase inhibitor; LNCaP	GROWTH-INHIBITION; CYCLIN; RECEPTOR; CELLS; BICALUTAMIDE; EXPRESSION; P27(KIP1); PHOSPHORYLATION; PROGRESSION; ANTAGONIST	Antiandrogens are initially effective in controlling prostate cancer (CaP), the second most common cancer in men, but resistance, associated with the loss of androgen-regulated cell cycle control, is a major problem. At present there is no effective treatment for androgen-independent prostate cancer ( AIPC). Cellular proliferation is driven by cyclin-dependent kinases (CDKs) with kinase inhibitors (for example, p27) applying the breaks. We present the first investigation of the therapeutic potential of CDK inhibitors, using the guanine-based CDK inhibitor NU2058 (CDK2 IC50=17 mu M, CDK1 IC50 26 mu M), in comparison with the antiandrogen bicalutamide ( Casodex) in AIPC cells. A panel of AIPC cells was found to be resistant to Casodex-induced growth inhibition, but with the exception of PC3 (GI(50)=38 mu M) and CWR22Rv1 (GI(50)=46 mu M) showed similar sensitivity to NU2058 (GI(50)=10-17 mu M) compared to androgen-sensitive LNCaP cells (GI(50)=15 mu M). In LNCaP cells and their Casodex-resistant derivative, LNCaP-cdxR, growth inhibition by NU2058 was accompanied by a concentration-dependent increase in p27 levels, reduced CDK2 activity and pRb phosphorylation, a decrease in early gene expression and G1 cell cycle phase arrest in both cell lines. In response to Casodex, there were similar observations in LNCaP cells ( GI(50)=6 +/- 3 mu M Casodex) but not in LNCaP-cdxR cells (GI(50)=24 +/- 5 lM Casodex).	[Rigas, A. C.; Robson, C. N.; Curtin, N. J.] Newcastle Univ, No Inst Canc Res, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England	Newcastle University - UK	Curtin, NJ (corresponding author), Newcastle Univ, No Inst Canc Res, Paul OGorman Bldg,Framlington Pl, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.	n.j.curtin@ncl.ac.uk		Curtin, Nicola/0000-0003-1369-1843	MRC [G0500966] Funding Source: UKRI; Medical Research Council [G0500966] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Aleem E, 2005, NAT CELL BIOL, V7, P831, DOI 10.1038/ncb1284; Angus SP, 2002, J BIOL CHEM, V277, P44376, DOI 10.1074/jbc.M205911200; Arris CE, 2000, J MED CHEM, V43, P2797, DOI 10.1021/jm990628o; Cai DP, 2006, CANCER RES, V66, P9270, DOI 10.1158/0008-5472.CAN-06-1758; Drees M, 1997, CLIN CANCER RES, V3, P273; Edwards BK, 2005, JNCI-J NATL CANCER I, V97, P1407, DOI 10.1093/jnci/dji289; Feldman BJ, 2001, NAT REV CANCER, V1, P34, DOI 10.1038/35094009; Ferrando AA, 1996, HUM GENET, V97, P91; Gregory CW, 2001, J ANDROL, V22, P537; Guo YP, 1997, CLIN CANCER RES, V3, P2269; Halkidou K, 2003, ONCOGENE, V22, P2466, DOI 10.1038/sj.onc.1206342; Hara T, 2003, CANCER RES, V63, P149; Harbour JW, 1999, CELL, V98, P859, DOI 10.1016/S0092-8674(00)81519-6; Hardcastle IR, 2004, J MED CHEM, V47, P3710, DOI 10.1021/jm0311442; Hu B, 2001, MOL CELL BIOL, V21, P2755, DOI 10.1128/MCB.21.8.2755-2766.2001; Karan D, 2002, CARCINOGENESIS, V23, P967, DOI 10.1093/carcin/23.6.967; KAWAMATA N, 1995, CANCER RES, V55, P2266; Knillova J, 2004, NEOPLASMA, V51, P358; Knudsen ES, 1997, MOL CELL BIOL, V17, P5771, DOI 10.1128/MCB.17.10.5771; Kokontis JM, 2005, PROSTATE, V65, P287, DOI 10.1002/pros.20285; Li YW, 2000, INT J ONCOL, V17, P755; Macri E, 1998, CANCER METAST REV, V17, P337, DOI 10.1023/A:1006133620914; Masiello D, 2002, J BIOL CHEM, V277, P26321, DOI 10.1074/jbc.M203310200; Montagnoli A, 1999, GENE DEV, V13, P1181, DOI 10.1101/gad.13.9.1181; PONCECASTANEDA MV, 1995, CANCER RES, V55, P1211; SKEHAN P, 1990, J NATL CANCER I, V82, P1107, DOI 10.1093/jnci/82.13.1107; Taneja SS, 2002, J CELL BIOCHEM, V84, P188, DOI 10.1002/jcb.1278; Tepper CG, 2002, CANCER RES, V62, P6606; Tetsu O, 2003, CANCER CELL, V3, P233, DOI 10.1016/S1535-6108(03)00053-9	29	25	26	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 6	2007	26	55					7611	7619		10.1038/sj.onc.1210586	http://dx.doi.org/10.1038/sj.onc.1210586			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	239SK	17599054				2022-12-28	WOS:000251537800002
J	Jin, H; Wang, X; Ying, J; Wong, AHY; Li, H; Lee, KY; Srivastava, G; Chan, ATC; Yeo, W; Ma, BBY; Putti, TC; Lung, ML; Shen, ZY; Xu, LY; Langford, C; Tao, Q				Jin, H.; Wang, X.; Ying, J.; Wong, A. H. Y.; Li, H.; Lee, K. Y.; Srivastava, G.; Chan, A. T. C.; Yeo, W.; Ma, B. B. Y.; Putti, T. C.; Lung, M. L.; Shen, Z-Y; Xu, L-Y; Langford, C.; Tao, Q.			Epigenetic identification of ADAMTS18 as a novel 16q23.1 tumor suppressor frequently silenced in esophageal, nasopharyngeal and multiple other carcinomas	ONCOGENE			English	Article						ADAMTS18; methylation; tumor suppressor gene; carcinoma; promoter	STRESS-RESPONSIVE GENE; METHYLATION STATUS; HUMAN BREAST; CANCER; DNA; EXPRESSION; HYPERMETHYLATION; METALLOPROTEINASES; TRANSFORMATION; TUMORIGENESIS	Tumor suppressor genes (TSGs) often locate at chromosomal regions with frequent deletions in tumors. Loss of 16q23 occurs frequently in multiple tumors, indicating the presence of critical TSGs at this locus, such as the well-studied WWOX. Herein, we found that ADAMTS18, located next to WWOX, was significantly downregulated in multiple carcinoma cell lines. No deletion of ADAMTS18 was detected with multiplex differential DNA-PCR or high-resolution 1-Mb array-based comparative genomic hybridization (CGH) analysis. Instead, methylation of the ADAMTS18 promoter CpG Island was frequently detected with methylation-specific PCR and bisulfite genome sequencing in multiple carcinoma cell lines and primary carcinomas, but not in any nontumor cell line and normal epithelial tissue. Both pharmacological and genetic demethylation dramatically induced the ADAMTS18 expression, indicating that CpG methylation directly contributes to the tumor-specific silencing of ADAMTS18. Ectopic ADAMTS18 expression led to significant inhibition of both anchorage-dependent and - independent growth of carcinoma cells lacking the expression. Thus, through functional epigenetics, we identified ADAMTS18 as a novel functional tumor suppressor, being frequently inactivated epigenetically in multiple carcinomas.	Chinese Univ Hong Kong, Hong Kong Canc Inst & Li Ka Shing Inst Hlth Sci, Dept Clin Oncol, Sir YK Pao Ctr Canc State Key Lab Oncol S China, Hong Kong, Peoples R China; Univ Hong Kong, Dept Pathol, Hong Kong, Peoples R China; Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Pathol, Singapore, Singapore; Hong Kong Univ Sci & Technol, Canc Res Ctr, Dept Biol, Hong Kong, Peoples R China; Shantou Univ, Coll Med, SUMC CUHK Joint Epigenet Grp, Shantou, Peoples R China; Well Trust Sanger Inst, Microarray Facil, Cambridge, England	Chinese University of Hong Kong; University of Hong Kong; National University of Singapore; Hong Kong University of Science & Technology; Shantou University; Wellcome Trust Sanger Institute	Tao, Q (corresponding author), Chinese Univ Hong Kong, Dept Clin Oncol, Ctr Canc, PWH, Rm 315, Shatin, Hong Kong, Peoples R China.	qtao@clo.cuhk.edu.hk	Jin, Hongchuan/C-3686-2009; Tao, Qian/T-4743-2018; Chan, Anthony Tak Cheung/R-3940-2018; Yeo, Winnie/R-4792-2018; B.Y., Brigette/H-4681-2017; Lung, Maria Li/C-4495-2009	Tao, Qian/0000-0001-5383-4808; Chan, Anthony Tak Cheung/0000-0002-6912-8091; Yeo, Winnie/0000-0002-0863-8469; B.Y., Brigette/0000-0003-4802-1102; Lung, Maria Li/0000-0003-2559-3626; Jin, Hongchuan/0000-0002-6697-3097; Wang, Xian/0000-0003-0041-7589	Wellcome Trust [079643] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Balsara BR, 2001, GENE CHROMOSOME CANC, V30, P245, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1083>3.0.CO;2-M; Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X; Bishop JM, 1996, FASEB J, V10, P362, DOI 10.1096/fasebj.10.2.8641572; BUSSON P, 1988, INT J CANCER, V42, P599, DOI 10.1002/ijc.2910420422; Cal S, 2002, GENE, V283, P49, DOI 10.1016/S0378-1119(01)00861-7; Cottrell SE, 2003, ANN NY ACAD SCI, V983, P120, DOI 10.1111/j.1749-6632.2003.tb05967.x; Cui Y, 2007, LAB INVEST; Deng W, 2004, ONCOGENE, V23, P9090, DOI 10.1038/sj.onc.1208119; Dunn JR, 2004, BRIT J CANCER, V91, P1149, DOI 10.1038/sj.bjc.6602107; Gius D, 2005, CANCER, V104, P1789, DOI 10.1002/cncr.21395; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Jin HC, 2006, NATURE, V442, P576, DOI 10.1038/nature04856; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Knudson AG, 2001, NAT REV CANCER, V1, P157, DOI 10.1038/35101031; Lind GE, 2006, CELL ONCOL, V28, P259; Lo KW, 2000, CANCER RES, V60, P3348; Lo PHY, 2007, ONCOGENE, V26, P148, DOI 10.1038/sj.onc.1209767; Luque A, 2003, J BIOL CHEM, V278, P23656, DOI 10.1074/jbc.M212964200; Masui T, 2001, CLIN CANCER RES, V7, P3437; Morin D, 1999, PC WEEK, V16, P80; Nakata S, 2006, CANCER-AM CANCER SOC, V106, P2190, DOI 10.1002/cncr.21870; Paige AJW, 2001, P NATL ACAD SCI USA, V98, P11417, DOI 10.1073/pnas.191175898; Pinkel D, 1998, NAT GENET, V20, P207, DOI 10.1038/2524; Ponder BAJ, 2001, NATURE, V411, P336, DOI 10.1038/35077207; Porter S, 2004, CLIN CANCER RES, V10, P2429, DOI 10.1158/1078-0432.CCR-0398-3; Porter S, 2005, BIOCHEM J, V386, P15, DOI 10.1042/BJ20040424; Qiu GH, 2004, ONCOGENE, V23, P4793, DOI 10.1038/sj.onc.1207632; Riegman PHJ, 2001, CANCER RES, V61, P3164; Seng TJ, 2007, ONCOGENE, V26, P934, DOI 10.1038/sj.onc.1209839; Sjoblom T, 2006, SCIENCE, V314, P268, DOI 10.1126/science.1133427; Tao Q, 1999, AM J PATHOL, V155, P619, DOI 10.1016/S0002-9440(10)65157-7; Tao Q, 2002, HUM MOL GENET, V11, P2091, DOI 10.1093/hmg/11.18.2091; Ying J, 2006, ONCOGENE, V25, P1070, DOI 10.1038/sj.onc.1209154; Ying JM, 2005, CLIN CANCER RES, V11, P6442, DOI 10.1158/1078-0432.CCR-05-0267; Zhou L, 2005, NEOPLASIA, V7, P809, DOI 10.1593/neo.05217	35	90	94	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 22	2007	26	53					7490	7498		10.1038/sj.onc.1210559	http://dx.doi.org/10.1038/sj.onc.1210559			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	236DA	17546048	Green Accepted			2022-12-28	WOS:000251282000010
J	Salon, C; Merdzhanova, G; Brambilla, C; Brambilla, E; Gazzeri, S; Eymin, B				Salon, C.; Merdzhanova, G.; Brambilla, C.; Brambilla, E.; Gazzeri, S.; Eymin, B.			E2F-1, Skp2 and cyclin E oncoproteins are upregulated and directly correlated in high-grade neuroendocrine lung tumors	ONCOGENE			English	Article						cyclin E; E2F-1; Skp2; lung tumors	BOX PROTEIN SKP2; CELL; DEGRADATION; OVEREXPRESSION; EXPRESSION; TARGET; CARCINOMA; BINDS; GENE; SCF	The transcription factor E2F-1 plays a crucial role in the control of cellular growth. We previously reported its differential pattern of expression in human lung tumors. In this study, we have investigated the relationships linking the status of E2F-1 and a mediator of its proteasomal degradation, the S-phase kinase-associated protein 2 (Skp2) F-box protein. Using immunohistochemistry in a series of 129 lung tumors of all histological types, we demonstrate that Skp2 accumulates preferentially in high-grade neuroendocrine (HGNE) lung carcinomas (86%, P<0.0001), and show that Skp2 overexpression is associated with advanced stages (P<0.0001) and nodal metastasis (P<0.0001) in neuroendocrine (NE) lung tumors. Unexpectedly, we observe that Skp2 and E2F-1 expression directly correlates in NE lung tumors (P<0.0001). Moreover, using cellular models, we identify Skp2 as a new E2F-1 transcriptional target. Furthermore, we also provide evidence that Skp2 interacts physiologically with E2F-1 and stimulates its transcriptional activity toward the cyclin E promoter. Consistently, we demonstrate that cyclin E expression directly correlates with Skp2 (P<0.0001) and E2F-1 (P = 0.0001) status in NE lung tumors. Overall, our data provide the first evidence of a direct and functional interconnection between the E2F-1, Skp2 and cyclin E oncoproteins in HGNE lung carcinomas.	Inst Albert Bonniot, INSERM, Equipe Bases Mol Progress Canc Poumon, Ctr Rech,U823, F-38042 Grenoble 09, France; Univ Grenoble 1, Grenoble, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA)	Eymin, B (corresponding author), Inst Albert Bonniot, INSERM, Equipe Bases Mol Progress Canc Poumon, Ctr Rech,U823, BP170, F-38042 Grenoble 09, France.	Beatrice.Eymin@ujf-grenoble.fr	Eymin, Beatrice/M-1962-2013; gazzeri, sylvie/U-4669-2019; eymin, beatrice/U-4670-2019; gazzeri, sylvie/M-1961-2013	Eymin, Beatrice/0000-0002-7311-3810; gazzeri, sylvie/0000-0001-5817-1839; eymin, beatrice/0000-0002-7311-3810; gazzeri, sylvie/0000-0001-5817-1839				Bai C, 1996, CELL, V86, P263, DOI 10.1016/S0092-8674(00)80098-7; Brambilla E, 1999, J PATHOL, V188, P351, DOI 10.1002/(SICI)1096-9896(199908)188:4<351::AID-PATH385>3.0.CO;2-W; BRAMBILLA E, 1993, AM J PATHOL, V143, P199; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; DeGregori J, 2002, BBA-REV CANCER, V1602, P131, DOI 10.1016/S0304-419X(02)00051-3; Deshaies RJ, 1999, ANNU REV CELL DEV BI, V15, P435, DOI 10.1146/annurev.cellbio.15.1.435; Eymin B, 2001, ONCOGENE, V20, P1678, DOI 10.1038/sj.onc.1204242; Eymin B, 2001, ONCOGENE, V20, P1033, DOI 10.1038/sj.onc.1204220; Ginsberg D, 2002, FEBS LETT, V529, P122, DOI 10.1016/S0014-5793(02)03270-2; Gouyer V, 1998, AM J RESP CELL MOL, V18, P188, DOI 10.1165/ajrcmb.18.2.3008; Gstaiger M, 2001, P NATL ACAD SCI USA, V98, P5043, DOI 10.1073/pnas.081474898; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; Kim SY, 2003, MOL CELL, V11, P1177, DOI 10.1016/S1097-2765(03)00173-4; Marti A, 1999, NAT CELL BIOL, V1, P14, DOI 10.1038/8984; Nakayama K, 2000, EMBO J, V19, P2069, DOI 10.1093/emboj/19.9.2069; Nakayama K, 2004, DEV CELL, V6, P661, DOI 10.1016/S1534-5807(04)00131-5; Nakayama KI, 2006, NAT REV CANCER, V6, P369, DOI 10.1038/nrc1881; Osoegawa A, 2004, J CLIN ONCOL, V22, P4165, DOI 10.1200/JCO.2004.01.035; Salon C, 2006, CELL DEATH DIFFER, V13, P260, DOI 10.1038/sj.cdd.4401739; Soucek T, 1997, ONCOGENE, V14, P2251, DOI 10.1038/sj.onc.1201061; Takanami I, 2005, ONCOL REP, V13, P727; TRAVIS WD, 1999, WHO INT HIST CLASSIF; Vernell R, 2003, J BIOL CHEM, V278, P46124, DOI 10.1074/jbc.M304930200; von der Lehr N, 2003, MOL CELL, V11, P1189, DOI 10.1016/S1097-2765(03)00193-X; Yeh KH, 2001, BIOCHEM BIOPH RES CO, V281, P884, DOI 10.1006/bbrc.2001.4442; Yokoi S, 2004, AM J PATHOL, V165, P175, DOI 10.1016/S0002-9440(10)63286-5; Yokoi S, 2002, AM J PATHOL, V161, P207, DOI 10.1016/S0002-9440(10)64172-7; ZHANG H, 1995, CELL, V82, P915, DOI 10.1016/0092-8674(95)90271-6; Zhang L, 2006, ONCOGENE, V25, P2615, DOI 10.1038/sj.onc.1209286; Zheng N, 2002, NATURE, V416, P703, DOI 10.1038/416703a; Zhu CQ, 2004, CLIN CANCER RES, V10, P1984, DOI 10.1158/1078-0432.CCR-03-0470	31	61	64	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 18	2007	26	48					6927	6936		10.1038/sj.onc.1210499	http://dx.doi.org/10.1038/sj.onc.1210499			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	220WQ	17471231	Green Submitted			2022-12-28	WOS:000250188400008
J	Bostner, J; Waltersson, MA; Fornander, T; Skoog, L; Nordenskjold, B; Stal, O				Bostner, J.; Waltersson, M. Ahnstrom; Fornander, T.; Skoog, L.; Nordenskjold, B.; Stal, O.			Amplification of CCND1 and PAK1 as predictors of recurrence and tamoxifen resistance in postmenopausal breast cancer	ONCOGENE			English	Article						cyclin D1; pak1; drug resistance; breast cancer; real-time PCR	COMPARATIVE GENOMIC HYBRIDIZATION; CYCLIN D1; ESTROGEN-RECEPTOR; GENE AMPLIFICATION; PROGNOSTIC-SIGNIFICANCE; 11Q13 AMPLIFICATION; P21-ACTIVATED-KINASE-1; CELLS; EXPRESSION; ACTIVATION	The 11q13 region is amplified in approximately 15% of all breast tumors. Situated in this region are the cyclin D1 gene (CCND1) and the p-21-activated kinase 1 (PAK1) gene. Both genes encode proteins shown to activate the estrogen receptor (ER), leading to transcription of CCND1 and other ER-responsive genes. Here, we investigate the prognostic and treatment predictive role of CCND1 and PAK1 gene ampli. cation in postmenopausal breast cancer patients randomized to tamoxifen treatment or no adjuvant treatment. Amplification of CCND1 and PAK1, assessed by real-time PCR, was observed in 12.5 and 9.3%, respectively. Amplification of PAK1 was seen in 37% of the CCND1-amplified tumors, indicating coamplification (Po0.001). In ER-positive patients, ampli. cation of at least one of the genes indicated a reduced recurrence-free survival (P = 0.025). When response to tamoxifen treatment was analysed, patients with PAK1 ampli. cation showed decreased benefit from the drug (ER+; relative risk ratio (RR) = 1.62; 95% confedence interval (CI), 0.47 -5.55) compared to patients without ampli. cation (ER+; RR = 0.53; 95% CI, 0.32 0.88). This was not evident for CCND1 ampli. cation. We show that PAK1 may be a predictor of tamoxifen resistance and furthermore, we do not discard PAK1 as a potential candidate oncogene in the 11q13 amplicon. In addition, we show that high pak1 protein levels may predict tamoxifen insensitivity.	Linkoping Univ, Fac Hlth Sci, Div Oncol, Dept Biomed & Surg, Linkoping, Sweden; Karolinska Univ Hosp, Dept Oncol, Stockholm, Sweden; Karolinska Univ Hosp, Dept Cytol, Stockholm, Sweden	Linkoping University; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska University Hospital	Waltersson, MA (corresponding author), Univ Hosp, Dept Oncol, SE-58185 Linkoping, Sweden.	marah@ibk.liu.se						Ahnstrom M, 2005, BREAST CANCER RES TR, V91, P145, DOI 10.1007/s10549-004-6457-4; Al-Kuraya K, 2004, CANCER RES, V64, P8534, DOI 10.1158/0008-5472.CAN-04-1945; Albertson DG, 2006, TRENDS GENET, V22, P447, DOI 10.1016/j.tig.2006.06.007; Ali S, 2002, NAT REV CANCER, V2, P101, DOI 10.1038/nrc721; Askmalm MS, 2004, ACTA ONCOL, V43, P235, DOI 10.1080/02841860410029474; Balasenthil S, 2004, FEBS LETT, V567, P243, DOI 10.1016/j.febslet.2004.04.071; Balasenthil S, 2004, J BIOL CHEM, V279, P1422, DOI 10.1074/jbc.M309937200; Bekri S, 1997, CYTOGENET CELL GENET, V79, P125, DOI 10.1159/000134699; BERNARDS R, 1999, BIOCHIM BIOPHYS ACTA, V1424, P17; Bieche I, 2002, BRIT J CANCER, V86, P580, DOI 10.1038/sj.bjc.6600109; Brown LA, 2006, GYNECOL ONCOL, V100, P264, DOI 10.1016/j.ygyno.2005.08.026; CHAMPEME MH, 1995, GENE CHROMOSOME CANC, V12, P128, DOI 10.1002/gcc.2870120207; Cuny M, 2000, CANCER RES, V60, P1077; Doisneau-Sixou SF, 2003, ENDOCR-RELAT CANCER, V10, P179, DOI 10.1677/erc.0.0100179; FANTL V, 1990, EUR J CANCER, V26, P423, DOI 10.1016/0277-5379(90)90009-I; Fu MF, 2004, ENDOCRINOLOGY, V145, P5439, DOI 10.1210/en.2004-0959; Hodges LC, 2003, MOL CANCER RES, V1, P300; Holm C, 2006, JNCI-J NATL CANCER I, V98, P671, DOI 10.1093/jnci/djj185; Jin SH, 2005, J BIOL CHEM, V280, P24698, DOI 10.1074/jbc.M413374200; Jirstrom K, 2005, CANCER RES, V65, P8009, DOI 10.1158/0008-5472.CAN-05-0746; Jordan VC, 2006, JNCI-J NATL CANCER I, V98, P657, DOI 10.1093/jnci/djj204; KARLSEDER J, 1994, GENE CHROMOSOME CANC, V9, P42, DOI 10.1002/gcc.2870090108; Kyomoto R, 1997, INT J CANCER, V74, P576, DOI 10.1002/(SICI)1097-0215(19971219)74:6<576::AID-IJC3>3.0.CO;2-R; Li F, 2002, EMBO REP, V3, P767, DOI 10.1093/embo-reports/kvf157; Mayr D, 2006, AM J CLIN PATHOL, V126, P101, DOI 10.1309/N6X5MB24BP42KP20; Menard RE, 2005, NEOPLASIA, V7, P638, DOI 10.1593/neo.04736; Miyamoto R, 2003, ORAL ONCOL, V39, P610, DOI 10.1016/S1368-8375(03)00048-4; Neuman E, 1997, MOL CELL BIOL, V17, P5338, DOI 10.1128/MCB.17.9.5338; Ormandy CJ, 2003, BREAST CANCER RES TR, V78, P323, DOI 10.1023/A:1023033708204; Rayala SK, 2006, CANCER RES, V66, P1694, DOI 10.1158/0008-5472.CAN-05-2922; Rayala SK, 2006, CANCER RES, V66, P5985, DOI 10.1158/0008-5472.CAN-06-0978; Rennstam K, 2001, CANCER RES, V61, P1214; Rutqvist LE, 2006, ACTA ONCOL, V45, P517, DOI 10.1080/02841860600702068; Schraml P, 2003, AM J PATHOL, V163, P985, DOI 10.1016/S0002-9440(10)63458-X; SCHUURING E, 1995, GENE, V159, P83, DOI 10.1016/0378-1119(94)00562-7; Singh AP, 2005, WORLD J MICROB BIOT, V21, P1, DOI 10.1007/s11274-004-0872-x; Vadlamudi RK, 2005, MOL CELL BIOL, V25, P3726, DOI 10.1128/MCB.25.9.3726-3736.2005; Vadlamudi RK, 2000, J BIOL CHEM, V275, P36238, DOI 10.1074/jbc.M002138200; Wang DN, 2002, MOL BIOTECHNOL, V21, P1, DOI 10.1385/MB:21:1:001; Wang RA, 2006, ONCOGENE, V25, P2931, DOI 10.1038/sj.onc.1209309; Wong LJC, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-111; Zwijsen RML, 1997, CELL, V88, P405, DOI 10.1016/S0092-8674(00)81879-6; Zwijsen RML, 1998, GENE DEV, V12, P3488, DOI 10.1101/gad.12.22.3488	43	115	122	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2007	26	49					6997	7005		10.1038/sj.onc.1210506	http://dx.doi.org/10.1038/sj.onc.1210506			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	223YN	17486065				2022-12-28	WOS:000250412200005
J	Giagkousiklidis, S; Vellanki, SH; Debatin, KM; Fulda, S				Giagkousiklidis, S.; Vellanki, S. H.; Debatin, K-M; Fulda, S.			Sensitization of pancreatic carcinoma cells for gamma-irradiation-induced apoptosis by XIAP inhibition	ONCOGENE			English	Article						apoptosis; radiotherapy; IAPs; pancreatic cancer	RADIATION-INDUCED APOPTOSIS; DRUG-INDUCED APOPTOSIS; X-LINKED INHIBITOR; PROTEIN XIAP; SURVIVIN; CANCER; MITOCHONDRIA; ACTIVATOR	Resistance of pancreatic cancer to current treatments including radiotherapy remains a major challenge in oncology and may be caused by defects in apoptosis programs. Since 'inhibitor of apoptosis proteins' (IAPs) block apoptosis at the core of the apoptotic machinery by inhibiting caspases, therapeutic modulation of IAPs could tackle a key resistance mechanism. Here, we report that targeting X-linked inhibitor of apoptosis (XIAP) by RNA-interference-mediated knockdown or overexpression of second mitochondria-derived activator of caspase significantly enhanced apoptosis and markedly reduced clonogenic growth of pancreatic carcinoma cells upon gamma-irradiation. Analysis of signaling pathways revealed that antagonizing XIAP increased activation of caspase-2, -3, -8 and -9 and loss of mitochondrial membrane potential upon gamma-irradiation. Interestingly, inhibition of caspases also reduced the cooperative effect of XIAP targeting and gamma-irradiation to trigger mitochondrial perturbations, suggesting that XIAP controls a feedback mitochondrial amplification loop by regulating caspase activity. Importantly, our data demonstrate for the first time that small molecule XIAP inhibitors sensitized pancreatic carcinoma cells for gamma-irradiation-induced apoptosis, whereas they had no effect on gamma-irradiation-mediated apoptosis of non-malignant fibroblasts indicating some tumor specification. In conclusion, targeting XIAP, for example by small molecules, is a promising novel approach to enhance radiosensitivity of pancreatic cancer that warrants further investigation.	Univ Childrens Hosp, D-89075 Ulm, Germany	Ulm University; University of Hamburg; University Medical Center Hamburg-Eppendorf	Fulda, S (corresponding author), Univ Childrens Hosp, Eythstr 24, D-89075 Ulm, Germany.	simone.fulda@uniklinik-ulm.de	Fulda, Simone/D-5864-2011; Debatin, Klaus-Michael/J-9704-2014	Debatin, Klaus-Michael/0000-0002-8397-1886; Fulda, Simone/0000-0002-0459-6417				Cao C, 2004, ONCOGENE, V23, P7047, DOI 10.1038/sj.onc.1207929; Cummins JM, 2004, CANCER RES, V64, P3006, DOI 10.1158/0008-5472.CAN-04-0046; Fulda S, 2006, ONCOGENE, V25, P4798, DOI 10.1038/sj.onc.1209608; Fulda S, 2002, NAT MED, V8, P808, DOI 10.1038/nm735; Fulda S, 1997, CANCER RES, V57, P3823; FULDA S, 2006, APOPTOSIS CANC THERA, P849; Fulda S, 2006, RECENT PAT ANTI-CANC, V1, P81, DOI 10.2174/157489206775246539; Giagkousiklidis S, 2005, CANCER RES, V65, P10502, DOI 10.1158/0008-5472.CAN-05-0866; Guo F, 2002, BLOOD, V99, P3419, DOI 10.1182/blood.V99.9.3419; Holcik M, 2000, ONCOGENE, V19, P4174, DOI 10.1038/sj.onc.1203765; JENDROSSEK V, 2006, APOPTOSIS CANC THERA, P1049; Lu B, 2004, CANCER RES, V64, P2840, DOI 10.1158/0008-5472.CAN-03-3547; McManus DC, 2004, ONCOGENE, V23, P8105, DOI 10.1038/sj.onc.1207967; Oost TK, 2004, J MED CHEM, V47, P4417, DOI 10.1021/jm040037k; Rodel C, 2003, INT J RADIAT ONCOL, V55, P1341, DOI 10.1016/S0360-3016(02)04618-7; Saelens X, 2004, ONCOGENE, V23, P2861, DOI 10.1038/sj.onc.1207523; Salvesen GS, 2002, NAT REV MOL CELL BIO, V3, P401, DOI 10.1038/nrm830; Schmidt-Ullrich RK, 2000, RADIAT RES, V153, P245, DOI 10.1667/0033-7587(2000)153[0245:STACRR]2.0.CO;2; Schneider G, 2005, GASTROENTEROLOGY, V128, P1606, DOI 10.1053/j.gastro.2005.04.001; Slee EA, 1999, CELL DEATH DIFFER, V6, P1067, DOI 10.1038/sj.cdd.4400601; Slee EA, 2000, CELL DEATH DIFFER, V7, P556, DOI 10.1038/sj.cdd.4400689; Sohn D, 2005, J BIOL CHEM, V280, P5267, DOI 10.1074/jbc.M408585200; Turk B, 2002, CURR PHARM DESIGN, V8, P1623, DOI 10.2174/1381612023394124; van Engeland M, 1998, CYTOMETRY, V31, P1, DOI 10.1002/(SICI)1097-0320(19980101)31:1<1::AID-CYTO1>3.0.CO;2-R; Vogler M, 2007, ONCOGENE, V26, P248, DOI 10.1038/sj.onc.1209776; Vogler M, 2005, ONCOGENE, V24, P7190, DOI 10.1038/sj.onc.1208876; Westphal Sabine, 2003, Mol Cancer, V2, P6, DOI 10.1186/1476-4598-2-6; Wilkinson JC, 2004, MOL CELL BIOL, V24, P7003, DOI 10.1128/MCB.24.16.7003-7014.2004	28	55	58	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2007	26	49					7006	7016		10.1038/sj.onc.1210502	http://dx.doi.org/10.1038/sj.onc.1210502			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	223YN	17471230				2022-12-28	WOS:000250412200006
J	Kamimura, K; Mishima, Y; Obata, M; Endo, T; Aoyagi, Y; Kominami, R				Kamimura, K.; Mishima, Y.; Obata, M.; Endo, T.; Aoyagi, Y.; Kominami, R.			Lack of Bcl11b tumor suppressor results in vulnerability to DNA replication stress and damages	ONCOGENE			English	Article						DNA replication stress; Chk1; p27; apoptosis; Bcl11b tumor suppressor	CELL-DEATH; TRANSCRIPTIONAL REPRESSION; CHECKPOINT KINASE-1; THYMIC LYMPHOMAS; T-LYMPHOCYTES; GENE; MICE; CHK1; PATHWAY; MOUSE	Bcl11b/Rit1 is involved in T-cell development and undergoes chromosomal rearrangements in human T-cell leukemias. Thymocytes of Bcl11b(-/-) newborn mice exhibit apoptosis at a certain developmental stage when thymocytes re-enter into the cell-cycle. Here, we show that Bcl11b-knockdown T-cell lines, when exposed to growth stimuli, exhibited a poptosis at the S phase with concomitant decreases in a cell-cycle inhibitor, p27 and an antiapoptotic protein, Bcl-xL, owing to transcriptional repression. This repression was a likely consequence of the impairment of Sirt1, a nicotinamide adenine dinucleotide-dependent deacetylase associating with Bcl11b. Activation of the apoptotic process cleaved the mediator protein, Claspin, and inhibited phosphorylation of cell-cycle checkpoint kinase 1 ( Chk1) that plays a central role in sensing and responding to incomplete replication. Bcl11b(-/-) thymocytes also failed to phosphorylate Chk1 when UV irradiated. These results implicate Bcl11b in the remedy for DNA replication stress and maintenance of genomic integrity.	Niigata Univ, Dept Mol Genet, Grad Sch Med & Dent Sci, Niigata 9518510, Japan; Niigata Univ, Ctr Trandisciplinary Res, Niigata 9518510, Japan	Niigata University; Niigata University	Kominami, R (corresponding author), Niigata Univ, Dept Mol Genet, Grad Sch Med & Dent Sci, Asahimachi 1-757, Niigata 9518510, Japan.	rykomina@med.niigata-u.ac.jp	Kamimura, Kenya/U-6797-2019					Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Alam A, 1999, J EXP MED, V190, P1879, DOI 10.1084/jem.190.12.1879; Andegeko Y, 2001, J BIOL CHEM, V276, P38224; Avram D, 2000, J BIOL CHEM, V275, P10315, DOI 10.1074/jbc.275.14.10315; Bagheri-Yarmand R, 2004, DEVELOPMENT, V131, P3469, DOI 10.1242/dev.01213; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Brunet A, 2004, SCIENCE, V303, P2011, DOI 10.1126/science.1094637; Chen YH, 2004, DNA REPAIR, V3, P1025, DOI 10.1016/j.dnarep.2004.03.003; Cismasiu VB, 2005, ONCOGENE, V24, P6753, DOI 10.1038/sj.onc.1208904; Clarke CAL, 2005, J BIOL CHEM, V280, P35337, DOI 10.1074/jbc.M506460200; Di Cristofano A, 2001, NAT GENET, V27, P222, DOI 10.1038/84879; Eguchi-Ishimae M, 2001, BLOOD, V97, P737, DOI 10.1182/blood.V97.3.737; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; Fero ML, 1998, NATURE, V396, P177, DOI 10.1038/24179; Flatten K, 2005, J BIOL CHEM, V280, P14349, DOI 10.1074/jbc.M411890200; Gorgoulis VG, 2005, NATURE, V434, P907, DOI 10.1038/nature03485; Gounari F, 2001, NAT IMMUNOL, V2, P863, DOI 10.1038/ni0901-863; Hoeppner DJ, 2001, NATURE, V412, P202, DOI 10.1038/35084103; Inoue J, 2006, J IMMUNOL, V176, P5871, DOI 10.4049/jimmunol.176.10.5871; Kastan MB, 2004, NATURE, V432, P316, DOI 10.1038/nature03097; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; Lam MH, 2004, CANCER CELL, V6, P45, DOI 10.1016/j.ccr.2004.06.015; Levine AJ, 2006, GENE DEV, V20, P267, DOI 10.1101/gad.1363206; Lin SY, 2004, P NATL ACAD SCI USA, V101, P6484, DOI 10.1073/pnas.0401847101; Liu QH, 2000, GENE DEV, V14, P1448; MOTOYAMA N, 1995, SCIENCE, V267, P1506, DOI 10.1126/science.7878471; Motta MC, 2004, CELL, V116, P551, DOI 10.1016/S0092-8674(04)00126-6; Nagel S, 2003, CANCER RES, V63, P5329; Nakano T, 1996, SYST COMPUT JPN, V27, P1, DOI 10.1002/scj.4690270601; Nakayama K, 2004, DEV CELL, V6, P661, DOI 10.1016/S1534-5807(04)00131-5; Przybylski GK, 2005, LEUKEMIA, V19, P201, DOI 10.1038/sj.leu.2403619; Reddien PW, 2001, NATURE, V412, P198, DOI 10.1038/35084096; Sakata J, 2004, CARCINOGENESIS, V25, P1069, DOI 10.1093/carcin/bgh094; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; Satterwhite E, 2001, BLOOD, V98, P3413, DOI 10.1182/blood.V98.12.3413; Senawong T, 2003, J BIOL CHEM, V278, P43041, DOI 10.1074/jbc.M307477200; Shinbo T, 1999, ONCOGENE, V18, P4131, DOI 10.1038/sj.onc.1202767; Takai H, 2000, GENE DEV, V14, P1439; van de Wetering M, 2002, CELL, V109, pS13, DOI 10.1016/S0092-8674(02)00709-2; Wakabayashi Y, 2003, NAT IMMUNOL, V4, P533, DOI 10.1038/ni927; Wakabayashi Y, 2003, BIOCHEM BIOPH RES CO, V301, P598, DOI 10.1016/S0006-291X(02)03069-3; WALWORTH N, 1993, NATURE, V363, P368, DOI 10.1038/363368a0; Zhao H, 2002, P NATL ACAD SCI USA, V99, P14795, DOI 10.1073/pnas.182557299; Zhou BBS, 2004, NAT REV CANCER, V4, P216, DOI 10.1038/nrc1296; Zou L, 2003, SCIENCE, V300, P1542, DOI 10.1126/science.1083430	45	36	37	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 30	2007	26	40					5840	5850		10.1038/sj.onc.1210388	http://dx.doi.org/10.1038/sj.onc.1210388			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	205OH	17369851				2022-12-28	WOS:000249123100002
J	Matsumoto, S; Iwakawa, R; Takahashi, K; Kohno, T; Nakanishi, Y; Matsuno, Y; Suzuki, K; Nakamoto, M; Shimizu, E; Minna, JD; Yokota, J				Matsumoto, S.; Iwakawa, R.; Takahashi, K.; Kohno, T.; Nakanishi, Y.; Matsuno, Y.; Suzuki, K.; Nakamoto, M.; Shimizu, E.; Minna, J. D.; Yokota, J.			Prevalence and specificity of LKB1 genetic alterations in lung cancers	ONCOGENE			English	Article						LKB1; lung cancer mutation; deletion; smoking; poor differentiation	PEUTZ-JEGHERS-SYNDROME; FREQUENT EGFR MUTATIONS; SOMATIC MUTATIONS; TUMOR-SUPPRESSOR; EPIGENETIC INACTIVATION; LKB1/STK11; STK11/LKB1; CARCINOMA; INDUCTION; DELETIONS	Germline LKB1 mutations cause Peutz-Jeghers syndrome, a hereditary disorder that predisposes to gastrointestinal hamartomatous polyposis and several types of malignant tumors. Somatic LKB1 alterations are rare in sporadic cancers, however, a few reports showed the presence of somatic alterations in a considerable fraction of lung cancers. To determine the prevalence and the specificity of LKB1 alterations in lung cancers, we examined a large number of lung cancer cell lines and lung adenocarcinoma ( AdC) specimens for the alterations. LKB1 genetic alterations were frequently detected in the cell lines ( 21/70, 30%), especially in non-small cell lung cancers ( NSCLCs) ( 20/51, 39%), and were significantly more frequent in cell lines with KRAS mutations. Point mutations were detected only in AdCs and large cell carcinomas, whereas homozygous deletions were detected in all histological types of lung cancer. Among lung AdC specimens, LKB1 mutations were found in seven ( 8%) of 91 male smokers but in none of 64 females and/or nonsmokers, and were significantly more frequent in poorly differentiated tumors. The difference in the frequency of LKB1 alterations between cell lines and tumor specimens was likely to be owing to masking of deletions by the contamination of noncancerous cells in the tumor specimens. These results indicate that somatic LKB1 genetic alterations preferentially occur in a subset of poorly differentiated lung AdCs that appear to correlate with smoking males.	Natl Canc Ctr, Res Inst, Div Biol, Chuo Ku, Tokyo 1040045, Japan; Natl Canc Ctr, Res Inst, Div Pathol, Tokyo 1040045, Japan; Natl Canc Ctr, Diagnost Pathol Div, Tokyo, Japan; Natl Canc Ctr, Thorac Surg Div, Tokyo, Japan; Tottori Univ, Fac Med, Div Med Oncol & Mol Respirol, Tottori 680, Japan; Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, Dallas, TX 75230 USA	National Cancer Center - Japan; National Cancer Center - Japan; National Cancer Center - Japan; National Cancer Center - Japan; Tottori University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Yokota, J (corresponding author), Natl Canc Ctr, Res Inst, Div Biol, Chuo Ku, 1-1 Tsukiji 5 Chome, Tokyo 1040045, Japan.	jyokota@gan2.ncc.go.jp			NCI NIH HHS [P50 CA 70907, P50 CA070907] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA070907] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alessi DR, 2006, ANNU REV BIOCHEM, V75, P137, DOI 10.1146/annurev.biochem.75.103004.142702; Avizienyte E, 1999, AM J PATHOL, V154, P677, DOI 10.1016/S0002-9440(10)65314-X; Baas AF, 2004, TRENDS CELL BIOL, V14, P312, DOI 10.1016/j.tcb.2004.04.001; Bignell GR, 1998, CANCER RES, V58, P1384; Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691; Carretero J, 2004, ONCOGENE, V23, P4037, DOI 10.1038/sj.onc.1207502; Fujita T, 1999, INT J ONCOL, V15, P927; Ghaffar H, 2003, CLIN CANCER RES, V9, P2998; GUDLBERG P, 1999, ONCOGENE, V18, P1777; Hearle NCM, 2005, BMC GENOMICS, V6, DOI 10.1186/1471-2164-6-38; Hearle NCM, 2006, J MED GENET, V43, DOI 10.1136/jmg.2005.036830; Hemminki A, 1998, NATURE, V391, P184, DOI 10.1038/34432; Hemminki A, 1999, CELL MOL LIFE SCI, V55, P735, DOI 10.1007/s000180050329; Jenne DE, 1998, NAT GENET, V18, P38, DOI 10.1038/ng0198-38; Karuman P, 2001, MOL CELL, V7, P1307, DOI 10.1016/S1097-2765(01)00258-1; Kishimoto M, 2005, CLIN CANCER RES, V11, P512; Kosaka T, 2004, CANCER RES, V64, P8919, DOI 10.1158/0008-5472.CAN-04-2818; Launonen V, 2005, HUM MUTAT, V26, P291, DOI 10.1002/humu.20222; Matsumoto S, 2006, INT J CANCER, V118, P2498, DOI 10.1002/ijc.21670; Matsumoto S, 2006, INT J CANCER, V119, P1491, DOI 10.1002/ijc.21940; Park MJ, 2003, CANCER GENET CYTOGEN, V141, P5, DOI 10.1016/S0165-4608(02)00645-3; Sanchez-Cespedes M, 2002, CANCER RES, V62, P3659; Sanchez-Cespedes M, 2001, CANCER RES, V61, P1309; Shigematsu H, 2006, INT J CANCER, V118, P257, DOI 10.1002/ijc.21496; Su GH, 1999, AM J PATHOL, V154, P1835, DOI 10.1016/S0002-9440(10)65440-5; Tiainen M, 2002, HUM MOL GENET, V11, P1497, DOI 10.1093/hmg/11.13.1497; Tomizawa Y, 2002, CLIN CANCER RES, V8, P2362; Upadhyay S, 2006, CANCER RES, V66, P7870, DOI 10.1158/0008-5472.CAN-05-2902; Volikos E, 2006, J MED GENET, V43, DOI 10.1136/jmg.2005.039875; Westerman AM, 1999, LANCET, V353, P1211, DOI 10.1016/S0140-6736(98)08018-0; Zhong DS, 2006, LUNG CANCER, V53, P285, DOI 10.1016/j.lungcan.2006.05.018	31	209	225	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 30	2007	26	40					5911	5918		10.1038/sj.onc.1210418	http://dx.doi.org/10.1038/sj.onc.1210418			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	205OH	17384680	Green Accepted			2022-12-28	WOS:000249123100008
J	Miquel, C; Jacob, S; Grandjouan, S; Aime, A; Viguier, J; Sabourin, JC; Sarasin, A; Duval, A; Praz, F				Miquel, C.; Jacob, S.; Grandjouan, S.; Aime, A.; Viguier, J.; Sabourin, J-C; Sarasin, A.; Duval, A.; Praz, F.			Frequent alteration of DNA damage signalling and repair pathways in human colorectal cancers with microsatellite instability	ONCOGENE			English	Article						colorectal cancer; MSI phenotype; DNA repair; DNA damage signalling; chemotherapy	MONONUCLEOTIDE REPEATS; DEFICIENT CANCERS; MRE11 EXPRESSION; TARGET GENES; MUTATIONS; SEQUENCES; CARCINOGENESIS; PATHOGENESIS	Accumulation of frameshift mutations at genes containing coding mononucleotide repeats is thought to be the major molecular mechanism by which mismatch repair-deficient cells accumulate functional alterations. These mutations resulting from microsatellite instability ( MSI) can affect genes involved in pathways with a putative oncogenic role, but may also arise in genes without any expected role in MSI carcinogenesis because of the high mutation background of these tumours. We here screened 39 MSI colorectal tumours for the presence of mutations in 25 genes involved in DNA damage signalling and repair pathways. Using a maximum likelihood statistical method, these genes were divided into two different groups that differed significantly in their mutation frequencies, and likely represent mutations that do or do not provide selective pressure during MSI tumour progression. Interestingly, the so-called real-target mutational events were found to be distributed among genes involved in different functional pathways of the DNA metabolism, for example, DNA damage signalling ( DNA-PKcs, ATR), double-strand break ( DSB) repair ( DNA-PKcs, RAD50), mismatch repair ( MSH3, MSH6, MBD4) and replication ( POLD3). In particular, mutations in MRE11 and/or RAD50 were observed in the vast majority of the tumours and resulted in the concomitant loss of immunohistochemical expression of both proteins. These data might explain why MSI colorectal cancers ( CRC) behave differently in response to a wide variety of chemotherapeutic agents, notably those targeting DNA. More generally, they give further insights into how MSI leads to functional changes with synergistic effects in oncogenic pathways.	Univ Paris 06, U762, INSERM, CEPH, F-75010 Paris, France; Inst Gustave Roussy, Dept Pathol, Villejuif, France; Hop Cochin, Serv Oncogenet Digest, F-75674 Paris, France; CNRS Genet Instabil & Canc, Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; UNICANCER; Gustave Roussy; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS)	Praz, F (corresponding author), Univ Paris 06, U762, INSERM, CEPH, 27 Rue Juliette Dodu, F-75010 Paris, France.	praz@cephb.fr	miquel, catherine/B-5536-2013; PRAZ, Françoise/A-7291-2008; PRAZ, Françoise/AAF-7761-2020	PRAZ, Françoise/0000-0002-5353-8889; PRAZ, Françoise/0000-0002-5353-8889				AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Boland CR, 1998, CANCER RES, V58, P5248; Brennetot C, 2005, INT J CANCER, V113, P446, DOI 10.1002/ijc.20586; Duval A, 2002, CANCER RES, V62, P2447; Duval A, 2001, HUM MOL GENET, V10, P513, DOI 10.1093/hmg/10.5.513; Fallik D, 2003, CANCER RES, V63, P5738; Giannini G, 2004, ONCOGENE, V23, P2640, DOI 10.1038/sj.onc.1207409; Giannini G, 2002, EMBO REP, V3, P248, DOI 10.1093/embo-reports/kvf044; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; Jacob S, 2002, BIOCHIMIE, V84, P27, DOI 10.1016/S0300-9084(01)01362-1; Jiricny J, 2006, NAT REV MOL CELL BIO, V7, P335, DOI 10.1038/nrm1907; Li HR, 2004, CANCER RES, V64, P4760, DOI 10.1158/0008-5472.CAN-04-0975; Mori Y, 2001, CANCER RES, V61, P6046; Ottini L, 2004, CARCINOGENESIS, V25, P2337, DOI 10.1093/carcin/bgh257; Pommier Y, 2006, NAT REV CANCER, V6, P789, DOI 10.1038/nrc1977; Sonoda E, 2003, EMBO J, V22, P3188, DOI 10.1093/emboj/cdg308; Suzuki K, 2002, CANCER RES, V62, P1961; Takemura H, 2006, J BIOL CHEM, V281, P30814, DOI 10.1074/jbc.M603747200; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; Woerner SM, 2003, ONCOGENE, V22, P2226, DOI 10.1038/sj.onc.1206421; Yanamadala S, 2003, MOL CANCER RES, V1, P747	22	94	96	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 30	2007	26	40					5919	5926		10.1038/sj.onc.1210419	http://dx.doi.org/10.1038/sj.onc.1210419			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	205OH	17384679				2022-12-28	WOS:000249123100009
J	Chen, D; Zhang, Z; Li, M; Wang, W; Li, Y; Rayburn, ER; Hill, DL; Wang, H; Zhang, R				Chen, D.; Zhang, Z.; Li, M.; Wang, W.; Li, Y.; Rayburn, E. R.; Hill, D. L.; Wang, H.; Zhang, R.			Ribosomal protein S7 as a novel modulator of p53-MDM2 interaction: binding to MDM2, stabilization of p53 protein, and activation of p53 function	ONCOGENE			English	Article						p53; MDM2; RPS7; protein degradation; proteasome; ubiquitination; tumor suppressor	IN-VIVO ACTIVITIES; RIBOSOME BIOGENESIS; NEGATIVE REGULATOR; TUMOR SUPPRESSION; ONCOPROTEIN MDM2; PROSTATE-CANCER; PATHWAY; INHIBITION; UBIQUITINATION; DEGRADATION	As a major negative regulator of p53, the MDM2 oncogene plays an important role in carcinogenesis and tumor progression. MDM2 promotes p53 proteasomal degradation and negatively regulates p53 function. The mechanisms by which the MDM2-p53 interaction is regulated are not fully understood, although several MDM2interacting molecules have recently been identified. To search for novel MDM2-binding partners, we screened a human prostate cDNA library by the yeast two-hybrid assay using full-length MDM2 protein as the bait. Among the candidate proteins, ribosomal protein S7 was identified and confirmed as a novel MDM2-interacting protein. Herein, we demonstrate that S7 binds to MDM2, in vitro and in vivo, and that the interaction between MDM2 and S7 leads to modulation of MDM2-p53 binding by forming a ternary complex among MDM2, p53 and S7. This results in the stabilization of p53 protein through abrogation of MDM2-mediated p53 ubiquitination. Consequently, S7 overexpression increases p53 transactivational activities, induces apoptosis, and inhibits cell proliferation. The identification of S7 as a novel MDM2-interacting partner contributes to elucidation of the complex regulation of the MDM2-p53 interaction and has implications in cancer prevention and therapy.	Univ Alabama, Dept Pharmacol & Toxicol, Div Clin Pharmacol, Birmingham, AL 35294 USA; Univ Alabama, Ctr Comprehens Canc, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Wang, H (corresponding author), Univ Alabama, Dept Pharmacol & Toxicol, Div Clin Pharmacol, VH 113,1670 Univ Blvd, Birmingham, AL 35294 USA.	hui.wang@ccc.uab.edu; ruiwen.zhang@ccc.uab.edu	高, 雨莉/HGU-8187-2022		NATIONAL CANCER INSTITUTE [R01CA112029] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA112029] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Attardi LD, 1999, CELL MOL LIFE SCI, V55, P48, DOI 10.1007/s000180050269; Bhat KP, 2004, EMBO J, V23, P2402, DOI 10.1038/sj.emboj.7600247; Bond GL, 2004, CELL, V119, P591, DOI 10.1016/j.cell.2004.11.022; Budde A, 1999, ONCOGENE, V18, P1119, DOI 10.1038/sj.onc.1202402; Dai MS, 2004, J BIOL CHEM, V279, P44475, DOI 10.1074/jbc.M403722200; Dai MS, 2004, MOL CELL BIOL, V24, P7654, DOI 10.1128/MCB.24.17.7654-7668.2004; Dai MS, 2006, J BIOL CHEM, V281, P24304, DOI 10.1074/jbc.M602596200; Du YCN, 2002, CELL, V109, P835, DOI 10.1016/S0092-8674(02)00773-0; Francoz S, 2006, P NATL ACAD SCI USA, V103, P3232, DOI 10.1073/pnas.0508476103; Grossman SR, 2003, SCIENCE, V300, P342, DOI 10.1126/science.1080386; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Higashitsuji H, 2005, CANCER CELL, V8, P75, DOI 10.1016/j.ccr.2005.06.006; Jin YT, 2003, EMBO J, V22, P6365, DOI 10.1093/emboj/cdg600; Lane DP, 1997, TRENDS BIOCHEM SCI, V22, P372, DOI 10.1016/S0968-0004(97)01119-5; LANE DP, 1992, NATURE, V358, P16; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li M, 2005, CANCER RES, V65, P8200, DOI 10.1158/0008-5472.CAN-05-1302; Li MY, 2002, NATURE, V416, P648, DOI 10.1038/nature737; Liu G, 2006, MOL CELL BIOL, V26, P1398, DOI 10.1128/MCB.26.4.1398-1413.2006; Lohrum MAE, 2003, CANCER CELL, V3, P577, DOI 10.1016/S1535-6108(03)00134-X; Pestov DG, 2001, MOL CELL BIOL, V21, P4246, DOI 10.1128/MCB.21.13.4246-4255.2001; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Poyurovsky MV, 2006, GENE DEV, V20, P125, DOI 10.1101/gad.1397506; Sui GC, 2004, CELL, V117, P859, DOI 10.1016/j.cell.2004.06.004; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wang H, 2003, PROSTATE, V54, P194, DOI 10.1002/pros.10187; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0; Xiong SB, 2006, P NATL ACAD SCI USA, V103, P3226, DOI 10.1073/pnas.0508500103; Zhang RW, 2005, CURR CANCER DRUG TAR, V5, P43, DOI 10.2174/1568009053332663; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zhang YP, 2003, MOL CELL BIOL, V23, P8902, DOI 10.1128/MCB.23.23.8902-8912.2003; Zhang Z, 2005, ONCOGENE, V24, P7238, DOI 10.1038/sj.onc.1208814; Zhang Z, 2004, J BIOL CHEM, V279, P16000, DOI 10.1074/jbc.M312264200; Zhang Z, 2003, P NATL ACAD SCI USA, V100, P11636, DOI 10.1073/pnas.1934692100; Zhang Z, 2005, CURR CANCER DRUG TAR, V5, P9, DOI 10.2174/1568009053332618; Zhou BHP, 2001, NAT CELL BIOL, V3, P973, DOI 10.1038/ncb1101-973	37	190	198	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 2	2007	26	35					5029	5037		10.1038/sj.onc.1210327	http://dx.doi.org/10.1038/sj.onc.1210327			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	196MT	17310983				2022-12-28	WOS:000248487400001
J	Dahl, E; Wiesmann, F; Woenckhaus, M; Stoehr, R; Wild, PJ; Veeck, J; Knuechell, R; Klopocki, E; Sauter, G; Simon, R; Wieland, WF; Walter, B; Denzinger, S; Hartmann, A; Hammerschmied, CG				Dahl, E.; Wiesmann, F.; Woenckhaus, M.; Stoehr, R.; Wild, P. J.; Veeck, J.; Knuechell, R.; Klopocki, E.; Sauter, G.; Simon, R.; Wieland, W. F.; Walter, B.; Denzinger, S.; Hartmann, A.; Hammerschmied, C. G.			Frequent loss of SFRP1 expression in multiple human solid tumours: association with aberrant promoter methylation in renal cell carcinoma	ONCOGENE			English	Article						loss of SFRP1 in human tumours; renal cell carcinoma; tumour suppressor gene; Wnt pathway; SFRP1 methylation; tissue microarray	WNT ANTAGONIST SFRP1; BETA-CATENIN; EPIGENETIC INACTIVATION; BREAST-CANCER; GENES; TARGET; IDENTIFICATION; NONPAPILLARY; PROGRESSION; SUPPRESSOR	Oncogenic wingless-related mouse mammary tumour virus (Wnt) signalling, caused by epigenetic inactivation of specific pathway regulators like the putative tumour suppressor secreted frizzled-related protein 1 (SFRP1), may be causally involved in the carcinogenesis of many human solid tumours including breast, colon and kidney cancer. To evaluate the incidence of SFRP1 deficiency in human tumours, we performed a large-scale SFRP1 expression analysis using immunohistochemistry on a comprehensive tissue microarray (TMA) comprising 3448 tumours from 36 organs. This TMA contained 132 different tumour subtypes as well as 26 different normal tissues. Although tumour precursor stages of, for example kidney, colon, endometrium or adrenal gland still exhibited moderate to abundant SFRP1 expression, this expression was frequently lost in the corresponding genuine tumours. We defined nine novel tumour entities with apparent loss of SFRP1 expression, i.e., cancers of the kidney, stomach, small intestine, pancreas, parathyroid, adrenal gland, gall bladder, endometrium and testis. Renal cell carcinoma (RCC) exhibited the highest frequency of SFRP1 loss (89% on mRNA level; 75% on protein level) and was selected for further analysis to investigate the cause of SFRP1 loss in human tumours. We performed expression, mutation and methylation analysis in RCC and their matching normal kidney tissues. SFRP1 promoter methylation was frequently found in RCC (68%, n=38) and was correlated with loss of SFRP1 mRNA expression ( p < 0.05). Although loss of heterozygosity was found in 16% of RCC, structural mutations in the coding or promoter region of the SFRP1 gene were not observed. Our results indicate that loss of SFRP1 expression is a very common event in human cancer, arguing for a fundamental role of aberrant Wnt signalling in the development of solid tumours. In RCC, promoter hypermethylation seems to be the predominant mechanism of SFRP1 gene silencing and may contribute to initiation and progression of this disease.	Rhein Westfal TH Aachen, Univ Hosp, Inst Pathol, Mol Oncol Grp, D-52074 Aachen, Germany; Univ Regensburg, Inst Pathol, D-8400 Regensburg, Germany; Univ Regensburg, Dept Urol, D-8400 Regensburg, Germany; Univ Zurich, Inst Pathol, Zurich, Switzerland; Univ Med Berlin, Charite, Inst Med Genet, Berlin, Germany; Univ Hamburg Hosp, Inst Pathol, D-2000 Hamburg, Germany	RWTH Aachen University; RWTH Aachen University Hospital; University of Regensburg; University of Regensburg; University of Zurich; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Hamburg; University Medical Center Hamburg-Eppendorf	Dahl, E (corresponding author), Rhein Westfal TH Aachen, Univ Hosp, Inst Pathol, Mol Oncol Grp, Pauwelsstr 30, D-52074 Aachen, Germany.	edahl@ukaachen.de	Klopocki, Eva/B-6823-2017; Veeck, Jürgen/B-9256-2008; Stoehr, Christine/N-6637-2018; Stoehr, Robert/D-7504-2011	Klopocki, Eva/0000-0003-1438-2081; Veeck, Jürgen/0000-0002-2952-6159; Stoehr, Christine/0000-0001-7501-4886; 				Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Bohm M, 1997, UROL RES, V25, P161; Bubendorf L, 2001, J PATHOL, V195, P72, DOI 10.1002/path.893; Caldwell GM, 2004, CANCER RES, V64, P883, DOI 10.1158/0008-5472.CAN-03-1346; Dressler GR, 2002, TRENDS CELL BIOL, V12, P390, DOI 10.1016/S0962-8924(02)02334-6; Esteller M, 2005, ANNU REV PHARMACOL, V45, P629, DOI 10.1146/annurev.pharmtox.45.120403.095832; Finch PW, 1997, P NATL ACAD SCI USA, V94, P6770, DOI 10.1073/pnas.94.13.6770; Fink L, 1998, NAT MED, V4, P1329, DOI 10.1038/3327; Fukui T, 2005, ONCOGENE, V24, P6323, DOI 10.1038/sj.onc.1208777; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Hoei-Hansen CE, 2004, MOL HUM REPROD, V10, P423, DOI 10.1093/molehr/gah059; HUGHSON MD, 1993, MODERN PATHOL, V6, P449; Janssens N, 2004, TUMOR BIOL, V25, P161, DOI 10.1159/000081098; Kim YS, 2000, PATHOL INT, V50, P725, DOI 10.1046/j.1440-1827.2000.01111.x; Klopocki E, 2004, INT J ONCOL, V25, P641; Lee AY, 2004, ONCOGENE, V23, P6672, DOI 10.1038/sj.onc.1207881; Li CH, 2006, J DENT RES, V85, P374, DOI 10.1177/154405910608500418; Lodygin D, 2005, CANCER RES, V65, P4218, DOI 10.1158/0008-5472.CAN-04-4407; MANCILLAJIMENEZ R, 1976, CANCER, V38, P2469, DOI 10.1002/1097-0142(197612)38:6<2469::AID-CNCR2820380636>3.0.CO;2-R; Mann B, 1999, P NATL ACAD SCI USA, V96, P1603, DOI 10.1073/pnas.96.4.1603; Marsit CJ, 2005, CANCER RES, V65, P7081, DOI 10.1158/0008-5472.CAN-05-0267; Melkonyan HS, 1997, P NATL ACAD SCI USA, V94, P13636, DOI 10.1073/pnas.94.25.13636; ORTMANN M, 1991, VIRCHOWS ARCH B, V61, P123; Presti JC, 2002, J UROLOGY, V167, P1464, DOI 10.1016/S0022-5347(05)65346-3; Reutzel D, 2001, CYTOGENET CELL GENET, V93, P221, DOI 10.1159/000056987; SCHLEGEL J, 1995, VIRCHOWS ARCH, V426, P223; Stoehr R, 2004, LAB INVEST, V84, P465, DOI 10.1038/labinvest.3700068; STORKEL S, 1989, VIRCHOWS ARCH B, V56, P237; Suzuki H, 1997, ONCOLOGY-BASEL, V54, P252; Suzuki H, 2004, NAT GENET, V36, P417, DOI 10.1038/ng1330; Suzuki H, 2002, NAT GENET, V31, P141, DOI 10.1038/ng892; Takada T, 2004, CANCER SCI, V95, P741, DOI 10.1111/j.1349-7006.2004.tb03255.x; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Togashi A, 2005, CANCER RES, V65, P4817, DOI 10.1158/0008-5472.CAN-05-0120; Ueda M, 2001, BRIT J CANCER, V85, P64, DOI 10.1054/bjoc.2001.1863; Vainio SJ, 1999, INT J DEV BIOL, V43, P419; Veeck J, 2006, ONCOGENE, V25, P3479, DOI 10.1038/sj.onc.1209386; Waki T, 2003, ONCOGENE, V22, P4128, DOI 10.1038/sj.onc.1206651; Watanabe H, 2006, PANCREAS, V32, P382, DOI 10.1097/01.mpa.0000221617.89376.38; Zafrakas M, 2006, BMC CANCER, V6, P1, DOI 10.1186/1471-2407-6-88; ZANG T, 2000, CHINESE SCI BULL, V45, P1703; Zhang L, 1997, SCIENCE, V276, P1268, DOI 10.1126/science.276.5316.1268	42	112	118	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2007	26	38					5680	5691		10.1038/sj.onc.1210345	http://dx.doi.org/10.1038/sj.onc.1210345			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	200ZS	17353908				2022-12-28	WOS:000248801900015
J	Marzec, M; Kasprzycka, M; Liu, X; El-Salem, M; Halasa, K; Raghunath, PN; Bucki, R; Wlodarski, P; Wasik, MA				Marzec, M.; Kasprzycka, M.; Liu, X.; El-Salem, M.; Halasa, K.; Raghunath, P. N.; Bucki, R.; Wlodarski, P.; Wasik, M. A.			Oncogenic tyrosine kinase NPM/ALK induces activation of the rapamycin-sensitive mTOR signaling pathway	ONCOGENE			English	Article						anaplastic lymphoma kinase (ALK); mammalian target of rapamycin (mTOR); mitogen-activated protein kinase pathway (MAPK); protein kinase B (PKB/Akt)	TRANSFORMED B-LYMPHOCYTES; NON-HODGKINS-LYMPHOMA; T-CELL LYMPHOMA; TUBEROUS SCLEROSIS; MAMMALIAN TARGET; ANAPLASTIC LYMPHOMA; S6 KINASE; MEDIATED LYMPHOMAGENESIS; AMINO-ACIDS; IN-VITRO	The mechanisms of cell transformation mediated by the nucleophosmin (NPM)/anaplastic lymphoma kinase (ALK) tyrosine kinase are only partially understood. Here, we report that cell lines and native tissues derived from the NPM/ALK-expressing T-cell lymphoma display persistent activation of mammalian target of rapamycin ( mTOR) as determined by phosphorylation of mTOR targets S6rp and 4E-binding protein 1 (4E-BP1). The mTOR activation is serum growth factor-independent but nutrient-dependent. It is also dependent on the expression and enzymatic activity of NPM/ALK as demonstrated by cell transfection with wild-type and functionally deficient NPM/ALK, small interfering RNA (siRNA)-mediated NPM/ALK depletion and kinase activity suppression using the inhibitor WHI-P154. The NPM/ALK-induced mTOR activation is transduced through the mitogen-induced extracellular kinase (MEK)/extracellular signal-regulated kinase (ERK) signaling pathway and, to a much lesser degree, through the phosphatidylinositol 3-kinase (PI3K)/protein kinase B (Akt) pathway. Accordingly, whereas the low-dose PI3K inhibitor wortmannin and Akt inhibitor III profoundly inhibited Akt phosphorylation, they had a very modest effect on S6rp and 4E-BP1 phosphorylation. In turn, MEK inhibitors U0126 and PD98059 and siRNA-mediated depletion of either ERK1 or ERK2 inhibited S6rp phosphorylation much more effectively. Finally, the mTOR inhibitor rapamycin markedly decreased proliferation and increased the apoptotic rate of ALK+TCL cells. These findings identify mTOR as a novel key target of NPM/ALK and suggest that mTOR inhibitors may prove effective in therapy of ALK-induced malignancies.	Univ Penn, Med Ctr, Dept Pathol, Philadelphia, PA 19104 USA; Univ Penn, Med Ctr, Lab Med, Philadelphia, PA 19104 USA; Univ Penn, Dept Physiol, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania	Wasik, MA (corresponding author), Univ Penn, Med Ctr, Dept Pathol, 3400 Spruce St,7-106 Founders Pavil, Philadelphia, PA 19104 USA.	wasik@mail.med.upenn.edu	Marzec, Michal/O-6387-2016	Marzec, Michal/0000-0001-9698-6019; Bucki, Robert/0000-0001-7664-9226; Wlodarski, Pawel/0000-0002-0683-1791	NCI NIH HHS [R01 CA96856] Funding Source: Medline; NIDCR NIH HHS [R01-DE-017337] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA096856] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE017337] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Arvisais EW, 2006, J BIOL CHEM, V281, P26904, DOI 10.1074/jbc.M605371200; Bischof D, 1997, MOL CELL BIOL, V17, P2312, DOI 10.1128/MCB.17.4.2312; Brunn GJ, 1996, EMBO J, V15, P5256, DOI 10.1002/j.1460-2075.1996.tb00911.x; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Byfield MP, 2005, J BIOL CHEM, V280, P33076, DOI 10.1074/jbc.M507201200; Chiarle R, 2005, NAT MED, V11, P623, DOI 10.1038/nm1249; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Dong JX, 2004, GENE DEV, V18, P2479, DOI 10.1101/gad.1240504; Fujimoto J, 1996, P NATL ACAD SCI USA, V93, P4181, DOI 10.1073/pnas.93.9.4181; Hara K, 2002, CELL, V110, P177, DOI 10.1016/S0092-8674(02)00833-4; Hay N, 2004, GENE DEV, V18, P1926, DOI 10.1101/gad.1212704; Kasprzycka M, 2006, P NATL ACAD SCI USA, V103, P9964, DOI 10.1073/pnas.0603507103; Kuefer MU, 1997, BLOOD, V90, P2901, DOI 10.1182/blood.V90.8.2901; Ma L, 2005, CELL, V121, P179, DOI 10.1016/j.cell.2005.02.031; Majewski M, 2003, TRANSPLANTATION, V75, P1710, DOI 10.1097/01.TP.0000063934.89714.19; Majewski M, 2000, P NATL ACAD SCI USA, V97, P4285, DOI 10.1073/pnas.080068597; Manning BD, 2002, MOL CELL, V10, P151, DOI 10.1016/S1097-2765(02)00568-3; Marzec M, 2007, ONCOGENE, V26, P813, DOI 10.1038/sj.onc.1209843; Marzec M, 2005, LAB INVEST, V85, P1544, DOI 10.1038/labinvest.3700348; MORRIS SW, 1994, SCIENCE, V263, P1281, DOI 10.1126/science.8122112; Motegi A, 2004, J CELL SCI, V117, P3319, DOI 10.1242/jcs.01183; Nobukuni T, 2005, P NATL ACAD SCI USA, V102, P14238, DOI 10.1073/pnas.0506925102; Peng T, 2002, MOL CELL BIOL, V22, P5575, DOI 10.1128/MCB.22.15.5575-5584.2002; Roux PP, 2004, P NATL ACAD SCI USA, V101, P13489, DOI 10.1073/pnas.0405659101; SABATINI DM, 1994, CELL, V78, P35, DOI 10.1016/0092-8674(94)90570-3; Sakata A, 1999, IMMUNOL LETT, V68, P301, DOI 10.1016/S0165-2478(99)00053-X; Sekulic A, 2000, CANCER RES, V60, P3504; Shaw RJ, 2006, NATURE, V441, P424, DOI 10.1038/nature04869; Shillingford JM, 2006, P NATL ACAD SCI USA, V103, P5466, DOI 10.1073/pnas.0509694103; SHIOTA M, 1994, ONCOGENE, V9, P1567; Slupianek A, 2001, CANCER RES, V61, P2194; Smith EM, 2005, J BIOL CHEM, V280, P18717, DOI 10.1074/jbc.M414499200; Souttou B, 2001, J BIOL CHEM, V276, P9526, DOI 10.1074/jbc.M007333200; Suh JM, 2003, J BIOL CHEM, V278, P21960, DOI 10.1074/jbc.M300805200; Takano T, 2001, MOL CELL BIOL, V21, P5050, DOI 10.1128/MCB.21.15.5050-5062.2001; Tee AR, 2003, J BIOL CHEM, V278, P37288, DOI 10.1074/jbc.M303257200; Vega F, 2006, CANCER RES, V66, P6589, DOI 10.1158/0008-5472.CAN-05-3018; WASIK MA, 2002, J CLIN PATHOL S, V118, pS81; Wlodarski P, 2005, CANCER RES, V65, P7800, DOI 10.1158/0008-5472.CAN-04-4180; Zhang Q, 1996, P NATL ACAD SCI USA, V93, P9148, DOI 10.1073/pnas.93.17.9148; Zhang Q, 2002, J IMMUNOL, V168, P466, DOI 10.4049/jimmunol.168.1.466	41	76	83	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2007	26	38					5606	5614		10.1038/sj.onc.1210346	http://dx.doi.org/10.1038/sj.onc.1210346			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	200ZS	17353907				2022-12-28	WOS:000248801900006
J	Chun, SY; Chen, F; Washburn, JG; MacDonald, JW; Innes, KL; Zhao, R; Cruz-Correa, MR; Dang, LH; Dang, DT				Chun, S. Y.; Chen, F.; Washburn, J. G.; MacDonald, J. W.; Innes, K. L.; Zhao, R.; Cruz-Correa, M. R.; Dang, L. H.; Dang, D. T.			CDX2 promotes anchorage-independent growth bytranscriptional repression of IGFBP-3	ONCOGENE			English	Article						CDX2; IGFBP-3; colorectal cancer; anchorageindependent growth	FACTOR BINDING PROTEIN-3; GENE-EXPRESSION; FACTOR (IGF)-I; MUTANT MICE; CANCER; TRANSCRIPTION; CELLS	CDX2 is a Drosophila caudal-related homeobox transcription factor that is important for the establishment and maintenance of intestinal epithelial cells. We have reported that CDX2 promotes tumorigenicity in a subset of human colorectal cancer cell lines. Here, we present evidence that CDX2 negatively regulates the well-documented growth inhibitor insulin-like growth factor binding protein-3 IGFBP-3). Specifically, CDX2 binds to the IGFBP-3 gene promoter and can repress IGFBP-3 transcription, protein expression and secretion. Furthermore, inhibition of IGFBP-3 partially rescues the decreased anchorage-independent growth phenotype observed in CDX2 knockout cells. These data demonstrate for the first time that (1) CDX2 can function as a transcriptional repressor, and ( 2) one mechanism by which CDX2 promotes anchorage-independent growth is by transcriptional repression of IGFBP-3.	Univ Michigan, Dept Internal Med, Div Gastroenterol, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Internal Med, Div Hematol Oncol, Ann Arbor, MI 48109 USA; Univ Michigan, Ctr Comprehens Canc, Affymetrix & cDNA Microarray Core Facil, Ann Arbor, MI 48109 USA; Univ Puerto Rico, Ctr Comprehens Canc, Dept Internal Med, Div Gastroenterol, San Juan, PR 00936 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Puerto Rico; University of Puerto Rico Medical Sciences Campus	Dang, DT (corresponding author), Univ Michigan, Dept Internal Med, Div Gastroenterol, 1150 W Med Ctr Dr,MSRB I,Room 6514, Ann Arbor, MI 48109 USA.	dangd@umich.edu			NATIONAL CANCER INSTITUTE [P30CA046592, K22CA111897] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK059970] Funding Source: NIH RePORTER; NCI NIH HHS [K22CA111897, 5 P30 CA46592] Funding Source: Medline; NIDDK NIH HHS [K08DK59970] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aoki K, 2003, NAT GENET, V35, P323, DOI 10.1038/ng1265; Baxter RC, 2001, J CLIN PATHOL-MOL PA, V54, P145, DOI 10.1136/mp.54.3.145; Chawengsaksophak K, 1997, NATURE, V386, P84, DOI 10.1038/386084a0; CUBBAGE ML, 1990, J BIOL CHEM, V265, P12642; Dang LH, 2006, ONCOGENE, V25, P2264, DOI 10.1038/sj.onc.1209247; Escaffit F, 2006, BIOCHEM BIOPH RES CO, V342, P66, DOI 10.1016/j.bbrc.2006.01.128; FRANCIS GL, 1992, J MOL ENDOCRINOL, V8, P213, DOI 10.1677/jme.0.0080213; GERMAN MS, 1994, GENOMICS, V24, P403, DOI 10.1006/geno.1994.1639; Guo RJ, 2004, CANCER BIOL THER, V3, P593, DOI 10.4161/cbt.3.7.913; Heckman CA, 2000, J BIOL CHEM, V275, P6499, DOI 10.1074/jbc.275.9.6499; Heinemeyer T, 1998, NUCLEIC ACIDS RES, V26, P362, DOI 10.1093/nar/26.1.362; JAMES R, 1994, J BIOL CHEM, V269, P15229; Krasinski SD, 2001, AM J PHYSIOL-GASTR L, V281, pG69, DOI 10.1152/ajpgi.2001.281.1.G69; Lee HY, 2002, CANCER RES, V62, P3530; Pollak MN, 2004, NAT REV CANCER, V4, P505, DOI 10.1038/nrc1387; Rawat VPS, 2004, P NATL ACAD SCI USA, V101, P817, DOI 10.1073/pnas.0305555101; Renehan AG, 2004, LANCET, V363, P1346, DOI 10.1016/S0140-6736(04)16044-3; Sims RJ, 2004, CURR OPIN CELL BIOL, V16, P263, DOI 10.1016/j.ceb.2004.04.004; Yamamoto H, 2003, BIOCHEM BIOPH RES CO, V300, P813, DOI 10.1016/S0006-291X(02)02935-2	19	20	20	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 12	2007	26	32					4725	4729		10.1038/sj.onc.1210258	http://dx.doi.org/10.1038/sj.onc.1210258			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	190DJ	17297462				2022-12-28	WOS:000248037900013
J	Leupold, JH; Yang, HS; Colburn, NH; Asangani, I; Post, S; Allgayer, H				Leupold, J. H.; Yang, H-S; Colburn, N. H.; Asangani, I.; Post, S.; Allgayer, H.			Tumor suppressor Pdcd4 inhibits invasion/intravasation and regulates urokinase receptor (u-PAR) gene expression via Sp-transcription factors	ONCOGENE			English	Article						Pdcd4; Sp1; Sp3; invasion; intravasation; u-PAR	PLASMINOGEN-ACTIVATOR SYSTEM; TRANSFORMATION SUPPRESSOR; EUKARYOTIC TRANSLATION; PROGNOSTIC IMPACT; BINDING-PROTEIN; GROWTH-FACTOR; CELL-LINE; REQUIREMENT; PROMOTER; INVASION	Tumor suppressor Pdcd4 has recently been shown to inhibit invasion by activating activator protein-1 (AP-1); however, little is known of the functionally significant Pdcd4-target genes. The urokinase receptor (u-PAR) promotes invasion/metastasis, and is associated with poor cancer-patient survival. The present study was conducted (1) to investigate a role for Pdcd4 in intravasation, invasion and u-PAR regulation, and (2) to describe mechanisms by which this is achieved. Fourteen cell lines showed reciprocal expression of u-PAR/Pdcd4. Resected tumor/normal tissues of 29 colorectal cancer patients demonstrated a significant inverse correlation between Pdcd4/u-PAR. siRNA-Pdcd4-transfected GEO cells significantly increased endogenous u-PAR mRNA/protein. A u-PAR-promoter-chloramphenicol acetyl transferase (CAT)-reporter was reduced in activity with increasing Pdcd4 expression in RKO. Deletion of a putative Sp-1-binding site (-402/-350) inhibited u-PAR promoter regulation by Pdcd4, this being paralleled by a reduction of Sp1 binding to this region in pdcd4-transfected cells. Pdcd4-transfected cells showed an increase in Sp3 binding to u-PAR promoter region -152/-135, the deletion of which reduces the ability of Pdcd4 to suppress u- PAR promoter activity. Surprisingly, the u-PAR-AP-1 site was not targeted by Pdcd4. Finally, RKO cells overexpressing Pdcd4 showed an inhibition of invasion/intravasation (chicken embryo metastasis assay). These data suggest Pdcd4 as a new negative regulator of intravasation, and qas the invasion-related gene u-PAR. It is the first study to implicate Pdcd4 regulation of gene expression via Sp1/Sp3.	Heidelberg Univ, DKFZ Heidelberg, Med Fac Mannheim, Dept Expt Surg & Mol Oncol Solid Tumors, D-6900 Heidelberg, Germany; NCI, Basic Res Lab, Gene Regulat Sect, Frederick, MD USA; Heidelberg Univ, Med Fac Mannheim, Dept Surg, Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Ruprecht Karls University Heidelberg	Allgayer, H (corresponding author), Heidelberg Univ, Med Fac Mannheim, Dept Expt Surg Mol Oncol Solid Tumors, Collaborat Unit German Canc Res Ctr DKFZ Heidelbe, D-68167 Mannheim, Germany.	heike.allgayer@chir.ma.uni-heidelberg.de	Yang, Hsin-Sheng/A-6419-2008; Yang, Hsin-Sheng/AAF-6793-2020	Yang, Hsin-Sheng/0000-0002-0566-3036; Yang, Hsin-Sheng/0000-0002-0566-3036; asangani, irfan/0000-0001-5381-1702	NATIONAL CANCER INSTITUTE [ZIABC010026, Z01BC010026] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aguirre-Ghiso JA, 2001, MOL BIOL CELL, V12, P863, DOI 10.1091/mbc.12.4.863; Aguirre-Ghiso JA, 2003, CANCER RES, V63, P1684; Ahmed N, 2003, BRIT J CANCER, V89, P374, DOI 10.1038/sj.bjc.6601098; ALBINI A, 1987, CANCER RES, V47, P3239; Allgayer H, 1999, J BIOL CHEM, V274, P4702, DOI 10.1074/jbc.274.8.4702; Allgayer H, 1999, J BIOL CHEM, V274, P18428, DOI 10.1074/jbc.274.26.18428; Allgayer H, 1999, BRIT J CANCER, V80, P1884, DOI 10.1038/sj.bjc.6690616; Azzoni L, 1998, J IMMUNOL, V161, P3493; Bitomsky N, 2004, ONCOGENE, V23, P7484, DOI 10.1038/sj.onc.1208064; BLASI F, 1993, BIOESSAYS, V15, P105, DOI 10.1002/bies.950150206; BOYD D, 1988, CANCER RES, V48, P3112; BOYD D, 1989, CANCER RES, V49, P1948; CHEN S, 2003, P ICASSP HONG KONG C, V4, P640; Cmarik JL, 1999, P NATL ACAD SCI USA, V96, P14037, DOI 10.1073/pnas.96.24.14037; DIKIC I, 1995, J BIOL CHEM, V270, P15125, DOI 10.1074/jbc.270.25.15125; DUFFY MJ, 1987, EUR J CANCER CLIN ON, V23, P583, DOI 10.1016/0277-5379(87)90326-9; Fuchs T, 2003, BIOL CHEM, V384, P755, DOI 10.1515/BC.2003.084; GALLI G, 1992, COMPUTER SIMULATION, P261; GANESH S, 1994, LANCET, V344, P401, DOI 10.1016/S0140-6736(94)91427-3; Goke R, 2004, ANN NY ACAD SCI, V1014, P220, DOI 10.1196/annals.1294.024; Hapke S, 2001, MOL CELL BIOL, V21, P2118, DOI 10.1128/MCB.21.6.2118-2132.2001; Heiss MM, 1996, EUR J SURG ONCOL, V22, P74, DOI 10.1016/S0748-7983(96)91649-2; HEISS MM, 1995, NAT MED, V1, P1035, DOI 10.1038/nm1095-1035; JANICKE F, 1993, BREAST CANCER RES TR, V24, P195, DOI 10.1007/BF01833260; Jansen AP, 2005, CANCER RES, V65, P6034, DOI 10.1158/0008-5472.CAN-04-2119; Jansen AP, 2004, MOL CANCER THER, V3, P103; Kang MJ, 2002, BIOCHEM BIOPH RES CO, V293, P617, DOI 10.1016/S0006-291X(02)00264-4; Kim J, 1998, CELL, V94, P353, DOI 10.1016/S0092-8674(00)81478-6; Lankat-Buttgereit B, 2004, MOL CELL ENDOCRINOL, V214, P149, DOI 10.1016/j.mce.2003.10.058; Lengyel E, 1996, J BIOL CHEM, V271, P23176, DOI 10.1074/jbc.271.38.23176; MONTE S, 2002, BIOTECHNIQUES, V33, P98; Muehlenweg B, 2001, EXPERT OPIN BIOL TH, V1, P683; NEKARDA H, 1994, CANCER RES, V54, P2900; Onishi Y, 1996, BIOCHEM BIOPH RES CO, V228, P7, DOI 10.1006/bbrc.1996.1609; Onishi Y, 1998, GENE, V215, P453, DOI 10.1016/S0378-1119(98)00313-8; OSSOWSKI L, 1988, J CELL BIOL, V107, P2437, DOI 10.1083/jcb.107.6.2437; OSSOWSKI L, 1991, J CELL BIOL, V115, P1107, DOI 10.1083/jcb.115.4.1107; Palamarchuk A, 2005, CANCER RES, V65, P11282, DOI 10.1158/0008-5472.CAN-05-3469; Qin HW, 1999, J BIOL CHEM, V274, P29130, DOI 10.1074/jbc.274.41.29130; Ritchie S, 2000, J BIOL CHEM, V275, P847, DOI 10.1074/jbc.275.2.847; Schewe DM, 2005, CLIN CANCER RES, V11, P8538, DOI 10.1158/1078-0432.CCR-05-0786; Schlichter U, 2001, ONCOGENE, V20, P231, DOI 10.1038/sj.onc.1204071; Shetty S, 2004, AM J RESP CELL MOL, V31, P100, DOI 10.1165/rcmb.2003-0104OC; Shetty S, 1997, MOL CELL BIOL, V17, P1075, DOI 10.1128/MCB.17.3.1075; Shibahara K, 1995, GENE, V166, P297, DOI 10.1016/0378-1119(95)00607-9; Soejima H, 1999, CYTOGENET CELL GENET, V87, P113, DOI 10.1159/000015408; Stalberg P, 2001, BIOCHEM BIOPH RES CO, V281, P227, DOI 10.1006/bbrc.2001.4329; Su KH, 1999, J BIOL CHEM, V274, P15194, DOI 10.1074/jbc.274.21.15194; WAGNER SN, 1995, AM J PATHOL, V147, P183; Wang AY, 2000, EUR J BIOCHEM, V267, P3248, DOI 10.1046/j.1432-1327.2000.01350.x; WANG H, 1994, INT J CANCER, V58, P650, DOI 10.1002/ijc.2910580506; Yang HS, 2003, MOL CELL BIOL, V23, P26, DOI 10.1128/MCB.23.1.26-37.2003; Yang HS, 2006, MOL CELL BIOL, V26, P1297, DOI 10.1128/MCB.26.4.1297-1306.2006; Yang HS, 2004, MOL CELL BIOL, V24, P3894, DOI 10.1128/MCB.24.9.3894-3906.2004; Yang HS, 2003, ONCOGENE, V22, P3712, DOI 10.1038/sj.onc.1206433; Yang HS, 2001, ONCOGENE, V20, P669, DOI 10.1038/sj.onc.1204137; Yang XY, 2001, P NATL ACAD SCI USA, V98, P6611, DOI 10.1073/pnas.111099998; Yoshinaga H, 1999, PATHOL INT, V49, P1067, DOI 10.1046/j.1440-1827.1999.00995.x; Zakowicz H, 2005, RNA, V11, P261, DOI 10.1261/rna.7191905; Zhang ZH, 2001, ONCOGENE, V20, P4450, DOI 10.1038/sj.onc.1204588; Zijlstra A, 2002, CANCER RES, V62, P7083	61	139	143	1	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2007	26	31					4550	4562		10.1038/sj.onc.1210234	http://dx.doi.org/10.1038/sj.onc.1210234			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	187GR	17297470				2022-12-28	WOS:000247836100009
J	Fabre, C; Carvalho, G; Tasdemir, E; Braun, T; Ades, L; Grosjean, J; Boehrer, S; Metivier, D; Souquere, S; Pierron, G; Fenaux, P; Kroemer, G				Fabre, C.; Carvalho, G.; Tasdemir, E.; Braun, T.; Ades, L.; Grosjean, J.; Boehrer, S.; Metivier, D.; Souquere, S.; Pierron, G.; Fenaux, P.; Kroemer, G.			NF-kappa B inhibition sensitizes to starvation-induced cell death in high-risk myelodysplastic syndrome and acute myeloid leukemia	ONCOGENE			English	Article						apoptosis; autophagy; caspases; chemotherapy; mitochondria	THERAPEUTIC TARGET; APOPTOSIS; AUTOPHAGY; CANCER; PATHWAY; LINE	CD34(+) bone marrow blasts from high-risk myelodysplastic syndrome (MDS) patients as well as MDS patient-derived cell lines (P39 and MOLM13) constitutively activate the nuclear factor-kappa B (NF-kappa B) pathway and undergo apoptosis when NF-kappa B is inhibited. Here, we show that the combination of conventional chemotherapeutic agents (daunorubicin, mitoxantrone, 5-azacytidine or camptothecin) with the NF-kappa B inhibitor BAY11-7082 did not yield a synergistic cytotoxicity. In contrast, BAY11-7082 (which targets the NF-kappa B-activating I-kappa B kinase (IKK) complex) or knockdown of essential components of the NF-kappa B system (such as the IKK1 and IKK2 subunits of the IKK complex and the p65 subunit of NF-kappa B), by small interfering RNAs sensitized MDS cell lines to starvation-induced apoptosis. The combination of BAY11-7082 and nutrient depletion synergistically killed the acute myeloid leukemia (AML) cell line U937 as well as primary CD34+ bone marrow blasts from AML and high-risk MDS patients. The synergistic killing by BAY11-7082, combined with nutrient depletion, led to cell death accompanied by all hallmarks of apoptosis, including an early loss of the mitochondrial transmembrane potential, the release of cytochrome c and apoptosis-inducing factor (AIF) from mitochondria, activation of caspase-3, phosphatidylserine exposure on the plasma membrane surface and nuclear chromatin condensation. Transmission electron microscopy revealed the presence of numerous autophagic vacuoles in the cytoplasm before cells underwent nuclear apoptosis. Nonetheless, cell death was neither inhibited by the pan-caspase inhibitor z-VAD-fmk nor by knockdown of AIF or of essential components of the autophagy pathway (ATG5, ATG6/ Beclin-1, ATG10, ATG12). In contrast, external supply of glucose, insulin or insulin-like growth factor-I could retard the cell death induced by BAY11-7082 combined with starvation. These results suggest that in MDS cells, NF-kappa B inhibition can precipitate a bioenergetic crisis that leads to an autophagic stress response followed by apoptotic cell death.	Inst Gustave Roussy, CNRS, FRE 2939, F-94805 Villejuif, France; INSERM, Unit Apoptosis Canc & Immun, F-94800 Villejuif, France; Univ Paris 11, Fac Paris Sud, F-94800 Villejuif, France; Univ Paris 11, Hop Paul Brousse, INSERM U542, F-94800 Villejuif, France; Univ Paris 13, AP HP, Hop Avicenne, Serv Hematol Clin, Bobigny, France; Inst Andre Lwoff, CNRS, Villejuif, France	Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Paul-Brousse - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Avicenne - APHP; Universite Paris 13; Centre National de la Recherche Scientifique (CNRS)	Kroemer, G (corresponding author), Inst Gustave Roussy, CNRS, FRE 2939, 39 Rue Camille Desmoulins, F-94805 Villejuif, France.	kroemer@igr.fr	Ades, lionel/T-6882-2019; KROEMER, Guido/B-4263-2013	KROEMER, Guido/0000-0002-9334-4405				Akdemir F, 2006, DEVELOPMENT, V133, P1457, DOI 10.1242/dev.02332; Birkenkamp KU, 2004, LEUKEMIA, V18, P103, DOI 10.1038/sj.leu.2403145; Boya P, 2005, MOL CELL BIOL, V25, P1025, DOI 10.1128/MCB.25.3.1025-1040.2005; Braun T, 2006, CELL DEATH DIFFER, V13, P748, DOI 10.1038/sj.cdd.4401874; Braun T, 2006, BLOOD, V107, P1156; CARVALHO G, 2006, ONCOGENE        1016; Chipuk JE, 2005, NAT REV MOL CELL BIO, V6, P268, DOI [10.1038/nrm1573, 10.1038/nrm2239]; Dombret H, 2002, SEMIN HEMATOL, V39, P8, DOI 10.1053/shem.2002.33608; Engedal N, 2003, J BIOL CHEM, V278, P10934, DOI 10.1074/jbc.M211556200; Fenaux P, 2005, SEMIN ONCOL, V32, pS11, DOI 10.1053/j.seminoncol.2005.06.016; Gonzalez-Polo RA, 2005, J CELL SCI, V118, P3091, DOI 10.1242/jcs.02447; Guzman ML, 2001, BLOOD, V98, P2301, DOI 10.1182/blood.V98.8.2301; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hassan Z, 1999, EXP HEMATOL, V27, P1322, DOI 10.1016/S0301-472X(99)00066-1; Igney FH, 2002, NAT REV CANCER, V2, P277, DOI 10.1038/nrc776; Israel A, 2006, CELL DEATH DIFFER, V13, P685, DOI 10.1038/sj.cdd.4401891; Karin M, 2004, NAT REV DRUG DISCOV, V3, P17, DOI 10.1038/nrd1279; Kroemer G, 2005, NAT MED, V11, P725, DOI 10.1038/nm1263; Kroemer G, 2005, CELL DEATH DIFFER, V12, P1463, DOI 10.1038/sj.cdd.4401724; Kroemer G, 2005, NAT REV CANCER, V5, P886, DOI 10.1038/nrc1738; Levine B, 2005, J CLIN INVEST, V115, P2679, DOI 10.1172/JCI26390; Lum JJ, 2005, CELL, V120, P237, DOI 10.1016/j.cell.2004.11.046; Luo JL, 2005, J CLIN INVEST, V115, P2625, DOI 10.1172/JCI26322; Mani A, 2005, J CLIN ONCOL, V23, P4776, DOI 10.1200/JCO.2005.05.081; Martin DN, 2004, DEVELOPMENT, V131, P275, DOI 10.1242/dev.00933; Matsuo Y, 1997, LEUKEMIA, V11, P1469, DOI 10.1038/sj.leu.2400768; Mizushima N, 2004, MOL BIOL CELL, V15, P1101, DOI 10.1091/mbc.E03-09-0704; Modjtahedi N, 2006, TRENDS CELL BIOL, V16, P264, DOI 10.1016/j.tcb.2006.03.008; NAGAI M, 1984, GANN, V75, P1100; Rajkumar SV, 2005, J CLIN ONCOL, V23, P630, DOI 10.1200/JCO.2005.11.030; Ribrag V, 2003, LEUKEMIA, V17, P319, DOI 10.1038/sj.leu.2402726; Shimizu S, 2004, NAT CELL BIOL, V6, P1221, DOI 10.1038/ncb1192; Shintani T, 2004, SCIENCE, V306, P990, DOI 10.1126/science.1099993; Silverman Lewis R, 2005, Nat Clin Pract Oncol, V2 Suppl 1, pS12, DOI 10.1038/ncponc0347; Vahsen N, 2004, EMBO J, V23, P4679, DOI 10.1038/sj.emboj.7600461; Yu L, 2004, SCIENCE, V304, P1500, DOI 10.1126/science.1096645	36	80	92	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 14	2007	26	28					4071	4083		10.1038/sj.onc.1210187	http://dx.doi.org/10.1038/sj.onc.1210187			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	178XD	17213804				2022-12-28	WOS:000247252700003
J	Boelaert, K; Smith, VE; Stratford, AL; Kogai, T; Tannahill, LA; Watkinson, JC; Eggo, MC; Franklyn, JA; McCabe, CJ				Boelaert, K.; Smith, V. E.; Stratford, A. L.; Kogai, T.; Tannahill, L. A.; Watkinson, J. C.; Eggo, M. C.; Franklyn, J. A.; McCabe, C. J.			PTTG and PBF repress the human sodium iodide symporter	ONCOGENE			English	Article						PTTG; PBF; NIS; thyroid cancer	TUMOR-TRANSFORMING GENE; PAPILLARY THYROID CARCINOMAS; TRANSCRIPTIONAL ACTIVATION FUNCTION; SODIUM/IODIDE-SYMPORTER; NA+/I-SYMPORTER; GROWTH-FACTOR; CYCLIC ADENOSINE-3',5'-MONOPHOSPHATE; CHROMATID SEPARATION; PITUITARY-ADENOMAS; FOLLICULAR CELLS	The ability of the thyroid to accumulate iodide provides the basis for radioiodine ablation of differentiated thyroid cancers and their metastases. Most thyroid tumours exhibit reduced iodide uptake, although the mechanisms accounting for this remain poorly understood. Pituitary tumour transforming gene (PTTG) is a proto-oncogene implicated in the pathogenesis of thyroid tumours. We now show that PTTG and its binding factor PBF repress expression of sodium iodide symporter (NIS) messenger RNA (mRNA), and inhibit iodide uptake. This process is mediated at least in part through. fibroblast growth factor-2. In detailed studies of the NIS promoter in rat FRTL-5 cells, PTTG and PBF demonstrated specific inhibition of promoter activity via the human upstream enhancer element (hNUE). Within this similar to 1 kb element, a complex PAX8-upstream stimulating factor 1 (USF1) response element proved critical both to basal promoter activity and to PTTG and PBF repression of NIS. In particular, repression by PTTG was contingent upon the USF1, but not the PAX8, site. Finally, in human primary thyroid cells, PTTG and PBF similarly repressed the NIS promoter via hNUE. Taken together, our data suggest that the reported overexpression of PTTG and PBF in differentiated thyroid cancer has profound implications for activity of the NIS gene, and hence significantly impacts upon the ef. ficacy of radioiodine treatment.	Univ Birmingham, Dept Med, Inst Biomed Res, Div Med Sci, Birmingham B15 2TH, W Midlands, England; Univ Coll Los Angeles, V A Greater Los Angeles Healthcare Syst, Dept Med Endocrinol & Diabet Div, Los Angeles, CA USA	University of Birmingham	McCabe, CJ (corresponding author), Univ Birmingham, Dept Med, Inst Biomed Res, Div Med Sci, Birmingham B15 2TH, W Midlands, England.	mccabcjz@bham.ac.uk	Smith, Vicki E/F-6972-2010	Smith, Vicki E/0000-0003-0757-7198	MRC [G0601811] Funding Source: UKRI; Medical Research Council [G0601811] Funding Source: Medline; Wellcome Trust Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust)		AMBESIIMPIOMBATO FS, 1980, P NATL ACAD SCI-BIOL, V77, P3455, DOI 10.1073/pnas.77.6.3455; Arturi F, 2000, EUR J ENDOCRINOL, V143, P623, DOI 10.1530/eje.0.1430623; Arturi F, 2001, EUR J ENDOCRINOL, V145, P129, DOI 10.1530/eje.0.1450129; Behr M, 1998, BIOCHEM J, V331, P359, DOI 10.1042/bj3310359; Boelaert K, 2004, J MOL ENDOCRINOL, V33, P663, DOI 10.1677/jme.1.01606; Boelaert K, 2003, FASEB J, V17, P1631, DOI 10.1096/fj.02-0948com; Boelaert K, 2003, J CLIN ENDOCR METAB, V88, P2341, DOI 10.1210/jc.2002-021113; Boelaert K, 2003, LANCET, V361, P796, DOI 10.1016/S0140-6736(03)12720-1; Caillou B, 1998, J CLIN ENDOCR METAB, V83, P4102, DOI 10.1210/jc.83.11.4102; Castro MR, 1999, J ENDOCRINOL, V163, P495, DOI 10.1677/joe.0.1630495; Chien WW, 2000, J BIOL CHEM, V275, P19422, DOI 10.1074/jbc.M910105199; Chun JT, 2004, MOL ENDOCRINOL, V18, P2817, DOI 10.1210/me.2004-0020; Cocks HC, 2003, AM J PHYSIOL-ENDOC M, V285, pE460, DOI 10.1152/ajpendo.00519.2002; Dai G, 1996, NATURE, V379, P458, DOI 10.1038/379458a0; Dohan O, 2003, ENDOCR REV, V24, P48, DOI 10.1210/er.2001-0029; Dominguez A, 1998, ONCOGENE, V17, P2187, DOI 10.1038/sj.onc.1202140; Eggo MC, 1996, J CLIN ENDOCR METAB, V81, P3056, DOI 10.1210/jc.81.8.3056; EGGO MC, 1995, J CLIN ENDOCR METAB, V80, P1006, DOI 10.1210/jc.80.3.1006; Heaney AP, 2001, J CLIN ENDOCR METAB, V86, P5025, DOI 10.1210/jc.86.10.5025; Heaney AP, 2000, LANCET, V355, P716, DOI 10.1016/S0140-6736(99)10238-1; Ishikawa H, 2001, J CLIN ENDOCR METAB, V86, P867, DOI 10.1210/jc.86.2.867; Jhiang SM, 1998, ENDOCRINOLOGY, V139, P4416, DOI 10.1210/en.139.10.4416; Kim D, 2005, ONCOGENE, V24, P4861, DOI 10.1038/sj.onc.1208659; Kim DS, 2006, J CLIN ENDOCR METAB, V91, P4603, DOI 10.1210/jc.2006-1291; Kogai T, 2000, P NATL ACAD SCI USA, V97, P8519, DOI 10.1073/pnas.140217197; Kogai T, 1997, ENDOCRINOLOGY, V138, P2227, DOI 10.1210/en.138.6.2227; Lazar V, 1999, J CLIN ENDOCR METAB, V84, P3228, DOI 10.1210/jc.84.9.3228; Lin XQ, 2004, THYROID, V14, P19, DOI 10.1089/105072504322783803; Liou MJ, 2000, CANCER LETT, V160, P75, DOI 10.1016/S0304-3835(00)00565-6; McCabe Chris, 2001, Current Opinion in Pharmacology, V1, P620, DOI 10.1016/S1471-4892(01)00106-0; McCabe CJ, 2003, CLIN ENDOCRINOL, V58, P141, DOI 10.1046/j.1365-2265.2003.01598.x; McCabe CJ, 2002, J CLIN ENDOCR METAB, V87, P4238, DOI 10.1210/jc.2002-020309; Park HJ, 2000, THYROID, V10, P211, DOI 10.1089/thy.2000.10.211; Pei L, 1997, MOL ENDOCRINOL, V11, P433, DOI 10.1210/me.11.4.433; Pei L, 2001, J BIOL CHEM, V276, P8484, DOI 10.1074/jbc.M009654200; Pei L, 2000, J BIOL CHEM, V275, P31191, DOI 10.1074/jbc.M002451200; Puri R, 2001, CANCER LETT, V163, P131, DOI 10.1016/S0304-3835(00)00688-1; Ramsden JD, 2001, J CLIN ENDOCR METAB, V86, P2709, DOI 10.1210/jc.86.6.2709; Ringel MD, 2001, MODERN PATHOL, V14, P289, DOI 10.1038/modpathol.3880305; Romero F, 2001, NUCLEIC ACIDS RES, V29, P1300, DOI 10.1093/nar/29.6.1300; Ryu KY, 1999, THYROID, V9, P405, DOI 10.1089/thy.1999.9.405; Ryu KY, 1998, J CLIN ENDOCR METAB, V83, P3247, DOI 10.1210/jc.83.9.3247; Saez C, 2006, J CLIN ENDOCR METAB, V91, P1404, DOI 10.1210/jc.2005-2532; Saito T, 1998, J CLIN INVEST, V101, P1296, DOI 10.1172/JCI1259; Schmidt D, 2001, CURR OPIN HEMATOL, V8, P1, DOI 10.1097/00062752-200101000-00001; Shibata Y, 2002, JPN J CLIN ONCOL, V32, P233, DOI 10.1093/jjco/hyf058; Smanik PA, 1996, BIOCHEM BIOPH RES CO, V226, P339, DOI 10.1006/bbrc.1996.1358; Smanik PA, 1997, ENDOCRINOLOGY, V138, P3555, DOI 10.1210/en.138.8.3555; Spitzweg C, 1999, THYROID, V9, P821, DOI 10.1089/thy.1999.9.821; Stratford AL, 2005, J CLIN ENDOCR METAB, V90, P4341, DOI 10.1210/jc.2005-0523; Taki K, 2002, MOL ENDOCRINOL, V16, P2266, DOI 10.1210/me.2002-0109; Tanaka K, 2000, EUR J ENDOCRINOL, V142, P340, DOI 10.1530/eje.0.1420340; Yaspo ML, 1998, GENOMICS, V49, P133, DOI 10.1006/geno.1998.5217; Yu R, 2000, MOL ENDOCRINOL, V14, P1137, DOI 10.1210/me.14.8.1137; Yu R, 2001, BRAIN PATHOL, V11, P328; Zhang X, 1999, MOL ENDOCRINOL, V13, P156, DOI 10.1210/me.13.1.156; Zhang X, 1999, J CLIN ENDOCR METAB, V84, P761, DOI 10.1210/jc.84.2.761; Zou H, 1999, SCIENCE, V285, P418, DOI 10.1126/science.285.5426.418; Zur A, 2001, EMBO J, V20, P792, DOI 10.1093/emboj/20.4.792	59	40	41	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2007	26	30					4344	4356		10.1038/sj.onc.1210221	http://dx.doi.org/10.1038/sj.onc.1210221			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	184CZ	17297475				2022-12-28	WOS:000247620000003
J	Iwakuma, T; Lozano, G				Iwakuma, T.; Lozano, G.			Crippling p53 activities via knock-in mutations in mouse models	ONCOGENE			English	Review						mutant p53; mouse model; knock-in mouse	LI-FRAUMENI-SYNDROME; GAIN-OF-FUNCTION; SUPPRESSOR PROTEIN P53; INDUCED DNA-DAMAGE; C-TERMINAL DOMAIN; EMBRYONIC LETHALITY; MUTANT P53; POSTTRANSLATIONAL MODIFICATIONS; TRANSCRIPTIONAL ACTIVATION; APOPTOTIC ACTIVITY	The tumor suppressor p53 is the most frequently mutated gene in human cancer. In vivo models have been generated using knock-in alleles in which missense mutations are introduced that mimic the kinds of mutations found in human cancers, or that abolish specific p53 functions. Critically, these studies examine the in vivo and physiological functions of p53. Studies indicate that p53 missense mutations in the DNA-binding domain identical with those inherited in the Li-Fraumeni syndrome, have distinct properties. Studies in mice with mutants that separate cell- cycle arrest and apoptosis functions of p53 show delayed onset of tumor development, suggesting that both p53 functions are crucial for suppressing tumors. Mice with mutations at post-translational modi. cation sites exhibit subtle effects on p53 activity and tumor development, indicating a fine-tuning mechanism of p53 activity in vivo. Importantly, each mutant mouse has a distinct phenotype, suggesting diverse and exquisite mechanisms of p53 regulation in different environments, different tissues and different genetic backgrounds. The generation of these mutant p53 knock-in mice has laid the groundwork for future studies to elucidate the in vivo physiological function of mutant p53 and to examine cooperating effects in combination with other alterations.	Univ Texas, MD Anderson Canc Ctr, Dept Canc Genet, Houston, TX USA; Louisiana State Univ, Hlth Sci Ctr, Dept Genet, New Orleans, LA USA	University of Texas System; UTMD Anderson Cancer Center; Louisiana State University System; Louisiana State University Health Sciences Center New Orleans	Lozano, G (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Canc Genet, Houston, TX USA.	gglozano@mdanderson.org			NCI NIH HHS [CA34936, CA82577] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA034936, R01CA082577] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Achison M, 2003, ONCOGENE, V22, P3431, DOI 10.1038/sj.onc.1206434; Appella E, 2001, EUR J BIOCHEM, V268, P2764, DOI 10.1046/j.1432-1327.2001.02225.x; Appella E, 2000, PATHOL BIOL, V48, P227; BARTEK J, 1991, ONCOGENE, V6, P1699; Bruins W, 2004, MOL CELL BIOL, V24, P8884, DOI 10.1128/mcb.24.20.8884-8894.2004; Cadwell C, 2001, GENE, V277, P15, DOI 10.1016/S0378-1119(01)00696-5; Chao C, 2000, P NATL ACAD SCI USA, V97, P11936, DOI 10.1073/pnas.220252297; Chao C, 2006, EMBO J, V25, P2615, DOI 10.1038/sj.emboj.7601167; Chehab NH, 1999, P NATL ACAD SCI USA, V96, P13777, DOI 10.1073/pnas.96.24.13777; Chuikov S, 2004, NATURE, V432, P353, DOI 10.1038/nature03117; Craig AL, 1999, BIOCHEM J, V342, P133, DOI 10.1042/0264-6021:3420133; CROOK T, 1994, CELL, V79, P817, DOI 10.1016/0092-8674(94)90071-X; de Vries A, 2002, P NATL ACAD SCI USA, V99, P2948, DOI 10.1073/pnas.052713099; DELMOLINO L, 1993, CARCINOGENESIS, V14, P827, DOI 10.1093/carcin/14.5.827; Deppert W, 2000, J CELL BIOCHEM, P115; Di Como CJ, 1999, MOL CELL BIOL, V19, P1438; DONEHOWER LA, 1995, MOL CARCINOGEN, V14, P16, DOI 10.1002/mc.2940140105; Dumaz N, 1997, CARCINOGENESIS, V18, P897, DOI 10.1093/carcin/18.5.897; Feng LJ, 2005, MOL CELL BIOL, V25, P5389, DOI 10.1128/MCB.25.13.5389-5395.2005; Flores ER, 2005, CANCER CELL, V7, P363, DOI 10.1016/j.ccr.2005.02.019; Friedler A, 2005, STRUCTURE, V13, P629, DOI 10.1016/j.str.2005.01.020; Gaiddon C, 2001, MOL CELL BIOL, V21, P1874, DOI 10.1128/MCB.21.5.1874-1887.2001; Gao YJ, 2000, NATURE, V404, P897, DOI 10.1038/35009138; Gostissa M, 1999, EMBO J, V18, P6462, DOI 10.1093/emboj/18.22.6462; Gu JJ, 2000, MOL CELL BIOL, V20, P1243, DOI 10.1128/MCB.20.4.1243-1253.2000; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Hao MM, 1996, J BIOL CHEM, V271, P29380, DOI 10.1074/jbc.271.46.29380; Harper JW, 2004, CELL, V118, P2, DOI 10.1016/j.cell.2004.06.015; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HUPP TR, 1994, CURR BIOL, V4, P865, DOI 10.1016/S0960-9822(00)00195-0; Iacopetta B, 2003, HUM MUTAT, V21, P271, DOI 10.1002/humu.10175; Iwakuma T, 2005, CELL CYCLE, V4, P865, DOI 10.4161/cc.4.7.1800; Iwakuma T, 2004, ONCOGENE, V23, P7644, DOI 10.1038/sj.onc.1207793; Iwakuma T, 2003, MOL CANCER RES, V1, P993; Johnson TM, 2005, CELL CYCLE, V4, P731, DOI 10.4161/cc.4.6.1696; Johnson TM, 2005, NAT GENET, V37, P145, DOI 10.1038/ng1498; Kapoor M, 1998, P NATL ACAD SCI USA, V95, P2834, DOI 10.1073/pnas.95.6.2834; Krummel KA, 2005, P NATL ACAD SCI USA, V102, P10188, DOI 10.1073/pnas.0503068102; Kurz EU, 2004, J BIOL CHEM, V279, P53272, DOI 10.1074/jbc.M406879200; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; Lai SL, 2000, J BIOMED SCI, V7, P64, DOI 10.1007/BF02255920; Lang GA, 2004, CELL, V119, P861, DOI 10.1016/j.cell.2004.11.006; Lavin MF, 2006, CELL DEATH DIFFER, V13, P941, DOI 10.1038/sj.cdd.4401925; LEVINE HB, 1993, PSYCHOANAL QUART, V62, P651; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; Liu G, 2000, P NATL ACAD SCI USA, V97, P4174, DOI 10.1073/pnas.97.8.4174; Liu G, 2004, NAT GENET, V36, P63, DOI 10.1038/ng1282; Liu ZP, 2005, CANCER RES, V65, P2583, DOI 10.1158/0008-5472.CAN-04-3675; Lu H, 1998, P NATL ACAD SCI USA, V95, P6399, DOI 10.1073/pnas.95.11.6399; Ludwig RL, 1996, MOL CELL BIOL, V16, P4952; LUNA RMD, 1995, NATURE, V378, P203; Luo JL, 2001, ONCOGENE, V20, P320, DOI 10.1038/sj.onc.1204080; Luo JL, 2001, CANCER RES, V61, P8158; MacPherson D, 2004, EMBO J, V23, P3689, DOI 10.1038/sj.emboj.7600363; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; McKinney K, 2004, MOL CELL, V16, P413, DOI 10.1016/j.molcel.2004.09.032; MILNE DM, 1992, NUCLEIC ACIDS RES, V20, P5565, DOI 10.1093/nar/20.21.5565; Olive KP, 2004, CELL, V119, P847, DOI 10.1016/j.cell.2004.11.004; Parant J, 2001, NAT GENET, V29, P92, DOI 10.1038/ng714; Powell B, 2000, CLIN CANCER RES, V6, P443; Rodriguez MS, 1999, EMBO J, V18, P6455, DOI 10.1093/emboj/18.22.6455; Rodriguez MS, 2000, MOL CELL BIOL, V20, P8458, DOI 10.1128/MCB.20.22.8458-8467.2000; Roemer K, 1999, BIOL CHEM, V380, P879, DOI 10.1515/BC.1999.108; Rowan S, 1996, EMBO J, V15, P827, DOI 10.1002/j.1460-2075.1996.tb00418.x; Sakaguchi K, 1997, BIOCHEMISTRY-US, V36, P10117, DOI 10.1021/bi970759w; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Shieh SY, 1999, EMBO J, V18, P1815, DOI 10.1093/emboj/18.7.1815; Skaug V, 2000, CLIN CANCER RES, V6, P1031; Sluss HK, 2004, MOL CELL BIOL, V24, P976, DOI 10.1128/MCB.24.3.976-984.2004; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; Strano S, 2002, J BIOL CHEM, V277, P18817, DOI 10.1074/jbc.M201405200; Takai H, 2002, EMBO J, V21, P5195, DOI 10.1093/emboj/cdf506; Toledo F, 2006, CANCER CELL, V9, P273, DOI 10.1016/j.ccr.2006.03.014; Uesugi M, 1999, P NATL ACAD SCI USA, V96, P14801, DOI 10.1073/pnas.96.26.14801; Unger T, 1999, EMBO J, V18, P1805, DOI 10.1093/emboj/18.7.1805; Unger T, 1999, ONCOGENE, V18, P3205, DOI 10.1038/sj.onc.1202656; van Oijen MGCT, 2000, CLIN CANCER RES, V6, P2138; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; Wu ZQ, 2002, MOL CELL BIOL, V22, P2441, DOI 10.1128/MCB.22.8.2441-2449.2002; Xirodimas DP, 2004, CELL, V118, P83, DOI 10.1016/j.cell.2004.06.016	80	52	55	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 2	2007	26	15					2177	2184		10.1038/sj.onc.1210278	http://dx.doi.org/10.1038/sj.onc.1210278			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	152XE	17401426				2022-12-28	WOS:000245394800006
J	Weisz, L; Oren, M; Rotter, V				Weisz, L.; Oren, M.; Rotter, V.			Transcription regulation by mutant p53	ONCOGENE			English	Review						mutant p53; gain of function; transcription; mechanism	GAIN-OF-FUNCTION; CELLULAR TUMOR-ANTIGEN; LI-FRAUMENI-SYNDROME; P53-INDEPENDENT APOPTOTIC PATHWAYS; HYDROPHOBIC AMINO-ACIDS; C-TERMINAL DOMAIN; WILD-TYPE P53; GENE-EXPRESSION; FUNCTION PHENOTYPE; SV40-TRANSFORMED CELLS	In addition to the loss of wild-type p53 activity, a high percentage of tumor cells accumulate mutant p53 protein isoforms. Whereas the hallmark of the wild-type p53 is its tumor suppressor activities, tumor-associated mutant p53 proteins acquire novel functions enabling them to promote a large spectrum of cancer phenotypes. During the last years, it became clear that tumor-associated mutant p53 proteins are not only distinct from the wild-type p53, but they also represent a heterogeneous population of proteins with a variety of structure-function features. One of the major mechanisms underlying mutant p53 gain of function is the ability to regulate gene expression. Although a large number of specific target genes were identified, the molecular basis for this regulation is not fully elucidated. This review describes the present knowledge about the transcriptional activities of mutant p53 and the mechanisms that might underlie its target gene specificity.	Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Rotter, V (corresponding author), Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel.	varda.rotter@weizmann.ac.il						BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; Bargonetti J, 1997, CELL MOL BIOL, V43, P935; Blandino G, 1999, ONCOGENE, V18, P477, DOI 10.1038/sj.onc.1202314; Bossi G, 2006, ONCOGENE, V25, P304, DOI 10.1038/sj.onc.1209026; Buganim Y, 2006, CANCER RES, V66, P10750, DOI 10.1158/0008-5472.CAN-06-0916; Bullock AN, 2001, NAT REV CANCER, V1, P68, DOI 10.1038/35094077; CHANG C, 1979, J VIROL, V31, P463, DOI 10.1128/JVI.31.2.463-471.1979; Chicas A, 2000, BIOCHEM BIOPH RES CO, V279, P383, DOI 10.1006/bbrc.2000.3965; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; CHOW V, 1987, J VIROL, V61, P2777, DOI 10.1128/JVI.61.9.2777-2781.1987; DAVID YB, 1988, ONCOGENE, V3, P179; Deb D, 2002, ONCOGENE, V21, P176, DOI 10.1038/sj/onc/1205035; DELEO AB, 1979, P NATL ACAD SCI USA, V76, P2420, DOI 10.1073/pnas.76.5.2420; Di Agostino S, 2006, CANCER CELL, V10, P191, DOI 10.1016/j.ccr.2006.08.013; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; El-Hizawi S, 2002, CANCER RES, V62, P3264; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; ELIYAHU D, 1985, NATURE, V316, P158, DOI 10.1038/316158a0; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; ELIYAHU D, 1988, ONCOGENE, V3, P313; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; Frazier MW, 1998, MOL CELL BIOL, V18, P3735, DOI 10.1128/MCB.18.7.3735; Gohler T, 2005, NUCLEIC ACIDS RES, V33, P1087, DOI 10.1093/nar/gki252; Gualberto A, 1998, P NATL ACAD SCI USA, V95, P5166, DOI 10.1073/pnas.95.9.5166; GUALBERTO A, 1995, J BIOL CHEM, V270, P19680, DOI 10.1074/jbc.270.34.19680; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; HINDS PW, 1987, MOL CELL BIOL, V7, P2863, DOI 10.1128/MCB.7.8.2863; HSIAO M, 1994, AM J PATHOL, V145, P702; Hussain SP, 1998, CANCER RES, V58, P4023; Imbriano C, 2005, MOL CELL BIOL, V25, P3737, DOI 10.1128/MCB.25.9.3737-3751.2005; Inga A, 2002, MOL CELL BIOL, V22, P8612, DOI 10.1128/MCB.22.24.8612-8625.2002; Irwin MS, 2003, CANCER CELL, V3, P403, DOI 10.1016/S1535-6108(03)00078-3; Iwamoto KS, 1996, CANCER RES, V56, P3862; Iwanaga Y, 2002, CANCER RES, V62, P2618; JENKINS JR, 1985, NATURE, V317, P816, DOI 10.1038/317816a0; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; Joerger AC, 2005, J BIOL CHEM, V280, P16030, DOI 10.1074/jbc.M500179200; Joerger AC, 2006, P NATL ACAD SCI USA, V103, P15056, DOI 10.1073/pnas.0607286103; Kato S, 2003, P NATL ACAD SCI USA, V100, P8424, DOI 10.1073/pnas.1431692100; Kim E, 2003, BIOCHEM CELL BIOL, V81, P141, DOI 10.1139/o03-046; Knaup KX, 2004, FEBS LETT, V569, P70, DOI 10.1016/j.febslet.2004.05.052; KRESS M, 1979, J VIROL, V31, P472, DOI 10.1128/JVI.31.2.472-483.1979; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; Lang GA, 2004, CELL, V119, P861, DOI 10.1016/j.cell.2004.11.006; Lanyi A, 1998, ONCOGENE, V16, P3169, DOI 10.1038/sj.onc.1201857; Lee YI, 2000, ONCOGENE, V19, P3717, DOI 10.1038/sj.onc.1203694; Li RZ, 1998, ONCOGENE, V16, P3269, DOI 10.1038/sj.onc.1201867; LIN JY, 1995, ONCOGENE, V10, P2387; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; LINZER DIH, 1979, VIROLOGY, V98, P308, DOI 10.1016/0042-6822(79)90554-3; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; Loging WT, 1999, CANCER EPIDEM BIOMAR, V8, P1011; LudesMeyers JH, 1996, MOL CELL BIOL, V16, P6009; Matas D, 2001, EMBO J, V20, P4163, DOI 10.1093/emboj/20.15.4163; MERCER WE, 1982, P NATL ACAD SCI-BIOL, V79, P6309, DOI 10.1073/pnas.79.20.6309; MILNER J, 1984, NATURE, V310, P143, DOI 10.1038/310143a0; MILNER J, 1981, VIROLOGY, V112, P785, DOI 10.1016/0042-6822(81)90327-5; MILNER J, 1986, VIROLOGY, V154, P21, DOI 10.1016/0042-6822(86)90426-5; Mizuarai S, 2006, CANCER RES, V66, P6319, DOI 10.1158/0008-5472.CAN-05-4629; Moll UM, 2001, BBA-REV CANCER, V1552, P47, DOI 10.1016/S0304-419X(01)00036-1; MOWAT M, 1985, NATURE, V314, P633, DOI 10.1038/314633a0; Muller BF, 1996, ONCOGENE, V12, P1941; MUNROE DG, 1988, ONCOGENE, V2, P621; Murphy KL, 2000, FASEB J, V14, P2291, DOI 10.1096/fj.00-0128com; O'Farrell TJ, 2004, CANCER RES, V64, P8199, DOI 10.1158/0008-5472.CAN-03-3639; Olive KP, 2004, CELL, V119, P847, DOI 10.1016/j.cell.2004.11.004; OREN M, 1982, MOL CELL BIOL, V2, P443, DOI 10.1128/MCB.2.4.443; Pan Y, 2000, ONCOGENE, V19, P3095, DOI 10.1038/sj.onc.1203663; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; Pastorcic M, 2000, J BIOL CHEM, V275, P34938, DOI 10.1074/jbc.M005411200; Peled A, 1996, CANCER RES, V56, P2148; Preuss U, 2000, INT J CANCER, V88, P162, DOI 10.1002/1097-0215(20001015)88:2<162::AID-IJC3>3.0.CO;2-M; Pugacheva EN, 2002, ONCOGENE, V21, P4595, DOI 10.1038/sj.onc.1205704; REICH NC, 1984, NATURE, V308, P199, DOI 10.1038/308199a0; ROTTER V, 1980, J VIROL, V36, P547, DOI 10.1128/JVI.36.2.547-555.1980; Sampath J, 2001, J BIOL CHEM, V276, P39359, DOI 10.1074/jbc.M103429200; Scian MJ, 2005, MOL CELL BIOL, V25, P10097, DOI 10.1128/MCB.25.22.10097-10110.2005; Scian MJ, 2004, CANCER RES, V64, P7447, DOI 10.1158/0008-5472.CAN-04-1568; Scian MJ, 2004, ONCOGENE, V23, P4430, DOI 10.1038/sj.onc.1207553; SHAULSKY G, 1991, CANCER RES, V51, P5232; SHOHAT O, 1987, ONCOGENE, V1, P277; Sigal A, 2001, ONCOGENE, V20, P4891, DOI 10.1038/sj.onc.1204724; Sigal A, 2000, CANCER RES, V60, P6788; Soussi T, 2005, BIOCHEM BIOPH RES CO, V331, P834, DOI 10.1016/j.bbrc.2005.03.190; Soussi T, 2001, NAT REV CANCER, V1, P233, DOI 10.1038/35106009; Trkova M, 2003, CANCER GENET CYTOGEN, V145, P60, DOI 10.1016/S0165-4608(03)00031-1; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Weisz L, 2004, CANCER RES, V64, P8318, DOI 10.1158/0008-5472.CAN-04-1145; Werner H, 1996, P NATL ACAD SCI USA, V93, P8318, DOI 10.1073/pnas.93.16.8318; Will K, 1998, P NATL ACAD SCI USA, V95, P13681, DOI 10.1073/pnas.95.23.13681; WOLF D, 1984, CELL, V38, P119, DOI 10.1016/0092-8674(84)90532-4; Yakovleva T, 2001, J BIOL CHEM, V276, P15650, DOI 10.1074/jbc.M100482200; Yap DBS, 2004, CANCER RES, V64, P4749, DOI 10.1158/0008-5472.CAN-1305-2; ZAKUTHOURI R, 1985, EMBO J, V4, P1251, DOI 10.1002/j.1460-2075.1985.tb03768.x; ZAKUTHOURI R, 1983, NATURE, V306, P594, DOI 10.1038/306594a0; Zalcenstein A, 2006, ONCOGENE, V25, P359, DOI 10.1038/sj.onc.1209061; Zalcenstein A, 2003, ONCOGENE, V22, P5667, DOI 10.1038/sj.onc.1206724	98	154	162	1	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 2	2007	26	15					2202	2211		10.1038/sj.onc.1210294	http://dx.doi.org/10.1038/sj.onc.1210294			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	152XE	17401429				2022-12-28	WOS:000245394800009
J	Furge, KA; Tan, MH; Dykema, K; Kort, E; Stadler, W; Yao, X; Zhou, M; Teh, BT				Furge, K. A.; Tan, M. H.; Dykema, K.; Kort, E.; Stadler, W.; Yao, X.; Zhou, M.; Teh, B. T.			Identification of deregulated oncogenic pathways in renal cell carcinoma: an integrated oncogenomic approach based on gene expression profiling	ONCOGENE			English	Review						renal; cancer; pathways; GSEA; PGSEA; CGMA	SET ENRICHMENT; SIGNATURES; ANEUPLOIDY; PATTERNS	In this age of targeted therapy, identification of molecular pathways that are deregulated in cancer will not only elucidate underlying tumorigenic mechanisms, but may also help to determine the classes of drugs that are used for treatment. In kidney cancer, a spectrum of histological subtypes exists that are characterized both by distinct molecular signatures and increasingly by distinct molecular pathways that are deregulated in each subtype. For example, the VHL/hypoxia pathway is well-known to be deregulated in clear cell renal cell carcinoma (RCC) whereas in papillary RCC activation of the HGF/Met pathway has been implicated. Additional molecular pathways, many not yet identified, may also be involved in the development of the different histologic subtypes. Moreover, differences in pathway activation may reflect differences in tumor progression and response to treatment. In this article, we describe an oncogenomic approach, based on integrative analysis of gene expression pro. ling data. In this approach, gene expression data is used to identify both cytogenetic abnormalities and molecular pathways that are deregulated in RCC. Ideally, predicted pathway abnormalities can be linked to predicted cytogenetic abnormalities to identify likely candidate genes. Although further cellular and functional studies are warranted to validate the computational models, development of such models in RCC have the potential to open up new avenues of molecular research and may have significant diagnostic and therapeutic implications.	Van Andel Res Inst, Lab Computat Biol, Grand Rapids, MI 49503 USA; Natl Canc Ctr Singapore, Dept Med Oncol, Singapore, Singapore; Van Andel Res Inst, Canc Genet Lab, Grand Rapids, MI 49503 USA; Univ Chicago, Dept Med, Chicago, IL 60637 USA; Univ Chicago, Dept Surg, Chicago, IL 60637 USA; Tianjin Canc Ctr, Dept Pelv & Urol Oncol, Tianjin, Peoples R China; Cleveland Clin, Dept Anat Pathol, Cleveland, OH 44106 USA	Van Andel Institute; National Cancer Centre Singapore (NCCS); Van Andel Institute; University of Chicago; University of Chicago; Cleveland Clinic Foundation	Furge, KA (corresponding author), Van Andel Res Inst, Lab Computat Biol, 333 Bostwick Ave NE, Grand Rapids, MI 49503 USA.	kyle.furge@vai.org; bin.teh@vai.org	Tan, Min Han/D-9205-2014	Tan, Min Han/0000-0002-0644-3457; Teh, Bin Tean/0000-0003-1514-1124	NCI NIH HHS [R33 CA 10113-01] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adler AS, 2006, NAT GENET, V38, P421, DOI 10.1038/ng1752; Bild AH, 2006, NATURE, V439, P353, DOI 10.1038/nature04296; Chi JT, 2006, PLOS MED, V3, P395, DOI 10.1371/journal.pmed.0030047; Cohen HT, 2005, NEW ENGL J MED, V353, P2477, DOI 10.1056/NEJMra043172; Crawley JJ, 2002, GENOME BIOL, V3; Desai KV, 2002, P NATL ACAD SCI USA, V99, P6967, DOI 10.1073/pnas.102172399; Dupont J, 2001, ENDOCRINOLOGY, V142, P4969, DOI 10.1210/en.142.11.4969; Ferrando AA, 2002, CANCER CELL, V1, P75, DOI 10.1016/S1535-6108(02)00018-1; Furge KA, 2004, CANCER RES, V64, P4117, DOI 10.1158/0008-5472.CAN-04-0534; Gerritsen ME, 2003, BRIT J PHARMACOL, V140, P595, DOI 10.1038/sj.bjp.0705494; Harding MA, 2002, CANCER RES, V62, P6981; Huang E, 2003, NAT GENET, V34, P226, DOI 10.1038/ng1167; Hughes TR, 2000, NAT GENET, V25, P333, DOI 10.1038/77116; Kim SY, 2005, BMC BIOINFORMATICS, V6, DOI 10.1186/1471-2105-6-144; Lamb J, 2006, SCIENCE, V313, P1929, DOI 10.1126/science.1132939; Phillips JL, 2001, CANCER RES, V61, P8143; Staller P, 2003, NATURE, V425, P307, DOI 10.1038/nature01874; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Sweet-Cordero A, 2005, NAT GENET, V37, P48, DOI 10.1038/ng1490; Tomlinson IPM, 2002, NAT GENET, V30, P406, DOI 10.1038/ng849; Vanharanta S, 2006, HUM MOL GENET, V15, P97, DOI 10.1093/hmg/ddi431; Virtaneva K, 2001, P NATL ACAD SCI USA, V98, P1124, DOI 10.1073/pnas.98.3.1124; Xu XR, 2001, P NATL ACAD SCI USA, V98, P15089, DOI 10.1073/pnas.241522398	23	34	34	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 26	2007	26	9					1346	1350		10.1038/sj.onc.1210256	http://dx.doi.org/10.1038/sj.onc.1210256			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	141DU	17322920				2022-12-28	WOS:000244558700012
J	Kikuno, N; Shiina, H; Urakami, S; Kawamoto, K; Hirata, H; Tanaka, Y; Place, RF; Pookot, D; Majid, S; Igawa, M; Dahiya, R				Kikuno, N.; Shiina, H.; Urakami, S.; Kawamoto, K.; Hirata, H.; Tanaka, Y.; Place, R. F.; Pookot, D.; Majid, S.; Igawa, M.; Dahiya, R.			RETRACTED: Knockdown of astrocyte-elevated gene-1 inhibits prostate cancer progression through upregulation of FOXO3a activity (Retracted article. See vol. 41, pg. 4981, 2022)	ONCOGENE			English	Article; Retracted Publication						AEG-1; FOXO3a; AKT; PTEN; prostate cancer	FACTOR-KAPPA-B; RAPID SUBTRACTION HYBRIDIZATION; PROTEIN-KINASE; ANDROGEN RECEPTOR; SIGNALING PATHWAY; AKT ACTIVATION; EXPRESSION; CELLS; TRANSCRIPTION; APOPTOSIS	Astrocyte-elevated gene-1 (AEG-1) has been reported to be upregulated in several malignancies and play a critical role in Ha-ras-mediated oncogenesis through the phosphatidylinositol 3-kinase/AKT signaling pathway. However, the role of AEG-1 in prostate cancer ( PC) has never been reported. We now show that AEG-1 is overexpressed in clinical PC tissue samples and cultured PC cells compared to benign prostatic hyperplasia tissue samples and normal prostate epithelial cells. Interestingly, AEG-1 knockdown induced cell apoptosis through upregulation of forkhead box (FOXO) 3a activity. This alteration of FOXO3a activity was dependent on reduction of AKT activity in LNCaP and PC-3 cells with high constitutive AKT activity, but not in DU145 cells with low constitutive AKT activity, although AEG-1 knockdown had no impact on phosphatase and tensin homolog expression in these cells. AEG-1 knockdown also attenuated the constitutive activity of the nuclear factor kB (NF-kB) and the activator protein 1 (AP-1) with a corresponding depletion in the expression of NF-kappa B and AP-1-regulated genes ( interleukin (IL)-6, IL-8 and matrix metalloproteinase-9) and significantly decreased cell invasion properties of PC-3 and DU145 cells. Overall, our findings suggest that aberrant AEG-1 expression plays a dominant role as a positive auto-feedback activator of AKT and as a suppressor of FOXO3a in PC cells. AEG-1 may therefore represent a novel genetic biomarker to serve as an attractive molecular target for new anticancer agents to prevent PC cell progression and metastasis.	[Kikuno, N.; Kawamoto, K.; Hirata, H.; Tanaka, Y.; Place, R. F.; Pookot, D.; Majid, S.; Dahiya, R.] Vet Affairs Med Ctr, Urol Res Ctr 112F, Dept Urol, San Francisco, CA 94121 USA; [Kikuno, N.; Kawamoto, K.; Hirata, H.; Tanaka, Y.; Place, R. F.; Pookot, D.; Majid, S.; Dahiya, R.] Univ Calif San Francisco, San Francisco, CA 94143 USA; [Shiina, H.; Urakami, S.; Igawa, M.] Shimane Univ, Sch Med, Dept Urol, Izumo, Shimane, Japan	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Francisco; Shimane University	Dahiya, R (corresponding author), Vet Affairs Med Ctr, Urol Res Ctr 112F, Dept Urol, 4150 Clement St, San Francisco, CA 94121 USA.	rdahiya@urology.ucsf.edu			NATIONAL CANCER INSTITUTE [R01CA101844, R01CA111470, R01CA108612] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007790] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG021418] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Bader AG, 2005, NAT REV CANCER, V5, P921, DOI 10.1038/nrc1753; Bentires-Alj M, 1999, CANCER RES, V59, P811; Biggs WH, 1999, P NATL ACAD SCI USA, V96, P7421, DOI 10.1073/pnas.96.13.7421; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brown DM, 2004, CANCER CELL, V5, P365, DOI 10.1016/S1535-6108(04)00079-0; Chen XF, 2001, ONCOGENE, V20, P6073, DOI 10.1038/sj.onc.1204736; Damen JE, 1996, P NATL ACAD SCI USA, V93, P1689, DOI 10.1073/pnas.93.4.1689; Emdad L, 2006, CANCER RES, V66, P1509, DOI 10.1158/0008-5472.CAN-05-3029; Festuccia C, 2005, ENDOCR-RELAT CANCER, V12, P983, DOI 10.1677/erc.1.00986; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Kang DC, 2005, GENE, V353, P8, DOI [10.1016/j.gene.2005.04.006, 10.1016/j.gene.2005.04.005]; Lee SG, 2006, P NATL ACAD SCI USA, V103, P17390, DOI 10.1073/pnas.0608386103; Li PF, 2003, MOL CELL BIOL, V23, P104, DOI 10.1128/MCB.23.1.104-118.2003; Lu T, 2004, P NATL ACAD SCI USA, V101, P7112, DOI 10.1073/pnas.0402048101; Lynch RL, 2005, MOL CANCER RES, V3, P163, DOI 10.1158/1541-7786.MCR-04-0163; Nakashima H, 2006, CANCER RES, V66, P7041, DOI 10.1158/0008-5472.CAN-05-4588; Nakatani K, 1999, J BIOL CHEM, V274, P21528, DOI 10.1074/jbc.274.31.21528; Nicholson KM, 2002, CELL SIGNAL, V14, P381, DOI 10.1016/S0898-6568(01)00271-6; Pajonk F, 1999, J NATL CANCER I, V91, P1956, DOI 10.1093/jnci/91.22.1956; Place RF, 2005, BIOCHEM PHARMACOL, V70, P394, DOI 10.1016/j.bcp.2005.04.030; Plas DR, 2003, J BIOL CHEM, V278, P12361, DOI 10.1074/jbc.M213069200; Su ZZ, 2003, GENE, V306, P67, DOI 10.1016/S0378-1119(03)00404-9; Su ZZ, 2002, ONCOGENE, V21, P3592, DOI 10.1038/sj.onc.1205445; Takaishi H, 1999, P NATL ACAD SCI USA, V96, P11836, DOI 10.1073/pnas.96.21.11836; Yang L, 2005, J BIOL CHEM, V280, P33558, DOI 10.1074/jbc.M504461200; Zerbini LF, 2003, CANCER RES, V63, P2206; Zhang MC, 2007, BIOCHEM PHARMACOL, V73, P15, DOI 10.1016/j.bcp.2006.07.034	28	191	210	0	13	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 6	2007	26	55					7647	7655		10.1038/sj.onc.1210572	http://dx.doi.org/10.1038/sj.onc.1210572			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	239SK	17563745				2022-12-28	WOS:000251537800006
J	Maxwell, PJ; Gallagher, R; Seaton, A; Wilson, C; Scullin, P; Pettigrew, J; Stratford, IJ; Williams, KJ; Johnston, PG; Waugh, DJJ				Maxwell, P. J.; Gallagher, R.; Seaton, A.; Wilson, C.; Scullin, P.; Pettigrew, J.; Stratford, I. J.; Williams, K. J.; Johnston, P. G.; Waugh, D. J. J.			HIF-1 and NF-kappa B-mediated upregulation of CXCR1 and CXCR2 expression promotes cell survival in hypoxic prostate cancer cells	ONCOGENE			English	Article						IL-8; hypoxia; CXCR1; CXCR2; HIF-1; NF-kappa B	ENDOTHELIAL GROWTH-FACTOR; CHEMOKINE RECEPTOR CXCR4; INTERLEUKIN-8 EXPRESSION; INDUCIBLE FACTOR; GENE-EXPRESSION; ACTIVATION; ANGIOGENESIS; TUMORIGENICITY; TRANSCRIPTION; METASTASIS	Hypoxic cancer cells are resistant to treatment, leading to the selection of cells with a more malignant phenotype. The expression of interleukin-8 (IL-8) plays an important role in the tumorigenesis and metastasis of solid tumors including prostate cancer. Recently, we detected elevated expression of IL-8 and IL-8 receptors in human prostate cancer tissue. The objective of the current study was to determine whether hypoxia increases IL-8 and IL-8 receptor expression in prostate cancer cells and whether this contributes to a survival advantage in hypoxic cells. IL-8, CXCR1 and CXCR2 messenger RNA (mRNA) expression in PC3 cells was upregulated in response to hypoxia in a time-dependent manner. Elevated IL-8 secretion following hypoxia was detected by enzyme-linked immunosorbent assay, while immunoblotting confirmed elevated receptor expression. Attenuation of hypoxia-inducible factor (HIF-1) and nuclear factor-kappa B (NF-kappa B) transcriptional activity using small interfering RNA (siRNA), a HIF-1 dominant-negative and pharmacological inhibitors, abrogated hypoxia-induced transcription of CXCR1 and CXCR2 in PC3 cells. Furthermore, chromatin-IP analysis demonstrated binding of HIF-1 and NF-kappa B to CXCR1. Finally, inhibition of IL-8 signaling potentiated etoposide-induced cell death in hypoxic PC3 cells. These results suggest that IL-8 signaling confers a survival advantage to hypoxic prostate cancer cells, and therefore, strategies to inhibit IL-8 signaling may sensitize hypoxic tumor cells to conventional treatments.	Queens Univ Belfast, Ctr Canc Res &Cell Biol, Belfast BT9 7AB, Antrim, North Ireland; Univ Manchester, Sch Pharm & Pharmaceut Sci, Manchester, Lancs, England	Queens University Belfast; University of Manchester	Waugh, DJJ (corresponding author), Queens Univ Belfast, Ctr Canc Res &Cell Biol, Univ Flr, Lisburn Rd, Belfast BT9 7AB, Antrim, North Ireland.	d.waugh@qub.ac.uk		WAUGH, DAVID/0000-0002-4022-3765; stratford, ian/0000-0002-5222-4765	Medical Research Council [G0500366] Funding Source: Medline; Wellcome Trust [067104/Z/02/Z] Funding Source: Medline; MRC [G0500366] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Boland MP, 1997, J BIOL CHEM, V272, P12952, DOI 10.1074/jbc.272.20.12952; Brown LM, 2006, MOL PHARMACOL, V69, P411, DOI 10.1124/mol.105.015743; Cairns RA, 2003, CURR MOL MED, V3, P659, DOI 10.2174/1566524033479447; Cairns RA, 2004, CANCER RES, V64, P2054, DOI 10.1158/0008-5472.CAN-03-3196; Carnell DM, 2006, INT J RADIAT ONCOL, V65, P91, DOI 10.1016/j.ijrobp.2005.11.044; Coffey RNT, 2005, CANCER-AM CANCER SOC, V103, P1363, DOI 10.1002/cncr.20918; Cvetkovic D, 2001, UROLOGY, V57, P821, DOI 10.1016/S0090-4295(00)01044-X; Desbaillets I, 1997, J EXP MED, V186, P1201, DOI 10.1084/jem.186.8.1201; Fernandez A, 2001, J NATL CANCER I, V93, P208, DOI 10.1093/jnci/93.3.208; Ghafar MA, 2003, PROSTATE, V54, P58, DOI 10.1002/pros.10162; GRAEBER TG, 1994, MOL CELL BIOL, V14, P6264, DOI 10.1128/MCB.14.9.6264; Grutkoski PS, 1999, J LEUKOCYTE BIOL, V65, P171, DOI 10.1002/jlb.65.2.171; Heidemann J, 2003, J BIOL CHEM, V278, P8508, DOI 10.1074/jbc.M208231200; Hirota K, 2006, CRIT REV ONCOL HEMAT, V59, P15, DOI 10.1016/j.critrevonc.2005.12.003; Inoue K, 2000, CANCER RES, V60, P2290; Inoue K, 2000, CLIN CANCER RES, V6, P2104; Kim KS, 2006, J IMMUNOL, V177, P7211, DOI 10.4049/jimmunol.177.10.7211; KOONG AC, 1994, CANCER RES, V54, P1425; Kunz M, 1999, AM J PATHOL, V155, P753, DOI 10.1016/S0002-9440(10)65174-7; Lee TH, 2002, J BIOL CHEM, V277, P10445, DOI 10.1074/jbc.M107348200; Li AH, 2003, J IMMUNOL, V170, P3369, DOI 10.4049/jimmunol.170.6.3369; Li Aihua, 2005, Angiogenesis, V8, P63, DOI 10.1007/s10456-005-5208-4; MACMANUS CF, 2007, IN PRESS MOL CANC RE; Mizukami Y, 2005, NAT MED, V11, P992, DOI 10.1038/nm1294; Moldobaeva A, 2005, AM J PHYSIOL-LUNG C, V288, pL1117, DOI 10.1152/ajplung.00370.2004; Moore BB, 1999, AM J PATHOL, V154, P1503, DOI 10.1016/S0002-9440(10)65404-1; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Movsas B, 1999, UROLOGY, V53, P11, DOI 10.1016/S0090-4295(98)00500-7; MURPHY C, 2005, CLIN CANCER RES, V11, P4702; Schioppa T, 2003, J EXP MED, V198, P1391, DOI 10.1084/jem.20030267; SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447; Shi Q, 2001, J INTERF CYTOK RES, V21, P553, DOI 10.1089/10799900152547812; Shi QA, 1999, J INTERF CYTOK RES, V19, P1363, DOI 10.1089/107999099312821; SMITH DR, 1994, J EXP MED, V179, P1409, DOI 10.1084/jem.179.5.1409; Sowter HM, 2003, CANCER RES, V63, P6130; Staller P, 2003, NATURE, V425, P307, DOI 10.1038/nature01874; Subarsky P, 2003, CLIN EXP METASTAS, V20, P237, DOI 10.1023/A:1022939318102; Takaesu G, 2003, J MOL BIOL, V326, P105, DOI 10.1016/S0022-2836(02)01404-3; Takami M, 2002, J IMMUNOL, V168, P4559, DOI 10.4049/jimmunol.168.9.4559; Trisciuoglio D, 2005, MOL BIOL CELL, V16, P4153, DOI 10.1091/mbc.E04-12-1087; Vaupel P, 2004, ONCOLOGIST, V9, P4, DOI 10.1634/theoncologist.9-90005-4; Wingender E, 2000, NUCLEIC ACIDS RES, V28, P316, DOI 10.1093/nar/28.1.316; Xu L, 1999, CANCER RES, V59, P5822; Xu L, 2004, CLIN CANCER RES, V10, P701, DOI 10.1158/1078-0432.CCR-0953-03; Yan SF, 1997, J BIOL CHEM, V272, P4287, DOI 10.1074/jbc.272.7.4287; Yan SF, 1999, J BIOL CHEM, V274, P15030, DOI 10.1074/jbc.274.21.15030; YAO KS, 1994, MOL CELL BIOL, V14, P5997, DOI 10.1128/MCB.14.9.5997; YASUMOTO K, 1992, J BIOL CHEM, V267, P22506; Yoneda J, 1998, JNCI-J NATL CANCER I, V90, P447, DOI 10.1093/jnci/90.6.447	49	173	184	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 15	2007	26	52					7333	7345		10.1038/sj.onc.1210536	http://dx.doi.org/10.1038/sj.onc.1210536			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	231NP	17533374				2022-12-28	WOS:000250955700005
J	Depaux, A; Regnier-Ricard, F; Germani, A; Varin-Blank, N				Depaux, A.; Regnier-Ricard, F.; Germani, A.; Varin-Blank, N.			A crosstalk between hSiah2 and Pias E3-ligases modulates Pias-dependent activation	ONCOGENE			English	Article						Siah; Pias; ubiquitination; proteasome	C-JUN; PROTEIN INHIBITOR; SIAH-1 INTERACTS; GENE-ACTIVATION; P53 ACTIVITY; RECEPTOR; SUMO; DEGRADATION; HOMOLOGS; DEGRADES	Protein inhibitor of activated STAT ( Pias) and human homologues of seven in absentia ( hSiah) proteins both exhibit properties of ubiquitin- family peptides conjugating enzymes. Pias present E3- ligase activity for small ubiquitin-related modifiers ( Sumo) covalent attachment to their targets. This post- translational modi. cation is responsible for the activation of different transcription factors such as AP1. HSiah proteins possess ubiquitin- E3-ligase activity that triggers their partners to proteasomal-dependent degradation. The present study identifies Pias as a new hSiah2- interacting protein. We demonstrate that hSiah2 regulates specifically the proteasome-dependent degradation of Pias proteins. On reverse, Pias does not prevent hSiah2 degradation. We provide evidences for hSiah2- dependent degradation of Pias as being a mechanism in the regulation of c- jun N- terminal kinase- activating pathways. This report describes a new interconnection between sumoylation and ubiquitination pathways by regulating the levels of the E3-ligases available for these processes.	Univ Paris 05, Inst Cochin, Dept Hematol, CNRS, F-75014 Paris, France; Inserm, U567, Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Varin-Blank, N (corresponding author), Univ Paris 05, Inst Cochin, Dept Hematol, CNRS, Bat G Roussy ,7eme etage,27 Rue Fg St Jacques, F-75014 Paris, France.	varin@cochin.inserm.fr		VARIN-BLANK, Nadine/0000-0003-2769-018X				Chung CD, 1997, SCIENCE, V278, P1803, DOI 10.1126/science.278.5344.1803; DELLA NG, 1993, DEVELOPMENT, V117, P1333; Depaux A, 2006, BIOCHEM BIOPH RES CO, V348, P857, DOI 10.1016/j.bbrc.2006.07.092; Desterro JMP, 1997, FEBS LETT, V417, P297, DOI 10.1016/S0014-5793(97)01305-7; Desterro JMP, 1999, J BIOL CHEM, V274, P10618, DOI 10.1074/jbc.274.15.10618; DRISCOLL J, 1990, J BIOL CHEM, V265, P4789; Duval D, 2003, FEBS LETT, V554, P111, DOI 10.1016/S0014-5793(03)01116-5; Floyd ZE, 2001, J BIOL CHEM, V276, P22468, DOI 10.1074/jbc.M009388200; Fogal V, 2000, EMBO J, V19, P6185, DOI 10.1093/emboj/19.22.6185; Freemont PS, 2000, CURR BIOL, V10, pR84, DOI 10.1016/S0960-9822(00)00287-6; Germani A, 2003, ONCOGENE, V22, P8845, DOI 10.1038/sj.onc.1206994; Germani A, 1999, MOL CELL BIOL, V19, P3798; Germani A, 2000, ONCOGENE, V19, P5997, DOI 10.1038/sj.onc.1204002; Gross M, 2001, ONCOGENE, V20, P3880, DOI 10.1038/sj.onc.1204489; Habelhah H, 2002, EMBO J, V21, P5756, DOI 10.1093/emboj/cdf576; House CM, 2003, P NATL ACAD SCI USA, V100, P3101, DOI 10.1073/pnas.0534783100; Hu G, 1997, GENOMICS, V46, P103, DOI 10.1006/geno.1997.4997; Hu G, 1997, GENE DEV, V11, P2701, DOI 10.1101/gad.11.20.2701; Johnson ES, 2001, CELL, V106, P735, DOI 10.1016/S0092-8674(01)00491-3; Kahyo T, 2001, MOL CELL, V8, P713, DOI 10.1016/S1097-2765(01)00349-5; Kotaja N, 2002, J BIOL CHEM, V277, P17781, DOI 10.1074/jbc.M106354200; Lallemand-Breitenbach V, 2001, J EXP MED, V193, P1361, DOI 10.1084/jem.193.12.1361; Liu B, 2001, J BIOL CHEM, V276, P36624, DOI 10.1074/jbc.M101085200; Liu B, 2001, P NATL ACAD SCI USA, V98, P3203, DOI 10.1073/pnas.051489598; Liu J, 2001, MOL CELL, V7, P927, DOI 10.1016/S1097-2765(01)00241-6; Liu YC, 2004, ANNU REV IMMUNOL, V22, P81, DOI 10.1146/annurev.immunol.22.012703.104813; Liu ZH, 1998, ACTA POLYM SIN, P1; Matsuzawa S, 2001, MOL CELL, V7, P915, DOI 10.1016/S1097-2765(01)00242-8; Megidish T, 2002, J BIOL CHEM, V277, P8255, DOI 10.1074/jbc.C200001200; Melchior F, 2000, ANNU REV CELL DEV BI, V16, P591, DOI 10.1146/annurev.cellbio.16.1.591; Millot GA, 2002, EXP HEMATOL, V30, P166, DOI 10.1016/S0301-472X(01)00776-7; Muller S, 2000, J BIOL CHEM, V275, P13321, DOI 10.1074/jbc.275.18.13321; Muller S, 1998, EMBO J, V17, P61, DOI 10.1093/emboj/17.1.61; Nakayama K, 2004, CELL CYCLE, V3, P1345, DOI 10.4161/cc.3.11.1207; Polekhina G, 2002, NAT STRUCT BIOL, V9, P68, DOI 10.1038/nsb743; Reed JC, 2002, NAT STRUCT BIOL, V9, P8, DOI 10.1038/nsb0102-8; Rodriguez MS, 1999, EMBO J, V18, P6455, DOI 10.1093/emboj/18.22.6455; Sachdev S, 2001, GENE DEV, V15, P3088, DOI 10.1101/gad.944801; Schmidt D, 2002, P NATL ACAD SCI USA, V99, P2872, DOI 10.1073/pnas.052559499; Shuai K, 2005, NAT REV IMMUNOL, V5, P593, DOI 10.1038/nri1667; Simon MC, 2004, CELL, V117, P851, DOI 10.1016/j.cell.2004.06.010; Sun LJ, 2004, CURR OPIN CELL BIOL, V16, P119, DOI 10.1016/j.ceb.2004.02.005; Susini L, 2001, P NATL ACAD SCI USA, V98, P15067, DOI 10.1073/pnas.261571998; Tan JA, 2002, J BIOL CHEM, V277, P16993, DOI 10.1074/jbc.M109217200; Tang AH, 1997, CELL, V90, P459, DOI 10.1016/S0092-8674(00)80506-1; Tanikawa J, 2000, J BIOL CHEM, V275, P15578, DOI 10.1074/jbc.M000372200; Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563; Yaron A, 1997, EMBO J, V16, P6486, DOI 10.1093/emboj/16.21.6486; Yeh WC, 1997, IMMUNITY, V7, P715, DOI 10.1016/S1074-7613(00)80391-X; Zhang JS, 1998, GENE DEV, V12, P1775, DOI 10.1101/gad.12.12.1775	50	17	17	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 11	2007	26	46					6665	6676		10.1038/sj.onc.1210486	http://dx.doi.org/10.1038/sj.onc.1210486			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	219JT	17533377				2022-12-28	WOS:000250081500008
J	Johnson, C; Marriott, SJ; Levy, LS				Johnson, C.; Marriott, S. J.; Levy, L. S.			Overexpression of p101 activates PI3K gamma signaling in T cells and contributes to cell survival	ONCOGENE			English	Article						phosphatidylinositol-3-kinase-gamma; retrovirus integration site; lymphoma; apoptosis	G-BETA-GAMMA; PHOSPHOINOSITIDE 3-KINASE; REGULATORY SUBUNIT; FREQUENT INACTIVATION; CANCER; PIK3CA; P110-GAMMA; P110-DELTA; EXPRESSION; MUTATIONS	p101, the regulatory subunit of phosphatidylinositol--3-kinase- gamma (PI3KC gamma), was recently reported as a common site of retroviral insertion in T-cell lymphomas induced in mice by MoFe2-MuLV, a unique recombinant gammaretrovirus. The common interruption of p101 by retroviral integration suggests that the locus encodes an oncogene whose altered expression is related to the induction of T-cell malignancy. To examine a possible role in the malignant process, p101 was overexpressed in human T-cell lines Molt-4 and Jurkat. Transient overexpression of p101 induced apoptosis in recipient cells; however, stable expression could be established in cells that expressed moderate levels of p101. Constitutive p101 overexpression in those cells conferred significant protection against ultraviolet-induced apoptosis. Protection against apoptotic induction was attributed to p101-mediated activation of the Akt pathway. Constitutive overexpression of p101 enhanced the activity of p110 gamma and further sensitized it to activation upon stimulation of G protein-coupled receptor. These findings are the first to implicate altered expression of p101 in malignancy, specifically in T-cell lymphoma. The findings further provide insight into the regulation of p110 gamma, indicating that the stoichiometry of p110 gamma and p101 are important in regulating PI3K gamma signaling.	Tulane Univ, Sch Med, Dept Microbiol & Immunol, New Orleans, LA 70112 USA; Tulane Univ, Hlth Sci Ctr, Tualne Canc Ctr, New Orleans, LA 70112 USA; Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA; Baylor Coll Med, Interdepartmental Program Cell & Mol Biol, Houston, TX 77030 USA	Tulane University; Tulane University; Baylor College of Medicine; Baylor College of Medicine	Levy, LS (corresponding author), Tulane Univ, Sch Med, Dept Microbiol & Immunol, 1430 Tulane Ave SL-38, New Orleans, LA 70112 USA.	llevy@tulane.edu			NATIONAL CANCER INSTITUTE [R01CA083823] Funding Source: NIH RePORTER; NCI NIH HHS [CA83823] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AbdelMageed AB, 1997, CANCER GENE THER, V4, P199; Bader AG, 2006, P NATL ACAD SCI USA, V103, P1475, DOI 10.1073/pnas.0510857103; Brock C, 2003, J CELL BIOL, V160, P89, DOI 10.1083/jcb.200210115; Cairns P, 1997, CANCER RES, V57, P4997; Campbell IG, 2004, CANCER RES, V64, P7678, DOI 10.1158/0008-5472.CAN-04-2933; Curnock AP, 2002, IMMUNOLOGY, V105, P125, DOI 10.1046/j.1365-2567.2002.01345.x; Foukas LC, 2002, J BIOL CHEM, V277, P37124, DOI 10.1074/jbc.M202101200; Freeburn RW, 2002, J IMMUNOL, V169, P5441, DOI 10.4049/jimmunol.169.10.5441; Goel A, 2004, CANCER RES, V64, P3014, DOI 10.1158/0008-5472.CAN-2401-2; Grandori C, 2000, ANNU REV CELL DEV BI, V16, P653, DOI 10.1146/annurev.cellbio.16.1.653; Hennessy BT, 2005, NAT REV DRUG DISCOV, V4, P988, DOI 10.1038/nrd1902; Hickey FB, 2006, J BIOL CHEM, V281, P2441, DOI 10.1074/jbc.M511173200; Hirsch E, 2000, SCIENCE, V287, P1049, DOI 10.1126/science.287.5455.1049; Jimenez C, 1998, EMBO J, V17, P743, DOI 10.1093/emboj/17.3.743; Johnson C, 2005, J VIROL, V79, P57, DOI 10.1128/JVI.79.1.57-66.2005; Jucker M, 2002, LEUKEMIA, V16, P894, DOI 10.1038/sj.leu.2402484; Kang S, 2006, P NATL ACAD SCI USA, V103, P1289, DOI 10.1073/pnas.0510772103; Kang S, 2005, CELL CYCLE, V4, P578, DOI 10.4161/cc.4.4.1593; Khan S, 2004, INT J CANCER, V112, P407, DOI 10.1002/ijc.20447; Okkenhaug K, 2003, NAT REV IMMUNOL, V3, P317, DOI 10.1038/nri1056; Samuels Y, 2004, CELL CYCLE, V3, P1221, DOI 10.4161/cc.3.10.1164; Sasaki T, 2000, SCIENCE, V287, P1040, DOI 10.1126/science.287.5455.1040; Shayesteh L, 1999, NAT GENET, V21, P99, DOI 10.1038/5042; STEPHENS L, 1994, CELL, V77, P83, DOI 10.1016/0092-8674(94)90237-2; Stephens LR, 1997, CELL, V89, P105, DOI 10.1016/S0092-8674(00)80187-7; Suire S, 2005, CURR BIOL, V15, P566, DOI 10.1016/j.cub.2005.02.020; Vanhaesebroeck B, 1997, P NATL ACAD SCI USA, V94, P4330, DOI 10.1073/pnas.94.9.4330; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; Voigt P, 2006, J BIOL CHEM, V281, P9977, DOI 10.1074/jbc.M512502200; Voigt P, 2005, J BIOL CHEM, V280, P5121, DOI 10.1074/jbc.M413104200; Woenckhaus J, 2002, J PATHOL, V198, P335, DOI 10.1002/path.1207	31	14	15	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT	2007	26	49					7049	7057		10.1038/sj.onc.1210504	http://dx.doi.org/10.1038/sj.onc.1210504			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	223YN	17486067	Bronze			2022-12-28	WOS:000250412200010
J	Wang, ZH; Shen, B; Yao, HL; Jia, Y; Ren, J; Feng, Y; Wang, YZ				Wang, Z. H.; Shen, B.; Yao, H. L.; Jia, Y. C.; Ren, J.; Feng, Y. J.; Wang, Y. Z.			Blockage of intermediate-conductance-Ca2(+)-activated K+ channels inhibits progression of human endometrial cancer	ONCOGENE			English	Article						endometrial cancer; proliferation; intermediate-conductance Ca2+-activated K+ (IKCa1) channel; electrophysiology	INTERMEDIATE-CONDUCTANCE; CELL-PROLIFERATION; UP-REGULATION; POTASSIUM CHANNELS; GROWTH-FACTOR; INVOLVEMENT; CYCLE; MECHANISM; LINE; IDENTIFICATION	Potassium ( K+) channels have been implicated in proliferation of some tumor cells. However, whether K+ channels are important to the pathogenesis of endometrial cancer ( EC) remains unknown. In the present study, we report that intermediate-conductance Ca2+ activated K+ ( IKCa1) channels play a critical role in the development of EC. The expression of IKCa1 at both mRNA and protein levels in EC tissues was greatly increased than that in atypical hyperplasia and normal tissues. Treatment of EC cells with clotrimazole and TRAM-34, two agents kn own to inhibit IKCa1 channels, suppressed the proliferation of EC cells a nd blocked EC cell cycle at G(0)/G(1) phase. Similarly, downregulation of IKCa1 by siRNA against IKCa1 inhibited EC cell proliferation and arrested its cell cycle at G0/G1 phase. A clotrimazole-sensitive K+ current was induced in EC cells in response to the increased Ca2+. The current density induced by Ca2+ was great ly reduced by clotrimazole, TRAM-34, charybdotoxin or downregulation of IKCa1 by the siRNA against IKCa1. Furthermore, TRAM-34 and clotrimazole slowed the formation in nude mice of tumor generated by injection of EC cells. Our results suggest that increased activity of IKCa1 channel is necessary for the development of EC.	Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Neurosci, Shanghai 200031, Peoples R China; Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Mat Med, Shanghai 200031, Peoples R China; Fudan Univ, Med Ctr, Obstet & Gynecol Hosp, Shanghai 200433, Peoples R China	Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Chinese Academy of Sciences; Shanghai Institute of Materia Medica, CAS; Shanghai Institutes for Biological Sciences, CAS; Fudan University	Wang, YZ (corresponding author), Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Neurosci, 320 Yue Yang Rd, Shanghai 200031, Peoples R China.	fengyj4806@sohu.com; yzwang@ion.ac.cn						Ahn SC, 2004, PFLUG ARCH EUR J PHY, V447, P426, DOI 10.1007/s00424-003-1201-1; Begenisich T, 2004, J BIOL CHEM, V279, P47681, DOI 10.1074/jbc.M409627200; Chittajallu R, 2002, P NATL ACAD SCI USA, V99, P2350, DOI 10.1073/pnas.042698399; Dunn PM, 1998, J MEMBRANE BIOL, V165, P133, DOI 10.1007/s002329900427; Farias LMB, 2004, CANCER RES, V64, P6996, DOI 10.1158/0008-5472.CAN-04-1204; Fraser SP, 2003, PFLUG ARCH EUR J PHY, V446, P559, DOI 10.1007/s00424-003-1077-0; Ghanshani S, 2000, J BIOL CHEM, V275, P37137, DOI 10.1074/jbc.M003941200; Jager H, 2004, MOL PHARMACOL, V65, P630, DOI 10.1124/mol.65.3.630; Lang F, 2003, CELL PHYSIOL BIOCHEM, V13, P41, DOI 10.1159/000070248; Legrand G, 2001, J BIOL CHEM, V276, P47608, DOI 10.1074/jbc.M107011200; Levine DA, 2002, CANCER J, V8, pS31; Lu XH, 1999, J GEN PHYSIOL, V113, P81, DOI 10.1085/jgp.113.1.81; Mork HK, 2005, ACTA PHYSIOL SCAND, V184, P141, DOI 10.1111/j.1365-201X.2005.01441.x; Nehrke K, 2003, AM J PHYSIOL-CELL PH, V284, pC535, DOI 10.1152/ajpcell.00044.2002; NILIUS B, 1992, J PHYSIOL-LONDON, V445, P537, DOI 10.1113/jphysiol.1992.sp018938; Ouadid-Ahidouch H, 2001, RECEPTOR CHANNEL, V7, P345; Ouadid-Ahidouch H, 2000, BIOCHEM BIOPH RES CO, V278, P272, DOI 10.1006/bbrc.2000.3790; Pardo LA, 1999, EMBO J, V18, P5540, DOI 10.1093/emboj/18.20.5540; Parihar AS, 2003, EUR J PHARMACOL, V471, P157, DOI 10.1016/S0014-2999(03)01825-9; Pena TL, 2000, J BIOL CHEM, V275, P13677, DOI 10.1074/jbc.275.18.13677; Rane SG, 1999, ADV SEC MESS PHOSPH, V33, P107; Rane SG, 2000, BIOCHEM BIOPH RES CO, V269, P457, DOI 10.1006/bbrc.2000.2309; Rouzaire-Dubois B, 1998, J PHYSIOL-LONDON, V510, P93, DOI 10.1111/j.1469-7793.1998.093bz.x; Ryan AJ, 2005, CELL TISSUE RES, V322, P53, DOI 10.1007/s00441-005-1109-5; Schneider JJ, 2005, GYNECOL ONCOL, V97, P246, DOI 10.1016/j.ygyno.2004.12.016; Skryma RN, 1997, PROSTATE, V33, P112, DOI 10.1002/(SICI)1097-0045(19971001)33:2<112::AID-PROS5>3.0.CO;2-M; Smith GAM, 2002, J BIOL CHEM, V277, P18528, DOI 10.1074/jbc.M200592200; Wang J, 2003, AM J PHYSIOL-CELL PH, V284, pC77, DOI 10.1152/ajpcell.00132.2002; Wang SY, 1998, J CELL PHYSIOL, V176, P456, DOI 10.1002/(SICI)1097-4652(199809)176:3<456::AID-JCP2>3.0.CO;2-N; WONDERLIN WF, 1995, J CELL PHYSIOL, V165, P177, DOI 10.1002/jcp.1041650121	30	85	98	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 2	2007	26	35					5107	5114		10.1038/sj.onc.1210308	http://dx.doi.org/10.1038/sj.onc.1210308			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	196MT	17310992				2022-12-28	WOS:000248487400009
J	Fan, S; Meng, Q; Laterra, JJ; Rosen, EM				Fan, S.; Meng, Q.; Laterra, J. J.; Rosen, E. M.			Ras effector pathways modulate scatter factor-stimulated NF-kappa B signaling and protection against DNA damage	ONCOGENE			English	Article						scatter factor; ras; Ra1A; raf1; protection; adriamycin	ACTIVATED PROTEIN-KINASE; NUCLEOTIDE DISSOCIATION STIMULATOR; CELL-TRANSFORMATION; EPITHELIAL-CELLS; GENE-EXPRESSION; MET RECEPTOR; CANCER-CELLS; GROWTH; IDENTIFICATION; APOPTOSIS	Scatter factor (SF) (hepatocyte growth factor) is a pleiotrophic cytokine that accumulates within tumors in vivo and protects tumor cells against cytotoxicity and apoptosis due to DNA damaging agents in vitro. Previous studies have established that SF- mediated cell protection involves antiapoptotic signaling from its receptor (c-Met) to PI3 kinase -> c-Akt -> Pak1 (p21-activated kinase -1)-> NF- kappa B (nuclear factor-kappa B). Here, we found that Ras proteins (H-Ras and R-Ras) enhance SF-mediated activation of NF-kappa B and protection of DU-145 and MDCK (Madin-Darby canine kidney) cells against the topoisomerase II alpha inhibitor adriamycin. Studies of Ras effector loop mutants and their downstream effectors suggest that Ras/PI3 kinase and Ras/Raf1 pathways contribute to SF stimulation of NF-kappa B signaling and cell protection. Further studies revealed that Raf1 positively regulates the ability of SF to stimulate NF-kappa B activity and cell protection. The ability of Raf1 to stimulate NF-kappa B activity was not due to the classical Raf1 -> MEK1/2 -> ERK1/ 2 pathway. However, we found that a MEK3/6p -> 38 pathway contributes to SF-mediated activation of NF-kappa B. In contrast, RalA, a target of the Ras/RalGDS pathway negatively regulated the ability of SF to stimulate NF-kappa B activity and cell protection. Ras, Raf1 and RalA modulate SF stimulation of NF-kappa B activity, in part, by regulating I kappa B kinase (IKK)-kappa kinase activity. These findings suggest that Ras/ Raf1/ RalA pathways may converge to modulate NF-kappa B activation and SF-mediated survival signaling at the IKK complex and/or a kinase upstream of this complex.	Georgetown Univ, Dept Oncol, Lombard Comprehens Canc Ctr, Washington, DC 20057 USA; Kennedy Krieger Inst, Dept Neurol, Baltimore, MD USA; Johns Hopkins Univ, Sch Med, Baltimore, MD USA	Georgetown University; Kennedy Krieger Institute; Johns Hopkins University	Rosen, EM (corresponding author), Georgetown Univ, Dept Oncol, Lombard Comprehens Canc Ctr, 3970 Reservoir Rd NW,Box 571469, Washington, DC 20057 USA.	emr36@georgetown.edu			NIEHS NIH HHS [R01-ES09169] Funding Source: Medline; NINDS NIH HHS [R01-NS43987] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES009169] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS043987] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALBRIGHT CF, 1993, EMBO J, V12, P339, DOI 10.1002/j.1460-2075.1993.tb05662.x; ALLEY MC, 1988, CANCER RES, V48, P589; Bardelli A, 1996, EMBO J, V15, P6205, DOI 10.1002/j.1460-2075.1996.tb01009.x; Baumann B, 2000, P NATL ACAD SCI USA, V97, P4615, DOI 10.1073/pnas.080583397; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; Bowers DC, 2000, CANCER RES, V60, P4277; Camonis JH, 2005, TRENDS CELL BIOL, V15, P327, DOI 10.1016/j.tcb.2005.04.002; CANTOR SB, 1995, MOL CELL BIOL, V15, P4578; CHUNG HH, 1993, SCIENCE, V259, P806, DOI 10.1126/science.8430333; Cong LN, 1997, MOL ENDOCRINOL, V11, P1881, DOI 10.1210/me.11.13.1881; Costantini C, 2005, J MOL NEUROSCI, V25, P141, DOI 10.1385/JMN:25:2:141; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DEVOS AM, 1988, SCIENCE, V239, P888, DOI 10.1126/science.2448879; Fan SJ, 2000, ONCOGENE, V19, P2212, DOI 10.1038/sj.onc.1203566; Fan SJ, 2005, ONCOGENE, V24, P1749, DOI 10.1038/sj.onc.1208327; Fan SJ, 1998, ONCOGENE, V17, P131, DOI 10.1038/sj.onc.1201943; Fan SJ, 2001, MOL CELL BIOL, V21, P4968, DOI 10.1128/MCB.21.15.4968-4984.2001; Fitzgerald EM, 2000, J PHYSIOL-LONDON, V527, P433, DOI 10.1111/j.1469-7793.2000.00433.x; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; GRAZIANI A, 1993, J BIOL CHEM, V268, P9165; Herrmann C, 2003, CURR OPIN STRUC BIOL, V13, P122, DOI 10.1016/S0959-440X(02)00007-6; HOFER F, 1994, P NATL ACAD SCI USA, V91, P11089, DOI 10.1073/pnas.91.23.11089; Hu MCT, 1998, GENE, V222, P31, DOI 10.1016/S0378-1119(98)00462-4; Jin L, 1997, CANCER, V79, P749, DOI 10.1002/(SICI)1097-0142(19970215)79:4<749::AID-CNCR12>3.0.CO;2-#; KRAUS MH, 1984, P NATL ACAD SCI-BIOL, V81, P5384, DOI 10.1073/pnas.81.17.5384; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; Luo JQ, 1998, P NATL ACAD SCI USA, V95, P3632, DOI 10.1073/pnas.95.7.3632; Matteucci E, 2003, ONCOGENE, V22, P4062, DOI 10.1038/sj.onc.1206519; May MJ, 2000, SCIENCE, V289, P1550, DOI 10.1126/science.289.5484.1550; McFarlin DR, 2003, CARCINOGENESIS, V24, P99, DOI 10.1093/carcin/24.1.99; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; Mochizuki N, 2000, J BIOL CHEM, V275, P12667, DOI 10.1074/jbc.275.17.12667; Mody N, 2003, BIOCHEM J, V372, P567, DOI 10.1042/BJ20030193; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; Murai H, 1997, J BIOL CHEM, V272, P10483; Nick JA, 1999, J CLIN INVEST, V103, P851, DOI 10.1172/JCI5257; Oxford G, 2005, CANCER RES, V65, P7111, DOI 10.1158/0008-5472.CAN-04-1957; Peyssonnaux C, 2000, MOL CELL BIOL, V20, P7068, DOI 10.1128/MCB.20.19.7068-7079.2000; Rahman A, 2004, AM J PHYSIOL-LUNG C, V287, pL1017, DOI 10.1152/ajplung.00072.2004; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; Rosen EM, 1997, CIBA F SYMP, V212, P215; Shao HP, 1999, ARCH BIOCHEM BIOPHYS, V371, P207, DOI 10.1006/abbi.1999.1448; Shuto T, 2001, P NATL ACAD SCI USA, V98, P8774, DOI 10.1073/pnas.151236098; Song KS, 2003, J BIOL CHEM, V278, P34890, DOI 10.1074/jbc.M303911200; Stewart S, 2000, J BIOL CHEM, V275, P8854, DOI 10.1074/jbc.275.12.8854; Stuckler D, 2005, CANCER RES, V65, P991; Tulasne D, 1999, MOL BIOL CELL, V10, P551, DOI 10.1091/mbc.10.3.551; Vitale N, 2005, J BIOL CHEM, V280, P29921, DOI 10.1074/jbc.M413748200; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; Voss M, 1999, J BIOL CHEM, V274, P34691, DOI 10.1074/jbc.274.49.34691; Wang XS, 1997, J BIOL CHEM, V272, P23668, DOI 10.1074/jbc.272.38.23668; Webb CP, 1998, P NATL ACAD SCI USA, V95, P8773, DOI 10.1073/pnas.95.15.8773; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; Wohlgemuth S, 2005, J MOL BIOL, V348, P741, DOI 10.1016/j.jmb.2005.02.048; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; YAN MH, 1994, J BIOL CHEM, V269, P19067; Yang JJ, 1998, MOL CELL BIOL, V18, P2586, DOI 10.1128/MCB.18.5.2586; ZHENG CF, 1993, J BIOL CHEM, V268, P23933; Zhong H, 2000, CANCER RES, V60, P1541	60	22	24	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 19	2007	26	33					4774	4796		10.1038/sj.onc.1210271	http://dx.doi.org/10.1038/sj.onc.1210271			23	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	191ZL	17297451				2022-12-28	WOS:000248170400003
J	Vendrell, JA; Ghayad, S; Ben-Larbi, S; Dumontet, C; Mechti, N; Cohen, PA				Vendrell, J. A.; Ghayad, S.; Ben-Larbi, S.; Dumontet, C.; Mechti, N.; Cohen, P. A.			A20/TNFAIP3, a new estrogen-regulated gene that confers tamoxifen resistance in breast cancer cells	ONCOGENE			English	Article						A20/TNFAIP3; breast cancer; tamoxifen; resistance; estrogen receptor status; endocrine treatment	NF-KAPPA-B; NECROSIS-FACTOR-ALPHA; ZINC-FINGER PROTEIN; INDUCED APOPTOSIS; TRANSCRIPTIONAL ACTIVATION; ENDOTHELIAL-CELLS; UP-REGULATION; A20; EXPRESSION; RECEPTOR	The zinc-finger protein A20/TNFAIP3, an inhibitor of nuclear factor-kappa B (NF-kappa B) activation, has been shown to protect MCF-7 breast carcinoma cells from TNF alpha-induced apoptosis. As estrogen receptor (ER) status is an important parameter in the development and progression of breast cancer, we analysed the effect of 17 beta-estradiol (E-2) treatment on the expression of A20. We found that A20 is a new E-2-regulated gene, whose expression correlates with ER expression in both cell lines and tumor samples. With the aim of investigating the impact of A20 expression on MCF-7 cells in response to ER ligands, we established stably transfected-MCF-7 cells overexpressing A20 (MCF-7-A20). These cells exhibited a phenotype of resistance to the 4-hydroxytamoxifen cytostatic and pro-apoptotic actions and of hyper-response to E-2. Dysregulations in bax, bcl2, bak, phospho-bad, cyclin D1, cyclin E2, cyclin D2 and cyclin A2 proteins expression were shown to be related to the resistant phenotype developed by the MCF-7-A20 cells. Interestingly, we found that A20 was also overexpressed in MVLN and VP tamoxifen-resistant cell lines. Furthermore, high A20 expression levels were observed in more aggressive breast tumors (ER-negative, progesterone receptor-negative and high histological grade). These overall findings strongly suggest that A20 is a key protein involved in tamoxifen resistance, and thus represents both a new breast cancer marker and a promising target for developing new strategies to prevent the emergence of acquired mechanisms of drug resistance in breast cancer.	Univ Lyon 1, Fac Pharm Lyon, ISPB, F-69008 Lyon, France; Fac Pharm Montpellier, CNRS, UMR 5160, Ctr Pharmacol & Biotechnol Sante Fac Pharm, Montpellier, France; INSERM, UMR 590, F-69008 Lyon, France	UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; Institut National de la Sante et de la Recherche Medicale (Inserm)	Cohen, PA (corresponding author), Univ Lyon 1, Fac Pharm Lyon, ISPB, 8 Av Rockefeller, F-69008 Lyon, France.	pascale.cohen@recherche.univ-lyon1.fr	Vendrell, Julie A/I-5867-2012; Cohen, Pascale/I-5875-2012	Cohen, Pascale/0000-0001-7016-9598; Dumontet, Charles/0000-0003-1875-134X				Ainbinder E, 2002, MOL CELL BIOL, V22, P6354, DOI 10.1128/MCB.22.18.6354-6362.2002; Badia E, 2000, CANCER RES, V60, P4130; Berstein LM, 2004, CLIN CANCER RES, V10, P1530, DOI 10.1158/1078-0432.CCR-0433-03; BLOOM HJG, 1957, BRIT J CANCER, V11, P359, DOI 10.1038/bjc.1957.43; Bredel M, 2006, J CLIN ONCOL, V24, P274, DOI 10.1200/JCO.2005.02.9405; Campbell RA, 2001, J BIOL CHEM, V276, P9817, DOI 10.1074/jbc.M010840200; Clarke M, 1998, LANCET, V351, P1451; Codd JD, 1999, J PATHOL, V187, P549; DEGOEIJ AFPM, 1988, J STEROID BIOCHEM, V29, P465, DOI 10.1016/0022-4731(88)90180-X; DEMIRPENCE E, 1993, J STEROID BIOCHEM, V46, P355, DOI 10.1016/0960-0760(93)90225-L; DIXIT VM, 1990, J BIOL CHEM, V265, P2973; Faridi J, 2003, CLIN CANCER RES, V9, P2933; Ferran C, 1998, BLOOD, V91, P2249, DOI 10.1182/blood.V91.7.2249.2249_2249_2258; GOTTARDIS MM, 1988, CANCER RES, V48, P5183; Grey ST, 1999, J EXP MED, V190, P1135, DOI 10.1084/jem.190.8.1135; Harnish DC, 2000, ENDOCRINOLOGY, V141, P3403, DOI 10.1210/en.141.9.3403; Heyninck K, 1999, ANTICANCER RES, V19, P2863; HONIG SF, 1996, DIS BREAST, P669; Jaattela M, 1996, J IMMUNOL, V156, P1166; JANICKE RU, 1994, MOL CELL BIOL, V14, P5661; Johnston SRD, 1997, ANTI-CANCER DRUG, V8, P911, DOI 10.1097/00001813-199711000-00002; Kim R, 2005, CANCER-AM CANCER SOC, V103, P2199, DOI 10.1002/cncr.21029; KRIKOS A, 1992, J BIOL CHEM, V267, P17971; Kurokawa H, 2000, CANCER RES, V60, P5887; LAHERTY CD, 1992, J BIOL CHEM, V267, P24157; Lee EG, 2000, SCIENCE, V289, P2350, DOI 10.1126/science.289.5488.2350; Li HL, 2006, J CELL PHYSIOL, V208, P307, DOI 10.1002/jcp.20665; Longo CR, 2005, HEPATOLOGY, V42, P156, DOI 10.1002/hep.20741; Louie MC, 2004, MOL CELL BIOL, V24, P5157, DOI 10.1128/MCB.24.12.5157-5171.2004; Lu M, 2003, CANCER RES, V63, P3425; Martin LA, 2003, J BIOL CHEM, V278, P30458, DOI 10.1074/jbc.M305226200; Mauro C, 2006, J BIOL CHEM, V281, P18482, DOI 10.1074/jbc.M601502200; McCallum HM, 1996, BREAST CANCER RES TR, V39, P247, DOI 10.1007/BF01806153; Murphy LC, 2005, J MOL ENDOCRINOL, V34, P553, DOI 10.1677/jme.1.01688; Nabha SM, 2005, ONCOGENE, V24, P3166, DOI 10.1038/sj.onc.1208502; Nguyen H, 2006, VIROLOGY, V354, P58, DOI 10.1016/j.virol.2006.04.028; Onose A, 2006, EUR J PHARMACOL, V541, P198, DOI 10.1016/j.ejphar.2006.03.073; OPIPARI AW, 1992, J BIOL CHEM, V267, P12424; Patel VI, 2006, FASEB J, V20, P1418, DOI 10.1096/fj.05-4981com; Pichon MF, 1996, BRIT J CANCER, V73, P1545, DOI 10.1038/bjc.1996.291; PIKE MC, 1993, EPIDEMIOL REV, V15, P17, DOI 10.1093/oxfordjournals.epirev.a036102; Ring A, 2004, ENDOCR-RELAT CANCER, V11, P643, DOI 10.1677/erc.1.00776; Safe S, 2001, VITAM HORM, V62, P231, DOI 10.1016/S0083-6729(01)62006-5; Santen RJ, 2004, CLIN CANCER RES, V10, p337S, DOI 10.1158/1078-0432.CCR-031207; SARMA V, 1995, J BIOL CHEM, V270, P12343, DOI 10.1074/jbc.270.21.12343; STEIN B, 1995, MOL CELL BIOL, V15, P4971; Storz P, 2005, BIOCHEM J, V387, P47, DOI 10.1042/BJ20041443; TEWARI M, 1995, J IMMUNOL, V154, P1699; THOMPSON EW, 1992, J CELL PHYSIOL, V150, P534, DOI 10.1002/jcp.1041500314; Tonetti DA, 2000, BRIT J CANCER, V83, P782, DOI 10.1054/bjoc.2000.1326; Tsai MS, 2002, ONCOGENE, V21, P8178, DOI 10.1038/sj.onc.1205682; Vendrell JA, 2005, ENDOCR-RELAT CANCER, V12, P75, DOI 10.1677/erc.1.00899; Vendrell JA, 2004, J MOL ENDOCRINOL, V32, P397, DOI 10.1677/jme.0.0320397; Wertz IE, 2004, NATURE, V430, P694, DOI 10.1038/nature02794; Yamit-Hezi E, 2000, J BIOL CHEM, V275, P18180, DOI 10.1074/jbc.275.24.18180; Yue W, 2002, ENDOCRINOLOGY, V143, P3221, DOI 10.1210/en.2002-220186; Zetoune FS, 2001, CYTOKINE, V15, P282, DOI 10.1006/cyto.2001.0921; Zhang GJ, 1999, CLIN CANCER RES, V5, P2971	58	74	81	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 12	2007	26	32					4656	4667		10.1038/sj.onc.1210269	http://dx.doi.org/10.1038/sj.onc.1210269			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	190DJ	17297453				2022-12-28	WOS:000248037900006
J	Schwartz, B; Melnikova, VO; Tellez, C; Mourad-Zeidan, A; Blehm, K; Zhao, YJ; McCarty, M; Adam, L; Bar-Eli, M				Schwartz, B.; Melnikova, V. O.; Tellez, C.; Mourad-Zeidan, A.; Blehm, K.; Zhao, Y-J; McCarty, M.; Adam, L.; Bar-Eli, M.			Loss of AP-2 alpha results in deregulation of E-cadherin and MMP-9 and an increase in tumorigenicity of colon cancer cells in vivo	ONCOGENE			English	Review						AP-2 alpha; colon cancer; MMP-9; E-cadherin; transcriptional regulation	TRANSCRIPTION FACTOR AP-2; GENE-EXPRESSION; HUMAN-MELANOMA; COLORECTAL-CARCINOMA; DOWN-REGULATION; BREAST-CANCER; UP-REGULATION; TUMOR-GROWTH; METASTASIS; CLONING	Activator protein-2 (AP-2) is a transcription factor that regulates proliferation and differentiation in mammalian cells and has been implicated in the acquisition of the metastatic phenotype in several types of cancer. Herein, we examine the role of AP-2 alpha in colon cancer progression. We provide evidence for the lack of AP-2 alpha expression in the late stages of colon cancer cells. Re-expression of the AP-2 alpha gene in the AP-2 alpha-negative SW480 colon cancer cells suppressed their tumorigenicity following orthotopic injection into the cecal wall of nude mice. The inhibition of tumor growth could be attributed to the increased expression of E-cadherin and decreased expression and activity of matrix-metalloproteinase-9 (MMP-9) in the transfected cells, as well as a substantial loss of their in vitro invasive properties. Conversely, targeting constitutive expression of AP-2 alpha in AP-2-positive KM12C colon cancer cells with small interfering RNA resulted in an increase in their invasive potential, downregulation of E-cadherin and increased expression of MMP-9. In SW480 cells, re-expression of AP-2 alpha resulted in a fourfold increase in the activity of E-cadherin promoter, and a 5-14-fold decrease in the activity of MMP-9 promoter, indicating transcriptional regulation of these genes by AP-2 alpha. Chromatin immunoprecipitation assay showed that re-expressed AP-2 alpha directly binds to the promoter of E-cadherin, where it has been previously reported to act as a transcriptional activator. Furthermore, chromatin immunoprecipitation assay revealed AP-2 alpha binding to the MMP-9 promoter, which ensued by decreased binding of transcription factor Sp-1 and changes in the recruitment of transcription factors to a distal AP-1 element, thus, contributing to the overall downregulation of MMP-9 promoter activity. Collectively, our data provide evidence that AP-2 alpha acts as a tumor suppressor gene in colon cancer.	Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Bar-Eli, M (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol, Unit 173,1515 Holcombe Blvd, Houston, TX 77030 USA.	mbareli@mdanderson.org			NCI NIH HHS [CA-76098] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA076098] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bar-Eli M, 2001, PIGM CELL RES, V14, P78, DOI 10.1034/j.1600-0749.2001.140202.x; Batsche E, 1998, MOL CELL BIOL, V18, P3647, DOI 10.1128/MCB.18.7.3647; Boedefeld WM, 2003, ANN SURG ONCOL, V10, P839, DOI 10.1245/ASO.2003.02.021; Bosher JM, 1996, ONCOGENE, V13, P1701; Comijn J, 2001, MOL CELL, V7, P1267, DOI 10.1016/S1097-2765(01)00260-X; Gershenwald JE, 2001, ONCOGENE, V20, P3363, DOI 10.1038/sj.onc.1204450; Gum R, 1996, J BIOL CHEM, V271, P10672, DOI 10.1074/jbc.271.18.10672; Hilger-Eversheim K, 2000, GENE, V260, P1, DOI 10.1016/S0378-1119(00)00454-6; Ho AT, 2001, J BIOL CHEM, V276, P40215, DOI 10.1074/jbc.M101647200; Huang S, 1998, EMBO J, V17, P4358, DOI 10.1093/emboj/17.15.4358; Huang WH, 2002, J MOL MODEL, V8, P8, DOI 10.1007/s00894-001-0060-y; Jean D, 1998, J BIOL CHEM, V273, P16501, DOI 10.1074/jbc.273.26.16501; Karjalainen JM, 1998, J CLIN ONCOL, V16, P3584, DOI 10.1200/JCO.1998.16.11.3584; Melnikova VO, 2006, J BIOL CHEM, V281, P2911, DOI 10.1074/jbc.M508683200; MITCHELL PJ, 1991, GENE DEV, V5, P105, DOI 10.1101/gad.5.1.105; MORIKAWA K, 1988, CANCER RES, V48, P6863; MOSER M, 1995, DEVELOPMENT, V121, P2779; Pellikainen J, 2004, EUR J CANCER, V40, P1485, DOI 10.1016/j.ejca.2004.02.020; Pellikainen MJ, 2003, J CLIN PATHOL, V56, P214, DOI 10.1136/jcp.56.3.214; Ropponen KM, 2001, J CLIN PATHOL, V54, P533, DOI 10.1136/jcp.54.7.533; Ropponen KM, 1999, BRIT J CANCER, V81, P133, DOI 10.1038/sj.bjc.6690662; Rozen P, 2004, EUR J CANCER PREV, V13, P71, DOI 10.1097/00008469-200402000-00011; Ruiz M, 2004, CANCER RES, V64, P631, DOI 10.1158/0008-5472.CAN-03-2751; SATO H, 1993, ONCOGENE, V8, P395; Sumigama S, 2004, ONCOGENE, V23, P5496, DOI 10.1038/sj.onc.1207723; Tellez C, 2003, J BIOL CHEM, V278, P46632, DOI 10.1074/jbc.M309159200; Tellez C, 2003, ONCOGENE, V22, P3130, DOI 10.1038/sj.onc.1206453; Tummala R, 2003, GENE, V321, P93, DOI 10.1016/S0378-1119(03)00840-0; Vainio H, 2003, ACTA ONCOL, V42, P809, DOI 10.1080/02841860310010673; Wajapeyee N, 2003, J BIOL CHEM, V278, P52093, DOI 10.1074/jbc.M305624200; West-Mays JA, 2003, DIFFERENTIATION, V71, P206, DOI 10.1046/j.1432-0436.2003.710302.x; WILLIAMS T, 1988, GENE DEV, V2, P1557, DOI 10.1101/gad.2.12a.1557; Yan CH, 2004, FASEB J, V18, P540, DOI 10.1096/fj.03-0960fje; Zeng YX, 1997, NAT GENET, V15, P78, DOI 10.1038/ng0197-78; Zhao F, 2001, J BIOL CHEM, V276, P40755, DOI 10.1074/jbc.M106284200	35	59	67	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 14	2007	26	28					4049	4058		10.1038/sj.onc.1210193	http://dx.doi.org/10.1038/sj.onc.1210193			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	178XD	17224907				2022-12-28	WOS:000247252700001
J	Carie, AE; Sebti, SM				Carie, A. E.; Sebti, S. M.			A chemical biology approach identifies a beta-2 adrenergic receptor agonist that causes human tumor regression by blocking the Raf-1/Mek-1/Erk1/2 pathway	ONCOGENE			English	Article						cAMP; Raf-1; Erk1/2; beta 2 adrenergic receptor; Pirbuterol; cancer therapy	ACTIVATED PROTEIN-KINASE; BREAST-CANCER CELLS; EPIDERMAL-GROWTH-FACTOR; GERANYLGERANYLTRANSFERASE-I INHIBITOR; MAP KINASE; SIGNAL-TRANSDUCTION; CYCLIC-AMP; H-RAS; K-RAS; B-RAF	A chemical biology approach identifies a beta 2 adrenergic receptor (beta 2AR) agonist ARA-211 (Pirbuterol), which causes apoptosis and human tumor regression in animal models. b2AR stimulation of cAMP formation and protein kinase A (PKA) activation leads to Raf-1 (but not B-Raf) kinase inactivation, inhibition of Mek-1 kinase and decreased phospho-extracellular signal-regulated kinase (Erk)1/2 levels. ARA-211 inhibition of the Raf/Mek/Erk1/2 pathway is mediated by PKA and not exchange protein activated by cAMP (EPAC). ARA-211 is selective and suppresses P-Erk1/2 but not P-JNK, P-p38, P-Akt or P-STAT3 levels. b2AR stimulation results in inhibition of anchorage-dependent and -independent growth, induction of apoptosis in vitro and tumor regression in vivo. b2AR antagonists and constitutively active Mek-1 rescue from the effects of ARA-211, demonstrating that b2AR stimulation and Mek kinase inhibition are required for ARA-211 antitumor activity. Furthermore, suppression of growth occurs only in human tumors where ARA-211 induces cAMP formation and decreases P-Erk1/2 levels. Thus, b2AR stimulation results in significant suppression of malignant transformation in cancers where it blocks the Raf-1/Mek-1/Erk1/2 pathway by a cAMP-dependent activation of PKA but not EPAC.	Univ S Florida, H Lee Moffit Canc Ctr & Res Inst, Drug Discovery Program, Tampa, FL 33612 USA; Univ S Florida, Dept Interdisciplinary Oncol, Tampa, FL 33612 USA	State University System of Florida; University of South Florida; State University System of Florida; University of South Florida	Sebti, SM (corresponding author), Univ S Florida, H Lee Moffit Canc Ctr & Res Inst, Drug Discovery Program, 12902 Magnolia Dr, Tampa, FL 33612 USA.	sebti@moffitt.usf.edu		Carie, Adam/0000-0001-7804-0465				Alvarez JV, 2004, CANCER BIOL THER, V3, P1045, DOI 10.4161/cbt.3.11.1172; Blaskovich MA, 2003, CANCER RES, V63, P1270; BOS JL, 1989, CANCER RES, V49, P4682; Carman CV, 1998, CURR OPIN NEUROBIOL, V8, P335, DOI 10.1016/S0959-4388(98)80058-5; Cox ME, 2000, J BIOL CHEM, V275, P13812, DOI 10.1074/jbc.275.18.13812; Dhillon AS, 2002, ARCH BIOCHEM BIOPHYS, V404, P3, DOI 10.1016/S0003-9861(02)00244-8; DIMARCO E, 1989, ONCOGENE, V4, P831; Dumaz N, 2005, FEBS J, V272, P3491, DOI 10.1111/j.1742-4658.2005.04763.x; English JM, 2002, TRENDS PHARMACOL SCI, V23, P40, DOI 10.1016/S0165-6147(00)01865-4; Enserink JM, 2002, NAT CELL BIOL, V4, P901, DOI 10.1038/ncb874; ERHARDT P, 1995, MOL CELL BIOL, V15, P5524; FLEMING TP, 1992, EXP GERONTOL, V27, P523, DOI 10.1016/0531-5565(92)90007-M; Graells J, 2004, J INVEST DERMATOL, V123, P1151, DOI 10.1111/j.0022-202X.2004.23460.x; GRASSI V, 1986, INT J CLIN PHARM RES, V6, P93; GRAVES LM, 1993, P NATL ACAD SCI USA, V90, P10300, DOI 10.1073/pnas.90.21.10300; HAFNER S, 1994, MOL CELL BIOL, V14, P6696; Hagemann C, 2001, CELL SIGNAL, V13, P863, DOI 10.1016/S0898-6568(01)00220-0; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hao D, 2002, CANCER INVEST, V20, P387, DOI 10.1081/CNV-120001184; Jiang Z, 2004, HISTOPATHOLOGY, V45, P218, DOI 10.1111/j.1365-2559.2004.01930.x; Jin W, 2003, BRIT J CANCER, V89, P185, DOI 10.1038/sj.bjc.6601048; Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682; Johnson JR, 2005, CLIN CANCER RES, V11, P6414, DOI 10.1158/1078-0432.CCR-05-0790; Lerner EC, 1997, ONCOGENE, V15, P1283, DOI 10.1038/sj.onc.1201296; Maudsley S, 2000, J BIOL CHEM, V275, P9572, DOI 10.1074/jbc.275.13.9572; MOORE PF, 1978, J PHARMACOL EXP THER, V207, P410; Redell MS, 2005, CURR PHARM DESIGN, V11, P2873, DOI 10.2174/1381612054546699; Schmitt JM, 2002, MOL CELL, V9, P85, DOI 10.1016/S1097-2765(01)00432-4; Schmitt JM, 2001, MOL CELL BIOL, V21, P3671, DOI 10.1128/MCB.21.11.3671-3683.2001; Sebolt-Leopold JS, 1999, NAT MED, V5, P810, DOI 10.1038/10533; Sebolt-Leopold JS, 2000, ONCOGENE, V19, P6594, DOI 10.1038/sj.onc.1204083; SEBTI SM, 1991, CANCER COMMUN, V3, P141, DOI 10.3727/095535491820873371; SEVETSON BR, 1993, P NATL ACAD SCI USA, V90, P10305, DOI 10.1073/pnas.90.21.10305; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Slotkin TA, 2000, BREAST CANCER RES TR, V60, P153, DOI 10.1023/A:1006338232150; Slotkin TA, 2000, BREAST CANCER RES TR, V64, P259, DOI 10.1023/A:1026508605951; STEEN SN, 1974, CURR THER RES CLIN E, V16, P1077; Steinberg SF, 2000, CIRC RES, V87, P1079, DOI 10.1161/01.RES.87.12.1079; Stork PJS, 2002, TRENDS CELL BIOL, V12, P258, DOI 10.1016/S0962-8924(02)02294-8; Strobl JS, 1995, GEN PHARMACOL, V26, P1643, DOI 10.1016/0306-3623(95)00062-3; Sun JZ, 2005, ONCOGENE, V24, P4701, DOI 10.1038/sj.onc.1208391; Sun JZ, 2003, CANCER RES, V63, P8922; Tortora G, 2002, ANN NY ACAD SCI, V968, P139, DOI 10.1111/j.1749-6632.2002.tb04332.x; Troadec JD, 2002, MOL PHARMACOL, V62, P1043, DOI 10.1124/mol.62.5.1043; Vara JAF, 2004, CANCER TREAT REV, V30, P193, DOI 10.1016/j.ctrv.2003.07.007; VEBER N, 1994, EUR J CANCER, V30A, P1352, DOI 10.1016/0959-8049(94)90186-4; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; Watanabe M, 1996, INT J CANCER, V67, P264, DOI 10.1002/(SICI)1097-0215(19960717)67:2<264::AID-IJC18>3.0.CO;2-B; Weinstein-Oppenheimer CR, 2000, PHARMACOL THERAPEUT, V88, P229, DOI 10.1016/S0163-7258(00)00085-1; Weldon CB, 2002, SURGERY, V132, P293, DOI 10.1067/msy.2002.125389; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; Yu M, 1998, CLIN EXP METASTAS, V16, P185	52	59	63	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 31	2007	26	26					3777	3788		10.1038/sj.onc.1210172	http://dx.doi.org/10.1038/sj.onc.1210172			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	175PV	17260025				2022-12-28	WOS:000247026400002
J	Nekhai, S; Bhat, UG; Ammosova, T; Radhakrishnan, SK; Jerebtsova, M; Niu, X; Foster, A; Layden, TJ; Gartel, AL				Nekhai, S.; Bhat, U. G.; Ammosova, T.; Radhakrishnan, S. K.; Jerebtsova, M.; Niu, X.; Foster, A.; Layden, T. J.; Gartel, A. L.			A novel anticancer agent ARC antagonizes HIV-1 and HCV	ONCOGENE			English	Article						HIV; HCV; anticancer drug; nucleoside analog	RNA-POLYMERASE-II; CARBOXYL-TERMINAL DOMAIN; CYCLIN T1; P-TEFB; LARGE SUBUNIT; TAT; TRANSCRIPTION; PROTEIN; HEPATITIS; INTERACTS	Human immunodeficiency virus (HIV) and hepatitis C virus (HCV) pose major public health concerns worldwide. HCV is clearly associated with the occurrence of hepatocellular carcinoma, and recently HIV infection has also been linked to the development of a multitude of cancers. Previously, we identified a novel nucleoside analog transcriptional inhibitor ARC (4-amino-6-hydrazino-7-beta-D-ribofuranosyl-7H-pyrrolo[2,3-d]-pyrimidine-5-carboxamide) that exhibited proapoptotic and antiangiogenic properties in vitro. Here, we evaluated the effect of ARC on HIV-1 transcription and HCV replication. Using reporter assays, we found that ARC inhibited HIV-1 Tat-based transactivation in different cell systems. Also, using hepatoma cells that harbor subgenomic and full-length replicons of HCV, we found that ARC inhibited HCV replication. Together, our data indicate that ARC could be a promising candidate for the development of antiviral therapeutics against HIV and HCV.	Univ Illinois, Coll Med, Dept Med, Chicago, IL 60612 USA; Univ Illinois, Coll Med, Dept Microbiol & Immunol, Chicago, IL 60612 USA; Howard Univ, Coll Med, Ctr Sickle Cell Dis, Washington, DC 20059 USA; Howard Univ, Coll Med, Dept Biochem & Mol Biol, Washington, DC 20059 USA; CRI Ctr, Childrens Natl Med Ctr, Washington, DC 20059 USA; Howard Univ, Coll Med, Dept Microbiol, Washington, DC 20059 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Howard University; Howard University; Children's National Health System; Howard University	Nekhai, S (corresponding author), Univ Illinois, Coll Med, Dept Med, 840 S Wood,Room 1041, Chicago, IL 60612 USA.	snekhai@howard.edu; agartel@uic.edu	, nekhai/AFO-2652-2022; Ammosova, Tatiana/HIA-0704-2022; , nekhai/AAW-3105-2021; Ammosova, Tatiana/J-7564-2018	Ammosova, Tatiana/0000-0001-8777-1032; Radhakrishnan, Senthil/0000-0002-5211-9498	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [UH1HL003679] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI056973] Funding Source: NIH RePORTER; NHLBI NIH HHS [UH1HL 03679] Funding Source: Medline; NIAID NIH HHS [R21 AI156973-01, R21 AI056973-02, R21 AI056973] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ammosova T, 2005, J BIOL CHEM, V280, P36364, DOI 10.1074/jbc.M503673200; Ammosova T, 2003, J BIOL CHEM, V278, P32189, DOI 10.1074/jbc.M300521200; Bark-Jones SJ, 2006, ONCOGENE, V25, P1775, DOI 10.1038/sj.onc.1209205; Berretta M, 2003, ONCOGENE, V22, P6646, DOI 10.1038/sj.onc.1206771; Bieniasz PD, 1998, EMBO J, V17, P7056, DOI 10.1093/emboj/17.23.7056; Blight KJ, 2002, J VIROL, V76, P13001, DOI 10.1128/JVI.76.24.13001-13014.2002; Blight KJ, 2000, SCIENCE, V290, P1972, DOI 10.1126/science.290.5498.1972; Brady J, 2005, RETROVIROLOGY, V2, DOI 10.1186/1742-4690-2-69; Brigati C, 2003, FEMS MICROBIOL LETT, V220, P57, DOI 10.1016/S0378-1097(03)00067-3; Chao SH, 2000, J BIOL CHEM, V275, P28345, DOI 10.1074/jbc.C000446200; Deng LW, 2002, J BIOL CHEM, V277, P33922, DOI 10.1074/jbc.M111349200; Garber ME, 1998, COLD SPRING HARB SYM, V63, P371, DOI 10.1101/sqb.1998.63.371; Garber ME, 1998, GENE DEV, V12, P3512, DOI 10.1101/gad.12.22.3512; Giacca Mauro, 2004, Current Drug Targets - Immune Endocrine and Metabolic Disorders, V4, P277, DOI 10.2174/1568008043339767; HERRMANN CH, 1995, J VIROL, V69, P1612, DOI 10.1128/JVI.69.3.1612-1620.1995; Lau JYN, 2002, HEPATOLOGY, V35, P1002, DOI 10.1053/jhep.2002.32672; Levrero M, 2006, ONCOGENE, V25, P3834, DOI 10.1038/sj.onc.1209562; Liang Chen, 2002, AIDS Reviews, V4, P41; Liang TJ, 2004, GASTROENTEROLOGY, V127, pS62, DOI 10.1053/j.gastro.2004.09.017; Lohmann V, 1999, SCIENCE, V285, P110, DOI 10.1126/science.285.5424.110; MacCallum DE, 2005, CANCER RES, V65, P5399, DOI 10.1158/0008-5472.CAN-05-0233; Marcello A, 2001, IUBMB LIFE, V51, P175, DOI 10.1080/152165401753544241; Nekhai S, 2000, PEPTIDES, V21, P1449, DOI 10.1016/S0196-9781(00)00297-7; PETRYSHYN R, 1984, BIOCHEM BIOPH RES CO, V119, P891, DOI 10.1016/0006-291X(84)90857-X; Radhakrishnan SK, 2006, CANCER RES, V66, P9731, DOI 10.1158/0008-5472.CAN-06-1576; Radhakrishnan SK, 2006, CANCER RES, V66, P3264, DOI 10.1158/0008-5472.CAN-05-3940; Radhakrishnan SK, 2004, VIROLOGY, V323, P173, DOI 10.1016/j.virol.2004.02.021; Roden R, 2006, NAT REV CANCER, V6, P753, DOI 10.1038/nrc1973; Sano M, 2002, NAT MED, V8, P1310, DOI 10.1038/nm778; SOBELL HM, 1985, P NATL ACAD SCI USA, V82, P5328, DOI 10.1073/pnas.82.16.5328; Tamrakar S, 2005, J VIROL, V79, P15477, DOI 10.1128/JVI.79.24.15477-15493.2005; Wang D, 2001, J VIROL, V75, P7266, DOI 10.1128/JVI.75.16.7266-7279.2001; Wei P, 1998, CELL, V92, P451, DOI 10.1016/S0092-8674(00)80939-3; Zhou MS, 2006, J VIROL, V80, P4781, DOI 10.1128/JVI.80.10.4781-4791.2006	34	18	20	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 31	2007	26	26					3899	3903		10.1038/sj.onc.1210158	http://dx.doi.org/10.1038/sj.onc.1210158			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	175PV	17173067				2022-12-28	WOS:000247026400013
J	Poppe, M; Feller, SM; Romer, G; Wessler, S				Poppe, M.; Feller, S. M.; Romer, G.; Wessler, S.			Phosphorylation of Helicobacter pylori CagA by c-Abl leads to cell motility	ONCOGENE			English	Article						c-Abl; CagA; helicobacter pylori; Src	GASTRIC EPITHELIAL-CELLS; IV SECRETION SYSTEM; TYROSINE KINASES; PATHOGENICITY ISLAND; FAMILY KINASES; GROWTH-FACTOR; PROTEIN; CRK; TRANSLOCATION; SRC	Helicobacter pylori induces a strong motogenic response in infected gastric epithelial host cells, which is enhanced by translocation of the pathogenic factor cytotoxinassociated gene A (CagA) into host cells via a specialized type IV secretion system. Once injected into the cytosol CagA is rapidly tyrosine phosphorylated by Src family kinases followed by Src inactivation. Hence, it remained unknown why CagA is constantly phosphorylated in sustained H. pylori infections to induce cell migration, whereas other substrates of Src kinases are dephosphorylated. Here, we identify the non- receptor tyrosine kinase c-Abl as a crucial mediator of H. pylori-induced migration and novel CagA kinase in epithelial cells. Upon H. pylori infection c-Abl directly interacts with CagA and localizes in focal adhesion complexes and membrane ruf. es, which are highly dynamic cytoskeletal structures necessary for cell motility. Selective inhibition of c-Abl kinase activity by STI571 or shRNA abrogates sustained CagA phosphorylation and epithelial cell migration, indicating a pivotal role of c-Abl in H. pylori infection and pathogenicity. These results implicate c-Abl as a novel molecular target for therapeutic intervention in H. pylor-related gastric diseases.	Paul Ehrlich Inst, Jr Res Grp, D-63225 Langen, Hessen, Germany; Weatherall Inst Mol Med, Canc Res UK, Oxford, England	Paul Ehrlich Institute; Cancer Research UK; University of Oxford	Wessler, S (corresponding author), Paul Ehrlich Inst, Jr Res Grp, Paul Ehrlich Str 51-59, D-63225 Langen, Hessen, Germany.	wessi@pei.de	Wessler, Silja/C-6309-2015	Wessler, Silja/0000-0001-7011-6162				Al-Ghoul L, 2004, BIOCHEM BIOPH RES CO, V322, P860, DOI 10.1016/j.bbrc.2004.07.199; Amieva MR, 2003, SCIENCE, V300, P1430, DOI 10.1126/science.1081919; Argent RH, 2005, J CLIN MICROBIOL, V43, P791, DOI 10.1128/JCM.43.2.791-795.2005; Asahi M, 2000, J EXP MED, V191, P593, DOI 10.1084/jem.191.4.593; Backert S, 2001, MOL MICROBIOL, V42, P631, DOI 10.1046/j.1365-2958.2001.02649.x; Backert S, 2000, CELL MICROBIOL, V2, P155, DOI 10.1046/j.1462-5822.2000.00043.x; Bagnoli F, 2005, P NATL ACAD SCI USA, V102, P16339, DOI 10.1073/pnas.0502598102; Barila D, 2003, MOL CELL BIOL, V23, P2790, DOI 10.1128/MCB.23.8.2790-2799.2003; Bauer B, 2005, INFECT IMMUN, V73, P4643, DOI 10.1128/IAI.73.8.4643-4652.2005; Churin Y, 2003, J CELL BIOL, V161, P249, DOI 10.1083/jcb.200208039; CorthesyTheulaz I, 1996, INFECT IMMUN, V64, P3827; Echarri A, 2001, CURR BIOL, V11, P1759, DOI 10.1016/S0960-9822(01)00538-3; Escalante M, 2000, J BIOL CHEM, V275, P24787, DOI 10.1074/jbc.M000711200; FELLER SM, 1994, TRENDS BIOCHEM SCI, V19, P453, DOI 10.1016/0968-0004(94)90129-5; FELLER SM, 1994, EMBO J, V13, P2341, DOI 10.1002/j.1460-2075.1994.tb06518.x; Feller SM, 2001, ONCOGENE, V20, P6348, DOI 10.1038/sj.onc.1204779; Frasca F, 2001, ONCOGENE, V20, P3845, DOI 10.1038/sj.onc.1204531; Hantschel O, 2004, NAT REV MOL CELL BIO, V5, P33, DOI 10.1038/nrm1280; Hatakeyama M, 2004, NAT REV CANCER, V4, P688, DOI 10.1038/nrc1433; Hernandez SE, 2004, TRENDS CELL BIOL, V14, P36, DOI 10.1016/j.tcb.2003.11.003; Higashi H, 2002, SCIENCE, V295, P683, DOI 10.1126/science.1067147; Ito Y, 2001, MOL CELL BIOL, V21, P6233, DOI 10.1128/MCB.21.18.6233-6242.2001; Kain KH, 2001, J BIOL CHEM, V276, P16185, DOI 10.1074/jbc.M100095200; Lewis JM, 1998, J BIOL CHEM, V273, P14225, DOI 10.1074/jbc.273.23.14225; Machuy N, 2004, CELL DEATH DIFFER, V11, P290, DOI 10.1038/sj.cdd.4401336; MAYER BJ, 1995, CURR BIOL, V5, P296, DOI 10.1016/S0960-9822(95)00060-1; Mimuro H, 2002, MOL CELL, V10, P745, DOI 10.1016/S1097-2765(02)00681-0; Moese S, 2004, INFECT IMMUN, V72, P3646, DOI 10.1128/IAI.72.6.3646-3649.2004; Odenbreit S, 2000, SCIENCE, V287, P1497, DOI 10.1126/science.287.5457.1497; Plattner R, 1999, GENE DEV, V13, P2400, DOI 10.1101/gad.13.18.2400; SCHMITT W, 1994, MOL MICROBIOL, V12, P307, DOI 10.1111/j.1365-2958.1994.tb01019.x; Segal ED, 1999, P NATL ACAD SCI USA, V96, P14559, DOI 10.1073/pnas.96.25.14559; Selbach M, 2004, PROTEOMICS, V4, P2961, DOI 10.1002/pmic.200400915; Selbach M, 2003, EMBO J, V22, P515, DOI 10.1093/emboj/cdg050; Selbach M, 2002, J BIOL CHEM, V277, P6775, DOI 10.1074/jbc.C100754200; Srinivasan D, 2006, CANCER RES, V66, P5648, DOI 10.1158/0008-5472.CAN-06-0734; Stein M, 2000, P NATL ACAD SCI USA, V97, P1263, DOI 10.1073/pnas.97.3.1263; Stein M, 2002, MOL MICROBIOL, V43, P971, DOI 10.1046/j.1365-2958.2002.02781.x; Suzuki M, 2005, J EXP MED, V202, P1235, DOI 10.1084/jem.20051027; Tomb JF, 1997, NATURE, V388, P539, DOI 10.1038/41483; Van Etten RA, 2003, CURR BIOL, V13, pR608, DOI 10.1016/S0960-9822(03)00528-1; Viala J, 2004, NAT IMMUNOL, V5, P1166, DOI 10.1038/ni1131; Wessler S, 2000, J BIOL CHEM, V275, P3629, DOI 10.1074/jbc.275.5.3629; *WHO, 1994, IARC MON EV CARC RIS, V61, P1; Woodring PJ, 2002, J CELL BIOL, V156, P879, DOI 10.1083/jcb.200110014; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704	46	131	138	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2007	26	24					3462	3472		10.1038/sj.onc.1210139	http://dx.doi.org/10.1038/sj.onc.1210139			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	172JC	17160020				2022-12-28	WOS:000246799200002
J	Selivanova, G; Wiman, KG				Selivanova, G.; Wiman, K. G.			Reactivation of mutant p53: molecular mechanisms and therapeutic potential	ONCOGENE			English	Review						mutant p53; apoptosis; cancer therapy	TUMOR-SUPPRESSOR PROTEIN; DNA-BINDING DOMAIN; CYTOPROTECTIVE AMINOTHIOL WR1065; TEMPERATURE-SENSITIVE MUTANT; C-TERMINAL PEPTIDE; HUMAN CANCER-CELLS; CORE DOMAIN; WILD-TYPE; IN-VITRO; CRYSTAL-STRUCTURE	The p53 tumor suppressor gene is the most frequently mutated gene in cancer. Most p53 mutations are missense point mutations that cluster in the DNA-binding core domain. This results in distortion of core domain folding and disruption of DNA binding and transcriptional transactivation of p53 target genes. Structural studies have demonstrated that mutant p53 core domain unfolding is not irreversible. Mutant p53 is expressed at high levels in many tumors. Therefore, mutant p53 is a promising target for novel cancer therapy. Mutant p53 reactivation will restore p53-dependent apoptosis, resulting in efficient removal of tumor cells. A number of strategies for targeting mutant p53 have been designed, including peptides and small molecules that restore the active conformation and DNA binding to mutant p53 and induce p53-dependent suppression of tumor cell growth in vitro and in vivo. This opens possibilities for the clinical application of mutant p53 reactivation in the treatment of cancer.	Karolinska Inst, Dept Oncol Pathol, Canc Ctr, Stockholm, Sweden; Karolinska Inst, Dept Microbiol Tumor & Cell Biol, Stockholm, Sweden	Karolinska Institutet; Karolinska Institutet	Wiman, KG (corresponding author), Karolinska Inst, Dept Oncol Pathol, Canc Ctr, Stockholm, Sweden.	Galina.Selivanova@ki.se; Klas.Wiman@ki.se	Wiman, Klas/AAB-8399-2021	Wiman, Klas/0000-0002-7113-524X; Selivanova, Galina/0000-0002-8698-4332				ABARZUA P, 1995, CANCER RES, V55, P3490; Ang HC, 2006, J BIOL CHEM, V281, P21934, DOI 10.1074/jbc.M604209200; BARGONETTI J, 1993, GENE DEV, V7, P2565, DOI 10.1101/gad.7.12b.2565; Bell S, 2002, J MOL BIOL, V322, P917, DOI 10.1016/S0022-2836(02)00848-3; Bensaad K, 2003, J BIOL CHEM, V278, P10546, DOI 10.1074/jbc.M208233200; Beroud C, 1998, NUCLEIC ACIDS RES, V26, P200, DOI 10.1093/nar/26.1.200; Blagosklonny MV, 1996, P NATL ACAD SCI USA, V93, P8379, DOI 10.1073/pnas.93.16.8379; Brachmann RK, 1998, EMBO J, V17, P1847, DOI 10.1093/emboj/17.7.1847; Bullock AN, 2000, ONCOGENE, V19, P1245, DOI 10.1038/sj.onc.1203434; Bullock AN, 1997, P NATL ACAD SCI USA, V94, P14338, DOI 10.1073/pnas.94.26.14338; Butler JS, 2003, BIOCHEMISTRY-US, V42, P2396, DOI 10.1021/bi026635n; Buzek J, 2002, NUCLEIC ACIDS RES, V30, P2340, DOI 10.1093/nar/30.11.2340; Bykov VJN, 2005, J BIOL CHEM, V280, P30384, DOI 10.1074/jbc.M501664200; Bykov VJN, 2005, ONCOGENE, V24, P3484, DOI 10.1038/sj.onc.1208419; Bykov VJN, 2003, EUR J CANCER, V39, P1828, DOI 10.1016/S0959-8049(03)00454-4; Bykov VJN, 2002, CARCINOGENESIS, V23, P2011, DOI 10.1093/carcin/23.12.2011; Bykov VJN, 2002, NAT MED, V8, P282, DOI 10.1038/nm0302-282; Canadillas JMP, 2006, P NATL ACAD SCI USA, V103, P2109, DOI 10.1073/pnas.0510941103; Chen Yabing, 2002, Int J Exp Diabetes Res, V3, P109, DOI 10.1080/15604280214488; Chipuk JE, 2003, CANCER CELL, V4, P371, DOI 10.1016/S1535-6108(03)00272-1; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; Christophorou MA, 2006, NATURE, V443, P214, DOI 10.1038/nature05077; Christophorou MA, 2005, NAT GENET, V37, P718, DOI 10.1038/ng1572; Cohen PA, 1999, FEBS LETT, V463, P179, DOI 10.1016/S0014-5793(99)01603-8; COOK A, 1990, BRIT J CANCER, V61, P548, DOI 10.1038/bjc.1990.123; de Fromentel CC, 1999, ONCOGENE, V18, P551, DOI 10.1038/sj.onc.1202338; Di Como CJ, 1998, ONCOGENE, V16, P2527; Espinosa JM, 2001, MOL CELL, V8, P57, DOI 10.1016/S1097-2765(01)00283-0; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; Foster BA, 1999, SCIENCE, V286, P2507, DOI 10.1126/science.286.5449.2507; Friedlander P, 1996, J BIOL CHEM, V271, P25468, DOI 10.1074/jbc.271.41.25468; Friedler A, 2003, J BIOL CHEM, V278, P24108, DOI 10.1074/jbc.M302458200; Friedler A, 2002, P NATL ACAD SCI USA, V99, P937, DOI 10.1073/pnas.241629998; Gaiddon C, 2001, MOL CELL BIOL, V21, P1874, DOI 10.1128/MCB.21.5.1874-1887.2001; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; Gorina S, 1996, SCIENCE, V274, P1001, DOI 10.1126/science.274.5289.1001; HALAZONETIS TD, 1993, EMBO J, V12, P5057, DOI 10.1002/j.1460-2075.1993.tb06199.x; Hansen S, 1996, J BIOL CHEM, V271, P3917; HUPP TR, 1994, CURR BIOL, V4, P865, DOI 10.1016/S0960-9822(00)00195-0; HUPP TR, 1993, NUCLEIC ACIDS RES, V21, P3167, DOI 10.1093/nar/21.14.3167; Issaeva N, 2003, P NATL ACAD SCI USA, V100, P13303, DOI 10.1073/pnas.1835733100; Joerger AC, 2005, J BIOL CHEM, V280, P16030, DOI 10.1074/jbc.M500179200; Joerger AC, 2004, J BIOL CHEM, V279, P1291, DOI 10.1074/jbc.M309732200; Joerger AC, 2005, 25 YEARS OF P53 RESEARCH, P377, DOI 10.1007/1-4020-2922-5_17; Joerger AC, 2006, P NATL ACAD SCI USA, V103, P15056, DOI 10.1073/pnas.0607286103; Kim AL, 1999, J BIOL CHEM, V274, P34924, DOI 10.1074/jbc.274.49.34924; Lane DP, 2002, TRENDS MOL MED, V8, pS38, DOI 10.1016/S1471-4914(02)02309-2; Li Y, 2005, MOL CANCER THER, V4, P901, DOI 10.1158/1535-7163.MCT-04-0206; Liu WL, 2001, J MOL BIOL, V313, P711, DOI 10.1006/jmbi.2001.5082; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; Luu Y, 2002, EXP CELL RES, V276, P214, DOI 10.1006/excr.2002.5526; Marin MC, 2000, NAT GENET, V25, P47, DOI 10.1038/75586; McCormick F, 2001, NAT REV CANCER, V1, P130, DOI 10.1038/35101008; McKinney K, 2004, MOL CELL, V16, P413, DOI 10.1016/j.molcel.2004.09.032; McKinney K, 2002, MOL CELL BIOL, V22, P6797, DOI 10.1128/MCB.22.19.6797-6808.2002; Midgley CA, 2000, ONCOGENE, V19, P2312, DOI 10.1038/sj.onc.1203593; MILNER J, 1990, ONCOGENE, V5, P1683; Muller-Tiemann BF, 1998, P NATL ACAD SCI USA, V95, P6079, DOI 10.1073/pnas.95.11.6079; Nahi H, 2004, BRIT J HAEMATOL, V127, P285, DOI 10.1111/j.1365-2141.2004.05210.x; Nevins JR, 2001, HUM MOL GENET, V10, P699, DOI 10.1093/hmg/10.7.699; Nichols NM, 2002, BIOCHEMISTRY-US, V41, P170, DOI 10.1021/bi011736r; NIEWOLIK D, 1995, ONCOGENE, V10, P881; Nikolova PV, 2000, EMBO J, V19, P370, DOI 10.1093/emboj/19.3.370; North S, 2002, MOL CARCINOGEN, V33, P181, DOI 10.1002/mc.10038; Okorokov AL, 2006, EMBO J, V25, P5191, DOI 10.1038/sj.emboj.7601382; Olivier M, 2002, HUM MUTAT, V19, P607, DOI 10.1002/humu.10081; ORY K, 1994, EMBO J, V13, P3496, DOI 10.1002/j.1460-2075.1994.tb06656.x; Peng YH, 2001, J BIOL CHEM, V276, P40583, DOI 10.1074/jbc.M102817200; Pluquet O, 2003, BIOCHEM PHARMACOL, V65, P1129, DOI 10.1016/S0006-2952(02)01655-6; Rehman A, 2005, BREAST CANCER RES, V7, pR765, DOI 10.1186/bcr1290; Rippin TM, 2002, ONCOGENE, V21, P2119, DOI 10.1038/sj.onc.1205362; ROKAEUS N, 2006, ONCOGENE; Roth J, 2000, ONCOGENE, V19, P1834, DOI 10.1038/sj.onc.1203500; Rudiger S, 2002, P NATL ACAD SCI USA, V99, P11085, DOI 10.1073/pnas.132393699; Sabapathy K, 1997, EMBO J, V16, P6217, DOI 10.1093/emboj/16.20.6217; Samuels-Lev Y, 2001, MOL CELL, V8, P781, DOI 10.1016/S1097-2765(01)00367-7; Selivanova G, 1998, SEMIN CANCER BIOL, V8, P369, DOI 10.1006/scbi.1998.0099; Selivanova G, 1999, MOL CELL BIOL, V19, P3395; Selivanova G, 2001, Curr Opin Investig Drugs, V2, P1136; Selivanova G, 1997, NAT MED, V3, P632, DOI 10.1038/nm0697-632; SELIVANOVA G, 2001, TUMOR SUPPRESSING VI, P397; Seo YR, 2002, P NATL ACAD SCI USA, V99, P14548, DOI 10.1073/pnas.212319799; Sharp S, 2006, ADV CANCER RES, V95, P323, DOI 10.1016/S0065-230X(06)95009-X; Shiraishi K, 2004, J BIOL CHEM, V279, P348, DOI 10.1074/jbc.M310815200; Sjoblom T, 2006, SCIENCE, V314, P268, DOI 10.1126/science.1133427; Snyder EL, 2004, PLOS BIOL, V2, P186, DOI 10.1371/journal.pbio.0020036; Strano S, 2000, J BIOL CHEM, V275, P29503, DOI 10.1074/jbc.M003360200; Takimoto R, 2002, CANCER BIOL THER, V1, P47, DOI 10.4161/cbt.1.1.41; Vives V, 2006, CELL CYCLE, V5, P2187, DOI 10.4161/cc.5.19.3266; VOJTESEK B, 1995, ONCOGENE, V10, P389; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Walerych D, 2004, J BIOL CHEM, V279, P48836, DOI 10.1074/jbc.M407601200; Wang PL, 2001, ONCOGENE, V20, P2318, DOI 10.1038/sj.onc.1204316; Wang WG, 2006, P NATL ACAD SCI USA, V103, P11003, DOI 10.1073/pnas.0604507103; Wang WG, 2003, MOL CELL BIOL, V23, P2171, DOI 10.1128/MCB.23.6.2171-2181.2003; Wieczorek AM, 1996, NAT MED, V2, P1143, DOI 10.1038/nm1096-1143; Wiman KG, 2006, CELL DEATH DIFFER, V13, P921, DOI 10.1038/sj.cdd.4401921; Wischhusen J, 2003, ONCOGENE, V22, P8233, DOI 10.1038/sj.onc.1207198; Wong KB, 1999, P NATL ACAD SCI USA, V96, P8438, DOI 10.1073/pnas.96.15.8438; ZHANG W, 1994, EMBO J, V13, P2535, DOI 10.1002/j.1460-2075.1994.tb06543.x; Zheleva DI, 2003, MINI-REV MED CHEM, V3, P257, DOI 10.2174/1389557033488178	101	157	167	1	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 2	2007	26	15					2243	2254		10.1038/sj.onc.1210295	http://dx.doi.org/10.1038/sj.onc.1210295			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	152XE	17401433				2022-12-28	WOS:000245394800013
J	Pawson, T; Warner, N				Pawson, T.; Warner, N.			Oncogenic re-wiring of cellular signaling pathways	ONCOGENE			English	Review						fusion proteins; domains; protein-protein interactions	RECEPTOR TYROSINE KINASE; LEUKEMIA-LIKE DISEASE; CRYSTAL-STRUCTURE; STRUCTURAL BASIS; SH2 DOMAIN; BCR; BINDING; ACTIVATION; PHOSPHORYLATION; AUTOINHIBITION	Signaling pathways in mammalian cells are assembled and regulated by a finely controlled network of protein - protein and protein - phospholipid interactions, mediated by dedicated signaling domains and their cognate binding motifs. The domain-based modular architecture of signaling proteins may have facilitated the evolution of complex biological systems, and can be exploited experimentally to generate synthetic signaling pathways and artificial mechanisms of autoregulation. Pathogenic proteins, such as those encoded by bacteria and viruses, frequently form ectopic signaling complexes to respecify cellular behavior. In a similar fashion, proteins expressed as a consequence of oncogenic fusions, mutations or amplifications can elicit ectopic protein - protein interactions that re-wire signaling pathways, in a fashion that promotes malignancy. Compounds that directly or indirectly reverse these aberrant interactions offer new possibilities for therapy in cancer.	Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Ctr Syst Biol, Toronto, ON M5G 1X5, Canada; Univ Toronto, Dept Med Genet & Microbiol, Toronto, ON, Canada	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto	Pawson, T (corresponding author), Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Ctr Syst Biol, 600 Univ Ave, Toronto, ON M5G 1X5, Canada.	pawson@mshri.on.ca	Pawson, Tony J/E-4578-2013; Warner, Neil/ABE-7329-2020	Warner, Neil/0000-0002-9207-5979				Aghazadeh B, 2000, CELL, V102, P625, DOI 10.1016/S0092-8674(00)00085-4; ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; Bhattacharyya RP, 2006, ANNU REV BIOCHEM, V75, P655, DOI 10.1146/annurev.biochem.75.103004.142710; Bilder D, 2004, GENE DEV, V18, P1909, DOI 10.1101/gad.1211604; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Bustelo XR, 2000, MOL CELL BIOL, V20, P1461, DOI 10.1128/MCB.20.5.1461-1477.2000; Dueber JE, 2003, SCIENCE, V301, P1904, DOI 10.1126/science.1085945; Engelman JA, 2006, NAT REV GENET, V7, P606, DOI 10.1038/nrg1879; Frischknecht F, 1999, NATURE, V401, P926, DOI 10.1038/44860; Gruenheid S, 2001, NAT CELL BIOL, V3, P856, DOI 10.1038/ncb0901-856; Haglund K, 2005, EMBO J, V24, P3353, DOI 10.1038/sj.emboj.7600808; He YP, 2002, BLOOD, V99, P2957, DOI 10.1182/blood.V99.8.2957; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; Howard PL, 2003, P NATL ACAD SCI USA, V100, P11267, DOI 10.1073/pnas.1934711100; Hu JJ, 2003, MOL CELL, V12, P1379, DOI 10.1016/S1097-2765(03)00487-8; Hubbard SR, 2000, ANNU REV BIOCHEM, V69, P373, DOI 10.1146/annurev.biochem.69.1.373; Hubbard SR, 1997, EMBO J, V16, P5572, DOI 10.1093/emboj/16.18.5572; Hunter T, 2000, CELL, V100, P113, DOI 10.1016/S0092-8674(00)81688-8; Jones RB, 2006, NATURE, V439, P168, DOI 10.1038/nature04177; Kim AS, 2000, NATURE, V404, P151, DOI 10.1038/35004513; Kim JH, 2005, BLOOD, V105, P1717, DOI 10.1182/blood-2004-03-0849; Kong-Beltran M, 2006, CANCER RES, V66, P283, DOI 10.1158/0008-5472.CAN-05-2749; Liu BA, 2006, MOL CELL, V22, P851, DOI 10.1016/j.molcel.2006.06.001; Llorca O, 2005, EMBO J, V24, P1330, DOI 10.1038/sj.emboj.7600617; Macara IG, 2004, NAT REV MOL CELL BIO, V5, P220, DOI 10.1038/nrm1332; MCWHIRTER JR, 1993, MOL CELL BIOL, V13, P7587, DOI 10.1128/MCB.13.12.7587; Million RP, 2000, BLOOD, V96, P664; Minucci S, 2001, ONCOGENE, V20, P3110, DOI 10.1038/sj.onc.1204336; Nagar B, 2003, CELL, V112, P859, DOI 10.1016/S0092-8674(03)00194-6; Pawson T, 2000, GENE DEV, V14, P1027; Pawson T, 2003, SCIENCE, V300, P445, DOI 10.1126/science.1083653; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/S0092-8674(05)80094-7; PUIL L, 1994, EMBO J, V13, P764, DOI 10.1002/j.1460-2075.1994.tb06319.x; ROWLEY JD, 1990, CANCER, V65, P2178, DOI 10.1002/1097-0142(19900515)65:10<2178::AID-CNCR2820651004>3.0.CO;2-#; Sattler M, 2002, CANCER CELL, V1, P479, DOI 10.1016/S1535-6108(02)00074-0; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; Thomas M, 2005, ONCOGENE, V24, P6222, DOI 10.1038/sj.onc.1208757; WEINMASTER G, 1984, CELL, V37, P559, DOI 10.1016/0092-8674(84)90386-6; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; Zarrinpar Ali, 2003, Sci STKE, V2003, pRE8, DOI 10.1126/stke.2003.179.re8; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zhou J, 2006, P NATL ACAD SCI USA, V103, P9238, DOI 10.1073/pnas.0603324103; Zhu J, 2005, CANCER CELL, V7, P143, DOI 10.1016/j.ccr.2005.01.005	44	94	98	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 26	2007	26	9					1268	1275		10.1038/sj.onc.1210255	http://dx.doi.org/10.1038/sj.onc.1210255			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	141DU	17322911	Bronze			2022-12-28	WOS:000244558700003
J	Gery, S; Virk, RK; Chumakov, K; Yu, A; Koeffler, HP				Gery, S.; Virk, R. K.; Chumakov, K.; Yu, A.; Koeffler, H. P.			The clock gene Per2 links the circadian system to the estrogen receptor	ONCOGENE			English	Article						circadian rhythms; ER alpha; breast cancer; Per2; transcriptional activation; estrogen	EXPRESSION; CANCER; MOUSE	Circadian rhythms regulate diverse physiological processes including homeostatic functions of steroid hormones and their receptors. Estrogen receptor-alpha (ER alpha) is essential for normal mammary gland physiology and is a prognostic marker for the treatment of breast cancer. We report that Per2, a core clock gene, links the circadian cycle to the ER alpha signaling network. Binding of enhances ER alpha degradation, while suppression of Per2 levels leads to ER alpha stabilization. In turn, Per2 itself is estrogen inducible in these cells, suggesting a feedback mechanism to attenuate stimulation by estrogen. In addition, overexpression of Per2 in breast cancer cells leads to significant growth inhibition, loss of clonogenic ability and apoptosis. Taken together, these results further support a critical role for peripheral circadian regulation in tissue homeostasis and suggest a novel role for clock genes in estrogen receptor-positive breast cancer.	[Gery, S.; Virk, R. K.; Chumakov, K.; Yu, A.; Koeffler, H. P.] Univ Calif Los Angeles, Cedars Sinai Med Ctr, Div Hematol Oncol, UCLA Sch Med, Los Angeles, CA 90048 USA	Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Gery, S (corresponding author), Univ Calif Los Angeles, Cedars Sinai Med Ctr, Div Hematol Oncol, UCLA Sch Med, Davis Bldg 5066,8700 Beverly Blvd, Los Angeles, CA 90048 USA.	gerys@cshs.org						Chen ST, 2005, CARCINOGENESIS, V26, P1241, DOI 10.1093/carcin/bgi075; Fu LN, 2002, CELL, V111, P41, DOI 10.1016/S0092-8674(02)00961-3; Gallego M, 2007, NAT REV MOL CELL BIO, V8, P139, DOI 10.1038/nrm2106; Hansen J, 2001, JNCI-J NATL CANCER I, V93, P1513, DOI 10.1093/jnci/93.20.1513; Hua H, 2006, CANCER SCI, V97, P589, DOI 10.1111/j.1349-7006.2006.00225.x; Ishida N, 2007, NEUROSCI RES, V57, P483, DOI 10.1016/j.neures.2006.12.012; Ko CH, 2006, HUM MOL GENET, V15, pR271, DOI 10.1093/hmg/ddl207; Lowrey PL, 2004, ANNU REV GENOM HUM G, V5, P407, DOI 10.1146/annurev.genom.5.061903.175925; Matsuo T, 2003, SCIENCE, V302, P255, DOI 10.1126/science.1086271; McDonnell DP, 2002, SCIENCE, V296, P1642, DOI 10.1126/science.1071884; Metz RP, 2006, DEV DYNAM, V235, P263, DOI 10.1002/dvdy.20605; Miller BH, 2007, P NATL ACAD SCI USA, V104, P3342, DOI 10.1073/pnas.0611724104; Nakamura TJ, 2005, J NEUROSCI RES, V82, P622, DOI 10.1002/jnr.20677; Panda S, 2002, CELL, V109, P307, DOI 10.1016/S0092-8674(02)00722-5; Perrin JS, 2006, P NATL ACAD SCI USA, V103, P5591, DOI 10.1073/pnas.0601310103; Reid G, 2002, CELL MOL LIFE SCI, V59, P821, DOI 10.1007/s00018-002-8470-2; Reppert SM, 2002, NATURE, V418, P935, DOI 10.1038/nature00965; Romagnolo D, 1998, MOL CARCINOGEN, V22, P102, DOI 10.1002/(SICI)1098-2744(199806)22:2<102::AID-MC5>3.0.CO;2-O; Schibler U, 2002, CELL, V111, P919, DOI 10.1016/S0092-8674(02)01225-4; Shearman LP, 2000, SCIENCE, V288, P1013, DOI 10.1126/science.288.5468.1013; Shi YH, 2001, GENE DEV, V15, P1140, DOI 10.1101/gad.871201; Sternlicht MD, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1368; Storch KF, 2002, NATURE, V417, P78, DOI 10.1038/nature744; Yager JD, 2006, NEW ENGL J MED, V354, P270, DOI 10.1056/NEJMra050776; Yagita K, 2002, EMBO J, V21, P1301, DOI 10.1093/emboj/21.6.1301; Yang XY, 2006, CELL, V126, P801, DOI 10.1016/j.cell.2006.06.050	26	141	145	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 13	2007	26	57					7916	7920		10.1038/sj.onc.1210585	http://dx.doi.org/10.1038/sj.onc.1210585			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	248ON	17599055				2022-12-28	WOS:000252163500010
J	Bauer, S; Duensing, A; Demetri, GD; Fletcher, JA				Bauer, S.; Duensing, A.; Demetri, G. D.; Fletcher, J. A.			KIT oncogenic signaling mechanisms in imatinib-resistant gastrointestinal stromal tumor: PI3-kinase/AKT is a crucial survival pathway	ONCOGENE			English	Article						KIT; oncogenic signaling; sarcoma; gastrointestinal; neoplasm; PI3-K	C-KIT; ACQUIRED-RESISTANCE; MUTATIONS; INHIBITION; ACTIVATION; MESYLATE; MUTANTS; ABL	Most gastrointestinal stromal tumor (GIST) patients respond to KIT inhibition with imatinib, yet will eventually exhibit resistance. Imatinib-resistance mechanisms are heterogeneous, and little is known about KIT functional roles in imatinib-resistant GIST. Biological consequences of biochemical inhibition of KIT, phospha-tidyl-inositol- 3-kinase (PI3-K), PLC gamma, MAPK/ERK kinase/mitogen-activated protein kinase (MEK/MAPK), mammalian target of rapamycin (mTOR) and JAK were determined by immunoblotting for protein activation, and by cell proliferation and apoptosis assays in GIST cell lines from imatinib-sensitive GIST (GIST882), imatinib-resistant GISTs (GIST430 and GIST48) and KIT-negative GIST (GIST62). KIT activation was 3- to 6-fold higher in GIST430 and GIST48 than in GIST882, whereas total KIT expression was comparable in these three GIST lines. In addition to the higher set point for KIT activation, GIST430 and GIST48 had intrinsic imatinib resistance. After treatment with 1 mu M imatinib, residual KIT activation was 6- and 2.8-fold higher in GIST430 and GIST48, respectively, compared to GIST882. In all GIST lines, cell growth arrest resulted from PI3-K inhibition, and - to a lesser extent - from MEK/MAPK and mTOR inhibition. Inhibition of JAK/STAT or PLC gamma did not affect cell proliferation. Similarly, only PI3-K inhibition resulted in substantial apoptosis in the imatinib-resistant GISTs. We conclude that GIST secondary KIT mutations can be associated with KIT hyperactivation and imatinib resistance. Targeting critical downstream signaling proteins, such as PI3-K, is a promising therapeutic strategy in imatinib-resistant GISTs.	Brigham & Womens Hosp, Harvard Med Sch, Dept Pathol, Boston, MA USA; Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA USA; Harvard Med Sch, Ludwig Ctr, Dana Farber Canc Inst, Boston, MA USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Bauer, S (corresponding author), W German Canc Res Ctr, Dept Internal Med, Ctr Canc Res, Hufelandstr 55, D-45122 Essen, Germany.	sebastian.bauer@uni-due.de; jflecher@partners.org	Bauer, Sebastian/HHR-9319-2022; Bauer, Sebastian/D-8120-2012; ravegnini, gloria/K-1330-2016	Bauer, Sebastian/0000-0001-5949-8120; ravegnini, gloria/0000-0002-7774-402X; Duensing, Anette/0000-0002-0168-4067				Antonescu CR, 2005, CLIN CANCER RES, V11, P4182, DOI 10.1158/1078-0432.CCR-04-2245; Bauer S, 2005, INT J CANCER, V117, P316, DOI 10.1002/ijc.21164; BAUER S, 2005, P AN M AM SOC CLIN, V23, pA9034; Bauer S, 2006, CANCER RES, V66, P9153, DOI 10.1158/0008-5472.CAN-06-0165; Cammenga J, 2005, BLOOD, V106, P3958, DOI 10.1182/blood-2005-02-0583; Carter TA, 2005, P NATL ACAD SCI USA, V102, P11011, DOI 10.1073/pnas.0504952102; Corless CL, 2002, AM J PATHOL, V160, P1567, DOI 10.1016/S0002-9440(10)61103-0; Debiec-Rychter M, 2005, GASTROENTEROLOGY, V128, P270, DOI 10.1053/j.gastro.2004.11.020; DeMatteo RP, 2000, ANN SURG, V231, P51, DOI 10.1097/00000658-200001000-00008; Demetri GD, 2002, NEW ENGL J MED, V347, P472, DOI 10.1056/NEJMoa020461; Demetri GD, 2006, LANCET, V368, P1329, DOI 10.1016/S0140-6736(06)69446-4; Duensing A, 2004, ONCOGENE, V23, P3999, DOI 10.1038/sj.onc.1207525; FLETCHER JA, 2003, P AN M AM SOC CLIN, V22, pA3275; Frank DA, 1999, MOL MED, V5, P432; Heinrich MC, 2003, J CLIN ONCOL, V21, P4342, DOI 10.1200/JCO.2003.04.190; Heinrich MC, 2006, J CLIN ONCOL, V24, P4764, DOI 10.1200/JCO.2006.06.2265; Hirota S, 1998, SCIENCE, V279, P577, DOI 10.1126/science.279.5350.577; Linnekin D, 1999, INT J BIOCHEM CELL B, V31, P1053, DOI 10.1016/S1357-2725(99)00078-3; Mohi MG, 2004, P NATL ACAD SCI USA, V101, P3130, DOI 10.1073/pnas.0400063101; Ning ZQ, 2001, ONCOGENE, V20, P4528, DOI 10.1038/sj.onc.1204590; Rossi F, 2006, P NATL ACAD SCI USA, V103, P12843, DOI 10.1073/pnas.0511076103; Rubin BP, 2001, CANCER RES, V61, P8118; Sawka-Verhelle D, 2000, ENDOCRINOLOGY, V141, P1977, DOI 10.1210/en.141.6.1977; Shah NP, 2004, SCIENCE, V305, P399, DOI 10.1126/science.1099480; Shivas T, 2003, AM J BIOETHICS, V3, P63, DOI 10.1162/152651603321612042; Tuveson DA, 2001, ONCOGENE, V20, P5054, DOI 10.1038/sj.onc.1204704; Verweij J, 2004, LANCET, V364, P1127, DOI 10.1016/S0140-6736(04)17098-0; Wardelmann E, 2006, CLIN CANCER RES, V12, P1743, DOI 10.1158/1078-0432.CCR-05-1211; Wardelmann E, 2005, LANCET ONCOL, V6, P249, DOI 10.1016/S1470-2045(05)70097-8	29	195	205	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 29	2007	26	54					7560	7568		10.1038/sj.onc.1210558	http://dx.doi.org/10.1038/sj.onc.1210558			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	236DB	17546049				2022-12-28	WOS:000251282100008
J	Pecha, J; Ankrapp, D; Jiang, C; Tang, W; Hoshino, I; Bruck, K; Wagner, KU; Xiao, H				Pecha, J.; Ankrapp, D.; Jiang, C.; Tang, W.; Hoshino, I.; Bruck, K.; Wagner, K-U; Xiao, H.			Deletion of Tip30 leads to rapid immortalization of murine mammary epithelial cells and ductal hyperplasia in the mammary gland	ONCOGENE			English	Article						tip30; mammary epithelial cell; hyperplasia; proliferation	HUMAN BREAST-CANCER; EXPRESSION; ESTROGEN; MICE; SUSCEPTIBILITY; PROGRESSION; ALPHA; GENE	Transformation of mammary epithelial cells (MECs) from the normal to the neoplastic stage requires the dysregulation of tumor suppressor genes and proto-oncogenes. Tip30 is a tumor suppressor that can inhibit estrogen receptor-mediated transcription in MECs, but its role in MEC proliferation remains unknown. Here, we show that deleting the Tip30 gene leads to ductal hyperplasia in mouse mammary glands early in life and extensive mammary hyperplasia with age. Tip30 (-/-) mammary glands transplanted into wild-type mammary fat pads also display mammary trees with extensive ductal hyperplasia. Strikingly, Tip30 deletion promotes proliferation of primary MECs and results in rapid immortalization of MECs in vitro relative to wild-type cells. Gene array analysis identified significant increases in the expression of mammary epithelial growth factors Wisp2 and Igf-1 in Tip30(-/-) cells. Knockdown of either Wisp2 or Igf-1 using short interfering RNA dramatically inhibited proliferation of Tip30(-/-) cells. Together, these results suggest that Tip30 is an intrinsic and negative regulator of MEC proliferation partly through the inhibition of Wisp2 and Igf-1 expression, and its absence in the mammary gland may predispose MECs to neoplastic transformation.	Michigan State Univ, Dept Pathol Physiol, E Lansing, MI 48824 USA; Univ Nebraska Med Ctr, Eppley Inst Res Canc & Allied Dis, Omaha, NE USA; Univ Nebraska Med Ctr, Dept Pathol & Microbiol, Omaha, NE USA	Michigan State University; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center	Xiao, H (corresponding author), Michigan State Univ, Dept Pathol Physiol, 3193 Biomed & Phys Sci Bldg, E Lansing, MI 48824 USA.	xiaoh@msu.edu	Wagner, Kay-Uwe/B-6044-2009	Wagner, Kay-Uwe/0000-0002-5081-0226	NIDDK NIH HHS [DK066110-01] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK066110] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Banerjee S, 2003, NEOPLASIA, V5, P63, DOI 10.1016/S1476-5586(03)80018-0; Cardiff RD, 2000, ONCOGENE, V19, P968, DOI 10.1038/sj.onc.1203277; Dimri GP, 2002, CANCER RES, V62, P4736; Hewitt RE, 2000, J PATHOL, V192, P455; Ito M, 2003, CANCER RES, V63, P8763; Jiang C, 2004, J BIOL CHEM, V279, P27781, DOI 10.1074/jbc.M401809200; King FW, 2004, MOL CELL BIOL, V24, P7091, DOI 10.1128/MCB.24.16.7091-7101.2004; Lee H, 2002, AM J PATHOL, V161, P1357, DOI 10.1016/S0002-9440(10)64412-4; Lee L W, 2004, Ann Acad Med Singap, V33, pS30; Ma ZQ, 1999, ONCOGENE, V18, P4564, DOI 10.1038/sj.onc.1202809; MEDINA D, 1993, CARCINOGENESIS, V14, P25, DOI 10.1093/carcin/14.1.25; Medina D, 2002, BBA-REV CANCER, V1603, P1, DOI 10.1016/S0304-419X(02)00053-7; MEDINA D, 2000, METHODS MAMMARY GLAN, P137; Nonet GH, 2001, CANCER RES, V61, P1250; Oh A, 2004, CANCER RES, V64, P8299, DOI 10.1158/0008-5472.CAN-04-0354; Radice GL, 1997, J CELL BIOL, V139, P1025, DOI 10.1083/jcb.139.4.1025; Saxena N, 2001, MOL CELL BIOCHEM, V228, P99, DOI 10.1023/A:1013338912642; Shillingford JM, 2002, MOL ENDOCRINOL, V16, P1309, DOI 10.1210/me.16.6.1309; Shtivelman E, 1997, ONCOGENE, V14, P2167, DOI 10.1038/sj.onc.1201059; Ullrich RL, 1996, RADIAT RES, V146, P353, DOI 10.2307/3579468; Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075; Wang J, 1998, GENE DEV, V12, P1769, DOI 10.1101/gad.12.12.1769; Xiao H, 1998, P NATL ACAD SCI USA, V95, P2146, DOI 10.1073/pnas.95.5.2146; Xu XL, 1999, NAT GENET, V22, P37, DOI 10.1038/8743; Zhang S, 2005, J MOL ENDOCRINOL, V35, P433, DOI 10.1677/jme.1.01858; Zhang Y, 2004, J BIOL CHEM, V279, P34353, DOI 10.1074/jbc.M401300200; Zhao J, 2007, HUM PATHOL, V38, P293, DOI 10.1016/j.humpath.2006.08.005	27	23	23	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 22	2007	26	53					7423	7431		10.1038/sj.onc.1210548	http://dx.doi.org/10.1038/sj.onc.1210548			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	236DA	17533366				2022-12-28	WOS:000251282000004
J	Gutzman, JH; Rugowski, DE; Nikolai, SE; Schuler, LA				Gutzman, J. H.; Rugowski, D. E.; Nikolai, S. E.; Schuler, L. A.			Stat5 activation inhibits prolactin-induced AP-1 activity: distinct prolactin-initiated signals in tumorigenesis dependent on cell context	ONCOGENE			English	Article						prolactin; breast cancer; AP-1; Stat5	BREAST-CANCER CELLS; C-FOS; TRANSCRIPTION FACTORS; MAMMARY-GLAND; CYCLIN D1; TRANSDUCER; EXPRESSION; PROTEIN-1; INVASION; JUN	The essential role of prolactin (PRL) in normal mammary gland growth and differentiation has implicated this hormone in the development and progression of breast cancer. Although Stat5 is the best-characterized mediator of PRL signals, PRL also activates multiple other signals, whose roles in normal and pathologic processes are not well understood. We have shown that PRL stimulates activating protein-1 (AP-1) activity in breast cancer cells, and can cooperate with estradiol in this pathway. AP-1 modulates many processes critical for carcinogenesis, including cell proliferation, survival, transformation, invasion and angiogenesis, and is elevated in many neoplasms, including breast tumors. Here, we investigated the relationship between PRL signals to AP-1 and Stat5. We found that PRL activation of Stat5a and Stat5b, but not Stat1 or Stat3, reduced PRL signals to AP-1, without altering estradiol-induced AP-1 activity. The truncation mutant, Stat5/Delta 53C, but not Stat5Y699F, was an effective inhibitor, consistent with a requirement for Stat5 dimerization and nuclear accumulation, but not its C-terminal transactivation activity. The association of Stat5 with AP-1 proteins suggests that this underlies the inhibition. Predictably, the ability of PRL to activate Stat5 and AP-1 was inversely related in mammary cell lines. Further, reduction of Stat5 protein with siRNA in T47D cells, which contain elevated Stat5, increased PRL-induced AP-1 signals, transcripts for the AP-1 target, matrix metalloproteinase-2 and associated invasive behavior. This study points to the importance of cell context in determining the spectrum of PRL-induced actions, which is critical for understanding the contributions of PRL to breast cancer.	Univ Wisconsin, Dept Comparat Biosci, Madison, WI 53706 USA; Univ Wisconsin, Mol & Environm Toxicol Program, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Schuler, LA (corresponding author), Univ Wisconsin, Dept Comparat Biosci, 2015 Linden Dr, Madison, WI 53706 USA.	schulerl@svm.vetmed.wisc.edu	Gutzman, Jennifer/AAA-9058-2020	Gutzman, Jennifer/0000-0002-7725-6923	NATIONAL CANCER INSTITUTE [R01CA078312] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA78312, R01 CA078312] Funding Source: Medline; NIDDK NIH HHS [DK07623] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bjornstrom L, 2002, MOL ENDOCRINOL, V16, P2202, DOI 10.1210/me.2002-0072; BLAND KI, 1995, ANN SURG, V221, P706, DOI 10.1097/00000658-199506000-00010; Brockman JL, 2002, MOL ENDOCRINOL, V16, P774, DOI 10.1210/me.16.4.774; Bromberg J, 2002, J CLIN INVEST, V109, P1139, DOI 10.1172/JCI200215617; Buettner R, 2002, CLIN CANCER RES, V8, P945; Cao JS, 2004, ENDOCRINOLOGY, V145, P1739, DOI 10.1210/en.2003-0752; Clevenger CV, 2003, ENDOCR REV, V24, P1, DOI 10.1210/er.2001-0036; Cotarla I, 2004, INT J CANCER, V108, P665, DOI 10.1002/ijc.11619; DaSilva L, 1996, MOL CELL ENDOCRINOL, V117, P131, DOI 10.1016/0303-7207(95)03738-1; Eferl R, 2003, NAT REV CANCER, V3, P859, DOI 10.1038/nrc1209; Faulds MH, 2001, MOL ENDOCRINOL, V15, P1929, DOI 10.1210/me.15.11.1929; Gee JMW, 2000, INT J CANCER, V89, P177, DOI 10.1002/(SICI)1097-0215(20000320)89:2<177::AID-IJC13>3.0.CO;2-0; Goffin V, 2005, ENDOCR REV, V26, P400, DOI 10.1210/er.2004-0016; Gutzman JH, 2005, MOL ENDOCRINOL, V19, P1765, DOI 10.1210/me.2004-0339; Gutzman JH, 2004, MOL ENDOCRINOL, V18, P3064, DOI 10.1210/me.2004-0187; Hennighausen L, 2005, NAT REV MOL CELL BIO, V6, P715, DOI 10.1038/nrm1714; Horvai AE, 1997, P NATL ACAD SCI USA, V94, P1074, DOI 10.1073/pnas.94.4.1074; Humphreys RC, 1999, CELL GROWTH DIFFER, V10, P685; Iavnilovitch E, 2002, MOL CANCER RES, V1, P32; Ilaria RL, 1999, BLOOD, V93, P4154, DOI 10.1182/blood.V93.12.4154.412k15_4154_4166; Johnston SRD, 1999, CLIN CANCER RES, V5, P251; Keely PJ, 2001, METHODS ENZYMOL, V333, P256; Levy DE, 2002, NAT REV MOL CELL BIO, V3, P651, DOI 10.1038/nrm909; Luo GY, 2000, MOL ENDOCRINOL, V14, P114, DOI 10.1210/me.14.1.114; Milde-Langosch K, 2000, INT J CANCER, V87, P468, DOI 10.1002/1097-0215(20000815)87:4<468::AID-IJC2>3.0.CO;2-R; Milde-Langosch K, 2004, BREAST CANCER RES TR, V86, P139, DOI 10.1023/B:BREA.0000032982.49024.71; Nakamura T, 2002, J BIOL CHEM, V277, P6254, DOI 10.1074/jbc.M109878200; Nevalainen MT, 2004, J CLIN ONCOL, V22, P2053, DOI 10.1200/JCO.2004.11.046; Nouhi Z, 2006, CANCER RES, V66, P1824, DOI 10.1158/0008-5472.CAN-05-2292; ORMANDY CJ, 2001, MAMMARY GLAND DEV PR, P219; Ren SX, 2002, ONCOGENE, V21, P4335, DOI 10.1038/sj.onc.1205484; Schroeder MD, 2002, MOL ENDOCRINOL, V16, P45, DOI 10.1210/me.16.1.45; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Shuai K, 2000, ONCOGENE, V19, P2638, DOI 10.1038/sj.onc.1203522; Sultan AS, 2005, ONCOGENE, V24, P746, DOI 10.1038/sj.onc.1208203; Tworoger SS, 2006, CANCER LETT, V243, P160, DOI 10.1016/j.canlet.2006.01.032; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Vincenti MP, 2000, METH MOL B, V151, P121, DOI 10.1385/1-59259-046-2:121; Vonderhaar BK, 2000, CONT ENDOCRINOL, P101; Wang YX, 2005, LANCET, V365, P671, DOI 10.1016/S0140-6736(05)17947-1; Watson CJ, 2001, J MAMMARY GLAND BIOL, V6, P115, DOI 10.1023/A:1009524817155; Weaver AM, 2006, MOL ENDOCRINOL, V20, P2392, DOI 10.1210/me.2005-0418; Yang E, 2003, J BIOL CHEM, V278, P15794, DOI 10.1074/jbc.M213073200; Zhang XK, 1999, MOL CELL BIOL, V19, P7138	44	37	38	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 20	2007	26	43					6341	6348		10.1038/sj.onc.1210454	http://dx.doi.org/10.1038/sj.onc.1210454			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	212GW	17438530	Green Accepted			2022-12-28	WOS:000249583300010
J	Li, Y; Huang, J; Zhao, YL; He, J; Wang, W; Davies, KE; Nose, V; Xiao, S				Li, Y.; Huang, J.; Zhao, Y-L; He, J.; Wang, W.; Davies, K. E.; Nose, V.; Xiao, S.			UTRN on chromosome 6q24 is mutated in multiple tumors	ONCOGENE			English	Article						tumor suppressor; UTRN; functional screening	DUCHENNE MUSCULAR-DYSTROPHY; SUPPRESSOR GENE; BREAST-CANCER; TERMINAL DOMAIN; UTROPHIN GENE; CELL-LINES; ARM 6Q; TUMORIGENICITY; DELETION; HETEROZYGOSITY	Though deletion of the long arm of chromosome 6 is one of the most common aberrations in tumors, its targeted gene(s) has not been convincingly identified. Using a functional screening approach, we found that UTRN ( which encodes utrophin, a dystrophin-related protein) at 6q24, when expressed in an antisense orientation, induced cellular transformation, consistent with a tumor suppressor role. Northern blot analysis, semiquantitative reverse transcription-polymerase chain reaction (RT-PCR), and gene expression arrays all showed that UTRN expression was downregulated in primary tumors compared with matched normal tissues. Several UTRN neighbor genes were not affected in some tumors with UTRN downregulation, suggesting that UTRN was specifically targeted. RT-PCR, coupled with an in vitro transcription and translation assay, revealed inactivation mutations in 21/62 breast cancers, 4/20 neuroblastomas and 4/15 malignant melanomas. Most of the mutations were deletions involving one or more exons that led to the truncation of utrophin. Splicing errors were found in two cases, and nonsense mutation in one case. Overexpression of a wild-type UTRN in breast cancer cells inhibited tumor cell growth in vitro and reduced their tumor potential in nude mice. Our studies suggest that UTRN is a candidate tumor suppressor gene.	Harbin Inst Technol, Harbin, Peoples R China; Brigham & Womens Hosp, Harvard Med Sch, Dept Pathol, Boston, MA USA; Cornell Univ, Microarray Core Facility, Ithaca, NY USA; Univ Oxford, Dept Biochem, Oxford OX1 2JD, England	Harbin Institute of Technology; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Cornell University; University of Oxford	Xiao, S (corresponding author), Brigham & Womens Hosp, Dept Pathol, 75 Francis St, Boston, MA 02115 USA.	sxiao@rics.bwh.harvard.edu						Abe T, 1999, GENE CHROMOSOME CANC, V25, P60, DOI 10.1002/(SICI)1098-2264(199905)25:1<60::AID-GCC9>3.0.CO;2-Y; Acevedo CM, 2002, CANCER-AM CANCER SOC, V94, P793, DOI 10.1002/cncr.10275; Atkin NB, 1996, CANCER GENET CYTOGEN, V92, P87, DOI 10.1016/S0165-4608(96)00131-8; Barghorn A, 2001, AM J PATHOL, V158, P1903, DOI 10.1016/S0002-9440(10)64658-5; Biroccio A, 2003, ONCOGENE, V22, P6579, DOI 10.1038/sj.onc.1206812; BLAKE DJ, 1995, P NATL ACAD SCI USA, V92, P3697, DOI 10.1073/pnas.92.9.3697; Brault E, 2001, J CELL SCI, V114, P1901; Chappell SA, 1997, BRIT J CANCER, V75, P1324, DOI 10.1038/bjc.1997.224; Deconinck AE, 1997, CELL, V90, P717, DOI 10.1016/S0092-8674(00)80532-2; Fujioka Y, 2001, J BIOL CHEM, V276, P45137, DOI 10.1074/jbc.M106127200; Gutmann DH, 1999, HUM MOL GENET, V8, P267, DOI 10.1093/hmg/8.2.267; Hoffman PJ, 2004, FERTIL STERIL, V82, P639, DOI 10.1016/j.fertnstert.2004.01.047; Hu J, 2001, ONCOGENE, V20, P8042, DOI 10.1038/sj.onc.1204961; Huang LW, 2000, HUM PATHOL, V31, P367, DOI 10.1016/S0046-8177(00)80252-X; Jensen RH, 2003, ANTICANCER RES, V23, P2281; Li LM, 1996, CELL, V85, P319, DOI 10.1016/S0092-8674(00)81111-3; Mertens F, 1997, CANCER RES, V57, P2765; Morris GE, 1998, BIOCHEMISTRY-US, V37, P11117, DOI 10.1021/bi9805137; MOSER H, 1984, HUM GENET, V66, P17, DOI 10.1007/BF00275183; NEGRINI M, 1994, CANCER RES, V54, P1331; Noviello C, 1996, CLIN CANCER RES, V2, P1601; OFFIT K, 1993, BLOOD, V82, P2157; OFFIT K, 1994, BLOOD, V83, P2611, DOI 10.1182/blood.V83.9.2611.bloodjournal8392611; PEARCE M, 1993, HUM MOL GENET, V2, P1765, DOI 10.1093/hmg/2.11.1765; Pozzoli U, 2002, GENETICS, V160, P793; Qu XY, 1998, DNA SEQUENCE, V9, P189, DOI 10.3109/10425179809105206; Rhodes DR, 2004, NEOPLASIA, V6, P1, DOI 10.1016/S1476-5586(04)80047-2; Roque L, 2003, GENE CHROMOSOME CANC, V36, P292, DOI 10.1002/gcc.10146; SCHOFIELD J, 1993, DEV DYNAM, V198, P254, DOI 10.1002/aja.1001980403; Theile M, 1996, ONCOGENE, V13, P677; Tibiletti MB, 2000, CLIN CANCER RES, V6, P1422; Tibiletti MG, 1996, CANCER RES, V56, P4493; Tibiletti MG, 2001, CLIN CANCER RES, V7, P3404; TRENT JM, 1990, SCIENCE, V247, P568, DOI 10.1126/science.2300817; Wan MH, 1999, ONCOGENE, V18, P1545, DOI 10.1038/sj.onc.1202476; WELCH DR, 1994, ONCOGENE, V9, P255; YAMADA H, 1990, ONCOGENE, V5, P1141	37	32	33	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 13	2007	26	42					6220	6228		10.1038/sj.onc.1210432	http://dx.doi.org/10.1038/sj.onc.1210432			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	209PU	17384672				2022-12-28	WOS:000249401300013
J	Suzuki, E; Umezawa, K; Bonavida, B				Suzuki, E.; Umezawa, K.; Bonavida, B.			Rituximab inhibits the constitutively activated PI3K-Akt pathway in B-NHL cell lines: involvement in chemosensitization to drug-induced apoptosis	ONCOGENE			English	Article						rituximab; Akt pathway; chemosensitization; apoptosis	NON-HODGKINS-LYMPHOMA; THERAPEUTIC INTERVENTION; 3-KINASE-AKT PATHWAY; SIGNALING PATHWAY; PROSTATE-CANCER; DOWN-REGULATION; BCL-XL; EXPRESSION; PTEN; KINASE	Rituximab ( chimeric anti-CD20 monoclonal antibody) is currently being used, alone or in combination with chemotherapy, in the treatment of B-non-Hodgkin's lymphoma (B-NHL). We have reported that rituximab treatment of B-NHL cell lines sensitizes the drug-resistant tumor cells to apoptosis by various chemotherapeutic drugs and chemosensitization was, in large part, owing to the selective inhibition of the anti-apoptotic Bcl-XL gene product. The constitutive activation of the Akt pathway in B-NHL results in overexpression and functional activation of Bcl-xL. Hence, we hypothesized that rituximab- induced inhibition of Bcl-xL expression and chemosensitization may result, in part, from its inhibitory activity of the Akt pathway. This hypothesis was tested using the drug-resistant Ramos and Daudi B-NHL cell lines. Time kinetic analysis revealed that treatment with rituximab inhibited phosphorylation of Akt, but not unphosphorylated Akt, and the inhibition was first detected at 6 h post-rituximab treatment. Similar time kinetics revealed rituximab- induced inhibition of p-PDK1, p-Bad, p-IKK alpha/beta and p- I kappa beta alpha and no inhibition of unphosphorylated proteins. In addition, rituximab treatment resulted in significant increase of Bcl-(xL)-Bad heterodimeric complexes as compared to untreated cells. The role of the Akt pathway in the regulation of resistance was corroborated by the use of the Akt inhibitor, LY294002, and by transfection with siRNA Akt. Treatment of tumor cells with LY294002 or with Akt siRNA, but not control siRNA, resulted in inhibition of Bcl-xL expression and sensitization to drug-induced apoptosis. Although rituximab did not inhibit the Akt pathway nor sensitized the rituximab- resistant Ramos RR1 clone, treatment with LY294002 or Akt siRNA sensitized the clone to drug-induced apoptosis. The present. findings demonstrate for the first time that rituximab inhibits the constitutively activated Akt pathway in B-NHL cell lines, and this inhibition contributes to sensitization of drug-resistant cells to apoptosis by chemotherapeutic drugs. The findings also identify the Akt pathway as target for therapeutic intervention in the reversal of rituximab and drug-resistant B-NHL.	Calif State Univ Los Angeles, Jonsson Comprehensive Canc Ctr, David Geffen Medicine, Dept Microbiol Immunol & Mol Genet, Los Angeles, CA USA; Keio Univ, Dept Appl Chem, Yokohama, Kanagawa, Japan	California State University System; California State University Los Angeles; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Keio University	Bonavida, B (corresponding author), Univ Calif Los Angeles, Dept Microbiol Immunol & Mol Genet, Le Conte Ave, Los Angeles, CA 90095 USA.	bbonavida@mednet.ucla.edu						Alas S, 2001, CANCER RES, V61, P5137; Arranz E, 1996, CANCER GENET CYTOGEN, V87, P1, DOI 10.1016/0165-4608(95)00230-8; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Cheng JQ, 1996, P NATL ACAD SCI USA, V93, P3636, DOI 10.1073/pnas.93.8.3636; Cheng JQ, 2005, ONCOGENE, V24, P7482, DOI 10.1038/sj.onc.1209088; Cuni S, 2004, LEUKEMIA, V18, P1391, DOI 10.1038/sj.leu.2403398; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Di Cristofano A, 2000, CELL, V100, P387, DOI 10.1016/S0092-8674(00)80674-1; Ernst JA, 2005, BIOCHEMISTRY-US, V44, P15150, DOI 10.1021/bi0511078; Goswami A, 2006, CANCER RES, V66, P2889, DOI 10.1158/0008-5472.CAN-05-4458; Haiman CA, 2006, CANCER EPIDEM BIOMAR, V15, P1021, DOI 10.1158/1055-9965.EPI-05-0896; Hayakawa J, 2000, CANCER RES, V60, P5988; Jazirehi AR, 2007, CANCER RES, V67, P1270, DOI 10.1158/0008-5472.CAN-06-2184; Jazirehi AR, 2005, ONCOGENE, V24, P2121, DOI 10.1038/sj.onc.1208349; Jazirehi AR, 2004, CANCER RES, V64, P7117, DOI 10.1158/0008-5472.CAN-03-3500; Jazirehi AR, 2005, CANCER RES, V65, P264; Marsit CJ, 2005, HUM PATHOL, V36, P768, DOI 10.1016/j.humpath.2005.05.006; Osaki M, 2004, APOPTOSIS, V9, P667, DOI 10.1023/B:APPT.0000045801.15585.dd; Ozes ON, 1999, NATURE, V401, P82; Poh TW, 2005, CANCER RES, V65, P6264, DOI 10.1158/0008-5472.CAN-05-0152; Rennie PS, 1998, CANCER METAST REV, V17, P401, DOI 10.1023/A:1006121219097; Rogers Barbara Barnes, 2006, Semin Oncol Nurs, V22, P67, DOI 10.1016/j.soncn.2006.01.002; Shan D, 1998, BLOOD, V91, P1644, DOI 10.1182/blood.V91.5.1644.1644_1644_1652; Sugimori K, 2005, J BONE MINER METAB, V23, P411, DOI 10.1007/s00774-005-0622-7; Tachiiri S, 2000, JPN J CANCER RES, V91, P1314, DOI 10.1111/j.1349-7006.2000.tb00919.x; Toker A, 2006, CANCER RES, V66, P3963, DOI 10.1158/0008-5472.CAN-06-0743; Uddin S, 2004, BIOCHEM BIOPH RES CO, V320, P932, DOI 10.1016/j.bbrc.2004.06.038; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Weintraub SJ, 2004, CANCER CELL, V5, P3, DOI 10.1016/S1535-6108(03)00338-6; Wetzker R, 2004, CURR PHARM DESIGN, V10, P1915, DOI 10.2174/1381612043384402; Xerri L, 1996, BRIT J HAEMATOL, V92, P900, DOI 10.1046/j.1365-2141.1996.423958.x; Yin DL, 2006, J NEUROIMMUNOL, V174, P101, DOI 10.1016/j.jneuroim.2006.02.001; Zhao WL, 2004, BLOOD, V103, P695, DOI 10.1182/blood-2003-06-1901	33	59	65	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 13	2007	26	42					6184	6193		10.1038/sj.onc.1210448	http://dx.doi.org/10.1038/sj.onc.1210448			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	209PU	17420722				2022-12-28	WOS:000249401300009
J	Brien, G; Trescol-Bierriont, MC; Bonnefoy-Berard, N				Brien, G.; Trescol-Bierriont, M-C; Bonnefoy-Berard, N.			Downregulation of Bfl-1 protein expression sensitizes malignant B cells to apoptosis	ONCOGENE			English	Article						bcl-2; bfl-1; apoptosis; B lymphoma	NF-KAPPA-B; ELDERLY-PATIENTS; UP-REGULATION; R-CHOP; BCL-X; LYMPHOMA; SURVIVAL; GENE; CHEMOTHERAPY; A1/BFL-1	Elevated expression of the antiapoptotic protein Bfl-1 (A1) was previously reported in several cancer cell lines. Recently, molecular profiling of large B-cell lymphoma identified Bfl-1 as a gene signature in 'OxPhos' diffuse large B-cell lymphoma subtype and in primary mediastinal large B-cell lymphoma, suggesting that in addition to Bcl-2, Bcl-xL and Mcl-1, Bfl-1 may be a relevant target in the design of new strategies for cancer therapy. Using short hairpin RNA strategy, we show here that Bfl-1 silencing in one lymphoblastoid B-cell line and in two diffuse large B-cell lymphoma cell lines potently induces their apoptosis and sensitizes those cell lines to anti-CD20 (Rituximab)-mediated cell death as well as to apoptosis induced by chemotherapeutic molecules such as doxorubicin, vincristine, cisplatin and fludarabine. These results demonstrate for the first time that Bfl-1 is an essential protein for survival of malignant B cells and suggest Bfl-1 may represent a potential target for future drug development against B cell lymphoma.	INSERM, U 503, Lab Homeostasie Lymphocytaire, F-69007 Lyon, France; Univ Lyon 1, F-69003 Lyon, France; IFR128, F-69007 Lyon, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Claude Bernard Lyon 1	Bonnefoy-Berard, N (corresponding author), INSERM, U 503, Lab Homeostasie Lymphocytaire, 21 Ave Tony Garnier, F-69007 Lyon, France.	bonnefoy@cervi-lyon.inserm.fr	Bonnefoy, Nathalie/J-2536-2012	Bonnefoy, Nathalie/0000-0003-4814-6722				Cheng QW, 2000, ONCOGENE, V19, P4936, DOI 10.1038/sj.onc.1203861; Coiffier B, 2005, J CLIN ONCOL, V23, P6387, DOI 10.1200/JCO.2005.05.015; Cottalorda A, 2006, EUR J IMMUNOL, V36, P1684, DOI 10.1002/eji.200636181; Dave SS, 2006, NEW ENGL J MED, V354, P2431, DOI 10.1056/NEJMoa055759; Davis RE, 2001, J EXP MED, V194, P1861, DOI 10.1084/jem.194.12.1861; Feuerhake F, 2005, BLOOD, V106, P1392, DOI 10.1182/blood-2004-12-4901; Feugier P, 2005, J CLIN ONCOL, V23, P4117, DOI 10.1200/JCO.2005.09.131; Grumont RJ, 1999, GENE DEV, V13, P400, DOI 10.1101/gad.13.4.400; Hatada EN, 2003, J IMMUNOL, V171, P761, DOI 10.4049/jimmunol.171.2.761; Hsu BL, 2002, J IMMUNOL, V168, P5993, DOI 10.4049/jimmunol.168.12.5993; Iqbal J, 2006, J CLIN ONCOL, V24, P961, DOI 10.1200/JCO.2005.03.4264; Kuss AW, 1999, EUR J IMMUNOL, V29, P3077, DOI 10.1002/(SICI)1521-4141(199910)29:10<3077::AID-IMMU3077>3.0.CO;2-R; Lam LT, 2005, CLIN CANCER RES, V11, P28; Lee HH, 1999, P NATL ACAD SCI USA, V96, P9136, DOI 10.1073/pnas.96.16.9136; Monti S, 2005, BLOOD, V105, P1851, DOI 10.1182/blood-2004-07-2947; Morales AA, 2005, INT J CANCER, V113, P730, DOI 10.1002/ijc.20614; Mounier N, 2003, BLOOD, V101, P4279, DOI 10.1182/blood-2002-11-3442; Reed JC, 2005, BLOOD, V106, P408, DOI 10.1182/blood-2004-07-2761; Sehn LH, 2005, J CLIN ONCOL, V23, P5027, DOI 10.1200/JCO.2005.09.137; Trescol-Biemont MC, 2004, BIOCHIMIE, V86, P287, DOI 10.1016/j.biochi.2004.04.001; TSUJIMOTO Y, 1985, SCIENCE, V228, P1440, DOI 10.1126/science.3874430; Wang CY, 1999, MOL CELL BIOL, V19, P5923; Werner AB, 2002, J BIOL CHEM, V277, P22781, DOI 10.1074/jbc.M201469200; Willis SN, 2005, CURR OPIN CELL BIOL, V17, P617, DOI 10.1016/j.ceb.2005.10.001; Zong WX, 1999, GENE DEV, V13, P382, DOI 10.1101/gad.13.4.382	25	67	71	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG	2007	26	39					5828	5832		10.1038/sj.onc.1210363	http://dx.doi.org/10.1038/sj.onc.1210363			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	202EP	17353899				2022-12-28	WOS:000248885100015
J	Tong, Y; Tan, Y; Zhou, C; Melmed, S				Tong, Y.; Tan, Y.; Zhou, C.; Melmed, S.			Pituitary tumor transforming gene interacts with Sp1 to modulate G1/S cell phase transition	ONCOGENE			English	Article						PTTG1; pituitary; cell cycle	TRANSCRIPTIONAL ACTIVATION FUNCTION; BREAST-CANCER CELLS; CYCLE PROGRESSION; POTENTIAL ROLE; GROWTH-FACTOR; C-MYC; EXPRESSION; PTTG; MICE; IDENTIFICATION	Pituitary tumor transforming gene (PTTG1) was isolated from rat pituitary tumor cells, and subsequently identified as a securin protein as well as a transcription factor. We show here a global transcriptional effect of PTTG1 in human choriocarcinoma JEG-3 cells by simultaneously assessing 20 000 gene promoters using chromatin immunoprecipitation (ChIP)-on-Chip experiments. Seven hundred and forty-six gene promoters (P < 0.001) were found enriched, with functions relating to cell cycle, metabolic control and signal transduction. Significant interaction between PTTG1 and Sp1 (P < 0.000001) was found by transcriptional pattern analysis of ChIP data and further confirmed by immunoprecipitation and pull-down assays. PTTG1 acts coordinately with Sp1 to induce cyclin D3 expression similar to threefold, and promotes G1/S-phase transition independently of p21. PTTG1 deletion was also protective for anchorage-independent cell colony formation. The results show that PTTG1 exhibits properties of a global transcription factor, and specifically modulates the G1/S-phase transition by interacting with Sp1. This novel signaling pathway may be required for PTTG1 transforming activity.	Univ Calif Los Angeles, Dept Med, David Geffen Sch Med, Cedars Sinai Res Inst, Los Angeles, CA 90024 USA	Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Melmed, S (corresponding author), Acad Affairs, Room 2015,8700 Beverly Blvd, Los Angeles, CA 90048 USA.	melmed@csmc.edu	Zhou, Cuiqi/B-1568-2010		NATIONAL CANCER INSTITUTE [R01CA075979, K99CA138914] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA075979, K99 CA138914, R01 CA075979-09, CA 75979] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abdelrahim M, 2002, J BIOL CHEM, V277, P28815, DOI 10.1074/jbc.M203828200; Bernal JA, 2002, NAT GENET, V32, P306, DOI 10.1038/ng997; Boelaert K, 2003, FASEB J, V17, P1631, DOI 10.1096/fj.02-0948com; Chesnokova V, 2005, MOL ENDOCRINOL, V19, P2371, DOI 10.1210/me.2005-0137; Chien WW, 2000, J BIOL CHEM, V275, P19422, DOI 10.1074/jbc.M910105199; Clem AL, 2003, GENE, V322, P113, DOI 10.1016/j.gene.2003.08.012; Dominguez A, 1998, ONCOGENE, V17, P2187, DOI 10.1038/sj.onc.1202140; Grinstein E, 2002, ONCOGENE, V21, P1485, DOI 10.1038/sj.onc.1205211; Heaney AP, 1999, NAT MED, V5, P1317, DOI 10.1038/15275; Heaney AP, 2000, LANCET, V355, P716, DOI 10.1016/S0140-6736(99)10238-1; Honda S, 2003, ANTICANCER RES, V23, P3775; Khan S, 2003, ENDOCRINOLOGY, V144, P2325, DOI 10.1210/en.2002-0149; Li ZR, 2003, P NATL ACAD SCI USA, V100, P8164, DOI 10.1073/pnas.1332764100; McCabe CJ, 2003, CLIN ENDOCRINOL, V58, P141, DOI 10.1046/j.1365-2265.2003.01598.x; Pei L, 1997, MOL ENDOCRINOL, V11, P433, DOI 10.1210/me.11.4.433; Pei L, 2001, J BIOL CHEM, V276, P8484, DOI 10.1074/jbc.M009654200; Pei L, 2000, J BIOL CHEM, V275, P31191, DOI 10.1074/jbc.M002451200; Ren B, 2000, SCIENCE, V290, P2306, DOI 10.1126/science.290.5500.2306; Ryuto M, 1996, J BIOL CHEM, V271, P28220, DOI 10.1074/jbc.271.45.28220; Saez C, 1999, ONCOGENE, V18, P5473, DOI 10.1038/sj.onc.1202914; Safe S, 2005, EUR J CANCER, V41, P2438, DOI 10.1016/j.ejca.2005.08.006; Solbach C, 2004, BREAST, V13, P80, DOI 10.1016/j.breast.2003.09.008; Tarabykin V, 2000, MECH DEVELOP, V92, P301, DOI 10.1016/S0925-4773(00)00243-4; Wang ZY, 1999, BLOOD, V93, P4208, DOI 10.1182/blood.V93.12.4208.412k17_4208_4221; Wang ZY, 2000, J BIOL CHEM, V275, P7459, DOI 10.1074/jbc.275.11.7459; Wang ZY, 2003, P NATL ACAD SCI USA, V100, P3428, DOI 10.1073/pnas.0638052100; Wang ZY, 2001, MOL ENDOCRINOL, V15, P1870, DOI 10.1210/me.15.11.1870; Yu R, 2000, MOL ENDOCRINOL, V14, P1137, DOI 10.1210/me.14.8.1137; Zou H, 1999, SCIENCE, V285, P418, DOI 10.1126/science.285.5426.418	29	63	69	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG	2007	26	38					5596	5605		10.1038/sj.onc.1210339	http://dx.doi.org/10.1038/sj.onc.1210339			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	200ZS	17353909	Green Accepted			2022-12-28	WOS:000248801900005
J	Jonsson, G; Dahl, C; Staaf, J; Sandberg, T; Bendahl, PO; Ringner, M; Guldberg, P; Borg, A				Joensson, G.; Dahl, C.; Staaf, J.; Sandberg, T.; Bendahl, P-O; Ringner, M.; Guldberg, P.; Borg, A.			Genomic profiling of malignant melanoma using tiling-resolution arrayCGH	ONCOGENE			English	Article						melanoma; arrayCGH; mutation	BRAF MUTATIONS; SUSCEPTIBILITY LOCUS; CUTANEOUS MELANOMA; GENE; DELETION; PATHWAY; TBX2; INACTIVATION; DISRUPTION; SENESCENCE	Malignant melanoma is an aggressive, heterogeneous disease where new biomarkers for diagnosis and clinical outcome are needed. We searched for chromosomal aberrations that characterize its pathogenesis using 47 different melanoma cell lines and tiling-resolution bacterial artificial chromosome-arrays for comparative genomic hybridization. Major melanoma genes, including BRAF, NRAS, CDKN2A, TP53, CTNNB1, CDK4 and PTEN, were examined for mutations. Distinct copy number alterations were detected, including loss or gain of whole chromosomes but also minute amplifications and homozygous deletions. Most common overlapping regions with losses were mapped to 9p24.3-q13, 10 and 11q14.1-qter, whereas copy number gains were most frequent on chromosomes 1q, 7, 17q and 20q. Amplifications were delineated to oncogenes such as MITF (3p14), CCND1 (11q13), MDM2 (12q15), CCNE1 (19q12) and NOTCH2 (1p12). Frequent findings of homozygous deletions on 9p21 and 10q23 confirmed the importance of CDKN2A and PTEN. Pair-wise comparisons revealed distinct sets of alterations, for example, mutually exclusive mutations in BRAF and NRAS, mutual mutations in BRAF and PTEN, concomitant chromosome 7 gain and 10 loss and concomitant chromosome 15q22.2-q26.3 gain and 20 gain. Moreover, alterations of the various melanoma genes were associated with distinct chromosomal imbalances suggestive of specific genomic programs in melanoma development.	Univ Lund Hosp, Dept Oncol, S-22185 Lund, Sweden; Danish Canc Soc, Inst Canc Biol, Copenhagen, Denmark; Lund Univ, Dept Theoret Phys, S-22362 Lund, Sweden	Lund University; Skane University Hospital; Danish Cancer Society; Lund University	Borg, A (corresponding author), Lund Univ, Dept Oncol, SE-22185 Lund, Sweden.	ake.borg@med.lu.se	Jönsson, Göran/D-1212-2014; Ringnér, Markus/G-3641-2011	Ringnér, Markus/0000-0001-5469-8940				Autio R, 2003, BIOINFORMATICS, V19, P1714, DOI 10.1093/bioinformatics/btg230; Bittner M, 2000, NATURE, V406, P536, DOI 10.1038/35020115; Cachia AR, 2000, CLIN CANCER RES, V6, P3511; Carreira S, 2000, J BIOL CHEM, V275, P21920, DOI 10.1074/jbc.M000035200; Christensen C, 2005, ONCOGENE, V24, P6292, DOI 10.1038/sj.onc.1208758; Curtin JA, 2005, NEW ENGL J MED, V353, P2135, DOI 10.1056/NEJMoa050092; Daniotti M, 2004, ONCOGENE, V23, P5968, DOI 10.1038/sj.onc.1207780; Gillanders E, 2003, AM J HUM GENET, V73, P301, DOI 10.1086/377140; Grafstrom E, 2005, CLIN CANCER RES, V11, P2991, DOI 10.1158/1078-0432.CCR-04-1731; Gronbaek K, 2000, LEUKEMIA, V14, P1727, DOI 10.1038/sj.leu.2401901; Guldberg P, 1997, HUM MUTAT, V9, P348, DOI 10.1002/(SICI)1098-1004(1997)9:4<348::AID-HUMU8>3.3.CO;2-7; Guldberg P, 1997, CANCER RES, V57, P3660; Haqq C, 2005, P NATL ACAD SCI USA, V102, P6092, DOI 10.1073/pnas.0501564102; Hayward NK, 2003, ONCOGENE, V22, P3053, DOI 10.1038/sj.onc.1206445; Jacobs JJL, 2000, NAT GENET, V26, P291, DOI 10.1038/81583; Jonsson G, 2005, JNCI-J NATL CANCER I, V97, P1377, DOI 10.1093/jnci/dji280; Jonsson G, 2005, CANCER RES, V65, P7612, DOI 10.1158/0008-5472.CAN-05-0570; Kannan K, 2003, P NATL ACAD SCI USA, V100, P1221, DOI 10.1073/pnas.0336397100; Liu ZJ, 2006, CANCER RES, V66, P4182, DOI 10.1158/0008-5472.CAN-05-3589; Macara IG, 2004, NAT REV MOL CELL BIO, V5, P220, DOI 10.1038/nrm1332; Maldonado JL, 2003, J NATL CANCER I, V95, P1878, DOI 10.1093/jnci/djg123; Massi D, 2006, MODERN PATHOL, V19, P616, DOI 10.1038/modpathol.3800585; McLean WHI, 2003, HUM MOL GENET, V12, P2395, DOI 10.1093/hmg/ddg234; Omholt K, 2003, CLIN CANCER RES, V9, P6483; Pavey S, 2004, ONCOGENE, V23, P4060, DOI 10.1038/sj.onc.1207563; Pollock PM, 2003, NAT GENET, V33, P19, DOI 10.1038/ng1054; Pollock PM, 2002, MELANOMA RES, V12, P565, DOI 10.1097/00008390-200212000-00006; Ren SJ, 2004, CELL, V117, P239, DOI 10.1016/S0092-8674(04)00300-9; Saal LH, 2002, GENOME BIOL, V3; Sauter ER, 2002, CANCER RES, V62, P3200; Snijders AM, 2001, NAT GENET, V29, P263, DOI 10.1038/ng754; Takata M, 2005, J INVEST DERMATOL, V125, P318, DOI 10.1111/j.0022-202X.2005.23812.x; Tanami H, 2004, ONCOGENE, V23, P8796, DOI 10.1038/sj.onc.1208152; Tsao H, 2004, J INVEST DERMATOL, V122, P337, DOI 10.1046/j.0022-202X.2004.22243.x; Tucker MA, 2003, ONCOGENE, V22, P3042, DOI 10.1038/sj.onc.1206444; Vance KW, 2005, CANCER RES, V65, P2260, DOI 10.1158/0008-5472.CAN-04-3045; Walker GJ, 2004, GENE CHROMOSOME CANC, V41, P56, DOI 10.1002/gcc.20056; ZIPPELIUS A, 2006, CANC IMMUNOL IMMUNOT	38	89	94	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 12	2007	26	32					4738	4748		10.1038/sj.onc.1210252	http://dx.doi.org/10.1038/sj.onc.1210252			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	190DJ	17260012				2022-12-28	WOS:000248037900015
J	Waters, LC; Veverka, V; Bohm, M; Schmedt, T; Choong, PT; Muskett, FW; Klempnauer, KH; Carr, MD				Waters, L. C.; Veverka, V.; Boehm, M.; Schmedt, T.; Choong, P. T.; Muskett, F. W.; Klempnauer, K-H; Carr, M. D.			Structure of the C-terminal MA-3 domain of the tumour suppressor protein Pdcd4 and characterization of its interaction with eIF4A	ONCOGENE			English	Article						Pdcd4; MA-3; eIF4A; HEAT; NMR; translation	BOX RNA HELICASE; TRANSLATION INITIATION FACTOR-4A; TORSION ANGLE DYNAMICS; TRANSFORMATION SUPPRESSOR; EUKARYOTIC TRANSLATION; MUTATIONAL ANALYSIS; TISSUE INHIBITOR; CHEMICAL-SHIFT; BINDING; METALLOPROTEINASES-2	Programmed cell death protein 4(Pdcd4) is a novel tumour suppressor protein, which is involved in the control of eukaryotic transcription and translation. The regulation of translation involves specific interactions with eukaryotic initiation factor (eIF) 4A and eIF4G, which are mediated via the two tandem MA-3 domains. We have determined the structure of the C-terminal MA-3 domain of Pdcd4(Pdc d4MA-3 C), characterized its interaction with eIF4A and compared the features of nuclear magnetic resonance (NMR) spectra obtained from the single domain and tandem MA-3 region. Pdcd4M A-3(C) is composed of three layers of helix-turn-helix hairpins capped by a single helix and shows close structural homology to the atypical HEAT repeats found in many eIFs. The sequence conservation and NMR data strongly suggest that the tandem MA-3 region is composed of two equivalent domains connected by a somewhat. exible linker. Pdcd4 MA-3 C was found to interact with the Nterminal domain of eIF4A through a conserved surface region encompassing the loop connecting alpha 5 and alpha 6 and the turn linking alpha 3 and alpha 4. This site is strongly conserved in other MA-3 domains known to interact with eIF4A, including the preceding domain of Pdcd4, suggesting a common mode of binding.	Univ Leicester, Dept Biochem, Henry Wellcome Bldg,Lancaster Rd, Leicester LE1 9HN, Leics, England; Univ Munster, Inst Biochem, D-4400 Munster, Germany	University of Leicester; University of Munster	Carr, MD (corresponding author), Univ Leicester, Dept Biochem, Henry Wellcome Bldg,Lancaster Rd, Leicester LE1 9HN, Leics, England.	mdc12@le.ac.uk	Veverka, Vaclav/P-5251-2019; Veverka, Vaclav/G-9174-2014	Veverka, Vaclav/0000-0003-3782-5279; Veverka, Vaclav/0000-0003-3782-5279; Choong, Peter/0000-0001-7333-7665; Carr, Mark/0000-0002-3939-0996	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Afonja O, 2004, ONCOGENE, V23, P8135, DOI 10.1038/sj.onc.1207983; ANDRADE MA, 1995, NAT GENET, V11, P115, DOI 10.1038/ng1095-115; Bellsolell L, 2006, STRUCTURE, V14, P913, DOI 10.1016/j.str.2006.03.012; Bitomsky N, 2004, ONCOGENE, V23, P7484, DOI 10.1038/sj.onc.1208064; Bohm M, 2003, ONCOGENE, V22, P4905, DOI 10.1038/sj.onc.1206710; CHEN S, 2003, P ICASSP HONG KONG C, V4, P640; Cmarik JL, 1999, P NATL ACAD SCI USA, V96, P14037, DOI 10.1073/pnas.96.24.14037; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; Cuff JA, 1998, BIOINFORMATICS, V14, P892, DOI 10.1093/bioinformatics/14.10.892; Finn RD, 2006, NUCLEIC ACIDS RES, V34, pD247, DOI 10.1093/nar/gkj149; Groves MR, 1999, CURR OPIN STRUC BIOL, V9, P383, DOI 10.1016/S0959-440X(99)80052-9; Guntert P, 1997, J MOL BIOL, V273, P283, DOI 10.1006/jmbi.1997.1284; Herrmann T, 2002, J MOL BIOL, V319, P209, DOI 10.1016/S0022-2836(02)00241-3; Hershey JWB, 2000, COLD SPRING HARBOR M, V39, P33; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Imataka H, 1997, MOL CELL BIOL, V17, P6940, DOI 10.1128/MCB.17.12.6940; Jansen AP, 2004, MOL CANCER THER, V3, P103; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; LaRonde-LeBlanc N, 2007, MOL CELL BIOL, V27, P147, DOI 10.1128/MCB.00867-06; Marcotrigiano J, 2001, MOL CELL, V7, P193, DOI 10.1016/S1097-2765(01)00167-8; Marintchev A, 2004, Q REV BIOPHYS, V37, P197, DOI 10.1017/S0033583505004026; Mazza C, 2001, MOL CELL, V8, P383, DOI 10.1016/S1097-2765(01)00299-4; Muskett FW, 1998, J BIOL CHEM, V273, P21736, DOI 10.1074/jbc.273.34.21736; Oberer M, 2005, GENE DEV, V19, P2212, DOI 10.1101/gad.1335305; Palamarchuk A, 2005, CANCER RES, V65, P11282, DOI 10.1158/0008-5472.CAN-05-3469; PAUSE A, 1993, MOL CELL BIOL, V13, P6789, DOI 10.1128/MCB.13.11.6789; PAUSE A, 1992, EMBO J, V11, P2643, DOI 10.1002/j.1460-2075.1992.tb05330.x; Ponting CP, 2000, TRENDS BIOCHEM SCI, V25, P423, DOI 10.1016/S0968-0004(00)01628-5; Renshaw PS, 2002, J BIOL CHEM, V277, P21598, DOI 10.1074/jbc.M201625200; Renshaw PS, 2005, EMBO J, V24, P2491, DOI 10.1038/sj.emboj.7600732; ROZEN F, 1990, MOL CELL BIOL, V10, P1134, DOI 10.1128/MCB.10.3.1134; Shibahara K, 1995, GENE, V166, P297, DOI 10.1016/0378-1119(95)00607-9; Svitkin YV, 2001, RNA, V7, P1743; Tanner NK, 2003, MOL CELL, V11, P127, DOI 10.1016/S1097-2765(03)00006-6; Waters L, 2006, J BIOL CHEM, V281, P14787, DOI 10.1074/jbc.M600237200; Waters LC, 2006, J BIOMOL NMR, V36, P18, DOI 10.1007/s10858-005-5887-6; Williamson RA, 1997, BIOCHEMISTRY-US, V36, P13882, DOI 10.1021/bi9712091; Yamamoto Y, 2005, P NATL ACAD SCI USA, V102, P16164, DOI 10.1073/pnas.0507960102; Yang HS, 2003, MOL CELL BIOL, V23, P26, DOI 10.1128/MCB.23.1.26-37.2003; Yang HS, 2004, MOL CELL BIOL, V24, P3894, DOI 10.1128/MCB.24.9.3894-3906.2004; Yang HS, 2003, ONCOGENE, V22, P3712, DOI 10.1038/sj.onc.1206433; Yang HS, 2001, ONCOGENE, V20, P669, DOI 10.1038/sj.onc.1204137; Zakowicz H, 2005, RNA, V11, P261, DOI 10.1261/rna.7191905	43	46	51	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2007	26	34					4941	4950		10.1038/sj.onc.1210305	http://dx.doi.org/10.1038/sj.onc.1210305			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	194CV	17310995				2022-12-28	WOS:000248322500006
J	Cui, X; Zhang, L; Luo, J; Rajasekaran, A; Hazra, S; Cacalano, N; Dubinett, SM				Cui, X.; Zhang, L.; Luo, J.; Rajasekaran, A.; Hazra, S.; Cacalano, N.; Dubinett, S. M.			Unphosphorylated STAT6 contributes to constitutive cyclooxygenase-2 expression in human non-small cell lung cancer	ONCOGENE			English	Article						STAT6; COX-2; NSCLC	TYROSINE PHOSPHORYLATION; GENE-EXPRESSION; APOPTOSIS; TRANSCRIPTION; ACTIVATION; RESISTANCE; P300/CBP; IL-4	Cyclooxygenase-2 (COX-2) is frequently overexpressed in human cancers and contributes to the malignant phenotype. Our data indicate unphosphorylated signal transducers and activators of transcription 6 (STAT6) may transcriptionally upregulate COX-2 expression and protect against apoptosis in NSCLC cells. In A427 and H2122, NSCLC cell lines that constitutively express COX-2, only unphosphorylated STAT6 was detectable by western blot, thus, all of the following STAT6-dependent effects are attributed to the unphosphorylated protein. In both cell lines, small-interfering RNA-mediated knockdown of STAT6 or stable expression of dominant-negative STAT6 decreased COX-2 expression. In contrast, transfection with a phosphorylation-deficient mutant STAT6 increased COX-2 levels. Immunofluorescent staining revealed the presence of STAT6 in H2122 nuclei, suggesting a direct role in gene regulation for the unphosphorylated protein. Consistent with this hypothesis, unphosphorylated STAT6 increased luciferase expression from a COX-2 promoter reporter construct. STAT6 co-immunoprecipitated with the transcriptional co-activator, p300, and chromatin immunoprecipitation assays demonstrated that these proteins bind a consensus STAT6 binding site located within the COX-2 promoter. STAT6 DNA-binding specificity was confirmed by electrophoretic mobility shift assay. As COX-2 over-expression has been clearly linked to apoptosis resistance and other hallmarks of malignancy, these findings suggest a novel role of unphosphorylated STAT6 in the pathogenesis of non-small cell lung cancer.	Univ Calif Los Angeles, David Geffen Sch Med,Dept Med, Lung Canc Res Program Jonsson Comprehens Canc Ctr, Div Pulm & Crit Care Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol, Los Angeles, CA USA; Univ Calif Los Angeles, David Geffen Sch Med, Dept Radiat Oncol, Los Angeles, CA USA	UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Dubinett, SM (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med,Dept Med, Lung Canc Res Program Jonsson Comprehens Canc Ctr, Div Pulm & Crit Care Med, 37-131 CHS 10833 Le Conte Ave, Los Angeles, CA 90095 USA.	sdubinett@mednet.ucla.edu			NCI NIH HHS [R01 CA111851, P50 CA90388] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA111851, P50CA090388] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bhattacharya S, 2003, J CLIN INVEST, V111, P553, DOI 10.1172/JCI200315372; Chatterjee-Kishore M, 2000, EMBO J, V19, P4111, DOI 10.1093/emboj/19.15.4111; Chattopadhyay S, 2006, ONCOGENE, V25, P3335, DOI 10.1038/sj.onc.1209364; Deng WG, 2004, BLOOD, V103, P2135, DOI 10.1182/blood-2003-09-3131; Dohadwala M, 2002, J BIOL CHEM, V277, P50828, DOI 10.1074/jbc.M210707200; Gagarin D, 2005, J MOL CELL CARDIOL, V39, P453, DOI 10.1016/j.yjmcc.2005.01.015; Galka E, 2004, J SURG RES, V122, P14, DOI 10.1016/j.jss.2004.05.004; Gingras S, 1999, NUCLEIC ACIDS RES, V27, P2722, DOI 10.1093/nar/27.13.2722; Herschman HR, 1999, ADV EXP MED BIOL, V469, P3; HOU JZ, 1994, SCIENCE, V265, P1701, DOI 10.1126/science.8085155; KOTANIDES H, 1993, SCIENCE, V262, P1265, DOI 10.1126/science.7694370; Krysan K, 2004, CANCER RES, V64, P6359, DOI 10.1158/0008-5472.CAN-04-1681; Kumar A, 1997, SCIENCE, V278, P1630, DOI 10.1126/science.278.5343.1630; Leonard WJ, 1998, ANNU REV IMMUNOL, V16, P293, DOI 10.1146/annurev.immunol.16.1.293; McDonald C, 1999, J INTERF CYTOK RES, V19, P711, DOI 10.1089/107999099313550; Meyer T, 2002, EXP CELL RES, V272, P45, DOI 10.1006/excr.2001.5405; Mikita T, 1996, MOL CELL BIOL, V16, P5811; Pold M, 2004, CANCER RES, V64, P1853, DOI 10.1158/0008-5472.CAN-03-3262; SCHINDLER C, 1994, EMBO J, V13, P1350, DOI 10.1002/j.1460-2075.1994.tb06388.x; Sheng HM, 1998, CANCER RES, V58, P362; Shikama N, 1997, TRENDS CELL BIOL, V7, P230, DOI 10.1016/S0962-8924(97)01048-9; Stolina M, 2000, J IMMUNOL, V164, P361, DOI 10.4049/jimmunol.164.1.361; Wang D, 2005, NAT REV DRUG DISCOV, V4, P307, DOI 10.1038/nrd1691; Yang J, 2005, CANCER RES, V65, P939; Zeng R, 2002, J IMMUNOL, V168, P4567, DOI 10.4049/jimmunol.168.9.4567; Zhang MS, 2006, CANCER LETT, V243, P38, DOI 10.1016/j.canlet.2005.11.020	26	52	54	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 21	2007	26	29					4253	4260		10.1038/sj.onc.1210222	http://dx.doi.org/10.1038/sj.onc.1210222			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	184CY	17237818				2022-12-28	WOS:000247619900008
J	Nunoda, K; Tauchi, T; Takaku, T; Okabe, S; Akahane, D; Sashida, G; Ohyashiki, JH; Ohyashiki, K				Nunoda, K.; Tauchi, T.; Takaku, T.; Okabe, S.; Akahane, D.; Sashida, G.; Ohyashiki, J. H.; Ohyashiki, K.			Identification and functional signature of genes regulated by structurally different ABL kinase inhibitors	ONCOGENE			English	Article						BCR-ABL; tyrosine kinase inhibitor; imatinib; dasatinib	BCR-ABL; CELL-PROLIFERATION; LEUKEMIA-CELLS; IMATINIB; RESISTANCE; EXPRESSION; INDEPENDENCE; P27(KIP1); MECHANISM; BINDING	Dasatinib is an ATP-competitive, multi-targeted SRC and ABL kinase inhibitor that can bind BCR-ABL in both the active and inactive conformations. From a clinical standpoint, dasatinib is particularly attractive because it has been shown to induce hematologic and cytogenetic responses in imatinib-resistant chronic myeloid leukemia patients. The fact because the combination of imatinib and dasatinib shows the additive/synergistic growth inhibition on wild-type p210 BCR-ABL-expressing cells, we reasoned that these ABL kinase inhibitors might induce the different molecular pathways. To address this question, we used DNA microarrays to identify genes whose transcription was altered by imatinib and dasatinib. K562 cells were cultured with imatinib or dasatinib for 16 h, and gene expression data were obtained from three independent microarray hybridizations. Almost all of the imatinib-and dasatinib-responsive genes appeared to be similarly increased or decreased in K562 cells; however, small subsets of genes were identified as selectively altered expression by either imatinib or dasatinib. The distinct genes that are selectively modulated by dasatinib are cyclin-dependent kinase 2 (CDK2) and CDK8, which had a maximal reduction of <5-fold in microarray screen. To assess the functional importance of dasatinib regulated genes, we used RNA interference to determine whether reduction of CDK2 and CDK8 affected the growth inhibition. K562 and TF-1BCR-ABL cells, pretreated with CDK2 or CDK8 small interfering RNA, showed additive growth inhibition with imatinib, but not with dasatinib. These findings demonstrate that the additive/ synergistic growth inhibition by imatinib and dasatinib may be mediated in part by CDK2 and CDK8.	Tokyo Med Univ, Dept Internal Med 1, Shinjuku Ku, Tokyo 1600023, Japan; Tokyo Med Univ, Intractable Dis Res Ctr, Shinjuku Ku, Tokyo, Japan	Tokyo Medical University; Tokyo Medical University	Tauchi, T (corresponding author), Tokyo Med Univ, Dept Internal Med 1, Shinjuku Ku, 6-7-1 Nishinhijuku, Tokyo 1600023, Japan.	tauchi@tokyo-med.ac.jp	Sashida, Goro/N-5259-2014	Sashida, Goro/0000-0003-2318-5987				Burgess MR, 2005, P NATL ACAD SCI USA, V102, P3395, DOI 10.1073/pnas.0409770102; Dai Y, 2004, J BIOL CHEM, V279, P34227, DOI 10.1074/jbc.M402290200; Donato NJ, 2003, BLOOD, V101, P690, DOI 10.1182/blood.V101.2.690; Gambacorti-Passerini C, 2005, LEUKEMIA, V19, P1267, DOI 10.1038/sj.leu.2403775; Gesbert F, 2000, J BIOL CHEM, V275, P39223, DOI 10.1074/jbc.M007291200; Hofmann WK, 2002, LANCET, V359, P481, DOI 10.1016/S0140-6736(02)07678-X; Jiang YH, 2000, P NATL ACAD SCI USA, V97, P10538, DOI 10.1073/pnas.190104497; Komatsu N, 2003, J BIOL CHEM, V278, P6411, DOI 10.1074/jbc.M211562200; Lionberger JM, 2000, J BIOL CHEM, V275, P18581, DOI 10.1074/jbc.C000126200; Nakajima A, 2003, MOL CANCER THER, V2, P219; O'Hare T, 2005, CANCER RES, V65, P4500, DOI 10.1158/0008-5472.CAN-05-0259; Ohyashiki JH, 2005, BIOCHEM BIOPH RES CO, V329, P11, DOI 10.1016/j.bbrc.2005.01.090; Parada Y, 2001, J BIOL CHEM, V276, P23572, DOI 10.1074/jbc.M101885200; Prathapam T, 2006, P NATL ACAD SCI USA, V103, P2695, DOI 10.1073/pnas.0511186103; Ptasznik A, 2004, NAT MED, V10, P1187, DOI 10.1038/nm1127; Riley D, 2001, ONCOGENE, V20, P5941, DOI 10.1038/sj.onc.1204826; Samanta AK, 2006, CANCER RES, V66, P6468, DOI 10.1158/0008-5472.CAN-06-0025; Shah NP, 2004, SCIENCE, V305, P399, DOI 10.1126/science.1099480; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Stanglmaier M, 2003, LEUKEMIA, V17, P283, DOI 10.1038/sj.leu.2402778; Takaku T, 2005, BIOCHEM BIOPH RES CO, V336, P469, DOI 10.1016/j.bbrc.2005.08.104; Talpaz M, 2006, NEW ENGL J MED, V354, P2531, DOI 10.1056/NEJMoa055229; TAUCHI T, 1994, J BIOL CHEM, V269, P15381; Tetsu O, 2003, CANCER CELL, V3, P233, DOI 10.1016/S1535-6108(03)00053-9; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Warmuth M, 1997, J BIOL CHEM, V272, P33260, DOI 10.1074/jbc.272.52.33260; Zhang Y, 2006, BRIT J CANCER, V94, P599, DOI 10.1038/sj.bjc.6602968	27	17	17	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 14	2007	26	28					4179	4188		10.1038/sj.onc.1210179	http://dx.doi.org/10.1038/sj.onc.1210179			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	178XD	17213809				2022-12-28	WOS:000247252700013
J	Claperon, A; Therrien, M				Claperon, A.; Therrien, M.			KSR and CNK: two scaffolds regulating RAS-mediated RAF activation	ONCOGENE			English	Review						RAF; RAS; KSR; CNK; scaffold; signal transduction	CYSTEINE-RICH DOMAIN; PROTEIN-KINASE; MAP KINASE; B-RAF; SIGNAL-TRANSDUCTION; PHOSPHATASE 2A; GROWTH-FACTOR; RAS/RAF/MEK/ERK PATHWAY; CAENORHABDITIS-ELEGANS; FUNCTIONAL-ANALYSIS	The RAS-RAF-MEK-extracellular-regulated kinase (RAS/ERK) pathway is a major intracellular route used by metazoan cells to channel to downstream targets a diverse array of signals, including those controlling cell proliferation and survival. Recent findings suggest that the pathway is assembled by specific scaffolding proteins that in turn regulate the efficiency, the location and/or the duration of signal transmission. Here, through the angle of studies conducted in Drosophila and C. elegans, we present two such proteins, the kinase suppressor of RAS (KSR) and connector enhancer of KSR (CNK) scaffolds, and highlight their implication in a novel mechanism regulating RAS-mediated RAF activation. Based on recent findings, we discuss the possibility that KSR, a RAF-like protein, does not solely act as a scaffold, but directly induces RAF catalytic function by a kinase-independent mechanism apparently shared by RAF-like proteins.	Univ Montreal, Inst Res Immunol & Canc, Lab Intracellular Signaling, Montreal, PQ H3C 3J7, Canada; Univ Montreal, Dept Pathol & Biol Cellulaire, Montreal, PQ H2X 3J4, Canada	Universite de Montreal; Universite de Montreal	Therrien, M (corresponding author), Univ Montreal, Inst Res Immunol & Canc, Lab Intracellular Signaling, CP 6128 Succursale Ctr Ville, Montreal, PQ H3C 3J7, Canada.	marc.therrien@umontreal.ca						Anselmo AN, 2002, J BIOL CHEM, V277, P5940, DOI 10.1074/jbc.M110498200; Baonza A, 2000, P NATL ACAD SCI USA, V97, P7331, DOI 10.1073/pnas.97.13.7331; Bell B, 1999, J BIOL CHEM, V274, P7982, DOI 10.1074/jbc.274.12.7982; Boudeau J, 2006, TRENDS CELL BIOL, V16, P443, DOI 10.1016/j.tcb.2006.07.003; BRTVA TR, 1995, J BIOL CHEM, V270, P9809, DOI 10.1074/jbc.270.17.9809; Bumeister R, 2004, CURR BIOL, V14, P439, DOI 10.1016/j.cub.2004.02.037; Cabernard C, 2005, DEV CELL, V9, P831, DOI 10.1016/j.devcel.2005.10.008; Cacabelos R, 1999, INT J GERIATR PSYCH, V14, P3, DOI 10.1002/(SICI)1099-1166(199901)14:1<3::AID-GPS897>3.0.CO;2-7; Chadee DN, 2006, P NATL ACAD SCI USA, V103, P4463, DOI 10.1073/pnas.0510651103; Chang F, 2003, LEUKEMIA, V17, P1263, DOI 10.1038/sj.leu.2402945; Chang HC, 1997, GENE DEV, V11, P1132, DOI 10.1101/gad.11.9.1132; Channavajhala PL, 2005, BIOCHEM BIOPH RES CO, V334, P1214, DOI 10.1016/j.bbrc.2005.07.009; Channavajhala PL, 2003, J BIOL CHEM, V278, P47089, DOI 10.1074/jbc.M306002200; Chiloeches A, 2001, MOL CELL BIOL, V21, P2423, DOI 10.1128/MCB.21.7.2423-2434.2001; Chong H, 2003, CELL SIGNAL, V15, P463, DOI 10.1016/S0898-6568(02)00139-0; Chong H, 2001, EMBO J, V20, P3716, DOI 10.1093/emboj/20.14.3716; Colon-Gonzalez F, 2006, BBA-MOL CELL BIOL L, V1761, P827, DOI 10.1016/j.bbalip.2006.05.001; Cutler RE, 1998, P NATL ACAD SCI USA, V95, P9214, DOI 10.1073/pnas.95.16.9214; Dard N, 2006, BIOESSAYS, V28, P146, DOI 10.1002/bies.20351; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Denouel-Galy A, 1998, CURR BIOL, V8, P46, DOI 10.1016/S0960-9822(98)70019-3; Dhillon AS, 2002, ARCH BIOCHEM BIOPHYS, V404, P3, DOI 10.1016/S0003-9861(02)00244-8; Dhillon AS, 2002, MOL CELL BIOL, V22, P3237, DOI 10.1128/MCB.22.10.3237-3246.2002; Dhillon AS, 2002, EMBO J, V21, P64, DOI 10.1093/emboj/21.1.64; Douziech M, 2006, GENE DEV, V20, P807, DOI 10.1101/gad.1390406; Douziech M, 2003, EMBO J, V22, P5068, DOI 10.1093/emboj/cdg506; Dumaz N, 2003, J BIOL CHEM, V278, P29819, DOI 10.1074/jbc.C300182200; English J, 1999, EXP CELL RES, V253, P255, DOI 10.1006/excr.1999.4687; FABIAN JR, 1993, MOL CELL BIOL, V13, P7170, DOI 10.1128/MCB.13.11.7170; Farrar MA, 1996, NATURE, V383, P178, DOI 10.1038/383178a0; Friedman A, 2006, NATURE, V444, P230, DOI 10.1038/nature05280; Fritz RD, 2005, BIOCHEM BIOPH RES CO, V338, P1906, DOI 10.1016/j.bbrc.2005.10.168; Garnett MJ, 2005, MOL CELL, V20, P963, DOI 10.1016/j.molcel.2005.10.022; Gollob JA, 2006, SEMIN ONCOL, V33, P392, DOI 10.1053/j.seminoncol.2006.04.002; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; Hu CD, 1995, J BIOL CHEM, V270, P30274, DOI 10.1074/jbc.270.51.30274; Huwiler A, 1996, P NATL ACAD SCI USA, V93, P6959, DOI 10.1073/pnas.93.14.6959; Jacobs D, 1999, GENE DEV, V13, P163, DOI 10.1101/gad.13.2.163; Jaffe AB, 2005, CURR BIOL, V15, P405, DOI 10.1016/j.cub.2004.12.082; Jaffe AB, 2004, MOL CELL BIOL, V24, P1736, DOI 10.1128/MCB.24.4.1736-1746.2004; Jaumot M, 2001, ONCOGENE, V20, P3949, DOI 10.1038/sj.onc.1204526; Kao GT, 2004, DEVELOPMENT, V131, P755, DOI 10.1242/dev.00987; Kolch W, 2005, NAT REV MOL CELL BIO, V6, P827, DOI 10.1038/nrm1743; KORNFELD K, 1995, CELL, V83, P903, DOI 10.1016/0092-8674(95)90206-6; KREMER NE, 1991, J CELL BIOL, V115, P809, DOI 10.1083/jcb.115.3.809; Krugmann S, 2002, MOL CELL, V9, P95, DOI 10.1016/S1097-2765(02)00434-3; Laberge G, 2005, EMBO J, V24, P487, DOI 10.1038/sj.emboj.7600558; Lanigan TM, 2003, FASEB J, V17, P2048, DOI 10.1096/fj.02-1096com; Lemmon MA, 2004, BIOCHEM SOC T, V32, P707, DOI 10.1042/BST0320707; Li W, 1997, DEVELOPMENT, V124, P4163; Lopez-Ilasaca MA, 2005, FEBS LETT, V579, P648, DOI 10.1016/j.febslet.2004.12.039; Luo ZJ, 1997, MOL CELL BIOL, V17, P46, DOI 10.1128/MCB.17.1.46; Luo ZJ, 1996, NATURE, V383, P181, DOI 10.1038/383181a0; Manning G, 2002, TRENDS BIOCHEM SCI, V27, P514, DOI 10.1016/S0968-0004(02)02179-5; Marais R, 1997, J BIOL CHEM, V272, P4378, DOI 10.1074/jbc.272.7.4378; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; Mason CS, 1999, EMBO J, V18, P2137, DOI 10.1093/emboj/18.8.2137; Matheny SA, 2004, NATURE, V427, P256, DOI 10.1038/nature02237; Michaud NR, 1997, P NATL ACAD SCI USA, V94, P12792, DOI 10.1073/pnas.94.24.12792; MORRISON DK, 1993, J BIOL CHEM, V268, P17309; Mott HR, 1996, P NATL ACAD SCI USA, V93, P8312, DOI 10.1073/pnas.93.16.8312; Muller J, 2001, MOL CELL, V8, P983, DOI 10.1016/S1097-2765(01)00383-5; Muller J, 2000, MOL CELL BIOL, V20, P5529, DOI 10.1128/MCB.20.15.5529-5539.2000; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; Nguyen A, 2002, MOL CELL BIOL, V22, P3035, DOI 10.1128/MCB.22.9.3035-3045.2002; NOURRY C, 2003, SCI STKE; Ohmachi M, 2002, CURR BIOL, V12, P427, DOI 10.1016/S0960-9822(02)00690-5; Ohtakara K, 2002, GENES CELLS, V7, P1149, DOI 10.1046/j.1365-2443.2002.00589.x; Ory S, 2003, CURR BIOL, V13, P1356, DOI 10.1016/S0960-9822(03)00535-9; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; QIAO F, 2005, SCI STKE; Rabizadeh S, 2004, J BIOL CHEM, V279, P29247, DOI 10.1074/jbc.M401699200; Robinson MJ, 1996, BIOCHEMISTRY-US, V35, P5641, DOI 10.1021/bi952723e; Rocheleau CE, 2005, P NATL ACAD SCI USA, V102, P11757, DOI 10.1073/pnas.0500937102; Roignant JY, 2006, GENE DEV, V20, P795, DOI 10.1101/gad.1390506; Rommel C, 1997, MECH DEVELOP, V64, P95, DOI 10.1016/S0925-4773(97)00052-X; Rommel C, 1996, ONCOGENE, V12, P609; Roy F, 2002, GENE DEV, V16, P427, DOI 10.1101/gad.962902; Roy S, 1997, J BIOL CHEM, V272, P20139, DOI 10.1074/jbc.272.32.20139; Rushworth LK, 2006, MOL CELL BIOL, V26, P2262, DOI 10.1128/MCB.26.6.2262-2272.2006; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; Sieburth DS, 1998, CELL, V94, P119, DOI 10.1016/S0092-8674(00)81227-1; Stewart S, 1999, MOL CELL BIOL, V19, P5523; Sugimoto T, 1998, EMBO J, V17, P1717, DOI 10.1093/emboj/17.6.1717; SUNDARAM M, 1995, CELL, V83, P889, DOI 10.1016/0092-8674(95)90205-8; Terai K, 2006, EMBO J, V25, P3556, DOI 10.1038/sj.emboj.7601241; Therrien M, 1999, P NATL ACAD SCI USA, V96, P13259, DOI 10.1073/pnas.96.23.13259; THERRIEN M, 1995, CELL, V83, P879, DOI 10.1016/0092-8674(95)90204-X; Therrien M, 1996, GENE DEV, V10, P2684, DOI 10.1101/gad.10.21.2684; Therrien M, 1998, CELL, V95, P343, DOI 10.1016/S0092-8674(00)81766-3; Torii S, 2004, J BIOCHEM, V136, P557, DOI 10.1093/jb/mvh159; TSUDA L, 1993, CELL, V72, P407, DOI 10.1016/0092-8674(93)90117-9; VAILLANCOURT RR, 1994, MOL CELL BIOL, V14, P6522, DOI 10.1128/MCB.14.10.6522; Vaudry D, 2002, SCIENCE, V296, P1648, DOI 10.1126/science.1071552; Venkateswarlu K, 2003, J BIOL CHEM, V278, P43460, DOI 10.1074/jbc.M304078200; von Kriegsheim A, 2006, NAT CELL BIOL, V8, P1011, DOI 10.1038/ncb1465; Wan PTC, 2004, CELL, V116, P855, DOI 10.1016/S0092-8674(04)00215-6; Wassarman DA, 1996, GENE DEV, V10, P272, DOI 10.1101/gad.10.3.272; Weber CK, 2001, CANCER RES, V61, P3595; Wellbrock C, 2004, NAT REV MOL CELL BIO, V5, P875, DOI 10.1038/nrm1498; Werry TD, 2006, CURR PHARM DESIGN, V12, P1683, DOI 10.2174/138161206776873725; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; Williams JG, 2000, J BIOL CHEM, V275, P22172, DOI 10.1074/jbc.M000397200; Xing HM, 1997, CURR BIOL, V7, P294, DOI 10.1016/S0960-9822(06)00152-7; Xu BE, 2000, J BIOL CHEM, V275, P16795, DOI 10.1074/jbc.275.22.16795; Yan F, 2001, CANCER RES, V61, P963; Yao I, 1999, J BIOL CHEM, V274, P11889, DOI 10.1074/jbc.274.17.11889; Yao I, 2000, BIOCHEM BIOPH RES CO, V270, P538, DOI 10.1006/bbrc.2000.2475; Yoder JH, 2004, EMBO J, V23, P111, DOI 10.1038/sj.emboj.7600025; Yu W, 1998, CURR BIOL, V8, P56, DOI 10.1016/S0960-9822(98)70020-X; Zhang BH, 2000, EMBO J, V19, P5429, DOI 10.1093/emboj/19.20.5429; Zhang XW, 2006, CELL, V125, P1137, DOI 10.1016/j.cell.2006.05.013; Zhang YH, 1997, CELL, V89, P63, DOI 10.1016/S0092-8674(00)80183-X; Zhou M, 2002, J MOL BIOL, V315, P435, DOI 10.1006/jmbi.2001.5263; Zimmermann S, 1999, SCIENCE, V286, P1741, DOI 10.1126/science.286.5445.1741; Ziogas A, 2005, J BIOL CHEM, V280, P24205, DOI 10.1074/jbc.M413327200	117	101	103	2	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 15	2007	26	22					3143	3158		10.1038/sj.onc.1210408	http://dx.doi.org/10.1038/sj.onc.1210408			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	169PH	17496912				2022-12-28	WOS:000246603600005
J	Alinari, L; Lapalombella, R; Andritsos, L; Baiocchi, RA; Lin, TS; Byrd, JC				Alinari, L.; Lapalombella, R.; Andritsos, L.; Baiocchi, R. A.; Lin, T. S.; Byrd, J. C.			Alemtuzumab (Campath-1H) in the treatment of chronic lymphocytic leukemia	ONCOGENE			English	Review						B-cell chronic lymphocytic leukemia; CD52 antigen; alemtuzumab; monoclonal antibody therapy; T-cell depletion; immunosuppression	MONOCLONAL-ANTIBODY THERAPY; STEM-CELL TRANSPLANTATION; INTENSITY ALLOGENEIC TRANSPLANTATION; BONE-MARROW-TRANSPLANTATION; PHASE-II TRIAL; RESIDUAL DISEASE; T-CELLS; LYMPHOPROLIFERATIVE DISORDERS; SUBCUTANEOUS ALEMTUZUMAB; PROLYMPHOCYTIC LEUKEMIA	Alemtuzumab (Campath-1H) is a humanized IgG1 monoclonal antibody that targets the human CD52 antigen. CD52 is expressed by a variety of lymphoid neoplasms and most human mononuclear cell subsets. In 2001, alemtuzumab was approved for marketing in the United States and Europe for use in patients with fludarabine-refractory chronic lymphocytic leukemia (CLL). In heavily pretreated patients with CLL, the overall response rate (ORR) is approximately 35%, and in previously untreated patients the ORR is greater than 80%, with a recent randomized study suggesting it is superior to alkylator-based therapy. Importantly, alemtuzumab is effective in patients with high-risk del(17p13.1) and del(11q22.3) CLL. Alemtuzumab combination studies with fludarabine and/or monoclonal antibodies such as rituximab have demonstrated promising results. Alemtuzumab is also being studied in CLL patients as consolidation therapy for treatment of minimal residual disease, in preparation for stem cell transplantation and to prevent acute and chronic graft versus host disease. Alemtuzumab is frequently associated with acute 'first-dose' reactions when administered intravenously, but is much better tolerated when administered subcutaneously without loss of therapeutic efficacy. Additional potential adverse events associated with alemtuzumab administration include myelosuppression as well as profound cellular immune dysfunction with the associated risk of viral reactivation and other opportunistic infections. Additional studies detailing the mechanism of action of alemtuzumab as well as new strategies for prevention of opportunistic infections will aid in the future therapeutic development of this agent.	Ohio State Univ, Dept Med, Div Hematol Oncol, Columbus, OH 43210 USA	University System of Ohio; Ohio State University	Byrd, JC (corresponding author), Ohio State Univ, Dept Internal Med, Div Hematol Oncol, B301 Starling Loving Hall,320 W 10th Ave, Columbus, OH 43210 USA.	john.byrd@osumc.edu	Lapalombella, Rosa/C-2837-2014; Lapalombella, Rosa/AAG-1856-2021					Bowen AL, 1997, BRIT J HAEMATOL, V96, P617, DOI 10.1046/j.1365-2141.1997.d01-2061.x; Buggins AGS, 2002, BLOOD, V100, P1715, DOI 10.1182/blood.V100.5.1715.h81702001715_1715_1720; Byrd John C, 2004, Hematology Am Soc Hematol Educ Program, P163; Cartron G, 2002, BLOOD, V99, P754, DOI 10.1182/blood.V99.3.754; Cheson BD, 2006, CANCER IMMUNOL IMMUN, V55, P188, DOI 10.1007/s00262-005-0010-0; Clynes RA, 2000, NAT MED, V6, P443, DOI 10.1038/74704; CROWE JS, 1992, CLIN EXP IMMUNOL, V87, P105; Deans JP, 2002, IMMUNOLOGY, V107, P176, DOI 10.1046/j.1365-2567.2002.01495.x; Delgado J, 2006, BLOOD, V107, P1724, DOI 10.1182/blood-2005-08-3372; Dyer MJS, 1997, BRIT J HAEMATOL, V97, P669, DOI 10.1046/j.1365-2141.1997.1062924.x; Elsner J, 1996, BLOOD, V88, P4684, DOI 10.1182/blood.V88.12.4684.bloodjournal88124684; Elter T, 2005, J CLIN ONCOL, V23, P7024, DOI 10.1200/JCO.2005.01.9950; Faderl S, 2003, BLOOD, V101, P3413, DOI 10.1182/blood-2002-07-1952; Faulkner RD, 2004, BLOOD, V103, P428, DOI 10.1182/blood-2003-05-1406; Ferrajoli A, 2003, CANCER, V98, P773, DOI 10.1002/cncr.11551; Flinn IW, 1998, SEMIN ONCOL, V25, P60; Flynn JM, 2000, CURR OPIN ONCOL, V12, P574, DOI 10.1097/00001622-200011000-00010; Frampton JE, 2003, DRUGS, V63, P1229, DOI 10.2165/00003495-200363120-00003; Garcia A, 2003, BIOCHIMIE, V85, P727, DOI 10.1016/j.biochi.2003.09.005; GILLEECE MH, 1993, BLOOD, V82, P807; Ginaldi L, 1998, LEUKEMIA RES, V22, P185, DOI 10.1016/S0145-2126(97)00158-6; Golay J, 2004, HAEMATOLOGICA, V89, P1476; Hale G, 2004, BLOOD, V104, P948, DOI 10.1182/blood-2004-02-0593; HALE G, 1985, J IMMUNOL, V134, P3056; HALE G, 1990, TISSUE ANTIGENS, V35, P118, DOI 10.1111/j.1399-0039.1990.tb01767.x; Hale G, 2001, CYTOTHERAPY, V3, P137, DOI 10.1080/146532401753174098; HALE G, 1993, J REPROD IMMUNOL, V23, P189, DOI 10.1016/0165-0378(93)90007-5; Hale G, 2002, BONE MARROW TRANSPL, V30, P797, DOI 10.1038/sj.bmt.1703733; HALE G, 1983, BLOOD, V62, P873; Hillmen P, 2006, J CLIN ONCOL, V24, p339S; ISAACS JD, 1992, LANCET, V340, P748, DOI 10.1016/0140-6736(92)92294-P; Juliusson G, 2006, BONE MARROW TRANSPL, V37, P503, DOI 10.1038/sj.bmt.1705263; Keating MJ, 2002, BLOOD, V99, P3554, DOI 10.1182/blood.V99.10.3554; Kennedy B, 2002, BLOOD, V99, P2245, DOI 10.1182/blood.V99.6.2245; Klangsinsirikul P, 2002, BLOOD, V99, P2586, DOI 10.1182/blood.V99.7.2586; Kottaridis PD, 2000, BLOOD, V96, P2419; Lenihan DJ, 2004, BLOOD, V104, P655, DOI 10.1182/blood-2003-07-2345; Lin TS, 2005, LEUKEMIA, V19, P1207, DOI 10.1038/sj.leu.2403782; Lin TS, 2005, BLOOD, V105, P289, DOI 10.1182/blood-2004-02-0651; Lozanski G, 2004, BLOOD, V103, P3278, DOI 10.1182/blood-2003-10-3729; Lundin J, 2004, LEUKEMIA, V18, P484, DOI 10.1038/sj.leu.2403258; Lundin J, 2002, BLOOD, V100, P768, DOI 10.1182/blood-2002-01-0159; Martino R, 2001, BRIT J HAEMATOL, V115, P653, DOI 10.1046/j.1365-2141.2001.03153.x; Michallet M, 1996, ANN INTERN MED, V124, P311, DOI 10.7326/0003-4819-124-3-199602010-00005; Mone AP, 2006, LEUKEMIA, V20, P272, DOI 10.1038/sj.leu.2404014; Montillo M, 2006, J CLIN ONCOL, V24, P2337, DOI 10.1200/JCO.2005.04.6037; Moreton P, 2005, J CLIN ONCOL, V23, P2971, DOI 10.1200/JCO.2005.04.021; Morris E, 2004, BLOOD, V104, P3865, DOI 10.1182/blood-2004-03-1105; Nguyen DD, 2002, CLIN LYMPHOMA, V3, P105, DOI 10.3816/CLM.2002.n.016; Nuckel H, 2005, EUR J PHARMACOL, V514, P217, DOI 10.1016/j.ejphar.2005.03.024; O'Brien S, 2005, BLOOD, V106, p830A; O'Brien SM, 2003, CANCER, V98, P2657, DOI 10.1002/cncr.11871; Osterborg A, 1996, BRIT J HAEMATOL, V93, P151, DOI 10.1046/j.1365-2141.1996.450989.x; Osterborg A, 1997, J CLIN ONCOL, V15, P1567, DOI 10.1200/JCO.1997.15.4.1567; Osterborg A, 2006, SEMIN ONCOL, V33, pS29, DOI 10.1053/j.seminoncol.2006.01.027; Perez-Simon JA, 2002, BLOOD, V100, P3121, DOI 10.1182/blood-2002-03-0701; Perkins JG, 2002, CANCER-AM CANCER SOC, V94, P2033, DOI 10.1002/cncr.0680; Rai KR, 2002, J CLIN ONCOL, V20, P3891, DOI 10.1200/JCO.2002.06.119; Ratzinger G, 2003, BLOOD, V101, P1422, DOI 10.1182/blood-2002-04-1093; Robak T, 2005, BIODRUGS, V19, P9, DOI 10.2165/00063030-200519010-00002; Rossmann E D, 2001, Hematol J, V2, P300, DOI 10.1038/sj.thj.6200119; Rowan W, 1998, IMMUNOLOGY, V95, P427; ROZMAN C, 1995, NEW ENGL J MED, V333, P1052, DOI 10.1056/NEJM199510193331606; Smolewski P, 2005, LEUKEMIA LYMPHOMA, V46, P87, DOI 10.1080/13693780400007151; Sorror ML, 2005, J CLIN ONCOL, V23, P3819, DOI 10.1200/JCO.2005.04.569; Stanglmaier M, 2004, ANN HEMATOL, V83, P634, DOI 10.1007/s00277-004-0917-0; Stilgenbauer S, 2002, NEW ENGL J MED, V347, P452, DOI 10.1056/NEJM200208083470619; Watanabe T, 2006, CLIN IMMUNOL, V120, P247, DOI 10.1016/j.clim.2006.05.006; Wendtner CM, 2004, LEUKEMIA, V18, P1093, DOI 10.1038/sj.leu.2403354; Wierda W, 2004, BLOOD, V104, p101A, DOI 10.1182/blood.V104.11.340.340; Wing MG, 1996, J CLIN INVEST, V98, P2819, DOI 10.1172/JCI119110; XIA MQ, 1993, MOL IMMUNOL, V30, P1089; XIA MQ, 1993, BIOCHEM J, V293, P633, DOI 10.1042/bj2930633; Zent CS, 2004, LEUKEMIA RES, V28, P495, DOI 10.1016/j.leukres.2003.09.011; Zhang ML, 2006, BLOOD, V108, P705, DOI 10.1182/blood-2005-11-4607	75	81	93	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2007	26	25					3644	3653		10.1038/sj.onc.1210380	http://dx.doi.org/10.1038/sj.onc.1210380			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	172PK	17530018				2022-12-28	WOS:000246816100007
J	Klein, E; Kis, LL; Klein, G				Klein, E.; Kis, L. L.; Klein, G.			Epstein-Barr virus infection in humans: from harmless to life endangering virus-lymphocyte interactions	ONCOGENE			English	Review						EBV; mononucleosis; lymphomas; B-CLL; cytokines	REED-STERNBERG CELLS; CENTER B-CELLS; LATENT MEMBRANE-PROTEIN; CLASSICAL HODGKIN LYMPHOMA; REGULATORY T-CELLS; BURKITTS-LYMPHOMA; GENE-EXPRESSION; NASOPHARYNGEAL CARCINOMA; TRANSCRIPTION FACTORS; LEUKEMIC-CELLS	After the primary infection, that may or may not cause infectious mononucleosis, the ubiquitous Epstein - Barr virus (EBV) is carried for lifetime. The great majority of adult humans are virus carriers. EBV was discovered in a B-cell lymphoma (Burkitt lymphoma). EBV infection in humans is the example for the power of immune surveillance against virus transformed, potentially malignant cells. Although the virus can transform B lymphocytes in vitro into proliferating lines, it induces malignancy directly only in immunosuppressed hosts. EBV-induced growth transformation occurs only in B lymphocytes. It is the result of a complex interaction between virally encoded and cellular proteins. Different forms of the virus - cell and the cell - host interactions have evolved during a long period of coexistence between the virus and all Old World ( but not New World) primates. The asymptomatic carrier state is based on a viral-strategy that downregulates the expression of the transforming proteins in the virus-carrying cell. In addition to the silent viral-gene carriers and the expressors of the nine virus-encoded genes that drive the growth program, virus carrying cells exist that show other patterns of gene expression, depending on the differentiated state of the host cell. Certain combinations contribute to malignant transformation, but only in conjunction with additional cellular changes. These are induced by direct or cytokine-mediated interactions with normal cells of the immune system.	Karolinska Inst, Dept Microbiol Tumor & Cell Biol, MTC, Tumor & Cell Biol Ctr, S-17177 Stockholm, Sweden	Karolinska Institutet	Klein, E (corresponding author), Karolinska Inst, Dept Microbiol Tumor & Cell Biol, MTC, Tumor & Cell Biol Ctr, S-17177 Stockholm, Sweden.	eva.klein@ki.se						AB RICKINSON, 2001, FIELDS VIROLOGY, P2575; ABBOT SD, 1990, J VIROL, V64, P2126, DOI 10.1128/JVI.64.5.2126-2134.1990; ALTIOK E, 1992, P NATL ACAD SCI USA, V89, P905, DOI 10.1073/pnas.89.3.905; ALTIOK E, 1992, P NATL ACAD SCI USA, V89, P6225; Atayar C, 2006, J PATHOL, V208, P423, DOI 10.1002/path.1894; Babcock GJ, 1998, IMMUNITY, V9, P395, DOI 10.1016/S1074-7613(00)80622-6; Bandobashi K, 2005, VIRUS GENES, V30, P323, DOI 10.1007/s11262-004-6774-z; Bargou RC, 1997, J CLIN INVEST, V100, P2961, DOI 10.1172/JCI119849; Baumforth KRN, 2005, BLOOD, V106, P2138, DOI 10.1182/blood-2005-02-0471; Bechtel D, 2005, BLOOD, V106, P4345, DOI 10.1182/blood-2005-06-2342; Cabannes E, 1999, ONCOGENE, V18, P3063, DOI 10.1038/sj.onc.1202893; Caligaris-Cappio F, 1999, J CLIN ONCOL, V17, P399, DOI 10.1200/JCO.1999.17.1.399; CARBONE A, 1995, AM J PATHOL, V147, P912; Chaganti S, 2005, BLOOD, V106, P4249, DOI 10.1182/blood-2005-06-2327; CHEN F, 1995, J VIROL, V69, P3752, DOI 10.1128/JVI.69.6.3752-3758.1995; CHENG ADY, 1995, GRAVITATION COSMOLOG, V1, P1; Chiang AKS, 1996, INT J CANCER, V68, P285, DOI 10.1002/(SICI)1097-0215(19961104)68:3<285::AID-IJC3>3.0.CO;2-Y; ContrerasBrodin B, 1996, J GEN VIROL, V77, P1159, DOI 10.1099/0022-1317-77-6-1159; CONTRERASBRODIN BA, 1991, J GEN VIROL, V72, P3025, DOI 10.1099/0022-1317-72-12-3025; DEACON EM, 1993, J EXP MED, V177, P339, DOI 10.1084/jem.177.2.339; DOYLE MG, 1993, LEUKEMIA, V7, P1858; Dukers DF, 2000, J IMMUNOL, V165, P663, DOI 10.4049/jimmunol.165.2.663; EPSTEIN MA, 1964, LANCET, V1, P702, DOI 10.1016/s0140-6736(64)91524-7; FAHRAEUS R, 1988, INT J CANCER, V42, P329, DOI 10.1002/ijc.2910420305; FAHRAEUS R, 1990, P NATL ACAD SCI USA, V87, P7390, DOI 10.1073/pnas.87.19.7390; FALK K, 1995, J MED VIROL, V46, P349, DOI 10.1002/jmv.1890460410; FRISAN T, 1995, BLOOD, V86, P1493, DOI 10.1182/blood.V86.4.1493.bloodjournal8641493; HAMMERSCHMIDT W, 1989, NATURE, V340, P393, DOI 10.1038/340393a0; HARABUCHI Y, 1990, LANCET, V335, P128, DOI 10.1016/0140-6736(90)90002-M; HENLE W, 1979, SCI AM, V241, P48, DOI 10.1038/scientificamerican0779-48; Hertel CB, 2002, ONCOGENE, V21, P4908, DOI 10.1038/sj.onc.1205629; Hjalgrim H, 2003, NEW ENGL J MED, V349, P1324, DOI 10.1056/NEJMoa023141; Hochberg D, 2004, P NATL ACAD SCI USA, V101, P239, DOI 10.1073/pnas.2237267100; Horie R, 2002, ONCOGENE, V21, P2493, DOI 10.1038/sj.onc.1205337; Ishida T, 2006, CANCER RES, V66, P5716, DOI 10.1158/0008-5472.CAN-06-0261; Kanzler H, 2000, BLOOD, V95, P1023, DOI 10.1182/blood.V95.3.1023.003k07_1023_1031; Kanzler H, 1996, J EXP MED, V184, P1495, DOI 10.1084/jem.184.4.1495; Kennedy G, 2003, P NATL ACAD SCI USA, V100, P14269, DOI 10.1073/pnas.2336099100; Kis LL, 2006, IMMUNOL LETT, V104, P83, DOI 10.1016/j.imlet.2005.11.003; Kis LL, 2005, INT J CANCER, V113, P937, DOI 10.1002/ijc.20654; KIS LL, 2006, INT J CANCER, V107, P2928; KLEIN G, 1994, CELL, V77, P791, DOI 10.1016/0092-8674(94)90125-2; Komano J, 1999, J VIROL, V73, P9827, DOI 10.1128/JVI.73.12.9827-9831.1999; Kuppers R, 2002, ADV CANCER RES, V84, P277, DOI 10.1016/S0065-230X(02)84009-X; KUPPERS R, 1994, P NATL ACAD SCI USA, V91, P10962, DOI 10.1073/pnas.91.23.10962; Kurth J, 2000, IMMUNITY, V13, P485, DOI 10.1016/S1074-7613(00)00048-0; Kurth J, 2003, P NATL ACAD SCI USA, V100, P4730, DOI 10.1073/pnas.2627966100; LENNETTE ET, 1993, EUR J CANCER, V29A, P1584, DOI 10.1016/0959-8049(93)90299-U; LEVITSKAYA J, 1995, NATURE, V375, P685, DOI 10.1038/375685a0; LEWIN N, 1991, INT J CANCER, V48, P62, DOI 10.1002/ijc.2910480112; Maeda A, 2001, J HUMAN VIROL, V4, P227; Mancao C, 2005, BLOOD, V106, P4339, DOI 10.1182/blood-2005-06-2341; Marshall NA, 2004, BLOOD, V103, P1755, DOI 10.1182/blood-2003-07-2594; Martin-Subero JI, 2002, BLOOD, V99, P1474, DOI 10.1182/blood.V99.4.1474; Nakayama T, 2004, J VIROL, V78, P1665, DOI 10.1128/JVI.78.4.1665-1674.2004; NILSSON K, 1975, INT J CANCER, V15, P321, DOI 10.1002/ijc.2910150217; OUDEJANS JJ, 1995, AM J PATHOL, V147, P923; PALLESEN G, 1991, LANCET, V337, P320, DOI 10.1016/0140-6736(91)90943-J; POPE JH, 1968, INT J CANCER, V3, P857, DOI 10.1002/ijc.2910030619; RICKINSON AB, 1982, CLIN EXP IMMUNOL, V50, P347; Roschke V, 1997, ONCOGENE, V14, P3011, DOI 10.1038/sj.onc.1201156; ROWE M, 1992, J VIROL, V66, P122, DOI 10.1128/JVI.66.1.122-131.1992; ROWE M, 1987, EMBO J, V6, P2743, DOI 10.1002/j.1460-2075.1987.tb02568.x; SCHAEFER BC, 1995, P NATL ACAD SCI USA, V92, P10565, DOI 10.1073/pnas.92.23.10565; Schwering I, 2003, BLOOD, V101, P1505, DOI 10.1182/blood-2002-03-0839; STARATSCHEKJOX A, 2000, HUMAN CELL CULTURE, V3, P339; TAKADA K, 1980, INTERVIROLOGY, V13, P223, DOI 10.1159/000149129; Takahara M, 2006, INT J CANCER, V119, P2775, DOI 10.1002/ijc.22139; Teramoto N, 2000, J HUMAN VIROL, V3, P125; Thorley-Lawson DA, 2001, NAT REV IMMUNOL, V1, P75, DOI 10.1038/35095584; Tierney R, 2000, J VIROL, V74, P10458, DOI 10.1128/JVI.74.22.10458-10467.2000; Tomita Y, 1998, IMMUNOL LETT, V60, P73, DOI 10.1016/S0165-2478(97)00142-9; Tsimberidou AM, 2006, LEUKEMIA LYMPHOMA, V47, P827, DOI 10.1080/10428190500398856; Tsuge I, 1999, CLIN EXP IMMUNOL, V115, P385; van den Berg A, 1999, AM J PATHOL, V154, P1685, DOI 10.1016/S0002-9440(10)65424-7; Vockerodt M, 2002, BRIT J HAEMATOL, V119, P640, DOI 10.1046/j.1365-2141.2002.03894.x; WALLS EV, 1989, INT J CANCER, V44, P846, DOI 10.1002/ijc.2910440517; WANG FH, 1990, CATHAYA, V2, P1; YOUNG L, 1989, NEW ENGL J MED, V321, P1080, DOI 10.1056/NEJM198910193211604; Zhang Y, 2003, BRIT J HAEMATOL, V121, P805, DOI 10.1046/j.1365-2141.2003.04359.x	80	119	128	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 26	2007	26	9					1297	1305		10.1038/sj.onc.1210240	http://dx.doi.org/10.1038/sj.onc.1210240			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	141DU	17322915				2022-12-28	WOS:000244558700007
J	Moussa, O; Riker, J; Klein, J; Fraig, M; Halushka, P; Watson, D				Moussa, O.; Riker, Jm; Klein, J.; Fraig, M.; Halushka, Pv; Watson, Dk			Inhibition of thromboxane synthase activity modulates bladder cancer cell responses to chemotherapeutic agents	ONCOGENE			English	Article						bladder cancer; thromboxane synthase; chemosensitivity	INTRACELLULAR ACCUMULATION; LINES; CIS-DIAMMINEDICHLOROPLATINUM(II); CARCINOMA; CISPLATIN; APOPTOSIS; A(2); PACLITAXEL; RESISTANCE; MIGRATION	Recently, we reported prognostic significance of thromboxane synthase (TXAS) gene expression in invasive bladder cancer. The positive correlation between elevated TXAS expression and shorter patient survival supports a potential role for TXAS-regulated pathways in tumor metastases. In this study, using immunohistochemical analysis, we found an increased expression of TXAS protein in bladder cancer. Treatment of T24 and transitional cell carcinoma TCC-SUP bladder cancer cells with the TXAS inhibitors furegrelate or ozagrel induced an apoptotic effect measured as an increase in caspase-3 activation and cell death, and decreased survivin expression. Pharmacological inhibition of TXAS using the TXAS inhibitor furegrelate increased sensitivity to the chemotherapeutic agents cisplatin and paclitaxel. Molecular inhibition of TXAS expression by siRNA significantly decreased cell growth and migration. In concordance with the pharmacological data, siRNA-mediated reduction of TXAS expression increased sensitivity to cisplatin and paclitaxel in T24 and TCC-SUP cells. In summary, the data support a role for the thromboxane A(2) pathway in the pathogenesis of bladder cancer and the potential utility of modulation of this signaling pathway for cancer chemotherapy.	[Moussa, O.; Riker, Jm; Klein, J.; Watson, Dk] Med Univ S Carolina, Hollings Canc Ctr, Charleston, SC 29425 USA; [Moussa, O.; Riker, Jm; Klein, J.; Fraig, M.; Watson, Dk] Med Univ S Carolina, Dept Pathol & Lab Med, Charleston, SC 29425 USA; [Halushka, Pv] Med Univ S Carolina, Dept Pathol & Lab Med, Charleston, SC 29425 USA; [Halushka, Pv] Med Univ S Carolina, Dept Pharmacol, Charleston, SC 29425 USA; [Halushka, Pv] Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA; [Watson, Dk] Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA	Medical University of South Carolina; Medical University of South Carolina; Medical University of South Carolina; Medical University of South Carolina; Medical University of South Carolina; Medical University of South Carolina	Moussa, O (corresponding author), Med Univ S Carolina, Hollings Canc Ctr, Room 313,86 Jonathan Lucas St, Charleston, SC 29425 USA.	moussa@musc.edu	Fraig, Mostafa M/I-1670-2016	Fraig, Mostafa M/0000-0003-1119-3672				Bando T, 1997, ANTICANCER RES, V17, P3345; Bando T, 1998, ANTICANCER RES, V18, P1079; Bando T, 1998, ANTICANCER RES, V18, P1085; Bokemeyer C, 1998, WORLD J UROL, V16, P155, DOI 10.1007/s003450050044; Calabro Fabio, 2002, Curr Opin Urol, V12, P441, DOI 10.1097/00042307-200209000-00013; Giese A, 1999, Neuro Oncol, V1, P3, DOI 10.1093/neuonc/1.1.3; Hour TC, 2000, ANTICANCER RES, V20, P3221; Jantke J, 2004, ACTA NEUROCHIR, V146, P483, DOI 10.1007/s00701-004-0238-z; Jariyawat S, 1997, BIOCHEM MOL BIOL INT, V42, P113; Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43; Kamath K, 2005, J BIOL CHEM, V280, P12902, DOI 10.1074/jbc.M414477200; Kasahara K, 1996, BRIT J CANCER, V74, P1553, DOI 10.1038/bjc.1996.588; Kim E, 2003, ONCOGENE, V22, P7716, DOI 10.1038/sj.onc.1207155; Moussa O, 2005, CANCER RES, V65, P11581, DOI 10.1158/0008-5472.CAN-05-1622; MURPHY S, 1990, GLIA, V3, P205, DOI 10.1002/glia.440030307; Nie DT, 2004, AM J PATHOL, V164, P429, DOI 10.1016/S0002-9440(10)63133-1; PASCUAL J, 1988, PROSTAG LEUKOTR ESS, V33, P53, DOI 10.1016/0952-3278(88)90123-8; Pradono P, 2002, CANCER RES, V62, P63; Safirstein R, 1985, AM J PHYSIOL, V249, P490; Sakai H, 2006, FEBS LETT, V580, P3368, DOI 10.1016/j.febslet.2006.05.007; SCHIFF PB, 1979, NATURE, V277, P665, DOI 10.1038/277665a0; Stein JP, 2001, J CLIN ONCOL, V19, P666, DOI 10.1200/JCO.2001.19.3.666; WALD M, 1989, BIOCHEM PHARMACOL, V38, P3347, DOI 10.1016/0006-2952(89)90633-3; Watkins Gareth, 2005, Int Semin Surg Oncol, V2, P23, DOI 10.1186/1477-7800-2-23; Yoshizato K, 2002, NEUROSURGERY, V50, P343, DOI 10.1097/00006123-200202000-00021	25	34	34	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 3	2008	27	1					55	62		10.1038/sj.onc.1210629	http://dx.doi.org/10.1038/sj.onc.1210629			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	247YO	17603559				2022-12-28	WOS:000252118700006
J	Jin, W; Yun, C; Kwak, MK; Kim, TA; Kim, SJ				Jin, W.; Yun, C.; Kwak, M-K; Kim, T-A; Kim, S-J			TrkC binds to the type II TGF-beta receptor to suppress TGF-beta signaling	ONCOGENE			English	Article						neurotrophin receptors; TrkC; TGF-beta; cancer; signaling; ETV6-NTRK3	ETV6-NTRK3 GENE FUSION; GASTRIC-CANCER CELLS; HUMAN NEUROBLASTOMAS; EXPRESSION; TUMORS; NEUROTROPHINS; INHIBITOR; PROGNOSIS; PROSTATE; COMPLEX	Growing evidence suggests that overexpression of TrkC, a member of the Trk family of neurotrophin receptors, could drive tumorigenesis, invasion and metastatic capability in cancer cells. However, relatively little is known about the mechanism of TrkC-mediated oncogenesis. The TrkC gene is a partner of the Tel-TrkC (ETV6-NTRK3) chimeric tyrosine kinase, a potent oncoprotein expressed in tumors derived from multiple cell lineages. Recently, we have shown that ETV6-NTRK3 suppresses transforming growth factor-beta (TGF-beta) signaling by directly binding to the type II TGF-beta receptor (TbRII). Here, we report that expression of TrkC also suppresses TGF-beta-induced Smad2/3 phosphorylation and transcriptional activation. Silencing TrkC expression by small interfering RNA in the highly metastatic 4T1 mammary tumor cell line expressing endogenous TrkC significantly enhanced TGF-beta-induced Smad2/3 phosphorylation and restored TGF-b growth inhibitory activity. In contrast, expression of TrkC in 67NR cells, in which TrkC is not expressed, suppressed TGF-beta transcriptional activation. Moreover, we show that TrkC directly binds to the TbRII, thereby preventing it from interacting with the type I TGF-beta receptor (T beta RI). These results indicate that TrkC is an inhibitor of TGF-beta tumor suppressor activity.	[Jin, W.; Yun, C.; Kwak, M-K; Kim, T-A; Kim, S-J] NCI, Lab Canc Biol & Genet, NIH, Bethesda, MD 20892 USA; [Kim, S-J] Gachon Univ Med & Sci, Lee Gil Ya Canc & Diabet Inst, Lab Cell Regulat & Carcinogenesis, Inchon, South Korea	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Gachon University	Kim, SJ (corresponding author), NCI, Lab Canc Biol & Genet, NIH, Bldg 37,Room 5046D,9000 Rockville Pike, Bethesda, MD 20892 USA.	kims@mail.nih.gov			Intramural NIH HHS Funding Source: Medline	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Bardelli A, 2003, SCIENCE, V300, P949, DOI 10.1126/science.1082596; Brodeur GM, 1997, J NEURO-ONCOL, V31, P49, DOI 10.1023/A:1005729329526; Chang J, 1997, CANCER RES, V57, P2856; Chao MV, 2002, NEURON, V33, P9, DOI 10.1016/S0896-6273(01)00573-6; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Douma S, 2004, NATURE, V430, P1034, DOI 10.1038/nature02765; Eguchi M, 1999, BLOOD, V93, P1355, DOI 10.1182/blood.V93.4.1355; Grotzer MA, 2000, J CLIN ONCOL, V18, P1027, DOI 10.1200/JCO.2000.18.5.1027; Guate JL, 1999, BJU INT, V84, P495; Hahm KB, 1999, NAT GENET, V23, P222, DOI 10.1038/13854; Hisaoka M, 2002, J PATHOL, V197, P661, DOI 10.1002/path.1138; Horton CD, 2001, J NEUROCHEM, V76, P201, DOI 10.1046/j.1471-4159.2001.00017.x; Jin W, 2005, P NATL ACAD SCI USA, V102, P16239, DOI 10.1073/pnas.0503137102; Kim SJ, 2000, CYTOKINE GROWTH F R, V11, P159, DOI 10.1016/S1359-6101(99)00039-8; Knezevich SR, 1998, NAT GENET, V18, P184, DOI 10.1038/ng0298-184; Lee BI, 2001, CANCER RES, V61, P931; Markowitz Sanford D., 1996, Cytokine and Growth Factor Reviews, V7, P93, DOI 10.1016/1359-6101(96)00001-9; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Nakagawara A, 2001, CANCER LETT, V169, P107, DOI 10.1016/S0304-3835(01)00530-4; PARK KC, 1994, P NATL ACAD SCI USA, V91, P8772, DOI 10.1073/pnas.91.19.8772; Rickert CH, 2004, J NEUROPATH EXP NEUR, V63, P1211, DOI 10.1093/jnen/63.12.1211; ROBERTS AB, 1993, GROWTH FACTORS, V8, P1; Ruggeri BA, 1999, CURR MED CHEM, V6, P845; Ryden M, 1996, BRIT J CANCER, V74, P773, DOI 10.1038/bjc.1996.435; Satoh F, 2001, INT J UROL, V8, pS28, DOI 10.1046/j.1442-2042.2001.00331.x; SEGAL RA, 1994, P NATL ACAD SCI USA, V91, P12867, DOI 10.1073/pnas.91.26.12867; SUN LZ, 1994, J BIOL CHEM, V269, P26449; Tognon C, 2002, CANCER CELL, V2, P367, DOI 10.1016/S1535-6108(02)00180-0; WIESER R, 1995, EMBO J, V14, P2199, DOI 10.1002/j.1460-2075.1995.tb07214.x; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; Yamashiro DJ, 1997, EUR J CANCER, V33, P2054, DOI 10.1016/S0959-8049(97)00309-2; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1	32	26	26	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 6	2007	26	55					7684	7691		10.1038/sj.onc.1210571	http://dx.doi.org/10.1038/sj.onc.1210571			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	239SK	17546043				2022-12-28	WOS:000251537800010
J	Wells, V; Downward, J; Mallucci, L				Wells, V.; Downward, J.; Mallucci, L.			Functional inhibition of PI3K by the beta GBP molecule suppresses Ras-MAPK signalling to block cell proliferation	ONCOGENE			English	Article						beta GBP; beta-galactoside binding protein; PI3K; Ras; MAPK	GALACTOSIDE-BINDING-PROTEIN; NEGATIVE GROWTH-FACTOR; PHOSPHOINOSITIDE 3-KINASE; KINASE; CANCER; ACTIVATION; CHROMOSOME-22; ABNORMALITIES; EXPRESSION; SARCOMA	The mechanisms of signal transduction from cell surface receptors to the interior of the cell are fundamental to the understanding of the role that positive and negative growth factors play in cell physiology and in human diseases. Here, we show that a functional link between phosphatidylinositol-3-OH kinase (PI3K) and Ras is suppressed by the beta-galactoside binding protein (bGBP) molecule, a cytokine and a negative cell-cycle regulator. Ras-mitogen-activated protein kinase (MAPK) signalling is blocked by bGBP owing to its ability to inhibit the p110 catalytic subunit of PI3K, whose basal activity is required for Ras activation. Functional inhibition of p110 by bGBP results in downregulation of PI3K activity, suppression of Ras-GTP loading, consequent loss of MAPK activation and block of cell proliferation. This study sheds light on the molecular mechanisms whereby bGBP can control cell proliferation and, by extension, may potentially control tumorigenesis by controlling PI3K.	[Wells, V.; Mallucci, L.] Kings Coll London, Pharmaceut Sci Res Div, Cell Signalling & Growth Lab, London SE1 9NH, England; [Downward, J.] Canc Res UK, Lincolns Inn Fields Labs, London Res Inst, Signal Transduct Lab, London, England	University of London; King's College London; Cancer Research UK	Mallucci, L (corresponding author), Kings Coll London, Pharmaceut Sci Res Div, Cell Signalling & Growth Lab, Franklin Wilkins Bldg,150 Stamford St, London SE1 9NH, England.	livio.mallucci@kcl.ac.uk	Downward, Julian/A-3251-2012	Downward, Julian/0000-0002-2331-4729				AURIAS A, 1984, CANCER GENET CYTOGEN, V12, P21, DOI 10.1016/0165-4608(84)90003-7; BALDINI A, 1993, GENOMICS, V15, P216, DOI 10.1006/geno.1993.1039; Blaser C, 1998, EUR J IMMUNOL, V28, P2311, DOI 10.1002/(SICI)1521-4141(199808)28:08<2311::AID-IMMU2311>3.0.CO;2-G; BRIDGE JA, 1990, AM J CLIN PATHOL, V93, P26, DOI 10.1093/ajcp/93.1.26; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; CHIARIOTTI L, 1991, BIOCHIM BIOPHYS ACTA, V1089, P54, DOI 10.1016/0167-4781(91)90084-Y; Downward J, 2003, NAT REV CANCER, V3, P11, DOI 10.1038/nrc969; FINNEY RE, 1993, CURR BIOL, V3, P805, DOI 10.1016/0960-9822(93)90214-9; Garcia Z, 2006, EMBO J, V25, P655, DOI 10.1038/sj.emboj.7600967; Hawes BE, 1996, J BIOL CHEM, V271, P12133, DOI 10.1074/jbc.271.21.12133; Hennessy BT, 2005, NAT REV DRUG DISCOV, V4, P988, DOI 10.1038/nrd1902; HIRABAYASHI J, 1989, FEBS LETT, V250, P161, DOI 10.1016/0014-5793(89)80711-2; Kharitonenkov A, 1997, NATURE, V386, P181, DOI 10.1038/386181a0; KOCH WJ, 1994, P NATL ACAD SCI USA, V91, P12706, DOI 10.1073/pnas.91.26.12706; Leopoldt D, 1998, J BIOL CHEM, V273, P7024, DOI 10.1074/jbc.273.12.7024; Mallucci L, 2003, BIOCHEM PHARMACOL, V66, P1563, DOI 10.1016/S0006-2952(03)00512-4; Mitin N, 2005, CURR BIOL, V15, pR563, DOI 10.1016/j.cub.2005.07.010; PANAYOTOU G, 1992, EMBO J, V11, P4261, DOI 10.1002/j.1460-2075.1992.tb05524.x; POWIS G, 1994, CANCER RES, V54, P2419; Ravatn R, 2005, CANCER RES, V65, P1631, DOI 10.1158/0008-5472.CAN-04-1970; REY JA, 1993, CANCER GENET CYTOGEN, V66, P1, DOI 10.1016/0165-4608(93)90140-H; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; Schonwasser DC, 1998, MOL CELL BIOL, V18, P790, DOI 10.1128/MCB.18.2.790; Suire S, 2005, CURR BIOL, V15, P566, DOI 10.1016/j.cub.2005.02.020; TURCCAREL C, 1988, CANCER GENET CYTOGEN, V30, P145, DOI 10.1016/0165-4608(88)90103-3; Vanhaesebroeck B, 2001, ANNU REV BIOCHEM, V70, P535, DOI 10.1146/annurev.biochem.70.1.535; Vanhaesebroeck B, 1997, TRENDS BIOCHEM SCI, V22, P267, DOI 10.1016/S0968-0004(97)01061-X; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Walker EH, 2000, MOL CELL, V6, P909, DOI 10.1016/S1097-2765(05)00089-4; WELLS V, 1992, BIOCHIM BIOPHYS ACTA, V1121, P239, DOI 10.1016/0167-4838(92)90152-4; WELLS V, 1991, CELL, V64, P91, DOI 10.1016/0092-8674(91)90211-G; Wennstrom S, 1999, MOL CELL BIOL, V19, P4279	33	23	24	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 6	2007	26	55					7709	7714		10.1038/sj.onc.1210580	http://dx.doi.org/10.1038/sj.onc.1210580			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	239SK	17603562				2022-12-28	WOS:000251537800013
J	Yang, HY; Wen, YY; Lin, YI; Pham, L; Su, CH; Yang, H; Chen, J; Lee, MH				Yang, H-Y; Wen, Y-Y; Lin, Y-I; Pham, L.; Su, C-H; Yang, H.; Chen, J.; Lee, M-H			Roles for negative cell regulator 14-3-3 sigma in control of MDM2 activities	ONCOGENE			English	Article						MDM2; 14-3-3; NEDDylation; p53; RB	NUCLEAR EXPORT; DNA-DAMAGE; P53; PROTEIN; CANCER; DOMAIN; AMPLIFICATION; PROGRESSION; INHIBITOR	The 14-3-3 sigma, upregulated by p53 in response to DNA damage, can have a positive-feedback impact driving p53 activities and is a human cancer epithelial marker downregulated in various tumors. However, the precise roles of 14-3-3 sigma during tumorigenesis are not well characterized. Here, we show that 14-3-3 sigma is a critical regulator of murine double minute oncogene (MDM2). 14-3-3 sigma interacts with MDM2 at the RING domain. The C-terminal region of 14-3-3 sigma binds to MDM2 very efficiently. Importantly, 14-3-3 sigma overexpression leads to destabilization of MDM2 through enhancing MDM2 self-ubiquitination and accelerating turnover rate. Conversely, loss of 14-3-3 sigma results in a significant increase in MDM2 protein. Moreover, live-cell images indicated that 14-3-3 sigma can affect the location of MDM2 from the nucleus to the cytoplasm, and that MDM2-mediated cytoplasmic localization of p53 can be reversed by the presence of 14-3-3 sigma. Significantly, we further showed that 14-3-3 sigma causes MDM2 downregulation, thereby stabilizing p53 and inhibiting tumor growth in animal tumors. Also, 14-3-3 sigma blocks MDM2-mediated retinoblastoma degradation and p53 NEDDylation. Our results provide evidence that 14-3-3 sigma is a pivotal MDM2 regulator involved in blocking a variety of activities of MDM2.	Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA; Univ Texas, Grad Sch Biomed Sci, Program Gen & Dev, Houston, TX USA; Univ Texas, Grad Sch Biomed Sci, Program Canc Biol, Houston, TX USA; Zhongshan Univ, Dept Pathophysiol, Guangzhou, Peoples R China; Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Texas System; Sun Yat Sen University; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida	Lee, MH (corresponding author), Univ Texas, MD Anderson Canc Ctr, 1515 Holcombe Blvd, Houston, TX 77030 USA.	mhlee@mdanderson.org		Phan, Liem/0000-0003-1194-216X; Lee, Mong-Hong/0000-0001-8675-8215	NATIONAL CANCER INSTITUTE [R01CA089266, P30CA016672, R56CA089266] Funding Source: NIH RePORTER; NCI NIH HHS [CA16672, R01 CA089266, R56 CA089266, R01CA089266] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188; Fang SY, 2000, J BIOL CHEM, V275, P8945, DOI 10.1074/jbc.275.12.8945; Ferguson AT, 2000, P NATL ACAD SCI USA, V97, P6049, DOI 10.1073/pnas.100566997; Fu HA, 2000, ANNU REV PHARMACOL, V40, P617, DOI 10.1146/annurev.pharmtox.40.1.617; Geyer RK, 2000, NAT CELL BIOL, V2, P569, DOI 10.1038/35023507; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Iwakuma T, 2003, MOL CANCER RES, V1, P993; Laronga C, 2000, J BIOL CHEM, V275, P23106, DOI 10.1074/jbc.M905616199; LEE MH, 1995, GENE DEV, V9, P639, DOI 10.1101/gad.9.6.639; Lee MH, 2006, SEMIN CANCER BIOL, V16, P225, DOI 10.1016/j.semcancer.2006.03.009; Miwa S, 2006, BIOCHEM BIOPH RES CO, V340, P54, DOI 10.1016/j.bbrc.2005.11.148; Momand J, 1998, NUCLEIC ACIDS RES, V26, P3453, DOI 10.1093/nar/26.15.3453; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; Sdek P, 2005, MOL CELL, V20, P699, DOI 10.1016/j.molcel.2005.10.017; Stommel JM, 1999, EMBO J, V18, P1660, DOI 10.1093/emboj/18.6.1660; Wang LK, 2005, HANDB ENVIRON ENG, V2, P1; Xirodimas DP, 2004, CELL, V118, P83, DOI 10.1016/j.cell.2004.06.016; Yang HL, 2006, CANCER RES, V66, P3096, DOI 10.1158/0008-5472.CAN-05-3620; Yang HY, 2003, MOL CELL BIOL, V23, P7096, DOI 10.1128/MCB.23.20.7096-7107.2003; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1; Zhang RW, 2000, CURR PHARM DESIGN, V6, P393, DOI 10.2174/1381612003400911; Zhou BHP, 2001, NAT CELL BIOL, V3, P973, DOI 10.1038/ncb1101-973	23	41	43	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 15	2007	26	52					7355	7362		10.1038/sj.onc.1210540	http://dx.doi.org/10.1038/sj.onc.1210540			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	231NP	17546054				2022-12-28	WOS:000250955700007
J	Yuen, JSP; Cockman, ME; Sullivan, M; Protheroe, A; Turner, GDH; Roberts, IS; Pugh, CW; Werner, H; Macaulay, VM				Yuen, J. S. P.; Cockman, M. E.; Sullivan, M.; Protheroe, A.; Turner, G. D. H.; Roberts, I. S.; Pugh, C. W.; Werner, H.; Macaulay, V. M.			The VHL tumor suppressor inhibits expression of the IGF1R and its loss induces IGF1R upregulation in human clear cell renal carcinoma	ONCOGENE			English	Article						type IIGF receptor; renal cancer; VHL; Sp1; HuR	GROWTH-FACTOR-I; MESSENGER-RNA TURNOVER; LINDAU GENE-PRODUCT; FACTOR RECEPTOR; COLORECTAL-CANCER; PROSTATE-CANCER; HIF-ALPHA; HYPOXIA; BINDING; PROTEIN	Clear cell renal cell cancer (CC-RCC) is a highly chemoresistant tumor characterized by frequent inactivation of the von Hippel-Lindau (VHL) gene. The prognosis is reportedly worse in patients whose tumors express immunoreactive type I insulin-like growth factor receptor (IGF1R), a key mediator of tumor cell survival. We aimed to investigate how IGF1R expression is regulated, and found that IGF1R protein levels were unaffected by hypoxia, but were higher in CC-RCC cells harboring mutant inactive VHL than in isogenic cells expressing wild-type (WT) VHL. IGF1R mRNA and promoter activities were significantly lower in CC-RCC cells expressing WT VHL, consistent with a transcriptional effect. In Sp1-null Drosophila Schneider cells, IGF1R promoter activity was dependent on exogenous Sp1, and was suppressed by full-length VHL protein (pVHL) but only partially by truncated VHL lacking the Sp1-binding motif. pVHL also reduced the stability of IGF1R mRNA via sequestration of HuR protein. Finally, IGF1R mRNA levels were significantly higher in CC-RCC biopsies than benign kidney, confirming the clinical relevance of these findings. Thus, we have identified a new hypoxia-independent role for VHL in suppressing IGF1R transcription and mRNA stability. VHL inactivation leads to IGF1R upregulation, contributing to renal tumorigenesis and potentially also to chemoresistance.	Univ Oxford, John Radcliffe Hosp, Weatherall Inst Mol Med, Canc Res UK Lab, Oxford OX3 9DS, England; Henry Wellcome Bldg Mol Pathol, Oxford, England; Churchill Hosp, Dept Urol, Oxford OX3 7LJ, England; Churchill Hosp, Dept Med Oncol, Oxford OX3 7LJ, England; John Radcliffe Hosp, Dept Cell Pathol, Oxford OX3 9DU, England; Tel Aviv Univ, Sackler Sch Med, IL-69978 Tel Aviv, Israel	Cancer Research UK; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; Tel Aviv University; Sackler Faculty of Medicine	Macaulay, VM (corresponding author), Univ Oxford, John Radcliffe Hosp, Weatherall Inst Mol Med, Canc Res UK Lab, Headley Way, Oxford OX3 9DS, England.	macaulay@cancer.org.uk	Cockman, Matthew/V-9619-2019	Cockman, Matthew/0000-0002-3310-4821; Pugh, Chris/0000-0002-5170-1662	MRC [G0601061] Funding Source: UKRI; Medical Research Council [G0601061] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Abramovitch S, 2003, FEBS LETT, V541, P149, DOI 10.1016/S0014-5793(03)00315-6; Ahmad N, 2004, HUM PATHOL, V35, P1132, DOI 10.1016/j.humpath.2004.05.012; Banks RE, 2006, CANCER RES, V66, P2000, DOI 10.1158/0008-5472.CAN-05-3074; Bohula EA, 2003, J BIOL CHEM, V278, P15991, DOI 10.1074/jbc.M300714200; Chen CYA, 2002, MOL CELL BIOL, V22, P7268, DOI 10.1128/MCB.22.20.7268-7278.2002; Cockman ME, 2000, J BIOL CHEM, V275, P25733, DOI 10.1074/jbc.M002740200; Cohen HT, 1999, BIOCHEM BIOPH RES CO, V266, P43, DOI 10.1006/bbrc.1999.1767; Conaway RC, 2002, ADV CANCER RES, V85, P1, DOI 10.1016/S0065-230X(02)85001-1; COOKE DW, 1991, BIOCHEM BIOPH RES CO, V177, P1113, DOI 10.1016/0006-291X(91)90654-P; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; Datta K, 2000, J BIOL CHEM, V275, P20700, DOI 10.1074/jbc.M909970199; Datta K, 2005, ONCOGENE, V24, P7850, DOI 10.1038/sj.onc.1208912; Dunn SE, 1997, CANCER RES, V57, P2687; Fukuda R, 2002, J BIOL CHEM, V277, P38205, DOI 10.1074/jbc.M203781200; Gherzi R, 2004, MOL CELL, V14, P571, DOI 10.1016/j.molcel.2004.05.002; GNARRA JR, 1994, NAT GENET, V7, P85, DOI 10.1038/ng0594-85; Gnarra JR, 1996, P NATL ACAD SCI USA, V93, P10589, DOI 10.1073/pnas.93.20.10589; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; Hakam A, 1999, HUM PATHOL, V30, P1128, DOI 10.1016/S0046-8177(99)90027-8; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; Hellawell GO, 2002, CANCER RES, V62, P2942; Iliopoulos O, 1997, MOL MED, V3, P289, DOI 10.1007/BF03401807; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Kim KW, 1998, CANCER RES, V58, P348; Kruhoffer M, 2005, BRIT J CANCER, V92, P2240, DOI 10.1038/sj.bjc.6602621; Lee S, 2005, CANCER CELL, V8, P155, DOI 10.1016/j.ccr.2005.06.015; Macaulay VM, 2001, ONCOGENE, V20, P4029, DOI 10.1038/sj.onc.1204565; MAMULA PW, 1992, DNA CELL BIOL, V11, P43, DOI 10.1089/dna.1992.11.43; Mandriota SJ, 2002, CANCER CELL, V1, P459, DOI 10.1016/S1535-6108(02)00071-5; Maranchie JK, 2002, CANCER CELL, V1, P247, DOI 10.1016/S1535-6108(02)00044-2; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Meng Z, 2005, NUCLEIC ACIDS RES, V33, P2962, DOI 10.1093/nar/gki603; Mukhopadhyay D, 1997, MOL CELL BIOL, V17, P5629, DOI 10.1128/MCB.17.9.5629; Ohh M, 2000, NAT CELL BIOL, V2, P423, DOI 10.1038/35017054; Ohlsson C, 1998, ENDOCRINOLOGY, V139, P1101, DOI 10.1210/en.139.3.1101; Ord JJ, 2005, BRIT J CANCER, V93, P346, DOI 10.1038/sj.bjc.6602666; Parker AS, 2004, CANCER-AM CANCER SOC, V100, P2577, DOI 10.1002/cncr.20322; Parker AS, 2003, J UROLOGY, V170, P420, DOI 10.1097/01.ju.0000071474.70103.92; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Rafty LA, 2002, J CELL BIOCHEM, V85, P490, DOI 10.1002/jcb.10152; Raineri I, 2004, NUCLEIC ACIDS RES, V32, P1279, DOI 10.1093/nar/gkh282; Riedemann J, 2007, BIOCHEM BIOPH RES CO, V355, P707, DOI 10.1016/j.bbrc.2007.02.012; Rochester MA, 2005, CANCER GENE THER, V12, P90, DOI 10.1038/sj.cgt.7700775; SELL C, 1995, CANCER RES, V55, P303; Semenza GL, 1999, ANNU REV CELL DEV BI, V15, P551, DOI 10.1146/annurev.cellbio.15.1.551; Steinbrech DS, 2000, ANN PLAS SURG, V44, P529, DOI 10.1097/00000637-200044050-00012; Treins C, 2005, MOL ENDOCRINOL, V19, P1304, DOI 10.1210/me.2004-0239; Valentinis, 1997, BIOCHIM BIOPHYS ACTA, V1332, P105; Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034; Werner H, 2000, CELL MOL LIFE SCI, V57, P932, DOI 10.1007/PL00000735; WERNER H, 1994, J BIOL CHEM, V269, P12577; WERNER H, 1992, MOL ENDOCRINOL, V6, P1545, DOI 10.1210/me.6.10.1545; Wykoff CC, 2004, BRIT J CANCER, V90, P1235, DOI 10.1038/sj.bjc.6601657; Zelzer E, 1998, EMBO J, V17, P5085, DOI 10.1093/emboj/17.17.5085	55	70	71	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2007	26	45					6499	6508		10.1038/sj.onc.1210474	http://dx.doi.org/10.1038/sj.onc.1210474			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	217AF	17486080				2022-12-28	WOS:000249919800003
J	Mott, JL; Kobayashi, S; Bronk, SF; Gores, GJ				Mott, J. L.; Kobayashi, S.; Bronk, S. F.; Gores, G. J.			mir-29 regulates Mcl-1 protein expression and apoptosis	ONCOGENE			English	Article						apoptosis; post-transcriptional regulation; cholangiocarcinoma; microRNA; TRAIL	CHOLANGIOCARCINOMA CELLS; INDUCE APOPTOSIS; RESISTANCE; CANCER; GENES; MICRORNAS; MECHANISM; LEUKEMIA; TARGETS; RELAPSE	Cellular expression of Mcl-1, an anti-apoptotic Bcl-2 family member, is tightly regulated. Recently, Bcl-2 expression was shown to be regulated by microRNAs, small endogenous RNA molecules that regulate protein expression through sequence-specific interaction with messenger RNA. By analogy, we reasoned that Mcl-1 expression may also be regulated by microRNAs. We chose human immortalized, but non-malignant, H69 cholangiocyte and malignant KMCH cholangiocarcinoma cell lines for these studies, because Mcl-1 is dysregulated in cells with the malignant phenotype. By in silico analysis, we identified a putative target site in the Mcl-1 mRNA for the mir-29 family, and found that mir-29b was highly expressed in cholangiocytes. Interestingly, mir-29b was downregulated in malignant cells, consistent with Mcl-1 protein upregulation. Enforced mir-29b expression reduced Mcl-1 protein expression in KMCH cells. This effect was direct, as mir-29b negatively regulated the expression of an Mcl-1 30 untranslated region (UTR)based reporter construct. Enforced mir-29b expression reduced Mcl-1 cellular protein levels and sensitized the cancer cells to tumor necrosis factor-related apoptosis-inducing ligand ( TRAIL) cytotoxicity. Transfection of non-malignant cells ( that express high levels of mir-29) with a locked-nucleic acid antagonist of mir-29b increased Mcl-1 levels and reduced TRAIL-mediated apoptosis. Thus mir-29 is an endogenous regulator of Mcl-1 protein expression, and thereby, apoptosis.	Mayo Clin, Coll Med, Miles & Shirley Fiterman Ctr Digest Dis, Div Gastroenterol & Hepatol, Rochester, MN USA	Mayo Clinic	Gores, GJ (corresponding author), Mayo Clin, Coll Med, Rochester, MN 55905 USA.	gores.gregory@mayo.edu		Mott, Justin/0000-0002-2927-6962	NIDDK NIH HHS [R01 DK059427-08, R01 DK059427, DK59427, R56 DK059427] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK059427, R56DK059427] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Calin GA, 2004, P NATL ACAD SCI USA, V101, P2999, DOI 10.1073/pnas.0307323101; Calin GA, 2005, NEW ENGL J MED, V353, P1793, DOI 10.1056/NEJMoa050995; Chen L, 2005, MOL CELL, V17, P393, DOI 10.1016/j.molcel.2004.12.030; Cimmino A, 2005, P NATL ACAD SCI USA, V102, P13944, DOI 10.1073/pnas.0506654102; Cuconati A, 2003, GENE DEV, V17, P2922, DOI 10.1101/gad.1156903; Cummins JM, 2006, P NATL ACAD SCI USA, V103, P3687, DOI 10.1073/pnas.0511155103; Griffiths-Jones S, 2006, NUCLEIC ACIDS RES, V34, pD140, DOI 10.1093/nar/gkj112; Iorio MV, 2005, CANCER RES, V65, P7065, DOI 10.1158/0008-5472.CAN-05-1783; John B, 2004, PLOS BIOL, V2, P1862, DOI 10.1371/journal.pbio.0020363; Kaufmann SH, 1998, BLOOD, V91, P991, DOI 10.1182/blood.V91.3.991.991_991_1000; Kobayashi S, 2005, GASTROENTEROLOGY, V128, P2054, DOI 10.1053/j.gastro.2005.03.010; Konopleva M, 2006, CANCER CELL, V10, P375, DOI 10.1016/j.ccr.2006.10.006; Krek A, 2005, NAT GENET, V37, P495, DOI 10.1038/ng1536; Lagos-Quintana M, 2001, SCIENCE, V294, P853, DOI 10.1126/science.1064921; Lee Y, 2002, EMBO J, V21, P4663, DOI 10.1093/emboj/cdf476; Leu JIJ, 2004, NAT CELL BIOL, V6, P443, DOI 10.1038/ncb1123; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; McManus MT, 2003, SEMIN CANCER BIOL, V13, P253, DOI 10.1016/S1044-579X(03)00038-5; Michels J, 2005, INT J BIOCHEM CELL B, V37, P267, DOI 10.1016/j.biocel.2004.04.007; Neville PJ, 2002, NEOPLASIA, V4, P424, DOI 10.1038/sj.neo.7900254; Nijhawan D, 2003, GENE DEV, V17, P1475, DOI 10.1101/gad.1093903; Opferman JT, 2003, NATURE, V426, P671, DOI 10.1038/nature02067; Taniai M, 2004, CANCER RES, V64, P3517, DOI 10.1158/0008-5472.CAN-03-2770; Valencia-Sanchez MA, 2006, GENE DEV, V20, P515, DOI 10.1101/gad.1399806; van Delft MF, 2006, CELL RES, V16, P203, DOI 10.1038/sj.cr.7310028; Willis SN, 2005, CURR OPIN CELL BIOL, V17, P617, DOI 10.1016/j.ceb.2005.10.001; Wuilleme-Toumi S, 2005, LEUKEMIA, V19, P1248, DOI 10.1038/sj.leu.2403784; Yanaihara N, 2006, CANCER CELL, V9, P189, DOI 10.1016/j.ccr.2006.01.025; Yoon JH, 2002, CANCER RES, V62, P6500; Zhong Q, 2005, CELL, V121, P1085, DOI 10.1016/j.cell.2005.06.009; Zhou P, 2001, BLOOD, V97, P3902, DOI 10.1182/blood.V97.12.3902	32	662	719	0	43	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 13	2007	26	42					6133	6140		10.1038/sj.onc.1210436	http://dx.doi.org/10.1038/sj.onc.1210436			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	209PU	17404574	Green Accepted, Green Submitted			2022-12-28	WOS:000249401300003
J	Yuli, C; Shao, N; Rao, R; Aysola, P; Reddy, V; Oprea-llies, G; Lee, L; Okoli, J; Partridge, E; Reddy, ESP; Rao, VN				Yuli, C.; Shao, N.; Rao, R.; Aysola, P.; Reddy, V.; Oprea-llies, G.; Lee, L.; Okoli, J.; Partridge, E.; Reddy, E. S. P.; Rao, V. N.			BRCA1a has antitumor activity in TN breast, ovarian and prostate cancers	ONCOGENE			English	Article						BRCA1a/1b; ovarian cancers; prostate cancer; tumor suppressor; estrogen receptor; triple-negative breast cancers	MAMMARY EPITHELIAL-CELLS; SPLICE VARIANTS; GENE BRCA1; EXPRESSION; P53; SUPPRESSION; INHIBITION; INTERACTS; DISTINCT; RNA	Breast cancer gene 1 ( BRCA1) mutations predispose women to breast and ovarian cancers and men to increased risks for prostate cancer. We have previously showed BRCA1 splice variant BRCA1a/p110 to induce apoptosis of human breast cancer cells. In the current study, stable expression of BRCA1a/p110 resulted in inhibition of growth of estrogen receptor ( ER)- positive and triple-negative ( TN) human breast, ovarian, prostate and colon cancer cells and mouse fibroblast cells. Similar to wildtype BRCA1, only those cells with wild- type Rb were sensitive to BRCA1a-induced growth suppression and the status of p53 did not affect the ability of BRCA1a to suppress growth of tumor cells. BRCA1a also significantly inhibited tumor mass in nude mice bearing human CAL- 51 TN breast cancer, ES- 2 ovarian cancer and PC- 3 prostate cancer xenografts. These results suggest that the majority of exon 11 sequences ( residues 263 - 1365) are not required for the tumor suppressor function of BRCA1 proteins. This is the first report demonstrating antitumor activity of BRCA1a in human ER- positive and TN breast, hormone-independent ovarian and prostate cancer cells. Currently, there are no effective treatments against TN breast cancers and results from these studies will provide new treatments for one of the biggest needs in breast cancer research.	Grady Hlth Syst, Georgia Canc Ctr Excellence, Morehouse Sch Med,RM 10C011, Dept Obstet & Gynecol,Canc Biol Program, Atlanta, GA 30303 USA; Drexel Univ, Dept Biochem, Program Canc Genet, Philadelphia, PA 19104 USA; Emory Univ, Dept Pathol, Atlanta, GA 30322 USA; Sci Applicat Int Corp, Frederick, MD USA; Grady Hlth Syst, Georgia Canc Ctr Excellence, Morehouse Sch Med, Dept Surg, Atlanta, GA USA; Univ Alabama Birmingham, Ctr Comprehens Canc, Dept Gynecol Oncol, Birmingham, AL USA	Morehouse School of Medicine; Drexel University; Emory University; Science Applications International Corporation (SAIC); Morehouse School of Medicine; University of Alabama System; University of Alabama Birmingham	Rao, VN (corresponding author), Grady Hlth Syst, Georgia Canc Ctr Excellence, Morehouse Sch Med,RM 10C011, Dept Obstet & Gynecol,Canc Biol Program, 80 Jesse Hill Jr Dr, Atlanta, GA 30303 USA.	vrao@msm.edu			NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR011104, G12RR003034] Funding Source: NIH RePORTER; NCRR NIH HHS [SP20RR11104, G-12-RR03034] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Aprelikova ON, 1999, P NATL ACAD SCI USA, V96, P11866, DOI 10.1073/pnas.96.21.11866; Chai YL, 2001, ONCOGENE, V20, P1357, DOI 10.1038/sj.onc.1204256; GIOANNI J, 1990, BRIT J CANCER, V62, P8, DOI 10.1038/bjc.1990.219; Grunberg E, 2000, TUMOR BIOL, V21, P211, DOI 10.1159/000030127; Harkin DP, 1999, CELL, V97, P575, DOI 10.1016/S0092-8674(00)80769-2; Holt JT, 1996, NAT GENET, V12, P298, DOI 10.1038/ng0396-298; Huber LJ, 2001, MOL CELL BIOL, V21, P4005, DOI 10.1128/MCB.21.12.4005-4015.2001; Lu ML, 1996, CANCER RES, V56, P4578; Lu ML, 2000, ONCOGENE, V19, P6351, DOI 10.1038/sj.onc.1204025; Marot D, 2006, GENE THER, V13, P235, DOI 10.1038/sj.gt.3302637; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Orban TI, 2003, J CLIN PATHOL-MOL PA, V56, P191, DOI 10.1136/mp.56.4.191; Orban TI, 2001, BIOCHEM BIOPH RES CO, V280, P32, DOI 10.1006/bbrc.2000.4068; Ouchi T, 1998, P NATL ACAD SCI USA, V95, P2302, DOI 10.1073/pnas.95.5.2302; Randrianarison V, 2001, CANCER GENE THER, V8, P759, DOI 10.1038/sj.cgt.7700366; Rao VN, 1996, ONCOGENE, V12, P523; Rosen ED, 2003, J THROMB HAEMOST, V1, P19, DOI 10.1046/j.1538-7836.2003.00030.x; SHAO Q, 1996, CARDIOVASC PATHOBIOL, V1, P1; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; Tait DL, 2000, GYNECOL ONCOL, V79, P471, DOI 10.1006/gyno.2000.5969; THEILE M, 1995, ONCOGENE, V10, P439; Tischkowitz MD, 2006, CELL CYCLE, V5, P963, DOI 10.4161/cc.5.9.2713; Wang G, 2002, INT J CAST METAL RES, V15, P143; Welcsh PL, 2001, HUM MOL GENET, V10, P705, DOI 10.1093/hmg/10.7.705; Wilson CA, 1997, ONCOGENE, V14, P1, DOI 10.1038/sj.onc.1200924; Yarden RI, 1999, P NATL ACAD SCI USA, V96, P4983, DOI 10.1073/pnas.96.9.4983; You FL, 2004, ONCOGENE, V23, P5792, DOI 10.1038/sj.onc.1207739; Zhang HB, 1998, ONCOGENE, V16, P1713, DOI 10.1038/sj.onc.1201932	28	23	27	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2007	26	41					6031	6037		10.1038/sj.onc.1210420	http://dx.doi.org/10.1038/sj.onc.1210420			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	207US	17384678				2022-12-28	WOS:000249277200006
J	Ma, J; Arnold, HK; Lilly, MB; Sears, RC; Kraft, AS				Ma, J.; Arnold, H. K.; Lilly, M. B.; Sears, R. C.; Kraft, A. S.			Negative regulation of Pim-1 protein kinase levels by the B56 beta subunit of PP2A	ONCOGENE			English	Article						Pim-1; PP2A; B56 beta; protein kinase; Pin1	CONSTITUTIVELY ACTIVATED FLT3; PHOSPHATASE 2A; C-MYC; ALPHA-SUBUNIT; TRANSFORMATION; GROWTH; PIN1; DEGRADATION; STABILITY; SURVIVAL	The Pim protein kinases are serine threonine protein kinases that regulate important cellular signaling pathway molecules, and enhance the ability of c-Myc to induce lymphomas. We demonstrate that a cascade of events controls the cellular levels of Pim. We find that overexpression of the protein phosphatase ( PP) 2A catalytic subunit decreases the activity and protein levels of Pim-1. This effect is reversed by the application of okadaic acid, an inhibitor of PP2A, and is blocked by SV40 small T antigen that is known to disrupt B subunit binding to PP2A A and C subunits. Pim-1 can coimmunoprecipitate with th e PP2A regulatory B subunit, B56 beta, but not B56 alpha, c, delta, e or B55 alpha. Using short hairpin RNA targeted at B56b, we demonstrate that decreasing the level of B56b increases the half-life of Pim-1 from 0.7 to 2.8 h, and decreases the ubiquitinylation level of Pim-1. We also find that Pin1, a prolyl-isomerase, is capable of binding Pim-1 and leads to a decrease in the protein level of Pim-1. On the basis of these observations, we hypothesize that phosphorylated Pim-1 binds Pin1 allowing the interaction of PP2A through B56b. Dephosphorylation of Pim-1 then allows for ubiquitinylation and protein degradation of Pim-1.	Med Univ S Carolina, Hollings Canc Ctr, Charleston, SC 29425 USA; Oregon Hlth & Sci Univ, Dept Mol & Med Genet, Portland, OR 97201 USA; Univ Calif Irvine, Chao Family Comprehens Canc Ctr, Irvine, CA USA	Medical University of South Carolina; Oregon Health & Science University; University of California System; University of California Irvine	Kraft, AS (corresponding author), Med Univ S Carolina, Hollings Canc Ctr, 86 Jonathan Lucas St, Charleston, SC 29425 USA.	kraft@musc.edu			NATIONAL CANCER INSTITUTE [R01CA100855, K01CA086957] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008617] Funding Source: NIH RePORTER; NCI NIH HHS [K01 CA086957, R01 CA100855] Funding Source: Medline; NIGMS NIH HHS [5 T32 GM08617] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adam M, 2006, CANCER RES, V66, P3828, DOI 10.1158/0008-5472.CAN-05-2309; Aho TLT, 2004, FEBS LETT, V571, P43, DOI 10.1016/j.febslet.2004.06.050; Amaravadi R, 2005, J CLIN INVEST, V115, P2618, DOI 10.1172/JCI26273; Arnold HK, 2006, MOL CELL BIOL, V26, P2832, DOI 10.1128/MCB.26.7.2832-2844.2006; Arroyo JD, 2005, ONCOGENE, V24, P7746, DOI 10.1038/sj.onc.1209038; Bachmann M, 2005, INT J BIOCHEM CELL B, V37, P726, DOI 10.1016/j.biocel.2004.11.005; Boudreau RTM, 2005, INT IMMUNOPHARMACOL, V5, P1507, DOI 10.1016/j.intimp.2005.05.007; Campaner S, 2005, MOL CELL BIOL, V25, P6660, DOI 10.1128/MCB.25.15.6660-6672.2005; Chen W, 2004, CANCER CELL, V5, P127, DOI 10.1016/S1535-6108(04)00026-1; Chen WW, 2005, MOL CANCER RES, V3, P443, DOI 10.1158/1541-7786.MCR-05-0007; Chen XP, 2002, P NATL ACAD SCI USA, V99, P2175, DOI 10.1073/pnas.042035699; Cibull TL, 2006, J CLIN PATHOL, V59, P285, DOI 10.1136/jcp.2005.027672; CUYPERS HT, 1984, CELL, V37, P141; Ellwood-Yen K, 2003, CANCER CELL, V4, P223, DOI 10.1016/S1535-6108(03)00197-1; Fox CJ, 2003, GENE DEV, V17, P1841, DOI 10.1101/gad.1105003; Hammerman PS, 2004, CANCER RES, V64, P8341, DOI 10.1158/0008-5472.CAN-04-2284; Ionov Y, 2003, ANTICANCER RES, V23, P167; Janssens IA, 2005, BIOGEOSCIENCES, V2, P15, DOI 10.5194/bg-2-15-2005; Janssens V, 2001, BIOCHEM J, V353, P417, DOI 10.1042/0264-6021:3530417; Kim KT, 2005, BLOOD, V105, P1759, DOI 10.1182/blood-2004-05-2006; Kim KT, 2006, BRIT J HAEMATOL, V134, P500, DOI 10.1111/j.1365-2141.2006.06225.x; Lechward K, 2001, ACTA BIOCHIM POL, V48, P921; Losman JA, 2003, J BIOL CHEM, V278, P4800, DOI 10.1074/jbc.M208246200; Macdonald A, 2006, BMC CELL BIOL, V7, DOI 10.1186/1471-2121-7-1; McCright B, 1996, J BIOL CHEM, V271, P22081, DOI 10.1074/jbc.271.36.22081; Mikkers H, 2004, MOL CELL BIOL, V24, P6104, DOI 10.1128/MCB.24.13.6104-6115.2004; Monje P, 2005, J BIOL CHEM, V280, P35081, DOI 10.1074/jbc.C500353200; Qian KC, 2005, ACTA CRYSTALLOGR F, V61, P96, DOI 10.1107/S1744309104029963; Qian KC, 2005, J BIOL CHEM, V280, P6130, DOI 10.1074/jbc.M409123200; Richardson Paul G, 2005, Future Oncol, V1, P161, DOI 10.1517/14796694.1.2.161; Ruediger R, 2001, ONCOGENE, V20, P1892, DOI 10.1038/sj.onc.1204279; Ruediger R, 2001, ONCOGENE, V20, P10, DOI 10.1038/sj.onc.1204059; Ruvolo PP, 2002, J BIOL CHEM, V277, P22847, DOI 10.1074/jbc.M201830200; Sears RC, 2004, CELL CYCLE, V3, P1133, DOI 10.4161/cc.3.9.1145; SELTEN G, 1985, EMBO J, V4, P1793, DOI 10.1002/j.1460-2075.1985.tb03852.x; Shay KP, 2005, MOL CANCER RES, V3, P170; Shirogane T, 1999, IMMUNITY, V11, P709, DOI 10.1016/S1074-7613(00)80145-4; Stukenberg PT, 2001, MOL CELL, V7, P1071, DOI 10.1016/S1097-2765(01)00245-3; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; Ugi S, 2004, MOL CELL BIOL, V24, P8778, DOI 10.1128/MCB.24.19.8778-8789.2004; Van Hoof C, 2004, CANCER CELL, V5, P105, DOI 10.1016/S1535-6108(04)00027-3; Van Kanegan MJ, 2005, J BIOL CHEM, V280, P36029, DOI 10.1074/jbc.M506986200; VANLOHUIZEN M, 1989, CELL, V56, P673, DOI 10.1016/0092-8674(89)90589-8; VERBEEK S, 1991, MOL CELL BIOL, V11, P1176, DOI 10.1128/MCB.11.2.1176; Wang Z, 2001, J Vet Sci, V2, P167; Xu Y, 2005, J SURG ONCOL, V92, P326, DOI 10.1002/jso.20325; Xu YX, 2003, GENE DEV, V17, P2765, DOI 10.1101/gad.1135503; Yeh E, 2004, NAT CELL BIOL, V6, P308, DOI 10.1038/ncb1110; Zhou XZ, 2000, MOL CELL, V6, P873, DOI 10.1016/S1097-2765(00)00085-X	49	58	58	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 2	2007	26	35					5145	5153		10.1038/sj.onc.1210323	http://dx.doi.org/10.1038/sj.onc.1210323			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	196MT	17297438				2022-12-28	WOS:000248487400013
J	Oricchio, E; Sciamanna, I; Beraldi, R; Tolstonog, GV; Schumann, GG; Spadafora, C				Oricchio, E.; Sciamanna, I.; Beraldi, R.; Tolstonog, G. V.; Schumann, G. G.; Spadafora, C.			Distinct roles for LINE-1 and HERV-K retroelements in cell proliferation, differentiation and tumor progression	ONCOGENE			English	Article						retrotransposons; endogenous retroviruses; cell proliferation; differentiation; tumorigenesis	ENDOGENOUS REVERSE-TRANSCRIPTASE; NUCLEAR LAMINA; EXPRESSION; ENVELOPE; GROWTH; RETROVIRUS; MICE	Transformed cells express high levels of non-telomeric reverse-transcriptase (RT) activity of retrotransposon and endogenous retrovirus origin. We previously reported that RT inhibition, either pharmacological or through transient silencing of RT-encoding LINE-1 (L1) elements by RNA interference (RNAi), reduced proliferation, induced differentiation and reprogrammed gene expression in human tumorigenic cell lines. Moreover, the antiretroviral drug efavirenz antagonized tumor progression in animal models in vivo. To get insight into the role of retroelements in tumorigenesis, we have now produced two cell lines derived from A-375 melanoma, in which the expression of either L1 retrotransposon, or HERV-K endogenous retrovirus, was stably suppressed by RNAi. Compared to the parental A-375 cell line, cells with stably interfered L1 expression show a lower proliferation rate, a differentiated morphology and lower tumorigenicity when inoculated in nude mice. L1 silencing modulates expression of several genes and, unexpectedly, also downregulates HERV-K expression. In HERV-K interfered cells, instead, L1 expression was unaffected, and cell proliferation and differentiation remained unchanged compared to parental A-375 cells. In vivo, however, their tumorigenic potential was found to be reduced after inoculation in nude mice. These results suggest that L1 and HERV-K play specific and distinct roles in cell transformation and tumor progression.	Ist Super Sanita, Serv BGSA, I-00161 Rome, Italy; Univ Roma Tor Vergata, Dept Expt Med & Biochem Sci, Rome, Italy; Univ Siena, Dept Pediat & Obstet, I-53100 Siena, Italy; Univ Hamburg, Heinrich Pette Inst Expt Virol & Immunol, D-2000 Hamburg, Germany; Paul Ehrlich Inst, Div Med Biotechnol, D-6070 Langen, Germany	Istituto Superiore di Sanita (ISS); University of Rome Tor Vergata; University of Siena; Heinrich Pette Institute; University of Hamburg; Paul Ehrlich Institute	Spadafora, C (corresponding author), Ist Super Sanita, Serv BGSA, Viale Regina Elena 299, I-00161 Rome, Italy.	cspadaf@tin.it		Sciamanna, Ilaria/0000-0002-5629-6184; Oricchio, Elisa/0000-0002-1690-0447; Spadafora, Corrado/0000-0002-5743-3224				Batzer MA, 2002, NAT REV GENET, V3, P370, DOI 10.1038/nrg798; Beraldi R, 2006, MOL REPROD DEV, V73, P279, DOI 10.1002/mrd.20423; Blaise S, 2001, J GEN VIROL, V82, P1597, DOI 10.1099/0022-1317-82-7-1597; Brouha B, 2003, P NATL ACAD SCI USA, V100, P5280, DOI 10.1073/pnas.0831042100; Dent P, 2005, J CELL BIOCHEM, V95, P712, DOI 10.1002/jcb.20502; Ergun S, 2004, J BIOL CHEM, V279, P27753, DOI 10.1074/jbc.M312985200; Farag SS, 2006, BLOOD REV, V20, P123, DOI 10.1016/j.blre.2005.10.001; Goldman RD, 2002, GENE DEV, V16, P533, DOI 10.1101/gad.960502; Gruenbaum Y, 2005, NAT REV MOL CELL BIO, V6, P21, DOI 10.1038/nrm1550; Gruenbaum Y, 2003, INT REV CYTOL, V226, P1, DOI 10.1016/S0074-7696(03)01001-5; Han JS, 2005, BIOESSAYS, V27, P775, DOI 10.1002/bies.20257; HASUI M, 1989, CELL IMMUNOL, V120, P230, DOI 10.1016/0008-8749(89)90190-1; Humer J, 2006, CANCER RES, V66, P1658, DOI 10.1158/0008-5472.CAN-05-2452; Kazazian HH, 2004, SCIENCE, V303, P1626, DOI 10.1126/science.1089670; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Landriscina M, 2005, J CLIN ENDOCR METAB, V90, P5663, DOI 10.1210/jc.2005-0367; Mangeney M, 2005, CANCER RES, V65, P2588, DOI 10.1158/0008-5472.CAN-04-4231; Mangeney M, 1998, P NATL ACAD SCI USA, V95, P14920, DOI 10.1073/pnas.95.25.14920; Mangeney M, 2001, J GEN VIROL, V82, P2515, DOI 10.1099/0022-1317-82-10-2515; Mangiacasale R, 2003, ONCOGENE, V22, P2750, DOI 10.1038/sj.onc.1206354; Nickerson JA, 1997, P NATL ACAD SCI USA, V94, P4446, DOI 10.1073/pnas.94.9.4446; ORGEL LE, 1980, NATURE, V284, P604, DOI 10.1038/284604a0; Pittoggi C, 2003, MOL REPROD DEV, V66, P225, DOI 10.1002/mrd.10349; Qian F, 2005, BIOCHEM BIOPH RES CO, V333, P1269, DOI 10.1016/j.bbrc.2005.06.039; Ross DA, 2006, EJSO-EUR J SURG ONC, V32, P80, DOI 10.1016/j.ejso.2005.08.005; Sauter ER, 2002, CANCER RES, V62, P3200; Sciamanna E, 2005, ONCOGENE, V24, P3923, DOI 10.1038/sj.onc.1208562; Shapiro JA, 2005, BIOL REV, V80, P227, DOI 10.1017/S1464793104006657; Sinibaldi-Vallebona P, 2006, GENE CHROMOSOME CANC, V45, P1, DOI 10.1002/gcc.20266; Umekita Y, 1996, P NATL ACAD SCI USA, V93, P11802, DOI 10.1073/pnas.93.21.11802	30	99	105	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 21	2007	26	29					4226	4233		10.1038/sj.onc.1210214	http://dx.doi.org/10.1038/sj.onc.1210214			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	184CY	17237820				2022-12-28	WOS:000247619900005
J	Mohankumar, KM; Xu, XQ; Zhu, T; Kannan, N; Miller, LD; Liu, ET; Gluckman, PD; Sukumar, S; Emerald, BS; Lobie, PE				Mohankumar, K. M.; Xu, X. Q.; Zhu, T.; Kannan, N.; Miller, L. D.; Liu, E. T.; Gluckman, P. D.; Sukumar, S.; Emerald, B. S.; Lobie, P. E.			HOXA1-stimulated oncogenicity is mediated by selective upregulation of components of the p44/42 MAP kinase pathway in human mammary carcinoma cells	ONCOGENE			English	Article						HOXA1; gene expression; p44/42 MAP kinase; MEK; oncogenicity	HUMAN GROWTH-HORMONE; GENE-EXPRESSION; BREAST; PHOSPHORYLATION; TRANSACTIVATION; TRANSFORMATION; PROLIFERATION; ACTIVATION; SURVIVAL; HOXA1	Expression of homeobox A1 ( HOXA1) results in oncogenic transformation of immortalized human mammary epithelial cells with aggressive tumor formation in vivo. However, the mechanisms by which HOXA1 mediates oncogenic transformation is not well defined. To identify molecules that could potentially be involved in HOXA1-mediated oncogenic transformation, microarray analysis was utilized to characterize and compare the gene expression pattern in response to forced expression or depletion of HOXA1 in human mammary carcinoma cells. Gene expression pro. ling identified that genes involved in the p44/42 mitogen-activated protein ( MAP) kinase activation pathway ( GRB2, MAP kinase kinase ( MEK1) and SDFR1) or p44/42 MAP kinase-regulated genes ( IER3, EPAS1, PCNA and catalase) are downstream expression targets of HOXA1. Forced expression of HOXA1 increased GRB2 and MEK1 mRNA and protein expression and increased p44/42 MAP kinase phosphorylation, activity and Elk-1-mediated transcription. Use of a MEK1 inhibitor demonstrated that increased p44/42 MAP kinase activity is required for the HOXA1-mediated increase in cell proliferation, survival, oncogenicity and oncogenic transformation. Thus, modulation of the p44/42 MAP kinase pathway is one mechanism by which HOXA1 mediates oncogenic transformation of the human mammary epithelial cell.	Univ Auckland, Liggins Inst, Auckland, New Zealand; Univ Auckland, Natl Res Ctr Growth & Dev, Auckland, New Zealand; Genome Inst Singapore, Singapore, Singapore; Johns Hopkins Univ, Breast Canc Program, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA	University of Auckland; University of Auckland; Agency for Science Technology & Research (A*STAR); A*STAR - Genome Institute of Singapore (GIS); Johns Hopkins University; Johns Hopkins Medicine	Lobie, PE (corresponding author), Univ Auckland, Liggins Inst, 2-6 Pk Ave,Private Bag 92019, Auckland, New Zealand.	p.lobie@auckland.ac.nz	David, Starling Emerald Bright/R-6034-2019; Liu, Edison/C-4141-2008; Miller, Lance/A-5633-2009; Kumarasamypet Murugesan, Mohankumar/F-4231-2012	David, Starling Emerald Bright/0000-0001-6875-2258; Kannan, Nagarajan/0000-0002-8825-2178; Miller, Lance/0000-0003-3799-2528; KM, Mohankumar/0000-0001-9407-1800				Bajetto A, 2001, J NEUROCHEM, V77, P1226, DOI 10.1046/j.1471-4159.2001.00350.x; Chariot A, 1996, BIOCHEM BIOPH RES CO, V222, P292, DOI 10.1006/bbrc.1996.0737; Chen HX, 2003, J MAMMARY GLAND BIOL, V8, P159, DOI 10.1023/A:1025996707117; Cheng AM, 1998, CELL, V95, P793, DOI 10.1016/S0092-8674(00)81702-X; Clark JH, 1999, GREEN CHEM, V1, P1, DOI 10.1039/a807961g; Conrad PW, 1999, J BIOL CHEM, V274, P33709, DOI 10.1074/jbc.274.47.33709; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; Diehn M, 2003, NUCLEIC ACIDS RES, V31, P219, DOI 10.1093/nar/gkg014; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; Garcia J, 2002, EMBO J, V21, P5151, DOI 10.1093/emboj/cdf488; GILLE H, 1995, EMBO J, V14, P951, DOI 10.1002/j.1460-2075.1995.tb07076.x; Grill C, 2004, BIOCHEM J, V381, P635, DOI 10.1042/BJ20031688; Hattori R, 2001, J MOL CELL CARDIOL, V33, P1929, DOI 10.1006/jmcc.2001.1456; Lord JD, 2000, J IMMUNOL, V164, P2533, DOI 10.4049/jimmunol.164.5.2533; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; Mertani HC, 2001, J BIOL CHEM, V276, P21464, DOI 10.1074/jbc.M100437200; Mueller H, 2000, INT J CANCER, V89, P384, DOI 10.1002/1097-0215(20000720)89:4<384::AID-IJC11>3.0.CO;2-R; Prosperi E, 1997, Prog Cell Cycle Res, V3, P193; Rinehart J, 2004, J CLIN ONCOL, V22, P4456, DOI 10.1200/JCO.2004.01.185; Ruvolo PP, 2001, LEUKEMIA, V15, P515, DOI 10.1038/sj.leu.2402090; Salh B, 1999, ANTICANCER RES, V19, P731; Sebolt-Leopold JS, 1999, NAT MED, V5, P810, DOI 10.1038/10533; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; SHIN SI, 1975, P NATL ACAD SCI USA, V72, P4435, DOI 10.1073/pnas.72.11.4435; Wang CX, 2006, CELL DEATH DIFFER, V13, P1203, DOI 10.1038/sj.cdd.4401804; Xu XQ, 2005, J BIOL CHEM, V280, P23987, DOI 10.1074/jbc.M503869200; Yu FQ, 2005, FRONT BIOSCI-LANDMRK, V10, P896, DOI 10.2741/1584; Zhang X, 2003, J BIOL CHEM, V278, P7580, DOI 10.1074/jbc.M212050200; Zhu T, 2005, CANCER RES, V65, P317; Zhu Z, 2005, ONCOGENE, V24, P3774, DOI 10.1038/sj.onc.1208541	30	53	57	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 7	2007	26	27					3998	4008		10.1038/sj.onc.1210180	http://dx.doi.org/10.1038/sj.onc.1210180			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	177HP	17213808				2022-12-28	WOS:000247144500010
J	Kosmider, O; Denis, N; Dubreuil, P; Moreau-Gachelin, F				Kosmider, O.; Denis, N.; Dubreuil, P.; Moreau-Gachelin, F.			Semaxinib (SU5416) as a therapeutic agent targeting oncogenic Kit mutants resistant to imatinib mesylate	ONCOGENE			English	Article						erythroleukemia; Kit; SU5416; semaxinib; imatinib mesylate	ACUTE MYELOID-LEUKEMIA; RECEPTOR TYROSINE KINASE; GASTROINTESTINAL STROMAL TUMORS; C-KIT; WILD-TYPE; INHIBITOR; MUTATIONS; MASTOCYTOSIS; ACTIVATION; GROWTH	Activating mutations in the Kit receptor are frequently observed in various malignancies, pointing Kit as a molecule of interest for drug inhibit ion. When mutated on Asp 816 (corresponding to Asp 814 in the mouse), as preferentially found in human mastocytosis and acute myeloid leukemia, Kit became non-sensitive to imatinib mesylate (Gleevec). Erythroleukemic cells isolated from Spi-1/PU.1 transgenic mice express Kit mutated at codon 814 (Kit(D814Y) or Kit(D814V)) or codon 818 (Kit(D818Y)). Using these cells in vitro, we demonstrate that the tyrosine kinase inhibitor SU5416 (Semaxinib) induces growth arrest and apoptosis independent of the mutation type by inhibiting the functions of Kit, including Kit autophosphorylation and activation of Akt, Erk1/Erk2 and Stat3 downstream signaling pathways. These findings indicate that SU5416 may be a promising tool to kill cancer cells driven by Kit oncogenic mutations that are resistant to treatment with imatinib mesylate.	Inst Curie, INSERM, U528, F-75248 Paris 05, France; Inst J Paoli I Calmettes, INSERM, UMR 599, F-13009 Marseille, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Institut Paoli-Calmette (IPC)	Moreau-Gachelin, F (corresponding author), Inst Curie, INSERM, U528, 26 Rue Ulm, F-75248 Paris 05, France.	framoreau@curie.fr	dubreuil, patrice/F-5346-2011; Dubreuil, Patrice/V-4816-2019	dubreuil, patrice/0000-0003-1155-1150; Dubreuil, Patrice/0000-0003-1155-1150; KOSMIDER, olivier/0000-0002-6021-4057				Akin C, 2004, BLOOD, V103, P3222, DOI 10.1182/blood-2003-11-3816; Beghini A, 2000, BLOOD, V95, P726, DOI 10.1182/blood.V95.2.726; Chen H, 2003, INT J CANCER, V105, P130, DOI 10.1002/ijc.11025; Fiedler W, 2003, BLOOD, V102, P2763, DOI 10.1182/blood-2002-10-2998; Fong TAT, 1999, CANCER RES, V59, P99; Giles FJ, 2003, BLOOD, V102, P795, DOI 10.1182/blood-2002-10-3023; Heinrich MC, 2000, BLOOD, V96, P925, DOI 10.1182/blood.V96.3.925.015k50_925_932; Heymach JV, 2004, CLIN CANCER RES, V10, P5732, DOI 10.1158/1078-0432.CCR-04-0157; Hirota S, 1998, SCIENCE, V279, P577, DOI 10.1126/science.279.5350.577; Itokawa T, 2002, MOL CANCER THER, V1, P295; Kosmider O, 2005, CANCER CELL, V8, P467, DOI 10.1016/j.ccr.2005.11.009; Krystal GW, 2001, CANCER RES, V61, P3660; Lennartsson J, 2005, STEM CELLS, V23, P16, DOI 10.1634/stemcells.2004-0117; Longley BJ, 1996, NAT GENET, V12, P312, DOI 10.1038/ng0396-312; Ma YS, 2002, BLOOD, V99, P1741, DOI 10.1182/blood.V99.5.1741; Mesters RM, 2001, BLOOD, V98, P241, DOI 10.1182/blood.V98.1.241; MoreauGachelin F, 1996, MOL CELL BIOL, V16, P2453; Ning ZQ, 2001, BLOOD, V97, P3559, DOI 10.1182/blood.V97.11.3559; O'Farrell AM, 2004, LEUKEMIA RES, V28, P679, DOI 10.1016/j.leukres.2003.11.004; Pignon JM, 1997, BRIT J HAEMATOL, V96, P374, DOI 10.1046/j.1365-2141.1997.d01-2042.x; Smolich BD, 2001, BLOOD, V97, P1413, DOI 10.1182/blood.V97.5.1413; Wang YY, 2005, P NATL ACAD SCI USA, V102, P1104, DOI 10.1073/pnas.0408831102; Yee KWH, 2002, BLOOD, V100, P2941, DOI 10.1182/blood-2002-02-0531; Zermati Y, 2003, ONCOGENE, V22, P660, DOI 10.1038/sj.onc.1206120	24	24	24	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 31	2007	26	26					3904	3908		10.1038/sj.onc.1210159	http://dx.doi.org/10.1038/sj.onc.1210159			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	175PV	17173066				2022-12-28	WOS:000247026400014
J	Yang, J; Runeberg-Roos, P; Leppanen, VM; Saarma, M				Yang, J.; Runeberg-Roos, P.; Leppanen, V-M; Saarma, M.			The mouse soluble GFR alpha 4 receptor activates RET independently of its ligand persephin	ONCOGENE			English	Article						GFR alpha 4; RET; PSPN; neurite outgrowth; survival	NEURONAL SURVIVAL; LIPID RAFTS; GDNF; BINDING; DIFFERENTIATION; PROTOONCOGENE; MECHANISM; FAMILY; MODEL	Glial cell line-derived neurotrophic factor (GDNF) family ligands (GFLs) all signal through the transmembrane receptor tyrosine kinase RET. The signalling complex consists of GFLs, GPI-anchored ligand binding GDNF family receptor alphas (GFRas) and RET. Signalling via RET is required for the development of the nervous system and the kidney, as well as for spermatogenesis. However, constitutive activation of RET is implicated as a cause in several diseases. Mutations of the RET proto-oncogene cause the inherited cancer syndrome multiple endocrine neoplasia type 2 (MEN 2). Recently, it has been suggested that mutations in the persephin binding GFR alpha 4 receptor may have a potentially modifying role in MEN 2. Several naturally occurring, different splice variants of the mammalian GFRa4 have been reported. A 7 bp insertion - mutation in the human GFRa4 gene causes a shift of reading frame and thereby changes the balance between the transcripts encoding GPI-anchored and soluble GFRa4 receptors. We report here that the mammalian soluble GFRa4 can activate RET independently of its preferential ligand, persephin. Our data show that soluble GFRa4 can associate with, and induce, phosphorylation of RET. In addition, our data show that this isoform of GFRa4 can induce downstream signalling, as well as neuronal survival and differentiation, in the absence of persephin. These results suggest that, in line with the previous report, GFRa4 may be a candidate gene for, or modi. er of, the MEN 2 diseases.	Univ Helsinki, Inst Biotechnol, Viikki Bioctr, FIN-00014 Helsinki, Finland	University of Helsinki	Saarma, M (corresponding author), Univ Helsinki, Inst Biotechnol, Viikki Bioctr, Viikinkaari 9,POB 56, FIN-00014 Helsinki, Finland.	mart.saarma@helsinki.fi		Leppanen, Veli-Matti/0000-0001-7100-965X				Airaksinen MS, 2002, NAT REV NEUROSCI, V3, P383, DOI 10.1038/nrn812; ASAI N, 1995, MOL CELL BIOL, V15, P1613; Eketjall S, 1999, EMBO J, V18, P5901, DOI 10.1093/emboj/18.21.5901; Kato M, 2000, MOL BIOL CELL, V11, P93, DOI 10.1091/mbc.11.1.93; Kodama Y, 2005, CANCER SCI, V96, P143, DOI 10.1111/j.1349-7006.2005.00023.x; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Leppanen VM, 2004, EMBO J, V23, P1452, DOI 10.1038/sj.emboj.7600174; Lindahl M, 2000, MOL CELL NEUROSCI, V15, P522, DOI 10.1006/mcne.2000.0845; Lindahl M, 2001, J BIOL CHEM, V276, P9344, DOI 10.1074/jbc.M008279200; Lindfors PH, 2006, ENDOCRINOLOGY, V147, P2237, DOI 10.1210/en.2005-1620; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Milbrandt J, 1998, NEURON, V20, P245, DOI 10.1016/S0896-6273(00)80453-5; Paratcha G, 2001, NEURON, V29, P171, DOI 10.1016/S0896-6273(01)00188-X; Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520; Scott RP, 2001, J BIOL CHEM, V276, P1450, DOI 10.1074/jbc.M006157200; Tansey MG, 2000, NEURON, V25, P611, DOI 10.1016/S0896-6273(00)81064-8; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Vanhorne JB, 2005, ONCOGENE, V24, P1091, DOI 10.1038/sj.onc.1207826; Virtanen H, 2005, BIOCHEM J, V387, P817, DOI 10.1042/BJ20041257; Wang XQ, 2006, STRUCTURE, V14, P1083, DOI 10.1016/j.str.2006.05.010; Yang JM, 2004, FEBS LETT, V569, P267, DOI 10.1016/j.febslet.2004.06.007	21	10	12	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 31	2007	26	26					3892	3898		10.1038/sj.onc.1210161	http://dx.doi.org/10.1038/sj.onc.1210161			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	175PV	17213820				2022-12-28	WOS:000247026400012
J	Sirvent, A; Boureux, A; Simon, V; Leroy, C; Roche, S				Sirvent, A.; Boureux, A.; Simon, V.; Leroy, C.; Roche, S.			The tyrosine kinase Abl is required for Src-transforming activity in mouse fibroblasts and human breast cancer cells	ONCOGENE			English	Article						Src; Abl; ERK5; Rac; cell transformation; breast cancer	VASCULAR SMOOTH-MUSCLE; MIDDLE-T-ANTIGEN; C-ABL; FAMILY KINASES; GROWTH-FACTORS; DNA-SYNTHESIS; TRANSCRIPTIONAL ACTIVITY; GENE-EXPRESSION; MYC EXPRESSION; RAC ACTIVATION	The cytoplasmic tyrosine kinase Src has been implicated in signal transduction induced by growth factors and integrins. Src also shows oncogenic activity when deregulated. Accumulating evidence indicates that the tyrosine kinase Abl is an important substrate for Src signalling in normal cells. Here we show that Abl is also required for Src-induced transformation of mouse fibroblasts. Abl does not mediate tyrosine phosphorylation of Stat3 and Shc, two important regulators of Src oncogenic activity. In contrast, Abl controls the activation of the small GTPase Rac for oncogenic signalling and active Rac partly rescued Src transformation in cells with inactive Abl. Moreover, Abl mediates Src-induced extracellular regulated kinase 5 (ERK5) activation to drive cell transformation. Finally, we find that Abl/Rac and Abl/ERK5 pathways also operate in human MCF7 and BT549 breast cancer cells, where neoplastic transformation depends on Src-like activities. Therefore, Abl is an important regulator of Src oncogenic activity both in mouse fibroblasts and in human cancer cells. Targeting these Abl-dependent signalling cascades may be of therapeutic value in breast cancers where Src-like function is important.	CNRS, CRBM, UMR 5237, F-34033 Montpellier, France; IGH, UPR1142 UMII, F-34095 Montpellier, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier; Universite de Montpellier	Roche, S (corresponding author), CNRS, CRBM, UMR 5237, BP 5051, F-34033 Montpellier, France.	serge.roche@crbm.cnrs.fr		roche, serge/0000-0003-3413-3859				Barros JC, 2005, J CELL SCI, V118, P1663, DOI 10.1242/jcs.02308; Boureux A, 2005, J CELL SCI, V118, P3717, DOI 10.1242/jcs.02491; Bromann PA, 2004, ONCOGENE, V23, P7957, DOI 10.1038/sj.onc.1208079; Bromberg JF, 1998, MOL CELL BIOL, V18, P2553, DOI 10.1128/MCB.18.5.2553; Buschbeck M, 2005, EMBO REP, V6, P63, DOI 10.1038/sj.embor.7400316; Chan AY, 2005, ONCOGENE, V24, P7821, DOI 10.1038/sj.onc.1208909; Chen T, 2006, ANTI-CANCER DRUG, V17, P123, DOI 10.1097/00001813-200602000-00002; Daniels CE, 2004, J CLIN INVEST, V114, P1308, DOI 10.1175/JCI200419603; Deroanne C, 2003, J CELL SCI, V116, P1367, DOI 10.1242/jcs.00308; Dilworth SM, 2002, NAT REV CANCER, V2, P951, DOI 10.1038/nrc946; FINN RS, 2007, IN PRESS BREAST CANC; Frame MC, 2004, J CELL SCI, V117, P989, DOI 10.1242/jcs.01111; Franco M, 2006, MOL CELL BIOL, V26, P1932, DOI 10.1128/MCB.26.5.1932-1947.2006; Furstoss O, 2002, EMBO J, V21, P514, DOI 10.1093/emboj/21.4.514; Garaude J, 2006, J IMMUNOL, V177, P7607, DOI 10.4049/jimmunol.177.11.7607; Hantschel O, 2004, NAT REV MOL CELL BIO, V5, P33, DOI 10.1038/nrm1280; Ishizawar R, 2004, CANCER CELL, V6, P209, DOI 10.1016/j.ccr.2004.09.001; Kato Y, 1997, EMBO J, V16, P7054, DOI 10.1093/emboj/16.23.7054; Kayahara M, 2005, MOL CELL BIOL, V25, P3784, DOI 10.1128/MCB.25.9.3784-3792.2005; Kovalenko M, 1997, BIOCHEMISTRY-US, V36, P6260, DOI 10.1021/bi962553l; Krause DS, 2005, NEW ENGL J MED, V353, P172, DOI 10.1056/NEJMra044389; Lewis JM, 1996, P NATL ACAD SCI USA, V93, P15174, DOI 10.1073/pnas.93.26.15174; Martin GS, 2001, NAT REV MOL CELL BIO, V2, P467, DOI 10.1038/35073094; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Mulloy R, 2003, ONCOGENE, V22, P5387, DOI 10.1038/sj.onc.1206839; Nicholson PR, 2001, EMBO J, V20, P6337, DOI 10.1093/emboj/20.22.6337; Pendergast AM, 2002, ADV CANCER RES, V85, P51, DOI 10.1016/S0065-230X(02)85003-5; Plattner R, 1999, GENE DEV, V13, P2400, DOI 10.1101/gad.13.18.2400; Plattner R, 2003, NAT CELL BIOL, V5, P309, DOI 10.1038/ncb949; Roussidis AE, 2004, ANTICANCER RES, V24, P1445; SEGINA NV, 2007, NATURE, V445, P437; Servitja JM, 2003, J BIOL CHEM, V278, P34339, DOI 10.1074/jbc.M302960200; Sini P, 2004, NAT CELL BIOL, V6, P268, DOI 10.1038/ncb1096; Srinivasan D, 2006, CANCER RES, V66, P5648, DOI 10.1158/0008-5472.CAN-06-0734; Suzuki J, 2004, ONCOGENE, V23, P8527, DOI 10.1038/sj.onc.1207894; Tanis KQ, 2003, MOL CELL BIOL, V23, P3884, DOI 10.1128/MCB.23.11.3884-3896.2003; Turkson J, 1999, MOL CELL BIOL, V19, P7519; Urich M, 1997, ONCOGENE, V14, P1235, DOI 10.1038/sj.onc.1200982; Ushio-Fukai M, 2005, CIRC RES, V97, P829, DOI 10.1161/01.RES.0000185322.46009.F5; Veracini L, 2006, J CELL SCI, V119, P2921, DOI 10.1242/jcs.03015; Yang LQ, 2006, CELL, V127, P139, DOI 10.1016/j.cell.2006.08.036; Yeatman TJ, 2004, NAT REV CANCER, V4, P470, DOI 10.1038/nrc1366; Zipfel PA, 2004, CURR BIOL, V14, P1222, DOI 10.1016/j.cub.2004.07.021; Zou XM, 1999, J BIOL CHEM, V274, P18141, DOI 10.1074/jbc.274.26.18141	44	49	52	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 15	2007	26	52					7313	7323		10.1038/sj.onc.1210543	http://dx.doi.org/10.1038/sj.onc.1210543			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	231NP	17533370	Green Submitted			2022-12-28	WOS:000250955700003
J	Broude, EV; Swift, ME; Vivo, C; Chang, BD; Davis, BM; Kalurupalle, S; Blagosklonny, MV; Roninson, IB				Broude, E. V.; Swift, M. E.; Vivo, C.; Chang, B-D; Davis, B. M.; Kalurupalle, S.; Blagosklonny, M. V.; Roninson, I. B.			p21(Waf1/Cip1/Sdi1) mediates retinoblastoma protein degradation	ONCOGENE			English	Article						p21; Rb; p27; damage response	RETROVIRAL VECTORS; TUMOR-CELLS; DNA-DAMAGE; SENESCENCE; ARREST; P21; P53; FIBROBLASTS; REQUIREMENT; SUPPRESSION	Damage-induced G1 checkpoint in mammalian cells involves upregulation of p53, which activates transcription of p21(Waf1) (CDKN1A). Inhibition of cyclin-dependent kinase (CDK)2 and CDK4/6 by p21 leads to dephosphorylation and activation of Rb. We now show that ectopic p21. expression in human HT1080 fibrosarcoma cells causes not only dephosphorylation but also depletion of Rb; this effect was p53-independent and susceptible to a proteasome inhibitor. CDK inhibitor p27 (CDKN1B) also caused Rb dephosphorylation and depletion, but another CDK inhibitor p16 (CDKN2A) induced only dephosphorylation but not depletion of Rb. Rb depletion was observed in both HT1080 and HCT116 colon carcinoma cells, where p21. was induced by DNA-damaging agents. Rb depletion after DNA damage did not occur in the absence of p21, and it was reduced when p21 induction was inhibited by p21-targeting short hairpin RNA or by a transdominant inhibitor of p53. These results indicate that p2l both activates Rb through dephosphorylation and inactivates it through degradation, suggesting negative feedback regulation of damage-induced cell-cycle checkpoint arrest.	Ordway Res Inst, Ctr Canc, Albany, NY 12208 USA; Univ Illinois, Dept Mol Genet, Chicago, IL USA	Ordway Research Institute; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Roninson, IB (corresponding author), Ordway Res Inst, Ctr Canc, 150 New Scotland Ave, Albany, NY 12208 USA.	roninson@ordwayresearch.org	Roninson, Igor/K-1310-2017	Roninson, Igor/0000-0002-9211-1327	NCI NIH HHS [R01 CA95727, R01 CA62099] Funding Source: Medline; NIA NIH HHS [R01 AG17921] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA062099, R01CA095727] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG017921] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Boyer SN, 1996, CANCER RES, V56, P4620; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Chang BD, 2002, P NATL ACAD SCI USA, V99, P389, DOI 10.1073/pnas.012602599; Chang BD, 1999, ONCOGENE, V18, P4808, DOI 10.1038/sj.onc.1203078; Chang BD, 2000, P NATL ACAD SCI USA, V97, P4291, DOI 10.1073/pnas.97.8.4291; Chang BD, 1996, GENE, V183, P137, DOI 10.1016/S0378-1119(96)00532-X; Drexler HCA, 1997, P NATL ACAD SCI USA, V94, P855, DOI 10.1073/pnas.94.3.855; Higashitsuji H, 2000, NAT MED, V6, P96, DOI 10.1038/71600; Jiang H, 1998, MOL CELL BIOL, V18, P5284, DOI 10.1128/MCB.18.9.5284; Kandel ES, 1997, SOMAT CELL MOLEC GEN, V23, P325, DOI 10.1007/BF02674280; Kehn K, 2005, ONCOGENE, V24, P525, DOI 10.1038/sj.onc.1208105; Maliyekkel A, 2006, CELL CYCLE, V5, P2390, DOI 10.4161/cc.5.20.3363; Ossovskaya VS, 1996, P NATL ACAD SCI USA, V93, P10309, DOI 10.1073/pnas.93.19.10309; Roninson IB, 2002, CANCER LETT, V179, P1, DOI 10.1016/S0304-3835(01)00847-3; Sdek P, 2005, MOL CELL, V20, P699, DOI 10.1016/j.molcel.2005.10.017; SMITH ML, 1994, EXP CELL RES, V215, P386, DOI 10.1006/excr.1994.1356; Stein GH, 1999, MOL CELL BIOL, V19, P2109; Tan XQ, 1997, J BIOL CHEM, V272, P9613; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Wiznerowicz M, 2003, J VIROL, V77, P8957, DOI 10.1128/JVI.77.16.8957-8951.2003; Ying HQ, 2006, CELL CYCLE, V5, P506, DOI 10.4161/cc.5.5.2515	21	64	65	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 18	2007	26	48					6954	6958		10.1038/sj.onc.1210516	http://dx.doi.org/10.1038/sj.onc.1210516			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	220WQ	17486059				2022-12-28	WOS:000250188400011
J	Shtiegman, K; Kochupurakkal, BS; Zwang, Y; Pines, G; Starr, A; Vexler, A; Citri, A; Katz, M; Lavi, S; Ben-Basat, Y; Benjamin, S; Corso, S; Gan, J; Yosef, RB; Giordano, S; Yarden, Y				Shtiegman, K.; Kochupurakkal, B. S.; Zwang, Y.; Pines, G.; Starr, A.; Vexler, A.; Citri, A.; Katz, M.; Lavi, S.; Ben-Basat, Y.; Benjamin, S.; Corso, S.; Gan, J.; Yosef, R. B.; Giordano, S.; Yarden, Y.			Defective ubiquitinylation of EGFR mutants of lung cancer confers prolonged signaling	ONCOGENE			English	Article						endocytosis; Gefitinib; growth factor; NSCLC; tyrosine kinase	GROWTH-FACTOR RECEPTOR; DOWN-REGULATION; TYROSINE KINASES; ERBB RECEPTORS; BREAST-CANCER; GEFITINIB; ENDOCYTOSIS; MUTATIONS; PROTEINS; PHOSPHORYLATION	Several distinct mutations within the kinase domain of the epidermal growth factor receptor (EGFR) are associated with non-small cell lung cancer, but mechanisms underlying their oncogenic potential are incompletely understood. Although normally ligand-induced kinase activation targets EGFR to Cbl-mediated receptor ubiquitinylation and subsequent degradation in lysosomes, we report that certain EGFR mutants escape this regulation. Defective endocytosis characterizes a deletion mutant of EGFR, as well as a point mutant (L858R-EGFR), whose association with c-Cbl and ubiquitinylation are impaired. Our data raise the possibility that refractoriness of L858R-EGFR to downregulation is due to enhanced heterodimerization with the oncogene product HER2, which leads to persistent stimulation.	Weizmann Inst Sci, Dept Regulat Biol, IL-76100 Rehovot, Israel; Tel Aviv Sourasky Med Ctr, Div Oncol, Ramat Aviv, Israel; Tel Aviv Univ, Sch Med, Ramat Aviv, Israel; Tel Aviv Univ, Dept Cell Res & Immunol, Ramat Aviv, Israel; Univ Turin, Sch Med, Inst Cancer Res & Treatment, Dept Oncol Sci,Div Mol Oncol, Turin, Italy	Weizmann Institute of Science; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv Sourasky Medical Center; Tel Aviv University; Tel Aviv University; University of Turin	Yarden, Y (corresponding author), Weizmann Inst Sci, Dept Regulat Biol, Room 32 Candiotty Bldg,1 Hertzl St, IL-76100 Rehovot, Israel.	yosef.yarden@weizmann.ac.il	Pines, Gur/X-7501-2019; YARDEN, YOSEF/K-1467-2012; Giordano, Silvia/J-9858-2018; Citri, Ami/R-8973-2019	Pines, Gur/0000-0002-1757-6722; Giordano, Silvia/0000-0003-1854-1086; Citri, Ami/0000-0002-9914-0278; Starr, Alexander/0000-0002-9329-3740; CORSO, Simona/0000-0002-5069-1503	NATIONAL CANCER INSTITUTE [R01CA072981, R37CA072981] Funding Source: NIH RePORTER; NCI NIH HHS [CA72981] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Amann J, 2005, CANCER RES, V65, P226; Baulida J, 1996, J BIOL CHEM, V271, P5251; Dikic I, 2003, CURR OPIN CELL BIOL, V15, P128, DOI 10.1016/S0955-0674(03)00004-8; Engelman JA, 2005, P NATL ACAD SCI USA, V102, P3788, DOI 10.1073/pnas.0409773102; Friedman LM, 2005, P NATL ACAD SCI USA, V102, P1915, DOI 10.1073/pnas.0409610102; Hynes NE, 2001, ENDOCR-RELAT CANCER, V8, P151, DOI 10.1677/erc.0.0080151; Karunagaran D, 1996, EMBO J, V15, P254, DOI 10.1002/j.1460-2075.1996.tb00356.x; Kobayashi S, 2005, NEW ENGL J MED, V352, P786, DOI 10.1056/NEJMoa044238; KOKAI Y, 1989, CELL, V58, P287, DOI 10.1016/0092-8674(89)90843-X; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; Levkowitz G, 1996, ONCOGENE, V12, P1117; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Marmor MD, 2004, ONCOGENE, V23, P2057, DOI 10.1038/sj.onc.1207390; Muthuswamy SK, 1999, MOL CELL BIOL, V19, P6845; Ouyang XM, 2001, MOL CELL BIOCHEM, V218, P47, DOI 10.1023/A:1007249004222; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Pao W, 2005, PLOS MED, V2, P225, DOI 10.1371/journal.pmed.0020073; Pao W, 2004, P NATL ACAD SCI USA, V101, P13306, DOI 10.1073/pnas.0405220101; Polo S, 2002, NATURE, V416, P451, DOI 10.1038/416451a; PORTA DG, 1997, EMBO J, V16, P1647; Sigismund S, 2005, P NATL ACAD SCI USA, V102, P2760, DOI 10.1073/pnas.0409817102; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; Sordella R, 2004, SCIENCE, V305, P1163, DOI 10.1126/science.1101637; Tracy S, 2004, CANCER RES, V64, P7241, DOI 10.1158/0008-5472.CAN-04-1905; Waterman H, 1999, EMBO J, V18, P3348, DOI 10.1093/emboj/18.12.3348; Waterman H, 2002, EMBO J, V21, P303, DOI 10.1093/emboj/21.3.303; WELLS A, 1990, SCIENCE, V247, P962, DOI 10.1126/science.2305263; Wiley HS, 2001, TRAFFIC, V2, P12, DOI 10.1034/j.1600-0854.2001.020103.x; Worthylake R, 1999, J BIOL CHEM, V274, P8865, DOI 10.1074/jbc.274.13.8865; Yang SC, 2006, CANCER RES, V66, P6990, DOI 10.1158/0008-5472.CAN-06-1042; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073	31	103	106	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT	2007	26	49					6968	6978		10.1038/sj.onc.1210503	http://dx.doi.org/10.1038/sj.onc.1210503			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	223YN	17486068				2022-12-28	WOS:000250412200002
J	McBryan, J; Howlin, J; Kenny, PA; Shioda, T; Martin, F				McBryan, J.; Howlin, J.; Kenny, P. A.; Shioda, T.; Martin, F.			ER alpha-CITED1 co-regulated genes expressed during pubertal mammary gland development: implications for breast cancer prognosis	ONCOGENE			English	Article						mammary gland; puberty; development; CITEDI; ER alpha	DUCTAL MORPHOGENESIS; BRANCHING MORPHOGENESIS; EPITHELIAL-CELLS; IN-VIVO; GROWTH; CITED1; TRANSCRIPTION; PROTEINS; REVEALS; DIFFERENTIATION	Expression microarray analysis identified over 930 genes regulated during puberty in the mouse mammary gland. Most prominent were genes whose expression increased in parallel with pubertal development and remained high thereafter. Members of the Wnt, transforming growth factor-beta and oestrogen-signalling pathways were significantly overrepresented. Comparison to expression data from CITED1 knockout mice identified a subset of oestrogen-responsive genes displaying altered expression in the absence of CITED1. Included in this subset are stanniocalcin2 (Stc2) and amphiregulin (Areg). Chromatin immunoprecipitation revealed that ER alpha binds to oestrogen response elements in both the Stc2 and Areg genes in the mammary gland during puberty. Additionally, CITED1 and ER alpha localize to the same epithelial cells of the pubertal mammary gland, supporting a role for interaction of these two proteins during normal development. In a human breast cancer data set, expression of Stc2, Areg and CITED1 parallel that of ER alpha. Similar to ERa, CITED1 expression correlates with good outcome in breast cancer, implying that potential maintenance of the ER alpha-CITED1 co-regulated signalling pathwayin breast tumours can indicate good prognosis.	Univ Coll Dublin, Conway Inst, UCD Sch Biomol & Biomed Sci, Dublin 4, Ireland; Univ Calif Berkeley, Lawrence Berkeley Lab, Berkeley, CA 94720 USA; Massachusetts Gen Hosp, Ctr Canc, Lab Tumour Biol, Charlestown, MA USA	University College Dublin; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; Harvard University; Massachusetts General Hospital	Martin, F (corresponding author), Univ Coll Dublin, Conway Inst, UCD Sch Biomol & Biomed Sci, Dublin 4, Ireland.	finian.martin@ucd.ie	Howlin, Jill/G-9665-2011; Kenny, Paraic/A-3120-2008	Howlin, Jill/0000-0002-2766-3002; McBryan, Jean/0000-0002-7568-2208				Allar MA, 2004, ENDOCRINOLOGY, V145, P2467, DOI 10.1210/en.2003-1641; Bajic VB, 2003, NUCLEIC ACIDS RES, V31, P3605, DOI 10.1093/nar/gkg517; Ball SM, 1998, ANAT REC, V250, P459, DOI 10.1002/(SICI)1097-0185(199804)250:4<459::AID-AR9>3.0.CO;2-S; Brisken C, 2000, GENE DEV, V14, P650; Clarke RB, 1997, CANCER RES, V57, P4987; Clarkson RWE, 2004, BREAST CANCER RES, V6, pR92, DOI 10.1186/bcr754; Crowley MR, 2000, DEV BIOL, V225, P407, DOI 10.1006/dbio.2000.9844; D'Cruz CM, 2002, MOL ENDOCRINOL, V16, P2034, DOI 10.1210/me.2002-0073; DANIEL C, 2000, METHODS MAMMARY GLAN; Draghici S, 2003, NUCLEIC ACIDS RES, V31, P3775, DOI 10.1093/nar/gkg624; Fournier MV, 2006, CANCER RES, V66, P7095, DOI 10.1158/0008-5472.CAN-06-0515; Galang CK, 2004, J BIOL CHEM, V279, P11281, DOI 10.1074/jbc.M311887200; Gass S, 2003, J MAMMARY GLAND BIOL, V8, P269, DOI 10.1023/B:JOMG.0000010029.85796.63; Herrington EE, 1997, J CELL PHYSIOL, V170, P47; Howlin J, 2006, ONCOGENE, V25, P1532, DOI 10.1038/sj.onc.1209183; Howlin J, 2006, J MAMMARY GLAND BIOL, V11, P283, DOI 10.1007/s10911-006-9024-2; Humphreys RC, 1996, DEVELOPMENT, V122, P4013; Juncker-Jensen A, 2006, GROWTH HORM IGF RES, V16, P224, DOI 10.1016/j.ghir.2006.06.005; Kenney NJ, 1996, CELL GROWTH DIFFER, V7, P1769; Klopocki E, 2004, INT J ONCOL, V25, P641; Kouros-Mehr H, 2006, DEV DYNAM, V235, P3404, DOI 10.1002/dvdy.20978; Li HC, 1998, EXP CELL RES, V242, P478, DOI 10.1006/excr.1998.4123; Lincoln DW, 2005, FRONT BIOSCI-LANDMRK, V10, P506, DOI 10.2741/1546; Maeda T, 2006, ONCOGENE, V25, P1408, DOI 10.1038/sj.onc.1209168; Mailleux AA, 2007, DEV CELL, V12, P221, DOI 10.1016/j.devcel.2006.12.003; Master SR, 2002, MOL ENDOCRINOL, V16, P1185, DOI 10.1210/me.16.6.1185; Michaelson JS, 2005, ONCOGENE, V24, P2613, DOI 10.1038/sj.onc.1208208; Morris JS, 2006, J CELL PHYSIOL, V206, P16, DOI 10.1002/jcp.20427; Murtagh J, 2004, J CELL BIOL, V166, P133, DOI 10.1083/jcb.200403020; PHANG TL, 2003, PC S BIOCOMPUT, V8, P351; Plisov S, 2005, J AM SOC NEPHROL, V16, P1632, DOI 10.1681/ASN.2004060476; Rudolph MC, 2003, J MAMMARY GLAND BIOL, V8, P287, DOI 10.1023/B:JOMG.0000010030.73983.57; Russo J, 2005, BREAST CANCER RES, V7, P131, DOI 10.1186/bcr1029; Shi GB, 2006, J BIOL CHEM, V281, P27426, DOI 10.1074/jbc.M602631200; Steimel A, 2004, EUR T ELECTR POWER, V14, P3, DOI 10.1002/etep.4; Tang SH, 2004, NUCLEIC ACIDS RES, V32, pD533, DOI 10.1093/nar/gkh083; Uehara N, 2006, ONCOL REP, V15, P903; van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967; WEBERHALL SJ, 1994, DIFFERENTIATION, V57, P205, DOI 10.1046/j.1432-0436.1994.5730205.x; Werling RW, 2003, AM J SURG PATHOL, V27, P82, DOI 10.1097/00000478-200301000-00009; WILLIAMS JM, 1983, DEV BIOL, V97, P274, DOI 10.1016/0012-1606(83)90086-6; Yahata T, 2001, GENE DEV, V15, P2598, DOI 10.1101/gad.906301; Yook JI, 2006, NAT CELL BIOL, V8, P1398, DOI 10.1038/ncb1508; Zeps N, 1998, DIFFERENTIATION, V62, P221, DOI 10.1046/j.1432-0436.1998.6250221.x; Zhang N, 1997, J BIOL CHEM, V272, P16733, DOI 10.1074/jbc.272.27.16733	45	52	55	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 27	2007	26	44					6406	6419		10.1038/sj.onc.1210468	http://dx.doi.org/10.1038/sj.onc.1210468			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	214KY	17486082				2022-12-28	WOS:000249737600005
J	Zhen, Y; Sorensen, VS; Jin, Y; Suo, Z; Wiedlocha, A				Zhen, Y.; Sorensen, V. S.; Jin, Y.; Suo, Z.; Wiedlocha, A.			Indirubin-3 '-monoxime inhibits autophosphorylation of FGFR1 and stimulates ERK1/2 activity via p38 MAPK	ONCOGENE			English	Article						indirubin-3 '-monoxime; FGFR1; p38 MAPK; ERK1/2; CDK2; cell proliferation	ACTIVATED PROTEIN-KINASE; CELL MYELOPROLIFERATIVE DISORDER; CHINESE ANTILEUKEMIA MEDICINE; THR-160 PHOSPHORYLATION; INDIRUBIN DERIVATIVES; HEPARAN-SULFATE; TRANSLOCATION; APOPTOSIS; RECEPTOR; MECHANISMS	Indirubin-3'-monoxime is a derivative of the bis-indole alkaloid indirubin, an active ingredient of a traditional Chinese medical preparation that exhibits anti-inflammatory and anti-leukemic activities. Indirubin-3'-monoxime is mainly recognized as an inhibitor of cyclin-dependent kinases (CDKs) and glycogen synthase kinase-3. It inhibits proliferation of cultured cells, mainly through arresting the cells in the G1/S or G2/M phase of the cell cycle. Here, we report that indirubin-3'-monoxime is able to inhibit proliferation of NIH/3T3 cells by specifically inhibiting autophosphorylation of fibroblast growth factor receptor 1(FGFR1), blocking in this way the receptor-mediated cell signaling. Indirubin-3'-monoxime inhibits the activity of FGFR1 at a concentration lower than that required for inhibition of phosphorylation of CDK2 and retinoblastoma protein and cell proliferation stimulated by fetal calf serum. The ability of indirubin-3'-monoxime to inhibit FGFR1 signa ling was similar to that of the FGFR1 inhibitor SU5402. In addition, we found that indirubin-3'-monoxime activates long-term p38 mitogen-activated protein kinase activity, which stimulates extracellular signal-regulated kinase 1/2 in a way unrelated to the activity of FGFR1. Furthermore, we show that indirubin-3'- monoxime can inhibit proliferation of the myeloid leukemia cell line KG-1a through inhibition of the activity of the FGFR1 tyrosine kinase. The data presented here demonstrate previously unknown activities of indirubin-3'-monoxime that may have clinical implications.	Univ Oslo, Norwegian Radium Hosp, Natl Hosp, Inst Canc Res,Dept Biochem, N-0310 Oslo, Norway; Univ Oslo, Norwegian Radium Hosp, Natl Hosp, Inst Canc Res,Dept Pathol, N-0310 Oslo, Norway	University of Oslo; National Hospital Norway; University of Oslo; National Hospital Norway	Wiedlocha, A (corresponding author), Univ Oslo, Norwegian Radium Hosp, Natl Hosp, Inst Canc Res,Dept Biochem, N-0310 Oslo, Norway.	antoni.wiedlocha@rr-research.no						Adachi J, 2001, J BIOL CHEM, V276, P31475, DOI 10.1074/jbc.C100238200; Benhar M, 2001, MOL CELL BIOL, V21, P6913, DOI 10.1128/MCB.21.20.6913-6926.2001; Boilly B, 2000, CYTOKINE GROWTH F R, V11, P295, DOI 10.1016/S1359-6101(00)00014-9; Brancho D, 2003, GENE DEV, V17, P1969, DOI 10.1101/gad.1107303; Bulavin DV, 1999, EMBO J, V18, P6845, DOI 10.1093/emboj/18.23.6845; Chaffanet M, 1998, ONCOGENE, V16, P945, DOI 10.1038/sj.onc.1201601; Chiariello M, 2000, BIOCHEM J, V349, P869, DOI 10.1042/bj3490869; Dailey L, 2005, CYTOKINE GROWTH F R, V16, P233, DOI 10.1016/j.cytogfr.2005.01.007; Davies TG, 2001, STRUCTURE, V9, P389, DOI 10.1016/S0969-2126(01)00598-6; Eswarakumar VP, 2005, CYTOKINE GROWTH F R, V16, P139, DOI 10.1016/j.cytogfr.2005.01.001; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; Furdui CM, 2006, MOL CELL, V21, P711, DOI 10.1016/j.molcel.2006.01.022; Gu TL, 2006, BLOOD, V108, P4202, DOI 10.1182/blood-2006-06-026666; Guasch G, 2001, MOL CELL BIOL, V21, P8129, DOI 10.1128/MCB.21.23.8129-8142.2001; Heredia A, 2005, AIDS, V19, P2087, DOI 10.1097/01.aids.0000194805.74293.11; Hoessel R, 1999, NAT CELL BIOL, V1, P60, DOI 10.1038/9035; IMAMURA T, 1994, EXP CELL RES, V215, P363, DOI 10.1006/excr.1994.1353; Itoh N, 2004, TRENDS GENET, V20, P563, DOI 10.1016/j.tig.2004.08.007; Jautelat R, 2005, CHEMBIOCHEM, V6, P531, DOI 10.1002/cbic.200400108; Kang YJ, 2006, J BIOL CHEM, V281, P26225, DOI 10.1074/jbc.M606800200; Keenan SM, 2001, J BIOL CHEM, V276, P22404, DOI 10.1074/jbc.M100409200; Kosmopoulou MN, 2004, EUR J BIOCHEM, V271, P2280, DOI 10.1111/j.1432-1033.2004.04173.x; Leclerc S, 2001, J BIOL CHEM, V276, P251, DOI 10.1074/jbc.M002466200; Lents NH, 2002, J BIOL CHEM, V277, P47469, DOI 10.1074/jbc.M207425200; Lin XH, 1999, DEVELOPMENT, V126, P3715; Losa JH, 2003, ONCOGENE, V22, P3998, DOI 10.1038/sj.onc.1206608; Lundberg AS, 1998, MOL CELL BIOL, V18, P753, DOI 10.1128/MCB.18.2.753; MACDONALD D, 1995, LEUKEMIA, V9, P1628; Marko D, 2001, BRIT J CANCER, V84, P283, DOI 10.1054/bjoc.2000.1546; Mohammadi M, 1997, SCIENCE, V276, P955, DOI 10.1126/science.276.5314.955; Nam S, 2005, P NATL ACAD SCI USA, V102, P5998, DOI 10.1073/pnas.0409467102; Nguyen DT, 2006, FREE RADICAL BIO MED, V41, P1225, DOI 10.1016/j.freeradbiomed.2006.06.026; Ornitz DM, 2000, BIOESSAYS, V22, P108, DOI 10.1002/(SICI)1521-1878(200002)22:2<108::AID-BIES2>3.0.CO;2-M; Polychronopoulos P, 2004, J MED CHEM, V47, P935, DOI 10.1021/jm031016d; Popovici C, 1999, BLOOD, V93, P1381, DOI 10.1182/blood.V93.4.1381.404k30_1381_1389; Powers CJ, 2000, ENDOCR-RELAT CANCER, V7, P165, DOI 10.1677/erc.0.0070165; Ribas J, 2006, ONCOGENE, V25, P6304, DOI 10.1038/sj.onc.1209648; Roux PP, 2004, MICROBIOL MOL BIOL R, V68, P320, DOI 10.1128/MMBR.68.2.320-344.2004; Sanchez-Prieto R, 2000, CANCER RES, V60, P2464; SANDVIG K, 1982, J BIOL CHEM, V257, P7504; Sethi G, 2006, J BIOL CHEM, V281, P23425, DOI 10.1074/jbc.M602627200; Tibbles LA, 1999, CELL MOL LIFE SCI, V55, P1230, DOI 10.1007/s000180050369; WIEDLOCHA A, 1994, CELL, V76, P1039, DOI 10.1016/0092-8674(94)90381-6; Xie YB, 2004, NEUROSCI LETT, V367, P355, DOI 10.1016/j.neulet.2004.06.044; Yu ZP, 2000, TOXICOL APPL PHARM, V168, P200, DOI 10.1006/taap.2000.9033; ZHAN X, 1993, J BIOL CHEM, V268, P9611	46	48	54	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 27	2007	26	44					6372	6385		10.1038/sj.onc.1210473	http://dx.doi.org/10.1038/sj.onc.1210473			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	214KY	17533378				2022-12-28	WOS:000249737600002
J	Li, Q; Dashwood, WM; Zhong, X; Nakagama, H; Dashwood, RH				Li, Q.; Dashwood, W. M.; Zhong, X.; Nakagama, H.; Dashwood, R. H.			Bcl-2 overexpression in PhIP-induced colon tumors: cloning of the rat Bcl-2 promoter and characterization of a pathway involving beta-catenin, c-Myc and E2F1	ONCOGENE			English	Article						beta-catenin; Bcl-2; c-Myc; E2F1; wnt signaling; colorectal cancer	TRANSCRIPTION FACTOR; EXPRESSION; GENE; APOPTOSIS; CELLS; INHIBITION; ACTIVATION; EPIGALLOCATECHIN-3-GALLATE; MUTATION; ELEMENT	beta-Catenin/T-cell factor (Tcf) signaling is constitutively active in the majority of human colorectal cancers, and there are accompanying changes in Bcl-2 expression. Similarly, 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine(PhIP)-induced colon tumors in the rat have increased beta-catenin and elevated Bcl-2. To examine the possible direct transcriptional regulation of rat Bcl-2 by beta-catenin/Tcf, we cloned and characterized the corresponding promoter region and found 70.1% similarity with its human counterpart, BCL2. Bcl- 2 promoter activity was increased in response to LiCl and exogenous b-catenin, including oncogenic mutants of beta-catenin found in PhIP-induced colon tumors. Protein/DNA arrays identified E2F1, but not beta-catenin/Tcf, as interactingmost strongly with the rat Bcl- 2 promoter. Exogenous E2F1 increased the promoter activity of rat Bcl- 2, except in mutants lacking the E2F1 sites. As expected, b-catenin induced its downstream target c-Myc, as well as E2F1 and Bcl- 2, and this was blocked by siRNA to c-Myc or E2F1. These findings suggest an indirect pathway for Bcl- 2 overexpression in PhIP-induced colon tumors involving beta-catenin, c-Myc and E2F1.	Oregon State Univ, Linus Pauling Inst, Corvallis, OR 97331 USA; Natl Canc Ctr, Tokyo, Japan	Oregon State University; National Cancer Center - Japan	Dashwood, RH (corresponding author), Oregon State Univ, Linus Pauling Inst, Weniger 503, Corvallis, OR 97331 USA.	Rod.Dashwood@oregonstate.edu	Dashwood, Roderick/AAF-2025-2020; Dashwood, Roderick H/E-9090-2011	Li, Qingjie/0000-0003-1405-7000	NCI NIH HHS [CA65525, P01 CA090890-01A29001, R01 CA080176-05, R01 CA065525-09, P01 CA090890, P01 CA090890-01A20003, R01 CA080176, CA90890, CA80176, R29 CA065525, P01 CA090890-05, R01 CA065525, R01 CA065525-08] Funding Source: Medline; NIEHS NIH HHS [P30 ES00210, P30 ES000210] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA065525, P01CA090890, R29CA065525, R01CA080176] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000210] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Al-Fageeh M, 2004, ONCOGENE, V23, P4839, DOI 10.1038/sj.onc.1207634; BEDI A, 1995, CANCER RES, V55, P1811; Behrens J, 2005, BIOCHEM SOC T, V33, P672, DOI 10.1042/BST0330672; Blum CA, 2001, CARCINOGENESIS, V22, P315, DOI 10.1093/carcin/22.2.315; Blumberg Stephen J, 2003, Vital Health Stat 1, P1; Dashwood RH, 1998, CANCER RES, V58, P1127; Dashwood WM, 2005, MUTAT RES-FUND MOL M, V591, P161, DOI 10.1016/j.mrfmmm.2005.03.029; Dashwood WM, 2002, BIOCHEM BIOPH RES CO, V296, P584, DOI 10.1016/S0006-291X(02)00914-2; Fujiwara K, 2004, CARCINOGENESIS, V25, P1495, DOI 10.1093/carcin/bgh155; Gomez-Manzano C, 2001, CANCER RES, V61, P6693; GROSS TM, 2000, DIABETES TECHNOL THE, V2, P19, DOI DOI 10.1089/15209150050214087; Harigai M, 1996, ONCOGENE, V12, P1369; Hayashi R, 1996, CANCER RES, V56, P4307; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Huang XH, 2003, INVEST OPHTH VIS SCI, V44, P347, DOI 10.1167/iovs.02-0198; Li QJ, 2004, J BIOL CHEM, V279, P45669, DOI 10.1074/jbc.M405025200; Li QJ, 2004, GENOMICS, V83, P231, DOI 10.1016/j.ygeno.2003.08.004; Manji HK, 2000, J CLIN PSYCHIAT, V61, P82; Mayo MW, 1999, EMBO J, V18, P3990, DOI 10.1093/emboj/18.14.3990; Muller M J, 2001, Obes Rev, V2, P15; O'Donnell KA, 2005, NATURE, V435, P839, DOI 10.1038/nature03677; Ochiai M, 2003, AM J PATHOL, V163, P1607, DOI 10.1016/S0002-9440(10)63517-1; Park S, 2006, MOL PHARMACOL, V70, P960, DOI 10.1124/mol.106.024729; Pugazhenthi S, 1999, J BIOL CHEM, V274, P2829, DOI 10.1074/jbc.274.5.2829; Romero F, 1999, EMBO J, V18, P3419, DOI 10.1093/emboj/18.12.3419; Salomoni P, 1997, P NATL ACAD SCI USA, V94, P3296, DOI 10.1073/pnas.94.7.3296; SETO M, 1988, EMBO J, V7, P123, DOI 10.1002/j.1460-2075.1988.tb02791.x; Smith MD, 1998, J BIOL CHEM, V273, P16715, DOI 10.1074/jbc.273.27.16715; Tamatani M, 1999, J BIOL CHEM, V274, P8531, DOI 10.1074/jbc.274.13.8531; Wilson BE, 1996, MOL CELL BIOL, V16, P5546; Zeng GC, 2003, BBA-GENE STRUCT EXPR, V1625, P30, DOI 10.1016/S0167-4781(02)00573-0	32	52	55	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 13	2007	26	42					6194	6202		10.1038/sj.onc.1210438	http://dx.doi.org/10.1038/sj.onc.1210438			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	209PU	17404573	Green Accepted			2022-12-28	WOS:000249401300010
J	Min, JN; Huang, L; Zimonjic, DB; Moskophidis, D; Mivechi, NF				Min, J-N; Huang, L.; Zimonjic, D. B.; Moskophidis, D.; Mivechi, N. F.			Selective suppression of lymphomas by functional loss of Hsf1 in a p53-deficient mouse model for spontaneous tumors	ONCOGENE			English	Article						Hsf1; p53; tumorigenesis; molecular chaperone	HEAT-SHOCK PROTEINS; MOLECULAR CHAPERONES; MICE; TUMORIGENESIS; CANCER; APOPTOSIS; INFLAMMATION; PATHWAYS; CELLS	A hallmark in the pathogenesis of cancer is the increased expression of heat shock proteins (Hsps) and other molecular chaperones observed in many tumor types, which is considered to be an adaptive response to enhance tumor cell survival. Heat shock transcription factor 1 (Hsf1) is a major transactivator of Hsp induction and has been proposed to affect tumor initiation and progression, regulating expression of Hsps and other molecular targets. In this report, we provide direct in vivo evidence that Hsf1 plays a critical role in the evolution of spontaneous tumors arising in p53 -/- mice. Thus, loss of Hsf1 function did not prolong tumor- free survival, but surprisingly altered the spectrum of tumors that arose in p53(-/-) mice. Tumor development is rapid in p53(-/-) mice, which predominantly (about 70%) succumb to lymphomas. In contrast, hsf1(-/-) p53(-/-) mice rarely develop lymphomas (<8%), but succumb to other tumor types including testicular carcinomas and soft tissue sarcomas. Our findings suggest that an increase in p53- independent apoptotic cell death in association with altered cytokine signaling and suppressed production of in. flammatory factors in hsf1(-/-) mice may contribute to selective lymphoma suppression. In conclusion, the data presented here link the loss of Hsf1- dependent function to decreased susceptibility to spontaneous lymphomagenesis, which may have implications for cancer prevention and therapy.	Med Coll Georgia, Ctr Mol Chaperone Radiobiol & Canc Virol, Augusta, GA 30912 USA; NCI, Expt Carcinogenesis Lab, Bethesda, MD 20892 USA	University System of Georgia; Augusta University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Mivechi, NF (corresponding author), Med Coll Georgia, Ctr Mol Chaperone Radiobiol & Canc Virol, 1410 Laney Walker Blvd, CN 3153, Augusta, GA 30912 USA.	dmoskophidis@mcg.edu; nmivechi@mcg.edu	Zimonjic, Drazen/AAX-7513-2020		NATIONAL CANCER INSTITUTE [R01CA062130, R01CA121951, Z01BC010038] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM070451] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline; NCI NIH HHS [CA121951, CA62130] Funding Source: Medline; NIGMS NIH HHS [GM070451] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Bukau B, 2006, CELL, V125, P443, DOI 10.1016/j.cell.2006.04.014; Ciocca DR, 2005, CELL STRESS CHAPERON, V10, P86, DOI 10.1379/CSC-99r.1; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; Donehower LA, 1997, CANCER SURV, V29, P329; Flohe SB, 2003, J IMMUNOL, V170, P2340, DOI 10.4049/jimmunol.170.5.2340; Fukatsu K, 1997, SEN-I GAKKAISHI, V53, P15, DOI 10.2115/fiber.53.15; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HARVEY M, 1993, NAT GENET, V5, P225, DOI 10.1038/ng1193-225; Hill R, 2005, CELL, V123, P1001, DOI 10.1016/j.cell.2005.09.030; Inouye S, 2004, J BIOL CHEM, V279, P38701, DOI 10.1074/jbc.M405986200; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Jiang LI, 2001, MAMM GENOME, V12, P89, DOI 10.1007/s003350010257; Jolly C, 2000, JNCI-J NATL CANCER I, V92, P1564, DOI 10.1093/jnci/92.19.1564; Karin M, 2006, CELL, V124, P823, DOI 10.1016/j.cell.2006.02.016; Knowlton AA, 2006, CARDIOVASC RES, V69, P7, DOI 10.1016/j.cardiores.2005.10.009; Leonard WJ, 2005, NAT REV IMMUNOL, V5, P688, DOI 10.1038/nri1688; Li ZW, 2006, BLOOD REV, V20, P333, DOI 10.1016/j.blre.2005.08.003; Liu G, 2004, NAT GENET, V36, P63, DOI 10.1038/ng1282; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; Morimoto RI, 1998, GENE DEV, V12, P3788, DOI 10.1101/gad.12.24.3788; Oosterhuis JW, 2005, NAT REV CANCER, V5, P210, DOI 10.1038/nrc1568; RENAULD JC, 1995, BLOOD, V85, P1300, DOI 10.1182/blood.V85.5.1300.bloodjournal8551300; Takaki E, 2006, J BIOL CHEM, V281, P4931, DOI 10.1074/jbc.M506911200; Wang YQ, 2004, J BIOL CHEM, V279, P32651, DOI 10.1074/jbc.M401475200; Whitesell L, 2005, NAT REV CANCER, V5, P761, DOI 10.1038/nrc1716; Xiao XZ, 1999, EMBO J, V18, P5943, DOI 10.1093/emboj/18.21.5943; Zhang Y, 2002, J CELL BIOCHEM, V86, P376, DOI 10.1002/jcb.10232; Zimonjic DB, 2000, P NATL ACAD SCI USA, V97, P13306, DOI 10.1073/pnas.97.24.13306	30	123	130	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 2	2007	26	35					5086	5097		10.1038/sj.onc.1210317	http://dx.doi.org/10.1038/sj.onc.1210317			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	196MT	17310987				2022-12-28	WOS:000248487400007
J	Bieler, G; Hasmim, M; Monnier, Y; Imaizumi, N; Ameyar, M; Bamat, J; Ponsonnet, L; Choualb, S; Grell, M; Goodman, SL; Lejeune, F; Ruegg, C				Bieler, G.; Hasmim, M.; Monnier, Y.; Imaizumi, N.; Ameyar, M.; Bamat, J.; Ponsonnet, L.; Choualb, S.; Grell, M.; Goodman, S. L.; Lejeune, F.; Rueegg, C.			Distinctive role of integrin-mediated adhesion in TNF-induced PKB/Akt and NF-kappa B activation and endothelial cell survival	ONCOGENE			English	Article						endothelium; cell death; cancer; signaling; angiogenesis	TUMOR-NECROSIS-FACTOR; ALPHA-INDUCED APOPTOSIS; PROTEIN-KINASE B/AKT; SHEAR-STRESS; CANCER CELLS; IFN-GAMMA; DEATH; INTERFERON; INHIBITION; PATHWAY	Tumor necrosis factor (TNF) is a pro-inflammatory cytokine exerting pleiotropic effects on endothelial cells. Depending on the vascular context it can induce endothelial cell activation and survival or death. The microenvironmental cues determining whether endothelial cells will survive or die, however, have remained elusive. Here we report that integrin ligation acts permissive for TNF-induced protein kinase B (PKB/Akt) but not nuclear factor (NF)-kappa B activation. Concomitant activation of PKB/Akt and NF-kappa B is essential for the survival of endothelial cells exposed to TNF. Active PKB/Akt strengthens integrin-dependent endothelial cell adhesion, whereas disruption of actin stress fibers abolishes the protective effect of PKB/Akt. Integrin-mediated adhesion also represses TNF-induced JNK activation, but JNK activity is not required for cell death. The alpha V beta 3/alpha V beta 5 integrin inhibitor EMD121974 sensitizes endothelial cells to TNF-dependent cytotoxicity and active PKB/ Akt attenuates this effect. Interferon gamma synergistically enhanced TNF-induced endothelial cell death in all conditions tested. Taken together, these observations reveal a novel permissive role for integrins in TNF-induced PKB/ Akt activation and prevention of TNF-induced death distinct of NF-kappa B, and implicate the actin cytoskeleton in PKB/Akt-mediated cell survival. The sensitizing effect of EMD121974 on TNF cytotoxicity may open new perspectives to the therapeutic use of TNF as anticancer agent.	Lausanne Canc Ctr, Div Expt Oncol, CH-1066 Epalinges, Switzerland; Swiss Inst Expt Canc Res, NCCR Mol Oncol, CH-1066 Epalinges, Switzerland; Inst Gustave Roussy, INSERM, UNIT U487, F-94805 Villejuif, France; Merck KGaA, Preclin Res Oncol, Darmstadt, Germany	Swiss Institute Experimental Cancer Research; Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy; Merck KGaA	Ruegg, C (corresponding author), Lwoff Inst, CNRS, FRE 2944, 7 Rue Guy Moquet, F-94801 Villejuif, France.	curzio.ruegg@isrec.ch	Chouaib, Salem/F-7939-2016	Goodman, Simon L./0000-0002-3480-1346; Hasmim, Meriem/0000-0002-7920-2443				Agrawal S, 2002, MOL CELL BIOL, V22, P1981, DOI 10.1128/MCB.22.7.1981-1992.2002; Alghisi GC, 2006, ENDOTHELIUM-J ENDOTH, V13, P113, DOI 10.1080/10623320600698037; Baker SJ, 1998, ONCOGENE, V17, P3261, DOI 10.1038/sj.onc.1202568; BALKWILL FR, 1987, CANCER RES, V47, P4755; Battle T. E., 2002, Current Molecular Medicine (Hilversum), V2, P381, DOI 10.2174/1566524023362456; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Beyaert R, 2002, INT REV CYTOL, V214, P225; Bezzi M, 2003, J BIOL CHEM, V278, P43603, DOI 10.1074/jbc.M308114200; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; Burow ME, 2000, BIOCHEM BIOPH RES CO, V271, P342, DOI 10.1006/bbrc.2000.2626; Byzova TV, 2000, MOL CELL, V6, P851, DOI 10.1016/S1097-2765(05)00076-6; Cai ZZ, 1997, J BIOL CHEM, V272, P96; Chen JX, 2004, AM J PHYSIOL-HEART C, V287, pH187, DOI 10.1152/ajpheart.01058.2003; COLLINS T, 1995, FASEB J, V9, P899, DOI 10.1096/fasebj.9.10.7542214; Corada M, 1999, P NATL ACAD SCI USA, V96, P9815, DOI 10.1073/pnas.96.17.9815; Dechantsreiter MA, 1999, J MED CHEM, V42, P3033, DOI 10.1021/jm970832g; Fornaro M, 2003, J BIOL CHEM, V278, P50402, DOI 10.1074/jbc.M307627200; Gooch JL, 2000, CELL GROWTH DIFFER, V11, P335; Gourlay CW, 2005, NAT REV MOL CELL BIO, V6, P583, DOI 10.1038/nrm1682; Hermann C, 2000, ARTERIOSCL THROM VAS, V20, P402, DOI 10.1161/01.ATV.20.2.402; Imose M, 2003, LIVER INT, V23, P386, DOI 10.1034/j.1478-3231.2003.00867.x; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; Kim AH, 2002, NEURON, V35, P697, DOI 10.1016/S0896-6273(02)00821-8; Korff T, 1998, J CELL BIOL, V143, P1341, DOI 10.1083/jcb.143.5.1341; Laird SM, 1998, CELL SIGNAL, V10, P473, DOI 10.1016/S0898-6568(97)00173-3; Lejeune Ferdy J, 2006, Cancer Immun, V6, P6; MAREEL M, 1988, INT J CANCER, V42, P470, DOI 10.1002/ijc.2910420327; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; NOLOP KB, 1990, AM J PHYSIOL, V259, P123; Papadakis CM, 2000, EUR PHYS J E, V1, P275, DOI 10.1007/s101890050029; Pober JS, 1998, PATHOL BIOL, V46, P159; Ruegg C, 1998, NAT MED, V4, P408, DOI 10.1038/nm0498-408; SCANLON M, 1989, P NATL ACAD SCI USA, V86, P182, DOI 10.1073/pnas.86.1.182; Shyy JY, 2002, CIRC RES, V91, P769, DOI 10.1161/01.RES.0000038487.19924.18; Spagnuolo R, 2004, BLOOD, V103, P3005, DOI 10.1182/blood-2003-07-2459; Suk K, 2001, J IMMUNOL, V166, P4481, DOI 10.4049/jimmunol.166.7.4481; Surapisitchat J, 2001, P NATL ACAD SCI USA, V98, P6476, DOI 10.1073/pnas.101134098; Thorburn A, 2004, CELL SIGNAL, V16, P139, DOI 10.1016/j.cellsig.2003.08.007; Yilmaz A, 1998, INT J CANCER, V77, P592; Zhang R, 2005, ONCOGENE, V24, P3954, DOI 10.1038/sj.onc.1208548	40	26	27	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG	2007	26	39					5722	5732		10.1038/sj.onc.1210354	http://dx.doi.org/10.1038/sj.onc.1210354			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	202EP	17369858				2022-12-28	WOS:000248885100004
J	Hu, B; Guo, P; Bar-Joseph, I; Imanishi, Y; Jarzynka, MJ; Bogler, O; Mikkelsen, T; Hirose, T; Nishikawa, R; Cheng, SY				Hu, B.; Guo, P.; Bar-Joseph, I.; Imanishi, Y.; Jarzynka, M. J.; Bogler, O.; Mikkelsen, T.; Hirose, T.; Nishikawa, R.; Cheng, S. Y.			Neuropilin-1 promotes human glioma progression through potentiating the activity of the HGF/SF autocrine pathway	ONCOGENE			English	Article						neuropilin-1; HGF/SF; c-Met; glioma	ENDOTHELIAL GROWTH-FACTOR; TUMOR ANGIOGENESIS; CANCER CELLS; EXPRESSION; RECEPTORS; INDUCTION	Neuropilin-1 (NRP1) functions as a coreceptor through interaction with plexin A1 or vascular endothelial growth factor (VEGF) receptor during neuronal development and angiogenesis. NRP1 potentiates the signaling pathways stimulated by semaphorin 3A and VEGF-A in neuronal and endothelial cells, respectively. In this study, we investigate the role of tumor cell-expressed NRP1 in glioma progression. Analyses of human glioma specimens (WHO grade I-IV tumors) revealed a significant correlation of NRP1 expression with glioma progression. In tumor xenografts, overexpression of NRP1 by U87MG gliomas strongly promoted tumor growth and angiogenesis. Overexpression of NRP1 by U87MG cells stimulated cell survival through the enhancement of autocrine hepatocyte growth factor/scatter factor (HGF/SF)/c-Met signaling. NRP1 not only potentiated the activity of endogenous HGF/SF on glioma cell survival but also enhanced HGF/SF-promoted cell proliferation. Inhibition of HGF/SF, c-Met and NRP1 abrogated NRP1-potentiated autocrine HGF/SF stimulation. Furthermore, increased phosphorylation of c-Met correlated with glioma progression in human glioma biopsies in which NRP1 is upregulated and in U87MG NRP1-overexpressing tumors. Together, these data suggest that tumor cell-expressed NRP1 promotes glioma progression through potentiating the activity of the HGF/SF autocrine c-Met signaling pathway, in addition to enhancing angiogenesis, suggesting a novel mechanism of NRP1 in promoting human glioma progression.	Univ Pittsburgh, Inst Canc, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Dept Pathol, Pittsburgh, PA 15213 USA; Res Pavil Hillman Canc Ctr, Dept Pathol, Pittsburgh, PA USA; Univ Texas, MD Anderson Canc Ctr, Dept Neurosurg, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Brain Tumor Ctr, Houston, TX 77030 USA; Henry Ford Hosp, Hermelin Brain Tumor Ctr, Dept Neurosurg, Detroit, MI 48202 USA; Saitama Med Univ, Dept Pathol, Saitama, Japan; Saitama Med Univ, Dept Neurosurg, Saitama, Japan	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Henry Ford Health System; Henry Ford Hospital; Saitama Medical University; Saitama Medical University	Cheng, SY (corresponding author), Univ Pittsburgh, Inst Canc, Suite 2-26,5117 Ctr Ave, Pittsburgh, PA 15213 USA.	hub@upmc.edu; chengs@upmc.edu	Imanishi, Yorihisa/AAL-3018-2021	Imanishi, Yorihisa/0000-0003-0047-7987; Bogler, Oliver/0000-0002-3700-0480	NATIONAL CANCER INSTITUTE [R24CA095809, R01CA130966, R01CA102011] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA130966-01A1, CA102011, R01 CA130966, R24 CA095809, R01 CA102011-04, R01 CA102011-02, R01 CA102011, CA095809, R01 CA102011-03] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abounader R, 2005, NEURO-ONCOLOGY, V7, P436, DOI 10.1215/S1152851705000050; Abounader R, 2001, FASEB J, V15, P108, DOI 10.1096/fj.01-0421fje; Akagi M, 2003, BRIT J CANCER, V88, P796, DOI 10.1038/sj.bjc.6600811; Bachelder RE, 2003, CANCER RES, V63, P5230; Bagri A, 2002, ADV EXP MED BIOL, V515, P13; Ding H, 2000, INT J CANCER, V88, P584, DOI 10.1002/1097-0215(20001115)88:4<584::AID-IJC11>3.0.CO;2-T; Gagnon ML, 2000, P NATL ACAD SCI USA, V97, P2573, DOI 10.1073/pnas.040337597; Gao CF, 2005, CELL RES, V15, P49, DOI 10.1038/sj.cr.7290264; Guo P, 2001, CANCER RES, V61, P8569; Hu B, 2003, P NATL ACAD SCI USA, V100, P8904, DOI 10.1073/pnas.1533394100; Klagsbrun M, 2002, ADV EXP MED BIOL, V515, P33; Laterra J, 1997, BIOCHEM BIOPH RES CO, V235, P743, DOI 10.1006/bbrc.1997.6853; Miao HQ, 2000, FASEB J, V14, P2532, DOI 10.1096/fj.00-0250com; Parikh AA, 2004, AM J PATHOL, V164, P2139, DOI 10.1016/S0002-9440(10)63772-8; Rieger J, 2003, GLIA, V42, P379, DOI 10.1002/glia.10210; West DC, 2005, J BIOL CHEM, V280, P13457, DOI 10.1074/jbc.M410924200; Wey JS, 2005, BRIT J CANCER, V93, P233, DOI 10.1038/sj.bjc.6602663	17	140	145	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2007	26	38					5577	5586		10.1038/sj.onc.1210348	http://dx.doi.org/10.1038/sj.onc.1210348			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	200ZS	17369861	Green Accepted			2022-12-28	WOS:000248801900003
J	Matskova, LV; Helmstetter, C; Ingham, RJ; Gish, G; Lindholm, CK; Ernberg, I; Pawson, T; Winberg, G				Matskova, L. V.; Helmstetter, C.; Ingham, R. J.; Gish, G.; Lindholm, C. K.; Ernberg, I.; Pawson, T.; Winberg, G.			The Shb signalling scaffold binds to and regulates constitutive signals from the Epstein-Barr virus LMP2A membrane protein	ONCOGENE			English	Article						Epstein-Barr virus; latency-associated membrane protein 2A (LMP2A); Syk; Shb; AIP4; Akt	SYK TYROSINE KINASE; T-CELL-RECEPTOR; EPITHELIAL-CELLS; PHOSPHATIDYLINOSITOL 3-KINASE; NEGATIVE REGULATION; DOMAIN-PROTEIN; IN-VIVO; CBL; 2A; LYMPHOCYTES	The Epstein-Barr virus latency-associated membrane protein LMP2A has been shown to activate the survival kinase Akt in epithelial and B cells in a phosphoinositide 3-kinase-dependent fashion. In this study, we demonstrate that the signalling scaffold Shb associates through SH2 and PTB domain interactions with phosphorylated tyrosine motifs in the LMP2A N-terminal tail. Additionally, we show that mutation of tyrosines in these motifs as well as shRNA-mediated downregulation of Shb leads to a loss of constitutive Akt-activation in LMP2A-expressing cells. Furthermore, utilization by Shb of the LMP2A ITAM motif regulates stability of the Syk tyrosine kinase in LMP2A-expressing cells. Our data set the precedent for viral utilization of the Shb signalling scaffold and implicate Shb as a regulator of LMP2A-dependent Akt activation.	Karolinska Inst, MTC, SE-17177 Stockholm, Sweden; Univ Victoria, Dept Biol, Victoria, BC V8W 2Y2, Canada; Mt Sinai Hosp, Samuel Res Inst, Toronto, ON M5G 1X5, Canada; Univ Lausanne, Lausanne Branch, Ludwig Inst Canc Res, CH-1066 Epalinges, Switzerland	Karolinska Institutet; University of Victoria; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Ludwig Institute for Cancer Research; University of Lausanne	Matskova, LV (corresponding author), Karolinska Inst, MTC, Nobels Vag 16,Box 280, SE-17177 Stockholm, Sweden.	ludmat@ki.se	Pawson, Tony J/E-4578-2013; Matskova, Liudmila/AAF-4201-2020; Winberg, Gosta/I-5686-2013; Gish, Gerald D/C-7228-2017; Matskova, Liudmila/J-3843-2017	Matskova, Liudmila/0000-0002-3174-1560; Matskova, Liudmila/0000-0002-3174-1560; Peine, Caroline/0000-0001-6267-3452; Winberg, Gosta/0000-0002-3371-4056				Abdallah B, 1996, HUM GENE THER, V7, P1947, DOI 10.1089/hum.1996.7.16-1947; BEAUFILS P, 1993, EMBO J, V12, P5105, DOI 10.1002/j.1460-2075.1993.tb06205.x; Caldwell RG, 1998, IMMUNITY, V9, P405, DOI 10.1016/S1074-7613(00)80623-8; Casola S, 2004, NAT IMMUNOL, V5, P317, DOI 10.1038/ni1036; Coligan JE, 2001, CURRENT PROTOCOLS PR; Coopman PJP, 2000, NATURE, V406, P742, DOI 10.1038/35021086; Courbard JR, 2002, J BIOL CHEM, V277, P45267, DOI 10.1074/jbc.M206460200; DIANZANI U, 1994, J IMMUNOL, V153, P952; Engels N, 2001, J EXP MED, V194, P255, DOI 10.1084/jem.194.3.255; Ettenberg SA, 2001, J BIOL CHEM, V276, P27677, DOI 10.1074/jbc.M102641200; Fodor S, 2006, IMMUNOL LETT, V104, P29, DOI 10.1016/j.imlet.2005.11.001; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Fruehling S, 1996, J VIROL, V70, P6216, DOI 10.1128/JVI.70.9.6216-6226.1996; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; Grande Shannon M, 2006, Future Oncol, V2, P301, DOI 10.2217/14796694.2.2.301; HARLOWE E, 1988, ANTIBODIES LAB MANUA; Holmqvist K, 2004, J BIOL CHEM, V279, P22267, DOI 10.1074/jbc.M312729200; Ikeda M, 2000, VIROLOGY, V268, P178, DOI 10.1006/viro.1999.0166; Ikeda M, 2002, VIROLOGY, V300, P153, DOI 10.1006/viro.2002.1562; Ingham RJ, 2005, J BIOL CHEM, V280, P34133, DOI 10.1074/jbc.M507831200; KARLSSON T, 1995, ONCOGENE, V10, P1475; Katz E, 2005, J EXP MED, V201, P431, DOI 10.1084/jem.20041471; Koretzky GA, 2006, NAT REV IMMUNOL, V6, P67, DOI 10.1038/nri1750; Kunath T, 2003, NAT BIOTECHNOL, V21, P559, DOI 10.1038/nbt813; LAUX G, 1988, EMBO J, V7, P769, DOI 10.1002/j.1460-2075.1988.tb02874.x; Lindholm CK, 2002, EUR J BIOCHEM, V269, P3279, DOI 10.1046/j.1432-1033.2002.03008.x; LONGNECKER R, 1991, J VIROL, V65, P3681, DOI 10.1128/JVI.65.7.3681-3692.1991; Lu J, 2006, J BIOL CHEM, V281, P8806, DOI 10.1074/jbc.M507305200; Lupher ML, 1998, J BIOL CHEM, V273, P35273, DOI 10.1074/jbc.273.52.35273; Magnifico A, 2003, J BIOL CHEM, V278, P43169, DOI 10.1074/jbc.M308009200; Matskova L, 2001, J VIROL, V75, P10941, DOI 10.1128/JVI.75.22.10941-10949.2001; Merchant M, 2000, J VIROL, V74, P9115, DOI 10.1128/JVI.74.19.9115-9124.2000; Morrison JA, 2005, J VIROL, V79, P2375, DOI 10.1128/JVI.79.4.2375-2382.2005; Ota S, 2000, J BIOL CHEM, V275, P414, DOI 10.1074/jbc.275.1.414; Rao N, 2001, EMBO J, V20, P7085, DOI 10.1093/emboj/20.24.7085; Scholle F, 2000, J VIROL, V74, P10681, DOI 10.1128/JVI.74.22.10681-10689.2000; Scholle F, 2001, VIROLOGY, V291, P208, DOI 10.1006/viro.2001.1197; Shaw G, 2002, FASEB J, V16, P869, DOI 10.1096/fj.01-0995fje; Silvennoinen O, 1996, J IMMUNOL, V156, P100; Swart R, 2000, J VIROL, V74, P10838, DOI 10.1128/JVI.74.22.10838-10845.2000; Swart R, 1999, VIROLOGY, V263, P485, DOI 10.1006/viro.1999.9964; Tomlinson CC, 2004, J VIROL, V78, P1918, DOI 10.1128/JVI.78.4.1918-1927.2004; WELSH M, 1994, ONCOGENE, V9, P19; Welsh M, 1998, ONCOGENE, V16, P891, DOI 10.1038/sj.onc.1201607; Welsh N, 2002, MOL MED, V8, P695, DOI 10.1007/BF03402033; Winberg G, 2000, MOL CELL BIOL, V20, P8526, DOI 10.1128/MCB.20.22.8526-8535.2000; Zubiaur M, 1997, J IMMUNOL, V159, P193	47	16	18	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2007	26	34					4908	4917		10.1038/sj.onc.1210298	http://dx.doi.org/10.1038/sj.onc.1210298			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	194CV	17311000				2022-12-28	WOS:000248322500003
J	Camus, S; Menendez, S; Cheok, CF; Stevenson, LF; Lain, S; Lane, DP				Camus, S.; Menendez, S.; Cheok, C. F.; Stevenson, L. F.; Lain, S.; Lane, D. P.			Ubiquitin-independent degradation of p53 mediated by high-risk human papillomavirus protein E6	ONCOGENE			English	Article						ubiquitination; p53; human papillomavirus; E6; degradation; proteasome	MDM2 PROMOTES; ORNITHINE-DECARBOXYLASE; PROTEASOMAL DEGRADATION; GROWTH SUPPRESSION; CONJUGATING ENZYME; DNA-BINDING; CELL-LINES; C-TERMINUS; ONCOPROTEIN; E6-AP	In vitro, high-risk human papillomavirus E6 proteins have been shown, in conjunction with E6-associated protein (E6AP), to mediate ubiquitination of p53 and its degradation by the 26S proteasome by a pathway that is thought to be analogous to Mdm2-mediated p53 degradation. However, differences in the requirements of E6/E6AP and Mdm2 to promote the degradation of p53, both in vivo and in vitro, suggest that these two E3 ligases may promote p53 degradation by distinct pathways. Using tools that disrupt ubiquitination and degradation, clear differences between E6-and Mdm2-mediated p53 degradation are presented. The consistent failure to fully protect p53 protein from E6-mediated degradation by disrupting the ubiquitin-degradation pathway provides the first evidence of an E6-dependent, ubiquitin-independent, p53 degradation pathway in vivo.	Inst Mol & Cell Biol, Dept Cell Cycle Control, Proteos 138673, Singapore; Univ Dundee, Dept Surg & Mol Oncol, Dundee DD1 4HN, Scotland; Ninewells Hosp & Med Sch, Dundee, Scotland	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); University of Dundee; University of Dundee	Camus, S (corresponding author), Inst Mol & Cell Biol, Dept Cell Cycle Control, 61 Biopolis Dr, Proteos 138673, Singapore.	scamus@imcb.a-star.edu.sg	Lane, David P/C-4920-2008; Lain, Sonia/B-6980-2014	Lain, Sonia/0000-0001-9693-5246; Menendez, Sergio/0000-0002-7929-8641; Lane, David/0000-0003-0551-3545	Cancer Research UK [A6613] Funding Source: Medline	Cancer Research UK(Cancer Research UK)		Benaroudj N, 2001, BIOCHIMIE, V83, P311, DOI 10.1016/S0300-9084(01)01244-5; BERCOVICH Z, 1993, EUR J BIOCHEM, V213, P205, DOI 10.1111/j.1432-1033.1993.tb17749.x; Camus S, 2003, FEBS LETT, V536, P220, DOI 10.1016/S0014-5793(03)00054-1; Chen Z, 2004, SHOCK, V21, P1; CHOWDARY DR, 1994, MOL CELL BIOL, V14, P1997, DOI 10.1128/MCB.14.3.1997; Coffino P, 2001, BIOCHIMIE, V83, P319, DOI 10.1016/S0300-9084(01)01252-4; Courtois S, 2002, ONCOGENE, V21, P6722, DOI 10.1038/sj.onc.1205874; Crook T, 1996, VIROLOGY, V217, P285, DOI 10.1006/viro.1996.0115; Dalal S, 1996, J VIROL, V70, P683, DOI 10.1128/JVI.70.2.683-688.1996; FOSTER SA, 1994, J VIROL, V68, P5698, DOI 10.1128/JVI.68.9.5698-5705.1994; Gardiol D, 1998, J GEN VIROL, V79, P1963, DOI 10.1099/0022-1317-79-8-1963; Ghosh A, 2004, MOL CELL BIOL, V24, P7987, DOI 10.1128/MCB.24.18.7987-7997.2004; Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001; Glockzin S, 2003, MOL CELL BIOL, V23, P8960, DOI 10.1128/MCB.23.24.8960-8969.2003; Harris SL, 2005, ONCOGENE, V24, P2899, DOI 10.1038/sj.onc.1208615; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hengstermann A, 2005, J VIROL, V79, P9296, DOI 10.1128/JVI.79.14.9296-9300.2005; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Hoyt MA, 2005, METHOD ENZYMOL, V398, P399, DOI 10.1016/S0076-6879(05)98033-6; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P775, DOI 10.1128/MCB.13.2.775; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; Hwang SG, 2005, J BIOL CHEM, V280, P12758, DOI 10.1074/jbc.M413367200; Jin YT, 2003, EMBO J, V22, P6365, DOI 10.1093/emboj/cdg600; Ju DH, 2004, J BIOL CHEM, V279, P23851, DOI 10.1074/jbc.C400111200; Kahana Chaim, 2005, V301, P83; Kalejta RF, 2003, P NATL ACAD SCI USA, V100, P3263, DOI 10.1073/pnas.0538058100; Kelley ML, 2005, J VIROL, V79, P3737, DOI 10.1128/JVI.79.6.3737-3747.2005; Kretz-Remy C, 2003, BIOL CHEM, V384, P589, DOI 10.1515/BC.2003.066; Kubbutat MHG, 1998, MOL CELL BIOL, V18, P5690, DOI 10.1128/MCB.18.10.5690; Lagrange M, 2005, J GEN VIROL, V86, P1001, DOI 10.1099/vir.0.80607-0; LECHNER MS, 1994, J VIROL, V68, P4262, DOI 10.1128/JVI.68.7.4262-4273.1994; Li XQ, 1996, J VIROL, V70, P4509, DOI 10.1128/JVI.70.7.4509-4516.1996; Li XQ, 1996, J BIOL CHEM, V271, P4447; Li XT, 2006, CELL, V124, P381, DOI 10.1016/j.cell.2005.11.037; Liu Y, 1999, J VIROL, V73, P7297, DOI 10.1128/JVI.73.9.7297-7307.1999; Nakamura S, 2002, ONCOGENE, V21, P2605, DOI 10.1038/sj.onc.1205343; Ness GC, 2005, FEBS LETT, V579, P3126, DOI 10.1016/j.febslet.2005.05.001; Nomine Y, 2006, MOL CELL, V21, P665, DOI 10.1016/j.molcel.2006.01.024; PENA MM, 2005, BIOCHEM J, V394, P355; ROLFE M, 1995, P NATL ACAD SCI USA, V92, P3264, DOI 10.1073/pnas.92.8.3264; ROSENBERGHASSON Y, 1989, EUR J BIOCHEM, V185, P469, DOI 10.1111/j.1432-1033.1989.tb15138.x; Saeki Y, 2004, GENES GENET SYST, V79, P77, DOI 10.1266/ggs.79.77; Salvat C, 2000, EUR J BIOCHEM, V267, P3712, DOI 10.1046/j.1432-1327.2000.01404.x; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; Scheffner M, 1998, PHARMACOL THERAPEUT, V78, P129, DOI 10.1016/S0163-7258(98)00003-5; SCHEFFNER M, 1994, P NATL ACAD SCI USA, V91, P8797, DOI 10.1073/pnas.91.19.8797; Sdek P, 2005, MOL CELL, V20, P699, DOI 10.1016/j.molcel.2005.10.017; Stewart D, 2005, J VIROL, V79, P8773, DOI 10.1128/JVI.79.14.8773-8783.2005; Tofaris GK, 2001, FEBS LETT, V509, P22, DOI 10.1016/S0014-5793(01)03115-5; Xirodimas D, 2001, ONCOGENE, V20, P4972, DOI 10.1038/sj.onc.1204656; Yin YL, 2002, NAT CELL BIOL, V4, P462, DOI 10.1038/ncb801; zur Hausen H, 2000, JNCI-J NATL CANCER I, V92, P690, DOI 10.1093/jnci/92.9.690	53	55	56	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 14	2007	26	28					4059	4070		10.1038/sj.onc.1210188	http://dx.doi.org/10.1038/sj.onc.1210188			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	178XD	17224909	Green Accepted			2022-12-28	WOS:000247252700002
J	Hao, N; Behar, M; Elston, TC; Dohlman, HG				Hao, N.; Behar, M.; Elston, T. C.; Dohlman, H. G.			Systems biology analysis of G protein and MAP kinase signaling in yeast	ONCOGENE			English	Review						mitogen-activated protein kinases; yeast; genetics; modeling; systems biology; desensitization	COUPLED RECEPTORS; ALPHA-SUBUNIT; RGS PROTEIN; GENETIC-ANALYSIS; GLOBAL ANALYSIS; A-FACTOR; FEEDBACK; PHOSPHORYLATION; PHEROMONE; INHIBITION	Approximately a third of all drugs act by binding directly to cell surface receptors coupled to G proteins. Other drugs act indirectly on these same pathways, for example, by inhibiting neurotransmitter reuptake or by blocking the inactivation of intracellular second messengers. The se drugs have revolutionized the treatment of human disease. However, the complexity of G protein signaling mechanisms has significantly hampered our ability to identify additional new drug targets. Moreover, today's molecular pharmacologists are accustomed to working on narrowly focused problems centered on a single protein or enzymatic process. Here we describe emerging efforts in yeast aimed at identifying proteins and processes that modulate the function of receptors, G proteins and MAP kinase effectors. The scope of these efforts is far more systematic, comprehensive and quantitative than anything attempted previously, and includes integrated approaches in genetics, proteomics and computational biology.	Univ N Carolina, Dept Pharmacol, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Phys, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Elston, TC (corresponding author), Univ N Carolina, Dept Pharmacol, CB 7365, Chapel Hill, NC 27599 USA.	telston@med.unc.edu; hdohlman@med.unc.edu	Hao, Nan/O-3462-2016	Hao, Nan/0000-0003-2857-4789; Dohlman, Henrik/0000-0003-2443-0729				Alon U, 1999, NATURE, V397, P168, DOI 10.1038/16483; ALON U, 2006, INTRO SYSTEMS BIOL; Apanovitch DM, 1998, J BIOL CHEM, V273, P28597, DOI 10.1074/jbc.273.44.28597; Apanovitch DM, 1998, BIOCHEMISTRY-US, V37, P4815, DOI 10.1021/bi9729965; Barnes DJ, 2003, SEMIN HEMATOL, V40, P34, DOI 10.1053/shem.2003.50002; Bhalla US, 2002, SCIENCE, V297, P1018, DOI 10.1126/science.1068873; Bornheimer SJ, 2004, P NATL ACAD SCI USA, V101, P15899, DOI 10.1073/pnas.0407009101; BREWSTER JL, 1993, SCIENCE, V259, P1760, DOI 10.1126/science.7681220; CHAN RK, 1982, MOL CELL BIOL, V2, P21, DOI 10.1128/MCB.2.1.21; CHAN RK, 1982, MOL CELL BIOL, V2, P11, DOI 10.1128/MCB.2.1.11; Chasse SA, 2006, EUKARYOT CELL, V5, P330, DOI 10.1128/EC.5.2.330-346.2006; Chasse SA, 2003, ASSAY DRUG DEV TECHN, V1, P357, DOI 10.1089/154065803764958649; Dohlman HG, 2001, ANNU REV BIOCHEM, V70, P703, DOI 10.1146/annurev.biochem.70.1.703; Dohlman HG, 2002, NATURE, V418, P591, DOI 10.1038/418591a; DOHLMAN HG, 1995, MOL CELL BIOL, V15, P3635; Dohlman HG, 1996, MOL CELL BIOL, V16, P5194; Farfel Z, 1999, NEW ENGL J MED, V340, P1012, DOI 10.1056/NEJM199904013401306; Ferrell JE, 2001, CHAOS, V11, P227, DOI 10.1063/1.1349894; Force T, 2004, CIRCULATION, V109, P1196, DOI 10.1161/01.CIR.0000118538.21306.A9; Garrison TR, 1999, J BIOL CHEM, V274, P36387, DOI 10.1074/jbc.274.51.36387; Gelperin DM, 2005, GENE DEV, V19, P2816, DOI 10.1101/gad.1362105; Ghaemmaghami S, 2003, NATURE, V425, P737, DOI 10.1038/nature02046; GIBBS JB, 1994, CELL, V79, P193, DOI 10.1016/0092-8674(94)90189-9; Goffeau A, 1996, SCIENCE, V274, P546, DOI 10.1126/science.274.5287.546; Gold SJ, 1997, J NEUROSCI, V17, P8024; GOLDBETER A, 1981, P NATL ACAD SCI-BIOL, V78, P6840, DOI 10.1073/pnas.78.11.6840; Guo M, 2003, MOL CELL, V12, P517, DOI 10.1016/S1097-2765(03)00307-1; Gutkind JS, 1998, J BIOL CHEM, V273, P1839, DOI 10.1074/jbc.273.4.1839; Hao N, 2003, J BIOL CHEM, V278, P46506, DOI 10.1074/jbc.M308432200; HAO N, 2007, IN PRESS CURR BIOL; Hardcastle JL, 2000, ULTRASON SONOCHEM, V7, P7, DOI 10.1016/S1350-4177(99)00026-7; Hartwell LH, 1997, SCIENCE, V278, P1064, DOI 10.1126/science.278.5340.1064; Heinrich R, 2002, MOL CELL, V9, P957, DOI 10.1016/S1097-2765(02)00528-2; Hohmann S, 2002, MICROBIOL MOL BIOL R, V66, P300, DOI 10.1128/MMBR.66.2.300-372.2002; Hornberg JJ, 2005, FEBS J, V272, P244, DOI 10.1111/j.1432-1033.2004.04404.x; Huang CYF, 1996, P NATL ACAD SCI USA, V93, P10078, DOI 10.1073/pnas.93.19.10078; Huh WK, 2003, NATURE, V425, P686, DOI 10.1038/nature02026; Jacoby T, 1997, J BIOL CHEM, V272, P17749, DOI 10.1074/jbc.272.28.17749; Johnson GL, 2005, CURR OPIN CHEM BIOL, V9, P325, DOI 10.1016/j.cbpa.2005.04.004; Kenakin T, 2004, TRENDS PHARMACOL SCI, V25, P186, DOI 10.1016/j.tips.2004.02.012; Kholodenko BN, 2000, EUR J BIOCHEM, V267, P1583, DOI 10.1046/j.1432-1327.2000.01197.x; Klipp E, 2005, NAT BIOTECHNOL, V23, P975, DOI 10.1038/nbt1114; Kofahl B, 2004, YEAST, V21, P831, DOI 10.1002/yea.1122; Komarova NL, 2005, MOL SYST BIOL, V1, DOI 10.1038/msb4100031; Kumar S, 2003, NAT REV DRUG DISCOV, V2, P717, DOI 10.1038/nrd1177; Lin FT, 1999, J BIOL CHEM, V274, P15971, DOI 10.1074/jbc.274.23.15971; Marinissen MJ, 2001, TRENDS PHARMACOL SCI, V22, P368, DOI 10.1016/S0165-6147(00)01678-3; Markevich NI, 2004, J CELL BIOL, V164, P353, DOI 10.1083/jcb.200308060; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Martin H, 2005, MOL MICROBIOL, V58, P6, DOI 10.1111/j.1365-2958.2005.04822.x; Martzen MR, 1999, SCIENCE, V286, P1153, DOI 10.1126/science.286.5442.1153; Morrison DK, 2003, ANNU REV CELL DEV BI, V19, P91, DOI 10.1146/annurev.cellbio.19.111401.091942; Neubig RR, 2002, NAT REV DRUG DISCOV, V1, P187, DOI 10.1038/nrd747; Neves SR, 2002, SCIENCE, V296, P1636, DOI 10.1126/science.1071550; Ogier-Denis E, 2000, J BIOL CHEM, V275, P39090, DOI 10.1074/jbc.M006198200; Parnell SC, 2005, BIOCHEMISTRY-US, V44, P8159, DOI 10.1021/bi0503091; Pitcher JA, 1999, J BIOL CHEM, V274, P34531, DOI 10.1074/jbc.274.49.34531; Roberts CJ, 2000, SCIENCE, V287, P873, DOI 10.1126/science.287.5454.873; Roman DL, 2007, MOL PHARMACOL, V71, P169, DOI 10.1124/mol.106.028670; Sabbagh W, 2001, MOL CELL, V8, P683, DOI 10.1016/S1097-2765(01)00322-7; Sasagawa S, 2005, NAT CELL BIOL, V7, P365, DOI 10.1038/ncb1233; Schaber J, 2006, FEBS J, V273, P3520, DOI 10.1111/j.1742-4658.2006.05359.x; Schoeberl B, 2002, NAT BIOTECHNOL, V20, P370, DOI 10.1038/nbt0402-370; Sebolt-Leopold JS, 2006, NATURE, V441, P457, DOI 10.1038/nature04874; Shao DY, 2006, BIOPHYS J, V91, P3986, DOI 10.1529/biophysj.106.081661; Shenoy S.K., 2005, SCI STKE, V2005, pcm10; Slessareva JE, 2006, CELL, V126, P191, DOI 10.1016/j.cell.2006.04.045; Somsen OJG, 2002, J THEOR BIOL, V218, P343, DOI 10.1006/jtbi.2002.3082; Spiegel AM, 2000, HORM RES, V53, P17, DOI 10.1159/000023526; Sprang SR, 1997, ANNU REV BIOCHEM, V66, P639, DOI 10.1146/annurev.biochem.66.1.639; Tyson JJ, 2003, CURR OPIN CELL BIOL, V15, P221, DOI 10.1016/S0955-0674(03)00017-6; Wang X, 2006, BIOPHYS J, V90, P1961, DOI 10.1529/biophysj.105.073874; Wang YQ, 2003, J BIOL CHEM, V278, P22284, DOI 10.1074/jbc.M301272200; Wang YQ, 2002, J BIOL CHEM, V277, P15766, DOI 10.1074/jbc.M111733200; Winzeler EA, 1999, SCIENCE, V285, P901, DOI 10.1126/science.285.5429.901; WurglerMurphy SM, 1997, MOL CELL BIOL, V17, P1289, DOI 10.1128/MCB.17.3.1289; Xiong W, 2003, NATURE, V426, P460, DOI 10.1038/nature02089; Yi TM, 2003, P NATL ACAD SCI USA, V100, P10764, DOI 10.1073/pnas.1834247100; Yi TM, 2000, P NATL ACAD SCI USA, V97, P4649, DOI 10.1073/pnas.97.9.4649; Zhong HL, 2003, J BIOL CHEM, V278, P7278, DOI 10.1074/jbc.M208819200	80	30	30	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 15	2007	26	22					3254	3266		10.1038/sj.onc.1210416	http://dx.doi.org/10.1038/sj.onc.1210416			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	169PH	17496920				2022-12-28	WOS:000246603600013
J	Owens, DM; Keyse, SM				Owens, D. M.; Keyse, S. M.			Differential regulation of MAP kinase signalling by dual-specificity protein phosphatases	ONCOGENE			English	Review						DUSP; MKP; MAP kinase; phosphatase; signal transduction	CATALYTIC ACTIVATION; CRYSTAL-STRUCTURE; DOCKING SITES; ERK2; BINDING; MKP3; DOMAIN; PAC-1; INSIGHTS; INNATE	The regulated dephosphorylation of mitogen-activated protein kinases (MAPKs) plays a key role in determining the magnitude and duration of kinase activation and hence the physiological outcome of signalling. In mammalian cells, an important component of this control is mediated by the differential expression and activities of a family of 10 dual-specificity (Thr/Tyr) MAPK phosphatases (MKPs). These enzymes share a common structure in which MAPK substrate recognition is determined by sequences within an amino-terminal non-catalytic domain whereas MAPK binding often leads to a conformational change within the C-terminal catalytic domain resulting in increased enzyme activity. MKPs can either recognize and inactivate a single class of MAP kinase, as in the specific inactivation of extracellular signal regulated kinase (ERK) by the cytoplasmic phosphatase DUSP6/MKP-3 or can regulate more than one MAPK pathway as illustrated by the ability of DUSP1/MKP-1 to dephosphorylate ERK, c-Jun amino-terminal kinase and p38 in the cell nucleus. These properties, coupled with transcriptional regulation of MKP expression in response to stimuli that activate MAPK signalling, suggest a complex negative regulatory network in which individual MAPK activities can be subject to negative feedback control, but also raise the possibility that signalling through multiple MAPK pathways may be integrated at the level of regulation by MKPs.	Univ Dundee, Ninewells Hosp & Med Sch, Biomed Res Ctr, Canc Res UK Stress Response Lab, Dundee DD1 9SY, Scotland	University of Dundee	Keyse, SM (corresponding author), Univ Dundee, Ninewells Hosp & Med Sch, Biomed Res Ctr, Canc Res UK Stress Response Lab, Dundee DD1 9SY, Scotland.	Stephen.Keyse@cancer.org.uk	Li, Chia Cheng/D-9906-2015; Keyse, Stephen M./B-9575-2009	Keyse, Stephen M./0000-0002-5150-8221				Adams RH, 2000, MOL CELL, V6, P109, DOI 10.1016/S1097-2765(00)00012-5; Bordo D, 2002, EMBO REP, V3, P741, DOI 10.1093/embo-reports/kvf150; BOTT CM, 1994, FEBS LETT, V352, P201, DOI 10.1016/0014-5793(94)00958-9; Camps M, 1998, SCIENCE, V280, P1262, DOI 10.1126/science.280.5367.1262; Camps M, 2000, FASEB J, V14, P6, DOI 10.1096/fasebj.14.1.6; Chang CI, 2002, MOL CELL, V9, P1241, DOI 10.1016/S1097-2765(02)00525-7; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Chen PL, 2001, J BIOL CHEM, V276, P29440, DOI 10.1074/jbc.M103463200; Chi HB, 2006, P NATL ACAD SCI USA, V103, P2274, DOI 10.1073/pnas.0510965103; Christie GR, 2005, MOL CELL BIOL, V25, P8323, DOI 10.1128/MCB.25.18.8323-8333.2005; Chu YF, 1996, J BIOL CHEM, V271, P6497, DOI 10.1074/jbc.271.11.6497; Dickinson RJ, 2002, BIOCHEM J, V364, P145, DOI 10.1042/bj3640145; Dickinson RJ, 2002, MECH DEVELOP, V113, P193, DOI 10.1016/S0925-4773(02)00024-2; Dimitri CA, 2005, CURR BIOL, V15, P1319, DOI 10.1016/j.cub.2005.06.037; Dong C, 2002, ANNU REV IMMUNOL, V20, P55, DOI 10.1146/annurev.immunol.20.091301.131133; Dong C, 1998, SCIENCE, V282, P2092, DOI 10.1126/science.282.5396.2092; Dorfman K, 1996, ONCOGENE, V13, P925; Ebisuya M, 2005, J CELL SCI, V118, P2997, DOI 10.1242/jcs.02505; Eblaghie MC, 2003, CURR BIOL, V13, P1009, DOI 10.1016/S0960-9822(03)00381-6; Farooq A, 2003, STRUCTURE, V11, P155, DOI 10.1016/S0969-2126(02)00943-7; Farooq A, 2001, MOL CELL, V7, P387, DOI 10.1016/S1097-2765(01)00186-1; Giroux S, 1999, CURR BIOL, V9, P369, DOI 10.1016/S0960-9822(99)80164-X; Gomez AR, 2005, DEV DYNAM, V232, P695, DOI 10.1002/dvdy.20227; Groom LA, 1996, EMBO J, V15, P3621, DOI 10.1002/j.1460-2075.1996.tb00731.x; Grumont RJ, 1996, MOL CELL BIOL, V16, P2913; Hammer M, 2006, J EXP MED, V203, P15, DOI 10.1084/jem.20051753; Jeffrey KL, 2006, NAT IMMUNOL, V7, P274, DOI 10.1038/ni1310; Jeong DG, 2007, PROTEINS, V66, P253, DOI 10.1002/prot.21224; Jeong DG, 2006, J MOL BIOL, V360, P946, DOI 10.1016/j.jmb.2006.05.059; Kawakami Y, 2003, NAT CELL BIOL, V5, P513, DOI 10.1038/ncb989; Keyse SM, 2000, CURR OPIN CELL BIOL, V12, P186, DOI 10.1016/S0955-0674(99)00075-7; KEYSE SM, 1993, TRENDS BIOCHEM SCI, V18, P377, DOI 10.1016/0968-0004(93)90092-2; Lee T, 2004, MOL CELL, V14, P43, DOI 10.1016/S1097-2765(04)00161-3; Li CY, 2007, DEVELOPMENT, V134, P167, DOI 10.1242/dev.02701; Liu SJ, 2006, P NATL ACAD SCI USA, V103, P5326, DOI 10.1073/pnas.0510506103; Mandell JG, 1998, P NATL ACAD SCI USA, V95, P14705, DOI 10.1073/pnas.95.25.14705; Mandl M, 2005, MOL CELL BIOL, V25, P1830, DOI 10.1128/MCB.25.5.1830-1845.2005; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; Morrison DK, 2003, ANNU REV CELL DEV BI, V19, P91, DOI 10.1146/annurev.cellbio.19.111401.091942; Muda M, 1996, J BIOL CHEM, V271, P27205, DOI 10.1074/jbc.271.44.27205; Muda M, 1998, J BIOL CHEM, V273, P9323, DOI 10.1074/jbc.273.15.9323; Murphy LO, 2006, TRENDS BIOCHEM SCI, V31, P268, DOI 10.1016/j.tibs.2006.03.009; Nichols A, 2000, J BIOL CHEM, V275, P24613, DOI 10.1074/jbc.M001515200; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; Rigas JD, 2001, BIOCHEMISTRY-US, V40, P4398, DOI 10.1021/bi002951v; ROHAN PJ, 1993, SCIENCE, V259, P1763, DOI 10.1126/science.7681221; Salojin KV, 2006, J IMMUNOL, V176, P1899, DOI 10.4049/jimmunol.176.3.1899; Saxena M, 2000, SEMIN IMMUNOL, V12, P387, DOI 10.1006/smim.2000.0219; Slack DN, 2001, J BIOL CHEM, V276, P16491, DOI 10.1074/jbc.M010966200; Smith TG, 2006, FEBS LETT, V580, P4242, DOI 10.1016/j.febslet.2006.06.081; Smith TG, 2005, DEVELOPMENT, V132, P1305, DOI 10.1242/dev.01699; Stewart AE, 1999, NAT STRUCT BIOL, V6, P174; Tanoue T, 1999, J BIOL CHEM, V274, P19949, DOI 10.1074/jbc.274.28.19949; Tanoue T, 2002, J BIOL CHEM, V277, P22942, DOI 10.1074/jbc.M202096200; Tanoue T, 2001, J BIOL CHEM, V276, P26629, DOI 10.1074/jbc.M101981200; Tanoue T, 2001, EMBO J, V20, P466, DOI 10.1093/emboj/20.3.466; Tanoue T, 2000, NAT CELL BIOL, V2, P110, DOI 10.1038/35000065; Theodosiou A, 2002, GENOME BIOL, V3; Tsang M, 2004, DEVELOPMENT, V131, P2769, DOI 10.1242/dev.01157; Volmat V, 2001, BIOL CELL, V93, P71, DOI 10.1016/S0248-4900(01)01129-7; Wada T, 2004, ONCOGENE, V23, P2838, DOI 10.1038/sj.onc.1207556; Willoughby EA, 2005, J BIOL CHEM, V280, P25651, DOI 10.1074/jbc.M501926200; Willoughby EA, 2003, J BIOL CHEM, V278, P10731, DOI 10.1074/jbc.M207324200; Wu JJ, 2006, CELL METAB, V4, P61, DOI 10.1016/j.cmet.2006.05.010; Wu JJ, 2005, MOL CELL BIOL, V25, P4792, DOI 10.1128/MCB.25.11.4792-4803.2005; Yin YX, 2003, NATURE, V422, P527, DOI 10.1038/nature01519; Zhang Q, 2005, J MOL BIOL, V354, P777, DOI 10.1016/j.jmb.2005.10.006; Zhang YL, 2004, NATURE, V430, P793, DOI 10.1038/nature02764; Zhao L, 2006, CHEM-ASIAN J, V1, P203, DOI 10.1002/asia.200600097; Zhou B, 2001, J BIOL CHEM, V276, P6506, DOI 10.1074/jbc.M009753200; Zhou B, 1999, J BIOL CHEM, V274, P35526, DOI 10.1074/jbc.274.50.35526; Zhou B, 2006, J BIOL CHEM, V281, P38834, DOI 10.1074/jbc.M608916200	73	607	645	2	75	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 15	2007	26	22					3203	3213		10.1038/sj.onc.1210412	http://dx.doi.org/10.1038/sj.onc.1210412			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	169PH	17496916	Bronze			2022-12-28	WOS:000246603600009
J	Roberts, PJ; Der, CJ				Roberts, P. J.; Der, C. J.			Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer	ONCOGENE			English	Review						mitogen-activated protein kinases; ERK; Ras; epidermal growth factor receptor; small molecule inhibitors; monoclonal antibodies	GROWTH-FACTOR RECEPTOR; SMALL-CELL LUNG; METASTATIC COLORECTAL-CANCER; FACIO-CUTANEOUS SYNDROME; REFRACTORY SOLID TUMORS; SIGNAL-REGULATED KINASE; HRAS MUTATION ANALYSIS; DAYS ON/7 DAYS; PHASE-I; COSTELLO-SYNDROME	Mitogen-activated protein kinase (MAPK) cascades are key signaling pathways involved in the regulation of normal cell proliferation, survival and differentiation. Aberrant regulation of MAPK cascades contribute to cancer and other human diseases. In particular, the extracellular signal-regulated kinase (ERK) MAPK pathway has been the subject of intense research scrutiny leading to the development of pharmacologic inhibitors for the treatment of cancer. ERK is a downstream component of an evolutionarily conserved signaling module that is activated by the Raf serine/threonine kinases. Raf activates the MAPK/ERK kinase (MEK) 1/2 dual-specificity protein kinases, which then activate ERK1/2. The mutational activation of Raf in human cancers supports the important role of this pathway in human oncogenesis. Additionally, the Raf-MEK-ERK pathway is a key downstream effector of the Ras small GTPase, the most frequently mutated oncogene in human cancers. Finally, Ras is a key downstream effector of the epidermal growth factor receptor (EGFR), which is mutationally activated and/or overexpressed in a wide variety of human cancers. ERK activation also promotes upregulated expression of EGFR ligands, promoting an autocrine growth loop critical for tumor growth. Thus, the EGFR-Ras-Raf-MEK-ERK signaling network has been the subject of intense research and pharmaceutical scrutiny to identify novel target-based approaches for cancer treatment. In this review, we summarize the current status of the different approaches and targets that are under evaluation and development for the therapeutic intervention of this key signaling pathway in human disease.	Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Pharmacol, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Div Pharmacotherapy & Expt Therapeut, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Der, CJ (corresponding author), Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Pharmacol, CB 7295, Chapel Hill, NC 27599 USA.	cjder@med.unc.edu		Der, Channing/0000-0002-7751-2747				Abi-Habib RJ, 2005, MOL CANCER THER, V4, P1303, DOI 10.1158/1535-7163.MCT-05-0145; Agus DB, 2005, J CLIN ONCOL, V23, P2534, DOI 10.1200/JCO.2005.03.184; Aoki Y, 2005, NAT GENET, V37, P1038, DOI 10.1038/ng1641; Arslan MA, 2006, CURR CANCER DRUG TAR, V6, P623, DOI 10.2174/156800906778742479; Awada A, 2005, BRIT J CANCER, V92, P1855, DOI 10.1038/sj.bjc.6602584; Bain J, 2003, BIOCHEM J, V371, P199, DOI 10.1042/BJ20021535; Baselga J, 2005, J CLIN ONCOL, V23, P2445, DOI 10.1200/JCO.2005.11.890; Basso AD, 2006, J LIPID RES, V47, P15, DOI 10.1194/jlr.R500012-JLR200; Benson JD, 2006, NATURE, V441, P451, DOI 10.1038/nature04873; Bergo MO, 2004, J CLIN INVEST, V113, P539, DOI 10.1172/JCI200418829; Bergo MO, 2002, MOL CELL BIOL, V22, P171, DOI 10.1128/MCB.22.1.171-181.2002; Bergo MO, 2000, J BIOL CHEM, V275, P17605, DOI 10.1074/jbc.C000079200; Bergo MO, 2001, J BIOL CHEM, V276, P5841, DOI 10.1074/jbc.C000831200; Bier H, 1998, CANCER IMMUNOL IMMUN, V46, P167, DOI 10.1007/s002620050475; Bodart JF, 2002, CELL CYCLE, V1, P10, DOI 10.4161/cc.1.1.95; Bonner JA, 2006, NEW ENGL J MED, V354, P567, DOI 10.1056/NEJMoa053422; Cappuzzo F, 2005, JNCI-J NATL CANCER I, V97, P643, DOI 10.1093/jnci/dji112; Carta C, 2006, AM J HUM GENET, V79, P129, DOI 10.1086/504394; Cheng KW, 2005, CANCER RES, V65, P2516, DOI 10.1158/0008-5472.CAN-05-0573; Citri A, 2003, EXP CELL RES, V284, P54, DOI 10.1016/S0014-4827(02)00101-5; Clarke S, 2004, J CLIN INVEST, V113, P513, DOI 10.1072/JCI200421059; Collisson EA, 2003, CANCER RES, V63, P5669; CORTES J, 2005, ASCO M, V22; Cox AD, 2002, CURR OPIN PHARMACOL, V2, P388, DOI 10.1016/S1471-4892(02)00181-9; Cox AD, 2002, CANCER BIOL THER, V1, P599, DOI 10.4161/cbt.306; Cripps MC, 2002, CLIN CANCER RES, V8, P2188; Cunningham D, 2004, NEW ENGL J MED, V351, P337, DOI 10.1056/NEJMoa033025; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Davies M, 2006, EXPERT OPIN PHARMACO, V7, P2243, DOI 10.1517/14656566.7.16.2243; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; DEBONO JS, 2005, ASCO M, V22; Dias SD, 2005, CANCER RES, V65, P10686, DOI 10.1158/0008-5472.CAN-05-2632; DOI T, 2005, ASCO M, V22; Dominguez C, 2005, CURR OPIN DRUG DISC, V8, P421; Dritschilo A, 2006, CLIN CANCER RES, V12, P1251, DOI 10.1158/1078-0432.CCR-05-1260; DUESBERY N, 2006, SCI STKE; Duesbery NS, 2001, P NATL ACAD SCI USA, V98, P4089, DOI 10.1073/pnas.061031898; Eberhard DA, 2005, J CLIN ONCOL, V23, P5900, DOI 10.1200/JCO.2005.02.857; Eisen T, 2006, BRIT J CANCER, V95, P581, DOI 10.1038/sj.bjc.6603291; ESCUDIER B, 2005, J CLIN ONCOL; Estep AL, 2006, AM J MED GENET A, V140A, P8, DOI 10.1002/ajmg.a.31078; Friess T, 2005, CLIN CANCER RES, V11, P5300, DOI 10.1158/1078-0432.CCR-04-2642; Gangarosa LM, 1997, J BIOL CHEM, V272, P18926, DOI 10.1074/jbc.272.30.18926; Gibson TB, 2006, CLIN COLORECTAL CANC, V6, P29, DOI 10.3816/CCC.2006.n.01; Gokhale PC, 2002, CLIN CANCER RES, V8, P3611; GORDON MS, 2005, ASCO M, V22; Grandis JR, 2004, PHARMACOL THERAPEUT, V102, P37, DOI 10.1016/j.pharmthera.2004.01.002; Grbovic OM, 2006, P NATL ACAD SCI USA, V103, P57, DOI 10.1073/pnas.0609973103; Gripp KW, 2006, AM J MED GENET A, V140A, P1, DOI 10.1002/ajmg.a.31047; Hahn W, 2006, CURR OPIN ONCOL, V18, P615, DOI 10.1097/01.cco.0000245316.82391.52; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hingorani SR, 2003, CANCER RES, V63, P5198; Hoeflich MP, 2006, CANCER RES, V66, P999, DOI 10.1158/0008-5472.CAN-05-2720; Hoshino R, 1999, ONCOGENE, V18, P813, DOI 10.1038/sj.onc.1202367; Hynes J, 2005, CURR TOP MED CHEM, V5, P967, DOI 10.2174/1568026054985920; Hynes NE, 2005, NAT REV CANCER, V5, P341, DOI 10.1038/nrc1609; Jemal A, 2005, CA-CANCER J CLIN, V55, P10, DOI 10.3322/canjclin.55.1.10; Jimeno A, 2006, BBA-REV CANCER, V1766, P217, DOI 10.1016/j.bbcan.2006.08.008; Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682; Karin M, 2006, NATURE, V441, P431, DOI 10.1038/nature04870; Kato-Stankiewicz J, 2002, P NATL ACAD SCI USA, V99, P14398, DOI 10.1073/pnas.222222699; Kerr B, 2006, J MED GENET, V43, P401, DOI 10.1136/jmg.2005.040352; Kim E, 1999, J BIOL CHEM, V274, P8383, DOI 10.1074/jbc.274.13.8383; Kolch W, 2005, NAT REV MOL CELL BIO, V6, P827, DOI 10.1038/nrm1743; Kortum RL, 2004, MOL CELL BIOL, V24, P4407, DOI 10.1128/MCB.24.10.4407-4416.2004; Lacouture ME, 2006, NAT REV CANCER, V6, P803, DOI 10.1038/nrc1970; Lancet JE, 2007, BLOOD, V109, P1387, DOI 10.1182/blood-2006-04-014357; LEE P, 2004, AACR M; Leung KF, 2006, J LIPID RES, V47, P467, DOI 10.1194/jlr.R500017-JLR200; LoRusso PM, 2005, J CLIN ONCOL, V23, P5281, DOI 10.1200/JCO.2005.14.415; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Lyons JF, 2001, ENDOCR-RELAT CANCER, V8, P219, DOI 10.1677/erc.0.0080219; LYSSIKATOS J, 2004, AACR M, V45; Malumbres M, 2003, NAT REV CANCER, V3, P459, DOI 10.1038/nrc1097; Manning AM, 2003, NAT REV DRUG DISCOV, V2, P554, DOI 10.1038/nrd1132; MCCARTHY SA, 1995, GENE DEV, V9, P1953, DOI 10.1101/gad.9.16.1953; Mendelsohn J, 2006, SEMIN ONCOL, V33, P369, DOI 10.1053/j.seminoncol.2006.04.003; Mercer KE, 2003, BBA-REV CANCER, V1653, P25, DOI 10.1016/S0304-419X(03)00016-7; Mewani RR, 2004, INT J ONCOL, V24, P1181; Michaelson D, 2005, MOL BIOL CELL, V16, P1606, DOI 10.1091/mbc.e04-11-0960; Mitin N, 2005, CURR BIOL, V15, pR563, DOI 10.1016/j.cub.2005.07.010; Monia BP, 1996, P NATL ACAD SCI USA, V93, P15481, DOI 10.1073/pnas.93.26.15481; Moore M, 2005, ANN ONCOL, V16, P1688, DOI 10.1093/annonc/mdi310; MOORE MJ, 2005, ASCO M, V22; Moy B, 2006, ONCOLOGIST, V11, P1047, DOI 10.1634/theoncologist.11-10-1047; Mukherjee S, 2006, SCIENCE, V312, P1211, DOI 10.1126/science.1126867; Neckers L, 2006, CURR TOP MED CHEM, V6, P1163, DOI 10.2174/156802606777811979; Nelson MH, 2006, ANN PHARMACOTHER, V40, P261, DOI 10.1345/aph.1G387; Niihori T, 2006, NAT GENET, V38, P294, DOI 10.1038/ng1749; O'Neill LAJ, 2006, NAT REV DRUG DISCOV, V5, P549, DOI 10.1038/nrd2070; Ohren JF, 2004, NAT STRUCT MOL BIOL, V11, P1192, DOI 10.1038/nsmb859; Orth K, 1999, SCIENCE, V285, P1920, DOI 10.1126/science.285.5435.1920; Overington JP, 2006, NAT REV DRUG DISCOV, V5, P993, DOI 10.1038/nrd2199; Oza AM, 2003, GYNECOL ONCOL, V89, P129, DOI 10.1016/S0090-8258(02)00144-0; Pao W, 2005, PLOS MED, V2, P57, DOI 10.1371/journal.pmed.0020017; Parulekar WR, 2004, JNCI-J NATL CANCER I, V96, P990, DOI 10.1093/jnci/djh182; Perez-Soler R, 2005, J CLIN ONCOL, V23, P5235, DOI 10.1200/JCO.2005.00.6916; Rajagopalan H, 2002, NATURE, V418, P934, DOI 10.1038/418934a; Reid TS, 2004, J MOL BIOL, V343, P417, DOI 10.1016/j.jmb.2004.08.056; Repasky GA, 2004, TRENDS CELL BIOL, V14, P639, DOI 10.1016/j.tcb.2004.09.014; Rinehart J, 2004, J CLIN ONCOL, V22, P4456, DOI 10.1200/JCO.2004.01.185; Rini BI, 2006, EXPERT OPIN PHARMACO, V7, P453, DOI 10.1517/14656566.7.4.453; Rodriguez-Viciana P, 2006, SCIENCE, V311, P1287, DOI 10.1126/science.1124642; Rowinsky EK, 2006, J CLIN ONCOL, V24, P2981, DOI 10.1200/JCO.2006.05.9808; Rudin CM, 2004, CLIN CANCER RES, V10, P7244, DOI 10.1158/1078-0432.CCR-04-0642; SALAZAR R, 2004, ASCO M, V22; Sausville EA, 2006, CANCER RES, V66, P3351, DOI 10.1158/0008-5472.CAN-05-3627; Scaltriti M, 2006, CLIN CANCER RES, V12, P5268, DOI 10.1158/1078-0432.CCR-05-1554; Schreck R, 2006, INT J CANCER, V119, P2261, DOI 10.1002/ijc.22144; Schubbert S, 2006, NAT GENET, V38, P331, DOI 10.1038/ng1748; Schulze A, 2004, MOL BIOL CELL, V15, P3450, DOI 10.1091/mbc.E03-11-0807; Schulze A, 2001, GENE DEV, V15, P981, DOI 10.1101/gad.191101; Sebolt-Leopold JS, 1999, NAT MED, V5, P810, DOI 10.1038/10533; Sebolt-Leopold JS, 2004, NAT REV CANCER, V4, P937, DOI 10.1038/nrc1503; Sebolt-Leopold JS, 2006, NATURE, V441, P457, DOI 10.1038/nature04874; Sebti SM, 2003, NAT REV CANCER, V3, P945, DOI 10.1038/nrc1234; Sharma A, 2005, CANCER RES, V65, P2412, DOI 10.1158/0008-5472.CAN-04-2423; Sharp S, 2006, ADV CANCER RES, V95, P323, DOI 10.1016/S0065-230X(06)95009-X; Sharpless NE, 2006, NAT REV DRUG DISCOV, V5, P741, DOI 10.1038/nrd2110; Shaw RJ, 2006, NATURE, V441, P424, DOI 10.1038/nature04869; Shields JM, 2000, TRENDS CELL BIOL, V10, P147, DOI 10.1016/S0962-8924(00)01740-2; Sieben NLG, 2004, J PATHOL, V202, P336, DOI 10.1002/path.1521; Singer G, 2003, J NATL CANCER I, V95, P484, DOI 10.1093/jnci/95.6.484; SKOBELEVA N, 2007, IN PRESS MOL CANC TH; Smith RA, 2006, CURR TOP MED CHEM, V6, P1071, DOI 10.2174/156802606777812077; Solit DB, 2006, NATURE, V439, P358, DOI 10.1038/nature04304; Stephens P, 2004, NATURE, V431, P525, DOI 10.1038/431525b; Sumimoto H, 2006, INT J CANCER, V118, P472, DOI 10.1002/ijc.21286; TABERNERO J, 2003, ASCO M, V22; Thompson N, 2005, CURR OPIN PHARMACOL, V5, P350, DOI 10.1016/j.coph.2005.04.007; Tolcher AW, 2002, CLIN CANCER RES, V8, P2530; van Steensel MAM, 2006, EXP DERMATOL, V15, P731, DOI 10.1111/j.1600-0625.2006.00474.x; Vanhoefer U, 2004, J CLIN ONCOL, V22, P175, DOI 10.1200/JCO.2004.05.114; Vos MD, 2003, J BIOL CHEM, V278, P21938, DOI 10.1074/jbc.M211019200; Wan PTC, 2004, CELL, V116, P855, DOI 10.1016/S0092-8674(04)00215-6; Wellbrock C, 2004, NAT REV MOL CELL BIO, V5, P875, DOI 10.1038/nrm1498; Wiley HS, 2003, EXP CELL RES, V284, P78, DOI 10.1016/S0014-4827(03)00002-8; Wilhelm SM, 2004, CANCER RES, V64, P7099, DOI 10.1158/0008-5472.CAN-04-1443; Winter-Vann AM, 2005, NAT REV CANCER, V5, P405, DOI 10.1038/nrc1612; Winter-Vann AM, 2003, P NATL ACAD SCI USA, V100, P6529, DOI 10.1073/pnas.1135239100; Xing HR, 2003, NAT MED, V9, P1266, DOI 10.1038/nm927; Yang XD, 1999, CANCER RES, V59, P1236; Yarden Y, 2001, EUR J CANCER, V37, pS3; YEH T, 2004, AACR M, V45; Yoon S, 2006, GROWTH FACTORS, V24, P21, DOI 10.1080/02699050500284218; Zuber J, 2000, NAT GENET, V24, P144, DOI 10.1038/72799	146	2059	2160	13	421	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 15	2007	26	22					3291	3310		10.1038/sj.onc.1210422	http://dx.doi.org/10.1038/sj.onc.1210422			20	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	169PH	17496923				2022-12-28	WOS:000246603600016
J	Horn, HF; Vousden, KH				Horn, H. F.; Vousden, K. H.			Coping with stress: multiple ways to activate p53	ONCOGENE			English	Review						p53; tumour suppression; MDM2; ubiquitination; apoptosis	E3 UBIQUITIN LIGASE; ATM-DEPENDENT PHOSPHORYLATION; RIBOSOMAL-PROTEIN L11; DNA-DAMAGE RESPONSE; SMALL-MOLECULE RITA; TUMOR-SUPPRESSOR; BREAST-CANCER; PROTEASOMAL DEGRADATION; ONCOPROTEIN GANKYRIN; MDM2-DEFICIENT MICE	Over the years, p53 has been shown to sit at the centre of an increasingly complex web of incoming stress signals and outgoing effector pathways. The number and diversity of stress signals that lead to p53 activation illustrates the breadth of p53's remit - responding to a wide variety of potentially oncogenic insults to prevent tumour development. Interestingly, different stress signals can use different and independent pathways to activate p53, and there is some evidence that different stress signals can mediate different responses. How each of the responses to p53 contributes to inhibition of malignant progression is beginning to be clarified, with the hope that identification of responses that are key to tumour suppression will allow a more focused and effective search for new therapeutic targets. In this review, we will highlight some recently identified roles for p53 in tumour suppression, and discuss some of the numerous mechanisms through which p53 can be regulated and activated.	Beatson Inst Canc Res, Glasgow G61 1BD, Lanark, Scotland	Beatson Institute	Vousden, KH (corresponding author), Beatson Inst Canc Res, Garscube Estate,Switchback Rd, Glasgow G61 1BD, Lanark, Scotland.	k.vousden@beatson.gla.ac.uk	高, 雨莉/HGU-8187-2022	Horn, Henning/0000-0002-5885-8996				ABIDA WM, 2006, J BIOL CHEM; Adhikary S, 2005, CELL, V123, P409, DOI 10.1016/j.cell.2005.08.016; Amsterdam A, 2004, PLOS BIOL, V2, P690, DOI 10.1371/journal.pbio.0020139; Andrews P, 2006, ONCOGENE, V25, P4534, DOI 10.1038/sj.onc.1209490; Asher G, 2001, P NATL ACAD SCI USA, V98, P1188, DOI 10.1073/pnas.021558898; Asher G, 2005, CELL CYCLE, V4, P1015, DOI 10.4161/cc.4.8.1900; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Bensaad K, 2005, NAT MED, V11, P1278, DOI 10.1038/nm1205-1278; Bensaad K, 2006, CELL, V126, P107, DOI 10.1016/j.cell.2006.05.036; Bhat KP, 2004, EMBO J, V23, P2402, DOI 10.1038/sj.emboj.7600247; Bischof O, 2006, MOL CELL, V22, P783, DOI 10.1016/j.molcel.2006.05.016; Bode AM, 2004, NAT REV CANCER, V4, P793, DOI 10.1038/nrc1455; Bond GL, 2004, CELL, V119, P591, DOI 10.1016/j.cell.2004.11.022; Boyd SD, 2000, NAT CELL BIOL, V2, P563, DOI 10.1038/35023500; Brady M, 2005, MOL CELL BIOL, V25, P545, DOI 10.1128/MCB.25.2.545-553.2005; Budanov AV, 2004, SCIENCE, V304, P596, DOI 10.1126/science.1095569; Bykov VJN, 2003, ANN MED, V35, P458, DOI 10.1080/07853890310017152; Chen CS, 2005, J BIOL CHEM, V280, P41553, DOI 10.1074/jbc.M506183200; Chen DL, 2005, CELL, V121, P1071, DOI 10.1016/j.cell.2005.03.037; Cheng TH, 2007, MOL CELL BIOL, V27, P111, DOI 10.1128/MCB.00235-06; Chipuk JE, 2005, SCIENCE, V309, P1732, DOI 10.1126/science.1114297; Chipuk JE, 2004, SCIENCE, V303, P1010, DOI 10.1126/science.1092734; Christophorou MA, 2006, NATURE, V443, P214, DOI 10.1038/nature05077; Crighton D, 2006, CELL, V126, P121, DOI 10.1016/j.cell.2006.05.034; Cummins JM, 2004, CELL CYCLE, V3, P689, DOI 10.4161/cc.3.6.924; Dai MS, 2004, J BIOL CHEM, V279, P44475, DOI 10.1074/jbc.M403722200; Dai MS, 2004, MOL CELL BIOL, V24, P7654, DOI 10.1128/MCB.24.17.7654-7668.2004; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; Dawson S, 2002, J BIOL CHEM, V277, P10893, DOI 10.1074/jbc.M107313200; de Graaf P, 2003, J BIOL CHEM, V278, P38315, DOI 10.1074/jbc.M213034200; de Toledo SM, 2000, ONCOGENE, V19, P6185, DOI 10.1038/sj.onc.1204020; DiTullio RA, 2002, NAT CELL BIOL, V4, P998, DOI 10.1038/ncb892; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Dornan D, 2004, NATURE, V429, P86, DOI 10.1038/nature02514; Dornan D, 2006, SCIENCE, V313, P1122, DOI 10.1126/science.1127335; Dumaz N, 1999, EMBO J, V18, P7002, DOI 10.1093/emboj/18.24.7002; Efeyan A, 2006, NATURE, V443, P159, DOI 10.1038/443159a; ELDEIRY WS, 1994, CANCER RES, V54, P1169; Esser C, 2005, J BIOL CHEM, V280, P27443, DOI 10.1074/jbc.M501574200; Fang SY, 2000, J BIOL CHEM, V275, P8945, DOI 10.1074/jbc.275.12.8945; Francoz S, 2006, P NATL ACAD SCI USA, V103, P3232, DOI 10.1073/pnas.0508476103; Fu XY, 2002, WORLD J GASTROENTERO, V8, P638, DOI 10.3748/wjg.v8.i4.638; Garcia-Cao I, 2006, EMBO REP, V7, P546, DOI 10.1038/sj.embor.7400667; Garcia-Cao I, 2002, EMBO J, V21, P6225, DOI 10.1093/emboj/cdf595; Gatz SA, 2006, CELL DEATH DIFFER, V13, P1003, DOI 10.1038/sj.cdd.4401903; Gilkes DM, 2006, EMBO J, V25, P5614, DOI 10.1038/sj.emboj.7601424; Gorgoulis VG, 2005, NATURE, V434, P907, DOI 10.1038/nature03485; Gronroos E, 2004, P NATL ACAD SCI USA, V101, P12165, DOI 10.1073/pnas.0402283101; Grossman SR, 2003, SCIENCE, V300, P342, DOI 10.1126/science.1080386; Grossman SR, 2001, EUR J BIOCHEM, V268, P2773, DOI 10.1046/j.1432-1327.2001.02226.x; Grossmann J, 2002, APOPTOSIS, V7, P247, DOI 10.1023/A:1015312119693; Gu JJ, 2002, J BIOL CHEM, V277, P19251, DOI 10.1074/jbc.C200150200; Gu JJ, 2001, MOL CELL BIOL, V21, P8533, DOI 10.1128/MCB.21.24.8533-8546.2001; Hainaut P, 2000, ADV CANCER RES, V77, P81; Hammond EM, 2005, BIOCHEM BIOPH RES CO, V331, P718, DOI 10.1016/j.bbrc.2005.03.154; Higashitsuji H, 2005, CELL CYCLE, V4, P1335, DOI 10.4161/cc.4.10.2107; HIGASHITSUJI H, 2005, CANCER CELL, V8, P745; Hu BL, 2006, J BIOL CHEM, V281, P33030, DOI 10.1074/jbc.C600147200; Issaeva N, 2004, NAT MED, V10, P1321, DOI 10.1038/nm1146; Iwakuma T, 2003, MOL CANCER RES, V1, P993; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Jackson MW, 2000, MOL CELL BIOL, V20, P1001, DOI 10.1128/MCB.20.3.1001-1007.2000; Jeffers JR, 2003, CANCER CELL, V4, P321, DOI 10.1016/S1535-6108(03)00244-7; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; Kahyo T, 2001, MOL CELL, V8, P713, DOI 10.1016/S1097-2765(01)00349-5; Kamijo T, 1999, CANCER RES, V59, P2464; Kawai H, 2003, J BIOL CHEM, V278, P45946, DOI 10.1074/jbc.M308295200; Khosravi R, 1999, P NATL ACAD SCI USA, V96, P14973, DOI 10.1073/pnas.96.26.14973; Krajewski M, 2005, NAT MED, V11, P1135, DOI 10.1038/nm1105-1135; Krieg AJ, 2006, MOL CELL BIOL, V26, P7030, DOI 10.1128/MCB.00322-06; LAINE A, 2006, ONCOGENE; Laine A, 2006, MOL CELL BIOL, V26, P8901, DOI 10.1128/MCB.01156-06; Lambert PF, 1998, J BIOL CHEM, V273, P33048, DOI 10.1074/jbc.273.49.33048; Le Cam L, 2006, CELL, V127, P775, DOI 10.1016/j.cell.2006.09.031; Lee MH, 2006, NAT CELL BIOL, V8, P1424, DOI 10.1038/ncb1512; Leng RP, 2003, CELL, V112, P779, DOI 10.1016/S0092-8674(03)00193-4; Leu JIJ, 2004, NAT CELL BIOL, V6, P443, DOI 10.1038/ncb1123; Li MY, 2002, NATURE, V416, P648, DOI 10.1038/nature737; Li MY, 2004, MOL CELL, V13, P879, DOI 10.1016/S1097-2765(04)00157-1; Li MY, 2003, SCIENCE, V302, P1972, DOI 10.1126/science.1091362; Li TW, 2006, J BIOL CHEM, V281, P36221, DOI 10.1074/jbc.M608236200; LINDSTROM MS, 2006, MOL CELL BIOL; Logan IR, 2006, MOL CELL BIOL, V26, P6502, DOI 10.1128/MCB.00147-06; Lohrum MAE, 2003, CANCER CELL, V3, P577, DOI 10.1016/S1535-6108(03)00134-X; Lohrum MAE, 2001, MOL CELL BIOL, V21, P8521, DOI 10.1128/MCB.21.24.8521-8532.2001; Longworth MS, 2004, MICROBIOL MOL BIOL R, V68, P362, DOI 10.1128/MMBR.68.2.362-372.2004; Lu YL, 1999, ONCOGENE, V18, P7034, DOI 10.1038/sj.onc.1203183; LUNA RMD, 1995, NATURE, V378, P203; Maier B, 2004, GENE DEV, V18, P306, DOI 10.1101/gad.1162404; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; Mani A, 2006, CANCER RES, V66, P8680, DOI 10.1158/0008-5472.CAN-06-0557; Marine JC, 2005, BIOCHEM BIOPH RES CO, V331, P750, DOI 10.1016/j.bbrc.2005.03.151; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Maya R, 2001, GENE DEV, V15, P1067, DOI 10.1101/gad.886901; McDonald ER, 2004, P NATL ACAD SCI USA, V101, P6170, DOI 10.1073/pnas.0307459101; McDonough H, 2003, CELL STRESS CHAPERON, V8, P303, DOI 10.1379/1466-1268(2003)008<0303:CALBTC>2.0.CO;2; Megidish T, 2002, J BIOL CHEM, V277, P8255, DOI 10.1074/jbc.C200001200; Melchior F, 2002, CELL CYCLE, V1, P243, DOI 10.4161/cc.1.4.131; Mendrysa SM, 2006, GENE DEV, V20, P16, DOI 10.1101/gad.1378506; Mendrysa SM, 2006, CELL CYCLE, V5, P714, DOI 10.4161/cc.5.7.2632; Meulmeester E, 2005, CELL CYCLE, V4, P1166, DOI 10.4161/cc.4.9.1981; Meulmeester E, 2005, MOL CELL, V18, P565, DOI 10.1016/j.molcel.2005.04.024; Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9; Moll UM, 2006, ONCOGENE, V25, P4725, DOI 10.1038/sj.onc.1209601; MOLL UM, 1995, P NATL ACAD SCI USA, V92, P4407, DOI 10.1073/pnas.92.10.4407; MOLL UM, 1992, P NATL ACAD SCI USA, V89, P7262, DOI 10.1073/pnas.89.15.7262; Moren A, 2005, J BIOL CHEM, V280, P22115, DOI 10.1074/jbc.M414027200; Nagao T, 2003, J BIOL CHEM, V278, P10668, DOI 10.1074/jbc.M206104200; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Nelson V, 2001, APOPTOSIS, V6, P221, DOI 10.1023/A:1011392811628; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Pan Y, 2003, MOL CELL BIOL, V23, P5113, DOI 10.1128/MCB.23.15.5113-5121.2003; Patton JT, 2006, CANCER RES, V66, P3169, DOI 10.1158/0008-5472.CAN-05-3832; Pietsch EC, 2006, ONCOGENE, V25, P1602, DOI 10.1038/sj.onc.1209367; Pim D, 2004, INT J CANCER, V108, P196, DOI 10.1002/ijc.11548; Poyurovsky MV, 2006, GENE DEV, V20, P125, DOI 10.1101/gad.1397506; POYUROVSKY MV, 2006, EMBO J; PURDIE CA, 1994, ONCOGENE, V9, P603; Qi L, 2006, SCIENCE, V312, P1763, DOI 10.1126/science.1123374; Rajendra R, 2004, J BIOL CHEM, V279, P36440, DOI 10.1074/jbc.C400300200; Roe JS, 2006, MOL CELL, V22, P395, DOI 10.1016/j.molcel.2006.04.006; Rubbi CP, 2003, EMBO J, V22, P6068, DOI 10.1093/emboj/cdg579; Sablina AA, 2005, NAT MED, V11, P1306, DOI 10.1038/nm1320; Sakaguchi K, 2000, J BIOL CHEM, V275, P9278, DOI 10.1074/jbc.275.13.9278; Salcedo A, 2006, EMBO J, V25, P4752, DOI 10.1038/sj.emboj.7601351; Schmidt D, 2002, P NATL ACAD SCI USA, V99, P2872, DOI 10.1073/pnas.052559499; Secombe J, 2004, J BIOL CHEM, V279, P17126, DOI 10.1074/jbc.M310097200; Semenza GL, 2001, CELL, V107, P1, DOI 10.1016/S0092-8674(01)00518-9; Sharp DA, 1999, J BIOL CHEM, V274, P38189, DOI 10.1074/jbc.274.53.38189; Sherr CJ, 2006, NAT REV CANCER, V6, P663, DOI 10.1038/nrc1954; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Shvarts A, 1996, EMBO J, V15, P5349, DOI 10.1002/j.1460-2075.1996.tb00919.x; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; Stad R, 2001, EMBO REP, V2, P1029, DOI 10.1093/embo-reports/kve227; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Sui GC, 2004, CELL, V117, P859, DOI 10.1016/j.cell.2004.06.004; Tang J, 2006, NAT CELL BIOL, V8, P855, DOI 10.1038/ncb1442; Tanimura S, 1999, FEBS LETT, V447, P5, DOI 10.1016/S0014-5793(99)00254-9; Toledo F, 2006, NAT REV CANCER, V6, P909, DOI 10.1038/nrc2012; Tyner SD, 2002, NATURE, V415, P45, DOI 10.1038/415045a; ULDRIJAN S, 2006, EMBO J; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; Villunger A, 2003, SCIENCE, V302, P1036, DOI 10.1126/science.1090072; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wade M, 2006, J BIOL CHEM, V281, P33036, DOI 10.1074/jbc.M605405200; Wang WJ, 2002, J CELL BIOL, V159, P169, DOI 10.1083/jcb.200204050; Watson IR, 2006, NEOPLASIA, V8, P655, DOI 10.1593/neo.06439; Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563; Xiong SB, 2006, P NATL ACAD SCI USA, V103, P3226, DOI 10.1073/pnas.0508500103; Xirodimas DP, 2004, CELL, V118, P83, DOI 10.1016/j.cell.2004.06.016; Yang JY, 2006, MOL CELL BIOL, V26, P7269, DOI 10.1128/MCB.00172-06; Yang WH, 2006, NAT CELL BIOL, V8, P1074, DOI 10.1038/ncb1470; Yang X, 2002, REACT FUNCT POLYM, V53, P53, DOI 10.1016/S1381-5148(02)00145-1; Yang YL, 2005, CANCER CELL, V7, P547, DOI 10.1016/j.ccr.2005.04.029; Yee KS, 2005, CARCINOGENESIS, V26, P1317, DOI 10.1093/carcin/bgi122; Yoon KA, 2004, J HUM GENET, V49, P134, DOI 10.1007/s10038-003-0122-3; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1; Yu J, 2003, P NATL ACAD SCI USA, V100, P1931, DOI 10.1073/pnas.2627984100; Yuan XJ, 2005, MOL CELL, V19, P77, DOI 10.1016/j.molcel.2005.05.023; ZAUBERMAN A, 1993, EMBO J, V12, P2799, DOI 10.1002/j.1460-2075.1993.tb05941.x; Zhang XL, 2004, BIOCHEM BIOPH RES CO, V316, P139, DOI 10.1016/j.bbrc.2004.02.033; Zhang YP, 2003, MOL CELL BIOL, V23, P8902, DOI 10.1128/MCB.23.23.8902-8912.2003; Zhang Z, 2005, CURR CANCER DRUG TAR, V5, P9, DOI 10.2174/1568009053332618; Zhong Q, 2005, CELL, V121, P1085, DOI 10.1016/j.cell.2005.06.009	167	381	400	0	43	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 26	2007	26	9					1306	1316		10.1038/sj.onc.1210263	http://dx.doi.org/10.1038/sj.onc.1210263			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	141DU	17322916				2022-12-28	WOS:000244558700008
J	Pollock, PM; Gartside, MG; Dejeza, LC; Powell, MA; Mallon, MA; Davies, H; Mohammadi, M; Futreal, PA; Stratton, MR; Trent, JM; Goodfellow, PJ				Pollock, P. M.; Gartside, M. G.; Dejeza, L. C.; Powell, M. A.; Mallon, M. A.; Davies, H.; Mohammadi, M.; Futreal, P. A.; Stratton, M. R.; Trent, J. M.; Goodfellow, P. J.			Frequent activating FGFR2 mutations in endometrial carcinomas parallel germline mutations associated with craniosynostosis and skeletal dysplasia syndromes	ONCOGENE			English	Article						endometrial cancer; mutation; FGFR2; apert; syndrome	FIBROBLAST-GROWTH-FACTOR; FACTOR RECEPTOR-3; STRUCTURAL BASIS; SPLICE SITES; EXPRESSION; CANCER; SPECIFICITY	Endometrial carcinoma is the most common gynecological malignancy in the United States. Although most women present with early disease confined to the uterus, the majority of persistent or recurrent tumors are refractory to current chemotherapies. We have identified a total of 11 different FGFR2 mutations in 3/10 ( 30%) of endometrial cell lines and 19/187 ( 10%) of primary uterine tumors. Mutations were seen primarily in tumors of the endometrioid histologic subtype ( 18/115 cases investigated, 16%). The majority of the somatic mutations identified were identical to germline activating mutations in FGFR2 and FGFR3 that cause Apert Syndrome, Beare-Stevenson Syndrome, hypochondroplasia, achondroplasia and SADDAN syndrome. The two most common somatic mutations identified were S252W ( in eight tumors) and N550K ( in five samples). Four novel mutations were identified, three of which are also likely to result in receptor gain-of-function. Extensive functional analyses have already been performed on many of these mutations, demonstrating they result in receptor activation through a variety of mechanisms. The discovery of activating FGFR2 mutations in endometrial carcinoma raises the possibility of employing anti-FGFR molecularly targeted therapies in patients with advanced or recurrent endometrial carcinoma.	Translat Genom Res Inst, Canc & Cell Biol Div, Phoenix, AZ 85004 USA; Translat Genom Res Inst, DNA Sequencing Ctr, Pharmaceut Genom Div, Phoenix, AZ 85004 USA; Washington Univ, Sch Med, Dept Obstet & Gynecol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Surg, St Louis, MO 63110 USA; NYU, Sch Med, Dept Pharmacol, New York, NY USA; Translat Genom Res Inst, Genet Basis Human Dis Div, Phoenix, AZ 85004 USA	Translational Genomics Research Institute; Translational Genomics Research Institute; Washington University (WUSTL); Washington University (WUSTL); New York University; Translational Genomics Research Institute	Pollock, PM (corresponding author), Translat Genom Res Inst, Canc & Cell Biol Div, 445 N 5th St, Phoenix, AZ 85004 USA.	ppollock@tgen.org	kasaei, fahime/T-7197-2018; Mohammadi, Moosa/ABA-6745-2020	Mohammadi, Moosa/0000-0003-2434-9437; Pollock, Pamela/0000-0001-8420-1026	NATIONAL CANCER INSTITUTE [R01CA071754, P30CA091842, R01CA109544] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA109544, P30 CA091842, CA091842, R01 CA071754, R01 CA71754] Funding Source: Medline; Wellcome Trust [077012] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Wellcome Trust(Wellcome TrustEuropean Commission)		Burgar HR, 2002, J BIOL CHEM, V277, P4018, DOI 10.1074/jbc.M107785200; Burset M, 2000, NUCLEIC ACIDS RES, V28, P4364, DOI 10.1093/nar/28.21.4364; Cho JY, 2004, P NATL ACAD SCI USA, V101, P609, DOI 10.1073/pnas.2237184100; Chong A, 2004, GENOMICS, V84, P762, DOI 10.1016/j.ygeno.2004.05.007; GOLD LI, 1994, CANCER RES, V54, P2347; Greenman C, 2007, NATURE, V446, P153, DOI 10.1038/nature05610; Ibrahimi OA, 2004, HUM MOL GENET, V13, P2313, DOI 10.1093/hmg/ddh235; Ibrahimi OA, 2001, P NATL ACAD SCI USA, V98, P7182, DOI 10.1073/pnas.121183798; Jemal A, 2006, CA-CANCER J CLIN, V56, P106, DOI 10.3322/canjclin.56.2.106; Mohammadi M, 2005, CYTOKINE GROWTH F R, V16, P107, DOI 10.1016/j.cytogfr.2005.01.008; Moller B, 2001, MOL HUM REPROD, V7, P65, DOI 10.1093/molehr/7.1.65; Monsonego-Ornan E, 2000, MOL CELL BIOL, V20, P516, DOI 10.1128/MCB.20.2.516-522.2000; Obel Jennifer C, 2006, Clin Adv Hematol Oncol, V4, P459; Ornitz DM, 2001, GENOME BIOL, V2; Passos-Bueno MR, 1999, HUM MUTAT, V14, P115; Sangha RK, 1997, LAB INVEST, V77, P389; Tsai SJ, 2002, ENDOCRINOLOGY, V143, P2715, DOI 10.1210/en.143.7.2715; van Rhijn BWG, 2001, CANCER RES, V61, P1265; Wilkie AOM, 2005, CYTOKINE GROWTH F R, V16, P187, DOI 10.1016/j.cytogfr.2005.03.001; Wilkie AOM, 2002, AM J MED GENET, V112, P266, DOI 10.1002/ajmg.10775; Yu K, 2000, P NATL ACAD SCI USA, V97, P14536, DOI 10.1073/pnas.97.26.14536; Zhang XQ, 2006, J BIOL CHEM, V281, P15694, DOI 10.1074/jbc.M601252200	22	229	279	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 1	2007	26	50					7158	7162		10.1038/sj.onc.1210529	http://dx.doi.org/10.1038/sj.onc.1210529			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	228GF	17525745	Green Accepted			2022-12-28	WOS:000250715000010
J	Ticchioni, M; Essafi, M; Jeandel, PY; Davi, F; Cassuto, JP; Deckert, M; Bernard, A				Ticchioni, M.; Essafi, M.; Jeandel, P. Y.; Davi, F.; Cassuto, J. P.; Deckert, M.; Bernard, A.			Homeostatic chemokines increase survival of B-chronic lymphocytic leukemia cells through inactivation of transcription factor FOXO3a	ONCOGENE			English	Article						B-CLL; chemokines; survival; akt; FOXO3a	FACTOR-I; UP-REGULATION; APOPTOSIS; ACTIVATION; KINASE; INHIBITION; EXPRESSION; MIGRATION; PATHWAY; DIFFERENTIATION	B-chronic lymphocytic leukemia (B-CLL) cell is characterized by the accumulation of long-lived CD5+ B lymphocytes, whose survival in vivo is in part dependent on exogenous factors such as cytokines and/or extracellular matrix proteins. Homeostatic chemokines are critical mediators of lymphoid cell trafficking. However, how they function in cell signaling and survival remains ill-defined. In this study, we have investigated the role of the homeostatic chemokines, CXCL12, CCL21, CCL19 and CXCL13, in B-CLL cell survival. Using primary leukemic cells isolated from 26 patients, we observed that each chemokine enhances cell survival. Chemokines induced the phosphorylation of ERK1/2 and p90RSK, and of Akt and its effectors GSK3 and FOXO3a. Consistently, inhibitors against mitogen-activated protein kinase/extracellular signal-regulated kinase and phosphatidylinositol 3-kinase inhibited chemokine-induced survival. Moreover, using a constitutively active mutated form of FOXO3a or siRNAs against FOXO3a in transfection experiments performed in primary B-CLL cells, we directly demonstrated the critical role of FOXO3a in both spontaneous and chemokine-induced B-CLL cell survival. Overall, our data support the notion that homeostatic chemokines contribute to B-CLL resistance to cell death through inactivation of the transcription factor FOXO3a, which may represent a novel therapeutic target in this hematopoietic malignancy.	Univ Nice, Hop Archet, Dept Immunol, Immunol Lab, F-06202 Nice 3, France; Hop Archet, INSERM, UMR576, F-06202 Nice, France; Univ Nice, Hop Archet, Dept Med Interne, F-06202 Nice 3, France; Univ Paris 06, Grp Hosp Pitie Salpetriere, Dept Hematol, Paris, France; Univ Nice, Hop Archet, Dept Hematol, F-06202 Nice 3, France	CHU Nice; UDICE-French Research Universities; Universite Cote d'Azur; CHU Nice; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; CHU Nice; UDICE-French Research Universities; Universite Cote d'Azur; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; CHU Nice; UDICE-French Research Universities; Universite Cote d'Azur	Ticchioni, M (corresponding author), Univ Nice, Hop Archet, Dept Immunol, Immunol Lab, Route St Antoine Ginestiere, F-06202 Nice 3, France.	michel.ticchioni@unice.fr; deckert@unice.fr	Deckert, Marcel/M-4998-2016; Ticchioni, Michel/P-8095-2016; Essafi, Makram/V-8411-2019; Jeandel, Pierre-Yves/ABD-6658-2020; Deckert, Marcel/T-3566-2019	Deckert, Marcel/0000-0003-2094-559X				AUBIN J, 1995, LEUKEMIA, V9, P471; Baccarini M, 2002, CELL DEATH DIFFER, V9, P783, DOI 10.1038/sj.cdd.4401070; Birkenkamp KU, 2003, J IMMUNOL, V171, P1623, DOI 10.4049/jimmunol.171.4.1623; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Burger JA, 2000, BLOOD, V96, P2655; Burger M, 2005, BLOOD, V106, P1824, DOI 10.1182/blood-2004-12-4918; Burgering BMT, 2003, J LEUKOCYTE BIOL, V73, P689, DOI 10.1189/jlb.1202629; Caligaris-Cappio F, 1999, J CLIN ONCOL, V17, P399, DOI 10.1200/JCO.1999.17.1.399; Charvet C, 2003, ONCOGENE, V22, P4557, DOI 10.1038/sj.onc.1206778; Colamussi ML, 2001, J LEUKOCYTE BIOL, V69, P263; Crespo M, 2003, NEW ENGL J MED, V348, P1764, DOI 10.1056/NEJMoa023143; Durig J, 2002, LEUKEMIA, V16, P30, DOI 10.1038/sj.leu.2402339; Eldar-Finkelman H, 2002, TRENDS MOL MED, V8, P126, DOI 10.1016/S1471-4914(01)02266-3; Glimm H, 2002, BLOOD, V99, P3454, DOI 10.1182/blood.V99.9.3454; Hodohara K, 2000, BLOOD, V95, P769, DOI 10.1182/blood.V95.3.769.003a49_769_775; Hu MCT, 2004, CELL, V117, P225, DOI 10.1016/S0092-8674(04)00302-2; Kamiguti AS, 2003, ONCOGENE, V22, P2272, DOI 10.1038/sj.onc.1206398; Kipps TJ, 2003, CURR OPIN HEMATOL, V10, P312, DOI 10.1097/00062752-200307000-00010; Lataillade JJ, 2002, BLOOD, V99, P1117, DOI 10.1182/blood.V99.4.1117; Lee Y, 2002, BLOOD, V99, P4307, DOI 10.1182/blood.V99.12.4307; Leupin N, 2003, BRIT J HAEMATOL, V121, P97, DOI 10.1046/j.1365-2141.2003.04227.x; Luther SA, 2001, NAT IMMUNOL, V2, P102, DOI 10.1038/84205; Majka M, 2000, BLOOD, V96, P4142, DOI 10.1182/blood.V96.13.4142.h8004142_4142_4151; Mori M, 2003, J CELL PHYSIOL, V195, P290, DOI 10.1002/jcp.10245; Moser B, 2001, NAT IMMUNOL, V2, P123, DOI 10.1038/84219; Nagata Y, 1999, BLOOD, V94, P853, DOI 10.1182/blood.V94.3.853.415a12_853_863; Nishio M, 2005, BLOOD, V106, P1012, DOI 10.1182/blood-2004-03-0889; Okada T, 2002, J EXP MED, V196, P65, DOI 10.1084/jem.20020201; Pepper C, 2003, BLOOD, V101, P2454, DOI 10.1182/blood-2002-07-1984; Ringshausen I, 2002, BLOOD, V100, P3741, DOI 10.1182/blood-2002-02-0539; Suzuki Y, 2001, J IMMUNOL, V167, P3064, DOI 10.4049/jimmunol.167.6.3064; Ticchioni M, 2002, BLOOD, V99, P3111, DOI 10.1182/blood.V99.9.3111; van Dongen JJM, 2003, LEUKEMIA, V17, P2257, DOI 10.1038/sj.leu.2403202; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; von Andrian UH, 2000, NEW ENGL J MED, V343, P1020, DOI 10.1056/NEJM200010053431407	35	76	78	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 1	2007	26	50					7081	7091		10.1038/sj.onc.1210519	http://dx.doi.org/10.1038/sj.onc.1210519			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	228GF	17496928				2022-12-28	WOS:000250715000002
J	Saeki, N; Kim, DH; Usui, T; Aoyagi, K; Tatsuta, T; Aoki, K; Yanagihara, K; Tamura, M; Mizushima, H; Sakamoto, H; Ogawa, K; Ohki, M; Shiroishi, T; Yoshida, T; Sasaki, H				Saeki, N.; Kim, D. H.; Usui, T.; Aoyagi, K.; Tatsuta, T.; Aoki, K.; Yanagihara, K.; Tamura, M.; Mizushima, H.; Sakamoto, H.; Ogawa, K.; Ohki, M.; Shiroishi, T.; Yoshida, T.; Sasaki, H.			GASDERMIN, suppressed frequently in gastric cancer, is a target of LMO1 in TGF-beta-dependent apoptotic signalling	ONCOGENE			English	Article						gastric pit cells; apoptosis; LMO1; TGF-beta; GASDERMIN	MOUSE-CHROMOSOME 11; RUNX3 KNOCKOUTS; STOMACH-CANCER; CELL-LINES; NUDE-MICE; EXPRESSION; GENE; ESTABLISHMENT; CARCINOMA; EMBRYOGENESIS	Defining apoptosis-regulatory cascades of the epithelium is important for understanding carcinogenesis, since cancer cells are considered to arise as a result of the collapse of the cascades. We previously reported that a novel gene GASDERMIN (GSDM) is expressed in the stomach but suppressed in gastric cancer cell lines. Furthermore, in this study, we demonstrated that GSDM is expressed in the mucus-secreting pit cells of the gastric epithelium and frequently silenced in primary gastric cancers. We found that GSDM has a highly apoptotic activity and its expression is regulated by a transcription factor LIM domain only 1 (LMO1) through a sequence to which Runt-related transcription factor 3 (RUNX3) binds, in a GSDM promoter region. We observed coexpression of GSDM with LMO1, RUNX3 and type II transforming growth factor-beta receptor (TGF-beta RII) in the pit cells, and found that TGF-beta upregulates the LMO1- and GSDM-expression in the gastric epithelial cell line and induces apoptosis, which was confirmed by the finding that the apoptosis induction is inhibited by suppression of each LMO1-, RUNX3- and GSDM expression, respectively. The present data suggest that TGF-beta, LMO1, possibly RUNX3, and GSDM form a regulatory pathway for directing the pit cells to apoptosis.	Natl Canc Ctr, Res Inst, Div Genet, Chuo Ku, Tokyo 104, Japan; Natl Inst Canc Res, Ctr Med Genom, Chuo Ku, Tokyo, Japan; Tokyo Womens Med Univ, Sch Med, Med Ctr E, Tokyo, Japan; Natl Inst Canc Res, Sect Studies Host Immune Response, Chuo Ku, Tokyo, Japan; Natl Inst Canc Res, Cent Anim Lab, Chuo Ku, Tokyo, Japan; Natl Inst Genet, Genet Strains Res Ctr, Mammalian Genet Lab, Shizuoka, Japan	National Cancer Center - Japan; National Cancer Center - Japan; Tokyo Women's Medical University; National Cancer Center - Japan; National Cancer Center - Japan; Research Organization of Information & Systems (ROIS); National Institute of Genetics (NIG) - Japan	Sasaki, H (corresponding author), Natl Canc Ctr, Res Inst, Div Genet, Chuo Ku, Tukiji 5-Chome, Tokyo 104, Japan.	hksasaki@gan2.res.ncc.go.jp	Tamura, Masaru/D-1416-2017	Tamura, Masaru/0000-0002-0311-8827				Aoyagi K, 2003, BIOCHEM BIOPH RES CO, V300, P915, DOI 10.1016/S0006-291X(02)02967-4; Bae SC, 2003, EMBO REP, V4, P538, DOI 10.1038/sj.embor.embor875; Crawford SE, 1998, CELL, V93, P1159, DOI 10.1016/S0092-8674(00)81460-9; DEBOLOS C, 1995, GASTROENTEROLOGY, V109, P723, DOI 10.1016/0016-5085(95)90379-8; FORONI L, 1992, J MOL BIOL, V226, P747, DOI 10.1016/0022-2836(92)90630-3; Fujihara T, 1998, CLIN EXP METASTAS, V16, P389; Fukaya M, 2006, GASTROENTEROLOGY, V131, P14, DOI 10.1053/j.gastro.2006.05.008; HO SB, 1995, GASTROENTEROLOGY, V109, P735, DOI 10.1016/0016-5085(95)90380-1; KARAM S, 1995, MICROSC RES TECHNIQ, V31, P93; Kenny DA, 1998, P NATL ACAD SCI USA, V95, P11257, DOI 10.1073/pnas.95.19.11257; Levanon D, 2003, EMBO REP, V4, P560, DOI 10.1038/sj.embor.embor868; Levanon D, 2001, MECH DEVELOP, V109, P413, DOI 10.1016/S0925-4773(01)00537-8; Levanon D, 2002, EMBO J, V21, P3454, DOI 10.1093/emboj/cdf370; Li QL, 2002, CELL, V109, P113, DOI 10.1016/S0092-8674(02)00690-6; Lunny DP, 2005, J INVEST DERMATOL, V124, P615, DOI 10.1111/j.0022-202X.2005.23623.x; MCGUIRE EA, 1989, MOL CELL BIOL, V9, P2124, DOI 10.1128/MCB.9.5.2124; Meyers S, 1996, ONCOGENE, V13, P303; Nishigaki M, 2005, CANCER RES, V65, P2115, DOI 10.1158/0008-5472.CAN-04-3340; Rabbitts TH, 1998, GENE DEV, V12, P2651, DOI 10.1101/gad.12.17.2651; Runkel F, 2004, GENOMICS, V84, P824, DOI 10.1016/j.ygeno.2004.07.003; Saeki N, 2000, MAMM GENOME, V11, P718, DOI 10.1007/s003350010138; Sato H, 1998, MAMM GENOME, V9, P20, DOI 10.1007/s003359900673; SEKIGUCHI M, 1978, JPN J EXP MED, V48, P61; Sekiguchi M., 1994, ATLAS HUMAN TUMOR CE, P287; Yanagihara K, 2004, CANCER SCI, V95, P575, DOI 10.1111/j.1349-7006.2004.tb02489.x; YANAGIHARA K, 1992, CANCER RES, V52, P4042	26	97	105	3	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT	2007	26	45					6488	6498		10.1038/sj.onc.1210475	http://dx.doi.org/10.1038/sj.onc.1210475			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	217AF	17471240				2022-12-28	WOS:000249919800002
J	Wu, J; Jin, YJ; Calaf, GM; Huang, WL; Yin, Y				Wu, J.; Jin, Y. J.; Calaf, G. M.; Huang, W-L; Yin, Y.			PAC1 is a direct transcription target of E2F-1 in apoptotic signaling	ONCOGENE			English	Article						E2F-1; PAC1; MAP kinases; 4-HPR; apoptosis; chemotherapeutics	STRESS-INDUCED APOPTOSIS; MAP KINASE; OXIDATIVE STRESS; E2F-1-INDUCED APOPTOSIS; CELL-PROLIFERATION; GROWTH SUPPRESSION; NITRIC-OXIDE; IN-VIVO; PHOSPHATASE; ACTIVATION	E2F-1 controls multiple cellular activities through transcriptional regulation of its target genes. As a mediator of cell death, E2F-1 can eliminate latent neoplastic cells through apoptosis. However, the mechanism by which E2F-1 mediates cancer cell killing is largely unknown. In this paper, we report that phosphatase of activated cells 1 (PAC1) phosphatase is a direct transcription target of E2F-1 in signaling apoptosis. We show that ectopic E2F-1 increases expression of PAC1 at both transcriptional and translational levels in breast cancer cells. E2F-1 physically interacts with the promoter of PAC1, binds to its consensus sequence in the promoter and transactivates the PAC1 promoter. E2F-1 suppresses extracellular signal-regulated kinase (ERK) phosphorylation through PAC1 and causes cancer cell death by apoptosis following treatment with a chemotherapeutic agent N-4-hydroxy-phenylretinamide (4-HPR). Furthermore, ectopic PAC1 inhibits ERK phosphorylation and mediates cell killing. Moreover, endogenous E2F-1 upregulates PAC1 and suppresses ERK activity, leading to cell death in response to 4-HPR. These results reveal a crucial role of PAC1 in E2F-1-directed apoptosis. Our study demonstrates that E2F-1 mediates apoptosis through transcriptional regulation of PAC1 and subsequent suppression of the ERK signaling. Our findings establish a functional link between E2F-1 and mitogen-activated protein kinases. The E2F-1 PAC1 cascade in cancer cell killing may provide a molecular basis for cancer therapeutic intervention.	Columbia Univ Coll Phys & Surg, Ctr Radiol Res, Dept Radiat Oncol, New York, NY 10032 USA; Sun Yat Sen Univ, Ctr Canc, State Key Lab Oncol So China, Guangzhou, Peoples R China	Columbia University; Sun Yat Sen University	Yin, Y (corresponding author), Columbia Univ Coll Phys & Surg, Ctr Radiol Res, Dept Radiat Oncol, VC11-213,630 W 168th St, New York, NY 10032 USA.	yy151@columbia.edu	huang, wen/GXW-0661-2022		NCI NIH HHS [CA102447] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA102447] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bednarek A, 1999, CARCINOGENESIS, V20, P879, DOI 10.1093/carcin/20.5.879; Bell R, 2004, EJC SUPPL, V2, P1, DOI 10.1016/J.EJCSUP.2004.01.001; Cam H, 2003, CANCER CELL, V3, P311, DOI 10.1016/S1535-6108(03)00080-1; Chu YF, 1996, J BIOL CHEM, V271, P6497, DOI 10.1074/jbc.271.11.6497; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; Conklin Kenneth A, 2004, Integr Cancer Ther, V3, P294, DOI 10.1177/1534735404270335; Creagh EM, 2003, IMMUNOL REV, V193, P10, DOI 10.1034/j.1600-065X.2003.00048.x; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; Furukawa Y, 2002, J BIOL CHEM, V277, P39760, DOI 10.1074/jbc.M200805200; Ginsberg D, 2002, FEBS LETT, V529, P122, DOI 10.1016/S0014-5793(02)03270-2; Huang LC, 1996, P NATL ACAD SCI USA, V93, P4827, DOI 10.1073/pnas.93.10.4827; Husain SS, 2001, LIFE SCI, V69, P3045, DOI 10.1016/S0024-3205(01)01411-4; Irwin M, 2000, NATURE, V407, P645, DOI 10.1038/35036614; Kim HJ, 2006, ONCOGENE, V25, P2785, DOI 10.1038/sj.onc.1209303; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; Lissy NA, 2000, NATURE, V407, P642, DOI 10.1038/35036608; Malone W, 2003, EXPERT OPIN INV DRUG, V12, P1829, DOI 10.1517/eoid.12.11.1829.21882; Mates JM, 2000, INT J BIOCHEM CELL B, V32, P157, DOI 10.1016/S1357-2725(99)00088-6; Miyata Y, 1999, BIOCHEM BIOPH RES CO, V266, P291, DOI 10.1006/bbrc.1999.1705; MOON RC, 1989, PREV MED, V18, P576, DOI 10.1016/0091-7435(89)90031-5; Ookawa K, 1997, ONCOGENE, V14, P1389, DOI 10.1038/sj.onc.1200976; ROHAN PJ, 1993, SCIENCE, V259, P1763, DOI 10.1126/science.7681221; Shen WH, 2006, CANCER RES, V66, P6033, DOI 10.1158/0008-5472.CAN-05-3878; Shen WH, 2004, J BIOL CHEM, V279, P7438, DOI 10.1074/jbc.M310264200; Simeone AM, 2003, ONCOGENE, V22, P6739, DOI 10.1038/sj.onc.1206786; Simeone AM, 2002, MOL CANCER THER, V1, P1009; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; Trinei M, 2002, ONCOGENE, V21, P3872, DOI 10.1038/sj.onc.1205513; WARD Y, 1994, NATURE, V367, P651, DOI 10.1038/367651a0; WHITMARSH AJ, 1999, SCI STKE; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4; Yan WS, 2006, J BIOL CHEM, V281, P7856, DOI 10.1074/jbc.M512655200; Yin YX, 1999, MOL CARCINOGEN, V24, P15, DOI 10.1002/(SICI)1098-2744(199901)24:1<15::AID-MC3>3.3.CO;2-P; Yin YX, 2003, NATURE, V422, P527, DOI 10.1038/nature01519; Zhang Q, 2005, J MOL BIOL, V354, P777, DOI 10.1016/j.jmb.2005.10.006; ZHU L, 1994, COLD SPRING HARB SYM, V59, P75, DOI 10.1101/SQB.1994.059.01.011	37	22	23	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2007	26	45					6526	6535		10.1038/sj.onc.1210484	http://dx.doi.org/10.1038/sj.onc.1210484			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	217AF	17471234				2022-12-28	WOS:000249919800006
J	Mei, Y; Xie, C; Xie, W; Wu, Z; Wu, M				Mei, Y.; Xie, C.; Xie, W.; Wu, Z.; Wu, M.			Siah-1S, a novel splice variant of Siah-1 (seven in absentia homolog), counteracts Siah-1-mediated downregulation of beta-catenin	ONCOGENE			English	Article						Siah-1S; beta-catenin; splice variant; self-ubiquitination; tumorigenesis	UBIQUITIN-PROTEASOME PATHWAY; INHIBITS CELL-GROWTH; TRANSCRIPTIONAL REPRESSOR; DEGRADATION PATHWAY; STRUCTURAL-ANALYSIS; MAMMALIAN HOMOLOGS; SIGNALING PATHWAYS; RAPID DEGRADATION; TUMOR SUPPRESSION; SINA GENE	Siah-1 ( seven in absentia homolog) is known to cause indirect degradation of beta-catenin through formation of a complex with Siah-interacting protein ( SIP), Skp1 and Ebi. Here, we report the characterization of a novel splice variant of human Siah-1, designated Siah-1S, which is produced by an alternative splicing mechanism. The novel intron/exon junctions used to generate Siah-1S follow a non-conventional CT-AC rule. Siah-1S exhibits an even shorter half-life than Siah-1 and is able to catalyse self-ubiquitination that results in its subsequent degradation by proteasome. Siah-1S is shown to upregulate beta-catenin-dependent Tcf/Lef transcriptional activation and antagonize Siah-1's potentiation effect on the apoptosis induced by etoposide in MCF-7 cells. Additionally, Siah-1S is found to interact with Siah-1 to form heterodimer or with itself to form homodimer. Unlike homodimer Siah-1*Siah-1, neither Siah-1*Siah-1S nor Siah-1S*Siah-1S is able to bind to Siah-1-interacting protein, which may explain the underlying mechanism for Siah-1S's dominant negative effect on Siah-1. Importantly, results from in vitro soft agar assay demonstrated that Siah-1S displays a promotion effect on cells tumorigenicity.	Univ Sci & Technol China, Hefei Natl Lab Phys Sci Microscale, Hefei 230027, Anhui, Peoples R China; Univ Sci & Technol China, Sch Life Sci, Hefei 230027, Anhui, Peoples R China; Anhui Med Univ, Dept Pathol, Hefei, Anhui, Peoples R China	Chinese Academy of Sciences; University of Science & Technology of China, CAS; Chinese Academy of Sciences; University of Science & Technology of China, CAS; Anhui Medical University	Wu, M (corresponding author), Univ Sci & Technol China, Hefei Natl Lab Phys Sci Microscale, Hefei 230027, Anhui, Peoples R China.	wumian@ustc.edu.cn	Wu, Mian/H-2494-2018; Mei, Yide/M-4468-2013; Xie, Chongwei/GOP-0158-2022	Wu, Mian/0000-0002-2714-0500				Amson RB, 1996, P NATL ACAD SCI USA, V93, P3953, DOI 10.1073/pnas.93.9.3953; Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092-8674(00)00122-7; Boehm J, 2001, EMBO J, V20, P4153, DOI 10.1093/emboj/20.15.4153; Bruzzoni-Giovanelli H, 1999, ONCOGENE, V18, P7101, DOI 10.1038/sj.onc.1203187; CARTHEW RW, 1990, CELL, V63, P561, DOI 10.1016/0092-8674(90)90452-K; Dong XZ, 1999, GENE DEV, V13, P954, DOI 10.1101/gad.13.8.954; French C, 1999, VIROLOGY, V262, P139, DOI 10.1006/viro.1999.9875; Fukushima T, 2006, IMMUNITY, V24, P29, DOI 10.1016/j.immuni.2005.12.002; Germani A, 2003, ONCOGENE, V22, P8845, DOI 10.1038/sj.onc.1206994; Germani A, 1999, MOL CELL BIOL, V19, P3798; Germani A, 2000, ONCOGENE, V19, P5997, DOI 10.1038/sj.onc.1204002; Gutierrez GJ, 2006, NAT CELL BIOL, V8, P1084, DOI 10.1038/ncb1472; Habelhah H, 2004, J BIOL CHEM, V279, P53782, DOI 10.1074/jbc.M410315200; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Hu G, 1999, MOL CELL BIOL, V19, P724; Hu G, 1997, GENOMICS, V46, P103, DOI 10.1006/geno.1997.4997; Hu G, 1997, GENE DEV, V11, P2701, DOI 10.1101/gad.11.20.2701; Iwai A, 2004, ONCOGENE, V23, P7593, DOI 10.1038/sj.onc.1208016; Johnsen SA, 2002, J BIOL CHEM, V277, P30754, DOI 10.1074/jbc.M204812200; Kim H, 2004, J AM SOC NEPHROL, V15, P2042, DOI 10.1097/01.ASN.0000133490.00348.59; Kramer A, 1996, ANNU REV BIOCHEM, V65, P367, DOI 10.1146/annurev.biochem.65.1.367; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Li SH, 1997, CELL, V90, P469, DOI 10.1016/S0092-8674(00)80507-3; Liu J, 2001, MOL CELL, V7, P927, DOI 10.1016/S1097-2765(01)00241-6; Lorick KL, 1999, P NATL ACAD SCI USA, V96, P11364, DOI 10.1073/pnas.96.20.11364; Matsuzawa S, 2001, MOL CELL, V7, P915, DOI 10.1016/S1097-2765(01)00242-8; Matsuzawa S, 2003, J BIOL CHEM, V278, P1837, DOI 10.1074/jbc.M210263200; Matsuzawa S, 1998, EMBO J, V17, P2736, DOI 10.1093/emboj/17.10.2736; Mei YD, 2005, ONCOGENE, V24, P7224, DOI 10.1038/sj.onc.1208873; Nagano Y, 2003, J BIOL CHEM, V278, P51504, DOI 10.1074/jbc.M306347200; Nakamura N, 2004, J PHYS CONF SER, V2, P1, DOI 10.1088/1742-6596/2/1/001; Nemani M, 1996, P NATL ACAD SCI USA, V93, P9039, DOI 10.1073/pnas.93.17.9039; Oliver PL, 2004, P NATL ACAD SCI USA, V101, P14901, DOI 10.1073/pnas.0406196101; Peifer M, 2000, SCIENCE, V287, P1606, DOI 10.1126/science.287.5458.1606; Polekhina G, 2002, NAT STRUCT BIOL, V9, P68, DOI 10.1038/nsb743; Provost E, 1999, CURR OPIN CELL BIOL, V11, P567, DOI 10.1016/S0955-0674(99)00015-0; Roperch JP, 1999, P NATL ACAD SCI USA, V96, P8070, DOI 10.1073/pnas.96.14.8070; Santelli E, 2005, J BIOL CHEM, V280, P34278, DOI 10.1074/jbc.M506707200; Susini L, 2001, P NATL ACAD SCI USA, V98, P15067, DOI 10.1073/pnas.261571998; Tang AH, 1997, CELL, V90, P459, DOI 10.1016/S0092-8674(00)80506-1; Tanikawa J, 2000, J BIOL CHEM, V275, P15578, DOI 10.1074/jbc.M000372200; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Tiedt R, 2001, EMBO J, V20, P4143, DOI 10.1093/emboj/20.15.4143; Tuynder M, 2002, P NATL ACAD SCI USA, V99, P14976, DOI 10.1073/pnas.222470799; Venables JP, 2004, HUM MOL GENET, V13, P1525, DOI 10.1093/hmg/ddh165; Wheeler TC, 2002, J BIOL CHEM, V277, P10273, DOI 10.1074/jbc.M107857200; Yang Y, 2000, SCIENCE, V288, P874, DOI 10.1126/science.288.5467.874; Zhang JS, 1998, GENE DEV, V12, P1775, DOI 10.1101/gad.12.12.1775	49	14	17	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 20	2007	26	43					6319	6331		10.1038/sj.onc.1210449	http://dx.doi.org/10.1038/sj.onc.1210449			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	212GW	17420721				2022-12-28	WOS:000249583300008
J	Brandes, JC; Carraway, H; Herman, JG				Brandes, J. C.; Carraway, H.; Herman, J. G.			Optimal primer design using the novel primer design program: MSPprimer provides accurate methylation analysis of the ATM promoter	ONCOGENE			English	Article						DNA methylation; ATM; breast cancer; lung cancer; methylation Specific PCR	NEAREST-NEIGHBOR THERMODYNAMICS; SQUAMOUS-CELL CARCINOMA; DOT-T MISMATCHES; LUNG-CANCER; DNA METHYLTRANSFERASE; ATAXIA-TELANGIECTASIA; BREAST-CANCER; GENE; HYPERMETHYLATION; INACTIVATION	Methylation-specific polymerase chain reaction (PCR) (MSP) is frequently used to study gene silencing by promoter hypermethylation. However, non-specific primer design can lead to false-positive detection of methylation. We present a novel, web-based algorithm for the design of primers for bisulfate-PCRs ( MSP, sequencing, COBRA and multiplex-MSP), allowing the determination of a specificity score, which is based on the thermodynamic characteristics of the primer 3'-end. PCR amplification with primers not reaching a high specificity score can result in false-positive findings. We used MSPprimer to design MSP primers for analysis of the ATM promoter. In 37 non-small cell lung cancer (NSCLC) samples and 43 breast cancer samples no promoter methylation was detected. Conversely, published MSP primers not reaching the required specificity score led to non-specific amplification of DNA not converted by bisul. te. The result was a false-positive incidence of ATM promoter methylation of 24% in NSCLC and 48% in breast cancers, similar to published studies. This highlights the critical need for specific primer design for MSP. MSPprimer is a convenient tool to achieve this goal, which is available free of charge to the scientific community.	Sidney Kimmel Comprehens Canc Ctr, Dept Oncol, Canc Biol Program, Baltimore, MD USA	Johns Hopkins University; Johns Hopkins Medicine	Herman, JG (corresponding author), Sidney Kimmel Comprehens Canc Ctr, Dept Oncol, Bunting Blaustein Canc Res Bldg, 1650 Orleans Str Suite 543, Baltimore, MD 21231 USA.	hermanji@jhmi.edu	Carraway, Hetty/AAR-4977-2020	Carraway, Hetty/0000-0001-5241-3614; Brandes, Johann/0000-0002-1815-8311				Ai LB, 2004, CANCER EPIDEM BIOMAR, V13, P150, DOI 10.1158/1055-9965.EPI-082-3; Allawi HT, 1998, BIOCHEMISTRY-US, V37, P9435, DOI 10.1021/bi9803729; Allawi HT, 1998, BIOCHEMISTRY-US, V37, P2170, DOI 10.1021/bi9724873; Allawi HT, 1997, BIOCHEMISTRY-US, V36, P10581, DOI 10.1021/bi962590c; Allawi HT, 1998, NUCLEIC ACIDS RES, V26, P2694, DOI 10.1093/nar/26.11.2694; Allinen M, 2002, GENE CHROMOSOME CANC, V34, P384, DOI 10.1002/gcc.10079; Austen B, 2005, BLOOD, V106, P3175, DOI 10.1182/blood-2004-11-4516; Belinsky SA, 2005, CLIN CANCER RES, V11, P6505, DOI 10.1158/1078-0432.CCR-05-0625; Bolt J, 2005, ORAL ONCOL, V41, P1013, DOI 10.1016/j.oraloncology.2005.06.003; Brandes JC, 2005, CARCINOGENESIS, V26, P1152, DOI 10.1093/carcin/bgi058; Brandes JC, 2006, CANCER RES, V66, P6892, DOI 10.1158/0008-5472.CAN-06-0116; BRANES JC, 2006, CANCER RES, V66, P6893; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; Esteller M, 1999, CANCER RES, V59, P67; Esteller M, 2000, NEW ENGL J MED, V343, P1350, DOI 10.1056/NEJM200011093431901; FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827; Gronbaek K, 2002, BLOOD, V100, P1430, DOI 10.1182/blood-2002-02-0382; Gumy-Pause F, 2006, LEUKEMIA RES, V30, P335, DOI 10.1016/j.leukres.2005.07.012; Hegi ME, 2005, NEW ENGL J MED, V352, P997, DOI 10.1056/NEJMoa043331; Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Karpf AR, 2001, MOL PHARMACOL, V59, P751, DOI 10.1124/mol.59.4.751; Kim WJ, 2002, ONCOGENE, V21, P3864, DOI 10.1038/sj.onc.1205485; Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427; Luo LP, 1998, CANCER RES, V58, P2293; Miura F, 2005, BIOINFORMATICS, V21, P4363, DOI 10.1093/bioinformatics/bti716; Owczarzy R, 2004, BIOCHEMISTRY-US, V43, P3537, DOI 10.1021/bi034621r; Pellise M, 2004, CLIN CANCER RES, V10, P4444, DOI 10.1158/1078-0432.CCR-03-0600; Peyret N, 1999, BIOCHEMISTRY-US, V38, P3468, DOI 10.1021/bi9825091; Roy K, 2006, BIOCHEM BIOPH RES CO, V344, P821, DOI 10.1016/j.bbrc.2006.03.222; Safar AM, 2005, CLIN CANCER RES, V11, P4400, DOI 10.1158/1078-0432.CCR-04-2378; SantaLucia J, 1996, BIOCHEMISTRY-US, V35, P3555, DOI 10.1021/bi951907q; Stresemann C, 2006, CANCER RES, V66, P2794, DOI 10.1158/0008-5472.CAN-05-2821; Tusnady GE, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni012; Vallone PM, 2004, BIOTECHNIQUES, V37, P226, DOI 10.2144/04372ST03; Vo QN, 2004, ONCOGENE, V23, P9432, DOI 10.1038/sj.onc.1208092; Xiong ZG, 1997, NUCLEIC ACIDS RES, V25, P2532, DOI 10.1093/nar/25.12.2532	37	60	66	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 13	2007	26	42					6229	6237		10.1038/sj.onc.1210433	http://dx.doi.org/10.1038/sj.onc.1210433			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	209PU	17384671				2022-12-28	WOS:000249401300014
J	Kurabe, N; Katagiri, K; Komiya, Y; Ito, R; Sugiyama, A; Kawasaki, Y; Tashiro, F				Kurabe, N.; Katagiri, K.; Komiya, Y.; Ito, R.; Sugiyama, A.; Kawasaki, Y.; Tashiro, F.			Deregulated expression of a novel component of TFTC/STAGA histone acetyltransferase complexes, rat SGF29, in hepatocellular carcinoma: possible implication for the oncogenic potential of c-Myc	ONCOGENE			English	Article						c-Myc; metastasis; STAGA; transcription control; tumorigenicity	ACETYLASE COMPLEX; ORNITHINE-DECARBOXYLASE; NUCLEOSOME ACETYLATION; ESSENTIAL COFACTOR; IN-VIVO; IDENTIFICATION; MACHINERY; TRRAP; ONCOPROTEINS; INVOLVEMENT	c-Myc N-terminal conserved domains, MbI and MbII, are essential for c-Myc-mediated transformation and transactivation. These domains recruit the STAGA (SPT3-TAF9-GCN5-acetyltransferase) coactivator complex, but not TFTC (TATA-binding protein-free TAF-containing) to the target gene promoter. Although components of this complex are well conserved between yeast and mammals, four mammalian orthologs of yeast SPT8, SPT20, SGF11 and SGF29 remain to be identified. Here, we isolated a rat ortholog of yeast SGF29, a component of yeast SAGA (SPT-ADA-GCN5-acetyltransferase) complex. Both rat (r) SGF29 and c-myc mRNAs were overexpressed in five out of the eight tested rodent tumor cells. rSGF29 directly interacted with rADA3 and co-immunoprecipitated with two other TFTC/STAGA components, rGCN5 and rSPT3. rSGF29 was recruited to the c-Myc target gene promoters together with c-Myc, and it activated c-Myc target gene expressions. Downregulation of rSGF29 suppressed the expression of c-Myc target genes and inhibited anchorage-independent growth and tumorigenicity and lung metastasis of rat hepatoma K2 cells when injected into nude mice. These results show that rSGF29 is a novel component of TFTC/STAGA complexes and could be involved in the c-Myc-mediated malignant transformation.	Tokyo Univ Sci, Fac Ind Sci & Technol, Dept Biol Sci & Technol, Noda, Chiba 2788510, Japan	Tokyo University of Science	Tashiro, F (corresponding author), Tokyo Univ Sci, Fac Ind Sci & Technol, Dept Biol Sci & Technol, Yamazaki 2641, Noda, Chiba 2788510, Japan.	ftashir@rs.noda.tus.ac.jp						Brand M, 1999, J BIOL CHEM, V274, P18285, DOI 10.1074/jbc.274.26.18285; Frank SR, 2001, GENE DEV, V15, P2069, DOI 10.1101/gad.906601; Grant PA, 1998, CELL, V94, P45, DOI 10.1016/S0092-8674(00)81220-9; Hampsey M, 1998, MICROBIOL MOL BIOL R, V62, P465, DOI 10.1128/MMBR.62.2.465-503.1998; Ikura T, 2000, CELL, V102, P463, DOI 10.1016/S0092-8674(00)00051-9; Liu XH, 2003, J BIOL CHEM, V278, P20405, DOI 10.1074/jbc.M211795200; Luscher B, 1999, ONCOGENE, V18, P2955, DOI 10.1038/sj.onc.1202750; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; Martinez E, 1998, J BIOL CHEM, V273, P23781, DOI 10.1074/jbc.273.37.23781; McMahon SB, 1998, CELL, V94, P363, DOI 10.1016/S0092-8674(00)81479-8; McMahon SB, 2000, MOL CELL BIOL, V20, P556, DOI 10.1128/MCB.20.2.556-562.2000; Nilsson JA, 2005, CANCER CELL, V7, P433, DOI 10.1016/j.ccr.2005.03.036; Ogryzko VV, 1998, CELL, V94, P35, DOI 10.1016/S0092-8674(00)81219-2; Pelengaris S, 2002, CELL, V109, P321, DOI 10.1016/S0092-8674(02)00738-9; PENA A, 1993, J BIOL CHEM, V268, P27277; Rodriguez-Navarro S, 2004, CELL, V116, P75, DOI 10.1016/S0092-8674(03)01025-0; Saleh A, 1997, J BIOL CHEM, V272, P5571, DOI 10.1074/jbc.272.9.5571; Saleh A, 1998, J BIOL CHEM, V273, P26559, DOI 10.1074/jbc.273.41.26559; Sanders SL, 2002, MOL CELL BIOL, V22, P4723, DOI 10.1128/MCB.22.13.4723-4738.2002; Strausberg RL, 2002, P NATL ACAD SCI USA, V99, P16899, DOI 10.1073/pnas.242603899; Sugiyama A, 2003, CARCINOGENESIS, V24, P1549, DOI 10.1093/carcin/bgg113; Urano Y, 2006, J BIOL CHEM, V281, P7498, DOI 10.1074/jbc.M510881200; Wang L, 1998, GENE DEV, V12, P640, DOI 10.1101/gad.12.5.640; Zhang XY, 2005, P NATL ACAD SCI USA, V102, P13968, DOI 10.1073/pnas.0502330102	24	23	26	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG	2007	26	38					5626	5634		10.1038/sj.onc.1210349	http://dx.doi.org/10.1038/sj.onc.1210349			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	200ZS	17334388				2022-12-28	WOS:000248801900008
J	Angeloni, D; Danilkovitch-Miagkova, A; Ivanova, T; Braga, E; Zabarovsky, E; Lerman, MI				Angeloni, D.; Danilkovitch-Miagkova, A.; Ivanova, T.; Braga, E.; Zabarovsky, E.; Lerman, M. I.			Hypermethylation of Ron proximal promoter associates with lack of full-length Ron and transcription of oncogenic short-Ron from an internal promoter	ONCOGENE			English	Article						3p21.3; differentiation; erythroleukemia; lung cancer; promoter methylation; Ron (MST1R)	RECEPTOR TYROSINE KINASE; ACTIVATION; FAMILY; CANCER; GENE; MET; PROGRESSION; DOMAIN; MOUSE; CELLS	The gene for tyrosine-kinase receptor Ron (MST1R) resides in the chromosome 3p21.3 region, frequently affected in common human malignancies. The gene generates two transcripts, 5 and 2 kb-long, full-length Ron (flRon) and short-form Ron (sfRon), respectively. Here, we show for the first time that the variegated Ron expression is associated with variations in the methylation patterns of two distinct CpG islands in Ron proximal promoter. Widespread hypermethylation associates with lack of flRon whereas hypermethylation of the distal island associates with transcription of sfRon, a constitutively active tyrosine-kinase that drives cell proliferation. sfRon inhibition with kinase-dead transgenes decreases cancer cell growth and induces cellular differentiation. sfRon could be a new drug target in cancer types in which it contributes to tumor progression.	NCI, Ctr Canc Res, Immunol Lab, Frederick, MD USA; Karolinska Inst, MTC, Stockholm, Sweden; Russian Acad Med Sci, Blokhin Canc Res Ctr, Inst Carcinogenesis, Moscow, Russia; CNR, Scuola Super St Anna, Inst Clin Physiol, Pisa, Italy; Russian State Genet Ctr, Lab Mol Diagnost, Moscow, Russia; Osiris Therapeut Inc, Baltimore, MD USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Karolinska Institutet; N.N. Blokhin Russian Cancer Research Center; Russian Academy of Medical Sciences; Consiglio Nazionale delle Ricerche (CNR); Istituto di Fisiologia Clinica (IFC-CNR); Scuola Superiore Sant'Anna; Osiris Therapeutics	Angeloni, D (corresponding author), Scuola Super Sant Anna, Inst Clin Physiol, Via Mourzzi,1, I-56124 Pisa, Italy.	angeloni@ifc.cnr.it	Zabarovsky, Eugene R/A-6645-2010; Braga, Eleonora A./P-5574-2016	Braga, Eleonora/0000-0001-5188-4094; Angeloni, Debora/0000-0002-3850-5392	Intramural NIH HHS Funding Source: Medline; NATIONAL CANCER INSTITUTE [Z01BC008579] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Angeloni D, 2004, J BIOL CHEM, V279, P3726, DOI 10.1074/jbc.M309342200; Angeloni D, 2000, GENE CHROMOSOME CANC, V29, P147, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1015>3.3.CO;2-E; Bardella C, 2004, CANCER RES, V64, P5154, DOI 10.1158/0008-5472.CAN-04-0600; Bix M, 1998, SCIENCE, V281, P1352, DOI 10.1126/science.281.5381.1352; Camp ER, 2005, ANN SURG ONCOL, V12, P273, DOI 10.1245/ASO.2005.08.013; Carninci P, 2006, NAT GENET, V38, P626, DOI 10.1038/ng1789; Correll Pamela H., 1997, Genes and Function, V1, P69; Danilkovitch-Miagkova A, 2001, MOL CELL BIOL, V21, P5857, DOI 10.1128/MCB.21.17.5857-5868.2001; Danilkovitch-Miagkova A, 2000, J BIOL CHEM, V275, P14783, DOI 10.1074/jbc.C000028200; DELGATTO F, 1995, BBA-GENE STRUCT EXPR, V1263, P93, DOI 10.1016/0167-4781(95)00082-R; GAUDINO G, 1994, EMBO J, V13, P3524, DOI 10.1002/j.1460-2075.1994.tb06659.x; Ghigna C, 2005, MOL CELL, V20, P881, DOI 10.1016/j.molcel.2005.10.026; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Iwama A, 1996, EMBO J, V15, P5866, DOI 10.1002/j.1460-2075.1996.tb00973.x; JOHNSON BE, 1988, CANCER RES, V48, P5163; Momparler RL, 2005, SEMIN ONCOL, V32, P443, DOI 10.1053/j.seminoncol.2005.07.008; Muraoka RS, 1999, J CLIN INVEST, V103, P1277, DOI 10.1172/JCI6091; Persons DA, 1999, NAT GENET, V23, P159, DOI 10.1038/13787; Phelps RM, 1996, J CELL BIOCHEM, P32; RONSIN C, 1993, ONCOGENE, V8, P1195; Saleh A, 2004, IMMUNITY, V21, P55, DOI 10.1016/j.immuni.2004.06.005; Sambrook J., 2001, MOL CLONING LAB MANU; SUDA T, 1997, LEUKEMIA, V3, P451; Talley CJ, 1997, AM J HEMATOL, V54, P301, DOI 10.1002/(SICI)1096-8652(199704)54:4<301::AID-AJH7>3.0.CO;2-Z; Thiery JP, 2003, CURR OPIN CELL BIOL, V15, P740, DOI 10.1016/j.ceb.2003.10.006; Villa-Moruzzi E, 1998, BIOCHEM J, V336, P235, DOI 10.1042/bj3360235; Waltz SE, 2001, J CLIN INVEST, V108, P567, DOI 10.1172/JCI11881; Wang MH, 1996, EXP CELL RES, V226, P39, DOI 10.1006/excr.1996.0200; Wei X, 2005, J BIOL CHEM, V280, P40241, DOI 10.1074/jbc.M506806200	29	37	41	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2007	26	31					4499	4512		10.1038/sj.onc.1210238	http://dx.doi.org/10.1038/sj.onc.1210238			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	187GR	17297469				2022-12-28	WOS:000247836100004
J	Liu, X; Hu, Y; Hao, C; Rempel, SA; Ye, K				Liu, X.; Hu, Y.; Hao, C.; Rempel, S. A.; Ye, K.			PIKE-A is a proto-oncogene promoting cell growth, transformation and invasion	ONCOGENE			English	Article						PIKE-A; Akt; proto-oncogene; transformation; cell invasion	HUMAN-MALIGNANT GLIOMAS; PROTEIN-KINASE B/AKT; NUCLEAR GTPASE; AKT; AMPLIFICATION; PHOSPHORYLATION; ONCOGENE; CANCER; HETEROZYGOSITY; IDENTIFICATION	PIKE-A (phosphoinositide 3-kinases (PI 3)-kinase enhancer) is a ubiquitously expressed GTPase, which binds to and enhances protein kinase B (Akt) kinase activity in a guanine nucleotide-dependent manner. PIKE-A is one of the components of the CDK4 amplicon that is ampli. ed in numerous human cancers. However, whether PIKE-A itself can mediate cell transformation, proliferation and migration remains unknown. Here, we show that PIKE-A is overexpressed in various human cancer samples, escalates U87MG glioblastoma invasion and provokes NIH3T3 cell transformation. Overexpression of wild-type (WT) PIKE-A enhances NIH3T3 and U87MG cell growth, which is further increased by cancer cell-derived PIKE-A active mutants. In contrast, both the dominant-negative mutant and the phosphoinositide lipids interaction-defective mutant antagonize cell proliferation. Moreover, PIKE-A and its active and inactive mutants similarly enhance or antagonize U87MG cell survival and invasion, and their ability to do so is coupled with the catalytic effect they have on Akt activation. Furthermore, PIKE-A WT and its active mutants signifi. cantly elicit NIH3T3 cell transformation. Thus, our. ndings support the concept that PIKE-A acts as a proto-oncogene, promoting cell transformation through Akt activation.	Emory Univ, Sch Med, Dept Pathol & Lab Med, Atlanta, GA 30322 USA; Henry Ford Hosp, Hermelin Brain Tumor Ctr, Dept Neurosurg, Barbara Jane Levy Lab Mol Neurooncol, Detroit, MI 48202 USA	Emory University; Henry Ford Health System; Henry Ford Hospital	Ye, K (corresponding author), Emory Univ, Sch Med, Dept Pathol & Lab Med, Room 145,Whitehead Bldg,615 Michael St, Atlanta, GA 30322 USA.	kye@emory.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS045627] Funding Source: NIH RePORTER; NINDS NIH HHS [R01 NS045627] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ahn JY, 2004, EMBO J, V23, P3995, DOI 10.1038/sj.emboj.7600392; Ahn JY, 2004, P NATL ACAD SCI USA, V101, P6993, DOI 10.1073/pnas.0400921101; Ahn JY, 2004, J BIOL CHEM, V279, P16441, DOI 10.1074/jbc.M312175200; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; Brazil DP, 2002, CELL, V111, P293, DOI 10.1016/S0092-8674(02)01083-8; CHENG JQ, 1992, P NATL ACAD SCI USA, V89, P9267, DOI 10.1073/pnas.89.19.9267; Cheng JQ, 1996, P NATL ACAD SCI USA, V93, P3636, DOI 10.1073/pnas.93.8.3636; Coffer PJ, 1998, BIOCHEM J, V335, P1; COLLINS VP, 1995, GLIA, V15, P289, DOI 10.1002/glia.440150309; COX AD, 1994, METHOD ENZYMOL, V238, P277; Gallis B, 1999, J BIOL CHEM, V274, P30101, DOI 10.1074/jbc.274.42.30101; Hill MM, 2002, PHARMACOL THERAPEUT, V93, P243, DOI 10.1016/S0163-7258(02)00193-6; Hu YX, 2005, P NATL ACAD SCI USA, V102, P16853, DOI 10.1073/pnas.0507365102; Huang ZY, 2002, ONCOGENE, V21, P1325, DOI 10.1038/sj.onc.1205206; Lee MJ, 2001, MOL CELL, V8, P693, DOI 10.1016/S1097-2765(01)00324-0; Nakatani K, 1999, BIOCHEM BIOPH RES CO, V257, P906, DOI 10.1006/bbrc.1999.0559; Nicholson KM, 2002, CELL SIGNAL, V14, P381, DOI 10.1016/S0898-6568(01)00271-6; Ortega S, 2002, BBA-REV CANCER, V1602, P73, DOI 10.1016/S0304-419X(02)00037-9; Park BK, 2001, CANCER RES, V61, P7647; REIFENBERGER G, 1995, CANCER RES, V55, P731; REIFENBERGER G, 1994, CANCER RES, V54, P4299; Rempel SA, 2001, J NEURO-ONCOL, V53, P149, DOI 10.1023/A:1012201300188; Rong R, 2003, NAT NEUROSCI, V6, P1153, DOI 10.1038/nn1134; SMITH SH, 1992, CANCER RES, V52, P3746; STAAL SP, 1987, P NATL ACAD SCI USA, V84, P5034, DOI 10.1073/pnas.84.14.5034; Ye KQ, 2000, CELL, V103, P919, DOI 10.1016/S0092-8674(00)00195-1; Ye KQ, 2005, J CELL BIOCHEM, V96, P463, DOI 10.1002/jcb.20549; Ye KQ, 2002, NATURE, V415, P541, DOI 10.1038/415541a	28	42	44	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2007	26	34					4918	4927		10.1038/sj.onc.1210290	http://dx.doi.org/10.1038/sj.onc.1210290			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	194CV	17297440				2022-12-28	WOS:000248322500004
J	Welch, C; Chen, Y; Stallings, RL				Welch, C.; Chen, Y.; Stallings, R. L.			MicroRNA-34a functions as a potential tumor suppressor by inducing apoptosis in neuroblastoma cells	ONCOGENE			English	Article						apoptosis; CGH; E2F3; microRNA; neuroblastoma; tumour suppressors	CHRONIC LYMPHOCYTIC-LEUKEMIA; N-MYC; HEPATOCELLULAR-CARCINOMA; COPY NUMBER; SHORT ARM; GENES; DIFFERENTIATION; EXPRESSION; DELETIONS; HETEROZYGOSITY	Neuroblastoma (NB) is one of the most common forms of cancer in children, accounting for 15% of pediatric cancer deaths. The clinical course of these tumors is highly variable and is dependent on such factors as age at presentation, stage, ploidy and genomic abnormalities. Hemizygous deletion of chromosome 1p occurs in approximately 30% of advanced stage tumors, is associated with a poor prognosis, and likely leads to the loss of one or more tumor suppressor genes. We show here that microRNA (miRNA)-34a (1p36.23) is generally expressed at lower levels in unfavorable primary NB tumors and cell lines relative to normal adrenal tissue and that reintroduction of this miRNA into three different NB cell lines causes a dramatic reduction in cell proliferation through the induction of a caspase-dependent apoptotic pathway. As a potential mechanistic explanation for this observation, we demonstrate that miR-34a directly targets the messenger ribonucleic acid (mRNA) encoding E2F3 and signi. cantly reduces the levels of E2F3 protein, a potent transcriptional inducer of cell-cycle progression. Furthermore, miR-34a expression increases during retinoic acid-induced differentiation of the SK-N-BE cell line, whereas E2F3 protein levels decrease. Thus, addingto the increasing role of miRNAs in cancer, miR-34a may act as a suppressor of NB tumorgenesis.	Univ Texas, Hlth Sci Ctr, Childrens Canc Res Inst, San Antonio, TX 78284 USA; Univ Texas, Hlth Sci Ctr, Dept Pediat, San Antonio, TX USA	University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio	Stallings, RL (corresponding author), Univ Texas, Hlth Sci Ctr, Childrens Canc Res Inst, 8403 Floyd Curl Dr,MC 7784, San Antonio, TX 78284 USA.	STALLINGS@uthscsa.edu	Stallings, Raymond/A-7213-2008					Attiyeh EF, 2005, NEW ENGL J MED, V353, P2243, DOI 10.1056/NEJMoa052399; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; Brodeur GM, 2003, NAT REV CANCER, V3, P203, DOI 10.1038/nrc1014; Calin GA, 2002, P NATL ACAD SCI USA, V99, P15524, DOI 10.1073/pnas.242606799; Calin GA, 2005, NEW ENGL J MED, V353, P1793, DOI 10.1056/NEJMoa050995; Chan JA, 2005, CANCER RES, V65, P6029, DOI 10.1158/0008-5472.CAN-05-0137; Chen CF, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni178; Cimmino A, 2005, P NATL ACAD SCI USA, V102, P13944, DOI 10.1073/pnas.0506654102; Ejeskar K, 2005, BMC CANCER, V5, DOI 10.1186/1471-2407-5-161; Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840; FONG CT, 1989, P NATL ACAD SCI USA, V86, P3753, DOI 10.1073/pnas.86.10.3753; Guo YQ, 2006, GENE, V384, P51, DOI 10.1016/j.gene.2006.07.011; He L, 2005, NATURE, V435, P828, DOI 10.1038/nature03552; Janoueix-Lerosey I, 2004, ONCOGENE, V23, P5912, DOI 10.1038/sj.onc.1207784; Johnson DG, 2006, CURR MOL MED, V6, P731; Lin YW, 1999, EUR J CANCER, V35, P1730, DOI 10.1016/S0959-8049(99)00205-1; Miska EA, 2005, CURR OPIN GENET DEV, V15, P563, DOI 10.1016/j.gde.2005.08.005; Mosse YP, 2005, GENE CHROMOSOME CANC, V43, P390, DOI 10.1002/gcc.20198; O'Donnell KA, 2005, NATURE, V435, P839, DOI 10.1038/nature03677; SCHLEIERMACHER G, 1994, GENE CHROMOSOME CANC, V10, P275, DOI 10.1002/gcc.2870100409; Spitz R, 2003, CLIN CANCER RES, V9, P52; Stallings RL, 2006, CANCER RES, V66, P3673, DOI 10.1158/0008-5472.CAN-05-4154; THIELE CJ, 1985, NATURE, V313, P404, DOI 10.1038/313404a0; Valentijn LJ, 2005, CANCER RES, V65, P3136, DOI 10.1158/0008-5472.CAN-04-2469; Vandesompele J, 2005, J CLIN ONCOL, V23, P2280, DOI 10.1200/JCO.2005.06.104; VANROY N, 1994, GENE CHROMOSOME CANC, V10, P103, DOI 10.1002/gcc.2870100205; Wang Q, 2006, CANCER RES, V66, P6050, DOI 10.1158/0008-5472.CAN-05-4618	27	639	695	0	50	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2007	26	34					5017	5022		10.1038/sj.onc.1210293	http://dx.doi.org/10.1038/sj.onc.1210293			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	194CV	17297439				2022-12-28	WOS:000248322500014
J	Berenjeno, IM; Nunez, F; Bustelo, XR				Berenjeno, I. M.; Nunez, F.; Bustelo, X. R.			Transcriptomal profiling of the cellular transformation induced by Rho subfamily GTPases	ONCOGENE			English	Article						Rho/Rac GTPases; microarray; proliferation; gene expression; transcription; rock; c-Myc	FACTOR-KAPPA-B; C-MYC; ACTIVATION; EXPRESSION; PROTEINS; KINASES; BIOLOGY; PHOSPHORYLATION; METASTASIS; GADD153	We have used microarray technology to identify the transcriptional targets of Rho subfamily guanosine 5'-triphosphate (GTP)ases in NIH3T3 cells. This analysis indicated that murine fibroblasts transformed by these proteins show similar transcriptomal profiles. Functional annotation of the regulated genes indicate that Rho subfamily GTPases target a wide spectrum of functions, although loci encoding proteins linked to proliferation and DNA synthesis/transcription are upregulated preferentially. Rho proteins promote four main networks of interacting proteins nucleated around E2F, c-Jun, c-Myc and p53. Of those, E2F, c-Jun and c-Myc are essential for the maintenance of cell transformation. Inhibition of Rock, one of the main Rho GTPase targets, leads to small changes in the transcriptome of Rho-transformed cells. Rock inhibition decreases c-myc gene expression without affecting the E2F and c-Jun pathways. Loss-of-function studies demonstrate that c-Myc is important for the blockage of cell-contact inhibition rather than for promoting the proliferation of Rho-transformed cells. However, c-Myc overexpression does not bypass the inhibition of cell transformation induced by Rock blockage, indicating that c-Myc is essential, but not sufficient, for Rock-dependent transformation. These results reveal the complexity of the genetic program orchestrated by the Rho subfamily and pinpoint protein networks that mediate different aspects of the malignant phenotype of Rho-transformed cells.	Univ Salamanca, CSIC, Ctr Invest Canc, E-37007 Salamanca, Spain; Univ Salamanca, CSIC, IBMCC, E-37007 Salamanca, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigacion del Cancer (CIC); CSIC-USAL - Instituto de Biologia Molecular y Celular del Cancer de Salamanca (IBMCC); University of Salamanca; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-USAL - Instituto de Biologia Molecular y Celular del Cancer de Salamanca (IBMCC); University of Salamanca	Bustelo, XR (corresponding author), Univ Salamanca, CSIC, Ctr Invest Canc, Campus Unamuno, E-37007 Salamanca, Spain.	xbustelo@usal.es	Bustelo, Xose R./A-9526-2010; Bustelo, Xose R./AAD-2081-2022	Bustelo, Xose R./0000-0001-9398-6072; Bustelo, Xose R./0000-0001-9398-6072	NCI NIH HHS [R01 CA073735, 5R01-CA73735-10] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA073735] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Barsyte-Lovejoy D, 2004, ONCOGENE, V23, P3481, DOI 10.1038/sj.onc.1207487; Bolstad BM, 2004, INT REV NEUROBIOL, V60, P25; Budzyn K, 2006, TRENDS PHARMACOL SCI, V27, P97, DOI 10.1016/j.tips.2005.12.002; Calvano SE, 2005, NATURE, V437, P1032, DOI 10.1038/nature03985; Chen CH, 1996, ONCOGENE, V13, P1659; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Gautier L, 2004, BIOINFORMATICS, V20, P307, DOI 10.1093/bioinformatics/btg405; Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80; Hakem A, 2005, GENE DEV, V19, P1974, DOI 10.1101/gad.1310805; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Jaffe AB, 2005, ANNU REV CELL DEV BI, V21, P247, DOI 10.1146/annurev.cellbio.21.020604.150721; Leng XH, 1997, CURR BIOL, V7, P709, DOI 10.1016/S0960-9822(06)00301-0; Liu AX, 2001, MOL CELL BIOL, V21, P6906, DOI 10.1128/MCB.21.20.6906-6912.2001; Marinissen MJ, 2004, MOL CELL, V14, P29, DOI 10.1016/S1097-2765(04)00153-4; Montaner S, 1998, J BIOL CHEM, V273, P12779, DOI 10.1074/jbc.273.21.12779; Montaner S, 1999, J BIOL CHEM, V274, P8506, DOI 10.1074/jbc.274.13.8506; Parrish Rudolph S, 2004, J Biopharm Stat, V14, P575, DOI 10.1081/BIP-200025650; Perona R, 1997, GENE DEV, V11, P463, DOI 10.1101/gad.11.4.463; Riento K, 2003, NAT REV MOL CELL BIO, V4, P446, DOI 10.1038/nrm1128; Sahai E, 1999, CURR BIOL, V9, P136, DOI 10.1016/S0960-9822(99)80067-0; Schuebel KE, 1998, EMBO J, V17, P6608, DOI 10.1093/emboj/17.22.6608; Simpson KJ, 2004, CANCER RES, V64, P8694, DOI 10.1158/0008-5472.CAN-04-2247; Teramoto H, 2003, ONCOGENE, V22, P2689, DOI 10.1038/sj.onc.1206364; Uehata M, 1997, NATURE, V389, P990, DOI 10.1038/40187; van der Eb A J, 1980, Methods Enzymol, V65, P826; Watnick RS, 2003, CANCER CELL, V3, P219, DOI 10.1016/S1535-6108(03)00030-8; Wheeler AP, 2004, EXP CELL RES, V301, P43, DOI 10.1016/j.yexcr.2004.08.012; Wu M, 2004, BREAST CANCER RES TR, V84, P3, DOI 10.1023/B:BREA.0000018426.76893.21	28	32	32	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 21	2007	26	29					4295	4305		10.1038/sj.onc.1210194	http://dx.doi.org/10.1038/sj.onc.1210194			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	184CY	17213802	Green Accepted, Green Submitted			2022-12-28	WOS:000247619900012
J	Borges, HL; Hunton, IC; Wang, JYJ				Borges, H. L.; Hunton, I. C.; Wang, J. Y. J.			Reduction of apoptosis in Rb-deficient embryos via Abl knockout	ONCOGENE			English	Article						central nervous system; fetal live; haploid insufficiency; knockout mice; tumor suppressor	RETINOBLASTOMA TUMOR-SUPPRESSOR; KINASE C-ABL; TYROSINE KINASE; NERVOUS-SYSTEM; DNA-DAMAGE; NUCLEAR ENTRAPMENT; MICE DEFICIENT; MOUSE EMBRYOS; CELL-DEATH; PROTEIN	The retinoblastoma protein RB regulates cell proliferation, differentiation and apoptosis. Homozygous knockout of Rb in mice causes embryonic lethality owing to placental defects that result in excessive apoptosis. RB binds to a number of cellular proteins including the nuclear Abl protein and inhibits its tyrosine kinase activity. Ex vivo experiments have shown that genotoxic or inflammatory stress can activate Abl kinase to stimulate apoptosis. Employing the Rb-null embryos as an in vivo model of apoptosis, we have shown that the genetic ablation of Abl can reduce apoptosis in the developing central nervous system and the embryonic liver. These results are consistent with the inhibitory interaction between RB and Abl, and provide in vivo evidence for the proapoptotic function of Abl.	Univ Calif San Diego, Sch Med, Moores Canc Ctr, Div Hematol Oncol,Dept Med, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Wang, JYJ (corresponding author), Univ Calif San Diego, Sch Med, Moores Canc Ctr, Div Hematol Oncol,Dept Med, 4328,3855 Hlth Sci Dr, La Jolla, CA 92093 USA.	jywang@ucsd.edu	Borges, Helena/W-7533-2019; Borges, Helena/AAG-3701-2020; Borges, Helena L/E-5044-2013	Borges, Helena/0000-0003-2866-4223; Borges, Helena L/0000-0003-2866-4223	NATIONAL CANCER INSTITUTE [R37CA043054, R01CA058320, R01CA043054] Funding Source: NIH RePORTER; NCI NIH HHS [R37 CA043054, R01 CA043054, R01 CA058320, CA58320] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams PD, 1999, MOL CELL BIOL, V19, P1068; Agami R, 1999, NATURE, V399, P809; Aloisi A, 2006, BLOOD, V107, P1591, DOI 10.1182/blood-2005-05-2123; Alvarez AR, 2004, NEUROBIOL DIS, V17, P326, DOI 10.1016/j.nbd.2004.06.007; Borges HL, 2004, CELL DEATH DIFFER, V11, P494, DOI 10.1038/sj.cdd.4401366; Chau BN, 2004, MOL CELL BIOL, V24, P4438, DOI 10.1128/MCB.24.10.4438-4447.2004; Chau BN, 2003, NAT REV CANCER, V3, P130, DOI 10.1038/nrc993; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; Darnell GA, 2003, MOL CELL BIOL, V23, P6520, DOI 10.1128/MCB.23.18.6520-6532.2003; de Bruin A, 2003, P NATL ACAD SCI USA, V100, P6546, DOI 10.1073/pnas.1031853100; GOGA A, 1995, ONCOGENE, V11, P791; Goldberg Z, 2002, EMBO J, V21, P3715, DOI 10.1093/emboj/cdf384; Gong JG, 1999, NATURE, V399, P806; Guo Z, 2001, CANCER RES, V61, P8395; Hickman ES, 2002, CURR OPIN GENET DEV, V12, P60, DOI 10.1016/S0959-437X(01)00265-9; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; Kaufman M.H., 1992, ATLAS MOUSE DEV; Lasorella A, 2000, NATURE, V407, P592, DOI 10.1038/35036504; Lee C, 2002, GENE DEV, V16, P3199, DOI 10.1101/gad.1046102; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; Lee JO, 1998, NATURE, V391, P859, DOI 10.1038/36038; Levinson NM, 2006, PLOS BIOL, V4, P753, DOI 10.1371/journal.pbio.0040144; Li BJ, 2000, NAT GENET, V24, P304, DOI 10.1038/73542; Liu HP, 2004, CURR OPIN GENET DEV, V14, P55, DOI 10.1016/j.gde.2003.11.005; Liu X, 2006, J BIOL CHEM, V281, P578, DOI 10.1074/jbc.M508455200; Macleod KF, 1996, EMBO J, V15, P6178, DOI 10.1002/j.1460-2075.1996.tb01006.x; MacPherson D, 2003, MOL CELL BIOL, V23, P1044, DOI 10.1128/MCB.23.3.1044-1053.2003; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; Morris EJ, 2001, ADV CANCER RES, V82, P1, DOI 10.1016/S0065-230X(01)82001-7; Nguyen DX, 2005, J CELL BIOCHEM, V94, P870, DOI 10.1002/jcb.20375; Rubin SM, 2005, CELL, V123, P1093, DOI 10.1016/j.cell.2005.09.044; Sherr CJ, 2002, CANCER CELL, V2, P103, DOI 10.1016/S1535-6108(02)00102-2; Simpson MTW, 2001, J NEUROSCI, V21, P7089, DOI 10.1523/JNEUROSCI.21-18-07089.2001; Sionov RV, 1999, J BIOL CHEM, V274, P8371, DOI 10.1074/jbc.274.13.8371; Takao N, 2000, J BIOL CHEM, V275, P725, DOI 10.1074/jbc.275.2.725; Tsai KY, 2002, CURR BIOL, V12, P159, DOI 10.1016/S0960-9822(01)00659-5; Tsai KY, 1998, MOL CELL, V2, P293, DOI 10.1016/S1097-2765(00)80274-9; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; Vella V, 2003, J BIOL CHEM, V278, P25151, DOI 10.1074/jbc.M301962200; Vigneri P, 2001, NAT MED, V7, P228, DOI 10.1038/84683; Wang JYJ, 2000, ONCOGENE, V19, P5643, DOI 10.1038/sj.onc.1203878; WELCH PJ, 1995, MOL CELL BIOL, V15, P5542; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E; Woodring PJ, 2003, J CELL SCI, V116, P2613, DOI 10.1242/jcs.00622; Wu LZ, 2003, NATURE, V421, P942, DOI 10.1038/nature01417; Xiao B, 2003, P NATL ACAD SCI USA, V100, P2363, DOI 10.1073/pnas.0436813100; Yuan ZM, 1997, P NATL ACAD SCI USA, V94, P1437, DOI 10.1073/pnas.94.4.1437; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704; Zacksenhaus E, 1996, GENE DEV, V10, P3051, DOI 10.1101/gad.10.23.3051; Ziebold U, 2001, GENE DEV, V15, P386, DOI 10.1101/gad.858801	50	8	9	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 31	2007	26	26					3868	3877		10.1038/sj.onc.1210157	http://dx.doi.org/10.1038/sj.onc.1210157			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	175PV	17173068				2022-12-28	WOS:000247026400010
J	Strano, S; Dell'Orso, S; Di Agostino, S; Fontemaggi, G; Sacchi, A; Blandino, G				Strano, S.; Dell'Orso, S.; Di Agostino, S.; Fontemaggi, G.; Sacchi, A.; Blandino, G.			Mutant p53: an oncogenic transcription factor	ONCOGENE			English	Review						mutant p53; transcription; interaction; signature chip	GAIN-OF-FUNCTION; ADVANCED BREAST-CANCER; LI-FRAUMENI-SYNDROME; WILD-TYPE P53; TUMOR-SUPPRESSOR; GENE-EXPRESSION; SV40-TRANSFORMED CELLS; FUNCTIONAL-ANALYSIS; TERMINAL DOMAIN; TARGET GENES	Inactivation of tumor-suppressor genes is one of the key hallmarks of a tumor. Unlike other tumor-suppressor genes, p53 is inactivated by missense mutations in half of all human cancers. It has become increasingly clear that the resulting mutant p53 proteins do not represent only the mere loss of wild-type p53 tumor suppressor activity, but gain new oncogenic properties favoring the insurgence, the maintenance, the spreading and the chemoresistance of malignant tumors. The actual challenge is the. ne deciphering of the molecular mechanisms underlying the gain of function of mutant p53 proteins. In this review, we will focus mainly on the transcriptional activity of mutant p53 proteins as one of the potential molecular mechanisms. To date, the related knowledge is still quite scarce and many of the raised questions of this review are yet unanswered.	Regina Elena Inst Canc Res, Dept Expt Oncol, I-00158 Rome, Italy; Regina Elena Inst Canc Res, Rome Oncogenom Ctr, Rome, Italy	IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena	Blandino, G (corresponding author), Regina Elena Inst Canc Res, Dept Expt Oncol, Via Messi Oro 156, I-00158 Rome, Italy.	blandino@ifo.it	Blandino, Giovanni/B-1137-2013; Di Agostino, Silvia/S-8566-2019; Di Agostino, Silvia/H-1121-2018; Fontemaggi, Giulia/K-9702-2016; strano, sabrina/B-6743-2013; Strano, Sabrina/K-9654-2016	Blandino, Giovanni/0000-0002-6970-2241; Di Agostino, Silvia/0000-0003-3730-1125; Fontemaggi, Giulia/0000-0001-8332-8842; strano, sabrina/0000-0002-6341-4230; Dell'Orso, Stefania/0000-0002-1634-5631				Aas T, 1996, NAT MED, V2, P811, DOI 10.1038/nm0796-811; Augustin M, 1998, MAMM GENOME, V9, P899, DOI 10.1007/s003359900891; Balint E, 2002, P NATL ACAD SCI USA, V99, P3529, DOI 10.1073/pnas.062491899; Berns EMJJ, 2000, CANCER RES, V60, P2155; BIENZ B, 1984, EMBO J, V3, P2179, DOI 10.1002/j.1460-2075.1984.tb02110.x; Blandino G, 1999, ONCOGENE, V18, P477, DOI 10.1038/sj.onc.1202314; Bode AM, 2004, NAT REV CANCER, V4, P793, DOI 10.1038/nrc1455; Brooks CL, 2003, CURR OPIN CELL BIOL, V15, P164, DOI 10.1016/S0955-0674(03)00003-6; Buck MJ, 2004, GENOMICS, V83, P349, DOI 10.1016/j.ygeno.2003.11.004; Bullock AN, 2001, NAT REV CANCER, V1, P68, DOI 10.1038/35094077; Buschmann T, 2000, J MOL BIOL, V295, P1009, DOI 10.1006/jmbi.1999.3387; Cadwell C, 2001, GENE, V277, P15, DOI 10.1016/S0378-1119(01)00696-5; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; Costanzo A, 2002, MOL CELL, V9, P175, DOI 10.1016/S1097-2765(02)00431-8; DEB S, 1992, J VIROL, V66, P6164, DOI 10.1128/JVI.66.10.6164-6170.1992; Di Agostino S, 2006, CANCER CELL, V10, P191, DOI 10.1016/j.ccr.2006.08.013; Di Como CJ, 1999, MOL CELL BIOL, V19, P1438; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; Donehower LA, 1996, SEMIN CANCER BIOL, V7, P269, DOI 10.1006/scbi.1996.0035; Fontemaggi G, 2002, J BIOL CHEM, V277, P43359, DOI 10.1074/jbc.M205573200; Frazier MW, 1998, MOL CELL BIOL, V18, P3735, DOI 10.1128/MCB.18.7.3735; Gaiddon C, 2001, MOL CELL BIOL, V21, P1874, DOI 10.1128/MCB.21.5.1874-1887.2001; Geisler S, 2003, CLIN CANCER RES, V9, P5582; Gohler T, 2005, NUCLEIC ACIDS RES, V33, P1087, DOI 10.1093/nar/gki252; Gualberto A, 1998, P NATL ACAD SCI USA, V95, P5166, DOI 10.1073/pnas.95.9.5166; HALEVY O, 1990, SCIENCE, V250, P113, DOI 10.1126/science.2218501; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hoh J, 2002, P NATL ACAD SCI USA, V99, P8467, DOI 10.1073/pnas.132268899; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Hussain SP, 1998, CANCER RES, V58, P4023; Irwin MS, 2003, CANCER CELL, V3, P403, DOI 10.1016/S1535-6108(03)00078-3; Iwanaga Y, 2002, CANCER RES, V62, P2618; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Jayaraman L, 1999, CELL MOL LIFE SCI, V55, P76, DOI 10.1007/s000180050271; JOERGER AC, 2005, WILD TYPE P53 CONFOR, P377; Kaelin WG, 1999, J NATL CANCER I, V91, P594, DOI 10.1093/jnci/91.7.594; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Kim E, 2006, CELL DEATH DIFFER, V13, P885, DOI 10.1038/sj.cdd.4401909; Koga H, 2000, ONCOGENE, V19, P4178, DOI 10.1038/sj.onc.1203745; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; LAIN S, 2005, NOVEL P53 BASED THER, P353; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; Lang GA, 2004, CELL, V119, P861, DOI 10.1016/j.cell.2004.11.006; Lapi E, 2006, ONCOGENE, V25, P3628, DOI 10.1038/sj.onc.1209401; Lee YI, 2000, ONCOGENE, V19, P3717, DOI 10.1038/sj.onc.1203694; Levrero M, 2000, J CELL SCI, V113, P1661; Li RZ, 1998, ONCOGENE, V16, P3269, DOI 10.1038/sj.onc.1201867; LIN JY, 1995, ONCOGENE, V10, P2387; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; Lowe SW, 2004, NATURE, V432, P307, DOI 10.1038/nature03098; LudesMeyers JH, 1996, MOL CELL BIOL, V16, P6009; MARGULIES L, 1993, J BIOL CHEM, V268, P15096; Marin MC, 2000, NAT GENET, V25, P47, DOI 10.1038/75586; MCKINNEY C, 2005, REGULATION P53 DNA B, P27; Midgley CA, 1997, ONCOGENE, V15, P1179, DOI 10.1038/sj.onc.1201459; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; Mizuarai S, 2006, CANCER RES, V66, P6319, DOI 10.1158/0008-5472.CAN-05-4629; Moll UM, 2003, MOL CANCER RES, V1, P1001; MOLL UM, 1992, P NATL ACAD SCI USA, V89, P7262, DOI 10.1073/pnas.89.15.7262; MONTI O, 2005, P73 P63 MUTANT P53 M, P223; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; O'Farrell TJ, 2004, CANCER RES, V64, P8199, DOI 10.1158/0008-5472.CAN-03-3639; Olive KP, 2004, CELL, V119, P847, DOI 10.1016/j.cell.2004.11.004; Olivier M, 2002, HUM MUTAT, V19, P607, DOI 10.1002/humu.10081; OREN M, 1983, P NATL ACAD SCI-BIOL, V80, P56, DOI 10.1073/pnas.80.1.56; Osada M, 1998, NAT MED, V4, P839, DOI 10.1038/nm0798-839; Prives C, 1999, J PATHOL, V187, P112; PURDIE CA, 1994, ONCOGENE, V9, P603; Schmale H, 1997, ONCOGENE, V15, P1363, DOI 10.1038/sj.onc.1201500; Scian MJ, 2005, MOL CELL BIOL, V25, P10097, DOI 10.1128/MCB.25.22.10097-10110.2005; Scian MJ, 2004, CANCER RES, V64, P7447, DOI 10.1158/0008-5472.CAN-04-1568; Senoo M, 1998, BIOCHEM BIOPH RES CO, V248, P603, DOI 10.1006/bbrc.1998.9013; Sigal A, 2000, CANCER RES, V60, P6788; Soussi T, 2000, CANCER RES, V60, P1777; SOUSSI T, 2005, ANAL P53 GENE ALTERA, P255; Stiewe T, 2003, J BIOL CHEM, V278, P14230, DOI 10.1074/jbc.M300357200; Strano S, 2005, MOL CELL, V19, P429, DOI 10.1016/j.molcel.2005.07.010; Strano S, 2002, J BIOL CHEM, V277, P18817, DOI 10.1074/jbc.M201405200; Strano S, 2000, J BIOL CHEM, V275, P29503, DOI 10.1074/jbc.M003360200; Strano S, 2003, CELL CYCLE, V2, P348, DOI 10.4161/cc.2.4.426; SUBLER MA, 1994, J VIROL, V68, P103, DOI 10.1128/JVI.68.1.103-110.1994; Sunahara M, 1998, INT J ONCOL, V13, P319; Takahashi H, 1998, CANCER RES, V58, P2076; Tepper CG, 2005, PROSTATE, V65, P375, DOI 10.1002/pros.20308; Trink B, 1998, NAT MED, V4, P747, DOI 10.1038/nm0798-747; TSUTSUMIISHII Y, 1995, CELL GROWTH DIFFER, V6, P1; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Waltermann A, 2003, ONCOGENE, V22, P5686, DOI 10.1038/sj.onc.1206859; WEISZ L, 2004, CANCER RES, V64, P7447; Will K, 1998, P NATL ACAD SCI USA, V95, P13681, DOI 10.1073/pnas.95.23.13681; Wu JJ, 2006, CANCER RES, V66, P6899, DOI 10.1158/0008-5472.CAN-06-0276; Xu Y, 2003, CELL DEATH DIFFER, V10, P1213, DOI 10.1038/sj.cdd.4401292; Yang A, 2000, NAT REV MOL CELL BIO, V1, P199, DOI 10.1038/35043127; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607; Zalcenstein A, 2006, ONCOGENE, V25, P359, DOI 10.1038/sj.onc.1209061	96	193	204	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 2	2007	26	15					2212	2219		10.1038/sj.onc.1210296	http://dx.doi.org/10.1038/sj.onc.1210296			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	152XE	17401430				2022-12-28	WOS:000245394800010
J	Marks, PA				Marks, P. A.			Discovery and development of SAHA as an anticancer agent	ONCOGENE			English	Review						deacetylases; histones; histone deacetylase inhibitors; apoptosis	HISTONE DEACETYLASE INHIBITORS; SUBEROYLANILIDE HYDROXAMIC ACID; HUMAN PROSTATE-CANCER; TRANSFORMED-CELL DIFFERENTIATION; GENE-EXPRESSION; (ARYLOXOPROPENYL)PYRROLYL HYDROXYAMIDES; ERYTHROID DIFFERENTIATION; ERYTHROLEUKEMIA CELLS; SELECTIVE INHIBITORS; POTENT INDUCERS	The path to the discovery of suberoylanilide hydroxamic acid (SAHA, vorinostat) began over three decades ago with our studies designed to understand why dimethylsulfoxide causes terminal differentiation of the virus-transformed cells, murine erythroleukemia cells. SAHA can cause growth arrest and death of a broad variety of transformed cells both in vitro and in vivo at concentrations that have little or no toxic effects on normal cells. It was discovered that SAHA inhibits the activity of histone deacetylases (HDACs), including all 11 known human class I and class II HDACs. HDACs have many protein targets whose structure and function are altered by acetylation including histones and non-histone proteins component of transcription factors controlling gene expression and proteins that regulate cell proliferation, migration and death. SAHA is in clinical trials and has significant anticancer activity against both hematologic and solid tumors at doses well tolerated by patients. A new drug application has been approved for SAHA ( vorinostat) treatment of cutaneous T-cell lymphoma.	Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center	Marks, PA (corresponding author), Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.	marksp@MSKCC.ORG						ANDREEFF M, 1992, BLOOD, V80, P2604; Arner ESJ, 2000, EUR J BIOCHEM, V267, P6102, DOI 10.1046/j.1432-1327.2000.01701.x; Bhalla KN, 2005, J CLIN ONCOL, V23, P3971, DOI 10.1200/JCO.2005.16.600; BRESLOW R, 1991, P NATL ACAD SCI USA, V88, P5542, DOI 10.1073/pnas.88.13.5542; Butler LM, 2002, P NATL ACAD SCI USA, V99, P11700, DOI 10.1073/pnas.182372299; Butler LM, 2000, CANCER RES, V60, P5165; Dokmanovic M, 2005, J CELL BIOCHEM, V96, P293, DOI 10.1002/jcb.20532; Finnin MS, 1999, NATURE, V401, P188, DOI 10.1038/43710; FRIEND C, 1971, P NATL ACAD SCI USA, V68, P378; Fuino L, 2003, MOL CANCER THER, V2, P971; Gui CY, 2004, P NATL ACAD SCI USA, V101, P1241, DOI 10.1073/pnas.0307708100; Haggerty TJ, 2003, P NATL ACAD SCI USA, V100, P5313, DOI 10.1073/pnas.0931346100; Hail N, 2005, APOPTOSIS, V10, P687, DOI 10.1007/s10495-005-0792-8; Hu ED, 2003, J PHARMACOL EXP THER, V307, P720, DOI 10.1124/jpet.103.055541; Insinga A, 2005, NAT MED, V11, P71, DOI 10.1038/nm1160; Johnstone RW, 2003, CANCER CELL, V4, P13, DOI 10.1016/S1535-6108(03)00165-X; Kelly WK, 2005, NAT CLIN PRACT ONCOL, V2, P150, DOI 10.1038/ncponc0106; Kelly WK, 2005, J CLIN ONCOL, V23, P3923, DOI 10.1200/JCO.2005.14.167; Kelly WK, 2003, CLIN CANCER RES, V9, P3578; Lehrmann H, 2002, ADV CANCER RES, V86, P41, DOI 10.1016/S0065-230X(02)86002-X; Li LC, 2005, JNCI-J NATL CANCER I, V97, P103, DOI 10.1093/jnci/dji010; Li X, 2005, MOL CANCER, V4, DOI 10.1186/1476-4598-4-30; Mai A, 2005, J MED CHEM, V48, P3344, DOI 10.1021/jm049002a; Mai A, 2003, J MED CHEM, V46, P4826, DOI 10.1021/jm034167p; MARKS PA, 1978, ANNU REV BIOCHEM, V47, P419, DOI 10.1146/annurev.bi.47.070178.002223; MARKS PA, 1987, CANCER RES, V47, P659; McEleny KR, 2002, PROSTATE, V51, P133, DOI 10.1002/pros.10061; Miller TA, 2003, J MED CHEM, V46, P5097, DOI 10.1021/jm0303094; Minucci S, 2006, NAT REV CANCER, V6, P38, DOI 10.1038/nrc1779; OLSEN EO, 2006, P AM SOC CLIN ONCOLO, V24; Peart MJ, 2005, P NATL ACAD SCI USA, V102, P3697, DOI 10.1073/pnas.0500369102; Peart MJ, 2003, CANCER RES, V63, P4460; Powis G, 2000, FREE RADICAL BIO MED, V29, P312, DOI 10.1016/S0891-5849(00)00313-0; REUBEN RC, 1976, P NATL ACAD SCI USA, V73, P862, DOI 10.1073/pnas.73.3.862; RICHON VM, 1989, ONCOGENE, V4, P165; Richon VM, 2000, P NATL ACAD SCI USA, V97, P10014, DOI 10.1073/pnas.180316197; Richon VM, 1996, P NATL ACAD SCI USA, V93, P5705, DOI 10.1073/pnas.93.12.5705; Richon VM, 1998, P NATL ACAD SCI USA, V95, P3003, DOI 10.1073/pnas.95.6.3003; Rosato RR, 2003, MOL CANCER THER, V2, P1273; Rosato RR, 2003, CANCER RES, V63, P3637; Scott GK, 2006, CANCER RES, V66, P1277, DOI 10.1158/0008-5472.CAN-05-3632; Shao YF, 2004, P NATL ACAD SCI USA, V101, P18030, DOI 10.1073/pnas.0408345102; Smirnov DA, 2005, CANCER RES, V65, P4993, DOI 10.1158/0008-5472.CAN-04-4330; TANAKA M, 1975, P NATL ACAD SCI USA, V72, P1003, DOI 10.1073/pnas.72.3.1003; Ungerstedt JS, 2005, P NATL ACAD SCI USA, V102, P673, DOI 10.1073/pnas.0408732102; Waghray A, 2001, CANCER RES, V61, P4283; Xu WS, 2006, P NATL ACAD SCI USA, V103, P15540, DOI 10.1073/pnas.0607518103; Yamanaka K, 2005, MOL CANCER THER, V4, P1689, DOI 10.1158/1535-7163.MCT-05-0064; Yoo CB, 2006, NAT REV DRUG DISCOV, V5, P37, DOI 10.1038/nrd1930; YOSHIDA M, 1990, J BIOL CHEM, V265, P17174	50	501	528	1	56	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 26	2007	26	9					1351	1356		10.1038/sj.onc.1210204	http://dx.doi.org/10.1038/sj.onc.1210204			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	141DU	17322921				2022-12-28	WOS:000244558700013
J	Desnoyers, L; Pai, R; Ferrando, R; Hotzel, K; Le, T; Ross, J; Carano, R; D'Souza, A; Qing, J; Mohtashemi, I; Ashkenazi, A; French, D				Desnoyers, Lr; Pai, R.; Ferrando, Re; Hotzel, K.; Le, T.; Ross, J.; Carano, R.; D'Souza, A.; Qing, J.; Mohtashemi, I.; Ashkenazi, A.; French, Dm			Targeting FGF19 inhibits tumor growth in colon cancer xenograft and FGF19 transgenic hepatocellular carcinoma models	ONCOGENE			English	Article						fibroblast growth factor; hepatocellular carcinoma; FGF19; colon adenocarcinoma; FGFR4; beta-catenin	FACTOR RECEPTOR-3; HUMAN BREAST; ACTIVATING MUTATIONS; INCREASED EXPRESSION; MULTIPLE-MYELOMA; PROSTATE-CANCER; FIBROBLAST; FGFR4; GENE; TRANSLOCATION	Although fibroblast growth factor 19 (FGF19) can promote liver carcinogenesis in mice its involvement in human cancer is not well characterized. Here we report that FGF19 and its cognate receptor FGF receptor 4 (FGFR4) are coexpressed in primary human liver, lung and colon tumors and in a subset of human colon cancer cell lines. To test the importance of FGF19 for tumor growth, we developed an anti-FGF19 monoclonal antibody that selectively blocks the interaction of FGF19 with FGFR4. This antibody abolished FGF19-mediated activity in vitro and inhibited growth of colon tumor xenografts in vivo and effectively prevented hepatocellular carcinomas in FGF19 transgenic mice. The efficacy of the antibody in these models was linked to inhibition of FGF19-dependent activation of FGFR4, FRS2, ERK and beta-catenin. These findings suggest that the inactivation of FGF19 could be beneficial for the treatment of colon cancer, liver cancer and other malignancies involving interaction of FGF19 and FGFR4.	[Desnoyers, Lr; D'Souza, A.; Qing, J.; Ashkenazi, A.] Genentech Inc, Dept Mol Oncol, San Francisco, CA 94080 USA; [Pai, R.; Ferrando, Re; Hotzel, K.; French, Dm] Genentech Inc, Dept Pathol, San Francisco, CA 94080 USA; [Le, T.; Ross, J.; Carano, R.] Genentech Inc, Dept Biomed Imaging, San Francisco, CA 94080 USA; [Mohtashemi, I.] Genentech Inc, Dept Protein Chem, San Francisco, CA 94080 USA	Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech	French, D (corresponding author), Genentech Inc, Dept Mol Oncol, MS 72B,1 DNA Way, San Francisco, CA 94080 USA.	dfrench@gene.com	Ashkenazi, Avi/ABG-2712-2020	Ashkenazi, Avi/0000-0002-6890-4589				ANTHONY PP, 1979, J TOXICOL ENV HEALTH, V5, P301, DOI 10.1080/15287397909529751; Bange J, 2002, CANCER RES, V62, P840; Cappellen D, 1999, NAT GENET, V23, P18, DOI 10.1038/12615; Chesi M, 1997, NAT GENET, V16, P260, DOI 10.1038/ng0797-260; Chesi M, 2001, BLOOD, V97, P729, DOI 10.1182/blood.V97.3.729; Dorkin TJ, 1999, ONCOGENE, V18, P2755, DOI 10.1038/sj.onc.1202624; ERIKSSON A, 1992, EMBO J, V11, P543, DOI 10.1002/j.1460-2075.1992.tb05085.x; Eswarakumar VP, 2005, CYTOKINE GROWTH F R, V16, P139, DOI 10.1016/j.cytogfr.2005.01.001; Gowardhan B, 2005, BRIT J CANCER, V92, P320, DOI 10.1038/sj.bjc.6602274; Harmer NJ, 2004, BIOCHEMISTRY-US, V43, P629, DOI 10.1021/bi035320k; Holt JA, 2003, GENE DEV, V17, P1581, DOI 10.1101/gad.1083503; Holzmann K, 2004, CANCER RES, V64, P4428, DOI 10.1158/0008-5472.CAN-04-0431; Huang Yao Qi, 1993, Anticancer Research, V13, P887; JAAKKOLA S, 1993, INT J CANCER, V54, P378, DOI 10.1002/ijc.2910540305; Jang JH, 2000, CANCER RES, V60, P4049; Jang JH, 2001, CANCER RES, V61, P3541; Jeffers Michael, 2002, Expert Opin Ther Targets, V6, P469, DOI 10.1517/14728222.6.4.469; Jubb Adrian M, 2006, Methods Mol Biol, V326, P255; Kiuru-Kuhlefelt S, 2000, MODERN PATHOL, V13, P433, DOI 10.1038/modpathol.3880074; Kobayashi M, 2006, CANCER-AM CANCER SOC, V106, P636, DOI 10.1002/cncr.21607; Krejci P, 2001, LEUKEMIA, V15, P228, DOI 10.1038/sj.leu.2402012; Lee FT, 1997, RADIOLOGY, V203, P465, DOI 10.1148/radiology.203.2.9114106; LISCIA DS, 1989, ONCOGENE, V4, P1219; Marsh SK, 1999, ONCOGENE, V18, P1053, DOI 10.1038/sj.onc.1202392; Mattila MMT, 2001, ONCOGENE, V20, P2791, DOI 10.1038/sj.onc.1204430; MAUAD TH, 1994, AM J PATHOL, V145, P1237; Morimoto Y, 2003, CANCER, V98, P2245, DOI 10.1002/cncr.11778; Nicholes K, 2002, AM J PATHOL, V160, P2295, DOI 10.1016/S0002-9440(10)61177-7; Ornitz DM, 2001, GENOME BIOL, V2; Ornitz DM, 1996, J BIOL CHEM, V271, P15292, DOI 10.1074/jbc.271.25.15292; Popovici C, 1999, BLOOD, V93, P1381, DOI 10.1182/blood.V93.4.1381.404k30_1381_1389; Powers CJ, 2000, ENDOCR-RELAT CANCER, V7, P165, DOI 10.1677/erc.0.0070165; Qian ZR, 2004, J CLIN ENDOCR METAB, V89, P1904, DOI 10.1210/jc.2003-031489; Richelda R, 1997, BLOOD, V90, P4062, DOI 10.1182/blood.V90.10.4062; Ruohola JK, 2001, CANCER RES, V61, P4229; Schlessinger J, 2004, SCIENCE, V306, P1506, DOI 10.1126/science.1105396; Shima K, 2003, IEEE T ENERGY CONVER, V18, P63, DOI 10.1109/TEC.2002.808337; Sleeman M, 2001, GENE, V271, P171, DOI 10.1016/S0378-1119(01)00518-2; Spinola M, 2005, J CLIN ONCOL, V23, P7307, DOI 10.1200/JCO.2005.17.350; Streit S, 2004, INT J CANCER, V111, P213, DOI 10.1002/ijc.20204; Wang JH, 2004, CLIN CANCER RES, V10, P6169, DOI 10.1158/1078-0432.CCR-04-0408; Xiao S, 1998, NAT GENET, V18, P84, DOI 10.1038/ng0198-84; Xie MH, 1999, CYTOKINE, V11, P729, DOI 10.1006/cyto.1999.0485; Yamada SM, 2002, NEUROL RES, V24, P244, DOI 10.1179/016164102101199864; Yu CD, 2005, J BIOL CHEM, V280, P17707, DOI 10.1074/jbc.M411771200; Zaharieva BM, 2003, J PATHOL, V201, P603, DOI 10.1002/path.1481	46	202	238	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 3	2008	27	1					85	97		10.1038/sj.onc.1210623	http://dx.doi.org/10.1038/sj.onc.1210623			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	247YO	17599042				2022-12-28	WOS:000252118700009
J	Scotlandi, K; Zuntini, M; Manara, MC; Sciandra, M; Rocchi, A; Benini, S; Nicoletti, G; Bernard, G; Nanni, P; Lollini, PL; Bernard, A; Picci, P				Scotlandi, K.; Zuntini, M.; Manara, M. C.; Sciandra, M.; Rocchi, A.; Benini, S.; Nicoletti, G.; Bernard, G.; Nanni, P.; Lollini, P-L; Bernard, A.; Picci, P.			CD99 isoforms dictate opposite functions in tumour malignancy and metastases by activating or repressing c-Src kinase activity	ONCOGENE			English	Article						CD99; splice variants; osteosarcoma; migration; metastases	PROSTATE-CANCER CELLS; EWINGS-SARCOMA CELLS; HUMAN OSTEOSARCOMA CELLS; EXPRESSION; ADHESION; PATHWAY; ENGAGEMENT; APOPTOSIS; MOTILITY; MIC2	CD99 gene encodes two distinct proteins, produced by alternative splicing of CD99 gene transcript. Full- length CD99 isoform ( CD99wt) is formed by an extracellular domain, followed by a transmembrane domain and a 36 amino- acid intracytoplasmic domain, which is partially deleted in the truncated, short form ( CD99sh). A differential expression of these two CD99 molecules can lead to distinct functional outcomes in lymphocytes. To investigate the functional effects of CD99 molecules on malignancy, forced overexpression of the two CD99 isoforms was induced in osteosarcoma and prostate cancer cells. The two isoforms exhibited opposite functions: the major form dramatically inhibits anchorage- independent growth, anoikis resistance, migration and metastasis, whereas the CD99sh remarkably favours the phenomena. A mechanistic analysis of CD99-transfected osteosarcoma cells points to involvement of c-Src family kinase activity in regulating CD99 functions in malignancy. Ser168 residue of CD99 plays a pivotal role in the reversion of the malignant phenotype. Our findings highlight the involvement of CD99 in crucial processes of cancer malignancy, serving as a curtain raiser for this, so far neglected molecule. In addition, a dualistic role for the two CD99 isoforms was shown in agreement with what was observed for other cell adhesion molecules.	Inst Orthoped Rizzoli, Lab Ric Oncol, I-40136 Bologna, Italy; Hosp Archet, INSERM, UMR 576, Nice, France; Univ Bologna, Dipt Patol Sperimentale, Sez Cancerol, Bologna, Italy	CHU Nice; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; University of Bologna	Scotlandi, K (corresponding author), Inst Orthoped Rizzoli, Lab Ric Oncol, Via Barbiano 1-10, I-40136 Bologna, Italy.	katia.scotlandi@ior.it	Rocchi, Anna/AAA-7748-2019; Scotlandi, Katia/J-9009-2016; Sciandra, Marika/C-8724-2018; Lollini, Pier Luigi/A-7644-2008; Manara, Maria Cristina/K-3366-2018; Picci, Piero/J-5979-2016; BENINI, STEFANIA/D-1804-2019	Rocchi, Anna/0000-0002-1334-9063; Scotlandi, Katia/0000-0001-6114-9499; Sciandra, Marika/0000-0001-7147-6960; Lollini, Pier Luigi/0000-0003-1702-4108; Manara, Maria Cristina/0000-0001-5686-720X; Picci, Piero/0000-0002-8519-4101; BENINI, STEFANIA/0000-0003-0958-9088; Nanni, Patrizia/0000-0001-5319-0803				Alberti I, 2002, FASEB J, V16, P1946, DOI 10.1096/fj.02-0049fje; AMBROS IM, 1991, CANCER, V67, P1886, DOI 10.1002/1097-0142(19910401)67:7<1886::AID-CNCR2820670712>3.0.CO;2-U; Ayrapetov MK, 2006, J BIOL CHEM, V281, P23776, DOI 10.1074/jbc.M604219200; Benini S, 1999, INT J CANCER, V80, P581, DOI 10.1002/(SICI)1097-0215(19990209)80:4<581::AID-IJC16>3.3.CO;2-F; Bernard G, 2000, EUR J IMMUNOL, V30, P3061, DOI 10.1002/1521-4141(200010)30:10<3061::AID-IMMU3061>3.0.CO;2-M; Bernard G, 1997, J IMMUNOL, V158, P2543; Boyer B, 2002, ONCOGENE, V21, P2347, DOI 10.1038/sj.onc.1205298; Byun HJ, 2006, J BIOL CHEM, V281, P34833, DOI 10.1074/jbc.M605483200; Cerisano V, 2004, ONCOGENE, V23, P5664, DOI 10.1038/sj.onc.1207741; Dworzak MN, 2004, LEUKEMIA, V18, P703, DOI 10.1038/sj.leu.2403303; Fouchet C, 2000, BLOOD, V95, P1819, DOI 10.1182/blood.V95.5.1819.005k05_1819_1826; Goto A, 2004, HISTOPATHOLOGY, V45, P384, DOI 10.1111/j.1365-2559.2004.01967.x; Hahn JH, 1997, J IMMUNOL, V159, P2250; Huang WC, 2005, CANCER RES, V65, P2303, DOI 10.1158/0008-5472.CAN-04-3448; Irby RB, 2000, ONCOGENE, V19, P5636, DOI 10.1038/sj.onc.1203912; Jee B, 2003, EXP MOL MED, V35, P30, DOI 10.1038/emm.2003.5; Jung KC, 2002, J KOREAN MED SCI, V17, P483, DOI 10.3346/jkms.2002.17.4.483; Kim SH, 2000, BLOOD, V95, P294; Kreppel M, 2006, ONCOGENE, V25, P2795, DOI 10.1038/sj.onc.1209300; Maitra A, 2003, CLIN CANCER RES, V9, P5988; Manara MC, 2006, MOL BIOL CELL, V17, P1910, DOI 10.1091/mbc.E05-10-0971; Marzia M, 2000, J CELL BIOL, V151, P311, DOI 10.1083/jcb.151.2.311; Porter M, 2000, J BIOL CHEM, V275, P2721, DOI 10.1074/jbc.275.4.2721; Recchi I, 2003, EUR J CANCER, V39, P1927, DOI 10.1016/S0959-8049(03)00394-0; Schenkel AR, 2002, NAT IMMUNOL, V3, P143, DOI 10.1038/ni749; Scotlandi K, 2000, CANCER RES, V60, P5134; Scotlandi K, 1996, HUM PATHOL, V27, P408, DOI 10.1016/S0046-8177(96)90115-X; SCOTLANDI K, 1993, INT J ONCOL, V3, P963; Sohn HW, 1998, AM J PATHOL, V153, P1937, DOI 10.1016/S0002-9440(10)65707-0; Wijetunge S, 1996, FEBS LETT, V399, P63, DOI 10.1016/S0014-5793(96)01177-5	30	46	50	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 11	2007	26	46					6604	6618		10.1038/sj.onc.1210481	http://dx.doi.org/10.1038/sj.onc.1210481			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	219JT	17471235				2022-12-28	WOS:000250081500003
J	Lin, J; Sun, T; Ji, L; Deng, W; Roth, J; Minna, J; Arlinghaus, R				Lin, J.; Sun, T.; Ji, L.; Deng, W.; Roth, J.; Minna, J.; Arlinghaus, R.			Oncogenic activation of c-Abl in non-small cell lung cancer cells lacking FUS1 expression: inhibition of c-Abl by the tumor suppressor gene product Fus1	ONCOGENE			English	Article						c-Abl; FUS1; NSCLC; lung cancer; imatinib	HOMOZYGOUS DELETION REGION; EPIDERMAL-GROWTH-FACTOR; TYROSINE KINASE; IN-VIVO; PROTEIN; BCR; FAMILY; VITRO; EXON; CRK	In lung cancer, frequent loss of one allele of chromosome 3p is seen in both small cell lung cancer and non-small cell lung cancer (NSCLC), providing evidence of tumor suppressor genes (TSGs) in this chromosomal region. The mechanism of Fus1 tumor suppressor activity is unknown. We have found that a Fus1 peptide inhibits the Ab1 tyrosine kinase in vitro (IC50 35 mu M). The inhibitory Fus1 sequence was derived from a region that was deleted in a mutant FUS1 gene (FUS1 (1-80)) detected in some lung cancer cell lines. Importantly, a stearic acid-modified form of this peptide was required for the inhibition, but stearic acid alone was not inhibitory. Two NSCLC cell lines, which lack expression of wild-type Fus1, contain activated c-Abl. Forced expression of an inducible FUS1 cDNA in H1299 NSCLC cells decreased levels of activated c-Abl and inhibited its tyrosine kinase activity. Similarly, treatment of c-Abl immune complexes with the inhibitory Fus1 peptide also reduced the level of c-Abl in these immune complexes. The size and number of colonies of the NSCLC cell line, H1299, in soft agar was strongly inhibited by the Abl kinase inhibitor imatinib mesylate. Co-expression of FUS1 and c-ABL in COS1 cells blocked activation of c-Abl tyrosine kinase. In contrast, coexpression of mutant FUS1(1-80) with c-ABL had little inhibitory activity against c-Abl. These findings provide strong evidence that c-Abl is a possible target in NSCLC patients that have reduced expression of Fus1 in their tumor cells.	Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Thorac Surg, Houston, TX 77030 USA; Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, Dallas, TX USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Arlinghaus, R (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, 1515 Holcombe Blvd, Houston, TX 77030 USA.	rarlingh@mdanderson.org			NCI NIH HHS [P50CA70907, P50 CA070907] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA070907] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Brasher BB, 2000, J BIOL CHEM, V275, P35631, DOI 10.1074/jbc.M005401200; Buchdunger E, 1996, CANCER RES, V56, P100; Das AK, 2006, CANCER RES, V66, P9601, DOI 10.1158/0008-5472.CAN-06-2627; Dowell JE, 2005, NEW ENGL J MED, V352, P830, DOI 10.1056/NEJMe058033; FELLER SM, 1994, TRENDS BIOCHEM SCI, V19, P453, DOI 10.1016/0968-0004(94)90129-5; Girard L, 2000, CANCER RES, V60, P4894; Hantschel O, 2003, CELL, V112, P845, DOI 10.1016/S0092-8674(03)00191-0; Ito I, 2004, CANCER GENE THER, V11, P733, DOI 10.1038/sj.cgt.7700756; Ji L, 2002, CANCER RES, V62, P2715; Kondo M, 2001, ONCOGENE, V20, P6258, DOI 10.1038/sj.onc.1204832; Ling XY, 2003, CANCER RES, V63, P298; Liu JX, 1996, CANCER RES, V56, P5120; LIU JX, 1993, ONCOGENE, V8, P101; Miller CT, 2003, ONCOGENE, V22, P7950, DOI 10.1038/sj.onc.1206529; Pendergast AM, 2002, ADV CANCER RES, V85, P51, DOI 10.1016/S0065-230X(02)85003-5; Plattner R, 1999, GENE DEV, V13, P2400, DOI 10.1101/gad.13.18.2400; Pluk H, 2002, CELL, V108, P247, DOI 10.1016/S0092-8674(02)00623-2; Samanta AK, 2006, CANCER RES, V66, P6468, DOI 10.1158/0008-5472.CAN-06-0025; Srinivasan D, 2006, CANCER RES, V66, P5648, DOI 10.1158/0008-5472.CAN-06-0734; Taagepera S, 1998, P NATL ACAD SCI USA, V95, P7457, DOI 10.1073/pnas.95.13.7457; Tanos B, 2006, J BIOL CHEM, V281, P32714, DOI 10.1074/jbc.M603126200; Uno F, 2004, CANCER RES, V64, P2969, DOI 10.1158/0008-5472.CAN-03-3702; *US CANC STAT WORK, 2004, UC CANC STAT 2001 IN; Wang JYJ, 2000, ONCOGENE, V19, P5643, DOI 10.1038/sj.onc.1203878; Wen ST, 1997, GENE DEV, V11, P2456, DOI 10.1101/gad.11.19.2456; Woodring PJ, 2003, J CELL SCI, V116, P2613, DOI 10.1242/jcs.00622; Zabarovsky ER, 2002, ONCOGENE, V21, P6915, DOI 10.1038/sj.onc.1205835; Zhang M, 2004, ACTA PHARMACOL SIN, V25, P61; Zhang Peilin, 2003, Mol Cancer, V2, P1	29	51	51	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2007	26	49					6989	6996		10.1038/sj.onc.1210500	http://dx.doi.org/10.1038/sj.onc.1210500			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	223YN	17486070	Green Accepted			2022-12-28	WOS:000250412200004
J	Ambrose, HE; Papadopoulou, V; Beswick, RW; Wagner, SD				Ambrose, H. E.; Papadopoulou, V.; Beswick, R. W.; Wagner, S. D.			Poly-(ADP-ribose) polymerase-1 (Parp-1) binds in a sequence-specific manner at the Bcl-6 locus and contributes to the regulation of Bcl-6 transcription	ONCOGENE			English	Article						Parp-1; Bcl-6; lymphoma	B-CELL LYMPHOMA; GERMINAL-CENTER FORMATION; POLY(ADP-RIBOSE) POLYMERASE; DNA-BINDING; NEGATIVE AUTOREGULATION; CHROMATIN-STRUCTURE; GENE-EXPRESSION; SCL LOCI; COACTIVATOR; PROMOTER	Bcl-6 is a transcription factor that is normally expressed in germinal centre B cells. It is essential for the formation of germinal centres and the production of high-affinity antibodies. Transcriptional downregulation of Bcl-6 occurs on terminal differentiation to plasma cells. Bcl-6 is highly expressed in B-cell non-Hodgkin's lymphoma and, in a subset of cases of diffuse large cell lymphoma, the mechanism of Bcl-6 overexpression involves interruption of normal transcriptional controls. Transcriptional control of Bcl-6 is, therefore, important for normal antibody responses and lymphomagenesis, but little is known of the cis-acting control elements. This report focuses on a region of mouse/human sequence homology in the first intron of Bcl-6, which is a candidate site for such a control element. We demonstrate that poly-(ADP-ribose) polymerase-1 (Parp-1) binds in vitro and in vivo to specific sequences in this region. We further show that PARP inhibitors, and Parp-1 knockdown by siRNA induce Bcl-6 mRNA expression in Bcl-6 expressing cell lines. We speculate that Parp-1 activation plays a role in switching off Bcl-6 transcription and subsequent B-cell exit from the germinal centre.	Hammersmith Hosp, Imperial Coll London, Dept Haematol, Div Invest Sci, London, England	Imperial College London	Wagner, SD (corresponding author), Hammersmith Hosp, Imperial Coll London, Dept Haematol, Du Cane rd, London W12 0NN, England.	simon.wagner@imperial.ac.uk		Wagner, Simon/0000-0002-8914-0370	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Akiyama T, 2001, P NATL ACAD SCI USA, V98, P48, DOI 10.1073/pnas.240458597; Ame JC, 2004, BIOESSAYS, V26, P882, DOI 10.1002/bies.20085; Amiri KI, 2006, ONCOGENE, V25, P7714, DOI 10.1038/sj.onc.1209751; Bereshchenko OR, 2002, NAT GENET, V32, P606, DOI 10.1038/ng1018; Bernardin F, 1997, ONCOGENE, V14, P849, DOI 10.1038/sj.onc.1200903; Borggrefe T, 1998, J BIOL CHEM, V273, P17025, DOI 10.1074/jbc.273.27.17025; Bross L, 2000, IMMUNITY, V13, P589, DOI 10.1016/S1074-7613(00)00059-5; Butler AJ, 1999, MOL CELL BIOL, V19, P296; CATTORETTI G, 1995, BLOOD, V86, P45, DOI 10.1182/blood.V86.1.45.bloodjournal86145; Cervellera MN, 2000, J BIOL CHEM, V275, P10692, DOI 10.1074/jbc.275.14.10692; Chang CC, 1996, P NATL ACAD SCI USA, V93, P6947, DOI 10.1073/pnas.93.14.6947; Chapman MA, 2004, GENOME RES, V14, P313, DOI 10.1101/gr.1759004; Chattopadhyay A, 2006, ONCOGENE, V25, P2223, DOI 10.1038/sj.onc.1209252; Chevallier N, 2004, BLOOD, V103, P1454, DOI 10.1182/blood-2003-06-2081; D'Amours D, 1999, BIOCHEM J, V342, P249, DOI 10.1042/0264-6021:3420249; Dent AL, 1997, SCIENCE, V276, P589, DOI 10.1126/science.276.5312.589; DURKACZ BW, 1980, NATURE, V283, P593, DOI 10.1038/283593a0; Fujita N, 2004, CELL, V119, P75, DOI 10.1016/j.cell.2004.09.014; Gottgens B, 2001, GENOME RES, V11, P87, DOI 10.1101/gr.153001; GREGORY CD, 1990, J GEN VIROL, V71, P1481, DOI 10.1099/0022-1317-71-7-1481; Haince JF, 2006, SCIENCE, V312, P1752, DOI 10.1126/science.1129808; Hassa PO, 2001, J BIOL CHEM, V276, P45588, DOI 10.1074/jbc.M106528200; Huang K, 2004, BIOCHEMISTRY-US, V43, P217, DOI 10.1021/bi0301800; Huber A, 2004, DNA REPAIR, V3, P1103, DOI 10.1016/j.dnarep.2004.06.002; Huynh KD, 1998, ONCOGENE, V17, P2473, DOI 10.1038/sj.onc.1202197; Ju BG, 2004, CELL, V119, P815, DOI 10.1016/j.cell.2004.11.017; Ju BG, 2006, SCIENCE, V312, P1798, DOI 10.1126/science.1127196; Kikuchi M, 2000, ONCOGENE, V19, P4941, DOI 10.1038/sj.onc.1203864; Kim MY, 2004, CELL, V119, P803, DOI 10.1016/j.cell.2004.11.002; Kraus WL, 2003, CELL, V113, P677, DOI 10.1016/S0092-8674(03)00433-1; Lonskaya I, 2005, J BIOL CHEM, V280, P17076, DOI 10.1074/jbc.M413483200; Ma LM, 2002, J IMMUNOL, V168, P2835, DOI 10.4049/jimmunol.168.6.2835; Margalit O, 2006, BLOOD, V107, P1599, DOI 10.1182/blood-2005-04-1629; Masson M, 1998, MOL CELL BIOL, V18, P3563, DOI 10.1128/MCB.18.6.3563; Nirodi C, 2001, J BIOL CHEM, V276, P9366, DOI 10.1074/jbc.M009897200; Niu HF, 1998, GENE DEV, V12, P1953, DOI 10.1101/gad.12.13.1953; OFFIT K, 1994, NEW ENGL J MED, V331, P74, DOI 10.1056/NEJM199407143310202; Ouararhni K, 2006, GENE DEV, V20, P3324, DOI 10.1101/gad.396106; Pasqualucci L, 2003, BLOOD, V101, P2914, DOI 10.1182/blood-2002-11-3387; Pavri R, 2005, MOL CELL, V18, P83, DOI 10.1016/j.molcel.2005.02.034; Pirrotta V, 2003, SCIENCE, V299, P528, DOI 10.1126/science.1081520; POIRIER GG, 1982, P NATL ACAD SCI-BIOL, V79, P3423, DOI 10.1073/pnas.79.11.3423; Polo JM, 2004, NAT MED, V10, P1329, DOI 10.1038/nm1134; Potaman VN, 2005, J MOL BIOL, V348, P609, DOI 10.1016/j.jmb.2005.03.010; Rouleau M, 2004, J CELL SCI, V117, P815, DOI 10.1242/jcs.01080; Sale JE, 1998, IMMUNITY, V9, P859, DOI 10.1016/S1074-7613(00)80651-2; SATOH MS, 1992, NATURE, V356, P356, DOI 10.1038/356356a0; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Schreiber V, 2006, NAT REV MOL CELL BIO, V7, P517, DOI 10.1038/nrm1963; Simbulan-Rosenthal CM, 2003, ONCOGENE, V22, P8460, DOI 10.1038/sj.onc.1206897; Soldatenkov VA, 2002, J BIOL CHEM, V277, P665, DOI 10.1074/jbc.M108551200; Walker SR, 2007, ONCOGENE, V26, P224, DOI 10.1038/sj.onc.1209775; Wang X, 2002, P NATL ACAD SCI USA, V99, P15018, DOI 10.1073/pnas.232581199; Ye BH, 1997, NAT GENET, V16, P161, DOI 10.1038/ng0697-161; Ye BH, 1995, EMBO J, V14, P6209, DOI 10.1002/j.1460-2075.1995.tb00311.x; YE BH, 1993, SCIENCE, V262, P747, DOI 10.1126/science.8235596; Zhang Z, 2002, VIROLOGY, V296, P107, DOI 10.1006/viro.2002.1385	57	35	36	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 13	2007	26	42					6244	6252		10.1038/sj.onc.1210434	http://dx.doi.org/10.1038/sj.onc.1210434			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	209PU	17404575				2022-12-28	WOS:000249401300016
J	Bilanges, B; Stokoe, D				Bilanges, B.; Stokoe, D.			Mechanisms of translational deregulation in human tumors and therapeutic intervention strategies	ONCOGENE			English	Review						protein synthesis; tumor suppressor genes; mTOR; targeted therapy	INITIATION-FACTOR 4E; TRANSFORMATION SUPPRESSOR PDCD4; MESSENGER-RNA TRANSLATION; GENE-EXPRESSION PROFILES; ELONGATION-FACTOR EEF1A2; PROTEIN-SYNTHESIS; EUKARYOTIC TRANSLATION; MAMMALIAN TARGET; BINDING-PROTEIN; CELL-GROWTH	Analysis of the recurrent genetic aberrations present in human tumors provides insight into how normal cells escape appropriate proliferation and survival cues. Commonly mutated genes encode proteins that monitor DNA damage ( e. g., p53), proteins that regulate the cell cycle ( such as Rb), and proteins that regulate signal transduction pathways ( such as APC, PTEN and Ras). Analysis of the relevant targets and downstream events of these genes in normal and tumor cells will clearly highlight important pathways for tumorigenesis. However, more infrequent mutations are also informative in de. ning events critical for the process of tumorigenesis, and often delineate important pathways lying downstream of commonly mutated oncogenes and tumor suppressors. Together, these studies have led to the conclusion that deregulated protein synthesis plays an important role in human cancer. This review will discuss the evidence implicating mRNA translation as an important downstream consequence of signal transduction pathways initiated by mutated oncogenes and tumor suppressors, as well as additional genetic findings implicating the importance of global and specific translational control in human cancer. It will also discuss therapeutic strategies that take advantage of differences in translational regulation between normal and tumor cells.	Univ Calif San Francisco, Canc Res Inst, San Francisco, CA 94115 USA	University of California System; University of California San Francisco	Bilanges, B (corresponding author), Univ Calif San Francisco, Canc Res Inst, 2340 Sutter St,Room N319, San Francisco, CA 94115 USA.	bbilanges@cc.ucsf.edu; dstokoe@cc.ucsf.edu	Bilanges, Benoit/AAP-6078-2020	Bilanges, Benoit/0000-0002-6115-3997; Bilanges, Benoit/0000-0003-4400-3716	NCI NIH HHS [P50 CA97257] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA097257] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alessi DR, 2006, ANNU REV BIOCHEM, V75, P137, DOI 10.1146/annurev.biochem.75.103004.142702; Amsterdam A, 2004, PLOS BIOL, V2, P690, DOI 10.1371/journal.pbio.0020139; Anand N, 2002, NAT GENET, V31, P301, DOI 10.1038/ng904; Avdulov S, 2004, CANCER CELL, V5, P553, DOI 10.1016/j.ccr.2004.05.024; Ayala G, 2006, MOL THER, V13, P716, DOI 10.1016/j.ymthe.2005.11.022; Bader AG, 2003, P NATL ACAD SCI USA, V100, P12384, DOI 10.1073/pnas.2135336100; Bader AG, 2005, MOL CELL BIOL, V25, P2095, DOI 10.1128/MCB.25.6.2095-2106.2005; Balachandran S, 2004, CANCER CELL, V5, P51, DOI 10.1016/S1535-6108(03)00330-1; Balachandran S, 2000, IUBMB LIFE, V50, P135, DOI 10.1080/15216540050212169; Barlund M, 2000, J NATL CANCER I, V92, P1252, DOI 10.1093/jnci/92.15.1252; Bauer C, 2001, CANCER, V92, P822, DOI 10.1002/1097-0142(20010815)92:4<822::AID-CNCR1388>3.0.CO;2-A; Bentwich I, 2005, FEBS LETT, V579, P5904, DOI 10.1016/j.febslet.2005.09.040; Beretta L, 1996, EMBO J, V15, P658, DOI 10.1002/j.1460-2075.1996.tb00398.x; Beuvink I, 2005, CELL, V120, P747, DOI 10.1016/j.cell.2004.12.040; BILANGES B, UNPUB TSC1 TSC2 CONT; Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; Brugarolas J, 2004, GENE DEV, V18, P2893, DOI 10.1101/gad.1256804; Buttitta F, 2005, CLIN CANCER RES, V11, P3198, DOI 10.1158/1078-0432.CCR-04-2308; Byrnes K, 2006, ANN SURG, V243, P684, DOI 10.1097/01.sla.0000216770.23642.d8; Cai DX, 2001, AM J CLIN PATHOL, V115, P213; Calin GA, 2002, P NATL ACAD SCI USA, V99, P15524, DOI 10.1073/pnas.242606799; Calin GA, 2004, P NATL ACAD SCI USA, V101, P11755, DOI 10.1073/pnas.0404432101; Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997; Chen CN, 2004, J SURG ONCOL, V86, P22, DOI 10.1002/jso.20037; CHEN S, 2003, P ICASSP HONG KONG C, V4, P640; Choesmel V, 2007, BLOOD, V109, P1275, DOI 10.1182/blood-2006-07-038372; Cimmino A, 2005, P NATL ACAD SCI USA, V102, P13944, DOI 10.1073/pnas.0506654102; Cmejlova J, 2006, HAEMATOLOGICA, V91, P1456; Costinean S, 2006, P NATL ACAD SCI USA, V103, P7024, DOI 10.1073/pnas.0602266103; Couch FJ, 1999, CANCER RES, V59, P1408; CRAMTON SE, 1994, GENETICS, V137, P1039; Culjkovic B, 2005, J CELL BIOL, V169, P245, DOI 10.1083/jcb.200501019; Cummins JM, 2006, ONCOGENE, V25, P6220, DOI 10.1038/sj.onc.1209914; Dai MS, 2006, J BIOL CHEM, V281, P24304, DOI 10.1074/jbc.M602596200; De Benedetti A, 2004, ONCOGENE, V23, P3189, DOI 10.1038/sj.onc.1207545; De Benedetti A, 1999, INT J BIOCHEM CELL B, V31, P59, DOI 10.1016/S1357-2725(98)00132-0; DeFatta RJ, 2002, CANCER GENE THER, V9, P573, DOI 10.1038/sj.cgt.7700468; deGraffenried LA, 2004, ANN ONCOL, V15, P1510, DOI 10.1093/annonc/mdh388; Dez C, 2004, CURR OPIN MICROBIOL, V7, P631, DOI 10.1016/j.mib.2004.10.007; Dizin E, 2006, J BIOL CHEM, V281, P24236, DOI 10.1074/jbc.M602176200; Dong ZZ, 2006, CRIT REV ONCOL HEMAT, V59, P169, DOI 10.1016/j.critrevonc.2006.03.005; Dong ZZ, 2004, ONCOGENE, V23, P3790, DOI 10.1038/sj.onc.1207465; Dong ZZ, 2003, MOL BIOL CELL, V14, P3942, DOI 10.1091/mbc.E02-12-0784; DONZE O, 1995, EMBO J, V14, P3828, DOI 10.1002/j.1460-2075.1995.tb00052.x; Dorrello NV, 2006, SCIENCE, V314, P467, DOI 10.1126/science.1130276; Draptchinskaia N, 1999, NAT GENET, V21, P169, DOI 10.1038/5951; DUMONT FJ, 1990, J IMMUNOL, V144, P251; DUNCAN MR, 1978, J VIROL, V28, P444, DOI 10.1128/JVI.28.2.444-449.1978; Easton JB, 2006, ONCOGENE, V25, P6436, DOI 10.1038/sj.onc.1209886; Eberle J, 1997, INT J CANCER, V71, P396, DOI 10.1002/(SICI)1097-0215(19970502)71:3<396::AID-IJC16>3.0.CO;2-E; Eng C, 2003, HUM MUTAT, V22, P183, DOI 10.1002/humu.10257; ENG CP, 1984, J ANTIBIOT, V37, P1231, DOI 10.7164/antibiotics.37.1231; Eshleman JS, 2002, CANCER RES, V62, P7291; Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840; Evdokimova V, 2006, MOL CELL BIOL, V26, P277, DOI 10.1128/MCB.26.1.277-292.2006; Flygare J, 2007, BLOOD, V109, P980, DOI 10.1182/blood-2006-07-038232; FukuchiShimogori T, 1997, CANCER RES, V57, P5041; Galanis E, 2005, J CLIN ONCOL, V23, P5294, DOI 10.1200/JCO.2005.23.622; Gazda HT, 2006, STEM CELLS, V24, P2034, DOI 10.1634/stemcells.2005-0554; Gera JF, 2004, J BIOL CHEM, V279, P2737, DOI 10.1074/jbc.M309999200; Gill T, 2004, MOL CELL BIOL, V24, P945, DOI 10.1128/MCB.24.3.945-953.2004; Gingras AC, 2001, GENE DEV, V15, P807, DOI 10.1101/gad.887201; Graff JR, 2003, CLIN EXP METASTAS, V20, P265, DOI 10.1023/A:1022943419011; Gregory MA, 2005, ANGEW CHEM INT EDIT, V44, P4757, DOI 10.1002/anie.200462784; Grolleau A, 2002, J BIOL CHEM, V277, P22175, DOI 10.1074/jbc.M202014200; Guertin DA, 2006, DEV CELL, V11, P859, DOI 10.1016/j.devcel.2006.10.007; Hahn-Windgassen A, 2005, J BIOL CHEM, V280, P32081, DOI 10.1074/jbc.M502876200; Handley TPB, 2006, ORAL ONCOL, V42, P331, DOI 10.1016/j.oraloncology.2005.06.007; Haydon MS, 2000, CANCER-AM CANCER SOC, V88, P2803, DOI 10.1002/1097-0142(20000615)88:12<2803::AID-CNCR20>3.0.CO;2-5; He L, 2005, NATURE, V435, P828, DOI 10.1038/nature03552; Hershey JWB, 2000, COLD SPRING HARBOR M, V39, P33; Hilliard A, 2006, J IMMUNOL, V177, P8095, DOI 10.4049/jimmunol.177.11.8095; Hirasawa K, 2002, CANCER RES, V62, P1696; Hirasawa K, 2003, CANCER RES, V63, P348; Holland EC, 2000, NAT GENET, V25, P55, DOI 10.1038/75596; Holz MK, 2005, CELL, V123, P569, DOI 10.1016/j.cell.2005.10.024; Iorio MV, 2005, CANCER RES, V65, P7065, DOI 10.1158/0008-5472.CAN-05-1783; Jansen AP, 2004, MOL CANCER THER, V3, P103; Jefferies HBJ, 1997, EMBO J, V16, P3693, DOI 10.1093/emboj/16.12.3693; JEFFERIES HBJ, 1994, P NATL ACAD SCI USA, V91, P4441, DOI 10.1073/pnas.91.10.4441; Johnson SM, 2005, CELL, V120, P635, DOI 10.1016/j.cell.2005.01.014; Kaufman RJ, 2000, COLD SPRING HARBOR M, V39, P503; Kent OA, 2006, ONCOGENE, V25, P6188, DOI 10.1038/sj.onc.1209913; Kevil CG, 1996, INT J CANCER, V65, P785, DOI 10.1002/(SICI)1097-0215(19960315)65:6<785::AID-IJC14>3.0.CO;2-3; Kitahara O, 2001, CANCER RES, V61, P3544; Koga Y, 2006, J PEDIAT HEMATOL ONC, V28, P355, DOI 10.1097/00043426-200606000-00007; KONGSUWAN K, 1985, NATURE, V317, P555, DOI 10.1038/317555a0; Kwiatkowski DJ, 2003, ANN HUM GENET, V67, P87, DOI 10.1046/j.1469-1809.2003.00012.x; Larsson O, 2006, NUCLEIC ACIDS RES, V34, P4375, DOI 10.1093/nar/gkl558; Law M, 2006, CANCER RES, V66, P1070, DOI 10.1158/0008-5472.CAN-05-1672; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; Leslie NR, 2002, CELL SIGNAL, V14, P285, DOI 10.1016/S0898-6568(01)00234-0; Li R, 2006, ONCOGENE, V25, P2628, DOI 10.1038/sj.onc.1209289; Li S, 2003, J BIOL CHEM, V278, P3015, DOI 10.1074/jbc.M208821200; Liu JM, 2006, BLOOD, V107, P4583, DOI 10.1182/blood-2005-12-4831; Lynch M, 2004, J BIOL CHEM, V279, P3327, DOI 10.1074/jbc.M310872200; Majumder PK, 2004, NAT MED, V10, P594, DOI 10.1038/nm1052; Mamane Y, 2006, ONCOGENE, V25, P6416, DOI 10.1038/sj.onc.1209888; Mamane Y, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000242; MARECHAL V, 1994, MOL CELL BIOL, V14, P7414, DOI 10.1128/MCB.14.11.7414; Martin ME, 2000, INT J BIOCHEM CELL B, V32, P633, DOI 10.1016/S1357-2725(00)00007-8; Mathis JM, 2006, J GENE MED, V8, P1105, DOI 10.1002/jgm.935; Matsson H, 2006, BLOOD CELL MOL DIS, V36, P259, DOI 10.1016/j.bcmd.2005.12.002; Matsumoto Ken, 2005, J Mol Genet Med, V1, P11; Mayer C, 2006, ONCOGENE, V25, P6384, DOI 10.1038/sj.onc.1209883; McManus EJ, 2002, NAT CELL BIOL, V4, pE214, DOI 10.1038/ncb0902-e214; Michael MZ, 2003, MOL CANCER RES, V1, P882; Mochizuki Y, 2004, P NATL ACAD SCI USA, V101, P10756, DOI 10.1073/pnas.0402560101; Morley SJ, 2001, PROG MOLEC, V27, P1; Nekrasov MP, 2003, J BIOL CHEM, V278, P13936, DOI 10.1074/jbc.M209145200; Neshat MS, 2001, P NATL ACAD SCI USA, V98, P10314, DOI 10.1073/pnas.171076798; Noh WC, 2004, CLIN CANCER RES, V10, P1013, DOI 10.1158/1078-0432.CCR-03-0043; Norman KL, 2002, HUM GENE THER, V13, P641, DOI 10.1089/10430340252837233; Norman KL, 2004, P NATL ACAD SCI USA, V101, P11099, DOI 10.1073/pnas.0404310101; Nupponen NN, 2000, GENE CHROMOSOME CANC, V28, P203; Okamoto H, 2003, HEPATOLOGY, V38, P1242, DOI 10.1053/jhep.2003.50457; Oshiro N, 2004, GENES CELLS, V9, P359, DOI 10.1111/j.1356-9597.2004.00727.x; Panner A, 2005, MOL CELL BIOL, V25, P8809, DOI 10.1128/MCB.25.20.8809-8823.2005; Pende M, 2004, MOL CELL BIOL, V24, P3112, DOI 10.1128/MCB.24.8.3112-3124.2004; Perrotti D, 2004, ONCOGENE, V23, P3222, DOI 10.1038/sj.onc.1207543; Plas DR, 2005, ONCOGENE, V24, P7435, DOI 10.1038/sj.onc.1209097; Provenzani A, 2006, CARCINOGENESIS, V27, P1323, DOI 10.1093/carcin/bgi377; Rajasekhar VK, 2003, MOL CELL, V12, P889, DOI 10.1016/S1097-2765(03)00395-2; Rajasekhar VK, 2004, ONCOGENE, V23, P3248, DOI 10.1038/sj.onc.1207546; Rao RD, 2005, NEOPLASIA, V7, P921, DOI 10.1593/neo.05361; Raught B, 2004, EMBO J, V23, P1761, DOI 10.1038/sj.emboj.7600193; Ridanpaa M, 2001, CELL, V104, P195, DOI 10.1016/S0092-8674(01)00205-7; Rousseau D, 1996, P NATL ACAD SCI USA, V93, P1065, DOI 10.1073/pnas.93.3.1065; Ruggero D, 2004, NAT MED, V10, P484, DOI 10.1038/nm1042; Ruggero D, 2003, SCIENCE, V299, P259, DOI 10.1126/science.1079447; Ruggero D, 2003, NAT REV CANCER, V3, P179, DOI 10.1038/nrc1015; Ruvinsky I, 2005, GENE DEV, V19, P2199, DOI 10.1101/gad.351605; Ruvinsky I, 2006, TRENDS BIOCHEM SCI, V31, P342, DOI 10.1016/j.tibs.2006.04.003; Salehi Z, 2006, CLIN BIOCHEM, V39, P404, DOI 10.1016/j.clinbiochem.2005.11.007; Samuels Y, 2004, CELL CYCLE, V3, P1221, DOI 10.4161/cc.3.10.1164; Scheuner D, 2006, J BIOL CHEM, V281, P21458, DOI 10.1074/jbc.M603784200; Schmidt EV, 2004, ONCOGENE, V23, P3217, DOI 10.1038/sj.onc.1207548; Shayesteh L, 1999, NAT GENET, V21, P99, DOI 10.1038/5042; Shi J, 2006, ONCOGENE, V25, P4923, DOI 10.1038/sj.onc.1209495; Shinohara ET, 2005, ONCOGENE, V24, P5414, DOI 10.1038/sj.onc.1208715; Shuda M, 2000, ANTICANCER RES, V20, P2489; Skeen JE, 2006, CANCER CELL, V10, P269, DOI 10.1016/j.ccr.2006.08.022; Sorrells DL, 1999, J ORAL MAXIL SURG, V57, P294, DOI 10.1016/S0278-2391(99)90676-6; Stephens L, 2005, CURR OPIN PHARMACOL, V5, P357, DOI 10.1016/j.coph.2005.03.002; Stojdl DF, 2003, CANCER CELL, V4, P263, DOI 10.1016/S1535-6108(03)00241-1; Stokoe David, 2005, Expert Reviews in Molecular Medicine, V7, P1, DOI 10.1017/S1462399405009361; Strong JE, 1998, EMBO J, V17, P3351, DOI 10.1093/emboj/17.12.3351; Takagi M, 2005, CELL, V123, P49, DOI 10.1016/j.cell.2005.07.034; Thiel CT, 2005, AM J HUM GENET, V77, P795, DOI 10.1086/497708; Thomas GV, 2006, NAT MED, V12, P122, DOI 10.1038/nm1337; TOCZYSKI DP, 1994, P NATL ACAD SCI USA, V91, P3463, DOI 10.1073/pnas.91.8.3463; Tominaga Y, 2005, MOL CELL BIOL, V25, P8465, DOI 10.1128/MCB.25.19.8465-8475.2005; Tomlinson VAL, 2005, BMC CANCER, V5, DOI 10.1186/1471-2407-5-113; Tuxworth WJ, 2004, BIOCHEM J, V378, P73, DOI 10.1042/BJ20031027; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; Vulliamy TJ, 2006, BLOOD, V107, P2680, DOI 10.1182/blood-2005-07-2622; Wang MY, 2006, CANCER RES, V66, P7864, DOI 10.1158/0008-5472.CAN-04-4392; Wang XM, 2001, EMBO J, V20, P4370, DOI 10.1093/emboj/20.16.4370; WEBER GEORGE, 1966, ADVANC ENZYME REGULAT, V4., P115, DOI 10.1016/0065-2571(66)90011-2; Welsh JB, 2001, P NATL ACAD SCI USA, V98, P1176, DOI 10.1073/pnas.98.3.1176; Wendel HG, 2004, NATURE, V428, P332, DOI 10.1038/nature02369; Wong JMY, 2006, GENE DEV, V20, P2848, DOI 10.1101/gad.1476206; Yang HS, 2003, MOL CELL BIOL, V23, P26, DOI 10.1128/MCB.23.1.26-37.2003; Yang WQ, 2004, GENE THER, V11, P1579, DOI 10.1038/sj.gt.3302319; Yang ZZ, 2004, BIOCHEM SOC T, V32, P350, DOI 10.1042/BST0320350; Yokogami K, 2000, CURR BIOL, V10, P47, DOI 10.1016/S0960-9822(99)00268-7; Yonezawa K, 2003, CURR TOP MICROBIOL, V279, P271; Yoon A, 2006, SCIENCE, V312, P902, DOI 10.1126/science.1123835; Yu D, 2006, CANCER GENE THER, V13, P32, DOI 10.1038/sj.cgt.7700885; Yu K, 2001, ENDOCR-RELAT CANCER, V8, P249, DOI 10.1677/erc.0.0080249; Zakowicz H, 2005, RNA, V11, P261, DOI 10.1261/rna.7191905; Zhai WG, 2000, MOL CELL BIOL, V20, P5930, DOI 10.1128/MCB.20.16.5930-5938.2000; Zhang L, 1997, SCIENCE, V276, P1268, DOI 10.1126/science.276.5316.1268; Zhou S, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-231	174	68	70	2	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2007	26	41					5973	5990		10.1038/sj.onc.1210431	http://dx.doi.org/10.1038/sj.onc.1210431			18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	207US	17404576				2022-12-28	WOS:000249277200001
J	Lau, WM; Ho, TH; Hui, KM				Lau, W. M.; Ho, T. H.; Hui, K. M.			p16(INK4A)-silencing augments DNA damage-induced apoptosis in cervical cancer cells	ONCOGENE			English	Article						p16; RNAi; cervical cancer; DNA damage; apoptosis	HUMAN-PAPILLOMAVIRUS TYPE-16; G(1) ARREST; POSTTRANSLATIONAL MODIFICATION; GROWTH ARREST; P53 PROTEIN; EXPRESSION; DEGRADATION; GENE; RNA; E6	p16(INK4A) ( p16) has been suggested to be an early biomarker for the detection of cervical cancer. However, its functional role in cervical cancer is not well characterized. In this study, we reported the consistent and significant upregulation of p16 in cervical cancer tissues when compared to both matched non-tumourous tissues of the same patient and normal cervical tissues from non- cancer patients. We have employed p16 small interfering RNA ( siRNA) to dissect the role of p16 in cervical carcinogenesis. Although the silencing of p16 was accompanied by the upregulation of p53, p21 and RB in the p16 siRNA- transfected cells, no significant effect on cell cycle progression was observed. When the p16 siRNA-silenced cells were subjected to DNA damage stress including ultraviolet-irradiation and cisplatin treatments, a significantly higher percentage of apoptotic cells could be observed in the p16- siRNA silenced cells compared to control siRNA- treated cells. Moreover, induction of apoptosis was associated with the activation of p53 through phosphorylation, and this process, when studied by gene pro. ling experiments, involved both the intrinsic and extrinsic apoptotic pathways. The observation that silencing of p16 expression augments DNA damage-induced apoptosis in cervical cancer cells offers alternative strategies for anti-cancer therapies for human cervical cancer.	Natl Canc Ctr, Div Cellular & Mol Res, Singapore 169610, Singapore; Singapore Gen Hosp, Singapore, Singapore; KK Womens & Childrens Hosp, Gynaecol Oncol Unit, Singapore, Singapore	National Cancer Centre Singapore (NCCS); Singapore General Hospital; KK Women's & Children's Hospital	Hui, KM (corresponding author), Natl Canc Ctr, Div Cellular & Mol Res, 11 Hosp Dr, Singapore 169610, Singapore.	cmrhkm@nccs.com.sg	Hui, Kam/C-6186-2011	Hui, Kam/0000-0003-1820-1399				Andersson S, 2006, INT J ONCOL, V29, P705; Bode AM, 2004, NAT REV CANCER, V4, P793, DOI 10.1038/nrc1455; BUTZ K, 1995, ONCOGENE, V10, P927; Cheng Q, 2002, INT J CANCER, V98, P419, DOI 10.1002/ijc.10177; DEMERS GW, 1994, P NATL ACAD SCI USA, V91, P4382, DOI 10.1073/pnas.91.10.4382; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Freedman DA, 1998, MOL CELL BIOL, V18, P7288, DOI 10.1128/MCB.18.12.7288; Giarre M, 2001, J VIROL, V75, P4705, DOI 10.1128/JVI.75.10.4705-4712.2001; Goodwin EC, 2000, P NATL ACAD SCI USA, V97, P12513, DOI 10.1073/pnas.97.23.12513; Goodwin EC, 2000, P NATL ACAD SCI USA, V97, P10978, DOI 10.1073/pnas.97.20.10978; Gu W, 2006, CANCER GENE THER, V13, P1023, DOI 10.1038/sj.cgt.7700971; Haapajarvi T, 1999, EXP CELL RES, V248, P272, DOI 10.1006/excr.1999.4403; HAWLEYNELSON P, 1989, EMBO J, V8, P3905, DOI 10.1002/j.1460-2075.1989.tb08570.x; Ishikawa M, 2006, INT J GYNECOL CANCER, V16, P347, DOI 10.1111/j.1525-1438.2006.00355.x; Jiang M, 2002, ONCOGENE, V21, P6041, DOI 10.1038/sj.onc.1205878; Jimenez GS, 1999, ONCOGENE, V18, P7656, DOI 10.1038/sj.onc.1203013; Jones DL, 1997, J VIROL, V71, P2905, DOI 10.1128/JVI.71.4.2905-2912.1997; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; Kanao H, 2004, CANCER LETT, V213, P31, DOI 10.1016/j.canlet.2004.03.030; Klaes R, 2001, INT J CANCER, V92, P276, DOI 10.1002/ijc.1174; Lee YS, 2006, J PHARMACOL EXP THER, V317, P202, DOI 10.1124/jpet.105.096719; Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9; Muller M, 1998, J EXP MED, V188, P2033, DOI 10.1084/jem.188.11.2033; MUNGER K, 1992, CANCER SURV, V12, P197; NEVINS JR, 1992, SCIENCE, V258, P424; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Parkin DM, 2001, EUR J CANCER, V37, pS4, DOI 10.1016/S0959-8049(01)00267-2; Putral LN, 2005, MOL PHARMACOL, V68, P1311, DOI 10.1124/mol.105.014191; Queiroz C, 2006, PATHOL RES PRACT, V202, P77, DOI 10.1016/j.prp.2005.08.012; Sano T, 1998, AM J PATHOL, V153, P1741, DOI 10.1016/S0002-9440(10)65689-1; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; Shapiro GI, 1998, MOL CELL BIOL, V18, P378, DOI 10.1128/MCB.18.1.378; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; SLEBOS RJC, 1994, P NATL ACAD SCI USA, V91, P5320, DOI 10.1073/pnas.91.12.5320; SMOTKIN D, 1986, P NATL ACAD SCI USA, V83, P4680, DOI 10.1073/pnas.83.13.4680; Walboomers JMM, 1999, J PATHOL, V189, P12, DOI 10.1002/(SICI)1096-9896(199909)189:1&lt;12::AID-PATH431&gt;3.0.CO;2-F; Yamamoto A, 2003, INT J CANCER, V106, P301, DOI 10.1002/ijc.11219; Zhang JM, 2006, CANCER RES, V66, P10325, DOI 10.1158/0008-5472.CAN-06-1594; zur Hausen H, 2002, NAT REV CANCER, V2, P342, DOI 10.1038/nrc798; zurHausen H, 1996, BBA-REV CANCER, V1288, pF55	43	17	18	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2007	26	41					6050	6060		10.1038/sj.onc.1210405	http://dx.doi.org/10.1038/sj.onc.1210405			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	207US	17369842				2022-12-28	WOS:000249277200008
J	Jie, X; Lang, C; Jian, Q; Chaoqun, L; Dehua, Y; Yu, S; Yanping, J; Luokun, X; Qiuping, Z; Hui, W; Feili, G; Boquan, J; Youxin, J; Jinquan, T				Jie, X.; Lang, C.; Jian, Q.; Chaoqun, L.; Dehua, Y.; Yu, S.; Yanping, J.; Luokun, X.; Qiuping, Z.; Hui, W.; Feili, G.; Boquan, J.; Youxin, J.; Jinquan, T.			RETRACTED: Androgen activates PEG10 to promote carcinogenesis in hepatic cancer cells (Retracted article. See vol. 30, pg. 2798, 2011)	ONCOGENE			English	Article; Retracted Publication						hepatocellular carcinoma; androgen; androgen; receptor; PEG10; apoptosis	HEPATOCELLULAR-CARCINOMA; IMPRINTED GENE; APOPTOSIS; EXPRESSION; INTERACTS; RECEPTOR; PROTEIN; RETROTRANSPOSON	The molecular mechanism of striking higher prevalence of hepatocellular carcinoma (HCC) in male subjects has not yet been fully elucidated. Here, we report that androgen receptor (AR) is differentially expressed in different HCC cell lines. AR agonist dihydrotestosterone (DHT) enhances HCC cell growth and apoptotic resistance. Antagonist flutamide (FLU) blocks the effects of DHT on the HCC cell lines. Paternally expressed gene 10 (PEGI10) is expressed in HCC cell lines at substantial high level. Using small interfering RNAs against AR and PEG10 in AR- and PEG10-expressing BEL-7404 hepatoma cells and HuH7 hepatoma cells (HuH7) cells, and AR-transfection technique in AR-lacking and PEG10-expressing HepG2 cells, we have confirmed that through upregulation and activation of PEG10, DHT enhances HCC cell growth and apoptotic resistance. We have further demonstrated that DHT upregulates expression of human telomerase reverse transcriptase (hTERT) in HCC cell lines in a PEG10-dependent manner. Moreover, AR directly interacts in vivo with androgen-responsive elements in the regions of promoter and exon 2 of PEG10 gene in HCC cell lines. DHT promotes the hepatoma formation in viro nude mice through PEG10 activation. AR antagonists (FLU and valproate) inhibit the hepatoma formation. These findings suggest that PEG10 plays an essential role in hepatocarcinogenesis. The PEG10 inhibition can be a novel approach for therapy of HCC.	Wuhan Univ, Sch Med, Dept Immunol, Wuhan 430071, Hubei, Peoples R China; Wuhan Univ, Sch Med, Inst Allergy & Immune Related Dis, Lab Allergy & Clin Immunol, Wuhan 430072, Peoples R China; Wuhan Univ, Sch Med, Med Res Ctr, Wuhan 430072, Peoples R China; Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol, State Key Lab Mol Biol, Shanghai, Peoples R China; Shanghai Med Univ 2, Ruijin Hosp, Dept Infect Dis, Shanghai, Peoples R China; S China Normal Univ, Coll Life Sci, Guangzhou, Peoples R China; Wuhan Univ, Sch Med, Dept Pharmacol, Wuhan 430072, Peoples R China; Huazhong Univ Sci & Technol, Tongji Med Coll, Dept Immunol, Wuhan 430074, Peoples R China; Fourth Mil Med Univ, Dept Immunol, Xian 710032, Peoples R China	Wuhan University; Wuhan University; Wuhan University; Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Shanghai Jiao Tong University; South China Normal University; Wuhan University; Huazhong University of Science & Technology; Air Force Military Medical University	Jinquan, T (corresponding author), Wuhan Univ, Sch Med, Dept Immunol, Dong Hu Rd 115, Wuhan 430071, Hubei, Peoples R China.	jinquan_tan@hotmail.com						Death AK, 2005, STEROIDS, V70, P946, DOI 10.1016/j.steroids.2005.07.003; Greider CW, 1999, TRENDS GENET, V15, P109, DOI 10.1016/S0168-9525(98)01681-3; Hu CS, 2006, J IMMUNOL, V177, P6713, DOI 10.4049/jimmunol.177.10.6713; Huang RM, 2003, CANCER RES, V63, P3775; Kim DH, 2005, NAT BIOTECHNOL, V23, P222, DOI 10.1038/nbt1051; Komine F, 2000, J HEPATOL, V32, P235, DOI 10.1016/S0168-8278(00)80068-9; Li CM, 2006, CANCER RES, V66, P665, DOI 10.1158/0008-5472.CAN-05-1553; Lu ML, 2001, J BIOL CHEM, V276, P13442, DOI 10.1074/jbc.M006598200; Massari P, 2000, P NATL ACAD SCI USA, V97, P9070, DOI 10.1073/pnas.97.16.9070; NAGASUE N, 1995, BRIT J SURG, V82, P542, DOI 10.1002/bjs.1800820435; Okabe H, 2001, CANCER RES, V61, P2129; Okabe H, 2003, CANCER RES, V63, P3043; Ono R, 2006, NAT GENET, V38, P101, DOI 10.1038/ng1699; Ono R, 2001, GENOMICS, V73, P232, DOI 10.1006/geno.2001.6494; Ramirez R, 2003, J BIOL CHEM, V278, P836, DOI 10.1074/jbc.M206818200; Rokhlin OW, 2005, ONCOGENE, V24, P6773, DOI 10.1038/sj.onc.1208833; Sathya G, 2003, CANCER RES, V63, P8029; Shammas MA, 2005, MOL CANCER, V4, DOI 10.1186/1476-4598-4-24; Sica A, 1997, J EXP MED, V185, P969, DOI 10.1084/jem.185.5.969; Steplewski A, 1998, BIOCHEM BIOPH RES CO, V243, P295, DOI 10.1006/bbrc.1997.7821; Tan JQ, 2003, J IMMUNOL, V171, P1722, DOI 10.4049/jimmunol.171.4.1722; Tsou AP, 2003, J BIOMED SCI, V10, P625, DOI 10.1159/000073528; Youssef N, 2001, J PATHOL, V194, P459, DOI 10.1002/path.901; Yu MW, 2001, J NATL CANCER I, V93, P1644, DOI 10.1093/jnci/93.21.1644; Zhang DY, 2004, HEPATOLOGY, V39, P954, DOI 10.1002/hep.20135; Zhang YX, 2005, P NATL ACAD SCI USA, V102, P9890, DOI 10.1073/pnas.0503829102	26	34	38	0	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2007	26	39					5741	5751		10.1038/sj.onc.1210362	http://dx.doi.org/10.1038/sj.onc.1210362			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	202EP	17369855				2022-12-28	WOS:000248885100006
J	Wu, YH; Chang, JHT; Cheng, YW; Wu, TC; Chen, CY; Lee, H				Wu, Y-H; Chang, J-H Tsai; Cheng, Y-W; Wu, T-C; Chen, C-Y; Lee, H.			Xeroderma pigmentosum group C gene expression is predominantly regulated by promoter hypermethylation and contributes to p53 mutation in lung cancers	ONCOGENE			English	Article						xeroderma pigmentosum group C (XPC); promoter methylation; p53 mutation; non-small cell; lung cancer	NUCLEOTIDE EXCISION-REPAIR; DNA-REPAIR; HEPATOCELLULAR-CARCINOMA; O-6-METHYLGUANINE-DNA METHYLTRANSFERASE; MUTANT MICE; TOBACCO-SMOKE; DAMAGED DNA; CPG ISLANDS; GROUP-A; XPC	Reduced DNA repair capability is associated with developing lung cancer, especially in nonsmokers. XPC participates in the initial recognition of DNA damage during the DNA nucleotide excision repair process. We hypothesize that inactivation of XPC by promoter hypermethylation may play an important role in the reduction of DNA repair capability to cause p53 mutation during lung carcinogenesis. In this report we demonstrate that hypermethylation of 17 CpG islands between - 175 and - 1 of the XPC promoter correlates very well with XPC expression levels in eight lung cancer cell lines. When cells with hypermethylated XPC promoters were treated with the demethylating agent 5-aza-20-deoxycytidine, XPC expression was de-repressed. Interestingly, XPC hypermethylation was found in 4 of 5 (80%) lung cancer cell lines harbored p53 mutation, but not observed in two lung cancer cells which had a wild- type p53 gene. Among the analysis of the hypermethylation status of 158 lung tumors, XPC hypermethylation is more common in nonsmokers (39 of 94, 41%) than in smokers (14 of 64, 22%; P = 0.010). Additionally, XPC hypermethylation is more often with G -> T or G -> C mutations in the p53 gene. To verify whether XPC inactivation is involved in the occurrence of p53 mutation, XPC gene of A549 cells was knockdown by a small interference RNA and then XPC-inactivated cells were treated with benzo[a] pynrene for different passages. Surprisingly, G-T mutation in p53 gene at codon 215 was indeed detected in XPC-inactivated A549 cells of passages 15 and confirmed by loss of transcription activity of mdm2. These results show that hypermethylation of the XPC promoter may play a crucial role in XPC inactivation, which may partly contribute to the occurrence of p53 mutations during lung tumorigenesis, especially nonsmokers.	Chung Shan Med Univ, Inst Med & Mol Toxicol, Lung Canc Res Ctr, Taichung, Taiwan; Chung Shan Med Univ, Inst Med, Taichung, Taiwan; Chung Shan Med Univ, Dept Internal Med, Taichung, Taiwan; Chung Shan Med Univ, Lung Canc Res Ctr, Taichung, Taiwan; China Med Univ, Dept Thorac Surg, Taichung, Taiwan	Chung Shan Medical University; Chung Shan Medical University; Chung Shan Medical University; Chung Shan Medical University; China Medical University Taiwan	Lee, H (corresponding author), Chung Shan Med Univ, Inst Med & Mol Toxicol, Lung Canc Res Ctr, 110,Sec 1,Chien Kuo N Rd, Taichung, Taiwan.	hl@csmu.edu.tw	Lee, Huei/B-2664-2010					Adimoolam S, 2002, P NATL ACAD SCI USA, V99, P12985, DOI 10.1073/pnas.202485699; ALAIN S, 2001, CANCER RES, V61, P2480; Azzam EI, 2002, J INVEST DERMATOL, V119, P1350, DOI 10.1046/j.1523-1747.2002.19628.x; Bosken CH, 2002, JNCI-J NATL CANCER I, V94, P1091; Chang JT, 2004, ANAL BIOCHEM, V334, P199, DOI 10.1016/j.ab.2004.07.018; Chang MY, 2005, CANCER LETT, V222, P195, DOI 10.1016/j.canlet.2004.11.020; Cheo DL, 1999, CANCER RES, V59, P771; Emmert S, 2000, P NATL ACAD SCI USA, V97, P2151, DOI 10.1073/pnas.040559697; Esteller M, 2000, CANCER RES, V60, P2368; Friedberg EC, 2001, NAT REV CANCER, V1, P22, DOI 10.1038/35094000; Gao WM, 2003, LUNG CANCER-J IASLC, V40, P141, DOI 10.1016/S0169-5002(03)00035-7; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Hollander MC, 2005, P NATL ACAD SCI USA, V102, P13200, DOI 10.1073/pnas.0503133102; Hu ZB, 2005, INT J CANCER, V115, P478, DOI 10.1002/ijc.20911; Inga A, 2002, ONCOGENE, V21, P5704, DOI 10.1038/sj.onc.1205779; Janicijevic A, 2003, DNA REPAIR, V2, P325, DOI 10.1016/S1568-7864(02)00222-7; Kang MS, 1996, INT J CANCER, V67, P898, DOI 10.1002/(SICI)1097-0215(19960917)67:6<898::AID-IJC22>3.0.CO;2-X; Kim DH, 2001, CANCER RES, V61, P3419; Ko JL, 2002, DNA REPAIR, V1, P755, DOI 10.1016/S1568-7864(02)00094-0; Ko JL, 2000, INT J CANCER, V89, P265, DOI 10.1002/1097-0215(20000520)89:3<265::AID-IJC9>3.0.CO;2-N; Le Calvez F, 2005, CANCER RES, V65, P5076, DOI 10.1158/0008-5472.CAN-05-0551; Marin MS, 2004, CANCER EPIDEM BIOMAR, V13, P1788; Marsit CJ, 2006, CARCINOGENESIS, V27, P112, DOI 10.1093/carcin/bgi172; Matsukura S, 2003, BRIT J CANCER, V88, P521, DOI 10.1038/sj.bjc.6600743; Mellon I, 2002, DNA REPAIR, V1, P531, DOI 10.1016/S1568-7864(02)00053-8; Nahari D, 2004, DNA REPAIR, V3, P379, DOI 10.1016/j.dnarep.2003.03.001; Neumann AS, 2005, MOL CARCINOGEN, V42, P65, DOI 10.1002/mc.20069; Nutt CL, 1999, CARCINOGENESIS, V20, P2361, DOI 10.1093/carcin/20.12.2361; Park JY, 2002, CANCER EPIDEM BIOMAR, V11, P993; Pavanello S, 2005, CARCINOGENESIS, V26, P169, DOI 10.1093/carcin/bgh303; Piao CQ, 1999, CARCINOGENESIS, V20, P1529, DOI 10.1093/carcin/20.8.1529; Pulling LC, 2004, CANCER RES, V64, P3844, DOI 10.1158/0008-5472.CAN-03-2119; Reis AM, 2000, CANCER RES, V60, P1571; Riedl T, 2003, EMBO J, V22, P5293, DOI 10.1093/emboj/cdg489; RYK C, 2006, CANC LETT, V8, P142; SANDS AT, 1995, NATURE, V377, P162, DOI 10.1038/377162a0; Schagdarsurengin U, 2003, ONCOGENE, V22, P1866, DOI 10.1038/sj.onc.1206338; Shen HB, 2003, INT J CANCER, V107, P84, DOI 10.1002/ijc.11346; Soria JC, 2002, CANCER RES, V62, P351; Srivenugopal KS, 2001, CLIN CANCER RES, V7, P1398; Suk R, 2005, CLIN CANCER RES, V11, P1534, DOI 10.1158/1078-0432.CCR-04-1953; Tapias A, 2004, J BIOL CHEM, V279, P19074, DOI 10.1074/jbc.M312611200; Toyooka S, 2003, INT J CANCER, V103, P153, DOI 10.1002/ijc.10787; Toyooka S, 2003, HUM MUTAT, V21, P229, DOI 10.1002/humu.10177; Vodicka P, 2004, ENVIRON MOL MUTAGEN, V44, P283, DOI 10.1002/em.20055; Wei QY, 2000, J NATL CANCER I, V92, P1764; Wolf P, 2001, CANCER RES, V61, P8113; Wu MF, 2005, INT J CANCER, V113, P440, DOI 10.1002/ijc.20597; Zhang YJ, 2003, INT J CANCER, V103, P440, DOI 10.1002/ijc.10852	49	41	41	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 19	2007	26	33					4761	4773		10.1038/sj.onc.1210284	http://dx.doi.org/10.1038/sj.onc.1210284			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	191ZL	17325666				2022-12-28	WOS:000248170400002
J	Kang, Y; Hong, JA; Chen, GA; Nguyen, DM; Schrump, DS				Kang, Y.; Hong, J. A.; Chen, G. A.; Nguyen, D. M.; Schrump, D. S.			Dynamic transcriptional regulatory complexes including BORIS, CTCF and Sp1 modulate NY-ESO-1 expression in lung cancer cells	ONCOGENE			English	Article						lung cancer; epigenetics; NY-ESO-1; BORIS; CTCF; Sp1	GC-RICH DNA; GENE-TRANSCRIPTION; BINDING; FAMILY; IDENTIFICATION; DEREPRESSION; EPIGENETICS; ANTIGEN; DOMAIN; P300	Previously, we reported that the paralogous zinc-finger proteins-CTCF and brother of the regulator of imprinted sites (BORIS), directly contribute to transcriptional regulation of NY-ESO-1 in lung cancer cells. To further examine mechanisms that mediate expression of this cancer-testis gene, we performed software-guided analysis of the NY-ESO-1 promoter region, which revealed several potential Sp1- binding motifs. Sequential 5-aza-2 ' deoxycytidine/ depsipeptide FK228 treatment markedly induced BORIS expression and enhanced nuclear translocation of Sp1 in lung cancer cells. Transient transfection assays using promoter-reporter constructs, as well as gel-shift and chromatin immunoprecipitation experiments revealed that NY-ESO-1 promoter activity coincided with occupancy of the proximal Spi-binding site in lung cancer cells. Mutations within the Sp1 recognition sequence specifi. cally eliminated binding of Sp1 to this motif in vitro, and markedly diminished NY-ESO-1 promoter activity in vivo. siRNA-mediated inhibition of Sp1 expression decreased NY-ESO-1 promoter activity, whereas knock down of CTCF expression augmented NY-ESO-1 transcription in lung cancer cells. Co-immunoprecipitation experiments indicated that Sp1 physically interacts with BORIS but not with CTCF in vivo. Collectively, these. findings suggest that BORIS recruits Sp1 to mediate de-repression of NY-ESO-1 during pulmonary carcinogenesis.	NCI, Ctr Canc Res, Surg Branch, Thorac Oncol Sect, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Schrump, DS (corresponding author), NCI, Ctr Canc Res, Surg Branch, Thorac Oncol Sect, Bldg 10,Rm 4-3942,10 Ctr Dr, Bethesda, MD 20892 USA.	David_Schrump@nih.gov			NATIONAL CANCER INSTITUTE [ZIASC010093, Z01BC010519, Z01SC010093] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Albertini V, 2006, NUCLEIC ACIDS RES, V34, P1721, DOI 10.1093/nar/gkl063; DePlaen E, 1997, GENOMICS, V40, P305, DOI 10.1006/geno.1996.4566; Gnjatic S, 2006, ADV CANCER RES, V95, P1, DOI 10.1016/S0065-230X(06)95001-5; Hong JA, 2005, CANCER RES, V65, P7763, DOI 10.1158/0008-5472.CAN-05-0823; Hosoi Y, 2004, INT J ONCOL, V25, P461; Huang WQ, 2005, J BIOL CHEM, V280, P10047, DOI 10.1074/jbc.M408680200; Hung JJ, 2006, MOL CELL BIOL, V26, P1770, DOI 10.1128/MCB.26.5.1770-1785.2006; Husmann M, 2000, BIOCHEM J, V352, P763, DOI 10.1042/0264-6021:3520763; James SR, 2006, ONCOGENE, V25, P6975, DOI 10.1038/sj.onc.1209678; Klenova EA, 2002, SEMIN CANCER BIOL, V12, P399, DOI 10.1016/S1044-579X(02)00060-3; Loukinov DI, 2002, P NATL ACAD SCI USA, V99, P6806, DOI 10.1073/pnas.092123699; Nguyen DM, 2004, CLIN CANCER RES, V10, P1813, DOI 10.1158/1078-0432.CCR-0901-3; Ohlsson R, 2001, TRENDS GENET, V17, P520, DOI 10.1016/S0168-9525(01)02366-6; Persengiev SP, 1996, ENDOCRINOLOGY, V137, P638, DOI 10.1210/en.137.2.638; Pore N, 2004, MOL BIOL CELL, V15, P4841, DOI 10.1091/mbc.E04-05-0374; Ryu H, 2003, P NATL ACAD SCI USA, V100, P4281, DOI 10.1073/pnas.0737363100; Safe S, 2005, EUR J CANCER, V41, P2438, DOI 10.1016/j.ejca.2005.08.006; Schrump DS, 2005, SEMIN ONCOL, V32, P488, DOI 10.1053/j.seminoncol.2005.07.007; Scott GK, 2006, CANCER RES, V66, P1277, DOI 10.1158/0008-5472.CAN-05-3632; Simpson AJG, 2005, NAT REV CANCER, V5, P615, DOI 10.1038/nrc1669; Suske G, 1999, GENE, V238, P291, DOI 10.1016/S0378-1119(99)00357-1; Suzuki T, 2000, GENES CELLS, V5, P29, DOI 10.1046/j.1365-2443.2000.00302.x; Thomas K, 2005, BIOL REPROD, V72, P898, DOI 10.1095/biolreprod.104.030528; Vatolin S, 2005, CANCER RES, V65, P7751, DOI 10.1158/0008-5472.CAN-05-0858; Yao JC, 2004, CLIN CANCER RES, V10, P4109, DOI 10.1158/1078-0432.CCR-03-0628; Zendman AJW, 2003, J CELL PHYSIOL, V194, P272, DOI 10.1002/jcp.10215; Zhang Y, 2005, MOL CELL BIOL, V25, P7929, DOI 10.1128/MCB.25.18.7929-7939.2005	27	54	54	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN	2007	26	30					4394	4403		10.1038/sj.onc.1210218	http://dx.doi.org/10.1038/sj.onc.1210218			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	184CZ	17260018				2022-12-28	WOS:000247620000007
J	Galizia, G; Lieto, E; De Vita, F; Orditura, M; Castellano, P; Troiani, T; Imperatore, V; Ciardiello, F				Galizia, G.; Lieto, E.; De Vita, F.; Orditura, M.; Castellano, P.; Troiani, T.; Imperatore, V.; Ciardiello, F.			Cetuximab, a chimeric human mouse anti-epidermal growth factor receptor monoclonal antibody, in the treatment of human colorectal cancer	ONCOGENE			English	Review						colorectal cancer; EGFR-targeted therapy; monoclonal antibodies; cetuximab; combination therapies	ANTITUMOR-ACTIVITY; G(1) ARREST; PHASE-I; C225; COMBINATION; EXPRESSION; RADIATION; BLOCKADE; THERAPY; IRINOTECAN	The recent successful development of monoclonal antibodies that target key components of biological pathways has expanded the armamentarium of treatment options for patients with colorectal cancer (CRC). In particular, the epidermal growth factor receptor (EGFR), a tyrosine kinase growth factor receptor involved in CRC development and progression, is exploited by the newest monoclonal antibody that is available for use in CRC patients. Cetuximab, the first chimeric monoclonal antibody, which has been generated against the EGFR, is currently registered in USA, Europe and worldwide, in combination with irinotecan in the treatment of metastatic CRC patients who have progressed on irinotecan containing chemotherapy. Cetuximab is well tolerated and does not exacerbate the toxicity of concomitant chemotherapy. Furthermore, a series of phase III clinical trials are currently evaluating the combination of cetuximab with standard chemotherapy regimens in the first-line treatment chemotherapy-naive patients with metastatic CRC.	Univ Naples 2, Sch Med, Policlin 2,F Magrassi A Lanzara,Dept Clin & Expt, Div Surg,PhD Degree Program Med & Surg Oncol & Cl, I-80131 Naples, Italy; Univ Naples 2, Sch Med, F Magrassi A Lanzara Dept Clin & Expt Med & Surg, Div Med Oncol,PhD Degree Program Med & Surg Oncol, Naples, Italy	Universita della Campania Vanvitelli; Universita della Campania Vanvitelli	Galizia, G (corresponding author), Univ Naples 2, Sch Med, Policlin 2,F Magrassi A Lanzara,Dept Clin & Expt, Div Surg,PhD Degree Program Med & Surg Oncol & Cl, Edificio 17,Via Pansini 5, I-80131 Naples, Italy.	gennaro.galizia@unina2.it	Galizia, Gennaro/A-3924-2010	troiani, teresa/0000-0002-0646-4901; GALIZIA, Gennaro/0000-0002-6897-0391; Ciardiello, Fortunato/0000-0002-3369-4841; ORDITURA, Michele/0000-0001-9105-8563				Abubakr Y, 2006, J CLIN ONCOL, V24, p160S; Akimoto T, 1999, CLIN CANCER RES, V5, P2884; Arteaga CL, 2001, J CLIN ONCOL, V19, p32S; BADARINATH SME, 2004, 2004 AM SOC CLIN ONC; Barber TD, 2004, NEW ENGL J MED, V351, P2883, DOI 10.1056/NEJM200412303512724; Baselga J, 2000, J CLIN ONCOL, V18, P904, DOI 10.1200/JCO.2000.18.4.904; Bianco C, 2000, CLIN CANCER RES, V6, P4343; Braun AH, 2004, CANCER-AM CANCER SOC, V100, P1558, DOI 10.1002/cncr.20154; Bruns CJ, 2000, CLIN CANCER RES, V6, P1936; Busam KJ, 2001, BRIT J DERMATOL, V144, P1169, DOI 10.1046/j.1365-2133.2001.04226.x; Ciardiello F, 2000, CLIN CANCER RES, V6, P3739; Ciardiello F, 2001, CLIN CANCER RES, V7, P2958; Ciardiello F, 2002, EXPERT OPIN INV DRUG, V11, P755; Ciardiello F, 1999, CLIN CANCER RES, V5, P909; COHEN RB, 2000, P AM SOC CLIN ONCOL, V19; Cunningham D, 2004, NEW ENGL J MED, V351, P337, DOI 10.1056/NEJMoa033025; DEBALDO C, 2003, EUR J CANC S, V1; Folprecht G, 2006, ANN ONCOL, V17, P450, DOI 10.1093/annonc/mdj084; Galizia G, 2006, ANN SURG ONCOL, V13, P823, DOI 10.1245/ASO.2006.05.052; Grunwald V, 2003, JNCI-J NATL CANCER I, V95, P851, DOI 10.1093/jnci/95.12.851; Herbst RS, 2002, CANCER-AM CANCER SOC, V94, P1593, DOI 10.1002/cncr.10372; HOHLER T, 2004, EUR SOC MED ONC C VI; Hollywood Ellen, 2002, Semin Oncol Nurs, V18, P30, DOI 10.1053/sonu.2002.33070; Huang SM, 2000, CLIN CANCER RES, V6, P2166; Huang SM, 1999, CANCER RES, V59, P1935; Humblet Y, 2004, EXPERT OPIN PHARMACO, V5, P1621, DOI 10.1517/14656566.5.7.1621; Inoue K, 2000, CLIN CANCER RES, V6, P4874; Kim ES, 2001, CURR OPIN ONCOL, V13, P506, DOI 10.1097/00001622-200111000-00014; LEE E, 2004, J CLIN ONCOL, V22, P1177; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; McClelland RA, 2001, ENDOCRINOLOGY, V142, P2776, DOI 10.1210/en.142.7.2776; Mendelsohn J, 2000, CLIN CANCER RES, V6, P747; Mendelsohn J, 2003, J CLIN ONCOL, V21, P2787, DOI 10.1200/JCO.2003.01.504; Mendelsohn J, 2001, ENDOCR-RELAT CANCER, V8, P3, DOI 10.1677/erc.0.0080003; Milas L, 2000, CLIN CANCER RES, V6, P701; Olayioye MA, 2000, EMBO J, V19, P3159, DOI 10.1093/emboj/19.13.3159; Peng D, 1996, CANCER RES, V56, P3666; Perrotte P, 1999, CLIN CANCER RES, V5, P257; Prewett MC, 2002, CLIN CANCER RES, V8, P994; Robert F, 2001, J CLIN ONCOL, V19, P3234, DOI 10.1200/JCO.2001.19.13.3234; ROSEMBERG AH, 2002, P AM SOC CLIN ONCOL; Saleh MN, 1999, CANCER BIOTHER RADIO, V14, P451, DOI 10.1089/cbr.1999.14.451; SALOMON DS, 1995, CRIT REV ONCOL HEMAT, V19, P183, DOI 10.1016/1040-8428(94)00144-I; SALOMON DS, 2001, SIGNAL, V2, P4; SALTZ L, 2005, AM SOC CLIN ONC GAST; SALTZ L, 2003, P AM SOC CLIN ONCOL, V22; Saltz L., 2001, P AM SOC CLIN ONCOL, V20, p3a; Saltz LB, 2004, J CLIN ONCOL, V22, P1201, DOI 10.1200/JCO.2004.10.182; Wosikowski K, 1997, CLIN CANCER RES, V3, P2405; Wu XP, 1996, ONCOGENE, V12, P1397; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073	51	113	119	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2007	26	25					3654	3660		10.1038/sj.onc.1210381	http://dx.doi.org/10.1038/sj.onc.1210381			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	172PK	17530019	Bronze			2022-12-28	WOS:000246816100008
J	Ma, Y; Cress, WD				Ma, Y.; Cress, W. D.			Transcriptional upregulation of p57 (Kip2) by the cyclin-dependent kinase inhibitor BMS-387032 is E2F dependent and serves as a negative feedback loop limiting cytotoxicity	ONCOGENE			English	Article						CDK; CDKN1C; E2F; BMS-387032; SNS-032; apoptosis	FLAVOPIRIDOL-INDUCED APOPTOSIS; S-PHASE; POTENTIAL MEDIATOR; GENE-EXPRESSION; P57(KIP2); ACTIVATION; PROMOTER; PROTEIN; CELLS; P21(WAF1/CIP1)	In spite of the fact that cyclin-dependent kinase (cdk) inhibiting drugs are potent transcriptional repressors, we discover that p57 (Kip2, CDKN1C) transcription is significantly upregulated by three small molecule cdk inhibitors, including BMS-387032. Treatment of MDAMB231 breast cancer cells with BMS-387032 led to a stabilization of the E2F1 protein that was accompanied by significant increases in the p57 mRNA and protein. This increase did not occur in an E2F1-deficient cell line. An E2F1-estrogen receptor fusion protein activated the endogenous p57 promoter in response to hydroxytamoxifen treatment in the presence of cycloheximide. Luciferase constructs driven by the p57 promoter verified that upregulation of p57 mRNA byBMS-38 7032 is transcriptional and dependent on E2F-binding sites in the promoter. Expression of exogenous p57 significantly decreased the fraction of cells in S phase. Furthermore, p57-deficient MDA-MB-231 cell lines were significantly more sensitive to BMS-387032-induced apoptosis than controls. The results presented in this manuscript demonstrate that small molecule cdk inhibitors transcriptionally activate p57 dependent upon E2F1 and that this activation in turn serves to limit E2F1's death-inducing activity.	Univ S Florida, Coll Med, H Lee Moffit Canc Ctr & Res Inst, Mol Oncol Program, Tampa, FL 33612 USA	State University System of Florida; University of South Florida	Cress, WD (corresponding author), Univ S Florida, Coll Med, H Lee Moffit Canc Ctr & Res Inst, Mol Oncol Program, 12902 Magnolia Dr, Tampa, FL 33612 USA.	cressd@moffitt.usf.edu			NCI NIH HHS [R01 CA090489-05, CA90489-01, R01 CA090489-04, R01 CA090489] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA090489] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Afshari CA, 1996, CELL GROWTH DIFFER, V7, P979; Alheim K, 2003, J MOL ENDOCRINOL, V30, P359, DOI 10.1677/jme.0.0300359; Balint E, 2002, P NATL ACAD SCI USA, V99, P3529, DOI 10.1073/pnas.062491899; Brideau AD, 1998, J VIROL, V72, P4560, DOI 10.1128/JVI.72.6.4560-4570.1998; CRESS WD, 1993, MOL CELL BIOL, V13, P6314, DOI 10.1128/MCB.13.10.6314; CRESS WD, 1994, J VIROL, V68, P4212, DOI 10.1128/JVI.68.7.4213-4219.1994; Delavaine L, 1999, ONCOGENE, V18, P5381, DOI 10.1038/sj.onc.1202923; Devgan V, 2005, GENE DEV, V19, P1485, DOI 10.1101/gad.341405; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Gartel AL, 1998, ONCOGENE, V17, P3463, DOI 10.1038/sj.onc.1202240; Gartel AL, 2000, ONCOGENE, V19, P961, DOI 10.1038/sj.onc.1203411; Geng Y, 2003, CELL, V114, P431, DOI 10.1016/S0092-8674(03)00645-7; Gonzalez S, 2005, CANCER RES, V65, P2186, DOI 10.1158/0008-5472.CAN-04-3047; HARPER JW, 1993, CELL, V75, P805; Hiyama H, 1997, ONCOGENE, V14, P2533, DOI 10.1038/sj.onc.1201080; Irwin M, 2000, NATURE, V407, P645, DOI 10.1038/35036614; Ishida S, 2001, MOL CELL BIOL, V21, P4684, DOI 10.1128/MCB.21.14.4684-4699.2001; Jackson JF, 2002, MOLEC METH PLAN ANAL, V21, P1; Jackson RJ, 2003, CANCER RES, V63, P3021; Jiang J, 2003, CANCER RES, V63, P7410; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; JOHNSON DG, 1995, ONCOGENE, V11, P1685; Kalejta RF, 1999, EXP CELL RES, V248, P322, DOI 10.1006/excr.1999.4427; KOVESDI I, 1987, P NATL ACAD SCI USA, V84, P2180, DOI 10.1073/pnas.84.8.2180; Lam LT, 2001, GENOME BIOL, V2; LEE MH, 1995, GENE DEV, V9, P639, DOI 10.1101/gad.9.6.639; Lu X, 2004, MOL CANCER THER, V3, P861; Ma YH, 2004, CANCER BIOL THER, V3, P1262, DOI 10.4161/cbt.3.12.1239; Ma YH, 2002, ARCH BIOCHEM BIOPHYS, V399, P212, DOI 10.1006/abbi.2002.2761; Ma YH, 2003, J BIOL CHEM, V278, P16770, DOI 10.1074/jbc.M212702200; Ma YH, 2003, MOL CANCER THER, V2, P73; Matranga CB, 2002, CANCER RES, V62, P1707; MATSUOKA S, 1995, GENE DEV, V9, P650, DOI 10.1101/gad.9.6.650; Merlo P, 2005, J BIOL CHEM, V280, P30354, DOI 10.1074/jbc.M500635200; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; Nevins JR, 2001, HUM MOL GENET, V10, P699, DOI 10.1093/hmg/10.7.699; Ortega S, 2003, NAT GENET, V35, P25, DOI 10.1038/ng1232; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; Samuelsson MKR, 2002, BIOCHEM BIOPH RES CO, V296, P702, DOI 10.1016/S0006-291X(02)00912-9; SCHULZE A, 1995, P NATL ACAD SCI USA, V92, P11264, DOI 10.1073/pnas.92.24.11264; SHAN B, 1994, MOL CELL BIOL, V14, P299, DOI 10.1128/MCB.14.1.299; Shapiro GI, 2006, J CLIN ONCOL, V24, P1770, DOI 10.1200/JCO.2005.03.7689; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Stewart MC, 2004, J BONE MINER RES, V19, P123, DOI 10.1359/JBMR.0301209; Stiewe T, 2000, NAT GENET, V26, P464, DOI 10.1038/82617; Tetsu O, 2003, CANCER CELL, V3, P233, DOI 10.1016/S1535-6108(03)00053-9; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Vigo E, 1999, MOL CELL BIOL, V19, P6379; Wang CG, 2005, J BIOL CHEM, V280, P12339, DOI 10.1074/jbc.C400536200; ZHU LG, 1995, MOL CELL BIOL, V15, P3552	50	25	27	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2007	26	24					3532	3540		10.1038/sj.onc.1210143	http://dx.doi.org/10.1038/sj.onc.1210143			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	172JC	17173074	Green Accepted			2022-12-28	WOS:000246799200009
J	Deppert, W				Deppert, W.			Introduction - Mutant p53: from guardian to fallen angel?	ONCOGENE			English	Editorial Material							MUTATIONS; COMPLEX; GAIN		Tumor Virol, Heinrich Pette Inst Expt Virol & Immunol, D-20251 Hamburg, Germany	Heinrich Pette Institute	Deppert, W (corresponding author), Tumor Virol, Heinrich Pette Inst Expt Virol & Immunol, Martinistr 52, D-20251 Hamburg, Germany.	wolfgang.deppert@hpi.uni-hamburg.de						Di Agostino S, 2006, CANCER CELL, V10, P191, DOI 10.1016/j.ccr.2006.08.013; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; HALEVY O, 1990, SCIENCE, V250, P113, DOI 10.1126/science.2218501; Kim E, 2004, J CELL BIOCHEM, V93, P878, DOI 10.1002/jcb.20271	5	9	9	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 2	2007	26	15					2142	2144		10.1038/sj.onc.1210276	http://dx.doi.org/10.1038/sj.onc.1210276			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	152XE	17401422				2022-12-28	WOS:000245394800002
J	Hunter, T; Simon, J				Hunter, T.; Simon, J.			A not so brief history of the Oncogene Meeting and its Cartoons	ONCOGENE			English	Article									Salk Inst Biol Studies, La Jolla, CA 92037 USA	Salk Institute	Hunter, T (corresponding author), Salk Inst Biol Studies, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.	hunter@salk.edu							0	2	2	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 26	2007	26	9					1260	1267		10.1038/sj.onc.1210262	http://dx.doi.org/10.1038/sj.onc.1210262			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	141DU	17322910				2022-12-28	WOS:000244558700002
J	Zhou, H; Hou, Q; Hansen, JL; Hsu, YT				Zhou, H.; Hou, Q.; Hansen, J. L.; Hsu, Y-T			Complete activation of Bax by a single site mutation	ONCOGENE			English	Article						bax; mitochondria; apoptosis; Bcl-X-L	CYTOCHROME-C RELEASE; MITOCHONDRIAL-MEMBRANE; BH3-ONLY PROTEINS; CELL-SURVIVAL; APOPTOSIS; BCL-2; OLIGOMERIZATION; DIMERIZATION; DOMAIN; TRANSLOCATION	Bax translocation from the cytosol to mitochondria culminates a key step by which this protein mediates cell death. Here, we identified two amino acids, L70 and D71, within the BH3 domain of Bax that play a critical role in regulating Bax's cytosolic vs mitochondrial distribution. Individual substitution of these amino acids with alanine resulted in Bax conformational change, oligomerization, localization to mitochondria and cell death. Further mutational analysis indicated that L70 interacts with T174, V177 and A178 of Bax's C-terminal hydrophobic segment, while the negative charge of D71 is required for maintaining Bax in its soluble monomeric state. In summary, we have identified a new regulatory site that controls Bax's subcellular distribution and activation.	Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA; Peking Union Med Coll, Dept Pharmacol, Inst Mat Med, Beijing, Peoples R China; Chinese Acad Med Sci, Beijing 100037, Peoples R China	Medical University of South Carolina; Chinese Academy of Medical Sciences - Peking Union Medical College; Institute of Materia Medica - CAMS; Peking Union Medical College; Chinese Academy of Medical Sciences - Peking Union Medical College	Hsu, YT (corresponding author), Med Univ S Carolina, Dept Biochem & Mol Biol, 173 Ashley Ave,POB 250509, Charleston, SC 29425 USA.	hsuy@musc.edu			NATIONAL CENTER FOR RESEARCH RESOURCES [C06RR015455] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS040932] Funding Source: NIH RePORTER; NCRR NIH HHS [COG RR01 5455] Funding Source: Medline; NINDS NIH HHS [R01 NS40932] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; BOWIE JU, 1991, SCIENCE, V253, P164, DOI 10.1126/science.1853201; Cartron PF, 2003, J BIOL CHEM, V278, P11633, DOI 10.1074/jbc.M208955200; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; Finucane DM, 1999, J BIOL CHEM, V274, P2225, DOI 10.1074/jbc.274.4.2225; Goping IS, 1998, J CELL BIOL, V143, P207, DOI 10.1083/jcb.143.1.207; Gross A, 1998, EMBO J, V17, P3878, DOI 10.1093/emboj/17.14.3878; Hsu YT, 1997, P NATL ACAD SCI USA, V94, P3668, DOI 10.1073/pnas.94.8.3668; Hsu YT, 1997, J BIOL CHEM, V272, P13829, DOI 10.1074/jbc.272.21.13829; Hsu YT, 1998, J BIOL CHEM, V273, P10777, DOI 10.1074/jbc.273.17.10777; Kuwana T, 2005, MOL CELL, V17, P525, DOI 10.1016/j.molcel.2005.02.003; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Manon S, 1997, FEBS LETT, V415, P29, DOI 10.1016/S0014-5793(97)01087-9; Mateu MG, 1999, P NATL ACAD SCI USA, V96, P3595, DOI 10.1073/pnas.96.7.3595; Meijerink JPP, 1998, BLOOD, V91, P2991, DOI 10.1182/blood.V91.8.2991.2991_2991_2997; Mikhailov V, 2001, J BIOL CHEM, V276, P18361, DOI 10.1074/jbc.M100655200; Nechushtan A, 1999, EMBO J, V18, P2330, DOI 10.1093/emboj/18.9.2330; Nechushtan A, 2001, J CELL BIOL, V153, P1265, DOI 10.1083/jcb.153.6.1265; OLTVAI ZN, 1993, CELL, V74, P619; Pagliari LJ, 2005, P NATL ACAD SCI USA, V102, P17975, DOI 10.1073/pnas.0506712102; Rampino N, 1997, SCIENCE, V275, P967, DOI 10.1126/science.275.5302.967; Rosse T, 1998, NATURE, V391, P496, DOI 10.1038/35160; Smaili SS, 2001, CELL DEATH DIFFER, V8, P909, DOI 10.1038/sj.cdd.4400889; Suzuki M, 2000, CELL, V103, P645, DOI 10.1016/S0092-8674(00)00167-7; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Wang K, 1998, MOL CELL BIOL, V18, P6083, DOI 10.1128/MCB.18.10.6083; Willis SN, 2005, GENE DEV, V19, P1294, DOI 10.1101/gad.1304105; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; Zha HB, 1996, J BIOL CHEM, V271, P7440, DOI 10.1074/jbc.271.13.7440	31	17	17	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 1	2007	26	50					7092	7102		10.1038/sj.onc.1210517	http://dx.doi.org/10.1038/sj.onc.1210517			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	228GF	17486058				2022-12-28	WOS:000250715000003
J	Dairkee, SH; Nicolau, M; Sayeed, A; Champion, S; Ji, Y; Moore, DH; Yong, B; Meng, Z; Jeffrey, SS				Dairkee, S. H.; Nicolau, M.; Sayeed, A.; Champion, S.; Ji, Y.; Moore, D. H.; Yong, B.; Meng, Z.; Jeffrey, S. S.			Oxidative stress pathways highlighted in tumor cell immortalization: association with breast cancer outcome	ONCOGENE			English	Article						primary tumor culture; telomerase ( hTERT); gene expression	GENE-EXPRESSION SIGNATURE; LENS EPITHELIAL-CELLS; HUMAN FIBROBLASTS; TELOMERASE; GROWTH; HTERT; APOPTOSIS; PATTERNS; RECEPTOR; BINDING	An improved understanding of cell immortalization and its manifestation in clinical tumors could facilitate novel therapeutic approaches. However, only rare tumor cells, which maintain telomerase expression in vitro, immortalize spontaneously. By expression-profiling analyses of limited-life primary breast tumor cultures pre- and post-hTERT transduction, and spontaneously immortalized breast cancer cell lines, we identified a common signature characteristic of tumor cell immortalization. A predominant feature of this immortalization signature ( ImmSig) was the significant overexpression of oxidoreductase genes. In contrast to epithelial cells derived from low histologic grade primary tumors, which required hTERT transduction for the acquisition of ImmSig, spontaneously immortalizing high-grade tumor cultures displayed similar molecular changes independent of exogenous hTERT. Silencing the hTERT gene reversed ImmSig expression, increased cellular reactive oxygen species levels, altered mitochondrial membrane potential and induced apoptotic and proliferation changes in immortalized cells. In clinical breast cancer samples, cell-proliferation-pathway genes were significantly associated with ImmSig. In these cases, ImmSig expression itself was inversely correlated with patient survival ( P = 0), and was particularly relevant to the outcome of estrogen receptor-positive tumors. Our data support the notion that ImmSig assists in surmounting normal barriers related to oxidative and replicative stress response. Targeting a subset of aggressive breast cancers by reversing ImmSig components could be a practical therapeutic strategy.	Calif Pacific Med Ctr, Res Inst, San Francisco, CA 94107 USA; Stanford Univ, Sch Med, Dept Surg, Stanford, CA 94305 USA	California Pacific Medical Center; California Pacific Medical Center Research Institute; Stanford University	Dairkee, SH (corresponding author), Calif Pacific Med Ctr, Res Inst, 475 Brannan St, San Francisco, CA 94107 USA.	dairkes@sutterhealth.org; ssj@stanford.edu	Dairkee, Shanaz Hashmi/D-6743-2012	Jeffrey, Stefanie/0000-0003-4478-2764; Dairkee, Shanaz/0000-0002-2073-9684	NCI NIH HHS [R01 CA109325, U01 CA85129] Funding Source: Medline; NHGRI NIH HHS [K01 HG00030] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U01CA085129, R01CA109325] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [K01HG000030] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		Ben-Porath I, 2005, INT J BIOCHEM CELL B, V37, P961, DOI 10.1016/j.biocel.2004.10.013; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Boyle EI, 2004, BIOINFORMATICS, V20, P3710, DOI 10.1093/bioinformatics/bth456; Chang HY, 2005, P NATL ACAD SCI USA, V102, P3738, DOI 10.1073/pnas.0409462102; Chen QM, 1998, BIOCHEM J, V332, P43, DOI 10.1042/bj3320043; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; DAIRKEE SH, 1995, CANCER RES, V55, P2516; Dairkee SH, 2004, BMC GENOMICS, V5, DOI 10.1186/1471-2164-5-47; Dairkee SH, 1997, CANCER RES, V57, P1590; Dudognon C, 2004, ONCOGENE, V23, P7469, DOI 10.1038/sj.onc.1208029; Elkak A E, 2005, J Carcinog, V4, P17, DOI 10.1186/1477-3163-4-17; Kurz DJ, 2004, J CELL SCI, V117, P2417, DOI 10.1242/jcs.01097; Li Z, 1998, CANCER RES, V58, P5271; Liang XS, 1998, MOL CELL ENDOCRINOL, V146, P151, DOI 10.1016/S0303-7207(98)00161-0; Ma XJ, 2004, CANCER CELL, V5, P607, DOI 10.1016/j.ccr.2004.05.015; Masutomi K, 2005, P NATL ACAD SCI USA, V102, P8222, DOI 10.1073/pnas.0503095102; MICHIELS C, 1990, J CELL PHYSIOL, V144, P295, DOI 10.1002/jcp.1041440216; Paik S, 2004, NEW ENGL J MED, V351, P2817, DOI 10.1056/NEJMoa041588; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Schiff R, 2000, J NATL CANCER I, V92, P1926, DOI 10.1093/jnci/92.23.1926; Serrano M, 2001, CURR OPIN CELL BIOL, V13, P748, DOI 10.1016/S0955-0674(00)00278-7; Shami PJ, 1998, LEUKEMIA, V12, P1461, DOI 10.1038/sj.leu.2401131; Smith LL, 2003, NAT CELL BIOL, V5, P474, DOI 10.1038/ncb985; Sorlie T, 2003, P NATL ACAD SCI USA, V100, P8418, DOI 10.1073/pnas.0932692100; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Sotiriou C, 2006, JNCI-J NATL CANCER I, V98, P262, DOI 10.1093/jnci/djj052; Stampfer MR, 2001, P NATL ACAD SCI USA, V98, P4498, DOI 10.1073/pnas.071483998; Storz P, 2005, FRONT BIOSCI-LANDMRK, V10, P1881, DOI 10.2741/1667; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Wang J, 2005, J BIOL CHEM, V280, P22776, DOI 10.1074/jbc.M500032200; Wu YL, 2006, J CELL SCI, V119, P2797, DOI 10.1242/jcs.03001; Xiang H, 2002, ONCOGENE, V21, P3784, DOI 10.1038/sj.onc.1205455; Zhang PS, 2003, FASEB J, V17, P767, DOI 10.1096/fj.02-0603fje	35	31	32	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 20	2007	26	43					6269	6279		10.1038/sj.onc.1210452	http://dx.doi.org/10.1038/sj.onc.1210452			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	212GW	17471242				2022-12-28	WOS:000249583300003
J	Sakamoto, S; Iijima, K; Mochizuki, D; Nakamura, K; Teshigawara, K; Kobayashi, J; Matsuura, S; Tauchi, H; Komatsu, K				Sakamoto, S.; Iijima, K.; Mochizuki, D.; Nakamura, K.; Teshigawara, K.; Kobayashi, J.; Matsuura, S.; Tauchi, H.; Komatsu, K.			Homologous recombination repair is regulated by domains at the N- and C-terminus of NBS1 and is dissociated with ATM functions	ONCOGENE			English	Article						NBS1; ATM; MRE11; homologous recombination; FHA/BRCT domains	FORKHEAD-ASSOCIATED DOMAIN; DNA-DAMAGE RESPONSE; STRAND BREAK REPAIR; IONIZING-RADIATION; CELLULAR-RESPONSE; GAMMA-H2AX FOCI; MRE11 COMPLEX; HISTONE H2AX; CELLS; PATHWAY	The proteins responsible for radiation sensitive disorders, NBS1, kinase ataxia- telangiectasia-( A- T)- mutated ( ATM) and MRE11, interact through the C- terminus of NBS1 in response to the generation of DNA double- strand breaks ( DSBs) and are all implicated in checkpoint regulation and DSB repair, such as homologous recombination ( HR). We measured the ability of several NBS1 mutant clones and A- T cells to regulate HR repair using the DR- GFP or SCneo systems. ATM deficiency did not reduce the HR repair frequency of an induced DSB, and it was confirmed by findings that HR frequencies are only slightly affected by deletion of ATM- binding site at the extreme C-terminus of NBS1. In contrast, The HR- regulating ability is dramatically reduced by deletion of the MRE11- binding domain at the C- terminus of NBS1 and markedly inhibited by mutations in the FHA/ BRCT domains at the N- terminus. This impaired capability in HR is consistent with a failure to observe MRE11 foci formation. Furthermore, normal HR using sister chromatid was completely inhibited by the absence of FHA/ BRCT domains. These results suggested that the N- and C- terminal domains of NBS1 are the major regulatory domains for HR pathways, very likely through the recruitment and retention of the MRE11 nuclease to DSB sites in an ATM-independent fashion.	Ibaraki Univ, Dept Environm Sci, Ibaraki 3108512, Japan; Kyoto Univ, Ctr Radiat Biol, Dept Radiat Repair Dynam, Kyoto, Japan; Ibaraki Univ, Dept Environm Sci, Ibaraki, Japan; Lymphocyte Bank Co Ltd, Kyoto, Japan; Hiroshima Univ, Res Inst Radiat Biol & Med, Dept Radiat Biol, Hiroshima, Japan	Ibaraki University; Kyoto University; Ibaraki University; Hiroshima University	Tauchi, H (corresponding author), Ibaraki Univ, Dept Environm Sci, Ibaraki 3108512, Japan.	htauchi@mx.ibaraki.ac.jp; komatsu@house.rbc.kyoto-u.ac.jp	Matsuura, Shinya/U-4182-2017; Kobayashi, Junya/AAX-6390-2021	Matsuura, Shinya/0000-0001-5294-081X; Kobayashi, Junya/0000-0003-4645-7500; Sakamoto, Shuichi/0000-0001-9396-9475; Nakamura, Kyosuke/0000-0003-1809-639X				Bolderson E, 2004, HUM MOL GENET, V13, P2937, DOI 10.1093/hmg/ddh316; Bressan DA, 1999, MOL CELL BIOL, V19, P7681; Celeste A, 2003, NAT CELL BIOL, V5, P675, DOI 10.1038/ncb1004; Cerosaletti KM, 2003, J BIOL CHEM, V278, P21944, DOI 10.1074/jbc.M211689200; Falck J, 2005, NATURE, V434, P605, DOI 10.1038/nature03442; Golding SE, 2004, J BIOL CHEM, V279, P15402, DOI 10.1074/jbc.M314191200; Greenberg RA, 2006, GENE DEV, V20, P34, DOI 10.1101/gad.1381306; Hiel JA, 2000, ARCH DIS CHILD, V82, P400; Horejsi Z, 2004, ONCOGENE, V23, P3122, DOI 10.1038/sj.onc.1207447; Jasin M, 2002, ONCOGENE, V21, P8981, DOI 10.1038/sj.onc.1206176; Kim JS, 2002, J BIOL CHEM, V277, P45149, DOI 10.1074/jbc.M209123200; Kobayashi J, 2004, DNA REPAIR, V3, P855, DOI 10.1016/j.dnarep.2004.03.023; Kobayashi J, 2002, CURR BIOL, V12, P1846, DOI 10.1016/S0960-9822(02)01259-9; Lavin MF, 2004, DNA REPAIR, V3, P1515, DOI 10.1016/j.dnarep.2004.07.001; Lim DS, 2000, NATURE, V404, P613, DOI 10.1038/35007091; Mirzoeva OK, 2001, MOL CELL BIOL, V21, P281, DOI 10.1128/MCB.21.1.281-288.2001; Nakanishi K, 2005, P NATL ACAD SCI USA, V102, P1110, DOI 10.1073/pnas.0407796102; Pierce AJ, 1999, GENE DEV, V13, P2633, DOI 10.1101/gad.13.20.2633; Riballo E, 2004, MOL CELL, V16, P715, DOI 10.1016/j.molcel.2004.10.029; Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011; Takao N, 1999, ONCOGENE, V18, P7002, DOI 10.1038/sj.onc.1203172; Tauchi H, 2002, NATURE, V420, P93, DOI 10.1038/nature01125; Tauchi H, 2001, J BIOL CHEM, V276, P12, DOI 10.1074/jbc.C000578200; Uziel T, 2003, EMBO J, V22, P5612, DOI 10.1093/emboj/cdg541; Xie AY, 2004, MOL CELL, V16, P1017, DOI 10.1016/j.molcel.2004.12.007; Yamamoto K, 2005, MOL CELL BIOL, V25, P34, DOI 10.1128/MCB.25.1.34-43.2005; Zhao S, 2002, NUCLEIC ACIDS RES, V30, P4815, DOI 10.1093/nar/gkf612	27	52	53	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP	2007	26	41					6002	6009		10.1038/sj.onc.1210428	http://dx.doi.org/10.1038/sj.onc.1210428			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	207US	17384674				2022-12-28	WOS:000249277200003
J	Syljuasen, RG				Syljuasen, R. G.			Checkpoint adaptation in human cells	ONCOGENE			English	Review						cell cycle checkpoints; genomic instability; ionizing radiation; G2-arrest; cell death; repair of DNA damage	DOUBLE-STRAND BREAK; DNA-DAMAGE CHECKPOINT; PHOSPHORYLATED HISTONE H2AX; POLO-LIKE KINASE; IONIZING-RADIATION; G2/M ARREST; MITOTIC CHROMOSOMES; CYCLE CHECKPOINTS; HELA-CELLS; RECOVERY	Checkpoint adaptation was originally described in Saccharomyces Cerevisiae as the ability to divide following a sustained checkpoint arrest in the presence of unrepairable DNA breaks. A process of checkpoint adaptation was also reported in Xenopus in response to the replication inhibitor aphidicolin. Recently, we showed that checkpoint adaptation also occurs in human cells. Although cells undergoing checkpoint adaptation will frequently die in subsequent cell cycles owing to excessive DNA damage, some of the cells may be able to survive and proliferate with damaged DNA. Thus, checkpoint adaptation in human cells may potentially promote genomic instability and lead to cancer. Here, I discuss the current evidence for checkpoint adaptation in human cells and possible mechanisms and implications of this phenomenon.	Danish Canc Soc, Inst Canc Biol, Copenhagen, Denmark; Danish Canc Soc, Ctr Genotox Stress Res, Copenhagen, Denmark	Danish Cancer Society; Danish Cancer Society	Syljuasen, RG (corresponding author), Univ Copenhagen, BRIC Bioctr, Ole Maaloes Vej 5, DK-2200 Copenhagen, Denmark.	rs@cancer.dk						Arnaud L, 1998, CHROMOSOMA, V107, P424, DOI 10.1007/s004120050326; Brown JM, 2005, NAT REV CANCER, V5, P231, DOI 10.1038/nrc1560; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Carballo JA, 2006, BIOL RES, V39, P331, DOI 10.4067/S0716-97602006000200015; Chen YH, 2004, DNA REPAIR, V3, P1025, DOI 10.1016/j.dnarep.2004.03.003; Chu K, 2002, RADIAT RES, V158, P667, DOI 10.1667/0033-7587(2002)158[0667:CVTLCA]2.0.CO;2; Cohen-Jonathan E, 1999, CURR OPIN CHEM BIOL, V3, P77, DOI 10.1016/S1367-5931(99)80014-3; De Souza CPC, 2000, EXP CELL RES, V257, P11, DOI 10.1006/excr.2000.4872; den Elzen N, 2004, CELL CYCLE, V3, P529; DEWEY WC, 1995, INT J RADIAT ONCOL, V33, P781, DOI 10.1016/0360-3016(95)00214-8; Forand A, 2004, BIOL REPROD, V71, P643, DOI 10.1095/biolreprod.104.027466; Forrester HB, 2000, RADIAT RES, V154, P625, DOI 10.1667/0033-7587(2000)154[0625:CVTLAO]2.0.CO;2; Friedberg EC, 2002, SCIENCE, V296, P1627, DOI 10.1126/science.1070236; Furuno N, 1999, J CELL BIOL, V147, P295, DOI 10.1083/jcb.147.2.295; Galgoczy DJ, 2001, MOL CELL BIOL, V21, P1710, DOI 10.1128/MCB.21.5.1710-1718.2001; HALL EJ, 2006, RADIOBIOLOGY RADILOG; Harrison JC, 2006, ANNU REV GENET, V40, P209, DOI 10.1146/annurev.genet.40.051206.105231; Ianzini F, 1997, INT J RADIAT BIOL, V72, P409, DOI 10.1080/095530097143185; Kao GD, 1997, CANCER RES, V57, P753; Kastan MB, 2004, NATURE, V432, P316, DOI 10.1038/nature03097; Kim SM, 2005, J BIOL CHEM, V280, P38355, DOI 10.1074/jbc.M508673200; Klokov D, 2006, RADIOTHER ONCOL, V80, P223, DOI 10.1016/j.radonc.2006.07.026; Koniaras K, 2001, ONCOGENE, V20, P7453, DOI 10.1038/sj.onc.1204942; Kramer A, 2004, NAT CELL BIOL, V6, P884, DOI 10.1038/ncb1165; Lee SE, 2001, CURR BIOL, V11, P1053, DOI 10.1016/S0960-9822(01)00296-2; Lee SE, 2003, MOL CELL BIOL, V23, P8913, DOI 10.1128/MCB.23.23.8913-8923.2003; Lee SE, 1998, CELL, V94, P399, DOI 10.1016/S0092-8674(00)81482-8; Leroy C, 2003, MOL CELL, V11, P827, DOI 10.1016/S1097-2765(03)00058-3; Lin SY, 2004, P NATL ACAD SCI USA, V101, P6484, DOI 10.1073/pnas.0401847101; Linke SP, 1997, CANCER RES, V57, P1171; Loffler H, 2006, EXP CELL RES, V312, P2633, DOI 10.1016/j.yexcr.2006.06.008; Lu CR, 2006, MOL CELL, V23, P121, DOI 10.1016/j.molcel.2006.05.023; Lu XB, 2005, GENE DEV, V19, P1162, DOI 10.1101/gad.1291305; Lupardus PJ, 2004, CELL, V117, P555, DOI 10.1016/j.cell.2004.05.005; Mailand N, 2006, MOL CELL, V23, P307, DOI 10.1016/j.molcel.2006.06.016; Maity A, 1996, ONCOGENE, V13, P1647; Mamely I, 2006, CURR BIOL, V16, P1950, DOI 10.1016/j.cub.2006.08.026; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; MUSCHEL RJ, 1992, RADIAT RES, V132, P153, DOI 10.2307/3578520; Pellicioli A, 2001, MOL CELL, V7, P293, DOI 10.1016/S1097-2765(01)00177-0; Peschiaroli A, 2006, MOL CELL, V23, P319, DOI 10.1016/j.molcel.2006.06.013; Rothkamm K, 2003, P NATL ACAD SCI USA, V100, P5057, DOI 10.1073/pnas.0830918100; Rothkamm K, 2003, MOL CELL BIOL, V23, P5706, DOI 10.1128/MCB.23.16.5706-5715.2003; SANDELL LL, 1993, CELL, V75, P729, DOI 10.1016/0092-8674(93)90493-A; Suzuki M, 2006, RADIAT RES, V165, P269, DOI 10.1667/RR3508.1; Syljuasen RG, 2006, CANCER RES, V66, P10253, DOI 10.1158/0008-5472.CAN-06-2144; Takizawa CG, 2000, CURR OPIN CELL BIOL, V12, P658, DOI 10.1016/S0955-0674(00)00149-6; THOMPSON LH, 1969, INT J RADIAT BIOL RE, V15, P347, DOI 10.1080/09553006914550571; Toczyski DP, 1997, CELL, V90, P1097, DOI 10.1016/S0092-8674(00)80375-X; van Vugt MATM, 2005, CANCER RES, V65, P7037, DOI 10.1158/0008-5472.CAN-05-1054; van Vugt MATM, 2004, MOL CELL, V15, P799, DOI 10.1016/j.molcel.2004.07.015; Yoo HY, 2006, GENE DEV, V20, P772, DOI 10.1101/gad.1398806; Yoo HY, 2004, CELL, V117, P575, DOI 10.1016/S0092-8674(04)00417-9	53	47	47	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 30	2007	26	40					5833	5839		10.1038/sj.onc.1210402	http://dx.doi.org/10.1038/sj.onc.1210402			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	205OH	17384683				2022-12-28	WOS:000249123100001
J	Singh, MK; Nicolas, E; Gherraby, W; Dadke, D; Lessin, S; Golemis, EA				Singh, M. K.; Nicolas, E.; Gherraby, W.; Dadke, D.; Lessin, S.; Golemis, E. A.			HEI10 negatively regulates cell invasion by inhibiting cyclin B/Cdk1 and other promotility proteins	ONCOGENE			English	Article						hEI10; Cdk1; cyclin B; migration; invasion; cell cycle	FOCAL ADHESION KINASE; TYROSINE PHOSPHORYLATION; NEUROFIBROMATOSIS TYPE-2; MIGRATION; CANCER; GENE; IDENTIFICATION; PROGRESSION; NF2/MERLIN; EXPRESSION	Human enhancer of invasion, clone 10 ( HEI10) (CCNB1IP1) was. rst described as a RING-finger family ubiquitin ligase that regulates cell cycle by interacting with cyclin B and promoting its degradation. Subsequently, other studies suggested specific upregulation of HEI10 in metastatic melanoma and demonstrated direct interaction between HEI10 and the tumor suppressor Merlin, encoded by the neurofibromatosis 2 gene. These and other results led us to hypothesize that HEI10 also influences the processes of cell migration and metastasis. We here show that cells with depleted HEI10 both migrate more rapidly and invade more effectively than control cells. HEI10 depletion post-transcriptionally increases the expression of a group of promotility regulatory proteins including p130Cas, paxillin, Cdk1 and cyclin B2, but excluding Merlin. Among these, only inhibition of Cdk1/ cyclin B activity specifically reversed the motility and invasion of HEI10-depleted cells. Finally, HEI10 is abundantly transcribed in many human tissues, and particularly abundant in some tumor cell lines, suggesting that it may be commonly involved in coordinating cell cycle with cell migration and invasion.	Fox Chase Canc Ctr, Inst Canc Res, Philadelphia, PA 19111 USA	Fox Chase Cancer Center	Golemis, EA (corresponding author), Fox Chase Canc Ctr, Inst Canc Res, W406,333 Cottman Ave, Philadelphia, PA 19111 USA.	ea_golemis@fccc.edu	Singh, Mahendra K./K-6267-2019	Golemis, Erica/0000-0003-3618-3673	NCI NIH HHS [P30 CA006927-44, P30 CA006927, CA-06927, R01 CA063366, R01 CA063366-12, R01 CA63366] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA006927, R01CA063366] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bouton AH, 1997, HYBRIDOMA, V16, P403, DOI 10.1089/hyb.1997.16.403; Brabek J, 2005, MOL CANCER RES, V3, P307, DOI 10.1158/1541-7786.MCR-05-0015; Draviam VM, 2001, J CELL BIOL, V152, P945, DOI 10.1083/jcb.152.5.945; Evans DGR, 2000, J MED GENET, V37, P897, DOI 10.1136/jmg.37.12.897; Fesik SW, 2005, NAT REV CANCER, V5, P876, DOI 10.1038/nrc1736; Gronholm M, 2006, ONCOGENE, V25, P4389, DOI 10.1038/sj.onc.1209475; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hirokawa Y, 2004, CANCER J, V10, P20, DOI 10.1097/00130404-200401000-00006; Jackson PK, 2000, TRENDS CELL BIOL, V10, P429, DOI 10.1016/S0962-8924(00)01834-1; James MF, 2004, J CELL SCI, V117, P2951, DOI 10.1242/jcs.01156; Juliano R, 2003, NAT CELL BIOL, V5, P589, DOI 10.1038/ncb0703-589; Kaempchen K, 2003, HUM MOL GENET, V12, P1211, DOI 10.1093/hmg/ddg146; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; Manes T, 2003, J CELL BIOL, V161, P817, DOI 10.1083/jcb.200212172; Mine N, 2001, JPN J CANCER RES, V92, P135, DOI 10.1111/j.1349-7006.2001.tb01075.x; Nymark P, 2006, CANCER RES, V66, P5737, DOI 10.1158/0008-5472.CAN-06-0199; Poulikakos PI, 2006, ONCOGENE, V25, P5960, DOI 10.1038/sj.onc.1209587; Rual JF, 2005, NATURE, V437, P1173, DOI 10.1038/nature04209; Ruest PJ, 2000, CELL GROWTH DIFFER, V11, P41; Schwikowski B, 2000, NAT BIOTECHNOL, V18, P1257, DOI 10.1038/82360; Smith AP, 2004, CANCER BIOL THER, V3, P104, DOI 10.4161/cbt.3.1.661; Toby GG, 2003, MOL CELL BIOL, V23, P2109, DOI 10.1128/MCB.23.6.2109-2122.2003; Wade R, 2006, BIOCHEM J, V393, P565, DOI 10.1042/BJ20051241; Worthylake RA, 2003, J BIOL CHEM, V278, P13578, DOI 10.1074/jbc.M211584200; Xiao GH, 2005, MOL CELL BIOL, V25, P2384, DOI 10.1128/MCB.25.6.2384-2394.2005; Zhao ZS, 2000, MOL CELL BIOL, V20, P6354, DOI 10.1128/MCB.20.17.6354-6363.2000	26	25	26	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 19	2007	26	33					4825	4832		10.1038/sj.onc.1210282	http://dx.doi.org/10.1038/sj.onc.1210282			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	191ZL	17297447	Green Accepted			2022-12-28	WOS:000248170400007
J	He, X; Pool, M; Darcy, KM; Lim, SB; Auersperg, N; Coon, JS; Beck, WT				He, X.; Pool, M.; Darcy, K. M.; Lim, S. B.; Auersperg, N.; Coon, J. S.; Beck, W. T.			Knockdown of polypyrimidine tract-binding protein suppresses ovarian tumor cell growth and invasiveness in vitro	ONCOGENE			English	Article						epithelial ovarian cancer; polypyrimidine tract-binding protein; RNA interference; tissue microarray; tumorigenesis	PERINUCLEOLAR COMPARTMENT; MESSENGER-RNA; HNRNP-I; CANCER; EXPRESSION; RESISTANCE; COMPLEX; ELEMENT; GENE	Polypyrimidine tract-binding protein (PTB) is an RNA-binding protein with multiple functions in the regulation of RNA processing and IRES-mediated translation. We report here overexpression of PTB in a majority of epithelial ovarian tumors revealed by immunoblotting and tissue microarray (TMA) staining. By western blotting, we found that PTB was overexpressed in 17 out of 19 ovarian tumor specimens compared to their matched-normal tissues. By TMA staining, we found PTB expression in 38 out of 44 ovarian cancer cases but only in two out of nine normal adjacent tissues. PTB is also overexpressed in SV40 large T-antigen immortalized ovarian epithelial cells compared to normal human ovarian epithelial cells. Using doxycycline-inducible small interfering RNA technology, we found that knockdown of PTB expression in the ovarian tumor cell line A2780 substantially impaired tumor cell proliferation, anchorageindependent growth and in vitro invasiveness. These results suggest that overexpression of PTB is an important component of the multistep process of tumorigenesis, and might be required for the development and maintenance of epithelial ovarian tumors. Moreover, because of its novel role in tumor cell growth and invasiveness, shown here for the. rst time, PTB may be a novel therapeutic target in the treatment of ovarian cancer.	Univ Illinois, GOG, Core Lab Mol Pharmacol, Chicago, IL 60612 USA; Univ Illinois, Dept Biopharmaceut Sci, Coll Pharm, Chicago, IL 60607 USA; Univ Illinois, Ctr Canc, Chicago, IL 60607 USA; Rush Univ, Ctr Med, Dept Pathol, Chicago, IL USA; Roswell Pk Canc Inst, GOG Stat & Data Ctr, Buffalo, NY USA; Univ British Columbia, Dept Obstet & Gynecol, Vancouver, BC V5Z 1M9, Canada	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Rush University; Roswell Park Cancer Institute; University of British Columbia	Beck, WT (corresponding author), Univ Illinois, Dept Biopharmaceut Sci, MC865, 833 S Wood St, Chicago, IL 60612 USA.	WTBeck@uic.edu			NATIONAL CENTER FOR RESEARCH RESOURCES [C06RR015482] Funding Source: NIH RePORTER; NCRR NIH HHS [C06 RR015482-01, C06RR15482, C06 RR015482] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Bast RC, 2005, CLIN CANCER RES, V11, P6103, DOI 10.1158/1078-0432.CCR-04-2213; Black DL, 2003, ANNU REV BIOCHEM, V72, P291, DOI 10.1146/annurev.biochem.72.121801.161720; BRYAN TM, 1994, CRIT REV ONCOGENESIS, V5, P331, DOI 10.1615/CritRevOncog.v5.i4.10; Bushell M, 2006, MOL CELL, V23, P401, DOI 10.1016/j.molcel.2006.06.012; Castelo-Branco P, 2004, MOL CELL BIOL, V24, P4174, DOI 10.1128/MCB.24.10.4174-4183.2004; Cornelis S, 2005, NUCLEIC ACIDS RES, V33, P3095, DOI 10.1093/nar/gki611; Cote CA, 1999, MOL CELL, V4, P431, DOI 10.1016/S1097-2765(00)80345-7; Faustino NA, 2003, GENE DEV, V17, P419, DOI 10.1101/gad.1048803; GARCIABLANCO MA, 1989, GENE DEV, V3, P1874, DOI 10.1101/gad.3.12a.1874; He XL, 2004, CLIN CANCER RES, V10, P4652, DOI 10.1158/1078-0432.CCR-03-0439; Huang S, 1997, J CELL BIOL, V137, P965, DOI 10.1083/jcb.137.5.965; Jemal A, 2003, CA-CANCER J CLIN, V53, P5, DOI 10.3322/canjclin.53.1.5; JIN W, 1990, NUCLEIC ACIDS RES, V18, P5995, DOI 10.1093/nar/18.20.5995; Jin W, 2000, CANCER RES, V60, P1221; Jin W, 2003, CANCER RES, V63, P6154; Jin X, 2002, ANTICANCER RES, V22, P659; Kamath RV, 2005, CANCER RES, V65, P246; Kasper JS, 2005, J VIROL, V79, P11685, DOI 10.1128/JVI.79.18.11685-11692.2005; Knoch KP, 2004, NAT CELL BIOL, V6, P207, DOI 10.1038/ncb1099; Kosinski PA, 2003, J IMMUNOL, V170, P979, DOI 10.4049/jimmunol.170.2.979; Liu JS, 2004, CANCER RES, V64, P1655, DOI 10.1158/0008-5472.CAN-03-3380; MAINESBANDIERA SL, 1992, AM J OBSTET GYNECOL, V167, P729, DOI 10.1016/S0002-9378(11)91579-8; MATERA AG, 1995, J CELL BIOL, V129, P1181, DOI 10.1083/jcb.129.5.1181; Mitchell SA, 2001, MOL CELL BIOL, V21, P3364, DOI 10.1128/MCB.21.10.3364-3374.2001; Ozols RF, 2004, CANCER CELL, V5, P19, DOI 10.1016/S1535-6108(04)00002-9; Venables JP, 2004, CANCER RES, V64, P7647, DOI 10.1158/0008-5472.CAN-04-1910; Wagner EJ, 2001, MOL CELL BIOL, V21, P3281, DOI 10.1128/MCB.21.10.3281-3288.2001; Wang ZN, 2003, CANCER RES, V63, P655; Wiznerowicz M, 2003, J VIROL, V77, P8957, DOI 10.1128/JVI.77.16.8957-8951.2003; Wollerton MC, 2004, MOL CELL, V13, P91, DOI 10.1016/S1097-2765(03)00502-1; Xu Q, 2003, NUCLEIC ACIDS RES, V31, P5635, DOI 10.1093/nar/gkg786; Zang WQ, 2001, J VIROL, V75, P10779, DOI 10.1128/JVI.75.22.10779-10786.2001	32	97	103	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2007	26	34					4961	4968		10.1038/sj.onc.1210307	http://dx.doi.org/10.1038/sj.onc.1210307			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	194CV	17310993	Green Accepted			2022-12-28	WOS:000248322500008
J	Whitwam, T; VanBrocklin, MW; Russo, ME; Haak, PT; Bilgili, D; Resau, JH; Koo, HM; Holmen, SL				Whitwam, T.; VanBrocklin, M. W.; Russo, M. E.; Haak, P. T.; Bilgili, D.; Resau, J. H.; Koo, H-M; Holmen, S. L.			Differential oncogenic potential of activated RAS isoforms in melanocytes	ONCOGENE			English	Article						RAS; MYC; melanocytes; transformation	C-MYC; H-RAS; N-RAS; TUMOR SUPPRESSION; GENE-EXPRESSION; INK4A LOCUS; K-RAS; MELANOMA; PHOSPHORYLATION; GROWTH	RAS genes are mutated in approximately 30% of all human cancers. Interestingly, there exists a strong bias in favor of mutation of only one of the three major RAS genes in tumors of different cellular origins. NRAS mutations occur in approximately 20% of human melanomas, whereas HRAS and KRAS mutations are rare in this disease. To de. ne the mechanism(s) responsible for this preference in melanocytes, we compared the transformation efficiencies of mutant NRAS and KRAS in immortal, non-transformed Ink4a/Arf-deficient melanocytes. NRAS mutation leads to increased cellular proliferation and is potently tumorigenic. In contrast, KRAS mutation does not enhance melanocyte proliferation and is only weakly tumorigenic on its own. Although both NRAS and KRAS activate mitogen-activated protein kinase signaling, only NRAS enhances MYC activity in these cells. Our data suggest that the activity of specific RAS isoforms is context-dependent and provide a possible explanation for the prevalence of NRAS mutations in melanoma. In addition, understanding this mechanism will have important implications for cancer therapies targeting RAS pathways.	Van Andel Res Inst, Mol Med & Virol Grp, Grand Rapids, MI USA; Van Andel Res Inst, Lab Pharmacogenet, Grand Rapids, MI USA; Van Andel Res Inst, Lab Microarray, Grand Rapids, MI USA; No Illinois Univ, Dept Math Sci, De Kalb, IL 60115 USA	Van Andel Institute; Van Andel Institute; Van Andel Institute; Northern Illinois University	Holmen, SL (corresponding author), Nevada Canc Inst, Translat Res Div, 10441 W Twain Ave, Las Vegas, NV 89135 USA.	sholmen@nvcancer.org						Ackermann J, 2005, CANCER RES, V65, P4005, DOI 10.1158/0008-5472.CAN-04-2970; AROCA P, 1993, J BIOL CHEM, V268, P25650; BENNETT DC, 1987, INT J CANCER, V39, P414, DOI 10.1002/ijc.2910390324; Castellano M, 1999, MELANOMA RES, V9, P421, DOI 10.1097/00008390-199910000-00001; Chin L, 1997, GENE DEV, V11, P2822, DOI 10.1101/gad.11.21.2822; Chin L, 2006, GENE DEV, V20, P2149, DOI 10.1101/gad.1437206; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Edgar R, 2002, NUCLEIC ACIDS RES, V30, P207, DOI 10.1093/nar/30.1.207; Esteban LM, 2001, MOL CELL BIOL, V21, P1444, DOI 10.1128/MCB.21.5.1444-1452.2001; Giehl K, 2005, BIOL CHEM, V386, P193, DOI 10.1515/BC.2005.025; Goel VK, 2006, J INVEST DERMATOL, V126, P154, DOI 10.1038/sj.jid.5700026; Gregory MA, 2003, J BIOL CHEM, V278, P51606, DOI 10.1074/jbc.M310722200; HENRIKSSON M, 1993, ONCOGENE, V8, P3199; Holmen SL, 2005, CANCER RES, V65, P8250, DOI 10.1158/0008-5472.CAN-05-1173; Kamemura K, 2002, J BIOL CHEM, V277, P19229, DOI 10.1074/jbc.M201729200; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Kim K, 2002, CANCER RES, V62, P1241; Klein PS, 1996, P NATL ACAD SCI USA, V93, P8455, DOI 10.1073/pnas.93.16.8455; Koera K, 1997, ONCOGENE, V15, P1151, DOI 10.1038/sj.onc.1201284; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; MAHER J, 1995, ONCOGENE, V11, P1639; Prior IA, 2001, J CELL SCI, V114, P1603; Scherf U, 2000, NAT GENET, V24, P236, DOI 10.1038/73439; Sears RC, 2004, CELL CYCLE, V3, P1133, DOI 10.4161/cc.3.9.1145; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; Solit DB, 2006, NATURE, V439, P358, DOI 10.1038/nature04304; Sviderskaya EV, 2002, JNCI-J NATL CANCER I, V94, P446; UMANOFF H, 1995, P NATL ACAD SCI USA, V92, P1709, DOI 10.1073/pnas.92.5.1709; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; Yan J, 1998, J BIOL CHEM, V273, P24052, DOI 10.1074/jbc.273.37.24052	31	48	50	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2007	26	31					4563	4570		10.1038/sj.onc.1210239	http://dx.doi.org/10.1038/sj.onc.1210239			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	187GR	17297468				2022-12-28	WOS:000247836100010
J	Darwish, H; Cho, JM; Loignon, M; Alaoui-Jamali, MA				Darwish, H.; Cho, J. M.; Loignon, M.; Alaoui-Jamali, M. A.			Overexpression of SERTAD3, a putative oncogene located within the 19q13 amplicon, induces E2F activity and promotes tumor growth	ONCOGENE			English	Article						SERTAD; 19q13; cell cycle; oncogenesis; E2F	DNA-SEQUENCES; BREAST-CANCER; CELL-LINES; OVARIAN-CANCER; C-MYC; GENE; AMPLIFICATION; PROTEIN; IDENTIFICATION; TRANSFORMATION	The amplified region of chromosome 19q13.1-13.2 has been associated with several cancers. The well-characterized oncogene AKT2 is located in this amplicon. Two members of the same gene family (SERTAD1 and SERTAD3) are also located within this region. We report herein the genomic structure and potential functions of SERTAD3. SERTAD3 has two transcript variants with short mRNA half-lives, and one of the variants is tightly regulated throughout G1 and S phases of the cell cycle. Overexpression of SERTAD3 induces cell transformation in vitro and tumor formation in mice, whereas inhibition of SERTAD3 by small interfering RNA (siRNA) results in a reduction in cell growth rate. Furthermore, luciferase assays based on E2F-1 binding indicate that SERTAD3 increases the activity of E2F, which is reduced by inhibition of SERTAD3 by siRNA. Together, our data support that SERTAD3 contributes to oncogenesis, at least in part, via an E2F-dependent mechanism.	Sir Mortimer B Davis Jewish Hosp, Lady Davis Inst Med Res, Fac Med, Dept Oncol, Montreal, PQ H3T 1E2, Canada; McGill Univ, Sir Mortimer B Davis Jewish Gen Hosp, Segal Comprehens Canc Ctr, Montreal, PQ H3T 1E2, Canada; Sir Mortimer B Davis Jewish Hosp, Lady Davis Inst Med Res, Fac Med, Dept Med, Montreal, PQ H3T 1E2, Canada	Lady Davis Institute; McGill University; McGill University; Lady Davis Institute; McGill University	Alaoui-Jamali, MA (corresponding author), Sir Mortimer B Davis Jewish Hosp, Lady Davis Inst Med Res, Fac Med, Dept Med, Room E534,3755 Cote St Catherine, Montreal, PQ H3T 1E2, Canada.	moulay.alaoui-jamali@mcgill.ca						Abdullah JM, 2001, BLOOD CELL MOL DIS, V27, P667, DOI 10.1006/bcmd.2001.0434; Alarcon-Vargas D, 2004, J BIOL CHEM, V279, P5008, DOI 10.1074/jbc.M312054200; ALITALO K, 1983, P NATL ACAD SCI-BIOL, V80, P1707, DOI 10.1073/pnas.80.6.1707; BARKER PE, 1982, CANCER GENET CYTOGEN, V5, P81, DOI 10.1016/0165-4608(82)90043-7; Beghini A, 2003, ONCOGENE, V22, P2581, DOI 10.1038/sj.onc.1206336; Bicher A, 1997, GYNECOL ONCOL, V66, P36, DOI 10.1006/gyno.1997.4709; Bienz M, 2006, TRENDS BIOCHEM SCI, V31, P35, DOI 10.1016/j.tibs.2005.11.001; Calgaro S, 2002, GENETICS, V160, P547; Cho JM, 2000, NUCLEIC ACIDS RES, V28, P3478, DOI 10.1093/nar/28.18.3478; Curtis LJ, 1998, GENOMICS, V53, P42, DOI 10.1006/geno.1998.5405; Gupta S, 2003, VIROLOGY, V317, P155, DOI 10.1016/j.virol.2003.08.008; Hiemstra J L, 1994, Prog Clin Biol Res, V385, P51; Hoglund M, 1998, GENE CHROMOSOME CANC, V21, P8; Hsu SIH, 2001, EMBO J, V20, P2273, DOI 10.1093/emboj/20.9.2273; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Loignon M, 2002, CARCINOGENESIS, V23, P35, DOI 10.1093/carcin/23.1.35; Luoh SW, 2002, CANCER GENET CYTOGEN, V136, P43, DOI 10.1016/S0165-4608(01)00657-4; Marchio A, 1997, GENE CHROMOSOME CANC, V18, P59, DOI 10.1002/(SICI)1098-2264(199701)18:1<59::AID-GCC7>3.0.CO;2-0; Miwa W, 1996, BIOCHEM BIOPH RES CO, V225, P968, DOI 10.1006/bbrc.1996.1280; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; MULERIS M, 1995, GENE CHROMOSOME CANC, V14, P155, DOI 10.1002/gcc.2870140302; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; Ormandy CJ, 2003, BREAST CANCER RES TR, V78, P323, DOI 10.1023/A:1023033708204; Petersen I, 1997, BRIT J CANCER, V75, P79, DOI 10.1038/bjc.1997.13; REIFENBERGER G, 1993, CANCER RES, V53, P2736; Ross JS, 1999, SEMIN CANCER BIOL, V9, P125, DOI 10.1006/scbi.1998.0083; SCHNEIDER SS, 1992, MOL CELL BIOL, V12, P5563, DOI 10.1128/MCB.12.12.5563; SHILOH Y, 1986, CANCER RES, V46, P5297; Sieber OM, 2003, NAT REV CANCER, V3, P701, DOI 10.1038/nrc1170; SINGH P, 1994, EMBO J, V13, P3329, DOI 10.1002/j.1460-2075.1994.tb06635.x; Sugimoto M, 1999, GENE DEV, V13, P3027, DOI 10.1101/gad.13.22.3027; Tang TCM, 2002, CANCER RES, V62, P7157; Thompson G, 1996, J GEOM PHYS, V19, P1, DOI 10.1016/0393-0440(95)00014-3; Wang ZJ, 1999, BRIT J CANCER, V80, P70, DOI 10.1038/sj.bjc.6690323; Yang Xiao-He, 1995, Gene Expression, V4, P195; Yen L, 2002, MOL BIOL CELL, V13, P4029, DOI 10.1091/mbc.e02-02-0084; Zaharieva BM, 2003, J PATHOL, V201, P603, DOI 10.1002/path.1481	37	31	32	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 21	2007	26	29					4319	4328		10.1038/sj.onc.1210195	http://dx.doi.org/10.1038/sj.onc.1210195			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	184CY	17260023				2022-12-28	WOS:000247619900014
J	Lin, X; Morgan-Lappe, S; Huang, X; Li, L; Zakula, DM; Vernetti, LA; Fesik, SW; Shen, Y				Lin, X.; Morgan-Lappe, S.; Huang, X.; Li, L.; Zakula, D. M.; Vernetti, L. A.; Fesik, S. W.; Shen, Y.			'Seed' analysis of off-target siRNAs reveals an essential role of Mcl-1 in resistance to the small-molecule Bcl-2/Bcl-X-L inhibitor ABT-737	ONCOGENE			English	Article						siRNA; off-target; seed; Mcl-1; ABT-737; Bcl-X-L	RNA; EXPRESSION; PROTEINS; CELLS	ABT-737 is a subnanomolar inhibitor of the antiapoptotic proteins Bcl-2, Bcl-XL and Bcl-w. Although ABT-737 triggers extensive cell death in many small-cell lung carcinoma ( SCLC) cell lines, some of the SCLC cell lines and the majority of the cancer cell lines derived from other solid tumors were found to be resistant to ABT-737. To better understand the mechanism of resistance to ABT-737, we screened a short interfering RNA library consisting of short interfering RNA against 4000 'druggable' targets in an SCLC-derived cell line, NCI-H196. By comparing the knockdowns with phenotypes, all of the three top 'hits' from the screen were found to result from off-target gene silencing. Interestingly, the three off-target siRNAs were found to knock down an antiapoptotic Bcl-2 family protein Mcl-1 owing to the complementation between their seed regions with the 30 untranslated region ( 30 UTR) of Mcl-1. Furthermore, reducing the level of Mcl-1 using siRNAs or the small-molecule compounds Bay43-9006 and Seliciclib was sufficient to overcome the resistance to ABT-737 in the resistant SCLC cell line and cancer cell lines derived from other solid tumors. These results provide further evidence that Mcl-1 is the major factor that causes resistance to ABT-737 in cancer cells derived from diverse solid tumors, and the combination of Mcl-1 downregulating agents with ABT-737 could be potent therapeutic regimens for patient with ABT-737 resistant SCLC and many other types of solid tumors.	Abbott Labs, Global Pharmaceut Res & Dev, Canc Res, Abbott Pk, IL 60064 USA	Abbott Laboratories	Shen, Y (corresponding author), Abbott Labs, Global Pharmaceut Res & Dev, Canc Res, AP10,100 Abbott Pk Rd, Abbott Pk, IL 60064 USA.	yu.shen@abbott.com		Vernetti, Lawrence/0000-0003-4861-3167				Birmingham A, 2006, NAT METHODS, V3, P199, DOI 10.1038/NMETH854; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Jackson AL, 2003, NAT BIOTECHNOL, V21, P635, DOI 10.1038/nbt831; Kirkin V, 2004, BBA-MOL CELL RES, V1644, P229, DOI 10.1016/j.bbamcr.2003.08.009; Kitada S, 2000, BLOOD, V96, P393; Lin XY, 2005, NUCLEIC ACIDS RES, V33, P4527, DOI 10.1093/nar/gki762; Oltersdorf T, 2005, NATURE, V435, P677, DOI 10.1038/nature03579; Saxena S, 2003, J BIOL CHEM, V278, P44312, DOI 10.1074/jbc.M307089200; Tijsterman M, 2002, ANNU REV GENET, V36, P489, DOI 10.1146/annurev.genet.36.043002.091619; van de Donk NWCJ, 2003, BLOOD, V102, P3354, DOI 10.1182/blood-2003-03-0970; Waterhouse PM, 2001, NATURE, V411, P834, DOI 10.1038/35081168; Yu CR, 2005, ONCOGENE, V24, P6861, DOI 10.1038/sj.onc.1208841; Zeng Y, 2003, P NATL ACAD SCI USA, V100, P9779, DOI 10.1073/pnas.1630797100	14	216	229	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 7	2007	26	27					3972	3979		10.1038/sj.onc.1210166	http://dx.doi.org/10.1038/sj.onc.1210166			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	177HP	17173063				2022-12-28	WOS:000247144500007
J	Turjanski, AG; Vaque, JP; Gutkind, JS				Turjanski, A. G.; Vaque, J. P.; Gutkind, J. S.			MAP kinases and the control of nuclear events	ONCOGENE			English	Review						signal transduction; Ras GTPases; Rho GTPases; chromatin remodeling; transcription factors; growth factors	ACTIVATED PROTEIN-KINASE; SIGNAL-TRANSDUCTION PATHWAY; EPIDERMAL-GROWTH-FACTOR; STRESS-INDUCED PHOSPHORYLATION; HISTONE H3 PHOSPHORYLATION; RECEPTOR TYROSINE KINASES; JUN NH2-TERMINAL KINASE; SERUM RESPONSE ELEMENT; C-MYC EXPRESSION; DOCKING SITES	The mitogen-activated protein kinases (MAPKs) are a family of serine/threonine kinases that play an essential role in signal transduction by modulating gene transcription in the nucleus in response to changes in the cellular environment. They include the extracellular signal-regulated protein kinases (ERK1 and ERK2); c-Jun N-terminal kinases (JNK1, JNK2, JNK3); p38s (p38a, p38b, p38c, p38d) an d ERK5. The molecular events in which MAPKs function can be separated in discrete and yet interrelated steps: activation of the MAPK by their upstream kinases, changes in the subcellular localization of MAPKs, and recognition, binding and phosphorylation of MAPK downstream targets. The resulting pattern of gene expression will ultimately depend on the integration of the combinatorial signals provided by the temporal activation of each group of MAPKs. This review will focus on how the specificity of signal transmission by MAPKs is achieved by scaffolding molecules and by the presence of structural motifs in MAPKs that are dynamically regulated by phosphorylation and protein-protein interactions. We discuss also how MAPKs recognize and phosphorylate their target nuclear proteins, including transcription factors, co-activators and repressors and chromatin-remodeling molecules, thereby affecting an intricate balance of nuclear regulatory molecules that ultimately control gene expression in response to environmental cues.	Natl Inst Dent & Craniofacial Res, Oral & Pharyngeal Canc Branch, NIH, Bethesda, MD USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Gutkind, JS (corresponding author), Natl Inst Dent & Craniofacial Res, Oral & Pharyngeal Canc Branch, NIH, Bethesda, MD USA.	sg39v@nih.gov	Vaqué, José P/H-8413-2015; Gutkind, J. Silvio/J-1201-2016; Gutkind, J. Silvio/A-1053-2009; Leon, Javier/K-4615-2014	Vaqué, José P/0000-0002-3913-2495; Gutkind, J. Silvio/0000-0002-5150-4482; Turjanski, Adrian/0000-0003-2190-137X	Intramural NIH HHS Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000551] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000551] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Adachi M, 1999, EMBO J, V18, P5347, DOI 10.1093/emboj/18.19.5347; Adams RH, 2000, MOL CELL, V6, P109, DOI 10.1016/S1097-2765(00)00012-5; ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; Ben-Levy R, 1998, CURR BIOL, V8, P1049, DOI 10.1016/S0960-9822(98)70442-7; Benkhelifa S, 2001, MOL CELL BIOL, V21, P4441, DOI 10.1128/MCB.21.14.4441-4452.2001; Bernstein E, 2006, BIOCHEM CELL BIOL, V84, P505, DOI 10.1139/O06-085; Biondi RM, 2003, BIOCHEM J, V372, P1, DOI 10.1042/BJ20021641; Blank TA, 1996, J MOL BIOL, V260, P1, DOI 10.1006/jmbi.1996.0377; Briata P, 2005, MOL CELL, V20, P891, DOI 10.1016/j.molcel.2005.10.021; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; Buschbeck M, 2005, J BIOL CHEM, V280, P2659, DOI 10.1074/jbc.M412599200; Buschmann T, 2001, MOL CELL BIOL, V21, P2743, DOI 10.1128/MCB.21.8.2743-2754.2001; Callaway K, 2005, BBA-PROTEINS PROTEOM, V1754, P316, DOI 10.1016/j.bbapap.2005.11.002; Campbell KM, 2002, BIOCHEMISTRY-US, V41, P13956, DOI 10.1021/bi026222m; Campbell KM, 2000, BIOCHEMISTRY-US, V39, P2708, DOI 10.1021/bi9923555; Canagarajah BJ, 1997, CELL, V90, P859, DOI 10.1016/S0092-8674(00)80351-7; CAVIGELLI M, 1995, EMBO J, V14, P5957, DOI 10.1002/j.1460-2075.1995.tb00284.x; Chang CI, 2002, MOL CELL, V9, P1241, DOI 10.1016/S1097-2765(02)00525-7; Chen Z, 2001, CHEM REV, V101, P2449, DOI 10.1021/cr000241p; Cheung P, 2000, MOL CELL, V5, P905, DOI 10.1016/S1097-2765(00)80256-7; Chiariello M, 2001, NAT CELL BIOL, V3, P580, DOI 10.1038/35078555; Chow CW, 1997, SCIENCE, V278, P1638, DOI 10.1126/science.278.5343.1638; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; Conrad PW, 1999, J BIOL CHEM, V274, P23570, DOI 10.1074/jbc.274.33.23570; COSO OA, 1995, J BIOL CHEM, V270, P5620, DOI 10.1074/jbc.270.10.5620; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; Cruzalegui FH, 1999, ONCOGENE, V18, P7948, DOI 10.1038/sj.onc.1203362; Dai JX, 2000, MAR BIOTECHNOL, V2, P1; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Dean JLE, 2004, CELL SIGNAL, V16, P1113, DOI 10.1016/j.cellsig.2004.04.006; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Dimitri CA, 2005, CURR BIOL, V15, P1319, DOI 10.1016/j.cub.2005.06.037; Ducret C, 2000, ONCOGENE, V19, P5063, DOI 10.1038/sj.onc.1203892; Dwivedi PP, 2002, J BIOL CHEM, V277, P29643, DOI 10.1074/jbc.M204561200; Eisenman RN, 2001, GENE DEV, V15, P2023, DOI 10.1101/gad928101; Elion EA, 2001, J CELL SCI, V114, P3967; English JM, 1998, J BIOL CHEM, V273, P3854, DOI 10.1074/jbc.273.7.3854; Fitzgerald JB, 2006, NAT CHEM BIOL, V2, P458, DOI 10.1038/nchembio817; Frank SR, 2003, EMBO REP, V4, P575, DOI 10.1038/sj.embor.embor861; Galanis A, 2001, J BIOL CHEM, V276, P965, DOI 10.1074/jbc.M007697200; Gerwins P, 1997, J BIOL CHEM, V272, P8288, DOI 10.1074/jbc.272.13.8288; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GONZALEZ FA, 1993, J CELL BIOL, V122, P1089, DOI 10.1083/jcb.122.5.1089; Guccione E, 2006, NAT CELL BIOL, V8, P764, DOI 10.1038/ncb1434; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; Gutkind J. S., 2000, SCI STKE, pre1, DOI DOI 10.1126/STKE.2000.40.RE1; Hayashi M, 2004, J CLIN INVEST, V113, P1138, DOI 10.1172/JCI200419890; Heo JS, 2004, EMBO J, V23, P2185, DOI 10.1038/sj.emboj.7600212; HERRERA RE, 1989, NATURE, V340, P68, DOI 10.1038/340068a0; Hitti E, 2006, MOL CELL BIOL, V26, P2399, DOI 10.1128/MCB.26.6.2399-2407.2006; Ho DT, 2006, J BIOL CHEM, V281, P13169, DOI 10.1074/jbc.M601010200; Hoofnagle AN, 2004, BIOPHYS J, V86, P395, DOI 10.1016/S0006-3495(04)74115-6; Hoofnagle AN, 2001, P NATL ACAD SCI USA, V98, P956, DOI 10.1073/pnas.98.3.956; Hornberg JJ, 2005, ONCOGENE, V24, P5533, DOI 10.1038/sj.onc.1208817; Hoshino R, 1999, ONCOGENE, V18, P813, DOI 10.1038/sj.onc.1202367; Hu MCT, 1999, J BIOL CHEM, V274, P7095, DOI 10.1074/jbc.274.11.7095; Huang ZH, 2004, J BIOL CHEM, V279, P52150, DOI 10.1074/jbc.M407820200; Iavarone C, 2003, J BIOL CHEM, V278, P50024, DOI 10.1074/jbc.M308617200; Illi B, 2005, CIRC RES, V96, P501, DOI 10.1161/01.RES.0000159181.06379.63; Jacobs D, 1999, GENE DEV, V13, P163, DOI 10.1101/gad.13.2.163; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Jiang Y, 1996, J BIOL CHEM, V271, P17920, DOI 10.1074/jbc.271.30.17920; Kamakura S, 1999, J BIOL CHEM, V274, P26563, DOI 10.1074/jbc.274.37.26563; Kato Y, 1997, EMBO J, V16, P7054, DOI 10.1093/emboj/16.23.7054; Kato Y, 1998, NATURE, V395, P713, DOI 10.1038/27234; Kawasaki H, 2000, NATURE, V405, P195, DOI 10.1038/35012097; Khokhlatchev AV, 1998, CELL, V93, P605, DOI 10.1016/S0092-8674(00)81189-7; Knebel A, 2001, EMBO J, V20, P4360, DOI 10.1093/emboj/20.16.4360; Kondoh K, 2006, MOL CELL BIOL, V26, P1679, DOI 10.1128/MCB.26.5.1679-1690.2006; Kretzschmar M, 1999, GENE DEV, V13, P804, DOI 10.1101/gad.13.7.804; Kretzschmar M, 1997, NATURE, V389, P618, DOI 10.1038/39348; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; Lai WC, 2003, J IMMUNOL, V170, P6244, DOI 10.4049/jimmunol.170.12.6244; Lee CM, 2002, P NATL ACAD SCI USA, V99, P14189, DOI 10.1073/pnas.232310199; LEE DY, 1993, CELL, V72, P73, DOI 10.1016/0092-8674(93)90051-Q; Lee ER, 2006, J BIOL CHEM, V281, P21162, DOI 10.1074/jbc.M602734200; Lee SJ, 2006, METHODS, V40, P224, DOI 10.1016/j.ymeth.2006.05.003; Lee T, 2004, MOL CELL, V14, P43, DOI 10.1016/S1097-2765(04)00161-3; Lee T, 2005, J MOL BIOL, V353, P600, DOI 10.1016/j.jmb.2005.08.029; Lenormand P, 1998, J CELL BIOL, V142, P625, DOI 10.1083/jcb.142.3.625; Li J, 2001, MOL CELL BIOL, V21, P8213, DOI 10.1128/MCB.21.23.8213-8224.2001; Li L, 2004, BIOCHEM CELL BIOL, V82, P460, DOI 10.1139/O04-045; Lindorff-Larsen K, 2005, NATURE, V433, P128, DOI 10.1038/nature03199; Lisnock J, 2000, BIOCHEMISTRY-US, V39, P3141, DOI 10.1021/bi992410+; Liu LD, 2006, P NATL ACAD SCI USA, V103, P9697, DOI 10.1073/pnas.0603373103; Liu SJ, 2006, P NATL ACAD SCI USA, V103, P5326, DOI 10.1073/pnas.0510506103; LIVINGSTONE C, 1995, EMBO J, V14, P1785, DOI 10.1002/j.1460-2075.1995.tb07167.x; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; Marinissen MJ, 2004, MOL CELL, V14, P29, DOI 10.1016/S1097-2765(04)00153-4; Marinissen MJ, 1999, MOL CELL BIOL, V19, P4289; Milanini-Mongiat J, 2002, J BIOL CHEM, V277, P20631, DOI 10.1074/jbc.M201753200; MINDEN A, 1994, MOL CELL BIOL, V14, P6683, DOI 10.1128/MCB.14.10.6683; Miralles F, 2003, CELL, V113, P329, DOI 10.1016/S0092-8674(03)00278-2; Monje P, 2003, MOL CELL BIOL, V23, P7030, DOI 10.1128/MCB.23.19.7030-7043.2003; Monje P, 2005, J BIOL CHEM, V280, P35081, DOI 10.1074/jbc.C500353200; Morrison DK, 2003, ANNU REV CELL DEV BI, V19, P91, DOI 10.1146/annurev.cellbio.19.111401.091942; Murphy LO, 2002, NAT CELL BIOL, V4, P556, DOI 10.1038/ncb822; Musti AM, 1997, SCIENCE, V275, P400, DOI 10.1126/science.275.5298.400; Nakamura K, 2006, MOL CELL BIOL, V26, P2065, DOI 10.1128/MCB.26.6.2065-2079.2006; Nishimoto S, 2006, EMBO REP, V7, P782, DOI 10.1038/sj.embor.7400755; Noguchi K, 1999, J BIOL CHEM, V274, P32580, DOI 10.1074/jbc.274.46.32580; OFIR R, 1990, NATURE, V348, P80, DOI 10.1038/348080a0; Ory S, 2003, CURR BIOL, V13, P1356, DOI 10.1016/S0960-9822(03)00535-9; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; Pokholok DK, 2006, SCIENCE, V313, P533, DOI 10.1126/science.1127677; Pramanik R, 2003, J BIOL CHEM, V278, P4831, DOI 10.1074/jbc.M207732200; Prowse CN, 2000, BIOCHEMISTRY-US, V39, P6258, DOI 10.1021/bi000277b; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; Radhakrishnan I, 1997, CELL, V91, P741, DOI 10.1016/S0092-8674(00)80463-8; Roelen BAJ, 2003, AM J PHYSIOL-CELL PH, V285, pC823, DOI 10.1152/ajpcell.00053.2003; ROGIDOUX J, 2005, MOL CELL BIOL, V25, P5466; ROSSOMANDO AJ, 1989, P NATL ACAD SCI USA, V86, P6940, DOI 10.1073/pnas.86.18.6940; Saccani S, 2002, NAT IMMUNOL, V3, P69, DOI 10.1038/ni748; Sanchez-Prieto R, 2000, CANCER RES, V60, P2464; Sanchez-Prieto R, 2002, ONCOGENE, V21, P974, DOI 10.1038/sj.onc.1205134; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; Schmeck B, 2005, J IMMUNOL, V175, P2843, DOI 10.4049/jimmunol.175.5.2843; Schoeberl B, 2002, NAT BIOTECHNOL, V20, P370, DOI 10.1038/nbt0402-370; Schweppe RE, 2006, J BIOL CHEM, V281, P20993, DOI 10.1074/jbc.M604208200; Sears R, 1999, MOL CELL, V3, P169, DOI 10.1016/S1097-2765(00)80308-1; Sears RC, 2002, J BIOL CHEM, V277, P11617, DOI 10.1074/jbc.R100063200; Simone C, 2004, NAT GENET, V36, P738, DOI 10.1038/ng1378; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; Sohn SJ, 2005, MOL CELL BIOL, V25, P8553, DOI 10.1128/MCB.25.19.8553-8566.2005; Soloaga A, 2003, EMBO J, V22, P2788, DOI 10.1093/emboj/cdg273; Strahl T, 1996, P NATL ACAD SCI USA, V93, P11563, DOI 10.1073/pnas.93.21.11563; Takaesu G, 2006, J CELL BIOL, V175, P383, DOI 10.1083/jcb.200608031; Tamura K, 2000, CELL, V102, P221, DOI 10.1016/S0092-8674(00)00027-1; Tanos T, 2005, J BIOL CHEM, V280, P18842, DOI 10.1074/jbc.M500620200; Tanoue TJ, 2003, CELL SIGNAL, V15, P455, DOI 10.1016/S0898-6568(02)00112-2; Terasawa K, 2003, GENES CELLS, V8, P263, DOI 10.1046/j.1365-2443.2003.00631.x; Uhlik MT, 2003, NAT CELL BIOL, V5, P1104, DOI 10.1038/ncb1071; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANDAM H, 1993, EMBO J, V12, P479, DOI 10.1002/j.1460-2075.1993.tb05680.x; Vicent GP, 2006, MOL CELL, V24, P367, DOI 10.1016/j.molcel.2006.10.011; Visconti R, 2000, BLOOD, V96, P1844, DOI 10.1182/blood.V96.5.1844.h8001844_1844_1852; Vorbrueggen G, 1996, BIOL CHEM, V377, P721, DOI 10.1515/bchm3.1996.377.11.721; Waetzig GH, 2002, J IMMUNOL, V168, P5342, DOI 10.4049/jimmunol.168.10.5342; Wang SW, 2001, CARCINOGENESIS, V22, P757, DOI 10.1093/carcin/22.5.757; Wang XZ, 1996, SCIENCE, V272, P1347, DOI 10.1126/science.272.5266.1347; Watson FL, 2001, NAT NEUROSCI, V4, P981, DOI 10.1038/nn720; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; Wulf G, 2005, NAT CELL BIOL, V7, P435, DOI 10.1038/ncb0505-435; Yan C, 2001, J BIOL CHEM, V276, P10870, DOI 10.1074/jbc.M009286200; Yan Lijun, 2003, BMC Dev Biol, V3, P11, DOI 10.1186/1471-213X-3-11; Yang J, 2004, J MOL BIOL, V336, P473, DOI 10.1016/j.jmb.2003.11.044; Yang SH, 1999, MOL CELL BIOL, V19, P4028; Yang SH, 1998, EMBO J, V17, P1740, DOI 10.1093/emboj/17.6.1740; Zarubin T, 2005, CELL RES, V15, P11, DOI 10.1038/sj.cr.7290257; Zhong SP, 2001, J BIOL CHEM, V276, P12932, DOI 10.1074/jbc.M010931200; Zhou B, 2002, J BIOL CHEM, V277, P31818, DOI 10.1074/jbc.M203969200; Zhou B, 2002, J BIOL CHEM, V277, P13889, DOI 10.1074/jbc.M200377200; ZHOU GC, 1995, J BIOL CHEM, V270, P12665, DOI 10.1074/jbc.270.21.12665; Zhou TJ, 2006, STRUCTURE, V14, P1011, DOI 10.1016/j.str.2006.04.006	159	328	342	0	25	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 15	2007	26	22					3240	3253		10.1038/sj.onc.1210415	http://dx.doi.org/10.1038/sj.onc.1210415			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	169PH	17496919				2022-12-28	WOS:000246603600012
J	Joerger, AC; Fersht, AR				Joerger, A. C.; Fersht, A. R.			Structure-function-rescue: the diverse nature of common p53 cancer mutants	ONCOGENE			English	Review						p53; cancer; mutation; structure; drug design	DNA-BINDING DOMAIN; TUMOR-SUPPRESSOR PROTEIN; FULL-LENGTH P53; CAVITY-CREATING MUTATIONS; C-TERMINAL DOMAIN; CORE DOMAIN; CRYSTAL-STRUCTURE; TETRAMERIZATION DOMAIN; TRANSCRIPTIONAL ACTIVATION; ONCOGENIC MUTATIONS	The tumor suppressor protein p53 is inactivated by mutation in about half of all human cancers. Most mutations are located in the DNA-binding domain of the protein. It is, therefore, important to understand the structure of p53 and how it responds to mutation, so as to predict the phenotypic response and cancer prognosis. In this review, we present recent structural and systematic functional data that elucidate the molecular basis of how p53 is inactivated by different types of cancer mutation. Intriguingly, common cancer mutants exhibit a variety of distinct local structural changes, while the overall structural scaffold is largely preserved. The diverse structural and energetic response to mutation determines: (i) the folding state of a particular mutant under physiological conditions; (ii) its affinity for the various p53 target DNA sequences; and (iii) its protein-protein interactions both within the p53 tetramer and with a multitude of regulatory proteins. Further, the structural details of individual mutants provide the basis for the design of specific and generic drugs for cancer therapy purposes. In combination with studies on second-site suppressor mutations, it appears that some mutants are ideal rescue candidates, whereas for others simple pharmacological rescue by small molecule drugs may not be successful.	MRC Ctr, Ctr Prot Engn, Cambridge CB2 0QH, England	MRC Laboratory Molecular Biology; University of Cambridge	Joerger, AC (corresponding author), MRC Ctr, Ctr Prot Engn, Hills rd, Cambridge CB2 0QH, England.	acj2@mrc-lmb.cam.ac.uk; arf25@cam.ac.uk	Fersht, Alan R/B-2189-2008	Joerger, Andreas/0000-0002-1232-0138	MRC [MC_U105474168] Funding Source: UKRI; Medical Research Council [MC_U105474168] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		AGUILAR F, 1993, P NATL ACAD SCI USA, V90, P8586, DOI 10.1073/pnas.90.18.8586; Ang HC, 2006, J BIOL CHEM, V281, P21934, DOI 10.1074/jbc.M604209200; BALAGURUMOORTHY P, 1995, P NATL ACAD SCI USA, V92, P8591, DOI 10.1073/pnas.92.19.8591; Baroni TE, 2004, P NATL ACAD SCI USA, V101, P4930, DOI 10.1073/pnas.0401162101; Bell S, 2002, J MOL BIOL, V322, P917, DOI 10.1016/S0022-2836(02)00848-3; Blagosklonny MV, 2000, FASEB J, V14, P1901, DOI 10.1096/fj.99-1078rev; Bode AM, 2004, NAT REV CANCER, V4, P793, DOI 10.1038/nrc1455; Brachmann RK, 1998, EMBO J, V17, P1847, DOI 10.1093/emboj/17.7.1847; Braithwaite AW, 2006, CELL DEATH DIFFER, V13, P984, DOI 10.1038/sj.cdd.4401924; BUCKLE AM, 1993, J MOL BIOL, V234, P847, DOI 10.1006/jmbi.1993.1630; Buckle AM, 1996, BIOCHEMISTRY-US, V35, P4298, DOI 10.1021/bi9524676; Bullock AN, 2000, ONCOGENE, V19, P1245, DOI 10.1038/sj.onc.1203434; Buschmann T, 2000, J MOL BIOL, V295, P1009, DOI 10.1006/jmbi.1999.3387; Butler JS, 2005, J MOL BIOL, V350, P906, DOI 10.1016/j.jmb.2005.05.060; Butler JS, 2003, BIOCHEMISTRY-US, V42, P2396, DOI 10.1021/bi026635n; Bykov VJN, 2003, EUR J CANCER, V39, P1828, DOI 10.1016/S0959-8049(03)00454-4; Canadillas JMP, 2006, P NATL ACAD SCI USA, V103, P2109, DOI 10.1073/pnas.0510941103; Chan WM, 2004, MOL CELL BIOL, V24, P3536, DOI 10.1128/MCB.24.8.3536-3551.2004; Chene P, 2001, ONCOGENE, V20, P2611, DOI 10.1038/sj.onc.1204373; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CLORE GM, 1995, NAT STRUCT BIOL, V2, P321, DOI 10.1038/nsb0495-321; COOK A, 1990, BRIT J CANCER, V61, P548, DOI 10.1038/bjc.1990.123; Cuff AL, 2004, J MOL BIOL, V344, P1199, DOI 10.1016/j.jmb.2004.10.015; Cuff AL, 2006, BIOINFORMATICS, V22, P1464, DOI 10.1093/bioinformatics/btl120; Dawson R, 2003, J MOL BIOL, V332, P1131, DOI 10.1016/j.jmb.2003.08.008; Dearth LR, 2007, CARCINOGENESIS, V28, P289, DOI 10.1093/carcin/bgl132; Dehner A, 2005, ANGEW CHEM INT EDIT, V44, P5247, DOI 10.1002/anie.200501887; DeLano W.L, PYMOL MOL GRAPHICS S; Derbyshire DJ, 2002, EMBO J, V21, P3863, DOI 10.1093/emboj/cdf383; Di Como CJ, 1998, ONCOGENE, V16, P2527; DiGiammarino EL, 2002, NAT STRUCT BIOL, V9, P12, DOI 10.1038/nsb730; Duan JX, 2006, BIOCHEMISTRY-US, V45, P7483, DOI 10.1021/bi0603165; Dunker AK, 2005, FEBS J, V272, P5129, DOI 10.1111/j.1742-4658.2005.04948.x; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ERIKSSON AE, 1992, SCIENCE, V255, P178, DOI 10.1126/science.1553543; Friedler A, 2005, J BIOL CHEM, V280, P8051, DOI 10.1074/jbc.M411176200; Friedler A, 2004, J MOL BIOL, V336, P187, DOI 10.1016/j.jmb.2003.12.005; Friedler A, 2003, J BIOL CHEM, V278, P24108, DOI 10.1074/jbc.M302458200; Friedler A, 2002, P NATL ACAD SCI USA, V99, P937, DOI 10.1073/pnas.241629998; Friedler A, 2005, STRUCTURE, V13, P629, DOI 10.1016/j.str.2005.01.020; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GHEBRANIOUS N, 1995, MOL CARCINOGEN, V13, P104, DOI 10.1002/mc.2940130207; Gorina S, 1996, SCIENCE, V274, P1001, DOI 10.1126/science.274.5289.1001; Grossman SR, 2001, EUR J BIOCHEM, V268, P2773, DOI 10.1046/j.1432-1327.2001.02226.x; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; Hamroun D, 2006, HUM MUTAT, V27, P14, DOI 10.1002/humu.20269; HARTMAN PE, 1973, ADV GENET, V17, P1, DOI 10.1016/S0065-2660(08)60170-4; Higashimoto Y, 2006, BIOCHEMISTRY-US, V45, P1608, DOI 10.1021/bi051192j; Ho WC, 2006, J BIOL CHEM, V281, P20494, DOI 10.1074/jbc.M603634200; Huyen Y, 2004, STRUCTURE, V12, P1237, DOI 10.1016/j.str.2004.05.007; Inga A, 2001, ONCOGENE, V20, P501, DOI 10.1038/sj.onc.1204116; Ishioka C, 1997, BIOCHEM BIOPH RES CO, V232, P54, DOI 10.1006/bbrc.1997.6216; Issaeva N, 2003, P NATL ACAD SCI USA, V100, P13303, DOI 10.1073/pnas.1835733100; JEFFREY PD, 1995, SCIENCE, V267, P1498, DOI 10.1126/science.7878469; Joerger AC, 2005, J BIOL CHEM, V280, P16030, DOI 10.1074/jbc.M500179200; Joerger AC, 2004, J BIOL CHEM, V279, P1291, DOI 10.1074/jbc.M309732200; Joerger AC, 2006, P NATL ACAD SCI USA, V103, P15056, DOI 10.1073/pnas.0607286103; Joo WS, 2002, GENE DEV, V16, P583, DOI 10.1101/gad.959202; Kato S, 2003, P NATL ACAD SCI USA, V100, P8424, DOI 10.1073/pnas.1431692100; Kawaguchi T, 2005, ONCOGENE, V24, P6976, DOI 10.1038/sj.onc.1208839; Kitayner M, 2006, MOL CELL, V22, P741, DOI 10.1016/j.molcel.2006.05.015; Klein C, 2001, J BIOL CHEM, V276, P49020, DOI 10.1074/jbc.M107516200; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; Laurent-Puig P, 2006, ONCOGENE, V25, P3778, DOI 10.1038/sj.onc.1209547; Lavin MF, 2006, CELL DEATH DIFFER, V13, P941, DOI 10.1038/sj.cdd.4401925; Lee H, 2000, J BIOL CHEM, V275, P29426, DOI 10.1074/jbc.M003107200; LEGROS Y, 1994, ONCOGENE, V9, P3689; Lilyestrom W, 2006, GENE DEV, V20, P2373, DOI 10.1101/gad.1456306; LU H, 1995, P NATL ACAD SCI USA, V92, P5154, DOI 10.1073/pnas.92.11.5154; Lunter G, 2004, BIOINFORMATICS, V20, P216, DOI 10.1093/bioinformatics/bth901; Marine JC, 2006, CELL DEATH DIFFER, V13, P927, DOI 10.1038/sj.cdd.4401912; Mateu MG, 1998, EMBO J, V17, P2748, DOI 10.1093/emboj/17.10.2748; Mateu MG, 1999, P NATL ACAD SCI USA, V96, P3595, DOI 10.1073/pnas.96.7.3595; Mathe E, 2006, NUCLEIC ACIDS RES, V34, P1317, DOI 10.1093/nar/gkj518; Mathe E, 2006, HUM MUTAT, V27, P163, DOI 10.1002/humu.20284; Matsumura I, 1999, PROTEIN SCI, V8, P731; Menendez D, 2006, MOL CELL BIOL, V26, P2297, DOI 10.1128/MCB.26.6.2297-2308.2006; Midgley CA, 1997, ONCOGENE, V15, P1179, DOI 10.1038/sj.onc.1201459; Mittl PRE, 1998, ACTA CRYSTALLOGR D, V54, P86, DOI 10.1107/S0907444997006550; Momand J, 2000, GENE, V242, P15, DOI 10.1016/S0378-1119(99)00487-4; Muller-Tiemann BF, 1998, P NATL ACAD SCI USA, V95, P6079, DOI 10.1073/pnas.95.11.6079; Nicholls CD, 2002, J BIOL CHEM, V277, P12937, DOI 10.1074/jbc.M108815200; Nikolova PV, 2000, EMBO J, V19, P370, DOI 10.1093/emboj/19.3.370; Nikolova PV, 1998, P NATL ACAD SCI USA, V95, P14675, DOI 10.1073/pnas.95.25.14675; OLIVEIRA LS, 1994, DRY TECHNOL, V12, P1167, DOI 10.1080/07373939408960994; Olivier M, 2002, HUM MUTAT, V19, P607, DOI 10.1002/humu.10081; Olivier M, 2003, CANCER RES, V63, P6643; Pan YP, 2006, BIOCHEMISTRY-US, V45, P3925, DOI 10.1021/bi052242n; Pan YP, 2005, BIOCHEMISTRY-US, V44, P1423, DOI 10.1021/bi047845y; PETITJEAN A, 2007, IN PRESS ONCOGENE; Poon A, 2005, GENETICS, V170, P1323, DOI 10.1534/genetics.104.037259; POTEETE AR, 1991, BIOCHEMISTRY-US, V30, P1425, DOI 10.1021/bi00219a037; Prives C, 2001, CELL, V107, P815, DOI 10.1016/S0092-8674(01)00619-5; Qian H, 2002, ONCOGENE, V21, P7901, DOI 10.1038/sj.onc.1205974; Resnick MA, 2003, P NATL ACAD SCI USA, V100, P9934, DOI 10.1073/pnas.1633803100; Rippin TM, 2002, J MOL BIOL, V319, P351, DOI 10.1016/S0022-2836(02)00326-1; Rosal R, 2004, BIOCHEMISTRY-US, V43, P1854, DOI 10.1021/bi035718g; Rustandi RR, 2000, NAT STRUCT BIOL, V7, P570; Ryan KM, 1998, MOL CELL BIOL, V18, P3692, DOI 10.1128/MCB.18.7.3692; Sakaguchi K, 1997, J PROTEIN CHEM, V16, P553, DOI 10.1023/A:1026334116189; Saller E, 1999, EMBO J, V18, P4424, DOI 10.1093/emboj/18.16.4424; SERRANO L, 1992, J MOL BIOL, V224, P783, DOI 10.1016/0022-2836(92)90562-X; Shiraishi K, 2004, J BIOL CHEM, V279, P348, DOI 10.1074/jbc.M310815200; Sigal A, 2000, CANCER RES, V60, P6788; STEPHEN CW, 1992, J MOL BIOL, V225, P577, DOI 10.1016/0022-2836(92)90386-X; Sujatha S, 2001, MOL GEN GENET, V264, P531, DOI 10.1007/s004380000353; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; Tidow H, 2006, J BIOL CHEM, V281, P32526, DOI 10.1074/jbc.M604725200; Trigiante G, 2006, NAT REV CANCER, V6, P217, DOI 10.1038/nrc1818; Veprintsev DB, 2006, P NATL ACAD SCI USA, V103, P2115, DOI 10.1073/pnas.0511130103; Walker KK, 1996, P NATL ACAD SCI USA, V93, P15335, DOI 10.1073/pnas.93.26.15335; Wang PL, 2001, ONCOGENE, V20, P2318, DOI 10.1038/sj.onc.1204316; Weinberg RL, 2005, J MOL BIOL, V348, P589, DOI 10.1016/j.jmb.2005.03.014; Weinberg RL, 2004, J MOL BIOL, V341, P1145, DOI 10.1016/j.jmb.2004.06.071; Weinberg RL, 2004, J MOL BIOL, V342, P801, DOI 10.1016/j.jmb.2004.07.042; Wieczorek AM, 1996, NAT MED, V2, P1143, DOI 10.1038/nm1096-1143; Wiman KG, 2006, CELL DEATH DIFFER, V13, P921, DOI 10.1038/sj.cdd.4401921; Wong KB, 1999, P NATL ACAD SCI USA, V96, P8438, DOI 10.1073/pnas.96.15.8438; Wray JW, 1999, J MOL BIOL, V292, P1111, DOI 10.1006/jmbi.1999.3102; Xu JA, 1998, PROTEIN SCI, V7, P158, DOI 10.1002/pro.5560070117; Yip YL, 2006, HUM MUTAT, V27, P926, DOI 10.1002/humu.20379; ZHANG W, 1994, EMBO J, V13, P2535, DOI 10.1002/j.1460-2075.1994.tb06543.x; Zhao KH, 2001, J BIOL CHEM, V276, P12120, DOI 10.1074/jbc.M011644200; Zupnick A, 2006, J BIOL CHEM, V281, P20464, DOI 10.1074/jbc.M603387200	124	300	307	0	44	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 2	2007	26	15					2226	2242		10.1038/sj.onc.1210291	http://dx.doi.org/10.1038/sj.onc.1210291			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	152XE	17401432				2022-12-28	WOS:000245394800012
J	Charette, ST; McCance, DJ				Charette, S. T.; McCance, D. J.			The E7 protein from human papillomavirus type 16 enhances keratinocyte migration in an Akt-dependent manner	ONCOGENE			English	Article						Akt; cervical cancer; HPV-16; migration; p27; RhoA	CELL-MIGRATION; EXPRESSION; P27(KIP1); P27; PROGRESSION; ARREST	Cyclin-dependent kinase inhibitor p27(kip1) (p27) has recently been implicated as a positive regulator of cellular motility and is a marker of poor prognosis in several forms of cancer when localized to the cytoplasm. Cytoplasmic p27 exerts its effect on migration by binding to and inhibiting the activation of the small GTPase and cytoskeletal organizer RhoA, consequentially loosening cell substrate grip and enhancing movement. Using DNA damage as a p27 nuclear import signal, we found that the E7 oncoprotein from human papillomavirus type 16 (HPV-16), the etiological agent of cervical cancer, enhanced both the cytoplasmic retention of p27 and the migration of human foreskin keratinocytes (HFKs) in a phosphoinositide-3 kinase (PI3K)/Akt-dependent manner using a standard wound assay. Increased migration in E7-expressing HFKs correlated with an Akt-regulated downregulation of RhoA activity through p27 binding under conditions where a p27 nuclear import signal is given (that is, DNA damage). Under these conditions, inhibition of the downstream RhoA effector ROCK enhanced control cell migration, whereas relatively unaffecting E7-expressing cells, further implicating that the inhibitory effect of E7 on RhoA positively regulates migration. We believe that the E7 protein from HPV-16 can modulate the cytoplasmic localization of p27 and may in turn regulate tumor metastasis/aggressiveness through the PI3K/Akt pathway.	Univ Rochester, Dept Microbiol & Immunol, Rochester, NY USA; Univ Rochester, James P Wilmot Canc Ctr, Rochester, NY USA	University of Rochester; University of Rochester	McCance, DJ (corresponding author), Queens Univ, Belfast City Hosp, Ctr Canc Res & Cell Biol, Belfast BTQ 7BL, Antrim, North Ireland.	d.mccance@qub.ac.uk			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI030798] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM068411] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI030798, AI030798] Funding Source: Medline; NIGMS NIH HHS [T32 GM068411, GM068411] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baseman JG, 2005, J CLIN VIROL, V32, pS16, DOI 10.1016/j.jcv.2004.12.008; Besson A, 2004, GENE DEV, V18, P862, DOI 10.1101/gad.1185504; Dellas A, 1998, ANTICANCER RES, V18, P3991; Doorbar J, 2006, CLIN SCI, V110, P525, DOI 10.1042/CS20050369; Fiedler M, 2004, FASEB J, V18, P1120, DOI 10.1096/fj.03-1332fje; Hudelist G, 2004, GYNECOL ONCOL, V92, P873, DOI 10.1016/j.ygyno.2003.11.035; Incassati A, 2006, ONCOGENE, V25, P2444, DOI 10.1038/sj.onc.1209276; Li R, 2006, J UROLOGY, V175, P528, DOI 10.1016/S0022-5347(05)00151-5; McAllister SS, 2003, MOL CELL BIOL, V23, P216, DOI 10.1128/MCB.23.1.216-228.2003; Menges CW, 2006, CANCER RES, V66, P5555, DOI 10.1158/0008-5472.CAN-06-0499; Motti ML, 2005, AM J PATHOL, V166, P737, DOI 10.1016/S0002-9440(10)62295-X; Nobes CD, 1999, J CELL BIOL, V144, P1235, DOI 10.1083/jcb.144.6.1235; Shin I, 2002, NAT MED, V8, P1145, DOI 10.1038/nm759; Shiozawa T, 2001, CANCER, V92, P3005, DOI 10.1002/1097-0142(20011215)92:12<3005::AID-CNCR10153>3.0.CO;2-6; Vasko V, 2004, J MED GENET, V41, P161, DOI 10.1136/jmg.2003.015339; Walboomers JMM, 1999, J PATHOL, V189, P12, DOI 10.1002/(SICI)1096-9896(199909)189:1&lt;12::AID-PATH431&gt;3.0.CO;2-F; Watanabe J, 2002, BRIT J CANCER, V87, P81, DOI 10.1038/sj.bjc.6600434; Westbrook TF, 2002, MOL CELL BIOL, V22, P7041, DOI 10.1128/MCB.22.20.7041-7052.2002; Wu FY, 2006, CANCER RES, V66, P2162, DOI 10.1158/0008-5472.CAN-05-3304; WU S, 1960, CLIN CANCER RES, V12, P2032	20	61	65	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 15	2007	26	52					7386	7390		10.1038/sj.onc.1210541	http://dx.doi.org/10.1038/sj.onc.1210541			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	231NP	17533372	Green Accepted			2022-12-28	WOS:000250955700011
J	Tang, X; Milyavsky, M; Goldfinger, N; Rotter, V				Tang, X.; Milyavsky, M.; Goldfinger, N.; Rotter, V.			Amyloid-beta precursor-like protein APLP1 is a novel p53 transcriptional target gene that augments neuroblastoma cell death upon genotoxic stress	ONCOGENE			English	Article						p53; APLP1; transcription; apoptosis; senescence; neuroblastoma and Alzheimer's disease	ALZHEIMERS-DISEASE; P53-INDUCED APOPTOSIS; NEURONAL APOPTOSIS; FAMILY-MEMBERS; MOUSE-BRAIN; EXPRESSION; CARCINOMA; CLEAVAGE; DENSITY; IMPAIRS	The tumor suppressor p53 is a key modulator of the cellular stress response, inducing cell-cycle arrest, apoptosis, senescence and cell differentiation. To evaluate further the molecular mechanism underlying p53 function, the transcriptional profiles of proliferating and senescent WI-38 cells, both wild-type p53 expressers and counterparts with an inactivated p53, were compared by DNA microarray analysis. In particular, the amyloid-beta precursor-like protein 1 (APLP1) is induced in senescent cells in a p53-dependent manner. APLP1 was confirmed to be a novel transcriptional target of p53 by in vivo and in vitro characterization of a p53 responsive element found in the first intron of the APLP1 gene locus. APLP1 knockdown experiments demonstrate that APLP1 is required for the proliferation of fibroblastic and epithelial cells. Moreover, depletion of APLP1 expression diminishes stress-induced apoptosis of neural cells, whereas ectopic APLP1 expression augments apoptosis. Based on these data, a mechanism is proposed whereby p53-dependent induction of APLP1 is involved in neural cell death, and which may exacerbate neuronal cell loss in some acute or chronic neurodegenerative disorders.	Weizmann Inst Sci, Dept Mol & Cell Biol, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Rotter, V (corresponding author), Weizmann Inst Sci, Dept Mol & Cell Biol, IL-76100 Rehovot, Israel.	varda.rotter@weizmann.ac.il	Milyavsky, Michael/E-8306-2011					Anandatheerthavarada HK, 2003, J CELL BIOL, V161, P41, DOI 10.1083/jcb.200207030; Attardi LD, 2000, GENE DEV, V14, P704; Bargonetti J, 2002, CURR OPIN ONCOL, V14, P86, DOI 10.1097/00001622-200201000-00015; Bayer TA, 1999, MOL PSYCHIATR, V4, P524, DOI 10.1038/sj.mp.4000552; Bayer TA, 1997, ACTA NEUROPATHOL, V94, P519, DOI 10.1007/s004010050745; Brummelkamp TR, 2002, CANCER CELL, V2, P243, DOI 10.1016/S1535-6108(02)00122-8; Cregan SP, 1999, J NEUROSCI, V19, P7860; Culmsee C, 2005, BIOCHEM BIOPH RES CO, V331, P761, DOI 10.1016/j.bbrc.2005.03.149; delaMonte SM, 1997, J NEUROL SCI, V152, P73, DOI 10.1016/S0022-510X(97)00131-7; Eggert S, 2004, J BIOL CHEM, V279, P18146, DOI 10.1074/jbc.M311601200; El-Deiry WS, 1998, SEMIN CANCER BIOL, V8, P345, DOI 10.1006/scbi.1998.0097; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; Galvan V, 2002, J NEUROCHEM, V82, P283, DOI 10.1046/j.1471-4159.2002.00970.x; Hainaut P, 1997, NUCLEIC ACIDS RES, V25, P151, DOI 10.1093/nar/25.1.151; Heber S, 2000, J NEUROSCI, V20, P7951; KIM TW, 1995, MOL BRAIN RES, V32, P36, DOI 10.1016/0169-328X(95)00328-P; Ko SY, 2004, INT J CANCER, V111, P727, DOI 10.1002/ijc.20328; LaFerla FM, 1996, J CLIN INVEST, V98, P1626, DOI 10.1172/JCI118957; Li QM, 2004, J BIOL CHEM, V279, P10542, DOI 10.1074/jbc.M310001200; LORENT K, 1995, NEUROSCIENCE, V65, P1009, DOI 10.1016/0306-4522(94)00555-J; Mattson MP, 2004, NATURE, V430, P631, DOI 10.1038/nature02621; McNamara MJ, 1998, BRAIN RES, V804, P45, DOI 10.1016/S0006-8993(98)00653-2; Meng JY, 2001, INT J CANCER, V92, P31, DOI 10.1002/1097-0215(200102)9999:9999<::AID-IJC1155>3.3.CO;2-8; Milyavsky M, 2005, CANCER RES, V65, P4530, DOI 10.1158/0008-5472.CAN-04-3880; Moll UM, 1996, MOL CELL BIOL, V16, P1126; Morrison RS, 2000, CELL DEATH DIFFER, V7, P868, DOI 10.1038/sj.cdd.4400741; Ossovskaya VS, 1996, P NATL ACAD SCI USA, V93, P10309, DOI 10.1073/pnas.93.19.10309; Pietrzik CU, 1998, P NATL ACAD SCI USA, V95, P1770, DOI 10.1073/pnas.95.4.1770; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Ryan KM, 2001, CURR OPIN CELL BIOL, V13, P332, DOI 10.1016/S0955-0674(00)00216-7; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; Stambolsky P, 2006, CELL DEATH DIFFER, V13, P2140, DOI 10.1038/sj.cdd.4401965; Takahashi M, 2000, NEURON, V28, P461, DOI 10.1016/S0896-6273(00)00125-2; Tang XH, 2004, ONCOGENE, V23, P5759, DOI 10.1038/sj.onc.1207706; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Ward MW, 2004, J BIOENERG BIOMEMBR, V36, P295, DOI 10.1023/B:JOBB.0000041756.23918.11; WASCO W, 1992, P NATL ACAD SCI USA, V89, P10758, DOI 10.1073/pnas.89.22.10758	37	24	27	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 15	2007	26	52					7302	7312		10.1038/sj.onc.1210542	http://dx.doi.org/10.1038/sj.onc.1210542			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	231NP	17533371				2022-12-28	WOS:000250955700002
J	Oxford, G; Smith, SC; Hampton, G; Theodorescu, D				Oxford, G.; Smith, S. C.; Hampton, G.; Theodorescu, D.			Expression profiling of Ral-depleted bladder cancer cells identifies RREB-1 as a novel transcriptional Ral effector	ONCOGENE			English	Article						GTPases; bladder neoplasms; biomarker; metastasis	GTPASES; CARCINOMA; ACTIVATION; PROTEIN; KINASE; GROWTH; RLIP76; PROLIFERATION; METASTASIS; CONTRIBUTE	Although the monomeric GTPases RalA and RalB have been shown to regulate a variety of transcription factors, little is known regarding the differences or similarities in transcriptional programs regulated by RalA compared to RalB. Further, the association of these transcriptional pathways to human carcinogenesis and progression remains unclear. Here, we studied the role of RalA and/or RalB in transcriptional regulation by combining short interfering RNA depletion of Ral with gene expression pro. ling via microarray in the human bladder cancer cell line, UMUC-3. A large number of genes were found to be similarly modulated in cells with RalA and RalB depletion, suggesting that RalA and RalB impinge on overlapping transcriptional signaling pathways. However, smaller sets of genes were modulated by depletion of RalA or RalB, indicating that these closely related proteins also regulate nonoverlapping transcriptional pathways. Computational analysis of upstream sequences of genes modulated by Ral depletion identified Ras-responsive element-binding protein ( RREB)-1, as a putative Ral transcriptional target, which we verified experimentally. Importantly, as a group, Ral-regulated probe sets identified here were disproportionally represented among those differentially expressed as a function of human bladder transformation. Taken together, these data strongly suggest that Ral family members mediate both common and specific transcriptional programs that are associated with human cancer and identify RREB-1 as a novel transcriptional effector of Ral.	Univ Virginia, Hlth Sci Ctr, Dept Mol Physiol & Biol Phys, Charlottesville, VA 22908 USA; Genom Inst Novartis Res Fdn, San Diego, CA USA	University of Virginia; Novartis	Theodorescu, D (corresponding author), Univ Virginia, Hlth Sci Ctr, Dept Mol Physiol & Biol Phys, Box 422, Charlottesville, VA 22908 USA.	dt9d@virginia.edu	Smith, Steven Christopher/S-9375-2019; Smith, Steven/HDM-9496-2022	Smith, Steven Christopher/0000-0003-0982-4607; 	NCI NIH HHS [R01 CA075115, P01CA104106, CA075115, CA009109-29] Funding Source: Medline; NIGMS NIH HHS [T32GM007267] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA075115, R29CA075115, P01CA104106] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007267] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Awasthi S, 2000, BIOCHEMISTRY-US, V39, P9327, DOI 10.1021/bi992964c; Awasthi S, 2003, INT J CANCER, V106, P635, DOI 10.1002/ijc.11260; Bigler D, 2003, ONCOGENE, V22, P1261, DOI 10.1038/sj.onc.1206242; Camonis JH, 2005, TRENDS CELL BIOL, V15, P327, DOI 10.1016/j.tcb.2005.04.002; Carmeliet P, 2005, ONCOLOGY-BASEL, V69, P4, DOI 10.1159/000088478; Chien YC, 2003, EMBO REP, V4, P800, DOI 10.1038/sj.embor.embor899; Dyrskjot L, 2004, CANCER RES, V64, P4040, DOI 10.1158/0008-5472.CAN-03-3620; Feig LA, 2003, TRENDS CELL BIOL, V13, P419, DOI 10.1016/S0962-8924(03)00152-1; Gildea JJ, 2002, CANCER RES, V62, P982; GROSSMAN HB, 1986, J UROLOGY, V136, P953, DOI 10.1016/S0022-5347(17)45139-1; Hamad NM, 2002, GENE DEV, V16, P2045, DOI 10.1101/gad.993902; Haverty PM, 2004, NUCLEIC ACIDS RES, V32, pW213, DOI 10.1093/nar/gkh402; Henry DO, 2000, MOL CELL BIOL, V20, P8084, DOI 10.1128/MCB.20.21.8084-8092.2000; Jebar AH, 2005, ONCOGENE, V24, P5218, DOI 10.1038/sj.onc.1208705; JULLIENFLORES V, 1995, J BIOL CHEM, V270, P22473, DOI 10.1074/jbc.270.38.22473; Lebreton S, 2004, MECH DEVELOP, V121, P1481, DOI 10.1016/j.mod.2004.07.008; Lim KH, 2005, CANCER CELL, V7, P533, DOI 10.1016/j.ccr.2005.04.030; Lim KH, 2006, CURR BIOL, V16, P2385, DOI 10.1016/j.cub.2006.10.023; Moskalenko S, 2003, J BIOL CHEM, V278, P51743, DOI 10.1074/jbc.M308702200; Nicholson BE, 2004, CANCER RES, V64, P7813, DOI 10.1158/0008-5472.CAN-04-0826; Ohta Y, 1999, P NATL ACAD SCI USA, V96, P2122, DOI 10.1073/pnas.96.5.2122; Oxford G, 2005, CANCER RES, V65, P7111, DOI 10.1158/0008-5472.CAN-04-1957; Shi YJ, 2003, NATURE, V422, P735, DOI 10.1038/nature01550; Shipitsin M, 2004, MOL CELL BIOL, V24, P5746, DOI 10.1128/MCB.24.13.5746-5756.2004; Smith SC, 2006, CANCER RES, V66, P1917, DOI 10.1158/0008-5472.CAN-05-3855; Thiagalingam A, 1996, MOL CELL BIOL, V16, P5335; Ward Y, 2001, MOL CELL BIOL, V21, P5958, DOI 10.1128/MCB.21.17.5958-5969.2001; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; Wolthuis RMF, 1998, CURR BIOL, V8, P471, DOI 10.1016/S0960-9822(98)70183-6; Wu X, 2004, BJU INT, V93, P143, DOI 10.1111/j.1464-410X.2004.04574.x; Zhang SL, 2003, ONCOGENE, V22, P2285, DOI 10.1038/sj.onc.1206257	31	17	19	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 1	2007	26	50					7143	7152		10.1038/sj.onc.1210521	http://dx.doi.org/10.1038/sj.onc.1210521			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	228GF	17496927				2022-12-28	WOS:000250715000008
J	Di Maira, G; Brustolon, F; Bertacchini, J; Tosoni, K; Marmiroli, S; Pinna, LA; Ruzzene, M				Di Maira, G.; Brustolon, F.; Bertacchini, J.; Tosoni, K.; Marmiroli, S.; Pinna, L. A.; Ruzzene, M.			Pharmacological inhibition of protein kinase CK2 reverts the multidrug resistance phenotype of a CEM cell line characterized by high CK2 level	ONCOGENE			English	Article						CK2; MDR; CEM cells; inhibitors; casein kinase 2; CKII	INDUCED APOPTOSIS; CASEIN KINASE-2; P-GLYCOPROTEIN; CANCER-CELLS; II-ALPHA; IN-VIVO; 4,5,6,7-TETRABROMOBENZOTRIAZOLE; PHOSPHORYLATES; EXPRESSION; AKT/PKB	Protein kinase CK2 is an ubiquitous and constitutively active kinase, which phosphorylates many cellular proteins and is implicated in the regulation of cell survival, proliferation and transformation. We investigated its possible involvement in the multidrug resistance phenotype (MDR) by analysing its level in two variants of CEM cells, namely S-CEM and R.-CEM, normally sensitive or resistant to chemical apoptosis, respectively. We found that, while the CK2 regulatory subunit beta was equally expressed in the two cell variants, CK2 alpha catalytic subunit was higher in R-CEM and this was accompanied by a higher phosphorylation of endogenous protein substrates. Pharmacological downregulation of CK2 activity by a panel of specific inhibitors, or knockdown of CK2 alpha expression by RNA interference, were able to induce cell death in R-CEM. CK2 inhibitors could promote an increased uptake of chemotherapeutic drugs inside the cells and sensitize them to drug-induced apoptosis in a co-operative manner. CK2 blockade was also effective in inducing cell death of a different MDR line (U2OS). We therefore conclude that inhibition of CK2 can be considered as a promising tool to revert the MDR phenotype.	Univ Padua, Dept Biol Chem, I-35121 Padua, Italy; Univ Padua, Inst Neurosci, CNR, Padua, Italy; VIMM, Padua, Italy; Univ Modena & Reggio Emilia, Dept Anat & Histol, Modena, Italy	University of Padua; Consiglio Nazionale delle Ricerche (CNR); University of Padua; Veneto Institute Molecular Medicine; Universita di Modena e Reggio Emilia	Ruzzene, M (corresponding author), Univ Padua, Dept Biol Chem, Viale G Colombo 3, I-35121 Padua, Italy.	maria.ruzzene@unipd.it	BERTACCHINI, JESSIKA/F-4382-2017; Marmiroli, Sandra/J-5242-2016	BERTACCHINI, JESSIKA/0000-0001-9218-9215; Marmiroli, Sandra/0000-0001-5545-9319; Di Maira, Giovanni/0000-0003-2041-6022; Ruzzene, Maria/0000-0001-8712-8151; Pinna, Lorenzo A./0000-0002-8856-4956				Ahmad KA, 2005, ANTI-CANCER DRUG, V16, P1037, DOI 10.1097/00001813-200511000-00001; Ahmad KA, 2007, MOL CANCER THER, V6, P1006, DOI 10.1158/1535-7163.MCT-06-0491; Ahmed K, 2002, TRENDS CELL BIOL, V12, P226, DOI 10.1016/S0962-8924(02)02279-1; Allende CC, 1998, J CELL BIOCHEM, P129; Borst P, 1997, SEMIN CANCER BIOL, V8, P131, DOI 10.1006/scbi.1997.0072; Cenni V, 2004, INT J ONCOL, V25, P1599; De Moliner E, 2003, J BIOL CHEM, V278, P1831, DOI 10.1074/jbc.M209367200; Di Maira G, 2005, CELL DEATH DIFFER, V12, P668, DOI 10.1038/sj.cdd.4401604; Dupuis ML, 2003, CHEMOTHERAPY, V49, P8, DOI 10.1159/000069782; Filhol O, 2004, EMBO REP, V5, P351, DOI 10.1038/sj.embor.7400115; Giovannetti E, 2004, CLIN CANCER RES, V10, P2936, DOI 10.1158/1078-0432.CCR-03-0520; Glavy JS, 1997, J BIOL CHEM, V272, P5909, DOI 10.1074/jbc.272.9.5909; Guerra B, 1999, ELECTROPHORESIS, V20, P391, DOI 10.1002/(SICI)1522-2683(19990201)20:2<391::AID-ELPS391>3.0.CO;2-N; Guo CH, 2001, J BIOL CHEM, V276, P5992, DOI 10.1074/jbc.M004862200; Kelliher MA, 1996, EMBO J, V15, P5160, DOI 10.1002/j.1460-2075.1996.tb00900.x; Klumpp S, 2004, NEUROCHEM INT, V45, P747, DOI 10.1016/j.neuint.2004.02.006; Landesman-Bollag E, 1998, ONCOGENE, V16, P2965, DOI 10.1038/sj.onc.1201854; Ling V, 1997, CANCER CHEMOTH PHARM, V40, pS3, DOI 10.1007/s002800051053; Litchfield DW, 2003, BIOCHEM J, V369, P1, DOI 10.1042/BJ20021469; Matsumoto Y, 2001, JPN J CANCER RES, V92, P778, DOI 10.1111/j.1349-7006.2001.tb01161.x; Meggio F, 2003, FASEB J, V17, P349, DOI 10.1096/fj.02-0473rev; Meggio F, 2004, BIOCHEMISTRY-US, V43, P12931, DOI 10.1021/bi048999g; Orlandini M, 1998, J BIOL CHEM, V273, P21291, DOI 10.1074/jbc.273.33.21291; Pagano MA, 2004, J MED CHEM, V47, P6239, DOI 10.1021/jm049854a; Pinna LA, 2002, J CELL SCI, V115, P3873, DOI 10.1242/jcs.00074; PINNA LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P267, DOI 10.1016/0167-4889(90)90098-X; Ruzzene M, 2002, BIOCHEM J, V364, P41, DOI 10.1042/bj3640041; Salvi M, 2006, FEBS LETT, V580, P3948, DOI 10.1016/j.febslet.2006.06.031; Sarno S, 2005, BBA-PROTEINS PROTEOM, V1754, P263, DOI 10.1016/j.bbapap.2005.07.043; Sarno S, 2005, MOL CELL BIOCHEM, V274, P69, DOI 10.1007/s11010-005-3079-z; Sarno S, 2003, BIOCHEM J, V374, P639, DOI 10.1042/BJ20030674; Sarno S, 2001, FEBS LETT, V496, P44, DOI 10.1016/S0014-5793(01)02404-8; Sawicka M, 2004, J PHARM PHARMACOL, V56, P1067, DOI 10.1211/0022357044265; Seeber S, 2005, APOPTOSIS, V10, P875, DOI 10.1007/s10495-005-0380-y; SELDIN DC, 1995, SCIENCE, V267, P894, DOI 10.1126/science.7846532; SZYSZKA R, 1995, BIOCHEM BIOPH RES CO, V208, P418, DOI 10.1006/bbrc.1995.1354; Tapia JC, 2006, P NATL ACAD SCI USA, V103, P15079, DOI 10.1073/pnas.0606845103	37	70	71	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 18	2007	26	48					6915	6926		10.1038/sj.onc.1210495	http://dx.doi.org/10.1038/sj.onc.1210495			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	220WQ	17486073				2022-12-28	WOS:000250188400007
J	Manuylov, NL; Smagulova, FO; Tevosian, SG				Manuylov, N. L.; Smagulova, F. O.; Tevosian, S. G.			Fog2 excision in mice leads to premature mammary gland involution and reduced Esr1 gene expression	ONCOGENE			English	Article						GATA; FOG2; estrogen receptor; transcription factor; mammary; involution	ESTROGEN-RECEPTOR-ALPHA; HUMAN BREAST-CANCER; PROGESTERONE-RECEPTOR; COFACTOR; DIFFERENTIATION; PROTEIN; FAMILY; GATA-3; BCL-2; IDENTIFICATION	The critical role for GATA family proteins in maintaining the normal (non-transformed) cell state is corroborated by the recent findings of mutations or methylation in GATA genes both in primary cancers and tumor lines including breast. Previously, microarray pro. ling studies determined that the highest expression of both GATA3 and ESR1 ( estrogen receptor a) is seen in tumors associated with the most favorable survival outcomes, whereas the lowest expression of GATA3 is detected in tumor subtypes showing the worst outcomes. At this time, genes and pathways that are regulated by GATA3 in the mammary gland are not well defined. We have previously established a requirement for FOG ( Friend Of GATA) cofactors during mouse development. Here we report that in the murine mammary gland Fog2 gene expression is upregulated upon pregnancy and lactation with prominent expression in the epithelial cells of the gland during post-lactational regression. Mammary-specific deletion of Fog2 identified a role for this gene during gland involution; excision of the Fog2 gene leads to the accelerated involution of the gland despite diminished levels of the remodeling enzymes. Importantly, the levels of several genes linked to the control of cancerous transformation in the breast ( Esr1, Prg and Foxa1) are significantly reduced upon Fog2 excision. This implicates FOG2 in the maintenance of epithelial cell differentiation in the mammary gland and in performing a protective role in breast cancer.	Dartmouth Coll, Sch Med, Dept Genet, Hanover, NH 03755 USA; Dartmouth Coll, Sch Med, Norris Cotton Canc Ctr, Hanover, NH 03755 USA	Dartmouth College; Dartmouth College; Norris Cotton Cancer Center	Tevosian, SG (corresponding author), Dartmouth Coll, Sch Med, Dept Genet, Hanover, NH 03755 USA.	sergei.g.tevosian@dartmouth.edu	Smagulova, Fatima/K-5459-2015	Smagulova, Fatima/0000-0001-6883-1968				Adameyko II, 2005, DEV DYNAM, V233, P540, DOI 10.1002/dvdy.20368; Akiyama Y, 2003, MOL CELL BIOL, V23, P8429, DOI 10.1128/MCB.23.23.8429-8439.2003; Allar MA, 2004, ENDOCRINOLOGY, V145, P2467, DOI 10.1210/en.2003-1641; Amin DN, 2004, ONCOGENE, V23, P1428, DOI 10.1038/sj.onc.1207257; Bertucci F, 2004, ONCOGENE, V23, P2564, DOI 10.1038/sj.onc.1207361; Bertucci F, 2000, HUM MOL GENET, V9, P2981, DOI 10.1093/hmg/9.20.2981; Booth BW, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1538; Cantor AB, 2005, SEMIN CELL DEV BIOL, V16, P117, DOI 10.1016/j.semcdb.2004.10.006; Crispino JD, 2005, SEMIN CELL DEV BIOL, V16, P137, DOI 10.1016/j.semcdb.2004.11.002; Crispino JD, 1999, MOL CELL, V3, P219, DOI 10.1016/S1097-2765(00)80312-3; Eeckhoute J, 2006, GENE DEV, V20, P2513, DOI 10.1101/gad.1446006; Gruvberger S, 2001, CANCER RES, V61, P5979; Han XY, 2003, J BIOL CHEM, V278, P47785, DOI 10.1074/jbc.M309482200; Hoch RV, 1999, INT J CANCER, V84, P122; Huggins GS, 2006, CANCER RES, V66, P1384, DOI 10.1158/0008-5472.CAN-05-2715; Jordan VC, 2004, CANCER CELL, V5, P207, DOI 10.1016/S1535-6108(04)00059-5; Kobayashi S, 2006, FASEB J, V20, P800, DOI 10.1096/fj.05-5426fje; Kouros-Mehr H, 2006, CELL, V127, P1041, DOI 10.1016/j.cell.2006.09.048; Lacroix M, 2004, MOL CELL ENDOCRINOL, V219, P1, DOI 10.1016/j.mce.2004.02.021; Laganiere J, 2005, P NATL ACAD SCI USA, V102, P11651, DOI 10.1073/pnas.0505575102; Lu JR, 1999, MOL CELL BIOL, V19, P4495; Mallepell S, 2006, P NATL ACAD SCI USA, V103, P2196, DOI 10.1073/pnas.0510974103; Master SR, 2002, MOL ENDOCRINOL, V16, P1185, DOI 10.1210/me.16.6.1185; Mehra R, 2005, CANCER RES, V65, P11259, DOI 10.1158/0008-5472.CAN-05-2495; Metcalfe AD, 1999, J CELL SCI, V112, P1771; Mundschau G, 2003, BLOOD, V101, P4298, DOI 10.1182/blood-2002-12-3904; Murphy KL, 1999, ONCOGENE, V18, P6597, DOI 10.1038/sj.onc.1203099; Parikh P, 2005, J AM COLL SURGEONS, V200, P705, DOI 10.1016/j.jamcollsurg.2004.12.025; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Polyak K, 2006, CANCER CELL, V9, P151, DOI 10.1016/j.ccr.2006.02.026; Schorr K, 1999, CANCER RES, V59, P2541; Shen DJ, 2005, BIOCHEM BIOPH RES CO, V326, P218, DOI 10.1016/j.bbrc.2004.10.214; Sorlie T, 2003, P NATL ACAD SCI USA, V100, P8418, DOI 10.1073/pnas.0932692100; Svensson EC, 1999, P NATL ACAD SCI USA, V96, P956, DOI 10.1073/pnas.96.3.956; Tevosian SG, 2000, CELL, V101, P729, DOI 10.1016/S0092-8674(00)80885-5; Tevosian SG, 2002, DEVELOPMENT, V129, P4627; Tevosian SG, 1999, P NATL ACAD SCI USA, V96, P950, DOI 10.1073/pnas.96.3.950; Thangaraju M, 2005, DEVELOPMENT, V132, P4675, DOI 10.1242/dev.02050; Thangaraju M, 2004, ONCOGENE, V23, P2548, DOI 10.1038/sj.onc.1207363; Tsang AP, 1997, CELL, V90, P109, DOI 10.1016/S0092-8674(00)80318-9; Usary J, 2004, ONCOGENE, V23, P7669, DOI 10.1038/sj.onc.1207966; van de Rijn M, 2002, AM J PATHOL, V161, P1991, DOI 10.1016/S0002-9440(10)64476-8; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Wagner KU, 1997, NUCLEIC ACIDS RES, V25, P4323, DOI 10.1093/nar/25.21.4323; Wagner KU, 2001, TRANSGENIC RES, V10, P545, DOI 10.1023/A:1013063514007; Wechsler J, 2002, NAT GENET, V32, P148, DOI 10.1038/ng955; West M, 2001, P NATL ACAD SCI USA, V98, P11462, DOI 10.1073/pnas.201162998; Wolf I, 2007, INT J CANCER, V120, P1013, DOI 10.1002/ijc.22389	48	22	23	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 9	2007	26	36					5204	5213		10.1038/sj.onc.1210333	http://dx.doi.org/10.1038/sj.onc.1210333			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	199CQ	17310981				2022-12-28	WOS:000248674200004
J	Pulukuri, SM; Patibandla, S; Patel, J; Estes, N; Rao, JS				Pulukuri, S. M.; Patibandla, S.; Patel, J.; Estes, N.; Rao, J. S.			Epigenetic inactivation of the tissue inhibitor of metalloproteinase-2 (TIMP-2) gene in human prostate tumors	ONCOGENE			English	Article						CpG methylation; TIMP-2; MeCP2; prostate cancer	IN-VIVO; TRANSCRIPTIONAL REPRESSION; CANCER STATISTICS; DNA METHYLATION; GELATINASE-A; EXPRESSION; INVASION; CELLS; HYPERMETHYLATION; ANGIOGENESIS	Gene silencing via CpG island methylation in the promoter region is one of the mechanisms by which tumor suppressor genes are inactivated in human cancers. Previous studies have shown that the tissue inhibitors of metalloproteinases (TIMP)-2 gene, which is an endogenous inhibitor of matrix metalloproteinases involved in cell invasion and tumorigenesis, is downregulated or silenced in a variety of human cancer cell lines. Here, we investigated the mechanism underlying TIMP-2 expression in prostate cancer cell lines and primary prostate tumor samples. We observed a strong correlation between promoter hypermethylation and lost expression of TIMP-2 gene, which was supported by other results demonstrating that promoter demethylation by 5-aza-2'-deoxycytidine and trichostatin A reactivated TIMP-2 and restored its expression in TIMP-2-silenced metastatic prostate cell lines. These results were further substantiated by a chromatin immunoprecipitation assay, showing the preferential binding of MeCP2 to methylated CpG island in TIMP-2-silenced metastatic prostate cell lines. In vitro Matrigel invasion assays showed that re-expression of TIMP- 2 after a combined treatment with 5-aza and trichostatin-A in metastatic prostate cells resulted in a significant reduction of tumor cell invasion. Furthermore, CpG methylation of TIMP- 2 promoter was also shown in primary prostate tumors that expressed decreased TIMP-2 protein levels. These results suggest that the downregulation of the TIMP- 2 gene is associated with promoter methylation and that this may play an important role in prostate cancer progression during the invasive and metastatic stages of the disease.	Univ Illinois, Coll Med, Dept Canc Biol & Pharmacol, Peoria, IL 61656 USA; Univ Illinois, Coll Med, Dept Pathol, Peoria, IL 61656 USA; Univ Illinois, Coll Med, Dept Surg, Peoria, IL 61656 USA; Univ Illinois, Coll Med, Dept Neurosurg, Peoria, IL 61656 USA	University of Illinois System; University of Illinois Peoria; University of Illinois System; University of Illinois Peoria; University of Illinois System; University of Illinois Peoria; University of Illinois System; University of Illinois Peoria	Rao, JS (corresponding author), Univ Illinois, Coll Med, Dept Canc Biol & Pharmacol, Box-1649, Peoria, IL 61656 USA.	jsrao@uic.edu			NCI NIH HHS [R01 CA075557, CA75557, CA116708, CA95058, R01 CA116708, CA92393, R01 CA092393, R01 CA095058] Funding Source: Medline; NINDS NIH HHS [R01 NS047699, NS57529, NS47699, R01 NS057529] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA075557, R01CA092393, R01CA095058, R01CA116708] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS057529, R01NS047699] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bachman KE, 1999, CANCER RES, V59, P798; Das PM, 2004, J CLIN ONCOL, V22, P4632, DOI 10.1200/JCO.2004.07.151; DECLERCK YA, 1992, CANCER RES, V52, P701; Esteller M, 2001, CANCER RES, V61, P3225; Galm O, 2005, ONCOGENE, V24, P4799, DOI 10.1038/sj.onc.1208599; Gokaslan ZL, 1998, CLIN EXP METASTAS, V16, P721, DOI 10.1023/A:1006580728338; Gomez DE, 1997, EUR J CELL BIOL, V74, P111; Hajitou A, 2001, CANCER RES, V61, P3450; Hegeman Robert B, 2004, Clin Prostate Cancer, V3, P150, DOI 10.3816/CGC.2004.n.025; Imren S, 1996, CANCER RES, V56, P2891; Ivanova T, 2004, INT J CANCER, V108, P882, DOI 10.1002/ijc.11652; Jemal A, 2003, CA-CANCER J CLIN, V53, P5, DOI 10.3322/canjclin.53.1.5; Jemal A, 2004, CA-CANCER J CLIN, V54, P8, DOI 10.3322/canjclin.54.1.8; Kasamon KM, 2004, CURR OPIN UROL, V14, P185, DOI 10.1097/00042307-200405000-00008; LIOTTA LA, 1980, NATURE, V284, P67, DOI 10.1038/284067a0; MOHANAM S, 1995, CLIN EXP METASTAS, V13, P57, DOI 10.1007/BF00144019; Nagase H, 1998, Cell Res, V8, P179; Oliver GW, 1997, ANAL BIOCHEM, V244, P161, DOI 10.1006/abio.1996.9895; Pennie WD, 1999, CELL GROWTH DIFFER, V10, P279; Pulukuri SM, 2006, ONCOGENE, V25, P4559, DOI 10.1038/sj.onc.1209462; Rao JS, 2003, NAT REV CANCER, V3, P489, DOI 10.1038/nrc1121; Suzuki H, 2002, NAT GENET, V31, P141, DOI 10.1038/ng892; Valente P, 1998, INT J CANCER, V75, P246, DOI 10.1002/(SICI)1097-0215(19980119)75:2<246::AID-IJC13>3.0.CO;2-B; Wajed SA, 2001, ANN SURG, V234, P10, DOI 10.1097/00000658-200107000-00003; Yamamoto M, 1996, CANCER RES, V56, P384; Yoon SO, 2001, J BIOL CHEM, V276, P20085, DOI 10.1074/jbc.M101143200; Yu F, 2000, NUCLEIC ACIDS RES, V28, P2201, DOI 10.1093/nar/28.10.2201	27	70	71	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 9	2007	26	36					5229	5237		10.1038/sj.onc.1210329	http://dx.doi.org/10.1038/sj.onc.1210329			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	199CQ	17325663	Green Accepted			2022-12-28	WOS:000248674200006
J	Thirunarayanan, N; Cifire, F; Fichtner, I; Posner, S; Benga, J; Relterer, P; Krernmer, E; Koble, K; Lipp, M				Thirunarayanan, N.; Cifire, F.; Fichtner, I.; Posner, S.; Benga, J.; Relterer, P.; Krernmer, E.; Koeble, K.; Lipp, M.			Enhanced tumorigenicity of fibroblasts transformed with human herpesvirus 8 chemokine receptor vGPCR by successive passage in nude and immunocompetent mice	ONCOGENE			English	Article						chemokine receptor; vGPCR; Kaposi's sarcoma; animal model; HHV-8	PROTEIN-COUPLED RECEPTOR; SARCOMA-ASSOCIATED HERPESVIRUS; ENDOTHELIAL GROWTH-FACTOR; KAPOSIS-SARCOMA; MAMMALIAN-CELLS; EXPRESSION; ACTIVATION; INFECTION; ORF74; MODEL	The human herpes virus 8 (HHV-8)-encoded G protein-coupled chemokine receptor (vGPCR) has been implicated in the pathogenesis of Kaposi's sarcoma (KS), particularly because of its high constitutive signaling activity. Here, we used retroviral transduction to generate vGPCR-expressing 3T3 fibroblasts that are tumorigenic in nude mice, but as expected fail to induce tumors in their immunocompetent counterparts. However, tumor fragments obtained from nude mice grow progressively in immunocompetent BALB/c mice. Unexpectedly, vGPCR-expressing cells established from grafted tumor fragments gave rise to tumors in immunocompetent mice. These tumors exhibit a striking histological resemblance to KS including plump spindle cell morphology, a high degree of vascularization and brisk mitotic activity. High expression of vGPCR was confirmed in the cell lines and tumors using a newly developed vGPCR-specific monoclonal antibody. Finally, short interfering RNA directed at vGPCR abrogated or significantly delayed tumorigenesis in mice, demonstrating that the tumor development is specifically driven by vGPCR. This novel model for vGPCR-mediated oncogenesis will contribute to our understanding of the role of vGPCR in the pathogenesis of HHV-8 and may even be important in identifying critical molecular and epigenetic changes during tumor progression in vivo.	Max Delbruck Ctr Mol Med, Dept Tumor Genet & Immunogenet, D-13125 Berlin, Germany; Max Delbruck Ctr Mol Med, Dept Expt Pharmacol, D-13125 Berlin, Germany; GSF Munich, Res Ctr, Inst Mol Immunol, Munich, Germany; Univ Klinikum Charite, Inst Pathol, Berlin, Germany	Helmholtz Association; Max Delbruck Center for Molecular Medicine; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Lipp, M (corresponding author), Max Delbruck Ctr Mol Med, Dept Tumor Genet & Immunogenet, Robert Rossle Str 10, D-13125 Berlin, Germany.	mLIPP@mdc-berlin.de	Lipp, Martin/G-2235-2010	Lipp, Martin/0000-0002-0087-2672				Akula SM, 2003, J VIROL, V77, P7978, DOI 10.1128/JVI.77.14.7978-7990.2003; Arvanitakis L, 1997, NATURE, V385, P347, DOI 10.1038/385347a0; Bais C, 2003, CANCER CELL, V3, P131, DOI 10.1016/S1535-6108(03)00024-2; Bais C, 1998, NATURE, V391, P86, DOI 10.1038/34193; Brekken RA, 2001, J CONTROL RELEASE, V74, P173, DOI 10.1016/S0168-3659(01)00333-9; Cerimele F, 2001, J VIROL, V75, P2435, DOI 10.1128/JVI.75.5.2435-2443.2001; Cesarman E, 2000, J EXP MED, V191, P417, DOI 10.1084/jem.191.3.417; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; Chiou CJ, 2002, J VIROL, V76, P3421, DOI 10.1128/JVI.76.7.3421-3439.2002; EMRICH T, 1993, BIOCHEM BIOPH RES CO, V197, P214, DOI 10.1006/bbrc.1993.2463; Flore O, 1998, NATURE, V394, P588, DOI 10.1038/29093; Forster R, 1998, J IMMUNOL, V160, P1522; Gallo RC, 1998, SCIENCE, V282, P1837, DOI 10.1126/science.282.5395.1837; Gershengorn MC, 1998, J CLIN INVEST, V102, P1469, DOI 10.1172/JCI4461; Guo HG, 2003, J VIROL, V77, P2631, DOI 10.1128/JVI.77.4.2631-2639.2003; Holst PJ, 2001, J CLIN INVEST, V108, P1789, DOI 10.1172/JCI13622; Hopken UE, 2004, EUR J IMMUNOL, V34, P461, DOI 10.1002/eji.200324690; Jensen KK, 2005, J IMMUNOL, V174, P3686, DOI 10.4049/jimmunol.174.6.3686; KAAYA EE, 1995, J ACQ IMMUN DEF SYND, V10, P295; Kirshner JR, 1999, J VIROL, V73, P6006, DOI 10.1128/JVI.73.7.6006-6014.1999; Kolble K, 1999, LAB INVEST, V79, P1145; Monini P, 1999, BLOOD, V93, P4044; Montaner S, 2003, CANCER CELL, V3, P23, DOI 10.1016/S1535-6108(02)00237-4; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Muller G, 2001, BIOL CHEM, V382, P1387, DOI 10.1515/BC.2001.171; Ochsenbein AF, 1999, P NATL ACAD SCI USA, V96, P2233, DOI 10.1073/pnas.96.5.2233; Ochsenbein AF, 2001, NATURE, V411, P1058, DOI 10.1038/35082583; Pati S, 2001, J VIROL, V75, P8660, DOI 10.1128/JVI.75.18.8660-8673.2001; QIN ZH, 1995, CANCER RES, V55, P4747; Quan N, 1999, CANCER RES, V59, P1080; Rubinson DA, 2003, NAT GENET, V33, P401, DOI 10.1038/ng1117; Samaniego F, 2002, CELL GROWTH DIFFER, V13, P387; Skobe M, 1999, J INVEST DERMATOL, V113, P1047, DOI 10.1046/j.1523-1747.1999.00798.x; Yang TY, 2000, J EXP MED, V191, P445, DOI 10.1084/jem.191.3.445	34	5	5	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2007	26	39					5702	5712		10.1038/sj.onc.1210357	http://dx.doi.org/10.1038/sj.onc.1210357			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	202EP	17353903				2022-12-28	WOS:000248885100002
J	Hsieh, PC; Chang, JC; Sun, WT; Hsieh, SC; Wang, MC; Wang, FF				Hsieh, P-C; Chang, J-C; Sun, W-T; Hsieh, S-C; Wang, M-C; Wang, F-F			p53 downstream target DDA3 is a novel microtubule-associated protein that interacts with end-binding protein EB3 and activates ss-catenin pathway	ONCOGENE			English	Article						DDA3; microtubule; EB3; p53; ss-catenin	CELL-LINES; GENE; IDENTIFICATION; FAMILY; EXPRESSION; INDUCTION; HOMOLOG; SYSTEM; GROWTH; APC2	We have previously identified mouse DDA3 as a p53-inducible gene. To explore the functional role of DDA3, we screened a mouse brain cDNA library by the yeast two-hybrid assay, and identi. ed the microtubule plus-end binding protein EB3 as a DDA3-interacting protein. Binding of DDA3 to EB3 was veri. ed by glutathione S-transferase (GST) pull-down assay and subcellular colocalization; co-immunoprecipitation further indicated that interaction of these two proteins within cells required intact microtubules. Domains of DDA3-EB3 interaction were mapped by GST pull-down assay to amino acids 118-241 and 242-329 of DDA3 and the N-and C-termini of EB3. Immuno. uorescence analysis revealed colocalization of DDA3 with microtubules in various cell phases, and regions encompassing aa 118-241 and 242-329 contained microtubule-interacting and bundling activities. In vitro microtubule-binding assay showed that DDA3 and EB3 associated directly with microtubules, and cooperated with each other for microtubule binding. In addition, DDA3 bound to the EB3 interacting partner adenomatous polyposis coli 2 (APC2), a homolog of the tumor suppressor APC, which is a component of the beta-catenin destruction complex. Ectopic expression of DDA3 and EB3 enhanced b-catenin-dependent transactivation and cyclin D1 production, whereas knockdown of endogenous DDA3 or EB3 inhibited b-catenin-mediated transactivation and the ability of cells to form colonies. Together, our results identify DDA3 as a novel microtubule-associated protein that binds to EB3, and implicate DDA3 and EB3 in the b-catenin-mediated growth signaling.	Natl Yang Ming Univ, Inst Biochem & Mol Biol, Taipei 112, Taiwan; Ind Technol Res Inst, Biomed Engn Ctr, Div Biomat & Tissue Engn, Hsinchu, Taiwan	National Yang Ming Chiao Tung University; Industrial Technology Research Institute - Taiwan	Wang, FF (corresponding author), Natl Yang Ming Univ, Inst Biochem & Mol Biol, Taipei 112, Taiwan.	ffwang@ym.edu.tw		HSIEH, SHU-CHEN/0000-0002-0844-7435; Wang, Mei-Chih/0000-0003-0520-9316				Behrens J, 2000, ANN NY ACAD SCI, V910, P21; Bensaad K, 2006, CELL, V126, P107, DOI 10.1016/j.cell.2006.05.036; Bienz M, 2002, NAT REV MOL CELL BIO, V3, P328, DOI 10.1038/nrm806; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Bu W, 2003, J BIOL CHEM, V278, P49721, DOI 10.1074/jbc.M306194200; Bu W, 2001, ONCOGENE, V20, P3185, DOI 10.1038/sj.onc.1204429; Fang L, 2001, EMBO J, V20, P1931, DOI 10.1093/emboj/20.8.1931; Hainaut P, 1998, NUCLEIC ACIDS RES, V26, P205, DOI 10.1093/nar/26.1.205; Han JA, 2002, EMBO J, V21, P5635, DOI 10.1093/emboj/cdf591; Hanson CA, 2005, GENE, V361, P1, DOI 10.1016/j.gene.2005.07.024; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Hoffman WH, 2002, J BIOL CHEM, V277, P3247, DOI 10.1074/jbc.M106643200; Hofseth LJ, 2004, TRENDS PHARMACOL SCI, V25, P177, DOI 10.1016/j.tips.2004.02.009; Honnappa S, 2005, EMBO J, V24, P261, DOI 10.1038/sj.emboj.7600529; Hsieh SC, 2002, ONCOGENE, V21, P3050, DOI 10.1038/sj.onc.1205417; Iwai A, 2004, ONCOGENE, V23, P7593, DOI 10.1038/sj.onc.1208016; Jarrett CR, 2001, CANCER RES, V61, P7978; Johnsen JI, 2000, INT J CANCER, V88, P685, DOI 10.1002/1097-0215(20001201)88:5<685::AID-IJC1>3.0.CO;2-Z; Levine Arnold J., 2004, Cell, VS116, pS67, DOI 10.1016/S0092-8674(04)00036-4; Lo PK, 1999, ONCOGENE, V18, P7765, DOI 10.1038/sj.onc.1203167; Matsuzawa S, 2001, MOL CELL, V7, P915, DOI 10.1016/S1097-2765(01)00242-8; Miller SJ, 2006, CANCER RES, V66, P2584, DOI 10.1158/0008-5472.CAN-05-3330; Moon RT, 2004, NAT REV GENET, V5, P689, DOI 10.1038/nrg1427; Nakagawa H, 1998, CANCER RES, V58, P5176; Nakagawa H, 2000, ONCOGENE, V19, P210, DOI 10.1038/sj.onc.1203308; Nakamura M, 2001, CURR BIOL, V11, P1062, DOI 10.1016/S0960-9822(01)00297-4; Ongusaha PP, 2003, EMBO J, V22, P1289, DOI 10.1093/emboj/cdg129; Park WR, 2005, CANCER RES, V65, P1197, DOI 10.1158/0008-5472.CAN-04-3339; Senda Takao, 2005, Anatomical Science International, V80, P121, DOI 10.1111/j.1447-073x.2005.00106.x; SU LK, 1995, CANCER RES, V55, P2972; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; van Es JH, 1999, CURR BIOL, V9, P105, DOI 10.1016/S0960-9822(99)80024-4; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wang YH, 2005, ONCOGENE, V24, P6637, DOI 10.1038/sj.onc.1208819	34	37	41	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2007	26	34					4928	4940		10.1038/sj.onc.1210304	http://dx.doi.org/10.1038/sj.onc.1210304			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	194CV	17310996				2022-12-28	WOS:000248322500005
J	Okuyama, R; Ogawa, E; Nagoshi, H; Yabuki, M; Kurihara, A; Terui, T; Aiba, S; Obinata, M; Tagami, H; Ikawa, S				Okuyama, R.; Ogawa, E.; Nagoshi, H.; Yabuki, M.; Kurihara, A.; Terui, T.; Aiba, S.; Obinata, M.; Tagami, H.; Ikawa, S.			p53 homologue, p51/p63, maintains the immaturity of keratinocyte stem cells by inhibiting Notch1 activity	ONCOGENE			English	Article						p51/p63; Notch; keratinocyte; stem cell; p53; tumor suppressor	NF-KAPPA-B; SPONTANEOUS TUMORS; MICE LACKING; IKK-ALPHA; P63; DIFFERENTIATION; EXPRESSION; MECHANISM; ONCOGENE; KINASE	p53 homologue, p51/p63, predominantly expressed in keratinocyte stem cells, is indispensable for the formation of epidermis. Notch1, another such gene indispensable for the process, induces growth arrest and differentiation in keratinocytes. We found that exogenous expression of Delta Np51B (Delta Np63 alpha), one of the isoforms of p51 specifically expressed in basal keratinocytes, blocked Notch 1-dependent growth arrest and differentiation in mouse keratinocytes by inhibiting p21 expression and maintaining integrins expression. Furthermore, DNp51B by itself was found to have ability to induce expression of integrin alpha 6 beta 4, which promotes attachment of basal cells to basal membrane thereby keeping the cells in immature state. Therefore, we conclude that DNp51B expression warrants integrin expression even under the influence of Notch1 and that Delta Np51B is a long-sought factor required to maintain basal cell keratinocytes immaturity by inhibiting Notch1 activity. We will postulate a plausible model explaining the maintenance of the squamous epithelium architectures as well as offering mechanistic explanations for pathological features of skin diseases, including cancers, psoriasis along with physiological wound healings.	Tohoku Univ, Grad Sch Med, Dept Dermatol, Aoba Ku, Sendai, Miyagi, Japan; Tohoku Univ, Interdisciplinary Res Ctr, Ikawa Grp, Aoba Ku, Sendai, Miyagi, Japan; Tohoku Univ, Inst Dev Aging & Canc, Dept Cell Biol, Aoba Ku, Sendai, Miyagi, Japan; Tohoku Univ, Grad Sch Life Sci, Lab Cell Differentiat, Aoba Ku, Sendai, Miyagi, Japan	Tohoku University; Tohoku University; Tohoku University; Tohoku University	Ikawa, S (corresponding author), Tohoku Univ, Interdisciplinary Res Ctr, Aoba Ku, Aramaki,6-3 Aoba, Sendai, Miyagi 9808578, Japan.	sikawa@cir.tohoku.ac.jp	井川, 俊太郎/L-5911-2015					Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Bourdon JC, 2005, GENE DEV, V19, P2122, DOI 10.1101/gad.1339905; Celli J, 1999, CELL, V99, P143, DOI 10.1016/S0092-8674(00)81646-3; Crook T, 2000, ONCOGENE, V19, P3439, DOI 10.1038/sj.onc.1203656; CUI R, 2005, IN PRESS BIOCH BIOPH; Dajee M, 2003, NATURE, V421, P639, DOI 10.1038/nature01283; Dohn M, 2001, ONCOGENE, V20, P3193, DOI 10.1038/sj.onc.1204427; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Duijf PHG, 2002, HUM MOL GENET, V11, P799, DOI 10.1093/hmg/11.7.799; FUCHS E, 1990, J CELL BIOL, V111, P2807, DOI 10.1083/jcb.111.6.2807; Hagiwara K, 1999, CANCER RES, V59, P4165; HENNINGS H, 1980, CELL, V19, P245, DOI 10.1016/0092-8674(80)90406-7; Hibi K, 2000, P NATL ACAD SCI USA, V97, P5462, DOI 10.1073/pnas.97.10.5462; Hu YL, 1999, SCIENCE, V284, P316, DOI 10.1126/science.284.5412.316; Huber MA, 2004, J CLIN INVEST, V114, P569, DOI 10.1172/JCI200421358; Ikawa S, 1999, CELL DEATH DIFFER, V6, P1154, DOI 10.1038/sj.cdd.4400631; JARRIAULT S, 1995, NATURE, V377, P355, DOI 10.1038/377355a0; Koster MI, 2004, GENE DEV, V18, P126, DOI 10.1101/gad.1165104; Mainiero F, 1997, EMBO J, V16, P2365, DOI 10.1093/emboj/16.9.2365; McGrath JA, 2001, HUM MOL GENET, V10, P221, DOI 10.1093/hmg/10.3.221; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; Mills AA, 2006, CURR OPIN GENET DEV, V16, P38, DOI 10.1016/j.gde.2005.12.001; Nguyen BC, 2006, GENE DEV, V20, P1028, DOI 10.1101/gad.1406006; Nicolas M, 2003, NAT GENET, V33, P416, DOI 10.1038/ng1099; Okuyama R, 2004, DEV CELL, V6, P551, DOI 10.1016/S1534-5807(04)00098-X; Osada M, 1998, NAT MED, V4, P839, DOI 10.1038/nm0798-839; Park BJ, 2000, CANCER RES, V60, P3370; Parsa R, 1999, J INVEST DERMATOL, V113, P1099, DOI 10.1046/j.1523-1747.1999.00780.x; Patturajan M, 2002, CANCER CELL, V1, P369, DOI 10.1016/S1535-6108(02)00057-0; Rangarajan A, 2001, EMBO J, V20, P3427, DOI 10.1093/emboj/20.13.3427; Ratovitski EA, 2001, P NATL ACAD SCI USA, V98, P1817, DOI 10.1073/pnas.98.4.1817; Serber Z, 2002, MOL CELL BIOL, V22, P8601, DOI 10.1128/MCB.22.24.8601-8611.2002; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Stiewe T, 2002, CANCER RES, V62, P3598; Takeda K, 1999, SCIENCE, V284, P313, DOI 10.1126/science.284.5412.313; Thelu Jacques, 2002, BMC Dermatol, V2, P7, DOI 10.1186/1471-5945-2-7; Uyttendaele H, 2004, DIFFERENTIATION, V72, P396, DOI 10.1111/j.1432-0436.2004.07208006.x; Wu GJ, 2003, CANCER RES, V63, P2351; Yang A, 2000, NAT REV MOL CELL BIO, V1, P199, DOI 10.1038/35043127; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Zhu AJ, 1999, P NATL ACAD SCI USA, V96, P6728, DOI 10.1073/pnas.96.12.6728	43	57	59	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2007	26	31					4478	4488		10.1038/sj.onc.1210235	http://dx.doi.org/10.1038/sj.onc.1210235			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	187GR	17237812				2022-12-28	WOS:000247836100002
J	Vecchi, M; Nuciforo, P; Romagnoli, S; Confalonieri, S; Pellegrini, C; Serio, G; Quarto, M; Capra, M; Roviaro, GC; Contessini Avesani, E; Corsi, C; Coggi, G; Di Fiore, PP; Bosari, S				Vecchi, M.; Nuciforo, P.; Romagnoli, S.; Confalonieri, S.; Pellegrini, C.; Serio, G.; Quarto, M.; Capra, M.; Roviaro, G. C.; Contessini Avesani, E.; Corsi, C.; Coggi, G.; Di Fiore, P. P.; Bosari, S.			Gene expression analysis of early and advanced gastric cancers	ONCOGENE			English	Article						gastric cancer; early gastric cancer; advanced gastric cancer; gene expression profiling; tissue microarrays	LONG-TERM; MUCOSA; CARCINOGENESIS; METASTASIS; PROFILES; INVASION; CLAUDINS	Gastric carcinoma is one of the major causes of cancer mortality worldwide. Early detection results in excellent prognosis for patients with early cancer (EGC), whereas the prognosis of advanced cancer (AGC) patients remains poor. It is not clear whether EGC and AGC are molecularly distinct, and whether they represent progressive stages of the same tumor or different entities ab initio. Gene expression profiles of EGC and AGC were determined by Affymetrix technology and quantitative polymerase chain reaction. Representative regulated genes were further analysed by in situ hybridization (ISH) on tissue microarrays. Expression analysis allowed the identification of a signature that differentiates AGC from EGC. In addition, comparison with normal gastric mucosa indicated that the majority of alterations associated with EGC are retained in AGC, and that further expression changes mark the transition from EGC to AGC. Finally, ISH analysis showed that representative genes, differentially expressed in the invasive areas of EGC and AGC, are not differentially expressed in the non-invasive areas of the same tumors. Our data are more directly compatible with a progression model of gastric carcinogenesis, whereby EGC and AGC may represent different molecular stages of the same tumor. Finally, the identification of an AGC-specific signature might help devising novel therapeutic strategies for advanced gastric cancer.	Univ Milan, Dipartimento Med Chirurgia & Odontoiatria, Osped San Paolo & Fdn IRCCS Osped Maggiore Policl, Pathol Unit, I-20142 Milan, Italy; IFOM Fdn, Ist FIRC Oncol Mol, Milan, Italy; Univ Milan, Fdn IRCCS Osped Maggiore Policlin Mangiagalli & R, Dipartimento Sci Chirurg, Milan, Italy; AO San Paolo, Dipartimento Chirurg & Special Chirurg, Milan, Italy; Ist Europeo Oncol, Dipartimento Oncol Sperimentale, Milan, Italy; Univ Milan, Dipartimento Med Chirurg & Odontoiatria, Milan, Italy	University of Milan; IFOM - FIRC Institute of Molecular Oncology; IRCCS Ca Granda Ospedale Maggiore Policlinico; University of Milan; IRCCS European Institute of Oncology (IEO); University of Milan	Bosari, S (corresponding author), Univ Milan, Dipartimento Med Chirurgia & Odontoiatria, Osped San Paolo & Fdn IRCCS Osped Maggiore Policl, Pathol Unit, I-20142 Milan, Italy.	pierpaolo.difiore@ifom-ieocampus.it; silvano.bosari@unimi.it	Serio, Gabriella/AAU-4967-2020; Nuciforo, Paolo/Q-2885-2019; Vecchi, Manuela/L-3502-2017; Bosari, Silvano/K-7744-2016; Confalonieri, Stefano/AAQ-6786-2020; Di Fiore, Pier Paolo/K-2130-2012	Serio, Gabriella/0000-0001-9021-4560; Vecchi, Manuela/0000-0002-2750-9160; Bosari, Silvano/0000-0002-9744-6951; Confalonieri, Stefano/0000-0001-6886-9851; Di Fiore, Pier Paolo/0000-0002-2252-0950; Nuciforo, Paolo/0000-0003-1380-0990				Balkwill F, 2001, LANCET, V357, P539, DOI 10.1016/S0140-6736(00)04046-0; Bhowmick NA, 2004, SCIENCE, V303, P848, DOI 10.1126/science.1090922; Boussioutas A, 2003, CANCER RES, V63, P2569; Cunha GR, 2003, INT J CANCER, V107, P1, DOI 10.1002/ijc.11335; Dicken BJ, 2005, ANN SURG, V241, P27, DOI 10.1097/01.sla.0000149300.28588.23; EBERWINE J, 1992, P NATL ACAD SCI USA, V89, P3010, DOI 10.1073/pnas.89.7.3010; Farrell JJ, 2002, J CLIN INVEST, V109, P193, DOI 10.1172/JCI200212529; Hasegawa S, 2002, CANCER RES, V62, P7012; HENDERSON BE, 1990, J NATL CANCER I, V82, P1186, DOI 10.1093/jnci/82.14.1186; Hippo Y, 2001, CANCER RES, V61, P889; Houghton J, 2004, SCIENCE, V306, P1568, DOI 10.1126/science.1099513; Jinawath N, 2004, ONCOGENE, V23, P6830, DOI 10.1038/sj.onc.1207886; KAJITANI T, 1981, JPN J SURG, V11, P127; Katoh M, 2003, INT J MOL MED, V11, P683; Kim B, 2003, CANCER RES, V63, P8248; Kirikoshi H, 2002, INT J ONCOL, V21, P655; Kononen J, 1998, NAT MED, V4, P844, DOI 10.1038/nm0798-844; LAWRENCE M, 1991, ANN SURG, V213, P327, DOI 10.1097/00000658-199104000-00007; Lee Jong Hoon, 2003, Korean J Gastroenterol, V42, P484; Lefebvre O, 1996, SCIENCE, V274, P259, DOI 10.1126/science.274.5285.259; Meireles SI, 2004, CANCER RES, V64, P1255, DOI 10.1158/0008-5472.CAN-03-1850; Moody SE, 2005, CANCER CELL, V8, P197, DOI 10.1016/j.ccr.2005.07.009; MULLIN JM, 2004, SCI STKE; Norsett KG, 2004, CANCER LETT, V210, P227, DOI 10.1016/j.canlet.2004.01.022; Oue N, 2004, CANCER RES, V64, P2397, DOI 10.1158/0008-5472.CAN-03-3514; Parkin DM, 2004, ONCOGENE, V23, P6329, DOI 10.1038/sj.onc.1207726; Ramaswamy S, 2003, NAT GENET, V33, P49, DOI 10.1038/ng1060; Rugge M, 2003, GUT, V52, P1111, DOI 10.1136/gut.52.8.1111; Swisshelm K, 2005, ADV DRUG DELIVER REV, V57, P919, DOI 10.1016/j.addr.2005.01.006; Tsukuma H, 2000, GUT, V47, P618, DOI 10.1136/gut.47.5.618; TSUKUMA H, 1983, INT J CANCER, V31, P421, DOI 10.1002/ijc.2910310405; Van Itallie CM, 2006, ANNU REV PHYSIOL, V68, P403, DOI 10.1146/annurev.physiol.68.040104.131404; Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034; Wang CS, 1997, J AM COLL SURGEONS, V185, P476, DOI 10.1016/S1072-7515(97)00076-8; Wang TC, 1998, GASTROENTEROLOGY, V115, P780, DOI 10.1016/S0016-5085(98)70159-3; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006; Yu CD, 2005, WORLD J GASTROENTERO, V11, P2390, DOI 10.3748/wjg.v11.i16.2390	37	60	63	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 21	2007	26	29					4284	4294		10.1038/sj.onc.1210208	http://dx.doi.org/10.1038/sj.onc.1210208			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	184CY	17297478				2022-12-28	WOS:000247619900011
J	Kim, M; Egan, C; Alain, T; Urbanski, SJ; Lee, PW; Forsyth, PA; Johnston, RN				Kim, M.; Egan, C.; Alain, T.; Urbanski, S. J.; Lee, P. W.; Forsyth, P. A.; Johnston, R. N.			Acquired resistance to reoviral oncolysis in Ras-transformed brosarcoma cells	ONCOGENE			English	Article						reovirus; Ras; oncolysis; resistance	CATHEPSIN-B; PERSISTENT INFECTION; CANCER-THERAPY; INTERFERON; PATHWAY; VIRUS; GENE; MACROPHAGES; ACTIVATION; EXPRESSION	Reovirus shows considerable potential as an oncolytic agent for Ras- activated tumors and is currently in clinical trials. Here we ask whether such tumor cell lines can acquire resistance to reoviral oncolysis. We challenged human HT1080. fibrosarcoma cells that carry a Ras mutation by prolonged exposure to reovirus, thereby yielding highly virus- resistant HTR1 cells. These cells are persistently infected with reovirus, exhibit high Ras activity and retain the original Ras gene mutation, showing that resistance to reovirus can be displayed in cells with active Ras. The HTR1 cells also exhibit reduced cellular cathepsin B activity, which normally contributes to viral entry and activation. Persistently infected HTR1 cells were not tumorigenic in vivo, whereas immunologically cured virus- free HTR1 cells were highly tumorigenic. Thus, acquisition of resistance to reovirus may constrain therapeutic strategies. To determine whether reoviral resistance is associated with a general reduction in apoptotic potential, we challenged the HTR1 cells with apoptotic inducers and E1B- defective adenovirus, resulting in significant apoptosis and cell death following both approaches. Therefore, even if resistance to reoviral oncolysis should arise in tumor cells in vivo, other therapeutic strategies may nevertheless remain effective.	Univ Calgary, Fac Med, Dept Biochem & Mol Biol, Calgary, AB T2N 4N1, Canada; Univ Calgary, Fac Med, Dept Oncol, Calgary, AB T2N 4N1, Canada; Univ Calgary, Fac Med, Dept Pathol, Calgary, AB T2N 4N1, Canada; Dalhousie Univ, Dept Microbiol & Immunol, Halifax, NS B3H 3J5, Canada	University of Calgary; University of Calgary; University of Calgary; Dalhousie University	Johnston, RN (corresponding author), Univ Calgary, Fac Med, Dept Biochem & Mol Biol, Room HMRB 371,3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.	rnjohnst@ucalgary.ca	Johnston, Randal/B-9247-2009					AHMED R, 1981, CELL, V25, P325, DOI 10.1016/0092-8674(81)90050-7; Baer GS, 1999, J VIROL, V73, P9532, DOI 10.1128/JVI.73.11.9532-9543.1999; BARRETT AJ, 1981, METHOD ENZYMOL, V80, P535; BROWN R, 1984, EMBO J, V3, P1321, DOI 10.1002/j.1460-2075.1984.tb01970.x; BUTTLE DJ, 1992, ARCH BIOCHEM BIOPHYS, V299, P377, DOI 10.1016/0003-9861(92)90290-D; Clarke P, 2001, ONCOGENE, V20, P6910, DOI 10.1038/sj.onc.1204842; Coffey MC, 1998, SCIENCE, V282, P1332, DOI 10.1126/science.282.5392.1332; Connolly JL, 2002, J VIROL, V76, P1632, DOI 10.1128/JVI.76.4.1632-1641.2002; Danis C, 1997, VIRUS RES, V51, P139, DOI 10.1016/S0168-1702(97)00088-9; Dermody TS, 1998, CURR TOP MICROBIOL, V233, P1; DERMODY TS, 1995, VIROLOGY, V212, P272, DOI 10.1006/viro.1995.1483; deRooij J, 1997, ONCOGENE, V14, P623, DOI 10.1038/sj.onc.1201005; DUNCAN MR, 1978, J VIROL, V28, P444, DOI 10.1128/JVI.28.2.444-449.1978; Duursma AM, 2003, SEMIN CANCER BIOL, V13, P267, DOI 10.1016/S1044-579X(03)00040-3; Ebert DH, 2004, J BIOL CHEM, V279, P3837, DOI 10.1074/jbc.M310048200; HASHIRO G, 1977, ARCH VIROL, V54, P307, DOI 10.1007/BF01314776; Kominsky DJ, 2002, CELL DEATH DIFFER, V9, P926, DOI 10.1038/sj.cdd.4401045; Langland JO, 2006, VIRUS RES, V119, P100, DOI 10.1016/j.virusres.2005.10.014; Loken SD, 2004, CANCER BIOL THER, V3, P734, DOI 10.4161/cbt.3.8.963; Meusel TR, 2003, J IMMUNOL, V171, P3768, DOI 10.4049/jimmunol.171.7.3768; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; NAGATA L, 1984, NUCLEIC ACIDS RES, V12, P8699, DOI 10.1093/nar/12.22.8699; Norman KL, 2005, DRUG DISCOV TODAY, V10, P847, DOI 10.1016/S1359-6446(05)03483-5; PATERSON H, 1987, CELL, V51, P803, DOI 10.1016/0092-8674(87)90103-6; Samuel CE, 1998, CURR TOP MICROBIOL, V233, P125; Schotte P, 2001, J BIOL CHEM, V276, P21153, DOI 10.1074/jbc.M102239200; Shiratsuchi A, 2000, J VIROL, V74, P9240, DOI 10.1128/JVI.74.19.9240-9244.2000; SMITH RE, 1969, VIROLOGY, V39, P791, DOI 10.1016/0042-6822(69)90017-8; Steele TA, 2005, EXP BIOL MED, V230, P487; Steele TA, 1996, P SOC EXP BIOL MED, V212, P63; Stewart MJ, 2005, J VIROL, V79, P2979, DOI 10.1128/JVI.79.5.2979-2987.2005; Stoeckel J, 2006, CURR OPIN MOL THER, V8, P249; Strong JE, 1998, EMBO J, V17, P3351, DOI 10.1093/emboj/17.12.3351; TABER R, 1976, J VIROL, V17, P513, DOI 10.1128/JVI.17.2.513-524.1976; TEODORO JG, 1994, J VIROL, V68, P776, DOI 10.1128/JVI.68.2.776-786.1994; TYLER KL, 2001, LIPPINCOTT FIELDS VI, P1729; WONG H, 1994, ANAL BIOCHEM, V223, P251, DOI 10.1006/abio.1994.1581; Yeung MC, 1999, P NATL ACAD SCI USA, V96, P11860, DOI 10.1073/pnas.96.21.11860	38	38	42	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 14	2007	26	28					4124	4134		10.1038/sj.onc.1210189	http://dx.doi.org/10.1038/sj.onc.1210189			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	178XD	17213803				2022-12-28	WOS:000247252700008
J	Riz, I; Akimov, SS; Eaker, SS; Baxter, KK; Lee, HJ; Marino-Ramirez, L; Landsman, D; Hawley, TS; Hawley, RG				Riz, I.; Akimov, S. S.; Eaker, S. S.; Baxter, K. K.; Lee, H. J.; Marino-Ramirez, L.; Landsman, D.; Hawley, T. S.; Hawley, R. G.			TLX1/HOX11-induced hematopoietic differentiation blockade	ONCOGENE			English	Article						TLX1/HOX11 oncogene; erythropoiesis; conditional differentiation block; CBP; GATA-1; repressive chromatin domains	TRANSCRIPTION FACTOR GATA-1; CREB-BINDING PROTEIN; T-CELL LEUKEMIA; THYMOCYTE DIFFERENTIATION; ERYTHROID-CELLS; HOX11 INTERACTS; HOMEOBOX GENES; CBP; ACETYLATION; ONCOPROTEIN	Aberrant expression of the human homeobox-containing proto-oncogene TLX1/HOX11 inhibits hematopoietic differentiation programs in a number of murine model systems. Here, we report the establishment of a murine erythroid progenitor cell line, iEBHX1S-4, developmentally arrested by regulatable TLX1 expression. Extinction of TLX1 expression released the iEBHX1S-4 differentiation block, allowing erythropoietin-dependent acquisition of erythroid markers and hemoglobin synthesis. Coordinated activation of erythroid transcriptional networks integrated by the acetyltransferase co-activator CREB-binding protein (CBP) was suggested by bioinformatic analysis of the upstream regulatory regions of several conditionally induced iEBHX1S-4 gene sets. In accord with this notion, CBP-associated acetylation of GATA-1, an essential regulator of erythroid differentiation, increased concomitantly with TLX1 downregulation. Coimmunoprecipitation experiments and glutathione-S-transferase pull-down assays revealed that TLX1 directly binds to CBP, and confocal laser microscopy demonstrated that the two proteins partially colocalize at intranuclear sites in iEBHX1S-4 cells. Notably, the distribution of CBP in conditionally blocked iEBHX1S-4 cells partially overlapped with chromatin marked by a repressive histone methylation pattern, and downregulation of TLX1 coincided with exit of CBP from these heterochromatic regions. Thus, we propose that TLX1-mediated differentiation arrest may be achieved in part through a mechanism that involves redirection of CBP and/or its sequestration in repressive chromatin domains.	George Washington Univ, Dept Anat & Cell Biol, Med Ctr, Washington, DC 20037 USA; NanoDetect Technol, Knoxville, TN USA; George Washington Univ, Mol Med Program, Med Ctr, Washington, DC 20037 USA; George Washington Univ, Genom & Bioinformat Program, Med Ctr, Washington, DC 20037 USA; Natl Ctr Biotechnol Informat, Computat Biol Branch, Natl Lib Med, NIH, Bethesda, MD USA; George Washington Univ, Flow Cytometry Core Facil, Med Ctr, Washington, DC 20037 USA	George Washington University; George Washington University; George Washington University; National Institutes of Health (NIH) - USA; NIH National Library of Medicine (NLM); George Washington University	Hawley, TS (corresponding author), George Washington Univ, Dept Anat & Cell Biol, Med Ctr, 2300 I St NW, Washington, DC 20037 USA.	rghawley@gwu.edu	Mariño-Ramírez, Leonardo/N-5395-2019; Landsman, David/GZK-5496-2022; Landsman, David/C-5923-2009; Mariño-Ramírez, Leonardo/I-5759-2013	Mariño-Ramírez, Leonardo/0000-0002-5716-8512; Landsman, David/0000-0002-9819-6675; Mariño-Ramírez, Leonardo/0000-0002-5716-8512; Hawley, Robert/0000-0003-3512-5818	Intramural NIH HHS [Z99 LM999999] Funding Source: Medline; NHLBI NIH HHS [R01 HL066305-05, R01 HL065519-04, R01 HL066305-02, R01 HL065519-01A1, R01 HL065519-02, R01 HL065519, R01 HL065519-06, R01 HL065519-03, R01 HL066305-04, R01 HL066305-03, R01 HL065519-05, R01 HL066305, R01 HL066305-01A1] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL065519, R01HL066305] Funding Source: NIH RePORTER; NATIONAL LIBRARY OF MEDICINE [Z01LM000084] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL LIBRARY OF MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM))		Ait-Si-Ali S, 2000, ONCOGENE, V19, P2430, DOI 10.1038/sj.onc.1203562; Akimov SS, 2005, STEM CELLS, V23, P1423, DOI 10.1634/stemcells.2005-0390; Allen TD, 2000, LEUKEMIA LYMPHOMA, V39, P241, DOI 10.3109/10428190009065824; Bayly R, 2004, J BIOL CHEM, V279, P55362, DOI 10.1074/jbc.M408654200; Berger LC, 1997, BLOOD, V89, P261, DOI 10.1182/blood.V89.1.261.261_261_271; Blobel GA, 2000, BLOOD, V95, P745, DOI 10.1182/blood.V95.3.745.003k05_745_755; Blobel GA, 1998, P NATL ACAD SCI USA, V95, P2061, DOI 10.1073/pnas.95.5.2061; Choi YJ, 2006, CANCER RES, V66, P2990, DOI 10.1158/0008-5472.CAN-05-2944; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; DEAR TN, 1993, P NATL ACAD SCI USA, V90, P4431, DOI 10.1073/pnas.90.10.4431; Deguchi K, 2003, CANCER CELL, V3, P259, DOI 10.1016/S1535-6108(03)00051-5; Greer L, 1998, INT J NON-EQUILIB PR, V11, P1; Guenatri M, 2004, J CELL BIOL, V166, P493, DOI 10.1083/jcb.200403109; HAWLEY RG, 1994, ONCOGENE, V9, P1; Hawley RG, 1997, CANCER RES, V57, P337; Heidari M, 2006, LEUKEMIA, V20, P304, DOI 10.1038/sj.leu.2404071; Helt AM, 2003, CARCINOGENESIS, V24, P159, DOI 10.1093/carcin/24.2.159; Herblot S, 2000, NAT IMMUNOL, V1, P138, DOI 10.1038/77819; Hernandez-Hernandez A, 2006, EMBO J, V25, P3264, DOI 10.1038/sj.emboj.7601228; Hong W, 2002, MOL CELL BIOL, V22, P3729, DOI 10.1128/MCB.22.11.3729-3743.2002; Huang SM, 1999, ONCOGENE, V18, P4958, DOI 10.1038/sj.onc.1202889; Hung HL, 1999, MOL CELL BIOL, V19, P3496; Iyer NG, 2004, ONCOGENE, V23, P4225, DOI 10.1038/sj.onc.1207118; KAMPS MP, 1994, ONCOGENE, V9, P3159; Kang-Decker N, 2004, CANCER CELL, V5, P177, DOI 10.1016/S1535-6108(04)00022-4; Karuppayil SM, 1998, J BIOL CHEM, V273, P17303, DOI 10.1074/jbc.273.28.17303; Kasper LH, 2006, MOL CELL BIOL, V26, P789, DOI 10.1128/MCB.26.3.789-809.2006; Kawabe T, 1997, NATURE, V385, P454, DOI 10.1038/385454a0; Keller G, 1998, BLOOD, V92, P877, DOI 10.1182/blood.V92.3.877.415k11_877_887; Kostic C, 2000, ONCOGENE, V19, P3978, DOI 10.1038/sj.onc.1203747; Krasnoselskaya-Riz I, 2002, AIDS RES HUM RETROV, V18, P591, DOI 10.1089/088922202753747941; Kung AL, 2000, GENE DEV, V14, P272; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; Kyba M, 2002, CELL, V109, P29, DOI 10.1016/S0092-8674(02)00680-3; Lahlil R, 2004, MOL CELL BIOL, V24, P1439, DOI 10.1128/MCB.24.4.1439-1452.2004; LARSON RC, 1995, ONCOGENE, V11, P853; Owens BM, 2006, BRIT J HAEMATOL, V132, P216, DOI 10.1111/j.1365-2141.2005.05850.x; Owens BM, 2003, BLOOD, V101, P4966, DOI 10.1182/blood-2002-09-2857; Owens BM, 2002, STEM CELLS, V20, P364, DOI 10.1634/stemcells.20-5-364; Popratiloff A, 2003, J COMP NEUROL, V461, P466, DOI 10.1002/cne.10702; Riz I, 2005, ONCOGENE, V24, P5561, DOI 10.1038/sj.onc.1208727; Rodriguez P, 2005, EMBO J, V24, P2354, DOI 10.1038/sj.emboj.7600702; Schaufele F, 2001, MOL ENDOCRINOL, V15, P1665, DOI 10.1210/me.15.10.1665; Schuh AH, 2005, MOL CELL BIOL, V25, P10235, DOI 10.1128/MCB.25.23.10235-10250.2005; Shen WF, 2001, MOL CELL BIOL, V21, P7509, DOI 10.1128/MCB.21.21.7509-7522.2001; Soulier J, 2005, BLOOD, V106, P274, DOI 10.1182/blood-2004-10-3900; Sykes DB, 2001, BLOOD, V98, P2308, DOI 10.1182/blood.V98.8.2308; Wadman IA, 1997, EMBO J, V16, P3145, DOI 10.1093/emboj/16.11.3145; Watabiki Y, 2003, J HIGH ENERGY PHYS; Wen J, 2005, J BIOL CHEM, V280, P12956, DOI 10.1074/jbc.M412721200; Wu R, 2005, MOL BIOL CELL, V16, P2872, DOI 10.1091/mbc.e04-11-0997; Yang LV, 2001, MECH DEVELOP, V104, P105, DOI 10.1016/S0925-4773(01)00376-8; Yang XJ, 2004, BIOESSAYS, V26, P1076, DOI 10.1002/bies.20104; YOSHIDA M, 1987, CANCER RES, V47, P3688; Zhang N, 1999, ONCOGENE, V18, P2273, DOI 10.1038/sj.onc.1202545	55	17	17	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 14	2007	26	28					4115	4123		10.1038/sj.onc.1210185	http://dx.doi.org/10.1038/sj.onc.1210185			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	178XD	17213805	Green Accepted			2022-12-28	WOS:000247252700007
J	Rothhammer, T; Bataille, F; Spruss, T; Eissner, G; Bosserhoff, AK				Rothhammer, T.; Bataille, F.; Spruss, T.; Eissner, G.; Bosserhoff, A-K			Functional implication of BMP4 expression on angiogenesis in malignant melanoma	ONCOGENE			English	Article						malignant melanoma; endothelium; migration; invasion; angiogenesis	BONE MORPHOGENETIC PROTEIN-2; VASCULOGENIC MIMICRY; TUMOR ANGIOGENESIS; ENDOTHELIAL-CELLS; EPITHELIAL-CELLS; GENE-THERAPY; ID PROTEINS; IN-VITRO; GROWTH; CANCER	Analyses of malignant melanomas revealed a strong expression of bone morphogenic proteins (BMPs) and their autocrine effect in promoting cell invasion and migration. Here, we report a paracrine effect of BMPs on the vascular network. Both BMP2 and BMP4 induced tube formation as well as the migratory efficiency of microvascular endothelial cells. Melanoma cells with reduced BMP activity attracted less endothelial cells in invasion assays than control cells. Furthermore, reduction of BMPs in melanoma cells had a strong effect on vasculogenic mimicry. Tube formation on matrigel was analysed for melanoma cells as well as in co-cultures of endothelial and melanoma cells. Melanoma cells with reduced BMP activity were not capable of forming cordlike structures by themselves and additionally inhibited tube formation of the endothelial cells. Genes involved in angiogenesis turned out to be strongly downregulated in these cell clones. Tumors derived from cells with impaired BMP activity showed reduced tumor growth or large necrotic areas owing to lack of angiogenesis in in vivo analyses.	Univ Regensburg, Univ Hosp, Inst Pathol & Mol Pathol, D-93053 Regensburg, Germany; Univ Regensburg, Inst Pharm, D-93053 Regensburg, Germany; Univ Regensburg, Univ Hosp, Dept Hematol & Oncol, D-93053 Regensburg, Germany	University of Regensburg; University of Regensburg; University of Regensburg	Bosserhoff, AK (corresponding author), Univ Regensburg, Inst Pathol, Franz Josef Str Allee 11, D-93053 Regensburg, Germany.	anja.bosserhoff@klinik.uni-regensburg.de	Bosserhoff, Anja/GNH-4801-2022	Bosserhoff, Anja/0000-0001-8147-394X				ADES EW, 1992, J INVEST DERMATOL, V99, P683, DOI 10.1111/1523-1747.ep12613748; Alani RM, 2004, CANCER BIOL THER, V3, P498, DOI 10.4161/cbt.3.6.930; Balemans W, 2002, DEV BIOL, V250, P231, DOI 10.1006/dbio.2002.0779; Benezra R, 2001, ONCOGENE, V20, P8334, DOI 10.1038/sj.onc.1205160; Benezra R, 2001, TRENDS CARDIOVAS MED, V11, P237, DOI 10.1016/S1050-1738(01)00117-7; Botchkarev VA, 2004, DIFFERENTIATION, V72, P512, DOI 10.1111/j.1432-0436.2004.07209005.x; Cavallaro U, 2000, J NEURO-ONCOL, V50, P63, DOI 10.1023/A:1006414621286; Deckers MML, 2002, ENDOCRINOLOGY, V143, P1545, DOI 10.1210/en.143.4.1545; Ding Z, 2005, LYMPHOLOGY, V38, P87; Folberg R, 2000, AM J PATHOL, V156, P361, DOI 10.1016/S0002-9440(10)64739-6; Folberg R, 2004, APMIS, V112, P508, DOI 10.1111/j.1600-0463.2004.apm11207-0810.x; Hatakeyama S, 1997, BIOCHEM MOL BIOL INT, V42, P497; HATAKEYAMA S, 1993, BIOCHEM BIOPH RES CO, V190, P695, DOI 10.1006/bbrc.1993.1105; Hendrix MJC, 2003, ONCOGENE, V22, P3070, DOI 10.1038/sj.onc.1206447; Hogan BLM, 1996, CURR OPIN GENET DEV, V6, P432, DOI 10.1016/S0959-437X(96)80064-5; Ide H, 1997, CANCER RES, V57, P5022; Jones N, 2000, CANCER METAST REV, V19, P13, DOI 10.1023/A:1026555121511; Kiyozuka Y, 2001, ANTICANCER RES, V21, P1723; Kleeff J, 1999, GASTROENTEROLOGY, V116, P1202, DOI 10.1016/S0016-5085(99)70024-7; Langenfeld EM, 2004, MOL CANCER RES, V2, P141; Lin PN, 1998, P NATL ACAD SCI USA, V95, P8829, DOI 10.1073/pnas.95.15.8829; Maniotis AJ, 1999, AM J PATHOL, V155, P739, DOI 10.1016/S0002-9440(10)65173-5; McDonald DM, 2000, CANCER METAST REV, V19, P109, DOI 10.1023/A:1026529222845; McDonald DM, 2000, AM J PATHOL, V156, P383, DOI 10.1016/S0002-9440(10)64740-2; Mehler MF, 1997, TRENDS NEUROSCI, V20, P309, DOI 10.1016/S0166-2236(96)01046-6; Miyazawa K, 2002, GENES CELLS, V7, P1191, DOI 10.1046/j.1365-2443.2002.00599.x; Pache G, 2006, AM J PHYSIOL-RENAL, V291, pF654, DOI 10.1152/ajprenal.00214.2004; Peng HR, 2005, J BONE MINER RES, V20, P2017, DOI 10.1359/JBMR.050708; Peng HR, 2002, J CLIN INVEST, V110, P751, DOI 10.1172/JCI200215153; Peters KG, 2004, RECENT PROG HORM RES, V59, P51, DOI 10.1210/rp.59.1.51; Raida M, 2005, J CANCER RES CLIN, V131, P741, DOI 10.1007/s00432-005-0024-1; Rothhammer T, 2005, CANCER RES, V65, P448; Saalbach A, 2005, ONCOGENE, V24, P4710, DOI 10.1038/sj.onc.1208559; Seftor EA, 2002, CRIT REV ONCOL HEMAT, V44, P17, DOI 10.1016/S1040-8428(01)00199-8; Straume O, 2005, BRIT J CANCER, V93, P933, DOI 10.1038/sj.bjc.6602792; ten Dijke P, 2003, MOL CELL ENDOCRINOL, V211, P105, DOI 10.1016/j.mce.2003.09.016; Turgeman G, 2001, J GENE MED, V3, P240; Ushio-Fukai M, 2002, CIRC RES, V91, P1160, DOI 10.1161/01.RES.0000046227.65158.F8; Valdimarsdottir G, 2002, CIRCULATION, V106, P2263, DOI 10.1161/01.CIR.0000033830.36431.46; Vogt RR, 2006, J CELL BIOCHEM, V98, P1196, DOI 10.1002/jcb.20831; WANG EA, 1990, P NATL ACAD SCI USA, V87, P2220, DOI 10.1073/pnas.87.6.2220; Ward NL, 2002, SEMIN CELL DEV BIOL, V13, P19, DOI 10.1006/scdb.2001.0288; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241; Yamamoto Y, 2004, NATURWISSENSCHAFTEN, V91, P519, DOI 10.1007/s00114-004-0575-z	44	132	138	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 14	2007	26	28					4158	4170		10.1038/sj.onc.1210182	http://dx.doi.org/10.1038/sj.onc.1210182			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	178XD	17173062				2022-12-28	WOS:000247252700011
J	Karagiannis, TC; Kn, H; El-Osta, A				Karagiannis, T. C.; Kn, H.; El-Osta, A.			Disparity of histone deacetylase inhibition on repair of radiation-induced DNA damage on euchromatin and constitutive heterochromatin compartments	ONCOGENE			English	Article						histone acetylation; HDAC inhibitor; trichostatin A; radiation sensitivity; gamma H2AX; ChIP	NUCLEOTIDE EXCISION-REPAIR; ACTIVE CHROMATIN; IN-VIVO; SACCHAROMYCES-CEREVISIAE; TUMOR RADIOSENSITIVITY; HUMAN-CELLS; ENHANCEMENT; METHYLATION; PHOTOLYASE; CANCER	Epigenetic regulation of chromatin structure is central to the process of DNA repair. A well-characterized epigenetic feature is the dynamic phosphorylation of the histone H2AX ( gamma H2AX) and mobilization of double strand break ( DSB) recognition and repair factors to the site. How chromatin structure is altered in response to DNA damage and how such alterations influence DSB repair mechanisms are currently relevant issues. Despite the clear link between histone deacetylases ( HDACs) and radiosensitivity, how histone hyperacetylation influence DSB repair remains poorly understood. We have determined the structure of chromatin is a major factor determining radiosensitivity and repair in human cells. Trichostatin A ( TSA) enhances radiosensitivity with dose modi. cation factors of 1.2 and 1.9 at 0.2 and 1 mu M, respectively. Cells treated with TSA causing hyperacetylation and remodelling on euchromatic alleles coexist with gamma H2AX accumulation in radiosensitized cells. Formation of gamma H2AX on heterochromatin was significantly reduced even when cells were treated with TSA, suggesting that chromatin structure and histone hyperacetylation are pronounced features of radiation sensitivity and repair in euchromatic regions.	Baker Med Res Inst, Epigenet Human Hlth & Dis Lab, Alfred Med Res & Educ Precinct, Melbourne, Vic 3004, Australia; Peter MacCallum Canc Ctr, Trescowthick Res Labs, Dept Mol Radiat Biol, Melbourne, Vic, Australia; Univ Melbourne, Dept Pathol, Parkville, Vic 3052, Australia	Baker Heart and Diabetes Institute; Peter Maccallum Cancer Center; University of Melbourne	El-Osta, A (corresponding author), Baker Med Res Inst, Epigenet Human Hlth & Dis Lab, Alfred Med Res & Educ Precinct, 2nd Floor,Commercial Rd, Melbourne, Vic 3004, Australia.	assam.el-osta@baker.edu.au		Kaipananickal, Harikrishnan/0000-0002-4662-659X; El-Osta, Assam/0000-0001-7968-7375; El-Osta, Assam/0000-0003-2969-9137; Karagiannis, Tom/0000-0002-9967-1546				Baylin Stephen B, 2005, Nat Clin Pract Oncol, V2 Suppl 1, pS4, DOI 10.1038/ncponc0354; Camphausen K, 2005, INT J CANCER, V114, P380, DOI 10.1002/ijc.20774; Camphausen K, 2004, CLIN CANCER RES, V10, P6066, DOI 10.1158/1078-0432.CCR-04-0537; Camphausen K, 2004, CANCER RES, V64, P316, DOI 10.1158/0008-5472.CAN-03-2630; Chinnaiyan P, 2005, INT J RADIAT ONCOL, V62, P223, DOI 10.1016/j.ijrobp.2004.12.088; CHIU SM, 1982, BIOCHIM BIOPHYS ACTA, V699, P15, DOI 10.1016/0167-4781(82)90166-X; Ehrlich M, 2002, ONCOGENE, V21, P5400, DOI 10.1038/sj.onc.1205651; El-Osta A, 2000, GENE EXPRESSION, V9, P63; Foster ER, 2005, FEBS J, V272, P3231, DOI 10.1111/j.1742-4658.2005.04741.x; Harikrishnan KN, 2005, NAT GENET, V37, P254, DOI 10.1038/ng1516; Jiang GC, 2004, J CELL BIOCHEM, V93, P286, DOI 10.1002/jcb.20146; Jung M, 2005, RADIAT RES, V163, P488, DOI 10.1667/RR3345; Karagiannis TC, 2005, CANCER BIOL THER, V4, P787, DOI 10.4161/cbt.4.7.1922; Kass SU, 1997, TRENDS GENET, V13, P444, DOI 10.1016/S0168-9525(97)01268-7; Kelly WK, 2005, NAT CLIN PRACT ONCOL, V2, P150, DOI 10.1038/ncponc0106; Kim JH, 2001, COMPOS INTERFACE, V7, P443, DOI 10.1163/156855400750262932; Kladde MP, 1996, EMBO J, V15, P6290, DOI 10.1002/j.1460-2075.1996.tb01019.x; Livingstone-Zatchej M, 2003, J BIOL CHEM, V278, P37471, DOI 10.1074/jbc.M306335200; Lyko F, 2005, JNCI-J NATL CANCER I, V97, P1498, DOI 10.1093/jnci/dji311; Marks PA, 2005, EXPERT OPIN INV DRUG, V14, P1497, DOI 10.1517/13543784.14.12.1497; Marks Paul A, 2004, Novartis Found Symp, V259, P269; Meier A, 2002, J BIOL CHEM, V277, P11845, DOI 10.1074/jbc.M110941200; MELLON I, 1986, P NATL ACAD SCI USA, V83, P8878, DOI 10.1073/pnas.83.23.8878; Munshi A, 2005, CLIN CANCER RES, V11, P4912, DOI 10.1158/1078-0432.CCR-04-2088; Orphanides G, 2000, NATURE, V407, P471, DOI 10.1038/35035000; Piekarz RL, 2004, BLOOD, V103, P4636, DOI 10.1182/blood-2003-09-3068; Reyes JC, 1997, J CELL BIOL, V137, P263, DOI 10.1083/jcb.137.2.263; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Suter B, 1997, EMBO J, V16, P2150, DOI 10.1093/emboj/16.8.2150; Taddei A, 2001, NAT CELL BIOL, V3, P114, DOI 10.1038/35055010; Taddei A, 1999, J CELL BIOL, V147, P1153, DOI 10.1083/jcb.147.6.1153; TERLETH C, 1990, MOL CELL BIOL, V10, P4678, DOI 10.1128/MCB.10.9.4678; Thoma F, 1999, EMBO J, V18, P6585, DOI 10.1093/emboj/18.23.6585; Tsukuda T, 2005, NATURE, V438, P379, DOI 10.1038/nature04148; Vidanes GM, 2005, CELL, V121, P973, DOI 10.1016/j.cell.2005.06.013; Xu M, 1998, MOL CELL BIOL, V18, P1201, DOI 10.1128/MCB.18.3.1201; Zhang Y, 2004, RADIAT RES, V161, P667, DOI 10.1667/RR3192; Zhivotovsky B, 1999, EXP CELL RES, V248, P10, DOI 10.1006/excr.1999.4452	38	54	56	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 7	2007	26	27					3963	3971		10.1038/sj.onc.1210174	http://dx.doi.org/10.1038/sj.onc.1210174			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	177HP	17213813				2022-12-28	WOS:000247144500006
J	Dhillon, AS; Hagan, S; Rath, O; Kolch, W				Dhillon, A. S.; Hagan, S.; Rath, O.; Kolch, W.			MAP kinase signalling pathways in cancer	ONCOGENE			English	Review						MAPK; cancer; signal transduction; oncogenes	ACTIVATED PROTEIN-KINASE; CELL-CYCLE ARREST; NF-KAPPA-B; METASTASIS SUPPRESSOR GENE; CROSS-CASCADE ACTIVATION; C-JUN; HEPATOCELLULAR-CARCINOMA; TRANSDUCTION PATHWAY; TUMOR-SUPPRESSOR; REGULATED KINASE	Cancer can be perceived as a disease of communication between and within cells. The aberrations are pleiotropic, but mitogen-activated protein kinase (MAPK) pathways feature prominently. Here, we discuss recent findings and hypotheses on the role of MAPK pathways in cancer. Cancerous mutations in MAPK pathways are frequently mostly affecting Ras and B-Raf in the extracellular signal-regulated kinase pathway. Stress-activated pathways, such as Jun N-terminal kinase and p38, largely seem to counteract malignant transformation. The balance and integration between these signals may widely vary in different tumours, but are important for the outcome and the sensitivity to drug therapy.	Beatson Inst Canc Res, Glasgow G61 1BD, Lanark, Scotland; Univ Glasgow, Sir Henry Wellcome Funct Genom Facil, Glasgow G12 8QQ, Lanark, Scotland	Beatson Institute; University of Glasgow	Dhillon, AS (corresponding author), Beatson Inst Canc Res, Garscube Estate,Switchback Rd, Glasgow G61 1BD, Lanark, Scotland.	a.dhillon@beatson.gla.ac.uk; wkolch@beatson.gla.ac.uk	Admin, SBI/HGB-2738-2022; Rath, Oliver/D-6523-2018; Kolch, Walter/ABF-2102-2021	Rath, Oliver/0000-0001-7986-591X; Kolch, Walter/0000-0001-5777-5016; Dhillon, Amardeep/0000-0002-6065-663X				ADLER V, 1992, P NATL ACAD SCI USA, V89, P5341, DOI 10.1073/pnas.89.12.5341; Beeram Muralidhar, 2003, Clin Adv Hematol Oncol, V1, P476; Bloethner S, 2005, CARCINOGENESIS, V26, P1224, DOI 10.1093/carcin/bgi066; Bradham C, 2006, CELL CYCLE, V5, P824, DOI 10.4161/cc.5.8.2685; Brancho D, 2003, GENE DEV, V17, P1969, DOI 10.1101/gad.1107303; Bubici C, 2004, CELL CYCLE, V3, P1524, DOI 10.4161/cc.3.12.1321; Bulavin DV, 2004, ADV CANCER RES, V92, P95, DOI 10.1016/S0065-230X(04)92005-2; Bulavin DV, 2003, MOL CELL BIOL, V23, P3859, DOI 10.1128/MCB.23.11.3859-3871.2003; Bulavin DV, 2002, NAT GENET, V31, P210, DOI 10.1038/ng894; Buschmann T, 2000, J BIOL CHEM, V275, P16590, DOI 10.1074/jbc.M910045199; Buschmann T, 2001, MOL CELL BIOL, V21, P2743, DOI 10.1128/MCB.21.8.2743-2754.2001; Chen D, 1996, J BIOL CHEM, V271, P6328, DOI 10.1074/jbc.271.11.6328; Chen J, 2001, P NATL ACAD SCI USA, V98, P7783, DOI 10.1073/pnas.141224398; Chen Z, 2001, CHEM REV, V101, P2449, DOI 10.1021/cr000241p; Cheng WH, 2003, BIOCHEM J, V370, P927, DOI 10.1042/BJ20021870; Chin L, 1999, NATURE, V400, P468, DOI 10.1038/22788; Chiosis G, 2006, EXPERT OPIN THER TAR, V10, P37, DOI 10.1517/14728222.10.1.37; Chong H, 2003, CELL SIGNAL, V15, P463, DOI 10.1016/S0898-6568(02)00139-0; Coleman ML, 2004, NAT REV MOL CELL BIO, V5, P355, DOI 10.1038/nrm1365; Coles LC, 2002, ONCOGENE, V21, P2236, DOI 10.1038/sj.onc.1205302; Cunningham SC, 2006, CANCER RES, V66, P5560, DOI 10.1158/0008-5472.CAN-06-0555; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Deacon K, 2003, MOL BIOL CELL, V14, P2071, DOI 10.1091/mbc.e02-10-0653; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Dhillon AS, 2002, ARCH BIOCHEM BIOPHYS, V404, P3, DOI 10.1016/S0003-9861(02)00244-8; Dougherty MK, 2005, MOL CELL, V17, P215, DOI 10.1016/j.molcel.2004.11.055; Douville E, 1997, ONCOGENE, V15, P373, DOI 10.1038/sj.onc.1201214; Downward J, 2003, NAT REV CANCER, V3, P11, DOI 10.1038/nrc969; Du W, 1999, CANCER RES, V59, P5492; Dumaz N, 2006, CANCER RES, V66, P9483, DOI 10.1158/0008-5472.CAN-05-4227; Dunn KL, 2005, BIOCHEM CELL BIOL, V83, P1, DOI 10.1139/O04-121; Eferl R, 2003, CELL, V112, P181, DOI 10.1016/S0092-8674(03)00042-4; Ehrenreiter K, 2005, J CELL BIOL, V168, P955, DOI 10.1083/jcb.200409162; Eisen T, 2006, BRIT J CANCER, V95, P581, DOI 10.1038/sj.bjc.6603291; Eliceiri BP, 1998, J CELL BIOL, V140, P1255, DOI 10.1083/jcb.140.5.1255; Ellinger-Ziegelbauer H, 1999, MOL CELL BIOL, V19, P3857; Emuss V, 2005, CANCER RES, V65, P9719, DOI 10.1158/0008-5472.CAN-05-1683; Eves EM, 2006, MOL CELL, V23, P561, DOI 10.1016/j.molcel.2006.07.015; Fong CW, 2006, CANCER RES, V66, P2048, DOI 10.1158/0008-5472.CAN-05-1072; Franzoso G, 2003, CELL DEATH DIFFER, V10, P13, DOI 10.1038/sj.cdd.4401154; Frost JA, 1997, EMBO J, V16, P6426, DOI 10.1093/emboj/16.21.6426; Fuchs SY, 1998, GENE DEV, V12, P2658, DOI 10.1101/gad.12.17.2658; Galabova-Kovacs G, 2006, CELL CYCLE, V5, P1514, DOI 10.4161/cc.5.14.2981; Garnett MJ, 2005, MOL CELL, V20, P963, DOI 10.1016/j.molcel.2005.10.022; Garnett MJ, 2004, CANCER CELL, V6, P313, DOI 10.1016/j.ccr.2004.09.022; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Giehl K, 2005, BIOL CHEM, V386, P193, DOI 10.1515/BC.2005.025; Gollob Jared A, 2005, Clin Genitourin Cancer, V4, P167, DOI 10.3816/CGC.2005.n.028; Gopalbhai K, 2003, J BIOL CHEM, V278, P8118, DOI 10.1074/jbc.M211870200; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hancock JF, 2005, BIOCHEM J, V389, P1, DOI 10.1042/BJ20050231; Hancock JF, 2003, NAT REV MOL CELL BIO, V4, P373, DOI 10.1038/nrm1105; Huang C, 2004, J CELL SCI, V117, P4619, DOI 10.1242/jcs.01481; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Iyoda K, 2003, CANCER-AM CANCER SOC, V97, P3017, DOI 10.1002/cncr.11425; Javelaud D, 2001, ONCOGENE, V20, P4365, DOI 10.1038/sj.onc.1204570; Johnson R, 1996, MOL CELL BIOL, V16, P4504; Kennedy NJ, 2003, GENE DEV, V17, P629, DOI 10.1101/gad.1062903; Kennedy NJ, 2003, CELL CYCLE, V2, P199, DOI 10.4161/cc.2.3.388; Keyse SM, 2000, CURR OPIN CELL BIOL, V12, P186, DOI 10.1016/S0955-0674(99)00075-7; Kim HL, 2001, CANCER RES, V61, P2833; Kohno M, 2006, ANN MED, V38, P200, DOI 10.1080/07853890600551037; Kolch W, 2005, NAT REV MOL CELL BIO, V6, P827, DOI 10.1038/nrm1743; Krens SFG, 2006, FEBS LETT, V580, P4984, DOI 10.1016/j.febslet.2006.08.025; Kucharczak J, 2003, ONCOGENE, V22, P8961, DOI 10.1038/sj.onc.1207230; Kumar S, 2003, NAT REV DRUG DISCOV, V2, P717, DOI 10.1038/nrd1177; Kummer JL, 1997, J BIOL CHEM, V272, P20490, DOI 10.1074/jbc.272.33.20490; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; Landi MT, 2006, SCIENCE, V313, P521, DOI 10.1126/science.1127515; Lee ER, 2006, BBA-MOL CELL RES, V1763, P958, DOI 10.1016/j.bbamcr.2006.06.006; Li WQ, 2000, GENE DEV, V14, P895; Losa JH, 2003, ONCOGENE, V22, P3998, DOI 10.1038/sj.onc.1206608; Maldonado JL, 2003, J NATL CANCER I, V95, P1878, DOI 10.1093/jnci/djg123; Marais R, 1997, J BIOL CHEM, V272, P4378, DOI 10.1074/jbc.272.7.4378; Marais R, 1998, SCIENCE, V280, P109, DOI 10.1126/science.280.5360.109; Mason JM, 2006, TRENDS CELL BIOL, V16, P45, DOI 10.1016/j.tcb.2005.11.004; Mavria G, 2006, CANCER CELL, V9, P33, DOI 10.1016/j.ccr.2005.12.021; Michaloglou C, 2005, NATURE, V436, P720, DOI 10.1038/nature03890; Mirza AM, 2004, MOL CELL BIOL, V24, P10868, DOI 10.1128/MCB.24.24.10868-10881.2004; Miyoshi K, 2004, ONCOGENE, V23, P5567, DOI 10.1038/sj.onc.1207759; Molnar A, 1997, J BIOL CHEM, V272, P13229, DOI 10.1074/jbc.272.20.13229; Mor A, 2006, ANNU REV IMMUNOL, V24, P771, DOI 10.1146/annurev.immunol.24.021605.090723; Morrison DK, 2003, ANNU REV CELL DEV BI, V19, P91, DOI 10.1146/annurev.cellbio.19.111401.091942; Murphy LO, 2006, TRENDS BIOCHEM SCI, V31, P268, DOI 10.1016/j.tibs.2006.03.009; Murphy LO, 2002, NAT CELL BIOL, V4, P556, DOI 10.1038/ncb822; Murphy LO, 2004, MOL CELL BIOL, V24, P144, DOI 10.1128/MCB.24.1.144-153.2004; Nagasaka T, 2004, J CLIN ONCOL, V22, P4584, DOI 10.1200/JCO.2004.02.154; Nakayama K, 2006, CANCER BIOL THER, V5, P630, DOI 10.4161/cbt.5.6.2675; Nguyen A, 2002, MOL CELL BIOL, V22, P3035, DOI 10.1128/MCB.22.9.3035-3045.2002; O'Neill E, 2004, BRIT J CANCER, V90, P283, DOI 10.1038/sj.bjc.6601488; Olson JM, 2004, TRENDS MOL MED, V10, P125, DOI 10.1016/j.molmed.2004.01.007; Olson MF, 1998, NATURE, V394, P295, DOI 10.1038/28425; Orlowski RZ, 2002, TRENDS MOL MED, V8, P385, DOI 10.1016/S1471-4914(02)02375-4; Orton RJ, 2005, BIOCHEM J, V392, P249, DOI 10.1042/BJ20050908; Petti C, 2006, CANCER RES, V66, P6503, DOI 10.1158/0008-5472.CAN-05-4671; Philips MR, 2005, BIOCHEM SOC T, V33, P657, DOI 10.1042/BST0330657; Piazzolla D, 2005, J CELL BIOL, V171, P1013, DOI 10.1083/jcb.200504137; Pollock CB, 2005, CANCER RES, V65, P1244, DOI 10.1158/0008-5472.CAN-04-1911; Pollock PM, 2003, NAT GENET, V33, P19, DOI 10.1038/ng1054; Pruitt K, 2002, J BIOL CHEM, V277, P31808, DOI 10.1074/jbc.M203964200; Reddy KB, 2003, CANCER METAST REV, V22, P395, DOI 10.1023/A:1023781114568; Richard DE, 1999, J BIOL CHEM, V274, P32631, DOI 10.1074/jbc.274.46.32631; RICHTER JE, 1999, CLIN PRACTICE GASTRO, V1, P1; Rinehart J, 2004, J CLIN ONCOL, V22, P4456, DOI 10.1200/JCO.2004.01.185; Robinson VL, 2003, CLIN EXP METASTAS, V20, P25, DOI 10.1023/A:1022586318678; Rodriguez-Viciana P, 2006, SCIENCE, V311, P1287, DOI 10.1126/science.1124642; Rushworth LK, 2006, MOL CELL BIOL, V26, P2262, DOI 10.1128/MCB.26.6.2262-2272.2006; Sahai E, 2001, EMBO J, V20, P755, DOI 10.1093/emboj/20.4.755; Sahai E, 2002, NAT REV CANCER, V2, P133, DOI 10.1038/nrc725; Samowitz WS, 2005, CANCER RES, V65, P6063, DOI 10.1158/0008-5472.CAN-05-0404; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; Schreiber M, 1999, GENE DEV, V13, P607, DOI 10.1101/gad.13.5.607; Schuierer MM, 2004, CANCER RES, V64, P5186, DOI 10.1158/0008-5472.CAN-03-3861; SCHUTTE J, 1989, P NATL ACAD SCI USA, V86, P2257, DOI 10.1073/pnas.86.7.2257; Sebolt-Leopold JS, 2004, NAT REV CANCER, V4, P937, DOI 10.1038/nrc1503; Sewing A, 1997, MOL CELL BIOL, V17, P5588, DOI 10.1128/MCB.17.9.5588; Sharp S, 2006, ADV CANCER RES, V95, P323, DOI 10.1016/S0065-230X(06)95009-X; She QB, 2002, ONCOGENE, V21, P1580, DOI 10.1038/sj.onc.1205239; She QB, 2001, CANCER RES, V61, P1604; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; Solit DB, 2006, NATURE, V439, P358, DOI 10.1038/nature04304; Spendlove HE, 2004, MELANOMA RES, V14, P449, DOI 10.1097/00008390-200412000-00003; Tang FM, 2002, MOL CELL BIOL, V22, P8571, DOI 10.1128/MCB.22.24.8571-8579.2002; Therrien M, 1996, GENE DEV, V10, P2684, DOI 10.1101/gad.10.21.2684; Timofeev O, 2005, CELL CYCLE, V4, P118, DOI 10.4161/cc.4.1.1342; To MD, 2006, NAT GENET, V38, P926, DOI 10.1038/ng1836; Torii S, 2006, CANCER SCI, V97, P697, DOI 10.1111/j.1349-7006.2006.00244.x; Tsavachidou D, 2004, CANCER RES, V64, P5556, DOI 10.1158/0008-5472.CAN-04-1669; Tsujita E, 2005, ONCOLOGY-BASEL, V69, P342, DOI 10.1159/000089766; Vasilevskaya I, 2003, DRUG RESIST UPDATE, V6, P147, DOI 10.1016/S1368-7646(03)00043-8; Vial E, 2003, CANCER CELL, V4, P67, DOI 10.1016/S1535-6108(03)00162-4; Wan PTC, 2004, CELL, V116, P855, DOI 10.1016/S0092-8674(04)00215-6; Wellbrock C, 2004, NAT REV MOL CELL BIO, V5, P875, DOI 10.1038/nrm1498; Weston CR, 2002, CURR OPIN GENET DEV, V12, P14, DOI 10.1016/S0959-437X(01)00258-1; Wilhelm S, 2002, CURR PHARM DESIGN, V8, P2255, DOI 10.2174/1381612023393026; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598; Wu GS, 2004, CANCER BIOL THER, V3, P156, DOI 10.4161/cbt.3.2.614; Wu XY, 1996, J BIOL CHEM, V271, P3265, DOI 10.1074/jbc.271.6.3265; Xiang XQ, 2002, J BIOL CHEM, V277, P44996, DOI 10.1074/jbc.M203953200; Yamada SD, 2002, CANCER RES, V62, P6717; Yamamoto T, 2006, CURR BIOL, V16, P1171, DOI 10.1016/j.cub.2006.04.044; Yeung K, 1999, NATURE, V401, P173, DOI 10.1038/43686; Yoon S, 2006, GROWTH FACTORS, V24, P21, DOI 10.1080/02699050500284218; Zarubin T, 2005, CELL RES, V15, P11, DOI 10.1038/sj.cr.7290257; Zebisch A, 2006, CANCER RES, V66, P3401, DOI 10.1158/0008-5472.CAN-05-0115; Zhu Kuichun, 2003, Curr Opin Investig Drugs, V4, P1428	147	2022	2078	8	259	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 15	2007	26	22					3279	3290		10.1038/sj.onc.1210421	http://dx.doi.org/10.1038/sj.onc.1210421			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	169PH	17496922				2022-12-28	WOS:000246603600015
J	Pagano, L; Fianchi, L; Caira, M; Rutella, S; Leone, G				Pagano, L.; Fianchi, L.; Caira, M.; Rutella, S.; Leone, G.			The role of Gemtuzumab Ozogamicin in the treatment of acute myeloid leukemia patients	ONCOGENE			English	Review						acute myeloid leukemia; elderly; mylotarg	ACUTE PROMYELOCYTIC LEUKEMIA; TRANS-RETINOIC ACID; ANTIBODY-TARGETED CHEMOTHERAPY; ACUTE MYELOGENOUS LEUKEMIA; COLONY-STIMULATING FACTOR; PHASE-II; IN-VITRO; VENOOCCLUSIVE DISEASE; COMBINATION REGIMEN; MOLECULAR REMISSION	Gemtuzumab Ozogamicin (GO) is an antibody-targeted chemotherapy agent consisting of the humanized murine CD33 antibody (clone P67.6) to which the calicheamicin-g1 derivative is attached via a hydrolysable bifunctional linker. GO is able to induce apoptosis in vitro in CD33-expressing cells and it has been approved in USA and in Europe as monotherapy for the treatment of elderly patients (older than 60 years) with relapsed acute myeloid leukemia (AML). GO administered as a single agent has resulted in overall response rates of about 30% in previously relapsed adults AML patients (including also with incomplete platelet recovery). Preliminary data indicate a potential role for GO also as a component of induction or consolidation regimens in adults and children. As for adverse events, veno-occlusive syndrome characterizes its tolerability profile, but GO is comparatively well tolerated by most patients.	Univ Cattolica Sacro Cuore, Ist Ematol, I-00168 Rome, Italy	Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli	Pagano, L (corresponding author), Univ Cattolica Sacro Cuore, Ist Ematol, Largo Francesco Vito 1, I-00168 Rome, Italy.	lpagano@rm.unicatt.it	Caira, Morena/A-3663-2009; Giuseppe Leone, Full Professor/I-9166-2019; Rutella, Sergio/AAF-9187-2020; pagano, livio/J-3020-2018; pagano, livio/A-2024-2008; Rutella, Sergio/AAF-9210-2020	Giuseppe Leone, Full Professor/0000-0002-7812-5300; pagano, livio/0000-0001-8287-928X; Rutella, Sergio/0000-0003-1970-7375; Fianchi, Luana/0000-0002-7113-7202				Alvarado Y, 2003, CANCER CHEMOTH PHARM, V51, P87, DOI 10.1007/s00280-002-0546-z; Amadori S, 2005, LEUKEMIA, V19, P1768, DOI 10.1038/sj.leu.2403901; Amadori S, 2004, HAEMATOLOGICA, V89, P950; Amico D, 2003, BLOOD, V101, P4589, DOI 10.1182/blood-2002-07-2311; Apostolidou E, 2003, LEUKEMIA RES, V27, P887, DOI 10.1016/S0145-2126(03)00021-3; Arceci RJ, 2005, BLOOD, V106, P1183, DOI 10.1182/blood-2004-10-3821; Balaian L, 2003, EXP HEMATOL, V31, P363, DOI 10.1016/S0301-472X(03)00044-4; Bearman SI, 2000, CURR OPIN ONCOL, V12, P103, DOI 10.1097/00001622-200003000-00001; Chevallier P, 2005, LEUKEMIA RES, V29, P1003, DOI 10.1016/j.leukres.2005.02.005; Cohen AD, 2002, BONE MARROW TRANSPL, V30, P23, DOI 10.1038/sj.bmt.1703602; Cortes J, 2002, CANCER CHEMOTH PHARM, V50, P497, DOI 10.1007/s00280-002-0539-y; Crocker PR, 2002, CURR OPIN STRUC BIOL, V12, P609, DOI 10.1016/S0959-440X(02)00375-5; DEANGELO DJ, 2003, BLOOD, V102; DINNDORF PA, 1986, BLOOD, V67, P1048; Estey EH, 2000, LEUKEMIA, V14, P476, DOI 10.1038/sj.leu.2401568; Estey EH, 2002, BLOOD, V99, P4222, DOI 10.1182/blood-2001-12-0174; Estey EH, 2002, BLOOD, V99, P4343, DOI 10.1182/blood.V99.12.4343; FIANCHI L, 2006, HAEMATOL REP, V2, pA83; GILES FJ, 2001, CANCER, V2, P406; Guglielmi C, 1998, BRIT J HAEMATOL, V102, P1035, DOI 10.1046/j.1365-2141.1998.00871.x; IKEMOTO N, 1995, P NATL ACAD SCI USA, V92, P10506, DOI 10.1073/pnas.92.23.10506; Jedema I, 2004, LEUKEMIA, V18, P316, DOI 10.1038/sj.leu.2403205; Jurcic JG, 2000, CLIN CANCER RES, V6, P372; KEATING MJ, 1989, J CLIN ONCOL, V7, P1071, DOI 10.1200/JCO.1989.7.8.1071; Kell WJ, 2003, BLOOD, V102, P4277, DOI 10.1182/blood-2003-05-1620; Langston AA, 2004, BLOOD, V104, p502A, DOI 10.1182/blood.V104.11.1814.1814; Larson RA, 2005, CANCER, V104, P1442, DOI 10.1002/cncr.21326; Larson RA, 2002, LEUKEMIA, V16, P1627, DOI 10.1038/sj.leu.2402677; Legrand O, 2000, BLOOD, V96, P870, DOI 10.1182/blood.V96.3.870.015k16_870_877; Leone G, 2004, HAEMATOLOGICA, V89, P634; Leopold Lance H, 2003, Clin Adv Hematol Oncol, V1, P220; Lo-Coco F, 2004, BLOOD, V104, P1995, DOI 10.1182/blood-2004-04-1550; MCKOY JM, 2006, LEUK RES; Mingari MC, 2001, IMMUNOL REV, V181, P260, DOI 10.1034/j.1600-065X.2001.1810122.x; Montillo M, 1998, AM J HEMATOL, V58, P105, DOI 10.1002/(SICI)1096-8652(199806)58:2<105::AID-AJH3>3.0.CO;2-W; Moore J, 2006, LEUKEMIA RES, V30, P777, DOI 10.1016/j.leukres.2005.10.025; Nabhan C, 2005, LEUKEMIA RES, V29, P53, DOI 10.1016/j.leukres.2004.04.011; Nabhan C, 2004, ANN ONCOL, V15, P1231, DOI 10.1093/annonc/mdh324; *NCCN, 2002, NCCN PRACT GUID ONC; O'Donnel MR, 2004, CANC MANAGEMENT MULT, P747; Paietta E, 2003, BEST PRACT RES CL HA, V16, P369, DOI 10.1016/S1521-6926(03)00042-2; Pallis M, 2004, LEUKEMIA, V18, P1927, DOI 10.1038/sj.leu.2403511; Petti MC, 2001, BRIT J HAEMATOL, V115, P63, DOI 10.1046/j.1365-2141.2001.03091.x; Piccaluga PP, 2004, LEUKEMIA RES, V28, P987, DOI 10.1016/j.leukres.2004.01.009; Piccaluga PP, 2004, LEUKEMIA LYMPHOMA, V45, P1791, DOI 10.1080/1042819042000219485; RAO AV, 2005, BLOOD, V106; RAZA A, 2002, BLOOD, V100; Reinhardt D, 2004, ONKOLOGIE, V27, P269, DOI 10.1159/000075606; Rutella S, 2000, BLOOD, V95, P4015; Rutella S, 2006, EXP HEMATOL, V34, P54, DOI 10.1016/j.exphem.2005.10.003; Schwarz J, 2004, HEMATOL J, V5, P279, DOI 10.1038/sj.thj.6200367; SIEVERDING M, 2000, Z MED PSYCHOL, V1, P7; Sievers EL, 1999, BLOOD, V93, P3678, DOI 10.1182/blood.V93.11.3678; Sievers EL, 2001, J CLIN ONCOL, V19, P3244, DOI 10.1200/JCO.2001.19.13.3244; SIVARAMAN S, 2002, BLOOD, V100; STONE RM, 2004, BLOOD, V104; Takeshita A, 2005, INT J HEMATOL, V82, P445, DOI 10.1532/IJH97.05069; Taksin AL, 2007, LEUKEMIA, V21, P66, DOI 10.1038/sj.leu.2404434; Thalhammer F, 1996, ANN HEMATOL, V72, P216, DOI 10.1007/s002770050163; THOMAS X, 2005, BLOOD, V106; Tsimberidou A, 2003, LEUKEMIA RES, V27, P893, DOI 10.1016/S0145-2126(03)00022-5; Tsimberidou A, 2003, CANCER-AM CANCER SOC, V97, P1481, DOI 10.1002/cncr.11239; Tsimberidou AM, 2004, LEUKEMIA RES, V28, P991, DOI 10.1016/j.leukres.2004.01.004; van der Heiden PLJ, 2006, EUR J HAEMATOL, V76, P409, DOI 10.1111/j.1600-0609.2005.00623.x; van der Velden VHJ, 2001, BLOOD, V97, P3197, DOI 10.1182/blood.V97.10.3197; VENUGOPAL P, 2002, BLOOD, V100; VOGLER WR, 1994, LEUKEMIA, V8, P1847; Wadleigh M, 2003, BLOOD, V102, P1578, DOI 10.1182/blood-2003-01-0255; Walter RB, 2004, BLOOD, V103, P4276, DOI 10.1182/blood-2003-11-3825; ZEIN N, 1989, SCIENCE, V244, P697, DOI 10.1126/science.2717946; Zwaan CM, 2003, BLOOD, V101, P3868, DOI 10.1182/blood-2002-07-1947	71	62	65	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2007	26	25					3679	3690		10.1038/sj.onc.1210364	http://dx.doi.org/10.1038/sj.onc.1210364			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	172PK	17530021				2022-12-28	WOS:000246816100010
J	Depeille, PE; Ding, Y; Bromberg-White, JL; Duesbery, NS				Depeille, P. E.; Ding, Y.; Bromberg-White, J. L.; Duesbery, N. S.			MKK signaling and vascularization	ONCOGENE			English	Review						kinase; cancer; angiogenesis	ACTIVATED PROTEIN-KINASE; ENDOTHELIAL GROWTH-FACTOR; MAP-KINASE; EMBRYONIC DEATH; NOONAN-SYNDROME; TUMOR-GROWTH; PERMEABILITY FACTOR; GERMLINE MUTATIONS; TARGETED DELETION; CELLS SECRETE	In 1998, George Vande Woude's lab discovered that anthrax lethal factor (LF), the principal virulence component of anthrax toxin, was a zinc-metalloprotease that cleaved and inactivated mitogen-activated protein kinase kinases (MKK). It was perhaps not surprising, given the known roles of MKK1 and 2 in cell proliferation, that LF was subsequently found to dramatically inhibit tumor growth in vivo. What was not anticipated, however, was that the tumors treated with LF would have a substantially reduced vascular content. This intriguing result was one of the first indications that MKK signaling plays an important role in promoting tumor vascularization in vivo. In the following short review, we will compare in vitro and in vivo evidence that supports the hypothesis that MKK signaling pathways are essential for vascularization.	Van Andel Res Inst, Lab Canc & Dev Cell Biol, Grand Rapids, MI 49503 USA	Van Andel Institute	Duesbery, NS (corresponding author), Van Andel Res Inst, Lab Canc & Dev Cell Biol, 333 Bostwick Ave,NE, Grand Rapids, MI 49503 USA.	duesbery@vai.org		DUESBERY, NICK/0000-0002-4258-5655; Duesbery, Nicholas/0000-0002-5708-4984	NATIONAL CANCER INSTITUTE [R21CA108438, R01CA109308] Funding Source: NIH RePORTER; NCI NIH HHS [CA 109308, CA 108438] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams RH, 2000, MOL CELL, V6, P109, DOI 10.1016/S1097-2765(00)00012-5; Aoki Y, 2005, NAT GENET, V37, P1038, DOI 10.1038/ng1641; Araki T, 2004, NAT MED, V10, P849, DOI 10.1038/nm1084; Beardmore VA, 2005, MOL CELL BIOL, V25, P10454, DOI 10.1128/MCB.25.23.10454-10464.2005; Belanger LF, 2003, MOL CELL BIOL, V23, P4778, DOI 10.1128/MCB.23.14.4778-4787.2003; Bonnesen B, 2005, BLOOD, V106, P3396, DOI 10.1182/blood-2005-04-1739; Bradley KA, 2001, NATURE, V414, P225, DOI 10.1038/n35101999; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Chen Z, 2001, CHEM REV, V101, P2449, DOI 10.1021/cr000241p; Chi HB, 2005, P NATL ACAD SCI USA, V102, P3846, DOI 10.1073/pnas.0500026102; CONNOLLY DT, 1989, J CLIN INVEST, V84, P1470, DOI 10.1172/JCI114322; DANGELO G, 1995, P NATL ACAD SCI USA, V92, P6374, DOI 10.1073/pnas.92.14.6374; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Dong C, 1998, SCIENCE, V282, P2092, DOI 10.1126/science.282.5396.2092; Duesbery NS, 1998, SCIENCE, V280, P734, DOI 10.1126/science.280.5364.734; Duesbery NS, 2001, P NATL ACAD SCI USA, V98, P4089, DOI 10.1073/pnas.061031898; Eliceiri BP, 1998, J CELL BIOL, V140, P1255, DOI 10.1083/jcb.140.5.1255; Ennis BW, 2005, J PHARMACOL EXP THER, V313, P325, DOI 10.1124/jpet.104.078873; Ergun S, 2001, ANGIOGENESIS, V4, P193, DOI DOI 10.1023/A:1014027218980; Estep AL, 2006, AM J MED GENET A, V140A, P8, DOI 10.1002/ajmg.a.31078; FERRARA N, 1989, BIOCHEM BIOPH RES CO, V161, P851, DOI 10.1016/0006-291X(89)92678-8; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; Fong GH, 1999, DEVELOPMENT, V126, P3015; Fragale A, 2004, HUM MUTAT, V23, P267, DOI 10.1002/humu.20005; Ganiatsas S, 1998, P NATL ACAD SCI USA, V95, P6881, DOI 10.1073/pnas.95.12.6881; Giroux S, 1999, CURR BIOL, V9, P369, DOI 10.1016/S0960-9822(99)80164-X; Gripp KW, 2005, AM J MED GENET C, V137C, P72, DOI 10.1002/ajmg.c.30065; Hatano N, 2003, GENES CELLS, V8, P847, DOI 10.1046/j.1365-2443.2003.00680.x; Hayashi M, 2005, CANCER RES, V65, P7699, DOI 10.1158/0008-5472.CAN-04-4540; Hayashi M, 2004, J CLIN INVEST, V113, P1138, DOI 10.1172/JCI200419890; Holash J, 1999, SCIENCE, V284, P1994, DOI 10.1126/science.284.5422.1994; Hood JD, 2003, J CELL BIOL, V162, P933, DOI 10.1083/jcb.200304105; Hood JD, 2002, SCIENCE, V296, P2404, DOI 10.1126/science.1070200; Huser M, 2001, EMBO J, V20, P1940, DOI 10.1093/emboj/20.8.1940; Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682; Keren B, 2004, J MED GENET, V41, DOI 10.1136/jmg.2004.021451; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; Kontaridis MI, 2006, J BIOL CHEM, V281, P6785, DOI 10.1074/jbc.M513068200; Kowanetz M, 2006, CLIN CANCER RES, V12, P5018, DOI 10.1158/1078-0432.CCR-06-1520; Lu HT, 1999, EMBO J, V18, P1845, DOI 10.1093/emboj/18.7.1845; Lyden D, 2001, NAT MED, V7, P1194, DOI 10.1038/nm1101-1194; MacKeigan JP, 2000, J BIOL CHEM, V275, P38953, DOI 10.1074/jbc.C000684200; Matsumoto T, 2002, J CELL BIOL, V156, P149, DOI 10.1083/jcb.200103096; Merks JHM, 2005, AM J MED GENET A, V134A, P132, DOI 10.1002/ajmg.a.30603; Mikula M, 2001, EMBO J, V20, P1952, DOI 10.1093/emboj/20.8.1952; Milanini J, 1998, J BIOL CHEM, V273, P18165, DOI 10.1074/jbc.273.29.18165; Mudgett JS, 2000, P NATL ACAD SCI USA, V97, P10454, DOI 10.1073/pnas.180316397; Niihori T, 2006, NAT GENET, V38, P294, DOI 10.1038/ng1749; Nishina H, 1999, DEVELOPMENT, V126, P505; Pages G, 2000, J BIOL CHEM, V275, P26484, DOI 10.1074/jbc.M002104200; Paget WJ, 1999, SOZ PRAVENTIV MED, V44, P1, DOI 10.1007/BF01624804; Pedram A, 1998, J BIOL CHEM, V273, P26722, DOI 10.1074/jbc.273.41.26722; Regan CP, 2002, P NATL ACAD SCI USA, V99, P9248, DOI 10.1073/pnas.142293999; REYNOLDS JF, 1986, AM J MED GENET, V25, P413, DOI 10.1002/ajmg.1320250303; Rodriguez-Viciana P, 2006, SCIENCE, V311, P1287, DOI 10.1126/science.1124642; Rousseau S, 1997, ONCOGENE, V15, P2169, DOI 10.1038/sj.onc.1201380; Roux PP, 2004, MICROBIOL MOL BIOL R, V68, P320, DOI 10.1128/MMBR.68.2.320-344.2004; Ruegg C, 2003, CELL MOL LIFE SCI, V60, P1135, DOI 10.1007/s00018-003-2297-3; Saba-El-Leil MK, 2003, EMBO REP, V4, P964, DOI 10.1038/sj.embor.embor939; SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; Shin EY, 2001, EXP MOL MED, V33, P276, DOI 10.1038/emm.2001.45; Sohn SJ, 2002, J BIOL CHEM, V277, P43344, DOI 10.1074/jbc.M207573200; St Croix B, 2000, SCIENCE, V289, P1197; Tamura K, 2000, CELL, V102, P221, DOI 10.1016/S0092-8674(00)00027-1; Tanaka N, 2002, EMBO REP, V3, P785, DOI 10.1093/embo-reports/kvf153; Tartaglia M, 2005, ANNU REV GENOM HUM G, V6, P45, DOI 10.1146/annurev.genom.6.080604.162305; Vitale G, 2000, BIOCHEM J, V352, P739, DOI 10.1042/0264-6021:3520739; Wang X, 2005, MOL CELL BIOL, V25, P336, DOI 10.1128/MCB.25.1.336-345.2005; Wilhelm SM, 2004, CANCER RES, V64, P7099, DOI 10.1158/0008-5472.CAN-04-1443; Wojnowski L, 1997, NAT GENET, V16, P293, DOI 10.1038/ng0797-293; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yan Lijun, 2003, BMC Dev Biol, V3, P11, DOI 10.1186/1471-213X-3-11; Yang D, 1997, P NATL ACAD SCI USA, V94, P3004, DOI 10.1073/pnas.94.7.3004; Yang DD, 1998, IMMUNITY, V9, P575, DOI 10.1016/S1074-7613(00)80640-8; Yang JH, 2000, NAT GENET, V24, P309, DOI 10.1038/73550	78	21	21	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 26	2007	26	9					1290	1296		10.1038/sj.onc.1210198	http://dx.doi.org/10.1038/sj.onc.1210198			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	141DU	17322914	Bronze			2022-12-28	WOS:000244558700006
J	Bellanger, S; de Gramont, A; Sobczak-Thepot, J				Bellanger, S.; de Gramont, A.; Sobczak-Thepot, J.			Cyclin B2 suppresses mitotic failure and DNA re-replication in human somatic cells knocked down for both cyclins B1 and B2	ONCOGENE			English	Article						cyclin; mitosis; RNA interference; replication; cell cycle	DEPENDENT KINASES; MAMMALIAN-CELLS; GEMININ BINDING; TUMOR-CELLS; IN-VITRO; PHOSPHORYLATION; MITOSIS; B1; LOCALIZATION; INHIBITOR	Cyclin-dependent kinase 1 (CDK1) plays a crucial role in establishing metaphase and has also been shown to prevent DNA re-replication. Cyclins B1 and B2 are two known activators of CDK1 operating during mitosis in human cells. Little is known about the specific roles of each of these cyclins in CDK1 activation, but cyclin B2 is thought to play a minor role and to be unable to replace cyclin B1 for mitosis completion. In our study, we found that severe reduction by separate RNA interference of either cyclin B1 or cyclin B2 protein levels results in little or no alteration of the cell cycle and, more specifically, of mitosis progression. In contrast, simultaneous depletion of both B-type cyclins leads to massive accumulation of 4N cells, mitotic failure, premature mitosis exit and DNA re-replication. These defects can be corrected by the ectopic expression of a cyclin B2 resistant to the short hairpin RNA. Altogether, these data show that, in cycling human cells, cyclin B2 can compensate for the downregulation of cyclin B1 during mitosis. They also clearly implicate cyclins B1 and B2 as crucial activators of CDK1 in its biological function of DNA re-replication prevention.	Univ Paris 06, CNRS, UMR 7098, Biochim Cellulaire Lab, F-75005 Paris, France; Inst Med Biol, Singapore 138673, Singapore; NIH, NIDDK, Cellular & Mol Biol Lab, Bethesda, MD 20892 USA	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Medical Biology (IMB); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Sobczak-Thepot, J (corresponding author), Univ Paris 06, CNRS, UMR 7098, Biochim Cellulaire Lab, F-75005 Paris, France.	Joelle.Sobczak-Thepot@snv.jussieu.fr	Sobczak, Joelle/HHZ-5610-2022	Sobczak, Joelle/0000-0001-7180-2789				Blangy A, 1995, CELL, V83, P1159, DOI 10.1016/0092-8674(95)90142-6; Blow JJ, 2005, NAT REV MOL CELL BIO, V6, P476, DOI 10.1038/nrm1663; Brandeis M, 1998, P NATL ACAD SCI USA, V95, P4344, DOI 10.1073/pnas.95.8.4344; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; DESSEV G, 1991, J CELL BIOL, V112, P523, DOI 10.1083/jcb.112.4.523; Draviam VM, 2001, J CELL BIOL, V152, P945, DOI 10.1083/jcb.152.5.945; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Furuno N, 1999, J CELL BIOL, V147, P295, DOI 10.1083/jcb.147.2.295; GALLANT P, 1992, J CELL BIOL, V117, P213, DOI 10.1083/jcb.117.1.213; Gong DQ, 2007, CURR BIOL, V17, P85, DOI 10.1016/j.cub.2006.11.066; Hagting A, 1999, CURR BIOL, V9, P680, DOI 10.1016/S0960-9822(99)80308-X; Hendzel MJ, 1997, CHROMOSOMA, V106, P348, DOI 10.1007/s004120050256; Itzhaki JE, 1997, NAT GENET, V15, P258, DOI 10.1038/ng0397-258; JACK DB, 1995, MOL MED TODAY, V1, P2; Kimura K, 1998, SCIENCE, V282, P487, DOI 10.1126/science.282.5388.487; Lee YM, 2006, CELL CYCLE, V5, P2110, DOI 10.4161/cc.5.18.3218; Lew DJ, 1996, CURR OPIN CELL BIOL, V8, P795, DOI 10.1016/S0955-0674(96)80080-9; Li CJ, 2004, MOL CELL BIOL, V24, P5875, DOI 10.1128/MCB.24.13.5875-5886.2004; Liu EB, 2004, J BIOL CHEM, V279, P17283, DOI 10.1074/jbc.C300549200; Machida YJ, 2007, GENE DEV, V21, P184, DOI 10.1101/gad.1495007; Mihaylov IS, 2002, MOL CELL BIOL, V22, P1868, DOI 10.1128/MCB.22.6.1868-1880.2002; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; Niiya F, 2005, J BIOL CHEM, V280, P36502, DOI 10.1074/jbc.M508007200; Ohi R, 1999, CURR OPIN CELL BIOL, V11, P267, DOI 10.1016/S0955-0674(99)80036-2; PETER M, 1991, EMBO J, V10, P1535, DOI 10.1002/j.1460-2075.1991.tb07673.x; Petersen BO, 1999, EMBO J, V18, P396, DOI 10.1093/emboj/18.2.396; PINES J, 1994, EMBO J, V13, P3772, DOI 10.1002/j.1460-2075.1994.tb06688.x; Seong YS, 2003, CANCER RES, V63, P7384; Sugimoto N, 2004, J BIOL CHEM, V279, P19691, DOI 10.1074/jbc.M313175200; Vassilev LT, 2006, P NATL ACAD SCI USA, V103, P10660, DOI 10.1073/pnas.0600447103; Wohlschlegel JA, 2000, SCIENCE, V290, P2309, DOI 10.1126/science.290.5500.2309; Yuan J, 2006, ONCOGENE, V25, P1753, DOI 10.1038/sj.onc.1209202; Yuan JP, 2004, ONCOGENE, V23, P5843, DOI 10.1038/sj.onc.1207757; Zhou Y, 2002, NUCLEIC ACIDS RES, V30, P1664, DOI 10.1093/nar/30.7.1664; Zhu WG, 2004, MOL CELL BIOL, V24, P7140, DOI 10.1128/MCB.24.16.7140-7150.2004	36	37	38	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 8	2007	26	51					7175	7184		10.1038/sj.onc.1210539	http://dx.doi.org/10.1038/sj.onc.1210539			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	231NO	17533373				2022-12-28	WOS:000250955600001
J	Li, XL; Arai, Y; Harada, H; Shima, Y; Yoshida, H; Rokudai, S; Aikawa, Y; Kimura, A; Kitabayashi, I				Li, X-L; Arai, Y.; Harada, H.; Shima, Y.; Yoshida, H.; Rokudai, S.; Aikawa, Y.; Kimura, A.; Kitabayashi, I.			Mutations of the HIPK2 gene in acute myeloid leukemia and myelodysplastic syndrome impair AML1-and p53-mediated transcription	ONCOGENE			English	Article						leukemia; HIPK2; mutation; AML1	INTERACTING PROTEIN KINASE-2; NUCLEAR-PORE COMPLEX; ACUTE LYMPHOBLASTIC-LEUKEMIA; GTPASE-ACTIVATING PROTEIN; FETAL LIVER HEMATOPOIESIS; ACUTE MONOCYTIC LEUKEMIA; SUMO-1 MODIFICATION; HOMEODOMAIN-INTERACTING-PROTEIN-KINASE-2 HIPK2; CHROMOSOME-TRANSLOCATION; AML1/PEBP2-ALPHA-B GENE	The AML1 transcription factor complex is the most frequent target of leukemia-associated chromosomal translocations. Homeodomain-interacting protein kinase 2 (HIPK2) is a part of the AML1 complex and activates AML1-mediated transcription. However, chromosomal translocations and mutations of HIPK2 have not been reported. In the current study, we screened mutations of the HIPK2 gene in 50 cases of acute myeloid leukemia (AML) and in 80 cases of myelodysplastic syndrome (MDS). Results indicated there were two missense mutations ( R868W and N958I) in the speckle-retention signal (SRS) domain of HIPK2. Subcellular localization analyses indicated that the two mutants were largely localized to nuclear regions with conical or ring shapes, and were somewhat diffused in the nucleus, in contrast to the wild type, which were mainly localized in nuclear speckles. The mutations impaired the overlapping localization of AML1 and HIPK2. The mutants showed decreased activities and a dominant-negative function over wild-type protein in AML1- and p53-dependent transcription. These findings suggest that dysfunction of HIPK2 may play a role in the pathogenesis of leukemia.	Natl Canc Ctr, Res Inst, Div Mol Oncol, Chuo Ku, Tokyo 104, Japan; Hiroshima Univ, Res Inst Radiat Biol & Med, Minami Ku, Hiroshima, Japan	National Cancer Center - Japan; Hiroshima University	Kitabayashi, I (corresponding author), Natl Canc Ctr, Res Inst, Div Mol Oncol, Chuo Ku, 5-1-1 Tsukiji, Tokyo 104, Japan.	ikitabay@gan2.ncc.go.jp	Rokudai, Susumu/O-6771-2018; Kitabayashi, Issay/G-2204-2017	Rokudai, Susumu/0000-0003-0300-0391; Kitabayashi, Issay/0000-0002-8409-0407				Aikawa Y, 2006, EMBO J, V25, P3955, DOI 10.1038/sj.emboj.7601273; Borrow J, 1996, NAT GENET, V14, P33, DOI 10.1038/ng0996-33; Carapeti M, 1999, CANCER GENET CYTOGEN, V113, P70, DOI 10.1016/S0165-4608(99)00007-2; Carapeti M, 1998, BLOOD, V91, P3127, DOI 10.1182/blood.V91.9.3127.3127_3127_3133; Chaffanet M, 2000, GENE CHROMOSOME CANC, V28, P138, DOI 10.1002/(SICI)1098-2264(200006)28:2<138::AID-GCC2>3.0.CO;2-2; Choi CY, 1999, J BIOL CHEM, V274, P33194, DOI 10.1074/jbc.274.47.33194; D'Orazi G, 2002, NAT CELL BIOL, V4, P11, DOI 10.1038/ncb714; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; Duprez E, 1999, J CELL SCI, V112, P381; Engelhardt OG, 2003, EXP CELL RES, V283, P36, DOI 10.1016/S0014-4827(02)00025-3; Gamou T, 1998, BLOOD, V91, P4028, DOI 10.1182/blood.V91.11.4028.411a45_4028_4037; GOLUB TR, 1995, P NATL ACAD SCI USA, V92, P4917, DOI 10.1073/pnas.92.11.4917; Harada H, 2004, BLOOD, V103, P2316, DOI 10.1182/blood-2003-09-3074; Hofmann TG, 2005, J BIOL CHEM, V280, P29224, DOI 10.1074/jbc.M503921200; Hofmann TG, 2003, CANCER RES, V63, P8271; Hofmann TG, 2002, NAT CELL BIOL, V4, P1, DOI 10.1038/ncb715; Hofmann TG, 2000, BIOCHIMIE, V82, P1123, DOI 10.1016/S0300-9084(00)01196-2; Ida K, 1997, BLOOD, V90, P4699, DOI 10.1182/blood.V90.12.4699.4699_4699_4704; Imai Y, 2000, BLOOD, V96, P3154, DOI 10.1182/blood.V96.9.3154.h8003154_3154_3160; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; Kamitani T, 1998, J BIOL CHEM, V273, P26675, DOI 10.1074/jbc.273.41.26675; KASTNER P, 1992, EMBO J, V11, P629, DOI 10.1002/j.1460-2075.1992.tb05095.x; Kim YH, 2005, FEBS LETT, V579, P6272, DOI 10.1016/j.febslet.2005.10.010; Kim YH, 1998, J BIOL CHEM, V273, P25875, DOI 10.1074/jbc.273.40.25875; Kim YH, 1999, P NATL ACAD SCI USA, V96, P12350, DOI 10.1073/pnas.96.22.12350; Kitabayashi I, 2001, EMBO J, V20, P7184, DOI 10.1093/emboj/20.24.7184; Kitabayashi I, 2001, LEUKEMIA, V15, P89, DOI 10.1038/sj.leu.2401983; Kitabayashi I, 1998, EMBO J, V17, P2994, DOI 10.1093/emboj/17.11.2994; Krug U, 2002, ONCOGENE, V21, P3475, DOI 10.1038/sj.onc.1205322; Lin X, 2003, MOL CELL, V11, P1389, DOI 10.1016/S1097-2765(03)00175-8; Mahajan R, 1997, CELL, V88, P97, DOI 10.1016/S0092-8674(00)81862-0; Matunis MJ, 1996, J CELL BIOL, V135, P1457, DOI 10.1083/jcb.135.6.1457; Matunis MJ, 1998, J CELL BIOL, V140, P499, DOI 10.1083/jcb.140.3.499; MEYERS S, 1993, MOL CELL BIOL, V13, P6336, DOI 10.1128/MCB.13.10.6336; MITANI K, 1994, EMBO J, V13, P504, DOI 10.1002/j.1460-2075.1994.tb06288.x; Mitelman F, 1997, NAT GENET, V15, P417, DOI 10.1038/ng0497supp-417; MIYOSHI H, 1991, P NATL ACAD SCI USA, V88, P10431, DOI 10.1073/pnas.88.23.10431; Moller A, 2003, ONCOGENE, V22, P8731, DOI 10.1038/sj.onc.1207079; Moller A, 2003, CANCER RES, V63, P4310; Nguyen LA, 2005, BLOOD, V105, P292, DOI 10.1182/blood-2004-03-1185; NUCIFORA G, 1993, P NATL ACAD SCI USA, V90, P7784, DOI 10.1073/pnas.90.16.7784; OGAWA E, 1993, P NATL ACAD SCI USA, V90, P6859, DOI 10.1073/pnas.90.14.6859; Okada H, 1998, ONCOGENE, V17, P2287, DOI 10.1038/sj.onc.1202151; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Osato M, 1999, BLOOD, V93, P1817, DOI 10.1182/blood.V93.6.1817.406k36_1817_1824; Pierantoni GM, 2001, ONCOGENE, V20, P6132, DOI 10.1038/sj.onc.1204635; Preudhomme C, 2000, BLOOD, V96, P2862, DOI 10.1182/blood.V96.8.2862.h8002862_2862_2869; ROMANA SP, 1995, BLOOD, V85, P3662, DOI 10.1182/blood.V85.12.3662.bloodjournal85123662; Rui YN, 2004, EMBO J, V23, P4583, DOI 10.1038/sj.emboj.7600475; Sasaki K, 1996, P NATL ACAD SCI USA, V93, P12359, DOI 10.1073/pnas.93.22.12359; Satake N, 1997, GENE CHROMOSOME CANC, V20, P60, DOI 10.1002/(SICI)1098-2264(199709)20:1<60::AID-GCC9>3.3.CO;2-O; Sobulo OM, 1997, P NATL ACAD SCI USA, V94, P8732, DOI 10.1073/pnas.94.16.8732; Sung KS, 2005, FEBS LETT, V579, P3001, DOI 10.1016/j.febslet.2005.04.053; Taki T, 1997, BLOOD, V89, P3945, DOI 10.1182/blood.V89.11.3945; Tomasini R, 2003, J BIOL CHEM, V278, P37722, DOI 10.1074/jbc.M301979200; Wang Q, 1996, CELL, V87, P697, DOI 10.1016/S0092-8674(00)81389-6; Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444; Wang Y, 2001, BBA-GENE STRUCT EXPR, V1518, P168, DOI 10.1016/S0167-4781(00)00308-0; Wiggins AK, 2004, J CELL BIOL, V167, P257, DOI 10.1083/jcb.200406131; Zhang OH, 2003, CELL, V115, P177, DOI 10.1016/S0092-8674(03)00802-X; Zhang QH, 2005, P NATL ACAD SCI USA, V102, P2802, DOI 10.1073/pnas.0409373102	62	55	56	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 8	2007	26	51					7231	7239		10.1038/sj.onc.1210523	http://dx.doi.org/10.1038/sj.onc.1210523			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	231NO	17533375				2022-12-28	WOS:000250955600007
J	Lackey, J; Barnett, J; Davidson, L; Batty, IH; Leslie, NR; Downes, CP				Lackey, J.; Barnett, J.; Davidson, L.; Batty, I. H.; Leslie, N. R.; Downes, C. P.			Loss of PTEN selectively desensitizes upstream IGF1 and insulin signaling	ONCOGENE			English	Article						phosphatase; signal transduction; feedback; insulin-like growth factor; phosphoinositide; tumor; suppressor	GROWTH-FACTOR RECEPTOR; TYROSINE KINASE-ACTIVITY; PHOSPHATIDYLINOSITOL 3-KINASE; C-ZETA; EXPRESSION; INHIBITION; PATHWAYS; DOWNSTREAM; ACTIVATION; IRS-1	Many tumors have chronically elevated activity of PI 3-kinase-dependent signaling pathways, caused largely by oncogenic mutation of PI 3-kinase itself or loss of the opposing tumor suppressor lipid phosphatase, PTEN. Several PI 3-kinase-dependent feedback mechanisms have been identified that may affect the sensitivity of upstream receptor signaling, but the events required to initiate an inhibited state have not been addressed. We show that in a variety of cell types, loss of PTEN via experimental knockdown or in tumor cell lines correlates with a block in insulin-like growth factor 1 (IGF1)/insulin signaling, without affecting the sensitivity of platelet-derived growth factor or epidermal growth factor signaling. These effects on IGF/insulin signaling include a reduction of up to. veto tenfold in IGF-stimulated PI 3-kinase activation, a failure to activate the ERK kinases and, in some cells, reduced expression of insulin receptor substrate 1, and both IGF1 and insulin receptors. These data indicate that chronically elevated PI 3-kinase-dependent signaling to the degree seen in many tumors causes a selective loss of sensitivity in IGF1/insulin signaling that could significantly reduce the selective advantage of deregulated activation of IGF1/IGF1-R signaling in tumor development.	Univ Dundee, Sch Life Sci, Div Mol Physiol, Coll Life Sci, Dundee DD1 5EH, Scotland	University of Dundee	Leslie, NR (corresponding author), Univ Dundee, Sch Life Sci, Div Mol Physiol, Coll Life Sci, Dow St, Dundee DD1 5EH, Scotland.	n.r.leslie@dundee.ac.uk	Leslie, Nicholas/D-2699-2009	LESLIE, Nicholas/0000-0001-5131-0541	MRC [G9403619] Funding Source: UKRI; Medical Research Council [G9403619(67505), G9403619] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Batty IH, 2004, BIOCHEM J, V379, P641, DOI 10.1042/BJ20031700; Board R, 2005, DRUG RESIST UPDATE, V8, P75, DOI 10.1016/j.drup.2005.03.004; Cheung PCF, 2003, EMBO J, V22, P5793, DOI 10.1093/emboj/cdg552; Cully M, 2006, NAT REV CANCER, V6, P184, DOI 10.1038/nrc1819; Cutillas PR, 2006, P NATL ACAD SCI USA, V103, P8959, DOI 10.1073/pnas.0602101103; Danilkovitch-Miagkova A, 2002, J CLIN INVEST, V109, P863; Darragh J, 2005, BIOCHEM J, V390, P749, DOI 10.1042/BJ20050196; Fisher TL, 2004, CURR BIOL, V14, pR1005, DOI 10.1016/j.cub.2004.11.024; Foukas LC, 2006, NATURE, V441, P366, DOI 10.1038/nature04694; Harrington LS, 2005, TRENDS BIOCHEM SCI, V30, P35, DOI 10.1016/j.tibs.2004.11.003; Harrington LS, 2004, J CELL BIOL, V166, P213, DOI 10.1083/jcb.200403069; Hellawell GO, 2002, CANCER RES, V62, P2942; Jackson JG, 1999, GROWTH HORM IGF RES, V9, P280, DOI 10.1054/ghir.1999.0113; Javelaud D, 2005, ONCOGENE, V24, P5742, DOI 10.1038/sj.onc.1208928; Keeton AB, 2005, ENDOCRINOLOGY, V146, P2716, DOI 10.1210/en.2004-1662; Kiepe D, 2005, ENDOCRINOLOGY, V146, P3096, DOI 10.1210/en.2005-0324; Knight ZA, 2006, CELL, V125, P733, DOI 10.1016/j.cell.2006.03.035; LAM K, 1994, J BIOL CHEM, V269, P20648; LeRoith D, 2003, CANCER LETT, V195, P127, DOI 10.1016/S0304-3835(03)00159-9; Leslie NR, 2001, BIOCHEM J, V357, P427, DOI 10.1042/0264-6021:3570427; Liu YF, 2001, J BIOL CHEM, V276, P14459, DOI 10.1074/jbc.M007281200; Macrae M, 2005, CANCER CELL, V8, P111, DOI 10.1016/j.ccr.2005.07.005; Mise-Omata S, 2005, BIOCHEM BIOPH RES CO, V328, P1034, DOI 10.1016/j.bbrc.2005.01.066; Mitsiades CS, 2004, CANCER CELL, V5, P221, DOI 10.1016/S1535-6108(04)00050-9; Myers MP, 1998, P NATL ACAD SCI USA, V95, P13513, DOI 10.1073/pnas.95.23.13513; Natarajan M, 2006, NAT CELL BIOL, V8, P571, DOI 10.1038/ncb1418; O'Reilly KE, 2006, CANCER RES, V66, P1500, DOI 10.1158/0008-5472.CAN-05-2925; Parrizas M, 1997, J BIOL CHEM, V272, P154; Pirola L, 2004, DIABETOLOGIA, V47, P170, DOI 10.1007/s00125-003-1313-3; Ravichandran LV, 2001, J BIOL CHEM, V276, P3543, DOI 10.1074/jbc.M007231200; Sajan MP, 1999, J BIOL CHEM, V274, P30495, DOI 10.1074/jbc.274.43.30495; Shaw RJ, 2006, NATURE, V441, P424, DOI 10.1038/nature04869; Shelton JG, 2005, EXPERT OPIN THER TAR, V9, P1009, DOI 10.1517/14728222.9.5.1009; Simpson L, 2001, MOL CELL BIOL, V21, P3947, DOI 10.1128/MCB.21.12.3947-3958.2001; Stiles B, 2002, MOL CELL BIOL, V22, P3842, DOI 10.1128/MCB.22.11.3842-3851.2002; Stocker H, 2002, SCIENCE, V295, P2088, DOI 10.1126/science. 1068094; Um SH, 2004, NATURE, V431, P200, DOI 10.1038/nature02866; Um SH, 2006, CELL METAB, V3, P393, DOI 10.1016/j.cmet.2006.05.003; Vivekanand P, 2006, ANNU REV GENET, V40, P139, DOI 10.1146/annurev.genet.40.110405.090555; White MF, 2002, AM J PHYSIOL-ENDOC M, V283, pE413, DOI 10.1152/ajpendo.00514.2001	40	30	30	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 1	2007	26	50					7132	7142		10.1038/sj.onc.1210520	http://dx.doi.org/10.1038/sj.onc.1210520			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	228GF	17486056	Green Accepted			2022-12-28	WOS:000250715000007
J	Darwiche, N; Ryscavage, A; Perez-Lorenzo, R; Wright, L; Bae, DS; Hennings, H; Yuspa, SH; Glick, AB				Darwiche, N.; Ryscavage, A.; Perez-Lorenzo, R.; Wright, L.; Bae, D-S; Hennings, H.; Yuspa, S. H.; Glick, A. B.			Expression profile of skin papillomas with high cancer risk displays a unique genetic signature that clusters with squamous cell carcinomas and predicts risk for malignant conversion	ONCOGENE			English	Article						skin carcinogenesis; microarray; squamous cell carcinoma; tumor immunology	MOUSE SKIN; EPITHELIAL-CELLS; MESSENGER-RNA; IN-VIVO; CARCINOGENESIS; TUMORS; INFLAMMATION; SURVEILLANCE; PROGRESSION; RECEPTORS	Chemical induction of squamous tumors in the mouse skin induces multiple benign papillomas: high-frequency terminally benign low-risk papillomas and low-frequency high-risk papillomas, the putative precursor lesions to squamous cell carcinoma (SCC). We have compared the gene expression profile of twenty different early low- and high-risk papillomas with normal skin and SCC. Unsupervised clustering of 514 differentially expressed genes (P<0.001) showed that 9/10 high-risk papillomas clustered with SCC, while 1/10 clustered with low-risk papillomas, and this correlated with keratin markers of tumor progression. Prediction analysis for microarrays (PAM) identified 87 genes that distinguished the two papilloma classes, and a majority of these had a similar expression pattern in both high-risk papillomas and SCC. Additional classifier algorithms generated a gene list that correctly classified unknown benign tumors as low- or high-risk concordant with promotion protocol and keratin profiling. Reduced expression of immune function genes characterized the high-risk papillomas and SCC. Immunohistochemistry confirmed reduced T-cell number in high-risk papillomas, suggesting that reduced adaptive immunity defines papillomas that progress to SCC. These results demonstrate that murine premalignant lesions can be segregated into subgroups; by gene expression patterns that correlate with risk for malignant conversion, and suggest a paradigm for generating diagnostic biomarkers for human premalignant lesions with unknown individual risk for malignant conversion.	Penn State Univ, Ctr Mol Toxicol & Carcinogenesis, Dept Vet & Biomed Sci, University Pk, PA 16801 USA; Amer Univ Beirut, Dept Biol, Beirut, Lebanon; NCI, Lab Canc Biol & Genet, Bethesda, MD USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; American University of Beirut; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Glick, AB (corresponding author), Penn State Univ, Ctr Mol Toxicol & Carcinogenesis, Dept Vet & Biomed Sci, University Pk, PA 16801 USA.	abg11@psu.edu		Perez-Lorenzo, Rolando/0000-0002-9355-9617; Ryscavage, Andrew/0000-0002-4156-6903; Darwiche, Nadine/0000-0002-1862-5426	NATIONAL CANCER INSTITUTE [Z01BC005445, R01CA117957] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline; NCI NIH HHS [CA117957] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Balkwill F, 2001, LANCET, V357, P539, DOI 10.1016/S0140-6736(00)04046-0; Brown K, 1998, CURR BIOL, V8, P516, DOI 10.1016/S0960-9822(98)70203-9; Callen JP, 1997, J AM ACAD DERMATOL, V36, P650, DOI 10.1016/S0190-9622(97)70265-2; Coussens LM, 1999, GENE DEV, V13, P1382, DOI 10.1101/gad.13.11.1382; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; Darwiche N, 1996, CANCER RES, V56, P4942; de Visser KE, 2005, CANCER CELL, V7, P411, DOI 10.1016/j.ccr.2005.04.014; DIGHE AS, 1994, IMMUNITY, V1, P447, DOI 10.1016/1074-7613(94)90087-6; Dong G, 1997, J CELL BIOCHEM, P90; Dooley TP, 2003, BIOCHEM BIOPH RES CO, V306, P1026, DOI 10.1016/S0006-291X(03)01099-4; Dumitriu IE, 2005, TRENDS IMMUNOL, V26, P381, DOI 10.1016/j.it.2005.04.009; Girardi M, 2003, J EXP MED, V198, P747, DOI 10.1084/jem.20021282; Girardi M, 2001, SCIENCE, V294, P605, DOI 10.1126/science.1063916; GLICK AB, 1993, P NATL ACAD SCI USA, V90, P6076, DOI 10.1073/pnas.90.13.6076; Glinsky GV, 2004, J CLIN INVEST, V113, P913, DOI 10.1172/JCI200420032; HENNINGS H, 1985, CARCINOGENESIS, V6, P1607, DOI 10.1093/carcin/6.11.1607; Hummerich L, 2006, ONCOGENE, V25, P111, DOI 10.1038/sj.onc.1209016; Juric D, 2005, P NATL ACAD SCI USA, V102, P17763, DOI 10.1073/pnas.0509082102; Kaplan DH, 1998, P NATL ACAD SCI USA, V95, P7556, DOI 10.1073/pnas.95.13.7556; LARCHER F, 1992, MOL CARCINOGEN, V6, P112, DOI 10.1002/mc.2940060206; Lossos IS, 2004, NEW ENGL J MED, V350, P1828, DOI 10.1056/NEJMoa032520; Ma C, 1996, BLOOD, V87, P734, DOI 10.1182/blood.V87.2.734.bloodjournal872734; Morris RJ, 1997, CANCER RES, V57, P3436; Morris RJ, 2000, CANCER RES, V60, P226; Nambiar PR, 2004, CANCER RES, V64, P6394, DOI 10.1158/0008-5472.CAN-04-0933; Nishimura H, 2000, J EXP MED, V191, P157, DOI 10.1084/jem.191.1.157; Nishimura H, 1998, J IMMUNOL, V160, P936; Ozaki K, 2004, NATURE, V429, P72, DOI 10.1038/nature02502; Perez-Losada J, 2003, NAT REV CANCER, V3, P434, DOI 10.1038/nrc1095; Peyssonnaux C, 2006, BLOOD, V107, P3727, DOI 10.1182/blood-2005-06-2259; Rhodes DR, 2004, NEOPLASIA, V6, P1, DOI 10.1016/S1476-5586(04)80047-2; Ridd K, 2006, CARCINOGENESIS, V27, P1556, DOI 10.1093/carcin/bgl007; Schlingemann J, 2003, INT J CANCER, V104, P699, DOI 10.1002/ijc.11008; Serewko MM, 2002, CANCER RES, V62, P3759; Smyth MJ, 2000, J EXP MED, V192, P755, DOI 10.1084/jem.192.5.755; TENNENBAUM T, 1993, CANCER RES, V53, P4803; Tibshirani R, 2002, P NATL ACAD SCI USA, V99, P6567, DOI 10.1073/pnas.082099299; Yuspa SH, 1998, J DERMATOL SCI, V17, P1, DOI 10.1016/S0923-1811(97)00071-6	38	35	36	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 18	2007	26	48					6885	6895		10.1038/sj.onc.1210491	http://dx.doi.org/10.1038/sj.onc.1210491			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	220WQ	17525749				2022-12-28	WOS:000250188400004
J	Jin, Z; Mori, Y; Yang, J; Sato, F; Ito, T; Cheng, Y; Paun, B; Hamilton, JP; Kan, T; Olaru, A; David, S; Agarwal, R; Abraham, JM; Beer, D; Montgomery, E; Meltzer, SJ				Jin, Z.; Mori, Y.; Yang, J.; Sato, F.; Ito, T.; Cheng, Y.; Paun, B.; Hamilton, J. P.; Kan, T.; Olaru, A.; David, S.; Agarwal, R.; Abraham, J. M.; Beer, D.; Montgomery, E.; Meltzer, S. J.			Hypermethylation of the nel-like 1 gene is a common and early event and is associated with poor prognosis in early-stage esophageal adenocarcinoma	ONCOGENE			English	Article						hypermethylation; NELL1; EAC; ESCC; biomarker	SEGMENT BARRETTS-ESOPHAGUS; PROMOTER HYPERMETHYLATION; FOLLOW-UP; NEOPLASTIC PROGRESSION; CANCER; DYSPLASIA; NELL-1; CRANIOSYNOSTOSIS; INACTIVATION; METHYLATION	The nel-like1 ( NELL1) gene maps to chromosome 11p15, which frequently undergoes loss of heterozygosity in esophageal adenocarcinoma ( EAC). NELL1 promoter hypermethylation was examined by real-time methylation-specific polymerase chain reaction in 259 human esophageal tissues. Hypermethylation of this promoter showed highly discriminative receiver-operator characteristic curve pro. les, clearly distinguishing esophageal squamous cell carcinoma ( ESCC) and EAC from normal esophagus ( NE) ( P < 0.001). NELL1 normalized methylation values were significantly higher in Barrett's metaplasia ( BE), dysplastic Barrett's ( D) and EAC than in NE ( P < 0.0000001). NELL1 hypermethylation frequency was zero in NE but increased early during neoplastic progression, to 41.7% in BE from patients with Barrett's alone, 52.5% in D and 47.8% in EAC. There was a significantly correlation between NELL1 hypermethylation and BE segment length. Three ( 11.5%) of 26 ESCCs exhibited NELL1 hypermethylation. Survival correlated inversely with NELL1 hypermethylation in patients with stages I-II (P = 0.0264) but not in stages III-IV ( P = 0.68) EAC. Treatment of KYSE220 ESCC and BIC EAC cells with 5-aza-2'-deoxycytidine reduced NELL1 methylation and increased NELL1 mRNA expression. NELL1 mRNA levels in EACs with an unmethylated NELL1 promoter were significantly higher than those in EACs with a methylated promoter ( P 0.02). Promoter hypermethylation of NELL1 is a common, tissue-specific event in human EAC, occurs early during Barrett's-associated esophageal neoplastic progression, and is a potential biomarker of poor prognosis in early-stage EAC.	Johns Hopkins Univ, Sch Med, Dept Med, Div Gastroenterol, Baltimore, MD 21231 USA; Univ Michigan, Sch Med, Dept Surg, Div Gen Thorac Surg, Ann Arbor, MI 48109 USA; Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21231 USA; Johns Hopkins Univ, Sch Med, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21231 USA	Johns Hopkins University; University of Michigan System; University of Michigan; Johns Hopkins University; Johns Hopkins University; Johns Hopkins Medicine	Meltzer, SJ (corresponding author), Johns Hopkins Univ, Sch Med, Dept Med, Div Gastroenterol, 1503 E Jefferson St,Room 112, Baltimore, MD 21231 USA.	smeltzer@jhmi.edu			NATIONAL CANCER INSTITUTE [R01CA001808, R21CA106763, U01CA085069] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK067872] Funding Source: NIH RePORTER; NCI NIH HHS [CA001808, CA085069, CA106763] Funding Source: Medline; NIDDK NIH HHS [T32 DK067872] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bender CM, 1999, MOL CELL BIOL, V19, P6690; Brock MV, 2003, CLIN CANCER RES, V9, P2912; Desai J, 2006, HUM MOL GENET, V15, P1329, DOI 10.1093/hmg/ddl053; Dolan K, 1998, BRIT J CANCER, V78, P950, DOI 10.1038/bjc.1998.607; Fang MZ, 2005, INT J ONCOL, V26, P615; Gleeson CM, 1998, GENE CHROMOSOME CANC, V21, P49, DOI 10.1002/(SICI)1098-2264(199801)21:1<49::AID-GCC7>3.0.CO;2-8; Hage M, 2004, SCAND J GASTROENTERO, V39, P1175, DOI 10.1080/00365520410003524; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075; Hirota WK, 1999, GASTROENTEROLOGY, V116, P277, DOI 10.1016/S0016-5085(99)70123-X; Ingber DE, 2002, DIFFERENTIATION, V70, P547, DOI 10.1046/j.1432-0436.2002.700908.x; International Union Against Cancer, 2002, TNM CLASS MAL TUM; Jemal A, 2005, CA-CANCER J CLIN, V55, P10, DOI 10.3322/canjclin.55.1.10; Kawakami K, 2000, J NATL CANCER I, V92, P1805, DOI 10.1093/jnci/92.22.1805; Knudson AG, 2001, NAT REV CANCER, V1, P157, DOI 10.1038/35101031; Kuroda S, 1999, BIOCHEM BIOPH RES CO, V265, P752, DOI 10.1006/bbrc.1999.1753; Lee EJ, 2006, EUR J CANCER, V42, P972, DOI 10.1016/j.ejca.2006.01.021; Lemaire M, 2005, ANTI-CANCER DRUG, V16, P301, DOI 10.1097/00001813-200503000-00009; MATSUHASHI S, 1995, DEV DYNAM, V203, P212, DOI 10.1002/aja.1002030209; Matsuhashi S, 1996, DEV DYNAM, V207, P233; Momparler RL, 2005, SEMIN ONCOL, V32, P443, DOI 10.1053/j.seminoncol.2005.07.008; Mori Y, 2006, GASTROENTEROLOGY, V131, P797, DOI 10.1053/j.gastro.2006.06.006; Rowinsky EK, 2005, J CLIN ONCOL, V23, P9394, DOI 10.1200/JCO.2005.02.2889; Rudolph RE, 2000, ANN INTERN MED, V132, P612, DOI 10.7326/0003-4819-132-8-200004180-00003; Schulmann K, 2005, ONCOGENE, V24, P4138, DOI 10.1038/sj.onc.1208598; Sharma P, 1997, AM J GASTROENTEROL, V92, P2012; Shibata DM, 2002, CANCER RES, V62, P5637; STEWART DM, 2003, WORLD CANC REPORT; WATANABE H, 2002, LANG COMPUT, V38, P273; Weston AP, 1997, AM J GASTROENTEROL, V92, P407; Zhang XL, 2006, LAB INVEST, V86, P633, DOI 10.1038/labinvest.3700430; Zhang XL, 2002, J CLIN INVEST, V110, P861, DOI 10.1172/JCI200215375; Zhang XL, 2003, J BONE MINER RES, V18, P2126, DOI 10.1359/jbmr.2003.18.12.2126	33	60	64	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 20	2007	26	43					6332	6340		10.1038/sj.onc.1210461	http://dx.doi.org/10.1038/sj.onc.1210461			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	212GW	17452981				2022-12-28	WOS:000249583300009
J	Sekaric, P; Shamanin, VA; Luo, J; Androphy, EJ				Sekaric, P.; Shamanin, V. A.; Luo, J.; Androphy, E. J.			HAda3 regulates p14ARF-induced p53 acetylation and senescence	ONCOGENE			English	Article						p53; p14ARF; senescence; papillomavirus E6; hAda3	HUMAN-PAPILLOMAVIRUS TYPE-16; MAMMARY EPITHELIAL-CELLS; E6 ONCOPROTEIN; ONCOGENIC RAS; DNA-DAMAGE; HUMAN ADA3; MDM2; ACTIVATION; IMMORTALIZATION; P21(WAF1/CIP1)	Acetylation is thought to be a key event for p53 activation. We demonstrate that p14ARF-induced senescence of human mammary epithelial cells ( MEC) is associated with p53 acetylation and requires hAda3, a component of histone acetyltransferase complexes and a p53 transcriptional coactivator. Expression of the N-terminal domain of hAda3 that binds p53 but not p300 blocked p14ARF-induced p53 acetylation and protected MECs from senescence. Consistent with these findings, the human papillomavirus 16 E6 mutant Y54D, which selectively targets hAda3 but not p53 for degradation and protects MECs from p14ARF-induced senescence, inhibited p53 acetylation. In H1299 cells, hAda3 overexpression increased p300-mediated p53 acetylation, which conversely decreased following small interfering RNA ( siRNA) knockdown of hAda3. Moreover, depletion of hAda3 by siRNA inhibited endogenous p53 acetylation and accumulation of p21cip1 in response to ectopic p14ARF. These studies reveal that, in addition to its known ability to inhibit Mdm2-mediated p53 degradation, p14ARF signals through hAda3 to stimulate p53 acetylation and the induction of cell senescence.	Univ Massachusetts, Sch Med, Dept Med, Worcester, MA 01605 USA; Russian Acad Sci, Inst Cytol & Genet, Novosibirsk 630090, Russia; Univ Massachusetts, Sch Med, Dept Canc Biol, Worcester, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester; Russian Academy of Sciences; Institute of Cytology & Genetics ICG SB RAS; University of Massachusetts System; University of Massachusetts Worcester	Androphy, EJ (corresponding author), Univ Massachusetts, Sch Med, Dept Med, LRB328,364 Plantat St, Worcester, MA 01605 USA.	elliot.androphy@umassmed.edu		Androphy, Elliot/0000-0002-8104-0703	NCI NIH HHS [R01 CA107394] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA107394] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Appella E, 2001, EUR J BIOCHEM, V268, P2763, DOI 10.1046/j.1432-1327.2001.02224.x; Balasubramanian R, 2002, J BIOL CHEM, V277, P7989, DOI 10.1074/jbc.M110849200; BAND V, 1990, P NATL ACAD SCI USA, V87, P463, DOI 10.1073/pnas.87.1.463; Espinosa JM, 2001, MOL CELL, V8, P57, DOI 10.1016/S1097-2765(01)00283-0; Grant PA, 1997, GENE DEV, V11, P1640, DOI 10.1101/gad.11.13.1640; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Ito A, 2001, EMBO J, V20, P1331, DOI 10.1093/emboj/20.6.1331; Jin YT, 2003, EMBO J, V22, P6365, DOI 10.1093/emboj/cdg600; Klingelhutz AJ, 1996, NATURE, V380, P79, DOI 10.1038/380079a0; Kumar A, 2002, MOL CELL BIOL, V22, P5801, DOI 10.1128/MCB.22.16.5801-5812.2002; Lee BY, 2006, AGING CELL, V5, P187, DOI 10.1111/j.1474-9726.2006.00199.x; Liu L, 1999, MOL CELL BIOL, V19, P1202; Liu Y, 1999, J VIROL, V73, P7297, DOI 10.1128/JVI.73.9.7297-7307.1999; Luo JY, 2001, CELL, V107, P137, DOI 10.1016/S0092-8674(01)00524-4; Michael D, 2003, SEMIN CANCER BIOL, V13, P49, DOI 10.1016/S1044-579X(02)00099-8; Nag A, 2007, J BIOL CHEM, V282, P8812, DOI 10.1074/jbc.M610443200; Ogryzko VV, 1998, CELL, V94, P35, DOI 10.1016/S0092-8674(00)81219-2; Patel D, 1999, EMBO J, V18, P5061, DOI 10.1093/emboj/18.18.5061; Pearson M, 2000, NATURE, V406, P207, DOI 10.1038/35018127; Pedeux R, 2005, MOL CELL BIOL, V25, P6639, DOI 10.1128/MCB.25.15.6639-6648.2005; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Shamanin VA, 2004, MOL CELL BIOL, V24, P2144, DOI 10.1128/MCB.24.5.2144-2152.2004; Sherr CJ, 2006, NAT REV CANCER, V6, P663, DOI 10.1038/nrc1954; Sugrue MM, 1997, P NATL ACAD SCI USA, V94, P9648, DOI 10.1073/pnas.94.18.9648; Thomas MC, 2005, MOL CELL, V17, P251, DOI 10.1016/j.molcel.2004.12.016; Vousden KH, 2002, CANCER CELL, V2, P351, DOI 10.1016/S1535-6108(02)00186-1; Wang T, 2001, EMBO J, V20, P6404, DOI 10.1093/emboj/20.22.6404; Wang XJ, 2004, FEBS LETT, V561, P195, DOI 10.1016/S0014-5793(04)00168-1; Wei WY, 2001, MOL CELL BIOL, V21, P6748, DOI 10.1128/MCB.21.20.6748-6757.2001; Zhang Z, 2004, J BIOL CHEM, V279, P16000, DOI 10.1074/jbc.M312264200; Zimmermann H, 1999, J VIROL, V73, P6209, DOI 10.1128/JVI.73.8.6209-6219.1999; 方岱宁, 1999, [力学与实践, Mechanics in Engineering], V21, P1	33	26	27	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 20	2007	26	43					6261	6268		10.1038/sj.onc.1210462	http://dx.doi.org/10.1038/sj.onc.1210462			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	212GW	17452980				2022-12-28	WOS:000249583300002
J	Law, FBF; Chen, YW; Wong, KY; Ying, J; Tao, Q; Langford, C; Lee, PY; Law, S; Cheung, RWL; Chui, CH; Tsao, SW; Lam, KY; Wong, J; Srivastava, G; Tang, JCO				Law, F. B. F.; Chen, Y. W.; Wong, K. Y.; Ying, J.; Tao, Q.; Langford, C.; Lee, P. Y.; Law, S.; Cheung, R. W. L.; Chui, C. H.; Tsao, S. W.; Lam, K. Y.; Wong, J.; Srivastava, G.; Tang, J. C. O.			Identifcation of a novel tumor transforming gene GAEC1 at 7q22 which encodes a nuclear protein and is frequently amplified and overexpressed in esophageal squamous cell carcinoma	ONCOGENE			English	Article						gene amplifcation; overexpression; transforming gene; esophageal cancer; 7q22	COMPARATIVE GENOMIC HYBRIDIZATION; CHROMOSOMAL IMBALANCES; KINASE-C; LINES; AMPLIFICATION; ABERRATIONS; MULTIPLE; SEQUENCE; CANCER; PCR	By comparative DNA. fingerprinting, we identified a 357-bp DNA fragment frequently amplified in esophageal squamous cell carcinomas ( ESCC). This fragment overlaps with an expressed sequence tag mapped to 7q22. Further 5' and 3'-rapid amplification of cDNA ends revealed that it is part of a novel, single-exon gene with full-length mRNA of 2052 bp and encodes a nuclear protein of 109 amino acids ( similar to 15 kDa). This gene, designated as gene amplified in esophageal cancer 1 ( GAEC1), was located within a 1-2 Mb amplicon at 7q22.1 identified by high-resolution 1 Mb array-comparative genomic hybridization in 6/10 ESCC cell lines. GAEC1 was ubiquitously expressed in normal tissues including esophageal and gastrointestinal organs; with amplification and overexpression in 6/10 ( 60%) ESCC cell lines and 34/99 ( 34%) primary tumors. Overexpression of GAEC1 in 3T3 mouse. broblasts caused foci formation and colony formation in soft agar, comparable to H-ras and injection of GAEC1-transfected 3T3 cells into athymic nude mice formed undifferentiated sarcoma in vivo, indicating that GAEC1 is a transforming oncogene. Although no significant correlation was observed between GAEC1 amplification and clinicopathological parameters and prognosis, our study demonstrated that overexpressed GAEC1 has tumorigenic potential and suggest that overexpressed GAEC1 may play an important role in ESCC pathogenesis.	Hong Kong Polytech Univ, Dept Appl Biol & Chem Technol, Kowloon, Hong Kong, Peoples R China; State Key Lab Chinese Med & Mol Pharmacol, Shenzhen, Peoples R China; Griffith Univ, Dept Pathol, Nathan, Qld 4111, Australia; Univ Hong Kong, Li Ka Shing Fac Med, Dept Anat, Hong Kong, Hong Kong, Peoples R China; Hong Kong Polytech Univ, Lo Ka Chung Ctr Nat Anti Canc Drug Dev, Kowloon, Hong Kong, Peoples R China; Univ Hong Kong, Li Ka Shing Fac Med, Dept Surg, Hong Kong, Hong Kong, Peoples R China; Wellcome Trust Sanger Inst, Microarray Facil, Cambridge, England; Chinese Univ Hong Kong, Li Ka Shing Inst Hlth Sci, Hong Kong, Hong Kong, Peoples R China; Chinese Univ Hong Kong, Hong Kong Canc Inst, Sir YK Pao Ctr Canc, Dept Clin Oncol,State Key Lab Oncol S China,Canc, Hong Kong, Hong Kong, Peoples R China; Univ Hong Kong, Li Ka Shing Fac Med, Dept Pathol, Hong Kong, Hong Kong, Peoples R China	Hong Kong Polytechnic University; Griffith University; University of Hong Kong; Hong Kong Polytechnic University; University of Hong Kong; Wellcome Trust Sanger Institute; Chinese University of Hong Kong; Chinese University of Hong Kong; University of Hong Kong	Tang, JCO (corresponding author), Hong Kong Polytech Univ, Dept Appl Biol & Chem Technol, Kowloon, Hong Kong, Peoples R China.	gopesh@pathology.hku.hk; bccotang@polyu.edu.hk	Tang, Johnny C. O./M-9639-2014; Tang, Johnny Cheuk-on/W-7214-2019; Tao, Qian/T-4743-2018; Law, Simon/C-4324-2009; Law, Fian/C-4692-2009; Tsao, George/C-4422-2009; Lam, Alfred/C-1652-2008	Tang, Johnny C. O./0000-0002-4261-3206; Tang, Johnny Cheuk-on/0000-0002-4261-3206; Tao, Qian/0000-0001-5383-4808; Law, Simon/0000-0002-6518-5806; Lam, Alfred/0000-0003-2771-564X	Wellcome Trust [079643] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Ahmed MN, 2000, CANCER GENET CYTOGEN, V116, P10, DOI 10.1016/S0165-4608(99)00103-X; Ariyama Y, 1999, J HUM GENET, V44, P357, DOI 10.1007/s100380050178; Beaudoing E, 2000, GENOME RES, V10, P1001, DOI 10.1101/gr.10.7.1001; Deng W, 2004, ONCOGENE, V23, P9090, DOI 10.1038/sj.onc.1208119; Forozan F, 2000, CANCER RES, V60, P4519; Fujibe T, 2006, BIOSCI BIOTECH BIOCH, V70, P1827, DOI 10.1271/bbb.50673; Glockner G, 1998, GENOME RES, V8, P1060; GREER CE, 1991, AM J CLIN PATHOL, V95, P117, DOI 10.1093/ajcp/95.2.117; Hu YC, 2001, CLIN CANCER RES, V7, P2213; Hurst CD, 2004, ONCOGENE, V23, P2250, DOI 10.1038/sj.onc.1207260; Ince N, 2000, CANCER RES, V60, P1261; Kang KF, 1996, J IMMUNOL, V156, P1402; Keenan C, 1998, CELL SIGNAL, V10, P225, DOI 10.1016/S0898-6568(97)00121-6; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; Kwong D, 2004, HUM PATHOL, V35, P309, DOI 10.1016/j.humpath.2003.10.020; Lam AKY, 2000, CRIT REV ONCOL HEMAT, V33, P71, DOI 10.1016/S1040-8428(99)00054-2; LITCHFIELD DW, 1993, MOL CELL BIOCHEM, V128, P187, DOI 10.1007/BF01076770; NOWELL PC, 1989, SEMIN ONCOL, V16, P116; SolinasToldo S, 1996, CANCER RES, V56, P3803; Tang JCO, 2001, CLIN CANCER RES, V7, P1539; Watters DJ, 1999, BIOCHEM PHARMACOL, V58, P383, DOI 10.1016/S0006-2952(99)00063-5; YANG DY, 2000, J KOREAN SOC PRECISI, V17, P5; Ying J, 2006, ONCOGENE, V25, P1070, DOI 10.1038/sj.onc.1209154	23	17	17	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 30	2007	26	40					5877	5888		10.1038/sj.onc.1210390	http://dx.doi.org/10.1038/sj.onc.1210390			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	205OH	17384685	Green Accepted			2022-12-28	WOS:000249123100005
J	Perks, CM; Vernon, EG; Rosendahl, AH; Tonge, D; Holly, JMP				Perks, C. M.; Vernon, E. G.; Rosendahl, A. H.; Tonge, D.; Holly, J. M. P.			IGF-II and IGFBP-2 differentially regulate PTEN in human breast cancer cells	ONCOGENE			English	Article						IGF-II; IGFBP-2; PTEN	FACTOR-BINDING PROTEIN-2; TUMOR-SUPPRESSOR PTEN; GROWTH-FACTOR-I; EPITHELIAL-CELLS; MAP KINASE; EXPRESSION; PHOSPHATASE; INHIBITION; PROLIFERATION; TUMORIGENESIS	The dual-function phosphatase and tensin homolog deleted on chromosome 10 ( PTEN) is the second most frequently mutated gene in human cancers. PTEN counteracts the functions of many growth factors, the most prevalent of which is insulin-like growth factor II ( IGF-II). PTEN expression is stimulated by IGF-II forming a feedback loop. Investigating IGF-binding protein ( IGFBP) modulation of IGF-II actions on MCF-7 breast cancer cells, we found that IGFBP-2 also regulates PTEN. The MCF-7 cells were not responsive to high doses of IGF-II due to induction of PTEN, which was not observed with an IGF-II-analog that does not bind to IGFBPs or in the presence of an inhibitor that prevents IGFs associating with IGFBPs. These cells predominantly produce IGFBP-2: blocking IGFBP-2 with a specific antibody, or preventing IGFBP-2 binding to integrins, restored the induction of PTEN and the cells were non-responsive to high doses of the IGF-II-analog. Our. findings indicate that breast cancer cells do not respond to high doses of IGF-II due to induction of PTEN, but IGFBP-2, when free from IGF-II can suppress PTEN. Levels of IGFBP-2 are elevated frequently in human tumors: its ability to regulate PTEN could have important implications in relation to therapeutic strategies targeting growth factor pathways.	Univ Bristol, Southmead Hosp, Sch Med, Dept Clin Sci N Bristol,IMEG,IGF & Metab Endocrin, Bristol BS10 5NB, Avon, England; Lund Univ, Dept Oncol Clin Sci, Lund, Sweden; AstraZeneca UK, Macclesfield, Cheshire, England	Southmead Hospital; University of Bristol; Lund University; AstraZeneca	Perks, CM (corresponding author), Univ Bristol, Southmead Hosp, Sch Med, Dept Clin Sci N Bristol,IMEG,IGF & Metab Endocrin, Bristol BS10 5NB, Avon, England.	Claire.m.perks@bristol.ac.uk		Perks, Claire/0000-0003-1562-891X; Vernon, Ellen/0000-0002-8344-1025				Busund LT, 2005, J CLIN PATHOL, V58, P361, DOI 10.1136/jcp.2004.020834; Chen ZB, 2005, NATURE, V436, P725, DOI 10.1038/nature03918; Clark AS, 2002, MOL CANCER THER, V1, P707; Clark MA, 2005, INT J CANCER, V116, P506, DOI 10.1002/ijc.21029; COULSON VJ, 1991, GROWTH REGULAT, V1, P119; Di Cristofano A, 2000, CELL, V100, P387, DOI 10.1016/S0092-8674(00)80674-1; DUBOIS V, 1995, EUR J BIOCHEM, V232, P47, DOI 10.1111/j.1432-1033.1995.tb20779.x; Dupont J, 2002, J CLIN INVEST, V110, P815, DOI [10.1172/JCI200213829, 10.1172/JCI0213829]; Dupont JL, 2003, J BIOL CHEM, V278, P37256, DOI 10.1074/jbc.M302355200; Freeman DJ, 2003, CANCER CELL, V3, P117, DOI 10.1016/S1535-6108(03)00021-7; Gu JG, 1998, J CELL BIOL, V143, P1375, DOI 10.1083/jcb.143.5.1375; Hoeflich A, 2001, CANCER RES, V61, P8601; Hwang PH, 2005, EXP MOL MED, V37, P391, DOI 10.1038/emm.2005.49; Kang-Park S, 2003, FEBS LETT, V545, P203, DOI 10.1016/S0014-5793(03)00535-0; Levitt RJ, 2005, BIOCHEM BIOPH RES CO, V336, P1056, DOI 10.1016/j.bbrc.2005.08.229; Li Y, 2001, BMC Mol Biol, V2, P2, DOI 10.1186/1471-2199-2-2; Liu XJ, 2001, J BIOL CHEM, V276, P32419, DOI 10.1074/jbc.C100299200; Maile LA, 1999, ENDOCRINOLOGY, V140, P4040, DOI 10.1210/en.140.9.4040; McCaig C, 2002, J CELL SCI, V115, P4293, DOI 10.1242/jcs.00097; Moorehead RA, 2003, J BIOL CHEM, V278, P50422, DOI 10.1074/jbc.M306894200; Nagata Y, 2004, CANCER CELL, V6, P117, DOI 10.1016/j.ccr.2004.06.022; Schmid AC, 2004, FEBS LETT, V566, P35, DOI 10.1016/j.febslet.2004.03.102; Schutt BS, 2004, J MOL ENDOCRINOL, V32, P859, DOI 10.1677/jme.0.0320859; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Stambolic V, 2001, MOL CELL, V8, P317, DOI 10.1016/S1097-2765(01)00323-9; Stokoe D, 2005, P NATL ACAD SCI USA, V102, P2677, DOI 10.1073/pnas.0500089102; Trotman LC, 2003, PLOS BIOL, V1, P385, DOI 10.1371/journal.pbio.0000059; Virolle T, 2001, NAT CELL BIOL, V3, P1124, DOI 10.1038/ncb1201-1124; Weng LP, 2002, HUM MOL GENET, V11, P1687, DOI 10.1093/hmg/11.15.1687; White ES, 2003, AM J RESP CRIT CARE, V168, P436, DOI 10.1164/rccm.200301-041OC; Wu RC, 2000, MOL CELL BIOCHEM, V203, P59, DOI 10.1023/A:1007024624967	32	85	87	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 30	2007	26	40					5966	5972		10.1038/sj.onc.1210397	http://dx.doi.org/10.1038/sj.onc.1210397			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	205OH	17369847				2022-12-28	WOS:000249123100014
J	Macpherson, IR; Hooper, S; Serrels, A; McGarry, L; Ozanne, BW; Harrington, K; Frame, MC; Sahai, E; Brunton, VG				Macpherson, I. R.; Hooper, S.; Serrels, A.; McGarry, L.; Ozanne, B. W.; Harrington, K.; Frame, M. C.; Sahai, E.; Brunton, V. G.			p120-catenin is required for the collective invasion of squamous cell carcinoma cells via a phosphorylation-independent mechanism	ONCOGENE			English	Article						p120; E-cadherin; invasion; phosphorylation	EPIDERMAL-GROWTH-FACTOR; MEDIATED TRANSCRIPTIONAL REPRESSION; E-CADHERIN EXPRESSION; RHO-FAMILY GTPASES; P120 CATENIN; NUCLEAR-LOCALIZATION; TYROSINE KINASES; COLON-CARCINOMA; BREAST-CANCER; TUMOR-CELLS	Loss of E-cadherin-mediated cell-cell junctions has been correlated with cancer cell invasion and poor patient survival. p120-catenin has emerged as a key player in promoting E-cadherin stability and adherens junction integrity and has been proposed as a potential invasion suppressor by preventing release of cells from the constraints imposed by cadherin-mediated cell-cell adhesion. However, it has been proposed that tyrosine phosphorylation of p120 may contribute to cadherin-dependent junction disassembly during invasion. Here, we use small interfering RNA ( siRNA) in A431 cells to show that knockdown of p120 promotes two-dimensional migration of cells. In contrast, p120 knockdown impairs epidermal growth factor-induced A431 invasion into three-dimensional matrix gels or in organotypic culture, whereas re-expression of siRNA-resistant p120, or a p120 isoform that cannot be phosphorylated on tyrosine, restores the collective mode of invasion employed by A431 cells in vitro. Thus, p120 promotes A431 cell invasion in a phosphorylation-independent manner. We show that the collective invasion of A431 cells depends on the presence of cadherin-mediated (P- and E-cadherin) cell-cell contacts, which are lost in cells where p120 expression is knocked down. Furthermore, membranous p120 is maintained in invasive squamous cell carcinomas in tumours suggesting that p120 may be important for the collective invasion of tumours cells in vivo.	Beatson Inst Canc Res, Glasgow G61 1BD, Lanark, Scotland; Canc Res UK London Res Inst, London, England; Inst Canc Res, London SW3 6JB, England	Beatson Institute; Cancer Research UK; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	Brunton, VG (corresponding author), Beatson Inst Canc Res, Garscube Estate,Switchback Rd, Glasgow G61 1BD, Lanark, Scotland.	v.brunton@beatson.gla.ac.uk		Frame, Margaret/0000-0001-5882-1942; Harrington, Kevin/0000-0002-6014-348X; Macpherson, Iain/0000-0003-4295-8885; Sahai, Erik/0000-0002-3932-5086				Anastasiadis PZ, 2000, J CELL SCI, V113, P1319; Aono S, 1999, J CELL BIOL, V145, P551, DOI 10.1083/jcb.145.3.551; Ardern H, 2006, CELL MOTIL CYTOSKEL, V63, P6, DOI 10.1002/cm.20101; Avizienyte E, 2002, NAT CELL BIOL, V4, P632, DOI 10.1038/ncb829; Bellovin DI, 2005, CANCER RES, V65, P10938, DOI 10.1158/0008-5472.CAN-05-1947; Brunton VG, 2005, CANCER RES, V65, P1335, DOI 10.1158/0008-5472.CAN-04-1949; Brunton VG, 2004, BBA-MOL CELL RES, V1692, P121, DOI 10.1016/j.bbamcr.2004.04.010; Cozzolino M, 2003, MOL BIOL CELL, V14, P1964, DOI 10.1091/mbc.E02-08-0469; Daniel JM, 1999, MOL CELL BIOL, V19, P3614; Davis MA, 2006, DEV CELL, V10, P21, DOI 10.1016/j.devcel.2005.12.004; Davis MA, 2003, J CELL BIOL, V163, P525, DOI 10.1083/jcb.200307111; Friedl P, 2004, INT J DEV BIOL, V48, P441, DOI 10.1387/ijdb.041821pf; Grosheva I, 2001, J CELL SCI, V114, P695; Hajra KM, 2002, GENE CHROMOSOME CANC, V34, P255, DOI 10.1002/gcc.10083; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hazan RB, 2000, J CELL BIOL, V148, P779, DOI 10.1083/jcb.148.4.779; Ireton RC, 2002, J CELL BIOL, V159, P465, DOI 10.1083/jcb.200205115; Ishizaki Y, 2004, J DERMATOL SCI, V34, P99, DOI 10.1016/j.jdermsci.2003.12.001; Islam S, 1996, J CELL BIOL, V135, P1643, DOI 10.1083/jcb.135.6.1643; Jensen PJ, 1997, CELL TISSUE RES, V288, P307, DOI 10.1007/s004410050816; Keirsebilck A, 1998, GENOMICS, V50, P129, DOI 10.1006/geno.1998.5325; Kelly KF, 2004, J CELL SCI, V117, P2675, DOI 10.1242/jcs.01101; Kurokawa K, 2004, MOL BIOL CELL, V15, P1003, DOI 10.1091/mbc.E03-08-0609; Lim YP, 2003, MOL CANCER THER, V2, P1369; Malliri A, 1998, J CELL BIOL, V143, P1087, DOI 10.1083/jcb.143.4.1087; Mareel M, 2003, PHYSIOL REV, V83, P337, DOI 10.1152/physrev.00024.2002; Mariner DJ, 2004, J CELL SCI, V117, P1339, DOI 10.1242/jcs.01001; Mariner DJ, 2001, J BIOL CHEM, V276, P28006, DOI 10.1074/jbc.M102443200; MCLEAN GW, 1991, J IMMUNOL METHODS, V137, P149, DOI 10.1016/0022-1759(91)90019-C; Noren NK, 2000, J CELL BIOL, V150, P567, DOI 10.1083/jcb.150.3.567; Ozawa M, 2001, J CELL SCI, V114, P503; Park JI, 2005, DEV CELL, V8, P843, DOI 10.1016/j.devcel.2005.04.010; Peifer M, 2000, SCIENCE, V287, P1606, DOI 10.1126/science.287.5458.1606; Perez-Moreno M, 2006, CELL, V124, P631, DOI 10.1016/j.cell.2005.11.043; Perl AK, 1998, NATURE, V392, P190, DOI 10.1038/32433; PLUMB JA, 1989, CANCER RES, V49, P4435; Qian XL, 2004, EMBO J, V23, P1739, DOI 10.1038/sj.emboj.7600136; Sahai E, 2005, CURR OPIN GENET DEV, V15, P87, DOI 10.1016/j.gde.2004.12.002; Scott LA, 2004, MOL CELL BIOL, V24, P1540, DOI 10.1128/MCB.24.4.1540-1559.2004; Shibata T, 2004, AM J PATHOL, V164, P2269, DOI 10.1016/S0002-9440(10)63783-2; Spring CM, 2005, EXP CELL RES, V305, P253, DOI 10.1016/j.yexcr.2005.01.007; Strathdee G, 2002, SEMIN CANCER BIOL, V12, P373, DOI 10.1016/S1044-579X(02)00057-3; Thelemann A, 2005, MOL CELL PROTEOMICS, V4, P356, DOI 10.1074/mcp.M400118-MCP200; Thoreson MA, 2002, DIFFERENTIATION, V70, P583, DOI 10.1046/j.1432-0436.2002.700911.x; van Hengel J, 1999, P NATL ACAD SCI USA, V96, P7980, DOI 10.1073/pnas.96.14.7980; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; Wheelock MJ, 2003, CURR OPIN CELL BIOL, V15, P509, DOI 10.1016/S0955-0674(03)00101-7; Xia XB, 2003, BIOCHEMISTRY-US, V42, P9195, DOI 10.1021/bi034597h; Xiao KY, 2003, J CELL BIOL, V163, P535, DOI 10.1083/jcb.200306001; Yanagisawa M, 2006, J CELL BIOL, V174, P1087, DOI 10.1083/jcb.200605022	50	44	45	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 9	2007	26	36					5214	5228		10.1038/sj.onc.1210334	http://dx.doi.org/10.1038/sj.onc.1210334			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	199CQ	17334396				2022-12-28	WOS:000248674200005
J	Saenz-Robles, MT; Toma, D; Cantalupo, P; Zhou, J; Gong, H; Edwards, C; Pipas, JM; Xie, W				Saenz-Robles, M. T.; Toma, D.; Cantalupo, P.; Zhou, J.; Gong, H.; Edwards, C.; Pipas, J. M.; Xie, W.			Repression of intestinal drug metabolizing enzymes by the SV40 large T antigen	ONCOGENE			English	Article						cytochrome P450; SV40 T antigen; retinoblastoma	VILLUS-ASSOCIATED ENTEROCYTES; NUCLEAR RECEPTOR; TRANSGENIC MICE; CELL-CYCLE; BILE-ACIDS; EXPRESSION; PROTEIN; CYTOCHROME-P450; TRANSFORMATION; TRANSPORTER	Toxic compounds such as carcinogens are removed from the body by the action of a series of detoxifying enzymes and transporters expressed in the liver and the small intestine. We have found that intestinal epithelial cells expressing the SV40 large T antigen ( TAg) contain significantly lower levels of mRNAs, encoding several drug metabolizing/ detoxifying enzymes and transporters compared to their non- transgenic littermates. In addition, TAg blocks the induction of these mRNAs by xenobiotics. The repression depends on an intact LXCXE motif in TAg, suggesting that inactivation of the retinoblastoma ( Rb) family of tumor suppressors plays a role in the process. These results imply that a functional Rb pathway in the intestine is necessary for the expression of the detoxification system used to clear carcinogens, and suggest that loss of this tumor suppressor might alter susceptibility to chemical injury. In addition, the effect of TAg on the detoxification pathway appears to be tissuespecific, as its ectopic expression in the liver failed to suppress the P450 enzymes. The TAg- mediated suppression of drug metabolizing/ detoxifying enzymes may have broad implications in the metabolism and mechanism of action of both carcinogens and prescription drugs.'	Univ Pittsburgh, Dept Biol Sci, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Sch Pharm, Ctr Pharmacogenet, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Sch Pharm, Dept Pharmaceut Sci, Pittsburgh, PA 15260 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Pipas, JM (corresponding author), Univ Pittsburgh, Dept Biol Sci, 578 Crawford Hall, Pittsburgh, PA 15260 USA.	pipas@pitt.edu; wex6@pitt.edu	Xie, Wen/M-1768-2016		NATIONAL CANCER INSTITUTE [R01CA040586, R37CA040586, R01CA098956, R01CA107011] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES012479] Funding Source: NIH RePORTER; NCI NIH HHS [CA40586, CA098956, CA107011] Funding Source: Medline; NIEHS NIH HHS [ES012479] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Ahuja D, 2005, ONCOGENE, V24, P7729, DOI 10.1038/sj.onc.1209046; Blumberg B, 1998, GENE DEV, V12, P3195, DOI 10.1101/gad.12.20.3195; Bosco EE, 2004, NUCLEIC ACIDS RES, V32, P25, DOI 10.1093/nar/gkg919; Chandrasekaran C, 1996, J BIOL CHEM, V271, P28414, DOI 10.1074/jbc.271.45.28414; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; COHN SM, 1992, J CELL BIOL, V119, P27, DOI 10.1083/jcb.119.1.27; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; EWEN ME, 1989, CELL, V58, P257, DOI 10.1016/0092-8674(89)90840-4; HAUFT SM, 1992, J CELL BIOL, V117, P825, DOI 10.1083/jcb.117.4.825; Kim RB, 2003, EUR J CLIN INVEST, V33, P1, DOI 10.1046/j.1365-2362.33.s2.5.x; KIM SH, 1994, P NATL ACAD SCI USA, V91, P6914, DOI 10.1073/pnas.91.15.6914; KIM SH, 1993, J CELL BIOL, V123, P877, DOI 10.1083/jcb.123.4.877; Kliewer SA, 1998, CELL, V92, P73, DOI 10.1016/S0092-8674(00)80900-9; Kullak-Ublick GA, 2003, J HEPATOL, V39, P628, DOI 10.1016/S0168-8278(03)00397-0; Liu F, 1999, GENE THER, V6, P1258, DOI 10.1038/sj.gt.3300947; MAUREL P, 1996, CYTOCHROMES P450 MET, P241; Mayhew CN, 2004, ONCOGENE, V23, P4107, DOI 10.1038/sj.onc.1207503; McFadyen MCE, 2001, BIOCHEM PHARMACOL, V62, P207, DOI 10.1016/S0006-2952(01)00643-8; Mizuno N, 2003, PHARMACOL REV, V55, P425, DOI 10.1124/pr.55.3.1; Oyama T, 2004, FRONT BIOSCI-LANDMRK, V9, P1967, DOI 10.2741/1378; Puga A, 2002, TOXICOLOGY, V181, P171, DOI 10.1016/S0300-483X(02)00276-7; Renton KW, 2004, CURR DRUG METAB, V5, P235, DOI 10.2174/1389200043335559; Rodriguez-Antona C, 2006, ONCOGENE, V25, P1679, DOI 10.1038/sj.onc.1209377; Rooseboom M, 2004, PHARMACOL REV, V56, P53, DOI 10.1124/pr.56.1.3; Saini SPS, 2005, HEPATOLOGY, V41, P497, DOI 10.1002/hep.20570; Sompayrac L, 1997, VIROLOGY, V233, P130, DOI 10.1006/viro.1997.8610; Srinivasan A, 1997, MOL CELL BIOL, V17, P4761, DOI 10.1128/MCB.17.8.4761; Uppal H, 2005, HEPATOLOGY, V41, P168, DOI 10.1002/hep.20512; Williams JA, 2004, DRUG METAB DISPOS, V32, P1201, DOI 10.1124/dmd.104.000794; Xie W, 2000, NATURE, V406, P435, DOI 10.1038/35019116; Xie W, 2004, DRUG DISCOV TODAY, V9, P442, DOI 10.1016/S1359-6446(04)03061-2	31	7	7	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 2	2007	26	35					5124	5131		10.1038/sj.onc.1210310	http://dx.doi.org/10.1038/sj.onc.1210310			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	196MT	17334401				2022-12-28	WOS:000248487400011
J	Rodrigues, S; De Wever, O; Bruyneel, E; Rooney, RJ; Gespach, C				Rodrigues, S.; De Wever, O.; Bruyneel, E.; Rooney, R. J.; Gespach, C.			Opposing roles of netrin-1 and the dependence receptor DCC in cancer cell invasion, tumor growth and metastasis	ONCOGENE			English	Article						adenosine A2B receptors; src; apoptosis; caspase-8; hypoxia; cDNA microarrays	NETRIN-1-MEDIATED AXON OUTGROWTH; UBIQUITIN-PROTEASOME PATHWAY; ADENOSINE A2B RECEPTOR; COLORECTAL-CANCER; ACTIVATION; ADHESION; KINASE; GENE; TUMORIGENESIS; EXPRESSION	Deleted in colon cancer (DCC) and UNC5 function as netrin dependence receptors by inducing apoptosis in the absence of their ligand and accordingly were recently designated as putative conditional tumor suppressors. Herein, we determined whether netrin-1 and its receptors are implicated in cancer cell invasion and tumor progression. Expression of DCC, UNC5 and adenosine A2B-receptors (A2B-Rs) was investigated by reverse transcription polymerase chain reaction in human colon cancer cells. The impact of DCC restitution and netrin-1 was evaluated on collagen type I invasion, tumor growth and metastasis in nude mice, cancer cell survival and gene expression pro. ling. Flow cytometry, poly(ADP-ribose)-polymerase-1 and caspase-8 activation were used to evaluate the impact of DCC on cell death. Both netrin-1 and A2B-R activation induced the invasive phenotype through the Rho-Rho kinase axis in DCC-deficient human colorectal cancer cells. Restitution of wild-type DCC blocked invasion induced by netrin-1, A2B-R agonist and other agents. Ectopic expression of netrin-1 led to increased growth of human colon tumor xenografts in athymic mice. Conversely, introduction of wt-DCC in kidney MDCKts. src-ggl cells strongly inhibited metastasis in lymph nodes and lungs and increased sensitivity to apoptosis in hypoxia. DNA microarrays revealed that netrin and DCC had common and divergent impacts on gene expression linked to cell cycle, survival, surface signaling and adhesion. Our findings underscore that netrin is a potent invasion and tumor growth-promoting agent and that DCC is a metastasis suppressor gene targeting both proinvasive and survival pathways in a cumulative manner.	INSERM, U673, F-75571 Paris 12, France; Univ Paris 06, Fac Med, Lab Mol & Clin Oncol Solid Tumors, Paris, France; State Univ Ghent Hosp, Expt Cancerol Lab, B-9000 Ghent, Belgium; Genome Explorat Inc, Memphis, TN USA	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Ghent University; Ghent University Hospital	Gespach, C (corresponding author), INSERM, U673, F-75571 Paris 12, France.	gespach@st-antoine.inserm.fr	de wever, olivier/J-3094-2013	de wever, olivier/0000-0002-5453-760X				Arakawa H, 2004, NAT REV CANCER, V4, P978, DOI 10.1038/nrc1504; Barbier M, 2001, NATURE, V413, P796, DOI 10.1038/35101660; Bouchard JF, 2004, J NEUROSCI, V24, P3040, DOI 10.1523/JNEUROSCI.4934-03.2004; Chen L, 2005, FEBS J, V272, P2746, DOI 10.1111/j.1742-4658.2005.04694.x; Corset V, 2000, NATURE, V407, P747, DOI 10.1038/35037600; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; Forcet C, 2002, NATURE, V417, P443, DOI 10.1038/nature748; Gao L, 2006, CANCER RES, V66, P7880, DOI 10.1158/0008-5472.CAN-06-0254; Grider JR, 2006, GASTROENTEROLOGY, V130, P771, DOI 10.1053/j.gastro.2005.12.026; Hebrok M, 2004, TRENDS CELL BIOL, V14, P153, DOI 10.1016/j.tcb.2004.02.005; Hill A, 2006, ONCOGENE, V25, P6079, DOI 10.1038/sj.onc.1209628; Hipfner DR, 2004, NAT REV MOL CELL BIO, V5, P805, DOI 10.1038/nrm1491; Hong KS, 1999, CELL, V97, P927, DOI 10.1016/S0092-8674(00)80804-1; Hu G, 1997, GENE DEV, V11, P2701, DOI 10.1101/gad.11.20.2701; Hucho TB, 2005, J NEUROSCI, V25, P6119, DOI 10.1523/JNEUROSCI.0285-05.2005; Kadono Y, 1998, CANCER RES, V58, P2240; Kim TH, 2005, J NEUROCHEM, V95, P1, DOI 10.1111/j.1471-4159.2005.03314.x; Kong TQ, 2006, FASEB J, V20, P2242, DOI 10.1096/fj.06-6419com; Kotelevets L, 1998, J BIOL CHEM, V273, P14138, DOI 10.1074/jbc.273.23.14138; Lahti JM, 2006, CANCER RES, V66, P5981, DOI 10.1158/0008-5472.CAN-06-0131; Linden J, 1999, MOL PHARMACOL, V56, P705; Lockhart DJ, 1996, NAT BIOTECHNOL, V14, P1675, DOI 10.1038/nbt1296-1675; Martin M, 2006, EUR J CELL BIOL, V85, P769, DOI 10.1016/j.ejcb.2006.02.013; Mazelin L, 2004, NATURE, V431, P80, DOI 10.1038/nature02788; Mehlen P, 2006, NAT REV CANCER, V6, P449, DOI 10.1038/nrc1886; Mehlen P, 1998, NATURE, V395, P801, DOI 10.1038/27441; MIYAKI M, 1990, CANCER RES, V50, P7166; Miyamoto Y, 2006, P NATL ACAD SCI USA, V103, P10444, DOI 10.1073/pnas.0603914103; Nguyen QD, 2005, ONCOGENE, V24, P8240, DOI 10.1038/sj.onc.1208990; Nguyen QD, 2006, MOL CANCER THER, V5, P2070, DOI 10.1158/1535-7163.MCT-06-0044; Ren XR, 2004, NAT NEUROSCI, V7, P1204, DOI 10.1038/nn1330; Rivat C, 2003, FASEB J, V17, P1721, DOI 10.1096/fj.03-0132fje; SERAFINI T, 1994, CELL, V78, P409, DOI 10.1016/0092-8674(94)90420-0; Shekarabi M, 2002, MOL CELL NEUROSCI, V19, P1, DOI 10.1006/mcne.2001.1075; Tan EY, 2006, AM J PHYSIOL-CELL PH, V291, pC433, DOI 10.1152/ajpcell.00238.2005; Taniguchi Y, 2003, J BIOL CHEM, V278, P30425, DOI 10.1074/jbc.C300239200; TessierLavigne M, 1996, SCIENCE, V274, P1123, DOI 10.1126/science.274.5290.1123; Wilson BD, 2006, SCIENCE, V313, P640, DOI 10.1126/science.1124704; Xie Y, 2006, J BIOL CHEM, V281, P2605, DOI 10.1074/jbc.M512767200; Yebra M, 2003, DEV CELL, V5, P695, DOI 10.1016/S1534-5807(03)00330-7	40	80	90	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG	2007	26	38					5615	5625		10.1038/sj.onc.1210347	http://dx.doi.org/10.1038/sj.onc.1210347			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	200ZS	17334389				2022-12-28	WOS:000248801900007
J	Winter, SF; Acevedo, VD; Gangula, RD; Freeman, KW; Spencer, DM; Greenberg, NM				Winter, S. F.; Acevedo, V. D.; Gangula, R. D.; Freeman, K. W.; Spencer, D. M.; Greenberg, N. M.			Conditional activation of FGFR1 in the prostate epithelium induces angiogenesis with concomitant differential regulation of Ang-1 and Ang-2	ONCOGENE			English	Article						FGFR1; prostate; angiogenesis; angiopoietin; transgenic	FIBROBLAST GROWTH-FACTORS; HYPOXIA-INDUCIBLE FACTOR-1; RECEPTOR TYROSINE KINASE; INTRAEPITHELIAL NEOPLASIA; CANCER PROGRESSION; TUMOR ANGIOGENESIS; GENE-EXPRESSION; ANGIOPOIETIN-2; PROMOTER; HYPERPLASIA	The expression of. broblast growth factor receptor (FGFR)-1 correlates with angiogenesis and is associated with prostate cancer (CaP) progression. To more precisely de. ne the molecular mechanisms whereby FGFR1 causes angiogenesis in the prostate we exploited a transgenic mouse model, JOCK-1, in which activation of a conditional FGFR1 allele in the prostate epithelium caused rapid angiogenesis and progressive hyperplasia. By labeling the vasculature in vivo and applying a novel method to measure the vasculature in three dimensions, we were able to observe a signi. cant increase in vascular volume 1 week after FGFR1 activation. Although vessel volume and branching both continued to increase throughout a 6-week period of FGFR1 activation, importantly, we discovered that continued activation of FGFR1 was not required to maintain the new vasculature. Exploring the molecular mediators of the angiogenic phenotype, we observed consistent upregulation of HIF-1 alpha, vascular endothelial growth factor (VEGF) and angiopoietin 2 (Ang-2), whereas expression of Ang-1 was lost. Further analysis revealed that loss of Ang-1 expression occurred in the basal epithelium, whereas the increase in Ang-2 expression occurred in the luminal epithelium. Reporter assays con. rmed that the Ang-2 promoter was regulated by FGFR1 signaling and a small molecule inhibitor of FGFR activity, PD173074, could abrogate this response. These. ndings establish a method to follow spontaneous angiogenesis in a conditional autochthonous system, implicate the angiopoietins as downstream effectors of FGFR1 activation in vivo, and suggest that therapies targeting FGFR1 could be used to inhibit neovascularization during initiation and progression of CaP.	Fred Hutchinson Canc Res Ctr, Clin Res Div, Seattle, WA 98109 USA; Baylor Coll Med, Dept Immunol, Houston, TX USA	Fred Hutchinson Cancer Center; Baylor College of Medicine	Greenberg, NM (corresponding author), Fred Hutchinson Canc Res Ctr, Clin Res Div, 1100 Fairview Ave N,D4-100, Seattle, WA 98109 USA.	ngreenberg@fhcrc.org			NCI NIH HHS [CA64851] Funding Source: Medline; NIGMS NIH HHS [R25 GM056929] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA064851] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R25GM056929] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		American Cancer Society, 2006, CANC FACTS FIG 2006; Bergers G, 2003, NAT REV CANCER, V3, P401, DOI 10.1038/nrc1093; Bicknell R, 2004, ANNU REV PHARMACOL, V44, P219, DOI 10.1146/annurev.pharmtox.44.101802.121650; Bikfalvi A, 1997, ENDOCR REV, V18, P26, DOI 10.1210/er.18.1.26; Dery MAC, 2005, INT J BIOCHEM CELL B, V37, P535, DOI 10.1016/j.biocel.2004.08.012; Doll JA, 2001, PROSTATE, V49, P293, DOI 10.1002/pros.10025; Dorkin TJ, 1999, J PATHOL, V189, P564, DOI 10.1002/(SICI)1096-9896(199912)189:4<564::AID-PATH480>3.0.CO;2-1; FOLEY KP, 1993, TRENDS GENET, V9, P380, DOI 10.1016/0168-9525(93)90137-7; FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; Folkman J, 1991, Princess Takamatsu Symp, V22, P339; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; Foster BA, 1999, PROSTATE CANCER P D, V2, P76; Freeman KW, 2003, CANCER RES, V63, P8256; Giri D, 1999, CLIN CANCER RES, V5, P1063; Gnanapragasam V, 2003, BRIT J CANCER, V88, P1432, DOI 10.1038/sj.bjc.6600875; GREENBERG NM, 1995, P NATL ACAD SCI USA, V92, P3439, DOI 10.1073/pnas.92.8.3439; GREENBERG NM, 1994, MOL ENDOCRINOL, V8, P230, DOI 10.1210/me.8.2.230; Hayward SW, 1996, ACTA ANAT, V155, P81; Hobbs S, 1998, BIOCHEM BIOPH RES CO, V252, P368, DOI 10.1006/bbrc.1998.9646; Huss WJ, 2003, PROSTATE, V54, P8, DOI 10.1002/pros.10163; Javerzat S, 2002, TRENDS MOL MED, V8, P483, DOI 10.1016/S1471-4914(02)02394-8; Jin CL, 2004, CANCER RES, V64, P4555, DOI 10.1158/0008-5472.CAN-03-3752; Kim I, 2000, J BIOL CHEM, V275, P18550, DOI 10.1074/jbc.M910084199; Kwabi-Addo B, 2004, ENDOCR-RELAT CANCER, V11, P709, DOI 10.1677/erc.1.00535; Lind AJ, 2005, PROSTATE, V62, P394, DOI 10.1002/pros.20163; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Mohammadi M, 1998, EMBO J, V17, P5896, DOI 10.1093/emboj/17.20.5896; Nakamura T, 2001, BIOCHEM BIOPH RES CO, V289, P801, DOI 10.1006/bbrc.2001.6046; Tait CR, 2004, J PATHOL, V204, P1, DOI 10.1002/path.1618; Thomson AA, 2001, REPRODUCTION, V121, P187, DOI 10.1530/rep.0.1210187; Wang F, 2004, PROSTATE, V58, P1, DOI 10.1002/pros.10311; WANG GL, 1995, J BIOL CHEM, V270, P1230, DOI 10.1074/jbc.270.3.1230; Wang SY, 2006, P NATL ACAD SCI USA, V103, P1480, DOI 10.1073/pnas.0510652103; WEIDNER N, 1991, NEW ENGL J MED, V324, P1, DOI 10.1056/NEJM199101033240101; WEIDNER N, 1993, AM J PATHOL, V143, P409; Welm BE, 2002, J CELL BIOL, V157, P703, DOI 10.1083/jcb.200107119; Winter SF, 2003, PROSTATE CANCER P D, V6, P204, DOI 10.1038/sj.pcan.4500655; Zhang JF, 2000, ENDOCRINOLOGY, V141, P4698, DOI 10.1210/en.141.12.4698; Zhang L, 2003, CANCER RES, V63, P3403	40	35	35	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL	2007	26	34					4897	4907		10.1038/sj.onc.1210288	http://dx.doi.org/10.1038/sj.onc.1210288			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	194CV	17297442				2022-12-28	WOS:000248322500002
J	Loffler, KA; Biondi, CA; Gartside, MG; Serewko-Auret, MM; Duncan, R; Tonks, ID; Mould, AW; Waring, P; Muller, HK; Kay, GF; Hayward, NK				Loffler, K. A.; Biondi, C. A.; Gartside, M. G.; Serewko-Auret, M. M.; Duncan, R.; Tonks, I. D.; Mould, A. W.; Waring, P.; Muller, H. K.; Kay, G. F.; Hayward, N. K.			Lack of augmentation of tumor spectrum or severity in dual heterozygous Men1 and Rb1 knockout mice	ONCOGENE			English	Article						endocrine; pancreas; pituitary; parathyroid; thyroid	MULTIPLE ENDOCRINE NEOPLASIA; CELL-CYCLE; CONDITIONAL INACTIVATION; RETINOBLASTOMA GENE; TYPE-1; SUPPRESSOR; GROWTH; TUMORIGENESIS; EXPRESSION; PROTEIN	To identify possible genetic interactions between the mechanisms of tumor suppression of menin and pRb, we intercrossed mice with targeted deletions of Men1 and Rb1, and compared tumor development in cohorts of animals carrying single or dual mutations of these tumor-suppressor genes. In mice lacking one copy of Men1, pancreatic islet and anterior pituitary adenomas are common. In animals lacking one copy of Rb1, intermediate pituitary and thyroid tumors occur at high frequency, with less frequent development of pancreatic islet hyperplasia and parathyroid lesions. In mice heterozygous for both Men1 and Rb1, pancreatic hyperplasia and tumors of the intermediate pituitary and thyroid occurred at high frequency. Serum measurements of calcium and glucose did not vary significantly between genotypic groups. Loss of heterozygosity at the Rb1 locus was common in pituitary and thyroid tumors, whereas loss of menin was observed in pancreatic and parathyroid lesions. The tumor spectrum in the double heterozygotes was a combination of pathologies seen in each of the individual heterozygotes, without decrease in age of onset, indicating independent, non-additive effects of the two mutations. Together with the lack of increased tumor spectrum, this suggests that menin and pRb function in a common pathway of tumor suppression.	Queensland Inst Med Res, Canc & Cell Biol Div, Herston, Qld 4029, Australia; Peter MacCallum Canc Inst, Dept Pathol, Melbourne, Vic, Australia; Univ Tasmania, Sch Med, Hobart, Tas, Australia	QIMR Berghofer Medical Research Institute; Peter Maccallum Cancer Center; University of Tasmania	Hayward, NK (corresponding author), Queensland Inst Med Res, Canc & Cell Biol Div, 300 Herston Rd, Herston, Qld 4029, Australia.	Nick.Hayward@qimr.edu.au	hayward, nicholas k/C-1367-2015; hayward, nick/AAV-8802-2020; Kay, Graham F/A-4130-2011	hayward, nicholas k/0000-0003-4760-1033; Loffler, Kelly/0000-0003-3302-5995; Mould, Arne/0000-0002-2004-4348				Agarwal SK, 2003, P NATL ACAD SCI USA, V100, P10770, DOI 10.1073/pnas.1834524100; Bertolino P, 2003, MOL ENDOCRINOL, V17, P1880, DOI 10.1210/me.2003-0154; Biondi C, 2002, GENESIS, V32, P150, DOI 10.1002/gene.10061; Biondi CA, 2004, MOL CELL BIOL, V24, P3125, DOI 10.1128/MCB.24.8.3125-3131.2004; Busygina V, 2004, HUM MOL GENET, V13, P2399, DOI 10.1093/hmg/ddh271; Casanovas O, 2005, ONCOGENE, V24, P6597, DOI 10.1038/sj.onc.1208823; CHANDRASEKHARAP.S, 2003, J INTERN MED, V253, P599; Chandrasekharappa SC, 1997, SCIENCE, V276, P404, DOI 10.1126/science.276.5311.404; Crabtree JS, 2001, P NATL ACAD SCI USA, V98, P1118, DOI 10.1073/pnas.98.3.1118; CRYNS VL, 1994, NEW ENGL J MED, V330, P757, DOI 10.1056/NEJM199403173301105; DUNN JM, 1988, SCIENCE, V241, P1797, DOI 10.1126/science.3175621; Gobl AE, 1999, BBA-GENE STRUCT EXPR, V1447, P51, DOI 10.1016/S0167-4781(99)00132-3; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; Heppner C, 2001, ONCOGENE, V20, P4917, DOI 10.1038/sj.onc.1204529; Hernando E, 2004, NATURE, V430, P797, DOI 10.1038/nature02820; Herrera RE, 1996, MOL CELL BIOL, V16, P2402; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; Jin SH, 2003, CANCER RES, V63, P4204; Kaji H, 2001, P NATL ACAD SCI USA, V98, P3837, DOI 10.1073/pnas.061358098; Karnik SK, 2005, P NATL ACAD SCI USA, V102, P14659, DOI 10.1073/pnas.0503484102; Kim H, 2003, CANCER RES, V63, P6135; Lemmens I, 1997, HUM MOL GENET, V6, P1177, DOI 10.1093/hmg/6.7.1177; LOFFLER KA, 2006, INT J CANC      1016; Park MS, 1999, P NATL ACAD SCI USA, V96, P6382, DOI 10.1073/pnas.96.11.6382; Poisson A, 2003, CANCER LETT, V189, P1, DOI 10.1016/S0304-3835(02)00509-8; Ratineau C, 2004, J BIOL CHEM, V279, P24477, DOI 10.1074/jbc.M401835200; Schnepp RW, 2004, J BIOL CHEM, V279, P10685, DOI 10.1074/jbc.M308073200; Sowa H, 2004, J BIOL CHEM, V279, P40267, DOI 10.1074/jbc.M401312200; Sowa H, 2003, J BIOL CHEM, V278, P21058, DOI 10.1074/jbc.M302044200; Tonks ID, 2005, PIGM CELL RES, V18, P252, DOI 10.1111/j.1600-0749.2005.00245.x; WILLIAMS BO, 1994, NAT GENET, V7, P480, DOI 10.1038/ng0894-480	31	22	23	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 7	2007	26	27					4009	4017		10.1038/sj.onc.1210163	http://dx.doi.org/10.1038/sj.onc.1210163			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	177HP	17173065	Bronze			2022-12-28	WOS:000247144500011
J	D'Errico, M; Parlanti, E; Teson, M; Degan, P; Lemma, T; Calcagnile, A; Iavarone, I; Jaruga, P; Ropolo, M; Pedrini, AM; Orioli, D; Frosina, G; Zambruno, G; Dizdaroglu, M; Stefanini, M; Dogliotti, E				D'Errico, M.; Parlanti, E.; Teson, M.; Degan, P.; Lemma, T.; Calcagnile, A.; Iavarone, I.; Jaruga, P.; Ropolo, M.; Pedrini, A. M.; Orioli, D.; Frosina, G.; Zambruno, G.; Dizdaroglu, M.; Stefanini, M.; Dogliotti, E.			The role of CSA in the response to oxidative DNA damage in human cells	ONCOGENE			English	Article						cockayne syndrome; DNA repair; keratinocytes; oxidative DNA damage	COCKAYNE-SYNDROME; EXCISION-REPAIR; GENE-PRODUCT; PROTEIN; TRANSCRIPTION; LESIONS; DEFICIENT; PATHWAY	Cockayne syndrome (CS) is a rare genetic disease characterized by severe growth, mental retardation and pronounced cachexia. CS is most frequently due to mutations in either of two genes, CSB and CSA. Evidence for a role of CSB protein in the repair of oxidative DNA damage has been provided recently. Here, we show that CSA is also involved in the response to oxidative stress. CS-A human primary. fibroblasts and keratinocytes showed hypersensitivity to potassium bromate, a specific inducer of oxidative damage. This was associated with inefficient repair of oxidatively induced DNA lesions, namely 8-hydroxyguanine (8-OH-Gua) and (5 ' S)-8,5 '-cyclo 2 '-deoxyadenosine. Expression of the wild-type CSA in the CS-A cell line CS3BE significantly decreased the steady-state level of 8-OH-Gua and increased its repair rate following oxidant treatment. CS-A cell extracts showed normal 8-OH-Gua cleavage activity in an in vitro assay, whereas CS-B cell extracts were con. firmed to be defective. Our data provide the. first in vivo evidence that CSA protein contributes to prevent accumulation of various oxidized DNA bases and underline specific functions of CSB not shared with CSA. These. findings support the hypothesis that defective repair of oxidative DNA damage is involved in the clinical features of CS patients.	Ist Super Sanita, Dept Environm & Primary Prevent, Consiglio Nazl Ricerche, I-00161 Rome, Italy; IRCCS, Ist Dermopat Immacolata, Lab Mol & Cell Biol, Rome, Italy; Ist Nazl Ric Canc, Dept Translat Oncol, I-16132 Genoa, Italy; Univ Maryland Baltimore Cty, Dept Chem & Biochem Engn, Baltimore, MD 21228 USA; Natl Inst Stand & Technol, Chem Sci & Technol Lab, Gaithersburg, MD 20899 USA; Ist Genet Mol, Pavia, Italy	Istituto Superiore di Sanita (ISS); IRCCS Istituto Dermopatico dell'Immacolata (IDI); University of Genoa; IRCCS AOU San Martino IST; University System of Maryland; University of Maryland Baltimore County; National Institute of Standards & Technology (NIST) - USA; Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica Molecolare (IGM-CNR)	Dogliotti, E (corresponding author), Ist Super Sanita, Dept Environm & Primary Prevent, Consiglio Nazl Ricerche, Viale Regina Elena 299, I-00161 Rome, Italy.	dogliott@iss.it	Parlanti, Eleonora/AAC-5978-2021; Zambruno, Giavanna/K-2933-2018; degan, paolo/AAB-4093-2019; Teson, Massimo/GSE-1949-2022; Frosina, Guido/Z-2382-2019; Jaruga, Pawel/M-4378-2015; degan, paolo/AAB-6713-2019	Frosina, Guido/0000-0002-6717-5097; degan, paolo/0000-0003-0855-8896; Jaruga, Pawel/0000-0001-9192-6084; ORIOLI, DONATA/0000-0002-3830-3408; Iavarone, Ivano/0000-0001-5856-9484; Zambruno, Giovanna/0000-0002-1295-056X				Brooks PJ, 2000, J BIOL CHEM, V275, P22355, DOI 10.1074/jbc.M002259200; Brooks PJ, 2002, MUTAT RES-FUND MOL M, V509, P93, DOI 10.1016/S0027-5107(02)00222-1; Cappelli E, 2000, CARCINOGENESIS, V21, P1135, DOI 10.1093/carcin/21.6.1135; Citterio E, 2000, MOL CELL BIOL, V20, P7643, DOI 10.1128/MCB.20.20.7643-7653.2000; de Waard H, 2004, MOL CELL BIOL, V24, P7941, DOI 10.1128/MCB.24.18.7941-7948.2004; de Waard H, 2003, DNA REPAIR, V2, P13, DOI 10.1016/S1568-7864(02)00188-X; Degan P, 2005, J CELL BIOCHEM, V94, P460, DOI 10.1002/jcb.20302; Dianov G, 1999, NUCLEIC ACIDS RES, V27, P1365, DOI 10.1093/nar/27.5.1365; ERRICO M, 2005, CANCER RES, V65, P432; ERRICO M, 2007, MUTAT RES, V614, P37; FOURSTERI M, 2006, MOL CELL, V23, P471; Groisman R, 2003, CELL, V113, P357, DOI 10.1016/S0092-8674(03)00316-7; HENNING KA, 1995, CELL, V82, P555, DOI 10.1016/0092-8674(95)90028-4; Jaruga P, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh087; Jaruga P, 2002, BIOCHEMISTRY-US, V41, P3703, DOI 10.1021/bi016004d; Kamiuchi S, 2002, P NATL ACAD SCI USA, V99, P201, DOI 10.1073/pnas.012473199; Kuraoka I, 2000, P NATL ACAD SCI USA, V97, P3832, DOI 10.1073/pnas.070471597; Kyng KJ, 2003, ONCOGENE, V22, P1135, DOI 10.1038/sj.onc.1206187; Laine JP, 2006, TRENDS GENET, V22, P430, DOI 10.1016/j.tig.2006.06.006; Lehmann AR, 2003, BIOCHIMIE, V85, P1101, DOI 10.1016/j.biochi.2003.09.010; Licht CL, 2003, AM J HUM GENET, V73, P1217, DOI 10.1086/380399; MCGOLDRICK JP, 1995, MOL CELL BIOL, V15, P989; NANCE MA, 1992, AM J MED GENET, V42, P68, DOI 10.1002/ajmg.1320420115; Newman JC, 2006, P NATL ACAD SCI USA, V103, P9613, DOI 10.1073/pnas.0510909103; Osterod M, 2002, ONCOGENE, V21, P8232, DOI 10.1038/sj.onc.1206027; Proietti-De-Santis L, 2006, EMBO J, V25, P1915, DOI 10.1038/sj.emboj.7601071; Spivak G, 2006, DNA REPAIR, V5, P13, DOI 10.1016/j.dnarep.2005.06.017; Tuo J, 2001, J BIOL CHEM, V276, P45772, DOI 10.1074/jbc.M107888200; Tuo JS, 2003, FASEB J, V17, P668, DOI 10.1096/fj.02-0851com; Tuo JS, 2002, DNA REPAIR, V1, P913, DOI 10.1016/S1568-7864(02)00116-7	30	117	119	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2007	26	30					4336	4343		10.1038/sj.onc.1210232	http://dx.doi.org/10.1038/sj.onc.1210232			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	184CZ	17297471				2022-12-28	WOS:000247620000002
J	Ayllon, V; O'Connor, R				Ayllon, V.; O'Connor, R.			TOPK promotes tumour cell proliferation through p38MAPK activity and regulation of the DNA damage response	ONCOGENE			English	Article						IGF-IR; p38; PBK; H2AX; tumour growth	INSULIN-LIKE-GROWTH; IGF-I RECEPTOR; PDZ-BINDING KINASE; NUCLEOTIDE EXCISION-REPAIR; DOUBLE-STRAND BREAKS; HOMOLOGOUS RECOMBINATION; PROTEIN-KINASE; MICROARRAY ANALYSIS; IONIZING-RADIATION; GENE-EXPRESSION	The contribution of the insulin-like growth-factor-I receptor (IGF-IR) to tumour progression is well documented. To identify new mediators of IGF-IR function in cancer, we recently isolated genes differentially expressed in cells overexpressing the IGF-IR. Among these was the serine/threonine kinase PBK/TOPK (PDZ-binding kinase/T-LAK cell-originated protein kinase), previously associated with highly proliferative cells and tissues. Here, we show that PBK is expressed at high levels in tumour cell lines compared with non-transformed cells. IGF-I could induce PBK expression only in transformed cells, whereas epidermal growth factor could induce PBK in non-transformed MCF-10A breast epithelial cells. Suppression of PBK expression using small interfering RNA did not prevent progression through the cell cycle, but caused decreased proliferation over time in culture, and reduced clonogenic growth in soft agarose. PBK knockdown impaired p38 activation after long-term stimulation with different growth factors and reduced DU145 cells motility. Suppressed PBK expression also resulted in an impaired response to DNA damage that was evident by the decreased generation of gamma-H2AX, increased DNA damage and decreased cell survival. Taken together, the data indicate that PBK is necessary for appropriate activation and function of the p38 pathway by growth factors. Thus, enhanced expression of PBK may facilitate tumour growth by mediating p38 activation and by helping cells to overcome DNA damage.	Natl Univ Ireland, BioSci Inst, Cell Biol Lab, Dept Biochem, Cork, Ireland	University College Cork	O'Connor, R (corresponding author), Natl Univ Ireland, BioSci Inst, Cell Biol Lab, Dept Biochem, Coll Rd, Cork, Ireland.	r.oconnor@ucc.ie	O'Connor, Rosemary/B-7902-2014; Ayllon, Veronica/L-7069-2014	O'Connor, Rosemary/0000-0002-0687-3422; Ayllon, Veronica/0000-0002-7322-9282				Abe Y, 2000, J BIOL CHEM, V275, P21525, DOI 10.1074/jbc.M909629199; Bartucci M, 2001, CANCER RES, V61, P6747; Cleaver JE, 2005, NAT REV CANCER, V5, P564, DOI 10.1038/nrc1652; Cote S, 2002, CYTOKINE, V20, P113, DOI 10.1006/cyto.2002.1988; Dendouga N, 2005, MOL CELL BIOL, V25, P7569, DOI 10.1128/MCB.25.17.7569-7579.2005; Dougherty JD, 2005, J NEUROSCI, V25, P10773, DOI 10.1523/JNEUROSCI.3207-05.2005; Dupont J, 2003, RECENT PROG HORM RES, V58, P325, DOI 10.1210/rp.58.1.325; Fernandez-Capetillo O, 2004, DNA REPAIR, V3, P959, DOI 10.1016/j.dnarep.2004.03.024; Friedmann B, 2004, CLIN CANCER RES, V10, P6476, DOI 10.1158/1078-0432.CCR-04-0586; Fujibuchi T, 2005, DEV GROWTH DIFFER, V47, P637, DOI 10.1111/j.1440-169X.2005.00834.x; Gaudet S, 2000, P NATL ACAD SCI USA, V97, P5167, DOI 10.1073/pnas.090102397; Heron-Milhavet L, 2002, J BIOL CHEM, V277, P15600, DOI 10.1074/jbc.M111142200; Heron-Milhavet L, 2001, J BIOL CHEM, V276, P18185, DOI 10.1074/jbc.M011490200; Hofmann F, 2005, DRUG DISCOV TODAY, V10, P1041, DOI 10.1016/S1359-6446(05)03512-9; Huang C, 2004, J CELL SCI, V117, P4619, DOI 10.1242/jcs.01481; Kiely PA, 2005, J BIOL CHEM, V280, P7624, DOI 10.1074/jbc.M412889200; Kim MS, 2003, CANCER RES, V63, P5454; Lee-Kwon W, 1998, EXP CELL RES, V241, P458, DOI 10.1006/excr.1998.4087; Lisby M, 2004, CURR OPIN CELL BIOL, V16, P328, DOI 10.1016/j.ceb.2004.03.011; Loughran G, 2005, ONCOGENE, V24, P6185, DOI 10.1038/sj.onc.1208772; Loughran G, 2005, MOL BIOL CELL, V16, P1811, DOI 10.1091/mbc.E04-12-1052; Macaulay VM, 2001, ONCOGENE, V20, P4029, DOI 10.1038/sj.onc.1204565; Madhusudan S, 2005, TRENDS MOL MED, V11, P503, DOI 10.1016/j.molmed.2005.09.004; Maldonado C, 2005, BIOCHEM BIOPH RES CO, V336, P1112, DOI 10.1016/j.bbrc.2005.08.245; Marti TM, 2006, P NATL ACAD SCI USA, V103, P9891, DOI 10.1073/pnas.0603779103; Matsumoto S, 2004, BIOCHEM BIOPH RES CO, V325, P997, DOI 10.1016/j.bbrc.2004.10.133; Mauro L, 2004, J MOL HISTOL, V35, P247; Mikhailov A, 2005, CELL CYCLE, V4, P57, DOI 10.4161/cc.4.1.1357; Mulligan C, 2002, J BIOL CHEM, V277, P42480, DOI 10.1074/jbc.M206206200; Nandi A, 2004, BLOOD CELL MOL DIS, V32, P240, DOI 10.1016/j.bcmd.2003.10.004; Nandi AK, 2006, LEUKEMIA RES, V30, P437, DOI 10.1016/j.leukres.2005.08.011; O'Connor R, 2003, HORM METAB RES, V35, P771; Paull TT, 2000, CURR BIOL, V10, P886, DOI 10.1016/S0960-9822(00)00610-2; Risinger MA, 2004, CANCER CELL, V6, P539, DOI 10.1016/j.ccr.2004.12.001; Rochester MA, 2005, CANCER GENE THER, V12, P90, DOI 10.1038/sj.cgt.7700775; Sartor CI, 2004, NAT CLIN PRACT ONCOL, V1, P80, DOI 10.1038/ncponc0048; SELL C, 1993, P NATL ACAD SCI USA, V90, P11217, DOI 10.1073/pnas.90.23.11217; Shen WH, 2004, J BIOL CHEM, V279, P7438, DOI 10.1074/jbc.M310264200; Simons-Evelyn M, 2001, BLOOD CELL MOL DIS, V27, P825, DOI 10.1006/bcmd.2001.0452; Sorensen CS, 2005, NAT CELL BIOL, V7, P195, DOI 10.1038/ncb1212; Speit G, 1999, METH MOL B, V113, P203; Stiff T, 2004, CANCER RES, V64, P2390, DOI 10.1158/0008-5472.CAN-03-3207; Stucki M, 2005, CELL, V123, P1213, DOI 10.1016/j.cell.2005.09.038; Surmacz E, 2003, ONCOGENE, V22, P6589, DOI 10.1038/sj.onc.1206772; Trojanek J, 2003, MOL CELL BIOL, V23, P7510, DOI 10.1128/MCB.23.21.7510-7524.2003; Vincent AM, 2002, GROWTH HORM IGF RES, V12, P193, DOI 10.1016/S1096-6374(02)00017-5; Wang WD, 2005, CLIN CANCER RES, V11, P5140, DOI 10.1158/1078-0432.CCR-04-2548; Yacoub A, 2003, RADIAT RES, V159, P439, DOI 10.1667/0033-7587(2003)159[0439:EGFAIR]2.0.CO;2; Yang S, 2005, AM J PHYSIOL-RENAL, V289, pF1144, DOI 10.1152/ajprenal.00094.2005	49	111	118	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY	2007	26	24					3451	3461		10.1038/sj.onc.1210142	http://dx.doi.org/10.1038/sj.onc.1210142			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	172JC	17160018				2022-12-28	WOS:000246799200001
J	Nakazawa, Y; Suzuki, M; Manabe, N; Yamada, T; Kihara-Negishi, F; Sakurai, T; Tenen, DG; Iwama, A; Mochizuki, M; Oikawa, T				Nakazawa, Y.; Suzuki, M.; Manabe, N.; Yamada, T.; Kihara-Negishi, F.; Sakurai, T.; Tenen, D. G.; Iwama, A.; Mochizuki, M.; Oikawa, T.			Cooperative interaction between ETS1 and GFI1 transcription factors in the repression of Bax gene expression	ONCOGENE			English	Article						ETS1; GFI1; Bax; transcription; cross-talk	ZINC-FINGER PROTEIN; T-CELL DEATH; TERNARY COMPLEX; DIFFERENTIATION; ACTIVATION; PU.1; FAMILY; DNA; HEMATOPOIESIS; LEUKEMIA	The proto-oncoproteins ETS1 and growth factor independent-1 (GFI1) are implicated in cell growth and differentiation in various types of cells, and their deregulated expression is involved in malignant transformation. Here, we report that ETS1 and GFI1 interact and affect gene expression through their cross-talk. Co-immunoprecipitation analyses and glutathione-S-transferase pull-down assays revealed that ETS1 bound directly to GFI1 via its Ets domain, and GFI1 bound to ETS1 via its zinc-finger domain. Luciferase (Luc) assays using artificial reporters showed that GFI1 repressed ETS1-mediated transcriptional activation and ETS1 repressed GFI1-mediated transcriptional activation, in a dose-dependent manner. However, in the Bax promoter where the Ets- and Gfi-binding sites (EBS and GBS) are adjacent, ETS1 and GFI1 cooperatively reduced activation. Site-directed mutagenesis on the EBS and GBS of the Bax promoter showed that both binding sites were necessary for full repression. Chromatin immunoprecipitation analyses con. rmed that an ETS1-GFI1 complex formed on the Bax promoter even when either EBS or GBS was mutated. Introduction of small interfering RNA against ETS1 and/ or GFI1 enhanced endogenous Bax gene expression. Our results suggest that the interaction between ETS1 and GFI1 facilitates their binding to speci. c sites on the Bax promoter and represses Bax expression in vivo.	Sasaki Inst, Dept Cell Genet, Chiyoda Ku, Tokyo 1010062, Japan; Kyoritsu Coll Pharmaceut Sci, Div Organ & Bioorgan Chem, Minato Ku, Tokyo, Japan; Harvard Univ, Sch Med, Harvard Inst Med, Boston, MA 02115 USA; Chiba Univ, Grad Sch Med, Dept Cellular & Mol Med, Chiba, Japan	Harvard University; Harvard Medical School; Chiba University	Oikawa, T (corresponding author), Sasaki Inst, Dept Cell Genet, Chiyoda Ku, 2-2 Kanda Surugadai, Tokyo 1010062, Japan.	oikawat@hoku-iryo-u.dc.jp		Tenen, Daniel/0000-0002-6423-3888				BORIES JC, 1995, NATURE, V377, P635, DOI 10.1038/377635a0; Davidson B, 2003, CANCER METAST REV, V22, P103, DOI 10.1023/A:1022272204045; Dittmer Jurgen, 2003, Mol Cancer, V2, P29, DOI 10.1186/1476-4598-2-29; Duan Zhijun, 2003, Hematology, V8, P339, DOI 10.1080/10245330310001612116; Duan ZJ, 2003, P NATL ACAD SCI USA, V100, P5932, DOI 10.1073/pnas.1031694100; Escalante CR, 2002, MOL CELL, V10, P1097, DOI 10.1016/S1097-2765(02)00703-7; GIESE K, 1995, GENE DEV, V9, P995, DOI 10.1101/gad.9.8.995; GILKS CB, 1993, MOL CELL BIOL, V13, P1759, DOI 10.1128/MCB.13.3.1759; Graf T, 2002, BLOOD, V99, P3089, DOI 10.1182/blood.V99.9.3089; Graves BJ, 1998, ADV CANCER RES, V75, P1, DOI 10.1016/S0065-230X(08)60738-1; Grimes HL, 1996, P NATL ACAD SCI USA, V93, P14569, DOI 10.1073/pnas.93.25.14569; Grimes HL, 1996, MOL CELL BIOL, V16, P6263; Hassler M, 2001, EMBO J, V20, P3018, DOI 10.1093/emboj/20.12.3018; HELLE JP, 1997, MOL CELL BIOL, V17, P4220; Hock H, 2003, IMMUNITY, V18, P109, DOI 10.1016/S1074-7613(02)00501-0; Hwang CK, 2004, J BIOL CHEM, V279, P19764, DOI 10.1074/jbc.M400755200; Jonsen MD, 1996, MOL CELL BIOL, V16, P2065; Karsunky H, 2002, ONCOGENE, V21, P1571, DOI 10.1038/sj/onc/1205216; Kazanjian A, 2004, CANCER RES, V64, P6874, DOI 10.1158/0008-5472.CAN-04-0633; Kihara-Negishi F, 2001, ONCOGENE, V20, P6039, DOI 10.1038/sj.onc.1204756; Kim WY, 1999, EMBO J, V18, P1609, DOI 10.1093/emboj/18.6.1609; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; McGhee L, 2003, J CELL BIOCHEM, V89, P1005, DOI 10.1002/jcb.10548; MUTHUSAMY N, 1995, NATURE, V377, P639, DOI 10.1038/377639a0; Oikawa T, 2003, GENE, V303, P11, DOI 10.1016/S0378-1119(02)01156-3; Oikawa T, 2004, CANCER SCI, V95, P626, DOI 10.1111/j.1349-7006.2004.tb03320.x; OIKAWA T, 2005, MOL GENETICS CANC, P119; Osawa M, 2002, BLOOD, V100, P2769, DOI 10.1182/blood-2002-01-0182; Rodel B, 2000, EMBO J, V19, P5845, DOI 10.1093/emboj/19.21.5845; SALMON P, 1993, P NATL ACAD SCI USA, V90, P7739, DOI 10.1073/pnas.90.16.7739; Schmidt T, 1998, ONCOGENE, V17, P2661, DOI 10.1038/sj.onc.1202191; Sharrocks AD, 2001, NAT REV MOL CELL BIO, V2, P827, DOI 10.1038/35099076; Shivdasani RA, 1996, BLOOD, V87, P4025, DOI 10.1182/blood.V87.10.4025.bloodjournal87104025; Sledz CA, 2005, BLOOD, V106, P787, DOI 10.1182/blood-2004-12-4643; Suzuki M, 2003, ONCOGENE, V22, P8688, DOI 10.1038/sj.onc.1207182; Tenen DG, 1997, BLOOD, V90, P489, DOI 10.1182/blood.V90.2.489.489_489_519; Tong B, 1998, MOL CELL BIOL, V18, P2462, DOI 10.1128/MCB.18.5.2462; Yamamoto H, 1999, ONCOGENE, V18, P1495, DOI 10.1038/sj.onc.1202427; Yucel R, 2003, J EXP MED, V197, P831, DOI 10.1084/jem.20021417; ZweidlerMcKay PA, 1996, MOL CELL BIOL, V16, P4024	40	29	29	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY	2007	26	24					3541	3550		10.1038/sj.onc.1210140	http://dx.doi.org/10.1038/sj.onc.1210140			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	172JC	17213822				2022-12-28	WOS:000246799200010
J	Petitjean, A; Achatz, MIW; Borresen-Dale, AL; Hainaut, P; Olivier, M				Petitjean, A.; Achatz, M. I. W.; Borresen-Dale, A. L.; Hainaut, P.; Olivier, M.			TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes	ONCOGENE			English	Review						TP53; p53; mutation; transactivation; phenotype	LI-FRAUMENI-SYNDROME; ACCELERATES TUMOR-FORMATION; P53 POLYMORPHIC VARIANTS; BREAST-CANCER; CODON-72 POLYMORPHISM; LUNG-CANCER; COLORECTAL-CANCER; SUPPRESSOR GENE; ARGININE ALLELE; MDM2 SNP309	A large amount of data is available on the functional impact of missense mutations in TP53 and on mutation patterns in many different cancers. New data on mutant p53protein function, cancer phenotype and prognosis have recently been integrated in the International Agency for Research on Cancer TP53database (http://wwwp53.iarc.fr/). Based on these data, we summarize here current knowledge on the respective roles of mutagenesis and biological selection of mutations with specific functional characteristic in shaping the patterns and phenotypes of mutations observed in human cancers. The main conclusion is that intrinsic mutagenicity rates, loss of transactivation activities, and to a lesser extent, dominant-negative activities are the main driving forces that determine TP53 mutation patterns and influence tumor phenotype. In contrast, current experimental data on the acquisition of oncogenic activities (gain of function) by p53 mutants are too scarce and heterogenous to assess whether this property has an impact on tumor development and outcome. In the case of inherited TP53 mutations causing Li-Fraumeni and related syndromes, the age at onset of some tumor types is in direct relation with the degree of loss of transactivation capacity of missense mutations. Finally, studies on large case series demonstrate that TP53 mutations are independent markers of bad prognosis in breast and several other cancers, and that the exact type and position of the mutation influences disease outcome. Further studies are needed to determine how TP53 haplotypes or loss of alleles interact with mutations to modulate their impact on cancer development and prognosis.	Int Agcy Res & Canc, Grp Mol Carcinogenesis, F-69372 Lyon 08, France; Hop Canc, Dept Oncogenet, Sao Paulo, Brazil; Int Agcy Res Canc, Lyon, France; Radiumhosp Med Ctr, Rikshosp, Inst Canc Res, Dept Genet, Oslo, Norway; Univ Oslo, Fac Med, Dept Genet, Oslo, Norway	World Health Organization; International Agency for Research on Cancer (IARC); A.C.Camargo Cancer Center; World Health Organization; International Agency for Research on Cancer (IARC); University of Oslo; National Hospital Norway; University of Oslo	Petitjean, A (corresponding author), Int Agcy Res & Canc, Grp Mol Carcinogenesis, 150 Cours Albert Thomas, F-69372 Lyon 08, France.	hainaut@iarc.fr; wrisez@iarc.fr	Achatz, Maria Isabel/C-5751-2013; Hainaut, Pierre/B-6018-2012; Olivier, Magali/G-3728-2010	Achatz, Maria Isabel/0000-0001-6894-1219; Hainaut, Pierre/0000-0002-1303-1610; Olivier, Magali/0000-0002-8202-342X				BECKMAN G, 1994, HUM HERED, V44, P266, DOI 10.1159/000154228; Bergamaschi D, 2003, CANCER CELL, V3, P387, DOI 10.1016/S1535-6108(03)00079-5; Birch JM, 1998, ONCOGENE, V17, P1061, DOI 10.1038/sj.onc.1202033; Bonafe M, 2003, CLIN CANCER RES, V9, P4860; Bond GL, 2006, CANCER RES, V66, P5104, DOI 10.1158/0008-5472.CAN-06-0180; Bond GL, 2004, CELL, V119, P591, DOI 10.1016/j.cell.2004.11.022; Bougeard G, 2006, J MED GENET, V43, P531, DOI 10.1136/jmg.2005.037952; Bougeard G, 2003, ONCOGENE, V22, P840, DOI 10.1038/sj.onc.1206155; Brachmann RK, 1996, P NATL ACAD SCI USA, V93, P4091, DOI 10.1073/pnas.93.9.4091; Bull SB, 2004, J CLIN ONCOL, V22, P86, DOI 10.1200/JCO.2004.09.128; DEARTH LR, 2006, CARCINOGENESIS; Denissenko MF, 1996, SCIENCE, V274, P430, DOI 10.1126/science.274.5286.430; DiGiammarino EL, 2002, NAT STRUCT BIOL, V9, P12, DOI 10.1038/nsb730; Dumont P, 2003, NAT GENET, V33, P357, DOI 10.1038/ng1093; Gemignani F, 2004, ONCOGENE, V23, P1954, DOI 10.1038/sj.onc.1207305; Hainaut P, 2000, ADV CANCER RES, V77, P81; Harris SL, 2005, COLD SH Q B, V70, P111, DOI 10.1101/sqb.2005.70.024; Helland A, 1998, NATURE, V396, P530, DOI 10.1038/25034; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; Kato S, 2003, P NATL ACAD SCI USA, V100, P8424, DOI 10.1073/pnas.1431692100; Klug SJ, 2001, CANCER EPIDEM BIOMAR, V10, P1009; Kochethu G, 2006, LEUKEMIA RES, V30, P1113, DOI 10.1016/j.leukres.2005.12.014; Koushik A, 2004, CANCER EPIDEM BIOMAR, V13, P11, DOI 10.1158/1055-9965.EPI-083-3; Lang GA, 2004, CELL, V119, P861, DOI 10.1016/j.cell.2004.11.006; Langerod A, 2002, CANCER EPIDEM BIOMAR, V11, P1684; LANGEROD A, 2006, IN PRESS HUM MUTAT; LANGEROD A, 2006, IN PRESS BREAST CANC; Le Calvez F, 2005, CLIN CHEM, V51, P1284, DOI 10.1373/clinchem.2005.048348; Lunter G, 2004, BIOINFORMATICS, V20, P216, DOI 10.1093/bioinformatics/bth901; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; Marin MC, 2000, NAT GENET, V25, P47, DOI 10.1038/75586; Miller LD, 2005, P NATL ACAD SCI USA, V102, P13550, DOI 10.1073/pnas.0506230102; Nelson HH, 2005, CARCINOGENESIS, V26, P1770, DOI 10.1093/carcin/bgi125; Olive KP, 2004, CELL, V119, P847, DOI 10.1016/j.cell.2004.11.004; OLIVEIRA LS, 1994, DRY TECHNOL, V12, P1167, DOI 10.1080/07373939408960994; Olivier M, 2002, HUM MUTAT, V19, P607, DOI 10.1002/humu.10081; Olivier M, 2003, CANCER RES, V63, P6643; ORY K, 1994, EMBO J, V13, P3496, DOI 10.1002/j.1460-2075.1994.tb06656.x; Pim D, 2004, INT J CANCER, V108, P196, DOI 10.1002/ijc.11548; Ribeiro RC, 2001, P NATL ACAD SCI USA, V98, P9330, DOI 10.1073/pnas.161479898; Santos AM, 2006, BIOCHEM BIOPH RES CO, V340, P256, DOI 10.1016/j.bbrc.2005.11.176; Schneider-Stock R, 2004, AM J PATHOL, V164, P1233, DOI 10.1016/S0002-9440(10)63211-7; Siddique M, 2006, ONCOGENE, V25, P3489, DOI 10.1038/sj.onc.1209405; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Storey A, 1998, NATURE, V393, P229, DOI 10.1038/30400; Sullivan A, 2004, ONCOGENE, V23, P3328, DOI 10.1038/sj.onc.1207428; Tada M, 2001, CARCINOGENESIS, V22, P515, DOI 10.1093/carcin/22.3.515; Thomas M, 1999, MOL CELL BIOL, V19, P1092; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Achatz MIW, 2007, CANCER LETT, V245, P96, DOI 10.1016/j.canlet.2005.12.039; Wang Y, 2004, HUM MUTAT, V24, P21, DOI 10.1002/humu.20055; Wegman P, 2006, PHARMACOGENET GENOM, V16, P347, DOI 10.1097/01.fpc.0000204997.84182.69; Wong P, 2006, GASTROENTEROLOGY, V130, P73, DOI 10.1053/j.gastro.2005.10.014; Wu XF, 2002, JNCI-J NATL CANCER I, V94, P681; Xu Y, 2005, CLIN CANCER RES, V11, P7328, DOI 10.1158/1078-0432.CCR-05-0507; Zajac V, 2000, NEOPLASMA, V47, P335	56	644	672	2	64	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 2	2007	26	15					2157	2165		10.1038/sj.onc.1210302	http://dx.doi.org/10.1038/sj.onc.1210302			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	152XE	17401424				2022-12-28	WOS:000245394800004
J	Ebauer, M; Wachtel, M; Niggli, FK; Schaefer, BW				Ebauer, M.; Wachtel, M.; Niggli, F. K.; Schaefer, B. W.			Comparative expression profiling identifies an in vivo target gene signature with TFAP2B as a mediator of the survival function of PAX3/FKHR	ONCOGENE			English	Article						alveolar RMS; chimeric transcription factor; expression profiling; TFAP2B; PAX3/FKHR	PAX3-FKHR FUSION PROTEIN; ALVEOLAR RHABDOMYOSARCOMA; TRANSCRIPTION FACTOR; PAX3; MICE; TRANSLOCATION; POTENT; CELLS; MET	The chromosomal translocation t(2;13), characteristic for the aggressive childhood cancer alveolar rhabdomyosarcoma (aRMS), generates the chimeric transcription factor PAX3/FKHR with a well known oncogenic role. However, the molecular mechanisms mediating essential pathophysiological functions remain poorly defined. Here, we used comparative expression pro. ling of PAX3/FKHR silencing in vitro and PAX3/FKHR-specific gene signatures in vivo to identify physiologically important target genes. Hereby, 51 activated genes, both novel and known, were identified. We also found repression of skeletal muscle-specific genes suggesting that PAX3/FKHR blocks further differentiation of aRMS cells. Importantly, TFAP2B was validated as direct target gene mediating the anti-apoptotic function of PAX3/FKHR. Hence, we developed a pathophysiologically relevant transcriptional profile of PAX3/FKHR and identified a critical target gene for aRMS development.	Univ Zurich, Childrens Hosp, Dept Oncol, CH-8032 Zurich, Switzerland	University Children's Hospital Zurich; University of Zurich	Schaefer, BW (corresponding author), Univ Zurich, Childrens Hosp, Dept Oncol, Steinwiesstr 75, CH-8032 Zurich, Switzerland.	beat.schaefer@kispi.unizh.ch	Niggli, Felix/L-6547-2017	Niggli, Felix/0000-0002-7553-3712; Wachtel, Marco/0000-0002-6077-3692; Schafer, Beat/0000-0001-5988-2915				Anderson J, 2001, AM J PATHOL, V159, P1089, DOI 10.1016/S0002-9440(10)61784-1; Ayyanathan K, 2000, CANCER RES, V60, P5803; Begum S, 2005, ONCOGENE, V24, P1860, DOI 10.1038/sj.onc.1208315; BENNICELLI JL, 1995, ONCOGENE, V11, P119; Bernasconi M, 1996, P NATL ACAD SCI USA, V93, P13164, DOI 10.1073/pnas.93.23.13164; Davicioni E, 2006, CANCER RES, V66, P6936, DOI 10.1158/0008-5472.CAN-05-4578; EDELMAN GM, 1995, PHILOS T R SOC B, V349, P305, DOI 10.1098/rstb.1995.0118; Elbashir SM, 2001, GENE DEV, V15, P188, DOI 10.1101/gad.862301; Epstein JA, 1998, MOL CELL BIOL, V18, P4118, DOI 10.1128/MCB.18.7.4118; Epstein JA, 1996, P NATL ACAD SCI USA, V93, P4213, DOI 10.1073/pnas.93.9.4213; FREDERICKS WJ, 1995, MOL CELL BIOL, V15, P1522; GALILI N, 1993, NAT GENET, V5, P230, DOI 10.1038/ng1193-230; Ginsberg JP, 1998, CANCER RES, V58, P3542; Keller C, 2004, GENE DEV, V18, P2614, DOI 10.1101/gad.1244004; Khan J, 1998, CANCER RES, V58, P5009; Lam PYP, 1999, MOL CELL BIOL, V19, P594; Lang D, 2005, NATURE, V433, P884, DOI 10.1038/nature03292; Li C, 2001, P NATL ACAD SCI USA, V98, P31, DOI 10.1073/pnas.011404098; Margue CM, 2000, ONCOGENE, V19, P2921, DOI 10.1038/sj.onc.1203607; Mayanil CSK, 2001, J BIOL CHEM, V276, P49299, DOI 10.1074/jbc.M107933200; Moser M, 1997, GENE DEV, V11, P1938, DOI 10.1101/gad.11.15.1938; Moser M, 2003, LAB INVEST, V83, P571, DOI 10.1097/01.LAB.0000064703.92382.50; Scheidler S, 1996, P NATL ACAD SCI USA, V93, P9805, DOI 10.1073/pnas.93.18.9805; Tomescu O, 2004, LAB INVEST, V84, P1060, DOI 10.1038/labinvest.3700125; Wachtel M, 2006, J CLIN ONCOL, V24, P816, DOI 10.1200/JCO.2005.03.4934; Wachtel M, 2004, CANCER RES, V64, P5539, DOI 10.1158/0008-5472.CAN-04-0844; Xia SJJ, 2004, ONCOGENE, V23, P6864, DOI 10.1038/sj.onc.1207850; Zhang L, 2007, ONCOGENE, V26, P1595, DOI 10.1038/sj.onc.1209958	28	67	67	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 8	2007	26	51					7267	7281		10.1038/sj.onc.1210525	http://dx.doi.org/10.1038/sj.onc.1210525			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	231NO	17525748				2022-12-28	WOS:000250955600011
J	Zheng, S; Ei-Naggar, AK; Kim, ES; Kurie, JM; Lozano, G				Zheng, S.; Ei-Naggar, A. K.; Kim, E. S.; Kurie, J. M.; Lozano, G.			A genetic mouse model for metastatic lung cancer with gender differences in survival	ONCOGENE			English	Article						p53; K-ras; mesotheliomas	RAS ONCOGENE ACTIVATION; CLINICAL-SIGNIFICANCE; P53 GENE; MESOTHELIOMA; MUTATIONS; ADENOCARCINOMA; ABNORMALITIES; PATHOGENESIS; PROGRESSION; XENOGRAFTS	Lung cancer is a devastating disease with poor prognosis. The design of better therapies for lung cancer patients would be greatly aided by good mouse models that closely resemble the human disease. Unfortunately, current models for lung adenocarcinoma are inadequate due to the absence of metastases. In this study, we incorporated both K-ras and p53 missense mutations into the mouse genome and established a more faithful genetic model for human lung adenocarcinoma, the most common type of lung cancer. Mice with both mutations developed advanced lung adenocarcinomas that were highly aggressive and metastasized to multiple intrathoracic and extrathoracic sites in a pattern similar to that of human lung cancer. These mice also showed a gender difference in cancer-related death. Additionally, the presence of both mutations induced pleural mesotheliomas in 23% of these mice. This mouse model recapitulates the metastatic nature of human lung cancer and will be invaluable to further probe the molecular basis of metastatic lung cancer and for translational studies.	Univ Texas, MD Anderson Canc Ctr, Dept Canc Genet, Unit 1010, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX 77030 USA; Univ Texas, Grad Sch Biomed Sci, Program Genes & Dev, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System	Lozano, G (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Canc Genet, Unit 1010, 1515 Holcombe Blvd, Houston, TX 77030 USA.	gglozano@mdanderson.org			NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER; NCI NIH HHS [CA16672] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abutaily AS, 2002, J CLIN PATHOL, V55, P662, DOI 10.1136/jcp.55.9.662; Bach PB, 2003, JNCI-J NATL CANCER I, V95, P470, DOI 10.1093/jnci/95.6.470; Bain C, 2004, JNCI-J NATL CANCER I, V96, P826, DOI 10.1093/jnci/djh143; Becher O. J., 2006, CANCER RES, V66, P3358; Becher OJ, 2006, CANCER RES, V66, P3355, DOI 10.1158/0008-5472.CAN-05-3827; Belinsky SA, 2003, CANCER RES, V63, P7089; BELINSKY SA, 1993, CANCER RES, V53, P410; CASTONGUAY A, 1991, EXP LUNG RES, V17, P485, DOI 10.3109/01902149109064434; CHIBA I, 1990, ONCOGENE, V5, P1603; GREENBLATT MS, 1994, CANCER RES, V54, P4855; HECHT SS, 1991, EXP LUNG RES, V17, P501, DOI 10.3109/01902149109064435; Hill R, 2005, CELL, V123, P1001, DOI 10.1016/j.cell.2005.09.030; Jackson EL, 2005, CANCER RES, V65, P10280, DOI 10.1158/0008-5472.CAN-05-2193; Jaurand MC, 2005, PATHOL BIOL, V53, P41, DOI 10.1016/j.patbio.2003.10.005; Johnson L, 2001, NATURE, V410, P1111, DOI 10.1038/35074129; KERR KM, 1992, THORAX, V47, P337, DOI 10.1136/thx.47.5.337; Kitamura H, 1999, AM J CLIN PATHOL, V111, P610; Lang GA, 2004, CELL, V119, P861, DOI 10.1016/j.cell.2004.11.006; Liu G, 2000, P NATL ACAD SCI USA, V97, P4174, DOI 10.1073/pnas.97.8.4174; MALKINSON AM, 1994, MOL CARCINOGEN, V10, P61, DOI 10.1002/mc.2940100202; Meuwissen R, 2005, GENE DEV, V19, P643, DOI 10.1101/gad.1284505; MITSUDOMI T, 1992, ONCOGENE, V7, P171; Nikitin AY, 2004, CANCER RES, V64, P2307, DOI 10.1158/0008-5472.CAN-03-3376; Olak J, 2004, J THORAC CARDIOV SUR, V128, P346, DOI 10.1016/j.jtcvs.2004.05.025; Olive KP, 2004, CELL, V119, P847, DOI 10.1016/j.cell.2004.11.004; Ordonez NG, 2003, AM J SURG PATHOL, V27, P1031, DOI 10.1097/00000478-200308000-00001; Payne S, 2001, SOC SCI MED, V53, P1067, DOI 10.1016/S0277-9536(00)00402-0; Quint LE, 1996, ANN THORAC SURG, V62, P246, DOI 10.1016/0003-4975(96)00220-2; RODENHUIS S, 1992, CANCER RES, V52, pS2665; RODENHUIS S, 1988, CANCER RES, V48, P5738; Sadikot RT, 1997, SOUTH MED J, V90, P1063, DOI 10.1097/00007611-199710000-00021; Salgia R, 1998, J CLIN ONCOL, V16, P1207, DOI 10.1200/JCO.1998.16.3.1207; Sausville E.A., 2006, CANCER RES, V66; Sausville EA, 2006, CANCER RES, V66, P3351, DOI 10.1158/0008-5472.CAN-05-3627; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; TAMURA A, 1992, CANCER, V70, P437, DOI 10.1002/1097-0142(19920715)70:2<437::AID-CNCR2820700211>3.0.CO;2-L; Toyooka S, 2003, HUM MUTAT, V21, P229, DOI 10.1002/humu.10177; Vahakangas KH, 2001, CANCER RES, V61, P4350; Wang Y, 2006, ONCOGENE, V25, P1277, DOI 10.1038/sj.onc.1209182; Wang Y, 2006, ONCOGENE, V25, P1320, DOI 10.1038/sj.onc.1209180; YOU M, 1992, P NATL ACAD SCI USA, V89, P5804, DOI 10.1073/pnas.89.13.5804; Zang EA, 1996, JNCI-J NATL CANCER I, V88, P183, DOI 10.1093/jnci/88.3-4.183	42	74	74	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 18	2007	26	48					6896	6904		10.1038/sj.onc.1210493	http://dx.doi.org/10.1038/sj.onc.1210493			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	220WQ	17486075	Bronze			2022-12-28	WOS:000250188400005
J	Hupe, P; La Rosa, P; Liva, S; Lair, S; Servant, N; Barillot, E				Hupe, P.; La Rosa, P.; Liva, S.; Lair, S.; Servant, N.; Barillot, E.			ACTuDB, a new database for the integrated analysis of array-CGHand clinical data for tumors	ONCOGENE			English	Article						DNA copy number; database; tumors; bioinformatics platform; molecular profiles; clinical data	COMPARATIVE GENOMIC HYBRIDIZATION; DNA COPY NUMBER; HIGH-RESOLUTION ANALYSIS; EXPRESSION PATTERNS; COLORECTAL-CANCER; BLADDER-CANCER; REVEALS; DEREGULATION; ABERRATIONS; REGIONS	In recent years, an increasing number of projects have investigated tumor genome structure, using microarray-based techniques like array comparative genomic hybridization ( array- CGH) or single nucleotide polymorphism ( SNP) arrays. The forthcoming studies have to integrate these former results and compare their findings to the existing sets of copy number data for validation. These sets also form the basis from which many comparative retrospective analyses can be carried out. Nevertheless, exploitation of this mass of data relies on a homogeneous preparation of copy number data, which will make it possible to compare them together, and their integration into a unified bioinformatics environment with ad hoc analysis tools and interfaces. To our knowledge, no such data integration has been proposed yet. Therefore the biologists and clinicians involved in cancer research urgently need such an integrative tool, which motivated us to undertake the construction of a database for array-CGH and other DNA copy number data for tumors ( ACTuDB). When available, the associated clinical, transcriptome and loss of heterozygosity data were also integrated into ACTuDB. ACTuDB contains currently about 1500 genomic profiles for tumors and cell lines for the bladder, brain, breast, colon, liver, lymphoma, neuroblastoma, mouth and pancreas, together with data for replication timing experiments. The CGH array data were processed, using ad hoc algorithms ( probe mapping, breakpoint detection, gain or loss status assignment and visualization) developed at Institut Curie. The database is available from http://bioinfo.curie.fr/actudb/ and can be browsed with a user- friendly interface. This database will be a useful resource for the genomic profiling of tumors, a field of highly active research. We invite research groups involved in tumor genome profiling to submit their data to ACTuDB.	Inst Curie, Serv Informmat, F-75248 Paris 05, France; CNRS, Inst Curie, UMR 144, Paris, France	UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Sorbonne Universite	Hupe, P (corresponding author), Inst Curie, Serv Informmat, 26 Rue Ulm, F-75248 Paris 05, France.	Philippe.Hupe@curie.fr	Hupe, Philippe/T-8793-2017	Hupe, Philippe/0000-0001-8468-3424; Servant, Nicolas/0000-0003-1678-7410; BARILLOT, Emmanuel/0000-0003-2724-2002				Albertson DG, 2003, NAT GENET, V34, P369, DOI 10.1038/ng1215; Baudis M, 2006, BIOTECHNIQUES, V40, P269, DOI 10.2144/000112102; Blaveri E, 2005, CLIN CANCER RES, V11, P7012, DOI 10.1158/1078-0432.CCR-05-0177; Bredel M, 2005, CANCER RES, V65, P4088, DOI 10.1158/0008-5472.CAN-04-4229; Chen X, 2002, MOL BIOL CELL, V13, P1929, DOI 10.1091/mbc.02-02-0023; de Leeuw RJ, 2004, HUM MOL GENET, V13, P1827, DOI 10.1093/hmg/ddh195; Douglas EJ, 2004, CANCER RES, V64, P4817, DOI 10.1158/0008-5472.CAN-04-0328; Fridlyand J, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-96; Griffiths-Jones Sam, 2006, V342, P129, DOI 10.1385/1-59745-123-1:129; Gysin S, 2005, GENE CHROMOSOME CANC, V44, P37, DOI 10.1002/gcc.20216; Hupe P, 2004, BIOINFORMATICS, V20, P3413, DOI 10.1093/bioinformatics/bth418; Hurst CD, 2004, ONCOGENE, V23, P2250, DOI 10.1038/sj.onc.1207260; Iafrate AJ, 2004, NAT GENET, V36, P949, DOI 10.1038/ng1416; Janoueix-Lerosey I, 2005, CELL CYCLE, V4, P1842, DOI 10.4161/cc.4.12.2257; Karolchik D, 2003, NUCLEIC ACIDS RES, V31, P51, DOI 10.1093/nar/gkg129; Kent WJ, 2002, GENOME RES, V12, P656, DOI [10.1101/gr.229202, 10.1101/gr.229202. Article published online before March 2002]; Kotliarov Y, 2006, CANCER RES, V66, P9428, DOI 10.1158/0008-5472.CAN-06-1691; La Rosa P, 2006, BIOINFORMATICS, V22, P2066, DOI 10.1093/bioinformatics/btl359; LEE RC, 1993, CELL, V75, P843, DOI 10.1016/0092-8674(93)90529-Y; Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702; Mosse YP, 2005, GENE CHROMOSOME CANC, V43, P390, DOI 10.1002/gcc.20198; Nakao K, 2004, CARCINOGENESIS, V25, P1345, DOI 10.1093/carcin/bgh134; Patil MA, 2005, CARCINOGENESIS, V26, P2050, DOI 10.1093/carcin/bgi178; Pinkel D, 2005, NAT GENET, V37, pS11, DOI 10.1038/ng1569; Pollack JR, 2002, P NATL ACAD SCI USA, V99, P12963, DOI 10.1073/pnas.162471999; Rouveirol C, 2006, BIOINFORMATICS, V22, P849, DOI 10.1093/bioinformatics/btl004; Snijders AM, 2005, ONCOGENE, V24, P4232, DOI 10.1038/sj.onc.1208601; Snijders AM, 2001, NAT GENET, V29, P263, DOI 10.1038/ng754; Stransky N, 2006, NAT GENET, V38, P1386, DOI 10.1038/ng1923; Veltman JA, 2003, CANCER RES, V63, P2872; Woodfine K, 2004, HUM MOL GENET, V13, P191, DOI 10.1093/hmg/ddh016; Ylstra B, 2006, NUCLEIC ACIDS RES, V34, P445, DOI 10.1093/nar/gkj456	32	11	11	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 11	2007	26	46					6641	6652		10.1038/sj.onc.1210488	http://dx.doi.org/10.1038/sj.onc.1210488			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	219JT	17496932				2022-12-28	WOS:000250081500006
J	Jacobs, AMF; Nicol, SM; Hislop, RG; Jaffray, EG; Hay, RT; Fuller-Pace, FV				Jacobs, A-M F.; Nicol, S. M.; Hislop, R. G.; Jaffray, E. G.; Hay, R. T.; Fuller-Pace, F. V.			SUMO modifcation of the DEAD box protein p68modulates its transcriptional activity and promotes its interaction with HDAC1	ONCOGENE			English	Article						p68; DEAD box protein; SUMO modifcation; transcriptional activity	P68 RNA HELICASE; ACTIVATION; UBIQUITIN; NUCLEAR; P53; COACTIVATOR; IDENTIFICATION; BINDING; ACTS	The nuclear protein p68 ( also known as Ddx5) is a prototypic member of the 'DEAD box' family of RNA helicases, which has been shown to be abnormally expressed and modified in colorectal tumors and to function as an important transcriptional regulator. Here, we show that p68 is modified in vivo on a single site ( K53) by the small ubiquitin-like modifier-2 ( SUMO-2). We demonstrate that the SUMO E3 ligase PIAS1 interacts with p68 and enhances its SUMO modi. cation in vivo. To determine the functional consequences of SUMO modi. cation, we compared the transcriptional activity of p68 and a K53R mutant that could not be SUMO-modified. Our data show that SUMO modi. cation enhances p68 transcriptional repression activity and inhibits the ability of p68 to function as a coactivator of p53. These findings may be explained by the ability of wild type, but not K53R p68, to alter the modification state of chromatin by recruitment of histone deacetylase 1 ( HDAC1).	Univ Dundee, Ninewells Hosp & Med Sch, Div Pathol & Neurosci, Canc Biol Grp, Dundee DD1 9SY, Scotland; Univ Dundee, Sch Life Sci, Div Gene Regulat & Epxress, Dundee DD1 9SY, Scotland	University of Dundee; University of Dundee	Fuller-Pace, FV (corresponding author), Univ Dundee, Ninewells Hosp & Med Sch, Div Pathol & Neurosci, Canc Biol Grp, Ninewells Dr, Dundee DD1 9SY, Scotland.	f.v.fullerpace@dundee.ac.uk	Hay, Ronald T/F-9338-2011; Hay, Ronald/S-3233-2019	Hay, Ronald T/0000-0001-7113-9024; Hay, Ronald/0000-0001-7113-9024				Bates GJ, 2005, EMBO J, V24, P543, DOI 10.1038/sj.emboj.7600550; Bond AT, 2001, MOL CELL BIOL, V21, P7366, DOI 10.1128/MCB.21.21.7366-7379.2001; Caretti G, 2006, DEV CELL, V11, P547, DOI 10.1016/j.devcel.2006.08.003; Causevic M, 2001, ONCOGENE, V20, P7734, DOI 10.1038/sj.onc.1204976; Desterro JMP, 1997, FEBS LETT, V417, P297, DOI 10.1016/S0014-5793(97)01305-7; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Endoh H, 1999, MOL CELL BIOL, V19, P5363; FORD MJ, 1988, NATURE, V332, P736, DOI 10.1038/332736a0; Gill G, 2005, CURR OPIN GENET DEV, V15, P536, DOI 10.1016/j.gde.2005.07.004; Gillian AL, 2004, J BIOL CHEM, V279, P9056, DOI 10.1074/jbc.M309308200; Girdwood D, 2003, MOL CELL, V11, P1043, DOI 10.1016/S1097-2765(03)00141-2; Gostissa M, 1999, EMBO J, V18, P6462, DOI 10.1093/emboj/18.22.6462; Guil S, 2003, MOL CELL BIOL, V23, P2927, DOI 10.1128/MCB.23.8.2927-2941.2003; Hay RT, 2005, MOL CELL, V18, P1, DOI 10.1016/j.molcel.2005.03.012; HIRLING H, 1989, NATURE, V339, P562, DOI 10.1038/339562a0; Hsieh JK, 1999, MOL CELL, V3, P181, DOI 10.1016/S1097-2765(00)80309-3; IGGO RD, 1989, EMBO J, V8, P1827, DOI 10.1002/j.1460-2075.1989.tb03577.x; IGGO RD, 1991, MOL CELL BIOL, V11, P1326, DOI 10.1128/MCB.11.3.1326; Kotaja N, 2002, MOL CELL BIOL, V22, P5222, DOI 10.1128/MCB.22.14.5222-5234.2002; Lee MB, 2005, MOL CELL BIOL, V25, P1879, DOI 10.1128/MCB.25.5.1879-1890.2005; LINDER P, 1989, NATURE, V337, P121, DOI 10.1038/337121a0; Liu G, 2006, BIOCHEM BIOPH RES CO, V349, P360, DOI 10.1016/j.bbrc.2006.08.049; Liu ZR, 2002, MOL CELL BIOL, V22, P5443, DOI 10.1128/MCB.22.15.5443-5450.2002; Mendoza HM, 2003, J BIOL CHEM, V278, P25637, DOI 10.1074/jbc.M212948200; Metivier R, 2003, CELL, V115, P751, DOI 10.1016/S0092-8674(03)00934-6; Ogilvie VC, 2003, NUCLEIC ACIDS RES, V31, P1470, DOI 10.1093/nar/gkg236; Rodriguez MS, 1999, EMBO J, V18, P6455, DOI 10.1093/emboj/18.22.6455; Rossow KL, 2003, ONCOGENE, V22, P151, DOI 10.1038/sj.onc.1206067; Saitoh H, 2000, J BIOL CHEM, V275, P6252, DOI 10.1074/jbc.275.9.6252; Sampson DA, 2001, J BIOL CHEM, V276, P21664, DOI 10.1074/jbc.M100006200; Seeler JS, 2003, NAT REV MOL CELL BIO, V4, P690, DOI 10.1038/nrm1200; Stevenson RJ, 1998, J PATHOL, V184, P351, DOI 10.1002/(SICI)1096-9896(199804)184:4<351::AID-PATH1235>3.0.CO;2-C; Tanner NK, 2001, MOL CELL, V8, P251, DOI 10.1016/S1097-2765(01)00329-X; Tatham MH, 2001, J BIOL CHEM, V276, P35368, DOI 10.1074/jbc.M104214200; Vertegaal ACO, 2004, J BIOL CHEM, V279, P33791, DOI 10.1074/jbc.M404201200; Watanabe M, 2001, EMBO J, V20, P1341, DOI 10.1093/emboj/20.6.1341; Webster GA, 1999, MOL CELL BIOL, V19, P3485; Wilson BJ, 2004, BMC MOL BIOL, V5, DOI 10.1186/1471-2199-5-11; Yang LQ, 2006, CELL, V127, P139, DOI 10.1016/j.cell.2006.08.036; Yang SH, 2004, MOL CELL, V13, P611, DOI 10.1016/S1097-2765(04)00060-7	40	58	61	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 30	2007	26	40					5866	5876		10.1038/sj.onc.1210387	http://dx.doi.org/10.1038/sj.onc.1210387			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	205OH	17369852				2022-12-28	WOS:000249123100004
J	Castilho, RM; Squarize, CH; Patel, V; Millar, SE; Zheng, Y; Molinolo, A; Gutkind, JS				Castilho, R. M.; Squarize, C. H.; Patel, V.; Millar, S. E.; Zheng, Y.; Molinolo, A.; Gutkind, J. S.			Requirement of Rac1 distinguishes follicular from interfollicular epithelial stem cells	ONCOGENE			English	Article						epithelial stem cells; hair follicle; Rho GTPases; Rac1; epidermal regeneration	LABEL-RETAINING CELLS; EPIDERMAL PROLIFERATIVE UNIT; POPULATIONS; SKIN; BIOLOGY	Epithelial stem cells in the bulge region within the hair follicle maintain the cyclic hair growth, but whether these stem cells also contribute to the epidermal renewal remains unclear. Here, we observed that the conditional deletion of the Rac1 gene in the mouse skin, including the potential follicular and epidermal stem cell compartments, results in alopecia owing to defective hair development. Surprisingly, mice lacking the expression of this Rho GTPase do not display major alterations in the interfollicular skin. Furthermore, Rac1 excision from primary epithelial keratinocytes results in the inability to reconstitute hair follicles and sebaceous glands when grafted onto mice, but epithelial cells lacking Rac1 can nonetheless form a healthy epidermi s. Together, these findings support the emerging view that the epidermis and the hair follicles are maintained by different epithelial stem cells, and provide evidence that the requirement for Rac1 function can distinguish these distinct stem cells populations.	Natl Inst Dent & Craniofacial Res, Oral & Pharyngeal Canc Branch, NIH, Bethesda, MD 20892 USA; Univ Penn, Sch Med, Dept Dermatol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Cell & Dev Biol, Philadelphia, PA 19104 USA; Univ Cincinnati, Childrens Hosp, Med Ctr, Div Expt Hematol, Cincinnati, OH USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); University of Pennsylvania; University of Pennsylvania; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati	Gutkind, JS (corresponding author), Natl Inst Dent & Craniofacial Res, Oral & Pharyngeal Canc Branch, NIH, 30 Convent Dr,Bldg 30,Room 211, Bethesda, MD 20892 USA.	sg39v@nih.gov	Zheng, Yi/J-7235-2015; Castilho, Rogerio M/E-4987-2010; Gutkind, J. Silvio/J-1201-2016; Gutkind, J. Silvio/A-1053-2009	Zheng, Yi/0000-0001-7089-6074; Castilho, Rogerio M/0000-0001-5358-612X; Gutkind, J. Silvio/0000-0002-5150-4482; Millar, Sarah/0000-0001-8792-6890; Squarize, Cristiane/0000-0002-6782-3429	Intramural NIH HHS Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000558] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000558] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Andl T, 2004, DEVELOPMENT, V131, P2257, DOI 10.1242/dev.01125; Benitah SA, 2005, SCIENCE, V309, P933, DOI 10.1126/science.1113579; BICKENBACH JR, 1981, J DENT RES, V60, P1611, DOI 10.1177/002203458106000311011; BICKENBACH JR, 1986, CELL TISSUE KINET, V19, P325, DOI 10.1111/j.1365-2184.1986.tb00684.x; Blanpain C, 2004, CELL, V118, P635, DOI 10.1016/j.cell.2004.08.012; Braun KM, 2003, DEVELOPMENT, V130, P5241, DOI 10.1242/dev.00703; Chrostek A, 2006, MOL CELL BIOL, V26, P6957, DOI 10.1128/MCB.00075-06; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; COTSARELIS G, 1990, CELL, V61, P1329, DOI 10.1016/0092-8674(90)90696-C; Cotsarelis G, 2001, TRENDS MOL MED, V7, P293, DOI 10.1016/S1471-4914(01)02027-5; Cotsarelis G, 2006, J INVEST DERMATOL, V126, P1459, DOI 10.1038/sj.jid.5700376; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Fuchs E, 2002, NAT REV GENET, V3, P199, DOI 10.1038/nrg758; Gu Y, 2003, SCIENCE, V302, P445, DOI 10.1126/science.1088485; GUTKIND JS, 1991, P NATL ACAD SCI USA, V88, P4703, DOI 10.1073/pnas.88.11.4703; Ito M, 2005, NAT MED, V11, P1351, DOI 10.1038/nm1328; Levy V, 2005, DEV CELL, V9, P855, DOI 10.1016/j.devcel.2005.11.003; LICHTI U, 1993, J INVEST DERMATOL, V101, pS124, DOI 10.1111/1523-1747.ep12363165; Millar SE, 2002, J INVEST DERMATOL, V118, P216, DOI 10.1046/j.0022-202x.2001.01670.x; MORRIS RJ, 1985, J INVEST DERMATOL, V84, P277, DOI 10.1111/1523-1747.ep12265358; POTTEN CS, 1974, CELL TISSUE KINET, V7, P77, DOI 10.1111/j.1365-2184.1974.tb00401.x; Squarize CH, 2002, J ORAL PATHOL MED, V31, P379, DOI 10.1034/j.1600-0714.2002.00142.x; Suwa H, 1998, BRIT J CANCER, V77, P147, DOI 10.1038/bjc.1998.23; Taylor G, 2000, CELL, V102, P451, DOI 10.1016/S0092-8674(00)00050-7; Verdier-Sevrain S, 2006, EXP DERMATOL, V15, P83, DOI 10.1111/j.1600-0625.2005.00377.x	25	47	49	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 2	2007	26	35					5078	5085		10.1038/sj.onc.1210322	http://dx.doi.org/10.1038/sj.onc.1210322			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	196MT	17334398				2022-12-28	WOS:000248487400006
J	Covey, TM; Edes, K; Fitzpatrick, FA				Covey, T. M.; Edes, K.; Fitzpatrick, F. A.			Akt activation by arachidonic acid metabolism occurs via oxidation and inactivation of PTEN tumor suppressor	ONCOGENE			English	Article						Akt; PTEN; cyclooxygenase-2; 5-lipoxygenase; tumor suppressor	SIGNALING PATHWAY; REDOX REGULATION; PHOSPHOINOSITIDE 3-KINASE; CANCER; KINASE; EXPRESSION; AKT/PKB; TARGETS; CELLS; SERUM	Cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5-LOX) enzymes are overexpressed during inflammation and multistage tumor progression in many neoplastic disorders including lung, breast and pancreatic cancers. Here we report that the tumor suppressor phosphatase and tensin homolog (PTEN) is oxidized and inactivated during arachidonic acid (AA) metabolism in pancreatic cancer cell lines expressing COX-2 or 5-LOX. Oxidation of PTEN decreases its phosphatase activity, favoring increased phosphatidylinositol 3,4,5-triphosphate production, activation of Akt and phosphorylation of downstream Akt targets including GSK-3 beta and S6K. These effects are recapitulated with pancreatic phospholipase A(2), which hydrolyses the release of membrane-bound AA. Interference with PTEN's physiological antagonism of signals from growth factors, insulin and oncogenes may confer risk for hypertrophic or neoplastic diseases associated with chronic inflammation or unwarranted oxidative metabolism of essential fatty acids.	Univ Utah, Dept Med Chem, Salt Lake City, UT 84112 USA	Utah System of Higher Education; University of Utah	Fitzpatrick, FA (corresponding author), Univ Utah, Huntsman Canc Inst, Dept Med Chem & Oncol Sci, 200 Circle Hope, Salt Lake City, UT 84112 USA.	frank.fitzpatrick@hci.utah.edu			NCI NIH HHS [T32 CA093247, P01 CA73992] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA073992, T32CA093247] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aggarwal BB, 2006, BIOCHEM PHARMACOL, V72, P1605, DOI 10.1016/j.bcp.2006.06.029; Asano T, 2004, ONCOGENE, V23, P8571, DOI 10.1038/sj.onc.1207902; Bianchi M, 2005, BIOCHEM J, V391, P359, DOI 10.1042/BJ20050282; Brugarolas J, 2004, CANCER CELL, V6, P7, DOI 10.1016/j.ccr.2004.06.020; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; Chan TO, 1999, ANNU REV BIOCHEM, V68, P965, DOI 10.1146/annurev.biochem.68.1.965; Cho SH, 2004, FEBS LETT, V560, P7, DOI 10.1016/S0014-5793(04)00112-7; Chu EC, 2004, MED SCI MONITOR, V10, pRA235; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Ding XZ, 2001, PANCREATOLOGY, V1, P291, DOI 10.1159/000055827; Gericke A, 2006, GENE, V374, P1, DOI 10.1016/j.gene.2006.02.024; Giardina C, 1998, BBA-MOL CELL RES, V1401, P277, DOI 10.1016/S0167-4889(97)00140-7; Goriely A, 2001, J NONLINEAR SCI, V11, P3, DOI 10.1007/s003320010009; Hii CST, 2001, J BIOL CHEM, V276, P27246, DOI 10.1074/jbc.M103250200; Hughes-Fulford M, 2006, CANCER RES, V66, P1427, DOI 10.1158/0008-5472.CAN-05-0914; Kim D, 2001, FASEB J, V15, P1953, DOI 10.1096/fj.01-0198com; Kwabi-Addo B, 2001, P NATL ACAD SCI USA, V98, P11563, DOI 10.1073/pnas.201167798; Kwon J, 2004, P NATL ACAD SCI USA, V101, P16419, DOI 10.1073/pnas.0407396101; Lee SR, 2002, J BIOL CHEM, V277, P20336, DOI 10.1074/jbc.M111899200; Leslie NR, 2003, EMBO J, V22, P5501, DOI 10.1093/emboj/cdg513; Leslie NR, 2002, CELL SIGNAL, V14, P285, DOI 10.1016/S0898-6568(01)00234-0; Li F, 2005, AM J PHYSIOL-HEART C, V288, pH2306, DOI 10.1152/ajpheart.00571.2004; Marks F, 2000, TOXICOLOGY, V153, P11, DOI 10.1016/S0300-483X(00)00301-2; Mimeault M, 2005, PANCREAS, V31, P301, DOI 10.1097/01.mpa.0000175893.04660.1b; NEVALAINEN TJ, 1985, CLIN CHEM, V31, P1116; Seo JH, 2005, MOL BIOL CELL, V16, P348, DOI 10.1091/mbc.E04-05-0369; Stanger BZ, 2005, CANCER CELL, V8, P185, DOI 10.1016/j.ccr.2005.07.015; Tonks NK, 2005, CELL, V121, P667, DOI 10.1016/j.cell.2005.05.016; Trotman LC, 2003, PLOS BIOL, V1, P385, DOI 10.1371/journal.pbio.0000059; Vara JAF, 2004, CANCER TREAT REV, V30, P193, DOI 10.1016/j.ctrv.2003.07.007; VINOKUROVA LV, 2001, ROSS GASTROENETEROL, V2, P72; Wagner TM, 2006, J BIOL CHEM, V281, P2598, DOI 10.1074/jbc.M509723200; Watkins SJ, 2002, BRIT J CANCER, V86, P1023, DOI 10.1038/sj/bjc/6600222; Wildroudt ML, 2006, BBA-MOL CELL BIOL L, V1761, P11, DOI 10.1016/j.bbalip.2005.11.009; Xiong HQ, 2004, CANCER CHEMOTH PHARM, V54, pS69, DOI 10.1007/s00280-004-0890-2; YAMASHITA S, 1994, CLIN CHIM ACTA, V228, P91, DOI 10.1016/0009-8981(94)90280-1; Yu CX, 2005, MOL PHARMACOL, V68, P847, DOI 10.1124/mol.104.010504	37	75	78	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2007	26	39					5784	5792		10.1038/sj.onc.1210391	http://dx.doi.org/10.1038/sj.onc.1210391			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	202EP	17369849				2022-12-28	WOS:000248885100010
J	Tews, B; Roerig, P; Hartmann, C; Hahn, M; Felsberg, J; Blaschke, B; Sabel, M; Kunitz, A; Toedt, G; Neben, K; Benner, A; von Deimling, A; Reifenberger, G; Lichter, P				Tews, B.; Roerig, P.; Hartmann, C.; Hahn, M.; Felsberg, J.; Blaschke, B.; Sabel, M.; Kunitz, A.; Toedt, G.; Neben, K.; Benner, A.; von Deimling, A.; Reifenberger, G.; Lichter, P.			Hypermethylation and transcriptional downregulation of the CITED4 gene at 1p34.2 in oligodendroglial tumours with allelic losses on 1p and 19q	ONCOGENE			English	Article						CITED4; gene expression profiling; oligodendroglioma; CpG island; hypermethylation; tumour suppressor gene	PHASE-III TRIAL; ANAPLASTIC OLIGODENDROGLIOMAS; MGMT GENE; EXPRESSION; SUPPRESSOR; CANCER; SURVIVAL; IDENTIFICATION; 19Q13.3; GLIOMAS	Deletions of chromosomal arms 1p and 19q are frequent in oligodendroglial tumours and have been associated with sensitivity to radio- and chemotherapy as well as favourable prognosis. By using microarray-based expression pro. ling, we found that oligodendroglial tumours with 1p and 19q losses showed signi. cantly lower expression of the CBP/p300-interacting transactivator with glutamic acid/ aspartic acid-rich carboxyl-terminal domain 4 gene (CITED4) at 1p34.2 as compared to tumours without 1p and 19q losses. Mutational analysis showed no CITED4 mutations in gliomas. However, 1p and 19q losses as well as low expression of CITED4 transcripts were significantly associated with hypermethylation of the CITED4-associated CpG island. In line with the latter. nding, treatment of CITED4 hypermethylated glioma cell lines with 5-aza-2'-deoxycytidine and trichostatine A resulted in a marked increase of the CITED4 transcript levels. Furthermore, CITED4 hypermethylation was signi. cantly associated with longer recurrence-free and overall survival of patients with oligodendroglial tumours. Taken together, our results indicate that CITED4 is epigenetically silenced in the vast majority of oligodendroglial tumours with 1p and 19q deletions and suggest CITED4 hypermethylation as a novel prognostic marker in oligodendroglioma patients.	Univ Dusseldorf, Dept Neuropathol, D-40225 Dusseldorf, Germany; Deutches Krebsforschungszentrum, Div Mol Genet B060, Heidelberg, Germany; Univ Med Berlin, Charite, Dept Neuropathol, Berlin, Germany; Univ Dusseldorf, Dept Neurosurg, D-4000 Dusseldorf, Germany; Deutches Krebsforschungszentrum, Cent Unit Biostat, C060, Heidelberg, Germany	Heinrich Heine University Dusseldorf; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Heinrich Heine University Dusseldorf	Reifenberger, G (corresponding author), Univ Dusseldorf, Dept Neuropathol, Moorenstr 5, D-40225 Dusseldorf, Germany.	reifenberger@med.uni-duesseldorf.de	von Deimling, Andreas/F-7774-2013; Reifenberger, Guido/AAE-3599-2019; Hartmann, Christian/D-1882-2010	von Deimling, Andreas/0000-0002-5863-540X; 	PHS HHS [01GS0462, 01GS0463, 01GS0460] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Alaminos M, 2005, CANCER RES, V65, P2565, DOI 10.1158/0008-5472.CAN-04-4283; Barbashina V, 2005, CLIN CANCER RES, V11, P1119; Braga D, 2002, CRYSTENGCOMM, V4, P277, DOI 10.1039/b201547a; Cairncross G, 2006, J CLIN ONCOL, V24, P2707, DOI 10.1200/JCO.2005.04.3414; Cairncross JG, 1998, J NATL CANCER I, V90, P1473, DOI 10.1093/jnci/90.19.1473; Dong SM, 2002, INT J CANCER, V98, P370, DOI 10.1002/ijc.10204; Felsberg J, 2004, BRAIN PATHOL, V14, P121, DOI 10.1111/j.1750-3639.2004.tb00044.x; Fox SB, 2004, CANCER RES, V64, P6075, DOI 10.1158/0008-5472.CAN-04-0708; Griffin CA, 2006, J NEUROPATH EXP NEUR, V65, P988, DOI 10.1097/01.jnen.0000235122.98052.8f; Grossman SR, 2001, EUR J BIOCHEM, V268, P2773, DOI 10.1046/j.1432-1327.2001.02226.x; Hegi ME, 2005, NEW ENGL J MED, V352, P997, DOI 10.1056/NEJMoa043331; Iyer NG, 2004, ONCOGENE, V23, P4225, DOI 10.1038/sj.onc.1207118; Jenkins RB, 2006, CANCER RES, V66, P9852, DOI 10.1158/0008-5472.CAN-06-1796; McDonald JM, 2006, CANCER BIOL THER, V5, P300, DOI 10.4161/cbt.5.3.2391; McDonald JM, 2005, MOL CANCER, V4, DOI 10.1186/1476-4598-4-35; Mollemann M, 2005, INT J CANCER, V113, P379, DOI 10.1002/ijc.20575; R Development Core Team, 2005, LANG ENV STAT COMP; Reifenberger G, 2003, J NEUROPATH EXP NEUR, V62, P111, DOI 10.1093/jnen/62.2.111; REIFENBERGER G, 2000, WHO CLASSIFICATION T, P55; Tews B, 2006, INT J CANCER, V119, P792, DOI 10.1002/ijc.21901; Tibshirani R, 2002, P NATL ACAD SCI USA, V99, P6567, DOI 10.1073/pnas.082099299; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; van den Bent MJ, 2006, J CLIN ONCOL, V24, P2715, DOI 10.1200/JCO.2005.04.6078; van den Boom J, 2003, AM J PATHOL, V163, P1033, DOI 10.1016/S0002-9440(10)63463-3; Wolf RM, 2003, GENE DEV, V17, P476, DOI 10.1101/gad.1040003	25	32	33	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2007	26	34					5010	5016		10.1038/sj.onc.1210297	http://dx.doi.org/10.1038/sj.onc.1210297			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	194CV	17311001				2022-12-28	WOS:000248322500013
J	Dhanasekaran, DN; Kashef, K; Lee, CM; Xu, H; Reddy, EP				Dhanasekaran, D. N.; Kashef, K.; Lee, C. M.; Xu, H.; Reddy, E. P.			Scaffold proteins of MAP-kinase modules	ONCOGENE			English	Review						scaffold proteins; ERK; JNK; p38MAPK; JLP; JIP	N-TERMINAL KINASE; CYTOKINE-INDUCED APOPTOSIS; SACCHAROMYCES-CEREVISIAE REQUIRES; AMYLOID PRECURSOR PROTEIN; INSULIN-SECRETING CELLS; FOCAL ADHESION KINASE; KSR-1 GENE ENCODES; SIGNAL-TRANSDUCTION; C-JUN; GROWTH-FACTOR	Mitogen-activated protein kinases (MAPKs) regulate critical signaling pathways involved in cell proliferation, differentiation and apoptosis. Recent studies have shown that a novel class of scaffold proteins mediates the structural and functional organization of the three-tier MAPK module. By linking the MAP3K, MAP2K and MAPK into a multienzyme complex, these MAPK-specific scaffold proteins provide an insulated physical conduit through which signals from the respective MAPK can be transmitted to the appropriate spatiotemporal cellular loci. Scaffold proteins play a determinant role in modulating the signaling strength of their cognate MAPK module by regulating the signal amplitude and duration. The scaffold proteins themselves are finely regulated resulting in dynamic intra- and inter-molecular interactions that can modulate the signaling outputs of MAPK modules. This review focuses on de. ning the diverse mechanisms by which these scaffold proteins interact with their respective MAPK modules and the role of such interactions in the spatiotemporal organization as well as context-specific signaling of the different MAPK modules.	Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19140 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Reddy, EP (corresponding author), Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, 3307 N Broad St, Philadelphia, PA 19140 USA.	reddy@temple.edu	Reddy, E. Premkumar/F-6233-2011; Lee, Clement M./E-7104-2012	Lee, Clement M./0000-0003-3486-8492	NIA NIH HHS [AG22022] Funding Source: Medline; NIGMS NIH HHS [GM49897] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG022022] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Barr AJ, 2002, BIOCHEM BIOPH RES CO, V293, P647, DOI 10.1016/S0006-291X(02)00259-0; Bell B, 1999, J BIOL CHEM, V274, P7982, DOI 10.1074/jbc.274.12.7982; Bogoyevitch MA, 2004, CELL SIGNAL, V16, P1345, DOI 10.1016/j.cellsig.2004.05.004; Bogoyevitch MA, 2006, BIOESSAYS, V28, P923, DOI 10.1002/bies.20458; Bonny C, 2000, J BIOL CHEM, V275, P16466, DOI 10.1074/jbc.M908297199; Bonny C, 1998, J BIOL CHEM, V273, P1843, DOI 10.1074/jbc.273.4.1843; Bowman AB, 2000, CELL, V103, P583, DOI 10.1016/S0092-8674(00)00162-8; BRADY ST, 1995, TRENDS CELL BIOL, V5, P159, DOI 10.1016/S0962-8924(00)88980-1; Bridges D., 2005, SCI STKE, V296, pre10, DOI DOI 10.1126/STKE.2962005RE10; Brown MC, 2004, PHYSIOL REV, V84, P1315, DOI 10.1152/physrev.00002.2004; Brunet A, 1999, EMBO J, V18, P664, DOI 10.1093/emboj/18.3.664; Buchsbaum RJ, 2002, MOL CELL BIOL, V22, P4073, DOI 10.1128/MCB.22.12.4073-4085.2002; Bumeister R, 2004, CURR BIOL, V14, P439, DOI 10.1016/j.cub.2004.02.037; Burack WR, 2000, CURR OPIN CELL BIOL, V12, P211, DOI 10.1016/S0955-0674(99)00078-2; Byrd DT, 2001, NEURON, V32, P787, DOI 10.1016/S0896-6273(01)00532-3; Cacace AM, 1999, MOL CELL BIOL, V19, P229; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Channavajhala PL, 2003, J BIOL CHEM, V278, P47089, DOI 10.1074/jbc.M306002200; CHOI KY, 1994, CELL, V78, P499; COULOMBE P, 2006, BIOCH BIOPHYS ACTA; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Denouel-Galy A, 1998, CURR BIOL, V8, P46, DOI 10.1016/S0960-9822(98)70019-3; Dhanasekaran N, 1998, ONCOGENE, V17, P1447, DOI 10.1038/sj.onc.1202251; Dickens M, 1997, SCIENCE, V277, P693, DOI 10.1126/science.277.5326.693; Elion EA, 2001, J CELL SCI, V114, P3967; Elion EA, 2005, SCIENCE, V307, P687, DOI 10.1126/science.1109500; Fanger GR, 1997, CURR OPIN GENET DEV, V7, P67, DOI 10.1016/S0959-437X(97)80111-6; Faux MC, 1996, CELL, V85, P9, DOI 10.1016/S0092-8674(00)81075-2; Feng JW, 1998, IEEE SIGNAL PROC LET, V5, P11, DOI 10.1109/97.654867; FERRELL JE, 2000, SCI STKE; Ferrer I, 2004, NEUROTOX RES, V6, P469, DOI 10.1007/BF03033283; Flatauer LJ, 2005, MOL CELL BIOL, V25, P1793, DOI 10.1128/MCB.25.5.1793-1803.2005; Formstecher E, 2001, DEV CELL, V1, P239, DOI 10.1016/S1534-5807(01)00035-1; Garrington TP, 1999, CURR OPIN CELL BIOL, V11, P211, DOI 10.1016/S0955-0674(99)80028-3; GARTNER A, 1992, GENE DEV, V6, P1280, DOI 10.1101/gad.6.7.1280; Gutkind JS, 1998, ONCOGENE, V17, P1331, DOI 10.1038/sj.onc.1202186; Ha HY, 2005, DEV BIOL, V277, P184, DOI 10.1016/j.ydbio.2004.09.019; Haefliger JA, 2003, J CELL SCI, V116, P1463, DOI 10.1242/jcs.00356; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; Huang C, 2004, J CELL SCI, V117, P4619, DOI 10.1242/jcs.01481; Hunter T, 2000, CELL, V100, P113, DOI 10.1016/S0092-8674(00)81688-8; Ishibe S, 2003, MOL CELL, V12, P1275, DOI 10.1016/S1097-2765(03)00406-4; Ito M, 1999, MOL CELL BIOL, V19, P7539; Ito M, 2000, GENE, V255, P229, DOI 10.1016/S0378-1119(00)00335-8; Jagadish N, 2005, J REPROD IMMUNOL, V67, P69, DOI 10.1016/j.jri.2005.06.004; Jagadish N, 2005, BIOCHEM J, V389, P73, DOI 10.1042/BJ20041577; Jho EH, 1997, J BIOL CHEM, V272, P24468, DOI 10.1074/jbc.272.39.24468; Joneson T, 1998, J BIOL CHEM, V273, P7743, DOI 10.1074/jbc.273.13.7743; Kang JS, 1998, J CELL BIOL, V143, P403, DOI 10.1083/jcb.143.2.403; Karandikar M, 1999, CELL CALCIUM, V26, P219, DOI 10.1054/ceca.1999.0074; Karandikar M, 2000, J BIOL CHEM, V275, P40120, DOI 10.1074/jbc.M005926200; Kashef K, 2005, BIOCHEMISTRY-US, V44, P14090, DOI 10.1021/bi050604l; Kashef K, 2006, J CELL BIOCHEM, V98, P715, DOI 10.1002/jcb.20930; Kelkar N, 2005, MOL CELL BIOL, V25, P2733, DOI 10.1128/MCB.25.7.2733-2743.2005; Kelkar N, 2003, P NATL ACAD SCI USA, V100, P9843, DOI 10.1073/pnas.1733944100; Kelkar N, 2000, MOL CELL BIOL, V20, P1030, DOI 10.1128/MCB.20.3.1030-1043.2000; Khokhlatchev AV, 1998, CELL, V93, P605, DOI 10.1016/S0092-8674(00)81189-7; Kolch W, 2005, NAT REV MOL CELL BIO, V6, P827, DOI 10.1038/nrm1743; KORNFELD K, 1995, CELL, V83, P903, DOI 10.1016/0092-8674(95)90206-6; KRANZ JE, 1994, GENE DEV, V8, P313, DOI 10.1101/gad.8.3.313; Krauss RS, 2005, J CELL SCI, V118, P2355, DOI 10.1242/jcs.02397; Kuboki Y, 2000, J BIOL CHEM, V275, P39815, DOI 10.1074/jbc.C000403200; Kukekov NV, 2006, J BIOL CHEM, V281, P15517, DOI 10.1074/jbc.M601056200; Lamark T, 2003, J BIOL CHEM, V278, P34568, DOI 10.1074/jbc.M303221200; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; Lee CM, 2002, P NATL ACAD SCI USA, V99, P14189, DOI 10.1073/pnas.232310199; Leftowitz RJ, 2005, SCIENCE, V308, P512, DOI 10.1126/science.1109237; Levchenko A, 2000, P NATL ACAD SCI USA, V97, P5818, DOI 10.1073/pnas.97.11.5818; Ling ZD, 2003, DIABETES, V52, P2497, DOI 10.2337/diabetes.52.10.2497; Lu ZM, 2002, MOL CELL, V9, P945, DOI 10.1016/S1097-2765(02)00519-1; MARCUS S, 1994, P NATL ACAD SCI USA, V91, P7762, DOI 10.1073/pnas.91.16.7762; Marinissen MJ, 2004, MOL CELL, V14, P29, DOI 10.1016/S1097-2765(04)00153-4; Matheny SA, 2004, NATURE, V427, P256, DOI 10.1038/nature02237; Matheny SA, 2006, METHOD ENZYMOL, V407, P237, DOI 10.1016/S0076-6879(05)07020-5; Matsuda S, 2001, J NEUROSCI, V21, P6597; Matsuguchi T, 2003, EMBO J, V22, P4455, DOI 10.1093/emboj/cdg438; Matsuura H, 2002, J BIOL CHEM, V277, P40703, DOI 10.1074/jbc.M202004200; Meyer D, 1999, J BIOL CHEM, V274, P35113, DOI 10.1074/jbc.274.49.35113; Michaud NR, 1997, P NATL ACAD SCI USA, V94, P12792, DOI 10.1073/pnas.94.24.12792; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; Minden A., 1997, BIOCHIM BIOPHYS ACTA, V1333, P85, DOI DOI 10.1016/S0304-419X(97)00018-8; Morrison DK, 2003, ANNU REV CELL DEV BI, V19, P91, DOI 10.1146/annurev.cellbio.19.111401.091942; Morrison DK, 2001, J CELL SCI, V114, P1609; Muller J, 2001, MOL CELL, V8, P983, DOI 10.1016/S1097-2765(01)00383-5; Muller J, 2000, MOL CELL BIOL, V20, P5529, DOI 10.1128/MCB.20.15.5529-5539.2000; Nakamura K, 2006, MOL CELL BIOL, V26, P2065, DOI 10.1128/MCB.26.6.2065-2079.2006; Nakamura K, 2003, J BIOL CHEM, V278, P36989, DOI 10.1074/jbc.C300313200; Negri S, 2000, GENOMICS, V64, P324, DOI 10.1006/geno.2000.6129; Nguyen A, 2002, MOL CELL BIOL, V22, P3035, DOI 10.1128/MCB.22.9.3035-3045.2002; Nguyen Q, 2005, J BIOL CHEM, V280, P30185, DOI 10.1074/jbc.M505499200; Nihalani D, 2001, EMBO J, V20, P3447, DOI 10.1093/emboj/20.13.3447; Nikulina MA, 2003, CYTOKINE, V24, P13, DOI 10.1016/S1043-4666(03)00242-4; Ohmachi M, 2002, CURR BIOL, V12, P427, DOI 10.1016/S0960-9822(02)00690-5; Ory S, 2004, CURR BIOL, V14, pR277, DOI 10.1016/j.cub.2004.03.023; Ory S, 2003, CURR BIOL, V13, P1356, DOI 10.1016/S0960-9822(03)00535-9; Park SH, 2003, SCIENCE, V299, P1061, DOI 10.1126/science.1076979; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; Ponting CP, 2002, TRENDS BIOCHEM SCI, V27, P10, DOI 10.1016/S0968-0004(01)02006-0; Posas F, 1998, CURR OPIN MICROBIOL, V1, P175, DOI 10.1016/S1369-5274(98)80008-8; Posas F, 1998, EMBO J, V17, P1385, DOI 10.1093/emboj/17.5.1385; PRINTEN JA, 1994, GENETICS, V138, P609; Ptashne M, 2003, SCIENCE, V299, P1025, DOI 10.1126/science.1081519; Pullikuth A, 2005, MOL CELL BIOL, V25, P5119, DOI 10.1128/MCB.25.12.5119-5133.2005; Qi MS, 2005, J CELL SCI, V118, P3569, DOI 10.1242/jcs.02470; Raabe T, 2003, CURR BIOL, V13, pR635, DOI 10.1016/S0960-9822(03)00568-2; Raman M, 2003, CURR BIOL, V13, pR886, DOI 10.1016/j.cub.2003.10.053; Renganathan H, 2005, BIOCHEM J, V390, P729, DOI 10.1042/BJ20050378; Robidoux J, 2005, MOL CELL BIOL, V25, P5466, DOI 10.1128/MCB.25.13.5466-5479.2005; Roemer T, 1998, J CELL SCI, V111, P479; Roy F, 2002, CURR BIOL, V12, pR325, DOI 10.1016/S0960-9822(02)00831-X; Roy F, 2002, GENE DEV, V16, P427, DOI 10.1101/gad.962902; Roy M, 2005, MOL CELL BIOL, V25, P7940, DOI 10.1128/MCB.25.18.7940-7952.2005; Roy M, 2004, J BIOL CHEM, V279, P17329, DOI 10.1074/jbc.M308405200; RUSSELL M, 1995, J BIOL CHEM, V270, P11757, DOI 10.1074/jbc.270.20.11757; Sabio G, 2005, EMBO J, V24, P1134, DOI 10.1038/sj.emboj.7600578; Schaeffer HJ, 1998, SCIENCE, V281, P1668, DOI 10.1126/science.281.5383.1668; Schermanz K, 2002, CATALY SCI, V2, P1, DOI 10.1142/9781860949654_0001; Schoorlemmer J, 2002, J BIOL CHEM, V277, P49111, DOI 10.1074/jbc.M205520200; Sette C, 2000, MOL BIOL CELL, V11, P4033, DOI 10.1091/mbc.11.11.4033; Shankar S, 2004, MOL REPROD DEV, V69, P186, DOI 10.1002/mrd.20164; Sieburth DS, 1999, GENE DEV, V13, P2562, DOI 10.1101/gad.13.19.2562; Stewart S, 1999, MOL CELL BIOL, V19, P5523; Su B, 1996, CURR OPIN IMMUNOL, V8, P402, DOI 10.1016/S0952-7915(96)80131-2; Sugimoto T, 1998, EMBO J, V17, P1717, DOI 10.1093/emboj/17.6.1717; SUNDARAM M, 1995, CELL, V83, P889, DOI 10.1016/0092-8674(95)90205-8; Takaesu G, 2006, J CELL BIOL, V175, P383, DOI 10.1083/jcb.200608031; Takekawa M, 2005, MOL CELL, V18, P295, DOI 10.1016/j.molcel.2005.04.001; Takino T, 2005, J BIOL CHEM, V280, P37772, DOI 10.1074/jbc.M505241200; Takino T, 2002, ONCOGENE, V21, P6488, DOI 10.1038/sj.onc.1205840; Tapon N, 1998, EMBO J, V17, P1395, DOI 10.1093/emboj/17.5.1395; Taru H, 2002, J BIOL CHEM, V277, P27567, DOI 10.1074/jbc.M203713200; Tatebayashi K, 2003, EMBO J, V22, P3624, DOI 10.1093/emboj/cdg353; Teis D, 2002, DEV CELL, V3, P803, DOI 10.1016/S1534-5807(02)00364-7; THERRIEN M, 1995, CELL, V83, P879, DOI 10.1016/0092-8674(95)90204-X; Therrien M, 1996, GENE DEV, V10, P2684, DOI 10.1101/gad.10.21.2684; Uhlik MT, 2004, BIOCHEM CELL BIOL, V82, P658, DOI 10.1139/O04-114; Uhlik MT, 2003, NAT CELL BIOL, V5, P1104, DOI 10.1038/ncb1071; VALE RD, 1985, CELL, V42, P39, DOI 10.1016/S0092-8674(85)80099-4; Van der Hoeven PCJ, 2000, BIOCHEM J, V345, P297, DOI 10.1042/0264-6021:3450297; Verhey KJ, 2001, J CELL BIOL, V152, P959, DOI 10.1083/jcb.152.5.959; Volmat V, 2001, BIOL CELL, V93, P71, DOI 10.1016/S0248-4900(01)01129-7; Vomastek T, 2004, P NATL ACAD SCI USA, V101, P6981, DOI 10.1073/pnas.0305894101; Whitmarsh AJ, 2006, BIOCHEM SOC T, V34, P828, DOI 10.1042/BST0340828; Whitmarsh AJ, 1998, TRENDS BIOCHEM SCI, V23, P481, DOI 10.1016/S0968-0004(98)01309-7; Whitmarsh AJ, 1998, SCIENCE, V281, P1671, DOI 10.1126/science.281.5383.1671; Whitmarsh AJ, 2001, GENE DEV, V15, P2421, DOI 10.1101/gad.922801; WHITMARSH AJ, 1999, SCI STKE, pPE1, DOI DOI 10.1126/STKE.1999.1.PE1; Willoughby EA, 2005, J BIOL CHEM, V280, P25651, DOI 10.1074/jbc.M501926200; Willoughby EA, 2003, J BIOL CHEM, V278, P10731, DOI 10.1074/jbc.M207324200; Witowsky JA, 2003, J BIOL CHEM, V278, P1403, DOI 10.1074/jbc.C200616200; Wunderlich W, 2001, J CELL BIOL, V152, P765, DOI 10.1083/jcb.152.4.765; Xia Y, 2007, MOL CELL BIOL, V27, P510, DOI 10.1128/MCB.01355-06; Xing HM, 1997, CURR BIOL, V7, P294, DOI 10.1016/S0960-9822(06)00152-7; XU SC, 1995, P NATL ACAD SCI USA, V92, P6808, DOI 10.1073/pnas.92.15.6808; Xu SC, 1996, P NATL ACAD SCI USA, V93, P5291, DOI 10.1073/pnas.93.11.5291; Xu SC, 1997, J BIOL CHEM, V272, P32056, DOI 10.1074/jbc.272.51.32056; Xu ZH, 2003, EMBO J, V22, P252, DOI 10.1093/emboj/cdg021; Yasuda J, 1999, MOL CELL BIOL, V19, P7245; Zarubin T, 2005, CELL RES, V15, P11, DOI 10.1038/sj.cr.7290257; ZHOU ZQ, 1993, MOL CELL BIOL, V13, P2069, DOI 10.1128/MCB.13.4.2069; Ziogas A, 2005, J BIOL CHEM, V280, P24205, DOI 10.1074/jbc.M413327200	162	210	219	2	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 15	2007	26	22					3185	3202		10.1038/sj.onc.1210411	http://dx.doi.org/10.1038/sj.onc.1210411			18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	169PH	17496915				2022-12-28	WOS:000246603600008
J	Goldenberg, DM; Sharkey, RM				Goldenberg, D. M.; Sharkey, R. M.			Novel radiolabeled antibody conjugates	ONCOGENE			English	Review						cancer; monoclonal antibodies; pretargeting; radioimmunotherapy; radionuclides	NON-HODGKINS-LYMPHOMA; MEDULLARY-THYROID CANCER; CEA MONOCLONAL-ANTIBODY; CARCINOEMBRYONIC-ANTIGEN RADIOIMMUNOTHERAPY; GENETICALLY-ENGINEERED ANTIBODIES; INDIUM-111-LABELED DTPA DIMER; I-131-LABELED BIVALENT HAPTEN; METASTATIC COLORECTAL-CANCER; ONCOLOGIC DRUG DEVELOPMENT; PHASE-I TRIAL	This article reviews the development of radioimmuno-conjugates as a new class of cancer therapeutics. Numerous conjugates involving different antigen targets, anti body forms, radionuclides and methods of radiochemistry have been studied in the half-century since radioactive antibodies were first used in model systems to selectively target radiation to tumors. Whereas directly conjugated antibodies, fragments and subfragments have shown promise preclinically, the same approaches have not gained success in patients except in radiosensitive hematological neoplasms, or in settings involving minimal or locoregional disease. The separation of tumor targeting from the delivery of the therapeutic radionuclide in a multistep process called pretargeting has the potential to overcome many of the limitations of conventional, or one-step, radio immunotherapy, with initial preclinical and clinical data showing increased sensitivity, specificity and higher radiation doses delivered. Our particular focus in pretargeting is the use of bispecific, trimeric (three Fab's) constructs made by a new antibody engineering method termed 'dock-and-lock.'	Garden State Canc Ctr, Ctr Mol Med & Immunol, Belleville, NJ 07109 USA		Goldenberg, DM (corresponding author), Garden State Canc Ctr, Ctr Mol Med & Immunol, 820 Belleville Ave, Belleville, NJ 07109 USA.	dmg.gscancer@att.net			NATIONAL CANCER INSTITUTE [P01CA103985] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA103985] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABDELNABI HH, 1990, J NUCL MED, V31, P1975; ABDELNABI HH, 1987, RADIOLOGY, V164, P617, DOI 10.1148/radiology.164.3.3303117; Alvarez RD, 1997, GYNECOL ONCOL, V65, P94, DOI 10.1006/gyno.1996.4577; Alvarez RD, 2002, CLIN CANCER RES, V8, P2806; Axworthy DB, 2000, P NATL ACAD SCI USA, V97, P1802, DOI 10.1073/pnas.97.4.1802; BALE W F, 1957, Adv Biol Med Phys, V5, P285; BALE WF, 1960, CANCER RES, V20, P1488; Batra SK, 2002, CURR OPIN BIOTECH, V13, P603, DOI 10.1016/S0958-1669(02)00352-X; BEHR TM, 1995, CANCER RES, V55, P3825; Binz HK, 2005, NAT BIOTECHNOL, V23, P1257, DOI 10.1038/nbt1127; Boerman OC, 1999, CANCER RES, V59, P4400; Boerman OC, 2003, J NUCL MED, V44, P400; BUCHSBAUM DJ, 1995, CANCER RES, V55, pS5729; Cardillo TM, 2002, INT J CANCER, V97, P386, DOI 10.1002/ijc.1613; Chatal JF, 2006, J CLIN ONCOL, V24, P1705, DOI 10.1200/JCO.2005.04.4917; CHETANNEAU A, 1994, NUCL MED COMMUN, V15, P972, DOI 10.1097/00006231-199412000-00009; Colcher D, 1998, Q J NUCL MED, V42, P225; Crow DM, 2005, BIOCONJUGATE CHEM, V16, P1117, DOI 10.1021/bc0500948; Davis TA, 2004, CLIN CANCER RES, V10, P7792, DOI 10.1158/1078-0432.CCR-04-0756; DENARDO GL, 1995, INT J BIOL MARKER, V10, P67, DOI 10.1177/172460089501000201; DeNardo SJ, 1997, P NATL ACAD SCI USA, V94, P4000, DOI 10.1073/pnas.94.8.4000; DeNardo SJ, 1997, J NUCL MED, V38, P1180; FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182; Forero A, 2005, CANCER BIOTHER RADIO, V20, P467, DOI 10.1089/cbr.2005.20.467; Gautherot E, 1997, CANCER, V80, P2618; Gautherot E, 2000, J NUCL MED, V41, P480; Gestin JF, 2001, J NUCL MED, V42, P146; Goetz C, 2003, J NEURO-ONCOL, V62, P321, DOI 10.1023/A:1023309927635; Gold DV, 2003, CLIN CANCER RES, V9, p3929S; Goldenberg D M, 1990, Cancer Treat Res, V51, P273; Goldenberg D M, 1997, J Nucl Med Technol, V25, P18; Goldenberg D. M., 1992, International Journal of Biological Markers, V7, P183; GOLDENBERG DM, 1980, SCIENCE, V208, P1284, DOI 10.1126/science.7375942; GOLDENBERG DM, 1974, CANCER RES, V34, P1; GOLDENBERG DM, 1990, CANCER RES, V50, pS909; GOLDENBERG DM, 1992, J NUCL MED, V33, P803; Goldenberg DM, 2006, J CLIN ONCOL, V24, P823, DOI 10.1200/JCO.2005.03.8471; GOLDENBERG DM, 1978, NEW ENGL J MED, V298, P1384, DOI 10.1056/NEJM197806222982503; GOLDENBERG DM, 1991, J CLIN ONCOL, V9, P548, DOI 10.1200/JCO.1991.9.4.548; GOLDENBERG DM, 1993, J NUCL MED, V34, P61; Goldenberg DM, 2001, CRIT REV ONCOL HEMAT, V39, P195; GOODWIN DA, 1994, CANCER RES, V54, P5937; GOODWIN DA, 1986, NUCL MED BIOL, V13, P383, DOI 10.1016/0883-2897(86)90015-2; Graves SS, 2003, CLIN CANCER RES, V9, P3712; Griffiths GL, 2004, J NUCL MED, V45, P30; Hernandez MC, 2004, INT J RADIAT ONCOL, V59, P1274, DOI 10.1016/j.ijrobp.2004.02.065; JAIN R K, 1991, Current Opinion in Oncology, V3, P1105, DOI 10.1097/00001622-199112000-00020; Jana S, 2006, SEMIN NUCL MED, V36, P51, DOI 10.1053/j.semnuclmed.2005.09.001; KAMINSKI MS, 1993, NEW ENGL J MED, V329, P459, DOI 10.1056/NEJM199308123290703; Karacay H, 2000, BIOCONJUGATE CHEM, V11, P842, DOI 10.1021/bc0000379; Karacay H, 2005, CLIN CANCER RES, V11, P7879, DOI 10.1158/1078-0432.CCR-05-1246; Karacay H, 2002, BIOCONJUGATE CHEM, V13, P1054, DOI 10.1021/bc0200172; Kelloff G, 2005, CLIN CANCER RES, V11, P2785, DOI 10.1158/1078-0432.CCR-04-2626; Kelloff GJ, 2005, CLIN CANCER RES, V11, P7967, DOI 10.1158/1078-0432.CCR-05-1302; Kelly MP, 2006, J NUCL MED, V47, P716; Kenanova Vania, 2006, Expert Opin Drug Deliv, V3, P53, DOI 10.1517/17425247.3.1.53; KIM EE, 1980, CANCER RES, V40, P3008; KORNGOLD L, 1954, CANCER RES, V14, P96; Kraeber-Bodere F, 2006, J NUCL MED, V47, P247; Kraeber-Bodere F, 2003, CLIN CANCER RES, V9, p3973S; Kraeber-Bodere F, 2002, MOL CANCER THER, V1, P267; Kraeber-Bodere F, 1999, CLIN CANCER RES, V5, p3190S; LAMKI LM, 1990, RADIOLOGY, V174, P147, DOI 10.1148/radiology.174.1.2294542; LARSON SM, 1990, CANCER RES, V50, pS892; LEDOUSSAL JM, 1993, J NUCL MED, V34, P1662; LEDOUSSAL JM, 1989, J NUCL MED, V30, P1358; Liersch T, 2005, J CLIN ONCOL, V23, P6763, DOI 10.1200/JCO.2005.18.622; MACH JP, 1980, ONCODEV BIOL MED, V1, P49; MACH JP, 1983, CANCER RES, V43, P5593; Mahe MA, 1999, CLIN CANCER RES, V5, p3249S; Masters GR, 2006, GYNECOL ONCOL, V102, P462, DOI 10.1016/j.ygyno.2005.12.004; McBride WJ, 2006, J NUCL MED, V47, P1678; MCCARDLE RJ, 1966, J NUCL MED, V7, P837; Meredith RF, 2001, CANCER BIOTHER RADIO, V16, P305, DOI 10.1089/108497801753131381; Meredith RF, 2006, INT J RADIAT ONCOL, V66, pS23, DOI 10.1016/j.ijrobp.2006.05.068; Meredith RF, 2006, INT J RADIAT ONCOL, V66, pS15, DOI 10.1016/j.ijrobp.2006.04.059; MURRAY JL, 1994, CANCER, V73, P1057, DOI 10.1002/1097-0142(19940201)73:3+<1057::AID-CNCR2820731345>3.0.CO;2-3; Paganelli G, 2006, NEUROL RES, V28, P518, DOI 10.1179/016164106X116782; PATT YZ, 1990, J CLIN ONCOL, V8, P1246, DOI 10.1200/JCO.1990.8.7.1246; PELTIER P, 1993, J NUCL MED, V34, P1267; PRESSMAN D, 1953, CANCER, V6, P619, DOI 10.1002/1097-0142(195305)6:3<619::AID-CNCR2820060319>3.0.CO;2-Y; REARDAN DT, 1985, NATURE, V316, P265, DOI 10.1038/316265a0; Reardon DA, 2006, J CLIN ONCOL, V24, P115, DOI 10.1200/JCO.2005.03.4082; Richman CM, 2005, CLIN CANCER RES, V11, P5920, DOI 10.1158/1078-0432.CCR-05-0211; Riva P, 1999, ACTA ONCOL, V38, P351; Rossi EA, 2006, P NATL ACAD SCI USA, V103, P6841, DOI 10.1073/pnas.0600982103; Rossi EA, 2005, CLIN CANCER RES, V11, p7122S, DOI 10.1158/1078-0432.CCR-1004-0020; Rossi EA, 2003, CLIN CANCER RES, V9, p3886S; Sharkey RM, 2006, CANCER INVEST, V24, P82, DOI 10.1080/07357900500449553; Sharkey RM, 2005, CLIN CANCER RES, V11, p7109S, DOI 10.1158/1078-0432.CCR-1004-0009; Sharkey RM, 2005, NAT MED, V11, P1250, DOI 10.1038/nm1322; Sharkey RM, 2005, LEUKEMIA, V19, P1064, DOI 10.1038/sj.leu.2403751; Sharkey RM, 2005, J NUCL MED, V46, P620; SHARKEY RM, 1990, CANCER RES, V50, P2330; Sharkey RM, 2005, J NUCL MED, V46, p115S; Sharkey RM, 2003, J NUCL MED, V44, P2000; Sharkey RM, 2003, CLIN CANCER RES, V9, p3897S; Sharkey RM, 2003, CANCER RES, V63, P354; SHARKEY RM, 2007, IN PRESS CLIN CANC R; SIEGEL JA, 1990, CANCER RES, V50, pS1039; SLAVINCHIORINI DC, 1993, INT J CANCER, V53, P97, DOI 10.1002/ijc.2910530119; STICKNEY DR, 1991, CANCER RES, V51, P6650; Unterhalt M, 2006, ANN HEMATOL, V85, P36; VANNAGELL JR, 1980, CANCER RES, V40, P502; Vuillez JP, 1999, CLIN CANCER RES, V5, p3259S; Wittel UA, 2005, NUCL MED BIOL, V32, P157, DOI 10.1016/j.nucmedbio.2004.11.003; Witzig TE, 2002, J CLIN ONCOL, V20, P2453, DOI 10.1200/JCO.2002.11.076; Witzig TE, 2006, BEST PRACT RES CL HA, V19, P655, DOI 10.1016/j.beha.2006.05.002; Wong JYC, 2006, INT J RADIAT ONCOL, V66, pS74, DOI 10.1016/j.ijrobp.2005.05.029; Wong JYC, 2003, CLIN CANCER RES, V9, P5842; Wu Anna M, 2004, Methods Mol Biol, V248, P209; Zalutsky MR, 2006, J NUCL MED, V47, P1238; Zalutsky MR, 2006, CLIN CANCER RES, V12, P1958, DOI 10.1158/1078-0432.CCR-06-0405	113	56	67	1	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2007	26	25					3734	3744		10.1038/sj.onc.1210373	http://dx.doi.org/10.1038/sj.onc.1210373			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	172PK	17530026	Green Published			2022-12-28	WOS:000246816100015
J	Hussain, SP; Schwank, J; Staib, F; Wang, XW; Harris, CC				Hussain, S. P.; Schwank, J.; Staib, F.; Wang, X. W.; Harris, C. C.			TP53 mutations and hepatocellular carcinoma: insights into the etiology and pathogenesis of liver cancer	ONCOGENE			English	Review						hepatocellular carcinoma; p53; aflatoxin B-1; HBV; HCV; oxidative/nitrosative stress	HEPATITIS-B-VIRUS; NITRIC-OXIDE SYNTHASE; P53 TUMOR-SUPPRESSOR; DIFFERENTIAL GENE-EXPRESSION; NUCLEOTIDE EXCISION-REPAIR; CHRONIC VIRAL-HEPATITIS; X-PROTEIN; DNA-REPAIR; TRANSCRIPTION FACTOR; AFLATOXIN EXPOSURE	Hepatocellular carcinoma (HCC) is one of the most common malignancies worldwide and the major risk factors include chronic infections with the hepatitis B (HBV) or C (HCV) virus, and exposure to dietary aflatoxin B-1 (AFB(1)) or alcohol consumption. Multiple genetic and epigenetic changes are involved in the molecular pathogenesis of HCC, for example, somatic mutations in the p53 tumor suppressor gene (TP53) and the activation of the WNT signal transduction pathway. AFB1 frequently induces G: C to T: A transversions at the third base in codon 249 of TP53 and cooperates with HBV in causing p53 mutations in HCC. The detection of TP53 mutant DNA in plasma is a biomarker of both AFB1 exposure and HCC risk. Chronic infection with HBV and HCV viruses, and oxyradical disorders including hemochromatosis, also generate reactive oxygen/nitrogen species that can both damage DNA and mutate cancer-related genes such as TP53. Certain mutant p53 proteins may exhibit a 'gain of oncogenic function'. The p53 biological network is a key responder to this oxidative and nitrosative stress. Depending on the extent of the DNA damage, p53 regulates the transcription of protective antioxidant genes and with extensive DNA damage, transactivates pro-oxidant genes that contribute to apoptosis. The X gene of HBV (HBx) is the most common open reading frame integrated into the host genome in HCC and the integrated HBx is frequently mutated. Mutant HBx proteins still retain their ability to bind to p53, and attenuate DNA repair and p53-mediated apoptosis. In summary, both viruses and chemicals are implicated in the etiology of TP53 mutations during the molecular pathogenesis of HCC.	NCI, Lab Human Carcinogenesis, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Harris, CC (corresponding author), NCI, Lab Human Carcinogenesis, NIH, Bldg 37,Room 3068, Bethesda, MD 20892 USA.	Curtis_Harris@nih.gov	Wang, Xin Wei/B-6162-2009	Wang, Xin Wei/0000-0001-9735-606X; Hussain, S. Perwez/0000-0002-2294-522X	NATIONAL CANCER INSTITUTE [ZIABC005480, ZIABC010313, Z01BC005480, Z01BC010313, Z01BC005795, ZIABC005795] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AGUILAR F, 1993, P NATL ACAD SCI USA, V90, P8586, DOI 10.1073/pnas.90.18.8586; AGUILAR F, 1994, SCIENCE, V264, P1317, DOI 10.1126/science.8191284; Amaro MJ, 1999, HEPATOLOGY, V29, P915, DOI 10.1002/hep.510290337; Ambs S, 1998, BRIT J CANCER, V78, P233, DOI 10.1038/bjc.1998.470; Ambs S, 1998, P NATL ACAD SCI USA, V95, P8823, DOI 10.1073/pnas.95.15.8823; Ambs S, 1999, J NATL CANCER I, V91, P86, DOI 10.1093/jnci/91.1.86; Ambs S, 1997, FASEB J, V11, P443, DOI 10.1096/fasebj.11.6.9194524; Araki Y, 2003, CANCER RES, V63, P728; Arbuthnot P, 2000, J GASTROEN HEPATOL, V15, P357, DOI 10.1046/j.1440-1746.2000.02069.x; Becker SA, 1998, J VIROL, V72, P266, DOI 10.1128/JVI.72.1.266-272.1998; BENNETT MR, 1995, CIRC RES, V77, P266, DOI 10.1161/01.RES.77.2.266; Bensaad K, 2006, CELL, V126, P107, DOI 10.1016/j.cell.2006.05.036; Bergsland EK, 2001, SEMIN ONCOL, V28, P521, DOI 10.1053/sonc.2001.26955; BREDT DS, 1994, ANNU REV BIOCHEM, V63, P175, DOI 10.1146/annurev.bi.63.070194.001135; BRESSAC B, 1991, NATURE, V350, P429, DOI 10.1038/350429a0; Buchanan FG, 2006, CANCER CELL, V9, P6, DOI 10.1016/j.ccr.2005.12.029; Budhu A, 2006, CANCER CELL, V10, P99, DOI 10.1016/j.ccr.2006.06.016; Budhu AS, 2005, ONCOLOGY-BASEL, V69, P23, DOI 10.1159/000086628; BUSS P, 1990, CARCINOGENESIS, V11, P2133, DOI 10.1093/carcin/11.12.2133; Castellone MD, 2005, SCIENCE, V310, P1504, DOI 10.1126/science.1116221; CERUTTI P, 1994, CANCER RES, V54, pS1934; Chan DW, 2006, J PATHOL, V208, P372, DOI 10.1002/path.1901; deVera ME, 1996, P NATL ACAD SCI USA, V93, P1054, DOI 10.1073/pnas.93.3.1054; Devereux TR, 2001, MOL CARCINOGEN, V31, P68, DOI 10.1002/mc.1041; DIBISCEGLIE AM, 1988, ANN INTERN MED, V108, P390, DOI 10.7326/0003-4819-108-3-390; Dominguez-Malagon H, 2001, ULTRASTRUCT PATHOL, V25, P497, DOI 10.1080/019131201753343539; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Dou J, 2005, J NANOSCI NANOTECHNO, V5, P1230, DOI 10.1166/jnn.2005.209; Du QA, 2006, CANCER RES, V66, P7024, DOI 10.1158/0008-5472.CAN-05-4110; DUMENCO L, 1995, HEPATOLOGY, V22, P1279, DOI 10.1016/0270-9139(95)90640-1; El-Serag HB, 1999, NEW ENGL J MED, V340, P745, DOI 10.1056/NEJM199903113401001; Elmore LW, 1997, P NATL ACAD SCI USA, V94, P14707, DOI 10.1073/pnas.94.26.14707; Farazi PA, 2006, NAT REV CANCER, V6, P674, DOI 10.1038/nrc1934; Farazi PA, 2006, CANCER RES, V66, P4766, DOI 10.1158/0008-5472.CAN-05-4608; FEITELSON MA, 1993, ONCOGENE, V8, P1109; FORRESTER K, 1995, ONCOGENE, V10, P2103; Forrester K, 1996, P NATL ACAD SCI USA, V93, P2442, DOI 10.1073/pnas.93.6.2442; FORSTERMANN U, 1995, N-S ARCH PHARMACOL, V352, P351; Fujimoto H, 1998, JPN J CANCER RES, V89, P696, DOI 10.1111/j.1349-7006.1998.tb03273.x; FUJITSUKA M, 1992, SYNTHETIC MET, V53, P1, DOI 10.1016/0379-6779(92)90002-Z; Fukutomi T, 2005, HEPATOLOGY, V41, P1096, DOI 10.1002/hep.20668; GONZALEZAMARO R, 1994, J EXP MED, V179, P841, DOI 10.1084/jem.179.3.841; Groisman IJ, 1999, CARCINOGENESIS, V20, P479, DOI 10.1093/carcin/20.3.479; Guengerich FP, 1996, ENVIRON HEALTH PERSP, V104, P557, DOI 10.2307/3432823; Gupta RA, 2001, NAT REV CANCER, V1, P11, DOI 10.1038/35094017; Hentze MW, 1996, P NATL ACAD SCI USA, V93, P8175, DOI 10.1073/pnas.93.16.8175; HILL AB, 1965, P ROY SOC MED, V58, P295, DOI 10.1177/003591576505800503; HOFSETH LJ, 2002, GASTROINTESTINAL ONC, P539; Honda M, 2001, GASTROENTEROLOGY, V120, P955, DOI 10.1053/gast.2001.22468; HSU IC, 1991, NATURE, V350, P427, DOI 10.1038/350427a0; Huo TI, 2001, ONCOGENE, V20, P3620, DOI 10.1038/sj.onc.1204495; Hussain SP, 2003, NAT REV CANCER, V3, P276, DOI 10.1038/nrc1046; Hussain SP, 1998, CANCER RES, V58, P4023; Hussain SP, 2001, LUNG CANCER, V34, pS7, DOI 10.1016/S0169-5002(01)00339-7; Hussain SP, 2004, CANCER RES, V64, P2350, DOI 10.1158/0008-5472.CAN-2287-2; Jia L, 1999, INT J CANCER, V80, P875, DOI 10.1002/(SICI)1097-0215(19990315)80:6<875::AID-IJC13>3.3.CO;2-Q; JIA L, 1997, MOL PATHOLOGY GASTRO, P209; Kane JM, 1997, J SURG RES, V69, P321, DOI 10.1006/jsre.1997.5057; Kew MC, 2003, LIVER INT, V23, P405, DOI 10.1111/j.1478-3231.2003.00869.x; Kim SF, 2005, SCIENCE, V310, P1966, DOI 10.1126/science.1119407; Kirk GD, 2005, ONCOGENE, V24, P5858, DOI 10.1038/sj.onc.1208732; Kirk GD, 2000, JNCI-J NATL CANCER I, V92, P148, DOI 10.1093/jnci/92.2.148; Kondo M, 1999, CLIN CANCER RES, V5, P4005; Kowdley KV, 2004, GASTROENTEROLOGY, V127, pS79, DOI 10.1016/j.gastro.2004.09.019; KRESS S, 1992, CANCER RES, V52, P3220; Kuang SY, 2005, CANCER EPIDEM BIOMAR, V14, P380, DOI 10.1158/1055-9965.EPI-04-0380; Kuang SY, 2004, P NATL ACAD SCI USA, V101, P3575, DOI 10.1073/pnas.0308232100; Laskin DL, 1998, TOXICOL LETT, V103, P289, DOI 10.1016/S0378-4274(98)00316-6; Lee JS, 2006, ONCOGENE, V25, P3801, DOI 10.1038/sj.onc.1209561; Lee SG, 2000, ONCOGENE, V19, P468, DOI 10.1038/sj.onc.1203312; LI DZ, 1993, CARCINOGENESIS, V14, P169, DOI 10.1093/carcin/14.2.169; LIU RH, 1994, CARCINOGENESIS, V15, P2875, DOI 10.1093/carcin/15.12.2875; Lombard DB, 2000, CANCER RES, V60, P2331; LUCITO R, 1992, J VIROL, V66, P983, DOI 10.1128/JVI.66.2.983-991.1992; Lunn RM, 1997, CANCER RES, V57, P3471; Mace K, 1997, CARCINOGENESIS, V18, P1291, DOI 10.1093/carcin/18.7.1291; Madden CR, 2002, J VIROL, V76, P11770, DOI 10.1128/JVI.76.22.11770-11774.2002; Majano PL, 1998, J CLIN INVEST, V101, P1343, DOI 10.1172/JCI774; MARLETTA MA, 1993, J BIOL CHEM, V268, P12231; Marrogi AJ, 2001, JNCI-J NATL CANCER I, V93, P1652, DOI 10.1093/jnci/93.21.1652; Mathonnet G, 2004, MUTAT RES-FUND MOL M, V554, P305, DOI 10.1016/j.mrfmmm.2004.05.010; Messmer UK, 1996, BIOCHEM J, V319, P299, DOI 10.1042/bj3190299; Mihm S, 1996, MED MICROBIOL IMMUN, V185, P95, DOI 10.1007/s004300050020; Ming L, 2002, HEPATOLOGY, V36, P1214, DOI 10.1053/jhep.2002.36366; Miura N, 1997, CANCER GENET CYTOGEN, V93, P56, DOI 10.1016/S0165-4608(96)00329-9; MONCADA S, 1991, PHARMACOL REV, V43, P109; MOWAT M, 1990, ONCOGENE, V5, P241; Murakami S, 2001, J GASTROENTEROL, V36, P651, DOI 10.1007/s005350170027; NATHAN C, 1994, CELL, V78, P915, DOI 10.1016/0092-8674(94)90266-6; NUSSLER AK, 1992, J EXP MED, V176, P261, DOI 10.1084/jem.176.1.261; ODA T, 1992, CANCER RES, V52, P6358; Okada T, 2003, FEBS LETT, V555, P583, DOI 10.1016/S0014-5793(03)01345-0; Olivier Magali, 2004, IARC Sci Publ, P247; OZTURK M, 1991, LANCET, V338, P1356, DOI 10.1016/0140-6736(91)92236-U; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Pisani P, 1999, INT J CANCER, V83, P18, DOI 10.1002/(SICI)1097-0215(19990924)83:1&lt;18::AID-IJC5&gt;3.0.CO;2-M; PONCHEL F, 1994, CANCER RES, V54, P2064; PUISIEUX A, 1995, P NATL ACAD SCI USA, V92, P1342, DOI 10.1073/pnas.92.5.1342; Qadri I, 1996, P NATL ACAD SCI USA, V93, P10578, DOI 10.1073/pnas.93.20.10578; QIAN GS, 1994, CANCER EPIDEM BIOMAR, V3, P3; ROSS RK, 1992, LANCET, V339, P943, DOI 10.1016/0140-6736(92)91528-G; Sablina AA, 2005, NAT MED, V11, P1306, DOI 10.1038/nm1320; SCHAEFFER L, 1993, SCIENCE, V260, P58, DOI 10.1126/science.8465201; SCORSONE KA, 1992, CANCER RES, V52, P1635; Sengupta S, 2005, NAT REV MOL CELL BIO, V6, P44, DOI 10.1038/nrm1546; Shackel NA, 2002, AM J PATHOL, V160, P641, DOI 10.1016/S0002-9440(10)64884-5; Sherman M, 1995, Gastroenterologist, V3, P55; Sirma H, 1999, ONCOGENE, V18, P4848, DOI 10.1038/sj.onc.1202867; Staib F, 2005, CANCER RES, V65, P10255, DOI 10.1158/0008-5472.CAN-05-1714; Staib F, 2003, HUM MUTAT, V21, P201, DOI 10.1002/humu.10176; Stewart BW, 2003, WORLD CANC REPORT, P1; TAMIR S, 1996, BIOCHIM BIOPHYS ACTA, V1288, P31; Tan MJ, 1999, J BIOL CHEM, V274, P12061, DOI 10.1074/jbc.274.17.12061; Tang H, 2006, CANCER SCI, V97, P977, DOI 10.1111/j.1349-7006.2006.00299.x; Thorgeirsson SS, 2002, NAT GENET, V31, P339, DOI 10.1038/ng0802-339; Tong WM, 2006, INT J CANCER, V119, P745, DOI 10.1002/ijc.21890; Tu H, 2001, CANCER RES, V61, P7803; UEDA H, 1995, NAT GENET, V9, P41, DOI 10.1038/ng0195-41; UNSAL H, 1994, P NATL ACAD SCI USA, V91, P822, DOI 10.1073/pnas.91.2.822; Vodovotz Y, 2004, CURR MOL MED, V4, P753, DOI 10.2174/1566524043359944; WANG XW, 1995, CANCER RES, V55, P6012; WANG XW, 1994, P NATL ACAD SCI USA, V91, P2230, DOI 10.1073/pnas.91.6.2230; Wang XW, 2002, TOXICOLOGY, V181, P43, DOI 10.1016/S0300-483X(02)00253-6; WILD CP, 1986, J CELL BIOCHEM, V30, P171, DOI 10.1002/jcb.240300206; XIE QW, 1992, SCIENCE, V256, P225, DOI 10.1126/science.1373522; Ye QH, 2003, NAT MED, V9, P416, DOI 10.1038/nm843; Yoon KA, 2004, J HUM GENET, V49, P134, DOI 10.1007/s10038-003-0122-3; Yu MC, 2004, GASTROENTEROLOGY, V127, pS72, DOI 10.1016/j.gastro.2004.09.018	128	412	436	4	64	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 2	2007	26	15					2166	2176		10.1038/sj.onc.1210279	http://dx.doi.org/10.1038/sj.onc.1210279			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	152XE	17401425				2022-12-28	WOS:000245394800005
J	Bond, GL; Levine, AJ				Bond, G. L.; Levine, A. J.			A single nucleotide polymorphism in the p53 pathway interacts with gender, environmental stresses and tumor genetics to influence cancer in humans	ONCOGENE			English	Review						MDM2; polymorphism; cancer; gender; stress; mutation	MDM2 PROMOTER POLYMORPHISM; ESTROGEN-RECEPTOR-ALPHA; SQUAMOUS-CELL CARCINOMA; LI-FRAUMENI-SYNDROME; BREAST-CANCER; LUNG-CANCER; COLORECTAL-CANCER; CHINESE POPULATION; PROTEIN EXPRESSION; NO ASSOCIATION	Cancer biology finds itself in a post-genomic era and the hopes of using inherited genetic variants to improve prevention and treatment strategies are widespread. One of the largest types of inherited genetic variation is the single nucleotide polymorphism (SNP), of which there are at least 4.5 million. The challenge now becomes how to discover which polymorphisms alter cancer in humans and how to begin to understand their mechanism of action. In this report, a series of recent publications will be reviewed that have studied a polymorphism in the p53 tumor suppressor pathway, MDM2 SNP309. These reports have lent insights into how germline genetic variants of the p53 pathway could interact with gender, environmental stresses and tumor genetics to affect cancer in humans. Importantly, these observations have also exposed potential nodes of intervention, which could prove valuable in both the prevention and treatment of this disease in humans.	Inst Adv Study, Simons Ctr Syst Biol, Princeton, NJ 08540 USA; Canc Inst New Jersey, New Brunswick, NJ USA	Institute for Advanced Study - USA; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey	Levine, AJ (corresponding author), Inst Adv Study, Simons Ctr Syst Biol, Princeton, NJ 08540 USA.	alevine@ias.edu						Alhopuro P, 2005, J MED GENET, V42, P694, DOI 10.1136/jmg.2005.031260; ALLAZZOUZI H, 2006, J MED GENET; Alt JR, 2003, EMBO J, V22, P1442, DOI 10.1093/emboj/cdg133; Arva NC, 2005, J BIOL CHEM, V280, P26776, DOI 10.1074/jbc.M505203200; Beckmann MW, 1997, J MOL MED, V75, P429, DOI 10.1007/s001090050128; Boersma BJ, 2006, J NATL CANCER I, V98, P911, DOI 10.1093/jnci/djj245; Bond GL, 2006, J MED GENET, V43, P950, DOI 10.1136/jmg.2006.043539; Bond GL, 2006, CANCER RES, V66, P5104, DOI 10.1158/0008-5472.CAN-06-0180; Bond GL, 2005, CANCER RES, V65, P5481, DOI 10.1158/0008-5472.CAN-05-0825; Bond GL, 2005, CURR CANCER DRUG TAR, V5, P3, DOI 10.2174/1568009053332627; Bond GL, 2004, CELL, V119, P591, DOI 10.1016/j.cell.2004.11.022; Bougeard G, 2006, J MED GENET, V43, P531, DOI 10.1136/jmg.2005.037952; Campbell IG, 2006, CANCER LETT, V240, P195, DOI 10.1016/j.canlet.2005.09.003; Copson ER, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-80; DeMarini DM, 2004, MUTAT RES-REV MUTAT, V567, P447, DOI 10.1016/j.mrrev.2004.02.001; Dharel N, 2006, CLIN CANCER RES, V12, P4867, DOI 10.1158/1078-0432.CCR-06-0111; Elledge RM, 2000, INT J CANCER, V89, P111, DOI 10.1002/(SICI)1097-0215(20000320)89:2<111::AID-IJC2>3.3.CO;2-N; Freedman DA, 1999, CELL MOL LIFE SCI, V55, P96, DOI 10.1007/s000180050273; Ganguli G, 2000, EMBO J, V19, P5135, DOI 10.1093/emboj/19.19.5135; GUDAS JM, 1995, CLIN CANCER RES, V1, P71; Hong Y, 2005, CANCER RES, V65, P9582, DOI 10.1158/0008-5472.CAN-05-1460; Hu ZB, 2006, INT J CANCER, V118, P1275, DOI 10.1002/ijc.21463; Johnson TM, 2006, CELL DEATH DIFFER, V13, P902, DOI 10.1038/sj.cdd.4401902; Jones SN, 1998, P NATL ACAD SCI USA, V95, P15608, DOI 10.1073/pnas.95.26.15608; Khan S, 2003, ENDOCRINOLOGY, V144, P2325, DOI 10.1210/en.2002-0149; Kinyamu HK, 2003, MOL CELL BIOL, V23, P5867, DOI 10.1128/MCB.23.16.5867-5881.2003; Lane DP, 2005, COLD SH Q B, V70, P489, DOI 10.1101/sqb.2005.70.049; Levrero M, 2006, ONCOGENE, V25, P3834, DOI 10.1038/sj.onc.1209562; Li GJ, 2006, CARCINOGENESIS, V27, P2028, DOI 10.1093/carcin/bgl047; Lind H, 2006, INT J CANCER, V119, P718, DOI 10.1002/ijc.21872; Lundgren K, 1997, GENE DEV, V11, P714, DOI 10.1101/gad.11.6.714; Ma HX, 2006, CANCER LETT, V240, P261, DOI 10.1016/j.canlet.2005.09.019; MARCHETTI A, 1995, J PATHOL, V175, P31, DOI 10.1002/path.1711750106; Mendrysa SM, 2006, GENE DEV, V20, P16, DOI 10.1101/gad.1378506; Menin C, 2006, J NATL CANCER I, V98, P285, DOI 10.1093/jnci/djj054; Millikan RC, 2006, CANCER EPIDEM BIOMAR, V15, P175, DOI 10.1158/1055-9965.EPI-05-0692; Ohkubo S, 2006, J BIOL CHEM, V281, P16943, DOI 10.1074/jbc.M601388200; Ohmiya N, 2006, J CLIN ONCOL, V24, P4434, DOI 10.1200/JCO.2005.04.1459; Okumura N, 2002, ONCOL REP, V9, P557; Olivier M, 2002, HUM MUTAT, V19, P607, DOI 10.1002/humu.10081; Onel K, 2004, MOL CANCER RES, V2, P1; Osborne CK, 1998, BREAST CANCER RES TR, V51, P227, DOI 10.1023/A:1006132427948; Park SH, 2006, LUNG CANCER, V54, P19, DOI 10.1016/j.lungcan.2006.06.008; Petz LN, 2004, J STEROID BIOCHEM, V88, P113, DOI 10.1016/j.jsbmb.2003.11.008; Pharoah PDP, 1999, BRIT J CANCER, V80, P1968, DOI 10.1038/sj.bjc.6690628; Phelps M, 2003, CANCER RES, V63, P2616; Pine SR, 2006, CANCER EPIDEM BIOMAR, V15, P1559, DOI 10.1158/1055-9965.EPI-06-0217; Poyurovsky MV, 2006, GENE DEV, V20, P125, DOI 10.1101/gad.1397506; Royds JA, 2006, CELL DEATH DIFFER, V13, P1017, DOI 10.1038/sj.cdd.4401913; Ruijs MWG, 2007, EUR J HUM GENET, V15, P110, DOI 10.1038/sj.ejhg.5201715; SHEIKH MS, 1993, CANCER RES, V53, P3226; Sotamaa K, 2005, CLIN CANCER RES, V11, P6840, DOI 10.1158/1078-0432.CCR-05-1139; Stoner M, 2004, ONCOGENE, V23, P1052, DOI 10.1038/sj.onc.1207201; Swinney RM, 2005, LEUKEMIA, V19, P1996, DOI 10.1038/sj.leu.2403941; Wilkening S, 2006, CANCER RES, V66, P646, DOI 10.1158/0008-5472.CAN-05-3168; Zhang XM, 2006, HUM MUTAT, V27, P110, DOI 10.1002/humu.20277	56	136	142	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 26	2007	26	9					1317	1323		10.1038/sj.onc.1210199	http://dx.doi.org/10.1038/sj.onc.1210199			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	141DU	17322917				2022-12-28	WOS:000244558700009
J	Goto, T; Takano, M; Albergaria, A; Briese, J; Pomeranz, K; Cloke, B; Fusi, L; Feroze-Zaidi, F; Maywald, N; Sajin, M; Dina, R; Ishihara, O; Takeda, S; Lam, EF; Bamberger, A; Ghaem-Maghami, S; Brosens, J				Goto, T.; Takano, M.; Albergaria, A.; Briese, J.; Pomeranz, K. M.; Cloke, B.; Fusi, L.; Feroze-Zaidi, F.; Maywald, N.; Sajin, M.; Dina, R. E.; Ishihara, O.; Takeda, S.; Lam, EW-F; Bamberger, A. M.; Ghaem-Maghami, S.; Brosens, J. J.			Mechanism and functional consequences of loss of FOXO1 expression in endometrioid endometrial cancer cells	ONCOGENE			English	Article						endometrial cancer; FOXO1; phosphatidylinositol-3 kinase/Akt; transcription; paclitaxel; GADD45 alpha	FORKHEAD TRANSCRIPTION FACTOR; ESTROGEN-RECEPTOR-ALPHA; BREAST-CANCER; STROMAL CELLS; PROTEIN; KINASE; PATHWAY; STRESS; FKHR; AKT	The forkhead transcription factor FOXO1, a downstream target of phosphatidylinositol-3-kinase/Akt signalling pathway, regulates cyclic differentiation and apoptosis in normal endometrium, but its role in endometrial carcinogenesis is unknown. Screening of endometrial cancer cell lines demonstrated that FOXO1 is expressed in HEC-1B cells, but not in Ishikawa cells, which in turn highly express the FOXO1 targeting E3-ubiquitin ligase Skp2. FOXO1 transcript levels were also lower in Ishikawa cells and treatment with the proteasomal inhibitor was insufficient to restore expression. Lack of FOXO1 expression in Ishikawa cells was not accounted for by differential promoter methylation or activity, but correlated with increased messenger RNA (mRNA) turnover. Comparative analysis demonstrated that HEC-1B cells proliferate slower, but are more resistant to paclitaxel-mediated cell death than Ishikawa cells, which were partially reversed upon silencing of FOXO1 in HEC-1B cells or its re-expression in Ishikawa cells. We further show that FOXO1 is required for the expression of the growth arrest-and DNA-damage-inducible gene GADD45 alpha. Analysis of biopsy samples demonstrated a marked loss of FOXO1 and GADD45 alpha mRNA and protein expression in endometrioid endometrial cancer compared to normal endometrium. Together, these observations suggest that loss of FOXO1 perturbs endometrial homeostasis, promotes uncontrolled cell proliferation and increases susceptibility to genotoxic insults.	[Goto, T.; Takano, M.; Cloke, B.; Fusi, L.; Feroze-Zaidi, F.; Ghaem-Maghami, S.; Brosens, J. J.] Univ London Imperial Coll Sci Technol & Med, Fac Med, Inst Reprod & Dev Biol, Hammersmith Hosp, London W12 0NN, England; [Albergaria, A.; Pomeranz, K. M.; Lam, EW-F] Univ London Imperial Coll Sci Technol & Med, Canc Res UK Labs, Dept Oncol, London, England; [Albergaria, A.; Pomeranz, K. M.; Lam, EW-F] Hammersmith Hosp, Sect Canc Cell Biol, London, England; [Briese, J.; Maywald, N.; Bamberger, A. M.] Univ Clin Hamburg, Sect Endocrinol & Metab Ageing, Dept Pathol, Hamburg, Germany; [Sajin, M.] Univ Bucharest, Dept Morphopathol, Bucharest, Romania; [Dina, R. E.] Univ London Imperial Coll Sci Technol & Med, Dept Histopathol, London, England; [Ishihara, O.; Takeda, S.] Saitama Med Univ, Dept Obstet & Gynaecol, Saitama, Japan; [Takano, M.] Univ Minho, Life & Hlth Sci Res Inst ICVS, Sch Hlth Sci, Braga, Portugal	Imperial College London; Cancer Research UK; Imperial College London; Imperial College London; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Bucharest; Imperial College London; Saitama Medical University; Universidade do Minho	Brosens, J (corresponding author), Univ London Imperial Coll Sci Technol & Med, Fac Med, Inst Reprod & Dev Biol, Hammersmith Hosp, London W12 0NN, England.	j.brosens@imperial.ac.uk	Lam, Eric W-F/AAW-8566-2020; Albergaria, André/J-6162-2013	Lam, Eric W-F/0000-0003-1274-3576; Albergaria, André/0000-0002-2315-2360; Ghaem-Maghami, Sadaf/0000-0002-7369-5080; Brosens, Jan/0000-0003-0116-9329; Takeda, Satoru/0000-0001-9547-1435				Amant F, 2005, LANCET, V366, P491, DOI 10.1016/S0140-6736(05)67063-8; Arden KC, 2006, EXP GERONTOL, V41, P709, DOI 10.1016/j.exger.2006.05.015; Bamberger AM, 1999, VIRCHOWS ARCH, V434, P423, DOI 10.1007/s004280050361; Brosens JJ, 1999, ENDOCRINOLOGY, V140, P4809, DOI 10.1210/en.140.10.4809; Brunet A, 2001, MOL CELL BIOL, V21, P952, DOI 10.1128/MCB.21.3.952-965.2001; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Brunet A, 2004, SCIENCE, V303, P2011, DOI 10.1126/science.1094637; Christian M, 2002, J BIOL CHEM, V277, P20825, DOI 10.1074/jbc.M201018200; Cully M, 2006, NAT REV CANCER, V6, P184, DOI 10.1038/nrc1819; Dijkers PF, 2000, MOL CELL BIOL, V20, P9138, DOI 10.1128/MCB.20.24.9138-9148.2000; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; Huang H, 2005, P NATL ACAD SCI USA, V102, P1649, DOI 10.1073/pnas.0406789102; Kajihara T, 2006, MOL ENDOCRINOL, V20, P2444, DOI 10.1210/me.2006-0118; Kau TR, 2003, CANCER CELL, V4, P463, DOI 10.1016/S1535-6108(03)00303-9; Kong DH, 1997, NAT GENET, V17, P143, DOI 10.1038/ng1097-143; Kops GJPL, 2002, NATURE, V419, P316, DOI 10.1038/nature01036; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; Labied S, 2006, MOL ENDOCRINOL, V20, P35, DOI 10.1210/me.2005-0275; Lahav-Baratz S, 2004, MOL HUM REPROD, V10, P567, DOI 10.1093/molehr/gah084; Lal A, 2006, MOL CELL, V22, P117, DOI 10.1016/j.molcel.2006.03.016; Laurent A, 2005, CANCER RES, V65, P948; Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427; Nemoto S, 2004, SCIENCE, V306, P2105, DOI 10.1126/science.1101731; Plas DR, 2003, J BIOL CHEM, V278, P12361, DOI 10.1074/jbc.M213069200; Rena G, 2002, EMBO J, V21, P2263, DOI 10.1093/emboj/21.9.2263; Risinger JI, 2003, CANCER RES, V63, P6; Schuur ER, 2001, J BIOL CHEM, V276, P33554, DOI 10.1074/jbc.M105555200; Shang YF, 2006, NAT REV CANCER, V6, P360, DOI 10.1038/nrc1879; Sun M, 2001, CANCER RES, V61, P5985; Sunters A, 2006, CANCER RES, V66, P212, DOI 10.1158/0008-5472.CAN-05-1997; Sunters A, 2003, J BIOL CHEM, V278, P49795, DOI 10.1074/jbc.M309523200; Tran H, 2002, SCIENCE, V296, P530, DOI 10.1126/science.1068712; Varbiro G, 2001, FREE RADICAL BIO MED, V31, P548, DOI 10.1016/S0891-5849(01)00616-5; VILGELM A, 2006, CANCER RES, V66, P335; Woods YL, 2001, BIOCHEM J, V355, P597, DOI 10.1042/bj3550597; Yeap BB, 2002, J BIOL CHEM, V277, P27183, DOI 10.1074/jbc.M202883200; Zheng L, 2000, MOL CELL, V6, P757, DOI 10.1016/S1097-2765(00)00075-7; Zoumpoulidou G, 2004, MOL ENDOCRINOL, V18, P1988, DOI 10.1210/me.2003-0467	38	86	90	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 3	2008	27	1					9	19		10.1038/sj.onc.1210626	http://dx.doi.org/10.1038/sj.onc.1210626			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	247YO	17599040				2022-12-28	WOS:000252118700002
J	Lufei, C; Koh, TH; Uchida, T; Cao, X				Lufei, C.; Koh, T. H.; Uchida, T.; Cao, X.			Pin1 is required for the Ser727 phosphorylation-dependent Stat3 activity	ONCOGENE			English	Article						Pin1; serine phosphorylation; Stat3; transcriptional activity	PROLYL ISOMERASE PIN1; SERINE PHOSPHORYLATION; CARCINOMA CELLS; BREAST-CANCER; ACTIVATION; ISOMERIZATION; TRANSCRIPTION; DETACHMENT; ONCOGENE; PROTEINS	Signal transducer and activator of transcription 3 (Stat3) belongs to a family of latent cytoplasmic transcription factors important for cytokine signaling. Stat3 is constitutively activated in various tumors, and activated Stat3 itself also acts as an oncogene. Transcriptional activity of Stat3 is controlled by Tyr-phosphorylation, followed by dimerization and nuclear translocation. However, phosphorylation on Ser727 is indispensable for its maximal transcriptional activity with unclear mechanism. Here, we report that peptidyl-prolyl cis/trans isomerase 1 (Pin1), which specifically recognizes the pSer/Thr-Pro motifs on its target proteins, interacts with Stat3 upon cytokine/growth factor stimulation. Overexpression of Pin1 promotes Stat3 transcriptional activity and target gene expression, as well as recruitment of transcription coactivator, p300. These effects, however, were compromised in the Pin1-deficient cells, and were totally dependent on the Ser727 phosphorylation site. Finally, we showed that Pin1 enhances Stat3-mediated epithelial mesenchymal transition in breast cancer cells induced by oncostatin M. Our data reveal a novel, Ser727 phosphorylation-dependent, post-translational regulation mechanism for Stat3.	[Lufei, C.; Koh, T. H.; Cao, X.] Inst Mol & Cell Biol, Signal Transduct Lab, Singapore, Singapore; [Uchida, T.] Tohoku Univ, Grad Sch Agr Sci, Sendai, Miyagi 980, Japan	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); Tohoku University	Cao, X (corresponding author), Inst Mol & Cell Biol, Cell Signaling Lab, 61 Proteos Bldg,61 Biopolis Dr, Singapore 138673, Singapore.	mcbcaoxm@imcb.a-star.edu.sg		Uchida, Takafumi/0000-0003-3665-4906				Bao L, 2004, AM J PATHOL, V164, P1727, DOI 10.1016/S0002-9440(10)63731-5; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Cao XM, 1996, MOL CELL BIOL, V16, P1595; Clevenger CV, 2004, AM J PATHOL, V165, P1449, DOI 10.1016/S0002-9440(10)63403-7; Crenshaw DG, 1998, EMBO J, V17, P1315, DOI 10.1093/emboj/17.5.1315; DANIAL NN, 1995, SCIENCE, V269, P1875, DOI 10.1126/science.7569929; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Decker T, 2000, ONCOGENE, V19, P2628, DOI 10.1038/sj.onc.1203481; Fujimori F, 1999, BIOCHEM BIOPH RES CO, V265, P658, DOI 10.1006/bbrc.1999.1736; Holzer RG, 2004, CLIN EXP METASTAS, V21, P167, DOI 10.1023/B:CLIN.0000024760.02667.db; Jorcyk CL, 2006, CYTOKINE, V33, P323, DOI 10.1016/j.cyto.2006.03.004; Levy DE, 2002, J CLIN INVEST, V109, P1143, DOI 10.1172/JCI200215650; Lim CP, 1999, J BIOL CHEM, V274, P31055, DOI 10.1074/jbc.274.43.31055; Lu KP, 1996, NATURE, V380, P544; Lu PJ, 1999, SCIENCE, V283, P1325, DOI 10.1126/science.283.5406.1325; Lufei CC, 2003, EMBO J, V22, P1325, DOI 10.1093/emboj/cdg135; Ng DCH, 2006, J CELL BIOL, V172, P245, DOI 10.1083/jcb.200503021; Sano S, 1999, EMBO J, V18, P4657, DOI 10.1093/emboj/18.17.4657; Thiery JP, 2003, CURR OPIN CELL BIOL, V15, P740, DOI 10.1016/j.ceb.2003.10.006; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; WINKLER S, 2000, P SOC PHOTO-OPT INS, V1, P287; Wulf G, 2004, EMBO J, V23, P3397, DOI 10.1038/sj.emboj.7600323; Wulf G, 2003, BREAST CANCER RES, V5, P76, DOI 10.1186/bcr572; Wulf G, 2005, NAT CELL BIOL, V7, P435, DOI 10.1038/ncb0505-435; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; Zacchi P, 2002, NATURE, V419, P853, DOI 10.1038/nature01120; Zhanel George G, 2002, Expert Opin Pharmacother, V3, P277; Zhang F, 2003, ONCOGENE, V22, P894, DOI 10.1038/sj.onc.1206158; Zheng HW, 2002, NATURE, V419, P849, DOI 10.1038/nature01116; Zhou XZ, 2000, MOL CELL, V6, P873, DOI 10.1016/S1097-2765(00)00085-X	32	84	85	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 6	2007	26	55					7656	7664		10.1038/sj.onc.1210567	http://dx.doi.org/10.1038/sj.onc.1210567			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	239SK	17563747				2022-12-28	WOS:000251537800007
J	Li, W; Xiao, C; Vonderhaar, BK; Deng, CX				Li, W.; Xiao, C.; Vonderhaar, B. K.; Deng, C-X			A role of estrogen/ER alpha signaling in BRCA1-associated tissue-specific tumor formation	ONCOGENE			English	Article						ERK1/2; cyclin D1; ER alpha; BRCA1; mammary tumors	BREAST-CANCER; CELL-CYCLE; BRCA2 MUTATIONS; OVARIAN-CANCER; RECEPTOR; SUSCEPTIBILITY; WOMEN; MICE; TUMORIGENESIS; OOPHORECTOMY	Estrogen and its receptor alpha (ER alpha) have been implicated in the tissue-specific tumorigenesis associated with BRCA1 mutations. However, the majority of breast cancers developed in human BRCA1 mutation carriers are ER alpha-negative, challenging the link between BRCA1 and estrogen/ER alpha in breast cancer formation. Using a mouse model lacking the full-length form of BRCA1, here we show that ERa is highly expressed in the premalignant mammary gland and initiation stages of tumorigenesis, although its expression is gradually diminished during mammary tumor progression. We demonstrate that the absence of full-length BRCA1 increases sensitivity of cells to estrogen-induced extracellular signal-regulated kinase 1/2 phosphorylation and cyclin D1 expression. The absence of BRCA1 turns the proliferation of ER alpha-positive cells from a paracrine fashion to an autocrine or endocrine fashion. Consequently, BRCA1-mutant cells are sensitized to estrogen-induced cell proliferation in vitro and mammary tumorigenesis in vivo. These findings illustrate a molecular mechanism for estrogen/ER alpha signals in BRCA1-associated tissue-specific tumor formation, and identify several key elements in the estrogen/ER alpha-signaling cascade that can serve as potential therapeutic targets for BRCA1-associated tumorigenesis.	Natl Inst Hlth, NIDDK, Genet Dev & Dis Branch, Bethesda, MD 20892 USA; Natl Inst Hlth, Natl Canc Inst, Mammary Biol & Tumorigen Lab, Bethesda, MD USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Deng, CX (corresponding author), Natl Inst Hlth, NIDDK, Genet Dev & Dis Branch, 10-9N105, 10 Ctr Dr, Bethesda, MD 20892 USA.	chuxiad@bdg10.niddk.nih.gov	deng, chuxia/N-6713-2016		NATIONAL CANCER INSTITUTE [ZIABC008226, Z01BC008226] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK056008] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Alberg Anthony J., 1999, Current Opinion in Oncology, V11, P435, DOI 10.1097/00001622-199911000-00003; Bachelier R, 2005, ONCOL REP, V14, P1117; Brodie SG, 2001, ONCOGENE, V20, P7514, DOI 10.1038/sj.onc.1204929; Calderon-Margalit R, 2004, INT J CANCER, V112, P357, DOI 10.1002/ijc.20429; Chodankar R, 2005, CURR BIOL, V15, P561, DOI 10.1016/j.cub.2005.01.052; Clarke RB, 1997, CANCER RES, V57, P4987; Deng Chu-Xia, 2004, Methods Mol Biol, V280, P185; Deng CX, 2006, NUCLEIC ACIDS RES, V34, P1416, DOI 10.1093/nar/gkl010; Deng CX, 2003, HUM MOL GENET, V12, pR113, DOI 10.1093/hmg/ddg082; Eisinger F, 1999, CANCER-AM CANCER SOC, V85, P2291, DOI 10.1002/(SICI)1097-0142(19990515)85:10<2291::AID-CNCR26>3.0.CO;2-9; Elledge SJ, 2002, CANCER CELL, V1, P129, DOI 10.1016/S1535-6108(02)00041-7; Fan S, 1999, SCIENCE, V284, P1354, DOI 10.1126/science.284.5418.1354; Gadducci A, 2005, GYNECOL ENDOCRINOL, V20, P343, DOI 10.1080/09513590500128492; Hu YF, 2005, ONCOGENE, V24, P8343, DOI 10.1038/sj.onc.1208985; Huo ZM, 2002, RADIOLOGY, V225, P519, DOI 10.1148/radiol.2252010845; Johannsson OT, 1997, EUR J CANCER, V33, P362, DOI 10.1016/S0959-8049(96)00469-8; Karp SE, 1997, CANCER-AM CANCER SOC, V80, P435, DOI 10.1002/(SICI)1097-0142(19970801)80:3<435::AID-CNCR11>3.0.CO;2-Y; Kauff ND, 2002, NEW ENGL J MED, V346, P1609, DOI 10.1056/NEJMoa020119; Korach KS, 1996, RECENT PROG HORM RES, V51, P159; Lane D., 1995, COMPLEXITY, V1, P9; Migliaccio A, 1996, EMBO J, V15, P1292, DOI 10.1002/j.1460-2075.1996.tb00471.x; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Monteiro ANA, 2003, TRENDS GENET, V19, P312, DOI 10.1016/S0168-9525(03)00110-0; Prall OWJ, 1998, J STEROID BIOCHEM, V65, P169, DOI 10.1016/S0960-0760(98)00021-1; Russo IH, 1998, J MAMMARY GLAND BIOL, V3, P49, DOI 10.1023/A:1018770218022; Russo J, 1999, BREAST CANCER RES TR, V53, P217, DOI 10.1023/A:1006186719322; Santen RJ, 2002, J STEROID BIOCHEM, V80, P239, DOI 10.1016/S0960-0760(01)00189-3; Trauernicht Amy M, 2003, Breast Dis, V18, P11; Turner JMA, 2004, CURR BIOL, V14, P2135, DOI 10.1016/j.cub.2004.11.032; Venkitaraman AR, 2002, CELL, V108, P171, DOI 10.1016/S0092-8674(02)00615-3; Xu XL, 1999, NAT GENET, V22, P37, DOI 10.1038/8743; Xu XL, 2001, NAT GENET, V28, P266, DOI 10.1038/90108; Zhang JR, 2005, MOL CANCER RES, V3, P531, DOI 10.1158/1541-7786.MCR-05-0192; Zheng L, 2001, P NATL ACAD SCI USA, V98, P9587, DOI 10.1073/pnas.171174298	34	40	41	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 8	2007	26	51					7204	7212		10.1038/sj.onc.1210527	http://dx.doi.org/10.1038/sj.onc.1210527			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	231NO	17496925				2022-12-28	WOS:000250955600004
J	Glaros, S; Cirrincione, GM; Muchardt, C; Kleer, CG; Michael, CW; Reisman, D				Glaros, S.; Cirrincione, G. M.; Muchardt, C.; Kleer, C. G.; Michael, C. W.; Reisman, D.			The reversible epigenetic silencing of BRM: implications for clinical targeted therapy	ONCOGENE			English	Article						Brahma; Brahma-related gene 1; BRG1/BRM-associated factor; tumor suppressor; lung cancer; SWI/SNF complex	CHROMATIN REMODELING FACTORS; HUMAN LUNG-CANCER; TUMOR-CELL LINES; SWI/SNF COMPLEX; SACCHAROMYCES-CEREVISIAE; GLUCOCORTICOID RECEPTOR; CD44 EXPRESSION; GROWTH; BRG1; TRANSCRIPTION	The SWI/SNF chromatin- remodeling complex serves as a master switch that directs and limits the execution of specific cellular programs, such as differentiation and growth control. SWI/SNF function requires one of two paralogous ATPase subunits, Brahma (BRM) or BRMrelated gene 1 (BRG1), which we previously found are lost together in cancer cell lines and primary lung cancers. Although BRG1 has been found to be mutated in cancer cell lines, the mechanisms underlying BRM silencing are not known. To address this question, we sequenced BRM in 10 BRM/BRG10 deficient cancer cell lines and found that BRM was devoid of abrogating mutations. Moreover, histone deacetylase (HDAC) inhibitors restored BRM expression in each of these BRG1/BRM-defficient cancer cell lines, indicating that epigenetic silencing is a major mechanism underlying the loss of BRM expression. Despite their ability restore BRM expression, these HDAC inhibitors also blocked BRM function when present. However, after their removal, we observed that BRM expression remained elevated for several days, and during this period, BRM activity was detected. We also found that the suppression of BRM occurs in a broad range of human tumor types and that loss of one or both BRM alleles potentiated tumor development in mice. Thus, BRG1 and BRM are silenced by different mechanisms, and it may be possible to clinically target and reexpress BRM in a number of tumor types, potentially impacting tumor development.	Univ Michigan, Div Hematol Oncol, Dept Internal Med, Ann Arbor, MI 48103 USA; Inst Pasteur, Dept Dev Biol, CNRS, URA1644, Paris, France; Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; University of Michigan System; University of Michigan	Reisman, D (corresponding author), Univ Michigan, Div Hematol Oncol, Dept Internal Med, MRSB2,B570B, Ann Arbor, MI 48103 USA.	dreisman@umich.edu			NATIONAL CANCER INSTITUTE [P30CA046592] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK020572, P60DK020572] Funding Source: NIH RePORTER; NCI NIH HHS [CA092149-03, 5-P30-CA46592] Funding Source: Medline; NIDDK NIH HHS [DK20572] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bourachot B, 2003, EMBO J, V22, P6505, DOI 10.1093/emboj/cdg621; Coisy-Quivy M, 2006, CANCER RES, V66, P5069, DOI 10.1158/0008-5472.CAN-05-0596; Fukuoka J, 2004, CLIN CANCER RES, V10, P4314, DOI 10.1158/1078-0432.CCR-03-0489; KHAVARI PA, 1993, NATURE, V366, P170, DOI 10.1038/366170a0; Klochendler-Yeivin A, 2002, CURR OPIN GENET DEV, V12, P73, DOI 10.1016/S0959-437X(01)00267-2; Machida Y, 2001, J BIOCHEM, V129, P43, DOI 10.1093/oxfordjournals.jbchem.a002834; MUCHARDT C, 1993, EMBO J, V12, P4279, DOI 10.1002/j.1460-2075.1993.tb06112.x; Muchardt C, 2001, ONCOGENE, V20, P3067, DOI 10.1038/sj.onc.1204331; Reisman DN, 2003, CANCER RES, V63, P560; Reisman DN, 2002, ONCOGENE, V21, P1196, DOI 10.1038/sj.onc.1205188; Roberts CWM, 2004, NAT REV CANCER, V4, P133, DOI 10.1038/nrc1273; Simone C, 2006, J CELL PHYSIOL, V207, P309, DOI 10.1002/jcp.20514; Strobeck MW, 2001, J BIOL CHEM, V276, P9273, DOI 10.1074/jbc.M009747200; STROBECK MW, 2002, J BIOL CHEM, V21, P21; Sudarsanam P, 2000, P NATL ACAD SCI USA, V97, P3364, DOI 10.1073/pnas.050407197; Trotter KW, 2004, MOL CELL BIOL, V24, P3347, DOI 10.1128/MCB.24.8.3347-3358.2004; Tuveson DA, 1999, ONCOGENE, V18, P5318, DOI 10.1038/sj.onc.1203107; Wang WD, 1996, GENE DEV, V10, P2117, DOI 10.1101/gad.10.17.2117; Wong AKC, 2000, CANCER RES, V60, P6171; Yamamichi N, 2005, ONCOGENE, V24, P5471, DOI 10.1038/sj.onc.1208716	20	111	116	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT	2007	26	49					7058	7066		10.1038/sj.onc.1210514	http://dx.doi.org/10.1038/sj.onc.1210514			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	223YN	17546055				2022-12-28	WOS:000250412200011
J	Allen, NPC; Donninger, H; Vos, MD; Eckfeld, K; Hesson, L; Gordon, L; Birrer, MJ; Latif, F; Clark, GJ				Allen, N. P. C.; Donninger, H.; Vos, M. D.; Eckfeld, K.; Hesson, L.; Gordon, L.; Birrer, M. J.; Latif, F.; Clark, G. J.			RASSF6 is a novel member of the RASSF family of tumor suppressors	ONCOGENE			English	Article						Ras; RASSF6; tumor suppressor	NF-KAPPA-B; EPIGENETIC INACTIVATION; EFFECTOR; ACTIVATION; GENE; ASSOCIATION; PROTEIN; NORE1; SUSCEPTIBILITY; IDENTIFICATION	RASSF family proteins are tumor suppressors that are frequently downregulated during the development of human cancer. The best-characterizedmember of the family is RASSF1A, which is downregulated by promoter methylation in 40-90% of primary human tumors. We now identify and characterize a novel member of the RASSF family, RASSF6. Like the other family members, RASSF6 possesses a Ras Association domain and binds activated Ras. Exogenous expression of RASSF6 promotedapoptosis, synergized with activated K-Ras to induce cell death and inhibited the survival of specific tumor cell lines. Suppression of RASSF6 enhanced the tumorigenic phenotype of a human lung tumor cell line. Furthermore, RASSF6 is often downregulated in primary human tumors. RASSF6 shares some similar overall properties as other RASSF proteins. However, there are significant differences in biological activity between RASSF6 and other family members including a discrete tissue expression pro. le, cell killing specificity and impact on signaling pathways. Moreover, RASSF6 may play a role in dictating the degree of in. ammatory response to the respiratory syncytial virus. Thus, RASSF6 is a novel RASSF family member that demonstrates the properties of a Ras effector and tumor suppressor but exhibits biological properties that are unique and distinct from those of other family members.	Natl Canc Inst, Dept Cell Canc Biol, Rockville, MD USA; Univ Louisville, JG Brown Canc Ctr, Dept Med, Mol Targets Grp, Louisville, KY USA; Univ Birmingham, Med Sect Mol Genet, Birmingham, W Midlands, England	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Louisville; University of Birmingham	Clark, GJ (corresponding author), Univ Louisville, Dept Med, Targets Grp, 580 S Preston Str, Louisville, KY 40202 USA.	gjclar01@louisville.edu	Donninger, Howard/I-9874-2019; Hesson, Luke/HDM-0311-2022	Donninger, Howard/0000-0002-8589-1660; 	Intramural NIH HHS Funding Source: Medline; NCRR NIH HHS [RR018733] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR018733] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Agathanggelou A, 2005, CANCER RES, V65, P3497, DOI 10.1158/0008-5472.CAN-04-4088; Akino K, 2005, GASTROENTEROLOGY, V129, P156, DOI 10.1053/j.gastro.2005.03.051; Baksh S, 2005, MOL CELL, V18, P637, DOI 10.1016/j.molcel.2005.05.010; Bitko V, 2004, BMC MICROBIOL, V4, DOI 10.1186/1471-2180-4-28; Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691; Chen JD, 2003, CANCER CELL, V4, P405, DOI 10.1016/S1535-6108(03)00269-1; Clark GJ, 1996, P NATL ACAD SCI USA, V93, P1577, DOI 10.1073/pnas.93.4.1577; Cox AD, 2003, ONCOGENE, V22, P8999, DOI 10.1038/sj.onc.1207111; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; Diep CB, 2004, MOL CANCER, V3, DOI 10.1186/1476-4598-3-6; Eckfeld K, 2004, CANCER RES, V64, P8688, DOI 10.1158/0008-5472.CAN-04-2065; Ellis CA, 2002, P NATL ACAD SCI USA, V99, P9876, DOI 10.1073/pnas.142193799; Feig LA, 2002, CURR BIOL, V12, pR259, DOI 10.1016/S0960-9822(02)00787-X; Fiordalisi JJ, 2001, METHOD ENZYMOL, V332, P3; Frame S, 2000, CURR OPIN GENET DEV, V10, P106, DOI 10.1016/S0959-437X(99)00052-0; Hueber AO, 1998, TRENDS GENET, V14, P364, DOI 10.1016/S0168-9525(98)01520-0; Hull J, 2004, HUM GENET, V114, P272, DOI 10.1007/s00439-003-1038-x; Khokhlatchev A, 2002, CURR BIOL, V12, P253, DOI 10.1016/S0960-9822(02)00683-8; Malumbres M, 2003, NAT REV CANCER, V3, P459, DOI 10.1038/nrc1097; Malumbres M, 1998, FRONT BIOSCI-LANDMRK, V3, P887; MARSHALL MS, 1993, TRENDS BIOCHEM SCI, V18, P250, DOI 10.1016/0968-0004(93)90175-M; Mayo MW, 1997, SCIENCE, V278, P1812, DOI 10.1126/science.278.5344.1812; Nicke B, 2005, MOL CELL, V20, P673, DOI 10.1016/j.molcel.2005.10.038; Okada T, 1996, J BIOL CHEM, V271, P4671; Pfeifer GP, 2002, BIOL CHEM, V383, P907, DOI 10.1515/BC.2002.097; Ponting CP, 1996, TRENDS BIOCHEM SCI, V21, P422, DOI 10.1016/S0968-0004(96)30038-8; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Shields JM, 2000, TRENDS CELL BIOL, V10, P147, DOI 10.1016/S0962-8924(00)01740-2; Smyth RL, 2006, LANCET, V368, P312, DOI 10.1016/S0140-6736(06)69077-6; SOLSKI PA, 1995, METHOD ENZYMOL, V250, P435; Tommasi S, 2005, CANCER RES, V65, P92; Tommasi S, 2002, ONCOGENE, V21, P2713, DOI 10.1038/sj.onc.1205365; Vos MD, 2003, J BIOL CHEM, V278, P21938, DOI 10.1074/jbc.M211019200; Vos MD, 2003, J BIOL CHEM, V278, P28045, DOI 10.1074/jbc.M300554200; Vos MD, 2006, J BIOL CHEM, V281, P4557, DOI 10.1074/jbc.M512128200; Vos MD, 2004, CANCER RES, V64, P4244, DOI 10.1158/0008-5472.CAN-04-0339; Vos MD, 2000, J BIOL CHEM, V275, P35669, DOI 10.1074/jbc.C000463200; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; Williams JG, 2000, J BIOL CHEM, V275, P22172, DOI 10.1074/jbc.M000397200	39	98	108	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 13	2007	26	42					6203	6211		10.1038/sj.onc.1210440	http://dx.doi.org/10.1038/sj.onc.1210440			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	209PU	17404571				2022-12-28	WOS:000249401300011
J	Raho, G; Miranda, C; Tamborini, E; Pierotti, MA; Greco, A				Raho, G.; Miranda, C.; Tamborini, E.; Pierotti, M. A.; Greco, A.			Detection of novel mRNA splice variants of human ING4 tumor suppressor gene	ONCOGENE			English	Article						ING4; alternative splicing; PHD domain	PHD-FINGER; CANCER; EXPRESSION; PROTEINS; APOPTOSIS; FAMILY; DOMAIN; P53; TRANSCRIPTION; ACETYLATION	Inhibitor of growth (ING) 4, member of a gene family encoding potential tumor suppressors, is implicated as a repressor of angiogenesis and tumor growth and suppresses loss of contact inhibition in vitro. Here, we report that ING4 undergoes alternative splicing. Expression analysis identified novel ING4 spliced variant mRNAs encoding proteins devoid of different portions. The ING4 variants were detected in both normal and tumor tissues. The existence of ING4 variants was confirmed by several approaches, including reverse transcriptase-polymerase chain reaction, real-time PCR and in silico experiments. To investigate the functional consequences of alternative splicing the ING4 variant cDNAs were expressed in mammalian cells. Our studies indicated that (i) the ING4 variants do not differ from wild-type in their nuclear localization, interaction with p53 and association to HBO1 complex; and (ii) the ING4-Delta Ex6A variant, devoid of the C-terminal portion, loses the capability to inhibit NF-kappa B. On the whole our data suggest that alternative splicing could modulate the activity of ING4 tumor suppressor protein.	Ist Nazl Tumori, Dept Expt Oncol, Operat Unit Mol Mech Canc Growth & Progress, I-20133 Milan, Italy; Ist Nazl Tumori, Dept Pathol Expt Mol Pathol, I-20133 Milan, Italy; Ist Nazl Tumori, Sci Direct, I-20133 Milan, Italy; IFOM Fdn, Milan, Italy	Fondazione IRCCS Istituto Nazionale Tumori Milan; Fondazione IRCCS Istituto Nazionale Tumori Milan; Fondazione IRCCS Istituto Nazionale Tumori Milan; IFOM - FIRC Institute of Molecular Oncology	Pierotti, MA (corresponding author), Ist Nazl Tumori, Dept Expt Oncol, Operat Unit Mol Mech Canc Growth & Progress, Via Venezian 1, I-20133 Milan, Italy.	marco.pierotti@istitutotumori.mi.it; angela.greco@istitutotumori.mi.it	Tamborini, Elena/C-3307-2017; Pierotti, Marco Alessandro/AAC-4728-2022; Greco, Angela/C-1953-2017	Tamborini, Elena/0000-0002-3819-8687; Pierotti, Marco Alessandro/0000-0002-7431-8332; Greco, Angela/0000-0003-2994-0349				Bienz M, 2006, TRENDS BIOCHEM SCI, V31, P35, DOI 10.1016/j.tibs.2005.11.001; Doyon Y, 2006, MOL CELL, V21, P51, DOI 10.1016/j.molcel.2005.12.007; Feng XL, 2002, TRENDS CELL BIOL, V12, P532, DOI 10.1016/S0962-8924(02)02391-7; Garkavtsev I, 2004, NATURE, V428, P328, DOI 10.1038/nature02329; Gong W, 2005, INT J BIOCHEM CELL B, V37, P1054, DOI 10.1016/j.biocel.2004.09.008; Gozani O, 2003, CELL, V114, P99, DOI 10.1016/S0092-8674(03)00480-X; GRECO A, 1995, MOL CELL BIOL, V15, P6118; Gunduz M, 2005, GENE, V356, P109, DOI 10.1016/j.gene.2005.02.014; Gunduz M, 2002, ONCOGENE, V21, P4462, DOI 10.1038/sj.onc.1205540; He GHY, 2005, MOL BIOL EVOL, V22, P104, DOI 10.1093/molbev/msh256; Huiping C, 2002, EUR J CANCER, V38, P728, DOI 10.1016/S0959-8049(01)00432-4; Kalnina Z, 2005, GENE CHROMOSOME CANC, V42, P342, DOI 10.1002/gcc.20156; Kataoka H, 2003, CANCER RES, V63, P5785; Kaufmann D, 2002, CANCER RES, V62, P1503; Kim S, 2004, P NATL ACAD SCI USA, V101, P16251, DOI 10.1073/pnas.0407158101; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; Loewith R, 2000, MOL CELL BIOL, V20, P3807, DOI 10.1128/MCB.20.11.3807-3816.2000; Lu F, 2006, BRIT J CANCER, V95, P80, DOI 10.1038/sj.bjc.6603205; Nagashima M, 2003, ONCOGENE, V22, P343, DOI 10.1038/sj.onc.1206115; Nagashima M, 2001, P NATL ACAD SCI USA, V98, P9671, DOI 10.1073/pnas.161151798; Nouman GS, 2002, HYBRIDOMA HYBRIDOM, V21, P1, DOI 10.1089/15368590252917584; Okano T, 2006, ONCOL REP, V15, P545; Ozer A, 2005, P NATL ACAD SCI USA, V102, P7481, DOI 10.1073/pnas.0502716102; Pena PV, 2006, NATURE, V442, P100, DOI 10.1038/nature04814; Russell M, 2006, EXP CELL RES, V312, P951, DOI 10.1016/j.yexcr.2006.01.020; Shi XB, 2006, NATURE, V442, P96, DOI 10.1038/nature04835; Shiseki M, 2003, CANCER RES, V63, P2373; Tsai KW, 2006, GENOMICS, V88, P855, DOI 10.1016/j.ygeno.2006.07.004; Unoki M, 2006, J BIOL CHEM, V281, P34677, DOI 10.1074/jbc.M606296200; Venables JP, 2004, CANCER RES, V64, P7647, DOI 10.1158/0008-5472.CAN-04-1910; Wagner MJ, 2005, GEN COMP ENDOCR, V144, P38, DOI 10.1016/j.ygcen.2005.04.008; Zhang X, 2005, BIOCHEM BIOPH RES CO, V331, P1032, DOI 10.1016/j.bbrc.2005.04.023; Zhou MI, 2005, P NATL ACAD SCI USA, V102, P11035, DOI 10.1073/pnas.0500757102	33	33	36	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 9	2007	26	36					5247	5257		10.1038/sj.onc.1210335	http://dx.doi.org/10.1038/sj.onc.1210335			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	199CQ	17325660				2022-12-28	WOS:000248674200008
J	Nojima, M; Suzuki, H; Toyota, M; Watanabe, Y; Maruyama, R; Sasaki, S; Sasaki, Y; Mita, H; Nishikawa, N; Yamaguchi, K; Hirata, K; Itoh, F; Tokino, T; Mori, M; Imai, K; Shinomura, Y				Nojima, M.; Suzuki, H.; Toyota, M.; Watanabe, Y.; Maruyama, R.; Sasaki, S.; Sasaki, Y.; Mita, H.; Nishikawa, N.; Yamaguchi, K.; Hirata, K.; Itoh, F.; Tokino, T.; Mori, M.; Imai, K.; Shinomura, Y.			Frequent epigenetic inactivation of SFRP genes and constitutive activation of Wnt signaling in gastric cancer	ONCOGENE			English	Article						SFRP; methylation; gastric cancer; Wnt signaling; apoptosis	BETA-CATENIN GENE; MATRIX METALLOPROTEINASE-7; ABERRANT METHYLATION; ANTAGONIST SFRP1; CYCLIN D1; EXPRESSION; APOPTOSIS; FAMILY; GROWTH; HYPERMETHYLATION	Activation of Wnt signaling has been implicated in gastric tumorigenesis, although mutations in APC (adenomatous polyposis coli), CTNNB1 (beta-catenin) and AXIN are seen much less frequently in gastric cancer (GC) than in colorectal cancer. In the present study, we investigated the relationship between activation of Wnt signaling and changes in the expression of secreted frizzled-related protein (SFRP) family genes in GC. We frequently observed nuclear beta-catenin accumulation (13/15; 87%) and detected the active form of beta-catenin in most (12/16; 75%) GC cell lines. CpG methylation-dependent silencing of SFRP1, SFRP2 and SFRP5 was frequently seen among GC cell lines (SFRP1, 16/16, 100%; SFRP2, 16/16, 100%; SFRP5, 13/16, 81%) and primary GC specimens (SFRP1, 42/46, 91%; SFRP2, 44/46, 96%; SFRP5, 30/46, 65%),and treatment with the DNA methyltransferase inhibitor 5-aza-2'-deoxycytidine rapidly restored SFRP expression. Ectopic expression of SFRPs downregulated T-cell factor/lymphocyte enhancer factor transcriptional activity, suppressed cell growth and induced apoptosis in GC cells. Analysis of global expression revealed that overexpression of SFRP2 repressed Wnt target genes and induced changes in the expression of numerous genes related to proliferation, growth and apoptosis in GC cells. It thus appears that aberrant SFRP methylation is one of the major mechanisms by which Wnt signaling is activated in GC.	Sapporo Med Univ, Dept Internal Med 1, Chuo Ku, Sapporo, Hokkaido 0608543, Japan; Sapporo Med Univ, Dept Publ Hlth, Sapporo, Hokkaido, Japan; Sapporo Med Univ, Dept Mol Biol, Inst Canc Res, Sapporo, Hokkaido, Japan; PRESTO JST, Kawaguchi, Japan; St Marianna Univ, Sch Med, Dept Internal Med, Div Gastroenterol & Hepatol, Kawasaki, Kanagawa, Japan; Sapporo Med Univ, Dept Surg 1, Sapporo, Hokkaido, Japan	Sapporo Medical University; Sapporo Medical University; Sapporo Medical University; Japan Science & Technology Agency (JST); Saint Marianna University; Sapporo Medical University	Suzuki, H (corresponding author), Sapporo Med Univ, Dept Internal Med 1, Chuo Ku, S1,W16, Sapporo, Hokkaido 0608543, Japan.	hsuzuki@sapmed.ac.jp	Sasaki, Yasushi/AAA-3079-2019; Tokino, Takashi/AAI-9887-2021	Sasaki, Yasushi/0000-0002-3500-8059; 				Arber N, 1999, HUM PATHOL, V30, P1087, DOI 10.1016/S0046-8177(99)90227-7; Brabletz T, 1999, AM J PATHOL, V155, P1033, DOI 10.1016/S0002-9440(10)65204-2; Caca K, 1999, CELL GROWTH DIFFER, V10, P369; Caldwell GM, 2004, CANCER RES, V64, P883, DOI 10.1158/0008-5472.CAN-03-1346; Clements WM, 2002, CANCER RES, V62, P3503; Fukui T, 2005, ONCOGENE, V24, P6323, DOI 10.1038/sj.onc.1208777; Gregorieff A, 2005, GENE DEV, V19, P877, DOI 10.1101/gad.1295405; He B, 2005, CANCER RES, V65, P743; He BA, 2005, ONCOGENE, V24, P3054, DOI 10.1038/sj.onc.1208511; Hollander MC, 2003, ONCOGENE, V22, P3827, DOI 10.1038/sj.onc.1206567; HORII A, 1992, CANCER RES, V52, P3231; Hovanes K, 2001, NAT GENET, V28, P53, DOI 10.1038/88264; Ii M, 2006, EXP BIOL MED, V231, P20; Jones SE, 2002, BIOESSAYS, V24, P811, DOI 10.1002/bies.10136; KOPPERT LB, 2000, BRIT J CANCER, V90, P892; Ku Ja-Lok, 2005, Cancer Res Treat, V37, P1, DOI 10.4143/crt.2005.37.1.1; Lee AY, 2004, ONCOGENE, V23, P6672, DOI 10.1038/sj.onc.1207881; Liu TH, 2006, CANCER RES, V66, P653, DOI 10.1158/0008-5472.CAN-05-3712; Lodygin D, 2005, CANCER RES, V65, P4218, DOI 10.1158/0008-5472.CAN-04-4407; Murai M, 2005, CLIN CANCER RES, V11, P1021; Naishiro Y, 2001, CANCER RES, V61, P2751; OFFERHAUS GJA, 1992, GASTROENTEROLOGY, V102, P1980, DOI 10.1016/0016-5085(92)90322-P; Rhee CS, 2002, ONCOGENE, V21, P6598, DOI 10.1038/sj.onc.1205920; Risinger JI, 2005, CANCER RES, V65, P5031, DOI 10.1158/0008-5472.CAN-04-0850; Saikawa Y, 2001, JPN J CANCER RES, V92, P1102, DOI 10.1111/j.1349-7006.2001.tb01065.x; Sasaki Y, 2001, TUMOR BIOL, V22, P123, DOI 10.1159/000050606; Satoh A, 2003, CANCER RES, V63, P8606; Stoehr R, 2004, LAB INVEST, V84, P465, DOI 10.1038/labinvest.3700068; Suriano G, 2005, GENE CHROMOSOME CANC, V42, P238, DOI 10.1002/gcc.20135; Suzuki H, 2004, NAT GENET, V36, P417, DOI 10.1038/ng1330; Suzuki H, 2002, NAT GENET, V31, P141, DOI 10.1038/ng892; Takayama S, 2001, NAT CELL BIOL, V3, pE237, DOI 10.1038/ncb1001-e237; Takekawa M, 1998, CELL, V95, P521, DOI 10.1016/S0092-8674(00)81619-0; Taketo MM, 2004, NAT GENET, V36, P320, DOI 10.1038/ng0404-320; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Toyota M, 2003, P NATL ACAD SCI USA, V100, P7818, DOI 10.1073/pnas.1337066100; Veeck J, 2006, ONCOGENE, V25, P3479, DOI 10.1038/sj.onc.1209386; Wielenga VJM, 1999, AM J PATHOL, V154, P515, DOI 10.1016/S0002-9440(10)65297-2; Woo DK, 2001, INT J CANCER, V95, P108, DOI 10.1002/1097-0215(20010320)95:2<108::AID-IJC1019>3.0.CO;2-#; Yokozaki H, 2000, PATHOL INT, V50, P767, DOI 10.1046/j.1440-1827.2000.01117.x; Yuasa Y, 2003, NAT REV CANCER, V3, P592, DOI 10.1038/nrc1141	41	182	199	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 12	2007	26	32					4699	4713		10.1038/sj.onc.1210259	http://dx.doi.org/10.1038/sj.onc.1210259			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	190DJ	17297461				2022-12-28	WOS:000248037900010
J	Kim, MM; Wiederschain, D; Kennedy, D; Hansen, E; Yuan, ZM				Kim, M. M.; Wiederschain, D.; Kennedy, D.; Hansen, E.; Yuan, Z-M			Modulation of p53 and MDM2 activity by novel interaction with Ras-GAP binding proteins (G3BP)	ONCOGENE			English	Article						G3BP; p53; MDM2	FUNCTIONAL INACTIVATION; EXPRESSION; GROWTH; DOMAIN; IDENTIFICATION; RNA	Inactivation of the p53 tumor suppressor pathway is a critical step in human tumorigenesis. In addition to mutations, p53 can be functionally silenced through its increased degradation, inhibition of its transcriptional activity and/or its inappropriate subcellular localization. Using a proteomic approach, we have found that members of the Ras network of proteins, Ras-GTPase activating protein-SH3-domain-binding proteins 1 and 2 (G3BP1 and 2), bind to p53 in vitro and in vivo. Our data show that expression of G3BPs leads to the redistribution of p53 from the nucleus to the cytoplasm. The G3BP2 isoform additionally associated with murine double minute 2 (MDM2), a negative regulator of p53. G3BP2 expression resulted in significant reduction in MDM2-mediated p53 ubiquitylation and degradation. Interestingly, MDM2 was also stabilized in G3BP2-expressing cells and its ability to ubiquitylate itself was compromised. Accordingly, short hairpin RNA (shRNA)-mediated knockdown of G3BP2 caused a reduction in MDM2 protein levels. Furthermore, expression of shRNA targeting either G3BP1 or G3BP2 in human cancer cell lines resulted in marked upregulation of p53 levels and activity. Our results suggest that both G3BP isoforms may act as negative regulators of p53.	Harvard Univ, Sch Publ Hlth, Dept Genet & Complex Dis, Boston, MA 02115 USA; Griffith Univ, Sch Biomol & Biomed Sci, Nathan, Qld 4111, Australia	Harvard University; Harvard T.H. Chan School of Public Health; Griffith University	Yuan, ZM (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Genet & Complex Dis, 665 Huntington Ave, Boston, MA 02115 USA.	zyuan@hsph.harvard.edu	Kennedy, Hendrick/A-7635-2010	Kennedy, Hendrick/0000-0001-7937-3069	NCI NIH HHS [CA009078, R01CA85679-02] Funding Source: Medline; NIEHS NIH HHS [5P30ES00002, T32ES007155] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009078, R01CA085679] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000002, T32ES007155] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Atlas R, 2004, J NEUROCHEM, V89, P613, DOI 10.1111/j.1471-4159.2004.02371.x; Barnes CJ, 2002, CANCER RES, V62, P1251; French J, 2002, HISTOCHEM J, V34, P223, DOI 10.1023/A:1021737413055; Gallouzi IE, 1998, MOL CELL BIOL, V18, P3956, DOI 10.1128/MCB.18.7.3956; Geyer RK, 2000, NAT CELL BIOL, V2, P569, DOI 10.1038/35023507; Gu JJ, 2002, J BIOL CHEM, V277, P19251, DOI 10.1074/jbc.C200150200; Gu JJ, 2001, CANCER RES, V61, P6703; Guitard E, 2001, CANCER LETT, V162, P213, DOI 10.1016/S0304-3835(00)00638-8; Huang YP, 2005, ONCOGENE, V24, P3819, DOI 10.1038/sj.onc.1208527; Kawai H, 2003, J BIOL CHEM, V278, P45946, DOI 10.1074/jbc.M308295200; Kedersha N, 2005, J CELL BIOL, V169, P871, DOI 10.1083/jcb.200502088; Kennedy D, 2002, J CELL BIOCHEM, V84, P173, DOI 10.1002/jcb.1277; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li MY, 2002, NATURE, V416, P648, DOI 10.1038/nature737; Liu YX, 2001, CHINESE MED J-PEKING, V114, P35; Molinari AM, 2000, CANCER RES, V60, P2594; Pazman C, 2000, DEVELOPMENT, V127, P1715; Soncini C, 2001, ONCOGENE, V20, P3869, DOI 10.1038/sj.onc.1204553; Tocque B, 1997, CELL SIGNAL, V9, P153, DOI 10.1016/S0898-6568(96)00135-0; Tourriere H, 2003, J CELL BIOL, V160, P823, DOI 10.1083/jcb.200212128; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wiederschain D, 2001, J BIOL CHEM, V276, P27999, DOI 10.1074/jbc.M102400200; Zekri L, 2005, MOL CELL BIOL, V25, P8703, DOI 10.1128/MCB.25.19.8703-8716.2005	23	61	65	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 21	2007	26	29					4209	4215		10.1038/sj.onc.1210212	http://dx.doi.org/10.1038/sj.onc.1210212			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	184CY	17297477				2022-12-28	WOS:000247619900003
J	Mahadevan, D; Cooke, L; Riley, C; Swart, R; Simons, B; Della Croce, K; Wisner, L; Iorio, M; Shakalya, K; Garewal, H; Nagle, R; Bearss, D				Mahadevan, D.; Cooke, L.; Riley, C.; Swart, R.; Simons, B.; Della Croce, K.; Wisner, L.; Iorio, M.; Shakalya, K.; Garewal, H.; Nagle, R.; Bearss, D.			A novel tyrosine kinase switch is a mechanism of imatinib resistance in gastrointestinal stromal tumors	ONCOGENE			English	Article						tyrosine kinases; morphological change; Kit mutations; GIST	CELL-ADHESION MOLECULE; C-KIT; CRYSTAL-STRUCTURE; GROWTH; MICROENVIRONMENT; IDENTIFICATION; INHIBITOR; MUTATIONS; INVASION; BIOLOGY	KIT or alpha-platelet-derived growth factor receptor (alpha-PDGFR) activating mutations are the pathogenic mechanisms that characterize gastrointestinal stromal tumors (GIST). Despite excellent responses to imatinib mesylate (IM), patients are relapsing. We developed an IM-resistant GIST cell line (GIST-R) from the IM-sensitive GIST882 cell line (GIST-S) by growing these cells in IM. Gene expression pro. ling (GEP) of GIST-S, GIST-R cells and two IM resistant GIST patients demonstrated that KIT is downregulated implying a major role in IM resistance. Instead, GIST-R cells have acquired IM resistance by overexpressing the oncogenic receptor tyrosine kinase-AXL-in a kinase switch'. Further, the two IM resistant GIST patients express AXL and not c-Kit, seen by immunohistochemistry (IHC). Real time reverse transcriptase-polymerase chain reaction and Western blotting of the GIST-S and GIST-R cells confirmed the switch from Kit to AXL. In GIST-R, AXL is tyrosine phosphorylated and its ligand growth-arrest-specific gene 6 is overexpressed implying autocrine activation. The kinase switch is associated with a morphological change from spindle to epithelioid. Molecular modeling of the kinase domain of mutant c-Kit (V654A) and AXL showed no binding to IM but efficient binding to MP470, a novel c-Kit/ AXL kinase inhibitor. MP470 synergizes with docetaxel (taxotere) and is cytotoxic to GIST cells.	Univ Arizona, Arizona Canc Ctr, Tucson, AZ 85724 USA; Radboud Univ Nijmegen Med Ctr, Dept Med Oncol, Nijmegen, Netherlands; Supergen Pharmaceut, Salt Lake City, UT USA	Arizona Center Cancer Care; University of Arizona; Radboud University Nijmegen	Mahadevan, D (corresponding author), Univ Arizona, Arizona Canc Ctr, 1515 N Campbell Ave,POB 245024, Tucson, AZ 85724 USA.	dmahadevan@azcc.arizona.edu	Bearss, David/Q-9141-2019	Riley, Christopher/0000-0001-7930-1495; Bearss, David/0000-0002-4458-826X; Bearss, David/0000-0002-4280-5670	NCI NIH HHS [CA23074] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA023074] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Allinen M, 2004, CANCER CELL, V6, P17, DOI 10.1016/j.ccr.2004.06.010; Andreasen PA, 2000, CELL MOL LIFE SCI, V57, P25, DOI 10.1007/s000180050497; Antonescu CR, 2005, CLIN CANCER RES, V11, P4182, DOI 10.1158/1078-0432.CCR-04-2245; BAUER S, 2005, ASCO9034, V23, pS824; Buchholz M, 2003, CANCER RES, V63, P4945; Chen J, 1997, ONCOGENE, V14, P2033, DOI 10.1038/sj.onc.1201039; Chen Lei L, 2005, Curr Oncol Rep, V7, P293, DOI 10.1007/s11912-005-0053-6; Chen LL, 2004, CANCER RES, V64, P5913, DOI 10.1158/0008-5472.CAN-04-0085; Corless CL, 2004, J CLIN ONCOL, V22, P3813, DOI 10.1200/JCO.2004.05.140; CUNNINGHAM BA, 1987, SCIENCE, V236, P799, DOI 10.1126/science.3576199; Debiec-Rychter M, 2005, GASTROENTEROLOGY, V128, P270, DOI 10.1053/j.gastro.2004.11.020; DeMatteo RP, 2000, ANN SURG, V231, P51, DOI 10.1097/00000658-200001000-00008; DeMatteo RP, 2002, HUM PATHOL, V33, P466, DOI 10.1053/hupa.2002.124122; Duffaud F, 2003, ONCOLOGY-BASEL, V65, P187, DOI 10.1159/000074470; Haldar S, 1997, CANCER RES, V57, P229; Heinrich MC, 2003, SCIENCE, V299, P708, DOI 10.1126/science.1079666; Hirota S, 1998, SCIENCE, V279, P577, DOI 10.1126/science.279.5350.577; Holland SJ, 2005, CANCER RES, V65, P9294, DOI 10.1158/0008-5472.CAN-05-0993; Kelley LA, 2000, J MOL BIOL, V299, P499, DOI 10.1006/jmbi.2000.3741; Kitamura Y, 2004, CELL MOL LIFE SCI, V61, P2924, DOI 10.1007/s00018-004-4273-y; Kristiansen G, 2004, J MOL HISTOL, V35, P255; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Mahadevan D, 2005, MOL CANCER THER, V4, P1867, DOI 10.1158/1535-7163.MCT-05-0146; MAHADEVAN D, 2005, 96 ANN M APR 16 20 2; McLean SR, 2005, MOL CANCER THER, V4, P2008, DOI 10.1158/1535-7163.MCT-05-0070; Michieli P, 2004, CANCER CELL, V6, P61, DOI 10.1016/j.ccr.2004.05.032; Mol CD, 2003, J BIOL CHEM, V278, P31461, DOI 10.1074/jbc.C300186200; Mol CD, 2004, J BIOL CHEM, V279, P31655, DOI 10.1074/jbc.M403319200; OBRYAN JP, 1991, MOL CELL BIOL, V11, P5016, DOI 10.1128/MCB.11.10.5016; Pautsch A, 2001, STRUCTURE, V9, P955, DOI 10.1016/S0969-2126(01)00655-4; PEREZATAYDE AR, 1993, AM J SURG PATHOL, V17, P706, DOI 10.1097/00000478-199307000-00008; Schiering N, 2003, P NATL ACAD SCI USA, V100, P12654, DOI 10.1073/pnas.1734128100; Sekiya T, 2004, J BIOL CHEM, V279, P6840, DOI 10.1074/jbc.M310876200; STITT TN, 1995, CELL, V80, P661, DOI 10.1016/0092-8674(95)90520-0; Theou N, 2005, CLIN CANCER RES, V11, P7593, DOI 10.1158/1078-0432.CCR-05-0710; Tuveson DA, 2001, ONCOGENE, V20, P5054, DOI 10.1038/sj.onc.1204704; Verweij J, 2004, LANCET, V364, P1127, DOI 10.1016/S0140-6736(04)17098-0; Wang LG, 1999, CANCER CHEMOTH PHARM, V44, P355, DOI 10.1007/s002800050989	38	213	238	3	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 7	2007	26	27					3909	3919		10.1038/sj.onc.1210173	http://dx.doi.org/10.1038/sj.onc.1210173			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	177HP	17325667				2022-12-28	WOS:000247144500001
J	Yao, JJ; Liu, Y; Lacorazza, HD; Soslow, RA; Scandura, JM; Nimer, SD; Hedvat, CV				Yao, J. J.; Liu, Y.; Lacorazza, H. D.; Soslow, R. A.; Scandura, J. M.; Nimer, S. D.; Hedvat, C. V.			Tumor promoting properties of the ETS protein MEF in ovarian cancer	ONCOGENE			English	Article						MEF; ELF4; RNA interference; ovarian cancer	TRANSCRIPTION FACTOR; EXPRESSION; GENE; PHOSPHORYLATION	We have previously shown that MEF ( myeloid ELF1-like factor, also known as ELF4) functions as a transcriptional activator of the interleukin ( IL)-8, perforin, granulocyte macrophage-colonyst imulating factor ( GM-CSF) and IL-3 genes in hematopoietic cells. MEF is also expressed in non-hematopoietic tissues including certain ovarian cancer cells. To de. ne the function of MEF in these cells, we examined primary human ovarian epithelial tumors and found that MEF is expressed in a significant proportion of ovarian carcinomas, and in the CAOV3 and SKOV3 ovarian cancer cell lines, but not in normal ovarian surface epithelium. Manipulating MEF levels in these cell lines altered their behavior; reducing MEF levels, using short hairpin RNA expressing vectors, significantly inhibited the proliferation of SKOV3 and CAOV3 cells in culture, and impaired the anchorage-independent growth of CAOV3 cells. Overexpression of MEF in SKOV3 cells ( via retroviral transduction) significantly increased their growth rate, enhanced colony formation in soft agar and promoted tumor formation in nude mice. The oncogenic activity of MEF was further shown by the ability of MEF to transform NIH3T3 cells, and induce their tumor formation in nude mice. MEF is an important regulator of the tumorigenic properties of ovarian cancer cells and could be used a therapeutic target in ovarian cancer.	Mem Sloan Kettering Canc Ctr, Dept Med, Div Hematol Oncol, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10021 USA; Sloan Kettering Inst, Lab Mol Aspects Haematopoiesis, Mol Pharmacol & Chem Program, New York, NY USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	Nimer, SD (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Med, Div Hematol Oncol, 1275 York Ave, New York, NY 10021 USA.	nimers@mskcc.org		HEDVAT, CYRUS/0000-0003-0045-3491; Soslow, Robert/0000-0002-7269-5898; Yao, JinJuan/0000-0003-4692-9969; Scandura, Joseph/0000-0002-9525-143X	NATIONAL CANCER INSTITUTE [P01CA052477, K01CA099156] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL004478] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052208] Funding Source: NIH RePORTER; NCI NIH HHS [K01 CA099156, CA052477] Funding Source: Medline; NHLBI NIH HHS [K08 HL4478] Funding Source: Medline; NIDDK NIH HHS [R01 DK052208] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aryee DNT, 1998, GENE, V210, P71, DOI 10.1016/S0378-1119(98)00022-5; Choi C, 1997, GENE CHROMOSOME CANC, V20, P234; Du Y, 2005, BLOOD, V106, P2498, DOI 10.1182/blood-2004-12-4840; Fukushima T, 2003, LEUKEMIA RES, V27, P387, DOI 10.1016/S0145-2126(02)00214-X; Hedvat CV, 2004, J BIOL CHEM, V279, P6395, DOI 10.1074/jbc.M307524200; Lacorazza HD, 2006, CANCER CELL, V9, P175, DOI 10.1016/j.ccr.2006.02.017; Lacorazza HD, 2003, BLOOD CELL MOL DIS, V31, P342, DOI 10.1016/S1079-9796(03)00162-1; Lacorazza HD, 2002, IMMUNITY, V17, P437, DOI 10.1016/S1074-7613(02)00422-3; Liu Y, 2006, MOL CELL BIOL, V26, P3114, DOI 10.1128/MCB.26.8.3114-3123.2006; Lund AH, 2002, NAT GENET, V32, P160, DOI 10.1038/ng956; Mikkers H, 2002, NAT GENET, V32, P459, DOI 10.1038/ng1102-459b; Milde-Langosch K, 2003, INT J GYNECOL PATHOL, V22, P168, DOI 10.1097/00004347-200304000-00009; Miyazaki Y, 2001, J BIOL CHEM, V276, P40528, DOI 10.1074/jbc.M103051200; Miyazaki Y, 1996, ONCOGENE, V13, P1721; Seki Y, 2002, CANCER RES, V62, P6579; Seth A, 2005, EUR J CANCER, V41, P2462, DOI 10.1016/j.ejca.2005.08.013; Takai N, 2003, INT J MOL MED, V12, P349; Tomlins SA, 2005, SCIENCE, V310, P644, DOI 10.1126/science.1117679; Yuan ZQ, 2000, ONCOGENE, V19, P2324, DOI 10.1038/sj.onc.1203598	19	27	29	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 7	2007	26	27					4032	4037		10.1038/sj.onc.1210170	http://dx.doi.org/10.1038/sj.onc.1210170			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	177HP	17213815				2022-12-28	WOS:000247144500014
J	Jiao, R; Harrigan, JA; Shevelev, I; Dietschy, T; Selak, N; Indig, FE; Piotrowski, J; Janscak, P; Bohr, VA; Stagljar, I				Jiao, R.; Harrigan, J. A.; Shevelev, I.; Dietschy, T.; Selak, N.; Indig, F. E.; Piotrowski, J.; Janscak, P.; Bohr, V. A.; Stagljar, I.			The Werner syndrome protein is required for recruitment of chromatin assembly factor 1 following DNA damage	ONCOGENE			English	Article						WRN; CAF-1; DNA damage; chromatin assembly; genome stability	SYNDROME GENE-PRODUCT; NUCLEOTIDE EXCISION-REPAIR; BLOOM-SYNDROME HELICASES; FUNCTIONAL INTERACTION; IN-VIVO; HUMAN-CELLS; FLAP ENDONUCLEASE-1; POLYMERASE-BETA; WRN HELICASES; STRAND BREAKS	The Werner syndrome protein (WRN) and chromatin assembly factor 1 (CAF-1) are both involved in the maintenance of genome stability. In response to DNA-damaging signals, both of these proteins relocate to sites where DNA synthesis occurs. However, the interaction between WRN and CAF-1 has not yet been investigated. In this report, we show that WRN interacts physically with the largest subunit of CAF-1, hp150, in vitro and in vivo. Although hp150 does not alter WRN catalytic activities in vitro, and the chromatin assembly activity of CAF-1 is not affected in the absence of WRN in vivo, this interaction may have an important role during the cellular response to DNA replication fork blockage and/or DNA damage signals. In hp150 RNA-mediated interference (RNAi) knockdown cells, WRN partially formed foci following hydroxyurea (HU) treatment. However, in the absence of WRN, hp150 did not relocate to form foci following exposure to HU and ultraviolet light. Thus, our results demonstrate that WRN responds to DNA damage before CAF-1 and suggest that WRN may recruit CAF-1, via interaction with hp150, to DNA damage sites during DNA synthesis.	Univ Toronto, Terrence Donnelly Ctr Cellular & Biomol Res, Dept Biochem, Toronto, ON M5S 3E1, Canada; Univ Toronto, Dept Med Genet & Microbiol, Toronto, ON M5S 3E1, Canada; Chinese Acad Sci, Natl Lab Biomacromol, Inst Biophys, Beijing 100080, Peoples R China; Chinese Acad Sci, State Key Lab Brain & Cognit Sci, Inst Biophys, Beijing 100080, Peoples R China; NIA, Lab Mol Gerontol, NIH, Baltimore, MD 21224 USA; Univ Toronto, Dept Med Genet & Microbiol, Toronto, ON M4X 1K9, Canada; Friedrich Miescher Inst Biomed Res, Basel, Switzerland; NIA, Res Resources Branch, NIH, Baltimore, MD 21224 USA; Univ Zurich, Inst Mol Canc Res, CH-8006 Zurich, Switzerland	University of Toronto; University of Toronto; Chinese Academy of Sciences; Institute of Biophysics, CAS; Chinese Academy of Sciences; Institute of Biophysics, CAS; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); University of Toronto; Friedrich Miescher Institute for Biomedical Research; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); University of Zurich	Jiao, R (corresponding author), Univ Toronto, Terrence Donnelly Ctr Cellular & Biomol Res, Dept Biochem, 160 Coll St, Toronto, ON M5S 3E1, Canada.	rjiao@sun5.ibp.ac.cn; igor.stagljar@utoronto.ca	Bohr, Vilhelm/AAP-5931-2020; Jiao, Renjie/AAE-8902-2019; Janscak, Pavel/G-6189-2014; Janscak, Pavel/Q-3795-2018	Janscak, Pavel/0000-0002-1748-7789	NATIONAL INSTITUTE ON AGING [Z01AG000615, ZICAG000615] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Adkins MW, 2004, MOL CELL, V14, P657, DOI 10.1016/j.molcel.2004.05.016; Bohr VA, 2005, MUTAT RES-FUND MOL M, V577, P252, DOI 10.1016/j.mrfmmm.2005.03.021; Bradshaw PS, 2005, NAT GENET, V37, P193, DOI 10.1038/ng1506; Cheng WH, 2004, J BIOL CHEM, V279, P21169, DOI 10.1074/jbc.M312770200; Doherty KM, 2005, J BIOL CHEM, V280, P29494, DOI 10.1074/jbc.M500653200; Franchitto A, 2004, CELL CYCLE, V3, P1331, DOI 10.4161/cc.3.10.1185; Gaillard PHL, 1996, CELL, V86, P887, DOI 10.1016/S0092-8674(00)80164-6; Garcia PL, 2004, NUCLEIC ACIDS RES, V32, P3771, DOI 10.1093/nar/gkh709; Green CM, 2003, EMBO J, V22, P5163, DOI 10.1093/emboj/cdg478; Guay D, 2006, INT J BIOCHEM CELL B, V38, P1300, DOI 10.1016/j.biocel.2006.01.008; Harrigan JA, 2006, NUCLEIC ACIDS RES, V34, P745, DOI 10.1093/nar/gkj475; Harrigan JA, 2003, J BIOL CHEM, V278, P22686, DOI 10.1074/jbc.M213103200; Hickson ID, 2003, NAT REV CANCER, V3, P169, DOI 10.1038/nrc1012; Hoek M, 2003, P NATL ACAD SCI USA, V100, P12183, DOI 10.1073/pnas.1635158100; Jiao RJ, 2004, MOL CELL BIOL, V24, P4710, DOI 10.1128/MCB.24.11.4710-4719.2004; Karmakar P, 2005, MECH AGEING DEV, V126, P1146, DOI 10.1016/j.mad.2005.06.004; Karmakar P, 2002, NUCLEIC ACIDS RES, V30, P3583, DOI 10.1093/nar/gkf482; Karmakar P, 2002, J BIOL CHEM, V277, P18291, DOI 10.1074/jbc.M111523200; Kaufman PD, 1997, GENE DEV, V11, P345, DOI 10.1101/gad.11.3.345; KAUFMAN PD, 1995, CELL, V81, P1105, DOI 10.1016/S0092-8674(05)80015-7; Krude T, 1999, EUR J BIOCHEM, V263, P1, DOI 10.1046/j.1432-1327.1999.00508.x; KRUDE T, 1995, EXP CELL RES, V220, P304, DOI 10.1006/excr.1995.1320; LAI JS, 1992, P NATL ACAD SCI USA, V89, P6958, DOI 10.1073/pnas.89.15.6958; Laud PR, 2005, GENE DEV, V19, P2560, DOI 10.1101/gad.1321305; Lee JW, 2005, J BIOL CHEM, V280, P39627, DOI 10.1074/jbc.M506112200; Li BM, 2000, J BIOL CHEM, V275, P28349, DOI 10.1074/jbc.C000289200; LI L, 2005, J CELL SCI, V118, P4153; Linger J, 2005, GENETICS, V171, P1513, DOI 10.1534/genetics.105.043000; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Marciniak RA, 1998, P NATL ACAD SCI USA, V95, P6887, DOI 10.1073/pnas.95.12.6887; Martini E, 1998, J CELL BIOL, V143, P563, DOI 10.1083/jcb.143.3.563; Moggs JG, 2000, MOL CELL BIOL, V20, P1206, DOI 10.1128/MCB.20.4.1206-1218.2000; Nabatiyan A, 2004, MOL CELL BIOL, V24, P2853, DOI 10.1128/MCB.24.7.2853-2862.2004; Nabatiyan A, 2006, MOL CELL BIOL, V26, P1839, DOI 10.1128/MCB.26.5.1839-1849.2006; Opresko PL, 2004, MOL CELL, V14, P763, DOI 10.1016/j.molcel.2004.05.023; Opresko PL, 2004, J BIOL CHEM, V279, P18099, DOI 10.1074/jbc.R300034200; Opresko PL, 2003, CARCINOGENESIS, V24, P791, DOI 10.1093/carcin/bgg034; Opresko PL, 2002, J BIOL CHEM, V277, P41110, DOI 10.1074/jbc.M205396200; Orren DK, 2001, NUCLEIC ACIDS RES, V29, P1926, DOI 10.1093/nar/29.9.1926; Oshima J, 2002, CANCER RES, V62, P547; Ozgenc A, 2005, MUTAT RES-FUND MOL M, V577, P237, DOI 10.1016/j.mrfmmm.2005.03.020; Pedrazzi G, 2003, BIOL CHEM, V384, P1155, DOI 10.1515/BC.2003.128; Petkovic M, 2005, J CELL SCI, V118, P4261, DOI 10.1242/jcs.02556; Poot M, 2001, FASEB J, V15, P1224, DOI 10.1096/fj.00-0611fje; Prakash S, 2000, MUTAT RES-FUND MOL M, V451, P13, DOI 10.1016/S0027-5107(00)00037-3; Rodriguez-Lopez AM, 2003, MECH AGEING DEV, V124, P167, DOI 10.1016/S0047-6374(02)00131-8; Sakamoto S, 2001, GENES CELLS, V6, P421, DOI 10.1046/j.1365-2443.2001.00433.x; Sharma S, 2004, HUM MOL GENET, V13, P2247, DOI 10.1093/hmg/ddh234; Sharma S, 2005, NUCLEIC ACIDS RES, V33, P6769, DOI 10.1093/nar/gki1002; Sharma S, 2004, J BIOL CHEM, V279, P9847, DOI 10.1074/jbc.M309898200; Shen JC, 1998, NUCLEIC ACIDS RES, V26, P2879, DOI 10.1093/nar/26.12.2879; Shibahara K, 1999, CELL, V96, P575, DOI 10.1016/S0092-8674(00)80661-3; SMITH S, 1989, CELL, V58, P15, DOI 10.1016/0092-8674(89)90398-X; Spillare EA, 1999, GENE DEV, V13, P1355, DOI 10.1101/gad.13.11.1355; Szekely AM, 2000, P NATL ACAD SCI USA, V97, P11365, DOI 10.1073/pnas.97.21.11365; Tyler JK, 1996, MOL CELL BIOL, V16, P6149; Tyler JK, 2001, MOL CELL BIOL, V21, P6574, DOI 10.1128/MCB.21.19.6574-6584.2001; Verreault A, 1996, CELL, V87, P95, DOI 10.1016/S0092-8674(00)81326-4; von Kobbe C, 2004, NUCLEIC ACIDS RES, V32, P4003, DOI 10.1093/nar/gkh721; von Kobbe C, 2003, MOL CELL BIOL, V23, P8601, DOI 10.1128/MCB.23.23.8601-8613.2003; von Kobbe C, 2002, J BIOL CHEM, V277, P22035, DOI 10.1074/jbc.M200914200; Wang XW, 2001, J BIOL CHEM, V276, P32948, DOI 10.1074/jbc.M103298200; Wolffe A., 1998, CHROMATIN STRUCTURE; Wu L, 2000, J BIOL CHEM, V275, P9636, DOI 10.1074/jbc.275.13.9636; Xue Y, 2002, BIOCHEMISTRY-US, V41, P2901, DOI 10.1021/bi0157161; Yang Q, 2002, J BIOL CHEM, V277, P31980, DOI 10.1074/jbc.M204111200; Yannone SM, 2001, J BIOL CHEM, V276, P38242; Ye XF, 2003, MOL CELL, V11, P341, DOI 10.1016/S1097-2765(03)00037-6; Yu CE, 1996, SCIENCE, V272, P258, DOI 10.1126/science.272.5259.258	69	18	18	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 31	2007	26	26					3811	3822		10.1038/sj.onc.1210150	http://dx.doi.org/10.1038/sj.onc.1210150			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	175PV	17173071				2022-12-28	WOS:000247026400005
J	Meloche, S; Pouyssegur, J				Meloche, S.; Pouyssegur, J.			The ERK1/2 mitogen-activated protein kinase pathway as a master regulator of the G1- to S-phase transition	ONCOGENE			English	Review						signal transduction; MAP kinase; ERK1/2; cell cycle; G1 phase	CELL-CYCLE ARREST; INITIATION-FACTOR 4E; NIH 3T3 CELLS; SIGNAL-TRANSDUCTION PATHWAYS; MESSENGER-RNA TRANSPORT; SMOOTH-MUSCLE-CELLS; EARLY GENE-PRODUCTS; MAP KINASE; DEPENDENT KINASE; DNA-SYNTHESIS	The Ras-dependent extracellular signal-regulated kinase (ERK) 1/2 mitogen-activated protein (MAP) kinase pathway plays a central role in cell proliferation control. In normal cells, sustained activation of ERK1/ERK2 is necessary for G1- to S-phase progression and is associated with induction of positive regulators of the cell cycle and inactivation of antiproliferative genes. In cells expressing activated Ras or Raf mutants, hyperactivation of the ERK1/2 pathway elicits cell cycle arrest by inducing the accumulation of cyclin-dependent kinase inhibitors. In this review, we discuss the mechanisms by which activated ERK1/ERK2 regulate growth and cell cycle progression of mammalian somatic cells. We also highlight the findings obtained from gene disruption studies.	Univ Montreal, Inst Rech Immunol & Cancerol, Dept Pharmacol, Montreal, PQ H3C 3J7, Canada; Univ Montreal, Inst Rech Immunol & Cancerol, Dept Mol Biol, Montreal, PQ H3C 3J7, Canada; Univ Nice, CNRS UMR 6543, Inst Signaling Dev Biol & Canc, Ctr A Lacassagne, F-06034 Nice, France	Universite de Montreal; Universite de Montreal; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur	Meloche, S (corresponding author), Univ Montreal, Inst Rech Immunol & Cancerol, Dept Pharmacol, Montreal, PQ H3C 3J7, Canada.	sylvain.meloche@umontreal.ca; jacques.pouyssegur@unice.fr						Abbott DW, 1999, J BIOL CHEM, V274, P2732, DOI 10.1074/jbc.274.5.2732; Adhikary S, 2005, NAT REV MOL CELL BIO, V6, P635, DOI 10.1038/nrm1703; ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; ANG XL, SCI STKE, pPE31; Arabi A, 2005, NAT CELL BIOL, V7, P303, DOI 10.1038/ncb1225; Arber N, 1996, ONCOGENE, V12, P1903; Bagui TK, 2003, MOL CELL BIOL, V23, P7285, DOI 10.1128/MCB.23.20.7285-7290.2003; Balmanno K, 1999, ONCOGENE, V18, P3085, DOI 10.1038/sj.onc.1202647; Bottazzi ME, 1999, J CELL BIOL, V146, P1255, DOI 10.1083/jcb.146.6.1255; Bouchard C, 1999, EMBO J, V18, P5321, DOI 10.1093/emboj/18.19.5321; Boucher MJ, 2004, AM J PHYSIOL-GASTR L, V286, pG736, DOI 10.1152/ajpgi.00453.2003; Bourcier C, 2006, CANCER RES, V66, P2700, DOI 10.1158/0008-5472.CAN-05-3129; Bracken AP, 2004, TRENDS BIOCHEM SCI, V29, P409, DOI 10.1016/j.tibs.2004.06.006; BRONDELLO JM, 1995, ONCOGENE, V10, P1895; BRUNET A, 1994, ONCOGENE, V9, P3379; Cardozo T, 2004, NAT REV MOL CELL BIO, V5, P739, DOI 10.1038/nrm1471; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Cha H, 2004, BIOCHEM J, V378, P857, DOI 10.1042/BJ20031173; Chen D, 1999, J IMMUNOL, V163, P5796; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; Cheng MG, 1998, P NATL ACAD SCI USA, V95, P1091, DOI 10.1073/pnas.95.3.1091; Claassen GF, 2000, P NATL ACAD SCI USA, V97, P9498, DOI 10.1073/pnas.150006697; Cobrinik D, 2005, ONCOGENE, V24, P2796, DOI 10.1038/sj.onc.1208619; Collado M, 2005, NATURE, V436, P642, DOI 10.1038/436642a; Coller HA, 2000, P NATL ACAD SCI USA, V97, P3260, DOI 10.1073/pnas.97.7.3260; Conlon I, 1999, CELL, V96, P235, DOI 10.1016/S0092-8674(00)80563-2; Cook SJ, 1999, MOL CELL BIOL, V19, P330; Cook SJ, 1996, BIOCHEM J, V320, P237, DOI 10.1042/bj3200237; COOPER JA, 1984, MOL CELL BIOL, V4, P30, DOI 10.1128/MCB.4.1.30; Corradetti MN, 2006, ONCOGENE, V25, P6347, DOI 10.1038/sj.onc.1209885; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; Culjkovic B, 2005, J CELL BIOL, V169, P245, DOI 10.1083/jcb.200501019; Delmas C, 2001, J BIOL CHEM, V276, P34958, DOI 10.1074/jbc.M101714200; DeSilva DR, 1998, J IMMUNOL, V160, P4175; Dever TE, 2002, CELL, V108, P545, DOI 10.1016/S0092-8674(02)00642-6; Dey A, 2000, MOL BIOL CELL, V11, P3835, DOI 10.1091/mbc.11.11.3835; Diehl JA, 2003, MOL CELL BIOL, V23, P1764, DOI 10.1128/MCB.23.5.1764-1774.2003; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Ebisuya M, 2005, J CELL SCI, V118, P2997, DOI 10.1242/jcs.02505; Edelmann HML, 1996, J BIOL CHEM, V271, P963, DOI 10.1074/jbc.271.2.963; Evans DR, 2004, J BIOL CHEM, V279, P33035, DOI 10.1074/jbc.R400007200; Fanton CP, 2001, J BIOL CHEM, V276, P18871, DOI 10.1074/jbc.M011514200; FILMUS J, 1994, ONCOGENE, V9, P3627; Fingar DC, 2004, ONCOGENE, V23, P3151, DOI 10.1038/sj.onc.1207542; Fischer AM, 2005, IMMUNITY, V23, P431, DOI 10.1016/j.immuni.2005.08.013; Flynn A, 1996, EUR J BIOCHEM, V236, P40, DOI 10.1111/j.1432-1033.1996.00040.x; Fukunaga R, 1997, EMBO J, V16, P1921, DOI 10.1093/emboj/16.8.1921; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; Ganoth D, 2001, NAT CELL BIOL, V3, P321, DOI 10.1038/35060126; Geng Y, 2001, P NATL ACAD SCI USA, V98, P194, DOI 10.1073/pnas.011522998; Gomez-Cambronero J, 1999, FEBS LETT, V443, P126, DOI 10.1016/S0014-5793(98)01685-8; Gotoh I, 1999, J BIOL CHEM, V274, P11874, DOI 10.1074/jbc.274.17.11874; Grandori C, 2005, NAT CELL BIOL, V7, P311, DOI 10.1038/ncb1224; Graves LM, 2000, NATURE, V403, P328, DOI 10.1038/35002111; Greulich H, 1998, J BIOL CHEM, V273, P13280, DOI 10.1074/jbc.273.21.13280; Gysin S, 2005, CANCER RES, V65, P4870, DOI 10.1158/0008-5472.CAN-04-2848; Han JH, 2005, J BIOL CHEM, V280, P31548, DOI 10.1074/jbc.M503431200; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; Harding A, 2003, J BIOL CHEM, V278, P16747, DOI 10.1074/jbc.M301015200; Hatano N, 2003, GENES CELLS, V8, P847, DOI 10.1046/j.1365-2443.2003.00680.x; Hay N, 2004, GENE DEV, V18, P1926, DOI 10.1101/gad.1212704; Hayne C, 2004, BIOCHEM BIOPH RES CO, V321, P675, DOI 10.1016/j.bbrc.2004.07.024; Hayne C, 2000, J BIOL CHEM, V275, P31876, DOI 10.1074/jbc.M002766200; HERBER, 1994, ONCOGENE, V9, P2105; Hermeking H, 2000, P NATL ACAD SCI USA, V97, P2229, DOI 10.1073/pnas.050586197; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; Hsu JY, 2002, NAT CELL BIOL, V4, P358, DOI 10.1038/ncb785; Jones SM, 2001, NAT CELL BIOL, V3, P165, DOI 10.1038/35055073; Jorgensen P, 2004, CURR BIOL, V14, pR1014, DOI 10.1016/j.cub.2004.11.027; KAHAN C, 1992, J BIOL CHEM, V267, P13369; Karpova AY, 1997, AM J PHYSIOL-LUNG C, V272, pL558, DOI 10.1152/ajplung.1997.272.3.L558; Kawada M, 1997, ONCOGENE, V15, P629, DOI 10.1038/sj.onc.1201228; Kerkhoff E, 1998, CANCER RES, V58, P1636; Kerkhoff E, 1997, MOL CELL BIOL, V17, P2576, DOI 10.1128/MCB.17.5.2576; Knauf JA, 2006, J BIOL CHEM, V281, P3800, DOI 10.1074/jbc.M511690200; KOHNO M, 1986, BIOCHEM J, V238, P451, DOI 10.1042/bj2380451; KOHNO M, 1985, J BIOL CHEM, V260, P1771; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Ladha MH, 1998, MOL CELL BIOL, V18, P6605, DOI 10.1128/MCB.18.11.6605; Lai HK, 2000, ONCOGENE, V19, P1623, DOI 10.1038/sj.onc.1203473; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; Lenferink AEG, 2000, P NATL ACAD SCI USA, V97, P9609, DOI 10.1073/pnas.160564197; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; Li L, 1996, EARLY CHINA, V21, P1; LI Y, 1994, ONCOGENE, V9, P2261; Lin AW, 1998, GENE DEV, V12, P3008, DOI 10.1101/gad.12.19.3008; Lips DJ, 2004, CIRCULATION, V109, P1938, DOI 10.1161/01.CIR.0000127126.73759.23; LIU JJ, 1995, MOL CELL BIOL, V15, P3654; Liu X, 2004, ONCOGENE, V23, P763, DOI 10.1038/sj.onc.1207188; Lloyd AC, 1997, GENE DEV, V11, P663, DOI 10.1101/gad.11.5.663; Lloyd AC, 1998, CURR OPIN GENET DEV, V8, P43, DOI 10.1016/S0959-437X(98)80060-9; Ma L, 2005, CELL, V121, P179, DOI 10.1016/j.cell.2005.02.031; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; Maekawa M, 2002, J BIOL CHEM, V277, P37783, DOI 10.1074/jbc.M204506200; Malumbres M, 2000, MOL CELL BIOL, V20, P2915, DOI 10.1128/MCB.20.8.2915-2925.2000; Malumbres M, 2001, NAT REV CANCER, V1, P222, DOI 10.1038/35106065; Mamane Y, 2004, ONCOGENE, V23, P3172, DOI 10.1038/sj.onc.1207549; Manning BD, 2003, TRENDS BIOCHEM SCI, V28, P573, DOI 10.1016/j.tibs.2003.09.003; Mayer C, 2006, ONCOGENE, V25, P6384, DOI 10.1038/sj.onc.1209883; MELOCHE S, 1995, J CELL PHYSIOL, V163, P577, DOI 10.1002/jcp.1041630319; MELOCHE S, 1992, MOL ENDOCRINOL, V6, P845, DOI 10.1210/me.6.5.845; Michaloglou C, 2005, NATURE, V436, P720, DOI 10.1038/nature03890; MICHIELI P, 1994, CANCER RES, V54, P3391; Mirza AM, 2004, MOL CELL BIOL, V24, P10868, DOI 10.1128/MCB.24.24.10868-10881.2004; Morgan D. O., 2007, CELL CYCLE PRINCIPLE; Morley SJ, 1997, J BIOL CHEM, V272, P17887, DOI 10.1074/jbc.272.28.17887; Murphy LO, 2002, NAT CELL BIOL, V4, P556, DOI 10.1038/ncb822; Murphy LO, 2004, MOL CELL BIOL, V24, P144, DOI 10.1128/MCB.24.1.144-153.2004; NAKAMURA KD, 1983, MOL CELL BIOL, V3, P380, DOI 10.1128/MCB.3.3.380; Nakayama K, 1998, BIOESSAYS, V20, P1020, DOI 10.1002/(SICI)1521-1878(199812)20:12<1020::AID-BIES8>3.0.CO;2-D; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; Paget WJ, 1999, SOZ PRAVENTIV MED, V44, P1, DOI 10.1007/BF01624804; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; Pelengaris S, 2002, NAT REV CANCER, V2, P764, DOI 10.1038/nrc904; Peters JM, 2002, MOL CELL, V9, P931, DOI 10.1016/S1097-2765(02)00540-3; Piatelli MJ, 2002, J BIOL CHEM, V277, P12144, DOI 10.1074/jbc.M200102200; Ptacek J, 2005, NATURE, V438, P679, DOI 10.1038/nature04187; Pumiglia KM, 1997, P NATL ACAD SCI USA, V94, P448, DOI 10.1073/pnas.94.2.448; Ravi RK, 1998, J CLIN INVEST, V101, P153, DOI 10.1172/JCI831; Rivard N, 1999, AM J PHYSIOL-CELL PH, V277, pC652, DOI 10.1152/ajpcell.1999.277.4.C652; Roberts EC, 2002, MOL CELL BIOL, V22, P7226, DOI 10.1128/MCB.22.20.7226-7241.2002; Roovers K, 1999, MOL BIOL CELL, V10, P3197, DOI 10.1091/mbc.10.10.3197; Roovers K, 2000, BIOESSAYS, V22, P818, DOI 10.1002/1521-1878(200009)22:9<818::AID-BIES7>3.3.CO;2-Y; Roper E, 2001, EMBO REP, V2, P145, DOI 10.1093/embo-reports/kve020; ROSENTHAL K, 1995, SEMIN AVIAN EXOT PET, V4, P1; Rossant J, 2001, NAT REV GENET, V2, P538, DOI 10.1038/35080570; ROSSOMANDO AJ, 1989, P NATL ACAD SCI USA, V86, P6940, DOI 10.1073/pnas.86.18.6940; ROSSOMANDO AJ, 1991, J BIOL CHEM, V266, P20270; Rousseau D, 1996, P NATL ACAD SCI USA, V93, P1065, DOI 10.1073/pnas.93.3.1065; Roux PP, 2004, P NATL ACAD SCI USA, V101, P13489, DOI 10.1073/pnas.0405659101; Saba-El-Leil MK, 2003, EMBO REP, V4, P964, DOI 10.1038/sj.embor.embor939; Sakakibara K, 2005, J BIOL CHEM, V280, P25470, DOI 10.1074/jbc.M502320200; SALE EM, 1995, EMBO J, V14, P674, DOI 10.1002/j.1460-2075.1995.tb07046.x; Scheper GC, 2002, EUR J BIOCHEM, V269, P5350, DOI 10.1046/j.1432-1033.2002.03291.x; Sears R, 2000, GENE DEV, V14, P2501, DOI 10.1101/gad.836800; Sebolt-Leopold JS, 1999, NAT MED, V5, P810, DOI 10.1038/10533; Sebolt-Leopold JS, 2004, NAT REV CANCER, V4, P937, DOI 10.1038/nrc1503; SEGER R, 1994, J BIOL CHEM, V269, P25699; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Servant MJ, 1996, J BIOL CHEM, V271, P16047, DOI 10.1074/jbc.271.27.16047; Seufferlein T, 1996, J BIOL CHEM, V271, P21471, DOI 10.1074/jbc.271.35.21471; Sewing A, 1997, MOL CELL BIOL, V17, P5588, DOI 10.1128/MCB.17.9.5588; Shapiro PS, 1998, J CELL BIOL, V142, P1533, DOI 10.1083/jcb.142.6.1533; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; SHEIKH MS, 1994, ONCOGENE, V9, P3407; Sherr CJ, 2000, CANCER RES, V60, P3689; Shinohara M, 2006, MOL BIOL CELL, V17, P5227, DOI 10.1091/mbc.E06-04-0284; Spruck C, 2001, MOL CELL, V7, P639, DOI 10.1016/S1097-2765(01)00210-6; Stefanovsky VY, 2001, MOL CELL, V8, P1063, DOI 10.1016/S1097-2765(01)00384-7; Strudwick S, 2002, DIFFERENTIATION, V70, P10, DOI 10.1046/j.1432-0436.2002.700102.x; SUN H, 1994, SCIENCE, V266, P285, DOI 10.1126/science.7939666; Sutterluty H, 1999, NAT CELL BIOL, V1, P207, DOI 10.1038/12027; Suzuki T, 2002, GENE DEV, V16, P1356, DOI 10.1101/gad.962802; Takenaka K, 1998, SCIENCE, V280, P599, DOI 10.1126/science.280.5363.599; Takuwa N, 1997, MOL CELL BIOL, V17, P5348, DOI 10.1128/MCB.17.9.5348; Talarmin H, 1999, MOL CELL BIOL, V19, P6003; TAMEMOTO H, 1992, J BIOL CHEM, V267, P20293; Tang DM, 2002, J BIOL CHEM, V277, P12710, DOI 10.1074/jbc.M111598200; Tetsu O, 2003, CANCER CELL, V3, P233, DOI 10.1016/S1535-6108(03)00053-9; Tombes RM, 1998, BIOCHEM J, V330, P1451; Tong W, 2001, MOL CELL BIOL, V21, P1319, DOI 10.1128/MCB.21.4.1319-1328.2001; Topisirovic I, 2004, CANCER RES, V64, P8639, DOI 10.1158/0008-5472.CAN-04-2677; Topisirovic I, 2002, MOL CELL BIOL, V22, P6183, DOI 10.1128/MCB.22.17.6183-6198.2002; Treinies I, 1999, MOL CELL BIOL, V19, P321; Tsvetkov LM, 1999, CURR BIOL, V9, P661, DOI 10.1016/S0960-9822(99)80290-5; Ueda T, 2004, MOL CELL BIOL, V24, P6539, DOI 10.1128/MCB.24.15.6539-6549.2004; Vantaggiato Chiara, 2006, J Biol, V5, P14, DOI 10.1186/jbiol38; Vlach J, 1997, EMBO J, V16, P5334, DOI 10.1093/emboj/16.17.5334; Waskiewicz AJ, 1999, MOL CELL BIOL, V19, P1871; Waskiewicz AJ, 1997, EMBO J, V16, P1909, DOI 10.1093/emboj/16.8.1909; Weber JD, 1997, BIOCHEM J, V326, P61, DOI 10.1042/bj3260061; Weber JD, 1997, J BIOL CHEM, V272, P32966, DOI 10.1074/jbc.272.52.32966; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Whitmarsh AJ, 1996, J MOL MED-JMM, V74, P589, DOI 10.1007/s001090050063; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; Willard FS, 2001, CELL SIGNAL, V13, P653, DOI 10.1016/S0898-6568(01)00185-1; Williams DH, 1998, BIOCHEMISTRY-US, V37, P9579, DOI 10.1021/bi972914c; Winston JT, 1996, ONCOGENE, V12, P127; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598; Wright JH, 1999, P NATL ACAD SCI USA, V96, P11335, DOI 10.1073/pnas.96.20.11335; Wullschleger S, 2006, CELL, V124, P471, DOI 10.1016/j.cell.2006.01.016; Yamamoto T, 2006, CURR BIOL, V16, P1171, DOI 10.1016/j.cub.2006.04.044; Yan Y, 2005, ONCOGENE, V24, P3285, DOI 10.1038/sj.onc.1208492; Yang HY, 2000, J BIOL CHEM, V275, P24735, DOI 10.1074/jbc.C000147200; Yao Y, 2003, P NATL ACAD SCI USA, V100, P12759, DOI 10.1073/pnas.2134254100; Yoon S, 2006, GROWTH FACTORS, V24, P21, DOI 10.1080/02699050500284218; Yoshida Y, 2003, GENE DEV, V17, P1201, DOI 10.1101/gad.1088003; Zecevic M, 1998, J CELL BIOL, V142, P1547, DOI 10.1083/jcb.142.6.1547; Zeller KI, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-10-r69; Zezula J, 1997, J BIOL CHEM, V272, P29967, DOI 10.1074/jbc.272.47.29967; Zhu JY, 1998, GENE DEV, V12, P2997, DOI 10.1101/gad.12.19.2997	193	826	862	0	66	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 15	2007	26	22					3227	3239		10.1038/sj.onc.1210414	http://dx.doi.org/10.1038/sj.onc.1210414			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	169PH	17496918				2022-12-28	WOS:000246603600011
J	Graessmann, M; Berg, B; Fuchs, B; Klein, A; Graessmann, A				Graessmann, M.; Berg, B.; Fuchs, B.; Klein, A.; Graessmann, A.			Chemotherapy resistance of mouse WAP-SVT/t breast cancer cells is mediated by osteopontin, inhibiting apoptosis downstream of caspase-3	ONCOGENE			English	Article						breast cancer cells; therapy resistance; osteopontin; inhibition of apoptosis; caspase-3; microarray	MITOCHONDRIA; ACTIVATION; PROTEINS; STRESS; DEATH; RECEPTOR; PHOSPHORYLATION; IDENTIFICATION; CLUSTERS; BINDING	Impairment of the complex regulatory network of cell death and survival is frequently the reason for therapy resistance of breast cancer cells and a major cause of tumor progression. We established two independent cell lines from a fast growing mouse breast tumor (WAP-SVT/t transgenic animal). Cells from one line (ME-A cells) are sensitive to apoptotic stimuli such as growth factor depletion or treatment with antitumor agents (e.g. doxorubicin). Cells from the second line (ME-C cells), which carry a missense mutation at the p53 codon 242, are very insensitive to apoptotic stimuli. Co-cultivation experiments revealed that the ME-C cells mediate cell death resistance to the ME-A cells. Microarray and Western blot analysis showed that osteopontin (OPN) is selectively overexpressed by the ME-C cells. This glycoprotein is the most abundant protein secreted by the ME-C cells and we obtained strong indications that OPN is the main antiapoptotic factor. However, the OPN containing ME-C cell medium does not alter the expression level of pro- or antiapoptotic genes or known inhibitors of apoptosis (IAPs). Its signaling involves mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) kinase (MEK)1/2 as the kinase inhibitor PD98059 restores apoptosis but not the Akt inhibitor. In the ME-A cells, mitochondrial cytochrome c release occurs with and without external apoptotic stimuli. OPN containing ME-C cell medium does not prevent the mitochondrial cytochrome c release and caspase-9 processing. In serum starved ME-A cells, the OPN containing ME-C cell medium prevents caspase-3 activation. However, in doxorubicin-treated cells, although apoptosis is blocked, it does not inhibit caspase-3. This indicates that the ME-A cells distinguish between the initial apoptotic stimuli and that the cells possess a further uncharacterized control element acting downstream from caspase-3.	Charite Univ Med Berlin, Inst Mol Biol & Bioinformat, D-14195 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Graessmann, M (corresponding author), Charite Univ Med Berlin, Inst Mol Biol & Bioinformat, Arnimallee 22,Farbeckstr,30, D-14195 Berlin, Germany.	adolf.graessmann@charite.de	Klein, Andreas/AAG-4506-2021	Klein, Andreas/0000-0002-3496-7215				Allan LA, 2003, NAT CELL BIOL, V5, P647, DOI 10.1038/ncb1005; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Beere HM, 2004, J CELL SCI, V117, P2641, DOI 10.1242/jcs.01284; Brown JM, 2005, NAT REV CANCER, V5, P231, DOI 10.1038/nrc1560; Caudevilla C, 2001, FEBS LETT, V507, P269, DOI 10.1016/S0014-5793(01)02957-X; Christensen B, 2005, BIOCHEM J, V390, P285, DOI 10.1042/BJ20050341; Costantini P, 2002, CELL DEATH DIFFER, V9, P82, DOI 10.1038/sj.cdd.4400932; DENHARDT DT, 1993, FASEB J, V7, P1475, DOI 10.1096/fasebj.7.15.8262332; Erhardt P, 1999, MOL CELL BIOL, V19, P5308; FUJII S, 1999, J CHINESE I ENV ENG, V9, P9; Furger Kara A., 2001, Current Molecular Medicine (Hilversum), V1, P621, DOI 10.2174/1566524013363339; Gardai SJ, 2004, J BIOL CHEM, V279, P44695, DOI 10.1074/jbc.M405313200; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; HU DD, 1995, J BIOL CHEM, V270, P26232, DOI 10.1074/jbc.270.44.26232; Hu P, 2004, J BIOL CHEM, V279, P49420, DOI 10.1074/jbc.M407700200; Igney FH, 2002, NAT REV CANCER, V2, P277, DOI 10.1038/nrc776; Jiang XJ, 2004, ANNU REV BIOCHEM, V73, P87, DOI 10.1146/annurev.biochem.73.011303.073706; Johnson CR, 2004, APOPTOSIS, V9, P423, DOI 10.1023/B:APPT.0000031457.90890.13; Kanda H, 2004, J BIOCHEM, V136, P1, DOI 10.1093/jb/mvh098; Khan SA, 2002, J CELL BIOCHEM, V85, P728, DOI 10.1002/jcb.10170; Klein A, 2005, J MOL MED, V83, P362, DOI 10.1007/s00109-004-0625-1; Kohlhoff S, 2000, FREE RADICAL BIO MED, V29, P497, DOI 10.1016/S0891-5849(00)00340-3; Krause D, 2001, J BIOL CHEM, V276, P19244, DOI 10.1074/jbc.M008186200; Kreuz S, 2004, J CELL BIOL, V166, P369, DOI 10.1083/jcb.200401036; LaCasse EC, 1998, ONCOGENE, V17, P3247, DOI 10.1038/sj.onc.1202569; Lin YH, 2001, J BIOL CHEM, V276, P46024, DOI 10.1074/jbc.M105132200; Mitra SK, 2005, NAT REV MOL CELL BIO, V6, P56, DOI 10.1038/nrm1549; Morimoto I, 2002, GENE CHROMOSOME CANC, V33, P270, DOI 10.1002/gcc.10020; Nechushtan A, 2001, J CELL BIOL, V153, P1265, DOI 10.1083/jcb.153.6.1265; Nomura M, 2003, J BIOL CHEM, V278, P2058, DOI 10.1074/jbc.M207880200; Osaki M, 2004, APOPTOSIS, V9, P667, DOI 10.1023/B:APPT.0000045801.15585.dd; Pommier Y, 2004, ONCOGENE, V23, P2934, DOI 10.1038/sj.onc.1207515; Reed JC, 2001, TRENDS MOL MED, V7, P314, DOI 10.1016/S1471-4914(01)02026-3; Riedl SJ, 2004, NAT REV MOL CELL BIO, V5, P897, DOI 10.1038/nrm1496; Schimmer AD, 2004, CANCER RES, V64, P7183, DOI 10.1158/0008-5472.CAN-04-1918; Shanmugam V, 1997, BIOCHEMISTRY-US, V36, P5729, DOI 10.1021/bi961687w; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; Talanian RV, 1997, J BIOL CHEM, V272, P9677; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; Tuck AB, 2001, J MAMMARY GLAND BIOL, V6, P419, DOI 10.1023/A:1014734930781; Tzeng YJ, 1998, ONCOGENE, V16, P2103, DOI 10.1038/sj.onc.1201733; TZENG YJ, 1993, ONCOGENE, V8, P1965; Wai PY, 2004, J SURG RES, V121, P228, DOI 10.1016/j.jss.2004.03.028; Weber GF, 1996, SCIENCE, V271, P509, DOI 10.1126/science.271.5248.509; Wessel Ralf, 2006, In Silico Biology, V6, P61	46	42	43	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 3	2007	26	20					2840	2850		10.1038/sj.onc.1210096	http://dx.doi.org/10.1038/sj.onc.1210096			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	164CR	17160024				2022-12-28	WOS:000246210800004
J	Rong, R; Jiang, LY; Sheikh, MS; Huang, Y				Rong, R.; Jiang, L. Y.; Sheikh, M. S.; Huang, Y.			Mitotic kinase Aurora-A phosphorylates RASSF1A and modulates RASSF1A-mediated microtubule interaction and M-phase cell cycle regulation	ONCOGENE			English	Article						tumor suppressor; mitotic kinase; RASSF1A; Aurora-A; cell cycle; microtubules	TUMOR-SUPPRESSOR RASSF1A; CENTROSOME AMPLIFICATION; CDC2 KINASE; PROTEIN; OVEREXPRESSION; SITES; MAP4	RASSF1A (RAS-association domain family 1, isoform A) is a newer tumor suppressor that binds to and stabilizes microtubules as well as induces M-phase cell cycle arrest. Several other proteins that interact with and stabilize microtubules also undergo mitotic phase phosphorylation to regulate microtubule dynamics and M-phase cell cycle progression. Currently, however, there is a paucity of information regarding the phosphorylation status of RASSF1A and its regulation during mitosis. In this study, for the first time, we demonstrate that Aurora-A is a RASSF1A kinase and, to the best of our knowledge, this is also the first study reporting the identification of a kinase for RASSF1A. We show that the mitotic kinase Aurora-A directly interacts with and phosphorylates RASSF1 and that RASSF1A is phosphorylated by Aurora-A during mitosis. These findings therefore link an important oncogenic mitotic kinase to regulate RASSF1A tumor suppressor. Aurora-A appears to phosphorylate RASSF1A at Threonine202 and/or Serine203 that reside within the known microtubule-binding domain of RASSF1A. Substitutions of these residues with glutamic acid at both positions, mimicking constitutive phosphorylation of RASSF1A, disrupt RASSF1A interactions with microtubules and abolish its ability to induce M-phase cell cycle arrest. Our results further demonstrate that Aurora-A overexpression also interferes with RASSF1A-mediated growth suppression. In view of our results, we propose that Aurora-A-mediated phosphorylation of RASSF1A is a novel mechanism that regulates the ability of this tumor suppressor to interact with microtubules and modulate M-phase cell cycle progression.	[Rong, R.; Jiang, L. Y.; Sheikh, M. S.; Huang, Y.] SUNY Upstate Med Univ, Dept Pharmacol, Syracuse, NY 13210 USA	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center	Huang, Y (corresponding author), SUNY Upstate Med Univ, Dept Pharmacol, 750 E Adams St, Syracuse, NY 13210 USA.	huangy@upstate.edu			NATIONAL CANCER INSTITUTE [R21CA113868, R01CA086945] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R21DK067271] Funding Source: NIH RePORTER; NCI NIH HHS [CA113868, CA86945] Funding Source: Medline; NIDDK NIH HHS [DK067271] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Carmena M, 2003, NAT REV MOL CELL BIO, V4, P842, DOI 10.1038/nrm1245; Crosio C, 2002, MOL CELL BIOL, V22, P874, DOI 10.1128/MCB.22.3.874-885.2002; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; FARUKI S, 1992, J CELL SCI, V101, P69; Illenberger S, 1996, J BIOL CHEM, V271, P10834, DOI 10.1074/jbc.271.18.10834; Katayama H, 2001, J BIOL CHEM, V276, P46219, DOI 10.1074/jbc.M107540200; Kufer TA, 2002, J CELL BIOL, V158, P617, DOI 10.1083/jcb.200204155; Meraldi P, 2002, EMBO J, V21, P483, DOI 10.1093/emboj/21.4.483; Ookata K, 1997, BIOCHEMISTRY-US, V36, P15873, DOI 10.1021/bi971251w; Rong R, 2004, ONCOGENE, V23, P8216, DOI 10.1038/sj.onc.1207901; Shiina N, 1999, MOL BIOL CELL, V10, P597, DOI 10.1091/mbc.10.3.597; Shivakumar L, 2002, MOL CELL BIOL, V22, P4309, DOI 10.1128/MCB.22.12.4309-4318.2002; Song MS, 2004, NAT CELL BIOL, V6, P129, DOI 10.1038/ncb1091; Trzepacz C, 1997, J BIOL CHEM, V272, P21681, DOI 10.1074/jbc.272.35.21681; Vos MD, 2004, CANCER RES, V64, P4244, DOI 10.1158/0008-5472.CAN-04-0339; Wang XX, 2006, CELL RES, V16, P356, DOI 10.1038/sj.cr.7310046; Wittmann T, 2001, NAT CELL BIOL, V3, pE28, DOI 10.1038/35050669; Yarm FR, 2002, MOL CELL BIOL, V22, P6209, DOI 10.1128/MCB.22.17.6209-6221.2002; Zhou HY, 1998, NAT GENET, V20, P189, DOI 10.1038/2496	19	66	68	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 6	2007	26	55					7700	7708		10.1038/sj.onc.1210575	http://dx.doi.org/10.1038/sj.onc.1210575			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	239SK	17563743				2022-12-28	WOS:000251537800012
J	Jung, HJ; Kim, EH; Mun, JY; Park, S; Smith, ML; Han, SS; Seo, YR				Jung, H. J.; Kim, E. H.; Mun, J-Y; Park, S.; Smith, M. L.; Han, S. S.; Seo, Y. R.			Base excision DNA repair defect in Gadd45a-deficient cells	ONCOGENE			English	Article						gadd45a; base excision repair; APE1/Ref1; PCNA	P53-REGULATED PROTEIN GADD45; P53 TUMOR-SUPPRESSOR; NUCLEAR ANTIGEN PCNA; IN-VIVO; DAMAGE; ENDONUCLEASE; ASSOCIATION; IRRADIATION; EXPRESSION; APOPTOSIS	As one of a number of p53-regulated genes, Gadd45a (growth arrest and DNA damage inducible gene) has been shown to delay carcinogenesis and decrease mutation frequency. Gadd45a is known to regulate nucleotide excision DNA repair (NER) in response to UV radiation. Here, we report an emerging role for Gadd45a in base excision repair (BER). Gadd45a-null mouse embryo fibroblasts MEF and gadd45a-deficient human colon cancer cells exhibited slow BER after treatment with methyl methanesulfonate (MMS) a pure base-damaging agent. In addition, removal of AP sites by apurinic/apyrimidinic endonuclease 1/redox factor 1 (APE1/Ref1) was significantly delayed in gadd45a-null cells. Moreover, the localization of APE1/Ref1 within the nucleus was observed in gadd45a wild-type cells, whereas APE1 become mainly distributed in the cytoplasm, and there is a reduced interaction with proliferating cell nuclear antigen (PCNA) in Gadd45a-deficient cells. Inasmuch as p53 has been shown to regulate BER in addition to the NER pathway, our data suggest that p53-regulated gene Gadd45a contributes to the BER response by affecting the interaction of cellular APE1/Ref1 with PCNA. Gadd45a might be a key component gene of the p53 pathway involved in protection from carcinogenic base damage and maintenance of genomic stability, although the downstream mechanism including APE1/Ref1 will need further study.	Kyung Hee Univ, Sch Med, Inst Basic Med Sci, Dept Pharmacol, Seoul 130701, South Korea; Korea Univ, Sch Life Sci & Biotechnol, Seoul, South Korea; Indiana Univ, Sch Med, Indiana Univ Canc Ctr, Indianapolis, IN USA	Kyung Hee University; Korea University; Indiana University System; Indiana University-Purdue University Indianapolis	Seo, YR (corresponding author), Kyung Hee Univ, Sch Med, Inst Basic Med Sci, Dept Pharmacol, Dongdaemun-gu, Seoul 130701, South Korea.	dream21@khu.ac.kr						ABOUSSEKHRA A, 1995, EXP CELL RES, V221, P326, DOI 10.1006/excr.1995.1382; Adimoolam S, 2002, P NATL ACAD SCI USA, V99, P12985, DOI 10.1073/pnas.202485699; Bae I, 1996, CANCER RES, V56, P840; Eller MS, 1997, P NATL ACAD SCI USA, V94, P12627, DOI 10.1073/pnas.94.23.12627; Fan JG, 1999, MOL PHARMACOL, V56, P966, DOI 10.1124/mol.56.5.966; Gaiddon C, 1999, EMBO J, V18, P5609, DOI 10.1093/emboj/18.20.5609; Hanson S, 2005, ONCOGENE, V24, P1641, DOI 10.1038/sj.onc.1208351; Hartman AR, 2002, NAT GENET, V32, P180, DOI 10.1038/ng953; Hildesheim J, 2002, CLIN CANCER RES, V8, P2475; Hildesheim J, 2002, CANCER RES, V62, P7305; Hollander MC, 2001, CANCER RES, V61, P2487; KEARSEY JM, 1995, ONCOGENE, V11, P1675; Kelley MR, 2001, CLIN CANCER RES, V7, P824; Lee JH, 2003, BIOTECHNOL BIOPROC E, V8, P106, DOI 10.1007/BF02940265; Maga G, 2003, J CELL SCI, V116, P3051, DOI 10.1242/jcs.00653; Offer H, 2001, CANCER RES, V61, P88; Ramana CV, 1998, P NATL ACAD SCI USA, V95, P5061, DOI 10.1073/pnas.95.9.5061; Seo YR, 2004, EXP MOL MED, V36, P505, DOI 10.1038/emm.2004.64; Seo YR, 2002, P NATL ACAD SCI USA, V99, P14548, DOI 10.1073/pnas.212319799; Seo YR, 2002, ONCOGENE, V21, P731, DOI 10.1038/sj.onc.1205129; Shibata Y, 2002, J BIOL CHEM, V277, P746, DOI 10.1074/jbc.M109461200; SMITH ML, 1995, ONCOGENE, V10, P1053; Smith ML, 2000, MOL CELL BIOL, V20, P3705, DOI 10.1128/MCB.20.10.3705-3714.2000; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; Srivastava DK, 1998, J BIOL CHEM, V273, P21203, DOI 10.1074/jbc.273.33.21203; Vairapandi M, 2000, J BIOL CHEM, V275, P16810, DOI 10.1074/jbc.275.22.16810; Xia LQ, 2005, J MOL BIOL, V346, P1259, DOI 10.1016/j.jmb.2005.01.014; Zhan QM, 1999, ONCOGENE, V18, P2892, DOI 10.1038/sj.onc.1202667; Zhou JM, 2001, EMBO J, V20, P914, DOI 10.1093/emboj/20.4.914	29	57	60	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 29	2007	26	54					7517	7525		10.1038/sj.onc.1210557	http://dx.doi.org/10.1038/sj.onc.1210557			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	236DB	17599061				2022-12-28	WOS:000251282100003
J	Yuan, TC; Lin, FF; Veeramani, S; Chen, SJ; Earp, HS; Lin, MF				Yuan, T-C; Lin, F-F; Veeramani, S.; Chen, S-J; Earp, H. S., III; Lin, M-F			ErbB-2 via PYK2 upregulates the adhesive ability of androgen receptor-positive human prostate cancer cells	ONCOGENE			English	Article						prostate cancer; cell adhesion; PYK2; ErbB-2	PROTEIN-TYROSINE-PHOSPHATASE; ACID-PHOSPHATASE; KINASE; PROLIFERATION; EXPRESSION; PHOSPHORYLATION; ASSOCIATION; ACTIVATION; PAXILLIN; INVASION	Aberrant regulation in the adhesive ability of cancer cells is closely associated with their metastatic activity. In this study, we examine the role of ErbB-2 in regulating the adhesive ability of androgen receptor (AR)-positive human prostate cancer (PCa) cells, the major cell population of PCa. Utilizing different LNCaP and MDA PCa2b cells as model systems, we found that ErbB-2 activity was correlated with PYK2 activity and adhesive ability in those cells. Increased ErbB-2 expression or activity in LNCaP C-33 cells enhanced PYK2 activation and cell adhesion, while the high PYK2 activity and the rapid adhesion of LNCaP C-81 cells were decreased by diminishing ErbB-2 expression or activity. Knockdown studies revealed the predominant role of ErbB-2 in regulating LNCaP C-81 cell adhesion. Coimmunoprecipitation showed that C-81 cells had increased interaction between ErbB-2 and PYK2. Elevated ErbB-2 activity in LNCaP cells correlated with increased ERK/MAPK activity and enhanced adhesive ability, which were abolished by the expression of K457A-PYK2 mutant or the treatment of PD98059, a MEK inhibitor. In summary, our data suggested that ErbB-2, via PYK2-ERK/MAPK, upregulates the adhesive ability of AR-positive human PCa cells.	Univ Nebraska Med Ctr, Coll Med, Dept Biochem & Mol Biol, Omaha, NE 68198 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Pathol & Lab Med, Chapel Hill, NC 27515 USA; Univ Nebraska Med Ctr, Eppley Inst Res Canc, Omaha, NE USA	University of Nebraska System; University of Nebraska Medical Center; University of North Carolina; University of North Carolina Chapel Hill; University of Nebraska System; University of Nebraska Medical Center	Lin, MF (corresponding author), Univ Nebraska Med Ctr, Coll Med, Dept Biochem & Mol Biol, Omaha, NE 68198 USA.	mlin@unmc.edu	Veeramani, Suresh/P-7838-2019	Veeramani, Suresh/0000-0001-9217-0872	NATIONAL CANCER INSTITUTE [R01CA088184] Funding Source: NIH RePORTER; NCI NIH HHS [CA88184] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Avraham H, 2000, CELL SIGNAL, V12, P123, DOI 10.1016/S0898-6568(99)00076-5; Chen SJ, 2007, PROSTATE, V67, P557, DOI 10.1002/pros.20551; Dikic I, 1998, J BIOL CHEM, V273, P14301, DOI 10.1074/jbc.273.23.14301; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; Haier J, 2001, APMIS, V109, P241, DOI 10.1034/j.1600-0463.2001.d01-118.x; Hynes NE, 2005, NAT REV CANCER, V5, P341, DOI 10.1038/nrc1609; Igawa T, 2002, PROSTATE, V50, P222, DOI 10.1002/pros.10054; Knudsen BS, 2006, J CELL BIOCHEM, V99, P345, DOI 10.1002/jcb.20934; Lakkakorpi PT, 2003, J BIOL CHEM, V278, P11502, DOI 10.1074/jbc.M206579200; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; Li X, 1997, J BIOL CHEM, V272, P14341, DOI 10.1074/jbc.272.22.14341; Li X, 1999, J BIOL CHEM, V274, P8917, DOI 10.1074/jbc.274.13.8917; Lin MF, 1998, J BIOL CHEM, V273, P5939, DOI 10.1074/jbc.273.10.5939; Lipinski CA, 2005, NEOPLASIA, V7, P435, DOI 10.1593/neo.04712; Meng TC, 2000, ONCOGENE, V19, P2664, DOI 10.1038/sj.onc.1203576; Meng TC, 1998, J BIOL CHEM, V273, P22096, DOI 10.1074/jbc.273.34.22096; Pandey P, 1999, J BIOL CHEM, V274, P10140, DOI 10.1074/jbc.274.15.10140; Park SY, 2007, CELL SIGNAL, V19, P289, DOI 10.1016/j.cellsig.2006.07.005; Robinson D, 1996, P NATL ACAD SCI USA, V93, P5958, DOI 10.1073/pnas.93.12.5958; Schlaepfer DD, 2004, BBA-MOL CELL RES, V1692, P77, DOI 10.1016/j.bbamcr.2004.04.008; Signoretti S, 2000, JNCI-J NATL CANCER I, V92, P1918, DOI 10.1093/jnci/92.23.1918; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; Tremblay L, 1996, INT J CANCER, V68, P164, DOI 10.1002/(SICI)1097-0215(19961009)68:2<169::AID-IJC4>3.0.CO;2-W; Vafa A, 1998, INT J ONCOL, V13, P1191; van der Horst EH, 2005, INT J CANCER, V113, P689, DOI 10.1002/ijc.20643; Veeramani S, 2005, ENDOCR-RELAT CANCER, V12, P805, DOI 10.1677/erc.1.00950; Wang X, 2002, J BIOL CHEM, V277, P15426, DOI 10.1074/jbc.M111218200; Zrihan-Licht S, 2000, ONCOGENE, V19, P1318, DOI 10.1038/sj.onc.1203422	29	21	24	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 29	2007	26	54					7552	7559		10.1038/sj.onc.1210570	http://dx.doi.org/10.1038/sj.onc.1210570			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	236DB	17563746				2022-12-28	WOS:000251282100007
J	Taneja, P; Mallakin, A; Matise, LA; Frazier, DP; Choudhary, M; Inoue, K				Taneja, P.; Mallakin, A.; Matise, L. A.; Frazier, D. P.; Choudhary, M.; Inoue, K.			Repression of Dmp1 and Arf transcription by anthracyclins: critical roles of the NF-kappa B subunit p65	ONCOGENE			English	Article						Dmp1; Arf; p53; NF-kappa B; anthracyclin; UV-C	CELL-CYCLE ARREST; TUMOR SUPPRESSION; GENE-EXPRESSION; P53; RAS; TRANSFORMATION; RESPONSES; CANCER	Both genotoxic and oncogenic stress activates the nuclear factor-kappa B (NF-kappa B) and p53 proteins however the p53 activity is antagonized by NF-kappa B signaling. Dmp1 is a Myb-like transcription factor that activates the Arf-p53 pathway. The Dmp1 promoter was activated by a classical NF-kappa B activator tumor necrosis factor a but repressed by treatment of cells with non classical NF-kappa B activators anthracyclins and UV-C. p65 and other subsets of NF-kappa B proteins were bound to the Dmp1 promoter following anthracyclin/UV-C treatment of rodent. broblasts. This resulted in the downregulation of Dmp1 mRNA and protein. Repression of the Dmp1 transcription by anthracyclins depended on the unique NF-kappa B site on the promoter. Downregulation of p65 significantly attenuated the repression of the Dmp1 promoter by anthracyclins/UV-C. The amount of Dmp1 bound to the Arf promoter decreased significantly upon anthracyclin treatment this in turn downregulated the Arf levels. Repression of the Arf promoter by p65 or anthracyclins depended on Dmp1 which was significantly attenuated in Dmp1(-/-) cells. Both Dmp1(-/-) and Arf(-/-) cells showed resistance to anthracyclin-induced cell death compared to wild-type cells non-immortalized p65-knockdown cells were much more sensitive. Thus the Dmp1-Arf pathway is repressed by p65 in response to genotoxic stress which implicates a novel mechanism of p53 inactivation by NF-kappa B.	Wake Forest Univ Hlth Sci, Dept Pathol, Winston Salem, NC USA; Wake Forest Univ Hlth Sci, Dept Canc Biol, Winston Salem, NC USA	Wake Forest University; Wake Forest University School of Medicine; Wake Forest University; Wake Forest University School of Medicine	Inoue, K (corresponding author), Wake Forest Univ Hlth Sci, Dept Pathol & Canc Biol, 2102 Gray Bldg, Med Ctr Blvd, Winston Salem, NC 27157 USA.	kinoue@wfubmc.edu	Choudhary, Mayur/AAU-3497-2021	Choudhary, Mayur/0000-0001-8056-011X	NCI NIH HHS [5R01CA106314, R01 CA106314-03, R01 CA106314-02, R01 CA106314, P30 CA012197, CA12197-31] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA106314, P30CA012197] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bakkenist CJ, 2004, CELL, V118, P9, DOI 10.1016/j.cell.2004.06.023; Campbell KJ, 2004, MOL CELL, V13, P853, DOI 10.1016/S1097-2765(04)00131-5; DeVita V. T., 2005, CANC PRINCIPLES PRAC; Gallagher S, 2005, CELL CYCLE, V4, P465, DOI 10.4161/cc.4.3.1526; Gapuzan MER, 2005, ONCOGENE, V24, P6574, DOI 10.1038/sj.onc.1208809; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; Huang DB, 2005, STRUCTURE, V13, P1365, DOI 10.1016/j.str.2005.06.018; Inoue K, 1999, P NATL ACAD SCI USA, V96, P3993, DOI 10.1073/pnas.96.7.3993; Inoue K, 2001, GENE DEV, V15, P2934, DOI 10.1101/gad.929901; Inoue K, 2000, GENE DEV, V14, P1797; INOUE K, 2007, ONCOGENE        0122; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Karin M, 2006, NATURE, V441, P431, DOI 10.1038/nature04870; Kurz EU, 2004, J BIOL CHEM, V279, P53272, DOI 10.1074/jbc.M406879200; Lowe SW, 2003, CURR OPIN GENET DEV, V13, P77, DOI 10.1016/S0959-437X(02)00013-8; Mallakin A, 2006, ONCOGENE, V25, P7703, DOI 10.1038/sj.onc.1209750; Perkins ND, 2004, TRENDS CELL BIOL, V14, P64, DOI 10.1016/j.tcb.2003.12.004; Rocha S, 2003, MOL CELL BIOL, V23, P4713, DOI 10.1128/MCB.23.13.4713-4727.2003; Ruas M, 1998, BBA-REV CANCER, V1378, pF115, DOI 10.1016/S0304-419X(98)00017-1; Ryan KM, 2000, NATURE, V404, P892, DOI 10.1038/35009130; Saccani S, 2003, MOL CELL, V11, P1563, DOI 10.1016/S1097-2765(03)00227-2; Sherr CJ, 2006, NAT REV CANCER, V6, P663, DOI 10.1038/nrc1954; Sherr CJ, 2001, NAT REV MOL CELL BIO, V2, P731, DOI 10.1038/35096061; Sreeramaneni R, 2005, MOL CELL BIOL, V25, P220, DOI 10.1128/MCB.25.1.220-232.2005; Tergaonkar V, 2002, CANCER CELL, V1, P493, DOI 10.1016/S1535-6108(02)00068-5; Watts TH, 2005, ANNU REV IMMUNOL, V23, P23, DOI 10.1146/annurev.immunol.23.021704.115839; Webster GA, 1999, MOL CELL BIOL, V19, P3485; Yoshimura A, 2006, CANCER SCI, V97, P439, DOI 10.1111/j.1349-7006.2006.00197.x	28	25	27	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 22	2007	26	53					7457	7466		10.1038/sj.onc.1210568	http://dx.doi.org/10.1038/sj.onc.1210568			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	236DA	17546045	Green Accepted			2022-12-28	WOS:000251282000007
J	Oleinik, NV; Krupenko, NI; Krupenko, SA				Oleinik, N. V.; Krupenko, N. I.; Krupenko, S. A.			Cooperation between JNK1 and JNK2 in activation of p53 apoptotic pathway	ONCOGENE			English	Article						apoptosis; FDH; jun kinases; p53; RNAi	CELL-CYCLE PROGRESSION; PROTEIN-KINASE INHIBITORS; PHOSPHORYLATED IN-VITRO; C-JUN KINASE; 10-FORMYLTETRAHYDROFOLATE DEHYDROGENASE; CANCER-CELLS; SIGNAL-TRANSDUCTION; STRESS; IDENTIFICATION; VIVO	FDH (10-formyltetrahydrofolate dehydrogenase) is strongly downregulated in tumors while its elevation suppresses proliferation of cancer cells and induces p53-dependent apoptosis. We have previously shown that FDH induces phosphorylation of p53 at Ser6, which is a required step in the activation of apoptosis. In the present study, we report that FDH-induced p53 phosphorylation is carried out by JNK1 and JNK2 (c-Jun N-terminal kinases) working in concert. We have demonstrated that FDH induces phosphorylation of JNK1 and JNK2, while treatment of FDH-expressing cells with JNK inhibitor SP600125, as well as knockdown of JNK1 or JNK2 by siRNA, prevents phosphorylation of p53 at Ser6 and protects cells from apoptosis. Interestingly, the knockdown of JNK1 abolished phosphorylation of JNK2 in response to FDH, while knockdown of JNK2 did not prevent JNK1 phosphorylation. Pull-down assay with the p53-specific antibody has shown that JNK2, but not JNK1, is physically associated with p53. Our studies revealed a novel mechanism in which phosphorylation of JNK2 is mediated by JNK1 before phosphorylation of p53, and then p53 is directly phosphorylated by JNK2 at Ser6.	Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA	Medical University of South Carolina	Krupenko, SA (corresponding author), Med Univ S Carolina, Dept Biochem & Mol Biol, 173 Ashley Ave, Rm 512-B BSB, Charleston, SC 29425 USA.	Krupenko@musc.edu			NATIONAL CANCER INSTITUTE [R01CA095030] Funding Source: NIH RePORTER; NCI NIH HHS [CA95030] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anguera MC, 2006, J BIOL CHEM, V281, P18335, DOI 10.1074/jbc.M510623200; Appella E, 2001, EUR J BIOCHEM, V268, P2764, DOI 10.1046/j.1432-1327.2001.02225.x; Bain J, 2003, BIOCHEM J, V371, P199, DOI 10.1042/BJ20021535; Barr RK, 2002, J BIOL CHEM, V277, P10987, DOI 10.1074/jbc.M107565200; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; Bost F, 1999, MOL CELL BIOL, V19, P1938; Buschmann T, 2001, MOL CELL BIOL, V21, P2743, DOI 10.1128/MCB.21.8.2743-2754.2001; CHAMPION KM, 1994, P NATL ACAD SCI USA, V91, P11338, DOI 10.1073/pnas.91.24.11338; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Du LH, 2004, J BIOL CHEM, V279, P11957, DOI 10.1074/jbc.M304935200; Fogarty MP, 2003, BIOCHEM J, V371, P789, DOI 10.1042/BJ20021660; Fuchs SY, 1998, GENE DEV, V12, P2658, DOI 10.1101/gad.12.17.2658; Fuchs SY, 1998, P NATL ACAD SCI USA, V95, P10541, DOI 10.1073/pnas.95.18.10541; GILLE H, 1995, EMBO J, V14, P951, DOI 10.1002/j.1460-2075.1995.tb07076.x; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; Higashimoto Y, 2000, J BIOL CHEM, V275, P23199, DOI 10.1074/jbc.M002674200; Hu MCT, 1997, ONCOGENE, V15, P2277, DOI 10.1038/sj.onc.1201401; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; Kelemen BR, 2002, J BIOL CHEM, V277, P8741, DOI 10.1074/jbc.M108459200; Knippschild U, 1997, ONCOGENE, V15, P1727, DOI 10.1038/sj.onc.1201541; Krupenko SA, 2002, CELL GROWTH DIFFER, V13, P227; Kuan CY, 1999, NEURON, V22, P667, DOI 10.1016/S0896-6273(00)80727-8; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Leppa S, 1999, ONCOGENE, V18, P6158, DOI 10.1038/sj.onc.1203173; Liu J, 2004, MOL CELL BIOL, V24, P10844, DOI 10.1128/MCB.24.24.10844-10856.2004; LIVINGSTONE C, 1995, EMBO J, V14, P1785, DOI 10.1002/j.1460-2075.1995.tb07167.x; MILNE DM, 1995, J BIOL CHEM, V270, P5511, DOI 10.1074/jbc.270.10.5511; MIN H, 1988, BIOCHIM BIOPHYS ACTA, V967, P348, DOI 10.1016/0304-4165(88)90097-9; Oleinik NV, 2005, BIOCHEM J, V391, P503, DOI 10.1042/BJ20050533; Oleinik NV, 2003, MOL CANCER RES, V1, P577; Oren M, 2003, CELL DEATH DIFFER, V10, P431, DOI 10.1038/sj.cdd.4401183; Sabapathy K, 2004, MOL CELL, V15, P713, DOI 10.1016/j.molcel.2004.08.028; Sabapathy K, 1999, CURR BIOL, V9, P116, DOI 10.1016/S0960-9822(99)80065-7; Schreiber M, 1999, GENE DEV, V13, P607, DOI 10.1101/gad.13.5.607; Smith LM, 1999, ONCOGENE, V18, P6063, DOI 10.1038/sj.onc.1202989; Tafolla E, 2005, J BIOL CHEM, V280, P19992, DOI 10.1074/jbc.M500331200; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; Ventura JJ, 2006, MOL CELL, V21, P701, DOI 10.1016/j.molcel.2006.01.018; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Weston CR, 2007, CURR OPIN CELL BIOL, V19, P142, DOI 10.1016/j.ceb.2007.02.001; Wisdom R, 1999, EMBO J, V18, P188, DOI 10.1093/emboj/18.1.188; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326	43	99	103	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 8	2007	26	51					7222	7230		10.1038/sj.onc.1210526	http://dx.doi.org/10.1038/sj.onc.1210526			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	231NO	17525747				2022-12-28	WOS:000250955600006
J	Mizutani, K; Ito, H; Iwamoto, I; Morishita, R; Deguchi, T; Nozawa, Y; Asano, T; Nagata, KI				Mizutani, K.; Ito, H.; Iwamoto, I.; Morishita, R.; Deguchi, T.; Nozawa, Y.; Asano, T.; Nagata, K-I			Essential roles of ERK-mediated phosphorylation of vinexin in cell spreading, migration and anchorage-independent growth	ONCOGENE			English	Article						ERK; vinexin; adaptor protein; cytokeleton; phosphorylation	ADHESION PROTEIN VINEXIN; SIGNAL-REGULATED KINASE; CYTOSKELETAL ORGANIZATION; ADAPTER PROTEIN; ACTIVATION; EXPRESSION; INTERACTS; VINCULIN; COMPLEX; GAMMA	Vinexin is an adaptor protein supposed to play pivotal roles in various cellular events such as cell adhesion, cytoskeletal organization, signa ling and gene expression. Despite the possible importance, physiological functions and regulatory mechanisms of vinexin are largely unknown. In addition, although vinexin was reported to be phosphorylated by extracellular signal-regulated kinase ( ERK), physiological significance of the phosphorylation remains to be elucidated. Here we carried out characterization of endogenous vinexin and found that it was enriched at the leading edge of migrating cells and focal adhesions of spread cells. In the analyses using ERK-phosphorylated vinexin-specific antibody, the phosphorylation signal was also detected at the leading edges of migrating cells and at cell periphery of spreading cells, whereas only faint signal was observed at focal adhesions of well-spread cells. We then established LNCaP cell lines stably expressing GFP-fused vinexin beta or two mutants at Ser189 that mimic the ERK-phosphorylated or -unphosphorylated vinexinb. Based on the analyses using the lines, the phosphorylation was likely to inhibit the cell spreading and migration. On the other hand, anchorage-independent cell growth was inhibited by unphosphorylated vinexin beta. Taken together, ERK-mediated phosphorylation of vinexinb is strongly suggested to occur in a spatio-temporally regulated manner and play important roles in cell spreading, migration and anchorage-independent growth.	Aichi Human Serv Ctr, Inst Dev Res, Dept Mol Neurobiol, Kasugai, Aichi 4800392, Japan; Gifu Univ, Sch Med, Dept Urol, Gifu 500, Japan; Gifu Int Inst Biotechnol, Gifu, Japan	Gifu University	Nagata, KI (corresponding author), Aichi Human Serv Ctr, Inst Dev Res, Dept Mol Neurobiol, 713-8 Kamiya, Kasugai, Aichi 4800392, Japan.	knagata@inst-hsc.jp		Ito, Hidenori/0000-0002-6527-477X				Akamatsu M, 1999, J BIOL CHEM, V274, P35933, DOI 10.1074/jbc.274.50.35933; Bour G, 2005, J BIOL CHEM, V280, P17027, DOI 10.1074/jbc.M501344200; Huang C, 2004, J CELL SCI, V117, P4619, DOI 10.1242/jcs.01481; Ito H, 2007, J NEUROCHEM, V100, P545, DOI 10.1111/j.1471-4159.2006.04222.x; Kioka N, 1999, J CELL BIOL, V144, P59, DOI 10.1083/jcb.144.1.59; Kioka N, 2002, CELL STRUCT FUNCT, V27, P1, DOI 10.1247/csf.27.1; Matsuyama M, 2005, GENES CELLS, V10, P421, DOI 10.1111/j.1365-2443.2005.00844.x; Mitsushima M, 2006, GENES CELLS, V11, P281, DOI 10.1111/j.1365-2443.2006.00932.x; Mitsushima M, 2004, J BIOL CHEM, V279, P34570, DOI 10.1074/jbc.M402304200; Nagata K, 2004, J BIOL CHEM, V279, P55895, DOI 10.1074/jbc.M406153200; Suwa A, 2002, J BIOL CHEM, V277, P13053, DOI 10.1074/jbc.M108644200; Takahashi H, 2005, BIOCHEM BIOPH RES CO, V336, P239, DOI 10.1016/j.bbrc.2005.08.064; Tujague M, 2004, J BIOL CHEM, V279, P9255, DOI 10.1074/jbc.M312160200	13	21	21	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 1	2007	26	50					7122	7131		10.1038/sj.onc.1210512	http://dx.doi.org/10.1038/sj.onc.1210512			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	228GF	17486060				2022-12-28	WOS:000250715000006
J	Flinterman, MB; Mymryk, JS; Klanrit, P; Yousef, AF; Lowe, SW; Caldas, C; Gaken, J; Farzaneh, F; Tavassoli, M				Flinterman, M. B.; Mymryk, J. S.; Klanrit, P.; Yousef, A. F.; Lowe, S. W.; Caldas, C.; Gaken, J.; Farzaneh, F.; Tavassoli, M.			p400 function is required for the adenovirus E1A-mediated suppression of EGFR and tumour cell killing	ONCOGENE			English	Article						p400; EGFR; E1A; apoptosis; head and neck cancer	GROWTH-FACTOR RECEPTOR; SIMIAN ADENOVIRUSES; SEQUENCE-ANALYSIS; E1A PROTEINS; TYPE-5 E1A; APOPTOSIS; P53; INDUCTION; BINDING; CANCER	We have recently shown that E1A protein of human adenovirus downregulates epidermal growth factor receptor (EGFR) expression and induces apoptosis in head and neck (HNSCC) and lung cancer cells independently of their p53 status. E1A has five isoforms of which the major ones E1A12S and E1A13S regulate transcription of cellular genes by binding to transcriptional modulators such as pRB, CtBP, p300 and p400. In this study, we have identified E1A12S isoform to) have the highest effect on EGFR suppression and induction of apoptosis in HNSCC cells. Similar to Ad5, E1A12S from human adenovirus types 2, 3, 9 and 12 suppressed EGFR, whereas E1A12S of adenovirus types 4 and 40 had no effect on EGFR expression. Using deletion mutants of E1A12S we have shown that interaction of E1A with p400, but not p300 or pRB, is required for EGFR suppression and apoptosis. Inhibition of p400 by short hairpin RNA confirmed that HNSCC cells with reduced p400 expression were less sensitive to E1A-induced suppression of EGFR and apoptosis. p300 function was shown to be dispensable, as cells expressing E1A mutants that are unable to bind p300, or p300 knockout cells., remained sensitive to E1A-induced apoptosis. In summary, this study identifies p400 as an important mediator of E1A-induced downregulation of EGFR and apoptosis.	Kings Coll London, Guys Kings & St Thomass Hosp, Inst Dent, Head & Neck Oncol Grp, London SE5 9NU, England; Univ Western Ontario, London Reg Canc Ctr, Dept Oncol & Microbiol, London, ON, Canada; Univ Western Ontario, London Reg Canc Ctr, Dept Immunol, London, ON, Canada; Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA; Univ Cambridge, Hutchison MRC Res Ctr, Canc Genom Program, Dept Oncol, Cambridge, England; Kings Coll London, Dept Haematol & Mol Med, London WC2R 2LS, England	University of London; King's College London; Western University (University of Western Ontario); Western University (University of Western Ontario); Cold Spring Harbor Laboratory; University of Cambridge; University of London; King's College London	Tavassoli, M (corresponding author), Kings Coll London, Guys Kings & St Thomass Hosp, Inst Dent, Head & Neck Oncol Grp, 123 Coldharbour Lane, London SE5 9NU, England.	mahvash.tavassoli@kcl.ac.uk	Caldas, Carlos/U-7250-2019; Farzaneh, Farzin/B-4902-2009; Caldas, Carlos/A-7543-2008	Caldas, Carlos/0000-0003-3547-1489; Farzaneh, Farzin/0000-0002-9275-2415; Yousef, Ahmed F./0000-0001-5734-489X	NCI NIH HHS [P01 CA013106, P30 CA008748] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA008748, P01CA013106] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Avvakumov N, 2004, VIROLOGY, V329, P477, DOI 10.1016/j.virol.2004.08.007; Avvakumov N, 2002, J VIROL, V76, P7968, DOI 10.1128/JVI.76.16.7968-7975.2002; BARBEAU D, 1994, ONCOGENE, V9, P359; Bergman LM, 2006, APOPTOSIS, V11, P879, DOI 10.1007/s10495-006-6651-4; Chan HM, 2005, GENE DEV, V19, P196, DOI 10.1101/gad.1280205; Chiou SK, 1997, J VIROL, V71, P3515, DOI 10.1128/JVI.71.5.3515-3525.1997; Cuff JA, 2000, PROTEINS, V40, P502, DOI 10.1002/1097-0134(20000815)40:3<502::AID-PROT170>3.0.CO;2-Q; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; EGAN C, 1988, MOL CELL BIOL, V8, P3955, DOI 10.1128/MCB.8.9.3955; Flinterman M, 2005, J BIOL CHEM, V280, P5945, DOI 10.1074/jbc.M406661200; Flinterman M, 2003, ONCOGENE, V22, P1965, DOI 10.1038/sj.onc.1206190; Frank SR, 2003, EMBO REP, V4, P575, DOI 10.1038/sj.embor.embor861; Frisch SM, 2002, NAT REV MOL CELL BIO, V3, P441, DOI 10.1038/nrm827; Fuchs M, 2001, CELL, V106, P297, DOI 10.1016/S0092-8674(01)00450-0; Graham F L, 1991, Methods Mol Biol, V7, P109, DOI 10.1385/0-89603-178-0:109; Grandis JR, 2004, PHARMACOL THERAPEUT, V102, P37, DOI 10.1016/j.pharmthera.2004.01.002; Grossman SR, 2003, SCIENCE, V300, P342, DOI 10.1126/science.1080386; Iyer NG, 2004, P NATL ACAD SCI USA, V101, P7386, DOI 10.1073/pnas.0401002101; JONES N, 1979, CELL, V17, P683, DOI 10.1016/0092-8674(79)90275-7; Kalyankrishna S, 2006, J CLIN ONCOL, V24, P2666, DOI 10.1200/JCO.2005.04.8306; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; MORAN E, 1986, J VIROL, V57, P765, DOI 10.1128/JVI.57.3.765-775.1986; MYMRYK JS, 1994, ONCOGENE, V9, P1187; Mymryk JS, 1998, NUCLEIC ACIDS RES, V26, P292, DOI 10.1093/nar/26.1.292; PATERSON IC, 1995, BRIT J CANCER, V72, P922, DOI 10.1038/bjc.1995.434; Prenzel N, 2001, ENDOCR-RELAT CANCER, V8, P11, DOI 10.1677/erc.0.0080011; Querido E, 1997, J VIROL, V71, P3526, DOI 10.1128/JVI.71.5.3526-3533.1997; Samuelson AV, 2005, J BIOL CHEM, V280, P21915, DOI 10.1074/jbc.M414564200; Samuelson AV, 1997, P NATL ACAD SCI USA, V94, P12094, DOI 10.1073/pnas.94.22.12094; Sartor M, 1999, BRIT J CANCER, V80, P79, DOI 10.1038/sj.bjc.6690505; SHEPHERD SE, 1993, J VIROL, V67, P2944, DOI 10.1128/JVI.67.5.2944-2949.1993; Vallian S, 1998, MOL CELL BIOL, V18, P7147, DOI 10.1128/MCB.18.12.7147; WANG HGH, 1993, J VIROL, V67, P476, DOI 10.1128/JVI.67.1.476-488.1993; YAN DH, 1991, ONCOGENE, V6, P343; Yu DH, 1998, CANCER METAST REV, V17, P195, DOI 10.1023/A:1006054421970	35	19	21	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 18	2007	26	48					6863	6874		10.1038/sj.onc.1210497	http://dx.doi.org/10.1038/sj.onc.1210497			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	220WQ	17486071	Green Accepted			2022-12-28	WOS:000250188400002
J	Aigner, K; Dampier, B; Descovich, L; Mikula, M; Sultan, A; Schreiber, M; Mikulits, W; Brabletz, T; Strand, D; Obrist, P; Sommergruber, W; Schweifer, N; Wernitznig, A; Beug, H; Foisner, R; Eger, A				Aigner, K.; Dampier, B.; Descovich, L.; Mikula, M.; Sultan, A.; Schreiber, M.; Mikulits, W.; Brabletz, T.; Strand, D.; Obrist, P.; Sommergruber, W.; Schweifer, N.; Wernitznig, A.; Beug, H.; Foisner, R.; Eger, A.			The transcription factor ZEB1 (delta EF1) promotes tumour cell dedifferentiation by repressing master regulators of epithelial polarity	ONCOGENE			English	Article						epithelial to mesenchymal transition; invasion; transcription; epithelial polarity; cell adhesion	VITAMIN-D-RECEPTOR; E-CADHERIN; FACTOR SNAIL; MESENCHYMAL TRANSITION; BETA-CATENIN; CANCER; EXPRESSION; METASTASIS; INVASION; SLUG	Epithelial to mesenchymal transition (EMT) is implicated in the progression of primary tumours towards metastasis andis likely caused by a pathological activation of transcription factors regulating EMT in embryonic development. To analyse EMT-causing pathways in tumourigenesis, we identified transcriptional targets of the E-cadherin repressor ZEB1 in invasive human cancer cells. We show that ZEB1 repressed multiple key determinants of epithelial differentiation and cell-cell adhesion, including the cell polarity genes Crumbs3, HUGL2 and Pa ls1-associated tight junction protein. ZEB1 associated with their endogenous promoters in vivo, and strongly repressed promotor activities in reporter assays. ZEB1 downregulation in undifferentiated cancer cells by RNA interference was sufficient to upregulate expression of these cell polarity genes on the RNA and protein level, to re-establish epithelial features and to impair cell motility in vitro. In human colorectal cancer, ZEB1 expression was limited to the tumour-host interface and was accompanied by loss of intercellular adhesion and tumour cell invasion. In invasive ductal and lobular breast cancer, upregulation of ZEB1 was stringently coupled to cancer cell dedifferentiation. Our data show that ZEB1 represents a key player in pathologic EMTs associated with tumour progression.	Med Univ Vienna, Dept Med Biochem, Max F Perutz Labs, A-1030 Vienna, Austria; Med Univ Vienna, Dept Obstet & Gynecol, A-1030 Vienna, Austria; Med Univ Vienna, Inst Canc Res, Dept Med 1, A-1030 Vienna, Austria; Univ Freiburg, Dept Visceral & Gen Surg, Freiburg, Germany; Johannes Gutenberg Univ Mainz, Dept Internal Med 1, D-6500 Mainz, Germany; Pathol Labs Obrist, Vienna, Austria; Brunhuber OEG, Vienna, Austria; Boehringer Ingelheim KG, Vienna, Austria	Medical University of Vienna; University of Vienna; Vienna Biocenter (VBC); Max F. Perutz Laboratories (MFPL); Medical University of Vienna; Medical University of Vienna; University of Freiburg; Johannes Gutenberg University of Mainz; Boehringer Ingelheim	Foisner, R (corresponding author), Med Univ Vienna, Dept Med Biochem, Max F Perutz Labs, Dr Bohrgasse 9, A-1030 Vienna, Austria.	roland.foisner@meduniwien.ac.at; andreas.eger@meduniwien.ac.at	Sultan, Aneesa/Q-7293-2016; Mikulits, Wolfgang/AAH-4043-2021; Foisner, Roland/AAD-1833-2019; Martin, Schreiber/F-2175-2013	Sultan, Aneesa/0000-0002-7017-815X; Martin, Schreiber/0000-0003-1102-7789; Foisner, Roland/0000-0003-4734-4647; Mikulits, Wolfgang/0000-0003-4612-7106; Mikula, Mario/0000-0001-5782-0681	Austrian Science Fund FWF [F 2806, F 2801, F 2802] Funding Source: Medline	Austrian Science Fund FWF(Austrian Science Fund (FWF))		Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Bilder D, 2004, GENE DEV, V18, P1909, DOI 10.1101/gad.1211604; Brabletz T, 2001, P NATL ACAD SCI USA, V98, P10356, DOI 10.1073/pnas.171610498; Brabletz T, 2005, NAT REV CANCER, V5, P744, DOI 10.1038/nrc1694; Brumby AM, 2005, NAT REV CANCER, V5, P626, DOI 10.1038/nrc1671; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Chua HL, 2007, ONCOGENE, V26, P711, DOI 10.1038/sj.onc.1209808; Comijn J, 2001, MOL CELL, V7, P1267, DOI 10.1016/S1097-2765(01)00260-X; Condeelis J, 2006, CELL, V124, P263, DOI 10.1016/j.cell.2006.01.007; De Craene B, 2005, CANCER RES, V65, P6237, DOI 10.1158/0008-5472.CAN-04-3545; De Craene B, 2005, CELL SIGNAL, V17, P535, DOI 10.1016/j.cellsig.2004.10.011; Dohadwala M, 2006, CANCER RES, V66, P5338, DOI 10.1158/0008-5472.CAN-05-3635; Eger A, 2005, ONCOGENE, V24, P2375, DOI 10.1038/sj.onc.1208429; Eger A, 2000, J CELL BIOL, V148, P173, DOI 10.1083/jcb.148.1.173; Eger A, 2005, DRUG DISCOVERY TODAY, V2, P57; Grooteclaes ML, 2000, ONCOGENE, V19, P3823, DOI 10.1038/sj.onc.1203721; Guaita S, 2002, J BIOL CHEM, V277, P39209, DOI 10.1074/jbc.M206400200; Gupta PB, 2005, NAT GENET, V37, P1047, DOI 10.1038/ng1634; Hajra KM, 2002, CANCER RES, V62, P1613; Huber MA, 2005, CURR OPIN CELL BIOL, V17, P548, DOI 10.1016/j.ceb.2005.08.001; Krishnamachary B, 2006, CANCER RES, V66, P2725, DOI 10.1158/0008-5472.CAN-05-3719; Lacroix M, 2004, BREAST CANCER RES TR, V83, P249, DOI 10.1023/B:BREA.0000014042.54925.cc; Michel D, 2005, J CELL SCI, V118, P4049, DOI 10.1242/jcs.02528; Moreno-Bueno G, 2006, CANCER RES, V66, P9543, DOI 10.1158/0008-5472.CAN-06-0479; Nishimura G, 2006, DEV CELL, V11, P93, DOI 10.1016/j.devcel.2006.05.011; Ohira T, 2003, P NATL ACAD SCI USA, V100, P10429, DOI 10.1073/pnas.1734137100; Pacher M, 2007, CARCINOGENESIS, V28, P49, DOI 10.1093/carcin/bgl091; Palmer HG, 2004, NAT MED, V10, P917, DOI 10.1038/nm1095; Peinado HC, 2004, INT J DEV BIOL, V48, P365, DOI 10.1387/ijdb.041794hp; Pena C, 2005, HUM MOL GENET, V14, P3361, DOI 10.1093/hmg/ddi366; Pena C, 2006, INT J CANCER, V119, P2098, DOI 10.1002/ijc.22083; Perez-Moreno MA, 2001, J BIOL CHEM, V276, P27424, DOI 10.1074/jbc.M100827200; Shin K, 2005, J CELL BIOL, V168, P705, DOI 10.1083/jcb.200408064; Spaderna S, 2006, GASTROENTEROLOGY, V131, P830, DOI 10.1053/j.gastro.2006.06.016; Spoelstra NS, 2006, CANCER RES, V66, P3893, DOI 10.1158/0008-5472.CAN-05-2881; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Thiery JP, 2006, NAT REV MOL CELL BIO, V7, P131, DOI 10.1038/nrm1835; Vandewalle C, 2005, NUCLEIC ACIDS RES, V33, P6566, DOI 10.1093/nar/gki965; Wheelock MJ, 2003, ANNU REV CELL DEV BI, V19, P207, DOI 10.1146/annurev.cellbio.19.011102.111135	39	446	465	0	40	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2007	26	49					6979	6988		10.1038/sj.onc.1210508	http://dx.doi.org/10.1038/sj.onc.1210508			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	223YN	17486063	Green Accepted			2022-12-28	WOS:000250412200003
J	Duensing, A; Liu, Y; Perdreau, SA; Kleylein-Sohn, J; Nigg, EA; Duensing, S				Duensing, A.; Liu, Y.; Perdreau, S. A.; Kleylein-Sohn, J.; Nigg, E. A.; Duensing, S.			Centriole overduplication through the concurrent formation of multiple daughter centrioles at single maternal templates	ONCOGENE			English	Article						centrioles; proteasome; CDK2; cyclin e; PLK4; HPV-16E7	CENTROSOME DUPLICATION; CYCLIN-E; CELLS; ASSOCIATION; INSTABILITY; DISRUPTION; DEFECTS	Abnormal centrosome numbers are detected in virtually all cancers. The molecular mechanisms that underlie centrosome amplification, however, are poorly characterized. Based on the model that each maternal centriole serves as a template for the formation of one and only one daughter centriole per cell division cycle, the prevailing view is that centriole overduplication arises from successive rounds of centriole reproduction. Here, we provide evidence that a single maternal centriole can concurrently generate multiple daughter centrioles. This mechanism was initially identified in cells treated with the peptide vinyl sulfone proteasome inhibitor Z- L3VS. We subsequently found that the formation of more than one daughter at maternal centrioles requires cyclin E/cyclin-dependent kinase 2 as well as Polo-like kinase 4 and that overexpression of these proteins mimics this phenotype in the absence of a proteasome inhibitor. Moreover, we show that the human papillomavirus type 16 E7 oncoprotein stimulates aberrant daughter centriole numbers in part through the formation of more than one daughter centriole at single maternal templates. These results help to explain how oncogenic stimuli can rapidly induce abnormal centriole numbers within a single cell-division cycle and provide insights into the regulation of centriole duplication.	Univ Pittsburgh, Inst Canc, Hillman Canc Ctr, Mol Virol Program, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA 15213 USA; Max Planck Inst Biochem, Dept Cell Biol, D-82152 Martinsried, Germany; Univ Pittsburgh, Sch Med, Dept Mol Genet & Biochem, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Max Planck Society; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Duensing, A (corresponding author), Univ Pittsburgh, Inst Canc, Hillman Canc Ctr, Mol Virol Program, Res Pavil Suite 1-8,5117 Ctr Ave, Pittsburgh, PA 15213 USA.	duensing@pitt.edu		nigg, erich/0000-0003-4835-5719; Duensing, Anette/0000-0002-0168-4067	NCI NIH HHS [R01 CA112598, R01 CA112598-03] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA112598] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON RG, 1971, J CELL BIOL, V50, P10, DOI 10.1083/jcb.50.1.10; Bettencourt-Dias M, 2005, CURR BIOL, V15, P2199, DOI 10.1016/j.cub.2005.11.042; Bogyo M, 1997, P NATL ACAD SCI USA, V94, P6629, DOI 10.1073/pnas.94.13.6629; Bornens M, 2002, CURR OPIN CELL BIOL, V14, P25, DOI 10.1016/S0955-0674(01)00290-3; Brinkley BR, 2001, TRENDS CELL BIOL, V11, P18, DOI 10.1016/S0962-8924(00)01872-9; DIRKSEN ER, 1971, J CELL BIOL, V51, P286, DOI 10.1083/jcb.51.1.286; Duensing A, 2007, ONCOGENE, V26, P215, DOI 10.1038/sj.onc.1209782; Duensing A, 2006, ONCOGENE, V25, P2943, DOI 10.1038/sj.onc.1209310; Duensing S, 2000, P NATL ACAD SCI USA, V97, P10002, DOI 10.1073/pnas.170093297; Duensing S, 2005, CELL BIOL INT, V29, P352, DOI 10.1016/j.cellbi.2005.03.005; Duensing S, 2004, ONCOGENE, V23, P8206, DOI 10.1038/sj.onc.1208012; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Fabunmi RP, 2000, J BIOL CHEM, V275, P409, DOI 10.1074/jbc.275.1.409; Freed E, 1999, GENE DEV, V13, P2242, DOI 10.1101/gad.13.17.2242; Gstaiger M, 1999, EXP CELL RES, V247, P554, DOI 10.1006/excr.1999.4386; Guarguaglini G, 2005, MOL BIOL CELL, V16, P1095, DOI 10.1091/mbc.E04-10-0939; Habedanck R, 2005, NAT CELL BIOL, V7, P1140, DOI 10.1038/ncb1320; Hagiwara H, 2004, INT REV CYTOL, V234, P101, DOI 10.1016/S0074-7696(04)34003-9; Hinchcliffe EH, 1999, SCIENCE, V283, P851, DOI 10.1126/science.283.5403.851; Lacey KR, 1999, P NATL ACAD SCI USA, V96, P2817, DOI 10.1073/pnas.96.6.2817; Lingle WL, 1998, P NATL ACAD SCI USA, V95, P2950, DOI 10.1073/pnas.95.6.2950; Martin LG, 1998, J VIROL, V72, P975, DOI 10.1128/JVI.72.2.975-985.1998; MATSUMOTO Y, 1999, P SPIE 3 DIM IM CAPT, V2, P2; McIntyre MC, 1996, VIROLOGY, V215, P73, DOI 10.1006/viro.1996.0008; Meraldi P, 1999, NAT CELL BIOL, V1, P88, DOI 10.1038/10054; Munger K, 2001, ONCOGENE, V20, P7888, DOI 10.1038/sj.onc.1204860; Nakayama K, 2000, EMBO J, V19, P2069, DOI 10.1093/emboj/19.9.2069; Nigg EA, 2002, NAT REV CANCER, V2, P815, DOI 10.1038/nrc924; NIGG EA, 2004, CENTROSOMES DEV DIS; Pihan GA, 1998, CANCER RES, V58, P3974; Salisbury JL, 1999, BIOL CELL, V91, P451, DOI 10.1016/S0248-4900(99)80086-0; SLUDER G, 2004, CENTROSOMES DEV DIS, P167, DOI DOI 10.1002/3527603808.CH9; Tsou MFB, 2006, NATURE, V442, P947, DOI 10.1038/nature04985; Tsou MFB, 2006, CURR OPIN CELL BIOL, V18, P74, DOI 10.1016/j.ceb.2005.12.008; Vidwans SJ, 2003, J CELL SCI, V116, P137, DOI 10.1242/jcs.00204; Wigley WC, 1999, J CELL BIOL, V145, P481; Wojcik EJ, 2000, CURR BIOL, V10, P1131, DOI 10.1016/S0960-9822(00)00703-X	37	87	88	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 20	2007	26	43					6280	6288		10.1038/sj.onc.1210456	http://dx.doi.org/10.1038/sj.onc.1210456			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	212GW	17438528	Green Accepted			2022-12-28	WOS:000249583300004
J	Rahmanto, YS; Dunn, LL; Richardson, DR				Rahmanto, Y. Suryo; Dunn, L. L.; Richardson, D. R.			The melanoma tumor antigen, melanotransferrin (p97): a 25-year hallmark - from iron metabolism to tumorigenesis	ONCOGENE			English	Review						melanotransferrin; tumorigenesis; iron metabolism; melanoma	PHOSPHATE-ACTIVATED GLUTAMINASE; BOUND TRANSFERRIN HOMOLOG; ENDOTHELIAL GROWTH-FACTOR; GPI-ANCHORED PROTEINS; CELL-SURFACE; PLASMINOGEN ACTIVATION; CHONDROGENIC DIFFERENTIATION; REACTIVE MICROGLIA; APOLIPOPROTEIN D; LINKED PROTEINS	Melanotransferrin (MTf) or melanoma tumor antigen p97 is a transferrin (Tf) homolog that is found predominantly bound to the cell membrane via a glycosyl phosphatidylinositol anchor. The molecule is a member of the Tf superfamily and binds iron through a single high-affinity iron(III)-binding site. Since its discovery on the plasma membrane of melanoma cells, the function of MTf has remained intriguing, particularly in relation to its role in cancer cell iron transport. In fact, considering the crucial role of iron in many metabolic pathways, e. g., DNA synthesis, it was important to understand the function of MTf in the transport of this vital nutrient. MTf has also been implicated in diverse physiological processes, such as plasminogen activation, angiogenesis and cell migration. However, recent studies using a knockout mouse and post-transcriptional gene silencing have demonstrated that MTf is not involved in iron metabolism, but plays a vital role in melanoma cell proliferation and tumorigenesis. In this review, we discuss the possible biological functions of MTf, particularly in relation to cancer.	Univ Sydney, Dept Pathol, Iron Metab & Chelation Program, Sydney, NSW 2006, Australia	University of Sydney	Richardson, DR (corresponding author), Univ Sydney, Sydney, NSW 2006, Australia.	d.richardson@pathology.usyd.edu.au	Suryo Rahmanto, Yohan/K-8043-2018	Suryo Rahmanto, Yohan/0000-0003-1453-7872; Richardson, Des/0000-0002-5506-3274; Richardson, Des/0000-0003-0960-6415				Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185; ALEDO JC, 1994, FEBS LETT, V341, P39, DOI 10.1016/0014-5793(94)80236-X; ALEMANY R, 1993, J CELL SCI, V104, P1155; Andreasen PA, 1997, INT J CANCER, V72, P1, DOI 10.1002/(SICI)1097-0215(19970703)72:1<1::AID-IJC1>3.0.CO;2-Z; Andreasen PA, 2000, CELL MOL LIFE SCI, V57, P25, DOI 10.1007/s000180050497; BAILEY S, 1988, BIOCHEMISTRY-US, V27, P5804, DOI 10.1021/bi00415a061; BAKER EN, 1992, J INORG BIOCHEM, V47, P147, DOI 10.1016/0162-0134(92)84061-Q; BAKER EN, 1992, FEBS LETT, V298, P215, DOI 10.1016/0014-5793(92)80060-T; BEARD JL, 1993, NUTR REV, V51, P157, DOI 10.1111/j.1753-4887.1993.tb03096.x; Birck A, 1999, MELANOMA RES, V9, P375, DOI 10.1097/00008390-199908000-00006; Black BL, 1998, ANNU REV CELL DEV BI, V14, P167, DOI 10.1146/annurev.cellbio.14.1.167; BROWN D, 1992, J AM SOC NEPHROL, V3, P895; BROWN D, 1993, CURR OPIN IMMUNOL, V5, P349, DOI 10.1016/0952-7915(93)90052-T; BROWN JP, 1982, NATURE, V296, P171, DOI 10.1038/296171a0; BROWN JP, 1981, P NATL ACAD SCI-BIOL, V78, P539, DOI 10.1073/pnas.78.1.539; BROWN JP, 1981, J IMMUNOL, V127, P539; Choong PFM, 2003, CLIN ORTHOP RELAT R, pS46, DOI 10.1097/01.blo.0000093845.72468.bd; COUREY AJ, 1989, CELL, V59, P827, DOI 10.1016/0092-8674(89)90606-5; DANIELSEN EM, 1995, J CELL BIOL, V131, P939, DOI 10.1083/jcb.131.4.939; Demeule M, 2003, BLOOD, V102, P1723, DOI 10.1182/blood-2003-01-0166; Demeule M, 2002, J NEUROCHEM, V83, P924, DOI 10.1046/j.1471-4159.2002.01201.x; DENIJN M, 1993, MELANOMA RES, V3, P5, DOI 10.1097/00008390-199304000-00002; Desrosiers RR, 2003, BIOCHEM J, V374, P463, DOI 10.1042/BJ20030240; DUCHANGE N, 1992, NUCLEIC ACIDS RES, V20, P2853, DOI 10.1093/nar/20.11.2853; Dunn LL, 2006, CARCINOGENESIS, V27, P2157, DOI 10.1093/carcin/bgl045; ESTIN CD, 1989, J NATL CANCER I, V81, P445, DOI 10.1093/jnci/81.6.445; Food MR, 2002, EUR J BIOCHEM, V269, P4435, DOI 10.1046/j.1432-1033.2002.03140.x; FOOD MR, 1994, J BIOL CHEM, V269, P3034; Furumura M, 2001, J BIOL CHEM, V276, P28147, DOI 10.1074/jbc.M101626200; GARRATT RC, 1992, FEBS LETT, V305, P55, DOI 10.1016/0014-5793(92)80654-Y; Graeven U, 2001, CANCER RES, V61, P7282; Graham TA, 2001, NAT STRUCT BIOL, V8, P1048, DOI 10.1038/nsb718; Jefferies WA, 1996, BRAIN RES, V712, P122, DOI 10.1016/0006-8993(95)01407-1; Kalinowski DS, 2005, PHARMACOL REV, V57, P547, DOI 10.1124/pr.57.4.2; KAMEYAMA K, 1986, J INVEST DERMATOL, V87, P313, DOI 10.1111/1523-1747.ep12524381; KATO Y, 2001, WO2001011368; Kawabata H, 2004, BRIT J HAEMATOL, V127, P464, DOI 10.1111/j.1365-2141.2004.05224.x; Kawamoto T, 1998, EUR J BIOCHEM, V256, P503, DOI 10.1046/j.1432-1327.1998.2560503.x; Kennard ML, 1996, NAT MED, V2, P1230, DOI 10.1038/nm1196-1230; KENNARD ML, 1995, EMBO J, V14, P4178, DOI 10.1002/j.1460-2075.1995.tb00091.x; Kim DK, 2001, NEUROPSYCHOPHARMACOL, V25, P84, DOI 10.1016/S0893-133X(00)00230-X; Kvamme E, 2000, NEUROCHEM RES, V25, P1407, DOI 10.1023/A:1007668801570; Kwok JC, 2002, CRIT REV ONCOL HEMAT, V42, P65, DOI 10.1016/S1040-8428(01)00213-X; Lambert LA, 2005, COMP BIOCHEM PHYS B, V142, P129, DOI 10.1016/j.cbpb.2005.07.007; Lambert LA, 2005, COMP BIOCHEM PHYS B, V140, P11, DOI 10.1016/j.cbpc.2004.09.012; LEBEAU MM, 1986, HUM GENET, V72, P294, DOI 10.1007/BF00290951; Liao SK, 1996, ANTICANCER RES, V16, P171; LISANTI MP, 1989, J CELL BIOL, V109, P2145, DOI 10.1083/jcb.109.5.2145; LISANTI MP, 1990, J MEMBRANE BIOL, V113, P155, DOI 10.1007/BF01872889; Loertscher R, 2002, TRANSPL IMMUNOL, V9, P93, DOI 10.1016/S0966-3274(02)00013-8; LOW MG, 1989, BIOCHIM BIOPHYS ACTA, V988, P427, DOI 10.1016/0304-4157(89)90014-2; LOW MG, 1991, BIOCHEM J, V279, P483, DOI 10.1042/bj2790483; Mann B, 1999, P NATL ACAD SCI USA, V96, P1603, DOI 10.1073/pnas.96.4.1603; McKinsey TA, 2002, TRENDS BIOCHEM SCI, V27, P40, DOI 10.1016/S0968-0004(01)02031-X; McNagny KM, 1996, BLOOD, V87, P1343, DOI 10.1182/blood.V87.4.1343.bloodjournal8741343; MEDINA MA, 1992, MOL CELL BIOCHEM, V113, P1; METZ CN, 1991, CELL BIOL INT REP, V15, P875, DOI 10.1016/0309-1651(91)90039-L; Michaud-Levesque J, 2005, EXP CELL RES, V308, P479, DOI 10.1016/j.yexcr.2005.05.004; Michaud-Levesque J, 2007, CARCINOGENESIS, V28, P280, DOI 10.1093/carcin/bgl123; MIYATA T, 1994, NEW ENGL J MED, V330, P249, DOI 10.1056/NEJM199401273300404; MONTGOMERY AMP, 1993, CANCER RES, V53, P693; MORGAN EH, 1981, MOL ASPECTS MED, V4, P1, DOI 10.1016/0098-2997(81)90003-0; Moroo I, 2003, MICROCIRCULATION, V10, P457, DOI 10.1038/sj.mn.7800213; Nakamasu K, 1999, BBA-GENE STRUCT EXPR, V1447, P258, DOI 10.1016/S0167-4781(99)00173-6; Nakamasu K, 2001, EUR J BIOCHEM, V268, P1468, DOI 10.1046/j.1432-1327.2001.02017.x; Nappi AJ, 2000, CELL MOL BIOL, V46, P637; NATALI PG, 1987, CANCER, V59, P55, DOI 10.1002/1097-0142(19870101)59:1<55::AID-CNCR2820590115>3.0.CO;2-R; Naya FJ, 2002, NAT MED, V8, P1303, DOI 10.1038/nm789; NECKERS LM, 1983, P NATL ACAD SCI-BIOL, V80, P3494, DOI 10.1073/pnas.80.11.3494; Neitzel LT, 1999, ANN SURG ONCOL, V6, P70, DOI 10.1007/s10434-999-0070-z; Pan WH, 2004, J CELL SCI, V117, P5071, DOI 10.1242/jcs.01381; PLOWMAN GD, 1983, NATURE, V303, P70, DOI 10.1038/303070a0; Ribatti D, 1992, EXS, V61, P415; RICHARDSON D, 1991, BIOCHIM BIOPHYS ACTA, V1093, P20, DOI 10.1016/0167-4889(91)90133-I; RICHARDSON D, 1992, J BIOL CHEM, V267, P13972; Richardson DR, 2004, BBA-MOL BASIS DIS, V1690, P124, DOI 10.1016/j.bbadis.2004.06.002; RICHARDSON DR, 1994, J CELL PHYSIOL, V161, P160, DOI 10.1002/jcp.1041610119; RICHARDSON DR, 1992, J BIOL CHEM, V267, P21384; RICHARDSON DR, 1990, BIOCHIM BIOPHYS ACTA, V1053, P1, DOI 10.1016/0167-4889(90)90018-9; RICHARDSON DR, 1991, BIOCHIM BIOPHYS ACTA, V1091, P294, DOI 10.1016/0167-4889(91)90192-Z; Richardson DR, 2000, EUR J BIOCHEM, V267, P1290, DOI 10.1046/j.1432-1327.2000.01079.x; Richardson DR, 1997, BBA-REV BIOMEMBRANES, V1331, P1, DOI 10.1016/S0304-4157(96)00014-7; ROSE TM, 1986, P NATL ACAD SCI USA, V83, P1261, DOI 10.1073/pnas.83.5.1261; Rothenberger S, 1996, BRAIN RES, V712, P117, DOI 10.1016/0006-8993(96)88505-2; RozeHeusse A, 1996, BIOCHEM J, V318, P883, DOI 10.1042/bj3180883; SAFFER JD, 1991, MOL CELL BIOL, V11, P2189, DOI 10.1128/MCB.11.4.2189; Sala R, 2002, EUR J CELL BIOL, V81, P599, DOI 10.1078/0171-9335-00280; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; SCIOT R, 1989, LIVER, V9, P110; Sekyere E, 2000, FEBS LETT, V483, P11, DOI 10.1016/S0014-5793(00)02079-2; Sekyere E, 2003, FEBS LETT, V547, P233, DOI 10.1016/S0014-5793(03)00658-6; Sekyere E, 2002, FEBS LETT, V512, P350, DOI 10.1016/S0014-5793(02)02248-2; Sekyere EO, 2006, BLOOD, V107, P2599, DOI 10.1182/blood-2005-10-4174; Sekyere EO, 2005, BBA-GEN SUBJECTS, V1722, P131, DOI 10.1016/j.bbagen.2004.12.002; SELIGMAN PA, 1986, AM J HUM GENET, V38, P540; Sharom FJ, 2002, BIOCHEM CELL BIOL, V80, P535, DOI 10.1139/O02-146; STAHL A, 1994, CANCER RES, V54, P3066; Suardita K, 2002, J BIOL CHEM, V277, P48579, DOI 10.1074/jbc.M209243200; SUGIMOTO K, 1994, J STEROID BIOCHEM, V51, P167, DOI 10.1016/0960-0760(94)90090-6; Terrisse L, 1998, J NEUROCHEM, V71, P1643; Ware RE, 1998, BLOOD, V92, P2541, DOI 10.1182/blood.V92.7.2541.2541_2541_2550; WOODBURY RG, 1980, P NATL ACAD SCI-BIOL, V77, P2183, DOI 10.1073/pnas.77.4.2183; Yamada T, 1999, BRAIN RES, V845, P1, DOI 10.1016/S0006-8993(99)01767-9; YANG FM, 1984, P NATL ACAD SCI-BIOL, V81, P2752, DOI 10.1073/pnas.81.9.2752; Zhao M, 1999, MOL CELL BIOL, V19, P21	105	41	43	2	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 13	2007	26	42					6113	6124		10.1038/sj.onc.1210442	http://dx.doi.org/10.1038/sj.onc.1210442			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	209PU	17452986				2022-12-28	WOS:000249401300001
J	Schmitt, E; Beauchemin, M; Bertrand, R				Schmitt, E.; Beauchemin, M.; Bertrand, R.			Nuclear colocalization and interaction between bcl-xL and cdk1(cdc2) duringG(2)/M cell-cycle checkpoint	ONCOGENE			English	Article						bcl-xL; cdk1(cdc2); apoptosis; cell cycle; senescence; DNA damage	DNA TOPOISOMERASE-I; PROTEIN-KINASE; CYTOCHROME-C; MITOCHONDRIAL CONTROL; REGULATED KINASE; HL-60 CELLS; G2 ARREST; S-PHASE; PHOSPHORYLATION; APOPTOSIS	In response to cancer chemotherapeutic drugs, cells rapidly trigger the apoptotic program or undergo growth arrest and senescence at specific phases of the cell cycle. Mitochondrial bcl-xL plays a central role in preventing alteration of mitochondrial dysfunction, cytochrome c release, caspase activation, DNA fragmentation and apoptosis. However, its pleitropic function depends on its subcellular localization. Here, we show that in addition to its mitochondrial effect that delays apoptosis, bcl-xL colocalizes and binds to cdk1( cdc2) during G(2)/M cell-cycle checkpoint and its overexpression stabilizes a G(2)/M-arrest senescence program in surviving cells after DNA damage. Bcl-xL potently inhibits cdk1( cdc2) kinase activity, which is reversible by a synthetic peptide between the 41st amino acid and 60th amino acid surrounding of the Thr47 and Ser62 phosphorylation sites, and Asn52 deamidation site, within the. exible loop domain of bcl-xL. A mutant deleted of this region does not alter the antiapoptotic function of bcl-xL, but impedes its effect on cdk1( cdc2) activity and on the G(2)/M-arrest senescence program after DNA damage. The nuclear interaction of bcl-xL and cdk1( cdc2) suggests that bcl-xL is coupled to the stabilization of a cell-cycle checkpoint induced by DNA damage, and this effect is genetically distinct from its function on apoptosis.	Univ Montreal, Notre Dame Hosp, Res Ctr, Ctr Hosp, Montreal, PQ H2L 4M1, Canada; Canc Montreal, Montreal, PQ, Canada; Univ Montreal, Dept Med, Montreal, PQ H2L 4M1, Canada	Universite de Montreal; Universite de Montreal	Bertrand, R (corresponding author), Univ Montreal, Notre Dame Hosp, Res Ctr, Ctr Hosp, 1560 Sherbrooke St E Room Y-5634, Montreal, PQ H2L 4M1, Canada.	richard.bertrand@umontreal.ca						Barboule N, 2005, CELL CYCLE, V4, P590; Basu A, 2003, FEBS LETT, V538, P41, DOI 10.1016/S0014-5793(03)00131-5; BERTRAND R, 1993, EXP CELL RES, V207, P388, DOI 10.1006/excr.1993.1206; BERTRAND R, 1992, EUR J CANCER, V28A, P743, DOI 10.1016/0959-8049(92)90107-D; Blagosklonny MV, 1997, CANCER RES, V57, P130; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; Booher RN, 1997, J BIOL CHEM, V272, P22300, DOI 10.1074/jbc.272.35.22300; Borner C, 1996, J BIOL CHEM, V271, P12695, DOI 10.1074/jbc.271.22.12695; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Burri SH, 1999, INT J RADIAT ONCOL, V43, P423, DOI 10.1016/S0360-3016(98)00385-X; Chang BD, 1999, CANCER RES, V59, P3761; Cliby WA, 2002, J BIOL CHEM, V277, P1599, DOI 10.1074/jbc.M106287200; Deverman BE, 2002, CELL, V111, P51, DOI 10.1016/S0092-8674(02)00972-8; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Domina AM, 2000, J BIOL CHEM, V275, P21688, DOI 10.1074/jbc.M000915200; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; Du LH, 2005, ONCOGENE, V24, P107, DOI 10.1038/sj.onc.1208189; Fan MY, 2000, CANCER RES, V60, P6403; Fujise K, 2000, J BIOL CHEM, V275, P39458, DOI 10.1074/jbc.M006626200; Furnari B, 1997, SCIENCE, V277, P1495, DOI 10.1126/science.277.5331.1495; Haldar S, 1996, CANCER RES, V56, P1253; Han ZY, 2002, J BIOL CHEM, V277, P17154, DOI 10.1074/jbc.M112401200; HOLM C, 1989, CANCER RES, V49, P6365; Jamil S, 2005, BIOCHEM J, V387, P659, DOI 10.1042/BJ20041596; Kamer I, 2005, CELL, V122, P593, DOI 10.1016/j.cell.2005.06.014; Kharbanda S, 2000, J BIOL CHEM, V275, P322, DOI 10.1074/jbc.275.1.322; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Komatsu K, 2000, NAT CELL BIOL, V2, P1, DOI 10.1038/71316; KOZOPAS KM, 1993, P NATL ACAD SCI USA, V90, P3516, DOI 10.1073/pnas.90.8.3516; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; Ling YH, 1998, J BIOL CHEM, V273, P18984, DOI 10.1074/jbc.273.30.18984; LOCK RB, 1990, CANCER RES, V50, P3761; LOCK RB, 1992, CANCER RES, V52, P1817; Marzo I, 1998, SCIENCE, V281, P2027, DOI 10.1126/science.281.5385.2027; Matsuyama S, 1998, MOL CELL, V1, P327, DOI 10.1016/S1097-2765(00)80033-7; MCGOWAN CH, 1995, EMBO J, V14, P2166, DOI 10.1002/j.1460-2075.1995.tb07210.x; Meikrantz W, 1996, J BIOL CHEM, V271, P10205, DOI 10.1074/jbc.271.17.10205; MEIKRANTZ W, 1994, P NATL ACAD SCI USA, V91, P3754, DOI 10.1073/pnas.91.9.3754; Minn AJ, 1996, GENE DEV, V10, P2621, DOI 10.1101/gad.10.20.2621; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MOTOYAMA N, 1995, SCIENCE, V267, P1506, DOI 10.1126/science.7878471; MUELLER PR, 1995, SCIENCE, V270, P86, DOI 10.1126/science.270.5233.86; OCONNOR PM, 1993, J BIOL CHEM, V268, P8298; OCONNOR PM, 1993, CANCER RES, V53, P4776; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; PINES J, 1991, J CELL BIOL, V115, P1, DOI 10.1083/jcb.115.1.1; Poruchynsky MS, 1998, CANCER RES, V58, P3331; Reed JC, 1998, ONCOGENE, V17, P3225, DOI 10.1038/sj.onc.1202591; Robles SJ, 1998, ONCOGENE, V16, P1113, DOI 10.1038/sj.onc.1201862; Saintigny Y, 2001, EMBO J, V20, P2596, DOI 10.1093/emboj/20.10.2596; Scatena CD, 1998, J BIOL CHEM, V273, P30777, DOI 10.1074/jbc.273.46.30777; Schmitt CA, 2002, CELL, V109, P335, DOI 10.1016/S0092-8674(02)00734-1; Schmitt E, 2002, RRD CANCER, V4, P453; Schmitt E, 1998, CELL DEATH DIFFER, V5, P506, DOI 10.1038/sj.cdd.4400376; Schmitt E, 1998, EXP CELL RES, V240, P107, DOI 10.1006/excr.1998.4003; Schmitt E, 2000, BIOCHEM BIOPH RES CO, V270, P868, DOI 10.1006/bbrc.2000.2537; Schmitt E, 2006, J CELL SCI, V119, P4269, DOI 10.1242/jcs.03200; SHI L, 1994, SCIENCE, V263, P1143, DOI 10.1126/science.8108732; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; SHIMIZU T, 1995, CANCER RES, V55, P228; TSAO YP, 1992, CANCER RES, V52, P1823; Vairo G, 1996, ONCOGENE, V13, P1511; Vander Heiden MG, 1999, MOL CELL, V3, P159; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Yamamoto K, 1999, MOL CELL BIOL, V19, P8469; Yang NC, 2004, ANAL BIOCHEM, V325, P337, DOI 10.1016/j.ab.2003.11.012; Yao SL, 1996, CANCER RES, V56, P4551; Yu Q, 2001, FEBS LETT, V505, P7, DOI 10.1016/S0014-5793(01)02756-9; Zamzami N, 1996, J EXP MED, V183, P1533, DOI 10.1084/jem.183.4.1533; Zeng Y, 1998, NATURE, V395, P507, DOI 10.1038/26766; Zinkel SS, 2005, CELL, V122, P579, DOI 10.1016/j.cell.2005.06.022	71	40	41	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 30	2007	26	40					5851	5865		10.1038/sj.onc.1210396	http://dx.doi.org/10.1038/sj.onc.1210396			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	205OH	17369848				2022-12-28	WOS:000249123100003
J	Ehtesham, M; Sarangi, A; Valadez, JG; Chanthaphaychith, S; Becher, MW; Abel, TW; Thompson, RC; Cooper, MK				Ehtesham, M.; Sarangi, A.; Valadez, J. G.; Chanthaphaychith, S.; Becher, M. W.; Abel, T. W.; Thompson, R. C.; Cooper, M. K.			Ligand-dependent activation of the hedgehog pathway in glioma progenitor cells	ONCOGENE			English	Article						brain tumor; glioma; Hedgehog; cancer stem; cell; Olig2; patched	NEURAL STEM-CELLS; SONIC-HEDGEHOG; BRAIN-TUMORS; NERVOUS-SYSTEM; IN-VIVO; GROWTH; CANCER; GLIOBLASTOMA; INHIBITION; DISEASE	The hedgehog (Hh) signaling pathway regulates progenitor cells during embryogenesis and tumorigenesis in multiple organ systems. We have investigated the activity of this pathway in adult gliomas, and demonstrate that the Hh pathway is operational and activated within grade II and III gliomas, but not grade IV de novo glioblastoma multiforme. Furthermore, our studies reveal that pathway activity and responsiveness is confined to progenitor cells within these tumors. Additionally, we demonstrate that Hh signaling in glioma progenitor cells is ligand-dependent and provide evidence documenting the in vivo source of Sonic hedgehog protein. These findings suggest a regulatory role for the Hh pathway in progenitor cells within grade II and III gliomas, and the potential clinical utility of monitoring and targeting this pathway in these primary brain tumors.	Vanderbilt Univ, Med Ctr, Dept Neurol, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Dept Neurol Surg, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Dept Canc Biol, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Dept Pathol, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Vanderbilt Ingram Canc Ctr, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University	Cooper, MK (corresponding author), Vanderbilt Univ, Med Ctr, Dept Neurol, MRBIII,Rm 6140,465 21st Ave S, Nashville, TN 37232 USA.	michael.cooper@vanderbilt.edu			NINDS NIH HHS [R01 NS051557, K08 NS02133] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS051557, K08NS002133] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ahn S, 2005, NATURE, V437, P894, DOI 10.1038/nature03994; Azzarelli B, 2004, J NEUROPATH EXP NEUR, V63, P170, DOI 10.1093/jnen/63.2.170; Bao SD, 2006, CANCER RES, V66, P7843, DOI 10.1158/0008-5472.CAN-06-1010; Beachy PA, 2004, NATURE, V432, P324, DOI 10.1038/nature03100; Becher MW, 1998, NEUROBIOL DIS, V4, P387, DOI 10.1006/nbdi.1998.0168; Berman DM, 2003, NATURE, V425, P846, DOI 10.1038/nature01972; Chen JK, 2002, GENE DEV, V16, P2743, DOI 10.1101/gad.1025302; Chen JK, 2002, P NATL ACAD SCI USA, V99, P14071, DOI 10.1073/pnas.182542899; Cooper MK, 1998, SCIENCE, V280, P1603, DOI 10.1126/science.280.5369.1603; Dahmane N, 2001, DEVELOPMENT, V128, P5201; Fan L, 2004, ENDOCRINOLOGY, V145, P3961, DOI 10.1210/en.2004-0079; Frank-Kamenetsky Maria, 2002, J Biol, V1, P10, DOI 10.1186/1475-4924-1-10; Galli R, 2004, CANCER RES, V64, P7011, DOI 10.1158/0008-5472.CAN-04-1364; Hemmati HD, 2003, P NATL ACAD SCI USA, V100, P15178, DOI 10.1073/pnas.2036535100; Johnson R.A., 2004, ORGANIC REACTIONS; Karhadkar SS, 2004, NATURE, V431, P707, DOI 10.1038/nature02962; Katayama M, 2002, J NEURO-ONCOL, V59, P107, DOI 10.1023/A:1019660421216; KLEIHUES P, 1995, GLIA, V15, P211, DOI 10.1002/glia.440150303; Kleihues P, 2002, J NEUROPATH EXP NEUR, V61, P215, DOI 10.1093/jnen/61.3.215; Lai K, 2003, NAT NEUROSCI, V6, P21, DOI 10.1038/nn983; Lee J, 2006, CANCER CELL, V9, P391, DOI 10.1016/j.ccr.2006.03.030; Ligon KL, 2006, GLIA, V54, P1, DOI 10.1002/glia.20273; Maher EA, 2006, CANCER RES, V66, P11502, DOI 10.1158/0008-5472.CAN-06-2072; Mokhtari K, 2005, NEUROPATH APPL NEURO, V31, P62, DOI 10.1111/j.1365-2990.2004.00612.x; Oh S, 2005, DEV DYNAM, V234, P489, DOI 10.1002/dvdy.20422; Ohgaki H, 2004, CANCER RES, V64, P6892, DOI 10.1158/0008-5472.CAN-04-1337; Sanai N, 2005, NEW ENGL J MED, V353, P811, DOI 10.1056/NEJMra043666; Sanchez P, 2004, P NATL ACAD SCI USA, V101, P12561, DOI 10.1073/pnas.0404956101; Singh SK, 2004, ONCOGENE, V23, P7267, DOI 10.1038/sj.onc.1207946; Singh SK, 2003, CANCER RES, V63, P5821; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; Taipale J, 2000, NATURE, V406, P1005, DOI 10.1038/35023008; Watkins DN, 2003, NATURE, V422, P313, DOI 10.1038/nature01493	33	112	120	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG	2007	26	39					5752	5761		10.1038/sj.onc.1210359	http://dx.doi.org/10.1038/sj.onc.1210359			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	202EP	17353902				2022-12-28	WOS:000248885100007
J	Demichelis, F; Fall, K; Perner, S; Andren, O; Schmidt, F; Setlur, SR; Hoshida, Y; Mosquera, JM; Pawitan, Y; Lee, C; Adami, HO; Mucci, LA; Kantoff, PW; Andersson, SO; Chinnaiyan, AM; Johansson, JE; Rubin, MA				Demichelis, F.; Fall, K.; Perner, S.; Andren, O.; Schmidt, F.; Setlur, S. R.; Hoshida, Y.; Mosquera, J-M; Pawitan, Y.; Lee, C.; Adami, H-O; Mucci, L. A.; Kantoff, P. W.; Andersson, S-O; Chinnaiyan, A. M.; Johansson, J-E; Rubin, M. A.			TMPRSS2 : ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort	ONCOGENE			English	Article						prostate cancer; cancer-specific death; prognosis; TMPRSS2 : ETS; ERG	RADICAL PROSTATECTOMY; BIOCHEMICAL RECURRENCE; NATURAL-HISTORY; SURVIVAL; SWEDEN; DEATH	The identification of the TMPRSS2:ERG fusion in prostate cancer suggests that distinct molecular subtypes may de. ne risk for disease progression. In surgical series, TMPRSS2:ERG fusion was identified in 50% of the tumors. Here, we report on a population-based cohort of men with localized prostate cancers followed by expectant (watchful waiting) therapy with 15% (17/111) TMPRSS2:ERG fusion. We identified a statistically significant association between TMPRSS2:ERG fusion and prostate cancer specific death (cumulative incidence ratio = 2.7, P < 0.01, 95% confidence interval = 1.3-5.8). Quantitative reverse-transcription-polymerase chain reaction demonstrated high estrogen-regulated gene (ERG) expression to be associated with TMPRSS2: ERG fusion (P < 0.005). These data suggest that TMPRSS2:ERG fusion prostate cancers may have a more aggressive phenotype, possibly mediated through increased ERG expression.	Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA USA; ITCirst, SRA, Bioinformat Grp, Trenton, NJ USA; Karolinska Inst, Dept Med Epidemiol & Biostat, Stockholm, Sweden; Univ Hosp Ulm, Inst Pathol, Ulm, Germany; Orebro Univ Hosp, Dept Urol, Orebro, Sweden; Dana Farber Canc Inst, Boston, MA 02115 USA; Broad Inst MIT & Harvard, Cambridge, MA USA; Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA; Brigham & Womens Hosp, Channing Lab, Boston, MA 02115 USA; Univ Michigan, Sch Med, Dept Urol AMC, Ann Arbor, MI USA; Univ Michigan, Sch Med, Dept Pathol AMC, Ann Arbor, MI USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; SRA International; Karolinska Institutet; Ulm University; Orebro University; Harvard University; Dana-Farber Cancer Institute; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Brigham & Women's Hospital; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Rubin, MA (corresponding author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Pathol, 221 Longwood Ave,EBRC 442A, Boston, MA 02115 USA.	marubin@partners.org	Jackson, Benjamin L/C-4297-2012; Fall, Katja/AAE-1876-2021; Fall, Katja/A-9186-2012; Demichelis, Francesca/J-9829-2016; Hoshida, Yujin/R-7513-2019	Fall, Katja/0000-0002-3649-2639; Demichelis, Francesca/0000-0002-8266-8631; Rubin, Mark/0000-0002-8321-9950; Kantoff, Philip/0000-0001-7275-0597	NATIONAL CANCER INSTITUTE [U01CA113913, P50CA090381] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG021404] Funding Source: NIH RePORTER; NCI NIH HHS [P50 CA090381, UO1CA113913] Funding Source: Medline; NIA NIH HHS [R01AG21404] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Andren O, 2006, J UROLOGY, V175, P1337, DOI 10.1016/S0022-5347(05)00734-2; Bill-Axelson A, 2005, NEW ENGL J MED, V352, P1977, DOI 10.1056/NEJMoa043739; Carver BS, 2006, J UROLOGY, V176, P564, DOI 10.1016/j.juro.2006.03.093; Holmberg L, 2002, NEW ENGL J MED, V347, P781, DOI 10.1056/NEJMoa012794; Jemal A, 2006, CA-CANCER J CLIN, V56, P106, DOI 10.3322/canjclin.56.2.106; JOHANSSON JE, 1989, LANCET, V1, P799; JOHANSSON JE, 1992, JAMA-J AM MED ASSOC, V267, P2191, DOI 10.1001/jama.267.16.2191; Johansson JE, 1997, JAMA-J AM MED ASSOC, V277, P467, DOI 10.1001/jama.277.6.467; Johansson JE, 2004, JAMA-J AM MED ASSOC, V291, P2713, DOI 10.1001/jama.291.22.2713; Kalbfleisch J.D., 2002, STAT ANAL FAILURE TI; PERNER S, AM J SURG PATHOL; Perner S, 2006, CANCER RES, V66, P8337, DOI 10.1158/0008-5472.CAN-06-1482; Petrovics G, 2005, ONCOGENE, V24, P3847, DOI 10.1038/sj.onc.1208518; Porter CR, 2006, J UROLOGY, V176, P569, DOI 10.1016/j.juro.2006.03.094; R Development Core Team, 2006, R LANG ENV STAT COMP; Rubin MA, 2005, CANCER EPIDEM BIOMAR, V14, P1424, DOI 10.1158/1055-9965.EPI-04-0801; Soller MJ, 2006, GENE CHROMOSOME CANC, V45, P717, DOI 10.1002/gcc.20329; Tomlins SA, 2006, CANCER RES, V66, P3396, DOI 10.1158/0008-5472.CAN-06-0168; Tomlins SA, 2005, SCIENCE, V310, P644, DOI 10.1126/science.1117679; Ward JF, 2003, J UROLOGY, V170, P1872, DOI 10.1097/01.ju.0000091876.13656.2e; Warlick C, 2006, JNCI-J NATL CANCER I, V98, P355, DOI 10.1093/jnci/djj072	21	473	525	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL	2007	26	31					4596	4599		10.1038/sj.onc.1210237	http://dx.doi.org/10.1038/sj.onc.1210237			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	187GR	17237811				2022-12-28	WOS:000247836100014
J	Durkin, ME; Ullmannova, V; Guan, M; Popescu, NC				Durkin, M. E.; Ullmannova, V.; Guan, M.; Popescu, N. C.			Deleted in liver cancer 3 (DLC-3), a novel Rho GTPase-activating protein, is downregulated in cancer and inhibits tumor cell growth	ONCOGENE			English	Article						tumor suppressor gene; Rho GTPase-activating protein; prostate cancer; breast cancer	HEPATOCELLULAR-CARCINOMA; SUPPRESSOR FUNCTION; GENE-EXPRESSION; HUMAN BREAST; IDENTIFICATION; PROLIFERATION; MUTATIONS; ENCODES; PROFILE; KINASE	Two related Rho GTPase-activating proteins, DLC-1 (deleted in liver cancer 1) and DLC-2, are emerging as bona. de tumor suppressor genes that inhibit cancer cell growth. In this report, we characterized a gene on chromosome Xq13 that encodes DLC-3 (also known as KIAA0189 and STARD8), a third member of the DLC family. The DLC-3 gene has transcripts with alternative 50 ends, one of which, DLC-3a, encodes an 1103-amino acid polypeptide highly similar to DLC-1 and DLC-2. A second isoform (DLC-3b) would yield a protein lacking the N-terminal sterile alpha motif domain. The DLC-3 gene is widely expressed in normal tissues, but DLC-3 mRNA levels were low or absent in a significant number of breast, ovarian, liver and prostate cancer cell lines. Using a cancer pro. ling array to compare matched tumor and normal human tissues, downregulation of DLC-3 mRNA was observed in kidney, lung, ovarian, uterine and breast cancer samples. By quantitative reverse transcriptase polymerase chain reaction, DLC-3 expression was reduced in primary prostate carcinomas relative to normal prostate tissue. Transfection of human breast and prostate cancer cells with a DLC-3a expression vector inhibited cell proliferation, colony formation and growth in soft agar. These results indicate that deregulation of DLC-3 may contribute to breast and prostate tumorigenesis.	NCI, Ctr Canc Res, Expt Carcinogenesis Lab, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Popescu, NC (corresponding author), NCI, Ctr Canc Res, Expt Carcinogenesis Lab, Bethesda, MD 20892 USA.	popescun@mail.nih.gov	Benson, Veronika/D-9942-2014	Benson, Veronika/0000-0003-4770-9909	NATIONAL CANCER INSTITUTE [ZIABC010038, Z01BC010038] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Alpy F, 2005, J CELL SCI, V118, P2791, DOI 10.1242/jcs.02485; Avila DM, 2001, J STEROID BIOCHEM, V76, P135, DOI 10.1016/S0960-0760(00)00158-8; Bernards A, 2004, TRENDS CELL BIOL, V14, P377, DOI 10.1016/j.tcb.2004.05.003; Bernards A, 2003, BBA-REV CANCER, V1603, P47, DOI 10.1016/S0304-419X(02)00082-3; Billuart P, 1998, NATURE, V392, P923, DOI 10.1038/31940; Brown MC, 1998, NAT STRUCT BIOL, V5, P677, DOI 10.1038/1370; Carrel L, 2005, NATURE, V434, P400, DOI 10.1038/nature03479; Ching YP, 2003, J BIOL CHEM, V278, P10824, DOI 10.1074/jbc.M208310200; del Pulgar TG, 2005, BIOESSAYS, V27, P602, DOI 10.1002/bies.20238; Denholm B, 2005, DEVELOPMENT, V132, P2389, DOI 10.1242/dev.01829; Durkin ME, 2005, FEBS LETT, V579, P1191, DOI 10.1016/j.febslet.2004.12.090; Durkin ME, 2002, GENE, V288, P119, DOI 10.1016/S0378-1119(02)00462-6; Edelson MI, 1998, ONCOGENE, V16, P197, DOI 10.1038/sj.onc.1201479; Goodison S, 2005, CANCER RES, V65, P6042, DOI 10.1158/0008-5472.CAN-04-3043; Guan M, 2006, CLIN CANCER RES, V12, P1412, DOI 10.1158/1078-0432.CCR-05-1906; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hers I, 2006, J BIOL CHEM, V281, P4762, DOI 10.1074/jbc.M511008200; HOMMA Y, 1995, EMBO J, V14, P286, DOI 10.1002/j.1460-2075.1995.tb07002.x; Jaffe AB, 2005, ANNU REV CELL DEV BI, V21, P247, DOI 10.1146/annurev.cellbio.21.020604.150721; Leung THY, 2005, P NATL ACAD SCI USA, V102, P15207, DOI 10.1073/pnas.0504501102; Li SSC, 2005, BIOCHEM J, V390, P641, DOI 10.1042/BJ20050411; McLysaght A, 2002, NAT GENET, V31, P200, DOI 10.1038/ng884; Moon SY, 2003, TRENDS CELL BIOL, V13, P13, DOI 10.1016/S0962-8924(02)00004-1; Murakami T, 2003, J BIOL CHEM, V278, P34364, DOI 10.1074/jbc.M301542200; Nagaraja GM, 2004, BIOCHEM BIOPH RES CO, V313, P654, DOI 10.1016/j.bbrc.2003.12.001; Nagase T, 1996, DNA Res, V3, P17, DOI 10.1093/dnares/3.1.17; Ng IOL, 2000, CANCER RES, V60, P6581; Ponting CP, 1999, TRENDS BIOCHEM SCI, V24, P130, DOI 10.1016/S0968-0004(99)01362-6; QIAO F, 2005, SCI STKE; Ridley AJ, 2001, TRENDS CELL BIOL, V11, P471, DOI 10.1016/S0962-8924(01)02153-5; Sekimata M, 1999, J BIOL CHEM, V274, P17757, DOI 10.1074/jbc.274.25.17757; SENG TJ, 2006, ONCOGENE; Sjoblom T, 2006, SCIENCE, V314, P268, DOI 10.1126/science.1133427; Song YF, 2006, J CLIN PATHOL, V59, P947, DOI 10.1136/jcp.2005.031377; Spatz A, 2004, NAT REV CANCER, V4, P617, DOI 10.1038/nrc1413; Syed V, 2005, ONCOGENE, V24, P1774, DOI 10.1038/sj.onc.1207991; Thakur A, 2005, BREAST CANCER RES TR, V93, P135, DOI 10.1007/s10549-005-4516-0; Twigg SRF, 2006, AM J HUM GENET, V78, P999, DOI 10.1086/504440; Ullmannova V, 2006, INT J ONCOL, V29, P1127; VAN AL, 1997, GENE DEV, V11, P2295; Wieland I, 2004, AM J HUM GENET, V74, P1209, DOI 10.1086/421532; Wong CM, 2003, CANCER RES, V63, P7646; Wong CM, 2005, CANCER RES, V65, P8861, DOI 10.1158/0008-5472.CAN-05-1318; Yuan BZ, 1998, CANCER RES, V58, P2196; Yuan BZ, 2004, ONCOGENE, V23, P1405, DOI 10.1038/sj.onc.1207291; Yuan BZ, 2003, ONCOGENE, V22, P445, DOI 10.1038/sj.onc.1206064; Zhou XL, 2004, ONCOGENE, V23, P1308, DOI 10.1038/sj.onc.1207246	47	64	65	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2007	26	31					4580	4589		10.1038/sj.onc.1210244	http://dx.doi.org/10.1038/sj.onc.1210244			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	187GR	17297465				2022-12-28	WOS:000247836100012
J	Wood, VHJ; O'Neil, JD; Wei, W; Stewart, SE; Dawson, CW; Young, LS				Wood, V. H. J.; O'Neil, J. D.; Wei, W.; Stewart, S. E.; Dawson, C. W.; Young, L. S.			Epstein-Barr virus-encoded EBNA1 regulates cellular gene transcription and modulates the STAT1 and TGF beta signaling pathways	ONCOGENE			English	Article						EBV; EBNA1; STAT1; TGF beta 1; SMAD2	GROWTH-FACTOR-BETA; NUCLEAR ANTIGEN 1; NASOPHARYNGEAL CARCINOMA; KAPOSIS-SARCOMA; LYMPHOMA-CELLS; KAPPA-B; EXPRESSION; CANCER; PROTEIN; PROMOTER	The Epstein-Barr virus (EBV)-encoded EBNA1 protein is expressed in all virus-associated tumors where it plays an essential role in the maintenance, replication and transcription of the EBV genome. Transcriptional pro. ling of EBNA1-expressing carcinoma cells demonstrated that EBNA1 also influences the expression of a range of cellular genes including those involved in translation, transcription and cell signaling. Of particular interest was the ability of EBNA1 to enhance expression of STAT1 and sensitize cells to interferon-induced STAT1 activation with resultant enhancement of major histocompatibility complex expression. A negative effect of EBNA1 on the expression of TGF beta 1-responsive beta ig-h3 and PAI-1 genes was confirmed at the protein level in EBV-infected carcinoma cells. This effect resulted from the ability of EBNA1 to repress TGFb1-induced transcription via a reduction in the interaction of SMAD2 with SMAD4. More detailed analysis revealed that EBNA1 induces a lower steady-state level of SMAD2 protein as a consequence of increased protein turnover. These data show that EBNA1 can influence cellular gene transcription resulting in effects that may contribute to the development of EBV-associated tumors.	Univ Birmingham, Canc Res UK Inst Canc Studies, Birmingham B15 2TT, W Midlands, England	Cancer Research UK; University of Birmingham	Young, LS (corresponding author), Univ Birmingham, Canc Res UK Inst Canc Studies, Birmingham B15 2TT, W Midlands, England.	L.S.Young@bham.ac.uk	Young, Lawrence S/B-7213-2009	Young, Lawrence S/0000-0003-3919-4298; Wei, Wenbin/0000-0003-1288-6999				AB RICKINSON, 2001, FIELDS VIROLOGY, P2575; Balkwill F, 2001, LANCET, V357, P539, DOI 10.1016/S0140-6736(00)04046-0; Baumforth KRN, 2005, BLOOD, V106, P2138, DOI 10.1182/blood-2005-02-0471; Cao WP, 2006, BLOOD, V107, P2777, DOI 10.1182/blood-2005-05-1803; Chen HL, 2003, J VIROL, V77, P4139, DOI 10.1128/JVI.77.7.4139-4148.2003; Chen HL, 1999, P NATL ACAD SCI USA, V96, P9339, DOI 10.1073/pnas.96.16.9339; Chen HL, 2001, J VIROL, V75, P2929, DOI 10.1128/JVI.75.6.2929-2937.2001; Choi SH, 2006, J BIOL CHEM, V281, P7468, DOI 10.1074/jbc.M512438200; Chow LSN, 2006, ONCOGENE, V25, P310, DOI 10.1038/sj.onc.1209001; Chuang TC, 2002, FEBS LETT, V532, P135, DOI 10.1016/S0014-5793(02)03658-X; Debonneville C, 2004, MOL CELL BIOL, V24, P2397, DOI 10.1128/MCB.24.6.2397-2409.2004; Fakhari FD, 2006, J CLIN INVEST, V116, P735, DOI 10.1172/JCI26190; Friborg J, 1999, NATURE, V402, P889, DOI 10.1038/47266; Fujimuro M, 2003, NAT MED, V9, P300, DOI 10.1038/nm829; Fukuda M, 2004, J VIROL, V78, P1697, DOI 10.1128/JVI.78.4.1697-1705.2004; Gupta A, 2006, NATURE, V442, P82, DOI 10.1038/nature04836; Haider AS, 2006, J INVEST DERMATOL, V126, P869, DOI 10.1038/sj.jid.5700157; Harn HJ, 2002, ORAL ONCOL, V38, P23, DOI 10.1016/S1368-8375(01)00008-2; Holowaty MN, 2003, J BIOL CHEM, V278, P29987, DOI 10.1074/jbc.M303977200; HUIBREGTSE JM, 1991, EMBO J, V10, P4129, DOI 10.1002/j.1460-2075.1991.tb04990.x; Humme S, 2003, P NATL ACAD SCI USA, V100, P10989, DOI 10.1073/pnas.1832776100; Kang MS, 2005, P NATL ACAD SCI USA, V102, P820, DOI 10.1073/pnas.0408774102; Kang MS, 2001, P NATL ACAD SCI USA, V98, P15233, DOI 10.1073/pnas.211556598; Kennedy G, 2003, P NATL ACAD SCI USA, V100, P14269, DOI 10.1073/pnas.2336099100; KIEFF E, 2001, FIELDS VIROLOGY, P2511; Komano J, 1998, J VIROL, V72, P9150, DOI 10.1128/JVI.72.11.9150-9156.1998; Kovacic B, 2006, CANCER CELL, V10, P77, DOI 10.1016/j.ccr.2006.05.025; Kube D, 1999, J VIROL, V73, P1630, DOI 10.1128/JVI.73.2.1630-1636.1999; Kuratomi G, 2005, BIOCHEM J, V386, P461, DOI 10.1042/BJ20040738; Lee CY, 2004, IEEE T EVOLUT COMPUT, V8, P1, DOI 10.1109/TEVC.2003.816583; Lee DK, 2002, J BIOL CHEM, V277, P38557, DOI 10.1074/jbc.M206786200; LEVITSKAYA J, 1995, NATURE, V375, P685, DOI 10.1038/375685a0; Liang CL, 2000, VIROLOGY, V277, P184, DOI 10.1006/viro.2000.0582; Liang CL, 2002, J BIOL CHEM, V277, P23345, DOI 10.1074/jbc.M107420200; Lo RS, 1999, NAT CELL BIOL, V1, P472, DOI 10.1038/70258; Mori N, 2003, INT J CANCER, V105, P661, DOI 10.1002/ijc.11146; Munier FL, 1997, NAT GENET, V15, P247, DOI 10.1038/ng0397-247; Nam JO, 2005, CANCER RES, V65, P4153, DOI 10.1158/0008-5472.CAN-04-2705; Oh JE, 2005, J BIOL CHEM, V280, P21629, DOI 10.1074/jbc.m412293200; Perk J, 2005, NAT REV CANCER, V5, P603, DOI 10.1038/nrc1673; Raab-Traub N, 2002, SEMIN CANCER BIOL, V12, P431, DOI 10.1016/S1044579X0200086X; Radkov SA, 2000, NAT MED, V6, P1121, DOI 10.1038/80459; Renne C, 2006, AM J PATHOL, V169, P655, DOI 10.2353/ajpath.2006.060020; Ruf IK, 2000, J VIROL, V74, P10223, DOI 10.1128/JVI.74.21.10223-10228.2000; Saridakis V, 2005, MOL CELL, V18, P25, DOI 10.1016/j.molcel.2005.02.029; Seo TG, 2005, CANCER RES, V65, P1738, DOI 10.1158/0008-5472.CAN-04-2374; Shao GZ, 2006, CANCER RES, V66, P4566, DOI 10.1158/0008-5472.CAN-05-2130; Sheng Y, 2006, NAT STRUCT MOL BIOL, V13, P285, DOI 10.1038/nsmb1067; Sheu LF, 1996, J PATHOL, V180, P243, DOI 10.1002/(SICI)1096-9896(199611)180:3<243::AID-PATH655>3.0.CO;2-7; Siegel PM, 2003, NAT REV CANCER, V3, P807, DOI 10.1038/nrc1208; SRINIVAS SK, 1995, J VIROL, V69, P8155, DOI 10.1128/JVI.69.12.8155-8158.1995; Stewart S, 2004, P NATL ACAD SCI USA, V101, P15730, DOI 10.1073/pnas.0402135101; Tellam J, 2004, J EXP MED, V199, P1421, DOI 10.1084/jem.20040191; Tsimbouri P, 2002, ONCOGENE, V21, P5182, DOI 10.1038/sj.onc.1205490; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Voo KS, 2004, J EXP MED, V199, P459, DOI 10.1084/jem.20031219; Wilson JB, 1996, EMBO J, V15, P3117, DOI 10.1002/j.1460-2075.1996.tb00674.x; Xi SC, 2006, JNCI-J NATL CANCER I, V98, P181, DOI 10.1093/jnci/djj020; Young LS, 2004, NAT REV CANCER, V4, P757, DOI 10.1038/nrc1452; Yu H, 2004, NAT REV CANCER, V4, P97, DOI 10.1038/nrc1275	60	96	103	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 14	2007	26	28					4135	4147		10.1038/sj.onc.1210496	http://dx.doi.org/10.1038/sj.onc.1210496			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	178XD	17486072				2022-12-28	WOS:000247252700009
J	Schild-Poulter, C; Shih, A; Tantin, D; Yarymowich, NC; Soubeyrand, S; Sharp, PA; Hache, RJG				Schild-Poulter, C.; Shih, A.; Tantin, D.; Yarymowich, N. C.; Soubeyrand, S.; Sharp, P. A.; Hache, R. J. G.			DNA-PK phosphorylation sites on Oct-1 promote cell survival following DNA damage	ONCOGENE			English	Article						Ku; DNA-dependent protein kinase; Oct-1; DNA damage; phosphorylation	DEPENDENT PROTEIN-KINASE; TRANSCRIPTION FACTOR OCT-1; DOUBLE-STRAND BREAKS; CATALYTIC SUBUNIT; HISTONE H2B; MULTISITE PHOSPHORYLATION; IONIZING-RADIATION; DOWN-REGULATION; POU DOMAIN; IN-VITRO	Octamer transcription factor-1 ( Oct-1) has recently been shown to function as a stress sensor that promotes cell survival subsequent to DNA damage. Here, we show that the survival signal imparted by Oct-1 following exposure to ionizing radiation ( IR) is dependent upon DNA-dependent protein kinase ( DNA-PK)-dependent phosphorylation of a cluster of 13 specific ser/thr residues within the N-terminal transcriptional regulatory domain of Oct-1. Although IR treatment did not affect the recruitment of Oct-1 to the histone H2B promoter, the recruitment of RNA polymerase II, TATA-binding protein and histone H4 acetylation were strongly reduced, consistent with a decrease in Oct-1 transcriptional regulatory potential following IR exposure. Ser/Thr-Ala substitution of 13 sites present in Oct-1 transcriptional regulatory domain eliminated Oct-1 phosphorylation subsequent to IR exposure. Further, these substitutions prevented Oct-1 from rescuing the survival of IR-treated Oct-1(-/-) murine embryonic fibroblasts, providing a direct link between DNA-PK- dependent phosphorylation and the contribution of Oct-1 to cell survival. These results implicate Oct-1 as a primary effector in a DNA-PK-dependent cell survival pathway that is activated by double-stranded DNA breaks.	Univ Ottawa, Dept Med, Ottawa Hlth Res Inst, Ottawa, ON K1Y 4E9, Canada; Univ Ottawa, Dept Biochem Microbiol & Immunol, Ottawa Hlth Res Inst, Ottawa, ON K1Y 4E9, Canada; MIT, Ctr Canc Res, Cambridge, MA 02139 USA; MIT, Dept Biol, Cambridge, MA 02139 USA	University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; Ottawa Hospital Research Institute; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	Schild-Poulter, C (corresponding author), Univ Ottawa, Dept Med, Ottawa Hlth Res Inst, 725 Parkdale Rd, Ottawa, ON K1Y 4E9, Canada.	cschild-poulter@robarts.ca; rhache@ohri.ca	Schild-Poulter, Caroline/K-4476-2013	soubeyrand, sebastien/0000-0002-9317-301X				Bailey SM, 2004, CYTOGENET GENOME RES, V104, P109, DOI 10.1159/000077474; Bharti A, 1998, MOL CELL BIOL, V18, P6719, DOI 10.1128/MCB.18.11.6719; Chan DW, 2002, GENE DEV, V16, P2333, DOI 10.1101/gad.1015202; Chan DW, 1999, BIOCHEMISTRY-US, V38, P1819, DOI 10.1021/bi982584b; Collis SJ, 2005, ONCOGENE, V24, P949, DOI 10.1038/sj.onc.1208332; de Jong RN, 1999, GENE, V236, P1, DOI 10.1016/S0378-1119(99)00249-8; Douglas P, 2002, BIOCHEM J, V368, P243, DOI 10.1042/BJ20020973; EBLE MJ, 1994, INT J RADIAT BIOL, V65, P193, DOI 10.1080/09553009414550231; Ferguson DO, 2001, ONCOGENE, V20, P5572, DOI 10.1038/sj.onc.1204767; FLETCHER C, 1987, CELL, V51, P773, DOI 10.1016/0092-8674(87)90100-0; Giffin W, 1997, J BIOL CHEM, V272, P5647, DOI 10.1074/jbc.272.9.5647; Gunawardena J, 2005, P NATL ACAD SCI USA, V102, P14617, DOI 10.1073/pnas.0507322102; HECKMAN CA, 2005, ONCOGENE, V26, P26; HERR W, 1995, GENE DEV, V9, P1679, DOI 10.1101/gad.9.14.1679; Holmberg CI, 2002, TRENDS BIOCHEM SCI, V27, P619, DOI 10.1016/S0968-0004(02)02207-7; Jin SQ, 2001, ONCOGENE, V20, P2683, DOI 10.1038/sj.onc.1204390; Kim ST, 1999, J BIOL CHEM, V274, P37538, DOI 10.1074/jbc.274.53.37538; Kraus WL, 1999, MOL CELL BIOL, V19, P8123; Lees-Miller SP, 2003, BIOCHIMIE, V85, P1161, DOI 10.1016/j.biochi.2003.10.011; Leo C, 2000, GENE, V245, P1, DOI 10.1016/S0378-1119(00)00024-X; Li L, 2004, BIOCHEM CELL BIOL, V82, P460, DOI 10.1139/O04-045; Lieber MR, 2003, NAT REV MOL CELL BIO, V4, P712, DOI 10.1038/nrm1202; Loong SLE, 2004, ONCOGENE, V23, P5562, DOI 10.1038/sj.onc.1207771; Luo XQ, 2003, ONCOGENE, V22, P7247, DOI 10.1038/sj.onc.1207010; Maiti NR, 2005, J INTERF CYTOK RES, V25, P553, DOI 10.1089/jir.2005.25.553; Meek K, 2004, IMMUNOL REV, V200, P132, DOI 10.1111/j.0105-2896.2004.00162.x; Meighan-Mantha RL, 1999, MOL CELL BIOCHEM, V199, P209, DOI 10.1023/A:1006958217143; Nash P, 2001, NATURE, V414, P514, DOI 10.1038/35107009; Okamura H, 2000, MOL CELL, V6, P539, DOI 10.1016/S1097-2765(00)00053-8; Phillips K, 2000, J MOL BIOL, V302, P1023, DOI 10.1006/jmbi.2000.4107; Pufall MA, 2005, SCIENCE, V309, P142, DOI 10.1126/science.1111915; Ryan AK, 1997, GENE DEV, V11, P1207, DOI 10.1101/gad.11.10.1207; Sawada M, 2003, NAT CELL BIOL, V5, P320, DOI 10.1038/ncb950; Schild-Poulter C, 2003, CANCER RES, V63, P7197; Schild-Poulter C, 2001, J BIOL CHEM, V276, P16848, DOI 10.1074/jbc.M100768200; SEIPEL K, 1992, EMBO J, V11, P4961, DOI 10.1002/j.1460-2075.1992.tb05603.x; Servillo G, 2002, EXP CELL RES, V275, P143, DOI 10.1006/excr.2002.5491; SIVE HL, 1986, P NATL ACAD SCI USA, V83, P6382, DOI 10.1073/pnas.83.17.6382; Smith GCM, 1999, GENE DEV, V13, P916, DOI 10.1101/gad.13.8.916; Soubeyrand S, 2004, EUR J BIOCHEM, V271, P3776, DOI 10.1111/j.1432-1033.2004.04319.x; Soubeyrand S, 2003, CANCER RES, V63, P1198; STRONG CB, 1996, ADV ENVIRONM MANAG, V1, P1; Su C, 2004, EMBO J, V23, P1133, DOI 10.1038/sj.emboj.7600120; Takahashi S, 2001, CANCER RES, V61, P1187; Tantin D, 2005, CANCER RES, V65, P10750, DOI 10.1158/0008-5472.CAN-05-2399; Valerie K, 2003, ONCOGENE, V22, P5792, DOI 10.1038/sj.onc.1206679; Wang S, 2000, P NATL ACAD SCI USA, V97, P1584, DOI 10.1073/pnas.97.4.1584; Wang VEH, 2004, MOL CELL BIOL, V24, P1022, DOI 10.1128/MCB.24.3.1022-1032.2004; Whitmarsh AJ, 2000, CELL MOL LIFE SCI, V57, P1172, DOI 10.1007/PL00000757; Wilkins RC, 1999, J MOL BIOL, V285, P515, DOI 10.1006/jmbi.1998.2356; Wiper-Bergeron N, 2003, EMBO J, V22, P2135, DOI 10.1093/emboj/cdg218; Woo RA, 2002, EMBO J, V21, P3000, DOI 10.1093/emboj/cdf307; Zhao HC, 2000, CANCER RES, V60, P6276; Zhao JY, 2000, GENE DEV, V14, P2283, DOI 10.1101/gad.827700	54	36	36	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 7	2007	26	27					3980	3988		10.1038/sj.onc.1210165	http://dx.doi.org/10.1038/sj.onc.1210165			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	177HP	17213819				2022-12-28	WOS:000247144500008
J	Haase, D; Meister, M; Muley, T; Hess, J; Teurich, S; Schnabel, P; Hartenstein, B; Angel, P				Haase, D.; Meister, M.; Muley, T.; Hess, J.; Teurich, S.; Schnabel, P.; Hartenstein, B.; Angel, P.			FRMD3, a novel putative tumour suppressor in NSCLC	ONCOGENE			English	Article						protein 4.1; lung cancer; ferm containing 3; apoptosis	PROTEIN 4.1B; EXPRESSION; GROWTH; CANCER; DAL-1; MENINGIOMA; GENE; DOMAIN; MEMBER; MERLIN	Lung cancer including non-small cell lung carcinoma (NSCLC) represents a leading cause of cancer death in Western countries. Yet, understanding its pathobiology to improve early diagnosis and therapeutic strategies is still a major challenge of today's biomedical research. We analyzed a set of differentially regulated genes that were identifi. ed in skin cancer by a comprehensive microarray study, for their expression in NSCLC. We found that ferm domain containing protein 3 (FRMD3), a member of the protein 4.1 superfamily, is expressed in normal lung tissue but silenced in 54 out of 58 independent primary NSCLC tumours compared to patient-matched normal lung tissue. FRMD3 overexpression in different epithelial cell lines resulted in a decreased clonogenicity as measured by colony formation assay. Although cell attachment capabilities and cell proliferation rate remained unchanged, this phenotype was most likely owing to induced apoptosis. Our data identify FRMD3 as a novel putative tumour suppressor gene suggesting an important role in the origin and progression of lung cancer.	Deutsch Krebsforschungszentrum, Div Signal Transduct & Growth Control A100, D-69120 Heidelberg, Germany; Thoraxklin Heidelberg GmbH, Sekt Translat Forschung, Heidelberg, Germany; Univ Hosp, Dept Gen Pathol, Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg	Hartenstein, B (corresponding author), Deutsch Krebsforschungszentrum, Div Signal Transduct & Growth Control A100, Neuenheimer Feld 280, D-69120 Heidelberg, Germany.	b.hartenstein@dkfz.de	Hess, Jochen/ABE-1144-2021	Hess, Jochen/0000-0003-3493-1711				Breitenbach U, 2001, J INVEST DERMATOL, V117, P634, DOI 10.1046/j.0022-202x.2001.01437.x; Charboneau AL, 2002, INT J CANCER, V100, P181, DOI 10.1002/ijc.10470; Forgacs Eva, 2001, Pathology and Oncology Research, V7, P6; Gerber MA, 2006, CANCER RES, V66, P5295, DOI 10.1158/0008-5472.CAN-05-1628; Greenlee RT, 2000, CA-CANCER J CLIN, V50, P7, DOI 10.3322/canjclin.50.1.7; Gutmann DH, 2001, NEUROBIOL DIS, V8, P266, DOI 10.1006/nbdi.2000.0376; Gutmann DH, 2000, HUM MOL GENET, V9, P1495, DOI 10.1093/hmg/9.10.1495; Hanada T, 2003, J BIOL CHEM, V278, P34445, DOI 10.1074/jbc.M305209200; Huang S, 2001, EUR J CLIN INVEST, V31, P907, DOI 10.1046/j.1365-2362.2001.00892.x; Hummerich L, 2006, ONCOGENE, V25, P111, DOI 10.1038/sj.onc.1209016; Jiang W, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-4; Kuns R, 2005, ONCOGENE, V24, P6502, DOI 10.1038/sj.onc.1208813; Mao XL, 2003, CANCER RES, V63, P7979; Minna JD, 2002, CANCER CELL, V1, P49, DOI 10.1016/S1535-6108(02)00027-2; Ni XH, 2003, J HUM GENET, V48, P101, DOI 10.1007/s100380300015; Panani AD, 2006, CANCER LETT, V239, P1, DOI 10.1016/j.canlet.2005.06.030; Perry A, 2000, J NEUROPATH EXP NEUR, V59, P872, DOI 10.1093/jnen/59.10.872; Rapp UR, 2003, ADV ENZYME REGUL, V43, P183, DOI 10.1016/S0065-2571(03)00002-5; Robb VA, 2003, NEUROBIOL DIS, V13, P191, DOI 10.1016/S0969-9961(03)00071-8; Robb VA, 2005, ONCOGENE, V24, P1946, DOI 10.1038/sj.onc.1208335; Robb VA, 2004, ONCOGENE, V23, P3589, DOI 10.1038/sj.onc.1207445; Schlingemann J, 2003, INT J CANCER, V104, P699, DOI 10.1002/ijc.11008; Shaw AT, 2005, CLIN CANCER RES, V11, p4999S, DOI 10.1158/1078-0432.CCR-05-9005; Sherman LS, 2001, TRENDS CELL BIOL, V11, P442, DOI 10.1016/S0962-8924(01)02128-6; Singh V, 2004, ONCOGENE, V23, P7761, DOI 10.1038/sj.onc.1208057; Sun CX, 2002, J CELL SCI, V115, P3991, DOI 10.1242/jcs.00094; Tran YK, 1999, CANCER RES, V59, P35; Yageta M, 2002, CANCER RES, V62, P5129	28	23	26	1	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2007	26	30					4464	4468		10.1038/sj.onc.1210225	http://dx.doi.org/10.1038/sj.onc.1210225			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	184CZ	17260017				2022-12-28	WOS:000247620000014
J	Adhikari, A; Xu, M; Chen, ZJ				Adhikari, A.; Xu, M.; Chen, Z. J.			Ubiquitin-mediated activation of TAK1 and IKK	ONCOGENE			English	Review						TAK1; IKK; ubiquitin; NF-kappa B; kinase	NF-KAPPA-B; NECROSIS-FACTOR-ALPHA; SIGNAL-TRANSDUCTION PATHWAY; RECEPTOR-ASSOCIATED KINASE; ZINC-FINGER PROTEIN; T-CELL DEVELOPMENT; INNATE IMMUNITY; POLYUBIQUITIN CHAINS; ADAPTER PROTEIN; TNF RECEPTOR	Transforming growth factor beta activated kinase-1 (TAK1), a member of the mitogen-activated protein kinase kinase kinase family, has emerged as a key regulator of signal transduction cascades leading to the activation of the transcription factors nuclear factor-kappa B (NF-kappa B) and activator protein-1 (AP-1). Stimulation of cells with cytokines and microbial pathogens results in the activation of TAK1, which subsequently activates the I-kappa B kinase complex (IKK) and mitogen-activated protein (MAP) kinases, culminating in the activation of NF-kappa B and AP-1, respectively. Recent studies have shown that polyubiquitination of signalling proteins through lysine (Lys)-63-linked polyubiquitin chains plays an important role in the activation of TAK1 and IKK. Unlike Lys-48-linked polyubiquitination, which normally targets proteins for degradation by the proteasome, Lys-63-linked polyubiquitin chains act as scaffolds to assemble protein kinase complexes and mediate their activation through proteasome-independent mechanisms. The concept of ubiquitin-mediated activation of protein kinases is supported by the discoveries of ubiquitination and deubiquitination enzymes as well as ubiquitin-binding proteins that function upstream of TAK1 and IKK. Recent biochemical and genetic studies provide further insights into the mechanism and function of ubiquitin signalling and these advances will be the focus of this review.	Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dept Mol Biol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dept Mol Biol, Dallas, TX USA	Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Chen, ZJ (corresponding author), Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dept Mol Biol, Dallas, TX 75390 USA.	zhijian.chen@utsouthwestern.edu	xu, ming/E-5524-2012; Chen, Zhijian/C-6039-2012	Chen, Zhijian/0000-0002-8475-8251				Abbott DW, 2004, CURR BIOL, V14, P2217, DOI 10.1016/j.cub.2004.12.032; Agou F, 2004, J BIOL CHEM, V279, P27861, DOI 10.1074/jbc.M314278200; Baud V, 1999, GENE DEV, V13, P1297, DOI 10.1101/gad.13.10.1297; Bignell GR, 2000, NAT GENET, V25, P160, DOI 10.1038/76006; Boone DL, 2004, NAT IMMUNOL, V5, P1052, DOI 10.1038/ni1110; Brummelkamp TR, 2003, NATURE, V424, P797, DOI 10.1038/nature01811; Cannons JL, 2002, J IMMUNOL, V169, P2828, DOI 10.4049/jimmunol.169.6.2828; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; Chen ZJ, 2006, CELL DEATH DIFFER, V13, P687, DOI 10.1038/sj.cdd.4401869; Chen ZJJ, 2005, NAT CELL BIOL, V7, P758, DOI 10.1038/ncb0805-758; Cheung PCF, 2004, BIOCHEM J, V378, P27, DOI 10.1042/BJ20031794; Chung JY, 2002, J CELL SCI, V115, P679; Conner SH, 2006, BIOCHEM J, V399, P427, DOI 10.1042/BJ20061077; COOK WJ, 1992, J BIOL CHEM, V267, P16467; Courtois G, 2006, ONCOGENE, V25, P6831, DOI 10.1038/sj.onc.1209939; Delaney JR, 2006, EMBO J, V25, P3068, DOI 10.1038/sj.emboj.7601182; Deng L, 2000, CELL, V103, P351, DOI 10.1016/S0092-8674(00)00126-4; Ea CK, 2006, MOL CELL, V22, P245, DOI 10.1016/j.molcel.2006.03.026; Eddins MJ, 2006, NAT STRUCT MOL BIOL, V13, P915, DOI 10.1038/nsmb1148; Evans PC, 2004, BIOCHEM J, V378, P727, DOI 10.1042/BJ20031377; Fitzgerald KA, 2003, NAT IMMUNOL, V4, P491, DOI 10.1038/ni921; Geuking P, 2005, GENETICS, V171, P1683, DOI 10.1534/genetics.105.045534; Hacker H, 2006, NATURE, V439, P204, DOI 10.1038/nature04369; Hauer J, 2005, P NATL ACAD SCI USA, V102, P2874, DOI 10.1073/pnas.0500187102; Hicke L, 2005, NAT REV MOL CELL BIO, V6, P610, DOI 10.1038/nrm1701; Hofmann RM, 1999, CELL, V96, P645, DOI 10.1016/S0092-8674(00)80575-9; Hofmann RM, 2001, J BIOL CHEM, V276, P27936, DOI 10.1074/jbc.M103378200; Huang QJ, 2004, NAT IMMUNOL, V5, P98, DOI 10.1038/ni1014; Huang TT, 2003, CELL, V115, P565, DOI 10.1016/S0092-8674(03)00895-X; Ishitani T, 1999, NATURE, V399, P798, DOI 10.1038/21674; Ishitani T, 2003, EMBO J, V22, P6277, DOI 10.1093/emboj/cdg605; Jaeschke A, 2006, MOL CELL, V23, P899, DOI 10.1016/j.molcel.2006.07.028; Janssens S, 2005, CELL, V123, P1079, DOI 10.1016/j.cell.2005.09.036; Jiang ZF, 2002, MOL CELL BIOL, V22, P7158, DOI 10.1128/MCB.22.20.7158-7167.2002; Jono H, 2004, J BIOL CHEM, V279, P36171, DOI 10.1074/jbc.M406638200; Kajino T, 2006, J BIOL CHEM, V281, P39891, DOI 10.1074/jbc.M608155200; Kanayama A, 2004, MOL CELL, V15, P535, DOI 10.1016/j.molcel.2004.08.008; Kaneko T, 2005, CELL MICROBIOL, V7, P1049, DOI 10.1111/j.1462-5822.2005.00542.x; Kawai T, 2005, NAT IMMUNOL, V6, P981, DOI 10.1038/ni1243; King CG, 2006, NAT MED, V12, P1088, DOI 10.1038/nm1449; Kleino A, 2005, EMBO J, V24, P3423, DOI 10.1038/sj.emboj.7600807; Kobayashi N, 2001, EMBO J, V20, P1271, DOI 10.1093/emboj/20.6.1271; Komatsu Y, 2002, MECH DEVELOP, V119, P239, DOI 10.1016/S0925-4773(02)00391-X; Kopp E, 1999, GENE DEV, V13, P2059, DOI 10.1101/gad.13.16.2059; Kovalenko A, 2003, NATURE, V424, P801, DOI 10.1038/nature01802; Kovalenko A, 2006, MOL CELL, V22, P433, DOI 10.1016/j.molcel.2006.05.002; Krappmann D, 2005, EMBO REP, V6, P321, DOI 10.1038/sj.embor.7400380; KRIKOS A, 1992, J BIOL CHEM, V267, P17971; Lamothe B, 2007, J BIOL CHEM, V282, P4102, DOI 10.1074/jbc.M609503200; Lee EG, 2000, SCIENCE, V289, P2350, DOI 10.1126/science.289.5488.2350; Lee S, 2006, NAT STRUCT MOL BIOL, V13, P264, DOI 10.1038/nsmb1064; Lee SY, 1997, IMMUNITY, V7, P703, DOI 10.1016/S1074-7613(00)80390-8; Lee TH, 2004, J BIOL CHEM, V279, P33185, DOI 10.1074/jbc.M404206200; Legler DF, 2003, IMMUNITY, V18, P655, DOI 10.1016/S1074-7613(03)00092-X; Li HX, 2006, J BIOL CHEM, V281, P13636, DOI 10.1074/jbc.M600620200; Li MG, 2003, J BIOL CHEM, V278, P12013, DOI 10.1074/jbc.M211474200; Li XX, 1999, MOL CELL BIOL, V19, P4643; Liu HH, 2006, P NATL ACAD SCI USA, V103, P11677, DOI 10.1073/pnas.0603089103; Mabb AM, 2006, NAT CELL BIOL, V8, P986, DOI 10.1038/ncb1458; Massoumi R, 2006, CELL, V125, P665, DOI 10.1016/j.cell.2006.03.041; Meylan E, 2005, NATURE, V437, P1167, DOI 10.1038/nature04193; Momcilovic M, 2006, J BIOL CHEM, V281, P25336, DOI 10.1074/jbc.M604399200; MURALIDHAR MG, 1993, NEURON, V11, P253, DOI 10.1016/0896-6273(93)90182-Q; Ninomiya-Tsuji J, 1999, NATURE, V398, P252, DOI 10.1038/18465; Oganesyan G, 2006, NATURE, V439, P208, DOI 10.1038/nature04374; Ono K, 2001, J BIOL CHEM, V276, P24396, DOI 10.1074/jbc.M102631200; Papa S, 2006, CELL DEATH DIFFER, V13, P712, DOI 10.1038/sj.cdd.4401865; Penengo L, 2006, CELL, V124, P1183, DOI 10.1016/j.cell.2006.02.020; Petroski MD, 2005, NAT REV MOL CELL BIO, V6, P9, DOI 10.1038/nrm1547; Qin JZ, 2006, J BIOL CHEM, V281, P21013, DOI 10.1074/jbc.M512908200; Rawlings DJ, 2006, NAT REV IMMUNOL, V6, P799, DOI 10.1038/nri1944; Reiley WW, 2006, NAT IMMUNOL, V7, P411, DOI 10.1038/ni1315; Saha SK, 2006, EMBO J, V25, P3257, DOI 10.1038/sj.emboj.7601220; Saha SK, 2006, CELL CYCLE, V5, P804, DOI 10.4161/cc.5.8.2637; Sanjo H, 2003, MOL CELL BIOL, V23, P1231, DOI 10.1128/MCB.23.4.1231-1238.2003; Sato S, 2005, NAT IMMUNOL, V6, P1087, DOI 10.1038/ni1255; Sato S, 2006, INT IMMUNOL, V18, P1405, DOI 10.1093/intimm/dxl082; Scheidereit C, 2006, ONCOGENE, V25, P6685, DOI 10.1038/sj.onc.1209934; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; Seth RB, 2005, CELL, V122, P669, DOI 10.1016/j.cell.2005.08.012; Seth RB, 2006, CELL RES, V16, P141, DOI 10.1038/sj.cr.7310019; Sharma S, 2003, SCIENCE, V300, P1148, DOI 10.1126/science.1081315; Shi CS, 2003, J BIOL CHEM, V278, P15429, DOI 10.1074/jbc.M211796200; Shibuya H, 1998, EMBO J, V17, P1019, DOI 10.1093/emboj/17.4.1019; Shibuya H, 1996, SCIENCE, V272, P1179, DOI 10.1126/science.272.5265.1179; Shim JH, 2005, GENE DEV, V19, P2668, DOI 10.1101/gad.1360605; Shinohara H, 2005, J EXP MED, V202, P1423, DOI 10.1084/jem.20051591; Silverman N, 2003, J BIOL CHEM, V278, P48928, DOI 10.1074/jbc.M304802200; Smit L, 2004, J BIOL CHEM, V279, P17232, DOI 10.1074/jbc.M307801200; SPENCE J, 1995, MOL CELL BIOL, V15, P1265; Sun LJ, 2004, CURR OPIN CELL BIOL, V16, P119, DOI 10.1016/j.ceb.2004.02.005; Sun LJ, 2004, MOL CELL, V14, P289, DOI 10.1016/S1097-2765(04)00236-9; Tada K, 2001, J BIOL CHEM, V276, P36530, DOI 10.1074/jbc.M104837200; Takaesu G, 2000, MOL CELL, V5, P649, DOI 10.1016/S1097-2765(00)80244-0; Takeuchi M, 1996, J BIOL CHEM, V271, P19935, DOI 10.1074/jbc.271.33.19935; Tang ED, 2003, J BIOL CHEM, V278, P37297, DOI 10.1074/jbc.M303389200; Trompouki E, 2003, NATURE, V424, P793, DOI 10.1038/nature01803; VanDemark AP, 2001, CELL, V105, P711, DOI 10.1016/S0092-8674(01)00387-7; Varadan R, 2004, J BIOL CHEM, V279, P7055, DOI 10.1074/jbc.M309184200; Vidal S, 2001, GENE DEV, V15, P1900, DOI 10.1101/gad.203301; Wan YSY, 2006, NAT IMMUNOL, V7, P851, DOI 10.1038/ni1355; Wang C, 2001, NATURE, V412, P346, DOI 10.1038/35085597; Weil R, 2006, CELL DEATH DIFFER, V13, P826, DOI 10.1038/sj.cdd.4401856; Wertz IE, 2004, NATURE, V430, P694, DOI 10.1038/nature02794; Wu CJ, 2006, NAT CELL BIOL, V8, P398, DOI 10.1038/ncb1384; Wu H, 2003, BIOESSAYS, V25, P1096, DOI 10.1002/bies.10352; Wu ZH, 2006, SCIENCE, V311, P1141, DOI 10.1126/science.1121513; Xiao CC, 2003, GENE DEV, V17, P2933, DOI 10.1101/gad.1145603; Xie M, 2006, P NATL ACAD SCI USA, V103, P17378, DOI 10.1073/pnas.0604708103; Xu LG, 2005, MOL CELL, V19, P727, DOI 10.1016/j.molcel.2005.08.014; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; Yamamoto M, 2006, J IMMUNOL, V177, P7520, DOI 10.4049/jimmunol.177.11.7520; Yamamoto O, 2006, IEEE T DIELECT EL IN, V13, P2, DOI 10.1109/TDEI.2006.1593395; Yang JH, 2001, NAT IMMUNOL, V2, P620, DOI 10.1038/89769; Yeh WC, 1997, IMMUNITY, V7, P715, DOI 10.1016/S1074-7613(00)80391-X; Yoneyama M, 2004, NAT IMMUNOL, V5, P730, DOI 10.1038/ni1087; Yujiri T, 2000, P NATL ACAD SCI USA, V97, P7272, DOI 10.1073/pnas.130176697; Zhang J, 2006, J CLIN INVEST, V116, P3042, DOI 10.1172/JCI28746; Zhang SQ, 2000, IMMUNITY, V12, P301, DOI 10.1016/S1074-7613(00)80183-1; Zhou HL, 2004, NATURE, V427, P167, DOI 10.1038/nature02273; Zhou R, 2005, J BIOL CHEM, V280, P34048, DOI 10.1074/jbc.M506655200; Zhuang ZH, 2006, CELL SIGNAL, V18, P964, DOI 10.1016/j.cellsig.2005.08.020	125	337	346	1	32	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 15	2007	26	22					3214	3226		10.1038/sj.onc.1210413	http://dx.doi.org/10.1038/sj.onc.1210413			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	169PH	17496917				2022-12-28	WOS:000246603600010
J	Prost, S; Lu, P; Caldwell, H; Harrison, D				Prost, S.; Lu, P.; Caldwell, H.; Harrison, D.			E2F regulates DDB2: consequences for DNA repair in Rb-deficient cells	ONCOGENE			English	Article						DDB2; retinoblastoma; E2F; transcription factor; hepatocytes; DNA repair	NUCLEOTIDE EXCISION-REPAIR; CYCLOBUTANE PYRIMIDINE DIMERS; BINDING-PROTEIN; IN-VIVO; TRANSCRIPTION FACTORS; UV-IRRADIATION; GENE-PRODUCT; MOUSE CELLS; WILD-TYPE; P53	DDB2, a gene mutated in XPE patients, is involved in global genomic repair especially the repair of cyclobutane pyrimidine dimers (CPDs), and is regulated by p53 in human cells. We show that DDB2 is expressed in mouse tissues and demonstrate, using primary mouse epithelial cells, that mouse DDB2 is regulated by E2F transcription factors. Retinoblastoma (Rb), a tumor suppressor critical for the control of cell cycle progression, regulates E2F activity. Using Cre-Lox technology to delete Rb in primary mouse hepatocytes, we show that DDB2 gene expression increases, leading to elevated DDB2 protein levels. Furthermore, we show that endogenous E2F1 and E2F3 bind to DDB2 promoter and that treatment with E2F1-antisense or E2F1-small interfering RNA (siRNA) decreases DDB2 transcription, demonstrating that E2F1 is a transcriptional regulator for DDB2. This has consequences for global genomic repair: in Rb-null cells, where E2F activity is elevated, global DNA repair is increased and removal of CPDs is more efficient than in wild-type cells. Treatment with DDB2-siRNA decreases DDB2 expression and abolishes the repair phenotype of Rb-null cells. In summary, these results identify a new regulatory pathway for DDB2 by E2F, which does not require but is potentiated by p53, and demonstrate that DDB2 is involved in global repair in mouse epithelial cells.	Univ Edinburgh, Queens Med Res Inst, Edinburgh EH16 4TJ, Midlothian, Scotland	University of Edinburgh	Prost, S (corresponding author), Univ Edinburgh, Queens Med Res Inst, 47 Little France Crescent, Edinburgh EH16 4TJ, Midlothian, Scotland.	s.prost@ed.ac.uk		harrison, david/0000-0001-9041-9988; prost, sandrine/0000-0002-0140-7115	Medical Research Council [G9900991B] Funding Source: researchfish	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)		Adimoolam S, 2003, DNA REPAIR, V2, P947, DOI 10.1016/S1568-7864(03)00087-9; Attwooll C, 2004, EMBO J, V23, P4709, DOI 10.1038/sj.emboj.7600481; Berton TR, 2005, ONCOGENE, V24, P2449, DOI 10.1038/sj.onc.1208462; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Fitch ME, 2003, J BIOL CHEM, V278, P46906, DOI 10.1074/jbc.M307254200; Fitch ME, 2003, CARCINOGENESIS, V24, P843, DOI 10.1093/carcin/bgg031; Ford JM, 1997, J BIOL CHEM, V272, P28073, DOI 10.1074/jbc.272.44.28073; FORD JM, 1995, P NATL ACAD SCI USA, V92, P8876, DOI 10.1073/pnas.92.19.8876; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES, P283; Hayes S, 1998, MOL CELL BIOL, V18, P240, DOI 10.1128/MCB.18.1.240; Hwang BJ, 1998, MOL CELL BIOL, V18, P4391, DOI 10.1128/MCB.18.7.4391; Hwang BJ, 1999, P NATL ACAD SCI USA, V96, P424, DOI 10.1073/pnas.96.2.424; Ishida S, 2001, MOL CELL BIOL, V21, P4684, DOI 10.1128/MCB.21.14.4684-4699.2001; ISHIZAKI K, 1994, INT J CANCER, V58, P254, DOI 10.1002/ijc.2910580218; Lin GY, 1998, VIROLOGY, V249, P189, DOI 10.1006/viro.1998.9317; MORI T, 1991, PHOTOCHEM PHOTOBIOL, V54, P225, DOI 10.1111/j.1751-1097.1991.tb02010.x; MULLER H, 2000, BIOCHIM BIOPHYS ACTA, V1470, P1; Nag A, 2001, MOL CELL BIOL, V21, P6738, DOI 10.1128/MCB.21.20.6738-6747.2001; Nicholson T, 2001, BMC Cardiovasc Disord, V1, P2, DOI 10.1186/1471-2261-1-2; Nishiwaki Y, 2004, J INVEST DERMATOL, V122, P526, DOI 10.1046/j.0022-202X.2004.22226.x; OConnor DJ, 1995, EMBO J, V14, P6184, DOI 10.1002/j.1460-2075.1995.tb00309.x; Prost S, 1998, FASEB J, V12, P181, DOI 10.1096/fasebj.12.2.181; Prost S, 1998, J BIOL CHEM, V273, P33327, DOI 10.1074/jbc.273.50.33327; Prost S, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.16.e80; PURDIE CA, 1994, ONCOGENE, V9, P603; RAGIMOV N, 1993, ONCOGENE, V8, P1183; Sheahan S, 2004, ONCOGENE, V23, P1489, DOI 10.1038/sj.onc.1207280; Shiyanov P, 1999, MOL CELL BIOL, V19, P4935; Stevceva L, 2004, CURR HIV RES, V2, P1, DOI 10.2174/1570162043485004; Takahashi Y, 2000, GENE DEV, V14, P804; Tan T, 2002, MOL CELL BIOL, V22, P3247, DOI 10.1128/MCB.22.10.3247-3254.2002; Tang J, 2002, DNA REPAIR, V1, P601, DOI 10.1016/S1568-7864(02)00052-6; Vooijs M, 2002, ONCOGENE, V21, P4635, DOI 10.1038/sj.onc.1205575; Wakasugi M, 2002, J BIOL CHEM, V277, P1637, DOI 10.1074/jbc.C100610200; Wang QE, 2004, CARCINOGENESIS, V25, P1033, DOI 10.1093/carcin/bgh085; Zhu QZ, 2000, J BIOL CHEM, V275, P11492, DOI 10.1074/jbc.275.15.11492; Zolezzi F, 2000, GENE, V245, P151, DOI 10.1016/S0378-1119(00)00022-6	37	24	25	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY	2007	26	24					3572	3581		10.1038/sj.onc.1210151	http://dx.doi.org/10.1038/sj.onc.1210151			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	172JC	17173070				2022-12-28	WOS:000246799200013
J	Lou, H; Dean, M				Lou, H.; Dean, M.			Targeted therapy for cancer stem cells: the patched pathway and ABC transporters	ONCOGENE			English	Review						cancer stem cell; hedgehog/patched pathway; smoothened; ABC transporters; ABCG2; cyclopamine	HUMAN HOMOLOG; TERATOCARCINOMA CELLS; MULTIDRUG-RESISTANCE; CARCINOMA SYNDROME; SIDE-POPULATION; HEDGEHOG; DROSOPHILA; INHIBITION; MUTATIONS; GENE	Data from certain leukemias as well as brain and breast cancer indicate that there is a small population of tumor cells with 'stem cell' characteristics and the capacity for self-renewal. The self-renewing cells have many of the properties of normal stem cells and have been termed 'cancer stem cells'. These cancer stem cells make up as few as 1% of the cells in a tumor, making them difficult to detect and study. Like normal stem cells, cancer stem cells have a number of properties permitting them to survive traditional cancer chemotherapy and radiation therapy. These cells express high levels of ATP-binding cassette (ABC) drug transporters, providing for a level of resistance; are relatively quiescent; have higher levels of DNA repair and a lowered ability to enter apoptosis. Combined cancer therapy approaches targeting the cancer stem cells and the non-stem cells may be developed with increased efficacy. Efforts to target the Hedgehog/Patched pathway, critical to embryonic growth and differentiation, and the ABCG2 drug efflux transporter will be presented.	NCI, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Dean, M (corresponding author), NCI, Frederick, MD 21702 USA.	dean@ncifcrf.gov	Dean, Michael C/G-8172-2012; Dean, Michael/R-7501-2019	Dean, Michael C/0000-0003-2234-0631; 	NATIONAL CANCER INSTITUTE [Z01BC005652, ZIABC005652, Z01BC005725, ZIABC005725] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Al-Hajj M, 2004, ONCOGENE, V23, P7274, DOI 10.1038/sj.onc.1207947; Athar M, 2004, CANCER RES, V64, P7545, DOI 10.1158/0008-5472.CAN-04-1393; Bale AE, 2001, HUM MOL GENET, V10, P757, DOI 10.1093/hmg/10.7.757; Berman DM, 2003, NATURE, V425, P846, DOI 10.1038/nature01972; Bijlsma MF, 2006, PLOS BIOL, V4, P1397, DOI 10.1371/journal.pbio.0040232; BRINSTER RL, 1976, CANCER RES, V36, P3412; Chen JK, 2002, GENE DEV, V16, P2743, DOI 10.1101/gad.1025302; Chidambaram A, 1996, CANCER RES, V56, P4599; Dean M, 2005, NAT REV CANCER, V5, P275, DOI 10.1038/nrc1590; Dean M, 2006, MOL INTERV, V6, P140, DOI 10.1124/mi.6.3.5; Dean M, 1997, BBA-REV CANCER, V1332, pM43, DOI 10.1016/S0304-419X(96)00043-1; Folkman J, 2002, SEMIN ONCOL, V29, P15, DOI 10.1053/sonc.2002.37263; Gailani MR, 1996, NAT GENET, V14, P78, DOI 10.1038/ng0996-78; Goodell MA, 1996, J EXP MED, V183, P1797, DOI 10.1084/jem.183.4.1797; Gottesman MM, 2002, NAT REV CANCER, V2, P48, DOI 10.1038/nrc706; Hahn H, 1996, CELL, V85, P841, DOI 10.1016/S0092-8674(00)81268-4; HAMBURGER AW, 1977, SCIENCE, V197, P461, DOI 10.1126/science.560061; Hemmati HD, 2003, P NATL ACAD SCI USA, V100, P15178, DOI 10.1073/pnas.2036535100; Henrich CJ, 2006, J BIOMOL SCREEN, V11, P176, DOI 10.1177/1087057105284576; Hirschmann-Jax C, 2004, P NATL ACAD SCI USA, V101, P14228, DOI 10.1073/pnas.0400067101; James LF, 2004, J AGR FOOD CHEM, V52, P3211, DOI 10.1021/jf0308206; Johnson RL, 1996, SCIENCE, V272, P1668, DOI 10.1126/science.272.5268.1668; Karhadkar SS, 2004, NATURE, V431, P707, DOI 10.1038/nature02962; Kim M, 2002, CLIN CANCER RES, V8, P22; Kondo T, 2004, P NATL ACAD SCI USA, V101, P781, DOI 10.1073/pnas.0307618100; Kruger JA, 2006, BLOOD, V108, P3906, DOI 10.1182/blood-2006-05-024687; LAPIDOT T, 1994, NATURE, V367, P645, DOI 10.1038/367645a0; MINTZ B, 1975, P NATL ACAD SCI USA, V72, P3585, DOI 10.1073/pnas.72.9.3585; Nakachi K, 2004, CANCER SCI, V95, P921, DOI 10.1111/j.1349-7006.2004.tb03178.x; NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0; Robey RW, 2004, CANCER RES, V64, P1242, DOI 10.1158/0008-5472.CAN-03-3298; Scharenberg CW, 2002, BLOOD, V99, P507, DOI 10.1182/blood.V99.2.507; Thayer SP, 2003, NATURE, V425, P851, DOI 10.1038/nature02009; Tostar U, 2006, J PATHOL, V208, P17, DOI 10.1002/path.1882; Watkins DN, 2003, NATURE, V422, P313, DOI 10.1038/nature01493; Zhou S, 2001, NAT MED, V7, P1028, DOI 10.1038/nm0901-1028	37	183	206	0	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 26	2007	26	9					1357	1360		10.1038/sj.onc.1210200	http://dx.doi.org/10.1038/sj.onc.1210200			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	141DU	17322922	Bronze			2022-12-28	WOS:000244558700014
J	Li, QF; Huang, WR; Duan, HF; Wang, H; Wu, CT; Wang, LS				Li, Q-F; Huang, W-R; Duan, H-F; Wang, H.; Wu, C-T; Wang, L-S			Sphingosine kinase-1 mediates BCR/ABL-induced upregulation of Mcl-1 in chronic myeloid leukemia cells	ONCOGENE			English	Article						BCR/ABL; sphingosine kinase-1; Mcl-1; CML	ABL TYROSINE KINASE; BCR-ABL; HEMATOPOIETIC-CELLS; ACTIVATION; APOPTOSIS; SURVIVAL; GROWTH; TRANSFORMATION; PROGRESSION; PATHWAY	The signaling mechanisms responsible for BCR/ABL-induced regulation of Mcl-1 expression in chronic myelogenous leukemia (CML) cells remain unclear. In this study, we show that BCR/ABL could upregulate sphingosine kinase-1 (SPK1) expression via multiple signal pathways, including mitogen-activated protein kinase ( MAPK), phosphoinositide 3-kinase (PI3K) and Janus kinase 2 (JAK2), leading to increase cellular SPK1 activity in CML cells. Retrovirus-mediated overexpression of bcr-abl gene in NIH-3T3, Ba/F3 and HL-60 cells results in upregulation and increased cellular activity of SPK1, whereas treatment of CML cells with specific inhibitors of the BCR/ABL, PI3K, MAPK and JAK2 pathways decreases BCR/ABLinduced SPK1 expression and cellular activity. BCR/ABL also induces upregulation of Mcl-1 expression in CML cells. Inhibition of SPK1 by adenovirus-mediated transfer of small interfering RNA or N,N-dimethylsphingosine reduced expression of Mcl-1 in CML cells. Our data indicated that BCR/ABL induces SPK1 expression and increases its cellular activity, leading to upregulation of Mcl-1 in CML cells. SPK1 silencing enhances the STI571-induced apoptosis of CML cell lines. It is suggested that SPK1 may be a potential therapeutic target in CML.	[Li, Q-F; Duan, H-F; Wang, H.; Wu, C-T; Wang, L-S] Beijing Inst Radiat Med, Dept Expt Hematol, Beijing 100850, Peoples R China; [Huang, W-R] Peoples Liberat Army Gen Hosp, Dept Hematol, Beijing, Peoples R China	Academy of Military Medical Sciences - China; Chinese People's Liberation Army General Hospital	Wang, LS (corresponding author), Beijing Inst Radiat Med, Dept Expt Hematol, 27 Taiping Rd, Beijing 100850, Peoples R China.	wangls@nic.bmi.ac.cn						Aichberger KJ, 2005, BLOOD, V105, P3303, DOI 10.1182/blood-2004-02-0749; Bektas M, 2005, ONCOGENE, V24, P178, DOI 10.1038/sj.onc.1208019; Bonhoure E, 2006, LEUKEMIA, V20, P95, DOI 10.1038/sj.leu.2404023; Cortez D, 1996, ONCOGENE, V13, P2589; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; Duan HF, 2004, EXP CELL RES, V298, P593, DOI 10.1016/j.yexcr.2004.04.049; Granata R, 2004, FASEB J, V18, P1456, DOI 10.1096/fj.04-1618fje; Le Scolan E, 2005, BLOOD, V106, P1808, DOI 10.1182/blood-2004-12-4832; Limaye V, 2005, BLOOD, V105, P3169, DOI 10.1182/blood-2004-02-0452; Lu ZZ, 2006, EXP HEMATOL, V34, P1171, DOI 10.1016/j.exphem.2006.05.005; LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149; Opferman JT, 2005, SCIENCE, V307, P1101, DOI 10.1126/science.1106114; Samanta AK, 2006, CANCER RES, V66, P6468, DOI 10.1158/0008-5472.CAN-06-0025; Sawyers CL, 1999, NEW ENGL J MED, V340, P1330, DOI 10.1056/NEJM199904293401706; Sillaber C, 2000, BLOOD, V95, P2118, DOI 10.1182/blood.V95.6.2118; Skorski T, 1997, EMBO J, V16, P6151, DOI 10.1093/emboj/16.20.6151; Steelman LS, 2004, LEUKEMIA, V18, P189, DOI 10.1038/sj.leu.2403241; Wattenberg BW, 2006, J LIPID RES, V47, P1128, DOI 10.1194/jlr.R600003-JLR200; Wu WC, 2004, MOL CELL BIOL, V24, P7359, DOI 10.1128/MCB.24.17.7359-7369.2004; Xie SH, 2002, ONCOGENE, V21, P7137, DOI 10.1038/sj.onc.1205942; Yatomi Y, 1996, BIOCHEMISTRY-US, V35, P626, DOI 10.1021/bi9515533; Zhou P, 1997, BLOOD, V89, P630, DOI 10.1182/blood.V89.2.630	22	59	72	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 13	2007	26	57					7904	7908		10.1038/sj.onc.1210587	http://dx.doi.org/10.1038/sj.onc.1210587			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	248ON	17599053				2022-12-28	WOS:000252163500008
J	Lien, HC; Hsiao, YH; Lin, YS; Yao, YT; Juan, HF; Kuo, WH; Hung, MC; Chang, KJ; Hsieh, FJ				Lien, H. C.; Hsiao, Y. H.; Lin, Y. S.; Yao, Y. T.; Juan, H. F.; Kuo, W. H.; Hung, Mien-Chie; Chang, K. J.; Hsieh, F. J.			Molecular signatures of metaplastic carcinoma of the breast by large-scale transcriptional profiling: identification of genes potentially related to epithelial-mesenchymal transition	ONCOGENE			English	Article						oligonucleotide microarray; metaplastic carcinoma of breast; epithelial-mesenchymal transition	PROGNOSTIC MARKERS; TGF-BETA; EXPRESSION; CANCER; CELLS; CARTILAGE; TISSUE; DIFFERENTIATION; MORPHOGENESIS; METASTASIS	Metaplastic carcinoma of the breast (MCB) is a poorly understood subtype of breast cancer. It is generally characterized by the coexistence of ductal carcinomatous and transdifferentiated sarcomatous components, but the underlying molecular alterations, possibly related to epithelial-mesenchymal transition (EMT), remain elusive. We performed transcriptional pro. ling using half-a-genome oligonucleotide microarrays to elucidate genetic profiles of MCBs and their differences to those of ductal carcinoma of breasts (DCBs) using discarded specimens of four MCBs and 34 DCBs. Unsupervised clustering disclosed distinctive expression profiles between MCBs and DCBs. Supervised analysis identified gene signatures discriminating MCBs from DCBs and between MCB subclasses. Notably, many of the discriminator genes were associated with downregulation of epithelial phenotypes and with synthesis, remodeling and adhesion of extracellular matrix, with some of them have known or inferred roles related to EMT. Importantly, several of the discriminator genes were upregulated in a mutant Snail-transfected MCF7 cell known to exhibit features of EMT, thereby indicating a crucial role for EMT in the pathogenesis of MCBs. Finally, the identification of SPARC and vimentin as poor prognostic factors reinforced the role of EMT in cancer progression. These data advance our understanding of MCB and offer clues to the molecular alterations underlying EMT.	[Kuo, W. H.; Chang, K. J.] Natl Taiwan Univ, Dept Surg, Coll Med, Taipei 10764, Taiwan; [Lien, H. C.; Yao, Y. T.] Natl Taiwan Univ, Dept Pathol, Coll Med, Taipei 10764, Taiwan; [Hsiao, Y. H.] Changhua Christian Hosp, Dept Obstet & Gynecol, Changhua, Taiwan; [Hsiao, Y. H.] Chang Jung Christian Univ, Inst Med Res, Tainan, Taiwan; [Lin, Y. S.] Welgene Biotech Co Ltd, Taipei, Taiwan; [Juan, H. F.; Hsieh, F. J.] Natl Taiwan Univ, Ctr Syst Biol & Bioinformat, Taipei 10764, Taiwan; [Juan, H. F.; Hsieh, F. J.] Natl Taiwan Univ, Dept Life Sci, Taipei 10764, Taiwan; [Hung, Mien-Chie] China Med Univ Hosp, Ctr Mol Med, Taichung, Taiwan; [Hung, Mien-Chie] Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX USA; [Hsieh, F. J.] Natl Taiwan Univ, Coll Med, Dept Obstet & Gynecol, Taipei 10764, Taiwan	National Taiwan University; National Taiwan University; Changhua Christian Hospital; Chang Jung Christian University; National Taiwan University; National Taiwan University; China Medical University Taiwan; China Medical University Hospital - Taiwan; University of Texas System; UTMD Anderson Cancer Center; National Taiwan University	Chang, KJ (corresponding author), Natl Taiwan Univ, Dept Surg, Coll Med, 1-1 Jen Ai Rd, Taipei 10764, Taiwan.	kingjen@ha.mc.ntu.edu.tw; fjhsieh@ha.mc.ntu.edu.tw	Hung, Mien-Chie/ABD-5911-2021	Hung, Mien-Chie/0000-0003-4317-4740; Chang, King jen/0000-0001-9811-3422; KUO, WEN-HUNG/0000-0002-9881-4605; JUAN, HSUEH-FEN/0000-0003-4876-3309; LIEN, HUANG-CHUN/0000-0003-1472-1231				Al Sayed AD, 2006, ACTA ONCOL, V45, P188, DOI 10.1080/02841860500513235; Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Barnes PJ, 2005, BREAST CANCER RES TR, V91, P173, DOI 10.1007/s10549-004-7260-y; Bilanges B, 1999, ONCOGENE, V18, P3979, DOI 10.1038/sj.onc.1202933; Bundy LM, 2003, ONCOGENE, V22, P869, DOI 10.1038/sj.onc.1206216; Carter MR, 2006, AM J SURG PATHOL, V30, P300; Doane AS, 2006, ONCOGENE, V25, P3994, DOI 10.1038/sj.onc.1209415; DOEGE KJ, 1991, J BIOL CHEM, V266, P894; Framson PE, 2004, J CELL BIOCHEM, V92, P679, DOI 10.1002/jcb.20091; Fujiwara S, 2001, J BIOL CHEM, V276, P13340, DOI 10.1074/jbc.M011386200; Gersch RP, 2005, J ORTHOP RES, V23, P882, DOI 10.1016/j.orthres.2005.02.005; Jansen S, 2005, J CELL SCI, V118, P3081, DOI 10.1242/jcs.02438; Jechlinger M, 2006, J CLIN INVEST, V116, P1561, DOI 10.1172/JCI24652; Jones C, 2004, CANCER RES, V64, P3037, DOI 10.1158/0008-5472.CAN-03-2028; Korsching E, 2005, J PATHOL, V206, P451, DOI 10.1002/path.1797; Kusafuka K, 2004, J PATHOL, V203, P953, DOI 10.1002/path.1599; Lee JM, 2006, J CELL BIOL, V172, P973, DOI 10.1083/jcb.200601018; Lemmers C, 2004, MOL BIOL CELL, V15, P1324, DOI 10.1091/mbc.E03-04-0235; Lien HC, 2004, J PATHOL, V204, P131, DOI 10.1002/path.1624; Liu Y, 2000, J CELL SCI, V113, P2363; Ma LJ, 2005, DEVELOPMENT, V132, P5601, DOI 10.1242/dev.02156; Oehler MK, 2003, BRIT J CANCER, V89, P1927, DOI 10.1038/sj.bjc.6601397; Pezzi CM, 2007, ANN SURG ONCOL, V14, P166, DOI 10.1245/s10434-006-9124-7; Pfister BE, 2001, BIOCHEM BIOPH RES CO, V286, P268, DOI 10.1006/bbrc.2001.5377; Reinholz MM, 2002, BREAST CANCER RES TR, V74, P255, DOI 10.1023/A:1016339120506; Reis JS, 2003, APPL IMMUNOHISTO M M, V11, P1, DOI 10.1097/00022744-200303000-00001; ROSAI J, 2004, ROSAI ACKERMANS SURG, P1828; Ryoo HM, 2006, GENE, V366, P51, DOI 10.1016/j.gene.2005.10.011; Saika S, 2003, INVEST OPHTH VIS SCI, V44, P2094, DOI 10.1167/iovs.02-1059; Siddiq F, 2004, LUNG CANCER, V45, P197, DOI 10.1016/j.lungcan.2004.01.020; Soda H, 1998, ANTI-CANCER DRUG, V9, P327, DOI 10.1097/00001813-199804000-00006; Stanton H, 2005, NATURE, V434, P648, DOI 10.1038/nature03417; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Wilson CA, 2004, BREAST CANCER RES, V6, P192, DOI 10.1186/bcr917; Xu X, 2005, DEV DYNAM, V232, P75, DOI 10.1002/dvdy.20197; Zavadil J, 2005, ONCOGENE, V24, P5764, DOI 10.1038/sj.onc.1208927; Zhou BHP, 2004, NAT CELL BIOL, V6, P931, DOI 10.1038/ncb1173; Zhuang ZP, 1997, MODERN PATHOL, V10, P354	38	158	165	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 13	2007	26	57					7859	7871		10.1038/sj.onc.1210593	http://dx.doi.org/10.1038/sj.onc.1210593			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	248ON	17603561	Green Published			2022-12-28	WOS:000252163500004
J	Lim, SK; Gopalan, G				Lim, S. K.; Gopalan, G.			Antizyme1 mediates AURKAIP1-dependent degradation of Aurora-A	ONCOGENE			English	Article						degradation; antizyme; Aurora-A; ubiquitin-independent	ORNITHINE-DECARBOXYLASE-ANTIZYME; CELL-GROWTH; PROTEASOME PATHWAY; PROTEIN-KINASE; PROLIFERATION; POLYAMINES; EXPRESSION; MECHANISM; CANCER; OVEREXPRESSION	Overexpression of Aurora- A oncogene has been shown to induce genomic instability and tumorigenesis. Cellular levels of Aurora- A are regulated by multiple mechanisms including the proteasome- dependent degradation of Aurora-A protein. Cell- cycle- dependent turnover of Aurora- A protein is mediated by cdh1 through ubiquitin ( Ub)- and proteasome- dependent pathway. However, Aurora- A kinase interacting protein 1 ( AURKAIP1), a negative regulator of Aurora- A, also promotes proteasome- dependent Aurora- A degradation through an Ub- independent mechanism. In an attempt to understand how AURKAIP1 promotes Aurora- A degradation through Ub- independent pathway, we demonstrate here that antizyme1 ( Az1), a well- studied mediator of Ub- independent protein degradation pathway, regulates Aurora- A protein stability. We show that ectopic or polyamine- induced expression of Az1 can lower the steady- state levels of Aurora- A. The effect of Az1 on Aurora- A turnover was shown to be proteasome-dependent, but Ub- independent. Az1 interacts with Aurora-A in vivo and the interaction between Aurora- A and Az1 is essential for the Az1- mediated Aurora- A degradation. Furthermore, we observed that AURKAIP1 could not promote degradation of Aurora- A mutant, which is defective in Az1 interaction. Coexpression of the Az inhibitor ( AzI), which downregulates Az1 functions, also abrogated AURKAIP1- mediated degradation of Aurora- A. We further demonstrated that AURKAIP1, Az1 and Aurora- A could exist as a ternary complex and AURKAIP1 enhances the interaction between Az1 and Aurora-A. We propose that AURKAIP1 might function upstream of the Az1 by enhancing the binding affinity of Az1 to Aurora- A to promote recognition, targeting to proteasome and subsequent degradation.	Natl Canc Ctr, Div Mol & Cellular Res, Gene Struct & Express Lab, Singapore, Singapore	National Cancer Centre Singapore (NCCS)	Gopalan, G (corresponding author), 03-03 Singhlth Res Facil,Block A 7 Hosp Dr, Singapore 169611, Singapore.	cmrgop@nccs.com.sg						Asher G, 2005, GENE DEV, V19, P316, DOI 10.1101/gad.319905; BERCOVICH Z, 1989, J BIOL CHEM, V264, P15949; Bischoff JR, 1998, EMBO J, V17, P3052, DOI 10.1093/emboj/17.11.3052; Buschhorn HM, 2005, PROSTATE, V64, P341, DOI 10.1002/pros.20247; Cheng N, 2002, MOL CANCER RES, V1, P2; Coffino P, 2001, NAT REV MOL CELL BIO, V2, P188, DOI 10.1038/35056508; Crane R, 2004, J CELL SCI, V117, P5975, DOI 10.1242/jcs.01418; Feith DJ, 2001, CANCER RES, V61, P6073; Fong LYY, 2003, CANCER RES, V63, P3945; Gandre S, 2002, EUR J BIOCHEM, V269, P1316, DOI 10.1046/j.1432-1033.2002.02774.x; Gardini G, 2003, J HEPATOL, V39, P793, DOI 10.1016/S0168-8278(03)00386-6; Gerner EW, 2004, NAT REV CANCER, V4, P781, DOI 10.1038/nrc1454; GLASS JR, 1987, J CELL PHYSIOL, V130, P133, DOI 10.1002/jcp.1041300119; Gritsko TM, 2003, CLIN CANCER RES, V9, P1420; Hoffman DW, 2005, BIOCHEMISTRY-US, V44, P11777, DOI 10.1021/bi051081k; Honda K, 2000, ONCOGENE, V19, P2812, DOI 10.1038/sj.onc.1203609; Ivanov IP, 2000, NUCLEIC ACIDS RES, V28, P3185, DOI 10.1093/nar/28.17.3185; Iwata S, 1999, ONCOGENE, V18, P165, DOI 10.1038/sj.onc.1202275; Jin YT, 2003, EMBO J, V22, P6365, DOI 10.1093/emboj/cdg600; Kiat LS, 2002, J BIOL CHEM, V277, P45558, DOI 10.1074/jbc.M206820200; Koike C, 1999, CANCER RES, V59, P6109; Li DH, 2003, CLIN CANCER RES, V9, P991; LI XQ, 1993, MOL CELL BIOL, V13, P2377, DOI 10.1128/MCB.13.4.2377; LI XQ, 1992, MOL CELL BIOL, V12, P3556, DOI 10.1128/MCB.12.8.3556; Lim SK, 2007, BIOCHEM J, V403, P119, DOI 10.1042/BJ20061272; Lin Y, 2002, BMC CELL BIOL, V3, DOI 10.1186/1471-2121-3-15; Littlepage LE, 2002, GENE DEV, V16, P2274, DOI 10.1101/gad.1007302; Mangold U, 2006, CELL MOL LIFE SCI, V63, P2095, DOI 10.1007/s00018-005-5583-4; Mao JH, 2004, NATURE, V432, P775, DOI 10.1038/nature03155; MURAKAMI Y, 1992, NATURE, V360, P597, DOI 10.1038/360597a0; Newman RM, 2004, J BIOL CHEM, V279, P41504, DOI 10.1074/jbc.M407349200; ROM E, 1994, P NATL ACAD SCI USA, V91, P3959, DOI 10.1073/pnas.91.9.3959; ROSENBERGHASSON Y, 1989, EUR J BIOCHEM, V185, P469, DOI 10.1111/j.1432-1033.1989.tb15138.x; Sakakura C, 2001, BRIT J CANCER, V84, P824, DOI 10.1054/bjoc.2000.1684; Satriano J, 1998, J BIOL CHEM, V273, P15313, DOI 10.1074/jbc.273.25.15313; Sdek P, 2005, MOL CELL, V20, P699, DOI 10.1016/j.molcel.2005.10.017; Strous GJ, 1996, EMBO J, V15, P3806, DOI 10.1002/j.1460-2075.1996.tb00754.x; Taguchi S, 2002, FEBS LETT, V519, P59, DOI 10.1016/S0014-5793(02)02711-4; Tanaka T, 1999, CANCER RES, V59, P2041; Walter AO, 2000, ONCOGENE, V19, P4906, DOI 10.1038/sj.onc.1203847; Yu XC, 2005, NAT GENET, V37, P401, DOI 10.1038/ng1538; Zhang MS, 2003, EMBO J, V22, P1488, DOI 10.1093/emboj/cdg158; Zhou HY, 1998, NAT GENET, V20, P189, DOI 10.1038/2496	43	60	60	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 11	2007	26	46					6593	6603		10.1038/sj.onc.1210482	http://dx.doi.org/10.1038/sj.onc.1210482			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	219JT	17452972				2022-12-28	WOS:000250081500002
J	Markey, MP; Bergseid, J; Bosco, EE; Stengel, K; Xu, H; Mayhew, C; Schwemberger, SJ; Braden, WA; Jiang, Y; Babcock, G; Jegga, AG; Aronow, BJ; Reed, MF; Wang, JYJ; Knudsen, ES				Markey, M. P.; Bergseid, J.; Bosco, E. E.; Stengel, K.; Xu, H.; Mayhew, Cn; Schwemberger, S. J.; Braden, W. A.; Jiang, Y.; Babcock, Gf; Jegga, A. G.; Aronow, B. J.; Reed, M. F.; Wang, J. Y. J.; Knudsen, E. S.			Loss of the retinoblastoma tumor suppressor: differential action on transcriptional programs related to cell cycle control and immune function	ONCOGENE			English	Article						RB; E2F; transcriptional repression; inflammation; cell cycle	ELEMENT CLUSTERS; GAMMA-INDUCTION; RB; PROTEIN; E2F; EXPRESSION; IDENTIFICATION; REPLICATION; ACTIVATION; TRANSITION	Functional inactivation of the retinoblastoma tumor suppressor gene product (RB) is a common event in human cancers. Classically, RB functions to constrain cellular proliferation, and loss of RB is proposed to facilitate the hyperplastic proliferation associated with tumorigenesis. To understand the repertoire of regulatory processes governed by RB, two models of RB loss were utilized to perform microarray analysis. In murine embryonic fibroblasts harboring germline loss of RB, there was a striking deregulation of gene expression, wherein distinct biological pathways were altered. Specifically, genes involved in cell cycle control and classically associated with E2F-dependent gene regulation were upregulated via RB loss. In contrast, a program of gene expression associated with immune function and response to pathogens was significantly downregulated with the loss of RB. To determine the specific influence of RB loss during a defined period and without the possibility of developmental compensation as occurs in embryonic fibroblasts, a second system was employed wherein Rb was acutely knocked out in adult fibroblasts. This model confirmed the distinct regulation of cell cycle and immune modulatory genes through RB loss. Analyses of cis-elements supported the hypothesis that the majority of those genes upregulated with RB loss are regulated via the E2F family of transcription factors. In contrast, those genes whose expression was reduced with the loss of RB harbored different promoter elements. Consistent with these analyses, we found that disruption of E2F-binding function of RB was associated with the upregulation of gene expression. In contrast, cells harboring an RB mutant protein ( RB-750F) that retains E2F-binding activity, but is specifically deficient in the association with LXCXE-containing proteins, failed to upregulate these same target genes. However, downregulation of genes involved in immune function was readily observed with disruption of the LXCXE-binding function of RB. Thus, these studies demonstrate that RB plays a significant role in both the positive and negative regulations of transcriptional programs and indicate that loss of RB has distinct biological effects related to both cell cycle control and immune function.	Univ Cincinnati, Coll Med, Dept Cell & Canc Biol, Vontz Ctr Mol Studies, Cincinnati, OH 45267 USA; Univ Calif San Diego, La Jolla, CA 92093 USA; Univ Cincinnati, Coll Med, Cincinnati, OH 45267 USA; Cincinnati Childrens Hosp Med Ctr, Div Biomed Informat, Cincinnati, OH USA; Univ Cincinnati, Dept Surg, Cincinnati, OH 45267 USA; Shriners Hosp Children, Cincinnati, OH USA	University System of Ohio; University of Cincinnati; University of California System; University of California San Diego; University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati	Knudsen, ES (corresponding author), Univ Cincinnati, Coll Med, Dept Cell & Canc Biol, Vontz Ctr Mol Studies, 3125 Eden Ave, Cincinnati, OH 45267 USA.	erik.knudsen@uc.edu	Jegga, Anil/H-6140-2011; Aronow, Bruce J/F-8438-2012; Mayhew, Christopher N/AGB-4929-2022	Jegga, Anil/0000-0002-4881-7752; Stengel, Kristy/0000-0002-8330-5744; Markey, Michael/0000-0002-8593-2290; Reed, Michael/0000-0001-8478-8605	NATIONAL CANCER INSTITUTE [T32CA117846, R01CA058320] Funding Source: NIH RePORTER; NCI NIH HHS [T32 CA117846, F32 CA174162, R01 CA058320] Funding Source: Medline; NIGMS NIH HHS [R35 GM147213] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arany I, 1996, SEX TRANSM DIS, V23, P475, DOI 10.1097/00007435-199611000-00007; Batsche E, 2005, J BIOL CHEM, V280, P16088, DOI 10.1074/jbc.M413427200; Black EP, 2003, CANCER RES, V63, P3716; Blais A, 2004, CURR OPIN GENET DEV, V14, P527, DOI 10.1016/j.gde.2004.07.003; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; Cam H, 2004, MOL CELL, V16, P399, DOI 10.1016/j.molcel.2004.09.037; Cam H, 2003, CANCER CELL, V3, P311, DOI 10.1016/S1535-6108(03)00080-1; Chen TT, 2000, MOL CELL BIOL, V20, P5571, DOI 10.1128/MCB.20.15.5571-5580.2000; Cobrinik D, 2005, ONCOGENE, V24, P2796, DOI 10.1038/sj.onc.1208619; Dimova DK, 2005, ONCOGENE, V24, P2810, DOI 10.1038/sj.onc.1208612; Eason DD, 2001, CANCER LETT, V171, P209, DOI 10.1016/S0304-3835(01)00603-6; Frolov MV, 2004, J CELL SCI, V117, P2173, DOI 10.1242/jcs.01227; Iavarone A, 2004, NATURE, V432, P1040, DOI 10.1038/nature03068; Iovino F, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-38; Ishida S, 2001, MOL CELL BIOL, V21, P4684, DOI 10.1128/MCB.21.14.4684-4699.2001; Jegga AG, 2005, NUCLEIC ACIDS RES, V33, pW408, DOI 10.1093/nar/gki486; Jegga AG, 2002, GENOME RES, V12, P1408, DOI 10.1101/gr.255002; Knudsen ES, 1998, GENE DEV, V12, P2278, DOI 10.1101/gad.12.15.2278; KOUZARIDES T, 1995, SEMIN CANCER BIOL, V6, P91, DOI 10.1006/scbi.1995.0012; Le Buanec H, 1999, BIOMED PHARMACOTHER, V53, P424, DOI 10.1016/S0753-3322(99)80122-X; LU YM, 1994, ONCOGENE, V9, P1015; Markey MP, 2002, CANCER RES, V62, P6587; Mayhew CN, 2004, ONCOGENE, V23, P4107, DOI 10.1038/sj.onc.1207503; Morris EJ, 2001, ADV CANCER RES, V82, P1, DOI 10.1016/S0065-230X(01)82001-7; Nevins JR, 2001, HUM MOL GENET, V10, P699, DOI 10.1093/hmg/10.7.699; Osborne A, 1997, NUCLEIC ACIDS RES, V25, P5095, DOI 10.1093/nar/25.24.5095; Osborne AR, 2004, J BIOL CHEM, V279, P28911, DOI 10.1074/jbc.M403118200; QIN XQ, 1995, MOL CELL BIOL, V15, P742; Ren B, 2002, GENE DEV, V16, P245, DOI 10.1101/gad.949802; Sage J, 2003, NATURE, V424, P223, DOI 10.1038/nature01764; Sherr CJ, 2002, CANCER CELL, V2, P103, DOI 10.1016/S1535-6108(02)00102-2; Strobeck MW, 2000, P NATL ACAD SCI USA, V97, P7748, DOI 10.1073/pnas.97.14.7748; Thomas DM, 2003, CANCER BIOL THER, V2, P124, DOI 10.4161/cbt.2.2.235; Thomas DM, 2001, MOL CELL, V8, P303, DOI 10.1016/S1097-2765(01)00327-6; Trouche D, 1997, P NATL ACAD SCI USA, V94, P11268, DOI 10.1073/pnas.94.21.11268; Vernell R, 2003, J BIOL CHEM, V278, P46124, DOI 10.1074/jbc.M304930200; WANG JYJ, 1994, ADV CANCER RES, V64, P25, DOI 10.1016/S0065-230X(08)60834-9; WELCH PJ, 1995, MOL CELL BIOL, V15, P5542; Xin H, 2003, ONCOGENE, V22, P4775, DOI 10.1038/sj.onc.1206780; Zhu X, 1999, ONCOGENE, V18, P4940, DOI 10.1038/sj.onc.1202876	40	59	59	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 20	2007	26	43					6307	6318		10.1038/sj.onc.1210450	http://dx.doi.org/10.1038/sj.onc.1210450			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	212GW	17452985				2022-12-28	WOS:000249583300007
J	Dai, B; Kang, SH; Gong, W; Liu, M; Aldape, KD; Sawaya, R; Huang, S				Dai, B.; Kang, S-H; Gong, W.; Liu, M.; Aldape, K. D.; Sawaya, R.; Huang, S.			Aberrant FoxM1B expression increases matrix metalloproteinase-2 transcription and enhances the invasion of glioma cells	ONCOGENE			English	Article						FoxM1B; MMP-2; glioma; invasion	GENE-EXPRESSION; IV COLLAGENASE; MALIGNANT GLIOMAS; GELATINASE-A; ACTIVATION; ANGIOPOIETIN-2; GROWTH; STAT3; TUMORIGENICITY; INVASIVENESS	We recently showed that FoxM1 is overexpressed in human glioblastomas and that forced FoxM1B expression in anaplastic astrocytoma cells leads to the formation of highly invasive glioblastoma multiforme (GBM) in nude mice. However, the molecular mechanisms by which FoxM1 enhances glioma invasion are unknown. In this study, we found that FoxM1 overexpression increased matrix metalloproteinase (MMP)-2 expression in glioma cells, whereas blockade of FoxM1 expression suppressed MMP-2 expression. Transfection of FoxM1 into glioma cells directly activated the MMP-2 promoter, whereas inhibition of FoxM1 expression by FoxM1-siRNA suppressed its activation. We identified a FoxM1-binding site in the MMP-2 promoter and demonstrated that FoxM1 protein bound directly to it. Mutation of this FoxM1-binding site significantly attenuated MMP-2 promoter activity. Furthermore, FoxM1 overexpression increased the invasiveness of glioma cells, whereas inhibition of FoxM1 expression suppressed the invasiveness of GBM cells. Inhibition of MMP-2 by a specific MMP-2 inhibitor reversed the invasive phenotype of glioma cells overexpressing FoxM1. Finally, immunohistochemical analysis of 45 human GBM specimens showed a significant correlation between FoxM1 overexpression and elevated MMP-2 expression. Collectively, these findings provide evidence that FoxM1 contributes to glioma progression by enhancing MMP-2 gene transcription and thus tumor-cell invasion.	Univ Texas, MD Anderson Canc Ctr, Dept Neurosurg, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Pathol, Houston, TX USA; Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX USA; Univ Texas, Grad Sch Biomed Sci, Program Canc Biol, Houston, TX USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System	Huang, S (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Neurosurg, 1515 Holcombe Blvd, Houston, TX 77030 USA.	suhuang@mdanderson.org	Dai, Bingbing/B-8417-2012	gang, sinhyeog/0000-0002-8912-7985	NATIONAL CANCER INSTITUTE [R01CA116528, P30CA016672] Funding Source: NIH RePORTER; NCI NIH HHS [CA 16672, R01-CA116528] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABE T, 1994, CLIN EXP METASTAS, V12, P296, DOI 10.1007/BF01753836; Allred DC, 1998, MODERN PATHOL, V11, P155; Bian JH, 1997, MOL CELL BIOL, V17, P6330, DOI 10.1128/MCB.17.11.6330; Emonard H, 1999, ANN NY ACAD SCI, V878, P647, DOI 10.1111/j.1749-6632.1999.tb07751.x; Giese A, 2003, J CLIN ONCOL, V21, P1624, DOI 10.1200/JCO.2003.05.063; Guo P, 2003, AM J PATHOL, V162, P1083, DOI 10.1016/S0002-9440(10)63905-3; Hu B, 2006, CANCER RES, V66, P775, DOI 10.1158/0008-5472.CAN-05-1149; Hu B, 2003, P NATL ACAD SCI USA, V100, P8904, DOI 10.1073/pnas.1533394100; Huang S, 1998, EMBO J, V17, P4358, DOI 10.1093/emboj/17.15.4358; Huang SY, 2002, J NATL CANCER I, V94, P1134; Konnikova L, 2003, BMC CANCER, V3, DOI 10.1186/1471-2407-3-23; Korver W, 1997, GENOMICS, V46, P435, DOI 10.1006/geno.1997.5065; Koul D, 2001, ONCOGENE, V20, P6669, DOI 10.1038/sj.onc.1204799; Lampert K, 1998, AM J PATHOL, V153, P429, DOI 10.1016/S0002-9440(10)65586-1; Laoukili J, 2005, NAT CELL BIOL, V7, P126, DOI 10.1038/ncb1217; Liu MG, 2006, CANCER RES, V66, P3593, DOI 10.1158/0008-5472.CAN-05-2912; Mertens PR, 1997, J BIOL CHEM, V272, P22905, DOI 10.1074/jbc.272.36.22905; Park CM, 2006, CANCER RES, V66, P8511, DOI 10.1158/0008-5472.CAN-05-4340; Qin HW, 1999, J BIOL CHEM, V274, P29130, DOI 10.1074/jbc.274.41.29130; Rickman DS, 2001, CANCER RES, V61, P6885; Sawaya RE, 1996, CLIN EXP METASTAS, V14, P35, DOI 10.1007/BF00157684; Tan YJ, 2007, MOL CELL BIOL, V27, P1007, DOI 10.1128/MCB.01068-06; Teh MT, 2002, CANCER RES, V62, P4773; van den Boom J, 2003, AM J PATHOL, V163, P1033, DOI 10.1016/S0002-9440(10)63463-3; Wang H, 2003, CANCER RES, V63, P4315; Wang HM, 2004, LAB INVEST, V84, P941, DOI 10.1038/labinvest.3700123; Wild-Bode C, 2001, CANCER RES, V61, P2744; Wild-Bode C, 2001, J NEUROSURG, V94, P976, DOI 10.3171/jns.2001.94.6.0978; Wonsey DR, 2005, CANCER RES, V65, P5181, DOI 10.1158/0008-5472.CAN-04-4059; Xie TX, 2004, ONCOGENE, V23, P3550, DOI 10.1038/sj.onc.1207383; Yao KM, 1997, J BIOL CHEM, V272, P19827, DOI 10.1074/jbc.272.32.19827; Ye HG, 1999, MOL CELL BIOL, V19, P8570; Ye HG, 1997, MOL CELL BIOL, V17, P1626, DOI 10.1128/MCB.17.3.1626	33	157	165	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 13	2007	26	42					6212	6219		10.1038/sj.onc.1210443	http://dx.doi.org/10.1038/sj.onc.1210443			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	209PU	17404569				2022-12-28	WOS:000249401300012
J	Iwata, T; Mizusawa, N; Taketani, Y; Itakura, M; Yoshimoto, K				Iwata, T.; Mizusawa, N.; Taketani, Y.; Itakura, M.; Yoshimoto, K.			Parafibromin tumor suppressor enhances cell growth in the cells expressing SV40 large T antigen	ONCOGENE			English	Article						HRPT2; parafibromin; SV40 large T antigen; tumorigenesis; tumor suppressor	FAMILIAL ISOLATED HYPERPARATHYROIDISM; RNA-POLYMERASE-II; HEREDITARY HYPERPARATHYROIDISM; PARATHYROID CARCINOMA; GENE HRPT2; HUMAN PAF1; MUTATIONS; COMPLEX; TRANSFORMATION; TRANSCRIPTION	Parabromin (PF) is a 531-amino acid protein encoded by HRPT2, a putative tumor suppressor gene recently implicated in the autosomal-dominant hyperparathyroidism-jaw tumor familial cancer syndrome and sporadic parathyroid carcinoma. To investigate effects of PF's overexpression on cell proliferation, we performed assays in four different cell lines. The transient overexpression of PF inhibited cell growth in HEK293 and NIH3T3 cells, but enhanced cell growth in the SV40 large T antigen-expressing cell lines such as 293FT and COS7 cells. In 293FT cells, PF was found to interact with SV40 large T antigen and its overexpression promoted entry into the S phase, implying that the interaction enhanced progression through the cell cycle. The tumor suppressor protein PF acts as a positive regulator of cell growth similar to an oncoprotein in the presence of SV40 large T antigen.	Univ Tokushima, Grad Sch, Inst Hlth Biosci, Dept Med & Pharmacol, Tokushima, Japan; Univ Tokushima, Grad Sch, Inst Hlth Biosci, Dept Clin Nutr, Tokushima, Japan; Univ Tokushima, Grad Sch, Inst Hlth Biosci, Div Genet Informat, Tokushima, Japan	Tokushima University; Tokushima University; Tokushima University	Yoshimoto, K (corresponding author), Univ Tokushima, Grad Sch, Inst Hlth Biosci, Dept Med & Pharmacol, 3-18-15 Kuramoto-cho, Tokushima, Japan.	yoshimot@dent.tokushima-u.ac.jp						Ali SH, 2001, SEMIN CANCER BIOL, V11, P15, DOI 10.1006/scbi.2000.0342; Arnold A, 2002, J BONE MINER RES, V17, pN30; Carpten JD, 2002, NAT GENET, V32, P676, DOI 10.1038/ng1048; CHEN S, 1990, J VIROL, V64, P3350, DOI 10.1128/JVI.64.7.3350-3357.1990; FANNING E, 1992, ANNU REV BIOCHEM, V61, P55; Grimelius L, 1997, SEMIN SURG ONCOL, V13, P142, DOI 10.1002/(SICI)1098-2388(199703/04)13:2<142::AID-SSU10>3.0.CO;2-0; Howell VM, 2003, J MED GENET, V40, P657, DOI 10.1136/jmg.40.9.657; JACKSON CE, 1990, SURGERY, V108, P1006; KASSEM M, 1994, CLIN ENDOCRINOL, V41, P415, DOI 10.1111/j.1365-2265.1994.tb02570.x; KIERSTEAD TD, 1993, J VIROL, V67, P1817, DOI 10.1128/JVI.67.4.1817-1829.1993; Marx S, 1998, ANN INTERN MED, V129, P484, DOI 10.7326/0003-4819-129-6-199809150-00011; Mizusawa N, 2006, CLIN ENDOCRINOL, V65, P9, DOI 10.1111/j.1365-2265.2006.02534.x; Moniaux N, 2006, ONCOGENE, V25, P3247, DOI 10.1038/sj.onc.1209353; Mosimann C, 2006, CELL, V125, P327, DOI 10.1016/j.cell.2006.01.053; Porter SE, 2002, EUKARYOT CELL, V1, P830, DOI 10.1128/EC.1.5.830-842.2002; ROWLAND BD, 2006, NAT REV CANCER, V6, P293; Rozenblatt-Rosen O, 2005, MOL CELL BIOL, V25, P612, DOI 10.1128/MCB.25.2.612-620.2005; Schuffenecker I, 1998, J CLIN ENDOCR METAB, V83, P487, DOI 10.1210/jc.83.2.487; Shattuck TM, 2003, NEW ENGL J MED, V349, P1722, DOI 10.1056/NEJMoa031237; Simmons DT, 2000, ADV VIRUS RES, V55, P75, DOI 10.1016/S0065-3527(00)55002-7; Simonds WF, 2004, J CLIN ENDOCR METAB, V89, P96, DOI 10.1210/jc.2003-030675; SZABO J, 1995, AM J HUM GENET, V56, P944; Tan MH, 2004, CLIN CANCER RES, V10, P6629, DOI 10.1158/1078-0432.CCR-04-0493; Villar JC, 2004, FILTR SEPARAT, V41, P32, DOI 10.1016/S0015-1882(04)00282-4; Wassif WS, 1999, CLIN ENDOCRINOL, V50, P191, DOI 10.1046/j.1365-2265.1999.00633.x; Woodard GE, 2005, ONCOGENE, V24, P1272, DOI 10.1038/sj.onc.1208274; Yart A, 2005, MOL CELL BIOL, V25, P5052, DOI 10.1128/MCB.25.12.5052-5060.2005; Yokoyama A, 2005, CELL, V123, P207, DOI 10.1016/j.cell.2005.09.025; Zhu B, 2005, GENE DEV, V19, P1668, DOI 10.1101/gad.1292105	29	26	28	4	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 13	2007	26	42					6176	6183		10.1038/sj.onc.1210445	http://dx.doi.org/10.1038/sj.onc.1210445			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	209PU	17404568				2022-12-28	WOS:000249401300008
J	Merolla, F; Pentimalli, F; Pacelli, R; Vecchio, G; Fusco, A; Grieco, M; Celetti, A				Merolla, F.; Pentimalli, F.; Pacelli, R.; Vecchio, G.; Fusco, A.; Grieco, M.; Celetti, A.			Involvement of H4(D10S170) protein in ATM-dependent response to DNA damage	ONCOGENE			English	Article						H4(D10S170); RET/PTC1; DNA damage; ATM; thyroid	THYROID PAPILLARY CARCINOMAS; FACTOR RECEPTOR-BETA; GENOMIC INSTABILITY; CHECKPOINT PATHWAY; IONIZING-RADIATION; CANCER; RET; REARRANGEMENTS; KINASE; CELLS	H4(D10S170) gene has been identified upon its frequent rearrangement with RET in papillary thyroid tumours (RET/PTC1). The kinase ataxia telangectasia mutated (ATM) phosphorylates a limited number of downstream protein targets in response to DNA damage. We investigated the potential role of H4( D10S170) in DNA damage signaling pathways. We found that in cells treated with etoposide or ionizing radiation (IR), H4( D10S170) underwent ATM-mediated phosphorylation at Thr 434, stabilizing nuclear H4. In ataxia telangectasia cells (A-T), endogenous H4( D10S170) was localized to cytoplasm and was excluded from the nucleus. Moreover, H4( D10S170) was not phosphorylated in ATM-deficient lymphoblasts after ionizing irradiation. Inhibition of ATM kinase interfered with H4( D10S170) apoptotic activity, and expression of H4 with threonine 434 mutated in Alanine, H4(T434A), protected the cells from genotoxic stress-induced apoptosis. Most importantly, after exposure to IR we found that silencing of H4( D10S170) in mammalian cells increased cell survival, as shown by clonogenic assay, allows for DNA synthesis as evaluated by bromodeoxyuridine incorporation and permits cells to progress into mitosis as demonstrated by phosphorylation on Histone H3. Our results suggest that H4( D10S170) is involved in cellular response to DNA damage ATM-mediated, and that the impairment of H4( D10S170) gene function might have a role in thyroid carcinogenesis.	Univ Naples Federico II, Dipartimento Biol Patol Cellulare Mol, Naples, Italy; CNR, Ist Biostrutt Bioimmagini, Naples, Italy; Magna Graecia Univ Catanzaro, Dipartimento Med Speriment Clin, Catanzaro, Italy; Ist Endocrinol Oncol Speriment, CNR, Naples, Italy	University of Naples Federico II; Consiglio Nazionale delle Ricerche (CNR); Istituto di Biostrutture e Bioimmagini (IBB-CNR); Magna Graecia University of Catanzaro; Consiglio Nazionale delle Ricerche (CNR); Istituto per Endocrinologia e Oncologia "Gaetano Salvatore" (IEOS-CNR)	Celetti, A (corresponding author), Univ Naples Federico II, Ist Endocrinol Oncol Sperimentale, CNR, Dipartimento Biol Patol Cellulare Mol, Via S Parsini, Naples, Italy.	celetti@unina.it2	Pentimalli, Francesca/K-4936-2014; Celetti, Angela/AAY-7172-2020; Pacelli, Roberto/AFS-0333-2022	Pentimalli, Francesca/0000-0003-4740-6801; Grieco, Michele/0000-0002-4212-7814; Fusco, Alfredo/0000-0003-3332-5197; Pacelli, Roberto/0000-0002-2048-7675				Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Canman CE, 1998, ONCOGENE, V17, P3301, DOI 10.1038/sj.onc.1202577; Caudill CM, 2005, J CLIN ENDOCR METAB, V90, P2364, DOI 10.1210/jc.2004-1811; Celetti A, 2004, ONCOGENE, V23, P109, DOI 10.1038/sj.onc.1206981; DiTullio RA, 2002, NAT CELL BIOL, V4, P998, DOI 10.1038/ncb892; FUSCO A, 1987, NATURE, V328, P170, DOI 10.1038/328170a0; GOODHEAD DT, 1994, INT J RADIAT BIOL, V65, P7, DOI 10.1080/09553009414550021; GRIECO M, 1990, CELL, V60, P557, DOI 10.1016/0092-8674(90)90659-3; GRIECO M, 1994, ONCOGENE, V9, P25331; Hickson I, 2004, CANCER RES, V64, P9152, DOI 10.1158/0008-5472.CAN-04-2727; Iliakis G, 2003, ONCOGENE, V22, P5834, DOI 10.1038/sj.onc.1206682; Jhiang SM, 2000, ONCOGENE, V19, P5590, DOI 10.1038/sj.onc.1203857; Jossart GH, 1996, CYTOGENET CELL GENET, V75, P254, DOI 10.1159/000134495; Kastan MB, 2000, NAT REV MOL CELL BIO, V1, P179, DOI 10.1038/35043058; Kim ST, 1999, J BIOL CHEM, V274, P37538, DOI 10.1074/jbc.274.53.37538; Kulkarni S, 2000, CANCER RES, V60, P3592; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee JH, 2004, SCIENCE, V304, P93, DOI 10.1126/science.1091496; Leskov KS, 2001, SEMIN RADIAT ONCOL, V11, P352, DOI 10.1053/srao.2001.26912; Lim DS, 2000, NATURE, V404, P613, DOI 10.1038/35007091; Little JB, 2003, ONCOGENE, V22, P6978, DOI 10.1038/sj.onc.1206988; Motoyama N, 2004, CURR OPIN GENET DEV, V14, P11, DOI 10.1016/j.gde.2003.12.003; Nikiforova MN, 2000, SCIENCE, V290, P138, DOI 10.1126/science.290.5489.138; Nikiforova MN, 2004, CANCER LETT, V209, P1, DOI 10.1016/j.canlet.2003.12.004; O'Neill T, 2000, J BIOL CHEM, V275, P22719, DOI 10.1074/jbc.M001002200; Obenauer JC, 2003, NUCLEIC ACIDS RES, V31, P3635, DOI 10.1093/nar/gkg584; Penserga ETP, 2007, ONCOGENE, V26, P11, DOI 10.1038/sj.onc.1209756; PIEROTTI MA, 1992, P NATL ACAD SCI USA, V89, P1616, DOI 10.1073/pnas.89.5.1616; Puxeddu E, 2005, MUTAT RES-FUND MOL M, V570, P17, DOI 10.1016/j.mrfmmm.2004.09.010; Radivoyevitch T, 2001, RADIAT ENVIRON BIOPH, V40, P191, DOI 10.1007/s004110100108; RON E, 1995, RADIAT RES, V141, P259, DOI 10.2307/3579003; Schwaller J, 2001, BLOOD, V97, P3910, DOI 10.1182/blood.V97.12.3910; Sheils OM, 2000, J PATHOL, V192, P32; Shiloh Y, 2003, CELL CYCLE, V2, P116, DOI 10.4161/cc.2.2.342; Smith LE, 2003, HEALTH PHYS, V85, P23, DOI 10.1097/00004032-200307000-00006; Tong Q, 1997, J BIOL CHEM, V272, P9043; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WARD JF, 1995, RADIAT RES, V142, P362, DOI 10.2307/3579145	38	37	38	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 13	2007	26	42					6167	6175		10.1038/sj.onc.1210446	http://dx.doi.org/10.1038/sj.onc.1210446			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	209PU	17420723				2022-12-28	WOS:000249401300007
J	Akdemir, F; Christich, A; Sogame, N; Chapo, J; Abrams, JM				Akdemir, F.; Christich, A.; Sogame, N.; Chapo, J.; Abrams, J. M.			p53 directs focused genomic responses in Drosophila	ONCOGENE			English	Article						apoptosis; p53; radiation; Drosophila; cell death	RIBONUCLEOTIDE REDUCTASE GENE; CELL-DEATH; DNA-DAMAGE; CASPASE DRONC; APOPTOSIS; MELANOGASTER; PROTEINS; SMAC/DIABLO; ACTIVATION; PATHWAYS	p53 is a fundamental determinant of cancer susceptibility and other age-related pathologies. Similar to mammalian counterparts, Drosophila p53 integrates stress signals and elicits apoptotic responses that maintain genomic stability. To illuminate core-adaptive functions controlled by this gene family, we examined the Drosophila p53 regulatory network at a genomic scale. In development, the absence of p53 impacted constitutive expression for a surprisingly broad scope of genes. By contrast, stimulus-dependent responses governed by Drosophila p53 were limited in scope. The vast majority of stress responders were induced and p53 dependent (RIPD) genes. The signature set of 29 'high stringency' RIPD genes identified here were enriched for intronless loci, with a non-uniform distribution that includes a recently evolved cluster unique to Drosophila melanogaster. Two RIPD genes, with known and unknown biochemical activities, were functionally examined. One RIPD gene, designated XRP1, maintains genome stability after genotoxic challenge and prevents cell proliferation upon induced expression. A second gene, RnrL, is an apoptogenic effector required for caspase activation in a model of p53-dependent killing. Together, these studies identify ancient and convergent features of the p53 regulatory network.	Univ Texas, SW Med Ctr, Dept Cell Biol, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Abrams, JM (corresponding author), Univ Texas, SW Med Ctr, Dept Cell Biol, Dallas, TX 75390 USA.	John.Abrams@utsouthwestern.edu	akdemir, fatih/AAR-5764-2021	AKDEMIR, FATIH/0000-0003-3023-9453	PHS HHS [R01G-M072124] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Bae BI, 2005, NEURON, V47, P29, DOI 10.1016/j.neuron.2005.06.005; Bauer JH, 2005, CURR BIOL, V15, P2063, DOI 10.1016/j.cub.2005.10.051; Blanchette M, 2004, MOL CELL, V14, P775, DOI 10.1016/j.molcel.2004.06.012; Brodsky MH, 2004, MOL CELL BIOL, V24, P1219, DOI 10.1128/MCB.24.3.1219-1231.2004; Brodsky MH, 2000, CELL, V101, P103, DOI 10.1016/S0092-8674(00)80627-3; Chai JJ, 2000, NATURE, V406, P855, DOI 10.1038/35022514; Chen P, 2004, CELL DEATH DIFFER, V11, P704, DOI 10.1038/sj.cdd.4401406; Chew SK, 2004, DEV CELL, V7, P897, DOI 10.1016/j.devcel.2004.09.016; Colombani J, 2006, CURR BIOL, V16, P1453, DOI 10.1016/j.cub.2006.05.059; COURGEON AM, 1972, NATURE-NEW BIOL, V238, P250, DOI 10.1038/newbio238250a0; Daish TJ, 2004, DEV CELL, V7, P909, DOI 10.1016/j.devcel.2004.09.018; Dorstyn L, 1999, P NATL ACAD SCI USA, V96, P4307, DOI 10.1073/pnas.96.8.4307; ECHALIER G, 1970, IN VITRO CELL DEV B, V6, P162; Jin SK, 2003, GENE DEV, V17, P359, DOI 10.1101/gad.1047003; Kauppila S, 2003, ONCOGENE, V22, P4860, DOI 10.1038/sj.onc.1206715; Lee CY, 2003, CURR BIOL, V13, P350, DOI 10.1016/S0960-9822(03)00085-X; Lee JH, 2003, FEBS LETT, V550, P5, DOI 10.1016/S0014-5793(03)00771-3; Lu WJ, 2006, CELL DEATH DIFFER, V13, P909, DOI 10.1038/sj.cdd.4401922; Martins LM, 2002, J BIOL CHEM, V277, P439, DOI 10.1074/jbc.M109784200; Nakano K, 2000, ONCOGENE, V19, P4283, DOI 10.1038/sj.onc.1203774; Nordstrom W, 2000, CELL DEATH DIFFER, V7, P1035, DOI 10.1038/sj.cdd.4400766; Nordstrom W, 1996, DEV BIOL, V180, P213, DOI 10.1006/dbio.1996.0296; Peters M, 2002, P NATL ACAD SCI USA, V99, P11305, DOI 10.1073/pnas.172382899; Sakharkar MK, 2004, BMC BIOINFORMATICS, V5, DOI 10.1186/1471-2105-5-67; Sharpless NE, 2002, CELL, V110, P9, DOI 10.1016/S0092-8674(02)00818-8; Sogame N, 2003, P NATL ACAD SCI USA, V100, P4696, DOI 10.1073/pnas.0736384100; Tanaka H, 2000, NATURE, V404, P42, DOI 10.1038/35003506; Verhagen AM, 2002, J BIOL CHEM, V277, P445, DOI 10.1074/jbc.M109891200; Vousden KH, 2005, CELL, V120, P7, DOI 10.1016/j.cell.2004.12.027; Wu G, 2000, NATURE, V408, P1008, DOI 10.1038/35050012	30	61	62	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 9	2007	26	36					5184	5193		10.1038/sj.onc.1210328	http://dx.doi.org/10.1038/sj.onc.1210328			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	199CQ	17310982				2022-12-28	WOS:000248674200002
J	Wakasugi, T; Izumi, H; Uchiumi, T; Suzuki, H; Arao, T; Nishio, K; Kohno, K				Wakasugi, T.; Izumi, H.; Uchiumi, T.; Suzuki, H.; Arao, T.; Nishio, K.; Kohno, K.			ZNF143 interacts with p73 and is involved in cisplatin resistance through the transcriptional regulation of DNA repair genes	ONCOGENE			English	Article						ZNF143; p73; Rad51; FEN-1; cisplatin; DNA repair	BOX-BINDING-PROTEIN; CANCER-CELL-LINES; DRUG-RESISTANCE; DAMAGING AGENTS; EXPRESSION; ACTIVATOR; YB-1; STAF	Zinc-finger protein 143 ( ZNF143) is a human homolog of Xenopus transcriptional activator staf that is involved in selenocystyl tRNA transcription. We previously showed that ZNF143 expression is induced by treatment with DNA-damaging agents and that it preferentially binds to cisplatin-modified DNA. In this study, the potential function of ZNF143 was investigated. ZNF143 was overexpressed in cisplatin-resistant cells. ZNF143 knockdown in prostate cancer caused increased sensitivity for cisplatin, but not for oxaliplatin, etoposide and vincristine. We also showed that ZNF143 is associated with tumor suppressor gene product p73 but not with p53.p73 could stimulate the binding of ZNF143 to both ZNF143 binding site and cisplatin-modified DNA, and modulate the function of ZNF143. We provide a direct evidence that both Rad51 and flap endonuclease-1 are target genes of ZNF143 and overexpressed in cisplatin-resistant cells. Taken together, these experiments demonstrate that an interplay of ZNF143, p73 and ZNF143 target genes is involved in DNA repair gene expression and cisplatin resistance.	Univ Occupat & Environm Hlth, Sch Med, Dept Biol Mol, Yahatanishi Ku, Kitakyushu, Fukuoka 8078555, Japan; Univ Occupat & Environm Hlth, Sch Med, Dept Otorhinolaryngol, Yahatanishi Ku, Kitakyushu, Fukuoka 8078555, Japan; Kinki Univ, Sch Med, Dept Genome Biol, Osaka, Japan	University of Occupational & Environmental Health - Japan; University of Occupational & Environmental Health - Japan; Kindai University (Kinki University)	Kohno, K (corresponding author), Univ Occupat & Environm Hlth, Sch Med, Dept Biol Mol, Yahatanishi Ku, 1-1 Iseigaoka, Kitakyushu, Fukuoka 8078555, Japan.	k-kohno@med.uoeh-u.ac.jp						Altaha R, 2004, INT J MOL MED, V14, P959; Bhattacharyya A, 2000, J BIOL CHEM, V275, P23899, DOI 10.1074/jbc.C000276200; Chaney SG, 1996, JNCI-J NATL CANCER I, V88, P1346, DOI 10.1093/jnci/88.19.1346; Cohen SM, 2001, PROG NUCLEIC ACID RE, V67, P93, DOI 10.1016/S0079-6603(01)67026-0; De Laurenzi V, 1998, J EXP MED, V188, P1763, DOI 10.1084/jem.188.9.1763; FUJII R, 1994, JPN J CANCER RES, V85, P426, DOI 10.1111/j.1349-7006.1994.tb02376.x; Imamura T, 2001, J BIOL CHEM, V276, P7534, DOI 10.1074/jbc.M008143200; Ise T, 1999, CANCER RES, V59, P342; Ishiguchi H, 2004, INT J CANCER, V111, P900, DOI 10.1002/ijc.20358; Izumi H, 2003, BIOCHEM J, V373, P713, DOI 10.1042/BJ20021902; Keshelava N, 2001, CANCER RES, V61, P6185; Kohno K, 2003, BIOESSAYS, V25, P691, DOI 10.1002/bies.10300; Kohno K, 2005, EUR J CANCER, V41, P2577, DOI 10.1016/j.ejca.2005.08.007; Kuwano M, 2004, MOL CANCER THER, V3, P1485; Lieber MR, 1997, BIOESSAYS, V19, P233, DOI 10.1002/bies.950190309; Murakami T, 2001, INT J CANCER, V93, P869, DOI 10.1002/ijc.1418; Myslinski E, 1998, J BIOL CHEM, V273, P21998, DOI 10.1074/jbc.273.34.21998; Ohga T, 1996, CANCER RES, V56, P4224; Raymond E, 2002, MOL CANCER THER, V1, P227; Rincon JC, 1998, NUCLEIC ACIDS RES, V26, P4846, DOI 10.1093/nar/26.21.4846; Schaub M, 1997, EMBO J, V16, P173, DOI 10.1093/emboj/16.1.173; Spiro C, 2003, MOL CELL BIOL, V23, P6063, DOI 10.1128/MCB.23.17.6063-6074.2003; Sugaya M, 2002, CHEST, V122, P282, DOI 10.1378/chest.122.1.282; Tanabe M, 2003, CANCER RES, V63, P8592; TEW KD, 1994, CANCER RES, V54, P4313; Torigoe Takayuki, 2005, Current Medicinal Chemistry - Anti-Cancer Agents, V5, P15, DOI 10.2174/1568011053352587; Uramoto H, 2003, BIOCHEM J, V371, P301, DOI 10.1042/BJ20021646; Uramoto H, 2002, J BIOL CHEM, V277, P31694, DOI 10.1074/jbc.M200266200; Vikhanskaya F, 2001, CANCER RES, V61, P935; Wood RD, 2005, MUTAT RES-FUND MOL M, V577, P275, DOI 10.1016/j.mrfmmm.2005.03.007; ZAMBLE DB, 1995, TRENDS BIOCHEM SCI, V20, P435, DOI 10.1016/S0968-0004(00)89095-7	31	47	50	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 9	2007	26	36					5194	5203		10.1038/sj.onc.1210326	http://dx.doi.org/10.1038/sj.onc.1210326			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	199CQ	17297437				2022-12-28	WOS:000248674200003
J	Chassot, AA; Turchi, L; Virolle, T; Fitsialos, G; Batoz, M; Deckert, M; Dulic, V; Meneguzzi, G; Busca, R; Ponzio, G				Chassot, A-A; Turchi, L.; Virolle, T.; Fitsialos, G.; Batoz, M.; Deckert, M.; Dulic, V.; Meneguzzi, G.; Busca, R.; Ponzio, G.			Id3 is a novel regulator of p27(kip1) mRNA in early G1 phase and is required for cell-cycle progression	ONCOGENE			English	Article						Ids; cell-cycle; p27mRNA; wound healing	LOOP-HELIX PROTEINS; CDK INHIBITOR P27; P16(INK4A) EXPRESSION; TRANSCRIPTION; DIFFERENTIATION; PROLIFERATION; FIBROBLASTS; DEGRADATION; SENESCENCE; PATHWAYS	P27kip is a key inhibitory protein of the cell-cycle progression, which is rapidly downregulated in early G1 phase by a post-translational mechanism involving the proteosomal degradation. In this study, using a wounding model that induces cell-cycle entry of human dermal fibroblasts, we demonstrate that p27mRNA is downregulated when cells progress into the G1 phase, and then it returns to its basal level when cells approach the S phase. By using a quantitative polymerase chain reaction screening we identified inhibitors of differentiation (10), a bHLH transcriptional repressor, as a candidate mediator accounting for p27 mRNA decrease. Id3 silencing, using an small interfering RNA approach, reversed the injury mediated p27 downregulation demonstrating that 143 is involved in the transcriptional repression of p27. Reporter gene experiments and a chromatin immunoprecipitation assay showed that Id3 likely exerts its repressive action through ELK1 inhibition. By inhibiting early p27 downregulation, Id3 depletion blocked (i) the G1-phase progression as assessed by the inhibition of pRb phosphorylation and p130 degradation and (ii) the G1/S transition as observed by the inhibition of cyclin A induction, demonstrating that p27 mRNA decrease is required for cell proliferation. Apart from its effect on the early p27 diminution, 143 appears also involved in the control of the steady-state level of p27 at the G1/S boundary. In conclusion, this study identifies a novel mechanism of p27 regulation which besides p27 protein degradation also implicates a transcriptional mechanism mediated by 10.	Univ Nice, Fac Med, INSERM, U634, F-06107 Nice 02, France; Univ Nice, Hop Larchet, INSERM, U576, Nice, France; CNRS, CRBM, FRE 2593, F-34033 Montpellier, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; CHU Nice; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier	Ponzio, G (corresponding author), Univ Nice, Fac Med, INSERM, U634, 28 Ave Valombrose, F-06107 Nice 02, France.	ponzio@unice.fr	Chassot, Anne-Amandine/O-2102-2016; Virolle, Thierry/E-5838-2016; Ponzio, Gilles/Q-1256-2016; Deckert, Marcel/M-4998-2016; Deckert, Marcel/T-3566-2019	Chassot, Anne-Amandine/0000-0003-1242-9456; Ponzio, Gilles/0000-0003-2741-0248; Deckert, Marcel/0000-0003-2094-559X; Dulic, Vjekoslav/0000-0003-1201-3901; Turchi, Laurent/0000-0003-2020-5831; Meneguzzi, Guerrino/0000-0002-1609-6540				Alani RM, 2001, P NATL ACAD SCI USA, V98, P7812, DOI 10.1073/pnas.141235398; Bagui TK, 2003, MOL CELL BIOL, V23, P7285, DOI 10.1128/MCB.23.20.7285-7290.2003; Benezra R, 2001, ONCOGENE, V20, P8288, DOI 10.1038/sj.onc.1205161; Blain SW, 1997, J BIOL CHEM, V272, P25863, DOI 10.1074/jbc.272.41.25863; Bloom J, 2003, SEMIN CANCER BIOL, V13, P41, DOI 10.1016/S1044-579X(02)00098-6; Busca R, 2005, J CELL BIOL, V170, P49, DOI 10.1083/jcb.200501067; Calderon M, 1996, J SURG RES, V61, P343, DOI 10.1006/jsre.1996.0127; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; Chraibi H, 2004, J Wound Care, V13, P447; Deed RW, 1997, MOL CELL BIOL, V17, P6815, DOI 10.1128/MCB.17.12.6815; Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-r60; Engel I, 2001, NAT REV IMMUNOL, V1, P193, DOI 10.1038/35105060; Everly DN, 2004, J VIROL, V78, P13470, DOI 10.1128/JVI.78.24.13470-13478.2004; Grana X, 1998, ONCOGENE, V17, P3365, DOI 10.1038/sj.onc.1202575; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; Kamura T, 2004, NAT CELL BIOL, V6, P1229, DOI 10.1038/ncb1194; Kee Y, 2005, GENE DEV, V19, P744, DOI 10.1101/gad.1257405; Kowanetz M, 2004, MOL CELL BIOL, V24, P4241, DOI 10.1128/MCB.24.10.4241-4254.2004; Kudo Y, 2005, ORAL ONCOL, V41, P105, DOI 10.1016/j.oraloncology.2004.05.003; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Lasorella A, 2000, NATURE, V407, P592, DOI 10.1038/35036504; Loots MAM, 1999, ARCH DERMATOL RES, V291, P93, DOI 10.1007/s004030050389; Lyden D, 1999, NATURE, V401, P670, DOI 10.1038/44334; Malek NP, 2001, NATURE, V413, P323, DOI 10.1038/35095083; Martin P, 1997, SCIENCE, V276, P75, DOI 10.1126/science.276.5309.75; Massari ME, 2000, MOL CELL BIOL, V20, P429, DOI 10.1128/MCB.20.2.429-440.2000; Minami S, 1997, FEBS LETT, V411, P1, DOI 10.1016/S0014-5793(97)00660-1; Montagnoli A, 1999, GENE DEV, V13, P1181, DOI 10.1101/gad.13.9.1181; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; Norton JD, 2000, J CELL SCI, V113, P3897; Ohtani N, 2001, NATURE, V409, P1067, DOI 10.1038/35059131; Okabe M, 2001, MODERN PATHOL, V14, P1008, DOI 10.1038/modpathol.3880426; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; Prabhu S, 1997, MOL CELL BIOL, V17, P5888, DOI 10.1128/MCB.17.10.5888; REZZONICO R, 1995, J BIOL CHEM, V270, P1261, DOI 10.1074/jbc.270.3.1261; RHEINWALD JG, 1975, CELL, V6, P331, DOI 10.1016/S0092-8674(75)80001-8; Roberts EC, 2001, MOL CELL BIOL, V21, P524, DOI 10.1128/MCB.21.2.524-533.2001; Sakakibara K, 2005, J BIOL CHEM, V280, P25470, DOI 10.1074/jbc.M502320200; Servant MJ, 2000, J CELL BIOL, V148, P543, DOI 10.1083/jcb.148.3.543; Sharma A, 1997, MOL ENDOCRINOL, V11, P1608, DOI 10.1210/me.11.11.1608; Sherr CJ, 2002, CELL CYCLE, V1, P36, DOI 10.4161/cc.1.1.106; SHERR CJ, 1995, TRENDS BIOCHEM SCI, V20, P187, DOI 10.1016/S0968-0004(00)89005-2; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Takahashi E, 2004, BIOCHEM BIOPH RES CO, V325, P1136, DOI 10.1016/j.bbrc.2004.10.148; Trausch-Azar JS, 2004, J BIOL CHEM, V279, P32614, DOI 10.1074/jbc.M403794200; Turchi L, 2002, J INVEST DERMATOL, V119, P56, DOI 10.1046/j.1523-1747.2002.01805.x; Yates PR, 1999, EMBO J, V18, P968, DOI 10.1093/emboj/18.4.968; Zheng WJ, 2004, J BIOL CHEM, V279, P31524, DOI 10.1074/jbc.M400365200	48	26	26	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2007	26	39					5772	5783		10.1038/sj.onc.1210386	http://dx.doi.org/10.1038/sj.onc.1210386			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	202EP	17404577				2022-12-28	WOS:000248885100009
J	Jiang, WQ; Zhong, ZH; Henson, JD; Reddel, RR				Jiang, W-Q; Zhong, Z-H; Henson, J. D.; Reddel, R. R.			Identification of candidate alternative lengthening of telomeres genes by methionine restriction and RNA interference	ONCOGENE			English	Article						telomeres; alternative lengthening of telomeres; ALT-associated PML bodies; PML; siRNA; methionine restriction	PROMYELOCYTIC LEUKEMIA BODIES; LARGE-BODY FORMATION; TUMOR-CELL-LINES; DNA-DAMAGE; MAMMALIAN-CELLS; METABOLIC DEFECT; PROTEIN COMPLEX; NUCLEAR-BODIES; CANCER-CELLS; HUMAN RAP1	Telomerase-negative cancer cells can maintain their telomeres by a recombination-mediated alternative lengthening of telomeres (ALT) process. We reported previously that sequestration of MRE11/RAD50/NBS1 complexes represses ALT-mediated telomere length maintenance, and suppresses formation of ALT-associated promyelocytic leukemia (PML) bodies (APBs). APBs are PML bodies containing telomeric DNA and telomere-binding proteins, and are observed only in a small fraction of cells within asynchronously dividing ALT-positive cell populations. Here, we report that methionine restriction caused a reversible arrest in G(0)/G(1) phase of the cell cycle and reversible induction of APB formation in most cells within an ALT-positive population. We combined methionine restriction with RNA interference to test whether the following proteins are required for APB formation: PML body-associated proteins, PML and Sp100; telomere-associated proteins, TRF1, TRF2, TIN2 and RAP1; and DNA repair proteins, MRE11, RAD50, NBS1 and 53BP1. APB formation was not decreased by depletion of Sp100 (as reported previously) or of 53BP1, although 53BP1 partially colocalizes with APBs. Depletion of the other proteins suppressed APB formation. Because of the close linkage between ALT-mediated telomere maintenance and ability to form APBs, the eight proteins identified by this screen as being required for APB formation are also likely to be required for the ALT mechanism. Oncogene	Childrens Med Res Inst, Canc Res Unit, Westmead, NSW 2145, Australia	Children's Medical Research Institute - Australia	Reddel, RR (corresponding author), Childrens Med Res Inst, Canc Res Unit, 214 Hawkesbury Rd, Westmead, NSW 2145, Australia.	rreddel@cmri.usyd.edu.au	Henson, Jeremy/ABD-3494-2021; Reddel, Roger R/A-6635-2014	Reddel, Roger R/0000-0002-6302-6107; Henson, Jeremy/0000-0002-1594-9310				Anderson L, 2001, MOL CELL BIOL, V21, P1719, DOI 10.1128/MCB.21.5.1719-1729.2001; Blow JJ, 2002, TRENDS CELL BIOL, V12, P72, DOI 10.1016/S0962-8924(01)02203-6; Brachner A, 2006, CANCER RES, V66, P3584, DOI 10.1158/0008-5472.CAN-05-2839; BRYAN TM, 1995, EMBO J, V14, P4240, DOI 10.1002/j.1460-2075.1995.tb00098.x; Bryan TM, 1997, NAT MED, V3, P1271, DOI 10.1038/nm1197-1271; Cerone MA, 2005, ONCOGENE, V24, P7893, DOI 10.1038/sj.onc.1208934; de Lange T, 2005, GENE DEV, V19, P2100, DOI 10.1101/gad.1346005; de Lange T, 2002, ONCOGENE, V21, P532, DOI 10.1038/sj.onc.1205080; Dunham MA, 2000, NAT GENET, V26, P447, DOI 10.1038/82586; Fasching CL, 2005, CANCER RES, V65, P2722, DOI 10.1158/0008-5472.CAN-04-2881; GERDES J, 1984, J IMMUNOL, V133, P1710; GERDES J, 1983, INT J CANCER, V31, P13, DOI 10.1002/ijc.2910310104; Goldberg M, 2003, NATURE, V421, P952, DOI 10.1038/nature01445; Gonzalo S, 2006, NAT CELL BIOL, V8, P416, DOI 10.1038/ncb1386; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; Grobelny JV, 2000, J CELL SCI, V113, P4577; HALPERN BC, 1974, P NATL ACAD SCI USA, V71, P1133, DOI 10.1073/pnas.71.4.1133; Henson JD, 2005, CLIN CANCER RES, V11, P217; Houghtaling BR, 2004, CURR BIOL, V14, P1621, DOI 10.1016/j.cub.2004.08.052; IWABUCHI K, 1994, P NATL ACAD SCI USA, V91, P6098, DOI 10.1073/pnas.91.13.6098; Jiang WQ, 2005, MOL CELL BIOL, V25, P2708, DOI 10.1128/MCB.25.7.2708-2721.2005; Johnson FB, 2001, EMBO J, V20, P905, DOI 10.1093/emboj/20.4.905; JUDDE JG, 1989, CANCER RES, V49, P4859; Kamei H, 1996, EXP CELL RES, V224, P302, DOI 10.1006/excr.1996.0140; Kamei H, 1997, EXP CELL RES, V237, P207, DOI 10.1006/excr.1997.3790; Karlseder J, 1999, SCIENCE, V283, P1321, DOI 10.1126/science.283.5406.1321; Kim S, 2004, J BIOL CHEM, V279, P43799, DOI 10.1074/jbc.M408650200; Lei M, 2001, J CELL SCI, V114, P1447; Li BB, 2000, CELL, V101, P471, DOI 10.1016/S0092-8674(00)80858-2; Li BB, 2003, MOL BIOL CELL, V14, P5060, DOI 10.1091/mbc.e03-06-0403; Lu S, 2000, NUTR CANCER, V38, P123, DOI 10.1207/S15327914NC381_17; Marciniak RA, 2005, CANCER RES, V65, P2730, DOI 10.1158/0008-5472.CAN-04-2888; MECHAM JO, 1983, BIOCHEM BIOPH RES CO, V117, P429, DOI 10.1016/0006-291X(83)91218-4; Molenaar C, 2003, EMBO J, V22, P6631, DOI 10.1093/emboj/cdg633; Moran-Jones K, 2005, NUCLEIC ACIDS RES, V33, P486, DOI 10.1093/nar/gki203; MURNANE JP, 1994, EMBO J, V13, P4953, DOI 10.1002/j.1460-2075.1994.tb06822.x; Nabetani A, 2004, J BIOL CHEM, V279, P25849, DOI 10.1074/jbc.M312652200; O'Connor MS, 2004, J BIOL CHEM, V279, P28585, DOI 10.1074/jbc.M312913200; Pavillard V, 2004, BIOCHEM PHARMACOL, V67, P1587, DOI 10.1016/j.bcp.2004.01.006; Perrem K, 2001, MOL CELL BIOL, V21, P3862, DOI 10.1128/MCB.21.12.3862-3875.2001; Rappold I, 2001, J CELL BIOL, V153, P613, DOI 10.1083/jcb.153.3.613; ROGAN EM, 1995, MOL CELL BIOL, V15, P4745; Schultz LB, 2000, J CELL BIOL, V151, P1381, DOI 10.1083/jcb.151.7.1381; Silverman J, 2004, GENE DEV, V18, P2108, DOI 10.1101/gad.1216004; SMYTH CM, 1993, PATHOLOGY, V25, P388, DOI 10.3109/00313029309090865; Stavropoulos DJ, 2002, HUM MOL GENET, V11, P3135, DOI 10.1093/hmg/11.25.3135; STERN PH, 1986, J NATL CANCER I, V76, P629, DOI 10.1093/jnci/76.4.629; STERN PH, 1984, IN VITRO CELL DEV B, V20, P663; Takai H, 2003, CURR BIOL, V13, P1549, DOI 10.1016/S0960-9822(03)00542-6; Tarsounas M, 2004, CELL, V117, P337, DOI 10.1016/S0092-8674(04)00337-X; TISDALE MJ, 1980, BRIT J CANCER, V42, P121, DOI 10.1038/bjc.1980.210; Toouli CD, 2002, ONCOGENE, V21, P128, DOI 10.1038/sj.onc.1205014; van Steensel B, 1998, CELL, V92, P401, DOI 10.1016/S0092-8674(00)80932-0; vanSteensel B, 1997, NATURE, V385, P740, DOI 10.1038/385740a0; Wang RC, 2004, CELL, V119, P355, DOI 10.1016/j.cell.2004.10.011; Wu GK, 2000, J BIOL CHEM, V275, P30618, DOI 10.1074/jbc.C000390200; Wu GK, 2003, CANCER RES, V63, P2589; Xu LF, 2004, J CELL BIOL, V167, P819, DOI 10.1083/jcb.200408181; Xu ZX, 2003, MOL CELL BIOL, V23, P4247, DOI 10.1128/MCB.23.12.4247-4256.2003; Yankiwski V, 2000, P NATL ACAD SCI USA, V97, P5214, DOI 10.1073/pnas.090525897; Ye JZS, 2004, J BIOL CHEM, V279, P47264, DOI 10.1074/jbc.M409047200; Ye JZS, 2004, NAT GENET, V36, P618, DOI 10.1038/ng1360; Yeager TR, 1999, CANCER RES, V59, P4175; Zhu XD, 2000, NAT GENET, V25, P347, DOI 10.1038/77139; Zhu XD, 2003, MOL CELL, V12, P1489, DOI 10.1016/S1097-2765(03)00478-7	65	86	96	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 12	2007	26	32					4635	4647		10.1038/sj.onc.1210260	http://dx.doi.org/10.1038/sj.onc.1210260			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	190DJ	17297460				2022-12-28	WOS:000248037900004
J	Miller, SL; Antico, G; Raghunath, PN; Tomaszewski, JE; Clevenger, CV				Miller, S. L.; Antico, G.; Raghunath, P. N.; Tomaszewski, J. E.; Clevenger, C. V.			Nek3 kinase regulates prolactin-mediated cytoskeletal reorganization and motility of breast cancer cells	ONCOGENE			English	Article						prolactin; breast neoplasms; invasion; Vav2; Rac; paxillin	FOCAL ADHESION KINASE; RHO-GTPASES; BINDING PROTEIN; V-SRC; PAXILLIN; GROWTH; ACTIN; VAV2; ACTIVATION; CDC42	Prolactin (PRL) stimulates the cytoskeletal re-organization and motility of breast cancer cells. During PRL receptor signaling, Vav2 becomes phosphorylated and activated, an event regulated by the serine/ threonine kinase Nek3. Given the regulatory role of Vav2, the function of Nek3 in PRL-mediated motility and invasion was examined. Overexpression of Nek3 in Chinese hamster ovary transfectants potentiated cytoskeletal re-organization in response to PRL. In contrast, downregulation of Nek3 expression by small-interfering RNA (siRNA) attenuated PRL-mediated cytoskeletal reorganization, activation of GTPase Rac1, cell migration and invasion of T47D cells. In addition, PRL stimulation induced an interaction between Nek3 and paxillin and significantly increased paxillin serine phosphorylation, whereas Nek3 siRNA-transfected cells showed a marked reduction in paxillin phosphorylation. Analysis of breast tissue microarrays also demonstrated a significant up-regulation of Nek3 expression in malignant versus normal specimens. These data suggest that Nek3 contributes to PRL-mediated breast cancer motility through mechanisms involving Rac1 activation and paxillin phosphorylation.	Northwestern Univ, Dept Pathol, Chicago, IL 60611 USA; Mem Sloan Kettering Canc Ctr, Dept Mol Pharmacol & Chem, New York, NY 10021 USA; Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA	Northwestern University; Memorial Sloan Kettering Cancer Center; University of Pennsylvania	Clevenger, CV (corresponding author), Northwestern Univ, Dept Pathol, Lurie 4-107,303 E Super St, Chicago, IL 60611 USA.	clevenger@northwestern.edu			NATIONAL CANCER INSTITUTE [R01CA069294, R01CA092265] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA69294, R01CA92265] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abe K, 2000, J BIOL CHEM, V275, P10141, DOI 10.1074/jbc.275.14.10141; Acosta JJ, 2003, MOL ENDOCRINOL, V17, P2268, DOI 10.1210/me.2002-0422; Beningo KA, 2001, J CELL BIOL, V153, P881, DOI 10.1083/jcb.153.4.881; BHATAVDEKAR JM, 1990, CANCER, V65, P2028, DOI 10.1002/1097-0142(19900501)65:9&lt;2028::AID-CNCR2820650924&gt;3.0.CO;2-9; Bouzahzah B, 2001, MOL MED, V7, P816, DOI 10.1007/BF03401974; Brakebusch C, 2003, EMBO J, V22, P2324, DOI 10.1093/emboj/cdg245; Brockman JL, 2002, MOL ENDOCRINOL, V16, P774, DOI 10.1210/me.16.4.774; Brown MC, 2004, PHYSIOL REV, V84, P1315, DOI 10.1152/physrev.00002.2004; BURBELO PD, 1995, J BIOL CHEM, V270, P29071, DOI 10.1074/jbc.270.49.29071; Canbay E, 1997, BIOCHEM J, V324, P231, DOI 10.1042/bj3240231; CLEVENGER CV, 1990, P NATL ACAD SCI USA, V87, P6460, DOI 10.1073/pnas.87.16.6460; Clevenger CV, 2003, ENDOCR REV, V24, P1, DOI 10.1210/er.2001-0036; de Oca PM, 2005, LAB INVEST, V85, P633, DOI 10.1038/labinvest.3700256; del Pozo MA, 2000, EMBO J, V19, P2008, DOI 10.1093/emboj/19.9.2008; DeMali KA, 2003, CURR OPIN CELL BIOL, V15, P572, DOI 10.1016/S0955-0674(03)00109-1; FINCHAM VJ, 1995, ONCOGENE, V10, P2247; Fritz G, 1999, INT J CANCER, V81, P682, DOI 10.1002/(SICI)1097-0215(19990531)81:5<682::AID-IJC2>3.0.CO;2-B; Gao J, 1999, CELL SIGNAL, V11, P205, DOI 10.1016/S0898-6568(98)00067-9; Gordon LA, 2003, INT J CANCER, V106, P8, DOI 10.1002/ijc.11172; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HOLTKAMP W, 1984, INT J CANCER, V34, P323, DOI 10.1002/ijc.2910340307; HOWARD TH, 1985, CELL MOTIL CYTOSKEL, V5, P545, DOI 10.1002/cm.970050609; Huang C, 2003, NATURE, V424, P219, DOI 10.1038/nature01745; ILLC D, 1995, NATURE, V377, P539; INOUE T, 1993, J CELL PHYSIOL, V156, P212, DOI 10.1002/jcp.1041560128; Kline JB, 2001, MOL ENDOCRINOL, V15, P832, DOI 10.1210/me.15.5.832; Kondo A, 2000, MOL BIOL CELL, V11, P1315, DOI 10.1091/mbc.11.4.1315; LISSONI P, 1995, ONCOLOGY, V52, P439; Liu BP, 2000, MOL CELL BIOL, V20, P7160, DOI 10.1128/MCB.20.19.7160-7169.2000; Marignani PA, 2001, J CELL BIOL, V154, P177, DOI 10.1083/jcb.200103134; Maus MV, 1999, ENDOCRINOLOGY, V140, P5447, DOI 10.1210/en.140.11.5447; Miller SL, 2005, MOL ENDOCRINOL, V19, P939, DOI 10.1210/me.2004-0443; NAWROCKI RB, 2001, INT J CANCER, V93, P644; Raftopoulou M, 2004, DEV BIOL, V265, P23, DOI 10.1016/j.ydbio.2003.06.003; Ren XD, 2000, J CELL SCI, V113, P3673; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; Roy S, 2002, J CELL BIOCHEM, V84, P377, DOI 10.1002/jcb.10025; Rycyzyn MA, 2002, P NATL ACAD SCI USA, V99, P6790, DOI 10.1073/pnas.092160699; Sahai E, 2002, NAT REV CANCER, V2, P133, DOI 10.1038/nrc725; Salcedo R, 2000, BLOOD, V96, P34, DOI 10.1182/blood.V96.1.34.013a49_34_40; Salcedo R, 2002, CLIN CANCER RES, V8, P2655; Schmitz AAP, 2000, EXP CELL RES, V261, P1, DOI 10.1006/excr.2000.5049; Schuebel KE, 1998, EMBO J, V17, P6608, DOI 10.1093/emboj/17.22.6608; SCHUPP G, 1996, COMPRAIL 96 COMPUTER, V2, P13; Tanaka K, 1999, J BIOL CHEM, V274, P13491, DOI 10.1074/jbc.274.19.13491; Turner CE, 1999, J CELL BIOL, V145, P851, DOI 10.1083/jcb.145.4.851; TURNER CE, 1994, J CELL SCI, V107, P1583; Yoneda T, 1997, J CLIN INVEST, V99, P2509, DOI 10.1172/JCI119435	48	58	62	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 12	2007	26	32					4668	4678		10.1038/sj.onc.1210264	http://dx.doi.org/10.1038/sj.onc.1210264			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	190DJ	17297458				2022-12-28	WOS:000248037900007
J	Yan, Y; Black, CP; Cowan, KH				Yan, Y.; Black, C. P.; Cowan, K. H.			Irradiation-induced G2/M checkpoint response requires ERK1/2 activation	ONCOGENE			English	Article						ATM/ATR; Cdc2; Cdc25A/C; Chk1; ERK1/2; irradiation and wee1	DNA-DAMAGE CHECKPOINT; CELL-CYCLE ARREST; 14-3-3 PROTEIN-BINDING; IONIZING-RADIATION; TYROSINE PHOSPHORYLATION; CDC25 PHOSPHATASES; S-PHASE; KINASE; CHK1; ATR	Following DNA damage, cells undergo G2/M cell cycle arrest, allowing time for DNA repair. G2/M checkpoint activation involves activation of Wee1 and Chk1 kinases and inhibition of Cdc25A and Cdc25C phosphatases, which results in inhibition of Cdc2 kinase. Results presented in this report indicate that gamma-irradiation (IR) exposure of MCF-7 cells resulted in extracellular signal regulated protein kinase 1 and 2 (ERK1/2) activation and induction of G2/M arrest. Furthermore, inhibition of ERK1/2 signaling resulted in >= 85% attenuation in IR-induced G2/M arrest and concomitant diminution of IR-induced activation of ataxia telangiectasia mutated-and rad3-related (ATR), Chk1 and Wee1 kinases as well as phosphorylation of Cdc25A-Thr506, Cdc25C-Ser216 and Cdc2-Tyr15. Moreover, incubation of cells with caffeine, which inhibits ataxia telangiectasia mutated (ATM)/ATR, or transfection of cells with short interfering RNA targeting ATR abrogated IR-induced Chk1 phosphorylation and G2/M arrest but had no effect on IR-induced ERK1/2 activation. In contrast, inhibition of ERK1/2 signaling resulted in marked attenuation in IR-induced ATR activity with little, if any, effect on IR-induced ATM activation. These results implicate IR-induced ERK1/2 activation as an important regulator of G2/M checkpoint response to IR in MCF-7 cells.	Univ Nebraska, Med Ctr, Eppley Inst Res Canc & Allied Dis, Omaha, NE 68198 USA	University of Nebraska System; University of Nebraska Medical Center	Cowan, KH (corresponding author), Univ Nebraska, Med Ctr, Eppley Inst Res Canc & Allied Dis, 986805 Nebraska Med Ctr,ECI 6010, Omaha, NE 68198 USA.	kcowan@unmc.edu						Abbott DW, 1999, J BIOL CHEM, V274, P2732, DOI 10.1074/jbc.274.5.2732; Ahn JY, 2000, CANCER RES, V60, P5934; Bulavin DV, 2003, NAT CELL BIOL, V5, P545, DOI 10.1038/ncb994; Chen MS, 2003, MOL CELL BIOL, V23, P7488, DOI 10.1128/MCB.23.21.7488-7497.2003; Chen YH, 2004, DNA REPAIR, V3, P1025, DOI 10.1016/j.dnarep.2004.03.003; Cui W, 2000, MOL CARCINOGEN, V29, P219, DOI 10.1002/1098-2744(200012)29:4<219::AID-MC1004>3.0.CO;2-D; Dart DA, 2004, J BIOL CHEM, V279, P16433, DOI 10.1074/jbc.M314212200; Dent P, 2003, ONCOGENE, V22, P5885, DOI 10.1038/sj.onc.1206701; Graves PR, 2001, ONCOGENE, V20, P1839, DOI 10.1038/sj.onc.1204259; Iliakis G, 2003, ONCOGENE, V22, P5834, DOI 10.1038/sj.onc.1206682; KHARBANDA S, 1994, CANCER RES, V54, P1412; Koundrioukoff S, 2004, DNA REPAIR, V3, P969, DOI 10.1016/j.dnarep.2004.03.010; Kristjansdottir K, 2004, CHEM BIOL, V11, P1043, DOI 10.1016/j.chembiol.2004.07.007; LUNDGREN K, 1991, CELL, V64, P1111, DOI 10.1016/0092-8674(91)90266-2; Matsuoka S, 2000, P NATL ACAD SCI USA, V97, P10389, DOI 10.1073/pnas.190030497; Nagasawa H, 1998, CANCER RES, V58, P2036; O'Connell MJ, 2005, J CELL SCI, V118, P1, DOI 10.1242/jcs.01626; OConnell MJ, 1997, EMBO J, V16, P545, DOI 10.1093/emboj/16.3.545; PARKER LL, 1992, P NATL ACAD SCI USA, V89, P2917, DOI 10.1073/pnas.89.7.2917; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; Rhind N, 1997, GENE DEV, V11, P504, DOI 10.1101/gad.11.4.504; Sarkaria JN, 1999, CANCER RES, V59, P4375; Smits VAJ, 2001, BBA-GENE STRUCT EXPR, V1519, P1, DOI 10.1016/S0167-4781(01)00204-4; Stewart GS, 1999, CELL, V99, P577, DOI 10.1016/S0092-8674(00)81547-0; Tang DM, 2002, J BIOL CHEM, V277, P12710, DOI 10.1074/jbc.M111598200; Wang XF, 2000, MOL CELL BIOL, V20, P4543, DOI 10.1128/MCB.20.13.4543-4552.2000; Ward I, 2004, CURR TOP DEV BIOL, V63, P1, DOI 10.1016/S0070-2153(04)63001-8; Wellbrock C, 2002, J BIOL CHEM, V277, P6443, DOI 10.1074/jbc.M110684200; Xu B, 2001, MOL CELL BIOL, V21, P3445, DOI 10.1128/MCB.21.10.3445-3450.2001; Xu Bo, 2004, Methods Mol Biol, V281, P283; Yan Y, 2005, ONCOGENE, V24, P3285, DOI 10.1038/sj.onc.1208492; Yan Y, 2002, J BIOL CHEM, V277, P33422, DOI 10.1074/jbc.M201147200; Zhao H, 2002, P NATL ACAD SCI USA, V99, P14795, DOI 10.1073/pnas.182557299; Zhao H, 2001, MOL CELL BIOL, V21, P4129, DOI 10.1128/MCB.21.13.4129-4139.2001	34	81	85	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 12	2007	26	32					4689	4698		10.1038/sj.onc.1210268	http://dx.doi.org/10.1038/sj.onc.1210268			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	190DJ	17297454				2022-12-28	WOS:000248037900009
J	Staub, J; Chien, J; Pan, Y; Qian, X; Narita, K; Aletti, G; Scheerer, M; Roberts, LR; Molina, J; Shridhar, V				Staub, J.; Chien, J.; Pan, Y.; Qian, X.; Narita, K.; Aletti, G.; Scheerer, M.; Roberts, L. R.; Molina, J.; Shridhar, V.			Epigenetic silencing of HSulf-1 in ovarian cancer: implications in chemoresistance	ONCOGENE			English	Article						methylation; histone modification; tumor suppressor; chemoresponse; apoptosis	HISTONE-DEACETYLASE INHIBITORS; H3 LYSINE-9 METHYLATION; IN-VIVO; CHROMATIN IMMUNOPRECIPITATION; TUMOR-GROWTH; CPG ISLANDS; GENE; HYPERMETHYLATION; CHEMOTHERAPY; CARCINOMA	To investigate the mechanism by which HSulf-1 expression is downregulated in ovarian cancer, DNA methylation and histone acetylation of HSulf-1 was analysed in ovarian cancer cell lines and primary tumors. Treatment of OV207 and SKOV3 by 5-aza-2'-deoxycytidine resulted in increased transcription of HSulf-1. Sequence analysis of bisulfi. te-modi. ed genomic DNA from ovarian cell lines and primary tumors without HSulf-1 expression revealed an increase in the frequency of methylation of 12 CpG sites in exon 1A. Chromatin immunoprecipitation assays showed an increase in histone H3 methylation in cell lines without HSulf-1 expression. To assess the signi. cance of HSulf-1 downregulation in ovarian cancer, OV167 and OV202 cells were transfected with HS ulf-1 siRNA. Downregulation of HSulf-1 expression in OV167 and OV202 cells lead to an attenuation of cisplatin-induced cytotoxicity. Moreover, patients with ovari an tumors expressing higher levels of HSulf-1 showed a 90% response rate (27/30) to chemotherapy compared to a response rate of 63% (19/30) in those with weak or moderate levels (P = 0.0146, chi(2) test). Collectively, these data indicate that HSulf-1 is epigenetically silenced in ovarian cancer and that epigenetic therapy targeting HSulf-1 might sensitize ovarian tumors to conventional. first-line therapies.	Mayo Coll Med, Div Expt Pathol, Dept Lab Med & Pathol, Rochester, MN 55905 USA; Mayo Clin, Coll Med, Div Med Oncol, Dept Oncol, Rochester, MN USA; Mayo Clin, Coll Med, Dept Med, Div Gastroenterol & Hepatol, Rochester, MN USA	Mayo Clinic; Mayo Clinic; Mayo Clinic	Shridhar, V (corresponding author), Mayo Coll Med, Div Expt Pathol, Dept Lab Med & Pathol, 200 1st St SW,2-46 Stabile, Rochester, MN 55905 USA.	shridhar.vijayalakshmi@mayo.edu	Seal, Sudipta/A-7698-2012; Aletti, Giovanni/AAM-9781-2020; Narita, Keishi/E-3539-2010; Chien, Jeremy/AID-8939-2022	Narita, Keishi/0000-0002-7602-8523; Roberts, Lewis/0000-0001-7885-8574; Aletti, Giovanni/0000-0003-4602-5601; Chien, Jeremy/0000-0003-4744-8374	NCI NIH HHS [CA106954-02] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA106954] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Batch C, 2004, AM J OBSTET GYNECOL, V191, P1552, DOI 10.1016/j.agoj.2004.05.025; Blagosklonny MV, 2002, MOL CANCER THER, V1, P937; Chadee DN, 1999, J BIOL CHEM, V274, P24914, DOI 10.1074/jbc.274.35.24914; Chien J, 2006, J CLIN INVEST, V116, P1994, DOI 10.1172/JCI27698; Conover CA, 1998, EXP CELL RES, V238, P439, DOI 10.1006/excr.1997.3861; CROSS SH, 1994, NAT GENET, V6, P236, DOI 10.1038/ng0394-236; Dai YM, 2005, J BIOL CHEM, V280, P40066, DOI 10.1074/jbc.M508136200; Douglas DB, 2004, CANCER RES, V64, P1611, DOI 10.1158/0008-5472.CAN-0318-2; Esteller M, 2002, J NATL CANCER I, V94, P26; Fujii S, 2003, HUM MOL GENET, V12, P1791, DOI 10.1093/hmg/ddg204; Galm O, 2002, GENOME RES, V12, P153, DOI 10.1101/gr.202501; Gifford G, 2004, CLIN CANCER RES, V10, P4420, DOI 10.1158/1078-0432.CCR-03-0732; Gius D, 2004, CANCER CELL, V6, P361, DOI 10.1016/j.ccr.2004.08.029; Greenlee RT, 2001, CA-CANCER J CLIN, V51, P15, DOI 10.3322/canjclin.51.1.15; Han JW, 2000, CANCER RES, V60, P6068; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Johnstone RW, 2002, NAT REV DRUG DISCOV, V1, P287, DOI 10.1038/nrd772; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Katsaros D, 2004, GYNECOL ONCOL, V94, P685, DOI 10.1016/j.ygyno.2004.06.018; Kondo Y, 2004, P NATL ACAD SCI USA, V101, P7398, DOI 10.1073/pnas.0306641101; Kopelovich L, 2003, JNCI-J NATL CANCER I, V95, P1747, DOI 10.1093/jnci/dig109; Lai JP, 2006, GASTROENTEROLOGY, V130, P2130, DOI 10.1053/j.gastro.2006.02.056; Lai JP, 2004, ONCOGENE, V23, P1439, DOI 10.1038/sj.onc.1207258; Lai JP, 2004, GASTROENTEROLOGY, V126, P231, DOI 10.1053/j.gastro.2003.09.043; Lai JP, 2003, J BIOL CHEM, V278, P23107, DOI 10.1074/jbc.M302203200; LaVoie HA, 2005, MOL CELL ENDOCRINOL, V243, P12, DOI 10.1016/j.mce.2005.09.005; Makarla PB, 2005, CLIN CANCER RES, V11, P5365, DOI 10.1158/1078-0432.CCR-04-2455; Marks PA, 2001, CURR OPIN ONCOL, V13, P477, DOI 10.1097/00001622-200111000-00010; Narita K, 2006, CANCER RES, V66, P6025, DOI 10.1158/0008-5472.CAN-05-3582; Nguyen CT, 2001, NUCLEIC ACIDS RES, V29, P4598, DOI 10.1093/nar/29.22.4598; Orlando V, 2000, TRENDS BIOCHEM SCI, V25, P99, DOI 10.1016/S0968-0004(99)01535-2; Overbergh L, 1999, CYTOKINE, V11, P305, DOI 10.1006/cyto.1998.0426; Plumb JA, 2000, CANCER RES, V60, P6039; Qian X, 2004, DIAGN MOL PATHOL, V13, P9, DOI 10.1097/00019606-200403000-00002; Seidl S, 2004, CANCER-AM CANCER SOC, V100, P2598, DOI 10.1002/cncr.20295; Shridhar V, 2001, CANCER RES, V61, P4258; Strathdee G, 2005, GYNECOL ONCOL, V97, P898, DOI 10.1016/j.ygyno.2005.03.023; Terasawa K, 2004, CLIN CANCER RES, V10, P2000, DOI 10.1158/1078-0432.CCR-0932-03; Xing MZ, 2004, CANCER RES, V64, P1664, DOI 10.1158/0008-5472.CAN-03-3242; Yamashita K, 2002, CANCER CELL, V2, P485, DOI 10.1016/S1535-6108(02)00215-5; Yang QW, 2003, CANCER RES, V63, P6299; Yoon JH, 2001, INT J CANCER, V94, P212, DOI 10.1002/ijc.1466	43	89	95	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2007	26	34					4969	4978		10.1038/sj.onc.1210300	http://dx.doi.org/10.1038/sj.onc.1210300			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	194CV	17310998	Green Published			2022-12-28	WOS:000248322500009
J	Allende-Vega, N; Saville, MK; Meek, DW				Allende-Vega, N.; Saville, M. K.; Meek, D. W.			Transcription factor TAFII250 promotes Mdm2-dependent turnover of p53	ONCOGENE			English	Article						p53; Mdm2; TAFII250; transcription factor; ubiquitylation	IN-VIVO; ACIDIC DOMAIN; BINDING-SITE; DNA-DAMAGE; CELL-LINE; MDM2; TAF(II)250; PHOSPHORYLATION; UBIQUITINATION; PROTEIN	The p53 tumour suppressor is regulated mainly by Mdm2, an E3 ubiquitin ligase that promotes the ubiquitylation and proteasome-mediated degradation of p53. Many agents that induce p53 are inhibitors of transcription, suggesting that the p53 pathway can detect a signal(s) arising from transcriptional malfunction. Mdm2 associates with TAFII250, a component of the general transcription factor TFIID. Inactivation of TAFII250 in ts13 cells, which express a temperature-sensitive mutant of TAFII250, leads to the induction of p53 and cell cycle arrest. In the present study, we show that TAFII250 stimulates the ubiquitylation and degradation of p53 in a manner that is dependent upon Mdm2 and requires its acidic domain. Mechanistically, TAFII250 downregulates Mdm2 auto-ubiquitylation, leading to Mdm2 stabilization, and promotes p53-Mdm2 association through a recently defined second binding site in the acidic domain of Mdm2. These data provide a novel route through which TAFII250 can directly influence p53 levels and are consistent with the idea that the maintenance of p53 turnover is coupled to the integrity of RNA polymerase II transcription.	Univ Dundee, Ninewells Hosp & Med Sch, Biomed Res Ctr, Dundee DD1 9SY, Scotland; Univ Dundee, Ninewells Hosp & Med Sch, Div Surg & Mol Oncol, Dundee DD1 9SY, Scotland	University of Dundee; University of Dundee	Meek, DW (corresponding author), Univ Dundee, Ninewells Hosp & Med Sch, Biomed Res Ctr, Dundee DD1 9SY, Scotland.	david.meek@cancer.org.uk		Allende-Vega, Nerea/0000-0001-5569-6461	Cancer Research UK [A6613] Funding Source: Medline	Cancer Research UK(Cancer Research UK)		Argentini M, 2001, ONCOGENE, V20, P1267, DOI 10.1038/sj.onc.1204241; Ashcroft M, 2000, MOL CELL BIOL, V20, P3224, DOI 10.1128/MCB.20.9.3224-3233.2000; Blattner C, 2002, MOL CELL BIOL, V22, P6170, DOI 10.1128/MCB.22.17.6170-6182.2002; Bottger A, 1997, CURR BIOL, V7, P860, DOI 10.1016/S0960-9822(06)00374-5; Buchmann AM, 2004, MOL CELL BIOL, V24, P5332, DOI 10.1128/MCB.24.12.5332-5339.2004; Dumaz N, 1999, EMBO J, V18, P7002, DOI 10.1093/emboj/18.24.7002; Fang SY, 2000, J BIOL CHEM, V275, P8945, DOI 10.1074/jbc.275.12.8945; Feng JH, 2004, J BIOL CHEM, V279, P35510, DOI 10.1074/jbc.M404936200; Ganguli G, 2003, MOL CANCER RES, V1, P1027; Gronroos E, 2004, P NATL ACAD SCI USA, V101, P12165, DOI 10.1073/pnas.0402283101; Honda R, 2000, ONCOGENE, V19, P1473, DOI 10.1038/sj.onc.1203464; Kawai H, 2003, MOL CELL BIOL, V23, P4939, DOI 10.1128/MCB.23.14.4939-4947.2003; Kulikov R, 2006, J BIOL CHEM, V281, P28575, DOI 10.1074/jbc.M513311200; Leveillard T, 1997, J BIOL CHEM, V272, P30651, DOI 10.1074/jbc.272.49.30651; Li HH, 2004, MOL CELL, V13, P867, DOI 10.1016/S1097-2765(04)00123-6; Ljungman M, 2004, NAT REV CANCER, V4, P727, DOI 10.1038/nrc1435; Meulmeester E, 2003, MOL CELL BIOL, V23, P4929, DOI 10.1128/MCB.23.14.4929-4938.2003; Michael D, 2003, SEMIN CANCER BIOL, V13, P49, DOI 10.1016/S1044-579X(02)00099-8; Midgley CA, 2000, ONCOGENE, V19, P2312, DOI 10.1038/sj.onc.1203593; O'Brien T, 2000, P NATL ACAD SCI USA, V97, P2456, DOI 10.1073/pnas.97.6.2456; Saville MK, 2004, J BIOL CHEM, V279, P42169, DOI 10.1074/jbc.M403362200; SEKIGUCHI T, 1988, EMBO J, V7, P1683, DOI 10.1002/j.1460-2075.1988.tb02996.x; Shimizu H, 2002, J BIOL CHEM, V277, P28446, DOI 10.1074/jbc.M202296200; Sui GC, 2004, CELL, V117, P859, DOI 10.1016/j.cell.2004.06.004; SuzukiYagawa Y, 1997, MOL CELL BIOL, V17, P3284, DOI 10.1128/MCB.17.6.3284; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Wallace M, 2006, MOL CELL, V23, P251, DOI 10.1016/j.molcel.2006.05.029; Wassarman DA, 2001, J CELL SCI, V114, P2895; Wasylyk C, 2000, MOL CELL BIOL, V20, P5554, DOI 10.1128/MCB.20.15.5554-5570.2000; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; Xirodimas D, 2001, ONCOGENE, V20, P4972, DOI 10.1038/sj.onc.1204656; Yee KS, 2005, CARCINOGENESIS, V26, P1317, DOI 10.1093/carcin/bgi122; Yu GW, 2006, P NATL ACAD SCI USA, V103, P1227, DOI 10.1073/pnas.0510343103; Zhu Y, 2001, Respir Res, V2, P300, DOI 10.1186/rr73	34	19	19	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 21	2007	26	29					4234	4242		10.1038/sj.onc.1210209	http://dx.doi.org/10.1038/sj.onc.1210209			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	184CY	17237821	Green Accepted			2022-12-28	WOS:000247619900006
J	Moschos, SJ; Smith, AP; Mandic, M; Athanassiou, C; Watson-Hurst, K; Jukic, DM; Edington, HD; Kirkwood, JM; Becker, D				Moschos, S. J.; Smith, A. P.; Mandic, M.; Athanassiou, C.; Watson-Hurst, K.; Jukic, D. M.; Edington, H. D.; Kirkwood, J. M.; Becker, D.			SAGE and antibody array analysis of melanoma-infiltrated lymph nodes: identification of Ubc9 as an important molecule in advanced-stage melanomas	ONCOGENE			English	Article						melanoma; molecular profiling; Ubc9; apoptosis; chemotherapy	UBIQUITIN-CONJUGATING ENZYME; TUMOR-SUPPRESSOR; HUMAN HOMOLOG; EXPRESSION; PROTEIN; GROWTH; GENE; NORMALIZATION; ASSOCIATION; SUMOYLATION	Although patients diagnosed with melanoma of <= 1.00mm thickness have a relatively good cure rate, the prognosis for patients with locally advanced and metastatic melanoma is grave. The discovery of new and effective therapies for this disease depends in large part on molecular studies that will resolve why advanced-stage melanoma is refractory to conventional chemotherapy and radiation therapy. To identify genes that have important functions in advanced-stage melanomas, in particular, in melanoma-infiltrated lymph nodes, which are not well characterized at the molecular level, we generated a LongSAGE library from a melanoma-positive lymph node, and subjected melanoma-infiltrated lymph nodes to protein expression profiling. The data document that the molecular signature of melanoma, which has spread to regional lymph nodes, is very similar to the molecular signature of primary melanomas. Equally important, we provide evidence that the ubiquitin-conjugating enzyme, Ubc9, is expressed at high levels in melanoma-positive lymph nodes, and that it plays a crucial role in preventing advanced-stage melanomas from undergoing chemotherapy-induced apoptosis.	Univ Pittsburgh, Dept Pathol, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Dept Med, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Dept Dermatol, Pittsburgh, PA 15213 USA; Automated Cell Inc, Pittsburgh, PA USA; Univ Pittsburgh, Dept Surg, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Becker, D (corresponding author), Univ Pittsburgh, Dept Pathol, HCC Res Pavil,Suite 1 46A,5117 Ctr Ave, Pittsburgh, PA 15213 USA.	dbecker@pitt.edu			NCATS NIH HHS [UL1 TR000005] Funding Source: Medline; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000005] Funding Source: NIH RePORTER	NCATS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS))		Balch CM, 2004, CA-CANCER J CLIN, V54, P131, DOI 10.3322/canjclin.54.3.131; Balch CM, 2000, CANCER-AM CANCER SOC, V88, P1484, DOI 10.1002/(SICI)1097-0142(20000315)88:6<1484::AID-CNCR29>3.0.CO;2-D; BECKER D, 1989, EMBO J, V8, P3685, DOI 10.1002/j.1460-2075.1989.tb08543.x; Bolstad BM, 2003, BIOINFORMATICS, V19, P185, DOI 10.1093/bioinformatics/19.2.185; Edwards D, 2003, BIOINFORMATICS, V19, P825, DOI 10.1093/bioinformatics/btg083; Hayashi T, 2002, EXP CELL RES, V280, P212, DOI 10.1006/excr.2002.5634; Herlyn M, 2006, INT J CANCER, V118, P523, DOI 10.1002/ijc.21605; HERLYN M, 1987, CANCER RES, V47, P3057; Hoege C, 2002, NATURE, V419, P135, DOI 10.1038/nature00991; Johnson EW, 1997, J BACK MUSCULOSKELET, V9, P3, DOI 10.3233/BMR-1997-9102; Kovalenko OV, 1996, P NATL ACAD SCI USA, V93, P2958, DOI 10.1073/pnas.93.7.2958; Lin JY, 2004, FEBS LETT, V573, P15, DOI 10.1016/j.febslet.2004.07.059; Lin X, 2003, J BIOL CHEM, V278, P31043, DOI 10.1074/jbc.C300112200; McDonald SL, 2004, CANCER BIOL THER, V3, P110, DOI 10.4161/cbt.3.1.662; Mo YY, 2005, ONCOGENE, V24, P2677, DOI 10.1038/sj.onc.1208210; Mo YY, 2004, CANCER RES, V64, P2793, DOI 10.1158/0008-5472.CAN-03-2410; Nacerddine K, 2005, DEV CELL, V9, P769, DOI 10.1016/j.devcel.2005.10.007; Perlis C, 2004, ONCOLOGIST, V9, P182, DOI 10.1634/theoncologist.9-2-182; Premont RT, 1998, P NATL ACAD SCI USA, V95, P14082, DOI 10.1073/pnas.95.24.14082; Rizos H, 2005, CELL CYCLE, V4, P597, DOI 10.4161/cc.4.4.1588; Rodriguez MS, 1999, EMBO J, V18, P6455, DOI 10.1093/emboj/18.22.6455; Saha S, 2002, NAT BIOTECHNOL, V20, P508, DOI 10.1038/nbt0502-508; SEUFERT W, 1995, NATURE, V373, P78, DOI 10.1038/373078a0; Smith AP, 2005, CANCER BIOL THER, V4, P1018, DOI 10.4161/cbt.4.9.2165; Smith AP, 2004, CANCER BIOL THER, V3, P104, DOI 10.4161/cbt.3.1.661; Tago K, 2005, P NATL ACAD SCI USA, V102, P7689, DOI 10.1073/pnas.0502978102; Tashiro K, 1997, P NATL ACAD SCI USA, V94, P7862, DOI 10.1073/pnas.94.15.7862; Tsao H, 2004, NEW ENGL J MED, V351, P998, DOI 10.1056/NEJMra041245; Ungureanu D, 2003, BLOOD, V102, P3311, DOI 10.1182/blood-2002-12-3816; Valesky M, 2002, MOL MED, V8, P103, DOI 10.1007/BF03402080; VELCULESCU VE, 1995, SCIENCE, V270, P484, DOI 10.1126/science.270.5235.484; WANG E, 2004, J TRANSL MED, V15, P34; Wang YP, 1996, CELL GROWTH DIFFER, V7, P1733; Wang YP, 1997, NAT MED, V3, P887, DOI 10.1038/nm0897-887; Wang ZY, 1996, J BIOL CHEM, V271, P24811, DOI 10.1074/jbc.271.40.24811; Watanabe TK, 1996, CYTOGENET CELL GENET, V72, P86, DOI 10.1159/000134169; Weeraratna AT, 2004, ONCOGENE, V23, P2264, DOI 10.1038/sj.onc.1207337; Xu WD, 2000, EXP CELL RES, V255, P135, DOI 10.1006/excr.2000.4803; Yasugi T, 1996, NUCLEIC ACIDS RES, V24, P2005, DOI 10.1093/nar/24.11.2005	39	67	73	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 21	2007	26	29					4216	4225		10.1038/sj.onc.1210216	http://dx.doi.org/10.1038/sj.onc.1210216			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	184CY	17297476				2022-12-28	WOS:000247619900004
J	Shi, Q; Bao, S; Song, L; Bigner, DD; Hjelmeland, AB; Rich, JN				Shi, Q.; Bao, S.; Song, L.; Bigner, D. D.; Hjelmeland, A. B.; Rich, J. N.			Targeting SPARC expression decreases glioma cellular survival and invasion associated with reduced activities of FAK and ILK kinases	ONCOGENE			English	Article						SPARC; AKT; glioma; invasion; siRNA	HUMAN-MELANOMA CELLS; BREAST-CANCER; GENE-EXPRESSION; TUMOR-GROWTH; IN-VITRO; PROTEIN; RICH; GLIOBLASTOMA; OSTEONECTIN; METASTASIS	Secreted protein acidic and rich in cysteine (SPARC) is an extracellular glycoprotein expressed in several solid cancers, including malignant gliomas, upon adoption of metastatic or invasive behaviors. SPARC expression in glioma cells promotes invasion and survival under stress, the latter process dependent on SPARC activation of AKT. Here we demonstrate that downregulation of SPARC expression with short interfering RNA (siRNA) in glioma cells decreased tumor cell survival and invasion. SPARC siRNA reduced the activating phosphorylation of AKT and two cytoplasmic kinases, focal adhesion kinase (FAK) and integrin-linked kinase (ILK). We determined the contributions of FAK and ILK to SPARC effects using SPARC protein and cell lines engineered to overexpress SPARC. SPARC activated FAK and ILK in glioma cells previously characterized as responsive to SPARC. Downregulation of either FAK or ILK expression inhibited SPARC-mediated AKT phosphorylation, and targeting both FAK and ILK attenuated AKT activation more potently than targeting either FAK or ILK alone. Decreased SPARC-mediated AKT activation correlated with a reduction in SPARC-dependent invasion and survival upon the downregulation of FAK and/or ILK expression. These data further demonstrate the role of SPARC in glioma tumor progression through the activation of intracellular kinases that may provide novel therapeutic targets for advanced cancers.	Duke Univ, Med Ctr, Preston Robert Tisch Brain Tumor Ctr, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Surg, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Pathol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Neurobiol, Durham, NC 27710 USA	Duke University; Duke University; Duke University; Duke University; Duke University	Rich, JN (corresponding author), Duke Univ, Med Ctr, Preston Robert Tisch Brain Tumor Ctr, POB 2900, Durham, NC 27710 USA.	rich0001@mc.duke.edu	Rich, Jeremy/AAM-1445-2021		NATIONAL CANCER INSTITUTE [P50CA108786, R01CA116659] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS054276, K02NS047409] Funding Source: NIH RePORTER; NCI NIH HHS [CA 108786, CA 116659] Funding Source: Medline; NINDS NIH HHS [NS047409, NS054276] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Alvarez MJ, 2005, CANCER RES, V65, P5123, DOI 10.1158/0008-5472.CAN-04-1102; Barker TH, 2005, J BIOL CHEM, V280, P36483, DOI 10.1074/jbc.M504663200; CHICOINE MR, 1995, J NEUROSURG, V82, P615, DOI 10.3171/jns.1995.82.4.0615; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Framson PE, 2004, J CELL BIOCHEM, V92, P679, DOI 10.1002/jcb.20091; Giese A, 2003, J CLIN ONCOL, V21, P1624, DOI 10.1200/JCO.2003.05.063; Gradishar WJ, 2006, EXPERT OPIN PHARMACO, V7, P1041, DOI 10.1517/14656566.7.8.1041; Hecker TP, 2002, CANCER RES, V62, P2699; Jones C, 2004, CANCER RES, V64, P3037, DOI 10.1158/0008-5472.CAN-03-2028; KENNEY J, 1992, MAGNET RESON MED, V27, P68, DOI 10.1002/mrm.1910270108; Koblinski JE, 2005, CANCER RES, V65, P7370, DOI 10.1158/0008-5472.CAN-05-0807; Lal A, 1999, CANCER RES, V59, P5403; Ledda MF, 1997, NAT MED, V3, P171, DOI 10.1038/nm0297-171; MUNDLOS S, 1992, J HISTOCHEM CYTOCHEM, V40, P283, DOI 10.1177/40.2.1552170; Obara S, 2004, CANCER LETT, V208, P115, DOI 10.1016/j.canlet.2003.11.020; Rempel SA, 1998, J NEUROPATH EXP NEUR, V57, P1112, DOI 10.1097/00005072-199812000-00002; Rich JN, 2005, CANCER RES, V65, P4051, DOI 10.1158/0008-5472.CAN-04-3936; Rich JN, 2003, J BIOL CHEM, V278, P15951, DOI 10.1074/jbc.M211498200; Schultz C, 2002, CANCER RES, V62, P6270; Shi Q, 2004, J BIOL CHEM, V279, P52200, DOI 10.1074/jbc.M409630200; Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330; Troussard AA, 2000, ONCOGENE, V19, P5444, DOI 10.1038/sj.onc.1203928; Watkins G, 2005, PROSTAG LEUKOTR ESS, V72, P267, DOI 10.1016/j.plefa.2004.12.003; Xie D, 2004, CANCER RES, V64, P1987, DOI 10.1158/0008-5472.CAN-03-0666; Yiu GK, 2001, AM J PATHOL, V159, P609, DOI 10.1016/S0002-9440(10)61732-4	25	113	117	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 14	2007	26	28					4084	4094		10.1038/sj.onc.1210181	http://dx.doi.org/10.1038/sj.onc.1210181			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	178XD	17213807				2022-12-28	WOS:000247252700004
J	Sutton, KM; Hayat, S; Chau, NM; Cook, S; Pouyssegur, J; Ahmed, A; Perusinghe, N; Le Floch, R; Yang, J; Ashcroft, M				Sutton, K. M.; Hayat, S.; Chau, N-M; Cook, S.; Pouyssegur, J.; Ahmed, A.; Perusinghe, N.; Le Floch, R.; Yang, J.; Ashcroft, M.			Selective inhibition of MEK1/2 reveals a differential requirement for ERK1/2 signalling in the regulation of HIF-1 in response to hypoxia and IGF-1	ONCOGENE			English	Article						hypoxia-inducible factor 1(HIF-1); hypoxia; growth factor; ERK1/2 signalling; small molecule inhibitor	INDUCIBLE FACTOR 1-ALPHA; GROWTH-FACTOR EXPRESSION; ACTIVATED PROTEIN-KINASE; MAP KINASE; FACTOR-I; FACTOR (HIF)-1-ALPHA; CANCER-THERAPY; BREAST-CANCER; FACTOR-1-ALPHA; ANGIOGENESIS	The transcription factor hypoxia-inducible factor 1 (HIF-1) plays a pivotal role in tumour growth and progression, and HIF-1 is regulated through a number of signalling pathways. Here, we investigated the involvement of the mitogen-activated protein kinase (MAPK) signalling pathway in HIF-1 regulation. We found that overexpression of wild-type (WT) extracellular signal regulated protein kinase 1 (ERK1) greatly potentiated HIF-1 activation in hypoxia and HIF-1 alpha induced in response to insulin growth-like factor 1 (IGF-1). Conversely, treatment of tumour cells with the MEK1/2 inhibitors PD98059 or U0216, or expression of a dominant-negative form of ERK1 blocked HIF-1 activation in hypoxia without affecting HIF-1 alpha induction, localization or binding of HIF-1 beta. Interestingly however, the highly selective MEK1/2 inhibitor PD184352 did not inhibit HIF-1 activity or vascular endothelial growth factor (VEGF) induced in response to hypoxia but blocked HIF-1a protein and HIF-1 activity induced by IGF-1 stimulation without affecting HIF-1 alpha mRNA levels. Finally, we found that ERK5 phosphorylation status was not significantly affected by hypoxia in the presence or absence of PD184352. Taken together, our data suggest that although ERK1/2 signalling is important for HIF-1 alpha induction and HIF-1 activity in response to IGF-1, it is dispensable for the induction of HIF-1 alpha and activation of HIF-1 in response to hypoxia.	Inst Canc Res, Cell Growth Regulat & Angiogenesis Team, Canc Res UK Ctr Canc Therapeut, Sutton SM2 5NG, Surrey, England; Babraham Inst, MAP Kinase Grp, Mol Signalling Lab, Signalling Programme, Cambridge, England; Inst Signalling Dev Biol & Canc Res, Nice, France; Inst Canc Res, Microscopy Facil, Canc Res UK Ctr Canc Therapeut, Sutton SM2 5NG, Surrey, England	Cancer Research UK; University of London; Institute of Cancer Research - UK; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute; Cancer Research UK; University of London; Institute of Cancer Research - UK	Ashcroft, M (corresponding author), Inst Canc Res, Cell Growth Regulat & Angiogenesis Team, Canc Res UK Ctr Canc Therapeut, 15 Cotswold Rd, Sutton SM2 5NG, Surrey, England.	margaret.ashcroft@icr.ac.uk	Yang, Jun/N-2309-2018	Yang, Jun/0000-0002-4233-3220				Allen LF, 2003, SEMIN ONCOL, V30, P105, DOI 10.1053/j.seminoncol.2003.08.012; Bardos JI, 2005, BBA-REV CANCER, V1755, P107, DOI 10.1016/j.bbcan.2005.05.001; Bardos JI, 2004, MOL CELL BIOL, V24, P2905, DOI 10.1128/MCB.24.7.2905-2914.2004; Bardos JI, 2004, BIOESSAYS, V26, P262, DOI 10.1002/bies.20002; Berra E, 2003, EMBO J, V22, P4082, DOI 10.1093/emboj/cdg392; Blancher C, 2001, CANCER RES, V61, P7349; Blancher C, 2000, CANCER RES, V60, P7106; Bos R, 2005, HISTOPATHOLOGY, V46, P31, DOI 10.1111/j.1365-2559.2005.02045.x; Carroll Veronica A., 2005, Expert Reviews in Molecular Medicine, V7, P1, DOI 10.1017/S1462399405009117; Chau NM, 2005, CANCER RES, V65, P4918, DOI 10.1158/0008-5472.CAN-04-4453; Dokladda K, 2005, FEBS LETT, V579, P236, DOI 10.1016/j.febslet.2004.11.084; Fukuda R, 2002, J BIOL CHEM, V277, P38205, DOI 10.1074/jbc.M203781200; Garnett MJ, 2004, CANCER CELL, V6, P313, DOI 10.1016/j.ccr.2004.09.022; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; Hockel M, 2001, SEMIN ONCOL, V28, P36, DOI 10.1016/S0093-7754(01)90211-8; Hur E, 2001, MOL PHARMACOL, V59, P1216, DOI 10.1124/mol.59.5.1216; Laughner E, 2001, MOL CELL BIOL, V21, P3995, DOI 10.1128/MCB.21.12.3995-4004.2001; Lee E, 2002, MOL CELLS, V14, P9; Maxwell PH, 2002, SEMIN CELL DEV BIOL, V13, P29, DOI 10.1006/scdb.2001.0287; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Mazure NM, 2003, CURR PHARM DESIGN, V9, P531, DOI 10.2174/1381612033391469; Michiels C, 2001, IUBMB LIFE, V52, P49, DOI 10.1080/15216540252774766; Minet E, 2000, FEBS LETT, V468, P53, DOI 10.1016/S0014-5793(00)01181-9; Mody N, 2001, FEBS LETT, V502, P21, DOI 10.1016/S0014-5793(01)02651-5; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; Richard DE, 1999, J BIOL CHEM, V274, P32631, DOI 10.1074/jbc.274.46.32631; RICHTER JE, 1999, CLIN PRACTICE GASTRO, V1, P1; Sang NL, 2003, J BIOL CHEM, V278, P14013, DOI 10.1074/jbc.M209702200; Semenza GL, 2001, CELL, V107, P1, DOI 10.1016/S0092-8674(01)00518-9; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Sodhi A, 2001, BIOCHEM BIOPH RES CO, V287, P292, DOI 10.1006/bbrc.2001.5532; Squires MS, 2002, BIOCHEM J, V366, P673, DOI 10.1042/BJ20020372; Suzuki H, 2001, ONCOGENE, V20, P5779, DOI 10.1038/sj.onc.1204742; Talks KL, 2000, AM J PATHOL, V157, P411, DOI 10.1016/S0002-9440(10)64554-3; TEICHER BA, 1994, CANCER METAST REV, V13, P139, DOI 10.1007/BF00689633; Ueda T, 2004, MOL CELL BIOL, V24, P6539, DOI 10.1128/MCB.24.15.6539-6549.2004; Wallace EM, 2005, CURR TOP MED CHEM, V5, P215, DOI 10.2174/1568026053507723; Zagzag D, 2000, CANCER-AM CANCER SOC, V88, P2606, DOI 10.1002/1097-0142(20000601)88:11<2606::AID-CNCR25>3.0.CO;2-W; Zhong H, 1999, CANCER RES, V59, P5830	40	51	57	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 7	2007	26	27					3920	3929		10.1038/sj.onc.1210168	http://dx.doi.org/10.1038/sj.onc.1210168			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	177HP	17213817				2022-12-28	WOS:000247144500002
J	Szafranska, AE; Davison, TS; John, J; Cannon, T; Sipos, B; Maghnouj, A; Labourier, E; Hahn, SA				Szafranska, A. E.; Davison, T. S.; John, J.; Cannon, T.; Sipos, B.; Maghnouj, A.; Labourier, E.; Hahn, S. A.			MicroRNA expression alterations are linked to tumorigenesis and non-neoplastic processes in pancreatic ductal adenocarcinoma	ONCOGENE			English	Article						pancreatic ductal adenocarcinoma; chronic pancreatitis; microRNA; expression profiling	PROGNOSIS; SIGNATURE; PROFILES; MIRNAS; TARGET; CANCER; HOXB8; SET	Pancreatic ductal adenocarcinoma (PDAC) is known for its very poor overall prognosis. Accurate early diagnosis and new therapeutic modalities are therefore urgently needed. We used 377 feature microRNA (miRNA) arrays to investigate miRNA expression in normal pancreas, chronic pancreatitis, and PDAC tissues as well as PDAC- derived cell lines. A pancreatic miRNome was established comparing the data from normal pancreas with a reference set of 33 human tissues. The expression of miR-216 and -217 and lack of expression of miR- 133a were identifi. ed as characteristic of pancreas tissue. Unsupervised clustering showed that the three pancreatic tissues types can be classifi. ed according to their respective miRNA expression pro. files. We identified 26 miRNAs most prominently misregulated in PDAC and a relative quantitative reverse transcriptase- polymerase chain reaction index using only miR-217 and -196a was found to discriminate normal pancreas, chronic pancreatitis and cancerous tissues, establishing a potential utility for miRNAs in diagnostic procedures. Lastly, comparing differentially expressed genes from PDAC with predicted miRNA target genes for the top 26 miRNAs, we identifi. ed potential novel links between aberrant miRNA expression and known target genes relevant to PDAC biology. Our data provides novel insights into the miRNA-driven pathophysiological mechanisms involved in PDAC development and offers new candidate targets to be exploited both for diagnostic and therapeutic strategies.	Ruhr Univ Bochum, Dept Internal Med, MGO, ZKF, D-44780 Bochum, Germany; Asuragen Inc, Austin, TX USA; Univ Kiel, Dept Pathol, D-2300 Kiel, Germany; Ruhr Univ Bochum, Knappschafts Krankenhaus, D-4630 Bochum, Germany	Ruhr University Bochum; Asuragen; University of Kiel; Ruhr University Bochum	Hahn, SA (corresponding author), Ruhr Univ Bochum, Dept Internal Med, MGO, ZKF, Univ Str 150, D-44780 Bochum, Germany.	elabourier@asuragen.com; stephan.hahn@rub.de	Hahn, Stephan A./AAV-6062-2021; Hahn, Stephan/E-3880-2010	Hahn, Stephan A./0000-0003-0855-9741; Hahn, Stephan/0000-0003-0855-9741; Labourier, Emmanuel/0000-0001-8010-0674				Al-Aynati MM, 2004, CLIN CANCER RES, V10, P1235, DOI 10.1158/1078-0432.CCR-03-0087; Altomare DA, 2003, J CELL BIOCHEM, V88, P470, DOI 10.1002/jcb.10287; Baskerville S, 2005, RNA, V11, P241, DOI 10.1261/rna.7240905; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Buchholz M, 2005, ONCOGENE, V24, P6626, DOI 10.1038/sj.onc.1208804; Calin GA, 2005, NEW ENGL J MED, V353, P1793, DOI 10.1056/NEJMoa050995; Ciafre SA, 2005, BIOCHEM BIOPH RES CO, V334, P1351, DOI 10.1016/j.bbrc.2005.07.030; Costinean S, 2006, P NATL ACAD SCI USA, V103, P7024, DOI 10.1073/pnas.0602266103; Davison TS, 2006, METHOD ENZYMOL, V411, P14, DOI 10.1016/S0076-6879(06)11002-2; Dessimoz J, 2005, CURR BIOL, V15, P1677, DOI 10.1016/j.cub.2005.08.037; Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840; Felli N, 2005, P NATL ACAD SCI USA, V102, P18081, DOI 10.1073/pnas.0506216102; He HL, 2005, P NATL ACAD SCI USA, V102, P19075, DOI 10.1073/pnas.0509603102; He L, 2005, NATURE, V435, P828, DOI 10.1038/nature03552; Heidenblut AM, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh130; Heiser PW, 2006, DEVELOPMENT, V133, P2023, DOI 10.1242/dev.02366; Hornstein E, 2005, NATURE, V438, P671, DOI 10.1038/nature04138; Hu YX, 2000, PANCREAS, V21, P226, DOI 10.1097/00006676-200010000-00002; Huber Wolfgang, 2002, Bioinformatics, V18 Suppl 1, pS96; Iorio MV, 2005, CANCER RES, V65, P7065, DOI 10.1158/0008-5472.CAN-05-1783; Krutzfeldt J, 2005, NATURE, V438, P685, DOI 10.1038/nature04303; Liu CG, 2004, P NATL ACAD SCI USA, V101, P9740, DOI 10.1073/pnas.0403293101; Lu CD, 1999, CANCER, V85, P1250, DOI 10.1002/(SICI)1097-0142(19990315)85:6<1250::AID-CNCR6>3.3.CO;2-R; Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702; Poy MN, 2004, NATURE, V432, P226, DOI 10.1038/nature03076; Prasad NB, 2005, CANCER RES, V65, P1619, DOI 10.1158/0008-5472.CAN-04-1413; Schlieman MG, 2003, BRIT J CANCER, V89, P2110, DOI 10.1038/sj.bjc.6601396; Segara D, 2005, CLIN CANCER RES, V11, P3587, DOI 10.1158/1078-0432.CCR-04-1813; Sevignani C, 2006, MAMM GENOME, V17, P189, DOI 10.1007/s00335-005-0066-3; Shingara J, 2005, RNA, V11, P1461, DOI 10.1261/rna.2610405; Sood P, 2006, P NATL ACAD SCI USA, V103, P2746, DOI 10.1073/pnas.0511045103; Taganov KD, 2006, P NATL ACAD SCI USA, V103, P12481, DOI 10.1073/pnas.0605298103; Valencia-Sanchez MA, 2006, GENE DEV, V20, P515, DOI 10.1101/gad.1399806; Volinia S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI 10.1073/pnas.0510565103; Weber F, 2006, J CLIN ENDOCR METAB, V91, P3584, DOI 10.1210/jc.2006-0693; Yekta S, 2004, SCIENCE, V304, P594, DOI 10.1126/science.1097434; Yeo Theresa Pluth, 2002, Curr Probl Cancer, V26, P176, DOI 10.1067/mcn.2002.129579; Zeng G, 2006, NEOPLASIA, V8, P279, DOI 10.1593/neo.05607	38	521	588	0	43	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2007	26	30					4442	4452		10.1038/sj.onc.1210228	http://dx.doi.org/10.1038/sj.onc.1210228			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	184CZ	17237814				2022-12-28	WOS:000247620000012
J	Aoki, K; Aoki, M; Sugai, M; Harada, N; Miyoshi, H; Tsukamoto, T; Mizoshita, T; Tatematsu, M; Seno, H; Chiba, T; Oshima, M; Hsieh, CL; Taketo, MM				Aoki, K.; Aoki, M.; Sugai, M.; Harada, N.; Miyoshi, H.; Tsukamoto, T.; Mizoshita, T.; Tatematsu, M.; Seno, H.; Chiba, T.; Oshima, M.; Hsieh, C-L; Taketo, M. M.			Chromosomal instability by beta-catenin/TCF transcription in APC or beta-catenin mutant cells	ONCOGENE			English	Article						APC; beta-catenin; chromosomal instability; cancer; Wnt signaling	ADENOMATOUS-POLYPOSIS-COLI; COLORECTAL TUMOR-CELLS; GASTRIC-CANCER; EXPRESSION; MUTATIONS; PROTEIN; MICE; GENE; TUMORIGENESIS; CARCINOMA	Adenomatous polyposis coli (APC/Apc) gene encodes a key tumor suppressor whose mutations activate beta-catenin/T-cell factor (TCF)-mediated transcription (canonical Wnt signaling). Here, we show that Wnt signaling can cause chromosomal instability (CIN). As an indicator of CIN, we scored anaphase bridge index (ABI) in mouse polyps and ES cells where Wnt signaling was activated by Apc or beta-catenin mutations. We found three to nine times higher ABI than in wild-type controls. Furthermore, karyotype analysis confirmed that the Wnt signal activated ES cells produced new chromosomal aberrations at higher rates; hence CIN. Consistently, expression of dominant-negative TCFs in these cells reduced their ABI. We also found that Wnt signal activation increased phosphorylation of Cdc2 (Cdk1) that inhibited its activity, and suppressed apoptosis upon exposure of the cells to nocodazole or colcemid. The data suggest that Wnt signaling stimulates the cells to escape from mitotic arrest and apoptosis, resulting in CIN. In human gastric cancer tissues with nuclear beta-catenin, ABI was significantly higher than in those without. These results collectively indicate that beta-catenin/TCF-mediated transcription itself increases CIN through dysregulation of G2/M progression.	Kyoto Univ, Grad Sch Med, Dept Pharmacol, Sakyo Ku, Kyoto 6068501, Japan; Kyoto Univ, Ctr Mol Biol & Genet, Kyoto 6068501, Japan; Banyu Tsukuba Res Inst Merck, Ibaraki, Japan; Aichi Canc Ctr, Res Inst, Div Oncol Pathol, Aichi, Japan; Kyoto Univ, Grad Sch Med, Dept Gastroenterol & Hepatol, Kyoto 6068501, Japan; Univ So Calif, Dept Urol, Los Angeles, CA 90033 USA; Univ So Calif, Dept Biochem & Mol Biol, Los Angeles, CA 90033 USA	Kyoto University; Kyoto University; Merck & Company; Aichi Cancer Center; Kyoto University; University of Southern California; University of Southern California	Taketo, MM (corresponding author), Kyoto Univ, Grad Sch Med, Dept Pharmacol, Sakyo Ku, Yoshida Konoe Cho, Kyoto 6068501, Japan.	taketo@mfour.med.kyoto-u.ac.jp	Tsukamoto, Tetsuya/ABD-4397-2020; Oshima, Masanobu/F-9958-2014; Aoki, Masahiro/A-5149-2016; Harada, Naomoto/Y-4591-2019; Aoki, Kazuhiro/I-5483-2019	Tsukamoto, Tetsuya/0000-0002-7502-8724; Oshima, Masanobu/0000-0002-3304-0004; Aoki, Masahiro/0000-0003-4316-9490; Aoki, Kazuhiro/0000-0001-7263-1555; Miyoshi, Hiroyuki/0000-0001-7400-0714; Seno, Hiroshi/0000-0002-8509-8128; Harada, Naomoto/0000-0003-1083-7253; Sugai, Manabu/0000-0003-1668-7647				Aoki K, 2003, NAT GENET, V35, P323, DOI 10.1038/ng1265; Botrugno OA, 2004, MOL CELL, V15, P499, DOI 10.1016/j.molcel.2004.07.009; Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; Danesi DT, 2000, CYTOMETRY, V42, P27, DOI 10.1002/(SICI)1097-0320(20000215)42:1<27::AID-CYTO5>3.0.CO;2-N; Dikovskaya D, 2004, MOL BIOL CELL, V15, P2978, DOI 10.1091/mbc.E03-08-0613; Fodde R, 2001, NAT CELL BIOL, V3, P433, DOI 10.1038/35070129; Giles RH, 2003, BBA-REV CANCER, V1653, P1, DOI 10.1016/S0304-419X(03)00005-2; Gisselsson D, 2003, ADV CANCER RES, V87, P1; Gisselsson D, 2000, P NATL ACAD SCI USA, V97, P5357, DOI 10.1073/pnas.090013497; Green RA, 2003, J CELL BIOL, V163, P949, DOI 10.1083/jcb.200307070; Harada N, 1999, EMBO J, V18, P5931, DOI 10.1093/emboj/18.21.5931; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Homfray TFR, 1998, HUM MUTAT, V11, P114, DOI 10.1002/(SICI)1098-1004(1998)11:2<114::AID-HUMU3>3.0.CO;2-J; HSIEH CL, 1997, CELL BIOL LAB HDB, P391; Ishikawa T, 2003, DEV BIOL, V253, P230, DOI 10.1016/S0012-1606(02)00020-9; Kaplan KB, 2001, NAT CELL BIOL, V3, P429, DOI 10.1038/35070123; Kielman MF, 2002, NAT GENET, V32, P594, DOI 10.1038/ng1045; Kolodner RD, 2002, SCIENCE, V297, P552, DOI 10.1126/science.1075277; Konishi Y, 2002, MOL CELL, V9, P1005, DOI 10.1016/S1097-2765(02)00524-5; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Li Q, 2005, CANCER RES, V65, P8622, DOI 10.1158/0008-5472.CAN-05-2145; McCartney BM, 2006, DEVELOPMENT, V133, P2407, DOI 10.1242/dev.02398; Michel LS, 2001, NATURE, V409, P355, DOI 10.1038/35053094; Mizoshita T, 2003, J CANCER RES CLIN, V129, P727, DOI 10.1007/s00432-003-0499-6; OSHIMA M, 1995, P NATL ACAD SCI USA, V92, P4482, DOI 10.1073/pnas.92.10.4482; Rajagopalan H, 2004, NATURE, V432, P338, DOI 10.1038/nature03099; Rajagopalan H, 2004, NATURE, V428, P77, DOI 10.1038/nature02313; Rudolph KL, 2001, NAT GENET, V28, P155, DOI 10.1038/88871; Sekiya T, 2004, J BIOL CHEM, V279, P6840, DOI 10.1074/jbc.M310876200; Sekiya T, 2002, CANCER RES, V62, P3322; Seno H, 2002, INT J ONCOL, V21, P769; Shih IM, 2001, CANCER RES, V61, P818; Shin HJ, 2003, CANCER CELL, V4, P483, DOI 10.1016/S1535-6108(03)00302-7; Sieber OM, 2003, NAT REV CANCER, V3, P701, DOI 10.1038/nrc1170; Stewenius Y, 2005, P NATL ACAD SCI USA, V102, P5541, DOI 10.1073/pnas.0408454102; Taketo MM, 2006, CANCER SCI, V97, P355, DOI 10.1111/j.1349-7006.2006.00190.x; Tan M, 2002, MOL CELL, V9, P993, DOI 10.1016/S1097-2765(02)00510-5; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Tighe A, 2004, J CELL SCI, V117, P6339, DOI 10.1242/jcs.01556; TRIEZENBERG SJ, 1988, GENE DEV, V2, P718, DOI 10.1101/gad.2.6.718; Ushijima T, 2004, CANCER CELL, V5, P121, DOI 10.1016/S1535-6108(04)00033-9; van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092-8674(02)01014-0	42	57	61	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY	2007	26	24					3511	3520		10.1038/sj.onc.1210141	http://dx.doi.org/10.1038/sj.onc.1210141			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	172JC	17160019				2022-12-28	WOS:000246799200007
J	Hao, H; d'Alincourt-Salazar, M; Kelley, KMM; Shatnawi, A; Mukherjee, S; Shah, YM; Ratnam, M				Hao, H.; d'Alincourt-Salazar, M.; Kelley, K. M. M.; Shatnawi, A.; Mukherjee, S.; Shah, Y. M.; Ratnam, M.			Estrogen-induced and TAFII30-mediated gene repression by direct recruitment of the estrogen receptor and co-repressors to the core promoter and its reversal by tamoxifen	ONCOGENE			English	Article						estrogen; estrogen receptor; folate receptor; SERM; TAFII30; gene repression	NUCLEAR HORMONE-RECEPTORS; TATA-BINDING PROTEIN; BREAST-CANCER CELLS; THYROID-HORMONE; TRANSCRIPTIONAL REPRESSION; RETINOIC ACID; N-COR; EXPRESSION; ACTIVATION; COMPLEX	Estradiol (E-2) acts through the estrogen receptor ( ER) to downregulate many genes, and tamoxifen (Tam) largely reverses this repression but the underlying mechanisms are unclear. Repression of the folate receptor (FR)-alpha P4 core promoter by ER is enhanced by E-2 and reversed by Tam. This effect was unaffected by inhibition of new protein synthesis and required the E/F and the DNA-binding domains of ER without direct binding of ER to DNA. The repression by E-2/ER was not specific for either Sp1 or TATA elements but was loosely selective for the initiator and flanking sequence. Insertion of a response element or a relatively strong Sp1 cluster to recruit ER upstream of the core promoters caused a switch to activation by E-2/ER that was inhibited by Tam. In nuclear extracts, association of ER witha biotinylated core promoter fragment was promoted by E-2 but Tam blocked this effect. Repression/ de-repression of the P4 promoter and endogenous FR-alpha expression by E-2/Tam required SMRT and/ or NCoR. ER associated with the chromosomal P4 promoter and SMRT and NCoR associated with it in an ER-dependent manner; these associations were favored by E-2 but disrupted by Tam, in the short term, without changes in ER expression. TAFII30 was required for optimal P4 promoter activity and for the repressive association of ER. E-2 may thus maintain a low transcriptional status of genes by favoring direct TAFII30-dependent association of ER with the core promoter in a co-repressor complex containing SMRT and/ or NCoR; this repression is overridden in target genes containing an upstream element that strongly recruits ER. In addition to suppressing the activation of classical E-2 target genes, Tam may upregulate genes by passively dissociating the ER co-repressor complex.	[Hao, H.; d'Alincourt-Salazar, M.; Kelley, K. M. M.; Shatnawi, A.; Mukherjee, S.; Shah, Y. M.; Ratnam, M.] Med Univ Ohio, Dept Biochem & Canc Biol, Toledo, OH 43614 USA		Ratnam, M (corresponding author), Med Univ Ohio, Dept Biochem & Canc Biol, Block Hlth Sci Bldg,3035 Arlington Ave, Toledo, OH 43614 USA.	mratnam@meduohio.edu	shatnawi, Aymen/AAF-5661-2020		NCI NIH HHS [CA 80183, R01 CA080183, CA 103964, R01 CA103964] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA080183, R01CA103964] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aranda A, 2001, PHYSIOL REV, V81, P1269, DOI 10.1152/physrev.2001.81.3.1269; BANIAHMAD A, 1993, P NATL ACAD SCI USA, V90, P8832, DOI 10.1073/pnas.90.19.8832; BLOBEL GA, 1995, MOL CELL BIOL, V15, P3147; Butler JEF, 2002, GENE DEV, V16, P2583, DOI 10.1101/gad.1026202; Cvoro A, 2006, MOL CELL, V21, P555, DOI 10.1016/j.molcel.2006.01.014; DAUVOIS S, 1993, J CELL SCI, V106, P1377; DeNardo DG, 2005, MOL ENDOCRINOL, V19, P362, DOI 10.1210/me.2004-0267; FONDELL JD, 1993, GENE DEV, V7, P1400, DOI 10.1101/gad.7.7b.1400; Fondell JD, 1996, MOL CELL BIOL, V16, P281; Frasor J, 2004, CANCER RES, V64, P1522, DOI 10.1158/0008-5472.CAN-03-3326; Frasor J, 2003, ENDOCRINOLOGY, V144, P4562, DOI 10.1210/en.2003-0567; Glass CK, 2000, GENE DEV, V14, P121; Hall JM, 2001, J BIOL CHEM, V276, P36869, DOI 10.1074/jbc.R100029200; Hao H, 2003, BLOOD, V101, P4551, DOI 10.1182/blood-2002-10-3174; Hayashi SI, 2004, BIOMED PHARMACOTHER, V58, P1, DOI 10.1016/j.biopha.2003.09.005; JACQ X, 1994, CELL, V79, P107, DOI 10.1016/0092-8674(94)90404-9; Kelley KMM, 2003, CANCER RES, V63, P2820; Kershah SM, 2004, GYNECOL ONCOL, V92, P304, DOI 10.1016/j.ygyno.2003.10.007; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Masuyama H, 1997, MOL ENDOCRINOL, V11, P218, DOI 10.1210/me.11.2.218; McDonnell DP, 2005, CLIN CANCER RES, V11, p871S; Mengus G, 1997, GENE DEV, V11, P1381, DOI 10.1101/gad.11.11.1381; Moehren U, 2004, ESSAYS BIOCHEM, V40, P89, DOI 10.1042/bse0400089; Muscat GEO, 1998, NUCLEIC ACIDS RES, V26, P2899, DOI 10.1093/nar/26.12.2899; PARKER MG, 1993, BREAST CANCER RES TR, V26, P131, DOI 10.1007/BF00689686; Pink JJ, 1996, CANCER RES, V56, P2321; SADOVSKY Y, 1995, MOL CELL BIOL, V15, P1554; Safe S, 2004, PROG NUCLEIC ACID RE, V77, P1, DOI 10.1016/S0079-6603(04)77001-4; SAIKAWA Y, 1995, BIOCHEMISTRY-US, V34, P9951, DOI 10.1021/bi00031a018; SCHMITT M, 1995, J NEUROSCI RES, V40, P152, DOI 10.1002/jnr.490400203; SCHULMAN IG, 1995, P NATL ACAD SCI USA, V92, P8288, DOI 10.1073/pnas.92.18.8288; Smale ST, 2003, ANNU REV BIOCHEM, V72, P449, DOI 10.1146/annurev.biochem.72.121801.161520; Smale ST, 2001, GENE DEV, V15, P2503, DOI 10.1101/gad.937701; Smith CL, 2004, ENDOCR REV, V25, P45, DOI 10.1210/er.2003-0023; STEINER MS, 1995, MOL ENDOCRINOL, V6, P15; Stoner M, 2000, J BIOL CHEM, V275, P22769, DOI 10.1074/jbc.M002188200; Stossi F, 2006, J BIOL CHEM, V281, P16272, DOI 10.1074/jbc.M513405200; TONG GX, 1995, J BIOL CHEM, V270, P10601, DOI 10.1074/jbc.270.18.10601; Varshochi R, 2005, J BIOL CHEM, V280, P3185, DOI 10.1074/jbc.M408063200; Wang DY, 2004, MOL ENDOCRINOL, V18, P402, DOI 10.1210/me.2003-0202; Wong CW, 1998, MOL CELL BIOL, V18, P5500, DOI 10.1128/MCB.18.9.5500; Yoon HG, 2003, EMBO J, V22, P1336, DOI 10.1093/emboj/cdg120	42	19	19	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 13	2007	26	57					7872	7884		10.1038/sj.onc.1210592	http://dx.doi.org/10.1038/sj.onc.1210592			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	248ON	17599049				2022-12-28	WOS:000252163500005
J	Kieffer, I; Lorenzo, C; Dozier, C; Schmitt, E; Ducommun, B				Kieffer, I.; Lorenzo, C.; Dozier, C.; Schmitt, E.; Ducommun, B.			Differential mitotic degradation of the CDC25B phosphatase variants	ONCOGENE			English	Article						CDC25B phosphatase; degradation; mitosis; biosensors; FRET	CELL-CYCLE; BETA-TRCP; G(2)/M TRANSITION; AURORA-A; KEN-BOX; S-PHASE; PHOSPHORYLATION; PROTEIN; TRIGGERS; MITOSIS	CDC25 phosphatases control cell-cycle progression by dephosphorylating and activating cyclin-dependent kinases. CDC25B, one of the three members of this family in human cells, is thought to regulate initial mitotic events. CDC25B is an unstable protein whose proteasomal degradation is proposed to be controlled by beta-TrCP. Here, we have investigated the regulation of CDC25B during mitosis, using time-lapse video microscopy. We found that CDC25B expression is high during early mitosis, and that its degradation occurs after the metaphase-anaphase transition and cyclin B1 destruction. We also show that CDC25B degradation after metaphase is dependent on the integrity of the KEN-box and RRKSE motifs that are located within the alternatively spliced B domain, and that the CDC25B2 splice variant, that lacks this domain, is stable during mitosis. Furthermore, we show that the N-terminal region of CDC25B, encompassing the B domain, undergoes major conformational changes during mitosis that can be monitored by intramolecular fluorescence resonance energy transfer variation of specific CDC25B biosensors. This study demonstrates that CDC25B splice variants have differential mitotic stabilities, a feature that is likely to have major consequences on the local control of cyclin-dependent kinase-cyclin activities during mitotic progression.	[Kieffer, I.; Lorenzo, C.; Dozier, C.; Schmitt, E.; Ducommun, B.] Univ Toulouse 3, CNRS, LBCMCP UMR5088 IFR109, Inst Explorat Fonct Genomes, F-31062 Toulouse, France; [Ducommun, B.] CHU Purpan, F-40031 Toulouse, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; CHU de Toulouse	Ducommun, B (corresponding author), Univ Toulouse 3, CNRS, LBCMCP UMR5088 IFR109, Inst Explorat Fonct Genomes, 118 Route Narbonne, F-31062 Toulouse, France.	ducommun@cict.fr	DOZIER, Christine/P-1539-2014; DUCOMMUN, Bernard/B-3208-2008	DUCOMMUN, Bernard/0000-0002-7126-8368				Baldin V, 1997, J BIOL CHEM, V272, P32731, DOI 10.1074/jbc.272.52.32731; Baldin V, 1997, ONCOGENE, V14, P2485, DOI 10.1038/sj.onc.1201063; Baldin V, 2003, BIOL CELL, V95, P547, DOI 10.1016/j.biolcel.2003.08.001; Baldin V, 2002, J BIOL CHEM, V277, P35176, DOI 10.1074/jbc.M204430200; Boutros R, 2006, CURR OPIN CELL BIOL, V18, P185, DOI 10.1016/j.ceb.2006.02.003; Bugler B, 2006, MOL CANCER THER, V5, P1446, DOI 10.1158/1535-7163.MCT-06-0099; Bulavin DV, 2002, CURR OPIN GENET DEV, V12, P92, DOI 10.1016/S0959-437X(01)00270-2; Busino L, 2003, NATURE, V426, P87, DOI 10.1038/nature02082; Cans C, 1999, MOL BIOL REP, V26, P53, DOI 10.1023/A:1006912105352; Cazales M, 2005, CELL CYCLE, V4, P1233, DOI 10.4161/cc.4.9.1964; Chen F, 2002, P NATL ACAD SCI USA, V99, P1990, DOI 10.1073/pnas.032428899; Clute P, 1999, NAT CELL BIOL, V1, P82, DOI 10.1038/10049; Davezac N, 2000, ONCOGENE, V19, P2179, DOI 10.1038/sj.onc.1203545; Donzelli M, 2002, EMBO J, V21, P4875, DOI 10.1093/emboj/cdf491; Donzelli M, 2004, CELL CYCLE, V3, P469; Dutertre S, 2004, J CELL SCI, V117, P2523, DOI 10.1242/jcs.01108; Escalas N, 2000, EXP CELL RES, V257, P206, DOI 10.1006/excr.2000.4878; Forrest ARR, 1999, BIOCHEM BIOPH RES CO, V260, P510, DOI 10.1006/bbrc.1999.0870; Gabrielli BG, 1996, J CELL SCI, V109, P1081; Hernandez S, 2000, INT J CANCER, V89, P148, DOI 10.1002/(SICI)1097-0215(20000320)89:2<148::AID-IJC8>3.0.CO;2-R; Hernandez S, 2001, LAB INVEST, V81, P465, DOI 10.1038/labinvest.3780254; Jin JP, 2003, GENE DEV, V17, P3062, DOI 10.1101/gad.1157503; Kanemori Y, 2005, P NATL ACAD SCI USA, V102, P6279, DOI 10.1073/pnas.0501873102; Karlsson C, 1999, J CELL BIOL, V146, P573, DOI 10.1083/jcb.146.3.573; Korner K, 2001, J BIOL CHEM, V276, P9662, DOI 10.1074/jbc.M008696200; Kristjansdottir K, 2004, CHEM BIOL, V11, P1043, DOI 10.1016/j.chembiol.2004.07.007; Lemaire M, 2006, CELL CYCLE, V5, P1649, DOI 10.4161/cc.5.15.3006; Lindqvist A, 2004, J CELL SCI, V117, P4979, DOI 10.1242/jcs.01395; Lindqvist A, 2005, J CELL BIOL, V171, P35, DOI 10.1083/jcb.200503066; Manke IA, 2005, MOL CELL, V17, P37, DOI 10.1016/j.molcel.2004.11.021; Mirey G, 2005, CELL CYCLE, V4, P806, DOI 10.4161/cc.4.6.1716; MIYATA H, 2005, CANCER RES, V61, P3188; Miyawaki A, 2000, METHOD ENZYMOL, V327, P472, DOI 10.1016/S0076-6879(00)27297-2; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Nishijima H, 1997, J CELL BIOL, V138, P1105, DOI 10.1083/jcb.138.5.1105; Pfleger CM, 2000, GENE DEV, V14, P655; Schmitt E, 2006, J CELL SCI, V119, P4269, DOI 10.1242/jcs.03200; Theis-Febvre N, 2003, ONCOGENE, V22, P220, DOI 10.1038/sj.onc.1206107; van Vugt MATM, 2005, ONCOGENE, V24, P2844, DOI 10.1038/sj.onc.1208617; van Vugt MATM, 2004, MOL CELL, V15, P799, DOI 10.1016/j.molcel.2004.07.015	40	26	27	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 13	2007	26	57					7847	7858		10.1038/sj.onc.1210596	http://dx.doi.org/10.1038/sj.onc.1210596			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	248ON	17599046	Bronze			2022-12-28	WOS:000252163500003
J	Andrianifahanana, M; Singh, AP; Nemos, C; Ponnusamy, MP; Moniaux, N; Mehta, PP; Varshney, GC; Batra, SK				Andrianifahanana, M.; Singh, A. P.; Nemos, C.; Ponnusamy, M. P.; Moniaux, N.; Mehta, P. P.; Varshney, G. C.; Batra, S. K.			IFN-gamma-induced expression of MUC4 in pancreatic cancer cells is mediated by STAT-1 upregulation: a novel mechanism for IFN-gamma response	ONCOGENE			English	Article						IFN-gamma; MUC4; STAT-1; pancreatic cancer; regulation	INTERFERON-GAMMA; TRANSCRIPTIONAL ACTIVATION; SERINE PHOSPHORYLATION; UNPHOSPHORYLATED STAT1; GENE-EXPRESSION; GROWTH; ALPHA; ASSOCIATION; INHIBITION; INDUCTION	MUC4 is a transmembrane mucin, which is aberrantly expressed in pancreatic adenocarcinoma with no detectable expression in the normal pancreas. Here, we present a novel mechanism of IFN-gamma-induced expression of MUC4 in pancreatic cancer cells. Our studies highlight the upregulation of STAT-1 as a basis for MUC4 induction and demonstrate that its activation and upregulation by IFN-gamma are two distinct, albeit temporally integrated, signalling events that drive the selective induction of IRF-1 and MUC4, respectively, within a single cell system. The pro. le of interferon regulatory factor (IRF)-1 gene induction by IFN-gamma is consistent with its rapid transactivation by phospho-Y701-STAT-1. In contrast, the induction of the MUC4 mucin gene expression is relatively delayed, and occurs only in response to an increase in STAT-1 expression. A progressive binding of STAT-1 to various gamma-interferon-activated sequences (GAS) in the MUC4 promoter is observed in chromatin immuno-precipitation assay, indicating its direct association. Stimulation of STAT-1 expression by double-stranded polynucleotides or ectopic expression is shown to induce MUC4 expression, without Y701 phosphorylation of STAT-1. This effect is abrogated by short interfering RNA (siRNA)-mediated inhibition of STAT-1 expression, supporting further the relevance of STAT-1 in MUC4 regulation. In conclusion, our findings identify a novel mechanism for MUC4 regulation in pancreatic cancer cells and unfold new perspectives on the foundation of IFN-gamma-dependent gene regulation.	Univ Nebraska Med Ctr, Eppley Inst Res Canc & Allied Dis, Dept Biochem & Mol Biol, Omaha, NE USA; Inst Microbial Technol, Chandigarh, India	University of Nebraska System; University of Nebraska Medical Center; Council of Scientific & Industrial Research (CSIR) - India; CSIR - Institute of Microbial Technology (IMTECH)	Batra, SK (corresponding author), Univ Nebraska, Med Ctr, Dept Biochem & Mol Biol, 985870 Nebraska Mad Ctr, Omaha, NE 68198 USA.	sbatra@unmc.edu	Moniaux, Nicolas/Y-3243-2018; Singh, Ajay/AAF-4414-2020	Moniaux, Nicolas/0000-0001-9718-1386; Palanimuthu Ponnusamy, Moorthy/0000-0001-5744-193X; Singh, Ajay/0000-0003-3492-6330	NCI NIH HHS [CA78590] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA078590] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Andrianifahanana M, 2001, CLIN CANCER RES, V7, P4033; Boehm U, 1997, ANNU REV IMMUNOL, V15, P749, DOI 10.1146/annurev.immunol.15.1.749; Chatterjee-Kishore M, 2000, EMBO J, V19, P4111, DOI 10.1093/emboj/19.15.4111; Choudhury A, 2000, J BIOL CHEM, V275, P33929, DOI 10.1074/jbc.M005115200; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Decker T, 2000, ONCOGENE, V19, P2628, DOI 10.1038/sj.onc.1203481; Goh KC, 1999, EMBO J, V18, P5601, DOI 10.1093/emboj/18.20.5601; Guo GG, 2002, J INTERF CYTOK RES, V22, P555, DOI 10.1089/10799900252982034; Kalvakolanu DV, 1996, CANCER INVEST, V14, P25, DOI 10.3109/07357909609018435; Lagow EL, 2002, J CELL BIOCHEM, V86, P759, DOI 10.1002/jcb.10261; LEE KAW, 1990, METHOD ENZYMOL, V181, P20; Mao X, 2005, MOL CELL, V17, P761, DOI 10.1016/j.molcel.2005.02.021; Marg A, 2004, J CELL BIOL, V165, P823, DOI 10.1083/jcb.200403057; Meydan N, 1996, NATURE, V379, P645, DOI 10.1038/379645a0; Meyer T, 2003, GENE DEV, V17, P1992, DOI 10.1101/gad.268003; Nelson JD, 2006, NUCLEIC ACIDS RES, V34, DOI 10.1093/nar/gnj004; Perrais M, 2001, J BIOL CHEM, V276, P30923, DOI 10.1074/jbc.M104204200; SHUAI K, 1993, SCIENCE, V261, P1744, DOI 10.1126/science.7690989; Singh AP, 2007, CANCER RES, V67, P433, DOI 10.1158/0008-5472.CAN-06-3114; Singh AP, 2004, CANCER RES, V64, P622, DOI 10.1158/0008-5472.CAN-03-2636; Suzuki K, 1999, P NATL ACAD SCI USA, V96, P2285, DOI 10.1073/pnas.96.5.2285; Swartz MJ, 2002, AM J CLIN PATHOL, V117, P791; Yang J, 2005, CANCER RES, V65, P939; Zhou YH, 2001, ONCOLOGY-BASEL, V60, P330, DOI 10.1159/000058529	25	40	42	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 8	2007	26	51					7251	7261		10.1038/sj.onc.1210532	http://dx.doi.org/10.1038/sj.onc.1210532			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	231NO	17525742				2022-12-28	WOS:000250955600009
J	Ito, TK; Ishii, G; Chiba, H; Ochiai, A				Ito, T-K; Ishii, G.; Chiba, H.; Ochiai, A.			The VEGF angiogenic switch of. broblasts is regulated by MMP-7 from cancer cells	ONCOGENE			English	Article						broblasts; angiogenesis; VEGF; MMP-7; CTGF	ENDOTHELIAL GROWTH-FACTOR; MATRIX METALLOPROTEINASES; TUMOR ANGIOGENESIS; FIBROBLASTS; BINDING; CARCINOGENESIS; MATRILYSIN; TUMORIGENESIS; MACROPHAGES; FIBRONECTIN	Vascular endothelial growth factor (VEGF) production by stromal fibroblasts plays an important role in tumor angiogenesis. However, VEGF is also expressed by normal tissue fibroblasts, raising the question of how the VEGF activity of fibroblasts is regulated. Here we report that the latent VEGF angiogenic activity of fibroblasts is activated by cancer cells, resulting in tumor-selective utilization of fibroblast-derived VEGF. Through the production of VEGF, human VA-13 fibroblasts promote angiogenesis in and growth of human pancreas cancer Capan-1 xenograft tumors, whereas VA-13 fibroblasts alone do not show significant angiogenesis. Treatment of VA-13 fibroblast supernatant with matrix metalloproteinase-7 (MMP- 7), an extracellular proteinase characteristically expressed by cancer cells, elicits endothelial tube formation. This effect is abrogated by anti-VEGF antibody or connective tissue growth factor (CTGF), which was previously reported to sequester VEGF and be degraded by MMP-7. Suppression of MMP-7 in Capan-1 cells abrogates the tumor angiogenic activity of VA-13 fibroblasts, which is restored by suppression of CTGF in VA-13 fibroblasts. We further show that these molecular mechanisms that trigger angiogenesis are effective in human primary fibroblasts and human colorectal tissue. These data suggest that fibroblasts may store VEGF in a latent state in the extracellular environment for urgent use in angiogenesis.	Natl Canc Ctr Hosp E, Res Ctr Innovat Oncol, Div Pathol, Kashiwa, Chiba 2778577, Japan; Univ Tokyo, Grad Sch Frontier Sci, Dept Integrat Biosci, Canc Biol Lab, Kashiwa, Chiba, Japan	National Cancer Center - Japan; University of Tokyo	Ochiai, A (corresponding author), Natl Canc Ctr Hosp E, Res Ctr Innovat Oncol, Div Pathol, 6-5-1 Kashiwanoba, Kashiwa, Chiba 2778577, Japan.	aochiai@east.ncc.go.jp	Ishii, Genichiro/E-2913-2012					Ambati BK, 2006, NATURE, V443, P993, DOI 10.1038/nature05249; Bergers G, 2000, NAT CELL BIOL, V2, P737, DOI 10.1038/35036374; BERSE B, 1992, MOL BIOL CELL, V3, P211, DOI 10.1091/mbc.3.2.211; Brigstock DR, 1999, ENDOCR REV, V20, P189, DOI 10.1210/er.20.2.189; Brigstock DR, 1997, J BIOL CHEM, V272, P20275, DOI 10.1074/jbc.272.32.20275; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Chen YL, 2004, MOL BIOL CELL, V15, P5635, DOI 10.1091/mbc.E04-06-0490; Coussens LM, 1999, GENE DEV, V13, P1382, DOI 10.1101/gad.13.11.1382; Crawford HC, 2002, J CLIN INVEST, V109, P1437, DOI 10.1172/JCI200215051; Dong JY, 2004, EMBO J, V23, P2800, DOI 10.1038/sj.emboj.7600289; DVORAK HF, 1986, NEW ENGL J MED, V315, P1650; FERRARA N, 1989, BIOCHEM BIOPH RES CO, V161, P851, DOI 10.1016/0006-291X(89)92678-8; Ferrara N, 1999, J MOL MED, V77, P527, DOI 10.1007/s001099900019; Fukumura D, 1998, CELL, V94, P715, DOI 10.1016/S0092-8674(00)81731-6; GENGRINOVITCH S, 1995, J BIOL CHEM, V270, P15059, DOI 10.1074/jbc.270.25.15059; Giraudo E, 2004, J CLIN INVEST, V114, P623, DOI 10.1172/JCI200422087; Gupta K, 1999, Angiogenesis, V3, P147, DOI 10.1023/A:1009018702832; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Hashimoto G, 2002, J BIOL CHEM, V277, P36288, DOI 10.1074/jbc.M201674200; HLATKY L, 1994, CANCER RES, V54, P6083; Huo N, 2002, CANCER LETT, V177, P95, DOI 10.1016/S0304-3835(01)00772-8; Ichikawa Y, 2006, ONCOL REP, V15, P311; Ii M, 2006, EXP BIOL MED, V231, P20; Inoki I, 2001, FASEB J, V15, P219, DOI 10.1096/fj.01-0332fje; Ishii G, 2005, INT J CANCER, V117, P212, DOI 10.1002/ijc.21199; Jang HS, 2004, MOL THER, V9, P464, DOI 10.1016/j.ymthe.2003.12.002; Jodele S, 2005, CANCER RES, V65, P3200, DOI 10.1158/0008-5472.CAN-04-3770; Kalluri R, 2006, NAT REV CANCER, V6, P392, DOI 10.1038/nrc1877; KENDALL RL, 1993, P NATL ACAD SCI USA, V90, P10705, DOI 10.1073/pnas.90.22.10705; Keyt BA, 1996, J BIOL CHEM, V271, P7788, DOI 10.1074/jbc.271.13.7788; Lee S, 2005, J CELL BIOL, V169, P681, DOI 10.1083/jcb.200409115; Luque A, 2003, J BIOL CHEM, V278, P23656, DOI 10.1074/jbc.M212964200; McCarthy M, 2003, LANCET, V361, P1959, DOI 10.1016/S0140-6736(03)13603-3; Orimo A, 2005, CELL, V121, P335, DOI 10.1016/j.cell.2005.02.034; Overall CM, 2006, NAT REV CANCER, V6, P227, DOI 10.1038/nrc1821; Parks WC, 1999, WOUND REPAIR REGEN, V7, P423, DOI 10.1046/j.1524-475X.1999.00423.x; Roy R, 2006, EXP CELL RES, V312, P608, DOI 10.1016/j.yexcr.2005.11.022; Wijelath ES, 2002, CIRC RES, V91, P25, DOI 10.1161/01.RES.0000026420.22406.79; Zanetta L, 2000, INT J CANCER, V85, P281, DOI 10.1002/(SICI)1097-0215(20000115)85:2<281::AID-IJC21>3.0.CO;2-3	39	86	93	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 8	2007	26	51					7194	7203		10.1038/sj.onc.1210535	http://dx.doi.org/10.1038/sj.onc.1210535			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	231NO	17525740				2022-12-28	WOS:000250955600003
J	Migliaccio, A; Varricchio, L; De Falco, A; Castoria, G; Arra, C; Yamaguchi, H; Ciociola, A; Lombardi, M; Di Stasio, R; Barbieri, A; Baldi, A; Barone, MV; Appella, E; Auricchio, F				Migliaccio, A.; Varricchio, L.; De Falco, A.; Castoria, G.; Arra, C.; Yamaguchi, H.; Ciociola, A.; Lombardi, M.; Di Stasio, R.; Barbieri, A.; Baldi, A.; Barone, M. V.; Appella, E.; Auricchio, F.			Inhibition of the SH3 domain-mediated binding of Src to the androgen receptor and its effect on tumor growth	ONCOGENE			English	Article						androgen receptor; estrogen receptor; receptor antagonist; Src; xenografts	PROSTATE-CANCER CELLS; ESTRADIOL-RECEPTOR; ESTROGEN-RECEPTOR; FACTOR-I; ACTIVATION; PATHWAY; PROTEIN; BREAST; PHOSPHORYLATION; COMPLEX	In human mammary and prostate cancer cells, steroid hormones or epidermal growth factor ( EGF) trigger association of the androgen receptor ( AR)- estradiol receptor ( ER) (alpha or beta) complex with Src. This interaction activates Src and affects the G1 to S cell cycle progression. In this report, we identify the sequence responsible for the AR/ Src interaction and describe a 10 amino- acid peptide that inhibits this interaction. Treatment of the human prostate or mammary cancer cells ( LNCaP or MCF- 7, respectively) with nanomolar concentrations of this peptide inhibits the androgen- or estradiol- induced association between the AR or the ER and Src the Src/ Erk pathway activation, cyclin D1 expression and DNA synthesis, without interfering in the receptor- dependent transcriptional activity. Similarly, the peptide prevents the S phase entry of LNCaP and MCF- 7 cells treated with EGF as well as mouse embryo fibroblasts stimulated with androgen or EGF. Interestingly, the peptide does not inhibit the S phase entry and cytoskeletal changes induced by EGF or serum treatment of AR- negative prostate cancer cell lines. The peptide is the first example of a specific inhibitor of steroid receptor-dependent signal transducing activity. The importance of these results is highlighted by the finding that the peptide strongly inhibits the growth of LNCaP xenografts established in nude mice.	Univ Naples 2, Fac Med & Chirurg, Dipartimento Patol Gen, I-80138 Naples, Italy; NCI, NIH, Cell Biol Lab, Bethesda, MD 20892 USA; Inst Cura Tumori Fdn, Naples, Italy; Univ Naples 2, Sez Anat Patol, Dipartimento Biochim & Biofis, Naples, Italy; Univ Naples Federico II, Fac Med, Dipartimento Pediat, Naples, Italy	Universita della Campania Vanvitelli; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Universita della Campania Vanvitelli; University of Naples Federico II	Auricchio, F (corresponding author), Univ Naples 2, Fac Med & Chirurg, Dipartimento Patol Gen, Via L Crecchio 7, I-80138 Naples, Italy.	ferdinando.auricchio@unina2.it	Barbieri, Antonio/AAG-8961-2019; Migliaccio, Antimo/AAB-3376-2019; Baldi, Alfonso/ABG-2397-2021; Castoria, Gabriella/I-3349-2019	Barbieri, Antonio/0000-0002-7788-6167; Castoria, Gabriella/0000-0002-0576-4494; Migliaccio, Antimo/0000-0002-4197-2055; Baldi, Alfonso/0000-0002-8693-3842; BARONE, Maria Vittoria/0000-0001-6190-4917; Arra, Claudio/0000-0003-3162-2091	Intramural NIH HHS Funding Source: Medline	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Bonaccorsi L, 2000, ENDOCRINOLOGY, V141, P3172, DOI 10.1210/en.141.9.3172; Castoria G, 2001, EMBO J, V20, P6050, DOI 10.1093/emboj/20.21.6050; Castoria G, 1999, EMBO J, V18, P2500, DOI 10.1093/emboj/18.9.2500; Castoria G, 2004, MOL CELL BIOL, V24, P7643, DOI 10.1128/MCB.24.17.7643-7653.2004; Castoria G, 2003, J CELL BIOL, V161, P547, DOI 10.1083/jcb.200211099; CASTORIA G, 1988, MOL ENDOCRINOL, V2, P167, DOI 10.1210/mend-2-2-167; Cato A.C., 2002, SCI STKE, V2002, pre9, DOI [10.1126/stke.2002.138.re9, DOI 10.1126/STKE.2002.138.RE9]; CHANG CS, 1988, SCIENCE, V240, P324, DOI 10.1126/science.3353726; Chen L, 2004, NEW ASTRON, V10, P39, DOI 10.1016/j.newast.2004.04.008; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; CULIG Z, 1994, CANCER RES, V54, P5474; Cunha GR, 2002, DIFFERENTIATION, V70, P473, DOI 10.1046/j.1432-0436.2002.700902.x; Gururaj AE, 2006, CLIN CANCER RES, V12, p1001S, DOI 10.1158/1078-0432.CCR-05-2110; Kay BK, 2000, FASEB J, V14, P231, DOI 10.1096/fasebj.14.2.231; Kousteni S, 2001, CELL, V104, P719, DOI 10.1016/S0092-8674(01)00268-9; Levin ER, 2003, MOL ENDOCRINOL, V17, P309, DOI 10.1210/me.2002-0368; Lopez-Otin C, 1998, ENDOCR REV, V19, P365, DOI 10.1210/er.19.4.365; Marquez DC, 2001, ENDOCRINE, V16, P73, DOI 10.1385/ENDO:16:2:073; Migliaccio A, 2005, CANCER RES, V65, P10585, DOI 10.1158/0008-5472.CAN-05-0912; Migliaccio A, 1996, EMBO J, V15, P1292, DOI 10.1002/j.1460-2075.1996.tb00471.x; Migliaccio A, 2000, EMBO J, V19, P5406, DOI 10.1093/emboj/19.20.5406; Migliaccio A, 1998, EMBO J, V17, P2008, DOI 10.1093/emboj/17.7.2008; Pandini G, 2005, CANCER RES, V65, P1849, DOI 10.1158/0008-5472.CAN-04-1837; Simoncini T, 2000, NATURE, V407, P538, DOI 10.1038/35035131; Singer CA, 1999, J NEUROSCI, V19, P2455; Song RXD, 2002, MOL ENDOCRINOL, V16, P116, DOI 10.1210/me.16.1.116; Vadlamudi RK, 2005, CANCER RES, V65, P7724, DOI 10.1158/0008-5472.CAN-05-0614; Verrijdt G, 2000, J BIOL CHEM, V275, P12298, DOI 10.1074/jbc.275.16.12298; Wong CW, 2002, P NATL ACAD SCI USA, V99, P14783, DOI 10.1073/pnas.192569699; Zhao XY, 2000, NAT MED, V6, P703, DOI 10.1038/76287	30	74	78	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 11	2007	26	46					6619	6629		10.1038/sj.onc.1210487	http://dx.doi.org/10.1038/sj.onc.1210487			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	219JT	17486077				2022-12-28	WOS:000250081500004
J	Azoitei, N; Brey, A; Busch, T; Fulda, S; Adler, G; Seufferlein, T				Azoitei, N.; Brey, A.; Busch, T.; Fulda, S.; Adler, G.; Seufferlein, T.			Thirty-eight-negative kinase 1 (TNK1) facilitates TNF alpha-induced apoptosis by blocking NF-kappa B activation	ONCOGENE			English	Article						apoptosis; NF-kappa B; p65 transactivation; TNF alpha; TNK1	TUMOR-NECROSIS-FACTOR; PROTEIN-TYROSINE KINASE; GENE-EXPRESSION; P65 SUBUNIT; RECEPTOR; PHOSPHORYLATION; CELLS; TRANSCRIPTION; DEATH	Thirty-eight-negative kinase 1 (TNK1) is a member of the ACK-family of nonreceptor tyrosine kinases and was originally cloned from CD34+/Lin-/CD38-hematopoietic stem/progenitor cells. The signaling pathways induced by TNK1 are largely unknown. Here, we report that expression and consequent activation of TNK1 enables tumor necrosis factor a (TNF alpha)-induced apoptosis by selectively inhibiting TNF alpha-induced activation of nuclear factor-kappa B (NF-kappa B). TNK1 has no effect on NF-kappa B DNA binding or the composition of the NF-kappa B complex; however, the kinase markedly prevents TNFa-induced NF-kappa B transactivation. TNK1 therefore acts as a novel molecular switch that can determine the properties of TNFa signaling and therefore cell death.	Univ Ulm, Dept Internal Med 1, D-89081 Ulm, Germany; Univ Ulm, Childrens Hosp, Ulm, Germany	Ulm University; Ulm University	Seufferlein, T (corresponding author), Univ Ulm, Dept Internal Med 1, Robert Koch St 8, D-89081 Ulm, Germany.	thomas.seufferlein@uniklinik-ulm.de	Fulda, Simone/D-5864-2011; Seufferlein, Thomas TW/P-7147-2018	Fulda, Simone/0000-0002-0459-6417				Abu-Amer Y, 1998, J BIOL CHEM, V273, P29417, DOI 10.1074/jbc.273.45.29417; BEG AA, 1996, SCIENCE, V274, P784; Boatright KM, 2003, CURR OPIN CELL BIOL, V15, P725, DOI 10.1016/j.ceb.2003.10.009; Campbell KJ, 2004, MOL CELL, V13, P853, DOI 10.1016/S1097-2765(04)00131-5; Dougall WC, 1999, GENE DEV, V13, P2412, DOI 10.1101/gad.13.18.2412; Eickhoff B, 2000, BIOL CHEM, V381, P1127, DOI 10.1515/BC.2000.138; Felschow DM, 2000, BIOCHEM BIOPH RES CO, V273, P294, DOI 10.1006/bbrc.2000.2887; Fuentes-Prior P, 2004, BIOCHEM J, V384, P201, DOI 10.1042/BJ20041142; Green DR, 2004, SCIENCE, V305, P626, DOI 10.1126/science.1099320; Grumont RJ, 1999, GENE DEV, V13, P400, DOI 10.1101/gad.13.4.400; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; Heyninck K, 2005, TRENDS BIOCHEM SCI, V30, P1, DOI 10.1016/j.tibs.2004.11.001; Hoehn GT, 1996, ONCOGENE, V12, P903; Imbert V, 1996, CELL, V86, P787, DOI 10.1016/S0092-8674(00)80153-1; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Mukhopadhyay A, 2002, J BIOL CHEM, V277, P30622, DOI 10.1074/jbc.M204748200; Navakauskiene R, 2004, PROTEOMICS, V4, P1029, DOI 10.1002/pmic.200300671; Neumann B, 1996, J EXP MED, V184, P259, DOI 10.1084/jem.184.1.259; Pasparakis M, 2000, CELL IMMUNOL, V201, P33, DOI 10.1006/cimm.2000.1636; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; Schwenzer R, 1999, J BIOL CHEM, V274, P19368, DOI 10.1074/jbc.274.27.19368; Taghiyev AF, 2005, CANCER BIOL THER, V4, P382; Takada Y, 2003, J BIOL CHEM, V278, P24233, DOI 10.1074/jbc.M212389200; Tulasne D, 2004, MOL CELL BIOL, V24, P10328, DOI 10.1128/MCB.24.23.10328-10339.2004; Vermeulen L, 2003, EMBO J, V22, P1313, DOI 10.1093/emboj/cdg139; Wajant H, 2003, CELL DEATH DIFFER, V10, P45, DOI 10.1038/sj.cdd.4401189; Zong WX, 1999, GENE DEV, V13, P382, DOI 10.1101/gad.13.4.382	28	22	23	2	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT	2007	26	45					6536	6545		10.1038/sj.onc.1210476	http://dx.doi.org/10.1038/sj.onc.1210476			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	217AF	17471239				2022-12-28	WOS:000249919800007
J	Stang, MT; Armstrong, MJ; Watson, GA; Sung, KY; Liu, Y; Ren, B; Yim, JH				Stang, M. T.; Armstrong, M. J.; Watson, G. A.; Sung, K. Y.; Liu, Y.; Ren, B.; Yim, J. H.			Interferon regulatory factor-1-induced apoptosis mediated by a ligand-independent fas-associated death domain pathway in breast cancer cells	ONCOGENE			English	Article						apoptosis; IRF-1; breast cancer; FADD	TRAIL-INDUCED APOPTOSIS; FACTOR-I; GROWTH-INHIBITION; TUMOR-GROWTH; IRF-1; GAMMA; ACTIVATION; EXPRESSION; INDUCTION; CASPASE-8	Interferon (IFN) regulatory factor-1 (IRF-1) is a transcription factor that has apoptotic anti-tumor activity. In breast cancer cell types, IRF-1 is implicated in mediating apoptosis by both novel and established anti-tumor agents, including the anti-estrogens tamoxifen and faslodex. Here we demonstrate that in MDA468 breast cancer cells, apoptosis by IFN-gamma is mediated by IRF-1 and IFN-gamma, and IRF-1-induced apoptosis is caspase-mediated. IRF-1 induction results in cleavage of caspase-8, -3 and -7, and application of caspase inhibitors attenuate activated cleavage products. IRF-1-induced apoptosis involves caspase-8 since apoptosis is significantly decreased by the caspase-8-specific inhibitor IETD, c-FLIP expression and in caspase-8-deficient cancer cells. Furthermore, we demonstrate that IRF-1-induced apoptosis requires fas-associated death domain (FADD) since dominant-negative FADD expressing cells resist IRF-1-induced apoptosis and activated downstream products. Immunofluorescent studies demonstrate perinuclear colocalization of FADD and caspase-8. Despite the known role of FADD in mediating death-ligand induced apoptosis, neutralizing antibodies against classical death receptors do not inhibit IRF-1 induced apoptosis, and no secreted ligand appears to be involved since MDA468 coincubated with IRF-1 transfected cells do not apoptose. Therefore, we demonstrate that IRF-1 induces a ligand-independent FADD/caspase-8-mediated apoptosis in breast cancer cells.	Univ Pittsburgh, Pittsburgh Canc Inst, Dept Surg, Div Surg Oncol, Pittsburgh, PA 15261 USA; Catholic Univ Korea, Dept Surg, Seoul, South Korea	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Magee-Womens Research Institute; Catholic University of Korea	Yim, JH (corresponding author), Univ Pittsburgh, Pittsburgh Canc Inst, Dept Surg, Div Surg Oncol, 497 Scaife Hall,3550 Terrace St, Pittsburgh, PA 15261 USA.	yimjh@upmc.edu	Yim, John/R-7555-2019	Watson, Gregory/0000-0001-7729-4818	NCI NIH HHS [CA098403] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K08CA098403] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Billecke CA, 2002, ONCOGENE, V21, P4481, DOI 10.1038/sj.onc.1205546; Bouker KB, 2004, CANCER RES, V64, P4030, DOI 10.1158/0008-5472.CAN-03-3602; Bowie ML, 2007, ONCOGENE, V26, P2017, DOI 10.1038/sj.onc.1210013; Bowie ML, 2004, ONCOGENE, V23, P8743, DOI 10.1038/sj.onc.1208120; Gupta V, 2005, P NATL ACAD SCI USA, V102, P3219, DOI 10.1073/pnas.0409709102; Keane MM, 1996, CANCER RES, V56, P4791; Kim EJ, 2002, J CELL BIOCHEM, V85, P369, DOI 10.1002/jcb.10142; Kim PKM, 2004, ONCOGENE, V23, P1125, DOI 10.1038/sj.onc.1207023; Kirchhoff S, 1999, ONCOGENE, V18, P3725, DOI 10.1038/sj.onc.1202704; KIRCHHOFF S, 1993, NUCLEIC ACIDS RES, V21, P2881, DOI 10.1093/nar/21.12.2881; Kirchhoff S, 2002, J IMMUNOL, V168, P1226, DOI 10.4049/jimmunol.168.3.1226; Knight MJ, 2001, ONCOGENE, V20, P5789, DOI 10.1038/sj.onc.1204810; Micheau O, 2003, CELL, V114, P181, DOI 10.1016/S0092-8674(03)00521-X; Muzio M, 1998, J BIOL CHEM, V273, P2926, DOI 10.1074/jbc.273.5.2926; Park SY, 2004, EUR J BIOCHEM, V271, P4222, DOI 10.1111/j.1432-1033.2004.04362.x; Perez D, 1998, J CELL BIOL, V141, P1255, DOI 10.1083/jcb.141.5.1255; Pizzoferrato E, 2004, CANCER RES, V64, P8381, DOI 10.1158/0008-5472.CAN-04-2223; Ruiz-Ruiz C, 2004, J BIOL CHEM, V279, P19712, DOI 10.1074/jbc.M313023200; Sanceau J, 2000, ONCOGENE, V19, P3372, DOI 10.1038/sj.onc.1203670; Shinoura N, 2000, HUM GENE THER, V11, P1123, DOI 10.1089/10430340050015185; TANAKA N, 1994, CANCER LETT, V83, P191, DOI 10.1016/0304-3835(94)90318-2; TANAKA N, 1994, CELL, V77, P829, DOI 10.1016/0092-8674(94)90132-5; Tang DM, 1999, J BIOL CHEM, V274, P7245, DOI 10.1074/jbc.274.11.7245; Wachter T, 2004, J BIOL CHEM, V279, P52824, DOI 10.1074/jbc.M409554200; Wang X, 2005, MOL CELL BIOL, V25, P4742, DOI 10.1128/MCB.25.11.4742-4751.2005; Yim JH, 2003, J INTERF CYTOK RES, V23, P501, DOI 10.1089/10799900360708623; Yim JH, 1997, J IMMUNOL, V158, P1284	27	44	46	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 27	2007	26	44					6420	6430		10.1038/sj.onc.1210470	http://dx.doi.org/10.1038/sj.onc.1210470			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	214KY	17452973				2022-12-28	WOS:000249737600006
J	Woo, Y; Wright, SM; Maas, SA; Alley, TL; Caddle, LB; Kamdar, S; Affourtit, J; Foreman, O; Akeson, EC; Shaffer, D; Bronson, RT; Morse, HC; Roopenian, D; Mills, KD				Woo, Y.; Wright, S. M.; Maas, S. A.; Alley, T. L.; Caddle, L. B.; Kamdar, S.; Affourtit, J.; Foreman, O.; Akeson, E. C.; Shaffer, D.; Bronson, R. T.; Morse, H. C., III; Roopenian, D.; Mills, K. D.			The nonhomologous end joining factor Artemis suppresses multi-tissue tumor formation and prevents loss of heterozygosity	ONCOGENE			English	Article						nonhomologous end joining; RS-SCID; Artemis; loss of heterozygosity; p53	QUANTITATIVE GENE-EXPRESSION; DNA BREAKS; P53; IMMUNODEFICIENCY; TRANSLOCATIONS; REPAIR; AMPLIFICATION; INSTABILITY; LYMPHOCYTE; DEFICIENT	Nonhomologous end joining ( NHEJ) is a critical DNA repair pathway, with proposed tumor suppression functions in many tissues. Mutations in the NHEJ factor ARTEMIS cause radiation- sensitive severe combined immunodeficiency in humans and may increase susceptibility to lymphoma in some settings. We now report that deficiency for Artemis (encoded by Dclre1c/Art in mouse) accelerates tumorigenesis in several tissues in a Trp53 heterozygous setting, revealing tumor suppression roles for NHEJ in lymphoid and non- lymphoid cells. We also show that B- lineage lymphomas in these mice undergo loss of Trp53 heterozygosity by allele replacement, but arise by mechanisms distinct from those in Art Trp53 double null mice. These findings demonstrate a general tumor suppression function for NHEJ, and reveal that interplay between NHEJ and Trp53 loss of heterozygosity influences the sequence of multi-hit oncogenesis. We present a model where p53 status at the time of tumor initiation is a key determinant of subsequent oncogenic mechanisms. Because Art deficient mice represent a model for radiation-sensitive severe combined immunodeficiency, our findings suggest that these patients maybe at risk for both lymphoid and non- lymphoid cancers.	Jackson Lab, Bar Harbor, ME 04609 USA; Univ Maine, Functional Genom PhD Program, Orono, ME USA; Bar Harbor Biotechnol, Trenton, NJ USA; Tufts Univ, Sch Vet Med, Cummings Sch, Dept Biomed Sci, North Grafton, MA 01536 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; NIAID, Immunopathol Lab, Rockville, MD USA	Jackson Laboratory; University of Maine System; University of Maine Orono; Tufts University; Harvard University; Harvard Medical School; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Mills, KD (corresponding author), Jackson Lab, 600 Main St, Bar Harbor, ME 04609 USA.	kevin.mills@jax.org		Morse, Herbert/0000-0002-9331-3705	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [T32HD007065] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA115665] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000858] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA115665] Funding Source: Medline; NICHD NIH HHS [T32 HD07065-27, T32 HD007065] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Akeson EC, 2006, GENOMICS, V87, P311, DOI 10.1016/j.ygeno.2005.09.022; Akeson EC, 2001, CYTOGENET CELL GENET, V93, P270, DOI 10.1159/000056997; Akilesh S, 2003, GENOME RES, V13, P1719, DOI 10.1101/gr.533003; Bassing CH, 2003, CELL, V114, P359, DOI 10.1016/S0092-8674(03)00566-X; Churchill GA, 2004, BIOTECHNIQUES, V37, P173, DOI 10.2144/04372TE01; de Villartay JP, 2003, CURR OPIN IMMUNOL, V15, P592, DOI 10.1016/S0952-7915(03)00101-8; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Ege M, 2005, BLOOD, V105, P4179, DOI 10.1182/blood-2004-12-4861; Eilers PHC, 2005, BIOINFORMATICS, V21, P1146, DOI 10.1093/bioinformatics/bti148; Ferguson DO, 2001, ONCOGENE, V20, P5572, DOI 10.1038/sj.onc.1204767; Hart GT, 2004, INFECT IMMUN, V72, P4471, DOI 10.1128/IAI.72.8.4471-4479.2004; HARVEY M, 1993, NAT GENET, V5, P225, DOI 10.1038/ng1193-225; Holcomb VB, 2006, ONCOGENE, V25, P7159, DOI 10.1038/sj.onc.1209704; Irizarry RA, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng015; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Jackson SP, 2002, CARCINOGENESIS, V23, P687, DOI 10.1093/carcin/23.5.687; Jasin M, 2000, CANCER INVEST, V18, P78, DOI 10.3109/07357900009023065; Jeggo PA, 2006, DNA REPAIR, V5, P1192, DOI 10.1016/j.dnarep.2006.05.011; Jiang WD, 2001, P NATL ACAD SCI USA, V98, P9790, DOI 10.1073/pnas.171066498; Kerr M K, 2001, Biostatistics, V2, P183, DOI 10.1093/biostatistics/2.2.183; LASKO D, 1991, ANNU REV GENET, V25, P281, DOI 10.1146/annurev.ge.25.120191.001433; Liang L, 2002, MUTAT RES-FUND MOL M, V502, P69, DOI 10.1016/S0027-5107(02)00029-5; Mills KD, 2003, IMMUNOL REV, V194, P77, DOI 10.1034/j.1600-065X.2003.00060.x; Moshous D, 2001, CELL, V105, P177, DOI 10.1016/S0092-8674(01)00309-9; Moshous D, 2003, J CLIN INVEST, V111, P381, DOI 10.1172/JCI200316774; Mostoslavsky G, 2006, P NATL ACAD SCI USA, V103, P16406, DOI 10.1073/pnas.0608130103; Nicolas N, 1998, J EXP MED, V188, P627, DOI 10.1084/jem.188.4.627; Olivier M, 2003, CANCER RES, V63, P6643; Rooney S, 2004, IMMUNOL REV, V200, P115, DOI 10.1111/j.0105-2896.2004.00165.x; Rooney S, 2004, P NATL ACAD SCI USA, V101, P2410, DOI 10.1073/pnas.0308757101; Rooney S, 2002, MOL CELL, V10, P1379, DOI 10.1016/S1097-2765(02)00755-4; Sharpless NE, 2001, MOL CELL, V8, P1187, DOI 10.1016/S1097-2765(01)00425-7; Stark JM, 2003, MOL CELL BIOL, V23, P733, DOI 10.1128/MCB.23.2.733-743.2003; Tischfield JA, 2003, NAT GENET, V33, P5, DOI 10.1038/ng0103-5; WU H, 2003, ANAL GENE EXPRESSION; Yan CT, 2006, P NATL ACAD SCI USA, V103, P7378, DOI 10.1073/pnas.0601938103; Zhu CM, 2002, CELL, V109, P811, DOI 10.1016/S0092-8674(02)00770-5	37	18	18	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2007	26	41					6010	6020		10.1038/sj.onc.1210430	http://dx.doi.org/10.1038/sj.onc.1210430			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	207US	17384673				2022-12-28	WOS:000249277200004
J	Pollice, A; Sepe, M; Villella, V; Tolino, F; Vivo, M; Calabro, V; La Mantia, G				Pollice, A.; Sepe, M.; Villella, V. R.; Tolino, F.; Vivo, M.; Calabro, V.; La Mantia, G.			TBP-1 protects the human oncosuppressor p14ARF from proteasomal degradation	ONCOGENE			English	Article						p14ARF; TBP-1; proteasome; N-terminal ubiquitination	ARF TUMOR-SUPPRESSOR; TAT-BINDING PROTEIN-1; 26S PROTEASOME; PROTEOLYSIS; NUCLEOLAR; INK4A/ARF; NUCLEOPHOSMIN; STABILITY; P14(ARF); SUBUNIT	The p14ARF tumor suppressor is a key regulator of cellular proliferation, frequently inactivated in human cancer. The mechanisms that regulate alternative reading frame (ARF) turnover have been obscure for longtime, being ARF a relatively stable protein. Recently, it has been described that its degradation depends, at least in part, on the proteasome and that it can be subjected to N- terminal ubiquitination. We have previously reported that ARF protein levels are regulated by TBP- 1 (Tat- Binding Protein 1), a multifunctional protein, component of the regulatory subunit of the proteasome, involved in different cellular processes. Here we demonstrate that the stabilization effect exerted by TBP- 1 requires an intact N- terminal 39 amino acids in ARF and occurs independently from N- terminal ubiquitination of the protein. Furthermore, we observed that ARF can be degraded in vitro by the 20S proteasome, in the absence of ubiquitination and this effect can be counteracted by TBP- 1. These observations seem relevant in the comprehension of the regulation of ARF metabolism as, among the plethora of cellular ARF's interactors already identifi. ed, only NPM/B23 and TBP- 1 appear to be involved in the control of ARF intracellular levels.	Univ Naples Federico 2, Dipartimento Biol Strutturale & Funz, I-80126 Naples, Italy	University of Naples Federico II	La Mantia, G (corresponding author), Univ Naples Federico 2, Dipartimento Biol Strutturale & Funz, I-80126 Naples, Italy.	lamantia@unina.it	Vivo, Maria/S-3390-2017; Calabro, Viola/H-6156-2013	Vivo, Maria/0000-0003-2458-4226; Calabro, Viola/0000-0002-6508-8889	Telethon [GGP030326] Funding Source: Medline	Telethon(Fondazione Telethon)		Bertwistle D, 2004, MOL CELL BIOL, V24, P985, DOI 10.1128/MCB.24.3.985-996.2004; Bothner B, 2001, J MOL BIOL, V314, P263, DOI 10.1006/jmbi.2001.5110; Chen Y, 1997, J BIOL CHEM, V272, P24081, DOI 10.1074/jbc.272.38.24081; Colombo E, 2005, MOL CELL BIOL, V25, P8874, DOI 10.1128/MCB.25.20.8874-8886.2005; Colucci-D'Amato GL, 2000, J BIOL CHEM, V275, P19306, DOI 10.1074/jbc.275.25.19306; Corn PG, 2003, NAT GENET, V35, P229, DOI 10.1038/ng1254; Gallagher SJ, 2006, INT J BIOCHEM CELL B, V38, P1637, DOI 10.1016/j.biocel.2006.02.008; Gonzalez F, 2002, SCIENCE, V296, P548, DOI 10.1126/science.1069490; Itahana K, 2003, MOL CELL, V12, P1151, DOI 10.1016/S1097-2765(03)00431-3; Kong XG, 2006, MOL CELL BIOL, V26, P2019, DOI 10.1128/MCB.26.6.2019-2028.2006; Korgaonkar C, 2005, MOL CELL BIOL, V25, P1258, DOI 10.1128/MCB.25.4.1258-1271.2005; Kuo ML, 2004, GENE DEV, V18, P1862, DOI 10.1101/gad.1213904; Lam YA, 2002, NATURE, V416, P763, DOI 10.1038/416763a; Liu CW, 2003, SCIENCE, V299, P408, DOI 10.1126/science.1079293; Lohrum MAE, 2000, CURR BIOL, V10, P539, DOI 10.1016/S0960-9822(00)00472-3; Paliwal S, 2006, MOL CELL BIOL, V26, P2360, DOI 10.1128/MCB.26.6.2360-2372.2006; Park BW, 1999, P NATL ACAD SCI USA, V96, P6434, DOI 10.1073/pnas.96.11.6434; Pollice A, 2004, J BIOL CHEM, V279, P6345, DOI 10.1074/jbc.M310957200; Reef S, 2006, MOL CELL, V22, P463, DOI 10.1016/j.molcel.2006.04.014; Rodway H, 2004, ONCOGENE, V23, P6186, DOI 10.1038/sj.onc.1207854; Russell SJ, 1999, MOL CELL, V3, P687, DOI 10.1016/S1097-2765(01)80001-0; Sdek P, 2005, MOL CELL, V20, P699, DOI 10.1016/j.molcel.2005.10.017; Sharpless NE, 2004, EXP GERONTOL, V39, P1751, DOI 10.1016/j.exger.2004.06.025; Sharpless NE, 2005, MUTAT RES-FUND MOL M, V576, P22, DOI 10.1016/j.mrfmmm.2004.08.021; Sherr CJ, 2001, NAT REV MOL CELL BIO, V2, P731, DOI 10.1038/35096061; Voges D, 1999, ANNU REV BIOCHEM, V68, P1015, DOI 10.1146/annurev.biochem.68.1.1015; Weber JD, 2000, MOL CELL BIOL, V20, P2517, DOI 10.1128/MCB.20.7.2517-2528.2000	27	17	17	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 2	2007	26	35					5154	5162		10.1038/sj.onc.1210313	http://dx.doi.org/10.1038/sj.onc.1210313			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	196MT	17334400				2022-12-28	WOS:000248487400014
J	Ostler, K; Davis, E; Payne, S; Gosalia, B; Exposito-Cespedes, J; Le Beau, MM; Godley, LA				Ostler, K. R.; Davis, E. M.; Payne, S. L.; Gosalia, B. B.; Exposito-Cespedes, J.; Le Beau, M. M.; Godley, L. A.			Cancer cells express aberrant DNMT3B transcripts encoding truncated proteins	ONCOGENE			English	Article						DNA methylation; DNMT3B; aberrant mRNA splicing; epigenetics	DNA METHYLTRANSFERASES DNMT3A; CHROMOSOMAL INSTABILITY; PROMOTER METHYLATION; CPG METHYLATION; MESSENGER-RNA; GENE; CHROMATIN; HYPOMETHYLATION; 3B; HYPERMETHYLATION	Cancer cells display an altered distribution of DNA methylation relative to normal cells. Certain tumor suppressor gene promoters are hypermethylated and transcriptionally inactivated, whereas repetitive DNA is hypomethylated and transcriptionally active. Little is understood about how the abnormal DNA methylation patterns of cancer cells are established and maintained. Here, we identify over 20 DNMT3B transcripts from many cancer cell lines and primary acute leukemia cells that contain aberrant splicing at the 50 end of the gene, encoding truncated proteins lacking the C-terminal catalytic domain. Many of these aberrant transcripts retain intron sequences. Although the aberrant transcripts represent a minority of the DNMT3B transcripts present, Western blot analysis demonstrates truncated DNMT3B isoforms in the nuclear protein extracts of cancer cells. To test if expression of a truncated DNMT3B protein could alter the DNA methylation patterns within cells, we expressed DNMT3B7, the most frequently expressed aberrant transcript, in 293 cells. DNMT3B7-expressing 293 cells have altered gene expression as identified by microarray analysis. Some of these changes in gene expression correlate with altered DNA methylation of corresponding CpG islands. These results suggest that truncated DNMT3B proteins could play a role in the abnormal distribution of DNA methylation found in cancer cells.	Univ Chicago, Dept Med, Hematol Oncol Sect, Chicago, IL 60637 USA; Univ Chicago, Canc Res Ctr, Chicago, IL 60637 USA	University of Chicago; University of Chicago	Ostler, K (corresponding author), Univ Chicago, Dept Med, Hematol Oncol Sect, 5841 S Maryland Ave,MC 2115, Chicago, IL 60637 USA.	lgodley@medicine.bsd.uchicago.edu		Raimondi, Stacey/0000-0001-7667-6814	NCI NIH HHS [P01 CA040046, CA 40046, R01 CA129831-01A1, R01 CA129831] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA040046, R01CA129831] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aggerholm A, 2006, EUR J HAEMATOL, V76, P23, DOI 10.1111/j.1600-0609.2005.00559.x; Bachman KE, 2003, CANCER CELL, V3, P89, DOI 10.1016/S1535-6108(02)00234-9; Bartel F, 2002, CANCER CELL, V2, P9, DOI 10.1016/S1535-6108(02)00091-0; Beaulieu N, 2002, J BIOL CHEM, V277, P28176, DOI 10.1074/jbc.M204734200; Bestor TH, 2000, HUM MOL GENET, V9, P2395, DOI 10.1093/hmg/9.16.2395; Chan AOO, 2006, WORLD J GASTROENTERO, V12, P199, DOI 10.3748/wjg.v12.i2.199; Charlet-B N, 2002, MOL CELL, V10, P45, DOI 10.1016/S1097-2765(02)00572-5; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; Cowin P, 2005, CURR OPIN CELL BIOL, V17, P499, DOI 10.1016/j.ceb.2005.08.014; Culbertson MR, 1999, TRENDS GENET, V15, P74, DOI 10.1016/S0168-9525(98)01658-8; Eden A, 2003, SCIENCE, V300, P455, DOI 10.1126/science.1083557; Ehrlich M, 2006, ONCOGENE, V25, P2636, DOI 10.1038/sj.onc.1209145; Ehrlich M, 2003, CLIN IMMUNOL, V109, P17, DOI 10.1016/S1521-6616(03)00201-8; Fan YH, 2005, CELL, V123, P1199, DOI 10.1016/j.cell.2005.10.028; Gaudet F, 2003, SCIENCE, V300, P489, DOI 10.1126/science.1083558; Geiman TM, 2004, NUCLEIC ACIDS RES, V32, P2716, DOI 10.1093/nar/gkh589; Geiman TM, 2004, BIOCHEM BIOPH RES CO, V318, P544, DOI 10.1016/j.bbrc.2004.04.058; Gore SD, 2006, CANCER RES, V66, P6361, DOI 10.1158/0008-5472.CAN-06-0080; Hansen RS, 1999, P NATL ACAD SCI USA, V96, P14412, DOI 10.1073/pnas.96.25.14412; Hansen RS, 2003, HUM MOL GENET, V12, P2559, DOI 10.1093/hmg/ddg268; Jumaa H, 2003, NATURE, V423, P452, DOI 10.1038/nature01608; Kanai Y, 2003, CANCER LETT, V192, P75, DOI 10.1016/S0304-3835(02)00689-4; Kang ES, 2001, BIOCHEM BIOPH RES CO, V289, P862, DOI 10.1006/bbrc.2001.6057; Karpf AR, 2005, CANCER RES, V65, P8635, DOI 10.1158/0008-5472.CAN-05-1961; Kim GD, 2002, EMBO J, V21, P4183, DOI 10.1093/emboj/cdf401; Kumar R, 2002, NATURE, V418, P654, DOI 10.1038/nature00889; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; Li E, 2002, NAT REV GENET, V3, P662, DOI 10.1038/nrg887; Lin HJ, 2006, MOL CELL BIOL, V26, P2976, DOI 10.1128/MCB.26.8.2976-2983.2006; Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6; Parolini O, 2003, IMMUNOGENETICS, V55, P116, DOI 10.1007/s00251-003-0557-x; Reuther GW, 2002, J BIOL CHEM, V277, P30508, DOI 10.1074/jbc.M111330200; Rhee I, 2000, NATURE, V404, P1003, DOI 10.1038/35010000; Rhee I, 2002, NATURE, V416, P552, DOI 10.1038/416552a; Robert MF, 2003, NAT GENET, V33, P61, DOI 10.1038/ng1068; Robertson KD, 1999, NUCLEIC ACIDS RES, V27, P2291, DOI 10.1093/nar/27.11.2291; Robertson KD, 2005, NAT REV GENET, V6, P597, DOI 10.1038/nrg1655; Robertson KD, 2002, ONCOGENE, V21, P5361, DOI 10.1038/sj.onc.1205609; Rountree MR, 2001, ONCOGENE, V20, P3156, DOI 10.1038/sj.onc.1204339; Saito Y, 2002, P NATL ACAD SCI USA, V99, P10060, DOI 10.1073/pnas.152121799; Shirohzu H, 2002, AM J MED GENET, V112, P31, DOI 10.1002/ajmg.10658; Sigalotti L, 2002, J IMMUNOTHER, V25, P16, DOI 10.1097/00002371-200201000-00002; Ueda Y, 2006, DEVELOPMENT, V133, P1183, DOI 10.1242/dev.02293; Venables JP, 2004, CANCER RES, V64, P7647, DOI 10.1158/0008-5472.CAN-04-1910; Wang J, 2006, CANCER RES, V66, P8361, DOI 10.1158/0008-5472.CAN-06-2031; Wang L, 2006, INT J ONCOL, V29, P201; Watermann DO, 2006, CANCER RES, V66, P4774, DOI 10.1158/0008-5472.CAN-04-3294; Wilkinson MF, 2002, NAT CELL BIOL, V4, pE144, DOI 10.1038/ncb0602-e144; Xu GL, 1999, NATURE, V402, P187, DOI 10.1038/46052; Yamada Y, 2005, P NATL ACAD SCI USA, V102, P13580, DOI 10.1073/pnas.0506612102; Yanagisawa Y, 2002, BBA-GENE STRUCT EXPR, V1577, P457, DOI 10.1016/S0167-4781(02)00482-7; Yang Y, 2002, J BIOL CHEM, V277, P25756, DOI 10.1074/jbc.M202575200	52	108	114	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2007	26	38					5553	5563		10.1038/sj.onc.1210351	http://dx.doi.org/10.1038/sj.onc.1210351			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	200ZS	17353906	Green Accepted			2022-12-28	WOS:000248801900001
J	Ramer, R; Eichele, K; Hinz, B				Ramer, R.; Eichele, K.; Hinz, B.			Upregulation of tissue inhibitor of matrix metalloproteinases-1 confers the anti-invasive action of cisplatin on human cancer cells	ONCOGENE			English	Article						cisplatin; matrigel cell invasion; tissue inhibitor of matrix metalloproteinases-1; matrix metalloproteinase-2; human cervical cancer cells; human lung; carcinoma cells	PROMOTES INVASION; INDUCED APOPTOSIS; EPITHELIAL-CELLS; TUMOR INVASION; KAPPA-B; P38; ACTIVATION; EXPRESSION; STRESS; TIMP-1	Cancer cell invasion is one of the crucial events in local spreading, growth and metastasis of tumors. The present study investigates the mechanism underlying the antiinvasive action of the chemotherapeutic cisplatin. In human cervical carcinoma cells (HeLa), cisplatin caused a time- and concentration-dependent suppression of cell invasion through Matrigel. Inhibition of invasion was accompanied by upregulation of tissue inhibitor of matrix metalloproteinases-1 (TIMP-1), whereas levels of matrix metalloproteinase-2 (MMP-2), MMP-9 and TIMP-2 remained unchanged. Cisplatin's effects on TIMP-I expression and invasion were associated with phosphorylations of p38 and p42/44 mitogen-activated protein kinases and were abrogated by specific inhibitors of both pathways. The impact of TIMP-I in the anti-invasive action of cisplatin was proven by transfecting cells with small interfering RNA targeting TIMP-1, which completely reversed suppression of invasion by cisplatin. A functional relevance of TIMP-1 upregulation was substantiated by findings showing a concentration-dependent inhibition of Matrigel invasion by recombinant TIMP-1. The essential role of TIMP-1 in the anti-invasive action of cisplatin was confirmed using another human cervical carcinoma cell line (C33A) and human lung carcinoma cells (A549). Altogether, our data demonstrate a hitherto unknown mechanism by which cisplatin exerts its antimetastatic properties on highly invasive cancer cells.	Univ Erlangen Nurnberg, Dept Expt & Clin Pharmacol & Toxicol, D-91054 Erlangen, Germany	University of Erlangen Nuremberg	Hinz, B (corresponding author), Univ Erlangen Nurnberg, Dept Expt & Clin Pharmacol & Toxicol, Fahrstr 17, D-91054 Erlangen, Germany.	hinz@pharmakologie.uni-eriangen.de						Biroccio A, 2004, NEOPLASIA, V6, P195, DOI 10.1593/neo.03370; Chan VYW, 2005, REGUL PEPTIDES, V127, P87, DOI 10.1016/j.regpep.2004.10.016; Chintala SK, 1997, CLIN EXP METASTAS, V15, P361, DOI 10.1023/A:1018442003163; Choi J, 2005, CANCER RES, V65, P5554, DOI 10.1158/0008-5472.CAN-04-4570; Curran S, 2000, EUR J CANCER, V36, P1621, DOI 10.1016/S0959-8049(00)00156-8; Han R, 2005, J IMMUNOL, V174, P3072, DOI 10.4049/jimmunol.174.5.3072; Hartmann JT, 2003, EXPERT OPIN PHARMACO, V4, P889, DOI 10.1517/14656566.4.6.889; Hinz B, 2005, FASEB J, V19, P1929, DOI 10.1096/fj.04-3626fje; HONG JH, 2006, CHEM REV, V99, P2467; Jamieson ER, 1999, CHEM REV, V99, P2467, DOI 10.1021/cr980421n; KHOKHA R, 1992, J NATL CANCER I, V84, P1017, DOI 10.1093/jnci/84.13.1017; KHOKHA R, 1989, SCIENCE, V243, P947, DOI 10.1126/science.2465572; LOCHRER PJ, 1984, ANN INTERN MED, V100, P704; Mabuchi S, 2004, J BIOL CHEM, V279, P23477, DOI 10.1074/jbc.M313709200; Mori K, 2004, CANCER RES, V64, P7464, DOI 10.1158/0008-5472.CAN-04-1725; Morikawa T, 1995, Nihon Ika Daigaku Zasshi, V62, P320; Park MJ, 2005, J CELL BIOCHEM, V95, P955, DOI 10.1002/jcb.20452; Razzaque MS, 1999, HISTOCHEM CELL BIOL, V111, P359, DOI 10.1007/s004180050368; Stamenkovic I, 2000, SEMIN CANCER BIOL, V10, P415, DOI 10.1006/scbi.2000.0379; Tong L, 2004, CELL SIGNAL, V16, P1123, DOI 10.1016/j.cellsig.2004.03.003; Villedieu M, 2006, GYNECOL ONCOL, V101, P507, DOI 10.1016/j.ygyno.2005.11.017; Zhang QX, 2005, WORLD J GASTROENTERO, V11, P4451, DOI 10.3748/wjg.v11.i29.4451	22	33	34	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2007	26	39					5822	5827		10.1038/sj.onc.1210358	http://dx.doi.org/10.1038/sj.onc.1210358			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	202EP	17369856				2022-12-28	WOS:000248885100014
J	Sumi, T; Tsuneyoshi, N; Nakatsuji, N; Suemori, H				Sumi, T.; Tsuneyoshi, N.; Nakatsuji, N.; Suemori, H.			Apoptosis and differentiation of human embryonic stem cells induced by sustained activation of c-Myc	ONCOGENE			English	Article						c-Myc; human ES cells; self-renewal; differentiation	SELF-RENEWAL; ERYTHROID-DIFFERENTIATION; P53-DEPENDENT APOPTOSIS; CASPASE-3 ACTIVITY; MOUSE EMBRYOS; CANCER CELLS; ES CELLS; IN-VIVO; PLURIPOTENCY; MAINTENANCE	Embryonic stem (ES) cells are self-renewing, pluripotent cell lines, characterized by their potential to differentiate into all cell types. The proto-oncogene product c-Myc has a crucial role in the self-renewal of mouse ES (mES) cells, but its role in human ES (hES) cells is unknown. To investigate c-Myc functions in hES cells, we expressed an inducible c-Myc fused to the hormone-binding domain of the estrogen receptor (c-MycER) protein that is activated by 4-hydroxy-tamoxifen. In contrast to its role in mES cells, activation of c-MycER in hES cells induced apoptosis and differentiation into extraembryonic endoderm and trophectoderm lineages concomitant with reduced expression of the pluripotent markers Oct4 and Nanog. Neither inhibition of caspase activity nor knockdown of p53 by RNA interference impaired the induction of differentiation markers induced by c-Myc activation. In addition, differentiation induced by c-Myc activation was associated with downregulation of alpha 6 integrin expression, suggesting an important role for the integrin/extracellular matrix interaction in the regulation of ES cell behavior. None of these effects occurred with deletion of the c-Myc transactivation domain, indicating that c-Myc promotes both apoptosis and differentiation in a transcriptional activity-dependent manner. Together, our results provide new insights into the c-Myc functions regulating hES cell fate.	Kyoto Univ, Inst Frontier Med Sci, Stem Cell Res Ctr, Lab Embryon Stem Cell Res,Sakyo Ku, Kyoto 6068507, Japan; Kyoto Univ, Inst Frontier Med Sci, Dept Dev & Differentiat, Kyoto, Japan	Kyoto University; Kyoto University	Suemori, H (corresponding author), Kyoto Univ, Inst Frontier Med Sci, Stem Cell Res Ctr, Lab Embryon Stem Cell Res,Sakyo Ku, 53 Kawahara Cho,Shogoin, Kyoto 6068507, Japan.	hsuemori@frontier.kyoto-u.ac.jp						Adhikary S, 2005, NAT REV MOL CELL BIO, V6, P635, DOI 10.1038/nrm1703; Babaie Y, 2007, STEM CELLS, V25, P500, DOI 10.1634/stemcells.2006-0426; Berns K, 2004, NATURE, V428, P431, DOI 10.1038/nature02371; Boiani M, 2005, NAT REV MOL CELL BIO, V6, P872, DOI 10.1038/nrm1744; Boyer LA, 2005, CELL, V122, P947, DOI 10.1016/j.cell.2005.08.020; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Canelles M, 1997, ONCOGENE, V14, P1315, DOI 10.1038/sj.onc.1200948; Cartwright P, 2005, DEVELOPMENT, V132, P885, DOI 10.1242/dev.01670; Chambers I, 2003, CELL, V113, P643, DOI 10.1016/S0092-8674(03)00392-1; Chen S.-C., 2000, KLUW INT S ADV DATA, V21; Czyz J, 2001, DIFFERENTIATION, V68, P167, DOI 10.1046/j.1432-0436.2001.680404.x; Duval D, 2006, CELL DEATH DIFFER, V13, P564, DOI 10.1038/sj.cdd.4401789; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; EVANS MJ, 1981, NATURE, V292, P154, DOI 10.1038/292154a0; Fernando P, 2005, FASEB J, V19, P1671, DOI 10.1096/fj.04-2981fje; Fernando P, 2002, P NATL ACAD SCI USA, V99, P11025, DOI 10.1073/pnas.162172899; Frye M, 2003, DEVELOPMENT, V130, P2793, DOI 10.1242/dev.00462; Fujioka T, 2004, INT J DEV BIOL, V48, P1149, DOI 10.1387/ijdb.041852tf; Gandarillas A, 1997, GENE DEV, V11, P2869, DOI 10.1101/gad.11.21.2869; Gebhardt A, 2006, J CELL BIOL, V172, P139, DOI 10.1083/jcb.200506057; Hatton KS, 1996, MOL CELL BIOL, V16, P1794; Hay DC, 2004, STEM CELLS, V22, P225, DOI 10.1634/stemcells.22-2-225; Hemann MT, 2005, NATURE, V436, P807, DOI 10.1038/nature03845; Hoffman LM, 2005, NAT BIOTECHNOL, V23, P699, DOI 10.1038/nbt1102; Humphrey RK, 2004, STEM CELLS, V22, P522, DOI 10.1634/stemcells.22-4-522; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Hyslop L, 2005, STEM CELLS, V23, P1035, DOI 10.1634/stemcells.2005-0080; Juin P, 1999, GENE DEV, V13, P1367, DOI 10.1101/gad.13.11.1367; Kippin TE, 2005, GENE DEV, V19, P756, DOI 10.1101/gad.1272305; Leung LK, 1999, BRIT J CANCER, V81, P387, DOI 10.1038/sj.bjc.6690706; Lin TX, 2005, NAT CELL BIOL, V7, P165, DOI 10.1038/ncb1211; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; Maclean KH, 2003, MOL CELL BIOL, V23, P7256, DOI 10.1128/MCB.23.20.7256-7270.2003; MARTIN GR, 1981, P NATL ACAD SCI-BIOL, V78, P7634, DOI 10.1073/pnas.78.12.7634; Matsuda T, 1999, EMBO J, V18, P4261, DOI 10.1093/emboj/18.15.4261; Meletis K, 2006, DEVELOPMENT, V133, P363, DOI 10.1242/dev.02208; Miner JH, 2004, ANNU REV CELL DEV BI, V20, P255, DOI 10.1146/annurev.cellbio.20.010403.094555; Mitsui K, 2003, CELL, V113, P631, DOI 10.1016/S0092-8674(03)00393-3; Molofsky AV, 2003, NATURE, V425, P962, DOI 10.1038/nature02060; MORGENBESSER SD, 1995, EMBO J, V14, P743, DOI 10.1002/j.1460-2075.1995.tb07053.x; Nguyen L, 2006, GENE DEV, V20, P1511, DOI 10.1101/gad.377106; Nichols J, 1998, CELL, V95, P379, DOI 10.1016/S0092-8674(00)81769-9; Niwa H, 1998, GENE DEV, V12, P2048, DOI 10.1101/gad.12.13.2048; Okuyama R, 2004, DEV CELL, V6, P551, DOI 10.1016/S1534-5807(04)00098-X; Park IK, 2003, NATURE, V423, P302, DOI 10.1038/nature01587; Sato N, 2004, NAT MED, V10, P55, DOI 10.1038/nm979; Sears R, 2000, GENE DEV, V14, P2501, DOI 10.1101/gad.836800; Selvakumaran M, 1996, BLOOD, V88, P1248, DOI 10.1182/blood.V88.4.1248.bloodjournal8841248; Soengas MS, 1999, SCIENCE, V284, P156, DOI 10.1126/science.284.5411.156; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; Strasser A, 2000, ANNU REV BIOCHEM, V69, P217, DOI 10.1146/annurev.biochem.69.1.217; Suemori H, 2006, BIOCHEM BIOPH RES CO, V345, P926, DOI 10.1016/j.bbrc.2006.04.135; Sumi T, 2004, STEM CELLS, V22, P861, DOI 10.1634/stemcells.22-5-861; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145; van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092-8674(02)01014-0; Wilson A, 2004, GENE DEV, V18, P2747, DOI 10.1101/gad.313104; Xu CH, 2001, NAT BIOTECHNOL, V19, P971, DOI 10.1038/nbt1001-971; Xu RH, 2002, NAT BIOTECHNOL, V20, P1261, DOI 10.1038/nbt761; Xu RH, 2005, NAT METHODS, V2, P185, DOI 10.1038/NMETH744; Yamane T, 2005, P NATL ACAD SCI USA, V102, P3312, DOI 10.1073/pnas.0500167102; Yao S, 2006, P NATL ACAD SCI USA, V103, P6907, DOI 10.1073/pnas.0602280103; Yeh E, 2004, NAT CELL BIOL, V6, P308, DOI 10.1038/ncb1110; Ying QL, 2003, CELL, V115, P281, DOI 10.1016/S0092-8674(03)00847-X; Yuan YZ, 2004, NAT CELL BIOL, V6, P436, DOI 10.1038/ncb1126; Zermati Y, 2001, J EXP MED, V193, P247, DOI 10.1084/jem.193.2.247; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	67	63	75	0	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG	2007	26	38					5564	5576		10.1038/sj.onc.1210353	http://dx.doi.org/10.1038/sj.onc.1210353			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	200ZS	17369859				2022-12-28	WOS:000248801900002
J	Waha, A; Koch, A; Hartmann, W; Milde, U; Felsberg, J; Hubner, A; Mikeska, T; Goodyer, CG; Sorensen, N; Lindberg, I; Wiestler, OD; Pietsch, T; Waha, A				Waha, A.; Koch, A.; Hartmann, W.; Milde, U.; Felsberg, J.; Huebner, A.; Mikeska, T.; Goodyer, C. G.; Soerensen, N.; Lindberg, I.; Wiestler, O. D.; Pietsch, T.; Waha, A.			SGNE1/7B2 is epigenetically altered and transcriptionally downregulated in human medulloblastomas	ONCOGENE			English	Article						medulloblastoma; SGNE1/7B2; methylation; DMH; cRT-PCR	PRIMITIVE NEUROECTODERMAL TUMORS; CENTRAL-NERVOUS-SYSTEM; COMPARATIVE GENOMIC HYBRIDIZATION; NEUROENDOCRINE PROTEIN 7B2; NH2-TERMINAL SEQUENCE; PITUITARY POLYPEPTIDE; CONVERTASE PC2; CELL-GROWTH; IN-VIVO; EXPRESSION	In a genome-wide screen using differential methylation hybridization (DMH), we have identified a CpG island within the 50 region and untranslated first exon of the secretory granule neuroendocrine protein 1 gene (SGNE1/7B2) that showed hypermethylation in medulloblastomas compared to fetal cerebellum. Bisulfite sequencing and combined bisulfite restriction assay were performed to confirm the methylation status of this CpG island in primary medulloblastomas and medulloblastoma cell lines. Hypermethylation was detected in 16/23 (70%) biopsies and 7/8 (87%) medulloblastoma cell lines, but not in nonneoplastic fetal (n=8) cerebellum. Expression of SGNE1 was investigated by semi-quantitative competitive reverse transcription-polymerase chain reaction and found to be significantly downregulated or absent in all, but one primary medulloblastomas and all cell lines compared to fetal cerebellum. After treatment of medulloblastoma cell lines with 5-aza-2'-deoxycytidine, transcription of SGNE1 was restored. No mutation was found in the coding region of SGNE1 by single-strand conformation polymorphism analysis. Reintroduction of SGNE1 into the medulloblastoma cell line D283Med led to a significant growth suppression and reduced colony formation. In summary, we have identified SGNE1 as a novel epigenetically silenced gene in medulloblastomas. Its frequent inactivation, as well as its inhibitory effect on tumor cell proliferation and focus formation strongly argues for a significant role in medulloblastoma development.	Univ Bonn, Med Ctr, Dept Neuropathol, D-53105 Bonn, Germany; McGill Univ, Montreal Childrens Hosp, Res Inst, Montreal, PQ H3H 1P3, Canada; Univ Wurzburg, Dept Pediat Neurosurg, D-97070 Wurzburg, Germany; Louisiana State Univ, Med Ctr, Dept Biochem & Mol Biol, New Orleans, LA USA; German Canc Res Ctr, D-6900 Heidelberg, Germany	University of Bonn; McGill University; University of Wurzburg; Louisiana State University System; Helmholtz Association; German Cancer Research Center (DKFZ)	Waha, A (corresponding author), Univ Bonn, Med Ctr, Dept Neuropathol, Sigmund Freud Str 25, D-53105 Bonn, Germany.	awaha1@uni-bonn.de	Lindberg, Iris/Q-3825-2019; Hartmann, Wolfgang/G-1893-2017; Mikeska, Thomas/B-4876-2008	Hartmann, Wolfgang/0000-0002-7609-5021; Mikeska, Thomas/0000-0003-1318-0859	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049703] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK049703] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BIEGEL JA, 1989, GENE CHROMOSOME CANC, V1, P139, DOI 10.1002/gcc.2870010206; BIGNER SH, 1990, CANCER RES, V50, P2347; Bock C, 2005, BIOINFORMATICS, V21, P4067, DOI 10.1093/bioinformatics/bti652; BRAKS JAM, 1994, CELL, V78, P263, DOI 10.1016/0092-8674(94)90296-8; Braks JAM, 1996, EUR J BIOCHEM, V236, P60, DOI 10.1111/j.1432-1033.1996.00060.x; Cassidy SB, 1997, J MED GENET, V34, P917, DOI 10.1136/jmg.34.11.917; Collini P, 1998, VIRCHOWS ARCH, V432, P505, DOI 10.1007/s004280050198; Fruhwald MC, 2001, ONCOGENE, V20, P5033, DOI 10.1038/sj.onc.1204613; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; Hartmann W, 2006, CLIN CANCER RES, V12, P3019, DOI 10.1158/1078-0432.CCR-05-2187; HSI KL, 1982, FEBS LETT, V147, P261, DOI 10.1016/0014-5793(82)81055-7; IGUCHI H, 1984, NEUROENDOCRINOLOGY, V39, P453, DOI 10.1159/000124020; Jeannotte R, 1997, DNA CELL BIOL, V16, P1175, DOI 10.1089/dna.1997.16.1175; Kleihues P, 2002, J NEUROPATH EXP NEUR, V61, P215, DOI 10.1093/jnen/61.3.215; Kobayashi I, 2003, ENDOCRINE, V22, P285, DOI 10.1385/ENDO:22:3:285; KOCH KR, 1996, ALLG VERMESS NACHR, V1, P1; Krause RM, 2001, ASM NEWS, V67, P15; Lindsey Janet C, 2005, Neurosurg Focus, V19, pE10, DOI 10.3171/foc.2005.19.5.11; MATTEI MG, 1990, GENOMICS, V6, P436, DOI 10.1016/0888-7543(90)90473-8; Mbikay M, 2001, BIOCHEM J, V357, P329, DOI 10.1042/0264-6021:3570329; Mercapide J, 2002, CLIN CANCER RES, V8, P1740; PIETSCH T, 1994, CANCER RES, V54, P3278; Pomeroy SL, 2002, NATURE, V415, P436, DOI 10.1038/415436a; Reardon DA, 1997, CANCER RES, V57, P4042; ROEBROEK AJM, 1989, CANCER RES, V49, P4154; Russo C, 1999, CANCER, V86, P331, DOI 10.1002/(SICI)1097-0142(19990715)86:2<331::AID-CNCR18>3.0.CO;2-#; Schmidt G, 2006, DIABETES, V55, P452, DOI 10.2337/diabetes.55.02.06.db05-0733; SEIDAH NG, 1983, ARCH BIOCHEM BIOPHYS, V225, P525, DOI 10.1016/0003-9861(83)90063-2; Seidel B, 1998, DNA CELL BIOL, V17, P1017, DOI 10.1089/dna.1998.17.1017; Strausberg RL, 2002, P NATL ACAD SCI USA, V99, P16899, DOI 10.1073/pnas.242603899; Uziel T, 2006, CELL CYCLE, V5, P363, DOI 10.4161/cc.5.4.2475; Waha A, 2005, NEOPLASIA, V7, P193, DOI 10.1593/neo.04490; Waha A, 2003, J NEUROPATH EXP NEUR, V62, P1192, DOI 10.1093/jnen/62.11.1192; Waha A, 1998, BRAIN PATHOL, V8, P13; WALDBIESER GC, 1991, ENDOCRINOLOGY, V128, P3228, DOI 10.1210/endo-128-6-3228; Westphal CH, 1999, CELL, V96, P689, DOI 10.1016/S0092-8674(00)80579-6; Yan PS, 2001, CANCER RES, V61, P8375; ZHU XR, 1995, J CELL BIOL, V129, P1641, DOI 10.1083/jcb.129.6.1641	38	17	17	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG	2007	26	38					5662	5668		10.1038/sj.onc.1210338	http://dx.doi.org/10.1038/sj.onc.1210338			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	200ZS	17334394				2022-12-28	WOS:000248801900012
J	Chang, DLF; Qiu, W; Ying, H; Zhang, Y; Chen, CY; Xiao, ZXJ				Chang, D. L. F.; Qiu, W.; Ying, H.; Zhang, Y.; Chen, C-Y; Xiao, Z-X J.			ARF promotes accumulation of retinoblastoma protein through inhibition of MDM2	ONCOGENE			English	Article						ARF; retinoblastoma protein; MDM2; cell; cycle; cancer	TUMOR-SUPPRESSOR; INK4A LOCUS; C-ABL; EXON 1-BETA; NUCLEOLAR LOCALIZATION; SELECTIVE DELETION; DEPENDENT KINASES; NUCLEAR EXPORT; STABILIZES P53; G(1) CONTROL	The INK4a/ARF locus, encoding two tumor suppressor proteins, p16(INK4a) and p14(ARF) (ARF), plays key roles in many cellular processes including cell proliferation, apoptosis, cellular senescence and differentiation. Inactivation of INK4a/ARF is one of the most frequent events during human cancer development. Although p16(INK4a) is a critical component in retinoblastoma protein (Rb)-mediated growth regulatory pathway, p14ARF plays a pivotal role in the activation of p53 upon oncogenic stress signals. A body of evidence indicates that ARF also possesses growth suppression functions independent of p53, the mechanism of which is not well understood. We have recently shown that MDM2 interacts with Rb and promotes proteasome-dependent Rb degradation. In this study, we show that ARF disrupts MDM2 -Rb interaction resulting in Rb accumulation. Wild-type ARF, but not ARF mutant defective in MDM2 interaction, stabilizes Rb and inhibits colony foci formation independent of p53. In addition, ablation of Rb impairs ARF function in growth suppression. Thus, this study demonstrates that ARF plays a direct role in regulation of Rb and suggests that inactivation of ARF may lead to defects in both p53 and Rb pathways in human cancer development.	Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Med, Grad Program Mol Med, Boston, MA 02118 USA; Boston Univ, Sch Med, Ctr Pulm, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Pathol, Boston, MA 02118 USA	Boston University; Boston University; Boston University; Boston University	Xiao, ZXJ (corresponding author), Boston Univ, Sch Med, Dept Biochem, 715 Albany St,K-423, Boston, MA 02118 USA.	jxiao@bu.edu	Ying, Haoqiang/AAK-4325-2020					Berezutskaya E, 1997, CELL GROWTH DIFFER, V8, P1277; Bothner B, 2001, J MOL BIOL, V314, P263, DOI 10.1006/jmbi.2001.5110; Boyer SN, 1996, CANCER RES, V56, P4620; BURNS JC, 1993, P NATL ACAD SCI USA, V90, P8033, DOI 10.1073/pnas.90.17.8033; Carness KH, 2000, ISSUES SCI TECHNOL, V16, P19; Chan HM, 2001, NAT CELL BIOL, V3, P667, DOI 10.1038/35083062; Christophorou MA, 2006, NATURE, V443, P214, DOI 10.1038/nature05077; Dannenberg JH, 2000, GENE DEV, V14, P3051, DOI 10.1101/gad.847700; Dias SS, 2006, ONCOGENE, V25, P6666, DOI 10.1038/sj.onc.1209671; Eischen CM, 1999, GENE DEV, V13, P2658, DOI 10.1101/gad.13.20.2658; Goldberg Z, 2002, EMBO J, V21, P3715, DOI 10.1093/emboj/cdf384; Groth A, 2000, J BIOL CHEM, V275, P27473; Hainaut P, 1997, NUCLEIC ACIDS RES, V25, P151, DOI 10.1093/nar/25.1.151; Hall M, 1996, ADV CANCER RES, V68, P67, DOI 10.1016/S0065-230X(08)60352-8; Higashitsuji H, 2000, NAT MED, V6, P96, DOI 10.1038/71600; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; Iida S, 2000, INT J CANCER, V87, P654, DOI 10.1002/1097-0215(20000901)87:5<654::AID-IJC6>3.0.CO;2-P; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Kumar R, 1998, GENE CHROMOSOME CANC, V23, P273, DOI 10.1002/(SICI)1098-2264(199811)23:3<273::AID-GCC11>3.0.CO;2-N; Leduc C, 2006, ONCOGENE, V25, P4147, DOI 10.1038/sj.onc.1209446; Llanos S, 2001, NAT CELL BIOL, V3, P445, DOI 10.1038/35074506; Midgley CA, 2000, ONCOGENE, V19, P2312, DOI 10.1038/sj.onc.1203593; Modestou M, 2001, CANCER RES, V61, P3145; Momand J, 1998, NUCLEIC ACIDS RES, V26, P3453, DOI 10.1093/nar/26.15.3453; Nguyen DX, 2004, EMBO J, V23, P1609, DOI 10.1038/sj.emboj.7600176; Pan W, 2003, ONCOGENE, V22, P5496, DOI 10.1038/sj.onc.1206857; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Quelle DE, 1997, P NATL ACAD SCI USA, V94, P669, DOI 10.1073/pnas.94.2.669; Randerson-Moor JA, 2001, HUM MOL GENET, V10, P55, DOI 10.1093/hmg/10.1.55; Rizos H, 2001, ONCOGENE, V20, P5543, DOI 10.1038/sj.onc.1204728; Sage J, 2000, GENE DEV, V14, P3037, DOI 10.1101/gad.843200; Sdek P, 2005, MOL CELL, V20, P699, DOI 10.1016/j.molcel.2005.10.017; Sdek P, 2004, J BIOL CHEM, V279, P53317, DOI 10.1074/jbc.M406062200; Serrano M, 2000, CARCINOGENESIS, V21, P865, DOI 10.1093/carcin/21.5.865; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; Sharpless NE, 2004, ONCOGENE, V23, P379, DOI 10.1038/sj.onc.1207074; Sherr CJ, 2001, NAT REV MOL CELL BIO, V2, P731, DOI 10.1038/35096061; Sionov RV, 2001, MOL CELL BIOL, V21, P5869; Sionov RV, 1999, J BIOL CHEM, V274, P8371, DOI 10.1074/jbc.274.13.8371; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Sui GC, 2004, CELL, V117, P859, DOI 10.1016/j.cell.2004.06.004; Tao WK, 1999, P NATL ACAD SCI USA, V96, P6937, DOI 10.1073/pnas.96.12.6937; Tsai KY, 2002, P NATL ACAD SCI USA, V99, P16865, DOI 10.1073/pnas.262499599; Uchida CH, 2005, EMBO J, V24, P160, DOI 10.1038/sj.emboj.7600486; Viswanathan M, 2001, ORAL ONCOL, V37, P341, DOI 10.1016/S1368-8375(00)00112-3; Wang CG, 2005, EMBO J, V24, P3279, DOI 10.1038/sj.emboj.7600791; Wang IJ, 2001, MOL VIS, V7, P20; Weber JD, 2000, MOL CELL BIOL, V20, P2517, DOI 10.1128/MCB.20.7.2517-2528.2000; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; Weber JD, 2000, GENE DEV, V14, P2358, DOI 10.1101/gad.827300; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0; Ying HQ, 2006, CELL CYCLE, V5, P506, DOI 10.4161/cc.5.5.2515; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zhang YP, 1999, MOL CELL, V3, P579, DOI 10.1016/S1097-2765(00)80351-2	56	12	17	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 12	2007	26	32					4627	4634		10.1038/sj.onc.1210254	http://dx.doi.org/10.1038/sj.onc.1210254			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	190DJ	17297463				2022-12-28	WOS:000248037900003
J	Murata-Kamiya, N; Kurashima, Y; Teishikata, Y; Yamahashi, Y; Saito, Y; Higashi, H; Aburatani, H; Akiyama, T; Peek, RM; Azuma, T; Hatakeyama, M				Murata-Kamiya, N.; Kurashima, Y.; Teishikata, Y.; Yamahashi, Y.; Saito, Y.; Higashi, H.; Aburatani, H.; Akiyama, T.; Peek, R. M., Jr.; Azuma, T.; Hatakeyama, M.			Helicobacter pylori CagA interacts with E-cadherin and deregulates the beta-catenin signal that promotes intestinal transdifferentiation in gastric epithelial cells	ONCOGENE			English	Article						Helicobacter pylori CagA; gastric adenocarcinoma; intestinal metaplasia; E-cadherin; beta-catenin	ATROPHIC GASTRITIS; WNT PATHWAY; PROTEIN; ACTIVATION; CANCER; EXPRESSION; CDX1; INFECTION; TARGET; GENE	Infection with Helicobacter pylori cagA-positive strains is associated with gastric adenocarcinoma. Intestinal metaplasia is a precancerous lesion of the stomach characterized by transdifferentiation of the gastric mucosa to an intestinal phenotype. The H. pylori cagA gene product, CagA, is delivered into gastric epithelial cells, where it undergoes tyrosine phosphorylation by Src family kinases. Tyrosine-phosphorylated CagA specifically binds to and activates SHP-2 phosphatase, thereby inducing cell-morphological transformation. We report here that CagA physically interacts with E-cadherin independently of CagA tyrosine phosphorylation. The CagA/E-cadherin interaction impairs the complex formation between E-cadherin and beta-catenin, causing cytoplasmic and nuclear accumulation of beta-catenin. CagA-deregulated beta-catenin then transactivates beta-catenin-dependent genes such as cdx1, which encodes intestinal specific CDX1 transcription factor. In addition to b-catenin signal, CagA also transactivates p21(WAF1/Cip1), again, in a phosphorylation-independent manner. Consequently, CagA induces aberrant expression of an intestinal-differentiation marker, goblet-cell mucin MUC2, in gastric epithelial cells that have been arrested in G1 by p21(WAF1/Cip1). These results indicate that perturbation of the E-cadherin/beta-catenin complex by H. pylori CagA plays an important role in the development of intestinal metaplasia, a premalignant transdifferentiation of gastric epithelial cells from which intestinal-type gastric adenocarcinoma arises.	Hokkaido Univ, Inst Med Genet, Div Mol Oncol, Kita Ku, Sapporo, Hokkaido 0600815, Japan; Univ Tokyo, Adv Sci & Technol Res Ctr, Tokyo, Japan; Univ Tokyo, Inst Mol & Cellular Biosci, Lab Mol & Genet Informat, Tokyo, Japan; Vanderbilt Univ, Sch Med, Dept Gastroenterol, Div Gastroenterol, Nashville, TN 37212 USA; Kobe Univ, Grad Sch Med, Int Ctr Med Res, Kobe, Hyogo, Japan	Hokkaido University; University of Tokyo; University of Tokyo; Vanderbilt University; Kobe University	Hatakeyama, M (corresponding author), Hokkaido Univ, Inst Med Genet, Div Mol Oncol, Kita Ku, Kita 15,Nishi 7, Sapporo, Hokkaido 0600815, Japan.	mhata@igm.hokudai.ac.jp	Higashi, Hideaki/F-6872-2012					Amieva MR, 2003, SCIENCE, V300, P1430, DOI 10.1126/science.1081919; Bailey T, 1998, AM J PATHOL, V152, P135; Bebb JR, 2006, J CLIN PATHOL, V59, P1261, DOI 10.1136/jcp.2006.036772; Berx G, 1998, HUM MUTAT, V12, P226, DOI 10.1002/(SICI)1098-1004(1998)12:4<226::AID-HUMU2>3.0.CO;2-D; Bierie B, 2003, ONCOGENE, V22, P3875, DOI 10.1038/sj.onc.1206426; Blache P, 2004, J CELL BIOL, V166, P37, DOI 10.1083/jcb.200311021; BLASER MJ, 1995, CANCER RES, V55, P2111; Churin Y, 2003, J CELL BIOL, V161, P249, DOI 10.1083/jcb.200208039; Duman-Scheel M, 2004, P NATL ACAD SCI USA, V101, P3857, DOI 10.1073/pnas.0400526101; Franco AT, 2005, P NATL ACAD SCI USA, V102, P10646, DOI 10.1073/pnas.0504927102; Gavert N, 2005, J CELL BIOL, V168, P633, DOI 10.1083/jcb.200408051; Giles RH, 2003, BBA-REV CANCER, V1653, P1, DOI 10.1016/S0304-419X(03)00005-2; Guilford P, 1998, NATURE, V392, P402, DOI 10.1038/32918; Guo RJ, 2004, CANCER BIOL THER, V3, P593, DOI 10.4161/cbt.3.7.913; Hatakeyama M, 2004, NAT REV CANCER, V4, P688, DOI 10.1038/nrc1433; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Higashi H, 2004, J BIOL CHEM, V279, P17205, DOI 10.1074/jbc.M309964200; Higashi H, 2002, SCIENCE, V295, P683, DOI 10.1126/science.1067147; Johnston LA, 1998, NATURE, V394, P82, DOI 10.1038/27925; Kenny PA, 2005, BMC CANCER, V5, DOI 10.1186/1471-2407-5-3; Kioussi C, 2002, CELL, V111, P673, DOI 10.1016/S0092-8674(02)01084-X; Knudsen S., 2002, BIOL GUIDE ANAL DNA; KUIPERS EJ, 1995, J NATL CANCER I, V87, P1777, DOI 10.1093/jnci/87.23.1777; Lickert H, 2000, DEVELOPMENT, V127, P3805; Mimuro H, 2002, MOL CELL, V10, P745, DOI 10.1016/S1097-2765(02)00681-0; Miyoshi K, 2002, P NATL ACAD SCI USA, V99, P219, DOI 10.1073/pnas.012414099; Mizoshita T, 2004, J CANCER RES CLIN, V130, P29, DOI 10.1007/s00432-003-0503-1; Mutoh H, 2004, GUT, V53, P1416, DOI 10.1136/gut.2003.032482; Odenbreit S, 2000, SCIENCE, V287, P1497, DOI 10.1126/science.287.5457.1497; Okubo Tadashi, 2004, J Biol, V3, P11, DOI 10.1186/jbiol3; Parsonnet J, 1997, GUT, V40, P297, DOI 10.1136/gut.40.3.297; Pinto D, 2003, GENE DEV, V17, P1709, DOI 10.1101/gad.267103; Segal ED, 1999, P NATL ACAD SCI USA, V96, P14559, DOI 10.1073/pnas.96.25.14559; Silberg DG, 1997, GASTROENTEROLOGY, V113, P478, DOI 10.1053/gast.1997.v113.pm9247467; Souaze F, 2006, CARCINOGENESIS, V27, P708, DOI 10.1093/carcin/bgi269; Sozzi M, 1998, AM J GASTROENTEROL, V93, P375, DOI 10.1111/j.1572-0241.1998.00375.x; Tago K, 2000, GENE DEV, V14, P1741; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; Togawa K, 2000, J CELL PHYSIOL, V183, P129, DOI 10.1002/(SICI)1097-4652(200004)183:1<129::AID-JCP15>3.0.CO;2-S; Wang JB, 2004, CURR OPIN GENET DEV, V14, P533, DOI 10.1016/j.gde.2004.07.013; Yokoyama K, 2005, P NATL ACAD SCI USA, V102, P9661, DOI 10.1073/pnas.0502529102	41	314	332	3	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 12	2007	26	32					4617	4626		10.1038/sj.onc.1210251	http://dx.doi.org/10.1038/sj.onc.1210251			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	190DJ	17237808				2022-12-28	WOS:000248037900002
J	Yu, J; Wang, P; Ming, L; Wood, MA; Zhang, L				Yu, J.; Wang, P.; Ming, L.; Wood, M. A.; Zhang, L.			SMAC/Diablo mediates the proapoptotic function of PUMA by regulating PUMA-induced mitochondrial events	ONCOGENE			English	Article						SMAC/Diablo; PUMA; apoptosis; mitochondria; DNA damage	STRESS-INDUCED APOPTOSIS; COLON-CANCER CELLS; DRUG-INDUCED APOPTOSIS; CYTOCHROME-C; CASPASE ACTIVATION; INTERFERING RNAS; MAMMALIAN-CELLS; TUMOR-CELLS; IN-VIVO; SMAC	p53-upregulated modulator of apoptosis (PUMA) is a BH3-only Bcl-2 family protein and an essential mediator of DNA damage-induced apoptosis. PUMA is localized in the mitochondria and induces apoptosis through the mitochondrial pathway. However, the mechanisms of PUMA-induced apoptosis remain unclear. In this study, we found that second mitochondria- derived activator of caspase (SMAC)/Diablo, a mitochondrial apoptogenic protein, mediates the proapoptotic function of PUMA by regulating PUMA-induced mitochondrial events. SMAC is consistently released into the cytosol in colon cancer cells undergoing PUMA-induced apoptosis. In SMAC-deficient cells, execution of PUMA-induced apoptosis is abrogated, in company with decreases in caspase activation, cytosolic release of cytochrome c and collapse of mitochondrial membrane potential. Reconstituting SMAC expression restored these events in the SMAC-deficient cells. Furthermore, SMAC and agents that mimic the inhibitor of apoptosis proteins (IAPs) inhibition function of SMAC significantly sensitize cells to PUMA-induced apoptosis. These results demonstrate an important role of SMAC in executing DNA damage-induced and PUMA-mediated apoptosis and suggest that SMAC participates in a feedback amplification loop to promote cytochrome c release and other mitochondrial events in apoptosis.	Univ Pittsburgh, Sch Med, Univ Pittsburgh Canc Inst, Hillman Canc Ctr Res Pavil,Dept Pharmacol, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Univ Pittsburgh Canc Inst, Hillman Canc Ctr Res Pavil,Dept Pathol, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Zhang, L (corresponding author), Univ Pittsburgh, Sch Med, Univ Pittsburgh Canc Inst, Hillman Canc Ctr Res Pavil,Dept Pharmacol, Suite 2 42D,5117 Ctr Ave, Pittsburgh, PA 15213 USA.	zhanglx@upmc.edu	Yu, Jian/A-8301-2009; Zhang, Lin/A-7389-2009; Wood-Trageser, Michelle/GPG-1868-2022	Yu, Jian/0000-0002-4021-1000; Zhang, Lin/0000-0003-0018-3903; Wood-Trageser, Michelle/0000-0002-1880-4926	NATIONAL CANCER INSTITUTE [R01CA106348] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA106348, CA106348] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arnt CR, 2003, CELL DEATH DIFFER, V10, P1118, DOI 10.1038/sj.cdd.4401294; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Chen Q, 2000, CELL DEATH DIFFER, V7, P227, DOI 10.1038/sj.cdd.4400629; Cory S, 2003, ONCOGENE, V22, P8590, DOI 10.1038/sj.onc.1207102; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; Deng YB, 2002, GENE DEV, V16, P33, DOI 10.1101/gad.949602; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Elbashir SM, 2002, METHODS, V26, P199, DOI 10.1016/S1046-2023(02)00023-3; Fulda S, 2002, NAT MED, V8, P808, DOI 10.1038/nm735; Giagkousiklidis S, 2005, CANCER RES, V65, P10502, DOI 10.1158/0008-5472.CAN-05-0866; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Han JW, 2001, P NATL ACAD SCI USA, V98, P11318, DOI 10.1073/pnas.201208798; Hansen T, 2006, CELL DEATH DIFFER, V13, P1181, DOI 10.1038/sj.cdd.4401795; Hao ZY, 2005, CELL, V121, P579, DOI 10.1016/j.cell.2005.03.016; Hemann MT, 2004, P NATL ACAD SCI USA, V101, P9333, DOI 10.1073/pnas.0403286101; Jeffers JR, 2003, CANCER CELL, V4, P321, DOI 10.1016/S1535-6108(03)00244-7; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; Kohli M, 2004, P NATL ACAD SCI USA, V101, P16897, DOI 10.1073/pnas.0403405101; Lakhani SA, 2006, SCIENCE, V311, P847, DOI 10.1126/science.1115035; Lassus P, 2002, SCIENCE, V297, P1352, DOI 10.1126/science.1074721; Li L, 2004, SCIENCE, V305, P1471, DOI 10.1126/science.1098231; Ming L, 2006, J BIOL CHEM, V281, P16034, DOI 10.1074/jbc.M513587200; Munoz-Pinedo C, 2006, P NATL ACAD SCI USA, V103, P11573, DOI 10.1073/pnas.0603007103; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Okada H, 2004, NAT REV CANCER, V4, P592, DOI 10.1038/nrc1412; Okada H, 2002, MOL CELL BIOL, V22, P3509, DOI 10.1128/MCB.22.10.3509-3517.2002; Perfettini JL, 2004, J EXP MED, V199, P629, DOI 10.1084/jem.20031216; Rashmi R, 2005, CARCINOGENESIS, V26, P713, DOI 10.1093/carcin/bgi025; Reimertz C, 2003, J CELL BIOL, V162, P587, DOI 10.1083/jcb.200305149; Sun HY, 2004, J AM CHEM SOC, V126, P16686, DOI 10.1021/ja047438+; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Villunger A, 2003, SCIENCE, V302, P1036, DOI 10.1126/science.1090072; WALDMAN T, 1995, CANCER RES, V55, P5187; Wang XD, 2001, GENE DEV, V15, P2922; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1; Yu J, 2003, CANCER CELL, V4, P248, DOI 10.1016/S1535-6108(03)00249-6; Yu J, 2003, P NATL ACAD SCI USA, V100, P1931, DOI 10.1073/pnas.2627984100; Yu SW, 2002, SCIENCE, V297, P259, DOI 10.1126/science.1072221; Zhang L, 2000, SCIENCE, V290, P989, DOI 10.1126/science.290.5493.989; Zhao J, 2006, CANCER GENE THER, V13, P420, DOI 10.1038/sj.cgt.7700910; Zhou LL, 2005, APOPTOSIS, V10, P289, DOI 10.1007/s10495-005-0803-9	42	68	76	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 21	2007	26	29					4189	4198		10.1038/sj.onc.1210196	http://dx.doi.org/10.1038/sj.onc.1210196			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	184CY	17237824				2022-12-28	WOS:000247619900001
J	Huang, P; Senga, T; Hamaguchi, M				Huang, P.; Senga, T.; Hamaguchi, M.			A novel role of phospho-beta-catenin in microtubule regrowth at centrosome	ONCOGENE			English	Article						phospho-beta-catenin; microtubule regrowth; centrosome	WNT-SIGNALING PATHWAY; TUMOR-SUPPRESSOR; MITOTIC SPINDLE; CELL-CYCLE; PROTEIN; KINASE; CANCER; IDENTIFICATION; LOCALIZATION; PROGRESSION	beta-Catenin is a biologically important molecule playing critical roles in both cell adhesion and transcriptional regulation in the Wnt pathway. Here, we show that phospho-beta-atenin (phosphorylated at Ser33/37/Thr41), which is reported to be degraded immediately after its phosphorylation, accumulated in the centrosome. Whereas phospho- mimicking mutant, S33/37/T41E-beta-catenin, could local ize to the centrosome, S33A-beta-catenin that lacks the phosphorylation site lost its localization to the centrosome. Phospho-beta-catenin localized mai nly to mother centrosome during the interphase and was recruited to daughter centrosome in M-phase. Depletion of beta-catenin with small interfering RNA or inhibition of its phosphorylation by LiCl treatment caused disruption of radial microtubule (MT) array and retardation of the MT regrowth during the recovery from nocodazole treatment. In addition, these treatments increased the frequency of mono-astral MT reorganization. Furthermore, overexpression of the nonphosphorylatable beta-catenin, but not the phospho-mimicking beta-catenin, markedly disrupted radial MT array and repressed the MT regrowth. In contrast, phospho-mimicking beta-atenin localized to both of the duplicated centrosomes with aberrant larger and denser radial MTs array formation. In addition, some of the cells overexpressing phospho-mimicking beta-catenin had mul tiple centrosomes. Taken together, this study demonstrates a novel role of phospho-beta-catenin in MT organization at the centrosomes.	Nagoya Univ, Grad Sch Med, Dept Oncol, Div Canc Biol,Showa Ku, Nagoya, Aichi 4668550, Japan	Nagoya University	Hamaguchi, M (corresponding author), Nagoya Univ, Grad Sch Med, Dept Oncol, Div Canc Biol,Showa Ku, 65 Tsurumaicho, Nagoya, Aichi 4668550, Japan.	mhamagu@med.nagoya-u.ac.jp						Amin ARMR, 2003, CANCER RES, V63, P6334; Askham JM, 2002, MOL BIOL CELL, V13, P3627, DOI 10.1091/mbc.E02-01-0061; Ciani L, 2004, J CELL BIOL, V164, P243, DOI 10.1083/jcb.200309096; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Guardavaccaro D, 2003, DEV CELL, V4, P799, DOI 10.1016/S1534-5807(03)00154-0; Gundersen GG, 1999, CURR OPIN CELL BIOL, V11, P81, DOI 10.1016/S0955-0674(99)80010-6; Harwood A, 2003, NAT CELL BIOL, V5, P275, DOI 10.1038/ncb0403-275; Hayward DG, 2004, CANCER RES, V64, P7370, DOI 10.1158/0008-5472.CAN-04-0960; Huelsken J, 2002, J CELL SCI, V115, P3977, DOI 10.1242/jcs.00089; Jimbo T, 2002, NAT CELL BIOL, V4, P323, DOI 10.1038/ncb779; Kaplan DD, 2004, J BIOL CHEM, V279, P10829, DOI 10.1074/jbc.C400035200; Kielhorn E, 2003, INT J CANCER, V103, P652, DOI 10.1002/ijc.10893; Krylova O, 2000, J CELL BIOL, V151, P83, DOI 10.1083/jcb.151.1.83; Ligon LA, 2001, NAT CELL BIOL, V3, P913, DOI 10.1038/ncb1001-913; Liu YZ, 2001, ONCOGENE, V20, P5908, DOI 10.1038/sj.onc.1204738; Lucas FR, 1998, J CELL SCI, V111, P1351; Nigg EA, 2002, NAT REV CANCER, V2, P815, DOI 10.1038/nrc924; Olmeda D, 2003, MOL BIOL CELL, V14, P2844, DOI 10.1091/mbc.E03-01-0865; Ou YY, 2002, J CELL SCI, V115, P1825; Pellman D, 2001, SCIENCE, V291, P2555, DOI 10.1126/science.1057337; Piel M, 2000, J CELL BIOL, V149, P317, DOI 10.1083/jcb.149.2.317; Quintyne NJ, 2002, J CELL BIOL, V159, P245, DOI 10.1083/jcb.200203089; Reinacher-Schick A, 2001, J CELL BIOL, V152, P491, DOI 10.1083/jcb.152.3.491; Sadot E, 2002, J CELL SCI, V115, P2771; Sluder G, 2004, CURR OPIN CELL BIOL, V16, P49, DOI 10.1016/j.ceb.2003.11.006; Tang QQ, 2003, P NATL ACAD SCI USA, V100, P44, DOI 10.1073/pnas.0137044100; Wakefield JG, 2003, J CELL SCI, V116, P637, DOI 10.1242/jcs.00273; Zumbrunn J, 2001, CURR BIOL, V11, P44, DOI 10.1016/S0960-9822(01)00002-1	28	87	89	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2007	26	30					4357	4371		10.1038/sj.onc.1210217	http://dx.doi.org/10.1038/sj.onc.1210217			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	184CZ	17260019				2022-12-28	WOS:000247620000004
J	Chaudhary, K; Deb, S; Moniaux, N; Ponnusamy, MP; Batra, SK				Chaudhary, K.; Deb, S.; Moniaux, N.; Ponnusamy, M. P.; Batra, S. K.			Human RNA polymerase II-associated factor complex: dysregulation in cancer	ONCOGENE			English	Review						PAF complex; transcription; tumor suppressor genes; Wnt signaling	COMPARATIVE GENOMIC HYBRIDIZATION; NUCLEAR-LOCALIZATION SIGNAL; PANCREATIC-CANCER; CHROMOSOMAL-ABERRATIONS; CELL-LINES; HUMAN HOMOLOG; PAF1 COMPLEX; EXPRESSION; GENE; PARAFIBROMIN	Genetic instabilities are believed to be one of the major causes of developing a cancer phenotype in humans. During the progression of cancer, aberrant expression of proteins, either owing to genetic (amplification, mutation and deletion) or epigenetic modi. cations (DNA methylation and histone deacetylation), contributes in different ways to the development of cancer. By differential screening analysis, an amplification of the 19q13 locus containing a novel pancreatic differentiation 2 (PD2) gene was identified. PD2 is the human homolog of the yeast RNA polymerase II-associated factor 1 (yPaf1) and is part of the human RNA polymerase II-associated factor (hPAF) complex. hPAF is comprised of five subunits that include PD2/hPaf1, parafibromin, hLeo1, hCtr9 and hSki8. This multifaceted complex was first identified in yeast (yPAF) and subsequently in Drosophila and human. Recent advances in the study on PAF have revealed various functions of the complex in human, which are similar to yPAF, including efficient transcription elongation, mRNA quality control and cell-cycle regulation. Although the precise function of this complex in cancer is not clearly known, some of its subunits have been linked to a malignant phenotype. Its core subunit, PD2/hPaf1, is amplified and overexpressed in many cancers. Further, an overexpression of PD2/hPaf1 results in the induction of a transformed phenotype, suggesting its possible involvement in tumorigenesis. The para. bromin subunit of the hPAF complex is a product of the HRPT-2 (hereditary hyperparathyroidism type 2) tumor suppressor gene, which is mutated in the germ line of hyperparathyroidism-jaw tumor patients. This review focuses on the functions of the PAF complex and its individual subunits, the interaction of the subunits with each other and/or with other molecules, and dysregulation of the complex, providing an insight into its potential involvement in the development of cancer.	Univ Nebraska Med Ctr, Dept Biochem & Mol Biol, Omaha, NE 68198 USA; Univ Nebraska Med Ctr, Eppley Inst Res Canc & Allied Dis, Omaha, NE USA	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center	Batra, SK (corresponding author), Univ Nebraska Med Ctr, Dept Biochem & Mol Biol, 600 S 42nd St, Omaha, NE 68198 USA.	sbatra@unmc.edu	Moniaux, Nicolas/Y-3243-2018	Moniaux, Nicolas/0000-0001-9718-1386; Palanimuthu Ponnusamy, Moorthy/0000-0001-5744-193X	NATIONAL CANCER INSTITUTE [R01CA078590, U01CA111294] Funding Source: NIH RePORTER; NCI NIH HHS [CA78590, CA111294] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Armengol G, 2000, CANCER GENET CYTOGEN, V116, P133, DOI 10.1016/S0165-4608(99)00118-1; Bashyam MD, 2005, NEOPLASIA, V7, P556, DOI 10.1593/neo.04586; BATRA SK, 1994, LAB INVEST, V71, P621; BATRA SK, 1991, J BIOL CHEM, V266, P6830; Birkenkamp-Demtroder K, 2002, CANCER RES, V62, P4352; Bradley KJ, 2007, ONCOGENE, V26, P1213, DOI 10.1038/sj.onc.1209893; Camps J, 2006, CARCINOGENESIS, V27, P419, DOI 10.1093/carcin/bgi244; Cavalli LR, 2003, CANCER GENET CYTOGEN, V146, P33, DOI 10.1016/S0165-4608(03)00123-7; Chang MC, 2005, ONCOL REP, V14, P867; Cheng JQ, 1996, P NATL ACAD SCI USA, V93, P3636, DOI 10.1073/pnas.93.8.3636; Curtis LJ, 1998, GENOMICS, V53, P42, DOI 10.1006/geno.1998.5405; DE PK, 2005, J CLIN ONCOL, V23, P3167; Grandori C, 2004, CELL CYCLE, V3, P22; Hahn MA, 2005, ONCOGENE, V24, P6241, DOI 10.1038/sj.onc.1208778; Heidenblad M, 2005, ONCOGENE, V24, P1794, DOI 10.1038/sj.onc.1208383; Honore B, 2002, ONCOGENE, V21, P1123, DOI 10.1038/sj.onc.1205186; Huntsman DG, 1999, ONCOGENE, V18, P7975, DOI 10.1038/sj.onc.1203291; Knudsen KE, 2006, ONCOGENE, V25, P1620, DOI 10.1038/sj.onc.1209371; Koch C, 1999, NUCLEIC ACIDS RES, V27, P2126, DOI 10.1093/nar/27.10.2126; Korshunov A, 2005, MODERN PATHOL, V18, P1258, DOI 10.1038/modpathol.3800415; Krogan NJ, 2002, MOL CELL BIOL, V22, P6979, DOI 10.1128/MCB.22.20.6979-6992.2002; Mahlamaki EH, 2004, NEOPLASIA, V6, P432, DOI 10.1593/neo.04130; Mao X, 2002, GENE CHROMOSOME CANC, V35, P144, DOI 10.1002/gcc.10104; Moniaux N, 2006, ONCOGENE, V25, P3247, DOI 10.1038/sj.onc.1209353; Mosimann C, 2006, CELL, V125, P327, DOI 10.1016/j.cell.2006.01.053; Mueller CL, 2004, MOL CELL, V14, P447, DOI 10.1016/S1097-2765(04)00257-6; Nathrath MH, 2002, ONCOGENE, V21, P5975, DOI 10.1038/sj.onc.1205764; Parada LA, 1998, GENE CHROMOSOME CANC, V23, P26; Pavri R, 2006, CELL, V125, P703, DOI 10.1016/j.cell.2006.04.029; REDEKER E, 1995, CYTOGENET CELL GENET, V68, P222, DOI 10.1159/000133917; Rozenblatt-Rosen O, 2005, MOL CELL BIOL, V25, P612, DOI 10.1128/MCB.25.2.612-620.2005; Rybakin V, 2005, BIOESSAYS, V27, P625, DOI 10.1002/bies.20235; Schleger C, 2000, J PATHOL, V191, P27, DOI 10.1002/(SICI)1096-9896(200005)191:1<27::AID-PATH582>3.0.CO;2-J; Schwienbacher C, 2000, P NATL ACAD SCI USA, V97, P5445, DOI 10.1073/pnas.090087497; Stange DE, 2006, CLIN CANCER RES, V12, P345, DOI 10.1158/1078-0432.CCR-05-1633; Tang TCM, 2002, CANCER RES, V62, P7157; Tarkkanen M, 2006, EUR J CANCER, V42, P1172, DOI 10.1016/j.ejca.2006.01.035; Thiagalingam S, 2006, CANCER RES, V66, P7379, DOI 10.1158/0008-5472.CAN-06-0993; Vogelstein B, 2004, NAT MED, V10, P789, DOI 10.1038/nm1087; Woodard GE, 2005, ONCOGENE, V24, P1272, DOI 10.1038/sj.onc.1208274; Zhang C, 2006, BIOCHEM BIOPH RES CO, V350, P17, DOI 10.1016/j.bbrc.2006.08.169; Zhu B, 2005, GENE DEV, V19, P1668, DOI 10.1101/gad.1292105	42	81	82	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 29	2007	26	54					7499	7507		10.1038/sj.onc.1210582	http://dx.doi.org/10.1038/sj.onc.1210582			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	236DB	17599057				2022-12-28	WOS:000251282100001
J	Rapisarda, A; Melillo, G				Rapisarda, A.; Melillo, G.			UVC inhibits HIF-1 alpha protein translation by a DNA damage- and topoisomerase I-independent pathway	ONCOGENE			English	Article						HIF-1; topoisomerase; UVC; translation; DNA damage; cancer therapeutics	HYPOXIA-INDUCIBLE FACTOR-1; RNA-POLYMERASE-II; XERODERMA-PIGMENTOSUM; ULTRAVIOLET-LIGHT; CANCER-THERAPY; TUMOR-GROWTH; HIF-ALPHA; TRANSCRIPTION; ACTIVATION; ATR	Hypoxia inducible factor 1 (HIF-1) is a key player in cancer progression and an attractive target for cancer therapy. Several small molecule inhibitors of HIF-1 alpha also induce a DNA damage response. However, whether or not DNA damage is required for or associated with the inhibition of HIF-1 alpha protein accumulation is poorly understood. In this report we investigated the effects of distinct DNA damaging conditions on the hypoxic induction of HIF-1 alpha protein in cancer cell lines. We demonstrate that in addition to topotecan (TPT), a known inhibitor of HIF-1 alpha, UVC, but not other DNA damaging agents (cisplatin, ionizing radiation and doxorubicin), inhibited HIF-1 alpha protein accumulation in a dose-dependent, p53-independent fashion. Low doses UVC decreased HIF-1 alpha translation without affecting global protein synthesis. Inhibition of HIF-1 alpha by UVC required ongoing RNA transcription, but not DNA replication. Moreover, a functional ATR was required for the activation of DNA damage-dependent responses by both UVC and TPT, but was dispensable for the inhibition of HIF-1 alpha protein. Notably, unlike TPT, inhibition of HIF-1 alpha protein by UVC did not require topoisomerase 1, suggesting a similar yet distinct mode of action. Our data reveal that UVC is a novel signal associated with inhibition of HIF-1 alpha protein accumulation, and they uncouple the DNA damage-dependent signaling pathway exerted by UVC and TPT from HIF-1 alpha inhibition.	Natl Canc Inst, SAIC Frederick Inc, DTP Tumor Hypoxia Lab, Ft Detrick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Melillo, G (corresponding author), Natl Canc Inst, SAIC Frederick Inc, DTP Tumor Hypoxia Lab, 1050 Boyles St,Bldg 432,Room 218, Ft Detrick, MD 21702 USA.	melillog@ncifcff.gov			NCI NIH HHS [N01-CO-12400] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Berneburg M, 2001, ADV GENET, V43, P71, DOI 10.1016/S0065-2660(01)43004-5; Bregman DB, 1996, P NATL ACAD SCI USA, V93, P11586, DOI 10.1073/pnas.93.21.11586; Brown JM, 1998, CANCER RES, V58, P1408; Cliby WA, 1998, EMBO J, V17, P159, DOI 10.1093/emboj/17.1.159; Demidenko ZN, 2005, ONCOGENE, V24, P4829, DOI 10.1038/sj.onc.1208636; Desai SD, 2003, MOL CELL BIOL, V23, P2341, DOI 10.1128/MCB.23.7.2341-2350.2003; DUBOIS MF, 1994, J BIOL CHEM, V269, P13331; Furuta T, 2003, J BIOL CHEM, V278, P20303, DOI 10.1074/jbc.M300198200; Furuta T, 2002, CANCER RES, V62, P4899; Hammond EM, 2004, DNA REPAIR, V3, P1117, DOI 10.1016/j.dnarep.2004.03.035; Hammond EM, 2003, MUTAT RES-FUND MOL M, V532, P205, DOI 10.1016/j.mrfmmm.2003.08.017; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; Heffernan TP, 2002, MOL CELL BIOL, V22, P8552, DOI 10.1128/MCB.22.24.8552-8561.2002; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Jiang HY, 2005, BIOCHEM J, V385, P371, DOI 10.1042/BJ20041164; Kurz EU, 2004, DNA REPAIR, V3, P889, DOI 10.1016/j.dnarep.2004.03.029; Laine JP, 2006, TRENDS GENET, V22, P430, DOI 10.1016/j.tig.2006.06.006; Lang KJD, 2002, MOL BIOL CELL, V13, P1792, DOI 10.1091/mbc.02-02-0017; Ljungman M, 2005, MUTAT RES-FUND MOL M, V577, P203, DOI 10.1016/j.mrfmmm.2005.02.014; MAYNE LV, 1982, CANCER RES, V42, P1473; Mazan-Mamczarz K, 2006, MOL CELL BIOL, V26, P2716, DOI 10.1128/MCB.26.7.2716-2727.2006; Melillo G, 2006, MOL CANCER RES, V4, P601, DOI 10.1158/1541-7786.MCR-06-0235; Mellon I, 2005, MUTAT RES-FUND MOL M, V577, P155, DOI 10.1016/j.mrfmmm.2005.03.016; Pfeifer GP, 2005, MUTAT RES-FUND MOL M, V571, P19, DOI 10.1016/j.mrfmmm.2004.06.057; Proietti-De-Santis L, 2006, EMBO J, V25, P1915, DOI 10.1038/sj.emboj.7601071; Rapisarda A, 2004, CELL CYCLE, V3, P172; Rapisarda A, 2004, CANCER RES, V64, P6845, DOI 10.1158/0008-5472.CAN-04-2116; Rapisarda A, 2004, CANCER RES, V64, P1475, DOI 10.1158/0008-5472.CAN-03-3139; Rapisarda A, 2002, CANCER RES, V62, P4316; Semenza GL, 2006, EXPERT OPIN THER TAR, V10, P267, DOI 10.1517/14728222.10.2.267; Shechter D, 2004, DNA REPAIR, V3, P901, DOI 10.1016/j.dnarep.2004.03.020; Sim RJ, 2004, GENE DEV, V18, P2437, DOI 10.1101/gad.1235904; Soe K, 2004, DNA REPAIR, V3, P387, DOI 10.1016/j.dnarep.2003.12.003; Tornaletti S, 2005, MUTAT RES-FUND MOL M, V577, P131, DOI 10.1016/j.mrfmmm.2005.03.014; Wu SY, 2002, J BIOL CHEM, V277, P18077, DOI 10.1074/jbc.M110164200; Yang J, 2003, CARCINOGENESIS, V24, P1571, DOI 10.1093/carcin/bgg137; Ziv Y, 1997, ONCOGENE, V15, P159, DOI 10.1038/sj.onc.1201319	38	12	12	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 18	2007	26	48					6875	6884		10.1038/sj.onc.1210489	http://dx.doi.org/10.1038/sj.onc.1210489			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	220WQ	17496931				2022-12-28	WOS:000250188400003
J	Wang, Q; Williamson, M; Bott, S; Brookman-Amissah, N; Freeman, A; Nariculam, J; Hubank, MJF; Ahmed, A; Masters, JR				Wang, Q.; Williamson, M.; Bott, S.; Brookman-Amissah, N.; Freeman, A.; Nariculam, J.; Hubank, M. J. F.; Ahmed, A.; Masters, J. R.			Hypomethylation of WNT5A, CRIP1 and S100P in prostate cancer	ONCOGENE			English	Article						cancer; epigenetics; prostate; WNT5A; S100P; CRIP1	TRANSCRIPTION FACTOR AP-2; C-MYB; ABERRANT EXPRESSION; OVARIAN-CARCINOMA; GENE-EXPRESSION; UP-REGULATION; CELL-LINES; ALPHA GENE; V-MYB; METHYLATION	Oligoarray analysis of a matched pair of prostate cancer and normal cell lines derived from the same radical prostatectomy specimen identified 113 candidate hypo-methylated genes that were overexpressed in the cancer cells and contained CpG islands. Hypomethylation of wingless-related MMTV integration site 5A (WNT5A), S100 calcium-binding protein P (S100P) and cysteine-rich protein 1(CRIP1) was confirmed in the cancer cells by bisulfate sequencing. Treatment of the corresponding normal prostate epithelial cells 1542-NPTX with the DNA methyltransferase inhibitor 5-Aza-2 '-deoxycytidine (5-aza-CdR) induced higher levels of mRNA expression and partial loss of methylation on these genes. Primary prostate cancers were tested using methylation-specific polymerase chain reaction. WNT5A was hypomethylated in 11/17 (65%) tumors, S100P in 8/16 (50%) and CRIP1 in 13/20 ( 65%). Bisulfate sequencing of a section of the 50 untranslated region (UTR) of WNT5A revealed that three CpG sites ( 15, 24 and 35) were consistently methylated (93%) in the normal cell line and normal tissues, but not in the prostate cancer cell line and eight primary prostate cancers. Multiple putative binding sites for the transcription factors SP1 and AP-2 were found adjacent to CpG sites 15 and 24. A putative c-Myb binding site was located within the CpG site 35. Anti-c-Myb antibody co-precipitation with WNT5A was methylation- sensitive in 1542-NPTX cells. It is likely that an epigenetic mechanism regulates WNT5A expression in prostate cancer.	UCL, Prostate Canc Res Ctr, Inst Urol & Nephrol, London W1W 7EJ, England; UCL Hosp Trust, Dept Histopathol, London, England; UCL, Gene Microarray Ctr, Inst Child Hlth, London, England	University of London; University College London; University College London Hospitals NHS Foundation Trust; University of London; University College London; University of London; University College London	Masters, JR (corresponding author), UCL, Prostate Canc Res Ctr, Inst Urol & Nephrol, 3rd Floor,67 Riding House St, London W1W 7EJ, England.	j.masters@ucl.ac.uk	Masters, John R/C-5694-2011; Hubank, Michael JF/C-1837-2008	Hubank, Michael JF/0000-0002-2901-0742; Williamson, Magali/0000-0002-7183-7495; Ahmed, Aamir/0000-0001-7405-5336	MRC [G0100116] Funding Source: UKRI; Medical Research Council [G0100116] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Akiyama Y, 2003, AM J PATHOL, V163, P1911, DOI 10.1016/S0002-9440(10)63549-3; Bender TP, 2004, NAT IMMUNOL, V5, P721, DOI 10.1038/ni1085; Black AR, 1999, J BIOL CHEM, V274, P1207, DOI 10.1074/jbc.274.3.1207; Bright RK, 1997, CANCER RES, V57, P995; Brothman AR, 2005, CANCER GENET CYTOGEN, V156, P31, DOI 10.1016/j.cancergencyto.2004.04.004; Cho M, 2001, BRIT J CANCER, V85, P563, DOI 10.1054/bjoc.2001.1951; Esteller M, 2001, CANCER RES, V61, P3225; Frampton J, 1996, GENE DEV, V10, P2720, DOI 10.1101/gad.10.21.2720; GAUBATZ S, 1995, EMBO J, V14, P1508, DOI 10.1002/j.1460-2075.1995.tb07137.x; Gaudet F, 2003, SCIENCE, V300, P489, DOI 10.1126/science.1083558; Gibadulinova A, 2005, ONCOL REP, V14, P575; Gupta A, 2003, CANCER RES, V63, P664; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Huang S, 1998, EMBO J, V17, P4358, DOI 10.1093/emboj/17.15.4358; IOZZO RV, 1995, CANCER RES, V55, P3495; Ishii Y, 2005, BBA-MOL CELL RES, V1745, P156, DOI 10.1016/j.bbamcr.2005.01.005; Jemal A, 2005, CA-CANCER J CLIN, V55, P10, DOI 10.3322/canjclin.55.1.10; Jiang MS, 1998, P NATL ACAD SCI USA, V95, P3467, DOI 10.1073/pnas.95.7.3467; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; Jurata LW, 1996, P NATL ACAD SCI USA, V93, P11693, DOI 10.1073/pnas.93.21.11693; KLEMPNAUER KH, 1993, ONCOGENE, V8, P111; Lang G, 2005, ONCOGENE, V24, P1375, DOI 10.1038/sj.onc.1208301; LEVENSON CW, 1993, P NATL ACAD SCI USA, V90, P712, DOI 10.1073/pnas.90.2.712; Li LC, 2004, BBA-REV CANCER, V1704, P87, DOI 10.1016/j.bbcan.2004.06.001; Liang HL, 2003, CANCER CELL, V4, P349, DOI 10.1016/S1535-6108(03)00268-X; Mackay A, 2003, ONCOGENE, V22, P2680, DOI 10.1038/sj.onc.1206349; Matei D, 2002, ONCOGENE, V21, P6289, DOI 10.1038/sj.onc.1205785; McPherson LA, 1997, P NATL ACAD SCI USA, V94, P4342, DOI 10.1073/pnas.94.9.4342; Miller JR, 1999, ONCOGENE, V18, P7860, DOI 10.1038/sj.onc.1203245; Mousses S, 2002, CURR OPIN CHEM BIOL, V6, P97, DOI 10.1016/S1367-5931(01)00283-6; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; Ogishima T, 2005, CLIN CANCER RES, V11, P1028; Ording E, 1996, ONCOGENE, V13, P1043; Oshimo Y, 2003, INT J ONCOL, V23, P1663; Pukrop T, 2006, P NATL ACAD SCI USA, V103, P5454, DOI 10.1073/pnas.0509703103; Sato N, 2004, ONCOGENE, V23, P1531, DOI 10.1038/sj.onc.1207269; Sato N, 2003, CANCER RES, V63, P4158; Tokizane T, 2005, CLIN CANCER RES, V11, P5793, DOI 10.1158/1078-0432.CCR-04-2545; Wang DY, 1997, J BIOL CHEM, V272, P14244, DOI 10.1074/jbc.272.22.14244; Zeng YX, 1997, NAT GENET, V15, P78, DOI 10.1038/ng0197-78; Zhu WG, 2003, MOL CELL BIOL, V23, P4056, DOI 10.1128/MCB.23.12.4056-4065.2003	41	113	121	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT	2007	26	45					6560	6565		10.1038/sj.onc.1210472	http://dx.doi.org/10.1038/sj.onc.1210472			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	217AF	17486081				2022-12-28	WOS:000249919800009
J	Tchougounova, E; Kastemar, M; Brasater, D; Holland, EC; Westermark, B; Uhrbom, L				Tchougounova, E.; Kastemar, M.; Brasater, D.; Holland, E. C.; Westermark, B.; Uhrbom, L.			Loss of Arf causes tumor progression of PDGFB-induced oligodendroglioma	ONCOGENE			English	Article						oligodendroglioma; PDGF; mouse model; ink4a; Arf; p70S6K	GROWTH-FACTOR RECEPTOR; NEURAL PROGENITORS; STEM-CELL; INK4A LOCUS; EXPRESSION; SUPPRESSION; P16(INK4A); P19(ARF); MICE; DIFFERENTIATION	In a subset of gliomas, the platelet-derived growth factor ( PDGF) signaling pathway is perturbed. This is usually an early event occurring in low-grade tumors. In high-grade gliomas, the subsequent loss of the INK4a-ARF locus is one of the most common mutations. Here, we dissected the separate roles of Ink4a and Arf in PDGFB-induced oligodendroglioma development in mice. We found that there were differential functions of the two tumor suppressor genes. In tumors induced from astrocytes, both Ink4a-loss and Arf-loss caused a significantly increased incidence compared to wild-type mice. In tumors induced from glial progenitor cells there was a slight increase in tumor incidence in Ink4a -/- mice and Ink4a- Arf -/- mice compared to wild-type mice. In both progenitor cells and astrocytes, Arf-loss caused a pronounced increase in tumor malignancy compared to Ink4a- loss. Hence, Ink4a- loss contributed to tumor initiation from astrocytes and Arf-loss caused tumor progression from both glial progenitor cells and astrocytes. Results from in vitro studies on primary brain cell cultures suggested that the PDGFB-induced activation of the mitogen-activated protein kinase pathway via extracellular signal-regulated kinase was involved in the initiation of low-grade oligodendrogliomas and that the additional loss of Arf may contribute to tumor progression through increased levels of cyclin D1 and a phosphoinositide 3-kinase-dependent activation of p70 ribosomal S6 kinase causing a strong proliferative response of tumor cells.	Uppsala Univ, Dept Genet & Pathol, Rudbeck Lab, SE-75185 Uppsala, Sweden; Mem Sloan Kettering Canc Ctr, Dept Surg Neurosurg, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Neurol, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Canc Biol & Genet, New York, NY 10021 USA	Uppsala University; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	Uhrbom, L (corresponding author), Uppsala Univ, Dept Genet & Pathol, Rudbeck Lab, SE-75185 Uppsala, Sweden.	lene.uhrbom@genpat.uu.se		Westermark, Bengt/0000-0001-7153-5545				Bachoo RM, 2002, CANCER CELL, V1, P269, DOI 10.1016/S1535-6108(02)00046-6; Bigner S H, 1999, Neuro Oncol, V1, P52, DOI 10.1093/neuonc/1.1.52; Cairncross JG, 1998, J NATL CANCER I, V90, P1473, DOI 10.1093/jnci/90.19.1473; Charest A, 2006, CANCER RES, V66, P7473, DOI 10.1158/0008-5472.CAN-06-1193; Dai C, 2001, GENE DEV, V15, P1913, DOI 10.1101/gad.903001; Di Rocco F, 1998, NEUROSURGERY, V42, P341, DOI 10.1097/00006123-199802000-00080; FISCHER AN, 2006, ONCOGENE; Grewe M, 1999, CANCER RES, V59, P3581; Holland EC, 2000, NAT GENET, V25, P55, DOI 10.1038/75596; IOFFE E, 1995, P NATL ACAD SCI USA, V92, P7357, DOI 10.1073/pnas.92.16.7357; JEN J, 1994, CANCER RES, V54, P6353; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; KLEIHUES P, 1997, PATHOLOGY GENETICS; Reifenberger J, 1996, AM J PATHOL, V149, P29; SCHERER H. J., 1938, AMER JOUR CANCER, V34, P333; SCHMIDT EE, 1994, CANCER RES, V54, P6321; Schumacher A, 2003, MOL CELL NEUROSCI, V23, P669, DOI 10.1016/S1044-7431(03)00170-2; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; Sharpless NE, 2001, NATURE, V413, P86, DOI 10.1038/35092592; Sharpless NE, 2004, ONCOGENE, V23, P379, DOI 10.1038/sj.onc.1207074; Uhrbom L, 2005, CANCER RES, V65, P2065, DOI 10.1158/0008-5472.CAN-04-3588; Uhrbom L, 2002, CANCER RES, V62, P5551; VanBrocklyn JR, 1997, J NEUROCHEM, V69, P116; Zindy F, 1997, ONCOGENE, V15, P203, DOI 10.1038/sj.onc.1201178	24	58	62	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 20	2007	26	43					6289	6296		10.1038/sj.onc.1210455	http://dx.doi.org/10.1038/sj.onc.1210455			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	212GW	17438529				2022-12-28	WOS:000249583300005
J	McCabe, NP; De, S; Vasanji, A; Brainard, J; Byzova, TV				McCabe, N. P.; De, S.; Vasanji, A.; Brainard, J.; Byzova, T. V.			Prostate cancer specific integrin alpha v beta 3 modulates bone metastatic growth and tissue remodeling	ONCOGENE			English	Article						prostate cancer; metastasis; bone; integrins	BREAST-CANCER; TUMOR-GROWTH; INTEGRIN; ACTIVATION; EXPRESSION; MUTATION; PLATELET; DOMAIN; IIIA	The management of pain and morbidity due to the spreading and growth of cancer within bone remains to be a paramount problem in clinical care. Cancer cells actively transform bone, however, the molecular requirements and mechanisms of this process remain unclear. This study shows that functional modulation of the alpha v beta 3 integrin receptor in prostate cancer cells is required for progression within bone and determines tumor-induced bone tissue transformation. Using histology and quantitative microCT analysis, we show that avb3 integrin is required not only for tumor growth within the bone but for tumor-induced bone gain, a response resembling bone lesions in prostate cancer patients. Expression of normal, fully functional avb3 enabled tumor growth in bone ( incidence: 4/4), whereas avb3 (-), inactive or constitutively active mutants of alpha v beta 3 did not ( incidence: 0/4, 0/6 and 1/7, respectively) within a 35-day-period. This response appeared to be bone-specific in comparison to the subcutis where tumor incidence was greater than 60% for all groups. Interestingly, bone residing prostate cancer cells expressing normal or dis-regulated alpha v beta 3 ( either inactive of constitutively active), but not those lacking beta 3 promoted bone gain or afforded protection from bone loss in the presence or absence of histologically detectable tumor 35 days following implantation. As bone is replete with ligands for beta 3 integrin, we next demonstrated that avb3 integrin activation on tumor cells is essential for the recognition of key bone-specific matrix proteins. As a result, prostate cancer cells expressing fully functional but not dis-regulated avb3 integrin are able to control their own adherence and migration to bone matrix, functions that facilitate tumor growth and control bone lesion development.	Cleveland Clin Fdn, Joseph J Jacobs Ctr Thrombosis & Vasc Biol, Dept Mol Cardiol, Cleveland, OH 44195 USA; Cleveland Clin Educ Fdn, Dept Biomed Engn, Cleveland, OH USA; Cleveland Clin Educ Fdn, Dept Anat & Pathol, Cleveland, OH USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation; Cleveland Clinic Foundation	Byzova, TV (corresponding author), Cleveland Clin Fdn, Joseph J Jacobs Ctr Thrombosis & Vasc Biol, Dept Mol Cardiol, 9500 Euclid Ave, Cleveland, OH 44195 USA.	byzovat@ccf.org		Byzova, Tatiana/0000-0002-2615-875X	NCI NIH HHS [R01 CA126847-05A1, CA1172462, R01 CA126847, R01 CA126847-06] Funding Source: Medline; NIAMS NIH HHS [1P30 AR-050953, P30 AR050953] Funding Source: Medline; NIDDK NIH HHS [DK060933, R01 DK060933-04, R01 DK060933] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA126847] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P30AR050953] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK060933] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bakewell SJ, 2003, P NATL ACAD SCI USA, V100, P14205, DOI 10.1073/pnas.2234372100; Byzova TV, 2000, EXP CELL RES, V254, P299, DOI 10.1006/excr.1999.4765; CHEN YP, 1992, P NATL ACAD SCI USA, V89, P10169, DOI 10.1073/pnas.89.21.10169; De S, 2005, P NATL ACAD SCI USA, V102, P7589, DOI 10.1073/pnas.0502935102; De S, 2003, J BIOL CHEM, V278, P39044, DOI 10.1074/jbc.M304494200; Felding-Habermann B, 2001, P NATL ACAD SCI USA, V98, P1853, DOI 10.1073/pnas.98.4.1853; Feng X, 2001, J CLIN INVEST, V107, P1137, DOI 10.1172/JCI12040; Ginsberg Mark H., 1992, Current Opinion in Cell Biology, V4, P766, DOI 10.1016/0955-0674(92)90099-X; Hughes PE, 1996, J BIOL CHEM, V271, P6571, DOI 10.1074/jbc.271.12.6571; JACOBS SC, 1983, UROLOGY, V21, P337, DOI 10.1016/0090-4295(83)90147-4; Kanamori M, 2004, CANCER RES, V64, P2751, DOI 10.1158/0008-5472.CAN-03-3354; Keller ET, 2004, J CELL BIOCHEM, V91, P718, DOI 10.1002/jcb.10662; Kitagawa Y, 2005, CANCER RES, V65, P10921, DOI 10.1158/0008-5472.CAN-05-1809; Latson L, 2003, P ANN INT IEEE EMBS, V25, P1058, DOI 10.1109/IEMBS.2003.1279427; Li W, 2005, P NATL ACAD SCI USA, V102, P1424, DOI 10.1073/pnas.0409334102; Nemeth JA, 2003, CLIN EXP METASTAS, V20, P413, DOI 10.1023/A:1025461507027; Pecheur I, 2002, FASEB J, V16, P1266, DOI 10.1096/fj.01-0911fje; Ruiz C, 2001, BLOOD, V98, P2432, DOI 10.1182/blood.V98.8.2432; Saad F, 2006, EUR UROL, V49, P429, DOI 10.1016/j.eururo.2005.12.045; Schwartz MA, 2002, NAT CELL BIOL, V4, pE65, DOI 10.1038/ncb0402-e65; Sloan EK, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1398; Stewart Delisha A, 2004, Reprod Biol Endocrinol, V2, P2, DOI 10.1186/1477-7827-2-2; Takayama S, 2005, ANTICANCER RES, V25, P79	23	150	154	1	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 13	2007	26	42					6238	6243		10.1038/sj.onc.1210429	http://dx.doi.org/10.1038/sj.onc.1210429			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	209PU	17369840	Green Accepted			2022-12-28	WOS:000249401300015
J	Ohi, H; Mishima, Y; Kamimura, K; Maruyama, M; Sasai, K; Kominami, R				Ohi, H.; Mishima, Y.; Kamimura, K.; Maruyama, M.; Sasai, K.; Kominami, R.			Multi-step lymphomagenesis deduced from DNA changes in thymic lymphomas and atrophic thymuses at various times after gamma-irradiation	ONCOGENE			English	Article						multistep lymphomagenesis; gamma-ray; atrophic thymuses; clonal growth; Bcl11b	ACUTE LYMPHOBLASTIC-LEUKEMIA; T-CELL DEVELOPMENT; TRANSCRIPTION FACTOR; TUMOR-SUPPRESSOR; DEFICIENT MICE; HOMOZYGOUS DELETIONS; N-METHYLNITROSOUREA; NOTCH1 MUTATIONS; POINT MUTATIONS; TRANSGENIC MICE	Whole-body gamma-irradiation to mice causes thymic atrophy where a population of precancerous cells with mutation can be found. Thus, clonal growth and DNA changes at Bcl11b, Ikaros, Pten, Notch1 and Myc were examined in not only thymic lymphomas but also in atrophic thymuses at various times after irradiation. Clonal expansion was detected from the distinct patterns of rearrangements at the TCR beta receptor locus in a fraction of atrophic thymuses at as early as 30 days after irradiation. This expansion may be in part owing to the rearranged TCR beta signaling because the transfer of bone marrow cells with the rearrangement and the wild-type locus into severe-combined immunodeficiency mice showed preferential growth of the rearranged thymocytes in atrophic thymus. Loss of heterozygosity (LOH) at Bcl11b and trisomy of Myc were found at high frequencies in both lymphomas and atrophic thymuses, and in contrast, LOH at Ikaros and Pten were rare in atrophic thymuses but prevalent in lymphomas. Notch1 activation was detected in lymphomas and in atrophic thymuses only at a late stage. Similar patterns of DNA changes were found in atrophic thymuses induced in Bcl11b(+/-) mice. These results suggest the order of genetic changes during lymphomagenesis, Bcl11b and Myc being at the early stage; whereas Ikaros, Pten and Notch1 at the late stage.	Niigata Univ, Grad Sch Med & Dent Sci, Dept Mol Genet, Div Mol Biol, Niigata 9518510, Japan; Niigata Univ, Ctr Transdisciplinary Res, Niigata, Japan	Niigata University; Niigata University	Kominami, R (corresponding author), Niigata Univ, Grad Sch Med & Dent Sci, Dept Mol Genet, Div Mol Biol, Asahimachi Doori 1-757, Niigata 9518510, Japan.	rykomina@med.niigata-u.ac.jp	Kamimura, Kenya/U-6797-2019	Maruyama, Masaki/0000-0002-9534-4652				ABRAHAM KM, 1991, P NATL ACAD SCI USA, V88, P3977, DOI 10.1073/pnas.88.9.3977; Avram D, 2000, J BIOL CHEM, V275, P10315, DOI 10.1074/jbc.275.14.10315; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Bernard OA, 2001, LEUKEMIA, V15, P1495, DOI 10.1038/sj.leu.2402249; Bezrookove V, 2004, CANCER GENET CYTOGEN, V149, P72, DOI 10.1016/S0165-4608(03)00302-9; BRATHWAITE O, 1992, CANCER RES, V52, P3791; Dumortier A, 2006, MOL CELL BIOL, V26, P209, DOI 10.1128/MCB.26.1.209-220.2006; Eischen CM, 1999, GENE DEV, V13, P2658, DOI 10.1101/gad.13.20.2658; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Freeman DJ, 2003, CANCER CELL, V3, P117, DOI 10.1016/S1535-6108(03)00021-7; GEORGOPOULOS K, 1992, SCIENCE, V258, P808, DOI 10.1126/science.1439790; Girard L, 1996, GENE DEV, V10, P1930, DOI 10.1101/gad.10.15.1930; Gorgoulis VG, 2005, NATURE, V434, P907, DOI 10.1038/nature03485; GRAHAM M, 1985, NATURE, V314, P740, DOI 10.1038/314740a0; Gray DHD, 2005, CURR OPIN IMMUNOL, V17, P137, DOI 10.1016/j.coi.2005.02.001; Hahn WC, 2002, NAT REV CANCER, V2, P331, DOI 10.1038/nrc795; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hoemann CD, 2000, MOL CELL BIOL, V20, P3831, DOI 10.1128/MCB.20.11.3831-3842.2000; Inoue J, 2006, J IMMUNOL, V176, P5871, DOI 10.4049/jimmunol.176.10.5871; Itoyama A, 2001, BLOOD, V97, P3612, DOI 10.1182/blood.V97.11.3612; Kabra NH, 2001, P NATL ACAD SCI USA, V98, P6307, DOI 10.1073/pnas.111158698; Kakinuma S, 2002, RADIAT RES, V157, P331, DOI 10.1667/0033-7587(2002)157[0331:SOZIIA]2.0.CO;2; KAMIMURA K, IN PRESS BIOCH BIOPH; KAPLAN HENRY S., 1964, NAT CANCER INST MONOGR, V14, P207; Kawamoto H, 2003, EUR J IMMUNOL, V33, P606, DOI 10.1002/eji.200323461; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; KLEIN G, 1979, P NATL ACAD SCI USA, V76, P2442, DOI 10.1073/pnas.76.5.2442; Kominami R, 2006, CANCER SCI, V97, P575, DOI 10.1111/j.1349-7006.2006.00218.x; Lin YW, 2006, BLOOD, V107, P2540, DOI 10.1182/blood-2005-07-3013; LUDWIG FC, 1968, LAB INVEST, V19, P240; MacLeod RAF, 2003, GENE CHROMOSOME CANC, V37, P84, DOI 10.1002/gcc.10194; Mao JH, 2003, ONCOGENE, V22, P8379, DOI 10.1038/sj.onc.1207083; Mayo LD, 2002, J BIOL CHEM, V277, P5484, DOI 10.1074/jbc.M108302200; McArthur GA, 2002, MOL CELL BIOL, V22, P3014, DOI 10.1128/MCB.22.9.3014-3023.2002; MCMORROW LE, 1988, LEUKEMIA, V2, P115; MOMBAERTS P, 1994, IMMUNITY, V1, P261, DOI 10.1016/1074-7613(94)90077-9; MURPHY KM, 1990, SCIENCE, V250, P1720, DOI 10.1126/science.2125367; MUTO M, 1987, CANCER RES, V47, P3469; Nagel S, 2003, CANCER RES, V63, P5329; NEWCOMB EW, 1988, CANCER RES, V48, P5514; Newton K, 2000, EMBO J, V19, P931, DOI 10.1093/emboj/19.5.931; O'Neil J, 2006, BLOOD, V107, P781, DOI 10.1182/blood-2005-06-2553; Okano H, 1999, ONCOGENE, V18, P6677, DOI 10.1038/sj.onc.1203100; Przybylski GK, 2005, LEUKEMIA, V19, P201, DOI 10.1038/sj.leu.2403619; Ruiz A, 2004, BRIT J HAEMATOL, V125, P31, DOI 10.1111/j.1365-2141.2004.04854.x; SADO T, 1991, J RADIAT RES, V32, P168, DOI 10.1269/jrr.32.SUPPLEMENT2_168; Shinbo T, 1999, ONCOGENE, V18, P4131, DOI 10.1038/sj.onc.1202767; SHINKAI Y, 1993, SCIENCE, V259, P822, DOI 10.1126/science.8430336; Sicinska E, 2003, CANCER CELL, V4, P451, DOI 10.1016/S1535-6108(03)00301-5; Sun L, 1999, P NATL ACAD SCI USA, V96, P680, DOI 10.1073/pnas.96.2.680; Tsuji H, 2004, CANCER RES, V64, P8882, DOI 10.1158/0008-5472.CAN-03-1163; VOGELSTEIN B, 1993, TRENDS GENET, V9, P138, DOI 10.1016/0168-9525(93)90209-Z; Wakabayashi Y, 2003, NAT IMMUNOL, V4, P533, DOI 10.1038/ni927; Wakabayashi Y, 2003, BIOCHEM BIOPH RES CO, V301, P598, DOI 10.1016/S0006-291X(02)03069-3; Weng AP, 2004, SCIENCE, V306, P269, DOI 10.1126/science.1102160; WINANDY S, 1995, CELL, V83, P289, DOI 10.1016/0092-8674(95)90170-1; Yagi T, 2002, BLOOD, V99, P1350, DOI 10.1182/blood.V99.4.1350	58	23	23	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 9	2007	26	36					5280	5289		10.1038/sj.onc.1210325	http://dx.doi.org/10.1038/sj.onc.1210325			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	199CQ	17325664				2022-12-28	WOS:000248674200011
J	Lucas, PC; Kuffa, P; Gu, S; Kohrt, D; Kim, DSL; Siu, K; Jin, X; Swenson, J; McAllister-Lucas, LM				Lucas, P. C.; Kuffa, P.; Gu, S.; Kohrt, D.; Kim, D. S. L.; Siu, K.; Jin, X.; Swenson, J.; McAllister-Lucas, L. M.			A dual role for the API2 moiety in API2-MALT1-dependent NF-kappa B activation: heterotypic oligomerization and TRAF2 recruitment	ONCOGENE			English	Article						MALT lymphoma; cIAP2; MALT1; NF-kappa B	HELICOBACTER-PYLORI ERADICATION; LYMPHOID-TISSUE LYMPHOMA; RECEPTOR-ASSOCIATED FACTOR-2; GASTRIC MALT LYMPHOMAS; CELL LYMPHOMA; UBIQUITIN LIGASE; BIR DOMAINS; FUSION; APOPTOSIS; BCL10	Mucosa-associated lymphoid tissue ( MALT) lymphoma is the most common extranodal lymphoid neoplasm. Chromosomal translocation t(11; 18)(q21, q21) is found in 30% of gastric MALT lymphomas and is associated with a failure to respond to standard treatment and a tendency to disseminate. This translocation generates a chimeric protein composed of N-terminal sequences of Inhibitor of Apoptosis 2 (API2, also known as BIRC3 and cIAP2) fused to C-terminal sequences of MALT1. API2-MALT1 promotes cell survival and proliferation via activation of nuclear factor-kappa B(NF-kappa B). Here, we investigate the mechanism by which the API2 moiety contributes to NF-kappa B stimulation. We find that the API2 moiety mediates oligomerization of API2-MALT1 as well as interaction with tumor necrosis factor receptor-associated factor 2 (TRAF2). Surprisingly, oligomerization does not occur via homotypic interaction; rather, the API2 moiety of one monomer interacts with the MALT1 moiety of another monomer. Further, the specific region of the API2 moiety responsible for mediating oligomerization is distinct from that mediating TRAF2 binding. Although deletion or mutation of the TRAF2 binding site does not inhibit oligomerization, it does lead to dramatically decreased NF-kappa B activation. Deletion of both TRAF2 binding and oligomerization regions results in near-complete loss of NF-kappa B activation. Thus, API2 moiety-mediated heterotypic oligomerization and TRAF2 binding both contribute to maximal API2-MALT1-dependent NF-kappa B stimulation.	Univ Michigan, Sch Med, Dept Pediat & Communicable Dis, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	McAllister-Lucas, LM (corresponding author), Univ Michigan, Sch Med, Dept Pediat & Communicable Dis, 3520D MSRB 1,1150 W Med Ctr Dr, Ann Arbor, MI 48109 USA.	lindaluc@umich.edu		Lucas, Peter/0000-0003-4880-7172	NCI NIH HHS [5K08 CA097986, 5K08 CA094920] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K08CA094920, K08CA097986] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akagi T, 1999, ONCOGENE, V18, P5785, DOI 10.1038/sj.onc.1203018; Baens M, 2006, CANCER RES, V66, P5270, DOI 10.1158/0008-5472.CAN-05-4590; Bishop GA, 2004, NAT REV IMMUNOL, V4, P775, DOI 10.1038/nri1462; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Dierlamm J, 1999, BLOOD, V93, P3601, DOI 10.1182/blood.V93.11.3601; Dong W, 2006, J BIOL CHEM, V281, P26029, DOI 10.1074/jbc.M513057200; Ho L, 2005, BLOOD, V105, P2891, DOI 10.1182/blood-2004-06-2297; Hosokawa Y, 2004, CANCER RES, V64, P3452, DOI 10.1158/0008-5472.CAN-03-3677; Hostager BS, 2003, J BIOL CHEM, V278, P45382, DOI 10.1074/jbc.M306708200; Hu SM, 2006, J CLIN INVEST, V116, P174, DOI 10.1172/JCI25641; Inagaki H, 2004, AM J SURG PATHOL, V28, P1560, DOI 10.1097/00000478-200412000-00003; Isaacson PG, 1999, SEMIN HEMATOL, V36, P139; Iwano M, 2004, J GASTROENTEROL, V39, P739, DOI 10.1007/s00535-004-1382-1; Levy M, 2005, J CLIN ONCOL, V23, P5061, DOI 10.1200/JCO.2005.05.660; Liu HX, 2001, BLOOD, V98, P1182, DOI 10.1182/blood.V98.4.1182; Liu HX, 2001, LANCET, V357, P39, DOI 10.1016/S0140-6736(00)03571-6; Liu HX, 2002, GASTROENTEROLOGY, V122, P1286, DOI 10.1053/gast.2002.33047; Lucas PC, 2001, J BIOL CHEM, V276, P19012, DOI 10.1074/jbc.M009984200; Lucas PC, 2004, J CELL SCI, V117, P31, DOI 10.1242/jcs.00904; Luque LE, 2002, BIOCHEMISTRY-US, V41, P13663, DOI 10.1021/bi0263964; McAllister-Lucas LM, 2001, J BIOL CHEM, V276, P30589, DOI 10.1074/jbc.M103824200; Morgan JA, 1999, CANCER RES, V59, P6205; Okabe M, 2003, AM J PATHOL, V162, P1113, DOI 10.1016/S0002-9440(10)63908-9; Penas EMM, 2003, LEUKEMIA, V17, P2225, DOI 10.1038/sj.leu.2403122; Remstein ED, 2000, AM J PATHOL, V156, P1183, DOI 10.1016/S0002-9440(10)64988-7; Rothe M, 1995, CELL, V83, P1243, DOI 10.1016/0092-8674(95)90149-3; Ruland J, 2003, IMMUNITY, V19, P749, DOI 10.1016/S1074-7613(03)00293-0; Sakugawa ST, 2003, MODERN PATHOL, V16, P1232, DOI 10.1097/01.MP.0000097283.47637.58; Salvesen GS, 2002, NAT REV MOL CELL BIO, V3, P401, DOI 10.1038/nrm830; Samuel T, 2006, J BIOL CHEM, V281, P1080, DOI 10.1074/jbc.M509381200; Senyuk V, 2005, CANCER RES, V65, P7603, DOI 10.1158/0008-5472.CAN-05-0412; So CW, 2004, BLOOD, V104, P919, DOI 10.1182/blood-2004-03-0992; Stoffel A, 2004, P NATL ACAD SCI USA, V101, P9079, DOI 10.1073/pnas.0402415101; Streubel B, 2003, BLOOD, V101, P2335, DOI 10.1182/blood-2002-09-2963; Sun LJ, 2004, MOL CELL, V14, P289, DOI 10.1016/S1097-2765(04)00236-9; Turner SD, 2006, LEUKEMIA, V20, P572, DOI 10.1038/sj.leu.2404125; Uren AG, 2000, MOL CELL, V6, P961, DOI 10.1016/S1097-2765(05)00086-9; Varfolomeev E, 2006, J BIOL CHEM, V281, P29022, DOI 10.1074/jbc.M605116200; Wang DH, 2002, NAT IMMUNOL, V3, P830, DOI 10.1038/ni824; Willis TG, 1999, CELL, V96, P35, DOI 10.1016/S0092-8674(00)80957-5; Wright CW, 2005, J CLIN INVEST, V115, P2673, DOI 10.1172/JCI26251; Ye HT, 2003, BLOOD, V101, P2547, DOI 10.1182/blood-2002-10-3167; Zhang QG, 1999, NAT GENET, V22, P63, DOI 10.1038/8767; Zhou HL, 2005, CANCER CELL, V7, P425, DOI 10.1016/j.ccr.2005.04.012; Zhou HL, 2004, NATURE, V427, P167, DOI 10.1038/nature02273; Zucca E, 2000, BLOOD, V96, P410	47	43	43	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2007	26	38					5643	5654		10.1038/sj.onc.1210342	http://dx.doi.org/10.1038/sj.onc.1210342			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	200ZS	17334391				2022-12-28	WOS:000248801900010
J	de Koning, JP; Wakabayashi, Y; Nagase, H; Mao, JH; Balmain, A				de Koning, J. P.; Wakabayashi, Y.; Nagase, H.; Mao, J-H; Balmain, A.			Convergence of congenic mapping and allele-specific alterations in tumors for the resolution of the Skts1 skin tumor susceptibility locus	ONCOGENE			English	Article						congenic; LOH; allele-specific; skin; papilloma; susceptibility	GENETIC ALTERATIONS; MODIFIER LOCI; MOUSE MODELS; LUNG-CANCER; MICE; IDENTIFICATION; RETINOBLASTOMA; CHROMOSOME-7; RESISTANCE; CANDIDATE	Although several familial cancer genes with high-penetrance mutations have been identified, the major genetic component of susceptibility to sporadic cancers is attributable to low-penetrance alleles. These 'weak' tumor susceptibility genes do not segregate as single Mendelian traits and are therefore difficult to find in studies of human populations. Previously, we have proposed that a combination of germline mapping and analysis of allele-specific imbalance in tumors may be used to re. ne the locations of susceptibility genes using mouse models of cancer. Here, we have used linkage analysis and congenic mouse strains to map the major skin tumor susceptibility locus Skts1 within a genetic interval of 0.9 cM on proximal chromosome 7. This interval lies in an apparent recombination cold spot, and corresponds to a physical distance of about 15 Mb. We therefore, used patterns of allele-specific imbalances in tumors from backcross and congenic mice to re. ne the location of Skts1. We demonstrate that this single tumor modi. er locus has a dramatic effect on the allelic preference for imbalance on chromosome 7, with at least 90% of tumors from the congenics showing preferential gain of markers on the chromosome carrying the susceptibility variant. Importantly, these alterations enabled us to re. ne the location of Skts1 at higher resolution than that attained using the congenic mice. We conclude that low-penetrance susceptibility genes can have strong effects on patterns of allele-specific somatic genetic changes in tumors, and that analysis of the directionality of these somatic events provides an important and rapid route to identification of germline genetic variants that confer increased cancer risk.	Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA; Univ Calif San Francisco, Ctr Comprehens Canc, San Francisco, CA 94143 USA; Roswell Pk Canc Inst, Dept Canc, Buffalo, NY 14263 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center; Roswell Park Cancer Institute	Balmain, A (corresponding author), Univ Calif San Francisco, Dept Biochem & Biophys, 2340 Sutter St,Room S-227, San Francisco, CA 94143 USA.	abalmain@cc.ucsf.edu	Mao, Jian-Hua/EIZ-8595-2022	Mao, Jian-Hua/0000-0001-9320-6021	NATIONAL CANCER INSTITUTE [U01CA084244] Funding Source: NIH RePORTER; NCI NIH HHS [U01 CA84244] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Balmain A, 2002, CELL, V108, P145, DOI 10.1016/S0092-8674(02)00622-0; Balmain A, 2003, NAT GENET, V33, P238, DOI 10.1038/ng1107; Cormier RT, 2000, ONCOGENE, V19, P3182, DOI 10.1038/sj.onc.1203646; Demant P, 2003, NAT REV GENET, V4, P721, DOI 10.1038/nrg1157; DIETRICH WF, 1993, CELL, V75, P631, DOI 10.1016/0092-8674(93)90484-8; Dragani TA, 2003, CANCER RES, V63, P3011; Ewart-Toland A, 2005, CARCINOGENESIS, V26, P1368, DOI 10.1093/carcin/bgi085; Ewart-Toland A, 2003, NAT GENET, V34, P403, DOI 10.1038/ng1220; Fijneman RJA, 1996, NAT GENET, V14, P465, DOI 10.1038/ng1296-465; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; Hienonen T, 2006, INT J CANCER, V118, P505, DOI 10.1002/ijc.21344; KEMP CJ, 1993, CANCER RES, V53, P6022; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; Legare ME, 2000, GENOMICS, V70, P62, DOI 10.1006/geno.2000.6368; Mao JH, 2003, CURR OPIN GENET DEV, V13, P14, DOI 10.1016/S0959-437X(03)00005-4; Mao JH, 2006, P NATL ACAD SCI USA, V103, P8125, DOI 10.1073/pnas.0602581103; Nagase H, 2003, CANCER RES, V63, P4849; NAGASE H, 1995, NAT GENET, V10, P424, DOI 10.1038/ng0895-424; Nagase H, 1999, P NATL ACAD SCI USA, V96, P15032, DOI 10.1073/pnas.96.26.15032; Peto J, 2001, NATURE, V411, P390, DOI 10.1038/35077256; Ponder BAJ, 2001, NATURE, V411, P336, DOI 10.1038/35077207; Ruivenkamp CAL, 2002, NAT GENET, V31, P295, DOI 10.1038/ng903; Saran A, 2004, ONCOGENE, V23, P4130, DOI 10.1038/sj.onc.1207565; Silver L.M., 1995, MOUSE GENETICS CONCE; To MD, 2006, NAT GENET, V38, P926, DOI 10.1038/ng1836; VOGEL SN, 1994, INFECT IMMUN, V62, P4454, DOI 10.1128/IAI.62.10.4454-4459.1994; Waterston RH, 2002, NATURE, V420, P520, DOI 10.1038/nature01262; Yu A, 2001, NATURE, V409, P951, DOI 10.1038/35057185	28	12	12	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 14	2007	26	28					4171	4178		10.1038/sj.onc.1210206	http://dx.doi.org/10.1038/sj.onc.1210206			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	178XD	17311004				2022-12-28	WOS:000247252700012
J	Jiang, X; Ellison, SJ; Alarid, ET; Shapiro, DJ				Jiang, X.; Ellison, S. J.; Alarid, E. T.; Shapiro, D. J.			Interplay between the levels of estrogen and estrogen receptor controls the level of the granzyme inhibitor, proteinase inhibitor 9 and susceptibility to immune surveillance by natural killer cells	ONCOGENE			English	Article						estrogen; estrogen receptor; tamoxifen; proteinase inhibitor 9; natural killer cell; granzyme; breast cancer	INVASIVE BREAST-CANCER; B-MEDIATED APOPTOSIS; AROMATASE INHIBITORS; ALPHA CONCENTRATION; TARGET-CELLS; CYTOTOXICITY; PROTEASE; POSTMENOPAUSAL; EXPRESSION; MODULATORS	Estrogens promote cell proliferation and metastases in several human cancers. Here, we describe a different action of estrogens likely to contribute to tumor development-blocking immunosurveillance. In breast cancer cells, increasing concentrations of estrogen induce increasing levels of the granzyme B inhibitor, SerpinB9/proteinase inhibitor 9 (PI-9) and progressively block cell death induced by NK92 natural killer (NK) cells, but do not block killing by a second NK cell line, NKL cells. RNA interference knockdown of PI-9 abolishes estrogen's ability to block NK92 cell-induced cytotoxicity. Expressing elevated levels of estrogen receptor a (ER alpha) increases the induced level of PI-9, and makes tamoxifen (TAM), but not raloxifene or ICI 182,780, a potent inducer of PI-9. At elevated levels of ERa, induct ion of PI-9 by estradiol or TAM blocks killing by both NK92 and NKL cells. When the Erk pathway is activated with epidermal growth factor, the concentration of estrogen required to induce a protective level of PI-9 is reduced to 10 pM. Elevated concentrations of estrogen and ER may provide a dual selective advantage to breast cancer cells by controlling PI-9 levels and thereby blocking immunosurveillance. Expressing elevated levels of ERa reveals a potentially important difference in the effects of TAM, raloxifene and ICI 182,780 on immunosurveillance in breast cancer.	Univ Illinois, Dept Biochem, Urbana, IL 61801 USA; Univ Wisconsin, Dept Physiol, Madison, WI 53706 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Wisconsin System; University of Wisconsin Madison	Shapiro, DJ (corresponding author), Univ Illinois, Dept Biochem, B-4 RAL,600 S Mathews Ave, Urbana, IL 61801 USA.	djshapir@uiuc.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD016720] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK064034, R01DK071909] Funding Source: NIH RePORTER; NICHD NIH HHS [HD16720] Funding Source: Medline; NIDDK NIH HHS [DK071909, DK64034] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Andrade F, 1998, IMMUNITY, V8, P451, DOI 10.1016/S1074-7613(00)80550-6; Barrie MB, 2004, J IMMUNOL, V172, P6453, DOI 10.4049/jimmunol.172.10.6453; Bird CH, 1998, MOL CELL BIOL, V18, P6387, DOI 10.1128/MCB.18.11.6387; Blomberg K, 1996, J IMMUNOL METHODS, V193, P199, DOI 10.1016/0022-1759(96)00063-4; Bots M, 2006, IMMUNOL CELL BIOL, V84, P79, DOI 10.1111/j.1440-1711.2005.01417.x; Bots M, 2005, BLOOD, V105, P1153, DOI 10.1182/blood-2004-03-0791; Bots M, 2006, BLOOD, V107, P4974, DOI 10.1182/blood-2006-01-0291; Clarke R, 2003, ONCOGENE, V22, P7316, DOI 10.1038/sj.onc.1206937; Dunn GP, 2004, IMMUNITY, V21, P137, DOI 10.1016/j.immuni.2004.07.017; Dunn GP, 2004, ANNU REV IMMUNOL, V22, P329, DOI 10.1146/annurev.immunol.22.012703.104803; Fowler AM, 2006, MOL ENDOCRINOL, V20, P291, DOI 10.1210/me.2005-0288; Fowler AM, 2004, FASEB J, V18, P81, DOI 10.1096/fj.03-0038com; Godal R, 2006, BLOOD, V107, P3205, DOI 10.1182/blood-2005-07-2880; Goping IS, 2003, IMMUNITY, V18, P355, DOI 10.1016/S1074-7613(03)00032-3; Gradishar WJ, 2006, JAMA-J AM MED ASSOC, V295, P2784, DOI 10.1001/jama.295.23.jed60037; Gritzapis AD, 2003, BREAST CANCER RES TR, V80, P1, DOI 10.1023/A:1024462416640; Hupperets PS, 1997, AM J CLIN ONCOL-CANC, V20, P546, DOI 10.1097/00000421-199712000-00002; Jiang XG, 2006, ENDOCRINOLOGY, V147, P1419, DOI 10.1210/en.2005-0996; Kanamori H, 2000, J BIOL CHEM, V275, P5867, DOI 10.1074/jbc.275.8.5867; Kannan-Thulasiraman P, 2002, J BIOL CHEM, V277, P41230, DOI 10.1074/jbc.M200379200; Kataoka T, 1996, J IMMUNOL, V156, P3678; Kisanga ER, 2004, CLIN CANCER RES, V10, P2336, DOI 10.1158/1078-0432.CCR-03-0538; Krieg AJ, 2004, J BIOL CHEM, V279, P5025, DOI 10.1074/jbc.M307076200; Krieg SA, 2001, MOL ENDOCRINOL, V15, P1971, DOI 10.1210/me.15.11.1971; Lamboley C, 2000, CELL MOL BIOL, V46, P13; Levin ER, 2003, MOL ENDOCRINOL, V17, P309, DOI 10.1210/me.2002-0368; Lewis JS, 2005, MUTAT RES-FUND MOL M, V591, P247, DOI 10.1016/j.mrfmmm.2005.02.028; Lieberman J, 2003, CURR OPIN IMMUNOL, V15, P553, DOI 10.1016/S0952-7915(03)00108-0; Lieberman J, 2003, NAT REV IMMUNOL, V3, P361, DOI 10.1038/nri1083; Lonning PE, 1997, J STEROID BIOCHEM, V61, P255; Mahrus S, 2005, CHEM BIOL, V12, P567, DOI 10.1016/j.chembiol.2005.03.006; Mahrus S, 2004, J BIOL CHEM, V279, P54275, DOI 10.1074/jbc.M411482200; Medema JP, 2001, P NATL ACAD SCI USA, V98, P11515, DOI 10.1073/pnas.201398198; MELDRUM DR, 1981, OBSTET GYNECOL, V57, P624; Phillips T, 2004, J IMMUNOL, V173, P3801, DOI 10.4049/jimmunol.173.6.3801; Riera J, 1999, AM J CLIN PATHOL, V111, P329; ROMAIN S, 1994, INT J CANCER, V59, P17, DOI 10.1002/ijc.2910590105; Russell JH, 2002, ANNU REV IMMUNOL, V20, P323, DOI 10.1146/annurev.immunol.20.100201.131730; SANCHOGARNIER H, 1995, EUR J CANCER, V31A, P1851, DOI 10.1016/0959-8049(95)00387-X; Sebbagh M, 2005, J EXP MED, V201, P465, DOI 10.1084/jem.20031877; Smith IE, 2003, NEW ENGL J MED, V348, P2431, DOI 10.1056/NEJMra023246; ten Berge RL, 2003, J PATHOL, V200, P4, DOI 10.1002/path.1331; Thomas DA, 2000, IMMUNITY, V12, P621, DOI 10.1016/S1074-7613(00)80213-7; THORPE SM, 1993, EUR J CANCER, V29A, P971, DOI 10.1016/S0959-8049(05)80204-7; van Houdt IS, 2005, CLIN CANCER RES, V11, P6400, DOI 10.1158/1078-0432.CCR-05-0306; Vogel VG, 2006, JAMA-J AM MED ASSOC, V295, P2727, DOI 10.1001/jama.295.23.joc60074; Yager JD, 2006, NEW ENGL J MED, V354, P270, DOI 10.1056/NEJMra050776; Zhang ZH, 2006, MOL ECOL NOTES, V6, P24, DOI 10.1111/j.1471-8286.2005.01117.x	48	75	80	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 14	2007	26	28					4106	4114		10.1038/sj.onc.1210197	http://dx.doi.org/10.1038/sj.onc.1210197			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	178XD	17237823				2022-12-28	WOS:000247252700006
J	Dhanasekaran, DN; Johnson, GL				Dhanasekaran, D. N.; Johnson, G. L.			MAPKs: function, regulation, role in cancer and therapeutic targeting	ONCOGENE			English	Editorial Material									Univ N Carolina, Sch Med, Lineberger Comprehens Canc Ctr, Dept Pharmacol, Chapel Hill, NC 27599 USA; Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19122 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Johnson, GL (corresponding author), Univ N Carolina, Sch Med, Lineberger Comprehens Canc Ctr, Dept Pharmacol, Chapel Hill, NC 27599 USA.	glj@med.unc.edu							0	88	90	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 15	2007	26	22					3097	3099		10.1038/sj.onc.1210395	http://dx.doi.org/10.1038/sj.onc.1210395			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	169PH	17496908	Bronze			2022-12-28	WOS:000246603600001
J	Adams, JM; Cory, S				Adams, J. M.; Cory, S.			The Bcl-2 apoptotic switch in cancer development and therapy	ONCOGENE			English	Review						Bcl-2; apoptosis; cancer; oncogenesis; chemotherapy; BH3 mimetic drugs	FAMILY-MEMBER BIM; T-CELL DEATH; MITOCHONDRIAL-MEMBRANE PERMEABILIZATION; PROAPOPTOTIC PROTEIN BIM; BH3 MIMETIC ABT-737; BH3-ONLY PROTEINS; IN-VIVO; X-L; INDUCE APOPTOSIS; TRANSGENIC MICE	Impaired apoptosis is both critical in cancer development and a major barrier to effective treatment. In response to diverse intracellular damage signals, including those evoked by cancer therapy, the cell's decision to undergo apoptosis is determined by interactions between three factions of the Bcl-2 protein family. The damage signals are transduced by the diverse 'BH3-only' proteins, distinguished by the BH3 domain used to engage their pro-survival relatives: Bcl-2, Bcl-x(L), Bcl-w, Mcl-1 and A1. This interaction ablates pro-survival function and allows activation of Bax and Bak, which commit the cell to apoptosis by permeabilizing the outer membrane of the mitochondrion. Certain 'BH3-only' proteins (e.g. Bim, Puma) can engage all the pro-survival proteins, but others (e.g. Bad, Noxa) engage only subsets. Activation of Bax and Bak appears to require that the BH3-only proteins engage the multiple pro-survival proteins guarding Bax and Bak, rather than binding to the latter. The balance between the pro-survival proteins and their BH3 ligands regulates tissue homeostasis, and either overexpression of a pro-survival family member or loss of a proapoptotic relative can be oncogenic. Better understanding of the Bcl-2 family is clarifying its role in cancer development, revealing how conventional therapy works and stimulating the search for 'BH3 mimetics' as a novel class of anticancer drugs.	Walter & Eliza Hall Inst Med Res, Dept Mol Genet Canc, Parkville, Vic 3050, Australia	Walter & Eliza Hall Institute	Adams, JM (corresponding author), Walter & Eliza Hall Inst Med Res, Dept Mol Genet Canc, IG Royal Parade, Parkville, Vic 3050, Australia.	adams@wehi.edu.au	Adams, Jerry M/E-1199-2013; Cory, Suzanne/E-1642-2013	Cory, Suzanne/0000-0002-6818-3451; Adams, Jerry/0000-0002-4360-8628	NCI NIH HHS [CA 43540, R01 CA043540, R01 CA080188-06, R01 CA080188, CA 80188, R01 CA043540-18] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA043540, R01CA080188] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams JM, 2003, GENE DEV, V17, P2481, DOI 10.1101/gad.1126903; Akiyama T, 2003, EMBO J, V22, P6653, DOI 10.1093/emboj/cdg635; Amundson SA, 2000, CANCER RES, V60, P6101; Annis MG, 2005, EMBO J, V24, P2096, DOI 10.1038/sj.emboj.7600675; BELLOT G, 2006, CELL DEATH DIFFER; Bouillet P, 2001, DEV CELL, V1, P645, DOI 10.1016/S1534-5807(01)00083-1; Bouillet P, 1999, SCIENCE, V286, P1735, DOI 10.1126/science.286.5445.1735; Bouillet P, 2002, NATURE, V415, P922, DOI 10.1038/415922a; Cartron PF, 2004, MOL CELL, V16, P807, DOI 10.1016/j.molcel.2004.10.028; Certo M, 2006, CANCER CELL, V9, P351, DOI 10.1016/j.ccr.2006.03.027; Chauhan D., 2006, ONCOGENE; Chen L, 2005, MOL CELL, V17, P393, DOI 10.1016/j.molcel.2004.12.030; Cheng EHY, 2003, SCIENCE, V301, P513, DOI 10.1126/science.1083995; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; Chipuk JE, 2004, SCIENCE, V303, P1010, DOI 10.1126/science.1092734; Chou CH, 2006, MOL BIOL CELL, V17, P3952, DOI 10.1091/mbc.E06-04-0319; Christophorou MA, 2006, NATURE, V443, P214, DOI 10.1038/nature05077; Cimmino A, 2005, P NATL ACAD SCI USA, V102, P13944, DOI 10.1073/pnas.0506654102; CONCANNON CG, 2006, ONCOGENE; Cory S, 2003, ONCOGENE, V22, P8590, DOI 10.1038/sj.onc.1207102; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; Cuconati A, 2003, GENE DEV, V17, P2922, DOI 10.1101/gad.1156903; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; Degenhardt K, 2002, CANCER CELL, V2, P193, DOI 10.1016/S1535-6108(02)00126-5; Deng XM, 2004, P NATL ACAD SCI USA, V101, P153, DOI 10.1073/pnas.2533920100; Deverman BE, 2002, CELL, V111, P51, DOI 10.1016/S0092-8674(02)00972-8; Deverman BE, 2003, CELL, V115, P503, DOI 10.1016/S0092-8674(03)00892-4; Dijkers PF, 2000, CURR BIOL, V10, P1201, DOI 10.1016/S0960-9822(00)00728-4; DZHAGALOV I, 2006, BLOOD; Egle A, 2004, P NATL ACAD SCI USA, V101, P6164, DOI 10.1073/pnas.0401471101; Egle A, 2004, BLOOD, V103, P2276, DOI 10.1182/blood-2003-07-2469; Eischen CM, 2002, CANCER RES, V62, P2184; Eischen CM, 2001, MOL CELL BIOL, V21, P5063, DOI 10.1128/MCB.21.15.5063-5070.2001; Erlacher M, 2005, BLOOD, V106, P4131, DOI 10.1182/blood-2005-04-1595; Fernandez Y, 2005, CANCER RES, V65, P6294, DOI 10.1158/0008-5472.CAN-05-0686; Fesik SW, 2005, NAT REV CANCER, V5, P876, DOI 10.1038/nrc1736; Fribley AM, 2006, J BIOL CHEM, V281, P31440, DOI 10.1074/jbc.M604356200; Gardai SJ, 2004, J BIOL CHEM, V279, P21085, DOI 10.1074/jbc.M400063200; Green DR, 2005, CELL, V121, P671, DOI 10.1016/j.cell.2005.05.019; Hamasaki A, 1998, J EXP MED, V188, P1985, DOI 10.1084/jem.188.11.1985; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hemann MT, 2005, NATURE, V436, P807, DOI 10.1038/nature03845; Hemann MT, 2004, P NATL ACAD SCI USA, V101, P9333, DOI 10.1073/pnas.0403286101; Hildeman DA, 2002, IMMUNITY, V16, P759, DOI 10.1016/S1074-7613(02)00322-9; Hinds MG, 2005, CURR OPIN STRUC BIOL, V15, P690, DOI 10.1016/j.sbi.2005.10.003; Hsu YT, 1997, J BIOL CHEM, V272, P13829, DOI 10.1074/jbc.272.21.13829; Hsu YT, 1998, J BIOL CHEM, V273, P10777, DOI 10.1074/jbc.273.17.10777; Huang DCS, 2000, CELL, V103, P839, DOI 10.1016/S0092-8674(00)00187-2; Huang DCS, 1999, P NATL ACAD SCI USA, V96, P14871, DOI 10.1073/pnas.96.26.14871; Ionov Y, 2000, P NATL ACAD SCI USA, V97, P10872, DOI 10.1073/pnas.190210897; Jeffers JR, 2003, CANCER CELL, V4, P321, DOI 10.1016/S1535-6108(03)00244-7; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; Karbowski M, 2006, NATURE, V443, P658, DOI 10.1038/nature05111; Kim BJ, 2006, J BIOL CHEM, V281, P21256, DOI 10.1074/jbc.M510644200; Kim H, 2006, NAT CELL BIOL, V8, P1348, DOI 10.1038/ncb1499; Kim YK, 2004, INT J CONTROL AUTOM, V2, P523; Knudson CM, 2001, CANCER RES, V61, P659; Kondo S, 2000, CANCER RES, V60, P4328; Konopleva M, 2006, CANCER CELL, V10, P375, DOI 10.1016/j.ccr.2006.10.006; Kuribara R, 2004, MOL CELL BIOL, V24, P6172, DOI 10.1128/MCB.24.14.6172-6183.2004; Kuroda J, 2006, P NATL ACAD SCI USA, V103, P14907, DOI 10.1073/pnas.0606176103; Kuwana T, 2005, MOL CELL, V17, P525, DOI 10.1016/j.molcel.2005.02.003; Kuwana T, 2002, CELL, V111, P331, DOI 10.1016/S0092-8674(02)01036-X; Lakhani SA, 2006, SCIENCE, V311, P847, DOI 10.1126/science.1115035; Letai A, 2002, CANCER CELL, V2, P183, DOI 10.1016/S1535-6108(02)00127-7; Ley R, 2003, J BIOL CHEM, V278, P18811, DOI 10.1074/jbc.M301010200; LINSTERN T, 2000, MOL CELL, V6, P1389; Liu XQ, 2003, IMMUNITY, V19, P341, DOI 10.1016/S1074-7613(03)00234-6; Luciano F, 2003, ONCOGENE, V22, P6785, DOI 10.1038/sj.onc.1206792; Lucken-Ardjomande S, 2005, J CELL SCI, V118, P473, DOI 10.1242/jcs.01654; MCDONNELL TJ, 1991, NATURE, V349, P254, DOI 10.1038/349254a0; MCDONNELL TJ, 1989, CELL, V57, P79, DOI 10.1016/0092-8674(89)90174-8; Meijerink JPP, 1998, BLOOD, V91, P2991, DOI 10.1182/blood.V91.8.2991.2991_2991_2997; MESTREESCOIHUEL.C, 2006, BLOOD; Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9; Ming L, 2006, J BIOL CHEM, V281, P16034, DOI 10.1074/jbc.M513587200; MIYASHITA T, 1995, CELL, V80, P293; Moldoveanu T, 2006, MOL CELL, V24, P677, DOI 10.1016/j.molcel.2006.10.014; MOTOYAMA N, 1995, SCIENCE, V267, P1506, DOI 10.1126/science.7878471; Motoyama N, 1999, J EXP MED, V189, P1691, DOI 10.1084/jem.189.11.1691; NAKAYAMA K, 1993, SCIENCE, V261, P1584, DOI 10.1126/science.8372353; NAKAYAMA K, 1994, P NATL ACAD SCI USA, V91, P3700, DOI 10.1073/pnas.91.9.3700; Newmeyer DD, 2003, CELL, V112, P481, DOI 10.1016/S0092-8674(03)00116-8; Nijhawan D, 2003, GENE DEV, V17, P1475, DOI 10.1101/gad.1093903; Nikrad M, 2005, MOL CANCER THER, V4, P443; Ogilvy S, 1999, P NATL ACAD SCI USA, V96, P14943, DOI 10.1073/pnas.96.26.14943; Oh KJ, 2006, J BIOL CHEM, V281, P36999, DOI 10.1074/jbc.M602341200; Oltersdorf T, 2005, NATURE, V435, P677, DOI 10.1038/nature03579; Opferman JT, 2003, NATURE, V426, P671, DOI 10.1038/nature02067; Opferman JT, 2005, SCIENCE, V307, P1101, DOI 10.1126/science.1106114; Parone PA, 2006, MOL CELL BIOL, V26, P7397, DOI 10.1128/MCB.02282-05; PATEL JH, 2006, J BIOL CHEM; Pellegrini M, 2003, P NATL ACAD SCI USA, V100, P14175, DOI 10.1073/pnas.2336198100; Print CG, 1998, P NATL ACAD SCI USA, V95, P12424, DOI 10.1073/pnas.95.21.12424; Putcha GV, 2003, NEURON, V38, P899, DOI 10.1016/S0896-6273(03)00355-6; Puthalakath H, 2002, CELL DEATH DIFFER, V9, P505, DOI 10.1038/sj.cdd.4400998; Puthalakath H, 2001, SCIENCE, V293, P1829, DOI 10.1126/science.1062257; Puthalakath H, 1999, MOL CELL, V3, P287, DOI 10.1016/S1097-2765(00)80456-6; Qin JZ, 2005, CANCER RES, V65, P6282, DOI 10.1158/0008-5472.CAN-05-0676; Rampino N, 1997, SCIENCE, V275, P967, DOI 10.1126/science.275.5302.967; Reginato MJ, 2005, MOL CELL BIOL, V25, P4591, DOI 10.1128/MCB.25.11.4591-4601.2005; Reginato MJ, 2003, NAT CELL BIOL, V5, P733, DOI 10.1038/ncb1026; Rinkenberger JL, 2000, GENE DEV, V14, P23; Ross AJ, 1998, NAT GENET, V18, P251, DOI 10.1038/ng0398-251; Sadowsky JD, 2005, J AM CHEM SOC, V127, P11966, DOI 10.1021/ja053678t; SADOWSKY JD, 2006, IN PRESS J AM CHEM S; Sattler M, 1997, SCIENCE, V275, P983, DOI 10.1126/science.275.5302.983; Schmidt T, 1999, CELL DEATH DIFFER, V6, P873, DOI 10.1038/sj.cdd.4400562; Schmitt CA, 2000, NAT MED, V6, P1029, DOI 10.1038/79542; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; Shibata MA, 1999, EMBO J, V18, P2692, DOI 10.1093/emboj/18.10.2692; Shoemaker AR, 2006, CANCER RES, V66, P8731, DOI 10.1158/0008-5472.CAN-06-0367; STRAIZYS V, 1993, BALT ASTRON, V2, P1, DOI DOI 10.1515/ASTRO-1993-0102; STRASSER A, 1991, P NATL ACAD SCI USA, V88, P8661, DOI 10.1073/pnas.88.19.8661; STRASSER A, 1991, CELL, V67, P889, DOI 10.1016/0092-8674(91)90362-3; STRASSER A, 1990, NATURE, V348, P331, DOI 10.1038/348331a0; Strasser A, 2005, NAT REV IMMUNOL, V5, P189, DOI 10.1038/nri1568; Strasser A, 1995, EMBO J, V14, P6136, DOI 10.1002/j.1460-2075.1995.tb00304.x; Strasser A, 2000, ANNU REV BIOCHEM, V69, P217, DOI 10.1146/annurev.biochem.69.1.217; Suzuki M, 2000, CELL, V103, P645, DOI 10.1016/S0092-8674(00)00167-7; Tagawa H, 2005, ONCOGENE, V24, P1348, DOI 10.1038/sj.onc.1208300; Tan TT, 2005, CANCER CELL, V7, P227, DOI 10.1016/j.ccr.2005.02.008; van Delft MF, 2006, CANCER CELL, V10, P389, DOI 10.1016/j.ccr.2006.08.027; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; VEIS DJ, 1993, CELL, V75, P229, DOI 10.1016/0092-8674(93)80065-M; Villunger A, 2003, SCIENCE, V302, P1036, DOI 10.1126/science.1090072; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Wagner KU, 2000, DEVELOPMENT, V127, P4949; Walensky LD, 2004, SCIENCE, V305, P1466, DOI 10.1126/science.1099191; Walensky LD, 2006, MOL CELL, V24, P199, DOI 10.1016/j.molcel.2006.08.020; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Willis SN, 2005, GENE DEV, V19, P1294, DOI 10.1101/gad.1304105; Willis SN, 2005, CURR OPIN CELL BIOL, V17, P617, DOI 10.1016/j.ceb.2005.10.001; WILLIS SN, 2007, IN PRESS SCIENCE; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; Yin CY, 1997, NATURE, V385, P637, DOI 10.1038/385637a0; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zha JP, 2000, SCIENCE, V290, P1761, DOI 10.1126/science.290.5497.1761; Zhang Y, 2006, CELL DEATH DIFFER, V13, P129, DOI 10.1038/sj.cdd.4401686; Zhao Y, 2005, P NATL ACAD SCI USA, V102, P16090, DOI 10.1073/pnas.0505585102; Zhong Q, 2005, CELL, V121, P1085, DOI 10.1016/j.cell.2005.06.009; Zhu YN, 2006, J EXP MED, V203, P1147, DOI 10.1084/jem.20051736; Zhu YN, 2004, P NATL ACAD SCI USA, V101, P7681, DOI 10.1073/pnas.0402293101; Zong WX, 2001, GENE DEV, V15, P1481, DOI 10.1101/gad.897601	144	1582	1700	4	281	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 26	2007	26	9					1324	1337		10.1038/sj.onc.1210220	http://dx.doi.org/10.1038/sj.onc.1210220			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	141DU	17322918	Green Accepted			2022-12-28	WOS:000244558700010
J	Anastasi, S; Baietti, MF; Frosi, Y; Alema, S; Segatto, O				Anastasi, S.; Baietti, M. F.; Frosi, Y.; Alema, S.; Segatto, O.			The evolutionarily conserved EBR module of RALT/MIG6 mediates suppression of the EGFR catalytic activity	ONCOGENE			English	Article						EGFR; RALT; MIG6; feedback inhibition; negative signalling; tumour suppression	GROWTH-FACTOR RECEPTOR; NEGATIVE REGULATOR; TYROSINE KINASE; ERBB RECEPTORS; ENDOCYTOSIS; DOMAIN; SIGNAL; INHIBITION; RALT; UBIQUITYLATION	Physiological signalling by the epidermal growth factor receptor ( EGFR) controls developmental processes and tissue homeostasis, whereas aberrant EGFR activity drives oncogenic cell transformation. Under normal conditions, the EGFR must therefore generate outputs of defined strength and duration. To this aim, cells balance EGFR activity via different modalities of negative signalling. Increasing attention is being drawn on transcriptionally controlled feedback inhibitors of EGFR, namely RALT/MIG6, LRIG1, SOCS4 and SOCS5. Genetic studies in mice have revealed the essential role of Ralt/Mig6 in regulating Egfr-driven skin morphogenesis and tumour formation, yet the mechanisms through which RALT abrogates EGFR activity are still undefined. We report that RALT suppresses EGFR function by inhibiting its catalytic activity. The evolutionarily conserved ErbB-binding region (EBR) is necessary and sufficient to carry out RALT-dependent suppression of EGFR kinase activity in vitro and in intact cells. The mechanism involves binding of the EBR to the 953RYLVIQ958 sequence, which is located in the alpha I helix of the EGFR kinase and has been shown to participate in allosteric control of EGFR catalytic activity. Our results uncover a novel mechanism of temporal regulation of EGFR activity in vertebrate organisms.	[Anastasi, S.; Baietti, M. F.; Frosi, Y.; Segatto, O.] Regina Elena Inst Canc Res, Immunol Lab, Dept Expt Oncol, I-00158 Rome, Italy; [Alema, S.] CNR, Inst Cell Biol, I-00016 Monterotondo, Italy	IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; Consiglio Nazionale delle Ricerche (CNR)	Anastasi, S (corresponding author), Regina Elena Inst Canc Res, Immunol Lab, Dept Expt Oncol, Via Delle Messi Oro 156-158, I-00158 Rome, Italy.	anastasi@ifo.it; segatto@ifo.it	anastasi, sergio/AAB-9585-2020; Baietti, Maria Francesca/AAA-6749-2019	anastasi, sergio/0000-0003-1009-6117; Baietti, Maria Francesca/0000-0002-1495-226X; Alema, Stefano/0000-0002-9869-6354; Segatto, Oreste/0000-0003-2561-1142				Anastasi S, 2005, ONCOGENE, V24, P4540, DOI 10.1038/sj.onc.1208658; Anastasi S, 2003, ONCOGENE, V22, P4221, DOI 10.1038/sj.onc.1206516; Ballaro C, 2005, EMBO REP, V6, P755, DOI 10.1038/sj.embor.7400458; Baulida J, 1996, J BIOL CHEM, V271, P5251; Bereziat V, 2002, J BIOL CHEM, V277, P4845, DOI 10.1074/jbc.M106574200; Citri A, 2006, NAT REV MOL CELL BIO, V7, P505, DOI 10.1038/nrm1962; DIFIORE PP, 1990, SCIENCE, V248, P79, DOI 10.1126/science.2181668; Ferby I, 2006, NAT MED, V12, P568, DOI 10.1038/nm1401; Fiorentino L, 2000, MOL CELL BIOL, V20, P7735, DOI 10.1128/MCB.20.20.7735-7750.2000; Fiorini M, 2001, FEBS LETT, V490, P132, DOI 10.1016/S0014-5793(01)02116-0; Gur G, 2004, EMBO J, V23, P3270, DOI 10.1038/sj.emboj.7600342; Hackel PO, 2001, BIOL CHEM, V382, P1649, DOI 10.1515/BC.2001.200; Haslekas C, 2005, MOL BIOL CELL, V16, P5832, DOI 10.1091/mbc.E05-05-0456; Hendriks BS, 2003, CANCER RES, V63, P1130; HSU CYJ, 1991, J BIOL CHEM, V266, P603; Huse M, 2002, CELL, V109, P275, DOI 10.1016/S0092-8674(02)00741-9; Kario E, 2005, J BIOL CHEM, V280, P7038, DOI 10.1074/jbc.M408575200; Kochupurakkal BS, 2005, J BIOL CHEM, V280, P8503, DOI 10.1074/jbc.M413919200; Laederich MB, 2004, J BIOL CHEM, V279, P47050, DOI 10.1074/jbc.M409703200; Lenferink AEG, 1998, EMBO J, V17, P3385, DOI 10.1093/emboj/17.12.3385; Longva KE, 2002, J CELL BIOL, V156, P843, DOI 10.1083/jcb.200106056; LUETTEKE NC, 1993, CELL, V73, P263, DOI 10.1016/0092-8674(93)90228-I; LUETTEKE NC, 1994, GENE DEV, V8, P399, DOI 10.1101/gad.8.4.399; Marmor MD, 2004, ONCOGENE, V23, P2057, DOI 10.1038/sj.onc.1207390; Miaczynska M, 2004, CURR OPIN CELL BIOL, V16, P400, DOI 10.1016/j.ceb.2004.06.005; Nicholson SE, 2005, P NATL ACAD SCI USA, V102, P2328, DOI 10.1073/pnas.0409675102; Polo S, 2004, CURR OPIN CELL BIOL, V16, P156, DOI 10.1016/j.ceb.2004.02.003; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; Schaefer G, 1999, J BIOL CHEM, V274, P859, DOI 10.1074/jbc.274.2.859; Schulze A, 2001, GENE DEV, V15, P981, DOI 10.1101/gad.191101; Shelly M, 1998, J BIOL CHEM, V273, P10496, DOI 10.1074/jbc.273.17.10496; Shilo BZ, 2003, EXP CELL RES, V284, P140, DOI 10.1016/S0014-4827(02)00094-0; Sigismund S, 2005, P NATL ACAD SCI USA, V102, P2760, DOI 10.1073/pnas.0409817102; Sigismund S, 2004, CURR TOP MICROBIOL, V286, P149; Stamos J, 2002, J BIOL CHEM, V277, P46265, DOI 10.1074/jbc.M207135200; Wiley HS, 2003, TRENDS CELL BIOL, V13, P43; Xu DZ, 2005, J BIOL CHEM, V280, P2924, DOI 10.1074/jbc.M408907200; Zhang XW, 2006, CELL, V125, P1137, DOI 10.1016/j.cell.2006.05.013; Zhang YW, 2007, ONCOGENE, V26, P269, DOI 10.1038/sj.onc.1209790	39	58	62	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 13	2007	26	57					7833	7846		10.1038/sj.onc.1210590	http://dx.doi.org/10.1038/sj.onc.1210590			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	248ON	17599051				2022-12-28	WOS:000252163500002
J	Kobel, M; Weidensdorfer, D; Reinke, C; Lederer, M; Schmitt, WD; Zeng, K; Thomssen, C; Hauptmann, S; Huettelmaier, S				Koebel, M.; Weidensdorfer, D.; Reinke, C.; Lederer, M.; Schmitt, W. D.; Zeng, K.; Thomssen, C.; Hauptmann, S.; Huettelmaier, S.			Expression of the RNA-binding protein IMP1 correlates with poor prognosis in ovarian carcinoma	ONCOGENE			English	Article						IMP1; ovarian carcinoma; c-myc	MYC MESSENGER-RNA; C-MYC; CRD-BP; FAMILY; CANCER; TUMORS; OVEREXPRESSION; TRANSLATION; CELLS; ZBP1	The IMP (IGFII mRNA-binding protein) family comprises a group of three RNA-binding proteins involved in the regulation of cytoplasmic mRNA-fate. Recent studies identified IMP proteins as oncofetal factors in various neoplasias, but knowledge of a potential role in ovarian carcinomas is still lacking. The immunohistochemical analysis of 107 ovarian carcinomas, 30 serous borderline tumors of the ovary and five normal ovaries revealed de novo synthesis of IMP1 in 69% of ovarian carcinomas. Elevated IMP1 expression was observed preferentially in high-grade and high-stage cases and was a significant prognostic indicator for reduced recurrence-free and overall survival. Phenotypic studies in ovarian carcinoma-derived ES-2 cells demonstrated that IMP1 knockdown affects proliferation and cell survival. Reduced proliferation was associated with decreased c-myc mRNA half-life, suggesting IMP1 as an oncogenic factor that is involved in promoting elevated proliferation by stabilizing the c-myc mRNA in ovarian carcinoma cells.	Univ Halle Wittenberg, Dept Med, D-06120 Halle, Germany; Univ Halle Wittenberg, Inst Pathol, Dept Med, Halle, Germany; Univ Halle Wittenberg, Dept Gynecol, Halle, Germany	Martin Luther University Halle Wittenberg; Martin Luther University Halle Wittenberg; Martin Luther University Halle Wittenberg	Huettelmaier, S (corresponding author), Univ Halle Wittenberg, Dept Med, Halle-Wittenberg Heinrich-Damerow-St 1, D-06120 Halle, Germany.	hauptmann@medizin.uni-halle.de; stefan.huettelmaier@medizin.uni-halle.de	Köbel, Martin/A-7373-2011; Thomssen, Christoph/ABC-3102-2021; Hüttelmaier, Stefan/AAQ-1203-2021; Schmitt, Wolfgang D/B-4729-2008	Schmitt, Wolfgang D/0000-0002-7870-138X; Kobel, Martin/0000-0002-6615-2037				Chen CH, 2005, INT J GYNECOL CANCER, V15, P878, DOI 10.1111/j.1525-1438.2005.00150.x; Dimova I, 2006, EUR J CANCER, V42, P674, DOI 10.1016/j.ejca.2005.11.022; Farina KL, 2003, J CELL BIOL, V160, P77, DOI 10.1083/jcb.200206003; Gu LJ, 2004, INT J ONCOL, V24, P671; Hansen TVO, 2004, MOL CELL BIOL, V24, P4448, DOI 10.1128/MCB.24.10.4448-4464.2004; Huttelmaier S, 2005, NATURE, V438, P512, DOI 10.1038/nature04115; Ioannidis P, 2005, J BIOL CHEM, V280, P20086, DOI 10.1074/jbc.M410036200; Ioannidis P, 2004, CANCER LETT, V209, P245, DOI 10.1016/j.canlet.2003.12.015; Ioannidis P, 2003, ANTICANCER RES, V23, P2179; Ioannidis P, 2001, INT J CANCER, V94, P480, DOI 10.1002/ijc.1512; Kobel M, 2006, INT J GYNECOL PATHOL, V25, P121, DOI 10.1097/01.pgp.0000185410.39050.ac; Lemm I, 2002, MOL CELL BIOL, V22, P3959, DOI 10.1128/MCB.22.12.3959-3969.2002; Liao BS, 2004, J BIOL CHEM, V279, P48716, DOI 10.1074/jbc.M405853200; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Mueller-Pillasch F, 1999, MECH DEVELOP, V88, P95, DOI 10.1016/S0925-4773(99)00160-4; Nielsen J, 1999, MOL CELL BIOL, V19, P1262; Noubissi FK, 2006, NATURE, V441, P898, DOI 10.1038/nature04839; Ross J, 2001, ONCOGENE, V20, P6544, DOI 10.1038/sj.onc.1204838; Shih IM, 2004, AM J PATHOL, V164, P1511, DOI 10.1016/S0002-9440(10)63708-X; Sparanese D, 2007, NUCLEIC ACIDS RES, V35, P1209, DOI 10.1093/nar/gkl1148; Vikesaa J, 2006, EMBO J, V25, P1456, DOI 10.1038/sj.emboj.7601039; Yaniv K, 2003, DEVELOPMENT, V130, P5649, DOI 10.1242/dev.00810; Yaniv K, 2002, GENE, V287, P49, DOI 10.1016/S0378-1119(01)00866-6; Yisraeli JK, 2005, BIOL CELL, V97, P87	24	84	86	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 29	2007	26	54					7584	7589		10.1038/sj.onc.1210563	http://dx.doi.org/10.1038/sj.onc.1210563			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	236DB	17546046				2022-12-28	WOS:000251282100011
J	Sundvall, M; Peri, L; Maatta, JA; Tvorogov, D; Paatero, I; Savisalo, M; Silvennoinen, O; Yarden, Y; Elenius, K				Sundvall, M.; Peri, L.; Maatta, J. A.; Tvorogov, D.; Paatero, I.; Savisalo, M.; Silvennoinen, O.; Yarden, Y.; Elenius, K.			Differential nuclear localization and kinase activity of alternative ErbB4 intracellular domains	ONCOGENE			English	Article						cancer; gamma-secretase; HER; neuregulin; nuclear shuttling; ubiquitin	GROWTH-FACTOR RECEPTOR; GAMMA-SECRETASE CLEAVAGE; BREAST-CANCER CELLS; TYROSINE KINASE; ESTROGEN-RECEPTOR; ISOFORM; ACTIVATION; PHOSPHORYLATION; TRANSACTIVATION; UBIQUITYLATION	Cleavable isoforms of the ErbB4 receptor tyrosine kinase release a soluble intracellular domain (ICD) that may translocate to the nucleus and regulate signaling. However, ErbB4 gene is alternatively spliced generating CYT-1 and CYT-2 isoforms with different cytoplasmic tails. Here, we addressed whether the two alternative ErbB4 ICDs of either CYT4 (ICD1) or CYT-2 (ICD2) type differ in signaling to the nucleus. Confocal microscopy and extraction of nuclear cell fractions indicated that significantly more ICD2 translocated to the nuclei when compared to ICD1. Unlike the membrane-anchored 80 kDa fragments derived from full-length ErbB4 isoforms, the two ICDs did not differ from each other in metabolic stability or ubiquitylation. However, ICD2 was phosphorylated at tyrosine residues to a higher extent and demonstrated greater in vitro kinase activity than ICDI. Mutating the ATP-binding site within ICD2 kinase domain (ICD2 K751R) blocked its tyrosine phosphorylation and significantly reduced its nuclear translocation. When expressed in the context of full-length ErbB4, ICD2 was also more efficient than ICD1 in promoting transcriptional activation of the STAT5 target gene beta-casein. These findings indicate that the two alternative ICDs of ErbB4 differ in their nuclear accumulation, and that the mechanism involves differential kinase activity but not ubiquitin-regulated ICD stability.	Univ Turku, Dept Med Biochem & Mol Biol, FIN-20520 Turku, Finland; Univ Turku, Medicity Res Lab, Turku, Finland; Univ Turku, Turku Grad Sch Biomed Sci, Turku, Finland; Univ Tampere, Inst Med Technol, FIN-33101 Tampere, Finland; Tampere Univ Hosp, Dept Clin Microbiol, Tampere, Finland; Weizmann Inst Sci, Dept Regulat Biol, IL-76100 Rehovot, Israel; Turku Univ, Cent Hosp, Dept Oncol, Turku, Finland	University of Turku; University of Turku; University of Turku; Tampere University; Tampere University; Tampere University Hospital; Weizmann Institute of Science; University of Turku	Elenius, K (corresponding author), Univ Turku, Dept Med Biochem & Mol Biol, Kiinamyllynkatu 10, FIN-20520 Turku, Finland.	klaus.elenius@utu.fi	Elenius, Klaus/AAI-7594-2021; YARDEN, YOSEF/K-1467-2012; Paatero, Ilkka/A-6391-2009; Paatero, Ilkka/AAE-7542-2019	Elenius, Klaus/0000-0001-5700-0827; Paatero, Ilkka/0000-0001-5926-2396; Maatta, Jorma/0000-0001-8752-6862; Tvorogov, Denis/0000-0002-2009-1347; Sundvall, Maria H/0000-0002-0494-2965				Aqeilan RI, 2005, CANCER RES, V65, P6764, DOI 10.1158/0008-5472.CAN-05-1150; Arasada RR, 2005, J BIOL CHEM, V280, P30783, DOI 10.1074/jbc.M506057200; Bjorge JD, 2000, ONCOGENE, V19, P5620, DOI 10.1038/sj.onc.1203923; Carpenter G, 2003, CURR OPIN CELL BIOL, V15, P143, DOI 10.1016/S0955-0674(03)00015-2; d'Azzo A, 2005, TRAFFIC, V6, P429, DOI 10.1111/j.1600-0854.2005.00294.x; Elenius K, 1997, J BIOL CHEM, V272, P26761, DOI 10.1074/jbc.272.42.26761; Elenius K, 1999, ONCOGENE, V18, P2607, DOI 10.1038/sj.onc.1202612; Gullick WJ, 2003, J PATHOL, V200, P279, DOI 10.1002/path.1335; Hynes NE, 2005, NAT REV CANCER, V5, P341, DOI 10.1038/nrc1609; Junttila TT, 2005, CANCER RES, V65, P1384, DOI 10.1158/0008-5472.CAN-04-3150; Junttila TT, 2000, TRENDS CARDIOVAS MED, V10, P304, DOI 10.1016/S1050-1738(01)00065-2; Junttila TT, 2003, CLIN CANCER RES, V9, P5346; Kainulainen V, 2000, J BIOL CHEM, V275, P8641, DOI 10.1074/jbc.275.12.8641; Katz M, 2002, TRAFFIC, V3, P740, DOI 10.1034/j.1600-0854.2002.31006.x; Komuro A, 2003, J BIOL CHEM, V278, P33334, DOI 10.1074/jbc.M305597200; Lee HJ, 2002, J BIOL CHEM, V277, P6318, DOI 10.1074/jbc.M110371200; Linggi B, 2006, ONCOGENE, V25, P160, DOI 10.1038/sj.onc.1209003; Litterst CM, 2003, J BIOL CHEM, V278, P45340, DOI 10.1074/jbc.M303644200; Maatta JA, 2006, MOL BIOL CELL, V17, P67, DOI 10.1091/mbc.E05-05-0402; Marmor MD, 2004, ONCOGENE, V23, P2057, DOI 10.1038/sj.onc.1207390; Muraoka-Cook RS, 2006, MOL BIOL CELL, V17, P4118, DOI 10.1091/mbc.E06-02-0101; Naresh A, 2006, CANCER RES, V66, P6412, DOI 10.1158/0008-5472.CAN-05-2368; Ni CY, 2003, J BIOL CHEM, V278, P4561, DOI 10.1074/jbc.M210504200; Ni CY, 2001, SCIENCE, V294, P2179, DOI 10.1126/science.1065412; Pircher TJ, 1997, MOL CELL ENDOCRINOL, V133, P169, DOI 10.1016/S0303-7207(97)00164-0; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; Rio C, 2000, J BIOL CHEM, V275, P10379, DOI 10.1074/jbc.275.14.10379; Sardi SP, 2006, CELL, V127, P185, DOI 10.1016/j.cell.2006.07.037; Srinivasan R, 2000, CANCER RES, V60, P1483; Vecchi M, 1996, J BIOL CHEM, V271, P18989, DOI 10.1074/jbc.271.31.18989; Vidal GA, 2005, J BIOL CHEM, V280, P19777, DOI 10.1074/jbc.M412457200; Wang SC, 2004, CANCER CELL, V6, P251, DOI 10.1016/j.ccr.2004.07.012; Williams CC, 2004, J CELL BIOL, V167, P469, DOI 10.1083/jcb.200403155; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Yu H, 2004, NAT REV CANCER, V4, P97, DOI 10.1038/nrc1275; Zhu Y, 2006, CANCER RES, V66, P7991, DOI 10.1158/0008-5472.CAN-05-4397	36	53	55	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 18	2007	26	48					6905	6914		10.1038/sj.onc.1210501	http://dx.doi.org/10.1038/sj.onc.1210501			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	220WQ	17486069				2022-12-28	WOS:000250188400006
J	Moasser, MM				Moasser, M. M.			Targeting the function of the HER2 oncogene in human cancer therapeutics	ONCOGENE			English	Review						HER2; ErbB2; trastuzumab; herceptin; kinase inhibitor; breast cancer	GROWTH-FACTOR RECEPTOR; TYROSINE KINASE INHIBITOR; METASTATIC BREAST-CANCER; PHASE-II TRIAL; DEPENDENT CELLULAR CYTOTOXICITY; HERCEPTIN-INDUCED INHIBITION; MULTIPLE SIGNALING PATHWAYS; TUMOR NECROSIS FACTOR; CELLS IN-VITRO; MONOCLONAL-ANTIBODIES	The year 2007 marks exactly two decades since human epidermal growth factor receptor- 2 ( HER2) was functionally implicated in the pathogenesis of human breast cancer ( Slamon et al., 1987). This finding established the HER2 oncogene hypothesis for the development of some human cancers. An abundance of experimental evidence compiled over the past two decades now solidly supports the HER2 oncogene hypothesis. A direct consequence of this hypothesis was the promise that inhibitors of oncogenic HER2 would be highly effective treatments for HER2- driven cancers. This treatment hypothesis has led to the development and widespread use of anti- HER2 antibodies ( trastuzumab) in clinical management resulting in significantly improved clinical antitumor efficacies that have transformed the clinical practice of oncology. In the shadows of this irrefutable clinical success, scientific studies have not yet been able to mechanistically validate that trastuzumab inhibits oncogenic HER2 function and it remains possible that the current clinical advances are a consequence of the oncogene hypothesis, but not a translation of it. These looming scientific uncertainties suggest that the full promise of the treatment hypothesis may not yet have been realized. The coming decade will see a second generation of HER2- targeting agents brought into clinical testing and a renewed attempt to treat HER2- driven cancers through the inactivation of HER2. Here, I review the development of treatments that target HER2 in the context of the HER2 oncogene hypothesis, and where we stand with regards to the clinical translation of the HER2 oncogene hypothesis.	Univ Calif San Francisco, Dept Med, Ctr Comprehens Canc, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center	Moasser, MM (corresponding author), Univ Calif San Francisco, Dept Med, Ctr Comprehens Canc, UCSF Box 0875, San Francisco, CA 94143 USA.	mmoasser@medicine.ucsf.edu			NATIONAL CANCER INSTITUTE [R01CA122216] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA122216, R01 CA122216-02, R01 CA122216-01A1] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams CW, 2006, CANCER IMMUNOL IMMUN, V55, P717, DOI 10.1007/s00262-005-0058-x; Agus DB, 2002, CANCER CELL, V2, P127, DOI 10.1016/S1535-6108(02)00097-1; Akita RW, 2003, SEMIN ONCOL, V30, P15, DOI 10.1016/S0093-7754(03)00187-8; Albain K, 2002, BREAST CANCER RES TR, V76, pS33; Arnould L, 2006, BRIT J CANCER, V94, P259, DOI 10.1038/sj.bjc.6602930; Austin CD, 2004, MOL BIOL CELL, V15, P5268, DOI 10.1091/mbc.E04-07-0591; Baasner S, 1996, ONCOGENE, V13, P901; BACUS SS, 1992, CANCER RES, V52, P2580; Baker AF, 2005, CLIN CANCER RES, V11, P4338, DOI 10.1158/1078-0432.CCR-05-0422; Barbacci EG, 2003, CANCER RES, V63, P4450; Baselga J, 2005, J CLIN ONCOL, V23, P5323, DOI 10.1200/JCO.2005.08.326; Baselga J, 1996, J CLIN ONCOL, V14, P737, DOI 10.1200/JCO.1996.14.3.737; Baselga J, 1998, CANCER RES, V58, P2825; BASELGA J, 2007, P AM SOC CLIN ONC, V25; BEERLI RR, 1994, J BIOL CHEM, V269, P23931; Belimezi MM, 2006, CANCER IMMUNOL IMMUN, V55, P1091, DOI 10.1007/s00262-005-0100-z; Bianco R, 2003, ONCOGENE, V22, P2812, DOI 10.1038/sj.onc.1206388; BLACKWELL K, 2004, P AM SOC CLIN ONC, V22; BLACKWELL KL, 2006, P AM SOC CLIN ONC, V23; Bookman MA, 2003, J CLIN ONCOL, V21, P283, DOI 10.1200/JCO.2003.10.104; Bose S, 2002, HUM PATHOL, V33, P405, DOI 10.1053/hupa.2002.124721; Brand FX, 2006, ANTICANCER RES, V26, P463; Brandt R, 2001, ONCOGENE, V20, P5459, DOI 10.1038/sj.onc.1204709; Burstein H, 2004, ANN ONCOL, V15, P27; Burstein HJ, 2003, J CLIN ONCOL, V21, P2889, DOI 10.1200/JCO.2003.02.018; Campos S, 2005, J CLIN ONCOL, V23, P5597, DOI 10.1200/JCO.2005.08.091; Carson WE, 2001, EUR J IMMUNOL, V31, P3016, DOI 10.1002/1521-4141(2001010)31:10<3016::AID-IMMU3016>3.0.CO;2-J; CARTER P, 1992, P NATL ACAD SCI USA, V89, P4285, DOI 10.1073/pnas.89.10.4285; CHAZIN VR, 1992, ONCOGENE, V7, P1859; Chen JS, 2003, DRUG RESIST UPDATE, V6, P129, DOI 10.1016/S1368-7646(03)00040-2; Cho HS, 2003, NATURE, V421, P756, DOI 10.1038/nature01392; Choudhury A, 2004, INT J CANCER, V108, P71, DOI 10.1002/ijc.11497; Christianson TA, 1998, CANCER RES, V58, P5123; Citri A, 2002, EMBO J, V21, P2407, DOI 10.1093/emboj/21.10.2407; Clynes RA, 2000, NAT MED, V6, P443, DOI 10.1038/74704; COLOMER R, 1994, BRIT J CANCER, V70, P819, DOI 10.1038/bjc.1994.405; Cooley S, 1999, EXP HEMATOL, V27, P1533, DOI 10.1016/S0301-472X(99)00089-2; CORTES JE, 2005, P AM SOC CLIN ONC, V23; Cuello M, 2001, CANCER RES, V61, P4892; De Lorenzo C, 2005, CARCINOGENESIS, V26, P1890, DOI 10.1093/carcin/bgi146; Deshane J, 1996, CANCER GENE THER, V3, P89; Diermeier S, 2005, EXP CELL RES, V304, P604, DOI 10.1016/j.yexcr.2004.12.008; Discafani CM, 1999, BIOCHEM PHARMACOL, V57, P917, DOI 10.1016/S0006-2952(98)00356-6; DREBIN JA, 1985, CELL, V41, P695, DOI 10.1016/S0092-8674(85)80050-7; DREBIN JA, 1988, ONCOGENE, V2, P273; Egeblad M, 2001, INT J CANCER, V94, P185, DOI 10.1002/ijc.1459; Emlet DR, 2006, BRIT J CANCER, V94, P1144, DOI 10.1038/sj.bjc.6603078; Faltus T, 2004, NEOPLASIA, V6, P786, DOI 10.1593/neo.04313; FINN RS, 2004, P AM ASS CAN RES, V45; FLEMING G, 2005, P AM SOC CLIN ONC, V23; FLEMING GF, 2003, P AM SOC CLIN ONC, V22; Friess T, 2005, CLIN CANCER RES, V11, P5300, DOI 10.1158/1078-0432.CCR-04-2642; FUJII A, 2005, P AM ASS CAN RES, V46; Fujita T, 2006, BRIT J CANCER, V94, P247, DOI 10.1038/sj.bjc.6602926; Garrett TPJ, 2003, MOL CELL, V11, P495, DOI 10.1016/S1097-2765(03)00048-0; Gennari R, 2004, CLIN CANCER RES, V10, P5650, DOI 10.1158/1078-0432.CCR-04-0225; Ghossein RA, 2001, SEMIN SURG ONCOL, V20, P304, DOI 10.1002/ssu.1048; Gomez HL, 2005, BREAST CANCER RES TR, V94, pS63; HARWERTH IM, 1992, J BIOL CHEM, V267, P15160; HARWERTH IM, 1993, BRIT J CANCER, V68, P1140, DOI 10.1038/bjc.1993.494; HUDZIAK RM, 1989, MOL CELL BIOL, V9, P1165, DOI 10.1128/MCB.9.3.1165; HURWITZ E, 1995, P NATL ACAD SCI USA, V92, P3353, DOI 10.1073/pnas.92.8.3353; IWATA H, 2006, SAN ANT BR CAN S; Izumi Y, 2002, NATURE, V416, P279, DOI 10.1038/416279b; JANI JP, 2004, P AM ASS CAN RES, V45; JANI JP, 2004, P AM SOC CLIN ONC, V22; Juhl H, 1997, J BIOL CHEM, V272, P29482, DOI 10.1074/jbc.272.47.29482; Kiewe P, 2006, CLIN CANCER RES, V12, P3085, DOI 10.1158/1078-0432.CCR-05-2436; KING CR, 1985, SCIENCE, V229, P974, DOI 10.1126/science.2992089; Kita Y, 1996, BIOCHEM BIOPH RES CO, V226, P59, DOI 10.1006/bbrc.1996.1311; Klapper LN, 1997, ONCOGENE, V14, P2099, DOI 10.1038/sj.onc.1201029; Konecny GE, 2006, CANCER RES, V66, P1630, DOI 10.1158/0008-5472.CAN-05-1182; Kubo M, 2003, ANTICANCER RES, V23, P4443; KUMAR PS, 2006, SEMIN ONCOL, V33, P386; Kurokawa H, 2000, CANCER RES, V60, P5887; Kwak EL, 2005, P NATL ACAD SCI USA, V102, P7665, DOI 10.1073/pnas.0502860102; Lane HA, 2000, MOL CELL BIOL, V20, P3210, DOI 10.1128/MCB.20.9.3210-3223.2000; Le XF, 2005, CELL CYCLE, V4, P87, DOI 10.4161/cc.4.1.1360; Lee S, 2002, CANCER RES, V62, P5703; Lenferink AEG, 2000, P NATL ACAD SCI USA, V97, P9609, DOI 10.1073/pnas.160564197; Lenferink AEG, 2001, CANCER RES, V61, P6583; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; LEWIS GD, 1993, CANCER IMMUNOL IMMUN, V37, P255, DOI 10.1007/BF01518520; Liu PCC, 2006, CANCER BIOL THER, V5, P657, DOI 10.4161/cbt.5.6.2708; Longva KE, 2005, INT J CANCER, V116, P359, DOI 10.1002/ijc.21015; Lydon NB, 1998, INT J CANCER, V76, P154, DOI 10.1002/(SICI)1097-0215(19980330)76:1<154::AID-IJC24>3.0.CO;2-B; Marches R, 2004, INT J CANCER, V112, P492, DOI 10.1002/ijc.20378; Marty M, 2005, J CLIN ONCOL, V23, P4265, DOI 10.1200/JCO.2005.04.173; Mass Robert D, 2005, Clin Breast Cancer, V6, P240, DOI 10.3816/CBC.2005.n.026; MCKENZIE SJ, 1989, ONCOGENE, V4, P543; McKillop D, 2005, MOL CANCER THER, V4, P641, DOI 10.1158/1535-7163.MCT-04-0329; Menard S, 2003, ONCOGENE, V22, P6570, DOI 10.1038/sj.onc.1206779; MESSERLE K, 1994, MOL CELL ENDOCRINOL, V105, P1, DOI 10.1016/0303-7207(94)90029-9; MIKNIS G, 2005, P AM ASS CAN RES, V24; Moasser MM, 2007, ONCOGENE, V26, P6469, DOI 10.1038/sj.onc.1210477; Moasser MM, 2001, CANCER RES, V61, P7184; Mohsin SK, 2005, J CLIN ONCOL, V23, P2460, DOI 10.1200/JCO.2005.00.661; Molina MA, 2002, CLIN CANCER RES, V8, P347; Molina MA, 2001, CANCER RES, V61, P4744; Moody SE, 2005, CANCER CELL, V8, P197, DOI 10.1016/j.ccr.2005.07.009; Moody SE, 2002, CANCER CELL, V2, P451, DOI 10.1016/S1535-6108(02)00212-X; Moulder SL, 2001, CANCER RES, V61, P8887; Moyer JD, 1997, CANCER RES, V57, P4838; Nagata Y, 2004, CANCER CELL, V6, P117, DOI 10.1016/j.ccr.2004.06.022; NAITO K, 2002, P AM ASS CAN RES, V43; Neve RM, 2001, BIOCHEM BIOPH RES CO, V280, P274, DOI 10.1006/bbrc.2000.4104; Normanno N, 2002, ANN ONCOL, V13, P65, DOI 10.1093/annonc/mdf020; Parsa AT, 2007, NAT MED, V13, P84, DOI 10.1038/nm1517; PHENEGER T, 2005, P AACRNCIEORTE C; Piccart-Gebhart MJ, 2005, NEW ENGL J MED, V353, P1659, DOI 10.1056/NEJMoa052306; QIAN XL, 1994, ONCOGENE, V9, P1507; Rabindran SK, 2005, CANCER LETT, V227, P9, DOI 10.1016/j.canlet.2004.11.015; Rabindran SK, 2004, CANCER RES, V64, P3958, DOI 10.1158/0008-5472.CAN-03-2868; Repka T, 2003, CLIN CANCER RES, V9, P2440; REWCASTLE GW, 1995, J MED CHEM, V38, P3482, DOI 10.1021/jm00018a008; ROBERTSON JFR, 2003, P AM SOC CLIN ONC, V22; Robinson MO, 2006, EJC SUPPL, V4, P169, DOI 10.1016/S1359-6349(06)70564-X; Roh H, 2000, CANCER RES, V60, P560; Romond EH, 2005, NEW ENGL J MED, V353, P1673, DOI 10.1056/NEJMoa052122; Rusnak DW, 2001, MOL CANCER THER, V1, P85; Saal LH, 2005, CANCER RES, V65, P2554, DOI 10.1158/0008-5472-CAN-04-3913; SARUP JC, 1991, GROWTH REGULAT, V1, P72; Schiffer IB, 2003, CANCER RES, V63, P7221; SEGATTO O, 1988, MOL CELL BIOL, V8, P5570, DOI 10.1128/MCB.8.12.5570; Sergina NV, 2007, NATURE, V445, P437, DOI 10.1038/nature05474; She QB, 2003, CLIN CANCER RES, V9, P4340; SHEPARD HM, 1991, J CLIN IMMUNOL, V11, P117, DOI 10.1007/BF00918679; Shepherd TG, 2001, CURR BIOL, V11, P1739, DOI 10.1016/S0960-9822(01)00536-X; SHIH C, 1981, NATURE, V290, P261, DOI 10.1038/290261a0; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Slichenmyer WJ, 2001, SEMIN ONCOL, V28, P80, DOI 10.1016/S0093-7754(01)90285-4; Sliwkowski MX, 2003, NAT STRUCT BIOL, V10, P158, DOI 10.1038/nsb0303-158; SOLCA F, 2006, P AACRNCIEORTC C; Spector NL, 2005, J CLIN ONCOL, V23, P2502, DOI 10.1200/JCO.2005.12.157; SRINIVAS U, 1993, CANCER IMMUNOL IMMUN, V36, P397, DOI 10.1007/BF01742256; Stamos J, 2002, J BIOL CHEM, V277, P46265, DOI 10.1074/jbc.M207135200; STANCOVSKI I, 1991, P NATL ACAD SCI USA, V88, P8691, DOI 10.1073/pnas.88.19.8691; Suzuki E, 2007, CLIN CANCER RES, V13, P1875, DOI 10.1158/1078-0432.CCR-06-1335; TAGLIABUE E, 1991, INT J CANCER, V47, P933, DOI 10.1002/ijc.2910470625; Takai N, 2005, CANCER-AM CANCER SOC, V104, P2701, DOI 10.1002/cncr.21533; Tan AR, 2004, J CLIN ONCOL, V22, P3080, DOI 10.1200/JCO.2004.08.189; Tokuda Y, 1996, BRIT J CANCER, V73, P1362, DOI 10.1038/bjc.1996.259; Torrance CJ, 2000, NAT MED, V6, P1024, DOI 10.1038/79534; Traxler P, 2004, CANCER RES, V64, P4931, DOI 10.1158/0008-5472.CAN-03-3681; Traxler P, 2001, MED RES REV, V21, P499, DOI 10.1002/med.1022; Tsou HR, 2005, J MED CHEM, V48, P1107, DOI 10.1021/jm040159c; VANLEEUWEN F, 1990, ONCOGENE, V5, P497; Vogel CL, 2002, J CLIN ONCOL, V20, P719, DOI 10.1200/JCO.20.3.719; Wakeling AE, 2002, CANCER RES, V62, P5749; Warburton C, 2004, CLIN CANCER RES, V10, P2512, DOI 10.1158/1078-0432.CCR-03-0244; WARD WHJ, 1994, BIOCHEM PHARMACOL, V48, P659, DOI 10.1016/0006-2952(94)90042-6; Wehrman TS, 2006, P NATL ACAD SCI USA, V103, P19063, DOI 10.1073/pnas.0605218103; WEINER DB, 1989, ONCOGENE, V4, P1175; Weinstein IB, 2002, SCIENCE, V297, P63, DOI 10.1126/science.1073096; WINER EP, 2002, SAN ANT BR CAN S; Wissner A, 2003, J MED CHEM, V46, P49, DOI 10.1021/jm020241c; Wong TW, 2006, CLIN CANCER RES, V12, P6186, DOI 10.1158/1078-0432.CCR-06-0642; Wood ER, 2004, CANCER RES, V64, P6652, DOI 10.1158/0008-5472.CAN-04-1168; Xie W, 1999, ONCOGENE, V18, P3593, DOI 10.1038/sj.onc.1202673; XU FG, 1993, INT J CANCER, V53, P401, DOI 10.1002/ijc.2910530310; Yakes FM, 2002, CANCER RES, V62, P4132; YARDEN Y, 1990, P NATL ACAD SCI USA, V87, P2569, DOI 10.1073/pnas.87.7.2569; Yokoyama H, 2006, BRIT J CANCER, V95, P1504, DOI 10.1038/sj.bjc.6603459; YOSHIDA S, 2002, P AM ASS CAN RES, V43	166	131	151	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 11	2007	26	46					6577	6592		10.1038/sj.onc.1210478	http://dx.doi.org/10.1038/sj.onc.1210478			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	219JT	17486079	Green Accepted			2022-12-28	WOS:000250081500001
J	Moasser, MM				Moasser, M. M.			The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis	ONCOGENE			English	Review						HER2; HER-2; ErbB2; ErbB-2; Neu; HER2/Neu	EPIDERMAL-GROWTH-FACTOR; IN-SITU HYBRIDIZATION; HUMAN-BREAST-CANCER; SRC-FAMILY KINASES; INVASIVE DUCTAL CARCINOMA; RECEPTOR TYROSINE KINASE; CELL-CYCLE PROGRESSION; TRANSGENIC MICE; MAMMARY-TUMORS; C-SRC	The year 2007 marks exactly two decades since Human Epidermal Growth Factor Receptor-2 (HER2) was functionally implicated in the pathogenesis of human breast cancer. This finding established the HER2 oncogene hypothesis for the development of some human cancers. The subsequent two decades have brought about an explosion of information about the biology of HER2 and the HER family. An abundance of experimental evidence now solidly supports the HER2 oncogene hypothesis and etiologically links amplification of the HER2 gene locus with human cancer pathogenesis. The molecular mechanisms underlying HER2 tumorigenesis appear to be complex and a unified mechanistic model of HER2-induced transformation has not emerged. Numerous hypotheses implicating diverse transforming pathways have been proposed and are individually supported by experimental models and HER2 may indeed induce cell transformation through multiple mechanisms. Here I review the evidence supporting the oncogenic function of HER2, the mechanisms that are felt to mediate its oncogenic functions, and the evidence that links the experimental evidence with human cancer pathogenesis.	Univ Calif San Francisco, Ctr Comprehens Canc, Dept Med, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center	Moasser, MM (corresponding author), Univ Calif San Francisco, Ctr Comprehens Canc, Dept Med, UCSF Box 0875, San Francisco, CA 94143 USA.	mmoasser@medicine.ucsf.edu			NATIONAL CANCER INSTITUTE [R01CA122216] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA122216-01A1, R01 CA122216, R01 CA122216-02] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahnstrom M, 2005, BREAST CANCER RES TR, V91, P145, DOI 10.1007/s10549-004-6457-4; AKIYAMA T, 1986, SCIENCE, V232, P1644, DOI 10.1126/science.3012781; ALIMANDI M, 1995, ONCOGENE, V10, P1813; Alpy F, 2006, BIOCHEM SOC T, V34, P343, DOI 10.1042/BST0340343; Amundadottir LT, 1998, ONCOGENE, V16, P737, DOI 10.1038/sj.onc.1201829; Andrechek ER, 2000, P NATL ACAD SCI USA, V97, P3444, DOI 10.1073/pnas.050408497; Andrechek ER, 2005, ONCOGENE, V24, P932, DOI 10.1038/sj.onc.1208230; Aranda V, 2006, NAT CELL BIOL, V8, P1235, DOI 10.1038/ncb1485; Baasner S, 1996, ONCOGENE, V13, P901; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; Barnes Christopher J, 2004, Cancer Treat Res, V119, P1; Baulida J, 1996, J BIOL CHEM, V271, P5251; Bazley LA, 2005, ENDOCR-RELAT CANCER, V12, pS17, DOI 10.1677/erc.1.01032; BEERLI RR, 1994, J BIOL CHEM, V269, P23931; Belsches-Jablonski AP, 2001, ONCOGENE, V20, P1465, DOI 10.1038/sj.onc.1204205; Benlimame N, 2005, J CELL BIOL, V171, P505, DOI 10.1083/jcb.200504124; Benusiglio PR, 2005, BREAST CANCER RES, V7, pR204, DOI 10.1186/bcr982; BENZ CC, 1992, BREAST CANCER RES TR, V24, P85, DOI 10.1007/BF01961241; Berger MB, 2004, FEBS LETT, V569, P332, DOI 10.1016/j.febslet.2004.06.014; Bol D, 1998, MOL CARCINOGEN, V21, P2, DOI 10.1002/(SICI)1098-2744(199801)21:1<2::AID-MC2>3.3.CO;2-7; Borg JP, 2000, NAT CELL BIOL, V2, P407, DOI 10.1038/35017038; BOUCHARD L, 1989, CELL, V57, P931, DOI 10.1016/0092-8674(89)90331-0; Bowe DB, 2002, ONCOGENE, V21, P291, DOI 10.1038/sj/onc/1205025; Brandt R, 2001, ONCOGENE, V20, P5459, DOI 10.1038/sj.onc.1204709; Britton A, 1998, HLTH TECHNOLOGY ASSE, V2, P1; Burgess AW, 2003, MOL CELL, V12, P541, DOI 10.1016/S1097-2765(03)00350-2; Carlsson J, 2004, BRIT J CANCER, V90, P2344, DOI 10.1038/sj.bjc.6601881; Carraway KL, 1999, J BIOL CHEM, V274, P5263, DOI 10.1074/jbc.274.9.5263; Castiglioni F, 2006, ENDOCR-RELAT CANCER, V13, P221, DOI 10.1677/erc.1.01047; CHAZIN VR, 1992, ONCOGENE, V7, P1859; Cho HS, 2003, NATURE, V421, P756, DOI 10.1038/nature01392; Choudhury A, 2004, INT J CANCER, V108, P71, DOI 10.1002/ijc.11497; COLOMER R, 1994, BRIT J CANCER, V70, P819, DOI 10.1038/bjc.1994.405; Cool M, 1999, CANCER RES, V59, P2438; Crowe JP, 2006, BREAST, V15, P728, DOI 10.1016/j.breast.2006.03.005; DEPOTTER CR, 1989, INT J CANCER, V44, P969, DOI 10.1002/ijc.2910440604; Deshane J, 1996, CANCER GENE THER, V3, P89; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; Donovan JCH, 2001, J BIOL CHEM, V276, P40888, DOI 10.1074/jbc.M106448200; Erickson SL, 1997, DEVELOPMENT, V124, P4999; Falcioni R, 1997, EXP CELL RES, V236, P76, DOI 10.1006/excr.1997.3695; Faltus T, 2004, NEOPLASIA, V6, P786, DOI 10.1593/neo.04313; FEDI P, 1994, MOL CELL BIOL, V14, P492, DOI 10.1128/MCB.14.1.492; Finkle D, 2004, CLIN CANCER RES, V10, P2499, DOI 10.1158/1078-0432.CCR-03-0448; Fleishman SJ, 2002, P NATL ACAD SCI USA, V99, P15937, DOI 10.1073/pnas.252640799; FUNES M, 2006, J BIOL CHEM; Gabos Z, 2006, J CLIN ONCOL, V24, P5658, DOI 10.1200/JCO.2006.07.0250; Gambaletta D, 2000, J BIOL CHEM, V275, P10604, DOI 10.1074/jbc.275.14.10604; Garrett TPJ, 2003, MOL CELL, V11, P495, DOI 10.1016/S1097-2765(03)00048-0; GASSMANN M, 1995, NATURE, V378, P390, DOI 10.1038/378390a0; Goel A, 2003, MOL CELL BIOL, V23, P6243, DOI 10.1128/MCB.23.17.6243-6254.2003; Goodearl A, 2001, DEV NEUROSCI-BASEL, V23, P25, DOI 10.1159/000048693; Goueli BS, 2004, MOL CELL BIOL, V24, P25, DOI 10.1128/MCB.24.1.25-35.2004; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; Guo WJ, 2006, CELL, V126, P489, DOI 10.1016/j.cell.2006.05.047; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; Hellyer NJ, 2001, J BIOL CHEM, V276, P42153, DOI 10.1074/jbc.M102079200; Hendriks BS, 2003, J BIOL CHEM, V278, P23343, DOI 10.1074/jbc.M300477200; Hendriks BS, 2003, BIOPHYS J, V85, P2732, DOI 10.1016/S0006-3495(03)74696-7; Hicks DG, 2005, HUM PATHOL, V36, P250, DOI 10.1016/j.humpath.2004.11.010; Hirsch FR, 2002, BRIT J CANCER, V86, P1449, DOI 10.1038/sj.bjc.6600286; Hodgson JG, 2005, CANCER RES, V65, P9695, DOI 10.1158/0008-5472.CAN-05-0755; Holbro T, 2003, P NATL ACAD SCI USA, V100, P8933, DOI 10.1073/pnas.1537685100; HORAN T, 1995, J BIOL CHEM, V270, P24604, DOI 10.1074/jbc.270.41.24604; Howe LR, 2005, CANCER RES, V65, P10113, DOI 10.1158/0008-5472.CAN-05-1524; Huang GC, 1999, J CELL BIOCHEM, V74, P23; HUDZIAK RM, 1987, P NATL ACAD SCI USA, V84, P7159, DOI 10.1073/pnas.84.20.7159; Hynes NE, 2001, J MAMMARY GLAND BIOL, V6, P141, DOI 10.1023/A:1009528918064; Ignatoski KMW, 2000, BRIT J CANCER, V82, P666, DOI 10.1054/bjoc.1999.0979; Ishizawar RC, 2007, ONCOGENE, V26, P3503, DOI 10.1038/sj.onc.1210138; Isola J, 1999, CLIN CANCER RES, V5, P4140; Janes PW, 1997, J BIOL CHEM, V272, P8490, DOI 10.1074/jbc.272.13.8490; Juhl H, 1997, J BIOL CHEM, V272, P29482, DOI 10.1074/jbc.272.47.29482; KALLIONIEMI OP, 1992, P NATL ACAD SCI USA, V89, P5321, DOI 10.1073/pnas.89.12.5321; Karunagaran D, 1996, EMBO J, V15, P254, DOI 10.1002/j.1460-2075.1996.tb00356.x; Kaur N, 2002, INDIAN J BIOCHEM BIO, V39, P49; Kauraniemi P, 2003, AM J PATHOL, V163, P1979, DOI 10.1016/S0002-9440(10)63556-0; Kauraniemi P, 2001, CANCER RES, V61, P8235; Keely SJ, 1999, J BIOL CHEM, V274, P33449, DOI 10.1074/jbc.274.47.33449; Khan AJ, 2002, CLIN CANCER RES, V8, P540; Kiguchi K, 2000, ONCOGENE, V19, P4243, DOI 10.1038/sj.onc.1203778; Kiguchi K, 2001, CANCER RES, V61, P6971; Kim H, 2005, ONCOGENE, V24, P7599, DOI 10.1038/sj.onc.1208898; Kim HH, 1998, BIOCHEM J, V334, P189, DOI 10.1042/bj3340189; KING CR, 1985, SCIENCE, V229, P974, DOI 10.1126/science.2992089; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; Kwong KY, 1998, MOL CARCINOGEN, V23, P62, DOI 10.1002/(SICI)1098-2744(199810)23:2<62::AID-MC2>3.0.CO;2-O; Lacenere C J, 2000, Breast Dis, V11, P19; Latif Z, 2003, BRIT J CANCER, V89, P1305, DOI 10.1038/sj.bjc.6601245; Latta EK, 2002, MODERN PATHOL, V15, P1318, DOI 10.1097/01.MP.0000038462.62634.B1; Laughner E, 2001, MOL CELL BIOL, V21, P3995, DOI 10.1128/MCB.21.12.3995-4004.2001; Lee JW, 2006, CLIN CANCER RES, V12, P57, DOI 10.1158/1078-0432.CCR-05-0976; LEE KF, 1995, NATURE, V378, P394, DOI 10.1038/378394a0; Lee RJ, 2000, MOL CELL BIOL, V20, P672, DOI 10.1128/MCB.20.2.672-683.2000; LEMOINE NR, 1992, BRIT J CANCER, V66, P1116, DOI 10.1038/bjc.1992.420; Lenferink AEG, 2001, CANCER RES, V61, P6583; Lenferink AEG, 1998, EMBO J, V17, P3385, DOI 10.1093/emboj/17.12.3385; Li BL, 1997, MOL CELL BIOL, V17, P3155, DOI 10.1128/MCB.17.6.3155; Li YM, 2005, CANCER RES, V65, P3257, DOI 10.1158/0008-5472.CAN-04-1284; Li YM, 2004, CANCER CELL, V6, P459, DOI 10.1016/j.ccr.2004.09.027; Li Z, 2006, CARCINOGENESIS, V27, P1054, DOI 10.1093/carcin/bgi324; Liang J, 2002, NAT MED, V8, P1153, DOI 10.1038/nm761; LIU E, 1992, ONCOGENE, V7, P1027; Loden M, 2003, ANTICANCER RES, V23, P2053; Lohrisch C, 2001, SEMIN ONCOL, V28, P3, DOI 10.1053/sonc.2001.29713; Loureiro RMB, 2005, BIOCHEM BIOPH RES CO, V326, P455, DOI 10.1016/j.bbrc.2004.11.053; Luo J, 2003, CANCER CELL, V4, P257, DOI 10.1016/S1535-6108(03)00248-4; Luoh SW, 2002, CANCER GENET CYTOGEN, V136, P43, DOI 10.1016/S0165-4608(01)00657-4; Makino K, 2004, ONCOGENE, V23, P3883, DOI 10.1038/sj.onc.1207485; Manning G, 2002, SCIENCE, V298, P1912, DOI 10.1126/science.1075762; Mano MS, 2007, CANCER TREAT REV, V33, P64, DOI 10.1016/j.ctrv.2006.10.001; Mendelsohn J, 2000, ONCOGENE, V19, P6550, DOI 10.1038/sj.onc.1204082; MESSERLE K, 1994, MOL CELL ENDOCRINOL, V105, P1, DOI 10.1016/0303-7207(94)90029-9; MIETTINEN PJ, 1995, NATURE, V376, P337, DOI 10.1038/376337a0; Mimura K, 2005, BRIT J CANCER, V92, P1253, DOI 10.1038/sj.bjc.6602499; Moghal N, 2003, EXP CELL RES, V284, P150, DOI 10.1016/S0014-4827(02)00097-6; Montgomery KG, 2003, CANCER EPIDEM BIOMAR, V12, P1109; Moody SE, 2002, CANCER CELL, V2, P451, DOI 10.1016/S1535-6108(02)00212-X; Morris JK, 1999, NEURON, V23, P273, DOI 10.1016/S0896-6273(00)80779-5; Morrison C, 2006, J CLIN ONCOL, V24, P2376, DOI 10.1200/JCO.2005.03.4827; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; MUTHUSWAMY SK, 1995, ONCOGENE, V11, P1801; Muthuswamy SK, 1999, MOL CELL BIOL, V19, P6845; MUTHUSWAMY SK, 1994, MOL CELL BIOL, V14, P735, DOI 10.1128/MCB.14.1.735; MUTHUSWAMY SK, 1995, ONCOGENE, V11, P271; Muthuswamy SK, 2001, NAT CELL BIOL, V3, P785, DOI 10.1038/ncb0901-785; Neve RM, 2002, ONCOGENE, V21, P3934, DOI 10.1038/sj.onc.1205503; Newman L, 2001, MOL CARCINOGEN, V30, P169, DOI 10.1002/mc.1025; Olayioye MA, 2000, EMBO J, V19, P3159, DOI 10.1093/emboj/19.13.3159; OTTENHOFFKALFF AE, 1992, CANCER RES, V52, P4773; Paez Juan, 2003, Cancer Treat Res, V115, P145; Park K, 2006, HISTOPATHOLOGY, V48, P702, DOI 10.1111/j.1365-2559.2006.02403.x; Pellikainen JM, 2004, CLIN CANCER RES, V10, P7621, DOI 10.1158/1078-0432.CCR-04-1061; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; Prenzel N, 2001, ENDOCR-RELAT CANCER, V8, P11, DOI 10.1677/erc.0.0080011; PRESS MF, 1990, ONCOGENE, V5, P953; PRIGENT SA, 1994, EMBO J, V13, P2831, DOI 10.1002/j.1460-2075.1994.tb06577.x; Ram TG, 1996, CELL GROWTH DIFFER, V7, P551; Ramsauer VP, 2003, J BIOL CHEM, V278, P30142, DOI 10.1074/jbc.M303220200; REAL FX, 1986, CANCER RES, V46, P4726; Reddy HKDL, 2005, CANCER RES, V65, P10174, DOI 10.1158/0008-5472.CAN-05-2639; Reissig D, 2001, J CANCER RES CLIN, V127, P226, DOI 10.1007/s004320000197; Riethmacher D, 1997, NATURE, V389, P725, DOI 10.1038/39593; Ritland SR, 1997, CANCER RES, V57, P3520; Roh H, 2000, CANCER RES, V60, P560; Ross JS, 2003, ONCOLOGIST, V8, P307, DOI 10.1634/theoncologist.8-4-307; Saitou M, 2005, J CLIN PATHOL, V58, P845, DOI 10.1136/jcp.2004.023572; SCHECHTER AL, 1984, NATURE, V312, P513, DOI 10.1038/312513a0; SCHECHTER AL, 1985, SCIENCE, V229, P976, DOI 10.1126/science.2992090; Schiffer IB, 2003, CANCER RES, V63, P7221; Schuster P, 2005, COMPLEXITY, V10, P10, DOI 10.1002/cplx.20096; SEGATTO O, 1988, MOL CELL BIOL, V8, P5570, DOI 10.1128/MCB.8.12.5570; Seton-Rogers SE, 2004, P NATL ACAD SCI USA, V101, P1257, DOI 10.1073/pnas.0308090100; Sheffield LG, 1998, BIOCHEM BIOPH RES CO, V250, P27, DOI 10.1006/bbrc.1998.9214; Shelly M, 2003, DEV CELL, V5, P475, DOI 10.1016/j.devcel.2003.08.001; Shepherd TG, 2001, CURR BIOL, V11, P1739, DOI 10.1016/S0960-9822(01)00536-X; Shibahara H, 2004, HEPATOLOGY, V39, P220, DOI 10.1002/hep.20031; Shigematsu H, 2005, CANCER RES, V65, P1642, DOI 10.1158/0008-5472.CAN-04-4235; SHIH C, 1981, NATURE, V290, P261, DOI 10.1038/290261a0; Shin I, 2002, NAT MED, V8, P1145, DOI 10.1038/nm759; Sibilia M, 1998, EMBO J, V17, P719, DOI 10.1093/emboj/17.3.719; SIBILIA M, 1995, SCIENCE, V269, P234, DOI 10.1126/science.7618085; Siegel PM, 1996, P NATL ACAD SCI USA, V93, P8878, DOI 10.1073/pnas.93.17.8878; Siegel PM, 1999, EMBO J, V18, P2149, DOI 10.1093/emboj/18.8.2149; SIEGEL PM, 1994, MOL CELL BIOL, V14, P7068, DOI 10.1128/MCB.14.11.7068; Sierke SL, 1997, BIOCHEM J, V322, P757, DOI 10.1042/bj3220757; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Sliwkowski MX, 2003, NAT STRUCT BIOL, V10, P158, DOI 10.1038/nsb0303-158; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; SOLTOFF SP, 1994, MOL CELL BIOL, V14, P3550, DOI 10.1128/MCB.14.6.3550; Spangenberg C, 2006, CANCER RES, V66, P3715, DOI 10.1158/0008-5472.CAN-05-2823; Spataro VJ, 2003, CANCER-AM CANCER SOC, V97, P1591, DOI 10.1002/cncr.11224; Stephens P, 2004, NATURE, V431, P525, DOI 10.1038/431525b; Subbaramaiah K, 2002, J BIOL CHEM, V277, P18649, DOI 10.1074/jbc.M111415200; Swede H, 2001, CANCER DETECT PREV, V25, P511; Tamada S, 2006, CLIN CANCER RES, V12, P4257, DOI 10.1158/1078-0432.CCR-05-2814; Tan M, 2005, CANCER RES, V65, P1858, DOI 10.1158/0008-5472.CAN-04-2353; TAN M, 1996, CANCER RES, V56, P3441; Tanner MM, 1996, CANCER RES, V56, P3441; Testa JR, 2001, P NATL ACAD SCI USA, V98, P10983, DOI 10.1073/pnas.211430998; THREADGILL DW, 1995, SCIENCE, V269, P230, DOI 10.1126/science.7618084; Timms JF, 2002, ONCOGENE, V21, P6573, DOI 10.1038/sj.onc.1205847; TIRESALJ M, 2007, CANCER RES, V67, P2420; Tokunaga E, 2006, INT J CANCER, V118, P284, DOI 10.1002/ijc.21358; Tsuda H, 2001, CANCER-AM CANCER SOC, V92, P2965, DOI 10.1002/1097-0142(20011215)92:12<2965::AID-CNCR10156>3.0.CO;2-A; Tsutsumida H, 2007, LUNG CANCER, V55, P195, DOI 10.1016/j.lungcan.2006.10.013; Tzahar E, 1996, MOL CELL BIOL, V16, P5276; Vadlamudi R, 1999, ONCOGENE, V18, P305, DOI 10.1038/sj.onc.1202307; Vadlamudi RK, 2003, FEBS LETT, V543, P76, DOI 10.1016/S0014-5793(03)00404-6; Vartanian T, 2000, BIOCHEM BIOPH RES CO, V271, P414, DOI 10.1006/bbrc.2000.2624; VENTER DJ, 1987, LANCET, V2, P69, DOI 10.1016/S0140-6736(87)92736-X; Viglietto G, 2002, NAT MED, V8, P1136, DOI 10.1038/nm762; Vijapurkar U, 2003, EXP CELL RES, V284, P291, DOI 10.1016/S0014-4827(02)00040-X; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; WALLASCH C, 1995, EMBO J, V14, P4267, DOI 10.1002/j.1460-2075.1995.tb00101.x; WANG BC, 1991, CANCER RES, V51, P5649; Wang SC, 2004, CANCER CELL, V6, P251, DOI 10.1016/j.ccr.2004.07.012; Wang SZE, 2006, CANCER CELL, V10, P25, DOI 10.1016/j.ccr.2006.05.023; Wang ZX, 1999, MOL BIOL CELL, V10, P1621, DOI 10.1091/mbc.10.5.1621; Waterman H, 1998, J BIOL CHEM, V273, P13819, DOI 10.1074/jbc.273.22.13819; Weigelt B, 2005, CANCER RES, V65, P9155, DOI 10.1158/0008-5472.CAN-05-2553; WEINER DB, 1989, ONCOGENE, V4, P1175; WEINER DB, 1989, NATURE, V339, P230, DOI 10.1038/339230a0; Weinstein EJ, 2000, MOL MED, V6, P4, DOI 10.1007/BF03401930; Weinstein IB, 2002, SCIENCE, V297, P63, DOI 10.1126/science.1073096; Wilson GR, 2006, BRIT J CANCER, V95, P1410, DOI 10.1038/sj.bjc.6603444; Wood J, 2003, SEMIN ROENTGENOL, V38, P4, DOI 10.1016/S0037-198X(03)00009-9; Xie DW, 2000, J NATL CANCER I, V92, P412, DOI 10.1093/jnci/92.5.412; Xie W, 1998, CELL GROWTH DIFFER, V9, P313; Xie W, 1999, ONCOGENE, V18, P3593, DOI 10.1038/sj.onc.1202673; Xie W, 1997, MOL ENDOCRINOL, V11, P1766, DOI 10.1210/me.11.12.1766; XIE YM, 1994, BIOCHEM BIOPH RES CO, V203, P1589, DOI 10.1006/bbrc.1994.2368; Xu WP, 2007, MOL CELL BIOL, V27, P220, DOI 10.1128/MCB.00899-06; Yang CW, 2004, AM J PATHOL, V164, P1031, DOI 10.1016/S0002-9440(10)63190-2; Yang HY, 2000, J BIOL CHEM, V275, P24735, DOI 10.1074/jbc.C000147200; Yang Y, 2001, BLOOD CELL MOL DIS, V27, P1, DOI 10.1006/bcmd.2000.0344; Yano T, 2006, ONCOL REP, V15, P65; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Yu QY, 2001, NATURE, V411, P1017, DOI 10.1038/35082500; Zhan LX, 2006, CANCER RES, V66, P5201, DOI 10.1158/0008-5472.CAN-05-4081; Zhou XY, 2004, CLIN CANCER RES, V10, P6779, DOI 10.1158/1078-0432.CCR-04-0112	224	648	674	15	94	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2007	26	45					6469	6487		10.1038/sj.onc.1210477	http://dx.doi.org/10.1038/sj.onc.1210477			19	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	217AF	17471238	Green Accepted			2022-12-28	WOS:000249919800001
J	Zhu, MJ; Ou, WB; Fletcher, CDM; Cohen, P; Demetri, GD; Fletcher, JA				Zhu, M-J; Ou, W-B; Fletcher, C. D. M.; Cohen, P. S.; Demetri, G. D.; Fletcher, J. A.			KIT oncoprotein interactions in gastrointestinal stromal tumors: therapeutic relevance	ONCOGENE			English	Article						KIT; PDGFRA; kinase; interaction; signal transduction	OF-FUNCTION MUTATIONS; C-KIT; IMATINIB MESYLATE; ACTIVATION; CELL; KINASE; SURVIVAL; PROLIFERATION; MECHANISMS; INHIBITOR	Most gastrointestinal stromal tumors (GISTs) express oncogenic and constitutively active forms of the KIT or platelet-derived growth factor receptor alpha (PDGFRA) receptor tyrosine kinase proteins, and these kinase oncoproteins serve as targets for effective therapies. Given that mutant KIT oncoproteins serve crucial transforming roles in GISTs, we evaluated interactions with the KIT oncoproteins and determined signaling pathways that are dependent on KIT oncogenic activation in GISTs. Tyrosine-phosphorylated KIT oncoproteins interacted with PDGFRA, PDGFRB, phosphatidylinositol 3-kinase (PI3-K) and PKC theta in GIST cells, and these interactions were abolished by KIT inhibition with imatinib or PKC412 or KIT RNAi. Notably, tyrosine-phosphorylated PDGFRA was prominent in frozen GIST tumors expressing KIT oncoproteins, suggesting that KIT-mediated PDGFRA phosphorylation is an efficient and biologically consequential mechanism in GISTs. Activated signaling intermediates were identified by immuno affinity purification of tyrosine-phosphorylated proteins in GIST cells before and after treatment with KIT inhibitors, and these analyses show that GRB2, SHC, CBL and MAPK activation are largely KIT dependent in GISTs, whereas PI3-K, STAT1 and STAT3 activation are partially KIT dependent. In addition, we found that phosphorylation of several tyrosine kinase proteinsincluding JAK1 and EPHA4 -did not depend on KIT activation. Likewise, paxillin activation was independent of the KIT oncogenic signal. These studies identify signaling pathways that can provide both KIT-dependent and KIT-independent therapeutic synergies in GIST, and thereby highlight clinical strategies that might consolidate GIST therapeutic response to KIT/PDGFRA inhibition.	Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; Novartis Oncol, Florham Pk, NJ USA; Dana Farber Canc Inst, Ludwig Ctr, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Novartis; Harvard University; Dana-Farber Cancer Institute	Zhu, MJ (corresponding author), Brigham & Womens Hosp, Dept Pathol, 75 Francis St, Boston, MA 02115 USA.	mzhu2@partners.org	Ou, Wen-Bin/J-1142-2019	, Wenbin/0000-0002-6311-9442				Blume-Jensen P, 1998, CURR BIOL, V8, P779, DOI 10.1016/S0960-9822(98)70302-1; Debiec-Rychter M, 2005, GASTROENTEROLOGY, V128, P270, DOI 10.1053/j.gastro.2004.11.020; Demetri GD, 2002, NEW ENGL J MED, V347, P472, DOI 10.1056/NEJMoa020461; Duensing A, 2004, ONCOGENE, V23, P3999, DOI 10.1038/sj.onc.1207525; Duensing A, 2004, CANCER RES, V64, P5127, DOI 10.1158/0008-5472.CAN-04-0559; Fabbro D, 2000, ANTI-CANCER DRUG DES, V15, P17; Hallek M, 1996, BRIT J HAEMATOL, V94, P5, DOI 10.1046/j.1365-2141.1996.6102053.x; Heinrich MC, 2002, HUM PATHOL, V33, P484, DOI 10.1053/hupa.2002.124124; Heinrich MC, 2003, SCIENCE, V299, P708, DOI 10.1126/science.1079666; HERBST R, 1995, BIOCHEMISTRY-US, V34, P5971, DOI 10.1021/bi00017a026; Hirota S, 1998, SCIENCE, V279, P577, DOI 10.1126/science.279.5350.577; Hirota S, 2003, GASTROENTEROLOGY, V125, P660, DOI 10.1016/S0016-5085(03)01046-1; Medeiros F, 2004, AM J SURG PATHOL, V28, P889, DOI 10.1097/00000478-200407000-00007; Ning ZQ, 2001, BLOOD, V97, P3559, DOI 10.1182/blood.V97.11.3559; Otto KG, 2001, BLOOD, V97, P3662, DOI 10.1182/blood.V97.11.3662; Rubin BP, 2001, CANCER RES, V61, P8118; Saucier C, 2002, ONCOGENE, V21, P1800, DOI 10.1038/sj.onc.1205261; Sordella R, 2004, SCIENCE, V305, P1163, DOI 10.1126/science.1101637; TAUCHI T, 1994, J BIOL CHEM, V269, P25206; Tuveson DA, 2001, ONCOGENE, V20, P5054, DOI 10.1038/sj.onc.1204704; Verweij J, 2004, LANCET, V364, P1127, DOI 10.1016/S0140-6736(04)17098-0; Vultur A, 2004, ONCOGENE, V23, P2600, DOI 10.1038/sj.onc.1207378	22	48	49	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 27	2007	26	44					6386	6395		10.1038/sj.onc.1210464	http://dx.doi.org/10.1038/sj.onc.1210464			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	214KY	17452978				2022-12-28	WOS:000249737600003
J	McConnell, JL; Gomez, RJ; McCorvey, LRA; Law, BK; Wadzinski, BE				McConnell, J. L.; Gomez, R. J.; McCorvey, L. R. A.; Law, B. K.; Wadzinski, B. E.			Identification of a PP2A-interacting protein that functions as a negative regulator of phosphatase activity in the ATM/ATR signaling pathway	ONCOGENE			English	Article						PP2A; TIP; alpha4; ATM/ATR; Tip41; Tap42	CATALYTIC SUBUNIT; TOR PROTEINS; CELL-GROWTH; 2A PP2A; BINDING; FAMILY; PURIFICATION; TAP42; ATM; PHOSPHORYLATION	Protein serine/ threonine phosphatase 2A ( PP2A) activity must be tightly controlled to maintain cell homeostasis. Here, we report the identification of a previously uncharacterized mammalian protein, type 2A- interacting protein ( TIP), as a novel regulatory protein of PP2A and the PP2A- like enzymes PP4 and PP6. TIP is a ubiquitously express ed protein and parallels the distribution of the PP2A catalytic subunit. Unlike its role in yeast, TIP does not interact with the mammalian homolog of type 2A-associated protein of 42 kDa ( Tap42), alpha 4, but instead associates with PP2A, PP4 and PP6 catalytic subunits independently of mammalian target of rapamycin kinase activity. Interestingly, the 20 kDa TIP splice variant TIP_i2, which lacks amino acids 173-272 of TIP's C- terminus, does not interact with PP2A; this finding indicates that residues 173 - 272 are important for the assembly of the TIP. phosphatase complex. In contrast to purified PP2A holoenzymes, TIP. PP2A complexes are devoid of phosphatase activity. Furthermore, alterations in the cellular levels of TIP influence the phosphorylation state of a specific protein substrate of ataxia- telangiectasia mutated ( ATM)/ ATM- and Rad3-related ( ATR) kinases. Elevated levels of TIP result in an increase in the phosphorylation state of this protein substrate, whereas TIP- depleted cells exhibit a significant decrease in this protein's phosphorylation state, which is reversed by treatment with the PP2A inhibitor okadaic acid. These results indicate TIP is a novel inhibitory regulator of PP2A and implicate a role for TIP. PP2A complexes within the ATM/ ATR signaling pathway controlling DNA replication and repair.	Vanderbilt Univ, Ctr Med, Dept Pharmacol, Nashville, TN 37232 USA; Univ Florida, Dept Pharmacol & Therapeut, Gainesville, FL USA	Vanderbilt University; State University System of Florida; University of Florida	Wadzinski, BE (corresponding author), Vanderbilt Univ, Ctr Med, Dept Pharmacol, 424 RRB, Nashville, TN 37232 USA.	brian.wadzinski@vanderbilt.edu	Law, Brian/L-6043-2019		NATIONAL CANCER INSTITUTE [P30CA068485] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK070787, P60DK020593] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R56GM051366, R01GM051366] Funding Source: NIH RePORTER; NCI NIH HHS [CA68485] Funding Source: Medline; NIDDK NIH HHS [DK070787, DK20593] Funding Source: Medline; NIGMS NIH HHS [GM51366] Funding Source: Medline; NIMH NIH HHS [MH19732] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Adams DG, 2005, J BIOL CHEM, V280, P42644, DOI 10.1074/jbc.M502464200; Beck T, 1999, NATURE, V402, P689, DOI 10.1038/45287; Bryant JC, 1999, BIOCHEM J, V339, P241, DOI 10.1042/0264-6021:3390241; CAYLA X, 1990, BIOCHEMISTRY-US, V29, P658, DOI 10.1021/bi00455a010; Chen J, 1998, BIOCHEM BIOPH RES CO, V247, P827, DOI 10.1006/bbrc.1998.8792; CHEN J, 1992, SCIENCE, V257, P1261, DOI 10.1126/science.1325671; DiComo CJ, 1996, GENE DEV, V10, P1904, DOI 10.1101/gad.10.15.1904; Dozier C, 2004, BIOL CELL, V96, P509, DOI 10.1016/j.biolcel.2004.04.010; Gavin AC, 2002, NATURE, V415, P141, DOI 10.1038/415141a; Gingras AC, 2005, MOL CELL PROTEOMICS, V4, P1725, DOI 10.1074/mcp.M500231-MCP200; Goodarzi AA, 2004, EMBO J, V23, P4451, DOI 10.1038/sj.emboj.7600455; Inui S, 1998, BLOOD, V92, P539, DOI 10.1182/blood.V92.2.539.414k23_539_546; Jacinto E, 2001, MOL CELL, V8, P1017, DOI 10.1016/S1097-2765(01)00386-0; Janssens V, 2001, BIOCHEM J, V353, P417, DOI 10.1042/0264-6021:3530417; Jiang Y, 1999, EMBO J, V18, P2782, DOI 10.1093/emboj/18.10.2782; Kloeker S, 2003, PROTEIN EXPRES PURIF, V31, P19, DOI 10.1016/S1046-5928(03)00141-4; Kloeker S, 1999, J BIOL CHEM, V274, P5339, DOI 10.1074/jbc.274.9.5339; LI M, 1995, BIOCHEMISTRY-US, V34, P1988, DOI 10.1021/bi00006a020; Luke MM, 1996, MOL CELL BIOL, V16, P2744; McCright B, 1996, J BIOL CHEM, V271, P22081, DOI 10.1074/jbc.271.36.22081; Murata K, 1997, P NATL ACAD SCI USA, V94, P10624, DOI 10.1073/pnas.94.20.10624; Nanahoshi M, 1998, BIOCHEM BIOPH RES CO, V251, P520, DOI 10.1006/bbrc.1998.9493; Petersen P, 2006, MOL CELL BIOL, V26, P1997, DOI 10.1128/MCB.26.5.1997-2011.2006; Sarkaria JN, 1999, CANCER RES, V59, P4375; SCHEIDTMANN KH, 1991, MOL CELL BIOL, V11, P1996, DOI 10.1128/MCB.11.4.1996; Schmidt A, 1998, EMBO J, V17, P6924, DOI 10.1093/emboj/17.23.6924; Sontag E, 1996, NEURON, V17, P1201, DOI 10.1016/S0896-6273(00)80250-0; Strasser G, 1998, PHYSICA E, V2, P515, DOI 10.1016/S1386-9477(98)00106-4; Trockenbacher A, 2001, NAT GENET, V29, P287, DOI 10.1038/ng762; Van Hoof C, 2005, BIOCHEM J, V386, P93, DOI 10.1042/BJ20040887; Wada T, 2001, J AM SOC NEPHROL, V12, P2601, DOI 10.1681/ASN.V12122601; Walsh AH, 1997, FEBS LETT, V416, P230, DOI 10.1016/S0014-5793(97)01210-6	33	63	65	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2007	26	41					6021	6030		10.1038/sj.onc.1210406	http://dx.doi.org/10.1038/sj.onc.1210406			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	207US	17384681				2022-12-28	WOS:000249277200005
J	van Wely, K; Meester-Smoor, MA; Janssen, MJFW; Aarnoudse, AJ; Grosveld, GC; Zwarthoff, EC				van Wely, Khm; Meester-Smoor, M. A.; Janssen, M. J. F. W.; Aarnoudse, A-J; Grosveld, G. C.; Zwarthoff, E. C.			The MN1-TEL myeloid leukemia-associated fusion protein has a dominant-negative effect on RAR-RXR-mediated transcription	ONCOGENE			English	Article						translocation; leukemia; retinoic acid; coactivator; mutant	HISTONE DEACETYLASE; CELL-GROWTH; DNA-BINDING; GENE; TRANSLOCATION; DEFECTS; SARCOMA; OVEREXPRESSION; COACTIVATORS; PATHWAYS	The translocation t(12;22)(p13;q11) creates an MN1-TEL fusion gene leading to acute myeloid leukemia. MN1 is a transcription coactivator of the retinoic acid and vitamin D receptors, and TEL (ETV6) is a member of the E26-transform ation-specific family of transcription factors. In MN1-TEL, the transactivating domains of MN1 are combined with the DNA-binding domain of TEL. We show that MN1-TEL inhibits retinoic acid receptor (RAR)-mediated transcription, counteracts coactivators such as p160 and p300, and acts as a dominant-negative mutant of MN1. Compared to MN1 the same transactivation domains in MIN1-TEL are poorly stimulated by p160, p300 or histone deacetylase inhibitors, indicating that the block of RAR-mediated transcription by MN1-TEL is caused by dysfunctional transactivation domains rather than by recruitment of corepressors. The mechanism leading to myeloid leukemia in t(12;22) thus differs from the translocations that involve RAR itself.	Erasmus MC, Josephine Nefkens Inst, Dept Pathol, NL-3000 CA Rotterdam, Netherlands; St Jude Childrens Hosp, Dept Genet & Tumor Cell Biol, Memphis, TN 38105 USA	Erasmus University Rotterdam; Erasmus MC; St Jude Children's Research Hospital	Zwarthoff, EC (corresponding author), Erasmus MC, Josephine Nefkens Inst, Dept Pathol, POB 2040, NL-3000 CA Rotterdam, Netherlands.	e.zwarthoff@erasmusmc.nl		van Wely, Karel Hermanus Martinus/0000-0001-8431-8072				BAILLY RA, 1994, MOL CELL BIOL, V14, P3230, DOI 10.1128/MCB.14.5.3230; Beverloo HB, 2001, CANCER RES, V61, P5374; Boer J, 1998, MOL CELL BIOL, V18, P1236, DOI 10.1128/MCB.18.3.1236; Bohlander SK, 2005, SEMIN CANCER BIOL, V15, P162, DOI 10.1016/j.semcancer.2005.01.008; BRAUN BS, 1995, MOL CELL BIOL, V15, P4623; BUIJS A, 1995, ONCOGENE, V10, P1511; Buijs A, 2000, MOL CELL BIOL, V20, P9281, DOI 10.1128/MCB.20.24.9281-9293.2000; BUIJS A, 1995, IN PRESS ONCOGENE, P809; Carella C, 2006, LEUKEMIA, V20, P1582, DOI 10.1038/sj.leu.2404298; Cazzaniga G, 2001, CANCER RES, V61, P4666; Chakrabarti SR, 1999, BIOCHEM BIOPH RES CO, V264, P871, DOI 10.1006/bbrc.1999.1605; Goodman RH, 2000, GENE DEV, V14, P1553; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Guidez F, 1998, BLOOD, V91, P2634, DOI 10.1182/blood.V91.8.2634.2634_2634_2642; GUNTHER CV, 1990, GENE DEV, V4, P667, DOI 10.1101/gad.4.4.667; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; Hisa T, 2004, EMBO J, V23, P450, DOI 10.1038/sj.emboj.7600038; Kawagoe H, 2005, BLOOD, V106, P4269, DOI 10.1182/blood-2005-04-1679; Leo C, 2000, GENE, V245, P1, DOI 10.1016/S0378-1119(00)00024-X; Meester-Smoor MA, 2005, MOL CELL BIOL, V25, P4229, DOI 10.1128/MCB.25.10.4229-4236.2005; Mercader N, 2000, DEVELOPMENT, V127, P3961; Pattyn F, 2003, NUCLEIC ACIDS RES, V31, P122, DOI 10.1093/nar/gkg011; Perissi V, 1999, GENE DEV, V13, P3198, DOI 10.1101/gad.13.24.3198; RUIZ MDMV, 1991, EMBO J, V10, P3829, DOI 10.1002/j.1460-2075.1991.tb04952.x; Sutton ALM, 2005, MOL ENDOCRINOL, V19, P2234, DOI 10.1210/me.2005-0081; van Wely KHM, 2003, ONCOGENE, V22, P699, DOI 10.1038/sj.onc.1206124; VANROOZENDAAL KEP, 1990, EXP CELL RES, V190, P137, DOI 10.1016/0014-4827(90)90155-4; Wan YJY, 1998, EXP CELL RES, V238, P241, DOI 10.1006/excr.1997.3851; Wang ZG, 1998, SCIENCE, V279, P1547; YOSHIDA M, 1990, J BIOL CHEM, V265, P17174	30	22	22	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG	2007	26	39					5733	5740		10.1038/sj.onc.1210382	http://dx.doi.org/10.1038/sj.onc.1210382			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	202EP	17369854				2022-12-28	WOS:000248885100005
J	Qian, J; Steigerwald, K; Combs, KA; CBarton, M; Groden, J				Qian, J.; Steigerwald, K.; Combs, K. A.; CBarton, M.; Groden, J.			Caspase cleavage of the APC tumor suppressor and release of an amino-terminal domain is required for the transcription-independent function of APC in apoptosis	ONCOGENE			English	Article						APC; apoptosis; transcription; independent-caspase; colon cancer	ADENOMATOUS POLYPOSIS; PROTEIN	The adenomatous polyposis coli (APC) tumor suppressor is inactivated by mutation in most colorectal tumors. APC is a component of the Wnt signaling pathway and is best known for its ability to downregulate beta-catenin and consequent effects on transcriptional regulation. Previous work demonstrated that APC accelerates apoptosis-associated caspase activity independently of transcription, and suggested novel tumor suppressor functions of APC. In this work, we have mapped the APC apoptosis-accelerating region to amino acids (aa) 1-760 by testing a series of nonoverlapping APC segments. Interestingly, this segment corresponds to a stable group II caspase cleavage product of APC released during apoptosis that includes the aminoterminal aa1-777. Mutation of the APC aspartic acid residue at position 777 to an alanine completely abolished in vitro cleavage of APC by a recombinant group II caspase and rendered the full-length protein unable to accelerate apoptosis in vitro. A truncated APC protein associated with familial and sporadic colorectal cancer, also unable to accelerate apoptosis in vitro and in vivo, is resistant to group II caspase cleavage. These results demonstrate that cleavage of APC and the subsequent release of an aminoterminal segment are necessary for the transcriptionindependent mechanism of APC-mediated apoptosis.	Ohio State Univ, Coll Med, Dept Mol Virol Immunol & Med Genet, Columbus, OH 43210 USA; Univ Cincinnati, Coll Med, Dept Mol Genet Biochem & Microbiol, Cincinnati, OH 45267 USA; Univ Texas, MD Anderson Canc Ctr, Dept Biochem & Mol Biol, Houston, TX 77030 USA	University System of Ohio; Ohio State University; University System of Ohio; University of Cincinnati; University of Texas System; UTMD Anderson Cancer Center	Groden, J (corresponding author), Ohio State Univ, Coll Med, Dept Mol Virol Immunol & Med Genet, 400 W 12th St, Columbus, OH 43210 USA.	joanna.groden@osumc.edu	Zhang, Spring/K-2787-2013	Barton, Michelle/0000-0002-4042-1374	NATIONAL CANCER INSTITUTE [R15CA063517] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053683] Funding Source: NIH RePORTER; NCI NIH HHS [CA 63517] Funding Source: Medline; NIGMS NIH HHS [R01 GM053683, R01 GM053683-07A2] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARTON MC, 1993, GENE DEV, V7, P1796, DOI 10.1101/gad.7.9.1796; Browne SJ, 1998, CELL DEATH DIFFER, V5, P206, DOI 10.1038/sj.cdd.4400331; FASSCHON DM, 1997, J CELL BIOL, V137, P1117; Goss KH, 2000, J CLIN ONCOL, V18, P1967, DOI 10.1200/JCO.2000.18.9.1967; GRODEN J, 1993, AM J HUM GENET, V52, P263; Kim K, 2000, MOL BIOL CELL, V11, P3509, DOI 10.1091/mbc.11.10.3509; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Lillard-Wetherell K, 2004, HUM MOL GENET, V13, P1919, DOI 10.1093/hmg/ddh193; NEWMEYER DD, 1994, CELL, V79, P453; Steigerwald K, 2005, MOL CANCER RES, V3, P78, DOI 10.1158/1541-7786.MCR-03-0189; Webb SJ, 1999, FASEB J, V13, P339, DOI 10.1096/fasebj.13.2.339	11	17	17	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 19	2007	26	33					4872	4876		10.1038/sj.onc.1210265	http://dx.doi.org/10.1038/sj.onc.1210265			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	191ZL	17297457				2022-12-28	WOS:000248170400012
J	Hausherr, A; Tavares, R; Schaffer, M; Obermeier, A; Miksch, C; Mitina, O; Ellwart, J; Hallek, M; Krause, G				Hausherr, A.; Tavares, R.; Schaeffer, M.; Obermeier, A.; Miksch, C.; Mitina, O.; Ellwart, J.; Hallek, M.; Krause, G.			Inhibition of IL-6-dependent growth of myeloma cells by an acidic peptide repressing the gp130-mediated activation of Src family kinases	ONCOGENE			English	Article						myeloma; interleukin-6 signalling; gp130; membrane-permeant peptide; Src family kinases	MULTIPLE-MYELOMA; TYROSINE PHOSPHORYLATION; SIGNAL-TRANSDUCTION; BCR-ABL; IN-VIVO; PROTEIN; RECEPTOR; HCK; INTERLEUKIN-6; SURVIVAL	An acidic domain (AD) of gp130 was previously found to interact with the Src family kinase (SFK) Hck. Here, the in. uence of myristoylated peptides derived from this AD was assessed in the mouse myeloma cell line, 7TD1. The IL-6-dependent growth of 7TD1 c ells was reduced by similar to 75%, if 100 mu M of myristoylated 18mer peptide (18AD) was included in the growth medium, but was unaffected by a control peptide with scrambled sequence (18sc). A similar differential inhibition by peptides 18AD and 18sc was observed for the erythropoietin-dependent growth of BaF-EH cells expressing chimeric erythropoietin receptor-gp130 and human Hck and for the human myeloma cell line INA-6. While the peptide 18AD concentration inhibiting 50% was similar to 30 mu M in 7TD1 and BaF-EH cells, peptide 18AD did not signifi. cantly inhibit growth of IL-6-independent MM1. S myeloma and OKT1 hybridoma cells or of BaF-EH cells supplied with IL-3. Treatment with 100 mu M peptide 18AD caused the same degree or 60% of apoptosis induction as IL-6 deprivation in 7TD1 or INA-6 cells, respectively. Co-immunoprecipitation experiments revealed that peptide 18AD interfered with the association of Hck and gp130 in 7TD1 lysates in a concentration-dependent manner. IL-6-treatment of INA-6 cells induced the kinase activities of Fyn, Lyn and Hck, but not Src, and the IL-6-induced SFK activities were inhibited by peptide 18AD. Expression in 7TD1 cells of a kinase-inactive Hck mutant (K269R) elicited a dominant-negative effect on cell number increases providing further evidence that SFKs are required for gp130 signalling in myeloma cells.	Univ Hosp Cologne, Clin Internal Med 1, D-50923 Cologne, Germany; GSF, Natl Res Ctr Environm & Hlth, Clin Cooperat Grp Gene Therapy, Munich, Germany; GRELUX GmbH, Martinsried, Germany; SIREEN AG, Martinsried, Germany; GSF, Natl Res Ctr Environm & Hlth, Inst Mol Immunol, Munich, Germany	University of Cologne; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Munich; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Munich	Krause, G (corresponding author), Univ Hosp Cologne, Clin Internal Med 1, Kerpener Str 62, D-50923 Cologne, Germany.	guenter.krause@uk-koeln.de	Hallek, Michael/Y-3191-2019; Krause, Günter/A-1858-2012	Hallek, Michael/0000-0002-7425-4455; Krause, Günter/0000-0003-3905-0921				Adachi T, 1999, J IMMUNOL, V162, P1496; Adachi T, 1999, J IMMUNOL, V163, P939; Ancey C, 2003, J BIOL CHEM, V278, P16968, DOI 10.1074/jbc.C300081200; Boehning D, 2005, P NATL ACAD SCI USA, V102, P1466, DOI 10.1073/pnas.0409650102; Brocke-Heidrich K, 2004, BLOOD, V103, P242, DOI 10.1182/blood-2003-04-1048; Burger R, 2001, Hematol J, V2, P42, DOI 10.1038/sj.thj.6200075; Chatterjee M, 2002, BLOOD, V100, P3311, DOI 10.1182/blood-2002-01-0102; Contri A, 2005, J CLIN INVEST, V115, P369, DOI 10.1172/JC1200522094; Cote S, 2002, CYTOKINE, V20, P113, DOI 10.1006/cyto.2002.1988; Covic L, 2002, P NATL ACAD SCI USA, V99, P643, DOI 10.1073/pnas.022460899; Dasgupta P, 2000, LIFE SCI, V66, P1557, DOI 10.1016/S0024-3205(00)00476-8; EICHHOLTZ T, 1993, J BIOL CHEM, V268, P1982; Ernst M, 2004, TRENDS GENET, V20, P23, DOI 10.1016/j.tig.2003.11.003; ERNST M, 1994, EMBO J, V13, P1574, DOI 10.1002/j.1460-2075.1994.tb06420.x; French JD, 2000, ACTA ONCOL, V39, P777; Georgii-Hemming P, 1999, BLOOD, V93, P1724, DOI 10.1182/blood.V93.5.1724.405k21_1724_1731; Greenstein S, 2003, EXP HEMATOL, V31, P271, DOI 10.1016/S0301-472X(03)00023-7; Hallek M, 1997, EXP HEMATOL, V25, P1367; Hallek M, 1998, BLOOD, V91, P3, DOI 10.1182/blood.V91.1.3.3_3_21; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; Heinrich PC, 2003, BIOCHEM J, V374, P1, DOI 10.1042/BJ20030407; Hideshima T, 2002, NAT REV CANCER, V2, P927, DOI 10.1038/nrc952; Hu YG, 2004, NAT GENET, V36, P453, DOI 10.1038/ng1343; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; Ishihara K, 2002, CYTOKINE GROWTH F R, V13, P357, DOI 10.1016/S1359-6101(02)00027-8; Kardinal C, 2000, FASEB J, V14, P1529, DOI 10.1096/fj.14.11.1529; Kelemen BR, 2002, J BIOL CHEM, V277, P8741, DOI 10.1074/jbc.M108459200; LaFevre-Bernt M, 1998, J BIOL CHEM, V273, P32129, DOI 10.1074/jbc.273.48.32129; Laszlo GS, 2003, J BIOL CHEM, V278, P27750, DOI 10.1074/jbc.M303670200; Manfredini R, 2003, PEPTIDES, V24, P1207, DOI 10.1016/j.peptides.2003.06.005; Neumann C, 1996, EUR J IMMUNOL, V26, P379, DOI 10.1002/eji.1830260217; Niv MY, 2004, J BIOL CHEM, V279, P1242, DOI 10.1074/jbc.M306723200; Ogata A, 1997, J IMMUNOL, V159, P2212; Ohtani T, 2000, IMMUNITY, V12, P95, DOI 10.1016/S1074-7613(00)80162-4; Podar K, 2004, J BIOL CHEM, V279, P21658, DOI 10.1074/jbc.M305783200; Podar K, 2003, J BIOL CHEM, V278, P5794, DOI 10.1074/jbc.M208636200; Posern G, 1998, ONCOGENE, V16, P1903, DOI 10.1038/sj.onc.1201714; Schaeffer M, 2001, MOL CELL BIOL, V21, P8068, DOI 10.1128/MCB.21.23.8068-8081.2001; Schulze WX, 2004, J BIOL CHEM, V279, P10756, DOI 10.1074/jbc.M309909200; Shah NP, 2004, SCIENCE, V305, P399, DOI 10.1126/science.1099480; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; Trikha M, 2003, CLIN CANCER RES, V9, P4653; Warmuth M, 2003, BLOOD, V101, P664, DOI 10.1182/blood-2002-01-0288; Warmuth M, 1997, J BIOL CHEM, V272, P33260, DOI 10.1074/jbc.272.52.33260	44	20	23	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL	2007	26	34					4987	4998		10.1038/sj.onc.1210306	http://dx.doi.org/10.1038/sj.onc.1210306			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	194CV	17310994				2022-12-28	WOS:000248322500011
J	Narla, G; Kremer-Tal, S; Matsumoto, N; Zhao, X; Yao, S; Kelley, K; Tarocchi, M; Friedman, SL				Narla, G.; Kremer-Tal, S.; Matsumoto, N.; Zhao, X.; Yao, S.; Kelley, K.; Tarocchi, M.; Friedman, S. L.			In vivo regulation of p21 by the Kruppel-like factor 6 tumor-suppressor gene in mouse liver and human hepatocellular carcinoma	ONCOGENE			English	Article						KLF6; Kruppel-like factor; tumor-suppressor gene; p21; haploinsufficiency	KRUPPEL-LIKE FACTOR-6; TRANSCRIPTION FACTOR KLF6; CELL LUNG-CANCER; PROSTATE-CANCER; EXPRESSION; PROGRESSION; ACTIVATION; HAPLOINSUFFICIENCY; INHIBITOR; PROMOTER	Kruppel-like factor (KLF) 6 is a tumor-suppressor gene functionally inactivated by loss of heterozygosity, somatic mutation and/or alternative splicing that generates a dominant-negative splice form, KLF6-SV1. Wild-type KLF6 (wtKLF6) expression is decreased in many human malignancies, which correlates with reduced patient survival. Additionally, loss of the KLF6 locus in the absence of somatic mutation in the remaining allele occurs in a number of human cancers, raising the possibility that haploinsuffi. ciency of the KLF6 gene alone contributes to cellular growth dysregulation and tumorigenesis. Our earlier studies identified the cyclin-dependent kinase inhibitor p21 as a transcriptional target of the KLF6 gene in cultured cells, but not in vivo. To address this issue, we have generated two genetic mouse models to de. ne the in vivo role of KLF6 in regulating cell proliferation and p21 expression. Transgenic overexpression of KLF6 in the liver resulted in a runted phenotype with decreased body and liver size, with evidence of decreased hepatocyte proliferation, increased p21 and reduced proliferating cell nuclear antigen expression. In contrast, mice with targeted deletion of one KLF6 allele (KLF6+/-) display increased liver mass with reduced p21 expression, compared to wild type littermates. Moreover, in primary hepatocellular carcinoma samples, there is a significant correlation between wtKLF6 and p21 mRNA expression. Combined, these data suggest that haploinsuffi. ciency of the KLF6 gene may regulate cellular proliferation in vivo through decreased transcriptional activation of the cyclin- dependent kinase inhibitor p21.	CUNY Mt Sinai Sch Med, Dept Med, New York, NY 10029 USA; CUNY Mt Sinai Sch Med, Dept Human Genet, New York, NY 10029 USA; CUNY Mt Sinai Sch Med, Div Liver Dis, New York, NY 10029 USA; CUNY Mt Sinai Sch Med, Div Hematol Oncol, New York, NY 10029 USA; CUNY Mt Sinai Sch Med, Dept Oncol Sci, New York, NY 10029 USA; CUNY Mt Sinai Sch Med, Brookdale Dept Mol Cell & Dev Biol, New York, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Friedman, SL (corresponding author), CUNY Mt Sinai Sch Med, Dept Med, Box 1123,1425 Madison Ave,Room 11-70, New York, NY 10029 USA.	scott.friedman@mssm.edu	Narla, Goutham/AAZ-5710-2020	Narla, Goutham/0000-0003-4098-4203; TAROCCHI, MIRKO/0000-0002-7767-5116	NIDDK NIH HHS [DK37340] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037340] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alberici P, 2006, ONCOGENE, V25, P1841, DOI 10.1038/sj.onc.1209226; Benzeno S, 2004, CANCER RES, V64, P3885, DOI 10.1158/0008-5472.CAN-03-2818; Bieker JJ, 2001, J BIOL CHEM, V276, P34355, DOI 10.1074/jbc.R100043200; Bissell D M, 1980, Ann N Y Acad Sci, V349, P85, DOI 10.1111/j.1749-6632.1980.tb29518.x; Botella LM, 2002, BLOOD, V100, P4001, DOI 10.1182/blood.V100.12.4001; Boyault S, 2005, HEPATOLOGY, V41, P681, DOI 10.1002/hep.20588; Chen CS, 2003, AM J PATHOL, V162, P1349, DOI 10.1016/S0002-9440(10)63930-2; Chen Han-kui, 2002, Ai Zheng, V21, P1047; Cho YG, 2005, ONCOGENE, V24, P4588, DOI 10.1038/sj.onc.1208670; Difeo A, 2006, ONCOGENE, V25, P6026, DOI 10.1038/sj.onc.1209611; Difeo A, 2006, CLIN CANCER RES, V12, P3730, DOI 10.1158/1078-0432.CCR-06-0054; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Glinsky GV, 2004, J CLIN INVEST, V113, P913, DOI 10.1172/JCI200420032; Ito G, 2004, CANCER RES, V64, P3838, DOI 10.1158/0008-5472.CAN-04-0185; Jeng YM, 2003, INT J CANCER, V105, P625, DOI 10.1002/ijc.11123; Kettunen E, 2004, CANCER GENET CYTOGEN, V149, P98, DOI 10.1016/s0165-4608(03)00300-5; Kim Y, 1998, J BIOL CHEM, V273, P33750, DOI 10.1074/jbc.273.50.33750; Kimmelman AC, 2004, ONCOGENE, V23, P5077, DOI 10.1038/sj.onc.1207662; Kremer-Tal S, 2004, HEPATOLOGY, V40, P1047, DOI 10.1002/hep.20460; KREMERTAL S, 2006, J HEPATOL       1127; Kwabi-Addo B, 2001, P NATL ACAD SCI USA, V98, P11563, DOI 10.1073/pnas.201167798; Lee JS, 2004, HEPATOLOGY, V40, P667, DOI 10.1002/hep.20375; MATSUMOTO N, 2006, HEPATOLOGY, V107, P1357; Narla G, 2005, CANCER RES, V65, P1213, DOI 10.1158/0008-5472.CAN-04-4249; Narla G, 2003, AM J PATHOL, V162, P1047, DOI 10.1016/S0002-9440(10)63901-6; Narla G, 2001, SCIENCE, V294, P2563, DOI 10.1126/science.1066326; Pan Xiu-cheng, 2006, J Zhejiang Univ Sci B, V7, P830, DOI 10.1631/jzus.2006.B0830; Reeves HL, 2004, GASTROENTEROLOGY, V126, P1090, DOI 10.1053/j.gastro.2004.01.005; Singh D, 2002, CANCER CELL, V1, P203, DOI 10.1016/S1535-6108(02)00030-2; Slavin DA, 2004, ONCOGENE, V23, P8196, DOI 10.1038/sj.onc.1208020; Song J, 2006, J GASTROEN HEPATOL, V21, P1286, DOI 10.1111/j.1440-1746.2006.04445.x; Venkatachalam S, 2001, TOXICOL PATHOL, V29, P147, DOI 10.1080/019262301753178555; Walthall K, 2005, BIRTH DEFECTS RES B, V74, P132, DOI 10.1002/bdrb.20040; Wang Shao-ping, 2004, Zhonghua Wai Ke Za Zhi, V42, P1258; Warke VG, 2003, J BIOL CHEM, V278, P14812, DOI 10.1074/jbc.M300787200; Wu H, 1996, GENE DEV, V10, P245, DOI 10.1101/gad.10.3.245	36	64	71	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2007	26	30					4428	4434		10.1038/sj.onc.1210223	http://dx.doi.org/10.1038/sj.onc.1210223			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	184CZ	17297474				2022-12-28	WOS:000247620000010
J	Burwell, EA; McCarty, GP; Simpson, LA; Thompson, KA; Loeb, DM				Burwell, E. A.; McCarty, G. P.; Simpson, L. A.; Thompson, K. A.; Loeb, D. M.			Isoforms of Wilms' tumor suppressor gene (WT1) have distinct effects on mammary epithelial cells	ONCOGENE			English	Article						breast cancer; oncogene; epithelial-mesenchymal transition; cell cycle; alternative splicing	BREAST-CANCER; EXPRESSION; DIFFERENTIATION; TRANSCRIPTION; INTERACTS; PRODUCT; TARGET; EXON; DNA	The role of WT1 (Wilm's tumor suppressor gene) in breast cancer is controversial, with evidence for both tumor-promoting and tumor-suppressing activities. In order to address this question, we expressed different WT1 isoforms in the mammary epithelial cell line H16N-2, which does not express endogenous WT1. Cells were stably transfected with either WT1 (- Ex5/ - KTS) or WT1 ( + Ex5/ + KTS) under the control of the inducible metallothionein promoter. Induction of WT1 (- Ex5/ - KTS) upregulated p21, causing a slowing of proliferation and a G2-phase cell cycle arrest. In artificial basement membrane, the WT1 (- Ex5/ - KTS) isoform promoted the appearance of highly organized acinar cellular aggregates. In contrast, WT1 (+ Ex5/ + KTS) had no effect on p21 or proliferation, but rather caused an epithelial-mesenchymal transition and a redistribution of E-cadherin from the cell membrane to the cytoplasm. This isoform also causes the cellular aggregates growing in artificial basement membrane to appear significantly less organized than control cells. Thus, different WT1 isoforms have distinct effects in this cell line, suggesting that depending on the ratio of WT1 isoform expression in mammary epithelial cells, WT1 could function to either promote or suppress a transformed phenotype.	Johns Hopkins Univ, Div Pediat Oncol, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21231 USA	Johns Hopkins University; Johns Hopkins Medicine	Loeb, DM (corresponding author), Johns Hopkins Univ, Div Pediat Oncol, Sidney Kimmel Comprehens Canc Ctr, Bunting Blaustein Canc Res Bldg, Baltimore, MD 21231 USA.	dmloeb@jhmi.edu			NATIONAL CANCER INSTITUTE [T32CA060441] Funding Source: NIH RePORTER; NCI NIH HHS [T32CA60441] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Barlund M, 2000, J NATL CANCER I, V92, P1252, DOI 10.1093/jnci/92.15.1252; Davies RC, 1998, GENE DEV, V12, P3217, DOI 10.1101/gad.12.20.3217; Englert C, 1997, CANCER RES, V57, P1429; HABER DA, 1991, P NATL ACAD SCI USA, V88, P9618, DOI 10.1073/pnas.88.21.9618; Hewitt SM, 1996, ANTICANCER RES, V16, P621; Inoue K, 1998, BLOOD, V91, P2969, DOI 10.1182/blood.V91.8.2969.2969_2969_2976; KOLCH W, 1995, BREAST CANCER RES TR, V36, P139, DOI 10.1007/BF00666036; LARSSON SH, 1995, CELL, V81, P391, DOI 10.1016/0092-8674(95)90392-5; LEMOINE NR, 1992, BRIT J CANCER, V66, P1116, DOI 10.1038/bjc.1992.420; LO HW, 2005, BREAST CANC RES TREA, V95, P1; Loeb DM, 2001, CANCER RES, V61, P921; Loeb DM, 2006, CELL CYCLE, V5, P1249, DOI 10.4161/cc.5.12.2807; Loeb DM, 2003, LEUKEMIA, V17, P965, DOI 10.1038/sj.leu.2402906; Loeb DM, 2002, J BIOL CHEM, V277, P19627, DOI 10.1074/jbc.M201336200; MAHESWARAN S, 1993, P NATL ACAD SCI USA, V90, P5100, DOI 10.1073/pnas.90.11.5100; Miyoshi Y, 2002, CLIN CANCER RES, V8, P1167; Natoli TA, 2002, MOL CELL BIOL, V22, P4433, DOI 10.1128/MCB.22.12.4433-4438.2002; Reizner N, 2005, J MOL ENDOCRINOL, V35, P135, DOI 10.1677/jme.1.01761; Reynolds PA, 2003, GENE DEV, V17, P2094, DOI 10.1101/gad.1110703; Silberstein GB, 1997, P NATL ACAD SCI USA, V94, P8132, DOI 10.1073/pnas.94.15.8132; Udabage L, 2005, EXP CELL RES, V310, P205, DOI 10.1016/j.yexcr.2005.07.026; Velona T, 1999, PEDIATR RES, V45, P658, DOI 10.1203/00006450-199905010-00008; Zapata-Benavides P, 2002, BIOCHEM BIOPH RES CO, V295, P784, DOI 10.1016/S0006-291X(02)00751-9; Zhang TF, 2003, ANTICANCER RES, V23, P3575	24	32	33	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 17	2007	26	23					3423	3430		10.1038/sj.onc.1210127	http://dx.doi.org/10.1038/sj.onc.1210127			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	169GB	17160023				2022-12-28	WOS:000246579600012
J	Kurbanov, BM; Fecker, LF; Geilen, CC; Sterry, W; Eberle, J				Kurbanov, B. M.; Fecker, L. F.; Geilen, C. C.; Sterry, W.; Eberle, J.			Resistance of melanoma cells to TRAIL does not result from upregulation of antiapoptotic proteins by NF-kappa B but is related to downregulation of initiator caspases and DR4	ONCOGENE			English	Article						melanoma; apoptosis; TRAIL; TRAIL-R1/DR4; initiator caspases	APOPTOSIS-INDUCING LIGAND; CANCER-CELLS; (TRAIL)-INDUCED APOPTOSIS; DEATH RECEPTORS; MALIGNANT-MELANOMA; CARCINOMA CELLS; IN-VIVO; PROTEASOME; EXPRESSION; OVERCOMES	Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) has attracted considerable attention as a novel anticancer agent. However, its efficiency may be diminished by occurring resistance in cancer cells. The mechanisms of TRAIL resistance in melanoma are still unsolved. Here we show for the first time that TRAIL-induced activation of NF-kappa B occurs in apoptosis-sensitive melanoma cell lines through TRAIL receptor 1/death receptor 4 (TRAIL-R1/DR4), whereas TRAIL failed to activate nuclear factor kappa B (NF-kappa B) in melanoma cells positive only for TRAIL receptor 2/death receptor 5 (TRAIL-R2/DR5). However, activation of NF-kappa B by TRAIL was not associated with enhanced expression of antiapoptotic factors: cellular FLICE-inhibitory protein (c-FLIP), Bcl-X-L, X-linked inhibitor of apoptosis protein (XIAP), Survivin, Livin. Rather in one of the cell lines, TRAIL induced the downregulation of DR4. In an established cell culture model for TRAIL resistance and regained TRAIL sensitivity, resistance was neither associated with increased NF-kappa B activity by TRAIL nor by an increased expression of antiapoptotic proteins. However, significant downregulation of caspase-8, caspase-10 and of DR4 was characteristic for TRAIL-resistant, DR4-positive melanoma cells, and regained TRAIL sensitivity coincided with re-expression of these factors. Sensitivity was also largely retained after their exogenous overexpression. Thus, initiator caspases and DR4 rather than NF-kappa B may control melanoma cell sensitivity to TRAIL, and strategies, which result in their upregulation, may be useful for enhancement of TRAIL sensitivity.	Univ Med Berlin, Skin Canc Ctr, Dept Dermatol & Allergy, D-12203 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Eberle, J (corresponding author), Univ Med Berlin, Skin Canc Ctr, Dept Dermatol & Allergy, Hindenburgdamm 30, D-12203 Berlin, Germany.	juergen.eberle@charite.de		Eberle, Jurgen/0000-0001-8533-1519				Bai JR, 2005, CANCER RES, V65, P2344, DOI 10.1158/0008-5472.CAN-04-3502; Chawla-Sarkar M, 2002, J IMMUNOL, V169, P847, DOI 10.4049/jimmunol.169.2.847; Chen XF, 2003, CANCER RES, V63, P1059; Di Pietro R, 2004, J CELL PHYSIOL, V201, P331, DOI 10.1002/jcp.20099; Eberle J, 1999, J INVEST DERMATOL, V112, P925, DOI 10.1046/j.1523-1747.1999.00598.x; Eberle J, 2003, ONCOGENE, V22, P9131, DOI 10.1038/sj.onc.1207228; Eggert A, 2001, CANCER RES, V61, P1314; Ehrhardt H, 2003, ONCOGENE, V22, P3842, DOI 10.1038/sj.onc.1206520; Fecker LF, 2006, J INVEST DERMATOL, V126, P1366, DOI 10.1038/sj.jid.5700192; Fischer U, 2005, CELL DEATH DIFFER, V12, P942, DOI 10.1038/sj.cdd.4401556; Franco AV, 2001, J IMMUNOL, V166, P5337, DOI 10.4049/jimmunol.166.9.5337; Fulda S, 2006, ONCOGENE, V25, P5125, DOI 10.1038/sj.onc.1209518; Fulda S, 2001, ONCOGENE, V20, P5865, DOI 10.1038/sj.onc.1204750; Ganten TM, 2005, HEPATOLOGY, V42, P588, DOI 10.1002/hep.20807; Harper N, 2001, J BIOL CHEM, V276, P34743, DOI 10.1074/jbc.M105693200; He Q, 2004, ONCOGENE, V23, P2554, DOI 10.1038/sj.onc.1207351; Ishimura N, 2006, AM J PHYSIOL-GASTR L, V290, pG129, DOI 10.1152/ajpgi.00242.2005; Ivanov VN, 2003, ONCOGENE, V22, P3152, DOI 10.1038/sj.onc.1206456; Jin ZY, 2004, J BIOL CHEM, V279, P35829, DOI 10.1074/jbc.M405538200; Johnson TR, 2003, ONCOGENE, V22, P4953, DOI 10.1038/sj.onc.1206656; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Karin M, 2005, NAT REV IMMUNOL, V5, P749, DOI 10.1038/nri1703; Kelley SK, 2004, CURR OPIN PHARMACOL, V4, P333, DOI 10.1016/j.coph.2004.02.006; Kim KH, 2000, CLIN CANCER RES, V6, P335; Kischkel FC, 2001, J BIOL CHEM, V276, P46639, DOI 10.1074/jbc.M105102200; Kurbanov BM, 2005, J INVEST DERMATOL, V125, P1010, DOI 10.1111/j.0022-202X.2005.23900.x; LeBlanc HN, 2003, CELL DEATH DIFFER, V10, P66, DOI 10.1038/sj.cdd.4401187; Lens MB, 2004, BRIT J DERMATOL, V150, P179, DOI 10.1111/j.1365-2133.2004.05708.x; Leverkus M, 2003, J INVEST DERMATOL, V121, P149, DOI 10.1046/j.1523-1747.2003.12332.x; Leverkus M, 2003, MOL CELL BIOL, V23, P777, DOI 10.1128/MCB.23.3.777-790.2003; Li-Weber M, 2003, SEMIN IMMUNOL, V15, P145, DOI 10.1016/S1044-5323(03)00030-7; Mitsiades CS, 2001, BLOOD, V98, P795, DOI 10.1182/blood.V98.3.795; Nguyen T, 2001, CLIN CANCER RES, V7, p966S; Ravi R, 2001, NAT CELL BIOL, V3, P409, DOI 10.1038/35070096; Ravi R, 2004, DRUG RESIST UPDATE, V7, P53, DOI 10.1016/j.drup.2004.01.003; Rudner J, 2005, ONCOGENE, V24, P130, DOI 10.1038/sj.onc.1208191; Secchiero P, 2003, J LEUKOCYTE BIOL, V74, P223, DOI 10.1189/jlb.0103004; Singh TR, 2003, CANCER RES, V63, P5390; Soengas MS, 2003, ONCOGENE, V22, P3138, DOI 10.1038/sj.onc.1206454; Sprick MR, 2002, EMBO J, V21, P4520, DOI 10.1093/emboj/cdf441; von Haefen C, 2004, ONCOGENE, V23, P8320, DOI 10.1038/sj.onc.1207971; Voorhees PM, 2003, CLIN CANCER RES, V9, P6316; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Wang SH, 2004, ONCOGENE, V23, P928, DOI 10.1038/sj.onc.1207213; Wang SL, 2003, ONCOGENE, V22, P8628, DOI 10.1038/sj.onc.1207232; Wendt J, 2005, ONCOGENE, V24, P4052, DOI 10.1038/sj.onc.1208580; Zauli G, 2005, J CELL PHYSIOL, V202, P900, DOI 10.1002/jcp.20202; Zhang LD, 2005, CANCER GENE THER, V12, P228, DOI 10.1038/sj.cgt.7700792; Zhang XD, 2003, ONCOGENE, V22, P2869, DOI 10.1038/sj.onc.1206427; Zhang XD, 2006, CLIN CANCER RES, V12, P1355, DOI 10.1158/1078-0432.CCR-05-2084; Zhu HB, 2005, CANCER BIOL THER, V4, P781, DOI 10.4161/cbt.4.7.1897	52	73	76	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 17	2007	26	23					3364	3377		10.1038/sj.onc.1210134	http://dx.doi.org/10.1038/sj.onc.1210134			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	169GB	17160022				2022-12-28	WOS:000246579600006
J	Li, Y; Prives, C				Li, Y.; Prives, C.			Are interactions with p63 and p73 involved in mutant p53 gain of oncogenic function?	ONCOGENE			English	Review						mutant p53; p63; p73; protein-protein interaction	SQUAMOUS-CELL CARCINOMA; LI-FRAUMENI-SYNDROME; TRANSCRIPTIONAL REGULATION; P53-DEPENDENT APOPTOSIS; P73-DEPENDENT APOPTOSIS; PHYSICAL INTERACTION; CORE DOMAIN; DNA-DAMAGE; COMMON; MUTATIONS	Although still controversial, the presence of mutant p53 in cancer cells may result in more aggressive tumors and correspondingly worse outcomes. The means by which mutant p53 exerts such pro-oncogenic activity are currently under extensive investigation and different models have been proposed. We focus here on a proposed mechanism by which a subset of tumor-derived p53 mutants physically interact with p53 family members, p63 and p73, and negatively regulate their proapoptotic function. Both cell-based assays and knock-in mice expressing mutant forms of p53 support this model. As more than half of human tumors harbor mutant forms of p53 protein, approaches aimed at disrupting the pathological interactions among p53 family members might be of clinical value.	Columbia Univ, Dept Biol Sci, New York, NY 10027 USA	Columbia University	Prives, C (corresponding author), Columbia Univ, Dept Biol Sci, New York, NY 10027 USA.	clp3@columbia.edu						Barbieri CE, 2006, CANCER RES, V66, P7589, DOI 10.1158/0008-5472.CAN-06-2020; Bensaad K, 2003, J BIOL CHEM, V278, P10546, DOI 10.1074/jbc.M208233200; Bergamaschi D, 2004, MOL CELL BIOL, V24, P1341, DOI 10.1128/MCB.24.3.1341-1350.2004; Bergamaschi D, 2003, CANCER CELL, V3, P387, DOI 10.1016/S1535-6108(03)00079-5; Brunner HG, 2002, AM J MED GENET, V112, P284, DOI 10.1002/ajmg.10778; Chipuk JE, 2006, CELL DEATH DIFFER, V13, P994, DOI 10.1038/sj.cdd.4401908; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; Davison TS, 1999, J BIOL CHEM, V274, P18709, DOI 10.1074/jbc.274.26.18709; Di Agostino S, 2006, CANCER CELL, V10, P191, DOI 10.1016/j.ccr.2006.08.013; Di Como CJ, 1999, MOL CELL BIOL, V19, P1438; Flores ER, 2002, NATURE, V416, P560, DOI 10.1038/416560a; Flores ER, 2005, CANCER CELL, V7, P363, DOI 10.1016/j.ccr.2005.02.019; Gaiddon C, 2001, MOL CELL BIOL, V21, P1874, DOI 10.1128/MCB.21.5.1874-1887.2001; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; Gorina S, 1996, SCIENCE, V274, P1001, DOI 10.1126/science.274.5289.1001; Gressner O, 2005, EMBO J, V24, P2458, DOI 10.1038/sj.emboj.7600708; Hibi K, 2000, P NATL ACAD SCI USA, V97, P5462, DOI 10.1073/pnas.97.10.5462; Irwin MS, 2003, CANCER CELL, V3, P403, DOI 10.1016/S1535-6108(03)00078-3; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Lang GA, 2004, CELL, V119, P861, DOI 10.1016/j.cell.2004.11.006; LANZA M, 2006, CELL CYCLE, V5; Laptenko O, 2006, CELL DEATH DIFFER, V13, P951, DOI 10.1038/sj.cdd.4401916; Lokshin M, 2005, COLD SH Q B, V70, P121, DOI 10.1101/sqb.2005.70.046; Lokshin M, 2007, NUCLEIC ACIDS RES, V35, P340, DOI 10.1093/nar/gkl1047; Marin MC, 2000, NAT GENET, V25, P47, DOI 10.1038/75586; Murray-Zmijewski F, 2006, CELL DEATH DIFFER, V13, P962, DOI 10.1038/sj.cdd.4401914; Olive KP, 2004, CELL, V119, P847, DOI 10.1016/j.cell.2004.11.004; Osada M, 1998, NAT MED, V4, P839, DOI 10.1038/nm0798-839; Resnick MA, 2003, P NATL ACAD SCI USA, V100, P9934, DOI 10.1073/pnas.1633803100; Rocco JW, 2006, CANCER CELL, V9, P45, DOI 10.1016/j.ccr.2005.12.013; Samuels-Lev Y, 2001, MOL CELL, V8, P781, DOI 10.1016/S1097-2765(01)00367-7; Strano S, 2001, J BIOL CHEM, V276, P15164, DOI 10.1074/jbc.M010484200; Strano S, 2002, J BIOL CHEM, V277, P18817, DOI 10.1074/jbc.M201405200; Strano S, 2000, J BIOL CHEM, V275, P29503, DOI 10.1074/jbc.M003360200; Urist M, 2004, GENE DEV, V18, P3041, DOI 10.1101/gad.1221004; van Bokhoven H, 2002, AM J HUM GENET, V71, P1, DOI 10.1086/341450; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Willis AC, 2003, ONCOGENE, V22, P5481, DOI 10.1038/sj.onc.1206505; Wiman KG, 2006, CELL DEATH DIFFER, V13, P921, DOI 10.1038/sj.cdd.4401921; Wong KB, 1999, P NATL ACAD SCI USA, V96, P8438, DOI 10.1073/pnas.96.15.8438; Wu GJ, 2003, CANCER RES, V63, P2351; Yang A, 2002, TRENDS GENET, V18, P90, DOI 10.1016/S0168-9525(02)02595-7; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Zeng SX, 2002, EMBO J, V21, P5487, DOI 10.1093/emboj/cdf540	45	131	138	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 2	2007	26	15					2220	2225		10.1038/sj.onc.1210311	http://dx.doi.org/10.1038/sj.onc.1210311			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	152XE	17401431				2022-12-28	WOS:000245394800011
J	Nakajima, A; Kojima, Y; Nakayama, M; Yagita, H; Okumura, K; Nakano, H				Nakajima, A.; Kojima, Y.; Nakayama, M.; Yagita, H.; Okumura, K.; Nakano, H.			Downregulation of c-FLIP promotes caspase-dependent JNK activation and reactive oxygen species accumulation in tumor cells	ONCOGENE			English	Article						c-FLIP; tumor necrosis factor; reactive oxygen species; c-Jun N-terminal kinase; apoptosis; necrosis	NF-KAPPA-B; ALPHA-INDUCED APOPTOSIS; INHIBITORY PROTEIN; CYTOCHROME-C; DEATH; KINASE; AUTOPHAGY; NECROSIS; PATHWAY; REQUIREMENT	Nuclear factor-kappa B (NF-kappa B) inhibits cell death through suppression of the caspase cascade, the c-Jun N-terminal kinase (JNK) pathway, and reactive oxygen species (ROS) accumulation. To suppress this antiapoptotic function of NF-kappa B might be a promising strategy to increase susceptibility of tumor cells to stress-induced cell death. We have recently shown that tumor necrosis factor (TNF)alpha induces caspase-dependent and -independent JNK activation and ROS accumulation in cellular FLICE-inhibitory protein (c-Flip)(-/-) murine embryonic fibroblasts (MEFs). To apply this observation to tumor therapy, we knocked down c-FLIP by RNA interference in various tumor cells. Consistent with the results using c-Flip(-/-) MEFs, we found that TNF alpha stimulation induced caspase-dependent prolonged JNK activation and ROS accumulation, followed by apoptotic and necrotic cell death in various tumor cells. Furthermore, TNF alpha and Fas induced the cleavage of mitogen-activated protein kinase/ ERK kinase kinase (MEKK)1, resulting in generation of a constitutive active form of MEKK1 leading to JNK activation in c-FLIP knockdown cells. Given that ROS accumulation and necrotic cell death enhance inflammation followed by compensatory proliferation of tumor cells, selective suppression of caspase-dependent ROS accumulation will be an alternative strategy to protect cells from ROS-dependent DNA damage and compensatory tumor progression.	[Nakajima, A.; Kojima, Y.; Nakayama, M.; Yagita, H.; Okumura, K.; Nakano, H.] Juntendo Univ, Sch Med, Dept Immunol, Bunkyo Ku, Tokyo 1138421, Japan	Juntendo University	Nakajima, A (corresponding author), Juntendo Univ, Sch Med, Dept Immunol, Bunkyo Ku, 2-1-1 Hongo, Tokyo 1138421, Japan.	hnakano@med.juntendo.ac.jp		Nakano, Hiroyasu/0000-0003-4843-1427; Nakayama, Masafumi/0000-0002-9839-7143				Balkwill F, 2004, NATURE, V431, P405, DOI 10.1038/431405a; Barkett M, 1999, ONCOGENE, V18, P6910, DOI 10.1038/sj.onc.1203238; Budd RC, 2006, NAT REV IMMUNOL, V6, P196, DOI 10.1038/nri1787; Chang LF, 2006, CELL, V124, P601, DOI 10.1016/j.cell.2006.01.021; Deng YB, 2003, CELL, V115, P61, DOI 10.1016/S0092-8674(03)00757-8; Djerbi M, 1999, J EXP MED, V190, P1025, DOI 10.1084/jem.190.7.1025; Edinger AL, 2004, CURR OPIN CELL BIOL, V16, P663, DOI 10.1016/j.ceb.2004.09.011; Giorgio M, 2005, CELL, V122, P221, DOI 10.1016/j.cell.2005.05.011; Kamata H, 2005, CELL, V120, P649, DOI 10.1016/j.cell.2004.12.041; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Lee KK, 1998, ONCOGENE, V16, P3029, DOI 10.1038/sj.onc.1201840; Levine B, 2005, J CLIN INVEST, V115, P2679, DOI 10.1172/JCI26390; Levine B, 2004, DEV CELL, V6, P463, DOI 10.1016/S1534-5807(04)00099-1; Maeda S, 2005, CELL, V121, P977, DOI 10.1016/j.cell.2005.04.014; Medema JP, 1999, J EXP MED, V190, P1033, DOI 10.1084/jem.190.7.1033; Micheau O, 2003, CELL, V114, P181, DOI 10.1016/S0092-8674(03)00521-X; Nakajima A, 2006, EMBO J, V25, P5549, DOI 10.1038/sj.emboj.7601423; Nakano H, 2006, CELL DEATH DIFFER, V13, P730, DOI 10.1038/sj.cdd.4401830; Nakayama M, 2002, J IMMUNOL, V168, P734, DOI 10.4049/jimmunol.168.2.734; Ohsumi Y, 2001, NAT REV MOL CELL BIO, V2, P211, DOI 10.1038/35056522; Pham CG, 2004, CELL, V119, P529, DOI 10.1016/j.cell.2004.10.017; Ricci JE, 2004, CELL, V117, P773, DOI 10.1016/j.cell.2004.05.008; Rudel T, 1998, J IMMUNOL, V160, P7; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; Sakon S, 2003, EMBO J, V22, P3898, DOI 10.1093/emboj/cdg379; Tobiume K, 2001, EMBO REP, V2, P222, DOI 10.1093/embo-reports/kve046; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; Vakkila J, 2004, NAT REV IMMUNOL, V4, P641, DOI 10.1038/nri1415; Ventura JJ, 2004, GENE DEV, V18, P2905, DOI 10.1101/gad.1223004; Widmann C, 1998, MOL CELL BIOL, V18, P2416, DOI 10.1128/MCB.18.4.2416; Yeh WC, 2000, IMMUNITY, V12, P633, DOI 10.1016/S1074-7613(00)80214-9	31	36	37	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 3	2008	27	1					76	84		10.1038/sj.onc.1210624	http://dx.doi.org/10.1038/sj.onc.1210624			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	247YO	17599041				2022-12-28	WOS:000252118700008
J	Schneider, L; Essmann, F; Kletke, A; Rio, P; Hanenberg, H; Schulze-Osthoff, K; Nurnberg, B; Piekorz, RP				Schneider, L.; Essmann, F.; Kletke, A.; Rio, P.; Hanenberg, H.; Schulze-Osthoff, K.; Nuernberg, B.; Piekorz, R. P.			TACC3 depletion sensitizes to paclitaxel-induced cell death and overrides p21(WAF)-mediated cell cycle arrest	ONCOGENE			English	Article						TACC3; paclitaxel; mitosis; apoptosis; p53; p21(WAF)	SPINDLE ASSEMBLY CHECKPOINT; SMOOTH-MUSCLE-CELLS; ACIDIC COILED-COIL; INDUCED APOPTOSIS; POLE ORGANIZATION; MITOTIC ARREST; CANCER-CELLS; P21; P53; D1	Regulators of the mitotic spindle apparatus are attractive cellular targets for antitumor therapy. The centrosomal protein transforming acidic coiled coil (TACC) 3 is required for spindle assembly and proper chromosome segregation. In this study, we employed an inducible RNA interference approach to downregulate TACC3 expression. We show that TACC3 knock-down in NIH3T3 fibroblasts caused aneuploidy, but failed to overtly impair mitotic progression. TACC3 depletion rather triggered a postmitotic p53-p21(WAF) pathway and led to a reversible cell cycle arrest. Similar effects were induced by low concentrations of paclitaxel, a spindle poison used in antitumor therapy. Interestingly, however, and unlike in TACC3-proficient cells, paclitaxel was able to induce strong polyploidy and subsequent apoptosis in TACC3-depleted cells. Even though paclitaxel treatment was associated with the activation of the survival kinase Akt and an antiapoptotic expression of cytoplasmic p21(WAF) and cyclin D1, this inhibition of cell death was abrogated by depletion of TACC3. Thus, our data identify TACC3 as a potential target to overcome p21(WAF)-associated protection of transformed cells against paclitaxel-induced cell death.	[Schneider, L.; Kletke, A.; Nuernberg, B.; Piekorz, R. P.] Univ Klinikum Dusseldorf, Inst Biochem & Molekularbiol 2, D-40225 Dusseldorf, Germany; [Essmann, F.; Schulze-Osthoff, K.] Univ Klinikum Dusseldorf, Inst Mol Med, Dusseldorf, Germany; [Rio, P.; Hanenberg, H.] Univ Klinikum Dusseldorf, Klin Kindeer Oncol Haematol, Dusseldorf, Germany; [Rio, P.; Hanenberg, H.] Univ Klinikum Dusseldorf, Klin Immunol, Dusseldorf, Germany; [Hanenberg, H.] Indiana Univ, Sch Med, Riley Hosp Children, Dept Pediat,Wells Ctr & Pediat Res, Indianapolis, IN 46204 USA	Heinrich Heine University Dusseldorf; Heinrich Heine University Dusseldorf Hospital; Heinrich Heine University Dusseldorf; Heinrich Heine University Dusseldorf Hospital; Heinrich Heine University Dusseldorf; Heinrich Heine University Dusseldorf Hospital; Heinrich Heine University Dusseldorf; Heinrich Heine University Dusseldorf Hospital; Indiana University System; Indiana University-Purdue University Indianapolis; James Whitcomb Riley Hospital Children	Piekorz, RP (corresponding author), Univ Klinikum Dusseldorf, Inst Biochem & Molekularbiol 2, D-40225 Dusseldorf, Germany.	roland.piekorz@uni-duesseldorf.de	Schulze-Osthoff, Klaus/N-9025-2013; Essmann, Frank/ABG-7409-2020; Rio, Paula/G-8681-2015; Schneider, Leonid/H-3275-2013	Schulze-Osthoff, Klaus/0000-0003-1443-2720; Essmann, Frank/0000-0003-4369-8456; Rio, Paula/0000-0002-5424-5543; Schneider, Leonid/0000-0002-6204-9470; Nurnberg, Bernd/0000-0002-5995-6555				Abal M, 2003, CURR CANCER DRUG TAR, V3, P193, DOI 10.2174/1568009033481967; Andreassen PR, 2003, MUTAT RES-FUND MOL M, V532, P245, DOI 10.1016/j.mrfmmm.2003.08.020; Blagosklonny MV, 2006, CELL CYCLE, V5, P1574, DOI 10.4161/cc.5.14.3113; Blagosklonny MV, 2002, CELL CYCLE, V1, P391, DOI 10.4161/cc.1.6.262; Blagosklonny MV, 2000, J CLIN INVEST, V105, P533, DOI 10.1172/JCI8625; Blagosklonny MV, 2004, CELL CYCLE, V3, P1050; Blagosklonny MV, 2006, CELL CYCLE, V5, P971, DOI 10.4161/cc.5.9.2711; Brito DA, 2006, CURR BIOL, V16, P1194, DOI 10.1016/j.cub.2006.04.043; Cassimeris L, 2004, MOL BIOL CELL, V15, P1580, DOI 10.1091/mbc.E03-07-0544; Chen JG, 2002, CANCER RES, V62, P1935; CHEN XB, 1995, CANCER RES, V55, P4257; Child ES, 2006, CELL CYCLE, V5, P1313, DOI 10.4161/cc.5.12.2863; Coqueret O, 2003, TRENDS CELL BIOL, V13, P65, DOI 10.1016/S0962-8924(02)00043-0; Cully M, 2005, CANCER RES, V65, P10363, DOI 10.1158/0008-5472.CAN-05-1633; DelSal G, 1996, ONCOGENE, V12, P177; Gergely F, 2003, GENE DEV, V17, P336, DOI 10.1101/gad.245603; Gergely F, 2002, BIOESSAYS, V24, P915, DOI 10.1002/bies.10162; Giannakakou P, 2001, ONCOGENE, V20, P3806, DOI 10.1038/sj.onc.1204487; Gladden AB, 2005, J CELL BIOCHEM, V96, P906, DOI 10.1002/jcb.20613; Groisman I, 2000, CELL, V103, P435, DOI 10.1016/S0092-8674(00)00135-5; Han EKH, 1999, APOPTOSIS, V4, P213, DOI 10.1023/A:1009618824145; Heliez C, 2003, ONCOGENE, V22, P3260, DOI 10.1038/sj.onc.1206409; Ikui AE, 2005, CELL CYCLE, V4, P1385, DOI 10.4161/cc.4.10.2061; Janicke RU, 2007, CELL CYCLE, V6, P407; Jordan MA, 2004, NAT REV CANCER, V4, P253, DOI 10.1038/nrc1317; Judson PL, 1999, CANCER RES, V59, P2425; Jung CK, 2006, PATHOL INT, V56, P503, DOI 10.1111/j.1440-1827.2006.01998.x; Kadura S, 2005, CELL MOTIL CYTOSKEL, V61, P145, DOI 10.1002/cm.20072; Lauffart Brenda, 2005, BMC Womens Health, V5, P8, DOI 10.1186/1472-6874-5-8; Leurs C, 2003, HUM GENE THER, V14, P509, DOI 10.1089/104303403764539305; Mikule K, 2007, NAT CELL BIOL, V9, P160, DOI 10.1038/ncb1529; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; Olashaw N, 2004, CELL CYCLE, V3, P263; Piekorz RP, 2002, EMBO J, V21, P653, DOI 10.1093/emboj/21.4.653; Schmidt M, 2000, ONCOGENE, V19, P2423, DOI 10.1038/sj.onc.1203546; Sohn D, 2006, CANCER RES, V66, P11254, DOI 10.1158/0008-5472.CAN-06-1569; Srsen V, 2006, J CELL BIOL, V174, P625, DOI 10.1083/jcb.200606051; Stewart ZA, 1999, CANCER RES, V59, P3831; Still IH, 1999, ONCOGENE, V18, P4032, DOI 10.1038/sj.onc.1202801; Still IH, 1999, GENOMICS, V58, P165, DOI 10.1006/geno.1999.5829; TAYLOR SL, 2001, FOOD ALLERGY INTOLER, V2, P53; Vogel C, 2004, ONCOGENE, V23, P6845, DOI 10.1038/sj.onc.1207860; West KA, 2002, DRUG RESIST UPDATE, V5, P234, DOI 10.1016/S1368-7646(02)00120-6; Wiznerowicz M, 2003, J VIROL, V77, P8957, DOI 10.1128/JVI.77.16.8957-8951.2003; Yao R, 2007, CANCER SCI, V98, P555, DOI 10.1111/j.1349-7006.2007.00433.x; Yu J, 2005, BIOCHEM BIOPH RES CO, V331, P851, DOI 10.1016/j.bbrc.2005.03.189; Zachos G, 2007, DEV CELL, V12, P247, DOI 10.1016/j.devcel.2007.01.003	47	34	35	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 3	2008	27	1					116	125		10.1038/sj.onc.1210628	http://dx.doi.org/10.1038/sj.onc.1210628			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	247YO	17599038				2022-12-28	WOS:000252118700012
J	Sanchez-Cespedes, M				Sanchez-Cespedes, M.			A role for LKB1 gene in human cancer beyond the Peutz-Jeghers syndrome	ONCOGENE			English	Review						LKB1; lung cancer; Peutz-Jeghers syndrome; tumor suppressor gene	TUMOR-SUPPRESSOR KINASE; SOMATIC MUTATIONS; LUNG-CANCER; LKB1/STK11 GENE; STK11/LKB1 GENE; KNOCKOUT MICE; GROWTH ARREST; EXPRESSION; STRAD; INDUCTION	Germline LKB1 mutations are responsible for Peutz Jeghers syndrome (PJS). Tumors at several locations frequently arise in these patients, confirming that LKB1 is linked to cancer predisposition and is therefore a bona. de tumor-suppressor gene. In humans, the LKB1 gene is located in the short arm of chromosome 19, which is frequently deleted in many tumors of sporadic origin. However, LKB1 alterations in tumors other than those of PJS are rarely reported. Notably, this is not the case for non-small-cell lung cancer, where nearly half of the tumors harbor somatic and homozygous inactivating mutations in LKB1. The present review considers the frequency and pattern of LKB1 gene mutations in sporadic cancers of various origins, and the role of the encoded protein in cancer development.	Spanish Natl Canc Ctr CNIO, Mol Pathol Programme, Madrid 28029, Spain	Centro Nacional de Investigaciones Oncologicas (CNIO)	Sanchez-Cespedes, M (corresponding author), Spanish Natl Canc Ctr CNIO, Mol Pathol Programme, Melchor Fernandez Almagro 3, Madrid 28029, Spain.	msanchez@cnio.es	Sanchez-Cespedes, Montse/H-8485-2012	Sanchez-Cespedes, Montse/0000-0002-6045-5627				Ahrendt SA, 2001, CANCER, V92, P1525, DOI 10.1002/1097-0142(20010915)92:6<1525::AID-CNCR1478>3.0.CO;2-H; Alessi DR, 2006, ANNU REV BIOCHEM, V75, P137, DOI 10.1146/annurev.biochem.75.103004.142702; Alhopuro P, 2005, BRIT J CANCER, V92, P1126, DOI 10.1038/sj.bjc.6602454; Avizienyte E, 1998, CANCER RES, V58, P2087; Avizienyte E, 1999, AM J PATHOL, V154, P677, DOI 10.1016/S0002-9440(10)65314-X; Baas AF, 2004, CELL, V116, P457, DOI 10.1016/S0092-8674(04)00114-X; Baas AF, 2003, EMBO J, V22, P3062, DOI 10.1093/emboj/cdg292; Bignell GR, 1998, CANCER RES, V58, P1384; Boudeau J, 2003, EMBO J, V22, P5102, DOI 10.1093/emboj/cdg490; Buchet-Poyau K, 2002, CYTOGENET GENOME RES, V97, P171, DOI 10.1159/000066620; Carretero J, 2007, ONCOGENE, V26, P1616, DOI 10.1038/sj.onc.1209951; Carretero J, 2004, ONCOGENE, V23, P4037, DOI 10.1038/sj.onc.1207502; CONDE E, 2007, HUMAN PATHOL; Connolly DC, 2000, AM J PATHOL, V156, P339, DOI 10.1016/S0002-9440(10)64735-9; Corradetti MN, 2004, GENE DEV, V18, P1533, DOI 10.1101/gad.1199104; Fernandez P, 2004, ONCOGENE, V23, P5084, DOI 10.1038/sj.onc.1207665; Ghaffar H, 2003, CLIN CANCER RES, V9, P2998; Giardiello FM, 2000, GASTROENTEROLOGY, V119, P1447, DOI 10.1053/gast.2000.20228; Greenman C, 2007, NATURE, V446, P153, DOI 10.1038/nature05610; Guldberg P, 1999, ONCOGENE, V18, P1777, DOI 10.1038/sj.onc.1202486; GUO S, 1995, CELL, V81, P611, DOI 10.1016/0092-8674(95)90082-9; Hainaut P, 2001, CARCINOGENESIS, V22, P367, DOI 10.1093/carcin/22.3.367; Hardie DG, 2003, ENDOCRINOLOGY, V144, P5179, DOI 10.1210/en.2003-0982; Hawley Simon A, 2003, J Biol, V2, P28, DOI 10.1186/1475-4924-2-28; Hearle NCM, 2006, J MED GENET, V43, DOI 10.1136/jmg.2005.036830; Hearle N, 2006, CLIN CANCER RES, V12, P3209, DOI 10.1158/1078-0432.CCR-06-0083; Hemminki A, 1998, NATURE, V391, P184, DOI 10.1038/34432; Ikediobi ON, 2006, MOL CANCER THER, V5, P2606, DOI 10.1158/1535-7163.MCT-06-0433; JEGHERS H, 1949, NEW ENGL J MED, V241, P1031, DOI 10.1056/NEJM194912292412601; Jenne DE, 1998, NAT GENET, V18, P38, DOI 10.1038/ng0198-38; Jimenez AI, 2003, CANCER RES, V63, P1382; Karuman P, 2001, MOL CELL, V7, P1307, DOI 10.1016/S1097-2765(01)00258-1; Katajisto P, 2007, BBA-REV CANCER, V1775, P63, DOI 10.1016/j.bbcan.2006.08.003; Kim CJ, 2004, EUR J CANCER, V40, P136, DOI 10.1016/S0959-8049(03)00659-2; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; Kuragaki C, 2003, LAB INVEST, V83, P35, DOI 10.1097/01.LAB.0000049821.16698.D0; Launonen V, 2005, HUM MUTAT, V26, P291, DOI 10.1002/humu.20222; Lim W, 2004, GASTROENTEROLOGY, V126, P1788, DOI 10.1053/j.gastro.2004.03.014; Lizcano JM, 2004, EMBO J, V23, P833, DOI 10.1038/sj.emboj.7600110; Luukko K, 1999, MECH DEVELOP, V83, P187, DOI 10.1016/S0925-4773(99)00050-7; Marignani PA, 2001, J BIOL CHEM, V276, P32415, DOI 10.1074/jbc.C100207200; Martone ME, 2003, NEUROINFORMATICS, V1, P379, DOI 10.1385/NI:1:4:379; MATSUMOTO S, 2007, ONCOGENE; Mehenni H, 1998, AM J HUM GENET, V63, P1641, DOI 10.1086/302159; Miyoshi H, 2002, CANCER RES, V62, P2261; Nakau M, 2002, CANCER RES, V62, P4549; NELLIST M, 1993, CELL, V75, P1305; Qiu W, 2006, ONCOGENE, V25, P2937, DOI 10.1038/sj.onc.1209325; Rossi DJ, 2002, P NATL ACAD SCI USA, V99, P12327, DOI 10.1073/pnas.192301399; Rowan A, 2000, J PATHOL, V192, P203; Rowan A, 1999, J INVEST DERMATOL, V112, P509, DOI 10.1046/j.1523-1747.1999.00551.x; Sanchez-Cespedes M, 2002, CANCER RES, V62, P3659; Shaw RJ, 2004, CANCER CELL, V6, P91, DOI 10.1016/j.ccr.2004.06.007; Spicer J, 2004, CURR BIOL, V14, pR383, DOI 10.1016/j.cub.2004.05.012; Su GH, 1999, AM J PATHOL, V154, P1835, DOI 10.1016/S0002-9440(10)65440-5; Thomas RK, 2006, NAT MED, V12, P852, DOI 10.1038/nm1437; Tiainen M, 1999, P NATL ACAD SCI USA, V96, P9248, DOI 10.1073/pnas.96.16.9248; Tiainen M, 2002, HUM MOL GENET, V11, P1497, DOI 10.1093/hmg/11.13.1497; Upadhyay S, 2006, CANCER RES, V66, P7870, DOI 10.1158/0008-5472.CAN-05-2902; Volikos E, 2006, J MED GENET, V43, DOI 10.1136/jmg.2005.039875; Wang ZJ, 1999, J MED GENET, V36, P365; Wang ZJ, 1999, BRIT J CANCER, V80, P70, DOI 10.1038/sj.bjc.6690323; Ylikorkala A, 1999, HUM MOL GENET, V8, P45, DOI 10.1093/hmg/8.1.45; Ylikorkala A, 2001, SCIENCE, V293, P1323, DOI 10.1126/science.1062074	64	172	180	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 13	2007	26	57					7825	7832		10.1038/sj.onc.1210594	http://dx.doi.org/10.1038/sj.onc.1210594			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	248ON	17599048				2022-12-28	WOS:000252163500001
J	Visone, R; Pallante, P; Vecchione, A; Cirombella, R; Ferracin, M; Ferraro, A; Volinia, S; Coluzzi, S; Leone, V; Borbone, E; Liu, CG; Petrocca, F; Troncone, G; Calin, GA; Scarpa, A; Colato, C; Tallini, G; Santoro, M; Croce, CM; Fusco, A				Visone, R.; Pallante, P.; Vecchione, A.; Cirombella, R.; Ferracin, M.; Ferraro, A.; Volinia, S.; Coluzzi, S.; Leone, V.; Borbone, E.; Liu, C-G; Petrocca, F.; Troncone, G.; Calin, G. A.; Scarpa, A.; Colato, C.; Tallini, G.; Santoro, M.; Croce, C. M.; Fusco, A.			Specific microRNAs are downregulated in human thyroid anaplastic carcinomas	ONCOGENE			English	Article						microRNA; miR-30d; miR-125b; miR-26a; miR-30a-5p; thyroid anaplastic carcinoma	CHRONIC LYMPHOCYTIC-LEUKEMIA; MALIGNANT PHENOTYPE; GENE-EXPRESSION; CELL-LINES; OVEREXPRESSION; PROTEINS; RNA; DIFFERENTIATION; TRANSFORMATION; PROLIFERATION	Thyroid carcinomas comprise a broad spectrum of tumors with different clinical behaviors. On the one side, there are occult papillary carcinomas (PTC), slow growing and clinically silent, and on the other side, rapidly growing anaplastic carcinomas (ATC), which are among the most lethal human neoplasms. We have analysed the microRNA (miR) pro. le of ATC in comparison to the normal thyroid using a microarray (miRNACHIP microarray). By this approach, we found an aberrant miR expression pro. le that clearly differentiates ATC from normal thyroid tissues and from PTC analysed in previous studies. In particular, a significant decrease in miR-30d, miR-125b, miR-26a and miR-30a-5p was detected in ATC in comparison to normal thyroid tissue. These results were further confirmed by northern blots, quantitative reverse transcription-PCR analyses and in situ hybridization. The overexpression of these four miRs in two human ATC-derived cell lines suggests a critical role of miR-125b and miR-26a downregulation in thyroid carcinogenesis, since a cell growth inhibition was achieved. Conversely, no effect on cell growth was observed after the overexpression of miR-30d and miR-30a-5p in the same cells. In conclusion, these data indicate a miR signature associated with ATC and suggest the miR deregulation as an important event in thyroid cell transformation.	Univ Naples Federico II, Fac Med & Chirurg, Ist Endocrinol & Oncol Sperimentale, Dipartimento Biol & Pathol, I-80131 Naples, Italy; European Sch Mol Med, Biotechnol Avanzate Napoli & SEMM, NOGEC, CEINGE, Naples, Italy; Ohio State Univ, Columbus, OH 43210 USA; Univ Roma La Sapienza, Dip Istopathol, Osped St Andrea, Dipartimento Anat Umana & Istol, Rome, Italy; Univ Ferrara, Ctr Interdipartipartmental Ricerca Cancro, Dipartimento Med Sperimentale & Diagnost, Ferrara, Italy; Univ Naples 2, Fac Med & Chirurg, Dipartimoento Anat Patol & Citopatol, Naples, Italy; Univ Verona, Dipartimento Patol, Verona, Italy; Univ Bologna, Osped Bellaria, Dipartimento Patol Sperimentale, Bologna, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto per Endocrinologia e Oncologia "Gaetano Salvatore" (IEOS-CNR); University of Naples Federico II; CEINGE Biotecnologie Avanzate; University System of Ohio; Ohio State University; Sapienza University Rome; Azienda Ospedaliera Sant'Andrea; University of Ferrara; Universita della Campania Vanvitelli; University of Verona; University of Bologna	Fusco, A (corresponding author), Univ Naples Federico II, Dipartimento Biol & Pathol Cellulare & Mol, Via Pansini 5 80131, I-80131 Naples, Italy.	carlo.croce@osumc.edu; afusco@napoli.com	Volinia, Stefano/A-3029-2010; Huang, H/E-9490-2010; scarpa, aldo/K-6832-2016; visone, rosa/K-7910-2016; Ferraro, Angelo/A-4172-2014; Young, Richard A/F-6495-2012; Volinia, Stefano/AAA-9264-2019; Calin, George/E-9390-2011; Pallante, Pierlorenzo/AAX-8758-2020; Ferracin, Manuela/K-2097-2016; Ferraro, Angelo/H-3193-2019; Tallini, Giovanni/F-7850-2013	Volinia, Stefano/0000-0003-0910-3893; scarpa, aldo/0000-0003-1678-739X; Ferraro, Angelo/0000-0002-2044-7569; Young, Richard A/0000-0001-8855-8647; Volinia, Stefano/0000-0003-0910-3893; Ferracin, Manuela/0000-0002-1595-6887; Ferraro, Angelo/0000-0002-2044-7569; Tallini, Giovanni/0000-0003-0113-6682; Fusco, Alfredo/0000-0003-3332-5197; Calin, George/0000-0001-6704-5615; Vecchione, Andrea/0000-0002-5497-6856; VISONE, Rosa/0000-0002-4993-0220; Coluzzi, Sabrina/0000-0003-4483-6232				Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Berlingieri MT, 2002, ONCOGENE, V21, P2971, DOI 10.1038/sj.onc.1205368; Califano D, 1998, CANCER RES, V58, P823; Calin GA, 2002, P NATL ACAD SCI USA, V99, P15524, DOI 10.1073/pnas.242606799; Calin GA, 2005, NEW ENGL J MED, V353, P1793, DOI 10.1056/NEJMoa050995; Cerutti J, 1996, CLIN CANCER RES, V2, P119; Chan JA, 2005, CANCER RES, V65, P6029, DOI 10.1158/0008-5472.CAN-05-0137; CHIAPPETTA G, 1995, ONCOGENE, V10, P1307; de Nigris F, 1998, CANCER RES, V58, P4745; DONGHI R, 1993, J CLIN INVEST, V91, P1753, DOI 10.1172/JCI116385; FAGIN JA, 1993, J CLIN INVEST, V91, P179, DOI 10.1172/JCI116168; Fedele M, 2001, CARCINOGENESIS, V22, P1583, DOI 10.1093/carcin/22.10.1583; He HL, 2005, P NATL ACAD SCI USA, V102, P19075, DOI 10.1073/pnas.0509603102; He L, 2004, NAT REV GENET, V5, P522, DOI 10.1038/nrg1379; Hunt JL, 2003, AM J SURG PATHOL, V27, P1559, DOI 10.1097/00000478-200312000-00009; Iorio MV, 2005, CANCER RES, V65, P7065, DOI 10.1158/0008-5472.CAN-05-1783; Kondo T, 2006, NAT REV CANCER, V6, P292, DOI 10.1038/nrc1836; LEDENT C, 1991, ENDOCRINOLOGY, V129, P1391, DOI 10.1210/endo-129-3-1391; Lee YS, 2005, J BIOL CHEM, V280, P16635, DOI 10.1074/jbc.M412247200; Liu CG, 2004, P NATL ACAD SCI USA, V101, P9740, DOI 10.1073/pnas.0403293101; Martelli ML, 2000, EUR J ENDOCRINOL, V143, P515, DOI 10.1530/eje.0.1430515; Metzler M, 2004, GENE CHROMOSOME CANC, V39, P167, DOI 10.1002/gcc.10316; Michael MZ, 2003, MOL CANCER RES, V1, P882; Pallante P, 2006, ENDOCR-RELAT CANCER, V13, P497, DOI 10.1677/erc.1.01209; Pallante P, 2005, BRIT J CANCER, V93, P464, DOI 10.1038/sj.bjc.6602721; Ros P, 1999, BIOCHIMIE, V81, P389, DOI 10.1016/S0300-9084(99)80086-8; Sempere LF, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-3-r13; Takamizawa J, 2004, CANCER RES, V64, P3753, DOI 10.1158/0008-5472.CAN-04-0637; Tallini G, 1999, ADV ANAT PATHOL, V6, P237, DOI 10.1097/00125480-199909000-00001; Volinia S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI 10.1073/pnas.0510565103; Weber F, 2006, J CLIN ENDOCR METAB, V91, P3584, DOI 10.1210/jc.2006-0693	31	316	348	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 29	2007	26	54					7590	7595		10.1038/sj.onc.1210564	http://dx.doi.org/10.1038/sj.onc.1210564			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	236DB	17563749				2022-12-28	WOS:000251282100012
J	Kitisin, K; Ganesan, N; Tang, Y; Jogunoori, W; Volpe, EA; Kim, SS; Katuri, V; Kallakury, B; Pishvaian, M; Albanese, C; Mendelson, J; Zasloff, M; Rashid, A; Fishbein, T; Evans, SRT; Sidawy, A; Reddy, EP; Mishra, B; Johnson, LB; Shetty, K; Mishra, L				Kitisin, K.; Ganesan, N.; Tang, Y.; Jogunoori, W.; Volpe, E. A.; Kim, S. S.; Katuri, V.; Kallakury, B.; Pishvaian, M.; Albanese, C.; Mendelson, J.; Zasloff, M.; Rashid, A.; Fishbein, T.; Evans, S. R. T.; Sidawy, A.; Reddy, E. P.; Mishra, B.; Johnson, L. B.; Shetty, K.; Mishra, L.			Disruption of transforming growth factor-beta signaling through beta-spectrin ELF leads to hepatocellular cancer through cyclin D1 activation	ONCOGENE			English	Article						hepatocellular carcinoma; ELF; cyclin D1; transforming growth factor-beta; cell cycle	HEPATITIS-B-VIRUS; TGF-BETA; MICROSATELLITE INSTABILITY; CARCINOMA; EXPRESSION; RECEPTOR; GENE; CATENIN; TUMOR; P53	Transforming growth factor-beta (TGF-beta) signaling members, TGF-beta receptor type II ( TBRII), Smad2, Smad4 and Smad adaptor, embryonic liver fodrin ( ELF), are prominent tumor suppressors in gastrointestinal cancers. Here, we show that 40% of elf(-+/-) mice spontaneously develop hepatocellular cancer ( HCC) with markedly increased cyclin D1, cyclin-dependent kinase 4 (Cdk4), c-Myc and MDM2 expression. Reduced ELF but not TBRII, or Smad4 was observed in 8 of 9 human HCCs (P < 0.017). ELF and TBRII are also markedly decreased in human HCC cell lines SNU-398 and SNU-475. Restoration of ELF and TBRII in SNU-398 cells markedly decreases cyclin D1 as well as hyperphosphorylated-retinoblastoma ( hyperphosphorylated-pRb). Thus, we show that TGF-b signaling and Smad adaptor ELF suppress human hepatocarcinogenesis, potentially through cyclin D1 deregulation. Loss of ELF could serve as a primary event in progression toward a fully transformed phenotype and could hold promise for new therapeutic approaches in human HCCs.	Georgetown Univ, Sch Med, Dept Surg Sci, Lombardi Comprehens Canc Ctr, Washington, DC 20007 USA; Georgetown Univ, Sch Med, Dept Pathol, Lombardi Comprehens Canc Ctr, Washington, DC 20007 USA; Georgetown Univ, Sch Med, Dept Med Oncol, Lombardi Comprehens Canc Ctr, Washington, DC 20007 USA; Georgetown Univ, Dept Oncol, Lombardi Comprehens Canc Ctr, Washington, DC 20007 USA; Univ Texas, MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA; Dept Vet Affairs Med Ctr, Washington, DC USA; Temple Univ, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19122 USA	Georgetown University; Georgetown University; Georgetown University; Georgetown University; University of Texas System; UTMD Anderson Cancer Center; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Mishra, L (corresponding author), Georgetown Univ, Dept Surg, Med Dent Bldg,Room NW 207-213,Reservoir Rd,NW, Washington, DC 20007 USA.	lm229@georgetown.edu	Reddy, E. Premkumar/F-6233-2011; Ganesan, Natarajan/C-8080-2012; Volpe, Eugene A./D-2000-2012	Volpe, Eugene A./0000-0002-9128-754X; Mishra, Lopa/0000-0002-6850-0808	NATIONAL CANCER INSTITUTE [R01CA042857, P01CA095569, R01CA106614] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056111] Funding Source: NIH RePORTER; NCI NIH HHS [P01CA095569, R01 CA4285718A, R01 CA106614A, P01 CA095569, R01 CA042857, R01 CA106614] Funding Source: Medline; NIDDK NIH HHS [R01 DK056111, R01 DK56111, R01 DK58637] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Attisano L, 2002, SCIENCE, V296, P1646, DOI 10.1126/science.1071809; Breuhahn K, 2006, ONCOGENE, V25, P3787, DOI 10.1038/sj.onc.1209556; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; Edamoto Y, 2003, INT J CANCER, V106, P334, DOI 10.1002/ijc.11254; EDMONDSON HA, 1954, CANCER-AM CANCER SOC, V7, P462, DOI 10.1002/1097-0142(195405)7:3<462::AID-CNCR2820070308>3.0.CO;2-E; El-Serag HB, 2004, GASTROENTEROLOGY, V127, pS27, DOI 10.1053/j.gastro.2004.09.013; Feitelson MA, 1999, J CELL PHYSIOL, V181, P188; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; Huo TI, 2001, ONCOGENE, V20, P3620, DOI 10.1038/sj.onc.1204495; Ishizaki Y, 2004, INT J ONCOL, V24, P1077; Ito Y, 1999, HEPATOLOGY, V30, P90, DOI 10.1002/hep.510300114; Joo M, 2001, LIVER, V21, P89, DOI 10.1034/j.1600-0676.2001.021002089.x; Kanzler S, 2001, ONCOGENE, V20, P5015, DOI 10.1038/sj.onc.1204544; Kiss A, 1997, CLIN CANCER RES, V3, P1059; Knudsen KE, 2006, ONCOGENE, V25, P1620, DOI 10.1038/sj.onc.1209371; Ko TC, 1998, ONCOGENE, V16, P3445, DOI 10.1038/sj.onc.1201902; Longerich T, 2004, VIRCHOWS ARCH, V445, P589, DOI 10.1007/s00428-004-1118-x; Macdonald GA, 1998, HEPATOLOGY, V28, P90, DOI 10.1002/hep.510280114; Malumbres M, 2001, NAT REV CANCER, V1, P222, DOI 10.1038/35106065; Masaki T, 2003, HEPATOLOGY, V37, P534, DOI 10.1053/jhep.2003.50112; Mishra L, 1999, ONCOGENE, V18, P353, DOI 10.1038/sj.onc.1202313; Mishra L, 2005, ONCOGENE, V24, P5775, DOI 10.1038/sj.onc.1208924; Park YN, 2004, HEPATO-GASTROENTEROL, V51, P396; Parkin DM, 2001, INT J CANCER, V94, P153, DOI 10.1002/ijc.1440; Pavio N, 2005, ONCOGENE, V24, P6119, DOI 10.1038/sj.onc.1208749; QUARONI A, 1979, J CELL BIOL, V80, P248, DOI 10.1083/jcb.80.2.248; Roberts LR, 2005, SEMIN LIVER DIS, V25, P212, DOI 10.1055/s-2005-871200; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Siegel PM, 2003, P NATL ACAD SCI USA, V100, P8430, DOI 10.1073/pnas.0932636100; SUE SR, 1995, ANN SURG, V222, P171, DOI 10.1097/00000658-199508000-00009; Sundarrajan M, 2002, CELL BIOL INT, V26, P699, DOI 10.1006/cbir.2002.0923; Tang BW, 1998, NAT MED, V4, P802, DOI 10.1038/nm0798-802; Tang Y, 2005, CANCER RES, V65, P4228, DOI 10.1158/0008-5472.CAN-04-4585; Tang Y, 2003, SCIENCE, V299, P574, DOI 10.1126/science.1075994; Tang Y, 2002, ONCOGENE, V21, P5255, DOI 10.1038/sj.onc.1205548; Taniguchi K, 2002, ONCOGENE, V21, P4863, DOI 10.1038/sj.onc.1205591; Thorgeirsson SS, 2002, NAT GENET, V31, P339, DOI 10.1038/ng0802-339; TINIAKOS D, 1993, HEPATO-GASTROENTEROL, V40, P37; Tsukazaki T, 1998, CELL, V95, P779, DOI 10.1016/S0092-8674(00)81701-8; UEDA H, 1995, NAT GENET, V9, P41, DOI 10.1038/ng0195-41; Ueta T, 2002, ONCOL REP, V9, P1197; Yakicier MC, 1999, ONCOGENE, V18, P4879, DOI 10.1038/sj.onc.1202866; Yamamoto H, 2000, INT J ONCOL, V16, P543; Zhang YJ, 2002, MOL CARCINOGEN, V33, P125, DOI 10.1002/mc.10028	44	100	103	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 1	2007	26	50					7103	7110		10.1038/sj.onc.1210513	http://dx.doi.org/10.1038/sj.onc.1210513			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	228GF	17546056	Green Accepted			2022-12-28	WOS:000250715000004
J	Pauleau, AL; Larochette, N; Giordanetto, F; Scholz, SR; Poncet, D; Zamzami, N; Goldmacher, VS; Kroemer, G				Pauleau, A-L; Larochette, N.; Giordanetto, F.; Scholz, S. R.; Poncet, D.; Zamzami, N.; Goldmacher, V. S.; Kroemer, G.			Structure-function analysis of the interaction between Bax and the cytomegalovirus-encoded protein vMIA	ONCOGENE			English	Article						cytomegalovirus; vMIA; mitochondria; Bak; Bax; apoptosis	CELL-DEATH; INDUCED APOPTOSIS; BCL-XL; MITOCHONDRIA; INHIBITOR; INFECTION; CANCER; LOCALIZATION; RECOGNITION; ACTIVATION	The viral mitochondrial inhibitor of apoptosis ( vMIA) encoded by the human cytomegalovirus exerts cytopathic effects and neutralizes the proapoptotic endogenous Bcl-2 family member Bax by recruiting it to mitochondria, inducing its oligomerization and membrane insertion. Using a combination of computational modeling and mutational analyses, we addressed the structure-function relationship of the molecular interaction between the protein Bax and the viral antiapoptotic protein vMIA. We propose a model in which vMIA exhibits an overall fold similar to Bcl-X-L. In contrast to Bcl-X-L, however, this predicted conformation of vMIA does not bind to the BH3 domain of Bax and rather engages in electrostatic interactions that involve a stretch of amino acids between the BH3 and BH2 domains of Bax and an alpha-helical domain located within the previously defined Bax-binding domain of vMIA, between the putative BH1-like and BH2-like domains. According to this model, vMIA is likely to bind Bax preferentially in its membrane-inserted conformation. The capacity of vMIA to cause fragmentation of the mitochondrial network and disorganization of the actin cytoskeleton is independent of its Bax-binding function. We found that Delta 131-147 vMIA mutant, which lacks both the Bax-binding function and cell-death suppression but has intact mitochondria-targeting capacity, is similar to vMIA in its ability to disrupt the mitochondrial network and to disorganize the actin cytoskeleton. vMIA Delta 131-147 is a dominant-negative inhibitor of the antiapoptotic function of wild-type vMIA. Our experiments with vMIA Delta 131-147 suggest that vMIA forms homo-oligomers, which may engage in cooperative and/or multivalent interactions with Bax, leading to its functional neutralization.	Inst Gustave Roussy, INSERM, U848, F-94805 Villejuif, France; Univ Paris 11, Fac Med, Villejuif, France; AstraZeneca R&D, Lead Generat, Molndal, Sweden; ImmunoGen Inc, Cambridge, MA USA	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy; UDICE-French Research Universities; Universite Paris Saclay; AstraZeneca; ImmunoGen, Inc.	Kroemer, G (corresponding author), Inst Gustave Roussy, INSERM, U848, PR1,39 Rue Camille Desmoulins, F-94805 Villejuif, France.	kroemer@igr.fr	Kroemer, Guido/AAY-9859-2020; Poncet, Delphine A/A-7190-2016; KROEMER, Guido/B-4263-2013; LAROCHETTE, Nathanael/R-4298-2017; Giordanetto, Fabrizio/E-2811-2012	Poncet, Delphine A/0000-0003-0446-5262; KROEMER, Guido/0000-0002-9334-4405; LAROCHETTE, Nathanael/0000-0002-7936-678X; Goldmakher, Viktor/0000-0001-6130-4436				ALTSCHUL SF, 1997, NUCLEIC ACIDS RES, V25, P3402; Annis MG, 2005, EMBO J, V24, P2096, DOI 10.1038/sj.emboj.7600675; Antonsson B, 2001, J BIOL CHEM, V276, P11615, DOI 10.1074/jbc.M010810200; Arnoult D, 2004, P NATL ACAD SCI USA, V101, P7988, DOI 10.1073/pnas.0401897101; Castedo M, 2002, J IMMUNOL METHODS, V265, P39, DOI 10.1016/S0022-1759(02)00069-8; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; Day CL, 2005, J BIOL CHEM, V280, P4738, DOI 10.1074/jbc.M411434200; Froberg MK, 2004, ANN CLIN LAB SCI, V34, P123; Gabb HA, 1997, J MOL BIOL, V272, P106, DOI 10.1006/jmbi.1997.1203; Galluzzi L, 2006, ONCOGENE, V25, P4812, DOI 10.1038/sj.onc.1209598; Garcia-Saez AJ, 2004, BIOCHEMISTRY-US, V43, P10930, DOI 10.1021/bi036044c; Goldmacher VS, 2005, APOPTOSIS, V10, P251, DOI 10.1007/s10495-005-0800-z; Goldmacher VS, 1999, P NATL ACAD SCI USA, V96, P12536, DOI 10.1073/pnas.96.22.12536; Green DR, 2005, CELL, V121, P671, DOI 10.1016/j.cell.2005.05.019; Harkins L, 2002, LANCET, V360, P1557, DOI 10.1016/S0140-6736(02)11524-8; Hassan M, 1996, MOL DIVERS, V2, P64, DOI 10.1007/BF01718702; Hayajneh WA, 2001, VIROLOGY, V279, P233, DOI 10.1006/viro.2000.0726; Hoever G, 2005, BIOCHEM BIOPH RES CO, V326, P395, DOI 10.1016/j.bbrc.2004.11.042; Huang JH, 2005, CIRCULATION, V112, P76, DOI 10.1161/CIRCULATIONAHA.105.535740; Jackson RM, 1998, J MOL BIOL, V276, P265, DOI 10.1006/jmbi.1997.1519; Jurak I, 2006, EMBO J, V25, P2634, DOI 10.1038/sj.emboj.7601133; Kelley LA, 2000, J MOL BIOL, V299, P499, DOI 10.1006/jmbi.2000.3741; Lang-Rollin I, 2005, APOPTOSIS, V10, P809, DOI 10.1007/s10495-005-0378-5; Matsuyama S, 2000, NAT CELL BIOL, V2, P318, DOI 10.1038/35014006; Mavinakere MS, 2006, J VIROL, V80, P6771, DOI 10.1128/JVI.00492-06; McCormick AL, 2005, J VIROL, V79, P12205, DOI 10.1128/JVI.79.19.12205-12217.2005; McDonnell JM, 1999, CELL, V96, P625, DOI 10.1016/S0092-8674(00)80573-5; McGuffin LJ, 2003, BIOINFORMATICS, V19, P874, DOI 10.1093/bioinformatics/btg097; McMartin C, 1997, J COMPUT AID MOL DES, V11, P333, DOI 10.1023/A:1007907728892; Michelson S, 2004, HUM IMMUNOL, V65, P465, DOI 10.1016/j.humimm.2004.02.002; Moont G, 1999, PROTEINS, V35, P364, DOI 10.1002/(SICI)1097-0134(19990515)35:3<364::AID-PROT11>3.0.CO;2-4; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; Obeid M, 2007, NAT MED, V13, P54, DOI 10.1038/nm1523; Poncet D, 2004, J BIOL CHEM, V279, P22605, DOI 10.1074/jbc.M308408200; Poncet D, 2006, J CELL BIOL, V174, P985, DOI 10.1083/jcb.200604069; Reboredo M, 2004, J GEN VIROL, V85, P3555, DOI 10.1099/vir.0.80379-0; Reed JC, 2006, CELL DEATH DIFFER, V13, P1378, DOI 10.1038/sj.cdd.4401975; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Samanta M, 2003, J UROLOGY, V170, P998, DOI 10.1097/01.ju.0000080263.46164.97; Sattler M, 1997, SCIENCE, V275, P983, DOI 10.1126/science.275.5302.983; Skaletskaya A, 2001, P NATL ACAD SCI USA, V98, P7829, DOI 10.1073/pnas.141108798; Smith MS, 2004, J LEUKOCYTE BIOL, V76, P65, DOI 10.1189/jlb.1203621; Suzuki M, 2000, CELL, V103, P645, DOI 10.1016/S0092-8674(00)00167-7; Terrasson J, 2005, CANCER RES, V65, P2787, DOI 10.1158/0008-5472.CAN-04-2019; Vieira HLA, 2001, ONCOGENE, V20, P4305, DOI 10.1038/sj.onc.1204575; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281	47	44	47	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 1	2007	26	50					7067	7080		10.1038/sj.onc.1210511	http://dx.doi.org/10.1038/sj.onc.1210511			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	228GF	17496930				2022-12-28	WOS:000250715000001
J	Meng, X; Fan, J; Shen, Z				Meng, X.; Fan, J.; Shen, Z.			Roles of BCCIP in chromosome stability and cytokinesis	ONCOGENE			English	Article						cytokinesis; chromosome instability; BRCA2; BCCIP; polyploidy	CENTROSOME AMPLIFICATION; CANCER SUSCEPTIBILITY; PROTEIN; BRCA2; P53; INHIBITION; EXPRESSION; PATHWAYS; ARREST; BREAST	The BRCA2 gene is involved in recombinational DNA repair and cytokinesis. BRCA2 defects are associated with chromosomal abnormalities, which is a hallmark of genomic instability that contributes to tumorigenesis. Here, we show that downregulation of a BRCA2 interacting protein ( BCCIP) in HT1080 cells leads to chromosomal polyploidization, centrosome amplification and abnormal mitotic spindle formation. The BCCIP knockdown cells can enter mitosis and retain spindle checkpoint, but fail to complete cytokinesis. Our data suggest an essential role of BCCIP in the maintenance of genomic integrity.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Canc Inst New Jersey, Dept Radiat Oncol, New Brunswick, NJ 08903 USA; Univ New Mexico, Sch Med, Dept Mol Genet & Microbiol, Albuquerque, NM 87131 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey; University of New Mexico	Shen, Z (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Canc Inst New Jersey, Dept Radiat Oncol, 195 Little Albany St, New Brunswick, NJ 08903 USA.	shenzh@umdnj.edu		Shen, Zhiyuan/0000-0003-2834-0309; meng, xiangbing/0000-0002-9612-6438	NCI NIH HHS [R01 CA115488, R01 CA115488-04, R01 CA115488-02, R01 CA115488-01, R01 CA115488-03, CA115488] Funding Source: Medline; NIEHS NIH HHS [ES08353, R01 ES008353, R29 ES008353] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA115488] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R29ES008353, R01ES008353] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Andreassen PR, 2001, MOL BIOL CELL, V12, P1315, DOI 10.1091/mbc.12.5.1315; Daniels MJ, 2004, SCIENCE, V306, P876, DOI 10.1126/science.1102574; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; Geddis AE, 2004, BLOOD, V104, P1017, DOI 10.1182/blood-2004-02-0419; Hans F, 2001, ONCOGENE, V20, P3021, DOI 10.1038/sj.onc.1204326; Jallepalli PV, 2001, CELL, V105, P445, DOI 10.1016/S0092-8674(01)00340-3; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Liu JM, 2001, ONCOGENE, V20, P336, DOI 10.1038/sj.onc.1204098; Lu HM, 2005, MOL CELL BIOL, V25, P1949, DOI 10.1128/MCB.25.5.1949-1957.2005; Maier D, 1998, ONCOGENE, V16, P3331, DOI 10.1038/sj.onc.1201832; Margolis RL, 2003, J CELL BIOCHEM, V88, P673, DOI 10.1002/jcb.10411; Meng XB, 2004, CELL CYCLE, V3, P1457, DOI 10.4161/cc.3.11.1213; Meng XB, 2004, CELL CYCLE, V3, P343; Meng XB, 2004, J BIOL CHEM, V279, P6098, DOI 10.1074/jbc.M306794200; Meng XB, 2003, GENE, V302, P139, DOI 10.1016/S0378-1119(02)01098-3; Meng XB, 2007, J BIOL CHEM, V282, P1570, DOI 10.1074/jbc.M607520200; Meraldi P, 2002, EMBO J, V21, P483, DOI 10.1093/emboj/21.4.483; Merlo A, 2003, NEUROSURG REV, V26, P145, DOI 10.1007/s10143-003-0267-8; Moynahan ME, 2001, MOL CELL, V7, P263, DOI 10.1016/S1097-2765(01)00174-5; Ohgaki H, 2004, CANCER RES, V64, P6892, DOI 10.1158/0008-5472.CAN-04-1337; Ono T, 2000, J BIOL CHEM, V275, P31145, DOI 10.1074/jbc.M003031200; Powell SN, 2003, ONCOGENE, V22, P5784, DOI 10.1038/sj.onc.1206678; RASHEED BKA, 1992, GENE CHROMOSOME CANC, V5, P75, DOI 10.1002/gcc.2870050111; Roversi G, 2006, ONCOGENE, V25, P1571, DOI 10.1038/sj.onc.1209177; Rudkin TM, 2005, TRENDS MOL MED, V11, P145, DOI 10.1016/j.molmed.2005.02.003; SHINMURA K, 2006, ONCOGENE; Tarapore P, 2002, ONCOGENE, V21, P6234, DOI 10.1038/sj.onc.1205707; Tarapore P, 2001, ONCOGENE, V20, P3173, DOI 10.1038/sj.onc.1204424; Venkitaraman AR, 2002, CELL, V108, P171, DOI 10.1016/S0092-8674(02)00615-3	29	38	38	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 20	2007	26	43					6253	6260		10.1038/sj.onc.1210460	http://dx.doi.org/10.1038/sj.onc.1210460			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	212GW	17452982	Green Accepted			2022-12-28	WOS:000249583300001
J	Aleksic, T; Bechtel, M; Krndija, D; von Wichert, G; Knobel, B; Giehl, K; Gress, TM; Michl, P				Aleksic, T.; Bechtel, M.; Krndija, D.; von Wichert, G.; Knobel, B.; Giehl, K.; Gress, T. M.; Michl, P.			CUTL1 promotes tumor cell migration by decreasing proteasome-mediated Src degradation	ONCOGENE			English	Article						CUTL1; migration; Src; Csk; spreading	PROTEIN-TYROSINE KINASES; FAMILY KINASES; ACTIVATION; ADHESION; BETA; DISPLACEMENT; MODULATION; MECHANISMS; MOTILITY; INTEGRIN	Recently, we identified the homeodomain transcription factor CUTL1 as important mediator of cell migration and tumor invasion downstream of transforming growth factor beta ( TGFb). The molecular mechanisms and effectors mediating the pro-migratory and pro-invasive phenotype induced by CUTL1 have not been elucidated so far. Therefore, the aim of this study was to identify signaling pathways downstream of CUTL1 which are responsible for its effects on tumor cell migration. We found that the reduced motility seen after knock down of CUTL1 by RNA interference is accompanied by a delay in tumor cell spreading. This spreading defect is paralleled by a marked reduction of Src protein levels. We show that CUTL1 leads to Src protein stabilization and activation of Src-regulated downstream signaling molecules such as RhoA, Rac1, Cdc42 and ROCK. In addition, we demonstrate that CUTL1 decreases proteasome-mediated Src protein degradation, possibly via transcriptionally upregulating C-terminal Src kinase (Csk). Based on experiments using Src knockout cells ( SYF), we present evidence that Src plays a crucial role in CUTL1-induced tumor cell migration. In conclusion, our findings linking the pro-invasive transcription factor CUTL1 and the Src pathway provide important new insights in the molecular effector pathways mediating CUTL-induced migration and invasion.	Univ Marburg, Dept Internal Med, Div Gastroenterol & Endocrinol, D-35043 Marburg, Germany; Univ Ulm, Dept Internal Med 1, D-7900 Ulm, Germany; Univ Ulm, Dept Pharmacol & Toxicol, D-7900 Ulm, Germany	Philipps University Marburg; Ulm University; Ulm University	Michl, P (corresponding author), Univ Marburg, Dept Internal Med, Div Gastroenterol, Baklingerstr, D-35043 Marburg, Germany.	michlp@med.uni-marburg.de	Krndija, Denis/AAR-5918-2020; Michl, Patrick/HDN-4172-2022; Michl, Patrick/AAG-3987-2021	Krndija, Denis/0000-0001-8686-7542; Gress, Thomas/0000-0002-9333-5461				Amano M, 1996, J BIOL CHEM, V271, P20246, DOI 10.1074/jbc.271.34.20246; Burridge K, 1996, ANNU REV CELL DEV BI, V12, P463, DOI 10.1146/annurev.cellbio.12.1.463; Hakak Y, 1999, CURR BIOL, V9, P1039, DOI 10.1016/S0960-9822(99)80453-9; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; HYNES RO, 1992, CELL, V68, P303, DOI 10.1016/0092-8674(92)90472-O; Johnson FM, 2005, CLIN CANCER RES, V11, P6924, DOI 10.1158/1078-0432.CCR-05-0757; Kaido T, 2004, J BIOL CHEM, V279, P53762, DOI 10.1074/jbc.M411202200; Klinghoffer RA, 1999, EMBO J, V18, P2459, DOI 10.1093/emboj/18.9.2459; Lowell CA, 1996, GENE DEV, V10, P1845, DOI 10.1101/gad.10.15.1845; Lowry WE, 2002, DEV CELL, V2, P733, DOI 10.1016/S1534-5807(02)00175-2; Ma YC, 2000, CELL, V102, P635, DOI 10.1016/S0092-8674(00)00086-6; Michl P, 2005, CANCER CELL, V7, P521, DOI 10.1016/j.ccr.2005.05.018; Moarefi I, 1997, NATURE, V385, P650, DOI 10.1038/385650a0; Nepveu A, 2001, GENE, V270, P1, DOI 10.1016/S0378-1119(01)00485-1; Parsons JT, 1997, CURR OPIN CELL BIOL, V9, P187, DOI 10.1016/S0955-0674(97)80062-2; Parsons JT, 1996, CURR OPIN CELL BIOL, V8, P146, DOI 10.1016/S0955-0674(96)80059-7; Price JT, 1997, CRIT REV BIOCHEM MOL, V32, P175, DOI 10.3109/10409239709082573; Riento K, 2003, NAT REV MOL CELL BIO, V4, P446, DOI 10.1038/nrm1128; Roskoski R, 2004, BIOCHEM BIOPH RES CO, V324, P1155, DOI 10.1016/j.bbrc.2004.09.171; Stahle M, 2003, J CELL SCI, V116, P3835, DOI 10.1242/jcs.00679; STOVER DR, 1994, J BIOL CHEM, V269, P26885; Tan M, 2005, CANCER RES, V65, P1858, DOI 10.1158/0008-5472.CAN-04-2353; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Weber CK, 2000, GASTROENTEROLOGY, V119, P1209, DOI 10.1053/gast.2000.19458; Zheng XM, 2000, EMBO J, V19, P964, DOI 10.1093/emboj/19.5.964	25	19	20	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 30	2007	26	40					5939	5949		10.1038/sj.onc.1210398	http://dx.doi.org/10.1038/sj.onc.1210398			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	205OH	17369846				2022-12-28	WOS:000249123100011
J	Rose-Hellekant, TA; Schroeder, MD; Brockman, JL; Zhdankin, O; Bolstad, R; Chen, KS; Gould, MN; Schuler, LA; Sandgren, EP				Rose-Hellekant, T. A.; Schroeder, M. D.; Brockman, J. L.; Zhdankin, O.; Bolstad, R.; Chen, K. S.; Gould, M. N.; Schuler, L. A.; Sandgren, E. P.			Estrogen receptor-positive mammary tumorigenesis in TGF alpha transgenic mice progresses with progesterone receptor loss	ONCOGENE			English	Article						breast cancer; mammary cancer; TGF alpha; transgenic mice; estrogen receptor; progesterone receptor	GROWTH-FACTOR-ALPHA; BREAST-CANCER CELLS; C-MYC; MOUSE MAMMARY; EXPRESSION; PROLACTIN; OVEREXPRESSION; INDUCTION; PHENOTYPE; CARCINOMA	We characterized the novel NRL-transforming growth factor alpha (NRL-TGF alpha) transgenic mouse model in which growth factor - steroid receptor interactions were explored. The NRL promoter directs transgene expression to mammary ductal and alveolar cells and is nonresponsive to estrogen manipulations in vitro and in vivo. NRL-TGF alpha mice acquire proliferative hyperplasias as well as cystic and solid tumors. Quantitative transcript analysis revealed a progressive decrease in estrogen receptor alpha ( ER) and progesterone receptor (PR) mRNA levels with tumorigenesis. However, ER protein was evident in all lesion types and in surrounding stromal cells using immunohistochemistry. PR protein was identified in normal epithelial cells and in very few cells of small epithelial hyperplasias, but never in stromal or tumor cells. Prophylactic ovariectomy significantly delayed tumor development and decreased incidence. Finally, while heterozygous (+/- ) p53 mice did not acquire mammary lesions, p53 +/- mice carrying the NRL-TGF alpha transgene developed ER negative/PR negative undifferentiated carcinomas. These data demonstrate that unregulated TGF alpha expression in the mammary gland leads to oncogenesis that is dependent on ovarian steroids early in tumorigenesis. Resulting tumors resemble a clinical phenotype of ER+/ PR-, and when combined with a heterozygous p53 genotype, ER-/PR-.	Univ Minnesota, Sch Med, Dept Physiol & Pharmacol, Duluth, MN 55812 USA; Univ Wisconsin, Dept Pathobiol Sci, Madison, WI 53706 USA; Univ Wisconsin, Sch Vet Med, Dept Comparat Biosci, Madison, WI USA; Univ Wisconsin, Sch Med, Dept Oncol, Madison, WI USA	University of Minnesota System; University of Minnesota Duluth; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Rose-Hellekant, TA (corresponding author), Univ Minnesota, Sch Med, Dept Physiol & Pharmacol, Duluth, MN 55812 USA.	trosehel@d.umn.edu	Gould, Michael N/C-7414-2014		NATIONAL CANCER INSTITUTE [R01CA078312, R01CA058328, R01CA064843] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [K01RR000145] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES009090] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA078312-03S2, R01-CA78312, R01 CA078312-03S1, R01 CA078312-03, R01-CA58328, R01-CA64843, R01 CA078312, R01 CA078312-04A1, R01 CA078312-02S1] Funding Source: Medline; NCRR NIH HHS [K01-RR00145] Funding Source: Medline; NIEHS NIH HHS [ES09090] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ADAN RAH, 1992, J BIOL CHEM, V267, P3771; AMUNDADOTTIR LT, 1995, CELL GROWTH DIFFER, V6, P737; Arendt LM, 2006, AM J PATHOL, V168, P1365, DOI 10.2353/ajpath.2006.050861; Arpino G, 2005, JNCI-J NATL CANCER I, V97, P1254, DOI 10.1093/jnci/dji249; Bieche I, 2003, INT J CANCER, V106, P758, DOI 10.1002/ijc.11273; Blackburn AC, 2003, CANCER RES, V63, P2364; Blackburn AC, 2002, BREAST CANCER RES, V4, P98; BRINSTER RL, 1985, P NATL ACAD SCI USA, V82, P4438, DOI 10.1073/pnas.82.13.4438; Creighton CJ, 2006, CANCER RES, V66, P3903, DOI 10.1158/0008-5472.CAN-05-4363; Gee JM, 2005, ENDOCR-RELAT CANCER, V12, pS99, DOI 10.1677/erc.1.01005; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; Grippo PJ, 2000, AM J PATHOL, V157, P805, DOI 10.1016/S0002-9440(10)64594-4; Gunther EJ, 2002, FASEB J, V16, DOI 10.1096/fj.01-0551com; GURURAJ AE, 2006, CLIN CANC RES, V12; Gutzman JH, 2005, MOL ENDOCRINOL, V19, P1765, DOI 10.1210/me.2004-0339; Hewitt SC, 2002, CANCER RES, V62, P2798; Holbro T, 2003, EXP CELL RES, V284, P99, DOI 10.1016/S0014-4827(02)00099-X; Humphreys RC, 2000, ONCOGENE, V19, P1085, DOI 10.1038/sj.onc.1203278; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Jerry DJ, 2000, ONCOGENE, V19, P1052, DOI 10.1038/sj.onc.1203270; Kisseberth WC, 1999, DEV BIOL, V214, P128, DOI 10.1006/dbio.1999.9417; Kuperwasser C, 2000, AM J PATHOL, V157, P2151, DOI 10.1016/S0002-9440(10)64853-5; Lee S, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1367; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Medina D, 2003, CANCER RES, V63, P6140; OTTEN AD, 1988, MOL ENDOCRINOL, V2, P143, DOI 10.1210/mend-2-2-143; Pfaffl MW, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.9.e36; Pfaffl MW, 2004, BIOTECHNOL LETT, V26, P509, DOI 10.1023/B:BILE.0000019559.84305.47; Pierson-Mullany Lisa K, 2003, Breast Dis, V18, P21; ROBINSON GW, 1995, DEVELOPMENT, V121, P2079; Rose-Hellekant TA, 2003, ONCOGENE, V22, P4664, DOI 10.1038/sj.onc.1206619; Rose-Hellekant TA, 2002, AM J PATHOL, V161, P1439, DOI 10.1016/S0002-9440(10)64419-7; Rose-Hellekant TA, 2000, ONCOGENE, V19, P1092, DOI 10.1038/sj.onc.1203350; Rudland PS, 1995, BIOMED PHARMACOTHER, V49, P389, DOI 10.1016/0753-3322(96)82676-X; SANDGREN EP, 1990, CELL, V61, P1121, DOI 10.1016/0092-8674(90)90075-P; SANDGREN EP, 1995, CANCER RES, V55, P3915; Stoesz SP, 1995, ONCOGENE, V11, P2233; Zhang XM, 2005, ONCOGENE, V24, P4220, DOI 10.1038/sj.onc.1208597	38	18	18	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 9	2007	26	36					5238	5246		10.1038/sj.onc.1210340	http://dx.doi.org/10.1038/sj.onc.1210340			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	199CQ	17334393	Green Accepted			2022-12-28	WOS:000248674200007
J	Ma, X; Kalakonda, S; Srinivasula, SM; Reddy, SP; Platanias, LC; Kalvakolanu, DV				Ma, X.; Kalakonda, S.; Srinivasula, S. M.; Reddy, S. P.; Platanias, L. C.; Kalvakolanu, D. V.			GRIM-19 associates with the serine protease HtrA2 for promoting cell death	ONCOGENE			English	Article						cytokines; vitamins; cancer; cell death; growth; suppression	RETINOIC ACID; TUMOR-DEVELOPMENT; CASPASE ACTIVITY; IFN-GAMMA; APOPTOSIS; INHIBITOR; OMI/HTRA2; MITOCHONDRIA; REGULATOR; INTERACTS	We have isolated a novel interferon (IFN)-retinoid regulated cell death regulatory protein genes associated with retinoid-IFN-induced mortality (GRIM)-19 earlier. To understand its mechanism of action, we have employed a yeast-two-hybrid screen and identified serine protease HtrA2 as its binding partner. GRIM-19 physically interacts with HtrA2 and augments cell death in an IFN/all-trans retinoic acid (RA)-dependent manner. In the presence of GRIM-19, the HtrA2-driven destruction of the antiapoptotic protein X-linked inhibitor of apoptosis (XIAP) is augmented. These interactions were disrupted by an human herpes virus-8 (HHV-8)-coded oncoprotein, vIRF1, and conferred resistance to IFN/RA-induced cell death. These data show a critical role of HtrA2 in a cytokine-induced cell death response for the. rst time and its inhibition by a viral protein.	Univ Maryland, Greenbaum Canc Ctr, Dept Microbiol & Immunol, Sch Med, Baltimore, MD 21201 USA; NCI, Lab Immune Cell Biol, Bethesda, MD 20892 USA; Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Environm Hlth Sci, Baltimore, MD USA; Northwestern Univ, Sch Med, Lurie Canc Ctr, Div Hematol & Oncol, Chicago, IL 60611 USA	University System of Maryland; University of Maryland Baltimore; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Northwestern University; Robert H. Lurie Comprehensive Cancer Center	Kalvakolanu, DV (corresponding author), Univ Maryland, Greenbaum Canc Ctr, Dept Microbiol & Immunol, Sch Med, Baltimore, MD 21201 USA.	dkalvako@umaryland.edu			NATIONAL CANCER INSTITUTE [R01CA105005] Funding Source: NIH RePORTER; NCI NIH HHS [CA105005] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Altucci L, 2001, NAT REV CANCER, V1, P181, DOI 10.1038/35106036; Angell JE, 2000, J BIOL CHEM, V275, P33416, DOI 10.1074/jbc.M003929200; CHOMIENNE C, 1990, BLOOD, V76, P1710; DALE TC, 1989, P NATL ACAD SCI USA, V86, P1203, DOI 10.1073/pnas.86.4.1203; Fearnley IM, 2001, J BIOL CHEM, V276, P38345, DOI 10.1074/jbc.C100444200; Gao SJ, 1997, ONCOGENE, V15, P1979, DOI 10.1038/sj.onc.1201571; Gresser I, 2002, CYTOKINE GROWTH F R, V13, P111, DOI 10.1016/S1359-6101(01)00035-1; Gupta S, 2004, J BIOL CHEM, V279, P45844, DOI 10.1074/jbc.M404940200; Hegde R, 2002, J BIOL CHEM, V277, P432, DOI 10.1074/jbc.M109721200; Hu JD, 2002, J INTERF CYTOK RES, V22, P1017, DOI 10.1089/107999002760624242; Ikeda H, 2002, CYTOKINE GROWTH F R, V13, P95, DOI 10.1016/S1359-6101(01)00038-7; Jayachandra S, 1999, P NATL ACAD SCI USA, V96, P11566, DOI 10.1073/pnas.96.20.11566; Jin SK, 2003, GENE DEV, V17, P359, DOI 10.1101/gad.1047003; Kalvakolanu DV, 2004, CYTOKINE GROWTH F R, V15, P169, DOI 10.1016/j.cytogfr.2004.01.002; KALVAKOLANU DV, 2002, ENCY CANC, V2, P511; Kuninaka S, 2005, ONCOGENE, V24, P5287, DOI 10.1038/sj.onc.1208682; Li WY, 2002, NAT STRUCT BIOL, V9, P436, DOI 10.1038/nsb795; Martins LM, 2002, J BIOL CHEM, V277, P439, DOI 10.1074/jbc.M109784200; Seo T, 2002, J VIROL, V76, P8797, DOI 10.1128/JVI.76.17.8797-8807.2002; Shankaran V, 2001, NATURE, V410, P1107, DOI 10.1038/35074122; Stennicke HR, 1999, J BIOL CHEM, V274, P8359, DOI 10.1074/jbc.274.13.8359; Suzuki Y, 2001, MOL CELL, V8, P613, DOI 10.1016/S1097-2765(01)00341-0; van Loo G, 2002, CELL DEATH DIFFER, V9, P20, DOI 10.1038/sj.cdd.4400970; VanderHeiden MG, 1997, CELL, V91, P627, DOI 10.1016/S0092-8674(00)80450-X; Vaux DL, 2003, BIOCHEM BIOPH RES CO, V304, P499, DOI 10.1016/S0006-291X(03)00622-3; Yang QH, 2003, GENE DEV, V17, P1487, DOI 10.1101/gad.1097903; Zhang J, 2003, P NATL ACAD SCI USA, V100, P9342, DOI 10.1073/pnas.1633516100; Zimring JC, 1998, J VIROL, V72, P701, DOI 10.1128/JVI.72.1.701-707.1998	28	32	33	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 19	2007	26	33					4842	4849		10.1038/sj.onc.1210287	http://dx.doi.org/10.1038/sj.onc.1210287			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	191ZL	17297443				2022-12-28	WOS:000248170400009
J	Kawada, K; Hosogi, H; Sonoshita, M; Sakashita, H; Manabe, T; Shimahara, Y; Sakai, Y; Takabayashi, A; Oshima, M; Taketo, MM				Kawada, K.; Hosogi, H.; Sonoshita, M.; Sakashita, H.; Manabe, T.; Shimahara, Y.; Sakai, Y.; Takabayashi, A.; Oshima, M.; Taketo, M. M.			Chemokine receptor CXCR3 promotes colon cancer metastasis to lymph nodes	ONCOGENE			English	Article						CXCR3; colon cancer; lymph node; metastasis	COLORECTAL-CANCER; ENDOTHELIAL-CELLS; BREAST-CANCER; IFN-GAMMA; EPITHELIAL-CELLS; CUTTING EDGE; PIVOTAL ROLE; T-CELLS; EXPRESSION; CC	Chemokines and their receptors are essential for leukocyte trafficking, and also implicated in cancer metastasis to specific organs. We have recently demonstrated that CXCR3 plays a critical role in metastasis of mouse melanoma cells to lymph nodes. Here, we show that some human colon cancer cell lines express CXCR3 constitutively. We constructed cells that expressed CXCR3 cDNA (`DLD-1-CXCR3'), and compared with nonexpressing controls by rectal transplantation in nude mice. Although both cell lines disseminated to lymph nodes at similar frequencies at 2 weeks, DLD-1-CXCR3 expanded more rapidly than the control in 4 weeks. In 6 weeks, 59% of mice inoculated with DLD1-CXCR3 showed macroscopic metastasis in para-aortic lymph nodes, whereas only 14% of those with the control (P < 0.05). In contrast, metastasis to the liver or lung was rare, and unaffected by CXCR3 expression. In clinical colon cancer samples, we found expression of CXCR3 in 34% cases, most of which had lymph node metastasis. Importantly, patients with CXCR3-positive cancer showed significantly poorer prognosis than those without CXCR3, or those expressing CXCR4 or CCR7. These results indicate that activation of CXCR3 with its ligands stimulates colon cancer metastasis preferentially to the draining lymph nodes with poorer prognosis.	Kyoto Univ, Grad Sch Med, Dept Pharmacol, Kyoto 6068501, Japan; Kyoto Univ, Grad Sch Med, Dept Surg, Kyoto, Japan; Kyoto Univ, Grad Sch Med, Dept Clin Pathol, Kyoto, Japan; Kitano Hosp, Inst Med, Osaka, Japan	Kyoto University; Kyoto University; Kyoto University; Kitano Hospital	Taketo, MM (corresponding author), Kyoto Univ, Grad Sch Med, Dept Pharmacol, Kyoto 6068501, Japan.	taketo@mfour.med.kyoto-u.ac.jp	Hosogi, Hisahiro/AAK-2585-2020; SONOSHITA, MASAHIRO/Q-1571-2019; Oshima, Masanobu/F-9958-2014; Sonoshita, Masahiro/AAE-5516-2019	SONOSHITA, MASAHIRO/0000-0003-2890-336X; Oshima, Masanobu/0000-0002-3304-0004; 				Amichay D, 1996, J IMMUNOL, V157, P4511; Balkwill F, 2004, NAT REV CANCER, V4, P540, DOI 10.1038/nrc1388; Bao SD, 2004, CANCER CELL, V5, P329, DOI 10.1016/S1535-6108(04)00081-9; Cella M, 1999, NAT MED, V5, P919, DOI 10.1038/11360; Chambers AF, 2002, NAT REV CANCER, V2, P563, DOI 10.1038/nrc865; Cyster JG, 1999, SCIENCE, V286, P2098, DOI 10.1126/science.286.5447.2098; Dijkstra IM, 2004, J IMMUNOL, V172, P2744, DOI 10.4049/jimmunol.172.5.2744; Dwinell MB, 2001, GASTROENTEROLOGY, V120, P49, DOI 10.1053/gast.2001.20914; FIDLER IJ, 1977, SCIENCE, V197, P893, DOI 10.1126/science.887927; Flatmark K, 2004, EUR J CANCER, V40, P1593, DOI 10.1016/j.ejca.2004.02.023; FLEMING JB, 1997, AJCC CANC STAGING MA, P83; GATTASS CR, 1994, J EXP MED, V179, P1373, DOI 10.1084/jem.179.4.1373; Janatpour MJ, 2001, J EXP MED, V194, P1375, DOI 10.1084/jem.194.9.1375; Jordan NJ, 1999, J CLIN INVEST, V104, P1061, DOI 10.1172/JCI6685; Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535-6108(03)00132-6; Kashtan H, 1992, Surg Oncol, V1, P251, DOI 10.1016/0960-7404(92)90072-S; Kawada K, 2004, CANCER RES, V64, P4010, DOI 10.1158/0008-5472.CAN-03-1757; Kim J, 2005, J CLIN ONCOL, V23, P2744, DOI 10.1200/JCO.2005.07.078; Luther SA, 2000, P NATL ACAD SCI USA, V97, P12694, DOI 10.1073/pnas.97.23.12694; Mancardi S, 2003, IMMUNOLOGY, V108, P523, DOI 10.1046/j.1365-2567.2003.01613.x; Martin-Fontecha A, 2004, NAT IMMUNOL, V5, P1260, DOI 10.1038/ni1138; Mashino K, 2002, CANCER RES, V62, P2937; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; Ninomiya I, 2004, INT J CANCER, V112, P135, DOI 10.1002/ijc.20360; Ochsenbein AF, 2001, NATURE, V411, P1058, DOI 10.1038/35082583; Palframan RT, 2001, J EXP MED, V194, P1361, DOI 10.1084/jem.194.9.1361; Petrova TV, 2002, EMBO J, V21, P4593, DOI 10.1093/emboj/cdf470; Poggi A, 2004, BLOOD, V103, P2205, DOI 10.1182/blood-2003-08-2928; Robledo MM, 2001, J BIOL CHEM, V276, P45098, DOI 10.1074/jbc.M106912200; Saeki H, 1999, J IMMUNOL, V162, P2472; Schimanski CC, 2005, CLIN CANCER RES, V11, P1743, DOI 10.1158/1078-0432.CCR-04-1195; Soejima K, 2001, J IMMUNOL, V167, P6576, DOI 10.4049/jimmunol.167.11.6576; Soto H, 1998, P NATL ACAD SCI USA, V95, P8205, DOI 10.1073/pnas.95.14.8205; Tannenbaum CS, 1998, J IMMUNOL, V161, P927; Trentin L, 1999, J CLIN INVEST, V104, P115, DOI 10.1172/JCI7335; Tsutsumi S, 2001, CANCER LETT, V169, P77, DOI 10.1016/S0304-3835(00)00622-4; Vicari AP, 2000, J IMMUNOL, V165, P1992, DOI 10.4049/jimmunol.165.4.1992; Vlahakis SR, 2002, J IMMUNOL, V169, P5546, DOI 10.4049/jimmunol.169.10.5546; von Andrian UH, 2003, NAT REV IMMUNOL, V3, P867, DOI 10.1038/nri1222; Walser TC, 2006, CANCER RES, V66, P7701, DOI 10.1158/0008-5472.CAN-06-0709; Wiley HE, 2001, J NATL CANCER I, V93, P1638, DOI 10.1093/jnci/93.21.1638; Yoneyama H, 2002, J EXP MED, V195, P1257, DOI 10.1084/jem.20011983; Zeelenberg IS, 2003, CANCER RES, V63, P3833; Zhang R, 1997, ONCOGENE, V14, P1607, DOI 10.1038/sj.onc.1200957	44	180	191	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 12	2007	26	32					4679	4688		10.1038/sj.onc.1210267	http://dx.doi.org/10.1038/sj.onc.1210267			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	190DJ	17297455				2022-12-28	WOS:000248037900008
J	Fan, Y; Gelinas, C				Fan, Y.; Gelinas, C.			An optimal range of transcription potency is necessary for efficient cell transformation by c-Rel to ensure optimal nuclear localization and gene-specific activation	ONCOGENE			English	Article						Rel; NF-kappa B; transcription; transactivation; transformation	CLASSICAL HODGKIN LYMPHOMA; CHICKEN SPLEEN-CELLS; V-REL; TRANSACTIVATION DOMAIN; MALIGNANT TRANSFORMATION; BREAST-CANCER; DNA-BINDING; EXPRESSION; MUTATIONS; PROTEIN	c-Rel is overexpressedin several B-cell lymphomas and c-rel gene overexpression can transform primary chicken lymphoid cells and induce tumors in animals. Although c-Rel is generally a stronger transcriptional activator than its viral derivative v-Rel, its oncogenic activity is significantly weaker. Among the mutations acquired during c-Rel's evolution into v-Rel are deletion of c-Rel's transactivation domain 2 ( cTAD2) and mutations in cTAD1. Given the critical role of the Rel TADs in cell transformation, we investigated how mutations in c-Rel's cTAD1 and cTAD2 contribute to its oncogenicity and that of v-Rel. Mutations in cTAD2 noticeably increased c-Rel's transforming activity by promoting its nuclear localization and gene-specific transactivation, despite an overall decrease in kappa B site-dependent transactivation potency. Conversely, substitution of vTAD by cTAD1 increased v-Rel's transactivation and transforming efficiencies, whereas its substitution by the stronger cTAD2 compromised activation of mip-1b but not irf-4 and was detrimental to cell transformation. These results suggest that the Rel TADs differentially contribute to gene specific activation and that an optimal range of transcription potency is necessary for efficient transformation. These findings may have important implications for understanding how Rel TAD mutations can lead to a more oncogenic phenotype.	Rutgers State Univ, Robert Wood Johnson Med Sch, Ctr Adv Biotechnol & Med, Piscataway, NJ 08854 USA; Rutgers State Univ, Robert Wood Johnson Med Sch, Dept Biochem, Piscataway, NJ 08854 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, Piscataway, NJ 08854 USA; Canc Inst New Jersey, New Brunswick, NJ USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey	Gelinas, C (corresponding author), Rutgers State Univ, Robert Wood Johnson Med Sch, Ctr Adv Biotechnol & Med, 679 Hoes Lane, Piscataway, NJ 08854 USA.	gelinas@cabm.rutgers.edu			NCI NIH HHS [CA54999] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA054999, R29CA054999] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Barth TFE, 2003, BLOOD, V101, P3681, DOI 10.1182/blood-2002-08-2577; CAPOBIANCO AJ, 1990, ONCOGENE, V5, P257; Carrasco D, 1998, J EXP MED, V187, P973, DOI 10.1084/jem.187.7.973; Chen CL, 1999, MOL CELL BIOL, V19, P307; Chen CL, 2001, MOL CELL BIOL, V21, P7115; Cogswell PC, 2000, ONCOGENE, V19, P1123, DOI 10.1038/sj.onc.1203412; DIEHL JA, 1993, MOL CELL BIOL, V13, P1769, DOI 10.1128/MCB.13.3.1769; Fan YJ, 2004, ONCOGENE, V23, P1030, DOI 10.1038/sj.onc.1207221; Feuerhake F, 2005, BLOOD, V106, P1392, DOI 10.1182/blood-2004-12-4901; Gilmore TD, 1999, ONCOGENE, V18, P6925, DOI 10.1038/sj.onc.1203222; Gilmore TD, 2004, ONCOGENE, V23, P2275, DOI 10.1038/sj.onc.1207410; Gilmore TD, 2001, ONCOGENE, V20, P7098, DOI 10.1038/sj.onc.1204898; HANNINK M, 1989, MOL CELL BIOL, V9, P4323, DOI 10.1128/MCB.9.10.4323; HRDLICKOVA R, 1994, J VIROL, V68, P308; Hrdlickova R, 2001, MOL CELL BIOL, V21, P6369; HRDLICKOVA R, 1994, J VIROL, V68, P2371; Iwai K, 2005, FEBS LETT, V579, P141, DOI 10.1016/j.febslet.2004.11.060; Kalaitzidis D, 2002, ONCOGENE, V21, P8759, DOI 10.1038/sj.onc.1206033; KAMENS J, 1990, MOL CELL BIOL, V10, P2840, DOI 10.1128/MCB.10.6.2840; Kralova J, 2002, J VIROL, V76, P11960, DOI 10.1128/JVI.76.23.11960-11970.2002; KRALOVA J, 1994, J VIROL, V68, P2073, DOI 10.1128/JVI.68.4.2073-2083.1994; Martin AG, 2000, J BIOL CHEM, V275, P24383, DOI 10.1074/jbc.M909396199; NEHYBA J, 1994, J VIROL, V68, P2039, DOI 10.1128/JVI.68.4.2039-2050.1994; Nehyba J, 1997, ONCOGENE, V14, P2881, DOI 10.1038/sj.onc.1201150; Petrenko O, 1997, ONCOGENE, V15, P1671, DOI 10.1038/sj.onc.1201334; Rayet B, 1999, ONCOGENE, V18, P6938, DOI 10.1038/sj.onc.1203221; Rayet B, 2003, MOL CELL BIOL, V23, P1520, DOI 10.1128/MCB.23.5.1520-1533.2003; Romieu-Mourez R, 2003, MOL CELL BIOL, V23, P5738, DOI 10.1128/MCB.23.16.5738-5754.2003; Savage KJ, 2003, BLOOD, V102, P3871, DOI 10.1182/blood-2003-06-1841; Sovak MA, 1997, J CLIN INVEST, V100, P2952, DOI 10.1172/JCI119848; Starczynowski DT, 2005, ONCOGENE, V24, P7355, DOI 10.1038/sj.onc.1208902; Starczynowski DT, 2003, ONCOGENE, V22, P6928, DOI 10.1038/sj.onc.1206801; STARCZYNOWSKI DT, 2006, ONCOGENE        1030	33	10	10	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 7	2007	26	27					4038	4043		10.1038/sj.onc.1210164	http://dx.doi.org/10.1038/sj.onc.1210164			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	177HP	17173064				2022-12-28	WOS:000247144500015
J	Sun, HL; Liu, YN; Huang, YT; Pan, SL; Huang, DY; Guh, JH; Lee, FY; Kuo, SC; Teng, CM				Sun, H-L; Liu, Y-N; Huang, Y-T; Pan, S-L; Huang, D-Y; Guh, J-H; Lee, F-Y; Kuo, S-C; Teng, C-M			YC-1 inhibits HIF-1 expression in prostate cancer cells: contribution of Akt/NF-kappa B signaling to HIF-1 alpha accumulation during hypoxia	ONCOGENE			English	Article						YC-1; HIF-1; Akt; NF-kappa B; prostate cancer	INDUCIBLE FACTOR 1-ALPHA; ENDOTHELIAL GROWTH-FACTOR; RIBOSOME ENTRY SITE; NUCLEAR-LOCALIZATION; GENE-EXPRESSION; TRANSCRIPTION FACTORS; DOWN-REGULATION; TUMOR HYPOXIA; UP-REGULATION; FACTOR-1-ALPHA	Hypoxia-inducible factor 1 ( HIF-1), a transcription factor that is critical for tumor adaptation to microenvironmental stimuli, represents an attractive chemotherapeutic target. YC-1 is a novel antitumor agent that inhibits HIF-1 through previously unexplained mechanisms. In the present study, YC-1 was found to prevent HIF-1 alpha and HIF-1 beta accumulation in response to hypoxia or mitogen treatment in PC-3 prostate cancer cells. Neither HIF-1 alpha protein half-life nor mRNA level was affected by YC-1. However, YC-1 was found to suppress the PI3K/Akt/mTOR/4E-BP pathway, which serves to regulate HIF-1 alpha expression at the translational step. We demonstrated that YC-1 also inhibited hypoxia-induced activation of nuclear factor ( NF)-kappa B, a downstream target of Akt. Two modulators of the Akt/NF-kappa B pathway, caffeic acid phenethyl ester and evodiamine, were observed to decrease HIF-1 alpha expression. Additionally, overexpression of NF-kappa B partly reversed the ability of wortmannin to inhibit HIF-1 alpha-dependent transcriptional activity, suggesting that NF-kappa B contributes to Akt-mediated HIF-1 alpha accumulation during hypoxia. Overall, we identify a potential molecular mechanism whereby YC-1 serves to reduce HIF-1 expression.	Natl Taiwan Univ, Inst Pharmacol, Coll Med, Taipei 100, Taiwan; Natl Taiwan Univ, Sch Pharm, Coll Med, Taipei 100, Taiwan; Yung Shin Pharmaceut Ind Co Ltd, China Med Coll, Taichung, Taiwan; China Med Coll, Grad Inst Pharmaceut Chem, Taichung, Taiwan	National Taiwan University; National Taiwan University; China Medical University Taiwan; China Medical University Taiwan	Teng, CM (corresponding author), Natl Taiwan Univ, Inst Pharmacol, Coll Med, 1 Jen Ai Rd,Sect 1, Taipei 100, Taiwan.	cmteng@ntumc.org	Pan, Shiow-Lin/C-1372-2010	Huang, Yao-Ting/0000-0001-5912-8090; GUH, JIH-HWA/0000-0002-6738-6054; TENG, CHE-MING/0000-0002-9719-7334				Ayala GE, 2004, CANCER RES, V64, P6082, DOI 10.1158/0008-5472.CAN-04-0838; Bilton RL, 2003, EUR J BIOCHEM, V270, P791, DOI 10.1046/j.1432-1033.2003.03446.x; Brown JM, 2004, NAT REV CANCER, V4, P437, DOI 10.1038/nrc1367; Chen EY, 2001, CANCER RES, V61, P2429; Chiang PC, 2005, J HEPATOL, V43, P679, DOI 10.1016/j.jhep.2005.02.049; Chun YS, 2001, BIOCHEM PHARMACOL, V61, P947, DOI 10.1016/S0006-2952(01)00564-0; Domingo-Domenech J, 2005, BRIT J CANCER, V93, P1285, DOI 10.1038/sj.bjc.6602851; Figueroa YG, 2002, EXP HEMATOL, V30, P1419, DOI 10.1016/S0301-472X(02)00934-7; Fradet V, 2004, CLIN CANCER RES, V10, P8460, DOI 10.1158/1078-0432.CCR-04-0764; Funasaka T, 2005, FASEB J, V19, P1422, DOI 10.1096/fj.05-3699com; Haddad JJE, 2000, J BIOL CHEM, V275, P21130, DOI 10.1074/jbc.M000737200; Hockel M, 2001, JNCI-J NATL CANCER I, V93, P266, DOI 10.1093/jnci/93.4.266; Huang DM, 2005, J UROLOGY, V173, P256, DOI 10.1097/01.ju.0000141587.72429.e3; Huang YT, 2005, MOL CANCER THER, V4, P1628, DOI 10.1158/1535-7163.MCT-05-0090; Hudson CC, 2002, MOL CELL BIOL, V22, P7004, DOI 10.1128/MCB.22.20.7004-7014.2002; Isaacs JS, 2004, J BIOL CHEM, V279, P16128, DOI 10.1074/jbc.M313342200; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Jung YJ, 2003, FASEB J, V17, P2115, DOI 10.1096/fj.03-0329fje; Kallio PJ, 1997, P NATL ACAD SCI USA, V94, P5667, DOI 10.1073/pnas.94.11.5667; Kaluzova M, 2004, MOL CELL BIOL, V24, P5757, DOI 10.1128/MCB.24.13.5757-5766.2004; Karni R, 2002, J BIOL CHEM, V277, P42919, DOI 10.1074/jbc.M206141200; Kim I, 2004, EXP CELL RES, V298, P229, DOI 10.1016/j.yexcr.2004.04.017; KO FN, 1994, BLOOD, V84, P4226, DOI 10.1182/blood.V84.12.4226.bloodjournal84124226; KOONG AC, 1994, CANCER RES, V54, P1425; Kung AL, 2000, NAT MED, V6, P1335, DOI 10.1038/82146; Lang KJD, 2002, MOL BIOL CELL, V13, P1792, DOI 10.1091/mbc.02-02-0017; Laughner E, 2001, MOL CELL BIOL, V21, P3995, DOI 10.1128/MCB.21.12.3995-4004.2001; Lessard L, 2005, BRIT J CANCER, V93, P1019, DOI 10.1038/sj.bjc.6602796; Lessard L, 2003, BJU INT, V91, P417, DOI 10.1046/j.1464-410X.2003.04104.x; Mabjeesh NJ, 2003, CANCER CELL, V3, P363, DOI 10.1016/S1535-6108(03)00077-1; Manna SK, 2000, FEBS LETT, V473, P113, DOI 10.1016/S0014-5793(00)01501-5; McCarty Mark F, 2004, Integr Cancer Ther, V3, P349, DOI 10.1177/1534735404270757; McEleny K, 2004, BJU INT, V94, P402, DOI 10.1111/j.1464-410X.2004.04936.x; Moeller BJ, 2004, CANCER CELL, V5, P429, DOI 10.1016/S1535-6108(04)00115-1; Mottet D, 2003, J BIOL CHEM, V278, P31277, DOI 10.1074/jbc.M300763200; Nieminen AL, 2005, J CELL PHYSIOL, V204, P364, DOI 10.1002/jcp.20406; Pan SL, 2005, J PHARMACOL EXP THER, V314, P35, DOI 10.1124/jpet.105.085126; Powis G, 2004, MOL CANCER THER, V3, P647; Rapisarda A, 2004, CANCER RES, V64, P1475, DOI 10.1158/0008-5472.CAN-03-3139; Ross JS, 2004, CLIN CANCER RES, V10, P2466, DOI 10.1158/1078-0432.CCR-0543-3; Ryan HE, 1998, EMBO J, V17, P3005, DOI 10.1093/emboj/17.11.3005; SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447; Takada Y, 2005, J BIOL CHEM, V280, P17203, DOI 10.1074/jbc.M500077200; Tang TTL, 2003, J BIOL CHEM, V278, P30125, DOI 10.1074/jbc.M302042200; Treins C, 2002, J BIOL CHEM, V277, P27975, DOI 10.1074/jbc.M204152200; Yeo EJ, 2003, J NATL CANCER I, V95, P516, DOI 10.1093/jnci/95.7.516; Zhong H, 2004, CANCER DETECT PREV, V28, P88, DOI 10.1016/j.cdp.2003.12.009; Zhong H, 2001, BIOCHEM BIOPH RES CO, V284, P352, DOI 10.1006/bbrc.2001.4981; Zhong H, 2000, CANCER RES, V60, P1541; Zhou J, 2004, CANCER RES, V64, P9041, DOI 10.1158/0008-5472.CAN-04-1437; Zhou J, 2004, J BIOL CHEM, V279, P13506, DOI 10.1074/jbc.M310164200; Zhou J, 2003, MOL BIOL CELL, V14, P2216, DOI 10.1091/mbc.E02-09-0598; Zundel W, 2000, GENE DEV, V14, P391	53	149	155	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 7	2007	26	27					3941	3951		10.1038/sj.onc.1210169	http://dx.doi.org/10.1038/sj.onc.1210169			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	177HP	17213816				2022-12-28	WOS:000247144500004
J	Kohonen-Corish, MRJ; Sigglekow, ND; Susanto, J; Chapuis, PH; Bokey, EL; Dent, OF; Chan, C; Lin, BPC; Seng, TJ; Laird, PW; Young, J; Leggett, BA; Jass, JR; Sutherland, RL				Kohonen-Corish, M. R. J.; Sigglekow, N. D.; Susanto, J.; Chapuis, P. H.; bokey, E. L.; Dent, O. F.; Chan, C.; Lin, B. P. C.; Seng, T. J.; Laird, P. W.; Young, J.; Leggett, B. A.; Jass, J. R.; Sutherland, R. L.			Promoter methylation of the mutated in colorectal cancer gene is a frequent early event in colorectal cancer	ONCOGENE			English	Article						mutated in colorectal cancer (MCC); promoter hypermethylation; serrated polyps; clinico-pathologic correlations	NF-KAPPA-B; MICROSATELLITE INSTABILITY; SERRATED POLYPS; DNA METHYLATION; BRAF MUTATION; COLON-CANCER; K-RAS; PHENOTYPE; MCC; HYPERMETHYLATION	The mutated in colorectal cancer (MCC) gene is in close linkage with the adenomatous polyposis coli (APC) gene on chromosome 5, in a region of frequent loss of heterozygosity in colorectal cancer. The role of MCC in carcinogenesis, however, has not been extensively analysed, and functional studies are emerging, which implicate it as a candidate tumor suppressor gene. The aim of this study was to examine loss of MCC expression due to promoter hypermethylation and its clinicopathologic signifi. cance in colorectal cancer. Correspondence of MCC methylation with gene silencing was demonstrated using bisulfi. te sequencing, reverse transcription-polymerase chain reaction and Western blotting. MCC methylation was detected in 45-52% of 187 primary colorectal cancers. There was a striking association with CDKN2A methylation (P < 0.0001), the CpG island methylator phenotype ( P < 0.0001) and the BRAF V600E mutation (P < 0.0001). MCC methylation was also more common (P = 0.0084) in serrated polyps than in adenomas. In contrast, there was no association with APC methylation or KRAS mutations. This study demonstrates for the. first time that MCC methylation is a frequent change during colorectal carcinogenesis. Furthermore, MCC methylation is significantly associated with a distinct spectrum of precursor lesions, which are suggested to give rise to cancers via the serrated neoplasia pathway.	Garvan Inst Med Res, Canc Res Program, Sydney, NSW 2010, Australia; Univ New S Wales, Fac Med, St Vincents Clin Sch, Kensington, NSW 2033, Australia; Concord Hosp, Dept Colorectal Surg, Sydney, NSW, Australia; Univ Sydney, Sydney, NSW, Australia; Concord Hosp, Dept Anat Pathol, Sydney, NSW, Australia; USC Norris Comprehens Canc Ctr, Los Angeles, CA USA; Queensland Inst Med Res, Mol Canc Epidemiol Lab, Herston, Qld, Australia; Royal Brisbane & Womens Hosp Fdn, Conjoint Gastroenterol Lab, Brisbane, Qld, Australia; Queensland Inst Med Res, Brisbane, Qld 4006, Australia; McGill Univ, Dept Pathol, Montreal, PQ, Canada	Garvan Institute of Medical Research; University of New South Wales Sydney; Concord Repatriation General Hospital; University of Sydney; Concord Repatriation General Hospital; University of Southern California; QIMR Berghofer Medical Research Institute; Royal Brisbane & Women's Hospital; QIMR Berghofer Medical Research Institute; McGill University	Kohonen-Corish, MRJ (corresponding author), Garvan Inst Med Res, Canc Res Program, 384 Victoria St, Sydney, NSW 2010, Australia.	m.corish@garvan.org.au	Laird, Peter W/G-8683-2012; Young, Joanne P/B-9981-2011; Sutherland, Robert L/A-8378-2008; Young, Joanne P/H-7774-2014; Kohonen-Corish, Maija/Q-9763-2019; Leggett, Barbara A/D-3579-2011	Laird, Peter W/0000-0001-9117-3641; Kohonen-Corish, Maija/0000-0002-4073-1479; Leggett, Barbara/0000-0003-2062-7380	NCI NIH HHS [R01 CA075090, R01 CA118699] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA075090, R01CA118699] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ASHTONRICKARDT PG, 1991, ONCOGENE, V6, P1881; Bouwmeester T, 2004, NAT CELL BIOL, V6, P97, DOI 10.1038/ncb1086; Eads CA, 1999, CANCER RES, V59, P2302; Eads CA, 2000, NUCLEIC ACIDS RES, V28, DOI 10.1093/nar/28.8.e32; Esteller M, 2000, CANCER RES, V60, P2368; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; Hawkins NJ, 2001, J NATL CANCER I, V93, P1307, DOI 10.1093/jnci/93.17.1307; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Ikenoue T, 2003, CANCER RES, V63, P8132; Jass JR, 2005, NAT CLIN PRACT ONCOL, V2, P398, DOI 10.1038/ncponc0248; Jass JR, 2000, GUT, V47, P43, DOI 10.1136/gut.47.1.43; Kambara T, 2004, GUT, V53, P1137, DOI 10.1136/gut.2003.037671; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; KINZLER KW, 1991, SCIENCE, V251, P1366, DOI 10.1126/science.1848370; Kohonen-Corish MRJ, 2005, J CLIN ONCOL, V23, P2318, DOI 10.1200/JCO.2005.00.109; Matsumine A, 1996, J BIOL CHEM, V271, P10341, DOI 10.1074/jbc.271.17.10341; Nagasaka T, 2004, J CLIN ONCOL, V22, P4584, DOI 10.1200/JCO.2004.02.154; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; O'Brien MJ, 2004, AM J SURG PATHOL, V28, P423, DOI 10.1097/00000478-200404000-00001; Rashid A, 2001, AM J PATHOL, V159, P1129, DOI 10.1016/S0002-9440(10)61789-0; Samowitz WS, 2005, CANCER RES, V65, P6063, DOI 10.1158/0008-5472.CAN-05-0404; Samowitz WS, 2005, GASTROENTEROLOGY, V129, P837, DOI 10.1053/j.gastro.2005.06.020; Senda T, 1999, J HISTOCHEM CYTOCHEM, V47, P1149, DOI 10.1177/002215549904700907; Toyota M, 1999, P NATL ACAD SCI USA, V96, P8681, DOI 10.1073/pnas.96.15.8681; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; Ward RL, 2003, J CLIN ONCOL, V21, P3729, DOI 10.1200/JCO.2003.03.123; Weisenberger DJ, 2006, NAT GENET, V38, P787, DOI 10.1038/ng1834; Wynter CVA, 2004, GUT, V53, P573, DOI 10.1136/gut.2003.030841	28	59	61	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2007	26	30					4435	4441		10.1038/sj.onc.1210210	http://dx.doi.org/10.1038/sj.onc.1210210			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	184CZ	17260021				2022-12-28	WOS:000247620000011
J	Peschard, P; Park, M				Peschard, P.; Park, M.			From Tpr-Met to Met, tumorigenesis and tubes	ONCOGENE			English	Review						signaling; downregulation; ubiquitination; mutations; oncogenic activation	HEPATOCYTE GROWTH-FACTOR; RECEPTOR TYROSINE KINASE; FACTOR SCATTER FACTOR; DOMAIN BINDING-SITE; EPITHELIAL MORPHOGENESIS DOWNSTREAM; SIGNAL-REGULATED KINASE; MESENCHYMAL STEM-CELLS; C-MET; EGF RECEPTOR; FACTOR/SCATTER FACTOR	The receptor for hepatocyte growth factor (HGF)/scatter factor (SF), Met, controls a program of invasive epithelial growth through the coordination of cell proliferation and survival, cell migration and epithelial morphogenesis. This process is important during embryogenesis and for organ regeneration in the adult. However, when deregulated the HGF/SF-Met signaling axis contributes to tumorigenesis and metastasis. Studies on the oncogenic activation of the Met receptor have shed light on the molecular mechanisms underlying the oncogenic activation of receptor tyrosine kinase (RTKs). More than a decade ago, work on the Met related oncogene, Tpr-Met, revealed the mechanism for activation of RTK-derived oncogenes generated following chromosomal translocation. More recently, studies on the mechanisms of downregulation of the Met RTK highlight a role for loss of downregulation in RTK oncogenic activation.	McGill Univ, Ctr Hlth, Mol Oncol Grp, Dept Biochem, Montreal, PQ H3A 1A1, Canada; McGill Univ, Ctr Hlth, Mol Oncol Grp, Dept Med, Montreal, PQ H3A 1A1, Canada; McGill Univ, Ctr Hlth, Mol Oncol Grp, Dept Oncol, Montreal, PQ H3A 1A1, Canada	McGill University; McGill University; McGill University	Park, M (corresponding author), McGill Univ, Ctr Hlth, Mol Oncol Grp, Dept Biochem, Montreal, PQ H3A 1A1, Canada.	morag.park@mcgill.ca		Peschard, Pascal/0000-0001-6395-5566				Abella JV, 2005, MOL CELL BIOL, V25, P9632, DOI 10.1128/MCB.25.21.9632-9645.2005; Bache KG, 2004, EMBO J, V23, P2707, DOI 10.1038/sj.emboj.7600292; Bao J, 2003, P NATL ACAD SCI USA, V100, P2438, DOI 10.1073/pnas.0437945100; Birchmeier C, 2003, NAT REV MOL CELL BIO, V4, P915, DOI 10.1038/nrm1261; Borowiak M, 2004, P NATL ACAD SCI USA, V101, P10608, DOI 10.1073/pnas.0403412101; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BRINKMANN V, 1995, J CELL BIOL, V131, P1573, DOI 10.1083/jcb.131.6.1573; Buchberger A, 2002, TRENDS CELL BIOL, V12, P216, DOI 10.1016/S0962-8924(02)02269-9; Carter S, 2004, J BIOL CHEM, V279, P52835, DOI 10.1074/jbc.M407769200; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; Crepaldi T, 1997, J CELL BIOL, V138, P423, DOI 10.1083/jcb.138.2.423; Davies GC, 2004, ONCOGENE, V23, P7104, DOI 10.1038/sj.onc.1207952; DEAN M, 1987, MOL CELL BIOL, V7, P921, DOI 10.1128/MCB.7.2.921; Duan L, 2003, J BIOL CHEM, V278, P28950, DOI 10.1074/jbc.M304474200; Ebens A, 1996, NEURON, V17, P1157, DOI 10.1016/S0896-6273(00)80247-0; FIXMAN ED, 1995, ONCOGENE, V10, P237; Fixman ED, 1996, J BIOL CHEM, V271, P13116, DOI 10.1074/jbc.271.22.13116; Forte G, 2006, STEM CELLS, V24, P23, DOI 10.1634/stemcells.2004-0176; Giordano S, 2002, NAT CELL BIOL, V4, P720, DOI 10.1038/ncb843; GRANT DS, 1993, P NATL ACAD SCI USA, V90, P1937, DOI 10.1073/pnas.90.5.1937; Graveel C, 2004, P NATL ACAD SCI USA, V101, P17198, DOI 10.1073/pnas.0407651101; Haglund K, 2003, NAT CELL BIOL, V5, P461, DOI 10.1038/ncb983; Hammond DE, 2003, MOL BIOL CELL, V14, P1346, DOI 10.1091/mbc.E02-09-0578; HERBST R, 1995, ONCOGENE, V10, P369; Huang FT, 2006, MOL CELL, V21, P737, DOI 10.1016/j.molcel.2006.02.018; Huh CG, 2004, P NATL ACAD SCI USA, V101, P4477, DOI 10.1073/pnas.0306068101; Itoh M, 2000, MOL CELL BIOL, V20, P3695, DOI 10.1128/MCB.20.10.3695-3704.2000; Jeffers M, 1998, P NATL ACAD SCI USA, V95, P14417, DOI 10.1073/pnas.95.24.14417; Jeffers M, 1997, P NATL ACAD SCI USA, V94, P11445, DOI 10.1073/pnas.94.21.11445; Jeffers M, 1997, MOL CELL BIOL, V17, P799, DOI 10.1128/MCB.17.2.799; Jeffers M, 1996, MOL CELL BIOL, V16, P1115; Jiang XJ, 2003, MOL BIOL CELL, V14, P858, DOI 10.1091/mbc.E02-08-0532; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; Kamei T, 1999, ONCOGENE, V18, P6776, DOI 10.1038/sj.onc.1203114; Katzmann DJ, 2001, CELL, V106, P145, DOI 10.1016/S0092-8674(01)00434-2; Keane MM, 1999, ONCOGENE, V18, P3365, DOI 10.1038/sj.onc.1202753; Khoury H, 2005, MOL BIOL CELL, V16, P550, DOI 10.1091/mbc.E04-07-0567; Kong-Beltran M, 2006, CANCER RES, V66, P283, DOI 10.1158/0008-5472.CAN-05-2749; Kuperwasser C, 2004, P NATL ACAD SCI USA, V101, P4966, DOI 10.1073/pnas.0401064101; Lamorte L, 2002, MOL BIOL CELL, V13, P1449, DOI 10.1091/mbc.01-10-0477; Lamorte L, 2002, J BIOL CHEM, V277, P37904, DOI 10.1074/jbc.M201743200; Lamorte L, 2001, Surg Oncol Clin N Am, V10, P271; Lee CC, 2004, ONCOGENE, V23, P5193, DOI 10.1038/sj.onc.1207646; Lee JH, 2000, ONCOGENE, V19, P4947, DOI 10.1038/sj.onc.1203874; Liu Y, 2002, FEBS LETT, V515, P1, DOI 10.1016/S0014-5793(02)02425-0; Lock LS, 2003, J BIOL CHEM, V278, P30083, DOI 10.1074/jbc.M302675200; Lock LS, 2002, MOL BIOL CELL, V13, P2132, DOI 10.1091/mbc.02-02-0031; Lock LS, 2000, J BIOL CHEM, V275, P31536, DOI 10.1074/jbc.M003597200; Longva KE, 2002, J CELL BIOL, V156, P843, DOI 10.1083/jcb.200106056; Ma PC, 2005, CANCER RES, V65, P1479, DOI 10.1158/0008-5472.CAN-04-2650; Ma PC, 2003, CANCER RES, V63, P6272; Machide M, 2006, J BIOL CHEM, V281, P8765, DOI 10.1074/jbc.M512298200; Maina F, 1997, GENE DEV, V11, P3341, DOI 10.1101/gad.11.24.3341; Mancini A, 2002, J BIOL CHEM, V277, P14635, DOI 10.1074/jbc.M109214200; Marmor MD, 2004, ONCOGENE, V23, P2057, DOI 10.1038/sj.onc.1207390; Maroun CR, 2000, MOL CELL BIOL, V20, P8513, DOI 10.1128/MCB.20.22.8513-8525.2000; Maroun CR, 2003, MOL BIOL CELL, V14, P1691, DOI 10.1091/mbc.E02-06-0352; Maroun CR, 1999, MOL CELL BIOL, V19, P1784; Matsumoto K, 2001, KIDNEY INT, V59, P2023, DOI 10.1046/j.1523-1755.2001.00717.x; Michalopoulos GK, 1997, SCIENCE, V276, P60, DOI 10.1126/science.276.5309.60; MONTESANO R, 1991, CELL, V67, P901, DOI 10.1016/0092-8674(91)90363-4; Mosesson Y, 2003, J BIOL CHEM, V278, P21323, DOI 10.1074/jbc.C300096200; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; Nakamura T, 2000, J CLIN INVEST, V106, P1511, DOI 10.1172/JCI10226; Neuss S, 2004, STEM CELLS, V22, P405, DOI 10.1634/stemcells.22-3-405; Nguyen L, 1997, J BIOL CHEM, V272, P20811, DOI 10.1074/jbc.272.33.20811; Orian-Rousseau V, 2002, GENE DEV, V16, P3074, DOI 10.1101/gad.242602; Otsuka T, 1998, CANCER RES, V58, P5157; Palka HL, 2003, J BIOL CHEM, V278, P5728, DOI 10.1074/jbc.M210656200; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; PARK M, 1987, P NATL ACAD SCI USA, V84, P6379, DOI 10.1073/pnas.84.18.6379; Peschard P, 2004, J BIOL CHEM, V279, P29565, DOI 10.1074/jbc.M403954200; Peschard P, 2001, MOL CELL, V8, P995, DOI 10.1016/S1097-2765(01)00378-1; Peschard P, 2003, CANCER CELL, V3, P519, DOI 10.1016/S1535-6108(03)00136-3; Pollack AL, 1998, DEV BIOL, V204, P64, DOI 10.1006/dbio.1998.9091; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; Rahimi N, 1998, J BIOL CHEM, V273, P33714, DOI 10.1074/jbc.273.50.33714; Raiborg C, 2003, CURR OPIN CELL BIOL, V15, P446, DOI 10.1016/S0955-0674(03)00080-2; Raiborg C, 2002, NAT CELL BIOL, V4, P394, DOI 10.1038/ncb791; RODRIGUES CA, 1994, CURR OPIN GENET DEV, V4, P15, DOI 10.1016/0959-437X(94)90086-8; RODRIGUES GA, 1993, MOL CELL BIOL, V13, P6711, DOI 10.1128/MCB.13.11.6711; Rodrigues SP, 2005, MOL CANCER RES, V3, P183; RONG S, 1994, P NATL ACAD SCI USA, V91, P4731, DOI 10.1073/pnas.91.11.4731; RONSIN C, 1993, ONCOGENE, V8, P1195; Royal I, 2000, MOL BIOL CELL, V11, P1709, DOI 10.1091/mbc.11.5.1709; Sachs M, 2000, J CELL BIOL, V150, P1375, DOI 10.1083/jcb.150.6.1375; Sangwan V, 2006, J BIOL CHEM, V281, P221, DOI 10.1074/jbc.M507858200; Saucier C, 2004, P NATL ACAD SCI USA, V101, P2345, DOI 10.1073/pnas.0308065101; Saucier C, 2002, ONCOGENE, V21, P1800, DOI 10.1038/sj.onc.1205261; Schaeper U, 2000, J CELL BIOL, V149, P1419, DOI 10.1083/jcb.149.7.1419; SCHMIDT C, 1995, NATURE, V373, P699, DOI 10.1038/373699a0; Schmidt L, 1998, CANCER RES, V58, P1719; Schmidt PR, 1997, J ANTHROPOL ARCHAEOL, V16, P73, DOI 10.1006/jaar.1997.0305; Shen Y, 2000, CELL, V103, P501, DOI 10.1016/S0092-8674(00)00141-0; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; Sun H, 2005, CELL MICROBIOL, V7, P443, DOI 10.1111/j.1462-5822.2004.00475.x; Thien CBF, 2001, NAT REV MOL CELL BIO, V2, P294, DOI 10.1038/35067100; Thiery JP, 2003, CURR OPIN CELL BIOL, V15, P740, DOI 10.1016/j.ceb.2003.10.006; Trusolino L, 2001, CELL, V107, P643, DOI 10.1016/S0092-8674(01)00567-0; UEHARA Y, 1995, NATURE, V373, P702, DOI 10.1038/373702a0; Urbe S, 2000, MOL CELL BIOL, V20, P7685, DOI 10.1128/MCB.20.20.7685-7692.2000; Wang R, 2001, J CELL BIOL, V153, P1023, DOI 10.1083/jcb.153.5.1023; WEIDNER KM, 1995, P NATL ACAD SCI USA, V92, P2597, DOI 10.1073/pnas.92.7.2597; Weidner KM, 1996, NATURE, V384, P173, DOI 10.1038/384173a0; WEIDNER KM, 1993, J CELL BIOL, V121, P145, DOI 10.1083/jcb.121.1.145; Wong ESM, 2002, EMBO J, V21, P4796, DOI 10.1093/emboj/cdf493; Wu WJ, 2003, CELL, V114, P715, DOI 10.1016/S0092-8674(03)00688-3; Yamasaki S, 2003, ONCOGENE, V22, P1546, DOI 10.1038/sj.onc.1206284; YANG XM, 1995, LAB INVEST, V73, P483; Yokouchi M, 1999, J BIOL CHEM, V274, P31707, DOI 10.1074/jbc.274.44.31707; ZARNEGAR R, 1989, CANCER RES, V49, P3314; Zhang YW, 2003, P NATL ACAD SCI USA, V100, P12718, DOI 10.1073/pnas.2135113100; ZHU H, 1994, CELL GROWTH DIFFER, V5, P359; ZHU H, 1994, J BIOL CHEM, V269, P29943	114	137	147	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 26	2007	26	9					1276	1285		10.1038/sj.onc.1210201	http://dx.doi.org/10.1038/sj.onc.1210201			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	141DU	17322912				2022-12-28	WOS:000244558700004
J	Suzuki, E; Imoto, I; Pimkhaokham, A; Nakagawa, T; Kamata, N; Kozaki, K; Amagasa, T; Inazawa, J				Suzuki, E.; Imoto, I.; Pimkhaokham, A.; Nakagawa, T.; Kamata, N.; Kozaki, K-i; Amagasa, T.; Inazawa, J.			PRTFDC1, a possible tumor-suppressor gene, is frequently silenced in oral squamous-cell carcinomas by aberrant promoter hypermethylation	ONCOGENE			English	Article						array-CGH; oral squamous-cell carcinoma; PRTFDC1; homozygous deletion; methylation	EPIGENETIC MECHANISMS; CANCER; METHYLATION; INACTIVATION; ABERRATIONS; EXPRESSION	Array-based comparative genomic hybridization (array-CGH) has good potential for the high-throughput identification of genetic aberrations in cell genomes. In the course of a program to screen a panel of oral squamous-cell carcinoma (OSCC), cell lines for genomic copy-number aberrations by array-CGH using our in-house arrays, we identified a 3-Mb homozygous deletion at 10p12 in 1 of 18 cell lines (5.6%). Among seven genes located within this region, expression of PRTFDC1 mRNA was not detected in 50% (9/18) or decreased in 5.6% (1/18) of OSCC cell lines, but detected in normal oral epithelia and restored in gene-silenced OSCC cells without its homozygous loss after treatment with 5-aza-2 '-deoxycytidine. Among 17 cell lines without a homozygous deletion, the hypermethylation of the PRTFDC1 CpG island, which showed promoter activity, was observed in all nine cell lines with no or reduced PRTFDC1 expression (52.9%). Methylation of this CpG island was also observed in primary OSCC tissues (8/47, 17.0%). In addition, restoration of PRTFDC1 in OSCC cells lacking its expression inhibited cell growth in colony-formation assays, whereas knockdown of PRTFDC1 expression in OSCC cells expressing the gene promoted cell growth. These results suggest that epigenetic silencing of PRTFDC1 by hypermethylation of the CpG island leads to a loss of PRTFDC1 function, which might be involved in squamous cell oral carcinogenesis.	[Suzuki, E.; Imoto, I.; Pimkhaokham, A.; Nakagawa, T.; Kozaki, K-i; Inazawa, J.] Tokyo Med & Dent Univ, Dept Mol Cytogenet, Med Res Inst, Bunkyo Ku, Tokyo 1138510, Japan; [Suzuki, E.; Imoto, I.; Pimkhaokham, A.; Nakagawa, T.; Kozaki, K-i; Inazawa, J.] Tokyo Med & Dent Univ, Sch Biomed Sci, Tokyo 1138510, Japan; [Suzuki, E.; Amagasa, T.] Tokyo Med & Dent Univ, Grad Sch, Dept Maxillofacial Surg, Tokyo 1138510, Japan; [Imoto, I.; Kozaki, K-i; Inazawa, J.] Tokyo Med & Dent Univ, Hard Tissue Genome Res Ctr, Tokyo 1138510, Japan; [Imoto, I.; Kozaki, K-i; Inazawa, J.] Japan Sci & Technol Corp, CREST, Saitama, Japan; [Pimkhaokham, A.] Chulalongkorn Univ, Fac Dent, Dept Oral & Maxillofacial Surg, Bangkok, Thailand; [Kamata, N.] Hiroshima Univ, Div Cervico Gnathostomatol, Dept Oral & Maxillofacial Surg, Grad Sch Biomed Sci,Minami Ku, Hiroshima, Japan; [Inazawa, J.] Tokyo Med & Dent Univ, Century Ctr Excellence Program Mol Destruct & Rec, Tokyo 1138510, Japan	Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU); Japan Science & Technology Agency (JST); Chulalongkorn University; Hiroshima University; Tokyo Medical & Dental University (TMDU)	Inazawa, J (corresponding author), Tokyo Med & Dent Univ, Dept Mol Cytogenet, Med Res Inst, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138510, Japan.	johinaz.cgen@mri.tmd.ac.jp	imoto, Issei/D-8065-2012; Kozaki, Ken-ichi/M-6281-2014; Pimkhaokham, Atiphan/AAQ-4177-2021; Imoto, Issei/AAD-5799-2020	Kozaki, Ken-ichi/0000-0003-3286-819X; Pimkhaokham, Atiphan/0000-0002-0170-243X				Akanuma D, 1999, ORAL ONCOL, V35, P476, DOI 10.1016/S1368-8375(99)00020-2; Baldwin C, 2005, CANCER RES, V65, P7561, DOI 10.1158/0008-5472.CAN-05-1513; Brinkman BMN, 2006, CURR OPIN ONCOL, V18, P228, DOI 10.1097/01.cco.0000219250.15041.f8; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; Fujimoto R., 2004, J JPN ORAL MUCO MEMB, V8, P1, DOI [10.6014/jjomm1995.8.1, DOI 10.6014/jjomm1995.8.1]; Ha PK, 2006, LANCET ONCOL, V7, P77, DOI 10.1016/S1470-2045(05)70540-4; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Hermsen MAJA, 1997, ORAL ONCOL, V33, P414, DOI 10.1016/S0964-1955(97)00031-6; Imoto I, 2006, CANCER RES, V66, P4617, DOI 10.1158/0008-5472.CAN-05-4437; Inazawa J, 2004, CANCER SCI, V95, P559, DOI 10.1111/j.1349-7006.2004.tb02486.x; Izumi H, 2005, HUM MOL GENET, V14, P997, DOI 10.1093/hmg/ddi092; Jin C, 2006, CANCER GENET CYTOGEN, V164, P44, DOI 10.1016/j.cancergencyto.2005.06.008; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; Kolb A, 2003, BIOCHEM BIOPH RES CO, V306, P1099, DOI 10.1016/S0006-291X(03)01104-5; Kusumoto Y, 2004, J PERIODONTOL, V75, P370, DOI 10.1902/jop.2004.75.3.370; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Misawa A, 2005, CANCER RES, V65, P10233, DOI 10.1158/0008-5472.CAN-05-1073; Nagpal JK, 2003, ORAL ONCOL, V39, P213, DOI 10.1016/S1368-8375(02)00162-8; Nakagawachi T, 2003, ONCOGENE, V22, P8835, DOI 10.1038/sj.onc.1207183; Nicklas JA, 2006, ENVIRON MOL MUTAGEN, V47, P212, DOI 10.1002/em.20187; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Saigusa K, 2007, ONCOGENE, V26, P1110, DOI 10.1038/sj.onc.1210148; Scully C, 2000, ORAL ONCOL, V36, P256, DOI 10.1016/S1368-8375(00)00007-5; Shaw R, 2006, INT J ORAL MAX SURG, V35, P101, DOI 10.1016/j.ijom.2005.06.014; Snijders AM, 2005, ONCOGENE, V24, P4232, DOI 10.1038/sj.onc.1208601; Snijders AM, 2001, NAT GENET, V29, P263, DOI 10.1038/ng754; Sonoda I, 2004, CANCER RES, V64, P3741, DOI 10.1158/0008-5472.CAN-04-0172; Takada H, 2006, ONCOGENE, V25, P6554, DOI 10.1038/sj.onc.1209657; Takada H, 2005, ONCOGENE, V24, P8051, DOI 10.1038/sj.onc.1208952; Takada H, 2005, CANCER SCI, V96, P100, DOI 10.1111/j.1349-7006.2005.00016.x; Wolff E, 1998, ORAL ONCOL, V34, P186, DOI 10.1016/S1368-8375(97)00079-1; Xiong ZG, 1997, NUCLEIC ACIDS RES, V25, P2532, DOI 10.1093/nar/25.12.2532	33	37	39	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 13	2007	26	57					7921	7932		10.1038/sj.onc.1210589	http://dx.doi.org/10.1038/sj.onc.1210589			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	248ON	17599052				2022-12-28	WOS:000252163500011
J	Harada, H; Kizaka-Kondoh, S; Li, G; Itasaka, S; Shibuya, K; Inoue, M; Hiraoka, M				Harada, H.; Kizaka-Kondoh, S.; Li, G.; Itasaka, S.; Shibuya, K.; Inoue, M.; Hiraoka, M.			Significance of HIF-1-active cells in angiogenesis and radioresistance	ONCOGENE			English	Article						tumor hypoxia; angiogenesis; HIF-1; radiotherapy	UBIQUITIN-PROTEASOME PATHWAY; HYPOXIA-INDUCIBLE FACTOR-1; TUMOR-SUPPRESSOR PROTEIN; SELECTIVE CANCER-THERAPY; FACTOR 1-ALPHA; NECK-CANCER; TRANSCRIPTIONAL ACTIVATION; RADIATION ONCOLOGY; GROWTH; HEAD	Human solid tumors contain hypoxic regions that have considerably lower oxygen tension than the normal tissues. Hypoxia offers resistance to radiotherapy and anticancer chemotherapy, as well as predispose to increased tumor metastases. Furthermore, hypoxia induces hypoxia-inducible factor-1 (HIF-1), which in turn increases tumor angiogenesis. Thus, eradication of HIF-1-active/hypoxic tumor cells is very important for cancer therapy. We have previously reported that procaspase-3 fused with a von Hippel-Lindau (VHL)-mediated protein destruction motif of alpha subunit of HIF-1 (HIF-1 alpha) containing Pro564, named TAT-ODD-procaspase-3 (TOP3), specifically induced cell death to hypoxic cells in vivo as well as in vitro. We now report that TOP3 also eradicates the radiation-induced HIF-1-active tumor cells. HIF-1 activity in the xenografts of human tumor cells, which express luciferase under the transcriptional control of HIF-1, were monitored and quantified daily with an in vivo bioluminescence photon-counting device. HIF-1 activity in tumors was more rapidly increased by ionizing radiation (IR) compared to untreated tumors. TOP3 efficiently decreased the HIF-1-activity in irradiated tumors as well as unirradiated ones, indicating TOP3 eradicated tumor cells with HIF-1-activity induced by IR as well as hypoxia. Eradication of HIF-1-active/hypoxic cells in the xenografts during irradiation exhibited significant suppression in angiogenesis and strong enhancement in a long-term growth suppression of tumor xenografts. These results further strengthen the argument that HIF-1-active/hypoxic cells play crucial roles in angiogenesis and radioresistance.	Kyoto Univ, Grad Sch Med, Dept Radiat Oncol & Image Appl Therapy, Kyoto 6068507, Japan; Kyoto Univ, Nano Med Merger Educ Unit, Kyoto, Japan; Kyoto Univ, Grad Sch Med, COE Format Genom Anal Dis Model Anim Multiple Gen, Kyoto, Japan; Osaka Med Ctr Canc & Cardiovasc Dis, Dept Biochem, Osaka, Japan	Kyoto University; Kyoto University; Kyoto University; Osaka Medical Center for Cancer & Cardiovascular Diseases	Kizaka-Kondoh, S (corresponding author), Kyoto Univ, Grad Sch Med, Dept Radiat Oncol & Image Appl Therapy, 54 Kawahara-cho, Kyoto 6068507, Japan.	skondoh@kuhp.kyoto-u.ac.jp	Kondoh, Shinae/AAF-8745-2020; Kondoh, Shinae/C-6937-2015	Kondoh, Shinae/0000-0003-3085-5782; Kondoh, Shinae/0000-0003-3085-5782				Abdollahi A, 2003, CANCER RES, V63, P3755; Brown JM, 1999, CANCER RES, V59, P5863; Brown JM, 2004, NAT REV CANCER, V4, P437, DOI 10.1038/nrc1367; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; Cockman ME, 2000, J BIOL CHEM, V275, P25733, DOI 10.1074/jbc.M002740200; de Candia P, 2003, P NATL ACAD SCI USA, V100, P12337, DOI 10.1073/pnas.2031337100; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; Geng L, 2001, CANCER RES, V61, P2413; Gorski DH, 1999, CANCER RES, V59, P3374; Harada H, 2002, CANCER RES, V62, P2013; Harada H, 2005, MOL IMAGING, V4, P182; Harada H, 2006, FEBS LETT, V580, P5718, DOI 10.1016/j.febslet.2006.09.025; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; HOCKEL M, 1993, RADIOTHER ONCOL, V26, P45, DOI 10.1016/0167-8140(93)90025-4; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; Inoue M, 2004, INT J ONCOL, V25, P713; Kallio PJ, 1999, J BIOL CHEM, V274, P6519, DOI 10.1074/jbc.274.10.6519; Kamura T, 2000, P NATL ACAD SCI USA, V97, P10430, DOI 10.1073/pnas.190332597; Kizaka-Kondoh S, 2003, CANCER SCI, V94, P1021, DOI 10.1111/j.1349-7006.2003.tb01395.x; Mabjeesh NJ, 2003, CANCER CELL, V3, P363, DOI 10.1016/S1535-6108(03)00077-1; Moeller BJ, 2004, CANCER CELL, V5, P429, DOI 10.1016/S1535-6108(04)00115-1; Ohh M, 2000, NAT CELL BIOL, V2, P423, DOI 10.1038/35017054; Overgaard J, 2005, LANCET ONCOL, V6, P757, DOI 10.1016/S1470-2045(05)70292-8; Raleigh JA, 1998, CANCER RES, V58, P3765; Rapisarda A, 2002, CANCER RES, V62, P4316; Rischin D, 2005, J CLIN ONCOL, V23, P79, DOI 10.1200/JCO.2005.01.072; Rowinsky EK, 1999, ONCOLOGY-NY, V13, P61; Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569; SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Sobhanifar S, 2005, CANCER RES, V65, P7259, DOI 10.1158/0008-5472.CAN-04-4480; Tanimoto K, 2000, EMBO J, V19, P4298, DOI 10.1093/emboj/19.16.4298; Vaupel P, 2004, SEMIN RADIAT ONCOL, V14, P198, DOI 10.1016/j.semradonc.2004.04.008; VAUPEL P, 1989, CANCER RES, V49, P6449; Welsh SJ, 2003, MOL CANCER THER, V2, P235; Yeo EJ, 2003, J NATL CANCER I, V95, P516, DOI 10.1093/jnci/95.7.516; Zackrisson B, 2003, ACTA ONCOL, V42, P443, DOI 10.1080/02841860310014886	38	109	112	1	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 29	2007	26	54					7508	7516		10.1038/sj.onc.1210556	http://dx.doi.org/10.1038/sj.onc.1210556			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	236DB	17563752				2022-12-28	WOS:000251282100002
J	Peng, Y; Stewart, D; Li, W; Hawkins, M; Kulak, S; Ballermann, B; Jahroudi, N				Peng, Y.; Stewart, D.; Li, W.; Hawkins, M.; Kulak, S.; Ballermann, B.; Jahroudi, N.			Irradiation modulates association of NF-Y with histone-modifying cofactors PCAF and HDAC	ONCOGENE			English	Article						NF-Y; HDAC; PCAF; von Willebrand factor; irradiation	WILLEBRAND-FACTOR PROMOTER; PROTEIN PHOSPHATASES; ENDOTHELIAL-CELLS; MDR1 GENE; INDUCTION; RECRUITMENT; ACTIVATION; INHIBITORS	Post-irradiation complications including thrombus formation result from increased procoagulant activity of vascular endothelial cells and elevated levels of von Willebrand factor (VWF) contribute to this process. We have previously demonstrated that irradiation induction of the VWF is mediated through interaction of NF-Y transcription factor with its cognate binding site in the VWF promoter. We have also demonstrated that irradiation increases the association of NF-Y with histone acetyltransferase p300/CBP-associated factor (PCAF). We now report that irradiation decreases the association of NF-Y with histone deacetylase 1 (HDAC1). We demonstrate that irradiation-induced changes in association of NF-Y with HDAC1 and PCAF lead to increased PCAF recruitment to the VWF promoter, increased association of acetylated histone H4 with the VWF promoter and subsequently increased transcription. We also demonstrate that this process is correlated to dephosphorylation of HDAC1 and is inhibited by calyculin A, an inhibitor of protein phosphatase1.	Univ Alberta, Dept Med, Edmonton, AB T6G 2S2, Canada; Albert Einstein Coll Med, Dept Med, Bronx, NY USA	University of Alberta; Yeshiva University; Albert Einstein College of Medicine	Jahroudi, N (corresponding author), Univ Alberta, Dept Med, 370-HMRC, Edmonton, AB T6G 2S2, Canada.	nadia.jahroudi@ualberta.ca	Ballermann, Barbara J/G-5349-2016	Ballermann, Barbara J/0000-0002-8220-6381	NHLBI NIH HHS [HL-67729] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL067729] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adachi N, 2000, GENE, V245, P49, DOI 10.1016/S0378-1119(00)00040-8; Barford D, 1998, ANNU REV BIOPH BIOM, V27, P133, DOI 10.1146/annurev.biophys.27.1.133; Bertagna A, 2001, THROMB HAEMOSTASIS, V85, P837; Brush MH, 2004, J BIOL CHEM, V279, P7685, DOI 10.1074/jbc.M310997200; Caretti G, 2003, J BIOL CHEM, V278, P30435, DOI 10.1074/jbc.M304606200; Criswell T, 2003, ONCOGENE, V22, P5813, DOI 10.1038/sj.onc.1206680; DICHEK D, 1989, IN VITRO CELL DEV B, V25, P289; Edwards E, 2002, CANCER RES, V62, P4671; FAJARDO LF, 1996, VASCULAR BRACHYTHERA, P74; Guo C, 2007, CELL SIGNAL, V19, P504, DOI 10.1016/j.cellsig.2006.08.001; Guo CY, 2002, J BIOL CHEM, V277, P41756, DOI 10.1074/jbc.M207519200; Hu Z, 2000, J BIOL CHEM, V275, P2979, DOI 10.1074/jbc.275.4.2979; ISHIHARA H, 1989, BIOCHEM BIOPH RES CO, V159, P871, DOI 10.1016/0006-291X(89)92189-X; JAHROUDI N, 1994, MOL CELL BIOL, V14, P999, DOI 10.1128/MCB.14.2.999; Jin SK, 1998, MOL CELL BIOL, V18, P4377, DOI 10.1128/MCB.18.7.4377; Jin SQ, 2001, ONCOGENE, V20, P2683, DOI 10.1038/sj.onc.1204390; Maity SN, 1998, TRENDS BIOCHEM SCI, V23, P174, DOI 10.1016/S0968-0004(98)01201-8; Manni I, 2001, J BIOL CHEM, V276, P5570, DOI 10.1074/jbc.M006052200; Mantovani R, 1999, GENE, V239, P15, DOI 10.1016/S0378-1119(99)00368-6; Mantovani R, 1998, NUCLEIC ACIDS RES, V26, P1135, DOI 10.1093/nar/26.5.1135; Peng YW, 2002, BLOOD, V99, P2408, DOI 10.1182/blood.V99.7.2408; Peng YW, 2003, J BIOL CHEM, V278, P8385, DOI 10.1074/jbc.M213156200; Rodeghiero F, 2002, HAEMOPHILIA, V8, P292, DOI 10.1046/j.1365-2516.2002.00611.x; WEICHSELBAUM RR, 1994, INT J RADIAT ONCOL, V30, P229, DOI 10.1016/0360-3016(94)90539-8	24	24	24	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 29	2007	26	54					7576	7583		10.1038/sj.onc.1210565	http://dx.doi.org/10.1038/sj.onc.1210565			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	236DB	17599060				2022-12-28	WOS:000251282100010
J	Zhang, X; Leung, YK; Ho, SM				Zhang, X.; Leung, Y-K; Ho, S-M			AP-2 regulates the transcription of estrogen receptor (ER)-beta by acting through a methylation hotspot of the 0N promoter in prostate cancer cells	ONCOGENE			English	Article						epigenetics; promoter analysis; non-canonical; cis-element; tumor suppressor; gene regulation	ER-BETA; ACTIVATOR PROTEIN-2-ALPHA; GENE-EXPRESSION; BREAST-CANCER; BINDING; CLONING; FAMILY; DNA; CARCINOGENESIS; CARCINOMA	We reported previously that the loss of expression of estrogen receptor (ER)-beta during the development of prostate cancer (PCa) is associated with methylation of a CpG island located in the 5'-flanking sequence of the 0N promoter. Three methylation hotspots, referred to as centers 1, 2 and 3, were identified in the CpG island. In this study, we demonstrated that a 581-bp region with these three centers within it is sufficient for the promoter activity in PCa cells. Deletion analyses indicated that center 1 ( 16 bp), with a putative activator protein-2 (AP-2) binding site, is essential for gene transactivation. Chromatin immunoprecipitation assays showed that AP-2 alpha occupies a short sequence containing center 1. Forced expression of AP-2 alpha or -2 gamma, but not -2 beta, increased activity of the ER beta 0N promoter and the accumulation of mRNA. Conversely, siRNA-mediated AP-2 alpha and -2 gamma knockdown reduced levels of ERb transcript and promoter activity. Quantitative reverse transcription - PCR showed that AP-2 alpha and -2 gamma are the predominant transcripts expressed in PCa cells, and levels of ERb transcript correlate with levels of these AP-2 transcripts among different PCa cell lines. These results provide the first evidence that ERb is an AP-2-regulated gene. They also support the hypothesis that certain cis-acting elements are methylation hotspots susceptible to epigenetic modi. cations during cancer progression.	Univ Cincinnati, Coll Med, Dept Environm Hlth, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati	Ho, SM (corresponding author), Univ Cincinnati, Coll Med, Dept Environm Hlth, 130 Kettering,3223 Eden Ave,PO Box 670056, Cincinnati, OH 45267 USA.	shuk-mei.ho@uc.edu	Zhang, Xiang/D-3632-2009; Leung, Ricky/H-5958-2019	Leung, Ricky/0000-0003-2063-277X	NIDDK NIH HHS [DK061084] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK061084] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bar-Eli M, 2001, PIGM CELL RES, V14, P78, DOI 10.1034/j.1600-0749.2001.140202.x; Baylin Stephen B, 2005, Nat Clin Pract Oncol, V2 Suppl 1, pS4, DOI 10.1038/ncponc0354; Bosher JM, 1996, ONCOGENE, V13, P1701; Carroll JS, 2006, NAT GENET, V38, P1289, DOI 10.1038/ng1901; Comhaire F, 2004, Aging Male, V7, P155; Garinis GA, 2002, HUM GENET, V111, P115, DOI 10.1007/s00439-002-0783-6; HERMANN R, 1991, FEBS LETT, V281, P191, DOI 10.1016/0014-5793(91)80391-F; Hilger-Eversheim K, 2000, GENE, V260, P1, DOI 10.1016/S0378-1119(00)00454-6; Hirata S, 2001, J STEROID BIOCHEM, V78, P33, DOI 10.1016/S0960-0760(01)00071-1; Ho SM, 2006, ANN NY ACAD SCI, V1089, P177, DOI 10.1196/annals.1386.005; Ho SM, 2006, CANCER RES, V66, P5624, DOI 10.1158/0008-5472.CAN-06-0516; Horvath LG, 2001, CANCER RES, V61, P5331; Imamov O, 2005, BIOL REPROD, V73, P866, DOI 10.1095/biolreprod.105.043497; Kuiper GGJM, 1996, P NATL ACAD SCI USA, V93, P5925, DOI 10.1073/pnas.93.12.5925; Lai JS, 2004, UROLOGY, V64, P814, DOI 10.1016/j.urology.2004.05.036; Lau KM, 2000, CANCER RES, V60, P3175; Leav I, 2001, AM J PATHOL, V159, P79, DOI 10.1016/S0002-9440(10)61676-8; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Marreiros A, 2005, ONCOGENE, V24, P637, DOI 10.1038/sj.onc.1208216; Mitchell DC, 2006, J BIOL CHEM, V281, P51, DOI 10.1074/jbc.M506245200; Mohibullah N, 1999, NUCLEIC ACIDS RES, V27, P2760, DOI 10.1093/nar/27.13.2760; Nieto M, 2007, INT J BIOCHEM CELL B, V39, P1562, DOI 10.1016/j.biocel.2007.01.005; Ockrim J, 2006, NAT CLIN PRACT ONCOL, V3, P552, DOI 10.1038/ncponc0602; Pellikainen JM, 2007, INT J CANCER, V120, P2061, DOI 10.1002/ijc.22648; Ruiz M, 2001, CLIN CANCER RES, V7, P4086; Shoda T, 2002, J STEROID BIOCHEM, V82, P201, DOI 10.1016/S0960-0760(02)00186-3; Signoretti S, 2001, AM J PATHOL, V159, P13, DOI 10.1016/S0002-9440(10)61666-5; Tummala R, 2003, GENE, V321, P93, DOI 10.1016/S0378-1119(03)00840-0; Zhu CH, 2001, J BIOL CHEM, V276, P14407, DOI 10.1074/jbc.M009708200; ZHU X, 2004, AM J PATHOL, V546, P17	30	35	41	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 15	2007	26	52					7346	7354		10.1038/sj.onc.1210537	http://dx.doi.org/10.1038/sj.onc.1210537			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	231NP	17525739				2022-12-28	WOS:000250955700006
J	Cordes, N; Frickz, S; Brunner, TB; Pilarsky, C; Grutzmann, R; Siposs, B; Kloppels, G; McKenna, WG; Bernhard, EJ				Cordes, N.; Frickz, S.; Brunner, T. B.; Pilarsky, C.; Gruetzmann, R.; Siposs, B.; Kloeppels, G.; McKenna, W. G.; Bernhard, E. J.			Human pancreatic tumor cells are sensitized to ionizing radiation by knockdown of caveolin-1	ONCOGENE			English	Article						caveolin-1; ionizing radiation; beta 1-integrin; FAK; pancreatic cancer	LUNG-CANCER CELLS; INDUCED GENOTOXIC INJURY; P42/44 MAP KINASE; EXTRACELLULAR-MATRIX; DOWN-REGULATION; DUCTAL ADENOCARCINOMA; EXPRESSION; SURVIVAL; ADHESION; GROWTH	Caveolin-1 (Cav-1) is an integral transmembrane protein and a critical component in interactions of integrin receptors with cytoskeleton-associated and signaling molecules. Since integrin-mediated cell adhesion generates signals conferring radiation resistance, we examined the effects of small interfering RNA-mediated knockdown of Cav-1 alone or in combination with beta 1-integrin or focal adhesion kinase (FAK) on radiation survival and proliferation of pancreatic carcinoma cell lines. Irradiation induced Cav-1 expression in PATU8902, MiaPaCa2 and Panel cell lines. The cell lines showed significant radio-sensitization after knockdown of Cav-1, beta 1-integrin or FAK and cholesterol depletion by beta-cyclodextrin relative to nonspecific controls. Under knockdown conditions, proliferation of non-irradiated and irradiated cells was significantly attenuated relative to controls. These findings correlated with changes in expression or phosphorylation of Akt, glycogen synthase kinase 3 beta, Paxillin, Src, c-Jun N-terminal kinase and mitogen-activated protein kinase. Analysis of DNA microarray data revealed a Cav-1 overexpression in a subset of pancreatic ductal adenocarcinoma samples. The data presented show, for the first time, that disruption of interactions of Cav-1 with beta 1-integrin or FAK affects radiation survival and proliferation of pancreatic carcinoma cells and suggest that Cav-1 is critical to these processes.. These results indicate that strategies targeting Cav-1 may be useful as an approach to improve conventional therapies, including radiotherapy, for pancreatic cancer.	Tech Univ Dresden, Med Fac Carl Gustav Carus, OncoRay Ctr Radiat Res Oncol, D-01307 Dresden, Germany; Bundeswehr Inst Radiobiol, Munich, Germany; Univ Erlangen Nurnberg, Erlangen, Germany; Univ Hosp Dresden, Dept Visceral Thorac, Dresden, Germany; Univ Hosp Dresden, Dept Vasc Surg, Dresden, Germany; Univ Hosp Kiel, Dept Pathol, Kiel, Germany; Univ Oxford, Churchill Hosp, Radiobiol Res Inst, Oxford, England	Technische Universitat Dresden; Carl Gustav Carus University Hospital; University of Erlangen Nuremberg; Technische Universitat Dresden; Carl Gustav Carus University Hospital; Technische Universitat Dresden; Carl Gustav Carus University Hospital; University of Kiel; Schleswig Holstein University Hospital; University of Oxford	Cordes, N (corresponding author), Tech Univ Dresden, Med Fac Carl Gustav Carus, OncoRay Ctr Radiat Res Oncol, Fetscherstasse 74-PF, D-01307 Dresden, Germany.	nils.cordes@oncoray.de	BERNHARD, ERIC/HIU-0025-2022	Cordes, Nils/0000-0001-5684-629X; Pilarsky, Christian/0000-0002-7968-3283	Medical Research Council [G0700730] Funding Source: Medline; NCI NIH HHS [R01 CA73820] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA073820] Funding Source: NIH RePORTER; MRC [G0700730] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Belanger MM, 2004, CANCER BIOL THER, V3, P954, DOI 10.4161/cbt.3.10.1112; Buttery RC, 2004, INT J BIOCHEM CELL B, V36, P1154, DOI 10.1016/S1357-2725(03)00261-9; Carver LA, 2003, NAT REV CANCER, V3, P571, DOI 10.1038/nrc1146; Cherubini A, 2005, MOL BIOL CELL, V16, P2972, DOI 10.1091/mbc.E04-10-0940; Cohen AW, 2003, AM J PHYSIOL-CELL PH, V284, pC457, DOI 10.1152/ajpcell.00380.2002; Cordes N, 2006, ONCOGENE, V25, P1378, DOI 10.1038/sj.onc.1209164; Cordes N, 2004, CANCER RES, V64, P5683, DOI 10.1158/0008-5472.CAN-04-1056; Cordes N, 2003, STRAHLENTHER ONKOL, V179, P337, DOI 10.1007/s00066-003-1074-4; Eke I, 2006, RADIOTHER ONCOL, V80, P178, DOI 10.1016/j.radonc.2006.07.028; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Estrugo D, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000269; Fiucci G, 2002, ONCOGENE, V21, P2365, DOI 10.1038/sj.onc.1205300; Fritz G, 2003, INT J RADIAT BIOL, V79, P601, DOI 10.1080/09553000310001609233; Galbiati F, 2001, MOL BIOL CELL, V12, P2229, DOI 10.1091/mbc.12.8.2229; Galbiati F, 1998, EMBO J, V17, P6633, DOI 10.1093/emboj/17.22.6633; Gonzalez E, 2004, J BIOL CHEM, V279, P40659, DOI 10.1074/jbc.M407051200; Grutzmann R, 2004, NEOPLASIA, V6, P611, DOI 10.1593/neo.04295; Grutzmann R, 2005, ONCOGENE, V24, P5079, DOI 10.1038/sj.onc.1208696; Grutzmann R, 2003, VIRCHOWS ARCH, V443, P508, DOI 10.1007/s00428-003-0884-1; Hailstones D, 1998, J LIPID RES, V39, P369; Hayashi K, 2001, CANCER RES, V61, P2361; Hehlgans S, 2007, BBA-REV CANCER, V1775, P163, DOI 10.1016/j.bbcan.2006.09.001; Hess F, 2007, ONCOGENE, V26, P1372, DOI 10.1038/sj.onc.1209947; Hodkinson PS, 2006, CELL DEATH DIFFER, V13, P1776, DOI 10.1038/sj.cdd.4401849; Iacobuzio-Donahue CA, 2003, AM J PATHOL, V162, P1151, DOI 10.1016/S0002-9440(10)63911-9; Iliakis G, 1997, SEMIN ONCOL, V24, P602; Kasahara T, 2002, ANTIOXID REDOX SIGN, V4, P491, DOI 10.1089/15230860260196290; KOLESKE AJ, 1995, P NATL ACAD SCI USA, V92, P1381, DOI 10.1073/pnas.92.5.1381; Lee SW, 1998, ONCOGENE, V16, P1391, DOI 10.1038/sj.onc.1201661; Li C, 2001, P NATL ACAD SCI USA, V98, P31, DOI 10.1073/pnas.011404098; Li JW, 2005, CELL CYCLE, V4, P1817, DOI 10.4161/cc.4.12.2199; Li LK, 2003, MOL CELL BIOL, V23, P9389, DOI 10.1128/MCB.23.24.9389-9404.2003; MILLER AC, 1993, INT J CANCER, V53, P302, DOI 10.1002/ijc.2910530222; Razani B, 2002, PHARMACOL REV, V54, P431, DOI 10.1124/pr.54.3.431; Regina A, 2004, J NEUROSCI RES, V75, P291, DOI 10.1002/jnr.10865; Sethi T, 1999, NAT MED, V5, P662, DOI 10.1038/9511; Shatz M, 2004, LEUKEMIA RES, V28, P907, DOI 10.1016/j.leukres.2004.03.013; Sunaga N, 2004, CANCER RES, V64, P4277, DOI 10.1158/0008-5472.CAN-03-3941; Suzuoki M, 2002, BRIT J CANCER, V87, P1140, DOI 10.1038/sj.bjc.6600619; Wary KK, 1998, CELL, V94, P625, DOI 10.1016/S0092-8674(00)81604-9; Willcox M, 2004, TRA HERB, V4, P279; Williams TM, 2005, AM J PHYSIOL-CELL PH, V288, pC494, DOI 10.1152/ajpcell.00458.2004; Yacoub A, 2007, MOL PHARMACOL, V71, P259, DOI 10.1124/mol.106.031153	43	95	100	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 18	2007	26	48					6851	6862		10.1038/sj.onc.1210498	http://dx.doi.org/10.1038/sj.onc.1210498			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	220WQ	17471232				2022-12-28	WOS:000250188400001
J	Banerjee, S; Brooks, WS; Crawford, DF				Banerjee, S.; Brooks, W. S.; Crawford, D. F.			Inactivation of the ubiquitin conjugating enzyme UBE2Q2 causes a prophase arrest and enhanced apoptosis in response to microtubule inhibiting agents	ONCOGENE			English	Article						UBE2Q2; checkpoint; mitosis; microtubule; inhibiting agents (MIAs); apoptosis; antephase	MITOTIC STRESS CHECKPOINT; CELL-CYCLE; KAPPA-B; SPINDLE CHECKPOINT; CHFR; DELAYS; DEGRADATION; EXPRESSION; METAPHASE; GENE	A putative ubiquitin conjugating enzyme known as UBE2Q2 was previously identified in a microarray screen for mitotic regulatory proteins. UBE2Q2 is very similar to another human protein, UBE2Q1 and orthologs from other higher eukaryotic species. In these studies, we demonstrate that UBE2Q2 can covalently bind ubiquitin on the active site cysteine in vitro and show that inhibition of this protein in vivo causes an early mitotic arrest and increased cytotoxicity when cells are treated with microtubule inhibiting agents (MIAs). Changes in cell cycle progression and viability are not observed in the absence of MIA treatment, indicating that UBE2Q2 is involved in the response to MIAs rather than performing a more general function in mitosis. Inhibition of the UBE2Q2 protein causes cells to undergo a prolonged prophase arrest suggesting that UBE2Q2 normally functions to antagonize an early mitotic checkpoint. Furthermore, UBE2Q2 inhibition sensitizes cells to the cytotoxic effects of MIAs through caspase-mediated apoptosis that is correlated with PARP-1 cleavage. These data provide insights into the cellular response to MIAs and demonstrate that inhibition of UBE2Q2 protein function may be useful in the treatment of malignancies.	Univ Alabama, Dept Pediat, Birmingham, AL USA; Univ Alabama, Dept Cell Biol, Birmingham, AL 35294 USA; Univ Alabama, Dept Biochem & Mol Genet, Birmingham, AL USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Crawford, DF (corresponding author), Univ Alabama, Dept Pediat & Cell Biol, 1600 7th Ave S,ACC 512, Birmingham, AL 35233 USA.	dfc@uab.edu			NCI NIH HHS [5K08CA86941-5] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K08CA086941] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aristarkhov A, 1996, P NATL ACAD SCI USA, V93, P4294, DOI 10.1073/pnas.93.9.4294; Baker DJ, 2005, CURR OPIN CELL BIOL, V17, P583, DOI 10.1016/j.ceb.2005.09.011; BANERJEE A, 1995, J BIOL CHEM, V270, P26209, DOI 10.1074/jbc.270.44.26209; Bhalla KN, 2003, ONCOGENE, V22, P9075, DOI 10.1038/sj.onc.1207233; CHEN C, 1987, MOL CELL BIOL, V7, P27; Corn PG, 2003, CARCINOGENESIS, V24, P47, DOI 10.1093/carcin/24.1.47; Crawford DF, 2001, J BIOL CHEM, V276, P37166, DOI 10.1074/jbc.M103414200; Gorbsky GJ, 2001, CURR BIOL, V11, pR1001, DOI 10.1016/S0960-9822(01)00609-1; Gu HD, 2003, P NATL ACAD SCI USA, V100, P8963, DOI 10.1073/pnas.1533420100; Huang Y, 2004, MOL CANCER THER, V3, P271; Koh DW, 2005, PHARMACOL RES, V52, P5, DOI 10.1016/j.phrs.2005.02.011; KUNG AL, 1990, P NATL ACAD SCI USA, V87, P9553, DOI 10.1073/pnas.87.24.9553; Lew DJ, 2003, ANNU REV GENET, V37, P251, DOI 10.1146/annurev.genet.37.042203.120656; Li L, 2004, CANCER-AM CANCER SOC, V101, P2351, DOI 10.1002/cncr.20605; Li YP, 2003, FASEB J, V17, P1048, DOI 10.1096/fj.02-0759com; Liu Q, 2006, INVEST OPHTH VIS SCI, V47, P1302, DOI 10.1167/iovs.05-0935; Matsusaka T, 2004, J CELL BIOL, V166, P507, DOI 10.1083/jcb.200401139; Melner MH, 2004, BIOL REPROD, V70, P406, DOI 10.1095/biolreprod.103.020719; Melner MH, 2006, BIOL REPROD, V75, P395, DOI 10.1095/biolreprod.106.051458; Mizuno K, 2002, ONCOGENE, V21, P2328, DOI 10.1038/sj.onc.1205402; Mollinedo F, 2003, APOPTOSIS, V8, P413, DOI 10.1023/A:1025513106330; Musacchio A, 2002, NAT REV MOL CELL BIO, V3, P731, DOI 10.1038/nrm929; Pallardy M, 1999, METHODS, V19, P36, DOI 10.1006/meth.1999.0825; Pati D, 1999, MOL CELL BIOL, V19, P5001; PINKERTON CR, 1988, CANCER CHEMOTH PHARM, V22, P271, DOI 10.1007/BF00273423; Pray TR, 2002, DRUG RESIST UPDATE, V5, P249, DOI 10.1016/S1368-7646(02)00121-8; RIEDER CL, 1994, J CELL BIOL, V127, P1301, DOI 10.1083/jcb.127.5.1301; RIEDER CL, 1992, J CELL SCI, V102, P387; Rieder CL, 2000, CURR BIOL, V10, P1067, DOI 10.1016/S0960-9822(00)00678-3; Schulze E, 2003, BIOCHEM BIOPH RES CO, V305, P691, DOI 10.1016/S0006-291X(03)00824-6; Scolnick DM, 2000, NATURE, V406, P430, DOI 10.1038/35019108; Seghatoleslam A, 2006, BIOCHEM BIOPH RES CO, V339, P422, DOI 10.1016/j.bbrc.2005.11.026; Skerra A, 1999, BIOMOL ENG, V16, P79, DOI 10.1016/S1050-3862(99)00033-9; Tashiro K, 1997, P NATL ACAD SCI USA, V94, P7862, DOI 10.1073/pnas.94.15.7862; Townsley FM, 1997, P NATL ACAD SCI USA, V94, P2362, DOI 10.1073/pnas.94.6.2362; Toyota M, 2003, P NATL ACAD SCI USA, V100, P7818, DOI 10.1073/pnas.1337066100; Vodermaier HC, 2004, CURR BIOL, V14, pR787, DOI 10.1016/j.cub.2004.09.020; WEISSMAN AM, 2001, NAT REV MOL CELL BIO, V21, P3445; Xu B, 2001, MOL CELL BIOL, V21, P3445, DOI 10.1128/MCB.21.10.3445-3450.2001; Zhang YW, 2005, MOL CELL, V19, P607, DOI 10.1016/j.molcel.2005.07.019	40	13	13	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2007	26	45					6509	6517		10.1038/sj.onc.1210471	http://dx.doi.org/10.1038/sj.onc.1210471			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	217AF	17471241				2022-12-28	WOS:000249919800004
J	Kanome, T; Itoh, N; Ishikawa, F; Mori, K; Kim-Kaneyama, JR; Nose, K; Shibanuma, M				Kanome, T.; Itoh, N.; Ishikawa, F.; Mori, K.; Kim-Kaneyama, J-R; Nose, K.; Shibanuma, M.			Characterization of Jumping translocation breakpoint (JTB) gene product isolated as a TGF-beta 1-inducible clone involved in regulation of mitochondrial function, cell growth and cell death	ONCOGENE			English	Article						JTB; mitochondria; TGF-beta	BETA-INDUCED APOPTOSIS; CANCER-CELLS; ACTIVATION; EXPRESSION; PATHWAY; PROTEIN; CHEMOTHERAPY; RESPIRATION; MUTATIONS; TARGET	Jumping translocation breakpoint ( JTB) is a gene located on human chromosome 1 at q21 that suffers an unbalanced translocation in various types of cancers, and potentially encodes a transmembrane protein of unknown function. The results of cancer pro. ling indicated that its expression was suppressed in many cancers from different organs, implying a role in the neoplastic transformation of cells. Recently, we isolated JTB as a TGF-beta 1-inducible clone by differential screening. In this study, we characterized its product and biological functions. We found that it was processed at the N- terminus and located mostly in mitochondria. When expressed in cells, JTB- induced clustering of mitochondria around the nuclear periphery and swelling of each mitochondrion. In those mitochondria, membrane potential, as monitored with a JC- 1 probe, was significantly reduced. Coinciding with these changes in mitochondria, JTB retarded the growth of the cells and conferred resistance to TGF-beta 1-induced apoptosis. These activities were dependent on the N- terminal processing and induced by wild- type JTB but not by a mutant resistant to cleavage. These findings raised the possibility that aberration of JTB in structure or expression induced neoplastic changes in cells through dysfunction of mitochondria leading to deregulated cell growth and/or death.	Showa Univ, Sch Pharmaceut Sci, Dept Microbiol, Shinagawa Ku, Tokyo 1428555, Japan	Showa University	Shibanuma, M (corresponding author), Showa Univ, Sch Pharmaceut Sci, Dept Microbiol, Shinagawa Ku, 1-5-8 Hatanodai, Tokyo 1428555, Japan.	smotoko@pharm.showa-u.ac.jp	Ishikawa, Fuyuki/AAU-4056-2021	Ishikawa, Fuyuki/0000-0002-5580-2305				Chen RH, 1997, CELL GROWTH DIFFER, V8, P821; Costantini P, 2000, J NATL CANCER I, V92, P1042, DOI 10.1093/jnci/92.13.1042; Dang CV, 1999, TRENDS BIOCHEM SCI, V24, P68, DOI 10.1016/S0968-0004(98)01344-9; Debatin KM, 2002, ONCOGENE, V21, P8786, DOI 10.1038/sj.onc.1206039; Goldenthal MJ, 2004, MOL CELL BIOCHEM, V262, P1, DOI 10.1023/B:MCBI.0000038228.85494.3b; Hatakeyama S, 1999, ONCOGENE, V18, P2085, DOI 10.1038/sj.onc.1202510; Jang CW, 2002, NAT CELL BIOL, V4, P51, DOI 10.1038/ncb731; Kaelin WG, 2005, CELL METAB, V1, P357, DOI 10.1016/j.cmet.2005.05.006; Keung YK, 1998, CANCER GENET CYTOGEN, V106, P135, DOI 10.1016/S0165-4608(97)00316-6; Kim SG, 2004, MOL BIOL CELL, V15, P420, DOI 10.1091/mbc.E03-04-0201; Kim-Kaneyama J, 2005, J CELL SCI, V118, P937, DOI 10.1242/jcs.01683; Kitamura T, 2003, EXP HEMATOL, V31, P1007, DOI 10.1016/j.exphem.2003.07.005; Kondoh H, 2005, CANCER RES, V65, P177; Kroemer G, 2003, CURR MED CHEM, V10, P1469, DOI 10.2174/0929867033457232; Larisch S, 2000, NAT CELL BIOL, V2, P915, DOI 10.1038/35046566; Marchetti P, 2002, ANN BIOL CLIN-PARIS, V60, P391; Matoba S, 2006, SCIENCE, V312, P1650, DOI 10.1126/science.1126863; McKenzie M, 2004, NEUROCHEM RES, V29, P589, DOI 10.1023/B:NERE.0000014829.42364.dd; Mori K, 2004, CANCER RES, V64, P7464, DOI 10.1158/0008-5472.CAN-04-1725; Pelicano H, 2006, J CELL BIOL, V175, P913, DOI 10.1083/jcb.200512100; Perlman R, 2001, NAT CELL BIOL, V3, P708, DOI 10.1038/35087019; Petros JA, 2005, P NATL ACAD SCI USA, V102, P719, DOI 10.1073/pnas.0408894102; Rotem R, 2005, CANCER RES, V65, P1984, DOI 10.1158/0008-5472.CAN-04-3091; Saltzman A, 1998, EXP CELL RES, V242, P244, DOI 10.1006/excr.1998.4096; Shibanuma M, 2003, MOL BIOL CELL, V14, P1158, DOI 10.1091/mbc.02-06-0099; Staniek K, 2002, FREE RADICAL RES, V36, P381, DOI 10.1080/10715760290021225; WARBURG O, 1956, SCIENCE, V124, P269; Wong N, 2003, J HEPATOL, V38, P298, DOI 10.1016/S0168-8278(02)00412-9	28	23	25	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2007	26	41					5991	6001		10.1038/sj.onc.1210423	http://dx.doi.org/10.1038/sj.onc.1210423			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	207US	17369841				2022-12-28	WOS:000249277200002
J	de Feraudy, S; Limoli, CL; Gledzinski, E; Karentz, D; Marti, TM; Feeney, L; Cleaver, JE				de Feraudy, S.; Limoli, C. L.; Gledzinski, E.; Karentz, D.; Marti, T. M.; Feeney, L.; Cleaver, J. E.			Pol eta is required for DNA replication during nucleotide deprivation by hydroxyurea	ONCOGENE			English	Article						pol eta; H2AX; hydroxyurea	DOUBLE-STRAND BREAKS; S PHASE CHECKPOINT; POLYMERASE-ETA; HOMOLOGOUS RECOMBINATION; HISTONE H2AX; ARREST; MECHANISM; PHOSPHORYLATION; SENSITIVITY; INHIBITION	Hydroxyurea reduces DNA replication by nucleotide deprivation, whereas UV damage generates DNA photoproducts that directly block replication fork progression. We show that the low fidelity class Y polymerase Pol eta is recruited to proliferating cell nuclear antigen at replication forks both by hydroxyurea and UV light. Under nucleotide deprivation, Pol I allows cells to accumulate at the G1/S boundary by facilitating slow S-phase progression and promotes apoptosis. Normal cells consequently enter apoptosis at a faster rate than Pol eta-deficient cells. Coincident with hydroxyurea-induced S-phase delay, Pol eta-deficient cells undergo more replication fork breakage and accumulate more foci of the Mre11/Rad50/Nbs1 complex and phosphorylated histone H2AX. We conclude that under conditions of nucleotide deprivation, Pol eta is required for S-phase progression but is proapoptotic. However, as Pol eta is reported to require higher nucleotide concentrations than class B replicative polymerases, its recruitment by hydroxyurea requires it to function under suboptimal conditions. Our results suggest that hydr-oxyurea-induced apoptosis occurs at the G1/S boundary and that initiation of the S-phase requires greater nucleotide concentrations than does S-phase progression.	Univ Calif San Francisco, UCSF Canc Ctr, Auerback Melanoma Lab, San Francisco, CA 94143 USA; Univ Calif Irvine, Dept Radiat Oncol, Irvine, CA USA; Univ Calif San Francisco, Dept Biol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; UCSF Medical Center; University of California System; University of California Irvine; University of California System; University of California San Francisco	Cleaver, JE (corresponding author), Univ Calif San Francisco, UCSF Canc Ctr, Auerback Melanoma Lab, Room N431, San Francisco, CA 94143 USA.	jcleaver@cc.ucsf.edu	Marti, Thomas/AAW-5232-2020; Limoli, Charles/AAW-1748-2020	Marti, Thomas/0000-0003-3005-220X; Limoli, Charles/0000-0002-1321-4142	NIEHS NIH HHS [1 RO1 ES 8061] Funding Source: Medline; NINDS NIH HHS [5R01NS052781] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES008061] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS052781] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Arnaudeau C, 2000, MUTAT RES-DNA REPAIR, V461, P221, DOI 10.1016/S0921-8777(00)00052-5; Arnaudeau C, 2001, J MOL BIOL, V307, P1235, DOI 10.1006/jmbi.2001.4564; Broughton BC, 2002, P NATL ACAD SCI USA, V99, P815, DOI 10.1073/pnas.022473899; Burgers PMJ, 2001, J BIOL CHEM, V276, P43487, DOI 10.1074/jbc.R100056200; Carter G L, 1989, Cancer Commun, V1, P13; Cleaver JE, 1999, CANCER RES, V59, P1102; Cleaver JE, 2002, DNA REPAIR, V1, P41, DOI 10.1016/S1568-7864(01)00004-0; Cordonnier AM, 1999, MOL CELL BIOL, V19, P2206; Feijoo C, 2001, J CELL BIOL, V154, P913, DOI 10.1083/jcb.200104099; Furuta T, 2003, J BIOL CHEM, V278, P20303, DOI 10.1074/jbc.M300198200; Halicka HD, 2005, CELL CYCLE, V4, P339; Hammond EM, 2003, MUTAT RES-FUND MOL M, V532, P205, DOI 10.1016/j.mrfmmm.2003.08.017; Johnson RE, 1999, SCIENCE, V285, P263, DOI 10.1126/science.285.5425.263; Kannouche P, 2001, GENE DEV, V15, P158, DOI 10.1101/gad.187501; Limoli CL, 2005, ONCOGENE, V24, P3708, DOI 10.1038/sj.onc.1208515; Limoli CL, 2002, MUTAT RES-FUND MOL M, V510, P121, DOI 10.1016/S0027-5107(02)00257-9; Limoli CL, 2002, P NATL ACAD SCI USA, V99, P233, DOI 10.1073/pnas.231611798; Limoli CL, 2000, P NATL ACAD SCI USA, V97, P7939, DOI 10.1073/pnas.130182897; Masutani C, 1999, NATURE, V399, P700, DOI 10.1038/21447; O'Driscoll M, 2003, NAT GENET, V33, P497, DOI 10.1038/ng1129; Robison JG, 2004, J BIOL CHEM, V279, P34802, DOI 10.1074/jbc.M404750200; Saintigny Y, 2001, EMBO J, V20, P3861, DOI 10.1093/emboj/20.14.3861; Thakur M, 2001, GENE CHROMOSOME CANC, V32, P222, DOI 10.1002/gcc.1186; Ward IM, 2001, J BIOL CHEM, V276, P47759, DOI 10.1074/jbc.C100569200; Washington MT, 2003, MOL CELL BIOL, V23, P8316, DOI 10.1128/MCB.23.22.8316-8322.2003	25	31	31	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2007	26	39					5713	5721		10.1038/sj.onc.1210385	http://dx.doi.org/10.1038/sj.onc.1210385			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	202EP	17369853				2022-12-28	WOS:000248885100003
J	Fleisig, HB; Orazio, N; Liang, H; Tyler, AF; Adams, HP; Weitzman, MD; Nagarajan, L				Fleisig, H. B.; Orazio, N. I.; Liang, H.; Tyler, A. F.; Adams, H. P.; Weitzman, M. D.; Nagarajan, L.			Adenoviral E1B55K oncoprotein sequesters candidate leukemia suppressor sequence-specific single-stranded DNA-binding protein 2 into aggresomes	ONCOGENE			English	Article						SSBP2; E1B55K; direct interaction; colocalization; aggresomes	TRANSCRIPTIONAL REPRESSION; 55-KILODALTON PROTEIN; CELL-TRANSFORMATION; E1B-55K ONCOPROTEIN; E4ORF6 PROTEINS; NUCLEAR EXPORT; INFECTED CELLS; MRE11 COMPLEX; P53; GENE	Sequence-specific single-stranded DNA-binding protein 2 (SSBP2) is a candidate tumor suppressor for human acute myelogenous leukemia (AML). Inducible expression of SSBP2 causes growth arrest and partial differentiation in AML cells. Here, we report that the adenoviral oncoprotein E1B55K directly binds to endogenous SSBP2 protein and sequesters it into juxtanuclear bodies in adenovirally transformed human embryonic kidney (HEK) 293 cells. Similarly, transient expression of E1B55K in IMR90 fibroblasts and HeLa cells result in the formation of juxtanuclear bodies containing SSBP2. When nuclear export of E1B55K is prevented, SSBP2 remains associated with E1B55K in nuclear foci. A requirement for intact microtubules to retain the integrity of the juxtanuclear bodies suggests them to be E1B55K containing aggresomes. The adenoviral E1B55K protein has been shown to localize to the Mre11 complex and p53 to aggresome structures; together with the viral E4orf6 protein, E1B55K recruits a cellular E3 ubiquitin ligase that induces degradation of Mre11 and p53. However, our present studies reveal that E1B55K does not degrade SSBP2. These data demonstrate that E1B55K targets the candidate leukemia suppressor SSBP2 and suggest that subverting its function may contribute to cell transformation by viral oncoproteins.	MD Anderson Canc Ctr, Dept Mol Genet, Houston, TX 77030 USA; Salk Inst Biol Studies, Genet Lab, La Jolla, CA 92037 USA; Univ Calif San Diego, Div Biol, Grad Program, San Diego, CA 92103 USA	University of Texas System; UTMD Anderson Cancer Center; Salk Institute; University of California System; University of California San Diego	Nagarajan, L (corresponding author), MD Anderson Canc Ctr, Dept Mol Genet, Box 1006,1515 Holcombe Blvd, Houston, TX 77030 USA.	lnagaraj@mdanderson.org			NCI NIH HHS [T32 CA064041, CA16672, CA97093] Funding Source: Medline; NHLBI NIH HHS [HL074449] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016672, T32CA064041, R01CA097093] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL074449] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ahuja D, 2005, ONCOGENE, V24, P7729, DOI 10.1038/sj.onc.1209046; Araujo FD, 2005, J VIROL, V79, P11382, DOI 10.1128/JVI.79.17.11382-11391.2005; Bayarsaihan D, 1996, BIOCHEM J, V314, P293, DOI 10.1042/bj3140293; BROWN CR, 1994, J CELL PHYSIOL, V160, P47, DOI 10.1002/jcp.1041600107; Carson CT, 2003, EMBO J, V22, P6610, DOI 10.1093/emboj/cdg630; Castro P, 2002, GENOMICS, V80, P78, DOI 10.1006/geno.2002.6805; Cathomen T, 2000, J VIROL, V74, P11407, DOI 10.1128/JVI.74.23.11407-11412.2000; Chen L, 2002, P NATL ACAD SCI USA, V99, P14320, DOI 10.1073/pnas.212532399; Dobner T, 2001, CURR TOP MICROBIOL, V259, P25; Dosch T, 2001, J VIROL, V75, P5677, DOI 10.1128/JVI.75.12.5677-5683.2001; Endter C, 2005, ONCOGENE, V24, P55, DOI 10.1038/sj.onc.1208170; Endter C, 2004, CURR TOP MICROBIOL, V273, P163; Felsani A, 2006, ONCOGENE, V25, P5277, DOI 10.1038/sj.onc.1209621; Flint SJ, 2003, CURR TOP MICROBIOL, V272, P287; Goardon N, 2006, EMBO J, V25, P357, DOI 10.1038/sj.emboj.7600934; Harada JN, 2002, J VIROL, V76, P9194, DOI 10.1128/JVI.76.18.9194-9206.2002; Kopito RR, 2000, TRENDS CELL BIOL, V10, P524, DOI 10.1016/S0962-8924(00)01852-3; Kratzer F, 2000, ONCOGENE, V19, P850, DOI 10.1038/sj.onc.1203395; Liang H, 2005, ONCOGENE, V24, P2625, DOI 10.1038/sj.onc.1208167; Liu Y, 2005, J VIROL, V79, P14004, DOI 10.1128/JVI.79.22.14004-14016.2005; Martin MED, 1998, J VIROL, V72, P3146, DOI 10.1128/JVI.72.4.3146-3154.1998; Nishioka N, 2005, DEVELOPMENT, V132, P2535, DOI 10.1242/dev.01844; O'Shea CC, 2005, CURR OPIN GENET DEV, V15, P18, DOI 10.1016/j.gde.2004.12.010; ORNELLES DA, 1991, J VIROL, V65, P424, DOI 10.1128/JVI.65.1.424-429.1991; Querido E, 2001, GENE DEV, V15, P3104, DOI 10.1101/gad.926401; Querido E, 1997, J VIROL, V71, P3788, DOI 10.1128/JVI.71.5.3788-3798.1997; Querido E, 2001, J VIROL, V75, P699, DOI 10.1128/JVI.75.2.699-709.2001; SARNOW P, 1982, VIROLOGY, V120, P510, DOI 10.1016/0042-6822(82)90054-X; Schuh AH, 2005, MOL CELL BIOL, V25, P10235, DOI 10.1128/MCB.25.23.10235-10250.2005; STEEGE MW, 1998, PROVEN PRACTICE PREV, V1, P4; Steegenga WT, 1999, MOL CELL BIOL, V19, P3885; Stracker TH, 2002, NATURE, V418, P348, DOI 10.1038/nature00863; Teodoro JG, 1997, J VIROL, V71, P3620, DOI 10.1128/JVI.71.5.3620-3627.1997; van Meyel DJ, 2003, DEVELOPMENT, V130, P1915, DOI 10.1242/dev.00389; Weitzman MD, 2005, ONCOGENE, V24, P7686, DOI 10.1038/sj.onc.1209063; Wienzek S, 2000, J VIROL, V74, P193, DOI 10.1128/JVI.74.1.193-202.2000; Wu LT, 2006, BIOCHEM BIOPH RES CO, V339, P977, DOI 10.1016/j.bbrc.2005.11.098; YEW PR, 1994, GENE DEV, V8, P190, DOI 10.1101/gad.8.2.190; YEW PR, 1992, NATURE, V357, P82, DOI 10.1038/357082a0; ZANTEMA A, 1985, VIROLOGY, V142, P44, DOI 10.1016/0042-6822(85)90421-0; Zhao LY, 2003, J VIROL, V77, P11809, DOI 10.1128/JVI.77.21.11809-11821.2003	41	17	17	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 19	2007	26	33					4797	4805		10.1038/sj.onc.1210281	http://dx.doi.org/10.1038/sj.onc.1210281			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	191ZL	17311003				2022-12-28	WOS:000248170400004
J	Ott, RG; Simma, O; Kollmann, K; Weisz, E; Zebedin, EM; Schorpp-Kistner, M; Heller, G; Zochbauer, S; Wagner, EF; Freissmuth, M; Sexl, V				Ott, R. G.; Simma, O.; Kollmann, K.; Weisz, E.; Zebedin, E. M.; Schorpp-Kistner, M.; Heller, G.; Zoechbauer, S.; Wagner, E. F.; Freissmuth, M.; Sexl, V.			JunB is a gatekeeper for B-lymphoid leukemia	ONCOGENE			English	Article						JunB; bcr/abl; AP-1; leukemia	CHRONIC MYELOID-LEUKEMIA; CYCLIN-DEPENDENT KINASE; MICE LACKING JUNB; C-JUN; TUMOR-DEVELOPMENT; CELL LYMPHOMAS; EXPRESSION; PHOSPHORYLATION; METHYLATION; GAMMA	Loss of JunB has been observed in human leukemia and lymphoma, but it remains unknown, whether this loss is relevant to disease progression. Here, we investigated the consequences of JunB de. ciency using Abelson-induced B- lymphoid leukemia as a model system. Mice de. cient in JunB expression succumbed to Abelson-induced leukemia with increased incidence and significantly reduced latency. Similarly, bcr/abl p185-transformed JunB-deficient (junBD/D) cells induced leukemia in RAG2(-/-) mice displaying a more malignant phenotype. These observations indicated that cell intrinsic effects within the junBD/D tumor cells accounted for the accelerated leukemia development. Indeed, explantated bcr/abl p185 transformed junBD/D cells proliferated faster than the control cells. The proliferative advantage emerged slowly after the initial transformation process and was associated with increased expression levels of the cell cycle kinase cdk6 and with decreased levels of the cell cycle inhibitor p16INK4a. These alterations were due to irreversible reprogramming of the cell, because - once established - accelerated disease induced by junBD/D cells was not reverted by re-introducing JunB. Consistent with this observation, we found that the p16 promoter was methylated. Thus, JunB functions as a gatekeeper during tumor evolution. In its absence, transformed leukemic cells acquire an enhanced proliferative capacity, which presages a more malignant disease.	MUV, Inst Pharmacol, Vienna, Austria; MUV, Dept Oncol, Vienna, Austria; DKFZ, German Canc Res Ctr, Vienna, Austria; IMP, Vienna, Austria	Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)	Sexl, V (corresponding author), Dept Pharmacol, Waehringerstr 13A, A-1090 Vienna, Austria.	sexl@meduniwien.ac.at	heller, gerwin/E-6521-2011; Zöchbauer-Müller, Sabine/B-8399-2012; Sexl, Veronika/B-8657-2016	heller, gerwin/0000-0001-8742-5631; Zöchbauer-Müller, Sabine/0000-0002-6777-1729; Wagner, Erwin F/0000-0001-7872-0196; Freissmuth, Michael/0000-0001-9398-1765; Sexl, Veronika/0000-0001-9363-0412; Kollmann, Karoline/0000-0002-7937-4245				BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; Corcoran MM, 1999, ONCOGENE, V18, P6271, DOI 10.1038/sj.onc.1203033; Deininger M, 2005, BLOOD, V105, P2640, DOI 10.1182/blood-2004-08-3097; Diehl JA, 1997, MOL CELL BIOL, V17, P7362, DOI 10.1128/MCB.17.12.7362; Eferl R, 2003, CELL, V112, P181, DOI 10.1016/S0092-8674(03)00042-4; Ezhevsky SA, 1997, P NATL ACAD SCI USA, V94, P10699, DOI 10.1073/pnas.94.20.10699; GRAWUNDER U, 1993, EUR J IMMUNOL, V23, P544, DOI 10.1002/eji.1830230237; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Kaplan DH, 1998, P NATL ACAD SCI USA, V95, P7556, DOI 10.1073/pnas.95.13.7556; Kenner L, 2004, J CELL BIOL, V164, P613, DOI 10.1083/jcb.200308155; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427; Mao X, 2002, GENE CHROMOSOME CANC, V35, P144, DOI 10.1002/gcc.10104; Mao X, 2003, BLOOD, V101, P1513, DOI 10.1182/blood-2002-08-2434; Marique T, 2001, J THEOR BIOL, V209, P3, DOI 10.1006/jtbi.2000.2237; Markevich NI, 2004, J CELL BIOL, V164, P353, DOI 10.1083/jcb.200308060; Mechta-Grigoriou F, 2001, ONCOGENE, V20, P2378, DOI 10.1038/sj.onc.1204381; Passegue E, 2001, CELL, V104, P21, DOI 10.1016/S0092-8674(01)00188-X; Passegue E, 2004, CELL, V119, P431, DOI 10.1016/j.cell.2004.10.010; Rassidakis GZ, 2005, MODERN PATHOL, V18, P1365, DOI 10.1038/modpathol.3800419; Schorpp-Kistner M, 1999, EMBO J, V18, P934, DOI 10.1093/emboj/18.4.934; Sexl V, 2000, BLOOD, V96, P2277, DOI 10.1182/blood.V96.6.2277; Sexl V, 1999, ONCOGENE, V18, P573, DOI 10.1038/sj.onc.1202362; Shankaran V, 2001, NATURE, V410, P1107, DOI 10.1038/35074122; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; Szabowski A, 2000, CELL, V103, P745, DOI 10.1016/S0092-8674(00)00178-1; Szremska AP, 2003, BLOOD, V102, P4159, DOI 10.1182/blood-2003-03-0915; Vogelstein B, 2004, NAT MED, V10, P789, DOI 10.1038/nm1087; Wolff L, 2003, ONCOGENE, V22, P9265, DOI 10.1038/sj.onc.1207092; WU JX, 1990, ONCOGENE, V5, P989; Yang MY, 2003, BLOOD, V101, P3205, DOI 10.1182/blood-2002-05-1598	35	18	18	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 19	2007	26	33					4863	4871		10.1038/sj.onc.1210285	http://dx.doi.org/10.1038/sj.onc.1210285			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	191ZL	17297445				2022-12-28	WOS:000248170400011
J	Schniewind, B; Groth, S; Muerkoster, SS; Sipos, B; Schaefer, H; Kalthoff, H; Fandrich, F; Ungefroren, H				Schniewind, B.; Groth, S.; Mueerkoester, S. Sebens; Sipos, B.; Schaefer, H.; Kalthoff, H.; Faendrich, F.; Ungefroren, H.			Dissecting the role of TGF-beta type I receptor/ALK5 in pancreatic ductal adenocarcinoma: Smad activation is crucial for both the tumor suppressive and prometastatic function	ONCOGENE			English	Article						TGF-beta; pancreatic carcinoma; ALK5; smad; metastasis	GROWTH-FACTOR-BETA; CANCER-CELLS; BREAST-CANCER; TRANSCRIPTIONAL REPRESSION; MESENCHYMAL TRANSITION; MAMMARY TUMORIGENESIS; ENHANCED EXPRESSION; SIGNALING PATHWAY; BONE METASTASIS; C-MYC	In the present study, we have analysed the effects of transforming growth factor-beta (TGF-beta) signaling on the growth behavior of pancreatic carcinoma cells in vitro and on their tumorigenicity in vivo. Ectopic expression of dominant-negative mutants of the TGF-beta type II receptor or type 1 receptor/activin receptor-like kinase 5(ALK5) in TGF-beta-sensitive pancreatic ductal adenocarcinoma PANC-1 cells prevented the TGF-beta-induced activation of transfected Smad-responsive reporter genes and growth arrest. The growth-inhibitory effect was mimicked by stable expression of kinase-active ALK5( A LK5- T204D), and was dependent on ALK5's ability to activate Smad signaling, as a ALK5-derived mutant with an intact kinase domain but deficient in its ability to activate Smads (RImL45) failed to suppress proliferation in the absence of added TGF-beta. Moreover, this mutant often displayed opposite effects to those of ALK5-TD and blocked various ligand-induced responses in vitro, indicating that it acts in a dominant-negative fashion to inhibit endogenous wild-type receptors. ALK5-TD-, but not RImL45-TD-transduced cells underwent epithelial-to-mesenchymal transition, exhibited a higher ratio of thrombospondin-1 to vascular endothelial growth factor-A expression and upregulated various metastasis-associated genes. Upon orthotopic transplantation of PANC-1 clones into immunodeficient mice, ALK5-TD, but not RImL45-TD, greatly reduced tumor size and induced the formation of liver metastases in otherwise non-metastatic PANC-1 cells. These results suggest a causal, dominant role for the endogenous Smad2/3 signaling pathway in the tumor suppressor and prometastatic activities of TGF-beta in pancreatic tumor cells.	UKSH, Dept Gen Surg & Thorac Surg, Kiel, Germany; Dept Med 1, Lab Mol Gastroenterol & Hepatol, Kiel, Germany; Dept Pathol, Kiel, Germany	University of Kiel; Schleswig Holstein University Hospital	Ungefroren, H (corresponding author), Univ Hosp Kiel, Arnold Heller Str 7, D-24105 Kiel, Germany.	hungefroren@chirurgie-sh.de	Sebens, Susanne/C-1222-2010; Ungefroren, Hendrik/E-2933-2010; Kalthoff, Holger/B-1618-2010; Schäfer, Heiner/C-1055-2011; Faendrich, Fred/B-1705-2010					Arnold NB, 2005, J BIOL CHEM, V280, P21858, DOI 10.1074/jbc.M500583200; Baldwin RL, 1996, INT J CANCER, V67, P283, DOI 10.1002/(SICI)1097-0215(19960717)67:2<283::AID-IJC21>3.0.CO;2-B; Bornstein P, 2001, J CLIN INVEST, V107, P929, DOI 10.1172/JCI12749; Bottinger EP, 1997, CANCER RES, V57, P5564; Chen WB, 2002, J BIOL CHEM, V277, P36118, DOI 10.1074/jbc.M203709200; Claassen GF, 2000, P NATL ACAD SCI USA, V97, P9498, DOI 10.1073/pnas.150006697; Dai JL, 1998, CANCER RES, V58, P4592; Deckers M, 2006, CANCER RES, V66, P2202, DOI 10.1158/0008-5472.CAN-05-3560; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Duda DG, 2003, ONCOGENE, V22, P6857, DOI 10.1038/sj.onc.1206751; Ellenrieder V, 2001, INT J CANCER, V93, P204, DOI 10.1002/ijc.1330; Ellenrieder V, 2001, CANCER RES, V61, P4222; Fensterer H, 2004, GENE CHROMOSOME CANC, V39, P224, DOI 10.1002/gcc.20000; FRANZEN P, 1993, CELL, V75, P681, DOI 10.1016/0092-8674(93)90489-D; Frederick JP, 2004, MOL CELL BIOL, V24, P2546, DOI 10.1128/MCB.24.6.2546-2559.2004; FREEMAN JW, 1995, J CELL PHYSIOL, V165, P155, DOI 10.1002/jcp.1041650118; FRIESS H, 1993, CANCER RES, V53, P2704; FRIESS H, 1993, GASTROENTEROLOGY, V105, P1846, DOI 10.1016/0016-5085(93)91084-U; Giehl K, 2000, ONCOGENE, V19, P4531, DOI 10.1038/sj.onc.1203806; Goggins M, 1998, CANCER RES, V58, P5329; Grau AM, 1997, CANCER RES, V57, P3929; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Iglesias M, 2000, ONCOGENE, V19, P4134, DOI 10.1038/sj.onc.1203764; Janda E, 2002, J CELL BIOL, V156, P299, DOI 10.1083/jcb.200109037; Javelaud D, 2005, ONCOGENE, V24, P5742, DOI 10.1038/sj.onc.1208928; Kang YB, 2005, P NATL ACAD SCI USA, V102, P13909, DOI 10.1073/pnas.0506517102; Kang YB, 2006, J CELL BIOCHEM, V98, P1380, DOI 10.1002/jcb.20928; Kleeff J, 1999, ONCOGENE, V18, P5363, DOI 10.1038/sj.onc.1202909; Kuang CZ, 2006, P NATL ACAD SCI USA, V103, P1858, DOI 10.1073/pnas.0508977103; Lawler J, 2000, CURR OPIN CELL BIOL, V12, P634, DOI 10.1016/S0955-0674(00)00143-5; Levy L, 2005, MOL CELL BIOL, V25, P8108, DOI 10.1128/MCB.25.18.8108-8125.2005; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; Moustakas A, 2002, IMMUNOL LETT, V82, P85, DOI 10.1016/S0165-2478(02)00023-8; Muraoka-Cook RS, 2006, ONCOGENE, V25, P3408, DOI 10.1038/sj.onc.1208964; Muraoka-Cook RS, 2005, CLIN CANCER RES, V11, p937S; Nakagawa T, 2004, KIDNEY INT, V66, P605, DOI 10.1111/j.1523-1755.2004.00780.x; Nicolas FJ, 2003, ONCOGENE, V22, P3698, DOI 10.1038/sj.onc.1206420; Oft M, 2002, NAT CELL BIOL, V4, P487, DOI 10.1038/ncb807; Oft M, 1996, GENE DEV, V10, P2462, DOI 10.1101/gad.10.19.2462; Peinado H, 2004, MOL CELL BIOL, V24, P306, DOI 10.1128/MCB.24.1.306-319.2004; Peng BL, 2002, CLIN CANCER RES, V8, P3628; Reiss M, 1997, BREAST CANCER RES TR, V45, P81, DOI 10.1023/A:1005865812918; Rowland-Goldsmith MA, 2002, MOL CANCER THER, V1, P161; Schwarte-Waldhoff I, 2000, P NATL ACAD SCI USA, V97, P9624, DOI 10.1073/pnas.97.17.9624; Siegel PM, 2003, P NATL ACAD SCI USA, V100, P8430, DOI 10.1073/pnas.0932636100; Tian F, 2004, CANCER RES, V64, P4523, DOI 10.1158/0008-5472.CAN-04-0030; Ungefroren H, 2005, J BIOL CHEM, V280, P2644, DOI 10.1074/jbc.M411925200; UNGEFROREN H, 2007, INT J CANC; Voss M, 1999, INT J ONCOL, V14, P93; WARSHAW AL, 1992, NEW ENGL J MED, V326, P455, DOI 10.1056/NEJM199202133260706; WEIDNER N, 1991, NEW ENGL J MED, V324, P1, DOI 10.1056/NEJM199101033240101; WIESER R, 1995, EMBO J, V14, P2199, DOI 10.1002/j.1460-2075.1995.tb07214.x; Yu L, 2002, EMBO J, V21, P3749, DOI 10.1093/emboj/cdf366; Zavadil J, 2005, ONCOGENE, V24, P5764, DOI 10.1038/sj.onc.1208927	56	47	49	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 19	2007	26	33					4850	4862		10.1038/sj.onc.1210272	http://dx.doi.org/10.1038/sj.onc.1210272			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	191ZL	17297450				2022-12-28	WOS:000248170400010
J	Wikman, H; Ruosaari, S; Nymark, P; Sarhadi, V; Saharinen, J; Vanhala, E; Karjalainen, A; Hollmen, J; Knuutila, S; Anttila, S				Wikman, H.; Ruosaari, S.; Nymark, P.; Sarhadi, V. K.; Saharinen, J.; Vanhala, E.; Karjalainen, A.; Hollmen, J.; Knuutila, S.; Anttila, S.			Gene expression and copy number profiling suggests the importance of allelic imbalance in 19p in asbestos-associated lung cancer	ONCOGENE			English	Article						lung cancer; asbestos; microarrays; microsatellite; analysis	CELL-LINES; ADENOCARCINOMA; DNA; IDENTIFICATION; WORKERS; EXPOSURE; SMOKING; TISSUE; BLOOD	Asbestos is a pulmonary carcinogen known to give rise to DNA and chromosomal damage, but the exact carcinogenic mechanisms are still largely unknown. In this study, gene expression arrays were performed on lung tumor samples from 14 heavily asbestos-exposed and 14 non-exposed patients matched for other characteristics. Using a two-step statistical analysis, 47 genes were revealed that could differentiate the tumors of asbestos-exposed from those of non-exposed patients. To identify asbestos-associated regions with DNA copy number and expressional changes, the gene expression data were combined with comparative genomic hybridization microarray data. As a result, a combinatory pro. le of DNA copy number aberrations and expressional changes significantly associated with asbestos exposure was obtained. Asbestos-related areas were detected in 2p21-p16.3, 3p21.31, 5q35.2-q35.3, 16p13.3, 19p13.3-p13.1 and 22q12.3-q13.1. The most prominent of these, 19p13, was further characterized by microsatellite analysis in 62 patients for the differences in allelic imbalance (AI) between the two groups of lung tumors. 79% of the exposed and 45% of the non-exposed patients (P = 0.008) were found to be carriers of AI in their lung tumors. In the exposed group, AI in 19p was prevalent regardless of the histological tumor type. In adenocarcinomas, AI in 19p appeared to occur independently of the asbestos exposure.	Finnish Inst Occupat Hlth, FI-00250 Helsinki, Finland; Univ Med Ctr Hamburg Eppendorf, Dept Tumor Biol, Hamburg, Germany; Aalto Univ, Lab Comp & Informat Sci, FIN-02150 Espoo, Finland; Univ Helsinki, Dept Pathol, Haartman Inst, Helsinki, Finland; Univ Helsinki, Cent Hosp, HUSLAB, Helsinki, Finland; Natl Publ Hlth Inst, Dept Mol Med, Biomedicum, Helsinki, Finland	Finnish Institute of Occupational Health; University of Hamburg; University Medical Center Hamburg-Eppendorf; Aalto University; University of Helsinki; University of Helsinki; Helsinki University Central Hospital; Finland National Institute for Health & Welfare; University of Helsinki	Anttila, S (corresponding author), Finnish Inst Occupat Hlth, Topeliuksenkatu 41aA, FI-00250 Helsinki, Finland.	sisko.anttila@ttl.fi	Nymark, Penny/AAC-9890-2019; Nymark, Penny/B-5246-2014	Nymark, Penny/0000-0002-3435-7775; Wikman, Harriet/0000-0001-6862-0888				Balsara BR, 2002, ONCOGENE, V21, P6877, DOI 10.1038/sj.onc.1205836; Blyth K, 2005, NAT REV CANCER, V5, P376, DOI 10.1038/nrc1607; Bossolasco M, 1999, MOL CARCINOGEN, V26, P189, DOI 10.1002/(SICI)1098-2744(199911)26:3<189::AID-MC8>3.0.CO;2-T; Dano L, 2000, GENE CHROMOSOME CANC, V29, P1, DOI 10.1002/1098-2264(2000)9999:9999<000::AID-GCC1000>3.3.CO;2-S; De Rienzo A, 2000, Clin Ter, V151, P433; FATMA N, 1991, BRIT J IND MED, V48, P103; Gupta N, 2005, BBA-MOL BASIS DIS, V1741, P215, DOI 10.1016/j.bbadis.2005.04.002; Hellstrom I, 2003, CANCER RES, V63, P3695; Hoang JM, 1997, CANCER RES, V57, P300; Hyman E, 2002, CANCER RES, V62, P6240; Ionov Y, 2004, ONCOGENE, V23, P639, DOI 10.1038/sj.onc.1207178; KARJALAINEN A, 1993, AM J IND MED, V23, P461, DOI 10.1002/ajim.4700230309; KARJALAINEN A, 1997, ADV ENV CONTROL TECH, P127; Kettunen E, 2004, CANCER GENET CYTOGEN, V149, P98, DOI 10.1016/s0165-4608(03)00300-5; Li R, 2006, ONCOGENE, V25, P2628, DOI 10.1038/sj.onc.1209289; Marczynski B, 2000, MUTAT RES-GEN TOX EN, V468, P195, DOI 10.1016/S1383-5718(00)00053-X; MARCZYNSKI B, 1994, HUM EXP TOXICOL, V13, P3, DOI 10.1177/096032719401300102; Marsit CJ, 2004, CANCER RES, V64, P8702, DOI 10.1158/0008-5472.CAN-04-2558; Medina PP, 2005, HUM MOL GENET, V14, P973, DOI 10.1093/hmg/ddi091; Michiels S, 2005, LANCET, V365, P488, DOI 10.1016/S0140-6736(05)17866-0; Nymark P, 2006, CANCER RES, V66, P5737, DOI 10.1158/0008-5472.CAN-06-0199; Radak Z, 2005, CANCER LETT, V219, P191, DOI 10.1016/j.canlet.2004.07.008; Reisman DN, 2003, CANCER RES, V63, P560; Safar AM, 2005, CLIN CANCER RES, V11, P4400, DOI 10.1158/1078-0432.CCR-04-2378; Sakakura C, 2005, INT J CANCER, V113, P221, DOI 10.1002/ijc.20551; Sanchez-Cespedes M, 2002, CANCER RES, V62, P3659; Sanchez-Cespedes M, 2001, CANCER RES, V61, P1309; SELIKOFF IJ, 1968, J AMER MED ASSOC, V204, P106, DOI 10.1001/jama.204.2.106; Shukla A, 2003, INT J BIOCHEM CELL B, V35, P1198, DOI 10.1016/S1357-2725(02)00315-1; Shukla A, 2003, FREE RADICAL BIO MED, V34, P1117, DOI 10.1016/S0891-5849(03)00060-1; Takamochi K, 2004, LUNG CANCER, V46, P271, DOI 10.1016/j.lungcan.2004.05.001; Upadhyay D, 2003, EXP BIOL MED, V228, P650, DOI 10.1177/153537020322800602; Wikman H, 2002, ONCOGENE, V21, P5804, DOI 10.1038/sj.onc.1205726	33	35	35	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 12	2007	26	32					4730	4737		10.1038/sj.onc.1210270	http://dx.doi.org/10.1038/sj.onc.1210270			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	190DJ	17297452				2022-12-28	WOS:000248037900014
J	Beke, L; Nuytten, M; Van Eynde, A; Beullens, M; Bollen, M				Beke, L.; Nuytten, M.; Van Eynde, A.; Beullens, M.; Bollen, M.			The gene encoding the prostatic tumor suppressor PSP94 is a target for repression by the Polycomb group protein EZH2	ONCOGENE			English	Article						EZH2; tumor suppressor; Polycomb group proteins; prostate cancer PSP94; epigenetics	SECRETORY PROTEIN; CANCER; METHYLATION; EXPRESSION; GROWTH; HYPERCALCEMIA; PROGRESSION; MALIGNANCY	PSP94, for prostatic secretory protein of 94 amino acids, is secreted by the prostate gland and functions as a suppressor of tumor growth and metastasis. The expression of PSP94 is lost in advanced, hormone-refractory prostate cancer and this correlates with an increased expression of the Polycomb protein EZH2 (enhancer of zeste homolog 2), which represses transcription via trimethylation of histone H3 on Lys27 (H3K27). We show here that these events are causally related and that the MSMB gene, which encodes PSP94, is trimethylated on H3K27 in androgen-refractory, but not in androgen-sensitive prostate cancer cells. Chromatin immunoprecipitation experiments confirmed an association of EZH2 with the MSMB gene. The RNAi-mediated knockdown of EZH2 resulted in a loss of H3K27 trimethylation and an increased expression of the MSMB gene. Conversely, the overexpression of EZH2 was associated with a decreased expression of the MSMB gene. We also demonstrate that MSMB is additionally repressed in androgen-refractory prostate cancer cells by the hypoacetylation of histone H3K9 and the hypermethylation of a CpG island in the promoter region. Our data disclose a hitherto unexplored link between the putative oncogene EZH2 and the tumor suppressor PSP94, and show that MSMB is silenced by EZH2 in advanced prostate cancer cells.	Katholieke Univ Leuven, Fac Med, Dept Mol Cell Biol, Lab Biosignaling & Therapeut, Louvain, Belgium	KU Leuven	Van Eynde, A (corresponding author), Afdeling Biochem, Campus Gasthuisberg,O&N1,Herestr 49,Bus 901, B-3000 Louvain, Belgium.	Aleyde.VanEynde@med.kuleuven.be						Annabi B, 2005, CLIN EXP METASTAS, V22, P429, DOI 10.1007/s10585-005-2669-1; Bracken AP, 2006, GENE DEV, V20, P1123, DOI 10.1101/gad.381706; Bracken AP, 2003, EMBO J, V22, P5323, DOI 10.1093/emboj/cdg542; Cao R, 2004, MOL CELL, V15, P57, DOI 10.1016/j.molcel.2004.06.020; Garde SV, 1999, PROSTATE, V38, P118, DOI 10.1002/(SICI)1097-0045(19990201)38:2<118::AID-PROS5>3.0.CO;2-G; Kirmizis A, 2004, GENE DEV, V18, P1592, DOI 10.1101/gad.1200204; Lamy S, 2006, INT J CANCER, V118, P2350, DOI 10.1002/ijc.21615; LaTulippe E, 2002, CANCER RES, V62, P4499; Martin C, 2005, NAT REV MOL CELL BIO, V6, P838, DOI 10.1038/nrm1761; Ringrose L, 2004, ANNU REV GENET, V38, P413, DOI 10.1146/annurev.genet.38.072902.091907; Saramaki OR, 2006, GENE CHROMOSOME CANC, V45, P639, DOI 10.1002/gcc.20327; Shukeir N, 2004, CANCER RES, V64, P5370, DOI 10.1158/0008-5472.CAN-04-0788; Shukeir N, 2003, CANCER RES, V63, P2072; Stanbrough M, 2006, CANCER RES, V66, P2815, DOI 10.1158/0008-5472.CAN-05-4000; van der Vlag J, 1999, NAT GENET, V23, P474, DOI 10.1038/70602; Vanaja DK, 2003, CANCER RES, V63, P3877; Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075; Vire E, 2006, NATURE, V439, P871, DOI 10.1038/nature04431	18	84	88	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL	2007	26	31					4590	4595		10.1038/sj.onc.1210248	http://dx.doi.org/10.1038/sj.onc.1210248			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	187GR	17237810				2022-12-28	WOS:000247836100013
J	Li, X; Deng, W; Lobo-Ruppert, SM; Ruppert, JM				Li, X.; Deng, W.; Lobo-Ruppert, S. M.; Ruppert, J. M.			Gli1 acts through Snail and E-cadherin to promote nuclear signaling by beta-catenin	ONCOGENE			English	Article						Hedgehog; Snail; Gli1; E-cadherin; beta-catenin; epithelial-mesenchymal transition	EPITHELIAL-MESENCHYMAL TRANSITION; BASAL-CELL CARCINOMA; STEM-CELLS; C-MYC; TUMOR-SUPPRESSOR; CANCER CELLS; WNT; TRANSFORMATION; ADHESION; EXPRESSION	The Hedgehog pathway transcription factor Gli1 induces transformation of epithelial cells via induction of Snail, a repressor of E-cadherin (E-cad). E-cad is normally complexed with beta-catenin at the cell membrane. Loss of E-cad during developmental epithelial-mesenchymal transitions can switch beta-catenin from its role at adherens junctions to its role in nuclear transcription. During tumorigenesis it is unclear which pathways trigger this switch. In the current study, gain- and loss-of-function approaches identified E-cad as a selective inhibitor of transformation by Gli1, and Snail knockdown was rescued by downregulation of E-cad. Gli1 induced relocalization of beta-catenin from the cell membrane to the nucleus. The ability of wild-type or mutant alleles of E-cad to modulate transformation by Gli1 correlated with their ability to regulate localization of beta-catenin. Inhibition of Wnt-beta-catenin signaling by dominant negative Tcf4 selectively blocked in vitro transformation by Gli1. In Gli1-transgenic mice, infiltrating skin tumor cells expressed active, unphosphorylated beta-catenin. Our studies identify E-cad as a selective suppressor of transformation by Gli1 and point to the Sonic Hedgehog-Gli1 pathway as a key regulator of the beta-catenin switch in epithelial cells and cancers.	Univ Alabama, Dept Cell Biol, Birmingham, AL 35294 USA; Univ Alabama, Dept Med, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Ruppert, JM (corresponding author), Univ Alabama, Sch Med, Dept Med, Room 570 WTI, Birmingham, AL 35294 USA.	mruppert@uab.edu			NCI NIH HHS [CA094030, R01 CA094030, CA065686, R29 CA065686, R01 CA065686, R01 CA094030-05] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA065686, R29CA065686, R01CA094030] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akiyoshi T, 2006, GUT, V55, P991, DOI 10.1136/gut.2005.080333; Alonso L, 2003, GENE DEV, V17, P1189, DOI 10.1101/gad.1086903; Ascano JM, 2003, J BIOL CHEM, V278, P8771, DOI 10.1074/jbc.M211427200; Bachelder RE, 2005, J CELL BIOL, V168, P29, DOI 10.1083/jcb.200409067; Barrallo-Gimeno A, 2005, DEVELOPMENT, V132, P3151, DOI 10.1242/dev.01907; Bienz M, 2005, CURR BIOL, V15, pR64, DOI 10.1016/j.cub.2004.12.058; Bonifas JM, 2001, J INVEST DERMATOL, V116, P739, DOI 10.1046/j.1523-1747.2001.01315.x; Brembeck FH, 2006, CURR OPIN GENET DEV, V16, P51, DOI 10.1016/j.gde.2005.12.007; Cavallaro U, 2004, NAT REV CANCER, V4, P118, DOI 10.1038/nrc1276; Ciruna B, 2001, DEV CELL, V1, P37, DOI 10.1016/S1534-5807(01)00017-X; El-Bahrawy M, 2003, BRIT J DERMATOL, V148, P964, DOI 10.1046/j.1365-2133.2003.05240.x; Foster KW, 1999, CELL GROWTH DIFFER, V10, P423; Gottardi CJ, 2004, J CELL BIOL, V167, P339, DOI 10.1083/jcb.200402153; Gottardi CJ, 2001, J CELL BIOL, V153, P1049, DOI 10.1083/jcb.153.5.1049; Gumbiner BM, 2005, NAT REV MOL CELL BIO, V6, P622, DOI 10.1038/nrm1699; Hooper JE, 2005, NAT REV MOL CELL BIO, V6, P306, DOI 10.1038/nrm1622; Huang CC, 2005, CANCER BIOL THER, V4, P1401, DOI 10.4161/cbt.4.12.2355; Inoki K, 2006, CELL, V126, P955, DOI 10.1016/j.cell.2006.06.055; Jian HY, 2006, GENE DEV, V20, P666, DOI 10.1101/gad.1388806; Kolligs FT, 2000, GENE DEV, V14, P1319; Kolligs FT, 1999, MOL CELL BIOL, V19, P5696; Li X, 2006, ONCOGENE, V25, P609, DOI 10.1038/sj.onc.1209077; Louro ID, 2002, CANCER RES, V62, P5867; Louro ID, 1999, CELL GROWTH DIFFER, V10, P503; Mullor JL, 2001, CURR BIOL, V11, P769, DOI 10.1016/S0960-9822(01)00229-9; NAGAFUCHI A, 1987, NATURE, V329, P341, DOI 10.1038/329341a0; Nelson WJ, 2004, SCIENCE, V303, P1483, DOI 10.1126/science.1094291; Nicolas M, 2003, NAT GENET, V33, P416, DOI 10.1038/ng1099; Nusse R, 2003, DEVELOPMENT, V130, P5297, DOI 10.1242/dev.00821; Price MA, 2006, GENE DEV, V20, P399, DOI 10.1101/gad.1394306; RUPPERT JM, 1991, MOL CELL BIOL, V11, P1724, DOI 10.1128/MCB.11.3.1724; Saldanha G, 2004, BRIT J DERMATOL, V151, P157, DOI 10.1111/j.1365-2133.2004.06048.x; Silva-Vargas V, 2005, DEV CELL, V9, P121, DOI 10.1016/j.devcel.2005.04.013; van de Wetering M, 2001, CANCER RES, V61, P278; van den Brink GR, 2004, NAT GENET, V36, P277, DOI 10.1038/ng1304; VonOhlen T, 1997, P NATL ACAD SCI USA, V94, P2404, DOI 10.1073/pnas.94.6.2404; Yook JI, 2005, J BIOL CHEM, V280, P11740, DOI 10.1074/jbc.M413878200; Zhou BHP, 2004, NAT CELL BIOL, V6, P931, DOI 10.1038/ncb1173	38	117	129	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL	2007	26	31					4489	4498		10.1038/sj.onc.1210241	http://dx.doi.org/10.1038/sj.onc.1210241			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	187GR	17297467	Green Accepted			2022-12-28	WOS:000247836100003
J	Strefford, JC; Worley, H; Barber, K; Wright, S; Stewart, ARM; Robinson, HM; Bettney, G; van Delft, FW; Atherton, MG; Davies, T; Griffiths, M; Hing, S; Ross, FM; Talley, P; Saha, V; Moorman, AV; Harrison, CJ				Strefford, J. C.; Worley, H.; Barber, K.; Wright, S.; Stewart, A. R. M.; Robinson, H. M.; Bettney, G.; van Delft, F. W.; Atherton, M. G.; Davies, T.; Griffiths, M.; Hing, S.; Ross, F. M.; Talley, P.; Saha, V.; Moorman, A. V.; Harrison, C. J.			Genome complexity in acute lymphoblastic leukemia is revealed by array-based comparative genomic hybridization	ONCOGENE			English	Article						array; CGH; acute lymphoblastic leukemia; copy number	ACUTE LYMPHOCYTIC-LEUKEMIA; CHROMOSOMAL-ABNORMALITIES; MYELOID-LEUKEMIA; CELL LYMPHOMA; DELETIONS; AMPLIFICATION; MALIGNANCIES; CYTOGENETICS; CGH; IDENTIFICATION	Chromosomal abnormalities are important for the classification and risk stratification of patients with acute lymphoblastic leukemia (ALL). However, approximately 30% of childhood and 50% of adult patients lack abnormalities with clinical relevance. Here, we describe the use of array-based comparative genomic hybridization (aCGH) to identify copy number alterations (CNA) in 58 ALL patients. CNA were identified in 83% of cases, and most frequently involved chromosomes 21 (n = 42), 9 (n = 21), 6 (n = 16), 12 (n = 11), 15 (n = 11), 8 (n = 10) and 17 (n = 10). Deletions of 6q (del(6q)) were heterogeneous in size, in agreement with previous data, demonstrating the sensitivity of aCGH to measure CNA. Although 9p deletions showed considerable variability in both the extent and location, all encompassed the CDKN2A locus. Six patients showed del(12p), with a common region encompassing the ETV6 gene. Complex CNA were observed involving chromosomes 6 (n = 2), 15 (n = 2) and 21 (n = 11) with multiple regions of loss and gain along each chromosome. Chromosome 21 CNA shared a common region of gain, with associated subtelomeric deletions. Other recurrent findings included dim(13q), dim(16q) and enh(17q). This is the first report of genome-wide detection of CNA in ALL patients using aCGH, and it has demonstrated a higher level of karyotype complexity than anticipated from conventional cytogenetic analysis.	Southmead Hosp, S W Reg Cytogenet Ctr, Bristol, Avon, England; Queen Mary Univ London, Inst Canc, Canc Res UK Childrens Canc Grp, London, England; Liverpool Womens Hosp, Merseyside & Cheshire Genet Lab, Liverpool, Merseyside, England; Birmingham Womens Hosp, W Midlands Reg Genet Lab, Birmingham, W Midlands, England; Inst Canc Res, Sect Paediat Oncol, Sutton, Surrey, England; Royal Marsden Hosp, Sutton, Surrey, England; Wessex Reg Genet Lab, Salisbury, Wilts, England; Sheffield Childrens Hosp, Sheffield Reg Cytogenet Serv, Sheffield, S Yorkshire, England; Univ Southampton, Canc Sci Div, Leukaemia Res Cytogenet Grp, Southampton SO9 5NH, Hants, England	Southmead Hospital; Cancer Research UK; University of London; Queen Mary University London; University of Liverpool; Birmingham Women's Hospital; University of London; Institute of Cancer Research - UK; Royal Marsden NHS Foundation Trust; Sheffield Children's NHS Foundation Trust; Sheffield Children's Hospital; University of Southampton	Strefford, JC (corresponding author), Univ Southampton, Southampton Gen Hosp, Canc Sci Div, Leukaemia Res Cytogenet Grp, MP822 Duthie Bldg, Southampton SO16 6YD, Hants, England.	JCS@soton.ac.uk	Moorman, Anthony/F-5518-2010; Strefford, Jonathan/B-2826-2009; Moorman, Anthony/G-1468-2014	Strefford, Jonathan/0000-0002-0972-2881; Moorman, Anthony/0000-0002-9781-6107; Harrison, Christine/0000-0002-0526-6794; van Delft, Frederik Willem/0000-0002-3704-3720; Saha, Vaskar/0000-0002-2916-9649				Attarbaschi A, 2004, LEUKEMIA, V18, P1611, DOI 10.1038/sj.leu.2403471; BEHRENDT H, 1995, LEUKEMIA, V9, P102; Berger R, 2003, LEUKEMIA, V17, P1851, DOI 10.1038/sj.leu.2403061; Bertin R, 2003, GENE CHROMOSOME CANC, V37, P44, DOI 10.1002/gcc.10188; Chung CY, 2000, CANCER, V88, P1359, DOI 10.1002/(SICI)1097-0142(20000315)88:6<1359::AID-CNCR12>3.3.CO;2-H; Clark R, 2000, LEUKEMIA, V14, P241, DOI 10.1038/sj.leu.2401654; Faderl S, 1998, BLOOD, V91, P3995, DOI 10.1182/blood.V91.11.3995; Fioretos T, 1999, BLOOD, V94, P225, DOI 10.1182/blood.V94.1.225.413k24_225_232; Foroni L, 2003, BLOOD, V102, p606A; Haas OA, 1998, LEUKEMIA, V12, P474, DOI 10.1038/sj.leu.2400943; Hann I, 2001, BRIT J HAEMATOL, V113, P103, DOI 10.1046/j.1365-2141.2001.02668.x; Harewood L, 2003, LEUKEMIA, V17, P547, DOI 10.1038/sj.leu.2402849; Harrison CJ, 2005, BRIT J HAEMATOL, V129, P520, DOI 10.1111/j.1365-2141.2005.05497.x; Heerema NA, 2000, J CLIN ONCOL, V18, P3837, DOI 10.1200/JCO.2000.18.22.3837; Heerema NA, 2004, LEUKEMIA, V18, P939, DOI 10.1038/sj.leu.2403327; Horsley SW, 2006, GENE CHROMOSOME CANC, V45, P554, DOI 10.1002/gcc.20317; HOSOYA N, 2006, GENES CHROMOSOMES CA; Iafrate AJ, 2004, NAT GENET, V36, P949, DOI 10.1038/ng1416; *ISCN, 2005, INT SYST HUM CYT NOM; Jackson A, 2000, CANCER RES, V60, P2775; Jong K, 2004, BIOINFORMATICS, V20, P3636, DOI 10.1093/bioinformatics/bth355; KALLIONIEMI A, 1992, SCIENCE, V258, P818, DOI 10.1126/science.1359641; Larramendy ML, 1998, LEUKEMIA, V12, P1638, DOI 10.1038/sj.leu.2401142; Martinez-Ramirez A, 2005, GENE CHROMOSOME CANC, V42, P287, DOI 10.1002/gcc.20154; Mirebeau D, 2006, HAEMATOL-HEMATOL J, V91, P881; Moorman AV, 2003, BLOOD, V102, P2756, DOI 10.1182/blood-2003-04-1128; Mrozek K, 2004, BLOOD REV, V18, P115, DOI 10.1016/S0268-960X(03)00040-7; Nakashima Y, 2005, GENE CHROMOSOME CANC, V44, P247, DOI 10.1002/gcc.20245; Paulsson K, 2006, LEUKEMIA, V20, P840, DOI 10.1038/sj.leu.2404145; Pinkel D, 1998, NAT GENET, V20, P207, DOI 10.1038/2524; PUI CH, 1989, BLOOD, V73, P1963; Pui CH, 2006, NEW ENGL J MED, V354, P166, DOI 10.1056/NEJMra052603; Raghavan M, 2005, CANCER RES, V65, P375; Robinson HM, 2003, LEUKEMIA, V17, P2249, DOI 10.1038/sj.leu.2403140; ROMANA SP, 1994, GENE CHROMOSOME CANC, V9, P186, DOI 10.1002/gcc.2870090307; Rubio-Moscardo F, 2005, BLOOD, V105, P4445, DOI 10.1182/blood-2004-10-3907; RUCKER FG, 2006, J CLIN ONCOL; Scheurlen WG, 1999, GENE CHROMOSOME CANC, V25, P230, DOI 10.1002/(SICI)1098-2264(199907)25:3<230::AID-GCC5>3.0.CO;2-E; Scholz I, 2001, CANCER GENET CYTOGEN, V124, P89, DOI 10.1016/S0165-4608(00)00330-7; Sebat J, 2004, SCIENCE, V305, P525, DOI 10.1126/science.1098918; Sinclair PB, 2004, CANCER RES, V64, P4089, DOI 10.1158/0008-5472.CAN-03-1871; Snijders AM, 2001, NAT GENET, V29, P263, DOI 10.1038/ng754; Strefford JC, 2006, P NATL ACAD SCI USA, V103, P8167, DOI 10.1073/pnas.0602360103; Strehl S, 2003, LEUKEMIA, V17, P1121, DOI 10.1038/sj.leu.2402923; Takeuchi S, 2003, ONCOGENE, V22, P6970, DOI 10.1038/sj.onc.1206974; Tyybakinoja A, 2006, GENE CHROMOSOME CANC, V45, P257, DOI 10.1002/gcc.20288; van Zutven L, 2005, LEUKEMIA, V19, P1281, DOI 10.1038/sj.leu.2403769; VANVLIERBERGHE P, 2006, BLOOD	48	77	81	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 21	2007	26	29					4306	4318		10.1038/sj.onc.1210190	http://dx.doi.org/10.1038/sj.onc.1210190			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	184CY	17237825				2022-12-28	WOS:000247619900013
J	Kluiver, J; van den Berg, A; de Jong, D; Blokzijl, T; Harms, G; Bouwman, E; Jacobs, S; Poppema, S; Kroesen, BJ				Kluiver, J.; van den Berg, A.; de Jong, D.; Blokzijl, T.; Harms, G.; Bouwman, E.; Jacobs, S.; Poppema, S.; Kroesen, B-J			Regulation of pri-microRNA BIC transcription and processing in Burkitt lymphoma	ONCOGENE			English	Article						BIC; microRNA-155; Burkitt lymphoma; microRNA processing; B-cell receptor; ADAR	VIRUS-INDUCED LYMPHOMAS; B-CELL LYMPHOMAS; HIGH EXPRESSION; RNA; MIR-155; IDENTIFICATION; MODULATION; ONCOGENES; PRECURSOR; COMPLEX	BIC is a primary microRNA (pri-miR-155) that can be processed to mature miR-155. In this study, we show the crucial involvement of protein kinase C (PKC) and nuclear factor-kappa B (NF-kappa B) in the regulation of BIC expression upon B-cell receptor triggering. Surprisingly, Northern blot analysis did not reveal any miR-155 expression upon induction of BIC expression in the Burkitt lymphoma-derived Ramos cell line, whereas other microRNAs were clearly detectable. Ectopic expression of BIC in Ramos and HEK293 cells resulted in miR-155 expression in HEK293, but not in Ramos cells, suggesting a specific block of BIC to miR-155 processing in Ramos. In line with the results obtained with Ramos, lack of miR-155 expression after induction of BIC expression was also observed in other Burkitt lymphoma cell lines, indicating a generic and specific blockade in the processing of BIC in Burkitt lymphoma. In contrast, induction of BIC expression in normal tonsillar B cells resulted in very high levels of miR-155 expression and induction of BIC expression in Hodgkin's lymphoma cell lines. It also resulted in elevated levels of miR-155. Our data provide evidence for two levels of regulation for mature miR-155 expression: one at the transcriptional level involving PKC and NF-kappa B, and one at the processing level. Burkitt lymphoma cells not only express low levels of BIC, but also prevent processing of BIC via an, as yet, unknown mechanism.	Univ Groningen, Med Ctr, Dept Pathol & Lab Med, Sect Med Biol, NL-9713 GZ Groningen, Netherlands; Univ Groningen, Med Ctr, Dept Pathol & Lab Med, Sect Pathol, NL-9713 GZ Groningen, Netherlands	University of Groningen; University of Groningen	Kroesen, BJ (corresponding author), Univ Groningen, Med Ctr, Dept Pathol & Lab Med, Sect Med Biol, Hanzeplein 1, NL-9713 GZ Groningen, Netherlands.	b.j.kroesen@med.umcg.nl	van den Berg, Anke/H-1718-2011; Poppema, Sibrand/D-1204-2012; Jones, Jeffrey A/E-9827-2013; Kluiver, Joost/G-6406-2014	van den Berg, Anke/0000-0002-8894-2638; Kluiver, Joost/0000-0001-7650-2937				Calin GA, 2004, P NATL ACAD SCI USA, V101, P11755, DOI 10.1073/pnas.0404432101; Chen CZ, 2005, NEW ENGL J MED, V353, P1768, DOI 10.1056/NEJMp058190; Chen CZ, 2004, SCIENCE, V303, P83, DOI 10.1126/science.1091903; Ciafre SA, 2005, BIOCHEM BIOPH RES CO, V334, P1351, DOI 10.1016/j.bbrc.2005.07.030; CLURMAN BE, 1989, MOL CELL BIOL, V9, P2657, DOI 10.1128/MCB.9.6.2657; Eis PS, 2005, P NATL ACAD SCI USA, V102, P3627, DOI 10.1073/pnas.0500613102; Gregory RI, 2004, NATURE, V432, P235, DOI 10.1038/nature03120; Haasch D, 2002, CELL IMMUNOL, V217, P78, DOI 10.1016/S0008-8749(02)00506-3; Hammond SM, 2006, CURR OPIN GENET DEV, V16, P4, DOI 10.1016/j.gde.2005.12.005; Hutvagner G, 2001, SCIENCE, V293, P834, DOI 10.1126/science.1062961; Hutvagner G, 2002, SCIENCE, V297, P2056, DOI 10.1126/science.1073827; Jiang JM, 2006, GENE CHROMOSOME CANC, V45, P103, DOI 10.1002/gcc.20264; Kluiver J, 2006, GENE CHROMOSOME CANC, V45, P147, DOI 10.1002/gcc.20273; Kluiver J, 2005, J PATHOL, V207, P243, DOI 10.1002/path.1825; Lagos-Quintana M, 2002, CURR BIOL, V12, P735, DOI 10.1016/S0960-9822(02)00809-6; Lee Y, 2003, NATURE, V425, P415, DOI 10.1038/nature01957; Luciano DJ, 2004, RNA, V10, P1174, DOI 10.1261/rna.7350304; Lund E, 2004, SCIENCE, V303, P95, DOI 10.1126/science.1090599; Metzler M, 2004, GENE CHROMOSOME CANC, V39, P167, DOI 10.1002/gcc.10316; Obernosterer G, 2006, RNA, V12, P1161, DOI 10.1261/rna.2322506; Pfeffer S, 2004, SCIENCE, V304, P734, DOI 10.1126/science.1096781; Poy MN, 2004, NATURE, V432, P226, DOI 10.1038/nature03076; Ramkissoon SH, 2006, LEUKEMIA RES, V30, P643, DOI 10.1016/j.leukres.2005.09.001; Schratt GM, 2006, NATURE, V439, P283, DOI 10.1038/nature04367; Specht K, 2001, AM J PATHOL, V158, P419, DOI 10.1016/S0002-9440(10)63985-5; Suh MR, 2004, DEV BIOL, V270, P488, DOI 10.1016/j.ydbio.2004.02.019; Tam W, 2002, J VIROL, V76, P4275, DOI 10.1128/JVI.76.9.4275-4286.2002; van den Berg A, 2003, GENE CHROMOSOME CANC, V37, P20, DOI 10.1002/gcc.10186; Yang WD, 2006, NAT STRUCT MOL BIOL, V13, P13, DOI 10.1038/nsmb1041; Zeng Y, 2005, J BIOL CHEM, V280, P27595, DOI 10.1074/jbc.M504714200	30	109	130	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 31	2007	26	26					3769	3776		10.1038/sj.onc.1210147	http://dx.doi.org/10.1038/sj.onc.1210147			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	175PV	17173072				2022-12-28	WOS:000247026400001
J	Whitmarsh, AJ; Davis, RJ				Whitmarsh, A. J.; Davis, R. J.			Role of mitogen-activated protein kinase kinase 4 in cancer	ONCOGENE			English	Review						MAP kinase; MKK4; JNK; p38; tumor suppressor	JUN NH2-TERMINAL KINASE; N-TERMINAL KINASE; METASTASIS-SUPPRESSOR GENE; EMBRYONIC STEM-CELLS; SIGNAL-TRANSDUCTION PATHWAY; BAX-DEPENDENT APOPTOSIS; HUMAN OVARIAN-CARCINOMA; PROLYL ISOMERASE PIN1; RETINOID-X-RECEPTOR; C-JUN	Mitogen-activated protein (MAP) kinase kinase 4 (MKK4) is a component of stress activated MAP kinase signaling modules. It directly phosphorylates and activates the c-Jun N-terminal kinase (JNK) and p38 families of MAP kinases in response to environmental stress, proinflammatory cytokines and developmental cues. MKK4 is ubiquitously expressed and the targeted deletion of the Mkk4 gene in mice results in early embryonic lethality. Further studies in mice have indicated a role for MKK4 in liver formation, the immune system and cardiac hypertrophy. In humans, it is reported that loss of function mutations in the MKK4 gene are found in approximately 5% of tumors from a variety of tissues, suggesting it may have a tumor suppression function. Further more, MKK4 has been identified as a suppressor of metastasis of prostate and ovarian cancers. However, the role of MKK4 in cancer development appears complex as other studies support a pro-oncogenic role for MKK4 and JNK. Here we review the biochemical and functional properties of MKK4 and discuss the likely mechanisms by which it may regulate the steps leading to the formation of cancers.	Univ Massachusetts, Sch Med, Howard Hughes Med Inst, Program Mol Med, Worcester, MA 01605 USA; Univ Massachusetts, Fac Life Sci, Worcester, MA 01605 USA	Howard Hughes Medical Institute; University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester	Davis, RJ (corresponding author), Univ Massachusetts, Sch Med, Howard Hughes Med Inst, Program Mol Med, 373 Plantat St, Worcester, MA 01605 USA.	roger.davis@umassmed.edu		Davis, Roger/0000-0002-0130-1652; Whitmarsh, Alan/0000-0003-1184-6610				Adam-Stitah S, 1999, J BIOL CHEM, V274, P18932, DOI 10.1074/jbc.274.27.18932; Alt JR, 2000, GENE DEV, V14, P3102, DOI 10.1101/gad.854900; Altucci L, 2001, NAT REV CANCER, V1, P181, DOI 10.1038/35106036; Bartek J, 2001, FEBS LETT, V490, P117, DOI 10.1016/S0014-5793(01)02114-7; Behrens A, 2000, ONCOGENE, V19, P2657, DOI 10.1038/sj.onc.1203603; Bierie B, 2006, NAT REV CANCER, V6, P506, DOI 10.1038/nrc1926; Bost F, 1999, MOL CELL BIOL, V19, P1938; Bost F, 2001, ONCOGENE, V20, P7425, DOI 10.1038/sj.onc.1204924; Brancho D, 2003, GENE DEV, V17, P1969, DOI 10.1101/gad.1107303; Bulavin DV, 2004, ADV CANCER RES, V92, P95, DOI 10.1016/S0065-230X(04)92005-2; Bulavin DV, 2004, NAT GENET, V36, P343, DOI 10.1038/ng1317; Bulavin DV, 1999, EMBO J, V18, P6845, DOI 10.1093/emboj/18.23.6845; Bulavin DV, 2002, NAT GENET, V31, P210, DOI 10.1038/ng894; Bulavin DV, 2001, NATURE, V411, P102, DOI 10.1038/35075107; Buschmann T, 2001, MOL CELL BIOL, V21, P2743, DOI 10.1128/MCB.21.8.2743-2754.2001; Carboni L, 1997, NEUROSCIENCE, V80, P147, DOI 10.1016/S0306-4522(97)00005-5; Casanovas O, 2000, J BIOL CHEM, V275, P35091, DOI 10.1074/jbc.M006324200; Cazillis M, 2004, ONCOGENE, V23, P4735, DOI 10.1038/sj.onc.1207619; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Chen NY, 2001, CANCER RES, V61, P3908; Choi BY, 2005, NAT STRUCT MOL BIOL, V12, P699, DOI 10.1038/nsmb960; Choukroun G, 1999, J CLIN INVEST, V104, P391, DOI 10.1172/JCI6350; Coffey ET, 2000, J NEUROSCI, V20, P7602; Cuenda A, 2000, INT J BIOCHEM CELL B, V32, P581, DOI 10.1016/S1357-2725(00)00003-0; Cui J, 2006, CANCER RES, V66, P10024, DOI 10.1158/0008-5472.CAN-06-0136; Cunningham SC, 2006, CANCER RES, V66, P5560, DOI 10.1158/0008-5472.CAN-06-0555; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; DEMIDOV ON, 2006, IN PRESS ONCOGENE; Deng XM, 2001, J BIOL CHEM, V276, P23681, DOI 10.1074/jbc.M100279200; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; Eferl R, 2003, CELL, V112, P181, DOI 10.1016/S0092-8674(03)00042-4; Fan MY, 2000, J BIOL CHEM, V275, P29980, DOI 10.1074/jbc.M003776200; Finch A, 1997, FEBS LETT, V418, P144, DOI 10.1016/S0014-5793(97)01364-1; Fleming Y, 2000, BIOCHEM J, V352, P145, DOI 10.1042/0264-6021:3520145; Ganiatsas S, 1998, P NATL ACAD SCI USA, V95, P6881, DOI 10.1073/pnas.95.12.6881; Gao YF, 2005, J IMMUNOL, V175, P5783, DOI 10.4049/jimmunol.175.9.5783; Gioeli D, 2006, MOL ENDOCRINOL, V20, P503, DOI 10.1210/me.2005-0351; Goloudina A, 2003, CELL CYCLE, V2, P473, DOI 10.4161/cc.2.5.482; Griend DJV, 2005, CANCER RES, V65, P10984, DOI 10.1158/0008-5472.CAN-05-2382; Ha HY, 2005, DEV BIOL, V277, P184, DOI 10.1016/j.ydbio.2004.09.019; Han ZQS, 1998, MOL CELL BIOL, V18, P3527, DOI 10.1128/MCB.18.6.3527; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; Hess P, 2002, NAT GENET, V32, P201, DOI 10.1038/ng946; Hickson JA, 2006, CANCER RES, V66, P2264, DOI 10.1158/0008-5472.CAN-05-3676; Ho DT, 2003, J BIOL CHEM, V278, P32662, DOI 10.1074/jbc.M304229200; Inoshita S, 2002, J BIOL CHEM, V277, P43730, DOI 10.1074/jbc.M207951200; Jaeschke A, 2006, MOL CELL, V23, P899, DOI 10.1016/j.molcel.2006.07.028; Jiang Y, 1996, J BIOL CHEM, V271, P17920, DOI 10.1074/jbc.271.30.17920; Johnson R, 1996, MOL CELL BIOL, V16, P4504; Kelkar N, 2003, P NATL ACAD SCI USA, V100, P9843, DOI 10.1073/pnas.1733944100; Kennedy NJ, 2003, GENE DEV, V17, P629, DOI 10.1101/gad.1062903; Kennedy NJ, 2003, CELL CYCLE, V2, P199, DOI 10.4161/cc.2.3.388; KHATLANI TS, 2006, IN PRESS ONCOGENE; Kim BJ, 2006, J BIOL CHEM, V281, P21256, DOI 10.1074/jbc.M510644200; Kim GH, 2005, DEV BIOL, V286, P256, DOI 10.1016/j.ydbio.2005.07.033; Kim HL, 2001, CANCER RES, V61, P2833; Kishimoto H, 2003, J BIOL CHEM, V278, P16595, DOI 10.1074/jbc.M213182200; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; Lawler S, 1997, FEBS LETT, V414, P153, DOI 10.1016/S0014-5793(97)00990-3; Lawler S, 1998, CURR BIOL, V8, P1387, DOI 10.1016/S0960-9822(98)00019-0; Lee HY, 2000, J BIOL CHEM, V275, P32193, DOI 10.1074/jbc.M005490200; Lee HY, 2005, CLIN CANCER RES, V11, P6065, DOI 10.1158/1078-0432.CCR-05-0009; Lee JK, 1999, MOL BRAIN RES, V66, P133, DOI 10.1016/S0169-328X(99)00035-2; Lei K, 2002, MOL CELL BIOL, V22, P4929, DOI 10.1128/MCB.22.13.4929-4942.2002; Lei K, 2003, P NATL ACAD SCI USA, V100, P2432, DOI 10.1073/pnas.0438011100; Leppa S, 1998, EMBO J, V17, P4404, DOI 10.1093/emboj/17.15.4404; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; Lisnock J, 2000, BIOCHEMISTRY-US, V39, P3141, DOI 10.1021/bi992410+; Lopez-Aviles S, 2005, MOL CELL, V17, P49, DOI 10.1016/j.molcel.2004.11.043; Manke IA, 2005, MOL CELL, V17, P37, DOI 10.1016/j.molcel.2004.11.021; Mann KK, 2005, J CLIN INVEST, V115, P2924, DOI 10.1172/JCI23628; Matsuo Y, 2006, J BIOL CHEM, V281, P36767, DOI 10.1074/jbc.M604371200; Maundrell K, 1997, J BIOL CHEM, V272, P25238, DOI 10.1074/jbc.272.40.25238; McDonald PH, 2000, SCIENCE, V290, P1574, DOI 10.1126/science.290.5496.1574; Mori S, 2004, ONCOGENE, V23, P7416, DOI 10.1038/sj.onc.1207981; Moriguchi T, 1997, EMBO J, V16, P7045, DOI 10.1093/emboj/16.23.7045; Morrison DK, 2003, ANNU REV CELL DEV BI, V19, P91, DOI 10.1146/annurev.cellbio.19.111401.091942; Nakayama K, 2006, CANCER BIOL THER, V5, P630, DOI 10.4161/cbt.5.6.2675; Nateri AS, 2005, NATURE, V437, P281, DOI 10.1038/nature03914; Nishina H, 1997, NATURE, V385, P350, DOI 10.1038/385350a0; Nishina H, 1997, J EXP MED, V186, P941, DOI 10.1084/jem.186.6.941; Nishina H, 1999, DEVELOPMENT, V126, P505; Ohren JF, 2004, NAT STRUCT MOL BIOL, V11, P1192, DOI 10.1038/nsmb859; Ortenblad A, 2002, INT J MANAG REV, V4, P87, DOI 10.1111/1468-2370.00078; Potapova O, 2000, J BIOL CHEM, V275, P24767, DOI 10.1074/jbc.M904591199; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; Putcha GV, 2003, NEURON, V38, P899, DOI 10.1016/S0896-6273(03)00355-6; Rodrigues GA, 1997, EMBO J, V16, P2634, DOI 10.1093/emboj/16.10.2634; Sabapathy K, 2004, MOL CELL, V15, P713, DOI 10.1016/j.molcel.2004.08.028; Sakurai T, 2006, P NATL ACAD SCI USA, V103, P10544, DOI 10.1073/pnas.0603499103; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SCHUTTE J, 1989, P NATL ACAD SCI USA, V86, P2257, DOI 10.1073/pnas.86.7.2257; Sharrocks AD, 2000, TRENDS BIOCHEM SCI, V25, P448, DOI 10.1016/S0968-0004(00)01627-3; She QB, 2002, CANCER RES, V62, P1343; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; Srinivas H, 2005, MOL CELL BIOL, V25, P1054, DOI 10.1128/MCB.25.3.1054-1069.2005; Stark AM, 2005, J CANCER RES CLIN, V131, P191, DOI 10.1007/s00432-004-0629-9; Su Gloria H, 2002, Hum Mutat, V19, P81, DOI 10.1002/humu.9002; Swat W, 1998, IMMUNITY, V8, P625, DOI 10.1016/S1074-7613(00)80567-1; Takekawa M, 2005, MOL CELL, V18, P295, DOI 10.1016/j.molcel.2005.04.001; Takekawa M, 2000, EMBO J, V19, P6517, DOI 10.1093/emboj/19.23.6517; Teng DHF, 1997, CANCER RES, V57, P4177; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; Tournier C, 1999, MOL CELL BIOL, V19, P1569; Tournier C, 2001, GENE DEV, V15, P1419, DOI 10.1101/gad.888501; Tournier C, 1997, P NATL ACAD SCI USA, V94, P7337, DOI 10.1073/pnas.94.14.7337; Tsuruta F, 2004, EMBO J, V23, P1889, DOI 10.1038/sj.emboj.7600194; Uhlirova M, 2005, P NATL ACAD SCI USA, V102, P13123, DOI 10.1073/pnas.0504170102; Ventura JJ, 2004, MOL CELL, V15, P269, DOI 10.1016/j.molcel.2004.06.007; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wada T, 2001, J BIOL CHEM, V276, P30892, DOI 10.1074/jbc.M011780200; Wang L, 2004, ONCOGENE, V23, P5978, DOI 10.1038/sj.onc.1207802; Whitmarsh AJ, 2006, BIOCHEM SOC T, V34, P828, DOI 10.1042/BST0340828; Xia Y, 1998, GENE DEV, V12, P3369, DOI 10.1101/gad.12.21.3369; Xiao L, 2000, CANCER RES, V60, P400; Xin W, 2004, CLIN CANCER RES, V10, P8516, DOI 10.1158/1078-0432.CCR-04-0885; Xiu M, 2003, MOL CELL BIOL, V23, P8890, DOI 10.1128/MCB.23.23.8890-8901.2003; Xu P, 2003, J BIOL CHEM, V278, P48422, DOI 10.1074/jbc.M307888200; Xu ZH, 2003, EMBO J, V22, P252, DOI 10.1093/emboj/cdg021; Yamada SD, 2002, CANCER RES, V62, P6717; Yamamoto K, 1999, MOL CELL BIOL, V19, P8469; Yang D, 1997, P NATL ACAD SCI USA, V94, P3004, DOI 10.1073/pnas.94.7.3004; Yang DD, 1997, NATURE, V389, P865, DOI 10.1038/39899; Yang YM, 2003, CLIN CANCER RES, V9, P391; YASHAR BM, 1993, MOL CELL BIOL, V13, P5738, DOI 10.1128/MCB.13.9.5738; Yoshida BA, 1999, CANCER RES, V59, P5483; Yoshida S, 2001, J HUM GENET, V46, P182, DOI 10.1007/s100380170086; Zacchi P, 2002, NATURE, V419, P853, DOI 10.1038/nature01120; Zheng HW, 2002, NATURE, V419, P849, DOI 10.1038/nature01116	132	114	128	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 15	2007	26	22					3172	3184		10.1038/sj.onc.1210410	http://dx.doi.org/10.1038/sj.onc.1210410			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	169PH	17496914				2022-12-28	WOS:000246603600007
J	Liu, J; Grimison, B; Maller, JL				Liu, J.; Grimison, B.; Maller, J. L.			New insight into metaphase arrest by cytostatic factor: from establishment to release	ONCOGENE			English	Review						cytostatic factor; CSF; Xenopus; cyclin E/Cdk2; Mps1; Emi2	XENOPUS EGGS; VERTEBRATE EGGS; MEIOTIC EXIT; CELL-CYCLES; MEIOSIS-II; CHECKPOINT; INHIBITOR; FERTILIZATION; EMI2; MOS	Since the discovery of cytostatic factor (CSF) 35 years ago, significant progress has been made in identifying molecular components of CSF activity and the mechanism of CSF-induced metaphase II arrest (CSF arrest). This short review focuses on recent discoveries in the field and discusses the implication of these results for a general picture of CSF establishment and release. One recent focus is on the cyclin E/Cdk2 pathway. The discovery of a downstream target for cyclin E/Cdk2, the spindle checkpoint protein Mps1, provides insight into how cyclin E/Cdk2 contributes to CSF arrest. The anaphase promoting complex/cyclosome (APC/C) inhib itor Emi2 is another recent focus of work in the field. It is now clear that not only is degradation of Emi2 critical for CSF release, but its abrupt accumulation during meiosis II ( M II) is also required for the establishment of CSF arrest. Thus, by discrete pathways of APC/C inhibition operative during CSF arrest, the stability of cell cycle arrest in the egg appears to be reinforced by multiple mechanisms.	Univ Colorado, Sch Med, Dept Pharm, Howard Hughes Med Inst, Aurora, CO 80045 USA	Howard Hughes Medical Institute; University of Colorado System; University of Colorado Anschutz Medical Campus	Maller, JL (corresponding author), Univ Colorado, Sch Med, Dept Pharm, Howard Hughes Med Inst, 12801 E 17th Ave,Mail Stop F8303,POB 6511, Aurora, CO 80045 USA.	jim.maller@uchsc.edu						Abrieu A, 2001, CELL, V106, P83, DOI 10.1016/S0092-8674(01)00410-X; Bhatt RR, 1999, SCIENCE, V286, P1362, DOI 10.1126/science.286.5443.1362; D'Angiolella V, 2001, CURR BIOL, V11, P1221, DOI 10.1016/S0960-9822(01)00352-9; Fisk HA, 2001, CELL, V106, P95, DOI 10.1016/S0092-8674(01)00411-1; Grimison B, 2006, CURR BIOL, V16, P1968, DOI 10.1016/j.cub.2006.08.055; Hansen DV, 2006, P NATL ACAD SCI USA, V103, P608, DOI 10.1073/pnas.0509549102; Liu JJ, 2005, CURR BIOL, V15, P1458, DOI 10.1016/j.cub.2005.07.030; Liu JJ, 2006, J BIOL CHEM, V281, P34736, DOI 10.1074/jbc.M606607200; LORCA T, 1993, NATURE, V366, P270, DOI 10.1038/366270a0; Madgwick S, 2006, J CELL BIOL, V174, P791, DOI 10.1083/jcb.200604140; MASUI Y, 1971, J EXP ZOOL, V177, P129, DOI 10.1002/jez.1401770202; Ohsumi K, 2004, P NATL ACAD SCI USA, V101, P12531, DOI 10.1073/pnas.0405300101; Phillips KP, 2002, DEV BIOL, V247, P210, DOI 10.1006/dbio.2002.0680; Rauh NR, 2005, NATURE, V437, P1048, DOI 10.1038/nature04093; Reimann JDR, 2002, NATURE, V416, P850, DOI 10.1038/416850a; REMPEL RE, 1995, J BIOL CHEM, V270, P6843, DOI 10.1074/jbc.270.12.6843; Roy LM, 1996, ONCOGENE, V12, P2203; SAGATA N, 1989, NATURE, V342, P512, DOI 10.1038/342512a0; Schmidt A, 2006, J CELL SCI, V119, P1213, DOI 10.1242/jcs.02919; Schmidt A, 2005, GENE DEV, V19, P502, DOI 10.1101/gad.320705; Sharp-Baker H, 2001, J CELL BIOL, V153, P1239, DOI 10.1083/jcb.153.6.1239; Shoji S, 2006, EMBO J, V25, P834, DOI 10.1038/sj.emboj.7600953; Tung JJ, 2005, P NATL ACAD SCI USA, V102, P4318, DOI 10.1073/pnas.0501108102; Tunquist BJ, 2003, J CELL BIOL, V163, P1231, DOI 10.1083/jcb.200306153; Tunquist BJ, 2003, GENE DEV, V17, P683, DOI 10.1101/gad.1071303; Tunquist BJ, 2002, CURR BIOL, V12, P1027, DOI 10.1016/S0960-9822(02)00894-1; WATANABE N, 1991, NATURE, V352, P247, DOI 10.1038/352247a0	27	21	24	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 26	2007	26	9					1286	1289		10.1038/sj.onc.1210203	http://dx.doi.org/10.1038/sj.onc.1210203			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	141DU	17322913				2022-12-28	WOS:000244558700005
J	Yokoyama, S; Chen, CJ; Nguyen, T; Shively, JE				Yokoyama, S.; Chen, C-J; Nguyen, T.; Shively, J. E.			Role of CEACAM1 isoforms in an in vivo model of mammary morphogenesis: mutational analysis of the cytoplasmic domain of CEACAM1-4S reveals key residues involved in lumen formation	ONCOGENE			English	Article						CEACAM1-4S; phosphorylation; breast cancer; lumen formation; myofibroblast	CELL-ADHESION MOLECULE; BILIARY GLYCOPROTEIN CD66A; BREAST-CANCER CELLS; CARCINOEMBRYONIC ANTIGEN; EXPRESSION; GROWTH; SUPPRESSION; APOPTOSIS; FAMILY; GENE	CEACAM1 (carcinoembryonic antigen-related cell adhesion molecule 1) is a type I transmembrane glycoprotein expressed in epithelial cells with three or four extracellular domains (ECDs) and either long or short cytoplasmic domain isoforms. We have previously shown that the four extracellular domains, short cytoplasmic domain isoform, CEACAM1-4S, plays an essential role in lumen formation in an in vitro model of mammary morphogenesis. In this study, we transfected MCF-7 cells with either the long or short cytoplasmic domain isoforms of CEACAM1, and grew the cells in humanized mammary mouse fat pads in NOD/SCID mice. In this in vivo model, only the long cytoplasmic domain isoform, CEACAM1-4L, formed glands with lumen. On the basis of other studies that revealed phosphorylation of key Thr and Ser residues in the short cytoplasmic domain, we introduced phosphorylation mimic ( for example, Thr or Ser to Asp) or null ( Thr or Ser to Ala) mutations into the cytoplasmic domain of CEACAM1-4S and tested them in the in vivo model. Mutation of either Thr or Ser to Asp or the double mutant Thr+Ser to Asp, but not the null mutants, induced gland formation with a central lumen-containing apoptotic cells. Moreover, the phosphorylation mimic mutants of CEACAM1-4S induced downregulation of beta 1-integrin, overexpression of beta 2-integrin, inhibited phosphorylation of focal adhesion kinase (pTyr-397) and resulted in myo.broblast differentiation as characterized by expression of vimentin, a-smooth muscle actin and beta 2-integrin, as well as the production of abundant extracellular matrix.	[Yokoyama, S.; Chen, C-J; Nguyen, T.; Shively, J. E.] City Hope Natl Med Ctr, Beckman Res Inst, Div Immunol, Duarte, CA 91010 USA	City of Hope; Beckman Research Institute of City of Hope	Shively, JE (corresponding author), City Hope Natl Med Ctr, Beckman Res Inst, Div Immunol, H138,Hilton Bldg,1500 E Duarte Rd, Duarte, CA 91010 USA.	jshively@coh.org						BARNETT TR, 1993, MOL CELL BIOL, V13, P1273, DOI 10.1128/MCB.13.2.1273; BRUMMER J, 1995, ONCOGENE, V11, P1649; Busch C, 2002, HUM PATHOL, V33, P290, DOI 10.1053/hupa.2002.32218; Chen CJ, 2007, J BIOL CHEM, V282, P5749, DOI 10.1074/jbc.M610903200; Edlund M, 1998, FEBS LETT, V425, P166, DOI 10.1016/S0014-5793(98)00222-1; Greenberg RS, 2006, FASEB J, V20, P1006, DOI 10.1096/fj.05-4838fje; Huang J, 1998, ANTICANCER RES, V18, P3203; Huang J, 1999, J CELL SCI, V112, P4193; Huber M, 1999, J BIOL CHEM, V274, P335, DOI 10.1074/jbc.274.1.335; Kirshner J, 2003, J BIOL CHEM, V278, P50338, DOI 10.1074/jbc.M309115200; Kirshner J, 2003, P NATL ACAD SCI USA, V100, P521, DOI 10.1073/pnas.232711199; Klein H, 1995, Violence Against Women, V1, P55, DOI 10.1177/1077801295001001004; Kleinerman DI, 1996, CANCER RES, V56, P3431; Kunath T, 1995, ONCOGENE, V11, P2375; Kuperwasser C, 2004, P NATL ACAD SCI USA, V101, P4966, DOI 10.1073/pnas.0401064101; Laurie NA, 2005, CANCER RES, V65, P11010, DOI 10.1158/0008-5472.CAN-04-2841; Leers MPG, 1999, J PATHOL, V187, P567, DOI 10.1002/(SICI)1096-9896(199904)187:5<567::AID-PATH288>3.0.CO;2-J; Luo WP, 1999, CANCER GENE THER, V6, P313, DOI 10.1038/sj.cgt.7700055; Luo WP, 1997, ONCOGENE, V14, P1697, DOI 10.1038/sj.onc.1200999; Mitra SK, 2006, CURR OPIN CELL BIOL, V18, P516, DOI 10.1016/j.ceb.2006.08.011; NEUMAIER M, 1993, P NATL ACAD SCI USA, V90, P10744, DOI 10.1073/pnas.90.22.10744; Nittka S, 2004, ONCOGENE, V23, P9306, DOI 10.1038/sj.onc.1208259; Nollau P, 1997, CANCER RES, V57, P2354; Obrink B, 1997, CURR OPIN CELL BIOL, V9, P616, DOI 10.1016/S0955-0674(97)80114-7; OHWADA A, 1994, AM J RESP CELL MOL, V11, P214, DOI 10.1165/ajrcmb.11.2.8049082; Park CC, 2006, CANCER RES, V66, P1526, DOI 10.1158/0008-5472.CAN-05-3071; Peters KS, 2005, J PHYS ORG CHEM, V18, P1, DOI 10.1002/poc.849; Powell DW, 2005, AM J PHYSIOL-GASTR L, V289, pG2, DOI 10.1152/ajpgi.00075.2005; Powell DW, 1999, AM J PHYSIOL-CELL PH, V277, pC1, DOI 10.1152/ajpcell.1999.277.1.C1; Schumann D, 2001, J BIOL CHEM, V276, P47421, DOI 10.1074/jbc.M109110200; Shi SR, 2001, J HISTOCHEM CYTOCHEM, V49, P931, DOI 10.1177/002215540104900801; SVENBERG T, 1979, CLIN EXP IMMUNOL, V36, P436; Tanaka K, 1997, INT J CANCER, V74, P15, DOI 10.1002/(SICI)1097-0215(19970220)74:1<15::AID-IJC3>3.0.CO;2-3; Tomasek JJ, 2002, NAT REV MOL CELL BIO, V3, P349, DOI 10.1038/nrm809; WAGENER C, 1983, J IMMUNOL, V130, P2302	35	35	35	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 6	2007	26	55					7637	7646		10.1038/sj.onc.1210577	http://dx.doi.org/10.1038/sj.onc.1210577			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	239SK	17546042				2022-12-28	WOS:000251537800005
J	Satoh, K; Hovey, RC; Malewski, T; Warri, A; Goldhar, AS; Ginsburg, E; Saito, K; Lydon, JP; Vonderhaar, BK				Satoh, K.; Hovey, R. C.; Malewski, T.; Warri, A.; Goldhar, A. S.; Ginsburg, E.; Saito, K.; Lydon, J. P.; Vonderhaar, B. K.			Progesterone enhances branching morphogenesis in the mouse mammary gland by increased expression of Msx2	ONCOGENE			English	Article						progesterone; mammary gland; msx2; homeo-box genes; branching morphogenesis	EPITHELIAL-CELL PROLIFERATION; HEPATOCYTE GROWTH-FACTOR; SERUM-FREE CULTURE; HOMEOBOX GENES; BREAST-CANCER; RECEPTOR-B; IN-VITRO; HORMONE; MICE; PROLACTIN	Branching morphogenesis within the peripubertal mouse mammary gland is directed by progesterone (P). A role for the homeobox-containing transcription factor, Msx2, during branching morphogenesis is suggested from its ontogenic expression pro. le and hormonal regulation. Herein, we de. ne the spatio-temporal control of Msx2 expression, the regulation of its expression by P and its direct role in ductal branching morphogenesis. P induces Msx2 in the presence of estrogen (E) both in vitro and in vivo while absence of the P receptor (PR) decreased Msx2 expression. Stable transfection of PR into mouse mammary epithelial cells increased the endogenous expression of Msx2 and their ability to undergo branching morphogenesis in vitro. Furthermore, normal mammary cells stably-transfected with Msx2 demonstrated increased branching morphogenesis in vitro while transgenic mice expressing Msx2 in their mammary glands demonstrated enhanced lateral branching during early development. The action of P on branching morphogenesis appears to involve Bmp2/4. Together, these data demonstrate that P, acting through PR-A and the Bmp2/4 pathway, induces Msx2 to enhance ductal branching in the mammary glands.	Natl Canc Inst, Ctr Canc Res, Mammary Biol & Tumorigenesis Lab, Bethesda, MD USA; Baylor Coll Med, Dept Cell Biol, Houston, TX USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Baylor College of Medicine	Vonderhaar, BK (corresponding author), NIH, Mol & Cellular Endocrinol Sect, Mammary Biol & Tumorigenesis Lab, Bldg 37 Room 1106a1,37 Convent Dr, Bethesda, MD 20892 USA.	bv10w@nih.gov	Malewski, Tadeusz/J-4930-2015; Malewski, Tadeusz/N-6883-2019; Malewski, Tadeusz/H-2915-2012	Malewski, Tadeusz/0000-0001-8061-435X; Malewski, Tadeusz/0000-0001-8061-435X; Warri, Anni/0000-0002-0535-847X	Intramural NIH HHS Funding Source: Medline; NATIONAL CANCER INSTITUTE [ZIABC008226, Z01BC008226] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abate-Shen C, 2002, NAT REV CANCER, V2, P777, DOI 10.1038/nrc907; Alappat S, 2003, CELL RES, V13, P429, DOI 10.1038/sj.cr.7290185; Atwood CS, 2000, J ENDOCRINOL, V167, P39, DOI 10.1677/joe.0.1670039; Aupperlee MD, 2005, ENDOCRINOLOGY, V146, P3577, DOI 10.1210/en.2005-0346; Bamberger AM, 1996, P NATL ACAD SCI USA, V93, P6169, DOI 10.1073/pnas.93.12.6169; Brisken C, 2000, GENE DEV, V14, P650; Capecchi MR, 1997, COLD SPRING HARB SYM, V62, P273, DOI 10.1101/SQB.1997.062.01.034; Chen HX, 2003, J MAMMARY GLAND BIOL, V8, P159, DOI 10.1023/A:1025996707117; Daniel CW, 1999, J MAMMARY GLAND BIOL, V4, P3, DOI 10.1023/A:1018796301609; DAVIDSON D, 1995, TRENDS GENET, V11, P405, DOI 10.1016/S0168-9525(00)89124-6; Fernandez-Valdivia R, 2005, SEMIN REPROD MED, V23, P22, DOI 10.1055/s-2005-864031; Friedmann Y, 1996, DEV BIOL, V177, P347, DOI 10.1006/dbio.1996.0168; Gupta IR, 2000, J CELL SCI, V113, P269; HASLAM SZ, 1988, J STEROID BIOCHEM, V31, P9, DOI 10.1016/0022-4731(88)90199-9; Hovey RC, 2002, J MAMMARY GLAND BIOL, V7, P17, DOI 10.1023/A:1015766322258; Hovey RC, 2001, DEV DYNAM, V222, P192, DOI 10.1002/dvdy.1179; Ismail PM, 2002, MOL ENDOCRINOL, V16, P2475, DOI 10.1210/me.2002-0169; Kelly PA, 2002, MOL CELL ENDOCRINOL, V197, P127, DOI 10.1016/S0303-7207(02)00286-1; Lanari C, 2001, CANCER RES, V61, P293; Lee S, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1367; Lewis MT, 2000, BREAST CANCER RES, V2, P158, DOI 10.1186/bcr49; Lydon JP, 1996, J STEROID BIOCHEM, V56, P67, DOI 10.1016/0960-0760(95)00254-5; Malewski T, 2005, CANCER INVEST, V23, P222, DOI 10.1081/CNV-200055958; Mote PA, 2002, BREAST CANCER RES TR, V72, P163, DOI 10.1023/A:1014820500738; Mulac-Jericevic B, 2003, P NATL ACAD SCI USA, V100, P9744, DOI 10.1073/pnas.1732707100; Nusse R, 2001, NATURE, V411, P254, DOI 10.1038/35077199; Phippard DJ, 1996, DEVELOPMENT, V122, P2729; Richer JK, 2002, J BIOL CHEM, V277, P5209, DOI 10.1074/jbc.M110090200; Ruan WF, 2005, ENDOCRINOLOGY, V146, P1170, DOI 10.1210/en.2004-1360; Satoh K, 2004, J MAMMARY GLAND BIOL, V9, P195, DOI 10.1023/B:JOMG.0000037162.84758.b5; Satokata I, 2000, NAT GENET, V24, P391, DOI 10.1038/74231; Shyamala G, 2000, P NATL ACAD SCI USA, V97, P3044, DOI 10.1073/pnas.97.7.3044; SMITH WC, 1992, CELL, V70, P829, DOI 10.1016/0092-8674(92)90316-5; Sunil N, 2002, ENDOCRINOLOGY, V143, P2953, DOI 10.1210/en.143.8.2953; Wang WD, 1996, MECH DEVELOP, V58, P203, DOI 10.1016/S0925-4773(96)00562-X; Wechselberger C, 2001, EXP CELL RES, V266, P95, DOI 10.1006/excr.2001.5195; Willert Jennifer, 2002, BMC Dev Biol, V2, P8, DOI 10.1186/1471-213X-2-8; Zhang HZ, 2002, ENDOCRINOLOGY, V143, P3427, DOI 10.1210/en.2002-220007	38	28	31	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 29	2007	26	54					7526	7534		10.1038/sj.onc.1210555	http://dx.doi.org/10.1038/sj.onc.1210555			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	236DB	17546050				2022-12-28	WOS:000251282100004
J	Le Bras, A; Lionneton, F; Mattot, V; Lelievre, E; Caetano, B; Spruyt, N; Soncin, F				Le Bras, A.; Lionneton, F.; Mattot, V.; Lelievre, E.; Caetano, B.; Spruyt, N.; Soncin, F.			HIF-2 alpha specifically activates the VE-cadherin promoter independently of hypoxia and in synergy with Ets-1 through two essential ETS-binding sites	ONCOGENE			English	Article						angiogenesis; endothelium; gene transcription	VASCULAR-ENDOTHELIAL-CADHERIN; PAS DOMAIN PROTEIN-1; INDUCIBLE FACTOR-I; TRANSCRIPTION FACTOR; EMBRYONIC-DEVELOPMENT; GENE-TRANSCRIPTION; TUMOR-GROWTH; HIF-ALPHA; EXPRESSION; FACTOR-1-ALPHA	The mechanisms that are responsible for the restricted pattern of express ion of the VE-cadherin gene in endothelial cells are not clearly understood. Regulation of express ion is under the control of an approximately 140 bp proximal promoter that provides basal, non-endothelial specific expression. A larger region contained within the 2.5 kb genomic DNA sequence located ahead of the transcription start is involved in the specific expression of the gene in endothelial cells. We show here that the VE-cadherin promoter contains several putative hypoxia response elements (HRE) which are able to bind endothelial nuclear factors under normoxia. The VE-cadherin gene is not responsive to hypoxia but hypoxia-inducible factor (HIF)-2 alpha specifically activates the promoter while HIF-1 alpha does not. The HRE, that are involved in this activity have been identified. Further, we show that HIF2 alpha cooperates with the Ets-1 transcription factor for activation of the VE-cadherin promoter and that this synergy is dependent on the binding of Ets-1 to DNA. This cooperative action of HIF-2 a with Ets-1 most probably participates to the transcriptional regulation of express ion of the gene in endothelial cells. This mechanism may also be involved in the expression of the VE-cadherin gene by tumor cells in the process of vascular mimicry.	CNRS, UMR 8161, Lille, France; Univ Lille 1, Lille, France; Univ Lille 2, Lille, France; Inst Pasteur, Lille, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Lille - ISITE; Universite de Lille; Universite de Lille - ISITE; Universite de Lille; Universite de Lille - ISITE; Universite de Lille; Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille	Soncin, F (corresponding author), CNRS, Inst Biol Lille, UMR 8161, 1 Rue Calmette, BP 447, F-59021 Lille, France.	fabrice.soncin@ibl.fr	SONCIN, Fabrice/A-1475-2009	SONCIN, Fabrice/0000-0001-6312-0673; Lelievre, Etienne/0000-0003-0452-1578; Le Bras, Alexandra/0000-0001-7898-4618				Baek JH, 2005, MOL CELL, V17, P503, DOI 10.1016/j.molcel.2005.01.011; Brahimi-Horn C, 2005, CELL SIGNAL, V17, P1, DOI 10.1016/j.cellsig.2004.04.010; Breier G, 1996, BLOOD, V87, P630, DOI 10.1182/blood.V87.2.630.bloodjournal872630; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; Carmeliet P, 1999, CELL, V98, P147, DOI 10.1016/S0092-8674(00)81010-7; Caveda L, 1996, J CLIN INVEST, V98, P886, DOI 10.1172/JCI118870; Corada M, 1999, P NATL ACAD SCI USA, V96, P9815, DOI 10.1073/pnas.96.17.9815; Coulet F, 2003, J BIOL CHEM, V278, P46230, DOI 10.1074/jbc.M305420200; Covello KL, 2006, GENE DEV, V20, P557, DOI 10.1101/gad.1399906; Covello KL, 2005, CANCER RES, V65, P2277, DOI 10.1158/0008-5472.CAN-04-3246; Duan LJ, 2005, CIRCULATION, V111, P2227, DOI 10.1161/01.CIR.0000163580.98098.A3; Elvert G, 2003, J BIOL CHEM, V278, P7520, DOI 10.1074/jbc.M211298200; Ema M, 1997, P NATL ACAD SCI USA, V94, P4273, DOI 10.1073/pnas.94.9.4273; Flamme I, 1997, MECH DEVELOP, V63, P51, DOI 10.1016/S0925-4773(97)00674-6; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; Gavard J, 2006, NAT CELL BIOL, V8, P1223, DOI 10.1038/ncb1486; Gory S, 1998, J BIOL CHEM, V273, P6750, DOI 10.1074/jbc.273.12.6750; Gory S, 1999, BLOOD, V93, P184, DOI 10.1182/blood.V93.1.184.401a20_184_192; Gory-Faure S, 1999, DEVELOPMENT, V126, P2093; Gulino D, 1998, J BIOL CHEM, V273, P29786, DOI 10.1074/jbc.273.45.29786; Hegen A, 2004, ARTERIOSCL THROM VAS, V24, P1803, DOI 10.1161/01.ATV.0000140819.81839.0e; Hisatsune H, 2005, BLOOD, V105, P4657, DOI 10.1182/blood-2004-09-3554; Hu CJ, 2003, MOL CELL BIOL, V23, P9361, DOI 10.1128/MCB.23.24.9361-9374.2003; Iurlaro M, 2004, AM J PATHOL, V165, P181, DOI 10.1016/S0002-9440(10)63287-7; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Jain S, 1998, MECH DEVELOP, V73, P117, DOI 10.1016/S0925-4773(98)00038-0; Jiang BH, 1996, J BIOL CHEM, V271, P17771, DOI 10.1074/jbc.271.30.17771; Kaelin WG, 2002, GENE DEV, V16, P1441, DOI 10.1101/gad.1003602; LAMPUGNANI MG, 1992, J CELL BIOL, V118, P1511, DOI 10.1083/jcb.118.6.1511; Lelievre E, 2002, J BIOL CHEM, V277, P25143, DOI 10.1074/jbc.M201628200; Lelievre E, 2001, INT J BIOCHEM CELL B, V33, P391, DOI 10.1016/S1357-2725(01)00025-5; Lelievre E, 2000, ONCOGENE, V19, P2438, DOI 10.1038/sj.onc.1203563; Lionneton F, 2003, ONCOGENE, V22, P9156, DOI 10.1038/sj.onc.1207241; Lofstedt T, 2007, CELL CYCLE, V6, P919, DOI 10.4161/cc.6.8.4133; May C, 2005, BLOOD, V105, P4337, DOI 10.1182/blood-2005-01-0010; Maynard MA, 2003, J BIOL CHEM, V278, P11032, DOI 10.1074/jbc.M208681200; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; Navarro P, 1995, J BIOL CHEM, V270, P30965, DOI 10.1074/jbc.270.52.30965; O'Rourke JF, 1999, J BIOL CHEM, V274, P2060, DOI 10.1074/jbc.274.4.2060; Peng J, 2000, P NATL ACAD SCI USA, V97, P8386, DOI 10.1073/pnas.140087397; Raval RR, 2005, MOL CELL BIOL, V25, P5675, DOI 10.1128/MCB.25.13.5675-5686.2005; Rosenberger C, 2002, J AM SOC NEPHROL, V13, DOI 10.1097/01.ASN.0000017223.49823.2A; Sambrook J., 2002, MOL CLONING LAB MANU; SATO TN, 1993, P NATL ACAD SCI USA, V90, P9355, DOI 10.1073/pnas.90.20.9355; SCHNURCH H, 1993, DEVELOPMENT, V119, P957; Semenza GL, 1996, J BIOL CHEM, V271, P32529, DOI 10.1074/jbc.271.51.32529; SEMENZA GL, 1991, P NATL ACAD SCI USA, V88, P5680, DOI 10.1073/pnas.88.13.5680; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; SHWEIKI D, 1992, NATURE, V359, P845; Soncin F, 2003, EMBO J, V22, P5700, DOI 10.1093/emboj/cdg549; Sowter HM, 2003, CANCER RES, V63, P6130; Talks KL, 2000, AM J PATHOL, V157, P411, DOI 10.1016/S0002-9440(10)64554-3; Teruyama K, 2001, FEBS LETT, V504, P1, DOI 10.1016/S0014-5793(01)02724-7; Tian H, 1997, GENE DEV, V11, P72, DOI 10.1101/gad.11.1.72; Tian H, 1998, GENE DEV, V12, P3320, DOI 10.1101/gad.12.21.3320; WANG GL, 1993, P NATL ACAD SCI USA, V90, P4304, DOI 10.1073/pnas.90.9.4304; WANG GL, 1995, J BIOL CHEM, V270, P1230, DOI 10.1074/jbc.270.3.1230; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Wang V, 2005, CANCER RES, V65, P3299, DOI 10.1158/0008-5472.CAN-04-4130; Wiesener MS, 2002, FASEB J, V16, P271, DOI 10.1096/fj.02-0445fje; Wiesener MS, 1998, BLOOD, V92, P2260, DOI 10.1182/blood.V92.7.2260.2260_2260_2268	62	60	61	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 22	2007	26	53					7480	7489		10.1038/sj.onc.1210566	http://dx.doi.org/10.1038/sj.onc.1210566			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	236DA	17563748				2022-12-28	WOS:000251282000009
J	Zhang, B; Chambers, KJ; Faller, DV; Wang, S				Zhang, B.; Chambers, K. J.; Faller, D. V.; Wang, S.			Reprogramming of the SWI/SNF complex for co-activation or co-repression in prohibitin-mediated estrogen receptor regulation	ONCOGENE			English	Article						ER; prohibitin; brg1; brm; HDAC; HAT	SWI-SNF COMPLEX; CHROMATIN REMODELING COMPLEX; E2F-DEPENDENT GENE-TRANSCRIPTION; HISTONE DEACETYLASE ACTIVITY; BREAST-CANCER CELLS; RETINOBLASTOMA PROTEIN; GLUCOCORTICOID-RECEPTOR; MUSCLE DIFFERENTIATION; GROWTH ARREST; CYCLE ARREST	The SWI/SNF complex participates as a co-activator in the transcriptional regulation of certain genes. Conversely, we and others have recently established that Brg1 and Brm, the central components of SWI/SNF, act instead as co-repressors for E2F-mediated transcriptional repression, and for the transcription of certain other promoters. We report here that Brg-1 and Brm can switch their mode of function at same promoter between activation and repression by ligand-directed differential coordination with BAF155, BAF170, HDAC1, p300 and prohibitin. This ligand and context-dependent reprogramming of the SWI/SNF complex allows it to differentially serve as either a co-repressor or a co-activator of transcription at the same promoter.	Boston Univ, Sch Med, Canc Res Ctr, Boston, MA 02118 USA	Boston University	Wang, S (corresponding author), Boston Univ, Sch Med, Canc Res Ctr, R-906,715 Albany St, Boston, MA 02118 USA.	sw184@bu.edu			NCI NIH HHS [1R03CA102940-01, CA101992] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA101992, R03CA102940] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Banchio C, 2006, J BIOL CHEM, V281, P10010, DOI 10.1074/jbc.M513503200; Belandia B, 2002, EMBO J, V21, P4094, DOI 10.1093/emboj/cdf412; Betz BL, 2002, ONCOGENE, V21, P5193, DOI 10.1038/sj.onc.1205706; Boutillier AL, 2003, J NEUROCHEM, V84, P814, DOI 10.1046/j.1471-4159.2003.01581.x; Brehm A, 1999, BRIT J CANCER, V80, P38; Brehm A, 1999, EMBO J, V18, P2449, DOI 10.1093/emboj/18.9.2449; Brehm A, 1999, TRENDS BIOCHEM SCI, V24, P142, DOI 10.1016/S0968-0004(99)01368-7; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; Chen JG, 2005, MOL CELL BIOL, V25, P9016, DOI 10.1128/MCB.25.20.9016-9027.2005; Chi TH, 2003, IMMUNITY, V19, P169, DOI 10.1016/S1074-7613(03)00199-7; Chi TH, 2002, NATURE, V418, P195, DOI 10.1038/nature00876; Dahiya A, 2000, MOL CELL BIOL, V20, P6799, DOI 10.1128/MCB.20.18.6799-6805.2000; Dasgupta P, 2004, MOL CELL BIOL, V24, P9527, DOI 10.1128/MCB.24.21.9527-9541.2004; de la Serna IL, 2001, J BIOL CHEM, V276, P41486, DOI 10.1074/jbc.M107281200; DeCristofaro MF, 1999, ONCOGENE, V18, P7559, DOI 10.1038/sj.onc.1203168; DeCristofaro MF, 2001, J CELL PHYSIOL, V186, P136; DiRenzo J, 2000, MOL CELL BIOL, V20, P7541, DOI 10.1128/MCB.20.20.7541-7549.2000; DUNAIEF JL, 1994, CELL, V79, P119, DOI 10.1016/0092-8674(94)90405-7; Ferreira R, 2001, EMBO REP, V2, P794, DOI 10.1093/embo-reports/kve173; Foster KSJ, 2006, ONCOGENE, V25, P4605, DOI 10.1038/sj.onc.1209496; Fryer CJ, 1998, NATURE, V393, P88, DOI 10.1038/30032; Fujita T, 2003, J BIOL CHEM, V278, P26704, DOI 10.1074/jbc.M301031200; Fukuoka J, 2004, CLIN CANCER RES, V10, P4314, DOI 10.1158/1078-0432.CCR-03-0489; Goodwin GH, 1997, GENE, V184, P27, DOI 10.1016/S0378-1119(96)00569-0; Gunawardena RW, 2004, J BIOL CHEM, V279, P29278, DOI 10.1074/jbc.M400395200; Hanstein B, 1996, P NATL ACAD SCI USA, V93, P11540, DOI 10.1073/pnas.93.21.11540; Inayoshi Y, 2006, J BIOCHEM, V139, P177, DOI 10.1093/jb/mvj015; Jeffy BD, 2005, NEOPLASIA, V7, P873, DOI 10.1593/neo.05256; Lee CH, 1999, P NATL ACAD SCI USA, V96, P12311, DOI 10.1073/pnas.96.22.12311; Lin HY, 2005, STEROIDS, V70, P444, DOI 10.1016/j.steroids.2005.03.001; Luo RX, 1999, J NATL CANCER I, V91, P1288, DOI 10.1093/jnci/91.15.1288; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; Margueron R, 2004, BIOCHEM PHARMACOL, V68, P1239, DOI 10.1016/j.bcp.2004.04.031; Matsuda KI, 2002, MOL ENDOCRINOL, V16, P2215, DOI 10.1210/me.2002-0110; Morris L, 2000, NAT CELL BIOL, V2, P232, DOI 10.1038/35008660; Morrison AJ, 2002, MOL CELL BIOL, V22, P856, DOI 10.1128/MCB.22.3.856-865.2002; Muchardt C, 1999, SEMIN CELL DEV BIOL, V10, P189, DOI 10.1006/scdb.1999.0300; Muchardt C, 1998, EMBO J, V17, P223, DOI 10.1093/emboj/17.1.223; MUCHARDT C, 1993, EMBO J, V12, P4279, DOI 10.1002/j.1460-2075.1993.tb06112.x; Muchardt C, 2001, ONCOGENE, V20, P3067, DOI 10.1038/sj.onc.1204331; Murphy DJ, 1999, MOL CELL BIOL, V19, P2724; Panteleeva I, 2004, ANN NY ACAD SCI, V1030, P656, DOI 10.1196/annals.1329.076; PETERSON CL, 1995, TRENDS BIOCHEM SCI, V20, P143, DOI 10.1016/S0968-0004(00)88990-2; Reisman DN, 2002, ONCOGENE, V21, P1196, DOI 10.1038/sj.onc.1205188; Roche KC, 2004, ONCOGENE, V23, P8185, DOI 10.1038/sj.onc.1208025; Roy K, 2002, J BIOL CHEM, V277, P33818, DOI 10.1074/jbc.M205159200; Shanahan F, 1999, MOL CELL BIOL, V19, P1460; Wang S, 2002, EMBO J, V21, P3019, DOI 10.1093/emboj/cdf302; Wang S, 2004, EMBO J, V23, P2293, DOI 10.1038/sj.emboj.7600231; Wang S, 2002, ONCOGENE, V21, P8388, DOI 10.1038/sj.onc.1205944; Wang WD, 1996, EMBO J, V15, P5370, DOI 10.1002/j.1460-2075.1996.tb00921.x; Wang WD, 1996, GENE DEV, V10, P2117, DOI 10.1101/gad.10.17.2117; Zhao LH, 2005, ACTA BIOCH BIOPH SIN, V37, P440, DOI 10.1111/j.1745-7270.2005.00061.x	54	51	54	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 1	2007	26	50					7153	7157		10.1038/sj.onc.1210509	http://dx.doi.org/10.1038/sj.onc.1210509			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	228GF	17486062				2022-12-28	WOS:000250715000009
J	Chipoy, C; Brounais, B; Trichet, V; Battaglia, S; Berreur, M; Oliver, L; Juin, P; Redini, F; Heymann, D; Blanchard, F				Chipoy, C.; Brounais, B.; Trichet, V.; Battaglia, S.; Berreur, M.; Oliver, L.; Juin, P.; Redini, F.; Heymann, D.; Blanchard, F.			Sensitization of osteosarcoma cells to apoptosis by oncostatin M depends on STAT5 and p53	ONCOGENE			English	Article						osteosarcoma; osteoblast; oncostatin M; STAT5; p53; apoptosis	SIGNAL TRANSDUCER; OSTEOBLAST DIFFERENTIATION; MITOCHONDRIAL-MEMBRANE; HEMATOPOIETIC-CELLS; GROWTH-HORMONE; DNA-DAMAGE; T-CELLS; GENE; PROTEIN; BAX	Oncostatin M ( OSM), a cytokine of the interleukin- 6 family, induces growth arrest and differentiation of osteoblastic cells into glial- like/ osteocytic cells. Here, we asked whether OSM regulates apoptosis of normal or transformed ( osteosarcoma) osteoblasts. We show that OSM sensitizes cells to apoptosis induced by various death inducers such as staurosporine, ultraviolet or tumor necrosis factor-alpha. Apoptosis is mediated by the mitochondrial pathway, with release of cytochrome c from the mitochondria to the cytosol and activation of caspases- 9 and - 3. DNA micro-arrays revealed that OSM modulates the expression of Bax, Bad, Bnip3, Bcl- 2 and Mcl- 1. Pharmacological inhibitors, dominant- negative signal transducer and activator of transcriptions ( STATs), stable RNA interference and knockout cells indicated that the transcription factors p53 and STAT5, which are activated by OSM, are implicated in the sensitization to apoptosis, being responsible for Bax induction and Bcl- 2 reduction, respectively. These results indicate that, in addition to growth arrest and induced differentiation, OSM also sensitizes normal and transformed osteoblasts to apoptosis by a mechanism implicating ( i) activation and nuclear translocation of STAT5 and p53 and ( ii) an increased Bax/ Bcl- 2 ratio. Therefore, association of OSM with kinase inhibitors such as Sts represents new therapeutic opportunities for wild- type p53 osteosarcoma.	Univ Nantes, Fac Med, Lab Physiopathol Resorpt Osseuse & Therapie Tumeu, EA3822, F-44035 Nantes 1, France; INSERM, ER17, Nantes, France; INSERM, U601, Nantes, France	Nantes Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm)	Chipoy, C (corresponding author), Univ Nantes, Fac Med, Lab Physiopathol Resorpt Osseuse & Therapie Tumeu, EA3822, 1 Rue Gaston Veil, F-44035 Nantes 1, France.	celine.chipoy@univ-nantes.fr	Heymann, Dominique/AAC-6014-2019; JUIN, Philippe/Q-1338-2019; ROYER, Bénédicte BROUNAIS-LE/AAY-8894-2020; Blanchard, Frederic/AAS-1930-2021; BATTAGLIA, Severine/K-8715-2015; Oliver, Lisa/L-3070-2015	Heymann, Dominique/0000-0001-7777-0669; JUIN, Philippe/0000-0002-4997-3888; ROYER, Bénédicte BROUNAIS-LE/0000-0002-4556-9853; Blanchard, Frederic/0000-0003-1055-2573; Oliver, Lisa/0000-0002-5588-7564; Trichet, Valerie/0000-0003-4183-9032				Auernhammer CJ, 2004, J ENDOCRINOL, V180, P479, DOI 10.1677/joe.0.1800479; Auguste P, 1997, J BIOL CHEM, V272, P15760, DOI 10.1074/jbc.272.25.15760; Battle T. E., 2002, Current Molecular Medicine (Hilversum), V2, P381, DOI 10.2174/1566524023362456; Baumann H, 2000, J BIOL CHEM, V275, P22014, DOI 10.1074/jbc.M002830200; Bellido T, 1997, ENDOCRINOLOGY, V138, P3666, DOI 10.1210/en.138.9.3666; Bellini MH, 1998, J ENDOCRINOL INVEST, V21, P1; Buitenhuis M, 2004, INT J BIOCHEM CELL B, V36, P2120, DOI 10.1016/j.biocel.2003.11.008; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; CASEY G, 1991, ONCOGENE, V6, P1791; CHANDAR N, 1992, BRIT J CANCER, V65, P208, DOI 10.1038/bjc.1992.43; Chapman RS, 1999, GENE DEV, V13, P2604, DOI 10.1101/gad.13.19.2604; Chen SH, 2004, CYTOKINE GROWTH F R, V15, P379, DOI 10.1016/j.cytogfr.2004.06.002; Chipoy C, 2004, J BONE MINER RES, V19, P1850, DOI 10.1359/JBMR.040817; Debierre-Grockiego F, 2004, APOPTOSIS, V9, P717, DOI 10.1023/B:APPT.0000045785.65546.a2; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; FLORENES VA, 1994, J NATL CANCER I, V86, P1297, DOI 10.1093/jnci/86.17.1297; Fuchs B, 2002, CLIN ORTHOP RELAT R, P40; Grant SL, 1999, MOL MED TODAY, V5, P406, DOI 10.1016/S1357-4310(99)01540-3; Haupt S, 2003, J CELL SCI, V116, P4077, DOI 10.1242/jcs.00739; Heath C, 2004, J BIOL CHEM, V279, P6666, DOI 10.1074/jbc.M308743200; Jilka RL, 1998, J BONE MINER RES, V13, P793, DOI 10.1359/jbmr.1998.13.5.793; Kamiya A, 1999, EMBO J, V18, P2127, DOI 10.1093/emboj/18.8.2127; Kashkar H, 2005, J BIOL CHEM, V280, P20804, DOI 10.1074/jbc.M410869200; Le Meur N, 2004, NUCLEIC ACIDS RES, V32, P5349, DOI 10.1093/nar/gkh870; Lengner CJ, 2006, J CELL BIOL, V172, P909, DOI 10.1083/jcb.200508130; Nosaka T, 1999, EMBO J, V18, P4754, DOI 10.1093/emboj/18.17.4754; Oren M, 2003, CELL DEATH DIFFER, V10, P431, DOI 10.1038/sj.cdd.4401183; Qin XF, 2003, P NATL ACAD SCI USA, V100, P183, DOI 10.1073/pnas.232688199; Sims NA, 2000, J CLIN INVEST, V106, P1095, DOI 10.1172/JCI10753; Stephanou A, 2000, CELL DEATH DIFFER, V7, P329, DOI 10.1038/sj.cdd.4400656; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Thornborrow EC, 1999, J BIOL CHEM, V274, P33747, DOI 10.1074/jbc.274.47.33747; Townsend PA, 2004, J BIOL CHEM, V279, P5811, DOI 10.1074/jbc.M302637200; Trichet V, 2006, J IMMUNOL, V177, P6129, DOI 10.4049/jimmunol.177.9.6129; WADAYAMA B, 1994, CANCER RES, V54, P3042; Wang XY, 2006, J CELL BIOL, V172, P115, DOI 10.1083/jcb.200507106; Wei QZ, 2005, J BIOL CHEM, V280, P37790, DOI 10.1074/jbc.M502974200	38	39	43	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 11	2007	26	46					6653	6664		10.1038/sj.onc.1210492	http://dx.doi.org/10.1038/sj.onc.1210492			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	219JT	17471233				2022-12-28	WOS:000250081500007
J	Reef, S; Shifman, O; Oren, M; Kimchi, A				Reef, S.; Shifman, O.; Oren, M.; Kimchi, A.			The autophagic inducer smARF interacts with and is stabilized bythe mitochondrial p32 protein	ONCOGENE			English	Article							TYPE-1 TAT TRANSACTIVATOR; IN-VITRO INTERACTION; CELLULAR-PROTEIN; BINDING-PROTEIN; SPLICING FACTOR; MOLECULAR-CLONING; ACTIVATION DOMAIN; GLOBULAR HEADS; VIRUS; RECEPTOR	The alternative reading frame ( ARF) mRNA encodes two pro- death proteins, the nucleolar p19ARF and a shorter mitochondrial isoform, named smARF ( hsmARF in human). While p19ARF can inhibit cell growth by causing cell cycle arrest or type I apoptotic cell death, smARF is able to induce type II autophagic cell death. Inappropriate proliferative signals generated by proto-oncogenes, such as c-Myc and E2F1, can elevate both p19ARF and smARF proteins. Here, we reveal a novel means of regulation of smARF protein steady state levels through its interactions with the mitochondrial p32. The p32 protein physically interacts with both human and murine smARF, and colocalizes with these short isoforms to the mitochondria. Remarkably, knocking down p32 protein levels significantly reduced the steady state levels of smARF by increasing its turn over. As a consequence, the ability of ectopically expressed smARF to induce autophagy and to cause mitochondrial membrane dissipation was significantly reduced. In contrast, the protein levels of full- length p19ARF, which mainly resides in the nucleolus, were not influenced by p32 depletion, suggesting that p32 exclusively stabilizes the mitochondrial smARF protein. Thus the interaction with p32 provides a means of specifically regulating the expression of the recently identified autophagic inducer, smARF, and adds yet another layer of complexity to the multifaceted regulation of the ARF gene.	Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel; Weizmann Inst Sci, Dept Mol & Cell Biol, IL-76100 Rehovot, Israel	Weizmann Institute of Science; Weizmann Institute of Science	Kimchi, A (corresponding author), Weizmann Inst Sci, Dept Mol Genet, Belfer 209, IL-76100 Rehovot, Israel.	adi.kimchi@weizmann.ac.il		Oren, Moshe/0000-0003-4311-7172				Brokstad KA, 2001, BIOCHEM BIOPH RES CO, V281, P1161, DOI 10.1006/bbrc.2001.4473; Bruni R, 1996, P NATL ACAD SCI USA, V93, P10423, DOI 10.1073/pnas.93.19.10423; Deb TB, 1996, J BIOL CHEM, V271, P2206, DOI 10.1074/jbc.271.4.2206; Dedio J, 1998, J IMMUNOL, V160, P3534; DESAI K, 1991, P NATL ACAD SCI USA, V88, P8875, DOI 10.1073/pnas.88.20.8875; FRIDELL RA, 1995, VIROLOGY, V209, P347, DOI 10.1006/viro.1995.1266; GHEBREHIWET B, 1994, J EXP MED, V179, P1809, DOI 10.1084/jem.179.6.1809; Granot Z, 2003, MOL ENDOCRINOL, V17, P2461, DOI 10.1210/me.2003-0074; Herwald H, 1996, J BIOL CHEM, V271, P13040, DOI 10.1074/jbc.271.22.13040; Jiang JZ, 1999, P NATL ACAD SCI USA, V96, P3572, DOI 10.1073/pnas.96.7.3572; Kuo ML, 2004, GENE DEV, V18, P1862, DOI 10.1101/gad.1213904; Lim BL, 1996, J BIOL CHEM, V271, P26739, DOI 10.1074/jbc.271.43.26739; LUO Y, 1994, J VIROL, V68, P3850, DOI 10.1128/JVI.68.6.3850-3856.1994; Matthews DA, 1998, J GEN VIROL, V79, P1677, DOI 10.1099/0022-1317-79-7-1677; Muta T, 1997, J BIOL CHEM, V272, P24363, DOI 10.1074/jbc.272.39.24363; Reef S, 2006, MOL CELL, V22, P463, DOI 10.1016/j.molcel.2006.04.014; Seytter T, 1998, YEAST, V14, P303, DOI 10.1002/(SICI)1097-0061(19980315)14:4<303::AID-YEA217>3.0.CO;2-N; Sherr CJ, 2006, NAT REV CANCER, V6, P663, DOI 10.1038/nrc1954; SIMOS G, 1994, FEBS LETT, V346, P225, DOI 10.1016/0014-5793(94)00479-X; Soltys BJ, 2000, HISTOCHEM CELL BIOL, V114, P245; Sunayama J, 2004, CELL DEATH DIFFER, V11, P771, DOI 10.1038/sj.cdd.4401418; Tange TO, 1996, J BIOL CHEM, V271, P10066, DOI 10.1074/jbc.271.17.10066; Wang YL, 1997, VIROLOGY, V236, P18, DOI 10.1006/viro.1997.8739; YU L, 1995, J VIROL, V69, P3007, DOI 10.1128/JVI.69.5.3007-3016.1995; YU L, 1995, J VIROL, V69, P3017, DOI 10.1128/JVI.69.5.3017-3023.1995	25	43	47	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 11	2007	26	46					6677	6683		10.1038/sj.onc.1210485	http://dx.doi.org/10.1038/sj.onc.1210485			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	219JT	17486078				2022-12-28	WOS:000250081500009
J	Ji, J; Liu, R; Tong, T; Song, Y; Jin, S; Wu, M; Zhan, Q				Ji, J.; Liu, R.; Tong, T.; Song, Y.; Jin, S.; Wu, M.; Zhan, Q.			Gadd45a regulates beta-catenin distribution and maintains cell-cell adhesion/contact	ONCOGENE			English	Article						Gadd45a; cell-cell adhesion; cell contact; inhibition; beta-catenin	DECREASED DNA-REPAIR; PROTEIN-COMPONENT; STRESS-PROTEIN; EXPRESSION; P53; COMPLEX; KINASE; GROWTH; INHIBITION; TYROSINE	Gadd45a, a growth arrest and DNA-damage gene, plays important roles in the control of cell cycle checkpoints, DNA repair and apoptosis. We show here that Gadd45a is involved in the control of cell contact inhibition and cell cell adhesion. Gadd45a can serve as an adapter to enhance the interaction between beta-catenin and Caveolin-1, and in turn induces beta-catenin translocation to cell membrane for maintaining cell - cell adhesion/contact inhibition. This is coupled with reduction of b-catenin in cytoplasm and nucleus following Gadd45a induction, which is reflected by the downregulation of cyclin D1, one of the beta-catenin targeted genes. Additionally, Gadd45a facilitates ultraviolet radiation-induced degradation of cytoplasmic and nuclear beta-catenin in a p53-dependent manner via activation of p38 kinase. These findings define a novel link that connects Gadd45a to cell - cell adhesion and cell contact inhibition, which might contribute to the role of Gadd45a in inhibiting tumorigenesis.	Chinese Acad Med Sci, Inst Canc, State Key Lab Mol Oncol, Beijing 100021, Peoples R China; Peking Union Med Coll, Beijing 100021, Peoples R China	Chinese Academy of Medical Sciences - Peking Union Medical College; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College	Zhan, Q (corresponding author), Chinese Acad Med Sci, Inst Canc, State Key Lab Mol Oncol, Beijing 100021, Peoples R China.	zhanqimin@pumc.edu.cn						Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Barker N, 2000, BIOESSAYS, V22, P961; BEHRENS J, 1993, J CELL BIOL, V120, P757, DOI 10.1083/jcb.120.3.757; Brabletz T, 1999, AM J PATHOL, V155, P1033, DOI 10.1016/S0002-9440(10)65204-2; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Carrier F, 1999, MOL CELL BIOL, V19, P1673; CARRO MJ, 1994, COLLECT MATH, V45, P53; Dietrich C, 2002, BIOCHEM BIOPH RES CO, V292, P195, DOI 10.1006/bbrc.2002.6625; Fan WH, 2002, J BIOL CHEM, V277, P8061, DOI 10.1074/jbc.M110225200; FORNACE AJ, 1988, P NATL ACAD SCI USA, V85, P8800, DOI 10.1073/pnas.85.23.8800; Galbiati F, 2000, J BIOL CHEM, V275, P23368, DOI 10.1074/jbc.M002020200; GLENNEY JR, 1992, P NATL ACAD SCI USA, V89, P10517, DOI 10.1073/pnas.89.21.10517; Gottardi CJ, 2001, CURR BIOL, V11, pR792, DOI 10.1016/S0960-9822(01)00473-0; Gumbiner BM, 2000, J CELL BIOL, V148, P399, DOI 10.1083/jcb.148.3.399; Hildesheim J, 2004, ONCOGENE, V23, P1829, DOI 10.1038/sj.onc.1207301; Hildesheim J, 2002, CANCER RES, V62, P7305; Hollander MC, 2001, CANCER RES, V61, P2487; Hollander MC, 1999, NAT GENET, V23, P176, DOI 10.1038/13802; Jin SQ, 2003, ONCOGENE, V22, P8536, DOI 10.1038/sj.onc.1206907; Jin SQ, 2000, J BIOL CHEM, V275, P16602, DOI 10.1074/jbc.M000284200; Jin SQ, 2002, ONCOGENE, V21, P8696, DOI 10.1038/sj.onc.1206034; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Kato Y, 2005, LUNG CANCER, V48, P323, DOI 10.1016/j.lungcan.2004.11.012; KEMLER R, 1993, TRENDS GENET, V9, P317, DOI 10.1016/0168-9525(93)90250-L; Kitagawa M, 1999, EMBO J, V18, P2401, DOI 10.1093/emboj/18.9.2401; Kudo Y, 2004, CLIN CANCER RES, V10, P5455, DOI 10.1158/1078-0432.CCR-04-0372; Leali D, 2001, J BIOL CHEM, V276, P37900; Li G, 1996, AM J PATHOL, V148, P1113; MARCHENKO GN, 2002, BIOCHEM J, V363, P263; Morin PJ, 1999, BIOESSAYS, V21, P1021, DOI 10.1002/(SICI)1521-1878(199912)22:1<1021::AID-BIES6>3.0.CO;2-P; Patturajan M, 2002, CANCER CELL, V1, P369, DOI 10.1016/S1535-6108(02)00057-0; Peifer M, 2000, SCIENCE, V287, P1606, DOI 10.1126/science.287.5458.1606; Piedra J, 2003, MOL CELL BIOL, V23, P2287, DOI 10.1128/MCB.23.7.2287-2297.2003; Ratovitski EA, 2001, P NATL ACAD SCI USA, V98, P1817, DOI 10.1073/pnas.98.4.1817; RICHARD C, 1995, J BIOL CHEM, V270, P24188, DOI 10.1074/jbc.270.41.24188; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; Salon C, 2004, HUM PATHOL, V35, P1148, DOI 10.1016/j.humpath.2004.04.015; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Smith ML, 2000, MOL CELL BIOL, V20, P3705, DOI 10.1128/MCB.20.10.3705-3714.2000; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; Tong T, 2005, MOL CELL BIOL, V25, P4488, DOI 10.1128/MCB.25.11.4488-4500.2005; van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092-8674(02)01014-0; Vizirianakis IS, 2002, INT J ONCOL, V21, P135; Wang W, 2005, ONCOGENE, V24, P2705, DOI 10.1038/sj.onc.1208464; Wang XW, 1999, P NATL ACAD SCI USA, V96, P3706, DOI 10.1073/pnas.96.7.3706; Yamasawa K, 2002, CLIN CANCER RES, V8, P2563; Zhan QM, 2005, MUTAT RES-FUND MOL M, V569, P133, DOI 10.1016/j.mrfmmm.2004.06.055; Zhan QM, 1999, ONCOGENE, V18, P2892, DOI 10.1038/sj.onc.1202667; Zhang XH, 2003, ONCOGENE, V22, P4166, DOI 10.1038/sj.onc.1206599	49	24	26	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 27	2007	26	44					6396	6405		10.1038/sj.onc.1210469	http://dx.doi.org/10.1038/sj.onc.1210469			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	214KY	17452974				2022-12-28	WOS:000249737600004
J	Tanaka, K; Imoto, I; Inoue, J; Kozaki, K; Tsuda, H; Shimada, Y; Aiko, S; Yoshizumi, Y; Iwai, T; Kawano, T; Inazawa, J				Tanaka, K.; Imoto, I.; Inoue, J.; Kozaki, K.; Tsuda, H.; Shimada, Y.; Aiko, S.; Yoshizumi, Y.; Iwai, T.; Kawano, T.; Inazawa, J.			Frequent methylation-associated silencing of a candidate tumor-suppressor, CRABP1, in esophageal squamous-cell carcinoma	ONCOGENE			English	Article						esophageal squamous-cell carcinoma; CRABP1; DNA methylation; BAMCA; tumor suppressor	ACID-BINDING-PROTEIN; PAPILLARY THYROID-CARCINOMA; CPG ISLAND AMPLIFICATION; RETINOIC-ACID; COLORECTAL-CANCER; I GENE; LYMPH-NODES; EXPRESSION; IDENTIFICATION; PROMOTER	Epigenetic alterations and the resulting inactivation of tumor suppressor genes often contribute to the development of various cancers. To identify novel candidates that may be silenced by aberrant methylation in esophageal squamous-cell carcinoma (ESCC), we analysed ESCC cell lines by a recently developed method known as bacterial artificial chromosome array-based methylated CpG island amplification (BAMCA), and selected candidates through BAMCA-assisted strategy. In the course of this program, we identified frequent CpG methylation-dependent silencing of the gene encoding cellular retinoic acid binding protein 1 (CRABP1) in our panel of ESCC cell lines. Expression of CRABP1 mRNA was restored in gene-silenced ESCC cells after treatment with 5-aza 2'-deoxycytidine. The DNA methylation status of the CRABP1 CpG island with clear promoter activity correlated inversely with expression of this gene. CpG methylation of CRABP1 was frequently observed in primary ESCC tissues as well. Restoration of CRABP1 expression in ESCC cells lacking the protein reduced cell growth by inducing arrest at G(0)-G(1), whereas knockdown of the gene in cells expressing CRABP1 promoted cell growth. Among 113 primary ESCC tumors, the absence of immunoreactive CRABP1 was significantly associated with de-differentiation of cancer cells and with distant lymph-node metastases in the patients. These results indicate that CRABP1 appears to have a tumor-suppressor function in esophageal epithelium, and its epigenetic silencing may play a pivotal role during esophageal carcinogenesis. Its expression status in biopsies or resected tumors might serve as an index for identifying ESCC patients for whom combined therapeutic modalities would be recommended.	Tokyo Med & Dent Univ, Med Res Inst, Dept Mol Cytogenet, Bunkyo Ku, Tokyo 1138510, Japan; Tokyo Med & Dent Univ, Sch Biomed Sci, Tokyo 1138510, Japan; Tokyo Med & Dent Univ, Grad Sch, Dept Vasc & Appl Surg, Tokyo 1138510, Japan; Tokyo Med & Dent Univ, Hard Tissue Genome Res Ctr, Dept Genome Med, Tokyo 1138510, Japan; Japan Sci & Technol Corp, CREST, Kawaguchi, Japan; Natl Def Med Coll, Dept Basic Pathol, Tokorozawa, Saitama 359, Japan; Hyogo Med Univ, Dept Surg 1, Nishinomiya, Hyogo, Japan; Natl Def Med Coll, Dept Surg, Tokorozawa, Saitama 359, Japan; Tokyo Med & Dent Univ, 21st Century Ctr Excellence Program Mol Destruct, Tokyo 1138510, Japan	Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU); Japan Science & Technology Agency (JST); National Defense Medical College - Japan; Hyogo College of Medicine; University of Hyogo; National Defense Medical College - Japan; Tokyo Medical & Dental University (TMDU)	Inazawa, J (corresponding author), Tokyo Med & Dent Univ, Med Res Inst, Dept Mol Cytogenet, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138510, Japan.	johinaz.cgen@mri.tmd.ac.jp	imoto, Issei/D-8065-2012; Imoto, Issei/AAD-5799-2020; Kozaki, Ken-ichi/M-6281-2014	Kozaki, Ken-ichi/0000-0003-3286-819X				DEBRUIJN DRH, 1994, DIFFERENTIATION, V58, P141; Dong D, 1999, J BIOL CHEM, V274, P23695, DOI 10.1074/jbc.274.34.23695; DONOVAN M, 1995, J STEROID BIOCHEM, V53, P459, DOI 10.1016/0960-0760(95)00092-E; DOWLATSHAHI K, 1984, CANCER, V54, P308, DOI 10.1002/1097-0142(19840715)54:2<308::AID-CNCR2820540221>3.0.CO;2-4; Egger G, 2004, NATURE, V429, P457, DOI 10.1038/nature02625; FIORELLA PD, 1993, J BIOL CHEM, V268, P21545; GORRY P, 1994, P NATL ACAD SCI USA, V91, P9032, DOI 10.1073/pnas.91.19.9032; Hawthorn L, 2004, HEAD NECK-J SCI SPEC, V26, P1069, DOI 10.1002/hed.20099; Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075; Huang Y, 2003, INT J CANCER, V104, P735, DOI 10.1002/ijc.11006; Imoto I, 2001, CANCER RES, V61, P6629; Inazawa J, 2004, CANCER SCI, V95, P559, DOI 10.1111/j.1349-7006.2004.tb02486.x; Ito T, 2003, CANCER RES, V63, P6320; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Kaifi JT, 2005, J NATL CANCER I, V97, P1840, DOI 10.1093/jnci/dji431; Kim MS, 2006, CANCER RES, V66, P3409, DOI 10.1158/0008-5472.CAN-05-1608; Kuroki T, 2003, CANCER RES, V63, P3724; Laird PW, 2003, NAT REV CANCER, V3, P253, DOI 10.1038/nrc1045; Mandelker DL, 2005, CANCER RES, V65, P4963, DOI 10.1158/0008-5472.CAN-04-3923; Means AL, 2000, CELL GROWTH DIFFER, V11, P71; Misawa A, 2005, CANCER RES, V65, P10233, DOI 10.1158/0008-5472.CAN-05-1073; Miyazaki T, 2000, CANCER-AM CANCER SOC, V89, P955, DOI 10.1002/1097-0142(20000901)89:5<955::AID-CNCR3>3.0.CO;2-Z; Miyazaki T, 2003, INT J CANCER, V103, P657, DOI 10.1002/ijc.10860; Ogino S, 2006, GUT, V55, P1000, DOI 10.1136/gut.2005.082933; Ohtsu Atsushi, 2004, Int J Clin Oncol, V9, P444, DOI 10.1007/s10147-004-0454-9; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Pfoertner S, 2005, TUMOR BIOL, V26, P313, DOI 10.1159/000089262; Pimkhaokham A, 2000, JPN J CANCER RES, V91, P1126, DOI 10.1111/j.1349-7006.2000.tb00895.x; RODER JD, 1994, BRIT J SURG, V81, P410, DOI 10.1002/bjs.1800810330; SHIBAGAKI I, 1994, CANCER RES, V54, P2996; Shibata H, 2001, PATHOL RES PRACT, V197, P157, DOI 10.1078/0344-0338-00027; SHIMADA Y, 1992, CANCER, V69, P277, DOI 10.1002/1097-0142(19920115)69:2<277::AID-CNCR2820690202>3.0.CO;2-C; Shirakawa Y, 2000, CLIN CANCER RES, V6, P541; Sobin LH., 2002, INT UNION CANC UICC, V6; Sonoda I, 2004, CANCER RES, V64, P3741, DOI 10.1158/0008-5472.CAN-04-0172; Stein HJ, 2005, ANN SURG, V242, P566, DOI 10.1097/01.sla.0000184211.75970.85; Suzuki H, 2002, NAT GENET, V31, P141, DOI 10.1038/ng892; Toyota M, 1999, CANCER RES, V59, P2307; Venepally P, 1996, ARCH BIOCHEM BIOPHYS, V336, P231, DOI 10.1006/abbi.1996.0553; WEI LN, 1994, DEV DYNAM, V201, P1, DOI 10.1002/aja.1002010102; Wei LN, 1996, J BIOL CHEM, V271, P5073; Xiong ZG, 1997, NUCLEIC ACIDS RES, V25, P2532, DOI 10.1093/nar/25.12.2532; Yamashita K, 2002, CANCER CELL, V2, P485, DOI 10.1016/S1535-6108(02)00215-5	43	57	67	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 27	2007	26	44					6456	6468		10.1038/sj.onc.1210459	http://dx.doi.org/10.1038/sj.onc.1210459			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	214KY	17438526				2022-12-28	WOS:000249737600010
J	Kanazawa, T; Iwashita, T; Kommareddi, P; Nair, T; Misawa, K; Misawa, Y; Ueda, Y; Tono, T; Carey, TE				Kanazawa, T.; Iwashita, T.; Kommareddi, P.; Nair, T.; Misawa, K.; Misawa, Y.; Ueda, Y.; Tono, T.; Carey, T. E.			Galanin and galanin receptor type 1 suppress proliferation in squamous carcinoma cells: activation of the extracellular signal regulated kinase pathway and induction of cyclin-dependent kinase inhibitors	ONCOGENE			English	Article						g protein-coupled receptors; mitogen-activated protein kinase; cyclin-dependent kinase inhibitor; head and neck neoplasm	PROTEIN-KINASE; CANCER CELLS; HEAD; ARREST; 18Q; P27; EXPRESSION; RAS	Galanin receptor 1(GALR1) maps to a common region of 18q loss in head and neck squamous cell carcinomas and is frequently inactivated by methylation. To investigate effects of GALR1 and its signaling pathways, we stably expressed hemaglutinin-tagged GALR1 in a human oral carcinoma cell line (UM-SCC-1-GALR1) that expresses no endogenous GALR1. In transfected cells, galanin induced activation of the extracellular-regulated protein kinase-1/2 (ERK1/2) and suppressed proliferation. Galanin stimulation mediated decreased expression of cyclin D1 and increased expression of the cyclin-dependent kinase inhibitors (CKI), p27(Kip1) and p57(Kip2). Pretreatment with the ERK1/2-specitic inhibitor U0126 prevented these galanin-induced effects. Phosphatidylinositol 3-kinase (PI3K) pathway activation did not differ in UM-SCC-1-GALR1 and UM-SCC-1-mock cells after galanin treatment. Pertussis toxin and LY294002 inhibition demonstrated that galanin and GALR1 induce ERK1/2 activation via God, not the PI3K pathway-linked to the G beta gamma subunit. Galanin and GALR1 also inhibit colony formation and tumor growth in vivo. Our results implicate GALR1, a Gi protein-coupled receptor, as a tumor suppressor gene that inhibits cell proliferation via ERK1/2 activation.	Univ Michigan, Dept Otolaryngol Head & Neck Surg, Lab Head & Neck Canc Biol, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Cell & Dev Biol, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Pharmacol, Ann Arbor, MI 48109 USA; Univ Ryukyus, Dept Otolaryngol Head & Neck Surg, Okinawa, Japan; Hamamatsu Univ Sch Med, Dept Otolaryngol, Hamamatsu, Shizuoka 43131, Japan	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of the Ryukyus; Hamamatsu University School of Medicine	Carey, TE (corresponding author), Univ Michigan, Dept Otolaryngol, 1301 E Ann St,6020 KHRI, Ann Arbor, MI 48109 USA.	careyte@umich.edu		Carey, Thomas/0000-0002-5202-7518	NATIONAL CANCER INSTITUTE [P50CA097248, P30CA046592] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE012477] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [P30DC005188] Funding Source: NIH RePORTER; NCI NIH HHS [P50 CA97248, P30 CA46592] Funding Source: Medline; NIDCD NIH HHS [P30 DC005188, P30 DC05188] Funding Source: Medline; NIDCR NIH HHS [R01 DE12477] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Akervall J, 2003, CLIN CANCER RES, V9, P1750; Berger A, 2004, ENDOCRINOLOGY, V145, P500, DOI 10.1210/en.2003-0649; Branchek TA, 2000, TRENDS PHARMACOL SCI, V21, P109, DOI 10.1016/S0165-6147(00)01446-2; Cody JD, 1997, AM J MED GENET, V71, P420, DOI 10.1002/(SICI)1096-8628(19970905)71:4<420::AID-AJMG9>3.3.CO;2-A; Dixon BS, 2002, AM J PHYSIOL-CELL PH, V283, pC193, DOI 10.1152/ajpcell.00289.2001; Esposito V, 1997, CANCER RES, V57, P3381; Facchinetti MM, 2004, CANCER RES, V64, P3629, DOI 10.1158/0008-5472.CAN-03-3741; Ferbeyre G, 2002, MOL CELL BIOL, V22, P3497, DOI 10.1128/MCB.22.10.3497-3508.2002; Gendron L, 2003, J BIOL CHEM, V278, P3606, DOI 10.1074/jbc.M202446200; Han JH, 2005, J BIOL CHEM, V280, P31548, DOI 10.1074/jbc.M503431200; Henson BS, 2005, J BIOL CHEM, V280, P22564, DOI 10.1074/jbc.M414589200; Hoffmann MJ, 2005, INT J CANCER, V114, P406, DOI 10.1002/ijc.20749; Kong SM, 2000, CANCER RES, V60, P249; Kranenburg O, 2001, ONCOGENE, V20, P1540, DOI 10.1038/sj.onc.1204187; Lahlou H, 2003, J BIOL CHEM, V278, P39356, DOI 10.1074/jbc.M304524200; Lu XY, 2005, NEUROPEPTIDES, V39, P165, DOI 10.1016/j.npep.2004.12.013; Massarelli E, 2005, CANCER-AM CANCER SOC, V103, P952, DOI 10.1002/cncr.20879; Masuda T, 2002, CANCER RES, V62, P3819; MISAWA K, 2004, P AM ASSOC CANC RES, V44, P4271; Mochizuki N, 1999, NATURE, V400, P891, DOI 10.1038/23738; Otis M, 2005, ENDOCRINOLOGY, V146, P633, DOI 10.1210/en.2004-0935; Pearlstein RP, 1998, GENE CHROMOSOME CANC, V21, P333, DOI 10.1002/(SICI)1098-2264(199804)21:4<333::AID-GCC7>3.0.CO;2-#; Pumiglia KM, 1997, P NATL ACAD SCI USA, V94, P448, DOI 10.1073/pnas.94.2.448; Seufferlein T, 1996, CANCER RES, V56, P5758; Takebayashi S, 2000, CANCER RES, V60, P3397; Takebayashi S, 2004, GENE CHROMOSOME CANC, V41, P145, DOI 10.1002/gcc.20066; TATEMOTO K, 1983, FEBS LETT, V164, P124, DOI 10.1016/0014-5793(83)80033-7; Tsukada Y, 2001, J BIOL CHEM, V276, P40968, DOI 10.1074/jbc.M010890200; Wang S, 1998, BIOCHEMISTRY-US, V37, P6711, DOI 10.1021/bi9728405; Wittau N, 2000, ONCOGENE, V19, P4199, DOI 10.1038/sj.onc.1203777; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598; Yang M, 2005, P NATL ACAD SCI USA, V102, P6027, DOI 10.1073/pnas.0501535102	32	50	50	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2007	26	39					5762	5771		10.1038/sj.onc.1210384	http://dx.doi.org/10.1038/sj.onc.1210384			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	202EP	17384686				2022-12-28	WOS:000248885100008
J	Sims-Mourtada, J; Izzo, JG; Ajani, J; Chao, KSC				Sims-Mourtada, J.; Izzo, J. G.; Ajani, J.; Chao, K. S. C.			Sonic Hedgehog promotes multiple drug resistance by regulation of drug transport	ONCOGENE			English	Article						hedgehog; multiple drug resistance; drug transport; chemoresistance	MULTIDRUG-RESISTANCE; STEM-CELLS; MUTATIONS; PTCH	A major obstacle to successful chemotherapy is intrinsic or acquired multi-drug resistance (MDR). The most common cause of MDR involves increased drug efflux from cancer cells mediated by members of the ATP-binding cassette (ABC) transporter family. The regulation of ABC transporters in the context of cancer is poorly understood, and clinical efforts to inhibit their function have not been fruitful. Constitutive activation of the Hedgehog (Hh) pathway has been shown to contribute to the growth and maintenance of various cancers. Here, we show that inhibition of Hh signaling increases the response of cancer cells to multiple structurally unrelated chemotherapies. We further show that Hh pathway activation induces chemoresistance in part by increasing drug efflux in an ABC transporter-dependent manner. We found that Hh signaling regulates the expression of the ABC transporter proteins multi-drug resistance protein-1 (MDR1, ABCB1, P-glycoprotein) and (BCRP, ABCG2), and that targeted knockdown of MDR1 and BCRP expression by small interfering RNA partially reverses Hh-induced chemoresistance. These results suggest that the Hh pathway may be a target to overcome MDR and increase chemotherapeutic response.	Univ Texas, MD Anderson Canc Ctr, Dept Radiat Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Chao, KSC (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Radiat Oncol, 1515 Holcombe Blvd,Unit 97, Houston, TX 77030 USA.	cchao@mdanderson.org			NATIONAL CANCER INSTITUTE [P50CA097007, R01CA089198, R21CA121551] Funding Source: NIH RePORTER; NCI NIH HHS [P50 CA97007, CA121551, CA89198] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Berman DM, 2003, NATURE, V425, P846, DOI 10.1038/nature01972; Bigelow RLH, 2004, J BIOL CHEM, V279, P1197, DOI 10.1074/jbc.M310589200; Bunting KD, 2000, BLOOD, V96, P902, DOI 10.1182/blood.V96.3.902.015k40_902_909; Chen JK, 2002, GENE DEV, V16, P2743, DOI 10.1101/gad.1025302; Chintamani, 2005, WORLD J SURG ONCOL, V3, P61; Doyle LA, 2003, ONCOGENE, V22, P7340, DOI 10.1038/sj.onc.1206938; Ingham PW, 2001, GENE DEV, V15, P3059, DOI 10.1101/gad.938601; Kubo A, 2004, AM J GASTROENTEROL, V99, P582, DOI 10.1111/j.1572-0241.2004.04131.x; Lindstrom E, 2006, HUM MUTAT, V27, P215, DOI 10.1002/humu.20296; Okano-Uchida T, 2004, P NATL ACAD SCI USA, V101, P1211, DOI 10.1073/pnas.0307972100; Perez-Tomas R, 2006, CURR MED CHEM, V13, P1859, DOI 10.2174/092986706777585077; Reifenberger J, 2005, BRIT J DERMATOL, V152, P43, DOI 10.1111/J.1365-2133.2005.06353.X; Ruel L, 2003, NAT CELL BIOL, V5, P907, DOI 10.1038/ncb1052; Sims-Mourtada J, 2006, CLIN CANCER RES, V12, P6565, DOI 10.1158/1078-0432.CCR-06-0176; Szakacs G, 2006, NAT REV DRUG DISCOV, V5, P219, DOI 10.1038/nrd1984; Takara K, 2006, CURR PHARM DESIGN, V12, P273, DOI 10.2174/138161206775201965; Zhou S, 2001, NAT MED, V7, P1028, DOI 10.1038/nm0901-1028	17	177	185	2	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2007	26	38					5674	5679		10.1038/sj.onc.1210356	http://dx.doi.org/10.1038/sj.onc.1210356			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	200ZS	17353904				2022-12-28	WOS:000248801900014
J	Chen, M; Rahman, L; Voeller, D; Kastanos, E; Yang, SX; Feigenbaum, L; Allegra, C; Kaye, FJ; Steeg, P; Zajac-Kaye, M				Chen, M.; Rahman, L.; Voeller, D.; Kastanos, E.; Yang, S. X.; Feigenbaum, L.; Allegra, C.; Kaye, F. J.; Steeg, P.; Zajac-Kaye, M.			Transgenic expression of human thymidylate synthase accelerates the development of hyperplasia and tumors in the endocrine pancreas	ONCOGENE			English	Article						thymidylate synthase; transgenic model; islet cell adenoma; endocrine pancreas	DEPENDENT KINASE INHIBITORS; GENE-EXPRESSION; BREAST-CANCER; DNA-SYNTHESIS; MOUSE MODEL; C-MYC; K-RAS; P53; MICE; 5-FLUOROURACIL	Thymidylate synthase ( TS) is an essential enzyme for DNA synthesis and repair and elevated levels of TS have been identified as an important prognostic biomarker for colorectal cancer and several other common human malignancies. In addition, TS gene expression has been linked with cell-cycle regulation and cell proliferation through the ability of retinoblastoma protein to repress the transcriptional activation of E2F target genes such as TS. Therefore, overproduction of TS could participate in the progression to a neoplastic phenotype. Consistent with this model, a recent study has suggested that ectopic TS express ion can induce a transformed phenotype in mammalian cells. To investigate the role of deregulated TS activity in tumor development, we generated transgenic mice that express high levels of catalytically active human TS( hTS) exclusively in the pancreas and low levels of hTS in multiple other tissues. Analyses of pancreatic tissue in TS transgenic mice revealed abnormalities within the endocrine pancreas, ranging from pancreatic islet hyperplasia to the detection of islet cell tumors. Overexpression of hTS in murine islets provides a new model to study genetic alterations associated with the progression from normal cells to hyperplasia to islet cell tumors, and suggests that this mouse model may be useful for regulating TS activity in vivo for development of cancer prevention and new therapies.	Ctr Canc Res, Mol Therapeut Program, Bethesda, MD USA; Natl Clin Target Validat Lab, Div Canc Treatment & Diag, Bethesda, MD USA; NCI, Frederick Canc Res, Lab Anim Sci, Frederick, MD 21701 USA; NCI, Genet Branch, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Zajac-Kaye, M (corresponding author), NCI, NIH, Bldg 37 RM 1122,37 Convent Dr, Bethesda, MD 20892 USA.	kayem@exchange.nih.gov	kaye, frederic/E-2437-2011		Intramural NIH HHS Funding Source: Medline; NATIONAL CANCER INSTITUTE [Z01SC007256, ZIASC007256] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALEXANDROVA N, 1995, MOL CELL BIOL, V15, P5188; Allegra CJ, 2003, J CLIN ONCOL, V21, P241, DOI 10.1200/JCO.2003.05.044; ALMOGUERA C, 1988, CELL, V53, P549, DOI 10.1016/0092-8674(88)90571-5; Angus SP, 2002, J BIOL CHEM, V277, P44376, DOI 10.1074/jbc.M205911200; Banerjee D, 1998, CANCER RES, V58, P4292; Bertino JR, 2003, CLIN CANCER RES, V9, P1235; Casanovas O, 2005, ONCOGENE, V24, P6597, DOI 10.1038/sj.onc.1208823; Chu E, 1996, Cancer Treat Res, V87, P175; Crabtree JS, 2003, MOL CELL BIOL, V23, P6075, DOI 10.1128/MCB.23.17.6075-6085.2003; Crabtree JS, 2001, P NATL ACAD SCI USA, V98, P1118, DOI 10.1073/pnas.98.3.1118; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; Edler D, 2000, CLIN CANCER RES, V6, P1378; Franklin DS, 2000, MOL CELL BIOL, V20, P6147, DOI 10.1128/MCB.20.16.6147-6158.2000; HANAHAN D, 1985, NATURE, V315, P115, DOI 10.1038/315115a0; Hoeflich A, 1999, ENDOCRINOLOGY, V140, P5488, DOI 10.1210/en.140.12.5488; Johnston PG, 1997, JNCI-J NATL CANCER I, V89, P308, DOI 10.1093/jnci/89.4.308; JOHNSTON PG, 1995, CANCER RES, V55, P1407; JOHNSTON PG, 1993, BIOCHEM PHARMACOL, V45, P2483, DOI 10.1016/0006-2952(93)90230-T; Lewis BC, 2003, GENE DEV, V17, P3127, DOI 10.1101/gad.1140403; Martinez A, 2001, J ENDOCRINOL, V170, P503, DOI 10.1677/joe.0.1700503; Milne TA, 2005, P NATL ACAD SCI USA, V102, P749, DOI 10.1073/pnas.0408836102; NAVALGUND LG, 1980, J BIOL CHEM, V255, P7386; PAVELIC K, 1995, J PATHOL, V177, P395, DOI 10.1002/path.1711770410; Pelengaris S, 2002, CELL, V109, P321, DOI 10.1016/S0092-8674(02)00738-9; Pestalozzi BC, 1997, J CLIN ONCOL, V15, P1923, DOI 10.1200/JCO.1997.15.5.1923; Rahman L, 2004, CANCER CELL, V5, P341, DOI 10.1016/S1535-6108(04)00080-7; Rane SG, 2002, MOL CELL BIOL, V22, P644, DOI 10.1128/MCB.22.2.644-656.2002; Sato T, 2000, HEPATO-GASTROENTEROL, V47, P875; Shintani Y, 2003, INT J CANCER, V104, P790, DOI 10.1002/ijc.11014; Takimoto Chris H, 2005, Cancer Chemother Biol Response Modif, V22, P1; Voeller DM, 2002, BIOCHEM BIOPH RES CO, V297, P24, DOI 10.1016/S0006-291X(02)02080-6; Wang EH, 1998, CANCER RES, V58, P4417; WILLIAMS BO, 1994, NAT GENET, V7, P480, DOI 10.1038/ng0894-480; Yang SX, 2005, CLIN CANCER RES, V11, P6226, DOI 10.1158/1078-0432.CCR-05-0270; Zhan Y, 2000, DNA CELL BIOL, V19, P639, DOI 10.1089/10445490050199045	35	20	23	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 19	2007	26	33					4817	4824		10.1038/sj.onc.1210273	http://dx.doi.org/10.1038/sj.onc.1210273			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	191ZL	17297449				2022-12-28	WOS:000248170400006
J	Minami, Y; Shimamura, T; Shah, K; LaFramboise, T; Glatt, KA; Liniker, E; Borgman, CL; Haringsma, HJ; Feng, W; Weir, BA; Lowell, AM; Lee, JC; Wolf, J; Shapiro, GI; Wong, KK; Meyerson, M; Thomas, RK				Minami, Y.; Shimamura, T.; Shah, K.; LaFramboise, T.; Glatt, K. A.; Liniker, E.; Borgman, C. L.; Haringsma, H. J.; Feng, W.; Weir, B. A.; Lowell, A. M.; Lee, J. C.; Wolf, J.; Shapiro, G. I.; Wong, K-K; Meyerson, M.; Thomas, R. K.			The major lung cancer-derived mutants of ERBB2 are oncogenic and are associated with sensitivity to the irreversible EGFR/ERBB2 inhibitor HKI-272	ONCOGENE			English	Article						lung cancer; targeted therapy; oncogene mutation; ERBB2; Her-2; kinase inhibitors	GROWTH-FACTOR RECEPTOR; EGF RECEPTOR; ACQUIRED-RESISTANCE; KINASE DOMAIN; CELL-LINES; BCR-ABL; GEFITINIB; MUTATIONS; ERLOTINIB; ADENOCARCINOMAS	Mutations in the ERBB2 gene were recently found in approximately 2% of primary non-small cell lung cancer (NSCLC) specimens; however, little is known about the functional consequences and the relevance to responsiveness to targeted drugs for most of these mutations. Here, we show tha t the major lung cancer-derived ERBB2 mutants, including the most frequent mutation, A775insYVMA, lead to oncogenic transformation in a cellular assay. Murine cells transformed with these mutants were relatively resistant to the reversible epidermal growth factor receptor (EGFR) inhibitor erlotinib, resembling the resistant phenotype found in cells carrying the homologous mutations in exon 20 of EGFR. However, the same cells were highly sensitive to the irreversible dual-specificity EGFR/ERBB2 kinase inhibitor HKI-272, as were those overexpressing wild-type ERBB2. Finally, the NSCLC cell line, Calu-3, overexpressing wild-type ERBB2 owing to a high-level amplification of the ERBB2 gene were highly sensitive to HKI-272. These results provide a rationale for treatment of patients with ERBB2-mutant or ERBB2-amplified lung tumors with HKI-272.	Univ Cologne, Klaus Joachim Zulch Labs, Max Planck Soc, D-50931 Cologne, Germany; Univ Cologne, Fac Med, D-50931 Cologne, Germany; Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; Harvard Univ, Cambridge, MA 02138 USA; MIT, Broad Inst, Cambridge, MA 02139 USA; Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA; Univ Cologne, Ctr Integrated Oncol, Dept Internal Med 1, D-5000 Cologne 41, Germany; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Dana Farber Canc Inst, Ctr Canc Genome Discovery, Boston, MA 02115 USA	Max Planck Society; University of Cologne; University of Cologne; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Harvard University; Brigham & Women's Hospital; University of Cologne; Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute	Thomas, RK (corresponding author), Univ Cologne, Klaus Joachim Zulch Labs, Max Planck Soc, Gleueler Str 50, D-50931 Cologne, Germany.	geoffrey_Shapiro@dfci.harvard.edu; kwong1@partners.org; matthew_meyerson@dfci.harvard.edu; roman.thomas@nf.mpg.de	Meyerson, Matthew L/E-7123-2012		NATIONAL CANCER INSTITUTE [P20CA090578] Funding Source: NIH RePORTER; NCI NIH HHS [P20 CA90578] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Azam M, 2003, CELL, V112, P831, DOI 10.1016/S0092-8674(03)00190-9; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; Engelman JA, 2005, P NATL ACAD SCI USA, V102, P3788, DOI 10.1073/pnas.0409773102; Fukuoka M, 2003, J CLIN ONCOL, V21, P2237, DOI 10.1200/JCO.2003.10.038; Gazdar AF, 1998, INT J CANCER, V78, P766, DOI 10.1002/(SICI)1097-0215(19981209)78:6<766::AID-IJC15>3.0.CO;2-L; Greulich H, 2005, PLOS MED, V2, P1167, DOI 10.1371/journal.pmed.0020313; JIANG J, 2004, BLOOD; Jiang JR, 2005, CANCER RES, V65, P8968, DOI 10.1158/0008-5472.CAN-05-1829; Kobayashi S, 2005, CANCER RES, V65, P7096, DOI 10.1158/0008-5472.CAN-05-1346; Kobayashi S, 2005, NEW ENGL J MED, V352, P786, DOI 10.1056/NEJMoa044238; Kris MG, 2003, JAMA-J AM MED ASSOC, V290, P2149, DOI 10.1001/jama.290.16.2149; Kwak EL, 2005, P NATL ACAD SCI USA, V102, P7665, DOI 10.1073/pnas.0502860102; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Pao W, 2005, PLOS MED, V2, P225, DOI 10.1371/journal.pmed.0020073; Pao W, 2004, P NATL ACAD SCI USA, V101, P13306, DOI 10.1073/pnas.0405220101; Perez-Soler R, 2004, J CLIN ONCOL, V22, P3238, DOI 10.1200/JCO.2004.11.057; PIERCE JH, 1991, ONCOGENE, V6, P1189; Rabindran SK, 2005, CANCER LETT, V227, P9, DOI 10.1016/j.canlet.2004.11.015; Sharma SV, 2006, CANCER CELL, V10, P425, DOI 10.1016/j.ccr.2006.09.014; Shepherd FA, 2005, NEW ENGL J MED, V353, P123, DOI 10.1056/NEJMoa050753; Shigematsu H, 2005, CANCER RES, V65, P1642, DOI 10.1158/0008-5472.CAN-04-4235; Shimamura T, 2006, CANCER RES, V66, P6487, DOI 10.1158/0008-5472.CAN-06-0971; Sordella R, 2004, SCIENCE, V305, P1163, DOI 10.1126/science.1101637; Stephens P, 2004, NATURE, V431, P525, DOI 10.1038/431525b; Zhao XJ, 2005, CANCER RES, V65, P5561, DOI 10.1158/0008-5472.CAN-04-4603	26	86	93	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2007	26	34					5023	5027		10.1038/sj.onc.1210292	http://dx.doi.org/10.1038/sj.onc.1210292			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	194CV	17311002				2022-12-28	WOS:000248322500015
J	Denning, G; Jean-Joseph, B; Prince, C; Durden, DL; Vogt, PK				Denning, G.; Jean-Joseph, B.; Prince, C.; Durden, D. L.; Vogt, P. K.			A short N-terminal sequence of PTEN controls cytoplasmic localization and is required for suppression of cell growth	ONCOGENE			English	Article						PTEN; tumor suppressor; mutation; lipid binding; cytoplasmic localization signal	HUMAN GLIOBLASTOMA CELLS; TUMOR-SUPPRESSOR; NUCLEAR-LOCALIZATION; CHROMOSOME-10 PTEN; PHOSPHATASE; PROTEIN; GENE; MEMBRANE; CANCER; CYCLE	Phosphatase and tensin homolog deleted on chromosome 10 ( PTEN) is an important negative regulator of cell growth and a tumor suppressor. Its growth-attenuating activity is based on the dephosphorylation of phosphatidylinositol 3,4,5-trisphosphate ( PIP3), an essential second messenger for the phosphoinositide 3-kinase/Akt signaling pathway. This activity may require localization of PTEN to cytoplasmic membranes. Yet PTEN can also localize to the cell nucleus where its functions remain unclear. Here we present data that de. ne a short sequence in the N-terminal region of PTEN required for cytoplasmic localization. We will refer to this sequence as cytoplasmic localization signal ( CLS). It could function as a non-canonical signal for nuclear export or as a cytoplasmic retention signal of PTEN. Mutations within the CLS induce nuclear localization and impair growth suppressive activities of PTEN while preserving lipid phosphatase activity. We propose that nuclear localization of PTEN is not compatible with plasma membrane-targeted growth suppressive functions of PTEN.	Emory Univ, Sch Med, Winship Canc Ctr, Dept Pediat, Atlanta, GA 30322 USA; Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA USA; Emory Univ, Sch Med, Dept Pediat,Div Pediat Hematol & Oncol, AFLAC Canc Ctr & Blood Disorder Serv, Atlanta, GA 30322 USA	Emory University; Scripps Research Institute; Emory University	Denning, G (corresponding author), Emory Univ, Sch Med, Winship Canc Ctr, Dept Pediat, 1365 Clifton Rd,Bldg C,Room 5054D, Atlanta, GA 30322 USA.	gabriela_denning@oz.ped.emory.edu	Vogt, Peter K./R-7547-2019	Vogt, Peter K./0000-0002-4519-7500	NATIONAL CANCER INSTITUTE [R01CA094233, P01CA078045, R01CA078230, R56CA094233] Funding Source: NIH RePORTER; NCI NIH HHS [CA078230, CA078045, CA94233] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bonneau D, 2000, HUM MUTAT, V16, P109, DOI 10.1002/1098-1004(200008)16:2<109::AID-HUMU3>3.0.CO;2-0; Chung JH, 2005, CANCER RES, V65, P8096, DOI 10.1158/0008-5472.CAN-05-1888; Chung JH, 2005, CANCER RES, V65, P4108, DOI 10.1158/0008-5472.CAN-05-0124; Das S, 2003, P NATL ACAD SCI USA, V100, P7491, DOI 10.1073/pnas.0932835100; Duerr EM, 1998, ONCOGENE, V16, P2259, DOI 10.1038/sj.onc.1201756; Fabbro M, 2003, EXP CELL RES, V282, P59, DOI 10.1016/S0014-4827(02)00019-8; Furnari FB, 1997, P NATL ACAD SCI USA, V94, P12479, DOI 10.1073/pnas.94.23.12479; Gil A, 2006, MOL BIOL CELL, V17, P4002, DOI 10.1091/mbc.E06-05-0380; Leslie NR, 2005, BIOCHEM SOC T, V33, P1507, DOI 10.1042/BST0331507; Leslie NR, 2004, BIOCHEM J, V382, P1, DOI 10.1042/BJ20040825; Li DM, 1997, CANCER RES, V57, P2124; Li DM, 1998, P NATL ACAD SCI USA, V95, P15406, DOI 10.1073/pnas.95.26.15406; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Lian ZL, 2005, ONCOGENE, V24, P7394, DOI 10.1038/sj.onc.1209089; Liu JL, 2005, MOL CELL BIOL, V25, P6211, DOI 10.1128/MCB.25.14.6211-6224.2005; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Maehama T, 1999, TRENDS CELL BIOL, V9, P125, DOI 10.1016/S0962-8924(99)01519-6; Mayo LD, 2002, J BIOL CHEM, V277, P5484, DOI 10.1074/jbc.M108302200; Myers MP, 1997, P NATL ACAD SCI USA, V94, P9052, DOI 10.1073/pnas.94.17.9052; Myers MP, 1998, P NATL ACAD SCI USA, V95, P13513, DOI 10.1073/pnas.95.23.13513; Ramaswamy S, 1999, P NATL ACAD SCI USA, V96, P2110, DOI 10.1073/pnas.96.5.2110; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Su JD, 2003, CANCER RES, V63, P3585; Sun H, 1999, P NATL ACAD SCI USA, V96, P6199, DOI 10.1073/pnas.96.11.6199; Trotman LC, 2003, CANCER CELL, V3, P97, DOI 10.1016/S1535-6108(03)00022-9; VAN MEIR EG, 1994, CANCER RES, V54, P649; Vazquez F, 2006, P NATL ACAD SCI USA, V103, P3633, DOI 10.1073/pnas.0510570103; Vazquez F, 2006, CELL CYCLE, V5, P1523, DOI 10.4161/cc.5.14.3005; Vogt PK, 2001, TRENDS MOL MED, V7, P482, DOI 10.1016/S1471-4914(01)02161-X; Walker SM, 2004, BIOCHEM J, V379, P301, DOI 10.1042/BJ20031839; Wen SH, 2001, P NATL ACAD SCI USA, V98, P4622, DOI 10.1073/pnas.081063798	31	81	83	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 7	2007	26	27					3930	3940		10.1038/sj.onc.1210175	http://dx.doi.org/10.1038/sj.onc.1210175			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	177HP	17213812				2022-12-28	WOS:000247144500003
J	Mitani, Y; Oue, N; Matsumura, S; Yoshida, K; Noguchi, T; Ito, M; Tanaka, S; Kuniyasu, H; Kamata, N; Yasui, W				Mitani, Y.; Oue, N.; Matsumura, S.; Yoshida, K.; Noguchi, T.; Ito, M.; Tanaka, S.; Kuniyasu, H.; Kamata, N.; Yasui, W.			Reg IV is a serum biomarker for gastric cancer patients and predicts response to 5-fluorouracil-based chemotherapy	ONCOGENE			English	Article						reg IV; apoptosis; 5-fluorouracil; serum tumor marker; SAGE; gastric cancer	DIHYDROPYRIMIDINE DEHYDROGENASE-ACTIVITY; GROWTH-FACTOR RECEPTOR; CELL-LINE TMK-1; GENE-EXPRESSION; COLONIC CARCINOMAS; SERIAL ANALYSIS; APOPTOSIS; SENSITIVITY; METASTASIS; SEARCH	Regenerating gene family, member 4 (Reg IV), a secreted protein, is overexpressed in several cancers, including gastric cancer (GC). In the present study, we measured Reg IV levels in sera from patients with GC by enzyme-linked immunosorbent assay. We also examined the effect of forced Reg IV expression on the apoptotic susceptibility to 5-fluorouracil(5-FU). Forced expression of Reg IV inhibited 5-FU-induced apoptosis. Induction of Bcl-2 and dihydropyrimidine dehydrogenase was involved in inhibition of apoptosis. Among 36 GC patients treated with a combination chemotherapy of low-dose 5-FU and cisplatin, all 14 Reg IV-positive patients showed no change or disease progression. The serum Reg IV concentration was similar between healthy individuals mean +/- s.e., (0.52 +/- 0.05 ng/ml) and patients with chronic-active gastritis (0.36 +/- 0.09 ng/ml). However, the serum Reg IV concentration in presurgical GC patients was signifi. cantly elevated (1.96 +/- 0.17 ng/ml), even at stage I. The diagnostic sensitivity of serum Reg IV (36.1%) was superior to that of serum carcinoembryonic antigen (11.5%) or carbohydrate antigen 19-9 (13.1%). These results indicate that expression of Reg IV is a marker for prediction of resistance to 5-FU-based chemotherapy in patients with GC. Serum Reg IV represents a novel biomarker for GC.	Hiroshima Univ, Grad Sch Biomed Sci, Dept Mol Pathol, Minami Ku, Hiroshima 7348551, Japan; Hiroshima Univ, Grad Sch Biomed Sci, Dept Oral & Maxillofacial Surg, Div Cervico Gnathostomatol, Hiroshima, Japan; Hiroshima Univ, Dept Surg Oncol, Res Inst Radiat Biol & Med, Hiroshima, Japan; Oita Univ, Fac Med, Dept Oncol Sci Surg 2, Oita 87011, Japan; Hiroshima Univ, Grad Sch Biomed Sci, Dept Med & Mol Sci, Hiroshima, Japan; Nara Med Univ, Dept Mol Pathol, Kashihara, Nara 634, Japan	Hiroshima University; Hiroshima University; Hiroshima University; Oita University; Hiroshima University; Nara Medical University	Yasui, W (corresponding author), Hiroshima Univ, Grad Sch Biomed Sci, Dept Mol Pathol, Minami Ku, 1-2-3 Kasumi, Hiroshima 7348551, Japan.	wyasui@hiroshima-u.ac.jp	Mitani, Yoshitsugu/ABA-2736-2021	Mitani, Yoshitsugu/0000-0002-8661-4702				ALLEY MC, 1988, CANCER RES, V48, P589; Ashkenazi A, 1999, CURR OPIN CELL BIOL, V11, P255, DOI 10.1016/S0955-0674(99)80034-9; Aung PP, 2006, ONCOGENE, V25, P2546, DOI 10.1038/sj.onc.1209279; Bishnupuri KS, 2006, GASTROENTEROLOGY, V130, P137, DOI 10.1053/j.gastro.2005.10.001; Buckhaults P, 2001, CANCER RES, V61, P6996; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HARRIS BE, 1990, CANCER RES, V50, P197; Hartupee JC, 2001, BBA-GENE STRUCT EXPR, V1518, P287, DOI 10.1016/S0167-4781(00)00284-0; Hohenberger P, 2003, LANCET, V362, P305, DOI 10.1016/S0140-6736(03)13975-X; Inada T, 2000, ANTICANCER RES, V20, P2457; Ishikawa Y, 2000, JPN J CANCER RES, V91, P105, DOI 10.1111/j.1349-7006.2000.tb00866.x; Kari C, 2003, CANCER RES, V63, P1; KAUFMANN SH, 1993, CANCER RES, V53, P3976; Kim R, 1999, INT J ONCOL, V15, P921; Kochi Mitsugu, 2000, Gastric Cancer, V3, P177, DOI 10.1007/PL00011715; Kuramochi H, 2006, INT J CANCER, V119, P522, DOI 10.1002/ijc.21692; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Longley DB, 2003, NAT REV CANCER, V3, P330, DOI 10.1038/nrc1074; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; Martinou JC, 2000, NAT CELL BIOL, V2, pE41, DOI 10.1038/35004069; OCHIAI A, 1985, JPN J CANCER RES, V76, P1064; Oue N, 2005, J PATHOL, V207, P185, DOI 10.1002/path.1827; Oue N, 2004, CANCER RES, V64, P2397, DOI 10.1158/0008-5472.CAN-03-3514; SOBIN LH, 2002, TNM CLASSIFICATION M, P65; Tahara E, 2005, CANCER IMMUNOL IMMUN, V54, P729, DOI 10.1007/s00262-004-0645-2; Takebe N, 2001, CANCER GENE THER, V8, P966, DOI 10.1038/sj.cgt.7700393; Ukon K, 2005, CANCER RES, V65, P1055; Vander Heiden MG, 1999, NAT CELL BIOL, V1, pE209, DOI 10.1038/70237; Violette S, 2003, INT J CANCER, V103, P185, DOI 10.1002/ijc.10788; YASUI W, 1993, INT J CANCER, V53, P36, DOI 10.1002/ijc.2910530108; Yasui W, 2004, CANCER SCI, V95, P385, DOI 10.1111/j.1349-7006.2004.tb03220.x; YASUI W, 1988, CANCER RES, V48, P137	33	91	101	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2007	26	30					4383	4393		10.1038/sj.onc.1210215	http://dx.doi.org/10.1038/sj.onc.1210215			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	184CZ	17237819	Green Submitted			2022-12-28	WOS:000247620000006
J	Grabarczyk, P; Przybylski, GK; Depke, M; Volker, U; Bahr, J; Assmus, K; Broker, BM; Walther, R; Schmidt, CA				Grabarczyk, P.; Przybylski, G. K.; Depke, M.; Voelker, U.; Bahr, J.; Assmus, K.; Broeker, B. M.; Walther, R.; Schmidt, C. A.			Inhibition of BCL11B expression leads to apoptosis of malignant but not normal mature T cells	ONCOGENE			English	Article						BCL11B; T-ALL; apoptosis; TRAIL; Bcl-xL	ACUTE LYMPHOBLASTIC-LEUKEMIA; TRANSCRIPTIONAL REPRESSION; THYMIC LYMPHOMAS; BINDING PROTEIN; NURD COMPLEX; GENE; PROMOTER; LYMPHOCYTES; BCL-X(L); TRAIL	The B-cell chronic lymphocytic leukemia (CLL)/lymphoma 11B gene (BCL11B) encodes a Kruppel-like zinc. finger protein, which plays a crucial role in thymopoiesis and has been associated with hematopoietic malignancies. It was hypothesized that BCL11B may act as a tumor-suppressor gene, but its precise function has not yet been elucidated. Here, we demonstrate that the survival of human T-cell leukemia and lymphoma cell lines is critically dependent on Bcl11b. Suppression of Bcl11b by RN A interference selectively induced apoptosis in transformed T cells whereas normal mature T cells remained unaffected. The apoptosis was effected by simultaneous activation of death receptor-mediated and intrinsic apoptotic pathways, most likely as a result of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) upregulation and suppression of the Bcl-xL antiapoptotic protein. Our data indicate an antiapoptotic function of Bcl11b. The resistance of normal mature T lymphocytes to Bcl11b suppression-induced apoptosis and restricted expression pattern make it an attractive therapeutic target in T-cell malignancies.	Ernst Moritz Arndt Univ Greifswald, Clin Internal Med C, D-17475 Greifswald, Germany; Polish Acad Sci, Inst Human Genet, PL-00901 Poznan, Poland; Ernst Moritz Arndt Univ Greifswald, Lab Funct Genom, D-17475 Greifswald, Germany; Ernst Moritz Arndt Univ Greifswald, Inst Immunol & Transfus Med, D-17475 Greifswald, Germany; Ernst Moritz Arndt Univ Greifswald, Dept Med Biochem & Mol Biol, D-17475 Greifswald, Germany	Ernst Moritz Arndt Universitat Greifswald; Polish Academy of Sciences; Institute of Human Genetics of the Polish Academy of Sciences; Ernst Moritz Arndt Universitat Greifswald; Ernst Moritz Arndt Universitat Greifswald; Ernst Moritz Arndt Universitat Greifswald	Schmidt, CA (corresponding author), Ernst Moritz Arndt Univ Greifswald, Clin Internal Med C, Sauerbruch Str, D-17475 Greifswald, Germany.	christian.schmidt@uni-greifswald.de	Bröker, Barbara M/O-4850-2015	Bröker, Barbara M/0000-0002-5020-8542; Volker, Uwe/0000-0002-5689-3448; Przybylski, Grzegorz/0000-0001-5783-1567				Avram D, 2000, J BIOL CHEM, V275, P10315, DOI 10.1074/jbc.275.14.10315; Avram D, 2002, BIOCHEM J, V368, P555, DOI 10.1042/BJ20020496; Bezrookove V, 2004, CANCER GENET CYTOGEN, V149, P72, DOI 10.1016/S0165-4608(03)00302-9; Bradham CA, 1998, MOL CELL BIOL, V18, P6353, DOI 10.1128/MCB.18.11.6353; Broome HE, 2002, LEUKEMIA RES, V26, P311, DOI 10.1016/S0145-2126(01)00118-7; Cismasiu VB, 2006, BLOOD, V108, P2695, DOI 10.1182/blood-2006-05-021790; Cismasiu VB, 2005, ONCOGENE, V24, P6753, DOI 10.1038/sj.onc.1208904; Ehrlich S, 2003, CYTOKINE, V24, P244, DOI 10.1016/S1043-4666(03)00094-2; Gesk S, 2003, LEUKEMIA, V17, P738, DOI 10.1038/sj.leu.2402884; GOOTENBERG JE, 1981, J EXP MED, V154, P1403, DOI 10.1084/jem.154.5.1403; GRILLOT DAM, 1995, J EXP MED, V182, P1973, DOI 10.1084/jem.182.6.1973; Inoue J, 2006, J IMMUNOL, V176, P5871, DOI 10.4049/jimmunol.176.10.5871; Insinga A, 2005, CELL CYCLE, V4, P741, DOI 10.4161/cc.4.6.1717; Jeremias I, 1998, EUR J IMMUNOL, V28, P143, DOI 10.1002/(SICI)1521-4141(199801)28:01<143::AID-IMMU143>3.0.CO;2-3; Kim KI, 2003, BRIT J CANCER, V88, P910, DOI 10.1038/sj.bjc.6600795; Klose R, 2005, TRANSPLANTATION, V80, P222, DOI 10.1097/01.TP.0000164817.59006.C2; Leid M, 2004, GENE EXPR PATTERNS, V4, P733, DOI 10.1016/j.modgep.2004.03.009; MacLeod RAF, 2003, GENE CHROMOSOME CANC, V37, P84, DOI 10.1002/gcc.10194; Medema JP, 1998, J BIOL CHEM, V273, P3388, DOI 10.1074/jbc.273.6.3388; Mori N, 2001, VIRUS GENES, V22, P279, DOI 10.1023/A:1011158021749; MOTOYAMA N, 1995, SCIENCE, V267, P1506, DOI 10.1126/science.7878471; Nagel S, 2003, CANCER RES, V63, P5329; Nebbioso A, 2005, NAT MED, V11, P77, DOI 10.1038/nm1161; Oshiro A, 2006, BLOOD, V107, P4500, DOI 10.1182/blood-2005-09-3801; Przybylski GK, 2005, LEUKEMIA, V19, P201, DOI 10.1038/sj.leu.2403619; Sakata J, 2004, CARCINOGENESIS, V25, P1069, DOI 10.1093/carcin/bgh094; SCHNEIDER U, 1977, INT J CANCER, V19, P621, DOI 10.1002/ijc.2910190505; Senawong T, 2005, ARCH BIOCHEM BIOPHYS, V434, P316, DOI 10.1016/j.abb.2004.10.028; Senawong T, 2003, J BIOL CHEM, V278, P43041, DOI 10.1074/jbc.M307477200; Simon AK, 2001, P NATL ACAD SCI USA, V98, P5158, DOI 10.1073/pnas.091100398; Sun XM, 2002, J BIOL CHEM, V277, P11345, DOI 10.1074/jbc.M109893200; Topark-Ngarm A, 2006, J BIOL CHEM, V281, P32272, DOI 10.1074/jbc.M602776200; Wakabayashi Y, 2003, NAT IMMUNOL, V4, P533, DOI 10.1038/ni927; Wakabayashi Y, 2003, BIOCHEM BIOPH RES CO, V301, P598, DOI 10.1016/S0006-291X(02)03069-3; Zhang LD, 2005, CANCER GENE THER, V12, P228, DOI 10.1038/sj.cgt.7700792; Zhang N, 2005, J IMMUNOL, V174, P6967, DOI 10.4049/jimmunol.174.11.6967	36	56	61	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 31	2007	26	26					3797	3810		10.1038/sj.onc.1210152	http://dx.doi.org/10.1038/sj.onc.1210152			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	175PV	17173069				2022-12-28	WOS:000247026400004
J	Keler, T; He, L; Ramakrishna, V; Champion, B				Keler, T.; He, L.; Ramakrishna, V.; Champion, B.			Antibody-targeted vaccines	ONCOGENE			English	Review						monoclonal antibodies; targeted vaccines; antigen cross-presentation; dendritic cells	HUMAN DENDRITIC CELLS; C-TYPE LECTIN; PATTERN-RECOGNITION RECEPTOR; HUMAN CHORIONIC-GONADOTROPIN; MACROPHAGE MANNOSE RECEPTOR; CLASS-II MHC; ANTIGEN-PRESENTING CELLS; IN-VIVO; STEADY-STATE; DC-SIGN	The specificity and high affinity binding of antibodies provides these molecules with ideal properties for delivering a payload to target cells. This concept has been commercialized for cancer therapies using toxin- or radionucleotide-conjugated antibodies that are designed to selectively deliver cytotoxic molecules to cancer cells. Exploiting the same effective characteristics of antibodies, antibody-targeted vaccines (ATV) are designed to deliver disease-specific antigens to professional antigen-presenting cells (APCs), thus enabling the host's immune system to recognize and eliminate malignant or infected cells through adaptive immunity. The concept of ATVs has been in development for many years, and recently has entered clinical trials. Early studies with ATVs focused on the ability to induce humoral immunity in the absence of adjuvants. More recently, ATVs targeted to C-type lectin receptors have been exploited for induction of potent helper and cytolytic T-cell responses. To maximize their stimulatory capacity, the ATVs are being evaluated with a variety of adjuvants or other immunostimulatory agents. In the absence of co-administered immunostimulatory signals, APC-targeting can induce antigen-specific tolerance and, thus, may also be exploited in developing specific treatments for autoimmune and allergic diseases, or for preventing transplant rejection. The successful clinical application of this new class of antibody-based products will clearly depend on using appropriate combinations with other strategies that influence the immune system.	Celldex Therapeut Inc, Phillipsburg, NJ 08865 USA; Celldex Therapeut Ltd, Cambridge, England		Keler, T (corresponding author), Celldex Therapeut Inc, 222 Cameron Dr,Suite 400, Phillipsburg, NJ 08865 USA.	tkeler@celldextherapeutics.com						Allavena P, 2004, CRIT REV IMMUNOL, V24, P179, DOI 10.1615/CritRevImmunol.v24.i3.20; Apostolopoulos V, 2000, EUR J IMMUNOL, V30, P1714, DOI 10.1002/1521-4141(200006)30:6<1714::AID-IMMU1714>3.0.CO;2-C; Ariizumi K, 2000, J BIOL CHEM, V275, P20157, DOI 10.1074/jbc.M909512199; Bashirova AA, 2001, J EXP MED, V193, P671, DOI 10.1084/jem.193.6.671; Berry JD, 2003, HYBRIDOMA HYBRIDOM, V22, P23, DOI 10.1089/153685903321538053; BEVAN MJ, 1976, J EXP MED, V143, P1283, DOI 10.1084/jem.143.5.1283; Bonifaz L, 2002, J EXP MED, V196, P1627, DOI 10.1084/jem.20021598; Bonifaz LC, 2004, J EXP MED, V199, P815, DOI 10.1084/jem.20032220; Boskovic J, 2006, J BIOL CHEM, V281, P8780, DOI 10.1074/jbc.M513277200; Brown GD, 2003, J EXP MED, V197, P1119, DOI 10.1084/jem.20021890; Brown GD, 2006, NAT REV IMMUNOL, V6, P33, DOI 10.1038/nri1745; Bruder D, 2005, DIABETES, V54, P3395, DOI 10.2337/diabetes.54.12.3395; Burgdorf S, 2006, J IMMUNOL, V176, P6770, DOI 10.4049/jimmunol.176.11.6770; Butler SA, 2003, CLIN CANCER RES, V9, P4666; CARAYANNIOTIS G, 1990, VACCINE, V8, P137, DOI 10.1016/0264-410X(90)90136-A; CARAYANNIOTIS G, 1987, NATURE, V327, P59, DOI 10.1038/327059a0; CARAYANNIOTIS G, 1991, MOL IMMUNOL, V28, P261, DOI 10.1016/0161-5890(91)90072-R; CARAYANNIOTIS G, 1988, MOL IMMUNOL, V25, P907, DOI 10.1016/0161-5890(88)90128-9; Carter RW, 2006, J IMMUNOL, V177, P2276, DOI 10.4049/jimmunol.177.4.2276; Carter RW, 2006, CELL IMMUNOL, V239, P87, DOI 10.1016/j.cellimm.2006.05.001; Charalambous A, 2006, J IMMUNOL, V177, P8410, DOI 10.4049/jimmunol.177.12.8410; Chen M, 2006, NAT CLIN PRACT NEURO, V2, P2, DOI 10.1038/ncpneuro0087; CHESNUT RW, 1981, J IMMUNOL, V126, P1075; Chieppa M, 2003, J IMMUNOL, V171, P4552, DOI 10.4049/jimmunol.171.9.4552; Dakappagari N, 2006, J IMMUNOL, V176, P426, DOI 10.4049/jimmunol.176.1.426; Deslee G, 2002, J ALLERGY CLIN IMMUN, V110, P763, DOI 10.1067/mai.2002.129121; EZEKOWITZ RAB, 1991, NATURE, V351, P155, DOI 10.1038/351155a0; Finkelman FD, 1996, J IMMUNOL, V157, P1406; Gantner BN, 2003, J EXP MED, V197, P1107, DOI 10.1084/jem.20021787; Geijtenbeek TBH, 2000, CELL, V100, P575, DOI 10.1016/S0092-8674(00)80693-5; Gordon S, 2002, CELL, V111, P927, DOI 10.1016/S0092-8674(02)01201-1; Guo M, 2000, HUM IMMUNOL, V61, P729, DOI 10.1016/S0198-8859(00)00144-0; Hawiger D, 2001, J EXP MED, V194, P769, DOI 10.1084/jem.194.6.769; He Lizhen, 2006, Proceedings of the American Association for Cancer Research Annual Meeting, V47, P334; He LZ, 2004, CLIN CANCER RES, V10, P1920, DOI 10.1158/1078-0432.CCR-03-0264; Heath WR, 2001, ANNU REV IMMUNOL, V19, P47, DOI 10.1146/annurev.immunol.19.1.47; JIANG WP, 1995, NATURE, V375, P151, DOI 10.1038/375151a0; Kato M, 2006, INT IMMUNOL, V18, P857, DOI 10.1093/intimm/dxl022; Keler T, 2005, CURR OPIN MOL THER, V7, P157; Keler T, 2004, EXPERT OPIN BIOL TH, V4, P1953, DOI 10.1517/14712598.4.12.1953; Larche M, 2005, NAT MED, V11, pS69, DOI 10.1038/nm1226; Larche M, 2006, NAT REV IMMUNOL, V6, P761, DOI 10.1038/nri1934; Le Cabec V, 2005, J LEUKOCYTE BIOL, V77, P934, DOI 10.1189/jlb.1204705; Mahnke K, 2005, CANCER RES, V65, P7007, DOI 10.1158/0008-5472.CAN-05-0938; Mahnke K, 2000, J CELL BIOL, V151, P673, DOI 10.1083/jcb.151.3.673; Maksimow M, 2006, BLOOD, V108, P1298, DOI 10.1182/blood-2005-11-008615; Mansour MK, 2006, J IMMUNOL, V176, P3053, DOI 10.4049/jimmunol.176.5.3053; McGreal EP, 2006, GLYCOBIOLOGY, V16, P422, DOI 10.1093/glycob/cwj077; McGreal EP, 2005, CURR OPIN IMMUNOL, V17, P18, DOI 10.1016/j.coi.2004.12.001; McKenzie EJ, 2002, TRENDS GLYCOSCI GLYC, V14, P273, DOI 10.4052/tigg.14.273; Melief CJM, 2003, EUR J IMMUNOL, V33, P2645, DOI 10.1002/eji.200324341; Mellman I, 2001, CELL, V106, P255, DOI 10.1016/S0092-8674(01)00449-4; Mommaas AM, 1999, EUR J IMMUNOL, V29, P571, DOI 10.1002/(SICI)1521-4141(199902)29:02<571::AID-IMMU571>3.0.CO;2-E; Pohlmann S, 2001, TRENDS IMMUNOL, V22, P643, DOI 10.1016/S1471-4906(01)02081-6; Pyz E, 2006, ANN MED, V38, P242, DOI 10.1080/07853890600608985; Ramakrishna V, 2004, J IMMUNOL, V172, P2845, DOI 10.4049/jimmunol.172.5.2845; Rock KL, 1996, IMMUNOL TODAY, V17, P131, DOI 10.1016/0167-5699(96)80605-0; Rogers NC, 2005, IMMUNITY, V22, P507, DOI 10.1016/j.immuni.2005.03.004; SALLUSTO F, 1995, J EXP MED, V182, P389, DOI 10.1084/jem.182.2.389; Sato K, 2006, J BIOL CHEM, V281, P38854, DOI 10.1074/jbc.M606542200; Schjetne KW, 2005, EUR J IMMUNOL, V35, P3142, DOI 10.1002/eji.200425947; Schjetne KW, 2002, INT IMMUNOL, V14, P1423, DOI 10.1093/intimm/dxf110; SNIDER DP, 1987, J IMMUNOL, V139, P1609; SNIDER DP, 1990, J EXP MED, V171, P1957, DOI 10.1084/jem.171.6.1957; SNIDER DP, 1989, J IMMUNOL, V143, P59; STAHL PD, 1992, CURR OPIN IMMUNOL, V4, P49, DOI 10.1016/0952-7915(92)90123-V; Steinman RM, 2003, ANN NY ACAD SCI, V987, P15, DOI 10.1111/j.1749-6632.2003.tb06029.x; Tacken PJ, 2006, IMMUNOBIOLOGY, V211, P599, DOI 10.1016/j.imbio.2006.05.021; Tacken PJ, 2005, BLOOD, V106, P1278, DOI 10.1182/blood-2005-01-0318; Tan MCAA, 1998, INT IMMUNOL, V10, P1299, DOI 10.1093/intimm/10.9.1299; Tan MCAA, 1997, EUR J IMMUNOL, V27, P2426, DOI 10.1002/eji.1830270942; TONY HP, 1985, J EXP MED, V161, P223, DOI 10.1084/jem.161.1.223; Triozzi PL, 1999, ONCOL REP, V6, P7; Trumpfheller C, 2006, J EXP MED, V203, P607, DOI 10.1084/jem.20052005; Turville S, 2003, J LEUKOCYTE BIOL, V74, P710, DOI 10.1189/jlb.0503208; Uccini S, 1997, AM J PATHOL, V150, P929; van Kooyk Y, 2004, CURR OPIN IMMUNOL, V16, P488, DOI 10.1016/j.coi.2004.05.010; van Vliet SJ, 2006, NAT IMMUNOL, V7, P1200, DOI 10.1038/ni1390; van Vuuren AJ, 2006, J IMMUNOL, V176, P5833, DOI 10.4049/jimmunol.176.10.5833; Wang H, 2000, P NATL ACAD SCI USA, V97, P847, DOI 10.1073/pnas.97.2.847; Wenink MH, 2006, NETH J MED, V64, P103; Wollenberg A, 2002, J INVEST DERMATOL, V118, P327, DOI 10.1046/j.0022-202x.2001.01665.x; Zhang JM, 2005, J LEUKOCYTE BIOL, V78, P665, DOI 10.1189/jlb.1204699	83	26	32	2	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2007	26	25					3758	3767		10.1038/sj.onc.1210375	http://dx.doi.org/10.1038/sj.onc.1210375			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	172PK	17530028	Bronze			2022-12-28	WOS:000246816100017
J	Leonard, JP; Goldenberg, DM				Leonard, J. P.; Goldenberg, D. M.			Preclinical and clinical evaluation of epratuzumab (anti-CD22 IgG) in B-cell malignancies	ONCOGENE			English	Review						non-Hodgkin's lymphoma; B-cell; CD20; CD22; efficacy; epratuzumab	NON-HODGKINS-LYMPHOMA; LL2 MONOCLONAL-ANTIBODY; Y-90 IBRITUMOMAB TIUXETAN; IODINE I-131 TOSITUMOMAB; MULTICENTER PHASE-II; LOW-GRADE; FOLLICULAR LYMPHOMA; IMMUNOGLOBULIN SUPERFAMILY; RADIOLABELED ANTIBODIES; HISTORICAL-PERSPECTIVE	The vast majority of non-Hodgkin's lymphomas are of B-cell phenotype. Development of unlabeled or radiolabeled therapeutic monoclonal antibodies against the cell surface antigen, CD20, has revolutionized the treatment of these malignancies. It is clear that antibodies targeting other B-cell-specific molecules, such as CD22, also offer potential therapeutic benefit. Epratuzumab is a humanized anti-CD22 monoclonal, which has undergone preclinical and phase I/II clinical evaluation in patients with indolent or aggressive lymphoma. Data suggest that this agent is well tolerated, and can induce tumor regressions. Trials are currently evaluating its safety and activity in combination with rituximab (chimeric anti-CD20) and standard chemotherapy are ongoing. Initial results suggest that these regimens have acceptable toxicity, and that epratuzumab warrants further evaluation as an adjunct to standard lymphoma treatment regimens.	Cornell Univ, Weill Med Coll, Ctr Lymphoma & Myeloma, Dept Med, New York, NY 10021 USA; New York Presbyterian Hosp, New York, NY 10021 USA; Garden State Canc Ctr, Ctr Mol Med & Immunol, Belleville, NJ USA; Immunomedics Inc, Morris Plains, NJ USA	Cornell University; NewYork-Presbyterian Hospital; Immunomedics Inc	Leonard, JP (corresponding author), Cornell Univ, Weill Med Coll, Ctr Lymphoma & Myeloma, Dept Med, Starr Bldg,Room 340,520 E 70th St, New York, NY 10021 USA.	jpleonar@med.cornell.edu	Leonard, John/M-4379-2014	Leonard, John/0000-0002-5083-1115				Ansell SM, 2002, J CLIN ONCOL, V20, P3885, DOI 10.1200/JCO.2002.10.143; ARMITAGE JO, 1993, NEW ENGL J MED, V328, P1023; BAUM RP, 1994, CANCER, V73, P896, DOI 10.1002/1097-0142(19940201)73:3+<896::AID-CNCR2820731322>3.0.CO;2-H; BECKER WS, 1995, CANCER RES, V55, pS5771; Behr TM, 1999, CLIN CANCER RES, V5, p3304S; BEHR TM, 2002, TUMOR TARGET, V3, P32; BLEND MJ, 1995, CANCER RES, V55, pS5764; BUCHSBAUM DJ, 1992, CANCER RES, V52, P6476; Carnahan J, 2003, CLIN CANCER RES, V9, p3982S; Carnahan J, 2007, MOL IMMUNOL, V44, P1331, DOI 10.1016/j.molimm.2006.05.007; Cesano A, 2002, BLOOD, V100, p350A; CHAOUCHI N, 1995, J IMMUNOL, V154, P3096; CHATAL JF, 2005, P SOC NUCL MED, pP155; Cheson BD, 2005, BIODRUGS, V19, P309, DOI 10.2165/00063030-200519050-00004; Cheson BD, 2003, BLOOD, V101, P391, DOI 10.1182/blood-2002-06-1793; Chow KU, 2002, HAEMATOLOGICA, V87, P33; Coffey J, 2003, EUR J NUCL MED MOL I, V30, pS28, DOI 10.1007/s00259-003-1157-6; Coiffier B, 2005, J CLIN ONCOL, V23, P6387, DOI 10.1200/JCO.2005.05.015; Coiffier B, 2002, NEW ENGL J MED, V346, P235, DOI 10.1056/NEJMoa011795; Coiffier B, 1998, BLOOD, V92, P1927; Czuczman MS, 2004, J CLIN ONCOL, V22, P4711, DOI 10.1200/JCO.2004.04.020; Davis TA, 2004, CLIN CANCER RES, V10, P7792, DOI 10.1158/1078-0432.CCR-04-0756; Davis TA, 2000, J CLIN ONCOL, V18, P3135, DOI 10.1200/JCO.2000.18.17.3135; Dorner T, 2006, ARTHRITIS RES THER, V8, DOI 10.1186/ar1942; DORKEN B, 1986, J IMMUNOL, V136, P4470; Dosik AD, 2006, CANCER-AM CANCER SOC, V106, P616, DOI 10.1002/cncr.21606; EMMANOUILIDES C, 2004, P AN M AM SOC CLIN, V23, P6580; ENGEL P, 1993, J IMMUNOL, V150, P4719; ENGEL P, 1995, J EXP MED, V181, P1581, DOI 10.1084/jem.181.4.1581; Fisher Richard I, 2004, Hematology Am Soc Hematol Educ Program, P221; Friedberg Jonathan W, 2004, Expert Rev Anticancer Ther, V4, P18, DOI 10.1586/14737140.4.1.18; FURMAN RR, 2006, CANC TREAT RES, V131, P141; GALLAGHER CJ, 1986, J CLIN ONCOL, V4, P1470, DOI 10.1200/JCO.1986.4.10.1470; GASPARINI M, 1995, TUMORI, V81, P173, DOI 10.1177/030089169508100304; Ghielmini M, 2004, BLOOD, V103, P4416, DOI 10.1182/blood-2003-10-3411; Golay J, 2000, BLOOD, V95, P3900; Goldenberg DM, 2003, CANCER IMMUNOL IMMUN, V52, P281, DOI 10.1007/s00262-002-0348-5; GOLDENBERG DM, 1991, J CLIN ONCOL, V9, P548, DOI 10.1200/JCO.1991.9.4.548; Goldenberg DM, 2001, CRIT REV ONCOL HEMAT, V39, P195; Gordon LI, 2004, CLIN LYMPHOMA, V5, P98, DOI 10.3816/CLM.2004.n.015; GREINER TC, 1995, CANCER-AM CANCER SOC, V75, P370, DOI 10.1002/1097-0142(19950101)75:1+<370::AID-CNCR2820751319>3.0.CO;2-Q; Griffiths GL, 2003, J NUCL MED, V44, P77; Grillo-Lopez AJ, 2000, SEMIN ONCOL, V27, P9, DOI 10.1053/sonc.2000.20444; Hainsworth JD, 2004, SEMIN ONCOL, V31, P17, DOI 10.1053/j.seminoncol.2003.12.005; Harjunpaa A, 2000, SCAND J IMMUNOL, V51, P634; Hiddemann W, 2005, J CLIN ONCOL, V23, P6394, DOI 10.1200/JCO.2005.07.019; Jazirehi AR, 2005, CANCER RES, V65, P264; Jemal A, 2006, CA-CANCER J CLIN, V56, P106, DOI 10.3322/canjclin.56.2.106; Johnson P, 2003, SEMIN ONCOL, V30, P3, DOI 10.1053/sonc.2003.50025; JUWEID M, 1995, CANCER RES, V55, pS5899; Juweid ME, 1999, CLIN CANCER RES, V5, p3292S; Kaminski MS, 2005, NEW ENGL J MED, V352, P441, DOI 10.1056/NEJMoa041511; KAMINSKI MS, 1992, J CLIN ONCOL, V10, P1696, DOI 10.1200/JCO.1992.10.11.1696; KELM S, 1994, CURR BIOL, V4, P965, DOI 10.1016/S0960-9822(00)00220-7; KREITMAN RJ, 1993, CANCER RES, V53, P819; Lamonica D, 2002, CANCER BIOTHER RADIO, V17, P689, DOI 10.1089/108497802320970307; LAW CL, 1993, J IMMUNOL, V151, P175; Leonard John P, 2005, Hematology Am Soc Hematol Educ Program, P335; Leonard JP, 2005, J CLIN ONCOL, V23, P5044, DOI 10.1200/JCO.2005.13.821; Leonard JP, 2003, J CLIN ONCOL, V21, P3051, DOI 10.1200/JCO.2003.01.082; Leonard JP, 2004, CLIN CANCER RES, V10, P5327, DOI 10.1158/1078-0432.CCR-04-0294; Leung SO, 1995, MOL IMMUNOL, V32, P1413, DOI 10.1016/0161-5890(95)00080-1; Linden O, 2002, ACTA ONCOL, V41, P297, DOI 10.1080/02841860260088854; Linden O, 1999, CLIN CANCER RES, V5, p3287S; Linden O, 2005, CLIN CANCER RES, V11, P5215, DOI 10.1158/1078-0432.CCR-05-0172; Maloney DG, 2002, SEMIN ONCOL, V29, P2, DOI 10.1053/sonc.2002.30156; McLaughlin P, 1998, J CLIN ONCOL, V16, P2825, DOI 10.1200/JCO.1998.16.8.2825; Micallef INM, 2006, CANCER-AM CANCER SOC, V107, P2826, DOI 10.1002/cncr.22342; Morschhauser F, 2005, BLOOD, V106, p683A; Morschhauser F, 2004, BLOOD, V104, p41A; MURTHY S, 1992, EUR J NUCL MED, V19, P394; Newton DL, 2001, CRIT REV ONCOL HEMAT, V39, P79, DOI 10.1016/S1040-8428(01)00116-0; Newton DL, 2001, BLOOD, V97, P528, DOI 10.1182/blood.V97.2.528; Nitschke L, 2005, CURR OPIN IMMUNOL, V17, P290, DOI 10.1016/j.coi.2005.03.005; Nitschke L, 1997, CURR BIOL, V7, P133, DOI 10.1016/S0960-9822(06)00057-1; OKeefe TL, 1996, SCIENCE, V274, P798, DOI 10.1126/science.274.5288.798; Otipoby KL, 1996, NATURE, V384, P634, DOI 10.1038/384634a0; PAWLAKBYCZKOWSKA EJ, 1989, CANCER RES, V49, P4568; Postema EJ, 2003, CLIN CANCER RES, V9, p3995S; Press OW, 2003, SEMIN ONCOL, V30, P10, DOI 10.1053/sonc.2003.23798; PRESS OW, 1989, J CLIN ONCOL, V7, P1027, DOI 10.1200/JCO.1989.7.8.1027; Sato S, 1996, IMMUNITY, V5, P551, DOI 10.1016/S1074-7613(00)80270-8; Sharkey RM, 2005, J NUCL MED, V46, p115S; Sharkey RM, 2003, J NUCL MED, V44, P2000; Sharkey Robert M, 2005, Expert Rev Clin Immunol, V1, P47, DOI 10.1586/1744666X.1.1.47; SHIH LB, 1994, INT J CANCER, V56, P538, DOI 10.1002/ijc.2910560413; SIEGEL JA, 1991, ANTIBODY IMMUNOCONJ, V4, P649; Silverman DH, 2004, CANCER TREAT REV, V30, P165, DOI 10.1016/j.ctrv.2003.07.006; Skarin AT, 1997, CA-CANCER J CLIN, V47, P351, DOI 10.3322/canjclin.47.6.351; Skvortsova I, 2005, J RADIAT RES, V46, P241, DOI 10.1269/jrr.46.241; STAMENKOVIC I, 1990, NATURE, V345, P74, DOI 10.1038/345074a0; Stein R, 2004, CLIN CANCER RES, V10, P2868, DOI 10.1158/1078-0432.CCR-03-0493; STEIN R, 1993, CANCER IMMUNOL IMMUN, V37, P293, DOI 10.1007/BF01518451; STEIN R, 1994, DRUGS FUTURE, V18, P997; Steinfeld SD, 2006, ARTHRITIS RES THER, V8, DOI 10.1186/ar2018; Steinfeld SD, 2006, EXPERT OPIN BIOL TH, V6, P943, DOI 10.1517/14712598.6.9.943; Strauss SJ, 2006, J CLIN ONCOL, V24, P3880, DOI 10.1200/JCO.2006.05.6291; Tedder TF, 2005, ADV IMMUNOL, V88, P1, DOI 10.1016/S0065-2776(05)88001-0; Teeling JL, 2004, BLOOD, V104, P1793, DOI 10.1182/blood-2004-01-0039; Theuer Charles P, 2004, Biotechnol Annu Rev, V10, P265; Tuscano JM, 1999, BLOOD, V94, P1382, DOI 10.1182/blood.V94.4.1382.416k14_1382_1392; Vose JM, 2004, ONCOLOGIST, V9, P160, DOI 10.1634/theoncologist.9-2-160; Vose JM, 2000, LEUKEMIA LYMPHOMA, V38, P91, DOI 10.3109/10428190009060322; Wagner HN, 2002, J NUCL MED, V43, P267; WILSON GL, 1991, J EXP MED, V173, P137, DOI 10.1084/jem.173.1.137; WILSON GL, 1993, J IMMUNOL, V150, P5013; Winter Jane N, 2004, Hematology Am Soc Hematol Educ Program, P203; Witzig TE, 2004, DRUGS TODAY, V40, P111, DOI 10.1358/dot.2004.40.2.799423; Witzig TE, 2002, J CLIN ONCOL, V20, P2453, DOI 10.1200/JCO.2002.11.076; Zelenetz AD, 2002, BLOOD, V100, p357A; Zinzani PL, 2005, SEMIN ONCOL, V32, pS4, DOI 10.1053/j.seminoncol.2005.01.008	111	72	103	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2007	26	25					3704	3713		10.1038/sj.onc.1210370	http://dx.doi.org/10.1038/sj.onc.1210370			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	172PK	17530024				2022-12-28	WOS:000246816100013
J	Portal, MM; Ferrero, GO; Caputto, BL				Portal, M. M.; Ferrero, G. O.; Caputto, B. L.			N-terminal c-Fos tyrosine phosphorylation regulates c-Fos/ER association and c-Fos-dependent phospholipid synthesis activation	ONCOGENE			English	Article						cytoplasmic c-Fos; phospholipid synthesis regulation; c-Fos/endoplasmic reticulum association; c-Fos-regulated lipid metabolism; c-Fos tyr phosphorylation; tyr-phosphorylation	TRANSCRIPTIONAL ACTIVATION; GENE-EXPRESSION; JUN; PROTEINS; BINDING; KINASE; CELLS; LIGHT; AP-1; DEGRADATION	c-Fos dephosphorylated on tyrosine (c-Fos), a component of the activator protein-1 (AP-1) family of transcription factors, is expressed at very low levels in resting cells. However, its expression is rapidly upregulated in cells undergoing G(0) to S phase transition leading to AP-1-dependent gene transcription responses. In addition, cytoplasmic c-Fos associates to the endoplasmic reticulum (ER) membranes and activates phospholipid synthesis during cell growth and differentiation. Herein, it is shown that in T98G cells, c-Fos/ER association and consequently phospholipid synthesis activation is regulated by the phosphorylated state of c-Fos tyrosine (tyr) residues. The small amount of c-Fos present in quiescent T98G cells is tyr-phosphorylated and not ER-membrane bound. In growing cells, it is dephosphorylated, associated to ER membranes and promotes phospholipid synthesis activation. Impairing tyr-dephosphorylation abrogates phospholipid synthesis activation and reduces proliferation rates to those of quiescent cells. Substitution of tyr residues 10, 30, 106 and 337 evidence tyr 10 and 30 as relevant for this regulatory phenomenon. It is concluded that phosphorylation of tyr residues 10 and 30 of c-Fos regulate the rate of synthesis of phospholipids by regulating c-Fos/ER association.	Univ Nacl Cordoba, Fac Ciencias Quim, Dept Quim Biol, CIQUIBIC,CONICET, RA-5000 Cordoba, Argentina	National University of Cordoba	Caputto, BL (corresponding author), Univ Nacl Cordoba, Fac Ciencias Quim, Dept Quim Biol, CIQUIBIC,CONICET, Pabellon Argentina,Ciudad Univ, RA-5000 Cordoba, Argentina.	bcaputto@dqb.fcq.unc.edu.ar		PORTAL, Maximiliano/0000-0002-2884-6900				ABATE C, 1993, P NATL ACAD SCI USA, V90, P6766, DOI 10.1073/pnas.90.14.6766; Acquaviva C, 2001, ONCOGENE, V20, P942, DOI 10.1038/sj.onc.1204155; ALITALO R, 1990, BLOOD, V75, P1974; ALLEGRETTO EA, 1990, J CELL BIOCHEM, V42, P193, DOI 10.1002/jcb.240420403; Blom N, 1999, J MOL BIOL, V294, P1351, DOI 10.1006/jmbi.1999.3310; Borioli GA, 2005, BBA-BIOMEMBRANES, V1668, P41, DOI 10.1016/j.bbamem.2004.11.007; Borioli GA, 2004, FEBS LETT, V570, P82, DOI 10.1016/j.febslet.2004.06.033; Borioli GA, 2001, BIOCHEM BIOPH RES CO, V280, P9, DOI 10.1006/bbrc.2000.4081; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bussolino DF, 2001, FASEB J, V15, P556; Bussolino DF, 1998, MOL BRAIN RES, V58, P10, DOI 10.1016/S0169-328X(98)00065-5; Coronella-Wood J, 2004, J BIOL CHEM, V279, P33567, DOI 10.1074/jbc.M404013200; CURRAN T, 1987, BIOESSAYS, V7, P255, DOI 10.1002/bies.950070606; Gil GA, 2004, MOL BIOL CELL, V15, P1881, DOI 10.1091/mbc.e03-09-0705; GIUS D, 1990, MOL CELL BIOL, V10, P4243, DOI 10.1128/MCB.10.8.4243; GUIDO ME, 1990, J NEUROCHEM, V55, P1855, DOI 10.1111/j.1471-4159.1990.tb05768.x; Guido ME, 1996, J NEUROSCI RES, V43, P93, DOI 10.1002/jnr.490430112; Herdegen T, 1998, BRAIN RES REV, V28, P370, DOI 10.1016/S0165-0173(98)00018-6; Jacobs D, 1999, GENE DEV, V13, P163, DOI 10.1101/gad.13.2.163; Kaludov NK, 1996, P NATL ACAD SCI USA, V93, P4465, DOI 10.1073/pnas.93.9.4465; KARIN M, 1994, CURR OPIN CELL BIOL, V6, P415, DOI 10.1016/0955-0674(94)90035-3; MEDEMA RH, 1991, J BIOL CHEM, V266, P21186; Monje P, 2003, MOL CELL BIOL, V23, P7030, DOI 10.1128/MCB.23.19.7030-7043.2003; OKAZAKI K, 1995, EMBO J, V14, P5048, DOI 10.1002/j.1460-2075.1995.tb00187.x; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; Stork PJS, 2002, CELL CYCLE, V1, P315, DOI 10.4161/cc.1.5.145; Tanos T, 2005, J BIOL CHEM, V280, P18842, DOI 10.1074/jbc.M500620200; TSURUMI C, 1995, MOL CELL BIOL, V15, P5682; Zerpa GAD, 1999, J NEUROCHEM, V73, P1228, DOI 10.1046/j.1471-4159.1999.0731228.x	29	31	32	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY	2007	26	24					3551	3558		10.1038/sj.onc.1210137	http://dx.doi.org/10.1038/sj.onc.1210137			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	172JC	17160021				2022-12-28	WOS:000246799200011
J	Stinchcombe, TE; Socinski, MA				Stinchcombe, T. E.; Socinski, M. A.			Bevacizumab in the treatment of non-small-cell lung cancer	ONCOGENE			English	Review						monoclonal antibody; targeted therapy; angiogenesis	ENDOTHELIAL GROWTH-FACTOR; VASCULAR-PERMEABILITY FACTOR; MONOCLONAL-ANTIBODY; BIOLOGIC MARKERS; PLUS CARBOPLATIN; CLINICAL-TRIAL; PHASE-II; CHEMOTHERAPY; COMBINATION; ANGIOGENESIS	Lung cancer is the leading cause of cancer death in the United States. The majority of patients present with advanced disease, and treatment with standard cytotoxic chemotherapy improves survival and quality of life in patients with a preserved functional status. However, the prognosis is poor with the majority of patients dying in less than a year. Treatment with standard cytotoxic chemotherapy has reached a therapeutic plateau, and new therapeutic approaches have investigated therapies that target the specific molecular pathways involved in carcinogenesis and angiogenesis. The most promising strategy for inhibiting angiogenesis involves agents that either target the proangiogenesis growth factor, vascular endothelial growth factor A (VEGF) by preventing binding to the receptor or inhibiting the downstream signaling of the vascular endothelial growth factor receptor. The only therapeutic agent approved for the treatment of lung cancer is bevacizumab, a monoclonal antibody that binds to VEGF. A recent phase III trial revealed a statistically significant improvement in response rate, progression free and overall survival with combination of bevacizumab with chemotherapy over chemotherapy alone. Attempts to identify surrogate markers of antiangiogenesis activity are currently ongoing, and may assist in the selection of patients for antiangiogenesis therapy and the development of this class of agents.	Univ N Carolina, Lineberger Comprehens Canc Ctr, Multidisciplinary Thorac Oncol Program, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill	Socinski, MA (corresponding author), Univ N Carolina, Lineberger Comprehens Canc Ctr, Multidisciplinary Thorac Oncol Program, 3009 Old Clin Bldg,CB 7305, Chapel Hill, NC 27599 USA.	Socinski@med.unc.edu						Adjei AA, 2006, J CLIN ONCOL, V24, P4054, DOI 10.1200/JCO.2006.07.4658; Bates DO, 2001, J PHYSIOL-LONDON, V533, P263, DOI 10.1111/j.1469-7793.2001.0263b.x; Brahmer JR, 2006, J CLIN ONCOL, V24, p373S; Brewer GJ, 2000, CLIN CANCER RES, V6, P1; BULZEBRUCK H, 1992, CANCER-AM CANCER SOC, V70, P1102, DOI 10.1002/1097-0142(19920901)70:5<1102::AID-CNCR2820700514>3.0.CO;2-5; CALVERT AH, 1989, J CLIN ONCOL, V7, P1748, DOI 10.1200/JCO.1989.7.11.1748; D'Amico TA, 1999, J THORAC CARDIOV SUR, V117, P736, DOI 10.1016/S0022-5223(99)70294-1; Davis DW, 2003, BRIT J CANCER, V89, P8, DOI 10.1038/sj.bjc.6601035; Delbaldo C, 2004, JAMA-J AM MED ASSOC, V292, P470, DOI 10.1001/jama.292.4.470; Douillard JY, 2005, J CLIN ONCOL, V23, p624S; Dowlati A, 2006, J CLIN ONCOL, V24, p370S; DVORAK HF, 1995, AM J PATHOL, V146, P1029; Dy GK, 2006, CLIN LUNG CANCER, V7, pS145, DOI 10.3816/CLC.2006.s.006; Fehrenbacher L, 2006, J CLIN ONCOL, V24, p379S; Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669; FOLKMAN J, 1990, CANCER METAST REV, V9, P171, DOI 10.1007/BF00046358; Folkman J, 1992, Semin Cancer Biol, V3, P65; FONTANINI G, 1995, J PATHOL, V177, P57, DOI 10.1002/path.1711770110; Gordon MS, 2001, J CLIN ONCOL, V19, P843, DOI 10.1200/JCO.2001.19.3.843; Govindan R, 2006, J CLIN ONCOL, V24, P4539, DOI 10.1200/JCO.2005.04.4859; Herbst RS, 2005, J CLIN ONCOL, V23, P3243, DOI 10.1200/JCO.2005.18.853; Herbst RS, 2005, J CLIN ONCOL, V23, P2544, DOI 10.1200/JCO.2005.02.477; Herbst RS, 2002, J CLIN ONCOL, V20, P3804, DOI 10.1200/JCO.2002.05.102; Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691; Jain RK, 2001, NAT MED, V7, P987, DOI 10.1038/nm0901-987; Jemal A, 2006, CA-CANCER J CLIN, V56, P106, DOI 10.3322/canjclin.56.2.106; Johnson DH, 2004, J CLIN ONCOL, V22, P2184, DOI 10.1200/JCO.2004.11.022; Le Chevalier T, 2004, NEW ENGL J MED, V350, P351, DOI 10.1056/nejmoa031644; Lucchi M, 1997, EUR J CARDIO-THORAC, V12, P535, DOI 10.1016/S1010-7940(97)00218-2; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Margolin K, 2001, J CLIN ONCOL, V19, P851, DOI 10.1200/JCO.2001.19.3.851; Morgan B, 2003, J CLIN ONCOL, V21, P3955, DOI 10.1200/JCO.2003.08.092; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Pao W, 2004, P NATL ACAD SCI USA, V101, P13306, DOI 10.1073/pnas.0405220101; Pfister DG, 2004, J CLIN ONCOL, V22, P330, DOI 10.1200/JCO.2004.09.053; Robinson CJ, 2001, J CELL SCI, V114, P853; SANDLER A, 2006, J CLIN ONCOLOGY 2006, V24; SANDLER A, 2006, 4I ANN M AM SOC CLIN; Sandler A, 2006, NEW ENGL J MED, V355, P2542, DOI 10.1056/NEJMoa061884; Schellinger PD, 1999, J NEURO-ONCOL, V44, P275, DOI 10.1023/A:1006308808769; Schiller JH, 2002, NEW ENGL J MED, V346, P92, DOI 10.1056/NEJMoa011954; SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562; Treat J, 2005, J CLIN ONCOL, V23, p627S; Ushijima C, 2001, LUNG CANCER-J IASLC, V34, P233, DOI 10.1016/S0169-5002(01)00246-X; Wakelee HA, 2006, CANCER-AM CANCER SOC, V106, P2208, DOI 10.1002/cncr.21869; Wakelee HA, 2006, CLIN LUNG CANCER, V8, P18, DOI 10.3816/CLC.2006.n.028; Winton T, 2005, NEW ENGL J MED, V352, P2589, DOI 10.1056/NEJMoa043623; Yanagawa H, 1999, CANCER IMMUNOL IMMUN, V48, P396, DOI 10.1007/s002620050592; Yano S, 2000, AM J PATHOL, V157, P1893, DOI 10.1016/S0002-9440(10)64828-6; Yano T, 2000, EUR J CANCER, V36, P601, DOI 10.1016/S0959-8049(99)00327-5	50	21	26	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2007	26	25					3691	3698		10.1038/sj.onc.1210366	http://dx.doi.org/10.1038/sj.onc.1210366			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	172PK	17530022				2022-12-28	WOS:000246816100011
J	Takeda, K; Stagg, J; Yagita, H; Okumura, K; Smyth, MJ				Takeda, K.; Stagg, J.; Yagita, H.; Okumura, K.; Smyth, M. J.			Targeting death-inducing receptors in cancer therapy	ONCOGENE			English	Review						TNF superfamily; TRAIL; DR5; DR4; apoptosis; anti-tumor immune response	TUMOR-NECROSIS-FACTOR; TRAIL-INDUCED APOPTOSIS; ANTI-DR5 ANTIBODY THERAPY; FLICE-INHIBITORY PROTEIN; ACTIVATING FC-RECEPTORS; I CLINICAL-TRIAL; T-CELL RESPONSES; MONOCLONAL-ANTIBODIES; DENDRITIC CELLS; LIGAND TRAIL	Deregulated cell death pathways may lead to the development of cancer, and induction of tumor cell apoptosis is the basis of many cancer therapies. Knowledge accumulated concerning the molecular mechanisms of apoptotic cell death has aided the development of new therapeutic strategies to treat cancer. Signals through death receptors of the tumor necrosis factor (TNF) superfamily have been well elucidated, and death receptors are now one of the most attractive therapeutic targets in cancer. In particular, DR5 and DR4, death receptors of TNF-related apoptosis-inducing ligand (TRAIL or Apo2L), are interesting targets of antibody-based therapy, since TRAIL may also bind decoy receptors that may prevent TRAIL-mediated apoptosis, whereas TRAIL ligand itself selectively induces apoptosis in cancer cells. Here, we review the potential therapeutic utility of agonistic antibodies against DR5 and DR4 and discuss the possible extension of this single-antibody-based strategy when combined with additional modalities that either synergizes to cause enhanced apoptosis or further engage the cellular immune response. Rational design of antibody-based therapies combining the induction of tumor cell apoptosis and activation of tumor-specific adaptive immunity enables promotion of distinct steps of the antitumor immune response, thereby enhancing tumor-specific lymphocytes that can eradicate TRAIL/DR5-resistant mutating, large established and heterogeneous tumors in a manner that does not require the definition of individual tumor-specific antigens.	Juntendo Univ, Sch Med, Dept Immunol, Tokyo 113, Japan; Peter MacCallum Canc Ctr, Canc Immunol Program, Melbourne, Vic, Australia	Juntendo University; Peter Maccallum Cancer Center	Takeda, K (corresponding author), Juntendo Univ, Sch Med, Dept Immunol, Tokyo 113, Japan.	ktakeda@med.juntendo.ac.jp	Smyth, Mark J/H-8709-2014	Smyth, Mark J/0000-0001-7098-7240				Akiyama K, 2003, J IMMUNOL, V170, P1641, DOI 10.4049/jimmunol.170.4.1641; Albert ML, 1998, NATURE, V392, P86, DOI 10.1038/32183; An JB, 2003, CLIN CANCER RES, V9, P4537; Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Ashkenazi A, 2002, NAT REV CANCER, V2, P420, DOI 10.1038/nrc821; BASOMBRIO MA, 1970, CANCER RES, V30, P2458; Bianco R, 2005, CURR DRUG TARGETS, V6, P275, DOI 10.2174/1389450053765842; Buchsbaum DJ, 2003, CLIN CANCER RES, V9, P3731; Bucur O, 2006, FRONT BIOSCI-LANDMRK, V11, P1549, DOI 10.2741/1903; CARTER P, 1992, P NATL ACAD SCI USA, V89, P4285, DOI 10.1073/pnas.89.10.4285; Chawla-Sarkar M, 2002, J IMMUNOL, V169, P847, DOI 10.4049/jimmunol.169.2.847; Chawla-Sarkar M, 2003, APOPTOSIS, V8, P237, DOI 10.1023/A:1023668705040; Chinnaiyan AM, 2000, P NATL ACAD SCI USA, V97, P1754, DOI 10.1073/pnas.030545097; Chuntharapai A, 2001, J IMMUNOL, V166, P4891, DOI 10.4049/jimmunol.166.8.4891; Clancy L, 2005, P NATL ACAD SCI USA, V102, P18099, DOI 10.1073/pnas.0507329102; Clarke N, 2004, EMBO J, V23, P3051, DOI 10.1038/sj.emboj.7600302; Clynes R, 1998, P NATL ACAD SCI USA, V95, P652, DOI 10.1073/pnas.95.2.652; Clynes RA, 2000, NAT MED, V6, P443, DOI 10.1038/74704; Cragg MS, 1999, CURR OPIN IMMUNOL, V11, P541, DOI 10.1016/S0952-7915(99)00010-2; CREAGAN ET, 1988, CANCER, V62, P2467, DOI 10.1002/1097-0142(19881215)62:12<2467::AID-CNCR2820621202>3.0.CO;2-5; CREAVEN PJ, 1987, CANCER CHEMOTH PHARM, V20, P137; Cretney E, 2002, J IMMUNOL, V168, P1356, DOI 10.4049/jimmunol.168.3.1356; Croft M, 2003, CYTOKINE GROWTH F R, V14, P265, DOI 10.1016/S1359-6101(03)00025-X; Croft M, 2003, NAT REV IMMUNOL, V3, P609, DOI 10.1038/nri1148; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; Daniels RA, 2005, CELL RES, V15, P430, DOI 10.1038/sj.cr.7290311; de Bono JS, 2002, BRIT MED BULL, V64, P227, DOI 10.1093/bmb/64.1.227; Degli-Esposti M, 1999, J LEUKOCYTE BIOL, V65, P535, DOI 10.1002/jlb.65.5.535; Dhodapkar KM, 2002, J EXP MED, V195, P125, DOI 10.1084/jem.20011097; Diehl GE, 2004, IMMUNITY, V21, P877, DOI 10.1016/j.immuni.2004.11.008; Diehl L, 1999, NAT MED, V5, P774, DOI 10.1038/10495; Dunn GP, 2004, IMMUNITY, V21, P137, DOI 10.1016/j.immuni.2004.07.017; Egen JG, 2002, NAT IMMUNOL, V3, P611, DOI 10.1038/ni0702-611; Fulda S, 2002, NAT MED, V8, P808, DOI 10.1038/nm735; Fulda S, 2002, ONCOGENE, V21, P2295, DOI 10.1038/sj.onc.1205255; Futagawa T, 2002, INT IMMUNOL, V14, P275, DOI 10.1093/intimm/14.3.275; Gallop JR, 1995, CERN REPORT, V95, P1; Ganten TM, 2005, HEPATOLOGY, V42, P588, DOI 10.1002/hep.20807; Gelderman KA, 2004, TRENDS IMMUNOL, V25, P158, DOI 10.1016/j.it.2004.01.008; Georgakis GV, 2005, BRIT J HAEMATOL, V130, P501, DOI 10.1111/j.1365-2141.2005.05656.x; Gliniak B, 1999, CANCER RES, V59, P6153; Griffith TS, 1999, J IMMUNOL, V162, P2597; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hao CH, 2004, CANCER RES, V64, P8502, DOI 10.1158/0008-5472.CAN-04-2599; Hayakawa Y, 2004, J IMMUNOL, V172, P123, DOI 10.4049/jimmunol.172.1.123; HERSH EM, 1991, J IMMUNOTHER, V10, P426, DOI 10.1097/00002371-199112000-00006; Higuchi H, 2002, J PHARMACOL EXP THER, V303, P461, DOI 10.1124/jpet.102.040030; Hinoda Y, 2004, CANCER SCI, V95, P621, DOI 10.1111/j.1349-7006.2004.tb03319.x; Ichikawa K, 2001, NAT MED, V7, P954, DOI 10.1038/91000; ITOH N, 1993, J BIOL CHEM, V268, P10932; Janssen HLA, 2003, J HEPATOL, V39, P414, DOI 10.1016/S0168-8278(03)00265-4; Jo M, 2000, NAT MED, V6, P564, DOI 10.1038/75045; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; Kaufmann SH, 2005, LEUKEMIA, V19, P2195, DOI 10.1038/sj.leu.2403946; Kelley SK, 2004, CURR OPIN PHARMACOL, V4, P333, DOI 10.1016/j.coph.2004.02.006; Khong HT, 2002, NAT IMMUNOL, V3, P999, DOI 10.1038/ni1102-999; Kim KH, 2000, CLIN CANCER RES, V6, P335; Kircheis R, 2002, GENE THER, V9, P731, DOI 10.1038/sj.gt.3301748; Kurbanov BM, 2005, J INVEST DERMATOL, V125, P1010, DOI 10.1111/j.0022-202X.2005.23900.x; Lawrence D, 2001, NAT MED, V7, P383, DOI 10.1038/86397; LeBlanc H, 2002, NAT MED, V8, P274, DOI 10.1038/nm0302-274; LeBlanc HN, 2003, CELL DEATH DIFFER, V10, P66, DOI 10.1038/sj.cdd.4401187; Lee SJ, 2004, J IMMUNOL, V173, P3002, DOI 10.4049/jimmunol.173.5.3002; Leverkus M, 2000, BLOOD, V96, P2628; Li L, 2004, SCIENCE, V305, P1471, DOI 10.1126/science.1098231; Marini P, 2006, ONCOGENE, V25, P5145, DOI 10.1038/sj.onc.1209516; Melero I, 1997, NAT MED, V3, P682, DOI 10.1038/nm0697-682; Melero I, 1998, CELL IMMUNOL, V190, P167, DOI 10.1006/cimm.1998.1396; Merchant MS, 2004, CANCER RES, V64, P8349, DOI 10.1158/0008-5472.CAN-04-1705; Mitsiades CS, 2001, BLOOD, V98, P795, DOI 10.1182/blood.V98.3.795; Mori E, 2004, CELL DEATH DIFFER, V11, P203, DOI 10.1038/sj.cdd.4401331; Motoki K, 2005, CLIN CANCER RES, V11, P3126, DOI 10.1158/1078-0432.CCR-04-1867; Mundt B, 2005, GUT, V54, P1590, DOI 10.1136/gut.2004.056929; Mundt B, 2002, FASEB J, V16, P94, DOI 10.1096/fj.02-0537fje; Nicholson DW, 2000, NATURE, V407, P810, DOI 10.1038/35037747; O'Kane HF, 2006, J UROLOGY, V175, P432, DOI 10.1016/S0022-5347(05)00160-6; OGASAWARA J, 1993, NATURE, V364, P806, DOI 10.1038/364806a0; Ohtsuka T, 2003, ONCOGENE, V22, P2034, DOI 10.1038/sj.onc.1206290; Papageorgiou A, 2004, CANCER RES, V64, P8973, DOI 10.1158/0008-5472.CAN-04-1909; Pardoll D, 2004, NAT MED, V10, P887, DOI 10.1038/nm0904-887; Pegram MD, 1998, J CLIN ONCOL, V16, P2659, DOI 10.1200/JCO.1998.16.8.2659; Pitt RM, 1996, J BIOL CHEM, V271, P12687, DOI 10.1074/jbc.271.22.12687; Pollard JW, 2004, NAT REV CANCER, V4, P71, DOI 10.1038/nrc1256; POLLOK KE, 1993, J IMMUNOL, V150, P771; Pukac L, 2005, BRIT J CANCER, V92, P1430, DOI 10.1038/sj.bjc.6602487; Pulendran B, 2001, TRENDS IMMUNOL, V22, P41, DOI 10.1016/S1471-4906(00)01794-4; Qin JZ, 2001, NAT MED, V7, P385, DOI 10.1038/86401; Rafiq K, 2002, J CLIN INVEST, V110, P71, DOI 10.1172/JCI200215640; Reed JC, 2002, SEMIN ONCOL, V29, P10, DOI 10.1053/sonc.2002.30155; Rowinsky EK, 2005, J CLIN ONCOL, V23, P9394, DOI 10.1200/JCO.2005.02.2889; SALOMON DS, 1995, CRIT REV ONCOL HEMAT, V19, P183, DOI 10.1016/1040-8428(94)00144-I; Sayers TJ, 2006, CANCER IMMUNOL IMMUN, V55, P76, DOI 10.1007/s00262-005-0676-3; Schmitz I, 2000, INT J BIOCHEM CELL B, V32, P1123, DOI 10.1016/S1357-2725(00)00048-0; Schneider P, 2003, J BIOL CHEM, V278, P5444, DOI 10.1074/jbc.M210783200; Selenko N, 2001, LEUKEMIA, V15, P1619, DOI 10.1038/sj.leu.2402226; Shankar S, 2004, DRUG RESIST UPDATE, V7, P139, DOI 10.1016/j.drup.2004.03.002; Sheikh MS, 1998, CANCER RES, V58, P1593; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; Shuford WW, 1997, J EXP MED, V186, P47, DOI 10.1084/jem.186.1.47; Smith MR, 2003, ONCOGENE, V22, P7359, DOI 10.1038/sj.onc.1206939; Smyth MJ, 2006, J IMMUNOL, V176, P6347, DOI 10.4049/jimmunol.176.10.6347; Smyth MJ, 2003, IMMUNITY, V18, P1, DOI 10.1016/S1074-7613(02)00502-2; Sotomayor EM, 1999, NAT MED, V5, P780, DOI 10.1038/10503; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; Takahashi C, 1999, J IMMUNOL, V162, P5037; Takeda K, 2004, J EXP MED, V199, P437, DOI 10.1084/jem.20031457; Takeda K, 2002, J EXP MED, V195, P161, DOI 10.1084/jem.20011171; Takimoto R, 2000, ONCOGENE, V19, P1735, DOI 10.1038/sj.onc.1203489; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Timmer T, 2002, J PATHOL, V196, P125, DOI 10.1002/path.1028; Trcka J, 2002, IMMUNITY, V16, P861, DOI 10.1016/S1074-7613(02)00327-8; Truneh A, 2000, J BIOL CHEM, V275, P23319, DOI 10.1074/jbc.M910438199; Uno T, 2006, NAT MED, V12, P693, DOI 10.1038/nm1405; van Geelen CMM, 2003, BRIT J CANCER, V89, P363, DOI 10.1038/sj.bjc.6601065; Varela N, 2001, J BIOL CHEM, V276, P17779, DOI 10.1074/jbc.M100815200; VASSALLI P, 1992, ANNU REV IMMUNOL, V10, P411, DOI 10.1146/annurev.iy.10.040192.002211; Voelkel-Johnson C, 2003, CANCER BIOL THER, V2, P283, DOI 10.4161/cbt.2.3.398; Wajant H, 2002, APOPTOSIS, V7, P449, DOI 10.1023/A:1020039225764; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Wallach D, 1999, ANNU REV IMMUNOL, V17, P331, DOI 10.1146/annurev.immunol.17.1.331; Watts TH, 2005, ANNU REV IMMUNOL, V23, P23, DOI 10.1146/annurev.immunol.23.021704.115839; Wilcox RA, 2002, J CLIN INVEST, V109, P651, DOI 10.1172/JCI200214184; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Yagita H, 2004, CANCER SCI, V95, P777, DOI 10.1111/j.1349-7006.2004.tb02181.x; Zeng Y, 2006, INT J ONCOL, V28, P421; Zhang ML, 2004, CANCER RES, V64, P5825, DOI 10.1158/0008-5472.CAN-04-1088; Zhang XD, 1999, CANCER RES, V59, P2747; zum Buschenfelde CM, 2002, CANCER RES, V62, P2244	131	161	171	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2007	26	25					3745	3757		10.1038/sj.onc.1210374	http://dx.doi.org/10.1038/sj.onc.1210374			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	172PK	17530027				2022-12-28	WOS:000246816100016
J	Menendez, D; Inga, A; Jordan, JJ; Resnick, MA				Menendez, D.; Inga, A.; Jordan, J. J.; Resnick, M. A.			Changing the p53 master regulatory network: ELEMENTary, my dear Mr Watson	ONCOGENE			English	Review						p53; response element; mutants; transactivation; SNP; evolution	WILD-TYPE P53; TUMOR-SUPPRESSOR PROTEIN; DNA-BINDING SITE; RNA-POLYMERASE-II; TRANSCRIPTIONAL REPRESSION; IN-VIVO; FUNCTIONAL ASSAY; HUMAN GENOME; MUTANT P53; DIRECTED MUTAGENESIS	The p53 master regulatory network provides for the stress-responsive direct control of a vast number of genes in humans that can be grouped into several biological categories including cell-cycle control, apoptosis and DNA repair. Similar to other sequence-specific master regulators, there is a matrix of key components, which provide for variation within the p53 master regulatory network that include p53 itself, target response element sequences (REs) that provide for p53 regulation of target genes, chromatin, accessory proteins and transcription machinery. Changes in any of these can impact the expression of individual genes, groups of genes and the eventual biological responses. The many REs represent the core of the master regulatory network. Since defects or altered expression of p53 are associated with over 50% of all cancers and greater than 90% of p53 mutations are in the sequence-specific DNA-binding domain, it is important to understand the relationship between wildtype or mutant p53 proteins and the target response elements. In the words of the legendary detective Sherlock Holmes, it is 'Elementary, my dear Mr. Watson.'	Natl Inst Environm Hlth Sci, Chromosome Stabil Sect, Lab Mol Genet, NIH, Res Triangle Pk, NC 27709 USA; IST, Natl Inst Canc Res, Mol Mutageneis Unit, Dept Translat Oncol, Genoa, Italy	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); University of Genoa; IRCCS AOU San Martino IST	Resnick, MA (corresponding author), Natl Inst Environm Hlth Sci, Chromosome Stabil Sect, Lab Mol Genet, NIH, 111 Alexander Dr,POB 12233, Res Triangle Pk, NC 27709 USA.	resnick@niehs.nih.gov	resnick, Michael/F-1668-2019; Inga, Alberto/AAC-3815-2022	resnick, Michael/0000-0002-8473-7506; Inga, Alberto/0000-0002-8767-1637	Intramural NIH HHS Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES065079, Z01ES065079] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Ahn J, 1999, ONCOGENE, V18, P5954, DOI 10.1038/sj.onc.1202986; Ahn J, 2001, NAT STRUCT BIOL, V8, P730, DOI 10.1038/nsb0901-730; An W, 2004, CELL, V117, P735, DOI 10.1016/j.cell.2004.05.009; Arva NC, 2005, J BIOL CHEM, V280, P26776, DOI 10.1074/jbc.M505203200; Ashur-Fabian C, 2004, P NATL ACAD SCI USA, V101, P12236, DOI 10.1073/pnas.0404998101; Avivi A, 2005, CELL CYCLE, V4, P368, DOI 10.4161/cc.4.3.1534; Bergamaschi D, 2003, CANCER CELL, V3, P387, DOI 10.1016/S1535-6108(03)00079-5; Bergamaschi D, 2006, NAT GENET, V38, P1133, DOI 10.1038/ng1879; Blandino G, 1999, ONCOGENE, V18, P477, DOI 10.1038/sj.onc.1202314; Bond GL, 2006, J MED GENET, V43, P950, DOI 10.1136/jmg.2006.043539; Bond GL, 2006, CANCER RES, V66, P5104, DOI 10.1158/0008-5472.CAN-06-0180; Bond GL, 2004, CELL, V119, P591, DOI 10.1016/j.cell.2004.11.022; Brachmann RK, 1996, P NATL ACAD SCI USA, V93, P4091, DOI 10.1073/pnas.93.9.4091; Campomenosi P, 2001, ONCOGENE, V20, P3573, DOI 10.1038/sj.onc.1204468; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; Contente A, 2002, NAT GENET, V30, P315, DOI 10.1038/ng836; Deppert W, 2000, J CELL BIOCHEM, P115; Di Agostino S, 2006, CANCER CELL, V10, P191, DOI 10.1016/j.ccr.2006.08.013; El-Deiry WS, 1998, SEMIN CANCER BIOL, V8, P345, DOI 10.1006/scbi.1998.0097; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; Espinosa JM, 2003, MOL CELL, V12, P1015, DOI 10.1016/S1097-2765(03)00359-9; Espinosa JM, 2001, MOL CELL, V8, P57, DOI 10.1016/S1097-2765(01)00283-0; FLAMAN JM, 1995, P NATL ACAD SCI USA, V92, P3963, DOI 10.1073/pnas.92.9.3963; FREEMAN J, 1994, EMBO J, V13, P5393, DOI 10.1002/j.1460-2075.1994.tb06874.x; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; Gomes NP, 2006, GENE DEV, V20, P601, DOI 10.1101/gad.1398206; Hamroun D, 2006, HUM MUTAT, V27, P14, DOI 10.1002/humu.20269; Ho J, 2003, CELL DEATH DIFFER, V10, P404, DOI 10.1038/sj.cdd.4401191; Ho JSL, 2005, MOL CELL BIOL, V25, P7423, DOI 10.1128/MCB.25.17.7423-7431.2005; Hoffman WH, 2002, J BIOL CHEM, V277, P3247, DOI 10.1074/jbc.M106643200; Hoh J, 2002, P NATL ACAD SCI USA, V99, P8467, DOI 10.1073/pnas.132268899; HUPP TR, 1994, CURR BIOL, V4, P865, DOI 10.1016/S0960-9822(00)00195-0; Inga A, 2005, HUM MOL GENET, V14, P1965, DOI 10.1093/hmg/ddi202; Inga A, 2002, ONCOGENE, V21, P5704, DOI 10.1038/sj.onc.1205779; Inga A, 2002, MOL CELL BIOL, V22, P8612, DOI 10.1128/MCB.22.24.8612-8625.2002; Inga A, 2001, ONCOGENE, V20, P3409, DOI 10.1038/sj.onc.1204457; Inga A, 2001, ONCOGENE, V20, P501, DOI 10.1038/sj.onc.1204116; ISHIOKA C, 1993, NAT GENET, V5, P124, DOI 10.1038/ng1093-124; Ito M, 1999, MOL CELL, V3, P361, DOI 10.1016/S1097-2765(00)80463-3; Johnson RA, 2001, J BIOL CHEM, V276, P27716, DOI 10.1074/jbc.C100121200; JOHNSTON M, 1987, MICROBIOL REV, V51, P458, DOI 10.1128/MMBR.51.4.458-476.1987; Kaeser MD, 2002, P NATL ACAD SCI USA, V99, P95, DOI 10.1073/pnas.012283399; Kannan K, 2001, ONCOGENE, V20, P3449, DOI 10.1038/sj.onc.1204446; Kato S, 2003, P NATL ACAD SCI USA, V100, P8424, DOI 10.1073/pnas.1431692100; Kitayner M, 2006, MOL CELL, V22, P741, DOI 10.1016/j.molcel.2006.05.015; Koumenis C, 2001, MOL CELL BIOL, V21, P1297, DOI 10.1128/MCB.21.4.1297-1310.2001; Lefstin JA, 1998, NATURE, V392, P885, DOI 10.1038/31860; Levine AJ, 2006, CELL DEATH DIFFER, V13, P1027, DOI 10.1038/sj.cdd.4401910; Li BQ, 2001, J BIOL CHEM, V276, P29729, DOI 10.1074/jbc.M101167200; LIM YP, 2006, ONCOGENE; Liu Suxing, 2004, Methods Mol Biol, V281, P33; LOHR D, 1995, FASEB J, V9, P777, DOI 10.1096/fasebj.9.9.7601342; MacIsaac KD, 2006, PLOS COMPUT BIOL, V2, P201, DOI 10.1371/journal.pcbi.0020036; May P, 1999, ONCOGENE, V18, P7621, DOI 10.1038/sj.onc.1203285; McKinney K, 2004, MOL CELL, V16, P413, DOI 10.1016/j.molcel.2004.09.032; McLure KG, 1998, EMBO J, V17, P3342, DOI 10.1093/emboj/17.12.3342; Menendez D, 2006, MOL CELL BIOL, V26, P2297, DOI 10.1128/MCB.26.6.2297-2308.2006; Menendez D, 2006, P NATL ACAD SCI USA, V103, P1406, DOI 10.1073/pnas.0508103103; MENENDEZ D, 2007, IN PRESS MOL CELL BI; Miled C, 2005, CANCER RES, V65, P5096, DOI 10.1158/0008-5472.CAN-04-4232; Minsky N, 2004, MOL CELL, V16, P631, DOI 10.1016/j.molcel.2004.10.016; Murphy M, 1999, GENE DEV, V13, P2490, DOI 10.1101/gad.13.19.2490; Nagaich AK, 1999, P NATL ACAD SCI USA, V96, P1875, DOI 10.1073/pnas.96.5.1875; Nagaich AK, 1997, J BIOL CHEM, V272, P14842, DOI 10.1074/jbc.272.23.14842; O'Farrell TJ, 2004, CANCER RES, V64, P8199, DOI 10.1158/0008-5472.CAN-03-3639; OLIVEIRA LS, 1994, DRY TECHNOL, V12, P1167, DOI 10.1080/07373939408960994; Olivier M, 2002, HUM MUTAT, V19, P607, DOI 10.1002/humu.10081; Prives C, 1999, J PATHOL, V187, P112; Qian Hua, 2002, Proceedings of the American Association for Cancer Research Annual Meeting, V43, P1141; Reis AM, 2000, CANCER RES, V60, P1571; Resnick MA, 2003, P NATL ACAD SCI USA, V100, P9934, DOI 10.1073/pnas.1633803100; Resnick-Silverman L, 1998, GENE DEV, V12, P2102, DOI 10.1101/gad.12.14.2102; Rubbi CP, 2003, EMBO J, V22, P975, DOI 10.1093/emboj/cdg082; Shiraishi K, 2004, J BIOL CHEM, V279, P348, DOI 10.1074/jbc.M310815200; Storey A, 1998, NATURE, V393, P229, DOI 10.1038/30400; Storici F, 2003, P NATL ACAD SCI USA, V100, P14994, DOI 10.1073/pnas.2036296100; Storici F, 2001, NAT BIOTECHNOL, V19, P773, DOI 10.1038/90837; Storici F, 2006, METHOD ENZYMOL, V409, P329, DOI 10.1016/S0076-6879(05)09019-1; Szak ST, 2001, MOL CELL BIOL, V21, P3375, DOI 10.1128/MCB.21.10.3375-3386.2001; Tan T, 2002, MOL CELL BIOL, V22, P3247, DOI 10.1128/MCB.22.10.3247-3254.2002; Thomas M, 1999, MOL CELL BIOL, V19, P1092; Thornborrow EC, 2002, ONCOGENE, V21, P990, DOI 10.1038/sj.onc.1205069; THUKRAL SK, 1995, MOL CELL BIOL, V15, P5196; TOKINO T, 1994, HUM MOL GENET, V3, P1537, DOI 10.1093/hmg/3.9.1537; Tomso DJ, 2005, P NATL ACAD SCI USA, V102, P6431, DOI 10.1073/pnas.0501721102; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2000, CELL, V103, P691, DOI 10.1016/S0092-8674(00)00171-9; Wallberg AE, 2003, MOL CELL, V12, P1137, DOI 10.1016/S1097-2765(03)00391-5; Wang LQ, 2001, J BIOL CHEM, V276, P43604, DOI 10.1074/jbc.M106570200; WANG Y, 1995, MOL CELL BIOL, V15, P2157; Wei CL, 2006, CELL, V124, P207, DOI 10.1016/j.cell.2005.10.043; Weinberg RL, 2005, J MOL BIOL, V348, P589, DOI 10.1016/j.jmb.2005.03.014; Xu H, 2003, ONCOL RES, V13, P429; Xu H, 2001, Biotechnol Annu Rev, V7, P131, DOI 10.1016/S1387-2656(01)07035-1; Yu J, 1999, P NATL ACAD SCI USA, V96, P14517, DOI 10.1073/pnas.96.25.14517; Zhai WG, 2000, MOL CELL BIOL, V20, P5930, DOI 10.1128/MCB.20.16.5930-5938.2000; Zhang XT, 2005, MOL CELL, V19, P89, DOI 10.1016/j.molcel.2005.05.015; Zhao RB, 2000, GENE DEV, V14, P981	98	26	27	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 2	2007	26	15					2191	2201		10.1038/sj.onc.1210277	http://dx.doi.org/10.1038/sj.onc.1210277			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	152XE	17401428				2022-12-28	WOS:000245394800008
J	Gibbs, J; Liebermann, D; Hoffman, B				Gibbs, Jd; Liebermann, Da; Hoffman, B.			Egr-1 abrogates the E2F-1 block in terminal myeloid differentiation and suppresses leukemia	ONCOGENE			English	Article						Egr-1; E2F-1; myeloid differentiation; leukemia; tumor suppressor	TRANSCRIPTION FACTOR EGR-1; C-MYC; MACROPHAGE DIFFERENTIATION; CELLS; LEUKEMOGENESIS; TRANSFORMATION; EXPRESSION; INDUCTION; ACTIVATOR; LINEAGE	Deregulated growth and blocks in differentiation collaborate in the multistage process of leukemogenesis. Previously, we have shown that ectopic expression of the zinc finger transcription factor Egr-1 in M1 myeloblastic leukemia cells promotes terminal differentiation with interleukin-6 (IL-6). In addition, we have shown that deregulated expression of the oncogene E2F-1 blocks the myeloid terminal differentiation program, resulting in proliferation of immature cells in the presence of IL-6. Here it is shown that the positive regulator of differentiation Egr-1 abrogates the E2F-1-driven block in myeloid terminal differentiation. The M1E2F-1/Egr-1 cells underwent G(0)/G(1) arrest and functional macrophage maturation following treatment with IL-6. Furthermore, Egr-1 diminished the aggressiveness of M1E2F-1 leukemias and abrogated the leukemic potential of IL-6-treated M1E2F-1 cells. Previously, we reported that Egr-1 abrogated the block in terminal myeloid differentiation imparted by deregulated c-myc, which blocks differentiation at a later stage than E2F-1, resulting in cells that have the characteristics of functionally mature macrophages that did not undergo G(0)/G(1) arrest. Taken together, this work extends and highlights the tumor suppressor role of Egr-1, with Egr-1 behaving as a tumor suppressor against two oncogenes, each blocking myeloid differentiation by a different mechanism. These findings suggest that Egr-1 and/or Egr-1 target genes may be useful tools to treat or suppress oncogene-driven hematological malignancies.	[Gibbs, Jd; Liebermann, Da; Hoffman, B.] Temple Univ, Fels Inst Canc Res & Mol Biol, Dept Biochem, Philadelphia, PA 19140 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Hoffman, B (corresponding author), Temple Univ, Fels Inst Canc Res & Mol Biol, Dept Biochem, 3307 N Broad St,AHB 331, Philadelphia, PA 19140 USA.	hoffman@temple.edu			NATIONAL CANCER INSTITUTE [R01CA081168] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA081168] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Amanullah A, 2000, BLOOD, V96, P475; Baron V, 2003, ONCOGENE, V22, P4194, DOI 10.1038/sj.onc.1206560; Beckmann AM, 1997, NEUROCHEM INT, V31, P477, DOI 10.1016/S0197-0186(96)00136-2; Bram S, 2004, CANCER GENET CYTOGEN, V155, P74, DOI 10.1016/j.cancergencyto.2004.03.003; Carter JH, 2007, J IMMUNOL, V178, P3038, DOI 10.4049/jimmunol.178.5.3038; Chen F, 2004, CANCER RES, V64, P5425, DOI 10.1158/0008-5472.CAN-04-0806; Giagounidis AAN, 2004, LEUKEMIA, V18, P113, DOI 10.1038/sj.leu.2403189; Hoffman B, 2002, ONCOGENE, V21, P3414, DOI 10.1038/sj.onc.1205400; HOFFMANLIEBERMANN B, 1991, MOL CELL BIOL, V11, P2375, DOI 10.1128/MCB.11.5.2375; Krishnaraju K, 1998, BLOOD, V92, P1957, DOI 10.1182/blood.V92.6.1957.418k24_1957_1966; KRISHNARAJU K, 1995, MOL CELL BIOL, V15, P5499; Krishnaraju K, 2001, BLOOD, V97, P1298, DOI 10.1182/blood.V97.5.1298; Laslo P, 2006, CELL, V126, P755, DOI 10.1016/j.cell.2006.06.052; Liu CT, 1999, J BIOL CHEM, V274, P4400, DOI 10.1074/jbc.274.7.4400; McMahon SB, 1996, J LEUKOCYTE BIOL, V60, P159, DOI 10.1002/jlb.60.2.159; NGUYEN HQ, 1993, CELL, V72, P197, DOI 10.1016/0092-8674(93)90660-I; SELVAKUMARAN M, 1992, MOL CELL BIOL, V12, P2493, DOI 10.1128/MCB.12.6.2493; Shafarenko M, 2005, BLOOD, V106, P871, DOI 10.1182/blood-2004-08-3056; STEINKAMP JA, 1982, SCIENCE, V215, P64, DOI 10.1126/science.7053559	19	45	46	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 3	2008	27	1					98	106		10.1038/sj.onc.1210627	http://dx.doi.org/10.1038/sj.onc.1210627			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	247YO	17599039				2022-12-28	WOS:000252118700010
J	Jeffers, LJ; Coull, BJ; Stack, SJ; Morrison, CG				Jeffers, L. J.; Coull, B. J.; Stack, S. J.; Morrison, C. G.			Distinct BRCT domains in Mcph1/Brit1 mediate ionizing radiation-induced focus formation and centrosomal localization	ONCOGENE			English	Article						DNA-damage response; microcephalin; BRCT; cell cycle checkpoint; centrosome	DOUBLE-STRAND BREAKS; HISTONE H2AX; DNA-DAMAGE; CHROMOSOME CONDENSATION; NUCLEAR FOCI; PROTEIN; MICROCEPHALIN; CHECKPOINT; REPAIR; UBIQUITINATION	Microcephalin (MCPH1/BRIT1) forms ionizing radiation-induced nuclear foci (IRIF) and is required for DNA damage-responsive S and G(2)-M-phase checkpoints. MCPH1 contains three BRCT domains. Here we report the cloning of chicken Mcph1 (cMcph1) and functional analysis of its individual BRCT domains. Full-length cMcph1 localized to centrosomes throughout the cell cycle and formed IRIF that colocalized with gamma-H2AX. The tandem C-terminal BRCT2 and BRCT3 domains of cMcph1 were necessary for IRIF formation, while the N-terminal BRCT1 was required for centrosomal localization in irradiated cells. Centrosomal targeting of cMcph1 was independent of ATM, Brca1 or Chk1. cMcph1 formed IRIF in ATM- and Brca1-deficient cells, but not in H2AX-deficient cells. Inability to form cMcph1 IRIF impaired the cellular response to DNA damage. These results suggest that the role of microcephalin in the vertebrate DNA damage response is controlled by interaction of the C-terminal BRCT domains with gamma-H2AX.	[Jeffers, L. J.; Coull, B. J.; Stack, S. J.; Morrison, C. G.] Natl Univ Ireland Galway, Dept Biochem & NCBES, Galway, Ireland	Ollscoil na Gaillimhe-University of Galway	Morrison, CG (corresponding author), Natl Univ Ireland Galway, Dept Biochem & NCBES, Univ Rd, Galway, Ireland.	ciaran.morrison@nuigalway.ie	Morrison, Ciaran/B-6568-2008; Morrison, Ciaran/AAH-2034-2019	Morrison, Ciaran/0000-0003-2401-7029; Morrison, Ciaran/0000-0003-2401-7029; Coull, Barry/0000-0001-5438-7085				Alderton GK, 2006, NAT CELL BIOL, V8, P725, DOI 10.1038/ncb1431; Au WWY, 2005, J BIOL CHEM, V280, P6993, DOI 10.1074/jbc.M408879200; Bartek J, 2003, CANCER CELL, V3, P421, DOI 10.1016/S1535-6108(03)00110-7; Bond J, 2005, NAT GENET, V37, P353, DOI 10.1038/ng1539; Celeste A, 2003, NAT CELL BIOL, V5, P675, DOI 10.1038/ncb1004; Celeste A, 2002, SCIENCE, V296, P922, DOI 10.1126/science.1069398; Dodson H, 2004, EMBO J, V23, P3864, DOI 10.1038/sj.emboj.7600393; Glover JNM, 2004, TRENDS BIOCHEM SCI, V29, P579, DOI 10.1016/j.tibs.2004.09.010; Haren L, 2006, J CELL BIOL, V172, P505, DOI 10.1083/jcb.200510028; Jackson AP, 2002, AM J HUM GENET, V71, P136, DOI 10.1086/341283; Lin SY, 2005, P NATL ACAD SCI USA, V102, P15105, DOI 10.1073/pnas.0507722102; Lin SY, 2003, CELL, V113, P881, DOI 10.1016/S0092-8674(03)00430-6; Manke IA, 2003, SCIENCE, V302, P636, DOI 10.1126/science.1088877; Neitzel H, 2002, AM J HUM GENET, V70, P1015, DOI 10.1086/339518; Paull TT, 2000, CURR BIOL, V10, P886, DOI 10.1016/S0960-9822(00)00610-2; RAI R, 2006, CANCER CELL, V10, P1; Rogakou EP, 1999, J CELL BIOL, V146, P905, DOI 10.1083/jcb.146.5.905; Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011; Sonoda E, 2007, DNA REPAIR, V6, P280, DOI 10.1016/j.dnarep.2006.10.025; Starita LM, 2003, CURR OPIN CELL BIOL, V15, P345, DOI 10.1016/S0955-0674(03)00042-5; Stucki M, 2005, CELL, V123, P1213, DOI 10.1016/j.cell.2005.09.038; Trimborn M, 2004, AM J HUM GENET, V75, P261, DOI 10.1086/422855; Vandenberg CJ, 2003, MOL CELL, V12, P247, DOI 10.1016/S1097-2765(03)00281-8; Xu XZ, 2004, J BIOL CHEM, V279, P34091, DOI 10.1074/jbc.C400139200; Yu XC, 2003, SCIENCE, V302, P639, DOI 10.1126/science.1088753; Zachos G, 2003, EMBO J, V22, P713, DOI 10.1093/emboj/cdg060	26	68	70	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 3	2008	27	1					139	144		10.1038/sj.onc.1210595	http://dx.doi.org/10.1038/sj.onc.1210595			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	247YO	17599047				2022-12-28	WOS:000252118700014
J	Craft, CS; Romero, D; Vary, CPH; Bergan, RC				Craft, C. S.; Romero, D.; Vary, C. P. H.; Bergan, R. C.			Endoglin inhibits prostate cancer motility via activation of the ALK2-Smad1 pathway	ONCOGENE			English	Article						transforming growth factor beta; prostate cancer; motility; endoglin; smad1; ALK2	GROWTH-FACTOR-BETA; MATRIX-METALLOPROTEINASE TYPE-2; HUMAN ENDOTHELIAL-CELLS; RECEPTOR-LIKE KINASE-2; TGF-BETA; SIGNAL-TRANSDUCTION; CELLULAR-RESPONSES; EPITHELIAL-CELLS; II RECEPTORS; ACTIVIN	Endoglin is a transforming growth factor beta (TGF beta) superfamily auxiliary receptor. We had previously shown that it suppressed prostate cancer (PCa) cell motility, and that its expression was lost during PCa progression. The mechanism by which endoglin inhibits PCa cell motility is unknown. Here we demonstrate that endoglin abrogates TGF beta-mediated cell motility, but does not alter cell surface binding of TGF beta. By measuring Smad-specific phosphorylation and Smad-responsive promoter activity, endoglin was shown to constitutively activate Smad1, with little-to-no effect upon Smad3. Knockdown of Smad1 increased motility and abrogated endoglin's effects. As type I activin receptor-like kinases (ALKs) are necessary for Smad activation, we went on to show that knockdown of ALK2, but not TGF beta RI (ALK5), abrogated endoglin-mediated decreases in cell motility and constitutively active ALK2 was sufficient to restore a low-motility phenotype in endoglin deficient cells. These findings provide the first evidence that endoglin decreases PCa cell motility through activation of the ALK2-Smad1 pathway.	Northwestern Univ, Sch Med, Dept Med, Div Hematol Oncol, Chicago, IL 60611 USA; Northwestern Univ, Robert H Lurie Canc Ctr, Chicago, IL 60611 USA; Maine Med Ctr, Res Inst, Ctr Mol Med, Scarborough, ME USA	Northwestern University; Northwestern University; Robert H. Lurie Comprehensive Cancer Center; Maine Medical Center	Bergan, RC (corresponding author), Northwestern Univ, Sch Med, Dept Med, Div Hematol Oncol, Olson 8321, 710 N Fairbanks, Chicago, IL 60611 USA.	r-bergan@northwestern.edu	Romero, Diana/GWU-9250-2022		NATIONAL CANCER INSTITUTE [T32CA009560, P50CA090386] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR015555] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL083151] Funding Source: NIH RePORTER; NCI NIH HHS [P50 CA090386, T32 CA009560, CA90386, T32CA09560] Funding Source: Medline; NCRR NIH HHS [P20 RR015555-076459, P20 RR015555, P20 RR015555-076465] Funding Source: Medline; NHLBI NIH HHS [R01 HL083151, R01 HL083151-01A2S1] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ATTISANO L, 1993, CELL, V75, P671, DOI 10.1016/0092-8674(93)90488-C; Barbara NP, 1999, J BIOL CHEM, V274, P584, DOI 10.1074/jbc.274.2.584; Bergan R, 1996, CLIN EXP METASTAS, V14, P389, DOI 10.1007/BF00123398; Bergan R, 1996, BLOOD, V88, P731, DOI 10.1182/blood.V88.2.731.bloodjournal882731; Bissell MJ, 2001, NAT REV CANCER, V1, P46, DOI 10.1038/35094059; Blanco FJ, 2005, J CELL PHYSIOL, V204, P574, DOI 10.1002/jcp.20311; CARROLL PR, 2001, CANC PRINCIPLES PRAC, P1418; CHEIFETZ S, 1992, J BIOL CHEM, V267, P19027; deCaestecker MP, 1997, J BIOL CHEM, V272, P13690, DOI 10.1074/jbc.272.21.13690; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Desgrosellier JS, 2005, DEV BIOL, V280, P201, DOI 10.1016/j.ydbio.2004.12.037; Ding Y, 2006, PROSTATE CANCER P D, V9, P379, DOI 10.1038/sj.pcan.4500888; EBNER R, 1993, SCIENCE, V262, P900, DOI 10.1126/science.8235612; EBNER R, 1993, SCIENCE, V260, P1344, DOI 10.1126/science.8388127; GOUGOS A, 1990, J BIOL CHEM, V265, P8361; Goumans MJ, 2003, MOL CELL, V12, P817, DOI 10.1016/S1097-2765(03)00386-1; Hayes SA, 2003, ONCOGENE, V22, P4841, DOI 10.1038/sj.onc.1206730; Huang XK, 2005, CANCER RES, V65, P3470, DOI 10.1158/0008-5472.CAN-04-2807; Jovanovic B D, 2001, Am J Pharmacogenomics, V1, P145, DOI 10.2165/00129785-200101020-00007; KOZLOWSKI JM, 1984, CANCER RES, V44, P3522; Lastres P, 1996, J CELL BIOL, V133, P1109, DOI 10.1083/jcb.133.5.1109; Lebrin F, 2004, EMBO J, V23, P4018, DOI 10.1038/sj.emboj.7600386; Letamendia A, 1998, J BIOL CHEM, V273, P33011, DOI 10.1074/jbc.273.49.33011; Liu YQ, 2002, ONCOGENE, V21, P8272, DOI 10.1038/sj.onc.1206117; Liu YQ, 2001, PROSTATE CANCER P D, V4, P81, DOI 10.1038/sj.pcan.4500506; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; MIETTINEN PJ, 1994, J CELL BIOL, V127, P2021, DOI 10.1083/jcb.127.6.2021; Monteiro RM, 2004, J CELL SCI, V117, P4653, DOI 10.1242/jcs.01337; Pece-Barbara N, 2005, J BIOL CHEM, V280, P27800, DOI 10.1074/jbc.M503471200; POSTE G, 1980, NATURE, V283, P139, DOI 10.1038/283139a0; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; TENDIJKE P, 1993, ONCOGENE, V8, P2879; Ulloa L, 1999, NATURE, V397, P710, DOI 10.1038/17826; Ward SM, 2002, J BIOL CHEM, V277, P50183, DOI 10.1074/jbc.M209668200; WIESER R, 1995, EMBO J, V14, P2199, DOI 10.1002/j.1460-2075.1995.tb07214.x; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; Xu L, 2006, ONCOGENE, V25, P2987, DOI 10.1038/sj.onc.1209337	37	53	58	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 8	2007	26	51					7240	7250		10.1038/sj.onc.1210533	http://dx.doi.org/10.1038/sj.onc.1210533			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	231NO	17496924	Green Accepted			2022-12-28	WOS:000250955600008
J	Klucky, B; Wintersberger, E				Klucky, B.; Wintersberger, E.			Polyomavirus small T antigen transactivates genes by its ability to provoke the synthesis and the stabilization of MYC	ONCOGENE			English	Article						polyomavirus; T antigens; MYC; S-phase induction	SIMIAN-VIRUS-40 SMALL-T; PROTEIN PHOSPHATASE 2A; HUMAN CELL-TRANSFORMATION; SMALL TUMOR-ANTIGEN; MOUSE FIBROBLASTS; CYCLIN-A; S-PHASE; C-MYC; INDUCTION; PATHWAY	DNA tumor viruses are capable of driving quiescent cells into the cell cycle. In case of polyomaviridae, two viral proteins, the large and the small ( ST) T antigens are responsible for this outcome. ST interacts with the protein phosphatase PP2A and with chaperons of the dnaK type and leads to the transactivation of several genes, which play a role in S-phase induction. One of these is the transcription factor myelocytomatosis ( MYC), which by itself is an important regulator of growth. Microarray analysis has revealed several ST-induced genes, which are also targets of MYC; hence, ST may induce these genes via MYC. Experiments shown here are in line with this assumption. MYC-regulated genes are induced by ST at later times than MYC and a MYC responsive promoter is stimulated by ST. Regulation of MYC occurs through signal transduction pathways, which are co-ordinated by PP2A suggesting that they may be targets of ST. Here, we show that this is the case as important kinases involved in these pathways appear in the active phosphorylated form in the presence of ST. Inhibition of these kinases interferes with MYC induction and inhibition of MYC activity blocks ST-mediated transactivation.	Med Univ Vienna, Dept Med Biochem, Div Mol Biol, MFPL, A-1030 Vienna, Austria	Medical University of Vienna; University of Vienna; Vienna Biocenter (VBC); Max F. Perutz Laboratories (MFPL)	Wintersberger, E (corresponding author), Med Univ Vienna, Dept Med Biochem, Div Mol Biol, MFPL, Dr Bohrgasse 9, A-1030 Vienna, Austria.	erhard.wintersberger@meduniwien.ac.at						Barker N, 2000, ADV CANCER RES, V77, P1; FROST JA, 1994, MOL CELL BIOL, V14, P6244, DOI 10.1128/MCB.14.9.6244; Hahn WC, 2002, MOL CELL BIOL, V22, P2111, DOI 10.1128/MCB.22.7.2111-2123.2002; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; Howe AK, 1998, J VIROL, V72, P9637, DOI 10.1128/JVI.72.12.9637-9644.1998; Klucky B, 2004, ONCOGENE, V23, P4707, DOI 10.1038/sj.onc.1207640; Levens DL, 2003, GENE DEV, V17, P1071, DOI 10.1101/gad.1095203; Millward TA, 1999, TRENDS BIOCHEM SCI, V24, P186, DOI 10.1016/S0968-0004(99)01375-4; MORAN E, 1993, CURR OPIN GENET DEV, V3, P63, DOI 10.1016/S0959-437X(05)80342-9; Nemethova M, 2004, MOL CELL BIOL, V24, P10986, DOI 10.1128/MCB.24.24.10986-10994.2004; Nesbit CE, 1999, ONCOGENE, V18, P3004, DOI 10.1038/sj.onc.1202746; OGRIS E, 1992, J VIROL, V66, P53, DOI 10.1128/JVI.66.1.53-61.1992; PASSAMATO R, 2004, CANCER CELL, V5, P127; Patel JH, 2004, NAT REV CANCER, V4, P562, DOI 10.1038/nrc1393; Pelengaris S, 2003, ARCH BIOCHEM BIOPHYS, V416, P129, DOI 10.1016/S0003-9861(03)00294-7; Porras A, 1996, J VIROL, V70, P6902; Porras A, 1999, J VIROL, V73, P3102; Reiss K, 2003, ONCOGENE, V22, P6517, DOI 10.1038/sj.onc.1206959; Schuchner S, 2001, J VIROL, V75, P6498, DOI 10.1128/JVI.75.14.6498-6507.2001; Schuchner S, 1999, J VIROL, V73, P9266; Sears R, 2000, GENE DEV, V14, P2501, DOI 10.1101/gad.836800; SONTAG E, 1993, CELL, V75, P887, DOI 10.1016/0092-8674(93)90533-V; Sullivan CS, 2002, MICROBIOL MOL BIOL R, V66, P179, DOI 10.1128/MMBR.66.2.179-202.2002; Virshup DM, 2000, CURR OPIN CELL BIOL, V12, P180, DOI 10.1016/S0955-0674(99)00074-5; Watanabe G, 1996, P NATL ACAD SCI USA, V93, P12861, DOI 10.1073/pnas.93.23.12861; YANG SI, 1991, MOL CELL BIOL, V11, P1988, DOI 10.1128/MCB.11.4.1988; Yeh E, 2004, NAT CELL BIOL, V6, P308, DOI 10.1038/ncb1110; Yu J, 2001, VIROLOGY, V290, P192, DOI 10.1006/viro.2001.1204	28	4	4	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 20	2007	26	43					6356	6360		10.1038/sj.onc.1210458	http://dx.doi.org/10.1038/sj.onc.1210458			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	212GW	17438527				2022-12-28	WOS:000249583300012
J	Adiga, SK; Toyoshima, M; Shiraishi, K; Shimura, T; Takeda, J; Taga, M; Nagai, H; Kumar, P; Niwa, O				Adiga, S. K.; Toyoshima, M.; Shiraishi, K.; Shimura, T.; Takeda, J.; Taga, M.; Nagai, H.; Kumar, P.; Niwa, O.			p21 provides stage specific DNA damage control to preimplantation embryos	ONCOGENE			English	Article						radiation; p21 activation; preimplantation stage embryos	CELL-CYCLE; MOUSE DEVELOPMENT; GENE-EXPRESSION; CARCINOMA-CELLS; IN-VITRO; X-RAY; APOPTOSIS; P21(WAF1/CIP1); ACTIVATION; SPERM	The early stage embryogenesis of higher eukaryotes lacks some of the damage response pathways such as G1/S checkpoint, G2/M checkpoint and apoptosis. We examined here the damage response of preimplantation stage embryos after fertilization with 6 Gy irradiated sperm. Sperm-irradiated embryos developed normally for the first 2.5 days, but started to exhibit a developmental delay at day 3.5. p21 was activated in the delayed embryos, which carried numerous micronuclei owing to delayed chromosome instability. Apoptosis was observed predominantly in the inner cell mass of the day 4.0 embryos. Sperm-irradiated p21 -/- embryos lacked the delay, but chromosome instability and apoptosis were more pronounced than the corresponding p21 wild-type embryos. We conclude from the result that damage responses come in a stagespeci. c manner during preimplantation stage development; p53-dependent S checkpoint at the zygote stage, p21-mediated cell cycle arrest at the morula/blastocyst stages and apoptosis after the blastocyst stage in the inner cell mass.	Kasturba Med Coll & Hosp, Manipal, India; Kyoto Univ, Radiat Biol Ctr, Kyoto, Japan; Osaka Prefecture Univ, Adv Sci & Technol Inst, Osaka, Japan; RIKEN, Genome Damage Respone Res Unit, Wako, Saitama, Japan	Manipal Academy of Higher Education (MAHE); Kasturba Medical College, Manipal; Kyoto University; Osaka Metropolitan University; RIKEN	Niwa, O (corresponding author), Kyoto Univ, Studies Rdiat Biol Ctr, Yoshida konoe Sakyo-ku, Kyoto 606850, Japan.	oniwa@house.rbc.kyoto-u.ac.jp	Adiga, Satish Kumar/AAU-4386-2020	Adiga, Satish Kumar/0000-0002-2897-4697; , pratap kumar/0000-0002-7245-1746				Baus F, 2003, EMBO J, V22, P3992, DOI 10.1093/emboj/cdg387; Clute P, 1997, DEV BIOL, V185, P1, DOI 10.1006/dbio.1997.8540; FENECH M, 1993, ENVIRON HEALTH PERSP, V101, P101, DOI 10.2307/3431708; FLEMING TP, 2001, FRONT BIOSCI, V6, P2566; FRIESNER JD, 2005, MOL BIOL CELL, V16, pD1000; Gartel AL, 2002, MOL CANCER THER, V1, P639; GOLDSTEIN LS, 1975, RADIAT RES, V62, P276, DOI 10.2307/3574220; Gottifredi V, 2004, J BIOL CHEM, V279, P5802, DOI 10.1074/jbc.M310373200; Hamatani T, 2004, P NATL ACAD SCI USA, V101, P10326, DOI 10.1073/pnas.0402597101; Hendzel MJ, 1997, CHROMOSOMA, V106, P348, DOI 10.1007/s004120050256; Heyer BS, 2000, GENE DEV, V14, P2072; Ikegami R, 1997, ZYGOTE, V5, P153, DOI 10.1017/S0967199400003828; Iliakis G, 2004, CYTOGENET GENOME RES, V104, P14, DOI 10.1159/000077461; Jascur T, 2005, MOL CELL, V17, P237, DOI 10.1016/j.molcel.2004.11.049; Jeong YJ, 2005, MOL REPROD DEV, V71, P284, DOI 10.1002/mrd.20269; Jurisicova A, 1998, MOL HUM REPROD, V4, P139, DOI 10.1093/molehr/4.2.139; KADHIM MA, 1992, NATURE, V355, P738, DOI 10.1038/355738a0; Kamjoo M, 2002, MOL REPROD DEV, V61, P67, DOI 10.1002/mrd.1132; Liu SX, 2003, DRUG RESIST UPDATE, V6, P183, DOI 10.1016/S1368-7646(03)00044-X; Malashicheva AB, 2000, ONCOGENE, V19, P3858, DOI 10.1038/sj.onc.1203736; Morgan WF, 2003, RADIAT RES, V159, P567, DOI 10.1667/0033-7587(2003)159[0567:NADEOE]2.0.CO;2; MUKHERJEE AB, 1976, P NATL ACAD SCI USA, V73, P1608, DOI 10.1073/pnas.73.5.1608; NEWPORT J, 1982, CELL, V30, P687, DOI 10.1016/0092-8674(82)90273-2; RAFF JW, 1988, J CELL BIOL, V107, P2009, DOI 10.1083/jcb.107.6.2009; Shimura T, 2002, MOL CELL BIOL, V22, P2220, DOI 10.1128/MCB.22.7.2220-2228.2002; Shimura T, 2002, RADIAT RES, V158, P735, DOI 10.1667/0033-7587(2002)158[0735:TNSMOT]2.0.CO;2; Taga M, 2000, J RADIAT RES, V41, P227, DOI 10.1269/jrr.41.227; TAYLOR SL, 2001, FOOD ALLERGY INTOLER, V2, P53; Toyoshima M, 2005, ONCOGENE, V24, P3229, DOI 10.1038/sj.onc.1208514; Wright SJ, 1999, CURR TOP DEV BIOL, V46, P133, DOI 10.1016/S0070-2153(08)60328-2; Zeng FY, 2004, DEV BIOL, V272, P483, DOI 10.1016/j.ydbio.2004.05.018; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005; ZIOMEK CA, 1980, CELL, V21, P935, DOI 10.1016/0092-8674(80)90457-2	33	54	55	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 13	2007	26	42					6141	6149		10.1038/sj.onc.1210444	http://dx.doi.org/10.1038/sj.onc.1210444			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	209PU	17420724				2022-12-28	WOS:000249401300004
J	Oh, KB; Stanton, MJ; West, WW; Todd, GL; Wagner, KU				Oh, K. B.; Stanton, M. J.; West, W. W.; Todd, G. L.; Wagner, K-U			Tsg101 is upregulated in a subset of invasive human breast cancers and its targeted overexpression in transgenic mice reveals weak oncogenic properties for mammary cancer initiation	ONCOGENE			English	Article						Tsg101; breast cancer; mammary gland; transgenic; epidermal growth factor receptor	TUMOR SUSCEPTIBILITY GENE; CELL-CYCLE ARREST; TRANSCRIPTIONAL ACTIVATION; EXPRESSION; RECEPTOR; PATHWAY; GROWTH; DIFFERENTIATION; PROLIFERATION; ABNORMALITIES	Previous studies reported that the Tumor Susceptibility Gene 101 ( TSG101) is upregulated in selected human malignancies, and the expression of exogenous Tsg101 was suggested to transform immortalized fibroblasts in culture. To date, the potential oncogenic properties of Tsg101 have not been examined in vivo owing to the lack of appropriate model systems. In this study, we show that Tsg101 is highly expressed in a subset of invasive human breast cancers. Based on this observation, we generated the first transgenic mouse model with a targeted overexpression of Tsg101 in the developing mammary gland to test whether exogenous Tsg101 is capable of initiating tumorigenesis. Normal functionality of exogenous Tsg101 was tested by rescuing the survival of Tsg101-deficient mammary epithelial cells in conditional knockout mice. The overexpression of Tsg101 resulted in increased phosphorylation of the epidermal growth factor receptor and downstream activation of MAP kinases. Despite an increase in the activation of these signal transducers, the mammary gland of females expressing exogenous Tsg101 developed normally throughout the reproductive cycle. In aging females, the overexpression of Tsg101 seemed to increase the susceptibility of mammary epithelia toward malignant transformation. However, owing to the long latency of tumor formation and the sporadic occurrence of bona. de mammary cancers, we conclude that the Tsg101 protein has only weak oncogenic properties. Instead of cancer initiation, it is therefore likely that Tsg101 plays a more predominant role in the progression of a subset of spontaneously arising breast cancers.	Univ Nebraska, Med Ctr, Eppley Inst Res Canc & Allied Dis, Omaha, NE 68198 USA; Univ Nebraska, Med Ctr, Dept Pathol & Microbiol, Omaha, NE 68198 USA; Univ Nebraska, Med Ctr, Dept Genet Cell Biol & Anat, Omaha, NE 68198 USA	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center	Wagner, KU (corresponding author), Univ Nebraska, Med Ctr, Eppley Inst Res Canc & Allied Dis, Room 8009,986805, Omaha, NE 68198 USA.	kuwagner@unmc.edu	Wagner, Kay-Uwe/B-6044-2009	Wagner, Kay-Uwe/0000-0002-5081-0226	NATIONAL CANCER INSTITUTE [R01CA093797] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR016469] Funding Source: NIH RePORTER; NCI NIH HHS [CA 93797] Funding Source: Medline; NCRR NIH HHS [P20 RR 16469] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Babst M, 2000, TRAFFIC, V1, P248, DOI 10.1034/j.1600-0854.2000.010307.x; BURDON T, 1991, J BIOL CHEM, V266, P6909; Carstens MJ, 2004, J BIOL CHEM, V279, P35984, DOI 10.1074/jbc.M400408200; Cerrito MG, 2004, J CELL PHYSIOL, V201, P244, DOI 10.1002/jcp.20077; Chapman RS, 1999, GENE DEV, V13, P2604, DOI 10.1101/gad.13.19.2604; Chin LS, 2001, J BIOL CHEM, V276, P7069, DOI 10.1074/jbc.M004129200; Garrus JE, 2001, CELL, V107, P55, DOI 10.1016/S0092-8674(01)00506-2; Gayther SA, 1997, ONCOGENE, V15, P2119, DOI 10.1038/sj.onc.1201591; Hennighausen L, 2001, DEV CELL, V1, P467, DOI 10.1016/S1534-5807(01)00064-8; Hittelman AB, 1999, EMBO J, V18, P5380, DOI 10.1093/emboj/18.19.5380; Katzmann DJ, 2001, CELL, V106, P145, DOI 10.1016/S0092-8674(01)00434-2; Krempler A, 2002, J BIOL CHEM, V277, P43216, DOI 10.1074/jbc.M207662200; Lee MP, 1997, CANCER RES, V57, P3131; Li LM, 1996, CELL, V85, P319, DOI 10.1016/S0092-8674(00)81111-3; Li LM, 1997, CELL, V88, P143, DOI 10.1016/S0092-8674(00)81866-8; Liu RT, 2002, ONCOGENE, V21, P4830, DOI 10.1038/sj.onc.1205612; Lo YF, 2000, BREAST CANCER RES TR, V60, P259, DOI 10.1023/A:1006426400524; Mahler JF, 1996, TOXICOL PATHOL, V24, P710, DOI 10.1177/019262339602400606; Merlo GR, 1996, EUR J CELL BIOL, V70, P97; Raiborg C, 2001, EMBO J, V20, P5008, DOI 10.1093/emboj/20.17.5008; Ruland J, 2001, P NATL ACAD SCI USA, V98, P1859, DOI 10.1073/pnas.98.4.1859; Steiner P, 1997, NAT GENET, V16, P332, DOI 10.1038/ng0897-332; Sun ZJ, 1997, ONCOGENE, V15, P3121, DOI 10.1038/sj.onc.1201521; Wagner KU, 2003, MOL CELL BIOL, V23, P150, DOI 10.1128/MCB.23.1.150-162.2003; Wagner KU, 1998, ONCOGENE, V17, P2761, DOI 10.1038/sj.onc.1202529; Wakefield LM, 2003, COMPARATIVE MED, V53, P424; Watanabe M, 1998, BIOCHEM BIOPH RES CO, V245, P900, DOI 10.1006/bbrc.1998.8547; Zhong Q, 1998, CANCER RES, V58, P2699; Zhu G, 2003, ONCOGENE, V22, P3742, DOI 10.1038/sj.onc.1206428	29	46	50	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 30	2007	26	40					5950	5959		10.1038/sj.onc.1210401	http://dx.doi.org/10.1038/sj.onc.1210401			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	205OH	17369844				2022-12-28	WOS:000249123100012
J	Kamranvar, SA; Gruhne, B; Szeles, A; Masucci, MG				Kamranvar, S. A.; Gruhne, B.; Szeles, A.; Masucci, M. G.			Epstein-Barr virus promotes genomic instability in Burkitt's lymphoma	ONCOGENE			English	Article						EBV; Burkitt's lymphoma; chromosome; aberrations; genomic instability	CELL-LINES; CHROMOSOMAL-ABERRATIONS; DNA-REPAIR; C-MYC; GENETIC INSTABILITY; B-CELLS; TELOMERASE; TRANSLOCATIONS; ABNORMALITIES; INFECTION	Epstein-Barr virus (EBV) has been implicated in the pathogenesis of human malignancies but the mechanisms of oncogenesis remain largely unknown. Genomic instability and chromosomal aberrations are hallmarks of malignant transformation. We report that EBV carriage promotes genomic instability in Burkitt's lymphoma (BL). Cytogenetic analysis of EBV-and EBV+ BL lines and their sublines derived by EBV conversion or spontaneous loss of the viral genome revealed a significant increase in dicentric chromosomes, chromosome fragments and chromatid gaps in EBV-carrying cells. Expression of EBV latency I was suf. ficient for this effect, whereas a stronger effect was observed in cells expressing latency III. Telomere analysis by. fluorescent in situ hybridization revealed an overall increase of telomere size and prevalence of telomere fusion and double strand-break fusion in dicentric chromosomes from EBV+ cells. Phosphorylated H2AX, a reporter of DNA damage and ongoing repair, was increased in virus-carrying cells in the absence of exogenous stimuli, whereas efficient activation of DNA repair was observed in both EBV + and EBV- cells following treatment withetopos ide. These. findings point to induction of telomere dysfunction and DNA damage as important mechanisms for EBV oncogenesis.	Karolinska Inst, Dept Cell & Mol Biol, S-17177 Stockholm, Sweden	Karolinska Institutet	Masucci, MG (corresponding author), Karolinska Inst, Dept Cell & Mol Biol, Box 275, S-17177 Stockholm, Sweden.	maria.masucci@ki.se	Masucci, Maria G/B-8588-2009; Masucci, Maria/AAC-6666-2019	Masucci, Maria/0000-0002-5541-2809				BERNHEIM A, 1981, CANCER GENET CYTOGEN, V3, P307, DOI 10.1016/0165-4608(81)90039-X; Cao J, 2002, MUTAT RES-FUND MOL M, V504, P85, DOI 10.1016/S0027-5107(02)00082-9; Chan SWL, 2003, MOL CELL, V11, P1379, DOI 10.1016/S1097-2765(03)00174-6; Chan WY, 2002, DIAGN MOL PATHOL, V11, P127, DOI 10.1097/00019606-200209000-00001; Chang S, 2001, SEMIN CANCER BIOL, V11, P227, DOI 10.1006/scbi.2000.0374; Chen F, 2005, INT J CANCER, V113, P284, DOI 10.1002/ijc.20594; Dolcetti R, 2003, J CELL PHYSIOL, V196, P207, DOI 10.1002/jcp.10263; Dolcetti R, 2006, PROGRESS IN VIRUS RESEARCH, P191; Gualandi G, 2001, MUTAGENESIS, V16, P203, DOI 10.1093/mutage/16.3.203; Hammerschmidt W, 2004, TRENDS MOL MED, V10, P331, DOI 10.1016/j.molmed.2004.05.006; Jox A, 1997, ANN ONCOL, V8, P131, DOI 10.1023/A:1008215207384; Karpova MB, 2006, INT J ONCOL, V28, P605; KLEIN G, 1986, AIDS RES HUM RETROV, V2, pS167; KUHNHALLEK I, 1995, BLOOD, V85, P1289, DOI 10.1182/blood.V85.5.1289.bloodjournal8551289; Liu MT, 2005, ONCOGENE, V24, P2635, DOI 10.1038/sj.onc.1208319; Liu MT, 2004, ONCOGENE, V23, P2531, DOI 10.1038/sj.onc.1207375; Lowndes NF, 2005, CURR BIOL, V15, pR99, DOI 10.1016/j.cub.2005.01.029; Mochida A, 2005, ARCH VIROL, V150, P2139, DOI 10.1007/s00705-005-0557-2; O'Nions J, 2003, ONCOGENE, V22, P7181, DOI 10.1038/sj.onc.1206838; Obe G, 2002, MUTAT RES-FUND MOL M, V504, P17, DOI 10.1016/S0027-5107(02)00076-3; Pfeffer S, 2004, SCIENCE, V304, P734, DOI 10.1126/science.1096781; Potter M, 1997, CURR TOP MICROBIOL, V224, P1; Raptis S, 2006, EXP SUPPL, V96, P303; RICKINSON AB, 1996, FIELDS VIROLOGY, P2397; ROWE M, 1987, EMBO J, V6, P2743, DOI 10.1002/j.1460-2075.1987.tb02568.x; Schuhmacher M, 1999, CURR BIOL, V9, P1255, DOI 10.1016/S0960-9822(99)80507-7; Shao JY, 2001, ANTICANCER RES, V21, P3021; Smogorzewska A, 2002, CURR BIOL, V12, P1635, DOI 10.1016/S0960-9822(02)01179-X; STOLLMANN B, 1985, BRIT J HAEMATOL, V60, P183, DOI 10.1111/j.1365-2141.1985.tb07399.x; Thorley-Lawson DA, 2001, NAT REV IMMUNOL, V1, P75, DOI 10.1038/35095584; Urushibara A, 2004, BIOCHEM BIOPH RES CO, V313, P1037, DOI 10.1016/j.bbrc.2003.12.039; YATES JL, 1985, NATURE, V313, P812, DOI 10.1038/313812a0; Young LS, 2003, ONCOGENE, V22, P5108, DOI 10.1038/sj.onc.1206556; ZattaraCannoni H, 1996, LEUKEMIA LYMPHOMA, V21, P515, DOI 10.3109/10428199609093453; ZECH L, 1976, INT J CANCER, V17, P47, DOI 10.1002/ijc.2910170108; Zimonjic DB, 2001, LEUKEMIA, V15, P1582, DOI 10.1038/sj.leu.2402281	36	77	80	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 2	2007	26	35					5115	5123		10.1038/sj.onc.1210324	http://dx.doi.org/10.1038/sj.onc.1210324			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	196MT	17325665				2022-12-28	WOS:000248487400010
J	Endo, Y; Marusawa, H; Kinoshita, K; Morisawa, T; Sakurai, T; Okazaki, IM; Watashi, K; Shimotohno, K; Honjo, T; Chiba, T				Endo, Y.; Marusawa, H.; Kinoshita, K.; Morisawa, T.; Sakurai, T.; Okazaki, I-M; Watashi, K.; Shimotohno, K.; Honjo, T.; Chiba, T.			Expression of activation-induced cytidine deaminase in human hepatocytes via NF-kappa B signaling	ONCOGENE			English	Article						activation-induced cytidine deaminase; TNF-alpha; NF-kappa B; hepatocellular carcinoma; hepatitis C virus; chronic hepatitis	CLASS-SWITCH RECOMBINATION; SOMATIC HYPERMUTATION; HEPATOCELLULAR-CARCINOMA; FACTOR-ALPHA; MEDIATED APOPTOSIS; GENE-EXPRESSION; MESSENGER-RNA; MOUSE MODEL; C-MYC; AID	Activation-induced cytidine deaminase (AID) is involved in somatic DNA alterations of the immunoglobulin gene for amplification of immune diversity. The fact that constitutive expression of AID in mice causes tumors in various organs, including lymphoid tissues and lungs, suggests the important role of the aberrant editing activity of AID on various tumor-related genes for carcinogenesis. AID expression, however, is restricted to activated B cells under physiological conditions. We demonstrate here that ectopic AID expression is induced in response to tumor necrosis factor-alpha stimulation in cultured human hepatocytes. The proinflammatory cytokine-mediated expression of AID is achieved by I kappa B kinase-dependent nuclear factor (NF)-kappa B signaling pathways. Hepatitis C virus, one of the leading causes of hepatocellular carcinoma (HCC), enhanced AID expression via NF-kappa B activation through expression of viral core protein. The aberrant expression of AID in hepatoma-derived cells resulted in accumulation of genetic alterations in the c-myc and pim1 genes, suggesting that inappropriate expression of AID acts as a DNA mutator that enhances the genetic susceptibility to mutagenesis in human hepatocytes. Our current findings indicate that the inappropriate expression of AID is induced by proinflammatory cytokine stimulation and may provide the link between hepatic inflammation and the development of HCC.	Kyoto Univ, Grad Sch Med, Dept Gastroenterol & Hepatol, Sakyo Ku, Kyoto 6068507, Japan; Shiga Med Ctr Res Inst, Moriyama, Japan; Kyoto Univ, Grad Sch Med, Dept Immunol & Genom Med, Kyoto, Japan; Kyoto Univ, Inst Virus Res, Dept Viral Oncol, Lab Human Tumor Viruses, Kyoto 606, Japan	Kyoto University; Kyoto University; Kyoto University	Chiba, T (corresponding author), Kyoto Univ, Grad Sch Med, Dept Gastroenterol & Hepatol, Sakyo Ku, 54 Kawara Cho,Shogoin, Kyoto 6068507, Japan.	chiba@kuhp.kyoto-u.ac.jp	Honjo, Tasuku/N-4470-2016	Marusawa, Hiroyuki/0000-0002-4286-2712				Aly HH, 2007, J HEPATOL, V46, P26, DOI 10.1016/j.jhep.2006.08.018; Balkwill F, 2001, LANCET, V357, P539, DOI 10.1016/S0140-6736(00)04046-0; Coulouarn C, 2006, HEPATOLOGY, V44, P1003, DOI 10.1002/hep.21293; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; Dedeoglu F, 2004, INT IMMUNOL, V16, P395, DOI 10.1093/intimm/dxh042; Doi T, 2003, P NATL ACAD SCI USA, V100, P2634, DOI 10.1073/pnas.0437710100; Feitelson MA, 2006, CANCER LETT, V239, P10, DOI 10.1016/j.canlet.2005.07.009; GONZALEZAMARO R, 1994, J EXP MED, V179, P841, DOI 10.1084/jem.179.3.841; Greeve J, 2003, BLOOD, V101, P3574, DOI 10.1182/blood-2002-08-2424; Greten FR, 2004, CELL, V118, P285, DOI 10.1016/j.cell.2004.07.013; Heintel D, 2004, LEUKEMIA, V18, P756, DOI 10.1038/sj.leu.2403294; Honjo T, 2002, ANNU REV IMMUNOL, V20, P165, DOI 10.1146/annurev.immunol.20.090501.112049; Ishii N, 2006, J VIROL, V80, P4510, DOI 10.1128/JVI.80.9.4510-4520.2006; Karin M, 2005, NAT REV IMMUNOL, V5, P749, DOI 10.1038/nri1703; Kinoshita K, 2006, INT J HEMATOL, V83, P201, DOI 10.1532/IJH97.06011; Kinoshita K, 2001, NAT REV MOL CELL BIO, V2, P493, DOI 10.1038/35080033; Kotani A, 2005, P NATL ACAD SCI USA, V102, P4506, DOI 10.1073/pnas.0500830102; Kou T, 2007, INT J CANCER, V120, P469, DOI 10.1002/ijc.22292; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Loeb LA, 2003, P NATL ACAD SCI USA, V100, P776, DOI 10.1073/pnas.0334858100; Machida K, 2004, P NATL ACAD SCI USA, V101, P4262, DOI 10.1073/pnas.0303971101; Martin A, 2002, P NATL ACAD SCI USA, V99, P12304, DOI 10.1073/pnas.192442899; Martin A, 2002, NATURE, V415, P802, DOI 10.1038/nature714; Marusawa H, 2000, HEPATOLOGY, V31, P488, DOI 10.1002/hep.510310232; Marusawa H, 1999, J VIROL, V73, P4713, DOI 10.1128/JVI.73.6.4713-4720.1999; Marusawa H, 2001, MICROBIOL IMMUNOL, V45, P483, DOI 10.1111/j.1348-0421.2001.tb02648.x; Matsumoto T, 2006, FEBS LETT, V580, P731, DOI 10.1016/j.febslet.2005.12.081; MURAKAMI H, 1993, CANCER RES, V53, P1719; Muramatsu M, 1999, J BIOL CHEM, V274, P18470, DOI 10.1074/jbc.274.26.18470; Muramatsu M, 2000, CELL, V102, P553, DOI 10.1016/S0092-8674(00)00078-7; Okazaki I, 2003, J EXP MED, V197, P1173, DOI 10.1084/jem.20030275; Okazaki IM, 2002, NATURE, V416, P340, DOI 10.1038/nature727; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Pelengaris S, 2002, NAT REV CANCER, V2, P764, DOI 10.1038/nrc904; Pikarsky E, 2004, NATURE, V431, P461, DOI 10.1038/nature02924; Revy P, 2000, CELL, V102, P565, DOI 10.1016/S0092-8674(00)00079-9; Ta VT, 2003, NAT IMMUNOL, V4, P843, DOI 10.1038/ni964; Tanaka Y, 2006, BIOCHEM BIOPH RES CO, V341, P314, DOI 10.1016/j.bbrc.2005.12.192; Tateno C, 2000, HEPATOLOGY, V31, P65, DOI 10.1002/hep.510310113; TENG BB, 1993, SCIENCE, V260, P1816, DOI 10.1126/science.8511591; Thorgeirsson SS, 2002, NAT GENET, V31, P339, DOI 10.1038/ng0802-339; TILG H, 1992, GASTROENTEROLOGY, V103, P264, DOI 10.1016/0016-5085(92)91122-K; TSUKUMA H, 1993, NEW ENGL J MED, V328, P1797, DOI 10.1056/NEJM199306243282501; Yoshikawa K, 2002, SCIENCE, V296, P2033, DOI 10.1126/science.1071556	44	136	139	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG	2007	26	38					5587	5595		10.1038/sj.onc.1210344	http://dx.doi.org/10.1038/sj.onc.1210344			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	200ZS	17404578	Green Submitted			2022-12-28	WOS:000248801900004
J	Le, LQ; Parada, LF				Le, L. Q.; Parada, L. F.			Tumor microenvironment and neurofibromatosis type I: connecting the GAPs	ONCOGENE			English	Review						neurofibromin; tumor microenvironment; mast cell; neurofibroma; NF1; GAP	GENE-PRODUCT; MAST-CELLS; ADENYLYL-CYCLASE; DROSOPHILA NF1; SCHWANN-CELLS; MOUSE MODEL; PROTEIN; MICE; INACTIVATION; MICROTUBULES	The human disease von Recklinghausen's neurofibromatosis (Nf1) is one of the most common genetic disorders. It is caused by mutations in the NF1 tumor suppressor gene, which encodes a GTPase activating protein ( GAP) that negatively regulates p21- RAS signaling. Dermal and plexiform neurofibromas as well as malignant peripheral nerve sheath tumors and other malignant tumors, are significant complications in Nf1. Neurofibromas are complex tumors and composed mainly of abnormal local cells including Schwann cells, endothelial cells, fibroblasts and additionally a large number of infiltrating inflammatory mast cells. Recent work has indicated a role for the microenvironment in plexiform neurofibroma genesis. The emerging evidence points to mast cells as crucial contributors to neurofibroma tumorigenesis. Therefore, further understanding of the molecular interactions between Schwann cells and their environment will provide tools to develop new therapies aimed at delaying or preventing tumor formation in Nf1 patients.	Univ Texas, SW Med Ctr, Ctr Basic Res Nerve Growth & Regenerat, Dept Dev Biol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Ctr Basic Res Nerve Growth & Regenerat, Kent Waldref Fdn, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Dermatol, Dallas, TX 75230 USA; Univ Texas, SW Med Ctr, Phys Sci Training Program, Dallas, TX 75230 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Le, LQ (corresponding author), Univ Texas, SW Med Ctr, Ctr Dev Biol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	Lu.Le.@UTSouthwestern.edu	Parada, luis F/B-9400-2014	Le, Lu/0000-0003-2817-5382	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P50NS052606] Funding Source: NIH RePORTER; NINDS NIH HHS [P50 NS052606, P50 NS052606-05] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Arun D, 2004, CURR OPIN NEUROL, V17, P101, DOI 10.1097/00019052-200404000-00004; Bajenaru ML, 2002, MOL CELL BIOL, V22, P5100, DOI 10.1128/MCB.22.14.5100-5113.2002; Bajenaru ML, 2003, CANCER RES, V63, P8573; BALLESTER R, 1990, CELL, V63, P851, DOI 10.1016/0092-8674(90)90151-4; BRANNAN CI, 1994, GENE DEV, V8, P1019, DOI 10.1101/gad.8.9.1019; Castle B, 2003, J MED GENET, V40, DOI 10.1136/jmg.40.10.e109; Cichowski K, 2001, CELL, V104, P593, DOI 10.1016/S0092-8674(01)00245-8; Cichowski K, 1999, SCIENCE, V286, P2172, DOI 10.1126/science.286.5447.2172; Costa RM, 2002, NATURE, V415, P526, DOI 10.1038/nature711; Dasgupta B, 2003, J NEUROSCI, V23, P8949; DASTON MM, 1992, NEURON, V8, P415, DOI 10.1016/0896-6273(92)90270-N; EASTON DF, 1993, AM J HUM GENET, V53, P305; FERNER RE, 2006, EUR J HUM GENET; GREGORY PE, 1993, SOMAT CELL MOLEC GEN, V19, P265, DOI 10.1007/BF01233074; Guo HF, 1997, SCIENCE, V276, P795, DOI 10.1126/science.276.5313.795; GUTMANN DH, 1991, P NATL ACAD SCI USA, V88, P9658, DOI 10.1073/pnas.88.21.9658; Ismat FA, 2006, J CLIN INVEST, V116, P2378, DOI 10.1172/JCI28341; JACKS T, 1994, NAT GENET, V7, P353, DOI 10.1038/ng0794-353; Jentarra Garilyn, 2006, Semin Pediatr Neurol, V13, P43, DOI 10.1016/j.spen.2006.01.010; Lakkis MM, 2000, J NEUROSCI RES, V62, P755, DOI 10.1002/1097-4547(20001215)62:6<755::AID-JNR1>3.3.CO;2-N; Levy P, 2004, MOL CANCER, V3, DOI 10.1186/1476-4598-3-20; Li WD, 2005, CURR BIOL, V15, P1961, DOI 10.1016/j.cub.2005.09.043; Mousley CJ, 2006, BIOCHEM SOC T, V34, P346, DOI 10.1042/BST0340346; Page PZ, 2006, AM J MED GENET A, V140A, P1893, DOI 10.1002/ajmg.a.31422; Parada LF, 2005, COLD SH Q B, V70, P173, DOI 10.1101/sqb.2005.70.025; Parada LF, 2000, BBA-REV CANCER, V1471, pM13, DOI 10.1016/S0304-419X(00)00014-7; Reilly KM, 2004, P NATL ACAD SCI USA, V101, P13008, DOI 10.1073/pnas.0401236101; Riccardi V. M., 1992, NEUROFIBROMATOSIS PH; Szudek J, 2000, GENET EPIDEMIOL, V19, P429, DOI 10.1002/1098-2272(200012)19:4<429::AID-GEPI13>3.0.CO;2-N; The I, 1997, SCIENCE, V276, P791, DOI 10.1126/science.276.5313.791; Theoharides TC, 2004, TRENDS IMMUNOL, V25, P235, DOI 10.1016/j.it.2004.02.013; Tong JY, 2002, NAT NEUROSCI, V5, P95, DOI 10.1038/nn792; Trovo-Marqui AB, 2006, CLIN GENET, V70, P1, DOI 10.1111/j.1399-0004.2006.00639.x; Vogel KS, 1999, SCIENCE, V286, P2176, DOI 10.1126/science.286.5447.2176; Ward BA, 2005, PEDIATR NEUROL, V32, P221, DOI 10.1016/j.pediatrneurol.2004.11.002; Weiss P, 1999, ISRAEL MED ASSOC J, V1, P89; XU GF, 1990, CELL, V62, P599, DOI 10.1016/0092-8674(90)90024-9; Xu HM, 1997, BRAIN RES, V759, P149, DOI 10.1016/S0006-8993(97)00328-4; Yang FC, 2003, J CLIN INVEST, V112, P1851, DOI 10.1172/JCI200319195; Yang FC, 2006, HUM MOL GENET, V15, P2421, DOI 10.1093/hmg/ddl165; Yohay Kaleb H, 2006, Semin Pediatr Neurol, V13, P21, DOI 10.1016/j.spen.2006.01.007; Zhu Y, 2002, SCIENCE, V296, P920, DOI 10.1126/science.1068452; Zhu Y, 2005, DEVELOPMENT, V132, P5577, DOI 10.1242/dev.02162; Zhu Y, 2001, GENE DEV, V15, P859, DOI 10.1101/gad.862101; Zhu YA, 2002, NAT REV CANCER, V2, P616, DOI 10.1038/nrc866	45	124	125	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 12	2007	26	32					4609	4616		10.1038/sj.onc.1210261	http://dx.doi.org/10.1038/sj.onc.1210261			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	190DJ	17297459	Green Accepted			2022-12-28	WOS:000248037900001
J	Garzon, R; Pichiorri, F; Palumbo, T; Visentini, M; Aqeilan, R; Cimmino, A; Wang, H; Sun, H; Volinia, S; Alder, H; Calin, GA; Liu, CG; Andreeff, M; Croce, CM				Garzon, R.; Pichiorri, F.; Palumbo, T.; Visentini, M.; Aqeilan, R.; Cimmino, A.; Wang, H.; Sun, H.; Volinia, S.; Alder, H.; Calin, G. A.; Liu, C-G; Andreeff, M.; Croce, C. M.			MicroRNA gene expression during retinoic acid-induced differentiation of human acute promyelocytic leukemia	ONCOGENE			English	Article						microRNAs; promyelocytic leukemia; NF-kappa B	NF-KAPPA-B; RAR-ALPHA; ACTIVATION; APOPTOSIS; BINDING; CELLS	MicroRNAs (miRNAs) are small non-coding RNAs of 19-25 nucleotides that are involved in the regulation of critical cell processes such as apoptosis, cell proliferation and differentiation. However, little is known about the role of miRNAs in granulopoiesis. Here, we report the expression of miRNAs in acute promyelocytic leukemia patients and cell lines during all-trans-retinoic acid (ATRA) treatment by using a miRNA microarrays platform and quantitative real time-polymerase chain reaction (qRT-PCR). We found upregulation of miR-15a, miR-15b, miR-16-1, let-7a-3, let-7c, let-7d, miR-223, miR-342 and miR-107, whereas miR-181b was downregulated. Among the upregulated miRNAs, miR-107 is predicted to target NFI-A, a gene that has been involved in a regulatory loop involving miR-223 and C/EBPa during granulocytic differentiation. Indeed, we have confirmed that miR-107 targets NF1-A. To get insights about ATRA regulation of miRNAs, we searched for ATRA-modulated transcription factors binding sites in the upstream genomic region of the let-7a-3/let-7b cluster and identified several putative nuclear factor-kappa B (NF-kappa B) consensus elements. The use of reporter gene assays, chromatin immunoprecipitation and site-directed mutagenesis revealed that one proximal NF-kappa B binding site is essential for the transactivation of the let-7a-3/let-7b cluster. Finally, we show that ATRA downregulation of RAS and Bcl2 correlate with the activation of known miRNA regulators of those proteins, let-7a and miR-15a/miR-16-1, respectively.	Ohio State Univ, Dept Mol Virol Immunol & Med Genet, Columbus, OH 43210 USA; Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA; Univ Catania, Dept Expt & Clin Pharmacol, I-95124 Catania, Italy; Univ Roma La Sapienza, Div Clin Immunol, I-00161 Rome, Italy; Univ Texas, MD Anderson Canc Ctr, Dept Blood & Bone Marrow Transplantat, Sect Mol Hematol & Therapy, Houston, TX 77030 USA	University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; University of Catania; Sapienza University Rome; University of Texas System; UTMD Anderson Cancer Center	Croce, CM (corresponding author), Ohio State Univ, Dept Mol Virol Immunol & Med Genet, Wiseman Hall,Room 445C,400 12th Ave, Columbus, OH 43210 USA.	Carlo.Croce@osumc.edu	Wang, Huating/C-6719-2014; Young, Richard A/F-6495-2012; Aqeilan, Rami/R-4443-2016; Sun, Hao/J-9964-2013; Calin, George/E-9390-2011; sun, hao/GRS-7732-2022; Volinia, Stefano/AAA-9264-2019; Aqeilan, Rami/AAT-7785-2020; Volinia, Stefano/A-3029-2010; Garzon, Ramiro/E-3104-2011; Sun, Hao/T-5576-2019; VISENTINI, MARCELLA/K-4161-2016	Wang, Huating/0000-0001-5474-2905; Young, Richard A/0000-0001-8855-8647; Aqeilan, Rami/0000-0002-6034-023X; Sun, Hao/0000-0002-5547-9501; Volinia, Stefano/0000-0003-0910-3893; Volinia, Stefano/0000-0003-0910-3893; Sun, Hao/0000-0002-5547-9501; Cimmino, Amelia/0000-0002-0004-9299; VISENTINI, MARCELLA/0000-0002-4053-6091; Calin, George/0000-0001-6704-5615	NCI NIH HHS [P01CA76259, P01CA81534, P01 CA055164, P01CA16058] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA076259, P01CA081534, P01CA055164] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Bowen DT, 2005, BLOOD, V106, P2113, DOI 10.1182/blood-2005-03-0867; BRUEL A, 1995, LEUKEMIA, V9, P1173; Chan IT, 2006, BLOOD, V108, P1708, DOI 10.1182/blood-2006-04-015040; Chen CZ, 2004, SCIENCE, V303, P83, DOI 10.1126/science.1091903; Cheng AM, 2005, NUCLEIC ACIDS RES, V33, P1290, DOI 10.1093/nar/gki200; Cimmino A, 2005, P NATL ACAD SCI USA, V102, P13944, DOI 10.1073/pnas.0506654102; Dechend R, 1999, ONCOGENE, V18, P3316, DOI 10.1038/sj.onc.1202717; Dresios J, 2005, P NATL ACAD SCI USA, V102, P1865, DOI 10.1073/pnas.0409764102; Fazi F, 2005, CELL, V123, P819, DOI 10.1016/j.cell.2005.09.023; John B, 2004, PLOS BIOL, V2, P1862, DOI 10.1371/journal.pbio.0020363; Johnson SM, 2005, CELL, V120, P635, DOI 10.1016/j.cell.2005.01.014; Kel AE, 2003, NUCLEIC ACIDS RES, V31, P3576, DOI 10.1093/nar/gkg585; Kolch W, 2005, NAT REV MOL CELL BIO, V6, P827, DOI 10.1038/nrm1743; Krek A, 2005, NAT GENET, V37, P495, DOI 10.1038/ng1536; KURLAND JF, 2001, J BIOCH CHEM, V30, P45380; Lewis BP, 2003, CELL, V115, P787, DOI 10.1016/S0092-8674(03)01018-3; Liu CG, 2004, P NATL ACAD SCI USA, V101, P9740, DOI 10.1073/pnas.0403293101; Mathieu J, 2005, ONCOGENE, V24, P7145, DOI 10.1038/sj.onc.1208889; Meani N, 2005, ONCOGENE, V24, P3358, DOI 10.1038/sj.onc.1208498; Melnick A, 1999, BLOOD, V93, P3167, DOI 10.1182/blood.V93.10.3167.410k44_3167_3215; Mori N, 1999, BLOOD, V93, P2360; Poy MN, 2004, NATURE, V432, P226, DOI 10.1038/nature03076; PRIEL IP, 2005, MOL CANC RESER, V3, P585; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Udalova IA, 2000, MOL CELL BIOL, V20, P9113, DOI 10.1128/MCB.20.24.9113-9119.2000	26	283	319	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 14	2007	26	28					4148	4157		10.1038/sj.onc.1210186	http://dx.doi.org/10.1038/sj.onc.1210186			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	178XD	17260024				2022-12-28	WOS:000247252700010
J	Cuevas, BD; Abell, AN; Johnson, GL				Cuevas, B. D.; Abell, A. N.; Johnson, G. L.			Role of mitogen-activated protein kinase kinase kinases in signal integration	ONCOGENE			English	Review						MAPK kinase kinases; MKKKs; signaling hubs	CEREBRAL CAVERNOUS MALFORMATIONS; RENAL-CELL CARCINOMA; RANDOMIZED DISCONTINUATION TRIAL; KAPPA-B PATHWAY; C-JUN; GENE-EXPRESSION; GROWTH-FACTOR; REGULATED KINASE-5; JNK ACTIVATION; BINDING DOMAIN	Mitogen-activated protein kinases (MAPKs) are members of a dynamic protein kinase network through which diverse stimuli regulate the spatio-temporal activities of complex biological systems. MAPKs regulate critical cellular functions required for homeostasis such as the expression of cytokines and proteases, cell cycle progression, cell adherence, motility and metabolism. MAPKs therefore influence cell proliferation, differentiation, survival, apoptosis and development. In vertebrates, five MAPK families are regulated by MAPK kinase kinase-MAPK kinase-MAPK (MKKK-MKK-MAPK) phosphorelay systems. There are at least 20 MKKKs that selectively phosphorylate and activate different combinations of the seven MKKs, resulting in a specific activation profile of members within the five MAPK families. MKKKs are differentially activated by upstream stimuli including cytokines, antigens, toxins and stress insults providing a mechanism to integrate the activation of different MAPKs with the cellular response to each stimulus. Thus, MKKKs can be considered as 'signaling hubs' that regulate the specificity of MAPK activation. In this review, we describe how the MKKK 'hub' function regulates the specificity of MAPK activation, highlighting MKKKs as targets for therapeutic intervention in cancer and other diseases.	Univ N Carolina, Sch Med, Dept Pharmacol, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Med, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Cuevas, BD (corresponding author), Univ N Carolina, Sch Med, Dept Pharmacol, 1108 Mary Ellen Jones Bldg,Campus Box 7365, Chapel Hill, NC 27599 USA.	bruce_cuevas@med.unc.edu; glj@med.unc.edu						Abell AN, 2005, MOL CELL BIOL, V25, P8948, DOI 10.1128/MCB.25.20.8948-8959.2005; Abell AN, 2005, J BIOL CHEM, V280, P35793, DOI 10.1074/jbc.C500260200; Akaike M, 2004, MOL CELL BIOL, V24, P8691, DOI 10.1128/MCB.24.19.8691-8704.2004; Beeram M, 2005, J CLIN ONCOL, V23, P6771, DOI 10.1200/JCO.2005.08.036; Blank JL, 1996, J BIOL CHEM, V271, P5361, DOI 10.1074/jbc.271.10.5361; Brancho D, 2005, MOL CELL BIOL, V25, P3670, DOI 10.1128/MCB.25.9.3670-3681.2005; Brown K, 2005, J MOL BIOL, V354, P1013, DOI 10.1016/j.jmb.2005.09.098; Camarero G, 2006, MOL CELL BIOL, V26, P7103, DOI 10.1128/MCB.00424-06; Castro A, 2001, BIOL CELL, V93, P15, DOI 10.1016/S0248-4900(01)01128-5; CHEN SJ, 1995, APPL SUPERCOND, V3, P15, DOI 10.1016/0964-1807(95)00026-2; Chen Z, 1999, J BIOL CHEM, V274, P28803, DOI 10.1074/jbc.274.40.28803; Chi HB, 2005, P NATL ACAD SCI USA, V102, P3846, DOI 10.1073/pnas.0500026102; Cho J, 2005, J BIOL CHEM, V280, P20442, DOI 10.1074/jbc.M413554200; Christoforidou AV, 2004, MOL CANCER, V3, DOI 10.1186/1476-4598-3-34; Cuevas BD, 2006, ONCOGENE, V25, P4998, DOI 10.1038/sj.onc.1209507; Cuevas BD, 2005, ONCOGENE, V24, P801, DOI 10.1038/sj.onc.1208239; Cuevas BD, 2003, EMBO J, V22, P3346, DOI 10.1093/emboj/cdg322; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Deng MX, 2006, MOL BIOL CELL, V17, P3446, DOI 10.1091/mbc.E06-02-0102; Dougherty MK, 2005, MOL CELL, V17, P215, DOI 10.1016/j.molcel.2004.11.055; Dumitru CD, 2000, CELL, V103, P1071, DOI 10.1016/S0092-8674(00)00210-5; Eisen T, 2006, BRIT J CANCER, V95, P581, DOI 10.1038/sj.bjc.6603291; Eliopoulos AG, 2003, EMBO J, V22, P3855, DOI 10.1093/emboj/cdg386; Fanger GR, 1997, EMBO J, V16, P4961, DOI 10.1093/emboj/16.16.4961; FIDLER IJ, 1997, ACTA ONCOL, V30, P668; Gallagher ED, 2004, J BIOL CHEM, V279, P1872, DOI 10.1074/jbc.M309525200; Gallo KA, 2002, NAT REV MOL CELL BIO, V3, P663, DOI 10.1038/nrm906; Gao M, 2004, SCIENCE, V306, P271, DOI 10.1126/science.1099414; Garrington TP, 2000, EMBO J, V19, P5387, DOI 10.1093/emboj/19.20.5387; Gerwins P, 1997, J BIOL CHEM, V272, P8288, DOI 10.1074/jbc.272.13.8288; Gollob JA, 2006, SEMIN ONCOL, V33, P392, DOI 10.1053/j.seminoncol.2006.04.002; Gorgoulis VG, 2001, CANCER RES, V61, P538; Gotoh I, 2001, J BIOL CHEM, V276, P4276, DOI 10.1074/jbc.M008595200; Hayakawa T, 2006, MICROBES INFECT, V8, P1098, DOI 10.1016/j.micinf.2005.12.001; Hayashi M, 2004, J CLIN INVEST, V113, P1138, DOI 10.1172/JCI200419890; Hollenbach E, 2004, FASEB J, V18, P1550, DOI 10.1096/fj.04-1642fje; Huang QJ, 2004, NAT IMMUNOL, V5, P98, DOI 10.1038/ni1014; Hutchison M, 1998, J BIOL CHEM, V273, P28625, DOI 10.1074/jbc.273.44.28625; Huttenlocher A, 1997, J BIOL CHEM, V272, P32719, DOI 10.1074/jbc.272.52.32719; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Irie T, 2000, FEBS LETT, V467, P160, DOI 10.1016/S0014-5793(00)01146-7; Izumi Y, 2003, CIRCULATION, V108, P2812, DOI 10.1161/01.CIR.0000096486.01652.FC; Jadrich JL, 2006, DEVELOPMENT, V133, P1529, DOI 10.1242/dev.02333; Johnson GL, 2005, CURR OPIN CHEM BIOL, V9, P325, DOI 10.1016/j.cbpa.2005.04.004; Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682; Kanayama A, 2004, MOL CELL, V15, P535, DOI 10.1016/j.molcel.2004.08.008; Karin M, 2005, IUBMB LIFE, V57, P283, DOI 10.1080/15216540500097111; Kato Y, 2000, J BIOL CHEM, V275, P18534, DOI 10.1074/jbc.M001573200; Kato Y, 1997, EMBO J, V16, P7054, DOI 10.1093/emboj/16.23.7054; Kesavan K, 2004, J CELL PHYSIOL, V199, P140, DOI 10.1002/jcp.10457; Larkin JMG, 2006, CRIT REV ONCOL HEMAT, V60, P216, DOI 10.1016/j.critrevonc.2006.06.008; Lee JW, 2005, APMIS, V113, P54, DOI 10.1111/j.1600-0463.2005.apm1130108.x; Li Y, 2005, CIRCULATION, V111, P1672, DOI 10.1161/01.CIR.0000160350.20810.0F; Liquori CL, 2003, AM J HUM GENET, V73, P1459, DOI 10.1086/380314; Lund S, 2005, J NEUROCHEM, V92, P1439, DOI 10.1111/j.1471-4159.2005.03014.x; Luo W, 2003, J BIOL CHEM, V278, P37451, DOI 10.1074/jbc.M305277200; Matsuzawa A, 2005, NAT IMMUNOL, V6, P587, DOI 10.1038/ni1200; Morrison DK, 2003, ANNU REV CELL DEV BI, V19, P91, DOI 10.1146/annurev.cellbio.19.111401.091942; Nakamura K, 2003, J BIOL CHEM, V278, P36989, DOI 10.1074/jbc.C300313200; Nicol RL, 2001, EMBO J, V20, P2757, DOI 10.1093/emboj/20.11.2757; OKA H, 1995, CANCER RES, V55, P4182; OKAZAKI K, 1995, EMBO J, V14, P5048, DOI 10.1002/j.1460-2075.1995.tb00187.x; Omori E, 2006, J BIOL CHEM, V281, P19610, DOI 10.1074/jbc.M603384200; Parameswaran N, 2006, J BIOL CHEM, V281, P34159, DOI 10.1074/jbc.M605376200; PATRIOTIS C, 1993, P NATL ACAD SCI USA, V90, P2251, DOI 10.1073/pnas.90.6.2251; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; Ratain MJ, 2006, J CLIN ONCOL, V24, P2505, DOI 10.1200/JCO.2005.03.6723; Regan CP, 2002, P NATL ACAD SCI USA, V99, P9248, DOI 10.1073/pnas.142293999; Regnier CH, 2002, P NATL ACAD SCI USA, V99, P5585, DOI 10.1073/pnas.052124799; Sagata N, 1997, BIOESSAYS, V19, P13, DOI 10.1002/bies.950190105; Sahoo T, 1999, HUM MOL GENET, V8, P2325, DOI 10.1093/hmg/8.12.2325; Sato S, 2005, NAT IMMUNOL, V6, P1087, DOI 10.1038/ni1255; Shim JH, 2005, GENE DEV, V19, P2668, DOI 10.1101/gad.1360605; Sohn SJ, 2002, J BIOL CHEM, V277, P43344, DOI 10.1074/jbc.M207573200; Sourvinos G, 1999, ONCOGENE, V18, P4968, DOI 10.1038/sj.onc.1202891; Sun WY, 2003, MOL CELL BIOL, V23, P2298, DOI 10.1128/MCB.23.7.2298-2308.2003; Sun WY, 2001, J BIOL CHEM, V276, P5093, DOI 10.1074/jbc.M003719200; Takaesu G, 2003, J MOL BIOL, V326, P105, DOI 10.1016/S0022-2836(02)01404-3; Takekawa M, 1998, CELL, V95, P521, DOI 10.1016/S0092-8674(00)81619-0; Tobiume K, 2001, EMBO REP, V2, P222, DOI 10.1093/embo-reports/kve046; Uhlik MT, 2004, BIOCHEM CELL BIOL, V82, P658, DOI 10.1139/O04-114; Uhlik MT, 2003, NAT CELL BIOL, V5, P1104, DOI 10.1038/ncb1071; Waldmeier P, 2006, BIOCHEM PHARMACOL, V72, P1197, DOI 10.1016/j.bcp.2006.06.031; Wang C, 2001, NATURE, V412, P346, DOI 10.1038/35085597; Wei XD, 2003, EUR J IMMUNOL, V33, P2903, DOI 10.1002/eji.200324127; Wellbrock C, 2004, NAT REV MOL CELL BIO, V5, P875, DOI 10.1038/nrm1498; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; Willis AE, 1999, INT J BIOCHEM CELL B, V31, P73, DOI 10.1016/S1357-2725(98)00133-2; Witowsky JA, 2003, J BIOL CHEM, V278, P1403, DOI 10.1074/jbc.C200616200; Wong CK, 2004, J BIOL CHEM, V279, P39366, DOI 10.1074/jbc.M404598200; Xia Y, 2007, MOL CELL BIOL, V27, P510, DOI 10.1128/MCB.01355-06; Xu LG, 2004, J BIOL CHEM, V279, P17278, DOI 10.1074/jbc.C400063200; Yamashita M, 2005, CELL, V121, P101, DOI 10.1016/j.cell.2005.01.035; Yan Lijun, 2003, BMC Dev Biol, V3, P11, DOI 10.1186/1471-213X-3-11; Yang JH, 2000, NAT GENET, V24, P309, DOI 10.1038/73550; YEW N, 1993, CURR OPIN GENET DEV, V3, P19, DOI 10.1016/S0959-437X(05)80336-3; Yue JB, 2006, MOL CELL BIOL, V26, P5300, DOI 10.1128/MCB.00273-06; Yujiri T, 1998, SCIENCE, V282, P1911, DOI 10.1126/science.282.5395.1911; Zawistowski JS, 2005, HUM MOL GENET, V14, P2521, DOI 10.1093/hmg/ddi256; Zhang L, 2003, EMBO J, V22, P4443, DOI 10.1093/emboj/cdg440	100	197	216	2	25	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 15	2007	26	22					3159	3171		10.1038/sj.onc.1210409	http://dx.doi.org/10.1038/sj.onc.1210409			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	169PH	17496913				2022-12-28	WOS:000246603600006
J	McKay, MM; Morrison, DK				McKay, M. M.; Morrison, D. K.			Integrating signals from RTKs to ERK/MAPK	ONCOGENE			English	Review						RTKs; ERK/MA PK; Ras; Raf; ERK scaffolds	NUCLEOTIDE EXCHANGE FACTORS; PROTEIN PHOSPHATASE 2A; RAS ACTIVATOR SON; PHOSPHORYLATION SITES; SCAFFOLD COMPLEX; KINASE PATHWAY; CAAX MOTIF; RAF-1; MECHANISM; SHP2	Signals received at the cell surface must be properly transmitted to critical targets within the cell to achieve the appropriate biological response. This process of signal transduction is often initiated by receptor tyrosine kinases (RTKs), which function as entry points for many extracellular cues and play a critical role in recruiting the intracellular signaling cascades that orchestrate a particular response. Essential for most RTK-mediated signaling is the engagement and activation of the mitogen-activated protein kinase (MAPK) cascade comprised of the Raf, MEK and extracellular signal-regulated kinase (ERK) kinases. For many years, it was thought that signaling from RTKs to ERK occurred only at the plasma membrane and was mediated by a simple, linear Ras-dependent pathway. However, the limitation of this model became apparent with the discovery that Ras and ERK can be activated at various intracellular compartments, and that RTKs can modulate Ras/ERK signaling from these sites. Moreover, ERK scaffolding proteins and signaling modulators have been identified that play critical roles in determining the strength, duration and location of RTK-mediated ERK signaling. Together, these factors contribute to the diversity of biological responses generated by RTK signaling.	NCI Frederick, Lab Cell & Dev Signaling, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC)	Morrison, DK (corresponding author), NCI Frederick, Lab Cell & Dev Signaling, POB B, Frederick, MD 21702 USA.	dmorrison@ncifcrf.gov						Abraham D, 2000, J BIOL CHEM, V275, P22300, DOI 10.1074/jbc.M003259200; Agazie YM, 2003, MOL CELL BIOL, V23, P7875, DOI 10.1128/MCB.23.21.7875-7886.2003; ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; BAASS PC, 1995, TRENDS CELL BIOL, V5, P465, DOI 10.1016/S0962-8924(00)89116-3; Bivona TG, 2006, MOL CELL, V21, P481, DOI 10.1016/j.molcel.2006.01.012; Bivona TG, 2003, NATURE, V424, P694, DOI 10.1038/nature01806; Bohn G, 2007, NAT MED, V13, P38, DOI 10.1038/nm1528; Boykevisch S, 2006, CURR BIOL, V16, P2173, DOI 10.1016/j.cub.2006.09.033; Brose N, 2002, J CELL SCI, V115, P4399, DOI 10.1242/jcs.00122; Burke P, 2001, MOL BIOL CELL, V12, P1897, DOI 10.1091/mbc.12.6.1897; Chiu VK, 2002, NAT CELL BIOL, V4, P343, DOI 10.1038/ncb783; Choy E, 1999, CELL, V98, P69, DOI 10.1016/S0092-8674(00)80607-8; Dai PG, 2006, J BIOL CHEM, V281, P927, DOI 10.1074/jbc.M507360200; Denouel-Galy A, 1998, CURR BIOL, V8, P46, DOI 10.1016/S0960-9822(98)70019-3; Dhillon AS, 2002, ARCH BIOCHEM BIOPHYS, V404, P3, DOI 10.1016/S0003-9861(02)00244-8; DIGUGLIELMO GM, 1994, EMBO J, V13, P4269, DOI 10.1002/j.1460-2075.1994.tb06747.x; Downward J, 1996, CANCER SURV, V27, P87; Ebinu JO, 1998, SCIENCE, V280, P1082, DOI 10.1126/science.280.5366.1082; Fivaz M, 2005, J CELL BIOL, V170, P429, DOI 10.1083/jcb.200409157; Freedman TS, 2006, P NATL ACAD SCI USA, V103, P16692, DOI 10.1073/pnas.0608127103; Garnett MJ, 2005, MOL CELL, V20, P963, DOI 10.1016/j.molcel.2005.10.022; Goodwin JS, 2005, J CELL BIOL, V170, P261, DOI 10.1083/jcb.200502063; Hanafusa H, 2004, J BIOL CHEM, V279, P22992, DOI 10.1074/jbc.M312498200; Hanafusa H, 2002, NAT CELL BIOL, V4, P850, DOI 10.1038/ncb867; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; Huang YZ, 2003, J BIOL CHEM, V278, P1108, DOI 10.1074/jbc.M205413200; Ishibe S, 2004, MOL CELL, V16, P257, DOI 10.1016/j.molcel.2004.10.006; Ishibe S, 2003, MOL CELL, V12, P1275, DOI 10.1016/S1097-2765(03)00406-4; Jacobs D, 1999, GENE DEV, V13, P163, DOI 10.1101/gad.13.2.163; Jaffe AB, 2005, CURR BIOL, V15, P405, DOI 10.1016/j.cub.2004.12.082; Jaffe AB, 2004, MOL CELL BIOL, V24, P1736, DOI 10.1128/MCB.24.4.1736-1746.2004; Jaumot M, 2001, ONCOGENE, V20, P3949, DOI 10.1038/sj.onc.1204526; Jiang XJ, 2002, MOL BIOL CELL, V13, P1522, DOI 10.1091/mbc.01-11-0552; Jura N, 2006, MOL CELL, V21, P679, DOI 10.1016/j.molcel.2006.02.011; KLINGHOFFER RA, 1995, J BIOL CHEM, V270, P22208, DOI 10.1074/jbc.270.38.22208; Kolch W, 2005, NAT REV MOL CELL BIO, V6, P827, DOI 10.1038/nrm1743; Li WQ, 2000, GENE DEV, V14, P895; MANSOUR SJ, 1994, J BIOCHEM-TOKYO, V116, P304, DOI 10.1093/oxfordjournals.jbchem.a124524; Margarit SM, 2003, CELL, V112, P685, DOI 10.1016/S0092-8674(03)00149-1; Marshall CJ, 1996, CURR OPIN CELL BIOL, V8, P197, DOI 10.1016/S0955-0674(96)80066-4; Matheny SA, 2004, NATURE, V427, P256, DOI 10.1038/nature02237; Montagner A, 2005, J BIOL CHEM, V280, P5350, DOI 10.1074/jbc.M410012200; Mor A, 2006, ANNU REV IMMUNOL, V24, P771, DOI 10.1146/annurev.immunol.24.021605.090723; Morrison DK, 2003, ANNU REV CELL DEV BI, V19, P91, DOI 10.1146/annurev.cellbio.19.111401.091942; Muller J, 2001, MOL CELL, V8, P983, DOI 10.1016/S1097-2765(01)00383-5; Neel BG, 2003, TRENDS BIOCHEM SCI, V28, P284, DOI 10.1016/S0968-0004(03)00091-4; Ory S, 2003, CURR BIOL, V13, P1356, DOI 10.1016/S0960-9822(03)00535-9; Pawson T, 2002, EUR J CANCER, V38, pS3, DOI 10.1016/S0959-8049(02)80597-4; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; Plowman SJ, 2005, BBA-MOL CELL RES, V1746, P274, DOI 10.1016/j.bbamcr.2005.06.004; QUILLIAM LA, 1995, BIOESSAYS, V17, P395, DOI 10.1002/bies.950170507; Ritt DA, 2007, CURR BIOL, V17, P179, DOI 10.1016/j.cub.2006.11.061; Roberts AE, 2007, NAT GENET, V39, P70, DOI 10.1038/ng1926; Rocks O, 2005, SCIENCE, V307, P1746, DOI 10.1126/science.1105654; Rodrigues A. C. C., 2006, Revista Brasileira de Plantas Medicinais, V8, P1; Rodriguez-Viciana P, 2006, MOL CELL, V22, P217, DOI 10.1016/j.molcel.2006.03.027; Rushworth LK, 2006, MOL CELL BIOL, V26, P2262, DOI 10.1128/MCB.26.6.2262-2272.2006; Sasaki A, 2003, NAT CELL BIOL, V5, P427, DOI 10.1038/ncb978; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Sondermann H, 2004, CELL, V119, P393, DOI 10.1016/j.cell.2004.10.005; Sorkin A, 2002, NAT REV MOL CELL BIO, V3, P600, DOI 10.1038/nrm883; Tartaglia M, 2007, NAT GENET, V39, P75, DOI 10.1038/ng1939; Teis D, 2002, DEV CELL, V3, P803, DOI 10.1016/S1534-5807(02)00364-7; Teis D, 2006, J CELL BIOL, V175, P861, DOI 10.1083/jcb.200607025; Torii S, 2004, DEV CELL, V7, P33, DOI 10.1016/j.devcel.2004.05.019; Wakioka T, 2001, NATURE, V412, P647, DOI 10.1038/35088082; Wan PTC, 2004, CELL, V116, P855, DOI 10.1016/S0092-8674(04)00215-6; Weber CK, 2001, CANCER RES, V61, P3595; Wellbrock C, 2004, NAT REV MOL CELL BIO, V5, P875, DOI 10.1038/nrm1498; Wunderlich W, 2001, J CELL BIOL, V152, P765, DOI 10.1083/jcb.152.4.765; Yeung K, 2000, MOL CELL BIOL, V20, P3079, DOI 10.1128/MCB.20.9.3079-3085.2000; Yu W, 1998, CURR BIOL, V8, P56, DOI 10.1016/S0960-9822(98)70020-X; Zhang SQ, 2004, MOL CELL, V13, P341, DOI 10.1016/S1097-2765(04)00050-4; ZHENG CF, 1994, EMBO J, V13, P1123, DOI 10.1002/j.1460-2075.1994.tb06361.x; Zhou M, 2002, J MOL BIOL, V315, P435, DOI 10.1006/jmbi.2001.5263; Ziogas A, 2005, J BIOL CHEM, V280, P24205, DOI 10.1074/jbc.M413327200	76	428	440	0	49	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 15	2007	26	22					3113	3121		10.1038/sj.onc.1210394	http://dx.doi.org/10.1038/sj.onc.1210394			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	169PH	17496910				2022-12-28	WOS:000246603600003
J	Ueki, N; Zhang, L; Haymann, MJ				Ueki, N.; Zhang, L.; Haymann, M. J.			Ski can negatively regulates macrophage differentiation through its interaction with PU.1	ONCOGENE			English	Article						ski oncoprotein; PU.1; HDAC3; hematopoiesis; leukemogenesis; transcriptional repression	TRANSFORMING-GROWTH-FACTOR; TRANSCRIPTION FACTOR PU.1; ACUTE MYELOID-LEUKEMIA; CO-REPRESSOR; ERYTHROID-DIFFERENTIATION; V-SKI; HEMATOPOIETIC-CELLS; LINEAGE COMMITMENT; DNA-BINDING; ONCOPROTEIN	In the hematopoietic cell system, the oncoprotein Ski dramatically affects growth and differentiation programs, in some cases leading to malignant leukemia. However, little is known about the interaction partners or signaling pathways involved in the Ski-mediated block of differentiation in hematopoietic cells. Here we show that Ski interacts with PU.1, a lineage-specific transcription factor essential for terminal myeloid differentiation, and thereby represses PU.1-dependent transcriptional activation. Consistent with this, Ski inhibits the biological function of PU.1 to promote myeloid cells to differentiate into macrophage colony-stimulating factor receptor (M-CSFR)positive macrophages. Using a Ski mutant deficient in PU.1 binding, we demonstrate that Ski-PU.1 interaction is critical for Ski's ability to repress PU.1-dependent transcription and block macrophage differentiation. Furthermore, we provide evidence that Ski-mediated repression of PU.1 is due to Ski's ability to recruit histone deacetylase 3 to PU.1 bound to DNA. Since inactivation of PU.1 is closely related to the development of myeloid leukemia and Ski strongly inhibits PU.1 function, we propose that aberrant Ski expression in certain types of myeloid cell lineages might contribute to leukemogenesis.	[Ueki, N.; Zhang, L.; Haymann, M. J.] SUNY Stony Brook, Dept Mol Genet & Microbiol, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Haymann, MJ (corresponding author), SUNY Stony Brook, Dept Mol Genet & Microbiol, Stony Brook, NY 11794 USA.	mhayman@ms.cc.sunysb.edu			NATIONAL CANCER INSTITUTE [R01CA042573] Funding Source: NIH RePORTER; NCI NIH HHS [CA42573, R01 CA042573-20, R01 CA042573] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akiyoshi S, 1999, J BIOL CHEM, V274, P35269, DOI 10.1074/jbc.274.49.35269; Ano S, 2004, J BIOL CHEM, V279, P2993, DOI 10.1074/jbc.M303816200; Behre G, 1999, J BIOL CHEM, V274, P4939, DOI 10.1074/jbc.274.8.4939; BEUG H, 1995, ONCOGENE, V11, P59; Dahl R, 1998, P NATL ACAD SCI USA, V95, P11187, DOI 10.1073/pnas.95.19.11187; Dahl R, 2003, BLOOD CELL MOL DIS, V31, P229, DOI 10.1016/S1079-9796(03)00152-9; Dahl R, 2007, J BIOL CHEM, V282, P6473, DOI 10.1074/jbc.M607613200; Fukuchi M, 2004, INT J CANCER, V108, P818, DOI 10.1002/ijc.11651; Jepsen K, 2002, J CELL SCI, V115, P689; Khan MM, 2001, MOL CELL, V7, P1233, DOI 10.1016/S1097-2765(01)00257-X; Kronenwett R, 2005, ONCOGENE, V24, P5313, DOI 10.1038/sj.onc.1208596; LARSEN J, 1992, ONCOGENE, V7, P1903; LARSEN J, 1993, ONCOGENE, V8, P3221; Liu XD, 2001, CYTOKINE GROWTH F R, V12, P1, DOI 10.1016/S1359-6101(00)00031-9; Luo KX, 1999, GENE DEV, V13, P2196, DOI 10.1101/gad.13.17.2196; McKercher SR, 1996, EMBO J, V15, P5647, DOI 10.1002/j.1460-2075.1996.tb00949.x; Metcalf D, 2006, P NATL ACAD SCI USA, V103, P1486, DOI 10.1073/pnas.0510616103; MoreauGachelin F, 1996, MOL CELL BIOL, V16, P2453; Nomura T, 1999, GENE DEV, V13, P412, DOI 10.1101/gad.13.4.412; Ohneda K, 2002, ACTA HAEMATOL-BASEL, V108, P237, DOI 10.1159/000065660; Reddy VA, 2002, BLOOD, V100, P483, DOI 10.1182/blood.V100.2.483; Reed JA, 2001, CANCER RES, V61, P8074; Rekhtman N, 1999, GENE DEV, V13, P1398, DOI 10.1101/gad.13.11.1398; Ritter M, 2006, LEUKEMIA, V20, P437, DOI 10.1038/sj.leu.2404093; Rosenbauer F, 2004, NAT GENET, V36, P624, DOI 10.1038/ng1361; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; Simon MC, 1996, CURR TOP MICROBIOL, V211, P113; STAVNEZER E, 1981, J VIROL, V39, P920, DOI 10.1128/JVI.39.3.920-934.1981; Sun Y, 1999, MOL CELL, V4, P499, DOI 10.1016/S1097-2765(00)80201-4; Suzuki M, 2003, ONCOGENE, V22, P8688, DOI 10.1038/sj.onc.1207182; Tokitou F, 1999, J BIOL CHEM, V274, P4485, DOI 10.1074/jbc.274.8.4485; Ueki N, 2004, MOL CELL BIOL, V24, P10118, DOI 10.1128/MCB.24.23.10118-10125.2004; Ueki N, 2003, J BIOL CHEM, V278, P32489, DOI 10.1074/jbc.C300276200; Ueki N, 2003, J BIOL CHEM, V278, P24858, DOI 10.1074/jbc.M303447200; Vangala RK, 2003, BLOOD, V101, P270, DOI 10.1182/blood-2002-04-1288; Xu WD, 2000, P NATL ACAD SCI USA, V97, P5924, DOI 10.1073/pnas.090097797; ZHANG DE, 1994, MOL CELL BIOL, V14, P373, DOI 10.1128/MCB.14.1.373; Zhang P, 2000, BLOOD, V96, P2641; Zhang P, 1999, P NATL ACAD SCI USA, V96, P8705, DOI 10.1073/pnas.96.15.8705	39	23	25	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 10	2008	27	3					300	307		10.1038/sj.onc.1210654	http://dx.doi.org/10.1038/sj.onc.1210654			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	249UR	17621263	Green Accepted			2022-12-28	WOS:000252256000005
J	Pilkinton, M; Sandoval, R; Colamonici, OR				Pilkinton, M.; Sandoval, R.; Colamonici, O. R.			Mammalian Mip/LIN-9 interacts with either the p107, p130/E2F4 repressor complex or B-Myb in a cell cycle-phase-dependent context distinct from the Drosophila dREAM complex	ONCOGENE			English	Article						cell cycle; LIN-9; pocket proteins; CDK; cyclin; Myb	IN-VIVO; PROTEIN; TRANSCRIPTION; PHOSPHORYLATION; E2F; ACTIVATION; IDENTIFICATION; EXPRESSION; LIN-9; PRB	Mammalian Mip/LIN-9 is a cell cycle regulatory protein that is negatively regulated by CDK4/cyclin D. It has been demonstrated that Mip/LIN-9 collaborates with B-Myb during S and G2/M in the induction of cyclins A and B, and CDK1. The ortholog of Mip/LIN-9 in (D) under bar rosophila, Mip130, is part of a large multisubunit protein complex that includes (R) under bar BF, repressor (E) under bar 2Fs (a) under bar nd (M) under bar yb, in what was termed the dREAM complex. A similar complex, although lacking B-Myb, was also described in Caenorhabditis elegans. Here, we demonstrate that unlike Drosophila, Mip/LIN-9 has mutually exclusive and cell cycle-phasespeci. c interactions with the mammalian orthologs of the dREAM complex. In G(0)/early G(1), Mip/LIN-9 forms a complex with E2F4 and p107 or p130, while in late G(1)/S phase, it associates with B-Myb. The separation of Mip/LIN-9 from p107, p130/E2F4 is likely driven by phosphorylation of the pocket proteins by CDK4 since Mip/LIN-9 fails to interact with phosphorylated forms of p107, p130. Importantly, the repressor complex that Mip/LIN-9 forms with p107 takes functional precedence over the transcriptional activation linked to the Mip/LIN-9 and B-Myb interaction since expression of p107 blocks the activation of the cyclin B promoter triggered by B-Myb and Mip/LIN-9.	Univ Illinois, Dept Pharmacol, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Colamonici, OR (corresponding author), Univ Illinois, Dept Pharmacol, 835 S Wolcott,Room E403 M-C 868, Chicago, IL 60612 USA.	ocolamon@uic.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007739] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054709] Funding Source: NIH RePORTER; NIDDK NIH HHS [T32 DK07739] Funding Source: Medline; NIGMS NIH HHS [GM54709] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bartsch O, 1999, EUR J BIOCHEM, V260, P384, DOI 10.1046/j.1432-1327.1999.00191.x; Beall EL, 2004, GENE DEV, V18, P1667, DOI 10.1101/gad.1206604; Beall EL, 2002, NATURE, V420, P833, DOI 10.1038/nature01228; BEIJERSBERGEN RL, 1995, GENE DEV, V9, P1340, DOI 10.1101/gad.9.11.1340; Beitel GJ, 2000, GENE, V254, P253, DOI 10.1016/S0378-1119(00)00296-1; Bhatt AM, 2004, GENE, V336, P219, DOI 10.1016/j.gene.2004.03.033; Bruce JL, 2000, MOL CELL, V6, P737, DOI 10.1016/S1097-2765(00)00072-1; Burgess A, 2006, J BIOL CHEM, V281, P9987, DOI 10.1074/jbc.M512714200; CHIPPERFIELD RG, 1985, MOL CELL BIOL, V5, P1809, DOI 10.1128/MCB.5.8.1809; Ciemerych MA, 2005, ONCOGENE, V24, P2877, DOI 10.1038/sj.onc.1208608; Classon M, 2002, NAT REV CANCER, V2, P910, DOI 10.1038/nrc950; Classon M, 2001, EXP CELL RES, V264, P135, DOI 10.1006/excr.2000.5135; Cobrinik D, 2005, ONCOGENE, V24, P2796, DOI 10.1038/sj.onc.1208619; Dimova DK, 2005, ONCOGENE, V24, P2810, DOI 10.1038/sj.onc.1208612; Du W, 2006, ONCOGENE, V25, P5190, DOI 10.1038/sj.onc.1209651; FERGUSON EL, 1989, GENETICS, V123, P109; Gabrielli BG, 1999, J BIOL CHEM, V274, P13961, DOI 10.1074/jbc.274.20.13961; Gagrica S, 2004, EMBO J, V23, P4627, DOI 10.1038/sj.emboj.7600470; GIBBS CS, 1994, BIOCHEMISTRY-US, V33, P14003, DOI 10.1021/bi00251a007; Hurford RK, 1997, GENE DEV, V11, P1447, DOI 10.1101/gad.11.11.1447; Joaquin M, 2003, CELL MOL LIFE SCI, V60, P2389, DOI 10.1007/s00018-003-3037-4; Johnson LR, 2002, J BIOL CHEM, V277, P4088, DOI 10.1074/jbc.M105112200; Korenjak M, 2004, CELL, V119, P181, DOI 10.1016/j.cell.2004.09.034; Lane S, 1997, ONCOGENE, V14, P2445, DOI 10.1038/sj.onc.1201086; Leng XH, 2002, MOL CELL BIOL, V22, P2242, DOI 10.1128/MCB.22.7.2242-2254.2002; Lewis PW, 2004, GENE DEV, V18, P2929, DOI 10.1101/gad.1255204; Muller-Tidow C, 2001, BLOOD, V97, P2091, DOI 10.1182/blood.V97.7.2091; Ness SA, 2003, BLOOD CELL MOL DIS, V31, P192, DOI 10.1016/S1079-9796(03)00151-7; Oh IH, 1999, ONCOGENE, V18, P3017, DOI 10.1038/sj.onc.1202839; Osterloh L, 2007, EMBO J, V26, P144, DOI 10.1038/sj.emboj.7601478; Petrovas C, 2003, ONCOGENE, V22, P2011, DOI 10.1038/sj.onc.1206231; Pilkinton M, 2007, J BIOL CHEM, V282, P168, DOI 10.1074/jbc.M609924200; Rayman JB, 2002, GENE DEV, V16, P933, DOI 10.1101/gad.969202; Ren SJ, 2004, CELL, V117, P239, DOI 10.1016/S0092-8674(04)00300-9; Robinson C, 1996, ONCOGENE, V12, P1855; Sala A, 1997, P NATL ACAD SCI USA, V94, P532, DOI 10.1073/pnas.94.2.532; Sala A, 1999, J CELL PHYSIOL, V179, P245; Sandoval R, 2006, EXP CELL RES, V312, P2465, DOI 10.1016/j.yexcr.2006.04.002; Saville MK, 1998, ONCOGENE, V17, P2679, DOI 10.1038/sj.onc.1202503; Saville MK, 1998, ADV CANCER RES, V72, P109; Sherr CJ, 2004, GENE DEV, V18, P2699, DOI 10.1101/gad.1256504; Sherr CJ, 2004, CELL, V116, P235, DOI 10.1016/S0092-8674(03)01075-4; Sherr CJ, 2002, CANCER CELL, V2, P103, DOI 10.1016/S1535-6108(02)00102-2; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Takahashi Y, 2000, GENE DEV, V14, P804; Vousden K H, 1990, Semin Cancer Biol, V1, P415; White-Cooper H, 1998, DEVELOPMENT, V125, P125; White-Cooper H, 2000, DEVELOPMENT, V127, P5463; Xiao ZX, 1996, P NATL ACAD SCI USA, V93, P4633, DOI 10.1073/pnas.93.10.4633; Zhu WC, 2004, EMBO J, V23, P4615, DOI 10.1038/sj.emboj.7600459; Ziebold U, 1997, CURR BIOL, V7, P253, DOI 10.1016/S0960-9822(06)00121-7	51	87	89	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 29	2007	26	54					7535	7543		10.1038/sj.onc.1210562	http://dx.doi.org/10.1038/sj.onc.1210562			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	236DB	17563750				2022-12-28	WOS:000251282100005
J	Lastowska, M; Viprey, V; Santibanez-Koref, M; Wappler, I; Peters, H; Cullinane, C; Roberts, P; Hall, AG; Tweddle, DA; Pearson, ADJ; Lewis, I; Burchill, SA; Jackson, MS				Lastowska, M.; Viprey, V.; Santibanez-Koref, M.; Wappler, I.; Peters, H.; Cullinane, C.; Roberts, P.; Hall, A. G.; Tweddle, D. A.; Pearson, A. D. J.; Lewis, I.; Burchill, S. A.; Jackson, M. S.			Identification of candidate genes involved in neuroblastoma progression by combining genomic and expression microarrays with survival data	ONCOGENE			English	Article						neuroblastoma; expression arrays; SNP arrays; candidate genes	HIGH-RESOLUTION ANALYSIS; TUMOR-SUPPRESSOR GENE; N-MYC ONCOGENE; COPY NUMBER; CHROMOSOME 1P; ALLELIC LOSS; 17Q; AMPLIFICATION; CGH; ABNORMALITIES	Identifying genes, whose expression is consistently altered by chromosomal gains or losses, is an important step in defining genes of biological relevance in a wide variety of tumour types. However, additional criteria are needed to discriminate further among the large number of candidate genes identified. This is particularly true for neuroblastoma, where multiple genomic copy number changes of proven prognostic value exist. We have used Affymetrix microarrays and a combination of. fluorescentin situ hybridization and single nucleotide polymorphism (SNP) microarrays to establish expression profiles and delineate copy number alterations in 30 primary neuroblastomas. Correlation of microarray data with patient survival and analysis of expression within rodent neuroblastoma cell lines were then used to define further genes likely to be involved in the disease process. Using this approach, we identify > 1000 genes within eight recurrent genomic alterations (loss of 1p, 3p, 4p, 10q and 11q, 2p gain, 17q gain, and the MYCN amplicon) whose expression is consistently altered by copy number change. Of these, 84 correlate with patient survival, with the minimal regions of 17q gain and 4p loss being enriched significantly for such genes. These include genes involved in RNA and DNA metabolism, and apoptosis. Orthologues of all but one of these genes on 17q are overexpressed in rodent neuroblastoma cell lines. A significant excess of SNPs whose copy number correlates with survival is also observed on proximal 4p in stage 4 tumours, and we find that deletion of 4p is associated with improved outcome in an extended cohort of tumours. These results de. ne the major impact of genomic copy number alterations upon transcription within neuroblastoma, and highlight genes on distal 17q and proximal 4p for downstream analyses. They also suggest that integration of discriminators, such as survival and comparative gene expression, with microarray data be useful in the identification of critical genes within regions of loss or gain in many human cancers.	Int Ctr Life, Inst Human Genet, Newcastle Upon Tyne NE1 3BZ, Tyne & Wear, England; St James Univ Hosp, Canc Res UK Clin Ctr, Childrens Canc Res Lab, Leeds, W Yorkshire, England; St James Univ Hosp, Dept Pathol, Leeds LS9 7TF, W Yorkshire, England; St James Univ Hosp, Dept Cytogenet, Leeds LS9 7TF, W Yorkshire, England; Newcastle Univ, Northern Inst Canc Res, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; Inst Canc Res, Sutton, Surrey, England; St James Univ Hosp, Dept Paediat Oncol & Haematol, Leeds LS9 7TF, W Yorkshire, England	Newcastle University - UK; Cancer Research UK; Saint James's University Hospital; University of Leeds; Saint James's University Hospital; Saint James's University Hospital; Newcastle University - UK; University of London; Institute of Cancer Research - UK; Saint James's University Hospital	Jackson, MS (corresponding author), Int Ctr Life, Inst Human Genet, Central Parkway, Newcastle Upon Tyne NE1 3BZ, Tyne & Wear, England.	m.s.jackson@ncl.ac.uk	Hall, Andrew G/B-3485-2009	Viprey, Virginie/0000-0001-6463-7092; Jackson, Michael/0000-0001-7179-1354; Lastowska, Maria/0000-0003-0632-6995				Ambros PF, 2001, MED PEDIATR ONCOL, V37, P492, DOI 10.1002/mpo.1242; Asgharzadeh S, 2006, JNCI-J NATL CANCER I, V98, P1193, DOI 10.1093/jnci/djj330; Attiyeh EF, 2005, NEW ENGL J MED, V353, P2243, DOI 10.1056/NEJMoa052399; Bown N, 1999, NEW ENGL J MED, V340, P1954, DOI 10.1056/NEJM199906243402504; BOWN NP, 1994, MED PEDIATR ONCOL, V23, P124, DOI 10.1002/mpo.2950230210; BRODEUR GM, 1993, J CLIN ONCOL, V11, P1466, DOI 10.1200/JCO.1993.11.8.1466; Bussey KJ, 2006, MOL CANCER THER, V5, P853, DOI 10.1158/1535-7163.MCT-05-0155; Caron H, 1996, NEW ENGL J MED, V334, P225, DOI 10.1056/NEJM199601253340404; Caron H, 1996, HUM GENET, V97, P834; Chen QR, 2006, GENE CHROMOSOME CANC, V45, P856, DOI 10.1002/gcc.20349; Chen QR, 2004, BMC GENOMICS, V5, DOI 10.1186/1471-2164-5-70; De Preter K, 2005, J CLIN ONCOL, V23, P3167, DOI 10.1200/JCO.2005.05.346; Deng CX, 2006, NUCLEIC ACIDS RES, V34, P1416, DOI 10.1093/nar/gkl010; Fischer M, 2005, J MOL DIAGN, V7, P89, DOI 10.1016/S1525-1578(10)60013-X; Hackett CS, 2003, CANCER RES, V63, P5266; Henrich KO, 2006, CLIN CANCER RES, V12, P131, DOI 10.1158/1078-0432.CCR-05-1431; Huang Jing, 2004, Human Genomics, V1, P287; Janoueix-Lerosey I, 2004, ONCOGENE, V23, P5912, DOI 10.1038/sj.onc.1207784; Lastowska M, 1997, GENE CHROMOSOME CANC, V18, P162; Lastowska M, 2004, GENE CHROMOSOME CANC, V40, P158, DOI 10.1002/gcc.20031; Lastowska M, 2002, GENE CHROMOSOME CANC, V34, P428, DOI 10.1002/gcc.10089; Lastowska M, 2001, J CLIN ONCOL, V19, P3080; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Miller MA, 2006, J PEDIAT HEMATOL ONC, V28, P412, DOI 10.1097/01.mph.0000212937.00287.e5; Nannya Y, 2005, CANCER RES, V65, P6071, DOI 10.1158/0008-5472.CAN-05-0465; Nigro JM, 2005, CANCER RES, V65, P1678, DOI 10.1158/0008-5472.CAN-04-2921; NISEN PD, 1988, J NATL CANCER I, V80, P1633, DOI 10.1093/jnci/80.20.1633; Perri P, 2002, ONCOGENE, V21, P8356, DOI 10.1038/sj.onc.1206009; Popescu NC, 1997, CANCER GENET CYTOGEN, V93, P10, DOI 10.1016/S0165-4608(96)00262-2; Rao CR, 1973, LINEAR STAT INTERFER; Schleiermacher G, 2005, ONCOGENE, V24, P3377, DOI 10.1038/sj.onc.1208486; SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802; SELTZER R, 2005, GENE CHROMOSOME CANC, V44, P305; SLAVC I, 1990, CANCER RES, V50, P1459; Stallings RL, 2006, CANCER RES, V66, P3673, DOI 10.1158/0008-5472.CAN-05-4154; Tsafrir D, 2006, CANCER RES, V66, P2129, DOI 10.1158/0008-5472.CAN-05-2569; Vandesompele J, 2005, J CLIN ONCOL, V23, P2280, DOI 10.1200/JCO.2005.06.104; Walker BA, 2006, BLOOD, V108, P1733, DOI 10.1182/blood-2006-02-005496; Wang Q, 2006, CANCER RES, V66, P6050, DOI 10.1158/0008-5472.CAN-05-4618; Weber A, 2004, J CLIN ONCOL, V22, P2681, DOI 10.1200/JCO.2004.07.192	41	65	67	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 22	2007	26	53					7432	7444		10.1038/sj.onc.1210552	http://dx.doi.org/10.1038/sj.onc.1210552			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	236DA	17533364				2022-12-28	WOS:000251282000005
J	Hesson, LB; Cooper, WN; Latif, F				Hesson, L. B.; Cooper, W. N.; Latif, F.			Evaluation of the 3p21.3 tumour-suppressor gene cluster	ONCOGENE			English	Review						3p21.3; RASSFIA; epigenetics; tumor suppressor gene	JAAGSIEKTE SHEEP RETROVIRUS; HOMOZYGOUS DELETION REGION; HUMAN-CHROMOSOME 3P21.3; CELL LUNG-CANCER; ADENOVIRUS E1A-ASSOCIATED PROTEIN; ISLAND PROMOTER HYPERMETHYLATION; FREQUENT EPIGENETIC INACTIVATION; CPG ISLAND; K-RAS; ABERRANT METHYLATION	Deletions of the 3p21.3 region are a frequent and early event in the formation of lung, breast, kidney and other cancers. Intense investigation of allelic losses and the discovery of overlapping homozygous deletions in lung and breast tumour-cell lines have defined a minimal critical 120 kb deletion region containing eight genes and likely to harbor one or more tumour-suppressor genes (TSGs). The candidate genes are HYAL2, FUS1, Ras-associated factor 1 (RASSF1), BLU/ZMYND10, NPR2L, 101F6, PL6 and CACNA2D2. Recent research indicates that several of these genes can suppress the growth of lung and other tumour cells. Furthermore, some genes (RASSF1A and BLU/ZMYND10) are very frequently inactivated by non-classical mechanisms such as promoter hypermethylation resulting in loss of expression. These data indicate that the 120 kb critical deletion region at 3p21.3 may represent a TSG cluster with preferential inactivation of particular genes depending on tumour type. The eight genes within this region and their potential role in cancer will be the focus of this review.	Univ Birmingham, Biomed Res Inst, Div Reprod & Child Hlth, Dept Med & Mol Genet, Birmingham B15 2TT, W Midlands, England; Univ Dundee, Coll Life Sci, MRC Protein Phosphorylat Unit, Dundee, Scotland	University of Birmingham; University of Dundee	Latif, F (corresponding author), Univ Birmingham, Biomed Res Inst, Div Reprod & Child Hlth, Dept Med & Mol Genet, Birmingham B15 2TT, W Midlands, England.	L.Hesson@dundee.ac.uk; f.latif@bham.ac.uk	Hesson, Luke/HDM-0311-2022		Breast Cancer Now [2005NOV13] Funding Source: Medline	Breast Cancer Now		Abe M, 2005, CANCER RES, V65, P828; Agathanggelou A, 2003, ONCOGENE, V22, P1580, DOI 10.1038/sj.onc.1206243; Agathanggelou A, 2005, CANCER RES, V65, P3497, DOI 10.1158/0008-5472.CAN-04-4088; Agathanggelou A, 2003, CANCER RES, V63, P5344; Ahmed-Choudhury J, 2005, CANCER RES, V65, P2690, DOI 10.1158/0008-5472.CAN-04-3593; Akino K, 2005, GASTROENTEROLOGY, V129, P156, DOI 10.1053/j.gastro.2005.03.051; Alden KJ, 2001, J PHARMACOL EXP THER, V297, P727; Amann JM, 2001, MOL CELL BIOL, V21, P6470, DOI 10.1128/MCB.21.19.6470-6483.2001; Anantharaman V, 2000, TRENDS BIOCHEM SCI, V25, P535, DOI 10.1016/S0968-0004(00)01672-8; Aoyama Y, 2004, ONCOGENE, V23, P3426, DOI 10.1038/sj.onc.1207486; Armesilla AL, 2004, J BIOL CHEM, V279, P31318, DOI 10.1074/jbc.M307557200; Bais AJ, 2004, MOL CANCER, V3, DOI 10.1186/1476-4598-3-22; Baksh S, 2005, MOL CELL, V18, P637, DOI 10.1016/j.molcel.2005.05.010; Barclay J, 2001, J NEUROSCI, V21, P6095, DOI 10.1523/JNEUROSCI.21-16-06095.2001; Bertrand P, 2005, INT J CANCER, V113, P207, DOI 10.1002/ijc.20562; Bourguignon LYW, 2004, J BIOL CHEM, V279, P26991, DOI 10.1074/jbc.M311838200; Brena RM, 2006, PLOS MED, V3, P2184, DOI 10.1371/journal.pmed.0030479; Brodbeck J, 2002, J BIOL CHEM, V277, P7684, DOI 10.1074/jbc.M109404200; Carboni GL, 2003, ONCOGENE, V22, P615, DOI 10.1038/sj.onc.1206134; Chen JD, 2003, CANCER CELL, V4, P405, DOI 10.1016/S1535-6108(03)00269-1; Chow LSN, 2004, INT J CANCER, V109, P839, DOI 10.1002/ijc.20079; Chow LSN, 2004, ONCOL REP, V12, P781; Csoka AB, 1999, GENOMICS, V60, P356, DOI 10.1006/geno.1999.5876; Csoka AB, 2001, MATRIX BIOL, V20, P499, DOI 10.1016/S0945-053X(01)00172-X; Dallol A, 2005, CANCER RES, V65, P7653, DOI 10.1158/0008-5472.CAN-05-0247; Dallol A, 2004, CANCER RES, V64, P4112, DOI 10.1158/0008-5472.CAN-04-0267; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; Danilkovitch-Miagkova A, 2003, P NATL ACAD SCI USA, V100, P4580, DOI 10.1073/pnas.0837136100; De las Heras M, 2000, EUR RESPIR J, V16, P330, DOI 10.1034/j.1399-3003.2000.16b23.x; Eckfeld K, 2004, CANCER RES, V64, P8688, DOI 10.1158/0008-5472.CAN-04-2065; Endoh M, 2005, BRIT J CANCER, V93, P1395, DOI 10.1038/sj.bjc.6602854; Enegd B, 2002, NEUROSURGERY, V50, P1311, DOI 10.1097/00006123-200206000-00023; Falvella FS, 2006, ONCOGENE, V25, P3934, DOI 10.1038/sj.onc.1209422; Fenton SL, 2004, CANCER RES, V64, P102, DOI 10.1158/0008-5472.CAN-03-2622; Fischer WH, 1996, J NEUROCHEM, V66, P2213; Fletcher CF, 2001, FASEB J, V15, P1288, DOI 10.1096/fj.00-0562fje; Frigola J, 2006, NAT GENET, V38, P540, DOI 10.1038/ng1781; Gao BN, 2000, J BIOL CHEM, V275, P12237, DOI 10.1074/jbc.275.16.12237; Gopalan B, 2004, TECHNOL CANCER RES T, V3, P647, DOI 10.1177/153303460400300615; Gurnett CA, 1996, NEURON, V16, P431, DOI 10.1016/S0896-6273(00)80061-6; Harjes E, 2006, STRUCTURE, V14, P881, DOI 10.1016/j.str.2006.03.008; HARJES E, 2006, NEURON, V14, P881; HATEBOER G, 1995, EMBO J, V14, P3159, DOI 10.1002/j.1460-2075.1995.tb07318.x; Hesson L, 2004, ONCOGENE, V23, P2408, DOI 10.1038/sj.onc.1207407; Hesson L, 2003, ONCOGENE, V22, P947, DOI 10.1038/sj.onc.1206191; Hesson LB, 2005, ONCOGENE, V24, P3987, DOI 10.1038/sj.onc.1208566; Hesson LB, 2007, DIS MARKERS, V23, P73, DOI 10.1155/2007/291538; HUNG J, 1995, JAMA-J AM MED ASSOC, V273, P1908; Irimia M, 2004, ONCOGENE, V23, P8695, DOI 10.1038/sj.onc.1207914; Ito I, 2004, CANCER GENE THER, V11, P733, DOI 10.1038/sj.cgt.7700756; Ito M, 2005, CANCER LETT, V225, P131, DOI 10.1016/j.canlet.2004.10.041; Ivanov SV, 2004, AM J PATHOL, V165, P1007, DOI 10.1016/S0002-9440(10)63362-7; Ji L, 2002, CANCER RES, V62, P2715; Khokhlatchev A, 2002, CURR BIOL, V12, P253, DOI 10.1016/S0960-9822(02)00683-8; Kitagawa D, 2006, EMBO J, V25, P3286, DOI 10.1038/sj.emboj.7601212; Klugbauer N, 1999, J NEUROSCI, V19, P684; Kochetkova M, 2002, CANCER RES, V62, P4599; Kok K, 1997, ADV CANCER RES, V71, P27, DOI 10.1016/S0065-230X(08)60096-2; Kondo M, 2001, ONCOGENE, V20, P6258, DOI 10.1038/sj.onc.1204832; Ladendorff NE, 2001, ONCOGENE, V20, P125, DOI 10.1038/sj.onc.1204048; LAI HC, 2006, HYPERMETHYLATION 2 C; LeBoeuf RD, 1998, J BIOL CHEM, V273, P361, DOI 10.1074/jbc.273.1.361; Lepperdinger G, 1998, J BIOL CHEM, V273, P22466, DOI 10.1074/jbc.273.35.22466; Lepperdinger G, 2001, MATRIX BIOL, V20, P509, DOI 10.1016/S0945-053X(01)00170-6; Lerman MI, 2000, CANCER RES, V60, P6116; Li F, 2004, CANCER RES, V64, P6438, DOI 10.1158/0008-5472.CAN-03-3869; Li JF, 2004, ONCOGENE, V23, P5941, DOI 10.1038/sj.onc.1207789; LI Y, 1994, VIROLOGY, V204, P266, DOI 10.1006/viro.1994.1531; Liu SL, 2007, ONCOGENE, V26, P789, DOI 10.1038/sj.onc.1209850; LOYI PH, 2006, CANC LETT, V234, P184; Lusher ME, 2002, CANCER RES, V62, P5906; Marsit CJ, 2005, INT J CANCER, V114, P219, DOI 10.1002/ijc.20714; Michalowski MB, 2006, CANCER GENET CYTOGEN, V166, P74, DOI 10.1016/j.cancergencyto.2005.09.004; Morris MR, 2003, ONCOGENE, V22, P6794, DOI 10.1038/sj.onc.1206914; Mullegger J, 2002, MECH DEVELOP, V111, P25, DOI 10.1016/S0925-4773(01)00593-7; Muller HM, 2004, LANCET, V363, P1283, DOI 10.1016/S0140-6736(04)16002-9; Novak U, 1999, CANCER RES, V59, P6246; Oh HJ, 2006, CANCER RES, V66, P2562, DOI 10.1158/0008-5472.CAN-05-2951; Ortiz-Vega S, 2002, ONCOGENE, V21, P1381, DOI 10.1038/sj.onc.1205192; Pan ZG, 2005, CANCER BIOL THER, V4, P1116, DOI 10.4161/cbt.4.10.2023; Polesello C, 2006, CURR BIOL, V16, P2459, DOI 10.1016/j.cub.2006.10.060; Praskova M, 2004, BIOCHEM J, V381, P453, DOI 10.1042/BJ20040025; Qiu GH, 2004, ONCOGENE, V23, P4793, DOI 10.1038/sj.onc.1207632; Rabizadeh S, 2004, J BIOL CHEM, V279, P29247, DOI 10.1074/jbc.M401699200; Rai SK, 2001, P NATL ACAD SCI USA, V98, P4443, DOI 10.1073/pnas.071572898; Riquelme E, 2007, CANCER LETT, V250, P100, DOI 10.1016/j.canlet.2006.09.019; Roche J, 1996, ONCOGENE, V12, P1289; Scheel H, 2003, CURR BIOL, V13, pR899, DOI 10.1016/j.cub.2003.11.007; Schenk PW, 2003, MOL PHARMACOL, V64, P259, DOI 10.1124/mol.64.2.259; Sekido Y, 1998, ONCOGENE, V16, P3151, DOI 10.1038/sj.onc.1201858; Shames DS, 2006, PLOS MED, V3, P2244, DOI 10.1371/journal.pmed.0030486; Shivakumar L, 2002, MOL CELL BIOL, V22, P4309, DOI 10.1128/MCB.22.12.4309-4318.2002; Shuster S, 2002, INT J CANCER, V102, P192, DOI 10.1002/ijc.10668; Song MS, 2004, NAT CELL BIOL, V6, P129, DOI 10.1038/ncb1091; Stern R, 2004, EUR J CELL BIOL, V83, P317, DOI 10.1078/0171-9335-00392; Sundaresan V, 1998, ONCOGENE, V17, P1723, DOI 10.1038/sj.onc.1202103; Tommasi S, 2005, CANCER RES, V65, P92; Toole BP, 2004, NAT REV CANCER, V4, P528, DOI 10.1038/nrc1391; Toyota M, 1999, CANCER RES, V59, P4535; Tsubaki M, 2005, BBA-PROTEINS PROTEOM, V1753, P174, DOI 10.1016/j.bbapap.2005.08.015; Udabage L, 2005, EXP CELL RES, V310, P205, DOI 10.1016/j.yexcr.2005.07.026; Ueda K, 2006, CANCER RES, V66, P9682, DOI 10.1158/0008-5472.CAN-06-1483; Uno F, 2004, CANCER RES, V64, P2969, DOI 10.1158/0008-5472.CAN-03-3702; van der Weyden L, 2005, MOL CELL BIOL, V25, P8356, DOI 10.1128/MCB.25.18.8356-8367.2005; Vavvas D, 1998, J BIOL CHEM, V273, P5439, DOI 10.1074/jbc.273.10.5439; Velasco G, 2006, J BIOL CHEM, V281, P16546, DOI 10.1074/jbc.M600573200; Vigdorovich V, 2005, J VIROL, V79, P79, DOI 10.1128/JVI.79.1.79-86.2005; Vos MD, 2003, J BIOL CHEM, V278, P21938, DOI 10.1074/jbc.M211019200; Vos MD, 2003, J BIOL CHEM, V278, P28045, DOI 10.1074/jbc.M300554200; Vos MD, 2006, J BIOL CHEM, V281, P4557, DOI 10.1074/jbc.M512128200; Vos MD, 2004, CANCER RES, V64, P4244, DOI 10.1158/0008-5472.CAN-04-0339; Vos MD, 2000, J BIOL CHEM, V275, P35669, DOI 10.1074/jbc.C000463200; Wan J, 2006, MOL CELL BIOL, V26, P448, DOI 10.1128/MCB.26.2.448-456.2006; Wei G, 2003, ANTICANCER RES, V23, P2173; Wei MH, 1996, CANCER RES, V56, P1487; Wistuba II, 2000, CANCER RES, V60, P1949; Yau WL, 2006, INT J CANCER, V119, P2821, DOI 10.1002/ijc.22232; Zaahl MG, 2004, HUM GENET, V115, P409, DOI 10.1007/s00439-004-1166-y; ZHANG LR, 1995, CANCER RES, V55, P428; Zhang Z, 2007, INT J CANCER, V120, P32, DOI 10.1002/ijc.22185; Zochbauer-Muller S, 2001, CANCER RES, V61, P249	121	128	133	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 15	2007	26	52					7283	7301		10.1038/sj.onc.1210547	http://dx.doi.org/10.1038/sj.onc.1210547			19	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	231NP	17533367				2022-12-28	WOS:000250955700001
J	Xu, X; Li, W; Fan, X; Liang, Y; Zhao, M; Zhang, J; Liang, Y; Tong, W; Wang, J; Yang, W; Lu, Y				Xu, X.; Li, W.; Fan, X.; Liang, Y.; Zhao, M.; Zhang, J.; Liang, Y.; Tong, W.; Wang, J.; Yang, W.; Lu, Y.			Identification and characterization of a novel p42.3 gene astumor-s pecific and mitosis phase-dependent expression in gastric cancer	ONCOGENE			English	Article						gastric cancer; p42.3; cell cycle; RNAi	CELL-CYCLE; MOLECULAR-CLONING; PROLIFERATION; CHECKPOINT; PHENOTYPE; PROTEINS	Multiple genetic alterations are attributed to gastric cancer (GC); however, only a few critical genes have been identified so far. In this study, we isolated and characterized a novel gene p42.3, represented as tumor-specific and mitosis phase-dependent expression protein in GC cell line BGC823. Our data showed that the expression of p42.3 was cell cycle-dependent in GC cell lines. Moreover, p42.3 was specifically expressed in primary GC tissues but not in the matched normal mucosa of stomach, and this gene was expressed in diverse embryonic tissues. Furthermore, significant suppression of cell proliferation and tumorigenicity were detected and G(2)/M phase arrest was observed in cell line BGC823 depleted of p42.3 expression by RNAi technique, and we confirmed the expression changes of cyclin B1 and Chk2 following the silence of p42.3. Taken together, we cloned and characterized p42.3 gene that was specifically expressed in GC tumors but not in normal gastric mucosa, and the gene was associated with M-phase regulation. Moreover, p42.3 might be involved in cell proliferation and tumorigenesis; therefore, this gene might have potential applications in the diagnosis or treatment of GC.	Peking Univ, Sch Oncol, Inst Canc Res, Oncol Mol Lab, Beijing 100871, Peoples R China; Chinese Acad Sci, Genom Inst, Beijing, Peoples R China; Tsinghua Univ, Natl Engn Res Ctr Biochip Technol, Sch Med, Beijing 100084, Peoples R China	Peking University; Chinese Academy of Sciences; Tsinghua University	Lu, Y (corresponding author), Peking Univ, Sch Oncol, Inst Canc Res, Oncol Mol Lab, Fu-Cheng rd 52,Hai-Dian Dist, Beijing 100871, Peoples R China.	yongylu@public.bta.net.cn						Chaturvedi P, 1999, ONCOGENE, V18, P4047, DOI 10.1038/sj.onc.1202925; Cobb JA, 2006, NUCLEIC ACIDS RES, V34, P4106, DOI 10.1093/nar/gkl557; Deng CX, 2006, NUCLEIC ACIDS RES, V34, P1416, DOI 10.1093/nar/gkl010; Deng H, 2005, BIOCHEM BIOPH RES CO, V326, P274, DOI 10.1016/j.bbrc.2004.11.027; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; Herness EA, 2003, CANCER RES, V63, P329; Ji JF, 2002, ONCOGENE, V21, P6549, DOI 10.1038/sj.onc.1205829; Kay BK, 2000, FASEB J, V14, P231, DOI 10.1096/fasebj.14.2.231; Kumagai A, 1999, GENE DEV, V13, P1067, DOI 10.1101/gad.13.9.1067; Li QL, 2002, CELL, V109, P113, DOI 10.1016/S0092-8674(02)00690-6; Lu M, 2005, CANCER RES, V65, P6159, DOI 10.1158/0008-5472.CAN-04-4016; Murata T, 2004, GENE EXPR PATTERNS, V5, P171, DOI 10.1016/j.modgep.2004.08.007; Murray AW, 2004, CELL, V116, P221, DOI 10.1016/S0092-8674(03)01080-8; Nasmyth K, 1996, SCIENCE, V274, P1643, DOI 10.1126/science.274.5293.1643; Pinto-Santini D, 2005, CANCER EPIDEM BIOMAR, V14, P1853, DOI 10.1158/1055-9965.EPI-04-0784; Santamaria-Kisiel L, 2006, BIOCHEM J, V396, P201, DOI 10.1042/BJ20060195; Stock M, 2005, GENE, V360, P1, DOI 10.1016/j.gene.2005.06.026; Strausberg RL, 2002, P NATL ACAD SCI USA, V99, P16899, DOI 10.1073/pnas.242603899; Tang ZB, 2004, ONCOL REP, V11, P333; Toyota M, 1999, CANCER RES, V59, P5438; You Wei Cheng, 2005, Chin J Dig Dis, V6, P149; Zeng JZ, 2002, ONCOGENE, V21, P4932, DOI 10.1038/sj.onc.1205652; Zhang PN, 2001, J BIOL CHEM, V276, P19862, DOI 10.1074/jbc.M100597200	25	38	41	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 15	2007	26	52					7371	7379		10.1038/sj.onc.1210538	http://dx.doi.org/10.1038/sj.onc.1210538			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	231NP	17525738				2022-12-28	WOS:000250955700009
J	Garcia-Morales, P; Carrasco-Garcia, E; Ruiz-Rico, P; Martinez-Mira, R; Menendez-Gutierrez, MP; Ferragut, JA; Saceda, M; Martinez-Lacaci, I				Garcia-Morales, P.; Carrasco-Garcia, E.; Ruiz-Rico, P.; Martinez-Mira, R.; Menendez-Gutierrez, M. P.; Ferragut, J. A.; Saceda, M.; Martinez-Lacaci, I.			Inhibition of Hsp90 function by ansamycins causes downregulation of cdc2 and cdc25c and G(2)/M arrest in glioblastoma cell lines	ONCOGENE			English	Article						ansamycins; G(2)/M arrest; cdc2; cdc25c; glioblastoma	CYCLE-ARREST; GELDANAMYCIN; APOPTOSIS; CHAPERONE; COMPLEX; AKT; DEGRADATION; PROTEINS; KINASE	Ansamycins exert their effects by binding heat shock protein 90 (Hsp90) and targeting important signalling molecules for degradation via the proteasome pathway. We wanted to study the effect of geldanamycin (GA) and its derivative 17-allylamino-17-demethoxygeldanamycin (17-AAG) on glioblastoma cell lines. We show that these cells are growth inhibited by ansamycins by being arrested in G(2)/M and, subsequently, cells undergo apoptosis. The protein levels of cell division cycle 2 (cdc2) kinase and cell division cycle 25c (cdc25c) were downregulated upon GA and 17-AAG treatment and cdc2 kinase activity was inhibited. However, other proteins involved in the G(2)/M checkpoint were not affected. The cdc2 and cdc25c mRNA levels did not show significant differences upon ansamycin treatment, but the stability of cdc2 protein was reduced. The association of cdc2 and cdc25c with p50(cdc37), an Hsp90 cochaperone, decreased, but the interaction of cdc2 and cdc25c with the Hsp70 co-chaperone increased after ansamycin treatment. Proteasome inhibitors were able to rescue the cdc2 downregulation, but not the cdc25c reduction. However, calpain inhibitors were able to rescue the cdc25c downregulation, suggesting that cdc25c is proteolysed by calpains in the presence of ansamycins, and not by the proteasome. We conclude that ansamycins downregulate cdc2 and cdc25c by two different mechanisms.	Univ Miguel Hernandez, Inst Mol & Cellular Biol, E-03202 Alicante, Spain; Hosp Gen Univ Elche, Unidad Invest, Alicante, Spain	Universidad Miguel Hernandez de Elche	Martinez-Lacaci, I (corresponding author), Univ Miguel Hernandez, Inst Mol & Cellular Biol, Edificio Torregaitan, E-03202 Alicante, Spain.	imlacaci@umh.es	Saceda, Miguel/A-1581-2008; Garcia Morales, Pilar/ABD-4362-2021	Saceda, Miguel/0000-0002-1564-3602; 				An WG, 2000, CELL GROWTH DIFFER, V11, P355; Basso AD, 2002, J BIOL CHEM, V277, P39858, DOI 10.1074/jbc.M206322200; Bellocq A, 1999, J BIOL CHEM, V274, P36891, DOI 10.1074/jbc.274.52.36891; BLAGOSKLONNY MV, 1995, ONCOGENE, V11, P933; de Carcer G, 2004, CANCER RES, V64, P5106, DOI 10.1158/0008-5472.CAN-03-2214; Demidenko ZN, 2006, CELL DEATH DIFFER, V13, P1434, DOI 10.1038/sj.cdd.4401812; Dias SD, 2005, CANCER RES, V65, P10686, DOI 10.1158/0008-5472.CAN-05-2632; Drysdale MJ, 2006, CURR OPIN DRUG DISC, V9, P483; Georgakis GV, 2006, BRIT J HAEMATOL, V135, P68, DOI 10.1111/j.1365-2141.2006.06247.x; Georgakis GV, 2006, CLIN CANCER RES, V12, P584, DOI 10.1158/1078-0432.CCR-05-1194; Grbovic OM, 2006, P NATL ACAD SCI USA, V103, P57, DOI 10.1073/pnas.0609973103; Hostein I, 2001, CANCER RES, V61, P4003; Kamal A, 2004, TRENDS MOL MED, V10, P283, DOI 10.1016/j.molmed.2004.04.006; Kim HR, 1999, IUBMB LIFE, V48, P425, DOI 10.1080/152165499306810; McIlwrath AJ, 1996, CANCER CHEMOTH PHARM, V37, P423, DOI 10.1007/s002800050407; MILLER P, 1994, CANCER RES, V54, P2724; Munster PN, 2002, CANCER RES, V62, P3132; Neckers L, 2002, TRENDS MOL MED, V8, pS55, DOI 10.1016/S1471-4914(02)02316-X; Nigg EA, 2001, NAT REV MOL CELL BIO, V2, P21, DOI 10.1038/35048096; Nomura M, 2004, J CELL PHYSIOL, V201, P374, DOI 10.1002/jcp.20090; SCHULTE TW, 1995, J BIOL CHEM, V270, P24585, DOI 10.1074/jbc.270.41.24585; Senju M, 2006, J CANCER RES CLIN, V132, P150, DOI 10.1007/s00432-005-0047-7; Sharp S, 2006, ADV CANCER RES, V95, P323, DOI 10.1016/S0065-230X(06)95009-X; Sorimachi H, 1997, BIOCHEM J, V328, P721, DOI 10.1042/bj3280721; Srethapakdi M, 2000, CANCER RES, V60, P3940; Stupp R, 2006, ONCOLOGIST, V11, P165, DOI 10.1634/theoncologist.11-2-165; WHITESELL L, 1994, P NATL ACAD SCI USA, V91, P8324, DOI 10.1073/pnas.91.18.8324; Xiao L, 2006, MINI-REV MED CHEM, V6, P1137, DOI 10.2174/138955706778560166	28	55	57	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 8	2007	26	51					7185	7193		10.1038/sj.onc.1210534	http://dx.doi.org/10.1038/sj.onc.1210534			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	231NO	17525741				2022-12-28	WOS:000250955600002
J	Taubert, H; Wurl, P; Greither, T; Kappler, M; Bache, M; Bartel, F; Kehlen, A; Lautenschlager, C; Harris, LC; Kaushal, D; Fussel, S; Meye, A; Bohnke, A; Schmidt, H				Taubert, H.; Wuerl, P.; Greither, T.; Kappler, M.; Bache, M.; Bartel, F.; Kehlen, A.; Lautenschlaeger, C.; Harris, L. C.; Kaushal, D.; Fuessel, S.; Meye, A.; Boehnke, A.; Schmidt, H.			Stem cell-associated genes are extremely poor prognostic factors for soft-tissue sarcoma patients	ONCOGENE			English	Article						stem cell-associated genes; soft-tissue sarcoma; prognosis; Hiwi; hTERT; survivin	TUMOR-RELATED DEATH; TELOMERASE ACTIVITY; CANCER; PROTEIN; EXPRESSION; SURVIVIN; HIWI; PROLIFERATION; PATHWAY; HTERT	Cancer stem cells can play an important role in tumorigenesis and tumor progression. However, it is still difficult to detect and isolate cancer stem cells. An alternative approach is to analyse stem cell-associated gene expression. We investigated the coexpression of three stem cell-associated genes, Hiwi, hTERT and survivin, by quantitative real-time-PCR in 104 primary soft-tissue sarcomas (STS). Multivariate Cox's proportional hazards regression analyses allowed correlating gene expression with overall survival for STS patients. Coexpression of all three stem cell-associated genes resulted in a significantly increased risk of tumor-related death. Importantly, tumors of patients with the poorest prognosis were of all four tumor stages, suggesting that their risk is based upon coexpression of stem cell-associated genes rather than on tumor stage.	Univ Halle Wittenberg, Fac Med, Inst Pathol, D-06097 Halle, Germany; Univ Ulm, Clin Gen & Transplantat Surg, Ulm, Germany; Univ Halle Wittenberg, Dept Radiotherapy, D-06097 Halle, Germany; Univ Halle Wittenberg, Inst Pathol, Junior Res Grp, D-06097 Halle, Germany; Probiodrug AG, Halle, Germany; Univ Halle Wittenberg, Inst Med Biometry & Informat, D-06097 Halle, Germany; St Jude Childrens Hosp, Hartwell Ctr Bioinformat & Biotechnol, Memphis, TN 38105 USA; Tech Univ Dresden, Dept Urol, D-8027 Dresden, Germany	Martin Luther University Halle Wittenberg; Ulm University; Martin Luther University Halle Wittenberg; Martin Luther University Halle Wittenberg; Vivoryon Therapeutics; Martin Luther University Halle Wittenberg; St Jude Children's Research Hospital; Technische Universitat Dresden	Taubert, H (corresponding author), Univ Halle Wittenberg, Fac Med, Inst Pathol, Magdeburger Str 14, D-06097 Halle, Germany.	helge.taubert@medizin.uni-halle.de	Greither, Thomas/M-5334-2019; Kappler, Matthias/ABG-9644-2020	Kappler, Matthias/0000-0003-2002-0271				Altieri DC, 2003, NAT REV CANCER, V3, P46, DOI 10.1038/nrc968; Aravin A, 2006, NATURE, V442, P203, DOI 10.1038/nature04916; Endoh T, 2005, EXP CELL RES, V305, P300, DOI 10.1016/j.yexcr.2004.12.014; Girard A, 2006, NATURE, V442, P199, DOI 10.1038/nature04917; Hill RP, 2006, CANCER RES, V66, P1891, DOI 10.1158/0008-5472.CAN-05-3450; Ju ZY, 2006, EUR J CANCER, V42, P1197, DOI 10.1016/j.ejca.2006.01.040; Kirkpatrick KL, 2001, EUR J SURG ONCOL, V27, P754, DOI 10.1053/ejso.2001.1151; Lee JH, 2006, HUM MOL GENET, V15, P201, DOI 10.1093/hmg/ddi430; Lingel A, 2005, CURR OPIN STRUC BIOL, V15, P107, DOI 10.1016/j.sbi.2005.01.010; Liu XY, 2006, INT J CANCER, V118, P1922, DOI 10.1002/ijc.21575; Morrison SJ, 1996, IMMUNITY, V5, P207, DOI 10.1016/S1074-7613(00)80316-7; Nguyen HG, 2006, J CELL PHYSIOL, V208, P12, DOI 10.1002/jcp.20565; Pendino F, 2006, CURR CANCER DRUG TAR, V6, P147, DOI 10.2174/156800906776056482; Polyak K, 2006, NAT MED, V12, P296, DOI 10.1038/nm1379; Qiao D, 2002, ONCOGENE, V21, P3988, DOI 10.1038/sj.onc.1205505; Smith LL, 2003, NAT CELL BIOL, V5, P474, DOI 10.1038/ncb985; Soltysova A, 2005, NEOPLASMA, V52, P435; Taubert H, 2007, ONCOGENE, V26, P1098, DOI 10.1038/sj.onc.1209880; Wurl P, 2002, LANCET, V359, P943, DOI 10.1016/S0140-6736(02)07990-4; Zhu CQ, 2006, BRIT J CANCER, V94, P1452, DOI 10.1038/sj.bjc.6603110	20	42	45	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 1	2007	26	50					7170	7174		10.1038/sj.onc.1210530	http://dx.doi.org/10.1038/sj.onc.1210530			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	228GF	17525744				2022-12-28	WOS:000250715000012
J	Lee, Y; Kawagoe, R; Sasai, K; Li, Y; Russell, HR; Curran, T; McKinnon, PJ				Lee, Y.; Kawagoe, R.; Sasai, K.; Li, Y.; Russell, H. R.; Curran, T.; McKinnon, P. J.			Loss of suppressor-of-fused function promotes tumorigenesis	ONCOGENE			English	Article						suppressor of fused; sufu; patched1; medulloblastoma; hedgehog; HhAntag	MEDULLOBLASTOMA CELLS; SONIC HEDGEHOG; MICE; PATHWAY; GLI; SUFU; TRANSCRIPTION; DISRUPTION; REGULATOR; PROTEINS	The Sonic Hedgehog (SHH) signaling pathway is indispensable for development, and functions to activate a transcriptional program modulated by the GLI transcription factors. Here, we report that loss of a regulator of the SHH pathway, Suppressor of Fused (Sufu), resulted in early embryonic lethality in the mouse similar to inactivation of another SHH regulator, Patched1 (Ptch1). In contrast to Ptch(+/-) mice, Sufu(+/-) mice were not tumor prone. However, in conjunction with p53 loss, Sufu(+/-) animals developed tumors including medulloblastoma and rhabdomyosarcoma. Tumors present in Sufu(+/-) p53(-/-) animals resulted from Sufu loss of heterozygosity. Sufu(+/-) p53(-/-) medulloblastomas also expressed a signature gene expression pro. le typical of aberrant SHH signaling, including upregulation of N-myc, Sfrp1, Ptch2 and cyclin D1. Finally, the Smoothened inhibitor, hedgehog antagonist, did not block growth of tumors arising from Sufu inactivation. These data demonstrate that Sufu is essential for development and functions as a tumor suppressor.	St Jude Childrens Hosp, Dept Genet & Tumor Cell Biol, Memphis, TN 38105 USA; St Jude Childrens Hosp, Dept Dev Neurobiol, Memphis, TN 38105 USA	St Jude Children's Research Hospital; St Jude Children's Research Hospital	McKinnon, PJ (corresponding author), St Jude Childrens Hosp, Dept Genet & Tumor Cell Biol, 332 N Lauderdale St, Memphis, TN 38105 USA.	peter.mckinnon@stjude.org	Curran, Tom/C-1164-2008; Curran, Tom/F-5234-2018; Curran, Tom/D-7515-2011; Curran, Thomas/AAE-7631-2019	Curran, Tom/0000-0003-1444-7551; Curran, Tom/0000-0003-1444-7551; Curran, Thomas/0000-0003-1444-7551; Lee, Youngsoo/0000-0003-4773-6464	NCI NIH HHS [CA-21765, P30-CA21765] Funding Source: Medline; NINDS NIH HHS [NS-37956] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS037956, R56NS037956] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Callahan CA, 2004, GENE DEV, V18, P2724, DOI 10.1101/gad.1221804; Chen MH, 2005, MOL CELL BIOL, V25, P7042, DOI 10.1128/MCB.25.16.7042-7053.2005; Cheng SY, 2002, P NATL ACAD SCI USA, V99, P5442, DOI 10.1073/pnas.082096999; Cooper AF, 2005, DEVELOPMENT, V132, P4407, DOI 10.1242/dev.02021; Dellovade T, 2006, ANNU REV NEUROSCI, V29, P539, DOI 10.1146/annurev.neuro.29.051605.112858; Di Marcotullio L, 2004, P NATL ACAD SCI USA, V101, P10833, DOI 10.1073/pnas.0400690101; Dunaeva M, 2003, J BIOL CHEM, V278, P5116, DOI 10.1074/jbc.M209492200; Ferretti E, 2005, TRENDS MOL MED, V11, P537, DOI 10.1016/j.molmed.2005.10.005; Goodrich LV, 1997, SCIENCE, V277, P1109, DOI 10.1126/science.277.5329.1109; Hooper JE, 2005, NAT REV MOL CELL BIO, V6, P306, DOI 10.1038/nrm1622; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Kimura H, 2005, ONCOGENE, V24, P4026, DOI 10.1038/sj.onc.1208567; Lawinger P, 2000, NAT MED, V6, P826, DOI 10.1038/77565; Lee Y, 2003, CANCER RES, V63, P5428; Lee Y, 2006, CANCER RES, V66, P6964, DOI 10.1158/0008-5472.CAN-06-0505; Lum L, 2004, SCIENCE, V304, P1755, DOI 10.1126/science.1098020; Marino S, 2005, TRENDS MOL MED, V11, P17, DOI 10.1016/j.molmed.2004.11.008; Oliver TG, 2005, DEVELOPMENT, V132, P2425, DOI 10.1242/dev.01793; Paces-Fessy M, 2004, BIOCHEM J, V378, P353, DOI 10.1042/BJ20030786; Romer JT, 2004, CANCER CELL, V6, P229, DOI 10.1016/j.ccr.2004.08.019; Sasai K, 2006, CANCER RES, V66, P4215, DOI 10.1158/0008-5472.CAN-05-4505; Svard J, 2006, DEV CELL, V10, P187, DOI 10.1016/j.devcel.2005.12.013; Taylor MD, 2002, NAT GENET, V31, P306, DOI 10.1038/ng916; Varjosalo M, 2006, DEV CELL, V10, P177, DOI 10.1016/j.devcel.2005.12.014; Weiner HL, 2002, CANCER RES, V62, P6385; Wetmore C, 2001, CANCER RES, V61, P513; Yan CT, 2006, P NATL ACAD SCI USA, V103, P7378, DOI 10.1073/pnas.0601938103	27	171	182	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 27	2007	26	44					6442	6447		10.1038/sj.onc.1210467	http://dx.doi.org/10.1038/sj.onc.1210467			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	214KY	17452975				2022-12-28	WOS:000249737600008
J	Han, EKH; Leverson, JD; McGonigal, T; Shah, OJ; Woods, KW; Hunter, T; Giranda, VL				Han, E. K-H; Leverson, J. D.; McGonigal, T.; Shah, O. J.; Woods, K. W.; Hunter, T.; Giranda, V. L.			Akt inhibitor A-443654 induces rapid Akt Ser-473 phosphorylation independent of mTORC1 inhibition	ONCOGENE			English	Article						A-443654; Akt; phosphorylation; rapamycin; mTOR	PROTEIN-KINASE; MAMMALIAN TARGET; IN-VIVO; ACTIVATION; PATHWAY; RAPAMYCIN; SURVIVAL; AKT/PKB; CANCER; PROGRESS	Rapamycin, a natural product inhibitor of the Raptor-mammalian target of rapamycin complex (mTORC1), is known to induce Protein kinase B (Akt/PKB) Ser-473 phosphorylation in a subset of human cancer cell lines through inactivation of S6K1, stabilization of insulin receptor substrate (IRS)-1, and increased signaling through the insulin/insulin-like growth factor-I/phosphatidylinositol 3-kinase (PI3K) axis. We report that A-443654, a potent small-molecule inhibitor of Akt serine/threonine kinases, induces Akt Ser-473 phosphorylation in all human cancer cell lines tested, including PTEN- and TSC2-deficient lines. This phenomenon is dose-dependent, manifests coincident with Akt inhibition and likely represents an alternative, rapid-feedback pathway that can be functionally dissociated from mTORC1 inhibition. Experiments performed in TSC2(-/-) cells indicate that TSC2 and IRS-1 cooperate with, but are dispensable for, A-443654-mediated Akt phosphorylation. This feedback event does require PI3K activity, however, as it can be inhibited by LY294002 or wortmannin. Small interfering RNA-mediated knockdown of mTOR or Rictor, components of the rapamycin-insensitive mTORC2 complex, but not the mTORC1 component Raptor, also inhibited Akt Ser-473 phosphorylation induced by A-443654. Our data thus indicate that Akt phosphorylation and activity are coupled in a manner not previously appreciated and provide a novel mode of Akt regulation that is distinct from the previously described rapamycin-induced IRS-1 stabilization mechanism.	Abbott Labs, Global Pharmaceut Res Div, Abbott Pk, IL 60064 USA; Salk Inst Biol Studies, Mol & Cell Biol Lab, La Jolla, CA 92037 USA	Abbott Laboratories; Salk Institute	Han, EKH (corresponding author), Abbott Labs, Global Pharmaceut Res Div, Dept R47S,Bldg AP9A, Abbott Pk, IL 60064 USA.	edward.k.han@abbott.com						Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Altomare DA, 2005, ONCOGENE, V24, P7455, DOI 10.1038/sj.onc.1209085; Balendran A, 1999, CURR BIOL, V9, P393, DOI 10.1016/S0960-9822(99)80186-9; Barnett SF, 2005, CURR TOP MED CHEM, V5, P109, DOI 10.2174/1568026053507714; Brunn GJ, 1996, EMBO J, V15, P5256, DOI 10.1002/j.1460-2075.1996.tb00911.x; Cheng JQ, 2005, ONCOGENE, V24, P7482, DOI 10.1038/sj.onc.1209088; Cheung PCF, 2003, EMBO J, V22, P5793, DOI 10.1093/emboj/cdg552; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Feng JH, 2004, J BIOL CHEM, V279, P41189, DOI 10.1074/jbc.M406731200; Granville CA, 2006, CLIN CANCER RES, V12, P679, DOI 10.1158/1078-0432.CCR-05-1654; Hall-Jackson CA, 1999, CHEM BIOL, V6, P559, DOI 10.1016/S1074-5521(99)80088-X; Harrington LS, 2004, J CELL BIOL, V166, P213, DOI 10.1083/jcb.200403069; Hay N, 2005, CANCER CELL, V8, P179, DOI 10.1016/j.ccr.2005.08.008; Li JP, 1999, J BIOL CHEM, V274, P9351, DOI 10.1074/jbc.274.14.9351; Luo Y, 2005, MOL CANCER THER, V4, P977, DOI 10.1158/1535-7163.MCT-05-0005; O'Reilly KE, 2006, CANCER RES, V66, P1500, DOI 10.1158/0008-5472.CAN-05-2925; Persad S, 2001, J BIOL CHEM, V276, P27462, DOI 10.1074/jbc.M102940200; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Shah OJ, 2004, CURR BIOL, V14, P1650, DOI 10.1016/j.cub.2004.08.026; Sun SY, 2005, CANCER RES, V65, P7052, DOI 10.1158/0008-5472.CAN-05-0917; Testa JR, 2005, ONCOGENE, V24, P7391, DOI 10.1038/sj.onc.1209100; Thompson JE, 2004, J CLIN ONCOL, V22, P4217, DOI 10.1200/jco.2004.01.103; Toker A, 2000, J BIOL CHEM, V275, P8271, DOI 10.1074/jbc.275.12.8271; Um SH, 2004, NATURE, V431, P200, DOI 10.1038/nature02866; Xu BE, 1999, J BIOL CHEM, V274, P34029, DOI 10.1074/jbc.274.48.34029; Zhang HB, 2003, J CLIN INVEST, V112, P1223, DOI 10.1172/JCI200317222	27	130	137	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG	2007	26	38					5655	5661		10.1038/sj.onc.1210343	http://dx.doi.org/10.1038/sj.onc.1210343			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	200ZS	17334390				2022-12-28	WOS:000248801900011
J	Berthet, C; Kaldis, P				Berthet, C.; Kaldis, P.			Cell-specific responses to loss of cyclin-dependent kinases	ONCOGENE			English	Review						cyclin; cyclin-dependent kinase; cell cycle; embryonic stem cells; tumor cells; differentiated cells	EMBRYONIC STEM-CELLS; SKIN TUMOR-DEVELOPMENT; CANCER-CELLS; DNA-DAMAGE; TARGETED DISRUPTION; THYMOCYTE APOPTOSIS; MOUSE MODELS; MICE LACKING; G(1) CONTROL; IN-VIVO	Inactivation of cyclin-dependent kinases (Cdks) and/or cyclins in mice has changed our view of cell cycle regulation. In general, cells are far more resistant to the loss of Cdks than originally anticipated, suggesting widespread compensation among the Cdks. Early embryonic cells are, so far, not sensitive to the lack of multiple Cdks or cyclins. In contrast, differentiated cells are more dependent on Cdk/cyclin complexes and the functional redundancy is more limited. Our challenge is to better understand these cell-type specific differences in cell cycle regulation that can be used to design efficient cancer therapy. Indeed, tumor cells seem to respond to inhibition of Cdk activities, however, with different outcome depending on the tumor cell type. Tumor cells share some proliferation features with stem cells, but appear more sensitive to loss of Cdk activity, somewhat resembling differentiated cells. We summarize the current knowledge of cell cycle regulation in different cell types and highlight their sensitivity to the lack of Cdk activities.	NCI, Ctr Canc Res, Mouse Canc Genet Program, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Kaldis, P (corresponding author), NCI, Ctr Canc Res, Mouse Canc Genet Program, Bldg 560-22-26,1050 Boyles St, Frederick, MD 21702 USA.	kaldis@ncifcrf.gov	Kaldis, Philipp/G-2714-2010; berthet, cyril/T-4842-2017	Kaldis, Philipp/0000-0002-7247-7591; berthet, cyril/0000-0003-3166-3141	NATIONAL CANCER INSTITUTE [Z01SC010367] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Aladjem MI, 1998, CURR BIOL, V8, P145, DOI 10.1016/S0960-9822(98)70061-2; Aleem E, 2005, NAT CELL BIOL, V7, P831, DOI 10.1038/ncb1284; Aleem Eiman, 2006, V42, P271, DOI 10.1007/023; Appert-Collin A, 2006, LIFE SCI, V79, P484, DOI 10.1016/j.lfs.2006.01.032; Arber N, 1997, CANCER RES, V57, P1569; Berthet C, 2003, CURR BIOL, V13, P1775, DOI 10.1016/j.cub.2003.09.024; Berthet C, 2006, DEV CELL, V10, P563, DOI 10.1016/j.devcel.2006.03.004; Bertolotti R, 2004, PROG GENE THERAPY, V2, P1; Bertram MJ, 1999, MOL CELL BIOL, V19, P1479; Blasco MA, 2005, EMBO J, V24, P1095, DOI 10.1038/sj.emboj.7600598; Brandeis M, 1998, P NATL ACAD SCI USA, V95, P4344, DOI 10.1073/pnas.95.8.4344; Burdon T, 2002, TRENDS CELL BIOL, V12, P432, DOI 10.1016/S0962-8924(02)02352-8; Cai DP, 2006, CANCER RES, V66, P9270, DOI 10.1158/0008-5472.CAN-06-1758; Campisi J, 2005, CELL, V120, P513, DOI 10.1016/j.cell.2005.02.003; Collado M, 2005, NATURE, V436, P642, DOI 10.1038/436642a; Dannenberg JH, 2000, GENE DEV, V14, P3051, DOI 10.1101/gad.847700; de Marval PLM, 2004, MOL CELL BIOL, V24, P7538, DOI 10.1128/MCB.24.17.7538-7547.2004; Dimri GP, 2005, CANCER CELL, V7, P505, DOI 10.1016/j.ccr.2005.05.025; Du LH, 2004, J BIOL CHEM, V279, P11957, DOI 10.1074/jbc.M304935200; FANTL V, 1995, GENE DEV, V9, P2364, DOI 10.1101/gad.9.19.2364; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; Furuno N, 1999, J CELL BIOL, V147, P295, DOI 10.1083/jcb.147.2.295; Geng Y, 2003, CELL, V114, P431, DOI 10.1016/S0092-8674(03)00645-7; Gil-Gomez G, 1998, EMBO J, V17, P7209, DOI 10.1093/emboj/17.24.7209; Hakem A, 1999, J EXP MED, V189, P957, DOI 10.1084/jem.189.6.957; Jirmanova L, 2002, ONCOGENE, V21, P5515, DOI 10.1038/sj.onc.1205728; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; Kiyokawa Hiroaki, 2006, V42, P257, DOI 10.1007/001; Knudsen ES, 2006, EXP BIOL MED, V231, P1271; Kornmann M, 1998, J CLIN INVEST, V101, P344, DOI 10.1172/JCI1323; Kozar K, 2004, CELL, V118, P477, DOI 10.1016/j.cell.2004.07.025; Landis MW, 2006, CANCER CELL, V9, P13, DOI 10.1016/j.ccr.2005.12.019; Lee RJ, 2000, MOL CELL BIOL, V20, P672, DOI 10.1128/MCB.20.2.672-683.2000; Li L, 2005, J CELL BIOCHEM, V94, P298, DOI 10.1002/jcb.20355; Malumbres M, 2004, CELL, V118, P493, DOI 10.1016/j.cell.2004.08.002; Martin A, 2005, CANCER CELL, V7, P591, DOI 10.1016/j.ccr.2005.05.006; MEIKRANTZ W, 1994, P NATL ACAD SCI USA, V91, P3754, DOI 10.1073/pnas.91.9.3754; Mittnacht S, 1998, CURR OPIN GENET DEV, V8, P21, DOI 10.1016/S0959-437X(98)80057-9; Miura T, 2004, AGING CELL, V3, P333, DOI 10.1111/j.1474-9728.2004.00134.x; Moffat J, 2006, CELL, V124, P1283, DOI 10.1016/j.cell.2006.01.040; Monaco EA, 2003, CURR MED CHEM, V10, P367, DOI 10.2174/0929867033368277; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; Muller-Tidow C, 2004, MOL CELL BIOL, V24, P8917, DOI 10.1128/MCB.24.20.8917-8928.2004; Murphy M, 1997, NAT GENET, V15, P83, DOI 10.1038/ng0197-83; Nakase H, 1996, STROKE, V27, P720, DOI 10.1161/01.STR.27.4.720; Ortega S, 2003, NAT GENET, V35, P25, DOI 10.1038/ng1232; Pagano M, 2004, CELL, V118, P535, DOI 10.1016/j.cell.2004.08.013; Parisi T, 2003, EMBO J, V22, P4794, DOI 10.1093/emboj/cdg482; Payton M, 2006, CANCER RES, V66, P4299, DOI 10.1158/0008-5472.CAN-05-2507; Pei XH, 2004, MOL CELL BIOL, V24, P6653, DOI 10.1128/mcb.24.15.6653-6664.2004; Price PM, 2006, J AM SOC NEPHROL, V17, P2434, DOI 10.1681/ASN.2006020162; Prost S, 1998, FEBS LETT, V425, P499, DOI 10.1016/S0014-5793(98)00296-8; Rane SG, 1999, NAT GENET, V22, P44, DOI 10.1038/8751; Reddy HKDL, 2005, CANCER RES, V65, P10174, DOI 10.1158/0008-5472.CAN-05-2639; Ribas J, 2006, EXP CELL RES, V312, P2394, DOI 10.1016/j.yexcr.2006.04.021; Robles AI, 1998, GENE DEV, V12, P2469, DOI 10.1101/gad.12.16.2469; Rodriguez-Puebla ML, 2002, AM J PATHOL, V161, P405, DOI 10.1016/S0002-9440(10)64196-X; Rossi AG, 2006, NAT MED, V12, P1056, DOI 10.1038/nm1468; Rouault JP, 1996, NAT GENET, V14, P482, DOI 10.1038/ng1296-482; Sage J, 2000, GENE DEV, V14, P3037, DOI 10.1101/gad.843200; Santamaria D, 2006, FRONT BIOSCI-LANDMRK, V11, P1164, DOI 10.2741/1871; Sauter ER, 1999, CANCER RES, V59, P4876; Savatier P, 1996, ONCOGENE, V12, P309; SAVATIER P, 1994, ONCOGENE, V9, P809; Sharpless NE, 2001, NATURE, V413, P86, DOI 10.1038/35092592; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SICINSKI P, 1995, CELL, V82, P621, DOI 10.1016/0092-8674(95)90034-9; Stanelle J, 2006, TRENDS MOL MED, V12, P177, DOI 10.1016/j.molmed.2006.02.002; Stead E, 2002, ONCOGENE, V21, P8320, DOI 10.1038/sj.onc.1206015; Tetsu O, 2003, CANCER CELL, V3, P233, DOI 10.1016/S1535-6108(03)00053-9; Tsutsui T, 1999, MOL CELL BIOL, V19, P7011; Tyner SD, 2002, NATURE, V415, P45, DOI 10.1038/415045a; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; WADHWA R, 1994, CELL STRUCT FUNCT, V19, P1, DOI 10.1247/csf.19.1; Wesierska-Gadek J, 2006, J CELL BIOCHEM, V98, P1367, DOI 10.1002/jcb.20960; Williams O, 2000, EUR J IMMUNOL, V30, P709; Yu QY, 2001, NATURE, V411, P1017, DOI 10.1038/35082500; Yu QY, 2006, CANCER CELL, V9, P23, DOI 10.1016/j.ccr.2005.12.012; ZHOU P, 1995, ONCOGENE, V11, P571; ZOU X, 2002, GENE DEV, V16, P2932	81	68	71	2	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL	2007	26	31					4469	4477		10.1038/sj.onc.1210243	http://dx.doi.org/10.1038/sj.onc.1210243			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	187GR	17297466				2022-12-28	WOS:000247836100001
J	Ke, Y; Wu, D; Princen, F; Nguyen, T; Pang, Y; Lesperance, J; Muller, WJ; Oshima, RG; Feng, GS				Ke, Y.; Wu, D.; Princen, F.; Nguyen, T.; Pang, Y.; Lesperance, J.; Muller, W. J.; Oshima, R. G.; Feng, G-S			Role of Gab2 in mammary tumorigenesis and metastasis	ONCOGENE			English	Article						Gab2; mammary tumor; metastasis; signal transduction; cell migration; scaffolding protein	HUMAN BREAST-CANCER; DOCKING PROTEIN GAB2; SIGNAL-TRANSDUCTION; TRANSGENIC MICE; GROWTH-FACTOR; INDUCTION; KINASE; ACTIVATION; EXPRESSION; MIGRATION	Overexpression of the adaptor/scaffolding protein Gab2 has been detected in primary human breast cancer cells and cell lines, although its functional signifi. cance in breast carcinogenesis is not fully understood. Here, we show a requirement for Gab2 in promoting mammary tumor metastasis. Although Gab2 expression levels were elevated in mammary tumors induced by the Neu (ErbB-2) oncogene, homozygous deletion of Gab2 in mice had only a modest effect on the initiation of Neu-induced mammary tumors. Notably, ablation of Gab2 severely suppressed lung metastasis. Gab2-deficient cancer cells displayed normal Akt activities, and their proliferative rate in vitro was similar to control cells. However, Gab2(-/-) cancer cells exhibited decreased migration and impaired Erk activation, and the defects were rescued by re-introduction of Gab2 into Gab2(-/-) cells. These. ndings suggest that although Gab2 overexpression may confer growth advantage to tumor cells, the functional requirement for Gab2 in mammary tumor initiation/growth may be dispensable, and that Gab2 may have a prominent role in promoting mammary tumor metastasis.	Burnham Inst Med Res, Ctr Canc, La Jolla, CA 92037 USA; Royal Victoria Hosp, Mol Oncol Grp, Montreal, PQ, Canada	Sanford Burnham Prebys Medical Discovery Institute; McGill University; Royal Victoria Hospital	Feng, GS (corresponding author), Burnham Inst Med Res, Ctr Canc, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	gfeng@burnham.org			NCI NIH HHS [CA78606, CA102583] Funding Source: Medline; NHLBI NIH HHS [HL66208] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA102583, R01CA078606] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL066208] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abassi YA, 2004, J IMMUNOL METHODS, V292, P195, DOI 10.1016/j.jim.2004.06.022; Amundadottir LT, 1998, ONCOGENE, V16, P737, DOI 10.1038/sj.onc.1201829; Bentires-Alj M, 2006, NAT MED, V12, P114, DOI 10.1038/nm1341; Bourguignon LYW, 1998, J CELL PHYSIOL, V176, P206, DOI 10.1002/(SICI)1097-4652(199807)176:1<206::AID-JCP22>3.0.CO;2-3; Brummer T, 2006, J BIOL CHEM, V281, P626, DOI 10.1074/jbc.M509567200; Daly RJ, 2002, ONCOGENE, V21, P5175, DOI 10.1038/sj.onc.1205522; Dankort D, 2001, MOL CELL BIOL, V21, P1540, DOI 10.1128/MCB.21.5.1540-1551.2001; Gu HH, 2003, TRENDS CELL BIOL, V13, P122, DOI 10.1016/S0962-8924(03)00002-3; Huang E, 2003, LANCET, V361, P1590, DOI 10.1016/S0140-6736(03)13308-9; Liu Y, 2002, FEBS LETT, V515, P1, DOI 10.1016/S0014-5793(02)02425-0; Meng SS, 2005, BIOCHEM J, V391, P143, DOI 10.1042/BJ20050229; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; Olayioye MA, 2000, EMBO J, V19, P3159, DOI 10.1093/emboj/19.13.3159; Reddy KB, 2003, CANCER METAST REV, V22, P395, DOI 10.1023/A:1023781114568; Siegel PM, 1999, EMBO J, V18, P2149, DOI 10.1093/emboj/18.8.2149; Sivaraman VS, 1997, J CLIN INVEST, V99, P1478, DOI 10.1172/JCI119309; Slamon D, 2001, SEMIN ONCOL, V28, P13, DOI 10.1053/sonc.2001.22812; Webster MA, 1998, MOL CELL BIOL, V18, P2344, DOI 10.1128/MCB.18.4.2344; White DE, 2004, CANCER CELL, V6, P159, DOI 10.1016/j.ccr.2004.06.025; Xing JZ, 2005, CHEM RES TOXICOL, V18, P154, DOI 10.1021/tx049721s; Yamada K, 2001, CYTOGENET CELL GENET, V94, P39, DOI 10.1159/000048780; Yu WM, 2002, BLOOD, V99, P2351, DOI 10.1182/blood.V99.7.2351; Zhang EE, 2004, P NATL ACAD SCI USA, V101, P16064, DOI 10.1073/pnas.0405041101; Zhao MS, 1999, INTERNET J CHEM, V2	24	69	71	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL	2007	26	34					4951	4960		10.1038/sj.onc.1210315	http://dx.doi.org/10.1038/sj.onc.1210315			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	194CV	17310989				2022-12-28	WOS:000248322500007
J	Lalier, L; Cartron, PF; Pedelaborde, F; Olivier, C; Loussouarn, D; Martin, SA; Meflah, K; Menanteau, J; Vallette, FM				Lalier, L.; Cartron, P-F; Pedelaborde, F.; Olivier, C.; Loussouarn, D.; Martin, S. A.; Meflah, K.; Menanteau, J.; Vallette, F. M.			Increase in PGE(2) biosynthesis induces a Bax dependent apoptosis correlated to patients' survival in glioblastoma multiforme	ONCOGENE			English	Article						gliomas; cyclooxygenase; prostaglandin synthase; apoptosis; Bax; PGE(2)	PROSTAGLANDIN-E SYNTHASE; CYCLOOXYGENASE-2 EXPRESSION; PROGNOSTIC-SIGNIFICANCE; PARKINSONS-DISEASE; COLON-CANCER; DEATH; NEURODEGENERATION; NEUROTOXICITY; INHIBITION; CELLS	Prostaglandin E-2 plays multiple roles both in the physiology and the physiopathology of human brain, which are not completely understood. We have identi. ed in a subset of human glioblastoma multiforme (GBM) tumors, the most common form of adult brain cancer, an increased expression of mPGES-1, the enzyme which catalyses the isomerization of PGH(2) into PGE(2) downstream of cyclooxygenase 2 (COX-2). The sensitivity of primary cultures of GBM to apoptosis was augmented by the overexpression of mPGES-1, whereas the knockdown of its expression by shRNA decreased the apoptotic threshold in vitro and stimulated tumor growth in vivo. Adding extracellular PGE(2) in the culture medium failed to reproduce mPGES-1 effect on the cell viability in vitro. However, the intracellular injection of PGE2 induced a dose-dependent apoptosis in GBM cultures, which was dependent on the presence of Bax, a pro-apoptotic protein. We show that PGE(2) physically associates with Bax, triggering its apoptotic-like change in conformation and its subsequent association with mitochondria. Our results raise questions about the role of PGE(2) in the control of apoptosis and in its potential impact in central nervous system pathologies.	INSERM, U601, F-44035 Nantes 01, France; Univ Nantes, Fac Med, F-44035 Nantes, France; CHU Nantes, G&R Laennec Hosp, Dept Anatomopathol, F-44035 Nantes 01, France; CHU Nantes, G&R Laennec Hosp, Dept Neurosurg, F-44035 Nantes 01, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Nantes Universite; Nantes Universite; CHU de Nantes; Nantes Universite; CHU de Nantes	Vallette, FM (corresponding author), INSERM, U601, 9 Quai MONSOUSU, F-44035 Nantes 01, France.	francois.vallette@univ-nantes.fr	Lalier, Lisenn/K-9230-2015; Cartron, Pierre Francois/K-9802-2015; OLIVIER, Christophe/L-1598-2015; Vallette, Francois M/K-9047-2015; Vallette, Francois/N-2361-2018	Vallette, Francois M/0000-0002-3296-8572; Cartron, Pierre-Francois/0000-0002-3393-784X				BERRY CN, 1983, BIOCHEM PHARMACOL, V32, P2863, DOI 10.1016/0006-2952(83)90390-8; Breyer RM, 2001, ANNU REV PHARMACOL, V41, P661, DOI 10.1146/annurev.pharmtox.41.1.661; Brown DM, 1996, J IMMUNOL, V157, P1359; Buccoliero AM, 2006, CLIN NEUROPATHOL, V25, P59; Cartron PF, 2004, FEBS LETT, V578, P41, DOI 10.1016/j.febslet.2004.10.080; Cartron PF, 2003, MOL CELL BIOL, V23, P4701, DOI 10.1128/MCB.23.13.4701-4712.2003; Cartron PF, 2003, J BIOL CHEM, V278, P11633, DOI 10.1074/jbc.M208955200; Cartron PF, 2004, MOL CELL, V16, P807, DOI 10.1016/j.molcel.2004.10.028; Castellone MD, 2005, SCIENCE, V310, P1504, DOI 10.1126/science.1116221; Cha YI, 2006, DEV BIOL, V289, P263, DOI 10.1016/j.ydbio.2005.10.013; Chen Z, 2005, CELL METAB, V1, P93, DOI 10.1016/j.cmet.2004.12.009; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; Gasparini G, 2003, LANCET ONCOL, V4, P605, DOI 10.1016/S1470-2045(03)01220-8; Gupta RA, 2001, NAT REV CANCER, V1, P11, DOI 10.1038/35094017; Hara A, 2004, ACTA NEUROPATHOL, V108, P43, DOI 10.1007/s00401-004-0860-0; Herrmann O, 2005, NAT MED, V11, P1322, DOI 10.1038/nm1323; Hinz B, 2004, MOL PHARMACOL, V66, P1643, DOI 10.1124/mol.104.002618; Hsu YT, 1997, P NATL ACAD SCI USA, V94, P3668, DOI 10.1073/pnas.94.8.3668; Hsu YT, 1997, J BIOL CHEM, V272, P13829, DOI 10.1074/jbc.272.21.13829; Hunot S, 2004, P NATL ACAD SCI USA, V101, P665, DOI 10.1073/pnas.0307453101; Jakobsson PJ, 1999, PROTEIN SCI, V8, P689, DOI 10.1110/ps.8.3.689; Jakobsson PJ, 1999, P NATL ACAD SCI USA, V96, P7220, DOI 10.1073/pnas.96.13.7220; Juin P, 1998, J BIOL CHEM, V273, P17559, DOI 10.1074/jbc.273.28.17559; Kawai N, 2002, PROSTAG OTH LIPID M, V68-9, P187, DOI 10.1016/S0090-6980(02)00030-8; Kawano T, 2006, NAT MED, V12, P225, DOI 10.1038/nm1362; Krunic N, 2000, DEV BRAIN RES, V121, P145, DOI 10.1016/S0165-3806(00)00033-X; Kudo I, 2005, J BIOCHEM MOL BIOL, V38, P633; Manabe Y, 2004, ANN NEUROL, V55, P668, DOI 10.1002/ana.20078; McCullough L, 2004, J NEUROSCI, V24, P257, DOI 10.1523/JNEUROSCI.4485-03.2004; Musiek ES, 2005, BRAIN PATHOL, V15, P149; Park JY, 2006, CLIN IMMUNOL, V119, P229, DOI 10.1016/j.clim.2006.01.016; Patsos HA, 2005, GUT, V54, P1741, DOI 10.1136/gut.2005.073403; Perez-Sala D, 2003, J BIOL CHEM, V278, P51251, DOI 10.1074/jbc.M309409200; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Reid G, 2003, P NATL ACAD SCI USA, V100, P9244, DOI 10.1073/pnas.1033060100; Sawada M, 2003, NAT CELL BIOL, V5, P320, DOI 10.1038/ncb950; Shono T, 2001, CANCER RES, V61, P4375; Takadera T, 2002, NEUROSCI LETT, V317, P61, DOI 10.1016/S0304-3940(01)02449-1; Teismann P, 2003, P NATL ACAD SCI USA, V100, P5473, DOI 10.1073/pnas.0837397100; Tessner TG, 2004, J CLIN INVEST, V114, P1676, DOI 10.1172/JCI200422218; Wang D, 2006, GUT, V55, P115, DOI 10.1136/gut.2004.047100; Williams CS, 2000, J CLIN INVEST, V105, P1589, DOI 10.1172/JCI9621; Yucel-Lindberg T, 2006, CELL SIGNAL, V18, P2131, DOI 10.1016/j.cellsig.2006.04.003	43	53	54	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL	2007	26	34					4999	5009		10.1038/sj.onc.1210303	http://dx.doi.org/10.1038/sj.onc.1210303			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	194CV	17369862				2022-12-28	WOS:000248322500012
J	Roche, KC; Rocha, S; Bracken, CP; Perkins, ND				Roche, K. C.; Rocha, S.; Bracken, C. P.; Perkins, N. D.			Regulation of ATR-dependent pathways by the FHA domain containing protein SNIP1	ONCOGENE			English	Article						p53; NF-kappa B; ARF; checkpoint kinases; DNA damage	NF-KAPPA-B; ARF TUMOR-SUPPRESSOR; DNA-DAMAGE; PHOSPHORYLATION EVENTS; CELL-CYCLE; P53; EXPRESSION; BINDING; CHK1; ACTIVATION	The forkhead associated (FHA) domain-containing protein Smad nuclear interacting protein 1 (SNIP1) has multiple cellular functions, including the ability to interact with DNA-binding transcription factors and transcriptional coactivators. Moreover, we have demonstrated previously that SNIP1 regulates cyclin D1 expression and promoter activity. Here, we identify a new function for SNIP1 as a regulator of ATR checkpoint kinase-dependent pathways in human U-2 OS osteosarcoma cells: SNIP1 is required for p53 induction in response to ultraviolet light treatment and selectively regulates the phosphorylation of known ATR target proteins, including p53, Chk1 and the histone variant H2AX. These activities are independent of its ability to regulate cyclin D1 expression. Significantly, SNIP1 is also required for ATR-dependent functions of the human p14(ARF) tumour suppressor, including its ability to modulate the activity of the RelA(p65) NF-kappa B subunit. This, together with its other described functions, suggests that SNIP1 could have an important role during tumorigenesis and cancer therapy.	Univ Dundee, Coll Life Sci, Div Gene Regulat & Express, Dundee DD1 5EH, Scotland; Univ Galway, Dept Biochem, Genome Stabil Lab, Galway, Ireland	University of Dundee; Ollscoil na Gaillimhe-University of Galway	Perkins, ND (corresponding author), Univ Dundee, Coll Life Sci, Div Gene Regulat & Express, MSI WTB JBC Complex,Dow St, Dundee DD1 5EH, Scotland.	n.d.perkins@dundee.ac.uk		Rocha, Sonia/0000-0002-2413-4981; Bracken, Cameron/0000-0001-7722-625X				Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Bartek J, 2003, CANCER CELL, V3, P421, DOI 10.1016/S1535-6108(03)00110-7; Campbell KJ, 2004, MOL CELL, V13, P853, DOI 10.1016/S1097-2765(04)00131-5; Chen CL, 2000, MOL CELL BIOL, V20, P2687, DOI 10.1128/MCB.20.8.2687-2695.2000; Cortez D, 2001, SCIENCE, V294, P1713, DOI 10.1126/science.1065521; Durocher D, 2002, FEBS LETT, V513, P58, DOI 10.1016/S0014-5793(01)03294-X; Durocher D, 2000, MOL CELL, V6, P1169, DOI 10.1016/S1097-2765(00)00114-3; Foray N, 2003, EMBO J, V22, P2860, DOI 10.1093/emboj/cdg274; Jowsey PA, 2004, J BIOL CHEM, V279, P55562, DOI 10.1074/jbc.M411021200; Kim RH, 2001, J BIOL CHEM, V276, P46297, DOI 10.1074/jbc.M103819200; Kim RH, 2000, GENE DEV, V14, P1605; Li JJ, 2002, MOL CELL, V9, P1045, DOI 10.1016/S1097-2765(02)00527-0; Liao H, 1999, J MOL BIOL, V294, P1041, DOI 10.1006/jmbi.1999.3313; Lin WC, 2001, GENE DEV, V15, P1833; Lowndes NF, 2005, CURR BIOL, V15, pR99, DOI 10.1016/j.cub.2005.01.029; Motoyama N, 2004, CURR OPIN GENET DEV, V14, P11, DOI 10.1016/j.gde.2003.12.003; Redon C, 2002, CURR OPIN GENET DEV, V12, P162, DOI 10.1016/S0959-437X(02)00282-4; Rocha S, 2003, MOL CELL BIOL, V23, P4713, DOI 10.1128/MCB.23.13.4713-4727.2003; Rocha S, 2003, MOL CELL, V12, P15, DOI 10.1016/S1097-2765(03)00223-5; Rocha S, 2005, EMBO J, V24, P1157, DOI 10.1038/sj.emboj.7600608; Roche KC, 2004, ONCOGENE, V23, P8185, DOI 10.1038/sj.onc.1208025; Stiff T, 2005, EMBO J, V24, P199, DOI 10.1038/sj.emboj.7600504; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Syljuasen RG, 2005, MOL CELL BIOL, V25, P3553, DOI 10.1128/MCB.25.9.3553-3562.2005; Wang Y, 2003, P NATL ACAD SCI USA, V100, P15387, DOI 10.1073/pnas.2536810100	25	14	15	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL	2007	26	31					4523	4530		10.1038/sj.onc.1210233	http://dx.doi.org/10.1038/sj.onc.1210233			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	187GR	17260016				2022-12-28	WOS:000247836100006
J	Duesbery, NS; Teh, BT				Duesbery, N. S.; Teh, B. T.			Cancer: biology and therapeutics - A tribute to George Vande Woude	ONCOGENE			English	Biographical-Item									Van Andel Res Inst, Lab Canc & Dev Cell Biol, Grand Rapids, MI 49503 USA	Van Andel Institute	Duesbery, NS (corresponding author), Van Andel Res Inst, Lab Canc & Dev Cell Biol, 333 Boostwick Ave,NE, Grand Rapids, MI 49503 USA.	duesbery@vai.org		Teh, Bin Tean/0000-0003-1514-1124; DUESBERY, NICK/0000-0002-4258-5655; Duesbery, Nicholas/0000-0002-5708-4984					0	1	1	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 26	2007	26	9					1258	1259		10.1038/sj.onc.1210257	http://dx.doi.org/10.1038/sj.onc.1210257			2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	141DU	17322909				2022-12-28	WOS:000244558700001
J	Zhao, Y; Hamza, M; Leong, H; Lim, CB; Pan, YF; Cheung, E; Soo, KC; Iyer, N				Zhao, Y.; Hamza, Ms; Leong, H. S.; Lim, C-B; Pan, Y-F; Cheung, E.; Soo, K-C; Iyer, Ng			Kruppel-like factor 5 modulates p53-independent apoptosis through Pim1 survival kinase in cancer cells	ONCOGENE			English	Article						KLF5; survival kinase; 5FU; bad phosphorylation	KLF5 TRANSCRIPTION FACTOR; FACTOR FAMILY; GENE; REGULATORS; GROWTH; AKT; PROLIFERATION; ACTIVATION; ONCOGENES; PATHWAY	Although Kruppel-like factor 5 (KLF5) is a transcription factor that has been implicated in pathways critical to carcinogenesis, controversy persists as to whether it functions as a tumor suppressor or as an oncogene. Here, we describe a novel role for KLF5 in a p53-independent apoptotic pathway. Using RNA-interference technology, we show that cells deficient in KLF5 have increased sensitivity to DNA damage, regardless of p53 status. Both p53 and p53-dependent factors are unaffected by KLF5 depletion. Instead, the apoptotic phenotype consequent to damage is associated with reduced bad phosphorylation, and downregulation of Pim1. Consistently, transfection of wild-type Pim1 is sufficient to rescue this phenotype. Previous data have shown a number of putative Sp1-binding consensus sequences on the Pim1 promoter. Remarkably, chromatin immunoprecipitation studies show that KLF5 binds to the Pim1 promoter, and that binding increases soon after damage. These results identify a novel, p53-independent apoptotic pathway through which KLF5 functions in response to DNA damage. Therapeutic deregulation of this pathway could be used to modulate chemosensitivity.	[Zhao, Y.; Leong, H. S.; Lim, C-B; Soo, K-C; Iyer, Ng] Natl Canc Ctr, Wee Kim Wee Lab Surg Oncol, Dept Surg Oncol, Singapore 169610, Singapore; [Hamza, Ms; Pan, Y-F; Cheung, E.] Genome Inst Singapore, Singapore, Singapore	National Cancer Centre Singapore (NCCS); Agency for Science Technology & Research (A*STAR); A*STAR - Genome Institute of Singapore (GIS)	Iyer, N (corresponding author), Natl Canc Ctr, Wee Kim Wee Lab Surg Oncol, Dept Surg Oncol, 11 Hosp Dr, Singapore 169610, Singapore.	gopaliyer@yahoo.com	Hamza, Sabry/B-8184-2011; Zhao, Yan/A-2197-2011	Pan, You-Fu/0000-0002-9996-8892; Zhao, Yan/0000-0003-0397-4049				Aho TLT, 2004, FEBS LETT, V571, P43, DOI 10.1016/j.febslet.2004.06.050; Amaravadi R, 2005, J CLIN INVEST, V115, P2618, DOI 10.1172/JCI26273; Bateman NW, 2004, J BIOL CHEM, V279, P12093, DOI 10.1074/jbc.M311532200; Bergmann A, 2002, DEV CELL, V3, P607, DOI 10.1016/S1534-5807(02)00328-3; Black AR, 2001, J CELL PHYSIOL, V188, P143, DOI 10.1002/jcp.1111; Chao DT, 1998, ANNU REV IMMUNOL, V16, P395, DOI 10.1146/annurev.immunol.16.1.395; Chen C, 2002, ONCOGENE, V21, P6567, DOI 10.1038/sj.onc.1205817; Chen C, 2003, PROSTATE, V55, P81, DOI 10.1002/pros.10205; Chen CH, 2006, INT J CANCER, V118, P1346, DOI 10.1002/ijc.21533; Chen CN, 2005, J CLIN ONCOL, V23, P7286, DOI 10.1200/JCO.2004.00.2253; Chen CS, 2005, ONCOGENE, V24, P3319, DOI 10.1038/sj.onc.1208497; Dong JT, 2001, CANCER METAST REV, V20, P173, DOI 10.1023/A:1015575125780; Felsher DW, 2003, NAT REV CANCER, V3, P375, DOI 10.1038/nrc1070; Ghaleb AM, 2005, CELL RES, V15, P92, DOI 10.1038/sj.cr.7290271; Hammerman PS, 2005, BLOOD, V105, P4477, DOI 10.1182/blood-2004-09-3706; Iyer NG, 2004, P NATL ACAD SCI USA, V101, P7386, DOI 10.1073/pnas.0401002101; Kaczynski J, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-2-206; Kho PS, 2004, J BIOL CHEM, V279, P21183, DOI 10.1074/jbc.M311912200; Macdonald A, 2006, BMC CELL BIOL, V7, DOI 10.1186/1471-2121-7-1; MEEKER TC, 1990, MOL CELL BIOL, V10, P1680, DOI 10.1128/MCB.10.4.1680; Mitsiades CS, 2004, CURR CANCER DRUG TAR, V4, P235, DOI 10.2174/1568009043333032; Nagai R, 2003, ADV EXP MED BIOL, V538, P57; Nandan MO, 2004, ONCOGENE, V23, P3404, DOI 10.1038/sj.onc.1207397; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; Rainio EM, 2005, VIROLOGY, V333, P201, DOI 10.1016/j.virol.2005.01.001; Ruvolo PP, 2001, LEUKEMIA, V15, P515, DOI 10.1038/sj.leu.2402090; Safe S, 2005, EUR J CANCER, V41, P2438, DOI 10.1016/j.ejca.2005.08.006; Seoane J, 2002, NATURE, V419, P729, DOI 10.1038/nature01119; Shi HP, 1999, NUCLEIC ACIDS RES, V27, P4807, DOI 10.1093/nar/27.24.4807; Sun RG, 2001, J BIOL CHEM, V276, P6897, DOI 10.1074/jbc.C000870200; Suzuki T, 2005, ARTERIOSCL THROM VAS, V25, P1135, DOI 10.1161/01.ATV.0000165656.65359.23; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Yang YZ, 2005, CANCER BIOL THER, V4, P1216, DOI 10.4161/cbt.4.11.2090; Zhao Y, 2005, P NATL ACAD SCI USA, V102, P16090, DOI 10.1073/pnas.0505585102	34	50	52	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 3	2008	27	1					1	8		10.1038/sj.onc.1210625	http://dx.doi.org/10.1038/sj.onc.1210625			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	247YO	17603560				2022-12-28	WOS:000252118700001
J	Zhao, LJ; Subramanian, T; Vijayalingam, S; Chinnadurai, G				Zhao, L-J; Subramanian, T.; Vijayalingam, S.; Chinnadurai, G.			PLDLS-dependent interaction of E1A with CtBP: regulation of CtBP nuclear localization and transcriptional functions	ONCOGENE			English	Article						E1A; CtBP; p300; acetylation; E-cadherin; c-fos	COREPRESSOR CTBP; CELLULAR PHOSPHOPROTEIN; NEGATIVE MODULATION; FAMILY PROTEINS; TERMINAL DOMAIN; ACETYLATION; BINDING; TRANSFORMATION; TUMORIGENESIS; ASSOCIATION	C-terminal binding proteins (CtBPs) are cellular corepressors that are targeted by adenovirus E1A. A conserved motif of E1A (PLDLS) interacts with an N-terminal hydrophobic cleft of CtBPs. Many cellular cofactors also interact with CtBPs through PLDLS-like motifs. E1A interaction with CtBP2 changed the composition of the CtBP2 protein complex and enhanced CtBP2 acetylation. We have identified a mutant of CtBP2 (M48A) that fails to interact with cellular cofactors while interacting normally with E1A. Other cleft mutations in CtBP2 affected interaction of both cellular cofactors and E1A. The M48A mutant did not repress the cellular E-cadherin promoter but inhibited transactivation mediated by the E1A N-terminal region through interaction with the E1A PLDLS motif. In vitro, E1A enhanced CtBP2 acetylation by p300 via a mechanism involving dissociation of acetylated CtBP2 from p300. E1A enhanced nuclear localization of CtBP1 as well as a cytoplasmically localized acetylation-deficient mutant of CtBP2 (3KR-CtBP2) through PLDLS-dependent interaction. Chromatin immunoprecipitation assays revealed presence of CtBP2 on E-cadherin and c-fos promoters. While E1A did not significantly alter targeting of CtBP2 to the E-cadherin and c-fos promoters, it dramatically enhanced promoter targeting of 3KR-CtBP2. Our results raise a possibility that E1A may gain access to cellular promoters through PLDLS-dependent interaction with CtBPs.	Jewish Hosp St Louis, Hlth Sci Ctr, Inst Mol Virol, St Louis, MO 63110 USA	Barnes-Jewish Hospital	Chinnadurai, G (corresponding author), Jewish Hosp St Louis, Hlth Sci Ctr, Inst Mol Virol, 3681 Pk Ave, St Louis, MO 63110 USA.	chinnag@slu.edu			NATIONAL CANCER INSTITUTE [R01CA033616, R01CA084941] Funding Source: NIH RePORTER; NCI NIH HHS [CA-33616, R01 CA084941-07, R01 CA033616, R01 CA084941, CA-84941, R01 CA033616-27] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bergman LM, 2006, BMC CELL BIOL, V7, DOI 10.1186/1471-2121-7-35; BOYD JM, 1993, EMBO J, V12, P469, DOI 10.1002/j.1460-2075.1993.tb05679.x; Chinnadurai G, 2002, MOL CELL, V9, P213, DOI 10.1016/S1097-2765(02)00443-4; Criqui-Filipe P, 1999, EMBO J, V18, P3392, DOI 10.1093/emboj/18.12.3392; Ghosh MK, 2003, MOL CELL, V12, P255, DOI 10.1016/S1097-2765(03)00225-9; Grooteclaes ML, 2000, ONCOGENE, V19, P3823, DOI 10.1038/sj.onc.1203721; Hildebrand JD, 2002, MOL CELL BIOL, V22, P5296, DOI 10.1128/MCB.22.15.5296-5307.2002; Kumar V, 2002, MOL CELL, V10, P857, DOI 10.1016/S1097-2765(02)00650-0; LUNDBLAD JR, 2006, CTBP FAMILY PROTEINS, P83; Madison DL, 2002, J BIOL CHEM, V277, P38755, DOI 10.1074/jbc.M207512200; Molloy D, 2006, VIROLOGY, V355, P115, DOI 10.1016/j.virol.2006.05.004; Nardini M, 2003, EMBO J, V22, P3122, DOI 10.1093/emboj/cdg283; Postigo AA, 1999, P NATL ACAD SCI USA, V96, P6683, DOI 10.1073/pnas.96.12.6683; Quinlan KGR, 2006, MOL CELL BIOL, V26, P8159, DOI 10.1128/MCB.00680-06; SCHAEPER U, 1995, P NATL ACAD SCI USA, V92, P10467, DOI 10.1073/pnas.92.23.10467; Shi YJ, 2003, NATURE, V422, P735, DOI 10.1038/nature01550; Sollerbrant K, 1996, NUCLEIC ACIDS RES, V24, P2578, DOI 10.1093/nar/24.13.2578; SUBRAMANIAN T, 1989, ONCOGENE, V4, P415; Verger A, 2006, MOL CELL BIOL, V26, P4882, DOI 10.1128/MCB.02402-05; Zhang QH, 2000, P NATL ACAD SCI USA, V97, P14323, DOI 10.1073/pnas.011283598; Zhao LJ, 2006, J BIOL CHEM, V281, P36613, DOI 10.1074/jbc.M603550200; Zhao LJ, 2006, J BIOL CHEM, V281, P4183, DOI 10.1074/jbc.M509051200	22	20	20	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 29	2007	26	54					7544	7551		10.1038/sj.onc.1210569	http://dx.doi.org/10.1038/sj.onc.1210569			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	236DB	17546044	Green Accepted			2022-12-28	WOS:000251282100006
J	Bartkova, J; Horejsi, Z; Sehested, M; Nesland, JM; Rajpert-De Meyts, E; Skakkebaek, NE; Stucki, M; Jackson, S; Lukas, J; Bartek, J				Bartkova, J.; Horejsi, Z.; Sehested, M.; Nesland, J. M.; Rajpert-De Meyts, E.; Skakkebaek, N. E.; Stucki, M.; Jackson, S.; Lukas, J.; Bartek, J.			DNA damage response mediators MDC1 and 53BP1: constitutive activation and aberrant loss in breast and lung cancer, but not in testicular germ cell tumours	ONCOGENE			English	Article						DNA damage response; breast cancer; lung cancer; testicular cancer; MDC1 and 53BP1 defects; tumour suppressors	ONCOGENE-INDUCED SENESCENCE; CARCINOMA IN-SITU; GENOMIC INSTABILITY; CYCLE CHECKPOINTS; ATM ACTIVATION; PROTEIN; P53; CHK1; DIFFERENTIATION; TUMORIGENESIS	MDC1 and 53BP1 are critical components of the DNA damage response (DDR) machinery that protects genome integrity and guards against cancer, yet the tissue expression patterns and involvement of these two DDR adaptors/mediators in human tumours remain largely unknown. Here we optimized immunohistochemical analyses of human 53BP1 and MDC1 proteins in situ and identified their virtually ubiquitous expression, both in proliferating and quiescent, differentiated tissues. Focus formation by 53BP1 and/or MDC1 in human spermatogenesis and subsets of breast and lung carcinomas indicated physiological and 'pathological' activation of the DDR, respectively. Furthermore, aberrant reduction or lack of either protein in significant proportions of carcinomas supported the candidacy of 53BP1 and MDC1 for tumour suppressors. Contrary to carcinomas, almost no activation or loss of MDC1 or 53BP1 were found among testicular germ-cell tumours (TGCTs), a tumour type with unique biology and exceptionally low incidence of p53 mutations. Such concomitant presence ( in carcinomas) or absence ( in TGCTs) of DDR activation and DDR aberrations supports the roles of MDC1 and 53BP1 within the ATM/ATR-regulated checkpoint network which, when activated, provides an early anticancer barrier the pressure of which selects for DDR defects such as p53 mutations or loss of 53BP1/MDC1 during cancer progression.	Danish Canc Soc, Ctr Genotox Stress Res, Inst Canc Biol, DK-2100 Copenhagen, Denmark; Acad Sci Czech Republ, Inst Mol Genet, Prague, Czech Republic; Copenhagen Univ Hosp, Dept Pathol, Copenhagen, Denmark; Univ Oslo, Norwegian Radium Hosp, Dept Pathol, Oslo, Norway; Univ Copenhagen Hosp, Dept Growth & Reproduct, DK-2100 Copenhagen, Denmark; Univ Zurich, Inst Vet Biochem & Mol Biol, Zurich, Switzerland; Gurdon Inst, Cambridge, England	Danish Cancer Society; Czech Academy of Sciences; Institute of Molecular Genetics of the Czech Academy of Sciences; University of Copenhagen; University of Oslo; University of Copenhagen; University of Zurich	Bartek, J (corresponding author), Danish Canc Soc, Ctr Genotox Stress Res, Inst Canc Biol, Strandboulevarden 49, DK-2100 Copenhagen, Denmark.	jb@cancer.dk	Dry, Kate/I-2328-2014; Rajpert-De Meyts, Ewa/H-6526-2019; Stucki, Manuel/H-4739-2017; Jackson, Stephen Philip/R-4548-2019; Bartek, Jiri/G-5870-2014	Rajpert-De Meyts, Ewa/0000-0002-5946-7559; Jackson, Stephen Philip/0000-0001-9317-7937; Licenikova Horejsi, Zuzana/0000-0002-9943-1649; Lukas, Jiri/0000-0001-9087-506X				Albanell J, 1999, J NATL CANCER I, V91, P1321, DOI 10.1093/jnci/91.15.1321; Bakkenist CJ, 2004, CELL, V118, P9, DOI 10.1016/j.cell.2004.06.023; Bartek J, 2006, CELL, V124, P888, DOI 10.1016/j.cell.2006.02.029; Bartek J, 2003, CANCER CELL, V3, P421, DOI 10.1016/S1535-6108(03)00110-7; Bartek J, 2004, NAT REV MOL CELL BIO, V5, P792, DOI 10.1038/nrm1493; Bartek J, 2007, CURR OPIN CELL BIOL, V19, P238, DOI 10.1016/j.ceb.2007.02.009; Bartkova J, 2003, APMIS, V111, P252, DOI 10.1034/j.1600-0463.2003.1110129.x; Bartkova J, 2005, CELL CYCLE, V4, P838, DOI 10.4161/cc.4.6.1742; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Bartkova J, 2006, NATURE, V444, P633, DOI 10.1038/nature05268; Bassing CH, 2004, DNA REPAIR, V3, P781, DOI 10.1016/j.dnarep.2004.06.001; Bekker-Jensen S, 2005, J CELL BIOL, V170, P201, DOI 10.1083/jcb.200503043; DADDA DF, 2003, NATURE, V426, P194, DOI DOI 10.1038/NATURE02118; Di Micco R, 2006, NATURE, V444, P638, DOI 10.1038/nature05327; DiTullio RA, 2002, NAT CELL BIOL, V4, P998, DOI 10.1038/ncb892; Goldberg M, 2003, NATURE, V421, P952, DOI 10.1038/nature01445; Gorgoulis VG, 2005, NATURE, V434, P907, DOI 10.1038/nature03485; Horejsi Z, 2004, ONCOGENE, V23, P3122, DOI 10.1038/sj.onc.1207447; Huyen Y, 2004, NATURE, V432, P406, DOI 10.1038/nature03114; Jazayeri A, 2006, NAT CELL BIOL, V8, P37, DOI 10.1038/ncb1337; Kastan MB, 2004, NATURE, V432, P316, DOI 10.1038/nature03097; Kumagai A, 2000, MOL CELL, V6, P839, DOI 10.1016/S1097-2765(00)00082-4; Kumagai A, 2006, CELL, V124, P943, DOI 10.1016/j.cell.2005.12.041; Latella L, 2004, MOL CELL BIOL, V24, P6350, DOI 10.1128/MCB.24.14.6350-6361.2004; Liu S, 2006, MOL CELL BIOL, V26, P6056, DOI 10.1128/MCB.00492-06; Lou ZK, 2006, MOL CELL, V21, P187, DOI 10.1016/j.molcel.2005.11.025; Lukas C, 2004, EMBO J, V23, P2674, DOI 10.1038/sj.emboj.7600269; Lukas C, 2001, CANCER RES, V61, P4990; Lukas J, 2004, DNA REPAIR, V3, P997, DOI 10.1016/j.dnarep.2004.03.006; Lutzker SG, 1996, NAT MED, V2, P804, DOI 10.1038/nm0796-804; Mochan TA, 2004, DNA REPAIR, V3, P945, DOI 10.1016/j.dnarep.2004.03.017; Mochan TA, 2003, CANCER RES, V63, P8586; Morales JC, 2006, P NATL ACAD SCI USA, V103, P3310, DOI 10.1073/pnas.0511259103; Nevanlinna H, 2006, ONCOGENE, V25, P5912, DOI 10.1038/sj.onc.1209877; Nowak R, 2000, ONCOGENE, V19, P4075, DOI 10.1038/sj.onc.1203746; Oosterhuis JW, 2005, NAT REV CANCER, V5, P210, DOI 10.1038/nrc1568; Petrini JHJ, 2003, TRENDS CELL BIOL, V13, P458, DOI 10.1016/S0962-8924(03)00170-3; Pusapati RV, 2006, P NATL ACAD SCI USA, V103, P1446, DOI 10.1073/pnas.0507367103; Rajpert-de Meyts E, 2003, APMIS, V111, P267, DOI 10.1034/j.1600-0463.2003.11101301.x; Rajpert-De Meyts E, 2006, HUM REPROD UPDATE, V12, P303, DOI 10.1093/humupd/dmk006; Schultz LB, 2000, J CELL BIOL, V151, P1381, DOI 10.1083/jcb.151.7.1381; Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011; Stewart GS, 2003, NATURE, V421, P961, DOI 10.1038/nature01446; Stucki M, 2006, DNA REPAIR, V5, P534, DOI 10.1016/j.dnarep.2006.01.012; Stucki M, 2005, CELL, V123, P1213, DOI 10.1016/j.cell.2005.09.038; Takai H, 2003, CURR BIOL, V13, P1549, DOI 10.1016/S0960-9822(03)00542-6; Tort F, 2006, CANCER RES, V66, P10258, DOI 10.1158/0008-5472.CAN-06-2178; Ward IM, 2003, MOL CELL BIOL, V23, P2556, DOI 10.1128/MCB.23.7.2556-2563.2003; Ward IM, 2005, MOL CELL BIOL, V25, P10079, DOI 10.1128/MCB.25.22.10079-10086.2005; Xu XZ, 2003, FASEB J, V17, P1842, DOI 10.1096/fj.03-0310com	50	96	108	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 22	2007	26	53					7414	7422		10.1038/sj.onc.1210553	http://dx.doi.org/10.1038/sj.onc.1210553			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	236DA	17546051				2022-12-28	WOS:000251282000003
J	Ginestier, C; Adelaide, J; Goncalves, A; Repellini, L; Sircoulomb, F; Letessier, A; Finetti, P; Geneix, J; Charafe-Jauffret, E; Bertucci, F; Jacquemier, J; Viens, P; Birnbaum, D				Ginestier, C.; Adelaiede, J.; Goncalves, A.; Repellini, L.; Sircoulomb, F.; Letessier, A.; Finetti, P.; Geneix, J.; Charafe-Jauffret, E.; Bertucci, F.; Jacquemier, J.; Viens, P.; Birnbaum, D.			ERBB2 phosphorylation and trastuzumab sensitivity of breast cancer cell lines	ONCOGENE			English	Article						herceptin; trastuzumab; ERBB2; breast cancer; phosphorylation; tyrosine kinase	ADJUVANT CHEMOTHERAPY; MONOCLONAL-ANTIBODY; 1ST-LINE TREATMENT; PHASE-II; THERAPY; EXPRESSION; HERCEPTIN; EFFICACY; RESISTANCE; COMPLEX	Breast cancers that overexpress the ERBB2 tyrosine kinase receptor may be treated with the recombinant humanized monoclonal anti-ERBB2 antibody trastuzumab (herceptin). However, resistance to this targeted therapy is frequent. We have determined the response of 18 breast tumor cell lines to trastuzumab and compared it with the ERBB2 phosphorylation status using antibodies directed against tyrosine residue 1248. We show that sensitivity to trastuzumab is frequently associated with the expression of a phosphorylated ERBB2 protein.	Inst J Paoli I Calmettes, Ctr Rech Cancerol Marseille, INSERM, UMR599,Dept Oncol Mol, F-13009 Marseille, France; Inst J Paoli I Calmettes, Ctr Rech Cancerol Marseille, INSERM, UMR599,Dept Oncol Med, F-13009 Marseille, France; Univ Mediterranee, Fac Med, Marseille, France; Inst J Paoli I Calmettes, Dept BioPathol, F-13009 Marseille, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; UNICANCER; Institut Paoli-Calmette (IPC); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; UNICANCER; Institut Paoli-Calmette (IPC); UDICE-French Research Universities; Aix-Marseille Universite; UNICANCER; Institut Paoli-Calmette (IPC)	Birnbaum, D (corresponding author), Inst J Paoli I Calmettes, Ctr Rech Cancerol Marseille, INSERM, UMR599,Dept Oncol Mol, 27 Bd Lei Roure, F-13009 Marseille, France.	birnbaum@marseille.inserm.fr	ADELAIDE, José JA/O-4390-2017; Letessier, Anne/M-3431-2017; Ginestier, Christophe/M-8828-2017; Finetti, Pascal/O-8669-2017; Charafe-Jauffret, emmanuelle/P-6009-2017	ADELAIDE, José JA/0000-0003-4364-9857; Letessier, Anne/0000-0002-1894-4072; Ginestier, Christophe/0000-0002-7477-3837; Birnbaum, Daniel/0000-0001-7920-9883; Finetti, Pascal/0000-0002-2674-3123; Charafe-Jauffret, emmanuelle/0000-0002-0286-1299				Adelaide J, 2003, GENE CHROMOSOME CANC, V37, P333, DOI 10.1002/gcc.10218; Anastasi S, 2005, ONCOGENE, V24, P4540, DOI 10.1038/sj.onc.1208658; BADACHE A, 2004, NAT CELL BIOL, V6, P515; Baselga J, 2004, SEMIN ONCOL, V31, P51, DOI 10.1053/j.seminoncol.2004.07.022; Baselga J, 2005, J CLIN ONCOL, V23, P2162, DOI 10.1200/JCO.2005.01.014; Bernard-Marty C, 2006, DRUGS, V66, P1577, DOI 10.2165/00003495-200666120-00004; Bertucci F, 2004, ONCOGENE, V23, P2564, DOI 10.1038/sj.onc.1207361; Borg JP, 2000, NAT CELL BIOL, V2, P407, DOI 10.1038/35017038; Charafe-Jauffret E, 2006, ONCOGENE, V25, P2273, DOI 10.1038/sj.onc.1209254; Cho HS, 2003, NATURE, V421, P756, DOI 10.1038/nature01392; Cobleigh MA, 1999, J CLIN ONCOL, V17, P2639, DOI 10.1200/JCO.1999.17.9.2639; Diermeier S, 2005, EXP CELL RES, V304, P604, DOI 10.1016/j.yexcr.2004.12.008; Emens Leisha A, 2005, Am J Ther, V12, P243; ETHIER SP, 1993, CANCER RES, V53, P627; Ghatak S, 2005, J BIOL CHEM, V280, P8875, DOI 10.1074/jbc.M410882200; Gonzalez-Angulo AM, 2006, ONCOLOGIST, V11, P857, DOI 10.1634/theoncologist.11-8-857; Hudelist G, 2006, INT J CANCER, V118, P1126, DOI 10.1002/ijc.21492; Kauraniemi P, 2004, ONCOGENE, V23, P1010, DOI 10.1038/sj.onc.1207200; Konecny GE, 2006, CANCER RES, V66, P1630, DOI 10.1158/0008-5472.CAN-05-1182; Lacroix M, 2004, BREAST CANCER RES TR, V83, P249, DOI 10.1023/B:BREA.0000014042.54925.cc; Lee JW, 2006, CLIN CANCER RES, V12, P57, DOI 10.1158/1078-0432.CCR-05-0976; Letessier A, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-245; Li YM, 2004, CANCER CELL, V6, P459, DOI 10.1016/j.ccr.2004.09.027; Marty M, 2005, J CLIN ONCOL, V23, P4265, DOI 10.1200/JCO.2005.04.173; Mass Robert D, 2005, Clin Breast Cancer, V6, P240, DOI 10.3816/CBC.2005.n.026; Nagata Y, 2004, CANCER CELL, V6, P117, DOI 10.1016/j.ccr.2004.06.022; Nagy P, 2005, CANCER RES, V65, P473; Nahta R, 2004, CANCER RES, V64, P3981, DOI 10.1158/0008-5472.CAN-03-3900; Nahta R, 2006, NAT CLIN PRACT ONCOL, V3, P269, DOI 10.1038/ncponc0509; Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008; Orsetti B, 2004, CANCER RES, V64, P6453, DOI 10.1158/0008-5472.CAN-04-0756; Pegram MD, 1999, SEMIN ONCOL, V26, P89; Piccart-Gebhart MJ, 2005, NEW ENGL J MED, V353, P1659, DOI 10.1056/NEJMoa052306; Ramsauer VP, 2003, J BIOL CHEM, V278, P30142, DOI 10.1074/jbc.M303220200; Romond EH, 2005, NEW ENGL J MED, V353, P1673, DOI 10.1056/NEJMoa052122; Tan-Chiu E, 2005, J CLIN ONCOL, V23, P7811, DOI 10.1200/JCO.2005.02.4091; Vogel CL, 2001, ONCOLOGY-BASEL, V61, P37, DOI 10.1159/000055400; Vogel CL, 2002, J CLIN ONCOL, V20, P719, DOI 10.1200/JCO.20.3.719; Wobus M, 2001, GYNECOL ONCOL, V83, P227, DOI 10.1006/gyno.2001.6369	39	50	51	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 1	2007	26	50					7163	7169		10.1038/sj.onc.1210528	http://dx.doi.org/10.1038/sj.onc.1210528			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	228GF	17525746				2022-12-28	WOS:000250715000011
J	Wang, N; Lin, KK; Lu, Z; Lam, KS; Newton, R; Xu, X; Yu, Z; Gill, GN; Andersen, B				Wang, N.; Lin, K. K.; Lu, Z.; Lam, K. S.; Newton, R.; Xu, X.; Yu, Z.; Gill, G. N.; Andersen, B.			The LIM-only factor LMO4 regulates expression of the BMP7 gene through an HDAC2-dependent mechanism, and controls cell proliferation and apoptosis of mammary epithelial cells	ONCOGENE			English	Article						breast cancer; lim domain; LMO; proliferation; apoptosis; HDAC	BONE MORPHOGENETIC PROTEIN-7; CANCER PROGRESSION; DOMAIN; RECEPTOR; GROWTH; GLAND; IDENTIFICATION; TRANSCRIPTION; ACTIVATION; INVASION	The nuclear LIM-only protein 4 (LMO4) is upregulated in breast cancer, especially estrogen receptor-negative tumors, and its overexpression in mice leads to hyperplasia and tumor formation. Here, we show that deletion of LMO4 in the mammary glands of mice leads to impaired lobuloalveolar development due to decreased epithelial cell proliferation. With the goal of discovering potential LMO4-target genes, we also developed a conditional expression system in MCF-7 cells for both LMO4 and a dominant negative (DN) form of its co-regulator, cofactor of LIM domains (Clim/Ldb/Nli). We then used DNA microarrays to identify genes responsive to LMO4 and DN-Clim upregulation. One of the genes common to both data sets was bone morphogenic protein 7 (BMP7), whose expression is also significantly correlated with LMO4 transcript levels in a large dataset of human breast cancers, suggesting that BMP7 is a bona. de target gene of LMO4 in breast cancer. Inhibition of BMP7 partially blocks the effects of LMO4 on apoptosis, indicating that BMP7 mediates at least some functions of LMO4. Gene transfer studies show that LMO4 regulates the BMP7 promoter, and chromatin immunoprecipitation studies show that LMO4 and its cofactor Clim2 are recruited to the BMP7 promoter. Furthermore, we demonstrate that HDAC2 recruitment to the BMP7 promoter is inhibited by upregulation of LMO4 and that HDAC2 knockdown upregulates the promoter. These studies suggest a novel mechanism of action for LMO4: LMO4, Clim2 and HDAC2 are part of a transcriptional complex, and increased LMO4 levels can disrupt the complex, leading to decreased HDAC2 recruitment and increased promoter activity.	Univ Calif Irvine, Dept Med, Irvine, CA 92697 USA; Univ Calif Irvine, Dept Biol Chem, Irvine, CA 92697 USA; Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA	University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California San Diego	Andersen, B (corresponding author), Univ Calif Irvine, Dept Med, Sprague Hall,Room 206, Irvine, CA 92697 USA.	bogi@uci.edu	Lin, Kevin/C-1959-2009; Lu, ZX/G-4586-2010	Lin, Kevin/0000-0003-4305-8352	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR044882] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR44882] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Alarmo EL, 2006, GENE CHROMOSOME CANC, V45, P411, DOI 10.1002/gcc.20307; Augsburger A, 1999, NEURON, V24, P127, DOI 10.1016/S0896-6273(00)80827-2; Bach I, 2000, MECH DEVELOP, V91, P5, DOI 10.1016/S0925-4773(99)00314-7; Baldi P, 2001, BIOINFORMATICS, V17, P509, DOI 10.1093/bioinformatics/17.6.509; Cheng N, 2005, ONCOGENE, V24, P5053, DOI 10.1038/sj.onc.1208685; Chi SJ, 1999, ONCOGENE, V18, P2281, DOI 10.1038/sj.onc.1202538; Dean C, 2004, DEVELOPMENT, V131, P4155, DOI 10.1242/dev.01285; Deane JE, 2004, EMBO J, V23, P3589, DOI 10.1038/sj.emboj.7600376; Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-r60; Farmer P, 2005, ONCOGENE, V24, P4660, DOI 10.1038/sj.onc.1208561; Gruvberger S, 2001, CANCER RES, V61, P5979; Hahm KM, 2004, MOL CELL BIOL, V24, P2074, DOI 10.1128/MCB.24.5.2074-2082.2004; Hogan BLM, 1996, GENE DEV, V10, P1580, DOI 10.1101/gad.10.13.1580; Jurata LW, 1998, J BIOL CHEM, V273, P3152, DOI 10.1074/jbc.273.6.3152; Kawai S, 2001, BONE, V29, P54, DOI 10.1016/S8756-3282(01)00470-7; Kusumegi T, 2004, J BIOCHEM MOL TOXIC, V18, P1, DOI 10.1002/jbt.20004; Landis MD, 2005, ONCOGENE, V24, P5173, DOI 10.1038/sj.onc.1208712; Lee SK, 2005, MOL CELL NEUROSCI, V28, P205, DOI 10.1016/j.mcn.2004.04.010; Lu Z, 2006, ONCOGENE, V25, P2920, DOI 10.1038/sj.onc.1209318; LUO G, 1995, GENE DEV, V9, P2808, DOI 10.1101/gad.9.22.2808; Maeda S, 2005, CELL, V121, P977, DOI 10.1016/j.cell.2005.04.014; Milan M, 1998, GENE DEV, V12, P2912, DOI 10.1101/gad.12.18.2912; Mizunuma H, 2003, BRIT J CANCER, V88, P1543, DOI 10.1038/sj.bjc.6600952; Monroe DG, 2000, MOL CELL BIOL, V20, P4626, DOI 10.1128/MCB.20.13.4626-4634.2000; Mousses S, 2002, CANCER RES, V62, P1256; Pelengaris S, 2002, NAT REV CANCER, V2, P764, DOI 10.1038/nrc904; Rabbitts TH, 1999, CANCER RES, V59, p1794S; Ryan DP, 2006, J MOL BIOL, V359, P66, DOI 10.1016/j.jmb.2006.02.074; Singh RR, 2005, CANCER RES, V65, P10594, DOI 10.1158/0008-5472.CAN-05-2268; Sugihara TM, 1998, P NATL ACAD SCI USA, V95, P15418, DOI 10.1073/pnas.95.26.15418; Sum EYM, 2005, P NATL ACAD SCI USA, V102, P7659, DOI 10.1073/pnas.0502990102; Sum EYM, 2005, J HISTOCHEM CYTOCHEM, V53, P475, DOI 10.1369/jhc.4A6553.2005; Sum EYM, 2005, ONCOGENE, V24, P4820, DOI 10.1038/sj.onc.1208638; Visvader JE, 2001, P NATL ACAD SCI USA, V98, P14452, DOI 10.1073/pnas.251547698; Wagner KU, 1997, NUCLEIC ACIDS RES, V25, P4323, DOI 10.1093/nar/25.21.4323; Wang N, 2004, ONCOGENE, V23, P1507, DOI 10.1038/sj.onc.1207288	36	51	51	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 27	2007	26	44					6431	6441		10.1038/sj.onc.1210465	http://dx.doi.org/10.1038/sj.onc.1210465			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	214KY	17452977				2022-12-28	WOS:000249737600007
J	Schavolt, KL; Pietenpol, JA				Schavolt, K. L.; Pietenpol, J. A.			p53 and Delta Np63 alpha differentially bind and regulate target genes involved in cell cycle arrest, DNA repair and apoptosis	ONCOGENE			English	Article						p21; 14-3-36; p48; p53R2; Noxa; Fas/APO1	IN-VIVO; PROMOTER; DAMAGE; P63; FAMILY; PHOSPHORYLATION; 14-3-3-SIGMA; EPITHELIUM; INHIBITOR; MEDIATOR	The mechanism by which the p53 family of proteins coordinately regulates select target genes after various types of cell stress is not well understood. To further de. ne factors that dictate regulation of target genes, we examined the binding of p53, Delta Np63 alpha and RNA polymerase II (pol II) to the regulatory regions of select target genes in primary human epidermal keratinocytes (HEKs) using chromatin immunoprecipitation. In rapidly proliferating cells, we observed constitutive binding of DNp63a and varying levels of p53 binding, to consensus sites in target genes involved in cell cycle arrest, DNA repair and apoptosis. Following genotoxic stress, p53 occupancy increased whereas DNp63a occupancy decreased at the majority of binding sites examined. Microarray analysis of transcripts isolated from HEKs ectopically expressing p53 and DNp63a revealed an inverse regulation of select target genes by the two family members. Collectively, our results suggest that DNp63a can function as a repressor of select p53 target genes involved in growth arrest, DNA repair and apoptosis, and that the location of the p53 consensus binding site(s) in a target gene may dictate whether pol II is constitutively bound in proliferating cells.	Vanderbilt Univ, Sch Med, Ctr Mol Toxicol, Dept Biochem, Nashville, TN USA	Vanderbilt University	Pietenpol, JA (corresponding author), Vanderbilt Ingram Canc Ctr, Nashville, TN 37232 USA.	j.pietenpol@vanderbilt.edu			NCI NIH HHS [CA70856, CA68485, CA105436] Funding Source: Medline; NIEHS NIH HHS [ES00267, T32 ES0702] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA068485, R01CA105436, R01CA070856] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000267] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Appella E, 2001, EUR J BIOCHEM, V268, P2764, DOI 10.1046/j.1432-1327.2001.02225.x; Bakkers J, 2002, DEV CELL, V2, P617, DOI 10.1016/S1534-5807(02)00163-6; Barbieri CE, 2005, CANCER RES, V65, P2314, DOI 10.1158/0008-5472.CAN-04-3449; Barbieri CE, 2006, CANCER RES, V66, P7589, DOI 10.1158/0008-5472.CAN-06-2020; Beretta C, 2005, CELL CYCLE, V4, P1625, DOI 10.4161/cc.4.11.2135; Bode AM, 2004, NAT REV CANCER, V4, P793, DOI 10.1038/nrc1455; Dohn M, 2001, ONCOGENE, V20, P3193, DOI 10.1038/sj.onc.1204427; Dumaz N, 1999, EMBO J, V18, P7002, DOI 10.1093/emboj/18.24.7002; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Espinosa JM, 2003, MOL CELL, V12, P1015, DOI 10.1016/S1097-2765(03)00359-9; Harms K, 2004, CELL MOL LIFE SCI, V61, P822, DOI 10.1007/s00018-003-3304-4; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Ihrie RA, 2005, CELL, V120, P843, DOI 10.1016/j.cell.2005.01.008; Jacobs WB, 2005, NEURON, V48, P743, DOI 10.1016/j.neuron.2005.10.027; Kaeser MD, 2002, P NATL ACAD SCI USA, V99, P95, DOI 10.1073/pnas.012283399; Kaeser MD, 2004, ONCOGENE, V23, P4007, DOI 10.1038/sj.onc.1207536; Lambert PF, 1998, J BIOL CHEM, V273, P33048, DOI 10.1074/jbc.273.49.33048; Muller M, 1998, J EXP MED, V188, P2033, DOI 10.1084/jem.188.11.2033; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Qian H, 2002, ONCOGENE, V21, P7901, DOI 10.1038/sj.onc.1205974; Sasaki Y, 2005, ONCOGENE, V24, P5131, DOI 10.1038/sj.onc.1208695; Szak ST, 2001, MOL CELL BIOL, V21, P3375, DOI 10.1128/MCB.21.10.3375-3386.2001; Tan T, 2002, MOL CELL BIOL, V22, P3247, DOI 10.1128/MCB.22.10.3247-3254.2002; Tanaka H, 2000, NATURE, V404, P42, DOI 10.1038/35003506; Weinberg RL, 2005, J MOL BIOL, V348, P589, DOI 10.1016/j.jmb.2005.03.014; Westfall MD, 2004, CARCINOGENESIS, V25, P857, DOI 10.1093/carcin/bgh148; Westfall MD, 2003, MOL CELL BIOL, V23, P2264, DOI 10.1128/MCB.23.7.2264-2276.2003; ZAUBERMAN A, 1995, NUCLEIC ACIDS RES, V23, P2584, DOI 10.1093/nar/23.14.2584	28	31	32	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 13	2007	26	42					6125	6132		10.1038/sj.onc.1210441	http://dx.doi.org/10.1038/sj.onc.1210441			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	209PU	17404570				2022-12-28	WOS:000249401300002
J	Liu, H; Zhou, Y; Boggs, SE; Belinsky, SA; Liu, J				Liu, H.; Zhou, Y.; Boggs, S. E.; Belinsky, S. A.; Liu, J.			Cigarette smoke induces demethylation of prometastatic oncogene synuclein-gamma in lung cancer cells by downregulation of DNMT3B	ONCOGENE			English	Article						synuclein-gamma; DNA methylation; DNMT3B; cigarette smoke extract; lung cancer; cell invasion	ABERRANT PROMOTER METHYLATION; HUMAN BREAST-CANCER; DNA METHYLTRANSFERASES; NOVO METHYLATION; PROTEIN-KINASE; GENE; EXPRESSION; HYPERMETHYLATION; HYPOMETHYLATION; IDENTIFICATION	The prometastatic oncogene synuclein-gamma ( SNCG) is not expressed in normal lung tissues, but it is highly expressed in lung tumors. Here, we show that cigarette smoke extract ( CSE) has strong inducing effects on SNCG gene expression in A549 lung cancer cells through demethylation of SNCG CpG island. CSE treatment also augments the invasive capacity of A549 cells in an SNCG-dependent manner. To elucidate the mechanisms underlying the demethylating effects of CSE, we examined expression levels of DNA methyltransferases ( DNMTs), 1, 3A and 3B in CSE-treated cells. We show that the mRNA expression of DNMT3B is specifically downregulated by CSE with a kinetics concurrent to SNCG reexpression. Utilizing siRNA to knockdown DNMT3B expression, we show that inhibition of DNMT3B directly increases SNCG mRNA expression. We further show that exogenous overexpression of DNMT3B in an SNCG-positive lung cancer cell line H292 suppresses SNCG mRNA and protein expression and induces de novo methylation of SNCG CpG island, whereas overexpression of DNMT1 or DNMT3A has no effects. Taken together, these new. findings demonstrate that tobacco exposure induces the abnormal expression of SNCG in lung cancer cells through downregulation of DNMT3B. This work sheds light on the molecular understanding of demethylation of this oncogene during cancer progression.	Palo Alto Hlth Care Syst, Dept Vet Affairs, Palo Alto, CA 94304 USA; Lovelace Respriatory Res Inst, Albuquerque, NM USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System; Lovelace Respiratory Research Institute	Liu, J (corresponding author), Palo Alto Hlth Care Syst, Dept Vet Affairs, 154P,3801 Miranda Ave, Palo Alto, CA 94304 USA.	Jingwen.Liu@med.va.gov						Bachman KE, 2001, J BIOL CHEM, V276, P32282, DOI 10.1074/jbc.M104661200; Belinsky SA, 2003, CANCER RES, V63, P7089; Belinsky SA, 1996, P NATL ACAD SCI USA, V93, P4045, DOI 10.1073/pnas.93.9.4045; BELINSKY SA, 2004, NAT REV CANCER, V4, P11; Brueckner B, 2004, TRENDS PHARMACOL SCI, V25, P551, DOI 10.1016/j.tips.2004.09.004; Bruening W, 2000, CANCER-AM CANCER SOC, V88, P2154, DOI 10.1002/(SICI)1097-0142(20000501)88:9<2154::AID-CNCR23>3.0.CO;2-9; Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691; CAO D, 2005, MODERN PATHOL, V1, P1; Dodge JE, 2005, J BIOL CHEM, V280, P17986, DOI 10.1074/jbc.M413246200; Fujiwara K, 2005, CLIN CANCER RES, V11, P1219; Gius D, 2004, CANCER CELL, V6, P361, DOI 10.1016/j.ccr.2004.08.029; Guo YJ, 2002, J BIOL CHEM, V277, P41571, DOI 10.1074/jbc.M201864200; Hecht SS, 1999, JNCI-J NATL CANCER I, V91, P1194, DOI 10.1093/jnci/91.14.1194; Hermann A, 2004, CELL MOL LIFE SCI, V61, P2571, DOI 10.1007/s00018-004-4201-1; Jemal A, 2002, CA-CANCER J CLIN, V52, P23, DOI 10.3322/canjclin.52.1.23; Ji HJ, 1997, CANCER RES, V57, P759; Lavedan C, 1998, HUM GENET, V103, P106, DOI 10.1007/s004390050792; Li ZK, 2004, CANCER-AM CANCER SOC, V101, P58, DOI 10.1002/cncr.20321; Lin RK, 2007, LUNG CANCER, V55, P205, DOI 10.1016/j.lungcan.2006.10.022; Liu HY, 2005, CANCER RES, V65, P7635, DOI 10.1158/0008-5472.CAN-05-1089; Loriot A, 2006, J BIOL CHEM, V281, P10118, DOI 10.1074/jbc.M510469200; Lu AP, 2001, ONCOGENE, V20, P5173, DOI 10.1038/sj.onc.1204668; Lyko F, 1999, NAT GENET, V23, P363, DOI 10.1038/15551; Mercer BA, 2004, J BIOL CHEM, V279, P17690, DOI 10.1074/jbc.M313842200; Oka M, 2006, J BIOL CHEM, V281, P9901, DOI 10.1074/jbc.M511100200; Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6; Pakneshan P, 2004, J BIOL CHEM, V279, P31735, DOI 10.1074/jbc.M401669200; Palmisano WA, 2000, CANCER RES, V60, P5954; Patra SK, 2002, MOL CARCINOGEN, V33, P163, DOI 10.1002/mc.10033; PFEIFER GP, 1986, FEBS LETT, V207, P75, DOI 10.1016/0014-5793(86)80015-1; Pruitt K, 2005, J BIOL CHEM, V280, P23363, DOI 10.1074/jbc.M503083200; Pulling LC, 2004, CANCER RES, V64, P3844, DOI 10.1158/0008-5472.CAN-03-2119; Rhee I, 2002, NATURE, V416, P552, DOI 10.1038/416552a; Robert MF, 2003, NAT GENET, V33, P61, DOI 10.1038/ng1068; Robertson KD, 1999, NUCLEIC ACIDS RES, V27, P2291, DOI 10.1093/nar/27.11.2291; Rountree MR, 2000, NAT GENET, V25, P269, DOI 10.1038/77023; Russo AL, 2005, CLIN CANCER RES, V11, P2466, DOI 10.1158/1078-0432.CCR-04-1962; Schrump DS, 2005, SEMIN ONCOL, V32, P488, DOI 10.1053/j.seminoncol.2005.07.007; Suzuki M, 2004, CANCER RES, V64, P3137, DOI 10.1158/0008-5472.CAN-03-3046; THOMPSON E, 1940, DRUG NEWS PERSPECT, V18, P405; Wu KJ, 2003, CANCER EPIDEM BIOMAR, V12, P920; Yanagawa N, 2004, CLIN CANCER RES, V10, P2447, DOI 10.1158/1078-0432.CCR-03-0107; Zhao W, 2006, INT J ONCOL, V28, P1081; Zochbauer-Muller S, 2001, CANCER RES, V61, P249	44	74	82	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 30	2007	26	40					5900	5910		10.1038/sj.onc.1210400	http://dx.doi.org/10.1038/sj.onc.1210400			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	205OH	17369845				2022-12-28	WOS:000249123100007
J	Feng, Q; Sekula, D; Muller, R; Freemantle, SJ; Dmitrovsky, E				Feng, Q.; Sekula, D.; Muller, R.; Freemantle, S. J.; Dmitrovsky, E.			Uncovering residues that regulate cyclin D1 proteasomal degradation	ONCOGENE			English	Article						cyclin D1; all-trans-retinoic acid; ubiquitination	N-TERMINAL UBIQUITINATION; NUCLEAR-LOCALIZATION; RETINOIC ACID; PHOSPHORYLATION; PROTEOLYSIS; CANCER; SIGNAL; TARGET; UBE1L; PREVENTION	Cyclin D1 regulates G1 cell-cycle progression and is aberrantly expressed in carcinogenesis. Proteasomal degradation of cyclin D1 was highlighted as a cancer chemopreventive mechanism. To understand this mechanism better, residues responsible for degradation and ubiquitination of cyclin D1 were investigated. Eighteen lysines in cyclin D1 had single, double or multiple mutations engineered before transfection into BEAS-2B human bronchial epithelial (HBE) cells to evaluate stabilities after all-trans-retinoic acid (RA) or cycloheximide treatments. Specific mutations stabilized cyclin D1, including substitutions of lysines surrounding the cyclin box domain that inhibited RA-mediated degradation and extended the cyclin D1 half-life. Mutation of all cyclin D1 lysines blocked polyubiquitination. N-terminus (but not C-terminus) modification stabilized cyclin D1. Ubiquitination resistant mutants preferentially localized cyclin D1 to the nucleus, directly implicating subcellular localization in regulating cyclin D1 degradation. Taken together, these findings uncover specific residues conferring ubiquitination of cyclin D1. These provide a mechanistic basis for proteasomal degradation of cyclin D1.	Dartmouth Med Sch, Dept Pharmacol & Toxicol, Hanover, NH 03755 USA; Univ Marburg, IMT, Marburg, Germany; Dartmouth Med Sch, Dept Med, Hanover, NH USA; Dartmouth Med Sch, Norris Cotton Canc Ctr, Hanover, NH USA; Dartmouth Hitchcock Med Ctr, Lebanon, NH 03766 USA	Dartmouth College; Philipps University Marburg; Dartmouth College; Dartmouth College; Norris Cotton Cancer Center; Dartmouth College	Dmitrovsky, E (corresponding author), Dartmouth Med Sch, Dept Pharmacol & Toxicol, Hanover, NH 03755 USA.	Ethan.Dmitrovsky@Dartmouth.EDU	Müller, Rolf/L-4997-2016	Müller, Rolf/0000-0003-3339-4248	NATIONAL CANCER INSTITUTE [R01CA087546, R01CA111422] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA111422, R01 CA087546] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agami R, 2000, CELL, V102, P55, DOI 10.1016/S0092-8674(00)00010-6; Aggarwal BB, 2004, ANTICANCER RES, V24, P2783; Alt JR, 2000, GENE DEV, V14, P3102, DOI 10.1101/gad.854900; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; Batonnet S, 2004, J BIOL CHEM, V279, P5413, DOI 10.1074/jbc.M310315200; Chernov MV, 2001, J BIOL CHEM, V276, P31819, DOI 10.1074/jbc.M103170200; Ciechanover A, 2004, TRENDS CELL BIOL, V14, P103, DOI 10.1016/j.tcb.2004.01.004; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; Coulombe P, 2004, MOL CELL BIOL, V24, P6140, DOI 10.1128/MCB.24.14.6140-6150.2004; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; Diehl JA, 1997, GENE DEV, V11, P957, DOI 10.1101/gad.11.8.957; Diehl JA, 2002, CANCER BIOL THER, V1, P226, DOI 10.4161/cbt.72; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; DMITROVSKY E, 2002, ENCY CANC, P449; Dragnev KH, 2005, J CLIN ONCOL, V23, P8757, DOI 10.1200/JCO.2005.01.9521; Dragnev KH, 2004, CLIN CANCER RES, V10, P2570, DOI 10.1158/1078-0432.CCR-03-0271; Dragnev KH, 2001, ANN NY ACAD SCI, V952, P13, DOI 10.1111/j.1749-6632.2001.tb02724.x; Fung TK, 2005, CELL CYCLE, V4, P1411, DOI 10.4161/cc.4.10.2046; Germain D, 2000, J BIOL CHEM, V275, P12074, DOI 10.1074/jbc.275.16.12074; Gladden AB, 2005, J CELL BIOCHEM, V96, P906, DOI 10.1002/jcb.20613; Gregory MA, 2000, MOL CELL BIOL, V20, P2423, DOI 10.1128/MCB.20.7.2423-2435.2000; King RW, 1996, MOL BIOL CELL, V7, P1343, DOI 10.1091/mbc.7.9.1343; Kitareewan S, 2002, P NATL ACAD SCI USA, V99, P3806, DOI 10.1073/pnas.052011299; Klotzbucher A, 1996, EMBO J, V15, P3053, DOI 10.1002/j.1460-2075.1996.tb00668.x; KOBAYASHI H, 1992, MOL BIOL CELL, V3, P1279, DOI 10.1091/mbc.3.11.1279; Langenfeld J, 1997, P NATL ACAD SCI USA, V94, P12070, DOI 10.1073/pnas.94.22.12070; Lu FM, 2003, CANCER RES, V63, P7056; Ma Y, 2005, CANCER RES, V65, P6476, DOI 10.1158/0008-5472.CAN-05-0370; Patel MI, 2005, CLIN CANCER RES, V11, P1999, DOI 10.1158/1078-0432.CCR-04-1877; Peters JM, 2002, MOL CELL, V9, P931, DOI 10.1016/S1097-2765(02)00540-3; Petty WJ, 2003, LUNG CANCER, V41, pS155, DOI 10.1016/S0169-5002(03)00159-4; Pitha-Rowe I, 2004, CANCER RES, V64, P8109, DOI 10.1158/0008-5472.CAN-03-3938; Pitha-Rowe I, 2004, J BIOL CHEM, V279, P18178, DOI 10.1074/jbc.M309259200; Radu A, 2003, MOL CELL BIOL, V23, P6139, DOI 10.1128/MCB.23.17.6139-6149.2003; SCHERER DC, 1995, P NATL ACAD SCI USA, V92, P11259, DOI 10.1073/pnas.92.24.11259; Solomon DA, 2003, J BIOL CHEM, V278, P30339, DOI 10.1074/jbc.M303969200; Spinella MJ, 1999, J BIOL CHEM, V274, P22013, DOI 10.1074/jbc.274.31.22013; Zwicker J, 1999, ONCOGENE, V18, P19, DOI 10.1038/sj.onc.1202286	38	26	28	0	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 2	2007	26	35					5098	5106		10.1038/sj.onc.1210309	http://dx.doi.org/10.1038/sj.onc.1210309			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	196MT	17310991				2022-12-28	WOS:000248487400008
J	Lue, H; Thiele, M; Franz, J; Dahl, E; Speckgens, S; Leng, L; Fingerle-Rowson, G; Bucala, R; Luscher, B; Bernhagen, J				Lue, H.; Thiele, M.; Franz, J.; Dahl, E.; Speckgens, S.; Leng, L.; Fingerle-Rowson, G.; Bucala, R.; Luscher, B.; Bernhagen, J.			Macrophage migration inhibitory factor (MIF) promotes cell survival by activation of the Akt pathway and role for CSN5/JAB1 in the control of autocrine MIF activity	ONCOGENE			English	Article						MIF; JAB1; apoptosis; survival; Akt pathway; cytokine	HUMAN BREAST-CANCER; COP9 SIGNALOSOME; PROTEIN-KINASE; SIGNALING PATHWAY; PI3K/AKT PATHWAY; PTEN EXPRESSION; REGULATORY ROLE; TUMOR-GROWTH; CYTOKINE; BINDING	The phosphoinositide-3-kinase (PI3K)/Akt signaling pathway plays an important role in cell survival and the development of cancer. Macrophage migration inhibitory factor (MIF) is a critical in. ammatory cytokine that was recently associated with tumorigenesis and that potently inhibits apoptosis. This may involve inhibition of p53-dependent genes, but the initiating molecular mechanism of how MIF controls survival/apoptosis is unknown. Here, we show that MIF prevents apoptosis and promotes tumor cell survival by directly activating the Akt pathway. MIF enhanced Akt activity in primary and immortalized. broblasts (MEF and NIH/3T3), HeLa cervix carcinoma cells and various breast cancer cell lines. Activation was abolished by kinase inhibitors Ly294002 and PP2 and in Src/Yes/Fyn(SYF)(-/-) and CD74(-/-)(MEFs), while being enhanced in CD74-overexpressing MEFs, demonstrating that the MIF-induced Akt pathway encompasses signaling through the MIF receptor CD74 and the upstream kinases Src and PI3K. Akt was activated by exogenous rMIF and autocrine MIF action, as revealed by experiments in MIF-/- MEFs and antibody blockade. siRNA knockdown of CSN5/JAB1, a tumor marker and MIF-binding protein, showed that JAB1 controls autocrine MIF-mediated Akt signaling by inhibition of MIF secretion. Akt activation by MIF led to phosphorylation of the proapoptotic proteins BAD and Foxo3a. Apoptosis inhibition by MIF was functionally associated with Akt activation as it was abolished by overexpression of the Akt pathway inhibitor PTEN and occurred independently of p53. This was shown by studying DNA damage-induced apoptosis in. broblasts, the Fas death pathway in HeLa cells that do not express functional p53, and etoposide-induced apoptosis in breast carcinoma cells expressing mutant p53. Importantly, dependence of breast cancer cell survival on MIF correlated with Akt activation and the PTEN status of these cells. Thus, MIF can directly promote cell survival through activation of the PI3K/Akt pathway and this effect is critical for tumor cell survival.	Univ Hosp, Rhein Westfal TH Aachen, Dept Biochem & Mol Cell Biol, Inst Biochem, D-52074 Aachen, Germany; Univ Hosp, Rhein Westfal TH Aachen, Inst Pathol, D-52074 Aachen, Germany; Univ Hosp, Rhein Westfal TH Aachen, Dept Biochem & Mol Biol, D-52074 Aachen, Germany; Yale Univ, Sch Med, Dept Pathol & Med, New Haven, CT USA; Univ Hosp Cologne, Med Clin 1, Cologne, Germany	RWTH Aachen University; RWTH Aachen University Hospital; RWTH Aachen University; RWTH Aachen University Hospital; RWTH Aachen University; RWTH Aachen University Hospital; Yale University; University of Cologne	Bernhagen, J (corresponding author), Univ Hosp, Rhein Westfal TH Aachen, Dept Biochem & Mol Cell Biol, Inst Biochem, Pauwelsstr 30, D-52074 Aachen, Germany.	jbernhagen@ukaachen.de	Luscher, Bernhard/A-7330-2011	Luscher, Bernhard/0000-0002-9622-8709	NIAID NIH HHS [AI43210] Funding Source: Medline; NIAMS NIH HHS [AR49610] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR049610] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Adler AS, 2006, NAT GENET, V38, P421, DOI 10.1038/ng1752; Alessi DR, 1998, CURR OPIN GENET DEV, V8, P55, DOI 10.1016/S0959-437X(98)80062-2; Amin MA, 2006, BLOOD, V107, P2252, DOI 10.1182/blood-2005-05-2011; Amin MA, 2003, CIRC RES, V93, P321, DOI 10.1161/01.RES.0000087641.56024.DA; Bando H, 2002, JPN J CANCER RES, V93, P389, DOI 10.1111/j.1349-7006.2002.tb01269.x; Bech-Otschir D, 2002, J CELL SCI, V115, P467; BERNHAGEN J, 1993, NATURE, V365, P756, DOI 10.1038/365756a0; Brazil DP, 2002, CELL, V111, P293, DOI 10.1016/S0092-8674(02)01083-8; Burger-Kentischer A, 2005, FEBS LETT, V579, P1693, DOI 10.1016/j.febslet.2005.01.080; Byrne AM, 2005, J CELL MOL MED, V9, P777, DOI 10.1111/j.1582-4934.2005.tb00379.x; Calandra T, 2003, NAT REV IMMUNOL, V3, P791, DOI 10.1038/nri1200; Chamovitz DA, 2001, EMBO REP, V2, P96, DOI 10.1093/embo-reports/kve028; Chang F, 2003, LEUKEMIA, V17, P590, DOI 10.1038/sj.leu.2402824; Cheng JQ, 2005, ONCOGENE, V24, P7482, DOI 10.1038/sj.onc.1209088; Chesney J, 1999, MOL MED, V5, P181, DOI 10.1007/BF03402061; Datta SR, 2002, DEV CELL, V3, P631, DOI 10.1016/S1534-5807(02)00326-X; deGraffenried LA, 2004, ANN ONCOL, V15, P1510, DOI 10.1093/annonc/mdh388; Fingerle-Rowson G, 2003, P NATL ACAD SCI USA, V100, P9354, DOI 10.1073/pnas.1533295100; Flieger O, 2003, FEBS LETT, V551, P78, DOI 10.1016/S0014-5793(03)00900-1; Hagemann T, 2005, J IMMUNOL, V175, P1197, DOI 10.4049/jimmunol.175.2.1197; Hennessy BT, 2005, NAT REV DRUG DISCOV, V4, P988, DOI 10.1038/nrd1902; Hudson JD, 1999, J EXP MED, V190, P1375, DOI 10.1084/jem.190.10.1375; Kleemann R, 2000, NATURE, V408, P211, DOI 10.1038/35041591; Koyasu S, 2003, NAT IMMUNOL, V4, P313, DOI 10.1038/ni0403-313; Leng L, 2003, J EXP MED, V197, P1467, DOI 10.1084/jem.20030286; Lue HQ, 2006, CELL SIGNAL, V18, P688, DOI 10.1016/j.cellsig.2005.06.013; Mitchell RA, 2000, SEMIN CANCER BIOL, V10, P359, DOI 10.1006/scbi.2000.0328; Mitchell RA, 1999, J BIOL CHEM, V274, P18100, DOI 10.1074/jbc.274.25.18100; Mitchell RA, 2004, CELL SIGNAL, V16, P13, DOI 10.1016/j.cellsig.2003.07.002; Mitchell RA, 2002, P NATL ACAD SCI USA, V99, P345, DOI 10.1073/pnas.012511599; Morand EF, 2006, NAT REV DRUG DISCOV, V5, P399, DOI 10.1038/nrd2029; Nguyen MT, 2003, J IMMUNOL, V170, P3337, DOI 10.4049/jimmunol.170.6.3337; Nickel W, 2003, EUR J BIOCHEM, V270, P2109, DOI 10.1046/j.1432-1033.2003.03577.x; Nishihira J, 2003, ANN NY ACAD SCI, V995, P171, DOI 10.1111/j.1749-6632.2003.tb03220.x; Osaki M, 2004, APOPTOSIS, V9, P667, DOI 10.1023/B:APPT.0000045801.15585.dd; Osoegawa A, 2006, CANCER, V107, P154, DOI 10.1002/cncr.21961; Perren A, 1999, AM J PATHOL, V155, P1253, DOI 10.1016/S0002-9440(10)65227-3; Schober A, 2004, CIRCULATION, V109, P380, DOI 10.1161/01.CIR.0000109201.72441.09; Shi XR, 2006, IMMUNITY, V25, P595, DOI 10.1016/j.immuni.2006.08.020; Shimizu T, 1999, BIOCHEM BIOPH RES CO, V264, P751, DOI 10.1006/bbrc.1999.1584; Shiojima I, 2002, CIRC RES, V90, P1243, DOI 10.1161/01.RES.0000022200.71892.9F; Song G, 2005, J CELL MOL MED, V9, P59, DOI 10.1111/j.1582-4934.2005.tb00337.x; Sun HW, 1996, P NATL ACAD SCI USA, V93, P5191, DOI 10.1073/pnas.93.11.5191; Takahashi N, 1998, MOL MED, V4, P707, DOI 10.1007/BF03401765; Tomoda K, 1999, NATURE, V398, P160, DOI 10.1038/18230; Veeck J, 2006, ONCOGENE, V25, P3479, DOI 10.1038/sj.onc.1209386; Wetzker R, 2003, NAT REV MOL CELL BIO, V4, P651, DOI 10.1038/nrm1173; Wolf DA, 2003, NAT CELL BIOL, V5, P1029, DOI 10.1038/ncb1203-1029; Zapata JM, 1998, BREAST CANCER RES TR, V47, P129, DOI 10.1023/A:1005940832123	49	270	285	1	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 2	2007	26	35					5046	5059		10.1038/sj.onc.1210318	http://dx.doi.org/10.1038/sj.onc.1210318			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	196MT	17310986				2022-12-28	WOS:000248487400003
J	Spankuch, B; Kurunci-Csacsko, E; Kaufmann, M; Strebhardt, K				Spaenkuch, B.; Kurunci-Csacsko, E.; Kaufmann, M.; Strebhardt, K.			Rational combinations of siRNAs targeting Plk1 with breast cancer drugs	ONCOGENE			English	Article						plk1-. siRNA; paclitaxel; drug sensitivity; Herceptin	POLO-LIKE KINASE; DOWN-REGULATION; IN-VIVO; TRASTUZUMAB RESISTANCE; INDUCED APOPTOSIS; RNA INTERFERENCE; MAMMALIAN-CELLS; TUMOR-CELLS; GENE; GROWTH	Commonly used drugs for the treatment of breast cancer patients like paclitaxel and Herceptin often show severe side effects or induce resistance in clinical settings. Thus, we analysed a combination of Plk1 (polo-like kinase 1)-specific small interfering RNAs (siRNAs), a powerful tool to induce 'mitotic catastrophe' in cancer cells, together with these drugs to identify conditions for enhanced drug sensitivity. After transfection, the antineoplastic agents were added and cell proliferation, apoptosis and cell cycle distribution in breast cancer cells (MCF-7, SK-BR-3, MDA-MIB-435 and BT-474) and in primary human mammary epithelial cells were determined. Downregulation of cellular Plk1 levels led to an elevated percentage of cells in G(2)/M phase. The percentage of apoptotic nuclei in MCF-7, MDA-MB-435, SK-BR-3 and BT-474 cells was clearly increased after incubation with Plk1-specific siRNAs and paclitaxel. Interestingly, the caspase pathway was activated after treatment with Plk1-specific siRNAs and paclitaxel or Herceptin. Treatment of breast cancer cells with siRNAs targeting Plk1 improved the sensitivity toward paclitaxel and Herceptin in a synergistic manner. In all experiments, very low concentrations across a wide range of clinically relevant concentrations were sufficient to induce an anti proliferative effect. The combination of Plk1-specific siRNAs with modern breast cancer drugs seems to represent rational combinations to be tested in preclinical trials.	Univ Frankfurt, Sch Med, Dept Obstet & Gynecol, D-60590 Frankfurt, Germany	Goethe University Frankfurt	Spankuch, B (corresponding author), Univ Frankfurt, Sch Med, Dept Obstet & Gynecol, Theodor Stern Kai 7, D-60590 Frankfurt, Germany.	birgit.spaenkuch@t-online.de	Strebhardt, Klaus/E-8765-2011	Strebhardt, Klaus/0000-0003-2173-9763				Ahmad N, 2004, FASEB J, V18, P5, DOI 10.1096/fj.03-0848hyp; Ando K, 2004, J BIOL CHEM, V279, P25549, DOI 10.1074/jbc.M314182200; Barr FA, 2004, NAT REV MOL CELL BIO, V5, P429, DOI 10.1038/nrm1401; Blain SW, 2003, CANCER CELL, V3, P111, DOI 10.1016/S1535-6108(03)00026-6; Blajeski AL, 2001, EXP CELL RES, V270, P277, DOI 10.1006/excr.2001.5349; Check E, 2005, NAT MED, V11, P243, DOI 10.1038/nm0305-243; Chen XM, 2000, BIOCHEM BIOPH RES CO, V277, P757, DOI 10.1006/bbrc.2000.3731; CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4; Clynes RA, 2000, NAT MED, V6, P443, DOI 10.1038/74704; Cogswell JP, 2000, CELL GROWTH DIFFER, V11, P615; Crown J, 2003, BREAST CANCER RES TR, V79, pS11; Dai DH, 2005, CANCER RES, V65, P9517, DOI 10.1158/0008-5472.CAN-05-1613; Dubska L, 2005, FEBS LETT, V579, P4149, DOI 10.1016/j.febslet.2005.06.047; Eckerdt F, 2005, ONCOGENE, V24, P267, DOI 10.1038/sj.onc.1208273; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Esteva FJ, 2002, J CLIN ONCOL, V20, P1800, DOI 10.1200/JCO.2002.07.058; Gleave ME, 2005, NAT REV CANCER, V5, P468, DOI 10.1038/nrc1631; Gumireddy K, 2005, CANCER CELL, V7, P275, DOI 10.1016/j.ccr.2005.02.009; Jordan MA, 2004, NAT REV CANCER, V4, P253, DOI 10.1038/nrc1317; Kauselmann G, 1999, EMBO J, V18, P5528, DOI 10.1093/emboj/18.20.5528; Lane HA, 2000, MOL CELL BIOL, V20, P3210, DOI 10.1128/MCB.20.9.3210-3223.2000; Lane HA, 1996, J CELL BIOL, V135, P1701, DOI 10.1083/jcb.135.6.1701; Liu XQ, 2006, MOL CELL BIOL, V26, P2093, DOI 10.1128/MCB.26.6.2093-2108.2006; Liu XQ, 2003, P NATL ACAD SCI USA, V100, P5789, DOI 10.1073/pnas.1031523100; Marches R, 2004, INT J CANCER, V112, P492, DOI 10.1002/ijc.20378; Mimura K, 2005, CLIN CANCER RES, V11, P4898, DOI 10.1158/1078-0432.CCR-04-2476; Nahta R, 2004, CANCER RES, V64, P3981, DOI 10.1158/0008-5472.CAN-03-3900; Nahta R, 2006, CANCER LETT, V232, P123, DOI 10.1016/j.canlet.2005.01.041; Nahta R, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1612; Nishii K, 1996, ONCOGENE, V13, P2225; Nogawa M, 2005, J CLIN INVEST, V115, P978, DOI 10.1172/JCI200523043; SCHIFF PB, 1980, P NATL ACAD SCI-BIOL, V77, P1561, DOI 10.1073/pnas.77.3.1561; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; Smith MR, 1997, BIOCHEM BIOPH RES CO, V234, P397, DOI 10.1006/bbrc.1997.6633; Smits VAJ, 2000, NAT CELL BIOL, V2, P672, DOI 10.1038/35023629; Soutschek J, 2004, NATURE, V432, P173, DOI 10.1038/nature03121; Spankuch B, 2006, CANCER RES, V66, P5836, DOI 10.1158/0008-5472.CAN-06-0343; Spankuch B, 2005, CURR PHARM DESIGN, V11, P3405, DOI 10.2174/138161205774370834; Spankuch B, 2004, JNCI-J NATL CANCER I, V96, P862, DOI 10.1093/jnci/djh146; Spankuch-Schmitt B, 2002, JNCI-J NATL CANCER I, V94, P1863, DOI 10.1093/jnci/94.24.1863; Spankuch-Schmitt B, 2002, ONCOGENE, V21, P3162, DOI 10.1038/sj.onc.1205412; STREBHARDT K, 2001, ENCY MOL MED, P2530; Templeton NS, 2002, BIOSCIENCE REP, V22, P283; Therasse P, 2002, EUR J CANCER, V38, P1817, DOI 10.1016/S0959-8049(02)00182-X; Vogel CL, 2002, J CLIN ONCOL, V20, P719, DOI 10.1200/JCO.20.3.719; Xia WL, 2006, CANCER RES, V66, P1640, DOI 10.1158/0008-5472.CAN-05-2000; Yuan J, 2006, ONCOGENE, V25, P1753, DOI 10.1038/sj.onc.1209202; Yuan JP, 1997, AM J PATHOL, V150, P1165; Zimmermann TS, 2006, NATURE, V441, P111, DOI 10.1038/nature04688	49	81	88	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG	2007	26	39					5793	5807		10.1038/sj.onc.1210355	http://dx.doi.org/10.1038/sj.onc.1210355			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	202EP	17369857				2022-12-28	WOS:000248885100011
J	Bubman, D; Guasparri, I; Cesarman, E				Bubman, D.; Guasparri, I.; Cesarman, E.			Deregulation of c-Myc in primary effusion lymphoma by Kaposi's sarcoma herpesvirus latency-associated nuclear antigen	ONCOGENE			English	Article						KSHV; HHV-8; PEL; c-Myc; LANA	GLYCOGEN-SYNTHASE KINASE-3; CELLULAR GENE-EXPRESSION; EPSTEIN-BARR-VIRUS; BURKITT-LYMPHOMA; DNA-SEQUENCES; TRANSACTIVATION DOMAIN; CELLS; PHOSPHORYLATION; MUTATIONS; ONCOGENE	Primary effusion lymphoma (PEL) is a rare subtype of non-Hodgkin's lymphoma, which is associated with infection by Kaposi's sarcoma herpesvirus (KSHV)/ human herpesvirus-8. The c-Myc transcription factor plays an important role in cellular proliferation, differentiation and apoptosis. Lymphomas frequently have deregulated c-Myc expression owing to chromosomal translocations, ampli. cations or abnormal stabilization. However, no structural abnormalities were found in the c-myc oncogene in PEL. Given that c-Myc is often involved in lymphomagenesis, we hypothesized that it is deregulated in PEL. We report that PEL cells have abnormally stable c-Myc protein. The turnover of c-Myc protein is stringently regulated by post-transcriptional modi. cations, including phosphorylation of c-Myc threonine 58 (T58) by glycogen synthase kinase-3 beta (GSK-3b). Our data show that the impaired c-Myc degradation in PEL cells is associated with a signi. cant underphosphorylation of c-Myc T58. The KSHV latency-associated nuclear antigen (LANA) is responsible for this deregulation. Overexpression of LANA in human embryonic kidney 293 or peripheral blood B cells leads to post-transcriptional deregulation of c-Myc protein. Conversely, when LANA is eliminated from PEL cells using RNA interference, GSK-3bmediated c-Myc T58 phosphorylation is restored. The presence of c-Myc and LANA in GSK-3 beta-containing complexes in PEL cells further con. rms the signi. cance of these interactions in naturally KSHV-infected cells.	Cornell Univ, Weill Med Coll, Dept Pathol & Lab Med, New York, NY 10021 USA; Cornell Univ, Weill Grad Sch Med Sci, Dept Pathol & Lab Med, New York, NY USA	Cornell University; Cornell University	Cesarman, E (corresponding author), Cornell Univ, Weill Med Coll, Dept Pathol & Lab Med, 1300 york Ave,Room C410, New York, NY 10021 USA.	ecesarm@med.cornell.edu			NATIONAL CANCER INSTITUTE [R01CA068939] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA068939] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		An FQ, 2005, J BIOL CHEM, V280, P3862, DOI 10.1074/jbc.M407435200; An JB, 2004, BLOOD, V103, P222, DOI 10.1182/blood-2003-05-1538; Arvanitakis L, 1996, BLOOD, V88, P2648, DOI 10.1182/blood.V88.7.2648.bloodjournal8872648; Ballestas ME, 1999, SCIENCE, V284, P641, DOI 10.1126/science.284.5414.641; BHATIA K, 1993, NAT GENET, V5, P56, DOI 10.1038/ng0993-56; Bijur GN, 2003, NEUROREPORT, V14, P2415, DOI 10.1097/00001756-200312190-00025; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; CESARMAN E, 1987, SCIENCE, V238, P1272, DOI 10.1126/science.3685977; CESARMAN E, 1995, BLOOD, V86, P2708, DOI 10.1182/blood.V86.7.2708.bloodjournal8672708; CESARMAN E, 1995, NEW ENGL J MED, V332, P1186, DOI 10.1056/NEJM199505043321802; Chang DW, 2000, MOL CELL BIOL, V20, P4309, DOI 10.1128/MCB.20.12.4309-4319.2000; Conzen SD, 2000, MOL CELL BIOL, V20, P6008, DOI 10.1128/MCB.20.16.6008-6018.2000; DALLAFAVERA R, 1982, P NATL ACAD SCI-BIOL, V79, P7824, DOI 10.1073/pnas.79.24.7824; Dominguez-Sola D, 2004, NAT CELL BIOL, V6, P288, DOI 10.1038/ncb0404-288; Fakhari FD, 2006, J CLIN INVEST, V116, P735, DOI 10.1172/JCI26190; Fan W, 2005, J VIROL, V79, P1244, DOI 10.1128/JVI.79.2.1244-1251.2005; Friborg J, 1999, NATURE, V402, P889, DOI 10.1038/47266; Fujimuro M, 2003, NAT MED, V9, P300, DOI 10.1038/nm829; Gaidano G, 2003, BLOOD, V102, P1833, DOI 10.1182/blood-2002-11-3606; Gaidano G, 1996, ACTA HAEMATOL-BASEL, V95, P193; Grandori C, 1997, TRENDS BIOCHEM SCI, V22, P177, DOI 10.1016/S0968-0004(97)01025-6; Gregory MA, 2000, MOL CELL BIOL, V20, P2423, DOI 10.1128/MCB.20.7.2423-2435.2000; Gregory MA, 2003, J BIOL CHEM, V278, P51606, DOI 10.1074/jbc.M310722200; HANN SR, 1984, MOL CELL BIOL, V4, P2486, DOI 10.1128/MCB.4.11.2486; Hayward S. D., 2006, SCI STKE, V335, pre4; HENRIKSSON M, 1993, ONCOGENE, V8, P3199; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; Horenstein MG, 1997, BLOOD, V90, P1186, DOI 10.1182/blood.V90.3.1186; Jope RS, 2004, TRENDS BIOCHEM SCI, V29, P95, DOI 10.1016/j.tibs.2003.12.004; KING MW, 1986, MOL CELL BIOL, V6, P4499, DOI 10.1128/MCB.6.12.4499; Knight JS, 2001, J BIOL CHEM, V276, P22971, DOI 10.1074/jbc.M101890200; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; MOORE PS, 1995, NEW ENGL J MED, V332, P1181, DOI 10.1056/NEJM199505043321801; Nador RG, 1996, BLOOD, V88, P645, DOI 10.1182/blood.V88.2.645.bloodjournal882645; PAPAS TS, 1985, NATURE, V318, P237, DOI 10.1038/318237a0; Pelengaris S, 2002, NAT REV CANCER, V2, P764, DOI 10.1038/nrc904; Pelengaris S, 2002, CELL, V109, P321, DOI 10.1016/S0092-8674(02)00738-9; Pelengaris S, 2003, ARCH BIOCHEM BIOPHYS, V416, P129, DOI 10.1016/S0003-9861(03)00294-7; Polakis P, 2000, GENE DEV, V14, P1837; PULVERER BJ, 1994, ONCOGENE, V9, P59; RABBITTS TH, 1983, NATURE, V306, P760, DOI 10.1038/306760a0; Radkov SA, 2000, NAT MED, V6, P1121, DOI 10.1038/80459; Rao PH, 1998, BLOOD, V92, P234, DOI 10.1182/blood.V92.1.234.413k22_234_240; Renne R, 1996, NAT MED, V2, P342, DOI 10.1038/nm0396-342; Renne R, 2001, J VIROL, V75, P458, DOI 10.1128/JVI.75.1.458-468.2001; Sears R, 2000, GENE DEV, V14, P2501, DOI 10.1101/gad.836800; SOULIER J, 1995, BLOOD, V86, P1275; TAUB R, 1982, P NATL ACAD SCI-BIOL, V79, P7837, DOI 10.1073/pnas.79.24.7837; YANO T, 1993, ONCOGENE, V8, P2741; Yeh E, 2004, NAT CELL BIOL, V6, P308, DOI 10.1038/ncb1110	50	86	87	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2007	26	34					4979	4986		10.1038/sj.onc.1210299	http://dx.doi.org/10.1038/sj.onc.1210299			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	194CV	17310999				2022-12-28	WOS:000248322500010
J	Kim, D; Rath, O; Kolch, W; Cho, KH				Kim, D.; Rath, O.; Kolch, W.; Cho, K-H			A hidden oncogenic positive feedback loop caused by crosstalk between Wnt and ERK Pathways	ONCOGENE			English	Article						signaling pathways; crosstalk; positive feed-back loop; Wnt pathway; ERK pathway; colorectal cancer	BETA-CATENIN; SIGNALING PATHWAYS; NEGATIVE FEEDBACK; UP-REGULATION; OKADAIC ACID; EXPRESSION; MUTATIONS; TRANSACTIVATION; OVEREXPRESSION; APOPTOSIS	The Wnt and the extracellular signal regulated-kinase (ERK) pathways are both involved in the pathogenesis of various kinds of cancers. Recently, the existence of crosstalk between Wnt and ERK pathways was reported. Gathering all reported results, we have discovered a positive feedback loop embedded in the crosstalk between the Wnt and ERK pathways. We have developed a plausible model that represents the role of this hidden positive feedback loop in the Wnt/ERK pathway crosstalk based on the integration of experimental reports and employing established basic mathematical models of each pathway. Our analysis shows that the positive feedback loop can generate bistability in both the Wnt and ERK signaling pathways, and this prediction was further validated by experiments. In particular, using the commonly accepted assumption that mutations in signaling proteins contribute to cancerogenesis, we have found two conditions through which mutations could evoke an irreversible response leading to a sustained activation of both pathways. One condition is enhanced production of beta-catenin, the other is a reduction of the velocity of MAP kinase phosphatase(s). This enables that high activities of Wnt and ERK pathways are maintained even without a persistent extracellular signal. Thus, our study adds a novel aspect to the molecular mechanisms of carcinogenesis by showing that mutational changes in individual proteins can cause fundamental functional changes well beyond the pathway they function in by a positive feedback loop embedded in crosstalk. Thus, crosstalk between signaling pathways provides a vehicle through which mutations of individual components can affect properties of the system at a larger scale.	Seoul Natl Univ, Bio MAX Inst, Seoul 151818, South Korea; Seoul Natl Univ, Coll Med, Seoul, South Korea; Beatson Inst Canc Res, Glasgow G61 1BD, Lanark, Scotland; Univ Glasgow, Inst Biomed & Life Sci, Glasgow, Lanark, Scotland	Seoul National University (SNU); Seoul National University (SNU); Beatson Institute; University of Glasgow	Cho, KH (corresponding author), Seoul Natl Univ, Bio MAX Inst, 3rd Floor,IVI,San 4-8,Bongcheon 7 Dong, Seoul 151818, South Korea.	w.kolch@beatson.gla.ac.uk; ckh-sb@snu.ac.kr	Cho, Kwang-Hyun/C-1684-2011; Kolch, Walter/ABF-2102-2021; Admin, SBI/HGB-2738-2022; Rath, Oliver/D-6523-2018	Rath, Oliver/0000-0001-7986-591X; Kolch, Walter/0000-0001-5777-5016				Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Almeida M, 2005, J BIOL CHEM, V280, P41342, DOI 10.1074/jbc.M502168200; AMARAL MC, 1993, IMMUNOLOGY, V79, P24; Aust DE, 2005, INT J CANCER, V115, P673, DOI 10.1002/ijc.20925; Behrens J, 2005, BIOCHEM SOC T, V33, P672, DOI 10.1042/BST0330672; Behrens J, 2004, INT J DEV BIOL, V48, P477, DOI 10.1387/ijdb.041815jb; CASILLAS AM, 1993, BIOCHEM J, V290, P545, DOI 10.1042/bj2900545; Cho KH, 2003, LECT NOTES COMPUT SC, V2602, P127; Cho KH, 2006, FEBS LETT, V580, P3665, DOI 10.1016/j.febslet.2006.05.053; Civenni G, 2003, EMBO REP, V4, P166, DOI 10.1038/sj.embor.embor735; Ding QQ, 2005, MOL CELL, V19, P159, DOI 10.1016/j.molcel.2005.06.009; Downward J, 2003, NAT REV CANCER, V3, P11, DOI 10.1038/nrc969; Esufali S, 2004, ONCOGENE, V23, P8260, DOI 10.1038/sj.onc.1208007; Fang JY, 2005, LANCET ONCOL, V6, P322, DOI 10.1016/S1470-2045(05)70168-6; Ferrell JE, 2002, CURR OPIN CELL BIOL, V14, P140, DOI 10.1016/S0955-0674(02)00314-9; Harada N, 1999, EMBO J, V18, P5931, DOI 10.1093/emboj/18.21.5931; Kim CJ, 2005, WORLD J GASTROENTERO, V11, P5006, DOI 10.3748/wjg.v11.i32.5006; Kim K, 2000, MOL BIOL CELL, V11, P3509, DOI 10.1091/mbc.11.10.3509; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Kolch W, 2005, FEBS LETT, V579, P1891, DOI 10.1016/j.febslet.2005.02.002; Kolch W, 2005, NAT REV MOL CELL BIO, V6, P827, DOI 10.1038/nrm1743; Kolch Walter, 2002, Expert Rev Mol Med, V4, P1, DOI 10.1017/S1462399402004386; Lee E, 2003, PLOS BIOL, V1, P116, DOI 10.1371/journal.pbio.0000010; Loda M, 1996, AM J PATHOL, V149, P1553; Lustig B, 2002, MOL CELL BIOL, V22, P1184, DOI 10.1128/MCB.22.4.1184-1193.2002; Minoo P, 2006, GUT, V55, DOI 10.1136/gut.2005.082859; Mirabelli-Primdahl L, 1999, CANCER RES, V59, P3346; Reya T, 2005, NATURE, V434, P843, DOI 10.1038/nature03319; Rottinger E, 2004, DEVELOPMENT, V131, P1075, DOI 10.1242/dev.01000; Sancho E, 2004, ANNU REV CELL DEV BI, V20, P695, DOI 10.1146/annurev.cellbio.20.010403.092805; Sancho E, 2003, CURR OPIN CELL BIOL, V15, P763, DOI 10.1016/j.ceb.2003.10.012; TAKATA K, 2000, BREED RES, V2, P11; Wolkenhauer O, 2005, BIOCHEM SOC T, V33, P507, DOI 10.1042/BST0330507; Yan H, 2002, NAT GENET, V30, P25, DOI 10.1038/ng799; Yeung K, 1999, NATURE, V401, P173, DOI 10.1038/43686; Yun MS, 2005, J CELL SCI, V118, P313, DOI 10.1242/jcs.01601	36	113	120	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2007	26	31					4571	4579		10.1038/sj.onc.1210230	http://dx.doi.org/10.1038/sj.onc.1210230			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	187GR	17237813				2022-12-28	WOS:000247836100011
J	Tomida, S; Yanagisawa, K; Koshikawa, K; Yatabe, Y; Mitsudomi, T; Osada, H; Takahashi, T				Tomida, S.; Yanagisawa, K.; Koshikawa, K.; Yatabe, Y.; Mitsudomi, T.; Osada, H.; Takahashi, T.			Identification of a metastasis signature and the DLX4 homeobox protein as a regulator of metastasis by combined transcriptome approach	ONCOGENE			English	Article						lung cancer; metastasis; expression profile; DLX4; gene ontology	LUNG-CANCER; MICROARRAY ANALYSIS; EXPRESSION; GENE; TUMORS; PROGRESSION; SURVIVAL; MODELS; GROWTH	Although widespread metastasis is the major cause of human lung cancer-related deaths, its underlying mechanism remains largely unclear. Our genome-wide comparison of the expression profiles of a highly metastatic lung cancer cell line, NCI-H460-LNM35 (LNM35), and its parental clone, NCI-H460-N15 (N15), resulted in the identification of a cancer metastasis signature composed of 45 genes. Through gene ontology analysis, our study also provided insights into how this 45-gene metastasis signature may contribute to the acquisition of metastatic potential. By applying the signature to datasets of human cancer cases, we could demonstrate significant associations with a subset of cases with poor prognosis not only for the two datasets of cancers of the lung but also for cancers of the breast. Furthermore, we were able to show that enforced expression of the DLX4 homeobox gene, which was identified as a gene with significant downregulation in LNM35 as well as with significant association with favorable prognosis for lung cancer patients, markedly inhibited in vitro motility and invasion as well as in vivo metastasis via both hematogenous and lymphogenous routes. Taken together, these findings indicate that our combined transcriptome analysis is an efficient approach in the search for genes possessing both clinical usefulness in terms of prognostic prediction in human cancer cases and clear functional relevance for studying cancer biology in relation to metastasis.	Nagoya Univ, Grad Sch Med, Ctr Neurol Dis & Canc, Div Mol Carcinogenesis, Nagoya, Aichi, Japan; Aichi Canc Ctr Hosp, Dept Pathol & Mol Diagnost, Nagoya, Aichi 464, Japan; Aichi Canc Ctr Hosp, Dept Thorac Surg, Nagoya, Aichi 464, Japan; Aichi Canc Ctr, Res Inst, Div Mol Oncol, Nagoya, Aichi 464, Japan	Nagoya University; Aichi Cancer Center; Aichi Cancer Center; Aichi Cancer Center	Takahashi, T (corresponding author), Nagoya Univ, Grad Sch Med, Ctr Neurol Dis & Canc, Div Mol Carcinogenesis,Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi, Japan.	tak@med.nagoya-u.ac.jp	Osada, Hiroyuki/AAY-6254-2020; Yanagisawa, Kiyoshi/I-7263-2014; Takahashi, Takashi/I-7262-2014; YATABE, Yasushi/J-6461-2014	Takahashi, Takashi/0000-0003-0615-7001; YATABE, Yasushi/0000-0003-1788-559X; Mitsudomi, Tetsuya/0000-0001-9860-8505				Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Ayala GE, 2004, CANCER RES, V64, P6082, DOI 10.1158/0008-5472.CAN-04-0838; Bernal JA, 2002, NAT GENET, V32, P306, DOI 10.1038/ng997; Bobrovnikova-Marjon EV, 2004, CANCER RES, V64, P4858, DOI 10.1158/0008-5472.CAN-04-0682; Cavallaro U, 2004, NAT REV CANCER, V4, P118, DOI 10.1038/nrc1276; Dasgupta B, 2005, CANCER RES, V65, P9843, DOI 10.1158/0008-5472.CAN-05-1842; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Fidler IJ, 2003, NAT REV CANCER, V3, P453, DOI 10.1038/nrc1098; Gallagher PG, 2005, CANCER RES, V65, P4134, DOI 10.1158/0008-5472.CAN-04-0415; GENTLEMAN RC, 1994, STAT MED, V13, P805, DOI 10.1002/sim.4780130803; Glinsky GV, 2005, J CLIN INVEST, V115, P1503, DOI 10.1172/JCI23412; Goswami S, 2004, CANCER RES, V64, P7664, DOI 10.1158/0008-5472.CAN-04-2027; Heaney AP, 2000, LANCET, V355, P716, DOI 10.1016/S0140-6736(99)10238-1; Jemal A, 2005, CA-CANCER J CLIN, V55, P10, DOI 10.3322/canjclin.55.1.10; Jordan MA, 2004, NAT REV CANCER, V4, P253, DOI 10.1038/nrc1317; Kang YB, 2004, CELL, V118, P277, DOI 10.1016/j.cell.2004.07.011; Kim YH, 2006, ONCOGENE, V25, P130, DOI 10.1038/sj.onc.1208997; Kozaki K, 2000, CANCER RES, V60, P2535; Liu FT, 2005, NAT REV CANCER, V5, P29, DOI 10.1038/nrc1527; Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799; Miyamoto K, 2005, INT J CANCER, V116, P407, DOI 10.1002/ijc.21054; Morowitz MJ, 2005, CLIN CANCER RES, V11, P2680, DOI 10.1158/1078-0432.CCR-04-1917; Nicholson BE, 2004, CANCER RES, V64, P7813, DOI 10.1158/0008-5472.CAN-04-0826; Osada H, 2002, ONCOGENE, V21, P7421, DOI 10.1038/sj.onc.1205802; Pantel K, 2004, NAT REV CANCER, V4, P448, DOI 10.1038/nrc1370; Quinn LM, 1998, PLACENTA, V19, P87, DOI 10.1016/S0143-4004(98)90103-5; Ramaswamy S, 2003, NAT GENET, V33, P49, DOI 10.1038/ng1060; Takeuchi T, 2006, J CLIN ONCOL, V24, P1679, DOI 10.1200/JCO.2005.03.8224; Tomida S, 2004, ONCOGENE, V23, P5360, DOI 10.1038/sj.onc.1207697	29	37	39	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2007	26	31					4600	4608		10.1038/sj.onc.1210242	http://dx.doi.org/10.1038/sj.onc.1210242			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	187GR	17260014				2022-12-28	WOS:000247836100015
J	Busa, R; Paronetto, MP; Farini, D; Pierantozzi, E; Botti, F; Angelini, DF; Attisani, F; Vespasiani, G; Sette, C				Busa, R.; Paronetto, M. P.; Farini, D.; Pierantozzi, E.; Botti, F.; Angelini, D. F.; Attisani, F.; Vespasiani, G.; Sette, C.			The RNA-binding protein Sam68 contributes to proliferation and survival of human prostate cancer cells	ONCOGENE			English	Article						prostate cancer; Sam68; cell proliferation; apoptosis; RNA metabolism	CYCLE PROGRESSION; TYROSINE KINASES; KH DOMAIN; SRC; RECEPTOR; ACTIVATION; PHOSPHORYLATION; INHIBITION; EXPRESSION; VARIANT	The tyrosine kinase Src is frequently activated in advanced human prostate carcinomas and its activation correlates with tyrosine phosphorylation of the RNA-binding protein Sam68. Herein, we have investigated the expression and function of Sam68 in human prostate cancer cells. Analysis of speci mens obtained from 20 patients revealed that Sam68 is upregulated at the protein level in 35% of the samples. Real-time polymerase chain reaction con. firmed the results at the mRNA level in most patients. Downregulation of Sam68 by RNAi in LNCaP prostate cancer cells delayed cell cycle progression and reduced the proliferation rate. Moreover, depletion of Sam68 sensitized cells to apoptosis induced by DNA-damaging agents. Similarly, stable cell lines expressing a truncated GFP-Sam68(GSG) protein displayed reduced growth rates and higher sensitivity to cisplatin-induced apoptosis. Microarray analyses revealed that a subset of genes involved in proliferation and apoptosis were altered when Sam68 was knocked down in LNCaP cells. Our results indicate that Sam68 expression supports prostate cancer cells proliferation and survival to cytotoxle agents.	Univ Roma Tor Vergata, Dept Publ Hlth & Cell Biol, I-00133 Rome, Italy; Univ Roma Tor Vergata, Dept Urol, Rome, Italy; IRCCS, Inst Neurosci, Fdn Santa Lucia, Rome, Italy	University of Rome Tor Vergata; University of Rome Tor Vergata; IRCCS Santa Lucia	Sette, C (corresponding author), Univ Roma Tor Vergata, Dept Publ Hlth & Cell Biol, Via Montpellier 1, I-00133 Rome, Italy.	claudio.sette@uniroma2.it	Paronetto, Maria Paola/A-9578-2012; Angelini, Daniela F/J-8001-2018; Sette, Claudio/S-4307-2019	Paronetto, Maria Paola/0000-0001-5324-0903; Angelini, Daniela F/0000-0003-4552-9226; Sette, Claudio/0000-0003-2864-8266; FARINI, DONATELLA/0000-0002-1991-3956; PIERANTOZZI, Enrico/0000-0003-2925-7339				Barlat I, 1997, J BIOL CHEM, V272, P3129, DOI 10.1074/jbc.272.6.3129; Burd CJ, 2006, P NATL ACAD SCI USA, V103, P2190, DOI 10.1073/pnas.0506281103; Chen TP, 1999, MOL BIOL CELL, V10, P3015, DOI 10.1091/mbc.10.9.3015; Cote J, 2003, MOL BIOL CELL, V14, P274, DOI 10.1091/mbc.E02-08-0484; Coyle JH, 2003, MOL CELL BIOL, V23, P92, DOI 10.1128/MCB.23.1.92-103.2003; Denegri M, 2001, MOL BIOL CELL, V12, P3502, DOI 10.1091/mbc.12.11.3502; Feldman BJ, 2001, NAT REV CANCER, V1, P34, DOI 10.1038/35094009; Grossmann ME, 2001, JNCI-J NATL CANCER I, V93, P1687, DOI 10.1093/jnci/93.22.1687; Irby RB, 2000, ONCOGENE, V19, P5636, DOI 10.1038/sj.onc.1203912; Lee LF, 2001, MOL CELL BIOL, V21, P8385, DOI 10.1128/MCB.21.24.8385-8397.2001; Li HR, 2006, CANCER RES, V66, P4079, DOI 10.1158/0008-5472.CAN-05-4264; Lukong KE, 2005, J BIOL CHEM, V280, P38639, DOI 10.1074/jbc.M505802200; Lukong KE, 2003, BBA-REV CANCER, V1653, P73, DOI 10.1016/j.bbcan.2003.09.001; Matter N, 2002, NATURE, V420, P691, DOI 10.1038/nature01153; Migliaccio A, 2000, EMBO J, V19, P5406, DOI 10.1093/emboj/19.20.5406; Nam S, 2005, CANCER RES, V65, P9185, DOI 10.1158/0008-5472.CAN-05-1731; Palapattu GS, 2005, CARCINOGENESIS, V26, P1170, DOI 10.1093/carcin/bgh317; Paronetto MP, 2006, MOL BIOL CELL, V17, P14, DOI 10.1091/mbc.e05-06-0548; Paronetto MP, 2004, AM J PATHOL, V164, P1243, DOI 10.1016/S0002-9440(10)63212-9; Paronetto MP, 2003, ONCOGENE, V22, P8707, DOI 10.1038/sj.onc.1207016; Reddy TR, 1999, NAT MED, V5, P635, DOI 10.1038/9479; RICHARD S, 1995, MOL CELL BIOL, V15, P186, DOI 10.1128/MCB.15.1.186; Ruggero D, 2005, ONCOGENE, V24, P7426, DOI 10.1038/sj.onc.1209098; Sette C, 2002, EMBO J, V21, P5386, DOI 10.1093/emboj/cdf553; Soros VB, 2001, J VIROL, V75, P8203, DOI 10.1128/JVI.75.17.8203-8215.2001; Taylor SJ, 2004, BMC CELL BIOL, V5, DOI 10.1186/1471-2121-5-5; Venables JP, 2006, BIOESSAYS, V28, P378, DOI 10.1002/bies.20390; Zhang CL, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-202; Zhou J, 2003, J BIOL CHEM, V278, P6936, DOI 10.1074/jbc.M210628200	29	140	145	2	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN	2007	26	30					4372	4382		10.1038/sj.onc.1210224	http://dx.doi.org/10.1038/sj.onc.1210224			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	184CZ	17237817				2022-12-28	WOS:000247620000005
J	Singh, B; Berry, JA; Shoher, A; Ayers, GD; Wei, C; Lucci, A				Singh, B.; Berry, J. A.; Shoher, A.; Ayers, G. D.; Wei, C.; Lucci, A.			COX-2 involvement in breast cancer metastasis to bone	ONCOGENE			English	Article						breast cancer; COX-2; mouse model; MF-tricyclic; bone metastasis; cancer prevention	CYCLOOXYGENASE-2 INHIBITOR; OSTEOCLAST FORMATION; PROSTAGLANDIN E-2; IL-11 PRODUCTION; KNOCKOUT MICE; MURINE MODEL; CELL-LINES; EXPRESSION; CELECOXIB; GROWTH	Cyclooxygenase-2 (COX- 2) is expressed in 40% of human invasive breast cancers. Bone is the predominant site of metastasis in case of breast cancer. We investigated the role of COX- 2 in a suitable mouse model of breast cancer metastasis to bone using the whole-body luciferase imaging of cancer cells. We provide several lines of evidence that COX- 2 produced in breast cancer cells is important for bone metastasis in this model including (1) COX- 2 transfection enhanced the bone metastasis of MDA-435S cells and (2) breast cancer cells isolated and cultured from the bone metastases produced significantly more prostaglandin E-2 (an important mediator of COX- 2) than the parental injected cell populations of breast cancer cells. Next, we found that a COX- 2 inhibitor, MF-tricyclic, inhibited bone metastasis caused by a bone-seeking clone both in prevention regimen (in which case mice started receiving MF-tricyclic 1 week before the injection of cancer cells) and in treatment regimen (in which case mice received MF-tricyclic after the development of bone metastasis). These studies indicate that COX- 2 produced in breast cancer cells may be vital to the development of osteolytic bone metastases in patients with breast cancer, and that COX- 2 inhibitors may be useful in halting this process.	Univ Texas, MD Anderson Canc Ctr, Dept Surg Oncol, Unit 444, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Adv Res Ctr Microscop Dis, Houston, TX 77030 USA; Baylor Coll Med, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Biostat & Appl Math, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Baylor College of Medicine; University of Texas System; UTMD Anderson Cancer Center	Lucci, A (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Surg Oncol, Unit 444, 1515 Holcombe Blvd, Houston, TX 77030 USA.	alucci@mdanderson.org		Lucci, Anthony/0000-0003-4039-174X; Berry, Jacob/0000-0002-5241-1720	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R21DK067682] Funding Source: NIH RePORTER; NIDDK NIH HHS [R21 DK067682] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARGUELLO F, 1988, CANCER RES, V48, P6876; Basu GD, 2004, MOL CANCER RES, V2, P632; Bendre MS, 2003, BONE, V33, P28, DOI 10.1016/S8756-3282(03)00086-3; Chang SH, 2004, P NATL ACAD SCI USA, V101, P591, DOI 10.1073/pnas.2535911100; Connolly EM, 2002, BRIT J CANCER, V87, P231, DOI 10.1038/sj.bjc.6600462; Crawford YG, 2004, CANCER CELL, V5, P263, DOI 10.1016/S1535-6108(04)00023-6; D Basu G, 2006, J IMMUNOL, V177, P2391, DOI 10.4049/jimmunol.177.4.2391; Fujita D, 2003, PROSTAG LEUKOTR ESS, V68, P351, DOI 10.1016/S0952-3278(03)00027-9; Gilhooly EM, 1999, INT J ONCOL, V15, P267; GIRASOLE G, 1994, J CLIN INVEST, V93, P1516, DOI 10.1172/JCI117130; Guo QP, 1996, J BIOL CHEM, V271, P19134, DOI 10.1074/jbc.271.32.19134; Harms JF, 2003, CLIN EXP METASTAS, V20, P327, DOI 10.1023/A:1024062911144; Harris RE, 2000, CANCER RES, V60, P2101; Hiraga T, 2006, CANCER RES, V66, P2067, DOI 10.1158/0008-5472.CAN-05-2012; Howe LR, 2005, CANCER RES, V65, P10113, DOI 10.1158/0008-5472.CAN-05-1524; Howe LR, 2002, CANCER RES, V62, P5405; Howe LR, 2003, J MAMMARY GLAND BIOL, V8, P31, DOI 10.1023/A:1025731204719; Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535-6108(03)00132-6; Khuder SA, 2001, BRIT J CANCER, V84, P1188, DOI 10.1054/bjoc.2000.1709; Kundu N, 2005, CANCER IMMUNOL IMMUN, V54, P981, DOI 10.1007/s00262-005-0669-2; Kundu N, 2001, INT J CANCER, V93, P681, DOI 10.1002/ijc.1397; Lal G, 2001, CANCER RES, V61, P6131; Li X, 2002, BONE, V30, P567, DOI 10.1016/S8756-3282(02)00683-X; Liu CH, 2001, J BIOL CHEM, V276, P18563, DOI 10.1074/jbc.M010787200; Morgan H, 2004, INT J CANCER, V109, P653, DOI 10.1002/ijc.20056; Ono K, 2002, J BONE MINER RES, V17, P774, DOI 10.1359/jbmr.2002.17.5.774; Ristimaki A, 2002, CANCER RES, V62, P632; Roche-Nagle G, 2004, BRIT J CANCER, V91, P359, DOI 10.1038/sj.bjc.6601967; Shaheen NJ, 2002, CANCER-AM CANCER SOC, V94, P950, DOI 10.1002/cncr.10333; Singh B, 2006, J SURG RES, V131, P267, DOI 10.1016/j.jss.2005.11.582; Singh B, 2005, INT J ONCOL, V26, P1393; Singh B, 2002, J SURG RES, V108, P173, DOI 10.1006/jsre.2002.6532; Singh B, 2006, J SURG RES, V134, P44, DOI 10.1016/j.jss.2006.03.018; Soslow RA, 2000, CANCER, V89, P2637, DOI 10.1002/1097-0142(20001215)89:12<2637::AID-CNCR17>3.0.CO;2-B; Subbaramaiah K, 2002, J BIOL CHEM, V277, P18649, DOI 10.1074/jbc.M111415200; Wang HS, 2004, ASSAY DRUG DEV TECHN, V2, P31, DOI 10.1089/154065804322966298; Zhang S, 2004, BREAST CANCER RES TR, V87, P111, DOI 10.1023/B:BREA.0000041593.69178.57	37	104	107	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 31	2007	26	26					3789	3796		10.1038/sj.onc.1210154	http://dx.doi.org/10.1038/sj.onc.1210154			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	175PV	17213821				2022-12-28	WOS:000247026400003
J	Zafir-Lavie, I; Michaeli, Y; Reiter, Y				Zafir-Lavie, I.; Michaeli, Y.; Reiter, Y.			Novel antibodies as anticancer agents	ONCOGENE			English	Review						antibody; cancer immunotherapy; tumor antigens; anti tumor mechanisms; targeted therapy; antibody fusions	GROWTH-FACTOR RECEPTOR; SINGLE-CHAIN ANTIBODY; T-CELL-RECEPTOR; PHASE-I TRIAL; MAJOR HISTOCOMPATIBILITY COMPLEX; METASTATIC BREAST-CANCER; RIBOSOME-INACTIVATING PROTEINS; HUMAN RECOMBINANT ANTIBODIES; CD19 BISPECIFIC ANTIBODIES; COLONY-STIMULATING FACTOR	In recent years antibodies, whether generated by traditional hybridoma technology or by recombinant DNA strategies, have evolved from Paul Ehrlich's 'magic bullets' to a modern age 'guided missile'. In the recent years of immunologic research, we are witnessing development in the fields of antigen screening and protein engineering in order to create specific anticancer remedies. The developments in the field of recombinant DNA, protein engineering and cancer biology have let us gain insight into many cancer-related mechanisms. Moreover, novel techniques have facilitated tools allowing unique distinction between malignantly transformed cells, and regular ones. This understanding has paved the way for the rational design of a new age of pharmaceuticals: monoclonal antibodies and their fragments. Antibodies can select antigens on both a specific and a high-affinity account, and further implementation of these qualities is used to target cancer cells by specifically identifying exogenous antigens of cancer cell populations. The structure of the antibody provides plasticity resonating from its functional sites. This review will screen some of the many novel antibodies and antibody-based approaches that are being currently developed for clinical applications as the new generation of anticancer agents.	Technion Israel Inst Technol, Fac Biol, IL-32000 Haifa, Israel	Technion Israel Institute of Technology	Reiter, Y (corresponding author), Technion Israel Inst Technol, Fac Biol, Room 333, IL-32000 Haifa, Israel.	reiter@tx.technion.ac.il						ABASTADO JP, 1989, RES IMMUNOL, V140, P581, DOI 10.1016/0923-2494(89)90121-1; Achen MG, 1998, P NATL ACAD SCI USA, V95, P548, DOI 10.1073/pnas.95.2.548; Agus DB, 2005, J CLIN ONCOL, V23, P2534, DOI 10.1200/JCO.2005.03.184; Albanell J, 2003, ADV EXP MED BIOL, V532, P253; Alitalo K, 2005, NATURE, V438, P946, DOI 10.1038/nature04480; Alvarez RD, 2000, CLIN CANCER RES, V6, P3081; Andersen PS, 1996, P NATL ACAD SCI USA, V93, P1820, DOI 10.1073/pnas.93.5.1820; ANTMAN KH, 1980, CELL, V19, P627, DOI 10.1016/S0092-8674(80)80039-0; Archer GE, 1999, CLIN CANCER RES, V5, P2646; Atkins MB, 1999, J CLIN ONCOL, V17, P2105, DOI 10.1200/JCO.1999.17.7.2105; Baggiolini M, 1998, NATURE, V392, P565, DOI 10.1038/33340; BAGSHAWE KD, 1988, BRIT J CANCER, V58, P700, DOI 10.1038/bjc.1988.293; BAGSHAWE KD, 1987, BRIT J CANCER, V55, P299, DOI 10.1038/bjc.1987.58; Bagshawe KD, 1996, TRANSPLANT P, V28, P3156; Barbieri L, 2000, J DRUG TARGET, V8, P281, DOI 10.3109/10611860008997906; BARBIERI L, 1993, BIOCHIM BIOPHYS ACTA, V1154, P237, DOI 10.1016/0304-4157(93)90002-6; BARTHELEMY I, 1993, J BIOL CHEM, V268, P6541; Barzilay E, 2005, BIOCHEM BIOPH RES CO, V330, P561, DOI 10.1016/j.bbrc.2005.03.014; Baselga J, 1996, J CLIN ONCOL, V14, P737, DOI 10.1200/JCO.1996.14.3.737; BASELGA J, 2001, EJC SUPPL, V37, P16; Beauchemin N, 1997, ONCOGENE, V14, P783, DOI 10.1038/sj.onc.1200888; Beers R, 2000, CLIN CANCER RES, V6, P2835; Bergamaschi G, 1996, BRIT J HAEMATOL, V93, P789, DOI 10.1046/j.1365-2141.1996.d01-1730.x; BIOCCA S, 1990, EMBO J, V9, P101, DOI 10.1002/j.1460-2075.1990.tb08085.x; Birchler M, 1999, NAT BIOTECHNOL, V17, P984, DOI 10.1038/13679; Birkle S, 2003, BIOCHIMIE, V85, P455, DOI 10.1016/S0300-9084(03)00006-3; BODMER WF, 1993, ANN NY ACAD SCI, V690, P42; Bolognesi A, 2002, J BIOL CHEM, V277, P13709, DOI 10.1074/jbc.M111514200; Brandl M, 1999, EXP HEMATOL, V27, P1264, DOI 10.1016/S0301-472X(99)00072-7; BRICHARD V, 1993, J EXP MED, V178, P489, DOI 10.1084/jem.178.2.489; Cahill DP, 1999, TRENDS CELL BIOL, V9, pM57, DOI 10.1016/S0962-8924(99)01661-X; Cao YH, 2004, SEMIN CANCER BIOL, V14, P139, DOI 10.1016/j.semcancer.2003.09.018; Cardoso L.R., 2002, Planta daninha, V20, P1, DOI 10.1590/S0100-83582002000400001; Carmeliet P, 2003, NAT MED, V9, P653, DOI 10.1038/nm0603-653; Cartron G, 2002, BLOOD, V99, P754, DOI 10.1182/blood.V99.3.754; Challita-Eid PM, 1998, J IMMUNOL, V161, P3729; Chang K, 1996, P NATL ACAD SCI USA, V93, P136, DOI 10.1073/pnas.93.1.136; CHARI RVJ, 1995, CANCER RES, V55, P4079; Chen X, 1998, Zhongguo Yi Xue Ke Xue Yuan Xue Bao, V20, P351; Chen YT, 1998, P NATL ACAD SCI USA, V95, P6919, DOI 10.1073/pnas.95.12.6919; Cheng TL, 1999, BRIT J CANCER, V79, P1378, DOI 10.1038/sj.bjc.6690221; Cobleigh MA, 1999, J CLIN ONCOL, V17, P2639, DOI 10.1200/JCO.1999.17.9.2639; Cohen CJ, 2002, CANCER RES, V62, P5835; Cohen CJ, 2003, J MOL RECOGNIT, V16, P324, DOI 10.1002/jmr.640; Cohen CJ, 2003, J IMMUNOL, V170, P4349, DOI 10.4049/jimmunol.170.8.4349; Cohen Cyril J, 2003, Methods Mol Biol, V207, P269; Colombo MP, 2002, CYTOKINE GROWTH F R, V13, P155, DOI 10.1016/S1359-6101(01)00032-6; Connor JP, 2004, J IMMUNOTHER, V27, P211, DOI 10.1097/00002371-200405000-00005; Csoka M, 1996, LEUKEMIA, V10, P1765; de Graaf M, 2002, BRIT J CANCER, V86, P811, DOI 10.1038/sj.bjc.6600143; Denkberg G, 2003, J IMMUNOL, V171, P2197, DOI 10.4049/jimmunol.171.5.2197; Denkberg G, 2002, J IMMUNOL, V169, P4399, DOI 10.4049/jimmunol.169.8.4399; Denkberg G, 2002, P NATL ACAD SCI USA, V99, P9421, DOI 10.1073/pnas.132285699; Denkberg G, 2006, AUTOIMMUN REV, V5, P252, DOI 10.1016/j.autrev.2005.07.004; Deshane J, 1995, J CLIN INVEST, V96, P2980, DOI 10.1172/JCI118370; DESHANE J, 1995, GYNECOL ONCOL, V59, P8, DOI 10.1006/gyno.1995.1260; DiJoseph JF, 2006, CLIN CANCER RES, V12, P242, DOI 10.1158/1078-0432.CCR-05-1905; Dreier T, 2003, J IMMUNOL, V170, P4397, DOI 10.4049/jimmunol.170.8.4397; Dreier T, 2002, INT J CANCER, V100, P690, DOI 10.1002/ijc.10557; DUC HT, 1993, INT IMMUNOL, V5, P427, DOI 10.1093/intimm/5.4.427; Dudley ME, 2003, NAT REV CANCER, V3, P666, DOI 10.1038/nrc1167; Eichhorn ME, 2004, DRUG RESIST UPDATE, V7, P125, DOI 10.1016/j.drup.2004.03.001; ENDO Y, 1987, J BIOL CHEM, V262, P5908; Endo Y, 1988, Cancer Treat Res, V37, P75; Engberg J, 1999, IMMUNOTECHNOLOGY, V4, P273; Engelhard VH, 2002, IMMUNOL REV, V188, P136, DOI 10.1034/j.1600-065X.2002.18812.x; Esteva FJ, 2002, J CLIN ONCOL, V20, P1800, DOI 10.1200/JCO.2002.07.058; FALINI B, 1992, LANCET, V339, P1195, DOI 10.1016/0140-6736(92)91135-U; FAVALORO EJ, 1987, DIS MARKERS, V5, P215; Ferguson KM, 2004, BIOCHEM SOC T, V32, P742, DOI 10.1042/BST0320742; Ferrara N, 2004, NAT REV DRUG DISCOV, V3, P391, DOI 10.1038/nrd1381; FitzGerald K, 1997, PROTEIN ENG, V10, P1221, DOI 10.1093/protein/10.10.1221; Fleischhauer K, 1996, J IMMUNOL, V157, P787; Foon KA, 2004, INT J RADIAT ONCOL, V58, P984, DOI 10.1016/j.ijrobp.2003.09.098; Francis RJ, 2002, BRIT J CANCER, V87, P600, DOI 10.1038/sj.bjc.6600517; Fraser HM, 2005, J CLIN ENDOCR METAB, V90, P1114, DOI 10.1210/jc.2004-1572; FROSCHER BG, 1986, J EXP MED, V164, P196, DOI 10.1084/jem.164.1.196; Gargano N, 1997, FEBS LETT, V414, P537, DOI 10.1016/S0014-5793(97)01065-X; GATELY MK, 1993, CANCER INVEST, V11, P500, DOI 10.3109/07357909309018881; Gibson TB, 2006, CLIN COLORECTAL CANC, V6, P29, DOI 10.3816/CCC.2006.n.01; Gillies SD, 2005, BLOOD, V105, P3972, DOI 10.1182/blood-2004-09-3533; GLENNIE MJ, 1987, J IMMUNOL, V139, P2367; GOLDMACHER VS, 1992, BIOCHEM BIOPH RES CO, V183, P758, DOI 10.1016/0006-291X(92)90548-Y; Graeven U, 2006, BRIT J CANCER, V94, P1293, DOI 10.1038/sj.bjc.6603083; Grana C, 2002, BRIT J CANCER, V86, P207, DOI 10.1038/sj.bjc.6600047; GRIFFIN JD, 1984, LEUKEMIA RES, V8, P521, DOI 10.1016/0145-2126(84)90001-8; Gutheil JC, 2000, CLIN CANCER RES, V6, P3056; Haagen I A, 1994, Ther Immunol, V1, P279; Hakamori S, 1998, ACTA ANAT, V161, P79; Harari PM, 2004, ENDOCR-RELAT CANCER, V11, P689, DOI 10.1677/erc.1.00600; Harding J, 2005, DRUG TODAY, V41, P107, DOI 10.1358/dot.2005.41.2.882662; Hassan R, 2004, CLIN CANCER RES, V10, P3937, DOI 10.1158/1078-0432.CCR-03-0801; Hassan R, 2002, CLIN CANCER RES, V8, P3520; Hassanizadeh SM, 2002, VADOSE ZONE J, V1, P38, DOI 10.2136/vzj2002.3800; Held G, 2004, EUR J IMMUNOL, V34, P2919, DOI 10.1002/eji.200425297; Hoffmann P, 2005, INT J CANCER, V115, P98, DOI 10.1002/ijc.20908; Holash J, 2002, P NATL ACAD SCI USA, V99, P11393, DOI 10.1073/pnas.172398299; Holliger P, 1999, CANCER RES, V59, P2909; HOLLIGER P, 1993, P NATL ACAD SCI USA, V90, P6444, DOI 10.1073/pnas.90.14.6444; Hoogenboom HR, 1998, IMMUNOTECHNOLOGY, V4, P1, DOI 10.1016/S1380-2933(98)00007-4; Howard OMZ, 2000, BLOOD, V96, P840, DOI 10.1182/blood.V96.3.840.015k32_840_845; Huang SM, 1999, CANCER RES, V59, P1935; Hyland S, 2003, ONCOGENE, V22, P1557, DOI 10.1038/sj.onc.1206299; Irie RF, 2004, CANCER IMMUNOL IMMUN, V53, P110, DOI 10.1007/s00262-003-0436-1; Jager E, 1998, J EXP MED, V187, P265, DOI 10.1084/jem.187.2.265; Jhanwar YS, 2005, J NUCL MED, V46, p141S; Juweid ME, 1999, CANCER, V85, P1828, DOI 10.1002/(SICI)1097-0142(19990415)85:8<1828::AID-CNCR25>3.0.CO;2-H; Kaminski MS, 2001, J CLIN ONCOL, V19, P3918, DOI 10.1200/JCO.2001.19.19.3918; Karashima T, 2002, CLIN CANCER RES, V8, P1253; Katayose Y, 1996, CANCER RES, V56, P4205; KAWAKAMI Y, 1994, J EXP MED, V180, P347, DOI 10.1084/jem.180.1.347; Kawakami Y, 2000, J IMMUNOTHER, V23, P17, DOI 10.1097/00002371-200001000-00004; KERR DE, 1995, CANCER RES, V55, P3558; Khong HT, 2002, NAT IMMUNOL, V3, P999, DOI 10.1038/ni1102-999; Kiessling R, 1999, CANCER IMMUNOL IMMUN, V48, P353, DOI 10.1007/s002620050586; Kiewe P, 2006, CLIN CANCER RES, V12, P3085, DOI 10.1158/1078-0432.CCR-05-2436; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; King DM, 2004, J CLIN ONCOL, V22, P4463, DOI 10.1200/JCO.2004.11.035; Kinugasa T, 1998, INT J CANCER, V76, P148, DOI 10.1002/(SICI)1097-0215(19980330)76:1<148::AID-IJC23>3.3.CO;2-J; Kipriyanov Sergey M, 2002, Methods Mol Biol, V178, P317; Kipriyanov SM, 1998, INT J CANCER, V77, P763, DOI 10.1002/(SICI)1097-0215(19980831)77:5<763::AID-IJC16>3.0.CO;2-2; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; Kollmannsberger C, 2006, ANN ONCOL, V17, P1007, DOI 10.1093/annonc/mdl042; Korn T, 2004, J GENE MED, V6, P642, DOI 10.1002/jgm.555; Kranz D M, 1995, J Hematother, V4, P403, DOI 10.1089/scd.1.1995.4.403; Kreitman RJ, 2005, J CLIN ONCOL, V23, P6719, DOI 10.1200/JCO.2005.11.437; Kushner BH, 2001, J CLIN ONCOL, V19, P4189, DOI 10.1200/JCO.2001.19.22.4189; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Leonard JP, 2004, CLIN CANCER RES, V10, P5327, DOI 10.1158/1078-0432.CCR-04-0294; Lewis LD, 2002, CANCER CHEMOTH PHARM, V49, P375, DOI 10.1007/s00280-002-0424-8; Li JL, 2004, HYBRIDOMA HYBRIDOM, V23, P1, DOI 10.1089/153685904322771962; Li JL, 2003, J IMMUNOTHER, V26, P320, DOI 10.1097/00002371-200307000-00004; Loffler A, 2000, BLOOD, V95, P2098, DOI 10.1182/blood.V95.6.2098; Loffler A, 2003, LEUKEMIA, V17, P900, DOI 10.1038/sj.leu.2402890; Maletz K, 2001, INT J CANCER, V93, P409, DOI 10.1002/ijc.1348; Manzke O, 2001, INT J CANCER, V91, P508, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1068>3.0.CO;2-D; Manzke O, 2001, INT J CANCER, V91, P516, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1069>3.0.CO;2-A; Mapara MY, 2004, J CLIN ONCOL, V22, P1136, DOI 10.1200/JCO.2004.10.041; Marasco WA, 1997, GENE THER, V4, P11, DOI 10.1038/sj.gt.3300346; Matthey B, 2004, INT J CANCER, V111, P568, DOI 10.1002/ijc.20278; McKeage K, 2002, DRUGS, V62, P209, DOI 10.2165/00003495-200262010-00008; McNeel DG, 2005, CLIN CANCER RES, V11, P7851, DOI 10.1158/1078-0432.CCR-05-0262; Mehta K, 2004, MOL CANCER THER, V3, P345; MIESCHER S, 1986, J IMMUNOL, V136, P1899; Mocellin S, 2001, J IMMUNOTHER, V24, P392, DOI 10.1097/00002371-200109000-00002; Modjtahedi H, 2003, INT J CANCER, V105, P273, DOI 10.1002/ijc.11055; MULE JJ, 1987, J IMMUNOL, V139, P285; Multani PS, 1998, CLIN CANCER RES, V4, P2599; NAGANE M, 2001, CANC LETT, V162, P17; Napier MP, 2000, CLIN CANCER RES, V6, P765; Offner S, 2006, MOL IMMUNOL, V43, P763, DOI 10.1016/j.molimm.2005.03.007; Ogg GS, 2000, BRIT J CANCER, V82, P1058; Okamoto I, 2003, CANCER SCI, V94, P50, DOI 10.1111/j.1349-7006.2003.tb01351.x; Omidfar K, 2004, TUMOR BIOL, V25, P179, DOI 10.1159/000081100; Osta WA, 2004, CANCER RES, V64, P5818, DOI 10.1158/0008-5472.CAN-04-0754; Oved K, 2005, CANCER IMMUNOL IMMUN, V54, P867, DOI 10.1007/s00262-005-0666-5; PAGANELLI G, 1991, NUCL MED COMMUN, V12, P211, DOI 10.1097/00006231-199103000-00006; Paganelli G, 2001, CANCER BIOTHER RADIO, V16, P227, DOI 10.1089/10849780152389410; Pascolo S, 2001, CANCER RES, V61, P4072; PASTAN I, 1992, ANNU REV BIOCHEM, V61, P331, DOI 10.1146/annurev.bi.61.070192.001555; Peumans WJ, 2001, FASEB J, V15, P1493, DOI 10.1096/fj.00-0751rev; Pittet MJ, 1999, J EXP MED, V190, P705, DOI 10.1084/jem.190.5.705; Plaksin D, 1997, J IMMUNOL, V158, P2218; Polito I, 2004, LEUKEMIA, V18, P1215, DOI 10.1038/sj.leu.2403378; Porgador A, 1997, IMMUNITY, V6, P715, DOI 10.1016/S1074-7613(00)80447-1; Rae JM, 2004, BREAST CANCER RES TR, V87, P87, DOI 10.1023/B:BREA.0000041585.26734.f9; REIST CJ, 1995, CANCER RES, V55, P4375; Reiter Y, 1997, P NATL ACAD SCI USA, V94, P4631, DOI 10.1073/pnas.94.9.4631; Repp R, 2003, BRIT J CANCER, V89, P2234, DOI 10.1038/sj.bjc.6601367; Reusch U, 2006, CLIN CANCER RES, V12, P183, DOI 10.1158/1078-0432.CCR-05-1855; Riesenberg R, 2001, J HISTOCHEM CYTOCHEM, V49, P911, DOI 10.1177/002215540104900711; Robert B, 2000, EUR J IMMUNOL, V30, P3165, DOI 10.1002/1521-4141(200011)30:11<3165::AID-IMMU3165>3.0.CO;2-R; Robinson BWS, 1998, J IMMUNOTHER, V21, P211, DOI 10.1097/00002371-199805000-00007; Romero P, 2002, IMMUNOL REV, V188, P81, DOI 10.1034/j.1600-065X.2002.18808.x; Rosenberg SA, 1998, ANN SURG, V228, P307, DOI 10.1097/00000658-199809000-00004; Rossi D, 2000, ANNU REV IMMUNOL, V18, P217, DOI 10.1146/annurev.immunol.18.1.217; Rowinsky EK, 2004, J CLIN ONCOL, V22, P3003, DOI 10.1200/JCO.2004.11.061; Sacchi S, 2001, CRIT REV ONCOL HEMAT, V37, P13, DOI 10.1016/S1040-8428(00)00069-X; Saleh MN, 2000, J CLIN ONCOL, V18, P2282, DOI 10.1200/JCO.2000.18.11.2282; Sanderson RJ, 2005, CLIN CANCER RES, V11, P843; Schaed SG, 2002, CLIN CANCER RES, V8, P967; Schlereth B, 2005, CANCER RES, V65, P2882, DOI 10.1158/0008-5472.CAN-04-2637; Schlosser KL, 2006, SOC NATUR RESOUR, V19, P3, DOI 10.1080/08941920500323096; Schnirring L, 2002, PHYSICIAN SPORTSMED, V30, P4, DOI 10.3810/psm.2002.04.243; Schwaab T, 2001, J IMMUNOTHER, V24, P79, DOI 10.1097/00002371-200101000-00009; Seidman AD, 2001, J CLIN ONCOL, V19, P2587, DOI 10.1200/JCO.2001.19.10.2587; Shan DM, 2000, CANCER IMMUNOL IMMUN, V48, P673, DOI 10.1007/s002620050016; Sharkey RM, 2005, J NUCL MED, V46, P620; Sharkey RM, 2005, J NUCL MED, V46, p115S; SHAW DR, 1988, J BIOL RESP MODIF, V7, P204; Smith J, 2005, FASEB J, V19, P331, DOI 10.1096/fj.04-2863rev; Smith-Jones PM, 2004, METHOD ENZYMOL, V386, P262; SOIFFER RJ, 1993, BLOOD, V82, P2790, DOI 10.1182/blood.V82.9.2790.bloodjournal8292790; Sperr WR, 2005, LEUKEMIA LYMPHOMA, V46, P1115, DOI 10.1080/10428190500126075; STEVENSON GT, 1989, ANTI-CANCER DRUG DES, V3, P219; Stocks M, 2005, CURR OPIN CHEM BIOL, V9, P359, DOI 10.1016/j.cbpa.2005.06.003; Strube RW, 2002, J IMMUNOL METHODS, V263, P149, DOI 10.1016/S0022-1759(02)00035-2; Takai N, 2005, CANCER-AM CANCER SOC, V104, P2701, DOI 10.1002/cncr.21533; TAMMINEN WL, 1987, EUR J IMMUNOL, V17, P999, DOI 10.1002/eji.1830170716; TIEBOUT RF, 1987, J IMMUNOL, V139, P3402; Tijink BM, 2006, J NUCL MED, V47, P1127; Tolcher AW, 1999, J CLIN ONCOL, V17, P478, DOI 10.1200/JCO.1999.17.2.478; Torres LA, 2005, NUCL MED COMMUN, V26, P1049, DOI 10.1097/00006231-200512000-00002; Tse E, 2002, J MOL BIOL, V317, P85, DOI 10.1006/jmbi.2002.5403; Tur MK, 2003, CANCER RES, V63, P8414; Verheul HMW, 2004, J PATHOL, V202, P5, DOI 10.1002/path.1473; Visintin M, 2002, J MOL BIOL, V317, P73, DOI 10.1006/jmbi.2002.5392; Visseren MJW, 1997, INT J CANCER, V73, P125, DOI 10.1002/(SICI)1097-0215(19970926)73:1<125::AID-IJC19>3.0.CO;2-F; Viti F, 1999, CANCER RES, V59, P347; Vogel CL, 2002, J CLIN ONCOL, V20, P719, DOI 10.1200/JCO.20.3.719; WALDMANN TA, 1992, ANN INTERN MED, V116, P148, DOI 10.7326/0003-4819-116-2-148; Waldmann TA, 2002, J CLIN IMMUNOL, V22, P51, DOI 10.1023/A:1014416616687; WALLACE PM, 1994, CANCER RES, V54, P2719; Weng WK, 2003, J CLIN ONCOL, V21, P3940, DOI 10.1200/JCO.2003.05.013; Went P, 2006, BRIT J CANCER, V94, P128, DOI 10.1038/sj.bjc.6602924; Went PT, 2004, HUM PATHOL, V35, P122, DOI 10.1016/j.humpath.2003.08.026; Whiteside TL, 1999, CANCER IMMUNOL IMMUN, V48, P346, DOI 10.1007/s002620050585; WIKSTRAND CJ, 1995, CANCER RES, V55, P3140; Wimberger P, 2003, INT J CANCER, V105, P241, DOI 10.1002/ijc.11056; Witlox MA, 2002, J GENE MED, V4, P510, DOI 10.1002/jgm.308; Witzig TE, 2002, J CLIN ONCOL, V20, P2453, DOI 10.1200/JCO.2002.11.076; Wolf E, 2005, DRUG DISCOV TODAY, V10, P1237, DOI 10.1016/S1359-6446(05)03554-3; WOLFE F, 1994, J MUSCULOSKELET PAIN, V2, P24; Wulff C, 2002, ENDOCRINOLOGY, V143, P2797, DOI 10.1210/en.143.7.2797; WULFING C, 1994, J MOL BIOL, V242, P655, DOI 10.1006/jmbi.1994.1615; WYLIE DE, 1982, J EXP MED, V155, P403, DOI 10.1084/jem.155.2.403; Xiong DS, 2002, CANCER LETT, V177, P29, DOI 10.1016/S0304-3835(01)00758-3; Yagita H, 2004, CANCER SCI, V95, P777, DOI 10.1111/j.1349-7006.2004.tb02181.x; Yamano Y, 2004, J EXP MED, V199, P1367, DOI 10.1084/jem.20032042; Yang XD, 2001, CRIT REV ONCOL HEMAT, V38, P17, DOI 10.1016/S1040-8428(00)00134-7; Yang XD, 1999, CANCER RES, V59, P1236; Yarden Y, 2001, EUR J CANCER, V37, pS3; Yu JL, 2002, SCIENCE, V295, P1526, DOI 10.1126/science.1068327; Yu Rui, 2005, Sheng Wu Gong Cheng Xue Bao, V21, P289; Zaki MH, 2002, J INVEST DERMATOL, V118, P366, DOI 10.1046/j.1523-1747.2002.01646.x; ZARDI L, 1987, EMBO J, V6, P2337, DOI 10.1002/j.1460-2075.1987.tb02509.x; ZEIN N, 1988, SCIENCE, V240, P1198, DOI 10.1126/science.3240341; Zhang Wei, 2002, Angiogenesis, V5, P35, DOI 10.1023/A:1021540120521; ZHOU H, 1993, CANCER RES, V53, P3817; Zhu ZP, 1996, BIO-TECHNOL, V14, P192, DOI 10.1038/nbt0296-192	240	60	67	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2007	26	25					3714	3733		10.1038/sj.onc.1210372	http://dx.doi.org/10.1038/sj.onc.1210372			20	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	172PK	17530025				2022-12-28	WOS:000246816100014
J	Kawasaki, Y; Sagara, M; Shibata, Y; Shirouzu, M; Yokoyama, S; Akiyama, T				Kawasaki, Y.; Sagara, M.; Shibata, Y.; Shirouzu, M.; Yokoyama, S.; Akiyama, T.			Identification and characterization of Asef2, a guanine-nucleotide exchange factor specific for Rac1 and Cdc42	ONCOGENE			English	Article						tumor suppressor; APC; Asef; GEF; Rac1; Cdc42	TUMOR-SUPPRESSOR APC; COLORECTAL-CANCER; ACTIN CYTOSKELETON; MIGRATION; PROTEIN; LINK	The tumor suppressor adenomatous polyposis coli (APC) is mutated in sporadic and familial colorectal tumors. APC interacts with the Rac1-specific guanine-nucleotide exchange factor (GEF) Asef, which contains an APC-binding region (ABR) in addition to Dbl homology (DH), Pleckstrin (PH) and Src homology 3 (SH3) domains. APC stimulates the GEF activity of Asef, and thereby regulates cell adhesion and migration. Here, we have identified a second Asef, termed Asef2, that shows significant structural and functional similarities to Asef. We found that both the N-terminal ABR and SH3 domains of Asef2 are responsible for its interaction with APC. When expressed in HeLa cells, a mutant Asef2 lacking the ABR and SH3 domains, Asef2-Delta ABR/SH3, induced increases in the levels of the active forms of Rac1 and Cdc42. Full-length Asef2 also showed this activity when co-transfected with truncated mutant APC expressed in colorectal tumor cells. Consistent with this, either Asef2-Delta ABR/SH3 or Asef2 plus truncated mutant APC stimulated lamellipodia formation in MDCK cells and filopodia formation in HeLa cells. Furthermore, RNA interference experiments showed that Asef2 is required for migration of colorectal tumor cells expressing truncated APC. These results suggest that similar to Asef, Asef2 plays an important role in cell migration, and that Asef2 activated by truncated mutant APC is required for aberrant migration of colorectal tumor cells.	[Kawasaki, Y.; Sagara, M.; Shibata, Y.; Akiyama, T.] Univ Tokyo, Inst Mol & Cellular Biosci, Lab Mol & Genet Informat, Bunkyo Ku, Tokyo 1130032, Japan; [Shirouzu, M.; Yokoyama, S.] RIKEN Genom Sci Ctr, Yokohama Inst, Bunkyo Ku, Tokyo, Japan; [Yokoyama, S.] Univ Tokyo, Grad Sch Sci, Dept Biophys & Biochem, Tokyo 113, Japan	University of Tokyo; RIKEN; University of Tokyo	Akiyama, T (corresponding author), Univ Tokyo, Inst Mol & Cellular Biosci, Lab Mol & Genet Informat, Bunkyo Ku, 1-1-1 Yayoi, Tokyo 1130032, Japan.	akiyama@imcbns.iam.u-tokyo.ac.jp	Shirouzu, Mikako/A-6521-2016; Yokoyama, Shigeyuki/N-6911-2015	Yokoyama, Shigeyuki/0000-0003-3133-7338				Akiyama T, 2006, ONCOGENE, V25, P7538, DOI 10.1038/sj.onc.1210063; Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092-8674(00)00122-7; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Feng QY, 2004, EMBO J, V23, P3492, DOI 10.1038/sj.emboj.7600331; Fodde R, 2001, NAT REV CANCER, V1, P55, DOI 10.1038/35094067; Gotthardt K, 2007, BIOL CHEM, V388, P67, DOI 10.1515/BC.2007.008; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hamann MJ, 2007, MOL CELL BIOL, V27, P1380, DOI 10.1128/MCB.01608-06; Jimbo T, 2002, NAT CELL BIOL, V4, P323, DOI 10.1038/ncb779; Kawasaki Y, 2003, NAT CELL BIOL, V5, P211, DOI 10.1038/ncb937; Kawasaki Y, 2000, SCIENCE, V289, P1194, DOI 10.1126/science.289.5482.1194; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Matsumine A, 1996, SCIENCE, V272, P1020, DOI 10.1126/science.272.5264.1020; Murayama K, 2007, J BIOL CHEM, V282, P4238, DOI 10.1074/jbc.C600234200; Oshima H, 1997, CANCER RES, V57, P1644; Polakis P, 2000, GENE DEV, V14, P1837; Sansom OJ, 2004, GENE DEV, V18, P1385, DOI 10.1101/gad.287404; VAN AL, 1997, GENE DEV, V11, P2295; Watanabe T, 2004, DEV CELL, V7, P871, DOI 10.1016/j.devcel.2004.10.017; Wong MH, 1996, P NATL ACAD SCI USA, V93, P9588, DOI 10.1073/pnas.93.18.9588	20	55	60	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 6	2007	26	55					7620	7627		10.1038/sj.onc.1210574	http://dx.doi.org/10.1038/sj.onc.1210574			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	239SK	17599059				2022-12-28	WOS:000251537800003
J	Cheng, K; Grisendi, S; Clohessy, JG; Majid, S; Bernardi, R; Sportoletti, P; Pandolfi, PP				Cheng, K.; Grisendi, S.; Clohessy, J. G.; Majid, S.; Bernardi, R.; Sportoletti, P.; Pandolfi, P. P.			The leukemia-associated cytoplasmic nucleophosmin mutant is an oncogene with paradoxical functions: Arf inactivation and induction of cellular senescence	ONCOGENE			English	Article						NPMc; E1A; Arf; senescence; cell transformation	TUMOR-SUPPRESSOR; GENE-EXPRESSION; ADENOVIRUS E1A; P53; INHIBITION; ACTIVATION; MUTATIONS; FUSION; NPM1	Mutations leading to aberrant cytoplasmic localization of Nucleophosmin 1 (NPM1) have been recently identified as the most frequent genetic alteration in acute myelogenous leukemia. However, the oncogenic potential of this nucleophosmin mutant (NPMc+) has never been established, which casts doubt on its role in leukemogenesis. By performing classical transformation assays, we find that NPMc+, but not wild-type NPM, cooperates specifically with adenovirus E1A to transform primary mouse embryonic. broblasts in soft agar. We demonstrate that NPMc+ blocks the p19(Arf) (Arf) induction elicited by E1A. Surprisingly, however, we find that NPMc+ induces cellular senescence and that E1A is able to overcome this response. We propose a model whereby the NPMc+ pro-senescence activity needs to be evaded for oncogenic transformation, even though NPMc+ can concomitantly blunt the Arf/p53 pathway. These findings identify for the first time NPMc+ as an oncogene and shed new unexpected light on its mechanism of action.	Mem Sloan Kettering Canc Ctr, Canc Biol & Genet Program, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Pathol, Canc Biol & Genet Program, New York, NY 10021 USA; Cornell Univ, Grad Program Biochem Mol & Cell Biol, Ithaca, NY 14853 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Cornell University	Pandolfi, PP (corresponding author), Mem Sloan Kettering Canc Ctr, Canc Biol & Genet Program, 1275 York Ave,Box 110, New York, NY 10021 USA.	p-pandol@ski.mskcc.org	bernardi, rosa/B-1650-2013; Sportoletti, Paolo/AAE-5907-2020; SPORTOLETTI, PAOLO/K-6013-2016	bernardi, rosa/0000-0002-3607-6336; SPORTOLETTI, PAOLO/0000-0002-5630-9862; Clohessy, John/0000-0001-5186-9775				Bartkova J, 2006, NATURE, V444, P633, DOI 10.1038/nature05268; Berk AJ, 2005, ONCOGENE, V24, P7673, DOI 10.1038/sj.onc.1209040; Colombo E, 2006, CANCER RES, V66, P3044, DOI 10.1158/0008-5472.CAN-05-2378; Colombo E, 2005, MOL CELL BIOL, V25, P8874, DOI 10.1128/MCB.25.20.8874-8886.2005; Colombo E, 2002, NAT CELL BIOL, V4, P529, DOI 10.1038/ncb814; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; den Besten W, 2005, CELL CYCLE, V4, P1593; Di Micco R, 2006, NATURE, V444, P638, DOI 10.1038/nature05327; DYSON N, 1992, CANCER SURV, V12, P161; Falini B, 2005, NEW ENGL J MED, V352, P254, DOI 10.1056/NEJMoa041974; Falini B, 2006, BLOOD, V107, P4514, DOI 10.1182/blood-2005-11-4745; Frehlick LJ, 2007, BIOESSAYS, V29, P49, DOI 10.1002/bies.20512; Gallimore PH, 2001, ONCOGENE, V20, P7824, DOI 10.1038/sj.onc.1204913; Grisendi S, 2005, NATURE, V437, P147, DOI 10.1038/nature03915; Grisendi S, 2006, NAT REV CANCER, V6, P493, DOI 10.1038/nrc1885; Grossman SR, 1998, MOL CELL, V2, P405, DOI 10.1016/S1097-2765(00)80140-9; Kondo T, 1997, ONCOGENE, V15, P1275, DOI 10.1038/sj.onc.1201286; Krug U, 2002, ONCOGENE, V21, P3475, DOI 10.1038/sj.onc.1205322; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; Lin CY, 2006, CELL SIGNAL, V18, P2041, DOI 10.1016/j.cellsig.2006.04.001; LIN HJL, 1995, MOL CELL BIOL, V15, P4536; Mendes-da-Silva P, 2000, J CLIN PATHOL-MOL PA, V53, P184, DOI 10.1136/mp.53.4.184; MORRIS SW, 1994, SCIENCE, V263, P1281, DOI 10.1126/science.8122112; Olney HJ, 2002, BAS CLIN ON, V27, P89; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; Redner RL, 1996, BLOOD, V87, P882, DOI 10.1182/blood.V87.3.882.bloodjournal873882; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; Sauerbrey A, 1998, LEUKEMIA LYMPHOMA, V28, P275, DOI 10.3109/10428199809092683; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sherr CJ, 2006, NAT REV CANCER, V6, P663, DOI 10.1038/nrc1954; Thiede C, 2006, BLOOD, V107, P4011, DOI 10.1182/blood-2005-08-3167; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; Verhaak RGW, 2005, BLOOD, V106, P3747, DOI 10.1182/blood-2005-05-2168; YEW PR, 1992, NATURE, V357, P82, DOI 10.1038/357082a0; YonedaKato N, 1996, ONCOGENE, V12, P265; Zhang X, 2004, J BIOL CHEM, V279, P25122, DOI 10.1074/jbc.M403287200	36	35	46	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 22	2007	26	53					7391	7400		10.1038/sj.onc.1210549	http://dx.doi.org/10.1038/sj.onc.1210549			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	236DA	17546053				2022-12-28	WOS:000251282000001
J	Brooks, CL; Li, M; Hu, M; Shi, Y; Gu, W				Brooks, C. L.; Li, M.; Hu, M.; Shi, Y.; Gu, W.			The p53-Mdm2-HAUSP complex is involved in p53 stabilization by HAUSP	ONCOGENE			English	Article						HAUSP; p53; deubiquitination; Mdm2 degradation	MDM2; PATHWAY; DEUBIQUITINATION; UBIQUITINATION; RECOGNITION; CONTRIBUTES; USP7/HAUSP	The ubiquitin-specific protease HAUSP is a critical component of the p53-Mdm2 pathway by acting as a specific deubiquitinase for both p53 and Mdm2. Recent structural studies have indicated that p53 and Mdm2 bind to the N-terminal TRAF-like domain of HAUSP in a mutually exclusive manner. To understand the mechanism of HAUSP-mediated effects, we have created a p53 mutant that lacks HAUSP binding based on the crystal structure analysis. Indeed, this mutant p53 protein can be degraded by Mdm2 but fails to interact with HAUSP both in vitro and in vivo. Surprisingly, however, we have found that direct interaction between HAUSP and p53 is not absolutely required for it to antagonize efficiently Mdm2-mediated ubiquitination of p53 and that HAUSP is capable of enzymatically functioning in trans on p53 by using Mdm2 as a bridge. Further, we show that a trimeric protein complex containing p53, Mdm2 and HAUSP can exist in vivo, despite mutually exclusive binding, with Mdm2 serving as a binding mediator for p53 and HAUSP. These findings reveal the complication of HAUSP-mediated effects in the p53-Mdm2 interplay. It also has important implications for the development of novel chemotherapeutic compounds aimed at blocking this protein-protein interaction.	Columbia Univ, Coll Phys & Surg, Inst Canc Genet, Dept Pathol, New York, NY USA; Princeton Univ, Lewis Thomas Lab, Dept Mol Biol, Princeton, NJ 08544 USA	Columbia University; Princeton University	Gu, W (corresponding author), Columbia Univ, Coll Phys & Surg, Inst Canc Genet, 1130 Nicholas Ave, New York, NY 10032 USA.	wg8@columbia.edu			NATIONAL CANCER INSTITUTE [R01CA098821, R01CA129627, R01CA104843, R01CA131439, R01CA085533, P01CA097403] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA097403, R01 CA098821, R01 CA085533, R01 CA104843, R01 CA131439, R01 CA129627] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Brooks CL, 2006, MOL CELL, V21, P307, DOI 10.1016/j.molcel.2006.01.020; CUMMINS JM, 2004, NATURE, V428, P486, DOI [DOI 10.1038/NATURE02501, 10.1038/nature02501]; Hu M, 2006, PLOS BIOL, V4, P228, DOI 10.1371/journal.pbio.0040027; Li MY, 2002, NATURE, V416, P648, DOI 10.1038/nature737; Li MY, 2004, MOL CELL, V13, P879, DOI 10.1016/S1097-2765(04)00157-1; Lohrum MAE, 2001, MOL CELL BIOL, V21, P8521, DOI 10.1128/MCB.21.24.8521-8532.2001; Marchenko ND, 2007, EMBO J, V26, P923, DOI 10.1038/sj.emboj.7601560; Marine JC, 2006, CELL DEATH DIFFER, V13, P927, DOI 10.1038/sj.cdd.4401912; Meulmeester E, 2005, MOL CELL, V18, P565, DOI 10.1016/j.molcel.2005.04.024; Nijman SMB, 2005, CELL, V123, P773, DOI 10.1016/j.cell.2005.11.007; Sheng Y, 2006, NAT STRUCT MOL BIOL, V13, P285, DOI 10.1038/nsmb1067; Tang J, 2006, NAT CELL BIOL, V8, P855, DOI 10.1038/ncb1442; van der Horst A, 2006, NAT CELL BIOL, V8, P1064, DOI 10.1038/ncb1469; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472	14	105	116	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 8	2007	26	51					7262	7266		10.1038/sj.onc.1210531	http://dx.doi.org/10.1038/sj.onc.1210531			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	231NO	17525743	Green Accepted			2022-12-28	WOS:000250955600010
J	Sommer, P; Le Rouzic, P; Gillingham, H; Berry, A; Kayahara, M; Huynh, T; White, A; Ray, DW				Sommer, P.; Le Rouzic, P.; Gillingham, H.; Berry, A.; Kayahara, M.; Huynh, T.; White, A.; Ray, D. W.			Glucocorticoid receptor overexpression exerts an antisurvival effect on human small cell lung cancer cells	ONCOGENE			English	Article						glucocorticoids; glucocorticoid receptor; small cell lung cancer	NF-KAPPA-B; GENE-EXPRESSION; PROOPIOMELANOCORTIN GENE; MICROARRAY ANALYSIS; INDUCED APOPTOSIS; MOLECULAR-BASIS; CYCLE ARREST; DNA-BINDING; GROWTH; DEXAMETHASONE	Small cell lung cancer ( SCLC) is an aggressive tumour with an abysmal prognosis. These cancers are characteristically resistant to glucocorticoid ( Gc) action, owing to impaired expression of the glucocorticoid receptor ( GR). We identified reduced GR expression in human SCLC cell lines, compared to a non-SCLC cell line. The SCLC cells also showed no Gc inhibition of proliferation, in contrast to non-SCLC cells. Retroviral overexpression of GR resulted in significantly increased cell death, which was partially blocked by the GR antagonist, RU486. Indeed, in cells sorted for GR expression, there was rapid, near complete loss of live cells by 72 h, in contrast to control cells that proliferated as expected. Flow cytometry using Annexin V revealed that cell death was by apoptosis. In addition, confocal analysis of fixed cells showed that cells overexpressing GR displayed a significant increase in fragmenting apoptotic nuclei. Microarray studies showed that transgenic GR expression upregulated the proapoptotic genes, BAD and BAX. We have, therefore, identified a profound apoptotic effect of GR in SCLC cells, which may explain the low levels of endogenous GR in SCLC cells. Understanding how GR overexpression leads to apoptotic cell death in SCLC cells may uncover new therapeutic strategies.	Univ Manchester, Fac Med & Human Sci, Dept Med, Ctr Mol Med, Manchester M13 9PT, Lancs, England; Univ Manchester, Endocrine Sci Res Grp, Manchester M13 9PT, Lancs, England; Univ Manchester, Fac Life Sci, Manchester M13 9PT, Lancs, England	University of Manchester; University of Manchester; University of Manchester	White, A (corresponding author), Univ Manchester, Fac Med & Human Sci, Dept Med, Ctr Mol Med, Stopford Bldg,Oxford Rd, Manchester M13 9PT, Lancs, England.	anne.white@manchester.ac.uk; david.w.ray@manchester.ac.uk	Zeef, Leo/D-6922-2011; White, Anne/G-7717-2015; Sommer, Paula/E-9454-2010; White, Anne/C-3753-2011	White, Anne/0000-0002-7686-2884; Kayahara, Midori/0000-0002-2967-1786; Ray, David/0000-0002-4739-6773; Smethurst, Helen/0000-0003-1234-7936	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Baldi P, 2001, BIOINFORMATICS, V17, P509, DOI 10.1093/bioinformatics/17.6.509; Bolstad BM, 2003, BIOINFORMATICS, V19, P185, DOI 10.1093/bioinformatics/19.2.185; BRAUNSCHWEIGER PG, 1983, CANCER RES, V43, P4757; CLARK AJL, 1990, J CLIN ENDOCR METAB, V70, P485, DOI 10.1210/jcem-70-2-485; COLE TJ, 1995, GENE DEV, V9, P1608, DOI 10.1101/gad.9.13.1608; CROSBY SR, 1988, J CLIN ENDOCR METAB, V67, P1272, DOI 10.1210/jcem-67-6-1272; Donn R, 2007, FASEB J, V21, P402, DOI 10.1096/fj.06-7236com; Doucas V, 2000, P NATL ACAD SCI USA, V97, P11893, DOI 10.1073/pnas.220413297; FARRELL WE, 1993, J MOL ENDOCRINOL, V10, P25, DOI 10.1677/jme.0.0100025; Galon J, 2002, FASEB J, V16, P61, DOI 10.1096/fj.01-0245com; Garside H, 2004, J BIOL CHEM, V279, P50050, DOI 10.1074/jbc.M407309200; GOYA L, 1993, MOL ENDOCRINOL, V7, P1121, DOI 10.1210/me.7.9.1121; HARMON JM, 1979, J CELL PHYSIOL, V98, P267, DOI 10.1002/jcp.1040980203; Hernandez J, 2000, CYTOKINE, V12, P791, DOI 10.1006/cyto.1999.0629; Herr I, 2003, CANCER RES, V63, P3112; Hofmann J, 1995, EUR J CANCER, V31A, P2053, DOI 10.1016/0959-8049(95)00431-9; Jackman DM, 2005, LANCET, V366, P1385, DOI 10.1016/S0140-6736(05)67569-1; Kim CFB, 2005, CELL, V121, P823, DOI 10.1016/j.cell.2005.03.032; Kim YH, 2006, ONCOGENE, V25, P130, DOI 10.1038/sj.onc.1208997; Kofler R, 2000, HISTOCHEM CELL BIOL, V114, P1; Leis H, 2004, MOL ENDOCRINOL, V18, P303, DOI 10.1210/me.2003-0350; Li C, 2001, P NATL ACAD SCI USA, V98, P31, DOI 10.1073/pnas.011404098; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lu YS, 2005, WORLD J GASTROENTERO, V11, P6373, DOI 10.3748/wjg.v11.i40.6373; Mathieu M, 1999, GENE THER, V6, P245, DOI 10.1038/sj.gt.3300814; Minna JD, 2003, CANCER CELL, V4, P163, DOI 10.1016/S1535-6108(03)00221-6; Mitelman F, 2000, MUTAT RES-REV MUTAT, V462, P247, DOI 10.1016/S1383-5742(00)00006-5; Mok CL, 1999, J EXP MED, V189, P575, DOI 10.1084/jem.189.3.575; Mortenson MM, 2005, LUNG CANCER, V49, P163, DOI 10.1016/j.lungcan.2005.01.006; NORMAN J, 1994, J SURG RES, V57, P33, DOI 10.1006/jsre.1994.1105; NORMAN MR, 1977, CANCER RES, V37, P3785; Pang D, 2004, BREAST CANCER RES TR, V88, pS27; RAY DW, 1994, J CLIN INVEST, V93, P1625, DOI 10.1172/JCI117143; Ray DW, 1996, CANCER RES, V56, P3276; Reichardt HM, 1998, CELL, V93, P531, DOI 10.1016/S0092-8674(00)81183-6; Rogatsky I, 1999, MOL CELL BIOL, V19, P5036; Rogatsky I, 1997, MOL CELL BIOL, V17, P3181, DOI 10.1128/MCB.17.6.3181; SANCHEZ I, 1993, CELL GROWTH DIFFER, V4, P215; Schmidt S, 2004, CELL DEATH DIFFER, V11, pS45, DOI 10.1038/sj.cdd.4401456; Tamura K, 2002, J HUM GENET, V47, P348, DOI 10.1007/s100380200048; Wang Z, 2003, J BIOL CHEM, V278, P50897, DOI 10.1074/jbc.M310297200; WHITE A, 1990, BAILLIERE CLIN ENDOC, V4, P1, DOI 10.1016/S0950-351X(05)80313-1; WHITE A, 1993, CLIN ENDOCRINOL, V39, P131, DOI 10.1111/j.1365-2265.1993.tb01765.x; Witschi H, 2005, INHAL TOXICOL, V17, P119, DOI 10.1080/08958370590899712; Wu W, 2004, CANCER RES, V64, P1757, DOI 10.1158/0008-5472.CAN-03-2546; Zhu XY, 2004, J STEROID BIOCHEM, V92, P375, DOI 10.1016/j.jsbmb.2004.07.010	46	31	32	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 1	2007	26	50					7111	7121		10.1038/sj.onc.1210524	http://dx.doi.org/10.1038/sj.onc.1210524			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	228GF	17496926				2022-12-28	WOS:000250715000005
J	Kida, A; Kakihana, K; Kotani, S; Kurosu, T; Miura, O				Kida, A.; Kakihana, K.; Kotani, S.; Kurosu, T.; Miura, O.			Glycogen synthase kinase-3 beta and p38 phosphorylate cyclin D2 on Thr280 to trigger its ubiquitin/proteasome-dependent degradation in hematopoietic cells	ONCOGENE			English	Article						cyclin D2; PI3K; GSK3 beta; p38; proteasomal degradation	ERYTHROPOIETIN RECEPTOR; CYCLE PROGRESSION; D2 EXPRESSION; BCR-ABL; D1; PROTEIN; DYSREGULATION; INHIBITION; PROLIFERATION; ACTIVATION	Cyclin D2 plays an important role in regulation of hematopoietic cell proliferation by cytokines and is implicated in oncogenesis of various hematopoietic malignancies. However, mechanisms regulating cyclin D2 stability and its expression level have remained to be known. Here, we demonstrate that interleukin- 3 signaling stabilizes cyclin D2 by inhibition of glycogen synthase kinase-3 beta ( GSK3 beta) through Janus kinase2-dependent activation of phosphatidylinositol 3'-kinase ( PI3K)/Akt signaling pathway in hematopoietic 32Dcl3 cells. On the other hand, osmotic stress was shown to induce a rapid proteasomal degradation of cyclin D2, which was mediated by activation of p38. GSK3 beta and p38 was demonstrated to phosphorylate cyclin D2 on Thr280 in vitro, while a cyclin D2 mutant with this residue substituted with Ala was found to be resistant to ubiquitination and proteasome- dependent degradation in 32Dcl3 cells. Inhibition of the PI3K pathway or induction of osmotic stress also caused a rapid proteasomal degradation of cyclin D2 in primary leukemic or myeloma cells. These results indicate that cyclin D2 expression in normal and malignant hematopoietic cells is regulated by ubiquitin/ proteasome- dependent degradation that is triggered by Thr280 phosphorylation by GSK3 beta or p38, which is induced by inhibition of the PI3K pathway or by osmotic stress, respectively.	Tokyo Med & Dent Univ, Grad Sch Med, Dept Hematol, Tokyo 1138519, Japan	Tokyo Medical & Dental University (TMDU)	Miura, O (corresponding author), Tokyo Med & Dent Univ, Grad Sch Med, Dept Hematol, 1-5-45 Yushima, Tokyo 1138519, Japan.	miura.hema@tmd.ac.jp		Miura, Osamu/0000-0002-0981-3054				Agami R, 2000, CELL, V102, P55, DOI 10.1016/S0092-8674(00)00010-6; ANDO K, 1993, P NATL ACAD SCI USA, V90, P9571, DOI 10.1073/pnas.90.20.9571; Benzeno S, 2006, ONCOGENE, V25, P6291, DOI 10.1038/sj.onc.1209644; Bergsagel PL, 2005, BLOOD, V106, P296, DOI 10.1182/blood-2005-01-0034; Brazil DP, 2004, TRENDS BIOCHEM SCI, V29, P233, DOI 10.1016/j.tibs.2004.03.006; Carthon BC, 2005, MOL CELL BIOL, V25, P1081, DOI 10.1128/MCB.25.3.1081-1088.2005; Casanovas O, 2000, J BIOL CHEM, V275, P35091, DOI 10.1074/jbc.M006324200; Casanovas O, 2004, ONCOGENE, V23, P7537, DOI 10.1038/sj.onc.1208040; Chiles TC, 2004, J IMMUNOL, V173, P2901, DOI 10.4049/jimmunol.173.5.2901; Chin H, 1998, BLOOD, V91, P3734; Clappier E, 2006, LEUKEMIA, V20, P82, DOI 10.1038/sj.leu.2404008; Deininger MWN, 2001, CANCER RES, V61, P8005; DELMER A, 1995, BLOOD, V85, P2870, DOI 10.1182/blood.V85.10.2870.bloodjournal85102870; Deshpande A, 2005, ONCOGENE, V24, P2909, DOI 10.1038/sj.onc.1208618; Diehl JA, 1997, GENE DEV, V11, P957, DOI 10.1101/gad.11.8.957; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Ely S, 2005, CANCER RES, V65, P11345, DOI 10.1158/0008-5472.CAN-05-2159; Fox BC, 2005, CELL SIGNAL, V17, P473, DOI 10.1016/j.cellsig.2004.09.004; Hu XT, 2002, J BIOL CHEM, V277, P16528, DOI 10.1074/jbc.M109929200; Huang W, 2007, ONCOGENE, V26, P2471, DOI 10.1038/sj.onc.1210033; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; Jena N, 2002, CANCER RES, V62, P535; Jope RS, 2004, TRENDS BIOCHEM SCI, V29, P95, DOI 10.1016/j.tibs.2003.12.004; Karrman K, 2006, EUR J HAEMATOL, V77, P27, DOI 10.1111/j.0902-4441.2006.t01-1-EJH2553.x; KATO JY, 1993, P NATL ACAD SCI USA, V90, P11513, DOI 10.1073/pnas.90.24.11513; Kozar K, 2005, CELL CYCLE, V4, P388, DOI 10.4161/cc.4.3.1551; Kurosu T, 2005, APOPTOSIS, V10, P1111, DOI 10.1007/s10495-005-3372-z; Kwak YT, 2005, J BIOL CHEM, V280, P33945, DOI 10.1074/jbc.M506206200; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; Lin DI, 2006, MOL CELL, V24, P355, DOI 10.1016/j.molcel.2006.09.007; Lucet IS, 2006, BLOOD, V107, P176, DOI 10.1182/blood-2005-06-2413; Ma Y, 2005, CANCER RES, V65, P6476, DOI 10.1158/0008-5472.CAN-05-0370; Malumbres M, 2001, NAT REV CANCER, V1, P222, DOI 10.1038/35106065; MIURA O, 1993, MOL CELL BIOL, V13, P1788, DOI 10.1128/MCB.13.3.1788; Murray AW, 2004, CELL, V116, P221, DOI 10.1016/S0092-8674(03)01080-8; Naderi S, 2004, J CELL SCI, V117, P3769, DOI 10.1242/jcs.01210; Okabe H, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000128; Parada Y, 2001, J BIOL CHEM, V276, P23572, DOI 10.1074/jbc.M101885200; Radosevic N, 2001, LEUKEMIA, V15, P559, DOI 10.1038/sj.leu.2402092; Shao JY, 2000, J BIOL CHEM, V275, P22916, DOI 10.1074/jbc.M002235200; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Yang GX, 2003, RRD PL CE P, V1, P7	42	42	44	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 11	2007	26	46					6630	6640		10.1038/sj.onc.1210490	http://dx.doi.org/10.1038/sj.onc.1210490			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	219JT	17486076				2022-12-28	WOS:000250081500005
J	Karlsson, J; Pietras, A; Beckman, S; Pettersson, HM; Larsson, C; Pahlman, S				Karlsson, J.; Pietras, A.; Beckman, S.; Pettersson, H. M.; Larsson, C.; Pahlman, S.			Arsenic trioxide-induced neuroblastoma cell death is accompanied by proteolytic activation of nuclear Bax	ONCOGENE			English	Article						arsenic trioxide; neuroblastoma; Bax; calpain; nuclear localization	ACUTE PROMYELOCYTIC LEUKEMIA; INDUCED APOPTOSIS; ENDOPLASMIC-RETICULUM; POLY(ADP-RIBOSE) POLYMERASE; CALPAIN ACTIVATION; CLEAVAGE; PROTEIN; BCL-2; LINES; P53	Arsenic trioxide (As2O3) is toxic to multidrug-resistant neuroblastoma cells in vivo and in vitro. In neuroblastoma, As2O3 does not exert its cell death-promoting effects via a classical apoptotic pathway. A death mechanism involving proteolytic cleavage of Bax to a p18 form seems to be of importance, because inhibition of Bax cleavage coincides with diminished cell death. As existing models of cell death implicate Bax in the intrinsic apoptotic pathway, triggering death after Bax translocation to the mitochondria, we investigated the cellular localization of p18 Bax by subcellular fractionation. After As2O3 treatment, p18 Bax was only present in nuclei-enriched, mitochondria-depleted fractions. Cytoplasmic p21 Bax levels decreased, whereas total (p21 and p18) nuclear Bax increased. Overexpressed p21 Bax localized to the cytoplasm and nuclei, whereas overexpressed p18 Bax localized to extranuclear structures only. The inability of overexpressed p18 Bax to locate to the nucleus, and the As2O3-induced reduction of p21 Bax in the cytosol, suggest an As2O3-induced mechanism where p18 Bax gets cleaved and 'trapped' in the nucleus. This model is strengthened by the observation that calpain, the protease responsible for p18 Bax generation, is present in the nuclei, and that nuclear calpain is induced by increasing As2O3 and Ca-2(+) levels.	Lund Univ, Univ Hosp MAS, Dept Lab Med, Div Mol Med, SE-20502 Malmo, Sweden	Lund University; Skane University Hospital	Pahlman, S (corresponding author), Lund Univ, Univ Hosp MAS, Dept Lab Med, Div Mol Med, SE-20502 Malmo, Sweden.	sven.pahlman@med.lu.se		Pietras, Alexander/0000-0002-5783-9347; Karlsson, Jenny/0000-0001-7681-0059				Breckenridge DG, 2003, ONCOGENE, V22, P8608, DOI 10.1038/sj.onc.1207108; Cai X, 2000, LEUKEMIA, V14, P262, DOI 10.1038/sj.leu.2401650; Cao XF, 2003, BLOOD, V102, P2605, DOI 10.1182/blood-2003-01-0211; Cartron PF, 2004, J BIOL CHEM, V279, P11503, DOI 10.1074/jbc.M311922200; Cartron PF, 2003, J BIOL CHEM, V278, P11633, DOI 10.1074/jbc.M208955200; Choi WS, 2001, J NEUROCHEM, V77, P1531, DOI 10.1046/j.1471-4159.2001.00368.x; Cohen MH, 2001, ONCOLOGIST, V6, P4, DOI 10.1634/theoncologist.6-1-4; Feldstein AE, 2004, HEPATOLOGY, V40, P185, DOI 10.1002/hep.20283; Friedrich P, 2004, BIOCHEM BIOPH RES CO, V323, P1131, DOI 10.1016/j.bbrc.2004.08.194; Gao G, 2000, J CELL BIOCHEM, V80, P53; Gobeil S, 2001, CELL DEATH DIFFER, V8, P588, DOI 10.1038/sj.cdd.4400851; Goll DE, 2003, PHYSIOL REV, V83, P731, DOI 10.1152/physrev.00029.2002; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Ho YS, 1999, BIOCHEM PHARMACOL, V57, P143, DOI 10.1016/S0006-2952(98)00272-X; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; Karlsson J, 2005, MOL CANCER THER, V4, P1128, DOI 10.1158/1535-7163.MCT-05-0047; Karlsson J, 2004, CLIN CANCER RES, V10, P3179, DOI 10.1158/1078-0432.CCR-03-0309; Keshelava N, 2001, CANCER RES, V61, P6185; Keshelava N, 1998, CANCER RES, V58, P5396; Mandal M, 1998, ONCOGENE, V17, P999, DOI 10.1038/sj.onc.1202020; Mattaj IW, 2004, NAT REV MOL CELL BIO, V5, P65, DOI 10.1038/nrm1263; Matthay KK, 1999, NEW ENGL J MED, V341, P1165, DOI 10.1056/NEJM199910143411601; Miller WH, 2002, CANCER RES, V62, P3893; Mishra S, 2005, TRENDS MOL MED, V11, P192, DOI 10.1016/j.molmed.2005.02.004; Niu C, 1999, BLOOD, V94, P3315, DOI 10.1182/blood.V94.10.3315.422k16_3315_3324; Oh SH, 2004, BIOCHEM PHARMACOL, V68, P1845, DOI 10.1016/j.bcp.2004.06.021; Ora I, 2000, BIOCHEM BIOPH RES CO, V277, P179, DOI 10.1006/bbrc.2000.3651; Pearson ADJ, 2000, NEUROBLASTOMA, P551; Philip T, 1997, EUR J CANCER, V33, P2130, DOI 10.1016/S0959-8049(97)00324-9; Poot M, 1997, CYTOMETRY, V27, P358, DOI 10.1002/(SICI)1097-0320(19970401)27:4<358::AID-CYTO7>3.0.CO;2-8; Raffo AJ, 2000, ONCOGENE, V19, P6216, DOI 10.1038/sj.onc.1203995; Scorrano L, 2003, SCIENCE, V300, P135, DOI 10.1126/science.1081208; Shah GM, 1996, BIOCHEM BIOPH RES CO, V229, P838, DOI 10.1006/bbrc.1996.1889; Shen ZX, 1997, BLOOD, V89, P3354, DOI 10.1182/blood.V89.9.3354; Soignet SL, 1998, NEW ENGL J MED, V339, P1341, DOI 10.1056/NEJM199811053391901; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Toyota H, 2003, CANCER LETT, V189, P221, DOI 10.1016/S0304-3835(02)00552-9; Tweddle DA, 2001, CANCER RES, V61, P8; Vandesompele J, 2002, ANAL BIOCHEM, V303, P95, DOI 10.1006/abio.2001.5564; Wang S, 2002, ONCOGENE, V21, P8388, DOI 10.1038/sj.onc.1205944; Wood DE, 2000, EXP CELL RES, V256, P375, DOI 10.1006/excr.2000.4859; Wood DE, 1998, ONCOGENE, V17, P1069, DOI 10.1038/sj.onc.1202034; Zhang TD, 2001, ONCOGENE, V20, P7146, DOI 10.1038/sj.onc.1204762	43	15	17	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 13	2007	26	42					6150	6159		10.1038/sj.onc.1210439	http://dx.doi.org/10.1038/sj.onc.1210439			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	209PU	17404572				2022-12-28	WOS:000249401300005
J	Sekine, Y; Ikeda, O; Hayakawa, Y; Tsuji, S; Imoto, S; Aoki, N; Sugiyama, K; Matsuda, T				Sekine, Y.; Ikeda, O.; Hayakawa, Y.; Tsuji, S.; Imoto, S.; Aoki, N.; Sugiyama, K.; Matsuda, T.			DUSP22/LMW-DSP2 regulates estrogen receptor-alpha-mediated signaling through dephosphorylation of Ser-118	ONCOGENE			English	Article						beta-estradiol; estrogen receptor; phosphatase; transcriptional regulation; breast cancer	DUAL-SPECIFICITY PHOSPHATASE; CELL ANTIGEN RECEPTOR; CROSS-TALK; TRANSCRIPTIONAL ACTIVATION; VACCINIA VIRUS; GERM-CELLS; PHOSPHORYLATION; PATHWAY; KINASE; TRANSDUCER	In the previous study, we demonstrated the involvement of dual specificity phosphatase 22 ( DUSP22/LMW-DSP2) in regulating the leukemia inhibitory factor/interleukin-6/ signal transducer and activator of transcription 3- mediated signaling pathway. In this study, we show beta-estradiol ( E2)- induced DUSP22 mRNA expression in estrogen receptor a ( ER alpha)- positive breast cancer cells, whereas E2- induced phosphorylation and activation of ERa was suppressed by overexpression of DUSP22 but not catalytically inactive mutants. Furthermore, small- interfering RNA- mediated reduction of DUSP22 expression enhanced ER alpha- mediated transcription and endogenous gene expression. In fact, DUSP22 associated with ERa in vivo and both endogenous proteins interacted in ERa- positive breast cancer T47D cells. These results strongly suggest that DUSP22 acts as a negative regulator of the ER alpha-amediated signaling pathway.	Hokkaido Univ, Grad Sch Pharmaceut Sci, Dept Immunol, Kita Ku, Sapporo, Hokkaido 0600812, Japan; Mie Univ, Fac Bioresources, Dept Life Sci, Lab Mol Food Chem & Biohem, Tsu, Mie 514, Japan; Nippon Boehringer Ingelheim Co Ltd, Kawanishi Pharma Res Inst, Kawanishi, Hyogo, Japan	Hokkaido University; Mie University; Boehringer Ingelheim	Matsuda, T (corresponding author), Hokkaido Univ, Grad Sch Pharmaceut Sci, Dept Immunol, Kita Ku, 12 Nishi 6, Sapporo, Hokkaido 0600812, Japan.	tmatsuda@pharm.hokudai.ac.jp	Sekine, Yuichi/S-8813-2019; Matsuda, Tadashi/A-3835-2012	Sekine, Yuichi/0000-0002-2861-603X; Matsuda, Tadashi/0000-0002-3089-3757				Alonso A, 2004, J BIOL CHEM, V279, P32586, DOI 10.1074/jbc.M403442200; Alonso A, 2002, J BIOL CHEM, V277, P5524, DOI 10.1074/jbc.M107653200; Alonso A, 2001, J BIOL CHEM, V276, P4766, DOI 10.1074/jbc.M006497200; ALTIOK N, 2006, IN PRESS BREAST CANC; Aoki N, 2001, J BIOCHEM, V130, P133, DOI 10.1093/oxfordjournals.jbchem.a002952; Aoki N, 1996, J BIOL CHEM, V271, P29422, DOI 10.1074/jbc.271.46.29422; Aoyama K, 2001, J BIOL CHEM, V276, P27575, DOI 10.1074/jbc.M100408200; Carreau S, 2002, MOL CELL ENDOCRINOL, V193, P137, DOI 10.1016/S0303-7207(02)00107-7; Castano E, 1998, J STEROID BIOCHEM, V65, P101, DOI 10.1016/S0960-0760(97)00179-9; Chen AJ, 2002, J BIOL CHEM, V277, P36592, DOI 10.1074/jbc.M200453200; Chen DS, 2000, MOL CELL, V6, P127, DOI 10.1016/S1097-2765(00)00014-9; Couse JF, 1999, ENDOCR REV, V20, P358, DOI 10.1210/er.20.3.358; Couse JF, 2001, REPROD FERT DEVELOP, V13, P211, DOI 10.1071/RD00128; DENU JM, 1995, P NATL ACAD SCI USA, V92, P5910, DOI 10.1073/pnas.92.13.5910; GUAN KL, 1991, NATURE, V350, P359, DOI 10.1038/350359a0; Ikeda K, 2004, MOL ENDOCRINOL, V18, P1131, DOI 10.1210/me.2003-0308; ISHIBASHI T, 1992, P NATL ACAD SCI USA, V89, P12170, DOI 10.1073/pnas.89.24.12170; Jenab S, 1998, ENDOCRINOLOGY, V139, P1883, DOI 10.1210/en.139.4.1883; Jenab S, 1997, ENDOCRINOLOGY, V138, P2740, DOI 10.1210/en.138.7.2740; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; Lannigan DA, 2003, STEROIDS, V68, P1, DOI 10.1016/S0039-128X(02)00110-1; Lu Q, 2003, J BIOL CHEM, V278, P4639, DOI 10.1074/jbc.M210949200; Ma ZQ, 2001, MOL CELL BIOL, V21, P8056, DOI 10.1128/MCB.21.23.8056-8067.2001; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Matsuda T, 2001, BIOCHEM BIOPH RES CO, V283, P179, DOI 10.1006/bbrc.2001.4758; Matsuda T, 2001, J BIOL CHEM, V276, P42908, DOI 10.1074/jbc.M105316200; Medunjanin S, 2005, J BIOL CHEM, V280, P33006, DOI 10.1074/jbc.M506758200; Meyer T, 2003, GENE DEV, V17, P1992, DOI 10.1101/gad.268003; Murphy K, 2005, GENE EXPR PATTERNS, V5, P475, DOI 10.1016/j.modgep.2004.12.007; Najarro P, 2001, J VIROL, V75, P3185, DOI 10.1128/JVI.75.7.3185-3196.2001; Proia DA, 2006, J BIOL CHEM, V281, P7089, DOI 10.1074/jbc.M511839200; Rogatsky I, 1999, J BIOL CHEM, V274, P22296, DOI 10.1074/jbc.274.32.22296; Safe S, 2004, TOXICOLOGY, V205, P3, DOI 10.1016/j.tox.2004.06.032; Sekine Y, 2006, ONCOGENE, V25, P5801, DOI 10.1038/sj.onc.1209578; Sekine Y, 2005, J BIOL CHEM, V280, P8188, DOI 10.1074/jbc.M411692200; Sekine Y, 2004, BIOCHEM BIOPH RES CO, V315, P692, DOI 10.1016/j.bbrc.2004.01.109; Shen Y, 2001, P NATL ACAD SCI USA, V98, P13613, DOI 10.1073/pnas.231499098; THEODOSIOU A, 2002, GENOME BIOL, V26; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; Wang LH, 2001, J BIOL CHEM, V276, P31839, DOI 10.1074/jbc.M105185200; Yamamoto T, 2002, ENDOCRINOLOGY, V143, P2635, DOI 10.1210/en.143.7.2635; Yamamoto T, 2000, FEBS LETT, V486, P143, DOI 10.1016/S0014-5793(00)02296-1; Zama T, 2002, J BIOL CHEM, V277, P23909, DOI 10.1074/jbc.M200837200	43	57	57	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP	2007	26	41					6038	6049		10.1038/sj.onc.1210426	http://dx.doi.org/10.1038/sj.onc.1210426			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	207US	17384676	Green Submitted			2022-12-28	WOS:000249277200007
J	Buchsbaum, S; Morris, C; Bochard, V; Jalinot, P				Buchsbaum, S.; Morris, C.; Bochard, V.; Jalinot, P.			Human INT6 interacts with MCM7 and regulates its stability during Sphase of the cell cycle	ONCOGENE			English	Article						INT6; MCM7; polyubiquitylation; protein degradation; DNA replication	MAMMARY-TUMOR VIRUS; DNA HELICASE ACTIVITY; EUKARYOTIC TRANSLATION INITIATION-FACTOR-3; FISSION YEAST HOMOLOG; COP9 SIGNALOSOME; NUCLEAR-BODIES; 26S PROTEASOME; HUMAN CLASPIN; SUBUNIT; PROTEIN	The mouse int6 gene is a frequent integration site of the mouse mammary tumor virus and INT6 silencing by RNA interference in HeLa cells causes an increased number of cells in the G2/M phases of the cell cycle, along with mitotic defects. In this report, we investigated the functional significance of the interaction between INT6 and MCM7, which was observed in a two-hybrid screen performed with INT6 as bait. It was found that proteasome inhibition strengthens interaction between both proteins and that INT6 stabilizes MCM7. Removal of MCM7 from chromatin as replication proceeds was accelerated in INT6-silenced cells and reduced amounts of protein were transiently observed, followed by a correction resulting from stimulation of mcm7 gene expression. Synchronized cells depleted for either INT6 or MCM7 display a reduction in thymidine incorporation and a reinforced association of RPA and claspin with chromatin. These data show that INT6 stabilizes chromatin-bound MCM7 and that alteration of this effect is associated with replication deficency.	Ecole Normale Super Lyon, CNRS, Lab Biol Mol Cellule, UMR 5161,IFR 128 Biosci Lyon Gerland, F-69364 Lyon 07, France	UDICE-French Research Universities; Universite Claude Bernard Lyon 1; CHU Lyon; Centre National de la Recherche Scientifique (CNRS); Ecole Normale Superieure de Lyon (ENS de LYON); Universite Jean Monnet	Jalinot, P (corresponding author), Ecole Normale Super Lyon, CNRS, Lab Biol Mol Cellule, UMR 5161,IFR 128 Biosci Lyon Gerland, 46 Allee Italie, F-69364 Lyon 07, France.	pjalinot@ens-lyon.fr	Morris, Christelle/M-8168-2014	Morris, Christelle/0000-0003-1575-4609				Akiyoshi Y, 2001, J BIOL CHEM, V276, P10056, DOI 10.1074/jbc.M010188200; Alves KH, 2002, FEBS LETT, V527, P15, DOI 10.1016/S0014-5793(02)03147-2; Asano K, 1997, J BIOL CHEM, V272, P23477, DOI 10.1074/jbc.272.38.23477; Bandyopadhyay A, 2000, MOL BIOL CELL, V11, P4005, DOI 10.1091/mbc.11.11.4005; Blow JJ, 2005, NAT REV MOL CELL BIO, V6, P476, DOI 10.1038/nrm1663; Burks EA, 2001, J BIOL CHEM, V276, P2122, DOI 10.1074/jbc.M007236200; Buttitta F, 2005, CLIN CANCER RES, V11, P3198, DOI 10.1158/1078-0432.CCR-04-2308; Cook JG, 2004, J BIOL CHEM, V279, P9625, DOI 10.1074/jbc.M311933200; Crane R, 2000, MOL BIOL CELL, V11, P3993, DOI 10.1091/mbc.11.11.3993; Desbois C, 1996, SCIENCE, V273, P951, DOI 10.1126/science.273.5277.951; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; Fitch MJ, 2003, J BIOL CHEM, V278, P25408, DOI 10.1074/jbc.M300699200; Fujita M, 1996, J BIOL CHEM, V271, P4349; Gillespie PJ, 2001, BMC BIOCHEM, V2, DOI 10.1186/1472-2091-2-15; Guo JJ, 2000, J VIROL, V74, P1892, DOI 10.1128/JVI.74.4.1892-1899.2000; Harlow E., 1988, ANTIBODIES LAB MANUA, P447; Holthoff HP, 1998, J BIOL CHEM, V273, P7320, DOI 10.1074/jbc.273.13.7320; Hwang GW, 2005, MOL PHARMACOL, V68, P1074, DOI 10.1124/mol.105.013516; Ishimi Y, 1997, J BIOL CHEM, V272, P24508, DOI 10.1074/jbc.272.39.24508; KIMURA H, 1995, NUCLEIC ACIDS RES, V23, P2097, DOI 10.1093/nar/23.12.2097; Kuhne C, 1998, J BIOL CHEM, V273, P34302, DOI 10.1074/jbc.273.51.34302; Kuo ML, 1997, INT J ONCOL, V10, P515; Lee JK, 2001, P NATL ACAD SCI USA, V98, P54, DOI 10.1073/pnas.98.1.54; Lin SY, 2004, P NATL ACAD SCI USA, V101, P6484, DOI 10.1073/pnas.0401847101; Maiorano D, 2005, CELL, V120, P315, DOI 10.1016/j.cell.2004.12.010; MARCHETTI A, 1995, J VIROL, V69, P1932, DOI 10.1128/JVI.69.3.1932-1938.1995; Mayeur GL, 2002, FEBS LETT, V514, P49, DOI 10.1016/S0014-5793(02)02307-4; Morris C, 2005, ONCOGENE, V24, P1203, DOI 10.1038/sj.onc.1208268; Morris-Desbois C, 1999, J CELL SCI, V112, P3331; Raasi S, 2003, J BIOL CHEM, V278, P8951, DOI 10.1074/jbc.M212841200; Rasmussen SB, 2001, ONCOGENE, V20, P5291, DOI 10.1038/sj.onc.1204624; Sar F, 2004, J BIOL CHEM, V279, P39289, DOI 10.1074/jbc.M405793200; Wang Y, 2000, FEBS LETT, V484, P17, DOI 10.1016/S0014-5793(00)02117-7; Yahalom A, 2001, J BIOL CHEM, V276, P334, DOI 10.1074/jbc.M006721200; Yanagi K, 2002, J BIOL CHEM, V277, P40871, DOI 10.1074/jbc.M206202200; Yen HCS, 2003, CELL, V112, P207, DOI 10.1016/S0092-8674(03)00043-6; Yen HCS, 2000, P NATL ACAD SCI USA, V97, P14370, DOI 10.1073/pnas.97.26.14370; You ZY, 2002, J BIOL CHEM, V277, P42471, DOI 10.1074/jbc.M205769200; Zhang X, 2004, J BIOL CHEM, V279, P25122, DOI 10.1074/jbc.M403287200; Zhou CS, 2005, BMC BIOL, V3, DOI 10.1186/1741-7007-3-14; Zhou HL, 2004, NATURE, V427, P167, DOI 10.1038/nature02273	41	15	17	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 2	2007	26	35					5132	5144		10.1038/sj.onc.1210314	http://dx.doi.org/10.1038/sj.onc.1210314			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	196MT	17310990				2022-12-28	WOS:000248487400012
J	Flotho, C; Steinemann, D; Mullighan, CG; Neale, G; Mayer, K; Kratz, CP; Schlegelberger, B; Downing, JR; Niemeyer, CM				Flotho, C.; Steinemann, D.; Mullighan, C. G.; Neale, G.; Mayer, K.; Kratz, C. P.; Schlegelberger, B.; Downing, J. R.; Niemeyer, C. M.			Genome-wide single-nucleotide polymorphism analysis in juvenile myelomonocytic leukemia identifies uniparental disomy surrounding the NF1 locus in cases associated with neurofibromatosis but not in cases with mutant RAS or PTPN11	ONCOGENE			English	Article						leukemia; JMML; SNP; NF1	BONE-MARROW-CELLS; INACTIVATION; CHILDREN	Juvenile myelomonocytic leukemia (JMML) is a malignant hematopoietic disorder whose proliferative component is a result of RAS pathway deregulation caused by somatic mutation in the RAS or PTPN11 oncogenes or in patients with underlying neurofibromatosis type 1 (NF-1), by loss of NF1 gene function. To search for potential collaborating genetic abnormalities, we used oligonucleotide arrays to analyse over 116000 sing le-nucleotide polymorphisms across the genome in 16 JMML samples with normal karyotype. Evaluation of the SNP genotypes identified large regions of homozygosity on chromosome 17q, including the NF1 locus, in four of the five samples from patients with JMML and NF-1. The homozygous region was at least 55 million base pairs in each case. The genomic copy number was normal within the homozygous region, indicating uniparental disomy (UPD). In contrast, the array data provided no evidence for 17q UPD in any of the 11 JMML cases without NF-1. We used array-based comparative genomic hybridization to confirm 17q disomy, and microsatellite analysis was performed to verify homozygosity. Mutational analysis demonstrated that the inactivating NF1 lesion was present on both alleles in each case. In summary, our data indicate that a mitotic recombination event in a JMML-initiating cell led to 17q UPD with homozygous loss of normal NF1, provide confirmatory evidence that the NF1 gene is crucial for the increased incidence of JMML in NF-1 patients, and corroborate the concept that RAS pathway deregulation is central to JMML pathogenesis.	Univ Freiburg, Div Pediat Hematol Oncol, Freiburg, Germany; Hannover Med Sch, Inst Cell & Mol Pathol, D-3000 Hannover, Germany; St Jude Childrens Res Hosp, Dept Pathol, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Hartwell Ctr Bioinformat & Biotechnol, Memphis, TN 38105 USA; Ctr Human Genet & Lab Med, Martinsried, Germany	University of Freiburg; Hannover Medical School; St Jude Children's Research Hospital; St Jude Children's Research Hospital	Flotho, C (corresponding author), Univ Kinderklin, Mathildenstr 1, D-79106 Freiburg, Germany.	christian.flotho@cuniklinik-freiburg.de	Kratz, Christian/AAC-9726-2021; Mullighan, Charles/H-3253-2011; Downing, James R./N-8102-2018	Mullighan, Charles/0000-0002-1871-1850; 				Arun D, 2004, CURR OPIN NEUROL, V17, P101, DOI 10.1097/00019052-200404000-00004; Dasgupta B, 2003, CURR OPIN GENET DEV, V13, P20, DOI 10.1016/S0959-437X(02)00015-1; EMANUEL PD, 1991, BLOOD, V77, P925; Engle LJ, 2006, ONCOGENE, V25, P1594, DOI 10.1038/sj.onc.1209368; Flotho C, 1999, LEUKEMIA, V13, P32, DOI 10.1038/sj.leu.2401240; FLOTHO C, 2007, IN PRESS CURR DRUG T; He L, 2005, NATURE, V435, P828, DOI 10.1038/nature03552; Hupe P, 2004, BIOINFORMATICS, V20, P3413, DOI 10.1093/bioinformatics/bth418; Lauchle JO, 2006, PEDIATR BLOOD CANCER, V46, P579, DOI 10.1002/pbc.20644; Lin M, 2004, BIOINFORMATICS, V20, P1233, DOI 10.1093/bioinformatics/bth069; MITELMAN F, 2006, MITELMAN DATABASE CH; Niemeyer CM, 1997, BLOOD, V89, P3534; Raghavan M, 2005, CANCER RES, V65, P375; Side L, 1997, NEW ENGL J MED, V336, P1713, DOI 10.1056/NEJM199706123362404; Steinemann D, 2003, GENE CHROMOSOME CANC, V37, P421, DOI 10.1002/gcc.10231; Stephens K, 2006, BLOOD, V108, P1684, DOI 10.1182/blood-2005-11-011486; Tonnies H, 2003, BLOOD, V101, P3872, DOI 10.1182/blood-2002-10-3243; Zhao XJ, 2004, CANCER RES, V64, P3060, DOI 10.1158/0008-5472.CAN-03-3308; Zielinski B, 2005, GENE CHROMOSOME CANC, V43, P294, DOI 10.1002/gcc.20186	19	56	59	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2007	26	39					5816	5821		10.1038/sj.onc.1210361	http://dx.doi.org/10.1038/sj.onc.1210361			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	202EP	17353900				2022-12-28	WOS:000248885100013
J	Park, IW; Reddy, MVR; Reddy, EP; Groopman, JE				Park, I-W; Reddy, M. V. R.; Reddy, E. P.; Groopman, J. E.			Evaluation of novel cell cycle inhibitors in mantle cell lymphoma	ONCOGENE			English	Article						mantle cell lymphoma; cell cycle; cytotoxicity; apoptosis; novel sulfonyl compounds (ON013100 and ON01370)	CDK INHIBITORS; CANCER CELLS; KINASE; PROTEIN; PHOSPHORYLATION; ACTIVATION; APOPTOSIS; SURVIVAL; DIFFERENTIATION; EXPRESSION	Signature abnormalities in the cell cycle and apoptotic pathway have been identified in mantle cell lymphoma (MCL), affording the opportunity to develop targeted therapies. In this study, we tested a novel class of kinase inhibitors, styryl sulfones, which differ from prior cell cycle inhibitors in that they are not related to purines or pyrimidines. We observed that two closely related compounds, ON013100 and ON01370, altered the growth and cell cycle status of MCL lines and potently inhibited the expression of several important molecules, including cyclin-dependent kinase4, p53, mouse double minute 2 (MDM2), and cyclin D as well as increased cyclin B expression. Using both terminal deoxy transferase uridine triphosphate nick end-labelling and poly ADP-ribose polymerase assays, we found that these compounds caused apoptosis in MCL cells. In addition, using molecular analyses, we observed the modulation of caspase-3 activity but not the expression of B-cell lymphoma family molecules. Next, we investigated the cytotoxicity of the MCL lines upon treatment with styryl sulfone compounds in combination with other currently used chemotherapeutic agents, such as doxorubicin (DOX) or vincristine (VCR). We found that the combination of DOX plus styryl sulfone or VCR plus styryl sulfone increased cytotoxicity by one log scale, compared with the single styryl sulfone compound. Thus, styryl sulfones alone, or in combination with chemotherapeutic agents, present attractive opportunities for new drug development in MCL.	Harvard Univ, Inst Med, Beth Israel Deaconess Med Ctr, Div Expt Med,Dept Med,Med Sch, Boston, MA 02115 USA; Temple Univ, Sch Med, Dept Biochem, Philadelphia, PA 19122 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Groopman, JE (corresponding author), Harvard Univ, Inst Med, Beth Israel Deaconess Med Ctr, Div Expt Med,Dept Med,Med Sch, 4 Blackfan Circle, Boston, MA 02115 USA.	jgroopma@bidmc.harvard.edu	Reddy, E. Premkumar/F-6233-2011		NATIONAL CANCER INSTITUTE [R01CA109820] Funding Source: NIH RePORTER; NCI NIH HHS [CA109820] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOSCH F, 1994, BLOOD, V84, P2725; Boutros R, 2005, EXP CELL RES, V310, P152, DOI 10.1016/j.yexcr.2005.07.009; Brady SC, 2005, MOL CELL BIOL, V25, P10543, DOI 10.1128/MCB.25.23.10543-10555.2005; Brauns SC, 2005, ANTICANCER RES, V25, P4197; Campo E, 1999, SEMIN HEMATOL, V36, P115; Chiarle R, 2000, BLOOD, V95, P619, DOI 10.1182/blood.V95.2.619; Choi S, 2005, CANCER RES, V65, P2035, DOI 10.1158/0008-5472.CAN-04-3616; CROWE DL, 2005, HEAD NECK-J SCI SPEC, V21, P15; Dash BC, 2005, MOL CELL BIOL, V25, P3364, DOI 10.1128/MCB.25.8.3364-3387.2005; de Leeuw RJ, 2004, HUM MOL GENET, V13, P1827, DOI 10.1093/hmg/ddh195; DEBOER CJ, 1995, ONCOGENE, V10, P1833; Elias B, 2005, ONCOGENE, V24, P2574, DOI 10.1038/sj.onc.1208488; Ely S, 2005, CANCER RES, V65, P11345, DOI 10.1158/0008-5472.CAN-05-2159; FERBABDEZ V, 2005, J CLIN ONCOL, V23, P6364; Fukuda T, 2005, GENES CELLS, V10, P655, DOI 10.1111/j.1365-2443.2005.00866.x; Gumireddy K, 2005, CANCER CELL, V7, P275, DOI 10.1016/j.ccr.2005.02.009; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; KIMBY E, 2005, ANN ONC 9 INT C M S5, V16, pV168; Kozar K, 2004, CELL, V118, P477, DOI 10.1016/j.cell.2004.07.025; LARDELLI P, 1990, AM J SURG PATHOL, V14, P752, DOI 10.1097/00000478-199008000-00007; Lee KH, 2001, P NATL ACAD SCI USA, V98, P3381, DOI 10.1073/pnas.051629198; Martin SA, 2005, CANCER RES, V65, P10657, DOI 10.1158/0008-5472.CAN-05-2087; Nevins JR, 1997, METHOD ENZYMOL, V283, P205; Nozoe T, 2005, J CANCER RES CLIN, V131, P179, DOI 10.1007/s00432-004-0607-2; Park IW, 2001, J IMMUNOL, V167, P2766, DOI 10.4049/jimmunol.167.5.2766; Rizzatti EG, 2005, BRIT J HAEMATOL, V130, P516, DOI 10.1111/j.1365-2141.2005.05630.x; Rosenwald A, 2003, CANCER CELL, V3, P185, DOI 10.1016/S1535-6108(03)00028-X; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; Sherr CJ, 2004, GENE DEV, V18, P2699, DOI 10.1101/gad.1256504; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Swerdlow SH, 2002, HUM PATHOL, V33, P7, DOI 10.1053/hupa.2002.30221; Tan J, 2005, CANCER RES, V65, P9012, DOI 10.1158/0008-5472.CAN-05-1226; Tiemann M, 2005, BRIT J HAEMATOL, V131, P29, DOI 10.1111/j.1365-2141.2005.05716.x; Witzig TE, 2005, J CLIN ONCOL, V23, P6409, DOI 10.1200/JCO.2005.55.017; Yamasaki L, 1998, Results Probl Cell Differ, V22, P199; ZUCCA E, 1995, ANN ONCOL, V6, P257, DOI 10.1093/oxfordjournals.annonc.a059155	36	14	15	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG	2007	26	38					5635	5642		10.1038/sj.onc.1210350	http://dx.doi.org/10.1038/sj.onc.1210350			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	200ZS	17369860				2022-12-28	WOS:000248801900009
J	Takahashi, M; Ozaki, T; Takahashi, A; Miyauchi, M; Ono, S; Takada, N; Koda, T; Todo, S; Kamijo, T; Nakagawara, A				Takahashi, M.; Ozaki, T.; Takahashi, A.; Miyauchi, M.; Ono, S.; Takada, N.; Koda, T.; Todo, S.; Kamijo, T.; Nakagawara, A.			DFF45/ICAD restores cisplatin-induced nuclear fragmentation but not DNA cleavage in DFF45-deficient neuroblastoma cells	ONCOGENE			English	Article						apoptosis; cisplatin; DFF45/ICAD; homozygous deletion; neuroblastoma	CASPASE-ACTIVATED DNASE; TUMOR-SUPPRESSOR GENES; CHROMATIN CONDENSATION; N-MYC; APOPTOSIS; INHIBITOR; DELETION; LINE; IDENTIFICATION; AMPLIFICATION	We have previously defined a homozygously deleted region at chromosome 1p36.2-p36.3 in human neuroblastoma cell lines, NB-1 and NB-C201, and identified six genes including DFF45/ICAD within this region. In this study, we found that NB-C201 cells are much more resistant to various genotoxic stresses such as cisplatin (CDDP) than CHP134 and SH-SY5Y cells that do not have the homozygous deletion. To examine a role(s) of DFF45 in the regulation of apoptosis in response to CDDP, we have established stably DFF45-expressing NB-C 201 cell clones (DFF45-1 and DFF45-3) and a control cell clone (NB-C201-C) using a retrovirus-mediated gene transfer. In contrast to NB-C201-C cells, DFF45-3 cells displayed apoptotic nuclear fragmentation in response to CDDP. Although CDDP-induced proteolytic cleavage of procaspase-3 and DFF45 in DFF45-3 cells, we could not detect a typical apoptotic DNA fragmentation. Additionally, deletion analysis revealed that C-terminal region of DFF45 is required for inducing nuclear fragmentation. Unexpectedly, (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assays demonstrated that DFF45 has undetectable effect on CDDP sensitivity of NB-C201 cells. Taken together, our present results suggest that DFF45/DFF40 system may be sufficient for CDDP-induced nuclear fragmentation but not DNA cleavage.	Chiba Canc Ctr, Res Inst, Div Biochem, Chuoh Ku, Chiba 2608717, Japan; Hokkaido Univ, Sch Med, Dept Gen Surg, Kita Ku, Sapporo, Hokkaido 060, Japan; Hisamitsu Pharmaceut Co Inc, Ctr Funct Genom, Chuoh Ku, Chiba, Japan; Chiba Canc Ctr, Res Inst, Div Pathol, Chuoh Ku, Chiba, Japan	Chiba Cancer Center; Hokkaido University; Hisamitsu Pharmaceutical Co Ltd; Chiba Cancer Center	Nakagawara, A (corresponding author), Chiba Canc Ctr, Res Inst, Div Biochem, Chuoh Ku, 666-2 Nitona, Chiba 2608717, Japan.	akiranak@chiba-cc.jp						AMLER LC, 1995, ONCOGENE, V10, P1095; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; BRODEUR GM, 1992, AM J PEDIAT HEMATOL, V14, P111; CHENG NC, 1995, ONCOGENE, V10, P291; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Gu JJ, 1999, J BIOL CHEM, V274, P20759, DOI 10.1074/jbc.274.30.20759; Halenbeck R, 1998, CURR BIOL, V8, P537, DOI 10.1016/S0960-9822(98)79298-X; Hosoda M, 2005, ONCOGENE, V24, P7156, DOI 10.1038/sj.onc.1208872; Inohara N, 1999, J BIOL CHEM, V274, P270, DOI 10.1074/jbc.274.1.270; Liu XS, 1998, P NATL ACAD SCI USA, V95, P8461, DOI 10.1073/pnas.95.15.8461; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; Lu CR, 2006, MOL CELL, V23, P121, DOI 10.1016/j.molcel.2006.05.023; Lu ZG, 2005, P NATL ACAD SCI USA, V102, P2778, DOI 10.1073/pnas.0405374102; MARTINSSON T, 1995, CANCER RES, V55, P5681; Mukae N, 1998, P NATL ACAD SCI USA, V95, P9123, DOI 10.1073/pnas.95.16.9123; Ohira M, 2000, ONCOGENE, V19, P4302, DOI 10.1038/sj.onc.1203786; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; Sakahira H, 1998, NATURE, V391, P96, DOI 10.1038/34214; SCHLEIERMACHER G, 1994, GENE CHROMOSOME CANC, V10, P275, DOI 10.1002/gcc.2870100409; TAKEDA O, 1994, GENE CHROMOSOME CANC, V10, P30, DOI 10.1002/gcc.2870100106; WHITE PS, 1995, P NATL ACAD SCI USA, V92, P5520, DOI 10.1073/pnas.92.12.5520; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; Yang HW, 2001, NEOPLASIA, V3, P165, DOI 10.1038/sj.neo.7900141; Zhang JH, 1999, J BIOL CHEM, V274, P37450, DOI 10.1074/jbc.274.52.37450	24	7	7	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2007	26	38					5669	5673		10.1038/sj.onc.1210352	http://dx.doi.org/10.1038/sj.onc.1210352			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	200ZS	17353905				2022-12-28	WOS:000248801900013
J	Chen, CH; Lu, PJ; Chen, YC; Fu, SL; Wu, KJ; Tsou, AP; Lee, YCG; Lin, TCE; Hsu, SL; Lin, WJ; Huang, CYF; Chou, CK				Chen, C-H; Lu, P-J; Chen, Y-C; Fu, S-L; Wu, K-J; Tsou, A-P; Lee, Y-C G.; Lin, T-C E.; Hsu, S-L; Lin, W-J; Huang, C-Y F.; Chou, C-K			FLJ10540-elicited cell transformation is through the activation of PI3-kinase/AKT pathway	ONCOGENE			English	Article						HCC; PI3K interaction protein; PI3K/AKT	HUMAN HEPATOCELLULAR-CARCINOMA; 3-KINASE PATHWAY; BETA-CATENIN; AURORA-A; C-MYC; EXPRESSION; PROTEIN; GENE; CANCER; PHOSPHORYLATION	A significant challenge in the post-genomic era is how to prioritize differentially expressed and uncharacterized novel genes found in hepatocellular carcinoma (HCC) microarray profiling. One such category is cell cycle regulated genes that have only evolved in higher organisms but not in lower eukaryotic cells. Characterization of these genes may reveal some novel human cancer-specific abnormalities. A novel transcript, FLJ10540 was identified. FLJ10540 is overexpressed in HCC as examined by quantitative reverse transcription-polymerase chain reaction and immunohistochemistry. The patients with higher FLJ10540 expression had a poor survival than those with lower FLJ10540 expression. Functional characterization indicates that FLJ10540 displays a number of characteristics associated with an oncogene, including anchorage-independent growth, enhanced cell growth at low serum levels and induction of tumorigenesis in nude mice. FLJ10540-elicited cell transformation is mediated by activation of the phosphatidylinositol 3'-kinase (PI3K)/AKT pathway. Moreover, FLJ10540 forms a complex with PI3K and can activate PI3K activity, which provides a mechanistic basis for FLJ10540-mediated oncogenesis. Together, using a combination of bioinformatics searches and empirical data, we have identified a novel oncogene, FLJ10540, which is conserved only in higher organisms. The finding raises the possibility that FLJ10540 is a potential new therapeutic target for HCC treatment. These findings may contribute to the development of new therapeutic strategies that are able to block the PI3K/AKT pathway in cancer cells.	Natl Hlth Res Inst, Canc Res Inst, Taipei 114, Taiwan; Natl Hlth Res Inst, Div Mol & Genom Med, Miaoli County, Taiwan; Kaohsiung Vet Gen Hosp, Dept Med Educ & Res, Kaohsiung, Taiwan; Kaohsiung Vet Gen Hosp, Dept Surg, Div Gen Surg, Kaohsiung, Taiwan; Natl Yang Ming Univ, Inst Tradit Med, Sch Med, Taipei 112, Taiwan; Natl Yang Ming Univ, Inst Biochem & Mol Biol, Taipei 112, Taiwan; Natl Yang Ming Univ, Inst Biotechnol Med, Taipei 112, Taiwan; Taipei Med Univ, Grad Inst Med Informat, Taipei, Taiwan; Taichung Vet Gen Hosp, Dept Educ & Res, Taichung, Taiwan; Natl Yang Ming Univ, Inst Bio Pharmaceut Sci, Taipei 112, Taiwan; Chang Gung Univ, Dept Life Sci, Tao Yuan, Taiwan	National Health Research Institutes - Taiwan; National Health Research Institutes - Taiwan; Kaohsiung Veterans General Hospital; Kaohsiung Veterans General Hospital; National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University; Taipei Medical University; Taichung Veterans General Hospital; National Yang Ming Chiao Tung University; Chang Gung University	Huang, CYF (corresponding author), Natl Hlth Res Inst, Canc Res Inst, Room 9321,No 161,Sect 6,Min Chuan E Rd, Taipei 114, Taiwan.	chiying@nhri.org.tw; ckchou@mail.cgu.edu.tw	Wu, Kou-Juey/P-4654-2015; Huang, Chi-Ying/AFL-7729-2022; Huang, Chi-Ying/AAG-7672-2022	Huang, Chi-Ying/0000-0003-4898-4937; Huang, Chi-Ying/0000-0003-4898-4937				Bellacosa A, 1998, ONCOGENE, V17, P313, DOI 10.1038/sj.onc.1201947; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Chen X, 2002, MOL BIOL CELL, V13, P1929, DOI 10.1091/mbc.02-02-0023; Chen YL, 2004, CANCER RES, V64, P8723, DOI 10.1158/0008-5472.CAN-03-3091; Fabbro M, 2005, DEV CELL, V9, P477, DOI 10.1016/j.devcel.2005.09.003; Foster KW, 1999, CELL GROWTH DIFFER, V10, P423; Fu SL, 2005, BIOCHEM BIOPH RES CO, V338, P830, DOI 10.1016/j.bbrc.2005.10.045; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hsu JM, 2004, J BIOL CHEM, V279, P32592, DOI 10.1074/jbc.M404950200; Kim SA, 2006, CANCER LETT, V235, P53, DOI 10.1016/j.canlet.2005.04.003; Kobayashi N, 2003, BLOOD, V102, P3186, DOI 10.1182/blood-2003-02-0567; Kolligs FT, 2000, GENE DEV, V14, P1319; Liang JY, 2003, CELL CYCLE, V2, P339, DOI 10.4161/cc.2.4.433; Ma XJ, 2003, P NATL ACAD SCI USA, V100, P5974, DOI 10.1073/pnas.0931261100; Nakanishi K, 2005, CANCER-AM CANCER SOC, V103, P307, DOI 10.1002/cncr.20774; Nicholson KM, 2003, BREAST CANCER RES TR, V81, P117, DOI 10.1023/A:1025765215765; Okano J, 2003, BIOCHEM BIOPH RES CO, V309, P298, DOI 10.1016/j.bbrc.2003.04.002; RUPPERT JM, 1991, MOL CELL BIOL, V11, P1724, DOI 10.1128/MCB.11.3.1724; Sakai M, 2006, ONCOGENE, V25, P480, DOI 10.1038/sj.onc.1209051; Su LJ, 2006, GENE EXPRESSION, V13, P107, DOI 10.3727/000000006783991872; Tsou AP, 2003, J BIOMED SCI, V10, P625, DOI 10.1159/000073528; Ueki K, 2000, MOL CELL BIOL, V20, P8035, DOI 10.1128/MCB.20.21.8035-8046.2000; Weng ZG, 2002, J BIOL CHEM, V277, P18677, DOI 10.1074/jbc.M105331200; Whitfield ML, 2002, MOL BIOL CELL, V13, P1977, DOI 10.1091/mbc.02-02-0030; Wu JC, 2005, J BIOL CHEM, V280, P9013, DOI 10.1074/jbc.M411068200; Xu XD, 2004, ONCOL REP, V11, P25; Yang CW, 2005, BIOCHEM BIOPH RES CO, V330, P489, DOI 10.1016/j.bbrc.2005.03.005; Yu CTR, 2005, MOL CELL BIOL, V25, P5789, DOI 10.1128/MCB.25.14.5789-5800.2005; Zhao WM, 2006, MOL BIOL CELL, V17, P3881, DOI 10.1091/mbc.E06-01-0015	29	71	73	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 21	2007	26	29					4272	4283		10.1038/sj.onc.1210207	http://dx.doi.org/10.1038/sj.onc.1210207			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	184CY	17237822				2022-12-28	WOS:000247619900010
J	Goldsmith, ZG; Dhanasekaran, DN				Goldsmith, Z. G.; Dhanasekaran, D. N.			G protein regulation of MAPK networks	ONCOGENE			English	Review						GPCR; signal transduction; G protein; MAPK; oncogene; cancer	N-TERMINAL KINASE; NUCLEOTIDE-EXCHANGE FACTOR; JUN NH2-TERMINAL KINASE; GROWTH-FACTOR RECEPTOR; G-BETA-GAMMA; HETEROTRIMERIC G-PROTEINS; RAS-DEPENDENT ACTIVATION; MUTANT ALPHA-SUBUNIT; MUSCARINIC ACETYLCHOLINE-RECEPTORS; EMBRYONAL CARCINOMA-CELLS	G proteins provide signal-coupling mechanisms to heptahelical cell surface receptors and are critically involved in the regulation of different mitogen-activated protein kinase (MAPK) networks. The four classes of G proteins, defined by the G(s), G(i), G(q) and G(12) families, regulate ERK1/2, JNK, p38MAPK, ERK5 and ERK6 modules by different mechanisms. The alpha- as well as beta gamma-subunits are involved in the regulation of these MAPK modules in a context-specific manner. While the alpha- and beta gamma-subunits primarily regulate the MAPK pathways via their respective effector-mediated signaling pathways, recent studies have unraveled several novel signaling intermediates including receptor tyrosine kinases and small GTPases through which these G-protein subunits positively as well as negatively regulate specific MAPK modules. Multiple mechanisms together with specific scaffold proteins that can link G-protein-coupled receptors or G proteins to distinct MAPK modules contribute to the context-specific and spatio-temporal regulation of mitogen-activated protein signaling networks by G proteins.	Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19104 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Dhanasekaran, DN (corresponding author), Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19104 USA.	danny001@temple.edu			NIGMS NIH HHS [GM 49897] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahn YH, 2005, CANCER RES, V65, P4896, DOI 10.1158/0008-5472.CAN-04-3122; Ahn YH, 2006, J CELL PHYSIOL, V209, P1039, DOI 10.1002/jcp.20821; Althoefer H, 1997, J BIOL CHEM, V272, P24380, DOI 10.1074/jbc.272.39.24380; Ambrosini A, 2000, MOL BRAIN RES, V75, P54, DOI 10.1016/S0169-328X(99)00294-6; Amsen EM, 2006, J BIOL CHEM, V281, P121, DOI 10.1074/jbc.M507595200; ARAGAY AM, 1995, J BIOL CHEM, V270, P20073, DOI 10.1074/jbc.270.34.20073; Arai K, 2003, MOL PHARMACOL, V63, P478, DOI 10.1124/mol.63.3.478; Araki S, 1997, KIDNEY INT, V51, P631, DOI 10.1038/ki.1997.92; Berestetskaya YV, 1998, J BIOL CHEM, V273, P27816, DOI 10.1074/jbc.273.43.27816; Blaukat A, 1999, J BIOL CHEM, V274, P14893, DOI 10.1074/jbc.274.21.14893; Blaukat A, 2000, MOL CELL BIOL, V20, P6837, DOI 10.1128/MCB.20.18.6837-6848.2000; Boire A, 2005, CELL, V120, P303, DOI 10.1016/j.cell.2004.12.018; Booden MA, 2004, MOL CELL BIOL, V24, P1990, DOI 10.1128/MCB.24.5.1990-1999.2004; Booden MA, 2002, MOL CELL BIOL, V22, P4053, DOI 10.1128/MCB.22.12.4053-4061.2002; Bos JL, 1998, EMBO J, V17, P6776, DOI 10.1093/emboj/17.23.6776; Bos JL, 2006, TRENDS BIOCHEM SCI, V31, P680, DOI 10.1016/j.tibs.2006.10.002; Brunet A, 1999, EMBO J, V18, P664, DOI 10.1093/emboj/18.3.664; Buchsbaum RJ, 2002, MOL CELL BIOL, V22, P4073, DOI 10.1128/MCB.22.12.4073-4085.2002; Busca R, 2000, EMBO J, V19, P2900, DOI 10.1093/emboj/19.12.2900; CAMPS M, 1992, NATURE, V360, P684, DOI 10.1038/360684a0; Chadee DN, 2004, NAT CELL BIOL, V6, P770, DOI 10.1038/ncb1152; CHAN AML, 1993, MOL CELL BIOL, V13, P762, DOI 10.1128/MCB.13.2.762; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Chikumi H, 2002, J BIOL CHEM, V277, P12463, DOI 10.1074/jbc.M108504200; Coffield VM, 2004, J EXP MED, V200, P1315, DOI 10.1084/jem.20040944; Collins LR, 1997, ONCOGENE, V15, P595, DOI 10.1038/sj.onc.1201220; Collins LR, 1996, J BIOL CHEM, V271, P17349, DOI 10.1074/jbc.271.29.17349; CONKLIN BR, 1993, CELL, V73, P631, DOI 10.1016/0092-8674(93)90245-L; Conway AM, 1999, BIOCHEM J, V337, P171, DOI 10.1042/0264-6021:3370171; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; COOK SJ, 1993, EMBO J, V12, P3475, DOI 10.1002/j.1460-2075.1993.tb06022.x; COSO OA, 1995, J BIOL CHEM, V270, P5620, DOI 10.1074/jbc.270.10.5620; Coso OA, 1996, J BIOL CHEM, V271, P3963; Crespo P, 1996, ONCOGENE, V13, P455; CRESPO P, 1995, J BIOL CHEM, V270, P25259, DOI 10.1074/jbc.270.42.25259; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; DAAKA Y, 2004, SCI STKE, V216, P2; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; Daub H, 1997, EMBO J, V16, P7032, DOI 10.1093/emboj/16.23.7032; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; de Rooij J, 1998, NATURE, V396, P474, DOI 10.1038/24884; DeFea KA, 2000, J CELL BIOL, V148, P1267, DOI 10.1083/jcb.148.6.1267; DellaRocca GJ, 1997, J BIOL CHEM, V272, P19125, DOI 10.1074/jbc.272.31.19125; Deng JB, 1998, J BIOL CHEM, V273, P16787, DOI 10.1074/jbc.273.27.16787; Denis-Henriot D, 1998, ENDOCRINOLOGY, V139, P2892, DOI 10.1210/en.139.6.2892; Dermott JM, 2004, ONCOGENE, V23, P226, DOI 10.1038/sj.onc.1207009; DHANASEKARAN DN, 2006, SCI STKE, V347, pPE31; Dhanasekaran N., 1995, Endocrine Reviews, V16, P259; Dhanasekaran N, 1996, CELL SIGNAL, V8, P235, DOI 10.1016/0898-6568(96)00048-4; Dhanasekaran N, 1998, ONCOGENE, V17, P1447, DOI 10.1038/sj.onc.1202251; Dhanasekaran N, 1998, BIOL SIGNAL RECEPT, V7, P109; Dhillon AS, 2002, MOL CELL BIOL, V22, P3237, DOI 10.1128/MCB.22.10.3237-3246.2002; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; DOLKI F, 1998, P NATL ACAD SCI USA, V95, P15394; Dumaz N, 2005, FEBS J, V272, P3491, DOI 10.1111/j.1742-4658.2005.04763.x; Edamatsu H, 1998, FEBS LETT, V440, P231, DOI 10.1016/S0014-5793(98)01457-4; Eguchi S, 1998, J BIOL CHEM, V273, P8890, DOI 10.1074/jbc.273.15.8890; Elion EA, 2001, J CELL SCI, V114, P3967; Elion EA, 2005, SCIENCE, V307, P687, DOI 10.1126/science.1109500; Enserink JM, 2002, NAT CELL BIOL, V4, P901, DOI 10.1038/ncb874; Fanger GR, 1997, EMBO J, V16, P4961, DOI 10.1093/emboj/16.16.4961; FAURE M, 1994, J BIOL CHEM, V269, P7851; Fleming Y, 2000, BIOCHEM J, V352, P145, DOI 10.1042/0264-6021:3520145; Freedman NJ, 1996, RECENT PROG HORM RES, V51, P319; Fukue M, 2000, DEV ARID REG RES SER, V1, P13; Fukuhara S, 2000, J BIOL CHEM, V275, P21730, DOI 10.1074/jbc.M002410200; Fukuhara S, 2000, FEBS LETT, V485, P183, DOI 10.1016/S0014-5793(00)02224-9; Garrington TP, 1999, CURR OPIN CELL BIOL, V11, P211, DOI 10.1016/S0955-0674(99)80028-3; Gerasimovskaya EV, 2002, J BIOL CHEM, V277, P44638, DOI 10.1074/jbc.M203012200; Ghosh SK, 2002, J BIOL CHEM, V277, P21325, DOI 10.1074/jbc.M201608200; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; Girardin SE, 2001, EMBO J, V20, P3437, DOI 10.1093/emboj/20.13.3437; GOTOH T, 1995, MOL CELL BIOL, V15, P6746; GOULD KL, 1985, CELL, V42, P849, DOI 10.1016/0092-8674(85)90281-8; GRAVES LM, 1993, P NATL ACAD SCI USA, V90, P10300, DOI 10.1073/pnas.90.21.10300; Gros R, 2006, CIRC RES, V99, P845, DOI 10.1161/01.RES.0000245189.21703.c0; Gross EA, 2002, J BIOL CHEM, V277, P13873, DOI 10.1074/jbc.M111994200; Gschwind A, 2001, ONCOGENE, V20, P1594, DOI 10.1038/sj.onc.1204192; Guo FF, 2001, J BIOL CHEM, V276, P25568, DOI 10.1074/jbc.M101277200; GUPTA KC, 1992, INT J MICROWAVE MILL, V2, P1; GUPTA SK, 1992, MOL CELL BIOL, V12, P190, DOI 10.1128/MCB.12.1.190; Gutkind JS, 1998, CONT ENDOCRINOL, V6, P101; Gutkind JS, 1998, ONCOGENE, V17, P1331, DOI 10.1038/sj.onc.1202186; GUTKIND JS, 2000, SCI STKE, V40, P1; HAFNER S, 1994, MOL CELL BIOL, V14, P6696; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; HAWES BE, 1995, J BIOL CHEM, V270, P17148, DOI 10.1074/jbc.270.29.17148; HEPLER JR, 1992, TRENDS BIOCHEM SCI, V17, P383, DOI 10.1016/0968-0004(92)90005-T; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; HIGASHIJIMA T, 1990, J BIOL CHEM, V265, P14176; Higashiyama S, 2005, BBA-PROTEINS PROTEOM, V1751, P110, DOI 10.1016/j.bbapap.2004.11.009; HINSHAW JE, 1995, NATURE, V374, P190, DOI 10.1038/374190a0; HOUSLAY MD, 2006, SCI STKE, V349, pPE32; Huang CC, 2004, J BIOL CHEM, V279, P12286, DOI 10.1074/jbc.M312868200; Hubbard KB, 2006, CELL SIGNAL, V18, P135, DOI 10.1016/j.cellsig.2005.08.004; Ichiba T, 1999, J BIOL CHEM, V274, P14376, DOI 10.1074/jbc.274.20.14376; Iwasaki H, 1999, ENDOCRINOLOGY, V140, P4659, DOI 10.1210/en.140.10.4659; Jho EH, 1997, J BIOL CHEM, V272, P24468, DOI 10.1074/jbc.272.39.24468; Jho EH, 1997, J BIOL CHEM, V272, P24461, DOI 10.1074/jbc.272.39.24461; JIANG HP, 1993, FEBS LETT, V330, P319, DOI 10.1016/0014-5793(93)80896-3; Jiang Y, 1998, NATURE, V395, P808, DOI 10.1038/27454; JOHNSON GL, 1989, ENDOCR REV, V10, P317, DOI 10.1210/edrv-10-3-317; Kam AYF, 2004, J NEUROCHEM, V89, P391, DOI 10.1111/j.1471-4159.2004.02338.x; Kashef K, 2005, BIOCHEMISTRY-US, V44, P14090, DOI 10.1021/bi050604l; Kashef K, 2006, J CELL BIOCHEM, V98, P715, DOI 10.1002/jcb.20930; KATZ A, 1992, NATURE, V360, P686, DOI 10.1038/360686a0; Khokhlatchev AV, 1998, CELL, V93, P605, DOI 10.1016/S0092-8674(00)81189-7; Kim KY, 2004, J BIOL CHEM, V279, P29478, DOI 10.1074/jbc.M313947200; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; Kiyokawa E, 1998, GENE DEV, V12, P3331, DOI 10.1101/gad.12.21.3331; KOCH WJ, 1994, P NATL ACAD SCI USA, V91, P12706, DOI 10.1073/pnas.91.26.12706; Kodama H, 2003, HYPERTENSION, V41, P1372, DOI 10.1161/01.HYP.0000069698.11814.F4; Kohout TA, 2003, MOL PHARMACOL, V63, P9, DOI 10.1124/mol.63.1.9; Kolch W, 2005, NAT REV MOL CELL BIO, V6, P827, DOI 10.1038/nrm1743; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KRAMER RM, 1995, J BIOL CHEM, V270, P27395, DOI 10.1074/jbc.270.46.27395; Kranenburg O, 2001, ONCOGENE, V20, P1540, DOI 10.1038/sj.onc.1204187; Kranenburg O, 1999, BIOCHEM J, V339, P11, DOI 10.1042/0264-6021:3390011; Kranenburg O, 1997, EMBO J, V16, P3097, DOI 10.1093/emboj/16.11.3097; Kranenburg O, 1999, J BIOL CHEM, V274, P35301, DOI 10.1074/jbc.274.50.35301; Krump E, 1997, J BIOL CHEM, V272, P937, DOI 10.1074/jbc.272.2.937; Kumar RN, 2006, MOL CELL BIOL, V26, P50, DOI 10.1128/MCB.26.1.50-62.2006; Kumar S, 1997, BIOCHEM BIOPH RES CO, V235, P533, DOI 10.1006/bbrc.1997.6849; LALLEMAIN G, 1991, CELL REGUL, V2, P675, DOI 10.1091/mbc.2.8.675; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; Laroche-Joubert N, 2002, J BIOL CHEM, V277, P18598, DOI 10.1074/jbc.M201868200; Lawler S, 1998, CURR BIOL, V8, P1387, DOI 10.1016/S0960-9822(98)00019-0; Lechner C, 1996, P NATL ACAD SCI USA, V93, P4355, DOI 10.1073/pnas.93.9.4355; Lee CM, 2002, P NATL ACAD SCI USA, V99, P14189, DOI 10.1073/pnas.232310199; Lee YN, 2004, J BIOL CHEM, V279, P54896, DOI 10.1074/jbc.M407581200; Leftowitz RJ, 2005, SCIENCE, V308, P512, DOI 10.1126/science.1109237; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; Lisnock J, 2000, BIOCHEMISTRY-US, V39, P3141, DOI 10.1021/bi992410+; Liu JL, 1997, J BIOL CHEM, V272, P29438, DOI 10.1074/jbc.272.47.29438; LOWNDES JM, 1991, J BIOL CHEM, V266, P14193; Luttrell LM, 1996, J BIOL CHEM, V271, P19443, DOI 10.1074/jbc.271.32.19443; Luttrell LM, 2001, P NATL ACAD SCI USA, V98, P2449, DOI 10.1073/pnas.041604898; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; LYONS J, 1990, SCIENCE, V249, P655, DOI 10.1126/science.2116665; Mao JH, 1998, EMBO J, V17, P5638, DOI 10.1093/emboj/17.19.5638; Marinissen MJ, 2003, J BIOL CHEM, V278, P46814, DOI 10.1074/jbc.M305709200; Marinissen MJ, 1999, MOL CELL BIOL, V19, P4289; Marinissen MT, 2001, GENE DEV, V15, P535, DOI 10.1101/gad.855801; McDonald PH, 2000, SCIENCE, V290, P1574, DOI 10.1126/science.290.5496.1574; Michiels F, 1997, J CELL BIOL, V137, P387, DOI 10.1083/jcb.137.2.387; Mills GB, 2003, NAT REV CANCER, V3, P582, DOI 10.1038/nrc1143; Minamino T, 2002, P NATL ACAD SCI USA, V99, P3866, DOI 10.1073/pnas.062453699; Minden A, 1997, BBA-REV CANCER, V1333, pF85, DOI 10.1016/S0304-419X(97)00018-8; Mischak H, 1996, MOL CELL BIOL, V16, P5409; MITCHELL FM, 1995, BIOCHEM J, V309, P381, DOI 10.1042/bj3090381; Mitsui H, 1997, J BIOL CHEM, V272, P4904, DOI 10.1074/jbc.272.8.4904; Miyamoto Y, 2003, J BIOL CHEM, V278, P29890, DOI 10.1074/jbc.M301559200; Mochizuki N, 2000, J BIOL CHEM, V275, P12667, DOI 10.1074/jbc.275.17.12667; Mochizuki N, 1999, NATURE, V400, P891, DOI 10.1038/23738; MORRISON DK, 1993, J BIOL CHEM, V268, P17309; Morrison DK, 2003, ANNU REV CELL DEV BI, V19, P91, DOI 10.1146/annurev.cellbio.19.111401.091942; MOYERS JS, 1993, MOL CELL BIOL, V13, P2391, DOI 10.1128/MCB.13.4.2391; Murasawa S, 1998, CIRC RES, V82, P1338, DOI 10.1161/01.RES.82.12.1338; Nagao M, 1999, ONCOGENE, V18, P4425, DOI 10.1038/sj.onc.1202832; Nagao M, 1998, J BIOL CHEM, V273, P22892, DOI 10.1074/jbc.273.36.22892; Needham LK, 1998, J BIOL CHEM, V273, P14626, DOI 10.1074/jbc.273.23.14626; Norum JH, 2007, FEBS LETT, V581, P15, DOI 10.1016/j.febslet.2006.11.069; Norum JH, 2005, FEBS J, V272, P2304, DOI 10.1111/j.1742-4658.2005.04658.x; Norum JH, 2003, J BIOL CHEM, V278, P3098, DOI 10.1074/jbc.M206237200; Obara Y, 2004, J CELL SCI, V117, P6085, DOI 10.1242/jcs.01527; Offermanns S, 1997, SCIENCE, V275, P533, DOI 10.1126/science.275.5299.533; Ohtsu H, 2006, AM J PHYSIOL-CELL PH, V291, pC1, DOI 10.1152/ajpcell.00620.2005; PACE AM, 1991, P NATL ACAD SCI USA, V88, P7031, DOI 10.1073/pnas.88.16.7031; PACE AM, 1995, MOL BIOL CELL, V6, P1685, DOI 10.1091/mbc.6.12.1685; Pearson GW, 2006, MOL CELL BIOL, V26, P3039, DOI 10.1128/MCB.26.8.3039-3047.2006; PIZON V, 1988, ONCOGENE, V3, P201; POUYSSEGUR J, 1992, ANNU REV PHYSIOL, V54, P195, DOI 10.1146/annurev.ph.54.030192.001211; Praefcke GJK, 2004, NAT REV MOL CELL BIO, V5, P133, DOI 10.1038/nrm1313; PRASAD MVVSV, 1994, ONCOGENE, V9, P2425; PRASAD MVVSV, 1995, J BIOL CHEM, V270, P18655, DOI 10.1074/jbc.270.31.18655; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; Quilliam LA, 2002, PROG NUCLEIC ACID RE, V71, P391, DOI 10.1016/S0079-6603(02)71047-7; Radhika V, 2004, J BIOL CHEM, V279, P49406, DOI 10.1074/jbc.M408836200; Radhika V, 2001, ONCOGENE, V20, P1607, DOI 10.1038/sj.onc.1204274; Ramirez MT, 1997, J BIOL CHEM, V272, P14057, DOI 10.1074/jbc.272.22.14057; Roy S, 2002, MOL CELL BIOL, V22, P5128, DOI 10.1128/MCB.22.14.5128-5140.2002; Rozengurt E, 1998, J CELL PHYSIOL, V177, P507, DOI 10.1002/(SICI)1097-4652(199812)177:4<507::AID-JCP2>3.0.CO;2-K; Schafer B, 2004, ONCOGENE, V23, P991, DOI 10.1038/sj.onc.1207278; Schmitt JM, 2000, J BIOL CHEM, V275, P25342, DOI 10.1074/jbc.M003213200; Schmitt JM, 2002, J BIOL CHEM, V277, P43024, DOI 10.1074/jbc.M204006200; Schmitt JM, 2002, MOL CELL, V9, P85, DOI 10.1016/S1097-2765(01)00432-4; Schmitt JM, 2001, MOL CELL BIOL, V21, P3671, DOI 10.1128/MCB.21.11.3671-3683.2001; Schonwasser DC, 1998, MOL CELL BIOL, V18, P790, DOI 10.1128/MCB.18.2.790; Sellers LA, 1999, J BIOL CHEM, V274, P16423, DOI 10.1074/jbc.274.23.16423; Servitja JM, 2003, J BIOL CHEM, V278, P34339, DOI 10.1074/jbc.M302960200; SEUWEN K, 1992, ADV CANCER RES, V58, P75, DOI 10.1016/S0065-230X(08)60291-2; Shan DD, 2006, DEV CELL, V10, P707, DOI 10.1016/j.devcel.2006.03.014; Shapiro PS, 1996, J BIOL CHEM, V271, P5750, DOI 10.1074/jbc.271.10.5750; Shenoy SK, 2003, BIOCHEM J, V375, P503, DOI 10.1042/BJ20031076; SHOU CC, 1995, ONCOGENE, V10, P1887; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; Sodhi A, 2000, CANCER RES, V60, P4873; Soltoff SP, 1998, J BIOL CHEM, V273, P23110, DOI 10.1074/jbc.273.36.23110; STEPHENS L, 1994, CELL, V77, P83, DOI 10.1016/0092-8674(94)90237-2; Stork PJS, 2002, TRENDS CELL BIOL, V12, P258, DOI 10.1016/S0962-8924(02)02294-8; Sun WY, 2001, J BIOL CHEM, V276, P5093, DOI 10.1074/jbc.M003719200; Suzuki N, 2003, P NATL ACAD SCI USA, V100, P733, DOI 10.1073/pnas.0234057100; Takahashi M, 2003, J BIOCHEM, V133, P181, DOI 10.1093/jb/mvg022; Takeuchi Y, 2003, J NEUROCHEM, V85, P729, DOI 10.1046/j.1471-4159.2003.01711.x; Tanaka S, 1998, J BIOL CHEM, V273, P1281, DOI 10.1074/jbc.273.3.1281; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; TANG WJ, 1992, CELL, V70, P869, DOI 10.1016/0092-8674(92)90236-6; Teramoto H, 1996, J BIOL CHEM, V271, P27225, DOI 10.1074/jbc.271.44.27225; THOMASON PA, 1994, J BIOL CHEM, V269, P16525; Todisco A, 1997, AM J PHYSIOL-GASTR L, V272, pG721, DOI 10.1152/ajpgi.1997.272.4.G721; Tohgo AK, 2002, J BIOL CHEM, V277, P9429, DOI 10.1074/jbc.M106457200; Tokiwa G, 1996, SCIENCE, V273, P792, DOI 10.1126/science.273.5276.792; Tsygankova OM, 2000, ONCOGENE, V19, P3609, DOI 10.1038/sj.onc.1203680; Ueda Y, 1996, J BIOL CHEM, V271, P23512, DOI 10.1074/jbc.271.38.23512; VAN BT, 1995, NATURE, V376, P781; Vomastek T, 2004, P NATL ACAD SCI USA, V101, P6981, DOI 10.1073/pnas.0305894101; von Kriegsheim A, 2006, NAT CELL BIOL, V8, P1011, DOI 10.1038/ncb1465; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; VOYNOYASENETSKAYA TA, 1994, ONCOGENE, V9, P2559; VoynoYasenetskaya TA, 1996, J BIOL CHEM, V271, P21081, DOI 10.1074/jbc.271.35.21081; Wan Y, 1998, J BIOL CHEM, V273, P14533, DOI 10.1074/jbc.273.23.14533; Wang HY, 2002, J BIOL CHEM, V277, P3530, DOI 10.1074/jbc.M107031200; Wang XF, 2000, MOL CELL BIOL, V20, P4543, DOI 10.1128/MCB.20.13.4543-4552.2000; Wang YP, 2006, J BIOL CHEM, V281, P35965, DOI 10.1074/jbc.M605503200; Wang ZP, 2006, MOL CELL BIOL, V26, P2130, DOI 10.1128/MCB.26.6.2130-2145.2006; Waters CM, 2005, CELL SIGNAL, V17, P263, DOI 10.1016/j.cellsig.2004.07.011; Weissman JT, 2004, ONCOGENE, V23, P241, DOI 10.1038/sj.onc.1207014; Werry TD, 2005, TRENDS ENDOCRIN MET, V16, P26, DOI 10.1016/j.tem.2004.11.008; WONG YH, 1991, NATURE, V351, P63, DOI 10.1038/351063a0; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; Wunderlich L, 1999, CELL SIGNAL, V11, P25, DOI 10.1016/S0898-6568(98)00027-8; Wylie PG, 1999, BIOCHEM J, V338, P619, DOI 10.1042/0264-6021:3380619; XU NZ, 1993, P NATL ACAD SCI USA, V90, P6741, DOI 10.1073/pnas.90.14.6741; XU NZ, 1994, BIOCHEM BIOPH RES CO, V201, P603, DOI 10.1006/bbrc.1994.1744; Yamaguchi Y, 2002, CURR BIOL, V12, P1353, DOI 10.1016/S0960-9822(02)01034-5; Yamauchi J, 2000, J BIOL CHEM, V275, P7633, DOI 10.1074/jbc.275.11.7633; Yamauchi J, 1999, J BIOL CHEM, V274, P1957, DOI 10.1074/jbc.274.4.1957; Yamauchi J, 2001, BIOCHEM BIOPH RES CO, V281, P1019, DOI 10.1006/bbrc.2001.4472; Yamauchi JJ, 1997, J BIOL CHEM, V272, P27771, DOI 10.1074/jbc.272.44.27771; Yang D, 1997, P NATL ACAD SCI USA, V94, P3004, DOI 10.1073/pnas.94.7.3004; Zheng M, 2000, J BIOL CHEM, V275, P40635, DOI 10.1074/jbc.M006325200; Zhong M, 2003, ENDOCRINOLOGY, V144, P2947, DOI 10.1210/en.2002-221039; Zhu DG, 2004, J BIOL CHEM, V279, P54983, DOI 10.1074/jbc.C400508200; ZOHN IE, 1995, MOL CELL BIOL, V15, P6160; Zwick E, 1997, J BIOL CHEM, V272, P24767, DOI 10.1074/jbc.272.40.24767	245	287	293	3	45	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 15	2007	26	22					3122	3142		10.1038/sj.onc.1210407	http://dx.doi.org/10.1038/sj.onc.1210407			21	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	169PH	17496911				2022-12-28	WOS:000246603600004
J	Liu, J; Lin, A				Liu, J.; Lin, A.			Wiring the cell signaling circuitry by the NF-kappa B and JNK1 crosstalk and its applications in human diseases	ONCOGENE			English	Review						NF-kappa B; JNK1; TNF-alpha; UV; signaling; crosstalk	TERMINAL KINASE ACTIVATION; TNF RECEPTOR 1; C-JUN KINASE; PROTEIN-KINASE; MAP KINASE; IKK-BETA; TRANSCRIPTION FACTOR; HA-RAS; SUPPRESSES APOPTOSIS; IONIZING-RADIATION	Integration of the cell signaling circuitry determines the ultimate response of a cell to extracellular stimuli. The transcription factor nuclear factor-kappa B (NF-kappa B) and mitogen-activated protein kinase JNK1 are major players in the cell signaling circuitry, regulating numerous cellular events and being implicated in the process of many human diseases and certain types of cancer. The interplay between NF-kappa B and JNK1 provides a paradigm that shows how the crosstalk between different signaling pathways decides the function of the cell signaling circuitry. Understanding the wiring of the cell signaling circuitry may hold the key for cell signaling-based therapy of human diseases.	Univ Chicago, Ben May Dept Canc Res, Chicago, IL 60637 USA	University of Chicago	Lin, A (corresponding author), Univ Chicago, Ben May Dept Canc Res, 929 E 57th St, Chicago, IL 60637 USA.	alin@huggins.bsd.uchicago.edu						ADLER V, 1992, P NATL ACAD SCI USA, V89, P5341, DOI 10.1073/pnas.89.12.5341; Amanullah A, 2003, NATURE, V424, P741, DOI 10.1038/424741b; Antonyak MA, 2002, ONCOGENE, V21, P5038, DOI 10.1038/sj.onc.1205593; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Bender K, 1998, EMBO J, V17, P5170, DOI 10.1093/emboj/17.17.5170; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; Campbell KJ, 2004, MOL CELL, V13, P853, DOI 10.1016/S1097-2765(04)00131-5; Chang LF, 2006, CELL, V124, P601, DOI 10.1016/j.cell.2006.01.021; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Courtois G, 2006, ONCOGENE, V25, P6831, DOI 10.1038/sj.onc.1209939; Cripe LD, 2002, LEUKEMIA, V16, P799, DOI 10.1038/sj.leu.2402457; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; De Smaele E, 2001, NATURE, V414, P308, DOI 10.1038/35104560; Deng YB, 2003, CELL, V115, P61, DOI 10.1016/S0092-8674(03)00757-8; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Gao M, 2004, SCIENCE, V306, P271, DOI 10.1126/science.1099414; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; He HP, 1999, CELL DEATH DIFFER, V6, P987, DOI 10.1038/sj.cdd.4400572; Herrlich P, 1997, BIOL CHEM, V378, P1217; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Hirosumi J, 2002, NATURE, V420, P333, DOI 10.1038/nature01137; Hutchison M, 1998, J BIOL CHEM, V273, P28625, DOI 10.1074/jbc.273.44.28625; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Ito M, 1999, MOL CELL BIOL, V19, P7539; Kamata H, 2005, CELL, V120, P649, DOI 10.1016/j.cell.2004.12.041; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Karin M, 2006, NATURE, V441, P431, DOI 10.1038/nature04870; Kasibhatla S, 1998, MOL CELL, V1, P543, DOI 10.1016/S1097-2765(00)80054-4; Kato T, 2003, MOL CELL, V12, P829, DOI 10.1016/S1097-2765(03)00358-7; Khelifi AF, 2005, CELL DEATH DIFFER, V12, P724, DOI 10.1038/sj.cdd.4401559; Lee SA, 1998, J BIOL CHEM, V273, P32889, DOI 10.1074/jbc.273.49.32889; Lei K, 2003, P NATL ACAD SCI USA, V100, P2432, DOI 10.1073/pnas.0438011100; Li NX, 1998, P NATL ACAD SCI USA, V95, P13012, DOI 10.1073/pnas.95.22.13012; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; Li ZW, 1999, J EXP MED, V189, P1839, DOI 10.1084/jem.189.11.1839; Lin A, 2003, SEMIN CANCER BIOL, V13, P107, DOI 10.1016/S1044-579X(02)00128-1; Lin A, 2003, BIOESSAYS, V25, P17, DOI 10.1002/bies.10204; LIN A, 2006, JNK SIGNALING PATHWA; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; Liu J, 2004, MOL CELL BIOL, V24, P10844, DOI 10.1128/MCB.24.24.10844-10856.2004; Liu J, 2006, MOL CELL, V21, P467, DOI 10.1016/j.molcel.2005.12.020; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Lopez-Bergami P, 2005, MOL CELL, V19, P309, DOI 10.1016/j.molcel.2005.06.025; Lu CR, 2006, MOL CELL, V23, P121, DOI 10.1016/j.molcel.2006.05.023; Lu XH, 1997, J BIOL CHEM, V272, P24751, DOI 10.1074/jbc.272.40.24751; Madrid LV, 2000, MOL CELL BIOL, V20, P1626, DOI 10.1128/MCB.20.5.1626-1638.2000; Maeda S, 2005, CELL, V121, P977, DOI 10.1016/j.cell.2005.04.014; Maeda S, 2003, IMMUNITY, V19, P725, DOI 10.1016/S1074-7613(03)00301-7; McDonald PH, 2000, SCIENCE, V290, P1574, DOI 10.1126/science.290.5496.1574; Micheau O, 2003, CELL, V114, P181, DOI 10.1016/S0092-8674(03)00521-X; Natoli G, 1997, SCIENCE, V275, P200, DOI 10.1126/science.275.5297.200; Nemoto S, 1998, MOL CELL BIOL, V18, P3518, DOI 10.1128/MCB.18.6.3518; Nijhawan D, 2003, GENE DEV, V17, P1475, DOI 10.1101/gad.1093903; Okazawa Hitohi, 2002, Am J Alzheimers Dis Other Demen, V17, P79, DOI 10.1177/153331750201700209; Pando MP, 2000, J BIOL CHEM, V275, P21278, DOI 10.1074/jbc.M002532200; Papa S, 2004, NAT CELL BIOL, V6, P146, DOI 10.1038/ncb1093; Park JM, 2004, GENE DEV, V18, P584, DOI 10.1101/gad.1168104; Pham CG, 2004, CELL, V119, P529, DOI 10.1016/j.cell.2004.10.017; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; Purcell NH, 2001, AM J PHYSIOL-GASTR L, V280, pG669, DOI 10.1152/ajpgi.2001.280.4.G669; Reimold A. M., 2002, Current Drug Targets - Inflammation and Allergy, V1, P377, DOI 10.2174/1568010023344535; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; Sabapathy K, 2004, MOL CELL, V15, P713, DOI 10.1016/j.molcel.2004.08.028; Sadoshima J, 2002, J CLIN INVEST, V110, P271, DOI 10.1172/JCI200214938; Sakon S, 2003, EMBO J, V22, P3898, DOI 10.1093/emboj/cdg379; Salmeron A, 1996, EMBO J, V15, P817, DOI 10.1002/j.1460-2075.1996.tb00417.x; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; Shaulian E, 2000, CELL, V103, P897, DOI 10.1016/S0092-8674(00)00193-8; She QB, 2002, CANCER RES, V62, P1343; Shibuya H, 1996, SCIENCE, V272, P1179, DOI 10.1126/science.272.5265.1179; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; Sigala JLD, 2004, SCIENCE, V304, P1963, DOI 10.1126/science.1098387; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; Tanaka M, 1999, IMMUNITY, V10, P421, DOI 10.1016/S1074-7613(00)80042-4; Tang FM, 2002, MOL CELL BIOL, V22, P8571, DOI 10.1128/MCB.22.24.8571-8579.2002; Tang GL, 2001, NATURE, V414, P313, DOI 10.1038/35104568; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; Tibbles LA, 1996, EMBO J, V15, P7026, DOI 10.1002/j.1460-2075.1996.tb01094.x; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; Tournier C, 1997, P NATL ACAD SCI USA, V94, P7337, DOI 10.1073/pnas.94.14.7337; Uehara T, 2005, J HEPATOL, V42, P850, DOI 10.1016/j.jhep.2005.01.030; VAN AD, 1996, SCIENCE, V274, P787; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Whitmarsh AJ, 1998, SCIENCE, V281, P1671, DOI 10.1126/science.281.5383.1671; Wisdom R, 1999, EMBO J, V18, P188, DOI 10.1093/emboj/18.1.188; Wu CJ, 2005, EMBO J, V24, P1886, DOI 10.1038/sj.emboj.7600649; Xia XG, 2001, P NATL ACAD SCI USA, V98, P10433, DOI 10.1073/pnas.181182298; Xia Y, 2000, P NATL ACAD SCI USA, V97, P5243, DOI 10.1073/pnas.97.10.5243; Yu CF, 2004, MOL CELL, V13, P329, DOI 10.1016/S1097-2765(04)00028-0; Yujiri T, 1998, SCIENCE, V282, P1911, DOI 10.1126/science.282.5395.1911; Zhang JY, 2006, MOL CELL BIOL, V26, P1223, DOI 10.1128/MCB.26.4.1223-1234.2006; Zheng CJ, 1999, J BIOL CHEM, V274, P28966, DOI 10.1074/jbc.274.41.28966	101	58	62	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 15	2007	26	22					3267	3278		10.1038/sj.onc.1210417	http://dx.doi.org/10.1038/sj.onc.1210417			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	169PH	17496921				2022-12-28	WOS:000246603600014
J	Davies, AJ				Davies, A. J.			Radioimmunotherapy for B-cell lymphoma: Y-90 ibritumomab tiuxetan and I-131 tositumomab	ONCOGENE			English	Review						radioimmunotherapy; non-Hodgkin's lymphoma; tositumomab; ibritumomab; monoclonal antibodies; CD20	NON-HODGKIN-LYMPHOMA; TERM-FOLLOW-UP; CHEMOTHERAPY PLUS RITUXIMAB; HIGH-DOSE THERAPY; MONOCLONAL-ANTIBODY THERAPY; BONE-MARROW-TRANSPLANTATION; RANDOMIZED CONTROLLED-TRIAL; MULTICENTER PHASE-II; REFRACTORY LOW-GRADE; FOLLICULAR LYMPHOMA	Radioimmunotherapy, targeting the CD20 antigen, in B-cell lymphoma has clearly demonstrated efficacy and tolerability over the preceding 15 years. As a result, two products are available with Food and Drug Administration approval for marketing - Y-90 ibritumomab tiuxetan and I-131 tositumomab, given as the Zevalin and Bexxar therapeutic regimens, respectively. Both demonstrate high-response rates and durability of remission in the relapsed/refractory disease setting. Data are emerging regarding their utility as initial therapy, and furthermore, they are been investigated for use sequentially with chemotherapy, and in the myeloablative setting. As yet however, how to best use these agents in the clinical disease course remains uncertain.	St Bartholomews Hosp, Dept Med Oncol, London EC1A 7BE, England	University of London; Queen Mary University London	Davies, AJ (corresponding author), St Bartholomews Hosp, Dept Med Oncol, 7th Floor Gloucester House, London EC1A 7BE, England.	Andrew.Davies1@Bartsandthelondon.nhs.uk		Davies, Andrew/0000-0002-7517-6938				Andersen NS, 2002, EUR J CANCER, V38, P401, DOI 10.1016/S0959-8049(01)00366-5; ANDERSON KC, 1984, BLOOD, V63, P1424, DOI 10.1182/blood.V63.6.1424.1424; Ansell SM, 2002, J CLIN ONCOL, V20, P3885, DOI 10.1200/JCO.2002.10.143; Apostolidis J, 2000, J CLIN ONCOL, V18, P527, DOI 10.1200/JCO.2000.18.3.527; Ardeshna KM, 2003, LANCET, V362, P516, DOI 10.1016/S0140-6736(03)14110-4; ARMITAGE JO, 1981, CANCER TREAT REP, V65, P413; BARTLETT N, 2002, P AM SOC CLIN ONCOL, V21; Bastion Y, 1997, J CLIN ONCOL, V15, P1587, DOI 10.1200/JCO.1997.15.4.1587; Bennett JM, 2005, BLOOD, V105, P4576, DOI 10.1182/blood-2004-12-4690; BUCHSBAUM DJ, 1992, CANCER RES, V52, P6476; BUCHSBAUM DJ, 1992, CANCER RES, V52, P637; Chan WC, 1997, BLOOD, V89, P3909; CHATAL JF, 2004, P AM SOC CLIN ONCOL, V22; Cheson BD, 2003, BLOOD, V101, P391, DOI 10.1182/blood-2002-06-1793; Coiffier B, 2002, NEW ENGL J MED, V346, P235, DOI 10.1056/NEJMoa011795; Connors JM, 2005, NEW ENGL J MED, V352, P496, DOI 10.1056/NEJMe048291; Conti PS, 2005, J NUCL MED, V46, P1812; Cragg MS, 2004, BLOOD, V103, P2738, DOI 10.1182/blood-2003-06-2031; CULLEN MH, 1979, CANCER, V44, P645, DOI 10.1002/1097-0142(197908)44:2<645::AID-CNCR2820440234>3.0.CO;2-Y; Czuczman M, 2002, BLOOD, V100, p357A; Davies A, 2005, ANN ONCOL, V16, P112; Davies AJ, 2004, J CLIN ONCOL, V22, P1469, DOI 10.1200/JCO.2004.06.055; Davis TA, 2004, CLIN CANCER RES, V10, P7792, DOI 10.1158/1078-0432.CCR-04-0756; Dosik AD, 2006, CANCER-AM CANCER SOC, V106, P616, DOI 10.1002/cncr.21606; Dreicer R, 2007, J CLIN ONCOL, V25; Fisher RI, 2005, J CLIN ONCOL, V23, P7565, DOI 10.1200/JCO.2004.00.9217; FLINN IW, 2004, BLOOD, V104; Forstpointner R, 2006, BLOOD, V108, P4003, DOI 10.1182/blood-2006-04-016725; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; Freedman AS, 1999, BLOOD, V94, P3325, DOI 10.1182/blood.V94.10.3325.422k13_3325_3333; FUNG H, 2003, BLOOD, V102; GALLAGHER CJ, 1986, J CLIN ONCOL, V4, P1470, DOI 10.1200/JCO.1986.4.10.1470; Gopal AK, 2006, BIOL BLOOD MARROW TR, V12, P697, DOI 10.1016/j.bbmt.2006.03.014; Gopal AK, 2002, BLOOD, V99, P3158, DOI 10.1182/blood.V99.9.3158; Gopal AK, 2003, BLOOD, V102, P2351, DOI 10.1182/blood-2003-02-0622; Gordon LI, 2004, BLOOD, V103, P4429, DOI 10.1182/blood-2003-11-3883; GORDON LI, 2003, P AN M AM SOC CLIN, V22, P576; Gregory SA, 2003, BLOOD, V102, p409A; GREGORY SA, 2005, P AN M AM SOC CLIN, V23, P585; GREGORY SA, 2004, P AN M AM SOC CLIN, V22, P6732; Hiddemann W, 2005, BLOOD, V106, P3725, DOI 10.1182/blood-2005-01-0016; HORNING SJ, 1993, SEMIN ONCOL, V20, P75; Horning SJ, 2005, J CLIN ONCOL, V23, P712, DOI 10.1200/JCO.2005.07.040; HUBBARD SM, 1982, BLOOD, V59, P258; Hunault-Berger M, 2002, BLOOD, V100, P1141, DOI 10.1182/blood.V100.4.1141.h81602001141_1141_1152; Hussein MA, 2004, BLOOD, V104, p314B, DOI 10.1182/blood.V104.11.4928.4928; Jacobs SA, 2005, CLIN CANCER RES, V11, p7146S, DOI 10.1158/1078-0432.CCR-1004-0003; JOHNSON PWM, 1995, J CLIN ONCOL, V13, P140, DOI 10.1200/JCO.1995.13.1.140; Johnson TA, 2000, INT J CANCER, V85, P104, DOI 10.1002/(SICI)1097-0215(20000101)85:1<104::AID-IJC19>3.0.CO;2-G; Justice TE, 2006, CANCER, V107, P433, DOI 10.1002/cncr.21998; KAMINSKI M, 2001, BLOOD, V98; Kaminski MS, 2007, J CLIN ONCOL, V25; Kaminski MS, 2005, NEW ENGL J MED, V352, P441, DOI 10.1056/NEJMoa041511; Kaminski MS, 2000, BLOOD, V96, P1259, DOI 10.1182/blood.V96.4.1259.h8001259_1259_1266; Kaminski MS, 2005, J CLIN ONCOL, V23, P7985, DOI 10.1200/JCO.2005.01.0892; Kaminski MS, 2001, J CLIN ONCOL, V19, P3918, DOI 10.1200/JCO.2001.19.19.3918; Kaminski MS, 1996, J CLIN ONCOL, V14, P1974, DOI 10.1200/JCO.1996.14.7.1974; KAMINSKI MS, 1993, NEW ENGL J MED, V329, P459, DOI 10.1056/NEJM199308123290703; Knox SJ, 1996, CLIN CANCER RES, V2, P457; Leahy MF, 2006, J CLIN ONCOL, V24, P4418, DOI 10.1200/JCO.2005.05.3470; Leonard JP, 2003, BLOOD, V102, p105A; Leonard JP, 2005, J CLIN ONCOL, V23, P5696, DOI 10.1200/JCO.2005.14.803; Leonard JP, 2001, BLOOD, V98, p133A; Link B, 2004, J CLIN ONCOL, V22, p562S; Liu SY, 1998, J CLIN ONCOL, V16, P3270, DOI 10.1200/JCO.1998.16.10.3270; MacManus MP, 1996, J CLIN ONCOL, V14, P1282, DOI 10.1200/JCO.1996.14.4.1282; Marcus R, 2005, BLOOD, V105, P1417, DOI 10.1182/blood-2004-08-3175; McLaughlin P, 1998, J CLIN ONCOL, V16, P2825, DOI 10.1200/JCO.1998.16.8.2825; MONES J, 2004, P AM SOC CLIN ONCOL, V22; MORSCHHAUSER HD, 2004, BLOOD, V104; Nademanee A, 2005, BLOOD, V106, P2896, DOI 10.1182/blood-2005-03-1310; NADLER LM, 1980, CANCER RES, V40, P3147; OKI Y, 2004, BLOOD, V104; Pfreundschuh M, 2006, LANCET ONCOL, V7, P379, DOI 10.1016/S1470-2045(06)70664-7; PHILIP T, 1995, NEW ENGL J MED, V333, P1540, DOI 10.1056/NEJM199512073332305; Press OW, 2006, J CLIN ONCOL, V24, P4143, DOI 10.1200/JCO.2006.05.8198; PRESS OW, 1993, NEW ENGL J MED, V329, P1219, DOI 10.1056/NEJM199310213291702; Press OW, 2000, BLOOD, V96, P2934; Press OW, 2003, BLOOD, V102, P1606, DOI 10.1182/blood-2003-01-0287; PRESS OW, 1995, LANCET, V346, P336, DOI 10.1016/S0140-6736(95)92225-3; Radford JA, 2003, BLOOD, V102, p408A; SCHILDER RJ, 2002, P AN M AM SOC CLIN, V21, P267; Schouten HC, 2003, J CLIN ONCOL, V21, P3918, DOI 10.1200/JCO.2003.10.023; Shah J, 2007, J CLIN ONCOL, V25; SHIPLEY DL, 2005, J CLIN ONCOL, V23; Shipp MA, 1999, J CLIN ONCOL, V17, P423, DOI 10.1200/JCO.1999.17.1.423; Siegel JA, 1998, J NUCL MED, V39, p28S; Siegel JA, 2002, J NUCL MED, V43, P354; STASHENKO P, 1980, J IMMUNOL, V125, P1678; Stern M, 2005, CRIT REV ONCOL HEMAT, V54, P11, DOI 10.1016/j.critrevonc.2004.10.011; Sweetenham JW, 2004, ASH ANN M, V104, P2633; TEDDER TF, 1986, EUR J IMMUNOL, V16, P881, DOI 10.1002/eji.1830160802; VANOERS MH, 2006, BLOOD; Vose JM, 2000, J CLIN ONCOL, V18, P1316, DOI 10.1200/JCO.2000.18.6.1316; Vose JM, 2004, ONCOLOGIST, V9, P160, DOI 10.1634/theoncologist.9-2-160; Vose JM, 2005, J CLIN ONCOL, V23, P461, DOI 10.1200/JCO.2005.05.117; VOSE JM, 1993, J CLIN ONCOL, V11, P1846, DOI 10.1200/JCO.1993.11.10.1846; Wahl RL, 2003, SEMIN ONCOL, V30, P31, DOI 10.1053/sonc.2003.23799; Wahl RL, 1998, J NUCL MED, V39, p21S; Wiseman GA, 2003, J NUCL MED, V44, P465; Wiseman GA, 2002, CANCER, V94, P1349, DOI 10.1002/cncr.10305; Wiseman GA, 2005, CANCER BIOTHER RADIO, V20, P185, DOI 10.1089/cbr.2005.20.185; Wiseman GA, 2002, BLOOD, V99, P4336, DOI 10.1182/blood.V99.12.4336; WITZIG T, 2003, BLOOD, V102; Witzig TE, 2002, J CLIN ONCOL, V20, P3262, DOI 10.1200/JCO.2002.11.017; Witzig TE, 1999, J CLIN ONCOL, V17, P3793, DOI 10.1200/JCO.1999.17.12.3793; Witzig TE, 2003, J CLIN ONCOL, V21, P1263, DOI 10.1200/JCO.2003.08.043; Witzig TE, 2002, J CLIN ONCOL, V20, P2453, DOI 10.1200/JCO.2002.11.076; Zelenetz AD, 2006, J CLIN ONCOL, V24, p436S; Zelenetz AD, 2002, BLOOD, V100, p357A	110	77	80	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2007	26	25					3614	3628		10.1038/sj.onc.1210378	http://dx.doi.org/10.1038/sj.onc.1210378			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	172PK	17530015				2022-12-28	WOS:000246816100004
J	Ishizawar, RC; Miyake, T; Parsons, SJ				Ishizawar, R. C.; Miyake, T.; Parsons, S. J.			c-Src modulates ErbB2 and ErbB3 heterocomplex formation and function	ONCOGENE			English	Article						c-Src; ErbB2; ErbB3; HRG; PI3-kinase; heterocomplex formation	HUMAN-BREAST-CANCER; GROWTH-FACTOR RECEPTOR; FOCAL ADHESION KINASE; PROTEIN; ACTIVATION; ONCOGENE; AUTOPHOSPHORYLATION; PHOSPHORYLATION; INVOLVEMENT	Overexpression and/or gene amplification of c-Src and members of the epidermal growth factor receptor (EGFR/ErbB) family have been implicated in the pathogenesis of breast cancer. Although members of the EGFR family are known to form heterocomplexes with one another, c-Src has also been shown to physically interact with members ofthis family in breast cancer cell lines and tumors. This paper investigates the role of c-Src in modulating the physical and functional interaction between ErbB2 and ErbB3, two family members that preferentially associate with one another and together exhibit high oncogenic potential. We show that overexpressed wild-type c-Src enhances heterocomplex formation of ErbB2 and ErbB3 that results in increased basal and/or heregulin induced activation of recept ors, and their downstream intracellular effectors. Expression of a kinase-inactive form of c-Src (K- c-Src) or pharmacological inhibition of c-Src by PP2 negatively affects these events. Furthermore, cellular motility and anchorage-independent growth promoted by the ErbB2/ ErbB3 heterocomplex are dependent upon c- Src, as demonstrated by the effects of K- c-Src overexpression or treatment with PP2. In contrast to previous studies that de. ned a role for c-Src downstream of ErbB2/ErbB3, the current work suggests an upstream mechanism, whereby c-Src enhances ErbB2/ErbB3 signaling and biological functions by positively modulating the association between ErbB2 and ErbB3.	Univ Virginia, Hlth Syst, Dept Microbiol, Charlottesville, VA 22908 USA; Univ Virginia, Hlth Syst, Ctr Canc, Charlottesville, VA 22908 USA	University of Virginia; University of Virginia	Parsons, SJ (corresponding author), Univ Virginia, Hlth Syst, Dept Microbiol, Charlottesville, VA 22908 USA.	sap@virginia.edu		Ishizawar, Rumey/0000-0001-5952-7884	NCI NIH HHS [CA71449] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA071449] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abu-Ghazaleh R, 2001, BIOCHEM J, V360, P255, DOI 10.1042/0264-6021:3600255; AKIYAMA T, 1991, MOL CELL BIOL, V11, P833, DOI 10.1128/MCB.11.2.833; Bao J, 2003, P NATL ACAD SCI USA, V100, P2438, DOI 10.1073/pnas.0437945100; Belsches-Jablonski AP, 2001, ONCOGENE, V20, P1465, DOI 10.1038/sj.onc.1204205; Biscardi JS, 1999, J BIOL CHEM, V274, P8335, DOI 10.1074/jbc.274.12.8335; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; Fan YX, 2004, J BIOL CHEM, V279, P38143, DOI 10.1074/jbc.M405760200; Holbro T, 2003, P NATL ACAD SCI USA, V100, P8933, DOI 10.1073/pnas.1537685100; Ishizawar R, 2004, CANCER CELL, V6, P209, DOI 10.1016/j.ccr.2004.09.001; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; Kim H, 2005, ONCOGENE, V24, P7599, DOI 10.1038/sj.onc.1208898; LUTTRELL DK, 1994, P NATL ACAD SCI USA, V91, P83, DOI 10.1073/pnas.91.1.83; MUTHUSWAMY SK, 1994, MOL CELL BIOL, V14, P735, DOI 10.1128/MCB.14.1.735; Nguyen DHD, 1998, J BIOL CHEM, V273, P8502, DOI 10.1074/jbc.273.14.8502; OTTENHOFFKALFF AE, 1992, CANCER RES, V52, P4773; Parsons JT, 2000, ONCOGENE, V19, P5606, DOI 10.1038/sj.onc.1203877; REUTER CWM, 1995, METHOD ENZYMOL, V255, P245; RIESE DJ, 1995, MOL CELL BIOL, V15, P5770; Schulze WX, 2005, MOL SYST BIOL, V1, DOI 10.1038/msb4100012; Sheffield LG, 1998, BIOCHEM BIOPH RES CO, V250, P27, DOI 10.1006/bbrc.1998.9214; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Tan M, 2005, CANCER RES, V65, P1858, DOI 10.1158/0008-5472.CAN-04-2353; Tzahar E, 1996, MOL CELL BIOL, V16, P5276; WALLASCH C, 1995, EMBO J, V14, P4267, DOI 10.1002/j.1460-2075.1995.tb00101.x; Waterman H, 1999, EMBO J, V18, P3348, DOI 10.1093/emboj/18.12.3348; Xu WQ, 1999, MOL CELL, V3, P629, DOI 10.1016/S1097-2765(00)80356-1; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073	27	78	83	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2007	26	24					3503	3510		10.1038/sj.onc.1210138	http://dx.doi.org/10.1038/sj.onc.1210138			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	172JC	17173075				2022-12-28	WOS:000246799200006
J	Waldmann, TA				Waldmann, T. A.			Daclizumab (anti-Tac, Zenapax) in the treatment of leukemia/lymphoma	ONCOGENE			English	Review						IL-2 receptor; adult T-cell leukemia; anti-Tac; monoclonal antibody	T-CELL LEUKEMIA; ANTI-CD25 MONOCLONAL-ANTIBODY; IN-VIVO BLOCKADE; INTERLEUKIN-2 RECEPTOR; MURINE MODEL; TRANSPLANT RECIPIENTS; MULTIPLE-SCLEROSIS; HUMANIZED ANTIBODY; ACUTE REJECTION; GROWTH-FACTOR	Daclizumab (Zenapax) identifies the alpha subunit of the interleukin-2 (IL-2) receptor and blocks the interaction of this cytokine with its growth factor receptor. The scientific basis for the choice of the IL-2 receptor alpha subunit as a target for monoclonal antibody-mediated therapy of leukemia/lymphoma is that very few normal cells express IL-2R alpha, whereas the abnormal T cells in patients with an array of lymphoid malignancies express this receptor. In 1997, daclizumab was approved by the FDA for use in the prevention of renal allograft rejection. In addition, anti-Tac provided effective therapy for select patients with T-cell malignancies and an array of inflammatory autoimmune disorders. Finally, therapy with this antibody armed with Y-90 has led to clinical responses in the majority of patients with adult T-cell leukemia. These insights concerning the IL-2/IL-2 receptor system facilitated the development of effective daclizumab antibody therapy for select patients with leukemia/lymphoma.	NCI, Metab Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Waldmann, TA (corresponding author), NCI, Metab Branch, Ctr Canc Res, NIH, Bldg 10,Room 4N115,10 Ctr Dr 1374, Bethesda, MD 20892 USA.	tawald@helix.nih.gov	Waldmann, Thomas/AAT-5972-2021	Waldmann, Thomas/0000-0003-4500-6660	NATIONAL CANCER INSTITUTE [Z01SC004002, ZIASC004002] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Beniaminovitz A, 2000, NEW ENGL J MED, V342, P613, DOI 10.1056/NEJM200003023420902; Bielekova B, 2006, P NATL ACAD SCI USA, V103, P5941, DOI 10.1073/pnas.0601335103; Bielekova B, 2004, P NATL ACAD SCI USA, V101, P8705, DOI 10.1073/pnas.0402653101; DEPPER JM, 1984, J IMMUNOL, V133, P3054; Eckhoff DE, 2000, TRANSPLANTATION, V69, P1867, DOI 10.1097/00007890-200005150-00022; Jeang KT, 2001, CYTOKINE GROWTH F R, V12, P207, DOI 10.1016/S1359-6101(00)00028-9; JUNGHANS RP, 1990, CANCER RES, V50, P1495; Kreitman RJ, 2000, J CLIN ONCOL, V18, P1622, DOI 10.1200/JCO.2000.18.8.1622; Krueger JG, 2000, J AM ACAD DERMATOL, V43, P448, DOI 10.1067/mjd.2000.106515; Lehky TJ, 1998, ANN NEUROL, V44, P942, DOI 10.1002/ana.410440613; LEONARD WJ, 1985, J BIOL CHEM, V260, P1872; LEONARD WJ, 1984, NATURE, V311, P626, DOI 10.1038/311626a0; LEONARD WJ, 1982, NATURE, V300, P267, DOI 10.1038/300267a0; Li ZQ, 2005, J IMMUNOL, V174, P5187, DOI 10.4049/jimmunol.174.9.5187; Maciejewski JP, 2003, BLOOD, V102, P3584, DOI 10.1182/blood-2003-04-1032; Morris JC, 2000, ANN RHEUM DIS, V59, P109, DOI 10.1136/ard.59.suppl_1.i109; Nashan B, 1999, TRANSPLANTATION, V67, P110, DOI 10.1097/00007890-199901150-00019; Nussenblatt RB, 1999, P NATL ACAD SCI USA, V96, P7462, DOI 10.1073/pnas.96.13.7462; OMAHONEY D, 2006, J NUCL MED, V47, pP98; Phillips KE, 2000, CANCER RES, V60, P6977; QUEEN C, 1989, P NATL ACAD SCI USA, V86, P10029, DOI 10.1073/pnas.86.24.10029; RUBIN LA, 1990, ANN INTERN MED, V113, P619, DOI 10.7326/0003-4819-113-8-619; Shapiro AMJ, 2000, NEW ENGL J MED, V343, P230, DOI 10.1056/NEJM200007273430401; SHARON M, 1986, SCIENCE, V234, P859, DOI 10.1126/science.3095922; Sloand EM, 2006, ANN INTERN MED, V144, P181, DOI 10.7326/0003-4819-144-3-200602070-00006; Sugamura K, 1996, ANNU REV IMMUNOL, V14, P179, DOI 10.1146/annurev.immunol.14.1.179; Tan C, 2002, CANCER RES, V62, P1083; TSUDO M, 1986, P NATL ACAD SCI USA, V83, P9694, DOI 10.1073/pnas.83.24.9694; UCHIYAMA T, 1981, J IMMUNOL, V126, P1398; UCHIYAMA T, 1981, J IMMUNOL, V126, P1393; UCHIYAMA T, 1977, BLOOD, V50, P481, DOI 10.1182/blood.V50.3.481.481; Vincenti F, 1998, NEW ENGL J MED, V338, P161, DOI 10.1056/NEJM199801153380304; WALDMANN TA, 1993, BLOOD, V82, P1701; WALDMANN TA, 1989, ANNU REV BIOCHEM, V58, P875, DOI 10.1146/annurev.bi.58.070189.004303; WALDMANN TA, 1995, BLOOD, V86, P4063, DOI 10.1182/blood.V86.11.4063.bloodjournal86114063; WALDMANN TA, 1986, SCIENCE, V232, P727, DOI 10.1126/science.3008337; Waldmann TA, 2003, ANNU REV IMMUNOL, V21, P1, DOI 10.1146/annurev.immunol.21.120601.140933; WALDMANN TA, 1988, BLOOD, V72, P1805; Wiseman LR, 1999, DRUGS, V58, P1029, DOI 10.2165/00003495-199958060-00006; Zhang ML, 2006, CANCER RES, V66, P8227, DOI 10.1158/0008-5472.CAN-06-1189; Zhang ML, 2005, BLOOD, V105, P1231, DOI 10.1182/blood-2004-05-1709; Zhang ML, 2004, CANCER RES, V64, P5825, DOI 10.1158/0008-5472.CAN-04-1088	42	59	60	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2007	26	25					3699	3703		10.1038/sj.onc.1210368	http://dx.doi.org/10.1038/sj.onc.1210368			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	172PK	17530023				2022-12-28	WOS:000246816100012
J	Gross, I; Duluc, I; Benameur, T; Calon, A; Martin, E; Brabletz, T; Kedinger, M; Domon-Dell, C; Freund, JN				Gross, I.; Duluc, I.; Benameur, T.; Calon, A.; Martin, E.; Brabletz, T.; Kedinger, M.; Domon-Dell, C.; Freund, J-N			The intestine-specific homeobox gene Cdx2 decreases mobility and antagonizes dissemination of colon cancer cells	ONCOGENE			English	Article						Cdx; colon cancer; metastasis; migration; wound healing	MALIGNANT-TUMOR PROGRESSION; COLORECTAL-CANCER; E-CADHERIN; CHROMOSOMAL INSTABILITY; EXPRESSION SIGNATURE; DOWN-REGULATION; MUTANT MICE; DIFFERENTIATION; CARCINOMA; PROTEIN	The gravity of colorectal cancer is mainly due to the capacity of tumor cells to migrate out of the tumor mass to invade the stroma and disseminate as metastases. The acquisition of a migratory phenotype also occurs during wound healing. Here, we show that several features characterizing invasive colon tumor cells are shared by migrating cells during wound repair in vitro. In particular, the expression of the intestine-specific transcription factor Cdx2, a key gene for intestinal identity downregulated in invasive cancer cells, is reduced during wound healing in vitro. Transcription factors involved in epithelial-mesenchymal transition such as Snail and Slug are upregulated during wound healing and are able to repress Cdx2 transcription. In vitro, forced expression of Cdx2 in human colon cancer cell lines retarded wound repair and reduced migration, whereas inhibition of Cdx2 expression by RNA interference enhanced migration. In vivo, forced expression of Cdx2 opposed tumor cells spreading in nude mice xenografted at three different sites. These data provide evidence that Cdx2 antagonizes the process of tumor cell dissemination, and they suggest that this homeobox gene might represent a new therapeutic target against metastatic spreading of colon cancer.	[Gross, I.; Duluc, I.; Benameur, T.; Calon, A.; Martin, E.; Kedinger, M.; Domon-Dell, C.; Freund, J-N] INSERM, U 682, F-67200 Strasbourg, France; [Gross, I.; Duluc, I.; Benameur, T.; Calon, A.; Martin, E.; Kedinger, M.; Domon-Dell, C.; Freund, J-N] Univ Strasbourg, Fac Med, Strasbourg, France; [Brabletz, T.] Univ Freiburg, Dept Surg, Freiburg, Germany	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; University of Freiburg	Freund, JN (corresponding author), INSERM, U 682, 3 Ave Moliere, F-67200 Strasbourg, France.	jean-noel.freund@inserm.u-strasbg.fr	DULUC, Isabelle/AAA-7062-2022; Gross, Isabelle/I-4972-2016; Domon-Dell, Claire/P-2368-2017; Gross, Isabelle/P-9859-2019; Calon, Alexandre/GPK-2061-2022; Duluc, Isabelle/O-1972-2017; BENAMEUR, TAREK/P-9053-2019; Freund, Jean-Noel/R-4383-2016	DULUC, Isabelle/0000-0001-8396-6385; Gross, Isabelle/0000-0002-2783-8773; Gross, Isabelle/0000-0002-2783-8773; Duluc, Isabelle/0000-0001-8396-6385; Freund, Jean-Noel/0000-0002-0971-3774; DOMON-DELL, Claire/0000-0002-8445-9593				Aoki K, 2003, NAT GENET, V35, P323, DOI 10.1038/ng1265; Beck F, 1999, P NATL ACAD SCI USA, V96, P7318, DOI 10.1073/pnas.96.13.7318; Benahmed F, 2007, AM J PATHOL, V170, P733, DOI 10.2353/ajpath.2007.060696; Blache P, 2004, J CELL BIOL, V166, P37, DOI 10.1083/jcb.200311021; Bonhomme C, 2003, GUT, V52, P1465, DOI 10.1136/gut.52.10.1465; Brabletz T, 2004, CANCER RES, V64, P6973, DOI 10.1158/0008-5472.CAN-04-1132; Brabletz T, 2005, NAT REV CANCER, V5, P744, DOI 10.1038/nrc1694; Calon A, 2007, NUCLEIC ACIDS RES, V35, P175, DOI 10.1093/nar/gkl1034; Carrio M, 2005, CANCER RES, V65, P7177, DOI 10.1158/0008-5472.CAN-04-1717; Cavallaro U, 2004, ANN NY ACAD SCI, V1014, P58, DOI 10.1196/annals.1294.006; Chang HY, 2005, P NATL ACAD SCI USA, V102, P3738, DOI 10.1073/pnas.0409462102; Chang HY, 2004, PLOS BIOL, V2, P206, DOI 10.1371/journal.pbio.0020007; CHANTRET I, 1994, J CELL SCI, V107, P213; Conacci-Sorrell M, 2003, J CELL BIOL, V163, P847, DOI 10.1083/jcb.200308162; Diep CB, 2006, GENE CHROMOSOME CANC, V45, P31, DOI 10.1002/gcc.20261; Domon-Dell C, 2002, FEBS LETT, V518, P83, DOI 10.1016/S0014-5793(02)02650-9; DVORAK HF, 1986, NEW ENGL J MED, V315, P1650; EE HC, 1995, AM J PATHOL, V147, P586; Franci C, 2006, ONCOGENE, V25, P5134, DOI 10.1038/sj.onc.1209519; Gauthier JL, 2003, WORLD CL PARASITES, V6, P1; Gavert N, 2005, J CELL BIOL, V168, P633, DOI 10.1083/jcb.200408051; Hamada J, 2001, INT J CANCER, V93, P516, DOI 10.1002/ijc.1357; Hansen SL, 2003, AM J PATHOL, V163, P2421, DOI 10.1016/S0002-9440(10)63597-3; Hartwell KA, 2006, P NATL ACAD SCI USA, V103, P18969, DOI 10.1073/pnas.0608636103; Hazan RB, 2004, ANN NY ACAD SCI, V1014, P155, DOI 10.1196/annals.1294.016; Hinoi T, 2003, J BIOL CHEM, V278, P44608, DOI 10.1074/jbc.M307435200; Hinoi T, 2002, GASTROENTEROLOGY, V123, P1565, DOI 10.1053/gast.2002.36598; Kaimaktchiev V, 2004, MODERN PATHOL, V17, P1392, DOI 10.1038/modpathol.3800205; Keller MS, 2004, AM J PHYSIOL-GASTR L, V287, pG104, DOI 10.1152/ajpgi.00484.2003; Lorentz O, 1999, ONCOGENE, V18, P87, DOI 10.1038/sj.onc.1202280; Lorentz O, 1997, J CELL BIOL, V139, P1553, DOI 10.1083/jcb.139.6.1553; Mallo GV, 1998, J BIOL CHEM, V273, P14030, DOI 10.1074/jbc.273.22.14030; Mesquita P, 2003, J BIOL CHEM, V278, P51549, DOI 10.1074/jbc.M309019200; Ohta H, 2006, CLIN EXP METASTAS, V23, P381, DOI 10.1007/s10585-006-9047-5; Pandrea IV, 2000, EXP MOL PATHOL, V69, P37, DOI 10.1006/exmp.2000.2309; Pedersen TX, 2003, ONCOGENE, V22, P3964, DOI 10.1038/sj.onc.1206614; Spaderna S, 2006, GASTROENTEROLOGY, V131, P830, DOI 10.1053/j.gastro.2006.06.016; Subtil C, 2007, CANCER LETT, V247, P197, DOI 10.1016/j.canlet.2006.04.004; SUH E, 1994, MOL CELL BIOL, V14, P7340, DOI 10.1128/MCB.14.11.7340; Yagi OK, 1999, BRIT J CANCER, V79, P440, DOI 10.1038/sj.bjc.6690068; Zhao YW, 2005, ONCOL REP, V13, P721	41	83	97	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 3	2008	27	1					107	115		10.1038/sj.onc.1210601	http://dx.doi.org/10.1038/sj.onc.1210601			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	247YO	17599044				2022-12-28	WOS:000252118700011
J	Li, Q; Falsey, RR; Gaitonde, S; Sotello, V; Kislin, K; Martinez, JD				Li, Q.; Falsey, R. R.; Gaitonde, S.; Sotello, V.; Kislin, K.; Martinez, J. D.			Genetic analysis of p53 nuclear importation	ONCOGENE			English	Article						p53; temperature sensitive; mutant; nuclear localization	LOCALIZATION; PROTEIN; SIGNAL	A key step in activation of the p53 tumor suppressor is its transport into the nucleus; however, despite intensive study of p53, the regulation of its subcellular localization is still poorly understood. Here we examined the p53 nuclear importation using a series of mutant cell lines that were resistant to the growth inhibitory effects of temperature-sensitive murine p53 (tsp53). Examination of the p53 subcellular localization in these cell lines showed that the protein was cytoplasmic in most of them. Using a digitonin-permeabilized cell in vitro nuclear import system, we show that cytosols from these cell lines do not support nuclear translocation of a p53 nuclear localization signal (NLS)-containing substrate protein, but promote nuclear localization of a SV40TAgNLS-containing substrate. Complementation assays and use of the mutant cells themselves in the in vitro assays demonstrate that both soluble and insoluble protein components are involved in p53 nuclear import. Collectively, our results suggest that there is a p53 NLS-selective nuclear import pathway and that both soluble and insoluble proteins are involved in its function.	[Li, Q.; Sotello, V.; Martinez, J. D.] Univ Arizona, Dept Cell Biol & Anat, Arizona Canc Ctr, Tucson, AZ 85724 USA; [Falsey, R. R.; Gaitonde, S.; Kislin, K.] Univ Arizona, Canc Biol Interdisciplinary Program, Tucson, AZ 85724 USA; [Falsey, R. R.] Univ Arizona, Undergrad Biol Res Program, Tucson, AZ 85724 USA	Arizona Center Cancer Care; University of Arizona; University of Arizona; University of Arizona	Martinez, JD (corresponding author), Univ Arizona, Dept Cell Biol & Anat, Arizona Canc Ctr, 1515 N Campbell Ave, Tucson, AZ 85724 USA.	jmartinez@azcc.arizona.edu			NCI NIH HHS [CA090776, R01 CA090776-03, R01 CA090776, P30 CA023074] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA090776, P30CA023074] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAM SA, 1990, J CELL BIOL, V111, P807, DOI 10.1083/jcb.111.3.807; Gaitonde SV, 2000, ONCOGENE, V19, P4042, DOI 10.1038/sj.onc.1203756; Goldman SC, 1996, AM J PATHOL, V148, P1381; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Liang SH, 1999, J BIOL CHEM, V274, P32699, DOI 10.1074/jbc.274.46.32699; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; Middeler G, 1997, ONCOGENE, V14, P1407, DOI 10.1038/sj.onc.1200949; NISHI K, 1994, J BIOL CHEM, V269, P6320; SHAULSKY G, 1990, MOL CELL BIOL, V10, P6565, DOI 10.1128/MCB.10.12.6565; Tran EJ, 2006, CELL, V125, P1041, DOI 10.1016/j.cell.2006.05.027	11	19	19	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 13	2007	26	57					7885	7893		10.1038/sj.onc.1210597	http://dx.doi.org/10.1038/sj.onc.1210597			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	248ON	17599045	Green Accepted			2022-12-28	WOS:000252163500006
J	Takafuji, V; Forgues, M; Unsworth, E; Goldsmith, P; Wang, XW				Takafuji, V.; Forgues, M.; Unsworth, E.; Goldsmith, P.; Wang, X. W.			An osteopontin fragment is essential for tumor cell invasion in hepatocellular carcinoma	ONCOGENE			English	Article						osteopontin; hepatocellular carcinoma; metastasis; cellular invasion; MMP-9; CD44	METASTASIS FORMATION; PROTEIN EXPRESSION; PLASMA OSTEOPONTIN; SURVIVAL; CANCER; CD44; TRANSGLUTAMINASE; BREAST; OVEREXPRESSION; PROGRESSION	Tumor cell invasion is a primary event in the metastatic progression of hepatocellular carcinoma (HCC). Our recent results indicate a concordant elevated expression of osteopontin (OPN) and matrix metalloproteinase-9 (MMP-9) in primary metastatic HCC. This study hypothesizes an MMP-9-directed cleavage of OPN that biologically contributes to HCC metastasis. We found that MMP-9 cleaved OPN into specific fragments in vitro, of which three could be identified by Edman degradation amino-acid sequencing. On e of these fragments (OPN-5 kDa, residues 167-210) induced low-metastatic HCC cellular invasion via CD44 receptors, which was effectively blocked by the addition of small peptides within the region of OPN-5 kDa. In creased expression of an OPN splice variant (OPN-c) was associated with clinical metastatic HCC. Overexpression of OPN-c with physiological levels of MMP-9 enhanced cellular invasion and coincided with elevated OPN-5 kDa levels. Our data suggest that an alternative splicing event (OPN-c) promotes extracellular cleavage of OPN by MMP-9, thus releasing a distinct region of OPN (OPN-5 kDa) that is essential for HCC cellular invasion and appears to correlate with metastatic potential. The findings of this study may help to improve advanced-stage HCC prognosis and suggest the utility of small peptides for novel therapies.	NCI, Human Carcinogenesis Lab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA; NCI, Antibody & Protein Purificat Grp, Ctr Canc Res, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Wang, XW (corresponding author), NCI, Human Carcinogenesis Lab, Ctr Canc Res, NIH, 37-3044A,37 Convent Dr MSC 4258, Bethesda, MD 20892 USA.	xw3u@nih.gov	Wang, Xin Wei/B-6162-2009	Wang, Xin Wei/0000-0001-9735-606X	NATIONAL CANCER INSTITUTE [Z01BC010313, ZIABC010313] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Agnihotri R, 2001, J BIOL CHEM, V276, P28261, DOI 10.1074/jbc.M103608200; Ashida K, 1996, AM J PATHOL, V149, P1803; Blum HE, 2005, EUR J GASTROEN HEPAT, V17, P475, DOI 10.1097/00042737-200505000-00001; BUTLER WT, 1995, ANN NY ACAD SCI, V760, P6, DOI 10.1111/j.1749-6632.1995.tb44615.x; Coppola D, 2004, CLIN CANCER RES, V10, P184, DOI 10.1158/1078-0432.CCR-1405-2; Denhardt DT, 2001, J CLIN INVEST, V107, P1055, DOI 10.1172/JCI12980; Endo K, 2000, J HEPATOL, V32, P78, DOI 10.1016/S0168-8278(00)80192-0; Fedarko NS, 2001, CLIN CANCER RES, V7, P4060; FRANCO D, 1990, GASTROENTEROLOGY, V98, P733, DOI 10.1016/0016-5085(90)90296-D; Harada N, 2001, INT J CANCER, V91, P67, DOI 10.1002/1097-0215(20010101)91:1<67::AID-IJC1011>3.0.CO;2-D; He B, 2006, ONCOGENE, V25, P2192, DOI 10.1038/sj.onc.1209248; Hotte SJ, 2002, CANCER-AM CANCER SOC, V95, P506, DOI 10.1002/cncr.10709; Kaartinen MT, 1999, J BIOL CHEM, V274, P1729, DOI 10.1074/jbc.274.3.1729; Kaneyoshi T, 2001, CLIN CANCER RES, V7, P4027; LESLEY J, 1998, FRONT BIOSCI, V3, P616; Lin LI, 1998, ONCOLOGY-BASEL, V55, P349, DOI 10.1159/000011876; MATSUMURA Y, 1992, LANCET, V340, P1053, DOI 10.1016/0140-6736(92)93077-Z; McKenna GJ, 2002, AM J SURG, V183, P588, DOI 10.1016/S0002-9610(02)00833-4; Pan HW, 2003, CANCER-AM CANCER SOC, V98, P119, DOI 10.1002/cncr.11487; Ponta H, 2003, NAT REV MOL CELL BIO, V4, P33, DOI 10.1038/nrm1004; PRINCE CW, 1991, BIOCHEM BIOPH RES CO, V177, P1205, DOI 10.1016/0006-291X(91)90669-X; Rittling SR, 2004, BRIT J CANCER, V90, P1877, DOI 10.1038/sj.bjc.6601839; Rittling SR, 2002, J BIOL CHEM, V277, P9175, DOI 10.1074/jbc.M109028200; Rudzki Z, 1997, J CLIN PATHOL-MOL PA, V50, P57, DOI 10.1136/mp.50.2.57; SAITOH Y, 1995, LAB INVEST, V72, P55; SENGER DR, 1988, CANCER RES, V48, P5770; Si MS, 2003, AM SURGEON, V69, P879; Singhal H, 1997, CLIN CANCER RES, V3, P605; SORENSEN ES, 1994, BIOCHEM J, V304, P13, DOI 10.1042/bj3040013; Takahashi K, 1998, BIOCHEM MOL BIOL INT, V46, P1081; Theret N, 2001, HEPATOLOGY, V34, P82, DOI 10.1053/jhep.2001.25758; Turpeenniemi-Hujanen T, 2005, BIOCHIMIE, V87, P287, DOI 10.1016/j.biochi.2005.01.014; van Kempen LCL, 2002, CANCER CELL, V2, P251, DOI 10.1016/S1535-6108(02)00157-5; Wai PY, 2004, J SURG RES, V121, P228, DOI 10.1016/j.jss.2004.03.028; Wang XW, 2005, HEPATOLOGY, V42, p391A; Weber GF, 1997, P ASSOC AM PHYSICIAN, V109, P1; Weber GF, 2001, BBA-REV CANCER, V1552, P61, DOI 10.1016/S0304-419X(01)00037-3; Weber GF, 2002, J LEUKOCYTE BIOL, V72, P752; Ye QH, 2003, NAT MED, V9, P416, DOI 10.1038/nm843	39	137	146	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 27	2007	26	44					6361	6371		10.1038/sj.onc.1210463	http://dx.doi.org/10.1038/sj.onc.1210463			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	214KY	17452979				2022-12-28	WOS:000249737600001
J	DeYoung, MP; Ellisen, LW				DeYoung, M. P.; Ellisen, L. W.			p63 and p73 in human cancer: defining the network	ONCOGENE			English	Review						p53; p63; p73; apoptosis; tumorigenesis; squamous cell carcinoma (SCC)	SQUAMOUS-CELL CARCINOMA; YES-ASSOCIATED PROTEIN; P53 FAMILY-MEMBERS; KINASE C-ABL; TUMOR-SUPPRESSOR; TRANSCRIPTIONAL ACTIVITY; APOPTOTIC RESPONSE; REGULATES P73; UP-REGULATION; LUNG-CANCER	The p53-related genes p63 and p73 exhibit signicant structural homology to p53; however, they do not function as classical tumor suppressors and are rarely mutated in human cancers. Both p63 and p73 exhibit tissue-specific roles in normal development and a complex contribution to tumorigenesis that is due to their expression as multiple protein isoforms. The predominant p63/p73 isoforms expressed both in normal development and in many tumors lack the conserved transactivation ( TA) domain; these isoforms instead exhibit a truncated N-terminus (DN) and function at least in part as transcriptional repressors. p63 and p73 isoforms are regulated through both transcriptional and post-translational mechanisms, and they in turn regulate diverse cellular functions including proliferation, survival and differentiation. The net effect of p63/p73 expression in a given context depends on the ratio of TA/DN isoforms expressed, on physical interaction between p63 and p73 isoforms, and on functional interactions with p53 at the promoters of specific downstream target genes. These multifaceted interactions occur in diverse ways in tumor-specific contexts, demonstrating a functional 'p53 family network' in human tumorigenesis. Understanding the regulation and mechanistic contributions of p63 and p73 in human cancers may ultimately provide new therapeutic opportunities for a variety of these diseases.	Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Ellisen, LW (corresponding author), Massachusetts Gen Hosp, Ctr Canc, GRJ-904,55 Fruit St, Boston, MA 02114 USA.	ellisen@helix.mgh.harvard.edu	Ellisen, Leif W/AAA-6572-2022	Ellisen, Leif W/0000-0003-0444-7910	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE015945] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE-15945, R01 DE015945] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Agami R, 1999, NATURE, V399, P809; Antonini D, 2006, MOL CELL BIOL, V26, P3308, DOI 10.1128/MCB.26.8.3308-3318.2006; Balint E, 1999, ONCOGENE, V18, P3923, DOI 10.1038/sj.onc.1202781; Balint E, 2002, P NATL ACAD SCI USA, V99, P3529, DOI 10.1073/pnas.062491899; Barbieri CE, 2006, EXP CELL RES, V312, P695, DOI 10.1016/j.yexcr.2005.11.028; Barbieri CE, 2005, CANCER RES, V65, P2314, DOI 10.1158/0008-5472.CAN-04-3449; Barbieri CE, 2003, J BIOL CHEM, V278, P51408, DOI 10.1074/jbc.M309943200; Barbieri CE, 2006, CANCER RES, V66, P7589, DOI 10.1158/0008-5472.CAN-06-2020; Basu S, 2003, MOL CELL, V11, P11, DOI 10.1016/S1097-2765(02)00776-1; Bergamaschi D, 2003, CANCER CELL, V3, P387, DOI 10.1016/S1535-6108(03)00079-5; Bjorkqvist AM, 1998, GENE CHROMOSOME CANC, V22, P79; Blandino G, 2004, CELL CYCLE, V3, P886; Bourdon JC, 2005, GENE DEV, V19, P2122, DOI 10.1101/gad.1339905; Calabro V, 2002, J BIOL CHEM, V277, P2674, DOI 10.1074/jbc.M107173200; Cam H, 2006, CANCER CELL, V10, P281, DOI 10.1016/j.ccr.2006.08.024; Carroll DK, 2006, NAT CELL BIOL, V8, P551, DOI 10.1038/ncb1420; Chan WM, 2004, MOL CELL BIOL, V24, P3536, DOI 10.1128/MCB.24.8.3536-3551.2004; Chi SG, 1999, CANCER RES, V59, P2791; Chi SW, 1999, EMBO J, V18, P4438, DOI 10.1093/emboj/18.16.4438; Choi HR, 2002, HUM PATHOL, V33, P158, DOI 10.1053/hupa.2002.30722; Concin N, 2004, CANCER RES, V64, P2449, DOI 10.1158/0008-5472.CAN-03-1060; Corn PG, 1999, CANCER RES, V59, P3352; Courtois S, 2004, ONCOGENE, V23, P631, DOI 10.1038/sj.onc.1206929; Cuadros M, 2006, LEUKEMIA RES, V30, P170, DOI 10.1016/j.leukres.2005.06.024; Cui Rutao, 2005, Biochem Biophys Res Commun, V336, P339; Davison TS, 1999, J BIOL CHEM, V274, P18709, DOI 10.1074/jbc.274.26.18709; De Laurenzi V, 2000, BIOCHEM BIOPH RES CO, V273, P342, DOI 10.1006/bbrc.2000.2932; De Laurenzi V, 1998, J EXP MED, V188, P1763, DOI 10.1084/jem.188.9.1763; De Laurenzi V, 2000, ANN NY ACAD SCI, V926, P90; DeYoung MP, 2006, CANCER RES, V66, P9362, DOI 10.1158/0008-5472.CAN-06-1619; Di Como CJ, 1999, MOL CELL BIOL, V19, P1438; Dohn M, 2001, ONCOGENE, V20, P3193, DOI 10.1038/sj.onc.1204427; Dominguez G, 2006, J CLIN ONCOL, V24, P805, DOI 10.1200/JCO.2005.02.2350; Dominguez G, 2001, BREAST CANCER RES TR, V66, P183, DOI 10.1023/A:1010624717311; Douc-Rasy S, 2002, AM J PATHOL, V160, P631, DOI 10.1016/S0002-9440(10)64883-3; Fillippovich I, 2001, ONCOGENE, V20, P514, DOI 10.1038/sj.onc.1204118; Flinterman M, 2005, J BIOL CHEM, V280, P5945, DOI 10.1074/jbc.M406661200; Flores ER, 2002, NATURE, V416, P560, DOI 10.1038/416560a; Flores ER, 2005, CANCER CELL, V7, P363, DOI 10.1016/j.ccr.2005.02.019; Fomenkov A, 2004, CELL CYCLE, V3, P1285, DOI 10.4161/cc.3.10.1155; Fontemaggi G, 2001, MOL CELL BIOL, V21, P8461, DOI 10.1128/MCB.21.24.8461-8470.2001; Gaiddon C, 2003, J BIOL CHEM, V278, P27421, DOI 10.1074/jbc.M300251200; Gaiddon C, 2001, MOL CELL BIOL, V21, P1874, DOI 10.1128/MCB.21.5.1874-1887.2001; Ghioni P, 2002, MOL CELL BIOL, V22, P8659, DOI 10.1128/MCB.22.24.8659-8668.2002; Ghioni P, 2005, CELL CYCLE, V4, P183, DOI 10.4161/cc.4.1.1359; Gong JG, 1999, NATURE, V399, P806; Gonzalez S, 2003, MOL CELL BIOL, V23, P8161, DOI 10.1128/MCB.23.22.8161-8171.2003; Green H, 2003, P NATL ACAD SCI USA, V100, P15625, DOI 10.1073/pnas.0307226100; Grob TJ, 2001, CELL DEATH DIFFER, V8, P1213, DOI 10.1038/sj.cdd.4400962; Hagiwara K, 1999, CANCER RES, V59, P4165; Hanamoto T, 2005, J BIOL CHEM, V280, P16665, DOI 10.1074/jbc.M414323200; Harmes DC, 2003, ONCOGENE, V22, P7607, DOI 10.1038/sj.onc.1207129; Harms K, 2004, CELL MOL LIFE SCI, V61, P822, DOI 10.1007/s00018-003-3304-4; Helton ES, 2006, J BIOL CHEM, V281, P2533, DOI 10.1074/jbc.M507964200; Hibi K, 2000, P NATL ACAD SCI USA, V97, P5462, DOI 10.1073/pnas.97.10.5462; Hu H, 2002, INT J CANCER, V102, P580, DOI 10.1002/ijc.10739; Irwin M, 2000, NATURE, V407, P645, DOI 10.1038/35036614; Irwin MS, 2003, CANCER CELL, V3, P403, DOI 10.1016/S1535-6108(03)00078-3; Ishimoto O, 2002, CANCER RES, V62, P636; Jacobs WB, 2005, NEURON, V48, P743, DOI 10.1016/j.neuron.2005.10.027; Jeong MH, 2006, J BIOL CHEM, V281, P8707, DOI 10.1074/jbc.M513853200; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Kamiya M, 2002, J NEURO-ONCOL, V59, P143, DOI 10.1023/A:1019633910603; Kawano S, 1999, BLOOD, V94, P1113; Keyes WM, 2006, P NATL ACAD SCI USA, V103, P8435, DOI 10.1073/pnas.0602477103; Keyes WM, 2005, GENE DEV, V19, P1986, DOI 10.1101/gad.342305; Koga F, 2003, CLIN CANCER RES, V9, P5501; Koker MM, 2004, AM J SURG PATHOL, V28, P1506, DOI 10.1097/01.pas.0000138183.97366.fd; Kovalev S, 1998, CELL GROWTH DIFFER, V9, P897; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; Lang GA, 2004, CELL, V119, P861, DOI 10.1016/j.cell.2004.11.006; Leupin N, 2004, LEUKEMIA LYMPHOMA, V45, P1205, DOI 10.1080/10298190310001623829; Li N, 2006, ONCOGENE, V25, P2349, DOI 10.1038/sj.onc.1209270; Little NA, 2001, ONCOGENE, V20, P4576, DOI 10.1038/sj.onc.1204615; Liu G, 2004, MOL CELL BIOL, V24, P487, DOI 10.1128/MCB.24.2.487-501.2004; Liu SS, 2006, CLIN CANCER RES, V12, P3922, DOI 10.1158/1078-0432.CCR-05-2573; Maisse C, 2004, CELL DEATH DIFFER, V11, P685, DOI 10.1038/sj.cdd.4401376; Mantovani F, 2004, MOL CELL, V14, P625, DOI 10.1016/j.molcel.2004.05.007; Marin MC, 2000, NAT GENET, V25, P47, DOI 10.1038/75586; Massion PP, 2003, CANCER RES, V63, P7113; Matheny KE, 2003, LARYNGOSCOPE, V113, P936, DOI 10.1097/00005537-200306000-00004; Melino G, 2002, NAT REV CANCER, V2, P605, DOI 10.1038/nrc861; Melino G, 2003, TRENDS BIOCHEM SCI, V28, P663, DOI 10.1016/j.tibs.2003.10.004; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; Mills AA, 2006, CURR OPIN GENET DEV, V16, P38, DOI 10.1016/j.gde.2005.12.001; Minty A, 2000, J BIOL CHEM, V275, P36316, DOI 10.1074/jbc.M004293200; Miyazaki K, 2003, BIOCHEM BIOPH RES CO, V308, P106, DOI 10.1016/S0006-291X(03)01347-0; Moll UM, 2004, MOL CANCER RES, V2, P371; Momand J, 2000, GENE, V242, P15, DOI 10.1016/S0378-1119(99)00487-4; Muller M, 2005, CELL DEATH DIFFER, V12, P1564, DOI 10.1038/sj.cdd.4401774; Nakagawa T, 2002, MOL CELL BIOL, V22, P2575, DOI 10.1128/MCB.22.8.2575-2585.2002; Nguyen BC, 2006, GENE DEV, V20, P1028, DOI 10.1101/gad.1406006; Nishi H, 2001, J BIOL CHEM, V276, P41717, DOI 10.1074/jbc.M101241200; Nylander K, 2002, J PATHOL, V198, P417, DOI 10.1002/path.1231; Oberst A, 2005, BIOCHEM BIOPH RES CO, V331, P707, DOI 10.1016/j.bbrc.2005.03.158; Park BJ, 2000, CANCER RES, V60, P3370; Parsa R, 1999, J INVEST DERMATOL, V113, P1099, DOI 10.1046/j.1523-1747.1999.00780.x; Patturajan M, 2002, CANCER CELL, V1, P369, DOI 10.1016/S1535-6108(02)00057-0; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Peters UR, 1999, CANCER RES, V59, P4233; Petrenko O, 2003, MOL CELL BIOL, V23, P5540, DOI 10.1128/MCB.23.16.5540-5555.2003; Pozniak CD, 2000, SCIENCE, V289, P304, DOI 10.1126/science.289.5477.304; Ramalho FS, 2006, J GASTROEN HEPATOL, V21, P1276, DOI 10.1111/j.1440-1746.2006.04309.x; Redon R, 2001, CANCER RES, V61, P4122; Reis JS, 2003, CANCER CYTOPATHOL, V99, P172, DOI 10.1002/cncr.11061; Ribeiro-Silva A, 2005, HISTOPATHOLOGY, V47, P458, DOI 10.1111/j.1365-2559.2005.02249.x; Rizzo MG, 2004, LEUKEMIA, V18, P1804, DOI 10.1038/sj.leu.2403483; Rocco JW, 2006, CANCER CELL, V9, P45, DOI 10.1016/j.ccr.2005.12.013; Romano RA, 2006, J INVEST DERMATOL, V126, P1469, DOI 10.1038/sj.jid.5700297; Rossi M, 2005, EMBO J, V24, P836, DOI 10.1038/sj.emboj.7600444; Rossi M, 2006, CELL CYCLE, V5, P1816, DOI 10.4161/cc.5.16.2861; Rossi M, 2006, P NATL ACAD SCI USA, V103, P12753, DOI 10.1073/pnas.0603449103; Seelan RS, 2002, NEOPLASIA, V4, P195, DOI 10.1038/sj.neo.7900237; Senoo M, 2004, CANCER CELL, V6, P85, DOI 10.1016/j.ccr.2004.06.005; Senoo M, 2002, ONCOGENE, V21, P2455, DOI 10.1038/sj.onc.1205330; Serber Z, 2002, MOL CELL BIOL, V22, P8601, DOI 10.1128/MCB.22.24.8601-8611.2002; Sniezek JC, 2004, LARYNGOSCOPE, V114, P2063, DOI 10.1097/01.mlg.0000149437.35855.4b; Stiewe T, 2002, J BIOL CHEM, V277, P14177, DOI 10.1074/jbc.M200480200; Stiewe T, 2002, CELL DEATH DIFFER, V9, P237, DOI 10.1038/sj.cdd.4400995; Strano S, 2005, MOL CELL, V18, P447, DOI 10.1016/j.molcel.2005.04.008; Strano S, 2001, J BIOL CHEM, V276, P15164, DOI 10.1074/jbc.M010484200; Suh EK, 2006, NATURE, V444, P624, DOI 10.1038/nature05337; Sunahara M, 1999, ONCOGENE, V18, P3761, DOI 10.1038/sj.onc.1202972; Tannapfel A, 2001, J PATHOL, V195, P163, DOI 10.1002/path.947; Thanos CD, 1999, PROTEIN SCI, V8, P1708, DOI 10.1110/ps.8.8.1708; Tokuchi Y, 1999, BRIT J CANCER, V80, P1623, DOI 10.1038/sj.bjc.6690572; Tonon G, 2005, P NATL ACAD SCI USA, V102, P9625, DOI 10.1073/pnas.0504126102; TROUNG AB, 2006, GENE DEV, V20, P3185; Tyner SD, 2002, NATURE, V415, P45, DOI 10.1038/415045a; Uramoto H, 2002, J BIOL CHEM, V277, P31694, DOI 10.1074/jbc.M200266200; Urist M, 2004, GENE DEV, V18, P3041, DOI 10.1101/gad.1221004; Urist MJ, 2002, AM J PATHOL, V161, P1199, DOI 10.1016/S0002-9440(10)64396-9; van Bokhoven H, 2002, AM J HUM GENET, V71, P1, DOI 10.1086/341450; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2000, CELL, V103, P691, DOI 10.1016/S0092-8674(00)00171-9; Wager M, 2006, BRIT J CANCER, V95, P1062, DOI 10.1038/sj.bjc.6603410; Waltermann A, 2003, ONCOGENE, V22, P5686, DOI 10.1038/sj.onc.1206859; Wan YSY, 2003, IMMUNITY, V18, P331, DOI 10.1016/S1074-7613(03)00053-0; Wang TY, 2001, HUM PATHOL, V32, P479, DOI 10.1053/hupa.2001.24324; Wang Xiaojuan, 2002, Breast Cancer, V9, P216, DOI 10.1007/BF02967592; Watanabe K, 2002, J BIOL CHEM, V277, P15113, DOI 10.1074/jbc.M111281200; Watson IR, 2006, NEOPLASIA, V8, P655, DOI 10.1593/neo.06439; Weber A, 2002, INT J CANCER, V99, P22, DOI 10.1002/ijc.10296; Westfall MD, 2005, CELL CYCLE, V4, P710, DOI 10.4161/cc.4.5.1685; Westfall MD, 2003, MOL CELL BIOL, V23, P2264, DOI 10.1128/MCB.23.7.2264-2276.2003; Yamamoto T, 2001, BREEDING SCI, V51, P63, DOI 10.1270/jsbbs.51.63; Yang A, 2000, NAT REV MOL CELL BIO, V1, P199, DOI 10.1038/35043127; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yang A, 2002, TRENDS GENET, V18, P90, DOI 10.1016/S0168-9525(02)02595-7; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Yang A, 2006, MOL CELL, V24, P593, DOI 10.1016/j.molcel.2006.10.018; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704; Zaika A, 2001, J BIOL CHEM, V276, P11310, DOI 10.1074/jbc.M005737200; Zaika AI, 2002, J EXP MED, V196, P765, DOI 10.1084/jem.20020179; Zamo A, 2005, MODERN PATHOL, V18, P1448, DOI 10.1038/modpathol.3800440; Zangen R, 2005, CELL CYCLE, V4, P1313, DOI 10.4161/cc.4.10.2066; Zeng XY, 1999, MOL CELL BIOL, V19, P3257; Zhu JH, 1998, CANCER RES, V58, P5061	159	205	218	0	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 9	2007	26	36					5169	5183		10.1038/sj.onc.1210337	http://dx.doi.org/10.1038/sj.onc.1210337			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	199CQ	17334395				2022-12-28	WOS:000248674200001
J	Kreimann, EL; Morales, FC; de Orbeta-Cruz, J; Takahashi, Y; Adams, H; Liu, TJ; McCrea, PD; Georgescu, MM				Kreimann, E. L.; Morales, F. C.; de Orbeta-Cruz, J.; Takahashi, Y.; Adams, H.; Liu, T-J; McCrea, P. D.; Georgescu, M-M			Cortical stabilization of beta-catenin contributes to NHERF1/EBP50 tumor suppressor function	ONCOGENE			English	Article						NHERF1/EBP50; beta-catenin; E-cadherin; transformation; colon cancer; mouse embryonic fibroblasts (MEFs)	E-CADHERIN; NHERF; PROTEINS; COMPLEX; IDENTIFICATION; INHIBITION; MEMBRANE; ADHESIVE; FAMILY; GROWTH	Anchorage-independent growth is a hallmark of tumor growth and results from enhanced proliferation and altered cell-cell and cell-matrix interactions. By using gene-deficient mouse embryonic fibroblasts ( MEFs), we showed for the first time that NHERF1/EBP50 (Na/H exchanger regulator factor 1/ezrin-radixin-moesin binding phosphoprotein 50), an adapter protein with membrane localization under physiological conditions, inhibits cell motility and is required to suppress anchorage-independent growth. Both NHERF1 PDZ domains are necessary for the tumor suppressor effect. NHERF1 associates directly through the PDZ2 domain with beta-catenin and is required for beta-catenin localization at the cell- cell junctions in MEFs. Mechanistically, the absence of NHERF1 selectively decreased the interaction of beta-catenin with E-cadherin, but not with N-cadherin. The ensuing disorganization of E-cadherinmediated adherens junctions as well as the observed moderate increase in beta-catenin transcriptional activity contributed most likely to the anchorage-independent growth of NHERF1-deficient MEFs. In vivo, NHERF1 is specifically localized at the apical brush-border membrane in intestinal epithelial cells and is required to maintain a fraction of the cortical beta-catenin at this level. Thus, NHERF1 emerges as a cofactor essential for the integrity of epithelial tissues by maintaining the proper localization and complex assembly of beta-catenin.	Univ Texas, MD Anderson Canc Ctr, Dept Neurooncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Mol Genet, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Biochem & Mol Biol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Georgescu, MM (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Neurooncol, 6767 Bertner Ave, Houston, TX 77030 USA.	mgeorges@mdanderson.org	Adams, Henry/AAV-6870-2021; Georgescu, Maria-Magdalena/AAJ-6359-2020; Kreimann, Erica/W-2082-2019		NIGMS NIH HHS [R01 GM052112] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Brembeck FH, 2004, GENE DEV, V18, P2225, DOI 10.1101/gad.317604; Chen YT, 1999, J CELL BIOL, V144, P687, DOI 10.1083/jcb.144.4.687; Dai JL, 2004, ONCOGENE, V23, P8681, DOI 10.1038/sj.onc.1207962; Georgescu MM, 1999, P NATL ACAD SCI USA, V96, P10182, DOI 10.1073/pnas.96.18.10182; Giles RH, 2003, BBA-REV CANCER, V1653, P1, DOI 10.1016/S0304-419X(03)00005-2; Gottardi CJ, 2004, J CELL BIOL, V167, P339, DOI 10.1083/jcb.200402153; MCCREA PD, 1991, J BIOL CHEM, V266, P4514; Morales FC, 2004, P NATL ACAD SCI USA, V101, P17705, DOI 10.1073/pnas.0407974101; Nelson WJ, 2004, SCIENCE, V303, P1483, DOI 10.1126/science.1094291; Provost E, 1999, CURR OPIN CELL BIOL, V11, P567, DOI 10.1016/S0955-0674(99)00015-0; Reczek D, 1997, J CELL BIOL, V139, P169, DOI 10.1083/jcb.139.1.169; REYNOLDS AB, 1994, MOL CELL BIOL, V14, P8333, DOI 10.1128/MCB.14.12.8333; Sadot E, 1998, P NATL ACAD SCI USA, V95, P15339, DOI 10.1073/pnas.95.26.15339; Shenolikar S, 2004, PHYSIOLOGY, V19, P362, DOI 10.1152/physiol.00020.2004; Shibata T, 2003, HEPATOLOGY, V38, P178, DOI 10.1053/jhep.2003.50270; Suzuki J, 2004, ONCOGENE, V23, P8527, DOI 10.1038/sj.onc.1207894; Takahashi Y, 2006, EMBO J, V25, P910, DOI 10.1038/sj.emboj.7600979; TAKEICHI M, 1995, CURR OPIN CELL BIOL, V7, P619, DOI 10.1016/0955-0674(95)80102-2; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Voltz JW, 2001, ONCOGENE, V20, P6309, DOI 10.1038/sj.onc.1204774; Weinman EJ, 2003, BIOCHEMISTRY-US, V42, P12662, DOI 10.1021/bi035244l	21	85	91	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 9	2007	26	36					5290	5299		10.1038/sj.onc.1210336	http://dx.doi.org/10.1038/sj.onc.1210336			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	199CQ	17325659				2022-12-28	WOS:000248674200012
J	Kehn, K; Berro, R; Alhaj, A; Bottazzi, M; Yeh, WI; Klase, Z; Van Duyne, R; Fu, S; Kashanchi, F				Kehn, K.; Berro, R.; Alhaj, A.; Bottazzi, M. E.; Yeh, W-I; Klase, Z.; Van Duyne, R.; Fu, S.; Kashanchi, F.			Functional consequences of cyclin D1/BRCA1 interaction in breast cancer cells	ONCOGENE			English	Article						BRCA1; cyclin D1; cdk4; transcription; phosphorylation	ESTROGEN-RECEPTOR; DEPENDENT KINASES; DNA-BINDING; BRCA1; GENE; PHOSPHORYLATION; TRANSCRIPTION; FASCAPLYSIN; INHIBITION; EXPRESSION	The inheritance of one defective BRCA1 or BRCA2 allele predisposes an individual to developing breast and ovarian cancers. BRCA1 is a multifunctional tumor suppressor protein, which through interaction with a vast array of proteins has implications in processes such as cell cycle, transcription, DNA damage response and chromatin remodeling. Conversely, the oncogene, cyclin D1 is overexpressed in about 35% of all breast cancer cases. In this study, we provide detailed analyses on the phosphorylation state of BRCA1 by cyclin D1/cdk4 complexes. In particular, we have identified Ser 632 of BRCA1 as a cyclin D1/cdk4 phosphorylation site in vitro. Using chromatin immunoprecipitation assays, we observed that the inhibition of cyclin D1/cdk4 activity resulted in increased BRC A1 DNA binding at particular promoters in vivo. In addition, we identified multiple novel genes that are bound by BRCA1 in vivo. Collectively, these results indicate that cyclin D1/cdk4- mediated phosphorylation of BRCA1 inhibits the ability of BRCA1 to be recruited to particular promoters in vivo. Therefore, cyclin D1/Cdk4 phosphorylation of BRCA1 could provide a mechanism to interfere with the DNA- dependent activities of BRCA1.	George Washington Univ, Sch Med, Dept Biochem & Mol Biol, Washington, DC 20037 USA; George Washington Univ, Dept Microbiol, Inst Proteom Technol & Applicat, Washington, DC 20037 USA; Inst Genom Res TIGR, Dept Biochem, Rockville, MD USA	George Washington University; George Washington University; J. Craig Venter Institute	Kashanchi, F (corresponding author), George Washington Univ, Sch Med, Dept Biochem & Mol Biol, 2300 Eye St,NW,Ross Hall,Rm 552, Washington, DC 20037 USA.	bcmfxk@gwumc.edu	Kehn-Hall, Kylene/I-5752-2013; Van Duyne, Rachel/I-7365-2019	Bottazzi, Maria Elena/0000-0002-8429-0476; Van Duyne, Rachel/0000-0003-2914-6874	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI043894, R21AI065236] Funding Source: NIH RePORTER; NIAID NIH HHS [AI043894, AI065236] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Aubry C, 2004, CHEM COMMUN, P1696, DOI 10.1039/b406076h; Boulton SJ, 2006, BIOCHEM SOC T, V34, P633, DOI 10.1042/BST0340633; Cable PL, 2003, MOL CARCINOGEN, V38, P85, DOI 10.1002/mc.10148; Chen YM, 1996, CANCER RES, V56, P3168; Coqueret O, 2002, GENE, V299, P35, DOI 10.1016/S0378-1119(02)01055-7; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; De La Fuente C, 2000, J VIROL, V74, P7270, DOI 10.1128/JVI.74.16.7270-7283.2000; Fabbro M, 2002, J BIOL CHEM, V277, P21315, DOI 10.1074/jbc.M200769200; Fan SJ, 2002, CANCER RES, V62, P141; Hejna M, 2002, ANN ONCOL, V13, P653, DOI 10.1093/annonc/mdf142; Hillion J, 1997, BLOOD, V90, P3714, DOI 10.1182/blood.V90.9.3714; Katoh M, 2004, INT J ONCOL, V25, P1495; Kehn Kylene, 2004, Retrovirology, V1, P6, DOI 10.1186/1742-4690-1-6; Lacroix M, 2004, BREAST CANCER RES TR, V83, P249, DOI 10.1023/B:BREA.0000014042.54925.cc; Lin L, 2002, CANCER RES, V62, P5273; Mark WY, 2005, J MOL BIOL, V345, P275, DOI 10.1016/j.jmb.2004.10.045; Matsuura I, 2004, NATURE, V430, P226, DOI 10.1038/nature02650; Moisan A, 2006, J BIOL CHEM, V281, P21119, DOI 10.1074/jbc.M600712200; Montminy M, 1996, METABOLISM, V45, P4, DOI 10.1016/S0026-0495(96)90068-2; Mullan PB, 2006, ONCOGENE, V25, P5854, DOI 10.1038/sj.onc.1209872; Nakamura T, 2004, ONCOGENE, V23, P2385, DOI 10.1038/sj.onc.1207392; Pao GM, 2000, P NATL ACAD SCI USA, V97, P1020, DOI 10.1073/pnas.97.3.1020; Paull TT, 2001, P NATL ACAD SCI USA, V98, P6086, DOI 10.1073/pnas.111125998; Rosen ED, 2003, J THROMB HAEMOST, V1, P19, DOI 10.1046/j.1538-7836.2003.00030.x; Rosen EM, 2006, CANCER LETT, V236, P175, DOI 10.1016/j.canlet.2005.04.037; Ruffner H, 1999, MOL CELL BIOL, V19, P4843; Santosh M, 1999, GONDWANA RES, V2, P1, DOI 10.1016/S1342-937X(05)70121-0; Soni R, 2000, BIOCHEM BIOPH RES CO, V275, P877, DOI 10.1006/bbrc.2000.3349; Teh MT, 2002, CANCER RES, V62, P4773; Wang CG, 2005, CANCER RES, V65, P6557, DOI 10.1158/0008-5472.CAN-05-0486; Wang HC, 1997, ONCOGENE, V15, P143, DOI 10.1038/sj.onc.1201252; Zheng L, 2001, P NATL ACAD SCI USA, V98, P9587, DOI 10.1073/pnas.171174298	32	32	34	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 2	2007	26	35					5060	5069		10.1038/sj.onc.1210319	http://dx.doi.org/10.1038/sj.onc.1210319			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	196MT	17334399				2022-12-28	WOS:000248487400004
J	Memezawa, A; Takada, I; Takeyama, K; Igarashi, M; Ito, S; Aiba, S; Kato, S; Kouzmenko, AP				Memezawa, A.; Takada, I.; Takeyama, K.; Igarashi, M.; Ito, S.; Aiba, S.; Kato, S.; Kouzmenko, A. P.			Id2 gene-targeted crosstalk between Wnt and retinoid signaling regulates proliferation in human keratinocytes	ONCOGENE			English	Article						keratinocytes; retinoids; Wnt; proliferation; Id2	BETA-CATENIN; SYNERGISTIC INDUCTION; NUCLEAR RECEPTORS; STEM-CELLS; ACID; PROTEINS; PATHWAY	We investigated the effect of all-trans-retinoic acid (atRA) on proliferation in several human skin cell lines and found that antiproliferative potency of atRA correlated with the endogenous activity of canonical Wnt signaling. In HaCaT keratinocytes, we found that atRA significantly suppressed the expression of Id2, a member of the inhibitor of differentiation family of transcription factors that regulate cell growth and differentiation. However, no apparent change in the expression of other Wnt targets, like c-Myc or cyclin D1, was observed. Retinoid-induced Id2 gene suppression was associated with decreased levels of histone H3 and H4 acetylation and histone H3 Lys-4 methylation, and with recruitment of the LSD1 demethylase at the Wnt-response element (WRE) (TCF/ LEF-binding site), in the Id2 gene promoter. None of such changes was detected at the WRE of c-Myc and cyclin D1 gene promoters. Inhibition of Id2 by short interfering RNA (siRNA) had a similar effect on the proliferation of HaCaT cells as exposure to atRA, whereas anti-beta-catenin siRNA significantly inhibited its antiproliferative effect. These data suggest that downregulation of Id2 gene expression through transcriptional convergence between Wnt and retinoid signaling pathways underlies the antiproliferative effect of retinoids in keratinocytes, and provide evidence of gene-targeted crosstalk between signaling pathways.	Univ Tokyo, Inst Mol & Cellular Biosci, Dept Nucl Signaling, Bunkyo Ku, Tokyo 1130032, Japan; Tohoku Univ, Grad Sch Med, Dept Dermatol, Aoba Ku, Sendai, Miyagi 980, Japan; Japan Sci & Technol Agcy, ERATO, Kawaguchi, Saitama, Japan	University of Tokyo; Tohoku University; Japan Science & Technology Agency (JST)	Kato, S (corresponding author), Univ Tokyo, Inst Mol & Cellular Biosci, Dept Nucl Signaling, Bunkyo Ku, Yayoi 1-1-1, Tokyo 1130032, Japan.	uskato@mail.ecc.u-tokyo.ac.jp; alexk@iam.u-tokyo.ac.jp						Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Alonso L, 2003, GENE DEV, V17, P1189, DOI 10.1101/gad.1086903; Baghdoyan S, 2005, J BIOL CHEM, V280, P15836, DOI 10.1074/jbc.M414216200; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; Buzzard JJ, 2003, ENDOCRINOLOGY, V144, P3722, DOI 10.1210/en.2003-0379; Easwaran V, 1999, CURR BIOL, V9, P1415, DOI 10.1016/S0960-9822(00)80088-3; Kitagawa H, 2003, CELL, V113, P905, DOI 10.1016/S0092-8674(03)00436-7; Kouzmenko AP, 2004, J BIOL CHEM, V279, P40255, DOI 10.1074/jbc.C400331200; Lasorella A, 2005, MOL CELL BIOL, V25, P3563, DOI 10.1128/MCB.25.9.3563-3574.2005; Lasorella A, 2001, ONCOGENE, V20, P8326, DOI 10.1038/sj.onc.1205093; Lasorella A, 2006, NATURE, V442, P471, DOI 10.1038/nature04895; Lee MG, 2005, NATURE, V437, P432, DOI 10.1038/nature04021; Liu T, 2002, J BIOL CHEM, V277, P30887, DOI 10.1074/jbc.M203852200; Ma Y, 2005, CANCER RES, V65, P6476, DOI 10.1158/0008-5472.CAN-05-0370; Mark M, 2006, ANNU REV PHARMACOL, V46, P451, DOI 10.1146/annurev.pharmtox.46.120604.141156; Moon RT, 2004, NAT REV GENET, V5, P689, DOI 10.1038/nrg1427; Mulholland DJ, 2005, ENDOCR REV, V26, P898, DOI 10.1210/er.2003-0034; NEUMAN K, 1995, FEBS LETT, V374, P279, DOI 10.1016/0014-5793(95)01128-2; Nigten J, 2005, LEUKEMIA, V19, P799, DOI 10.1038/sj.leu.2403699; Niles RM, 2004, MUTAT RES-FUND MOL M, V555, P81, DOI 10.1016/j.mrfmmm.2004.05.020; Ohtake F, 2003, NATURE, V423, P545, DOI 10.1038/nature01606; Okuno M, 2004, CURR CANCER DRUG TAR, V4, P285, DOI 10.2174/1568009043333023; Otero JJ, 2004, DEVELOPMENT, V131, P3545, DOI 10.1242/dev.01218; Shi YJ, 2004, CELL, V119, P941, DOI 10.1016/j.cell.2004.12.012; Sikder HA, 2003, CANCER CELL, V3, P525, DOI 10.1016/S1535-6108(03)00141-7; Simbulan-Rosenthal CM, 2005, ONCOGENE, V24, P5443, DOI 10.1038/sj.onc.1208709; Sundberg M, 2006, J NEUROSCI, V26, P5402, DOI 10.1523/JNEUROSCI.4906-05.2006; Szeto W, 2001, CANCER RES, V61, P4197; Tice DA, 2002, J BIOL CHEM, V277, P14329, DOI 10.1074/jbc.M200334200; Wagsater D, 2003, J EXP CLIN CANC RES, V22, P471; Weeraratna AT, 2005, CANCER METAST REV, V24, P237, DOI 10.1007/s10555-005-1574-z; Yanagisawa J, 2002, MOL CELL, V9, P553, DOI 10.1016/S1097-2765(02)00478-1	32	27	28	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 2	2007	26	35					5038	5045		10.1038/sj.onc.1210320	http://dx.doi.org/10.1038/sj.onc.1210320			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	196MT	17310985				2022-12-28	WOS:000248487400002
J	Hatch, T; Derijck, AAHA; Black, PD; van der Heijden, GW; de Boer, P; Dubrova, YE				Hatch, T.; Derijck, A. A. H. A.; Black, P. D.; van der Heijden, G. W.; de Boer, P.; Dubrova, Y. E.			Maternal effects of the scid mutation on radiation-induced transgenerational instability in mice	ONCOGENE			English	Article						radiation; transgenerational instability; maternal effects; scid; NHEJ; mouse	DEPENDENT PROTEIN-KINASE; DNA-REPAIR; CATALYTIC SUBUNIT; GENOME STABILITY; GERM-LINE; DAMAGE; SPERM; RATES; DEFICIENCY; EXPRESSION	The results of a number of recent studies show that mutation rates in the offspring of irradiated parents are substantially elevated, however, the effect of parental genotype on transgenerational instability remains poorly understood. Here, we have analysed the mutation frequency at an expanded simple tandem repeat (ESTR) locus in the germline and bone marrow of the first-generation male offspring of control and irradiated male mice. The frequency of ESTR mutation was studied in the offspring of two reciprocal matings male scid x female BALB/c and male BALB/c x female scid, which were compared with that in BALB/c mice. In the offspring of the BALB/c x BALB/c and male scid x female BALB/c matings, which were conceived after paternal sperm irradiation, the frequency of ESTR mutation was significantly elevated in both tissues. In contrast, ESTR mutation frequency was only slightly elevated in the offspring of male BALB/c x female scid mating conceived after paternal irradiation. The results of this study suggest that the oocytes of scid females are unable to fully support the repair of double-strand breaks induced in paternal sperm which may in turn result in the elimination of cells/embryos containing high levels of DNA damage, thus partially preventing the manifestation of genomic instability.	Univ Leicester, Dept Genet, Leicester LE1 7RH, Leics, England; Radboud Univ Nijmegen, Med Ctr, Dept Obstet & Gynaecol, Nijmegen, Netherlands	University of Leicester; Radboud University Nijmegen	Dubrova, YE (corresponding author), Univ Leicester, Dept Genet, Univ Rd, Leicester LE1 7RH, Leics, England.	yed2@le.ac.uk	Dubrova, Yuri/ABA-7148-2020; van der Heijden, Godfried/ABC-5623-2021	van der Heijden, Godfried/0000-0001-5894-7027; Dubrova, Yuri/0000-0001-5281-7539	MRC [G0300477, G9806740] Funding Source: UKRI; Medical Research Council [G9806740, G0300477] Funding Source: Medline; Wellcome Trust Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust)		Ahmadi A, 1999, J EXP ZOOL, V284, P696, DOI 10.1002/(SICI)1097-010X(19991101)284:6&lt;696::AID-JEZ11&gt;3.0.CO;2-E; Allen C, 2002, P NATL ACAD SCI USA, V99, P3758, DOI 10.1073/pnas.052545899; Barber R, 2002, P NATL ACAD SCI USA, V99, P6877, DOI 10.1073/pnas.102015399; Barber RC, 2006, ONCOGENE, V25, P7336, DOI 10.1038/sj.onc.1209723; Barber RC, 2004, MUTAT RES-FUND MOL M, V554, P287, DOI 10.1016/j.mrfmmm.2004.05.003; Barton TS, 2005, P NATL ACAD SCI USA, V102, P7865, DOI 10.1073/pnas.0501200102; BIEDERMANN KA, 1991, P NATL ACAD SCI USA, V88, P1394, DOI 10.1073/pnas.88.4.1394; Blunt T, 1996, P NATL ACAD SCI USA, V93, P10285, DOI 10.1073/pnas.93.19.10285; Derijck AAHA, 2006, DNA REPAIR, V5, P959, DOI 10.1016/j.dnarep.2006.05.043; Dubrova YE, 1998, P NATL ACAD SCI USA, V95, P6251, DOI 10.1073/pnas.95.11.6251; Dubrova YE, 2000, NATURE, V405, P37, DOI 10.1038/35011135; Festing MF, 1996, GENETIC VARIANTS STR, P1537; Fiorenza MT, 2001, DEV BIOL, V233, P214, DOI 10.1006/dbio.2001.0199; GENEROSO WM, 1979, P NATL ACAD SCI USA, V76, P435, DOI 10.1073/pnas.76.1.435; Harrouk W, 2000, MUTAT RES-DNA REPAIR, V461, P229, DOI 10.1016/S0921-8777(00)00053-7; Jimenez GS, 1999, NATURE, V400, P81, DOI 10.1038/21913; Marchetti Francesco, 2005, Birth Defects Res C Embryo Today, V75, P112, DOI 10.1002/bdrc.20040; MATSUDA Y, 1989, MUTAT RES, V210, P35, DOI 10.1016/0027-5107(89)90042-0; Mohrenweiser HW, 2003, MUTAT RES-FUND MOL M, V526, P93, DOI 10.1016/S0027-5107(03)00049-6; Okayasu R, 2000, CANCER RES, V60, P4342; Olsen Ann-Karin, 2005, Toxicol Appl Pharmacol, V207, P521, DOI 10.1016/j.taap.2005.01.060; Rassoulzadegan M, 2006, NATURE, V441, P469, DOI 10.1038/nature04674; Rothkamm K, 2003, MOL CELL BIOL, V23, P5706, DOI 10.1128/MCB.23.16.5706-5715.2003; Rousseaux S, 2005, GENE, V345, P139, DOI 10.1016/j.gene.2004.12.004; SEARLE AG, 1974, ADV RADIAT BIOL, V4, P131; Shimura T, 2002, MOL CELL BIOL, V22, P2220, DOI 10.1128/MCB.22.7.2220-2228.2002; Wallace M, 2001, ONCOGENE, V20, P3597, DOI 10.1038/sj.onc.1204496; Yauk CL, 2002, MUTAT RES-FUND MOL M, V500, P147, DOI 10.1016/S0027-5107(02)00005-2; Yu YJ, 2001, CANCER RES, V61, P1820; Zeng FY, 2004, DEV BIOL, V272, P483, DOI 10.1016/j.ydbio.2004.05.018; Zhang SL, 1998, P NATL ACAD SCI USA, V95, P2429, DOI 10.1073/pnas.95.5.2429; Zheng NJ, 2000, ENVIRON MOL MUTAGEN, V36, P134, DOI 10.1002/1098-2280(2000)36:2<134::AID-EM8>3.0.CO;2-D	32	25	25	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 12	2007	26	32					4720	4724		10.1038/sj.onc.1210253	http://dx.doi.org/10.1038/sj.onc.1210253			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	190DJ	17237807	Green Submitted			2022-12-28	WOS:000248037900012
J	Blouw, B; Haase, VH; Song, H; Bergers, G; Johnson, RS				Blouw, B.; Haase, V. H.; Song, H.; Bergers, G.; Johnson, R. S.			Loss of vascular endothelial growth factor expression reduces vascularization, but not growth, of tumors lacking the Von Hippel-Lindau tumor suppressor gene	ONCOGENE			English	Article						hypoxia; angiogenesis; HIF-1; VEGF; tumor	RENAL-CELL-CARCINOMA; HYPOXIA-INDUCIBLE FACTOR-1-ALPHA; RECEPTOR; VEGF; PVHL; TUMORIGENESIS; INACTIVATION; HIF-1-ALPHA; ACTIVATION; INDUCTION	Individuals bearing germ line mutations in the Von Hippel-Lindau (VHL) tumor suppressor gene are predisposed to the development of highly angiogenic tumors. This is correlated with an increased expression of the angiogenic factor vascular endothelial growth factor (VEGF) in these tumors, which is in part caused by elevated expression of the HIF-1 hypoxia inducible transcription factors. We created malignant astrocytes with genetic deletions of the VHL gene and implanted them in subcutaneous and intracranial sites; these sites are respectively vessel poor and vessel-rich tissues. When grown in a vessel poor site, VEGF expression in VHL null cells was important for both vascularization and tumor growth. However, when the same cells are grown in the vessel-rich intracranial environment, loss of VEGF expression reduces vascularization, but does not affect tumor growth. This indicates that antiangiogenic therapies for tumors that express high levels of angiogenic factors such as VEGF may vary in their efficacy, with potentially lowered effectiveness in sites, such as the brain, that are inherently vessel rich.	Univ Calif San Diego, Div Biol Sci, Mol Biol Sect, La Jolla, CA 92093 USA; Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA; Univ Calif San Francisco, Brain Tumor Res Ctr, Dept Neurosurg, San Francisco, CA USA	University of California System; University of California San Diego; University of Pennsylvania; University of California System; University of California San Francisco	Johnson, RS (corresponding author), Univ Calif San Diego, Div Biol Sci, Mol Biol Sect, 9500 Gilman Dr,Nat Sci Bldg Rm 5328, La Jolla, CA 92093 USA.	rjohnson@biomail.ucsd.edu	Haase, Volker Hans/A-6758-2013; Bergers, Gabriele/AAJ-5535-2020; Haase, Volker Hans/AAJ-5061-2021; Johnson, Randall/AAM-1189-2021	Haase, Volker Hans/0000-0002-7051-8994; Johnson, Randall/0000-0002-4084-6639; Bergers, Gabriele/0000-0003-3545-5171	NATIONAL CANCER INSTITUTE [R01CA082515, R01CA100787] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R03DK062060, K08DK002668] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA100787, CA082515, CA 100787] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Benjamin LE, 1997, P NATL ACAD SCI USA, V94, P8761, DOI 10.1073/pnas.94.16.8761; Bergers G, 2003, NAT REV CANCER, V3, P401, DOI 10.1038/nrc1093; Blouw B, 2003, CANCER CELL, V4, P133, DOI 10.1016/S1535-6108(03)00194-6; Carroll VA, 2006, CANCER RES, V66, P6264, DOI 10.1158/0008-5472.CAN-05-2519; Flamme I, 1998, AM J PATHOL, V153, P25, DOI 10.1016/S0002-9440(10)65541-1; Gerber HP, 1999, DEVELOPMENT, V126, P1149; Grunstein J, 1999, CANCER RES, V59, P1592; Haase VH, 2001, P NATL ACAD SCI USA, V98, P1583, DOI 10.1073/pnas.98.4.1583; Hansel DE, 2006, HISTOL HISTOPATHOL, V21, P437, DOI 10.14670/HH-21.437; Harris A L, 2000, Oncologist, V5 Suppl 1, P32; Hasselblatt M, 2005, NEUROPATH APPL NEURO, V31, P618, DOI 10.1111/j.1365-2990.2005.00669.x; Kaelin WG, 2002, NAT REV CANCER, V2, P673, DOI 10.1038/nrc885; Koochekpour S, 1999, MOL CELL BIOL, V19, P5902; Lonser RR, 2003, LANCET, V361, P2059, DOI 10.1016/S0140-6736(03)13643-4; Los M, 1999, CANCER RES, V59, P4440; Mack FA, 2005, MOL CELL BIOL, V25, P4565, DOI 10.1128/MCB.25.11.4565-4578.2005; Mack FA, 2003, CANCER CELL, V3, P75, DOI 10.1016/S1535-6108(02)00240-4; Mandriota SJ, 2002, CANCER CELL, V1, P459, DOI 10.1016/S1535-6108(02)00071-5; Rankin EB, 2005, MOL CELL BIOL, V25, P3163, DOI 10.1128/MCB.25.8.3163-3172.2005; Rathmell WK, 2004, ANTICANCER RES, V24, P167; Ryan HE, 2000, CANCER RES, V60, P4010; Ryan HE, 1998, EMBO J, V17, P3005, DOI 10.1093/emboj/17.11.3005; Seagroves TN, 2003, DEVELOPMENT, V130, P1713, DOI 10.1242/dev.00403; Staehler M, 2005, CURR DRUG TARGETS, V6, P835, DOI 10.2174/138945005774574498; Staller P, 2003, NATURE, V425, P307, DOI 10.1038/nature01874; Tang N, 2006, MOL CELL BIOL, V26, P2519, DOI 10.1128/MCB.26.7.2519-2530.2006; Tang N, 2004, CANCER CELL, V6, P485, DOI 10.1016/j.ccr.2004.09.026; Unruh A, 2003, ONCOGENE, V22, P3213, DOI 10.1038/sj.onc.1206385; Zagzag D, 2005, CANCER RES, V65, P6178, DOI 10.1158/0008-5472.CAN-04-4406; Zagzag D, 2000, CANCER-AM CANCER SOC, V88, P2606, DOI 10.1002/1097-0142(20000601)88:11<2606::AID-CNCR25>3.0.CO;2-W	30	6	6	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL	2007	26	31					4531	4540		10.1038/sj.onc.1210249	http://dx.doi.org/10.1038/sj.onc.1210249			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	187GR	17297464				2022-12-28	WOS:000247836100007
J	Brun, T; Duhamel, DL; He, KHH; Wollheim, CB; Gauthier, BR				Brun, T.; Duhamel, D. L.; He, K. H. Hu; Wollheim, C. B.; Gauthier, B. R.			The transcription factor PAX4 acts as a survival gene in INS-1E insulinoma cells	ONCOGENE			English	Article						RNAi; insulin; Pax4; proliferation; apoptosis; survival	GROWTH-FACTOR; BETA-CELLS; EXPRESSION; DIFFERENTIATION; PROLIFERATION; BETACELLULIN; DYSFUNCTION; SUSCEPTIBILITY; ASSOCIATION; METABOLISM	The paired/homeodomain transcription factor Pax4 is essential for islet beta-cell generation during pancreas development and their survival in adulthood. High Pax4 expression was reported in human insulinomas indicating that deregulation of the gene may be associated with tumorigenesis. We report that rat insulinoma INS-1E cells express 25-fold higher Pax4 mRNA levels than rat islets. In contrast to primary beta-cells, activin A but not betacellulin or glucose induced Pax4 mRNA levels indicating dissociation of Pax4 expression from insulinoma cell proliferation. Short hairpin RNA adenoviral constructs targeted to the paired domain or homeodomain (viPax4PD and viPax4HD) were generated. Pax4 mRNA levels were lowered by 73 and 50% in cells expressing either viPax4PD or viPax4HD. Transcript levels of the Pax4 target gene bcl-xl were reduced by 53 and 47%, whereas Pax6 and Pdx1 mRNA levels were unchanged. viPax4PD-infected cells displayed a twofold increase in spontaneous apoptosis and were more susceptible to cytokine-induced cell death. In contrast, proliferation was unaltered. RNA interference-mediated repression of insulin had no adverse effects on either Pax4 or Pdx1 expression as well as on cell replication or apoptosis. These results indicate that Pax4 is redundant for proliferation of insulinoma cells, whereas it is essential for survival through upregulation of the antiapoptotic gene bcl-xl.	Univ Geneva, Med Ctr, Dept Cell Physiol & Metab, CH-1211 Geneva 4, Switzerland	University of Geneva	Brun, T (corresponding author), Univ Geneva, Med Ctr, Dept Cell Physiol & Metab, CH-1211 Geneva 4, Switzerland.	thierry.brun@medecine.unige.ch; benoit.gauthier@medecine.unige.ch	Gauthier, Benoit R/C-3138-2017	Gauthier, Benoit R/0000-0001-8146-7486; BRUN, Thierry/0000-0002-1659-4283				ASFARI M, 1992, ENDOCRINOLOGY, V130, P167, DOI 10.1210/en.130.1.167; Barker CJ, 2002, AM J PHYSIOL-ENDOC M, V283, pE1113, DOI 10.1152/ajpendo.00088.2002; Bernasconi M, 1996, P NATL ACAD SCI USA, V93, P13164, DOI 10.1073/pnas.93.23.13164; Biason-Lauber A, 2005, DIABETOLOGIA, V48, P900, DOI 10.1007/s00125-005-1723-5; Blasco MA, 2005, NAT REV GENET, V6, P611, DOI 10.1038/nrg1656; Brun T, 2005, DIABETOLOGIA, V48, pA27; Brun T, 2004, J CELL BIOL, V167, P1123, DOI 10.1083/jcb.200405148; Buteau J, 2003, DIABETES, V52, P124, DOI 10.2337/diabetes.52.1.124; Collier Dawn C, 2003, J Appl Clin Med Phys, V4, P17, DOI 10.1120/1.1521271; Collombat P, 2005, DEVELOPMENT, V132, P2969, DOI 10.1242/dev.01870; Dor Y, 2004, NATURE, V429, P41, DOI 10.1038/nature02520; Feng XH, 2005, ANNU REV CELL DEV BI, V21, P659, DOI 10.1146/annurev.cellbio.21.022404.142018; Gauthier B, 1999, ATHEROSCLEROSIS, V142, P301, DOI 10.1016/S0021-9150(98)00245-7; Gauthier BR, 2004, J BIOL CHEM, V279, P31121, DOI 10.1074/jbc.M405030200; Gunton JE, 2005, CELL, V122, P337, DOI 10.1016/j.cell.2005.05.027; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; He SJ, 2005, MOL CANCER THER, V4, P996, DOI 10.1158/1535-7163.MCT-04-0252; Henderson CC, 2005, ONCOGENE, V24, P7120, DOI 10.1038/sj.onc.1208887; Heremans Y, 2002, J CELL BIOL, V159, P303, DOI 10.1083/jcb.200203074; Holm P, 2004, DIABETES, V53, P1584, DOI 10.2337/diabetes.53.6.1584; Hugl SR, 1998, J BIOL CHEM, V273, P17771, DOI 10.1074/jbc.273.28.17771; Huotari MA, 1998, ENDOCRINOLOGY, V139, P1494, DOI 10.1210/en.139.4.1494; Ishihara H, 2003, NAT CELL BIOL, V5, P330, DOI 10.1038/ncb951; Kanatsuka A, 2002, METABOLISM, V51, P1161, DOI 10.1053/meta.2002.34707; Kojima H, 2003, NAT MED, V9, P596, DOI 10.1038/nm867; LI Y, 2006, LEUKEMIA RES, V9, P1547; Margue CM, 2000, ONCOGENE, V19, P2921, DOI 10.1038/sj.onc.1203607; Mauvais-Jarvis F, 2004, HUM MOL GENET, V13, P3151, DOI 10.1093/hmg/ddh341; Merglen A, 2004, ENDOCRINOLOGY, V145, P667, DOI 10.1210/en.2003-1099; Miyamoto T, 2001, BIOCHEM BIOPH RES CO, V282, P34, DOI 10.1006/bbrc.2001.4552; Muratovska A, 2003, ONCOGENE, V22, P7989, DOI 10.1038/sj.onc.1206766; Ostrom L, 2000, DEV BIOL, V219, P250, DOI 10.1006/dbio.2000.9618; Park D, 2006, DEVELOPMENT, V133, P4193, DOI 10.1242/dev.02614; Robson EJD, 2006, NAT REV CANCER, V6, P52, DOI 10.1038/nrc1778; Shima Akihiro, 2003, EMBO Reports, V4, P121, DOI 10.1038/sj.embor.embor743; Shimajiri Y, 2001, DIABETES, V50, P2864, DOI 10.2337/diabetes.50.12.2864; SHING Y, 1993, SCIENCE, V259, P1604, DOI 10.1126/science.8456283; Sledz CA, 2003, NAT CELL BIOL, V5, P834, DOI 10.1038/ncb1038; SosaPineda B, 1997, NATURE, V386, P399, DOI 10.1038/386399a0; Theander-Carrillo C, 2006, J CLIN INVEST, V116, P1983, DOI 10.1172/JCI25811; Theis M, 2004, EXP CELL RES, V294, P18, DOI 10.1016/j.yexcr.2003.09.031; Tokuyama Y, 2006, METABOLISM, V55, P213, DOI 10.1016/j.metabol.2005.08.014; Ueda Y, 2000, FEBS LETT, V480, P101, DOI 10.1016/S0014-5793(00)01914-1; Wang JF, 2004, DEV BIOL, V266, P178, DOI 10.1016/j.ydbio.2003.10.018; Yamaoka T, 2000, DIABETOLOGIA, V43, P332, DOI 10.1007/s001250050051; Zalzman M, 2003, P NATL ACAD SCI USA, V100, P7253, DOI 10.1073/pnas.1136854100; Zhang YQ, 2001, DIABETES, V50, pS10, DOI 10.2337/diabetes.50.2007.S10; Zhou J, 2005, IEEE T INTELL TRANSP, V6, P229, DOI 10.1109/TITS.2005.848359; Zhou YH, 2003, CLIN CANCER RES, V9, P3369	49	32	34	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 21	2007	26	29					4261	4271		10.1038/sj.onc.1210205	http://dx.doi.org/10.1038/sj.onc.1210205			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	184CY	17260022				2022-12-28	WOS:000247619900009
J	Cras, A; Darsin-Bettinger, D; Balitrand, N; Cassinat, B; Soulie, A; Toubert, ME; Delva, L; Chomienne, C				Cras, A.; Darsin-Bettinger, D.; Balitrand, N.; Cassinat, B.; Soulie, A.; Toubert, M-E; Delva, L.; Chomienne, C.			Epigenetic patterns of the retinoic acid receptor beta(2) promoter in retinoic acid-resistant thyroid cancer cells	ONCOGENE			English	Article						RAR beta(2) promoter; RA; resistance; thyroid cells; histone acetylation	RECEPTOR-BETA GENE; REDIFFERENTIATION THERAPY; SODIUM/IODIDE SYMPORTER; MYELOID CELLS; RAR-ALPHA; EXPRESSION; CARCINOMA; LINES; TRANSCRIPTION; METHYLATION	Treatment with retinoic acid ( RA) is effective to restore radioactive iodine uptake in metastases of a small fraction of thyroid cancer patients. In order to find predictive markers of response, we took advantage of two thyroid cancer cell lines, FTC133 and FTC238, with low RA-receptor ( RAR)beta expression but differing in their response to RA. We report that in both cell lines, RA signalling pathways are functional, as transactivation of an exogenous RAR beta(2) promoter is effective in the presence of pharmacological concentrations of all-trans RA, and enhanced in RA-resistant FTC238 cells after ectopical expression of RAR beta, suggesting a defective endogenous RAR beta(2) promoter in these cells. Further analyses show that whereas the RAR beta(2) promoter is in an unmethylated permissive status in both FTC133 and FTC238 cells, it failed to be associated with acetylated forms of histones H3 or H4 in FTC238 cells upon RA treatment. Incubation with a histone deacetylase inhibitor, alone or in combination with RA, restored histone acetylation levels and reactivated RAR beta and differentiation marker Na+/I- symporter gene expression. Thus, histone modi. cation patterns may explain RA-refractoriness in differentiated thyroid cancer patients and suggest a potential benefit of combined transcriptional and differentiation therapies.	Hop St Louis, INSERM, UMR S 718, IUH,Unite Biol Cellulaire,AP HP, F-75010 Paris, France; Univ Paris 07, INSERM, UMR S 718, Inst Univ Hematol, Paris, France; Hop St Louis, Nucl Med Serv, AP HP, F-75010 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite	Chomienne, C (corresponding author), Hop St Louis, INSERM, UMR S 718, IUH,Unite Biol Cellulaire,AP HP, 1 Ave Claude Vellefaux, F-75010 Paris, France.	christine.chomienne@sls.ap-hop-paris.fr	Cras, Audrey/Q-8784-2017; CASSINAT, BRUNO/N-2752-2017	Cras, Audrey/0000-0002-6894-9584; CASSINAT, BRUNO/0000-0002-6514-3905; CHOMIENNE, Christine/0000-0001-5513-5752; DELVA, Laurent/0000-0002-1086-3964				Bastie JN, 2004, MOL ENDOCRINOL, V18, P2685, DOI 10.1210/me.2003-0412; Carpentier A, 1997, ONCOGENE, V15, P1805, DOI 10.1038/sj.onc.1201335; Carpentier AF, 1999, ANTICANCER RES, V19, P3189; Cassinat B, 2000, LEUKEMIA, V14, P324, DOI 10.1038/sj.leu.2401652; CHOMIENNE C, 1991, J CLIN INVEST, V88, P2150, DOI 10.1172/JCI115547; Cote S, 1998, ANTI-CANCER DRUG, V9, P743; De Vita G, 1998, CELL GROWTH DIFFER, V9, P97; Delva L, 1999, MOL CELL BIOL, V19, P7158; deThe H, 1996, FASEB J, V10, P955, DOI 10.1096/fasebj.10.9.8801177; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; di Magliano MP, 2000, P NATL ACAD SCI USA, V97, P13144; Filetti S, 1999, EUR J ENDOCRINOL, V141, P443, DOI 10.1530/eje.0.1410443; Goretzki P E, 1990, Recent Results Cancer Res, V118, P48; Grunwald F, 1998, J NUCL MED, V39, P1903; Hundahl SA, 1998, CANCER-AM CANCER SOC, V83, P2638, DOI 10.1002/(SICI)1097-0142(19981215)83:12<2638::AID-CNCR31>3.0.CO;2-1; Idres N, 2002, J BIOL CHEM, V277, P31491, DOI 10.1074/jbc.M205016200; Lazar V, 1999, J CLIN ENDOCR METAB, V84, P3228, DOI 10.1210/jc.84.9.3228; MAZZAFERRI EL, 1994, AM J MED, V97, P418, DOI 10.1016/0002-9343(94)90321-2; Momparler RL, 2003, ONCOGENE, V22, P6479, DOI 10.1038/sj.onc.1206774; Niles RM, 2004, MUTAT RES-FUND MOL M, V555, P81, DOI 10.1016/j.mrfmmm.2004.05.020; PINEDA JD, 1995, J CLIN ENDOCR METAB, V80, P1488, DOI 10.1210/jc.80.5.1488; Rochaix P, 1998, HISTOPATHOLOGY, V33, P337, DOI 10.1046/j.1365-2559.1998.00486.x; Rochette-Egly C, 2005, J BIOL CHEM, V280, P32565, DOI 10.1074/jbc.R500008200; ROUSSELOT P, 1994, ONCOGENE, V9, P545; Schmutzler C, 1998, INT J CANCER, V76, P368; Schmutzler C, 1997, BIOCHEM BIOPH RES CO, V240, P832, DOI 10.1006/bbrc.1997.7715; Schmutzler C, 2000, THYROID, V10, P393, DOI 10.1089/thy.2000.10.393; SCHRECK R, 1994, J CLIN ENDOCR METAB, V79, P791, DOI 10.1210/jc.79.3.791; Simon D, 2002, EUR J NUCL MED MOL I, V29, P775, DOI 10.1007/s00259-001-0737-6; Suh YA, 2002, CANCER RES, V62, P3945; Sun SY, 2002, CRIT REV ONCOL HEMAT, V41, P41, DOI 10.1016/S1040-8428(01)00144-5; Virmani AK, 2000, J NATL CANCER I, V92, P1303, DOI 10.1093/jnci/92.16.1303; Widschwendter M, 2000, J NATL CANCER I, V92, P826, DOI 10.1093/jnci/92.10.826; WYNFORDTHOMAS D, 1993, CANCER SURV, V16, P115; Youssef EM, 2004, CLIN CANCER RES, V10, P1733, DOI 10.1158/1078-0432.CCR-0989-3; Youssef EM, 2004, CANCER BIOL THER, V3, P82, DOI 10.4161/cbt.3.1.591	36	27	28	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 7	2007	26	27					4018	4024		10.1038/sj.onc.1210178	http://dx.doi.org/10.1038/sj.onc.1210178			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	177HP	17213810				2022-12-28	WOS:000247144500012
J	Bonavida, B				Bonavida, B.			'Rituximab-induced inhibition of antiapoptotic cell survival pathways: implications in chemo/immunoresistance, rituximab unresponsiveness, prognostic and novel therapeutic interventions'	ONCOGENE			English	Review						rituximab; CD20 signaling; rituximab resistance; rituximab-induced chemoimmunosensitization	NON-HODGKINS-LYMPHOMA; NF-KAPPA-B; TRAIL-MEDIATED APOPTOSIS; MONOCLONAL-ANTIBODY; DOWN-REGULATION; SIGNALING PATHWAY; STAT3 ACTIVITY; UP-REGULATION; NITRIC-OXIDE; PIVOTAL ROLE	Rituximab (chimeric anti-CD20 monoclonal antibody) is the first Food and Drug Administration approved antitumor antibody and is used in the treatment of B-non-Hodgkin's lymphoma (B-NHL). It is used as single monotherapy or in combination with chemotherapy and has improved the treatment outcome of patients with B-NHL. The in vivo mechanisms of rituximab-mediated antitumor effects include antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cell cytotoxicity (CDC), growth-inhibition and apoptosis. A subset of patients does not initially respond to rituximab and several responsive patients develop resistance to further rituximab treatment. The mechanism of rituximab unresponsiveness is not known. Besides the above-postulated mechanisms, rituximab has been shown to trigger the cells via CD20. Studies performed with B-NHL cell lines as model systems revealed several novel mechanisms of rituximab-mediated effects that are involved in chemo/immunosensitization and the development of resistance to rituximab. Rituximab has been shown to inhibit the p38 mitogen-activated protein kinase, nuclear factor-kappa B (NF-kappa B), extracellular signal-regulated kinase 1/2 (ERK 1/2) and AKT antiapoptotic survival pathways, all of which result in upregulation of phosphatase and tensin homolog deleted on chromosome ten and Raf kinase inhibitor protein and in the downregulation of antiapoptotic gene products (particularly Bcl-2, Bcl-(xL) and Mcl-1), and resulting in chemo/immunosensitization. Further, rituximab treatment inhibits the overexpressed transcription repressor Yin Yang 1 (YY1), which negatively regulates Fas and DR5 expression and its inhibition leads to sensitization to Fas ligand and tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis. Rituximab-resistant clones were generated as model to examine the mechanism of in vivo rituximab unresponsiveness. These clones showed reduced expression of CD20 and hyperactivation of the above antiapoptotic signaling pathways and failure of rituximab to trigger the cells leading to inhibition of ADCC, CDC and chemo/immunosensitization. Interference with the hyperactivated pathways with various pharmacological and proteasome inhibitors reversed resistance. Furthermore, the above findings have identified several gene products that can serve as new prognostic/diagnostic biomarkers as well as targets for therapeutic intervention in B-NHL.	Univ Calif Los Angeles, David Geffen Sch Med, Jonsson Comprehens Canc Ctr, Dept Microbiol Mol Genet & Immunol, Los Angeles, CA 90095 USA	UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Bonavida, B (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Jonsson Comprehens Canc Ctr, Dept Microbiol Mol Genet & Immunol, Los Angeles, CA 90095 USA.	BBonavida@mednet.ucla.edu						Alas S, 2003, CLIN CANCER RES, V9, P316; Alas S, 2001, CANCER RES, V61, P5137; Alas S, 2001, CLIN CANCER RES, V7, P709; Baritaki S, 2007, MOL CANCER THER, V6, P1387, DOI 10.1158/1535-7163.MCT-06-0521; Bezombes C, 2004, BLOOD, V104, P1166, DOI 10.1182/blood-2004-01-0277; BLAY JY, 1993, EUR J IMMUNOL, V23, P768; Coiffier Bertrand, 2005, Clin Adv Hematol Oncol, V3, P484; Cragg Mark S., 2005, V8, P140; DEANS JP, 1995, J BIOL CHEM, V270, P22632, DOI 10.1074/jbc.270.38.22632; DEANS JP, 1993, J IMMUNOL, V151, P4494; Deans JP, 1998, J BIOL CHEM, V273, P344, DOI 10.1074/jbc.273.1.344; Deans JP, 2002, IMMUNOLOGY, V107, P176, DOI 10.1046/j.1365-2567.2002.01495.x; Demidem A, 1997, CANCER BIOTHER RADIO, V12, P177, DOI 10.1089/cbr.1997.12.177; Dixit V, 2002, CELL, V111, P615, DOI 10.1016/S0092-8674(02)01166-2; FISHER RI, 1993, NEW ENGL J MED, V328, P1002, DOI 10.1056/NEJM199304083281404; FREEDMAN AS, 1991, HEMATOL ONCOL CLIN N, V5, P871, DOI 10.1016/S0889-8588(18)30390-3; Garban HJ, 2001, J IMMUNOL, V167, P75, DOI 10.4049/jimmunol.167.1.75; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Golay J, 2001, BLOOD, V98, P3383, DOI 10.1182/blood.V98.12.3383; Haidar JH, 2003, EUR J HAEMATOL, V70, P330, DOI 10.1034/j.1600-0609.2003.00007.x; Hainsworth JD, 2004, SEMIN ONCOL, V31, P17, DOI 10.1053/j.seminoncol.2003.12.005; Huerta-Yepez S, 2004, ONCOGENE, V23, P4993, DOI 10.1038/sj.onc.1207655; Janas E, 2005, CLIN EXP IMMUNOL, V139, P439, DOI 10.1111/j.1365-2249.2005.02720.x; Jazirehi AR, 2007, CANCER RES, V67, P1270, DOI 10.1158/0008-5472.CAN-06-2184; Jazirehi AR, 2004, BLOOD, V104, p930A, DOI 10.1182/blood.V104.11.3410.3410; Jazirehi AR, 2005, ONCOGENE, V24, P2121, DOI 10.1038/sj.onc.1208349; Jazirehi AR, 2004, CANCER RES, V64, P7117, DOI 10.1158/0008-5472.CAN-03-3500; Jazirehi AR, 2003, MOL CANCER THER, V2, P1183; Jazirehi AR, 2005, CANCER RES, V65, P264; JAZIREHI AR, 2006, P AM ASS CANC RES, V47; Kennedy AD, 2003, BLOOD, V101, P1071, DOI 10.1182/blood-2002-03-0876; Kennedy AD, 2004, J IMMUNOL, V172, P3280, DOI 10.4049/jimmunol.172.5.3280; MANSHOURI T, 2003, LEUKEMIA LYMPHOMA, V44, pS15; REFF ME, 1994, BLOOD, V83, P435; Semac I, 2003, CANCER RES, V63, P534; Shan DM, 2000, CANCER IMMUNOL IMMUN, V48, P673, DOI 10.1007/s002620050016; SUZUKI E, 2007, IN PRESS ONCOGENE; Vega MI, 2005, ONCOGENE, V24, P8114, DOI 10.1038/sj.onc.1208954; Vega MI, 2005, J IMMUNOL, V175, P2174, DOI 10.4049/jimmunol.175.4.2174; Vega MI, 2004, ONCOGENE, V23, P3530, DOI 10.1038/sj.onc.1207336; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Xerri L, 1996, BRIT J HAEMATOL, V92, P900, DOI 10.1046/j.1365-2141.1996.423958.x; Yeung K, 2000, MOL CELL BIOL, V20, P3079, DOI 10.1128/MCB.20.9.3079-3085.2000; Yeung K, 1999, NATURE, V401, P173, DOI 10.1038/43686; Yeung KC, 2001, MOL CELL BIOL, V21, P7207, DOI 10.1128/MCB.21.21.7207-7217.2001	45	161	166	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2007	26	25					3629	3636		10.1038/sj.onc.1210365	http://dx.doi.org/10.1038/sj.onc.1210365			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	172PK	17530016				2022-12-28	WOS:000246816100005
J	Quereda, V; Martinalbo, J; Dubus, P; Carnero, A; Malumbres, M				Quereda, V.; Martinalbo, J.; Dubus, P.; Carnero, A.; Malumbres, M.			Genetic cooperation between p21(Cip1) and INK4 inhibitors in cellular senescence and tumor suppression	ONCOGENE			English	Article						cell-cycle inhibition; cyclin-dependent kinase; senescence; tumor development; p21(Cip1) and INK4 inhibitors	CYCLIN-DEPENDENT KINASES; HUMAN FIBROBLASTS; REPLICATIVE SENESCENCE; ONCOGENIC RAS; SKIN CARCINOGENESIS; MURINE FIBROBLASTS; MAMMALIAN-CELLS; CDK INHIBITORS; G(1) CONTROL; MICE	Cell-cycle inhibitors of the Cip/Kip and INK4 families are involved in cellular senescence and tumor suppression. Some of these proteins, p21(Cip1), p16(INK4a) and p15(INK4b), are coexpressed in response to antiproliferative signals such as cellular senescence resulting in cell-cycle arrest. To understand the roles of these inhibitors and their synergistic effect, we have characterized the growth properties and senescent behavior of primary cells deficient in p21Cip1 and expressing an endogenous Cdk4(R24C) (cyclin-dependent kinase) mutant (Cdk4R24C knock-in cells) insensitive to INK4 proteins. Inactivation of both p21Cip1 and INK4 pathways strongly cooperate in suppressing cellular senescence in vitro. These double mutant cells behavior as immortal cultures and display high sensitivity to cellular transformation by oncogenes. Moreover, mice double mutant in the INK4 and p21Cip1 pathways (Cdk4R24C; p21(Cip1)-null mice) display an increased incidence of specific sarcomas, suggesting a significant cooperation between these two families of cell-cycle inhibitors in senescence responses and tumor suppression in vivo.	[Quereda, V.; Martinalbo, J.; Malumbres, M.] Ctr Nacl Invest Oncol, Cell Div, E-28029 Madrid, Spain; [Quereda, V.; Martinalbo, J.; Malumbres, M.] Ctr Nacl Invest Oncol, Canc Grp, E-28029 Madrid, Spain; [Dubus, P.] Univ Bordeaux 2, EA2406, F-33076 Bordeaux, France; [Carnero, A.] CNIO, Assays Dev Grp, Madrid, Spain	UDICE-French Research Universities; Universite de Bordeaux; Centro Nacional de Investigaciones Oncologicas (CNIO)	Malumbres, M (corresponding author), Ctr Nacl Invest Oncol, Cell Div, Melchor Fernandez Almagro 3, E-28029 Madrid, Spain.	acarnero@cnio.es; malumbres@cnio.es	IBIS, CANCER/P-3323-2015; Quereda, Victor/J-8120-2019; Malumbres, Marcos/E-8834-2011	Quereda, Victor/0000-0002-9966-9104; Malumbres, Marcos/0000-0002-0829-6315; Dubus, Pierre/0000-0003-1803-4711; Carnero, Amancio/0000-0003-4357-3979				Adnane J, 2000, ONCOGENE, V19, P5338, DOI 10.1038/sj.onc.1203956; Alcorta DA, 1996, P NATL ACAD SCI USA, V93, P13742, DOI 10.1073/pnas.93.24.13742; Attwooll C, 2004, EMBO J, V23, P4709, DOI 10.1038/sj.emboj.7600481; Bagui TK, 2003, MOL CELL BIOL, V23, P7285, DOI 10.1128/MCB.23.20.7285-7290.2003; Bearss DJ, 2002, CANCER RES, V62, P2077; Braig M, 2006, CANCER RES, V66, P2881, DOI 10.1158/0008-5472.CAN-05-4006; Brown JP, 1997, SCIENCE, V277, P831, DOI 10.1126/science.277.5327.831; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Carnero A, 2000, NUCLEIC ACIDS RES, V28, P2234, DOI 10.1093/nar/28.11.2234; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; Coqueret O, 2003, TRENDS CELL BIOL, V13, P65, DOI 10.1016/S0962-8924(02)00043-0; Coqueret O, 2002, GENE, V299, P35, DOI 10.1016/S0378-1119(02)01055-7; Dannenberg JH, 2000, GENE DEV, V14, P3051, DOI 10.1101/gad.847700; De la Cueva E, 2006, ONCOGENE, V25, P4128, DOI 10.1038/sj.onc.1209432; Duan ZJ, 2005, MOL CELL BIOL, V25, P10338, DOI 10.1128/MCB.25.23.10338-10351.2005; Franciotta D, 1998, CEPHALALGIA, V18, P4, DOI 10.1046/j.1468-2982.1998.1801001-5.x; Franklin DS, 2000, MOL CELL BIOL, V20, P6147, DOI 10.1128/MCB.20.16.6147-6158.2000; Gregory V, 2002, VIROLOGY, V300, P1, DOI 10.1006/viro.2002.1513; Hannon GJ, 1999, SCIENCE, V283, P1129, DOI 10.1126/science.283.5405.1129; HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9; Janzen V, 2006, NATURE, V443, P421, DOI 10.1038/nature05159; Korenjak M, 2005, CURR OPIN GENET DEV, V15, P520, DOI 10.1016/j.gde.2005.07.001; Krimpenfort P, 2001, NATURE, V413, P83, DOI 10.1038/35092584; Krishnamurthy J, 2006, NATURE, V443, P453, DOI 10.1038/nature05092; Latres E, 2000, EMBO J, V19, P3496, DOI 10.1093/emboj/19.13.3496; Macaluso M, 2006, ONCOGENE, V25, P5263, DOI 10.1038/sj.onc.1209680; Malumbres M, 2004, CELL, V118, P493, DOI 10.1016/j.cell.2004.08.002; Malumbres M, 2005, TRENDS BIOCHEM SCI, V30, P630, DOI 10.1016/j.tibs.2005.09.005; Malumbres M, 2000, MOL CELL BIOL, V20, P2915, DOI 10.1128/MCB.20.8.2915-2925.2000; Malumbres M, 2001, NAT REV CANCER, V1, P222, DOI 10.1038/35106065; Malumbres Marcos, 2003, Prog Cell Cycle Res, V5, P5; Martin A, 2005, CANCER CELL, V7, P591, DOI 10.1016/j.ccr.2005.05.006; Martin J A, 2001, Iowa Orthop J, V21, P1; Martin-Caballero J, 2004, ONCOGENE, V23, P8231, DOI 10.1038/sj.onc.1207863; Martins CP, 2002, EMBO J, V21, P3739, DOI 10.1093/emboj/cdf364; McConnell BB, 1998, CURR BIOL, V8, P351, DOI 10.1016/S0960-9822(98)70137-X; Medcalf ASC, 1996, CANCER RES, V56, P4582; Molofsky AV, 2006, NATURE, V443, P448, DOI 10.1038/nature05091; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; Palmero I, 1997, ONCOGENE, V15, P495, DOI 10.1038/sj.onc.1201212; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; Pantoja C, 1999, ONCOGENE, V18, P4974, DOI 10.1038/sj.onc.1202880; Philipp J, 1999, ONCOGENE, V18, P4689, DOI 10.1038/sj.onc.1202840; Rane SG, 2002, MOL CELL BIOL, V22, P644, DOI 10.1128/MCB.22.2.644-656.2002; Rane SG, 1999, NAT GENET, V22, P44, DOI 10.1038/8751; Sage J, 2000, GENE DEV, V14, P3037, DOI 10.1101/gad.843200; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sharpless NE, 2001, NATURE, V413, P86, DOI 10.1038/35092592; Sherr CJ, 2000, CANCER RES, V60, P3689; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Sotillo R, 2001, P NATL ACAD SCI USA, V98, P13312, DOI 10.1073/pnas.241338598; Sotillo R, 2001, EMBO J, V20, P6637, DOI 10.1093/emboj/20.23.6637; Stein GH, 1999, MOL CELL BIOL, V19, P2109; Topley GI, 1999, P NATL ACAD SCI USA, V96, P9089, DOI 10.1073/pnas.96.16.9089; Vogt M, 1998, CELL GROWTH DIFFER, V9, P139; Wang YA, 1997, P NATL ACAD SCI USA, V94, P14590, DOI 10.1073/pnas.94.26.14590; Weinberg WC, 1999, CANCER RES, V59, P2050; WOLFEL T, 1995, SCIENCE, V269, P1281, DOI 10.1126/science.7652577; Yang WC, 2001, CANCER RES, V61, P565; Zindy F, 2000, MOL CELL BIOL, V20, P372, DOI 10.1128/MCB.20.1.372-378.2000	60	36	37	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 6	2007	26	55					7665	7674		10.1038/sj.onc.1210578	http://dx.doi.org/10.1038/sj.onc.1210578			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	239SK	17599058				2022-12-28	WOS:000251537800008
J	Capel, E; Flejou, JF; Hamelin, R				Capel, E.; Flejou, J-F; Hamelin, R.			Assessment of MLH1 promoter methylation in relation to gene expression requires specific analysis	ONCOGENE			English	Article						microsatellite instability; HNPCC; MLH1; promoter; methylation	MICROSATELLITE INSTABILITY; DNA; HMLH1; CPG; CANCER; HYPERMETHYLATION; PREDISPOSITION; MUTATIONS; REGION; TUMORS	About 15% of colorectal cancers are called MSI because they demonstrate microsatellite instability. In most sporadic MSI cases, the DNA mismatch repair (MMR) defect is due to methylation of the MLH1 promoter. In hereditary MSI cases, it is the consequence of germline mutations of one of the MMR genes. We analysed the MLH1 promoter for methylation using the methylation-specific PCR technique. With a previously described and widely used primer set, a number of samples with an intact MMR system were found to have methylated MLH1 promoter, a finding normally associated with lack of MLH1 expression. Another primer set, specific for a more proximal region of the promoter, gave results that correlated more closely with loss of MLH1 expression. We then conducted a survey of the literature on the subject, and a total of 161 articles were examined. Although it was shown as early as 1999 that absence of MLH1 expression correlated with methylation of the proximal but not distal regions of the MLH1 promoter, 60% of published studies analysed nonspecific regions. Our findings suggest that these studies are likely to have wrongly estimated the association between methylation of the MLH1 gene and the lack of its protein expression.	INSERM, U762, F-75010 Paris, France; Univ Paris 06, IFR65, Paris, France; Hop St Antoine, Serv Anat Pathol, Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; UDICE-French Research Universities; Sorbonne Universite	Hamelin, R (corresponding author), INSERM, U762, 27 rue Juliette Dodu, F-75010 Paris, France.	richard.hamelin@cephb.fr		Capel, Emilie/0000-0001-8396-2843				AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; Boland CR, 1998, CANCER RES, V58, P5248; Brennetot C, 2005, INT J CANCER, V113, P446, DOI 10.1002/ijc.20586; Deng GR, 1999, CANCER RES, V59, P2029; Eads CA, 1999, CANCER RES, V59, P2302; Esteller M, 2001, CANCER RES, V61, P3225; FEINBERG AP, 1983, NATURE, V301, P89, DOI 10.1038/301089a0; Fiegl H, 2004, CANCER EPIDEM BIOMAR, V13, P882; FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827; Gayet J, 2001, ONCOGENE, V20, P5025, DOI 10.1038/sj.onc.1204611; Grady WM, 2001, CANCER RES, V61, P900; Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; Jourdan F, 2003, VIRCHOWS ARCH, V443, P115, DOI 10.1007/s00428-003-0833-z; Kane MF, 1997, CANCER RES, V57, P808; Kass SU, 1997, TRENDS GENET, V13, P444, DOI 10.1016/S0168-9525(97)01268-7; Miyakura Y, 2001, GASTROENTEROLOGY, V121, P1300, DOI 10.1053/gast.2001.29616; Park SJ, 2003, AM J PATHOL, V162, P815, DOI 10.1016/S0002-9440(10)63878-3; Peltomaki P, 2004, DIS MARKERS, V20, P269, DOI 10.1155/2004/305058; Samowitz WS, 2005, GASTROENTEROLOGY, V129, P837, DOI 10.1053/j.gastro.2005.06.020; Suraweera N, 2002, GASTROENTEROLOGY, V123, P1804, DOI 10.1053/gast.2002.37070; Suzuki H, 1999, INT J CANCER, V83, P309, DOI 10.1002/(SICI)1097-0215(19991029)83:3<309::AID-IJC4>3.0.CO;2-Z; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; Xiong ZG, 1997, NUCLEIC ACIDS RES, V25, P2532, DOI 10.1093/nar/25.12.2532; Yamamoto H, 2001, CANCER RES, V61, P3139	28	50	51	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 29	2007	26	54					7596	7600		10.1038/sj.onc.1210581	http://dx.doi.org/10.1038/sj.onc.1210581			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	236DB	17546041				2022-12-28	WOS:000251282100013
J	Bruton, RK; Rasti, M; Mapp, KL; Young, N; Carter, RZ; Abramowicz, IA; Sedgwick, GG; Onion, DF; Shuen, M; Mymryk, JS; Turnell, AS; Grand, RJA				Bruton, R. K.; Rasti, M.; Mapp, K. L.; Young, N.; Carter, R. Z.; Abramowicz, I. A.; Sedgwick, G. G.; Onion, D. F.; Shuen, M.; Mymryk, J. S.; Turnell, A. S.; Grand, R. J. A.			C-terminal-binding protein interacting protein binds directly to adenovirus early region 1A through its N-terminal region and conserved region 3	ONCOGENE			English	Article						adenovirus E1A; C-terminal-binding protein; interacting protein; CtIP; C-terminal-binding protein; CtBP	E1A PROTEIN; DNA-DAMAGE; ONCOGENIC TRANSFORMATION; STRUCTURAL DETERMINANTS; TRANSCRIPTIONAL ADAPTER; CELLULAR PHOSPHOPROTEIN; SIMIAN ADENOVIRUSES; NEGATIVE MODULATION; MOLECULAR-CLONING; SEQUENCE-ANALYSIS	C-terminal-binding protein interacting protein (CtIP) was first isolated as a binding partner of C-terminal-binding protein (CtBP). It is considered to contribute to the transcriptional repression and cell cycle regulatory properties of the retinoblastoma (Rb) family of proteins and to have a role in the cellular response to DNA damage. Here, we have shown that CtIP is a novel target for the adenovirus oncoprotein early region 1A (AdE1A). AdE1A associates with CtIP in both Ad5E1-transformed cells and Ad5-infected cells and binds directly in glutathione-S-transferase pull-down assays. Two binding sites have been mapped on Ad5E1A - the N-terminal alpha-helical region ( residues 1 - 30) and conserved region 3(CR3) - the transcriptional activation domain. CtIP can bind AdE1A and CtBP independently, raising the possibility that ternary complexes exist in Ad-transformed and - infected cells. Significantly, reduction of CtIP expression with small interfering RNAs results in reduction of the ability of a Gal4 DNA-binding domain-CR3 construct to transactivate a Gal 4-responsive luciferase reporter and this effect is reversed by reduction of CtBP expression. Therefore, in this model, CtIP acts as a transcriptional co-activator of AdE1A when dissociated from CtBP, through the action of AdE1A. These data are consistent with observations that CtIP expression is induced by AdE1A during viral infection and that reduction of CtIP expression with RNA interference can retard virus replication. In addition, AdE1A causes disruption of the CtIP/Rb complex during viral infection by its interaction with CtIP, possibly contributing to transcriptional derepression.	Univ Birmingham, Sch Med, Canc Res UK, Inst Canc Studies, Birmingham B15 2TT, W Midlands, England; Univ Western Ontario, Dept Oncol & Microbiol & Immunol, London, ON N6A 3K7, Canada	Cancer Research UK; University of Birmingham; Western University (University of Western Ontario)	Grand, RJA (corresponding author), Univ Birmingham, Sch Med, Canc Res UK, Inst Canc Studies, Birmingham B15 2TT, W Midlands, England.	R.J.A.Grand@bham.ac.uk		Onion, David/0000-0002-4522-2307	Breast Cancer Now [2001:218] Funding Source: Medline	Breast Cancer Now		ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; Avvakumov N, 2004, VIROLOGY, V329, P477, DOI 10.1016/j.virol.2004.08.007; Avvakumov N, 2002, J VIROL, V76, P7968, DOI 10.1128/JVI.76.16.7968-7975.2002; Barral PM, 2005, FEBS LETT, V579, P2752, DOI 10.1016/j.febslet.2005.03.095; Berk AJ, 2005, ONCOGENE, V24, P7673, DOI 10.1038/sj.onc.1209040; BOYD JM, 1993, EMBO J, V12, P469, DOI 10.1002/j.1460-2075.1993.tb05679.x; Boyer TG, 1999, NATURE, V399, P276, DOI 10.1038/20466; Chen PL, 2005, MOL CELL BIOL, V25, P3535, DOI 10.1128/MCB.25.9.3535-3542.2005; Chinnadurai G, 2006, BBA-REV CANCER, V1765, P67, DOI 10.1016/j.bbcan.2005.09.002; Chinnadurai G, 2004, CURR TOP MICROBIOL, V273, P139; Chinnadurai G, 2002, MOL CELL, V9, P213, DOI 10.1016/S1097-2765(02)00443-4; CHINNADURAI G, 2007, IN PRESS INT J BIOCH; Chinnadurai G., 2006, CTBP FAMILY PROTEINS, P1; CULP JS, 1988, P NATL ACAD SCI USA, V85, P6450, DOI 10.1073/pnas.85.17.6450; DOUGLAS JL, 1991, ONCOGENE, V6, P2093; DYSON N, 1992, J VIROL, V66, P6893, DOI 10.1128/JVI.66.12.6893-6902.1992; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; EGAN C, 1988, MOL CELL BIOL, V8, P3955, DOI 10.1128/MCB.8.9.3955; Gallimore PH, 2001, ONCOGENE, V20, P7824, DOI 10.1038/sj.onc.1204913; GEISBERG JV, 1995, MOL CELL BIOL, V15, P6283; GEISBERG JV, 1994, P NATL ACAD SCI USA, V91, P2488, DOI 10.1073/pnas.91.7.2488; Grand RJA, 1998, VIROLOGY, V244, P230, DOI 10.1006/viro.1998.9081; GRAND RJA, 1984, J GEN VIROL, V65, P2149, DOI 10.1099/0022-1317-65-12-2149; GRAND RJA, 2006, LANDES BIOSCIENCE, P44; HOWE JA, 1990, P NATL ACAD SCI USA, V87, P5883, DOI 10.1073/pnas.87.15.5883; JELMSA TN, 1989, VIROLOGY, V171, P120; JONES N, 1995, CURR TOP MICROBIOL I, V199, P58; Li S, 2000, NATURE, V406, P210, DOI 10.1038/35018134; Li S, 1999, J BIOL CHEM, V274, P11334, DOI 10.1074/jbc.274.16.11334; Meloni AR, 1999, P NATL ACAD SCI USA, V96, P9574, DOI 10.1073/pnas.96.17.9574; Molloy DP, 1998, J BIOL CHEM, V273, P20867, DOI 10.1074/jbc.273.33.20867; Molloy DP, 2001, BBA-PROTEIN STRUCT M, V1546, P55, DOI 10.1016/S0167-4838(00)00071-6; Murakami P, 1999, ANAL BIOCHEM, V274, P283, DOI 10.1006/abio.1999.4282; Rasti M, 2005, J VIROL, V79, P5594, DOI 10.1128/JVI.79.9.5594-5605.2005; Rasti M, 2006, EMBO J, V25, P2710, DOI 10.1038/sj.emboj.7601169; Schaeper U, 1998, J BIOL CHEM, V273, P8549, DOI 10.1074/jbc.273.15.8549; SCHAEPER U, 1995, P NATL ACAD SCI USA, V92, P10467, DOI 10.1073/pnas.92.23.10467; SUBRAMANIAN T, 1991, ONCOGENE, V6, P1171; SUBRAMANIAN T, 1989, ONCOGENE, V4, P415; Sum EYM, 2002, J BIOL CHEM, V277, P7849, DOI 10.1074/jbc.M110603200; Turner J, 2001, BIOESSAYS, V23, P683, DOI 10.1002/bies.1097; Wang G, 2002, J VIROL, V76, P9186, DOI 10.1128/JVI.76.18.9186-9193.2002; WANG HGH, 1993, J VIROL, V67, P4804, DOI 10.1128/JVI.67.8.4804-4813.1993; WEBSTER LC, 1991, MOL CELL BIOL, V11, P4287, DOI 10.1128/MCB.11.9.4287; Wong AKC, 1998, ONCOGENE, V17, P2279, DOI 10.1038/sj.onc.1202150; Wu-Baer F, 2001, Nature, V414, P36, DOI 10.1038/35102118; Yu X, 1998, J BIOL CHEM, V273, P25388, DOI 10.1074/jbc.273.39.25388; Yu X, 2000, J BIOL CHEM, V275, P18541, DOI 10.1074/jbc.M909494199; Yu XC, 2004, MOL CELL BIOL, V24, P9478, DOI 10.1128/MCB.24.21.9478-9486.2004; Yu XC, 2006, GENE DEV, V20, P1721, DOI 10.1101/gad.1431006	50	9	9	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 22	2007	26	53					7467	7479		10.1038/sj.onc.1210551	http://dx.doi.org/10.1038/sj.onc.1210551			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	236DA	17546052				2022-12-28	WOS:000251282000008
J	Berman-Golan, D; Elson, A				Berman-Golan, D.; Elson, A.			Neu-mediated phosphorylation of protein tyrosine phosphatase epsilon is critical for activation of Src in mammary tumor cells	ONCOGENE			English	Article						tyrosine phosphatase; breast cancer; mammary tumor; Src; Neu	HUMAN BREAST-CANCER; FAMILY KINASES; PTP-ALPHA; C-SRC; RPTP-ALPHA; CYTOPLASMIC FORMS; TRANSGENIC MICE; IN-VIVO; RECEPTOR; PP60(C-SRC)	The receptor-type protein tyrosine phosphatase epsilon (RPTPe) activates c-Src in mammary tumor cells induced in vivo by Neu. Tumor cells lacking RPTPe exhibit reduced c-Src activity, appear less transformed morphologically and proliferate slower in vitro and in vivo. Expression of Src rescues most of these phenotypes, indicating that c-Src activity is important for maintaining the transformed phenotype. However, the molecular mechanisms that control activation of c-Src by RPTPe are unknown. We show that Neu induces phosphorylation of RPTPe exclusively at its C-terminal Y695, and that this phosphorylation is required for activation of c-Src by RPTPe. Phosphorylation of RPTPe does not affect its activity toward another substrate, the voltage-gated potassium channel Kv2.1, suggesting that phosphorylation directs RPTPe activity toward c-Src. Phosphorylation of RPTPe reduces its dimerization at the cell membrane, although this does not affect its activity significantly. RPTPe is subject to strong auto-and trans-dephosphorylation, suggesting that dephosphorylation limits the activation of c-Src downstream of Neu. We conclude that an Neu-RPTP epsilon-Src signaling pathway exists in mammary tumor cells, in which phosphorylation of RPTPe by Neu directs RPTPe to activate c-Src. Reversible phosphorylation of RPTPe at Y695 may thus function as a 'molecular switch', which affects the substrate specificity of the phosphatase.	Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Elson, A (corresponding author), Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel.	ari.elson@weizmann.ac.il		Elson, Ari/0000-0001-9808-9135				Belsches-Jablonski AP, 2001, ONCOGENE, V20, P1465, DOI 10.1038/sj.onc.1204205; Bodrikov V, 2005, J CELL BIOL, V168, P127, DOI 10.1083/jcb.200405073; Boggon TJ, 2004, ONCOGENE, V23, P7918, DOI 10.1038/sj.onc.1208081; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; Chong YP, 2005, GROWTH FACTORS, V23, P233, DOI 10.1080/08977190500178877; Cole PA, 2003, CURR OPIN CHEM BIOL, V7, P580, DOI 10.1016/j.cbpa.2003.08.009; DENHERTOG J, 1993, EMBO J, V12, P3789, DOI 10.1002/j.1460-2075.1993.tb06057.x; ELSON A, 1995, J BIOL CHEM, V270, P26116, DOI 10.1074/jbc.270.44.26116; Elson A, 1995, P NATL ACAD SCI USA, V92, P12235, DOI 10.1073/pnas.92.26.12235; Flint AJ, 1997, P NATL ACAD SCI USA, V94, P1680, DOI 10.1073/pnas.94.5.1680; Gil-Henn H, 2000, ONCOGENE, V19, P4375, DOI 10.1038/sj.onc.1203790; Gil-Henn H, 2001, J BIOL CHEM, V276, P31772, DOI 10.1074/jbc.M103395200; Gil-Henn H, 2003, J BIOL CHEM, V278, P15579, DOI 10.1074/jbc.M210273200; Granot-Attas S, 2004, EXP CELL RES, V294, P236, DOI 10.1016/j.yexcr.2003.11.003; Guo SL, 2004, P NATL ACAD SCI USA, V101, P14180, DOI 10.1073/pnas.0405878101; GUY CT, 1994, GENE DEV, V8, P23, DOI 10.1101/gad.8.1.23; Harder KW, 1998, J BIOL CHEM, V273, P31890, DOI 10.1074/jbc.273.48.31890; Kim H, 2005, ONCOGENE, V24, P7599, DOI 10.1038/sj.onc.1208898; Klinghoffer RA, 1999, EMBO J, V18, P2459, DOI 10.1093/emboj/18.9.2459; Lau KHW, 2006, J CELL BIOCHEM, V97, P940, DOI 10.1002/jcb.20667; Le Pera I, 2005, ONCOGENE, V24, P3187, DOI 10.1038/sj.onc.1208510; LUTTRELL DK, 1994, P NATL ACAD SCI USA, V91, P83, DOI 10.1073/pnas.91.1.83; Maksumova L, 2005, J IMMUNOL, V175, P7947, DOI 10.4049/jimmunol.175.12.7947; Meyer RD, 2002, J BIOL CHEM, V277, P27081, DOI 10.1074/jbc.M110544200; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; MUSTELIN T, 2002, SCI STKE, pPE3; MUTHUSWAMY SK, 1995, ONCOGENE, V11, P1801; MUTHUSWAMY SK, 1994, MOL CELL BIOL, V14, P735, DOI 10.1128/MCB.14.1.735; MUTHUSWAMY SK, 1995, ONCOGENE, V11, P271; Pallen CJ, 2003, CURR TOP MED CHEM, V3, P821, DOI 10.2174/1568026033452320; Peretz A, 2000, EMBO J, V19, P4036, DOI 10.1093/emboj/19.15.4036; Ponniah S, 1999, CURR BIOL, V9, P535, DOI 10.1016/S0960-9822(99)80238-3; Roskoski R, 2005, BIOCHEM BIOPH RES CO, V331, P1, DOI 10.1016/j.bbrc.2005.03.012; Su J, 1999, CURR BIOL, V9, P505, DOI 10.1016/S0960-9822(99)80234-6; Tiran Z, 2003, J BIOL CHEM, V278, P17509, DOI 10.1074/jbc.M212766200; Toledano-Katchalski H, 1999, ONCOGENE, V18, P5024, DOI 10.1038/sj.onc.1202883; Toledano-Katchalski H, 2003, MOL CELL BIOL, V23, P5460, DOI 10.1128/MCB.23.15.5460-5471.2003; TRACY S, 1995, J BIOL CHEM, V270, P10587, DOI 10.1074/jbc.270.18.10587; von Wichert G, 2003, J CELL BIOL, V161, P143, DOI 10.1083/jcb.200211061; Zeng L, 2003, J CELL BIOL, V160, P137, DOI 10.1083/jcb.200206049; Zheng XM, 2000, EMBO J, V19, P964, DOI 10.1093/emboj/19.5.964; Zheng XM, 2002, J BIOL CHEM, V277, P21922, DOI 10.1074/jbc.M201394200; Zheng XM, 2001, EMBO J, V20, P6037, DOI 10.1093/emboj/20.21.6037; ZHENG XM, 1992, NATURE, V359, P336, DOI 10.1038/359336a0	44	27	27	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT	2007	26	49					7028	7037		10.1038/sj.onc.1210505	http://dx.doi.org/10.1038/sj.onc.1210505			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	223YN	17486066				2022-12-28	WOS:000250412200008
J	Sano, A; Kage, H; Sugimoto, K; Kitagawa, H; Aki, N; Goto, A; Fukayama, M; Nakajima, J; Takamoto, S; Nagase, T; Yatomi, Y; Ohishi, N; Takai, D				Sano, A.; Kage, H.; Sugimoto, K.; Kitagawa, H.; Aki, N.; Goto, A.; Fukayama, M.; Nakajima, J.; Takamoto, S.; Nagase, T.; Yatomi, Y.; Ohishi, N.; Takai, D.			A second-generation profiling system for quantitative methylation analysis of multiple gene promoters: application to lung cancer	ONCOGENE			English	Article						lung cancer; DNA methylation; CpG islands; EGFR mutation; epigenetic change; real-time PCR	DNA METHYLATION; CPG-ISLANDS; CELL-LINES; PCR ASSAY; HYPERMETHYLATION; ADENOCARCINOMA; EXPRESSION; SURVIVAL; PATTERNS; DISPLAY	Cancer-specific gene promoter methylation has been described in many types of cancers, and various semi-quantified results have shown their usefulness. Here, we show a more sensitive and specific second-generation system for pro. ling the DNA methylation status. This method is based on bisulfate reaction of DNA and real-time PCR using two TaqMan MGB probes labeled with different fluorescence, followed by clustering analysis. Primers were designed with CpG-less sequences, and TaqMan MGB probes were designed to contain three or four CpG sites and to be shorter than conventional TaqMan probes. We have added new criteria for primer and probe design for further specificity. We confirmed the reliability of this system and applied it to analysis of lung cancers. Using 10 promoters, 90 primary lung cancers were clustered into six groups consisting of cases having similar smoking status and pathological findings. EGFR mutation and p16 promoter DNA methylation were exclusive, as previously reported; however, DNA methylation in other genes was unrelated to EGFR mutation. This system was also useful to distinguish double primary lung cancers from a single cancer with intrapulmonary metastasis. As above, our system has widespread availability in clinical use and biological research.	Tokyo Univ Hosp, Dept Clin Lab, Bunkyo Ku, Tokyo 113, Japan; Tokyo Univ Hosp, Dept Gen Thorac Surg, Bunkyo Ku, Tokyo 113, Japan; Tokyo Univ Hosp, Dept Med Res, Bunkyo Ku, Tokyo 113, Japan; Tokyo Univ Hosp, Dept Pathol, Bunkyo Ku, Tokyo 113, Japan	University of Tokyo; University of Tokyo; University of Tokyo; University of Tokyo	Takai, D (corresponding author), Tokyo Univ Hosp, Dept Clin Lab, Bunkyo Ku, 7-3-1 Hongo, Tokyo 113, Japan.	dtakai-ind@umin.ac.jp	Goto, Akiteru/P-5775-2014; Sano, Atsushi/E-5868-2013	Yatomi, Yutaka/0000-0003-1719-4297; Nakajima, Jun/0000-0003-1174-0816; Goto, Akiteru/0000-0001-8776-9004				Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; Brabender J, 2001, ONCOGENE, V20, P3528, DOI 10.1038/sj.onc.1204455; Chen GA, 2003, P NATL ACAD SCI USA, V100, P13537, DOI 10.1073/pnas.2233850100; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; de Hoon MJL, 2004, BIOINFORMATICS, V20, P1453, DOI 10.1093/bioinformatics/bth078; Eads CA, 2000, NUCLEIC ACIDS RES, V28, DOI 10.1093/nar/28.8.e32; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Feil R, 1999, TRENDS GENET, V15, P431, DOI 10.1016/S0168-9525(99)01822-3; FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827; Fukami T, 2003, INT J CANCER, V107, P53, DOI 10.1002/ijc.11348; Gu J, 2006, CLIN CANCER RES, V12, P7329, DOI 10.1158/1078-0432.CCR-06-0894; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Izumi H, 2005, HUM MOL GENET, V14, P997, DOI 10.1093/hmg/ddi092; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Kim YT, 2005, J THORAC CARDIOV SUR, V130, P1378, DOI 10.1016/j.jtcvs.2005.06.015; Kutyavin IV, 2000, NUCLEIC ACIDS RES, V28, P655, DOI 10.1093/nar/28.2.655; Lehmann U, 2001, LAB INVEST, V81, P635, DOI 10.1038/labinvest.3780272; MARTINI N, 1975, J THORAC CARDIOV SUR, V70, P606; Mitsudomi T, 1997, J THORAC CARDIOV SUR, V114, P354, DOI 10.1016/S0022-5223(97)70180-6; Panning B, 1998, CELL, V93, P305, DOI 10.1016/S0092-8674(00)81155-1; Safar AM, 2005, CLIN CANCER RES, V11, P4400, DOI 10.1158/1078-0432.CCR-04-2378; SAMBROOK J, 2001, MOL CLONING, V2, pCH9; Suzuki M, 2006, CANCER-AM CANCER SOC, V106, P2200, DOI 10.1002/cncr.21853; Takai D, 2002, P NATL ACAD SCI USA, V99, P3740, DOI 10.1073/pnas.052410099; Takai D, 2001, ONCOGENE, V20, P7505, DOI 10.1038/sj.onc.1204940; Toyooka S, 2006, CANCER RES, V66, P1371, DOI 10.1158/0008-5472.CAN-05-2625; Tsou JA, 2005, LUNG CANCER, V47, P193, DOI 10.1016/j.lungcan.2004.08.003; Ushijima T, 2005, NAT REV CANCER, V5, P223, DOI 10.1038/nrc1571; USUDA K, 1996, JAPANESE J LUNG CANC, V36, P359; Virmani AK, 2002, CANCER EPIDEM BIOMAR, V11, P291; Wang PZ, 2004, ADV CEM RES, V16, P1, DOI 10.1680/adcr.16.1.1.36257; Zeschnigk M, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh122	32	10	12	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2007	26	45					6518	6525		10.1038/sj.onc.1210483	http://dx.doi.org/10.1038/sj.onc.1210483			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	217AF	17452971				2022-12-28	WOS:000249919800005
J	Kanehira, M; Harada, Y; Takata, R; Shuin, T; Miki, T; Fujioka, T; Nakamura, Y; Katagiri, T				Kanehira, M.; Harada, Y.; Takata, R.; Shuin, T.; Miki, T.; Fujioka, T.; Nakamura, Y.; Katagiri, T.			Involvement of upregulation of DEPDC1 (DEP domain containing 1) in bladder carcinogenesis	ONCOGENE			English	Article						bladder cancer; cDNA microarray; molecular-target; small-interfering RNA	GENE-EXPRESSION; PROTEIN; CHEMOTHERAPY; GROWTH; GEMCITABINE; CARCINOMA; PATHWAYS; CANCERS; KINASE; DOMAIN	In an attempt to disclose mechanisms of bladder carcinogenesis and discover novel target molecules for development of treatment, we applied a cDNA microarray to screen genes that were significantly transactivated in bladder cancer cells. Among the upregulated genes, we here focused on a novel gene, (DEPDC1) DEP domain containing 1, whose overexpression was confirmed by northern blot and immunohistochemical analyses. Immunocytochemical staining analysis detected strong staining of endogenous DEPDC1 protein in the nucleus of bladder cancer cells. Since DEPDC1 expression was hardly detectable in any of 24 normal human tissues we examined except the testis, we considered this gene-product to be a novel cancer/testis antigen. Suppression of DEPDC1 expression with small-interfering RNA significantly inhibited growth of bladder cancer cells. Taken together, these findings suggest that DEPDC1 might play an essential role in the growth of bladder cancer cells, and would be a promising molecular-target for novel therapeutic drugs or cancer peptide-vaccine to bladder cancers.	Univ Tokyo, Inst Med Sci, Human Genome Ctr, Mol Med Lab,Minato Ku, Tokyo 108, Japan; Iwate Med Univ, Dept Urol, Morioka, Iwate 020, Japan; Kochi Med Sch, Dept Urol, Nankoku, Kochi, Japan; Kyoto Prefectural Univ Med, Dept Urol, Kamigyo Ku, Kyoto, Japan	University of Tokyo; Iwate Medical University; Kochi University; Kyoto Prefectural University of Medicine	Katagiri, T (corresponding author), Univ Tokyo, Inst Med Sci, Human Genome Ctr, Mol Med Lab,Minato Ku, 4-6-1 Shirokanedai, Tokyo 108, Japan.	tkatagi@ims.u-tokyo.ac.jp	Katagiri, Toyomasa/I-7344-2012	Kanehira, Mitsugu/0000-0001-8811-8158				Anazawa Y, 2005, CANCER RES, V65, P4578, DOI 10.1158/0008-5472.CAN-04-4564; Ardavanis A, 2005, BRIT J CANCER, V92, P645, DOI 10.1038/sj.bjc.6602378; Ashida S, 2006, CLIN CANCER RES, V12, P2767, DOI 10.1158/1078-0432.CCR-05-1995; Boutros M, 1998, CELL, V94, P109, DOI 10.1016/S0092-8674(00)81226-X; Hamamoto R, 2004, NAT CELL BIOL, V6, P731, DOI 10.1038/ncb1151; Kharrat A, 1998, BBA-PROTEIN STRUCT M, V1385, P157, DOI 10.1016/S0167-4838(98)00041-7; Lehmann J, 2002, WORLD J UROL, V20, P144, DOI 10.1007/s00345-002-0252-9; Li L, 1999, J BIOL CHEM, V274, P129, DOI 10.1074/jbc.274.1.129; Marty-Roix R, 2003, TISSUE ENG, V9, P175, DOI 10.1089/107632703762687654; Nagayama S, 2004, ONCOGENE, V23, P5551, DOI 10.1038/sj.onc.1207710; Nagayama S, 2005, ONCOGENE, V24, P6201, DOI 10.1038/sj.onc.1208780; Park JH, 2006, CANCER RES, V66, P9186, DOI 10.1158/0008-5472.CAN-06-1601; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Petricoin EF, 2002, NAT GENET, V32, P474, DOI 10.1038/ng1029; Ponting CP, 1996, TRENDS BIOCHEM SCI, V21, P245, DOI 10.1016/S0968-0004(96)30027-3; Rosenberg JE, 2005, J UROLOGY, V174, P14, DOI 10.1097/01.ju.0000162039.38023.5f; Saito-Hisaminato A, 2002, DNA RES, V9, P35, DOI 10.1093/dnares/9.2.35; Shima K, 2003, IEEE T ENERGY CONVER, V18, P63, DOI 10.1109/TEC.2002.808337; Shimo A, 2007, CANCER SCI, V98, P174, DOI 10.1111/j.1349-7006.2006.00381.x; STERNBERG CN, 1995, ANN ONCOL, V6, P113, DOI 10.1093/oxfordjournals.annonc.a059105; Takata R, 2005, CLIN CANCER RES, V11, P2625, DOI 10.1158/1078-0432.CCR-04-1988; Taniuchi K, 2005, CANCER RES, V65, P3092, DOI 10.1158/0008.5472.CAN-04-3646; Taniuchi K, 2005, CANCER RES, V65, P105; Theodore C, 2005, EUR J CANCER, V41, P1150, DOI 10.1016/j.ejca.2005.02.015; Togashi A, 2005, CANCER RES, V65, P4817, DOI 10.1158/0008-5472.CAN-05-0120; Vaughn DJ, 1999, SEMIN ONCOL, V26, P117	26	83	93	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 27	2007	26	44					6448	6455		10.1038/sj.onc.1210466	http://dx.doi.org/10.1038/sj.onc.1210466			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	214KY	17452976				2022-12-28	WOS:000249737600009
J	Clarke, AR; Jones, N; Pryde, F; Adachi, Y; Sansom, OJ				Clarke, A. R.; Jones, N.; Pryde, F.; Adachi, Y.; Sansom, O. J.			53BP1 deficiency in intestinal enterocytes does not alter the immediate response to ionizing radiation, but leads to increased nuclear area consistent with polyploidy	ONCOGENE			English	Article						polyploidy; 53BP1; mice; apoptosis; DNA damage; p53	DNA-DAMAGE CHECKPOINT; TUMOR-SUPPRESSOR; GENOMIC INSTABILITY; GAMMA-IRRADIATION; PROTEIN 53BP1; P53; ACTIVATION; APOPTOSIS; MICE; TUMORIGENESIS	The p53-binding protein 53BP1 has been implicated in the DNA damage response and genomic instability. Previous reports have highlighted these roles in vivo in haematopoietic lineages. To investigate the importance of 53BP1 to the DNA damage response in epithelial cells in vivo, we have investigated the role of 53BP1 in mediating apoptosis and proliferation within the murine small intestine following gamma-irradiation. 53BP1 deficiency does not affect the immediate response to gamma-irradiation with normal levels of apoptosis, proliferation and p53 and p21 accumulation. However, 48 h post-gamma-irradiation there was a significant accumulation of cells with much larger nuclei marked by p53 and p21 accumulation. These data reflect increases in polyploidy observed 53BP1 -/- deficient fibroblasts following gamma-irradiation. At 72 h post-irradiation both the 4N and 8N populations were significantly increased in 53BP1 -/- MEFS. Taken together, these results show that following in vivo exposure to gamma-irradiation, 53BP1 is dispensable for signalling apoptosis and cell-cycle arrest in the intestinal epithelium. However, it is important for prevention of genomic instability within this epithelial cell population.	Beatson Inst Canc Res, Glasgow G61 1BD, Lanark, Scotland; Univ Edinburgh, Wellcome Trust Ctr Cell Biol, Edinburgh, Midlothian, Scotland; Univ Cardiff Wales, Cardiff Sch Biosci, Inst Cell Biol, Cardiff, Wales	Beatson Institute; University of Edinburgh; Cardiff University	Sansom, OJ (corresponding author), Beatson Inst Canc Res, Garscube Estate,Switchback Rd, Glasgow G61 1BD, Lanark, Scotland.	o.sansom@beatson.gla.ac.uk	Clarke, Alan R/A-6256-2008; clarke, alan r/P-2820-2014	Sansom, Owen J./0000-0001-9540-3010; Adachi, Yasuhisa/0000-0003-4197-092X; Clarke, Alan/0000-0002-4281-426X	MRC [G0301154] Funding Source: UKRI; Medical Research Council [G0301154] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Anderson L, 2001, MOL CELL BIOL, V21, P1719, DOI 10.1128/MCB.21.5.1719-1729.2001; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; CLARKE AR, 1994, ONCOGENE, V9, P1767; Clarke AR, 1997, ONCOGENE, V14, P2015, DOI 10.1038/sj.onc.1201040; Derbyshire DJ, 2002, EMBO J, V21, P3863, DOI 10.1093/emboj/cdf383; DiTullio RA, 2002, NAT CELL BIOL, V4, P998, DOI 10.1038/ncb892; Fernandez-Capetillo O, 2002, NAT CELL BIOL, V4, P993, DOI 10.1038/ncb884; Finke D, 2001, CURR OPIN GENET DEV, V11, P561, DOI 10.1016/S0959-437X(00)00233-1; Fujiwara T, 2005, NATURE, V437, P1043, DOI 10.1038/nature04217; Gorgoulis VG, 2005, NATURE, V434, P907, DOI 10.1038/nature03485; IWABUCHI K, 1994, P NATL ACAD SCI USA, V91, P6098, DOI 10.1073/pnas.91.13.6098; Iwabuchi K, 1998, J BIOL CHEM, V273, P26061, DOI 10.1074/jbc.273.40.26061; Joo WS, 2002, GENE DEV, V16, P583, DOI 10.1101/gad.959202; Lanni JS, 1998, MOL CELL BIOL, V18, P1055, DOI 10.1128/MCB.18.2.1055; Marshman E, 2001, J PATHOL, V195, P285; Merritt AJ, 1997, ONCOGENE, V14, P2759, DOI 10.1038/sj.onc.1201126; Morales JC, 2006, P NATL ACAD SCI USA, V103, P3310, DOI 10.1073/pnas.0511259103; Morales JC, 2003, J BIOL CHEM, V278, P14971, DOI 10.1074/jbc.M212484200; Motohashi Y, 2004, NUTR METAB CARDIOVAS, V14, P6, DOI 10.1016/S0939-4753(04)80041-3; Pryde F, 2005, J CELL SCI, V118, P2043, DOI 10.1242/jcs.02336; Rappold I, 2001, J CELL BIOL, V153, P613, DOI 10.1083/jcb.153.3.613; Sansom OJ, 2000, MUTAT RES-FUND MOL M, V452, P149, DOI 10.1016/S0027-5107(00)00089-0; Sansom OJ, 2004, GENE DEV, V18, P1385, DOI 10.1101/gad.287404; Schultz LB, 2000, J CELL BIOL, V151, P1381, DOI 10.1083/jcb.151.7.1381; Senger P, 2004, PROG PART NUCL PHYS, V53, P1, DOI 10.1016/j.ppnp.2004.02.005; Shi QH, 2005, NATURE, V437, P1038, DOI 10.1038/nature03958; Shigeta T, 1999, CANCER RES, V59, P2602; Strathdee G, 2001, ONCOGENE, V20, P1923, DOI 10.1038/sj.onc.1204276; Wang B, 2002, SCIENCE, V298, P1435, DOI 10.1126/science.1076182; Ward IM, 2003, MOL CELL BIOL, V23, P2556, DOI 10.1128/MCB.23.7.2556-2563.2003; Ward IM, 2005, MOL CELL BIOL, V25, P10079, DOI 10.1128/MCB.25.22.10079-10086.2005; Ward IM, 2004, J CELL BIOL, V165, P459, DOI 10.1083/jcb.200403021	32	13	14	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 20	2007	26	43					6349	6355		10.1038/sj.onc.1210457	http://dx.doi.org/10.1038/sj.onc.1210457			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	212GW	17452983				2022-12-28	WOS:000249583300011
J	Gonin-Laurent, N; Hadj-Hamou, NS; Vogt, N; Houdayer, C; Gauthiers-Villars, M; Dehainault, C; Sastre-Garau, X; Chevillard, S; Malfoy, B				Gonin-Laurent, N.; Hadj-Hamou, N. S.; Vogt, N.; Houdayer, C.; Gauthiers-Villars, M.; Dehainault, C.; Sastre-Garau, X.; Chevillard, S.; Malfoy, B.			RB1 and TP53 pathways in radiation-induced sarcomas	ONCOGENE			English	Article						ionising radiation; sarcoma; RB1; TP53; CDKN2A; MDMX	SOLID TUMORS; SOFT-TISSUE; PROMOTER METHYLATION; ORAL-CANCER; P53 PATHWAY; MDM2 GENES; RETINOBLASTOMA; OSTEOSARCOMA; INACTIVATION; EXPRESSION	The tumour suppressor genes, TP53 and RB1, and four genes involved in their regulation, INK4a, ARF, MDM2 and MDMX, were analysed in a series of 36 post-radiotherapy radiation- induced sarcomas. One- third of the tumours developed in patients carrying a germline mutation of RB1 that predisposed them to retinoblastoma and radiation- induced sarcomas. The genetic inactivation of RB1 and/ or TP53 genes was frequently observed in these sarcomas. These inactivations were owing to an interplay between point mutations and losses of large chromosome segments. Radiation- induced somatic mutations were observed in TP53, but not in RB1 or in the four other genes, indicating an early role of TP53 in the radio- sarcomagenesis. RB1 and TP53 genes were biallelically coinactivated in all sarcomas developing in the context of the predisposition, indicating that both genes played a major role in the formation of these sarcomas. In the absence of predisposition, TP53 was biallelically inactivated in one- third of the sarcomas, whereas at least one allele of RB1 was wild type. In both genetic contexts, the TP53 pathway was inactivated by genetic lesions and not by the activation of the ARF / MDM2/ MDMX pathway, as recently shown in retinoblastomas. Together, these findings highlight the intricate tissue- and aetiology-specific relationships between TP53 and RB1 pathways in tumorigenesis.	CNRS, UMR 7147, Paris 05, France; Ctr Rech, Inst Curie, Paris, France; Univ Paris 06, Paris, France; Inst Curie, Dept Genet, Paris, France; Inst Curie, Dept Pathol, Paris, France; DRR, DSV, CEA, Fontenay Aux Roses, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; UDICE-French Research Universities; Sorbonne Universite; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; CEA	Malfoy, B (corresponding author), CNRS, UMR 7147, 26 Rue Ulm, Paris 05, France.	bernard.malfoy@curie.fr	Britzen-Laurent, Nathalie/M-3982-2013	Britzen-Laurent, Nathalie/0000-0002-0494-7117; Sastre-Garau, Xavier/0000-0001-5992-2083; Chevillard, Sylvie/0000-0001-5889-4041				Aerts I, 2004, EUR J CANCER, V40, P1522, DOI 10.1016/j.ejca.2004.03.023; Chatterjee SJ, 2004, J PATHOL, V203, P762, DOI 10.1002/path.1567; Danovi D, 2004, MOL CELL BIOL, V24, P5835, DOI 10.1128/MCB.24.13.5835-5843.2004; Gonin-Laurent N, 2006, CARCINOGENESIS, V27, P1266, DOI 10.1093/carcin/bgi356; Goodrich DW, 2006, ONCOGENE, V25, P5233, DOI 10.1038/sj.onc.1209616; Houdayer C, 2004, HUM MUTAT, V23, P193, DOI 10.1002/humu.10303; Kato MV, 1996, CANCER LETT, V106, P75, DOI 10.1016/0304-3835(96)04305-4; Kawaguchi K, 2006, MODERN PATHOL, V19, P106, DOI 10.1038/modpathol.3800502; Kawaguchi K, 2003, J PATHOL, V201, P487, DOI 10.1002/path.1419; Kawaguchi K, 2002, MODERN PATHOL, V15, P878, DOI 10.1097/01.MP.0000024264.48690.EA; Kleinerman RA, 2005, J CLIN ONCOL, V23, P2272, DOI 10.1200/JCO.2005.05.054; Knudson AG, 2001, NAT REV CANCER, V1, P157, DOI 10.1038/35101031; Laurie NA, 2006, NATURE, V444, P61, DOI 10.1038/nature05194; Lavin MF, 2006, CELL DEATH DIFFER, V13, P941, DOI 10.1038/sj.cdd.4401925; Lefevre SH, 2001, ONCOGENE, V20, P8092, DOI 10.1038/sj.onc.1205009; Marine JC, 2004, CELL CYCLE, V3, P900; Menu-Branthomme A, 2004, INT J CANCER, V110, P87, DOI 10.1002/ijc.20002; Miller CW, 1996, J CANCER RES CLIN, V122, P559, DOI 10.1007/BF01213553; Moysich KB, 2002, LANCET ONCOL, V3, P269, DOI 10.1016/S1470-2045(02)00727-1; PatinoGarcia A, 1997, CANCER GENET CYTOGEN, V98, P50, DOI 10.1016/S0165-4608(96)00397-4; Perucca-Lostanlen D, 2004, GENE CHROMOSOME CANC, V39, P99, DOI 10.1002/gcc.10303; Ramos YFM, 2001, CANCER RES, V61, P1839; Sartor M, 1999, BRIT J CANCER, V80, P79, DOI 10.1038/sj.bjc.6690505; Sharpless NE, 2005, MUTAT RES-FUND MOL M, V576, P22, DOI 10.1016/j.mrfmmm.2004.08.021; Shaw RJ, 2006, BRIT J CANCER, V94, P561, DOI 10.1038/sj.bjc.6602972; Toledo F, 2006, NAT REV CANCER, V6, P909, DOI 10.1038/nrc2012; Travis LB, 2002, ACTA ONCOL, V41, P323, DOI 10.1080/028418602760169361; Tsuchiya T, 2000, CANCER GENET CYTOGEN, V120, P91, DOI 10.1016/S0165-4608(99)00255-1; Wakeford R, 2004, ONCOGENE, V23, P6404, DOI 10.1038/sj.onc.1207896	29	32	33	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP	2007	26	41					6106	6112		10.1038/sj.onc.1210404	http://dx.doi.org/10.1038/sj.onc.1210404			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	207US	17369843				2022-12-28	WOS:000249277200014
J	Matsubara, H; Takeuchi, T; Nishikawa, E; Yanagisawa, K; Hayashita, Y; Ebi, H; Yamada, H; Suzuki, M; Nagino, M; Nimura, Y; Osada, H; Takahashi, T				Matsubara, H.; Takeuchi, T.; Nishikawa, E.; Yanagisawa, K.; Hayashita, Y.; Ebi, H.; Yamada, H.; Suzuki, M.; Nagino, M.; Nimura, Y.; Osada, H.; Takahashi, T.			Apoptosis induction by antisense oligonucleotides against miR-17-5p and miR-20a in lung cancers overexpressing miR-17-92	ONCOGENE			English	Article						miRNA; lung cancer; antisense; apoptosis	MESSENGER-RNA; MICRORNAS; MECHANISM	Amplification and overexpression of the miR- 17- 92 microRNAs ( miRNA) cluster at 13q31.3 has recently reported, with pointers to functional involvement in the development of B- cell lymphomas and lung cancers. In the present study, we show that inhibition of miR- 17- 5p and miR- 20a with antisense oligonucleotides ( ONs) can induce apoptosis selectively in lung cancer cells overexpressing miR- 17- 92, suggesting the possibility of 'Oncomi R addiction to expression of these miRNAs in a subset of lung cancers. In marked contrast, antisense ONs against miR-18a and miR- 19a did not exhibit such inhibitory effects, whereas inhibition of miR-92-1 resulted in only modest reduction of cell growth, showing significant distinctions among miRNAs of the miR- 17- 92 cluster in terms of their roles in cancer cell growth. During the course of this study, we also found that enforced expression of a genomic region, termed C2, residing 30 to miR- 17- 92 in the intron 3 of C13orf25 led to marked growth inhibition in association with double stranded RNA- dependent protein kinase activation. Finally, this study also revealed that the vast majority of C13orf25 transcripts are detected as Drosha- processed cleavage products on Northern blot analysis and that a novel polyadenylation site is present 30 to the miR- 17- 92 cluster and 50 to the C2 region. Taken together, the present findings contribute towards better understanding of the oncogenic roles of miR- 17- 92, which might ultimately lead to the future translation into clinical applications.	Nagoya Univ, Grad Sch Med, Ctr Neurol Dis & Canc, Div Mol Carcinogenesis,Showa Ku, Nagoya, Aichi 4668550, Japan; Nagoya Univ, Grad Sch Med, Ctr Neurol Dis & Canc, Dept Surg Oncol,Showa Ku, Nagoya, Aichi, Japan; Aichi Canc Ctr, Res Inst, Div Mol Oncol, Nagoya, Aichi, Japan	Nagoya University; Nagoya University; Aichi Cancer Center	Takahashi, T (corresponding author), Nagoya Univ, Grad Sch Med, Ctr Neurol Dis & Canc, Div Mol Carcinogenesis,Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 4668550, Japan.	tak@med.nagoya-u.ac.jp	Suzuki, Motoshi/I-7246-2014; Takahashi, Takashi/I-7262-2014; Yanagisawa, Kiyoshi/I-7263-2014; Nagino, Masato/I-7342-2014; Osada, Hiroyuki/AAY-6254-2020; Ebi, Hiromichi/AAA-7358-2019	Suzuki, Motoshi/0000-0003-0682-5006; Takahashi, Takashi/0000-0003-0615-7001; Ebi, Hiromichi/0000-0003-3155-7576				Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Bommer UA, 2002, RNA, V8, P478, DOI 10.1017/S1355838202022586; Cullen BR, 2004, MOL CELL, V16, P861, DOI 10.1016/j.molcel.2004.12.002; Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840; Gil J, 2000, APOPTOSIS, V5, P107, DOI 10.1023/A:1009664109241; Gleave ME, 2005, NAT REV CANCER, V5, P468, DOI 10.1038/nrc1631; Hayashita Y, 2005, CANCER RES, V65, P9628, DOI 10.1158/0008-5472.CAN-05-2352; He L, 2005, NATURE, V435, P828, DOI 10.1038/nature03552; Johnson SM, 2005, CELL, V120, P635, DOI 10.1016/j.cell.2005.01.014; Krutzfeldt J, 2005, NATURE, V438, P685, DOI 10.1038/nature04303; Macleod K, 1999, CURR OPIN GENET DEV, V9, P31, DOI 10.1016/S0959-437X(99)80005-7; Maeno K, 2006, ONCOGENE, V25, P271, DOI 10.1038/sj.onc.1209018; MEURS EF, 1993, P NATL ACAD SCI USA, V90, P232, DOI 10.1073/pnas.90.1.232; O'Donnell KA, 2005, NATURE, V435, P839, DOI 10.1038/nature03677; Ota A, 2004, CANCER RES, V64, P3087, DOI 10.1158/0008-5472.CAN-03-3773; Takamizawa J, 2004, CANCER RES, V64, P3753, DOI 10.1158/0008-5472.CAN-04-0637; Zamore PD, 2005, SCIENCE, V309, P1519, DOI 10.1126/science.1111444; Zarudnaya MI, 2003, NUCLEIC ACIDS RES, V31, P1375, DOI 10.1093/nar/gkg241	19	281	321	1	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2007	26	41					6099	6105		10.1038/sj.onc.1210425	http://dx.doi.org/10.1038/sj.onc.1210425			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	207US	17384677				2022-12-28	WOS:000249277200013
J	Sakakura, C; Miyagawa, K; Fukuda, KI; Nakashima, S; Yoshikawa, T; Kin, S; Nakase, Y; Ida, H; Yazumi, S; Yamagishi, H; Okanoue, T; Chiba, T; Ito, K; Hagiwara, A; Ito, Y				Sakakura, C.; Miyagawa, K.; Fukuda, K. I.; Nakashima, S.; Yoshikawa, T.; Kin, S.; Nakase, Y.; Ida, H.; Yazumi, S.; Yamagishi, H.; Okanoue, T.; Chiba, T.; Ito, K.; Hagiwara, A.; Ito, Y.			Frequent silencing of RUNX3 in esophageal squamous cell carcinomas is associated with radioresistance and poor prognosis	ONCOGENE			English	Article						radioresistance; esophageal cancer; RUNX3; methylation	GROWTH-FACTOR-BETA; GENE-EXPRESSION PROFILES; GASTRIC-CANCER; RADIATION SENSITIVITY; EPITHELIAL-CELLS; TUMOR-SUPPRESSOR; APOPTOSIS; RADIOSENSITIVITY; CLASSIFICATION; COOPERATION	Radiotherapy is an effective treatment for some esophageal cancers, but the molecular mechanisms of radiosensitivity remain unknown. RUNX3, a novel tumor suppressor of gastric cancer, functions in transforming growth factor ( TGF)-beta-dependent apoptosis. We obtained paired samples from 62 patients with advanced esophageal cancers diagnosed initially as T3 or T4 with image diagnosis; one sample was obtained from a biopsy before presurgical radiotherapy, and the other was resected in surgical specimens after radiotherapy. RUNX3 was repressed in 67.7% cases of the pretreatment biopsy samples and 96.7% cases of the irradiated, resected samples. The nuclear expression of RUNX3 was associated with radiosensitivity and a better prognosis than cytoplasmic or no RUNX3 expression ( P < 0.003); cytoplasmic RUNX3 expression was strictly associated with radioresistance. RUNX3 was downregulated and its promoter was hypermethylated in all radioresistant esophageal cancer cell lines examined. Stable transfection of esophageal cancer cells with RUNX3 slightly inhibited cell proliferation in vitro, enhanced the antiproliferative and apoptotic effects of TGF-beta and increased radiosensitivity in conjunction with Bim induction. In contrast, transfection of RUNX3-expressing cells with a RUNX3 antisense construct or a Bim-specific small interfering RNA induced radioresistance. Treatment with 5-aza-2'-deoxycytidine restored RUNX3 expression, increased radiosensitivity and induced Bim in both control and radioresistant cells. These results suggest that RUNX3 silencing promotes radioresistance in esophageal cancers. Examination of RUNX3 expression in pretreatment specimens may predict radiosensitivity, and induction of RUNX3 expression may increase tumor radiosensitivity.	Kyoto Prefectural Univ Med, Grad Sch Med Sci, Div Surg & Physiol Digest Syst, Dept Surg & Regenerat Med,Kamigyo Ku, Kyoto 6028566, Japan; Kyoto Univ, Grad Sch Internal Med, Div Gastroenterol & Hepatol, Sakyo Ku, Kyoto, Japan; Kyoto Prefectural Univ Med, Grad Sch Med Sci, Div Surg & Oncol Digest Syst, Dept Surg & Regenerat Med,Kamigyo Ku, Kyoto 6028566, Japan; Kyoto Prefectural Univ Med, Grad Sch Internal Med, Div Gastroenterol, Kamigyo Ku, Kyoto 6028566, Japan; Natl Univ Singapore, Inst Mol & Cell Biol, Singapore 117548, Singapore	Kyoto Prefectural University of Medicine; Kyoto University; Kyoto Prefectural University of Medicine; Kyoto Prefectural University of Medicine; Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore	Sakakura, C (corresponding author), Kyoto Prefectural Univ Med, Grad Sch Med Sci, Div Surg & Oncol Digest Syst, Dept Surg & Regenerat Med,Kamigyo Ku, Kawaramachi Dori, Kyoto 6028566, Japan.	sakakura@koto.kpu-m.ac.jp		Nakase, Yuen/0000-0002-2351-2709				Alcock RA, 2002, ONCOGENE, V21, P7883, DOI 10.1038/sj.onc.1205948; BIARD DSF, 1994, CANCER RES, V54, P3361; Chi XZ, 2005, MOL CELL BIOL, V25, P8097, DOI 10.1128/MCB.25.18.8097-8107.2005; Coleman C N, 1996, Oncology (Williston Park), V10, P399; DEWEY WC, 1995, INT J RADIAT ONCOL, V33, P781, DOI 10.1016/0360-3016(95)00214-8; EIFEL PJ, 1994, INT J RADIAT ONCOL, V29, P9, DOI 10.1016/0360-3016(94)90220-8; Ewan KB, 2002, CANCER RES, V62, P5627; Fukuchi M, 2002, CANCER, V95, P737, DOI 10.1002/cncr.10727; Fukuda K, 2004, BRIT J CANCER, V91, P1543, DOI 10.1038/sj.bjc.6602187; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hanai J, 1999, J BIOL CHEM, V274, P31577, DOI 10.1074/jbc.274.44.31577; Hanna E, 2001, CANCER RES, V61, P2376; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Hsiao M, 1997, BIOCHEM BIOPH RES CO, V233, P329, DOI 10.1006/bbrc.1997.6450; Ito K, 2005, CANCER RES, V65, P7743, DOI 10.1158/0008-5472.CAN-05-0743; *JAP SOC ES DIS, 1999, GEN RUL CLIN PATH ST; KASID U, 1987, SCIENCE, V237, P1039, DOI 10.1126/science.3616625; Kim AH, 2003, INT J ONCOL, V23, P1593; Kim WJ, 2005, CANCER RES, V65, P9347, DOI 10.1158/0008-5472.CAN-05-1647; Kitada S, 1996, ONCOGENE, V12, P187; Kitahara O, 2002, NEOPLASIA, V4, P295, DOI 10.1038/sj.neo.7900251; Li QL, 2002, CELL, V109, P113, DOI 10.1016/S0092-8674(02)00690-6; Maity A, 1997, INT J RADIAT ONCOL, V37, P639, DOI 10.1016/S0360-3016(96)00598-6; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; Matsumura Y, 1997, CANCER LETT, V115, P91, DOI 10.1016/S0304-3835(97)04714-9; Meyn RE, 1996, CANCER METAST REV, V15, P119, DOI 10.1007/BF00049491; Nakase Y, 2005, BRIT J CANCER, V92, P562, DOI 10.1038/sj.bjc.6602372; Natsugoe S, 2002, CLIN CANCER RES, V8, P1838; NISHIHIRA T, 1993, J CANCER RES CLIN, V119, P441, DOI 10.1007/BF01215923; Sakai K, 1996, PROTEIN EXPRES PURIF, V7, P67, DOI 10.1006/prep.1996.0010; SAKAKURA C, 1994, P NATL ACAD SCI USA, V91, P11723, DOI 10.1073/pnas.91.24.11723; Sakakura C, 2005, CLIN CANCER RES, V11, P6479, DOI 10.1158/1078-0432.CCR-05-0729; Sakakura C, 2002, BRIT J CANCER, V87, P1153, DOI 10.1038/sj.bjc.6600580; SHIMADA Y, 1992, CANCER, V69, P277, DOI 10.1002/1097-0142(19920115)69:2<277::AID-CNCR2820690202>3.0.CO;2-C; SINCLAIR WK, 1966, RADIAT RES, V29, P450, DOI 10.2307/3572025; SKLAR MD, 1988, SCIENCE, V239, P645, DOI 10.1126/science.3277276; Sobin LH, 1997, CANCER, V80, P1803, DOI 10.1002/(SICI)1097-0142(19971101)80:9<1803::AID-CNCR16>3.0.CO;2-9; Vodovotz Y, 2000, INT J CANCER, V90, P13, DOI 10.1002/(SICI)1097-0215(20000220)90:1<13::AID-IJC2>3.3.CO;2-L; Willis SN, 2005, CURR OPIN CELL BIOL, V17, P617, DOI 10.1016/j.ceb.2005.10.001; Yamamura Y, 2006, J BIOL CHEM, V281, P5267, DOI 10.1074/jbc.M512151200; Yano T, 2006, MOL CELL BIOL, V26, P4474, DOI 10.1128/MCB.01926-05	41	46	47	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 30	2007	26	40					5927	5938		10.1038/sj.onc.1210403	http://dx.doi.org/10.1038/sj.onc.1210403			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	205OH	17384682				2022-12-28	WOS:000249123100010
J	Tomlinson, D; Hurst, CD; Knowles, MA				Tomlinson, D. C.; Hurst, C. D.; Knowles, M. A.			Knockdown by shRNA identifes S249C mutant FGFR3 as a potential therapeutic target in bladder cancer	ONCOGENE			English	Article						FGFR3; urothelial cell carcinoma; shRNA; therapeutic target	GROWTH-FACTOR RECEPTOR-3; UROTHELIAL CELL-CARCINOMA; MULTIPLE-MYELOMA PATIENTS; ACTIVATING MUTATIONS; GENE-MUTATIONS; TUMOR PROGRESSION; STAT ACTIVATION; LOW-GRADE; EXPRESSION; PROLIFERATION	More than 60% of low-grade non-invasive papillary urothelial cell carcinomas contain activating point mutations of fibroblast growth factor receptor 3 ( FGFR3). The phenotypic consequences of constitutive activation of FGFR3 in bladder cancer have not been elucidated and further studies are required to con. firm the consequences of inhibiting receptor activity in urothelial cells. We measured FGFR3 transcript levels and demonstrated that transcript levels were significantly more abundant in low-stage and grade tumours. We identified a tumour cell line, 97-7, expressing the most common FGFR3 mutation ( S249C) at similar FGFR3 transcript levels to low-stage and grade tumours. In these cells, S249C FGFR3 protein formed stable homodimers and was constitutively phosphorylated. We used retrovirus-mediated delivery of shRNA to knockdown S249C FGFR3. This induced cell. flattening, decreased cell proliferation and reduced clonogenicity on plastic and in soft agar. However, no effects of knockdown of wild-type FGFR3 were observed in telomerase immortalized normal human urothelial cells, indicating possible dependence of the tumour cell line on mutant FGFR3. Re-expression of S249C FGFR3 in shRNA-expressing 97-7 cells resulted in a reversal of phenotypic changes, con. firming the specificity of the shRNA. These results indicate that targeted inhibition of S249C FGFR3 may represent a useful therapeutic approach in superficial bladder cancer.	St James Univ Hosp, Leeds Inst Mol Med, Canc Res UK Clin Ctr, Leeds LS9 7TF, W Yorkshire, England	Cancer Research UK; Saint James's University Hospital; University of Leeds	Knowles, MA (corresponding author), St James Univ Hosp, Leeds Inst Mol Med, Canc Res UK Clin Ctr, Beckett St, Leeds LS9 7TF, W Yorkshire, England.	margaret.knowles@cancer.org.uk		Knowles, Margaret/0000-0002-9363-8657; Tomlinson, Darren/0000-0003-4134-7484	Cancer Research UK [A5433] Funding Source: Medline	Cancer Research UK(Cancer Research UK)		Adar R, 2002, J BONE MINER RES, V17, P860, DOI 10.1359/jbmr.2002.17.5.860; Bakkar AA, 2003, CANCER RES, V63, P8108; Bernard-Pierrot I, 2006, CARCINOGENESIS, V27, P740, DOI 10.1093/carcin/bgi290; Billerey C, 2001, AM J PATHOL, V158, P1955, DOI 10.1016/S0002-9440(10)64665-2; Birmingham A, 2006, NAT METHODS, V3, P199, DOI 10.1038/NMETH854; Cappellen D, 1999, NAT GENET, V23, P18, DOI 10.1038/12615; Chapman EJ, 2006, ONCOGENE, V25, P5037, DOI 10.1038/sj.onc.1209513; Chen J, 2005, ONCOGENE, V24, P8259, DOI 10.1038/sj.onc.1208989; Chesi M, 2002, CURR OPIN HEMATOL, V9, P288, DOI 10.1097/00062752-200207000-00005; Chesi M, 1998, BLOOD, V92, P3025, DOI 10.1182/blood.V92.9.3025.421k53_3025_3034; Chesi M, 1997, NAT GENET, V16, P260, DOI 10.1038/ng0797-260; Chesi M, 2001, BLOOD, V97, P729, DOI 10.1182/blood.V97.3.729; Davies-Adetugbo AA, 1998, TROP MED INT HEALTH, V3, P9, DOI 10.1046/j.1365-3156.1998.00162.x; Eswarakumar VP, 2005, CYTOKINE GROWTH F R, V16, P139, DOI 10.1016/j.cytogfr.2005.01.001; Gomez-Roman JJ, 2005, CLIN CANCER RES, V11, P459; Grand EK, 2004, LEUKEMIA, V18, P962, DOI 10.1038/sj.leu.2403347; Hart KC, 2000, ONCOGENE, V19, P3309, DOI 10.1038/sj.onc.1203650; Hart KC, 2001, MOL BIOL CELL, V12, P931, DOI 10.1091/mbc.12.4.931; HOLMANG S, 1995, J UROLOGY, V153, P1823, DOI 10.1016/S0022-5347(01)67321-X; HOLMANG S, 1995, J UROLOGY, V153, P1826; Intini D, 2001, BRIT J HAEMATOL, V114, P362, DOI 10.1046/j.1365-2141.2001.02957.x; Jebar AH, 2005, ONCOGENE, V24, P5218, DOI 10.1038/sj.onc.1208705; Keats JJ, 2005, BLOOD, V105, P4060, DOI 10.1182/blood-2004-09-3704; Kimura T, 2001, CANCER-AM CANCER SOC, V92, P2555, DOI 10.1002/1097-0142(20011115)92:10<2555::AID-CNCR1607>3.0.CO;2-M; Knowles MA, 2006, CARCINOGENESIS, V27, P361, DOI 10.1093/carcin/bgi310; KURTH KH, 1995, EUR J CANCER, V31A, P1840, DOI 10.1016/0959-8049(95)00287-S; Logie A, 2005, HUM MOL GENET, V14, P1153, DOI 10.1093/hmg/ddi127; Martinez-Torrecuadrada JM, 2005, CLIN CANCER RES, V11, P6280, DOI 10.1158/1078-0432.CCR-05-0282; Matsukura S, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng077; Matsumoto M, 2004, ONCOL REP, V12, P967; Mhawrech-Fauceglia P, 2006, EJSO-EUR J SURG ONC, V32, P231, DOI 10.1016/j.ejso.2005.11.018; Ornitz DM, 1996, J BIOL CHEM, V271, P15292, DOI 10.1074/jbc.271.25.15292; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Paterson JL, 2004, BRIT J HAEMATOL, V124, P595, DOI 10.1111/j.1365-2141.2004.04814.x; Richelda R, 1997, BLOOD, V90, P4062, DOI 10.1182/blood.V90.10.4062; Ronchetti D, 2001, ONCOGENE, V20, P3553, DOI 10.1038/sj.onc.1204465; Sarkar S, 2000, CANCER RES, V60, P3862; Sibley K, 2000, GENE CHROMOSOME CANC, V29, P378, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1045>3.0.CO;2-K; SOUTHGATE J, 1994, LAB INVEST, V71, P583; Strausberg RL, 2004, NATURE, V429, P469, DOI 10.1038/nature02627; Tomlinson DC, 2005, CANCER RES, V65, P10441, DOI 10.1158/0008-5472.CAN-05-1718; Trudel S, 2005, BLOOD, V105, P2941, DOI 10.1182/blood-2004-10-3913; Trudel S, 2004, BLOOD, V103, P3521, DOI 10.1182/blood-2003-10-3650; Trudel S, 2006, BLOOD, V107, P4039, DOI 10.1182/blood-2005-10-4179; van Rhijn BWG, 2001, CANCER RES, V61, P1265; van Rhijn BWG, 2003, CLIN CANCER RES, V9, P257; Voorhoeve PM, 2003, CANCER CELL, V4, P311, DOI 10.1016/S1535-6108(03)00223-X; Webster MK, 1997, TRENDS GENET, V13, P178, DOI 10.1016/S0168-9525(97)01131-1; Weinstein IB, 2002, SCIENCE, V297, P63, DOI 10.1126/science.1073096; Wu XR, 2005, NAT REV CANCER, V5, P713, DOI 10.1038/nrc1697; Zhu LJ, 2005, MOL CANCER THER, V4, P787, DOI 10.1158/1535-7163.MCT-04-0330	52	98	126	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 30	2007	26	40					5889	5899		10.1038/sj.onc.1210399	http://dx.doi.org/10.1038/sj.onc.1210399			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	205OH	17384684	Green Accepted			2022-12-28	WOS:000249123100006
J	Irmer, D; Funk, JO; Blaukat, A				Irmer, D.; Funk, J. O.; Blaukat, A.			EGFR kinase domain mutations - functional impact and relevance for lung cancer therapy	ONCOGENE			English	Review						EGFR; mutation; NSCLC; gefitinib; erlotimb; cetuximab	GROWTH-FACTOR-RECEPTOR; ACQUIRED-RESISTANCE; GENE-MUTATIONS; GEFITINIB SENSITIVITY; ACTIVATING MUTATIONS; PROLONGED SURVIVAL; SOMATIC MUTATIONS; MOLECULAR-BIOLOGY; DOWN-REGULATION; ERBB RECEPTORS	In 2004 remarkable clinical responses in non-small-cell lung cancer (NSCLC) patients treated with the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib were reported to correlate with the presence of certain somatic EGFR kinase domain mutations in tumors. Since then, a surge of enthusiasm has been encountered in the field of molecular and clinical oncology. Beyond the promise of a tailored medicine, questions about the molecular mechanisms underlying the observed effects have arisen. In vitro analysis of NSCLC cells with endogenous EGFR mutations, recombinant expression of EGFR variants by transfection of several cell lines and the generation of transgenic mice expressing mutant EGFR were applied to study the impact of these genetic alterations on cellular signaling and cell fate. This review outlines the current mechanistic knowledge derived from such studies and discusses the relevance of EGFR kinase domain mutations for EGFR-directed therapies, including monoclonal antibodies.	Merck KGaA, Oncol Res Darmstadt, D-64293 Darmstadt, Germany	Merck KGaA	Blaukat, A (corresponding author), Merck KGaA, Oncol Res Darmstadt, Frankfurter Str 250,A25-501, D-64293 Darmstadt, Germany.	andree.blaukat@merck.de						Amann J, 2005, CANCER RES, V65, P226; Ando K, 2005, CLIN CANCER RES, V11, P8872, DOI 10.1158/1078-0432.CCR-05-0811; Arao T, 2004, CANCER RES, V64, P9101, DOI 10.1158/0008-5472.CAN-04-2360; Asahina H, 2006, BRIT J CANCER, V95, P998, DOI 10.1038/sj.bjc.6603393; Barber TD, 2004, NEW ENGL J MED, V351, P2883, DOI 10.1056/NEJM200412303512724; Bell DW, 2005, NAT GENET, V37, P1315, DOI 10.1038/ng1671; Bell DW, 2005, J CLIN ONCOL, V23, P8081, DOI 10.1200/JCO.2005.02.7078; Blencke S, 2003, J BIOL CHEM, V278, P15435, DOI 10.1074/jbc.M211158200; Calvo E, 2006, J CLIN ONCOL, V24, P2158, DOI 10.1200/JCO.2006.06.5961; Cappuzzo F, 2005, JNCI-J NATL CANCER I, V97, P643, DOI 10.1093/jnci/dji112; Cappuzzo F, 2004, JNCI-J NATL CANCER I, V96, P1133, DOI 10.1093/jnci/djh217; Carey KD, 2006, CANCER RES, V66, P8163, DOI 10.1158/0008-5472.CAN-06-0453; Chen YR, 2006, ONCOGENE, V25, P1205, DOI 10.1038/sj.onc.1209159; Choong NW, 2006, NAT CLIN PRACT ONCOL, V3, P50, DOI 10.1038/ncponc0400; Coldren CD, 2006, MOL CANCER RES, V4, P521, DOI 10.1158/1541-7786.MCR-06-0095; Damstrup L, 2002, INT J CANCER, V97, P7, DOI 10.1002/ijc.1572; Eberhard DA, 2005, J CLIN ONCOL, V23, P5900, DOI 10.1200/JCO.2005.02.857; Engelman JA, 2005, P NATL ACAD SCI USA, V102, P3788, DOI 10.1073/pnas.0409773102; Engelman JA, 2006, J CLIN INVEST, V116, P2695, DOI 10.1172/JCI28656; Fabian MA, 2005, NAT BIOTECHNOL, V23, P329, DOI 10.1038/nbt1068; Fong KM, 2003, THORAX, V58, P892, DOI 10.1136/thorax.58.10.892; Fujimoto N, 2005, CANCER RES, V65, P11478, DOI 10.1158/0008-5472.CAN-05-1977; Gazdar AF, 2004, TRENDS MOL MED, V10, P481, DOI 10.1016/j.molmed.2004.08.008; Giaccone G, 2006, CLIN CANCER RES, V12, P6049, DOI 10.1158/1078-0432.CCR-06-0260; Gow CH, 2005, PLOS MED, V2, P924, DOI 10.1371/journal.pmed.0020269; Greulich H, 2005, PLOS MED, V2, P1167, DOI 10.1371/journal.pmed.0020313; Harari PM, 2004, ENDOCR-RELAT CANCER, V11, P689, DOI 10.1677/erc.1.00600; Heymach JV, 2006, CLIN CANCER RES, V12, p4441S, DOI 10.1158/1078-0432.CCR-06-0286; Hirsch FR, 2006, J CLIN ONCOL, V24, P5034, DOI 10.1200/JCO.2006.06.3958; Inukai M, 2006, CANCER RES, V66, P7854, DOI 10.1158/0008-5472.CAN-06-1951; Jackman DM, 2006, CLIN CANCER RES, V12, P3908, DOI 10.1158/1078-0432.CCR-06-0462; Janmaat ML, 2006, INT J CANCER, V118, P209, DOI 10.1002/ijc.21290; Janne PA, 2005, J CLIN ONCOL, V23, P3227, DOI 10.1200/JCO.2005.09.985; Ji HB, 2006, CANCER CELL, V9, P485, DOI 10.1016/j.ccr.2006.04.022; Jiang JR, 2005, CANCER RES, V65, P8968, DOI 10.1158/0008-5472.CAN-05-1829; Johnson BE, 2005, J CLIN ONCOL, V23, P6813, DOI 10.1200/JCO.2005.97.008; Jones RB, 2006, NATURE, V439, P168, DOI 10.1038/nature04177; Kobayashi S, 2005, CANCER RES, V65, P7096, DOI 10.1158/0008-5472.CAN-05-1346; Kobayashi S, 2005, NEW ENGL J MED, V352, P786, DOI 10.1056/NEJMoa044238; Kokubo Y, 2005, BRIT J CANCER, V92, P1711, DOI 10.1038/sj.bjc.6602559; Kwak EL, 2005, P NATL ACAD SCI USA, V102, P7665, DOI 10.1073/pnas.0502860102; Lee JW, 2005, CLIN CANCER RES, V11, P2879, DOI 10.1158/1078-0432.CCR-04-2029; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; LYNCH TJ, 2004, 40 ANN M AM SOC CLIN; Marchetti A, 2006, NEW ENGL J MED, V354, P526; Mellstedt H, 2003, DRUG TODAY, V39, P1; Mitsudomi T, 2005, J CLIN ONCOL, V23, P2513, DOI 10.1200/JCO.2005.00.992; MOSCATELLO DK, 1995, CANCER RES, V55, P5536; Mukohara T, 2005, JNCI-J NATL CANCER I, V97, P1185, DOI 10.1093/jnci/dji238; Nagai Y, 2005, CANCER RES, V65, P7276, DOI 10.1158/0008-5472.CAN-05-0331; Niho S, 2006, J CLIN ONCOL, V24, P64, DOI 10.1200/JCO.2005.02.5825; Noble MEM, 2004, SCIENCE, V303, P1800, DOI 10.1126/science.1095920; Normanno N, 2005, CURR DRUG TARGETS, V6, P243, DOI 10.2174/1389450053765879; Okamoto I, 2003, CANCER SCI, V94, P50, DOI 10.1111/j.1349-7006.2003.tb01351.x; Oliveira S, 2006, EXPERT OPIN BIOL TH, V6, P605, DOI 10.1517/14712598.6.6.605; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Pao W, 2005, PLOS MED, V2, P57, DOI 10.1371/journal.pmed.0020017; Pao W, 2005, PLOS MED, V2, P225, DOI 10.1371/journal.pmed.0020073; Pao W, 2004, P NATL ACAD SCI USA, V101, P13306, DOI 10.1073/pnas.0405220101; Pao W, 2005, J CLIN ONCOL, V23, P2556, DOI 10.1200/JCO.2005.07.799; Pawson T, 2001, TRENDS CELL BIOL, V11, P504, DOI 10.1016/S0962-8924(01)02154-7; PAZARES L, 2006, 42 ANN M AM SOC CLIN; Pedersen MW, 2001, ANN ONCOL, V12, P745, DOI 10.1023/A:1011177318162; Perez-Torres M, 2006, J BIOL CHEM, V281, P40183, DOI 10.1074/jbc.M607958200; Politi K, 2006, GENE DEV, V20, P1496, DOI 10.1101/gad.1417406; Reis JS, 2006, J PATHOL, V209, P445, DOI 10.1002/path.2004; Riely GJ, 2006, CLIN CANCER RES, V12, P839, DOI 10.1158/1078-0432.CCR-05-1846; ROBERSTON J, 2003, 39 ANN M AM SOC CLIN; Roche-Lestienne C, 2002, BLOOD, V100, P1014, DOI 10.1182/blood.V100.3.1014; Sato J D, 1983, Mol Biol Med, V1, P511; Shepherd FA, 2006, J CLIN ONCOL, V24, P1219, DOI 10.1200/JCO.2005.04.4420; Shigematsu H, 2005, JNCI-J NATL CANCER I, V97, P339, DOI 10.1093/jnci/dji055; Shimamura T, 2005, CANCER RES, V65, P6401, DOI 10.1158/0008-5472.CAN-05-0933; Sihto H, 2005, J MOL MED, V83, P976, DOI 10.1007/s00109-005-0699-4; Singh AB, 2005, CELL SIGNAL, V17, P1183, DOI 10.1016/j.cellsig.2005.03.026; Sordella R, 2004, SCIENCE, V305, P1163, DOI 10.1126/science.1101637; Takano T, 2005, J CLIN ONCOL, V23, P6829, DOI 10.1200/JCO.2005.01.0793; Toyooka S, 2005, NEW ENGL J MED, V352, P2136; Tracy S, 2004, CANCER RES, V64, P7241, DOI 10.1158/0008-5472.CAN-04-1905; Tsao MS, 2005, NEW ENGL J MED, V353, P133, DOI 10.1056/NEJMoa050736; Tsuchihashi Z, 2005, NEW ENGL J MED, V353, P208, DOI 10.1056/NEJM200507143530218; Worthylake R, 1999, J BIOL CHEM, V274, P8865, DOI 10.1074/jbc.274.13.8865; Yarden Y, 2001, EUR J CANCER, V37, pS3	83	55	63	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2007	26	39					5693	5701		10.1038/sj.onc.1210383	http://dx.doi.org/10.1038/sj.onc.1210383			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	202EP	17353898				2022-12-28	WOS:000248885100001
J	Meng, LH; Kohn, KW; Pommier, Y				Meng, L-H; Kohn, K. W.; Pommier, Y.			Dose-response transition from cell cycle arrest to apoptosis with selective degradation of Mdm2 and p21(WAF1/CIP1) in response to the novel anticancer agent, aminoflone (NSC 686288)	ONCOGENE			English	Article						p53; proteasome; Akt; apoptosis; histone H2AX; DNA damage	ATM-DEPENDENT PHOSPHORYLATION; MOLECULAR INTERACTION MAP; DNA-DAMAGE; AMINOFLAVONE NSC-686288; ADENOCARCINOMA CELLS; IONIZING-RADIATION; TOPOISOMERASE-I; P53 ACTIVATION; CANCER CELLS; KINASE	Aminoflavone (AF, NSC 686288) is beginning clinical trials. It induces replication-mediated histone H2AX phosphorylation, DNA-protein crosslinks and activates p53. Here, we studied p21(CIP1/WAF1) and Mdm2 responses to AF. Although p53 stabilization and phosphorylation at serine 15 increased with dose and time of exposure, Mdm2 and p21(CIP1/WAF1) protein levels displayed a biphasic response, as they accumulated at submicromolar doses and then decreased with increasing AF. As both Mdm2 and p21(CIP1/WAF1) mRNA levels increased with AF concentration without reduction at higher concentrations, we measured the half- lives of Mdm2 and p21(CIP1/WAF1) proteins. Mdm2 and p21(CIP1/WAF1) half-lives were shortened with increasing AF concentrations. Proteasomal degradation appears responsible for the decrease of both Mdm2 and p21(CIP1/WAF1), as MG-132 prevented their degradation and revealed AF-induced Mdm2 polyubiquitylation. AF also induced protein kinase B (Akt) activation, which was reduced with increasing AF concentrations. Suppression of Akt by small interfering RNA was associated with downregulation of Mdm2 and p21(CIP1/WAF1) and with enhanced apoptosis. These results suggest that the cellular responses to AF are determined at least in part by Mdm2 and p21(CIP1/WAF1) protein levels, as well as by Akt activity, leading either to cell cycle arrest when Mdm2 and p21(CIP1/WAF1) are elevated, or to apoptosis when Mdm2 and p21(CIP1/WAF1) are degraded by the proteasome and Akt insufficiently activated to protect against apoptosis.	NCI, Canc Res Ctr, Mol Pharmacol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Pommier, Y (corresponding author), NCI, Canc Res Ctr, Mol Pharmacol Lab, NIH, 37 Convent Dr,Bldg 37,Room 5068, Bethesda, MD 20892 USA.	pommier@nih.gov	meng, linghua/Y-8110-2019		Intramural NIH HHS Funding Source: Medline; NATIONAL CANCER INSTITUTE [Z01BC006150, ZIABC006150] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Brooks CL, 2003, CURR OPIN CELL BIOL, V15, P164, DOI 10.1016/S0955-0674(03)00003-6; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; CHEN C, 2006, J PHARM EXP THER; Dotto GP, 2000, BBA-REV CANCER, V1471, pM43, DOI 10.1016/S0304-419X(00)00019-6; Fang L, 2001, EMBO J, V20, P1931, DOI 10.1093/emboj/20.8.1931; Feng JH, 2004, J BIOL CHEM, V279, P35510, DOI 10.1074/jbc.M404936200; Fujiwara Y, 2006, BIOCHEM BIOPH RES CO, V340, P560, DOI 10.1016/j.bbrc.2005.12.039; Furuta T, 2006, ONCOGENE, V25, P2839, DOI 10.1038/sj.onc.1209313; Hayward RL, 2003, CLIN CANCER RES, V9, P2856; Jin YT, 2003, EMBO J, V22, P6365, DOI 10.1093/emboj/cdg600; Khosravi R, 1999, P NATL ACAD SCI USA, V96, P14973, DOI 10.1073/pnas.96.26.14973; Kim Y, 2002, IN VITRO CELL DEV-PL, V38, P1, DOI 10.1079/IVP2001243; Knuefermann C, 2003, ONCOGENE, V22, P3205, DOI 10.1038/sj.onc.1206394; Kohn KW, 1999, MOL BIOL CELL, V10, P2703, DOI 10.1091/mbc.10.8.2703; Kohn KW, 2005, BIOCHEM BIOPH RES CO, V331, P816, DOI 10.1016/j.bbrc.2005.03.186; Kulikov R, 2005, MOL CELL BIOL, V25, P7170, DOI 10.1128/MCB.25.16.7170-7180.2005; Li YH, 2002, J INFRARED MILLIM W, V21, P1; Maya R, 2001, GENE DEV, V15, P1067, DOI 10.1101/gad.886901; Meek DW, 2004, DNA REPAIR, V3, P1049, DOI 10.1016/j.dnarep.2004.03.027; Meng LH, 2005, CANCER RES, V65, P5337, DOI 10.1158/0008-5472.CAN-05-0003; Meng LH, 2004, CANCER RES, V64, P9086, DOI 10.1158/0008-5472.CAN-04-0313; Meng LH, 2006, CANCER RES, V66, P9656, DOI 10.1158/0008-5472.CAN-06-0796; Michael D, 2003, SEMIN CANCER BIOL, V13, P49, DOI 10.1016/S1044-579X(02)00099-8; Milne D, 2004, FEBS LETT, V577, P270, DOI 10.1016/j.febslet.2004.09.081; Monks A, 1997, ANTI-CANCER DRUG DES, V12, P533; PAULL KD, 1989, J NATL CANCER I, V81, P1088, DOI 10.1093/jnci/81.14.1088; Pommier Y, 2005, CURR PHARM DESIGN, V11, P2855, DOI 10.2174/1381612054546716; Rossig L, 2002, J BIOL CHEM, V277, P9684, DOI 10.1074/jbc.M106157200; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Shieh SY, 2000, GENE DEV, V14, P289; Sordet Olivier, 2003, Current Medicinal Chemistry - Anti-Cancer Agents, V3, P271, DOI 10.2174/1568011033482378; Stommel JM, 2004, EMBO J, V23, P1547, DOI 10.1038/sj.emboj.7600145; Takimoto R, 2001, P NATL ACAD SCI USA, V98, P781, DOI 10.1073/pnas.98.3.781; Touitou R, 2001, EMBO J, V20, P2367, DOI 10.1093/emboj/20.10.2367; Viniegra JG, 2005, J BIOL CHEM, V280, P4029, DOI 10.1074/jbc.M410344200; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; Yoeli-Lerner M, 2006, CELL CYCLE, V5, P603, DOI 10.4161/cc.5.6.2561; Yu J, 2005, BIOCHEM BIOPH RES CO, V331, P851, DOI 10.1016/j.bbrc.2005.03.189; Zhang Z, 2004, J BIOL CHEM, V279, P16000, DOI 10.1074/jbc.M312264200; Zhao YQ, 2004, J CELL BIOCHEM, V91, P621, DOI 10.1002/jcb.10751	40	28	29	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 19	2007	26	33					4806	4816		10.1038/sj.onc.1210283	http://dx.doi.org/10.1038/sj.onc.1210283			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	191ZL	17297446				2022-12-28	WOS:000248170400005
J	Saito, H; Yoshida, T; Yamazaki, H; Suzuki, N				Saito, H.; Yoshida, T.; Yamazaki, H.; Suzuki, N.			Conditional N-rasG12V expression promotes manifestations of neuro. bromatosis in a mouse model	ONCOGENE			English	Article						neurofibromatosis type 1; neurofibromatosis type 2; N-Ras	SUPPRESSOR GENE-PRODUCT; NEUROFIBROMATOSIS; RAS; INHIBITION; MERLIN; DEFICIENCY; PROTEIN; GROWTH; NF1; P53	Human clinical neurofibromatosis type 1 (NF1) and type 2 (NF2) result from mutations and inactivation of neurofibromin and merlin genes, respectively, which negatively regulate Ras pathways. To evaluate the contribution of N-Ras activity to the development of NF, we generated a novel transgenic mouse expressing oncogenic N-ras specifically in central nerve cells, neural crest-derived cells and lens epithelial cells. Soon after birth, the mouse skin showed hyperpigmentation of the epidermis and melanin-laden macrophages in the dermis, as observed in the cafe-au-lait spots of human cases. At 3 months of age, all the mice had neurofibromas in the skin and neurofibroma-like tumors with structure similar to Wagner Meissner bodies in the adrenal medulla. At 4 months of age, all the mice developed subcapsular cataract. In the 5th month, some developed protruding dermal neurofibromas involving subcutaneous fat. However, plexiform neurofibroma, schwannoma, astrocytoma and pheochromocytoma were not observed in the mice, suggesting a requirement for signal(s) other than the activated N-Ras pathway to induce these tumors. Thus, the activated N-Ras signal may be a main pathway for the development of the disease phenotypes characteristic of NF.	Mie Univ, Life Sci Res Ctr, Dept Anim Genom, Funct Genom Inst, Tsu, Mie 5148507, Japan; Mie Univ, Grad Sch Med, Dept Pathol & Matrix Biol, Tsu, Mie 514, Japan; Mie Univ, Grad Sch Med, Dept Physiol & Regenerat Med, Tsu, Mie 514, Japan	Mie University; Mie University; Mie University	Suzuki, N (corresponding author), Mie Univ, Life Sci Res Ctr, Dept Anim Genom, Funct Genom Inst, 2-174 Edobashi, Tsu, Mie 5148507, Japan.	nsuzuki@doc.medic.mie-u.ac.jp	Yoshida, Toshimichi/H-6204-2013	Yoshida, Toshimichi/0000-0001-8935-8217				Bajenaru ML, 2002, MOL CELL BIOL, V22, P5100, DOI 10.1128/MCB.22.14.5100-5113.2002; BASU TN, 1992, NATURE, V356, P713, DOI 10.1038/356713a0; Buchanan J.M., 1990, CONST POLITICAL ECON, V1, P1, DOI DOI 10.1007/BF02393031; Chadee DN, 2006, P NATL ACAD SCI USA, V103, P4463, DOI 10.1073/pnas.0510651103; ENZINGER FM, 1988, SOFT TISSUE TUMOR, P852; Evans DGR, 2000, J MED GENET, V37, P897, DOI 10.1136/jmg.37.12.897; Giovannini M, 2000, GENE DEV, V14, P1617; Hogan B, 1994, MANIPULATING MOUSE E; Ikeda K, 1999, J NEUROSURG, V91, P85, DOI 10.3171/jns.1999.91.1.0085; Kunisada T, 2000, MECH DEVELOP, V94, P67, DOI 10.1016/S0925-4773(00)00308-7; Lakkis MM, 1999, DEV BIOL, V212, P80, DOI 10.1006/dbio.1999.9327; Lim JY, 2003, BIOCHEM BIOPH RES CO, V302, P238, DOI 10.1016/S0006-291X(03)00124-4; Malumbres M, 1998, FRONT BIOSCI-LANDMRK, V3, P887; Mattingly RR, 2006, J PHARMACOL EXP THER, V316, P456, DOI 10.1124/jpet.105.091454; McClatchey AI, 1997, GENE DEV, V11, P1253, DOI 10.1101/gad.11.10.1253; Morrison H, 2001, GENE DEV, V15, P968, DOI 10.1101/gad.189601; North K, 2000, AM J MED GENET, V97, P119, DOI 10.1002/1096-8628(200022)97:2<119::AID-AJMG3>3.0.CO;2-3; Patton EE, 2005, CURR BIOL, V15, P249, DOI 10.1016/j.cub.2005.01.031; Reed N, 2001, TRENDS MOL MED, V7, P157, DOI 10.1016/S1471-4914(01)01955-4; Saito H, 2005, BIOCHEM BIOPH RES CO, V331, P1216, DOI 10.1016/j.bbrc.2005.04.043; SATO N, 1992, J CELL SCI, V103, P131; TIKOO A, 1994, J BIOL CHEM, V269, P23387; TSUKAMOTO K, 1992, EMBO J, V11, P519, DOI 10.1002/j.1460-2075.1992.tb05082.x; Tsumura H, 2006, ONCOGENE, V25, P7673, DOI 10.1038/sj.onc.1209749; Voice JK, 1999, J BIOL CHEM, V274, P17164, DOI 10.1074/jbc.274.24.17164; Zhu Y, 2002, SCIENCE, V296, P920, DOI 10.1126/science.1068452	26	14	14	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 12	2007	26	32					4714	4719		10.1038/sj.onc.1210250	http://dx.doi.org/10.1038/sj.onc.1210250			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	190DJ	17237809				2022-12-28	WOS:000248037900011
J	Nagai, H; Sugito, N; Matsubara, H; Tatematsu, Y; Hida, T; Sekido, Y; Nagino, M; Nimura, Y; Takahashi, T; Osada, H				Nagai, H.; Sugito, N.; Matsubara, H.; Tatematsu, Y.; Hida, T.; Sekido, Y.; Nagino, M.; Nimura, Y.; Takahashi, T.; Osada, H.			CLCP1 interacts with semaphorin 4B and regulates motility of lung cancer cells	ONCOGENE			English	Article						CLCP1; SEMA4B; lung cancer	POSTSYNAPTIC DENSITY PROTEIN; SUPPRESSES TUMOR-FORMATION; LINE NCI-H460-LNM35; ENDOCYTOSIS; METASTASIS; GENE	We previously established a highly metastatic subline, LNM35, from the NCI-H460 lung cancer cell line, and demonstrated upregulation of a novel gene, CLCP1 ( CUB, LCCL-homology, coagulation factor V/VIII homology domains protein), in LNM35 and lung cancer specimens. In this study, we focused on the potential roles of that gene in cancer metastasis. First, we established stable LNM35 RNAi clones, in which CLCP1 expression was suppressed by RNAi, and found that their motility was significantly reduced, although growth rates were not changed. Next, in vitro selection of a phage display library demonstrated that a phage clone displaying a peptide similar to a sequence within the Sema domain of semaphorin 4B ( SEMA4B) interacted with LNM35. Immunoprecipitation experiments confirmed interaction of CLCP1 with SEMA4B, regulation of CLCP1 protein by ubiquitination and proteasome degradation enhanced in the presence of SEMA4B. These results are the first to indicate that CLCP1 plays a role in cell motility, whereas they also showed that at least one of its ligands is SEMA4B and that their interaction mediates proteasome degradation by CLCP1. Although the physiological role of the interaction between CLCP1 and SEMA4B remains to be investigated, this novel gene may become a target of therapy to inhibit metastasis of lung cancers.	Aichi Canc Ctr, Res Inst, Div Mol Oncol, Chikusa Ku, Nagoya, Aichi 4648681, Japan; Nagoya Univ, Div Mol Carcinogenesis, Ctr Neurol Dis & Canc, Grad Sch Med, Nagoya, Aichi, Japan; Nagoya Univ, Div Surg Oncol, Dept Surg, Grad Sch Med, Nagoya, Aichi, Japan; Aichi Canc Ctr Hosp, Dept Pulm Med, Nagoya, Aichi 464, Japan	Aichi Cancer Center; Nagoya University; Nagoya University; Aichi Cancer Center	Osada, H (corresponding author), Aichi Canc Ctr, Res Inst, Div Mol Oncol, Chikusa Ku, 1-1 Kanokoden, Nagoya, Aichi 4648681, Japan.	hosada@aichi-cc.jp	Nagino, Masato/I-7342-2014; Sekido, Yoshitaka/P-9756-2015; Takahashi, Takashi/I-7262-2014	Takahashi, Takashi/0000-0003-0615-7001; Sekido, Yoshitaka/0000-0002-2428-3848				Bachelder RE, 2003, CANCER RES, V63, P5230; Burkhardt C, 2005, FEBS LETT, V579, P3821, DOI 10.1016/j.febslet.2005.05.079; Castellani V, 2004, MOL CELL NEUROSCI, V26, P89, DOI 10.1016/j.mcn.2004.01.010; Castro-Rivera E, 2004, P NATL ACAD SCI USA, V101, P11432, DOI 10.1073/pnas.0403969101; Conrotto P, 2005, BLOOD, V105, P4321, DOI 10.1182/blood-2004-07-2885; Fournier AE, 2000, J CELL BIOL, V149, P411, DOI 10.1083/jcb.149.2.411; Friedl P, 2003, NAT REV CANCER, V3, P362, DOI 10.1038/nrc1075; Herold C, 1996, J IMMUNOL, V157, P5262; Inagaki S, 2001, J BIOL CHEM, V276, P9174, DOI 10.1074/jbc.M009051200; Kobuke K, 2001, J BIOL CHEM, V276, P34105, DOI 10.1074/jbc.M105293200; Koshikawa K, 2002, ONCOGENE, V21, P2822, DOI 10.1038/sj.onc.1205405; Kozaki K, 2000, CANCER RES, V60, P2535; Kozaki K, 2001, ONCOGENE, V20, P4228, DOI 10.1038/sj.onc.1204561; Kruger RR, 2005, NAT REV MOL CELL BIO, V6, P789, DOI 10.1038/nrm1740; Oinuma I, 2004, SCIENCE, V305, P862, DOI 10.1126/science.1097545; Osada H, 2004, INT J CANCER, V112, P26, DOI 10.1002/ijc.20395; Tse C, 2002, CANCER RES, V62, P542; Xiang RH, 2002, CANCER RES, V62, P2637; Yanagisawa K, 2000, ONCOGENE, V19, P2305, DOI 10.1038/sj.onc.1203591	19	48	52	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 7	2007	26	27					4025	4031		10.1038/sj.onc.1210183	http://dx.doi.org/10.1038/sj.onc.1210183			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	177HP	17213806				2022-12-28	WOS:000247144500013
J	Tai, KY; Shiah, SG; Shieh, YS; Kao, YR; Chi, CY; Huang, E; Lee, HS; Chang, LC; Yang, PC; Wu, CW				Tai, K-Y; Shiah, S-G; Shieh, Y-S; Kao, Y-R; Chi, C-Y; Huang, E.; Lee, H-S; Chang, L-C; Yang, P-C; Wu, C-W			DNA methylation and histone modification regulate silencing of epithelial cell adhesion molecule for tumor invasion and progression	ONCOGENE			English	Article						Ep-CAM; invasion; promoter methylation	EP-CAM; LUNG ADENOCARCINOMA; BREAST-CANCER; EXPRESSION; CARCINOMA; EPCAM; ANTIGEN; MARKERS; TARGET; INHIBITION	Epithelial cell adhesion molecule ( Ep-CAM) is believed to have a critical role in carcinogenesis and cell proliferation. However, the association of Ep-CAM with cancer invasion and progression is less clear. We found that EpCAM was highly expressed on low-invasive cells compared with highly invasive cells. Forced expression of Ep-CAM decreased cancer invasiveness, and silencing Ep-CAM expression elevated cancer invasiveness. EpCAM expression was associated with promoter methylation. Treatment with a demethylating agent, and/or the histone deacetylase inhibitor reactivated Ep-CAM expression in Ep-CAM-negative cells and inhibited cancer invasiveness. Using a promoter-reporter construct, we demonstrated methylation of the promoter fragment drive Ep-CAM-silenced transcription. Additionally, silenced Ep-CAM gene in cancer cells was enriched for hyper-methylated histone 3 lysine 9. When unmethylated and active, this promoter was associated with acetylated histone 3 lysine 9. Furthermore, we observed an increased association of Ep-CAM promoter with repression components as tumor invasiveness increased. In cancer tissues, Ep-CAM expression significantly correlated with tumor progression and associated with promoter methylation. Our data support the idea that modulation of Ep-CAM plays a pivotal role in tumor invasion and progression. Moreover, aberrant DNA methylation of Ep-CAM is implicated in enhancing invasive/metastatic proclivity of tumors.	Inst Canc Res, Natl Hlth Res Inst, Miaoli, Taiwan; Natl Def Med Ctr, Sch Dent, Taipei, Taiwan; Natl Def Med Ctr, Canc Epigenet Lab, Taipei, Taiwan; Tri Serv Gen Hosp, Dept Oral Diag, Taipei, Taiwan; Tri Serv Gen Hosp, Dept Pathol, Taipei, Taiwan; Natl Taiwan Univ Hosp, Dept Internal Med, Taipei 100, Taiwan	National Health Research Institutes - Taiwan; National Defense Medical Center; National Defense Medical Center; Tri-Service General Hospital; Tri-Service General Hospital; National Taiwan University; National Taiwan University Hospital	Wu, CW (corresponding author), Inst Canc Res, Natl Hlth Res Inst, Miaoli, Taiwan.	ken@nhri.org.tw	Yang, Pan-Chyr/B-8808-2009; Shiah, Shine-Gwo/D-2087-2010	Tai, Kang-Yu/0000-0001-6867-3365; YANG, PAN-CHYR/0000-0001-6330-6048; Shiah, Shine-Gwo/0000-0002-1003-973X				Armstrong A, 2003, CANCER BIOL THER, V2, P320, DOI 10.4161/cbt.2.4.451; Basak S, 1998, JNCI-J NATL CANCER I, V90, P691, DOI 10.1093/jnci/90.9.691; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; Chu YW, 1997, AM J RESP CELL MOL, V17, P353, DOI 10.1165/ajrcmb.17.3.2837; Drapkin R, 2004, HUM PATHOL, V35, P1014, DOI 10.1016/j.humpath.2004.04.014; Fuks F, 2005, CURR OPIN GENET DEV, V15, P490, DOI 10.1016/j.gde.2005.08.002; Gastl G, 2000, LANCET, V356, P1981, DOI 10.1016/S0140-6736(00)03312-2; Jojovic M, 1998, HISTOCHEM J, V30, P723, DOI 10.1023/A:1003486630314; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Joo M, 2005, J GASTROEN HEPATOL, V20, P1039, DOI 10.1111/j.1440-1746.2005.03842.x; Kim JH, 2003, CLIN CANCER RES, V9, P4782; Klose RJ, 2006, TRENDS BIOCHEM SCI, V31, P89, DOI 10.1016/j.tibs.2005.12.008; Kumble S, 1996, INT J CANCER, V66, P48, DOI 10.1002/(SICI)1097-0215(19960328)66:1<48::AID-IJC9>3.0.CO;2-Z; LITVINOV SV, 1994, J CELL BIOL, V125, P437, DOI 10.1083/jcb.125.2.437; McLaughlin PMJ, 2004, CANCER GENE THER, V11, P603, DOI 10.1038/sj.cgt.7700725; Munz M, 2004, ONCOGENE, V23, P5748, DOI 10.1038/sj.onc.1207610; Osta WA, 2004, CANCER RES, V64, P5818, DOI 10.1158/0008-5472.CAN-04-0754; Rao CG, 2005, INT J ONCOL, V27, P49; Robertson KD, 2001, ONCOGENE, V20, P3139, DOI 10.1038/sj.onc.1204341; Seligson DB, 2004, CLIN CANCER RES, V10, P2659, DOI 10.1158/1078-0432.CCR-1132-03; Shieh YS, 2005, NEOPLASIA, V7, P1058, DOI 10.1593/neo.05640; Songun I, 2005, BRIT J CANCER, V92, P1767, DOI 10.1038/sj.bjc.6602519; Spizzo G, 2007, CANCER LETT, V246, P253, DOI 10.1016/j.canlet.2006.03.002; Takes RP, 2001, J PATHOL, V194, P298, DOI 10.1002/1096-9896(200107)194:3<298::AID-PATH900>3.0.CO;2-Q; Takes RP, 1997, ARCH OTOLARYNGOL, V123, P412; Went P, 2006, BRIT J CANCER, V94, P128, DOI 10.1038/sj.bjc.6602924; Went P, 2005, AM J SURG PATHOL, V29, P83, DOI 10.1097/01.pas.0000.146028.70868.7a; Went PT, 2004, HUM PATHOL, V35, P122, DOI 10.1016/j.humpath.2003.08.026; Winter MJ, 2003, AM J PATHOL, V163, P2139, DOI 10.1016/S0002-9440(10)63570-5	29	53	53	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 7	2007	26	27					3989	3997		10.1038/sj.onc.1210176	http://dx.doi.org/10.1038/sj.onc.1210176			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	177HP	17213811				2022-12-28	WOS:000247144500009
J	Luo, F; Brooks, DG; Ye, H; Hamoudi, R; Poulogiannis, G; Patek, CE; Winton, DJ; Arends, MJ				Luo, F.; Brooks, D. G.; Ye, H.; Hamoudi, R.; Poulogiannis, G.; Patek, C. E.; Winton, D. J.; Arends, M. J.			Conditional expression of mutated K-ras accelerates intestinal tumorigenesis in Msh2-deficient mice	ONCOGENE			English	Article						K-ras; cre-LoxP; intestine; tumour; mouse	COLORECTAL-CANCER; MOUSE MODELS; MISMATCH REPAIR; GENE-EXPRESSION; BETA-CATENIN; ACTIVATION; MUTATIONS; APOPTOSIS; ONCOGENE; TUMORS	K- ras mutation occurs in 40 - 50% of human colorectal adenomas and carcinomas, but its contribution to intestinal tumorigenesis in vivo is K-ras mutation occurs in 40-50% of human colorectal adenomas and carcinomas, but its contribution to intestinal tumorigenesis in vivo is unclear. We developed K-ras(V12) transgenic mice that were crossed with Ah-Cre mice to generate K-ras(V12)/Cre mice, which showed beta-naphthofla. avone- (i)nduction of Cre- mediated LoxP recombination that activated intestinal expression of K-ras(V12) 4A and 4B transcripts and proteins. Only very occasional intestinal adenomas were observed in beta-naphtho. flavonetreated K-ras(V12)/Cre mice aged up to 2 years, suggesting that mutated K-ras expression alone does not signifi. cantly initiate intestinal tumourigenesis. To investigate the effects of mutated K-ras on DNA mismatch repair (MMR)-deficient intestinal tumour formation, these mice were crossed with Msh2(-/-) mice to generate K-ras(V12)/ Cre/ Msh2(-/-) offspring. After beta-naphtho. flavone treatment, K- ras(V12)/ Cre/ Msh2(-/-) mice showed reduced average life-span of 17.3 +/- 5.0 weeks from 26.9 +/- 6.8 (control Msh2(-/-) mice) ( P < 0.01). They demonstrated increased adenomas in the small intestine from 1.41 ( Msh2(-/-) controls) to 7.75 per mouse (increased. fivefold, P < 0.01). In the large intestine, very few adenomas were found in Msh2(-/-) 2 mice ( 0.13 per mouse) whereas K- ras(V12)/Cre/ Msh2(-/-) mice produced 2.70 ade nomas per mouse (increased 20-fold, P < 0.01). Over 80% adenomas from K- ras(V12)/Cre/Msh2(-/-) mice showed transgene recombination with expression of K-ras(V12) 4A and 4B transcripts and proteins. Sequencing of endogenous murine K-ras showed mutations in two out of 10 tumours examined from Msh2(-/-) mice, but no mutations in 17 tumours from K-ras(V12)/ Cre/ Msh2(-/-) mice. Expression of K-ras(V12) in tumours caused activation of the mitogen-activated protein kinase and Akt/protein kinase B signaling pathways, demonstrated by phosphorylation of p44MAPK, Akt and GSK3 beta, as well as transcriptional upregulation of Pem, Tcl-1 and Trap1a genes (known targets of K-ras(V12) expression in stem cells). Thus, mutated K-ras cooperates synergistically with MMR de. ficiency to accelerate intestinal tumorigenesis, particularly in the large intestine.	Univ Cambridge, Addenbrookes Hosp, Dept Pathol, Cambridge CB2 2Q, England; Univ Edinburgh, Western Gen Hosp, Sir Alastair Currie Canc Res UK Lab, Mol Med Ctr, Edinburgh, Midlothian, Scotland; Univ Cambridge, Cambridge Inst Med Res, Dept Oncol, Cambridge, England	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; University of Edinburgh; University of Cambridge	Arends, MJ (corresponding author), Univ Cambridge, Addenbrookes Hosp, Dept Pathol, Box 235,Hills Rd, Cambridge CB2 2Q, England.	mja40@cam.ac.uk	Luo, Feijun/AAF-5708-2019; Luo, Feijun/B-1424-2012; Poulogiannis, George/AAY-2210-2021; Poulogiannis, George/AAE-1966-2019	Luo, Feijun/0000-0001-7489-544X; Poulogiannis, George/0000-0002-0529-8614; Luo, Feijun/0000-0003-1951-4071; Hamoudi, Rifat/0000-0002-1402-0868	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Al-Aynati MM, 2004, CLIN CANCER RES, V10, P1235, DOI 10.1158/1078-0432.CCR-03-0087; Andreyev HJN, 2001, BRIT J CANCER, V85, P692, DOI 10.1054/bjoc.2001.1964; ARENDS MJ, 1994, AM J PATHOL, V144, P1045; ARENDS MJ, 1993, BRIT J CANCER, V68, P1127, DOI 10.1038/bjc.1993.492; ARENDS MJ, 2004, KEY ADV EFFECTIVE MA, P25; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; Brooks DG, 2001, ONCOGENE, V20, P2144, DOI 10.1038/sj.onc.1204309; CAPON DJ, 1983, NATURE, V304, P507, DOI 10.1038/304507a0; Caulin C, 2004, CANCER RES, V64, P5054, DOI 10.1158/0008-5472.CAN-04-1488; de Wind N, 1998, CANCER RES, V58, P248; DEWIND N, 1995, CELL, V82, P321, DOI 10.1016/0092-8674(95)90319-4; Dinulescu DM, 2005, NAT MED, V11, P63, DOI 10.1038/nm1173; FEARON ER, 1987, SCIENCE, V238, P193, DOI 10.1126/science.2889267; Frayling IM, 2005, MOL DIAGNOSTICS CLIN, P375; Guerra C, 2003, CANCER CELL, V4, P111, DOI 10.1016/S1535-6108(03)00191-0; Ireland H, 2004, GASTROENTEROLOGY, V126, P1236, DOI 10.1053/j.gastro.2004.03.020; Jackson EL, 2001, GENE DEV, V15, P3243, DOI 10.1101/gad.943001; James RM, 2003, MOL CANCER RES, V1, P820; Janssen KP, 2005, BBA-REV CANCER, V1756, P145, DOI 10.1016/j.bbcan.2005.07.004; Janssen KP, 2002, GASTROENTEROLOGY, V123, P492, DOI 10.1053/gast.2002.34786; Jiricny J, 2000, CURR OPIN GENET DEV, V10, P157, DOI 10.1016/S0959-437X(00)00066-6; Johnson L, 2001, NATURE, V410, P1111, DOI 10.1038/35074129; KIM SH, 1993, J CELL BIOL, V123, P877, DOI 10.1083/jcb.123.4.877; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; LUO F, 2007, UNPUB BMC GENOMICS; Malumbres M, 2003, NAT REV CANCER, V3, P459, DOI 10.1038/nrc1097; Meuwissen R, 2001, ONCOGENE, V20, P6551, DOI 10.1038/sj.onc.1204837; Morris RG, 1996, J PATHOL, V180, P357; Otori K, 1997, GUT, V40, P660, DOI 10.1136/gut.40.5.660; Plowman SJ, 2006, J EXP CLIN CANC RES, V25, P259; Plowman SJ, 2006, EXP CELL RES, V312, P16, DOI 10.1016/j.yexcr.2005.10.004; Plowman SJ, 2003, MOL CELL BIOL, V23, P9245, DOI 10.1128/MCB.23.24.9245-9250.2003; Qian JY, 2005, CANCER RES, V65, P5045, DOI 10.1158/0008-5472.CAN-04-3208; Reitmair AH, 1996, CANCER RES, V56, P3842; REITMAIR AH, 1995, NAT GENET, V11, P64, DOI 10.1038/ng0995-64; Sansom OJ, 2006, P NATL ACAD SCI USA, V103, P14122, DOI 10.1073/pnas.0604130103; Shivapurkar N, 1997, CANCER LETT, V115, P39, DOI 10.1016/S0304-3835(97)04709-5; SPANDIDOS DA, 1984, NATURE, V310, P469, DOI 10.1038/310469a0; Toft NJ, 1998, J PATHOL, V185, P123; Toft NJ, 2002, ONCOGENE, V21, P6299, DOI 10.1038/sj.onc.1205727; Toft NJ, 1999, P NATL ACAD SCI USA, V96, P3911, DOI 10.1073/pnas.96.7.3911; Tuveson DA, 2004, CANCER CELL, V5, P375, DOI 10.1016/S1535-6108(04)00085-6; Yamada S, 2005, INT J CANCER, V113, P1015, DOI 10.1002/ijc.20666; Zhu CQ, 2004, CLIN CANCER RES, V10, P1984, DOI 10.1158/1078-0432.CCR-03-0470	44	31	34	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2007	26	30					4415	4427		10.1038/sj.onc.1210231	http://dx.doi.org/10.1038/sj.onc.1210231			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	184CZ	17297472				2022-12-28	WOS:000247620000009
J	Morrow, M; Samanta, A; Kioussis, D; Brady, HJM; Williams, O				Morrow, M.; Samanta, A.; Kioussis, D.; Brady, H. J. M.; Williams, O.			TEL-AML1 preleukemic activity requires the DNA binding domain of AML1 and the dimerization and corepressor binding domains of TEL	ONCOGENE			English	Article						leukemia; translocation; ETV6-RUNX1	ACUTE LYMPHOBLASTIC-LEUKEMIA; MULTIPLE CHROMOSOMAL TRANSLOCATIONS; RUNT DOMAIN; NUCLEAR-MATRIX; TRANSCRIPTIONAL REPRESSION; AML1/PEBP2-ALPHA-B GENE; ADULT HEMATOPOIESIS; MUTATION ANALYSIS; POINT MUTATIONS; FUSION PROTEIN	The t(12;21)(p13;q22) translocation generates the TEL-AML1 (TEL, translocation-Ets-leukemia; AML1, acute myeloid leukemia-1) (ETV6-RUNX1) fusion product and is the most common chromosomal abnormality in pediatric leukemia. Our previous studies using a murine fetal liver transplantation model demonstrated that TEL-AML1 promotes the self-renewal of B-cell precursors in vitro and enhances the expansion of hematopoietic stem cells (HSCs) in vivo. This is consistent with the hypothesis that TEL-AML1 induces expansion of a preleukemic clone. Several studies have described domains within TEL-AML1 involved in the transcriptional regulation of specific target genes. However, it is unclear which of these domains is important for the activity of TEL-AML1 in preleukemic hematopoiesis. In order to examine this, we have generated a panel of deletion mutants and expressed them in HSCs. These experiments demonstrate that TEL-AML1 requires multiple domains from both TEL and AML1 to alter hematopoiesis. Furthermore, mutation of a single amino-acid residue within the runt homology domain of AML1, required for DNA binding, was sufficient to abrogate TEL-AML1 activity. These data suggest that TEL-AML1 acts as an aberrant transcription factor to perturb multiple pathways during hematopoiesis.	UCL, Inst Child Hlth, Mol Haematol & Canc Biol Unit, London WC1N 1EH, England; Natl Inst Med Res, Div Mol Immunol, London NW7 1AA, England	University of London; University College London; MRC National Institute for Medical Research	Williams, O (corresponding author), UCL, Inst Child Hlth, Mol Haematol & Canc Biol Unit, 30 Guilford St, London WC1N 1EH, England.	owen.williams@ich.ucl.ac.uk	Williams, Owen/B-5003-2013	Williams, Owen/0000-0002-1760-6880; Morrow, Michelle/0000-0002-4565-2008; Brady, Hugh/0000-0002-3152-067X	Medical Research Council [MC_U117512796] Funding Source: Medline; MRC [MC_U117512796] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Andreasson P, 2001, CANCER GENET CYTOGEN, V130, P93, DOI 10.1016/S0165-4608(01)00518-0; Aronson BD, 1997, MOL CELL BIOL, V17, P5581, DOI 10.1128/MCB.17.9.5581; Bernardin F, 2002, CANCER RES, V62, P3904; Bruhn L, 1997, GENE DEV, V11, P640, DOI 10.1101/gad.11.5.640; Busson-Le Coniat M, 2001, GENE CHROMOSOME CANC, V32, P244, DOI 10.1002/gcc.1188; CAMERON ER, 2001, GENE CHROMOSOME CANC, V30, P407; Cin Paola Dal, 2001, Genes Chromosomes and Cancer, V30, P407; Durst KL, 2004, ONCOGENE, V23, P4220, DOI 10.1038/sj.onc.1207122; Fears S, 1997, P NATL ACAD SCI USA, V94, P1949, DOI 10.1073/pnas.94.5.1949; Fenrick R, 1999, MOL CELL BIOL, V19, P6566; Fischer M, 2005, ONCOGENE, V24, P7579, DOI 10.1038/sj.onc.1208931; GOLUB TR, 1995, P NATL ACAD SCI USA, V92, P4917, DOI 10.1073/pnas.92.11.4917; Greaves MF, 2003, BLOOD, V102, P2321, DOI 10.1182/blood-2002-12-3817; Growney JD, 2005, BLOOD, V106, P494, DOI 10.1182/blood-2004-08-3280; Guidez F, 2000, BLOOD, V96, P2557; Gunji H, 2004, BIOCHEM BIOPH RES CO, V322, P623, DOI 10.1016/j.bbrc.2004.07.169; Hiebert SW, 1996, MOL CELL BIOL, V16, P1349; Ichikawa M, 2004, NAT MED, V10, P299, DOI 10.1038/nm997; Imai Y, 1998, BIOCHEM BIOPH RES CO, V252, P582, DOI 10.1006/bbrc.1998.9705; Javed A, 2000, J CELL SCI, V113, P2221; Kim DH, 1996, BLOOD, V88, P785, DOI 10.1182/blood.V88.3.785.bloodjournal883785; Kitabayashi I, 1998, EMBO J, V17, P2994, DOI 10.1093/emboj/17.11.2994; Li Z, 2003, J BIOL CHEM, V278, P33088, DOI 10.1074/jbc.M303973200; Lopez R, 1999, J BIOL CHEM, V274, P30132, DOI 10.1074/jbc.274.42.30132; Lorsbach RB, 2004, BLOOD, V103, P2522, DOI 10.1182/blood-2003-07-2439; Lutterbach B, 2000, GENE, V245, P223, DOI 10.1016/S0378-1119(00)00014-7; Lutterbach B, 2000, J BIOL CHEM, V275, P651, DOI 10.1074/jbc.275.1.651; McLean TW, 1996, BLOOD, V88, P4252; MEYERS S, 1995, MOL CELL BIOL, V15, P1974; Mikhail FM, 2002, LEUKEMIA, V16, P658, DOI 10.1038/sj.leu.2402399; Mori H, 2002, P NATL ACAD SCI USA, V99, P8242, DOI 10.1073/pnas.112218799; Morrow M, 2004, BLOOD, V103, P3890, DOI 10.1182/blood-2003-10-3695; Niini T, 2000, HAEMATOLOGICA, V85, P362; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Osato M, 1999, BLOOD, V93, P1817, DOI 10.1182/blood.V93.6.1817.406k36_1817_1824; Otto F, 2002, HUM MUTAT, V19, P209, DOI 10.1002/humu.10043; Poirel H, 1998, ONCOGENE, V16, P2895, DOI 10.1038/sj.onc.1201817; Preudhomme C, 2000, BLOOD, V96, P2862, DOI 10.1182/blood.V96.8.2862.h8002862_2862_2869; Quack I, 1999, AM J HUM GENET, V65, P1268, DOI 10.1086/302622; Raynaud S, 1996, BLOOD, V87, P2891, DOI 10.1182/blood.V87.7.2891.bloodjournal8772891; Rho JK, 2002, BIOCHEM BIOPH RES CO, V297, P91, DOI 10.1016/S0006-291X(02)02075-2; ROMANA SP, 1995, BLOOD, V85, P3662, DOI 10.1182/blood.V85.12.3662.bloodjournal85123662; Scandura JM, 2002, ONCOGENE, V21, P3422, DOI 10.1038/sj.onc.1205315; Shurtleff SA, 1995, LEUKEMIA, V9, P1985; Song WJ, 1999, NAT GENET, V23, P166, DOI 10.1038/13793; Sun W, 2004, BLOOD, V104, P3565, DOI 10.1182/blood-2003-12-4349; Tsuzuki S, 2004, P NATL ACAD SCI USA, V101, P8443, DOI 10.1073/pnas.0402063101; Uchida H, 1999, ONCOGENE, V18, P1015, DOI 10.1038/sj.onc.1202383; Wang LC, 1997, EMBO J, V16, P4374, DOI 10.1093/emboj/16.14.4374; Wang LC, 1998, GENE DEV, V12, P2392, DOI 10.1101/gad.12.15.2392; Wang LL, 2001, ONCOGENE, V20, P3716, DOI 10.1038/sj.onc.1204479; Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444; Wiemels JL, 1999, BLOOD, V94, P1057, DOI 10.1182/blood.V94.3.1057.415k10_1057_1062; Yoshida T, 2002, AM J HUM GENET, V71, P724, DOI 10.1086/342717; Zeng CM, 1998, P NATL ACAD SCI USA, V95, P1585, DOI 10.1073/pnas.95.4.1585; Zeng CM, 1997, P NATL ACAD SCI USA, V94, P6746, DOI 10.1073/pnas.94.13.6746; Zhou G, 1999, HUM MOL GENET, V8, P2311, DOI 10.1093/hmg/8.12.2311	57	30	30	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2007	26	30					4404	4414		10.1038/sj.onc.1210227	http://dx.doi.org/10.1038/sj.onc.1210227			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	184CZ	17237815				2022-12-28	WOS:000247620000008
J	Takayama, K; Kaneshiro, K; Tsutsumi, S; Horie-Inoue, K; Ikeda, K; Urano, T; Ijichi, N; Ouchi, Y; Shirahige, K; Aburatani, H; Inoue, S				Takayama, K.; Kaneshiro, K.; Tsutsumi, S.; Horie-Inoue, K.; Ikeda, K.; Urano, T.; Ijichi, N.; Ouchi, Y.; Shirahige, K.; Aburatani, H.; Inoue, S.			Identification of novel androgen response genes in prostate cancer cells by coupling chromatin immunoprecipitation and genomic microarray analysis	ONCOGENE			English	Article						androgen receptor; androgen response element; chromatin immunoprecipitation; prostate cancer; UGT1A	FUNCTIONAL-ANALYSIS; C-MET; RECEPTOR; PROTEIN; EXPRESSION; CARCINOMA; ELEMENTS; LOCUS; TES; SPECIFICITY	The androgen receptor (AR) plays a key role as a transcriptional factor in prostate development and carcinogenesis. Identification of androgen-regulated genes is essential to elucidate the AR pathophysiology in prostate cancer. Here, we identifi. ed androgen target genes that are directly regulated by AR in LNCaP cells, by combining chromatin immunoprecipitation (ChIP) with tiling microarrays (ChIP-chip). ChIP-enriched or control DNAs from the cells treated with R1881 were hybridized with the ENCODE array, in which a set of regions representing approximately 1% of the whole genome. We chose 10 bona fide AR-binding sites (ARBSs) (P < 1e-5) and validated their signifi. cant AR recruitment ligand dependently. Eight upregulated genes by R1881 were identifi. ed in the vicinity of the ARBSs. Among the upregulated genes, we focused on UGT1A and CDH2 as AR target genes, because the ARBSs close to these genes (in UGT1A distal promoter and CDH2 intron 1) were most significantly associated with acetylated histone H3/H4, RNA polymerase II and p160 family co-activators. Luciferase reporter constructs including those two ARBSs exhibited ligand-dependent transcriptional regulator/enhancer activities. The present study would be powerful to extend our knowledge of the diversity of androgen genetic network and steroid action in prostate cancer cells.	Univ Tokyo, Grad Sch Sci, Dept Geriatr Med, Bunkyo Ku, Tokyo 1138655, Japan; Univ Tokyo, Adv Sci & Technol Res Ctr, Genome Sci Div, Tokyo, Japan; Saitama Med Univ, Res Ctr Genom Med, Div Gene Regulat & Signal Transduct, Saitama, Japan; Tokyo Inst Technol, Ctr Biol Res & Informat, Div Gene Res, Tokyo 152, Japan; Japan Sci & Technol Agcy, CREST, Tokyo, Japan	University of Tokyo; University of Tokyo; Saitama Medical University; Tokyo Institute of Technology; Japan Science & Technology Agency (JST)	Horie-Inoue, K (corresponding author), Univ Tokyo, Grad Sch Sci, Dept Geriatr Med, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.	INOUE-GER@h.u-tokyo.ac.jp	Takayama, Kenichi/AAK-9238-2020; Urano, Tomohiko/AFS-9574-2022					Bernstein BE, 2005, CELL, V120, P169, DOI 10.1016/j.cell.2005.01.001; Carroll JS, 2005, CELL, V122, P33, DOI 10.1016/j.cell.2005.05.008; Cawley S, 2004, CELL, V116, P499, DOI 10.1016/S0092-8674(04)00127-8; Chen L, 2004, NEW ASTRON, V10, P39, DOI 10.1016/j.newast.2004.04.008; Chen SJ, 2005, J BIOL CHEM, V280, P37547, DOI 10.1074/jbc.M506683200; Chene L, 2004, INT J CANCER, V111, P798, DOI 10.1002/ijc.20337; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; Coutts AS, 2003, J CELL SCI, V116, P897, DOI 10.1242/jcs.00278; Diaz M, 2002, INT J BIOL MARKER, V17, P125, DOI 10.1177/172460080201700208; Duguay Y, 2004, CANCER RES, V64, P1202, DOI 10.1158/0008-5472.CAN-03-3295; Feingold EA, 2004, SCIENCE, V306, P636, DOI 10.1126/science.1105136; Giuliani L, 2005, ONCOL REP, V13, P185; Gong QH, 2001, PHARMACOGENETICS, V11, P357, DOI 10.1097/00008571-200106000-00011; Grossmann ME, 2001, JNCI-J NATL CANCER I, V93, P1687, DOI 10.1093/jnci/93.22.1687; Harrington WR, 2006, ENDOCRINOLOGY, V147, P3843, DOI 10.1210/en.2006-0358; Hazan RB, 1996, CELL ADHES COMMUN, V4, P399, DOI 10.3109/15419069709004457; Horie-Inoue K, 2006, BIOCHEM BIOPH RES CO, V339, P99, DOI 10.1016/j.bbrc.2005.10.188; Horie-Inoue K, 2004, BIOCHEM BIOPH RES CO, V325, P1312, DOI 10.1016/j.bbrc.2004.10.174; HUMPHREY PA, 1995, AM J PATHOL, V147, P386; Jaggi M, 2006, PROSTATE, V66, P193, DOI 10.1002/pros.20334; Katou Y, 2006, METHOD ENZYMOL, V409, P389, DOI 10.1016/S0076-6879(05)09023-3; Kawana Y, 2002, PROSTATE, V53, P60, DOI 10.1002/pros.10131; Kent WJ, 2002, GENOME RES, V12, P996, DOI 10.1101/gr.229102; Laganiere J, 2005, P NATL ACAD SCI USA, V102, P11651, DOI 10.1073/pnas.0505575102; Lepine J, 2004, J CLIN ENDOCR METAB, V89, P5222, DOI 10.1210/jc.2004-0331; Maeda A, 2006, BIOCHEM BIOPH RES CO, V347, P1158, DOI 10.1016/j.bbrc.2006.07.040; Matys V, 2003, NUCLEIC ACIDS RES, V31, P374, DOI 10.1093/nar/gkg108; Monks DA, 2001, BRAIN RES, V895, P73, DOI 10.1016/S0006-8993(01)02031-5; OGAWA H, 1995, P NATL ACAD SCI USA, V92, P11899, DOI 10.1073/pnas.92.25.11899; PISTERS LL, 1995, J UROLOGY, V154, P293, DOI 10.1016/S0022-5347(01)67297-5; Porkka KP, 2002, LAB INVEST, V82, P1573, DOI 10.1097/01.LAB.0000038554.26102.C6; Sandelin A, 2004, NUCLEIC ACIDS RES, V32, pD91, DOI 10.1093/nar/gkh012; Shang YF, 2002, SCIENCE, V295, P2465, DOI 10.1126/science.1068537; Shang YF, 2002, MOL CELL, V9, P601, DOI 10.1016/S1097-2765(02)00471-9; Strassburg CP, 1997, CANCER RES, V57, P2979; Sugatani J, 2001, HEPATOLOGY, V33, P1232, DOI 10.1053/jhep.2001.24172; Tobias ES, 2001, ONCOGENE, V20, P2844, DOI 10.1038/sj.onc.1204433; Tomita K, 2000, CANCER RES, V60, P3650; Wang QB, 2005, MOL CELL, V19, P631, DOI 10.1016/j.molcel.2005.07.018; Xie W, 2003, P NATL ACAD SCI USA, V100, P4150, DOI 10.1073/pnas.0438010100	40	86	88	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2007	26	30					4453	4463		10.1038/sj.onc.1210229	http://dx.doi.org/10.1038/sj.onc.1210229			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	184CZ	17297473				2022-12-28	WOS:000247620000013
J	Raman, M; Chen, W; Cobb, MH				Raman, M.; Chen, W.; Cobb, M. H.			Differential regulation and properties of MAPKs	ONCOGENE			English	Review						kinase; MAPK; ERK; JNK; p38; phosphorylation	ACTIVATED PROTEIN-KINASE; NF-KAPPA-B; INNATE IMMUNE-RESPONSES; SCAFFOLD PROTEIN; SIGNAL-TRANSDUCTION; NUCLEOCYTOPLASMIC DISTRIBUTION; TRANSCRIPTION FACTORS; DOCKING INTERACTIONS; INSULIN-RESISTANCE; SPLICING VARIANT	Mitogen-activated protein kinases (MAPKs) regulate diverse cellular programs including embryogenesis, proliferation, differentiation and apoptosis based on cues derived from the cell surface and the metabolic state and environment of the cell. In mammals, there are more than a dozen MAPK genes. The best known are the extracellular signal-regulated kinases 1 and 2 (ERK1/2), c-Jun N-terminal kinase (JNK(1-3)) and p38(alpha, beta, gamma and delta) families. ERK3, ERK5 and ERK7 are other MAPKs that have distinct regulation and functions. MAPK cascades consist of a core of three protein kinases. Despite the apparently simple architecture of this pathway, these enzymes are capable of responding to a bewildering number of stimuli to produce exquisitely specific cellular outcomes. These responses depend on the kinetics of their activation and inactivation, the subcellular localization of the kinases, the complexes in which they act, and the availability of substrates. Fine-tuning of cascade activity can occur through modulatory inputs to cascade component from the primary kinases to the scaffolding accessory proteins. Here, we describe some of the properties of the three major MAPK pathways and discuss how these properties govern pathway regulation and activity.	Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75216 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Cobb, MH (corresponding author), 6001 Forest Pk Rd, Dallas, TX 75390 USA.	Melanie.Cobb@UTSouthwestern.edu		raman, malavika/0000-0002-4773-8673; Cobb, Melanie/0000-0003-0833-5473	NIDDK NIH HHS [DK34128] Funding Source: Medline; NIGMS NIH HHS [GM56498, GM53032] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK034128, R01DK034128] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056498] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adachi M, 2000, J CELL BIOL, V148, P849, DOI 10.1083/jcb.148.5.849; Aguirre V, 2000, J BIOL CHEM, V275, P9047, DOI 10.1074/jbc.275.12.9047; Alarcon-Vargas D, 2004, J BIOL CHEM, V279, P5008, DOI 10.1074/jbc.M312054200; Alonso A, 2004, CELL, V117, P699, DOI 10.1016/j.cell.2004.05.018; Aoyama K, 2001, J BIOL CHEM, V276, P27575, DOI 10.1074/jbc.M100408200; Aplin AE, 2002, J CELL SCI, V115, P2781; Arnette D, 2003, J BIOL CHEM, V278, P32517, DOI 10.1074/jbc.M301174200; Babu GR, 2006, BBA-MOL CELL RES, V1763, P174, DOI 10.1016/j.bbamcr.2005.12.010; Barsyte-Lovejoy D, 2002, J BIOL CHEM, V277, P9896, DOI 10.1074/jbc.M108145200; Ben-Levy R, 1998, CURR BIOL, V8, P1049, DOI 10.1016/S0960-9822(98)70442-7; Bonny C, 1998, J BIOL CHEM, V273, P1843, DOI 10.1074/jbc.273.4.1843; Brancho D, 2003, GENE DEV, V17, P1969, DOI 10.1101/gad.1107303; Buchsbaum RJ, 2002, MOL CELL BIOL, V22, P4073, DOI 10.1128/MCB.22.12.4073-4085.2002; Bulavin DV, 2001, NATURE, V411, P102, DOI 10.1038/35075107; Chang CI, 2002, MOL CELL, V9, P1241, DOI 10.1016/S1097-2765(02)00525-7; Chen Z, 2001, CHEM REV, V101, P2449, DOI 10.1021/cr000241p; Chi HB, 2006, P NATL ACAD SCI USA, V103, P2274, DOI 10.1073/pnas.0510965103; Chiariello M, 2000, MOL CELL BIOL, V20, P1747, DOI 10.1128/MCB.20.5.1747-1758.2000; Chinkers M, 2001, TRENDS ENDOCRIN MET, V12, P28, DOI 10.1016/S1043-2760(00)00335-0; Cho JH, 2005, P NATL ACAD SCI USA, V102, P2350, DOI 10.1073/pnas.0409856102; Conrad PW, 1999, J BIOL CHEM, V274, P33709, DOI 10.1074/jbc.274.47.33709; Conrad PW, 2000, ADV EXP MED BIOL, V475, P293; Court NW, 2002, J MOL CELL CARDIOL, V34, P413, DOI 10.1006/jmcc.2001.1523; Cuevas BD, 2005, ONCOGENE, V24, P801, DOI 10.1038/sj.onc.1208239; Das S, 2005, J BIOL CHEM, V280, P23748, DOI 10.1074/jbc.M412837200; Dougherty MK, 2005, MOL CELL, V17, P215, DOI 10.1016/j.molcel.2004.11.055; Dumitru CD, 2000, CELL, V103, P1071, DOI 10.1016/S0092-8674(00)00210-5; Efimova T, 2003, J BIOL CHEM, V278, P34277, DOI 10.1074/jbc.M302759200; Eftmova T, 2002, J BIOL CHEM, V277, P31753, DOI 10.1074/jbc.M205098200; Elion EA, 2001, J CELL SCI, V114, P3967; Enslen H, 1998, J BIOL CHEM, V273, P1741, DOI 10.1074/jbc.273.3.1741; Faccio L, 2000, AM J PHYSIOL-CELL PH, V278, pC781, DOI 10.1152/ajpcell.2000.278.4.C781; Formstecher E, 2001, DEV CELL, V1, P239, DOI 10.1016/S1534-5807(01)00035-1; Frantz B, 1998, BIOCHEMISTRY-US, V37, P13846, DOI 10.1021/bi980832y; Furuchi T, 1998, J BIOL CHEM, V273, P21099, DOI 10.1074/jbc.273.33.21099; Gang L, 2006, J BIOL CHEM, V281, P6087, DOI 10.1074/jbc.M507610200; Ganiatsas S, 1998, P NATL ACAD SCI USA, V95, P6881, DOI 10.1073/pnas.95.12.6881; Heo JS, 2004, EMBO J, V23, P2185, DOI 10.1038/sj.emboj.7600212; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Hirosumi J, 2002, NATURE, V420, P333, DOI 10.1038/nature01137; Horiuchi D, 2005, CURR BIOL, V15, P2137, DOI 10.1016/j.cub.2005.10.047; Hu JH, 2007, CELL SIGNAL, V19, P393, DOI 10.1016/j.cellsig.2006.07.010; Hu MCT, 1999, J BIOL CHEM, V274, P7095, DOI 10.1074/jbc.274.11.7095; Ishibe S, 2004, MOL CELL, V16, P257, DOI 10.1016/j.molcel.2004.10.006; Ito M, 1999, MOL CELL BIOL, V19, P7539; Jacobs D, 1999, GENE DEV, V13, P163, DOI 10.1101/gad.13.2.163; Jesch SA, 2001, MOL BIOL CELL, V12, P1811, DOI 10.1091/mbc.12.6.1811; Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682; Kashef K, 2005, BIOCHEMISTRY-US, V44, P14090, DOI 10.1021/bi050604l; Kelkar N, 2005, MOL CELL BIOL, V25, P2733, DOI 10.1128/MCB.25.7.2733-2743.2005; Kelkar N, 2000, MOL CELL BIOL, V20, P1030, DOI 10.1128/MCB.20.3.1030-1043.2000; Kolch W, 2005, NAT REV MOL CELL BIO, V6, P827, DOI 10.1038/nrm1743; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; Lawler S, 1998, CURR BIOL, V8, P1387, DOI 10.1016/S0960-9822(98)00019-0; Lee CM, 2002, P NATL ACAD SCI USA, V99, P14189, DOI 10.1073/pnas.232310199; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; Letourneux C, 2006, EMBO J, V25, P727, DOI 10.1038/sj.emboj.7600980; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; Lu ZM, 2002, MOL CELL, V9, P945, DOI 10.1016/S1097-2765(02)00519-1; Luo W, 2003, J BIOL CHEM, V278, P37451, DOI 10.1074/jbc.M305277200; Luttrell LM, 2001, P NATL ACAD SCI USA, V98, P2449, DOI 10.1073/pnas.041604898; Manke IA, 2005, MOL CELL, V17, P37, DOI 10.1016/j.molcel.2004.11.021; Marinissen MT, 2001, GENE DEV, V15, P535, DOI 10.1101/gad.855801; Matsubayashi Y, 2001, J BIOL CHEM, V276, P41755, DOI 10.1074/jbc.M106012200; Morrison DK, 2003, ANNU REV CELL DEV BI, V19, P91, DOI 10.1146/annurev.cellbio.19.111401.091942; Mukherjee S, 2006, SCIENCE, V312, P1211, DOI 10.1126/science.1126867; Orth K, 1999, SCIENCE, V285, P1920, DOI 10.1126/science.285.5435.1920; Parker CG, 1998, BIOCHEM BIOPH RES CO, V249, P791, DOI 10.1006/bbrc.1998.9250; Paul S, 2003, NAT NEUROSCI, V6, P34, DOI 10.1038/nn989; Pearson GW, 2006, MOL CELL BIOL, V26, P3039, DOI 10.1128/MCB.26.8.3039-3047.2006; Ranganathan A, 2006, J BIOL CHEM, V281, P15645, DOI 10.1074/jbc.M513866200; Rapp UR, 2006, CANCER CELL, V9, P9, DOI 10.1016/j.ccr.2005.12.022; RASAR M, 2006, IN PRESS J BIOL CHEM, V281; RESZKA AA, 1995, P NATL ACAD SCI USA, V92, P8881, DOI 10.1073/pnas.92.19.8881; Robinson CH, 2002, RADIOACTIV ENVIRONM, V2, P1; Roy M, 2004, J BIOL CHEM, V279, P17329, DOI 10.1074/jbc.M308405200; Rubinfeld H, 1999, J BIOL CHEM, V274, P30349, DOI 10.1074/jbc.274.43.30349; Sabapathy K, 2004, MOL CELL, V15, P713, DOI 10.1016/j.molcel.2004.08.028; Salmeron A, 1996, EMBO J, V15, P817, DOI 10.1002/j.1460-2075.1996.tb00417.x; Salojin KV, 2006, J IMMUNOL, V176, P1899, DOI 10.4049/jimmunol.176.3.1899; Sanz V, 2000, FEBS LETT, V474, P169, DOI 10.1016/S0014-5793(00)01598-2; Sanz-Moreno V, 2003, MOL CELL BIOL, V23, P3079, DOI 10.1128/MCB.23.9.3079-3090.2003; Saxena M, 2000, SEMIN IMMUNOL, V12, P387, DOI 10.1006/smim.2000.0219; Schoorlemmer J, 2002, J BIOL CHEM, V277, P49111, DOI 10.1074/jbc.M205520200; Seternes OM, 2002, MOL CELL BIOL, V22, P6931, DOI 10.1128/MCB.22.20.6931-6945.2002; Sharrocks AD, 2000, TRENDS BIOCHEM SCI, V25, P448, DOI 10.1016/S0968-0004(00)01627-3; Shaul YD, 2006, J CELL BIOL, V172, P885, DOI 10.1083/jcb.200509063; Sudo T, 2002, BIOCHEM BIOPH RES CO, V291, P838, DOI 10.1006/bbrc.2002.6529; Takekawa M, 2005, MOL CELL, V18, P295, DOI 10.1016/j.molcel.2005.04.001; Tanoue T, 2001, EMBO J, V20, P466, DOI 10.1093/emboj/20.3.466; Tanoue T, 2000, NAT CELL BIOL, V2, P110, DOI 10.1038/35000065; Tapon N, 1998, EMBO J, V17, P1395, DOI 10.1093/emboj/17.5.1395; Teis D, 2002, DEV CELL, V3, P803, DOI 10.1016/S1534-5807(02)00364-7; Torii S, 2004, DEV CELL, V7, P33, DOI 10.1016/j.devcel.2004.05.019; Tournier C, 1999, MOL CELL BIOL, V19, P1569; Tsuda M, 2006, FEBS LETT, V580, P3296, DOI 10.1016/j.febslet.2006.05.005; Uhlik MT, 2003, NAT CELL BIOL, V5, P1104, DOI 10.1038/ncb1071; Wang XF, 2000, MOL CELL BIOL, V20, P4543, DOI 10.1128/MCB.20.13.4543-4552.2000; Wang ZL, 1997, P NATL ACAD SCI USA, V94, P2327, DOI 10.1073/pnas.94.6.2327; Whitehurst AW, 2004, J BIOL CHEM, V279, P12840, DOI 10.1074/jbc.M310031200; Whitehurst AW, 2002, P NATL ACAD SCI USA, V99, P7496, DOI 10.1073/pnas.112495999; Whitmarsh AJ, 1998, SCIENCE, V281, P1671, DOI 10.1126/science.281.5383.1671; Wilson KP, 1996, J BIOL CHEM, V271, P27696, DOI 10.1074/jbc.271.44.27696; Witowsky JA, 2003, J BIOL CHEM, V278, P1403, DOI 10.1074/jbc.C200616200; Wu JJ, 2006, CELL METAB, V4, P61, DOI 10.1016/j.cmet.2006.05.010; Xia Y, 1998, GENE DEV, V12, P3369, DOI 10.1101/gad.12.21.3369; Xu SC, 1997, J BIOL CHEM, V272, P32056, DOI 10.1074/jbc.272.51.32056; Xu ZH, 2003, EMBO J, V22, P252, DOI 10.1093/emboj/cdg021; Yagasaki Y, 2004, FEBS LETT, V575, P136, DOI 10.1016/j.febslet.2004.08.050; Yamaguchi T, 2003, KIDNEY INT, V63, P1983, DOI 10.1046/j.1523-1755.2003.00023.x; Yoon S, 2006, GROWTH FACTORS, V24, P21, DOI 10.1080/02699050500284218; Yung Y, 2001, J BIOL CHEM, V276, P35280, DOI 10.1074/jbc.M105995200; ZERVOS AS, 1995, P NATL ACAD SCI USA, V92, P10531, DOI 10.1073/pnas.92.23.10531; Zhang H, 2001, J BIOL CHEM, V276, P6905, DOI 10.1074/jbc.C000917200; Zhang JL, 2003, J BIOL CHEM, V278, P29901, DOI 10.1074/jbc.M303909200; Zhang Y, 1999, J BIOL CHEM, V274, P35247, DOI 10.1074/jbc.274.49.35247; Zhou B, 2006, J BIOL CHEM, V281, P38834, DOI 10.1074/jbc.M608916200; Zhou GS, 2004, J BIOL CHEM, V279, P49551, DOI 10.1074/jbc.M410317200; Zhou TJ, 2006, STRUCTURE, V14, P1011, DOI 10.1016/j.str.2006.04.006	119	1073	1138	3	154	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 15	2007	26	22					3100	3112		10.1038/sj.onc.1210392	http://dx.doi.org/10.1038/sj.onc.1210392			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	169PH	17496909				2022-12-28	WOS:000246603600002
J	Gudmundsdottir, K; Lord, CJ; Ashworth, A				Gudmundsdottir, K.; Lord, C. J.; Ashworth, A.			The proteasome is involved in determining differential utilization of double-strand break repair pathways	ONCOGENE			English	Article						DSS1; BRCA2; proteasome; double-strand break	SACCHAROMYCES-CEREVISIAE; MAMMALIAN-CELLS; USTILAGO-MAYDIS; DNA-REPAIR; DSS1; STABILITY; YEAST; BRCA2; RECOMBINATION; PROTEIN	The DSS1 protein interacts with the breast cancer susceptibility protein BRCA2 that plays an integral role in the repair of DNA double-strand breaks (DSBs). DSS1 has also been shown to interact with components of the 26S proteasome in Saccharomyces cerevisiae and in human tumour cells. This raises the possibility of functional interplay between the DNA repair machinery and the proteasome. We show here that human DSS1 interacts with the RPN3 and RPN7 proteasome subunits and de. ne regions of DSS1 important for the interactions with RPN3, RPN7 and BRCA2. We also show that BRCA2 interacts with RPN3 and RPN7 and that the BRCA2/RPN7 interaction is independent of DSS1. Finally, and most significantly, we demonstrate that the proteolytic activity of the proteasome is a determinant of the choice of DSB repair pathway; inhibition of proteasome proteolytic activity results in an increase in the utilization of potentially mutagenic single-strand annealing at the expense of a reduction in the level of error-free gene conversion. This confirms a functional link between DSB repair and proteasomal activity.	Canc Res Inst, Breakthrough Breast Canc Res Ctr, Gene Funct Lab, London, England	University of London; Institute of Cancer Research - UK	Ashworth, A (corresponding author), Inst Canc Res, Breakthrough Breast Canc Res Ctr, Fulham Rd, London SW3 6JB, England.	alan.ashworth@icr.ac.uk	Lord, Christopher J/B-3295-2012; Lord, Christopher/AAX-7130-2021	Lord, Christopher J/0000-0002-3226-0515; 	Cancer Research UK [A8363] Funding Source: Medline; Breast Cancer Now [BREAST CANCER NOW RESEARCH CENTRE] Funding Source: Medline	Cancer Research UK(Cancer Research UK); Breast Cancer Now		Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Crackower MA, 1996, HUM MOL GENET, V5, P571, DOI 10.1093/hmg/5.5.571; Funakoshi M, 2004, J CELL SCI, V117, P6447, DOI 10.1242/jcs.01575; Gudmundsdottir K, 2004, EMBO REP, V5, P989, DOI 10.1038/sj.embor.7400255; Isono E, 2005, J BIOL CHEM, V280, P6537, DOI 10.1074/jbc.M409364200; Josse L, 2006, BIOCHEM J, V393, P303, DOI 10.1042/BJ20051238; Kojic M, 2005, MOL CELL BIOL, V25, P2547, DOI 10.1128/MCB.25.7.2547-2557.2005; Kojic M, 2003, MOL CELL, V12, P1043, DOI 10.1016/S1097-2765(03)00367-8; Krogan NJ, 2004, MOL CELL, V16, P1027, DOI 10.1016/j.molcel.2004.11.033; Li J, 2006, ONCOGENE, V25, P1186, DOI 10.1038/sj.onc.1209153; Marston NJ, 1999, MOL CELL BIOL, V19, P4633; Schauber C, 1998, NATURE, V391, P715, DOI 10.1038/35661; Sin N, 1999, BIOORG MED CHEM LETT, V9, P2283, DOI 10.1016/S0960-894X(99)00376-5; Sone T, 2004, J BIOL CHEM, V279, P28807, DOI 10.1074/jbc.M403165200; Tutt A, 2001, EMBO J, V20, P4704, DOI 10.1093/emboj/20.17.4704; Yang HJ, 2002, SCIENCE, V297, P1837, DOI 10.1126/science.297.5588.1837	16	44	45	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 29	2007	26	54					7601	7606		10.1038/sj.onc.1210579	http://dx.doi.org/10.1038/sj.onc.1210579			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	236DB	17563742				2022-12-28	WOS:000251282100014
J	Lin, YC; Diccianni, MB; Kim, Y; Lin, HH; Lee, CH; Lin, RJ; Joo, SH; Li, J; Chuang, TJ; Yang, AS; Kuo, HH; Tsai, MD; Yu, AL				Lin, Y-C; Diccianni, M. B.; Kim, Y.; Lin, H-H; Lee, C-H; Lin, R-J; Joo, S. H.; Li, J.; Chuang, T-J; Yang, A-S; Kuo, H-H; Tsai, M-D; Yu, A. L.			Human p16 gamma, a novel transcriptional variant of p16(INK4A), coexpresses with p16(INK4A) in cancer cells and inhibits cell-cycle progression	ONCOGENE			English	Article						INK4A; alternative splicing; cell-cycle inhibitor	TUMOR-SUPPRESSOR P16(INK4A); P16INK4A RNA TRANSCRIPTS; DEPENDENT KINASES; P16; GENE; MUTATIONS; PROTEINS; DELETION; FREQUENT; PATHWAY	The INK4A locus encodes two tumor suppressor genes, p16(INK4A) and p14(ARF), transcribed using alternative exons 1 alpha or 1 beta spliced onto the same exons 2 and 3. Both p16(INK4A) and p14(ARF) are capable of inhibiting the cell-cycle progression, albeit in different manner; p16(INK4A) is phosphorylation of retinoblastoma (pRB) dependent while p14(ARF) is p53-dependent. In this study, we report the discovery of a novel variant of p16(INK4A), termed p16 gamma, in a primary T-cell acute lymphoblastic leukemia (T-ALL) patient sample and a neuroblastoma cell line, which was expressed at both the transcriptional and translational levels. Cloning and sequencing of the p16 gamma cDNA revealed that p16 gamma was identical to p16(INK4A), except that it contained an in-frame insertion of 197 bp between exons 2 and 3. p16 gamma expression was detected in the majority of p16(INK4A)-expressing primary T-ALL and B-ALL patient samples and other p16(INK4A)-expressing tumor samples, but was only barely detectable in some normal mononuclear cells and other non-tumor samples. Structural analysis by nuclear magnetic resonance and circular dichroism con. firmed that p16 gamma, like p16(INK4A), is also an ankyrin-repeat protein. Functional analysis of p16 gamma revealed that p16 gamma protein interacted with cyclin D-dependent kinase4 and inhibited its kinase activity. Using a luciferase reporter assay, the transfection of p16 gamma repressed the E2F response, the downstream target of pRB, with an efficacy equivalent to that of p16(INK4A). Moreover p16 gamma, like p16(INK4A), induced cell-cycle arrest at G(0)/G(1), and inhibited cell growth in colony formation assay.	Acad Sinica, Ctr Gene Res, Taipei 115, Taiwan; Univ Calif San Diego, Dept Pediat Hematol Oncol, San Diego, CA USA; Ohio State Univ, Dept Chem, Columbus, OH 43210 USA	Academia Sinica - Taiwan; University of California System; University of California San Diego; University System of Ohio; Ohio State University	Yu, AL (corresponding author), Acad Sinica, Ctr Gene Res, 128 Acad Rd,Sec 2 Nankang Dist, Taipei 115, Taiwan.	aliceyu@ucsd.edu	Lin, Hsin-Hung/J-5254-2013; , MitchDiccianni/AAF-8486-2019; Tsai, Ming-Daw/G-4689-2019	Lin, Hsin-Hung/0000-0001-8327-6835; , MitchDiccianni/0000-0002-5017-9585; Tsai, Ming-Daw/0000-0003-1374-0414; Yang, An-Suei/0000-0002-4699-873X; yu, alice/0000-0003-2444-0505; Lin, Ruey-Jen/0000-0001-5586-1770	NATIONAL CANCER INSTITUTE [P30CA023100, R01CA069472] Funding Source: NIH RePORTER; NCI NIH HHS [2 P30CA23100-18, CA69472] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDRADE MA, 1993, PROTEIN ENG, V6, P383, DOI 10.1093/protein/6.4.383; Aretz S, 2004, HUM MUTAT, V24, P370, DOI 10.1002/humu.20087; Batova A, 1997, CANCER RES, V57, P832; Byeon IJL, 1998, MOL CELL, V1, P421, DOI 10.1016/S1097-2765(00)80042-8; CALDAS C, 1994, NAT GENET, V8, P27, DOI 10.1038/ng0994-27; Chen YJ, 1997, INT J CANCER, V71, P350, DOI 10.1002/(SICI)1097-0215(19970502)71:3<350::AID-IJC7>3.0.CO;2-X; CHENG JQ, 1994, CANCER RES, V54, P5547; Cho JW, 2003, LIVER INT, V23, P194, DOI 10.1034/j.1600-0676.2003.00821.x; Diccianni MB, 1996, CANCER LETT, V104, P183, DOI 10.1016/0304-3835(96)04250-4; Diccianni MB, 1999, INT J CANCER, V80, P145, DOI 10.1002/(SICI)1097-0215(19990105)80:1<145::AID-IJC26>3.3.CO;2-7; Diccianni Mitchell B, 2004, J Exp Ther Oncol, V4, P223; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; ElSharawy A, 2006, HUM MUTAT, V27, P1129, DOI 10.1002/humu.20377; Fu GH, 2005, FEBS LETT, V579, P2105, DOI 10.1016/j.febslet.2005.02.063; Harland M, 2001, HUM MOL GENET, V10, P2679, DOI 10.1093/hmg/10.23.2679; Hillman RT, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-2-r8; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; JEN J, 1994, CANCER RES, V54, P6353; Kim WY, 2006, CELL, V127, P265, DOI 10.1016/j.cell.2006.10.003; Komata T, 2003, BRIT J CANCER, V88, P1277, DOI 10.1038/sj.bjc.6600862; KREK W, 1993, SCIENCE, V262, P1557, DOI 10.1126/science.8248803; Li JN, 2003, BIOCHEMISTRY-US, V42, P13476, DOI 10.1021/bi035390r; Li JN, 2002, BIOCHEMISTRY-US, V41, P3977, DOI 10.1021/bi011550s; Li JN, 1999, BIOCHEMISTRY-US, V38, P2930, DOI 10.1021/bi982286e; Li JN, 2006, BIOCHEMISTRY-US, V45, P15168, DOI 10.1021/bi062188q; Lin YC, 2000, ONCOGENE, V19, P2704, DOI 10.1038/sj.onc.1203582; MAO L, 1995, CANCER RES, V55, P2995; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; OKAMOTO A, 1994, P NATL ACAD SCI USA, V91, P11045, DOI 10.1073/pnas.91.23.11045; Omura-Minamisawa M, 2001, CLIN CANCER RES, V7, P3481; Omura-Minamisawa M, 2000, CLIN CANCER RES, V6, P1219; Ortega S, 2002, BBA-REV CANCER, V1602, P73, DOI 10.1016/S0304-419X(02)00037-9; Pace C N, 1986, Methods Enzymol, V131, P266; QUELLE DE, 1995, CELL, V83, P993; Robertson KD, 1999, ONCOGENE, V18, P3810, DOI 10.1038/sj.onc.1202737; Russo AA, 1998, NATURE, V395, P237, DOI 10.1038/26155; Schutte M, 1997, CANCER RES, V57, P3126; Serrano M, 1997, EXP CELL RES, V237, P7, DOI 10.1006/excr.1997.3824; Sherr CJ, 2006, NAT REV CANCER, V6, P663, DOI 10.1038/nrc1954; STONE S, 1995, CANCER RES, V55, P2988; Suh SI, 2000, CANCER LETT, V160, P81, DOI 10.1016/S0304-3835(00)00566-8; Suh SI, 2000, CANCER LETT, V153, P175, DOI 10.1016/S0304-3835(00)00369-4; Tevelev A, 1996, BIOCHEMISTRY-US, V35, P9475, DOI 10.1021/bi960211+; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; Yi Y, 2006, HUM MOL GENET, V15, P2192, DOI 10.1093/hmg/ddl144; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4	46	26	29	0	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2007	26	49					7017	7027		10.1038/sj.onc.1210507	http://dx.doi.org/10.1038/sj.onc.1210507			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	223YN	17486064				2022-12-28	WOS:000250412200007
J	Jeng, YM; Cai-Ng, S; Li, A; Furuta, S; Chew, H; Chen, PL; Lee, EYH; Lee, WH				Jeng, Y-M; Cai-Ng, S.; Li, A.; Furuta, S.; Chew, H.; Chen, P-L; Lee, E-Y-H; Lee, W-H			Brca1 heterozygous mice have shortened life span and are prone to ovarian tumorigenesis with haploinsufficiency upon ionizing irradiation	ONCOGENE			English	Article						BRCA1; heterozygous mutant; ionizing radiation; ovarian tumor; haploinsufficiency	INDUCED MICRONUCLEUS FREQUENCIES; BREAST-CANCER RISK; MUTATION CARRIERS; SCREENING-TEST; EARLY-ONSET; DNA-REPAIR; GENE; LYMPHOCYTES; WOMEN; P53	BRCA1 mutation carriers have an 85% lifetime risk of breast cancer and 60% for ovarian cancer. BRCA1 facilitates DNA double-strand break repair, and dysfunction of BRCA1 leads to hypersensitivity to DNA damaging agents and consequently genomic instability of cells. In this communication, we have examined the tumor incidence and survival of Brca1 heterozygous female mice. Brca1 heterozygotes appear to have a shortened life span with 70% tumor incidence. Lymphoma, but not ovarian and mammary gland tumors, occurs commonly in these mice. After a whole-body exposure to ionizing radiation, Brca1 heterozygous mice have a 3-5- fold higher incidence specific to ovarian tumors, but not lymphoma, when compared with the Brca1+/+ mice. All the tumors from heterozygous mice examined retain the wild-type allele and the cancer cells express Brca1 protein, precluding the chromosomal mechanism for loss of heterozygosity of Brca1 locus. Although the manifestation of BRCA1 haploin sufficiency may be different between human and mouse, this study suggests that women carrying Brca1 mutations may be more prone to ovarian tumor formation after IR exposure than nonmutation carriers.	Univ Calif Irvine, Coll Med, Dept Biol Chem, Irvine, CA 92697 USA	University of California System; University of California Irvine	Lee, WH (corresponding author), Univ Calif Irvine, Dept Biol Chem, Coll Med, 839 Med Sci Court,124 Sprague hall, Irvine, CA 92697 USA.	whlee@uci.edu	Chen, Phang-Lang/J-5031-2013; Furuta, Saori/P-9677-2018	Furuta, Saori/0000-0003-1121-0487; JENG, YUNG-MING/0000-0002-3878-4491	PHS HHS [R01 94170] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Baeyens A, 2004, INT J RADIAT BIOL, V80, P745, DOI 10.1080/09553000400017937; Baldeyron C, 2002, ONCOGENE, V21, P1401, DOI 10.1038/sj.onc.1205200; Baria K, 2001, CANCER RES, V61, P5948; Brekelmans CTM, 2001, J CLIN ONCOL, V19, P924, DOI 10.1200/JCO.2001.19.4.924; Burke W, 1997, JAMA-J AM MED ASSOC, V277, P997, DOI 10.1001/jama.277.12.997; Cao L, 2003, GENE DEV, V17, P201, DOI 10.1101/gad.1050003; Couch FJ, 1997, NEW ENGL J MED, V336, P1409, DOI 10.1056/NEJM199705153362002; de Boer J, 2002, SCIENCE, V296, P1276, DOI 10.1126/science.1070174; Deng Chu-Xia, 2004, Methods Mol Biol, V280, P185; EASTON DF, 1995, AM J HUM GENET, V56, P265; FLETCHER SW, 1993, J NATL CANCER I, V85, P1644, DOI 10.1093/jnci/85.20.1644; Foray N, 1999, ONCOGENE, V18, P7334, DOI 10.1038/sj.onc.1203165; Friedenson B, 2000, MedGenMed, V2, pE9; Goldfrank D, 2006, CANCER EPIDEM BIOMAR, V15, P2311, DOI 10.1158/1055-9965.EPI-06-0176; Goss PE, 1998, J CLIN ONCOL, V16, P338, DOI 10.1200/JCO.1998.16.1.338; Greenblatt MS, 2001, CANCER RES, V61, P4092; Haffty BG, 2002, LANCET, V359, P1471, DOI 10.1016/S0140-6736(02)08434-9; Hashizume R, 2001, J BIOL CHEM, V276, P14537, DOI 10.1074/jbc.C000881200; Kirova YM, 2005, CANCER-AM CANCER SOC, V104, P856, DOI 10.1002/cncr.21223; Kote-Jarai Z, 2006, BRIT J CANCER, V94, P308, DOI 10.1038/sj.bjc.6602912; Kotsopoulos J, 2007, BRIT J CANCER, V96, P118, DOI 10.1038/sj.bjc.6603528; Li S, 2000, NATURE, V406, P210, DOI 10.1038/35018134; Li S, 1999, J BIOL CHEM, V274, P11334, DOI 10.1074/jbc.274.16.11334; Liu CY, 1996, GENE DEV, V10, P1835, DOI 10.1101/gad.10.14.1835; Metcalfe KA, 2005, GYNECOL ONCOL, V96, P222, DOI 10.1016/j.ygyno.2004.09.039; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Narod SA, 2006, LANCET ONCOL, V7, P402, DOI 10.1016/S1470-2045(06)70624-6; NEUHAUSEN SL, 1994, CANCER RES, V54, P6069; Nikitin AY, 1996, GENE DEV, V10, P1870, DOI 10.1101/gad.10.15.1870; Pao GM, 2000, P NATL ACAD SCI USA, V97, P1020, DOI 10.1073/pnas.97.3.1020; Rothfuss A, 2000, CANCER RES, V60, P390; Salim EI, 2003, CARCINOGENESIS, V24, P335, DOI 10.1093/carcin/24.2.335; Schildkraut JM, 1997, JNCI-J NATL CANCER I, V89, P932, DOI 10.1093/jnci/89.13.932; Scully R, 1997, P NATL ACAD SCI USA, V94, P5605, DOI 10.1073/pnas.94.11.5605; Shanley S, 2006, CLIN CANCER RES, V12, P7025, DOI 10.1158/1078-0432.CCR-06-1244; Shen SX, 1998, ONCOGENE, V17, P3115, DOI 10.1038/sj.onc.1202243; THOMPSON ME, 1995, NAT GENET, V9, P444, DOI 10.1038/ng0495-444; Ting NSY, 2004, DNA REPAIR, V3, P935, DOI 10.1016/j.dnarep.2004.03.026; Verhoog LC, 1998, LANCET, V351, P316, DOI 10.1016/S0140-6736(97)07065-7; Vogel H, 1999, P NATL ACAD SCI USA, V96, P10770, DOI 10.1073/pnas.96.19.10770; WAGNER EH, 1998, EFFECTIVE CLIN PRACT, V1, P1; Yarden RI, 1999, P NATL ACAD SCI USA, V96, P4983, DOI 10.1073/pnas.96.9.4983; Yu XC, 2003, SCIENCE, V302, P639, DOI 10.1126/science.1088753; Zhang JR, 2004, MOL CELL BIOL, V24, P708, DOI 10.1128/MCB.24.2.708-718.2004; Zheng L, 2000, MOL CELL, V6, P757, DOI 10.1016/S1097-2765(00)00075-7; Zheng L, 2000, ONCOGENE, V19, P6159, DOI 10.1038/sj.onc.1203968; Zhong Q, 1999, SCIENCE, V285, P747, DOI 10.1126/science.285.5428.747	47	28	28	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 13	2007	26	42					6160	6166		10.1038/sj.onc.1210451	http://dx.doi.org/10.1038/sj.onc.1210451			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	209PU	17420720				2022-12-28	WOS:000249401300006
J	Zisman-Rozen, S; Fink, D; Ben-Izhak, O; Fuchs, Y; Brodski, A; Kraus, MH; Bejar, J; Ron, D				Zisman-Rozen, S.; Fink, D.; Ben-Izhak, O.; Fuchs, Y.; Brodski, A.; Kraus, M. H.; Bejar, J.; Ron, D.			Downregulation of Sef, an inhibitor of receptor tyrosine kinase signaling, is common to a variety of human carcinomas	ONCOGENE			English	Article						Sef; RTK; cancer	PROSTATE-CANCER; SPECIFICITY; EXPRESSION; PATHWAYS; ISOFORM; GRADE	Carcinomas are tumors of epithelial origin accounting for over 80% of all human malignancies. A substantial body of evidence implicates oncogenic signaling by receptor tyrosine kinases ( RTKs) in carcinoma development. Here we investigated the expression of Sef, a novel inhibitor of RTK signaling, in normal human epithelial tissues and derived malignancies. Human Sef ( hSef) was highly expressed in normal epithelial cells of breast, prostate, thyroid gland and the ovarian surface. By comparison, substantial downregulation of hSef expression was observed in the majority of tumors originating from these epithelia. Among 186 primary carcinomas surveyed by RNA in situ hybridization, hSef expression was undetectable in 116 cases including 72/99 ( 73%) breast, 11/ 16 ( 69%) thyroid, 16/ 31 ( 52%) prostate and 17/ 40 ( 43%) ovarian carcinomas. Moderate reduction of expression was observed in 17/ 186, and marked reduction in 40/ 186 tumors. Only 13/ 186 cases including 12 low- grade and one intermediate grade tumor retained high hSef expression. The association of hSef downregulation and tumor progression was statistically significant ( P<0.001). Functionally, ectopic expression of hSef suppressed proliferation of breast carcinoma cells, whereas inhibition of endogenous hSef expression accelerated fibroblast growth factor and epidermal growth factor- dependent proliferation of cervical carcinoma cells. The inhibitory effect of hSef on cell proliferation combined with consistent downregulation in human carcinoma indicates a tumor suppressor- like role for hSef, and implicates loss of hSef expression as a common mechanism in epithelial neoplasia.	Technion Israel Inst Technol, Dept Biol, IL-32000 Haifa, Israel; Rambam Med Ctr, Dept Pathol, Haifa, Israel; Bnai Zion Med Ctr, Dept Gen Surg, Haifa, Israel; Univ Alabama, Dept Med, Birmingham, AL 35294 USA; Bnai Zion Med Ctr, Dept Pathol, Haifa, Israel	Technion Israel Institute of Technology; Rambam Health Care Campus; Technion Israel Institute of Technology; Bnai Zion Medical Center; University of Alabama System; University of Alabama Birmingham; Bnai Zion Medical Center	Ron, D (corresponding author), Technion Israel Inst Technol, Dept Biol, IL-32000 Haifa, Israel.	dinar@tx.technion.ac.il						Bell DA, 2005, MODERN PATHOL, V18, pS19, DOI 10.1038/modpathol.3800306; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; Darby S, 2006, ONCOGENE, V25, P4122, DOI 10.1038/sj.onc.1209428; De Marzo AM, 1999, UROLOGY, V53, P29, DOI 10.1016/S0090-4295(98)00536-6; Furthauer M, 2002, NAT CELL BIOL, V4, P170, DOI 10.1038/ncb750; Gimm O, 2001, CANCER LETT, V163, P143, DOI 10.1016/S0304-3835(00)00697-2; Grose R, 2005, CYTOKINE GROWTH F R, V16, P179, DOI 10.1016/j.cytogfr.2005.01.003; Harduf H, 2005, DEV DYNAM, V233, P301, DOI 10.1002/dvdy.20364; Jemal A, 2006, CA-CANCER J CLIN, V56, P106, DOI 10.3322/canjclin.56.2.106; KOSARY CL, 1994, SEMIN SURG ONCOL, V10, P31, DOI 10.1002/ssu.2980100107; Matsumoto S, 1997, GENE CHROMOSOME CANC, V20, P268; Normanno N, 2005, CURR DRUG TARGETS, V6, P243, DOI 10.2174/1389450053765879; Preger E, 2004, P NATL ACAD SCI USA, V101, P1229, DOI 10.1073/pnas.0307952100; SHAOUL E, 1995, ONCOGENE, V10, P1553; Sher I, 2006, J BIOL CHEM, V281, P5178, DOI 10.1074/jbc.M509500200; TAVASSOLI FA, 2003, GENETICS TUMORS BREA, P18; Thompson N, 2005, CURR OPIN PHARMACOL, V5, P350, DOI 10.1016/j.coph.2005.04.007; Torii S, 2004, DEV CELL, V7, P33, DOI 10.1016/j.devcel.2004.05.019; Tsang M, 2002, NAT CELL BIOL, V4, P165, DOI 10.1038/ncb749; Xiong SQ, 2003, J BIOL CHEM, V278, P50273, DOI 10.1074/jbc.M306936200; Yang RB, 2003, J BIOL CHEM, V278, P33232, DOI 10.1074/jbc.M305022200; Ziv I, 2006, J BIOL CHEM, V281, P39225, DOI 10.1074/jbc.M607327200	22	39	42	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2007	26	41					6093	6098		10.1038/sj.onc.1210424	http://dx.doi.org/10.1038/sj.onc.1210424			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	207US	17420726				2022-12-28	WOS:000249277200012
J	Nakaya, K; Yamagata, HD; Arita, N; Nakashiro, K; Nose, M; Miki, T; Hamakawa, H				Nakaya, K.; Yamagata, H. D.; Arita, N.; Nakashiro, K-i; Nose, M.; Miki, T.; Hamakawa, H.			Identification of homozygous deletions of tumor suppressor gene FAT in oral cancer using CGH-array	ONCOGENE			English	Article						oral cancer; CGH-array; tumor suppressor gene; homozygous deletion; FAT	COMPARATIVE GENOMIC HYBRIDIZATION; SQUAMOUS-CELL CARCINOMAS; COPY NUMBER; DROSOPHILA; MUTATIONS; BREAST; HEAD; NECK; AMPLIFICATION; EXPRESSION	Homozygous deletions (HD) provide an important resource for identifying the location of candidate tumor suppressor genes. To identify the tumor suppressor gene in oral cancer, we employed high-resolution comparative genomic hybridization (CGH)-array analysis. We identified a homozygous loss of FAT ( 4q35), a new member of the human cadherin superfamily, from genome-wide screening of copy number alterations in one primary oral cancer. This result was evaluated by genomic polymerase chain reaction in 13 oral cancer cell lines and 20 primary oral cancers and Southern blot in the cell lines. We found frequent exonic HD of FAT in the cell lines (3/13, 23%) and in primary oral cancers (16/20, 80%). FAT expression was absent in these cell lines. Homozygous deletion hot spots were observed in exon 1 (9/20, 45%) and exon 4 (7/20, 35%). Moreover, loss of gene expression was identified in other types of squamous cell carcinoma. The methylation status of the FAT CpG island in squamous cell carcinomas correlated negatively with its expression. Our results identify mutations in FAT as an important factor in the development of oral cancer and indicate the importance of FATs function in some squamous cell carcinomas.	Ehime Univ, Grad Sch Med, Dept Prevent Med, Toon, Ehime 7910295, Japan; Ehime Univ, Grad Sch Med, Dept Oral & Maxillofacial Surg, Organ Funct Regenerat & Reconstruct Surg, Toon, Ehime 7910295, Japan; Ehime Univ, Grad Sch Med, Dept Pathol, Div Pathogenom, Toon, Ehime 7910295, Japan; Ehime Univ, Grad Sch Med, Dept Geriatr Med, Toon, Ehime 7910295, Japan	Ehime University; Ehime University; Ehime University; Ehime University	Yamagata, HD (corresponding author), Ehime Univ, Grad Sch Med, Dept Prevent Med, Toon, Ehime 7910295, Japan.	hideyama@m.ehime-u.ac.jp	Nakashiro, Koichi/AAV-6317-2020	Nakashiro, Koh-ichi/0000-0002-9975-902X				Beder LB, 2003, LAB INVEST, V83, P99, DOI 10.1097/01.LAB.0000047489.26246.E1; BRYANT PJ, 1988, DEV BIOL, V129, P541, DOI 10.1016/0012-1606(88)90399-5; DRYJA TP, 1984, NEW ENGL J MED, V310, P550, DOI 10.1056/NEJM198403013100902; Frijters ACJ, 1997, THEOR APPL GENET, V94, P390, DOI 10.1007/s001220050428; Garoia F, 2000, MECH DEVELOP, V94, P95, DOI 10.1016/S0925-4773(00)00306-3; HAUGHEY BH, 1992, AM J OTOLARYNG, V13, P168, DOI 10.1016/0196-0709(92)90117-C; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Hodgson G, 2001, NAT GENET, V29, P459, DOI 10.1038/ng771; Ishwad CS, 1999, INT J CANCER, V80, P25, DOI 10.1002/(SICI)1097-0215(19990105)80:1<25::AID-IJC6>3.3.CO;2-7; Keller G, 1999, AM J PATHOL, V155, P337, DOI 10.1016/S0002-9440(10)65129-2; KIARIS H, 1995, BRIT J CANCER, V72, P123, DOI 10.1038/bjc.1995.287; LEWIS GJ, 1989, E MIDLANDS GEOGRAPHE, V11, P3; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Loughran O, 1997, ONCOGENE, V14, P1955, DOI 10.1038/sj.onc.1201028; MAHONEY PA, 1991, CELL, V67, P853, DOI 10.1016/0092-8674(91)90359-7; Pinkel D, 1998, NAT GENET, V20, P207, DOI 10.1038/2524; PINKEL D, 1986, P NATL ACAD SCI USA, V83, P2934, DOI 10.1073/pnas.83.9.2934; Ponassi M, 1999, MECH DEVELOP, V80, P207, DOI 10.1016/S0925-4773(98)00217-2; PRIME SS, 1990, J PATHOL, V160, P259, DOI 10.1002/path.1711600313; Rook MS, 2004, AM J PATHOL, V164, P23, DOI 10.1016/S0002-9440(10)63092-1; SAMBROOK J, 1989, MOL CLONING, V2, P9; Siegelmann-Danieli N, 2005, TUMORI J, V91, P346, DOI 10.1177/030089160509100412; Simon R, 2002, ONCOGENE, V21, P2476, DOI 10.1038/sj.onc.1205304; Tamura G, 2000, J NATL CANCER I, V92, P569, DOI 10.1093/jnci/92.7.569; Tanoue T, 2005, J CELL SCI, V118, P2347, DOI 10.1242/jcs.02398; Teni Tanuja, 2002, Pathology and Oncology Research, V8, P109; Veltman JA, 2002, AM J HUM GENET, V70, P1269, DOI 10.1086/340426; WATSON KL, 1994, J CELL SCI, P19; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0	29	64	69	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 9	2007	26	36					5300	5308		10.1038/sj.onc.1210330	http://dx.doi.org/10.1038/sj.onc.1210330			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	199CQ	17325662				2022-12-28	WOS:000248674200013
J	Lauth, M; Bergstrom, A; Toftgard, R				Lauth, M.; Bergstrom, A.; Toftgard, R.			Phorbol esters inhibit the Hedgehog signalling pathway downstream of Suppressor of Fused, but upstream of Gli	ONCOGENE			English	Article						hedgehog signalling; phorbol ester; protein kinase C	BASAL-CELL CARCINOMA; PROTEIN-KINASE-A; TRANSCRIPTIONAL ACTIVITY; BETA-TRCP; EXPRESSION; UBIQUITINATION; TRANSFORMATION; FIBROBLASTS; DEGRADATION; MODULATION	The developmentally important Hedgehog ( Hh) signal transduction pathway, which has recently been implicated in several forms of cancer, is subject to regulation by several protein kinases. Here, we address the role of protein kinase Cd in pathway inhibition and show that cellular depletion or pharmacological inhibition of this kinase isoform results in a blockade of signalling between Suppressor of Fused and the Gli transcription factors. We further provide evidence that the observed pathway inhibition is independent of primary cilia and the mitogen- activated protein kinase kinase ( Mek1) kinase. These. findings allowed for the rapid dissection of downstream Hh pathway activation mechanisms in human tumour cells and demonstrate a surprising variation in how cells can activate signalling in a ligand- and receptor-independent manner.	Karolinska Inst, Dept Biosci & Nutr, SE-14157 Huddinge, Sweden	Karolinska Institutet	Lauth, M (corresponding author), Karolinska Inst, Dept Biosci & Nutr, Novum Res Pk,Halsovagen 7, SE-14157 Huddinge, Sweden.	matthias.lauth@biosci.ki.se		Lauth, Matthias/0000-0001-5922-5384				Beachy PA, 2004, NATURE, V432, P324, DOI 10.1038/nature03100; Bhatia N, 2006, J BIOL CHEM, V281, P19320, DOI 10.1074/jbc.M513203200; Chen JK, 2002, P NATL ACAD SCI USA, V99, P14071, DOI 10.1073/pnas.182542899; Eichberger T, 2006, GENOMICS, V87, P616, DOI 10.1016/j.ygeno.2005.12.003; Frank-Kamenetsky Maria, 2002, J Biol, V1, P10, DOI 10.1186/1475-4924-1-10; GSCHWENDT M, 1994, BIOCHEM BIOPH RES CO, V199, P93, DOI 10.1006/bbrc.1994.1199; Haycraft CJ, 2005, PLOS GENET, V1, P480, DOI 10.1371/journal.pgen.0010053; Huangfu DW, 2003, NATURE, V426, P83, DOI 10.1038/nature02061; Kaesler S, 2000, BIOL CHEM, V381, P545, DOI 10.1515/BC.2000.070; Karhadkar SS, 2004, NATURE, V431, P707, DOI 10.1038/nature02962; Kasper M, 2006, MOL CELL BIOL, V26, P6283, DOI 10.1128/MCB.02317-05; Kogerman P, 1999, NAT CELL BIOL, V1, P312, DOI 10.1038/13031; Liu QY, 2000, CANCER LETT, V153, P13, DOI 10.1016/S0304-3835(99)00417-6; Liu WS, 1998, CELL SIGNAL, V10, P529, DOI 10.1016/S0898-6568(98)00012-6; Mao JH, 2002, J BIOL CHEM, V277, P35156, DOI 10.1074/jbc.M206743200; Neill GW, 2003, CANCER RES, V63, P4692; Ohno S, 2002, J BIOCHEM, V132, P509, DOI 10.1093/oxfordjournals.jbchem.a003249; OKAZAKI K, 1995, ONCOGENE, V10, P1149; Pan Y, 2006, MOL CELL BIOL, V26, P3365, DOI 10.1128/MCB.26.9.3365-3377.2006; Regl G, 2002, ONCOGENE, V21, P5529, DOI 10.1038/sj.onc.1205748; Riobo NA, 2006, P NATL ACAD SCI USA, V103, P4505, DOI 10.1073/pnas.0504337103; Riobo NA, 2006, CANCER RES, V66, P839, DOI 10.1158/0008-5472.CAN-05-2539; Sanchez P, 2004, P NATL ACAD SCI USA, V101, P12561, DOI 10.1073/pnas.0404956101; Sasaki H, 1997, DEVELOPMENT, V124, P1313; Schneider L, 2005, CURR BIOL, V15, P1861, DOI 10.1016/j.cub.2005.09.012; Sheng T, 2006, J BIOL CHEM, V281, P9, DOI 10.1074/jbc.C500300200; Svard J, 2006, DEV CELL, V10, P187, DOI 10.1016/j.devcel.2005.12.013; Taipale J, 2000, NATURE, V406, P1005, DOI 10.1038/35023008; Tempe D, 2006, MOL CELL BIOL, V26, P4316, DOI 10.1128/MCB.02183-05; Wang BW, 2006, P NATL ACAD SCI USA, V103, P33, DOI 10.1073/pnas.0509927103	30	31	32	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 2	2007	26	35					5163	5168		10.1038/sj.onc.1210321	http://dx.doi.org/10.1038/sj.onc.1210321			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	196MT	17310984				2022-12-28	WOS:000248487400015
J	Kusters, B; Kats, G; Roodink, I; Verrijp, K; Wesseling, P; Ruiter, DJ; de Waal, RMW; Leenders, WPJ				Kuesters, B.; Kats, G.; Roodink, I.; Verrijp, K.; Wesseling, P.; Ruiter, D. J.; de Waal, R. M. W.; Leenders, W. P. J.			Micronodular transformation as a novel mechanism of VEGF-A-induced metastasis	ONCOGENE			English	Article						VEGF-A; metastasis; melanoma; tumor; emboli; angiogenesis	ENDOTHELIAL GROWTH-FACTOR; INFLAMMATORY BREAST-CARCINOMA; VESSEL CO-OPTION; BRAIN METASTASIS; HUMAN-MELANOMA; TUMOR-CELLS; SPROUTING ANGIOGENESIS; CANCER METASTASIS; PROGNOSTIC-FACTOR; BONE-MARROW	How and why tumors metastasize is still a matter of debate. The assumption is that mutations render tumor cells with a metastatic phenotype, enabling entrance in and transport through lymph or blood vessels. Distant outgrowth is thought to occur only in a suitable microenvironment (the seed and soil hypothesis). However, the anatomical location of most metastases in cancer patients suggests entrapment of tumor cells in the first microcapillary bed that is encountered. We here investigated how vascular endothelial growth factor-A (VEGF-A) attributes to the metastatic process. We describe here that VEGF-A enhances spontaneous metastasis by inducing intravasation of heterogeneous tumor cell clusters, surrounded by vessel wall elements, via an invasion-independent mechanism. These tumor clusters generate metastatic tissue embolisms in pulmonary arteries. Treatment of tumor-bearing mice with the antiangiogenic compound ZD6474 prevented the development of this metastatic phenotype. This work shows that tumors with high constitutive VEGF-A expression metastasize via the formation of tumor emboli and provides an alternative rationale for anti-VEGF-A therapy, namely to inhibit metastasis formation.	Radboud Univ Nijmegen Med Ctr, Dept Pathol, NL-6500 HB Nijmegen, Netherlands	Radboud University Nijmegen	Leenders, WPJ (corresponding author), Radboud Univ Nijmegen Med Ctr, Dept Pathol, POB 9101, NL-6500 HB Nijmegen, Netherlands.	w.leenders@pathol.umcn.nl	Wesseling, P./H-8114-2014; Leenders, William P/O-9843-2014; Kusters, B./L-4465-2015; verrijp, kiek/F-4783-2018; Waal, R.M.W./L-4739-2015; Leenders, William/O-2541-2019; Ruiter, D.J./L-4617-2015	Wesseling, P./0000-0001-5453-5201; Leenders, William P/0000-0003-0066-220X; Leenders, William/0000-0003-0066-220X; 				Al-Mehdi AB, 2000, NAT MED, V6, P100, DOI 10.1038/71429; Alpaugh ML, 2002, ONCOGENE, V21, P3631, DOI 10.1038/sj.onc.1205389; Auguste P, 2005, CRIT REV ONCOL HEMAT, V54, P53, DOI 10.1016/j.critrevonc.2004.11.006; Ellis LM, 1996, EUR J CANCER, V32A, P2451, DOI 10.1016/S0959-8049(96)00389-9; Ferrara N, 2002, NAT REV CANCER, V2, P795, DOI 10.1038/nrc909; Fidler IJ, 1999, CANCER METAST REV, V18, P387, DOI 10.1023/A:1006329410433; Fidler IJ, 2003, NAT REV CANCER, V3, P453, DOI 10.1038/nrc1098; FIDLER IJ, 1973, EUR J CANCER, V9, P223, DOI 10.1016/S0014-2964(73)80022-2; Fidler IJ, 1996, JOURNAL OF INVESTIGATIVE DERMATOLOGY SYMPOSIUM PROCEEDINGS, VOL 1, NO 2, APRIL 1996, P203; FIDLER IJ, 1986, CANCER RES, V46, P5167; FOLKMAN J, 1990, JNCI-J NATL CANCER I, V82, P4, DOI 10.1093/jnci/82.1.4; Gannon G, 2002, CANCER RES, V62, P603; GLAVES D, 1983, BRIT J CANCER, V48, P665, DOI 10.1038/bjc.1983.248; Hasan J, 2002, BRIT J CANCER, V86, P1566, DOI 10.1038/sj.bjc.6600315; Kanayama H, 1999, CLIN EXP METASTAS, V17, P831, DOI 10.1023/A:1006792007063; Kaplan RN, 2005, NATURE, V438, P820, DOI 10.1038/nature04186; Killion JJ, 1998, CANCER METAST REV, V17, P279, DOI 10.1023/A:1006140513233; KIM ES, 2002, P NATL ACAD SCI USA, V12, P12; Kusters B, 2003, CANCER RES, V63, P5408; Kusters B, 2002, CANCER RES, V62, P341; Kusters B, 2001, INT J CANCER, V92, P176; Leenders WPJ, 2004, CLIN CANCER RES, V10, P6222, DOI 10.1158/1078-0432.CCR-04-0823; Leenders WPJ, 2002, ENDOTHELIUM-J ENDOTH, V9, P83, DOI 10.1080/10623320212006; LIOTTA LA, 1976, CANCER RES, V36, P889; MOFFETT BF, 1992, CANCER RES, V52, P1737; Neves S, 2001, CLIN NEUROPATHOL, V20, P38; Passalidou E, 2002, BRIT J CANCER, V86, P244, DOI 10.1038/sj.bjc.6600015; Pezzella F, 2000, LANCET, V355, P1787; Pezzella F, 1997, AM J PATHOL, V151, P1417; Ruiter DJ, 2001, LANCET ONCOL, V2, P109, DOI 10.1016/S1470-2045(00)00229-1; Span PN, 2000, INT J BIOL MARKER, V15, P184, DOI 10.1177/172460080001500210; Sugino T, 2002, AM J PATHOL, V160, P1973, DOI 10.1016/S0002-9440(10)61147-9; SUGINO T, 1993, INT J CANCER, V55, P141, DOI 10.1002/ijc.2910550125; Sugino T, 2004, BMC MED, V2, DOI 10.1186/1741-7015-2-9; Tomlinson JS, 2001, CANCER RES, V61, P5231; Vermeulen PB, 2001, J PATHOL, V195, P336, DOI 10.1002/path.966; Vlems FA, 2003, EUR J SURG ONCOL, V29, P289, DOI 10.1053/ejso.2002.1394; Wedge SR, 2002, CANCER RES, V62, P4645; Weidner N, 2002, AM J PATHOL, V160, P1937, DOI 10.1016/S0002-9440(10)61141-8; Weidner N, 1998, J PATHOL, V184, P119, DOI 10.1002/(SICI)1096-9896(199802)184:2<119::AID-PATH17>3.0.CO;2-D; Weidner Noel, 1996, P167; Westphal JR, 2000, INT J CANCER, V86, P768, DOI 10.1002/(SICI)1097-0215(20000615)86:6<768::AID-IJC3>3.3.CO;2-5; Yano S, 2000, CANCER RES, V60, P4959	43	41	46	2	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2007	26	39					5808	5815		10.1038/sj.onc.1210360	http://dx.doi.org/10.1038/sj.onc.1210360			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	202EP	17353901				2022-12-28	WOS:000248885100012
J	Murayama, K; Kimura, T; Tarutani, M; Tomooka, M; Hayashi, R; Okabe, M; Nishida, K; Itami, S; Katayama, I; Nakano, T				Murayama, K.; Kimura, T.; Tarutani, M.; Tomooka, M.; Hayashi, R.; Okabe, M.; Nishida, K.; Itami, S.; Katayama, I.; Nakano, T.			Akt activation induces epidermal hyperplasia and proliferation of epidermal progenitors	ONCOGENE			English	Article						Akt; epidermis; hair follicle; stem cells; proliferation	HAIR FOLLICLE MORPHOGENESIS; HEMATOPOIETIC STEM-CELLS; BETA-CATENIN; TRANSIENT ACTIVATION; PTEN; MOUSE; MICE; SKIN; POPULATIONS; SUFFICIENT	Various common signaling pathways maintain tissue stem cells, including Notch and Wnt/beta-catenin signals. Phosphoinositide3 kinase (PI3K)/Akt signaling regulates the 'stemness' of several stem cells in culture, specifically in maintaining embryonic stem and neural stem cells, and in deriving embryonic germ cells from primordial germ cells. We examined the effect of Akt signaling in epidermal cells in transgenic mice expressing an Akt-Mer fusion protein whose kinase activity was conditionally activated by treatment with 4-hydroxytamoxifen (4OHT). The topical application of 4OHT to adult skin of the transgenic mice induced new hair growth in resting phase follicles. In addition, the mice showed hyperplasia in interfollicular epidermis (IFE) and hair follicles, which was presumably caused by the extensive proliferation of keratinocytes in basal layer of IFE and outer root sheath of hair follicles, respectively. The progenitor cell population increased consistently in 4OHT-treated transgenic mice. Our results show that PI3K/Akt signaling induces epidermal hyperplasia and proliferation of epidermal progenitors.	Osaka Univ, Grad Sch Med, Dept Pathol, Suita, Osaka 565, Japan; Osaka Univ, Grad Sch Med, Dept Dermatol, Suita, Osaka 565, Japan; Osaka Univ, Grad Sch Frontier Biosci, Dept Pathol Div, Suita, Osaka 565, Japan; Tohoku Univ, Grad Sch Med, Dept Ophthalmol & Visual Sci, Aoba Ku, Sendai, Miyagi 980, Japan; Osaka Univ, Microbial Dis Res Inst, Dept Expt Genome Res, Genome Informat Res Ctr, Suita, Osaka 565, Japan; Grad Sch Med, Dept Regenerat Dermatol, Suita, Osaka, Japan	Osaka University; Osaka University; Osaka University; Tohoku University; Osaka University	Kimura, T (corresponding author), Osaka Univ, Grad Sch Med, Dept Pathol, 2-2 Yamada Oka, Suita, Osaka 565, Japan.	tkimura@patho.med.osaka-u.ac.jp	Hayashi, Ryuhei/AAW-4737-2020; Okabe, Masaru/B-6917-2015	Kimura, Tohru/0000-0001-9227-0996; Nishida, Kohji/0000-0001-9069-3610; Hayashi, Ryuhei/0000-0002-4699-8617; Okabe, Masaru/0000-0002-0803-9044				Backman SA, 2004, P NATL ACAD SCI USA, V101, P1725, DOI 10.1073/pnas.0308217100; Blanpain C, 2004, CELL, V118, P635, DOI 10.1016/j.cell.2004.08.012; Brazil DP, 2004, TRENDS BIOCHEM SCI, V29, P233, DOI 10.1016/j.tibs.2004.03.006; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Di-Poi N, 2005, MOL CELL BIOL, V25, P1696, DOI 10.1128/MCB.25.5.1696-1712.2005; Fuchs E, 2004, CELL, V116, P769, DOI 10.1016/S0092-8674(04)00255-7; Gat U, 1998, CELL, V95, P605, DOI 10.1016/S0092-8674(00)81631-1; Ghazizadeh S, 2001, EMBO J, V20, P1215, DOI 10.1093/emboj/20.6.1215; Groszer M, 2001, SCIENCE, V294, P2186, DOI 10.1126/science.1065518; Ito M, 2005, NAT MED, V11, P1351, DOI 10.1038/nm1328; JONES PH, 1995, CELL, V80, P83, DOI 10.1016/0092-8674(95)90453-0; Kimura T, 2003, DEVELOPMENT, V130, P1691, DOI 10.1242/dev.00392; Kishimoto H, 2003, CELL STRUCT FUNCT, V28, P11; Kohn AD, 1998, J BIOL CHEM, V273, P11937, DOI 10.1074/jbc.273.19.11937; Levy V, 2005, DEV CELL, V9, P855, DOI 10.1016/j.devcel.2005.11.003; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; Lo Celso C, 2004, DEVELOPMENT, V131, P1787, DOI 10.1242/dev.01052; MORRIS RJ, 1987, CANCER LETT, V34, P297, DOI 10.1016/0304-3835(87)90180-7; Muller-Rover S, 2001, J INVEST DERMATOL, V117, P3, DOI 10.1046/j.0022-202x.2001.01377.x; Okabe M, 1997, FEBS LETT, V407, P313, DOI 10.1016/S0014-5793(97)00313-X; Peng XD, 2003, GENE DEV, V17, P1352, DOI 10.1101/gad.1089403; Sarin KY, 2005, NATURE, V436, P1048, DOI 10.1038/nature03836; Silva-Vargas V, 2005, DEV CELL, V9, P121, DOI 10.1016/j.devcel.2005.04.013; Stenn KS, 2001, PHYSIOL REV, V81, P449, DOI 10.1152/physrev.2001.81.1.449; Suzuki A, 2003, CANCER RES, V63, P674; Van Mater D, 2003, GENE DEV, V17, P1219, DOI 10.1101/gad.1076103; Watanabe S, 2006, ONCOGENE, V25, P2697, DOI 10.1038/sj.onc.1209307; Watt FM, 2001, CURR OPIN GENET DEV, V11, P410, DOI 10.1016/S0959-437X(00)00211-2; Yang ZZ, 2005, MOL CELL BIOL, V25, P10407, DOI 10.1128/MCB.25.23.10407-10418.2005; Yilmaz OH, 2006, NATURE, V441, P475, DOI 10.1038/nature04703; Zhang JW, 2006, NATURE, V441, P518, DOI 10.1038/nature04747	31	59	61	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 19	2007	26	33					4882	4888		10.1038/sj.onc.1210274	http://dx.doi.org/10.1038/sj.onc.1210274			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	191ZL	17297448				2022-12-28	WOS:000248170400014
J	Zhu, Q; Wani, G; Yao, J; Patnaik, S; Wang, QE; El-Mahdy, MA; Praetorius-Ibba, M; Wani, AA				Zhu, Q.; Wani, G.; Yao, J.; Patnaik, S.; Wang, Q-E; El-Mahdy, M. A.; Praetorius-Ibba, M.; Wani, A. A.			The ubiquitin-proteasome system regulates p53-mediated transcription at p21(waf1) promoter	ONCOGENE			English	Article						ubiquitin; proteasome; degradationtranscription; p53	RNA-POLYMERASE-II; HORMONE-RECEPTOR; HUMAN HOMOLOG; DNA-REPAIR; P53; ACTIVATION; PROTEIN; COACTIVATOR; DEGRADATION; RECRUITMENT	The ubiquitin (Ub)-proteasome system (UPS) promotes the proteasomal degradation of target proteins by decorating them with Ub labels. Emerging evidence indicates a role of UPS in regulating gene transcription. In this study, we provided evidence for the involvement of UPS in the transcriptional activation function of tumor suppressor p53. We showed that both ubiquitylation and proteasomal functions are required for efficient transcription mediated by p53. Disruption of transcription by actinomycin D, 5,6-dichloro-1-beta-D-ribofuranosyl-benzimadazole or alpha-amanitin leads to accumulation of cellular p53 protein. Proteasome inhibition by MG132 increases the occupancy of p53 protein at p53-responsive p21(waf1) promoter. In addition, the Sug-1 component of 19S proteasome physically interacts with p53 in vitro and in vivo. Moreover, in response to ultraviolet-induced DNA damage, both the 19S proteasomal components, Sug1 and S1, are recruited to p21(waf1) promoter region in a kinetic pattern similar to that of p53. These results suggested that UPS positively regulates p53-mediated transcription at p21(waf1) promoter.	Ohio State Univ, Dept Radiol, Columbus, OH 43210 USA; Ohio State Univ, Dept Mol & Cellular Biochem, Columbus, OH 43210 USA; Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University	Wani, AA (corresponding author), Ohio State Univ, Dept Radiol, Columbus, OH 43210 USA.	wani.2@osu.edu	Zhu, Qianzheng/A-4902-2013		NATIONAL CANCER INSTITUTE [R01CA093413] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES002388, R01ES012991] Funding Source: NIH RePORTER; NCI NIH HHS [CA93413] Funding Source: Medline; NIEHS NIH HHS [R01 ES012991, ES12991, ES02388] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Adams J, 2004, CANCER INVEST, V22, P304, DOI 10.1081/CNV-120030218; Bres V, 2003, NAT CELL BIOL, V5, P754, DOI 10.1038/ncb1023; Brooks CL, 2006, MOL CELL, V21, P307, DOI 10.1016/j.molcel.2006.01.020; Conaway JW, 2000, TRENDS BIOCHEM SCI, V25, P375, DOI 10.1016/S0968-0004(00)01615-7; DeMartino GN, 1999, J BIOL CHEM, V274, P22123, DOI 10.1074/jbc.274.32.22123; Dvir A, 2001, CURR OPIN GENET DEV, V11, P209, DOI 10.1016/S0959-437X(00)00181-7; El-Deiry WS, 1998, CURR TOP MICROBIOL, V227, P121; Ferdous A, 2002, BIOCHEMISTRY-US, V41, P12798, DOI 10.1021/bi020425t; Ferdous A, 2001, MOL CELL, V7, P981, DOI 10.1016/S1097-2765(01)00250-7; FINLEY D, 1984, CELL, V37, P43, DOI 10.1016/0092-8674(84)90299-X; Gianni M, 2002, EMBO J, V21, P3760, DOI 10.1093/emboj/cdf374; Gillette TG, 2004, P NATL ACAD SCI USA, V101, P5904, DOI 10.1073/pnas.0305411101; Glickman MH, 1998, MOL CELL BIOL, V18, P3149, DOI 10.1128/MCB.18.6.3149; Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001; Gonzalez F, 2002, SCIENCE, V296, P548, DOI 10.1126/science.1069490; Grossman SR, 2003, SCIENCE, V300, P342, DOI 10.1126/science.1080386; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Imhof MO, 1996, MOL CELL BIOL, V16, P2594; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; Kim J, 2005, MOL CELL, V20, P759, DOI 10.1016/j.molcel.2005.11.012; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; LEE JW, 1995, NATURE, V374, P91, DOI 10.1038/374091a0; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lin L, 2005, ONCOGENE, V24, P3385, DOI 10.1038/sj.onc.1208554; Lipford JR, 2003, NAT CELL BIOL, V5, P845, DOI 10.1038/ncb1003-845; Lipford JR, 2005, NATURE, V438, P113, DOI 10.1038/nature04098; Ljungman M, 1999, ONCOGENE, V18, P583, DOI 10.1038/sj.onc.1202356; Malik S, 2005, TRENDS BIOCHEM SCI, V30, P256, DOI 10.1016/j.tibs.2005.03.009; Molinari E, 1999, EMBO J, V18, P6439, DOI 10.1093/emboj/18.22.6439; Muratani M, 2003, NAT REV MOL CELL BIO, V4, P192, DOI 10.1038/nrm1049; Nawaz Z, 1999, MOL CELL BIOL, V19, P1182; O'Hagan HM, 2004, ONCOGENE, V23, P5505, DOI 10.1038/sj.onc.1207709; Rajendra R, 2004, J BIOL CHEM, V279, P36440, DOI 10.1074/jbc.C400300200; Reid G, 2003, MOL CELL, V11, P695, DOI 10.1016/S1097-2765(03)00090-X; Roeder RG, 1996, TRENDS BIOCHEM SCI, V21, P327, DOI 10.1016/0968-0004(96)10050-5; Saccani S, 2001, J EXP MED, V193, P1351, DOI 10.1084/jem.193.12.1351; Saleh A, 1998, J MOL BIOL, V282, P933, DOI 10.1006/jmbi.1998.2036; Salghetti SE, 2001, SCIENCE, V293, P1651, DOI 10.1126/science.1062079; Salghetti SE, 2000, P NATL ACAD SCI USA, V97, P3118, DOI 10.1073/pnas.050007597; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; SWAFFIELD JC, 1995, NATURE, V374, P88, DOI 10.1038/374088a0; Szak ST, 2001, MOL CELL BIOL, V21, P3375, DOI 10.1128/MCB.21.10.3375-3386.2001; Varshavsky A, 1997, TRENDS BIOCHEM SCI, V22, P383, DOI 10.1016/S0968-0004(97)01122-5; VENKATACHALAM S, 1995, CARCINOGENESIS, V16, P2029, DOI 10.1093/carcin/16.9.2029; VOM BE, 1996, EMBO J, V15, P110; Wang DM, 2000, EMBO J, V19, P392, DOI 10.1093/emboj/19.3.392; Wani MA, 1999, CARCINOGENESIS, V20, P765, DOI 10.1093/carcin/20.5.765; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; Zhu QZ, 2004, FEBS LETT, V556, P19, DOI 10.1016/S0014-5793(03)01347-4	50	54	54	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 21	2007	26	29					4199	4208		10.1038/sj.onc.1210191	http://dx.doi.org/10.1038/sj.onc.1210191			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	184CY	17224908				2022-12-28	WOS:000247619900002
J	Trapp, C; Reite, K; Klungland, A; Epe, B				Trapp, C.; Reite, K.; Klungland, A.; Epe, B.			Deficiency of the Cockayne syndrome B (CSB) gene aggravates the genomic instability caused by endogenous oxidative DNA base damage in mice	ONCOGENE			English	Article						oxidative DNA damage; spontaneous mutations; DNA repair; OGG1	BIG BLUE(R); MAMMALIAN-CELLS; REPAIR; ACCUMULATION; MUTATIONS; TISSUE; AGE; 8-HYDROXYGUANINE; PREDISPOSITION; 8-OXOGUANINE	The Cockayne syndrome B protein ( CSB) has long been known to be involved in the repair of DNA modi. cations that block the RNA polymerase in transcribed DNA sequences ( transcription-coupled repair). Recent evidence suggests that it also has a more general role in the repair of oxidative DNA base modi. cations such as 7,8-dihydro-8-oxo-2'-deoxyguanosine ( 8-oxoG). In mammalian cells, 8-oxoG is a substrate of the repair glycosylase OGG1. Mice without this enzyme accumulate 8-oxoG in the genome and have elevated spontaneous mutation rates. To elucidate the role of CSB in the prevention of mutations by oxidative DNA base damage, we have generated mice that are deficient in Csb or Ogg1 or both genes and carry a non-transcribed bacterial lacI gene for mutation analysis ( Big Blue mice). Our results indicate that the overall spontaneous mutation frequencies in the livers of Csb(m/m)/Ogg1(-/-)-mice are elevated not only compared with heterozygous control mice ( factor 3.3), but also with Ogg1(-/-)-animals ( factor 1.6). Sequence analysis revealed that the additional mutations caused by CSB deficiency in an Ogg1(-/-) background are mostly G: C to T: A transversions and small deletions. For all mouse strains, the background levels of oxidative purine modi. cations in the livers correlate linearly with the numbers of G: C to T: A transversions observed. The data indicate that CSB is involved in the inhibition of mutations caused by spontaneous oxidative DNA base damage in a non-transcribed gene.	Johannes Gutenberg Univ Mainz, Inst Pharm, D-55099 Mainz, Germany; Rikshosp Radiumhosp, Ctr Mol Biol & Neurosci, Oslo, Norway; Rikshosp Radiumhosp, Inst Med Microbiol, Oslo, Norway	Johannes Gutenberg University of Mainz; University of Oslo; University of Oslo	Epe, B (corresponding author), Johannes Gutenberg Univ Mainz, Inst Pharm, Staudingerweg 5, D-55099 Mainz, Germany.	epe@uni-mainz.de	Klungland, Arne/X-1233-2019	Klungland, Arne/0000-0001-7274-3661				Bjelland S, 2003, MUTAT RES-FUND MOL M, V531, P37, DOI 10.1016/j.mrfmmm.2003.07.002; Bruner SD, 2000, NATURE, V403, P859, DOI 10.1038/35002510; CHENG KC, 1992, J BIOL CHEM, V267, P166; Collins A, 2003, FREE RADICAL BIO MED, V34, P1089, DOI 10.1016/s0891-5849(03)00041-8; Collins A, 2002, CARCINOGENESIS, V23, P2129, DOI 10.1093/carcin/23.12.2129; Dolle MET, 2006, MUTAT RES-FUND MOL M, V596, P22, DOI 10.1016/j.mrfmmm.2005.11.008; Flohr C, 2003, NUCLEIC ACIDS RES, V31, P5332, DOI 10.1093/nar/gkg715; Halangoda A, 2001, ENVIRON MOL MUTAGEN, V37, P311, DOI 10.1002/em.1038; Heinmoller PW, 2000, MUTAT RES-FUND MOL M, V453, P97, DOI 10.1016/S0027-5107(00)00091-9; Helbock HJ, 1998, P NATL ACAD SCI USA, V95, P288, DOI 10.1073/pnas.95.1.288; Hill KA, 2004, ENVIRON MOL MUTAGEN, V43, P110, DOI 10.1002/em.20004; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Klungland A, 1999, P NATL ACAD SCI USA, V96, P13300, DOI 10.1073/pnas.96.23.13300; KOHLER SW, 1991, ENVIRON MOL MUTAGEN, V18, P316, DOI 10.1002/em.2850180421; Licht CL, 2003, AM J HUM GENET, V73, P1217, DOI 10.1086/380399; Marnett LJ, 2000, CARCINOGENESIS, V21, P361, DOI 10.1093/carcin/21.3.361; MELLON I, 1986, P NATL ACAD SCI USA, V83, P8878, DOI 10.1073/pnas.83.23.8878; Minowa O, 2000, P NATL ACAD SCI USA, V97, P4156, DOI 10.1073/pnas.050404497; MORIYA M, 1993, P NATL ACAD SCI USA, V90, P1122, DOI 10.1073/pnas.90.3.1122; Nishino H, 1996, MUTAT RES-FUND MOL M, V372, P97, DOI 10.1016/S0027-5107(96)00172-8; Osterod M, 2002, ONCOGENE, V21, P8232, DOI 10.1038/sj.onc.1206027; Osterod M, 2001, CARCINOGENESIS, V22, P1459, DOI 10.1093/carcin/22.9.1459; Pflaum M, 1997, CARCINOGENESIS, V18, P2225, DOI 10.1093/carcin/18.11.2225; PROVOST GS, 1994, P NATL ACAD SCI USA, V91, P6564, DOI 10.1073/pnas.91.14.6564; Radicella JP, 1997, P NATL ACAD SCI USA, V94, P8010, DOI 10.1073/pnas.94.15.8010; SHIBUTANI S, 1991, NATURE, V349, P431, DOI 10.1038/349431a0; Svejstrup JQ, 2002, NAT REV MOL CELL BIO, V3, P21, DOI 10.1038/nrm703; vanderHorst GTJ, 1997, CELL, V89, P425, DOI 10.1016/S0092-8674(00)80223-8; VANHOFFEN A, 1993, NUCLEIC ACIDS RES, V21, P5890, DOI 10.1093/nar/21.25.5890; Xie YL, 2004, CANCER RES, V64, P3096, DOI 10.1158/0008-5472.CAN-03-3834; YOUNG RR, 1995, MUTAT RES-FUND MOL M, V327, P67, DOI 10.1016/0027-5107(94)00080-O	31	34	34	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 7	2007	26	27					4044	4048		10.1038/sj.onc.1210167	http://dx.doi.org/10.1038/sj.onc.1210167			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	177HP	17213818				2022-12-28	WOS:000247144500016
J	Kim, E; Deppert, W				Kim, E.; Deppert, W.			Interactions of mutant p53 with DNA: guilt by association	ONCOGENE			English	Review						mutant p53; DNA binding; chromatin interaction; non-B DNA; transcription	TUMOR-SUPPRESSOR P53; C-TERMINAL DOMAIN; ETS TRANSCRIPTION FACTORS; GENE-EXPRESSION; COMPLEX INTERACTIONS; BINDING-SITE; IN-VIVO; MUTATIONS; PROTEIN; ACTIVATION	Since the very early days of p53 research, the gain of oncogenic activities by some mutant p53 proteins had been suspected as an important factor contributing to cancer progression. Considerable progress towards understanding the biology of mutant p53 has been made during the last years, the quintessence being the realization that the impact of mutant p53 proteins on the transcriptome of a tumor cell is much more global than previously thought. The emerging role of mutant p53 proteins in coordinating oncogenic signaling and chromatin modifying activities reveals an until now unsuspected function of these proteins as important modifiers of the oncogenic transcriptional response. Notwithstanding the fact that the sequence specific DNA binding activity of mutant p53 proteins is impaired, they are still able to associate with specific loci on DNA by utilizing different mechanisms. The ability to associate with DNA appears to be crucial for the master role of mutant p53 proteins in coordinating oncogenic transcriptional responses.	Univ Gottingen, Dept Neurosurg, Translat Neurooncol Grp, D-37075 Gottingen, Germany; Heinrich Pette Inst, Hamburg, Germany	University of Gottingen; Heinrich Pette Institute	Kim, E (corresponding author), Univ Gottingen, Dept Neurosurg, Translat Neurooncol Grp, Robert Koch Str 40, D-37075 Gottingen, Germany.	ella.kim@med.uni-goettingen.de						Ahn J, 2001, NAT STRUCT BIOL, V8, P730, DOI 10.1038/nsb0901-730; Ang HC, 2006, J BIOL CHEM, V281, P21934, DOI 10.1074/jbc.M604209200; Bae BI, 2005, NEURON, V47, P29, DOI 10.1016/j.neuron.2005.06.005; Campomenosi P, 2001, ONCOGENE, V20, P3573, DOI 10.1038/sj.onc.1204468; Chicas A, 2000, BIOCHEM BIOPH RES CO, V279, P383, DOI 10.1006/bbrc.2000.3965; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; Di Agostino S, 2006, CANCER CELL, V10, P191, DOI 10.1016/j.ccr.2006.08.013; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; Feng Z, 2006, ONCOGENE, V25, P1, DOI 10.1038/sj.onc.1209021; Frazier MW, 1998, MOL CELL BIOL, V18, P3735, DOI 10.1128/MCB.18.7.3735; Gilliland DG, 2001, CLIN CANCER RES, V7, P451; Gohler T, 2002, J BIOL CHEM, V277, P41192, DOI 10.1074/jbc.M202344200; Gohler T, 2005, NUCLEIC ACIDS RES, V33, P1087, DOI 10.1093/nar/gki252; Gu LB, 2004, J BIOL CHEM, V279, P52141, DOI 10.1074/jbc.M407915200; Gu ZN, 1999, MOL CARCINOGEN, V24, P294, DOI 10.1002/(SICI)1098-2744(199904)24:4<294::AID-MC7>3.0.CO;2-Q; GUALBERTO A, 1995, MOL CELL BIOL, V15, P3450; HUPP TR, 1994, COLD SPRING HARB SYM, V59, P195, DOI 10.1101/SQB.1994.059.01.024; Imbriano C, 2005, MOL CELL BIOL, V25, P3737, DOI 10.1128/MCB.25.9.3737-3751.2005; Inga A, 2001, ONCOGENE, V20, P501, DOI 10.1038/sj.onc.1204116; JOERGER AC, 2007, ONCOGNEE; Joerger AC, 2006, P NATL ACAD SCI USA, V103, P15056, DOI 10.1073/pnas.0607286103; Kim E, 2004, J CELL BIOCHEM, V93, P878, DOI 10.1002/jcb.20271; Kim E, 2003, ONCOGENE, V22, P7716, DOI 10.1038/sj.onc.1207155; Kim E, 2003, BIOCHEM CELL BIOL, V81, P141, DOI 10.1139/o03-046; Koga H, 2000, ONCOGENE, V19, P4178, DOI 10.1038/sj.onc.1203745; Koutsodontis G, 2005, BIOCHEM J, V389, P443, DOI 10.1042/BJ20041980; Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132; Muller BF, 1996, ONCOGENE, V12, P1941; Nguyen TT, 2005, MOL CELL BIOL, V25, P2147, DOI 10.1128/MCB.25.6.2147-2157.2005; Oikawa T, 2004, CANCER SCI, V95, P626, DOI 10.1111/j.1349-7006.2004.tb03320.x; Okorokov AL, 2006, EMBO J, V25, P5191, DOI 10.1038/sj.emboj.7601382; Pang JH, 1996, EXP GERONTOL, V31, P97, DOI 10.1016/0531-5565(95)02019-5; Pastorcic M, 2000, J BIOL CHEM, V275, P34938, DOI 10.1074/jbc.M005411200; Sampath J, 2001, J BIOL CHEM, V276, P39359, DOI 10.1074/jbc.M103429200; Saveliev A, 2003, NATURE, V422, P909, DOI 10.1038/nature01596; Scian MJ, 2005, MOL CELL BIOL, V25, P10097, DOI 10.1128/MCB.25.22.10097-10110.2005; Scian MJ, 2004, CANCER RES, V64, P7447, DOI 10.1158/0008-5472.CAN-04-1568; Selivanova G, 1997, NAT MED, V3, P632, DOI 10.1038/nm0697-632; Sigal A, 2000, CANCER RES, V60, P6788; Sinden RR, 2002, J BIOSCIENCES, V27, P53, DOI 10.1007/BF02703683; STENGER JE, 1994, EMBO J, V13, P6011, DOI 10.1002/j.1460-2075.1994.tb06947.x; TSUTSUMIISHII Y, 1995, CELL GROWTH DIFFER, V6, P1; Walter K, 2005, J BIOL CHEM, V280, P42497, DOI 10.1074/jbc.M507038200; WANG YH, 1995, GENOMICS, V25, P570, DOI 10.1016/0888-7543(95)80061-P; WEISSKER SN, 1992, ONCOGENE, V7, P1921; Yang XL, 1999, ONCOGENE, V18, P4546, DOI 10.1038/sj.onc.1202843; Zalcenstein A, 2003, ONCOGENE, V22, P5667, DOI 10.1038/sj.onc.1206724	47	26	27	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 2	2007	26	15					2185	2190		10.1038/sj.onc.1210312	http://dx.doi.org/10.1038/sj.onc.1210312			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	152XE	17401427				2022-12-28	WOS:000245394800007
J	Caldon, C; Lee, C; Sutherland, R; Musgrove, E				Caldon, Ce; Lee, Csl; Sutherland, Rl; Musgrove, Ea			Wilms' tumor protein 1: an early target of progestin regulation in T-47D breast cancer cells that modulates proliferation and differentiation	ONCOGENE			English	Article						Wt1; progesterone; cyclin D1; proliferation; lipogenesis	SUPPRESSOR GENE WT1; DEPENDENT KINASE INHIBITORS; CYCLIN D1; TRANSCRIPTIONAL ACTIVATION; GROWTH-FACTOR; EXPRESSION; PROGRESSION; ESTROGEN; RECEPTOR; INDUCTION	Progesterone regulates the proliferation and differentiation of normal mammary epithelium. In breast cancer cells, progesterone and its synthetic analogs, progestins, induce long-term growth inhibition and differentiation. However, the mechanisms responsible are not fully understood. When T-47D breast cancer cells were treated with the synthetic progestin ORG 2058 (16 alpha-ethoxy-21-hydroxy-19-norpregn-4-en-3,20-dione), all isoforms of Wilms' tumor protein 1 (Wt1) mRNA and protein were rapidly downregulated. We reasoned that the decrease in Wt1 levels may contribute to the long-term antiproliferative and differentiative effects of progestins as proliferation and differentiation are known end points of Wt1 action. Consistent with this idea, Wt1 small interfering RNA led to a decrease in S phase and cyclin D1 levels, and increased Oil-Red-O staining, indicating increased lipogenesis. Conversely, overexpression of Wt1 attenuated the decrease in S phase induced by ORG 2058 at 48-96 h. This was accompanied by the sustained expression of cyclin D1 despite progestin treatment, and increased levels of retinoblastoma (Rb) phosphorylation at sites targeted by cyclin D1-Cdk4 (Ser249/ Thr252). Wt1 overexpression also attenuated the ORG 2058-mediated increase in fatty acid synthase levels and reduced lipogenesis. Thus, Wt1 downregulation was sufficient to mimic the effects of progestin and was necessary for complete progestin-mediated proliferative arrest and subsequent differentiation. Furthermore, Wt1 overexpression modulated the effects of progestins but not anti-estrogens or androgens. These results indicate that Wt1 is an important early target of progestins that regulates both proliferation and differentiation in breast cancer cells.	[Caldon, Ce; Lee, Csl; Sutherland, Rl; Musgrove, Ea] St Vincents Hosp, Garvan Inst Med Res, Canc Res Program, Darlinghurst, NSW 2010, Australia; [Caldon, Ce; Sutherland, Rl; Musgrove, Ea] Univ New S Wales, Fac Med, St Vincents Clin Sch, Kensington, NSW 2033, Australia	Garvan Institute of Medical Research; St Vincents Hospital Sydney; University of New South Wales Sydney	Caldon, C (corresponding author), St Vincents Hosp, Garvan Inst Med Res, Canc Res Program, 384 Victoria St, Darlinghurst, NSW 2010, Australia.	e.musgrove@garvan.org.au	Caldon, Liz/C-1559-2009; Sutherland, Robert L/A-8378-2008	Caldon, Liz/0000-0003-1392-3472; 				Anthony FW, 2003, J SOC GYNECOL INVEST, V10, P509, DOI 10.1016/S1071-5576(03)00147-3; Baudry D, 2000, CLIN CANCER RES, V6, P3957; Bray JD, 2005, J STEROID BIOCHEM, V97, P328, DOI 10.1016/j.jsbmb.2005.06.032; Burwell EA, 2007, ONCOGENE, V26, P3423, DOI 10.1038/sj.onc.1210127; Castro-Rivera E, 2001, J BIOL CHEM, V276, P30853, DOI 10.1074/jbc.M103339200; CHAMBON M, 1989, J STEROID BIOCHEM, V33, P915, DOI 10.1016/0022-4731(89)90240-9; Englert C, 1997, CANCER RES, V57, P1429; Fu MF, 2004, ENDOCRINOLOGY, V145, P5439, DOI 10.1210/en.2004-0959; Graham JD, 2005, MOL ENDOCRINOL, V19, P2713, DOI 10.1210/me.2005-0126; Groshong SD, 1997, MOL ENDOCRINOL, V11, P1593, DOI 10.1210/me.11.11.1593; HABER DA, 1991, P NATL ACAD SCI USA, V88, P9618, DOI 10.1073/pnas.88.21.9618; Han YQ, 2004, ONCOGENE, V23, P6933, DOI 10.1038/sj.onc.1207609; Horton JD, 2002, J CLIN INVEST, V109, P1125, DOI 10.1172/JCI200215593; Hui R, 2002, CANCER RES, V62, P6916; Jomgeow T, 2006, CANCER SCI, V97, P259, DOI 10.1111/j.1349-7006.2006.00169.x; Kester HA, 1997, J BIOL CHEM, V272, P16637, DOI 10.1074/jbc.272.26.16637; KUDOH T, 1995, P NATL ACAD SCI USA, V92, P4517, DOI 10.1073/pnas.92.10.4517; Lee SB, 2001, EXP CELL RES, V264, P74, DOI 10.1006/excr.2000.5131; Lee TH, 1999, NUCLEIC ACIDS RES, V27, P2889, DOI 10.1093/nar/27.14.2889; Loeb DM, 2001, CANCER RES, V61, P921; Loeb DM, 2002, INT J HEMATOL, V76, P117, DOI 10.1007/BF02982573; Loeb DM, 2002, J BIOL CHEM, V277, P19627, DOI 10.1074/jbc.M201336200; Martel PM, 2006, EXP CELL RES, V312, P278, DOI 10.1016/j.yexcr.2005.10.022; Miyoshi Y, 2002, CLIN CANCER RES, V8, P1167; Musgrove EA, 2001, J BIOL CHEM, V276, P47675, DOI 10.1074/jbc.M106371200; MUSGROVE EA, 1994, P NATL ACAD SCI USA, V91, P8022, DOI 10.1073/pnas.91.17.8022; MUSGROVE EA, 1993, MOL CELL BIOL, V13, P3577, DOI 10.1128/MCB.13.6.3577; Musgrove EA, 1998, MOL CELL BIOL, V18, P1812, DOI 10.1128/MCB.18.4.1812; MUSGROVE EA, 1991, MOL CELL BIOL, V11, P5032, DOI 10.1128/MCB.11.10.5032; MUSGROVE EA, 1995, INT J CANCER, V63, P584, DOI 10.1002/ijc.2910630420; Nakatsuka S, 2006, MODERN PATHOL, V19, P804, DOI 10.1038/modpathol.3800588; Oji Y, 1999, JPN J CANCER RES, V90, P194, DOI 10.1111/j.1349-7006.1999.tb00733.x; ORMANDY CJ, 1992, INT J CANCER, V50, P777, DOI 10.1002/ijc.2910500519; Rae FK, 2004, ONCOGENE, V23, P3067, DOI 10.1038/sj.onc.1207360; RAMIREZZACARIAS JL, 1992, HISTOCHEMISTRY, V97, P493, DOI 10.1007/BF00316069; Reizner N, 2005, J MOL ENDOCRINOL, V35, P135, DOI 10.1677/jme.1.01761; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; Sakamaki T, 2006, MOL CELL BIOL, V26, P5449, DOI 10.1128/MCB.02074-05; Scharnhorst V, 2001, GENE, V273, P141, DOI 10.1016/S0378-1119(01)00593-5; Siehl JM, 2004, ANN HEMATOL, V83, P745, DOI 10.1007/s00277-004-0941-0; Silberstein GB, 2002, ONCOGENE, V21, P1009, DOI 10.1038/sj.onc.1205172; Silberstein GB, 1997, P NATL ACAD SCI USA, V94, P8132, DOI 10.1073/pnas.94.15.8132; Sutherland RL, 1998, J MAMMARY GLAND BIOL, V3, P63, DOI 10.1023/A:1018774302092; Swarbrick A, 2000, MOL CELL BIOL, V20, P2581, DOI 10.1128/MCB.20.7.2581-2591.2000; Sweeney KJ, 1998, ONCOGENE, V16, P2865, DOI 10.1038/sj.onc.1201814; Tuna M, 2005, ONCOGENE, V24, P1648, DOI 10.1038/sj.onc.1208345; Wagner KD, 2002, EMBO J, V21, P1398, DOI 10.1093/emboj/21.6.1398; Wagner N, 2005, DEVELOPMENT, V132, P1327, DOI 10.1242/dev.01682; Wagner N, 2002, CELL GROWTH DIFFER, V13, P297; WATTS CKW, 1995, MOL ENDOCRINOL, V9, P1804, DOI 10.1210/me.9.12.1804; Zaia A, 2001, ANTICANCER RES, V21, P1; Zapata-Benavides P, 2002, BIOCHEM BIOPH RES CO, V295, P784, DOI 10.1016/S0006-291X(02)00751-9	52	25	27	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 3	2008	27	1					126	138		10.1038/sj.onc.1210622	http://dx.doi.org/10.1038/sj.onc.1210622			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	247YO	17599043				2022-12-28	WOS:000252118700013
J	Chetty, C; Bhoopathi, P; Lakka, SS; Rao, JS				Chetty, C.; Bhoopathi, P.; Lakka, S. S.; Rao, J. S.			MMP-2 siRNA induced Fas/CD95-mediated extrinsic II apoptotic pathway in the A549 lung adenocarcinoma cell line	ONCOGENE			English	Article						CD95 (APO/Fas); Fas-L; cytochrome c; apoptosis; MMP-2; TIMP-3	TISSUE INHIBITOR; METALLOPROTEINASE INHIBITORS; ANTITUMOR-ACTIVITY; GASTRIC-CANCER; CYTOCHROME-C; DEATH DOMAIN; TUMOR-GROWTH; EXPRESSION; GENE; OVEREXPRESSION	We have previously reported that the downregulation of MMP-2 by adenovirus-mediated delivery of MMP-2 siRNA (Ad-MMP-2) reduced spheroid invasion and angiogenesis in vitro, and, metastasis and tumor growth in vivo. In this study, we investigated the mechanism of Ad-MMP-2-mediated growth inhibition in vitro and in vivo. Ad-MMP-2 infection led to the induction of apoptosis as determined by TUNEL assay, Annexin-V staining and PARP-1 cleavage in a dose-dependent manner in A549 cells. Ad-MMP-2 decreased the content of the antiapoptotic members of the Bcl-2 family proteins (Bcl-2 and Bcl-xL) and increased the content of the proapoptotic members of the Bcl-2 family (Bax and Bcl-xS) as determined by immunoblotting analysis. Furthermore, Ad-MMP-2-mediated apoptosis was accompanied by increase in truncated Bid, release of cytochrome c and the activation of caspase-8, - 9 and -3. Immunoblot analysis showed that Ad-MMP-2 infection caused upregulation of Fas/Fas-L and FADD, and Anti-Fas-L antibody reversed Ad-MMP-2-induced apoptosis. Tissue inhibitor of metalloproteinases ( TIMP)- 3, an endogenous inhibitor of MMP-2, which cleaves Fas-L and activates the Fas/Fas-L inducing apoptotic pathway, was increased in Ad-MMP-2-treated cells. Adenovirus-mediated expression of MMP-2 siRNA in human lung xenografts in vivo resulted in increased immunostaining of Fas, Fas-L, cleaved Bid and TIMP-3. This is the first report, to our knowledge, showing that MMP-2 inhibition upregulates TIMP-3 levels, which in turn, promotes apoptosis in lung cancer.	[Chetty, C.; Bhoopathi, P.; Lakka, S. S.; Rao, J. S.] Univ Illinois, Coll Med, Dept Canc Biol & Pharmacol, Program Canc Biol, Peoria, IL 61656 USA; [Rao, J. S.] Univ Illinois, Coll Med, Dept Neurosurg, Peoria, IL 61656 USA	University of Illinois System; University of Illinois Peoria; University of Illinois System; University of Illinois Peoria	Rao, JS (corresponding author), Univ Illinois, Coll Med, Dept Canc Biol & Pharmacol, Program Canc Biol, Box 1649, Peoria, IL 61656 USA.	jsrao@uic.edu	bhoopathi, praveen/A-9410-2010		NCI NIH HHS [R01 CA092393, R01 CA075557-09, CA92393, R01 CA095058, CA95058, CA116708, R01 CA095058-03, CA75557, R01 CA075557, R01 CA116708-02, R01 CA116708, R01 CA092393-04] Funding Source: Medline; NINDS NIH HHS [NS57529, R01 NS057529-01, R01 NS057529, R01 NS047699, NS47699, R01 NS047699-03] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA116708, R01CA092393, R01CA075557, R01CA095058] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS047699, R01NS057529] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ahonen M, 2002, MOL THER, V5, P705, DOI 10.1006/mthe.2002.0606; Baker AH, 2002, J CELL SCI, V115, P3719, DOI 10.1242/jcs.00063; Baker AH, 1999, BRIT J CANCER, V79, P1347, DOI 10.1038/sj.bjc.6690217; Baker AH, 1998, J CLIN INVEST, V101, P1478, DOI 10.1172/JCI1584; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; Bond M, 2002, J BIOL CHEM, V277, P13787, DOI 10.1074/jbc.M111507200; Bond M, 2000, J BIOL CHEM, V275, P41358, DOI 10.1074/jbc.M007929200; Bramhall SR, 2002, BRIT J CANCER, V86, P1864, DOI 10.1038/sj.bjc.6600310; Brew K, 2000, BBA-PROTEIN STRUCT M, V1477, P267, DOI 10.1016/S0167-4838(99)00279-4; Brown PD, 1995, ANN ONCOL, V6, P967, DOI 10.1093/oxfordjournals.annonc.a059091; CAWSTON TE, 1995, BRIT MED BULL, V51, P385, DOI 10.1093/oxfordjournals.bmb.a072968; Chetty C, 2006, MOL CANCER THER, V5, P2289, DOI 10.1158/1535-7163.MCT-06-0169; CHINNAIYAN AM, 1995, CELL, V81, P512; Drynda A, 2005, J IMMUNOL, V174, P6524, DOI 10.4049/jimmunol.174.10.6524; Evans JD, 2001, BRIT J CANCER, V85, P1865, DOI 10.1054/bjoc.2001.2168; Fata JE, 2001, J CLIN INVEST, V108, P831, DOI 10.1172/JCI13171; Gomez DE, 1997, EUR J CELL BIOL, V74, P111; Haro H, 2000, J CLIN INVEST, V105, P143, DOI 10.1172/JCI7091; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Kang SH, 2000, INT J CANCER, V86, P632, DOI 10.1002/(SICI)1097-0215(20000601)86:5<632::AID-IJC5>3.0.CO;2-5; Khong HT, 2002, NAT IMMUNOL, V3, P999, DOI 10.1038/ni1102-999; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Li WQ, 1998, J IMMUNOL, V161, P5000; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Medema JP, 1997, EUR J IMMUNOL, V27, P3492, DOI 10.1002/eji.1830271250; Mitsiades N, 2001, EXPERT OPIN INV DRUG, V10, P1075, DOI 10.1517/13543784.10.6.1075; Nyormoi O, 2003, CELL DEATH DIFFER, V10, P558, DOI 10.1038/sj.cdd.4401209; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Spurbeck WW, 2002, BLOOD, V100, P3361, DOI 10.1182/blood.V100.9.3361; Strand S, 2004, ONCOGENE, V23, P3732, DOI 10.1038/sj.onc.1207387; TANAKA M, 1995, EMBO J, V14, P1129, DOI 10.1002/j.1460-2075.1995.tb07096.x; Uramoto H, 1999, EUR J CANCER, V35, P1462, DOI 10.1016/S0959-8049(99)00157-4	32	34	36	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 6	2007	26	55					7675	7683		10.1038/sj.onc.1210584	http://dx.doi.org/10.1038/sj.onc.1210584			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	239SK	17599056	Green Accepted			2022-12-28	WOS:000251537800009
J	Ceballos-Cancino, G; Espinosa, M; Maldonado, V; Melendez-Zajgla, J				Ceballos-Cancino, G.; Espinosa, M.; Maldonado, V.; Melendez-Zajgla, J.			Regulation of mitochondrial Smac/DIABLO-selective release by survivin	ONCOGENE			English	Article						antineoplastic drugs; cancer; DNA damage; inhibitor of apoptosis proteins; mitochondria	CYTOCHROME-C; INDUCED APOPTOSIS; IN-VITRO; SMAC; CELLS; ACTIVATION; EXPRESSION; PROTEIN; CANCER; BAX	The intrinsic apoptotic pathway is characterized by the release of several mitochondrial intermembrane proteins into the cytosol of dying cells. It is unclear whether the release of these proteins follows a common or specific pathway. In the present report we show that survivin and, to a lesser extent, the survivin splice variant survivin DeltaEx3 regulate the specific liberation of second mitochondria-derived activator of caspase/direct IAP binding protein with low pI (Smac/DIABLO), an inhibitor of apoptosis proteins binding protein, during apoptosis induced by etoposide, a DNA damaging agent. This antineoplastic drug induced posttranscriptional upregulation of survivin and survivin DeltaEx3. In turn, mitochondrial survivin associated with Smac/DIABLO, delaying its release. In addition, cytosolic survivin also stabilized the cytosolic levels of released Smac/DIABLO. These results provide an explanation for the observed differences in the release of mitochondrial intermembrane proteins in various apoptotic models and present a new mechanism for the anti-apoptotic effects of survivin in cancer cells.	Inst Nacl Cancerol, Subdirecc Invest Basica, Mol Biol Lab, Mexico City 14080, DF, Mexico	Instituto Nacional de Cancerologia (INCAN)	Maldonado, V (corresponding author), Inst Nacl Cancerol, Subdirecc Invest Basica, Mol Biol Lab, Av San Fernando 22, Mexico City 14080, DF, Mexico.	vilmaml@gmail.com; jorgezajgla@salud.gob.mx	Melendez-Zajgla, Jorge/A-5708-2008					Adrain C, 2001, EMBO J, V20, P6627, DOI 10.1093/emboj/20.23.6627; Chauhan D, 2003, J BIOL CHEM, V278, P17593, DOI 10.1074/jbc.C300076200; Deng YB, 2002, GENE DEV, V16, P33, DOI 10.1101/gad.949602; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Ishiyama M, 1996, BIOL PHARM BULL, V19, P1518; Kandasamy K, 2003, CANCER RES, V63, P1712; Karpinich NO, 2002, J BIOL CHEM, V277, P16547, DOI 10.1074/jbc.M110629200; Lim MLR, 2006, EXP CELL RES, V312, P1174, DOI 10.1016/j.yexcr.2006.01.026; Ling X, 2004, J BIOL CHEM, V279, P15196, DOI 10.1074/jbc.M310947200; MacFarlane M, 2002, J BIOL CHEM, V277, P36611, DOI 10.1074/jbc.M200317200; Martinez-Velazquez M, 2007, CELL SIGNAL, V19, P1212, DOI 10.1016/j.cellsig.2007.01.001; McNeish IA, 2005, EXP CELL RES, V302, P69, DOI 10.1016/j.yexcr.2004.08.029; Morizane Y, 2005, J BIOCHEM, V137, P125, DOI 10.1093/jb/mvi029; O'Connor DS, 2002, CANCER CELL, V2, P43, DOI 10.1016/S1535-6108(02)00084-3; Song ZY, 2003, J BIOL CHEM, V278, P23130, DOI 10.1074/jbc.M300957200; Tirro E, 2006, CANCER RES, V66, P4263, DOI 10.1158/0008-5472.CAN-05-3248; Verhagen AM, 2002, APOPTOSIS, V7, P163, DOI 10.1023/A:1014318615955; Wall NR, 2003, CANCER RES, V63, P230; Yamamoto S, 2002, J PHYS CHEM SOLIDS, V63, P1489, DOI 10.1016/S0022-3697(02)00032-X; Zhang WG, 2002, J EUR CERAM SOC, V22, P2869, DOI 10.1016/S0955-2219(02)00063-8; Zhou LL, 2005, APOPTOSIS, V10, P289, DOI 10.1007/s10495-005-0803-9	21	75	77	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 29	2007	26	54					7569	7575		10.1038/sj.onc.1210560	http://dx.doi.org/10.1038/sj.onc.1210560			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	236DB	17546047	Bronze			2022-12-28	WOS:000251282100009
J	Julien, S; Puig, I; Caretti, E; Bonaventure, J; Nelles, L; van Roy, F; Dargemont, C; Garcia de Herreros, A; Bellacosa, A; Larue, L				Julien, S.; Puig, I.; Caretti, E.; Bonaventure, J.; Nelles, L.; van Roy, F.; Dargemont, C.; Garcia de Herreros, A.; Bellacosa, A.; Larue, L.			Activation of NF-kappa B by Akt upregulates Snail expression and induces epithelium mesenchyme transition	ONCOGENE			English	Article						E-cadherin; metastasis; Zeb; slug; migration	E-CADHERIN EXPRESSION; TRANSCRIPTION FACTOR SNAIL; REPRESSES E-CADHERIN; GENE-EXPRESSION; BREAST-CANCER; SUPPRESSOR GENE; CELL INVASION; TUMOR-CELLS; BINDING; TARGET	Carcinoma progression is associated with the loss of epithelial features, and the acquisition of mesenchymal characteristics and invasive properties by tumour cells. The loss of cell-cell contacts may be the. first step of the epithelium mesenchyme transition (EMT) and involves the functional inactivation of the cell-cell adhesion molecule E-cadherin. Repression of E-cadherin expression by the transcription factor Snail is a central event during the loss of epithelial phenotype. Akt kinase activation is frequent in human carcinomas, and Akt regulates various cellular mechanisms including EMT. Here, we show that Snail activation and consequent repression of E- cadherin may depend on AKT-mediated nuclear factor-kappa B (NF-kappa B) activation, and that NF-kappa B induces Snail expression. Expression of the NF-kappa B subunit p65 is suficient for EMT induction, validating this signalling module during EMT. NF-kappa B pathway activation is associated with tumour progression and metastasis of several human tumour types; E-cadherin acts as a metastasis suppressor protein. Thus, this signalling and transcriptional network linking AKT, NF-kappa B, Snail and E-cadherin during EMT is a potential target for antimetastatic therapeutics.	CNRS, Inst Curie, Dev Genet Melanocytes, UMR 146, F-91405 Orsay, France; Fox Chase Canc Ctr, Human Genet Program, Philadelphia, PA USA; Univ Leuven, VIB7, Fladers Interuniv Ins Biotechnol, Lab Mol Biol Dept Dev Biol, Louvain, Belgium; Univ Ghent VIB, Dept Mol Biomed Res, Ghent, Belgium; Univ Paris 06, Inst Jacques Monod, Dept Biol Cellulaire, UMR 7592 CNRS, Paris, France; Univ Pompeu Fabra, Ins Municipal Invest Med, Unit Biol Cellular Mol, Barcelona, Spain; Regina Elena Inst Canc Res, Lab Dev Therapeut, Rome, Italy	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Fox Chase Cancer Center; KU Leuven; Flanders Institute for Biotechnology (VIB); Ghent University; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; Pompeu Fabra University; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena	Larue, L (corresponding author), CNRS, Inst Curie, Dev Genet Melanocytes, UMR 146, Bat 110, F-91405 Orsay, France.	lionel.larue@curie.fr	de Herreros, A Garcia/H-3104-2014; Larue, Lionel/F-7355-2013; van Roy, Frans M/C-6123-2009; Larue, Lionel/I-6532-2016	de Herreros, A Garcia/0000-0001-5270-0808; van Roy, Frans M/0000-0003-4358-1039; Puig Borreil, Isabel/0000-0001-5614-4298				ARENZANASEISDEDOS F, 1993, J VIROL, V67, P6596, DOI 10.1128/JVI.67.11.6596-6604.1993; Bachelder RE, 2005, J CELL BIOL, V168, P29, DOI 10.1083/jcb.200409067; Barbera MJ, 2004, ONCOGENE, V23, P7345, DOI 10.1038/sj.onc.1207990; Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Bellacosa A, 1998, ONCOGENE, V17, P313, DOI 10.1038/sj.onc.1201947; Bellacosa A, 2004, CANCER BIOL THER, V3, P268, DOI 10.4161/cbt.3.3.703; Berx G, 1998, HUM MUTAT, V12, P226, DOI 10.1002/(SICI)1098-1004(1998)12:4<226::AID-HUMU2>3.0.CO;2-D; BIRCHMEIER W, 1994, BBA-REV CANCER, V1198, P11, DOI 10.1016/0304-419X(94)90003-5; Bolos V, 2003, J CELL SCI, V116, P499, DOI 10.1242/jcs.00224; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Budunova IV, 1999, ONCOGENE, V18, P7423, DOI 10.1038/sj.onc.1203104; Cabannes E, 1999, ONCOGENE, V18, P3063, DOI 10.1038/sj.onc.1202893; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Christofori G, 1999, TRENDS BIOCHEM SCI, V24, P73, DOI 10.1016/S0968-0004(98)01343-7; Chua HL, 2007, ONCOGENE, V26, P711, DOI 10.1038/sj.onc.1209808; Cogswell PC, 2000, ONCOGENE, V19, P1123, DOI 10.1038/sj.onc.1203412; Cohen P, 2001, NAT REV MOL CELL BIO, V2, P769, DOI 10.1038/35096075; Comijn J, 2001, MOL CELL, V7, P1267, DOI 10.1016/S1097-2765(01)00260-X; De Craene B, 2005, CANCER RES, V65, P6237, DOI 10.1158/0008-5472.CAN-04-3545; Du KY, 1998, J BIOL CHEM, V273, P32377, DOI 10.1074/jbc.273.49.32377; Eger A, 2005, ONCOGENE, V24, P2375, DOI 10.1038/sj.onc.1208429; Giroldi LA, 1997, BIOCHEM BIOPH RES CO, V241, P453, DOI 10.1006/bbrc.1997.7831; Grille SJ, 2003, CANCER RES, V63, P2172; GRITZ L, 1983, GENE, V25, P179, DOI 10.1016/0378-1119(83)90223-8; Guaita S, 2002, J BIOL CHEM, V277, P39209, DOI 10.1074/jbc.M206400200; Gustin JA, 2006, J BIOL CHEM, V281, P16473, DOI 10.1074/jbc.M507373200; Hajra KM, 2002, CANCER RES, V62, P1613; Hajra KM, 1999, ONCOGENE, V18, P7274, DOI 10.1038/sj.onc.1203336; Hennig G, 1996, J BIOL CHEM, V271, P595, DOI 10.1074/jbc.271.1.595; HENNIG G, 1995, ONCOGENE, V11, P475; Huber MA, 2005, CURR OPIN CELL BIOL, V17, P548, DOI 10.1016/j.ceb.2005.08.001; Irie HY, 2005, J CELL BIOL, V171, P1023, DOI 10.1083/jcb.200505087; Ji XD, 1997, CELL GROWTH DIFFER, V8, P773; Kim D, 2001, FASEB J, V15, P1953, DOI 10.1096/fj.01-0198com; Larue L, 2005, ONCOGENE, V24, P7443, DOI 10.1038/sj.onc.1209091; Misra J, 2002, GENOME RES, V12, P1112, DOI 10.1101/gr.225302; Morali OG, 2005, MOL B INT U, P12; Morali OG, 2001, ONCOGENE, V20, P4942, DOI 10.1038/sj.onc.1204660; Nelles L, 2003, GENOMICS, V82, P460, DOI 10.1016/S0888-7543(03)00169-1; NIETO MA, 1992, DEVELOPMENT, V116, P227; Orlowski RZ, 2002, TRENDS MOL MED, V8, P385, DOI 10.1016/S1471-4914(02)02375-4; Ozes ON, 1999, NATURE, V401, P82; Park BK, 2001, CANCER RES, V61, P7647; Peinado HC, 2004, INT J DEV BIOL, V48, P365, DOI 10.1387/ijdb.041794hp; Perez-Moreno MA, 2001, J BIOL CHEM, V276, P27424, DOI 10.1074/jbc.M100827200; Remacle JE, 1999, EMBO J, V18, P5073, DOI 10.1093/emboj/18.18.5073; RISINGER JI, 1994, NAT GENET, V7, P98, DOI 10.1038/ng0594-98; Rodrigo I, 1999, EXP CELL RES, V248, P358, DOI 10.1006/excr.1999.4438; Rodriguez MS, 1996, ONCOGENE, V12, P2425; Schmid JA, 2000, J BIOL CHEM, V275, P17035, DOI 10.1074/jbc.M000291200; Stoyanova R, 2004, CANCER BIOL THER, V3, P1313, DOI 10.4161/cbt.3.12.1459; Stoyanova R, 2004, J CELL PHYSIOL, V201, P359, DOI 10.1002/jcp.20074; Tamura G, 2000, J NATL CANCER I, V92, P569, DOI 10.1093/jnci/92.7.569; Tang ED, 1999, J BIOL CHEM, V274, P16741, DOI 10.1074/jbc.274.24.16741; Testa JR, 2001, P NATL ACAD SCI USA, V98, P10983, DOI 10.1073/pnas.211430998; Thant AA, 2001, CLIN EXP METASTAS, V18, P423, DOI 10.1023/A:1010921730952; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Van de Putte T, 2003, AM J HUM GENET, V72, P465, DOI 10.1086/346092; Viatour P, 2005, TRENDS BIOCHEM SCI, V30, P43, DOI 10.1016/j.tibs.2004.11.009; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; Wang HD, 2004, WORLD J GASTROENTERO, V10, P3088; Wu JT, 2005, J SURG RES, V123, P158, DOI 10.1016/j.jss.2004.06.006; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006; YOSHIURA K, 1995, P NATL ACAD SCI USA, V92, P7416, DOI 10.1073/pnas.92.16.7416; Zhou BHP, 2004, NAT CELL BIOL, V6, P931, DOI 10.1038/ncb1173	66	383	398	0	33	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 22	2007	26	53					7445	7456		10.1038/sj.onc.1210546	http://dx.doi.org/10.1038/sj.onc.1210546			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	236DA	17563753				2022-12-28	WOS:000251282000006
J	Perez, CA; Ott, J; Mays, DJ; Pietenpol, JA				Perez, C. A.; Ott, J.; Mays, D. J.; Pietenpol, J. A.			p63 consensus DNA-binding site: identification, analysis and application into a p63MH algorithm	ONCOGENE			English	Article						SELEX; consensus DNA-binding site; p63MH; ING1; PTPN14	P53 FAMILY; BIOLOGICAL FUNCTIONS; HUMAN GENOME; GENES; PROTEIN; DELTA-NP63-ALPHA; TRANSCRIPTION; EXPRESSION; SEQUENCE; DISTINCT	p53 and p63 belong to a family of sequence-specific transcription factors regulating key cellular processes. Differential composition of the p53 and p63 DNA-binding sites may contribute to distinct functions of these protein homologues. We used SELEX (systematic evolution of ligands by exponential enrichment) methodology to identify nucleic acid ligands for p63. We found that p63 bound preferentially to DNA fragments conforming to the 20 bp sequence 5'- RRRC(A/G)(A/T)GYYYRRRC(A/T) (C/T)GYYY-3'. Relative to the p53 consensus, the p63 consensus DNA-binding site (DBS) was more degenerate, particularly at positions 10 and 11, and was enriched for A/G at position 5 and C/T at position 16 of the consensus. The differences in DNA-binding site preferences between p63 and p53 influenced their ability to activate transcription from select response elements (REs) in cells. A computer algorithm, p63MH, was developed to find candidate p63-binding motifs on input sequences. We identified genes responsive to p63 regulation that contain functional p63 REs. Our results suggest that the sequence composition of REs could be one contributing factor to target gene discrimination between p63 and p53.	Vanderbilt Univ, Med Ctr, Vanderbilt Ingram Canc Ctr, Dept Biochem, Nashville, TN 37203 USA; Rockefeller Univ, Lab Stat Gen, New York, NY 10021 USA	Vanderbilt University; Rockefeller University	Pietenpol, JA (corresponding author), Vanderbilt Univ, Med Ctr, Vanderbilt Ingram Canc Ctr, Dept Biochem, 221 Kirkland Hall, Nashville, TN 37203 USA.	j.pietenpol@vanderbilt.edu			NCI NIH HHS [CA105436, CA68485, CA70856] Funding Source: Medline; NIEHS NIH HHS [ES00267] Funding Source: Medline; NIMH NIH HHS [MH44292] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA070856, R01CA105436, P30CA068485] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000267] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH044292, R37MH044292] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Anwar A, 2003, J BIOL CHEM, V278, P10368, DOI 10.1074/jbc.M211981200; Barbieri CE, 2005, CANCER RES, V65, P2314, DOI 10.1158/0008-5472.CAN-04-3449; Barbieri CE, 2003, J BIOL CHEM, V278, P51408, DOI 10.1074/jbc.M309943200; BLACKWELL TK, 1995, METHOD ENZYMOL, V254, P604; Campos EI, 2004, CELL MOL LIFE SCI, V61, P2597, DOI 10.1007/s00018-004-4199-4; Candi E, 2006, J CELL SCI, V119, P4617, DOI 10.1242/jcs.03265; Caserta TM, 2006, MOL CANCER RES, V4, P759, DOI 10.1158/1541-7786.MCR-05-0149; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; Flatt PM, 1998, CELL GROWTH DIFFER, V9, P535; Flatt PM, 2000, CANCER LETT, V156, P63, DOI 10.1016/S0304-3835(00)00441-9; Harms K, 2004, CELL MOL LIFE SCI, V61, P822, DOI 10.1007/s00018-003-3304-4; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Hearnes JM, 2005, MOL CELL BIOL, V25, P10148, DOI 10.1128/MCB.25.22.10148-10158.2005; Hoh J, 2002, P NATL ACAD SCI USA, V99, P8467, DOI 10.1073/pnas.132268899; Inga A, 2002, MOL CELL BIOL, V22, P8612, DOI 10.1128/MCB.22.24.8612-8625.2002; Kent WJ, 2002, GENOME RES, V12, P996, DOI 10.1101/gr.229102; Klein C, 2001, J BIOL CHEM, V276, P37390, DOI 10.1074/jbc.M103801200; Liu G, 2002, ONCOGENE, V21, P7195, DOI 10.1038/sj.onc.1205862; MCKAY R, 1981, NATURE, V289, P810, DOI 10.1038/289810a0; Moll UM, 2004, MOL CANCER RES, V2, P371; Ortt K, 2006, FEBS LETT, V580, P4544, DOI 10.1016/j.febslet.2006.07.004; Osada M, 2005, MOL CELL BIOL, V25, P6077, DOI 10.1128/MCB.25.14.6077-6089.2005; Perez CA, 2007, CELL CYCLE, V6, P246, DOI 10.4161/cc.6.3.3801; Pietenpol JA, 1996, P NATL ACAD SCI USA, V93, P8390, DOI 10.1073/pnas.93.16.8390; Ponassi R, 2006, BIOCHEM PHARMACOL, V72, P1417, DOI 10.1016/j.bcp.2006.07.031; Sasaki Y, 2002, J BIOL CHEM, V277, P719, DOI 10.1074/jbc.M108080200; Shimada A, 1999, CANCER RES, V59, P2781; Sniezek JC, 2004, LARYNGOSCOPE, V114, P2063, DOI 10.1097/01.mlg.0000149437.35855.4b; Thijs G, 2002, J COMPUT BIOL, V9, P447, DOI 10.1089/10665270252935566; Tomso DJ, 2005, P NATL ACAD SCI USA, V102, P6431, DOI 10.1073/pnas.0501721102; Wadham C, 2003, MOL BIOL CELL, V14, P2520, DOI 10.1091/mbc.E02-09-0577; Westfall MD, 2003, MOL CELL BIOL, V23, P2264, DOI 10.1128/MCB.23.7.2264-2276.2003; Wu GJ, 2003, CANCER RES, V63, P2351; Yang A, 2006, MOL CELL, V24, P593, DOI 10.1016/j.molcel.2006.10.018; Ying HQ, 2005, MOL CELL BIOL, V25, P6154, DOI 10.1128/MCB.25.14.6154-6164.2005	35	74	78	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 15	2007	26	52					7363	7370		10.1038/sj.onc.1210561	http://dx.doi.org/10.1038/sj.onc.1210561			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	231NP	17563751				2022-12-28	WOS:000250955700008
J	Mak, HHL; Peschard, P; Lin, T; Naujokas, MA; Zuo, D; Park, M				Mak, H. H. L.; Peschard, P.; Lin, T.; Naujokas, M. A.; Zuo, D.; Park, M.			Oncogenic activation of the Met receptor tyrosine kinase fusion protein, Tpr-Met, involves exclusion from the endocytic degradative pathway	ONCOGENE			English	Article						transforming gene; signal transduction; endocytosis; RTK; Cbl; ubiquitin	GROWTH-FACTOR RECEPTOR; DOMAIN BINDING-SITE; DOWN-REGULATION; C-CBL; JUXTAMEMBRANE DOMAIN; UBIQUITINATION; MULTIUBIQUITINATION; UBIQUITYLATION; CANCER	Multiple mechanisms of dysregulation of receptor tyrosine kinases (RTKs) are observed in human cancers. In addition to gain-of-function, loss of negative regulation also contributes to oncogenic activation of RTKs. Negative regulation of many RTKs involves their internalization and degradation in the lysosome, a process regulated through ubiquitination. RTK oncoproteins activated following chromosomal translocation, are no longer transmembrane proteins, and are predicted to escape lysosomal degradation. To test this, we used the Tpr-Met oncogene, generated following chromosomal translocation of the hepatocyte growth factor receptor (Met). Unlike Met, Tpr-Met is localized in the cytoplasm and also lacks the binding site for Cbl ubiquitin ligases. We determined whether subcellular localization of Tpr-Met, and/or loss of its Cbl-binding site, is important for oncogenic activity. Presence of a Cbl-binding site and ubiquitination of cytosolic Tpr-Met oncoproteins does not alter their transforming activity. In contrast, plasma membrane targeting allows Tpr-Met to enter the endocytic pathway, and Tpr-Met transforming activity as well as protein stability are decreased in a Cbl-dependent manner. We show that transformation by Tpr-Met is in part dependent on its ability to escape normal downregulatory mechanisms. This provides a paradigm for many RTK oncoproteins activated following chromosomal translocation.	McGill Univ, Ctr Hlth, Mol Oncol Grp, Montreal, PQ, Canada; McGill Univ, Dept Biochem, Montreal, PQ, Canada; McGill Univ, Dept Med, Montreal, PQ, Canada; McGill Univ, Dept Oncol, Montreal, PQ, Canada	McGill University; McGill University; McGill University; McGill University	Park, M (corresponding author), McGill Univ, Ctr Hlth, Dept Med, Mol Oncol Grp, 687 Ave Pins Ouest, Rm H5-21, Montreal, PQ H3A 1A1, Canada.	morag.park@mcgill.ca		Peschard, Pascal/0000-0001-6395-5566				Abella JV, 2005, MOL CELL BIOL, V25, P9632, DOI 10.1128/MCB.25.21.9632-9645.2005; Bache KG, 2004, EMBO J, V23, P2707, DOI 10.1038/sj.emboj.7600292; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; Carter S, 2004, J BIOL CHEM, V279, P52835, DOI 10.1074/jbc.M407769200; Grovdal LM, 2004, EXP CELL RES, V300, P388, DOI 10.1016/j.yexcr.2004.07.003; Haglund K, 2003, NAT CELL BIOL, V5, P461, DOI 10.1038/ncb983; Huang FT, 2006, MOL CELL, V21, P737, DOI 10.1016/j.molcel.2006.02.018; Katzmann DJ, 2002, NAT REV MOL CELL BIO, V3, P893, DOI 10.1038/nrm973; Lamorte L, 2001, Surg Oncol Clin N Am, V10, P271; Lee PSW, 1999, EMBO J, V18, P3616, DOI 10.1093/emboj/18.13.3616; Levkowitz G, 1998, GENE DEV, V12, P3663, DOI 10.1101/gad.12.23.3663; Miyake S, 1998, P NATL ACAD SCI USA, V95, P7927, DOI 10.1073/pnas.95.14.7927; Mosesson Y, 2003, J BIOL CHEM, V278, P21323, DOI 10.1074/jbc.C300096200; Naslavsky N, 2003, MOL BIOL CELL, V14, P417, DOI 10.1091/mbc.02-04-0053; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; Peschard P, 2004, J BIOL CHEM, V279, P29565, DOI 10.1074/jbc.M403954200; Peschard P, 2001, MOL CELL, V8, P995, DOI 10.1016/S1097-2765(01)00378-1; Peschard P, 2003, CANCER CELL, V3, P519, DOI 10.1016/S1535-6108(03)00136-3; RODRIGUES CA, 1994, CURR OPIN GENET DEV, V4, P15, DOI 10.1016/0959-437X(94)90086-8; RODRIGUES GA, 1993, MOL CELL BIOL, V13, P6711, DOI 10.1128/MCB.13.11.6711; RODRIGUES GA, 1991, MOL CELL BIOL, V11, P2962, DOI 10.1128/MCB.11.6.2962; Shtiegman K, 2003, SEMIN CANCER BIOL, V13, P29, DOI 10.1016/S1044-579X(02)00097-4; Thien CBF, 2005, BIOCHEM J, V391, P153, DOI 10.1042/BJ20050892; Thrower JS, 2000, EMBO J, V19, P94, DOI 10.1093/emboj/19.1.94; Urbe S, 2003, J CELL SCI, V116, P4169, DOI 10.1242/jcs.00723; Vigna E, 1999, ONCOGENE, V18, P4275, DOI 10.1038/sj.onc.1202791; Waterman H, 1999, J BIOL CHEM, V274, P22151, DOI 10.1074/jbc.274.32.22151; Waterman H, 2002, EMBO J, V21, P303, DOI 10.1093/emboj/21.3.303	28	35	37	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 8	2007	26	51					7213	7221		10.1038/sj.onc.1210522	http://dx.doi.org/10.1038/sj.onc.1210522			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	231NO	17533376				2022-12-28	WOS:000250955600005
J	Zhong, Y; Jiang, L; Hiai, H; Toyokuni, S; Yamada, Y				Zhong, Y.; Jiang, L.; Hiai, H.; Toyokuni, S.; Yamada, Y.			Overexpression of a transcription factor LYL1 induces T- and B-cell lymphoma in mice	ONCOGENE			English	Article						LYL1; lymphoma; basic helix-loop-helix transcription factor; E2A; transgenic mice; two-hybrid assay	LOOP-HELIX PROTEINS; ACUTE LYMPHOBLASTIC-LEUKEMIA; TRANSGENIC MICE; SCL GENE; TARGETED DISRUPTION; EXPRESSION; MALIGNANCIES; TAL1; BHLH; IMMUNOGLOBULIN	LYL1, a member of the class II basic helix-loop-helix transcription factors, is aberrantly expressed in a fraction of human T-cell acute lymphoblastic leukemia. Here, we generated transgenic mice ubiquitously overexpressing LYL1 using a construct expressing full-length cDNA driven by a human elongation factor lot promoter. Four independent lines exhibiting high LYL1 expression were established. Of these transgenic mice, 96% displayed loss of hair with a short kinked tail. Furthermore, 30% of them developed malignant lymphoma, with an average latent period of 352 days. In these mice, histological examination revealed tumor cell infiltration in multiple organs and immunohistochemical analysis showed that the infiltrated tumor cells were either CD3 or CD45R/B220-positive; fluorescence-activated cell sorter analysis indicated that each tumor consisted either of mainly CD4, CD8 double-positive T cells or mature B cells; the clonality of LYL1-induced lymphoma was confirmed by T-cell receptor rearrangement and immunoglobulin heavy-chain gene rearrangement analyses. Mammalian two-hybrid analysis and luciferase assay suggested that excess LYL1 blocked the dimerization of E2A and thus inhibited the regulatory activity of E2A on the CD4 promoter. Reverse transcription-polymerase chain reaction results showed that the expression of certain E2A/HEB target genes was downregulated. Taken together, our results provide direct evidence that aberrant expression of LYL1 plays a role in lymphomagenesis.	Kyoto Univ, Grad Sch Med, Dept Pathol & Biol Dis, Sakyo Ku, Kyoto 6068501, Japan; Shiga Med Ctr Adults, Shiga, Japan; Aino Univ, Fac Nursing & Rehabil, Osaka, Japan	Kyoto University	Toyokuni, S (corresponding author), Kyoto Univ, Grad Sch Med, Dept Pathol & Biol Dis, Sakyo Ku, Kyoto 6068501, Japan.	toyokuni@path1.med.kyoto-u.ac.jp; yamada@aino.ac.jp	Toyokuni, Shinya/ABE-7714-2021; Zhong, Yi/K-7419-2012; Toyokuni, Shinya/C-1358-2010	Toyokuni, Shinya/0000-0002-5757-1109; Toyokuni, Shinya/0000-0002-5757-1109				Aplan PD, 1997, EMBO J, V16, P2408, DOI 10.1093/emboj/16.9.2408; BAER R, 1993, SEMIN CANCER BIOL, V4, P341; Bain G, 1997, MOL CELL BIOL, V17, P4782, DOI 10.1128/MCB.17.8.4782; Begley CG, 1999, BLOOD, V93, P2760; Chervinsky DS, 1999, MOL CELL BIOL, V19, P5025; Condorelli GL, 1996, CANCER RES, V56, P5113; Dolcet X, 2005, VIRCHOWS ARCH, V446, P475, DOI 10.1007/s00428-005-1264-9; Ferrando AA, 2003, SEMIN HEMATOL, V40, P274, DOI 10.1016/S0037-1963(03)00195-1; Ferrando AA, 2002, CANCER CELL, V1, P75, DOI 10.1016/S1535-6108(02)00018-1; Ferrier R, 1999, ONCOGENE, V18, P995, DOI 10.1038/sj.onc.1202374; Gilmore TD, 1996, ONCOGENE, V13, P1367; Herblot S, 2000, NAT IMMUNOL, V1, P138, DOI 10.1038/77819; Hjalt T, 2004, INT REV CYTOL, V236, P251, DOI 10.1016/S0074-7696(04)36006-7; HSU HL, 1994, P NATL ACAD SCI USA, V91, P3181, DOI 10.1073/pnas.91.8.3181; Jones S, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-6-226; KUO SS, 1991, ONCOGENE, V6, P961; LARSON RC, 1995, ONCOGENE, V11, P853; Larson RC, 1996, EMBO J, V15, P1021, DOI 10.1002/j.1460-2075.1996.tb00439.x; Lazorchak A, 2005, TRENDS IMMUNOL, V26, P334, DOI 10.1016/j.it.2005.03.011; MALISSEN M, 1984, CELL, V37, P1101, DOI 10.1016/0092-8674(84)90444-6; Massari ME, 2000, MOL CELL BIOL, V20, P429, DOI 10.1128/MCB.20.2.429-440.2000; MELLENTIN JD, 1989, CELL, V58, P77, DOI 10.1016/0092-8674(89)90404-2; Meng YS, 2005, LEUKEMIA, V19, P1941, DOI 10.1038/sj.leu.2403836; Miyamoto A, 1996, MOL CELL BIOL, V16, P2394; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Murre C, 2005, NAT IMMUNOL, V6, P1079, DOI 10.1038/ni1260; MURRE C, 1994, BBA-GENE STRUCT EXPR, V1218, P129, DOI 10.1016/0167-4781(94)90001-9; O'Neil J, 2004, CANCER CELL, V5, P587, DOI 10.1016/j.ccr.2004.05.023; ROBB L, 1995, P NATL ACAD SCI USA, V92, P7075, DOI 10.1073/pnas.92.15.7075; SAKANO H, 1980, NATURE, V286, P676, DOI 10.1038/286676a0; SAWADA S, 1993, MOL CELL BIOL, V13, P5620, DOI 10.1128/MCB.13.9.5620; SHIVDASANI RA, 1995, NATURE, V373, P432, DOI 10.1038/373432a0; Toyokuni S, 2003, PATHOL INT, V53, P259, DOI 10.1046/j.1320-5463.2003.01465.x; Toyokuni S, 1997, LAB INVEST, V76, P365; VANDONGEN JJM, 1991, CLIN CHIM ACTA, V198, P1; VISVADER J, 1991, ONCOGENE, V6, P187; WADMAN I, 1994, EMBO J, V13, P4831, DOI 10.1002/j.1460-2075.1994.tb06809.x; Wilm B, 1998, P NATL ACAD SCI USA, V95, P8692, DOI 10.1073/pnas.95.15.8692; Wilson V, 2002, GENOME BIOL, V3, P30081, DOI [10.1186/gb-2002-3-6-reviews3008, DOI 10.1186/GB-2002-3-6-REVIEWS3008]; XIA Y, 1994, ONCOGENE, V9, P1437; XIA Y, 1991, P NATL ACAD SCI USA, V88, P11416, DOI 10.1073/pnas.88.24.11416; Yan W, 1997, MOL CELL BIOL, V17, P7317, DOI 10.1128/MCB.17.12.7317	42	32	34	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 18	2007	26	48					6937	6947		10.1038/sj.onc.1210494	http://dx.doi.org/10.1038/sj.onc.1210494			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	220WQ	17486074	Green Submitted			2022-12-28	WOS:000250188400009
J	Donatello, S; Fiorino, A; Degl'Innocenti, D; Alberti, L; Miranda, C; Gorla, L; Bongarzone, I; Rizzetti, MG; Pierotti, MA; Borrello, MG				Donatello, S.; Fiorino, A.; Degl'Innocenti, D.; Alberti, L.; Miranda, C.; Gorla, L.; Bongarzone, I.; Rizzetti, M. G.; Pierotti, M. A.; Borrello, M. G.			SH2B1 beta adaptor is a key enhancer of RET tyrosine kinase signaling	ONCOGENE			English	Article						RET; SH2B1; signaling	INSULIN-RECEPTOR KINASE; SH2 DOMAIN; CELLULAR-TRANSFORMATION; REGULATED KINASE; ACTIVATION LOOP; DOCKING SITE; PROTEIN; SH2-B-BETA; IDENTIFICATION; JAK2	The RET gene encodes two main isoforms of a receptor tyrosine kinase (RTK) implicated in various human diseases. Activating germ-line point mutations are responsible for multiple endocrine neoplasia type 2-associated medullary thyroid carcinomas, inactivating germ-line mutations for Hirschsprung's disease, while somatic rearrangements (RET/PTCs) are specific to papillary thyroid carcinomas. SH2B1 beta, a member of the SH2B adaptors family, and binding partner for several RTKs, has been recently described to interact with proto-RET. Here, we show that both RET isoforms and its oncogenic derivatives bind to SH2B1 beta through the SRC homology 2 (SH2) domain and a kinase activity-dependent mechanism. As a result, RET phosphorylates SH2B1 beta, which in turn enhances its autophosphorylation, kinase activity, and downstream signaling. RET tyrosine residues 905 and 981 are important determinants for functional binding of the adaptor, as removal of both autophosphorylation sites displaces its recruitment. Binding of SH2B1 beta appears to protect RET from dephosphorylation by protein tyrosine phosphatases, and might represent a likely mechanism contributing to its upregulation. Thus, overexpression of SH2B1 beta, by enhancing phosphorylation/activation of RET transducers, potentiates the cellular differentiation and the neoplastic transformation thereby induced, and counteracts the action of RET inhibitors. Overall, our results identify SH2B1 beta as a key enhancer of RET physiologic and pathologic activities.	Ist Nazl Tumori, IRCCS, Dept Expt Oncol, UO3, I-20133 Milan, Italy; Dept Expt Oncol, Res Unit 3, Milan, Italy; Dept Expt Oncol, Res Unit 4, Milan, Italy; FIRC Inst Mol Oncol Fdn, Milan, Italy	Fondazione IRCCS Istituto Nazionale Tumori Milan; IFOM - FIRC Institute of Molecular Oncology	Borrello, MG (corresponding author), Ist Nazl Tumori, IRCCS, Dept Expt Oncol, UO3, Via Venezian 1, I-20133 Milan, Italy.	mariagrazia.borrello@istitutotumori.mi.it	Pierotti, Marco Alessandro/AAC-4728-2022; Borrello, Maria Grazia/C-3161-2017; Bongarzone, Italia/B-9544-2017; Fiorino, Antonio/D-5828-2017	Pierotti, Marco Alessandro/0000-0002-7431-8332; Borrello, Maria Grazia/0000-0002-6854-2848; Bongarzone, Italia/0000-0003-2530-9170; Fiorino, Antonio/0000-0002-2621-9276				Ahmed Z, 2003, BIOCHEM J, V371, P405, DOI 10.1042/BJ20021589; Ahmed Z, 2001, BIOCHEM SOC T, V29, P529, DOI 10.1042/BST0290529; Airaksinen MS, 2002, NAT REV NEUROSCI, V3, P383, DOI 10.1038/nrn812; Albert L, 2003, J CELL PHYSIOL, V195, P168, DOI 10.1002/jcp.10252; Arighi E, 2005, CYTOKINE GROWTH F R, V16, P441, DOI 10.1016/j.cytogfr.2005.05.010; Arighi E, 1997, ONCOGENE, V14, P773, DOI 10.1038/sj.onc.1200896; Besser D, 1999, MOL CELL BIOL, V19, P1401; BONGARZONE I, 1993, MOL CELL BIOL, V13, P358, DOI 10.1128/MCB.13.1.358; Borrello MG, 1995, ONCOGENE, V11, P2419; Borrello MG, 1996, MOL CELL BIOL, V16, P2151; Bromberg JF, 1998, MOL CELL BIOL, V18, P2553, DOI 10.1128/MCB.18.5.2553; Canu N, 1997, J NEUROCHEM, V68, P1390; Carlomagno F, 2002, CANCER RES, V62, P1077; Cuccuru G, 2004, JNCI-J NATL CANCER I, V96, P1006, DOI 10.1093/jnci/djh184; de Graaff E, 2001, GENE DEV, V15, P2433, DOI 10.1101/gad.205001; Dhe-Sirano D, 2004, NAT STRUCT MOL BIOL, V11, P968, DOI 10.1038/nsmb829; DONATELLO S, 2004, TUMORI, V4, P122; Duan CJ, 2004, MOL CELL BIOL, V24, P7435, DOI 10.1128/MCB.24.17.7435-7443.2004; Gorla L, 2006, CELL SIGNAL, V18, P2272, DOI 10.1016/j.cellsig.2006.05.016; Gryz EA, 2000, ONCOGENE, V19, P417, DOI 10.1038/sj.onc.1203330; Hennige AM, 2001, ENDOCRINOLOGY, V142, P4441, DOI 10.1210/en.142.10.4441; Hu JJ, 2003, MOL CELL, V12, P1379, DOI 10.1016/S1097-2765(03)00487-8; Ichihara M, 2004, CANCER LETT, V204, P197, DOI 10.1016/S0304-3835(03)00456-7; Kawamoto Y, 2004, J BIOL CHEM, V279, P14213, DOI 10.1074/jbc.M312600200; Kong M, 2002, J BIOL CHEM, V277, P15962, DOI 10.1074/jbc.M102777200; Kotani K, 1998, BIOCHEM J, V335, P103, DOI 10.1042/bj3350103; Kurzer JH, 2004, MOL CELL BIOL, V24, P4557, DOI 10.1128/MCB.24.10.4557-4570.2004; Lee RJ, 1999, J BIOL CHEM, V274, P7341, DOI 10.1074/jbc.274.11.7341; Lorenzo MJ, 1997, ONCOGENE, V14, P763, DOI 10.1038/sj.onc.1200894; Nelms K, 1999, MAMM GENOME, V10, P1160, DOI 10.1007/s003359901183; O'Brien KB, 2003, J BIOL CHEM, V278, P11970, DOI 10.1074/jbc.M210765200; Ohtsuka S, 2002, MOL CELL BIOL, V22, P3066, DOI 10.1128/MCB.22.9.3066-3077.2002; OSBORNE MA, 1995, BIO-TECHNOL, V13, P1474, DOI 10.1038/nbt1295-1474; Qian XZ, 2001, MOL CELL BIOL, V21, P1613, DOI 10.1128/MCB.21.5.1613-1620.2001; Qian XZ, 1998, NEURON, V21, P1017, DOI 10.1016/S0896-6273(00)80620-0; Ravichandran KS, 2001, ONCOGENE, V20, P6322, DOI 10.1038/sj.onc.1204776; Ren DC, 2005, CELL METAB, V2, P95, DOI 10.1016/j.cmet.2005.07.004; Riedel H, 1997, J BIOCHEM-TOKYO, V122, P1105; Roccato E, 2005, J BIOL CHEM, V280, P3382, DOI 10.1074/jbc.M407522200; Rui LY, 2000, MOL CELL BIOL, V20, P3168, DOI 10.1128/MCB.20.9.3168-3177.2000; Rui LY, 1998, J BIOL CHEM, V273, P21239, DOI 10.1074/jbc.273.33.21239; Rui LY, 1999, P NATL ACAD SCI USA, V96, P7172, DOI 10.1073/pnas.96.13.7172; Rui LY, 1997, MOL CELL BIOL, V17, P6633, DOI 10.1128/MCB.17.11.6633; Takahashi M, 2001, CYTOKINE GROWTH F R, V12, P361, DOI 10.1016/S1359-6101(01)00012-0; Wang CC, 1998, J ELECTROCERAM, V2, P273, DOI 10.1023/A:1009978607621; Yousaf N, 2001, J BIOL CHEM, V276, P40940, DOI 10.1074/jbc.M104191200; Zhang Y, 2006, J CELL SCI, V119, P1666, DOI 10.1242/jcs.02845	47	16	18	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2007	26	45					6546	6559		10.1038/sj.onc.1210480	http://dx.doi.org/10.1038/sj.onc.1210480			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	217AF	17471236				2022-12-28	WOS:000249919800008
J	Vincent, A; Perrais, M; Desseyn, JL; Aubert, JP; Pigny, P; Van Seuningen, I				Vincent, A.; Perrais, M.; Desseyn, J-L; Aubert, J-P; Pigny, P.; Van Seuningen, I.			Epigenetic regulation (DNA methylation, histone modifications) of the 11p15 mucin genes (MUC2, MUC5AC, MUC5B, MUC6) in epithelial cancer cells	ONCOGENE			English	Article						mucin; 11p15; methylation; acetylation; cancer; epithelial	TRANSCRIPTIONAL REGULATION; BILE-ACIDS; EXPRESSION; PROMOTER; CARCINOMA; HYPERMETHYLATION; IDENTIFICATION; CHROMOSOME-11; DEACETYLASES; SUPPRESSION	The human genes MUC2, MUC5AC, MUC5B and MUC6 are clustered on chromosome 11 and encode large secreted gel-forming mucins. The frequent occurrence of their silencing in cancers and the GC-rich structure of their promoters led us to study the influence of epigenetics on their expression. Pre- and post- confluent cells were treated with demethylating agent 5-aza-2 '-deoxycytidine and histone deacetylase ( HDAC) inhibitor, trichostatin A. Mapping of methylated cytosines was performed by bisulfate-treated genomic DNA sequencing. Histone modi. cation status at the promoters was assessed by chromatin immunoprecipitation assays. Our results indicate that MUC2 was regulated by site-specific DNA methylation associated with establishment of a repressive histone code, whereas hypermethylation of MUC5B promoter was the major mechanism responsible for its silencing. DNA methyltransferase 1 was identified by small interfering RNA approach as a regulator of MUC2 and MUC5B endogenous expression that was potentiated by HDAC2. MUC2 and MUC5B epigenetic regulation was cellspecific, depended on cell differentiation status and inhibited their activation by Sp1. The expression of MUC5AC was rarely influenced by epigenetic mechanisms and methylation of MUC6 promoter was not correlated to its silencing. In conclusion, this study demonstrates the important role for methylation and/or histone modi. cations in regulating the 11p15 mucin genes in epithelial cancer cells.	INSERM, U560, F-59045 Lille, France	Institut National de la Sante et de la Recherche Medicale (Inserm)	Van Seuningen, I (corresponding author), INSERM, U560, Place de Verdun, F-59045 Lille, France.	isabelvs@lille.inserm.fr	Desseyn, Jean-Luc/M-5070-2018; Vincent, Audrey/I-2934-2016; VAN SEUNINGEN, Isabelle/N-6176-2016	Desseyn, Jean-Luc/0000-0001-6876-8049; Vincent, Audrey/0000-0003-0058-2058; VAN SEUNINGEN, Isabelle/0000-0002-3131-2694				Bernier JN, 1999, ATHLET THER TODAY, V4, P5, DOI 10.1123/att.4.5.5; Blache P, 2004, J CELL BIOL, V166, P37, DOI 10.1083/jcb.200311021; Copin MC, 2001, FRONT BIOSCI, V6, pD1264, DOI 10.2741/Copin; De Ruijter AJM, 2003, BIOCHEM J, V370, P737, DOI 10.1042/BJ20021321; DEBUSTROS A, 1988, P NATL ACAD SCI USA, V85, P5693; Desseyn JL, 2000, MOL BIOL EVOL, V17, P1175, DOI 10.1093/oxfordjournals.molbev.a026400; Fahrner JA, 2002, CANCER RES, V62, P7213; Ferguson M, 2003, NUCLEIC ACIDS RES, V31, P3123, DOI 10.1093/nar/gkg403; Ghoshal K, 2000, J BIOL CHEM, V275, P539, DOI 10.1074/jbc.275.1.539; Gratchev A, 1998, ANN NY ACAD SCI, V859, P180, DOI 10.1111/j.1749-6632.1998.tb11122.x; Gratchev A, 2001, CANCER LETT, V168, P71, DOI 10.1016/S0304-3835(01)00498-0; Hamada T, 2005, CANCER LETT, V227, P175, DOI 10.1016/j.canlet.2004.11.058; Hanski C, 1997, LAB INVEST, V77, P685; Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075; Ho JJL, 2003, INT J ONCOL, V22, P273; Hollingsworth MA, 2004, NAT REV CANCER, V4, P45, DOI 10.1038/nrc1251; Koo JS, 1999, AM J RESP CELL MOL, V20, P43, DOI 10.1165/ajrcmb.20.1.3310; Laird PW, 2003, NAT REV CANCER, V3, P253, DOI 10.1038/nrc1045; Leteurtre E, 2004, BIOL CELL, V96, P145, DOI 10.1016/j.biolcel.2003.12.005; Mariette C, 2004, BIOCHEM J, V377, P701, DOI 10.1042/BJ20031132; Mesquita P, 2003, CANCER LETT, V189, P129, DOI 10.1016/S0304-3835(02)00549-9; Momparler RL, 2003, ONCOGENE, V22, P6479, DOI 10.1038/sj.onc.1206774; Perrais M, 2002, J BIOL CHEM, V277, P32258, DOI 10.1074/jbc.M204862200; Perrais M, 2001, J BIOL CHEM, V276, P30923, DOI 10.1074/jbc.M104204200; Perrais M, 2001, J BIOL CHEM, V276, P15386, DOI 10.1074/jbc.M010534200; Piessen G, 2007, BIOCHEM J, V402, P81, DOI 10.1042/BJ20061461; Pigny P, 1996, GENOMICS, V38, P340, DOI 10.1006/geno.1996.0637; Reis CA, 1998, GLYCOCONJUGATE J, V15, P51, DOI 10.1023/A:1006939432665; Rousseau K, 2003, HYBRIDOMA HYBRIDOM, V22, P293, DOI 10.1089/153685903322538818; Siedow A, 2002, TUMOR BIOL, V23, P54, DOI 10.1159/000048689; Sylvester PA, 2001, J PATHOL, V195, P327; Van Seuningen I, 2000, BIOCHEM J, V348, P675; Van Seuningen I, 2001, FRONT BIOSCI-LANDMRK, V6, pD1216; Yamada N, 2006, INT J CANCER, V119, P1850, DOI 10.1002/ijc.22047; Zhu P, 2004, CELL CYCLE, V3, P1240, DOI 10.4161/cc.3.10.1195	35	86	88	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2007	26	45					6566	6576		10.1038/sj.onc.1210479	http://dx.doi.org/10.1038/sj.onc.1210479			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	217AF	17471237	Green Published			2022-12-28	WOS:000249919800010
J	Yang, L; Lin, C; Sun, SY; Zhao, S; Liu, ZR				Yang, L.; Lin, C.; Sun, S-Y; Zhao, S.; Liu, Z-R			A double tyrosine phosphorylation of P68 RNA helicase confers resistance to TRAIL-induced apoptosis	ONCOGENE			English	Article						P68 RNA helicase; TRAIL; phosphorylation; XAF1; caspase; DEAD box; PDGF autocrine	MALIGNANT GLIOMA-CELLS; LIGAND TRAIL; CANCER CELLS; MECHANISMS; EXPRESSION; GROWTH; DEATH; XAF1; XIAP; IDENTIFICATION	Tumor necrosis factor- related apoptosis- inducing ligand ( TRAIL) is a promising anticancer agent with the capability of inducing apoptosis specifically in tumor cells. However, cancer cells of many cancer types developed TRAIL resistance, limiting the applications of TRAIL in cancer therapies. We show here that p68 acquires a double tyrosine phosphorylation at Y593 and Y595 in TRAIL- resistant T98G glioblastoma cells. The double phosphorylations are induced by platelet- derived growth factor autocrine loop. The double phosphorylation mediates resistance to TRAIL- induced apoptosis. Our data suggest that the phosphorylated p68 protects the cells from programmed cell death by preventing procaspase- 8 from proteolytic cleavage. The double- phosphorylated p68 may also confer apoptosis resistance by upregulation of X- chromosome- linked inhibitor apoptosis protein- associated factor 1. In addition, exogenous expression of p68 mutant that carries mutations at the phosphorylation sites ( Y593/595F) dramatically sensitizes TRAIL- resistant cells to TRAIL- induced apoptosis, suggesting a potential therapeutic strategy to overcome TRAIL resistance.	Georgia State Univ, Dept Biol, Atlanta, GA 30303 USA; Emory Univ, Sch Med, Winship Canc Inst, Atlanta, GA 30322 USA	University System of Georgia; Georgia State University; Emory University	Liu, ZR (corresponding author), Georgia State Univ, Dept Biol, Univ Plaza, Atlanta, GA 30303 USA.	biozrl@langate.gsu.edu	Yang, Liuqing/B-7935-2011		NIGMS NIH HHS [GM063874] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063874] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aggarwal BB, 2004, VITAM HORM, V67, P453; Boatright KM, 2003, CURR OPIN CELL BIOL, V15, P725, DOI 10.1016/j.ceb.2003.10.009; Bockbrader KM, 2005, ONCOGENE, V24, P7381, DOI 10.1038/sj.onc.1208888; Bouralexis S, 2005, APOPTOSIS, V10, P35, DOI 10.1007/s10495-005-6060-0; Causevic M, 2001, ONCOGENE, V20, P7734, DOI 10.1038/sj.onc.1204976; Clarke N, 2005, CELL CYCLE, V4, P914, DOI 10.4161/cc.4.7.1822; CRAWFORD L, 1982, J VIROL, V42, P612, DOI 10.1128/JVI.42.2.612-620.1982; Deng YB, 2002, GENE DEV, V16, P33, DOI 10.1101/gad.949602; Fong WG, 2000, GENOMICS, V70, P113, DOI 10.1006/geno.2000.6364; Griffith TS, 1998, CURR OPIN IMMUNOL, V10, P559, DOI 10.1016/S0952-7915(98)80224-0; Grotzer MA, 2000, ONCOGENE, V19, P4604, DOI 10.1038/sj.onc.1203816; Hao CH, 2001, CANCER RES, V61, P1162; Holcik M, 2001, APOPTOSIS, V6, P253, DOI 10.1023/A:1011379307472; Hwang RF, 2003, CLIN CANCER RES, V9, P6534; Kim Y, 2003, MOL CELLS, V15, P283; LANE DP, 1980, NATURE, V288, P167, DOI 10.1038/288167a0; Leaman DW, 2002, J BIOL CHEM, V277, P28504, DOI 10.1074/jbc.M204851200; LeBlanc H, 2002, NAT MED, V8, P274, DOI 10.1038/nm0302-274; Liston P, 2001, NAT CELL BIOL, V3, P128, DOI 10.1038/35055027; Nesterov A, 2001, J BIOL CHEM, V276, P10767, DOI 10.1074/jbc.M005196200; Ng KCP, 2004, J INVEST DERMATOL, V123, P1127, DOI 10.1111/j.0022-202X.2004.23467.x; Nicol SM, 2000, EXP CELL RES, V257, P272, DOI 10.1006/excr.2000.4886; Potapova O, 1996, CANCER RES, V56, P280; Roth W, 2004, VITAM HORM, V67, P189; Soldani C, 2002, APOPTOSIS, V7, P321, DOI 10.1023/A:1016119328968; Stevenson RJ, 1998, J PATHOL, V184, P351, DOI 10.1002/(SICI)1096-9896(199804)184:4<351::AID-PATH1235>3.0.CO;2-C; Takeuchi H, 2004, BRIT J CANCER, V90, P1069, DOI 10.1038/sj.bjc.6601605; Thorburn A, 2004, CELL SIGNAL, V16, P139, DOI 10.1016/j.cellsig.2003.08.007; Van Geelen CMM, 2004, DRUG RESIST UPDATE, V7, P345, DOI 10.1016/j.drup.2004.11.002; Wang J, 2000, J CELL SCI, V113, P753; Yagita H, 2004, CANCER SCI, V95, P777, DOI 10.1111/j.1349-7006.2004.tb02181.x; Yang LQ, 2006, CELL, V127, P139, DOI 10.1016/j.cell.2006.08.036; Yang LQ, 2005, MOL CANCER RES, V3, P355, DOI 10.1158/1541-7786.MCR-05-0022; Yang XZ, 2003, CANCER RES, V63, P1122; Zhang LD, 2005, CANCER GENE THER, V12, P228, DOI 10.1038/sj.cgt.7700792	35	25	25	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2007	26	41					6082	6092		10.1038/sj.onc.1210427	http://dx.doi.org/10.1038/sj.onc.1210427			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	207US	17384675				2022-12-28	WOS:000249277200011
J	Junttila, MR; Ala-Aho, R; Jokilehto, T; Peltonen, J; Kallajoki, M; Grenman, R; Jaakkola, P; Westermarck, J; Kahari, VM				Junttila, M. R.; Ala-aho, R.; Jokilehto, T.; Peltonen, J.; Kallajoki, M.; Grenman, R.; Jaakkola, P.; Westermarck, J.; Kahari, V-M			p38 alpha and p38 delta mitogen-activated protein kinase isoforms regulate invasion and growth of head and neck squamous carcinoma cells	ONCOGENE			English	Article						p38; mitogen-activated protein kinase; matrix metalloproteinase; squamous cell carcinoma	P38 MAP KINASE; COLLAGENASE-3 MMP-13; MATRIX METALLOPROTEINASES; SELECTIVE ACTIVATION; IN-VIVO; C-JUN; EXPRESSION; CANCER; P53; APOPTOSIS	Recent studies indicate that the specificity of p38 mitogen-activated protein kinase (MAPK)-mediated cellular stress responses is determined by the expression pattern of the distinct p38 isoforms. Here, we have analysed the function of distinct p38 isoforms in the growth and invasion of head and neck squamous cell carcinomas (HNSCCs). Activation of p38 MAPK by arsenite resulted in inactivation of the ERK1,2 signaling pathway by dephosphorylation of MEK1,2 in primary human epidermal keratinocytes (HEKs), whereas in HNSCC cells this p38-mediated inhibition of the ERK1,2 pathway was absent. Quantitation of p38 pathway component mRNA expression in HNSCC cell lines (n = 42) compared to HEKs ( n 8) revealed that p38 alpha and p38 delta isoforms are predominantly expressed in both cell types and that MKK3 is the primary upstream activator expressed. Inhibition of endogenous p38 alpha or p38 delta activity by adenoviral delivery of corresponding dominant-negative p38 isoforms potently reduced MMP-13 and MMP-1 expressions, and suppressed the invasion of HNSCC cells through collagen. Dominant-negative p38 alpha and p38 delta inhibited squamous cell carcinoma (SCC) cell proliferation and inhibition of p38 alpha activity also compromised survival of SCC cells. p38 alpha and p38 delta were predominantly expressed in HNSCCs ( n 24) and nonneoplastic epithelium in vivo (n = 6), with MKK3 being the primary upstream activator. Activation and expression of p38 alpha and p38 delta by tumor cells was detected in HNSCCs in vivo (n = 16). Adenoviral expression of dominant-negative p38 alpha or p38 delta in cutaneous SCC cells potently inhibited their implantation in skin of severe combined immunodeficiency mice and growth of xenografts in vivo. Our results indicate that p38 alpha and p38 delta specifically promote the malignant phenotype of SCC cells by regulating cell survival, proliferation and invasion, suggesting these p38 MAPK isoforms as potential therapeutic targets in HNSCCs.	Turku Univ, Dept Dermatol, FI-20521 Turku, Finland; Turku Univ, Cent Hosp, Dept Pathol, FI-20521 Turku, Finland; Turku Univ, Cent Hosp, Dept Otorhinolaryngol Head & Neck Surg, Turku, Finland; Univ Turku, Inst Biomed, Dept Anat, FIN-20520 Turku, Finland; Univ Turku, MediCity Res Lab, Turku, Finland; Turku Grad Sch Biomed Sci, Turku, Finland; Univ Turku, Ctr Biotechnol, Turku, Finland; Univ Turku, Dept Med Biochem & Mol Biol, Turku, Finland; Abo Akad Univ, Turku, Finland	University of Turku; University of Turku; University of Turku; University of Turku; University of Turku; University of Turku; University of Turku; University of Turku; Abo Akademi University	Kahari, VM (corresponding author), Turku Univ, Dept Dermatol, POB 52, FI-20521 Turku, Finland.	veli-matti.kahari@utu.fi	Peltonen, Juha/O-7159-2019; Westermarck, Jukka/AAL-6464-2020; Jaakkola, Panu M/B-4355-2012; Kahari, Veli-Matti/E-5144-2011	Peltonen, Juha/0000-0002-5732-4167; Westermarck, Jukka/0000-0001-7478-3018; Jaakkola, Panu/0000-0002-2365-4985; Kahari, Veli-Matti/0000-0003-2421-9368				Aguirre-Ghiso JA, 2001, MOL BIOL CELL, V12, P863, DOI 10.1091/mbc.12.4.863; Ala-aho R, 2004, ONCOGENE, V23, P5111, DOI 10.1038/sj.onc.1207678; Ala-Aho R, 2002, ONCOGENE, V21, P1187, DOI 10.1038/sj.onc.1205198; Ambrosino C, 2003, MOL CELL BIOL, V23, P370, DOI 10.1128/MCB.23.1.370-381.2003; Boyce S.T., 1983, J INVEST DERMATOL S, V81, P33; BRACHMAN DG, 1992, CANCER RES, V52, P4832; Bulavin DV, 1999, EMBO J, V18, P6845, DOI 10.1093/emboj/18.23.6845; Bulavin DV, 2002, NAT GENET, V31, P210, DOI 10.1038/ng894; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P159; Efimova T, 2003, J BIOL CHEM, V278, P34277, DOI 10.1074/jbc.M302759200; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Enslen H, 2000, EMBO J, V19, P1301, DOI 10.1093/emboj/19.6.1301; Enslen H, 1998, J BIOL CHEM, V273, P1741, DOI 10.1074/jbc.273.3.1741; Garrington TP, 1999, CURR OPIN CELL BIOL, V11, P211, DOI 10.1016/S0955-0674(99)80028-3; Hale KK, 1999, J IMMUNOL, V162, P4246; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Huang FY, 2000, INT J ENG SCI, V38, P275, DOI 10.1016/S0020-7225(99)00041-5; Hunter KD, 2005, NAT REV CANCER, V5, P127, DOI 10.1038/nrc1549; Johannes R.E., 1997, SPC LIVE REEF FISH I, V3, P13; Johansson N, 2000, J CELL SCI, V113, P227; Keesler GA, 1998, PROTEIN EXPRES PURIF, V14, P221, DOI 10.1006/prep.1998.0947; LANSFORD CD, 1999, HUMAN CELL CULTURE, V2, P185; Li SP, 2003, CANCER RES, V63, P3473; Liu QH, 2004, AM J PHYSIOL-HEART C, V286, pH2204, DOI 10.1152/ajpheart.01050.2003; Olson JM, 2004, TRENDS MOL MED, V10, P125, DOI 10.1016/j.molmed.2004.01.007; Ono K, 2000, CELL SIGNAL, V12, P1, DOI 10.1016/S0898-6568(99)00071-6; Pramanik R, 2003, J BIOL CHEM, V278, P4831, DOI 10.1074/jbc.M207732200; Pruitt K, 2002, J BIOL CHEM, V277, P31808, DOI 10.1074/jbc.M203964200; Ravanti L, 1999, J BIOL CHEM, V274, P37292, DOI 10.1074/jbc.274.52.37292; Reddy KB, 2003, CANCER METAST REV, V22, P395, DOI 10.1023/A:1023781114568; Reunanen N, 2002, J BIOL CHEM, V277, P32360, DOI 10.1074/jbc.M204296200; Simon C, 1998, CANCER RES, V58, P1135; SOMERS KD, 1992, CANCER RES, V52, P5997; Vihinen P, 2002, INT J CANCER, V99, P157, DOI 10.1002/ijc.10329; Wang YB, 1998, J BIOL CHEM, V273, P2161, DOI 10.1074/jbc.273.4.2161; Westermarck J, 2000, CANCER RES, V60, P7156; Westermarck J, 2001, MOL CELL BIOL, V21, P2373, DOI 10.1128/MCB.21.7.2373-2383.2001; WILKINSON GWG, 1992, NUCLEIC ACIDS RES, V20, P2233, DOI 10.1093/nar/20.9.2233; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326	39	106	110	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 9	2007	26	36					5267	5279		10.1038/sj.onc.1210332	http://dx.doi.org/10.1038/sj.onc.1210332			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	199CQ	17334397				2022-12-28	WOS:000248674200010
J	Rigby, RJ; Simmons, JG; Greenhalgh, CJ; Alexander, WS; Lund, PK				Rigby, R. J.; Simmons, J. G.; Greenhalgh, C. J.; Alexander, W. S.; Lund, P. K.			Suppressor of cytokine signaling 3 (SOCS3) limits damage-induced crypt hyper-proliferation and inflammation-associated tumorigenesis in the colon	ONCOGENE			English	Article						SOCS3; colon; cancer; mouse model	GROWTH-HORMONE; STAT3 ACTIVATION; TRANSGENIC MICE; CELL-GROWTH; CANCER; HYPERMETHYLATION; CARCINOMA; INACTIVATION; SUPPRESSORS; INHIBITION	Intestinal injury or chronic inflammation induce cytokines that promote crypt regeneration and mucosal repair. If excessive or prolonged, such mechanisms may increase colon cancer risk. Factors that terminate or limit cytokine action in intestinal epithelial cells (IEC) may protect against crypt hyperplasia and neoplasia. We hypothesized that suppressor of cytokine signaling-3 (SOCS3) is such a factor. Mice with Vilin-promoter/Cre-recombinase (VC)mediated IEC-specific SOCS3 gene disruption (VC/HO), WT/HO littermates with floxed but intact SOCS3 genes and VC/WT mice were studied. Colon was examined after acute dextran sodium sulfate (DSS)-induced mucosal injury or after azoxymethane (AOM) and chronic DSS. Signaling pathways were examined in colon, cultured IEC or colon cancer cell lines. VC/HO mice showed no basal phenotype. After acute DSS, VC/HO exhibited enhanced crypt proliferation and crypt hyperplasia and reduced transforming growth factor ( TGF) beta expression in colon. Inflammation and mucosal damage were similar across genotypes. Following AOM/DSS, VC/HO mice had increased size, number and load of colonic tumors and increased STAT3 and nuclear factor-kappa B (NF-kappa B) activation in colon. In vitro, SOCS3 overexpression reduced proliferation, IL-6-mediated STAT3 activation and tumor necrosis factor (TNF) alpha-mediated NF-kappa B activation. We conclude that cytokine induction of SOCS3 normally provides an intrinsic mechanism to limit injury-induced crypt hyperproliferation and inflammation-associated colon cancer by regulating both STAT3 and NF-kappa B pathways.	Univ N Carolina, Dept Cell & Mol Physiol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill	Rigby, RJ (corresponding author), Univ N Carolina, Dept Cell & Mol Physiol, Rm 6336,MBRB,CB 7545,103 Mason Farm Rd, Chapel Hill, NC 27599 USA.	rachael_rigby@med.unc.edu	Rigby, Rachael/C-8206-2011; , Histology Research Core Facility/ABF-6317-2021	Rigby, Rachael/0000-0002-6605-9609	NIDDK NIH HHS [P30 DK34987] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK034987] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alonzi T, 2004, CYTOKINE, V26, P45, DOI 10.1016/j.cyto.2003.12.002; Becker C, 2004, IMMUNITY, V21, P491, DOI 10.1016/j.immuni.2004.07.020; Campbell JS, 2001, J CLIN INVEST, V107, P1285, DOI 10.1172/JCI11867; Chen Z, 2006, P NATL ACAD SCI USA, V103, P8137, DOI 10.1073/pnas.0600666103; Chun KG, 2003, PHOTONIC NETW COMMUN, V6, P83, DOI 10.1023/A:1023642926131; Croker BA, 2003, NAT IMMUNOL, V4, P540, DOI 10.1038/ni931; Greenhalgh CJ, 2002, GASTROENTEROLOGY, V123, P2064, DOI 10.1053/gast.2002.37068; Hanada T, 2006, J EXP MED, V203, P1391, DOI 10.1084/jem.20060436; He B, 2003, P NATL ACAD SCI USA, V100, P14133, DOI 10.1073/pnas.2232790100; Heinrich PC, 2003, BIOCHEM J, V374, P1, DOI 10.1042/BJ20030407; Itzkowitz S, 2003, J CLIN GASTROENTEROL, V36, P70; Judd LM, 2004, GASTROENTEROLOGY, V126, P196, DOI 10.1053/j.gastro.2003.10.066; Judd LM, 2006, GASTROENTEROLOGY, V131, P1073, DOI 10.1053/j.gastro.2006.07.018; Kimura A, 2004, INT IMMUNOL, V16, P991, DOI 10.1093/intimm/dxh102; Landi S, 2003, CANCER RES, V63, P3560; Miller ME, 2004, GASTROENTEROLOGY, V127, P570, DOI 10.1053/j.gastro.2004.05.016; Miller Megan E., 2000, Regulatory Peptides, V94, P67, DOI 10.1016/S0167-0115(00)80135-4; Miscia S, 2002, CELL GROWTH DIFFER, V13, P13; Mizoguchi E, 2003, GASTROENTEROLOGY, V125, P148, DOI 10.1016/S0016-5085(03)00665-6; Munkholm P, 2003, ALIMENT PHARM THER, V18, P1, DOI 10.1046/j.1365-2036.18.s2.2.x; Nakamura Y, 2005, CARCINOGENESIS, V26, P665, DOI 10.1093/carcin/bgi003; Niwa Y, 2005, ONCOGENE, V24, P6406, DOI 10.1038/sj.onc.1208788; Ogata H, 2006, ONCOGENE, V25, P2520, DOI 10.1038/sj.onc.1209281; Ogata H, 2006, GASTROENTEROLOGY, V131, P179, DOI 10.1053/j.gastro.2006.04.025; Oshimo Y, 2004, INT J CANCER, V112, P1003, DOI 10.1002/ijc.20521; Rivat C, 2004, ONCOGENE, V23, P3317, DOI 10.1038/sj.onc.1207437; Schneider M, 2000, HAEMOPHILIA, V6, P38; Sutherland KD, 2004, ONCOGENE, V23, P7726, DOI 10.1038/sj.onc.1207787; Suzuki A, 2001, J EXP MED, V193, P471, DOI 10.1084/jem.193.4.471; Tebbutt NC, 2002, NAT MED, V8, P1089, DOI 10.1038/nm763; ULSHEN MH, 1993, GASTROENTEROLOGY, V104, P973, DOI 10.1016/0016-5085(93)90263-C; Wang LX, 2003, J IMMUNOL, V171, P3194, DOI 10.4049/jimmunol.171.6.3194; Weber A, 2005, ONCOGENE, V24, P6699, DOI 10.1038/sj.onc.1208818; Williams KL, 2001, GASTROENTEROLOGY, V120, P925, DOI 10.1053/gast.2001.22470; Yasukawa H, 2003, NAT IMMUNOL, V4, P551, DOI 10.1038/ni938	35	124	128	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 19	2007	26	33					4833	4841		10.1038/sj.onc.1210286	http://dx.doi.org/10.1038/sj.onc.1210286			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	191ZL	17297444				2022-12-28	WOS:000248170400008
J	Tsang, WP; Kwok, TT				Tsang, W. P.; Kwok, T. T.			Riboregulator H19 induction of MDR1-associated drug resistance in human hepatocellular carcinoma cells	ONCOGENE			English	Article						H19; MDR1; drug resistance; P-glycoprotein; DNA methylation	PROMOTER REGION; MDR1 GENE; NONCODING RNA; CANCER-CELLS; OVEREXPRESSION; METHYLATION; EXPRESSION	Acquisition of drug resistance is one of the main obstacles encountered in cancer chemotherapy. Overexpression of multi-drug resistance 1 (MDR1) gene and its protein product P-glycoprotein, accompanied with a decrease in doxorubicin accumulation level, was observed in doxorubicinresistant R-HepG2 cells, a subline derived by selection of human hepatocellular carcinoma HepG2 cells with doxorubicin. In addition, Northern-blot analysis revealed an eight fold upregulation of the imprinted H19 mRNA in R-HepG2 cells. H19 knockdown bytrans fection with antisense H19 oligonucleotides suppressed the MDR1/P-glycoprotein expression, increased the cellular doxorubicin accumulation level and sensitized doxorubicin toxicityin both HepG2 parent cells and R-HepG2 cells. Results from methylation-specific polymerase chain reaction analysis indicated that the MDR1 gene promoter was hypomethylated in R-HepG2 cells. Antisense H19 oligonucleotides transfection induced a marked increase in the percentage of MDR1 promoter methylation and decrease in MDR1 expression in R- HepG2 cells. Thus, the H19 gene is believed to induce P- glycoprotein expression and MDR1-associated drug resistance at least in liver cancer cells through regulation of MDR1 promoter methylation.	Chinese Univ Hong Kong, Dept Biochem, Shatin, Hong Kong, Peoples R China	Chinese University of Hong Kong	Kwok, TT (corresponding author), Chinese Univ Hong Kong, Dept Biochem, Shatin, Hong Kong, Peoples R China.	kwok2020@cuhk.edu.hk						Baylin SB, 1998, ADV CANCER RES, V72, P141; Doyle LA, 1996, CANCER RES, V56, P2904; Eddy SR, 2001, NAT REV GENET, V2, P919, DOI 10.1038/35103511; Enokida H, 2004, CANCER RES, V64, P5956, DOI 10.1158/0008-5472.CAN-04-0081; GLASER T, 1989, SOMAT CELL MOLEC GEN, V15, P477, DOI 10.1007/BF01534910; HAO Y, 1993, NATURE, V365, P764, DOI 10.1038/365764a0; Kusaba H, 1999, EUR J BIOCHEM, V262, P924, DOI 10.1046/j.1432-1327.1999.00469.x; Liu JQ, 1997, J CLIN ENDOCR METAB, V82, P1766, DOI 10.1210/jc.82.6.1766; Lottin S, 2002, ONCOGENE, V21, P1625, DOI 10.1038/sj.onc.1205233; Lottin S, 2002, CARCINOGENESIS, V23, P1885, DOI 10.1093/carcin/23.11.1885; Nakayama M, 1998, BLOOD, V92, P4296, DOI 10.1182/blood.V92.11.4296.423k25_4296_4307; PACHNIS V, 1984, P NATL ACAD SCI-BIOL, V81, P5523, DOI 10.1073/pnas.81.17.5523; Tada Y, 2000, CLIN CANCER RES, V6, P4618; Vernucci M, 2004, HUM MOL GENET, V13, P353, DOI 10.1093/hmg/ddh028	14	151	160	1	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 19	2007	26	33					4877	4881		10.1038/sj.onc.1210266	http://dx.doi.org/10.1038/sj.onc.1210266			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	191ZL	17297456				2022-12-28	WOS:000248170400013
J	Swaminathan, G; Feshchenko, EA; Tsygankov, AY				Swaminathan, G.; Feshchenko, E. A.; Tsygankov, A. Y.			c-Cbl-facilitated cytoskeletal effects in v-Abl-transformed. broblasts are regulated by membrane association of c-Cbl	ONCOGENE			English	Article						c-Cbl; SLAP; adaptor protein; membrane localization; cell spreading; cell migration	INTEGRIN SIGNALING PATHWAY; GROWTH-FACTOR RECEPTOR; ADAPTER PROTEIN SLAP; NIH 3T3 FIBROBLASTS; TYROSINE KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; NEGATIVE REGULATION; CELL MORPHOLOGY; LIPID RAFTS; SRC	The multi-functional protein c-Cbl is an important modulator of actin cytoskeletal dynamics in diverse biological systems. We had previously reported that c-Cbl facilitates cell spreading and adhesion and suppresses anchorage-independent growth of v-Abl-transformed fibroblasts. To assess the importance of membrane localization of c-Cbl for the observed effects of c-Cbl in v-Abl-3T3 cells, we. rst mapped the membrane interactive domain(s) of c-Cbl. Our studies indicate that localization of c-Cbl to the membrane is likely to be mediated by the tyrosine kinase binding (TKB) domain and the proline-rich region of c-Cbl, whereas C-terminal tyrosine phosphorylation does not play a role. The association of v-Cbl, which encompasses the TKB domain, with the membrane was unusual as it was not entirely dependent on SH2-phosphotyrosine interactions. Our studies further demonstrate that Src-like adaptor protein (SLAP), which binds to v-Cbl in a tyrosine phosphorylation-independent manner, facilitates membrane association of Cbl. The interaction between c-Cbl and SLAP in v-Abl-3T3 cells positively influenced c-Cbl-mediated spreading and adhesion of these cells. SLAP appears to exert its effects not simply by increasing the amount of c-Cbl in the membrane but by facilitating binding of p85-phosphatidylinositol-3-kinase (PI3K) with membrane-associated c-Cbl.	Temple Univ, Sch Med, Dept Microbiol & Immunol, Philadelphia, PA 19140 USA; Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19140 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Tsygankov, AY (corresponding author), Temple Univ, Sch Med, Dept Microbiol & Immunol, 3400 N Broad St, Philadelphia, PA 19140 USA.	alexander.tsygankov@temple.edu	Tsygankov, Alexander Y/K-6205-2017		NATIONAL CANCER INSTITUTE [R01CA078499] Funding Source: NIH RePORTER; NCI NIH HHS [CA78499] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abassi YA, 2002, EMBO J, V21, P4571, DOI 10.1093/emboj/cdf446; Arthur WT, 2004, J CELL BIOL, V167, P111, DOI 10.1083/jcb.200404068; Chiang SH, 2001, NATURE, V410, P944, DOI 10.1038/35073608; Feshchenko EA, 1999, ONCOGENE, V18, P3703, DOI 10.1038/sj.onc.1202672; Feshchenko EA, 1998, J BIOL CHEM, V273, P8323, DOI 10.1074/jbc.273.14.8323; Haglund K, 2004, J CELL SCI, V117, P2557, DOI 10.1242/jcs.01148; Hartley D, 1996, J BIOL CHEM, V271, P21939, DOI 10.1074/jbc.271.36.21939; Hasham MG, 2004, VIROLOGY, V320, P313, DOI 10.1016/j.virol.2003.11.032; Howlett CJ, 2002, ONCOGENE, V21, P1707, DOI 10.1038/sj.onc.1205228; Innocenti M, 2003, J CELL BIOL, V160, P17, DOI 10.1083/jcb.200206079; Kimura A, 2001, P NATL ACAD SCI USA, V98, P9098, DOI 10.1073/pnas.151252898; Klapper LN, 2000, CANCER RES, V60, P3384; Levkowitz G, 2000, J BIOL CHEM, V275, P35532, DOI 10.1074/jbc.M002661200; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; Manes G, 2000, MOL CELL BIOL, V20, P3396, DOI 10.1128/MCB.20.10.3396-3406.2000; MARAKOVA O, 2000, BIOTECHNIQUES, V29, P970; Meng FY, 1998, EMBO J, V17, P4391, DOI 10.1093/emboj/17.15.4391; Miyake S, 1999, J BIOL CHEM, V274, P16619, DOI 10.1074/jbc.274.23.16619; Ojaniemi M, 1997, J BIOL CHEM, V272, P3780, DOI 10.1074/jbc.272.6.3780; PANDEY A, 1995, J BIOL CHEM, V270, P19201, DOI 10.1074/jbc.270.33.19201; Rao N, 2001, EMBO J, V20, P7085, DOI 10.1093/emboj/20.24.7085; Roche S, 1998, CURR BIOL, V8, P975, DOI 10.1016/S0960-9822(98)70400-2; Sanjay A, 2001, J CELL BIOL, V152, P181, DOI 10.1083/jcb.152.1.181; Scaife RM, 2000, J CELL SCI, V113, P215; Scaife RM, 2003, MOL BIOL CELL, V14, P4605, DOI 10.1091/mbc.E02-11-0739; Scaife RM, 2003, J CELL SCI, V116, P463, DOI 10.1242/jcs.00244; Schmidt MHH, 2005, NAT REV MOL CELL BIO, V6, P907, DOI 10.1038/nrm1762; Sosinowski T, 2000, J EXP MED, V191, P463, DOI 10.1084/jem.191.3.463; Swaminathan G, 2006, J CELL PHYSIOL, V209, P21, DOI 10.1002/jcp.20694; Tanaka S, 1996, NATURE, V383, P528, DOI 10.1038/383528a0; Tang J, 1999, P NATL ACAD SCI USA, V96, P9775, DOI 10.1073/pnas.96.17.9775; Teckchandani AM, 2005, EXP CELL RES, V307, P247, DOI 10.1016/j.yexcr.2005.03.010; Teckchandani AM, 2005, EXP CELL RES, V306, P114, DOI 10.1016/j.yexcr.2005.02.014; Teckchandani AM, 2001, ONCOGENE, V20, P1739, DOI 10.1038/sj.onc.1204246; Thien CBF, 2005, BIOCHEM J, V391, P153, DOI 10.1042/BJ20050892; Wang J, 2001, BIOTECHNIQUES, V31, P722, DOI 10.2144/01314bm01; Waterman H, 1999, J BIOL CHEM, V274, P22151, DOI 10.1074/jbc.274.32.22151; Yokouchi M, 2001, J BIOL CHEM, V276, P35185, DOI 10.1074/jbc.M102219200	38	9	9	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 14	2007	26	28					4095	4105		10.1038/sj.onc.1210184	http://dx.doi.org/10.1038/sj.onc.1210184			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	178XD	17237826				2022-12-28	WOS:000247252700005
J	Karni-Schmidt, O; Friedler, A; Zupnick, A; McKinney, K; Mattia, M; Beckerman, R; Bouvet, P; Sheetz, M; Fersht, A; Prives, C				Karni-Schmidt, O.; Friedler, A.; Zupnick, A.; McKinney, K.; Mattia, M.; Beckerman, R.; Bouvet, P.; Sheetz, M.; Fersht, A.; Prives, C.			Energy-dependent nucleolar localization of p53 in vitro requires two discrete regions within the p53 carboxyl terminus	ONCOGENE			English	Article						p53; nucleolus; DNA damage; NoLS	TUMOR-SUPPRESSOR; DNA-DAMAGE; SUBCELLULAR LOCATION; BINDING PROTEIN; CELLULAR STRESS; NUCLEAR EXPORT; STABILIZES P53; CANCER-CELLS; HELA-CELLS; MDM2	The p53 tumor suppressor is a nucleocytoplasmic shuttling protein that is found predominantly in the nucleus of cells. In addition to mutation, abnormal p53 cellular localization is one of the mechanisms that inactivate p53 function. To further understand features of p53 that contribute to the regulation of its trafficking within the cell, we analysed the subnuclear localization of wild-type and mutant p53 in human cells that were either permeabilized with detergent or treated with the proteasome inhibitor MG132. We, here, show that either endogenously expressed or exogenously added p53 protein localizes to the nucleolus in detergent-permeabilized cells in a concentration- and ATP hydrolysis-dependent manner. Two discrete regions within the carboxyl terminus of p53 are essential for nucleolar localization in permeabilized cells. Similarly, localization of p53 to the nucleolus after proteasome inhibition in unpermeabilized cells requires sequences within the carboxyl terminus of p53. Interestingly, genotoxic stress markedly decreases the association of p53 with the nucleolus, and phosphorylation of p53 at S392, a site that is modified by such stress, partially impairs its nucleolar localization. The possible significance of these findings is discussed.	Columbia Univ, Dept Biol Sci, New York, NY 10027 USA; MRC, Ctr Prot Engn, Dept MRC CPE, Cambridge CB2 2BB, England; Hebrew Univ Jerusalem, Dept Organ Chem, IL-91010 Jerusalem, Israel; Ecole Normale Super Lyon, UMR 5161, Lab Biol Mol Cellule, F-69364 Lyon, France	Columbia University; University of Cambridge; Hebrew University of Jerusalem; UDICE-French Research Universities; Universite Claude Bernard Lyon 1; CHU Lyon; Centre National de la Recherche Scientifique (CNRS); Ecole Normale Superieure de Lyon (ENS de LYON); Universite Jean Monnet	Prives, C (corresponding author), Columbia Univ, Dept Biol Sci, 816 Fairchild, New York, NY 10027 USA.	clp3@columbia.edu	, Bouvet/AAC-8779-2020; Fersht, Alan R/B-2189-2008	Bouvet, Philippe/0000-0003-4524-2233	MRC [MC_U105474168] Funding Source: UKRI; Medical Research Council [MC_U105474168] Funding Source: Medline; NCI NIH HHS [CA58316, CA87497] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA058316, R37CA058316, P01CA087497] Funding Source: NIH RePORTER	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Appella E, 2001, EUR J BIOCHEM, V268, P2764, DOI 10.1046/j.1432-1327.2001.02225.x; Ashcroft M, 2000, MOL CELL BIOL, V20, P3224, DOI 10.1128/MCB.20.9.3224-3233.2000; Benninghoff J, 1999, CANCER LETT, V144, P55, DOI 10.1016/S0304-3835(99)00187-1; Budde A, 1999, ONCOGENE, V18, P1119, DOI 10.1038/sj.onc.1202402; Bykov VJN, 2002, CARCINOGENESIS, V23, P2011, DOI 10.1093/carcin/23.12.2011; Bykov VJN, 2002, NAT MED, V8, P282, DOI 10.1038/nm0302-282; Carmo-Fonseca M, 2000, NAT CELL BIOL, V2, pE107, DOI 10.1038/35014078; Carmo-Fonseca M, 2002, TRENDS CELL BIOL, V12, P491, DOI 10.1016/S0962-8924(02)02387-5; Chan PK, 1996, CANCER LETT, V100, P191, DOI 10.1016/0304-3835(95)04100-1; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; Colombo E, 2002, NAT CELL BIOL, V4, P529, DOI 10.1038/ncb814; Daniely Y, 2002, MOL CELL BIOL, V22, P6014, DOI 10.1128/MCB.22.16.6014-6022.2002; DUNDR M, 1995, J CELL SCI, V108, P2811; Fernandez-Fernandez MR, 2005, P NATL ACAD SCI USA, V102, P4735, DOI 10.1073/pnas.0501459102; GhisolfiNieto L, 1996, J MOL BIOL, V260, P34, DOI 10.1006/jmbi.1996.0380; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Gobert C, 1996, BIOCHEMISTRY-US, V35, P5778, DOI 10.1021/bi952327w; Haaf T, 1996, EXP CELL RES, V224, P163, DOI 10.1006/excr.1996.0124; Horky M, 2001, J CELL SCI, V114, P663; Issaeva N, 2003, P NATL ACAD SCI USA, V100, P13303, DOI 10.1073/pnas.1835733100; JAYARAMAN L, 1995, CELL, V81, P1021, DOI 10.1016/S0092-8674(05)80007-8; Jayaraman L, 1997, METHOD ENZYMOL, V283, P245; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; Klibanov SA, 2001, J CELL SCI, V114, P1867; Lamond AI, 2003, CURR BIOL, V13, pR825, DOI 10.1016/j.cub.2003.10.012; Latonen L, 2003, CELL SIGNAL, V15, P95, DOI 10.1016/S0898-6568(02)00044-X; Leung AKL, 2003, CRIT REV EUKAR GENE, V13, P39, DOI 10.1615/CritRevEukaryotGeneExpr.v13.i1.40; Leung AKL, 2003, BIOCHEM J, V376, P553, DOI 10.1042/BJ20031169; Liang SH, 2001, EUR J BIOCHEM, V268, P2779, DOI 10.1046/j.1432-1327.2001.02227.x; Liu G, 2002, ONCOGENE, V21, P7195, DOI 10.1038/sj.onc.1205862; Llanos S, 2001, NAT CELL BIOL, V3, P445, DOI 10.1038/35074506; Marciniak RA, 1998, P NATL ACAD SCI USA, V95, P6887, DOI 10.1073/pnas.95.12.6887; MARECHAL V, 1994, MOL CELL BIOL, V14, P7414, DOI 10.1128/MCB.14.11.7414; Mayer C, 2005, CELL CYCLE, V4, P1036, DOI 10.4161/cc.4.8.1925; Menendez D, 2006, MOL CELL BIOL, V26, P2297, DOI 10.1128/MCB.26.6.2297-2308.2006; MOGAKI M, 1993, CARCINOGENESIS, V14, P2589, DOI 10.1093/carcin/14.12.2589; Olson MOJ, 2005, HISTOCHEM CELL BIOL, V123, P203, DOI 10.1007/s00418-005-0754-9; Olson MOJ, 2000, TRENDS CELL BIOL, V10, P189, DOI 10.1016/S0962-8924(00)01738-4; Pokrovskaja K, 2001, J GEN VIROL, V82, P345, DOI 10.1099/0022-1317-82-2-345; Poyurovsky MV, 2003, MOL CELL, V12, P875, DOI 10.1016/S1097-2765(03)00400-3; Prives C, 1999, J PATHOL, V187, P112; Prives C, 2001, CELL, V107, P815, DOI 10.1016/S0092-8674(01)00619-5; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; ROKAEUS N, 2006, ONCOGENE; Rubbi CP, 2000, ONCOGENE, V19, P85, DOI 10.1038/sj.onc.1203378; Shirangi TR, 2002, FASEB J, V16, P420, DOI 10.1096/fj.01-0617fje; Stros M, 1998, EUR J BIOCHEM, V251, P427, DOI 10.1046/j.1432-1327.1998.2510427.x; Tao WK, 1999, P NATL ACAD SCI USA, V96, P6937, DOI 10.1073/pnas.96.12.6937; Thomas F, 2003, J CELL SCI, V116, P2409, DOI 10.1242/jcs.00464; Tsai RYL, 2002, GENE DEV, V16, P2991, DOI 10.1101/gad.55671; Visintin R, 2000, CURR OPIN CELL BIOL, V12, P752, DOI 10.1016/S0955-0674(00)00165-4; Visintin R, 1998, MOL CELL, V2, P709, DOI 10.1016/S1097-2765(00)80286-5; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; Wesierska-Gadek J, 2002, INT J CANCER, V101, P128, DOI 10.1002/ijc.10580; Wong JMY, 2002, NAT CELL BIOL, V4, P731, DOI 10.1038/ncb846; Xirodimas DP, 2001, EXP CELL RES, V270, P66, DOI 10.1006/excr.2001.5314; Young PJ, 2002, J BIOL CHEM, V277, P2852, DOI 10.1074/jbc.M108769200; ZATSEPINA OV, 1989, EXP CELL RES, V181, P94, DOI 10.1016/0014-4827(89)90185-7; ZERRAHN J, 1992, ONCOGENE, V7, P1371; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zimber A, 2004, CELL SIGNAL, V16, P1085, DOI 10.1016/j.cellsig.2004.03.020; Zolotukhin AS, 1999, J VIROL, V73, P120, DOI 10.1128/JVI.73.1.120-127.1999	62	26	26	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 31	2007	26	26					3878	3891		10.1038/sj.onc.1210162	http://dx.doi.org/10.1038/sj.onc.1210162			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	175PV	17237827				2022-12-28	WOS:000247026400011
J	Coiffier, B				Coiffier, B.			Rituximab therapy in malignant lymphoma	ONCOGENE			English	Review						rituximab; R-CHOP; follicular lymphoma; diffuse large B-cell lymphoma; monoclonal antibodies	B-CELL LYMPHOMA; NON-HODGKINS-LYMPHOMA; ANTI-CD20 MONOCLONAL-ANTIBODY; CHRONIC LYMPHOCYTIC-LEUKEMIA; PHASE-II TRIAL; CHEMOTHERAPY PLUS RITUXIMAB; SOLID-ORGAN TRANSPLANTATION; FOLLICULAR LYMPHOMA; R-CHOP; MAINTENANCE RITUXIMAB	Rituximab is the first monoclonal antibody to have been registered for the treatment of B-cell lymphomas. Randomized studies haves demonstrated its activity in follicular lymphoma ( FL), mantle cell lymphoma and diffuse large B-cell lymphoma (DLBCL) in untreated or relapsing patients. Non-comparative studies have shown an activity in all other lymphomas. Because of its high activity and low toxicity ratio, rituximab has transformed the outcome of patients with B-cell lymphoma. A combination of rituximab plus chemotherapy, rituximab + cyclophosphamide + doxorubicin + vincristine + prednisolone (R-CHOP), has the highest efficacy ever described with any chemotherapy in DLBCL and FL. Some patients are refractory to rituximab but the precise mechanisms of this refractoriness are not understood.	CH Lyon Sud, Dept Hematol, F-69495 Pierre Benite, France; Univ Lyon 1, Pierre Benite, France	CHU Lyon; UDICE-French Research Universities; Universite Claude Bernard Lyon 1	Coiffier, B (corresponding author), CH Lyon Sud, Dept Hematol, F-69495 Pierre Benite, France.	bertrand.coiffier@chu-lyon.fr						Alas S, 2000, ANTICANCER RES, V20, P2961; Alas S, 2001, CANCER RES, V61, P5137; Ardeshna KM, 2003, LANCET, V362, P516, DOI 10.1016/S0140-6736(03)14110-4; Belhadj K, 2004, ANN ONCOL, V15, P504, DOI 10.1093/annonc/mdh090; Berinstein NL, 1998, ANN ONCOL, V9, P995, DOI 10.1023/A:1008416911099; Bienvenu J, 2001, Hematol J, V2, P378, DOI 10.1038/sj.thj.6200133; Blaes AH, 2005, CANCER-AM CANCER SOC, V104, P1661, DOI 10.1002/cncr.21391; Boettcher S, 2004, BLOOD, V104, p170A, DOI 10.1182/blood.V104.11.590.590; Bohen SP, 2003, P NATL ACAD SCI USA, V100, P1926, DOI 10.1073/pnas.0437875100; Boue F, 2006, J CLIN ONCOL, V24, P4123, DOI 10.1200/JCO.2005.05.4684; Brugger W, 2004, SEMIN ONCOL, V31, P33, DOI 10.1053/j.seminoncol.2003.12.008; Byrd JC, 2003, BLOOD, V101, P6, DOI 10.1182/blood-2002-04-1258; Byrd JC, 2005, BLOOD, V105, P49, DOI 10.1182/blood-2004-03-0796; Byrd JC, 2001, J CLIN ONCOL, V19, P2153, DOI 10.1200/JCO.2001.19.8.2153; Cartron G, 2004, BLOOD, V104, P2635, DOI 10.1182/blood-2004-03-1110; Cartron G, 2002, BLOOD, V99, P754, DOI 10.1182/blood.V99.3.754; Coiffier B, 2005, J CLIN ONCOL, V23, P6387, DOI 10.1200/JCO.2005.05.015; Coiffier B, 2002, NEW ENGL J MED, V346, P235, DOI 10.1056/NEJMoa011795; COIFFIER B, 2005, ONCOLOGY, V18, P7; COIFFIER B, 2005, IN PRESS CURR OP HEM, V12; Coiffier B, 2006, SEMIN HEMATOL, V43, P213, DOI 10.1053/j.seminhematol.2006.07.004; Coiffier Bertrand, 2005, Clin Adv Hematol Oncol, V3, P484; Colombat P, 2001, BLOOD, V97, P101, DOI 10.1182/blood.V97.1.101; Conconi A, 2003, BLOOD, V102, P2741, DOI 10.1182/blood-2002-11-3496; Czuczman MS, 2004, J CLIN ONCOL, V22, P4711, DOI 10.1200/JCO.2004.04.020; Davis TA, 2000, CLIN CANCER RES, V6, P2644; Davis TA, 2000, J CLIN ONCOL, V18, P3135, DOI 10.1200/JCO.2000.18.17.3135; Demidem A, 1997, CANCER BIOTHER RADIO, V12, P177, DOI 10.1089/cbr.1997.12.177; Eisenbeis CF, 2004, CLIN CANCER RES, V10, P6101, DOI 10.1158/1078-0432.CCR-04-0525; Ekstrand BC, 2003, BLOOD, V101, P4285, DOI 10.1182/blood-2002-08-2644; Farinha P, 2006, BLOOD, V108, p245A; Feugier P, 2005, J CLIN ONCOL, V23, P4117, DOI 10.1200/JCO.2005.09.131; Foran JM, 2000, J CLIN ONCOL, V18, P317, DOI 10.1200/JCO.2000.18.2.317; Forstpointner R, 2004, BLOOD, V104, P3064, DOI 10.1182/blood-2004-04-1323; Forstpointner R, 2006, BLOOD, V108, P4003, DOI 10.1182/blood-2006-04-016725; Foussard C, 2006, J CLIN ONCOL, V24, p424S; Ghetie MA, 2001, BLOOD, V97, P1392, DOI 10.1182/blood.V97.5.1392; Ghetie MA, 2006, J IMMUNOTHER, V29, P536, DOI 10.1097/01.cji.0000211307.05869.6c; Ghielmini M, 2004, BLOOD, V103, P4416, DOI 10.1182/blood-2003-10-3411; Gianni AM, 2003, BLOOD, V102, P749, DOI 10.1182/blood-2002-08-2476; Gordan LN, 2005, J CLIN ONCOL, V23, P1096, DOI 10.1200/JCO.2005.12.171; Grillo-Lopez AJ, 2002, SEMIN ONCOL, V29, P105, DOI 10.1053/sonc.2002.30145; Habermann TM, 2006, J CLIN ONCOL, V24, P3121, DOI 10.1200/JCO.2005.05.1003; Habermann TM, 2003, BLOOD, V102, p6A; HAGBERG H, 2006, ANN ONCOL S4, V17; Hainsworth JD, 2003, J CLIN ONCOL, V21, P1746, DOI 10.1200/JCO.2003.09.027; Hainsworth JD, 2004, SEMIN ONCOL, V31, P17, DOI 10.1053/j.seminoncol.2003.12.005; Hainsworth JD, 2005, J CLIN ONCOL, V23, P1088, DOI 10.1200/JCO.2005.12.191; Hainsworth JD, 2002, J CLIN ONCOL, V20, P4261, DOI 10.1200/JCO.2002.08.674; Herold M, 2004, BLOOD, V104, p169A, DOI 10.1182/blood.V104.11.584.584; Hiddemann W, 2003, BLOOD, V102, p104A; Hiddemann W, 2005, BLOOD, V106, P3725, DOI 10.1182/blood-2005-01-0016; HOCHSTER HS, 2004, P ASCO NEW ORLEANS; Horwitz Steven M, 2004, Curr Hematol Rep, V3, P227; Jain AB, 2005, TRANSPLANTATION, V80, P1692, DOI 10.1097/01.tp.0000185570.41571.df; Janas E, 2005, CLIN EXP IMMUNOL, V139, P439, DOI 10.1111/j.1365-2249.2005.02720.x; Kahl BS, 2006, CLIN LYMPHOMA MYELOM, V6, P423, DOI 10.3816/CLM.2006.n.024; KAPLAN LD, 2004, P AM SOC CLIN ONCOL; Keating MJ, 2005, J CLIN ONCOL, V23, P4079, DOI 10.1200/JCO.2005.12.051; Kennedy AD, 2004, J IMMUNOL, V172, P3280, DOI 10.4049/jimmunol.172.5.3280; Kim DH, 2006, BLOOD, V108, P2720, DOI 10.1182/blood-2006-01-009480; Kimby E, 2005, CANCER TREAT REV, V31, P456, DOI 10.1016/j.ctrv.2005.05.007; Kimby E, 2002, SEMIN ONCOL, V29, P7, DOI 10.1053/sonc.2002.32747; Lemieux B, 2004, HEMATOL J, V5, P467, DOI 10.1038/sj.thj.6200559; Lemieux B, 2004, BONE MARROW TRANSPL, V33, P921, DOI 10.1038/sj.bmt.1704467; Lim SH, 2004, BLOOD, V104, p395A; Lim SH, 2005, BONE MARROW TRANSPL, V35, P207, DOI 10.1038/sj.bmt.1704742; Maloney DG, 1999, SEMIN ONCOL, V26, P74; Marcus R, 2005, BLOOD, V105, P1417, DOI 10.1182/blood-2004-08-3175; MARCUS R, 2006, BLOOD, V108; McLaughlin P, 1998, J CLIN ONCOL, V16, P2825, DOI 10.1200/JCO.1998.16.8.2825; Milpied N, 2000, ANN ONCOL, V11, P113, DOI 10.1023/A:1008372814223; Mounier N, 2006, HAEMATOLOGICA, V91, P715; Neumann F, 2006, ANN HEMATOL, V85, P530, DOI 10.1007/s00277-006-0113-5; O'Brien SM, 2001, J CLIN ONCOL, V19, P2165, DOI 10.1200/JCO.2001.19.8.2165; Paydas S, 2003, LEUKEMIA LYMPHOMA, V44, P2165, DOI 10.1080/1042819031000123555; PFREUNDSCHUH MG, 2004, P ASCO NEW ORLEANS; Pfreundschuh M, 2006, LANCET ONCOL, V7, P379, DOI 10.1016/S1470-2045(06)70664-7; Portlock CS, 2006, LEUKEMIA LYMPHOMA, V47, P1260, DOI 10.1080/10428190600565354; Rehwald U, 2003, BLOOD, V101, P420, DOI 10.1182/blood.V101.2.420; Salles GA, 2004, BLOOD, V104, p49A; Sehn LH, 2007, BLOOD, V109, P1857, DOI 10.1182/blood-2006-08-038257; Sehn LH, 2005, J CLIN ONCOL, V23, P5027, DOI 10.1200/JCO.2005.09.137; Smith MR, 2003, ONCOGENE, V22, P7359, DOI 10.1038/sj.onc.1206939; SOLALCELIGNY P, 2004, BLOOD, V104; Thomas DA, 2006, CANCER-AM CANCER SOC, V106, P1569, DOI 10.1002/cncr.21776; Traulle Catherine, 2005, Future Oncol, V1, P297; van der Kolk LE, 2002, LEUKEMIA, V16, P693, DOI 10.1038/sj.leu.2402424; van Oers MHJ, 2006, BLOOD, V108, P3295, DOI 10.1182/blood-2006-05-021113; Vega MI, 2004, ONCOGENE, V23, P3530, DOI 10.1038/sj.onc.1207336; Weng WK, 2001, BLOOD, V98, P1352, DOI 10.1182/blood.V98.5.1352; Weng WK, 2003, J CLIN ONCOL, V21, P3940, DOI 10.1200/JCO.2003.05.013; Wierda W, 2005, J CLIN ONCOL, V23, P4070, DOI 10.1200/JCO.2005.12.516; Winkler U, 1999, BLOOD, V94, P2217, DOI 10.1182/blood.V94.7.2217.419k02_2217_2224; Winter JN, 2006, BLOOD, V107, P4207, DOI 10.1182/blood-2005-10-4222; Younes A, 2003, CANCER, V98, P310, DOI 10.1002/cncr.11511	96	169	188	1	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2007	26	25					3603	3613		10.1038/sj.onc.1210376	http://dx.doi.org/10.1038/sj.onc.1210376			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	172PK	17530014				2022-12-28	WOS:000246816100003
J	Nahta, R; Esteva, FJ				Nahta, R.; Esteva, F. J.			Trastuzumab: triumphs and tribulations	ONCOGENE			English	Review						breast neoplasms; erbB-2 receptor; monoclonal antibodies; antineoplastic agents	METASTATIC BREAST-CANCER; DEPENDENT CELLULAR CYTOTOXICITY; PROGRESSION-FREE SURVIVAL; EXTRACELLULAR DOMAIN; MONOCLONAL-ANTIBODY; PHASE-II; ADJUVANT CHEMOTHERAPY; GENE AMPLIFICATION; LAPATINIB GW572016; 1ST-LINE TREATMENT	The human epidermal growth factor receptor 2 (HER2) tyrosine kinase receptor is overexpressed in approximately 20-30% of human breast cancers, and is associated with reduced survival. Hence, numerous therapeutic strategies have been tested for their ability to target the HER2 protein. The humanized monoclonal antibody trastuzumab (Herceptin) was the first HER2-targeted agent approved for clinical use in breast cancer patients. Response rates to single-agent trastuzumab range from 12 to 34% for metastatic breast cancer (MBC), and significant improvements in survival rates are achieved in patients with early-stage HER2-overexpressing breast cancer in the adjuvant setting. Despite its initial efficacy, acquired resistance to trastuzumab develops in a majority of patients with MBC, and a large subset never responds, demonstrating primary resistance. Molecular mechanisms of trastuzumab antineoplastic activity and potential mechanisms contributing to its resistance will be discussed in this review. Novel agents that may enhance trastuzumab efficacy will also be discussed.	Univ Texas, MD Anderson Canc Ctr, Dept Breast Med Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Breast Med Oncol, Breast Canc Translat Res Lab, Houston, TX 77030 USA; Univ Texas, Grad Sch Biomed Sci, Dept Mol & Cellular Oncol, Houston, TX USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System	Nahta, R (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Breast Med Oncol, 1515 Holocombe Blvd,Unit 1354, Houston, TX 77030 USA.	rnahta@mdanderson.org; festeva@mdanderson.org			NATIONAL CANCER INSTITUTE [K01CA118174, P30CA016672] Funding Source: NIH RePORTER; NCI NIH HHS [CA16672, K01 CA118174] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams CW, 2006, CANCER IMMUNOL IMMUN, V55, P717, DOI 10.1007/s00262-005-0058-x; Agus DB, 2002, CANCER CELL, V2, P127, DOI 10.1016/S1535-6108(02)00097-1; Ali SM, 2006, J CLIN ONCOL, V24, P500, DOI [10.1200/jco.2006.24.18_suppl.500, DOI 10.1200/JCO.2006.24.18_SUPPL.500]; Anido J, 2006, EMBO J, V25, P3234, DOI 10.1038/sj.emboj.7601191; Arnould L, 2006, BRIT J CANCER, V94, P259, DOI 10.1038/sj.bjc.6602930; Baselga J, 2001, SEMIN ONCOL, V28, P4, DOI 10.1053/sonc.2001.28544; Baselga J, 1996, J CLIN ONCOL, V14, P737, DOI 10.1200/JCO.1996.14.3.737; Burstein HJ, 2005, ANN ONCOL, V16, P1772, DOI 10.1093/annonc/mdi371; Buzdar AU, 2005, J CLIN ONCOL, V23, P3676, DOI 10.1200/JCO.2005.07.032; Camirand A, 2002, MED SCI MONITOR, V8, pBR521; CARTER P, 1992, P NATL ACAD SCI USA, V89, P4285, DOI 10.1073/pnas.89.10.4285; Christianson TA, 1998, CANCER RES, V58, P5123; Clynes RA, 2000, NAT MED, V6, P443, DOI 10.1038/74704; Cobleigh MA, 1999, J CLIN ONCOL, V17, P2639, DOI 10.1200/JCO.1999.17.9.2639; Colomer R, 2000, CLIN CANCER RES, V6, P2356; Cooley S, 1999, EXP HEMATOL, V27, P1533, DOI 10.1016/S0301-472X(99)00089-2; DIGIOVANNA MP, 2006, P AM ASSOC CANC RES, V47, P1226; Esteva FJ, 2002, J CLIN ONCOL, V20, P1800, DOI 10.1200/JCO.2002.07.058; Esteva FJ, 2005, BREAST CANCER RES, V7, pR436, DOI 10.1186/bcr1020; Franklin MC, 2004, CANCER CELL, V5, P317, DOI 10.1016/S1535-6108(04)00083-2; Gennari R, 2004, CLIN CANCER RES, V10, P5650, DOI 10.1158/1078-0432.CCR-04-0225; Geyer CE, 2006, NEW ENGL J MED, V355, P2733, DOI 10.1056/NEJMoa064320; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; Hayes DF, 2001, CLIN CANCER RES, V7, P2703; Izumi Y, 2002, NATURE, V416, P279, DOI 10.1038/416279b; Jerome L, 2006, CANCER RES, V66, P7245, DOI 10.1158/0008-5472.CAN-05-3555; Konecny GE, 2006, CANCER RES, V66, P1630, DOI 10.1158/0008-5472.CAN-05-1182; Kos KS, 2003, CANCER-AM CANCER SOC, V98, P1377, DOI 10.1002/cncr.11656; Kostler WJ, 2004, CLIN CANCER RES, V10, P1618, DOI 10.1158/1078-0432.CCR-0385-3; Lane HA, 2000, MOL CELL BIOL, V20, P3210, DOI 10.1128/MCB.20.9.3210-3223.2000; Le XF, 2003, J BIOL CHEM, V278, P23441, DOI 10.1074/jbc.M300848200; LEITZEL K, 1995, J CLIN ONCOL, V13, P1129, DOI 10.1200/JCO.1995.13.5.1129; LIN YZJ, 1991, ONCOGENE, V6, P639; Lu YH, 2004, INT J CANCER, V108, P334, DOI 10.1002/ijc.11445; Lu YH, 2001, JNCI-J NATL CANCER I, V93, P1852, DOI 10.1093/jnci/93.24.1852; Marty M, 2005, J CLIN ONCOL, V23, P4265, DOI 10.1200/JCO.2005.04.173; Molina MA, 2002, CLIN CANCER RES, V8, P347; Molina MA, 2001, CANCER RES, V61, P4744; Nahta R, 2004, CANCER RES, V64, P3981, DOI 10.1158/0008-5472.CAN-03-3900; Nahta R, 2006, CANCER LETT, V232, P123, DOI 10.1016/j.canlet.2005.01.041; Nahta R, 2005, CANCER RES, V65, P11118, DOI 10.1158/0008-5472.CAN-04-3841; Nahta R, 2004, CANCER RES, V64, P2343, DOI 10.1158/0008-5472.CAN-03-3856; Nahta R, 2006, NAT CLIN PRACT ONCOL, V3, P269, DOI 10.1038/ncponc0509; Neve RM, 2000, ONCOGENE, V19, P1647, DOI 10.1038/sj.onc.1203470; Piccart-Gebhart MJ, 2005, NEW ENGL J MED, V353, P1659, DOI 10.1056/NEJMoa052306; Press MF, 1997, J CLIN ONCOL, V15, P2894, DOI 10.1200/JCO.1997.15.8.2894; PUPA SM, 1993, ONCOGENE, V8, P2917; Romond EH, 2005, NEW ENGL J MED, V353, P1673, DOI 10.1056/NEJMoa052122; Seidman AD, 2001, J CLIN ONCOL, V19, P2587, DOI 10.1200/JCO.2001.19.10.2587; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Sliwkowski MX, 1999, SEMIN ONCOL, V26, P60; Tanner M, 2004, MOL CANCER THER, V3, P1585; Vogel CL, 2002, J CLIN ONCOL, V20, P719, DOI 10.1200/JCO.20.3.719; Wen XF, 2006, ONCOGENE, V25, P6986, DOI 10.1038/sj.onc.1209685; Xia WL, 2005, ONCOGENE, V24, P6213, DOI 10.1038/sj.onc.1208774; Xia WL, 2002, ONCOGENE, V21, P6255, DOI 10.1038/sj.onc.1205794; Yakes FM, 2002, CANCER RES, V62, P4132; Yamauchi H, 1997, J CLIN ONCOL, V15, P2518, DOI 10.1200/JCO.1997.15.7.2518; ZABRECKY JR, 1991, J BIOL CHEM, V266, P1716	61	255	271	1	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2007	26	25					3637	3643		10.1038/sj.onc.1210379	http://dx.doi.org/10.1038/sj.onc.1210379			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	172PK	17530017				2022-12-28	WOS:000246816100006
J	Soussi, T				Soussi, T.			p53 alterations in human cancer: more questions than answers	ONCOGENE			English	Review						p53 mutations; apoptosis; cancer; cell cyle; tumour suppressor gene	LARGE T-ANTIGEN; TUMOR-SUPPRESSOR; MUTANT P53; MOUSE MODEL; DNA-DAMAGE; ONCOGENIC MUTATIONS; CRYSTAL-STRUCTURE; POINT MUTATION; PROTEIN; MICE	The strongest and undisputed fact about p53 is the high frequency of p53 alterations in human cancer and that mutant p53 proteins constitute a complex family of several hundred proteins with heterogeneous properties. Beyond these observations, the p53 pathway and its regulation in a normal cell is like a desert trail, always moving with the wind of novel findings. The field is full of black boxes that are often ignored for sake of simplicity or because they do not fit with the current dominant view. Mutant p53 protein accumulation in tumours is the best example of a preconceived idea, as there is no experimental evidence to explain this observation. In this review, we will discuss several questions concerning the activity or selection of p53 mutations. The central domain of the p53 protein targeted by 80% of p53 mutations is associated with the DNA-binding activity of the p53 protein, but it is also the binding site for several proteins that play a key role in p53 regulation such as ASPP proteins or BclxL. The role of impaired DNA binding and/or protein interactions in tumour development has not been fully elucidated. Similarly, novel animal models carrying either missense p53 mutations or inducible p53 have provided abundant observations, some of which could challenge our view on p53 function as a tumour suppressor gene. Finally, the possible clinical applications of p53 will be discussed.	Karolinska Inst, CCK, Dept Oncol Pathol, SE-17176 Stockholm, Sweden; Univ Paris 06, Dept Life Sci, Paris, France	Karolinska Institutet; UDICE-French Research Universities; Sorbonne Universite	Soussi, T (corresponding author), Karolinska Inst, CCK, Dept Oncol Pathol, SE-17176 Stockholm, Sweden.	thierry.soussi@ki.se		soussi, thierry/0000-0001-8184-3293				Aas T, 1996, NAT MED, V2, P811, DOI 10.1038/nm0796-811; Appella E, 2001, EUR J BIOCHEM, V268, P2764, DOI 10.1046/j.1432-1327.2001.02225.x; Bader S, 1999, ONCOGENE, V18, P8044, DOI 10.1038/sj.onc.1203229; Baylin SB, 2000, J NATL CANCER I, V92, P1460, DOI 10.1093/jnci/92.18.1460; Bergamaschi D, 2003, CANCER CELL, V3, P387, DOI 10.1016/S1535-6108(03)00079-5; Blagosklonny MV, 2000, FASEB J, V14, P1901, DOI 10.1096/fj.99-1078rev; Blandino G, 1999, ONCOGENE, V18, P477, DOI 10.1038/sj.onc.1202314; Bourdon JC, 2005, GENE DEV, V19, P2122, DOI 10.1101/gad.1339905; Brash DE, 1996, NAT MED, V2, P525, DOI 10.1038/nm0596-525; Bruins W, 2004, MOL CELL BIOL, V24, P8884, DOI 10.1128/mcb.24.20.8884-8894.2004; Chipuk JE, 2003, J CLIN IMMUNOL, V23, P355, DOI 10.1023/A:1025365432325; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; Christophorou MA, 2006, NATURE, V443, P214, DOI 10.1038/nature05077; Denissenko MF, 1997, P NATL ACAD SCI USA, V94, P3893, DOI 10.1073/pnas.94.8.3893; Deppert W, 2000, J CELL BIOCHEM, P115; Di Como CJ, 1999, MOL CELL BIOL, V19, P1438; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DOWELL SP, 1994, CANCER RES, V54, P2914; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; Fan SJ, 2001, ONCOGENE, V20, P8215, DOI 10.1038/sj.onc.1205033; Fei PW, 2002, CANCER RES, V62, P7316; Freedman DA, 1999, CELL MOL LIFE SCI, V55, P96, DOI 10.1007/s000180050273; Gaiddon C, 2001, MOL CELL BIOL, V21, P1874, DOI 10.1128/MCB.21.5.1874-1887.2001; Gatz SA, 2006, CELL DEATH DIFFER, V13, P1003, DOI 10.1038/sj.cdd.4401903; Gorina S, 1996, SCIENCE, V274, P1001, DOI 10.1126/science.274.5289.1001; Gottlieb E, 1997, EMBO J, V16, P1381, DOI 10.1093/emboj/16.6.1381; Gudkov AV, 2002, NAT MED, V8, P1196, DOI 10.1038/nm1102-1196; HALEVY O, 1990, SCIENCE, V250, P113, DOI 10.1126/science.2218501; HALL PA, 1994, J PATHOL, V172, P1, DOI 10.1002/path.1711720103; HELTON ES, 2006, J CELL BIOCH; Irwin MS, 2003, CANCER CELL, V3, P403, DOI 10.1016/S1535-6108(03)00078-3; JENKINS JR, 1988, J VIROL, V62, P3903, DOI 10.1128/JVI.62.10.3903-3906.1988; Johnson TM, 2006, CELL DEATH DIFFER, V13, P902, DOI 10.1038/sj.cdd.4401902; Kato S, 2003, P NATL ACAD SCI USA, V100, P8424, DOI 10.1073/pnas.1431692100; Krummel KA, 2005, P NATL ACAD SCI USA, V102, P10188, DOI 10.1073/pnas.0503068102; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; Lang GA, 2004, CELL, V119, P861, DOI 10.1016/j.cell.2004.11.006; LAVIGUEUR A, 1989, MOL CELL BIOL, V9, P3982, DOI 10.1128/MCB.9.9.3982; Levine AJ, 2006, CELL DEATH DIFFER, V13, P1027, DOI 10.1038/sj.cdd.4401910; Lilyestrom W, 2006, GENE DEV, V20, P2373, DOI 10.1101/gad.1456306; Liu G, 2004, NAT GENET, V36, P63, DOI 10.1038/ng1282; Lozada MC, 2005, MONOGR COTSEN INST A, V53, P206; MacPherson D, 2004, EMBO J, V23, P3689, DOI 10.1038/sj.emboj.7600363; Marin MC, 2000, NAT GENET, V25, P47, DOI 10.1038/75586; Melino G, 2002, NAT REV CANCER, V2, P605, DOI 10.1038/nrc861; MIDGLEY CA, 1995, J CELL SCI, V108, P1843; Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9; MILNER J, 1995, TRENDS BIOCHEM SCI, V20, P49, DOI 10.1016/S0968-0004(00)88954-9; Mummenbrauer T, 1996, CELL, V85, P1089, DOI 10.1016/S0092-8674(00)81309-4; Norimura T, 1996, NAT MED, V2, P577, DOI 10.1038/nm0596-577; Olive KP, 2004, CELL, V119, P847, DOI 10.1016/j.cell.2004.11.004; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Prives C, 2005, MOL CELL, V19, P719, DOI 10.1016/j.molcel.2005.08.024; Resnick MA, 2003, P NATL ACAD SCI USA, V100, P9934, DOI 10.1073/pnas.1633803100; Rohaly G, 2005, CELL, V122, P21, DOI 10.1016/j.cell.2005.04.032; Rowan AJ, 2000, P NATL ACAD SCI USA, V97, P3352, DOI 10.1073/pnas.97.7.3352; Sablina AA, 2005, NAT MED, V11, P1306, DOI 10.1038/nm1320; Samuels-Lev Y, 2001, MOL CELL, V8, P781, DOI 10.1016/S1097-2765(01)00367-7; Selivanova G, 2007, ONCOGENE, V26, P2243, DOI 10.1038/sj.onc.1210295; Sengupta S, 2005, NAT REV MOL CELL BIO, V6, P44, DOI 10.1038/nrm1546; Seo YR, 2002, P NATL ACAD SCI USA, V99, P14548, DOI 10.1073/pnas.212319799; Sigal A, 2000, CANCER RES, V60, P6788; Sjoblom T, 2006, SCIENCE, V314, P268, DOI 10.1126/science.1133427; Sluss HK, 2004, MOL CELL BIOL, V24, P976, DOI 10.1128/MCB.24.3.976-984.2004; Soussi T, 2005, BIOCHEM BIOPH RES CO, V331, P834, DOI 10.1016/j.bbrc.2005.03.190; Soussi T, 2005, HUM MUTAT, V25, P6, DOI 10.1002/humu.20114; Soussi T, 2003, HUM MUTAT, V21, P192, DOI 10.1002/humu.10189; Soussi T, 2001, NAT REV CANCER, V1, P233, DOI 10.1038/35106009; SOUSSI T, 1989, J VIROL, V63, P3894, DOI 10.1128/JVI.63.9.3894-3901.1989; Soussi T, 2005, 25 YEARS OF P53 RESEARCH, P255, DOI 10.1007/1-4020-2922-5_12; Strano S, 2000, J BIOL CHEM, V275, P29503, DOI 10.1074/jbc.M003360200; Takagi M, 2005, CELL, V123, P49, DOI 10.1016/j.cell.2005.07.034; Tidow H, 2006, J BIOL CHEM, V281, P32526, DOI 10.1074/jbc.M604725200; Tomita Y, 2006, J BIOL CHEM, V281, P8600, DOI 10.1074/jbc.M507611200; TORNALETTI S, 1995, ONCOGENE, V10, P1493; Tyner SD, 2002, NATURE, V415, P45, DOI 10.1038/415045a; Vogelstein B, 2004, NAT MED, V10, P789, DOI 10.1038/nm1087; Wong KB, 1999, P NATL ACAD SCI USA, V96, P8438, DOI 10.1073/pnas.96.15.8438; Yang A, 2002, TRENDS GENET, V18, P90, DOI 10.1016/S0168-9525(02)02595-7; You YH, 1999, J MOL BIOL, V293, P493, DOI 10.1006/jmbi.1999.3174	81	186	194	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 2	2007	26	15					2145	2156		10.1038/sj.onc.1210280	http://dx.doi.org/10.1038/sj.onc.1210280			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	152XE	17401423				2022-12-28	WOS:000245394800003
J	Runeberg-Roos, P; Virtanen, H; Saarma, M				Runeberg-Roos, P.; Virtanen, H.; Saarma, M.			RET(MEN 2B) is active in the endoplasmic reticulum before reaching the cell surface	ONCOGENE			English	Article						RET; MEN 2B; precursor; downstream signalling; endoplasmic reticulum	ENDOCRINE NEOPLASIA TYPE-2; RET PROTOONCOGENE PRODUCTS; HIRSCHSPRUNGS-DISEASE; TYROSINE KINASE; THYROID-CELLS; ACTIVATION; MUTATIONS; MECHANISM; RECEPTOR; GDNF	MEN 2B ( multiple endocrine neoplasia type 2B) is an autosomal dominant cancer syndrome caused by an oncogenic form of the receptor tyrosine kinase REarranged during transfection (RET). The MEN 2B syndrome is associated with an abnormal autophosphorylation of the mutated receptor even without ligand-stimulation. Here, we characterize the activation of a RETMEN2B variant carrying the point mutation Met918Thr, and show that the 150 kDa precursor of RETMEN2B becomes phosphorylated already during synthesis in the endoplasmic reticulum (ER). At least three different tyrosine residues (Tyr905, Tyr1062, Tyr1096) of the RETMEN2B precursor are phosphorylated before the oncogenic receptor reaches the cell surface. We also demonstrate that the precursor of RETMEN2B interacts with both growth factor receptor-bound protein and Src homology 2 domain-containing already in the ER, and that this interaction is dependent on the kinase activity of RET. With the aid of two RET mutants (RETMEN2B/S32L and RETMEN2B/ F393L), which accumulate in the ER, we show that the oncogenic precursor of the receptor has the capacity to activate AKT, extracellular signal-regulated kinase and signal transducer and activator of transcription 3 from the ER. Taken together, our data demonstrate that the oncogenic precursor of RETMEN2B is phosphorylated, interacts with adapter proteins and induces downstream signalling from the ER.	[Runeberg-Roos, P.; Virtanen, H.; Saarma, M.] Univ Helsinki, Inst Biotechnol, Viikki Bioctr, FIN-00014 Helsinki, Finland	University of Helsinki	Runeberg-Roos, P (corresponding author), Univ Helsinki, Inst Biotechnol, Viikki Bioctr, Viikinkaari 9,POB 56, FIN-00014 Helsinki, Finland.	pia.runeberg@helsinki.fi						Airaksinen MS, 2002, NAT REV NEUROSCI, V3, P383, DOI 10.1038/nrn812; Asai N, 1996, J BIOL CHEM, V271, P17644, DOI 10.1074/jbc.271.30.17644; ASAI N, 1995, MOL CELL BIOL, V15, P1613; Bongarzone I, 1998, ONCOGENE, V16, P2295, DOI 10.1038/sj.onc.1201759; Carlomagno F, 1998, ENDOCRINOLOGY, V139, P3613, DOI 10.1210/en.139.8.3613; Carlomagno F, 1996, EMBO J, V15, P2717, DOI 10.1002/j.1460-2075.1996.tb00632.x; Cerchia L, 2003, BIOCHEM J, V372, P897, DOI 10.1042/BJ20021530; Chappuis-Flament S, 1998, ONCOGENE, V17, P2851, DOI 10.1038/sj.onc.1202202; Cosma MP, 1998, MOL CELL BIOL, V18, P3321, DOI 10.1128/MCB.18.6.3321; Freche B, 2005, J BIOL CHEM, V280, P36584, DOI 10.1074/jbc.M505707200; Hansford JR, 2000, J MED GENET, V37, P817, DOI 10.1136/jmg.37.11.817; Hwang JH, 2003, MOL ENDOCRINOL, V17, P1155, DOI 10.1210/me.2002-0401; Knauf JA, 2003, ONCOGENE, V22, P4406, DOI 10.1038/sj.onc.1206602; Kodama Y, 2005, CANCER SCI, V96, P143, DOI 10.1111/j.1349-7006.2005.00023.x; Miyagi E, 2004, MOL CARCINOGEN, V41, P98, DOI 10.1002/mc.20042; MIYAZAKI K, 1993, BIOCHEM BIOPH RES CO, V193, P565, DOI 10.1006/bbrc.1993.1661; MULLIGAN LM, 1995, J CLIN ENDOCR METAB, V80, P1989, DOI 10.1210/jc.80.7.1989; Pelet A, 1998, J CLIN INVEST, V101, P1415, DOI 10.1172/JCI375; Salvatore D, 2001, CANCER RES, V61, P1426; SANTORO M, 1995, SCIENCE, V267, P381, DOI 10.1126/science.7824936; TAKAHASHI M, 1991, ONCOGENE, V6, P297; Tsui-Pierchala BA, 2002, J BIOL CHEM, V277, P34618, DOI 10.1074/jbc.M203580200; van Weering DHJ, 1998, J BIOL CHEM, V273, P12077, DOI 10.1074/jbc.273.20.12077; Virtanen H, 2005, BIOCHEM J, V387, P817, DOI 10.1042/BJ20041257	24	24	25	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 13	2007	26	57					7909	7915		10.1038/sj.onc.1210591	http://dx.doi.org/10.1038/sj.onc.1210591			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	248ON	17599050				2022-12-28	WOS:000252163500009
J	Sethi, G; Ahn, KS; Chaturvedi, MM; Aggarwal, BB				Sethi, G.; Ahn, K. S.; Chaturvedi, M. M.; Aggarwal, B. B.			Epidermal growth factor (EGF) activates nuclear factor-kappa B through I kappa B alpha kinase-independent but EGF receptor-kinase dependent tyrosine 42 phosphorylation of I kappa B alpha	ONCOGENE			English	Article						NF; kappa B; EGF; TNF; IKK; AKT	TUMOR-NECROSIS-FACTOR; CELL LUNG-CANCER; GENE-EXPRESSION; DEGRADATION; INHIBITION; APOPTOSIS; INDUCTION; GEFITINIB; PATHWAY; COMPLEX	Overexpression of epidermal growth factor (EGF) receptor and constitutive activation of nuclear factor-kappa B (NF-kappa B) are frequently encountered in tumor cells. Although EGF has been shown to induce NF-kappa B activation, the mechanism is poorly understood. EGF activated NF-kappa B DNA binding, induced NF-kappa B reporter activity and the expression of antiapoptotic and cell-proliferative gene products. Interestingly, non-small cell lung adenocarcinoma cell lines (HCC827 and H3255), which exhibit EGFR amplification, showed ligand-independent activation of NF-kappa B. Unlike tumor-necrosis factor (TNF), however, EGF failed to induce I kappa B alpha phosphorylation and ubiquitination and the activation of I kappa B alpha kinase (IKK). Although DN-IKK beta inhibited TNF-induced NF-kappa B activity, DN-IKK beta had no effect on EGF-induced NF-kappa B activation, suggesting that EGF-induced NF-kappa B activation is IKK independent. Using dominant-negative plasmids, we also demonstrated the role of TRADD, TRAF2, NIK and Ras in EGF-induced NF-kappa B activation. By using specific antibodies and I kappa B alpha plasmid, which is mutated at tyrosine 42 to phenylalanine, we show that EGF induced the tyrosine phosphorylation of I kappa B alpha at residue 42. Furthermore, EGF receptor kinase inhibitor blocked I kappa B alpha phosphorylation and consequent NF-kappa B activation. Overall, our results indicate that tyrosine phosphorylation of I kappa B alpha at residue 42 is critical for EGF-induced NF-kappa B activation pathway.	Univ Texas, MD Anderson Canc Ctr, Cytokine Res Lab, Dept Expt Therapeut, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Aggarwal, BB (corresponding author), Univ Delhi, Dept Zool, Delhi 110007, India.	aggarwal@mdanderson.org	Aggarwal, Bharat B/G-3388-2013; Ahn, Kwang Seok/G-4249-2013; Sethi, Gautam/F-2372-2011	Sethi, Gautam/0000-0002-8677-8475	NCI NIH HHS [P01 CA91844] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA091844] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aggarwal BB, 2004, CANCER CELL, V6, P203, DOI 10.1016/j.ccr.2004.09.003; Amann J, 2005, CANCER RES, V65, P226; Biswas DK, 2000, P NATL ACAD SCI USA, V97, P8542, DOI 10.1073/pnas.97.15.8542; Campbell KJ, 2004, MOL CELL, V13, P853, DOI 10.1016/S1097-2765(04)00131-5; Chaturvedi MM, 2000, METHOD ENZYMOL, V319, P585; Digicaylioglu M, 2001, NATURE, V412, P641, DOI 10.1038/35088074; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; FINCO TS, 1993, J BIOL CHEM, V268, P17676; Habib AA, 1998, J BIOL CHEM, V273, P6885, DOI 10.1074/jbc.273.12.6885; Han YQ, 1999, J BIOL CHEM, V274, P787, DOI 10.1074/jbc.274.2.787; Haussler U, 2005, AM J PHYSIOL-RENAL, V289, pF808, DOI 10.1152/ajprenal.00434.2003; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Imbert V, 1996, CELL, V86, P787, DOI 10.1016/S0092-8674(00)80153-1; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Mendelsohn J, 2000, ONCOGENE, V19, P6550, DOI 10.1038/sj.onc.1204082; Mukhopadhyay A, 2000, J BIOL CHEM, V275, P8549, DOI 10.1074/jbc.275.12.8549; Obata H, 1996, BIOCHEM BIOPH RES CO, V224, P27, DOI 10.1006/bbrc.1996.0979; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Singh S, 1996, J BIOL CHEM, V271, P31049, DOI 10.1074/jbc.271.49.31049; Sun L, 1998, ONCOGENE, V16, P2095, DOI 10.1038/sj.onc.1201731; Takada Y, 2004, J BIOL CHEM, V279, P39541, DOI 10.1074/jbc.M403449200; Takada Y, 2004, J BIOL CHEM, V279, P26287, DOI 10.1074/jbc.M400963200; Takada Y, 2003, J IMMUNOL, V171, P3278, DOI 10.4049/jimmunol.171.6.3278; Takada Y, 2003, J BIOL CHEM, V278, P24233, DOI 10.1074/jbc.M212389200; Tracy S, 2004, CANCER RES, V64, P7241, DOI 10.1158/0008-5472.CAN-04-1905; Traxler P, 2004, CANCER RES, V64, P4931, DOI 10.1158/0008-5472.CAN-03-3681; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; VINITSKY A, 1992, BIOCHEMISTRY-US, V31, P9421, DOI 10.1021/bi00154a014	29	84	90	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 15	2007	26	52					7324	7332		10.1038/sj.onc.1210544	http://dx.doi.org/10.1038/sj.onc.1210544			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	231NP	17533369				2022-12-28	WOS:000250955700004
J	Minella, AC; Grim, JE; Welcker, M; Clurman, BE				Minella, A. C.; Grim, J. E.; Welcker, M.; Clurman, B. E.			P53 and SCFFbw7 cooperatively restrain cyclin E-associated genome instability	ONCOGENE			English	Article						cyclin E; p53; p21; Fbw7; hCdc4; genome instability	UBIQUITIN LIGASE; DEPENDENT DEGRADATION; C-MYC; PHOSPHORYLATION; FBW7; CANCER; NOTCH; HCDC4; TUMORIGENESIS; DEREGULATION	Cancers often exhibit high levels of cyclin E expression, and aberrant cyclin E activity causes genomic instability and increased tumorigenesis. Two tumor suppressor pathways protect cells against cyclin E deregulation. The p53 pathway is induced by excess cychn E in primary cells and opposes cyclin E activity through induction of p21Cip1. In contrast, the Fbw7 pathway targets cyclin E for degradation, and Fbw7 mutations occur commonly in cancers. We investigated the cooperativity of these two pathways in countering cyclin E-induced genomic instability in primary human cells. We find that loss of p53 and Fbw7 synergistically unmasks cyclin E-induced instability. In normal cells, impaired cychn E degradation produces genome instability, but this is rapidly mitigated by induction of p53 and p21. In contrast, p53 loss allows the high level of cyclin E kinase activity that results from Fbw7 loss to persist and continuously drive genome instability. Moreover, p21 plays a critical role in suppressing cyclin E when Fbw7 is disabled, and in the absence of p21, sustained cyclin E activity induces rapid cell death via apoptosis. These data directly demonstrate the cooperative roles of these Fbw7 and p53 pathways in restraining cyclin E activity and its associated genome instability.	Fred Hutchinson Canc Res Ctr, Div Clin Res & Human Biol, Seattle, WA 98109 USA; Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA	Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle	Clurman, BE (corresponding author), Fred Hutchinson Canc Res Ctr, Div Clin Res & Human Biol, 1100 Fairview Ave N,D2-100, Seattle, WA 98109 USA.	bclurman@fhcrc.org	Clurman, Bruce/AAV-3854-2021	Welcker, Markus/0000-0001-6723-4790; Minella, Alex/0000-0001-6693-3362	NATIONAL CANCER INSTITUTE [R01CA102742, K08CA101800, R01CA084069] Funding Source: NIH RePORTER; NCI NIH HHS [K08CA101800, R01CA84069, R01CA102742] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Clurman BE, 1996, GENE DEV, V10, P1979, DOI 10.1101/gad.10.16.1979; Dumaz N, 1999, EMBO J, V18, P7002, DOI 10.1093/emboj/18.24.7002; Ekholm-Reed S, 2004, J CELL BIOL, V165, P789, DOI 10.1083/jcb.200404092; Geng Y, 2007, MOL CELL, V25, P127, DOI 10.1016/j.molcel.2006.11.029; Hwang HC, 2005, ONCOGENE, V24, P2776, DOI 10.1038/sj.onc.1208613; Koepp DM, 2001, SCIENCE, V294, P173, DOI 10.1126/science.1065203; Loeb KR, 2005, CANCER CELL, V8, P35, DOI 10.1016/j.ccr.2005.06.010; Mao JH, 2004, NATURE, V432, P775, DOI 10.1038/nature03155; Minella AC, 2005, P NATL ACAD SCI USA, V102, P9649, DOI 10.1073/pnas.0503677102; Minella AC, 2002, CURR BIOL, V12, P1817, DOI 10.1016/S0960-9822(02)01225-3; Moberg KH, 2001, NATURE, V413, P311, DOI 10.1038/35095068; Nateri AS, 2004, SCIENCE, V303, P1374, DOI 10.1126/science.1092880; Noseda M, 2004, MOL CELL BIOL, V24, P8813, DOI 10.1128/MCB.24.20.8813-8822.2004; Oberg C, 2001, J BIOL CHEM, V276, P35847, DOI 10.1074/jbc.M103992200; Orlicky S, 2003, CELL, V112, P243, DOI 10.1016/S0092-8674(03)00034-5; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; Rajagopalan H, 2004, NATURE, V428, P77, DOI 10.1038/nature02313; Smith APL, 2006, ONCOGENE, V25, P7245, DOI 10.1038/sj.onc.1209713; Spruck CH, 2002, CANCER RES, V62, P4535; Spruck CH, 1999, NATURE, V401, P297, DOI 10.1038/45836; Strohmaier H, 2001, NATURE, V413, P316, DOI 10.1038/35095076; Wei WY, 2005, CANCER CELL, V8, P25, DOI 10.1016/j.ccr.2005.06.005; Welcker M, 2004, P NATL ACAD SCI USA, V101, P9085, DOI 10.1073/pnas.0402770101; Welcker M, 2003, MOL CELL, V12, P381, DOI 10.1016/S1097-2765(03)00287-9; Won KA, 1996, EMBO J, V15, P4182, DOI 10.1002/j.1460-2075.1996.tb00793.x; Wu GY, 2001, MOL CELL BIOL, V21, P7403, DOI 10.1128/MCB.21.21.7403-7415.2001; Yada M, 2004, EMBO J, V23, P2116, DOI 10.1038/sj.emboj.7600217	27	43	44	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 18	2007	26	48					6948	6953		10.1038/sj.onc.1210518	http://dx.doi.org/10.1038/sj.onc.1210518			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	220WQ	17486057				2022-12-28	WOS:000250188400010
J	Kucherlapati, M; Nguyen, A; Kuraguchi, M; Yang, K; Fan, K; Bronson, R; Wei, K; Lipkin, M; Edelmann, W; Kucherlapati, R				Kucherlapati, M.; Nguyen, A.; Kuraguchi, M.; Yang, K.; Fan, K.; Bronson, R.; Wei, K.; Lipkin, M.; Edelmann, W.; Kucherlapati, R.			Tumor progression in Apc(1638N) mice with Exo1 and Fen1 deficiencies	ONCOGENE			English	Article						mouse; Apc(1638N); Exo1; Fen1	MISMATCH REPAIR PROTEINS; COLORECTAL-CANCER; GENE; EXONUCLEASE; MUTATIONS; MOUSE; INTERACTS; SYSTEM; MODEL; MSH6	Flap endonuclease 1 (Fen1) and exonuclease 1 (Exo1) have sequence homology and similar nuclease capabilities. Both function in multiple pathways of DNA metabolism, but appear to have distinct in vivo nucleic acid substrates, and therefore distinct metabolic roles. When combined with Apc(1638N), Fen1 promotes tumor progression. Because of functional similarity to Fen1, and because Exo1 is involved in DNA mismatch repair (MMR) by interaction with Msh2 and Mlh1, genes that cause hereditary nonpolyposis colorectal cancer ( HNPCC), we investigated the possibility that Exo1 might also act as a modi. er to Apc(1638N). We present evidence that mice with combined mutations in Apc(1638N) and Exo1 and Apc(1638N), Exo1 and Fen1 genes show moderate increased tumor incidence and multiplicity in comparison to Apc(1638N) siblings, implying a low penetrance role for Exo1 in early gastrointestinal (GI) tumorigenesis. Despite a decrease in median survival (10 months) in Apc(1638N) Exo1 mice, their tumors do not progress any more rapidly than those of Apc(1638N). Instead these animals die from infections that are the result of impaired immune response. Apc(1638N) Exo1 Fen1 mice survive longer (18 months), and therefore appear relatively immune competent. They die of invasive GI tumors that display microsatellite instability (MSI). Our results show that Exo1 has a modest tumor suppressor function.	Harvard Univ, Sch Med, Harvard Partners Ctr Genet & Genom, Boston, MA 02115 USA; Rockefeller Univ, Strang Canc Res Lab, New York, NY 10021 USA; Harvard Univ, Sch Med, Rodent Histopathol Core, Boston, MA 02115 USA; Tufts Univ, Sch Med, Dept Pathol, Boston, MA 02111 USA; Tufts Univ, Sch Vet Med, Boston, MA 02111 USA; Albert Einstein Coll Med, Dept Cell Biol, Bronx, NY 10467 USA	Harvard University; Harvard Medical School; Rockefeller University; Harvard University; Harvard Medical School; Tufts University; Tufts University; Yeshiva University; Albert Einstein College of Medicine	Kucherlapati, R (corresponding author), Harvard Univ, Sch Med, Harvard Partners Ctr Genet & Genom, 77 Ave Louis Pasteur,NRB 160, Boston, MA 02115 USA.	mkucherlapati@rics.bwh.harvard.edu	Kucherlapati, Raju/ABC-8807-2021		NATIONAL CANCER INSTITUTE [U01CA084301] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [U01ES011040] Funding Source: NIH RePORTER; NCI NIH HHS [CA084301] Funding Source: Medline; NIEHS NIH HHS [ES011040] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Alam NA, 2003, CANCER GENET CYTOGEN, V147, P121, DOI 10.1016/S0165-4608(03)00196-1; Amin NS, 2001, MOL CELL BIOL, V21, P5142, DOI 10.1128/MCB.21.15.5142-5155.2001; Bardwell PD, 2004, NAT IMMUNOL, V5, P224, DOI 10.1038/ni1031; Coletta PL, 2004, BLOOD, V103, P1050, DOI 10.1182/blood-2003-03-0707; Dzantiev L, 2004, MOL CELL, V15, P31, DOI 10.1016/j.molcel.2004.06.016; Edelmann L, 2004, AM J MED GENET C, V129C, P91, DOI 10.1002/ajmg.c.30021; Edelmann W, 1999, CANCER RES, V59, P1301; Edelmann W, 2000, CANCER RES, V60, P803; FODDE R, 1994, P NATL ACAD SCI USA, V91, P8969, DOI 10.1073/pnas.91.19.8969; Gounari F, 2005, NAT IMMUNOL, V6, P800, DOI 10.1038/ni1228; Jagmohan-Changur S, 2003, CANCER RES, V63, P154; Kucherlapati M, 2002, P NATL ACAD SCI USA, V99, P9924, DOI 10.1073/pnas.152321699; Lee B, 2002, NUCLEIC ACIDS RES, V30, P942, DOI 10.1093/nar/30.4.942; Lee BI, 1999, J BIOL CHEM, V274, P37763, DOI 10.1074/jbc.274.53.37763; Liu Y, 2004, ANNU REV BIOCHEM, V73, P589, DOI 10.1146/annurev.biochem.73.012803.092453; Nielsen FC, 2004, ONCOGENE, V23, P1457, DOI 10.1038/sj.onc.1207265; Peltomaki P, 1997, GASTROENTEROLOGY, V113, P1146, DOI 10.1053/gast.1997.v113.pm9322509; Rudolph C, 1998, CURR GENET, V34, P343, DOI 10.1007/s002940050405; Schmutte C, 1998, CANCER RES, V58, P4537; Schmutte C, 2001, J BIOL CHEM, V276, P33011, DOI 10.1074/jbc.M102670200; Sokolsky T, 2000, GENETICS, V155, P589; Tishkoff DX, 1997, P NATL ACAD SCI USA, V94, P7487, DOI 10.1073/pnas.94.14.7487; Tran HT, 1999, MOL CELL BIOL, V19, P2000; Tran PT, 2004, DNA REPAIR, V3, P1549, DOI 10.1016/j.dnarep.2004.05.015; Tran PT, 2002, DNA REPAIR, V1, P895, DOI 10.1016/S1568-7864(02)00114-3; Tran PT, 2001, P NATL ACAD SCI USA, V98, P9760, DOI 10.1073/pnas.161175998; Wei KC, 2003, GENE DEV, V17, P603, DOI 10.1101/gad.1060603; Wu Y, 2001, GASTROENTEROLOGY, V120, P1580, DOI 10.1053/gast.2001.25117; Yamamoto H, 2005, CARCINOGENESIS, V26, P411, DOI 10.1093/carcin/bgh335	29	27	28	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 20	2007	26	43					6297	6306		10.1038/sj.onc.1210453	http://dx.doi.org/10.1038/sj.onc.1210453			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	212GW	17452984				2022-12-28	WOS:000249583300006
J	Grifoni, D; Garoia, F; Bellosta, P; Parisi, F; De Biase, D; Collina, G; Strand, D; Cavicchi, S; Pession, A				Grifoni, D.; Garoia, F.; Bellosta, P.; Parisi, F.; De Biase, D.; Collina, G.; Strand, D.; Cavicchi, S.; Pession, A.			aPKC zeta cortical loading is associated with Lgl cytoplasmic release and tumor growth in Drosophila and human epithelia	ONCOGENE			English	Article						lethal giant larvae; Hugl-1; aPKC zeta; cell polarity; ovarian epithelial cancers; Drosophila	OVARIAN SURFACE EPITHELIUM; PROTEIN-KINASE-C; CELL POLARITY; SUPPRESSOR GENE; GIANT LARVAE; CANCER; EXPRESSION; COMPLEX; PROLIFERATION; HUGL-1	Atypical protein kinase C ( aPKC) and Lethal giant larvae ( Lgl) regulate apical-basal polarity in Drosophila and mammalian epithelia. At the apical domain, aPKC phosphorylates and displaces Lgl that, in turn, maintains aPKC inactive at the basolateral region. The mutual exclusion of these two proteins seems to be crucial for the correct epithelial structure and function. Here we show that a cortical aPKC loading induces Lgl cytoplasmic release and massive overgrowth in Drosophila imaginal epithelia, whereas a cytoplasmic expression does not alter proliferation and epithelial overall structure. As two aPKC isoforms ( iota and zeta) exist in humans and we previously showed that Drosophila Lgl is the functional homologue of the Human giant larvae-1 ( Hugl-1) protein, we argued if the same mechanism of mutual exclusion could be impaired in human epithelial disorders and investigated aPKC iota, aPKC zeta and Hugl-1 localization in cancers deriving from ovarian surface epithelium. Both in mucinous and serous histotypes, aPKC zeta showed an apical-to-cortical redistribution and Hugl-1 showed a membrane-to-cytoplasm release, perfectly recapitulating the Drosophila model. Although several recent works support a causative role for aPKCi overexpression in human carcinomas, our results suggest a key role for aPKC zeta in apical-basal polarity loosening, a mechanism that seems to be driven by changes in protein localization rather than in protein abundance.	Alma Mater Studiorum, Dipartimento Biol Evoluzionist Sperimentale, I-40126 Bologna, Italy; Alma Mater Studiorum, Dipartimento Patol Sperimentale, I-40126 Bologna, Italy; CUNY City Coll, Dept Biol, New York, NY 10031 USA; Univ Bologna, Osped Bellaria, Sez Anat Patol, Alma Mater Studiorum, I-40139 Bologna, Italy; Johannes Gutenberg Univ Mainz, Dept Internal Med 1, D-6500 Mainz, Germany	City University of New York (CUNY) System; City College of New York (CUNY); University of Bologna; Johannes Gutenberg University of Mainz	Grifoni, D (corresponding author), Alma Mater Studiorum, Dipartimento Biol Evoluzionist Sperimentale, Via Selmi 3, I-40126 Bologna, Italy.	daniela.grifoni@unibo.it	Garoia, Flavio/AAL-4528-2020; de Biase, Dario/B-9274-2012; Messier, Claude/A-2322-2008; Garoia, Flavio/AAW-1313-2020; Grifoni, Daniela/A-3954-2012; Bellosta, Paola/AAA-3413-2020; Pession, Annalisa/B-9014-2012	de Biase, Dario/0000-0002-0609-8817; Messier, Claude/0000-0002-4791-1763; Bellosta, Paola/0000-0003-1913-5661; GRIFONI, DANIELA/0000-0001-7429-4062; Garoia, Flavio/0000-0001-7849-0036; Pession, Annalisa/0000-0001-9035-9698				Auersperg N, 2001, ENDOCR REV, V22, P255, DOI 10.1210/er.22.2.255; Bell DA, 2005, MODERN PATHOL, V18, pS19, DOI 10.1038/modpathol.3800306; Betschinger J, 2005, CURR BIOL, V15, P276, DOI 10.1016/j.cub.2005.01.012; Bilder D, 2004, GENE DEV, V18, P1909, DOI 10.1101/gad.1211604; Bilder D, 2000, SCIENCE, V289, P113, DOI 10.1126/science.289.5476.113; BRAND AH, 1993, DEVELOPMENT, V118, P401; BRYANT PJ, 1990, J CELL SCI, P169; Chalmers AD, 2005, DEVELOPMENT, V132, P977, DOI 10.1242/dev.01645; Christiansen JJ, 2006, CANCER RES, V66, P8319, DOI 10.1158/0008-5472.CAN-06-0410; Eder AM, 2005, P NATL ACAD SCI USA, V102, P12519, DOI 10.1073/pnas.0505641102; Filip S, 2006, NEOPLASMA, V53, P87; Gibson MC, 2006, NATURE, V442, P1038, DOI 10.1038/nature05014; Grifoni D, 2004, ONCOGENE, V23, P8688, DOI 10.1038/sj.onc.1208023; Harris TJC, 2004, J CELL BIOL, V167, P135, DOI 10.1083/jcb.200406024; Humbert P, 2003, BIOESSAYS, V25, P542, DOI 10.1002/bies.10286; Hutterer A, 2004, DEV CELL, V6, P845, DOI 10.1016/j.devcel.2004.05.003; Katabuchi Hidetaka, 2003, Medical Electron Microscopy, V36, P74; Kovac J, 2007, GENE EXPR PATTERNS, V7, P187, DOI 10.1016/j.modgep.2006.07.002; Kuphal S, 2006, ONCOGENE, V25, P103, DOI 10.1038/sj.onc.1209008; Lee CY, 2006, NATURE, V439, P594, DOI 10.1038/nature04299; Manfruelli P, 1996, DEVELOPMENT, V122, P2283; Naora H, 2005, NAT REV CANCER, V5, P355, DOI 10.1038/nrc1611; Nelson WJ, 2003, NATURE, V422, P766, DOI 10.1038/nature01602; Okamura H, 2006, MICROSC RES TECHNIQ, V69, P469, DOI 10.1002/jemt.20306; Ong A, 2000, INT J CANCER, V85, P430, DOI 10.1002/(SICI)1097-0215(20000201)85:3<430::AID-IJC21>3.0.CO;2-Q; Pilot F, 2005, DEV DYNAM, V232, P685, DOI 10.1002/dvdy.20334; Plant PJ, 2003, NAT CELL BIOL, V5, P301, DOI 10.1038/ncb948; Polyak K, 2006, NAT MED, V12, P296, DOI 10.1038/nm1379; Queenan AM, 1997, DEVELOPMENT, V124, P3871; Regala RP, 2005, CANCER RES, V65, P8905, DOI 10.1158/0008-5472.CAN-05-2372; Rolls MM, 2003, J CELL BIOL, V163, P1089, DOI 10.1083/jcb.200306079; Sarrio D, 2006, HUM PATHOL, V37, P1042, DOI 10.1016/j.humpath.2006.03.003; Schimanski CC, 2005, ONCOGENE, V24, P3100, DOI 10.1038/sj.onc.1208520; Scott M, 2006, HISTOL HISTOPATHOL, V21, P81, DOI 10.14670/HH-21.81; Shin K, 2006, ANNU REV CELL DEV BI, V22, P207, DOI 10.1146/annurev.cellbio.22.010305.104219; SIEMENS CH, 1988, J CELL PHYSIOL, V134, P347, DOI 10.1002/jcp.1041340305; Sundfeldt K, 2003, MOL CELL ENDOCRINOL, V202, P89, DOI 10.1016/S0303-7207(03)00068-6; Suzuki A, 2006, J CELL SCI, V119, P979, DOI 10.1242/jcs.02898; Suzuki A, 2001, J CELL BIOL, V152, P1183, DOI 10.1083/jcb.152.6.1183; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Vanderhyden Barbara C, 2003, Reprod Biol Endocrinol, V1, P67, DOI 10.1186/1477-7827-1-67; Weinkove D, 2000, CURR OPIN GENET DEV, V10, P75, DOI 10.1016/S0959-437X(99)00042-8; Yamanaka T, 2003, CURR BIOL, V13, P734, DOI 10.1016/S0960-9822(03)00244-6; Yamanaka T, 2006, J CELL SCI, V119, P2107, DOI 10.1242/jcs.02938	44	63	69	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 30	2007	26	40					5960	5965		10.1038/sj.onc.1210389	http://dx.doi.org/10.1038/sj.onc.1210389			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	205OH	17369850	Green Published			2022-12-28	WOS:000249123100013
J	Wu, D; Zhau, HE; Huang, WC; Iqbal, S; Habib, FK; Sartor, O; Cvitanovic, L; Marshall, FF; Xu, Z; Chung, LWK				Wu, D.; Zhau, H. E.; Huang, W-C; Iqbal, S.; Habib, F. K.; Sartor, O.; Cvitanovic, L.; Marshall, F. F.; Xu, Z.; Chung, L. W. K.			cAMP-responsive element-binding protein regulates vascular endothelial growth factor expression: implication in human prostate cancer bone metastasis	ONCOGENE			English	Article						prostate cancer; bone metastasis; EMT; CREB; VEGF; HIF	EPITHELIAL-MESENCHYMAL TRANSITION; HYPOXIA-INDUCIBLE FACTOR-1; GENOME-WIDE ANALYSIS; TRANSCRIPTIONAL REGULATION; TUMOR PROGRESSION; CELLS; CREB; ACTIVATION; GENE; VEGF	Aberrant expression of vascular endothelial growth factor (VEGF) is associated with human prostate cancer (PCa) metastasis and poor clinical outcome. We found that both phosphorylation of cyclic AMP- responsive element- binding protein (CREB) and VEGF levels were significantly elevated in patient bone metastatic PCa specimens. A PCa ARCaP progression model demonstrating epithelial- to-mesenchymal transition exhibited increased CREB phosphorylation and VEGF expression as ARCaP cells became progressively more mesenchymal and bone- metastatic. Activation of CREB induced, whereas inhibition of CREB blocked, VEGF expression in ARCaP cells. CREB may regulate VEGF transcription via a hypoxia- inducible factor- dependent mechanism in normoxic conditions. Activation of CREB signaling is involved in the coordinated regulation of VEGF and may pre- dispose to PCa bone metastasis.	Emory Univ, Sch Med, Mol Urol & Therapeut Program, Dept Urol, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Winship Canc Inst, Atlanta, GA 30322 USA; Western Gen Hosp, Sch Mol & Clin Med, Div Oncol, Prostate Res Grp, Edinburgh EH4 2XU, Midlothian, Scotland; Harvard Univ, Sch Med, Dana Farber Canc Inst, Lank Ctr Genitourinary Oncol, Boston, MA 02115 USA; LSU, Ctr Hlth Sci, Stanley Scott Canc Ctr, New Orleans, LA USA	Emory University; Emory University; University of Edinburgh; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Wu, D (corresponding author), Emory Univ, Sch Med, Mol Urol & Therapeut Program, Dept Urol, 1365-B Clifton Rd,Suite 5100, Atlanta, GA 30322 USA.	dwu2@emory.edu; lwchung@emory.edu		Huang, William/0000-0001-5261-0650; , Shareen/0000-0002-9489-7781; Huang, Wen-Chin/0000-0003-2342-9099	NCI NIH HHS [R01 CA256058, PC060566, 1 R01 CA108468, PC040260, 1 P01 CA098912] Funding Source: Medline; NIGMS NIH HHS [5 P20 GM072069] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA108468, P01CA098912] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P20GM072069] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abramovitch R, 2004, CANCER RES, V64, P1338, DOI 10.1158/0008-5472.CAN-03-2089; Arany Z, 1996, P NATL ACAD SCI USA, V93, P12969, DOI 10.1073/pnas.93.23.12969; Arcinas M, 2001, CANCER RES, V61, P5202; Bates RC, 2003, CURR BIOL, V13, P1721, DOI 10.1016/j.cub.2003.09.002; Chen JH, 2004, CELL COMMUN ADHES, V11, P1, DOI 10.1080/15419060490471739; Chen TS, 1999, CANCER RES, V59, P213; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; CHUNG LWK, 1991, CANCER SURV, V11, P91; Dang DT, 2006, CANCER RES, V66, P1684, DOI 10.1158/0008-5472.CAN-05-2887; Deeble PD, 2001, MOL CELL BIOL, V21, P8471, DOI 10.1128/MCB.21.24.8471-8482.2001; DESDOUETS C, 1995, MOL CELL BIOL, V15, P3301; Duque JLF, 1999, UROLOGY, V54, P523, DOI 10.1016/S0090-4295(99)00167-3; Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669; Ferrer FA, 1998, UROLOGY, V51, P161, DOI 10.1016/S0090-4295(97)00491-3; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; George DJ, 2001, CLIN CANCER RES, V7, P1932; Huang WC, 2005, CANCER RES, V65, P2303, DOI 10.1158/0008-5472.CAN-04-3448; Huang WC, 2006, CANCER RES, V66, P9108, DOI 10.1158/0008-5472.CAN-06-1996; Huber MA, 2005, CURR OPIN CELL BIOL, V17, P548, DOI 10.1016/j.ceb.2005.08.001; Impey S, 2004, CELL, V119, P1041, DOI 10.1016/j.cell.2004.10.032; Jiang BH, 1997, J BIOL CHEM, V272, P19253, DOI 10.1074/jbc.272.31.19253; Johannessen M, 2004, CELL SIGNAL, V16, P1211, DOI 10.1016/j.cellsig.2004.05.001; Kallio PJ, 1999, J BIOL CHEM, V274, P6519, DOI 10.1074/jbc.274.10.6519; Kinjo K, 2005, CELL CYCLE, V4, P1134, DOI 10.4161/cc.4.9.1991; Kitagawa Y, 2005, CANCER RES, V65, P10921, DOI 10.1158/0008-5472.CAN-05-1809; Kong DH, 2005, CANCER RES, V65, P9047, DOI 10.1158/0008-5472.CAN-05-1235; Loots GG, 2004, NUCLEIC ACIDS RES, V32, pW217, DOI 10.1093/nar/gkh383; Mayr B, 2001, NAT REV MOL CELL BIO, V2, P599, DOI 10.1038/35085068; Melnikova VO, 2006, J BIOL CHEM, V281, P2911, DOI 10.1074/jbc.M508683200; Niu GL, 2002, ONCOGENE, V21, P2000, DOI 10.1038/sj.onc.1205260; Sabbah M, 1999, P NATL ACAD SCI USA, V96, P11217, DOI 10.1073/pnas.96.20.11217; Vo N, 2001, J BIOL CHEM, V276, P13505, DOI 10.1074/jbc.R000025200; Xu JC, 2006, PROSTATE, V66, P1664, DOI 10.1002/pros.20488; Yang AD, 2006, CANCER RES, V66, P46, DOI 10.1158/0008-5472.CAN-05-3086; Yang YM, 1996, ONCOGENE, V12, P2223; Zhang XM, 2005, P NATL ACAD SCI USA, V102, P4459, DOI 10.1073/pnas.0501076102; Zhau HYE, 1996, P NATL ACAD SCI USA, V93, P15152, DOI 10.1073/pnas.93.26.15152; Ziel KA, 2004, FASEB J, V18, P986, DOI 10.1096/fj.03-1160fje	38	110	114	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 2	2007	26	35					5070	5077		10.1038/sj.onc.1210316	http://dx.doi.org/10.1038/sj.onc.1210316			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	196MT	17310988				2022-12-28	WOS:000248487400005
J	Igarashi, T; Izumi, H; Uchiumi, T; Nishio, K; Arao, T; Tanabe, M; Uramoto, H; Sugio, K; Yasumoto, K; Sasaguri, Y; Wang, KY; Otsuji, Y; Kohno, K				Igarashi, T.; Izumi, H.; Uchiumi, T.; Nishio, K.; Arao, T.; Tanabe, M.; Uramoto, H.; Sugio, K.; Yasumoto, K.; Sasaguri, Y.; Wang, K. Y.; Otsuji, Y.; Kohno, K.			Clock and ATF4 transcription system regulates drug resistance in human cancer cell lines	ONCOGENE			English	Article						clock; ATF4; multidrug resistance; glutathione; chronotherapy	GAMMA-GLUTAMYLCYSTEINE SYNTHETASE; ADENOSINE-TRIPHOSPHATASE ATP7B; MRP/GS-X PUMP; MULTIDRUG-RESISTANCE; CISPLATIN RESISTANCE; TUMOR SUPPRESSION; STRESS-RESPONSE; DNA-REPAIR; EXPRESSION; BINDING	The mechanisms underlying cellular drug resistance have been extensively studied, but little is known about its regulation. We have previously reported that activating transcription factor 4 (ATF4) is upregulated in cisplatin-resistant cells and plays a role in cisplatin resistance. Here, we find out a novel relationship between the circadian transcription factor Clock and drug resistance. Clock drives the periodical expression of many genes that regulate hormone release, cell division, sleep-awake cycle and tumor growth. We demonstrate that ATF4 is a direct target of Clock, and that Clock is overexpressed in cisplatin-resistant cells. Furthermore, Clock expression significantly correlates with cisplatin sensitivity, and that the downregulation of either Clock or ATF4 confers sensitivity of A549 cells to cisplatin and etoposide. Notably, ATF4-overexpressing cells show multidrug resistance and marked elevation of intracellular glutathione. The microarray study reveals that genes for glutathione metabolism are generally downregulated by the knockdown of ATF4 expression. These results suggest that the Clock and ATF4 transcription system might play an important role in multidrug resistance through glutathione-dependent redox system, and also indicate that physiological potentials of Clock-controlled redox system might be important to better understand the oxidative stress-associated disorders including cancer and systemic chronotherapy.	Univ Occupat & Environm Hlth, Sch Med, Dept Mol Biol, Yahatanishi Ku, Kitakyushu, Fukuoka 8078555, Japan; Univ Occupat & Environm Hlth, Sch Med, Dept Internal Med 2, Kitakyushu, Fukuoka 8078555, Japan; Kinki Univ, Sch Med, Dept Genome Biol, Osaka 589, Japan; Univ Occupat & Environm Hlth, Sch Med, Dept Surg 2, Kitakyushu, Fukuoka 8078555, Japan; Univ Occupat & Environm Hlth, Sch Med, Dept Pathol 2, Kitakyushu, Fukuoka 8078555, Japan	University of Occupational & Environmental Health - Japan; University of Occupational & Environmental Health - Japan; Kindai University (Kinki University); University of Occupational & Environmental Health - Japan; University of Occupational & Environmental Health - Japan	Kohno, K (corresponding author), Univ Occupat & Environm Hlth, Sch Med, Dept Mol Biol, Yahatanishi Ku, 1-1 Iseigaoka, Kitakyushu, Fukuoka 8078555, Japan.	k-kohno@med.uoeh-u.ac.jp		wang, ke-yong/0000-0001-8295-1229				Annereau JP, 2004, MOL PHARMACOL, V66, P1397, DOI 10.1124/mol.104.005009; Arao T, 2006, INT J CANCER, V118, P483, DOI 10.1002/ijc.21340; Blais JD, 2004, MOL CELL BIOL, V24, P7469, DOI 10.1128/MCB.24.17.7469-7482.2004; Canaple L, 2003, CANCER RES, V63, P7545; Chaney SG, 1996, JNCI-J NATL CANCER I, V88, P1346, DOI 10.1093/jnci/88.19.1346; Cui YH, 1999, MOL PHARMACOL, V55, P929; Deeley RG, 2006, PHYSIOL REV, V86, P849, DOI 10.1152/physrev.00035.2005; Dickinson DA, 2002, BIOCHEM PHARMACOL, V64, P1019, DOI 10.1016/S0006-2952(02)01172-3; Fawcett TW, 1999, BIOCHEM J, V339, P135, DOI 10.1042/0264-6021:3390135; Fojo T, 2003, ONCOGENE, V22, P7512, DOI 10.1038/sj.onc.1206951; Fu LN, 2002, CELL, V111, P41, DOI 10.1016/S0092-8674(02)00961-3; FUJII R, 1994, JPN J CANCER RES, V85, P426, DOI 10.1111/j.1349-7006.1994.tb02376.x; Gekakis N, 1998, SCIENCE, V280, P1564, DOI 10.1126/science.280.5369.1564; Gorbacheva VY, 2005, P NATL ACAD SCI USA, V102, P3407, DOI 10.1073/pnas.0409897102; Gottesman MM, 2002, NAT REV CANCER, V2, P48, DOI 10.1038/nrc706; Harding HP, 2003, MOL CELL, V11, P619, DOI 10.1016/S1097-2765(03)00105-9; Husain A, 1998, CANCER RES, V58, P1120; Ishikawa T, 1996, J BIOL CHEM, V271, P14981, DOI 10.1074/jbc.271.25.14981; Kohno K, 2005, EUR J CANCER, V41, P2577, DOI 10.1016/j.ejca.2005.08.007; Komatsu M, 2000, CANCER RES, V60, P1312; Krishnamurthy P, 2006, ANNU REV PHARMACOL, V46, P381, DOI 10.1146/annurev.pharmtox.46.120604.141238; Kuo MT, 1998, BIOCHEM PHARMACOL, V55, P605, DOI 10.1016/S0006-2952(97)00494-2; Kusaba H, 1999, EUR J BIOCHEM, V262, P924, DOI 10.1046/j.1432-1327.1999.00469.x; LAI GM, 1989, JNCI-J NATL CANCER I, V81, P535, DOI 10.1093/jnci/81.7.535; Lee C, 2001, CELL, V107, P855, DOI 10.1016/S0092-8674(01)00610-9; Liebermann DA, 2002, LEUKEMIA, V16, P527, DOI 10.1038/sj.leu.2402477; Masuoka HC, 2002, BLOOD, V99, P736, DOI 10.1182/blood.V99.3.736; Moore RY, 1997, ANNU REV MED, V48, P253, DOI 10.1146/annurev.med.48.1.253; Murakami T, 2001, INT J CANCER, V93, P869, DOI 10.1002/ijc.1418; Nakayama K, 2002, INT J CANCER, V101, P488, DOI 10.1002/ijc.10608; Ohga T, 1996, CANCER RES, V56, P4224; Renes J, 2000, DRUG RESIST UPDATE, V3, P289, DOI 10.1054/drup.2000.0156; Rutkowski DT, 2003, DEV CELL, V4, P442, DOI 10.1016/S1534-5807(03)00100-X; Rutter J, 2001, SCIENCE, V293, P510, DOI 10.1126/science.1060698; SABURI Y, 1989, CANCER RES, V49, P7020; Szakacs G, 2006, NAT REV DRUG DISCOV, V5, P219, DOI 10.1038/nrd1984; TAKANO H, 1992, ANTI-CANCER DRUG, V3, P323, DOI 10.1097/00001813-199208000-00002; Tanabe M, 2003, CANCER RES, V63, P8592; TEW KD, 1994, CANCER RES, V54, P4313; Tipnis SR, 1999, BIOCHEM J, V337, P559, DOI 10.1042/0264-6021:3370559; Torigoe Takayuki, 2005, Current Medicinal Chemistry - Anti-Cancer Agents, V5, P15, DOI 10.2174/1568011053352587; Uramoto H, 2002, J BIOL CHEM, V277, P31694, DOI 10.1074/jbc.M200266200; Wang D, 2005, NAT REV DRUG DISCOV, V4, P307, DOI 10.1038/nrd1691; Yang XG, 2004, CELL, V117, P387, DOI 10.1016/S0092-8674(04)00344-7; YAO KS, 1995, CANCER RES, V55, P4367; Yoshida A, 2006, CANCER RES, V66, P5772, DOI 10.1158/0008-5472.CAN-05-3916	46	108	113	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 19	2007	26	33					4749	4760		10.1038/sj.onc.1210289	http://dx.doi.org/10.1038/sj.onc.1210289			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	191ZL	17297441				2022-12-28	WOS:000248170400001
J	Chlenski, A; Guerrero, LJ; Yang, Q; Tian, Y; Peddinti, R; Salwen, HR; Cohn, SL				Chlenski, A.; Guerrero, L. J.; Yang, Q.; Tian, Y.; Peddinti, R.; Salwen, H. R.; Cohn, S. L.			SPARC enhances tumor stroma formation and prevents fibroblast activation	ONCOGENE			English	Article						tumor stroma; activated fibroblast; SPARC; tumor microenvironment	GRANULATION-TISSUE; CELL-PROLIFERATION; ENDOTHELIAL-CELLS; GROWTH; EXPRESSION; CARCINOMA; ANGIOGENESIS; GLYCOPROTEIN; MYOFIBROBLASTS; TUMORIGENESIS	Tumor growth is influenced by interactions between malignant cells and the tumor stroma. Although the normal host microenvironment is nonpermissive for neoplastic progression, tumor-reactive stroma, characterized by the presence of activated fibroblasts, promotes neoplastic growth and metastasis. Secreted protein, acidic and rich in cysteine (SPARC) is a matricellular glycoprotein that is capable of inhibiting the growth of several different types of cancer. Recently, we reported that SPARC also impairs the growth of xenografts comprised of 293 cells. In this study, we show that in addition to enhancing stroma formation, SPARC prevents fibroblast activation in 293 xenografts, suggesting that the anticancer effects of SPARC may be due, at least in part, to the formation of tumor stroma that is not supportive of tumor growth. In vitro, 3T3 fibroblasts cocultured with SPARC-transfected 293 cells remain negative for alpha-smooth muscle actin, whereas wild-type 293 cells induce fibroblast activation. Moreover, activation of 3T3 cells and primary fibroblasts by transforming growth factor beta is blocked by SPARC treatment. We also demonstrate that SPARC significantly increases basic fibroblast growth factor-induced fibroblast migration in vitro, indicating that it may recruit host fibroblasts to the tumor stroma. Taken together, our results suggest that in addition to blocking angiogenesis, SPARC may inhibit tumor growth by promoting the assembly of stroma that is nonpermissive for tumor progression.	Univ Chicago, Inst Mol Pediat Sci, Div Clin Sci, Chicago, IL 60637 USA; Robert H Lurie Comprehens Canc Ctr, Chicago, IL USA; Northwestern Univ, Feinberg Sch Med, Dept Pediat, Chicago, IL USA	University of Chicago; Ann & Robert H. Lurie Children's Hospital of Chicago; Robert H. Lurie Comprehensive Cancer Center; Northwestern University; Feinberg School of Medicine	Cohn, SL (corresponding author), Univ Chicago, Inst Mol Pediat Sci, Div Clin Sci, 5841 Maryland Ave,MC 4060,Rm N114, Chicago, IL 60637 USA.	scohn@peds.bsd.uchicago.edu	Cohn, Susan/AAB-6010-2021	Cohn, Susan/0000-0001-5749-7650; , Qiwei Yang/0000-0001-7131-8946	NCI NIH HHS [5P30CA60553] Funding Source: Medline; NINDS NIH HHS [NS 049814] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA060553] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS049814] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ARRICK BA, 1992, J CELL BIOL, V118, P715, DOI 10.1083/jcb.118.3.715; Barker TH, 2005, J BIOL CHEM, V280, P36483, DOI 10.1074/jbc.M504663200; Beacham DA, 2005, SEMIN CANCER BIOL, V15, P329, DOI 10.1016/j.semcancer.2005.05.003; Bradshaw AD, 2001, J CLIN INVEST, V107, P1049, DOI 10.1172/JCI12939; Brekken RA, 2003, J CLIN INVEST, V111, P487, DOI 10.1172/JCI200316804; Chlenski A, 2006, INT J CANCER, V118, P310, DOI 10.1002/ijc.21357; Chlenski A, 2002, CANCER RES, V62, P7357; DESMOULIERE A, 1993, J CELL BIOL, V122, P103, DOI 10.1083/jcb.122.1.103; Framson PE, 2004, J CELL BIOCHEM, V92, P679, DOI 10.1002/jcb.20091; Francki A, 2004, J CELL BIOCHEM, V91, P915, DOI 10.1002/jcb.20008; FUNK SE, 1991, P NATL ACAD SCI USA, V88, P2648, DOI 10.1073/pnas.88.7.2648; FUNK SE, 1993, J CELL PHYSIOL, V154, P53, DOI 10.1002/jcp.1041540108; GABBIANI G, 1971, EXPERIENTIA, V27, P549, DOI 10.1007/BF02147594; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hamid T, 2005, MOL CANCER, V4, DOI 10.1186/1476-4598-4-3; Kalluri R, 2006, NAT REV CANCER, V6, P392, DOI 10.1038/nrc1877; Liu SQ, 2005, AM J PATHOL, V166, P891, DOI 10.1016/S0002-9440(10)62309-7; Maeshima AM, 2002, CANCER, V95, P2546, DOI 10.1002/cncr.11006; Meyerhardt JA, 2005, NEW ENGL J MED, V352, P476, DOI 10.1056/NEJMra040958; Motamed K, 2002, J CELL BIOCHEM, V84, P759, DOI 10.1002/jcb.10095; Mueller MM, 2004, NAT REV CANCER, V4, P839, DOI 10.1038/nrc1477; Olumi AF, 1999, CANCER RES, V59, P5002; Orimo A, 2005, CELL, V121, P335, DOI 10.1016/j.cell.2005.02.034; Paget S, 1989, LANCET, V8, P98, DOI [DOI 10.1016/S0140-6736(00)49915-0, 10.1016/S0140-6736(00)49915-0]; Perdue N, 2006, EXP EYE RES, V83, P1154, DOI 10.1016/j.exer.2006.06.007; Pichler RH, 1996, AM J PATHOL, V148, P1153; Powell DW, 1999, AM J PHYSIOL-CELL PH, V277, pC1, DOI 10.1152/ajpcell.1999.277.1.C1; ROSEN ST, 1987, LAB INVEST, V56, P302; SAGE H, 1984, J BIOL CHEM, V259, P3993; Schiemann BJ, 2003, MOL BIOL CELL, V14, P3977, DOI 10.1091/mbc.E03-01-0001; Skobe M, 1997, NAT MED, V3, P1222, DOI 10.1038/nm1197-1222; STRUTZ F, 1995, J CELL BIOL, V130, P393, DOI 10.1083/jcb.130.2.393; Wilkes MC, 2005, CANCER RES, V65, P10431, DOI 10.1158/0008-5472.CAN-05-1522; Yan Q, 1999, J HISTOCHEM CYTOCHEM, V47, P1495, DOI 10.1177/002215549904701201; Yazhou C, 2004, TUMOR BIOL, V25, P290, DOI 10.1159/000081394	35	36	38	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2007	26	31					4513	4522		10.1038/sj.onc.1210247	http://dx.doi.org/10.1038/sj.onc.1210247			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	187GR	17260013				2022-12-28	WOS:000247836100005
J	Shimokawa, T; Svard, J; Heby-Henricson, K; Teglund, S; Toftgard, R; Zaphiropoulos, PG				Shimokawa, T.; Svard, J.; Heby-Henricson, K.; Teglund, S.; Toftgard, R.; Zaphiropoulos, P. G.			Distinct roles of first exon variants of the tumor-suppressor Patched1 in Hedgehog signaling	ONCOGENE			English	Article						alternative splicing; GLI; post-transcriptional regulation	BASAL-CELL CARCINOMA; SONIC HEDGEHOG; TRANSCRIPTIONAL ACTIVITY; HUMAN HOMOLOG; HUMAN GLI2; GENE; PATHWAY; PTCH2; EXPRESSION; PROTEIN	Patched1 (PTCH1) is one of the key molecules involved in the Hedgehog (HH) signaling pathway and acts as the receptor of HH ligands. Additionally, PTCH1 inhibits the positive signal transductor Smoothened (SMO). Several PTCH1 splice variants are known but the functional differences among them are not clear. Here, we demonstrate the unique biological properties of the PTCH1 isoforms generated by alternative. rst exon usage. All isoforms examined worked as functional receptors of both Sonic HH and Dese rt HH. However, the signaling upregulated isoform s PTCH1-1B and-1C inhibited SMO and the pathway transcription factors glioma 1 (GLI1) andGL I2 to a higher extent than PTCH1-1 and-1Ckid. Moreover, in situ hybridizations allowed the detection of the Ptch1 isoforms in speci. fic structures of the developing mouse embryo. Additionally, the differences in the N-terminal tail had a dramatic in. uence on the steady states of the proteins, with PTCH1-1B and-1C levels being signifi. cantly higher than PTCH1-1 and-1Ckid. This implies that the pronounced signaling inhibitory properties of PTCH1-1B and-1C may be mostly due to this high-protein expression rather than to intrinsic functional differences. Thus, our study supports a role of splicing variation and prom oter choice for HH signaling regulation.	Karolinska Inst, Dept biosci & Nutr, S-14157 Huddinge, Sweden	Karolinska Institutet	Shimokawa, T (corresponding author), Karolinska Inst, Dept biosci & Nutr, S-14157 Huddinge, Sweden.	Tash@biosci.ki.se; peza@cnt.ki.se	Shimokawa, Takashi/AAA-5870-2020	Shimokawa, Takashi/0000-0001-6549-9277; Zaphiropoulos, Peter/0000-0003-4298-3861				Agren M, 2004, GENE, V330, P101, DOI 10.1016/j.gene.2004.01.010; Bai CB, 2002, DEVELOPMENT, V129, P4753; Carninci P, 2006, NAT GENET, V38, P626, DOI 10.1038/ng1789; Carpenter D, 1998, P NATL ACAD SCI USA, V95, P13630, DOI 10.1073/pnas.95.23.13630; Eichberger T, 2006, GENOMICS, V87, P616, DOI 10.1016/j.ygeno.2005.12.003; Goodrich LV, 1997, SCIENCE, V277, P1109, DOI 10.1126/science.277.5329.1109; Hahn H, 1996, CELL, V85, P841, DOI 10.1016/S0092-8674(00)81268-4; Hahn H, 1996, J BIOL CHEM, V271, P12125, DOI 10.1074/jbc.271.21.12125; Hahn H, 1998, NAT MED, V4, P619, DOI 10.1038/nm0598-619; Hughes TA, 2006, TRENDS GENET, V22, P119, DOI 10.1016/j.tig.2006.01.001; Johnson RL, 1996, SCIENCE, V272, P1668, DOI 10.1126/science.272.5268.1668; Kalderon D, 2005, BIOCHEM SOC T, V33, P1509, DOI 10.1042/BST0331509; Kampa D, 2004, GENOME RES, V14, P331, DOI 10.1101/gr.2094104; Kogerman P, 2002, ONCOGENE, V21, P6007, DOI 10.1038/sj.onc.1205865; Lee Y, 2006, CANCER RES, V66, P6964, DOI 10.1158/0008-5472.CAN-06-0505; Liu W, 2002, DEV BIOL, V248, P240, DOI 10.1006/dbio.2002.0733; Motoyama J, 1998, NAT GENET, V18, P104, DOI 10.1038/ng0298-104; Nagao K, 2005, GENOMICS, V85, P462, DOI 10.1016/j.ygeno.2004.11.014; Nybakken K, 2005, NAT GENET, V37, P1323, DOI 10.1038/ng1682; Rahnama F, 2006, BIOCHEM J, V394, P19, DOI 10.1042/BJ20050941; Rahnama F, 2004, BIOCHEM J, V378, P325, DOI 10.1042/BJ20031200; Roessler E, 2005, HUM MOL GENET, V14, P2181, DOI 10.1093/hmg/ddi222; Sanchez P, 2004, P NATL ACAD SCI USA, V101, P12561, DOI 10.1073/pnas.0404956101; Shimokawa T, 2004, FEBS LETT, V578, P157, DOI 10.1016/j.febslet.2004.11.006; Smyth I, 1998, HUM GENET, V102, P598, DOI 10.1007/s004390050747; Smyth I, 1999, HUM MOL GENET, V8, P291, DOI 10.1093/hmg/8.2.291; Speek M, 2006, BMC MOL BIOL, V7, DOI 10.1186/1471-2199-7-13; Svard J, 2006, DEV CELL, V10, P187, DOI 10.1016/j.devcel.2005.12.013; Uchikawa H, 2006, BIOCHEM BIOPH RES CO, V349, P277, DOI 10.1016/j.bbrc.2006.08.046; Wang XQ, 2001, J BIOL CHEM, V276, P1311, DOI 10.1074/jbc.M005191200; Zaphiropoulos PG, 1999, CANCER RES, V59, P787	31	19	20	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2007	26	34					4889	4896		10.1038/sj.onc.1210301	http://dx.doi.org/10.1038/sj.onc.1210301			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	194CV	17310997				2022-12-28	WOS:000248322500001
J	Appierto, V; Villani, MG; Cavadini, E; Gariboldi, M; De Cecco, L; Pierotti, MA; Lambert, JR; Reid, J; Tiberio, P; Colombo, N; Formelli, F				Appierto, V.; Villani, M. G.; Cavadini, E.; Gariboldi, M.; De Cecco, L.; Pierotti, M. A.; Lambert, J. R.; Reid, J.; Tiberio, P.; Colombo, N.; Formelli, F.			Analysis of gene expression identifies PLAB as a mediator of the apoptotic activity of fenretinide in human ovarian cancer cells	ONCOGENE			English	Article						4-HPR; retinoids; PLAB; ovarian cancer; cDNA microarray	LUNG-CARCINOMA CELLS; DRUG-ACTIVATED GENE; TUMOR AGGRESSIVENESS; RANDOMIZED-TRIAL; INDUCTION; P53; N-(4-HYDROXYPHENYL)RETINAMIDE; LINES; 4-OXO-FENRETINIDE; ASSOCIATION	Fenretinide ( 4-HPR) is a synthetic retinoid with antitumor activity, which induces apoptosis in cancer cell lines of different histotypes. To identify genes contributing to its apoptotic activity in ovarian cancer cells, we monitored, by cDNA arrays, gene expression changes after 4-HPR exposure in A2780, a human ovarian carcinoma cell line sensitive to the retinoid. Among the differentially expressed transcripts, PLAcental Bone morphogenetic protein ( PLAB), a proapoptotic gene, was the most highly induced. In a panel of ovarian carcinoma cell lines with different 4-HPR sensitivities, PLAB upregulation was associated with cellular response to 4-HPR, its overexpression increased basal apoptosis and its silencing by small interfering RNA decreased the ability of 4-HPR to induce apoptosis. PLAB induction by 4-HPR was p53- and EGR-1 independent and was regulated, at least in part, by increased stability of PLAB mRNA. PLAB up-modulation by 4-HPR also occurred in vivo: in ascitic cells collected from patients with ovarian cancer before and after 4-HPR treatment, PLAB was upmodulated in 2/4 patients. Our results in certain ovarian cancer cell lines indicate a role for PLAB as a mediator of 4-HPR-induced apoptosis. The correlation of increased PLAB in vivo with antitumor activity remains to be established.	Ist Nazl Tumori, Dept Expt Oncol, I-20133 Milan, Italy; Fdn Ist FIRC Oncol Mol, Mol Canc Genet Grp, Milan, Italy; Univ Colorado, Dept Pathol, Denver, CO 80202 USA; Hlth Sci Ctr, Aurora, CO USA; Univ Milano Bicocca, Div Gynecol Oncol, European Inst Oncol, Milan, Italy	Fondazione IRCCS Istituto Nazionale Tumori Milan; IFOM - FIRC Institute of Molecular Oncology; University of Colorado System; University of Colorado Denver; IRCCS European Institute of Oncology (IEO); University of Milano-Bicocca	Formelli, F (corresponding author), Ist Nazl Tumori, Dept Expt Oncol, Via Venezian 1, I-20133 Milan, Italy.	franca.formelli@istitutotumori.mi.it	Appierto, Valentina/B-9325-2017; De Cecco, Loris/K-7036-2016; Pierotti, Marco Alessandro/AAC-4728-2022; Colombo, Nicoletta/AAB-8319-2019; Gariboldi, Manuela/K-4744-2016	Appierto, Valentina/0000-0002-8726-6981; De Cecco, Loris/0000-0002-7066-473X; Pierotti, Marco Alessandro/0000-0002-7431-8332; Gariboldi, Manuela/0000-0001-8406-165X; Reid, James/0000-0001-6997-2850				Albertoni M, 2002, ONCOGENE, V21, P4212, DOI 10.1038/sj.onc.1205610; Appierto V, 2004, CELL DEATH DIFFER, V11, P270, DOI 10.1038/sj.cdd.4401349; Appierto V, 2001, BRIT J CANCER, V84, P1528, DOI 10.1054/bjoc.2001.1826; Baek SJ, 2006, PROG LIPID RES, V45, P1, DOI 10.1016/j.plipres.2005.10.001; Baek SJ, 2002, CARCINOGENESIS, V23, P425, DOI 10.1093/carcin/23.3.425; Balmer JE, 2002, J LIPID RES, V43, P1773, DOI 10.1194/jlr.R100015-JLR200; Chiesa F, 2005, INT J CANCER, V115, P625, DOI 10.1002/ijc.20923; Clifford JL, 1999, CANCER RES, V59, P14; Colombo N, 2006, CANCER EPIDEM BIOMAR, V15, P1914, DOI 10.1158/1055-9965.EPI-06-0183; Cui WC, 2001, MOL BIOL REP, V28, P123, DOI 10.1023/A:1015288412047; De Cecco L, 2004, ONCOGENE, V23, P8171, DOI 10.1038/sj.onc.1207979; De Palo G, 2002, GYNECOL ONCOL, V86, P24, DOI 10.1006/gyno.2002.6663; DZIADEK M, 1985, DEV BIOL, V111, P372, DOI 10.1016/0012-1606(85)90491-9; FORMELLI F, 1993, CANCER RES, V53, P5374; Garaventa A, 2003, CLIN CANCER RES, V9, P2032; Hail N, 2001, J BIOL CHEM, V276, P45614, DOI 10.1074/jbc.M106559200; Hosack DA, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-10-r70; Kadara H, 2006, CANCER BIOL THER, V5, P518, DOI 10.4161/cbt.5.5.2602; Lovat PE, 2004, ANN NY ACAD SCI, V1028, P81, DOI 10.1196/annals.1322.009; Lu XH, 2001, CLIN CANCER RES, V7, P2114; Ma Y, 2003, ONCOGENE, V22, P4924, DOI 10.1038/sj.onc.1206728; Modlich O, 2004, CLIN CANCER RES, V10, P6418, DOI 10.1158/1078-0432.CCR-04-1031; Myatt SS, 2005, CLIN CANCER RES, V11, P3136, DOI 10.1158/1078-0432.CCR-04-2050; Nagy L, 1998, CELL DEATH DIFFER, V5, P11, DOI 10.1038/sj.cdd.4400337; Newman D, 2003, MOL PHARMACOL, V63, P557, DOI 10.1124/mol.63.3.557; OConnor PM, 1997, CANCER RES, V57, P4285; PELLEGRINI R, 1995, CELL GROWTH DIFFER, V6, P863; Perego P, 1996, CANCER RES, V56, P556; Prinetti A, 2003, J BIOL CHEM, V278, P5574, DOI 10.1074/jbc.M207269200; Sharma A, 2005, GYNECOL ONCOL, V99, P58, DOI 10.1016/j.ygyno.2005.05.024; Shishodia S, 2005, CANCER RES, V65, P9555, DOI 10.1158/0008-5472.CAN-05-1585; SKEHAN P, 1990, J NATL CANCER I, V82, P1107, DOI 10.1093/jnci/82.13.1107; Supino R, 1996, INT J CANCER, V65, P491, DOI 10.1002/(SICI)1097-0215(19960208)65:4<491::AID-IJC17>3.0.CO;2-D; Tsai MS, 2002, ONCOGENE, V21, P964, DOI 10.1038/sj/onc/1205131; Veronesi U, 2006, ANN ONCOL, V17, P1065, DOI 10.1093/annonc/mdl047; Veronesi U, 1999, J NATL CANCER I, V91, P1847, DOI 10.1093/jnci/91.21.1847; Villani MG, 2006, CANCER RES, V66, P3238, DOI 10.1158/0008-5472.CAN-05-3362; Villani MG, 2004, CLIN CANCER RES, V10, P6265, DOI 10.1158/1078-0432.CCR-04-0655; Wang HT, 2001, CANCER RES, V61, P5102; Wei JS, 2005, ONCOGENE, V24, P7976, DOI 10.1038/sj.onc.1208947; Zhao Q, 2004, LEUKEMIA, V18, P285, DOI 10.1038/sj.leu.2403226	41	15	17	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 7	2007	26	27					3952	3962		10.1038/sj.onc.1210171	http://dx.doi.org/10.1038/sj.onc.1210171			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	177HP	17213814				2022-12-28	WOS:000247144500005
J	Inoue, K; Mallakin, A; Frazier, DP				Inoue, K.; Mallakin, A.; Frazier, D. P.			Dmp1 and tumor suppression	ONCOGENE			English	Review						Dmp1; cyclin D; arf; p53; Ras; haplo-insufficiency	D-TYPE CYCLINS; TRANSCRIPTION FACTOR DMP1; DEPENDENT-KINASE; GENE-EXPRESSION; LEUKEMIC-CELLS; BREAST-CANCER; PROTEIN HDMP1; ARF; P53; MYB	Dmp1 (cyclin D binding myb-like protein 1; also called Dmtf1) is a transcription factor that was isolated in a yeast two-hybrid screen through its binding property to cyclin D2. Although it was initially predicted to be involved in the cyclin D-Rb pathway, overexpression of Dmp1 in primary cells induces cell cycle arrest in an Arf, p53-dependent fashion. Dmp1 is a unique Arf regulator, the promoter of which is activated by oncogenic Ras-Raf signaling. Dmp1 expression is repressed by physiological mitogenic stimuli as well as by overexpressed E2F proteins; thus, it is a novel marker of cells that have exited from the cell cycle. Spontaneous and oncogene-induced tumor formation is accelerated in both Dmp1(+/-) and Dmp1(-/-) mice; the Dmp1(+/-) tumors often retain and express the wild-type allele; thus, Dmp1 is haplo-insufficient for tumor suppression. Tumors from Dmp1(+/-) and Dmp1(+/-) mice often retain wild-type Arf and p53, suggesting that Dmp1 is a physiological regulator of the Arf-p53 pathway. The human DMP1 (hDMP1) gene is located on chromosome 7q21, the locus of which is often deleted in myeloid leukemia and also in some types of solid tumors. Post-translational modication of Dmp1 and its role in human malignancy remain to be investigated.	Wake Forest Univ Hlth Sci, Dept Pathol, Winston Salem, NC 27157 USA; Wake Forest Univ Hlth Sci, Dept Canc Biol, Winston Salem, NC 27157 USA	Wake Forest University; Wake Forest University School of Medicine; Wake Forest University; Wake Forest University School of Medicine	Inoue, K (corresponding author), Wake Forest Univ Hlth Sci, Dept Pathol, 2102 Gray Bldg,Med Ctr Blvd, Winston Salem, NC 27157 USA.	kinoue@wfubmc.edu			NCI NIH HHS [R01 CA106314, R01 CA106314-02, 5R01CA106314, R01 CA106314-03, R01 CA106314-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA106314] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aslanian A, 2004, GENE DEV, V18, P1413, DOI 10.1101/gad.1196704; Bernards R, 1999, BBA-REV CANCER, V1424, pM17, DOI 10.1016/S0304-419X(99)00024-4; BIECHE I, 1992, LANCET, V339, P139, DOI 10.1016/0140-6736(92)90208-K; Bodner SM, 1999, GENE, V229, P223, DOI 10.1016/S0378-1119(98)00591-5; Brooksbank C, 2001, NAT REV CANCER, V1, P174, DOI 10.1038/35106021; Calin GA, 2006, SEMIN ONCOL, V33, P167, DOI 10.1053/j.seminoncol.2006.01.010; Cheng MG, 1998, P NATL ACAD SCI USA, V95, P1091, DOI 10.1073/pnas.95.3.1091; Cimmino A, 2005, P NATL ACAD SCI USA, V102, P13944, DOI 10.1073/pnas.0506654102; Crowe DL, 2001, NUCLEIC ACIDS RES, V29, P2789, DOI 10.1093/nar/29.13.2789; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Eischen CM, 1999, GENE DEV, V13, P2658, DOI 10.1101/gad.13.20.2658; Elmaagacli AH, 2005, HAEMATOLOGICA, V90, P326; EVERS R, 1995, P NATL ACAD SCI USA, V92, P5827, DOI 10.1073/pnas.92.13.5827; Ganter B, 1998, EMBO J, V17, P255, DOI 10.1093/emboj/17.1.255; Giacinti C, 2006, ONCOGENE, V25, P5220, DOI 10.1038/sj.onc.1209615; Hirai H, 1996, MOL CELL BIOL, V16, P6457; Horstmann S, 2000, ONCOGENE, V19, P298, DOI 10.1038/sj.onc.1203302; Inoue K, 1997, BLOOD, V89, P1405, DOI 10.1182/blood.V89.4.1405; Inoue K, 1998, BLOOD, V91, P2969, DOI 10.1182/blood.V91.8.2969.2969_2969_2976; INOUE K, 1994, BLOOD, V84, P3071, DOI 10.1182/blood.V84.9.3071.3071; Inoue K, 1999, P NATL ACAD SCI USA, V96, P3993, DOI 10.1073/pnas.96.7.3993; Inoue K, 2001, GENE DEV, V15, P2934, DOI 10.1101/gad.929901; Inoue K, 2000, GENE DEV, V14, P1797; Inoue K, 1998, J BIOL CHEM, V273, P29188, DOI 10.1074/jbc.273.44.29188; Inoue K, 1998, MOL CELL BIOL, V18, P1590, DOI 10.1128/MCB.18.3.1590; Kamijo T, 1999, CANCER RES, V59, P2217; Kerr J, 1996, ONCOGENE, V13, P1815; Kim WY, 2006, CELL, V127, P265, DOI 10.1016/j.cell.2006.10.003; Kiriakidou M, 2004, GENE DEV, V18, P1165, DOI 10.1101/gad.1184704; Landis MW, 2006, CANCER CELL, V9, P13, DOI 10.1016/j.ccr.2005.12.019; Lin AW, 1998, GENE DEV, V12, P3008, DOI 10.1101/gad.12.19.3008; Lu Z, 2006, ONCOGENE, V25, P230, DOI 10.1038/sj.onc.1209025; Mallakin A, 2006, ONCOGENE, V25, P7703, DOI 10.1038/sj.onc.1209750; McMahon M, 2001, BBA-REV CANCER, V1471, pM63, DOI 10.1016/S0304-419X(00)00027-5; Oh IH, 1999, ONCOGENE, V18, P3017, DOI 10.1038/sj.onc.1202839; Palmero I, 2002, ONCOGENE, V21, P2939, DOI 10.1038/sj/onc/1205371; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; Quon KC, 2001, GENE DEV, V15, P2917, DOI 10.1101/gad.949001; Rowland BD, 2002, CANCER CELL, V2, P55, DOI 10.1016/S1535-6108(02)00085-5; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sherr CJ, 2006, NAT REV CANCER, V6, P663, DOI 10.1038/nrc1954; Sherr CJ, 2004, GENE DEV, V18, P2699, DOI 10.1101/gad.1256504; Sherr CJ, 2000, CANCER RES, V60, P3689; Sherr CJ, 2001, NAT REV MOL CELL BIO, V2, P731, DOI 10.1038/35096061; Sreeramaneni R, 2005, MOL CELL BIOL, V25, P220, DOI 10.1128/MCB.25.1.220-232.2005; Trovato M, 2004, ENDOCR-RELAT CANCER, V11, P365, DOI 10.1677/erc.0.0110365; Tschan MP, 2003, J BIOL CHEM, V278, P42750, DOI 10.1074/jbc.M307067200; Yamagami T, 1996, BLOOD, V87, P2878, DOI 10.1182/blood.V87.7.2878.bloodjournal8772878; Zwijsen RML, 1997, CELL, V88, P405, DOI 10.1016/S0092-8674(00)81879-6	49	45	46	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN	2007	26	30					4329	4335		10.1038/sj.onc.1210226	http://dx.doi.org/10.1038/sj.onc.1210226			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	184CZ	17237816	Green Accepted			2022-12-28	WOS:000247620000001
J	Li, B; Smith, CC; Laing, JM; Gober, MD; Liu, L; Aurelian, L				Li, B.; Smith, C. C.; Laing, J. M.; Gober, M. D.; Liu, L.; Aurelian, L.			Overload of the heat-shock protein H11/HspB8 triggers melanoma cell apoptosis through activation of transforming growth factor-beta-activated kinase 1	ONCOGENE			English	Article						H11/HspB8; heat shock protein; melanoma; apoptosis/growth arrest; TAK1; beta-catenin	CHAPERONE-LIKE ACTIVITY; PROSTATE-CANCER CELLS; TRANSCRIPTION FACTOR; DNA METHYLATION; BETA-CATENIN; RIBONUCLEOTIDE REDUCTASE; MALIGNANT-MELANOMA; EXPRESSION; KINASE; PATHWAY	Molecular therapeutics is a recognized promising approach for melanoma, but relevant target genes remain elusive. We report that overload of the recently cloned H11/HspB8 induces apoptosis in 55% of examined melanoma cultures. Apoptosis was determined by activation of caspases-9 and -3 and terminal deoxynucleotidyl-transferase-mediated dUTP nick end labeling (TUNEL), and was not seen in normal melanocytes. It was associated with H11/HspB8 complexation with transforming growth factor-beta-activated kinase (TAK) 1 and activation of TAK1 and p38 mitogen activated protein 3 kinases. TAK1 was not bound, nor activated by the H11/HspB8 mutant W51C, which has dominant antiapoptotic activity. beta-Catenin was phosphorylated by activated TAK1, inhibiting its nuclear accumulation and mictophthalmia-associated transcription factor and cyclin dependent kinase 2 expression. The dominant-negative TAK1 mutant K63W inhibited beta-catenin phosphorylation and caspase activation. The data indicate that H11/HspB8 overload causes melanoma growth arrest and apoptosis through TAK1 activation and suggest that H11/HspB8 is a promising molecular therapy target.	Univ Maryland, Virol Immunol Labs, Sch Med, Dept Pharmacol, Baltimore, MD 21201 USA; Univ Maryland, Dept Expt Therapeut, Sch Med, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore	Aurelian, L (corresponding author), Univ Maryland, Virol Immunol Labs, Sch Med, Dept Pharmacol, Room 4-023,655 W Baltimore St, Baltimore, MD 21201 USA.	laurelia@umaryland.edu			NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR053512, R01AR042647] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES007263] Funding Source: NIH RePORTER; NIAMS NIH HHS [R01 AR053512, AR42647, R01 AR042647, R01 AR053512-01A2] Funding Source: Medline; NIEHS NIH HHS [T32 ES007263, ES07263] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Aurelian L, 2005, CURR TOP MICROBIOL, V289, P79; Chabaud S, 2003, FEBS LETT, V545, P213, DOI 10.1016/S0014-5793(03)00547-7; Chae HD, 2004, ONCOGENE, V23, P4084, DOI 10.1038/sj.onc.1207482; Chowdary TK, 2004, BIOCHEM J, V381, P379, DOI 10.1042/BJ20031958; Ciocca DR, 2005, CELL STRESS CHAPERON, V10, P86, DOI 10.1379/CSC-99r.1; Cox AD, 2003, ONCOGENE, V22, P8999, DOI 10.1038/sj.onc.1207111; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Diao LR, 2005, EXP CELL RES, V308, P196, DOI 10.1016/j.yexcr.2005.04.016; Du JY, 2004, CANCER CELL, V6, P565, DOI 10.1016/j.ccr.2004.10.014; Edlund S, 2003, MOL BIOL CELL, V14, P529, DOI 10.1091/mbc.02-03-0037; Fink D, 2001, MELANOMA RES, V11, P385, DOI 10.1097/00008390-200108000-00009; Furuta J, 2004, CANCER SCI, V95, P962, DOI 10.1111/j.1349-7006.2004.tb03184.x; Gallagher WM, 2005, CARCINOGENESIS, V26, P1856, DOI 10.1093/carcin/bgi152; Gober MD, 2005, FRONT BIOSCI-LANDMRK, V10, P2788, DOI 10.2741/1736; Gober MD, 2003, J BIOL CHEM, V278, P37600, DOI 10.1074/jbc.M303834200; Hase M, 2005, BIOCHEM J, V388, P475, DOI 10.1042/BJ20041314; Ishitani T, 1999, NATURE, V399, P798, DOI 10.1038/21674; Ivanov VN, 2001, ONCOGENE, V20, P2243, DOI 10.1038/sj.onc.1204314; Karpf AR, 2004, MOL PHARMACOL, V65, P18, DOI 10.1124/mol.65.1.18; Kishimoto K, 2000, J BIOL CHEM, V275, P7359, DOI 10.1074/jbc.275.10.7359; Margolin KA, 2004, CANCER-AM CANCER SOC, V101, P435, DOI 10.1002/cncr.20402; Park CS, 2004, J BIOL CHEM, V279, P19592, DOI 10.1074/jbc.M314208200; Perez-Stable C, 2006, CANCER LETT, V231, P49, DOI 10.1016/j.canlet.2005.01.018; Reu FJ, 2006, CANCER RES, V66, P2785, DOI 10.1158/0008-5472.CAN-05-2303; Saito H, 2003, PIGM CELL RES, V16, P261, DOI 10.1034/j.1600-0749.2003.00039.x; Sharma BK, 2006, DERMATOLOGY, V213, P192, DOI 10.1159/000095035; Singhirunnusorn P, 2005, J BIOL CHEM, V280, P7359, DOI 10.1074/jbc.M407537200; Smith CC, 2000, J BIOL CHEM, V275, P25690, DOI 10.1074/jbc.M002140200; Soengas MS, 2001, NATURE, V409, P207, DOI 10.1038/35051606; Sun XK, 2004, J BIOL CHEM, V279, P2394, DOI 10.1074/jbc.M311324200; Tsao H, 2005, DERMATOL CLIN, V23, P323, DOI 10.1016/j.det.2004.09.005; Van der Velden PA, 2003, INT J CANCER, V106, P472, DOI 10.1002/ijc.11262; Wakefield LM, 2002, CURR OPIN GENET DEV, V12, P22, DOI 10.1016/S0959-437X(01)00259-3; Wang TH, 2006, ONCOGENE, V25, P4857, DOI 10.1038/sj.onc.1209498; Widlund HR, 2002, J CELL BIOL, V158, P1079, DOI 10.1083/jcb.200202049; Yu R, 2000, J BIOL CHEM, V275, P39907, DOI 10.1074/jbc.M004037200; Zendman AJW, 2002, INT J CANCER, V97, P195, DOI 10.1002/ijc.1584	37	25	25	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY	2007	26	24					3521	3531		10.1038/sj.onc.1210145	http://dx.doi.org/10.1038/sj.onc.1210145			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	172JC	17173073	Green Accepted			2022-12-28	WOS:000246799200008
J	Dillon, RL; White, DE; Muller, WJ				Dillon, R. L.; White, D. E.; Muller, W. J.			The phosphatidyl inositol 3-kinase signaling network: implications for human breast cancer	ONCOGENE			English	Review						PI3K; Akt; PTEN; ILK; breast cancer	INTEGRIN-LINKED KINASE; NF-KAPPA-B; GLYCOGEN-SYNTHASE KINASE; EPITHELIAL-MESENCHYMAL TRANSITION; MAMMARY-GLAND INVOLUTION; TUMOR-SUPPRESSOR GENE; PROTEIN-KINASE; COWDEN-DISEASE; EXPRESSION INCREASES; TRANSCRIPTION FACTOR	The phosphatidyl inositol 3-kinase (PI3K)/Akt pathway is activated downstream of a variety of extracellular signals and activation of this signaling pathway impacts a number of cellular processes including cell growth, proliferation and survival. The alteration of components of this pathway, through either activation of oncogenes or inactivation of tumor suppressors, disrupts a signaling equilibrium and can thus lead to cellular transformation. The frequent dysregulation of the PI3K/Akt pathway in human cancer has made components of this pathway attractive for therapeutic targeting; however, a more comprehensive understanding of the signaling intricacies is necessary to develop pharmacological agents to target not only specific molecules, but also specific functions. Here, we review a series of experiments examining the contribution of molecules of this signaling network including PI3K, phosphatase and tensin homolog deleted on chromosome 10, integrin-linked kinase and Akt and address the significance to human breast cancer.	McGill Univ, Mol Oncol Grp, Montreal, PQ, Canada; McGill Univ, Dept Biochem, Montreal, PQ, Canada; McGill Univ, Dept Med, Montreal, PQ, Canada	McGill University; McGill University; McGill University	Muller, WJ (corresponding author), Royal Victoria Hosp, Mol Oncol Grp, Room H5-63,687 Pine Ave W, Montreal, PQ H3A 1A1, Canada.	william.muller@mcgill.ca			PHS HHS [NCI 102036] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Ackler S, 2002, ONCOGENE, V21, P198, DOI 10.1038/sj.onc.1205052; Ahmed N, 2003, J PATHOL, V201, P229, DOI 10.1002/path.1441; Arboleda MJ, 2003, CANCER RES, V63, P196; Attwell S, 2000, ONCOGENE, V19, P3811, DOI 10.1038/sj.onc.1203711; Bachman KE, 2004, CANCER BIOL THER, V3, P772, DOI 10.4161/cbt.3.8.994; BELLACOSA A, 1995, INT J CANCER, V64, P280, DOI 10.1002/ijc.2910640412; Brakebusch C, 2003, EMBO J, V22, P2324, DOI 10.1093/emboj/cdg245; Bravou V, 2006, J PATHOL, V208, P91, DOI 10.1002/path.1860; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Chen WS, 2001, GENE DEV, V15, P2203, DOI 10.1101/gad.913901; Cho H, 2001, J BIOL CHEM, V276, P38349, DOI 10.1074/jbc.C100462200; Cho H, 2001, SCIENCE, V292, P1728, DOI 10.1126/science.292.5522.1728; Chung DH, 1998, VIRCHOWS ARCH, V433, P113, DOI 10.1007/s004280050225; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; D'Amico M, 2000, J BIOL CHEM, V275, P32649, DOI 10.1074/jbc.M000643200; Dahia PLM, 1997, CANCER RES, V57, P4710; Dai DL, 2003, CLIN CANCER RES, V9, P4409; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DEL PL, 1997, SCIENCE, V278, P687; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; Deprez J, 1997, J BIOL CHEM, V272, P17269, DOI 10.1074/jbc.272.28.17269; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Easton RM, 2005, MOL CELL BIOL, V25, P1869, DOI 10.1128/MCB.25.5.1869-1878.2005; Edwards LA, 2005, ONCOGENE, V24, P3596, DOI 10.1038/sj.onc.1208427; Garcia JM, 1999, BREAST CANCER RES TR, V57, P237, DOI 10.1023/A:1006273516976; Graff JR, 2001, CLIN CANCER RES, V7, P1987; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0; Hennessy BT, 2005, NAT REV DRUG DISCOV, V4, P988, DOI 10.1038/nrd1902; Hutchinson J, 2001, MOL CELL BIOL, V21, P2203, DOI 10.1128/MCB.21.6.2203-2212.2001; Hutchinson JN, 2004, CANCER RES, V64, P3171, DOI 10.1158/0008-5472.CAN-03-3465; Irie HY, 2005, J CELL BIOL, V171, P1023, DOI 10.1083/jcb.200505087; Kane LP, 1999, CURR BIOL, V9, P601, DOI 10.1016/S0960-9822(99)80265-6; Kang SY, 2005, P NATL ACAD SCI USA, V102, P802, DOI 10.1073/pnas.0408864102; Kawakami Y, 2004, J BIOL CHEM, V279, P47720, DOI 10.1074/jbc.M408797200; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; Koul D, 2005, MOL CANCER THER, V4, P1681, DOI 10.1158/1535-7163.MCT-05-0258; Larue L, 2005, ONCOGENE, V24, P7443, DOI 10.1038/sj.onc.1209091; Li G, 2002, DEVELOPMENT, V129, P4159; Li Y, 2004, TRENDS BIOCHEM SCI, V29, P32, DOI 10.1016/j.tibs.2003.11.007; Li Y, 2001, BMC Mol Biol, V2, P2, DOI 10.1186/1471-2199-2-2; Liaw D, 1997, NAT GENET, V16, P64, DOI 10.1038/ng0597-64; Lynch DK, 1999, ONCOGENE, V18, P8024, DOI 10.1038/sj.onc.1203258; Mackinnon AC, 2002, CURR BIOL, V12, P787, DOI 10.1016/S0960-9822(02)00810-2; Marotta A, 2001, ONCOGENE, V20, P6250, DOI 10.1038/sj.onc.1204791; Minobea K, 1999, CANCER LETT, V144, P9, DOI 10.1016/S0304-3835(99)00181-0; Nakatani K, 1999, J BIOL CHEM, V274, P21528, DOI 10.1074/jbc.274.31.21528; Nelen MR, 1997, HUM MOL GENET, V6, P1383, DOI 10.1093/hmg/6.8.1383; Ozes ON, 1999, NATURE, V401, P82; Persad S, 2000, P NATL ACAD SCI USA, V97, P3207, DOI 10.1073/pnas.060579697; Persad S, 2001, J BIOL CHEM, V276, P27462, DOI 10.1074/jbc.M102940200; Rhei E, 1997, CANCER RES, V57, P3657; Romashkova JA, 1999, NATURE, V401, P86, DOI 10.1038/43474; Saal LH, 2005, CANCER RES, V65, P2554, DOI 10.1158/0008-5472-CAN-04-3913; Samuels Y, 2004, SCIENCE, V304, P554, DOI 10.1126/science.1096502; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Schwertfeger KL, 2001, MOL ENDOCRINOL, V15, P867, DOI 10.1210/me.15.6.867; Schwertfeger KL, 2003, J LIPID RES, V44, P1100, DOI 10.1194/jlr.M300045-JLR200; Sizemore N, 1999, MOL CELL BIOL, V19, P4798; Stal O, 2003, BREAST CANCER RES, V5, pR37, DOI 10.1186/bcr569; Stambolic V, 2000, CANCER RES, V60, P3605; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Sun M, 2001, AM J PATHOL, V159, P431, DOI 10.1016/S0002-9440(10)61714-2; Tan C, 2004, CANCER CELL, V5, P79, DOI 10.1016/S1535-6108(03)00281-2; Teng DHF, 1997, CANCER RES, V57, P5221; Thant AA, 2001, CLIN EXP METASTAS, V18, P423, DOI 10.1023/A:1010921730952; Toker A, 2000, J BIOL CHEM, V275, P8271, DOI 10.1074/jbc.275.12.8271; Tschopp O, 2005, DEVELOPMENT, V132, P2943, DOI 10.1242/dev.01864; Tu YZ, 2001, J CELL BIOL, V153, P585, DOI 10.1083/jcb.153.3.585; Viglietto G, 2002, NAT MED, V8, P1136, DOI 10.1038/nm762; Wang SY, 2006, P NATL ACAD SCI USA, V103, P1480, DOI 10.1073/pnas.0510652103; West KA, 2002, DRUG RESIST UPDATE, V5, P234, DOI 10.1016/S1368-7646(02)00120-6; White DE, 2001, ONCOGENE, V20, P7064, DOI 10.1038/sj.onc.1204910; Wu CY, 2001, J CELL SCI, V114, P2549; Wu CY, 1998, J BIOL CHEM, V273, P528, DOI 10.1074/jbc.273.1.528; Yamaji S, 2001, J CELL BIOL, V153, P1251, DOI 10.1083/jcb.153.6.1251; Yoeli-Lerner M, 2005, MOL CELL, V20, P539, DOI 10.1016/j.molcel.2005.10.033; Younes MN, 2005, MOL CANCER THER, V4, P1146, DOI 10.1158/1535-7163.MCT-05-0078; Zervas CG, 2002, CURR BIOL, V12, pR350, DOI 10.1016/S0960-9822(02)00856-4; Zervas CG, 2001, J CELL BIOL, V152, P1007, DOI 10.1083/jcb.152.5.1007; Zhou BP, 2001, NAT CELL BIOL, V3, P438	81	230	244	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 26	2007	26	9					1338	1345		10.1038/sj.onc.1210202	http://dx.doi.org/10.1038/sj.onc.1210202			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	141DU	17322919				2022-12-28	WOS:000244558700011
